[
  {
    "id": "WO2010049489A1",
    "text": "Method for fast detection and identification of micro-organisms AbstractThe present invention relates to a specific method accomplishing fast and specific detection, identification and characterization of contaminating micro-organisms in various samples. A method has been developed based on the detection of species-specific and/or strain-specific nucleotide sequences that are uniquely identified and amplified and subsequently detected on a microarray using addressable identifier ZIP oligonucleotides. By using a two step screening process, the method of the present invention enables in first instance the fast screening of a multitude of samples for the presence or the absence of specific micro- organisms in such samples, while in a second screening step the positive results of the first step are further processed to identify and characterize the detected micro-organisms. Claims\n\n\n\n\n\n\n1. A method for determining the presence of micro-organisms in a sample and identifying and characterizing said micro-organisms if present, comprising the steps of: (a) extracting nucleic acids from micro-organisms, said nucleic acids comprising target nucleic acids,\n\n\n(b) performing a ligase detection reaction (LDR) on said target nucleic acids, comprising:\n\n\n(b1 ) providing a pair of a first nucleic acid probe and a second nucleic acid probe, said first nucleic acid probe comprising a 3' located target-specific sequence I complementary to a distinct part of said target nucleic acid and said second nucleic acid probe comprising a 5' located target-specific sequence Il complementary to a second part of said target nucleic acid located essentially adjacent to and 3' from said target-specific sequence I, wherein said first nucleic acid probe further comprises a 5' located primer binding section I (PBS(I)) and possibly a stuffer, and said second nucleic acid probe comprises a 3' located primer binding section Il\n\n\n(PBS(II)) and possibly a stuffer; and optionally wherein the first nucleic acid probe and/or the second nucleic acid probe further comprises at least one identifier region, which (i) corresponds to a corresponding region of a capture probe preferably on a microarray and (ii) is essentially non-complementary to said target nucleic acid, and (iii) is located in between the target specific sequence and the primer binding section,\n\n\n(b2) incubating said target nucleic acid with said first nucleic acid probe and said second nucleic acid probe under conditions allowing hybridisation of complementary nucleic acids, (b3) connecting any essentially adjacent probes,\n\n\n(b4) providing at least one set of two primers, wherein the first primer (primer I) is essentially identical to primer binding section I, and the second primer (primer II) is essentially complementary to primer binding section II, wherein said first or said second primer is optionally labelled, and (b5) amplifying any connected probe nucleic acid of step (b3), wherein amplification is initiated by binding of nucleic acid primer specific for a primer binding section, thereby providing amplified target nucleic acids, wherein one or more detector molecules, detecting the amplified target nucleic acids, are present in step (b5),  (c) monitoring the signal of said detector molecule and/or the modulation of the signal of said detector molecule, said modulation in the signal of said detector molecule indicating the presence of said target sequence whereby the presence of a microorganism is determined, (d) hybridizing the amplified target nucleic acids of step (c) to a capture probe, preferably present on a microarray, and,\n\n\n(e) detecting the hybridized target nucleic acids of step (d), whereby the micro-organism is identified.\n\n\n\n\n\n\n2. The method according to claim 1 , wherein hybridizing amplified target nucleic acids of step (d) are target sequences providing a positive signal in step (c).\n\n\n\n\n\n\n3. The method according to any of the claims 1 and 2, wherein said detector molecules are one or more oligonucleotide detector probes having a sequence at least partially complementary to a target nucleic acid sequence to be detected and including a fluorescent reporter molecule and a fluorescent quencher molecule capable of quenching the fluorescence of said reporter molecule, said oligonucleotide probe existing in at least one single-stranded, partially single-stranded or double-stranded conformation when unhybridized where said quencher molecule quenches the fluorescence of said reporter molecule, said oligonucleotide probe existing in at least one conformation when hybridized to said target nucleic acid where the fluorescence of said reporter molecule is unquenched.\n\n\n\n\n\n\n4. The method according to claim 3, wherein the sequence of said oligonucleotide detector probes is at least complementary to at least one region of the first nucleic acid probe or at least one region of the second nucleic acid probe.\n\n\n\n\n\n\n5. The method according to any of the claims 1 to 4, wherein the first nucleic acid probe and/or the second nucleic acid probe further comprise at least one DET which is\n\n\n(i) essentially complementary to one or more oligonucleotide detector probes used for detecting the accumulation of the reaction products during the amplification reaction of step (b5);\n\n\n(ii) essentially non-complementary to said target nucleic acid; and (iii) which is located in between the target sequence and the primer binding section.  \n\n\n\n\n\n\n6. The method according to any of the claims 1 to 5, wherein at least two groups of pairs of first and second nucleic acid probes are provided, wherein each group of first and second nucleic acid probes hybridises to a specific target nucleic acid, and comprises a specific primer binding site I and/or II.\n\n\n\n\n\n\n7. The method according to any of the claims 1 to 5, wherein at least two groups of pairs of first and second nucleic acid probes are provided, wherein each group of first and second nucleic acid probes hybridises to a specific target nucleic acid, and the first or second nucleic acid probe of each group comprises a specific identifier region, preferably a cZIP or ZIP.\n\n\n\n\n\n\n8. The method according to any of the claims 1 to 7, wherein said identifier region, preferably a cZIP or ZIP, on the first nucleic acid probe and/or the second nucleic acid probe are located in between the target-specific sequence and the primer binding sequence.\n\n\n\n\n\n\n9. The method according to any of the claims 1 to 8, wherein said first nucleic acid probe is coupled with its 5' end to the 3' end of said second nucleic acid probe, possibly via a stuffer region.\n\n\n\n\n\n\n10. The method according to any of the claims 1 to 9, wherein said connecting step (b3) comprises the use of a ligase.\n\n\n\n\n\n\n1 1. The method according to any of the claims 1 to 10, wherein the amplified target nucleic acid is labelled, preferably during amplification.\n\n\n\n\n\n\n12. The method according to any of the claims 1 to 1 1 , wherein said capture probe comprises a ZIP which is essentially complementary to a corresponding cZIP, or wherein said capture probe comprises a cZIP which is essentially complementary to a corresponding ZIP.\n\n\n\n\n\n\n13. The method according to any of the claims 1 to 12, wherein:\n\n\n(a) said first nucleic acid probe comprises from 5' to 3': a Primer Binding Sequence I (PBS(I)), cZIP, and a target specific sequence I (tss(l)), said second nucleic acid probe comprises from 5' to 3': a target specific sequence Il (tss(ll)), DET and a Primer Binding Sequence Il (PBS(II)), and preferably primer I is labelled;  (b) said first nucleic acid probe comprises from 5' to 3': a PBS(I), DET, and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), cZIP and PBS(II), and preferably primer I is labelled;\n\n\n(c) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cDET and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), cZIP and PBS(II), and preferably primer I is labelled;\n\n\n(d) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cZIP, DET and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer I is labelled; (e) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cZIP, cDET, and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer I is labelled;\n\n\n(f) said first nucleic acid probe comprises from 5' to 3': a PBS(I), DET, cZIP and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer I is labelled;\n\n\n(g) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cDET, cZIP and tss(l), and said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer I is labelled;\n\n\n(h) said first nucleic acid probe comprises from 5' to 3': a PBS(I) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), DET, cZIP and PBS(II), and preferably primer I is labelled; (i) said first nucleic acid probe comprises from 5' to 3': a PBS(I) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), cZIP, DET and PBS(II), and preferably primer I is labelled; (j) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZIP and tss(l), and said second nucleic acid probe comprises from 5' to 3': a tss(ll), DET and PBS(II), and preferably primer Il is labelled; (k) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cZIP, DET and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer Il is labelled,\n\n\n(I) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZIP, cDET and tss(l), and said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer Il is labelled;  (m) said first nucleic acid probe comprises from 5' to 3': a PBS(I), DET, ZIP and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer Il is labelled; and/or,\n\n\n(n) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cDET, ZIP and tss(l), and said second nucleic acid probe comprises: a tss(ll) and PBS(II), and preferably primer Il is labelled.\n\n\n\n\n\n\n14. The method according to any of the claims 1 to 13, wherein said capture probe is spatially addressable on a microarray.\n\n\n\n\n\n\n15. The method according to any of claims 1 to 14, wherein the amplified target nucleic acids derived from at least two samples are hybridised to capture probes present on a single microarray.\n\n\n\n\n\n\n16. The method according to any of claims 1 to 15, wherein the amplified target nucleic acids hybridised to the corresponding capture probes on a microarray results in a hybridisation pattern.\n\n\n\n\n\n\n17. A kit for determining the presence of micro-organisms in a sample, comprising means for extracting nucleic acids from said micro-organisms, means for specifically amplifying said nucleic acids, means for detecting the signal obtained from the amplified nucleic acids, means for analysing the amplified nucleic acids, and an instruction manual.\n\n\n\n\n\n\n18. Use of at least one pair of a first nucleic acid probe and a second nucleic acid probe as defined in claim 1 and/ore the use of at least one set of two primers as defined in any of the claims 1 or 12 in a method according to any of claims 1 to 16. Description\n\n\n\n\n METHOD FOR FAST DETECTION AND IDENTIFICATION OF MICRO-ORGANISMS\n\n\nField of the invention\n\n\nThe present invention relates to a fast and efficient method for detecting the presence of micro-organisms and identifying the micro-organisms in a sample.\n\n\nBackground of the invention\n\n\nBoth clinical applications as well as applications in the food industry require highly efficient methods for screening samples on the presence or the absence of pathogenic micro- organisms. Whereas screening methods for clinical applications require high-throughput, fast and correct identification of the micro-organisms present in the sample for diagnostical purposes, applications in the food industry require highly reliable high-throughput methods for the microbiological control and microbiological monitoring to validate the safety and quality of food products. For both instances, methods are required that allow the fast detection, identification and characterization of micro-organisms in various samples. Other important requirements for such screening methods are the ease of use and the elimination of errors (false positives and/or false negatives).\n\n\nVarious screening methods known in the art such as real-time PCR enable fast screening and provide a method for testing on presence or absence of pathogenic bacteria. However, e.g., after detecting the presence of micro-organisms, further identification requires multiparameter testing, which generally cannot be provided by these screening methods. For instance, real-time PCR allows only limited multiplexing of biomarkers. In addition, detection of small changes in DNA sequences such as SNPs is often difficult.\n\n\nTypical identification and characterization test methods are slow, laborious and require a high level of expertise to execute and to interpret the results. Subtyping bacteria, or determining of antibiotic resistance can only be done by classical expensive and laborious methods that require a large amount of expertise. Furthermore, the typical molecular typing methods (Ribotyping, MLST, AFLP, MLVA, MicroSeq, rep PCR etc.) require the tests to be done on pure strains. Purification of samples is often also a very tedious process, taking a long time. Many of these tests are therefore performed in specialized laboratories. The main disadvantage of this approach is that the results of the further identification of positive samples are very often too late for practical use as well as being relatively expensive, both in food and also in clinical field. \n\n A method for efficiently screening samples on the presence or the absence of pathogenic micro-organisms and the subsequent identification of the micro-organisms has been described in EP1633887. However, a problem of the method described in EP1633887 is that all of the samples are subjected to the entire process. Even if no micro-organisms are detected, the step of screening the samples on a microarray is performed for all samples. Since generally more than 95 % of food samples and water control samples are negative for the presence of micro-organisms, a lot of these samples are tested, and subjected to identification and characterization of micro-organisms which are not present in the sample. The described screening method therefore provides avoidable process steps. In view of time and cost considerations, the present invention provides an optimized method for the detection, identification and characterization of micro-organisms in samples. The method detects in first instance whether or not micro-organisms are present in the sample and in a next step identification and characterization is carried out on the positive samples only.\n\n\nSummary of the invention\n\n\nThe present invention relates to a specific method accomplishing fast and specific detection, identification and characterization of contaminating micro-organisms in various samples. A method has been developed based on the detection of species-specific and/or strain-specific nucleotide sequences that are uniquely identified and amplified and subsequently detected on a microarray using addressable identifier ZIP oligonucleotides (ZipComcode (cZIP) or Zipcode (ZIP)). By using a two step screening process, the method of the present invention enables in first instance the fast screening of a multitude of samples for the presence or the absence of specific micro-organisms in such samples, while in a second screening step the positive results of the first step are further processed to identify and characterize the detected micro-organisms.\n\n\nFigures\n\n\nFigure 1 : Schematic representation of target DNA and target-specific real-time ligation amplification probes.\n\n\nFigure 2: Schematic representation of target DNA and target-specific real-time ligation amplification probes, wherein probe I and probe Il are coupled. Only ligated probes provide exponential amplification, which is detected by a specific detector molecule. \n\n Figure 3: Real-time LDR plots of samples 1 to 6. The X-axis displays the cycle number; the Y-axis the Relative Fluoresence Units corrected for background fluoresence. Samples 1 and 2 give a high (positive signal), indicating the presence of Salmonella; samples 3 to 6 give a very low signal indicating the absence of Salmonella in these samples. Figure 4: Real-time LDR reaction products of samples 1 , 2 and 3 hybridized to a microarray using the PremiTest Salmonella detection protocol. The top panel (yellow) displays sample 1 , the middle panel (green) displays sample 2, and the bottom panel (blue) displays sample 3. Samples 1 and 2 display spot pattern typical for serovars Virchow and Paratyphi B, respectively. Sample 3 displays only the amplification control spots 16, 19 and 22: this indicates that the reaction was carried out properly and that this sample does not contain Salmonella DNA.\n\n\nFigure 5: Schematic representation of preferred probe pairs. Molecules resulting from amplification are depicted after the arrow. Real Time (RT) and/or microarray detection is indicated. The probe for RT detection comprises a region complementary (cDET) to the DET region. In this case, for array detection, the microarray comprises capture probes comprising a Zipcode (ZIP) essentially complementary to the ZipComcode (cZIP).\n\n\nFigure 6a, 6b and 6c: Schematic representation of the real time detection of the amplification reaction using respectively Taqman probes, Scorpion primers and Molecular Beacon probes.\n\n\nDetailed Description of the Invention\n\n\nThe present invention relates to methods for collecting, detecting, identifying and characterizing contaminating micro-organisms in food stuffs, bodily fluids and in the control of water. More specifically, the present invention relates to a method for determining the presence and characterization of micro-organisms in a sample by using two detection steps, in which a first step comprises the detection of the presence of micro-organisms via a detector molecule, and a second step comprises the further identification and characterization of said micro-organism preferably via a labelled primer. Preferably said first step comprises monitoring the signal of detector molecules, detecting amplified target nucleic acids resulting from a ligase detection reaction in which essentially adjacent probes hybridized to a target nucleic acid are connected, and subsequently amplified. Preferably said second step comprises detecting the hybridization of amplified target nucleic acids to a capture probe. \n\n In particular, the present invention relates to a method for determining the presence of microorganisms in a sample and identifying and characterizing said micro-organisms, comprising the steps of:\n\n\n(a) possibly extracting nucleic acids from micro-organisms, said nucleic acids comprising target nucleic acids,\n\n\n(b) performing a ligase detection reaction (LDR), preferably a real-time ligase detection reaction (RT-LDR), on said target nucleic acids, comprising:\n\n\n(b1 ) providing a pair of a first nucleic acid probe and a second nucleic acid probe, said first nucleic acid probe comprising a 3' located target-specific sequence I complementary to a distinct part of said target nucleic acid and said second nucleic acid probe comprising a 5' located target-specific sequence Il complementary to a second part of said target nucleic acid located essentially adjacent to and 3' from said target-specific sequence I, wherein said first nucleic acid probe further comprises a 5' located primer binding section I (PBS(I)) and possibly a stuffer, and said second nucleic acid probe comprises a 3' located primer binding section Il\n\n\n(PBS(II)) and possibly a stuffer; and optionally wherein the first nucleic acid probe and/or the second nucleic acid probe further comprises at least one identifier region, such as a ZipComcode or Zipcode (ZIP), which (i) corresponds to a corresponding region of a capture probe on a microarray and (ii) is essentially non- complementary to said target nucleic acid, and (iii) is located in between the target specific sequence and the primer binding section,\n\n\n(b2) incubating said target nucleic acid with said first nucleic acid probe and said second nucleic acid probe under conditions allowing hybridisation of complementary nucleic acids, (b3) connecting any essentially adjacent probes,\n\n\n(b4) providing at least one set of two primers, wherein the first primer (primer I) is essentially identical to primer binding section I, and the second primer (primer II) is essentially complementary to primer binding section II, wherein said first or said second primer is optionally labelled, and (b5) amplifying any connected probe nucleic acid, wherein amplification is initiated by binding of nucleic acid primer specific for a primer binding section, thereby providing amplified target nucleic acids, wherein one or more detector molecules, detecting the amplified target nucleic acids, are present in step (b5), \n\n (c) monitoring the signal of said detector molecule and/or the modulation of the signal of said detector molecule, a modulation in the signal of said detector molecule indicating the presence of said target sequence whereby the presence of a micro-organism is determined, (d) hybridizing the amplified target nucleic acids of step (c) to a capture probe, preferably present on a microarray, and said amplified target nucleic acids of step (c) optionally comprising an identifier region, such as a ZipComcode (cZIP) or Zipcode (ZIP), essentially complementary to a corresponding region of said capture probe, and, (e) detecting the hybridized target nucleic acids of step (d), whereby the micro-organism is identified.\n\n\nAs the method according to the present invention determines the presence of a microorganism using detector molecules, detecting amplified target nucleic acids, the method according to the present invention implicitly also determines the presence of specific DNA sequences present in said micro-organisms, thereby determining the presence of the micro- organism and/or specific genes of the organism, thereby further characterizing said microorganism.\n\n\nBefore the present method and devices used in the invention are described, it is to be understood that this invention is not limited to particular methods, components, or devices described, as such methods, components, and devices may, of course, vary. It is also to be understood that the terminology used herein is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.\n\n\nUnless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present invention, the preferred methods and materials are now described.\n\n\nAs used herein, the terms \"comprising\", \"comprises\" and \"comprised of\" as used herein are synonymous with \"including\", \"includes\" or \"containing\", \"contains\", and are inclusive or open-ended and do not exclude additional, non-recited members, elements or method steps. The terms \"comprising\", \"comprises\" and \"comprised of also include the term \"consisting of\". The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the respective ranges, as well as the recited endpoints. The term \"about\" as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, is meant to encompass variations of +/-10% or less, \n\n preferably +1-5% or less, more preferably +/-1 % or less, and still more preferably +/-0.1 % or less of and from the specified value, insofar such variations are appropriate to perform in the disclosed invention. It is to be understood that the value to which the modifier \"about\" refers is itself also specifically, and preferably, disclosed. All documents cited in the present specification are hereby incorporated by reference in their entirety.\n\n\nReference throughout this specification to \"one embodiment\" or \"an embodiment\" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases \"in one embodiment\" or \"in an embodiment\" in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention, and form different embodiments, as would be understood by those in the art. For example, in the following claims, any of the claimed embodiments can be used in any combination.\n\n\nUnless otherwise defined, all terms used in disclosing the invention, including technical and scientific terms, have the meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. By means of further guidance, definitions for the terms used in the description are included to better appreciate the teaching of the present invention.\n\n\nIn the present specification and the appended claims, the singular forms \"a\", \"an\", and \"the\" include the plural references, and vice versa, unless the context clearly indicates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.\n\n\nIn general, a sample or specimen will be taken as a part of anything. For applications in the food industry such samples are for instance food stuffs, dairy products, beverages and beer being produced presented for inspection, or shown as evidence of the quality of the whole. For clinical applications the sample or specimen can be any kind of bodily solid, semi-solid or fluid substance such as, but not limited to faeces, blood, blood plasma, serum, urine, bodily liquid, rectal swabs, nasal swabs, sputum, infected tissue, etc.\n\n\nIn one aspect of the invention, the present method is applicable to the micro-organisms which are known to contaminate food stuffs, dairy products, beer and other beverages, for example the micro-organisms presented herein. Alternatively, according to another aspect of \n\n the present invention, the present method is applicable to the micro-organisms which are known to cause infections and maladies.\n\n\nAs such, the present invention relates to a method for determining the presence of microorganisms in a sample, comprising the steps of optionally collecting said micro-organisms if present, extracting nucleic acids from said micro-organisms, specifically amplifying said nucleic acids thereby detecting the amplified target nucleic acids, whereby the presence of said micro-organisms is determined. For samples where the presence of said microorganisms is detected, the amplified nucleic acids are further analyzed, thereby identifying and characterizing the present micro-organisms. As a consequence, only the positive samples are subjected to a further analysis which constitutes in a time, work and/or material saving method.\n\n\nAs will be evident, the present invention relates to a method as described herein, wherein said micro-organism is selected from the group consisting of eukaryotic and/or prokaryotic micro-organisms as well as viruses. The micro-organism may be selected from the group comprising algae, archaea, bacteria, viruses, nematodes, protozoa, microsporidae and fungi including yeasts, moulds and mycorrhizae.\n\n\nSimilarly, it will be appreciated that the present invention relates to a method as described herein, wherein said micro-organism is selected from the group consisting of food borne and waterborne micro-organisms. Similarly, it will be appreciated that the present invention relates to a method as described herein, wherein said micro-organism is selected from the group consisting of human and/or animal parastitic, symbiotic, commensals and/or pathogenic micro-organisms.\n\n\nIn this respect, the present invention relates to a method as described herein, wherein said micro-organism is selected from: the group of bacteria and (sub)species thereof consisting of Escherichia, Salmonella, Shigella, Klebsiella, Citrobacter, Serratia, Averyella, Hafnia, Morganella, Pantoea, Photorhabdus, Pleosimonas, Proteus, Providencia, Raoultella, Edwardsiella, Ewingella, Cedecea, Kluyvera, Leclercia, Leminorella, Moellerella, Rahnella, Tatumella, Yokenella, Enterobacter, Yersinia, Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, Mycobacterium, Propionibacterium, Actinomyces, Lactobacillus, Eurobacterium, Eggerthella, Olsenella, Bifidobacterium, Mobiluncus, Alistipes, Bacteroides, Cetobacterium, Desulfovibrio, Dialister, Faecalibacterium, Fusobacterium, Porphyromonas, Prevotella, Sneathia, Tannerella Lactococcus, Listeria, Erysipelothrix, Leuconostoc, Bacillus, Staphylococcus, \n\n Clostridium, Vibrio, Enterococcus, Legionella, Campylobacter, Arcobacter, Helicobacter, Leptospira, Borrelia, Treponema, Mycoplasma, Ureoplasma, Chlamydia, Chlamydophila, Rickettsia, Orientia, Ehrlichia, Anaplasma, Neorickettsia, Aegyptianella, Coxiella, Tropheryma, Streptococcus, Micrococcus, Pseudomonas, Flavobacterium, Alcaligenes, Microbacterium, Neisseria, Actinobacillus, Capnocytophaga, Eikenella, Kingella, Pasteurella, Haemophilus, Aeromonas, Burkholderia, Stenotropomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas, Delftia, Acidovorax, Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, Bordetella, Psych robacter, Oligella, Haematobacter, Alcaligenes, Advenella, Alishewanella, Aquaspirillum, Laribacter, Myroides, Shewanella, Ochrobactrum, Rhizobium, Halomonas, Herbaspirillum, Inquilinus, Massilia, Sphingobacterium, Pedobacter, Paracoccus, Asaia, Methylobacterium, Roseomonas, Azospirillum, Elizabethkingia, Empedobacter, Weeksella, Bergeyella, Balneatrix, Bordetella, Francisella, Brucella, Bartonella, Peptostreptococcus, Finegoldia, Anaerococcus, Peptoniphilus, Veillonella, Gallicola, Sackia, Atopobium, Ruminococcus, Aerococcus, Abiotrophia, the group of viruses consisting of: Human Immunodeficiency Viruses (HIV), Humman T-CeII Lymphotropic Viruses, Influenza Viruses, Parainfluenza Viruses, Mumps Virus, Respiratory syncytial virus, Human metapneumoviruses, Measles Virus, Rubella virus, Enteroviruses, Pareochviruses, Hepatoviruses, Rhinoviruses, Coronaviruses, Rotaviruses, Caliciviruses, Astroviruses, Adenoviruses, Coronaviruses, Toroviruses, Aichi Virus, Picobirnaviruses, Rabies virus, Hendra and Nipah Viruses, Arboviruses, Hantaviruses, Arenaviruses, Filoviruses, Human Herpesviruses, Human Papillomaviruses, Human Polyomaviruses, Human Paroviruses, Poxviruses, Hepatitis Viruses the group of Fungi consisting of: Candida, Cryptococcus, Blastoschizomyces, Clavispora, Debaryomyces, Kluyveromyces, Geotrichum, Ustilago, Prototheca^ Dipodascus, Malassezia, Pichia, Rhodotorula, Saccharomyces, Sporobolomyces, Trichosporon, Pneumocystis, Aspergillus, Fusarium, Scedosporium, Penicillium, Scopulariopsis, Chaetomium, Schizophyllum, Acremonium, Lecythophora, Phialemonium, Phaeoacremonium, Arthrographis, Onychocola, Scytalidium, Beauveria, Engyodontium, Sporothix, Chrysosporium, Myceliophthora, Myriodontium, Metarrhizum, Trichoderma, Paecilomyces, Rhizopus, Rhizomucor, Absidia, Apophysomyces, Mucor, Cunninghamella, Basidiobolus, Conidiobolus, Mortierella, Cokeromyces, Syncephalastrum, Saksenaea, Histoplasma, Blastomyces, Coccidioides, Paracoccidioides, Emmonsia, Trichophyton, Microsporum, Epidermophyton, Malassezia, Piedraia, Calosphaeriales, Chaetothyriales, Dothideales, \n\n Microascales, ,Ophiostomatales, Pleosporales, Sordariales, Hypocreales, Diaporthales, and/or the group of parasites consisting of: Plasmodium, Babesia, Leishmania, Trypanosoma, Toxoplasma, Naegleria, Acanthamoeba, Balamuthia, Entamoeba, Endolimax, Iodamoeba, Blastocystis, Giardia, Dientamoeba, Trichomonas, Chilomastix, Enteromonas, Retortamonas, Isospora, Cyclospora, Sarcocystis, Cryptosporidium, Microsporidium.\n\n\nIn a particular embodiment of the present invention the micro-organisms are captured or collected prior to step (a) of the method of the present invention. The capturing or collection of the micro-organisms prior to step (a) of the method provides a concentration step which allow a concentration of the micro-organisms prior to the method of the invention, thereby providing a more accurate method.\n\n\nIn order to increase the amount of micro-organisms present in a sample, said microorganisms, if present, may be grown on media. Accordingly, the present invention relates to a method as described herein, wherein said method, for instance step (a) of above, is preceded by an enrichment of micro-organisms, comprising (i) growth of said microorganisms on selective media, or (ii) growth of said micro-organisms on non-selective media. Growth of said micro-organisms on selective media will preferably favour the growth of micro-organisms of interest, while the growth on non-selective media will sustain growth of most micro-organisms, e.g. not especially favouring the growth of a particular micro- organism.\n\n\nAlthough the sample can be used directly for DNA-isolation, some techniques require the growth and collection of the micro-organisms prior to the DNA-isolation. According to the method of the invention the growth and collection of the micro-organisms prior to the DNA- isolation is not required nor essential, thereby providing a faster detection method compared to the prior art methods. The growth and collection of the micro-organisms prior to the DNA- isolation may however be optionally included in the method of the invention. Accordingly, the present invention relates to a method as described herein, wherein said method, for instance step (a) of above, is preceded by an enrichment of micro-organisms, comprising concentrating the micro-organisms. Typical collection strategies known in the art are for instance, but not limited to, plating out the sample on a suitable solid culture medium, adding the sample in a suitable liquid culture medium or first providing the sample in a suitable liquid culture medium followed by plating it out on a suitable solid culture medium. From a solid culture medium, micro-organisms can be directly collected for DNA-isolation, while a liquid culture medium in general requires first a centrifugation step to collect the micro-organisms. \n\n The collection and/or capturing of said micro-organisms may be performed by means of centrifugation, filtration, such as filtering of an aqueous or liquid solution, whereby all particles larger than the sieving size are being captured, sedimentation, electrostatic forces, coagulation, flocculation, capturing of micro-organisms by antibodies, and/or capturing of micro-organisms by ligands.\n\n\nOther collection and/or capturing techniques may include microfiltration ad preferably membrane microfiltration such as the Micro Analytical Screen (MAS) method. This method achieves low flow resistance, a high chemical resistance and a well controlled pore size distribution of the membrane filters, in order to obtain a high operational flux, long standing times (e.g. a long life/operation time of the microsieve) and good separation behaviour. Preferably, the microsieve filters according to the present invention are characterised by thin membrane layers with uniformly sized pores. For most applications, the membrane layer is sustained by a support. A microsieve having a relatively thin filtration or sieving layer with a high pore density and a narrow pore size distribution on a macroporous support will show a satisfactory to good or even excellent separation behaviour and a high flow rate. In very dilute suspensions, it will be important to have a fast determination of the kind and concentration of particles, such as for example fruit juices contaminated with microorganisms. The low flow resistance of the microsieve allows a large amount of liquid to pass through the filter in a small amount of time, whereby the contaminating micro-organisms (if present) are concentrated on a very small surface (20-100 mm\n2\n). This fast concentration of the contaminating micro-organisms adds in simplifying and the quality of the subsequent analysis of these micro-organisms. With regard to the microfiltration technology, the present invention relates also to cross-flow microfiltration as described by Daufin et al. (2001 ), to a microfiltration technology described by the patent application WO 02/43937 (by Aquamarijn Holding Ltd.), or to a microfiltration technology developed by CEPAration B.V. (Helmond, The Netherlands). Accordingly, the present invention relates to a method as described herein, wherein said filtration is performed by using an Aquamarijn® filter or a CEPAration® filter. For instance, silicon nitride may be used as membrane, and silicium as carrier, or the filter may comprise a hollow fibre ceramic membrane. The size of pores may for instance be between 0.5 and 1.2 micron or between 0.15 and 1.4 micron.\n\n\nIt will be understood that the present invention relates to a method as described herein, wherein said concentrating is followed by separating the micro-organisms from the remainder of the sample. In addition, concentrating and separating may be performed simultaneously, thereby increasing the velocity of the analysis. \n\n A wide variety of colouring and/or staining techniques can be used in order to improve the recognition of the micro-organisms on the microsieve surface. Microsieves are preferably inert which makes it possible to use all present staining agents and chemicals without colouring or attacking the microsieve surface. Said microsieve may be used again. The presented MAS method may also be applied for the quality control of water in general and drinking water in particular on the presence of contaminating micro-organisms, such as, for example, Cryptosporidium, Escherichia coli and Legionella. Also in the meat industry, the MAS method can be applied to trace contaminating micro-organisms, such as, for example, Campylobacter and Salmonella contaminations. In order to characterise the contaminating micro-organism, the present invention may employ known techniques identifying the nucleic acid of the micro-organism at issue. The present invention relates preferably to the multiplexed amplification and labelling technique described below. Multiplexing provides the opportunity to perform multiple analyses during a single process step providing faster analysis times and lower amounts of consumables to be used. The term \"nucleic acid\" as used herein means a polymer composed of nucleotides, e.g. deoxyribonucleotides or ribonucleotides. The terms \"ribonucleic acid\" and \"RNA\" as used herein means a polymer composed of ribonucleotides. The terms \"deoxyribonucleic acid\" and \"DNA\" as used herein means a polymer composed of deoxyribonucleotides. The terms \"oligonucleotide\", \"primer\" and \"probe\" as used herein denotes single stranded nucleotide multimers of from about 10 to about 250 nucleotides in length. The term \"polynucleotide\" as used herein refers to single or double stranded polymer composed of nucleotide monomers of from about 10 to about 250 nucleotides in length, usually of greater than about 250 nucleotides in length up to about 2000 nucleotides in length.\n\n\nIt will be understood that the present invention relates to a method as described herein, wherein said nucleic acids are chosen from the group consisting of DNA, rRNA, tRNA, siRNA, mRNA, total RNA and tmRNA (dual tRNA-like and mRNA-like nature; also known as 10Sa RNA or SsrA).\n\n\nIn order to characterise the nucleic acid from a contaminating micro-organism, i.e. the target nucleic acid, said nucleic acid is normally isolated from the contaminating micro-organism after said organism has optionally been collected or captured. The collection or capturing of the contaminating organism and the isolation of the nucleic acids are performed using generally known techniques. In general, isolation of nucleic acids from micro-organisms requires as one of the first steps the lysis of said micro-organism. It will be apparent that the cell lysis strategies employed are dependent of the nature of the contaminating micro- \n\n organisms. In general, a treatment with a lysozyme, a pectinolytic, or a mechanical treatment such as sonication or a bead beater can be used for lysing the cells. A customary procedure is the direct injection of bacterial samples into a hot phenol solution, such as described by Selinger et al. (2000, Nature Biotechnol. 18, 1262-1268), which is incorporated herein by reference. Alternatively, cells can be quickly frozen in liquid nitrogen and mechanically broken before isolation with an acid phenol solution. Classical methods for isolating nucleic acids relating to combinations of enzymatic degradation, organic extraction and alcohol and/or salt precipitation are well known in the art, and contemplated by the present invention. In this regard, the techniques for isolating ribonucleic acids as described in Current Protocols in Molecular Biology, Wiley & Co, USA are especially incorporated herein by reference. The present invention also relates to rapid small scale purification of DNA and RNA from clinical samples. The latter method may be based on the lysing and nuclease inactivating properties of the chaotropic agent guanidinum thiocyanate (GuSCN) and the nucleic acid-binding properties of silica particles or diatoms in the presence of this agent, such as described by Boom et al. (1999; J. Clin. Microbiol. 37: 615-619). For the isolation of RNA typical techniques known in the art can be used. Most microbial mRNA species only have a half-life of minutes, mainly due to the activity of RNases. Therefore, the speed required to stabilize the RNA population, i.e. to arrest or decrease RNA degradation, becomes crucial and therefore the use of various inhibitors of ribonuclease activity, such as, for example, diethylpyrocarbonate, aurintricarboxylic acid, etc, may be employed in RNA isolation procedures, and belong to the common, general knowledge regarding isolation of RNA, and are incorporated herein. The lysis of said contaminating micro-organism may be performed before or after stabilising the nucleic acid population. The present invention relates also to a stop solution containing ethanol and phenol, as has been described for the isolation of total RNA from E.coli (Ye et al., 2001 , J.Microbiol. Methods 47, 257-272). This stop solution may be used successfully for other Gram negative bacteria. In addition, the present invention contemplates the use of the RNAIater® solution (Ambion and Qiagen). The main advantage of the latter solution is its rapid stabilisation of the mRNA population, allowing the samples to be stored for a long period of time under appropriate conditions prior to RNA isolation. It is especially useful for the collection of samples when immediate isolation of RNA is not possible. Accordingly, the present invention relates to a method as described herein, wherein said step of extracting nucleic acids from said micro-organisms comprises lysing the microorganisms, and optionally further inactivating RNAses.\n\n\nAs most of the mRNAs of bacteria do not have a poly A+ tail and are therefore difficult to separate from the total RNA, an enrichment step may be used. The present invention relates \n\n to an enrichment step for mRNA, by removing the ribosomal RNA as known in the art, e.g., as described by Affymetrix (http: // www.affymetrix.com/index.affx). In addition, the present invention incorporates a method to isolate E.coli mRNA by polyadenylating it in crude cell extracts with poly A+ polymerase I from E.coli and purifying it by oligo-dT chromatography as described by Wendisch et al. (2001 Anal. Biochem. 290: 205-213), incorporated herein by reference.\n\n\nA variety of RNA isolation kits are available from different commercial sources, e.g. from Ambion, Qiagen, Sigma-Aldrich and others, which may successfully be used in the method of the present invention. As described above for isolating RNA, in isolating DNA the method to lyse the microorganism depends on the type of micro-organism, e.g. moulds, fungi, yeast, Gram negative or Gram positive bacteria. In this regard, the techniques for isolating DNA as described in Current Protocols in Molecular Biology, Wiley & Co, USA are especially incorporated herein by reference. Accordingly, the present invention relates to a method as described herein, wherein said lysing is chosen from the group consisting of a treatment with a lysozyme, a pectinolytic, or guanidinium thiocyanate or by a mechanical treatment such as sonication or the use of a bead beater, by injecting the micro-organisms in hot phenol, and snap freezing the micro-organisms in liquid nitrogen followed by a mechanical treatment. A convenient method for isolating RNA from Gram negative organisms is to resuspend the cells in water and boil the water for at least one minute. Optionally EDTA and/or a detergent can be added to the water.\n\n\nA variety of genomic DNA isolation kits are available from different commercial sources, e.g. from Gentra, Promega, Qiagen and others, which may successfully be used in the methods of the present invention. A convenient way to estimate the concentration of the isolated nucleic acid is by spectrophotometry at 260 nm, which is well known in the art.\n\n\nAfter nucleic acids have been isolated from the contaminating micro-organisms, said nucleic acids need to be detected and possibly analysed. In general, only minute amounts of contaminating micro-organisms are present. Therefore, the isolated nucleic acids or a specific portion thereof, i.e. the target nucleic acid, may be amplified. In case of the target nucleic acid being RNA, said RNA may first be converted to cDNA before analysis. It will be understood that the terms \"amplified nucleic acids\" and \"amplified nucleic acid mixture\" as used throughout the invention have essentially the same meaning. \n\n Therefore, the present invention relates to a method as described herein, wherein said nucleic acid is rRNA, tRNA, mRNA, siRNA, total RNA, or tmRNA and wherein said rRNA, tRNA, mRNA, siRNA, total RNA, or tmRNA is converted to cDNA, e.g. by the activity of a reverse transcriptase, as is well known in the art. Various techniques are known by the person skilled in the art to amplify DNA and/or cDNA. All of these techniques are contemplated by the present invention. Accordingly, the present invention relates to a method as described herein, wherein said nucleic acid is DNA and/or cDNA, and wherein said DNA and/or cDNA is amplified using an amplification technique such as bDNA, Hybrid capture, SDA, TMA, PCR, LCR, TAS, 3SR, NASBA and Qβ amplification, as explained in Versalovic and Lupski (2002, Trends Microbiology 10: S15- S21 ), which is incorporated herein by reference.\n\n\nThe present invention especially contemplates multiplex amplification, such as multiplex PCR. Multiplex amplification, such as multiplex PCR, allows amplification, and thus analysis of two or more targets simultaneously. This amplification technique is used for genetic screening, micro satellite analysis, and other applications where it is necessary to amplify several products in a single reaction. By routine experimentation the person skilled in the art will be able to optimize the reaction conditions, in view of having multiple primer pairs in a single reaction, which may increase the likelihood of primer-dimers and other nonspecific products that may interfere with the amplification of specific products. In addition, the concentrations of individual primer pairs often need to be optimized since different multiplex amplicons are often amplified with differing efficiencies, and multiple primer pairs can compete with each other in the reaction. The person skilled in the art will make similar considerations and optimize the conditions for the other amplification techniques described above for multiplex amplifications, i.e. amplification of more than one target. In addition, the present invention relates to the direct amplification of RNA, such as, for example, via a modified Tyras method, wherein a primer/probe comprising a RNA polymerase recognition site and recognition site complementary to the target nucleic acid is used.\n\n\nAfter isolating the target nucleic acid, probes and/or primers are hybridised to the said target nucleic acid. The primers may be used to amplify the said target nucleic acid. Alternatively, the probes may be ligated and may be amplified with primers specifically recognising regions on said probes. The probes and/or primers may be labelled. Also, the label may be incorporated during the amplification step or attached after amplification. Accordingly, the present invention relates to a method as described herein, wherein the amplified nucleic acid \n\n is labelled. Virtually any label that produces a detectable and/or quantifiable signal and that is capable of being attached to or incorporated into the amplified nucleic acid, can be used in conjunction with the methods and arrays of the invention. Suitable labels include, by way of example and not limitation, radioisotopes, fluorophores, chromophores, chemiluminescent moieties, etc. In embodiments where the label is attached to the amplified nucleic acid, the label can be attached to any part of the nucleic acid, including the free terminus or one or more of the bases. Preferably, the position of the label will not interfere with hybridisation, detection and/or other post-hybridisation modifications of the labelled nucleic acid. A variety of different protocols may be used to generate the labelled nucleic acids, as is known in the art, where such methods typically rely on the enzymatic generation of labelled nucleic acid using an initial primer and template nucleic acid. Labelled primers can be employed to generate the labelled amplified nucleic acid. Alternatively, label can be incorporated into the nucleic acid during first strand synthesis or subsequent synthesis, labelling or amplification steps in order to produce labelled amplified nucleic acid. Label can also be incorporated directly to mRNA using chemical modification of RNA with reactive label derivatives or enzymatic modification using labelled substrates. Representative methods of producing labelled amplified nucleic acid are disclosed in U. S. Application Serial nos.: 08/859,998; 08/974,298; 09/225,998; the disclosures of which are incorporated herein by reference.\n\n\nThe amplified nucleic acids may be labelled, for example, by the labels and techniques described supra. Alternatively, they may be labelled by any other technique known in the art. Preferred techniques include direct chemical labelling methods and enzymatic labelling methods, such as kinasing and nick-translation. Accordingly, the present invention relates to methods as described herein, wherein the amplified target nucleic acid is labelled. Preferably, the nucleic acid is labelled during amplification, or the amplified target nucleic acid is labelled after amplification. As such, the present invention relates to methods as described herein, wherein primer I and/or primer Il are labelled. Labelling during amplification provides faster analysis times as it provides the opportunity to eliminate a process step where the amplified targets are labeled.\n\n\nA variety of different labels may be employed, where such labels include fluorescent labels, phosphorescent labels, isotopic labels, enzymatic labels, particulate labels, etc. For example, suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, such as rhodamine 123, R6G, IRDyes™, Texas Red, phycoerythrin, allophycocyanin, 6- carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxy-fluorescein (JOE), 6- carboxy-X-rhodamine (ROX), TET, JOE, NED, (ET-)ROX, 6-carboxy-2',4',7',4,7-hexachloro- fluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxy- \n\n rhodamine (TAMRA), fluor 488 , cyanine dyes, e.g. Cy5, Cy3, Cy2, BODIPY dyes, e.g. Biodipy™ 630/650, Biodipy 530, Biodipy™ FL, Alexa such as Alexa542, Alexafluor™ 532, etc. Suitable isotopic labels include radioactive labels, e.g. \n32\nP, \n33\nP, \n35\nS, \n3\nH. Other suitable labels include size particles that possess light scattering, fluorescent properties or contain entrapped multiple fluorophores. The label may be a two stage system, where the primer and/or probe is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc. The binding partner is conjugated to a detectable label, e.g. an enzymatic label capable of converting a substrate to a chromogenic product, a fluorescent label, an isotopic label, etc. In certain embodiments, the primers directed to different target nucleic acids may be differentially labelled. By \"differentially labelled\" and \"contain a different label\" is meant that the primers directed to different target nucleic acids are labelled differently from each other such that they can be simultaneously distinguished from each other. Hence, primer I may contain a label different from primer II. For instance, primer I or primer Il binding to a first pair of probes, may contain a different label from primer I or primer Il binding to a second pair of probes.\n\n\nAn embodiment of the invention relates to the combination of (1 ) multiplex Ligase Detection Reaction (LDR) and (2) multiplex Polymerase Chain Reaction (PCR). The Ligase Detection Reaction (LDR) is a sensitive assay for detecting Single Nucleotide Polymorphisms (SNPs), as described by Favis et al., (2000, Nature Biotechnology 18: 561-564), incorporated herein by reference. A difference in a single nucleotide along the 16S rRNA may be employed to distinguish between sequences of different micro-organisms, as described by Busti et al. (2002, BMC Microbiology 2: 27-39), which is incorporated herein by reference. Similarly, single nucleotide differences along the 18S, 23S or 28S rRNA may be employed to distinguish between sequences of different micro-organisms. Similarly, any nucleotide difference between two organisms in any type of DNA or RNA, such as chromosomal DNA, rDNA, plasmid DNA, mitochondrial DNA or any other organel DNA, rRNA, mRNA, tRNA or any other RNA molecule such as described infra, may be employed to distinguish between micro-organisms. A set of two probes (probe I and II) may be designed, based on the target sequence to be detected, of which at least a part is known. Both probes contain a region at the end (the 3' and the 5' end of the respective probes I and II) that is capable of hybridizing to the known section of the target sequence. In other words, one probe (probe I) comprises a region Ir or tss(l) (specifically hybridising to a target region, said region Ir or tss(l) being located at the ultimate 3' end of probe I. Said probe I further comprising a primer binding section (PBS(I)), located 5' from the region Ir. Said probe I and/or Il may contain a stuffer \n\n region and/or a ZipDectCode (ZDc or DET) also referred to herein as detector region (DET). For instance, said stuffer region and/or a DET on probe I may be located between region Ir or tss(l) and PBS(I).\n\n\nThe detector region (DET) comprises a unique sequence which can be used for identification of amplified products. The DET will hybridize to its complementary oligonucleotide detector probe (e.g. cDET) present during the amplification reaction. It should be noted that for all structures of ligated probes provided by the methods according to the invention, the ZDc (or\n\n\nDET) can be substituted by a complementary ZDc (cZDc or cDET) since upon amplification a double stranded nucleic acid will be formed from which at least one strand will comprise a ZDc (or DET) detectable by the oligonucleotide detector probe. DET and cDET refer to DNA segments used for real time detection during amplification, where cDET has the complementary sequence of DET.\n\n\nThe probe Il comprises a region Nr or tss(ll) specifically hybridising to a target region, said region Nr or tss(ll) being located at the ultimate 5' end of probe II. Said probe Il further comprising a primer binding section (PBS(II)), located 3' from the region Nr. Probe I or Probe Il may further comprise an identifier region, such as a Zipcode (Zc or ZIP) or ZipComcode (ZCc or cZIP), located in-between the region Ir or tss(l) and PBS(I) or the region Nr or tss(ll) and PBS(II), respectively. ZIP and cZIP refer to the DNA segments used for microarray detection, where cZIP has the complementary sequence of ZIP. The ZCc (or cZIP) or its complement the Zc (or ZIP) is a unique sequence for identification of the eventually amplified products. The ZCc (or cZIP) will hybridize to its complement the Zc (or ZIP). The complement of the amplified product is present on for instance a microchip (capture probe; see below). Upon hybridisation, the target region Ir of probe I (tss(l)) is located adjacent to the target region Nr of probe Il (tss(ll)). The ZCc (or cZIP) or Zc (or ZIP) and the PBSs are located at the ends of the probes, and are not capable of hybridizing to the target sequence. When both probes are hybridized to the target sequence, and are located adjacent to each other, the probes can be ligated using a ligase, such as for example Pfu DNA ligase. After ligation, the ligated probes may be amplified using at least one primer that is capable of hybridizing to a primer binding section. Preferably, amplification is carried out by PCR, using probe I with a PBS(I) which differ from probe Il with PBS(II). Hence, primer I binding to the region characterized by PBS(I) will differ from primer Il binding to the region characterized by PBS(II). It will be appreciated that if primer I comprises a sequence substantially complementary to PBS(I), then primer Il comprises a sequence substantially identical to PBS(II), and vice versa, that if primer I comprises a sequence substantially identical to PBS(I), then primer Il comprises a sequence substantially complementary to PBS(II). \n\n In a further embodiment, Probe I or Probe Il may comprise a Zipcode. Since it is the object of the present invention that upon ligation of Probe I and Probe II, the ligated probe is amplified, it can be understood that the amplified ligated probe should contain a ZipComcode for it to hybridise with the Zipcode, present on for instance a microchip. Therefore providing Probe I or Probe Il with a Zipcode would also result in an amplified ligated probe comprising a ZipComcode.\n\n\nOne of the primers may be labelled, for example at its 5' end. Either the first primer or second primer may be labelled at its 5' end. Alternatively, both primers may be labelled with the same or different labels. In a multiplex, the method may operate using one common primer, e.g. hybridising to PBS(I), and one probe specific primer, e.g. hybridising to PBS(II). It will be appreciated that the common primer may hybridise to PBS(II), while the probe specific primer hybridises to PBS(I). In a further embodiment, probe I contains a label.\n\n\nHence, in the method according to the present invention said nucleic acid and/or cDNA may be amplified using the Ligase Detection Reaction, comprising a first nucleic acid probe complementary to a distinct part of said target nucleic acid and a second nucleic acid probe complementary to a second part of said target nucleic acid located essentially adjacent to said distinct part of said target nucleic acid, wherein said first nucleic acid probe further comprises a 5' located primer binding section and possibly a stuffer, and said first or said second nucleic acid probe comprises a 3' located ZipComcode tag which is essentially non- complementary to said target nucleic acid and a primer binding section, which in case of said second nucleic acid probe is located 3' from the ZipComcode. The method further comprising incubating said nucleic acid and/or cDNA allowing hybridisation of complementary nucleic acids, connecting any essentially adjacent probes (by ligating), and amplifying any connected probe nucleic acid, wherein amplification is initiated by binding of nucleic acid primers specific for primer binding sections.\n\n\nThus, the present invention relates to a method as described herein, wherein said connecting step comprises the use or activity of a ligase, such as T4 DNA ligase, T4 RNA ligase, E.coli DNA ligase, or a thermostable ligase such as Taq DNA ligase, Pfu DNA ligase, Tth DNA ligase or Ampligase™. Conditions under which a ligation reaction may occur are well known in the art.\n\n\nA typical structure of ligated probes is the following:\n\n\nI: 5'-PBS(I) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - ZCc (or cZIP) - [stuffer] - PBS(ll)-3', \n\n II: 5'-PBS(I) - [stuffer] - ZCc (or cZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3\\ III: 5'-PBS(I) - [stuffer] - ZCc (or cZIP) - [stuffer] - ZDc (or DET) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3', IV: 5'-PBS(I) - [stuffer] - ZDc (or DET) - [stuffer] - ZCc (or cZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3', V: 5'-PBS(I) - [stuffer] - ZCc (or cZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - ZDc (or DET) - [stuffer] - PBS(ll)-3\\\n\n\nVl: 5'-PBS(I) - [stuffer] - ZDc (or DET) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - ZCc (or cZIP) - [stuffer] - PBS(ll)-3\\\n\n\nVII: 5'-PBS(I) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer]\n\n\n- ZDc (or DET) - [stuffer] - ZCc (or cZIP) - [stuffer] - PBS(ll)-3\\ or\n\n\nVIII: 5'-PBS(I) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer]\n\n\n- ZCc (or cZIP) - [stuffer] - ZDc (or DET) - [stuffer] - PBS(ll)-3'. (the regions between square brackets are optional)\n\n\nIn the case that labelled primer I comprises a sequence substantially identical to PBS(I) and non-labelled primer Il comprises a sequence substantially complementary to PBS(II), the typical structures of the ligated probe after amplification are:\n\n\nI: 5'- Label - PBS(I) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - ZCc (or cZIP) - [stuffer] - PBS(ll)-3\\\n\n\nII: 5'- Label - PBS(I) - [stuffer] - ZCc (or cZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3', III: 5'- Label - PBS(I) - [stuffer] - ZCc (or cZIP) - [stuffer] - ZDc (or DET) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3', IV: 5'- Label - PBS(I) - [stuffer] - ZDc (or DET) - [stuffer] - ZCc (or cZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3', V: 5'- Label - PBS(I) - [stuffer] - ZCc (or cZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - ZDc (or DET) - [stuffer] - PBS(ll)-3\\ Vl: 5'- Label - PBS(I) - [stuffer] - ZDc (or DET) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - ZCc (or cZIP) - [stuffer] - PBS(ll)-3\\\n\n\nVII: 5'- Label - PBS(I) - [stuffer] - target specific sequence I — target specific sequence Il -\n\n\n[stuffer] - ZDc (or DET) - [stuffer] - ZCc (or cZIP) - [stuffer] - PBS(ll)-3\\ or VIII: 5'- Label - PBS(I) - [stuffer] - target specific sequence I — target specific sequence Il -\n\n\n[stuffer] - ZCc (or cZIP) - [stuffer] - ZDc (or DET) - [stuffer] - PBS(ll)-3'. (the regions between square brackets are optional) \n\n In yet another embodiment, non-labelled primer I comprises a sequence substantially identical to PBS(I) and labelled primer Il comprises a sequence substantially complementary to PBS(II). The typical structure of ligated probes is the following:\n\n\nI: 5'-PBS(I) - [stuffer] - Zc (or ZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3\\\n\n\nII: 5'-PBS(I) - [stuffer] - Zc (or ZIP) - [stuffer] - ZDc (or DET) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3', III: 5'-PBS(I) - [stuffer] - ZDc (or DET) - [stuffer] - Zc (or ZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - PBS(ll)-3', or IV: 5'-PBS(I) - [stuffer] - Zc (or ZIP) - [stuffer] - target specific sequence I — target specific sequence Il - [stuffer] - ZDc (or DET) - [stuffer] - PBS(I I )-3'. (the regions between square brackets are optional)\n\n\nAnd the typical structures of the ligated probe after amplification are:\n\n\nI: 5'-Label-cPBS(ll) - [stuffer] - complementary target specific sequence Il (ctss II) — complementary target specific sequence I (ctss I) - [stuffer] - ZCc (or cZIP) - cPBS(l) -\n\n\n3', II: 5'-Label-cPBS(ll) - [stuffer] - ctss Il — ctss I - [stuffer] - cZDc (or cDET) - [stuffer]- ZCc\n\n\n(or cZIP) - [stuffer] - CPBS(I ) -3',\n\n\nIII: 5'-Label-cPBS(ll) - [stuffer] - ctss Il — ctss I - [stuffer] - ZCc (or cZIP) - [stuffer] - cZDc (or cDET) - [stuffer] - cPBS(l) -3',\n\n\nIV: 5'-Label-cPBS(ll) - [stuffer] - cZDc (or cDET) - [stuffer] - ctss Il — ctss I - [stuffer] -\n\n\nZCc (or cZIP) - [stuffer] - cPBS(l) -3'.\n\n\nIt should be noted that in case a labelled primer Il comprising a sequence substantially complementary to PBS(II) is used, the first and second nucleic acid probes should provide Zipcodes instead of ZipComcodes and preferably the Zipcode is positioned on the first nucleic acid probe. By providing the Zipcode on the first nucleic acid probe the labelled strand of the amplified ligated probe will contain a ZipComcode.\n\n\nIn a preferred embodiment of the present invention, the ZDc (or DET) is provided on the non- labelled strand of the amplified ligated probe. In a further embodiment, said first nucleic acid probe is coupled with its 5' end to the 3' end of said second nucleic acid probe, possibly via a stuffer region (Figure 2).\n\n\nIt should be noted that in the instance that either a labelled primer I or a labelled primer Il is used during the amplification of the ligated probe, a double stranded amplified ligated probe will be formed wherein one of the strands will be labelled, while the other strand will not be \n\n labelled. The present invention provides that the labelled strand of the amplified ligated probe comprises a ZipComcode, enabling this strand to hybridise with the Zipcode, present on for instance a microchip. Either the labelled or the non-labelled strand of the amplified ligated probe comprises a ZipDectcode, enabling this strand to be detected by the complementary oligonucleotide detector probe. By providing the ZCc (or cZIP) and the ZDc (or DET) on respectively the labelled and the non-labelled strand of the amplified ligated probe, the detection of both occurs separately from each other without any hindrance between both detection strategies. In first instance the detection of the ZDc (or DET) will provide information regarding the presence or absence of the amplified ligated probe and consequently the presence or absence of a contaminating micro-organism, whereas the samples that provide a positive detection signal of the ZDc (or DET) will subsequently be hybridized in the second screening step where the labelled strand of the amplified ligated probe containing the ZCc (or cZIP) will be detected.\n\n\nIn a preferred embodiment, primer I is labelled if the ZipComcode is located on the first or the second nucleic acid probe.\n\n\nIn an embodiment, the present invention relates to a method as described herein, wherein (see Figure 5):\n\n\n(a) said first nucleic acid probe comprises from 5' to 3': a Primer Binding Sequence I (PBS(I)), ZipComcode (ZCc or cZIP), and a target specific sequence I (tss(l)), said second nucleic acid probe comprises from 5' to 3': a target specific sequence Il (tss(ll)),\n\n\nZipDectCode (ZDc or DET) and a Primer Binding Sequence Il (PBS(II)), and preferably primer I is labelled;\n\n\n(b) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZDc (or DET), and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), ZCc (or cZIP) and PBS(II), and preferably primer I is labelled;\n\n\n(c) said first nucleic acid probe comprises from 5' to 3': a PBS(I), complementary ZDc (cZDc or cDET) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), ZCc (or cZIP) and PBS(II), and preferably primer I is labelled;\n\n\n(d) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZCc (or cZIP), ZDc (or DET) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and\n\n\nPBS(II), and preferably primer I is labelled;\n\n\n(e) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZCc (or cZIP), cZDc (or cDET), and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer I is labelled; \n\n (f) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZDc (or DET), ZCc (or cZIP) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer I is labelled;\n\n\n(g) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cZDc (or cDET), ZCc (or cZIP) and tss(l), and said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer I is labelled; (h) said first nucleic acid probe comprises from 5' to 3': a PBS(I) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), ZDc (or DET), ZCc (or cZIP) and\n\n\nPBS(II), and preferably primer I is labelled; (i) said first nucleic acid probe comprises from 5' to 3': a PBS(I) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll), ZCc (or cZIP), ZDc (or DET) and\n\n\nPBS(II), and preferably primer I is labelled; (j) said first nucleic acid probe comprises from 5' to 3': a PBS(I), Zc (or ZIP) and tss(l), and said second nucleic acid probe comprises from 5' to 3': a tss(ll), ZDc (or DET) and PBS(II), and preferably primer Il is labelled;\n\n\n(k) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZCc (or cZIP), ZDc (or\n\n\nDET) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and\n\n\nPBS(II), and preferably primer Il is labelled,\n\n\n(I) said first nucleic acid probe comprises from 5' to 3': a PBS(I), Zc (or ZIP), cZDc (or cDET) and tss(l), and said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer Il is labelled; (m) said first nucleic acid probe comprises from 5' to 3': a PBS(I), ZDc (or DET), Zc (or ZIP) and tss(l), said second nucleic acid probe comprises from 5' to 3': a tss(ll) and PBS(II), and preferably primer Il is labelled; and/or, (n) said first nucleic acid probe comprises from 5' to 3': a PBS(I), cZDc (or cDET), Zc (or\n\n\nZIP) and tss(l), and said second nucleic acid probe comprises: a tss(ll) and PBS(II), and preferably primer Il is labelled.\n\n\nEco and Mse refer to the primer binding regions 1 and 2, cEco and cMse to their respective complementary sequences. ZIP and cZIP refer to the DNA segments used for microarray detection, where cZIP has the complementary sequence of ZIP. DET and cDET refer to DNA segments used for real time detection during amplification, where cDET has the complementary sequence of DET. cSeq-1 and cSeq-2 refer to DNA segments complementary to the target DNA.\n\n\nIn this regard, the person skilled in the art will appreciate that equivalent terms are used interchangeably in the present description, such as, \n\n cSeq-1 and cSeq-2 relate to target-specific sequence I and target-specific sequence II, respectively.\n\n\nEco and cMse relate to primer binding section I and primer binding section II, respectively. In a double-stranded PCR product, one strand will always have the sense sequence (Eco or Mse) of one primer, and the antisense or complementary sequence\n\n\n(cEco or cMse) of the other primer. So either Eco and cMse or cEco and Mse. cZIP relates to ZipComcode, while ZIP relates to Zipcode DET relates to ZipDectCode, while cDET relates to complementary ZipDectCode.\n\n\nAlso, the present invention relates to a method as described herein, wherein said probe I and/or probe Il comprises a stuffer region. In this regard, a stuffer region is intended to part structural regions, such as the PBS, the ZCc (or cZIP), the Ir (tss(l))or Nr (tss(ll)), thereby avoiding or minimizing steric hindrance.\n\n\nAs already set out above, it will be appreciated that the label may be attached to at least one of the primers and/or probes, or in the alternative, may be incorporated during amplification. The label is for instance a fluorescent label. Accordingly, the present invention relates to a method as described herein, wherein at least one primer contains a label, and preferably a fluorescent label. This provides a cost efficient detection method.\n\n\nIt will be appreciated that RNA-DNA hybrids can act as substrates for T4 DNA ligase, as described by Charani Ranasinghe and Andrew A. Hobbs Affiliations in Elsevier Trends Journals Technical Tips Online, [Tip]01519 \"A simple method to obtain the 5\n'\n ends of mRNA sequences by direct ligation of cDNA-RNA hybrids to a plasmid vector\", which is incorporated herein by reference.\n\n\nIn the alternative, a probe or primer contains an RNA polymerase binding site. The ligated probes are subsequently amplified by the activity of an RNA polymerase, e.g. T4-, 17- or SP6 RNA polymerase.\n\n\nThe present invention especially contemplates that during the amplification procedure one or more detector molecules are present. The presence of detector molecules during the amplification enables the detection of the accumulation of amplified target nucleic acids and therefore this step provides a first screening of the samples. Since a large amount of the samples are presumed to be negative, the first fast and cheap screening step assesses whether or not contaminating micro-organisms are present or absent in the sample. Therefore, the more complicated, time consuming and more expensive second screening step can be avoided when no micro-organisms are present. \n\n The amplification of the target nucleic acids can be detected and/or quantified using the fluorescence or phosphorescence of a dye, which fluorescence or phosphorescence is associated either directly or indirectly with the multiplication of the amplified DNA. Since the amplification of the target nucleic acids is detected using detector molecules which can either be dyes intercalating double-stranded DNA or oligonucleotide detector probes complementary to the target nucleic acids, a person skilled in the art would expect these detector molecules to disrupt the hybridization reaction of the second screening step if these detector molecules are present during the hybridization. Since the hybridization of DNA is a very delicate process influenced by a large variety of environmental factors, the presence of these detector molecules during the hybridization reaction should be avoided. Removing these detector molecules prior to the second screening step is an elaborate process. However, the inventors have surprisingly found that the presence of these detector molecules during the second screening step does not disrupt the results obtained during this screening nor do they increase the number of false positive or false negative results. A direct detection method can for instance use a dye which binds nonspecifically to double- stranded DNA and only fluoresces or phosphoresces in connection with this binding. When the target nucleic acids are amplified, said dye binds to the newly formed double-stranded DNA such that the measurable fluorescence or phosphorescence increases. Examples of such dyes include, but are not limited to, SYBR Green-I®, ethidium bromide, propidium iodide, TOTO®-1{Quinolinium,1-1 '-[1 ,3-propanediylbis[(dimethyliminio)-3,1-propanediyl]]bis [4-[(3-methyl-2(3H)-benzothiazolylidene) methyl]]-,tetraiodide}, and YoPro® {Quinolinium,4- [(3-methyl-2(3H)-benzoxazolylidene) methyl]-1 -[3-(trimethylammonio)propyl]-,diiodide}. Most preferred dye for the instant invention is a non-asymmetrical cyanide dye such as SYBR Green-I®, manufactured by Molecular Probes, Inc. (Eugene, Oreg.). Another direct detection method that can be used in the method of the present invention is a method using oligonucleotide detector probes. Oligonucleotide detector probes are short oligonucleotides complementary to the target nucleic acids. These oligonucleotide detector probes provide a fluorescent signal upon binding with the amplified target nucleic acids. The method by which the fluorescent or phosphorescent signal is provided by the oligonucleotide detector probes can be any method known in the art.\n\n\nIn a specific embodiment of the present invention, the oligonucleotide detector probes are provided with the fluorescence resonance energy transfer (FRET) technique. The FRET oligonucleotide detector probe comprises of two fluorescent dyes, i.e. a \"reporter\" at one, for instance 5', end, and a \"quencher\" at the other, for instance 3', end, of the FRET \n\n oligonucleotide detector probe. In the FRET oligonucleotide detector probes, the dyes are held, in the unbound state, in spatial proximity by means of a loop arrangement (hairpin loop). The hairpin loop is generated by means of complementary sequences which are present at the ends of the actual probe sequence. Because of its proximity to the reporter, the quencher dye is able to quench its fluorescence by means of the FRET. Upon binding with the amplified target nucleic acids, the FRET oligonucleotide detector probe which is complementary to the target nucleic acid sequence disrupts the hairpin loop and thereby separates the two dyes, resulting in the FRET interference being abolished and the fluorescence of the reporter dye becoming measurable. In another specific embodiment of the present invention a FRET oligonucleotide detector probe is provided which, in contrast to the abovementioned probes, does not possess any hairpin loop. During the amplification step, the exonuclease activity of the polymerase enzyme which is replicating the target nucleic acids, degrades the FRET probe, which is bound to the target nucleic acid, at its 5' end such that the reporter dye is released from the probe. As a result, the reporter dye is no longer in the spatial vicinity of the quencher dye which means that its fluorescence is no longer quenched and can now be measured. The amplification of the target DNA, and, as a result, the increase in the release of the reporter dye, can then be detected using a suitable optical measuring system.\n\n\nMolecules that are frequently used as tags for FRET include fluorescein, 5- carboxyfluorescein (FAM), 2'7-dimethoxy-4'57-dichloro-6-carboxyfluorescein (JOE), rhodamine, 6-carboxyrhodamine (R6G), N,N,N7,N'-tetramethyl-6-carboxyrhodamine\n\n\n(TAMRA), 6-carboxy-X-rhodamine (ROX), 4-(4'-dimethylaminophenylazo)benzoic acid\n\n\n(DABCYL,), and 5-(2'-aminoethyl)aminonaphthalene-1 -sulfonic acid (EDANS). Other potential FRET donor or acceptor molecules are known in the art (See U.S. Pat. No. 5,866,336, Table 1 ). The skilled artisan will be familiar with the selection of pairs of tag molecules for FRET (U.S. Pat. No. 5,866,336).\n\n\nDifferent oligonucleotide detector probes may be used for carrying out the method of the present invention including, but not limited to a 5' nuclease assay in which the oligonucleotide detector probe carries a fluorogenic reporter dye at its 5' end and a quencher at its 3' end, Scorpion primers in which a primer is covalently linked to the probe, the primer probe complex comprising a fluorophore and a quencher molecule each linked to either the primer or the probe, and Molecular Beacons which are hairpin shaped molecules with an internally quenched fluorophore. \n\n In a 5' nuclease assay the oligonucleotide detector probe such as for instance a Taqman probe carries a fluorogenic reporter dye at its 5' end and a quencher at its 3' end. When the probe is intact, the reporter dye emission is quenched. During each cycle of PCR, the DNA polymerase cleaves the reporter dye from the probe. Once separated from the quencher, the reporter dye emits its characteristic fluorescence. Figure 6a provides as schematic representation of the real time amplification reaction using TaqMan probes for real time detection. Eco and Mse refer to the primer binding regions 1 and 2, cEco and cMse to their respective complementary sequences. ZIP and cZIP refer to the DNA segments used for microarray detection, where cZIP has the complementary sequence of ZIP. DET and cDET refer to DNA segments used for real time detection during amplification, where cDET has the complementary sequence of DET. cSeq-1 and cSeq-2 refer to DNA segments complementary to the target DNA. \"1. Annealing\" displays the probe pairs hybridized to the target DNA; \"2. Ligation\" displays the connected probe pairs as a result of the ligation reaction; \"3. Cycle 1\" displays the double-stranded structure that results from copying of the connected probe pairs through extension of the Mse primer by the DNA polymerase; \"4. Cycle n\" displays the Eco-primer and TaqMan probe hybridized to one of the strands of the PCR product. A fluorescent signal is generated when the DNA polymerase extends into the TaqMan probe and releases the fluorescent label from the TaqMan probe.\n\n\nScorpion primers comprise a primer that is linked to the oligonucleotide detector probe. This probe both carries a fluorophore and a quencher, which may be on the same DNA strand or on a complementary DNA strand. In the absence of the target sequence, the quencher nearly absorbs the fluorescence emitted by the fluorophore. During the PCR reaction, in the presence of the target, the fluorophore and the quencher separate which leads to an increase in the fluorescence emitted. The fluorescence can be detected and measured in the reaction tube. Figure 6b provides a schematic representation of the real time amplification reaction using Scorpion probes for real time detection. Eco and Mse refer to the primer binding regions 1 and 2, cEco and cMse to their respective complementary sequences. ZIP and cZIP refer to the DNA segments used for microarray detection, where cZIP has the complementary sequence of ZIP. DET and cDET refer to DNA segments used for real time detection during amplification, where cDET has the complementary sequence of DET. cSeq- 1 and cSeq-2 refer to DNA segments complementary to the target DNA. \"1. Annealing\" displays the probe pairs hybridized to the target DNA; \"2. Ligation\" displays the connected probe pairs as a result of the ligation reaction; \"3. Cycle 1\" displays the double-stranded structure that results from copying of the connected probe pairs through extension of the Mse primer by the DNA polymerase; \"4. Cycle 2\" displays the double-stranded extension product \n\n from the Scorpion primer. After denaturation one of the strands refolds (Scorpion reaction) to generate the Scorpion structure emitting the fluorescent signal.\n\n\nMolecular beacons refers to a method where the oligonucleotide hybridization probes are hairpin shaped molecules with an internally quenched fluorophore. Upon presence of the target sequence the hairpin is removed and the fluorophore is no longer quenched. Figure 6c provides a schematic representation of the real time amplification reaction using Molecular Beacons for real time detection. Eco and Mse refer to the primer binding regions 1 and 2, cEco and cMse to their respective complementary sequences. ZIP and cZIP refer to the DNA segments used for microarray detection, where cZIP has the complementary sequence of ZIP. DET and cDET refer to DNA segments used for real time detection during amplification, where cDET has the complementary sequence of DET. cSeq-1 and cSeq-2 refer to DNA segments complementary to the target DNA. \"1. Annealing\" displays the probe pairs hybridized to the target DNA; \"2. Ligation\" displays the connected probe pairs as a result of the ligation reaction; \"3. Cycle 1\" displays the double-stranded structure that results from copying of the connected probe pairs through extension of the Mse primer by the DNA polymerase. Denaturation of the extension product of the Mse primer and subsequent reannealing with the Molecular Beacon changes the conformation of the Molecular Beacon separating the fluorophor from the quencher thereby emitting the fluorescent signal.\n\n\nBesides enabling the real time detection of the amplified target nucleic acids the use of FRET oligonucleotide detector probes also enables the quantification of the target nucleic acids.\n\n\nIt will be apparent that the present invention relates to a method as described herein, wherein a signal is detected after and/or during amplification of the target nucleic acids. The said signal is preferably a fluorescent or phosphorescent signal, and said fluorescent or phosphorescent signal may be detected by a CCD camera or by laser scanning. By providing detector molecules during the amplification procedure it is possible to perform in the first step of the method of the present invention a screening towards the presence of contaminating micro-organisms in the samples. Since the second step of the method of the invention, which involves the further characterization and identification of the contaminating micro-organisms by hybridizing the amplified target nucleic acids on a microarray, has a larger cost per test, a reduction of the samples to be analyzed in the second step of the method of the present invention would be highly beneficial.\n\n\nTherefore, the present invention provides a method wherein the amplified target nucleic acids hybridized in step (d) are the target sequences providing a positive signal in step (c) of the method of the present invention. \n\n In a specific embodiment of the present invention, said detector molecules are one or more oligonucleotide detector probes and more preferably FRET oligonucleotide detector probes, having a sequence at least partially complementary to a target nucleic acid sequence to be detected and including a fluorescent reporter molecule and a fluorescent quencher molecule capable of quenching the fluorescence of said reporter molecule, said oligonucleotide probe existing in at least one single-stranded, partially single-stranded or double-stranded conformation when unhybridized where said quencher molecule quenches the fluorescence of said reporter molecule, said oligonucleotide probe existing in at least one conformation when hybridized to said target nucleic acid where the fluorescence of said reporter molecule is unquenched.\n\n\nIn a more specific embodiment of the present invention, the sequence of said oligonucleotide detector probes is at least complementary to at least one region, e.g. ZCc (or cZIP) or Zc (or ZIP) of the first nucleic acid probe and/or at least one region, e.g. ZCc (or cZIP) or Zc (or ZIP), of the second nucleic acid probe. The present invention provides that at least two oligonucleotide detector probes are provided with different fluorescent reporter molecules thereby providing an assay where depending on the detected type of fluorescent reporter molecule or the detected amount of each fluorescent reporter molecule information is obtained regarding the type of micro-organism that is detected as well as the amount of each type of micro-organism. In a further embodiment of the present invention the first nucleic acid probe and/or the second nucleic acid probe further comprise at least one ZipDectCode (ZDc or DET), which is (i) essentially complementary (for instance after amplification) to one or more oligonucleotide detector probes used for detecting the accumulation of the reaction products during the amplification reaction of step (b5), (ii) essentially non-complementary to said target nucleic acid and (iii) which is located in between the target sequence and the primer binding section.\n\n\nSaid ZipDectCode (ZDc or DET) is a unique sequence for identification of the eventually amplified products. The ZDc (or DET) will hybridize to its complementary oligonucleotide detector probe present during the amplification reaction. Consequently, when oligonucleotide detector probes are used for the detection of the amplified target nucleic acids, said oligonucleotide detector probe would comprise a complementary ZipDectCode (cZDc or cDET), an oligonucleotide sequence complementary with the ZDc (DET).\n\n\nIn a specific embodiment of the present invention, the method is provided in such a way that the entire screening process is performed in a closed system. To avoid contamination and provide highly reliable results the method of the present invention should be performed in an \n\n automated manner and in a closed system thereby reducing the risks for contamination and user errors.\n\n\nGenetic markers represent (mark the location of) specific loci in the genome of a species or closely related species. A sampling of different genotypes at these marker loci reveals genetic variation. The genetic variation at marker loci can then be described and applied to diagnostics and the like. Genetic variation between species may be ascribed to single nucleotide substitutions in the DNA or the 16S, 18S, 23S and/or 28S rRNA. The target binding region of the probes may be adapted correspondingly. For example, a set of four probes I may be provided, each of which comprising a different 3' ultimate nucleotide, e.g. probe I-A, probe I-C, probe I-G and probe I-T, containing the nucleotide A, C, G and T respectively at its 3' end. It will then be advantageous if the PBS of each probe I, is specific and corresponds to said ultimate nucleotide. In other words, the PBS of each probe I hybridises to a different primer I. Hence, the present invention contemplates probe I-A with PBS(I-A), which hybridises to the corresponding primer I-A, probe I-C with PBS(I-C), which hybridises to the corresponding primer I-C, probe I-G with PBS(I-G), which hybridises to the corresponding primer I-G, and probe I-T with PBS(I-T), which hybridises to the corresponding primer I-T. Each of said primers I-A, I-C, I-G and I-T may comprise a different label. It will be appreciated by the person skilled in the art that variations on this theme are conceivable, e.g. where the genetic marker is located within the target region of the probes, or on the ultimate 5' end of probe II. In the case that the genetic marker is located in probe II, the PBS(II) may be adapted as described above for probe I. Furthermore, the PBS, i.e. PBS(I) and PBS(II) may be identical or different. Accordingly, the present invention relates to a method as described herein, wherein probe I, i.e. said first nucleic acid probe, and/or probe II, i.e. said second nucleic acid probe, specifically hybridises to a genetic marker. Also, the present invention relates to a method as described herein, wherein 4 variants of probe I, i.e. said first nucleic acid probe, are provided, said 4 variants being substantially identical, except that each of the 4 variants containing a different nucleotide at its ultimate 3' end. In addition, the present invention relates to a method as described herein, wherein each of said 4 variants containing a different primer binding section I. In a further embodiment, the present invention relates to a method as described herein, wherein at least two groups of pairs of first and second nucleic acid probes are provided, wherein each group of first and second nucleic acid probes hybridises to a specific target nucleic acid, and comprises a specific primer binding site I and/or II. In a preferred embodiment each group of first and second nucleic acid probes have identical primer binding site I and/or II. In a further aspect, the invention relates to a method as described herein, \n\n wherein at least two groups of pairs of first and second nucleic acid probes are provided, wherein each group of first and second nucleic acid probes hybridises to a specific target nucleic acid, and the first nucleic acid probe of each group comprises a specific identifier region, preferably a ZipComcode or Zipcode. As such, the identifier region, such as a ZCc (or cZIP) or Zc (or ZIP) may be located on the nucleic acid probe in between the target-specific sequence and the primer binding sequence. In a further aspect, the first nucleic acid probe is attached or coupled with its 5' end to the 3' end of said second nucleic acid probe, possibly via a stuffer region. It will be understood that a circular probe results after ligating target- specific sequence I to target-specific sequence II. Accordingly, the present invention relates to a method as described herein, wherein each of the primers binding to each of the different primer binding section I of said 4 variants contains a different fluorescent label.\n\n\nAccordingly, the present invention relates to a method as described herein, wherein a set of two adjacent probes is provided for the micro-organisms as defined supra. Also, these probes may be coupled.\n\n\nThe method described herein relates to the simultaneous detection of various contaminating micro-organisms, by providing at least one set, and preferably more than one set of two probes, specifically designed to identify and/or characterise the presence of a contaminating micro-organism (multiplex). The different sets of probes should preferably not cross- hybridise, while on the other hand the melting temperature Tm of the different sets of probe/primers is about similar, e.g. all between 60 and 70 \n0\nC. Commonly available computer programmes, such as Probe Match, Michigan State University, East Lansing, Michigan USA, Oligo 5.0 software (PE Biosystems, Foster City, California, USA), and using Clustal W Algorithm, may facilitate the design of specific probes. Preferably, the primers/probes have a melting temperature Tm between about 37-85 \n0\nC, or 50-80 \n0\nC, or 55-75 \n0\nC, or 60-70 \n0\nC. As such, the present invention relates also to multiplex amplification.\n\n\nIn another aspect, the present invention relates to a method as described herein, comprising providing at least one set of two primers, wherein the first primer (primer A) comprises a 5' located label and a region A specifically hybridising to a first target nucleic acid region, said region A being located at the ultimate 3' end of primer A, and wherein the second primer (primer B) comprises a 3' located ZipComcode and a region B specifically hybridising to a second target nucleic acid region, said region B being located at the ultimate 5' end of primer B; the first target nucleic acid region target region being located 3' adjacent to the second target nucleic acid region; incubating said target nucleic acid with said primer A and said \n\n primer B under conditions allowing hybridisation of complementary nucleic acids; connecting any essentially adjacent primers; and hybridising the connected primers to a capture probe, which comprises a region essentially complementary to the ZipComcode, and which is present on a flow-through microarray. As such, said primer A may specifically hybridise to a genetic marker. In a further aspect, 4 variants of primer A are provided, said 4 variants being substantially identical, except that each of the 4 variants contain a different nucleotide at its ultimate 3' end, and each of the 4 variants contain a different fluorescent label.\n\n\nAfter collecting the contaminating micro-organism, isolation of its nucleic acid and amplification, the amplified nucleic acids or amplified nucleic acid mixture may be analysed. A convenient method to analyse said amplified nucleic acid or said amplified nucleic acid mixture is by determining the sequence thereof. Techniques to determine the sequence of nucleic acids are well known in the art. Accordingly, the present invention relates to a method as described herein, wherein the analysis comprises determining the sequence of the amplified nucleic acid mixture. Said sequence may be determined via enzymatic, chemical or physical means. The sequence determined of the contaminating organism may be compared with sequences stored in a databank. Also the step of analysing in the method for characterising micro-organisms possibly present in a sample according to the present invention, may comprise providing a computer readable medium carrying computer output data having a database characterising micro-organisms based on nucleotide sequences, providing a computer and algorithm, processing the computer output data to determine the micro-organism.\n\n\nAnother convenient method to characterise the contaminating micro-organisms is by performing an amplified fragment-length polymorphism analysis (AFLP), ribotyping, Multiple Loci VNTR Analysis (MLVA), REP-PCR, RFLP, Pulsed field gel electrophoresis or other fingerprinting techniques known in the art.\n\n\nAnother embodiment of the present invention relates to the use of arrays, e.g. microarrays, for the analysis of the amplified nucleic acids. Arrays may contain thousands of DNA spots. A single array has the potential for a broad identification capacity, i.e. many different contaminating micro-organisms may be analysed on one microarray, in one go. In addition, the method of the invention does not require laborious cross-hybridisations and may provide an open database of hybridisation profiles, avoiding the limitations of traditional DNA-DNA hybridisations.\n\n\nIn the presence of a perfectly matching template, the probes may be ligated by the action of a DNA ligase. After ligation, said probes may be amplified. Next, the ligated probes, which \n\n may be or may be not amplified, are brought into contact with a capture probe, under hybridizing conditions. Hybridizing conditions are well known in the art, or may be determined without difficulty by the person skilled in the art, see e.g. \"Molecular Cloning: A Laboratory Manual\" Second Edition (Sambrook et al.,1989) and \"Current Protocols in Molecular Biology\" (F. M. Ausubel et al., eds., 1987, and periodic updates). Said capture probe comprises a complementary sequence relative to the target nucleic acid sequence, or a part thereof, such as the ZCc (or cZIP). The capture probes may be located on a microarray. Hence, the microarray comprises the complementary sequences of the target nucleic acid sequences, i.e. the capture probe. The location of the capture probe on the microarray is known. Hence, the present invention relates to a method as described herein, wherein said analysing comprises hybridising the amplified nucleic acids or said amplified nucleic acid mixture to a capture probe, said capture probe hybridising specifically to said amplified nucleic acids or said amplified nucleic acid mixture. The term \"hybridising specifically\" relates to a perfect match between a region of the analyte, e.g. the ZCc (or cZIP) of the amplified product, and the capture probe on the microarray. Hybridising specifically takes the length, G/C content and hybridisation conditions, such as salt and temperature, into account as known by the person skilled in the art. Accordingly, the present invention relates to a method as described herein, wherein said capture probe is located on a microarray. The capture probe is spatially addressable on the microarray. The microarrays of the present invention may be of any desired size, from two spots to 10\n6\n spots or even more. The upper and lower limits on the size of the substrate are determined solely by the practical considerations of working with extremely small or large substrates.\n\n\nFor a given substrate size, the upper limit is determined only by the ability to create and detect the spots in the microarray. The preferred number of spots on a microarray generally depends on the particular use to which the microarray is to be put. For example, sequencing by hybridisation will generally require large arrays, while mutation detection may require only a small array. In general, microarrays contain from 2 to about 10\n6\n spots, or from about 4 to about 10\n5\n spots, or from about 8 to about 10\n4\n spots, or between about 10 and about 2000 spots, or from about 20 to about 200 spots. Furthermore, not all spots on the microarray need to be unique. Indeed, in many applications, redundancies in the spots are desirable for the purposes of acting as internal controls (see e.g. figure 4).\n\n\nA variety of techniques have been described for synthesizing and/or immobilizing arrays of polynucleotides, including in situ synthesis, where the polynucleotides are synthesized \n\n directly on the surface of the substrate (see, e.g., U.S. Pat. No. 5,744,305 to Fodor, et a/.) and attachment of pre-synthesized polynucleotides to the surface of a substrate at discrete locations (see, e.g., WO 98/31836). Additional methods are described in WO 98/31836 at pages 41-45 and 47-48, among other places. The present invention is suitable for use with any of these currently available, or later developed, techniques.\n\n\nImmobilization of pre-synthesized polynucleotides at different spatial addresses yields an array of polynucleotides whose sequences are identifiable by their spatial addresses.\n\n\nIn embodiments involving in situ synthesis of polynucleotides, the polynucleotides are synthesized in their usual manner. The synthetic scheme yields an array of polynucleotides whose sequences are identifiable by their spatial addresses.\n\n\nThe nature and geometry of the solid substrate will depend upon a variety of factors, including, among others, the type of array (e.g., one-dimensional, two-dimensional or three- dimensional) and the mode of attachment (e.g., covalent or non-covalent). Generally, the substrate can be composed of any material which will permit immobilization of the capture probe, e.g. polynucleotide, and which will not melt or otherwise substantially degrade under the conditions used to bind the capture probe, e.g. hybridise and/or denature nucleic acids. In addition, where covalent immobilization is contemplated, the substrate should be activated with reactive groups capable of forming a covalent bond with the capture probe to be immobilized. Other exemplary suitable materials for use as substrates in the present invention include metal oxides. Metal oxides provide a substrate having both a high channel density and a high porosity, allowing high density arrays comprising different first binding substances per unit of the surface for sample application. In addition, metal oxides are highly transparent for visible light. Metal oxides are relatively cheap substrates that do not require the use of any typical microfabrication technology and, that offers an improved control over the liquid distribution over the surface of the substrate, such as electrochemically manufactured metal oxide membrane. Metal oxide membranes having through-going, oriented channels can be manufactured through electrochemical etching of a metal sheet. Metal oxides considered are, among others, oxides of tantalum, titanium, and aluminium, as well as alloys of two or more metal oxides and doped metal oxides and alloys containing metal oxides. The metal oxide membranes are transparent, especially if wet, which allows for assays using various optical techniques. Such membranes have oriented through-going channels with well controlled diameter and useful chemical surface properties. Patent application EP-A-O 975 427 is exemplary in this respect, and is specifically incorporated in the present invention. \n\n Accordingly, the present invention relates to a method as described herein, wherein said microarray is a flow-through microarray. Also, the present invention relates to a method as described herein, wherein said substrate is a porous substrate, said substrate may be an electrochemically manufactured metal oxide membrane. Preferably, said substrate comprises aluminium oxide. Accordingly, the present invention relates to a method as described herein, wherein said microarray is a PamChip®.\n\n\nThe composition of the immobilized capture probes is not critical. The only requirement is that they be capable of hybridising to a target nucleic acid of complementary sequence, e.g. the amplified nucleic acid, if any. For example, the capture probes may be composed of all natural or all synthetic nucleotide bases, or a combination of both. Non-limiting examples of modified bases suitable for use with the instant invention are described, for example, in Practical Handbook of Biochemistry and Molecular Biology, G. Fasman, Ed., CRC Press, 1989, pp. 385-392. While in most instances the polynucleotides will be composed entirely of the natural bases (A, C, G, T or U), in certain circumstances the use of synthetic bases may be preferred.\n\n\nMoreover, while the backbones of the capture probes will typically be composed entirely of \"native\" phosphodiester linkages, they may contain one or more modified linkages, such as one or more phosphorothioate, phosphoramidite or other modified linkages. As a specific example, one or more immobilized polynucleotides may be a peptide nucleic acid (PNA), which contains amide interlinkages. Additional examples of modified bases and backbones that can be used in conjunction with the invention, as well as methods for their synthesis can be found, for example, in Uhlman & Peyman, 1990, Chemical Review 90(4):544-584; Goodchild, 1990, Bioconjugate Chem. 1 (3):165-186; Egholm et al., 1992, J. Am. Chem. Soc. 1 14:1895-1897; Gryaznov et al., J. Am. Chem. Soc. 1 16:3143-3144, as well as the references cited in all of the above.\n\n\nAs such, the capture probes may include polymers of ribonucleotides and deoxyribonucleotides, with the ribonucleotide and/or deoxy-ribonucleotides being connected together via 5' to 3' linkages. The capture probes of the invention may be ribonucleic acids, for example sense or antisense ribonucleic acids, full-length or partial fragments of cRNA, full-length or partial fragments of mRNA, and/or ribo-oligonucleotides. Alternatively, capture probes of the invention may be deoxy-ribonucleic acids, preferably single-stranded full-length or fragments of sequences encoding the corresponding mRNAs. The form of the capture probes should be chosen so that they are complimentary to and form appropriate Watson- \n\n Crick hydrogen bonds with the amplified target nucleic acid and/or ligated probes in a sample.\n\n\nAs mentioned above, the capture probes may be polymers of synthetic nucleotide analogs. Such capture probes may be utilised in certain embodiments because of their superior stability under assay conditions. Modifications in the native structure, including alterations in the backbone, sugars or heterocyclic bases, have been shown to increase intracellular stability and binding affinity. Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. A- chiral phosphate derivatives include 3'-O-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH\n2\n-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Locked nucleic acids give additional conformational stability of sugar moiety due to additional bonds between 2'- carboxyl and 5' carboxyl or 4'-carboxyl groups of deoxyribose. Sugar modifications are also used to enhance stability and affinity. The a-anomer of deoxyribose may be used, where the base is inverted with respect to the natural p-anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-OaIIyI sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases that find use in the method of the invention are those capable of appropriate base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'- deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.\n\n\nExamples of non-naturally occurring bases that are capable of forming base-pairing relationships include, but are not limited to, aza- and deaza-pyrimidine analogues, aza- and deaza-purine analogues, and other heterocyclic base analogues, wherein one or more of the carbon and nitrogen atoms of the purine and pyrimidine rings have been substituted by heteroatoms, e.g., oxygen, sulfur, selenium, phosphorus, and the like. Examples of suitable non-naturally occurring bases include but are not limited to 8-oxo-guanine, and 8-oxo- adenine, 8-bromo-guanine, guanosine, xanthosine, wyosine, pseudouridine, 6-mercapto- guanine, 8-mercaptoguanine, 2-thioxanthine, 6-thioxanthine, 6-mercaptopurine, 2-amino-6- carboxymethyl-mercaptopurine, 2-mercaptopurine, 6-methoxypurine, 2-acetylamino-6- hydroxypurine, 6-methylthio-2-hydroxypurine, 2-dimethylamino-6-hydroxypurine, 2-hydroxy- purine, 2-aminopurine, 6-amino-2-dimethylallyl-purine, 2-thioadenine, 8-hydroxy-adenine, 8- methoxyadenine. \n\n The immobilized capture probes may be as few as four, or as many as hundreds, or even more, nucleotides in length. Contemplated as capture probes according to the invention are nucleic acids that are typically referred to in the art as oligonucleotides and also those referred to as nucleic acids. Thus, the arrays of the present invention are useful not only in applications where amplified target nucleic acids or ligated probes are hybridised to immobilized arrays of relatively short (such as, for example, having a length of approximately 6, 8, 10, 20, 40, 60, 80, or 100 nucleotides) capture probes, but also in applications where relatively short capture probes are hybridised to arrays of immobilized target nucleic acids. The capture probes of the array can be of any desired sequence. In a further embodiment, the microarray of the invention comprises a capture probe comprising the Zipcode (Zc or ZIP) sequence which is essentially complementary to a corresponding ZipComcode (ZCc or cZIP). The capture probe comprising the Zipcode (or ZIP) sequence may be spotted or synthesized on a specified location on the microarray. The Zipcode (or ZIP) sequence is a unique identifier sequence, which is complementary to the ZipComcode sequence. The present invention relates particularly to microarrays and the use thereof, comprising unique 20 to 30 base oligonucleotides, for instance 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 base oligonucleotides, named Zipcodes that are coupled to a porous three dimensional substrate at known locations, as described by van Beuningen et al., (2001 , Clinical Chemistry 47: 1931-1933), which is specifically incorporated herein by reference. These Zipcodes hybridise specifically to molecules containing sequences that are complementary to the Zipcodes, i.e. the ZipComcodes. By linking these ZipComcodes to fluorescent primers via a ligation-amplification reaction, Zipcode microarrays may be used to detect and identify micro-organisms, such as for example microbial specimens. Because the Zipcodes represent unique artificial sequences, microarrays comprising Zipcodes can be used as a universal platform for molecular recognition simply by changing the gene specific sequences linked to the ZipComcodes.\n\n\nThe detection of label on a specified location on microarray, such as the Pamchip indicates the presence of a hybridisation product between the ligated product and the Zipcode sequence on the microarray. Accordingly, the present invention relates to a method as described herein, wherein said capture probe hybridises specifically to a corresponding ZipComcode. The amplified target nucleic acid or nucleic acids hybridised to a corresponding capture probe or probes on a microarray may result in a hybridisation pattern. The hybridisation pattern, including the intensity of hybridisation, may be characteristic for a given micro-organism. \n\n It will be apparent that the present invention relates to a method as described herein, wherein a signal is detected after hybridising the specifically amplified nucleic acids or the ligated probes to the capture probe. The said signal is preferably a fluorescent or phosphorescent signal, and said fluorescent or phosphorescent signal may be detected by a CCD camera or by laser scanning, such as for example an FD10 system® (Olympus) or a Pamalyzer® (PamGene NV). Alternatively, the present invention relates to a method as described herein, wherein said microarray is an Arraytube® and said fluorescent or phosphorescent signal may be detected by a CCD camera and/or laser scanning.\n\n\nAlternatively, the present invention relates to a method as described herein, wherein the hybridization signal is a colorimetrical signal using biotin labelled primers detected by any method known in the art such as for instance conjugation with horseradish peroxidase- streptavidine followed by a peroxidase coloring reaction. The latter reaction may be visualized using an ArrayTube Reader (Clondiag GMBH, Jena, Germany).\n\n\nAs already mentioned before, the price of a microarray presents the larger cost per test. In order to decrease the price per test, the microarray can be interrogated simultaneously with more than one sample. As such, it is contemplated that each individual sample is subjected to the method of the present invention until the hybridisation step, i.e. from each individual sample, the micro-organisms are captured, after which the nucleic acids are extracted (step a), which subsequently undergo a ligase detection reaction (step b). Next, the amplified target nucleic acids if present are detected (step c) and the positive samples are collectively hybridized to the capture probes on a single microarray (step d) and the hybridized target nucleic acids are detected (step e). The probes pair used per sample may be identical, e.g. detecting the same target nucleic acid, or may differ per sample, e.g. detecting different target nucleic acids. However, in order to differentiate between amplified target nucleic acids from different samples or between different amplified target nucleic acids derived from a single sample, each probe, and thus the amplified target nucleic acid, must be individually assignable and detectable. Hence, each probe comprises a distinct and individually identifiable tag (e.g. identifier region ZIP), such as a particular ZipComcode, complementary to a distinct capture probe on the microarray. Although the nucleic acid probe pairs may detect the same target nucleic acids in different samples, each amplified target nucleic acid derived from each sample is traceable because of its discrete tag, corresponding to a specific address on the microarray. In an alternative embodiment, the probes do not comprise tags, but only the primers used for amplification comprise a distinct and individually identifiable tag, such as a ZCc (or cZIP). Obviously, the same considerations as mentioned above apply, in that the tags should differ per sample, and/or per probe, making each \n\n individual sample and/or probe identifiable. Accordingly, the present invention relates to a method as described herein, wherein amplified target nucleic acids derived from at least two samples hybridized to capture probes present on a single microarray.\n\n\nThe person skilled in the art will understand that the ZIP region and its complementary sequence cZIP intend only to reference the complementarity i.e. the ability to hybridize to each other specifically, irrespective of the position of the ZIP and/or cZIP sequence. The capture probe on the microarray may therefore comprise a cZIP, provided that the to be detected molecules comprise the ZIP region.\n\n\nThe data obtained by the methods of the present invention may be further analysed, possibly in an automated fashion. For instance, the hybridisation pattern obtained may be compared to hybridisation patterns stored in a databank. In this regard, the present invention relates also to a computer program stored on computer readable medium capable of performing the comparison of the obtained hybridisation pattern with the hybridisation patterns stored in a databank. Accordingly, the present invention relates to a computer comprising a computer readable medium capable of performing the methods described above. Also, the present invention relates to a computer readable medium comprising a computer program according capable of performing the method described above. Furthermore, the present invention relates to a computer program capable of displaying a web page on a remote computer enabling the use of the method described before. In a further embodiment, the present invention relates to kits for determining the presence of micro-organisms in a sample comprising the essentials of the methods of the present inventions, for instance, said kits may comprise possibly a filter, possibly means for extracting nucleic acids from said micro-organisms, means for specifically amplifying said nucleic acids, means for detecting the amplified nucleic acids, possibly means for analysing the amplified nucleic acids, e.g. microarrays, such as flow through microarrays, possibly buffers and/or an instruction manual.\n\n\nThe characterisation of mixed microbial populations is not easily achieved by current methods and has wide potential application. In most environments where bacteria are found a complex mixture of species is present which may change as a response to local conditions or evolve time. Classical microbiological methods are generally not well suited to the study of these systems as they rely on culture and subsequent isolation of individual colonies. This may only recover a proportion of the species present and also results in large numbers of isolates, which must be characterised. Molecular methods involving the amplification of conserved genes from complex populations and their subsequent characterisation, by \n\n cloning and sequencing, or hybridisation, provide alternatives to culture but remain complex. Additionally the amplification step may also introduce bias.\n\n\nIn actively growing populations of cells, each cell contains many copies of the ribosomal RNAs the specific sequence of which are widely used to identify bacterial species (Woese 1987, Microbiol. Rev. 51 :221-271 ). Due to this natural \"amplification\" of these sequences within active cells it is possible to detect these sequences without amplification (Small J. et al. 2001 App. Environ. Micro. 67:4708-4716,). Here a method is presented for the extraction and direct identification of ribosomal RNA on a three dimensional array surface. This potentially allows the rapid parallel identification of a wide range of species in a sample without the need for enzymatic amplification or labelling. The method presented here demonstrates almost real time monitoring of complex bacterial communities will be possible which will have application in many areas.\n\n\nHence, it will be appreciated that the present invention relates to the methods described above, wherein said step of analysing comprises hybridising a stacking probe to the nucleic acids, nucleic acid mixture and/or cDNA, said stacking probe being complementary for a region of 16S, 18S, 23S or 28S rRNA, thereby providing a nucleic acid/stacking probe complex. Said step of analysing may further comprise hybridising said nucleic acid/stacking probe complex to a capture probe, said capture probe being complementary to a region of the nucleic acid different from the nucleic acid/stacking probe complex. Said capture probe may be specific for a micro-organism. The stacking probe may be labelled. The region of 16S, 18S, 23S or 28S rRNA may be conserved (over species).\n\n\nIt will be evident to the person skilled in the art that the present invention relates to the use of a microarray as mentioned herein in the method of the present invention. Also, the present invention relates to the use of at least one pair of a first nucleic acid probe and a second nucleic acid probe as defined supra, including coupled probes, the use of a filter as described above, and/or the use of at least one set of two primers as defined above, in the methods according to the invention.\n\n\nBefore the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described herein, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims. \n\n The following examples and figures are offered by way of illustration and not by way of limitation. Nevertheless, the content of said examples and figures may be generalised in the concept of the present invention.\n\n\nEXAMPLES\n\n\nExample 1 Design of real-time ligation-amplification probes\n\n\nTwo ligation-amplification probes were used, named \"I\" and \"II\", which have the following design (from 5'-3'), with segments a, b, c, d, e, f, going from the 5'-end to the 3'-end (Figure 1 ):\n\n\nSegment l-a of 20 nucleotides equal to amplification primer 1 (Figure 1 , Eco); Segment l-b of 24 nucleotides comprising the cZIP-sequence (Figure 2, cZIP); Segment l-c of 20-30 nucleotides complementary to the target sequence (Figure 1 , cSeq 2);\n\n\nSegment ll-d of 20-30 nucleotides complementary to the target sequence and located immediately downstream of segment l-c (Figure 1 , cSeq 1 ) Segment ll-e of 20 nucleotides comprising the DET-sequence (Figure 1 , DET); Segment ll-f of 20 nucleotides complementary to amplification primer 2 (Figure 1 , cMse); The cZIP sequences are as described in WO-2004-106547.\n\n\nAll probes were ordered at Biolegio B.V. (Nijmegen, The Netherlands).\n\n\nEco and Mse refer to the primer binding regions 1 and 2, cEco and cMse refer to their respective complementary sequences. ZIP and cZIP refer to the DNA segments used for microarray detection, where cZIP has the complementary sequence of ZIP. DET and cDET refer to DNA segments used for real time detection during amplification, where cDET has the complementary sequence of DET. cSeq-1 and cSeq-2 refer to DNA segments complementary to the target DNA.\n\n\nExample 2 Description of bacterial strains and DNA isolation The following 6 bacterial strains were chosen for real-time LDR\n\n\n1. Salmonella enterica ssp. enterica serovar Virchow\n\n\n2. Salmonella enterica ssp. enterica serovar Paratyphi B var Java\n\n\n3. Escherichia coli \n\n 4. Enterobacter cloaca\n\n\n5. Shigella flexneri\n\n\n6. Campylobacter jejuni\n\n\nPure cultures were inoculated into nutrient broth and grown o/n at 37 \n0\nC. 100 μl of this o/n culture was used for DNA isolation using the Qiagen genomic DNA isolation kit according to the procedures advised by the manufacturer (Qiagen, Venlo, The Netherlands).\n\n\nExample 3 Real-time Ligase Detection Reactions (Figure 2)\n\n\nThe amplification primers have the following sequence: Primer 1 (Eco): 5'-biotin-GTAGACTGCGTACCAATTC-3' Primer 2 (Mse): δ'-GACGATGAGTCCTGAGTAA-S'\n\n\nThe primers were ordered at Biolegio B.V. (Nijmegen, The Netherlands); Biotin is covalently attached to the 5'end of primer 1 , and was used to detect the amplification products on the microarray. The ligation reactions were carried out in a volume of 10 μl containing: 1.0 fMol of each real-time ligation-amplification probe oligonucleotide 0.5 ng of target-DNA of the organisms to be analyzed 1 unit Taq DNA ligase (New England Biolabs, Beverly, MA, U.S.A.) - 1.0 μl 10 x Taq DNA ligase buffer (New England Biolabs, Beverly, MA, U.S.A.) - sterile water to an end volume of 10 μl.\n\n\n23 real-time ligation-amplification probes were used based on the PremiTest Salmonella probes (DSM PremiTest, Geleen, The Netherlands; Wattiau et al., Int. J. Food Microbiol., 123 (2008), 293-298), and to which the DET segment Ne is added with the sequence 5'- TCCGATGAGTCGCAATCCTA-3. This DET-segment is not added to probes 16, 17, 19, 20, 22 and 23, because these constitute the reaction control probes. In these examples for each probe segments I and Il are joined creating single probes with the order Md-I Ie-I If-Ia-Ib-Ic in stead of two separate probe segments.\n\n\nThe ligation reaction was incubated for 30 seconds at 98\n0\nC, and subsequently for 16 hours at 55\n0\nC in a Biorad MyCycler (Biorad, Hercules, CA, U.S.A.). Subsequently, the real-time amplification reaction was carried out. For this purpose 40 μl of a solution was added containing 10 pMol of primer-1 , 10 pMol of primer-2, 2 pMol of Detector molecule D1 with the sequence δ'FAM-TAGGATTGCGACTCATGCCA-TAMRA-S', 0.5 units Amplitaq DNA polymerase (Applied Biosystems, Foster City, CA, U.S.A.), 0,25 mM dNTPs \n\n (from a 20 mM dNTP-mix, Amersham Biosciences, Piscataway, NJ, U.S.A.) in 20 mM Tris.HCI pH 8.5. The PCR was carried out using the amplification conditions as described by Vos et ai, Nucleic Acids Research 23(21 ), (1995), 4407-4414, using a Biorad iCycler IQ. (Biorad Inc., Hercules, CA, U.S.A.).\n\n\nExample 4 Detection and typing of Salmonella in 6 bacterial samples using real-time LDR\n\n\n1. DNA was isolated from the 6 bacterial strains described in example 2;\n\n\n2. Real-time ligation-amplification reactions were carried out as described in example 3. The reactions yield 6 real-time PCR profiles (see Figure 3).\n\n\n3. The reaction products of samples 1 , 2 and 3 (two positive and one negative real-time LDR) were hybridized to a Clondiag Array Tube using the \"Detection Step\" of the PremiTest Salmonella protocol (DSM PremiTest, Geleen, The Netherlands).\n\n\n4. The results are displayed in Figure 4, and confirm that the 2 real-time positive samples contain Salmonella serotypes Virchow and Paratyphi B var Java, respectively. The negative sample yields the array image of a Salmonella negative sample displaying the reaction control spots only."
  },
  {
    "id": "WO2010046013A1",
    "text": "Azaindole derivative AbstractThe invention relates to compounds of the formula (I), where X1, X2, X3, X4, R1, R2, R3, and R4have the meanings given in claim 1, being inhibitors of tyrosine kinases, particularly met kinase, and can be used for treating tumors, among other uses. Claims\n\n\n\n\n\n\n \n- 89 -Patentansprüche\n - 89 patent claims\n\n\n\n\n\n\n\n\n \n1. Verbindungen der Formel I\n1. Compounds of the formula I\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nR\n4\n worin\nR \n4\n wherein\n\n\n\n\n\n\n \nX\n1\n, X\n2\n,\nX \n1\n , X \n2\n ,\n\n\n\n\n\n\n \nX\n3\n, X\n4\n jeweils unabhängig voneinander CH oder N, wobei nur einer der Reste X\n1\n, X\n2\n, X\n3\n, X\n4\n N bedeutet, R\n1\n H, CN, HaI, Het\n2\n, A, COOH, COOA, CONH\n2\n,\nX \n3\n , X \n4 are\n each independently CH or N, where only one of X \n1\n , X \n2\n , X \n3\n , X \n4\n N, R \n1 is\n H, CN, Hal, Het \n2\n , A, COOH, COOA, CONH \n2\n .\n\n\n\n\n\n\n \nCONH(CH\n2\n)\nm\nNA\n2\n oder CONH(CH\n2\n)\nm\nHet\n2\n, R\n2\n H, Het\n1\n oder Ar,\nCONH (CH \n2\n ) \nm\n NA \n2\n or CONH (CH \n2\n ) \nm\n Het \n2\n , R \n2\n H, Het \n1\n or Ar,\n\n\n\n\n\n\n \nR\n3\n H, (CH\n2\n)\nn\nAr oder Het\n1\n, wobei einer der Reste R\n2\n oder R\n3\n ≠ H ist,\nR \n3 is\n H, (CH \n2\n ) \nn\n Ar or Het \n1\n , where one of the radicals R \n2\n or R \n3\n ≠ H,\n\n\n\n\n\n\n \nR\n4\n H, A, (CH\n2\n)\nn\nAr oder Het\n2\n,\nR \n4 is\n H, A, (CH \n2\n ) \nn\n Ar or Het \n2\n ,\n\n\n\n\n\n\n \nHet\n1\n einen ein- oder zweikernigen aromatischen Heterocyclus mit 1 bis 4 N-, O- und/oder S-Atomen, der unsubstituiert oder ein-, zwei- oder dreifach durch HaI, A, NH\n2\n und/oder\nHet \n1 is\n a mononuclear or dinuclear aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, NH \n2\n and / or\n\n\n\n\n\n\n \nNHCH\n2\nAr substituiert sein kann, Het\n2\n einen einkernigen ungesättigten oder gesättigten\nNHCH \n2\n Ar may be substituted, Het \n2 is\n a mononuclear unsaturated or saturated\n\n\n\n\n\n\n \nHeterocyclus mit 1 bis 2 N und/oder O-Atomen, der ein- oder zweifach durch A substituiert sein kann,\nHeterocycle having 1 to 2 N and / or O atoms, which may be monosubstituted or disubstituted by A,\n\n\n\n\n\n\n \nAr unsubstituiertes oder ein-, zwei- oder dreifach durch HaI,\nAr is unsubstituted or mono-, di- or trisubstituted by Hal,\n\n\n\n\n\n\n \nA, OH, OA, CN, NO\n2\n, SO\n2\nA, COOH\n1\n COOA, NH\n2i\n NHA, NA\n2\n, CHO, COA, CHO, CONH\n2\n, CONHA, CONA\n2\n, SO\n2\nNH\n2\n, SO\n2\nNHA und/oder NHCOA substituiertes Phenyl,\nA, OH, OA, CN, NO \n2\n , SO \n2\n A, COOH \n1\n COOA, NH \n2i\n NHA, NA \n2\n , CHO, COA, CHO, CONH \n2\n , CONHA, CONA \n2\n , SO \n2\n NH \n2\n , SO \n2\n NHA and / or NHCOA substituted phenyl,\n\n\n\n\n\n\n \nA unverzweigtes oder verzweigtes Alkyl mit 1-10 C-Atomen,  - 90 -\nA unbranched or branched alkyl having 1-10 C atoms,  - 90 -\n\n\n\n\n\n\n \nworin 1 -7 H-Atome durch OH, F, Cl und/oder Br ersetzt sein können,\nwhere 1 -7 H atoms can be replaced by OH, F, Cl and / or Br,\n\n\n\n\n\n\n \nHaI F, Cl\n1\n Br oder I, m 1 , 2, 3 oder 4,\nHal F, Cl \n1\n Br or I, m 1, 2, 3 or 4,\n\n\n\n\n\n\n \n \n5\n n 0, 1 , 2, 3 oder 4, bedeuten, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen. 10\n \n5\n n is 0, 1, 2, 3 or 4, as well as their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios. 10\n\n\n\n\n\n\n\n\n\n\n \n2. Verbindungen nach Anspruch 1 , worin R\n2\n Het\n1\n oder Ar bedeutet, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und ^ \n5\n Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\n2. Compounds according to claim 1, wherein R \n2\n is Het \n1\n or Ar, and pharmaceutically usable salts, tautomers and stereoisomers ^ \n5,\n including mixtures thereof in all ratios.\n\n\n\n\n\n\n\n\n\n\n \n3. Verbindungen nach Anspruch 1 oder 2, worin R\n3\n (CH\n2\n)\nn\nAr oder Het\n1\n bedeutet, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und 0\n3. Compounds according to claim 1 or 2, wherein R \n3 is\n (CH \n2\n ) \nn\n Ar or Het \n1\n , and their pharmaceutically acceptable salts, tautomers and 0\n\n\n\n\n\n\n \nStereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\nStereoisomers, including mixtures thereof in all ratios.\n\n\n\n\n\n\n\n\n\n\n \n4. Verbindungen nach einem oder mehreren der Ansprüche 1 -3, worin R\n4\n H bedeutet, 5 sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und\n4. Compounds according to one or more of claims 1 -3, wherein R \n4 is\n H, 5 and their pharmaceutically acceptable salts, tautomers and\n\n\n\n\n\n\n \nStereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\nStereoisomers, including mixtures thereof in all ratios.\n\n\n\n\n\n\n\n\n\n\n \n5. Verbindungen nach einem oder mehreren der Ansprüche 1-4, worin 0 Het\n1\n Thiazolyl, Thiophenyl, Furanyl, Pyrrolyl, Oxazolyl,\n5. Compounds according to one or more of claims 1-4, wherein 0 Het \n1\n thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl,\n\n\n\n\n\n\n \nIsoxazolyl, Oxadiazolyl, Pyrazolyl, Imidazolyl, Triazolyl, Thiadiazolyi, Pyridazinyl, Pyrazinyl, Pyridinyl, Pyrirnidinyi, Benzimidazolyl, Benzotriazolyl, Indolyl, Benzo[1 ,3]dioxolyl, Indazolyl, Benzo[2,1 ,3]thiadiazolyl oder Pyrrolo[2,3- b]pyridinyl,  - 91 -\nIsoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl, thiadiazolyi, pyridazinyl, pyrazinyl, pyridinyl, pyrirnidinyl, benzimidazolyl, benzotriazolyl, indolyl, benzo [1,3] dioxolyl, indazolyl, benzo [2,1,3] thiadiazolyl or pyrrolo [2, 3- b] pyridinyl,  - 91 -\n\n\n\n\n\n\n \nwobei die Heterocyclen auch ein-, zwei- oder dreifach durch HaI, A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein können, bedeutet, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\nwherein the heterocycles may also be mono-, di- or trisubstituted by Hal, A, NH \n2\n and / or NHCH \n2\n Ar, as well as their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.\n\n\n\n\n\n\n\n\n\n\n \n6. Verbindungen nach einem oder mehreren der Ansprüche 1-5, worin 10 Het\n2\n Piperidinyl, Pyrrolidinyl, Morpholinyl, Piperazinyl,\n6. Compounds according to one or more of claims 1-5, wherein 10 Het \n2\n piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl,\n\n\n\n\n\n\n \nImidazolidinyl, Oxazoiidinyi oder Tetrahydropyranyl, wobei die Heterocyclen auch ein- oder zweifach durch A substituiert sein können, ^ 5 bedeutet, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\nImidazolidinyl, Oxazoiidinyi or tetrahydropyranyl, wherein the heterocycles may also be monosubstituted or disubstituted by A, ^ 5, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions.\n\n\n\n\n\n\n\n\n\n\n \n7. Verbindungen nach einem oder mehreren der Ansprüche 1-8, worin\n7. Compounds according to one or more of claims 1-8, wherein\n\n\n\n\n\n\n \n20\n20\n\n\n\n\n\n\n \nA unverzweigtes oder verzweigtes Alkyl mit 1-6 C-Atomen, worin 1-5 H-Atome durch F und/oder Cl ersetzt sein können, bedeutet, 25 sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und\nA is unbranched or branched alkyl having 1-6 C atoms, wherein 1-5 H atoms may be replaced by F and / or Cl, and their pharmaceutically acceptable salts, tautomers and\n\n\n\n\n\n\n \nStereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\nStereoisomers, including mixtures thereof in all ratios.\n\n\n\n\n\n\n\n\n\n\n \n8. Verbindungen nach einem oder mehreren der Ansprüche 1-7, worin\n8. Compounds according to one or more of claims 1-7, wherein\n\n\n\n\n\n\n \nX\n1\n,, X x\n2\n \nX \n1\n ,, X x \n2\n \n\n\n\n\n\n\n \n30 , X\n3\n, X\n4\n jeweils unabhängig voneinander CH oder N, wobei nur einer der Reste X\n1\n, X\n2\n, X\n3\n, X\n4\n N bedeutet, R\n1\n H, CN, HaI, Het\n2\n, A, COOH, COOA, CONH\n2\n,\n30, X \n3\n , X \n4 are\n each, independently of one another, CH or N, where only one of the radicals X \n1\n , X \n2\n , X \n3\n , X \n4 is\n N, R \n1 is\n H, CN, Hal, Het \n2\n , A, COOH, COOA, CONH \n2\n ,\n\n\n\n\n\n\n \nCONH(CH\n2\n)\nm\nNA\n2\n oder CONH(CH\n2\n)\nm\nHet\n2\n, 3\n5\n R\n2\n Het\n1\n oder Ar,\nCONH (CH \n2\n ) \nm\n NA \n2\n or CONH (CH \n2\n ) \nm\n Het \n2\n , 3 \n5\n R \n2\n Het \n1\n or Ar,\n\n\n\n\n\n\n \nR\n3\n (CH\n2\n)\nn\nAr oder Het\n1\n,  - 92 -\nR \n3\n (CH \n2\n ) \nn\n Ar or Het \n1\n ,  - 92 -\n\n\n\n\n\n\n \nR\n4\n H,\nR \n4\n H,\n\n\n\n\n\n\n \nHet\n1\n Thiazolyl, Thiophenyl, Furanyl, Pyrrolyl, Oxazolyl,\nHet \n1\n thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl,\n\n\n\n\n\n\n \nIsoxazolyl, Oxadiazolyl, Pyrazolyl, Imidazolyl, Triazolyl,\nIsoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl,\n\n\n\n\n\n\n \nThiadiazolyl, Pyridazinyl, Pyrazinyl, Pyridinyl, Pyrimidinyl,\nThiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl, pyrimidinyl,\n\n\n\n\n\n\n \nBenzimidazolyl, Benzotriazolyl, Indolyl, Benzo[1 ,3]dioxolyl,\nBenzimidazolyl, benzotriazolyl, indolyl, benzo [1, 3] dioxolyl,\n\n\n\n\n\n\n \nIndazolyl, Benzo[2,1 ,3]thiadiazolyl oder Pyrrolo[2,3- b]pyridinyl, wobei die Heterocyclen auch ein-, zwei- oder dreifach 0 durch HaI, A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein können, Het\n2\n Piperidinyl, Pyrrolidinyl, Morpholinyl, Piperazinyl,\nIndazolyl, benzo [2,1,3] thiadiazolyl or pyrrolo [2,3-b] pyridinyl, where the heterocycles may also be mono-, di- or tri-0 substituted by Hal, A, NH \n2\n and / or NHCH \n2\n Ar , Het \n2\n piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl,\n\n\n\n\n\n\n \nImidazolidinyl, Oxazolidinyl oder Tetrahydropyranyl, \n5\n wobei die Heterocyclen auch ein- oder zweifach durch A substituiert sein können, Ar unsubstituiertes oder ein-, zwei- oder dreifach durch HaI,\nImidazolidinyl, oxazolidinyl or tetrahydropyranyl, \n5\n where the heterocycles may also be mono- or disubstituted by A, Ar is unsubstituted or mono-, di- or trisubstituted by Hal,\n\n\n\n\n\n\n \nA, OH, OA, CN, NO\n2\n und/oder SO\n2\nA substituiertes\nA, OH, OA, CN, NO \n2\n and / or SO \n2\n A substituted\n\n\n\n\n\n\n \nPhenyl, 0\nPhenyl, 0\n\n\n\n\n\n\n \nA unverzweigtes oder verzweigtes Alkyl mit 1-6 C-Atomen, worin 1-5 H-Atome durch F und/oder Cl ersetzt sein können,\nA is unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and / or Cl,\n\n\n\n\n\n\n \nHaI F, Cl, Br oder I, 5 m 1 , 2, 3 oder 4, n 0, 1 , 2, 3 oder 4, bedeuten, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Q Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\nHal is F, Cl, Br or I, 5 m is 1, 2, 3 or 4, n is 0, 1, 2, 3 or 4, and their pharmaceutically acceptable salts, tautomers and Q stereoisomers, including mixtures thereof in all ratios.\n\n\n\n\n\n\n\n\n\n\n \n9. Verbindungen nach einem oder mehreren der Ansprüche 1-8, worin\n9. Compounds according to one or more of claims 1-8, wherein\n\n\n\n\n\n\n \nX\n1\n, X\n2\n,\nX \n1\n , X \n2\n ,\n\n\n\n\n\n\n \nX\n3\n, X\n4\n jeweils unabhängig voneinander CH oder N, wobei nur einer der Reste X\n1\n, X\n2\n, X\n3\n, X\n4\n N bedeutet,  - 93 -\nX \n3\n , X \n4 are\n each, independently of one another, CH or N, where only one of the radicals X \n1\n , X \n2\n , X \n3\n , X \n4\n denotes N,  - 93 -\n\n\n\n\n\n\n \nR\n1\n H, CN, HaI, Het\n2\n, A, COOH, COOA, CONH\n2\n,\nR \n1 is\n H, CN, Hal, Het \n2\n , A, COOH, COOA, CONH \n2\n ,\n\n\n\n\n\n\n \nCONH(CH\n2\n)\nm\nNA\n2\n oder CONH(CH\n2\n)\nm\nHet\n2\n, R\n2\n H, Het\n1\n oder Ar,\nCONH (CH \n2\n ) \nm\n NA \n2\n or CONH (CH \n2\n ) \nm\n Het \n2\n , R \n2\n H, Het \n1\n or Ar,\n\n\n\n\n\n\n \nR\n3\n H, (CH\n2\n)\nn\nAr oder Het\n1\n, wobei einer der Reste R\n2\n oder R\n3\n ≠ H ist, R\n4\n H, A, (CH\n2\n)\nn\nAr oder Het\n2\n,\nR \n3 is\n H, (CH \n2\n ) \nn\n Ar or Het \n1\n , where one of the radicals R \n2\n or R \n3\n ≠ H, R \n4 is\n H, A, (CH \n2\n ) \nn\n Ar or Het \n2\n ,\n\n\n\n\n\n\n \nHet\n1\n Thiazolyl, Thiophenyl, Furanyl, Pyrrolyl, Oxazolyl,\nHet \n1\n thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl,\n\n\n\n\n\n\n \nIsoxazolyl, Oxadiazolyl, Pyrazolyl, Imidazolyl, Triazolyl, Thiadiazolyl, Pyridazinyl, Pyrazinyl, Pyridinyl, Pyrimidinyl,\nIsoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl, pyrimidinyl,\n\n\n\n\n\n\n \nBenzimidazolyi, Benzotriazoiyi, indoiyi, Benzo[1 ,3jdioxoly!,\nBenzimidazolyi, Benzotriazoiyi, indoiyi, Benzo [1, 3jdioxoly !,\n\n\n\n\n\n\n \nIndazolyl, Benzo[2,1 ,3]thiadiazolyl oder Pyrrolo[2,3- b]pyridinyl, wobei die Heterocyclen auch ein-, zwei- oder dreifach durch HaI, A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein können, Het\n2\n Piperidinyl, Pyrrolidinyl, Morpholinyl, Piperazinyl,\nIndazolyl, benzo [2,1,3] thiadiazolyl or pyrrolo [2,3-b] pyridinyl, where the heterocycles may also be mono-, di- or trisubstituted by Hal, A, NH \n2\n and / or NHCH \n2\n Ar, Het \n2\n piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl,\n\n\n\n\n\n\n \nImidazolidinyl, Oxazolidinyl oder Tetrahydropyranyl, wobei die Heterocyclen auch ein- oder zweifach durch A substituiert sein können, Ar unsubstituiertes oder ein-, zwei- oder dreifach durch HaI,\nImidazolidinyl, oxazolidinyl or tetrahydropyranyl, where the heterocycles may also be monosubstituted or disubstituted by A, Ar is unsubstituted or mono-, di- or trisubstituted by Hal,\n\n\n\n\n\n\n \nA, OH, OA, CN, NO\n2\n und/oder SO\n2\nA substituiertes Phenyl,\nA, OH, OA, CN, NO \n2\n and / or SO \n2\n A substituted phenyl,\n\n\n\n\n\n\n \nA unverzweigtes oder verzweigtes Alkyl mit 1-6 C-Atomen, worin 1-5 H-Atome durch F und/oder Cl ersetzt sein können, HaI F, Cl, Br oder I, m 1 , 2, 3 oder 4, n O, 1 , 2, 3 oder 4, bedeuten, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.  -94-\nA is unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and / or Cl, Hal F, Cl, Br or I, m is 1, 2, 3 or 4, nO , 1, 2, 3 or 4, as well as their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.  -94-\n\n\n\n\n\n\n\n\n\n\n \n10. Verbindungen nach Anspruch 1 , ausgewählt aus der Gruppe \n  - 95-\n10. Compounds according to claim 1, selected from the group \n - 95-\n\n\n\n\n\n\n \n \n -96 -\n \n -96 -\n\n\n\n\n\n\n \n \n -97-\n \n -97-\n\n\n\n\n\n\n \n \n - 98 -\n \n - 98 -\n\n\n\n\n\n\n \ncarbonsäure\ncarboxylic acid\n\n\n\n\n\n\n \n\"A60\" 3-(3-Chlor-phenyl)-2-pyridin-4-yl-1 H-pyrrolo[3,2-b]pyridin-5- carbonsäure-amid\n\"A60\" 3- (3-Chloro-phenyl) -2-pyridin-4-yl-1H-pyrrolo [3,2-b] pyridine-5-carboxylic acid amide\n\n\n\n\n\n\n \n\"A61 3-(3-Chlor-phenyl)-2-pyridin-4-yl-1 H-pyrrolo[3,2-b]pyridin-5- carbonsäure-(2-morpholin-4-yl-ethyl)-amid\n\"A61 3- (3-Chloro-phenyl) -2-pyridin-4-yl-1 H -pyrrolo [3,2-b] pyridine-5-carboxylic acid (2-morpholin-4-yl-ethyl) -amide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\"A62\" 3-(3-Chlor-phenyl)-2-pyrimidin-5-yl-1 H-pyrrolo[3,2-b]pyridin-\n\"A62\" 3- (3-Chloro-phenyl) -2-pyrimidin-5-yl-1H-pyrrolo [3,2-b] pyridine\n\n\n\n\n\n\n \n5-carbonitril\n5-carbonitrile\n\n\n\n\n\n\n \n\"A63\" 3-(4-Fluor-phenyl)-2-pyrimidin-5-yl-1 H-pyrrolo[3,2-b]pyridin-\n\"A63\" 3- (4-fluoro-phenyl) -2-pyrimidin-5-yl-1H-pyrrolo [3,2-b] pyridine\n\n\n\n\n\n\n \n5-carbonitril\n5-carbonitrile\n\n\n\n\n\n\n \n\"A64\" 2-(2-Chlor-pyridin-4-yl)-3-(4-fluor-phenyl)-1 H-pyrrolo[3,2- b]pyridin-5-carbonitril\n\"A64\" 2- (2-Chloro-pyridin-4-yl) -3- (4-fluoro-phenyl) -1H-pyrrolo [3,2-b] pyridine-5-carbonitrile\n\n\n\n\n\n\n \n\"A65\" 3-(3-Chlor-4-fluor-phenyl)-2-pyrimidin-5-yl-1 H-pyrrolo[3,2- b]pyridin-5-carbonitril\n\"A65\" 3- (3-Chloro-4-fluoro-phenyl) -2-pyrimidin-5-yl-1H-pyrrolo [3,2-b] pyridine-5-carbonitrile\n\n\n\n\n\n\n \n\"A66\" 2-(2-Amino-pyrimidin-5-yl)-3-(3-chlor-4-fluor-phenyl)-1 H- pyrrolo[3,2-b]pyridin-5-carbonitril\n\"A66\" 2- (2-Amino-pyrimidin-5-yl) -3- (3-chloro-4-fluoro-phenyl) -1H-pyrrolo [3,2-b] pyridine-5-carbonitrile\n\n\n\n\n\n\n \n\"A67\" 2-(2-Amino-pyridin-4-yl)-3-(3-chlor-4-fluor-phenyl)-1 H- pyrrolo[3,2-b]pyridin-5-carbonitril\n\"A67\" 2- (2-Amino-pyridin-4-yl) -3- (3-chloro-4-fluoro-phenyl) -1H-pyrrolo [3,2-b] pyridine-5-carbonitrile\n\n\n\n\n\n\n \n\"A68\" 3-(3-Chlor-4-fluor-phenyl)-2-(1 H-pyrrolo[2,3-b]pyridin-5-yl)- 1 H-pyrrolo[3,2-b]pyridin-5-carbonitril\n\"A68\" 3- (3-Chloro-4-fluoro-phenyl) -2- (1H-pyrrolo [2,3-b] pyridin-5-yl) -1 H -pyrrolo [3,2-b] pyridine -5-carbonitrile\n\n\n\n\n\n\n \n \n - 99 -\n \n - 99 -\n\n\n\n\n\n\n \nsowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.\nand their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.\n\n\n\n\n\n\n\n\n\n\n \n11. Verfahren zur Herstellung von Verbindungen der Formel I nach den 5\n11. A process for the preparation of compounds of the formula I according to the 5\n\n\n\n\n\n\n \nAnsprüchen 1-10 sowie ihrer pharmazeutisch verwendbaren Salze,\nClaims 1-10 and their pharmaceutically acceptable salts,\n\n\n\n\n\n\n \nTautomeren und Stereoisomeren, dadurch gekennzeichnet, daß man a) zur Herstellung einer Verbindung der Formel I\n1\n worin R\n4\n H bedeutet, eine Verbindung der Formel Il 10\nTautomers and stereoisomers, characterized in that a) for the preparation of a compound of formula I \n1\n in which R \n4 is\n H, a compound of formula II 10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nworin X\n1\n, X\n2\n, X\n3\n, X\n4\n, R\n1\n und R\n2\n die in Anspruch 1 angegebenen Bedeutungen haben\nwherein X \n1\n , X \n2\n , X \n3\n , X \n4\n , R \n1\n and R \n2 have\n the meanings given in claim 1\n\n\n\n\n\n\n \n20 mit einer Verbindung der Formel IM\n20 with a compound of formula IM\n\n\n\n\n\n\n \n25\n25\n\n\n\n\n\n\n \nR\n3\n-L\nR \n3\n -L\n\n\n\n\n\n\n \nworin R\n3\n die in Anspruch 1 angegebene Bedeutung hat,\nwherein R \n3 has\n the meaning given in claim 1,\n\n\n\n\n\n\n \nJU und L einen Boronsäure- oder Boronsäureesterrest bedeutet,\nJU and L denotes a boronic acid or boronic ester radical,\n\n\n\n\n\n\n \numsetzt, und anschließend oder gleichzeitig die Boc-Gruppe abspaltet, 35 oder  - 100 -\nand then or simultaneously splits off the Boc group, 35 or  - 100 -\n\n\n\n\n\n\n \nb) zur Herstellung einer Verbindung der Formel I\n1\n worin R\n4\n H bedeutet, eine Verbindung der Formel IV\nb) for the preparation of a compound of the formula I \n1\n in which R \n4 is\n H, a compound of the formula IV\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nworin X\n1\n, X\n2\n, X\n3\n, X\n4\n, R\n1\n und R\n3\n die in Anspruch 1 angegebenen Bedeutungen haben, und R\n4\n H bedeutet,\nin which X \n1\n , X \n2\n , X \n3\n , X \n4\n , R \n1\n and R \n3 have\n the meanings given in claim 1, and R \n4\n denotes H,\n\n\n\n\n\n\n \nmit einer Verbindung der Formel V\nwith a compound of formula V\n\n\n\n\n\n\n \nR -L V\nR -L V\n\n\n\n\n\n\n \nworin R\n2\n die in Anspruch 1 angegebene Bedeutung hat, und L einen Boronsäure- oder Boronsäureesterrest bedeutet,\nwherein R \n2 has\n the meaning given in claim 1, and L denotes a boronic acid or boronic ester radical,\n\n\n\n\n\n\n \numsetzt,\nimplements,\n\n\n\n\n\n\n \noder\nor\n\n\n\n\n\n\n \nc) zur Herstellung einer Verbindung der Formel I, worin R\n4\n H bedeutet, eine Verbindung der Formel VI\nc) for the preparation of a compound of the formula I in which R \n4 is\n H, a compound of the formula VI\n\n\n\n\n\n\n \n \n - 101 -\n \n - 101 -\n\n\n\n\n\n\n \nworin X\n1\n, X\n2\n, X\n3\n, X\n4\n und R\n1\n die in Anspruch 1 angegebenen Bedeutungen haben,\nin which X \n1\n , X \n2\n , X \n3\n , X \n4\n and R \n1 have\n the meanings given in claim 1,\n\n\n\n\n\n\n \nmit einer Verbindung der Formel VII\nwith a compound of formula VII\n\n\n\n\n\n\n \nR\n2\n-C≡C-R\n3\n VII\nR \n2\n -C≡CR \n3\n VII\n\n\n\n\n\n\n \nworin R\n2\n und R\n3\n die in Anspruch 1 angegebenen Bedeutungen 10 haben,\nwherein R \n2\n and R \n3 have\n the meanings given in claim 1,\n\n\n\n\n\n\n \numsetzt,\nimplements,\n\n\n\n\n\n\n \n^ \nc\n und/oder eine Base oder Säure der Formel I in eines ihrer Salze umwandelt.\n^ \nc\n and / or converts a base or acid of formula I into one of its salts.\n\n\n\n\n\n\n\n\n\n\n \n12. Arzneimittel, enthaltend mindestens eine Verbindung der Formel I nach Anspruch 1-10 und/oder ihre pharmazeutisch verwendbaren Salze,\n12. Medicaments containing at least one compound of the formula I according to claims 1-10 and / or their pharmaceutically usable salts,\n\n\n\n\n\n\n \n^\nυ\n Tautomeren und Stereoisomeren, einschließlich deren Mischungen in allen Verhältnissen, sowie gegebenenfalls Träger- und/oder Hilfsstoffe.\n^ \nΥ\n tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants.\n\n\n\n\n\n\n\n\n\n\n \n13. Verwendung von Verbindungen nach Anspruch 1-10 sowie ihrer 25 pharmazeutisch verwendbaren Salze, Tautomeren und Stereoisomeren, einschließlich deren Mischungen in allen Verhältnissen, zur Herstellung eines Arzneimittels zur Behandlung von Tumoren, Krebs, Tumorentstehung, -Wachstum und -Verbreitung, Arteriosklerose, Augenerkrankungen, wie altersbedingte Makula-Degeneration, choroidale Neovaskularisierung und diabetische Retinopathie, Entzündungserkrankungen, Arthritis, Thrombose, Fibrose, Glomerulonephritis, Neurodegeneration, Psoriasis, Restenose, Wundheilung, Transplantat- abstossung, metabolische und Erkrankungen des Immunsystems, Autoimmunerkrankungen, Zirrhose, Diabetes und Erkrankungen der Blutgefässe.  - 102 -\n13. Use of compounds according to claims 1-10 and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions, for the manufacture of a medicament for the treatment of tumors, cancer, tumor development, growth and spread, arteriosclerosis, eye diseases such as age-related macular degeneration, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulonephritis, neurodegeneration, psoriasis, restenosis, wound healing, graft rejection, metabolic and immune system disorders, autoimmune diseases, cirrhosis, diabetes and blood vessel diseases ,  - 102 -\n\n\n\n\n\n\n\n\n\n\n \n14. Verwendung nach Anspruch 13, wobei die zu behandelnde Krankheit ein fester Tumor ist.\nUse according to claim 13, wherein the disease to be treated is a solid tumor.\n\n\n\n\n\n\n\n\n\n\n \n15. Verwendung nach Anspruch 14, wobei der feste Tumor aus der Gruppe der Tumoren des Plattenepithel, der Blasen, des Magens, der Nieren, von Kopf und Hals, des Ösophagus, des Gebärmutterhals, der Schilddrüse, des Darm, der Leber, des Gehirns, der Prostata, des 0 Urogenitaltrakts, des lymphatischen Systems, des Magens, des\nThe use of claim 14, wherein the solid tumor is selected from the group of tumors of squamous epithelium, bladder, stomach, kidney, head and neck, esophagus, cervix, thyroid, intestine, liver, brain , the prostate, the urogenital tract, the lymphatic system, the stomach, the\n\n\n\n\n\n\n \nKehlkopf! und/oder der Lunge stammt.\nLarynx! and / or the lung is derived.\n\n\n\n\n\n\n\n\n\n\n \n16. Verwendung nach Anspruch 14, wobei der feste Tumor aus der Gruppe\n5\n Monozytenleukämie, Lungenadenokarzinom, kleinzellige\nUse according to claim 14, wherein the solid tumor is from group \n5\n monocytic leukemia, lung adenocarcinoma, small cell\n\n\n\n\n\n\n \nLungenkarzinome, Bauchspeicheldrüsenkrebs, Glioblastome und Brustkarzinom stammt.\nLung carcinoma, pancreatic cancer, glioblastoma and breast carcinoma.\n\n\n\n\n\n\n\n\n\n\n \n17. Verwendung nach Anspruch 14, wobei der feste Tumor aus der Gruppe0 der Lungenadenokarzinom, kleinzellige Lungenkarzinome,\nUse according to claim 14, wherein the solid tumor is of Group 0 lung adenocarcinoma, small cell lung carcinoma,\n\n\n\n\n\n\n\n\n\n\n \nBauchspeicheldrüsenkrebs, Glioblastome, Kolonkarzinom und Brustkarzinom stammt. 5 18. Verwendung nach Anspruch 13, wobei die zu behandelnde Krankheit ein Tumor des Blut- und Immunsystems ist.\nPancreatic cancer, glioblastoma, colon carcinoma and breast carcinoma. The use of claim 13, wherein the disease to be treated is a tumor of the blood and immune system.\n\n\n\n\n\n\n\n\n\n\n \n19. Verwendung nach Anspruch 18, wobei der Tumor aus der Gruppe derQ akuten myelotischen Leukämie, der chronischen myelotischen\n19. Use according to claim 18, wherein the tumor belongs to the group of acute myeloid leukemia, chronic myeloid\n\n\n\n\n\n\n \nLeukämie, akuten lymphatischen Leukämie und/oder chronischen lymphatischen Leukämie stammt.\nLeukemia, acute lymphoblastic leukemia and / or chronic lymphocytic leukemia.\n\n\n\n\n\n\n \n5 \n5 Description\n\n\n\n\n\n\n \n Azaindolderivate\n azaindole derivatives\n\n\n\n\n\n\n \nHINTERGRUND DER ERFINDUNG\nBACKGROUND OF THE INVENTION\n\n\n\n\n\n\n \nDer Erfindung lag die Aufgabe zugrunde, neue Verbindungen mit wertvollen Eigenschaften aufzufinden, insbesondere solche, die zur Herstellung von Arzneimitteln verwendet werden können.\nThe invention had the object of finding new compounds with valuable properties, in particular those that can be used for the production of medicaments.\n\n\n\n\n\n\n \nDie vorliegende Erfindung betrifft Verbindungen und die Verwendung von\nThe present invention relates to compounds and the use of\n\n\n\n\n\n\n \nVerbindungen, bei denen die Hemmung, Regulierung und/oder Modulation der Signaltransduktion von Kinasen, insbesondere der Tyrosinkinasen und/oder Serin/Threonin-Kinasen eine Rolle spielt, femer pharmazeutische Zusammensetzungen, die diese Verbindungen enthalten, sowie die\nCompounds in which the inhibition, regulation and / or modulation of the signal transduction of kinases, in particular the tyrosine kinases and / or serine / threonine kinases play a role, in addition to pharmaceutical compositions containing these compounds, and the\n\n\n\n\n\n\n \nVerwendung der Verbindungen zur Behandlung kinasebedingter\nUse of the compounds for the treatment of kinase-related\n\n\n\n\n\n\n \nKrankheiten.\nDiseases.\n\n\n\n\n\n\n \nDie vorliegende Erfindung betrifft insbesondere Verbindungen und die Verwendung von Verbindungen, bei denen die Hemmung, Regulierung und/oder Modulation der Signaltransduktion von Met-Kinase eine Rolle spielt.\nMore particularly, the present invention relates to compounds and to the use of compounds in which the inhibition, regulation and / or modulation of Met-kinase signal transduction play a role.\n\n\n\n\n\n\n \nEiner der Hauptmechanismen, durch den die Zellregulation bewirkt wird, ist durch die Transduktion der extrazellulären Signale über die Membran, die wiederum biochemische Wege in der Zelle modulieren. Protein-Phosphorylierung stellt einen Ablauf dar, über den intrazelluläre Signale von Molekül zu\nOne of the major mechanisms by which cell regulation is effected is through the transduction of extracellular signals across the membrane, which in turn modulate biochemical pathways in the cell. Protein phosphorylation is a process via which intracellular signals from molecule to\n\n\n\n\n\n\n \nMolekül propagiert werden, was schließlich in einer Zellantwort resultiert.\nMolecule be propagated, which eventually results in a cell response.\n\n\n\n\n\n\n \nDiese Signaltransduktionskaskaden sind hoch reguliert und überlappen häufig, wie aus dem Vorliegen vieler Proteinkinasen wie auch Phosphatasen hervorgeht. Phosphorylierung von Proteinen tritt vorwiegend bei Serin-, Threonin- oder Tyrosinresten auf, und Proteinkinasen wurden deshalb nach ihrer Spezifität des Phosporylierungsortes, d. h. der Serin-/ Threonin-Kinasen und Tyrosin-Kinasen klassifiziert. Da Phosphorylierung ein derartig weit \n\n verbreiteter Prozess in Zellen ist und da Zellphänotypen größtenteils von der Aktivität dieser Wege beeinflusst werden, wird zur Zeit angenommen, dass eine Anzahl von Krankheitszuständen und/oder Erkrankungen auf entweder abweichende Aktivierung oder funktionelle Mutationen in den molekularen\nThese signal transduction cascades are highly regulated and often overlap, as evidenced by the presence of many protein kinases as well as phosphatases. Phosphorylation of proteins occurs predominantly at serine, threonine or tyrosine residues, and protein kinases were therefore classified according to their specificity of the phosphorylation site, ie serine / threonine kinases and tyrosine kinases. Because phosphorylation is so far  is widespread process in cells, and since cell phenotypes are largely influenced by the activity of these pathways, it is presently believed that a number of disease states and / or diseases are due to either aberrant activation or functional mutations in the molecular\n\n\n\n\n\n\n \nKomponenten von Kinasekaskaden zurückzuführen sind. Folglich wurde der\nComponents of kinase cascades are due. Consequently, the\n\n\n\n\n\n\n \nCharakterisierung dieser Proteine und Verbindungen, die zur Modulation ihrer Aktivität fähig sind, erhebliche Aufmerksamkeit geschenkt (Übersichtsartikel siehe: Weinstein-Oppenheimer et al. Pharma. &. Therap., 2000, 88, 229-279).\nSignificant attention has been given to characterizing these proteins and compounds capable of modulating their activity (for review see: Weinstein-Oppenheimer et al., Pharm. &. Therap., 2000, 88, 229-279).\n\n\n\n\n\n\n \nDie Rolle der Rezeptortyrosinkinase Met bei der menschlichen Onkogenese, sowie die Möglichkeit der Inhibierung der HGF(hepatocycte growth factor)- abhängigen Met-Aktivierung wird von S. Berthou et al. in Oncogene, Vol. 23, Nr. 31 , Seiten 5387-5393 (2004) beschrieben. Der dort beschriebene Inhibitor SU11274, eine Pyrrol-Indolin-Verbindung, ist potentiell zur Krebsbekämpfung geeignet.\nThe role of receptor tyrosine kinase Met in human oncogenesis, as well as the possibility of inhibiting hepatocyte growth factor (HGF) -dependent Met activation, is described by S. Berthou et al. in Oncogene, Vol. 23, No. 31, pages 5387-5393 (2004). The inhibitor SU11274 described there, a pyrrole-indoline compound, is potentially suitable for combating cancer.\n\n\n\n\n\n\n \nEin anderer Met-Kinase-Inhibitor zur Krebstherapie ist von J. G. Christensen et al. in Cancer Res. 2003, 63(21 ), 7345-55 beschrieben. Von einem weiterem Tyrosinkinase-Inhibitor zur Krebsbekämpfung berichten H. Hov et al. in Clinical Cancer Research Vol. 10, 6686-6694 (2004). Die Verbindung PHA-665752, ein Indolderivat, ist gegen den HGF-Rezeptor c- Met gerichtet. Weiter wird dort berichtet, daß HGF und Met erheblich zum malignen Prozess verschiedener Krebsformen, wie z.B. multipler Myeloma, betragen.\nAnother met kinase inhibitor for cancer therapy is described by J. G. Christensen et al. in Cancer Res. 2003, 63 (21), 7345-55. Another anti-cancer tyrosine kinase inhibitor is reported by H. Hov et al. in Clinical Cancer Research Vol. 10, 6686-6694 (2004). The compound PHA-665752, an indole derivative, is directed against the HGF receptor c-Met. It is also reported there that HGF and Met significantly contribute to the malignant process of various types of cancers, e.g. multiple myeloma.\n\n\n\n\n\n\n \nDie Synthese von kleinen Verbindungen, die die Signaltransduktion der Tyrosinkinasen und/oder Serin/Threonin-Kinasen, insbesondere der Met- Kinase spezifisch hemmen, regulieren und/oder modulieren, ist daher wünschenswert und ein Ziel der vorliegenden Erfindung. \n\n Es wurde gefunden, daß die erfindungsgemäßen Verbindungen und ihre Salze bei guter Verträglichkeit sehr wertvolle pharmakologische Eigenschaften besitzen.\nThe synthesis of small compounds that specifically inhibit, regulate and / or modulate the signal transduction of the tyrosine kinases and / or serine / threonine kinases, particularly the Met kinase, is therefore desirable and an object of the present invention.  It has been found that the compounds according to the invention and their salts possess very valuable pharmacological properties with good compatibility.\n\n\n\n\n\n\n \nIm einzelnen betrifft die vorliegende Erfindung Verbindungen der Formel I, die die Signaltransduktion der Met-Kinase hemmen, regulieren und/oder modulieren, Zusammensetzungen, die diese Verbindungen enthalten, sowie Verfahren zu ihrer Verwendung zur Behandlung von Met-Kinasebedingten Krankheiten und Leiden wie Angiogenese, Krebs, Tumorentstehung, -Wachstum und -Verbreitung, Arteriosklerose, Augenerkrankungen, wie altersbedingte Makula-Degeneration, choroidale Neovaskularisierung und diabetische Retinopathie, Entzündungserkrankungen, Arthritis, Thrombose, Fibrose, Glomerulonephritis, Neurodegeneration, Psoriasis, Restenose,\nIn particular, the present invention relates to compounds of formula I which inhibit, regulate and / or modulate Met-kinase signal transduction, compositions containing these compounds, and methods for their use in the treatment of met-kinase-related diseases and conditions, such as angiogenesis, Cancer, tumor development, growth and spread, arteriosclerosis, eye diseases such as age-related macular degeneration, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulonephritis, neurodegeneration, psoriasis, restenosis,\n\n\n\n\n\n\n \nWundheilung, Transplantatabstossung, metabolische und Erkrankungen des Immunsystems, auch Autoimmunerkrankungen, Zirrhose, Diabetes und Erkrankungen der Blutgefässe, dabei auch Instabilität und Durchlässigkeit\nWound healing, graft rejection, metabolic and immune system disorders, including autoimmune diseases, cirrhosis, diabetes and blood vessel diseases, as well as instability and permeability\n\n\n\n\n\n\n \n(Permeabilität) und dergleichen bei Säugetieren.\n(Permeability) and the like in mammals.\n\n\n\n\n\n\n \nFeste Tumore, insbesondere schnell wachsende Tumore, können mit Met- Kinasehemmern behandelt werden. Zu diesen festen Tumoren zählen die Monozytenleukämie, Hirn-, Urogenital-, Lymphsystem-, Magen-, Kehlkopf- und Lungenkarzinom, darunter Lungenadenokarzinom und kleinzelliges Lungenkarzinom.\nSolid tumors, especially fast growing tumors, can be treated with Met kinase inhibitors. These solid tumors include monocytic leukemia, brain, urogenital, lymphatic, gastric, laryngeal and lung carcinomas, including lung adenocarcinoma and small cell lung carcinoma.\n\n\n\n\n\n\n \nDie vorliegende Erfindung richtet sich auf Verfahren zur Regulation, Modulation oder Hemmung der Met-Kinase zur Vorbeugung und/oder\nThe present invention is directed to methods for the regulation, modulation or inhibition of Met kinase for the prevention and / or\n\n\n\n\n\n\n \nBehandlung von Erkrankungen im Zusammenhang mit unregulierter oder gestörter Met-Kinase-Aktivität. Insbesondere lassen sich die Verbindungen der Formel I auch bei der Behandlung gewisser Krebsformen einsetzen.\nTreatment of Disorders Associated with Unregulated or Disturbed Met Kinase Activity. In particular, the compounds of the formula I can also be used in the treatment of certain forms of cancer.\n\n\n\n\n\n\n \nWeiterhin können die Verbindungen der Formel I verwendet werden, um bei gewissen existierenden Krebschemotherapien additive oder synergistische\nFurthermore, the compounds of Formula I can be used to be additive or synergistic in certain existing cancer chemotherapies\n\n\n\n\n\n\n \nEffekte bereitzustellen, und/oder können dazu verwendet werden, um die \n\n Wirksamkeit gewisser existierender Krebschemotherapien und -bestrahlun- gen wiederherzustellen.\nTo provide effects, and / or can be used to the  Restore the efficacy of certain existing cancer chemotherapies and radiation.\n\n\n\n\n\n\n \nWeiterhin können die Verbindungen der Formel I zur Isolierung und zur Untersuchung der Aktivität oder Expression von Met-Kinase verwendet werden. Außerdem eigenen sie sich insbesondere zur Verwendung in diagnostischen Verfahren zu Erkrankungen im Zusammenhang mit unregulierter oder gestörter Met-Kinase-Aktivität.\nFurthermore, the compounds of the formula I can be used for the isolation and for the investigation of the activity or expression of Met kinase. In addition, they are particularly suitable for use in diagnostic procedures for diseases associated with unregulated or disturbed met kinase activity.\n\n\n\n\n\n\n \nEs kann gezeigt werden, dass die erfindungsgemäßen Verbindungen in einem Xenotransplantat-Tumor-Modell eine in vivo antiproliferative Wirkung aufweisen. Die erfindungsgemäßen Verbindungen werden an einen Patienten mit einer hyperproliferativen Erkrankung verabreicht, z. B. zur Inhibition des Tumorwachstums, zur Verminderung der mit einer lympho- proliferativen Erkrankung einhergehenden Entzündung, zur Inhibition der Transplantatabstoßung oder neurologischer Schädigung aufgrund von\nIt can be shown that the compounds according to the invention have an in vivo antiproliferative action in a xenograft tumor model. The compounds of the invention are administered to a patient with a hyperproliferative disorder, e.g. To inhibit tumor growth, to reduce inflammation associated with lymphoproliferative disease, to inhibit graft rejection or neurological damage due to\n\n\n\n\n\n\n \nGewebereparatur usw. Die vorliegenden Verbindungen sind nützlich für prophylaktische oder therapeutische Zwecke. Wie hierin verwendet, wird der\nTissue repair, etc. The present compounds are useful for prophylactic or therapeutic purposes. As used herein, the\n\n\n\n\n\n\n \nBegriff „Behandeln\" als Bezugnahme sowohl auf die Verhinderung von Krankheiten als auch die Behandlung vorbestehender Leiden verwendet. Die Verhinderung von Proliferation wird durch Verabreichung der erfindungs- gemäßen Verbindungen vor Entwicklung der evidenten Krankheit, z. B. zur Verhinderung des Tumorwachstums, Verhinderung metastatischen Wachstums, der Herabsetzung von mit kardiovaskulärer Chirurgie einhergehenden Restenosen usw. erreicht. Als Alternative werden die Verbindungen zur Behandlung andauernder Krankheiten durch Stabilisation oder Verbesserung der klinischen Symptome des Patienten verwendet.\nThe term \"treating\" is used to refer to both the prevention of disease and the treatment of pre-existing conditions Prevention of proliferation by administration of the compounds of the present invention prevents development of the apparent disease, e.g., to prevent tumor growth, prevent metastatic growth which achieves reduction of cardiovascular surgery-associated restenosis, etc. Alternatively, the compounds are used to treat persistent diseases by stabilizing or ameliorating the clinical symptoms of the patient.\n\n\n\n\n\n\n \nDer Wirt oder Patient kann jeglicher Säugerspezies angehören, z. B. einer\nThe host or patient may be of any mammalian species, e.g. B. one\n\n\n\n\n\n\n \nPrimatenspezies, besonders Menschen; Nagetieren, einschließlich Mäusen,\nPrimate species, especially humans; Rodents, including mice,\n\n\n\n\n\n\n \nRatten und Hamstern; Kaninchen; Pferden, Rindern, Hunden, Katzen usw.\nRats and hamsters; Rabbits; Horses, cattle, dogs, cats etc.\n\n\n\n\n\n\n \nTiermodelle sind für experimentelle Untersuchungen von Interesse, wobei \n\n sie ein Modell zur Behandlung einer Krankheit des Menschen zur Verfügung stellen.\nAnimal models are of interest for experimental studies, wherein  they provide a model for treating a human disease.\n\n\n\n\n\n\n \nDie Suszeptibilität einer bestimmten Zelle gegenüber der Behandlung mit den erfindungsgemäßen Verbindungen kann durch Testen in vitro bestimmt werden. Typischerweise wird eine Kultur der Zelle mit einer erfindungsgemäßen Verbindung bei verschiedenen Konzentrationen für eine Zeitdauer kombiniert, die ausreicht, um den aktiven Mitteln zu ermöglichen, Zelltod zu induzieren oder Migration zu inhibieren, gewöhnlich zwischen ungefähr einer Stunde und einer Woche. Zum Testen in vitro können kultivierte Zeilen aus einer Biopsieprobe verwendet werden. Die nach der Behandlung zurückbleibenden lebensfähigen Zellen werden dann gezählt. Die Dosis variiert abhängig von der verwendeten spezifischen Verbindung, der spezifischen Erkrankung, dem Patientenstatus usw.. Typischerweise ist eine therapeutische Dosis ausreichend, um die unerwünschte Zellpopulation im Zielgewebe erheblich zu vermindern, während die Lebensfähigkeit des\nThe susceptibility of a particular cell to treatment with the compounds of the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound of the invention at various concentrations for a period of time sufficient to allow the active agents to induce cell death or inhibit migration, usually between about one hour and one week. Cultured cells from a biopsy sample can be used for testing in vitro. The viable cells remaining after treatment are then counted. The dose will vary depending on the specific compound used, the specific disease, the patient status, etc. Typically, a therapeutic dose will be sufficient to substantially reduce the undesirable cell population in the target tissue while increasing the viability of the patient\n\n\n\n\n\n\n \nPatienten aufrechterhalten wird. Die Behandlung wird im Allgemeinen fortgesetzt, bis eine erhebliche Reduktion vorliegt, z. B. mindestens ca. 50 %\nPatient is maintained. Treatment is generally continued until there is a significant reduction, e.g. At least about 50%\n\n\n\n\n\n\n \nVerminderung der Zelllast und kann fortgesetzt werden, bis im Wesentlichen keine unerwünschten Zellen mehr im Körper nachgewiesen werden.\nReduction of cell load and can be continued until essentially no more unwanted cells are detected in the body.\n\n\n\n\n\n\n \nZur Identifizierung eines Signalübertragungswegs und zum Nachweis von Wechselwirkungen zwischen verschiedenen Signalübertragungswegen wurden von verschiedenen Wissenschaftlern geeignete Modelle oder Modellsysteme entwickelt, z.B. Zellkulturmodelle (z.B. Khwaja et al., EMBO, 1997, 16, 2783-93) und Modelle transgener Tiere (z.B. White et al.,\nTo identify a signal transduction pathway and to detect interactions between different signal transduction pathways, appropriate models or model systems have been developed by various scientists, e.g. Cell culture models (e.g., Khwaja et al., EMBO, 1997, 16, 2783-93) and models of transgenic animals (e.g., White et al.\n\n\n\n\n\n\n \nOncogene, 2001 , 20, 7064-7072). Zur Bestimmung bestimmter Stufen in der Signalübertragungskaskade können wechselwirkende Verbindungen genutzt werden, um das Signal zu modulieren (z.B. Stephens et al., Biochemical J.,\nOncogene, 2001, 20, 7064-7072). To determine particular levels in the signal transduction cascade, interacting compounds can be used to modulate the signal (e.g., Stephens et al., Biochemical J., et al.\n\n\n\n\n\n\n \n2000, 351 , 95-105). Die erfindungsgemäßen Verbindungen können auch als\n2000, 351, 95-105). The compounds according to the invention can also be described as\n\n\n\n\n\n\n \nReagenzien zur Testung kinaseabhängiger Signalübertragungswege in \n\n Tieren und/oder Zellkulturmodellen oder in den in dieser Anmeldung genannten klinischen Erkrankungen verwendet werden.\nReagents for Testing Kinase - Dependent Signal Transduction Pathways in  Animals and / or cell culture models or in the clinical diseases mentioned in this application.\n\n\n\n\n\n\n \nDie Messung der Kinaseaktivität ist eine dem Fachmann wohlbekannte Technik. Generische Testsysteme zur Bestimmung der Kinaseaktivität mit Substraten, z.B. Histon (z.B. Alessi et al., FEBS Lett. 1996, 399, 3, Seiten 333-338) oder dem basischen Myelinprotein sind in der Literatur beschrieben (z.B. Campos-Gonzälez, R. und Glenney, Jr., J. R. 1992, J. Biol. Chem. 267, Seite 14535).\nThe measurement of kinase activity is a technique well known to those skilled in the art. Generic Assay Systems for Determining Kinase Activity with Substrates, e.g. Histone (eg Alessi et al., FEBS Lett. 1996, 399, 3, pages 333-338) or the myelin basic protein are described in the literature (eg Campos-Gonzalez, R. and Glenney, Jr., JR 1992, J. Biol. Chem. 267, page 14535).\n\n\n\n\n\n\n \nZur Identifikation von Kinase-Inhibitoren stehen verschiedene Assay- Systeme zur Verfügung. Beim Scintillation-Proximity-Assay (Sorg et al., J. of. Biomolecular Screening, 2002, 7, 11-19) und dem FlashPlate-Assay wird die radioaktive Phosphorylierung eines Proteins oder Peptids als Substrat mit γATP gemessen. Bei Vorliegen einer inhibitorischen Verbindung ist kein oder ein vermindertes radioaktives Signal nachweisbar. Ferner sind die Homogeneous Time-resolved Fluorescence Resonance Energy Transfer- (HTR-FRET-) und Fluoreszenzpolarisations- (FP-) Technologien als Assay- Verfahren nützlich (SiIIs et al., J. of Biomolecular Screening, 2002, 191-214).\nVarious assay systems are available for the identification of kinase inhibitors. In the Scintillation Proximity Assay (Sorg et al., J. of Biomolecular Screening, 2002, 7, 11-19) and the FlashPlate assay, the radioactive phosphorylation of a protein or peptide as a substrate is measured with γATP. In the presence of an inhibitory compound, no or a reduced radioactive signal is detectable. Further, Homogeneous Time-resolved Fluorescence Resonance Energy Transfer (HTR-FRET) and Fluorescence Polarization (FP) technologies are useful as assay methods (SiIIs et al., J. of Biomolecular Screening, 2002, 191-214).\n\n\n\n\n\n\n \nAndere nicht radioaktive ELISA-Assay-Verfahren verwenden spezifische Phospho-Antikörper (Phospho-AK). Der Phospho-AK bindet nur das phosphorylierte Substrat. Diese Bindung ist mit einem zweiten Peroxidase- konjugierten Anti-Schaf-Antikörper durch Chemilumineszenz nachweisbar\nOther non-radioactive ELISA assay methods use specific phospho-antibodies (Phospho-AK). The phospho-AK binds only the phosphorylated substrate. This binding is detectable with a second peroxidase-conjugated anti-sheep antibody by chemiluminescence\n\n\n\n\n\n\n \n(Ross et al., 2002, Biochem. J.).\n(Ross et al., 2002, Biochem J.).\n\n\n\n\n\n\n \nEs gibt viele mit einer Deregulation der Zeilproliferation und des Zelltods (Apoptose) einhergehende Erkrankungen. Die Leiden von Interesse schließen die folgenden Leiden ein, sind aber nicht darauf beschränkt. Die erfindungsgemäßen Verbindungen sind nützlich bei der Behandlung einer Reihe verschiedener Leiden, bei denen Proliferation und/oder Migration \n\n glatter Muskelzellen und/oder Entzündungszellen in die Intimaschicht eines Gefäßes vorliegt, resultierend in eingeschränkter Durchblutung dieses Gefäßes, z. B. bei neointimalen okklusiven Läsionen. Zu okklusiven\nThere are many diseases associated with deregulation of cell proliferation and cell death (apoptosis). The ailments of interest include, but are not limited to, the following conditions. The compounds of the invention are useful in the treatment of a variety of conditions involving proliferation and / or migration  smooth muscle cells and / or inflammatory cells in the intimal layer of a vessel is present, resulting in limited blood flow to this vessel, z. In neointimal occlusive lesions. Too occlusive\n\n\n\n\n\n\n \nTransplantat-Gefäßerkrankungen von Interesse zählen Atherosklerose, koronare Gefäßerkrankung nach Transplantation, Venentransplantatstenose, peri-anastomotische Prothesenrestenose, Restenose nach Angioplastie oder Stent-Platzierung und dergleichen.\nTransplant vascular diseases of interest include atherosclerosis, coronary vascular disease after transplantation, vein graft stenosis, peri-anastomotic prosthetic restenosis, restenosis after angioplasty or stent placement, and the like.\n\n\n\n\n\n\n \nSTAND DER TECHNIK\nSTATE OF THE ART\n\n\n\n\n\n\n \nAndere Azaindolderivate sind als Kinase-Inhibitoren in WO2004016609, WO1999020624, WO2004078756, WO2005062795, WO2005085244, WO2005095400, WO2006004984, WO2006127587, WO2006017443, WO2006112828, WO2004032874, WO2007002433 WO2007002325, WO2007007919, WO2007044779, WO2007067537 WO2007077949, US7282588, WO2007135398, WO2007076320,\nOther azaindole derivatives are useful as kinase inhibitors, in WO2004016609, WO1999020624, WO2004078756, WO2005062795, WO2005085244, WO2005095400, WO2006004984, WO2006127587, WO2006017443, WO2006112828, WO2004032874, WO2007002433 WO2007002325, WO2007007919, WO2007044779, WO2007067537 WO2007077949, US7282588, WO2007135398, WO2007076320,\n\n\n\n\n\n\n \nWO2006114520, WO2008014249 beschrieben.\nWO2006114520, WO2008014249 described.\n\n\n\n\n\n\n \nZUSAMMENFASSUNG DER ERFINDUNG\nSUMMARY OF THE INVENTION\n\n\n\n\n\n\n \nDie Erfindung betrifft Verbindungen der Formel I\nThe invention relates to compounds of the formula I.\n\n\n\n\n\n\n \n \n\n worin\n \n wherein\n\n\n\n\n\n\n \nX\n1\n, X\n2\n,\nX \n1\n , X \n2\n ,\n\n\n\n\n\n\n \nX\n3\n, X\n4\n jeweils unabhängig voneinander CH oder N, wobei nur einer der Reste X\n1\n, X\n2\n, X\n3\n, X\n4\n N bedeutet, R\n1\n H, CN, HaI, Het\n2\n, A, COOH, COOA oder CONH(CH\n2\n)\nm\nNA\n2\n, \n\n R\n2\n H, Het\n1\n oder Ar\n1\n \nX \n3\n , X \n4 are\n each, independently of one another, CH or N, where only one of the radicals X \n1\n , X \n2\n , X \n3\n , X \n4 is\n N, R \n1 is\n H, CN, Hal, Het \n2\n , A, COOH, COOA or CONH ( CH \n2\n ) \nm\n NA \n2\n ,  R \n2\n H, Het \n1\n or Ar \n1\n \n\n\n\n\n\n\n \nR\n3\n H, (CH\n2\n)\nn\nAr oder Het\n1\n, wobei einer der Reste R\n2\n oder R\n3\n ≠ H ist, R\n4\n H, A, (CH\n2\n)\nn\nAr oder Het\n2\n,\nR \n3 is\n H, (CH \n2\n ) \nn\n Ar or Het \n1\n , where one of the radicals R \n2\n or R \n3\n ≠ H, R \n4 is\n H, A, (CH \n2\n ) \nn\n Ar or Het \n2\n ,\n\n\n\n\n\n\n \nHet\n1\n einen ein- oder zweikernigen aromatischen Heterocyclus mit 1 bis 4 N-, O- und/oder S-Atomen, der unsubstituiert oder ein-, zwei- oder dreifach durch HaI, A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein kann, Het\n2\n einen einkernigen ungesättigten oder gesättigten Heterocyclus mit 1 bis 2 N und/oder O-Atomen, der ein- oder zweifach durch\nHet \n1 is\n a mono- or binuclear aromatic heterocycle having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NH \n2\n and / or NHCH \n2\n Ar Het \n2 may be\n a mononuclear unsaturated or saturated heterocycle having 1 to 2 N and / or O atoms, the one or two times by\n\n\n\n\n\n\n \nA substituiert sein kann,\nA can be substituted\n\n\n\n\n\n\n \nAr unsubstituiertes oder ein-, zwei- oder dreifach durch HaI, A, OH, OA, CN, NO\n2\n, SO\n2\nA, COOH, COOA, NH\n2\n, NHA, NA\n2\n,\nAr is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, CN, NO \n2\n , SO \n2\n A, COOH, COOA, NH \n2\n , NHA, NA \n2\n ,\n\n\n\n\n\n\n \nCHO, COA, CHO, CONH\n2\n, CONHA, SO\n2\nNH\n2\n, SO\n2\nNHA CONA\n2\n und/oder NHCOA substituiertes Phenyl,\nCHO, COA, CHO, CONH \n2\n , CONHA, SO \n2\n NH \n2\n , SO \n2\n NHA CONA \n2\n and / or NHCOA substituted phenyl,\n\n\n\n\n\n\n \nA unverzweigtes oder verzweigtes Alkyl mit 1-10 C-Atomen, worin 1-7 H-Atome durch OH, F, Cl und/oder Br ersetzt sein können,\nA is unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and / or Br,\n\n\n\n\n\n\n \nHaI F, Cl, Br oder I, m 1 , 2, 3 oder 4, n O, 1 , 2, 3 oder 4, bedeuten, sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen,\nHal is F, Cl, Br or I, m is 1, 2, 3 or 4, n is O, 1, 2, 3 or 4, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios,\n\n\n\n\n\n\n \nUnter Verbindungen der Formel I versteht man auch die Hydrate und Solvate dieser Verbindungen, ferner pharmazeutisch verwendbare Derivate. Gegenstand der Erfindung sind auch die optisch aktiven Formen (Stereoisomeren), die Enantiomeren, die Racemate, die Diastereomeren sowie die Hydrate und Solvate dieser Verbindungen. Unter Solvate der Verbindungen werden Anlagerungen von inerten Lösungsmittelmolekülen an die \n\n Verbindungen verstanden, die sich aufgrund ihrer gegenseitigen Anziehungskraft ausbilden. Solvate sind z.B. Mono- oder Dihydrate oder Alkoholate.\nCompounds of the formula I are also understood as meaning the hydrates and solvates of these compounds, and also pharmaceutically usable derivatives. The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. Among solvates of the compounds are additions of inert solvent molecules to the  Understand connections that develop because of their mutual attraction. Solvates are, for example, mono- or dihydrate or alcoholates.\n\n\n\n\n\n\n \nUnter pharmazeutisch verwendbaren Derivaten versteht man z.B. die Salze der erfindungsgemäßen Verbindungen als auch sogenannte Prodrug-\nPharmaceutically usable derivatives are understood, for example, as the salts of the compounds according to the invention as well as so-called prodrugs\n\n\n\n\n\n\n \nVerbindungen.\nLinks.\n\n\n\n\n\n\n \nUnter Prodrug-Derivaten versteht man mit z. B. Alkyl- oder Acylgruppen, Zuckern oder Oligopeptiden abgewandelte Verbindungen der Formel I\n1\n die im Organismus rasch zu den wirksamen erfindungsgemäßen Verbindungen gespalten werden.\nUnder prodrug derivatives is understood with z. As alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I \n1\n which are rapidly cleaved in the organism to the active compounds of the invention.\n\n\n\n\n\n\n \nHierzu gehören auch bioabbaubare Polymerderivate der erfindungsgemäßen Verbindungen, wie dies z. B. in Int. J. Pharm. 115, 61-67 (1995) beschrieben \nist\n \nThese include biodegradable polymer derivatives of the compounds of the invention, as z. In Int. J. Pharm. 115, 61-67 (1995) \ndescribed\n \n\n\n\n\n\n\n \nDer Ausdruck \"wirksame Menge\" bedeutet die Menge eines Arzneimittels oder eines pharmazeutischen Wirkstoffes, die eine biologische oder medizinische Antwort in einem Gewebe, System, Tier oder Menschen hervorruft, die z.B. von einem Forscher oder Mediziner gesucht oder erstrebt wird.\nThe term \"effective amount\" means the amount of a drug or pharmaceutical agent which elicits a biological or medical response in a tissue, system, animal or human, e.g. sought or desired by a researcher or physician.\n\n\n\n\n\n\n \nDarüberhinaus bedeutet der Ausdruck \"therapeutisch wirksame Menge\" eine\nIn addition, the term \"therapeutically effective amount\" means one\n\n\n\n\n\n\n \nMenge, die, verglichen zu einem entsprechenden Subjekt, das diese Menge nicht erhalten hat, folgendes zur Folge hat: verbesserte Heilbehandlung, Heilung, Prävention oder Beseitigung einer Krankheit, eines Krankheitsbildes, eines Krankheitszustandes, eines Leidens, einer Störung oder von Nebenwirkungen oder auch die Verminderung des Fortschreitens einer Krankheit, eines Leidens oder einer Störung.\nAmount which, compared to a corresponding subject, which has not received this amount, the following: improved treatment, cure, prevention or elimination of a disease, a disease, a disease state, a disease, a disorder or side effects or the Reduction of the progression of a disease, a disease or a disorder.\n\n\n\n\n\n\n \nDie Bezeichnung \"therapeutisch wirksame Menge\" umfaßt auch die Mengen, die wirkungsvoll sind, die normale physiologische Funktion zu erhöhen. \n\n Gegenstand der Erfindung ist auch die Verwendung von Mischungen der\nThe term \"therapeutically effective amount\" also includes the amounts effective to increase normal physiological function.  The invention also provides the use of mixtures of\n\n\n\n\n\n\n \nVerbindungen der Formel I\n1\n z.B. Gemische zweier Diastereomerer z.B. im\nCompounds of formula I \n1\n for example mixtures of two diastereomers, for example in\n\n\n\n\n\n\n \nVerhältnis 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :10, 1 :100 oder 1 :1000.\nRatio 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1:10, 1: 100 or 1: 1000.\n\n\n\n\n\n\n \nBesonders bevorzugt handelt es sich dabei um Mischungen stereoisomerer\nParticularly preferred are mixtures of stereoisomeric\n\n\n\n\n\n\n \nVerbindungen.\nLinks.\n\n\n\n\n\n\n \nGegenstand der Erfindung sind die Verbindungen der Formel I und ihre Salze sowie ein Verfahren zur Herstellung von Verbindungen der Formel I sowie ihrer pharmazeutisch verwendbaren Salze, Tautomeren und Stereoisomeren, dadurch gekennzeichnet, daß man a) zur Herstellung einer Verbindung der Formel I, worin R\n4\n H bedeutet, eine Verbindung der Formel Il\nThe invention relates to the compounds of formula I and their salts and to a process for the preparation of compounds of formula I and their pharmaceutically acceptable salts, tautomers and stereoisomers, characterized in that a) for the preparation of a compound of formula I, wherein R \n4\n H means a compound of formula II\n\n\n\n\n\n\n \n \n\n Boc\n \n Boc\n\n\n\n\n\n\n \nworin X\n1\n, X\n2\n, X\n3\n, X\n4\n, R\n1\n und R\n2\n die in Anspruch 1 angegebenen Bedeutungen haben\nwherein X \n1\n , X \n2\n , X \n3\n , X \n4\n , R \n1\n and R \n2 have\n the meanings given in claim 1\n\n\n\n\n\n\n \nmit einer Verbindung der Formel III\nwith a compound of formula III\n\n\n\n\n\n\n \nR\n3\n-L\nR \n3\n -L\n\n\n\n\n\n\n \nworin R\n3\n die in Anspruch 1 angegebene Bedeutung hat, und L einen Boronsäure- oder Boronsäureesterrest bedeutet, \n\n umsetzt, und anschließend oder gleichzeitig die Boc-Gruppe abspaltet,\nwherein R \n3 has\n the meaning given in claim 1, and L denotes a boronic acid or boronic ester radical,  and then or simultaneously splits off the Boc group,\n\n\n\n\n\n\n \noder\nor\n\n\n\n\n\n\n \nb) zur Herstellung einer Verbindung der Formel I, worin R\n4\n H bedeutet, eine Verbindung der Formel IV\nb) for the preparation of a compound of formula I, wherein R \n4 is\n H, a compound of formula IV\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nworin X\n1\n, X\n2\n, X\n3\n, X\n4\n, R\n1\n und R\n3\n die in Anspruch 1 angegebenen Bedeutungen haben, und R\n4\n H bedeutet,\nin which X \n1\n , X \n2\n , X \n3\n , X \n4\n , R \n1\n and R \n3 have\n the meanings given in claim 1, and R \n4\n denotes H,\n\n\n\n\n\n\n \nmit einer Verbindung der Formel V\nwith a compound of formula V\n\n\n\n\n\n\n \nR\n2\n-L V\nR \n2\n -LV\n\n\n\n\n\n\n \nworin R\n2\n die in Anspruch 1 angegebene Bedeutung hat, und L einen Boronsäure- oder Boronsäureesterrest bedeutet,\nwherein R \n2 has\n the meaning given in claim 1, and L denotes a boronic acid or boronic ester radical,\n\n\n\n\n\n\n \numsetzt,\nimplements,\n\n\n\n\n\n\n \noder\nor\n\n\n\n\n\n\n \nc) zur Herstellung einer Verbindung der Formel I, worin R\n4\n H bedeutet, eine Verbindung der Formel VI \n\n \n\n\n\nc) for the preparation of a compound of the formula I in which R \n4 is\n H, a compound of the formula VI \n \n\n\n\n\n\n\n \nworin X\n1\n, X\n2\n, X\n3\n, X\n4\n und R\n1\n die in Anspruch 1 angegebenen Bedeutungen haben,\nin which X \n1\n , X \n2\n , X \n3\n , X \n4\n and R \n1 have\n the meanings given in claim 1,\n\n\n\n\n\n\n \nmit einer Verbindung der Formel VII\nwith a compound of formula VII\n\n\n\n\n\n\n \nR\n2\n-C≡C-R\n3\n VII\nR \n2\n -C≡CR \n3\n VII\n\n\n\n\n\n\n \nworin R\n2\n und R\n3\n die in Anspruch 1 angegebenen Bedeutungen haben,\nwherein R \n2\n and R \n3 have\n the meanings given in claim 1,\n\n\n\n\n\n\n \numsetzt,\nimplements,\n\n\n\n\n\n\n \nund/oder eine Base oder Säure der Formel I in eines ihrer Salze umwandelt.\nand / or converting a base or acid of the formula I into one of its salts.\n\n\n\n\n\n\n \nVor- und nachstehend haben die Reste X\n1\n, X\n2\n, X\n3\n, X\n4\n, R\n1\n, R\n2\n, R\n3\n und R\n4\n die bei der Formel I angegebenen Bedeutungen, sofern nicht ausdrücklich etwas anderes angegeben ist.\nAbove and below, the radicals X \n1,\n X \n2,\n X \n3,\n X \n4,\n R \n1,\n R \n2,\n R \n3\n and R \n4\n have the meanings indicated for the formula I, unless expressly stated otherwise.\n\n\n\n\n\n\n \nFür alle Reste, die mehrfach auftreten, daß deren Bedeutungen unabhängig voneinander sind.\nFor all residues that occur several times, that their meanings are independent of each other.\n\n\n\n\n\n\n \nA bedeutet Alkyl, ist unverzweigt (linear) oder verzweigt, und hat 1 , 2, 3, 4, 5, 6, 7, 8, 9 oder 10 C-Atome. A bedeutet vorzugsweise Methyl, weiterhin Ethyl, Propyl, isopropyi, Butyi, Isobutyl, sek.-Butyl oder tert.-Butyl, ferner auch Pentyl, 1-, 2- oder 3-Methylbutyl, 1 ,1- , 1 ,2- oder 2,2-Dimethylpropyl, 1- Ethylpropyl, Hexyl, 1- , 2- , 3- oder 4-Methylpentyl, 1 ,1- , 1 ,2- , 1 ,3- , 2,2- , 2,3- oder 3,3-Dimethylbutyl, 1- oder 2-Ethylbutyl, 1 -Ethyl- 1-methyl- \n\n propyl, 1-Ethyl-2-methylpropyl, 1 ,1 ,2- oder 1 ,2,2-Trimethylpropyl, weiter bevorzugt z.B. Trifluormethyl.\nA is alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methyl-butyl, 1, 1, 1, 2 or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methyl  propyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, more preferably, for example, trifluoromethyl.\n\n\n\n\n\n\n \nA bedeutet besonders bevorzugt unverzweigtes oder verzweigtes Alkyl mit 1- 10 C-Atomen, worin 1-7 H-Atome durch OH, F, Cl und/oder Br ersetzt sein können.\nA particularly preferably denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms can be replaced by OH, F, Cl and / or Br.\n\n\n\n\n\n\n \nA bedeutet ganz besonders bevorzugt Alkyl mit 1 , 2, 3, 4, 5 oder 6 C- Atomen, vorzugsweise Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, sek.- Butyl, tert.-Butyl, Pentyl, Hexyl, Trifluormethyl, Pentafluorethyl oder 1 ,1 ,1- 10 Trifluorethyl.\nA very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl , Pentafluoroethyl or 1, 1, 1-10 trifluoroethyl.\n\n\n\n\n\n\n \nR\n1\n bedeutet vorzugsweise CN, HaI oder Het\n2\n, ferner H, A, COOH, COOA, CONH\n2\n, CONH(CH\n2\n)\nm\nNA\n2\n oder CONH(CH\n2\n)\nm\nHet\n2\n. ^ \nc\n R\n2\n bedeutet vorzugsweise Het\n1\n oder Ar, ferner H.\nR \n1\n is preferably CN, Hal or Het \n2\n , furthermore H, A, COOH, COOA, CONH \n2\n , CONH (CH \n2\n ) \nm\n NA \n2\n or CONH (CH \n2\n ) \nm\n Het \n2\n . ^ \nc\n R \n2\n is preferably Het \n1\n or Ar, furthermore H.\n\n\n\n\n\n\n \nR\n3\n bedeutet vorzugsweise (CH\n2\n)\nn\nAr oder Het\n1\n, ferner H. R\n4\n bedeutet vorzugsweise H, ferner A, (CH\n2\n)\nn\nAr oder Het\n2\n.\nR \n3\n is preferably (CH \n2\n ) \nn\n Ar or Het \n1\n , furthermore H. R \n4\n is preferably H, furthermore A, (CH \n2\n ) \nn\n Ar or Het \n2\n .\n\n\n\n\n\n\n \nAr bedeutet z.B. Phenyl, o-, m- oder p-Tolyl, o-, m- oder p-Ethylphenyl, o-,\nAr means e.g. Phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-,\n\n\n\n\n\n\n \n20 m- oder p-Propylphenyl, o-, m- oder p-lsopropylphenyl, o-, m- oder p-tert.-\n20 m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert.-\n\n\n\n\n\n\n \nButylphenyl, o-, m- oder p-Hydroxyphenyl, o-, m- oder p-Nitrophenyl, o-, m- oder p-Aminophenyl, o-, m- oder p-(N-Methylamino)-phenyl, o-, m- oder p- (N-Methylaminocarbonyl)-phenyl, o-, m- oder p-Acetamidophenyl, o-, m- 5 oder p-Methoxyphenyl, o-, m- oder p-Ethoxyphenyl, o-, m- oder p-Ethoxy- carbonylphenyl, o-, m- oder p-(N,N-Dimethylamino)-phenyl, o-, m- oder p- (N,N-Dimethylaminocarbonyl)-phenyl, o-, m- oder p-(N-Ethylamino)-phenyl, o-, m- oder p-(N,N-Diethylamino)-phenyl, o-, m- oder p-Fluorphenyl, o-, m- Q oder p-Bromphenyl, o-, m- oder p- Chlorphenyl, o-, m- oder p-(Methylsulfon- amido)-phenyl, o-, m- oder p-(Methylsulfonyl)-phenyl, o-, m- oder p- Cyanphenyl, o-, m- oder ρ-Carboxyρhenyi, o-, m- oder p- Methoxycarbonylphenyl, o-, m- oder p-Aminosulfonylphenyl, weiter bevorzugt\nButylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino) -phenyl, o- , m- or p- (N-methylaminocarbonyl) -phenyl, o-, m- or p-acetamidophenyl, o-, m-5 or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p- (N, N-dimethylamino) -phenyl, o-, m- or p- (N, N-dimethylaminocarbonyl) -phenyl, o-, m- or p (N-ethylamino) -phenyl, o-, m- or p- (N, N-diethylamino) -phenyl, o-, m- or p-fluorophenyl, o-, m-Q or p-bromophenyl, , m- or p-chlorophenyl, o-, m- or p- (methylsulfonamido) -phenyl, o-, m- or p- (methylsulfonyl) -phenyl, o-, m- or p-cyanophenyl, o- , m- or ρ-Carboxyρhenyi, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-Aminosulfonylphenyl, more preferred\n\n\n\n\n\n\n \n2,3-, 2,4-, 2,5-, 2,6-, 3,4- oder 3,5-Difluorphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- 5 oder 3,5-Dichlorphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- oder 3,5-Dibromphenyl,\n2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6- , 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl,\n\n\n\n\n\n\n \n2,4- oder 2,5-Dinitrophenyl, 2,5- oder 3,4-Dimethoxyphenyl, 3-Nitro-4-chlor- \n\n phenyl, S-Amino^-chlor-, 2-Amino-3-chlor-, 2-Amino-4-chlor-, 2-Amino-5- chlor- oder 2-Amino-6-chlorphenyl, 2-Nitro-4-N,N-dimethylamino- oder 3- Nitro-4-N,N-dimethylaminophenyl, 2,3-Diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-,\n2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chloro  phenyl, S-amino-chloro, 2-amino-3-chloro, 2-amino-4-chloro, 2-amino-5-chloro or 2-amino-6-chlorophenyl, 2-nitro-4 -N, N-dimethylamino or 3-nitro-4-N, N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-,\n\n\n\n\n\n\n \n2,4,6- oder 3,4,5-Trichlorphenyl, 2,4,6-Trimethoxyphenyl, 2-Hydroxy-3,5- dichlorphenyl, p-lodphenyl, 3,6-Dichlor-4-aminophenyl, 4-Fluor-3- chlorphenyl, 2-Fluor-4-bromphenyl, 2,5-Difluor-4-bromphenyl, 3-Brom-6- methoxyphenyl, 3-Chlor-6-methoxyphenyl, 3-Chlor-4-acetamidophenyl, 3- Fluor-4-methoxyphenyl, 3-Amino-6-methylphenyl, 3-Chlor-4-0 acetamidophenyl oder 2,5-Dimethyl-4-chlorphenyl.\n2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro 3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro 4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-O-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.\n\n\n\n\n\n\n \nAr bedeutet besonders bevorzugt unsubstituiertes oder ein-, zwei- oder dreifach durch HaI, A, OH, OA, CN, NO\n2\n und/oder SO\n2\nA substituiertes5 Phenyl.\nAr is particularly preferably unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, CN, NO \n2\n and / or SO \n2\n A 5 substituted phenyl.\n\n\n\n\n\n\n \nHet\n1\n bedeutet, ungeachtet weiterer Substitutionen, z.B. 2- oder 3-Furyl, 2- oder 3-Thienyl, 1-, 2- oder 3-Pyrrolyl, 1-, 2, 4- oder 5-lmidazolyl, 1-, 3-, A- oder 5-Pyrazolyl, 2-, 4- oder 5-Oxazolyl, 3-, 4- oder 5-lsoxazolyl, 2-, 4- oder0\nHet \n1\n means, notwithstanding further substitutions, for example 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3- , A- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 0\n\n\n\n\n\n\n \n5-Thiazolyl, 3-, 4- oder 5-lsothiazolyl, 2-, 3- oder 4-Pyridyl, 2-, 4-, 5- oder 6-\n5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-\n\n\n\n\n\n\n \nPyrimidinyl, weiterhin bevorzugt 1 ,2,3-TriazoM-, -4- oder -5-yl, 1 ,2,4-Triazol- 1-, -3- oder 5-yl, 1- oder 5-Tetrazolyl, 1 ,2,3-Oxadiazol-4- oder -5-yl, 1 ,2,4- Oxadiazol-3- oder -5-yl, 1 ,3,4-Thiadiazol-2- oder -5-yl, 1 ,2,4-Thiadiazol-3-5 oder -5-yl, 1,2,3-Thiadiazol-4- oder -5-yl, 3- oder 4-Pyridazinyl, Pyrazinyl, 1-, 2-, 3-, A-, 5-, 6- oder 7-lndolyl, A- oder 5-lsoindolyl, Indazolyl, 1-, 2-, A- oder 5-Benzimidazolyl, 1-, 3-, A-, 5-, 6- oder 7-Benzopyrazolyl, 2-, A-, 5-, 6- oder 7-Benzoxazolyl, 3-, A-, 5-, 6- oder 7- Benzisoxazolyl, 2-, A-, 5-, 6- oder 7-Q Benzothiazolyl, 2-, A-, 5-, 6- oder 7-Benzisothiazolyl, A-, 5-, 6- oder 7-Benz- 2,1 ,3-oxadiazolyl, 2-, 3-, A-, 5-, 6-, 7- oder 8-Chinolyl, 1-, 3-, A-, 5-, 6-, 7- oder 8-isochinoiyi, 3-, A-, 5-, 6-, 7- oder 8-Cιnnolϊnyϊ, 2-, 4-, 5-, 6-, 7- oder 8- Chinazolinyl, 5- oder 6-Chinoxalinyl, 2-, 3-, 5-, 6-, 7- oder 8-2H-\nPyrimidinyl, furthermore preferably 1, 2,3-triazoM, -4- or -5-yl, 1, 2,4-triazol-1, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1, 3,4-thiadiazol-2 or -5-yl, 1, 2, 4-thiadiazole-3-5 or -5-yl, 1,2,3-thiadiazol-4 or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, A-, 5-, 6- or 7-indolyl, A- or 5-isoindolyl, indazolyl, 1-, 2-, A- or 5-benzimidazolyl, 1-, 3-, A-, 5-, 6- or 7-benzopyrazolyl , 2-, A-, 5-, 6- or 7-benzoxazolyl, 3-, A-, 5-, 6- or 7- benzisoxazolyl, 2-, A-, 5-, 6- or 7-Q benzothiazolyl, 2-, A-, 5-, 6- or 7-Benzisothiazolyl, A, 5-, 6- or 7-Benz-2,1,3-oxadiazolyl, 2-, 3-, A-, 5-, 6 -, 7- or 8-quinolyl, 1-, 3-, A-, 5-, 6-, 7- or 8-isochinoiyi, 3-, A-, 5-, 6-, 7- or 8-Cιnnolϊnyϊ, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-\n\n\n\n\n\n\n \nBenzo[1 ,4]oxazinyl, weiter bevorzugt 1 ,3-Benzodioxol-5-yl, 1 ,4-Benzodioxan-5\nBenzo [1,4] oxazinyl, more preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-5\n\n\n\n\n\n\n \n6-yl, 2,1 ,3-Benzothiadiazol-4- oder -5-yl, 2,1 ,3-Benzoxadiazol-5-yl oder\n6-yl, 2,1,3-benzothiadiazol-4 or -5-yl, 2,1,3-benzoxadiazol-5-yl or\n\n\n\n\n\n\n \nDibenzofuranyl. \n\n Het\n1\n bedeutet besonders bevorzugt Thiazolyl, Thiophenyl, Furanyl, Pyrrolyl, Oxazolyl, Isoxazolyl, Oxadiazolyl, Pyrazolyl, Imidazolyl, Triazolyl,\nDibenzofuranyl.  Het \n1\n particularly preferably denotes thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl,\n\n\n\n\n\n\n \nThiadiazolyl, Pyridazinyl, Pyrazinyl, Pyridinyl, Pyrimidinyl, Benzimidazolyl, 5\nThiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl, pyrimidinyl, benzimidazolyl, 5\n\n\n\n\n\n\n \nBenzotriazolyl, Indolyl, Benzo[1 ,3]dioxolyl, Indazolyl, Benzo[2,1 ,3]thiadiazolyl oder Pyrrolo[2,3-b]pyridinyl, wobei die Heterocyclen auch ein-, zwei- oder dreifach durch HaI\n1\n A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein können.\nBenzotriazolyl, indolyl, benzo [1,3] dioxolyl, indazolyl, benzo [2,1,3] thiadiazolyl or pyrrolo [2,3-b] pyridinyl, where the heterocycles are also mono-, di- or trisubstituted by Hal \n1\n A, NH \n2\n and / or NHCH \n2\n Ar may be substituted.\n\n\n\n\n\n\n \n10\n10\n\n\n\n\n\n\n \nHet\n2\n bedeutet ungeachtet weiterer Substitutionen z. B. 2,3-Dihydro-2-, -3-, - A- oder -5-furyl, 2,5-Dihydro-2-, -3-, -A- oder 5-furyl, Tetrahydro-2- oder -3- furyl, 1 ,3-Dioxolan-4-yl, Tetrahydro-2- oder -3-thienyl, 2,3-Dihydro-1-, -2-, -3-,\nHet \n2\n means regardless of further substitutions z. For example, 2,3-dihydro-2-, -3-, - A- or -5-furyl, 2,5-dihydro-2-, -3-, -A- or 5-furyl, tetrahydro-2-or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-,\n\n\n\n\n\n\n \n^ c -4- oder -5-pyrrolyl, 2,5-Dihydro-1-, -2-, -3-, -4- oder -5-pyrrolyl, 1-, 2- oder 3- Pyrrolidinyl, Tetrahydro-1-, -2- oder -4-imidazolyl, 2,3-Dihydro-1-, -2-, -3-, -4- oder -5-pyrazolyl, Tetrahydro-1-, -3- oder -4-pyrazolyl, 1 ,4-Dihydro-1-, -2-, -3- oder -4-pyridyl, 1 ,2,3,4-Tetrahydro-1-, -2-, -3-, -A-, -5- oder -6-pyridyl, 1-, 2-,\n^ c -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1 -, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl , 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -A-, -5 - or -6-pyridyl, 1-, 2-,\n\n\n\n\n\n\n \n3- oder 4-Piperidinyl, 2-, 3- oder 4-Morpholinyl, Tetra hydro-2-, -3- oder -4-\n3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetra-hydro-2-, -3- or -4-\n\n\n\n\n\n\n \n20 pyranyl, 1 ,4-Dioxanyl, 1 ,3-Dioxan-2-, -A- oder -5-yl, Hexahydro-1-, -3- oder -\n20 pyranyl, 1, 4-dioxanyl, 1, 3-dioxane-2, -A- or -5-yl, hexahydro-1, -3- or -\n\n\n\n\n\n\n \n4-pyridazinyl, Hexahydro-1-, -2-, -A- oder -5-pyrimidinyl, 1-, 2- oder 3-\n4-pyridazinyl, hexahydro-1-, -2-, -A- or -5-pyrimidinyl, 1-, 2- or 3-\n\n\n\n\n\n\n \nPiperazinyl.\nPiperazinyl.\n\n\n\n\n\n\n \nHet\n2\n bedeutet besonders bevorzugt Piperidinyl, Pyrrolidinyl, Morpholinyl, 25 Imidazolidinyl, Piperazinyl, Oxazolidinyl oder Tetrahydropyranyl, wobei die Heterocyclen auch ein- oder zweifach durch A substituiert sein können.\nHet \n2\n particularly preferably denotes piperidinyl, pyrrolidinyl, morpholinyl, imidazolidinyl, piperazinyl, oxazolidinyl or tetrahydropyranyl, where the heterocycles may also be monosubstituted or disubstituted by A.\n\n\n\n\n\n\n \nHaI bedeutet vorzugsweise F, Cl oder Br, aber auch I, besonders bevorzugt Q F oder Cl; m bedeutet vorzugsweise 1 oder 2; n bedeutet vorzugsweise 0, 1 ,\nHal is preferably F, Cl or Br, but also I, more preferably Q is F or Cl; m is preferably 1 or 2; n is preferably 0, 1,\n\n\n\n\n\n\n \n2 oder 3.\n2 or 3.\n\n\n\n\n\n\n \nFür die gesamte Erfindung gilt, daß sämtliche Reste, die mehrfach auftreten, gleich oder verschieden sein können, d.h. unabhängig voneinander sind. 5 \n\n Die Verbindungen der Formel I können ein oder mehrere chirale Zentren besitzen und daher in verschiedenen stereoisomeren Formen vorkommen. Die Formel I umschließt alle diese Formen.\nIt is true for the entire invention that all radicals which occur more than once can be the same or different, ie are independent of one another. 5  The compounds of the formula I can possess one or more chiral centers and therefore occur in different stereoisomeric forms. Formula I encompasses all these forms.\n\n\n\n\n\n\n \nDementsprechend sind Gegenstand der Erfindung insbesondere diejenigen\nAccordingly, the invention is particularly those\n\n\n\n\n\n\n \nVerbindungen der Formel I\n1\n in denen mindestens einer der genannten Reste eine der vorstehend angegebenen bevorzugten Bedeutungen hat. Einige bevorzugte Gruppen von Verbindungen können durch die folgenden Teilformeln Ia bis Ij ausgedrückt werden, die der Formel I entsprechen und worin die nicht näher bezeichneten Reste die bei der Formel I angegebene Bedeutung haben, worin jedoch\nCompounds of the formula I \n1\n wherein at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds can be expressed by the following partial formulas Ia to Ij which correspond to the formula I and in which the unspecified radicals have the meaning given in the formula I but in which\n\n\n\n\n\n\n \nin Ia R\n1\n H, CN, HaI, Het\n2\n, A, COOH, COOA, CONH\n2\n,\nin Ia R \n1\n H, CN, Hal, Het \n2\n , A, COOH, COOA, CONH \n2\n ,\n\n\n\n\n\n\n \nCONH(CH\n2\n)\nm\nNA\n2\n oder CONH(CH\n2\n)\nm\nHet\n2\n bedeutet;\nCONH (CH \n2\n ) \nm\n NA \n2\n or CONH (CH \n2\n ) \nm\n Het \n2\n ;\n\n\n\n\n\n\n \nin Ib R\n2\n Het\n1\n oder Ar bedeutet;\nin Ib R \n2\n Het is \n1\n or Ar;\n\n\n\n\n\n\n \nin Ic R\n3\n (CH\n2\n)\nn\nAr oder Het\n1\n bedeutet;\nin Ic R \n3\n (CH \n2\n ) \nn\n Ar or Het \n1\n ;\n\n\n\n\n\n\n \nin Id R\n4\n H bedeutet;\nin Id R \n4\n denotes H;\n\n\n\n\n\n\n \nin Ie Het\n1\n Thiazolyl, Thiophenyl, Furanyl, Pyrrolyl, Oxazolyl, Isoxazolyl, Oxadiazolyl, Pyrazolyl, Imidazolyl, Triazolyl,\nin Ie Het \n1\n thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl,\n\n\n\n\n\n\n \nThiadiazolyl, Pyridazinyl, Pyrazinyl, Pyridinyl, Pyrimidinyl, Benzimidazoiyi, Benzotriazolyi, indoiyi, Benzo[1 ,3jdioxoiyi, Indazolyl, Benzo[2,1 ,3]thiadiazolyl oder Pyrrolo[2,3- b]pyridinyl, \n\n wobei die Heterocyclen auch ein-, zwei- oder dreifach durch HaI, A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein können, bedeutet;\nThiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl, pyrimidinyl, benzimidazoiyi, benzotriazolyi, indoiyi, benzo [1,3-dioxoyl, indazolyl, benzo [2,1,3] thiadiazolyl or pyrrolo [2,3-b] pyridinyl,  wherein the heterocycles may also be mono-, di- or trisubstituted by Hal, A, NH \n2\n and / or NHCH \n2\n Ar, means;\n\n\n\n\n\n\n \nin If Het\n2\n Piperidinyl, Pyrrolidinyl, Morpholinyl, Piperazinyl,\nin If Het \n2\n piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl,\n\n\n\n\n\n\n \nImidazolidinyl, Oxazolidinyl oder Tetrahydropyranyl, wobei die Heterocyclen auch ein- oder zweifach durch A substituiert sein können, bedeutet;\nImidazolidinyl, oxazolidinyl or tetrahydropyranyl, where the heterocycles may also be monosubstituted or disubstituted by A, means;\n\n\n\n\n\n\n \nin Ig Ar unsubstituiertes oder ein-, zwei- oder dreifach durch HaI, A, OH, OA, CN, NO\n2\n und/oder SO\n2\nA substituiertes\nunsubstituted or mono-, di- or trisubstituted by one of Hal, A, OH, OA, CN, NO \n2\n and / or SO \n2\n A in Ig Ar\n\n\n\n\n\n\n \nPhenyl, bedeutet;\nPhenyl, means;\n\n\n\n\n\n\n \nin Ih A unverzweigtes oder verzweigtes Alkyl mit 1-6 C-Atomen, worin 1-5 H-Atome durch F und/oder Cl ersetzt sein können, bedeutet;\nin Ih A is unbranched or branched alkyl having 1-6 C atoms, wherein 1-5 H atoms may be replaced by F and / or Cl;\n\n\n\n\n\n\n \nin Ii X\n1\n, X\n2\n,\nin II X \n1\n , X \n2\n ,\n\n\n\n\n\n\n \nX\n3\n, X\n4\n jeweils unabhängig voneinander CH oder N, wobei nur einer der Reste X\n1\n, X\n2\n, X\n3\n, X\n4\n N bedeutet,\nX \n3\n , X \n4 are\n each, independently of one another, CH or N, where only one of the radicals X \n1\n , X \n2\n , X \n3\n , X \n4\n denotes N,\n\n\n\n\n\n\n \nR\n1\n H, CN, HaI, Het\n2\n, A, COOH, COOA, CONH\n2\n, CONH(CH\n2\n)\nm\nNA\n2\n oder CONH(CH\n2\n)\nm\nHet\n2\n,\nR \n1 is\n H, CN, Hal, Het \n2\n , A, COOH, COOA, CONH \n2\n , CONH (CH \n2\n ) \nm\n NA \n2\n or CONH (CH \n2\n ) \nm\n Het \n2\n ,\n\n\n\n\n\n\n \nR\n2\n Het\n1\n oder Ar,\nR \n2\n Het \n1\n or Ar,\n\n\n\n\n\n\n \nR\n3\n (CH\n2\n)\nn\nAr oder Het\n1\n,\nR \n3\n (CH \n2\n ) \nn\n Ar or Het \n1\n ,\n\n\n\n\n\n\n \nR\n4\n H,\nR \n4\n H,\n\n\n\n\n\n\n \nHet\n1\n Thiazolyl, Thiophenyl, Furanyl, Pyrrolyl, Oxazolyl,\nHet \n1\n thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl,\n\n\n\n\n\n\n \nIsoxazolyl, Oxadiazolyl, Pyrazolyl, Imidazolyl, Triazolyl,\nIsoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl,\n\n\n\n\n\n\n \nThiadiazolyl, Pyridazinyl, Pyrazinyl, Pyridinyl, Pyrimidinyl, \n\n Benzimidazolyl, Benzotriazolyl, indolyl, Benzo[1 ,3]dioxolyl,\nThiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl, pyrimidinyl,  Benzimidazolyl, benzotriazolyl, indolyl, benzo [1,3] dioxolyl,\n\n\n\n\n\n\n \nIndazolyl, Benzo[2,1 ,3]thiadiazolyl oder Pyrrolo[2,3- b]pyridinyl, wobei die Heterocyclen auch ein-, zwei- oder dreifach durch HaI, A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein können, Het\n2\n Piperidinyl, Pyrrolidinyl, Morpholinyl, Piperazinyl,\nIndazolyl, benzo [2,1,3] thiadiazolyl or pyrrolo [2,3-b] pyridinyl, where the heterocycles may also be mono-, di- or trisubstituted by Hal, A, NH \n2\n and / or NHCH \n2\n Ar, Het \n2\n piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl,\n\n\n\n\n\n\n \nImidazolidinyl, Oxazolidinyl oder Tetrahydropyranyl, wobei die Heterocyclen auch ein- oder zweifach durch A substituiert sein können, Ar unsubstituiertes oder ein-, zwei- oder dreifach durch HaI,\nImidazolidinyl, oxazolidinyl or tetrahydropyranyl, where the heterocycles may also be monosubstituted or disubstituted by A, Ar is unsubstituted or mono-, di- or trisubstituted by Hal,\n\n\n\n\n\n\n \nA, OH, OA, CN, NO\n2\n und/oder SO\n2\nA substituiertes Phenyl,\nA, OH, OA, CN, NO \n2\n and / or SO \n2\n A substituted phenyl,\n\n\n\n\n\n\n \nA unverzweigtes oder verzweigtes Alkyl mit 1-6 C-Atomen, worin 1-5 H-Atome durch F und/oder Cl ersetzt sein können,\nA is unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and / or Cl,\n\n\n\n\n\n\n \nHaI F, Cl, Br oder I, m 1 , 2, 3 oder 4, n 0, 1 , 2, 3 oder 4, bedeuten;\nHal is F, Cl, Br or I, m is 1, 2, 3 or 4, n is 0, 1, 2, 3 or 4;\n\n\n\n\n\n\n \nX\n1\n, X\n2\n,\nX \n1\n , X \n2\n ,\n\n\n\n\n\n\n \nX\n3\n, X\n4\n jeweils unabhängig voneinander CH oder N, wobei nur einer der Reste X\n1\n, X\n2\n, X\n3\n, X\n4\n N bedeutet, R\n1\n H, CN, HaI, Het\n2\n, A, COOH, COOA, CONH\n2\n, CONH(CH\n2\n)\nm\nNA\n2\n oder CONH(CH\n2\n)\nm\nHet\n2\n,\nX \n3\n , X \n4 are\n each independently CH or N, where only one of X \n1\n , X \n2\n , X \n3\n , X \n4\n N, R \n1 is\n H, CN, Hal, Het \n2\n , A, COOH, COOA, CONH \n2\n , CONH (CH \n2\n ) \nm\n NA \n2\n or CONH (CH \n2\n ) \nm\n Het \n2\n ,\n\n\n\n\n\n\n \nR\n2\n H, Het\n1\n oder Ar,\nR \n2\n H, Het \n1\n or Ar,\n\n\n\n\n\n\n \nR\n3\n H, (CH\n2\n)\nn\nAr oder Het\n1\n, wobei einer der Reste R\n2\n oder R\n3\n ≠ H ist,\nR \n3 is\n H, (CH \n2\n ) \nn\n Ar or Het \n1\n , where one of the radicals R \n2\n or R \n3\n ≠ H,\n\n\n\n\n\n\n \nR\n4\n H\n1\n A, (CH\n2\n)\nn\nAr oder Het\n2\n, \n\n Het\n1\n Thiazolyl, Thiophenyl, Furanyl, Pyrrolyl, Oxazolyl,\nR \n4\n H \n1\n A, (CH \n2\n ) \nn\n Ar or Het \n2\n ,  Het \n1\n thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl,\n\n\n\n\n\n\n \nIsoxazolyl, Oxadiazolyl, Pyrazolyl, Imidazolyl, Triazolyl, Thiadiazolyl, Pyridazinyl, Pyrazinyl, Pyridinyl, Pyrimidinyl,\nIsoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl, pyrimidinyl,\n\n\n\n\n\n\n \nBenzimidazolyl, Benzotriazolyl, Indolyl, Benzo[1 ,3]dioxolyl, 5\nBenzimidazolyl, benzotriazolyl, indolyl, benzo [1,3] dioxolyl, 5\n\n\n\n\n\n\n \nIndazolyl, Benzo[2,1 ,3]thiadiazolyl oder Pyrrolo[2,3- bjpyridinyl, wobei die Heterocyclen auch ein-, zwei- oder dreifach durch HaI, A, NH\n2\n und/oder NHCH\n2\nAr substituiert sein 10 können,\nIndazolyl, benzo [2,1,3] thiadiazolyl or pyrrolo [2,3-bpyridinyl, where the heterocycles may also be monosubstituted, disubstituted or trisubstituted by Hal, A, NH \n2\n and / or NHCH \n2\n Ar,\n\n\n\n\n\n\n \nHet\n2\n Piperidinyl, Pyrrolidinyϊ, Morphoiinyi, Piperazinyi,\nHet \n2\n piperidinyl, pyrrolidinyl, morpholini, piperazinyl,\n\n\n\n\n\n\n \nImidazolidinyl, Oxazolidinyl oder Tetrahydropyranyl, wobei die Heterocyclen auch ein- oder zweifach durch A ^ \nc\n . substituiert sein können,\nImidazolidinyl, oxazolidinyl or tetrahydropyranyl, wherein the heterocycles are also one or two times by A ^ \nc\n . can be substituted\n\n\n\n\n\n\n \nAr unsubstituiertes oder ein-, zwei- oder dreifach durch HaI,\nAr is unsubstituted or mono-, di- or trisubstituted by Hal,\n\n\n\n\n\n\n \nA, OH, OA, CN, NO\n2\n und/oder SO\n2\nA substituiertes\nA, OH, OA, CN, NO \n2\n and / or SO \n2\n A substituted\n\n\n\n\n\n\n \nPhenyl,\nphenyl,\n\n\n\n\n\n\n \nA unverzweigtes oder verzweigtes Alkyl mit 1-6 C-Atomen, worin 1-5 H-Atome durch F und/oder Cl ersetzt sein können,\nA is unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and / or Cl,\n\n\n\n\n\n\n \nHaI F, Cl, Br oder I, m 1 , 2, 3 oder 4, 5 n 0, 1 , 2, 3 oder 4, bedeuten;\nHal is F, Cl, Br or I, m is 1, 2, 3 or 4, 5 n is 0, 1, 2, 3 or 4;\n\n\n\n\n\n\n \nsowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereo- 0 isomere, einschließlich deren Mischungen in allen Verhältnissen.\nand their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.\n\n\n\n\n\n\n \nDie Verbindungen der Formel I und auch die Ausgangsstoffe zu ihrer Herstellung werden im übrigen nach an sich bekannten Methoden hergestellt, wie sie in der Literatur (z.B. in den Standardwerken wie Houben-Weyl, Methoden der organischen Chemie, Georg-Thieme-Verlag, Stuttgart) \n\n beschrieben sind, und zwar unter Reaktionsbedingungen, die für die genannten Umsetzungen bekannt und geeignet sind. Dabei kann man auch von an sich bekannten, hier nicht näher erwähnten Varianten Gebrauch machen.\nThe compounds of formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (eg in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart)  are described, under reaction conditions which are known and suitable for the said reactions. One can also make use of known per se, not mentioned here variants.\n\n\n\n\n\n\n \nVerbindungen der Formel I können vorzugsweise erhalten werden, indem man eine Verbindung der Formel Il mit einer Verbindung der Formel III umsetzt.\nCompounds of the formula I can preferably be obtained by reacting a compound of the formula II with a compound of the formula III.\n\n\n\n\n\n\n \nDie Umsetzung erfolgt unter Bedingungen wie sie dem Fachmann für eine Suzuki-Reaktion bekannt sind.\nThe reaction takes place under conditions known to those skilled in the art for a Suzuki reaction.\n\n\n\n\n\n\n \nDie Ausgangsverbindungen der Formeln Il und III sind in der Regel bekannt. Sind sie neu, so können sie aber nach an sich bekannten Methoden hergestellt werden.\nThe starting compounds of formulas II and III are known in the rule. If they are new, they can be produced by methods known per se.\n\n\n\n\n\n\n \nIn den Verbindungen der Formel Il bedeutet L vorzugsweise\nIn the compounds of the formula II, L is preferably\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nDie Umsetzung erfolgt unter Standardbedingungen einer Suzuki-Kopplung. Die Reaktionszeit liegt je nach den angewendeten Bedingungen zwischen einigen Minuten und 14 Tagen, die Reaktionstemperatur zwischen etwa\nThe reaction is carried out under standard conditions of Suzuki coupling. The reaction time is between a few minutes and 14 days depending on the conditions used, the reaction temperature between about\n\n\n\n\n\n\n \n-30° und 140°, normalerweise zwischen 0° und 100°, insbesondere zwischen etwa 60° und etwa 90°.\n-30 ° and 140 °, normally between 0 ° and 100 °, in particular between about 60 ° and about 90 °.\n\n\n\n\n\n\n \nAls inerte Lösungsmittel eignen sich z.B. Kohlenwasserstoffe wie Hexan, Petrolether, Benzol, Toluol oder XyIoI; chlorierte Kohlenwasserstoffe wie Trichlorethylen, 1 ,2-Dichlorethan, Tetrachlorkohlenstoff, Chloroform oder Dichiormethan; Alkohole wie Methanol, Ethanol, isopropanoi, n-Proρanoi, n- Butanol oder tert.-Butanol; Ether wie Diethylether, Diisopropylether, Tetrahydrofuran (THF) oder Dioxan; Glykolether wie Ethylenglykolmono- methyl- oder -monoethylether (Methylglykol oder Ethylglykol), Ethylen- glykoldimethylether (Diglyme); Ketone wie Aceton oder Butanon; Amide wie \n\n Acetamid, Dimethylacetamid oder Dimethylformamid (DMF); Nitrile wie Acetonitril; Sulfoxide wie Dimethylsulfoxid (DMSO); Schwefelkohlenstoff; Carbonsäuren wie Ameisensäure oder Essigsäure; Nitroverbindungen wie Nitromethan oder Nitrobenzol; Ester wie Ethylacetat oder Gemische der genannten Lösungsmittel. Besonders bevorzugt ist Ethanol, Toluol, Dimethoxyethan und/oder Wasser.\nSuitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers, such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides like  Acetamide, dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethylsulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of said solvents. Particularly preferred is ethanol, toluene, dimethoxyethane and / or water.\n\n\n\n\n\n\n \nVerbindungen der Formel I können weiterhin vorzugsweise erhalten werden, indem man eine Verbindung der Formel IV mit einer Verbindung der Formel V umsetzt.\nCompounds of the formula I can furthermore preferably be obtained by reacting a compound of the formula IV with a compound of the formula V.\n\n\n\n\n\n\n \nDie Umsetzung erfolgt unter Bedingungen wie sie dem Fachmann für eine Suzuki-Reaktion bekannt sind.\nThe reaction takes place under conditions known to those skilled in the art for a Suzuki reaction.\n\n\n\n\n\n\n \nDie Ausgangsverbindungen der Formeln IV und V sind in der Regel bekannt.\nThe starting compounds of formulas IV and V are known in the rule.\n\n\n\n\n\n\n \nSind sie neu, so können sie aber nach an sich bekannten Methoden hergestellt werden.\nIf they are new, they can be produced by methods known per se.\n\n\n\n\n\n\n \nIn den Verbindungen der Formel V bedeutet L vorzugsweise\nIn the compounds of the formula V, L is preferably\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nDie Umsetzung erfolgt unter Standardbedingungen einer Suzuki-Kopplung.\nThe reaction is carried out under standard conditions of Suzuki coupling.\n\n\n\n\n\n\n \nDie Reaktionszeit liegt je nach den angewendeten Bedingungen zwischen einigen Minuten und 14 Tagen, die Reaktionstemperatur zwischen etwa -30° und 140°, normalerweise zwischen 0° und 100°, insbesondere zwischen etwa 60° und etwa 90°. Ais inerte Lösungsmittel eignen sich die oben genannten.\nDepending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature between about -30 ° and 140 °, normally between 0 ° and 100 °, in particular between about 60 ° and about 90 °. As inert solvents are those mentioned above.\n\n\n\n\n\n\n \nVerbindungen der Formel I können weiterhin vorzugsweise erhalten werden, indem man eine Verbindung der Formel VI mit einer Verbindung der Formel VII umsetzt. \n\n Die Ausgangsverbindungen der Formeln VI und VII sind in der Regel bekannt. Sind sie neu, so können sie aber nach an sich bekannten Methoden hergestellt werden.\nCompounds of the formula I can furthermore preferably be obtained by reacting a compound of the formula VI with a compound of the formula VII.  The starting compounds of the formulas VI and VII are generally known. If they are new, they can be produced by methods known per se.\n\n\n\n\n\n\n \nDie Reaktionszeit liegt je nach den angewendeten Bedingungen zwischen 5 einigen Minuten und 14 Tagen, die Reaktionstemperatur zwischen etwa\nThe reaction time is between 5 minutes and 14 days depending on the conditions used, the reaction temperature between about\n\n\n\n\n\n\n \n-30° und 140°, normalerweise zwischen 0° und 100°, insbesondere zwischen etwa 60° und etwa 90°.\n-30 ° and 140 °, normally between 0 ° and 100 °, in particular between about 60 ° and about 90 °.\n\n\n\n\n\n\n \nAls inerte Lösungsmittel eignen sich die oben genannten.\nSuitable inert solvents are the abovementioned.\n\n\n\n\n\n\n \n10\n10\n\n\n\n\n\n\n \nFerner kann man freie Aminogruppen in übiicher Weise mit einem Säurechlorid oder -anhydrid acylieren oder mit einem unsubstituierten oder substituierten Alkylhalogenid alkylieren, zweckmäßig in einem inerten\nFurther, one may acylate free amino groups in a conventional manner with an acid chloride or anhydride or alkylate with an unsubstituted or substituted alkyl halide, suitably in an inert\n\n\n\n\n\n\n \n^ \nc\n Lösungsmittel wie Dichlormethan oder THF und /oder in Gegenwart einer Base wie Triethylamin oder Pyridin bei Temperaturen zwischen -60 und +30°.\n^ \nc\n solvents such as dichloromethane or THF and / or in the presence of a base such as triethylamine or pyridine at temperatures between -60 and + 30 °.\n\n\n\n\n\n\n \nDie Verbindungen der Formeln I können ferner erhalten werden, indem man sie aus ihren funktionellen Derivaten durch Solvolyse, insbesondere Hydrolyse, oder durch Hydrogenolyse in Freiheit setzt.\nThe compounds of formula I can be further obtained by liberating them from their functional derivatives by solvolysis, in particular hydrolysis, or by hydrogenolysis.\n\n\n\n\n\n\n \nBevorzugte Ausgangsstoffe für die Solvolyse bzw. Hydrogenolyse sind solche, die anstelle einer oder mehrerer freier Amino- und/oder Hydroxy- 5 gruppen entsprechende geschützte Amino- und/oder Hydroxygruppen enthalten, vorzugsweise solche, die anstelle eines H-Atoms, das mit einem N-Atom verbunden ist, eine Aminoschutzgruppe tragen, z. B. solche, die der Formel I entsprechen, aber anstelle einer NH\n2\n-Gruppe eine NHR'-Gruppe (worin R\n1\n eine Aminoschutzgruppe bedeutet, z. B. BOC oder CBZ) enthalten. 0\nPreferred starting materials for the solvolysis or hydrogenolysis are those which contain, instead of one or more free amino and / or hydroxyl groups, corresponding protected amino and / or hydroxyl groups, preferably those which, instead of an H atom, which is reacted with an N Atom, carry an amino protecting group, e.g. For example, those corresponding to Formula I but containing, instead of an NH \n2\n group, an NHR 'group (wherein R \n1 represents\n an amino-protecting group, e.g., BOC or CBZ). 0\n\n\n\n\n\n\n \nFerner sind Ausgangsstoffe bevorzugt, die anstelle des H-Atoms einer Hydroxygruppe eine Hydroxyschutzgruppe tragen, z. B. solche, die der Formel I entsprechen, aber anstelle einer Hydroxyphenylgruppe eine R\n11\nO- phenylgruppe enthalten (worin R\" eine Hydroxyschutzgruppe bedeutet). 5 \n\n Es können auch mehrere - gleiche oder verschiedene - geschützte Amino- und/oder Hydroxygruppen im Molekül des Ausgangsstoffes vorhanden sein. Falls die vorhandenen Schutzgruppen voneinander verschieden sind, können sie in vielen Fällen selektiv abgespalten werden.\nFurthermore, preference is given to starting materials which, instead of the H atom of a hydroxy group, carry a hydroxyl-protecting group, eg. For example, those corresponding to Formula I but containing, instead of a hydroxyphenyl group, an R \n11\n O -phenyl group (wherein R \"represents a hydroxy-protecting group)  There may also be several - same or different - protected amino and / or hydroxy groups present in the molecule of the starting material. If the protecting groups present are different from each other, they can be selectively cleaved in many cases.\n\n\n\n\n\n\n \nDer Ausdruck \"Aminoschutzgruppe\" ist allgemein bekannt und bezieht sich auf Gruppen, die geeignet sind, eine Aminogruppe vor chemischen Umsetzungen zu schützen (zu blockieren), die aber leicht entfernbar sind, nachdem die gewünschte chemische Reaktion an anderen Stellen des Moleküls durchgeführt worden ist. Typisch für solche Gruppen sind insbesondere unsubstituierte oder substituierte Acyl-, Aryl-, Aralkoxymethyl- oder Araikyl- gruppen. Da die Aminoschutzgruppen nach der gewünschten Reaktion (oder Reaktionsfolge) entfernt werden, ist ihre Art und Größe im übrigen nicht kritisch; bevorzugt werden jedoch solche mit 1-20, insbesondere 1-8 C- Atomen. Der Ausdruck \"Acylgruppe\" ist im Zusammenhang mit dem vorliegenden Verfahren in weitestem Sinne aufzufassen. Er umschließt von aliphatischen, araliphatischen, aromatischen oder heterocyclischen Carbonsäuren oder Sulfonsäuren abgeleitete Acylgruppen sowie insbesondere Alkoxycarbonyl-, Aryloxycarbonyl- und vor allem Aralkoxycarbonylgruppen. Beispiele für derartige Acylgruppen sind Alkanoyl wie Acetyl, Propionyl,\nThe term \"amino protecting group\" is well known and refers to groups which are capable of protecting (blocking) an amino group from chemical reactions, but which are readily removable after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are in particular unsubstituted or substituted acyl, aryl, aralkoxymethyl or araikyl groups. Moreover, because the amino protecting groups are removed after the desired reaction (or reaction sequence), their type and size is not critical; however, preference is given to those having 1-20, in particular 1-8 C atoms. The term \"acyl group\" is to be understood in the broadest sense in the context of the present process. It encompasses acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of such acyl groups are alkanoyl, such as acetyl, propionyl,\n\n\n\n\n\n\n \nButyryl; Aralkanoyl wie Phenylacetyl; Aroyl wie Benzoyl oder Toluyl; Aryloxy- alkanoyl wie POA; Alkoxycarbonyl wie Methoxycarbonyl, Ethoxycarbonyl, 2,2,2-Trichlorethoxycarbonyl, BOC, 2-lodethoxycarbonyl; Aralkyloxycarbonyl wie CBZ (\"Carbobenzoxy\"), 4-Methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl wie Mtr, Pbf oder Pmc. Bevorzugte Aminoschutzgruppen sind BOC und Mtr, ferner CBZ, Fmoc, Benzyl und Acetyl.\nbutyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as POA; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; Aralkyloxycarbonyl such as CBZ (\"carbobenzoxy\"), 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl such as Mtr, Pbf or Pmc. Preferred amino protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.\n\n\n\n\n\n\n \nDer Ausdruck \"Hydroxyschutzgruppe\" ist ebenfalls allgemein bekannt und bezieht sich auf Gruppen, die geeignet sind, eine Hydroxygruppe vor chemischen Umsetzungen zu schützen, die aber leicht entfernbar sind, nachdem die gewünschte chemische Reaktion an anderen Stellen des Moleküls durchgeführt worden ist. Typisch für solche Gruppen sind die oben genannten unsubstituierten oder substituierten Aryl-, Aralkyl- oder Acylgruppen, ferner auch Alkylgruppen. Die Natur und Größe der Hydroxy- Schutzgruppen ist nicht kritisch, da sie nach der gewünschten chemischen Reaktion oder Reaktionsfolge wieder entfernt werden; bevorzugt sind Grup- \n\n pen mit 1-20, insbesondere 1-10 C-Atomen. Beispiele für Hydroxyschutz- gruppen sind u.a. tert.-Butoxycarbonyl, Benzyl, p-Nitrobenzoyl, p-Toluol- sulfonyl, tert.-Butyl und Acetyl, wobei Benzyl und tert.-Butyl besonders bevorzugt sind. Die COOH-Gruppen in Asparaginsäure und Glutaminsäure werden bevorzugt in Form ihrer tert.-Butylester geschützt (z. B. Asp(OBut)).\nThe term \"hydroxy protecting group\" is also well known and refers to groups which are suitable for protecting a hydroxy group from chemical reactions, but which are readily removable after the desired chemical reaction has been carried out at other sites on the molecule. Typical of such groups are the abovementioned unsubstituted or substituted aryl, aralkyl or acyl groups, and also alkyl groups. The nature and size of the hydroxy-protecting groups is not critical since they are removed after the desired chemical reaction or reaction sequence; preference is given to groups  pen with 1-20, in particular 1-10 C-atoms. Examples of hydroxy protective groups include tert-butoxycarbonyl, benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, with benzyl and tert-butyl being particularly preferred. The COOH groups in aspartic acid and glutamic acid are preferably protected in the form of their tert-butyl esters (eg, Asp (OBut)).\n\n\n\n\n\n\n \nDas In-Freiheit-Setzen der Verbindungen der Formel I aus ihren funktionellen Derivaten gelingt - je nach der benutzten Schutzgruppe - z. B. mit starken Säuren, zweckmäßig mit TFA oder Perchlorsäure, aber auch mit anderen starken anorganischen Säuren wie Salzsäure oder Schwefelsäure, starken organischen Carbonsäuren wie Trichioressigsäure oder Sulfonsäuren wie Benzol- oder p-Toluolsulfonsäure. Die Anwesenheit eines zusätzlichen inerten Lösungsmittels ist möglich, aber nicht immer erforderlich. Als inerte Lösungsmittel eignen sich vorzugsweise organische, beispielsweise Carbonsäuren wie Essigsäure, Ether wie Tetrahydrofuran oder Dioxan,\nThe in-freedom setting of the compounds of formula I from their functional derivatives succeed - depending on the protecting group used - z. B. with strong acids, useful with TFA or perchloric acid, but also with other strong inorganic acids such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids such as trichloroacetic acid or sulfonic acids such as benzene or p-toluenesulfonic acid. The presence of an additional inert solvent is possible, but not always necessary. Suitable inert solvents are preferably organic, for example carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane,\n\n\n\n\n\n\n \nAmide wie DMF, halogenierte Kohlenwasserstoffe wie Dichlormethan, ferner auch Alkohole wie Methanol, Ethanol oder Isopropanol, sowie Wasser. Ferner kommen Gemische der vorgenannten Lösungsmittel in Frage. TFA wird vorzugsweise im Überschuß ohne Zusatz eines weiteren Lösungsmittels verwendet, Perchlorsäure in Form eines Gemisches aus Essigsäure und 70 %iger Perchlorsäure im Verhältnis 9:1. Die Reaktionstemperaturen für die Spaltung liegen zweckmäßig zwischen etwa 0 und etwa 50°, vorzugsweise arbeitet man zwischen 15 und 30° (Raumtemperatur).\nAmides such as DMF, halogenated hydrocarbons such as dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, and water. Also suitable are mixtures of the abovementioned solvents. TFA is preferably used in excess without the addition of another solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9: 1. The reaction temperatures for the cleavage are suitably between about 0 and about 50 °, preferably between 15 and 30 ° (room temperature).\n\n\n\n\n\n\n \nDie Gruppen BOC, OBut, Pbf, Pmc und Mtr können z. B. bevorzugt mit TFA in Dichlormethan oder mit etwa 3 bis 5n HCl in Dioxan bei 15-30° abgespalten werden, die FMOC-Gruppe mit einer etwa 5- bis 50 %igen Lösung von Dimethylamin, Diethylamin oder Piperidin in DMF bei 15-30°.\nThe groups BOC, OBut, Pbf, Pmc and Mtr can, for. B. preferably cleaved with TFA in dichloromethane or with about 3 to 5n HCl in dioxane at 15-30 °, the FMOC group with an about 5- to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30 °.\n\n\n\n\n\n\n \nHydrogenolytisch entfernbare Schutzgruppen (z. B. CBZ oder Benzyl) können z. B. durch Behandeln mit Wasserstoff in Gegenwart eines Katalysators (z. B. eines Edelmetallkatalysators wie Palladium, zweckmäßig auf einem Träger wie Kohle) abgespalten werden. Als Lösungsmittel eignen sich dabei die oben angegebenen, insbesondere z. B. Alkohole wie Methanol oder Ethanol oder Amide wie DMF. Die Hydrogenolyse wird in der Regel bei \n\n Temperaturen zwischen etwa 0 und 100° und Drucken zwischen etwa 1 und 200 bar, bevorzugt bei 20-30° und 1-10 bar durchgeführt. Eine Hydrogenolyse der CBZ-Gruppe gelingt z. B. gut an 5 bis 10 %igem Pd/C in Methanol oder mit Ammomiumformiat (anstelle von Wasserstoff) an Pd/C in Methanol/DMF bei 20-30°.\nHydrogenolytically removable protecting groups (eg CBZ or benzyl) may e.g. By cleavage with hydrogen in the presence of a catalyst (e.g., a noble metal catalyst such as palladium, conveniently on a support such as carbon). Suitable solvents are those given above, in particular z. For example, alcohols such as methanol or ethanol or amides such as DMF. Hydrogenolysis is usually included  Temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably carried out at 20-30 ° and 1-10 bar. Hydrogenolysis of the CBZ group succeeds z. B. good at 5 to 10% Pd / C in methanol or with ammonium formate (instead of hydrogen) on Pd / C in methanol / DMF at 20-30 °.\n\n\n\n\n\n\n \nPharmazeutische Salze und andere Formen\nPharmaceutical salts and other forms\n\n\n\n\n\n\n \nDie genannten erfindungsgemäßen Verbindungen lassen sich in ihrer end- gültigen Nichtsalzform verwenden. Andererseits umfaßt die vorliegende\nThe abovementioned compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention\n\n\n\n\n\n\n \nErfindung auch die Verwendung dieser Verbindungen in Form ihrer pharmazeutisch unbedenklichen Salze, die von verschiedenen organischen und anorganischen Säuren und Basen nach fachbekannten Vorgehensweisen abgeleitet werden können. Pharmazeutisch unbedenkliche Salzformen der Verbindungen der Formel I werden größtenteils konventionell hergestellt. Sofern die Verbindung der Formel I eine Carbonsäuregruppe enthält, läßt sich eines ihrer geeigneten Salze dadurch bilden, daß man die Verbindung mit einer geeigneten Base zum entsprechenden Basenadditionssalz umsetzt. Solche Basen sind zum Beispiel Alkalimetallhydroxide, darunter\nThe invention also relates to the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases according to procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of formula I are for the most part prepared conventionally. If the compound of the formula I contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base addition salt. Such bases include, for example, alkali metal hydroxides, including\n\n\n\n\n\n\n \nKaliumhydroxid, Natriumhydroxid und Lithiumhydroxid; Erdalkalimetallhydroxide wie Bariumhydroxid und Calciumhydroxid; Alkalimetallalkoholate, z.B. Kaliumethanolat und Natriumpropanolat; sowie verschiedene organische Basen wie Piperidin, Diethanolamin und N-Methylglutamin. Die\nPotassium hydroxide, sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alcoholates, e.g. Potassium ethanolate and sodium propanolate; and various organic bases such as piperidine, diethanolamine and N-methylglutamine. The\n\n\n\n\n\n\n \nAluminiumsalze der Verbindungen der Formel I zählen ebenfalls dazu. Bei bestimmten Verbindungen der Formel I lassen sich Säureadditionssalze dadurch bilden, daß man diese Verbindungen mit pharmazeutisch unbedenklichen organischen und anorganischen Säuren, z.B.\nAluminum salts of the compounds of formula I are also included. For certain compounds of formula I, acid addition salts can be formed by reacting these compounds with pharmaceutically acceptable organic and inorganic acids, e.g.\n\n\n\n\n\n\n \nHalogenwasserstoffen wie Chlorwasserstoff, Bromwasserstoff oder Jodwasserstoff, anderen Mineralsäuren und ihren entsprechenden Salzen wie Sulfat, Nitrat oder Phosphat und dergleichen sowie Alkyl- und\nHydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like, and alkyl and\n\n\n\n\n\n\n \nMonoarylsulfonaten wie Ethansulfonat, Toluolsulfonat und Benzolsulfonat, sowie anderen organischen Säuren und ihren entsprechenden Salzen wie\nMonoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and their corresponding salts such as\n\n\n\n\n\n\n \nAcetat, Trifluoracetat, Tartrat, Maleat, Succinat, Citrat, Benzoat, Salicylat, \n\n Ascorbat und dergleichen behandelt. Dementsprechend zählen zu pharmazeutisch unbedenklichen Säureadditionssalzen der Verbindungen der Formel I die folgenden: Acetat, Adipat, Alginat, Arginat, Aspartat, Benzoat, Benzolsulfonat (Besylat), Bisulfat, Bisulfit, Bromid, Butyrat, Kampferat, Kampfersulfonat, Caprylat, Chlorid, Chlorbenzoat, Citrat, Cyclopentanpropionat, Digluconat, Dihydrogenphosphat, Dinitrobenzoat, Dodecylsulfat, Ethansulfonat, Fumarat, Galacterat (aus Schleimsäure), Galacturonat, Glucoheptanoat, Gluconat, Glutamat, Glycerophosphat,\nAcetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate,  Ascorbate and the like treated. Accordingly, pharmaceutically acceptable acid addition salts of the compounds of formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate , Cyclopentaneproprionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulphate, ethanesulphonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate,\n\n\n\n\n\n\n \n10 Hemisuccinat, Hemisulfat, Heptanoat, Hexanoat, Hippurat, Hydrochlorid, Hydrobromid, Hydroiodid, 2-Hydroxyethansuifonat, iodid, isethionai, Isobutyrat, Lactat, Lactobionat, Malat, Maleat, Malonat, Mandelat, Meta- phosphat, Methansulfonat, Methylbenzoat, Monohydrogenphosphat, 2-\n10 hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionai, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2 -\n\n\n\n\n\n\n \n^\n5\n Naphthalinsulfonat, Nicotinat, Nitrat, Oxalat, Oleat, Pamoat, Pectinat, Persulfat, Phenylacetat, 3-Phenylpropionat, Phosphat, Phosphonat, Phthalat, was jedoch keine Einschränkung darstellt.\n^ \n5\n naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this is not a limitation.\n\n\n\n\n\n\n \nWeiterhin zählen zu den Basensalzen der erfindungsgemäßen\nFurthermore, the base salts of the invention include\n\n\n\n\n\n\n \n20\n20\n\n\n\n\n\n\n \nVerbindungen Aluminium-, Ammonium-, Calcium-, Kupfer-, Eisen(lll)-,\nCompounds aluminum, ammonium, calcium, copper, iron (III) -,\n\n\n\n\n\n\n \nEisen(ll)-, Lithium-, Magnesium-, Mangan(lll)-, Mangan(ll), Kalium-, Natrium- und Zinksalze, was jedoch keine Einschränkung darstellen soll. Bevorzugt unter den oben genannten Salzen sind Ammonium; die Alkalimetallsalze 5 Natrium und Kalium, sowie die Erdalkalimetalsalze Calcium und Magnesium. Zu Salzen der Verbindungen der Formel I, die sich von pharmazeutisch unbedenklichen organischen nicht-toxischen Basen ableiten, zählen Salze primärer, sekundärer und tertiärer Amine, substituierter Amine, darunter\nIron (II), lithium, magnesium, manganese (III), manganese (II), potassium, sodium and zinc salts, but this is not intended to be limiting. Preferred among the above salts are ammonium; the alkali metal salts 5 sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of compounds of formula I derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, among them\n\n\n\n\n\n\n \n \n3Q\n auch natürlich vorkommender substituierter Amine, cyclischer Amine sowie basischer lonenaustauscherharze, z.B. Arginin, Betain, Koffein, Chlorprocain, Cholin, N,N'-Dibenzylethylendiamin (Benzathin), Dicyclohexylamin, Diethanolamin, Diethylamin, 2-Diethylaminoethanol, 2-\n \n3Q\n also of naturally occurring substituted amines, cyclic amines and basic ion exchange resins, eg arginine, betaine, caffeine, chloroprocaine, choline, N, N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-\n\n\n\n\n\n\n \nDimethylaminoethanol, Ethanolamin, Ethylendiamin, N-Ethylmorpholin, N-\nDimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-\n\n\n\n\n\n\n \n35\n35\n\n\n\n\n\n\n \nEthylpiperidin, Glucamin, Glucosamin, Histidin, Hydrabamin, Iso-propylamin,\nEthylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine,\n\n\n\n\n\n\n \nLidocain, Lysin, Meglumin, N-Methyl-D-glucamin, Morpholin, Piperazin, \n\n Piperidin, Polyaminharze, Procain, Purine, Theobromin, Triethanolamin, Triethylamin, Trimethylamin, Tripropylamin sowie Tris-(hydroxymethyl)- methylamin (Tromethamin), was jedoch keine Einschränkung darstellen soll.\nLidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine,  Piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris (hydroxymethyl) - methylamine (tromethamine), but this is not intended to be limiting.\n\n\n\n\n\n\n \nVerbindungen der vorliegenden Erfindung, die basische stickstoffhaltige Gruppen enthalten, lassen sich mit Mitteln wie (C\n1\n-C\n4\n) Alkylhalogeniden, z.B. Methyl-, Ethyl-, Isopropyl- und tert.-Butylchlorid, -bromid und -iodid; Di(Cr C\n4\n)Alkylsulfaten, z.B. Dimethyl-, Diethyl- und Diamylsulfat; (C\n10\n-C\n18\n)Alkyl-0 halogeniden, z.B. Decyl-, Dodecyl-, Lauryl-, Myristyl- und Stearylchlorid, -bromid und -iodid; sowie Aryl-(Ci-C\n4\n)Aikyiha!ogeniden, z.B. Benzyichiorid und Phenethylbromid, quarternisieren. Mit solchen Salzen können sowohl wasser- als auch öllösliche erfindungsgemäße Verbindungen hergestellt\nJ\n- werden.\nCompounds of the present invention containing basic nitrogen-containing groups can be reacted with agents such as (C \n1\n -C \n4\n ) alkyl halides, eg, methyl, ethyl, isopropyl, and tert-butyl chloride, bromide, and iodide; Di (Cr C \n4\n ) alkyl sulfates, eg dimethyl, diethyl and diamylsulfate; (C \n10\n -C \n18\n ) alkyl-0 halides, eg decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl- (Ci-C \n4\n ) Aikyiha! Ogeniden, eg Benzyichiorid and phenethyl bromide quaternize. With such salts both water- and oil-soluble compounds of the invention produced \nJ\n can - be.\n\n\n\n\n\n\n \nZu den oben genannten pharmazeutischen Salzen, die bevorzugt sind, zählen Acetat, Trifluoracetat, Besylat, Citrat, Fumarat, Gluconat, Hemi- succinat, Hippurat, Hydrochlorid, Hydrobromid, Isethionat, Mandelat, 0\nAmong the above-mentioned preferred pharmaceutical salts are acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemi-succinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, 0\n\n\n\n\n\n\n \nMeglumin, Nitrat, Oleat, Phosphonat, Pivalat, Natriumphosphat, Stearat,\nMeglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate,\n\n\n\n\n\n\n \nSulfat, Sulfosalicylat, Tartrat, Thiomalat, Tosylat und Tromethamin, was jedoch keine Einschränkung darstellen soll. 5 Besonders bevorzugt sind Hydrochlorid, Dihydrochlorid, Hydrobromid, Maleat, Mesylat, Phosphat, Sulfat und Succinat.\nSulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, which is not intended to be limiting. Particularly preferred are hydrochloride, dihydrochloride, hydrobromide, maleate, mesylate, phosphate, sulfate and succinate.\n\n\n\n\n\n\n \nDie Säureadditionssalze basischer Verbindungen der Formel I werden\nQ\n dadurch hergestellt, daß man die freie Basenform mit einer ausreichenden Menge der gewünschten Säure in Kontakt bringt, wodurch man auf übliche Weise das Salz darstellt. Die freie Base läßt sich durch In-Kontakt-Bringen der Salzform mit einer Base und Isolieren der freien Base auf übliche Weise regenerieren. Die freien Basenformen unterscheiden sich in gewissem Sinn5 von ihren entsprechenden Salzformen in bezug auf bestimmte physikalische \n\n Eigenschaften wie Löslichkeit in polaren Lösungsmitteln; im Rahmen der Erfindung entsprechen die Salze jedoch sonst ihren jeweiligen freien Basenformen.\nThe acid addition salts of basic compounds of formula I are \nQ\n prepared by bringing the free base form with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by contacting the salt form with a base and isolating the free base in a conventional manner. The free base forms differ, in a sense, from their corresponding salt forms with respect to certain physical ones  Properties such as solubility in polar solvents; however, in the context of the invention, the salts otherwise correspond to their respective free base forms.\n\n\n\n\n\n\n \nWie erwähnt werden die pharmazeutisch unbedenklichen Basenadditionssalze der Verbindungen der Formel I mit Metallen oder Aminen wie Alkalimetallen und Erdalkalimetallen oder organischen Aminen gebildet. Bevorzugte Metalle sind Natrium, Kalium, Magnesium und Calcium. Bevor- zugte organische Amine sind N,N'-Dibenzylethylendiamin, Chlorprocain, Cholin, Diethanolamin, Ethyiendiamin, N-Methyi-D-giucamin und Procain.\nAs mentioned, the pharmaceutically acceptable base addition salts of the compounds of formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-giucamine and procaine.\n\n\n\n\n\n\n \nDie Basenadditionssalze von erfindungsgemäßen sauren Verbindungen werden dadurch hergestellt, daß man die freie Säureform mit einer ausreichenden Menge der gewünschten Base in Kontakt bringt, wodurch man das Salz auf übliche Weise darstellt. Die freie Säure läßt sich durch In- Kontakt-Bringen der Salzform mit einer Säure und Isolieren der freien Säure auf übliche Weise regenerieren. Die freien Säureformen unterscheiden sich in gewissem Sinn von ihren entsprechenden Salzformen in bezug auf bestimmte physikalische Eigenschaften wie Löslichkeit in polaren Lösungsmitteln; im Rahmen der Erfindung entsprechen die Salze jedoch sonst ihren jeweiligen freien Säureformen.\nThe base addition salts of acidic compounds of the invention are prepared by contacting the free acid form with a sufficient amount of the desired base to form the salt in a conventional manner. The free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms in some sense differ from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; However, in the context of the invention, the salts otherwise correspond to their respective free acid forms.\n\n\n\n\n\n\n \nEnthält eine erfindungsgemäße Verbindung mehr als eine Gruppe, die solche pharmazeutisch unbedenklichen Salze bilden kann, so umfaßt die Erfindung auch mehrfache Salze. Zu typischen mehrfachen Salzformen zählen zum Beispiel Bitartrat, Diacetat, Difumarat, Dimeglumin, Diphosphat, Dinatrium und Trihydrochlorid, was jedoch keine Einschränkung darstellen soii.\nIf a compound according to the invention contains more than one group which can form such pharmaceutically acceptable salts, the invention also encompasses multiple salts. Typical multiple salt forms include, but are not limited to, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride.\n\n\n\n\n\n\n \nIm Hinblick auf das oben Gesagte sieht man, daß unter dem Ausdruck\nIn view of the above, one sees that under the expression\n\n\n\n\n\n\n \n\"pharmazeutisch unbedenkliches Salz\" im vorliegenden Zusammenhang ein\n\"pharmaceutically acceptable salt\" in the present context\n\n\n\n\n\n\n \nWirkstoff zu verstehen ist, der eine Verbindung der Formel I in der Form \n\n eines ihrer Salze enthält, insbesondere dann, wenn diese Salzform dem Wirkstoff im Vergleich zu der freien Form des Wirkstoffs oder irgendeiner anderen Salzform des Wirkstoffs, die früher verwendet wurde, verbesserte pharmakokinetische Eigenschaften verleiht. Die pharmazeutisch 5 unbedenkliche Salzform des Wirkstoffs kann auch diesem Wirkstoff erst eine gewünschte pharmakokinetische Eigenschaft verleihen, über die er früher nicht verfügt hat, und kann sogar die Pharmakodynamik dieses Wirkstoffs in bezug auf seine therapeutische Wirksamkeit im Körper positiv beeinflussen.\nIt is understood that the active substance is a compound of the formula I in the form  one of its salts, in particular when that salt form imparts to the active ingredient improved pharmacokinetic properties as compared to the free form of the active ingredient or any other salt form of the active ingredient which has previously been used. The pharmaceutically acceptable salt form of the active substance may also first impart a desired pharmacokinetic property to this active ingredient, which it has not previously possessed, and may even positively influence the pharmacodynamics of this active ingredient in terms of its therapeutic activity in the body.\n\n\n\n\n\n\n \n10\n10\n\n\n\n\n\n\n \nGegenstand der Erfindung sind ferner Arzneimittei, enthaltend mindestens eine Verbindung der Formel I und/oder ihre pharmazeutisch verwendbaren Salze und Stereoisomere, einschließlich deren Mischungen in allen\nThe invention furthermore relates to medicaments containing at least one compound of the formula I and / or their pharmaceutically usable salts and stereoisomers, including mixtures thereof in all\n\n\n\n\n\n\n \n,\nj c\n Verhältnissen, sowie gegebenenfalls Träger- und/oder Hilfsstoffe.\n, \njc\n ratios, and optionally excipients and / or adjuvants.\n\n\n\n\n\n\n \nPharmazeutische Formulierungen können in Form von Dosiseinheiten, die eine vorbestimmte Menge an Wirkstoff pro Dosiseinheit enthalten, dargereicht werden. Eine solche Einheit kann beispielsweise 0,5 mg bis 1 g,\nPharmaceutical formulations may be presented in the form of dosage units containing a predetermined amount of active ingredient per unit dose. Such a unit may for example be 0.5 mg to 1 g,\n\n\n\n\n\n\n \n20 vorzugsweise 1 mg bis 700 mg, besonders bevorzugt 5 mg bis 100 mg einer erfindungsgemäßen Verbindung enthalten, je nach dem behandelten Krankheitszustand, dem Verabreichungsweg und dem Alter, Gewicht und Zustand des Patienten, oder pharmazeutische Formulierungen können in\n20 preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg of a compound according to the invention, depending on the treated disease state, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations can in\n\n\n\n\n\n\n \n25 Form von Dosiseinheiten, die eine vorbestimmte Menge an Wirkstoff pro\n25 form of dosage units containing a predetermined amount of active ingredient per\n\n\n\n\n\n\n \nDosiseinheit enthalten, dargereicht werden. Bevorzugte Dosierungseinheits- formulierungen sind solche, die eine Tagesdosis oder Teildosis, wie oben angegeben, oder einen entsprechenden Bruchteil davon eines Wirkstoffs\nDose unit included, to be presented. Preferred dosage unit formulations are those containing a daily or partial dose as indicated above or a corresponding fraction thereof of an active ingredient\n\n\n\n\n\n\n \n \nO0\n enthalten. Weiterhin lassen sich solche pharmazeutischen Formulierungen mit einem der im pharmazeutischen Fachgebiet allgemein bekannten Verfahren herstellen.\n \nO0\n included. Furthermore, such pharmaceutical formulations can be prepared by any of the methods well known in the pharmaceutical art.\n\n\n\n\n\n\n \nPharmazeutische Formulierungen lassen sich zur Verabreichung über einen\nPharmaceutical formulations can be administered via a\n\n\n\n\n\n\n \n35 beliebigen geeigneten Weg, beispielsweise auf oralem (einschließlich buccalem bzw. sublingualem), rektalem, nasalem, topischem (einschließlich \n\n buccalem, sublingualem oder transdermalem), vaginalem oder parenteralem (einschließlich subkutanem, intramuskulärem, intravenösem oder intradermalem) Wege, anpassen. Solche Formulierungen können mit allen im pharmazeutischen Fachgebiet bekannten Verfahren hergestellt werden, indem beispielsweise der Wirkstoff mit dem bzw. den Trägerstoff(en) oder Hilfsstoff(en) zusammengebracht wird.\nIn any suitable route, for example oral (including buccal or sublingual), rectal, nasal, topical (including  buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) routes. Such formulations can be prepared by any method known in the pharmaceutical art, for example, by bringing the active ingredient together with the carrier (s) or excipient (s).\n\n\n\n\n\n\n \nAn die orale Verabreichung angepaßte pharmazeutische Formulierungen 10 können als separate Einheiten, wie z.B. Kapseln oder Tabletten; Pulver oder Granulate; Lösungen oder Suspensionen in wäßrigen oder πichtwäßrigen Flüssigkeiten; eßbare Schäume oder Schaumspeisen; oder Öl-in-Wasser- Flüssigemulsionen oder Wasser-in-ÖI-Flüssigemulsionen dargereicht . \nς\n werden.\nPharmaceutical formulations adapted for oral administration may be presented as separate entities such as capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or πichtwäßrigen liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions. \nς\n become.\n\n\n\n\n\n\n \nSo läßt sich beispielsweise bei der oralen Verabreichung in Form einer Tablette oder Kapsel die Wirkstoffkomponente mit einem oralen, nichttoxischen und pharmazeutisch unbedenklichen inerten Trägerstoff, wie z.B.\nThus, for example, in the case of oral administration in the form of a tablet or capsule, the active ingredient component can be mixed with an oral, non-toxic and pharmaceutically acceptable inert carrier, e.g.\n\n\n\n\n\n\n \n20\n20\n\n\n\n\n\n\n \nEthanol, Glyzerin, Wasser u.a. kombinieren. Pulver werden hergestellt, indem die Verbindung auf eine geeignete feine Größe zerkleinert und mit einem in ähnlicher Weise zerkleinerten pharmazeutischen Trägerstoff, wie z.B. einem eßbaren Kohlenhydrat wie beispielsweise Stärke oder Mannit 25 vermischt wird. Ein Geschmacksstoff, Konservierungsmittel, Dispersionsmittel und Farbstoff können ebenfalls vorhanden sein.\nEthanol, glycerin, water and the like. combine. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a similarly comminuted pharmaceutical excipient, e.g. an edible carbohydrate such as starch or mannitol. A flavor, preservative, dispersant and dye may also be present.\n\n\n\n\n\n\n \nKapseln werden hergestellt, indem ein Pulvergemisch wie oben beschrieben \nO0\n hergestellt und geformte Gelatinehüllen damit gefüllt werden. Gleit- und Schmiermittel wie z.B. hochdisperse Kieselsäure, Talkum, Magnesium- stearat, Kaiziumstearat oder Poiyethyienglykoi in Festform können dem Pulvergemisch vor dem Füllvorgang zugesetzt werden. Ein Sprengmittel oder Lösungsvermittler, wie z.B. Agar-Agar, Kalziumcarbonat oder Natrium-\nCapsules are prepared by \npreparing\n a powder \nmix\n as described \nabove\n and \nfilling\n shaped gelatin casings therewith. Lubricants and lubricants such as highly disperse silica, talc, magnesium stearate, Kaiziumstearat or Poiyethyienglykoi in solid form can be added to the powder mixture before the filling process. A disintegrating agent or solubilizer, such as agar-agar, calcium carbonate or sodium\n\n\n\n\n\n\n \n35 carbonat, kann ebenfalls zugesetzt werden, um die Verfügbarkeit des\n35 carbonate, can also be added to the availability of the\n\n\n\n\n\n\n \nMedikaments nach Einnahme der Kapsel zu verbessern. \n\n Außerdem können, falls gewünscht oder notwendig, geeignete Bindungs-, Schmier- und Sprengmittel sowie Farbstoffe ebenfalls in das Gemisch eingearbeitet werden. Zu den geeigneten Bindemitteln gehören Stärke, 5\nDrug after taking the capsule to improve.  In addition, if desired or necessary, suitable binding, lubricating and disintegrants as well as dyes can also be incorporated into the mixture. Suitable binders include starch, 5\n\n\n\n\n\n\n \nGelatine, natürliche Zucker, wie z.B. Glukose oder Beta-Lactose, Süßstoffe aus Mais, natürliche und synthetische Gummi, wie z.B. Akazia, Traganth oder Natriumalginat, Carboxymethylzellulose, Polyethylenglykol, Wachse, u.a. Zu den in diesen Dosierungsformen verwendeten Schmiermitteln\nGelatin, natural sugars, e.g. Glucose or beta-lactose, corn sweeteners, natural and synthetic gums, e.g. Acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like. To the lubricants used in these dosage forms\n\n\n\n\n\n\n \n10 gehören Natriumoleat, Natriumstearat, Magnesiumstearat, Natriumbenzoat, Natriumacetat, Natriumchlorid u.a. Zu den Sprengmittein gehören, ohne darauf beschränkt zu sein, Stärke, Methylzellulose, Agar, Bentonit, Xanthangummi u.a. Die Tabletten werden formuliert, indem beispielsweise\n10 include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The explosives include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. The tablets are formulated by, for example\n\n\n\n\n\n\n \n \n^ c\n ein Pulvergemisch hergestellt, granuliert oder trockenverpreßt wird, ein\n \n^ c\n a powder mixture prepared, granulated or pressed dry, a\n\n\n\n\n\n\n \nSchmiermittel und ein Sprengmittel zugegeben werden und das Ganze zu Tabletten verpreßt wird. Ein Pulvergemisch wird hergestellt, indem die in geeigneter Weise zerkleinerte Verbindung mit einem Verdünnungsmittel oder einer Base, wie oben beschrieben, und gegebenenfalls mit einem\nLubricant and a disintegrant are added and the whole is compressed into tablets. A powder mixture is prepared by treating the appropriately comminuted compound with a diluent or a base as described above, and optionally with a\n\n\n\n\n\n\n \n20\n20\n\n\n\n\n\n\n \nBindemittel, wie z.B. Carboxymethylzellulose, einem Alginat, Gelatine oder\nBinders, such as e.g. Carboxymethylcellulose, an alginate, gelatin or\n\n\n\n\n\n\n \nPolyvinylpyrrolidon, einem Lösungsverlangsamer, wie z.B. Paraffin, einem Resorptionsbeschleuniger, wie z.B. einem quaternären Salz und/oder einem Absorptionsmittel, wie z.B. Bentonit, Kaolin oder Dikalziumphosphat, 5 vermischt wird. Das Pulvergemisch läßt sich granulieren, indem es mit einem Bindemittel, wie z.B. Sirup, Stärkepaste, Acadia-Schleim oder Lösungen aus Zellulose- oder Polymermaterialen benetzt und durch ein Sieb gepreßt wird. Als Alternative zur Granulierung kann man das Pulvergemisch durch eine\nPolyvinylpyrrolidone, a dissolution reducer, such as e.g. Paraffin, a resorption accelerator, such as a quaternary salt and / or an absorbent, e.g. Bentonite, kaolin or dicalcium phosphate, 5 is mixed. The powder mixture can be granulated by mixing it with a binder, e.g. Syrup, starch paste, Acadia slime or solutions of cellulose or polymer materials wetted and pressed through a sieve. As an alternative to granulation, the powder mixture by a\n\n\n\n\n\n\n \n \n3Q\n Tablettiermaschine laufen lassen, wobei ungleichmäßig geformte Klumpen entstehen, die in Granulate aufgebrochen werden. Die Granulate können mittels Zugabe von Stearinsäure, einem Stearatsalz, Talkum oder Mineralöl gefettet werden, um ein Kleben an den Tablettengußformen zu verhindern.\n \n3Q\n tabletting run, resulting in irregularly shaped lumps, which are broken up into granules. The granules may be greased by the addition of stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds.\n\n\n\n\n\n\n \nDas gefettete Gemisch wird dann zu Tabletten verpreßt. Die erfindungs- 5 gemäßen Verbindungen können auch mit einem freifließenden inerten\nThe greased mixture is then compressed into tablets. The compounds according to the invention can also be reacted with a free-flowing inert\n\n\n\n\n\n\n \nTrägerstoff kombiniert und dann ohne Durchführung der Granulierungs- oder \n\n Trockenverpressungsschritte direkt zu Tabletten verpreßt werden. Eine durchsichtige oder undurchsichtige Schutzschicht, bestehend aus einer Versiegelung aus Schellack, einer Schicht aus Zucker oder Polymermaterial und einer Glanzschicht aus Wachs, kann vorhanden sein. Diesen\nCarrier combined and then without performing the granulation or  Trockenverpressungsschritte be pressed directly into tablets. A transparent or opaque protective layer consisting of a shellac sealant, a layer of sugar or polymeric material, and a glossy layer of wax may be present. this\n\n\n\n\n\n\n \nBeschichtungen können Farbstoffe zugesetzt werden, um zwischen unterschiedlichen Dosierungseinheiten unterscheiden zu können.\nCoatings can be added to dyes to distinguish between different dosage units.\n\n\n\n\n\n\n \nOrale Flüssigkeiten, wie z.B. Lösung, Sirupe und Elixiere, können in Form von Dosierungseinheiten hergestellt werden, so daß eine gegebene\nOral fluids, e.g. Solution, syrups and elixirs, can be prepared in the form of dosage units, so that a given\n\n\n\n\n\n\n \nQuantität eine vorgegebene Menge der Verbindung enthäit. Sirupe iassen sich herstellen, indem die Verbindung in einer wäßrigen Lösung mit geeignetem Geschmack gelöst wird, während Elixiere unter Verwendung eines nichttoxischen alkoholischen Vehikels hergestellt werden.\nQuantity contains a given amount of the compound. Syrups may be prepared by dissolving the compound in an appropriate taste aqueous solution while preparing elixirs using a non-toxic alcoholic vehicle.\n\n\n\n\n\n\n \nSuspensionen können durch Dispersion der Verbindung in einem nichttoxischen Vehikel formuliert werden. Lösungsvermittler und Emulgiermittel, wie z.B. ethoxylierte Isostearylalkohole und Polyoxyethylensorbitolether,\nSuspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers, e.g. ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers,\n\n\n\n\n\n\n \nKonservierungsmittel, Geschmackszusätze, wie z.B. Pfefferminzöl oder natürliche Süßstoffe oder Saccharin oder andere künstliche Süßstoffe, u.a. können ebenfalls zugegeben werden.\nPreservatives, flavoring additives, e.g. Peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, i.a. can also be added.\n\n\n\n\n\n\n \nDie Dosierungseinheitsformulierungen für die orale Verabreichung können gegebenenfalls in Mikrokapseln eingeschlossen werden. Die Formulierung läßt sich auch so herstellen, daß die Freisetzung verlängert oder retardiert wird, wie beispielsweise durch Beschichtung oder Einbettung von partikulärem Material in Polymere, Wachs u.a.\nThe unit dosage formulations for oral administration may optionally be encapsulated in microcapsules. The formulation may also be prepared to prolong or retard release, such as by coating or embedding particulate material in polymers, wax, and the like.\n\n\n\n\n\n\n \nDie Verbindungen der Formel I sowie deren Salze davon lassen sich auch in\nThe compounds of formula I and their salts thereof can also be in\n\n\n\n\n\n\n \nForm von Liposomenzuführsystemen, wie z.B. kleinen uniiameiiaren Vesikeln, großen uniiameiiaren Vesikeln und multilamellaren Vesikeln, verabreichen. Liposomen können aus verschiedenen Phospholipiden, wie z.B. Cholesterin, Stearylamin oder Phosphatidylcholinen, gebildet werden. \n\n Die Verbindungen der Formel I sowie die Salze davon können auch unter Verwendung monoklonaler Antikörper als individuelle Träger, an die die Verbindungsmoleküle gekoppelt werden, zugeführt werden. Die\nForm liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from various phospholipids such as cholesterol, stearylamine or phosphatidylcholines.  The compounds of formula I as well as the salts thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The\n\n\n\n\n\n\n \nVerbindungen können auch mit löslichen Polymeren als zielgerichtete\nCompounds may also be targeted with soluble polymers\n\n\n\n\n\n\n \nArzneistoffträger gekoppelt werden. Solche Polymere können Polyvinyl- pyrrolidon, Pyran-Copolymer, Polyhydroxypropylmethacrylamidphenol, Polyhydroxyethylaspartamidphenol oder Polyethylenoxidpolylysin, substituiert mit Palmitoylresten, umfassen. Weiterhin können die Verbindungen an eine Klasse von biologisch abbaubaren Polymeren, die zur Erzielung einer kontrollierten Freisetzung eines Arzneistoffs geeignet sind, z.B. Polymilchsäure, Polyepsilon-Caprolacton, Polyhydroxybuttersäure, Polyorthoester, Polyacetale, Polydihydroxypyrane, Polycyanoacrylate und quervernetzte oder amphipatische Blockcopolymere von Hydrogelen, gekoppelt sein.\nDrug carriers are coupled. Such polymers may include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol or polyethyleneoxidepolylysine substituted with palmitoyl radicals. Furthermore, the compounds can be attached to a class of biodegradable polymers suitable for the controlled release of a drug, e.g. Polylactic acid, polyepsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels.\n\n\n\n\n\n\n \nAn die transdermale Verabreichung angepaßte pharmazeutische\nPharmaceutical adapted to transdermal administration\n\n\n\n\n\n\n \nFormulierungen können als eigenständige Pflaster für längeren, engen\nFormulations can be used as separate patches for longer, narrow\n\n\n\n\n\n\n \nKontakt mit der Epidermis des Empfängers dargereicht werden. So kann beispielsweise der Wirkstoff aus dem Pflaster mittels lontophorese zugeführt werden, wie in Pharmaceutical Research, 3(6), 318 (1986) allgemein beschrieben.\nBe presented with contact with the epidermis of the recipient. For example, the drug may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3 (6), 318 (1986).\n\n\n\n\n\n\n \nAn die topische Verabreichung angepaßte pharmazeutische Verbindungen können als Salben, Cremes, Suspensionen, Lotionen, Pulver, Lösungen, Pasten, Gele, Sprays, Aerosole oder Öle formuliert sein.\nPharmaceutical compounds adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.\n\n\n\n\n\n\n \nFür Behandlungen des Auges oder anderer äußerer Gewebe, z.B. Mund und\nFor treatments of the eye or other external tissues, e.g. Mouth and\n\n\n\n\n\n\n \nHaut, werden die Formulierungen vorzugsweise als topische Salbe oder Creme appliziert. Bei Formulierung zu einer Salbe kann der Wirkstoff entweder mit einer paraffinischen oder einer mit Wasser mischbaren\nSkin, the formulations are preferably applied as a topical ointment or cream. When formulated into an ointment, the active ingredient may be either paraffinic or water-miscible\n\n\n\n\n\n\n \nCremebasis eingesetzt werden. Alternativ kann der Wirkstoff zu einer Creme \n\n mit einer Öl-in-Wasser-Cremebasis oder einer Wasser-in-ÖI-Basis formuliert werden.\nCream base can be used. Alternatively, the active ingredient can become a cream  be formulated with an oil-in-water cream base or a water-in-oil base.\n\n\n\n\n\n\n \nZu den an die topische Applikation am Auge angepaßten pharmazeutischen 5\nTo the adapted to the topical application to the eye pharmaceutical 5\n\n\n\n\n\n\n \nFormulierungen gehören Augentropfen, wobei der Wirkstoff in einem geeigneten Träger, insbesondere einem wäßrigen Lösungsmittel, gelöst oder suspendiert ist.\nFormulations include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.\n\n\n\n\n\n\n \n10 An die topische Applikation im Mund angepaßte pharmazeutische\n10 For the topical application in the mouth adapted pharmaceutical\n\n\n\n\n\n\n \nFormulierungen umfassen Lutschtabletten, Pastillen und Mundspüϊmittel.\nFormulations include lozenges, lozenges and mouthwashes.\n\n\n\n\n\n\n \nAn die rektale Verabreichung angepaßte pharmazeutische Formulierungen ^ \nc\n können in Form von Zäpfchen oder Einlaufen dargereicht werden.\nFor rectal administration adapted pharmaceutical formulations ^ \nc\n may be in the form of suppositories or enemas be presented.\n\n\n\n\n\n\n \nAn die nasale Verabreichung angepaßte pharmazeutische Formulierungen, in denen die Trägersubstanz ein Feststoff ist, enthalten ein grobes Pulver mit einer Teilchengröße beispielsweise im Bereich von 20-500 Mikrometern, das\nPharmaceutical formulations adapted for nasal administration in which the carrier is a solid contain a coarse powder having a particle size, for example, in the range of 20-500 microns, the\n\n\n\n\n\n\n \n20 in der Art und Weise, wie Schnupftabak aufgenommen wird, verabreicht wird, d.h. durch Schnellinhalation über die Nasenwege aus einem dicht an die Nase gehaltenen Behälter mit dem Pulver. Geeignete Formulierungen zur Verabreichung als Nasenspray oder Nasentropfen mit einer Flüssigkeit 25 als Trägersubstanz umfassen Wirkstofflösungen in Wasser oder Öl.\n20 is administered in the manner in which snuff is received, i. by rapid inhalation via the nasal passages from a container held close to the nose with the powder. Suitable formulations for administration as a nasal spray or nasal drops with a carrier liquid 25 include drug solutions in water or oil.\n\n\n\n\n\n\n \nAn die Verabreichung durch Inhalation angepaßte pharmazeutische Formulierungen umfassen feinpartikuläre Stäube oder Nebel, die mittels \nO0\n verschiedener Arten von unter Druck stehenden Dosierspendern mit Aerosolen, Vemeblern oder Insufflatoren erzeugt werden können.\nPharmaceutical formulations adapted for administration by inhalation include fine particulate dusts or mists which may be \ngenerated\n by \nO0 of\n various types of pressurized dosing dispensers with aerosols, foggers or insufflators.\n\n\n\n\n\n\n \nAn die vaginale Verabreichung angepaßte pharmazeutische Formulierungen können als Pessare, Tampons, Cremes, Gele, Pasten, Schäume oder\nPharmaceutical formulations adapted for vaginal administration may be used as pessaries, tampons, creams, gels, pastes, foams or\n\n\n\n\n\n\n \n35\n35\n\n\n\n\n\n\n \nSprayformulierungen dargereicht werden. \n\n Zu den an die parenterale Verabreichung angepaßten pharmazeutischen Formulierungen gehören wäßrige und nichtwäßrige sterile Injektionslösungen, die Antioxidantien, Puffer, Bakteriostatika und Solute, durch die die Formulierung isotonisch mit dem Blut des zu behandelnden Empfängers gemacht wird, enthalten; sowie wäßrige und nichtwäßrige sterile\nSpray formulations are presented.  Pharmaceutical formulations adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions containing antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient to be treated; as well as aqueous and non-aqueous sterile\n\n\n\n\n\n\n \nSuspensionen, die Suspensionsmittel und Verdicker enthalten können. Die Formulierungen können in Einzeldosis- oder Mehrfachdosisbehältern, z.B. versiegelten Ampullen und Fläschchen, dargereicht und in gefrier- getrocknetem (lyophilisiertem) Zustand gelagert werden, so daß nur die Zugabe der sterilen Trägerfiüssigkeit, z.B. Wasser für injektionszwecke, unmittelbar vor Gebrauch erforderlich ist. Rezepturmäßig hergestellte Injektionslösungen und Suspensionen können aus sterilen Pulvern, Granulaten und Tabletten hergestellt werden.\nSuspensions which may contain suspending agents and thickeners. The formulations may be administered in single or multiple dose containers, e.g. sealed vials and vials, and stored in the freeze-dried (lyophilized) state so that only the addition of the sterile carrier fluid, e.g. Water for injections, needed immediately before use. Injection solutions and suspensions prepared by formulation can be prepared from sterile powders, granules and tablets.\n\n\n\n\n\n\n \nEs versteht sich, daß die Formulierungen neben den obigen besonders erwähnten Bestandteilen andere im Fachgebiet übliche Mittel mit Bezug auf die jeweilige Art der Formulierung enthalten können; so können beispielsweise für die orale Verabreichung geeignete Formulierungen\nIt will be understood that in addition to the above particularly mentioned ingredients, the formulations may include other means conventional in the art with respect to the particular type of formulation; for example, formulations suitable for oral administration\n\n\n\n\n\n\n \nGeschmacksstoffe enthalten.\nFlavors contain.\n\n\n\n\n\n\n \nEine therapeutisch wirksame Menge einer Verbindung der Formel I hängt von einer Reihe von Faktoren ab, einschließlich z.B. dem Alter und Gewicht des Tiers, dem exakten Krankheitszustand, der der Behandlung bedarf, sowie seines Schweregrads, der Beschaffenheit der Formulierung sowie dem Verabreichungsweg, und wird letztendlich von dem behandelnden Arzt bzw. Tierarzt festgelegt. Jedoch liegt eine wirksame Menge einer erfindungsgemäßen Verbindung für die Behandlung von neoplastischem Wachstum, z.B. Dickdarm- oder Brustkarzinom, im aligemeinen im Bereich von 0,1 bis 100 mg/kg Körpergewicht des Empfängers (Säugers) pro Tag und besonders typisch im Bereich von 1 bis 10 mg/kg Körpergewicht pro\nA therapeutically effective amount of a compound of formula I depends on a number of factors, including e.g. the age and weight of the animal, the exact condition of the disease requiring treatment, as well as its severity, the nature of the formulation and the route of administration, and is ultimately determined by the attending physician or veterinarian. However, an effective amount of a compound of the invention is useful for the treatment of neoplastic growth, e.g. Colon or breast carcinoma, generally in the range of 0.1 to 100 mg / kg body weight of the recipient (mammal) per day and more typically in the range of 1 to 10 mg / kg body weight per\n\n\n\n\n\n\n \nTag. Somit läge für einen 70 kg schweren erwachsenen Säuger die tatsächliche Menge pro Tag für gewöhnlich zwischen 70 und 700 mg, wobei \n\n diese Menge als Einzeldosis pro Tag oder üblicher in einer Reihe von Teildosen (wie z.B. zwei, drei, vier, fünf oder sechs) pro Tag gegeben werden kann, so daß die Gesamttagesdosis die gleiche ist. Eine wirksame\nDay. Thus, for a 70 kg adult mammal, the actual amount per day would usually be between 70 and 700 mg, with  this amount may be given as a single dose per day or more commonly in a number of divided doses (such as two, three, four, five or six) per day so that the total daily dose is the same. An effective\n\n\n\n\n\n\n \nMenge eines Salzes oder Solvats oder eines physiologisch funktionellen\nAmount of a salt or solvate or a physiologically functional\n\n\n\n\n\n\n \n5\n5\n\n\n\n\n\n\n \nDerivats davon kann als Anteil der wirksamen Menge der erfindungsgemäßen Verbindung per se bestimmt werden. Es läßt sich annehmen, daß ähnliche Dosierungen für die Behandlung der anderen, obenerwähnten Krankheitszustände geeignet sind.\nDerivatives thereof can be determined as a proportion of the effective amount of the compound of the invention per se. It can be assumed that similar dosages are suitable for the treatment of the other, above-mentioned disease states.\n\n\n\n\n\n\n \n10\n10\n\n\n\n\n\n\n \nGegenstand der Erfindung sind ferner Arzneimittel enthaltend mindestens eine Verbindung der Formel I und/oder ihre pharmazeutisch verwendbaren Salze und Stereoisomere, einschließlich deren Mischungen in allen\nThe invention furthermore relates to medicaments containing at least one compound of the formula I and / or pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all\n\n\n\n\n\n\n \nA \nc\n Verhältnissen, und mindestens einen weiteren Arzneimittelwirkstoff.\nA \nc\n ratios, and at least one other drug.\n\n\n\n\n\n\n \nGegenstand der Erfindung ist auch ein Set (Kit), bestehend aus getrennten Packungen von\nThe invention is also a set (kit), consisting of separate packages of\n\n\n\n\n\n\n \n(a) einer wirksamen Menge an einer Verbindung der Formel I und/oder\n(A) an effective amount of a compound of formula I and / or\n\n\n\n\n\n\n \n20 ihrer pharmazeutisch verwendbaren Salze und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, und\n20 of their pharmaceutically acceptable salts and stereoisomers, including mixtures thereof in all proportions, and\n\n\n\n\n\n\n \n(b) einer wirksamen Menge eines weiteren Arzneimittelwirkstoffs. 25\n(b) an effective amount of another drug. 25\n\n\n\n\n\n\n \nDas Set enthält geeignete Behälter, wie Schachteln oder Kartons, individuelle Flaschen, Beutel oder Ampullen. Das Set kann z.B. separate Ampullen enthalten, in denen jeweils eine wirksame Menge an einer O\nQ\n Verbindung der Formel I und/oder ihrer pharmazeutisch verwendbaren Salze und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, und einer wirksamen Menge eines weiteren Arzneimittelwirkstoffs gelöst oder in lyophilisierter Form vorliegt.\nThe kit contains suitable containers, such as boxes or boxes, individual bottles, bags or ampoules. The kit may contain, for example, separate ampoules in each of which an effective amount of an O \nQ\n compound of formula I and / or its pharmaceutically acceptable salts and stereoisomers, including mixtures thereof in all proportions, and an effective amount of another drug active or in lyophilized Form is present.\n\n\n\n\n\n\n \n \n35\n VERWENDUNG \n\n Die vorliegenden Verbindungen eignen sich als pharmazeutische Wirkstoffe für Säugetiere, insbesondere für den Menschen, bei der Behandlung von tyrosinkinasebedingten Krankheiten. Zu diesen Krankheiten zählen die Proliferation von Tumorzellen, die pathologische Gefäßneubildung (oder Angio- 5 genese), die das Wachstum fester Tumoren fördert, die Gefäßneubildung im\n \n35\n USE  The present compounds are useful as pharmaceutical agents for mammals, particularly for humans, in the treatment of tyrosine kinase-related diseases. These diseases include the proliferation of tumor cells, the pathological neovascularization (or angiogenesis) that promotes the growth of solid tumors, the neovascularization of the tumor\n\n\n\n\n\n\n \nAuge (diabetische Retinopathie, altersbedingte Makula-Degeneration und dergleichen) sowie Entzündung (Schuppenflechte, rheumatoide Arthritis und dergleichen).\nEye (diabetic retinopathy, age-related macular degeneration and the like) and inflammation (psoriasis, rheumatoid arthritis and the like).\n\n\n\n\n\n\n \n10\n10\n\n\n\n\n\n\n \nDie vorliegende Erfindung umfasst die Verwendung der Verbindungen der Formel I und/oder ihre physiologisch unbedenklichen Salze zur Herstellung eines Arzneimittels zur Behandlung oder Vorbeugung von Krebs. Bevorzugte\nThe present invention encompasses the use of the compounds of the formula I and / or their physiologically acceptable salts for the preparation of a medicament for the treatment or prevention of cancer. preferred\n\n\n\n\n\n\n \n. \nc\n Karzinome für die Behandlung stammen aus der Gruppe Hirnkarzinom, Urogenitaltraktkarzinom, Karzinom des lymphatischen Systems, Magenkarzinom, Kehlkopfkarzinom und Lungenkarzinom. Eine weitere Gruppe bevorzugter Krebsformen sind Monozytenleukämie, Lungenadenokarzinom, kleinzellige Lungenkarzinome, Bauchspeicheldrüsenkrebs, Glioblastome und\n, \nc\n Carcinomas for treatment are from the brain carcinoma, genitourinary tract carcinoma, carcinoma of the lymphatic system, gastric carcinoma, laryngeal carcinoma and lung carcinoma. Another group of preferred forms of cancer are monocytic leukemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, and\n\n\n\n\n\n\n \n20 _ .. .\n20 _ ...\n\n\n\n\n\n\n \nBrustkarzinom.\nBreast carcinoma.\n\n\n\n\n\n\n \nEbensfalls umfasst ist die Verwendung der erfindungsgemäßen Verbindungen nach Anspruch 1 und/oder ihre physiologisch unbedenklichen Salze zur Herstellung eines Arzneimittels zur Behandlung oder Vorbeugung\nAlso included is the use of the compounds of the invention according to claim 1 and / or their physiologically acceptable salts for the preparation of a medicament for the treatment or prevention\n\n\n\n\n\n\n \n25 einer Krankheit, an der Angiogenese beteiligt ist.\n25 of a disease in which angiogenesis is involved.\n\n\n\n\n\n\n \nEine derartige Krankheit, an der Angiogenese beteiligt ist, ist eine Augenkrankheit, wie Retina-Vaskularisierung, diabetische Retinopathie, altersbedingte Makula-Degeneration und dergleichen.\nOne such disease involving angiogenesis is an eye disease such as retinal vascularization, diabetic retinopathy, age-related macular degeneration, and the like.\n\n\n\n\n\n\n \n \nO0\n Die Verwendung von Verbindungen der Formel I und/oder ihre physiologisch unbedenklichen Salze und Solvate zur Herstellung eines Arzneimittels zur Behandlung oder Vorbeugung von Entzündungskrankheiten, fäilt ebenfalls unter den Umfang der vorliegenden Erfindung. Zu solchen Entzündungskrankheiten zählen zum Beispiel rheumatoide Arthritis, Schuppenflechte,\n \nO0\n The use of compounds of the formula I and / or their physiologically acceptable salts and solvates thereof for the manufacture of a medicament for the treatment or prevention of inflammatory diseases also fäilt the scope of the present invention. Such inflammatory diseases include, for example, rheumatoid arthritis, psoriasis,\n\n\n\n\n\n\n \n35\n35\n\n\n\n\n\n\n \nKontaktdermatitis, Spät-Typ der Überempfindlichkeitsreaktion und dergleichen. \n\n Ebenfalls umfasst ist die Verwendung der Verbindungen der Formel I und/oder ihre physiologisch unbedenklichen Salze zur Herstellung eines Arzneimittels zur Behandlung oder Vorbeugung einer tyrosinkinasebedingten\nContact dermatitis, late-type hypersensitivity reaction and the like.  Also included is the use of the compounds of the formula I and / or their physiologically acceptable salts for the preparation of a medicament for the treatment or prevention of a tyrosine kinase-related\n\n\n\n\n\n\n \nKrankheit bzw. eines tyrosinkinasebedingten Leidens bei einem Säugetier, wobei man diesem Verfahren einem kranken Säugetier, das einer derartigen\nDisease or a tyrosine kinase-related condition in a mammal, this method being applied to a diseased mammal suffering from such a disease\n\n\n\n\n\n\n \nBehandlung bedarf, eine therapeutisch wirksame Menge einer erfindungsgemäßen Verbindung verabreicht. Die therapeutische Menge hängt von der jeweiligen Krankheit ab und kann vom Fachmann ohne allen großen Aufwand bestimmt werden.\nTreatment requires a therapeutically effective amount of a compound of the invention administered. The therapeutic amount depends on the particular disease and can be determined by the skilled person without great effort.\n\n\n\n\n\n\n \nDie vorliegende Erfindung umfasst auch die Verwendung Verbindungen der Formel I und/oder ihre physiologisch unbedenklichen Salze und Solvate zur Herstellung eines Arzneimittels zur Behandlung oder Vorbeugung von Retina-Vaskularisierung.\nThe present invention also encompasses the use of compounds of the formula I and / or their physiologically acceptable salts and solvates for the preparation of a medicament for the treatment or prevention of retinal vascularization.\n\n\n\n\n\n\n \nVerfahren zur Behandlung oder Vorbeugung von Augenkrankheiten wie diabetischer Retinopathie und altersbedingter Makula-Degeneration sind ebenfalls ein Bestandteil der Erfindung. Die Verwendung zur Behandlung oder Vorbeugung von Entzündungskrankheiten wie rheumatoider Arthritis,\nMethods for the treatment or prevention of ocular diseases such as diabetic retinopathy and age-related macular degeneration are also part of the invention. The use for the treatment or prevention of inflammatory diseases such as rheumatoid arthritis,\n\n\n\n\n\n\n \nSchuppenflechte, Kontaktdermatitis und Spät-Typen der Uberempfindlich- keitsreaktion, sowie die Behandlung oder Vorbeugung von Knochen- Pathologien aus der Gruppe Osteosarkom, Osteoarthritis und Rachitis, fällt ebenfalls unter den Umfang der vorliegenden Erfindung. Der Ausdruck „tyrosinkinasebedingte Krankheiten oder Leiden\" bezieht sich auf pathologische Zustände, die von der Aktivität einer oder mehrerer Tyrosinkinasen abhängig sind. Die Tyrosinkinasen sind entweder direkt oder indirekt an den Signaltransduktionswegen verschiedener Zellaktivitäten, darunter Proliferation, Adhäsion und Migration sowie Differenzierung beteiligt. Zu den Krankheiten, die mit Tyrosinkinaseaktivität assoziiert sind, zählen die Proliferation von Tumorzellen, die pathologische Gefäßneubildung, die das Wachstum fester Tumore fördert, Gefäßneubildung im Auge\nPsoriasis, contact dermatitis and late-type hypersensitivity reactions, as well as the treatment or prevention of bone pathologies from the group of osteosarcoma, osteoarthritis and rickets, are also within the scope of the present invention. The term \"tyrosine kinase-related diseases or conditions\" refers to pathological conditions that are dependent on the activity of one or more tyrosine kinases.The tyrosine kinases are involved either directly or indirectly in the signal transduction pathways of various cellular activities, including proliferation, adhesion and migration as well as differentiation Diseases associated with tyrosine kinase activity include the proliferation of tumor cells, the pathological neovascularization that promotes the growth of solid tumors, neovascularization in the eye\n\n\n\n\n\n\n \n(diabetische Retinopathie, altersbedingte Makula-Degeneration und dergleichen) sowie Entzündung (Schuppenflechte, rheumatoide Arthritis und dergleichen). \n\n Die Verbindungen der Formel I können an Patienten zur Behandlung von Krebs, insbesondere schnell wachsenden Tumoren, verabreicht werden.\n(diabetic retinopathy, age-related macular degeneration and the like) as well as inflammation (psoriasis, rheumatoid arthritis and the like).  The compounds of formula I can be administered to patients for the treatment of cancer, especially fast growing tumors.\n\n\n\n\n\n\n \nGegenstand der Erfindung ist somit die Verwendung von Verbindungen der\nThe invention thus relates to the use of compounds of\n\n\n\n\n\n\n \nFormel I\n1\n sowie ihrer pharmazeutisch verwendbaren Salze und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, zur Herstellung eines Arzneimittels zur Behandlung von Krankheiten, bei denen die Hemmung, Regulierung und/oder Modulation der Signaltransduktion von Kinasen eine Rolle spielt.\nFormula I \n1\n and its pharmaceutically acceptable salts and stereoisomers, including mixtures thereof in all ratios, for the manufacture of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation of the signal transduction of kinases play a role.\n\n\n\n\n\n\n \nBevorzugt ist hierbei die Met-Kinase.\nPreference is given to the met kinase.\n\n\n\n\n\n\n \nBevorzugt ist die Verwendung von Verbindungen der Formel I, sowie ihrer pharmazeutisch verwendbaren Salze und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, zur Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die durch Inhibierung der Tyrosinkinasen durch die Verbindungen nach\nPreferred is the use of compounds of formula I, as well as their pharmaceutically acceptable salts and stereoisomers, including mixtures thereof in all proportions, for the preparation of a medicament for the treatment of diseases resulting from inhibition of tyrosine kinases by the compounds\n\n\n\n\n\n\n \nAnspruch 1 beeinflußt werden.\nClaim 1 are affected.\n\n\n\n\n\n\n \nBesonders bevorzugt ist die Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die durch Inhibierung von Met-Kinase durch die Verbindungen nach Anspruch 1 beeinflußt werden. Insbesondere bevorzugt ist die Verwendung zur Behandlung einer Krankheit, wobei die Krankheit ein fester Tumor ist.\nParticularly preferred is the use for the manufacture of a medicament for the treatment of diseases which are affected by inhibition of Met kinase by the compounds of claim 1. Especially preferred is the use for treating a disease wherein the disease is a solid tumor.\n\n\n\n\n\n\n \nDer feste Tumor ist vorzugsweise ausgewählt aus der Gruppe der Tumoren der Lunge, des Plattenepithel, der Blasen, des Magens, der Nieren, von Kopf und Hals, des Ösophagus, des Gebärmutterhals, der Schilddrüse, des Darm, der Leber, des Gehirns, der Prostata, des Urogenitaltrakts, des lymphatischen Systems, des Magens und/oder des Kehlkopfs. \n\n Der feste Tumor ist weiterhin vorzugsweise ausgewählt aus der Gruppe Lungenadenokarzinom, kleinzellige Lungenkarzinome, Bauchspeicheldrüsenkrebs, Glioblastome, Kolonkarzinom und Brustkarzinom.\nThe solid tumor is preferably selected from the group of tumors of the lung, squamous epithelium, bladder, stomach, kidney, head and neck, esophagus, cervix, thyroid, intestine, liver, brain Prostate, genitourinary tract, lymphatic system, stomach and / or larynx.  The solid tumor is furthermore preferably selected from the group of lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, colon carcinoma and breast carcinoma.\n\n\n\n\n\n\n \nWeiterhin bevorzugt ist die Verwendung zur Behandlung eines Tumors des Blut- und Immunsystems, vorzugsweise zur Behandlung eines Tumors ausgewählt aus der Gruppe der akuten myeloischen Leukämie, der chronischen myeloischen Leukämie, akuten lymphatischen Leukämie und/oder chronischen lymphatischen Leukämie.\nFurther preferred is the use for the treatment of a tumor of the blood and immune system, preferably for the treatment of a tumor selected from the group of acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and / or chronic lymphocytic leukemia.\n\n\n\n\n\n\n \nDie offenbarten Verbindungen der Formel I können in Verbindung mit anderen Therapeutika, einschließlich Antikrebsmitteln, verabreicht werden. Wie hier verwendet, betrifft der Begriff \"Antikrebsmittel\" jedes Mittel, das einem Patienten mit Krebs zum Zweck der Behandlung des Krebses verabreicht wird.\nThe disclosed compounds of formula I may be administered in conjunction with other therapeutic agents, including anticancer agents. As used herein, the term \"anticancer agent\" refers to any agent that is administered to a patient with cancer for the purpose of treating the cancer.\n\n\n\n\n\n\n \nDie hier definierte Antikrebsbehandlung kann als alleinige Therapie ange- wendet werden oder zusätzlich zu der erfindungsgemäßen Verbindung herkömmliche Operation oder Strahlungstherapie oder Chemotherapie umfassen. Eine derartige Chemotherapie kann eine oder mehrere der folgenden Kategorien von Antitumormitteln umfassen: (i) antiproliferative/antineoplastische/DNA schädigende Mittel und\nThe anticancer treatment defined herein may be used as the sole therapy or in addition to the compound of the invention may include conventional surgery or radiation therapy or chemotherapy. Such chemotherapy may include one or more of the following categories of antitumour agents: (i) antiproliferative / antineoplastic / DNA damaging agents and\n\n\n\n\n\n\n \nKombinationen davon, wie in der medizinischen Onkologie verwendet, wie Alkylierungsmittel (zum Beispiel Cisplatin, Carboplatin, Cyclophosphamid, Nitrogen Mustard, Melphalan, Chlorambucil, Busulphan und Nitroso- hamstoffe); Antimetaboliten (z.B. Antifolate, wie Fluorpyrimidine, wie 5- Fluoruracil und Tegafur, Raltitrexed, Methotrexat, Cytosinarabinosid, Hydroxyharnstoff und Gemcitabin); Antitumor-Antibiotika (z.B. Anthracyciine, wie Adriamycin, Bleomycin, Doxorubicin, Daunomycin, Epirubicin, Idarubicin,\nCombinations thereof, as used in medical oncology, such as alkylating agents (for example, cisplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, and nitrosoureas); Antimetabolites (e.g., antifolates such as fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); Anti-tumor antibiotics (e.g., anthracyclines such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin,\n\n\n\n\n\n\n \nMitomycin-C, Dactinomycin und Mithramycin); antimitotische Mittel (zum\nMitomycin C, dactinomycin and mithramycin); antimitotic agents (for\n\n\n\n\n\n\n \nBeispiel Vinca-Alkaloide, wie Vincristin, Vinblastin, Vindesin und Vinorelbin, und Taxoide, wie Taxol und Taxoter); Topoisomerase-Inhibitoren (zum \n\n Beispiel Epipodophyllotoxine, wie Etoposid und Teniposid, Amsacrin, Topotecan, Irinotecan und Camptothecin) und zelldifferenzierende Mittel (zum Beispiel all-trans-Retinsäure, 13-cis-Retinsäure und Fenretinid);\nExample, vinca alkaloids such as vincristine, vinblastine, vindesine and vinorelbine, and taxoids such as taxol and taxotere); Topoisomerase inhibitors (for  Example, epipodophyllotoxins such as etoposide and teniposide, amsacrine, topotecan, irinotecan and camptothecin) and cell differentiating agents (for example, all-trans retinoic acid, 13-cis retinoic acid and fenretinide);\n\n\n\n\n\n\n \n(ii) zytostatische Mittel, wie Anti-Östrogene (z.B. Tamoxifen, Toremifen,\n(ii) cytostatic agents, such as anti-estrogens (e.g., tamoxifen, toremifene,\n\n\n\n\n\n\n \nRaloxifen, Droloxifen und lodoxyfen), den Östrogenrezeptor nach unten regulierende Mittel (zum Beispiel Fulvestrant), Anti-Androgene (z.B. Bicalutamid, Flutamid, Nilutamid und Cyproteronacetat), LHRH-Antagonisten oder LHRH-Agonisten (zum Beispiel Goserelin, Leuprorelin und Buserelin), Progesterone (zum Beispiel Megestrolacetat), Aromatase-Inhibitoren (zum Beispiel Anastrozol, Letrozol, Vorazol und Exemestan) und inhibitoren der 5α-Reduktase, wie Finasterid; (iii) Mittel, die die Invasion von Krebszellen hemmen (zum Beispiel Metalloproteinase-Inhibitoren, wie Marimastat und Inhibitoren der Urokinase- Plasminogenaktivator-Rezeptor-Funktion);\nRaloxifene, droloxifene and iodoxyfen), estrogen receptor downregulating agents (eg fulvestrant), anti-androgens (eg bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), Progesterone (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5α-reductase, such as finasteride; (iii) agents that inhibit the invasion of cancer cells (for example, metalloproteinase inhibitors such as marimastat and inhibitors of urokinase plasminogen activator receptor function);\n\n\n\n\n\n\n \n(iv) Inhibitoren der Wachstumsfaktor-Funktion, zum Beispiel umfassen solche Inhibitoren Wachstumsfaktor-Antikörper, Wachstumsfaktor-Rezeptor- Antikörper (zum Beispiel den Anti-erbb2-Antikörper Trastuzumab\n(iv) inhibitors of growth factor function, for example, such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example, the anti-erbb2 antibody trastuzumab\n\n\n\n\n\n\n \n[Herceptin™] und den Anti-erbb1 -Antikörper Cetuximab [C225]), Farnesyl- transferase-lnhibitoren, Tyrosinkinase-Inhibitoren und Serin / Threonin- Kinase-Inhibitoren, zum Beispiel Inhibitoren der epidermalen Wachstumsfaktor-Familie (zum Beispiel Inhibitoren der Tyrosinkinasen der EGFR- Familie, wie N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-(3-morpholinopropoxy)- chinazolin-4-amin (Gefitinib, AZD1839), N-(3-Ethinylphenyl)-6,7-bis(2- methoxyethoxy)chinazolin-4-amin (Erlotinib, OSI-774) und 6-Acrylamido-N- (3-chlor-4-fluorphenyl)-7-(3-morpholinopropoxy)chinazolin-4-amin (Cl 1033)), zum Beispiel Inhibitoren der von Plättchen abstammenden Wachstumsfaktor-Familie und zum Beispiel Inhibitoren der Hepatozytenwachstums- faktor-Familie; (v) antiangiogene Mittel, wie solche, die die Wirkungen des vaskulären endothelialen Wachstumsfaktors hemmen (zum Beispiel der Antikörper gegen den vaskulären Endothelzell-Wachstumsfaktor Bevacizumab \n\n [Avastin™], Verbindungen, wie die in den veröffentlichten internationalen Patentanmeldungen WO 97/22596, WO 97/30035, WO 97/32856 und WO 98/13354 offenbarten) und Verbindungen, die durch andere Mechanismen wirken (zum Beispiel Linomid, Inhibitoren der lntegrin-αvß3-Funktion und Angiostatin);\n[Herceptin ™] and the anti-erbb1 antibody cetuximab [C225]), farnesyltransferase inhibitors, tyrosine kinase inhibitors and serine / threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example inhibitors of the tyrosine kinases of the EGFR family such as N- (3-chloro-4-fluorophenyl) -7-methoxy-6- (3-morpholinopropoxy) quinazolin-4-amine (gefitinib, AZD1839), N- (3-ethynylphenyl) -6, 7-bis (2-methoxyethoxy) quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N- (3-chloro-4-fluorophenyl) -7- (3-morpholinopropoxy) quinazolin-4-amine ( Cl 1033)), for example platelet-derived growth factor family inhibitors and, for example, inhibitors of the hepatocyte growth factor family; (v) antiangiogenic agents, such as those that inhibit the effects of the vascular endothelial growth factor (for example, the vascular endothelial cell growth factor bevacizumab antibody  [Avastin ™], compounds such as those disclosed in published international patent applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds which act by other mechanisms (for example, linomide, inhibitors of integrin αvβ3 function and angiostatin);\n\n\n\n\n\n\n \n(vi) gefäßschädigende Mittel, wie Combretastatin A4 und in den internationalen Patentanmeldungen WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 und WO 02/08213 offenbarte Verbindungen;\n(vi) vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;\n\n\n\n\n\n\n \n(vü) Antisense-Therapien, zum Beispiel diejenigen, die gegen die vorstehend aufgelisteten Ziele gerichtet sind, wie ISIS 2503, ein anti-Ras- Antisense; (viii) Genetherapieansätze, einschließlich beispielsweise Ansätze zum Ersetzen von veränderten Genen, wie verändertem p53 oder verändertem BRCA1 oder BRCA2, GDEPT- (gene-directed enzyme pro-drug-Therapie-) Ansätze, die diejenigen, die Cytosindesaminase, Thymidinkinase oder ein bakterielles Nitroreduktase-Enzym verwenden, sowie Ansätze zur Erhöhung der Patiententoleranz gegenüber Chemotherapie oder Strahlungstherapie, wie Multi-Drug-Resistence-Gen-Therapie; und\n(vii) antisense therapies, for example, those directed against the targets listed above, such as ISIS 2503, an anti-Ras antisense; (viii) gene therapy approaches, including, for example, approaches to replace altered genes, such as altered p53 or altered BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches, those that include cytosine deaminase, thymidine kinase or a bacterial nitroreductase Use enzyme as well as approaches to increase patient tolerance to chemotherapy or radiation therapy, such as multi-drug resistance gene therapy; and\n\n\n\n\n\n\n \n(ix) Immuntherapieansätze, einschließlich beispielsweise Ex-vivo- und\n(ix) immunotherapy approaches, including, for example, ex vivo and\n\n\n\n\n\n\n \nIn-vivo-Ansätzen zur Erhöhung der Immunogenität von Patiententumor- zellen, wie Transfektion mit Cytokinen, wie Interieukin 2, Interleukin 4 oder Granulozyten-Makrophagen-Kolonie-stimulierendem Faktor, Ansätze zur Verringerung der T-Zell-Anergie, Ansätze unter Verwendung transfizierter Immunzellen, wie mit Cytokin transfizierter dendritischer Zellen, Ansätze unter Verwendung mit Cytokin transfizierter Tumorzelllinien und Ansätze unter Verwendung anti-idiotypischer Antikörper.\nIn vivo approaches to increase the immunogenicity of patient tumor cells such as transfection with cytokines such as interieukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to reducing T-cell anergy, approaches using transfected immune cells , as with cytokine-transfected dendritic cells, approaches using cytokine-transfected tumor cell lines and approaches using anti-idiotypic antibodies.\n\n\n\n\n\n\n \nBevorzugt aber nicht ausschliesslich werden die Arzneimittel der nachstehenden Tabelle 1 mit den Verbindungen der Formel I kombiniert. \n\n Tabelle 1.\nPreferably, but not exclusively, the medicaments of Table 1 below are combined with the compounds of the formula I.  Table 1.\n\n\n\n\n\n\n \nAlkylierungsmittel Cyclophosphamid Lomustin\nAlkylating agent Cyclophosphamide Lomustine\n\n\n\n\n\n\n \nBusulfan Procarbazin\nBusulfan procarbazine\n\n\n\n\n\n\n \nIfosfamid Altretamin\nIfosfamide altretamine\n\n\n\n\n\n\n \nMelphalan Estramustinphosphat\nMelphalan estramustin phosphate\n\n\n\n\n\n\n \nHexamethylmelamin Mechlorethamin\nHexamethylmelamine mechlorethamine\n\n\n\n\n\n\n \nThiotepa Streptozocin\nThiotepa streptozocin\n\n\n\n\n\n\n \nChlorambucil Temozolomid\nChlorambucil Temozolomide\n\n\n\n\n\n\n \nDacarbazin Semustin\nDacarbazine Semustin\n\n\n\n\n\n\n \nCarmustin\ncarmustine\n\n\n\n\n\n\n \nPlatinmittel Cisplatin Carboplatin\nPlatinum agent cisplatin carboplatin\n\n\n\n\n\n\n \nOxaliplatin ZD-0473 (AnorMED)\nOxaliplatin ZD-0473 (AnorMED)\n\n\n\n\n\n\n \nSpiroplatin Lobaplatin (Aetema)\nSpiroplatin Lobaplatin (Aetema)\n\n\n\n\n\n\n \nCarboxyphthalatoplatinum Satraplatin (Johnson\nCarboxyphthalatoplatinum Satraplatin (Johnson\n\n\n\n\n\n\n \nTetraplatin Matthey)\nTetraplatinum Matthey)\n\n\n\n\n\n\n \nOrmiplatin BBR-3464 (Hoffrnann-La\nOrmiplatin BBR-3464 (Hoffrnann-La\n\n\n\n\n\n\n \nIproplatin Roche)\nIproplatin Roche)\n\n\n\n\n\n\n \nSM-11355 (Sumitomo)\nSM-11355 (Sumitomo)\n\n\n\n\n\n\n \nAP-5280 (Access)\nAP-5280 (Access)\n\n\n\n\n\n\n \nAntimetabolite Azacytidin Tomudex\nAntimetabolite azacytidine Tomudex\n\n\n\n\n\n\n \nGemcitabin Trimetrexate\nGemcitabine trimetrexate\n\n\n\n\n\n\n \nCapecitabin Deoxycoformycin\nCapecitabine deoxycoformycin\n\n\n\n\n\n\n \n5-Fluoruracil Fludarabin\n5-fluorouracil fludarabine\n\n\n\n\n\n\n \nFloxuridin Pentostatin\nFloxuridine pentostatin\n\n\n\n\n\n\n \n2-Chlordesoxyadenosin Raltitrexed\n2-chlorodeoxyadenosine Raltitrexed\n\n\n\n\n\n\n \n6-Mercaptopurin Hydroxyharnstoff\n6-mercaptopurine hydroxyurea\n\n\n\n\n\n\n \n6-Thioguanin Decitabin (SuperGen)\n6-thioguanine decitabine (SuperGen)\n\n\n\n\n\n\n \nCytarabin Clofarabin (Bioenvision)\nCytarabine Clofarabine (Bioenvision)\n\n\n\n\n\n\n \n2-Fluordesoxycytidin Irofulven (MGI Pharma)\n2-Fluorodeoxycytidine Irofulvene (MGI Pharma)\n\n\n\n\n\n\n \nMethotrexat DMDC (Hoffmann-La Roche\nMethotrexate DMDC (Hoffmann-La Roche\n\n\n\n\n\n\n \nIdatrexate Ethinylcytidin (Taiho )\nIdatrexate Ethinylcytidine (Taiho)\n\n\n\n\n\n\n \nTopoisomerase- Amsacrin Rubitecan (SuperGen)\nTopoisomerase Amsacrine Rubitecane (SuperGen)\n\n\n\n\n\n\n \nInhibitoren Epirubicin Exatecanmesylat (Daiichi)\nInhibitors Epirubicin Exatecan Mesylate (Daiichi)\n\n\n\n\n\n\n \nEtoposid Quinamed (ChemGenex)\nEtoposide Quinamed (ChemGenex)\n\n\n\n\n\n\n \nTeniposid oder Mitoxantron Gimatecan (Sigma- Tau)\nTeniposide or Mitoxantrone Gimatecan (Sigma-Tau)\n\n\n\n\n\n\n \nIrinotecan (CPT-11 ) Diflomotecan (Beaufour-\nIrinotecan (CPT-11) diflomotecan (Beaufour\n\n\n\n\n\n\n \n7-Ethyl-10- Ipsen) hydroxycamptothecin TAS-103 (Taiho)\n7-ethyl-10-Ipsen) hydroxycamptothecin TAS-103 (Taiho)\n\n\n\n\n\n\n \nTopotecan Elsamitrucin (Spectrum)\nTopotecan Elsamitrucin (Spectrum)\n\n\n\n\n\n\n \nDexrazoxanet (TopoTarget) J-107088 (Merck & Co)\nDexrazoxanet (TopoTarget) J-107088 (Merck & Co)\n\n\n\n\n\n\n \nPixantron (Novuspharma) BNP-1350 (BioNumerik)\nPixantrone (Novuspharma) BNP-1350 (BioNumerik)\n\n\n\n\n\n\n \nRebeccamycin-Analogon CKD-602 (Chong Kun Dang\nRebeccamycin analog CKD-602 (Chong Kun Dang\n\n\n\n\n\n\n \n(Exelixis) KW-2170 (Kyowa Hakko)\n(Exelixis) KW-2170 (Kyowa Hakko)\n\n\n\n\n\n\n \nBBR-3576 (Novuspharma) \n\n Antitumor- Dactinomycin (Actinomycin Amonafid\nBBR-3576 (Novuspharma)  Antitumor Dactinomycin (Actinomycin Amonafide\n\n\n\n\n\n\n \nAntibiotika D) Azonafid\nAntibiotics D) Azonafide\n\n\n\n\n\n\n \nDoxorubicin (Adriamycin) Anthrapyrazol\nDoxorubicin (adriamycin) anthrapyrazole\n\n\n\n\n\n\n \nDeoxyrubicin Oxantrazol\nDeoxyrubicin Oxantrazole\n\n\n\n\n\n\n \nValrubicin Losoxantron\nValrubicin losoxantrone\n\n\n\n\n\n\n \nDaunorubicin (Daunomycin) Bleomycinsulfat (Blenoxan)\nDaunorubicin (Daunomycin) Bleomycin Sulfate (Blenoxan)\n\n\n\n\n\n\n \nEpirubicin Bleomycinsäure\nEpirubicin bleomycinic acid\n\n\n\n\n\n\n \nTherarubicin Bleomycin A\nTherarubicin Bleomycin A\n\n\n\n\n\n\n \nIdarubicin Bleomycin B\nIdarubicin bleomycin B\n\n\n\n\n\n\n \nRubidazon Mitomycin C\nRubidazone mitomycin C\n\n\n\n\n\n\n \nPlicamycinp MEN-10755 (Menarini)\nPlicamycin p MEN-10755 (Menarini)\n\n\n\n\n\n\n \nPorfiromycin GPX-100 (Gem\nPorfiromycin GPX-100 (gem\n\n\n\n\n\n\n \nCyanomorphoünodoxorubici Pharmaceuticals)\nCyanomorphoünodoxorubici Pharmaceuticals)\n\n\n\n\n\n\n \nMitoxantron (Novantron)\nMitoxantrone (Novantrone)\n\n\n\n\n\n\n \nAntimitotische Mitte Paclitaxel SB 408075\nAntimitotic Center Paclitaxel SB 408075\n\n\n\n\n\n\n \nDocetaxel (GlaxoSmithKline)\nDocetaxel (GlaxoSmithKline)\n\n\n\n\n\n\n \nColchicin E7010 (Abbott)\nColchicine E7010 (Abbott)\n\n\n\n\n\n\n \nVinblastin PG-TXL (Cell Therapeutics)\nVinblastine PG-TXL (Cell Therapeutics)\n\n\n\n\n\n\n \nVincristin IDN 5109 (Bayer)\nVincristine IDN 5109 (Bayer)\n\n\n\n\n\n\n \nVinorelbin A 105972 (Abbott)\nVinorelbine A 105972 (Abbott)\n\n\n\n\n\n\n \nVindesin A 204197 (Abbott)\nVindesin A 204197 (Abbott)\n\n\n\n\n\n\n \nDolastatin 10 (NCI) LU 223651 (BASF)\nDolastatin 10 (NCI) LU 223651 (BASF)\n\n\n\n\n\n\n \nRhizoxin (Fujisawa) D 24851 (ASTA Medica)\nRhizoxin (Fujisawa) D 24851 (ASTA Medica)\n\n\n\n\n\n\n \nMivobulin (Warner-Lambert) ER-86526 (Eisai)\nMivobulin (Warner-Lambert) ER-86526 (Eisai)\n\n\n\n\n\n\n \nCemadotin (BASF) Combretastatin A4 (BMS)\nCemadotin (BASF) Combretastatin A4 (BMS)\n\n\n\n\n\n\n \nRPR 109881A (Aventis) Isohomohalichondrin-B\nRPR 109881A (Aventis) isohomohalichondrin-B\n\n\n\n\n\n\n \nTXD 258 (Aventis) (PharmaMar)\nTXD 258 (Aventis) (PharmaMar)\n\n\n\n\n\n\n \nEpothilon B (Novartis) ZD 6126 (AstraZeneca)\nEpothilone B (Novartis) ZD 6126 (AstraZeneca)\n\n\n\n\n\n\n \nT 900607 (Tularik) PEG-Paclitaxel (Enzon)\nT 900607 (Tularik) PEG paclitaxel (Enzon)\n\n\n\n\n\n\n \nT 138067 (Tularik) AZ10992 (Asahi)\nT 138067 (Tularik) AZ10992 (Asahi)\n\n\n\n\n\n\n \nCryptophycin 52 (EIi Lilly) !DN-5109 (lndena)\nCryptophycin 52 (Eli Lilly)! DN-5109 (lndena)\n\n\n\n\n\n\n \nVinflunin (Fabre) AVLB (Prescient\nVinflunin (Fabre) AVLB (Prescient\n\n\n\n\n\n\n \nAuristatin PE (Teikoku NeuroPharma)\nAuristatin PE (Teikoku NeuroPharma)\n\n\n\n\n\n\n \nHormone) Azaepothilon B (BMS)\nHormones) azaepothilone B (BMS)\n\n\n\n\n\n\n \nBMS 247550 (BMS) BNP- 7787 (BioNumerik)\nBMS 247550 (BMS) BNP-7787 (BioNumerik)\n\n\n\n\n\n\n \nBMS 184476 (BMS) CA-4-Prodrug (OXiGENE)\nBMS 184476 (BMS) CA-4 prodrug (OXiGENE)\n\n\n\n\n\n\n \nBMS 188797 (BMS) Dolastatin-10 (NrH)\nBMS 188797 (BMS) Dolastatin-10 (NrH)\n\n\n\n\n\n\n \nTaxoprexin (Protarga) CA-4 (OXiGENE)\nTaxoprexin (Protarga) CA-4 (OXiGENE)\n\n\n\n\n\n\n \nAromatase- Aminoglutethimid Exemestan\nAromatase-aminoglutethimide exemestane\n\n\n\n\n\n\n \nInhibitoren Letrozol Atamestan (BioMedicines)\nInhibitors Letrozole Atamestane (BioMedicines)\n\n\n\n\n\n\n \nAnastrazol YM-511 (Yamanouchi)\nAnastrazole YM-511 (Yamanouchi)\n\n\n\n\n\n\n \nFormestan\nformestane\n\n\n\n\n\n\n \nThymidylatsynthas« Pemetrexed (EIi Lilly) Nolatrexed (Eximias) \n\n\n\n\n \n\n CTP-37 (AVI BioPharma) Norelin (Biostar)\nThymidylate synthas «Pemetrexed (EIi Lilly) Nolatrexed (Eximias) \n CTP-37 (AVI BioPharma) Norelin (Biostar)\n\n\n\n\n\n\n \nJRX-2 (Immuno-Rx) BLP-25 (Biomira)\nJRX-2 (Immuno-Rx) BLP-25 (Biomira)\n\n\n\n\n\n\n \nPEP-005 (Peplin Biotech) MGV (Progenics)\nPEP-005 (Peplin Biotech) MGV (Progenics)\n\n\n\n\n\n\n \nSynchrovax-Impf Stoffe (CTL !3-Alethin (Dovetail)\nSynchrovax vaccine substances (CTL! 3-alethine (Dovetail)\n\n\n\n\n\n\n \nImmuno) CLL-Thera (Vasogen)\nImmuno) CLL-Thera (Vasogen)\n\n\n\n\n\n\n \nMelanom-Impfstoff (CTL\nMelanoma vaccine (CTL\n\n\n\n\n\n\n \nImmuno) p21-RAS-lmpfstoff\nImmuno) p21 RAS vaccine\n\n\n\n\n\n\n \n(GemVax)\n(GemVax)\n\n\n\n\n\n\n \nHormonelle und Östrogene Prednison antihormonelle konjugierte Östrogene Methylprednisolon\nHormonal and estrogenic prednisone antihormonal conjugated estrogens methylprednisolone\n\n\n\n\n\n\n \nMittel Ethinylöstradiol Prednisolon\nAgent ethinyl estradiol prednisolone\n\n\n\n\n\n\n \nChlortrianisen Aminoglutethimid\nChlorotrienes Aminoglutethimide\n\n\n\n\n\n\n \nIdenestrol Leuprolid\nIdenestrol Leuprolide\n\n\n\n\n\n\n \nHydroxyprogesteroncaproat Goserelin\nHydroxyprogesterone caproate goserelin\n\n\n\n\n\n\n \nMedroxyprogesteron Leuporelin\nMedroxyprogesterone Leuporelin\n\n\n\n\n\n\n \nTestosteron Bicalutamid\nTestosterone Bicalutamide\n\n\n\n\n\n\n \nTestosteronpropionat Flutamid\nTestosterone Propionate Flutamide\n\n\n\n\n\n\n \nFluoxymesteron Octreotid\nFluoxymesterone octreotide\n\n\n\n\n\n\n \nMethyltestosteron Nilutamid\nMethyltestosterone Nilutamide\n\n\n\n\n\n\n \nDiethylstilbestrol Mitotan\nDiethylstilbestrol Mitotane\n\n\n\n\n\n\n \nMegestrol P-04 (Novogen)\nMegestrol P-04 (Novogen)\n\n\n\n\n\n\n \nTamoxifen 2-Methoxyöstradiol\nTamoxifen 2-methoxyestradiol\n\n\n\n\n\n\n \nToremofin (EntreMed)\nToremofin (EntreMed)\n\n\n\n\n\n\n \nDexamethason Arzoxifen (EIi Lilly)\nDexamethasone Arzoxifen (EIi Lilly)\n\n\n\n\n\n\n \nPhotodynamische Talaporfin (Light Sciences) Pd-Bacteriopheophorbid\nPhotodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbide\n\n\n\n\n\n\n \nMittel Theralux (Yeda)\nCentral Theralux (Yeda)\n\n\n\n\n\n\n \n(Theratechnologies) Lutetium-Texaphyrin\n(Theratechnologies) Lutetium Texaphyrin\n\n\n\n\n\n\n \nMotexafin-Gadolinium (Pharmacyclics)\nMotexafin Gadolinium (Pharmacyclics)\n\n\n\n\n\n\n \n(Pharmacyclics) Hypericin\n(Pharmacyclics) Hypericin\n\n\n\n\n\n\n \nTyrosinkinase- Imatinib (Novartis) Kahalid F (PharmaMar)\nTyrosine kinase imatinib (Novartis) Kahalid F (PharmaMar)\n\n\n\n\n\n\n \nInhibitoren Leflunomid CEP- 701 (Cephalon)\nInhibitors Leflunomide CEP-701 (Cephalon)\n\n\n\n\n\n\n \n(Sugen/Pharmacia) CEP-751 (Cephalon)\n(Sugen / Pharmacia) CEP-751 (Cephalon)\n\n\n\n\n\n\n \nZDI839 (AstraZeneca) MLN518 (Millenium)\nZDI839 (AstraZeneca) MLN518 (Millenium)\n\n\n\n\n\n\n \nErlotinib (Oncogene Science PKC412 (Novartis)\nErlotinib (Oncogene Science PKC412 (Novartis)\n\n\n\n\n\n\n \nCanertjnib (Pfizer) Phenoxodiol O\nCanertjnib (Pfizer) phenoxodiol O\n\n\n\n\n\n\n \nSqualamin (Genaera) Trastuzumab (Genentech)\nSqualamine (Genaera) trastuzumab (Genentech)\n\n\n\n\n\n\n \nSU5416 (Pharmacia) C225 (ImCIone)\nSU5416 (Pharmacia) C225 (ImCIone)\n\n\n\n\n\n\n \nSU6668 (Pharmacia) rhu-Mab (Genentech)\nSU6668 (Pharmacia) rhu-Mab (Genentech)\n\n\n\n\n\n\n \nZD4190 (AstraZeneca) MDX-H210 (Medarex)\nZD4190 (AstraZeneca) MDX-H210 (Medarex)\n\n\n\n\n\n\n \nZD6474 (AstraZeneca) 2C4 (Genentech)\nZD6474 (AstraZeneca) 2C4 (Genentech)\n\n\n\n\n\n\n \nVatalanib (Novartis) MDX-447 (Medarex)\nVatalanib (Novartis) MDX-447 (Medarex)\n\n\n\n\n\n\n \nPK1166 (Novartis) ABX-EGF (Abgenix)\nPK1166 (Novartis) ABX-EGF (Abgenix)\n\n\n\n\n\n\n \nGW2016 (GlaxoSmithKline) IMC-1C11 (ImCIone) \n\n EKB-509 (Wyeth) EKB-569 (Wyeth)\nGW2016 (GlaxoSmithKline) IMC-1C11 (ImCIone)  EKB-509 (Wyeth) EKB-569 (Wyeth)\n\n\n\n\n\n\n \nVerschiedene Mitte SR-27897 (CCK-A-Inhibitor, BCX-1777 (PNP-lnhibitor, Sanofi-Synthelabo) BioCryst) Tocladesin (cyclisches-AMP Ranpirnase (Ribonuclease- Agonist, Ribapharm) Stimulans, Alfacell) Alvocidib (CDK-Inhibitor, Galarubicin (RNA-Synthese Aventis) Inhibitor, Dong-A)\nVarious center SR-27897 (CCK-A inhibitor, BCX-1777 (PNP inhibitor, Sanofi-Synthelabo) BioCryst) Tocladesin (cyclic-AMP ranibonase (ribonuclease agonist, ribapharm) stimulant, Alfacell) Alvocidib (CDK inhibitor, galarubicin (RNA synthesis Aventis) inhibitor, Dong-A)\n\n\n\n\n\n\n \nCV-247 (COX-2-lnhibitor, Iv; Tirapazamin Medical) (Reduktionsmittel, SRI\nCV-247 (COX-2 inhibitor, Iv; Tirapazamine Medical) (reducing agent, SRI\n\n\n\n\n\n\n \nP54 (COX-2-lnhibitor, International) Phytopharm) N-Acetylcystein CapCell™ (CYP450- (Reduktionsmittel, Zambon) Stimulans, Bavarian Nordic) R-Flurbiprofen (NF-kappaB- GCS-IOO (gal3-Antagonist, Inhibitor, Encore) GlycoGenesys) 3CPA (NF-kappaB-lnhibitor G17DT-Immunogen (Gastrir Active Biotech) Inhibitor, Aphton) Seocalcitol (Vitamin-D- Efaproxiral (Oxygenator, Rezeptor-Agonist, Leo) Allos Therapeutics) 131-I-TM-601 (DNA- PI-88 (Heparanase-Inhibitor Antagonist, TransMolecular Progen) Eflomithin (ODC-Inhibitor,\nP54 (COX-2 inhibitor, International) Phytopharm) N-acetylcysteine CapCell ™ (CYP450 (reducing agent, Zambon) stimulant, Bavarian Nordic) R-Flurbiprofen (NF-kappaB-GCS-IOO (gal3 antagonist, inhibitor, Encore) GlycoGenesys) 3CPA (NF-kappaB inhibitor G17DT immunogen (Gastrir Active Biotech) inhibitor, Aphton) Seocalcitol (Vitamin D efaproxiral (oxygenator, receptor agonist, Leo) Allos Therapeutics) 131-I-TM-601 (DNA- PI-88 (heparanase inhibitor antagonist, TransMolecular Progen) eflomithine (ODC inhibitor,\n\n\n\n\n\n\n \nTesmilifen (Histamin- ILEX Oncology) Antagonist, YM BioSciences Minodronsäure Histamin (Histamin-H2- (Osteoclasten-Inhibitor, Rezeptor- Agonist, Maxim) Yamanouchi) Tiazofurin (IMPDH-Inhibitor, Indisulam (p53-Stimulans, Ribapharm) Eisai) Cilengitid (Integrin- Aplidin (PPT-Inhibitor, Antagonist, Merck KGaA) PharmaMar) SR-31747 (IL-1 -Antagonist, Rituximab (CD20-Antikörpe Sanofi-Synthelabo) Genentech) CCI-779 (mTOR-Kinase- Gemtuzumab (CD33- Inhibitor, Wyeth) Antikörper, Wyeth Ayerst) Exisulind (PDE-V-Inhibitor, PG2 (Hämatopoese- Cell Pathways) Verstärker, Pharmagenesis CP-461 (PDE-V-Inhibitor, Immunol™ (Triclosan- Cell Pathways) Oralspülung, Endo) AG-2037 (GART-Inhibitor, Triacetyluridin (Uridin- Pfizer) Prodrug, Wellstat) WX-UK1 SN-4071 (Sarkom-Mittel,\nTesmilifen (histamine ILEX Oncology) antagonist, YM BioSciences Minodronic acid histamine (histamine H2 (osteoclast inhibitor, receptor agonist, Maxim) Yamanouchi) Tiazofurin (IMPDH inhibitor, indisulam (p53 stimulant, Ribapharm) Eisai) Cilengitide (integrin - Aplidine (PPT inhibitor, antagonist, Merck KGaA) PharmaMar) SR-31747 (IL-1 antagonist, rituximab (CD20 antibody Sanofi-Synthelabo) Genentech) CCI-779 (mTOR kinase gemtuzumab (CD33 inhibitor, Wyeth ) Antibody, Wyeth Ayerst) Exisulind (PDE-V Inhibitor, PG2 (Haematopoietic Cell Pathways) Enhancer, Pharmagenesis CP-461 (PDE-V Inhibitor, Immunol ™ (Triclosan Cell Pathways) Oral Rinse, Endo) AG-2037 ( GART inhibitor, triacetyluridine (uridine-Pfizer) prodrug, Wellstat) WX-UK1 SN-4071 (sarcoma agent,\n\n\n\n\n\n\n \n(Plasminogenaktivator- Signature BioScience) Inhibitor, Wilex) TransMID-107™ PBI-1402 (PMN-Stimulans, (Immunotoxin, KS Biomedix ProMetic LifeSciences) PCK-3145 (Apoptose- Bortezomib (Proteasom- Förderer, Procyon) Inhibitor, Millennium) Doranidazol (Apoptose- \n\n SRL-172 (T-Zell-Stimulans, Förderer, PoIa)\n(Plasminogen Activator Signature BioScience) Inhibitor, Wilex) TransMID-107 ™ PBI-1402 (PMN Stimulant, (Immunotoxin, KS Biomedix ProMetic Life Sciences) PCK-3145 (Apoptosis Bortezomib (Proteasome Promoter, Procyon) Inhibitor, Millennium) Doranidazole ( apoptosis  SRL-172 (T-cell stimulant, promoter, PoIa)\n\n\n\n\n\n\n \nSR Pharma) CHS-828 (cytotoxisches\nSR Pharma) CHS-828 (cytotoxic\n\n\n\n\n\n\n \nTLK-286 (Glutathion-S- Mittel, Leo)\nTLK-286 (glutathione-S agent, Leo)\n\n\n\n\n\n\n \nTransferase-Inhibitor, Telik) trans-Retinsäure\nTransferase inhibitor, Telik) trans -retinoic acid\n\n\n\n\n\n\n \nPT-100 (Wachstumsfaktor- (Differentiator, NIH)\nPT-100 (growth factor (differentiator, NIH)\n\n\n\n\n\n\n \nAgonist, Point Therapeutics MX6 (Apoptose-Förderer,\nAgonist, Point Therapeutics MX6 (apoptosis promoter,\n\n\n\n\n\n\n \nMidostaurin (PKC-Inhibitor, MAXIA)\nMidostaurin (PKC inhibitor, MAXIA)\n\n\n\n\n\n\n \nNovartis) Apomin (Apoptose-Förderer\nNovartis) apomin (Apoptosis promoter\n\n\n\n\n\n\n \nBryostatin-1 (PKC-Stimulan; ILEX Oncology)\nBryostatin-1 (PKC stimulant; ILEX Oncology)\n\n\n\n\n\n\n \nGPC Biotech) Urocidin (Apoptose-Fördere\nGPC Biotech) Urocidin (Apoptosis-Fördere\n\n\n\n\n\n\n \nCDA-II (Apoptose-Förderer, Bioniche)\nCDA-II (Apoptosis promoter, Bioniche)\n\n\n\n\n\n\n \nEverlife) Ro-31-7453 (Apoptose-\nEverlife) Ro-31-7453 (Apoptosis\n\n\n\n\n\n\n \nSDX-101 (Apoptose- Förderer, La Roche)\nSDX-101 (Apoptosis promoter, La Roche)\n\n\n\n\n\n\n \nFörderer, Salmedix) Brostallicin (Apoptose-\nPromoter, salmedix) brostallicin (apoptosis\n\n\n\n\n\n\n \nCeflatonin (Apoptose- Förderer, Pharmacia)\nCeflatonin (Apoptosis promoter, Pharmacia)\n\n\n\n\n\n\n \nFörderer, ChemGenex)\nConveyor, ChemGenex)\n\n\n\n\n\n\n \nAlkylierungsmittel Cyclophosphamid Lomustin\nAlkylating agent Cyclophosphamide Lomustine\n\n\n\n\n\n\n \nBusulfan Procarbazin\nBusulfan procarbazine\n\n\n\n\n\n\n \nIfosfamid Altretamin\nIfosfamide altretamine\n\n\n\n\n\n\n \nMelphalan Estramustinphosphat\nMelphalan estramustin phosphate\n\n\n\n\n\n\n \nHexamethylmelamin Mechlorethamin\nHexamethylmelamine mechlorethamine\n\n\n\n\n\n\n \nThiotepa Streptozocin\nThiotepa streptozocin\n\n\n\n\n\n\n \nChlorambucil Temozolomid\nChlorambucil Temozolomide\n\n\n\n\n\n\n \nDacarbazin Semustin\nDacarbazine Semustin\n\n\n\n\n\n\n \nCarmustin\ncarmustine\n\n\n\n\n\n\n \nPlatinmittel Cisplatin Carboplatin\nPlatinum agent cisplatin carboplatin\n\n\n\n\n\n\n \nOxaliplatin ZD-0473 (AnorMED)\nOxaliplatin ZD-0473 (AnorMED)\n\n\n\n\n\n\n \nSpiroplatin Lobaplatin (Aetema)\nSpiroplatin Lobaplatin (Aetema)\n\n\n\n\n\n\n \nCarboxyphthalatoplatinum Satraplatin (Johnson\nCarboxyphthalatoplatinum Satraplatin (Johnson\n\n\n\n\n\n\n \nTetraplatin Matthey)\nTetraplatinum Matthey)\n\n\n\n\n\n\n \nOrmiplatin BBR-3464 (Hoffmann-La\nOrmiplatin BBR-3464 (Hoffmann-La\n\n\n\n\n\n\n \nIproplatin Roche)\nIproplatin Roche)\n\n\n\n\n\n\n \nSM-11355 (Sumitomo)\nSM-11355 (Sumitomo)\n\n\n\n\n\n\n \nAP-5280 (Access)\nAP-5280 (Access)\n\n\n\n\n\n\n \nAntimetabolite Azacytidin Tomudex\nAntimetabolite azacytidine Tomudex\n\n\n\n\n\n\n \nGemcitabin Trimetrexate\nGemcitabine trimetrexate\n\n\n\n\n\n\n \nCapecitabin Deoxycoformycin\nCapecitabine deoxycoformycin\n\n\n\n\n\n\n \n5-F!uoruraci! Fludarabin\n5-F! Uoruraci! fludarabine\n\n\n\n\n\n\n \nFloxuridin Pentostatin\nFloxuridine pentostatin\n\n\n\n\n\n\n \n2-Chlordesoxyadenosin Raltitrexed\n2-chlorodeoxyadenosine Raltitrexed\n\n\n\n\n\n\n \n6-Mercaptopurin Hydroxyhamstoff\n6-mercaptopurine hydroxyurea\n\n\n\n\n\n\n \n6-Thioguanin Decitabin (SuperGen)\n6-thioguanine decitabine (SuperGen)\n\n\n\n\n\n\n \nCytarabin Clofarabin (Bioenvision)\nCytarabine Clofarabine (Bioenvision)\n\n\n\n\n\n\n \n2-Fluordesoxycytidin Irofulven (MGI Pharma) \n\n Methotrexat DMDC (Hoffmann-La Röche\n2-Fluorodeoxycytidine Irofulvene (MGI Pharma)  Methotrexate DMDC (Hoffmann-La Roche\n\n\n\n\n\n\n \nIdatrexate Ethinylcytidin (Taiho )\nIdatrexate Ethinylcytidine (Taiho)\n\n\n\n\n\n\n \nTopoisomerase- Amsacrin Rubitecan (SuperGen)\nTopoisomerase Amsacrine Rubitecane (SuperGen)\n\n\n\n\n\n\n \nInhibitoren Epirubicin Exatecanmesylat (Daiichi)\nInhibitors Epirubicin Exatecan Mesylate (Daiichi)\n\n\n\n\n\n\n \nEtoposid Quinamed (ChemGenex)\nEtoposide Quinamed (ChemGenex)\n\n\n\n\n\n\n \nTeniposid oder Mitoxantron Gimatecan (Sigma- Tau) irinotecan (CPT-11 ) Diflornoiecan (Beaufour-\nTeniposide or mitoxantrone gimatecan (Sigma-Tau) irinotecan (CPT-11) diflornoiecan (Beaufour\n\n\n\n\n\n\n \n7-Ethyl-10- Ipsen) hydroxycamptothecin TAS-103 (Taiho)\n7-ethyl-10-Ipsen) hydroxycamptothecin TAS-103 (Taiho)\n\n\n\n\n\n\n \nTopotecan Elsamitrucin (Spectrum)\nTopotecan Elsamitrucin (Spectrum)\n\n\n\n\n\n\n \nDexrazoxanet (TopoTarget) J-107088 (Merck & Co)\nDexrazoxanet (TopoTarget) J-107088 (Merck & Co)\n\n\n\n\n\n\n \nPixantron (Novuspharrna) BNP-1350 (BioNumerik)\nPixantron (Novuspharrna) BNP-1350 (BioNumerik)\n\n\n\n\n\n\n \nRebeccamycin-Analogon CKD-602 (Chong Kun Dang\nRebeccamycin analog CKD-602 (Chong Kun Dang\n\n\n\n\n\n\n \n(Exelixis) KW-2170 (Kyowa Hakko)\n(Exelixis) KW-2170 (Kyowa Hakko)\n\n\n\n\n\n\n \nBBR-3576 (Novuspharrna)\nBBR-3576 (Novuspharrna)\n\n\n\n\n\n\n \nAntitumor- Dactinomycin (Actinomycin Amonafid\nAntitumor Dactinomycin (Actinomycin Amonafide\n\n\n\n\n\n\n \nAntibiotika D) Azonafid\nAntibiotics D) Azonafide\n\n\n\n\n\n\n \nDoxorubicin (Adriamycin) Anthrapyrazol\nDoxorubicin (adriamycin) anthrapyrazole\n\n\n\n\n\n\n \nDeoxyrubicin Oxantrazol\nDeoxyrubicin Oxantrazole\n\n\n\n\n\n\n \nValrubicin Losoxantron\nValrubicin losoxantrone\n\n\n\n\n\n\n \nDaunorubicin (Daunomycin) Bleomycinsulfat (Blenoxan)\nDaunorubicin (Daunomycin) Bleomycin Sulfate (Blenoxan)\n\n\n\n\n\n\n \nEpirubicin Bleomycinsäure\nEpirubicin bleomycinic acid\n\n\n\n\n\n\n \nTherarubicin Bleomycin A\nTherarubicin Bleomycin A\n\n\n\n\n\n\n \nIdarubicin Bleomycin B\nIdarubicin bleomycin B\n\n\n\n\n\n\n \nRubidazon Mitomycin C\nRubidazone mitomycin C\n\n\n\n\n\n\n \nPlicamycinp MEN-10755 (Menarini)\nPlicamycin p MEN-10755 (Menarini)\n\n\n\n\n\n\n \nPorfiromycin GPX-100 (Gem\nPorfiromycin GPX-100 (gem\n\n\n\n\n\n\n \nCyanomorpholinodoxorubici Pharmaceuticals)\nCyanomorpholinodoxorubici Pharmaceuticals)\n\n\n\n\n\n\n \nMitoxantron (Novantron) \n\n Antimitotische Mitt€ Paclitaxel SB 408075\nMitoxantrone (Novantrone)  Antimitotic Mitt € Paclitaxel SB 408075\n\n\n\n\n\n\n \nDocetaxel (GlaxoSmithKline)\nDocetaxel (GlaxoSmithKline)\n\n\n\n\n\n\n \nColchicin E7010 (Abbott)\nColchicine E7010 (Abbott)\n\n\n\n\n\n\n \nVinblastin PG-TXL (Cell Therapeutics)\nVinblastine PG-TXL (Cell Therapeutics)\n\n\n\n\n\n\n \nVincristin IDN 5109 (Bayer)\nVincristine IDN 5109 (Bayer)\n\n\n\n\n\n\n \nVinorelbin A 105972 (Abbott)\nVinorelbine A 105972 (Abbott)\n\n\n\n\n\n\n \nVindesin A 204197 (Abbott)\nVindesin A 204197 (Abbott)\n\n\n\n\n\n\n \nDolastatin 10 (NCI) LU 223651 (BASF)\nDolastatin 10 (NCI) LU 223651 (BASF)\n\n\n\n\n\n\n \nRhizoxin (Fujisawa) D 24851 (ASTA Medica)\nRhizoxin (Fujisawa) D 24851 (ASTA Medica)\n\n\n\n\n\n\n \nMivobulin (Warner-Lambert ) ER-86526 (Eisai)\nMivobulin (Warner-Lambert) ER-86526 (Eisai)\n\n\n\n\n\n\n \nCemadotin (BASF) Combretastatin A4 (BMS)\nCemadotin (BASF) Combretastatin A4 (BMS)\n\n\n\n\n\n\n \nRPR 109881A (Aventis) Isohomohalichondrin-B\nRPR 109881A (Aventis) isohomohalichondrin-B\n\n\n\n\n\n\n \nTXD 258 (Aventis) (PharmaMar)\nTXD 258 (Aventis) (PharmaMar)\n\n\n\n\n\n\n \nEpothilon B (Novartis) ZD 6126 (AstraZeneca)\nEpothilone B (Novartis) ZD 6126 (AstraZeneca)\n\n\n\n\n\n\n \nT 900607 (Tularik) PEG-Paclitaxel (Enzon)\nT 900607 (Tularik) PEG paclitaxel (Enzon)\n\n\n\n\n\n\n \nT 138067 (Tularik) AZ10992 (Asahi)\nT 138067 (Tularik) AZ10992 (Asahi)\n\n\n\n\n\n\n \nCryptophycin 52 (EIi Lilly) !DN-5109 (lndena)\nCryptophycin 52 (Eli Lilly)! DN-5109 (lndena)\n\n\n\n\n\n\n \nVinflunin (Fabre) AVLB (Prescient\nVinflunin (Fabre) AVLB (Prescient\n\n\n\n\n\n\n \nAuristatin PE (Teikoku NeuroPharma)\nAuristatin PE (Teikoku NeuroPharma)\n\n\n\n\n\n\n \nHormone) Azaepothilon B (BMS)\nHormones) azaepothilone B (BMS)\n\n\n\n\n\n\n \nBMS 247550 (BMS) BNP- 7787 (BioNumerik)\nBMS 247550 (BMS) BNP-7787 (BioNumerik)\n\n\n\n\n\n\n \nBMS 184476 (BMS) CA-4-Prodrug (OXiGENE)\nBMS 184476 (BMS) CA-4 prodrug (OXiGENE)\n\n\n\n\n\n\n \nBMS 188797 (BMS) Dolastatin-10 (NrH)\nBMS 188797 (BMS) Dolastatin-10 (NrH)\n\n\n\n\n\n\n \nTaxoprexin (Protarga) CA-4 (OXiGENE)\nTaxoprexin (Protarga) CA-4 (OXiGENE)\n\n\n\n\n\n\n \nAromatase- Aminoglutethimid Exemestan\nAromatase-aminoglutethimide exemestane\n\n\n\n\n\n\n \nInhibitoren Letrozol Atamestan (BioMedicines)\nInhibitors Letrozole Atamestane (BioMedicines)\n\n\n\n\n\n\n \nAnastrazol YM-511 (Yamanouchi)\nAnastrazole YM-511 (Yamanouchi)\n\n\n\n\n\n\n \nFormestan\nformestane\n\n\n\n\n\n\n \nThymidylatsynthasf Pemetrexed (EIi Lilly) Nolatrexed (Eximias)\nThymidylate synthase pemetrexed (EIi Lilly) Nolatrexed (Eximias)\n\n\n\n\n\n\n \nInhibitoren ZD-9331 (BTG) CoFactor™ (BioKeys)\nInhibitors ZD-9331 (BTG) CoFactor ™ (BioKeys)\n\n\n\n\n\n\n \nDNA-Antagonisten Trabectedin (PharmaMar) Mafosfamid (Baxter\nDNA antagonists Trabectedin (PharmaMar) Mafosfamide (Baxter\n\n\n\n\n\n\n \nGlufosfamid (Baxter International)\nGlufosfamide (Baxter International)\n\n\n\n\n\n\n \nInternational) Apaziquon (Spectrum\nInternational) Apaziquon (Spectrum\n\n\n\n\n\n\n \nAlbumin + 32P (Isotope Pharmaceuticals)\nAlbumin + 32P (Isotope Pharmaceuticals)\n\n\n\n\n\n\n \nSolutions) O6-Benzylguanin (Paligent)\nSolutions) O6 Benzylguanine (Paligent)\n\n\n\n\n\n\n \nThymectacin (NewBiotics)\nThymectacin (NewBiotics)\n\n\n\n\n\n\n \nEdotreotid (Novartis)\nEdotreotide (Novartis)\n\n\n\n\n\n\n \nFamesyltransferas« Arglabin (NuOncology Labs; Tipifamib (Johnson &\nFamesyltransferas «Arglabin (NuOncology Labs; Tipifamib (Johnson & Johnson)\n\n\n\n\n\n\n \nInhibitoren lonafamib (Schering-Plough Johnson)\nInhibitors of lonafamib (Schering-Plow Johnson)\n\n\n\n\n\n\n \nBAY-43-9006 (Bayer) Perillylalkohol (DOR\nBAY-43-9006 (Bayer) Perillyl Alcohol (DOR\n\n\n\n\n\n\n \nBioPharma) \n\n\n\n\n \n\n Hormonelle und Östrogene Prednison antihormonelle konjugierte Östrogene Methylprednisolon\nBioPharma) \n Hormonal and estrogenic prednisone antihormonal conjugated estrogens methylprednisolone\n\n\n\n\n\n\n \nMittel Ethinylöstradiol Prednisolon\nAgent ethinyl estradiol prednisolone\n\n\n\n\n\n\n \nChlortrianisen Aminoglutethimid\nChlorotrienes Aminoglutethimide\n\n\n\n\n\n\n \nIdenestrol Leuprolid\nIdenestrol Leuprolide\n\n\n\n\n\n\n \nHydroxyprogesteroncaproat Goserelin\nHydroxyprogesterone caproate goserelin\n\n\n\n\n\n\n \nMedroxyprogesteron Leuporelin\nMedroxyprogesterone Leuporelin\n\n\n\n\n\n\n \nTestosteron Bicalutamid\nTestosterone Bicalutamide\n\n\n\n\n\n\n \nTestosteronpropionat Flutamid\nTestosterone Propionate Flutamide\n\n\n\n\n\n\n \nFluoxymesteron Octreotid\nFluoxymesterone octreotide\n\n\n\n\n\n\n \nMethyltestosteron Nilutamid\nMethyltestosterone Nilutamide\n\n\n\n\n\n\n \nDiethylstilbestrol Mitotan\nDiethylstilbestrol Mitotane\n\n\n\n\n\n\n \nMegestrol P-04 (Novogen)\nMegestrol P-04 (Novogen)\n\n\n\n\n\n\n \nTamoxifen 2-Methoxyöstradiol\nTamoxifen 2-methoxyestradiol\n\n\n\n\n\n\n \nToremofin (EntreMed)\nToremofin (EntreMed)\n\n\n\n\n\n\n \nDexamethason Arzoxifen (EIi Lilly)\nDexamethasone Arzoxifen (EIi Lilly)\n\n\n\n\n\n\n \nPhotodynamische Talaporfin (Light Sciences) Pd-Bacteriopheophorbid\nPhotodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbide\n\n\n\n\n\n\n \nMittel Theralux (Yeda)\nCentral Theralux (Yeda)\n\n\n\n\n\n\n \n(Theratechnologies) Lutetium-Texaphyrin\n(Theratechnologies) Lutetium Texaphyrin\n\n\n\n\n\n\n \nMotexafin-Gadolinium (Pharmacyclics)\nMotexafin Gadolinium (Pharmacyclics)\n\n\n\n\n\n\n \n(Pharmacyclics) Hypericin\n(Pharmacyclics) Hypericin\n\n\n\n\n\n\n \nTyrosinkinase- Imatinib (Novartis) Kahalid F (PharmaMar)\nTyrosine kinase imatinib (Novartis) Kahalid F (PharmaMar)\n\n\n\n\n\n\n \nInhibitoren Leflunomid CEP- 701 (Cephalon)\nInhibitors Leflunomide CEP-701 (Cephalon)\n\n\n\n\n\n\n \n(Sugen/Pharmacia) CEP-751 (Cephalon)\n(Sugen / Pharmacia) CEP-751 (Cephalon)\n\n\n\n\n\n\n \nZDI839 (AstraZeneca) MLN518 (Millenium)\nZDI839 (AstraZeneca) MLN518 (Millenium)\n\n\n\n\n\n\n \nErlotinib (Oncogene Scienc« PKC412 (Novartis)\nErlotinib (Oncogene Scienc «PKC412 (Novartis)\n\n\n\n\n\n\n \nCanertjnib (Pfizer) Phenoxodiol O\nCanertjnib (Pfizer) phenoxodiol O\n\n\n\n\n\n\n \nSqualamin (Genaera) Trastuzumab (Genentech)\nSqualamine (Genaera) trastuzumab (Genentech)\n\n\n\n\n\n\n \nSU5416 (Pharmacia) C225 (ImCIone)\nSU5416 (Pharmacia) C225 (ImCIone)\n\n\n\n\n\n\n \nSU6668 (Pharmacia) rhu-Mab (Genentech)\nSU6668 (Pharmacia) rhu-Mab (Genentech)\n\n\n\n\n\n\n \nZD4190 (AstraZeneca) MDX-H210 (Medarex)\nZD4190 (AstraZeneca) MDX-H210 (Medarex)\n\n\n\n\n\n\n \nZD6474 (AstraZeneca) 2C4 (Genentech)\nZD6474 (AstraZeneca) 2C4 (Genentech)\n\n\n\n\n\n\n \nVatalanib (Novartis) MDX-447 (Medarex)\nVatalanib (Novartis) MDX-447 (Medarex)\n\n\n\n\n\n\n \nPK1166 (Novartis) ABX-EGF (Abgenix)\nPK1166 (Novartis) ABX-EGF (Abgenix)\n\n\n\n\n\n\n \nGW2016 (GlaxoSmithKline ) IMC-1C11 (ImCIone)\nGW2016 (GlaxoSmithKline) IMC-1C11 (ImCIone)\n\n\n\n\n\n\n \nEKB-509 (Wyeth)\nEKB-509 (Wyeth)\n\n\n\n\n\n\n \nEKB-569 (Wyeth)\nEKB-569 (Wyeth)\n\n\n\n\n\n\n \nVerschiedene Mitte SR-27897 (CCK-A-!nhibitor BCX-1777 (PNP-Inhibitor,\nVarious center SR-27897 (CCK-A inhibitor BCX-1777 (PNP inhibitor,\n\n\n\n\n\n\n \nSanofi-Synthelabo) BioCryst)\nSanofi-Synthelabo) BioCryst)\n\n\n\n\n\n\n \nTocladesin (cyclisches- Ranpirnase (Ribonuclease-\nTocladesin (cyclic ranibirnase (ribonuclease)\n\n\n\n\n\n\n \nAMP-Agonist, Ribapharm) Stimulans, Alfacell)\nAMP agonist, ribapharm) stimulant, Alfacell)\n\n\n\n\n\n\n \nAlvocidib (CDK-Inhibitor, Galarubicin (RNA-Synthese-\nAlvocidib (CDK inhibitor, galarubicin (RNA synthesis\n\n\n\n\n\n\n \nAventis) Inhibitor, Dong-A)\nAventis) inhibitor, Dong-A)\n\n\n\n\n\n\n \nCV-247 (COX-2-lnhibitor, Tirapazamin \n\n Ivy Medical) (Reduktionsmittel, SRI P54 (COX-2-lnhibitor, International) Phytopharm) N-Acetylcystein CapCell™ (CYP450- (Reduktionsmittel, Zambon) Stimulans, Bavarian Nordic R-Flurbiprofen (NF-kappaB- GCS-IOO (gal3-Antagonist, Inhibitor, Encore) GlycoGenesys) 3CPA (NF-kappaB-Inhibitor, G17DT-Immunogen Active Biotech) (Gastrin-Inhibitor, Aphton) Seocalcitol (Vitamin-D- Efaproxiral (Oxygenator, Rezeptor-Agonist, Leo) Allos Therapeutics) 131-I-TM-601 (DNA- PI-88 (Heparanase-Inhibito Antagonist, TransMolecular)\nCV-247 (COX-2 inhibitor, tirapazamine  Ivy Medical) (Reducing Agent, SRI P54 (COX-2 Inhibitor, International) Phytopharm) N-Acetylcysteine CapCell ™ (CYP450 (Reducing Agent, Zambon) Stimulant, Bavarian Nordic R-Flurbiprofen (NF-kappaB-GCS-IOO (gal3-) Antagonist, inhibitor, Encore) GlycoGenesys) 3CPA (NF-kappaB inhibitor, G17DT immunogen active biotech) (gastrin inhibitor, Aphton) Seocalcitol (vitamin D efaproxiral (oxygenator, receptor agonist, Leo) Allos Therapeutics) 131- I-TM-601 (DNA-PI-88 (Heparanase Inhibitor Antagonist, TransMolecular)\n\n\n\n\n\n\n \n10 Progen) Eflornithin (ODC-Inhibitor,\n10 progens) eflornithine (ODC inhibitor,\n\n\n\n\n\n\n \nTesmiüfen (Histamin- ILEX Oncology) Antagonist, YM Minodronsäure BioSciences) (Osteoclasten-Inhibitor, Histamin (Histamin-H2- Yamanouchi) Rezeptor- Agonist, Maxim) Indisulam (p53-Stimulans,\nTesmieugen (histamine ILEX oncology) antagonist, YM minodronic acid BioSciences) (osteoclast inhibitor, histamine (histamine H2-yamanouchi) receptor agonist, Maxim) indisulam (p53 stimulant,\n\n\n\n\n\n\n \n15 Tiazofurin (IMPDH-Inhibitor Eisai) Ribapharm) Aplidin (PPT-Inhibitor, Cilengitid (Integrin- PharmaMar) Antagonist, Merck KGaA) Rituximab (CD20-Antikörper SR-31747 (IL-1 -Antagonist, Genentech) Sanofi-Synthelabo) Gemtuzumab (CD33- CCI-779 (mTOR-Kinase- Antikörper, Wyeth Ayerst)\n15 Tiazofurin (IMPDH inhibitor Eisai) Ribapharm aplidine (PPT inhibitor, cilengitide (Integrin-PharmaMar) antagonist, Merck KGaA) Rituximab (CD20 antibody SR-31747 (IL-1 antagonist, Genentech) Sanofi-Synthelabo) Gemtuzumab ( CD33- CCI-779 (mTOR kinase antibody, Wyeth Ayerst)\n\n\n\n\n\n\n \n20 Inhibitor, Wyeth) PG2 (Hämatopoese- Exisulind (PDE-V-Inhibitor, Verstärker, Pharmagenesis) Cell Pathways) Immunol™ (Triclosan- CP-461 (PDE-V-Inhibitor, Oralspülung, Endo) Cell Pathways) Triacetyluridin (Uridin- AG-2037 (GART-Inhibitor, Prodrug, Wellstat) Pfizer) SN-4071 (Sarkom-Mittel,\n20 Inhibitor, Wyeth) PG2 (Hematopoiesis Exisulind (PDE-V Inhibitor, Enhancer, Pharmagenesis) Cell Pathways) Immunol ™ (Triclosan CP-461 (PDE-V Inhibitor, Oral Rinse, Endo) Cell Pathways) Triacetyluridine (uridine) AG-2037 (GART inhibitor, prodrug, Wellstat) Pfizer) SN-4071 (sarcoma agent,\n\n\n\n\n\n\n \n25 WX-UK1 Signature BioScience)\n25 WX-UK1 Signature BioScience)\n\n\n\n\n\n\n \n(Plasminogenaktivator- TransMID-107™ Inhibitor, Wilex) (Immunotoxin, KS Biomedix) PBI-1402 (PMN-Stimulans, PCK-3145 (Apoptose- ProMetic LifeSciences) Förderer, Procyon) Bortezomib (Proteasom- Doranidazol (Apoptose-\n(Plasminogen activator-TransMID-107 ™ inhibitor, Wilex) (immunotoxin, KS Biomedix) PBI-1402 (PMN stimulant, PCK-3145 (apoptosis-ProMetic LifeSciences) promoter, Procyon) bortezomib (proteasome-doranidazole (apoptosis)\n\n\n\n\n\n\n \n30 Inhibitor, Millennium) Förderer, PoIa) SRL-172 (T-Zell-Stimulans, CHS-828 (cytotoxisches SR Pharma) Mittel, Leo) TLK-286 (Glutathion-S- trans-Retinsäure Transferase-Inhibitor, Telik\n\"\n, (Differentiator, NIH) PT-100 (Wachstumsfaktor- MX6 (Apoptose-Förderer, Agonist, Point Therapeutics MAXIA)\n30 inhibitor, Millennium) promoter, PoIa) SRL-172 (T-cell stimulant, CHS-828 (cytotoxic SR Pharma) agent, Leo) TLK-286 (glutathione-S-trans-retinoic acid transferase inhibitor, Telik \n\"\n , ( Differentiator, NIH) PT-100 (Growth factor MX6 (Apoptosis promoter, agonist, Point Therapeutics MAXIA)\n\n\n\n\n\n\n \n35 Midostaurin (PKC-Inhibitor, Apomin (Apoptose-Förderer Novartis) ILEX Oncology) \n\n Bryostatin-1 (PKC- Urocidin (Apoptose-Förderer\n35 Midostaurin (PKC inhibitor, apomin (apoptosis promoter Novartis) ILEX Oncology)  Bryostatin-1 (PKC-uridine (apoptosis promoter\n\n\n\n\n\n\n \nStimulans, GPC Biotech) Bioniche)\nStimulant, GPC Biotech) Bioniche)\n\n\n\n\n\n\n \nCDA-II (Apoptose-Förderer Ro-31-7453 (Apoptose-\nCDA-II (apoptosis promoter Ro-31-7453 (apoptosis\n\n\n\n\n\n\n \nEverlife) Förderer, La Roche)\nEverlife) promoter, La Roche)\n\n\n\n\n\n\n \nSDX-101 (Apoptose- Brostallicin (Apoptose-\nSDX-101 (apoptosis-brostallicin (apoptosis)\n\n\n\n\n\n\n \nFörderer, Salmedix) Förderer, Pharmacia)\nPromoter, Salmedix) promoter, Pharmacia)\n\n\n\n\n\n\n \nCeflatonin (Apoptose-\nCeflatonin (apoptosis\n\n\n\n\n\n\n \nFörderer, ChemGenex)\nConveyor, ChemGenex)\n\n\n\n\n\n\n \nEine derartige gemeinsame Behandlung kann mithilfe gleichzeitiger, aufeinander folgender oder getrennter Dosierung der einzelnen Komponenten der Behandlung erzielt werden. Solche Kombinationsprodukte setzen die erfindungsgemäßen Verbindungen ein.\nSuch joint treatment can be achieved by simultaneously, sequentially or separately dosing the individual components of the treatment. Such combination products employ the compounds of the invention.\n\n\n\n\n\n\n \nASSAYS\nASSAYS\n\n\n\n\n\n\n \nDie in den Beispielen beschriebenen Verbindungen der Formel I wurden in den unten beschriebenen Assays geprüft, und es wurde gefunden, dass sie eine kinasehemmende Wirkung aufweisen. Weitere Assays sind aus der Literatur bekannt und könnten vom Fachmann leicht durchgeführt werden (siehe z.B. Dhanabal et al., Cancer Res. 59:189-197; Xin et al., J. Biol. Chem. 274:9116-9121 ; Sheu et al., Anticancer Res. 18:4435-4441 ; Ausprunk et al., Dev. Biol. 38:237-248; Gimbrone et al., J. Natl. Cancer Inst. 52:413-427; Nicosia et al., In Vitro 18:538- 549).\nThe compounds of formula I described in the Examples were tested in the assays described below and found to have kinase inhibitory activity. Other assays are known in the literature and could be readily performed by those skilled in the art (see, eg, Dhanabal et al., Cancer Res. 59: 189-197; Xin et al., J. Biol. Chem. 274: 9116-9121; Sheu et Biol. 38: 237-248; Gimbrone et al., J. Natl. Cancer Inst. 52: 413-427; Nicosia et al., Anticancer Res. 18: 4435-4441; Ausprunk et al., Dev. In Vitro 18: 538-549).\n\n\n\n\n\n\n \nMessung der Met Kinase Aktivität\nMeasurement of Met kinase activity\n\n\n\n\n\n\n \nDie Met Kinase wird laut Herstellerangaben (Met, active, Upstate, Katalog- Nr. 14-526) zum Zweck der Proteinproduktion in Insektenzellen (Sf21 ; S. frugiperda) und der anschließenden affinitätschromatographischen Aufreinigung als „N-terminal 6His-tagged\" rekombinantes humanes Protein in einem Baculovirus-Expressionsvektor exprimiert. \n\n Zur Messung der Kinase-Aktivität kann auf verschiedene zur Verfügung stehender Meßsysteme zurückgegriffen werden. Beim Scintillation-Proximity- (Sorg et al., J. of. Biomolecular Screening, 2002, 7, 11-19), dem FlashPlate- Verfahren oder dem Filterbindungstest wird die radioaktive Phosphorylierung eines Proteins oder Peptids als Substrat mit radioaktiv markiertem ATP (\n32\nP- ATP, \n33\nP-ATP) gemessen. Bei Vorliegen einer inhibitorischen Verbindung ist kein oder ein vermindertes radioaktives Signal nachweisbar. Ferner sind die Homogeneous Time-resolved Fluorescence Resonance Energy Transfer- (HTR-FRET-) und Fluoreszenzpolarisations- (FP-) Technologien als Assay- Verfahren nützlich (SiIIs et al., J. of Biomolecular Screening, 2002, 191-214).\nAccording to the manufacturer (Met, active, upstate, catalog No. 14-526), the Met kinase is recombinantly human as \"N-terminally 6His tagged\" for the purpose of protein production in insect cells (Sf21, S. frugiperda) and subsequent affinity chromatographic purification Protein expressed in a baculovirus expression vector.  To measure the kinase activity can be made of various available measuring systems. In scintillation proximity (Sorg et al., J. of Biomolecular Screening, 2002, 7, 11-19), the FlashPlate method or the filter binding assay, the radioactive phosphorylation of a protein or peptide as a substrate with radioactively labeled ATP ( \n32\n P-ATP, \n33\n P-ATP). In the presence of an inhibitory compound, no or a reduced radioactive signal is detectable. Further, Homogeneous Time-resolved Fluorescence Resonance Energy Transfer (HTR-FRET) and Fluorescence Polarization (FP) technologies are useful as assay methods (SiIIs et al., J. of Biomolecular Screening, 2002, 191-214).\n\n\n\n\n\n\n \nAndere nicht radioaktive ELISA-Assay-Verfahren verwenden spezifische Phospho-Antikörper (Phospho-AK). Der Phospho-Antikörper bindet nur das phosphorylierte Substrat. Diese Bindung ist mit einem zweiten Peroxidase- konjugierten Antikörper durch Chemilumineszenz nachweisbar (Ross et al., 2002, Biochem. J.).\nOther non-radioactive ELISA assay methods use specific phospho-antibodies (Phospho-AK). The phospho-antibody binds only the phosphorylated substrate. This binding is detectable by chemiluminescence with a second peroxidase-conjugated antibody (Ross et al., 2002, Biochem. J.).\n\n\n\n\n\n\n \nFlashplate-Verfahren (Met Kinase):\nFlashplate method (Met kinase):\n\n\n\n\n\n\n \nAls Testplatten dienen 96-well Flashplate\nR\n Mikrotiterplatten der Firma Perkin Eimer (Kat.-Nr. SMP200). In die Assay Platte werden die Komponenten der unten beschriebenen Kinasereaktion pipettiert.\nThe test plates are 96-well Flashplate \nR\n microtiter plates from Perkin Elmer (Cat. No. SMP200). The components of the kinase reaction described below are pipetted into the assay plate.\n\n\n\n\n\n\n \nDie Met Kinase und das Substrat poly Ala-Glu-Lys-Tyr, (pAGLT, 6:2:5:1 ). 3τ werden mit radioaktiv markiertem P-ATP in An- und Abwesenheit von\nThe Met kinase and the substrate poly Ala-Glu-Lys-Tyr, (pAGLT, 6: 2: 5: 1). 3τ are radiolabeled P-ATP in the presence and absence of\n\n\n\n\n\n\n \nTestsubstanzen in einem Gesamtvolumen von 100 μl bei Raumtemperatur 3 Std. inkubiert. Die Reaktion wird mit 150 μl einer 6OmM EDTA-Lösung abgestoppt. Nach Inkubation für weitere 30 min bei Raumtemperatur werden die Überstände abgesaugt und die Wells dreimal mit je 200 μl 0,9% NaCI- Lösung gewaschen. Die Messung der gebundenen Radioaktivität erfolgt mittels eines Szintillationsmessgerätes (Topcount NXT, Fa. Perkin-Elmer). Als Vollwert wird die Inhibitor-freie Kinasereaktion verwendet. Dieser sollte ca. im Bereich von 6000-9000 cpm liegen. Als pharmakologischer Nullwert wird Staurosporin in einer Endkonzentration von 0,1 mM verwendet. Eine \n\n Bestimmung der Hemmwerte (IC50) erfolgt unter Verwendung des Programms RS1_MTS ().\nTest substances in a total volume of 100 .mu.l incubated at room temperature for 3 hrs. The reaction is stopped with 150 μl of a 6OmM EDTA solution. After incubation for a further 30 min at room temperature, the supernatants are filtered off with suction and the wells are washed three times with 200 μl each of 0.9% NaCl solution. The measurement of the bound radioactivity is carried out by means of a scintillation meter (Topcount NXT, Perkin-Elmer). As a whole, the inhibitor-free kinase reaction is used. This should be approximately in the range of 6000-9000 cpm. The pharmacological zero value used is staurosporine at a final concentration of 0.1 mM. A  Determination of the inhibition values (IC50) is carried out using the program RS1_MTS ().\n\n\n\n\n\n\n \nKinase-Reaktionsbedingungen pro well:\nKinase reaction conditions per well:\n\n\n\n\n\n\n \n30 μl Assaypuffer\n30 μl assay buffer\n\n\n\n\n\n\n \n10 μl zu testende Substanz in Assaypuffer mit 10 % DMSO 10 μl ATP (Endkonzentration 1 μM kalt, 0,35 μCi \n33\nP-ATP) 50 μl Gemisch Met Kinase/Substrat in Assaypuffer; (10 ng Enzym/well, 50 ng pAGLT/well)\n10 μl substance to be tested in assay buffer with 10% DMSO 10 μl ATP (final concentration 1 μM cold, 0.35 μCi \n33\n P-ATP) 50 μl mixture Met kinase / substrate in assay buffer; (10 ng enzyme / well, 50 ng pAGLT / well)\n\n\n\n\n\n\n \nVerwendete Lösungen:\nUsed solutions:\n\n\n\n\n\n\n \n- Assay-Puffer: 5O mM HEPES\nAssay buffer: 50 mM HEPES\n\n\n\n\n\n\n \n3 mM Magnesiumchlorid 3 μM Natrium orthovanadat 3 mM Mangan (II) Chlorid 1 mM Dithiothreitol (DTT) pH= 7,5 (einzustellen mit Natriumhydroxid)\n3 mM magnesium chloride 3 μM sodium orthovanadate 3 mM manganese (II) chloride 1 mM dithiothreitol (DTT) pH = 7.5 (adjust with sodium hydroxide)\n\n\n\n\n\n\n \n- Stopp-Lösung:\n- Stop solution:\n\n\n\n\n\n\n \n60 mM Titriplex III (EDTA)\n60mM Titriplex III (EDTA)\n\n\n\n\n\n\n \n- \n33\nP-ATP: Perkin-Elmer;\n- \n33\n P-ATP: Perkin-Elmer;\n\n\n\n\n\n\n \n- Met Kinase: Upstate, Kat.-Nr. 14-526, Stock 1 μg/10 μl; spez.\n- Met Kinase: Upstate, cat.-no. 14-526, stock 1 μg / 10 μl; spec.\n\n\n\n\n\n\n \nAktivität 954 U/mg;\nActivity 954 U / mg;\n\n\n\n\n\n\n \nPoly-Ala-Glu-Lys-Tyr, 6:2:5:1 : Sigma Kat.-Nr. P1152\nPoly-Ala-Glu-Lys-Tyr, 6: 2: 5: 1: Sigma Cat. P1152\n\n\n\n\n\n\n \nIn vivo-Tests\nIn vivo tests\n\n\n\n\n\n\n \nExperimenteller Ablauf: Weibliche Balb/C Mäuse (Züchter: Charles River Wiga) waren bei der Ankunft im Alter von 5 Wochen. Sie wurden 7 Tage lang an unsere Haltungsbedingungen akklimatisiert. Anschließend wurden jeder Maus 4 Millionen TPR-Met / NIH3T3 - Zellen in 100 μl PBS (ohne Ca++ \n\n und Mg++) subkutan im Beckenbereich injiziert. Nach 5 Tagen wurden die Tiere in 3 Gruppen randomisiert, so dass jede Gruppe von 9 Mäusen ein mittleres Tumorvolumen von 110 μl (Spanne: 55 - 165) hatte. Der Kontrollgruppe wurden 100 μl Vehikel (0,25 % Methylzellulose / 100 mM Acetatpuffer, pH 5.5), den Behandlungsgruppen wurden 200 mg/kg \"A56\" bzw. \"A91 \" gelöst im Vehikel (Volumen ebenfalls 100 μl / Tier) per Schlundsonde täglich verabreicht. Nach 9 Tagen hatten die Kontrollen ein mittleres Volumen von 1530 μl und der Versuch wurde beendet.\nExperimental Procedure: Female Balb / C mice (breeder: Charles River Wiga) were on arrival at the age of 5 weeks. They were acclimated to our keeping conditions for 7 days. Subsequently, each mouse was given 4 million TPR-Met / NIH3T3 cells in 100 μl PBS (without Ca ++  and Mg ++) injected subcutaneously in the pelvic area. After 5 days, the animals were randomized into 3 groups so that each group of 9 mice had a mean tumor volume of 110 μl (range: 55-165). The control group received 100 μl of vehicle (0.25% methylcellulose / 100 mM acetate buffer, pH 5.5), the treatment groups were dissolved 200 mg / kg \"A56\" or \"A91\" in the vehicle (volume also 100 μl / animal) by gavage daily administered. After 9 days the controls had a mean volume of 1530 μl and the experiment was terminated.\n\n\n\n\n\n\n \nMessung des Tumorvolumens: Die Länge (L) und Breite (B) wurde mit einer Schubleere gemessen und das Tumorvolumen nach der Formel LxBxB/2 berechnet.\nMeasurement of tumor volume: The length (L) and width (B) were measured with a bifurcation and the tumor volume was calculated according to the formula LxBxB / 2.\n\n\n\n\n\n\n \nHaltungsbedinqungen: je 4 bzw. 5 Tiere pro Käfig, Fütterung mit kommerziellem Mäusefutter (Fa. Sniff).\nHousing conditions: 4 or 5 animals per cage, feeding with commercial mouse food (Sniff).\n\n\n\n\n\n\n \nVor- und nachstehend sind alle Temperaturen in \n0\nC angegeben. In den nachfolgenden Beispielen bedeutet \"übliche Aufarbeitung\": Man gibt, falls erforderlich, Wasser hinzu, stellt, falls erforderlich, je nach Konstitution des Endprodukts auf pH-Werte zwischen 2 und 10 ein, extrahiert mit Ethylacetat oder Dichlormethan, trennt ab, trocknet die organische Phase über Natrium- sulfat, dampft ein und reinigt durch Chromatographie an Kieselgel und /oder durch Kristallisation. Rf-Werte an Kieselgel; Laufmittel: Ethylacetat/Methanol 9:1.\nAbove and below all temperatures are given in \n0\n C. In the following examples, \"usual workup\" means adding water if necessary, adjusting to pH values between 2 and 10, if necessary, depending on the constitution of the final product, extracting with ethyl acetate or dichloromethane, separating, drying organic phase over sodium sulfate, evaporated and purified by chromatography on silica gel and / or by crystallization. Rf values on silica gel; Eluent: ethyl acetate / methanol 9: 1.\n\n\n\n\n\n\n \nMassenspektrometrie (MS): El (Elektronenstoß-Ionisation) M\n+\n \nMass spectrometry (MS): El (electron impact ionization) M \n+\n \n\n\n\n\n\n\n \nFAB (Fast Atom Bombardment) (M+H)\n+\n ESI (Electrospray lonization) (M+H)\n+\n APCI-MS (atmospheric pressure chemical ionization - mass spectrometry) \n(M+H\n>\n*\n- \n\n BEISPIEL 1\nFAB (Fast Atom Bombardment) (M + H) \n+\n ESI (Electrospray Ionization) (M + H) \n+\n APCI-MS (Mass Pressure Pressure Ionization - mass spectrometry) \n(M + H\n > \n*\n -  EXAMPLE 1\n\n\n\n\n\n\n \nDie Herstellung erfolgt analog nachstehendem allgemeinen Reaktionsschema\nThe preparation is carried out analogously to the general reaction scheme below\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nHerstellung von 3-(4-Fluorphenyl)-2-(pyridin-4-yl)-1 /-/-pyrrolo[3,2-b]pyridin-5- carbonitril (\"A1\")\nPreparation of 3- (4-fluorophenyl) -2- (pyridin-4-yl) -1 / - / - pyrrolo [3,2-b] pyridine-5-carbonitrile (\"A1\")\n\n\n\n\n\n\n \n1.1 In eine Lösung von 10.0 g (83.94 mmol) 5-Amino-2-cyanpyridin in 150 ml Ethanol werden 27.91 g (109.96 mmol) lod und 34.02 g (109.13 mmol) Silbersulfat direkt eingetragen und das Reaktionsgemisch bei Raumtemperatur über 11 h gerührt. Es wird vom Niederschlag abfiltriert, und der Rückstand mit Ethanol mehrfach nachgewaschen. Die vereinigten organischen Phasen werden im Vakuum eingeengt und der Rückstand über Kieselgel chromatographisch aufgereinigt (Eluent: Cyclohexan / Ethylacetat 8/2). Es werden 16.30 g (66.52 mmol, 79.2 %) 5-Amino-6-iodopicolinonitril als beige Kristalle erhalten\n1.1 27.91 g (109.96 mmol) of iodine and 34.02 g (109.13 mmol) of silver sulfate are added directly to a solution of 10.0 g (83.94 mmol) of 5-amino-2-cyanopyridine in 150 ml of ethanol, and the reaction mixture is stirred at room temperature for 11 h. It is filtered from the precipitate, and the residue washed with ethanol several times. The combined organic phases are concentrated in vacuo and the residue is purified by chromatography on silica gel (eluent: cyclohexane / ethyl acetate 8/2). 16.30 g (66.52 mmol, 79.2%) of 5-amino-6-iodopicolinonitrile are obtained as beige crystals\n\n\n\n\n\n\n \n \n\n ; ESI-MS: m/z: 246 ([IvHH]\n+\n). \n\n 1.2 5.02 g (20.50 mmol) 5-Amino-6-iodopicolinonitril und 33.39 g (102.50 mmol) Cs\n2\nCO\n3\n werden im Vakuum getrocknet und unter Stickstoff in 100 ml trockenem THF gelöst. Es werden 3.14 g (22.55 mmol) 4-Ethinylpyridin-\n \n ; ESI-MS: m / z: 246 ([IvHH] \n+\n ).  1.2 5.02 g (20.50 mmol) of 5-amino-6-iodopicolinonitrile and 33.39 g (102.50 mmol) of Cs \n2\n CO \n3\n are dried in vacuo and dissolved under nitrogen in 100 ml of dry THF. There are 3.14 g (22.55 mmol) of 4-ethynylpyridine\n\n\n\n\n\n\n \nHydrochlorid, 390 mg (2.05 mmol) CuI und 837 mg (1.02 mmol)\nHydrochloride, 390 mg (2.05 mmol) CuI and 837 mg (1.02 mmol)\n\n\n\n\n\n\n \nPd(dppf)\n2\nCI\n2\n'CH\n2\nCI\n2\n unter Stickstoff eingetragen und die Lösung bei 5O\n0\nC über 48 h, dann für weitere 72 h bei RT gerührt. Es wird vom Niederschlag abfiltriert und dieser mit Ethylacetat nachgewaschen. Die vereinigten organischen Phasen werden im Vakuum eingeengt und der Rückstand mit NaCI - Lösung versetzt, mit EE extrahiert und die vereinigten organischen Phasen über Na\n2\nSO\n4\n getrocknet. Nach Entfernen des Lösungsmittels erhält man nach Flash-Chromatographie über Kieselgel (Eluent: EE/MeOH 99/1 zu 95/5) 2.80 g (12.71 mmol, 62 %) 5-Amino-6-(pyridin-4-ylethinyl)picolinonitril als gelben Feststoff\nPd (dppf) \n2\n CI \n2\n 'CH \n2\n Cl \n2 added\n under nitrogen and the solution at 5O \n0\n C for 48 h, then stirred for a further 72 h at RT. It is filtered from the precipitate and this washed with ethyl acetate. The combined organic phases are concentrated in vacuo and the residue is treated with NaCl solution, extracted with EA and the combined organic phases are dried over Na \n2\n SO \n4\n . After removal of the solvent is obtained after flash chromatography on silica gel (eluent: EA / MeOH 99/1 to 95/5) 2.80 g (12.71 mmol, 62%) of 5-amino-6- (pyridin-4-ylethinyl) picolinonitrile as yellow solid\n\n\n\n\n\n\n \n \n\n ; ESI-MS: m/z: 221 ([IvHH]\n+\n), 463 ([2M+Na]\n+\n).\n \n ; ESI-MS: m / z: 221 ([IvHH] \n+\n ), 463 ([2M + Na] \n+\n ).\n\n\n\n\n\n\n \n1.3 1.75 g (4.90 mmol) 5-Amino-6-(pyridin-4-ylethinyl)picolinonitril werden im Vakuum getrocknet und unter Stickstoff in 15 ml NMP gelöst. Nach Eintragen von 935 mg (8.33 mmol) Kalium-tert.-butylat wird das Reaktionsgemisch für 4h auf 9O\n0\nC erhitzt. Anschließend wird auf 0\n0\nC gekühlt und eine Lösung von 1.65 g (7.35 mmol) N-Iodsuccinimid in 10 ml NMP hinzugetropft. Nach 1 h bei RT wird das Reaktionsgemisch erneut auf 0° gekühlt und eine Lösung von 5.35 g (24.52 mmol) Di-tert.-butyldicarbonat und 599 mg (4.90 mmol) 4-(Dimethylamino)-pyridin in 5 ml NMP hinzugetropft. Nach 1h bei 0\n0\nC wird das Reaktionsgemisch mit 250 ml\n1.3 1.75 g (4.90 mmol) of 5-amino-6- (pyridin-4-ylethynyl) picolinonitrile are dried in vacuo and dissolved under nitrogen in 15 ml of NMP. After adding 935 mg (8.33 mmol) of potassium tert-butoxide, the reaction mixture is heated to 9O \n0\n C for 4 h. The mixture is then cooled to 0 \n0\n C and a solution of 1.65 g (7.35 mmol) of N-iodosuccinimide was added dropwise in 10 ml NMP. After 1 h at RT, the reaction mixture is cooled again to 0 ° and a solution of 5.35 g (24.52 mmol) of di-tert-butyl dicarbonate and 599 mg (4.90 mmol) of 4- (dimethylamino) pyridine in 5 ml of NMP was added dropwise. After 1 h at 0 \n0\n C, the reaction mixture with 250 ml\n\n\n\n\n\n\n \nEiswasser versetzt und mit CH\n2\nCI\n2\n extrahiert. Die vereinigten organischen \n\n Phasen werden mit gesättigter NaCI - Lösung gewaschen und über Na\n2\nSO\n4\n getrocknet, und das Lösungsmittel im Vakuum entfernt. Nach Flash- Chromatographie über neutralem Aluminiumoxid (Eluent: EE/CH 9/1 ) erhält man 1750 mg (3.92 mmol, 80 %) tert.-butyl-5-cyan-3-iod-2-(pyridin-4-yl)-1 H- pyrrolo[3,2-b]pyridin-1-carboxylat als weißen Feststoff\nIce water and extracted with CH \n2\n Cl \n2\n . The combined organic  Phases are washed with saturated NaCl solution and dried over Na \n2\n SO \n4\n , and the solvent is removed in vacuo. After flash chromatography on neutral alumina (eluent: EA / CH 9/1), 1750 mg (3.92 mmol, 80%) of tert-butyl-5-cyano-3-iodo-2- (pyridin-4-yl) are obtained. -1 H -pyrrolo [3,2-b] pyridine-1-carboxylate as a white solid\n\n\n\n\n\n\n \n \n\n ; ESI-MS: m/z: 447 ([M+H]\n+\n), 347 ([M-BOC]\n+\n).\n \n ; ESI-MS: m / z: 447 ([M + H] \n+\n ), 347 ([M-BOC] \n+\n ).\n\n\n\n\n\n\n \n1.4 Eine Lösung aus 223 mg (0.5 mmol) tert.-butyl-5-cyan-3-iod-2-\n1.4 A solution of 223 mg (0.5 mmol) of tert-butyl-5-cyan-3-iodo-2-\n\n\n\n\n\n\n \n(pyridin-4-yl)-1 H-pyrrolo[3,2-b]pyridin-1-carboxylat, 104 mg (0.75 mmol) 4- Fluorbenzolboronsäure und 207 mg K\n2\nCO\n3\n in 7.5 ml DME/H\n2\nO (2/1 ) wird 10 min im Ultraschallbad gerührt und unter Stickstoff mit 20 mg (0.025 mmol) Pd(dppf)\n2\nCI\n2\n'CH\n2\nCI\n2\n [1 ,1 '-Bis(diphenylphosphino)ferrocen]- dichlorpalladium(ll)-dichlormethan complex] versetzt. Nach Erhitzen auf 80\n0\nC für 2.5 h wird das Reaktionsgemisch auf RT abgekühlt und 5 ml ethanol. HCl - Lösung hinzugetropft und anschließend für 16 h bei 60\n0\nC gerührt. Nach Abkühlen auf RT wird der pH mit verdünnter NaOH - Lösung auf ca. 12 eingestellt und die wässrige Phase mit Ethylacetat extrahiert. Die vereinigten organischen Phasen werden über Na\n2\nSO\n4\n getrocknet und das Lösungsmittel im Vakuum entfernt. Nach Flash-Chromatographie über Kieselgel (Eluent: EE/MeOH 9/1 ) erhält man 136 mg (0.43 mmol, 86 %) 3-(4- Fluorphenyl)-2-(pyridin-4-yl)-1 H-pyrrolo[3,2-b]pyridin-5-carbonitril (\"A1 \") als geiben Feststoff; \n\n\n(pyridin-4-yl) -1H-pyrrolo [3,2-b] pyridine-1-carboxylate, 104 mg (0.75 mmol) 4-fluorobenzeneboronic acid and 207 mg K \n2\n CO \n3\n in 7.5 ml DME / H \n2\n O ( 2/1) is stirred for 10 min in an ultrasound bath and under nitrogen with 20 mg (0.025 mmol) Pd (dppf) \n2\n Cl \n2\n 'CH \n2\n Cl \n2\n [1, 1' -Bis (diphenylphosphino) ferrocene] - dichloropalladium (II) - dichloromethane complex]. After heating to 80 \n0\n C for 2.5 h, the reaction mixture is cooled to RT and 5 ml of ethanol. HCl solution was added dropwise and then stirred at 60 \n0\n C for 16 h. After cooling to RT, the pH is adjusted to about 12 with dilute NaOH solution and the aqueous phase is extracted with ethyl acetate. The combined organic phases are dried over Na \n2\n SO \n4\n and the solvent removed in vacuo. After flash chromatography on silica gel (eluent: EA / MeOH 9/1), 136 mg (0.43 mmol, 86%) of 3- (4-fluorophenyl) -2- (pyridin-4-yl) -1H-pyrrolo are obtained. 3,2-b] pyridine-5-carbonitrile (\"A1\") as a solid; \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nESI-MS: m/z: 315 ([M+H]\n+\n), 651 ([2IVH-Na]\n+\n);\nESI-MS: m / z: 315 ([M + H] \n+\n ), 651 ([2IVH-Na] \n+\n );\n\n\n\n\n\n\n \nEI-MS: m/z (%): 313 (100, [M-H]\n+\n), 286 (15, [Ci\n7\nHi\n0\nFN\n3\n]\n+\n); F. 230\n0\nC; 1H-NMR (400 MHz, DMSO-d\n6\n): δ = 7.30 (dd, 2H, J = 8.8 Hz, J = 2.2 Hz), 7.48 - 7.53 (m, 4H), 7.81 (d, 1 H, J = 8.3 Hz), 8.08 (d, 1 H\n1\n J = 8.3 Hz), 8.63 (dd, 2H\n1\n J = 6.0 Hz, J = 1.6 Hz), 12.65 (br, 1 H) ppm.\nEI-MS: m / z (%): 313 (100, [MH] \n+\n ), 286 (15, [Ci \n7\n Hi \n0\n FN \n3\n ] \n+\n ); F. 230 \n0\n C; 1 H-NMR (400 MHz, DMSO-d \n6\n ): δ = 7.30 (dd, 2H, J = 8.8 Hz, J = 2.2 Hz), 7.48-7.53 (m, 4H), 7.81 (d, 1 H, J = 8.3 Hz), 8.08 (d, 1 H \n1\n J = 8.3 Hz), 8.63 (dd, 2H \n1\n J = 6.0 Hz, J = 1.6 Hz), 12.65 (br, 1H) ppm.\n\n\n\n\n\n\n \nBEISPIEL 2\nEXAMPLE 2\n\n\n\n\n\n\n \nDie Herstellung erfolgt analog nachstehendem allgemeinen Reaktionsschema\nThe preparation is carried out analogously to the general reaction scheme below\n\n\n\n\n\n\n \n \n\n Herstellung von 3-(4-Fluorphenyl)-2-(pyrimidin-5-yl)-1 H-pyrrolo[3,2-b]pyridin- 5-carbonitril (\"A14\")\n \n Preparation of 3- (4-fluorophenyl) -2- (pyrimidin-5-yl) -1H-pyrrolo [3,2-b] pyridine-5-carbonitrile (\"A14\")\n\n\n\n\n\n\n \n2.1 5.00 g (20.40 mmol) 5-Amino-6-iodpicolinonitril und 751 mg (4.08 5 mmol) MgBr\n2\n werden in 50 ml trockenem THF gelöst, mit 10 ml 3,4-Dihydro-\n2.1 5.00 g (20.40 mmol) of 5-amino-6-iodopicolinonitrile and 751 mg (4.08 mmol) of MgBr \n2\n are dissolved in 50 ml of dry THF, with 10 ml of 3,4-dihydrochloride.\n\n\n\n\n\n\n \n2H-pyran versetzt und für 48 h zum Rückfluss erhitzt. Das Lösungsmittel wird anschließend im Vakuum entfernt und der Rückstand über Kieselgel (Eluent: EE/CH 7/3) chromatographisch aufgereinigt. Man erhält 6.70 g (20.40 mmol, 10 quant.) 6-lod-5-(tetrahydro-2H-pyran-2-ylamino)picolinonitril als schwach gelbes Öl;\n2H-pyran and heated to reflux for 48 h. The solvent is then removed in vacuo and the residue is purified by chromatography on silica gel (eluent: EA / CH 7/3). This gives 6.70 g (20.40 mmol, 10 quant.) Of 6-iodo-5- (tetrahydro-2H-pyran-2-ylamino) picolinonitrile as a pale yellow oil;\n\n\n\n\n\n\n \n \n\n ESI-MS: m/z: 246 ([M-THP]\n+\n), 330 ([M+H]\n+\n), 681 ([2M+Na]\n+\n).\n \n ESI-MS: m / z: 246 ([M-THP] \n+\n ), 330 ([M + H] \n+\n ), 681 ([2M + Na] \n+\n ).\n\n\n\n\n\n\n \n2.2 6.35 g (60.0 mmol) Na\n2\nCO\n3\n und 953 mg (22.50 mmol) LiCI werden im Vakuum ausgeheizt und unter Stickstoff in 150 ml trockenem DMF gelöst. Es werden 4.93 g (15.0 mmol) 6-lod-5-(tetrahydro-2H-pyran-2- ylamino)picolinonitril, 5.27 g (22.50 mmol) Triethyl((4- fluorophenyl)ethinyl)silan und 1.22 g (1.50 mmol) Pd(dppf)\n2\nCI\n2\n*CH\n2\nCI\n2\n \n2.2 6.35 g (60.0 mmol) of Na \n2\n CO \n3\n and 953 mg (22.50 mmol) of LiCl are heated in vacuo and dissolved under nitrogen in 150 ml of dry DMF. There are 4.93 g (15.0 mmol) of 6-iodo-5- (tetrahydro-2H-pyran-2-ylamino) picolinonitrile, 5.27 g (22.50 mmol) of triethyl ((4-fluorophenyl) ethynyl) silane and 1.22 g (1.50 mmol) Pd (dppf) \n2\n Cl \n2\n * CH \n2\n Cl \n2\n \n\n\n\n\n\n\n \n25 eingetragen und für 30 h bei 110\n0\nC gerührt. Das Reaktionsgemisch wird mit gesättigter NaCI - Lösung versetzt und mit Ethylacetat extrahiert. Die vereinigten organischen Phasen werden über Na\n2\nSO\n4\n getrocknet und das Lösungsmittel im Vakuum entfernt. Nach Flash-Chromatographie über 30 Kieselgel (Eluent: CH/EE 9/1 zu 7/3) erhält man 2.70 g (6.19 mmol, 41 %) 3- (4-Fluorphenyl)-1-(tetrahydro-2H-pyran-2-yl)-2-(triethylsilyl)-1 H-pyrrolo[3,2- b]pyridin-5-carbonitril als weißen Feststoff;\n25 and stirred for 30 h at 110 \n0\n C stirred. The reaction mixture is mixed with saturated NaCl solution and extracted with ethyl acetate. The combined organic phases are dried over Na \n2\n SO \n4\n and the solvent removed in vacuo. After flash chromatography on 30 silica gel (eluent: CH / EE 9/1 to 7/3), 2.70 g (6.19 mmol, 41%) of 3- (4-fluorophenyl) -1- (tetrahydro-2H-pyran-2 -yl) -2- (triethylsilyl) -1H-pyrrolo [3,2-b] pyridine-5-carbonitrile as a white solid;\n\n\n\n\n\n\n \n35 \n\n\n35 \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nESI-MS: m/z: 436 ([M+H]\n+\n), 458 ([M+Na]\n+\n), 893 ([2M+Na]\n+\n).\nESI-MS: m / z: 436 ([M + H] \n+\n ), 458 ([M + Na] \n+\n ), 893 ([2M + Na] \n+\n ).\n\n\n\n\n\n\n \n2.3 1.30 g (2.98 mmol) 3-(4-Fluorphenyl)-1-(tetrahydro-2H-pyran-2-yl)-2-\n2.3 1.30 g (2.98 mmol) of 3- (4-fluorophenyl) -1- (tetrahydro-2H-pyran-2-yl) -2-\n\n\n\n\n\n\n \n(triethylsilyl)-1 H-pyrrolo[3,2-b]pyridin-5-carbonitril und 1.33 g (3.58 mmol) Bis(pyridin)iodonium tetrafluoroborat werden in 15 ml Dichlorethan gelöst und mit 523 μl (5.96 mmol) Trifluormethansulfonsäure versetzt. Das Reaktionsgemisch wird über Nacht zum Rückfluss erhitzt. Es werden weitere 700 mg (1.88 mmol) Bis(pyridin)iodonium tetrafluoroborat sowie 523 μl (5.96 mmol) Trifluormethansulfonsäure in der Hitze zugegeben und für weitere 5 h zum Rückfluss erhitzt. Nach Abkühlen auf RT wird mit Wasser versetzt, mit verdünnter NaOH - Lösung auf ca. pH 11 eingestellt und die wässrige Phase mit Dichlormethan extrahiert. Die vereinigten organischen Phasen werden über Na\n2\nSO\n4\n getrocknet. Nach Entfernen des Lösungsmittels im Vakuum wird der Rückstand mit Flash-Chromatographie über Kieselgel (Eluent:\n(Triethylsilyl) -1H-pyrrolo [3,2-b] pyridine-5-carbonitrile and 1.33 g (3.58 mmol) of bis (pyridine) iodonium tetrafluoroborate are dissolved in 15 ml of dichloroethane and mixed with 523 .mu.l (5.96 mmol) trifluoromethanesulfonic acid. The reaction mixture is heated to reflux overnight. A further 700 mg (1.88 mmol) of bis (pyridine) iodonium tetrafluoroborate and 523 μl (5.96 mmol) of trifluoromethanesulfonic acid are added in the heat and heated to reflux for a further 5 h. After cooling to RT, it is mixed with water, adjusted to about pH 11 with dilute NaOH solution, and the aqueous phase is extracted with dichloromethane. The combined organic phases are dried over Na \n2\n SO \n4\n . After removal of the solvent in vacuo, the residue is purified by flash chromatography on silica gel (eluent:\n\n\n\n\n\n\n \nCH/EE 7/3 zu 1/1 ) aufgereinigt. Man erhält 850 mg (2.34 mmol, 78 %) 3-(4-\nCH / EE 7/3 to 1/1). 850 mg (2.34 mmol, 78%) of 3- (4-\n\n\n\n\n\n\n \nFluorphenyl)-2-iod-1 H-pyrrolo[3,2-b]pyridin-5-carbonitril als schwach gelben\nFluorophenyl) -2-iodo-1H-pyrrolo [3,2-b] pyridine-5-carbonitrile as a pale yellow\n\n\n\n\n\n\n \nFeststoff;\nSolid;\n\n\n\n\n\n\n \n \n\n ; ESI-MS: m/z: 364 ([M+H]\n+\n), 386 ([M+Na]\n+\n). \n\n 2.4 Eine Lösung aus 181 mg (0.5 mmol) 3-(4-Fluorphenyl)-2-iod-1 H- pyrrolo[3,2-b]pyridin-5-carbonitril, 92 mg (0.75 mmol) 5- Pyrimidinylboronsäure und 207 mg K\n2\nCO\n3\n in 7.5 ml DMF/H\n2\nO (2/1 ) wird 10 min im Ultraschallbad gerührt und unter Stickstoff mit 20 mg (0.025 mmol)\n \n ; ESI-MS: m / z: 364 ([M + H] \n+\n ), 386 ([M + Na] \n+\n ).  2.4 A solution of 181 mg (0.5 mmol) of 3- (4-fluorophenyl) -2-iodo-1H-pyrrolo [3,2-b] pyridine-5-carbonitrile, 92 mg (0.75 mmol) of 5-pyrimidinylboronic acid and 207 mg K \n2\n CO \n3\n in 7.5 ml of DMF / H \n2\n O (2/1) is stirred for 10 min in an ultrasound bath and treated under nitrogen with 20 mg (0.025 mmol)\n\n\n\n\n\n\n \nPd(dppf)\n2\nCI\n2\n*CH\n2\nCI\n2\n versetzt. Nach Erhitzen auf 80\n0\nC für 5 h werden in das\nPd (dppf) \n2\n Cl \n2\n * CH \n2\n Cl \n2\n . After heating to 80 \n0\n C for 5 h in the\n\n\n\n\n\n\n \nReaktionsgemisch weitere 9.2 mg 5-Pyrimidinylboronsäure und 2 mg Pd(dppf)\n2\nCI\n2\n \n»\nCH\n2\nCI\n2\n eingetragen und für 23 h bei 80\n0\nC gerührt. Nach Abkühlen auf RT wird mit Wasser versetzt und die wässrige Phase mit Ethylacetat extrahiert. Die vereinigten organischen Phasen werden über\nReaction mixture further 9.2 mg 5-pyrimidinylboronic acid and 2 mg Pd (dppf) \n2\n CI \n2\n \n»\n CH \n2\n CI \n2\n and stirred for 23 h at 80 \n0\n C stirred. After cooling to RT, water is added and the aqueous phase is extracted with ethyl acetate. The combined organic phases are over\n\n\n\n\n\n\n \nNa\n2\nSO\n4\n getrocknet und das Lösungsmittel im Vakuum entfernt. Nach Flash- Chromatographie über Kieselgel (Eluent: EE/CH 7/3 zu EE) erhält man 15 mg (0.04 mmol, 9 %) 3-(4-Fluorphenyl)-2-(pyrimidin-5-yl)-1 H-pyrrolo[3,2- b]pyridin-5-carbonitril (\"A14\") als gelben Feststoff;\nNa \n2\n SO \n4\n dried and the solvent removed in vacuo. After flash chromatography on silica gel (eluent: EA / CH 7/3 to EA), 15 mg (0.04 mmol, 9%) of 3- (4-fluorophenyl) -2- (pyrimidin-5-yl) -1 H- pyrrolo [3,2-b] pyridine-5-carbonitrile (\"A14\") as a yellow solid;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nESI-MS: m/z: 316 ([M+H]\n+\n), 653 Q2M+NaJ\n+\n); EI-MS: m/z (%): 315 (100, [M]\n+\n), 314 (95, [M-H]\n+\n); F. 230-232°C; 1H-NMR (400 MHz, DMSO-d\n6\n): δ = 7.23 - 7.32 (m, 2H), 7.51 - 7.55 (m, 2H), 7.83 (d, 1 H, J = 8.4 Hz), 8.12 (d, 1 H, J = 8.4 Hz), 8.91 (s, 2H), 9.23 (s, 1 H), 12.04 (br, 1 H) ppm.\nESI-MS: m / z: 316 ([M + H] \n+\n ), 653 Q2M + NaJ \n+\n ); EI-MS: m / z (%): 315 (100, [M] \n+\n ), 314 (95, [MH] \n+\n ); F. 230-232 ° C; 1 H NMR (400 MHz, DMSO-d \n6\n ): δ = 7.23-7.32 (m, 2H), 7.51-7.55 (m, 2H), 7.83 (d, 1 H, J = 8.4 Hz), 8.12 (d, 1 H, J = 8.4 Hz), 8.91 (s, 2H), 9.23 (s, 1H), 12.04 (br, 1H) ppm.\n\n\n\n\n\n\n \nEine weitere Zugangsmöglichkeit bei identischer Substitution für R\n1\n und R\n2\n ergibt sich aus folgendem Schema (z.B. Verbindung \"A11\", s.u.) in Analogie zu o. g. Vorschriften: \n\n \n\n\n\nA further possibility of access with identical substitution for R \n1\n and R \n2\n results from the following scheme (eg compound \"A11\", see below) in analogy to the above-mentioned regulations: \n \n\n\n\n\n\n\n \noder\nor\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nAnalog den oben beschriebenen Beispielen erhält man die nachstehenden Verbindungen\nAnalogously to the examples described above, the following compounds are obtained\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n\n128.61 , 128.63, 128.69, 128.74, 128.86, 129.61 , 130.71 , 131.25, 132.94, 137.21 , 145.96, 149.12 ppm\n \n \n \n 128.61, 128.63, 128.69, 128.74, 128.86, 129.61, 130.71, 131.25, 132.94, 137.21, 145.96, 149.12 ppm\n\n\n\n\n\n\n \n\"A33\" 1 -[2-(4-Fluor-phenyl)-ethyl]-2-phenyl-1 H- 94; pyrrolo[2,3-b]pyridin-5-carbonitril m/z: 342 ([M+H]\n+\n)\n\"A33\" 1 - [2- (4-fluoro-phenyl) -ethyl] -2-phenyl-1 H-94; pyrrolo [2,3-b] pyridine-5-carbonitrile m / z: 342 ([M + H] \n+\n )\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\"A34\" 3-[2-(4-Fluor-phenyl)-ethyl]-2-phenyl-1 H- 141-143 pyrrolo[2,3-b]pyridin-5-carbonitril\n\"A34\" 3- [2- (4-Fluoro-phenyl) -ethyl] -2-phenyl-1 H-141-143-pyrrolo [2,3-b] pyridine-5-carbonitrile\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\"A35\" 5-Methyl-2,3-diphenyl-1 H-pyrrolo[2,3- 270-271 ; b]pyridin m/z (%): 454 ([M+H]\n+\n)\n\"A35\" 5-methyl-2,3-diphenyl-1H-pyrrolo [2,3- 270-271; b] pyridine m / z (%): 454 ([M + H] \n+\n )\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n1\nH-NMR (300 MHz, DMSO-d\n6\n): δ = 3.73 (s, 3H), 7.20 - 7.35 (m, 5H), 7.42 7.53 (m, 5H), 8.52 (d, I H, J = 1.8 Hz), 8.76 (d, 1H, J = 1.8 Hz) ppm; 1\n3\nC-NMR (75 MHz\n1\n DMSOd\n6\n): 29.61 , 100.76, 113.05, 118.12, 118.75, 126.49, 128.59, 128.73, 129.25, 129.78, 130.69, 131.73, 132.52, 140.04, 145.79, 148.03 ppm \n\n \n \n1\n H-NMR (300 MHz, DMSO-d \n6\n ): δ = 3.73 (s, 3H), 7.20-7.35 (m, 5H), 7.42 7.53 (m, 5H), 8.52 (d, IH, J = 1.8 Hz ), 8.76 (d, 1H, J = 1.8 Hz) ppm; 1 \n3\n C-NMR (75 MHz \n1\n DMSOd \n6\n ): 29.61, 100.76, 113.05, 118.12, 118.75, 126.49, 128.59, 128.73, 129.25, 129.78, 130.69, 131.73, 132.52, 140.04, 145.79, 148.03 ppm \n \n\n\n\n\n\n\n \n \n\n - 79 - \n\n \n \n - 79 - \n \n\n\n\n\n\n\n \n \n1\nH-NMR (300 MHz, DMSO-d\n6\n): δ = 7.21 - 7.30 (m, 2H), 7.43 - 7.54 (m, 3H)\n1\n 7.78 (d, 1 H\n1\n J = 8.4 Hz), 7.90 (m, 1 H), 8.0 (d, 1 H, J = 8.4 Hz), 8.61 (dd, 1 H, J = 4.8 Hz, J = 1.6), (8.70 (dd, 1 H, J = 2.4 Hz, J = 0.8), 12.58 (br, 1 H) ppm. \n13\nC-NMR (75 MHz\n1\n DMSO-d\n6\n): 113.33, 115.45 (d, \n2\nJ\n0\nF = 21 Hz), 118.92, 119.59, 122.10, 123.75, 125.32, 128.42 (d, %\nF\n = 3 Hz), 130.45, 131.87 (d, \n3\nJ\nCF\n = 8.1 Hz), 136.04, 137.94, 145.46, 149.39 (d, \n1\nJ\nCF\n = 243 Hz) ppm.\n \n1\n H-NMR (300 MHz, DMSO-d \n6\n ): δ = 7.21 - 7.30 (m, 2H), 7.43 - 7.54 (m, 3H) \n1\n 7.78 (d, 1 H \n1\n J = 8.4 Hz), 7.90 (m , 1 H), 8.0 (d, 1 H, J = 8.4 Hz), 8.61 (dd, 1 H, J = 4.8 Hz, J = 1.6), (8.70 (dd, 1 H, J = 2.4 Hz, J = 0.8), 12.58 (br, 1H) ppm, \n13\n C-NMR (75 MHz \n1\n DMSO-d \n6\n ): 113.33, 115.45 (d, \n2\n J \n0\n F = 21 Hz), 118.92, 119.59, 122.10, 123.75, 125.32 , 128.42 (d,% \nF\n = 3 Hz), 130.45, 131.87 (d, \n3\n J \nCF\n = 8.1 Hz), 136.04, 137.94, 145.46, 149.39 (d, \n1\n J \nCF\n = 243 Hz) ppm.\n\n\n\n\n\n\n \n\"A47\" 2-(6-Aminopyridin-3-yl)-3-(4-fiuorphenyl)-1 (- pyrrolo[3,2-b]pyridin-5-carbonitril\n\"A47\" 2- (6-Aminopyridin-3-yl) -3- (4-fluorophenyl) -1 (- pyrrolo [3,2-b] pyridine-5-carbonitrile\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\"A48\" 3-(4-Fluorphenyl)-2-phenyl-1 H-pyrrolo[3,2- 294-296; b]pyridin-5-carbonitril m/z (%): 314 ([M+H]\n+\n)\n\"A48\" 3- (4-fluorophenyl) -2-phenyl-1H-pyrrolo [3.2-294-296; b] pyridine-5-carbonitrile m / z (%): 314 ([M + H] \n+\n )\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n1\nH-NMR (500 MHz, DMSO-d\n6\n): δ = 7.21 - 7.25 (m, 2H)\n1\n 7.42 - 7.50 (m, 5H), 7.52 - 7.55 (m, 2H)\n1\n 7.73 (d, 1H\n1\n J = 8.3 Hz), 7.98 (d, 1 H, J = 8.3 Hz), 12.41 (br, 1 H) ppm. 3C-NMR (IOO MHz, DMSO-d\n6\n): 111.64, 114.65, 114.86, 118.52, 118.73, \n\n -80-\n \n1\n H-NMR (500 MHz, DMSO-d \n6\n ): δ = 7.21-2.25 (m, 2H) \n1\n 7.42-7.50 (m, 5H), 7.52-7.55 (m, 2H) \n1\n 7.73 (d, 1H \n1\n J = 8.3 Hz), 7.98 (d, 1 H, J = 8.3 Hz), 12.41 (br, 1 H) ppm. 3C-NMR (100 MHz, DMSO-d \n6\n ): 111.64, 114.65, 114.86, 118.52, 118.73,  -80-\n\n\n\n\n\n\n \n \n\n -81 -\n \n -81 -\n\n\n\n\n\n\n \n \n\n -82-\n \n -82-\n\n\n\n\n\n\n \n \n\n -83-\n \n -83-\n\n\n\n\n\n\n \n \n\n - 84 -\n \n - 84 -\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO-d\n6\n): δ = 2.37 - 2.43 (m, 4H), 3.41 - 3.53 (m, 8H), 7.40 - 7.52 (m, 6H)\n1\n 8.04 (d, 1 H\n1\n J = 8.4 Hz), 7.98 (d, 1 H\n1\n J = 8.4 Hz), 8.32 - 8.35 (m, 1H), 8.63 (dd, , 2H\n1\n J = 4.4 Hz, J = 1.7 Hz), 12.73 (br, 1H) ppm\n \n1\n H-NMR (400 MHz, DMSO-d \n6\n ): δ = 2.37-2.43 (m, 4H), 3.41- 3.53 (m, 8H), 7.40-7.52 (m, 6H) \n1\n 8.04 (d, 1 H \n1\n J = 8.4 Hz), 7.98 (d, 1 H \n1\n J = 8.4 Hz), 8.32-8.35 (m, 1H), 8.63 (dd,, 2H \n1\n J = 4.4 Hz, J = 1.7 Hz), 12.73 (br, 1H) ppm\n\n\n\n\n\n\n \n\"A62\" 3-(3-Chlor-phenyl)-2-pyrimidin-5-yl-1 H- m/z (%): 332 ([M+H]\n+\n) pyrrolo[3,2-b]pyridin-5-carbonitril\n\"A62\" 3- (3-Chloro-phenyl) -2-pyrimidin-5-yl-1 H-m / z (%): 332 ([M + H] \n+\n ) pyrrolo [3,2-b] pyridine 5-carbonitrile\n\n\n\n\n\n\n \n\"A63\" 3-(4-Fluor-phenyl)-2-pyrimidin-5-yl-1 H- m/z (%): 315 (100, pyrrolo[3,2-b]pyridin-5-carbonitril [M]\n+\n)\n\"A63\" 3- (4-Fluoro-phenyl) -2-pyrimidin-5-yl-1 H-m / z (%): 315 (100, pyrrolo [3,2-b] pyridine-5-carbonitrile [M. ] \n+\n )\n\n\n\n\n\n\n \nΗ-NMR (400 MHz, DMSO-de): δ = 7.26 - 7.34 (m, 2H), 7.50 - 7.55 (m, 2H), 7.83 (d, 1 H, J = 8.4 Hz), 8.12 (d, 1 H\n1\n J = 8.4 Hz), 8.91 (s, 2H)\n1\n 9.23 (s, 1H), 12.04 (br, 1 H) ppm\nΗ-NMR (400 MHz, DMSO-de): δ = 7.26-7.34 (m, 2H), 7.50-7.55 (m, 2H), 7.83 (d, 1 H, J = 8.4 Hz), 8.12 (d, 1 H \n1\n J = 8.4 Hz), 8.91 (s, 2H) \n1\n 9.23 (s, 1H), 12.04 (br, 1H) ppm\n\n\n\n\n\n\n \n\"A64\" 2-(2-Chlor-pyridin-4-yl)-3-(4-fluor-phenyl)- m/z (%): 313 (100, [M- 1 H-pyrrolo[3,2-b]pyridin-5-carbonitril Cl]\n+\n), 348 (85, [M]\n+\n)\n\"A64\" 2- (2-chloro-pyridin-4-yl) -3- (4-fluoro-phenyl) -m / z (%): 313 (100, [M-1H-pyrrolo [3,2- b] pyridine-5-carbonitrile Cl] \n+\n ), 348 (85, [M] \n+\n )\n\n\n\n\n\n\n \n \n1\nH-NMR (300 MHz, DMSO-d\n6\n): δ = 7.27 - 7.35 (m, 2H), 7.41 (dd, 1 H\n1\n J = 5.2 Hz, J = 1.5 Hz), 7.48 - 7.55 (m, 2H), 7.65 (m, 1 H), 7.82 (d, 1 H, J = 8.3 Hz), 8.09 (d, 1 H, J = 8.3 Hz), 8.45 (dd, 1 H, J = 5.3 Hz, J = 0.5 Hz), 12.70 (br, 1 H) ppm\n \n1\n H-NMR (300 MHz, DMSO-d \n6\n ): δ = 7.27-7.35 (m, 2H), 7.41 (dd, 1 H \n1\n J = 5.2 Hz, J = 1.5 Hz), 7.48-7.55 (m, 2H ), 7.65 (m, 1 H), 7.82 (d, 1 H, J = 8.3 Hz), 8.09 (d, 1 H, J = 8.3 Hz), 8.45 (dd, 1 H, J = 5.3 Hz, J = 0.5 Hz), 12.70 (br, 1H) ppm\n\n\n\n\n\n\n \n\"A65\" 3-(3-Chlor-4-fluor-phenyl)-2-pyrimidin-5-yl- m/z (%): 350 ([M+H] ) 1H-pyrrolo[3,2-b]pyridin-5-carbonitril\n\"A65\" 3- (3-Chloro-4-fluoro-phenyl) -2-pyrimidin-5-yl-m / z (%): 350 ([M + H]) 1 H -pyrrolo [3,2-b] pyridine-5-carbonitrile\n\n\n\n\n\n\n \nΗ-NMR (400 MHz, DMSO-de): δ = 7.50 - 7.55 (m, 2H), 7.84 (d, 1 H\n1\n J = 8.4 Hz), 7.87 (dd, 1 H, J = 8.2 Hz, J =2.1 Hz), 8.10 (d, 1 H, J = 8.4 Hz), 8.90 (s, 2H), 9.14 (s, 1 H), 12.81 (br, 1 H) ppm\nΗ-NMR (400 MHz, DMSO-de): δ = 7.50-7.55 (m, 2H), 7.84 (d, 1 H \n1\n J = 8.4 Hz), 7.87 (dd, 1 H, J = 8.2 Hz, J = 2.1 Hz), 8.10 (d, 1H, J = 8.4 Hz), 8.90 (s, 2H), 9.14 (s, 1H), 12.81 (br, 1H) ppm\n\n\n\n\n\n\n \n\"A66\" 2-(2-Amino-pyrimidin-5-yl)-3-(3-chlor-4- 272; fluor-phenyl)-1H-pyrrolo[3,2-b]pyridin-5- m/z (%): 364 (100, carbonitril [M]\n+\n), 328 (40, [M-\n\"A66\" 2- (2-Amino-pyrimidin-5-yl) -3- (3-chloro-4-272; fluoro-phenyl) -1H-pyrrolo [3,2-b] pyridine-5 m / z (%): 364 (100, carbonitrile [M] \n+\n ), 328 (40, [M\n\n\n\n\n\n\n \nHCI]\n+\n)\nHCI] \n+\n )\n\n\n\n\n\n\n \nΗ-NMR (300 MHz, DMSO-de): δ = 7.12 (br, 2H)\n1\n 7.46 - 7.51 (m, 2H), 7.72 - \n\n -85-\nΗ-NMR (300 MHz, DMSO-de): δ = 7.12 (br, 2H) \n1\n 7.46 - 7.51 (m, 2H), 7.72 -  -85-\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n-86-\n-86-\n\n\n\n\n\n\n \nPharmakologische Daten\nPharmacological data\n\n\n\n\n\n\n \nMet-Kinase-Inhibierung Tabelle 1\nMet Kinase Inhibition Table 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nIC\n50\n: 1 nM-0,1 μM = A 0,1 μM-10μM = B > 10 μM = C \n\n - 87 -\nIC \n50\n : 1 nM-0.1 μM = A 0.1 μM-10 μM = B> 10 μM = C  - 87 -\n\n\n\n\n\n\n \nDie nachfolgenden Beispiele betreffen Arzneimittel:\nThe following examples relate to drugs:\n\n\n\n\n\n\n \nBeispiel A: Injektionsgläser\nExample A: Injection glasses\n\n\n\n\n\n\n \nEine Lösung von 100 g eines Wirkstoffes der Formel I und 5 g Dinatrium- hydrogenphosphat wird in 3 I zweifach destilliertem Wasser mit 2 N SaIz- säure auf pH 6,5 eingestellt, steril filtriert, in Injektionsgläser abgefüllt, unter sterilen Bedingungen lyophilisiert und steril verschlossen. Jedes Injektionsglas enthält 5 mg Wirkstoff.\nA solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 l of bidistilled water with 2N hydrochloric acid, filtered sterile, filled into injection jars, lyophilized under sterile conditions and sealed under sterile conditions , Each injection jar contains 5 mg of active ingredient.\n\n\n\n\n\n\n \nBeispiel B: Suppositorien\nExample B: Suppositories\n\n\n\n\n\n\n \nMan schmilzt ein Gemisch von 20 g eines Wirkstoffes der Formel I mit 100 g Sojalecithin und 1400 g Kakaobutter, gießt in Formen und läßt erkalten.\nA mixture of 20 g of an active compound of the formula I is melted with 100 g of soya lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool.\n\n\n\n\n\n\n \nJedes Suppositorium enthält 20 mg Wirkstoff.\nEach suppository contains 20 mg of active ingredient.\n\n\n\n\n\n\n \nBeispiel C: Lösung\nExample C: Solution\n\n\n\n\n\n\n \nMan bereitet eine Lösung aus 1 g eines Wirkstoffes der Formel I, 9,38 g NaH\n2\nPO\n4\n • 2 H\n2\nO, 28,48 g Na\n2\nHPO\n4\n • 12 H\n2\nO und 0,1 g Benzalkonium- chlorid in 940 ml zweifach destilliertem Wasser. Man stellt auf pH 6,8 ein, füllt auf 1 I auf und sterilisiert durch Bestrahlung. Diese Lösung kann in Form von Augentropfen verwendet werden.\nA solution of 1 g of an active compound of the formula I, 9.38 g of NaH \n2\n PO \n4\n • 2H \n2\n O, 28.48 g of Na \n2\n HPO \n4\n • 12H \n2\n O and 0.1 g of benzalkonium chloride in 940 is prepared ml of double distilled water. Adjust to pH 6.8, make up to 1 liter and sterilize by irradiation. This solution can be used in the form of eye drops.\n\n\n\n\n\n\n \nBeispiel D: Salbe\nExample D: Ointment\n\n\n\n\n\n\n \nMan mischt 500 mg eines Wirkstoffes der Formel I mit 99,5 g Vaseline unter aseptischen Bedingungen. \n\n - 88 -\n500 mg of an active compound of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.  - 88 -\n\n\n\n\n\n\n \nBeispiei E: Tabletten\nExample E: Tablets\n\n\n\n\n\n\n \nEin Gemisch von 1 kg Wirkstoff der Formel I\n1\n 4 kg Lactose, 1 ,2 kg Kartoffelstärke, 0,2 kg Talk und 0,1 kg Magnesiumstearat wird in üblicher Weise zu\nA mixture of 1 kg of active ingredient of the formula I \n1\n 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate in the usual manner\n\n\n\n\n\n\n \nTabletten verpreßt, derart, daß jede Tablette 10 mg Wirkstoff enthält.\nTablets compressed so that each tablet contains 10 mg of active ingredient.\n\n\n\n\n\n\n \nBeispiel F: Dragees\nExample F: dragees\n\n\n\n\n\n\n \nAnalog Beispiel E werden Tabletten gepreßt, die anschließend in üblicher Weise mit einem Überzug aus Saccharose, Kartoffelstärke, Talk, Tragant und Farbstoff überzogen werden.\nTablets are pressed analogously to Example E, which are then coated in the usual way with a coating of sucrose, potato starch, talc, tragacanth and dye.\n\n\n\n\n\n\n \nBeispiel G: Kapseln\nExample G: Capsules\n\n\n\n\n\n\n \n2 kg Wirkstoff der Formel I werden in üblicher Weise in Hartgelatinekapseln gefüllt, so daß jede Kapsel 20 mg des Wirkstoffs enthält.\n2 kg of active compound of the formula I are filled in the usual way in hard gelatin capsules, so that each capsule contains 20 mg of the active ingredient.\n\n\n\n\n\n\n \nBeispiel H: Ampullen\nExample H: Ampoules\n\n\n\n\n\n\n \nEine Lösung von 1 kg Wirkstoff der Formel I in 60 I zweifach destilliertem Wasser wird steril filtriert, in Ampullen abgefüllt, unter sterilen Bedingungen lyophilisiert und steril verschlossen. Jede Ampulle enthält 10 mg Wirkstoff. \n\nA solution of 1 kg of active compound of the formula I in 60 l of bidistilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each vial contains 10 mg of active ingredient."
  },
  {
    "id": "WO2010048592A1",
    "text": "Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof AbstractThe present invention relates to compositions comprising 4-(2-(5-bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H- 1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid or pharmaceutically acceptable salts thereof, and to the preparation and use of such compositions, in particular for the treatment of diseases. Claims\n\n\n\n\n WHAT IS CLAIMED IS:\n\n\n\n\n1. A pharmaceutical composition comprising: a compound or mixture of compounds of structure (I):\n\n\n \n (I), wherein M is hydrogen, sodium, potassium, calcium, or arginine; and one or more diluents; one or more binders; one or more coating agents; one or more dispersing agents; and one or more plasticizers.\n\n\n\n\n\n\n2. The pharmaceutical composition of claim 1, wherein the diluent is microcrystalline cellulose, silicifϊed microcrystalline cellulose, cellulose, lactose, compressible sugar, mannitol, calcium silicate and calcium phosphate in powder and granular forms, sodium phosphate or sodium carbonate.\n\n\n\n\n\n\n3. The pharmaceutical composition of claim 1 , wherein the binder is hypromellose, povidone, hydroxypropyl cellulose, hydroxyethyl cellulose or starch.\n\n\n\n\n\n\n4. The pharmaceutical composition of claim 1 , wherein the coating agent is a methacrylic acid based copolymers, Eudragit L30D55, Acryl-Eze, hydroxypropylmethyl cellulose acetate succinate, polyvinylacetate phthalate or cellulose acetate phthalate.\n\n\n\n\n\n\n5. The pharmaceutical composition of claim 1, wherein the dispersing agent is talc, glycerol monostearate or colloidal silicon dioxide.\n\n\n\n\n\n\n6. The pharmaceutical composition of claim 1, wherein the plasticizer is triethyl citrate, triacetin, dibutyl phthalate, diethyl phthalate or glycerin. \n\n\n\n\n\n\n7. The pharmaceutical composition of claim 1, comprising from about lOmg to about lOOOmg of the compound or mixture of compounds of structure (I).\n\n\n\n\n\n\n8. The pharmaceutical composition of claim 1, comprising about lOOmg, or about 200mg, or about 300mg, or about 400mg, or about 500mg, or about 600mg, or about 700mg, or about 800mg, or about 900mg, or about lOOOmg of the compound or mixture of compounds of structure (I).\n\n\n\n\n\n\n9. A pharmaceutical composition comprising: a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n (IB); microcrystalline cellulose; hypromellose; methacrylic acid copolymer dispersion; talc; and triethyl citrate. \n\n\n\n\n\n\n10. The composition of claim 9 comprising: about 214mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form; about 35mg of microcrystalline cellulose; about 29mg of hypromellose; about 30mg of methacrylic acid copolymer dispersion; about 6mg of talc; and about 3mg of triethyl citrate.\n\n\n\n\n\n\n11. A pharmaceutical composition comprising: from about 60% to about 90% by weight of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid  form: \n (IB); from about 5% to about 15% by weight of microcrystalline cellulose; from about 5% to about 15% by weight of hypromellose; from about 5% to about 15% by weight of methacrylic acid copolymer dispersion; from about 0.5% to about 5% by weight of talc; and from about 0.1% to about 3% by weight of triethyl citrate.\n\n\n\n\n\n\n12. A pharmaceutical composition comprising: a compound of structure (IB) or a mixture of\n\n\na compound of structure (IB) and its free acid form: \n (IB); microcrystalline cellulose; and hypromellose; wherein the composition is in the form of granules. \n\n\n\n\n\n\n13. A pharmaceutical composition comprising : about 214mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n (IB); about 35mg of microcrystalline cellulose; about 13.5 mg of hypromellose; wherein the composition is in the form of granules which do not pass through a 40 mesh screen; and wherein the granules are coated with about 15.3 mg hypromellose; and wherein the coated granules are further coated with a composition comprising: about 30.4mg of methacrylic acid copolymer dispersion; about 6.1mg of talc; and about 3.0mg of triethyl citrate.\n\n\n\n\n\n\n14. The composition of any preceding claim, wherein the in vitro dissolution rate as measured using United States Pharmacopoeia Apparatus 1 operating at 75 rpm in 900 mL water at 37°C is not less than about 80% of the compound of structure (IB) is released within 30 minutes.\n\n\n\n\n\n\n15. A method for decreasing uric acid levels in one or more tissues or organs of a subject in need of decreased uric acid levels, comprising administering to the subject a uric acid level decreasing amount of the pharmacuetical composition according to any of the preceding claims.\n\n\n\n\n\n\n16. A method for reducing uric acid production, increasing uric acid excretion or both in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the preceding claims.\n\n\n\n\n\n\n17. A method for treating or preventing hyperuricemia in a subject comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the preceding claims.\n\n\n\n\n\n\n18. A method of treating a subject suffering from a condition characterized by abnormal tissue or organ levels of uric acid comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the preceding claims.  \n\n\n\n\n\n\n19. A method for preventing a condition characterized by abnormal tissue levels of uric acid in a subject at increased risk of developing the condition, comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the preceding claims. \n\n\n\n\n\n\n20. A method for treating gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosisin a subject comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the preceding claims.\n\n\n\n\n\n\n21. A method for treating gout in a subject comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the preceding claims.\n\n\n\n\n\n\n22. A method for preventing the formation or reducing the size of tophi/tophus in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the preceding claims. Description\n\n\n\n\n COMPOSITIONS COMPRISING\n\n\n4- (2- ( 5-BROMO-4- ( l-CYCLOPROPYLNAPHTHALEN-4-YL) -4H-1 , 2 , 4-TRIAZ0L-3-YLTHI0)\n\n\nACETAMIDO ) - S -CHLOROBENZOI C ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ,\n\n\nRELATED APPLICATION\n\n\n[0001] This application claims priority to U.S. Provisional Application No.61/108,412filed October 24, 2008, which is incorporated herein by reference in its entirety. BACKGROUND OF THE INVENTION\n\n\n[0002] 4-(2-(5-Bromo-4-(l-cyclopropylnaphthalen-4-yl)-4/f-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof, are useful in the treatment and prevention of diseases. Described herein are compositions comprising 4-(2-(5- bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof and methods of using the compositions, for example in the treatment of diseases.\n\n\n\n\n\n\n\n\nSUMMARY OF THE INVENTION\n\n\n[0003] Disclosed herein, in certain embodiments, is a composition comprising greater than about 35% by weight of a compound or mixture of compounds of structure (I):\n\n\n \n\n (I); wherein M is hydrogen, sodium, potassium, calcium or arginine. In some embodiments, the composition comprises greater than about 60% by weight of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises greater than about 70% by weight of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises greater than about 80% by weight of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises at least lOOmg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises at least 250mg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises at least 500mg of a compound or mixture of compounds of structure (I). In some embodiments, the composition\n\n\n- 1 -\n\n\nWSGR Docket No 18545-763.601 \n\n comprises at least 750mg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises at least 800mg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about lOOmg, about 200mg, about 300mg, about 400mg, about 500mg, about 600mg, about 700mg, about 800mg, about 900mg or about lOOOmg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 600mg, about 800mg or about lOOOmg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 600mg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 800mg of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about lOOOmg of a compound or mixture of compounds of structure (I). In some embodiments, the composition further comprises one or more pharmaceutically acceptable diluents, binders, lubricants, coating agents, barrier coatings, plasticizers, dispersing agents or film coating additives. In some embodiments, the composition further comprises one or more pharmaceutically acceptable diluents. In some embodiments, the diluent is microcrystalline cellulose, silicified microcrystalline cellulose, cellulose, lactose, compressible sugar, mannitol, calcium silicate and calcium phosphate, sodium phosphate, sodium carbonate, or a combination thereof. In some embodiments, the diluent is in powder form. In some embodiments, the diluent is in granular form. In some embodiments, the diluent is microcrystalline cellulose. In some embodiments, the composition further comprises one or more pharmaceutically acceptable binders. In some embodiments, the binder is hypromellose, povidone, hydroxypropyl cellulose, hydroxyethyl cellulose or starch. In some embodiments, the binder is hypromellose. In some embodiments, the composition further comprises one or more pharmaceutically acceptable lubricant. In some embodiments, the lubricant is magnesium stearate, stearic acid or sodium stearyl fumarate. In some embodiments, the lubricant is magnesium stearate. In some embodiments, the composition further comprises one or more pharmaceutically acceptable barrier coatings. In some embodiments, the pharmaceutically acceptable barrier coating is a pharmaceutically acceptable enteric coating. In some embodiments, the barrier coating is hypromellose or polyvinyl alcohol. In some embodiments, the barrier coating is hypromellose. In some embodiments, the composition further comprises one or more pharmaceutically acceptable coating agents. In some embodiments, the coating agent is a methacrylic acid based copolymer, Eudragit L30D55, Acryl- Eze, hydroxypropylmethyl cellulose acetate succinate, polyvinylacetate phthalate, cellulose acetate phthalate or a combination thereof. In some embodiments, the coating agent is a methacrylic acid based copolymer, Eudragit L30D55 or Acryl-Eze. In some embodiments, the composition further comprises one or more pharmaceutically acceptable plasticizers. In some\n\n\n- 7 - \n\n embodiments, the plasticizer is triethyl citrate, triacetin, dibutyl phthalate, diethyl phthalate or glycerin. In some embodiments, the plasticizer is triethyl citrate. In some embodiments, the composition further comprises one or more pharmaceutically acceptable film coating additives. In some embodiments, the film coating additive is talc, glycerol monostearate or colloidal silicon dioxide. In some embodiments, the film coating additive is talc. In some embodiments, the composition further comprises one or more pharmaceutically active compounds. In some embodiments, at least one of the one or more pharmaceutically active compounds has anti-viral activity. In some embodiments, the composition further comprises two pharmaceutically active compounds. In some embodiments, at least one of the two pharmaceutically active compounds has anti-viral activity. In some embodiments, the composition is a unitary dosage form. In some embodiments, M is hydrogen or potassium. In some embodiments, M is potassium. In some embodiments, the composition is suitable for oral administration to a mammal. In some embodiments, the composition is suitable for oral administration to a human. [0004] Disclosed herein, in certain embodiments, is a composition comprising: a compound or\n\n\nmixture of compounds of structure (I): \n\n\n (I); wherein M is hydrogen, sodium, potassium, calcium, or arginine; and one or more diluents; one or more binders; one or more coating agents; one or more dispersing agents; and one or more plasticizers. In some embodiments, the composition is a unitary dosage form. [0005] In some embodiments, the composition is encapsulated. In some embodiments, the composition is encapsulated within a hard gelatin capsule. In some embodiments, M is hydrogen or potassium. In some embodiments, M is potassium. In some embodiments, the diluent is microcrystalline cellulose, silicified microcrystalline cellulose, cellulose, lactose, compressible sugar, mannitol, calcium silicate and calcium phosphate in powder and granular forms, sodium phosphate or sodium carbonate. In some embodiments, the diluent is microcrystalline cellulose. In some embodiments, the binder is hypromellose, povidone, hydroxypropyl cellulose, hydroxyethyl cellulose or starch. In some embodiments, the binder is hypromellose. In some embodiments, the coating agent is a methacrylic acid based copolymers, Eudragit L30D55, Acryl-Eze, hydroxypropylmethyl cellulose acetate succinate, polyvinylacetate phthalate or cellulose acetate phthalate. In some embodiments, the coating agent is a methacrylic acid based copolymer. In some embodiments, the dispersing agent is talc, glycerol monostearate or colloidal silicon dioxide. In some embodiments, the dispersing agent is talc. In some embodiments, the plasticizer is triethyl citrate, triacetin, dibutyl phthalate, diethyl phthalate or glycerin. In some \n\n embodiments, the plasticizer is triethyl citrate. In some embodiments, the composition comprises from about lmg to about lOOOmg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises from about lOmg to about lOOOmg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises from about 50mg to about lOOOmg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about lOOmg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 200mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 300mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 400mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 500mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 600mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 700mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 800mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about 900mg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises about lOOOmg of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises from about 10% to about 90% by weight of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises from about 25% to about 90% by weight of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises from about 50% to about 90% by weight of the compound or mixture of compounds of structure (I). In some embodiments, the composition comprises from about 65% to about 90% by weight of the compound or mixture of compounds of structure (I).\n\n\n[0006] Disclosed herein, in certain embodiments, is a composition comprising: a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n\n (IB); microcrystalline cellulose; hypromellose; methacrylic acid copolymer dispersion; talc; and triethyl citrate. [0007] In some embodiments, the composition comprises: about 214mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form: \n\n\n (IB); about 35mg of microcrystalline cellulose; about 29mg of hypromellose; about 30mg of methacrylic acid copolymer dispersion; about 6mg of talc; and about 3mg of triethyl citrate. In some embodiments, the composition is a unitary dosage form. In some embodiments, the composition is encapsulated. In some embodiments, the composition is encapsulated within a hard gelatin capsule.\n\n\n[0008] Disclosed herein, in certain embodiments, is a composition comprising: from about 60% to about 90% by weight of a compound of structure (IB) or a mixture of a compound of structure\n\n\n(IB) and its free acid form: \n\n\n (IB); from about 5% to about 15% by weight of microcrystalline cellulose; from about 5% to about 15% by weight of hypromellose; from about 5% to about 15% by weight of methacrylic acid copolymer dispersion; from about 0.5% to about 5% by weight of talc; and from about 0.1% to about 3% by weight of triethyl citrate.\n\n\n[0009] In some embodiments, the composition comprises from about 60% to about 80% by weight of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form. In some embodiments, the composition comprises from about 60% to about 75% by weight of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form. In some embodiments, the composition comprises from about 65% to about 70% by weight of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form. In some embodiments, the composition comprises from about 67% by weight of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form. In some embodiments, the composition comprises from about 7% to about 13% by weight of microcrystalline cellulose. In some embodiments, the composition comprises about 11% by weight of microcrystalline cellulose. In some embodiments, the composition comprises from about 7% to about 11% by weight of hypromellose. In some embodiments, the composition comprises about 9% by weight of hypromellose. In some embodiments, the composition comprises from about 5% to about 15% by weight of methacrylic acid copolymer dispersion. In some embodiments, the composition comprises from about 8% to about 12% by weight of methacrylic acid copolymer dispersion. In some embodiments, the composition comprises about 10% by weight of methacrylic acid copolymer dispersion. In some embodiments, the \n\n composition comprises from about 1% to about 4% by weight of talc. In some embodiments, the composition comprises about 2% by weight of talc. In some embodiments, the composition comprises from about 0.2% to about 2.5% by weight of triethyl citrate. In some embodiments, the composition comprises from about 0.5% to about 2% by weight of triethyl citrate. In some embodiments, the composition comprises about 1% by weight of triethyl citrate. In some embodiments, the composition comprises: about 67% by weight of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form; about 11% by weight of microcrystalline cellulose; about 9% by weight of hypromellose; about 10% by weight of methacrylic acid copolymer dispersion; about 2% by weight of talc; and about 1% by weight of triethyl citrate.\n\n\n[0010] Disclosed herein, in certain embodiments, is a composition comprising: a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n\n (IB); microcrystalline cellulose; and hypromellose; wherein the composition is in the form of granules. In some embodiments, the granules will not pass through a 40 mesh screen. In some embodiments, the granules are coated with hypromellose. In some embodiments, the coated granules are further coated with a composition comprising: methacrylic acid copolymer dispersion; talc; and triethyl citrate.\n\n\n[0011] In some embodiments, the composition is a unitary dosage form. In some embodiments, the composition is encapsulated. In some embodiments, the composition is encapsulated within a hard gelatin capsule.\n\n\n[0012] Disclosed herein, in certain embodiments, is a composition comprising: about 214mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n\n (IB); about 35mg of microcrystalline cellulose; about 13.5 mg of hypromellose; wherein the composition is in the form of granules which do not pass through a 40 mesh screen; and wherein the granules are coated with about 15.3 mg hypromellose; and wherein the coated granules are further coated with a composition comprising: about 30.4mg of methacrylic acid copolymer dispersion; about 6.1mg of talc; and about 3.0mg of triethyl citrate. \n\n [0013] In some embodiments, the composition is encapsulated. In some embodiments, the composition is encapsulated within a hard gelatin capsule. In some embodiments, not less than about 85% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form is released within 30 mins; and not less than about 90% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form is released within 45 mins; as measured using United States Pharmacopoeia <711> method Disclosed herein, in certain embodiments, is a, using Disclosed herein, in certain embodiments, is apparatus 2 operating at 50 rpm in 900 mL of dissolution medium at pH 6.8 at 37°C. [0014] Disclosed herein, in certain embodiments, is a composition comprising: a compound or\n\n\nmixture of compounds of structure (I): \n\n\n (I); wherein M is hydrogen, sodium, potassium, calcium, or arginine; a diluent; and a disintegrant.\n\n\n[0015] In some embodiments, the diluent is microcrystalline cellulose. In some embodiments, the microcrystalline cellulose comprises from about 40% to about 60% by weight of the composition. In some embodiments, the microcrystalline cellulose comprises about 50% by weight of the composition. In some embodiments, the disintegrant is croscarmellose sodium. In some embodiments, the croscarmellose sodium comprises from about 0.1% to about 2% by weight of the composition. In some embodiments, the croscarmellose sodium comprises from about 0.5% by weight of the composition. In some embodiments, the composition comprises: about 50% by weight microcrystalline cellulose; and about 0.5% by weight croscarmellose sodium.\n\n\n[0016] In some embodiments, M is hydrogen and/or potassium. In some embodiments, M is potassium. In some embodiments, the composition comprises at least 50% by weight of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises at least 60% by weight of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises at least 70% by weight of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises at least 80% by weight of a compound or mixture of compounds of structure (I). In some embodiments, the composition comprises: about 50% by weight of a compound or mixture of compounds of structure (I); about 49.4% by weight of microcrystalline cellulose; and about 0.55% by weight of croscarmellose sodium.\n\n\n[0017] In some embodiments, the composition is a unitary dosage form. In some embodiments, the composition is encapsulated within a capsule. In some embodiments, the capsule comprises \n\n hard gelatin. In some embodiments, the hard gelatin capsule is over-encapsulated. In some embodiments, the hard gelatin capsule is over-encapsulated within a hypromellose capsule. [0018] Disclosed herein, in certain embodiments, is a composition comprising: about lOOmg of a\n\n\ncompound of structure \n\n\n about 98.9mg of microcrystalline cellulose; and about l.lmg of croscarmellose sodium. In some embodiments, the composition is encapsulated.\n\n\n[0019] Disclosed herein, in certain embodiments, is a composition comprising: about 106.8mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid\n\n\nform: \n\n\n (IB); about 92.1mg of microcrystalline cellulose; and about l.lmg of croscarmellose sodium.\n\n\n[0020] Disclosed herein, in certain embodiments, is a composition comprising: about 213mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n\n (IB); microcrystalline cellulose; and croscarmellose sodium. [0021] Disclosed herein, in certain embodiments, is a composition comprising: about 430mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n\n (IB); microcrystalline cellulose; and croscarmellose sodium. [0022] Disclosed herein, in certain embodiments, is a composition comprising: about 860mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n\n (IB); microcrystalline cellulose; and croscarmellose sodium. \n\n [0023] Disclosed herein, in certain embodiments, is a composition comprising: about lOOOmg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form:\n\n\n \n\n (IB); microcrystalline cellulose; and croscarmellose sodium. [0024] In some embodiments, the composition is encapsulated. In some embodiments, the composition is encapsulated within a hard gelatin capsule. In some embodiments, the hard gelatin capsule is over-encapsulated. In some embodiments, the hard gelatin capsule is over- encapsulated within a hypromellose capsule. In some embodiments, not less than about 80% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form dissolves within 30 minutes, as measured using United States Pharmacopoeia A apparatus 1 operating at 75 rpm in 900 mL water at 37°C. In some embodiments, the in vitro dissolution rate as measured using United States Pharmacopoeia A apparatus 1 operating at 75 rpm in 900 mL water at 37°C is not less than about 80% of the compound of structure (IB) is released within 30 minutes. In some embodiments, not less than about 78% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form dissolves within 30 minutes; and not less than about 95% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form dissolves within 45 minutes; as measured using United States Pharmacopoeia Disclosed herein, in certain embodiments, is apparatus 1 operating at 75 rpm in 900 mL water at 37°C. [0025] Disclosed herein, in certain embodiments, is a composition comprising: a compound of\n\n\nstructure (I) or a mixture of compounds of structure (I): \n\n\n (I); wherein\n\n\nM is hydrogen, sodium, potassium, calcium, or arginine; a diluent; a binder; a lubricant; and a coating. In some embodiments, the composition is a unitary dosage form. In some embodiments, the composition is a monolithic solid. [0026] Disclosed herein, in certain embodiments, is a composition comprising: about 200mg of a\n\n\ncompound of structure \n\n\n \n\n [0027] Disclosed herein, in certain embodiments, is a composition comprising: from about 60% to about 90% by weight of a compound of structure (IB) or a mixture of a compound of structure\n\n\n(IB) and its free acid form: \n\n\n from about 5% to about 15% by weight of microcrystalline cellulose; from about 2.5% to about 10% by weight of acryl-eze white from about 2.5% to about 10% by weight of hypromellose; from about 0.25% to about 2% by weight of magnesium stearate.\n\n\n[0028] Disclosed herein, in certain embodiments, is a composition comprising: about 213.6mg of a compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid\n\n\nform: \n\n\n about 34.0mg of microcrystalline cellulose; about 23.1mg of hypromellose; about 1.3mg of magnesium stearate; and about 27.1mg of acryl-eze white.\n\n\n[0029] In some embodiments, the granules are blended with magnesium stearate. In some embodiments, the composition is compressed into a monolithic solid. In some embodiments, the composition is coated with hypromellose. In some embodiments, the composition is further coated with acryl-eze white. In some embodiments, the in vitro dissolution rate as measured using United States Pharmacopoeia A apparatus 2 operating at 50 rpm in 700 mL of dissolution medium for two hours at pH 1.2 at 37°C is about 0% to about 5% of the compound of structure (IB) released within 2 hours; and after 2 hours, in 900 mL of buffer at pH 6.8 at 37°C is about 15% to about 45% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form released within 30 mins; is about 50% to about 85% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form released within 45 mins; is not less than about 80% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form released within 60 mins; is not less than about 90% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form released within 90 mins; and is not less than about 95% of the compound of structure (IB) or a mixture of a compound of structure (IB) and its free acid form released within 100 mins.\n\n\n[0030] Disclosed herein, in certain embodiments, is a method for decreasing uric acid levels in one or more tissues or organs of a subject in need of decreased uric acid levels, comprising \n\n administering to the subject a uric acid level decreasing amount of a composition disclosed herein.\n\n\n[0031] Disclosed herein, in certain embodiments, is a method for reducing uric acid production, increasing uric acid excretion or both in a subject, comprising administering to the subject an effective amount of a composition disclosed herein.\n\n\n[0032] Disclosed herein, in certain embodiments, is a method for treating or preventing hyperuricemia in a subject comprising administering to the subject an effective amount of a composition disclosed herein. [0033] Disclosed herein, in certain embodiments, is a method of treating a subject suffering from a condition characterized by abnormal tissue or organ levels of uric acid comprising administering to the subject an effective amount of a composition disclosed herein. In some embodiments, the condition is selected from gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis. [0034] Disclosed herein, in certain embodiments, is a method for preventing a condition characterized by abnormal tissue levels of uric acid in a subject at increased risk of developing the condition, comprising administering to the subject an effective amount of a composition disclosed herein. [0035] Disclosed herein, in certain embodiments, is a method for treating gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosisin a subject comprising administering to the subject an effective amount of a composition disclosed herein.\n\n\n[0036] Disclosed herein, in certain embodiments, is a method for treating gout in a subject comprising administering to the subject an effective amount of a composition disclosed herein. [0037] Disclosed herein, in certain embodiments, is a method for preventing the formation or reducing the size of tophi/tophus in a subject, comprising administering to the subject an effective amount of a composition disclosed herein.\n\n\n[0038] In some embodiments, the AUCτ (μg\n»\nhr/mL) of a composition disclosed herein is between about 0.6 and about 18. In some embodiments, the AUCτ (μg»hr/mL) of a composition disclosed herein is between about 2.5 and about 11. In some embodiments, the AUCτ (μg\n»\nhr/mL) of a composition disclosed herein is between about 4.8 and about 8. In some embodiments, the Cmax (μg/mL) of a composition disclosed herein is between about 0.15 and about 6. In some \n\n embodiments, the Cmax (μg/mL) of a composition disclosed herein is between about 0.5 and about 5. In some embodiments, the Cmax (μg/mL) of a composition disclosed herein is between about 1 and about 4.\n\n\n[0039] In some embodiments, a composition disclosed herein provides the metabolite M6 (2-(5- bromo-4-(4-cyclopropylnaphthalen-l-yl)-4H-l,2,4-triazol-3-ylthio)acetic acid). In some embodiments, a composition disclosed herein provides an AUCτ (μg\n»\nhr/mL) of metabolite M6 between about 2.5 and about 30. In some embodiments, a composition disclosed herein provides an AUCτ (μg\n»\nhr/mL) of metabolite M6 between about 8 and about 25. In some embodiments, a composition disclosed herein provides an AUCτ ( (μg\n»\nhr/mL) of metabolite M6 between about 12 and about 20. In some embodiments, the Cmax (μg/mL) of metabolite M6 is between about 0.25 and about 4. In some embodiments, the Cmax (μg/mL) of metabolite M6 is between about 1 and about 3. In some embodiments, the Cmax (μg/mL) of metabolite M6 is between about 2.4 and about 3. In some embodiments, the molar ratio of the AUCτ (μg\n»\nhr/mL) of the metabolite M6 to the AUCτ (μg\n»\nhr/mL) of Compound I is about 2 to about 11. In some embodiments, the molar ratio of the AUCτ (μg\n»\nhr/mL) of the metabolite M6 to the AUCτ (μg\n»\nhr/mL) of\n\n\nCompound I is about 4 to about 8. In some embodiments, the molar ratio of the Cmax (μg/mL) of the metabolite M6 to the Cmax (μg/mL) of Compound I is about is about 1 to about 7. In some embodiments, the molar ratio of the Cmax (μg/mL) of the metabolite M6 to the Cmax (μg/mL) of Compound I is about is about 2 to about 6. INCORPORATION BY REFERENCE\n\n\n[0040] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.\n\n\nBRIEF DESCRIPTION OF THE DRAWINGS [0041] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which: [0042] Figure 1 shows a flow chart depicting the steps for the preparation of the composition described in example 2 A.\n\n\n[0043] Figure 2 shows a flow chart depicting the steps for the preparation of the composition described in example 3A.\n\n\n[0044] Figure 3 shows a flow chart depicting the steps for the preparation of the composition described in example 4A. \n\n [0045] Figure 4 shows a flow chart depicting the steps for the preparation of the composition described in example 5A.\n\n\n[0046] Figure 5 shows Serum Uric Acid Levels (measured on Day 9), after administration of compositions comprising compound 1. DETAILED DESCRIPTION OF THE INVENTION\n\n\n[0047] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Pharmaceutical compositions\n\n\n[0048] Described herein are pharmaceutical compositions comprising 4-(2-(5-bromo-4-(l- cyclopropylnaphthalen-4-yl)-4H- 1 ,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions comprise an effective amount of 4-(2-(5-bromo-4-(l- cyclopropylnaphthalen-4-yl)-4H- 1 ,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions comprise an effective amount of 4-(2-(5-bromo-4-(l- cyclopropylnaphthalen-4-yl)-4H- 1 ,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier. In some embodiments the pharmaceutical compositions are for the treatment of disorders. In some embodiments the pharmaceutical compositions are for the treatment of disorders in a mammal. In some embodiments the pharmaceutical compositions are for the treatment of disorders in a human. Methods: Aberrant uric Acid Levels [0049] The present invention also provides methods useful for diseases or disorders related to aberrant uric acid levels. The method includes administering an effective amount of a composition as described herein to a subject with aberrant levels of uric acid such as to restore acceptable or non-aberrant levels of uric acid. The present invention also provides methods useful for decreasing uric acid levels in one or more tissues or organs of a subject in need of decreased uric acid levels, comprising administering to the subject a uric acid level decreasing \n\n amount of a composition as described herein. The present invention also provides methods useful for reducing uric acid production, increasing uric acid excretion or both in a subject, comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating or preventing hyperuricemia in a subject comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating a subject suffering from a condition characterized by abnormal tissue or organ levels of uric acid comprising administering to the subject an effective amount of a composition as described herein The present invention also provides methods useful for treating a subject suffering from gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis, comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for preventing a condition characterized by abnormal tissue levels of uric acid in a subject at increased risk of developing the condition, comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley- Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosisin a subject comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for treating gout in a subject comprising administering to the subject an effective amount of a composition as described herein. The present invention also provides methods useful for preventing the formation or reducing the size of tophi/tophus in a subject, comprising administering to the subject an effective amount of a composition as described herein. Terminology [0050] The term \"subject\", \"patient\" or \"individual\" as used herein in reference to individuals suffering from a disorder, and the like, encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non- human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non- \n\n mammals include, but are not limited to, birds, fish and the like. In one embodiment of the methods and compositions provided herein, the mammal is a human.\n\n\n[0051] The terms \"effective amount\", \"therapeutically effective amount\" or \"pharmaceutically effective amount\" as used herein, refer to an amount of at least one agent or compound being administered that is sufficient to treat or prevent the particular disease or condition. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an \"effective amount\" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease. An appropriate \"effective\" amount in any individual case may be determined using techniques, such as a dose escalation study.\n\n\n[0052] The term \"pharmaceutically acceptable\" as used herein, refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compounds described herein, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.\n\n\n[0053] The terms \"composition\" and \"pharmaceutical composition,\" as used herein, refer to 4-(2- (5-bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof, optionally mixed with at least one pharmaceutically acceptable chemical component, such as, though not limited to carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, excipients and the like.\n\n\n[0054] The term \"pharmaceutically acceptable salt\" as used herein, includes salts of 4-(2-(5- bromo-4-(4-cyclopropylnaphthalen-l-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoate with any pharmaceutically acceptable cation, that retain the biological effectiveness of the free acid. For example, the free acid group of 4-(2-(5-bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H- l,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid may react with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N\n+\n(C \n1-4\n alkyl)4, and the like. Representative organic amines useful for the formation of base addition salts include arginine, lysine, ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. Salts can be prepared in situ during final isolation and purification, or by separate reaction and isolation of the salt thus formed. \n\n [0055] The term \"prodrug\" as used herein, refers to a drug precursor that, following administration to a subject and subsequent absorption, is converted to an active, or a more active species via some process, such as conversion by a metabolic pathway. Thus, the term encompasses any derivative of a compound, which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or a pharmaceutically active metabolite or residue thereof. Some prodrugs have a chemical group present on the prodrug that renders it less active and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug the active drug is generated. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g. by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g. the brain or lymphatic system). Doses\n\n\n[0056] The total amount of 4-(2-(5-bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3- ylthio)acetamido)-3-chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof, administered will firstly be dependent on the mammal being treated. In the instances where administration is to a human subject, the amount will normally be determined by the prescribing physician with the dosage generally varying according to the age, sex, diet, weight, general health and response of the individual patient, the severity of the patient's symptoms, the precise indication or condition being treated, the severity of the indication or condition being treated, time of administration, route of administration, the disposition of the composition, rate of excretion, drug combination, and the discretion of the prescribing physician. The pharmaceutical composition may be in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose. Determination of the proper dosage for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. The amount and frequency of administration, and if applicable other therapeutic agents and/or therapies, will be regulated according to the judgment of the attending clinician (physician) considering such factors as described above. Thus the amount of pharmaceutical composition to be administered may vary widely. Administration may occur in an amount of between about 0.001 mg/kg of body weight to about 100 mg/kg of body weight per day (administered in single or divided doses), or at least about 0.1 \n\n mg/kg of body weight per day. A particular therapeutic dosage includes, e.g., from about 0.01 mg to about 7000 mg of compound, or, e.g., from about 0.05 mg to about 2500 mg. The quantity of 4-(2-(5-bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid, prodrugs, and/or pharmaceutically acceptable salts thereof in a unit dose may occur in an amount of between about lmg to 3000 mg, from about 2 mg to 2000 mg, or 10 mg to 2000 mg, according to the particular application. In some embodiments, the amount is from about lOOmg to about 1500mg, from about 150mg to about 1200mg, or from about 200mg to about lOOOmg. In further or additional embodiments, the amount is at least lOOmg, at least 200mg, at least 250mg, at least 300mg, at least 400mg, at least 500mg, at least 600mg, at least 700mg, at least 750mg, at least 800mg, at least 900mg or at least lOOOmg. In further or additional embodiments, the amount is about lOOmg, about 200mg, about 250mg, about 300mg, about 400mg, about 500mg, about 600mg, about 700mg, about 750mg, about 800mg, about 900mg or about lOOOmg. In some embodiments the compositions are administered once daily. In further or additional embodiments, the compositions are administered twice daily. In further or additional embodiments, the compositions are administered at least twice daily. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day. In combinational applications in which the compound is not the sole therapy, it may be possible to administer lesser amounts of compound and still have therapeutic or prophylactic effect. Dosage Forms\n\n\n[0057] The pharmaceutical compositions described herein are typically useful for oral administration as solid dosage forms, such as tablets, capsules, pills, powders, granules and the like. They may be administered for immediate release, delayed release or sustained release of 4- (2-(5-bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid, prodrugs, and/or a pharmaceutically acceptable salts thereof. Kits\n\n\n[0058] The compositions and methods described herein provide kits for the treatment of diseases and disorders. These kits comprise a compositions described herein in a container and, optionally, instructions teaching the use of the kit. Such kits may also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the composition, and/or which describe dosing, administration, side effects, drug interactions, or other information useful to the health care provider. Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo \n\n models and studies based on human clinical trials. Kits described herein can be provided, marketed and/or promoted to health providers, including physicians, nurses, pharmacists, formulary officials, and the like. Kits may also, in some embodiments, be marketed directly to the consumer.\n\n\n[0059] The compositions described herein are also useful for diagnostics and as research reagents. For example, the compounds described herein, either alone or in combination with other compounds, may be useful as tools in differential and/or combinatorial analyses to elucidate expression patterns of genes expressed within cells and tissues. As one non-limiting example, expression patterns within cells or tissues treated with one or more compounds are compared to control cells or tissues not treated with compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns. [0060] Besides being useful for human treatment, the compositions described herein may also be useful for veterinary treatment of other animals.\n\n\nEXAMPLES\n\n\n[0061] The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. / Chemical Syntheses\n\n\nExample 1 : Synthesis of 4-(2-(5-bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3- ylthio)acetamido)-3-chlorobenzoic acid (compound 1)\n\n\n\n\n\n\n\n\n[0062] 4-(2-(5-Bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid (compound 1) was prepared as described previously (see US published patent application US 2006-0270725) and outlined below. \n\n\n\n\n -C yclopropylnaphthalen- 1 -amine [0063] Palladium acetate (23mg, 0.1 mmol) was added to a solution of 4-bromonaphthalen-l- amine (500mg, 2.01 mmol), cyclopropyl boronic acid (225mg, 2.62 mmol), potassium phosphate (1.49g, 7.04 mmol) and tricyclohexylphosphine (56mg, 0.2 mmol) in toluene (10 mL) and water (0.4 mL) under nitrogen atmosphere. The mixture was heated at 100\n0\nC for 3h and then cooled to room temperature. Water was added and the mixture extracted with ethyl acetate, dried over sodium sulfate and concentrated to give crude 4-cyclopropylnaphthalen-l -amine (550mg) which was used in the next step without further purification. \n\n\n l-Cyclopropyl-4-isothiocyanatonaphthalene [0064] Sodium bicarbonate (7mL, sat. solution) and thiophosgene (0.2mL, 2.6mmol) were added to a solution of 4-cyclopropylnaphthalen-l -amine (440mg, 2.6mmol) in dichloromethane (14mL) and the mixture stirred at room temperature for Ih. The organic layer was separated, dried over sodium sulfate and concentrated to give crude l-cyclopropyl-4-isothiocyanatonaphthalene (877mg, 99%) which was used in the next step without further purification.\n\n\n5-Amino-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazole-3-thiol\n\n\n\n\n\n[0065] Aminoguanidine hydrochloride (355mg, 3.2mmol) and diisopropyl ethylamine (0.56mL, 3.2mmol) were added to a solution of l-cyclopropyl-4-isothiocyanatonaphthalene (447mg, 2.1mmol) in dimethylformamide (DMF, 3mL) and the mixture stirred at 50\n0\nC for 18 hours. The mixture was then concentrated and aqueous sodium hydroxide solution (2M, 10 mL) added. The mixture was stirred at 50\n0\nC for 18 hours, cooled to room temperature and neutralized with aqueous IN HCl. The resulting precipitate was isolated to give 5-amino-4-(l- cyclopropylnaphthalen-4-yl)-4H- 1 ,2,4-triazole-3 -thiol (240mg, 44%). 4-(2-(5-Amino-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid\n\n\n\n\n\n\n\n\n[0066] 5-Amino-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazole-3-thiol (789mg, 2.79mmol) and 3-chloro-4-(2-chloroacetamido)benzoic acid (693mg, 2.79mmol) were dissolved in DMF (6mL) and the solution stirred at 50\n0\nC for 18 hours. Water was then added and the mixture extracted with ethyl acetate. The organic layer was separated, dried over sodium sulfate and \n\n concentrated to give 4-(2-(5-amino-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3- ylthio)acetamido)-3-chlorobenzoic acid (1.04g, 75%).\n\n\n4-(2-(5-Bromo-4-(l-cvclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid\n\n\n\n\n\n\n\n\n[0067] Dichloroacetic acid (0.35 rnL, 4.2 mmol) was added to a mixture of give 4-(2-(5-amino- 4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid (1.04g, 2.1mmol), benzyltriethyl ammonium bromide (1.65g, β.lmmol) and sodium nitrite (2.9g, 42.1mmol) in dibromomethane (44mL). The mixture was stirred at room temperature for 18 hours in the dark, then concentrated and the resulting residue purified by column chromatography (95% dichloromethane /5% methanol) to give 4-(2-(5-bromo-4-(l- cyclopropylnaphthalen-4-yl)-4H- 1 ,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid (393 mg, 34%). II Preparation and Analysis of Compositions Example 2A: Preparation of Immediate Release Capsules, 100 mg\n\n\n[0068] 4-(2-(5-Bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid (compound 1 , prepared as described herein) and microcrystalline cellulose were screened through a #40 mesh screen. The screened mixture and croscarmellose sodium were blended together using a Turbular Type TlOB Shaker Mixer for approximately 15 minutes. 200mg of the powder blend was encapsulated into a size # 2 dark green opaque hard gelatin Coni-Snap capsule.\n\n\n[0069] Two batches of capsules were prepared according to this procedure; the first batch size was 3380 capsules and the second 4400 capsules. The capsules were analyzed for identity, strength, purity, content uniformity and dissolution profiles, as described below. Unit Composition\n\n\n \n\n Batch Composition\n\n\n\n\n\n\n\n\n* As free acid, equivalent to 106.8 mg of potassium salt. The quantity of compound 1 used was adjusted based on the actual potency and a corresponding adjustment with microcrystalline cellulose made.\n\n\nExample 2B: Identification of compound 1 in capsules prepared in example 2A [0070] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase of 45% 10 mM KH\n2\nPO\n4\n (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to confirm the identity of compound 1. The capsules were extracted with 50/50 (v/v) acetonitrile/water. The identity of compound 1 was determined by comparing the retention time of the peak in the sample preparation with that of a standard preparation and showed relative retention values (Rr) 0.97 - 1.03 relative to reference standard, confirming the presence of compound 1. Example 2C: Determination of quantity of compound 1 in capsules prepared in example 2A [0071] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column,; mobile phase of 45% 10 mM KH\n2\nPO\n4\n (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to determine the amount of compound 1 present. The capsules were extracted with 50/50 (v/v) acetonitrile/water. The quantity of compound 1 present was determined by comparing sample peaks with standard preparations obtained concomitantly. Example 2D: Determination of impurities in capsules prepared in example 2A\n\n\n[0072] A gradient elution reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase A lO mM KH\n2\nPO\n4\n (pH 3.0) and mobile phase B acetonitrile) with UV detection at 220 nm, was used to determine impurity content. The capsules were extracted with 50/50 (v/v) acetonitrile/water. Impurities were determined by comparing the impurity peak areas in the sample preparation chromatogram to the area of the compound 1 peak in the standard preparation obtained concomitantly. Known impurities were calculated by \n\n applying the response factor of the respective impurities. The method reporting limit was 0.05%. The results of the analyses are shown in the table below.\n\n\n\n\n\n\n\n\nNMT - not more than; RRT = relative retention time\n\n\nExample 2E: Determination of water content in capsules prepared in example 2 A\n\n\n[0073] Water content was determined using the USP <921>, Karl Fischer method. The results are shown below: \n\n\n\n\n\nExample 2F: Dissolution Profile of compound 1 from capsules prepared in example 2A [0074] Dissolution of compound 1 from the capsules was determined in 900 mL of water at 37°C using USP Apparatus 1 operating at 75 rpm. A filtered sample of the dissolution medium was taken at the specified time(s) and analyzed by an HPLC procedure using the same chromatographic conditions as for content determination, as described above. The release was determined by comparing the peak responses of the sample chromatograms to the peak responses of the standard chromatograms obtained concomitantly and the results are shown below.\n\n\n\n\n\n\n\n\nNLT = not less than; RRT = relative retention time\n\n\nExample 3A: Preparation of Over-Encapsulated Capsules, 100 mg\n\n\n[0075] Size 1 white Vcaps capsule shells were loaded into Profill encapsulator trays and the\n\n\nVcaps caps were separated from the capsule bodies. A size # 2 dark green opaque hard gelatin\n\n\nConi-Snap capsule (prepared as described in example 2A above) was placed into each of the\n\n\nVcaps capsule bodies. The capsule caps were placed back onto capsule bodies using the Profill equipment and gently pressed shut to secure the caps on the bodies. This process was repeated using additional trays as necessary. \n\n [0076] Two batches of capsules were prepared according to this procedure; the first batch size was 680 capsules and the second 2200 capsules. The capsules were analyzed for identity, strength, purity, content uniformity and dissolution profiles, as described below. Unit Composition\n\n\n \n\n a As free acid, equivalent to 106.8 mg of potassium salt. The quantity of compound 1 used was adjusted based on the actual potency and a corresponding adjustment with microcrystalline cellulose made.\n\n\nExample 3B: Identification of compound 1 in capsules prepared in example 3 A [0077] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase of 45% 10 mM KH\n2\nPO\n4\n (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to confirm the of identity of compound 1. The capsules were extracted with 50/50 (v/v) acetonitrile/water. The identity of compound 1 was determined by comparing the retention time of the peak in the sample preparation with that of a standard preparation and showed relative retention values (Rr) 0.97 - 1.03 relative to reference standard, confirming the presence of compound 1.\n\n\nExample 3C: Determination of quantity of compound 1 in capsules prepared in example 3 A [0078] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column,; mobile phase of 45% 10 mM KH\n2\nPO\n4\n (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to determine the amount of compound 1 present. The capsules were extracted with 50/50 (v/v) acetonitrile/water. The quantity of compound 1 present was determined by comparing sample peaks with standard preparations obtained concomitantly and is shown below. \n\n\n\n\n\nExample 3D: Determination of impurities in capsules prepared in example 3 A \n\n [0079] A gradient elution reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase A lO mM KH\n2\nPO\n4\n (pH 3.0) and mobile phase B acetonitrile) with UV detection at 220 nm, was used to determine impurity content. The capsules were extracted with 50/50 (v/v) acetonitrile/water. Impurities were determined by comparing the impurity peak areas in the sample preparation chromatogram to the area of the compound 1 peak in the standard preparation obtained concomitantly. Known impurities were calculated by applying the response factor of the respective impurities. The method reporting limit was 0.05%. The results of the analyses are shown in the table below.\n\n\n\n\n\n\n\n\nNMT - not more than; RRT = relative retention time\n\n\nExample 3E: Determination of water content in capsules prepared in example 3 A\n\n\n[0080] Water content was determined using the USP <921>, Karl Fischer method. The results are shown below: \n\n\n\n\n\nExample 3F: Dissolution Profile of compound 1 from capsules prepared in example 3 A [0081] Dissolution of compound 1 from the capsules was determined in 900 mL of water at 37°C using USP Apparatus 1 operating at 75 rpm. A filtered sample of the dissolution medium was taken at the specified times (15, 30, 45 and 60 minutes) and analyzed by HPLC using the same chromatographic conditions as described above for content determination. Compound release was determined by comparing the peak responses of the sample chromatograms to the peak responses of the standard chromatograms obtained concomitantly and the results are shown below. \n\n Batch number 1 2\n\n\nDissolution profile Ave. RSD Min. Max. Ave. RSD Min. Max.\n\n\n15min = 7% 122% 0% 15min = 8% 163% 0%\n\n\n20% 34%\n\n\n30min = 92% 11% 77% 30min = 93% 4% 87%\n\n\n102% 97%\n\n\n45min = 101% 2% 98% 45min = 107% 3% 101%\n\n\n103% 109%\n\n\n60min = 101% 2% 98% 60min = 107% 3% 102%\n\n\n103% 109%\n\n\nNLT = not less than; RRT = relative retention time\n\n\nExample 4A: Preparation of Enteric Coated Granules, 200 mg\n\n\n[0082] 4-(2-(5-Bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid (compound 1 , prepared as described herein) was milled and then blended in a planetary mixer with microcrystalline cellulose and hypromellose. The blended ingredients in the planetary mixer were granulated with purified water and the wet granulation was sieved through a No. 8 mesh screen and dried on trays in an oven at 4O\n0\nC to a moisture content of less than 5% as determined by loss on drying (LOD). The dried granulation was sieved through a No. 40 mesh screen; the granules retained on the 40 mesh screen were collected, and the remaining fines transferred to recovered waste. Using a fluidized bed coating unit, a hypromellose solution (7% w/w in purified water) was applied to the > 40 mesh granules, followed by application of a talc, triethyl citrate and methacrylic acid dispersion (previously sieved through an 80 mesh screen).\n\n\nApproximately 317 mg of the coated granules was manually filled into each of 1700 hard gelatin capsules, Swedish Orange Opaque, Size 1.\n\n\n[0083] One batch of 1700 capsules was prepared according to this procedure. The capsules were analyzed for identity, strength, purity, content uniformity and dissolution profiles, as described below.\n\n\nUnit Composition\n\n\n \n\n Batch Composition\n\n\n \n\n a As free acid, equivalent to 213.6 mg of potassium salt. The quantity of compound 1 used was adjusted based on the actual potency and a corresponding adjustment with microcrystalline cellulose made. b Quantity sufficient to facilitate granule formation, removed during the drying process \nc\n Eudragit L30D-55 is a dispersion containing 30% solids\n\n\nExample 4B: Identification of compound 1 in capsules prepared in example 4A\n\n\n[0084] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase of 45% 1OmM KH2PO4 (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to confirm the identity of compound 1. The capsules were extracted with 20:80 (v/v) methanol/phosphate buffer (pH 7.4) and diluted 1 :10 with methanol/water (20:80 v/v ratio). The target concentration of compound 1 for assay is 0.1 mg/mL. The identity of compound 1 was determined by comparing the retention time of the peak in the sample preparation with that of a standard preparation and showed relative retention values (Rr) 1.00 ± 0.03 relative to reference standard, confirming the presence of compound 1.\n\n\n[0085] Example 4C: Determination of quantity of compound 1 in capsules prepared in example\n\n\n4A\n\n\n[0086] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column,; mobile phase of 45% 10 mM KH\n2\nPO\n4\n (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to determine the amount of compound 1 present. The capsules \n\n were extracted with extracted with 20:80 (v/v) methanol/phosphate buffer (pH 7.4) and diluted 1 :10 with methanol/water (20:80 v/v ratio). The target concentration of compound 1 for assay is 0.1 mg/mL. The quantity of compound 1 present was determined by comparing sample peaks with standard preparations obtained concomitantly, and confirmed the quantity to be 98.2%, within the 90.0 - 110.0 % limit set.\n\n\nExample 4D: Determination of impurities in capsules prepared in example 4A [0087] A gradient elution reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase A lO mM KH\n2\nPO\n4\n (pH 3.0) and mobile phase B acetonitrile) with UV detection at 220 nm, was used to determine impurity content. The capsules were extracted with 20/80 (v/v) methanol/phosphate buffer (pH 7.4). Impurities were determined by comparing the impurity peak areas in the sample preparation chromatogram to the area of the compound 1 peak in the standard preparation obtained concomitantly. Known impurities were calculated by applying the response factor of the respective impurities. The method reporting limit was 0.05%. The results of the analyses are shown in the table below.\n\n\n\n\n\n\n\n\nExample 4E: Determination of water content in capsules prepared in example 4 A [0088] Water content was determined using the USP <921>, Karl Fischer method and measured at 6.9%.\n\n\nExample 4F: Dissolution Profile of compound 1 from capsules prepared in example 4A [0089] Dissolution of compound 1 from the capsules was determined following the principles of the USP <711> method A for delayed-release dosage forms, using USP Apparatus 2 at 37°C, set at 50 rpm. Acid stage was performed for 2 hours in 700 mL of dissolution medium at pH 1.2 followed by buffer stage performed in 900 mL of dissolution medium at pH 6.8. A filtered \n\n aliquot of the test dissolution medium was taken at the specified times (15, 30, 45 and 60 minutes) and analyzed by HPLC using the same chromatographic conditions as described above for content determination. Compound release was determined by comparing the peak responses of the sample chromatograms to the peak responses of the standard chromatograms obtained concomitantly and the results are shown below.\n\n\n\n\n\n\n\n\nNMT = not more than; RRT = relative retention time\n\n\nExample 5A: Preparation of Enteric Coated Tablets, 200 mg\n\n\n[0090] 4-(2-(5-Bromo-4-(l-cyclopropylnaphthalen-4-yl)-4H-l,2,4-triazol-3-ylthio)acetamido)-3- chlorobenzoic acid (compound 1, prepared as described herein) was milled through a Fitzmill fitted with a 0.033\" round-hole screen. The milled compound 1, microcrystalline cellulose and hypromellose were blended with a Robot Coupe RSI-3 VG high-shear roto-granulator for approximately 5 minutes and the blended ingredients granulated with purified water. The wet granulation was sieved through a No. 10 mesh screen and dried on trays in an oven at 4O\n0\nC to a moisture content of NMT 3% as determined by loss on drying (LOD). The dried granulation was sieved through a No. 10 mesh screen and approximately half of the granulation was charged into a Bohle MC-5 (5.0 liter) bin. Magnesium stearate, NF was sieved through a No. 30 mesh screen into the MC-5 bin and the remaining granulation was charged to the bin. The mixture was \n\n blended with a Bohle LM 40 Bin blender at 25 RPM for 3 minutes and the blended granulation compressed to a target tablet weight of 262 mg using a rotary tablet press. A 7% w/w coating solution of hypromellose 2910, in purified water was prepared using a lab mixer and applied to the compressed tablets using a Vector LCDS-3 coating system to achieve an approximate 3% weight gain (~8 mg/tablet). An 18% w/w enteric coating suspension of Acryl-Eze White (methacrylic acid co-polymer) in purified water was prepared using a lab mixer, and the suspension applied to the previously coated tablets using the Vector LCDS-3 coating system to achieve an approximate 10% weight gain (~27 mg/tablet). The isolated tablets were white, caplet-shaped tablets approximately 0.2\" x 0.43\" in dimension, weighing approximately 298 mg each and containing 200mg of compound 1 (present as the potassium salt). [0091] One batch of 1700 capsules was prepared according to this procedure. The capsules were analyzed for identity, strength, purity, content uniformity and dissolution profiles, as described below. Unit Composition\n\n\n\n\n\n\n\n\nBatch Composition\n\n\n \n \na\n As free acid, equivalent to 213.6 mg of potassium salt. The quantity of compound 1 used was adjusted based on the actual potency and a corresponding adjustment with microcrystalline cellulose made. b Quantity sufficient to facilitate granule formation, removed during the drying process Example 5B: Identification of compound 1 in capsules prepared in example 5 A\n\n\n[0092] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase of 45% 1OmM KH\n2\nPO\n4\n (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to confirm the identity of compound 1. The capsules were extracted with 20:80 (v/v) methanol/phosphate buffer (pH 7.4) and diluted 1 :10 with methanol/water (20:80 v/v ratio). The target concentration of compound 1 for assay is 0.1 mg/mL. The identity of compound 1 was determined by comparing the retention time of the peak in the sample preparation with that of a standard preparation and showed relative retention values (Rr) 1.00 ± 0.03 relative to reference standard, confirming the presence of compound 1. Example 5C: Determination of quantity of compound 1 in capsules prepared in example 5 A [0093] An isocratic reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column,; mobile phase of 45% 10 mM KH2PO4 (pH 3.0) and 55% acetonitrile) with UV detection at 220 nm, was used to determine the amount of compound 1 present. The capsules were extracted with extracted with 20:80 (v/v) methanol/phosphate buffer (pH 7.4) and diluted 1 :10 with methanol/water (20:80 v/v ratio). The target concentration of compound 1 for assay is 0.1 mg/mL. The quantity of compound 1 present was determined by comparing sample peaks with standard preparations obtained concomitantly, and confirmed the quantity to be 102.8%, within the 90.0 - 110.0 % limit set.\n\n\nExample 5D: Determination of impurities in capsules prepared in example 5 A [0094] A gradient elution reversed-phase HPLC method, (4.6 x 150 mm YMC ODS AQ, 3 μm size particles column; mobile phase A lO mM KH\n2\nPO\n4\n (pH 3.0) and mobile phase B acetonitrile) with UV detection at 220 nm, was used to determine impurity content. The capsules were extracted with 20/80 (v/v) methanol/phosphate buffer (pH 7.4). Target concentration of compound 1 for impurities assay was 1 mg/mL. Impurities were determined by comparing the impurity peak areas in the sample preparation chromatogram to the area of the compound 1 peak in the standard preparation obtained concomitantly. Known impurities were calculated by applying the response factor of the respective impurities. The method reporting limit was 0.05%. The results of the analyses are shown in the table below.\n\n\n\n\n\n\n\n\n\n\nExample 5E: Determination of water content in capsules prepared in example 5 A\n\n\n[0095] Water content was determined using the USP <921>, Karl Fischer method and measured at 4.75%.\n\n\nExample 5F: Dissolution Profile of compound 1 from capsules prepared in example 5 A\n\n\n[0096] Dissolution of compound 1 from the capsules was determined following the principles of the USP <711> method A for delayed-release dosage forms, using USP Apparatus 2 at 37°C, set at 50 rpm. Acid stage was performed for 2 hours in 700 mL of dissolution medium at pH 1.2 followed by buffer stage performed in 900 mL of dissolution medium at pH 6.8. A filtered aliquot of the test dissolution medium was taken at the specified times (30, 45, 60, 90 and 100 minutes) and analyzed by HPLC using isocratic elution and UV detection at 226 nm (same chromatographic conditions as described above for content determination). Compound release was determined by comparing the peak responses of the sample chromatograms to the peak responses of the standard chromatograms obtained concomitantly and the results are shown below.\n\n\n \n\n Mean = 91.2%\n\n\n% RSD = 4.1%\n\n\n60 min\n\n\nMin = 84.3%\n\n\nMax = 95.2%\n\n\nMean = 96.8%\n\n\n% RSD = 2.0%\n\n\n90 min\n\n\nMin = 94.4%\n\n\nMax = 99.4%\n\n\nMean = 101.3%\n\n\n% RSD = 2.8%\n\n\n100 min\n\n\nMin = 97.0%\n\n\nMax = 105.1%\n\n\nNMT = not more than III Human Clinical Studies Example 6\n\n\n[0097] Human clinical studies using the compositions described in examples 2A, 3A, 4A, 5A were conducted as described: A multi-center, double-blind, placebo-controlled study in 48 treatment-naϊve HIV-I -infected subjects, randomized 3: 1 (treatmentplacebo). Patients were male, 18-65 years with chronic HIV infection, but no history of AIDS-defining illness. Patients were antiretro viral treatment naϊve or < 14 days prior therapy and had no pre-existing RTI or PI drug resistance and no co-infection with acute HAV, chronic HBV, active HCV. Patient CD4+ cell count was > 50 cells/mm\n3\n for 2 cohorts, then > 200 cells/mm\n3\n or > 350 cells/mm\n3\n depending on site.\n\n\n[0098] The compositions were administered over a 7-day treatment period plus one morning dose for PK purposes on day 8. (It should be noted that in some instances multiple doses of the same composition were administered, in order to achieve the required total dose of compound 1; i.e. in order to achieve a dose of 400mg compound 1, a patient may have taken four lOOmg compositions or two 200mg compositions, depending on the dosage form.) Four sequential dose cohorts were administered as follows:\n\n\nCapsules EC Tablets\n\n\n400mg BID Fasted 800mg QD Fed\n\n\n600mg QD Fasted lOOOmg QD Fasted Assessments were made as follows:\n\n\n• PK and tolerability Days 1-10 & 2 wks post-dose • Safety labs, immunology Days 1, 4, 9 & 2 wks post-dose\n\n\n• ECGs Days 1, 3, 4, 7, 9 and 2 wks post-dose\n\n\n• Genotype and phenotype Days 1 , 9 & 2 wks post-dose\n\n\nSafety / Tolerability Observations: No serious adverse events (grade 3/4) or premature discontinuations occurred during the trail. There was no indication of CNS toxicity, no drug \n\n related rashes, no clinically significant laboratory abnormalities, no apparent effects on lipid profile, no clinically relevant ECG findings and no characteristic changes in genotypes or phenotypic susceptibility observed. Adverse events were generally mild (grade 1) with no required intervention. Patient Baseline Characteristics were determined as shown below:\n\n\nCompound 1 PLACEBO\n\n\n400mg BID* 600mg QD* 800mg QD lOOOmg QD*\n\n\nN=9 N=9 N=9 N=9 N=12\n\n\nAge\n\n\nMean years 35.3 39.9 31.2 33.0 36.3\n\n\nRace\n\n\nCaucasian 7 9 7 7 8\n\n\nBlack 2 - 1 2 1\n\n\nAsian - - - - -\n\n\nOther - - 1 - -\n\n\nCD4 Cell\n\n\nCount\n\n\nMean\n\n\n288.1 319.9 303.6 407.2 325.9 cells/mL\n\n\nViral Load\n\n\nCopies/ml 31,815 46,845 40,161 39,852 32,551\n\n\n4880- 6060- 15900- 5730-\n\n\nRange 7520-469000\n\n\n113000 879000 244000 233000\n\n\nThe Steady-State Pharmacokinetics of the various dosage forms were determined and are shown below:\n\n\n\n\n\n\n\n\nSerum uric acid levels were recorded on day 9 of the study, and are shown in the table below and graphically in figure 5.\n\n\nPLACEBO 600mg QD 800mg QD \n100\n<jmg \n40\n0mg BID\n\n\nMean serum UA\n\n\n-6 -21 -21 -28 -30 reduction (%) T-test vs placebo 0.0011 0.0010 <0.0001 <0.0001\n\n\nExample 7 \n\n [0099] Additional human clinical studies were undertaken to further investigate the PK properties of the compositions described herein. The results are summarized in the table below.\n\n\n\n\n\n\n\n\n \n1\n State: Fa = Fasted; EF = Evening Fasted; FeS = Fed Standard Breakfast; FeH = Fed FDA High\n\n\nFat Breakfast\n\n\n \n2\nM6 is 2-(5-bromo-4-(4-cyclopropylnaphthalen-l-yl)-4H-l,2,4-triazol-3-ylthio)acetic acid - the predominant metabolite of Compound 1\n\n\n \n3\nMolar Ratio M6/Compound 1"
  },
  {
    "id": "JP2010209121A",
    "text": "New pyridopyrazine and use thereof as kinase modulator Abstract<P>PROBLEM TO BE SOLVED: To provide a new compound suitable as a modulator for a receptor tyrosine kinase, a cytoplasmic tyrosine kinase and a serine/threonine kinase.  <P>SOLUTION: A specified pyrido[2,3-b]pyrazine is substituted at its sixth or seventh position with, for example, a urea, thiourea, guanidine or amidine group.  <P>COPYRIGHT: (C)2010,JPO&INPIT Claims (\n14\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  一般式Ｉ\n\n\n \n \n\n［式中、置換基Ｒ１〜Ｒ４は以下の意味を有する：\n\n  Ｒ１及びＲ２は互いに無関係に以下のものであってよい：\n\n（ｉ）水素、\n\n（ｉｉ）ヒドロキシル、\n\n（ｉｉｉ）ハロゲン、\n\n（ｉｖ）アルキル、その際、アルキル基は飽和であり、かつ１〜８個のＣ原子からなるものであってよい、\n\n（ｖ）非置換又は置換のアリール、その際、アリール基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、ｎは１、２又は３の値を取ることができ、かつここで更にアルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基、ヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基及びアルキル−ヘテロアリール置換基は置換されていてよい、\n\n（ｖｉ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、かつここで更にアルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基は置換されていてよい、\n\n（ｖｉｉ）ＯＲ５、その際、Ｒ５はアルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよい、\n\n（ｖｉｉｉ）ＳＲ６、その際、Ｒ６はアルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基、ヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよい、\n\n（ｉｘ）ＮＲ７Ｒ８、その際、Ｒ７及びＲ８は互いに無関係に水素、アルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよいか、又はＲ７及びＲ８は一緒になってシクロアルキル又はヘテロシクリルを意味し、その際、ここで更に前記シクロアルキル及びヘテロシクリルは置換されていてよい、\n\n  Ｒ３及びＲ４は互いに無関係に水素又はＮＲ９Ｒ１０を意味してよいが、但し、Ｒ３＝ＮＲ９Ｒ１０である場合にはＲ４＝Ｈであり、かつＲ４＝ＮＲ９Ｒ１０である場合にはＲ３＝Ｈであり、その際、Ｒ９は水素、アルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよく、かつ\n\n  Ｒ１０は：−Ｃ（Ｙ）ＮＲ１１Ｒ１２を意味してよく、その際、Ｙ＝Ｏ、Ｓであり、かつ\n\n  Ｒ１１及びＲ１２は互いに無関係に以下のものを意味する\n\n（ｉ）水素、\n\n（ｉｉ）非置換又は置換のアルキル、その際、アルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉｉ）非置換又は置換のシクロアルキル、その際、シクロアルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＯＨ、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｖ）非置換又は置換のヘテロシクリル、その際、ヘテロシクリル基はＯＨ、Ｏ−アルキル、Ｏ−アリール、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−アリール、アルキル、アルキル−アリール又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｖ）非置換又は置換のアリール、その際、アリール基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、ｎは１、２又は３の値を取ることができる、\n\n（ｖｉ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｖｉｉ）−Ｃ（Ｏ）Ｒ１７、その際、Ｒ１７はアルキル、アリール又はヘテロアリールであってよく、かつここで更に前記アルキル置換基及びアリール置換基は置換されていてよいか、又は\n\n  Ｒ１１及びＲ１２は一緒になって\n\n（ｖｉｉｉ）シクロアルキル又はヘテロシクリルを意味してよく、\n\n  Ｒ１０は：−Ｃ（Ｙ）ＮＲ１３Ｒ１４を意味してよく、その際、Ｙ＝ＮＨであり、かつ\n\n  Ｒ１３及びＲ１４は互いに無関係に以下のものを意味する\n\n（ｉ）水素、\n\n（ｉｉ）非置換又は置換のアルキル、その際、アルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n３\nＨ、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉｉ）非置換又は置換のシクロアルキル、その際、シクロアルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＯＨ、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｖ）非置換又は置換のヘテロシクリル、その際、ヘテロシクリル基はＯＨ、Ｏ−アルキル、Ｏ−アリール、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−アリール、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｖ）非置換又は置換のアリール、その際、アリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、かつｎは１、２又は３の値を取ることができる、\n\n（ｖｉ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよいか、又は\n\n  Ｒ１３及びＲ１４は一緒になって\n\n（ｖｉｉ）シクロアルキル又はヘテロシクリルを意味してよい、\n\n  Ｒ１０は：−Ｃ（ＮＲ１５）Ｒ１６を意味してよく、その際、Ｒ１５＝Ｈであり、かつ\n\n  Ｒ１６は以下のものを意味してよい\n\n（ｉ）非置換又は置換のアルキル、その際、アルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n３\nＨ、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉ）非置換又は置換のシクロアルキル、その際、シクロアルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＯＨ、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉｉ）非置換又は置換のヘテロシクリル、その際、ヘテロシクリル基はＯＨ、Ｏ−アルキル、Ｏ−アリール、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−アリール、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｖ）非置換又は置換のアリール、その際、アリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、かつｎは１、２又は３の値を取ることができる、\n\n（ｖ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい］で示される新規のピリド［２，３−ｂ］ピラジン誘導体、並びに式Ｉによる化合物の生理学的に認容性の塩、誘導体又は類似体（その際、塩は塩基性化合物と無機酸及び有機酸との中和あるいは酸性化合物と無機塩基及び有機塩基との中和によって得られる）、並びにそれらの溶媒和物、水和物及び多形（その際、一般式Ｉの化合物並びにそれらの塩、誘導体又は類似体、それらの溶媒和物、水和物及び多形はそれらのラセミ体の形で、純粋なエナンチオマー及び／又はジアステレオマーの形で又はこれらのエナンチオマー及び／又はジアステレオマーの混合物の形で又は互変異性体の形で存在してよい）。\n\nFormula I \n \n \n \n [Wherein the substituents R1 to R4 have the following meanings: \n R1 and R2 may be independent of each other as follows: \n (I) hydrogen, \n (Ii) hydroxyl, \n (Iii) halogen, \n (Iv) alkyl, in which case the alkyl group is saturated and may consist of 1 to 8 C atoms, \n (V) unsubstituted or substituted aryl, wherein the aryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O -Alkyl-OH, O- (CH \n2\n ) \nn\n -O, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted, n may take the values 1, 2 or 3 and Further, the alkyl substituent, cycloalkyl substituent, heterocyclyl substituent, aryl substituent, heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent and alkyl-heteroaryl substituent are substituted. May have been, \n (Vi) unsubstituted or substituted heteroaryl, wherein the heteroaryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O)- Alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl , OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted, and here further alkyl substituents, cycloalkyl substituents, heterocyclyl substituents, aryl Substituents and heteroaryl substituents may be substituted, \n (Vii) OR5, wherein R5 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, wherein Substituent, cycloalkyl substituent, heterocyclyl substituent, aryl substituent and heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or alkyl-heteroaryl substituent are substituted You can, \n (Viii) SR6, wherein R6 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, wherein Substituent, cycloalkyl substituent, heterocyclyl substituent, aryl substituent, heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or alkyl-heteroaryl substituent are substituted You can, \n (Ix) NR7R8, wherein R7 and R8 are independently of one another hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl And further wherein said alkyl substituent, cycloalkyl substituent, heterocyclyl substituent, aryl substituent and heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or alkyl-hetero The aryl substituent may be substituted or R7 and R8 taken together mean cycloalkyl or heterocyclyl, wherein further said cycloalkyl and heterocyclyl may be substituted, \n R3 and R4 may mean hydrogen or NR9R10 independently of each other, provided that R4 = H when R3 = NR9R10 and R3 = H when R4 = NR9R10, , R9 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, and further wherein said alkyl substituent, cycloalkyl The substituent, heterocyclyl substituent, aryl substituent and heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or alkyl-heteroaryl substituent may be substituted; and \n R10 may mean: —C (Y) NR11R12, where Y═O, S, and \n R11 and R12 independently mean the following: \n (I) hydrogen, \n (Ii) unsubstituted or substituted alkyl, wherein the alkyl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (Alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O)- Alkyl-heteroaryl, OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted \n (Iii) unsubstituted or substituted cycloalkyl, wherein the cycloalkyl group is F, Cl, Br, I, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, OH, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , May be mono-substituted or the same or different poly-substituted with alkyl or aryl, \n (Iv) unsubstituted or substituted heterocyclyl, wherein the heterocyclyl group is OH, O-alkyl, O-aryl, NH \n2\n , NH-alkyl, NH-aryl, alkyl, alkyl-aryl or aryl, which may be monosubstituted or identically or differently polysubstituted. \n (V) unsubstituted or substituted aryl, wherein the aryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O -Alkyl-OH, O- (CH \n2\n ) \nn\n -O, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or differently polysubstituted and n may take the values 1, 2 or 3. \n (Vi) unsubstituted or substituted heteroaryl, wherein the heteroaryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O)- Alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl , OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or differently polysubstituted, \n (Vii) -C (O) R17, wherein R17 may be alkyl, aryl or heteroaryl, and further wherein the alkyl and aryl substituents may be substituted, or \n R11 and R12 together \n (Viii) may mean cycloalkyl or heterocyclyl; \n R10 may mean: —C (Y) NR13R14, where Y═NH, and \n R13 and R14 independently mean the following: \n (I) hydrogen, \n (Ii) unsubstituted or substituted alkyl, wherein the alkyl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n3\n H, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or different and may be polysubstituted. \n (Iii) unsubstituted or substituted cycloalkyl, wherein the cycloalkyl group is F, Cl, Br, I, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, OH, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC ( O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , May be mono-substituted or the same or different poly-substituted with alkyl or aryl, \n (Iv) unsubstituted or substituted heterocyclyl, wherein the heterocyclyl group is OH, O-alkyl, O-aryl, NH \n2\n , NH-alkyl, NH-aryl, alkyl or aryl, which may be monosubstituted or identically or differently polysubstituted. \n (V) unsubstituted or substituted aryl, wherein the aryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O -Alkyl-OH, O- (CH \n2\n ) \nn\n -O, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted and n may take the values 1, 2 or 3. \n (Vi) unsubstituted or substituted heteroaryl, wherein the heteroaryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O)- Aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted, or \n R13 and R14 together \n (Vii) may mean cycloalkyl or heterocyclyl; \n R10 may mean: -C (NR15) R16, where R15 = H and \n R16 may mean: \n (I) unsubstituted or substituted alkyl, wherein the alkyl group is F, Cl, Br, I, CF \n3\n , NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n3\n H, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or different and may be polysubstituted. \n (Ii) unsubstituted or substituted cycloalkyl, wherein the cycloalkyl group is F, Cl, Br, I, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, OH, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC ( O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , May be mono-substituted or the same or different poly-substituted with alkyl or aryl, \n (Iii) unsubstituted or substituted heterocyclyl, wherein the heterocyclyl group is OH, O-alkyl, O-aryl, NH \n2\n , NH-alkyl, NH-aryl, alkyl or aryl, which may be monosubstituted or identically or differently polysubstituted. \n (Iv) unsubstituted or substituted aryl, wherein the aryl group is F, Cl, Br, I, CF \n3\n , NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O -Alkyl-OH, O- (CH \n2\n ) \nn\n -O, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted and n may take the values 1, 2 or 3. \n (V) unsubstituted or substituted heteroaryl, wherein the heteroaryl group is F, Cl, Br, I, CF \n3\n , NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O)- Aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n A novel pyrido [2,3-b] pyrazine derivative represented by O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, which may be monosubstituted, identically or differently polysubstituted], and compounds of formula I Physiologically tolerable salts, derivatives or analogues of compounds according to (wherein the salts are obtained by neutralization of basic compounds with inorganic and organic acids or neutralization of acidic compounds with inorganic and organic bases) ), And their solvates, hydrates and polymorphs (wherein the compounds of general formula I and their salts, derivatives or analogues, their solvates, hydrates and polymorphs are racemic In the form of compounds, in the form of pure enantiomers and / or diastereomers, or in the form of mixtures of these enantiomers and / or diastereomers It may be present in the form).\n\n\n\n\n\n\n\n\n\n\n \n\n  アルキル基が、メチル、エチル、ｎ−プロピル、２−プロピル、ｎ−ブチル、ｓ−ブチル、ｔ−ブチル、ｎ−ペンチル、イソ−ペンチル、ネオ−ペンチル、ｎ−ヘキシル、２−ヘキシル、ｎ−オクチル、エチレニル（ビニル）、エチニル、プロペニル（−ＣＨ\n２\nＣＨ＝ＣＨ\n２\n；−ＣＨ＝ＣＨ−ＣＨ\n３\n、−Ｃ（＝ＣＨ\n２\n）−ＣＨ\n３\n）、プロピニル（−ＣＨ\n２\n−Ｃ≡ＣＨ、−Ｃ≡Ｃ−ＣＨ\n３\n）、ブテニル、ブチニル、ペンテニル、ペンチニル、ヘキセニル、ヘキシニル、ヘプテニル、ヘプチニル、オクテニル及びオクチニルであってよい、請求項１記載の一般式Ｉのピリド［２，３−ｂ］ピラジン誘導体。\n\nThe alkyl group is methyl, ethyl, n-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl, n- Octyl, ethylenyl (vinyl), ethynyl, propenyl (—CH \n2\n CH═CH \n2\n ; —CH═CH—CH \n3\n , —C (═CH \n2\n ) —CH \n3\n ), propynyl (—CH \n2\n —C≡CH, — \nC≡C-CH\n 3), butenyl, butynyl, pentenyl, pentynyl, hexenyl, hexynyl, heptenyl, heptynyl, octenyl and may be octynyl, pyrido of general formula I according to claim 1, wherein [2,3-b] pyrazine Derivative.\n\n\n\n\n\n\n\n\n\n\n \n\n  ヘテロシクリル基がテトラヒドロフリル、テトラヒドロピラニル、ピロリジニル、ピペリジニル、ピペラジニル及びモルホリニルであってよい、請求項１記載の一般式Ｉのピリド［２，３−ｂ］ピラジン誘導体。\n\n\n  The pyrido [2,3-b] pyrazine derivative of general formula I according to claim 1, wherein the heterocyclyl group may be tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  ヘテロアリール基がピロリル、フリル、チエニル、チアゾリル、オキサゾリル、イソキサゾリル、ピラゾリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル、ピラジニル、フタラジニル、インドリル、インダゾリル、インドリジニル、キノリニル、イソキノリニル、キノキサリニル、キナゾリニル、カルバゾリル、フェナジニル、フェノチアジニル、アクリジニルであってよい、請求項１記載の一般式Ｉのピリド［２，３−ｂ］ピラジン誘導体。\n\n\n  Heteroaryl group is pyrrolyl, furyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, phthalazinyl, indolyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinazolinyl, quinazolinyl, quinazolinyl The pyrido [2,3-b] pyrazine derivative of general formula I according to claim 1, which may be acridinyl.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  特に以下の化合物：\n\n１−アリル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−アリル−３−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−アリル−３−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素、\n\n１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素塩酸塩、\n\n１−（２−メチル−アリル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−（２−メチル−アリル）−３−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（２−メチル−アリル）−チオ尿素、\n\n１−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−（４−ニトロ−フェニル）−チオ尿素、\n\n１−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（４−ニトロ−フェニル）−チオ尿素、\n\n１−ｔ−ブチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−シクロプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−メチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−ベンジル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−（４−フルオロ−フェニル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−シクロヘキシル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−イソプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−フラン−２−イルメチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−メチル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素、\n\n１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−メチル−チオ尿素、\n\n１−アリル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素、\n\n４−［６−（３−アリル−チオ尿素）−ピリド［２，３−ｂ］ピラジン−３−イル］−安息香酸エチル−エステル、\n\n１−アリル−３−［３−（３−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素、\n\n１−アリル−３−（３−ベンゾ［１，３］ジオキソール−５−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素、\n\n１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−プロピ−２−イニル−チオ尿素、\n\n１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素、\n\n１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（（プロペニル）−チオ尿素、\n\n１−アリル−３−［２，３−ビス−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素、\n\n１−［２，３−ビス−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（（プロペニル）−チオ尿素、\n\n１−アリル−３−［２−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素、\n\n１−アリル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−７−イル］−チオ尿素、\n\n１−シクロプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素、\n\n１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−尿素、\n\n１−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−ｐ−トリル−尿素、\n\n１−（４−クロロ−３−トリフルオロメチル−フェニル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素、\n\n１−（２−モルホリン−４−イル−エチル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素、\n\n１−フェネチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素、\n\n１−（２，３−ジ−ピリジン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−エチル−尿素、\n\n１−（２，３−ジメチル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−エチル−尿素\n\nの１つである、請求項１から４までのいずれか１項記載の一般式Ｉのピリド［２，３−ｂ］ピラジン誘導体。\n\nIn particular the following compounds: \n 1-allyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-allyl-3- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-allyl-3- [3- (4-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea, \n 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea hydrochloride, \n 1- (2-methyl-allyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1- (2-methyl-allyl) -3- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1- [3- (4-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3- (2-methyl-allyl) -thiourea, \n 1- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -3- (4-nitro-phenyl) -thiourea, \n 1- [3- (4-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3- (4-nitro-phenyl) -thiourea, \n 1-t-butyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-cyclopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-methyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-benzyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1- (4-fluoro-phenyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-cyclohexyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-isopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-furan-2-ylmethyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1-methyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea, \n 1- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-methyl-thiourea, \n 1-allyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea, \n 4- [6- (3-allyl-thiourea) -pyrido [2,3-b] pyrazin-3-yl] -benzoic acid ethyl ester \n 1-allyl-3- [3- (3-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea, \n 1-allyl-3- (3-benzo [1,3] dioxol-5-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea, \n 1- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-prop-2-ynyl-thiourea, \n 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea, \n 1- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-((propenyl) -thiourea, \n 1-allyl-3- [2,3-bis- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea, \n 1- [2,3-bis- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-((propenyl) -thiourea, \n 1-allyl-3- [2- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea, \n 1-allyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-7-yl] -thiourea, \n 1-cyclopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea, \n 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -urea, \n 1- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -3-p-tolyl-urea, \n 1- (4-chloro-3-trifluoromethyl-phenyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea, \n 1- (2-morpholin-4-yl-ethyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea, \n 1-phenethyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea, \n 1- (2,3-di-pyridin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea, \n The general formula according to claim 1, which is one of 1- (2,3-dimethyl-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea. A pyrido [2,3-b] pyrazine derivative of I.\n\n\n\n\n\n\n\n\n\n\n \n\n  請求項１から５までのいずれか１項記載の一般式Ｉの少なくとも１種の化合物を含有する医薬品。\n\n\n  A medicament comprising at least one compound of the general formula I according to any one of claims 1 to 5.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  前記化合物が組成中に少なくとも１種の他の医薬品作用物質及び／又は医薬品担体物質及び／又は希釈剤あるいはその他の助剤と組み合わされて存在する、請求項６記載の医薬品。\n\n\n  7. A pharmaceutical product according to claim 6, wherein the compound is present in the composition in combination with at least one other pharmaceutical agent and / or pharmaceutical carrier material and / or diluent or other adjuvant.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  請求項６及び７の医薬品の製造方法において、請求項１から５までのいずれか１項記載の一般式Ｉの１種以上のピリド［２，３−ｂ］ピラジン誘導体を慣用の医薬品担体物質及び／又は希釈剤あるいはその他の助剤と一緒に加工して医薬品調剤にするか、あるいは治療学的に使用可能な形状にすることを特徴とする方法。\n\n\n  A method for producing a pharmaceutical product according to claims 6 and 7, wherein one or more pyrido [2,3-b] pyrazine derivatives of general formula I according to any one of claims 1 to 5 are used as conventional pharmaceutical carrier substances and A process characterized in that it is processed together with a diluent or other auxiliaries to make a pharmaceutical preparation or into a therapeutically usable form.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  医薬として使用するための、請求項１から５までのいずれか１項記載の化合物。\n\n\n  6. A compound according to any one of claims 1 to 5 for use as a medicament.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  誤って導かれた細胞シグナル伝達過程から生ずる疾患の治療のための医薬品の製造のための治療学的作用物質としての、請求項１から５までのいずれか１項記載の一般式Ｉのピリド［２，３−ｂ］ピラジン誘導体の使用。\n\n\n  6. A pyrido of general formula I according to any one of claims 1 to 5 as a therapeutic agent for the manufacture of a medicament for the treatment of diseases resulting from misdirected cell signaling processes [6]. Use of 2,3-b] pyrazine derivatives.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  病理学的細胞増殖に基づく疾患、例えば再狭窄、乾癬、動脈硬化症及び肝硬変の治療のための医薬品の製造のための治療学的作用物質としての、請求項１０記載の使用。\n\n\n  Use according to claim 10 as a therapeutic agent for the manufacture of a medicament for the treatment of diseases based on pathological cell proliferation such as restenosis, psoriasis, arteriosclerosis and cirrhosis.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  悪性もしくは良性の腫瘍疾患、特に胸部、前立腺、肺、皮膚及び卵巣の腫瘍疾患の治療のための医薬品の製造のための治療学的作用物質としての、請求項１０記載の使用。\n\n\n  11. Use according to claim 10 as a therapeutic agent for the manufacture of a medicament for the treatment of malignant or benign tumor diseases, in particular breast, prostate, lung, skin and ovarian tumor diseases.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  誤って導かれた細胞シグナル伝達過程から生ずる疾患、病理学的細胞増殖に基づく疾患並びに悪性もしくは良性の腫瘍疾患をヒト、哺乳動物及び家禽において治療するための医薬品の製造のための治療学的作用物質としての、請求項１０から１２までのいずれか１項記載の使用。\n\n\n  Therapeutic effects for the manufacture of pharmaceuticals for the treatment of diseases arising from misdirected cell signaling processes, diseases based on pathological cell proliferation and malignant or benign tumor diseases in humans, mammals and poultry Use according to any one of claims 10 to 12, as a substance.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  誤って導かれた細胞シグナル伝達過程の調節のため、特に活性及び不活性なチロシンキナーゼ及びセリン／トレオニンキナーゼ、例えばｃ−Ｒａｆ、Ｂ−Ｒａｆ、Ｍｅｋ、ＭＡＰＫ、ＰＤＧＦＲベータ、Ｆｌｔ−３、ＩＧＦ１Ｒ、ＰＫＢ／Ａｋｔ１、ｃ−Ｋｉｔ、ｃ−Ａｂｌ、ＦＧＦＲ１及びＫＤＲの機能に影響を及ぼすための、請求項１０記載の使用。\n\n\n  For the regulation of misdirected cell signaling processes, particularly active and inactive tyrosine kinases and serine / threonine kinases such as c-Raf, B-Raf, Mek, MAPK, PDGFRbeta, Flt-3, IGF1R, 11. Use according to claim 10 to affect the function of PKB / Akt1, c-Kit, c-Abl, FGFR1 and KDR. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は、ピリド［２，３−ｂ］ピラジン型のキナーゼモジュレーター、その製造及び、誤って導かれた細胞シグナル伝達過程の調節のための、特にチロシンキナーゼ及びセリン／トレオニンキナーゼの機能に影響を及ぼすための、及び悪性もしくは良性の腫瘍疾患及び病理学的細胞増殖に基づく別の疾患、例えば再狭窄、乾癬、動脈硬化症及び肝硬変の治療のための医薬品としての使用に関する。\n\n\n  The present invention relates to pyrido [2,3-b] pyrazine-type kinase modulators, their production and influence on the function of tyrosine kinases and serine / threonine kinases, in particular for the regulation of misdirected cell signaling processes. It relates to the use as a medicament for the treatment of and for the treatment of malignant or benign tumor diseases and other diseases based on pathological cell proliferation such as restenosis, psoriasis, arteriosclerosis and cirrhosis.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  プロテインキナーゼの活性化は、細胞シグナル伝達過程では主要な事象である。幾つかの疾患状態で異常なキナーゼ活性化が認められる。従って、集中的なキナーゼの阻害が極めて重要な治療標的である。\n\n\n  Protein kinase activation is a major event in cell signaling processes. Abnormal kinase activation is observed in several disease states. Thus, intensive kinase inhibition is a critical therapeutic target.\n\n\n\n\n\n\n\n \n\n  タンパク質のリン酸化は、一般に細胞外シグナルによって引き起こされ、そしてそれは種々の細胞事象、例えば代謝経路、細胞成長、細胞移動、細胞分化、膜輸送及びアポトーシスの制御のための多岐に亘る機構である。キナーゼのタンパク質ファミリーがタンパク質リン酸化を調整する。これらの酵素は、特異的な基質タンパク質にリン酸を転移することを触媒する。基質特異性に基づいて、キナーゼは、チロシンキナーゼとセリン／トレオニンキナーゼといった２つの主要なクラスに分けられる。受容体チロシンキナーゼも細胞質チロシンキナーゼ及びセリン／トレオニンキナーゼも、細胞のシグナル伝達の重要なタンパク質である。これらのタンパク質の過剰発現もしくは変質は、病理学的細胞増殖に基づく疾患において重要な役割を担う。これには、とりわけ代謝疾患、結合組織及び血管の疾患並びに悪性及び良性の腫瘍疾患が該当する。腫瘍発生及び腫瘍形成において、しばしば癌遺伝子として、すなわち異常な構成的活性なキナーゼタンパク質として生ずる。前記の過度のキナーゼ活性化の結果として、例えば細胞増殖が制御不能となり、かつ細胞死が減少する。腫瘍が誘発される成長因子の刺激もキナーゼの過剰刺激の原因となることがある。従ってキナーゼモジュレーターの開発は、キナーゼによって影響される全ての病原過程のために特に関心が持たれている。\n\n\n  Protein phosphorylation is generally triggered by extracellular signals, and it is a diverse mechanism for the control of various cellular events such as metabolic pathways, cell growth, cell migration, cell differentiation, membrane trafficking and apoptosis. The protein family of kinases regulates protein phosphorylation. These enzymes catalyze the transfer of phosphate to specific substrate proteins. Based on substrate specificity, kinases are divided into two major classes: tyrosine kinases and serine / threonine kinases. Both receptor tyrosine kinases, cytoplasmic tyrosine kinases and serine / threonine kinases are important proteins for cellular signaling. Overexpression or alteration of these proteins plays an important role in diseases based on pathological cell proliferation. This applies in particular to metabolic diseases, connective tissue and vascular diseases and malignant and benign tumor diseases. In tumorigenesis and tumorigenesis, it often occurs as an oncogene, ie as an abnormal constitutively active kinase protein. As a result of this excessive kinase activation, for example, cell proliferation becomes uncontrollable and cell death is reduced. Tumor-induced growth factor stimulation can also cause kinase overstimulation. Therefore, the development of kinase modulators is of particular interest for all pathogenic processes affected by kinases.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nＷＯ９９／１７７５９号\nWO99 / 17759\n\n\n\n\n\n\n\n\n\n\n \nＷＯ０４／００５４７２号\nWO04 / 005472\n\n\n\n\n\n\n\n\n\n\n \nＷＯ０３／０８４４７３号\nWO03 / 084473\n\n\n\n\n\n\n\n\n\n\n \nＷＯ０３／０８６３９４号\nWO03 / 086394\n\n\n\n\n\n\n\n\n\n\n \nＷＯ０３／０８６４０３号\nWO03 / 0886403\n\n\n\n\n\n\n\n\n\n\n \nＷＯ０３／０２４４４８号\nWO03 / 024448\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nJ. Med. Chem. 1990, 3044-3050\nJ. Med. Chem. 1990, 3044-3050\n\n\n\n\n\n\n\n\n\n\n \nJ. Org. Chem. 1968, 2393-2397\nJ. Org. Chem. 1968, 2393-2397\n\n\n\n\n\n\n\n\n\n\n \nJ. Med. Chem. 1968, 1216-1218\nJ. Med. Chem. 1968, 1216-1218\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  従って、本発明は、受容体チロシンキナーゼ及び細胞質チロシンキナーゼ及びセリン／トレオニンキナーゼのモジュレーターとして適している新規の化合物を作成することに導くものである。負の調節にあるシグナル伝達カスケードでカスケードをなす全てのキナーゼ（例えばＲａｆ／Ｍｅｋ／Ｅｒｋの場合にのように）が癌遺伝子キナーゼもしくは構成的活性な酵素として存在する必要はないので、本発明では不活性なキナーゼも治療的標的タンパク質として見なされる、すなわち新規の化合物は活性のキナーゼにも不活性なキナーゼにも結合し、それによりシグナル伝達に影響を及ぼす。\n\n\n  The present invention therefore leads to the creation of novel compounds suitable as modulators of receptor tyrosine kinases and cytoplasmic tyrosine kinases and serine / threonine kinases. In the present invention, it is not necessary that all kinases cascaded by a signaling cascade in negative regulation (eg as in Raf / Mek / Erk) be present as oncogene kinases or constitutively active enzymes. Inactive kinases are also considered therapeutic target proteins, i.e., novel compounds bind to both active and inactive kinases, thereby affecting signaling.\n\n\n\n\n\n\n\n \n\n  ６位又は７位で置換されたピリド［２，３−ｂ］ピラジン誘導体は薬理学的に活性な化合物として、かつ合成用構成分子として医薬品化学において頻繁に使用される。例えば、特許文献ＷＯ９９／１７７５９号には、６位において、とりわけアルキル置換、アリール置換及びヘテロアリール置換されたカルバメートを有するピリド［２，３−ｂ］ピラジンが記載されている。これらの化合物は、セリン−トレオニン−プロテインキナーゼの機能を調節するために使用することが望ましい。Ｗｈｉｔｅ他による特許ＷＯ０４／００５４７２号には、とりわけ６位でカルバメート置換されたピリド［２，３−ｂ］ピラジンが記載され、これらの化合物は抗細菌性物質として細菌の増殖を阻害する。抗腫瘍作用は記載されていない。\n\n\n  Pyrido [2,3-b] pyrazine derivatives substituted at the 6- or 7-position are frequently used in medicinal chemistry as pharmacologically active compounds and as constituent molecules for synthesis. For example, the patent document WO 99/17759 describes pyrido [2,3-b] pyrazine having a carbamate which is especially alkyl-substituted, aryl-substituted and heteroaryl-substituted at the 6-position. These compounds are desirably used to modulate the function of serine-threonine-protein kinase. The patent WO 04/005472 by White et al. Describes pyrido [2,3-b] pyrazines that are carbamate substituted in position 6 among others, and these compounds inhibit bacterial growth as antibacterial substances. Antitumor effects are not described.\n\n\n\n\n\n\n\n \n\n  フェニル環上に特定のアルキルピロリジン基、アルキルピペリジン基又はアルキルスルホンアミド基を有し、付加的に６位又は７位に尿素置換基又はカルバメート置換基を有してもよい一定のジフェニルキノキサリン及びジフェニルピリド［２，３−ｂ］ピラジンは特許文献ＷＯ０３／０８４４７３号（Ｂａｒｎｅｔｔ他）、ＷＯ０３／０８６３９４号（Ｂｉｌｏｄｅａｕ他）及びＷＯ０３／０８６４０３号（Ｌｉｎｄｓｌｅｙ他）においてセリン／トレオニンキナーゼＡｋｔの活性の阻害剤として記載されている。これらの化合物について、癌疾患の治療での使用が報告されている。そこに記載されるピリド［２，３−ｂ］ピラジンの例示化合物に関して、生物学的作用について言及された示唆は示されていない。更に、本発明に記載される本発明によるピリド［２，３−ｂ］ピラジンとの明らかな構造的差異が存在する。\n\n\n  Certain diphenylquinoxalines and diphenyls which have a specific alkylpyrrolidine group, alkylpiperidine group or alkylsulfonamide group on the phenyl ring and may additionally have a urea substituent or carbamate substituent at the 6- or 7-position Pyrido [2,3-b] pyrazine is an inhibitor of serine / threonine kinase Akt activity in the patent documents WO03 / 084473 (Barnett et al.), WO03 / 086394 (Bildeau et al.) And WO03 / 0886403 (Lindsley et al.). It is described as. These compounds have been reported for use in the treatment of cancer diseases. Regarding the exemplary compounds of pyrido [2,3-b] pyrazine described therein, no suggested mention is made of biological effects. Furthermore, there are obvious structural differences from the pyrido [2,3-b] pyrazine according to the invention described in the present invention.\n\n\n\n\n\n\n\n \n\n  更に、Ｄｅｌｏｒｍｅ他による特許ＷＯ０３／０２４４４８号には、アミド置換及びアクリルアミド置換され、付加的な置換基としてカルバメートも有するピリド［２，３−ｂ］ピラジンが記載され、この化合物はヒストンデアセチラーゼ阻害剤として細胞増殖疾患の治療のために使用できる。\n\n\n  In addition, Patent WO 03/024448 by Delorme et al. Describes pyrido [2,3-b] pyrazine which is amide and acrylamide substituted and also has carbamate as an additional substituent, which compound inhibits histone deacetylase. It can be used as an agent for the treatment of cell proliferative disorders.\n\n\n\n\n\n\n\n \n\n  他の文献（C. Temple, Jr.; J. Med. Chem. 1990, 3044-3050）には、例として６−エチルカルバメート置換されたピリド［２，３−ｂ］ピラジン誘導体の合成が記載されている。抗腫瘍作用は開示されていなければ、示唆もされていない。\n\n\n  Other literature (C. Temple, Jr .; J. Med. Chem. 1990, 3044-3050) describes the synthesis of pyrido [2,3-b] pyrazine derivatives substituted with 6-ethylcarbamate as an example. ing. Antitumor effects are not disclosed or suggested.\n\n\n\n\n\n\n\n \n\n  ６−エチルカルバメート置換されたピリド［２，３−ｂ］ピラジンの他の誘導体の合成は、Ｒ．Ｄ．Ｅｌｌｉｏｔｔによる刊行物（J. Org. Chem. 1968, 2393-2397）に記載されている。これらの化合物の生物学的作用は記載されていなければ、示唆もされていない。\n\n\n  Synthesis of other derivatives of 6-ethylcarbamate substituted pyrido [2,3-b] pyrazine is described in R.C. D. It is described in a publication by Elliott (J. Org. Chem. 1968, 2393-2397). The biological effects of these compounds have not been described or suggested.\n\n\n\n\n\n\n\n \n\n  Ｃ．Ｔｅｍｐｌｅ，Ｊｒによる文献（J. Med. Chem. 1968, 1216-1218）には、潜在的な抗マラリア作用物質としての６−エチルカルバメート置換されたピリド［２，３−ｂ］ピラジンの合成と調査が記載されている。抗腫瘍作用は開示されていなければ、示唆もされていない。\n\n\n  C. Reference to Temple, Jr (J. Med. Chem. 1968, 1216-1218) describes the synthesis and investigation of 6-ethylcarbamate-substituted pyrido [2,3-b] pyrazine as a potential antimalarial agent. Is described. Antitumor effects are not disclosed or suggested.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  ここで驚くべきことに、６位又は７位において、例えば尿素基、チオ尿素基、グアニジン基又はアミジン基で置換されている一連のピリド［２，３−ｂ］ピラジンからの新規の化合物が、誤って導かれた細胞シグナル伝達過程の調節のための、特にチロシンキナーゼ及びセリン／トレオニンキナーゼの機能に影響を及ぼすための、及び悪性もしくは良性の腫瘍疾患、例えば胸部、前立腺、肺、皮膚、卵巣などの腫瘍疾患及び病理学的細胞増殖に基づく別の疾患の治療のための医薬品の製造のために適していることが判明した。この観点で、本願において一般式Ｉ\n\n\n \n \n\n［式中、置換基Ｒ１〜Ｒ４は以下の意味を有する：\n\n  Ｒ１及びＲ２は互いに無関係に以下のものを意味する：\n\n（ｉ）水素、\n\n（ｉｉ）ヒドロキシル、\n\n（ｉｉｉ）ハロゲン、例えば塩素又は臭素、\n\n（ｉｖ）アルキル、その際、アルキル基は飽和であり、かつ１〜８個のＣ原子からなるものであってよい、\n\n（ｖ）非置換又は置換のアリール、その際、アリール基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、ｎは１、２又は３の値を取ることができ、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基、ヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基及びアルキル−ヘテロアリール置換基は置換されていてよい、\n\n（ｖｉ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基は置換されていてよい、\n\n（ｖｉｉ）ＯＲ５、その際、Ｒ５はアルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基、ヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよい、\n\n（ｖｉｉｉ）ＳＲ６、その際、Ｒ６はアルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよい、\n\n（ｉｘ）ＮＲ７Ｒ８、その際、Ｒ７及びＲ８は互いに無関係に水素、アルキル、シクロアルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよいか、又はＲ７及びＲ８は一緒になってシクロアルキル又はヘテロシクリルを意味し、その際、ここで更に前記シクロアルキル及びヘテロシクリルは置換されていてよい。\n\nSurprisingly here, novel compounds from a series of pyrido [2,3-b] pyrazines substituted in the 6- or 7-position, for example with urea, thiourea, guanidine or amidine groups, For the regulation of misdirected cell signaling processes, especially for affecting the function of tyrosine kinases and serine / threonine kinases, and for malignant or benign tumor diseases such as breast, prostate, lung, skin, ovary It has been found suitable for the manufacture of a medicament for the treatment of tumor diseases such as and other diseases based on pathological cell proliferation. In this regard, in this application, the general formula I \n \n \n \n [Wherein the substituents R1 to R4 have the following meanings: \n R1 and R2 independently of one another mean the following: \n (I) hydrogen, \n (Ii) hydroxyl, \n (Iii) halogen, such as chlorine or bromine, \n (Iv) alkyl, in which case the alkyl group is saturated and may consist of 1 to 8 C atoms, \n (V) unsubstituted or substituted aryl, in which the aryl \ngroup, F, Cl, Br, I\n , CF 3, CN, NH 2, NH- alkyl, NH- cycloalkyl, NH- heterocyclyl, NH- aryl, NH- heteroaryl, NH- alkyl - cycloalkyl, NH- alkyl - heterocyclyl, NH- alkyl - aryl, NH- alkyl - heteroaryl, NH- alkyl \n-NH\n 2, NH- alkyl -OH, N \n(alkyl)\n 2, NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) - alkyl - heteroaryl, NHSO \n2\n - alkyl, NHSO \n2\n - cycloalkyl, NHSO \n2\n - f Roshikuriru, NHSO \n2\n - aryl, NHSO \n2\n - heteroaryl, NHSO \n2\n - alkyl - aryl, NHSO \n2\n - alkyl - \nheteroaryl,\n NO 2, SH, S- alkyl, S- aryl, S- heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O - alkyl \n \n-OH, O- (CH 2) n\n \n -O, OC (O) - alkyl, OC (O) - cycloalkyl, OC (O) - heterocyclyl, OC (O) - aryl, OC (O) - heteroaryl Aryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, O O \n3\n H, OSO \n2\n - alkyl, OSO \n2\n - cycloalkyl, OSO \n2\n - heterocyclyl, OSO \n2\n - aryl, OSO \n2\n - heteroaryl, OSO \n2\n - alkyl - aryl, OSO \n2\n - alkyl - heteroaryl, OP (O) \n(OH) 2, C (O\n ) - alkyl, C (O) - aryl, C (O) - \nheteroaryl,\n CO \n2\n \nH,\n CO 2 - alkyl, CO \n2\n - cycloalkyl, CO \n2\n - heterocyclyl, CO \n2\n - aryl, CO \n2\n - heteroaryl, CO \n2\n - alkyl - cycloalkyl, CO \n2\n - alkyl - heterocyclyl, CO \n2\n - alkyl - aryl, CO \n2\n - alkyl - \nheteroaryl, C (O) -NH 2,\n C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) H-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH- Alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl , SO- aryl, SO \n2\n - alkyl, SO \n2\n - \n \n \naryl, SO 2 NH 2, SO 2\n \n \n NH- \nalkyl,\n SO 2 NH- \naryl,\n SO 2 NH- \nheteroaryl,\n SO 2 NH- alkyl - aryl, \nSO\n 3 H , \nSO\n 2 O-alkyl, \nSO\n 2 O-aryl, \nSO\n 2 O-alkyl - aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl May be mono-substituted or the same or different and poly-substituted, n may take the value of 1, 2 or 3, and further wherein said alkyl substituent, cycloalkyl substituent, heterocyclyl substituent, aryl Substituents, heteroaryl substituents, alkyl-cycloalkyl substituents, alkyl-heterocyclyl substituents, alkyl-aryl substituents and alkyl-heteroaryl substituents may be substituted, \n (Vi) unsubstituted or substituted heteroaryl, in which heteroaryl \ngroup, F, Cl, Br, I\n , CF 3, CN, NH 2, NH- alkyl, NH- cycloalkyl, NH- heterocyclyl, NH- aryl, NH- heteroaryl, NH- alkyl - cycloalkyl, NH- alkyl - heterocyclyl, NH- alkyl - aryl, NH- alkyl - heteroaryl, NH- alkyl \n-NH\n 2, NH- alkyl -OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC ( O) - alkyl - heteroaryl, NHSO \n2\n - alkyl, NHSO \n2\n - cycloalkyl, N SO \n2\n - heterocyclyl, NHSO \n2\n - aryl, NHSO \n2\n - heteroaryl, NHSO \n2\n - alkyl - aryl, NHSO \n2\n - alkyl - \nheteroaryl,\n NO 2, SH, S- alkyl, S- aryl, S- heteroaryl, OH , OCF \n3\n , O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC ( O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl - \nheteroaryl,\n OSO 3 \nH,\n OSO \n2\n - alkyl, OSO \n2\n - Shikuroa Alkyl, OSO \n2\n - heterocyclyl, OSO \n2\n - aryl, OSO \n2\n - heteroaryl, OSO \n2\n - alkyl - aryl, OSO \n2\n - alkyl - \nheteroaryl, OP (O) (OH)\n 2, C (O) - alkyl, C (O) - aryl, C (O) - \nheteroaryl,\n CO \n2\n \nH,\n CO 2 - alkyl, CO \n2\n - cycloalkyl, CO \n2\n - heterocyclyl, CO \n2\n - aryl, CO \n2\n - heteroaryl, CO \n2\n - alkyl - cycloalkyl, CO \n2\n - alkyl - heterocyclyl, CO \n2\n - alkyl - aryl, CO \n2\n - alkyl - \nheteroaryl, C (O) -NH 2,\n C (O) NH- alkyl, C (O) NH- cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O ) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH- \nheteroaryl,\n SO 2 NH- alkyl - \naryl,\n \nSO\n 3 \nH,\n SO 2 O- alkyl, \nSO\n 2 O-aryl, \nSO\n 2 O-alkyl - aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl one May be substituted or the same or different and may be multi-substituted, and the alkyl substituent, cycloalkyl substituent, heterocycle Kuryl substituent, aryl substituent and heteroaryl substituent may be substituted, \n (Vii) OR5, wherein R5 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, wherein Substituent, cycloalkyl substituent, heterocyclyl substituent, aryl substituent, heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or alkyl-heteroaryl substituent are substituted You can, \n (Viii) SR6, wherein R6 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, wherein Substituent, cycloalkyl substituent, heterocyclyl substituent, aryl substituent and heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or alkyl-heteroaryl substituent are substituted You can, \n (Ix) NR7R8, wherein R7 and R8 are independently of one another hydrogen, alkyl, cycloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl. And further wherein said alkyl substituent, cycloalkyl substituent, heterocyclyl substituent, aryl substituent and heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or Alkyl-heteroaryl substituents may be substituted or R7 and R8 taken together mean cycloalkyl or heterocyclyl, wherein said cycloalkyl and heterocyclyl may be further substituted. .\n\n\n\n\n\n\n \n\n  Ｒ３及びＲ４は互いに無関係に水素又はＮＲ９Ｒ１０を意味してよいが、但し、Ｒ３＝ＮＲ９Ｒ１０である場合にはＲ４＝Ｈであり、かつＲ４＝ＮＲ９Ｒ１０である場合にはＲ３＝Ｈであり、その際、Ｒ９は水素、アルキル、シクロアルキル、ヘテロシクリル、アリール、ヘテロアリール、アルキル−シクロアルキル、アルキル−ヘテロシクリル、アルキル−アリール又はアルキル−ヘテロアリールであってよく、かつここで更に前記アルキル置換基、シクロアルキル置換基、ヘテロシクリル置換基、アリール置換基及びヘテロアリール置換基、アルキル−シクロアルキル置換基、アルキル−ヘテロシクリル置換基、アルキル−アリール置換基又はアルキル−ヘテロアリール置換基は置換されていてよく、かつ\n\n  Ｒ１０は：−Ｃ（Ｙ）ＮＲ１１Ｒ１２を意味してよく、その際、Ｙ＝Ｏ、Ｓであり、かつ\n\n  Ｒ１１及びＲ１２は互いに無関係に以下のものを意味する\n\n（ｉ）水素、\n\n（ｉｉ）非置換又は置換のアルキル、その際、アルキル基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉｉ）非置換又は置換のシクロアルキル、その際、シクロアルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＯＨ、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｖ）非置換又は置換のヘテロシクリル、その際、ヘテロシクリル基はＯＨ、Ｏ−アルキル、Ｏ−アリール、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−アリール、アルキル、アルキル−アリール又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｖ）非置換又は置換のアリール、その際、アリール基は、Ｆ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、ｎは１、２又は３の値を取ることができる、\n\n（ｖｉ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＣ（Ｏ）−アルキル−アリール、ＮＨＣ（Ｏ）−アルキル−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−ヘテロシクリル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル−アリール、ＮＨＳＯ\n２\n−アルキル−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＣ（Ｏ）−アルキル−アリール、ＯＣ（Ｏ）−アルキル−ヘテロアリール、ＯＳＯ\n３\nＨ、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−ヘテロシクリル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＯＳＯ\n２\n−アルキル−アリール、ＯＳＯ\n２\n−アルキル−ヘテロアリール、ＯＰ（Ｏ）（ＯＨ）\n２\n、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n２\nＮＨ−アルキル−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯーアルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−アルキル−アリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｖｉｉ）−Ｃ（Ｏ）Ｒ１７、その際、Ｒ１７はアルキル、アリール又はヘテロアリールであってよく、かつここで更に前記アルキル置換基及びアリール置換基は置換されていてよいか、又は\n\n  Ｒ１１及びＲ１２は一緒になって\n\n（ｖｉｉｉ）シクロアルキル又はヘテロシクリルを意味してよい、\n\n  Ｒ１０は：−Ｃ（Ｙ）ＮＲ１３Ｒ１４を意味してよく、その際、Ｙ＝ＮＨであり、かつ\n\n  Ｒ１３及びＲ１４は互いに無関係に以下のものを意味する\n\n（ｉ）水素、\n\n（ｉｉ）非置換又は置換のアルキル、その際、アルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n３\nＨ、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉｉ）非置換又は置換のシクロアルキル、その際、シクロアルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＯＨ、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｖ）非置換又は置換のヘテロシクリル、その際、ヘテロシクリル基はＯＨ、Ｏ−アルキル、Ｏ−アリール、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−アリール、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｖ）非置換又は置換のアリール、その際、アリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、かつｎは１、２又は３の値を取ることができる、\n\n（ｖｉ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＣＮ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよいか、又は\n\n  Ｒ１３及びＲ１４は一緒になって\n\n（ｖｉｉ）シクロアルキル又はヘテロシクリルを意味してよい、\n\n  Ｒ１０は：−Ｃ（ＮＲ１５）Ｒ１６を意味してよく、その際、Ｒ１５＝Ｈであり、かつ\n\n  Ｒ１６は以下のものを意味してよい\n\n（ｉ）非置換又は置換のアルキル、その際、アルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n３\nＨ、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉ）非置換又は置換のシクロアルキル、その際、シクロアルキル基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−シクロアルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＯＨ、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｉｉ）非置換又は置換のヘテロシクリル、その際、ヘテロシクリル基はＯＨ、Ｏ−アルキル、Ｏ−アリール、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−アリール、アルキル又はアリールで一置換又は同一もしくは異なって多置換されていてよい、\n\n（ｉｖ）非置換又は置換のアリール、その際、アリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−シクロアルキル、ＮＨ−アルキル−ヘテロシクリル、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、ＮＨ−アルキル−ＮＨ\n２\n、ＮＨ−アルキル−ＯＨ、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−シクロアルキル、Ｓ−ヘテロシクリル、Ｓ−アリール、Ｓ−ヘテロアリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、Ｏ−アルキル−シクロアルキル、Ｏ−アルキル−ヘテロシクリル、Ｏ−アルキル−アリール、Ｏ−アルキル−ヘテロアリール、Ｏ−アルキル−ＯＨ、Ｏ−（ＣＨ\n２\n）\nｎ\n−Ｏ、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ−アルキル、ＳＯ−アリール、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n２\nＮＨ−ヘテロアリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよく、かつｎは１、２又は３の値を取ることができる、\n\n（ｖ）非置換又は置換のヘテロアリール、その際、ヘテロアリール基はＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＦ\n３\n、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−シクロアルキル、ＮＨ−ヘテロシクリル、ＮＨ−アリール、ＮＨ−ヘテロアリール、ＮＨ−アルキル−アリール、ＮＨ−アルキル−ヘテロアリール、Ｎ（アルキル）\n２\n、ＮＨＣ（Ｏ）−アルキル、ＮＨＣ（Ｏ）−シクロアルキル、ＮＨＣ（Ｏ）−ヘテロシクリル、ＮＨＣ（Ｏ）−アリール、ＮＨＣ（Ｏ）−ヘテロアリール、ＮＨＳＯ\n２\n−アルキル、ＮＨＳＯ\n２\n−アリール、ＮＨＳＯ\n２\n−ヘテロアリール、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、Ｓ−アリール、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−シクロアルキル、Ｏ−ヘテロシクリル、Ｏ−アリール、Ｏ−ヘテロアリール、ＯＣ（Ｏ）−アルキル、ＯＣ（Ｏ）−シクロアルキル、ＯＣ（Ｏ）−ヘテロシクリル、ＯＣ（Ｏ）−アリール、ＯＣ（Ｏ）−ヘテロアリール、ＯＳＯ\n２\n−アルキル、ＯＳＯ\n２\n−シクロアルキル、ＯＳＯ\n２\n−アリール、ＯＳＯ\n２\n−ヘテロアリール、Ｃ（Ｏ）−アルキル、Ｃ（Ｏ）−アリール、Ｃ（Ｏ）−ヘテロアリール、ＣＯ\n２\nＨ、ＣＯ\n２\n−アルキル、ＣＯ\n２\n−シクロアルキル、ＣＯ\n２\n−ヘテロシクリル、ＣＯ\n２\n−アリール、ＣＯ\n２\n−ヘテロアリール、ＣＯ\n２\n−アルキル−シクロアルキル、ＣＯ\n２\n−アルキル−ヘテロシクリル、ＣＯ\n２\n−アルキル−アリール、ＣＯ\n２\n−アルキル−ヘテロアリール、Ｃ（Ｏ）−ＮＨ\n２\n、Ｃ（Ｏ）ＮＨ−アルキル、Ｃ（Ｏ）ＮＨ−シクロアルキル、Ｃ（Ｏ）ＮＨ−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アリール、Ｃ（Ｏ）ＮＨ−ヘテロアリール、Ｃ（Ｏ）ＮＨ−アルキル−シクロアルキル、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロシクリル、Ｃ（Ｏ）ＮＨ−アルキル−アリール、Ｃ（Ｏ）ＮＨ−アルキル−ヘテロアリール、Ｃ（Ｏ）Ｎ（アルキル）\n２\n、Ｃ（Ｏ）Ｎ（シクロアルキル）\n２\n、Ｃ（Ｏ）Ｎ（アリール）\n２\n、Ｃ（Ｏ）Ｎ（ヘテロアリール）\n２\n、ＳＯ\n２\n−アルキル、ＳＯ\n２\n−アリール、ＳＯ\n２\nＮＨ\n２\n、ＳＯ\n２\nＮＨ−アルキル、ＳＯ\n２\nＮＨ−アリール、ＳＯ\n３\nＨ、ＳＯ\n２\nＯ−アルキル、ＳＯ\n２\nＯ−アリール、ＳＯ\n２\nＯ−ヘテロアリール、アルキル、シクロアルキル、ヘテロシクリル、アリール又はヘテロアリールで一置換又は同一もしくは異なって多置換されていてよい］で示される一連のピリド［２，３−ｂ］ピラジンからの新規の化合物を記載している。\n\nR3 and R4 may mean hydrogen or NR9R10 independently of each other, provided that R4 = H when R3 = NR9R10 and R3 = H when R4 = NR9R10, , R9 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, and further wherein said alkyl substituent, cycloalkyl The substituent, heterocyclyl substituent, aryl substituent and heteroaryl substituent, alkyl-cycloalkyl substituent, alkyl-heterocyclyl substituent, alkyl-aryl substituent or alkyl-heteroaryl substituent may be substituted; and \n R10 may mean: —C (Y) NR11R12, where Y═O, S, and \n R11 and R12 independently mean the following: \n (I) hydrogen, \n (Ii) unsubstituted or substituted alkyl, wherein the alkyl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (Alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O)- Alkyl-heteroaryl, OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted \n (Iii) unsubstituted or substituted cycloalkyl, wherein the cycloalkyl group is F, Cl, Br, I, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, OH, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , May be mono-substituted or the same or different poly-substituted with alkyl or aryl, \n (Iv) unsubstituted or substituted heterocyclyl, wherein the heterocyclyl group is OH, O-alkyl, O-aryl, NH \n2\n , NH-alkyl, NH-aryl, alkyl, alkyl-aryl or aryl, which may be monosubstituted or identically or differently polysubstituted. \n (V) unsubstituted or substituted aryl, wherein the aryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O -Alkyl-OH, O- (CH \n2\n ) \nn\n -O, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or differently polysubstituted and n may take the values 1, 2 or 3. \n (Vi) unsubstituted or substituted heteroaryl, wherein the heteroaryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O ) -Alkyl-heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Heterocyclyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NHSO \n2\n -Alkyl-aryl, NHSO \n2\n -Alkyl-heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O)- Alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl , OSO \n3\n H, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Heterocyclyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, OSO \n2\n -Alkyl-aryl, OSO \n2\n -Alkyl-heteroaryl, OP (O) (OH) \n2\n , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n2\n NH-alkyl-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or differently polysubstituted, \n (Vii) -C (O) R17, wherein R17 may be alkyl, aryl or heteroaryl, and further wherein the alkyl and aryl substituents may be substituted, or \n R11 and R12 together \n (Viii) may mean cycloalkyl or heterocyclyl; \n R10 may mean: —C (Y) NR13R14, where Y═NH, and \n R13 and R14 independently mean the following: \n (I) hydrogen, \n (Ii) unsubstituted or substituted alkyl, wherein the alkyl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -alkyl, C (O) -aryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n3\n H, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or different and may be polysubstituted. \n (Iii) unsubstituted or substituted cycloalkyl, wherein the cycloalkyl group is F, Cl, Br, I, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, OH, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC ( O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , May be mono-substituted or the same or different poly-substituted with alkyl or aryl, \n (Iv) unsubstituted or substituted heterocyclyl, wherein the heterocyclyl group is OH, O-alkyl, O-aryl, NH \n2\n , NH-alkyl, NH-aryl, alkyl or aryl, which may be monosubstituted or identically or differently polysubstituted. \n (V) unsubstituted or substituted aryl, wherein the aryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O -Alkyl-OH, O- (CH \n2\n ) \nn\n -O, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted and n may take the values 1, 2 or 3. \n (Vi) unsubstituted or substituted heteroaryl, wherein the heteroaryl group is F, Cl, Br, I, CF \n3\n , CN, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O)- Aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted, or \n R13 and R14 together \n (Vii) may mean cycloalkyl or heterocyclyl; \n R10 may mean: -C (NR15) R16, where R15 = H and \n R16 may mean: \n (I) unsubstituted or substituted alkyl, wherein the alkyl group is F, Cl, Br, I, CF \n3\n , NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n3\n H, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or the same or different and may be polysubstituted. \n (Ii) unsubstituted or substituted cycloalkyl, wherein the cycloalkyl group is F, Cl, Br, I, NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Cycloalkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, OH, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC ( O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , May be mono-substituted or the same or different poly-substituted with alkyl or aryl, \n (Iii) unsubstituted or substituted heterocyclyl, wherein the heterocyclyl group is OH, O-alkyl, O-aryl, NH \n2\n , NH-alkyl, NH-aryl, alkyl or aryl, which may be monosubstituted or identically or differently polysubstituted. \n (Iv) unsubstituted or substituted aryl, wherein the aryl group is F, Cl, Br, I, CF \n3\n , NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH -Alkyl-NH \n2\n , NH-alkyl-OH, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF \n3\n O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O -Alkyl-OH, O- (CH \n2\n ) \nn\n -O, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO-alkyl, SO-aryl, SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n2\n NH-heteroaryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or identically or differently polysubstituted and n may take the values 1, 2 or 3. \n (V) unsubstituted or substituted heteroaryl, wherein the heteroaryl group is F, Cl, Br, I, CF \n3\n , NH \n2\n , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) \n2\n , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHSO \n2\n -Alkyl, NHSO \n2\n -Aryl, NHSO \n2\n -Heteroaryl, NO \n2\n , SH, S-alkyl, S-aryl, OH, OCF \n3\n , O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O)- Aryl, OC (O) -heteroaryl, OSO \n2\n -Alkyl, OSO \n2\n -Cycloalkyl, OSO \n2\n -Aryl, OSO \n2\n -Heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO \n2\n H, CO \n2\n -Alkyl, CO \n2\n -Cycloalkyl, CO \n2\n -Heterocyclyl, CO \n2\n -Aryl, CO \n2\n -Heteroaryl, CO \n2\n -Alkyl-cycloalkyl, CO \n2\n -Alkyl-heterocyclyl, CO \n2\n -Alkyl-aryl, CO \n2\n -Alkyl-heteroaryl, C (O) -NH \n2\n , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl -Cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) \n2\n , C (O) N (cycloalkyl) \n2\n , C (O) N (aryl) \n2\n , C (O) N (heteroaryl) \n2\n , SO \n2\n -Alkyl, SO \n2\n -Aryl, SO \n2\n NH \n2\n , SO \n2\n NH-alkyl, SO \n2\n NH-aryl, SO \n3\n H, SO \n2\n O-alkyl, SO \n2\n O-aryl, SO \n2\n Novel compounds from a series of pyrido [2,3-b] pyrazines represented by O-heteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, which may be monosubstituted or identically or differently polysubstituted] Is described.\n\n\n\n\n\n\n \n\n  表現\"アルキル\"は、本発明の範囲では、分枝鎖状又は直鎖状であってよく、１〜８個の炭素原子を有する非環式の飽和又は不飽和の炭化水素基、すなわちＣ\n１\n〜Ｃ\n８\n−アルカニル、Ｃ\n２\n〜Ｃ\n８\n−アルケニル及びＣ\n２\n〜Ｃ\n８\n−アルキニルを含む。この場合、アルケニルは少なくとも１個のＣ−Ｃ−二重結合を有し、アルキニルは少なくとも１種のＣ−Ｃ三重結合を有する。有利に、アルキルは、メチル、エチル、ｎ−プロピル、２−プロピル、ｎ−ブチル、ｓ−ブチル、ｔ−ブチル、ｎ−ペンチル、イソ−ペンチル、ネオ−ペンチル、ｎ−ヘキシル、２−ヘキシル、ｎ−オクチル、エチレニル（ビニル）、エチニル、プロペニル（−ＣＨ\n２\nＣＨ＝ＣＨ\n２\n；−ＣＨ＝ＣＨ−ＣＨ\n３\n、−Ｃ（＝ＣＨ\n２\n）−ＣＨ\n３\n）、プロピニル（−ＣＨ\n２\n−Ｃ≡ＣＨ、−Ｃ≡Ｃ−ＣＨ\n３\n）、ブテニル、ブチニル、ペンテニル、ペンチニル、ヘキセニル、ヘキシニル、ヘプテニル、ヘプチニル、オクテニル及びオクチニルを有する群から選択される。\n\nThe expression “alkyl”, within the scope of the present invention, may be branched or straight chain and is an acyclic saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms, ie C \n1.\n -C \n8\n - \nalkanyl,\n C 2 ~C \n8\n - alkenyl and \nC\n 2 -C \n8\n - includes alkynyl. In this case, the alkenyl has at least one C—C—double bond and the alkynyl has at least one C—C triple bond. Preferably, alkyl is methyl, ethyl, n-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl, n-octyl, ethylenyl (vinyl), ethynyl, propenyl (—CH \n2\n CH═CH \n2\n ; —CH═CH—CH \n3\n , —C (═CH \n2\n ) —CH \n3\n ), propynyl (—CH \n2\n —C≡CH) , —C≡C—CH \n3\n ), butenyl, butynyl, pentenyl, pentynyl, hexenyl, hexynyl, heptenyl, heptynyl, octenyl and octynyl.\n\n\n\n\n\n\n \n\n  表現\"シクロアルキル\"は、本発明の目的のためには、飽和又は不飽和であってよく、３〜１２個の炭素原子を有する環式炭化水素基を意味する。一般構造Ｉの化合物へは、それぞれシクロアルキル基の任意の可能な環員を介して結合されていてよい。このシクロアルキル基は、二環系又は多環系の一部であってもよい。\n\n\n  The expression “cycloalkyl” means, for the purposes of the present invention, a cyclic hydrocarbon group which may be saturated or unsaturated and has 3 to 12 carbon atoms. Each of the compounds of general structure I may be linked via any possible ring member of the cycloalkyl group. The cycloalkyl group may be part of a bicyclic or polycyclic system.\n\n\n\n\n\n\n\n \n\n  表現\"ヘテロシクリルは、少なくとも１個、場合により２、３、４又は５個のヘテロ原子を含有する３、４、５、６、７又は８員の環式有機基を表し、その際、このヘテロ原子は同一又は異なり、かつこの環式基は飽和又は不飽和で芳香族ではない。一般構造Ｉの化合物へは、それぞれヘテロシクリル基の任意の可能な環員を介して結合されていてよい。この複素環は、二環系又は多環系の一部であってもよい。有利なヘテロ原子は、窒素、酸素及び硫黄である。ヘテロシクリル基が、テトラヒドロフリル、テトラヒドロピラニル、ピロリジニル、ピペリジニル、ピペラジニル及びモルホリニルを有する群から選択されることが好ましい。\n\n\n  The expression “heterocyclyl” represents a 3, 4, 5, 6, 7 or 8 membered cyclic organic group containing at least 1, optionally 2, 3, 4 or 5 heteroatoms, The atoms are the same or different and the cyclic group is saturated or unsaturated and not aromatic, each compound of general structure I may be bonded via any possible ring member of the heterocyclyl group. Heterocycles may be part of a bicyclic or polycyclic system.Preferred heteroatoms are nitrogen, oxygen and sulfur, where the heterocyclyl group is tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl And preferably selected from the group having morpholinyl.\n\n\n\n\n\n\n\n \n\n  表現\"アリール\"は、本発明の範囲では、６〜１４個の炭素原子を有する芳香族炭化水素、とりわけフェニル、ナフチル及びアントラセニルを意味する。これらの基は付加的な飽和、（部分）不飽和又は芳香族環系と縮合していてもよい。一般構造Ｉの化合物へは、それぞれアリール基の任意の可能な環員を介して結合されていてよい。\n\n\n  The expression “aryl” means within the scope of the invention aromatic hydrocarbons having 6 to 14 carbon atoms, in particular phenyl, naphthyl and anthracenyl. These groups may be condensed with additional saturated, (partially) unsaturated or aromatic ring systems. Each of the compounds of general structure I may be linked via any possible ring member of the aryl group.\n\n\n\n\n\n\n\n \n\n  表現\"ヘテロアリール\"は、少なくとも１個、また２、３、４又は５個のヘテロ原子を有する５、６又は７員の環式芳香族基を表し、その際、前記ヘテロ原子は同一又は異なる。一般構造Ｉの化合物へは、それぞれヘテロアリール基の任意の可能な環員を介して結合されていてよい。この複素環は、二環系又は多環系の一部であってもよい。有利なヘテロ原子は、窒素、酸素及び硫黄である。ヘテロアリール基が、ピロリル、フリル、チエニル、チアゾリル、オキサゾリル、イソキサゾリル、ピラゾリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル、ピラジニル、フタラジニル、インドリル、インダゾリル、インドリジニル、キノリニル、イソキノリニル、キノキサリニル、キナゾリニル、カルバゾリル、フェナジニル、フェノチアジニル、アクリジニルを有する群から選択されることが好ましい。\n\n\n  The expression “heteroaryl” denotes a 5, 6 or 7-membered cyclic aromatic group having at least 1, and 2, 3, 4 or 5 heteroatoms, the heteroatoms being identical or different . Each of the compounds of general structure I may be linked via any possible ring member of the heteroaryl group. This heterocycle may be part of a bicyclic or polycyclic system. Preferred heteroatoms are nitrogen, oxygen and sulfur. Heteroaryl groups are pyrrolyl, furyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, phthalazinyl, indolyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinazolinyl, quinazolinyl, quinazolinyl, quinazolinyl It is preferably selected from the group having thiazinyl, acridinyl.\n\n\n\n\n\n\n\n \n\n  表現\"アルキル−シクロアルキル\"、\"アルキル−ヘテロシクリル\"、\"アルキル−アリール\"又は\"アルキル−ヘテロアリール\"は、本発明の目的のためには、アルキル、シクロアルキル、ヘテロシクリル、アリール及びヘテロアリールが前記の意味を表し、かつシクロアルキル基、ヘテロシクリル基、アリール基及びヘテロアリール基はＣ\n１\n〜Ｃ\n８\n−アルキル基を介して一般式Ｉの化合物と結合していることを意味する。\n\nThe expressions “alkyl-cycloalkyl”, “alkyl-heterocyclyl”, “alkyl-aryl” or “alkyl-heteroaryl” are for the purposes of the present invention alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl as defined above. the meaning of, and cycloalkyl group, a heterocyclyl group, aryl and heteroaryl groups are C \n1\n -C 8 \n-\n it means that it is combined with a compound of general formula I through an alkyl group.\n\n\n\n\n\n\n \n\n  \"アルキル\"、\"シクロアルキル\"、\"ヘテロシクリル\"、\"アリール\"、\"ヘテロアリール\"、\"アルキル−シクロアルキル\"、\"アルキル−ヘテロシクリル\"、\"アルキル−アリール\"及び\"アルキル−ヘテロアリール\"を有する文脈において、置換されたという表現は本発明の範囲では、明細書又は特許請求の範囲で特に明示されていない限りは、１つ以上の水素基がＦ、Ｃｌ、Ｂｒ、Ｉ、ＣＮ、ＣＦ\n３\n、ＮＨ\n２\n、ＮＨ−アルキル、ＮＨ−アリール、Ｎ（アルキル）\n２\n、ＮＯ\n２\n、ＳＨ、Ｓ−アルキル、ＯＨ、ＯＣＦ\n３\n、Ｏ−アルキル、Ｏ−アリール、ＯＳＯ\n３\nＨ、ＯＰ（Ｏ）（ＯＨ）\n２\n、ＣＨＯ、ＣＯ\n２\nＨ、ＳＯ\n３\nＨ又はアルキルによって置換されていることを表す。これらの置換基は同一もしくは異なってよく、かつ置換はアルキル基、シクロアルキル基、ヘテロシクリル基、アリール基及びヘテロアリール基のそれぞれ任意の可能な位置に存在してよい。\n\nContext with “alkyl”, “cycloalkyl”, “heterocyclyl”, “aryl”, “heteroaryl”, “alkyl-cycloalkyl”, “alkyl-heterocyclyl”, “alkyl-aryl” and “alkyl-heteroaryl” In the scope of the present invention, unless otherwise specified in the specification or claims, one or more hydrogen groups are F, Cl, Br, I, CN, CF \n3\n , NH \n2,\n NH- alkyl, NH- aryl, N \n \n(alkyl) 2, NO 2, SH,\n \n S- alkyl, OH, \nOCF\n 3, O- alkyl, O- \naryl, OSO 3 H, OP (O\n ) (OH) \n2\n , represents substituted with CHO, CO \n2\n H, SO \n3\n H or alkyl. These substituents may be the same or different, and the substitution may be present at any possible position of the alkyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group.\n\n\n\n\n\n\n \n\n  多置換された基とは、異なる原子又は同一の原子のいずれかで複数箇所、例えば２箇所又は３箇所で置換されている基、例えばＣＦ\n３\n、−ＣＨ\n２\nＣＦ\n３\nの場合のように同一のＣ原子で３箇所で置換されているか、又は−ＣＨ（ＯＨ）−ＣＨ＝ＣＨ−ＣＨＣｌ\n２\nの場合のように異なる位置で３箇所で置換されている基を表すべきである。多置換は同じ又は異なる置換基で行うことができる。\n\nThe multi-substituted group, different atom or a plurality of locations in one of the same atoms, for example groups substituted with two points or three points, for example CF \n3,\n same as in the case of -CH \n2\n CF \n3\n or it is substituted at three positions by C atoms, or should represent a group substituted with -CH (OH) 3 places at different positions as in the case of -CH = CH-CHCl \n2.\n Multiple substitutions can be made with the same or different substituents.\n\n\n\n\n\n\n \n\n  一般式Ｉの本発明による化合物が少なくとも１つの不斉中心を有する場合には、この化合物はラセミ体の形、純粋なエナンチオマー及び／又はジアステレオマーの形又はエナンチオマー及び／又はジアステレオマーの混合物の形で存在することができる。この混合物は、立体異性体のそれぞれ任意の混合比で存在することができる。\n\n\n  If the compounds according to the invention of the general formula I have at least one asymmetric center, the compounds are in racemic form, pure enantiomers and / or diastereomeric forms or mixtures of enantiomers and / or diastereomers. Can exist in the form of This mixture can be present in any mixing ratio of the stereoisomers.\n\n\n\n\n\n\n\n \n\n  例えば、１つ以上のキラル中心を有しかつラセミ体として存在する一般式Ｉの本発明による化合物は、自体公知の方法により、光学的異性体、つまりエナンチオマー又はジアステレオマーに分離することができる。この分離は、キラル相でのカラム分離により又は光学活性溶液からの再結晶により又は光学活性酸又は塩基の使用下で又は光学活性試薬、例えば光学活性アルコールを用いた誘導化により、及び引き続く残分の分離により行うことができる。\n\n\n  For example, the compounds according to the invention of the general formula I which have one or more chiral centers and exist as racemates can be separated into optical isomers, ie enantiomers or diastereomers, by methods known per se. . This separation may be accomplished by column separation in a chiral phase or by recrystallization from an optically active solution or by use of an optically active acid or base or by derivatization with an optically active reagent such as an optically active alcohol, and subsequent residues. Separation can be performed.\n\n\n\n\n\n\n\n \n\n  可能な場合には、本発明による化合物は互変異性体の形で存在することができる。\n\n\n  If possible, the compounds according to the invention can exist in tautomeric forms.\n\n\n\n\n\n\n\n \n\n  一般式Ｉの本発明による化合物は、十分に塩基性の基、例えば第１級、第２級又は第３級アミンを有する場合に、無機酸及び有機酸を用いて生理学的に認容性の塩に変換することができる。一般式Ｉによる本発明による化合物の調剤学的に許容される塩は、塩酸、臭化水素酸、硫酸、リン酸、メタンスルホン酸、ｐ−トルエンスルホン酸、炭酸、ギ酸、酢酸、トリフルオロ酢酸、スルホ酢酸、シュウ酸、マロン酸、マレイン酸、コハク酸、酒石酸、ブドウ酸、リンゴ酸、エンボン酸、マンデル酸、フマル酸、乳酸、クエン酸、グルタミン酸又はアスパラギン酸と共に形成される。生成された塩は、特に、塩酸塩、臭化水素酸塩、硫酸塩、硫酸水素塩、リン酸塩、メタンスルホン酸塩、トシル酸塩、炭酸塩、炭酸水素塩、ギ酸塩、酢酸塩、トリフルオロメタンスルホン酸塩、スルホ酢酸塩、シュウ酸塩、マロン酸塩、マレイン酸塩、コハク酸塩、酒石酸塩、リンゴ酸塩、エンボン酸塩、マンデル酸塩、フマル酸塩、乳酸塩、クエン酸塩、グルタミン酸塩及びアスパラギン酸塩である。本発明による化合物の生成された塩の化学量論は、この場合に１の整数倍の数であるか又は１の非整数倍の数である。\n\n\n  The compounds according to the invention of the general formula I are physiologically tolerable salts with inorganic and organic acids when they have a sufficiently basic group, for example a primary, secondary or tertiary amine. Can be converted to The pharmaceutically acceptable salts of the compounds according to the invention according to general formula I are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, trifluoroacetic acid , Sulfoacetic acid, oxalic acid, malonic acid, maleic acid, succinic acid, tartaric acid, glucose acid, malic acid, embonic acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid. The salts produced are in particular the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, methanesulfonate, tosylate, carbonate, bicarbonate, formate, acetate, Trifluoromethanesulfonate, sulfoacetate, oxalate, malonate, maleate, succinate, tartrate, malate, embonate, mandelate, fumarate, lactate, citric acid Salts, glutamate and aspartate. The stoichiometry of the salts produced of the compounds according to the invention is in this case an integer multiple of 1 or a non-integer multiple of 1.\n\n\n\n\n\n\n\n \n\n  一般式Ｉの本発明による化合物は、十分に酸性の基、例えばカルボキシル基を有する場合に、無機塩基及び有機塩基を用いて生理学的に許容される塩に変換することができる。無機塩基として、例えば水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、有機塩基としてエタノールアミン、ジエタノールアミン、トリエタノールアミン、シクロヘキシルアミン、ジベンジルエチレンジアミン及びリシンが挙げられる。本発明による化合物の生成された塩の化学量論は、この場合に１の整数倍の数であるか又は１の非整数倍の数である。\n\n\n  A compound according to the invention of the general formula I, when it has a sufficiently acidic group, for example a carboxyl group, can be converted into a physiologically acceptable salt using inorganic and organic bases. Examples of the inorganic base include sodium hydroxide, potassium hydroxide and calcium hydroxide, and examples of the organic base include ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dibenzylethylenediamine and lysine. The stoichiometry of the salts produced of the compounds according to the invention is in this case an integer multiple of 1 or a non-integer multiple of 1.\n\n\n\n\n\n\n\n \n\n  同様に、例えば溶媒又は水溶液からの晶出により得ることができる本発明による化合物の溶媒和物、特に水和物が有利である。この場合に、１、２、３又は任意の数の溶媒分子又は水分子が本発明による化合物と結合して溶媒和物及び水和物になることができる。\n\n\n  Preference is likewise given to solvates, in particular hydrates, of the compounds according to the invention which can be obtained, for example, by crystallization from solvents or aqueous solutions. In this case, 1, 2, 3 or any number of solvent molecules or water molecules can be combined with the compounds according to the invention to form solvates and hydrates.\n\n\n\n\n\n\n\n \n\n  化学物質が、多形又は変態として表される多様な規則状態で存在する固体を形成することは公知である。多形物質の多様な変態は、その物理特性において著しく異なる。一般式Ｉの本発明による化合物は、多様な多形で存在することができ、その際、所定の変態が準安定性である。\n\n\n  It is known that chemicals form solids that exist in a variety of ordered states expressed as polymorphs or transformations. The various transformations of polymorphic substances differ significantly in their physical properties. The compounds according to the invention of the general formula I can exist in various polymorphs, in which the given modification is metastable.\n\n\n\n\n\n\n\n \n\n  本発明による置換されたピリド［２，３−ｂ］ピラジンの製造方法を以下に詳説する。\n\n\n  The method for preparing substituted pyrido [2,3-b] pyrazine according to the present invention is described in detail below.\n\n\n\n\n\n\n\n \n\n  一般式Ｉの化合物は以下の反応式（反応式１〜５）に従って得られる：\n\n\n反応式１\n \n\n\n \n \n\n\nCompounds of general formula I are obtained according to the following reaction schemes (reaction schemes 1-5): \n \nReaction formula 1\n \n \n \n \n \n\n\n\n\n\n\n \n\n  一般式Ｉで示され、式中、置換基Ｒ１及び／又はＲ２は基ＯＲ５、ＳＲ６、ＮＲ７Ｒ８であることが望ましい本発明によるピリド［２，３−ｂ］ピラジンの選択された例のための前駆物質は、例えば反応式２の方法もしくは当業者に公知の相応の方法に従って得られる。\n\n\n  Precursor for selected examples of pyrido [2,3-b] pyrazines according to the invention of the general formula I, wherein the substituents R1 and / or R2 are preferably the groups OR5, SR6, NR7R8 The material is obtained, for example, according to the method of Scheme 2 or a corresponding method known to those skilled in the art.\n\n\n\n\n\n\n\n\n\n \n反応式２\nReaction formula 2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  一般式Ｉで示され、式中、Ｒ９≠Ｈであることが望ましい本発明によるピリド［２，３−ｂ］ピラジンの選択された例の前駆物質は、例えば反応式３の方法に従って得られる。\n\n\n  Selected examples of precursors of pyrido [2,3-b] pyrazine according to the present invention represented by the general formula I, wherein R9 ≠ H are preferably obtained according to the method of Scheme 3, for example.\n\n\n\n\n\n\n\n\n\n \n反応式３\nReaction formula 3\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  反応式１〜３からの前駆物質４、７及び１３を一般式Ｉによる本発明による置換されたピリド［２，３−ｂ］に変換することは、例えば反応式４に従って実施できる。\n\n\n  Conversion of precursors 4, 7, and 13 from Schemes 1-3 to substituted pyrido [2,3-b] according to the invention according to general formula I can be carried out, for example, according to Scheme 4.\n\n\n\n\n\n\n\n\n\n \n反応式４\nReaction formula 4\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  一般式Ｉで示され、式中、置換基Ｒ１及びＲ２は選択されたカルボン酸エステル、カルボン酸アミド、スルホン酸エステル又はスルホンアミド基で置換された基であってよい本発明によるピリド［２，３−ｂ］ピラジンの選択された例は、例えば反応式５の方法又は当業者に公知の相応の方法に従って得られる。\n\n\n  The pyrido [2, 2, wherein the substituents R1 and R2 can be a group substituted with a selected carboxylic acid ester, carboxylic acid amide, sulfonic acid ester or sulfonamide group, represented by the general formula I Selected examples of 3-b] pyrazine are obtained, for example, according to the method of Scheme 5 or corresponding methods known to those skilled in the art.\n\n\n\n\n\n\n\n\n\n \n反応式５\nReaction formula 5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  これらの出発化合物は、市販されているか又は自体公知の方法により製造することができる。出発物質４、７及び１０〜１３は、一般式Ｉの本発明によるピリドピラジンの製造のための有用な中間化合物である。\n\n\n  These starting compounds are commercially available or can be prepared by methods known per se. Starting materials 4, 7, and 10-13 are useful intermediate compounds for the preparation of pyridopyrazine according to the invention of general formula I.\n\n\n\n\n\n\n\n \n\n  出発化合物及び目標化合物の製造のために、例えば以下の一次文献を指摘したい。そしてその内容はこれをもって本願の開示の要素となるべきである：\n\n\n \n \n\n\nFor the preparation of the starting and target compounds, for example, the following primary literature is pointed out. And its contents should be an element of the disclosure of this application: \n \n \n \n \n\n\n\n\n\n\n \n\n  一般式Ｉの化合物の製造のための一般的な指示：\n\n  反応式１：第一段階\n\n  ２，６−ジアミノ−３−ニトロピリジン又は２−アミノ−３，５−ジニトロ−ピリジンを好適な不活性溶剤、例えばメタノール、エタノール、ジメチルホルムアミド又はジオキサン中に溶解させる。触媒、例えばラネーニッケル、炭素上パラジウム又は二酸化白金（ＩＶ）を添加した後に、反応混合物を水素雰囲気下で、圧力を１〜５バールに調節した状態にしておく。該反応混合物を複数時間、例えば１〜１６時間２０℃〜６０℃の温度範囲で反応させてよい。反応が完了した後に、不溶の残留物を濾過分離し、その際、濾材は、例えばシリカゲル、セライト又は市販のガラス繊維フィルタを含んでなってよく、そして引き続き相応の溶剤で洗浄する。粗生成物は、溶液中に存在して、更なる後精製無くして後続の反応に使用される。\n\nGeneral instructions for the preparation of compounds of general formula I: \n Scheme 1: First Step 2,6-diamino-3-nitropyridine or 2-amino-3,5-dinitro-pyridine is dissolved in a suitable inert solvent such as methanol, ethanol, dimethylformamide or dioxane. After the addition of a catalyst such as Raney nickel, palladium on carbon or platinum (IV) dioxide, the reaction mixture is left under a hydrogen atmosphere and the pressure is adjusted to 1-5 bar. The reaction mixture may be reacted at a temperature range of 20 ° C. to 60 ° C. for a plurality of hours, for example 1 to 16 hours. After the reaction is complete, the insoluble residue is filtered off, in which case the filter medium may comprise, for example, silica gel, celite or commercially available glass fiber filters and is subsequently washed with a corresponding solvent. The crude product is present in solution and is used in subsequent reactions without further purification.\n\n\n\n\n\n\n \n\n  第二段階\n\n  １，２−ジオン誘導体を好適な不活性溶剤、例えばメタノール、エタノール、ジオキサン、トルエン又はジメチルホルムアミド中に装入する。２，３，６−トリアミノピリジン又は２，３，５−トリアミノピリジンを還元の直後に、装入された１，２−ジオンに対して前述した溶剤の１種に粗生成物を溶かした溶液として、場合により酸、例えば酢酸又は塩基、例えば水酸化カリウムを添加しつつ添加する。該反応混合物を、２０℃〜８０℃の温度範囲において幾らかの時間、例えば２０分〜４０時間反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機溶剤を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばジオキサンからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\nSecond Step The 1,2-dione derivative is charged into a suitable inert solvent such as methanol, ethanol, dioxane, toluene or dimethylformamide. Immediately after the reduction of 2,3,6-triaminopyridine or 2,3,5-triaminopyridine, the crude product was dissolved in one of the solvents described above for the 1,2-dione charged. As a solution, an acid, for example acetic acid or a base, for example potassium hydroxide, is optionally added. The reaction mixture may be reacted at a temperature range of 20 ° C. to 80 ° C. for some time, for example 20 minutes to 40 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. If dimethylformamide is used, the reaction mixture is stirred into a large amount of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and organic Concentrate the solvent in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, such as dioxane, or by column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n \n\n  反応式２：第一段階\n\n  ２，３，６−トリアミノピリジン又は２，３，５−トリアミノピリジンを還元の直後に、前記の溶剤の１種中に粗生成物を溶かした溶液として装入する。シュウ酸誘導体、例えばシュウ酸ジエチルエステル又は塩化オキサリルを添加した後に、反応混合物を、場合により酸、例えば塩酸、硫酸又は酢酸を添加しつつ２０℃〜１５０℃の温度範囲で幾らかの時間、例えば１０分〜２４時間反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機溶剤を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばジオキサン又はトルエンからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\nReaction Formula 2: First Stage 2,3,6-triaminopyridine or 2,3,5-triaminopyridine is charged immediately after the reduction as a solution in which the crude product is dissolved in one of the above solvents. To do. After adding an oxalic acid derivative, such as oxalic acid diethyl ester or oxalyl chloride, the reaction mixture is allowed to react for some time at a temperature range of 20 ° C. to 150 ° C. with optional addition of an acid such as hydrochloric acid, sulfuric acid or acetic acid, for example You may make it react for 10 minutes-24 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. If dimethylformamide is used, the reaction mixture is stirred into a large amount of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and organic Concentrate the solvent in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, such as dioxane or toluene, or by column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n \n\n  第二段階\n\n  ジオン誘導体８を好適な不活性溶剤、例えばジメチルホルムアミド、ジオキサン又はトルエン中に又は溶剤無しで装入する。塩素化剤、例えば塩化ホスホリル又は塩化チオニルを室温で添加し、そして反応混合物を２０℃〜１００℃の温度範囲で幾らかの時間、例えば１時間〜２４時間反応させてよい。反応が完了した後に、反応混合物を水に注ぎ、そして好適な水性塩基、例えば水酸化ナトリウム液で中和する。場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、そして残留する固体を真空中で乾燥させるか、又は水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機相を真空中で濃縮させる。残留する粗生成物の精製は、好適な溶剤、例えばジオキサン又はトルエンからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\nSecond Step The dione derivative 8 is charged in a suitable inert solvent such as dimethylformamide, dioxane or toluene or without solvent. A chlorinating agent such as phosphoryl chloride or thionyl chloride may be added at room temperature and the reaction mixture may be allowed to react at a temperature range of 20 ° C. to 100 ° C. for some time, eg 1 hour to 24 hours. After the reaction is complete, the reaction mixture is poured into water and neutralized with a suitable aqueous base such as sodium hydroxide solution. The optionally settled precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a suitable solvent and the remaining solid is dried in vacuo, or The aqueous phase is extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and the organic phase is concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, such as dioxane or toluene, or by column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n \n\n  第三段階\n\n  中間段階物質９を相応のアルコール、チオール又はアミンと、かつ場合により好適な塩基、有利には水酸化ナトリウム、ピリジン、トリエチルアミン、炭酸カリウム又はメタノール中のナトリウムエタノラートと、好適な不活性溶剤、例えばジメチルホルムアミド、ジメチルスルホキシド、メタノール、トルエン中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を、幾らかの時間、例えば３０分〜２日、２０℃〜１４０℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミド又はジメチルスルホキシドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機溶剤を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばジオキサン又はトルエンからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\nThird stage Intermediate stage material 9 with the corresponding alcohol, thiol or amine and optionally with a suitable base, preferably sodium ethanolate in sodium hydroxide, pyridine, triethylamine, potassium carbonate or methanol, and a suitable inertness The reaction may be in a solvent such as dimethylformamide, dimethyl sulfoxide, methanol, toluene or in a base as a solvent such as pyridine or triethylamine or without solvent. The reaction mixture may be reacted at a temperature range of 20 ° C. to 140 ° C. for some time, eg 30 minutes to 2 days. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. If dimethylformamide or dimethyl sulfoxide is used, the reaction mixture is stirred into a large amount of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent such as dichloromethane or ethyl acetate. And the organic solvent is concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, such as dioxane or toluene, or by column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n \n\n  反応式３：第一段階\n\n  中間段階物質４及び７を相応の好適な塩化物、臭化物又はトシル酸塩と、かつ場合により好適な塩基、有利には水素化ナトリウム、ピリジン、トリエチルアミン、炭酸カリウム又はメタノール中のナトリウムエタノラートと、好適な不活性溶剤、例えばジメチルホルムアミド、ジメチルスルホキシド、メタノール中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を、幾らかの時間、例えば１時間〜２４時間、２０℃〜１５０℃の温度範囲で反応させてよい。選択的に、中間段階物質４及び７を相応の臭化アリール又はヨウ化アリールと、かつ好適な触媒、例えば酢酸パラジウム又はＰｄ\n２\n（ｄｂａ）\n３\n及び好適な配位子、例えばＢＩＮＡＰと、かつ好適な塩基、例えば炭酸カリウム又はナトリウム−ｔ−ブタノラートと、好適な溶剤、例えばトルエン又はジオキサン中で反応させてよい。該反応混合物を、幾らかの時間、例えば１０時間〜３０時間、６０℃〜１２０℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは場合により存在する触媒残留物を濾過分離し、そして引き続き相応の溶剤で洗浄し、そして溶剤を真空中で除去するか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミド又はジメチルスルホキシドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機溶剤を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばＥｔＯＨからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\nScheme 3: First Stage Intermediate Stage Materials 4 and 7 with the corresponding suitable chloride, bromide or tosylate salt and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or methanol It may be reacted with sodium ethanolate in a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, methanol or a base as solvent such as pyridine or triethylamine or without solvent. The reaction mixture may be reacted at a temperature range of 20 ° C. to 150 ° C. for some time, for example 1-24 hours. Optionally, intermediate stage materials 4 and 7 with the corresponding aryl bromide or aryl iodide and a suitable catalyst such as palladium acetate or Pd \n2\n (dba) \n3\n and a suitable ligand such as BINAP and It may be reacted with a suitable base such as potassium carbonate or sodium-t-butanolate in a suitable solvent such as toluene or dioxane. The reaction mixture may be reacted at a temperature range of 60 ° C. to 120 ° C. for some time, for example 10 to 30 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or filter off any catalyst residue present and subsequently wash with the corresponding solvent and remove the solvent in vacuo or remove the solvent from the reaction mixture in vacuo. If dimethylformamide or dimethyl sulfoxide is used, the reaction mixture is stirred into a large amount of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent such as dichloromethane or ethyl acetate. And the organic solvent is concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as EtOH or by column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n \n\n  反応式４：第一段階\n\n  前記の単位操作に引き続いて、後続反応において、単位操作により生じる生成物を当業者に公知の方法で反応させて本発明による式Ｉの最終生成物を得ることができる。\n\nScheme 4: First Step Subsequent to the unit operation described above, in the subsequent reaction, the product resulting from the unit operation can be reacted in a manner known to those skilled in the art to obtain the final product of formula I according to the present invention. .\n\n\n\n\n\n\n \n\n  こうして、該生成物が反応式４による化合物１４の誘導体であることが望ましい場合に、前記の基本反応を行った後に、反応生成物４、７又は１３を相応のイソシアネート及び場合により好適な塩基、有利には水素化ナトリウム、カリウムヘキサメチルジシラジド、ピリジン、トリエチルアミン又は炭酸カリウムと、好適な不活性溶剤、例えばジメチルホルムアミド、ジメチルスルホキシド、アセトニトリル、ジクロロメタン、１，２−ジクロロエタン又はジオキサン中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を複数時間、例えば１〜２４時間０℃〜８０℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミド又はジメチルスルホキシドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機溶剤を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばエタノール又は酢酸エチルからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\n\n  Thus, if it is desired that the product is a derivative of compound 14 according to Scheme 4, after carrying out the basic reaction, reaction product 4, 7 or 13 is converted to the corresponding isocyanate and optionally a suitable base, Preferably in sodium hydride, potassium hexamethyldisilazide, pyridine, triethylamine or potassium carbonate and in a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, dichloromethane, 1,2-dichloroethane or dioxane or in a solvent In a base such as pyridine or triethylamine or without solvent. The reaction mixture may be reacted at a temperature range of 0 ° C. to 80 ° C. for a plurality of hours, for example 1 to 24 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. When dimethylformamide or dimethyl sulfoxide is used, the reaction mixture is stirred into a large amount of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent such as dichloromethane or ethyl acetate. And the organic solvent is concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as ethanol or ethyl acetate or column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n\n \n\n  又は選択的に、生成物が反応式４による化合物１５の誘導体であることが望ましい場合に、前記の基本反応を行った後に反応生成物４、７又は１３をホスゲン又はカルボニルジイミダゾールと、かつ相応のアミンと、好適な不活性溶剤、例えばジメチルホルムアミド、テトラヒドロフラン、トルエン、ジクロロメタン又はアセトニトリル中で反応させてよい。場合により、好適な塩基、有利にはピリジン、炭酸水素ナトリウム、トリエチルアミン、Ｎ−メチルモルホリン又は酢酸ナトリウムが使用される。該反応混合物を、幾らかの時間、例えば１５分〜２４時間、０℃〜６０℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機溶剤を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばエタノール又は酢酸エチルからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\n\n  Or alternatively, if it is desired that the product is a derivative of compound 15 according to scheme 4, the reaction product 4, 7 or 13 is reacted with phosgene or carbonyldiimidazole after the above basic reaction and correspondingly. May be reacted with a suitable inert solvent such as dimethylformamide, tetrahydrofuran, toluene, dichloromethane or acetonitrile. In some cases, a suitable base is used, preferably pyridine, sodium bicarbonate, triethylamine, N-methylmorpholine or sodium acetate. The reaction mixture may be reacted at a temperature range of 0 ° C. to 60 ° C. for some time, eg 15 minutes to 24 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. If dimethylformamide is used, the reaction mixture is stirred into a large volume of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and organic Concentrate the solvent in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as ethanol or ethyl acetate or column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n\n \n\n  こうして、該生成物が反応式４による化合物１６の誘導体であることが望ましい場合に、前記の基本反応を行った後に、反応混合物４、７又は１３を、相応のイソチオシアネート及び場合により好適な塩基、有利には水素化ナトリウム、トリエチルアミン、炭酸カリウム又はピリジンと、好適な不活性溶剤、例えばジメチルホルムアミド、テトラヒドロフラン、アセトン又はトルエン中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を、幾らかの時間、例えば３０分〜９０時間、０℃〜１１５℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機溶剤を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばエタノール又は酢酸エチルからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\n\n  Thus, if it is desired that the product is a derivative of compound 16 according to Scheme 4, after carrying out the basic reaction, the reaction mixture 4, 7 or 13 is converted to the corresponding isothiocyanate and optionally a suitable base. Reaction, preferably with sodium hydride, triethylamine, potassium carbonate or pyridine, in a suitable inert solvent such as dimethylformamide, tetrahydrofuran, acetone or toluene or as a solvent such as pyridine or triethylamine or without solvent You may let me. The reaction mixture may be reacted at a temperature range of 0 ° C. to 115 ° C. for some time, for example 30 minutes to 90 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. If dimethylformamide is used, the reaction mixture is stirred into a large volume of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and organic Concentrate the solvent in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as ethanol or ethyl acetate or column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n\n \n\n  又は選択的に、生成物が反応式４による化合物１７の誘導体であることが望ましい場合に、前記の基本反応を行った後に反応生成物４、７又は１３をチオホスゲン又はチオカルボニルジイミダゾールと、かつ相応のアミンと、好適な不活性溶剤、例えばジメチルホルムアミド、テトラヒドロフラン、トルエン、ジクロロメタン、エタノール又はアセトニトリル中で反応させてよい。場合により、好適な塩基、有利にはピリジン、炭酸水素ナトリウム、炭酸カリウム、トリエチルアミン又はイミダゾールが使用される。該反応混合物を複数時間、例えば１〜２４時間−１０℃〜８０℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。ジメチルホルムアミドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機相を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばエタノール又は酢酸エチルからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\n\n  Or alternatively, if it is desired that the product is a derivative of compound 17 according to Scheme 4, the reaction product 4, 7 or 13 is reacted with thiophosgene or thiocarbonyldiimidazole after carrying out the above basic reaction, and The corresponding amine may be reacted in a suitable inert solvent such as dimethylformamide, tetrahydrofuran, toluene, dichloromethane, ethanol or acetonitrile. In some cases, a suitable base is used, preferably pyridine, sodium bicarbonate, potassium carbonate, triethylamine or imidazole. The reaction mixture may be reacted for a plurality of hours, for example 1-24 hours at a temperature range of -10 ° C to 80 ° C. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. If dimethylformamide is used, the reaction mixture is stirred into a large volume of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and organic The phase is concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as ethanol or ethyl acetate or column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n\n \n\n  こうして、該生成物が反応式４による化合物１８の誘導体であることが望ましい場合に、前記の基本反応を行った後に、反応生成物４、７又は１３を相応のアミノニトリル及び場合により好適な塩基、有利にはトリエチルアミン又はピリジン又は好適な酸、有利には塩酸と、好適な不活性溶剤、例えばアセトン、トルエン、クロロベンゼン、エタノール、テトラヒドロフラン又はジメチルスルホキシド中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を複数時間、例えば２〜１４０時間２０℃〜１３５℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。残留する粗生成物の精製は、好適な溶剤、例えばジオキサンからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィー又はＨＰＬＣによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられ、あるいはＨＰＬＣ精製の場合には、例えば移動相はアセトニトリル及び水からなる混合物である。\n\n\n  Thus, if it is desired that the product is a derivative of compound 18 according to Scheme 4, after carrying out the basic reaction, the reaction product 4, 7 or 13 is converted to the corresponding aminonitrile and optionally a suitable base. In a suitable inert solvent such as acetone, toluene, chlorobenzene, ethanol, tetrahydrofuran or dimethyl sulfoxide or preferably in a base such as pyridine or triethylamine, preferably triethylamine or pyridine or a suitable acid, preferably hydrochloric acid. Or may be reacted without solvent. The reaction mixture may be reacted in the temperature range of 20 ° C. to 135 ° C. for a plurality of hours, for example 2 to 140 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as dioxane or by column or flash chromatography on silica gel or aluminum oxide or HPLC. As the mobile phase, for example, a mixture consisting of methanol and dichloromethane is used, or in the case of HPLC purification, for example, the mobile phase is a mixture consisting of acetonitrile and water.\n\n\n\n\n\n\n\n \n\n  又は、該生成物が反応式４による化合物１９の誘導体であることが望ましい場合に、前記の基本反応を行った後に、反応生成物４、７又は１３を相応のニトリル及び場合により好適な塩基、有利には水素化ナトリウム、ピリジン、トリエチルアミン又はナトリウムヘキサメチルジシラジド又は好適な触媒、例えば三塩化アルミニウム、トリメチルアルミニウム、酢酸又は硫酸と、好適な不活性溶剤、例えばジオキサン、トルエン又はエタノール中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を、幾らかの時間、例えば３０分〜２４時間、０℃〜２００℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。残留する粗生成物の精製は、好適な溶剤、例えばジオキサンからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィー又はＨＰＬＣによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられ、あるいはＨＰＬＣ精製の場合には、例えばアセトニトリル及び水からなる移動相混合物である。\n\n\n  Or, if it is desired that the product is a derivative of compound 19 according to Scheme 4, after carrying out the basic reaction, the reaction product 4, 7 or 13 is converted to the corresponding nitrile and optionally a suitable base, Preferably in sodium hydride, pyridine, triethylamine or sodium hexamethyldisilazide or a suitable catalyst such as aluminum trichloride, trimethylaluminum, acetic acid or sulfuric acid and a suitable inert solvent such as dioxane, toluene or ethanol or The reaction may be carried out in a base as a solvent, such as pyridine or triethylamine or without solvent. The reaction mixture may be allowed to react in the temperature range of 0 ° C. to 200 ° C. for some time, for example 30 minutes to 24 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as dioxane or by column or flash chromatography on silica gel or aluminum oxide or HPLC. As the mobile phase, for example, a mixture of methanol and dichloromethane is used, or in the case of HPLC purification, for example, a mobile phase mixture of acetonitrile and water.\n\n\n\n\n\n\n\n \n\n  反応式５：第一段階\n\n  前記の単位操作に引き続いて、後続反応において、単位操作により生じる生成物を当業者に公知の方法で反応させて本発明による式Ｉの最終生成物を得ることができる。\n\nReaction Scheme 5: First Step Subsequent to the unit operation described above, in the subsequent reaction, the product resulting from the unit operation can be reacted in a manner known to those skilled in the art to obtain the final product of Formula I according to the present invention. .\n\n\n\n\n\n\n \n\n  こうして、該生成物が反応式５による化合物２１又は２４の誘導体であることが望ましい場合に、前記の基本反応を行った後に、反応生成物２０又は２３を相応の塩化カルボン酸及び場合により好適な塩基、有利には水素化ナトリウム、水酸化カリウム、ピリジン、トリエチルアミン又は炭酸カリウムと、好適な不活性溶剤、例えばテトラヒドロフラン、トルエン、アセトニトリル、ジクロロメタン、アセトン又はジオキサン中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を、幾らかの時間、例えば３０分〜１２時間、０℃〜１１０℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。選択的に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を、好適な水性酸、例えば塩酸での中和の後に好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機相を真空中で濃縮させてよい。残留する粗生成物の精製は、好適な溶剤、例えばエタノールからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\n\n  Thus, if it is desired that the product is a derivative of compound 21 or 24 according to Reaction Scheme 5, after carrying out the basic reaction, the reaction product 20 or 23 is converted to the corresponding chlorocarboxylic acid and optionally more suitable. A base, such as sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone or dioxane or as a solvent such as pyridine or The reaction may be carried out in triethylamine or without solvent. The reaction mixture may be reacted at a temperature range of 0 ° C. to 110 ° C. for some time, for example 30 minutes to 12 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. Optionally, the reaction mixture is stirred into a large amount of water and the precipitated precipitate is filtered off, or the aqueous phase is neutralized with a suitable aqueous acid, for example hydrochloric acid, and a suitable organic solvent, for example Extraction with dichloromethane or ethyl acetate and the organic phase may be concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as ethanol or by column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n\n \n\n  又は選択的に、該生成物が反応式５による化合物２２又は２５の誘導体であることが望ましい場合に、前記の基本反応を行った後に、反応生成物２０又は２３を相応の塩化スルホン酸及び場合により好適な塩基、有利には水素化ナトリウム、水酸化カリウム、ピリジン、トリエチルアミン又は炭酸カリウムと、好適な不活性溶剤、例えばテトラヒドロフラン、トルエン、アセトニトリル、ジクロロメタン、アセトン、ジメチルホルムアミド又はジオキサン中で又は溶剤としての塩基、例えばピリジン又はトリエチルアミン中で又は溶剤無しで反応させてよい。該反応混合物を、幾らかの時間、例えば３０分〜１６時間、０℃〜８０℃の温度範囲で反応させてよい。反応が完了したら、場合により沈殿する沈殿物を濾過分離し、その際、濾材は、例えば市販の濾紙を含んでなってよく、そして引き続き相応の溶剤で洗浄し、かつ残留する固体を真空中で乾燥させるか、あるいは反応混合物から真空中で溶剤を除去する。選択的に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を、好適な水性酸、例えば塩酸での中和の後に好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機相を真空中で濃縮させてよい。ジメチルホルムアミドを使用する場合に、反応混合物を大量の水中に撹拌導入し、そして沈殿する沈殿物を濾過分離するか、あるいは水相を好適な有機溶剤、例えばジクロロメタン又は酢酸エチルで抽出し、そして有機相を真空中で濃縮する。残留する粗生成物の精製は、好適な溶剤、例えばエタノールからの再結晶又はシリカゲル又は酸化アルミニウム上でのカラムクロマトグラフィーもしくはフラッシュクロマトグラフィーによって行われる。移動相として、例えばメタノール及びジクロロメタンからなる混合物が用いられる。\n\n\n  Or alternatively, if it is desired that the product is a derivative of compound 22 or 25 according to Scheme 5, after carrying out the basic reaction, the reaction product 20 or 23 is converted to the corresponding chlorinated sulfonic acid and In a suitable base, preferably sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and in a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone, dimethylformamide or dioxane or as a solvent In a base such as pyridine or triethylamine or without solvent. The reaction mixture may be reacted at a temperature range of 0 ° C. to 80 ° C. for some time, for example 30 minutes to 16 hours. When the reaction is complete, the optionally precipitated precipitate is filtered off, in which case the filter medium may comprise, for example, commercially available filter paper and is subsequently washed with a corresponding solvent, and the remaining solid is removed in vacuo. Dry or remove the solvent from the reaction mixture in vacuo. Optionally, the reaction mixture is stirred into a large amount of water and the precipitated precipitate is filtered off, or the aqueous phase is neutralized with a suitable aqueous acid, for example hydrochloric acid, and a suitable organic solvent, for example Extraction with dichloromethane or ethyl acetate and the organic phase may be concentrated in vacuo. If dimethylformamide is used, the reaction mixture is stirred into a large volume of water and the precipitated precipitate is filtered off or the aqueous phase is extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and organic The phase is concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent such as ethanol or by column or flash chromatography on silica gel or aluminum oxide. As the mobile phase, for example, a mixture of methanol and dichloromethane is used.\n\n\n\n\n\n\n\n \n\n  前記の幾つかの反応条件下に、ＯＨ基、ＳＨ基及びＮＨ\n２\n基は副反応されることがある。従って、前記の基に保護基を設けるか、又はＮＨ\n２\nの場合にはＮＯ\n２\nに交換して、後に保護基を離脱させるか、又はＮＯ\n２\n基を還元させることが好ましい。こうして、前記の方法の変法では、出発化合物において少なくとも１つのＯＨ基は、例えばベンジルオキシ基によって、かつ／又は少なくとも１つのＳＨ基は、例えばＳ−ベンジル基によって、かつ／又は少なくとも１つのＮＨ\n２\n基はＮＯ\n２\n基によって交換されてよい。以下に、少なくとも１つの、好ましくは全てのベンジルオキシ基は、例えば水素と炭素上パラジウムを用いて、かつ／又は少なくとも１つの、好ましくは全てのＳ−ベンジル基は、例えばナトリウムを用いてアンモニア中で離脱され、かつ／又は少なくとも１つの、好ましくは全てのＮＯ\n２\n基は、例えば水素とラネーニッケルを用いて還元して、ＮＨ\n２\nにしてよい。\n\nUnder some of the above reaction conditions, OH, SH and NH \n2\n groups may be side-reacted. Accordingly, it is preferable to provide a protecting group for the above-mentioned group, or in the case of NH \n2\n , exchange it with NO \n2\n to later remove the protecting group or reduce the NO \n2\n group. Thus, in a variant of the above process, at least one OH group in the starting compound is for example by a benzyloxy group and / or at least one SH group is for example by an S-benzyl group and / or at least one NH \nThe two\n groups may be exchanged for NO \n2\n groups. In the following, at least one, preferably all benzyloxy groups are used in ammonia, for example using hydrogen and palladium on carbon, and / or at least one, preferably all S-benzyl groups, are used in ammonia, for example using sodium. And / or at least one, preferably all, NO \n2\n groups may be reduced, for example with hydrogen and Raney nickel, to NH \n2\n .\n\n\n\n\n\n\n \n\n  前記の幾つかの反応条件下に、ＯＨ基、ＮＨ\n２\n基及びＣＯＯＨ基は副反応されることがある。従って、少なくとも１つのＯＨ基及び／又は少なくとも１つのＮＨ\n２\n基及び／又は少なくとも１つのＣＯＯＨ基を有する出発化合物及び中間段階物質を相応のカルボン酸エステル誘導体及びカルボン酸アミド誘導体に変換することが好ましい。前記の方法の変法において、少なくとも１つのＯＨ基を有する、及び／又は少なくとも１つのＮＨ\n２\n基を有する出発化合物及び中間段階物質を、活性化されたカルボン酸基、例えば塩化カルボン酸基との反応によってカルボン酸エステル誘導体もしくはカルボン酸アミド誘導体に変換してよい。前記の方法の変法において、少なくとも１つのＣＯＯＨ基を有する出発化合物及び中間段階物質を、活性化剤、例えば塩化チオニル又はカルボニルジイミダゾールと反応させ、引き続き好適なアルコール又はアミンとの反応させてカルボン酸エステル誘導体もしくはカルボン酸アミド誘導体に変換してよい。\n\nUnder some of the above reaction conditions, OH, NH \n2\n and COOH groups may be side-reacted. It is therefore preferred to convert starting compounds and intermediate-stage substances having at least one OH group and / or at least one NH \n2\n group and / or at least one COOH group into the corresponding carboxylic acid ester derivatives and carboxylic acid amide derivatives. . In a variant of the above process, the starting compound and the intermediate substance having at least one OH group and / or having at least one NH \n2\n group are reacted with an activated carboxylic acid group, for example a chlorocarboxylic acid group. The reaction may be converted to a carboxylic acid ester derivative or a carboxylic acid amide derivative. In a variation of the above process, the starting compound and intermediate stage material having at least one COOH group is reacted with an activator, such as thionyl chloride or carbonyldiimidazole, followed by reaction with a suitable alcohol or amine to give a carboxylic acid. You may convert into an acid ester derivative or a carboxylic acid amide derivative.\n\n\n\n\n\n\n \n\n  一般式Ｉによる本発明によるピリド［２，３−ｂ］ピラジン誘導体は、誤って導かれた細胞シグナル伝達過程の調節のための、特にチロシンキナーゼ及びセリン／トレオニンキナーゼの機能に影響を及ぼすための、及び悪性もしくは良性の腫瘍疾患、例えば胸部、前立腺、肺、皮膚、卵巣などの腫瘍疾患及び病理学的細胞増殖に基づく別の疾患、例えば再狭窄、乾癬、動脈硬化症及び肝硬変の場合のヒト、哺乳動物及び家禽の治療のための医薬品における作用物質として適している。哺乳動物とは、家畜、例えばウマ、ウシ、イヌ、ネコ、ウサギ、ヒツジ等であることができる。\n\n\n  The pyrido [2,3-b] pyrazine derivatives according to the invention according to general formula I are for the regulation of misdirected cell signaling processes, in particular for affecting the function of tyrosine kinases and serine / threonine kinases. , And malignant or benign tumor diseases such as breast, prostate, lung, skin, ovarian tumor diseases and other diseases based on pathological cell proliferation such as restenosis, psoriasis, arteriosclerosis and cirrhosis Suitable as an agent in pharmaceuticals for the treatment of mammals and poultry. Mammals can be livestock such as horses, cows, dogs, cats, rabbits, sheep and the like.\n\n\n\n\n\n\n\n \n\n  本発明によるピリド［２，３−ｂ］ピラジン誘導体の薬理作用は、例えば受容体チロシンキナーゼ、また細胞質チロシンキナーゼ及びセリン／トレオニンキナーゼを伴う代謝によるシグナル伝達の調節に基づくものであってよい。その他に、悪性過程に対抗するための他の公知の及び公知でない作用メカニズムも考えられる。\n\n\n  The pharmacological action of pyrido [2,3-b] pyrazine derivatives according to the present invention may be based on the modulation of signal transduction by metabolism involving, for example, receptor tyrosine kinases, also cytoplasmic tyrosine kinases and serine / threonine kinases. In addition, other known and unknown mechanisms of action for combating malignant processes are also conceivable.\n\n\n\n\n\n\n\n \n\n  本発明の更なる実施態様の場合には、一般式Ｉの本発明によるピリド［２，３−ｂ］ピラジン誘導体の少なくとも１種をヒト、哺乳動物及び家禽に腫瘍治療のために有効量で投与することを特徴とするヒト、哺乳動物又は家禽の腫瘍に対抗するための方法が提供される。それぞれの本発明によるピリド［２，３−ｂ］ピラジン誘導体の治療のために投与すべき治療効果のある用量は、特に腫瘍疾患の種類及び段階、患者の年齢及び性別、投与形態及び治療期間に依存する。本発明による医薬品は、液状、半固体及び固体の医薬形状として投与することができる。この投与は、それぞれ適当な方法で、エアロゾル、粉末、パウダー及び分散パウダー、錠剤、糖衣錠剤、エマルション、フォーム、溶液、懸濁剤、ゲル、軟膏、ペースト、ピル、トローチ剤、カプセル剤又は坐剤の形で行われる。\n\n\n  In a further embodiment of the invention, at least one pyrido [2,3-b] pyrazine derivative according to the invention of general formula I is administered to humans, mammals and poultry in an effective amount for tumor therapy. A method for combating human, mammalian or poultry tumors is provided. The therapeutically effective dose to be administered for the treatment of the respective pyrido [2,3-b] pyrazine derivatives according to the invention depends in particular on the type and stage of the tumor disease, the age and sex of the patient, the dosage form and the duration of treatment. Dependent. The medicament according to the invention can be administered as liquid, semi-solid and solid pharmaceutical forms. This administration is carried out by an appropriate method, respectively, aerosol, powder, powder and dispersion powder, tablet, sugar-coated tablet, emulsion, foam, solution, suspension, gel, ointment, paste, pill, troche, capsule or suppository It is done in the form of\n\n\n\n\n\n\n\n \n\n  この剤形は、本発明による少なくとも１種の成分の他に、製剤学的形状に応じて、場合により助剤、特に溶媒、溶解促進剤、溶解助剤、乳化剤、湿潤剤、消泡剤、ゲル化剤、増粘剤、皮膜形成剤、結合剤、緩衝剤、塩形成剤、乾燥剤、流動調節剤、充填剤、保存剤、酸化防止剤、着色剤、離型剤、滑剤、崩壊剤、矯味剤及び矯臭剤を含有する。助剤の選択並びにその使用量は、選択された医薬形状に依存し、かつ当業者に公知の処方に従う。\n\n\n  In addition to the at least one component according to the invention, this dosage form may optionally comprise auxiliaries, in particular solvents, dissolution promoters, dissolution aids, emulsifiers, wetting agents, antifoaming agents, depending on the pharmaceutical form. Gelling agent, thickener, film forming agent, binder, buffer, salt forming agent, drying agent, flow regulator, filler, preservative, antioxidant, colorant, mold release agent, lubricant, disintegrant Contains a flavoring agent and a flavoring agent. The choice of auxiliaries as well as the amount used depends on the selected pharmaceutical form and follows prescriptions known to those skilled in the art.\n\n\n\n\n\n\n\n \n\n  本発明による医薬品は、適当な投与形態で、皮膚に対して、溶液、懸濁液、エマルション、フォーム、軟膏、ペースト又はプラスターとして経皮的に；口腔粘膜及び舌粘膜を介して、錠剤、トローチ剤、糖衣錠剤、リンクタス剤又はうがい水としてバッカル、舌又は舌下に；胃粘膜及び腸粘膜を介して、錠剤、糖衣錠剤、カプセル剤、溶液、懸濁液又はエマルションとして消化管に；直腸粘膜を介して、坐剤、レクタルカプセル剤又は軟膏を介して直腸に；鼻粘膜を介して、滴下剤、軟膏又はスプレーとして鼻に；気管支上皮及び歯槽上皮を介して、エアロゾル又は吸入剤として肺に又は吸入により；結膜を介して、点眼剤、点眼軟膏、眼内錠剤、ラメラ、点眼水として結膜に；生殖器の粘膜を介して、膣坐剤、軟膏及び洗浄剤として膣内に、子宮ペッサリーとして子宮内に；誘導する尿路を介して、洗浄剤、軟膏又は尿道坐剤として尿管内に；動脈中に、注射剤として動脈内に；静脈中に、注射剤又は注入剤として静脈内に；皮膚中に、注射剤又はインプラントとして皮内に；皮膚の下に、注射剤又はインプラントとして皮下に；筋肉中に、注射剤又はインプラントとして筋肉内に；腹腔中に、注射剤又は注入剤として腹腔内に投与される。\n\n\n  The medicament according to the invention can be percutaneously applied to the skin as a solution, suspension, emulsion, foam, ointment, paste or plaster in the appropriate dosage form; via the oral and lingual mucosa, the tablets, troches Buccal, tongue or sublingual as an agent, sugar-coated tablet, rinktas or gargle; through the gastric mucosa and intestinal mucosa to the digestive tract as a tablet, sugar-coated tablet, capsule, solution, suspension or emulsion; rectal mucosa Via the suppository, rectal capsule or ointment to the rectum; via the nasal mucosa to the nose as a drop, ointment or spray; via the bronchial epithelium and alveolar epithelium to the lung as an aerosol or inhalant Or by inhalation; through the conjunctiva to the conjunctiva as eye drops, ophthalmic ointments, intraocular tablets, lamellae, ophthalmic water; Intrauterine as uterine pessary; via urinary tract, into ureter as irrigant, ointment or urethral suppository; into artery, as artery for injection; into vein, intravenously as injection or infusion In the skin, intradermally as an injection or implant; below the skin, subcutaneously as an injection or implant; into the muscle, intramuscularly as an injection or implant; into the abdominal cavity, injection or infusion It is administered intraperitoneally as an agent.\n\n\n\n\n\n\n\n \n\n  一般式Ｉの本発明による化合物は、実際の治療的な必要性の観点で、適当な手法を用いてその薬剤効果を延長することができる。この目的は化学的及び／製剤学的手法で達成することができる。作用延長に至る例は、インプラント及びリポソームの使用、難溶性塩及び錯体の形成又は結晶懸濁液の使用である。\n\n\n  The compounds according to the invention of the general formula I can prolong their drug effect using appropriate techniques in view of the actual therapeutic need. This goal can be achieved by chemical and / or pharmaceutical techniques. Examples leading to prolonged action are the use of implants and liposomes, the formation of sparingly soluble salts and complexes or the use of crystal suspensions.\n\n\n\n\n\n\n\n \n\n  この場合に、一般式Ｉのピリド［２，３−ｂ］ピラジン誘導体の以下：\n\n１−アリル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１）、\n\n１−アリル−３−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例２）、\n\n１−アリル−３−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素（実施例３）、\n\n１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素塩酸塩（実施例４）、\n\n１−（２−メチル−アリル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例５）、\n\n１−（２−メチル−アリル）−３−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例６）、\n\n１−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（２−メチル−アリル）−チオ尿素（実施例７）、\n\n１−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−（４−ニトロ−フェニル）−チオ尿素（実施例８）、\n\n１−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（４−ニトロ−フェニル）−チオ尿素（実施例９）、\n\n１−ｔ−ブチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１０）、\n\n１−シクロプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１１）、\n\n１−メチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１２）、\n\n１−ベンジル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１３）、\n\n１−（４−フルオロ−フェニル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１４）、\n\n１−シクロヘキシル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１５）、\n\n１−イソプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１６）、\n\n１−フラン−２−イルメチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例１７）、\n\n１−メチル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素（実施例１８）、\n\n１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−メチル−チオ尿素（実施例１９）、\n\n１−アリル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素（実施例２０）、\n\n４−［６−（３−アリル−チオ尿素）−ピリド［２，３−ｂ］ピラジン−３−イル］−安息香酸エチル−エステル（実施例２１）、\n\n１−アリル−３−［３−（３−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素（実施例２２）、\n\n１−アリル−３−（３−ベンゾ［１，３］ジオキソール−５−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素（実施例２３）、\n\n１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−プロピ−２−イニル−チオ尿素（実施例２４）、\n\n１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素（実施例２５）、\n\n１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（（プロペニル）−チオ尿素（実施例２６）、\n\n１−アリル−３−［２，３−ビス−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素（実施例２７）、\n\n１−［２，３−ビス−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（（プロペニル）−チオ尿素（実施例２８）、\n\n１−アリル−３−［２−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素（実施例２９）、\n\n１−アリル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−７−イル］−チオ尿素（実施例３０）、\n\n１−シクロプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素（実施例３１）、\n\n１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−尿素（実施例３２）、\n\n１−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−ｐ−トリル−尿素（実施例３３）、\n\n１−（４−クロロ−３−トリフルオロメチル−フェニル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素（実施例３４）、\n\n１−（２−モルホリン−４−イル−エチル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素（実施例３５）、\n\n１−フェネチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素（実施例３６）、\n\n１−（２，３−ジ−ピリジン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−エチル−尿素（実施例３７）、\n\n１−（２，３−ジメチル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−エチル−尿素（実施例３８）\n\nの群からの少なくとも１種の化合物を含有し、かつそれらの遊離塩基の形で又は生理学的に認容性の酸の製剤学的に認容性の塩としても存在してよい医薬品が特に好ましい。\n\nIn this case, the following pyrido [2,3-b] pyrazine derivatives of general formula I: \n 1-allyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 1), \n 1-allyl-3- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 2), \n 1-allyl-3- [3- (4-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea (Example 3), \n 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea hydrochloride (Example 4), \n 1- (2-methyl-allyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 5), \n 1- (2-methyl-allyl) -3- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 6), \n 1- [3- (4-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3- (2-methyl-allyl) -thiourea (Example 7), \n 1- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -3- (4-nitro-phenyl) -thiourea (Example 8), \n 1- [3- (4-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3- (4-nitro-phenyl) -thiourea (Example 9), \n 1-t-butyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 10), \n 1-cyclopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 11), \n 1-methyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 12), \n 1-benzyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 13), \n 1- (4-fluoro-phenyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 14), \n 1-cyclohexyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 15), \n 1-isopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 16), \n 1-furan-2-ylmethyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 17), \n 1-methyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea (Example 18), \n 1- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-methyl-thiourea (Example 19), \n 1-allyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea (Example 20), \n 4- [6- (3-Allyl-thiourea) -pyrido [2,3-b] pyrazin-3-yl] -benzoic acid ethyl ester (Example 21), \n 1-allyl-3- [3- (3-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea (Example 22), \n 1-allyl-3- (3-benzo [1,3] dioxol-5-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (Example 23), \n 1- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-prop-2-ynyl-thiourea (Example 24), \n 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea (Example 25), \n 1- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-((propenyl) -thiourea (Example 26), \n 1-allyl-3- [2,3-bis- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea (Example 27), \n 1- [2,3-bis- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-((propenyl) -thiourea (Example 28), \n 1-allyl-3- [2- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea (Example 29), \n 1-allyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-7-yl] -thiourea (Example 30), \n 1-cyclopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea (Example 31), \n 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -urea (Example 32), \n 1- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -3-p-tolyl-urea (Example 33), \n 1- (4-Chloro-3-trifluoromethyl-phenyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea (Example 34), \n 1- (2-morpholin-4-yl-ethyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea (Example 35), \n 1-phenethyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea (Example 36), \n 1- (2,3-di-pyridin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea (Example 37), \n 1- (2,3-Dimethyl-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea (Example 38) \n Particular preference is given to medicaments which contain at least one compound from the group and which may also be present in their free base form or as a pharmaceutically acceptable salt of a physiologically acceptable acid.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  合成反応式１〜４に基づく一般的な指示に基づき、以下の化合物を合成した。これらの化合物は、それぞれの化学的名称の記載の下で次の概要から明らかになる。更にそれらのＮＭＲ分光データ及び融点を付け加える。続く第１表において、一般式ＩＩ及び置換基Ｒ１、Ｒ２、Ｒ３、Ｒ４並びにＲ５及びＹからこれらの化合物の構造は認識されるべきである。\n\n\n  The following compounds were synthesized based on general instructions based on synthesis reaction formulas 1 to 4. These compounds will become apparent from the following summary under the description of the respective chemical names. In addition, their NMR spectral data and melting point are added. In the following Table 1, the structures of these compounds should be recognized from the general formula II and the substituents R1, R2, R3, R4 and R5 and Y.\n\n\n\n\n\n\n\n \n\n  使用した薬品及び溶媒は、通常の提供元（Ａｃｒｏｓ社、Ａｌｄｒｉｃｈ社、Ｆｌｕｋａ社、Ｌａｎｃａｓｔｅｒ社、Ｍａｙｂｒｉｄｇｅ社、Ｍｅｒｃｋ社、Ｓｉｇｍａ社、ＴＣＩ社等）から市販されているか又は合成した。\n\n\n  The chemicals and solvents used were either commercially available or synthesized from common sources (Acros, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, etc.).\n\n\n\n\n\n\n\n \n\n  次の実施例を用いて、本発明を詳細に説明するが、本発明はこの実施例に限定されるものではない。\n\n\n  The present invention will be described in detail with reference to the following examples, but the present invention is not limited to these examples.\n\n\n\n\n\n\n\n \n\n  実施例１：\n\n  ３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イルアミンの製造（反応式１の第一段階と第二段階による反応）\n\n  １．２２ｇの２，６−ジアミノ−３−ニトロピリジン（７．９２ミリモル）を２１０ｍｌのエタノール中に溶かした溶液を触媒としてのラネーニッケルを用いて５０℃及び５バールで水素添加する。水素添加が完了した後に、触媒をガラス繊維フィルタを介して吸引により分離する。受容器中には、濾過前には１．６８ｇのフェニルグリオキサール水和物（１１．０３ミリモル）が５０ｍｌのエタノール中に存在している。次いで、触媒を保護ガスとしての窒素下に濾過分離し、そして水素添加溶液を直接反応フラスコ中に吸入する。青緑色の反応混合物を窒素下に３０分間還流下に加熱する。該混合物を冷却し、そして溶剤を真空中で除去する。最終的に暗褐色の固体が得られる。シリカゲル上でのカラムクロマトグラフィーによる精製（移動相混合物  ジクロロメタン／メタノール）により淡黄色の結晶性固体が得られる。\n\nExample 1: \n Preparation of 3-phenyl-pyrido [2,3-b] pyrazin-6-ylamine (reaction according to the first step and the second step of Reaction Scheme 1) \n A solution of 1.22 g of 2,6-diamino-3-nitropyridine (7.92 mmol) in 210 ml of ethanol is hydrogenated at 50 ° C. and 5 bar using Raney nickel as catalyst. After the hydrogenation is complete, the catalyst is separated by suction through a glass fiber filter. In the receiver, 1.68 g of phenylglyoxal hydrate (11.03 mmol) is present in 50 ml of ethanol before filtration. The catalyst is then filtered off under nitrogen as protective gas and the hydrogenation solution is drawn directly into the reaction flask. The blue-green reaction mixture is heated under reflux for 30 minutes under nitrogen. The mixture is cooled and the solvent is removed in vacuo. Finally a dark brown solid is obtained. Purification by column chromatography on silica gel (mobile phase mixture dichloromethane / methanol) gives a pale yellow crystalline solid.\n\n\n\n\n\n\n \n\n  １−アリル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素の製造（反応式４の第一段階による反応）\n\n０．２４６ｇのナトリウム水素化物（６．１４ミリモル）を５ｍｌの無水ジメチルホルムアミド中に保護ガスとしての窒素下に装入する。該混合物を氷浴中で０℃に冷却する。１．０５ｇの３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イルアミン（４．７２ミリモル）を５ｍｌの無水ジメチルホルムアミド中に溶解させ、そして滴加する。氷浴から取り出し、そして該混合物を室温で３０分間撹拌する。次いで混合物を氷浴中で０℃に冷却し、そして０．４６９ｇのアリルイソチオシアネート（４．７２ミリモル）を４ｍｌの無水ジメチルホルムアミド中に溶解させて滴加する。添加が完了した後に氷浴から取り出し、そして該混合物を室温で更に１．５時間撹拌する。後処理のために、混合物を約２５０ｍｌの蒸留水中に注ぎ、そして沈殿する橙色の固体を吸引により分離する。カラムクロマトグラフィーによる精製（移動相混合物  ジクロロメタン／メタノール）を複数回行い、引き続き分取ＨＰＬＣでの後精製を行うことにより黄色の固体が得られる。\n\nPreparation of 1-allyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea (reaction according to the first step of scheme 4) \n 0.246 g of sodium hydride (6.14 mmol) is charged into 5 ml of anhydrous dimethylformamide under nitrogen as protective gas. The mixture is cooled to 0 ° C. in an ice bath. 1.05 g of 3-phenyl-pyrido [2,3-b] pyrazin-6-ylamine (4.72 mmol) is dissolved in 5 ml of anhydrous dimethylformamide and added dropwise. Remove from the ice bath and stir the mixture at room temperature for 30 minutes. The mixture is then cooled to 0 ° C. in an ice bath and 0.469 g of allyl isothiocyanate (4.72 mmol) is dissolved in 4 ml of anhydrous dimethylformamide and added dropwise. After the addition is complete, remove from the ice bath and stir the mixture at room temperature for an additional 1.5 hours. For workup, the mixture is poured into about 250 ml of distilled water and the precipitated orange solid is separated by suction. Purification by column chromatography (mobile phase mixture dichloromethane / methanol) is performed several times, followed by post-purification by preparative HPLC to give a yellow solid.\n\n\n\n\n\n\n \n\n  融点：２３９〜２４０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４０（ｍ，２Ｈ），５．３０（ｄ，１Ｈ），５．６０（ｄ，１Ｈ），６．０７−６．１７（ｍ，１Ｈ），７．５５−７．７０（ｍ，４Ｈ），８．３５（ｄ，２Ｈ），８．４５（ｄ，１Ｈ），９．５０（ｓ，１Ｈ），１１．３５（ｓ，１Ｈ），１２．５５（ｍ，１Ｈ）\n\n  以下の実施例は実施例１と一般的な合成指示に従って合成した：\n\n  実施例２：１−アリル−３−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２４２〜２４３℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４２（ｍ，２Ｈ），５．３７（ｄ，１Ｈ），５．６５（ｄ，１Ｈ），６．０７−６．１９（ｍ，１Ｈ），７．５７−７．６８（ｍ，３Ｈ），７．９７−８．０５（ｍ，１Ｈ），８．０７−８．１９（ｍ，２Ｈ），８．４０−８．５２（ｍ，２Ｈ），８．９９（ｓ，１Ｈ），９．７０（ｓ，１Ｈ），１１．３６（ｓ，１Ｈ），１２．５６（ｔ，１Ｈ）\n\n  実施例３：１−アリル−３−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素\n\n  融点：２４０〜２４１℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝３．８７（ｓ，３Ｈ），４．３６−４．４２（ｍ，２Ｈ），５．３２（ｄ，１Ｈ），５．６０（ｄ，１Ｈ），６．０６−６．１６（ｍ，１Ｈ），７．１６（ｄ，２Ｈ），７．６０（ｄ，１Ｈ），８．３２（ｄ，２Ｈ），８．４２（ｄ，１Ｈ），９．５６（ｓ，１Ｈ），１１．２９（ｓ，１Ｈ），１２．５６（ｍ，１Ｈ）\n\n  実施例４：１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素塩酸塩\n\n  融点：１６０〜１６１℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．３６−４．４３（ｍ，２Ｈ），５．３１（ｄ，１Ｈ），５．５９（ｄ，１Ｈ），６．０５−６．１６（ｍ，１Ｈ），６．９７（ｄ，２Ｈ），７．５７（ｄ，１Ｈ），８．２０（ｄ，２Ｈ），８．４０（ｄ，１Ｈ），９．４１（ｓ，１Ｈ），１０．１７（ｂｓ，１Ｈ），１１．２４（ｓ，１Ｈ），１２．５６（ｍ，１Ｈ）\n\n  実施例５：１−（２−メチル−アリル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２２５〜２２６℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．９０（ｓ，３Ｈ），４．３０−４．３５（ｍ，２Ｈ），５．０１（ｓ，１Ｈ），５．２２（ｓ，１Ｈ），７．５５−７．８０（ｍ，４Ｈ），８．３０−８．３８（ｍ，２Ｈ），８．４５（ｄ，１Ｈ），９．５２（ｓ，１Ｈ），１１．３２（ｓ，１Ｈ），１２．６５（ｍ，１Ｈ）\n\n  実施例６：１−（２−メチル−アリル）−３−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２３９〜２４０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．９４（ｓ，３Ｈ），４．３２（ｍ，２Ｈ），５．０７（ｓ，１Ｈ），５．２８（ｓ，１Ｈ），７．６０−７．６９（ｍ，３Ｈ），８．００−８．０５（ｍ，１Ｈ），８．０７−８．１２（ｍ，１Ｈ），８．１４（ｄ，１Ｈ），８．４２−８．５１（ｍ，２Ｈ），８．９８（ｓ，１Ｈ），９．６８（ｓ，１Ｈ），１１．３２（ｓ，１Ｈ），１２．７８（ｍ，１Ｈ）\n\n  実施例７：１−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（２−メチル−アリル）−チオ尿素\n\n  融点：２５１〜２５２℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．９２（ｓ，３Ｈ），３．８５（ｓ，３Ｈ），４．２７−４．３５（ｍ，２Ｈ），５．０２（ｓ，１Ｈ），５．２４（ｓ，１Ｈ），７．１５（ｄ，２Ｈ），７．５８（ｄ，１Ｈ），８．３１（ｄ，２Ｈ），８．４１（ｄ，１Ｈ），９．４６（ｓ，１Ｈ），１１．２９（ｓ，１Ｈ），１２．６８（ｍ，１Ｈ）\n\n  実施例８：１−（３−ナフタリン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−（４−ニトロ−フェニル）−チオ尿素\n\n  融点：２６０〜２６１℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝７．６１−７．６８（ｍ，３Ｈ），７．７２（ｄ，２Ｈ），７．７５（ｄ，１Ｈ），８．０１−８．０６（ｍ，１Ｈ），８．１６（ｍ，２Ｈ），８．２６（ｄ，２Ｈ），８．５３（ｄ，１Ｈ），８．５８（ｄ，１Ｈ），９．０４（ｓ，１Ｈ），９．６２（ｓ，１Ｈ），９．７６（ｓ，１Ｈ），１１．８１（ｓ，１Ｈ）\n\n  実施例９：１−［３−（４−メトキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（４−ニトロ−フェニル）−チオ尿素\n\n  融点：２５０〜２５１℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝３．８５（ｓ，３Ｈ），７．１７（ｄ，２Ｈ），７．７１（ｄ，２Ｈ），８．２１（ｄ，２Ｈ），８．２２−８．２７（ｍ，１Ｈ），８．３６−８．４２（ｍ，３Ｈ），９．５３（ｓ，１Ｈ），９．６５（ｓ，１Ｈ），１１．７７（ｓ，１Ｈ）\n\n  実施例１０：１−ｔ−ブチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２２７℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．６５（ｓ，９Ｈ），７．５３−７．６９（ｍ，４Ｈ），８．３４（ｄ，２Ｈ），８．４１（ｄ，１Ｈ），９．５１（ｓ，１Ｈ），１０．９８（ｓ，１Ｈ），１２．７５（ｓ，１Ｈ）\n\n  実施例１１：１−シクロプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２３３〜２３４℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝０．７０−０．８０（ｍ，２Ｈ），０．９１−１．００（ｍ，２Ｈ），３．２０−３．２８（ｍ，１Ｈ），７．５１−７．７２（ｍ，４Ｈ），８．３６（ｄ，２Ｈ），８．４５（ｄ，１Ｈ），９．５２（ｓ，１Ｈ），１１．３１（ｓ，１Ｈ），１２．４５（ｓ，１Ｈ）\n\n  実施例１２：１−メチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２５３〜２５４℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝３．２５（ｓ，３Ｈ），７．５９−７．６７（ｍ，４Ｈ），８．３８（ｄ，２Ｈ），８．４６（ｄ，１Ｈ），９．５２（ｓ，１Ｈ），１１．３１（ｓ，１Ｈ），１２．１０（ｓ，１Ｈ）\n\n  実施例１３：１−ベンジル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２３２〜２３３℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．９６（ｍ，２Ｈ），７．３７−７．４８（ｍ，３Ｈ），７．５４−７．６７（ｍ，６Ｈ），８．３２（ｄ，２Ｈ），８．４７（ｄ，１Ｈ），９．５２（ｓ，１Ｈ），１１．４３（ｓ，１Ｈ），１２．９１（ｓ，１Ｈ）\n\n  実施例１４：１−（４−フルオロ−フェニル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２２５〜２２６℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝７．３３（ｍ，２Ｈ），７．５７−７．６５（ｍ，３Ｈ），７．７０−７．８１（ｍ，３Ｈ），８．３４（ｄ，２Ｈ），８．５４（ｄ，１Ｈ），９．５７（ｓ，１Ｈ），１１．６２（ｓ，１Ｈ）\n\n  実施例１５：１−シクロヘキシル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２３０〜２３２℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．５０−１．７５（ｍ，６Ｈ），１．８０−２．００（ｍ，４Ｈ），７．５５−７．７０（ｍ，４Ｈ），８．３７（ｄ，２Ｈ），８．４５（ｄ，１Ｈ），９．５５（ｓ，１Ｈ），１１．２０（ｓ，１Ｈ），１２．８０（ｓ，１Ｈ）\n\n  実施例１６：１−イソプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２２９〜２３０℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．４０（ｄ，６Ｈ），４．４０−４．５０（ｍ，１Ｈ），７．５８−７．６６（ｍ，４Ｈ），８．３６（ｄ，２Ｈ），８．４４（ｄ，１Ｈ），９．５２（ｓ，１Ｈ），１１．２０（ｓ，１Ｈ），１２．４８（ｓ，１Ｈ）\n\n  実施例１７：１−フラン−２−イルメチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２５０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．９５（ｓ，２Ｈ），６．５５（ｍ，１Ｈ），６．６８（ｄ，１Ｈ），７．５９−７．６８（ｍ，４Ｈ），７．７４（ｄ，１Ｈ），８．３７（ｄ，２Ｈ），８．４８（ｄ，１Ｈ），９．５５（ｓ，１Ｈ），１１．４５（ｓ，１Ｈ），１２．８３（ｓ、１Ｈ）\n\n  実施例１８：１−メチル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素\n\n  融点：２７０℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝３．２５（ｓ，３Ｈ），７．７０（ｄ，１Ｈ），８．４４（ｄ，２Ｈ），８．５０（ｄ，１Ｈ），８．６４（ｄ，２Ｈ），９．６４（ｓ，１Ｈ），１１．３８（ｓ，１Ｈ），１２．０３（ｓ，１Ｈ）\n\n  実施例１９：１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−メチル−チオ尿素\n\n  融点：２８２℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝３．２５（ｓ，３Ｈ），６．９８（ｄ，２Ｈ），７．５７（ｄ，１Ｈ），８．２６（ｄ，２Ｈ），８．４０（ｄ，１Ｈ），９．４５（ｓ，１Ｈ），１０．１８（ｓ，１Ｈ），１１．２５（ｓ，１Ｈ），１２．１０（ｓ，１Ｈ）\n\n  実施例２０：１−アリル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素\n\n  融点：２４４℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４０（ｓ，２Ｈ），５．３６（ｄ，１Ｈ），５．５９（ｄ，１Ｈ），６．０８−６．１５（ｍ，１Ｈ），７．７１（ｄ，１Ｈ），８．４６（ｄ，２Ｈ），８．５１（ｄ，１Ｈ），８．６０（ｄ，２Ｈ），９．６４（ｓ，１Ｈ），１１．４５（ｓ，１Ｈ），１２．５１（ｔ，１Ｈ）\n\n  実施例２１：４−［６−（３−アリル−チオ尿素）−ピリド［２，３−ｂ］ピラジン−３−イル］−安息香酸エチル−エステル\n\n  融点：２２３〜２２４℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．３９（ｔ，３Ｈ），４．３５−４．４２（ｍ，４Ｈ），５．３５（ｄ，１Ｈ），５．６０（ｄ，１Ｈ），６．０８−６．１５（ｍ，１Ｈ），７．６８（ｄ，１Ｈ），８．１７（ｄ，２Ｈ），８．４７（ｄ，２Ｈ），８．５０（ｄ，１Ｈ），９．６０（ｓ，１Ｈ），１１．４０（ｓ，１Ｈ），１２．５２（ｔ，１Ｈ）\n\n  実施例２２：１−アリル−３−［３−（３−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素\n\n  融点：２０５℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４１（ｓ，２Ｈ），５．３３（ｄ，１Ｈ），５．５８（ｄ，１Ｈ），６．０７−６．１５（ｍ，１Ｈ），６．９９（ｄ，１Ｈ），７．４２（ｔ，１Ｈ），７．６４（ｄ，１Ｈ），７．７２（ｓ，１Ｈ），７．７７（ｄ，１Ｈ），８．４６（ｄ，１Ｈ），９．４５（ｓ，１Ｈ），９．８０（ｓ，１Ｈ），１１．３７（ｓ，１Ｈ），１２．５５（ｓ，１Ｈ）\n\n  実施例２３：１−アリル−３−（３−ベンゾ［１，３］ジオキソール−５−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−チオ尿素\n\n  融点：２１８〜２２０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４０（ｓ，２Ｈ），５．３１（ｄ，１Ｈ），５．６０（ｄ，１Ｈ），６．０８−６．２０（ｍ，３Ｈ），７．１６（ｄ，１Ｈ），７．６１（ｄ，１Ｈ），７．９０（ｓ，１Ｈ），７．９６（ｄ，１Ｈ），８．４３（ｄ，１Ｈ），９．４９（ｓ，１Ｈ），１１．３４（ｓ，１Ｈ），１２．５８（ｓ，１Ｈ）\n\n  実施例２４：１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−プロピ−２−イニル−チオ尿素\n\n  融点：３５０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝２．０９（ｓ，１Ｈ），２．４４（ｓ，２Ｈ），６．９９（ｄ，２Ｈ），７．１９（ｓ，１Ｈ），７．４４（ｓ，１Ｈ），８．２４（ｄ，２Ｈ），８．２６（ｄ，１Ｈ），９．２９（ｓ，１Ｈ），１０．０８（ｓ，１Ｈ），１１．８１（ｓ，１Ｈ）\n\n  実施例２５：１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素\n\n  融点：２３０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４０（ｓ，２Ｈ），５．３４（ｄ，１Ｈ），５．６０（ｄ，１Ｈ），６．０７−６．１５（ｍ，１Ｈ），６．９８（ｄ，２Ｈ），７．５８（ｄ，１Ｈ），８．２４（ｄ，２Ｈ），８．４２（ｄ，１Ｈ），９．４５（ｄ，１Ｈ），１０．１９（ｓ，１Ｈ），１１．３４（ｓ，１Ｈ），１２．６０（ｓ，１Ｈ）\n\n  実施例２６：１−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（（プロペニル）−チオ尿素\n\n  融点：\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝２．１２（ｄ，３Ｈ），５．１７（ｍ，１Ｈ），６．９６（ｄ，２Ｈ），７．２２−７．２６（ｍ，１Ｈ），７．５９（ｄ，１Ｈ），８．２５（ｄ，２Ｈ），８．４５（ｄ，１Ｈ），９．４８（ｓ，１Ｈ），１０．２０（ｓ，１Ｈ），１１．５６（ｓ，１Ｈ），１４．６７（ｓ，１Ｈ）\n\n  実施例２７：１−アリル−３−［２，３−ビス−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素\n\n  融点：２７０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４０（ｓ，２Ｈ），５．２５（ｄ，１Ｈ），５．５０（ｄ，１Ｈ），６．０２−６．１３（ｍ，１Ｈ），６．７４（ｄ，２Ｈ），６．７６（ｄ，２Ｈ），７．３１（ｄ，２Ｈ），７．３６（ｄ，２Ｈ），７．６２（ｄ，１Ｈ），８．４２（ｄ，１Ｈ），９．７８（ｓ，１Ｈ），９．８５（ｓ，１Ｈ），１１．３０（ｓ，１Ｈ），１２．４７（ｓ，１Ｈ）\n\n  実施例２８：１−［２，３−ビス−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−３−（（プロペニル）−チオ尿素\n\n  融点：２４０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝２．０５（ｄ，３Ｈ），５．１０−５．１８（ｍ，１Ｈ），６．７４（ｄ，２Ｈ），６．７６（ｄ，２Ｈ），７．２０−７．２６（ｍ，１Ｈ），７．３４（ｄ，２Ｈ），７．３９（ｄ，２Ｈ），７．６３（ｄ，１Ｈ），８．４５（ｄ，１Ｈ），９．７９（ｓ，１Ｈ），９．８９（ｓ，１Ｈ），１１．５５（ｓ，１Ｈ），１４．５６（ｄ，１Ｈ）\n\n  実施例２９：１−アリル−３−［２−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−チオ尿素\n\n  融点：２６０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．４０（ｓ，２Ｈ），５．２８（ｄ，１Ｈ），５．４８（ｄ，１Ｈ），６．０３−６．１２（ｍ，１Ｈ），６．９６（ｄ，２Ｈ），７．６６（ｄ，１Ｈ），８．１６（ｄ，２Ｈ），８．４３（ｄ，１Ｈ），９．５２（ｓ，１Ｈ），１０．０６（ｓ，１Ｈ），１１．３１（ｓ，１Ｈ），１２．４０（ｓ，１Ｈ）\n\n  実施例３０：１−アリル−３−［３−（４−ニトロ−フェニル）−ピリド［２，３−ｂ］ピラジン−７−イル］−チオ尿素\n\n  融点：２５０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝４．２３（ｓ，２Ｈ），５．１９（ｄ，１Ｈ），５．２９（ｄ，１Ｈ），５．９０−６．００（ｍ，１Ｈ），８．４６（ｄ，２Ｈ），８．５５（ｓ，１Ｈ），８．６４（ｄ，２Ｈ），８．９２（ｓ，１Ｈ），９．２３（ｓ，１Ｈ），９．７７（ｓ，１Ｈ），１０．３５（ｓ，１Ｈ）\n\n  実施例３１：１−シクロプロピル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素\n\n  融点：１５８〜１６０℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝０．５２−０．６０（ｍ，２Ｈ），０．７２−０．８２（ｍ，２Ｈ），２．７０−２．７９（ｍ，１Ｈ），７．５７−７．６５（ｍ，３Ｈ），７．７１（ｄ，１Ｈ），８．３４（ｄ，２Ｈ），８．３８（ｄ，１Ｈ），９．２１（ｓ，１Ｈ），９．４６（ｓ，１Ｈ），１０．１２（ｓ，１Ｈ）\n\n  実施例３２：１−アリル−３−［３−（４−ヒドロキシ−フェニル）−ピリド［２，３−ｂ］ピラジン−６−イル］−尿素\n\n  融点：２４０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝３．９８（ｓ，２Ｈ），５．１９（ｄ，１Ｈ），５．３７（ｄ，１Ｈ），５．９６−６．０５（ｍ，１Ｈ），６．９７（ｄ，２Ｈ），７．５９（ｄ，１Ｈ），８．２２（ｄ，２Ｈ），８．３３（ｄ，１Ｈ），９．３８（ｓ，１Ｈ），９．４５（ｓ，１Ｈ），１０．１３（ｓ，１Ｈ），１０．１８（ｓ，１Ｈ）\n\n  実施例３３：１−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−ｐ−トリル−尿素\n\n  融点：２９８〜２９９℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝２．２９（ｓ，３Ｈ），７．２０（ｄ，２Ｈ），７．５２（ｄ，２Ｈ），７．５９−７．６７（ｍ，３Ｈ），７．８０（ｄ，１Ｈ），８．３８（ｄ，２Ｈ），８．４４（ｄ，１Ｈ），９．５９（ｓ，１Ｈ），１０．３６（ｓ，１Ｈ），１１．４６（ｓ，１Ｈ）\n\n  実施例３４：１−（４−クロロ−３−トリフルオロメチル−フェニル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素\n\n  融点：２５０℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝７．５８−７．６７（ｍ，３Ｈ），７．７４（ｄ，１Ｈ），７．８０（ｄ，１Ｈ），７．８７（ｄ，１Ｈ），８．２１（ｓ，１Ｈ），８．３９（ｄ，２Ｈ），８．４８（ｄ，１Ｈ），９．５３（ｓ，１Ｈ），１０．５５（ｓ，１Ｈ），１１．８２（ｓ，１Ｈ）\n\n  実施例３５：１−（２−モルホリン−４−イル−エチル）−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素\n\n  融点：２２６℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝２．４５−２．６７（ｍ，６Ｈ），３．４０−３．４８（ｍ，２Ｈ），３．６０−３．６９（ｍ，４Ｈ），７．５５−７．７０（ｍ，４Ｈ），８．３０−８．４０（ｍ，３Ｈ），９．２９（ｓ，１Ｈ），９．４２（ｓ，１Ｈ），１０．１８（ｓ，１Ｈ）\n\n  実施例３６：１−フェネチル−３−（３−フェニル−ピリド［２，３−ｂ］ピラジン−６−イル）−尿素\n\n  融点：２５０℃（分解）\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝２．８８−２．９５（ｍ，２Ｈ），３．５２−３．６０（ｍ，２Ｈ），７．１８（ｔ，１Ｈ），７．２８（ｔ，２Ｈ），７．４２（ｄ，２Ｈ），７．５８−７．６８（ｍ，４Ｈ），８．３７（ｄ，３Ｈ），９．２５（ｓ，１Ｈ），９．４８（ｓ，１Ｈ），１０．１８（ｓ，１Ｈ）\n\n  実施例３７：１−（２，３−ジ−ピリジン−２−イル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−エチル−尿素\n\n  融点：２３６〜２３７℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．１３−１．２２（ｍ，３Ｈ），３．２８−３．３９（ｍ，２Ｈ），３．６０−３．６９（ｍ，４Ｈ），７．３１−７．３９（ｍ，２Ｈ），７．７９（ｄ，１Ｈ），７．９１−７．９９（ｍ，４Ｈ），８．２６（ｄ，１Ｈ），８．２９（ｄ，１Ｈ），８．４７（ｄ，１Ｈ），９．０８（ｓ，１Ｈ），１０．２０（ｓ，１Ｈ）\n\n  実施例３８：１−（２，３−ジメチル−ピリド［２，３−ｂ］ピラジン−６−イル）−３−エチル−尿素\n\n  融点：２４６〜２４８℃\n\n\n１\nＨ−ＮＭＲ（ｄ\n６\n−ＤＭＳＯ）：δ＝１．１７（ｔ，３Ｈ），２．６４（ｓ，３Ｈ），２．６７（ｓ，３Ｈ），３．２４−３．４０（ｍ，２Ｈ），７．５５（ｄ，１Ｈ），８．２４（ｄ，１Ｈ），９．１４（ｓ，１Ｈ），９．９１（ｓ，１Ｈ）\n\nMelting point: 239-240 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.40 (m, 2H), 5.30 (d, 1H), 5.60 (d, 1H), 6.07-6.17 (m, 1H), 7.55-7.70 (m, 4H), 8.35 (d, 2H), 8.45 (d, 1H), 9.50 (s, 1H), 11.35 (s, 1H) ), 12.55 (m, 1H) \n The following examples were synthesized according to Example 1 and general synthetic instructions: \n Example 2: 1-allyl-3- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 242-243 ° C (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.42 (m, 2H), 5.37 (d, 1H), 5.65 (d, 1H), 6.07-6.19 (m, 1H), 7.57-7.68 (m, 3H), 7.97-8.05 (m, 1H), 8.07-8.19 (m, 2H), 8.40-8.52 ( m, 2H), 8.99 (s, 1H), 9.70 (s, 1H), 11.36 (s, 1H), 12.56 (t, 1H) \n Example 3: 1-allyl-3- [3- (4-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea Melting point: 240-241 ° C (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 3.87 (s, 3H), 4.36-4.42 (m, 2H), 5.32 (d, 1H), 5.60 (d, 1H), 6.06-6.16 (m, 1H), 7.16 (d, 2H), 7.60 (d, 1H), 8.32 (d, 2H), 8.42 (d, 1H) ), 9.56 (s, 1H), 11.29 (s, 1H), 12.56 (m, 1H) \n Example 4: 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea hydrochloride Melting point: 160-161 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.36-4.43 (m, 2H), 5.31 (d, 1H), 5.59 (d, 1H), 6.05-6. 16 (m, 1H), 6.97 (d, 2H), 7.57 (d, 1H), 8.20 (d, 2H), 8.40 (d, 1H), 9.41 (s, 1H) ), 10.17 (bs, 1H), 11.24 (s, 1H), 12.56 (m, 1H) \n Example 5: 1- (2-Methyl-allyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 225-226 ° C (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.90 (s, 3H), 4.30-4.35 (m, 2H), 5.01 (s, 1H), 5.22 (s, 1H), 7.55-7.80 (m, 4H), 8.30-8.38 (m, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 11.32 (S, 1H), 12.65 (m, 1H) \n Example 6: 1- (2-Methyl-allyl) -3- (3-naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 239-240 ° C (decomposition) ) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.94 (s, 3H), 4.32 (m, 2H), 5.07 (s, 1H), 5.28 (s, 1H), 7 .60-7.69 (m, 3H), 8.00-8.05 (m, 1H), 8.07-8.12 (m, 1H), 8.14 (d, 1H), 8.42 -8.51 (m, 2H), 8.98 (s, 1H), 9.68 (s, 1H), 11.32 (s, 1H), 12.78 (m, 1H) \n Example 7: 1- [3- (4-Methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3- (2-methyl-allyl) -thiourea Melting point: 251-252 ° C (Disassembly) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.92 (s, 3H), 3.85 (s, 3H), 4.27-4.35 (m, 2H), 5.02 (s, 1H), 5.24 (s, 1H), 7.15 (d, 2H), 7.58 (d, 1H), 8.31 (d, 2H), 8.41 (d, 1H), 9. 46 (s, 1H), 11.29 (s, 1H), 12.68 (m, 1H) \n Example 8: 1- (3-Naphthalin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -3- (4-nitro-phenyl) -thiourea Melting point: 260-261 ° C. (decomposition) ) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 7.61-7.68 (m, 3H), 7.72 (d, 2H), 7.75 (d, 1H), 8.01-8. 06 (m, 1H), 8.16 (m, 2H), 8.26 (d, 2H), 8.53 (d, 1H), 8.58 (d, 1H), 9.04 (s, 1H) ), 9.62 (s, 1H), 9.76 (s, 1H), 11.81 (s, 1H) \n Example 9: 1- [3- (4-Methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3- (4-nitro-phenyl) -thiourea Melting point: 250-251 [deg.] C. (Disassembly) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 3.85 (s, 3H), 7.17 (d, 2H), 7.71 (d, 2H), 8.21 (d, 2H), 8 .22-8.27 (m, 1H), 8.36-8.42 (m, 3H), 9.53 (s, 1H), 9.65 (s, 1H), 11.77 (s, 1H) ) \n Example 10: 1-tert-butyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 227 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.65 (s, 9H), 7.53-7.69 (m, 4H), 8.34 (d, 2H), 8.41 (d, 1H), 9.51 (s, 1H), 10.98 (s, 1H), 12.75 (s, 1H) \n Example 11: 1-cyclopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 233-234 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 0.70-0.80 (m, 2H), 0.91-1.00 (m, 2H), 3.20-3.28 (m, 1H) ), 7.51-7.72 (m, 4H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 11.31 (s, 1H) , 12.45 (s, 1H) \n Example 12: 1-methyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 253-254 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 3.25 (s, 3H), 7.59-7.67 (m, 4H), 8.38 (d, 2H), 8.46 (d, 1H), 9.52 (s, 1H), 11.31 (s, 1H), 12.10 (s, 1H) \n Example 13: 1-Benzyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 232-233 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.96 (m, 2H), 7.37-7.48 (m, 3H), 7.54-7.67 (m, 6H), 8. 32 (d, 2H), 8.47 (d, 1H), 9.52 (s, 1H), 11.43 (s, 1H), 12.91 (s, 1H) \n Example 14: 1- (4-Fluoro-phenyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 225-226 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 7.33 (m, 2H), 7.57-7.65 (m, 3H), 7.70-7.81 (m, 3H), 8. 34 (d, 2H), 8.54 (d, 1H), 9.57 (s, 1H), 11.62 (s, 1H) \n Example 15: 1-cyclohexyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 230-232C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.50-1.75 (m, 6H), 1.80-2.00 (m, 4H), 7.55-7.70 (m, 4H) ), 8.37 (d, 2H), 8.45 (d, 1H), 9.55 (s, 1H), 11.20 (s, 1H), 12.80 (s, 1H) \n Example 16: 1-Isopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 229-230 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.40 (d, 6H), 4.40-4.50 (m, 1H), 7.58-7.66 (m, 4H), 8. 36 (d, 2H), 8.44 (d, 1H), 9.52 (s, 1H), 11.20 (s, 1H), 12.48 (s, 1H) \n Example 17: 1-furan-2-ylmethyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 250 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.95 (s, 2H), 6.55 (m, 1H), 6.68 (d, 1H), 7.59-7.68 (m, 4H), 7.74 (d, 1H), 8.37 (d, 2H), 8.48 (d, 1H), 9.55 (s, 1H), 11.45 (s, 1H), 12. 83 (s, 1H) \n Example 18: 1-methyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea Melting point: 270 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 3.25 (s, 3H), 7.70 (d, 1H), 8.44 (d, 2H), 8.50 (d, 1H), 8 .64 (d, 2H), 9.64 (s, 1H), 11.38 (s, 1H), 12.03 (s, 1H) \n Example 19: 1- [3- (4-Hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-methyl-thiourea Melting point: 282 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 3.25 (s, 3H), 6.98 (d, 2H), 7.57 (d, 1H), 8.26 (d, 2H), 8 .40 (d, 1H), 9.45 (s, 1H), 10.18 (s, 1H), 11.25 (s, 1H), 12.10 (s, 1H) \n Example 20: 1-allyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea Melting point: 244 ° C (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.40 (s, 2H), 5.36 (d, 1H), 5.59 (d, 1H), 6.08-6.15 (m, 1H), 7.71 (d, 1H), 8.46 (d, 2H), 8.51 (d, 1H), 8.60 (d, 2H), 9.64 (s, 1H), 11. 45 (s, 1H), 12.51 (t, 1H) \n Example 21: 4- [6- (3-Allyl-thiourea) -pyrido [2,3-b] pyrazin-3-yl] -benzoic acid ethyl ester Melting point: 223-224 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.39 (t, 3H), 4.35-4.42 (m, 4H), 5.35 (d, 1H), 5.60 (d, 1H), 6.08-6.15 (m, 1H), 7.68 (d, 1H), 8.17 (d, 2H), 8.47 (d, 2H), 8.50 (d, 1H) ), 9.60 (s, 1H), 11.40 (s, 1H), 12.52 (t, 1H) \n Example 22: 1-allyl-3- [3- (3-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea Melting point: 205 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.41 (s, 2H), 5.33 (d, 1H), 5.58 (d, 1H), 6.07-6.15 (m, 1H), 6.99 (d, 1H), 7.42 (t, 1H), 7.64 (d, 1H), 7.72 (s, 1H), 7.77 (d, 1H), 8. 46 (d, 1H), 9.45 (s, 1H), 9.80 (s, 1H), 11.37 (s, 1H), 12.55 (s, 1H) \n Example 23: 1-allyl-3- (3-benzo [1,3] dioxol-5-yl-pyrido [2,3-b] pyrazin-6-yl) -thiourea Melting point: 218-220 ° C (decomposition) ) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.40 (s, 2H), 5.31 (d, 1H), 5.60 (d, 1H), 6.08-6.20 (m, 3H), 7.16 (d, 1H), 7.61 (d, 1H), 7.90 (s, 1H), 7.96 (d, 1H), 8.43 (d, 1H), 9. 49 (s, 1H), 11.34 (s, 1H), 12.58 (s, 1H) \n Example 24: 1- [3- (4-Hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-prop-2-ynyl-thiourea Melting point: 350 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 2.09 (s, 1H), 2.44 (s, 2H), 6.99 (d, 2H), 7.19 (s, 1H), 7 .44 (s, 1H), 8.24 (d, 2H), 8.26 (d, 1H), 9.29 (s, 1H), 10.08 (s, 1H), 11.81 (s, 1H) \n Example 25: 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea Melting point: 230 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.40 (s, 2H), 5.34 (d, 1H), 5.60 (d, 1H), 6.07-6.15 (m, 1H), 6.98 (d, 2H), 7.58 (d, 1H), 8.24 (d, 2H), 8.42 (d, 1H), 9.45 (d, 1H), 10. 19 (s, 1H), 11.34 (s, 1H), 12.60 (s, 1H) \n Example 26: 1- [3- (4-Hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-((propenyl) -thiourea Melting point: \n \n1\n H-NMR (d \n6\n -DMSO): δ = 2.12 (d, 3H), 5.17 (m, 1H), 6.96 (d, 2H), 7.22-7.26 (m, 1H), 7.59 (d, 1H), 8.25 (d, 2H), 8.45 (d, 1H), 9.48 (s, 1H), 10.20 (s, 1H), 11. 56 (s, 1H), 14.67 (s, 1H) \n Example 27: 1-allyl-3- [2,3-bis- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea Melting point: 270 ° C (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.40 (s, 2H), 5.25 (d, 1H), 5.50 (d, 1H), 6.02-6.13 (m, 1H), 6.74 (d, 2H), 6.76 (d, 2H), 7.31 (d, 2H), 7.36 (d, 2H), 7.62 (d, 1H), 8. 42 (d, 1H), 9.78 (s, 1H), 9.85 (s, 1H), 11.30 (s, 1H), 12.47 (s, 1H) \n Example 28: 1- [2,3-bis- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -3-((propenyl) -thiourea Melting point: 240 ° C. Disassembly) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 2.05 (d, 3H), 5.10-5.18 (m, 1H), 6.74 (d, 2H), 6.76 (d, 2H), 7.20-7.26 (m, 1H), 7.34 (d, 2H), 7.39 (d, 2H), 7.63 (d, 1H), 8.45 (d, 1H) ), 9.79 (s, 1H), 9.89 (s, 1H), 11.55 (s, 1H), 14.56 (d, 1H) \n Example 29: 1-allyl-3- [2- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -thiourea Melting point: 260 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.40 (s, 2H), 5.28 (d, 1H), 5.48 (d, 1H), 6.03-6.12 (m, 1H), 6.96 (d, 2H), 7.66 (d, 1H), 8.16 (d, 2H), 8.43 (d, 1H), 9.52 (s, 1H), 10. 06 (s, 1H), 11.31 (s, 1H), 12.40 (s, 1H) \n Example 30: 1-allyl-3- [3- (4-nitro-phenyl) -pyrido [2,3-b] pyrazin-7-yl] -thiourea Melting point: 250 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 4.23 (s, 2H), 5.19 (d, 1H), 5.29 (d, 1H), 5.90-6.00 (m, 1H), 8.46 (d, 2H), 8.55 (s, 1H), 8.64 (d, 2H), 8.92 (s, 1H), 9.23 (s, 1H), 9. 77 (s, 1H), 10.35 (s, 1H) \n Example 31: 1-cyclopropyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea Melting point: 158-160 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 0.52-0.60 (m, 2H), 0.72-0.82 (m, 2H), 2.70-2.79 (m, 1H) ), 7.57-7.65 (m, 3H), 7.71 (d, 1H), 8.34 (d, 2H), 8.38 (d, 1H), 9.21 (s, 1H) , 9.46 (s, 1H), 10.12 (s, 1H) \n Example 32: 1-allyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -urea Melting point: 240 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 3.98 (s, 2H), 5.19 (d, 1H), 5.37 (d, 1H), 5.96-6.05 (m, 1H), 6.97 (d, 2H), 7.59 (d, 1H), 8.22 (d, 2H), 8.33 (d, 1H), 9.38 (s, 1H), 9. 45 (s, 1H), 10.13 (s, 1H), 10.18 (s, 1H) \n Example 33: 1- (3-Phenyl-pyrido [2,3-b] pyrazin-6-yl) -3-p-tolyl-urea Melting point: 298-299 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 2.29 (s, 3H), 7.20 (d, 2H), 7.52 (d, 2H), 7.59-7.67 (m, 3H), 7.80 (d, 1H), 8.38 (d, 2H), 8.44 (d, 1H), 9.59 (s, 1H), 10.36 (s, 1H), 11. 46 (s, 1H) \n Example 34: 1- (4-Chloro-3-trifluoromethyl-phenyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea Melting point: 250 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 7.58-7.67 (m, 3H), 7.74 (d, 1H), 7.80 (d, 1H), 7.87 (d, 1H), 8.21 (s, 1H), 8.39 (d, 2H), 8.48 (d, 1H), 9.53 (s, 1H), 10.55 (s, 1H), 11. 82 (s, 1H) \n Example 35: 1- (2-morpholin-4-yl-ethyl) -3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea Melting point: 226 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 2.45-2.67 (m, 6H), 3.40-3.48 (m, 2H), 3.60-3.69 (m, 4H) ), 7.55-7.70 (m, 4H), 8.30-8.40 (m, 3H), 9.29 (s, 1H), 9.42 (s, 1H), 10.18 ( s, 1H) \n Example 36: 1-phenethyl-3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea Melting point: 250 ° C. (decomposition) \n \n1\n H-NMR (d \n6\n -DMSO): δ = 2.88-2.95 (m, 2H), 3.52-3.60 (m, 2H), 7.18 (t, 1H), 7. 28 (t, 2H), 7.42 (d, 2H), 7.58-7.68 (m, 4H), 8.37 (d, 3H), 9.25 (s, 1H), 9.48 (S, 1H), 10.18 (s, 1H) \n Example 37: 1- (2,3-Di-pyridin-2-yl-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea Melting point: 236-237 [deg.] C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.3-1.22 (m, 3H), 3.28-3.39 (m, 2H), 3.60-3.69 (m, 4H) ), 7.31-7.39 (m, 2H), 7.79 (d, 1H), 7.91-7.99 (m, 4H), 8.26 (d, 1H), 8.29 ( d, 1H), 8.47 (d, 1H), 9.08 (s, 1H), 10.20 (s, 1H) \n Example 38: 1- (2,3-Dimethyl-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea Melting point: 246-248 ° C \n \n1\n H-NMR (d \n6\n -DMSO): δ = 1.17 (t, 3H), 2.64 (s, 3H), 2.67 (s, 3H), 3.24-3.40 (m, 2H), 7.55 (d, 1H), 8.24 (d, 1H), 9.14 (s, 1H), 9.91 (s, 1H)\n\n\n\n\n\n\n \n\n  第１表：\n\n\n \n \n\n\nTable 1: \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明による化合物の生物学的作用\n\n  本発明による化合物の阻害作用を、以下のヒトのセリン／トレオニンキナーゼ及びチロシンキナーゼ：ＰＫＢ／Ａｋｔ１、ｃ−Ｒａｆ−Ｍｅｋ−Ｅｒｋ、Ｂ−Ｒａｆ−Ｍｅｋ−Ｅｒｋ、Ｍｅｋ−Ｅｒｋ、ＭＡＰＫ、ＰＤＧＦＲベータ、Ｆｌｔ−３、ｃ−Ｋｉｔ、ｃ−Ａｂｌ、ＫＤＲ、ＦＧＦＲ１及びＩＧＦ１Ｒについて古典的なキナーゼアッセイで試験した。全長キナーゼと同様に、短縮されているが、少なくとも細胞質キナーゼドメインを含む断片も使用した。これらのキナーゼはＧＳＴ−（グルタチオン−Ｓ−トランスフェラーゼ）又はＨＩＳ−タグを有する組み換え融合タンパク質としてＳｆ９細胞培養中で製造した。基質の種類に応じて、サンドウィッチ型ＥＬＩＳＡ方式でか又は簡単な基質吸着試験によって９６ウェルのフラッシュプレート（パーキンエルマー社）において種々のキナーゼ反応を実施した。\n\nBiological action of the compounds according to the invention The inhibitory action of the compounds according to the invention is determined by the following human serine / threonine kinases and tyrosine kinases: PKB / Akt1, c-Raf-Mek-Erk, B-Raf-Mek-Erk, Mek-Erk, MAPK, PDGFR beta, Flt-3, c-Kit, c-Abl, KDR, FGFR1 and IGF1R were tested in a classic kinase assay. Similar to the full-length kinase, a truncated but at least fragment containing the cytoplasmic kinase domain was also used. These kinases were produced in Sf9 cell culture as recombinant fusion proteins with GST- (glutathione-S-transferase) or HIS-tag. Depending on the type of substrate, various kinase reactions were performed in 96-well flash plates (Perkin Elmer) in a sandwich ELISA format or by a simple substrate adsorption test.\n\n\n\n\n\n\n \n\n  以下にｃ−Ｒａｆ−Ｍｅｋ−Ｅｒｋカスケードについての物質試験を正確に記載する。ｃ−Ｒａｆ−Ｍｅｋ−Ｅｒｋアッセイの選択された試験結果を引き続き挙げる。\n\n\n  The substance tests for the c-Raf-Mek-Erk cascade are described accurately below. The selected test results of the c-Raf-Mek-Erk assay continue to be listed.\n\n\n\n\n\n\n\n \n\n  手順：ｃ−Ｒａｆ−Ｍｅｋ−Ｅｒｋ−ＥＬＩＳＡ\n\n  潜在的な阻害剤をまず、最初に一回量測定において２０μｇ／ｍｌの濃度で９６マイクロタイタープレート（ＭＴＰ）上で調査した。７０％阻害を上回る物質を用量−作用研究に使用した。ｃ−Ｒａｆ−Ｍｅｋ−Ｅｒｋカスケードの再構成は無細胞ＥＬＩＳＡを用いて定量化した。組み換えにより製造された以下のキナーゼタンパク質：１）Ｓｆ９細胞由来の構成的活性なＧＳＴ−ｃ−Ｒａｆ−ＤＤ、２）Ｅ．コリ由来の不活性なＧＳＴ−Ｍｅｋ１及び３）Ｅ．コリ由来の不活性なＨｉｓ−Ｅｒｋ２を使用した。\n\nProcedure: c-Raf-Mek-Erk-ELISA \n Potential inhibitors were first investigated on 96 microtiter plates (MTP) at a concentration of 20 μg / ml in a single dose measurement. Substances exceeding 70% inhibition were used for dose-effect studies. Reconstitution of the c-Raf-Mek-Erk cascade was quantified using a cell-free ELISA. The following kinase proteins produced recombinantly: 1) constitutively active GST-c-Raf-DD from Sf9 cells, 2) E. coli. Inactive GST-Mek1 and 3) E. coli derived from E. coli Inactive His-Erk2 derived from E. coli was used.\n\n\n\n\n\n\n \n\n  典型的なキナーゼの配合は、それぞれ２０〜１５０ｎｇのＲａｆタンパク質、Ｍｅｋタンパク質、Ｅｒｋタンパク質、１ｍＭのＡＴＰ、１０ｍＭのＭｇＣｌ\n２\n、１５０ｍＭのＮａＣｌ、２５ｍＭのβ−グリセロリン酸塩、２５ｍＭのＨｅｐｅｓ（ｐＨ７．５）を有する最終容量５０μｌで実施した。キナーゼ反応の前に、試験物質をそれぞれ３０分間室温で、３種のキナーゼタンパク質のそれぞれ単独と一緒に事前にインキュベートした。キナーゼ反応のために、試験物質と一緒に事前にインキュベートされたキナーゼを一緒にして、２６℃で３０分間インキュベートした。最終濃度２％のＳＤＳと加熱ブロック中で５０℃を１０分間によって、反応を停止させた。\n\nTypical kinases formulation, Raf protein respectively 20~150ng, Mek protein, Erk protein, 1mM of ATP, 10 mM of MgCl \n2,\n 150 mM of NaCl, of 25 mM beta-glycerophosphate, 25 mM of Hepes (pH 7.5 ) In a final volume of 50 μl. Prior to the kinase reaction, the test substances were preincubated with each of the three kinase proteins alone for 30 minutes each at room temperature. For the kinase reaction, the preincubated kinase with the test substance was combined and incubated at 26 ° C. for 30 minutes. The reaction was stopped by SDS at a final concentration of 2% and 50 ° C. for 10 minutes in a heating block.\n\n\n\n\n\n\n \n\n  免疫検出のために、反応配合物を抗Ｅｒｋ−Ａｋ（Ｋ−２３、サンタクルーズバイオテクノロジー社）で被覆された９６ＭＴＰに移し、室温で６０分間インキュベートし、そしてＴＢＳＴで３回洗浄した。抗ホスホＥｒｋ−Ａｋ（番号９１０６、ニューイングランドバイオラボ社）を５０μｌのＴＢＳＴ／１％ＢＳＡ中に１：５００で添加し、そして一晩４℃でインキュベートした。ＭＴＰをＴＢＳＴで３回洗浄した後に、二次的な抗マウスＩｇＧ\nＰＯＤ\n複合体（番号ＮＡ９３１、ファルマシア社）を１：２５００で混合し、室温で１時間インキュベートし、そして再びＴＢＳＴで３回洗浄した。キナーゼ反応の比色検出のために、それぞれ５０μｌのＯＰＤ（ｏ−フェニルジアミン二塩酸塩）発色バッファーを窪みにピペットで加え、そして３７℃で３０分間インキュベートした。呈色反応を引き続きＥＬＩＳＡリーダで４９２ｎｍで測定した。\n\nFor immunodetection, the reaction formulation was transferred to 96MTP coated with anti-Erk-Ak (K-23, Santa Cruz Biotechnology), incubated for 60 minutes at room temperature, and washed 3 times with TBST. Anti-phospho Erk-Ak (# 9106, New England Biolabs) was added 1: 500 in 50 μl TBST / 1% BSA and incubated overnight at 4 ° C. After MTP was washed 3 times with TBST, secondary anti-mouse IgG \nPOD\n complex (No. NA931, Pharmacia) was mixed 1: 2500, incubated for 1 hour at room temperature, and again washed 3 times with TBST. . For colorimetric detection of the kinase reaction, 50 μl each of OPD (o-phenyldiamine dihydrochloride) color development buffer was pipetted into the wells and incubated at 37 ° C. for 30 minutes. The color reaction was subsequently measured at 492 nm with an ELISA reader.\n\n\n\n\n\n\n \n\n  用量−作用曲線の実験的な決定は、同じ試験構成によって、半対数的に段階づけられた３１．６ｐＭ〜１００μＭの１０種の濃度で実施した。ＩＣ\n５０\n値はＧｒａｐｈＰａｄＰｒｉｓｍにおいて計算した。\n\nExperimental determination of dose-effect curves was performed at 10 concentrations from 31.6 pM to 100 μM, semi-logarithmically stepped by the same test setup. IC \n50\n values were calculated in GraphPad Prism.\n\n\n\n\n\n\n \n\n  本発明による化合物は４００ｎＭまでのＩＣ\n５０\n値で効果的なＥｒｋリン酸化の阻害を示した（実施例４及び１２を参照のこと）。\n\nCompounds according to the invention showed effective inhibition of Erk phosphorylation with IC \n50\n values up to 400 nM (see Examples 4 and 12)."
  },
  {
    "id": "WO2010046944A1",
    "text": "Proteases targeting agents AbstractA protein inhibitor from Sulfolobulus Solfataricus and peptides thereof, which both have the ability to inhibit AARE and elastase are described. Similarly to the eukaryotic counterparts, the recombinant protein is able to inhibit in vitro the bovine alf a-chymotrypsin with a high specificity, and the porcine elastase but not all commercial available trypsins, features which distinguish all the members belonging to the family PEBP. Through site-specific mutagenesis techniques of the gene codifying SsCEI, it has been recognized the \"reactive site loop\" - RCL - on the inhibitor, responsible for the interaction with the eukarial protease target already identified. The inhibitor and the peptides thereof can be used as new compounds capable of modulating cognitive enhancement cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases. Claims\n\n\n\n\n\n\n1) A proteic inhibitor belonging to PEBP family and characterised by: a. molecular weight from 16 to 19 kDa and a pi value equal to 6.7 b. Identified and isolated in thermophilic microorganism c. high heat stability and resistant to common denaturating agents of proteins d. resistant to proteolytic digestion by the common proteases\n\n\n2) The proteic inhibitor of claim 1 where the extremophilic microorganism is Sulfolobus solfataricus\n\n\n3) A proteic inhibitor belonging to PEBP family with amino acid sequence of SEQ ID NO: 1\n\n\n4) A proteic inhibitor belonging to PEBP family enconded by the nucleic acid of SEQ ID NO: 2\n\n\n5) An isolated nucleic acid comprising the nucleic acid of SEQ ID NO: 2 or variants thereof, where in the variants have one or more substitutions, insertions and/or deletions as compared to the nucleic acid of SEQ ID NO: 2 and encoded a protein characterized by high heat stability, resistance to common denaturating agents of proteins and proteolytic digestion by the common proteases and isolated from extremophilic microorganism, provided that: \n\n a) these variants hybridise with a nucleic acid according to the sequence of SEQ ID NO: 2 under stringent conditions, and further provided that these variants encode a protein having the same characteristics of proteic inhibitor of claims 1 b) these variants have nucleic acid changes due to the degeneration of the genetic code and encoding the same amino acid having the same activity as the nucleic acid of SEQ ID NO: 2, and c) the nucleic acid does not exclusively consist of the bases 1-471 of SEQ ID NO: 2 or fragments thereof.\n\n\n6) A nucleic acid which is a transcriptional product of one of the nucleic acids according to preceding claim or which selectively hybridises with such a transcription product under stringent conditions and is an antisense DNA or RNA.\n\n\n7) An inhibitor active site sequence (T123-N130) that interacts with proteases and that represent a no canonic sequence no before known.\n\n\n8) The manufacture of proteic inhibitor according to claim 1 by recombinant DNA technology in prokaryote and eukaryote or by chemical synthesis.\n\n\n9) A vector which comprises a nucleic acid according to one or more of the claims 4, 5 e 6 and which is preferably a plasmid. \n\n 10) A peptide with formula I:\n\n\nI : Yl-Xl-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-Y2\n\n\nwherein,\n\n\nXl is the L- or D- enantiomer of Tyrosine or null; X2 is the L- or D- enantiomer of Alanine or null when Xl is null;\n\n\nX3 is the L- or D- enantiomer of Isoleucine or null when\n\n\nXl and X2 are null; X4 is the L- or D- enantiomer of Aspartic acid or null when Xl through X3 are null; X5 is the L- or D- enantiomer of Threonine or null when\n\n\nXl through X4 are null;\n\n\nX6 is the L- or D- enantiomer of Isoleucine, or D- enantiomer of Aspartic acid, or D-enantiomer of Cysteine with an acetamidomethyl (Acm) protection group on the sulphidryl group (abbreviated as Cys (Acm) , or D-enantiomer of Proline.\n\n\nX7 is the L- or D-enantiomer of Leucine or of Alanine, or the D- enantiomer of Methionine, or D-enantiomer of Cys (Acm) , or D-enantiomer of Aspartic acid.\n\n\nX8 is the L- or D-enantiomer of Leucine, or D-enantiomer of Methionine, or D-enantiomer of Cys (Acm) .\n\n\nX9 is the L- or D-enantiomer of Glutamic acid, or D- enantiomer of Aspartic acid or D-enantiomer of Cys (Acm) , or D-enantiomer of Arginine, or D-enantiomer of Histidine. XlO is the L- or D- enantiomer of Isoleucine or null when XIl through Xl 6 are null; \n\n XIl is the L- or D- enantiomer of Lysine or null when X12 through Xl 6 are null ; X12 is the L- or D- enantiomer of Asparagine or null when\n\n\nX13 through X16 are null ; X13 is the L- or D- enantiomer of Isoleucine or null when\n\n\nXl 4 through Xl 6 are null ; X14 is the L- or D- enantiomer of Asparagine or null when\n\n\nX15 and X16 are null ;\n\n\nX15 is the L- or D- enantiomer of Alanine or null when X16 is null ;\n\n\nX16 is the L- or D- enantiomer of Aspartic acid or null .\n\n\n11) Derivates of compound of formula I according to preceding claim, where said derivates are selected form the group consisting of : a ) oligomers or multimers of molecules of the compound of formula I , said oligomers and multimers comprising two or more molecules of the compound of formula I each linked to a common scaffold moiety via an amide bond formed between an amine or carboxylic acid group present in molecules of the compound of formula I and an opposite amine or carboxylic acid group on a scaffold moiety said scaffold moiety participating in at least 2 amide bonds ,\n\n\nb ) derivatives comprising a molecule of the compound of formula I or an oligomer or multimer as defined above in part a ) conj ugated via an ester bond, an ether bond or a thioether bond, on the N \n\n or C terminal amino- or carboxylic acid group of the peptide moiety to: PEG,\n\n\nPEG-based compounds, fatty acids, and c) salts and solvates of a molecule of the compound of formula I or of a derivative as defined in part a) or b) above.\n\n\n12) Peptides generated by the general formula I according to claim 10, and carrying at least one methyl group on an amide nitrogen (N-methyl- aminoacids) .\n\n\n13) A host cell which has been transformed with a vector according to claim 9 and which is preferably an eukaryotic cell, more preferably a mammal cell, preferably an adult or embryonic stem cell, plant cell, yeast cell or insect cell, even more preferably a CHO, COS, HeLa, 293T, HEH o BHK, or a prokaryotic cell, preferably E.coli or Bacillus subtilis, wherein human embryonic stem cells are excluded.\n\n\n14) A method to isolate Sso0767 gene from total genomic DNA of hyperthermophilic microorganism S. solfataricus by polymerase chain reaction technique (PCR) using the following oligonucleotides: Pl 5 ' -CCATGGGCTTGAATAGTGAAAGTATATA-3 ' e\n\n\nP2 5' -GAGCTCTTTTCTCTTATATTTACCCATTACGAAT-S ' \n\n 15) Use of the proteic inhibitor according to anyone of claims 1-4 for the manufacture of a medicament for the therapy of pathologies characterized by pathologic alteration of proteases activities.\n\n\n16) A pharmaceutical composition comprising a terapeutically effective of a nucleic acid according to one or more the claims 4, 5 e 6 or of a vector according to claim 9 in combination with a pharmaceutically acceptable carrier, or a therapeutically effective dose of protein according to claim 1 in combination with a pharmaceutically acceptable carrier.\n\n\n17) Use of the pharmaceutical composition according to claim 16 for the manufacture of a medicament for the \n•\n therapy of pathologies characterized by pathologic alteration of proteases activities.\n\n\n18) Use of the pharmaceutical composition according to claims 16 or 17 wherein the proteases are Serin- Protease .\n\n\n19) Use of the pharmaceutical composition according to claims 16 or 17 for the manufacture of a medicament for the therapy of pathologies characterized by pathologic alteration of proteases activities where said pathologies are Alzheimer's disease and pulmonary emphysema.\n\n\n20) Use of the pharmaceutical composition according to claims 16 or 17 for the manufacture of a medicament \n\n for the therapy of pathologies characterized by alteration of proteasome proteolytic activity.\n\n\n21) A pharmaceutical composition comprising a terapeutically effective of a compound according to one or more of claims 10, 11 and 12 in combination with a pharmaceutically acceptable carrier, for treating of cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases\n\n\n22) A method to inhibit proteases keeping in touch with an appropriate amount of inhibitor according one of claims 1, 7, 10, 11 and 12.\n\n\n23) A method to inhibit the proteasome proteolytic components keeping in touch with an appropriate amount of inhibitor according to claim 1, or 7, or 10, or 11, or 12.\n\n\n24) A method to inhibit proteases and regulate thereof activity when, in different pathologies, a proteolysis activity alteration is set (cancer, neuron-pathologies, pulmonary diseases e more over) keeping in touch with an appropriate amount of inhibitor according to claim 1, or I\n1\n or 10, or 11 or 12.\n\n\n25) A method of treating cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases administering a therapeutically effective amount of \n\ncompound according to claim 1, or 7, or 10, or, or 12. Description\n\n\n\n\n PROTEASES TARGETING AGENTS\n\n\nField of invention The invention relates to cognitive enhancement, cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases, urological diseases and therapeutic modulation thereof. In particular, the invention relates to compounds based on peptides and derivatives capable of modulating cognitive enhancement cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases.\n\n\nBackground of the invention\n\n\nEndogenous protease inhibitors.\n\n\nProtease inhibitors are divided into different classes that are widely distributed in all three domains of life, but so far considerable attention has been dedicated exclusively to those from eukaryotes, where the number of genes codifying for these proteins varies from 10 up to hundreds for each family. Moreover, the genome comparative analysis of the different microorganisms available in the network, has revealed that only three families of protease inhibitors are present in Archaea in common with prokaryotes and eukaryotes, the \"serpins\" (clan 14), \"chagasins\" (clan 142) (Rawlings et al. 2004) and the \"phosphatidylethanolamine binding proteins\" (PEBP, 151 clans) . In particular, the family 151 constitutes a distinct '\"cluster\", whose members do not have any \n\nregion homologous to the other protease inhibitors studied so far. The founder of the family 151 is the protein of the yeast TFSl able to inhibit the carboxypeptidase Y with an inhibition constant of 1.8 nM, while in rats, the pebp3 inhibits thrombin, the neuropsin and the chymotrypsin (Hengst et al. 2001) with an inhibition constant in the micro-molar range. The PEBPs represent a family of multifunctional proteins, involved in a number of physiological and cellular processes of the body, as the spermatogenesis, the control of heart activity, cerebral development in mammals, or inflorescence in plants (Serre et al . 1998). Proteins belonging to this family show unique structural characteristics. Despite highly conserved conformations, they have significant structural differences, especially on their N and C-terminal ends, which could provide the discriminatory properties for the various biological functions, such as the modulation of their interaction with proteins or ligands The biological activity of the PEBPs may be divided into two broad categories: i) they are able to interact and therefore to regulate the activity of various enzymes and proteins, such as serin proteases, kinases (Yeung et al. 1999) and transcription factors in the cells; ii) they show the capacity to specifically interact with many anionic ligands such as phospholipids, nucleotides and derivatives of cholesterol and hormones. Despite the wide dissemination of PEBPs in tissue and cellular compartments of many species, little is known about the several functions they perform. The cellular localization and the binding with phospholipids on the \n\ninner surface of plasma membrane has suggested for some members of this family a role in the organization of plasma membrane, during growth, development and differentiation of cells. Furthermore, in the central nervous system some serine proteases are able to block the morphological changes of neuronal cells associated with the activity of proteolytic enzymes, as shown in rats by PEBP. These findings suggest a role of this class of inhibitors in the development and control of neuronal processes (Hengst et al. 2001) . Therefore, there is today a strong request to better define the biological roles of this class of proteins in humans. For example, changes in the expression of PEBPs are related to many pathological conditions that affect a significant percentage of the population, for which the current therapeutic strategies are often ineffective (primary and metastatic cancer, diabetes, Alzheimer's disease, sterility, (Chen et al.2006) . It is therefore clear that these proteins are a starting point for medical research. Currently, the pebp-1 human is recognized in the US as a prognostic factor for assessing the risk of spread of prostate cancer cells in the body.\n\n\nProteases Proteases play a central role in controlled processes, such as blood coagulation, fibrinolysis, complement activation, fertilization, and hormone production. These enzymes are also used in a variety of diagnostic, therapeutic, and industrial contexts. [Jones et al. (1991), Proc. Nat. Acad. Sci . 88: 2194-2198; WO 02/068579] . \n\n Proteases belong systematically to the C-N Hydrolases. More specifically, proteases catalyze the hydrolytic cleavage of a peptide bond and are therefore called peptidases as well. Peptidases located extracellularly in the blood or other extracellular compartments of the body play often regulatory roles in processes like for example blood clotting, fibrinolysis, or activation of complement constituents .\n\n\nIntracellularly located proteases also exhibit a wide variety of roles. They are found in compartments like the ER, the Golgi apparatus, or the lysosomes. Their functions include for example activation of peptide hormons, ubiquitin mediated proteolysis, among others. Proteases are most commonly classified according to their mechanism of action, or to specific active groups that are present in the so-called reactive center.\n\n\nSerine peptidases\n\n\nSerine proteases exhibit a serine in the catalytic site which forms a covalent ester intermediate during the catalytic reaction pathway by a nucleophilic attack on the carboxy carbon of the peptide bond. In the active site of serine proteases, a catalytic triad comprised of an aspartate, a histidine and the above mentioned serine is found. This triad functions in the reaction mechanism as a charge relay system. To the large family of serine proteases belong, for example, the digestive enzymes trypsin and chymotrypsin, components of the complement cascade, enzymes involved in the blood clotting cascade, as well \n\nas enzymes that function in degradation, rebuilding and maintenance of constituents of the extracellular matrix.\n\n\nElastase and Acyl-aminoacyl-peptidase (AARE or APH or ACPH or APEH) are also members of the group of serine protease enzymes.\n\n\nElastase\n\n\nHuman neutrophil elastase (elastase) is believed to be a main responsible for inflammatory conditions in the lung, where an imbalance between elastase and antiproteases leads to proteolytic destruction of lung elastin and tissue (Snider GL. Emphysema: the first two centuries and beyond. Am Rev Respir Dis 1992; 146:1334- 44, 1615-22) . Elastase is a serine protease of the chymotrypsin family that is stored in the primary (azurophil) granules of polymorphonuclear neutrophils (PMNs) . It was first identified as degradative enzymes responsible for eliminating intracellular pathogens and breaking down tissues at inflammatory sites [A. Janoff, J. Scherer, Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes, J. Exp. Med. 128 (1968) 1137ell55. R. C. Kao, N. G. Wehner, K. M. Skubitz, B. H. Gray, J. R. Hoidal, Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters, J. Clin. Invest. 82 (1988) 1963el973. M. Baggiolini, J. Schnyder, U. Bretz, B. Dewald, W. Ruch, Cellular mechanisms of proteinase release from inflammatory cells and the degradation of extracellular proteins, Ciba Found. Symp. (1979) 105- 121], and was soon recognized as a possible molecular \n\n target for anti-inflammatory agents [G. D. Virca, G. Metz, H. P. Schnebli, Similarities between human and rat leukocyte elastase and cathepsin G, Eur. J. Biochem. 144 (1984) 1-9.] . The imbalance between human neutrophil elastase and endogenous serine proteinase inhibitors is considered to cause a variety of elastase-mediated inflammatory disorders, including emphysema, which is due to al-antitrypsin deficiency, and cystic fibrosis (CF) [Bettina Siedle, Andrea Hrenn, Irmgard Merfort, Natural Compounds as Inhibitors of Human Neutrophil Elastase, Planta Med., 2007; 73: 401- 420, Georg Thieme Verlag KG Stuttgart] . Thus, elastase has been the object of intensive research to find potent inhibitors that target its destructive and pro- inflammatory action. A large body of work has been so far carried out on alpha-1 antitrypsin [Camelier AA, Winter DH, Jardim JR, Barboza CE, Cukier A, Miravitlles, \"Alpha-1 antitrypsin deficiency: diagnosis and treatment\" J Bras Pneumol. 2008 JuI; 34 (7 ) : 514-27] , a serpin which is the natural inhibitor of elastase. The block of al-antitrypsin processing in hepatocytes significantly reduces levels of circulating al- antitrypsin, which may lead to emphysema due to insufficient protection of the lower respiratory tract from elastase, permitting progressive destruction of the alveoli. In CF, impaired mucocilliary clearance leads to chronic bacterial infections and subsequent vigorous influx of neutrophils in the airways. High levels of elastase are released and induce progressive proteolytic impairment of multiple defense pathways leading to endobronchial obstruction and airway wall destruction. Studies also indicate that elastase \n\ncontributes to chronic inflammatory airway diseases by inducing mucin production in airway epithelial cells. Elastase is also often associated with ARDS, although observational studies of humans do not yet convincingly demonstrate the role for elastase.\n\n\nAARE\n\n\nAARE catalyses the hydrolysis of the amino-terminal peptide bond of an N-acetylated protein to generate a N-acetylated amino acid and a protein with a free amino-terminus . NH2 terminal acetylation of intracellular proteins occurs in many eukaryotic cells and more rarely in prokaryotic cells. About 40% of these acetylated proteins are structural proteins, consisting mostly of histones, virus coat proteins, keratins, actins, ribosomal proteins, crystallins, myelin proteins, tropomyosin.\n\n\nThe acetylamino acid formed by acylpeptide hydrolase is further processed to acetate and a free amino acid by an aminoacylase . The substrates for the acylpeptide hydrolase and the acylase behave in a reciprocal manner since acylpeptide hydrolase binds but does not process acetylamino acids and the acylase binds acetylpeptides but does not hydrolyze them; however, the 2 enzymes share the same specificity for the acyl group. All of these findings indicate common functional features in the protein structures of the 2 enzymes, which are encoded by the same region of human chromosome 3, namely, 3p21. [Jones et al. (1991), Proc. Nat. Acad. Sci. 88: 2194-2198] suggested that there may be a relationship between the expression of these 2 enzymes \n\nand acetylated peptide growth factors in some carcinomas .\n\n\nAs a huge number of proteases play a central role in several important cellular and intracellular processes, their value as pharmaceutical targets has been proven for several of these enzymes. Therefore, the identification of specific inhibitors or modulators may lead to the development of novel compounds useful in pharmacological approaches to treat diseases and conditions in which protease activities are involved. In the specific case of elastase and AARE, these diseases may include, but are not limited to cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases in a mammal (see Patent Application WO/2007/147496) .\n\n\nThe invention relates to pharmaceutical compositions for the treatment of cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases in a mammals, which are due to an altered activity of AARE and elastase.\n\n\nIn particular, a protein inhibitor from Sulfolobulus Solfataricus and peptides thereof, which both have the ability to inhibit AARE and elastase are here described as the object of the invention. The inhibitor has been obtained in recombinant form and purified to homogeneity from the hyperthermophile Sulfolobus solfataricus. It is a monomer of molecular mass of 19.0 kDa that shows a high degree of similarity with the sequences of rat PEBPl (28% identity) , human PEBPl (27% \n\nidentity), TFSl yeast (33% identity) and E. coli YBCL (38% identity) . Similarly to the eukaryotic counterparts, the recombinant protein is able to inhibit in vitro the bovine alfa-chymotrypsin with a high specificity, and the porcine elastase but not all commercial available trypsins, features which distinguish all the members belonging to the family PEBP. Moreover, through site-specific mutagenesis techniques of the gene codifying SsCEI, it has been recognized the \"reactive site loop\" - RCL - on the inhibitor, responsible for the interaction with the eukarial protease target already identified. Such a site shows an aminoacid sequence never found in any protease inhibitor of chymotrypsin-like enzymes, so far characterized.\n\n\nOn the basis of the inhibitor RCL, isolated peptides of different length, sequence and structure, can be designed and tested in vitro for their capacity to block or enhance (modulate) the activity of the target proteases. These peptides, where provided of the suitable properties of stability, potency and selectivity, can be used as new compounds for the treatment of diseases whereby the proteases are involved.\n\n\nSUMMARY OF INVENTION\n\n\nAccording to a first aspect of the invention there is provided a protein having the following nucleotide sequence (SEQUENCE 1) : \n\nORIGIN ttgaatagtg aaagtatata ttcgatgaga gtagtatctt cagcctttaa gaatgaggat 60 tttataccta ttaaatatac ttgtgatgga caagatctgt ctccggagtt agagtgggat 120 cttgttacta acgctaaaag ttatgcgata atcgtagaag atccagatgc gcctggagga 180 actttcatac attgggtaat atacaacata actaccaata gattgccaga aggagtgcca 240 agactgtaca aatcacaata tggtgtacaa ggtgtaaacg attttgggaa tatagggtat 300 aacggtccgt gtcctcctaa gacacatcca cctcatagat attattttta tgtttatgca 360 attgatacaa tactacttga aattaaaaat attaatgctg ataagttaaa atcactaatg 420 gagggacatg ggatagagag aggattcgta atgggtaaat ataagagaaa ataa\n\n\nwhich is translated into the following protein sequence :\n\n\nMNSESIYSMRVVSSAFKNEDFIPIKYTCDGQDLSPELEWDLVTNAKSYAIIVEDP DAPGGTFIHWVIYNITTNRLPEGVPRLYKSQYGVQGVNDFGNIGYNGPCPPKTHP PHRYYFYVYAIDTILLEIKNINADKLKSLMEGHGIERGFVMGKYKR.\n\n\nThis protein is one of 1323 cytosolic proteins identified from the organism and expressed in the middle exponential phase of growth (Chong, et al, 2005) , although no functional role has yet been assigned. The S. solfataricus inhibitor has been isolated following its ability to inhibit the activity of bovine alpha - chymotrypsin. The protein is monomeric with an isoelectric point of 6.7 and a molecular mass of 19.0 kDa.\n\n\nOn the basis of the inhibitor RCL, isolated peptides of different length, sequence and structure, have been designed and tested in vitro for their capacity to \n\nblock the activity of the target protease. These peptides do block the activity of AARE, therefore, according to a second aspect of the invention there is provided a compound of formula I:\n\n\nI : Yl-Xl-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14- X15-X16-Y2\n\n\nwherein,\n\n\nXl is the L- or D- enantiomer of Tyrosine or null; X2 is the L- or D- enantiomer of Alanine or null when Xl is null;\n\n\nX3 is the L- or D- enantiomer of Isoleucine or null when Xl and X2 are null;\n\n\nX4 is the L- or D- enantiomer of Aspartic acid or null when Xl through X3 are null; X5 is the L- or D- enantiomer of Threonine or null when Xl through X4 are null; X6 is the L- or D- enantiomer of Isoleucine, or D- enantiomer of Aspartic acid, or D-enantiomer of Cysteine with an acetamidomethyl (Acm) protection group on the sulphidryl group (abbreviated as Cys (Acm) , or D-enantiomer of Proline. X7 is the L- or D-enantiomer of Leucine or of Alanine, or the D- enantiomer of Methionine, or D- enantiomer of Cys (Acm) , or D-enantiomer of Aspartic acid.\n\n\nX8 is the L- or D-enantiomer of Leucine, or D- enantiomer of Methionine, or D-enantiomer of Cys (Acm) . \n\nX9 is the L- or D-enantiomer of Glutamic acid, or\n\n\nD-enantiomer of Aspartic acid or D-enantiomer of\n\n\nCys (Acm) , or D-enantiomer of Arginine, or D- enantiomer of Histidine. XlO is the L- or D- enantiomer of Isoleucine or null when XIl through X16 are null; XlI is the L- or D- enantiomer of Lysine or null when X12 through X16 are null;\n\n\nX12 is the L- or D- enantiomer of Asparagine or null when X13 through Xlβ are null;\n\n\nX13 is the L- or D- enantiomer of Isoleucine or null when X14 through X16 are null; X14 is the L- or D- enantiomer of Asparagine or null when X15 and Xlβ are null; X15 is the L- or D- enantiomer of Alanine or null when Xlβ is null; and Xlβ is the L- or D- enantiomer of Aspartic acid or null.\n\n\nThe \"null\" notation, indicates that a number of other peptide sequences can be generated by the formula I with the indicated combination of L- and D-aminoacids, by progressively shortening the sequence from the N- and/or the C-termini until at least tetrapeptides of formula :\n\n\nYl-(D or L)-IIe-(D or L) -Leu (or AIa)-(D or L)-LeU-(D or L) -G1U-Y2 are generated. In this formula: lie is the aminoacid Isoleucine; \n\n Leu is the aminoacid Leucine; Ala is the aminoacid Alanaine; GIu is the aminoacid glutamic acid.\n\n\nAll the retro variants corresponding to each single sequence generated from the general formula I, according to Fischer PM, Curr Protein Pept Sci. 2003 Oct ; 4 ( 5) : 339-56, \"The design, synthesis and application of stereochemical and directional peptide isomers: a critical review\", represent a further embodiment to this invention. The retro variant of a generic peptide is intended a new molecule whereby any carbonyl group within the peptide backbone is exchanged with an NH group and viceversa and where the C-terminal carboxylic group and the N-terminal amino group are interconverted.\n\n\nAn amide bond is intended to occur between each single aminoacid of the sequences, as it is well known to those skilled in peptide and protein chemistry. Likewise, in the general formula reported above, Yl and Y2 represent chemical groups, forming amide bonds, added to the N-terminal amino-group or to the C- terminal carbonyl of the peptide.\n\n\nFollowing this notation, when Yl is an hydrogen, a free amine is generated at the N-terminus; when Yl is an acetyl group, an N-terminal acetylated peptide is generated. Alternatively Yl can be one of the following chemical groups which can help to improve the half-life of resulting molecules or improve their delivery properties by increasing cell permeability: \n\n - any linear carboxylic acid having from 3 up to 20 carbon atoms\n\n\n- any PEG derivative having a carbonyl group so as to form an amide bond with the N-terminal amine.\n\n\nYl can also be an acetyl group, whenever the first aminoacid on the N-terminus is in its D configuration.\n\n\nY2 is an hydroxyl group so as to generate a terminal carboxylic acid or is one of the following groups added to the carbonyl acid terminal of the oligopeptide sequence so as to form an amide bond:\n\n\n- an amine group to form an amide or\n\n\n- any linear primary amine having from 1 up to 20 carbon atoms or\n\n\n- any PEG derivative having an amine group so as to form an anide bond with the C-. terminal carboxylic group.\n\n\nIn a further embodiment of this invention, derivatives of compound of formula I are included; said derivatives are selected from the group consisting of: a) oligomers or multimers of molecules of the compound of formula I, said oligomers and multimers comprising two or more molecules of the compound of formula I each linked to a common scaffold moiety via an amide bond formed between an amine or carboxylic acid group present in molecules of the compound of formula I and an opposite amine or carboxylic acid group \n\n on a scaffold moiety said scaffold moiety participating in at least 2 amide bonds,\n\n\nb) derivatives comprising a molecule of the compound of formula I or an oligomer or multimer as defined above in part a) conjugated via an ester bond, an ether bond or a thioether bond, on the N or C terminal amino- or carboxylic acid group of the peptide moiety to: PEG,\n\n\nPEG-based compounds, fatty acids, and c) salts and solvates of a molecule of the compound of formula I or of a derivative as defined in part a) or b) above.\n\n\nIn a further embodiment of this invention, peptides generated by the general formula I and carrying at least one methyl group on an amide nitrogen (N-methyl- aminoacids) are disclosed. Such derivatives, reportedly have an increased capacity to pass cell membranes and also the BBB (Blood Brain Barrier) . See reference [Malakoutikhah M, Teixidό M, Giralt E, \"Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries\". J Med Chem. 2008 Aug 28;51 (16) :4881-9] .\n\n\nAccording to a third aspect of the invention, there is provided a pharmaceutical composition comprising a compound according to the first and the second aspect \n\n of the invention and a pharmaceutically acceptable carrier.\n\n\nAccording to the first and the second aspect of the invention, there is provided a method of treating cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases, comprising administering a compound according to the first and the second aspect of the invention or, according to the third aspect of the invention, a pharmaceutical composition comprising a compound according to the first and the second aspect of the invention to a subject in need thereof. According to a fourth aspect of the invention, there is provided a compound according to the first and second aspect of the invention or a composition according to the third aspect of the invention for use as a medicament .\n\n\nAccording to a fifth aspect of the invention, there is provided use of a compound according to the first and second aspects of the invention or a pharmaceutical composition according to the third aspect of the invention , for the manufacture of a medicament for the treatment of cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases.\n\n\nDetailed description of the invention\n\n\nThe strategy underlining the present invention arises from an understanding that modulating (blocking, reducing or increasing) the activity of the proteases\n\n\nAARE and elastase is a way to control a number of \n\ndiseases including cognitive enhancement, cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases. In particular, recent evidences have pointed out that blocking the activity of AARE can enhance the cognitive abilities of individuals with neurodegerative or neurovegetative disorders [Olmos C, Sandoval R, Rozas C, Navarro S, Wyneken U, Zeise M, Morales B, Pancetti F. \"Effect of short-term exposure to dichlorvos on synaptic plasticity of rat hippocampal slices: involvement of acylpeptide hydrolase and alpha (7) nicotinic receptors\". Toxicol Appl Pharmacol. 2009 JuI 1;238 (1) : 37-46] , whereas, enhancing its activity would be a way to reduce symptoms associated with cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases. Also blocking or reducing the activity of elastase is a widely accepted approach for controlling inflammation in lung diseases such as emphysema.\n\n\nTo this end, the inventors have identified a protein derived from Sulfolobulus solfataricus and several peptides thereof isolated from the Reactive Center Loop (RCL) [Palmieri G, Catara G, Saviano M, Langella E, Gogliettino M, Rossi M.J \"First Archaeal PEPB-Serine Protease Inhibitor from Sulfolobus solfataricus with Noncanonical Amino Acid Sequence in the Reactive-Site Loop\", Proteome Res. 2009 Jan; 8 (1) : 327-34 ], possessing the ability to modulate the activity of such proteases. Peptides with inhibitory activity of AARE and of elastase have been \n\n identified by biochemical assays and have inhibitory activity in the range of the micromolar concentration.\n\n\nAccording to the convention, all peptides presented herein are described from the N terminus to the C terminus. According to certain preferred embodiments, the compounds are essentially short peptides having from 4 up to 16 aminoacids with optional blocking groups Yl and Y2 at one or more of the termini.\n\n\nDerivatives\n\n\nPreferably, derivatives of the compound of the first and second aspect of the invention are functional derivatives. The term \"functional derivative\" is used herein to denote a chemical derivative of the protein or of the compound of formula I having the same physiological function as the corresponding unmodified counterpart or, alternatively, having the same in vitro function in a functional assay (for example, in one of the assays described in one of the examples disclosed herein) .\n\n\nPolyethylene glycol (PEG)\n\n\nThe invention encompasses PEGylated derivates. For ease in handling and manufacturing, the preferred molecular weight of a polyethylene glycol for derivatisation of a compound of the invention is from about 1 kDa to about 100 kDa, the term \"about\" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight. Polymers of other molecular weights may be used, depending on the desired therapeutic profile, for \n\nexample the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog. For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa . Preferably, derivatives of the protein or of the peptides in formula I, retain at least 50% of its capacity to modulate the activity of AARE and elastase, compared to the underivatized counterparts, as assessed in an in vitro inhibition assay. According to certain preferred embodiments, the oligopeptide core moiety of the compound, identified as Xl trough X16 in Formula I, has an amino acid sequence selected from the group consisting of:\n\n\n(L-IIe) - (L-Leu) - (L-Leu) - (L-GIu) , (L-IIe) - (L-Leu) - (L-AIa) - (L-GIu) ,\n\n\n(D-IIe) - (D-Leu) - (D-Leu) - (D-GIu) , (D-IIe) - (D-Leu) - (D-AIa) - (D-GIu) ,\n\n\n(D-IIe) - (L-Leu) - (L-Leu) - (L-GIu) , (L-IIe) - (D-Leu) - (L- Leu) - (L-GIu) , \n\n (L-IIe) - (L-Leu) - (D- Leu) - (L-GIu) , (L-IIe) - (L-Leu) - (L- Leu) - (D-GIu) ,\n\n\n(D-IIe) - (L-Leu) - (L-AIa) - (L-GIu) , (L-IIe) - (D-Leu) - (L-AIa) - (L-GIu) ,\n\n\n(L-IIe) - (L-Leu) - (D-AIa) - (L-GIu) ,\n\n\n(L-IIe) - (L-Leu) - (L-AIa) - (D-GIu) ,\n\n\n(D-IIe) - (D-Leu) - (L-Leu) - (L-GIu) , (L-IIe)- (D-LeU)- (D- Leu) - (L-GIu) ,\n\n\n(L-IIe) - (L-Leu) - (D- Leu) - (D-GIu) ,\n\n\n(D-IIe) - (L-Leu) - (L- Leu) - (D-GIu) , (L-IIe) - (D-Leu) - (D-Leu) - (L-GIu) ,\n\n\n(D-IIe) - (L-Leu) - (D-Leu) - (L-GIu) , (L-IIe) - (D-Leu) - (L-Leu) - (D-GIu) ,\n\n\n(D-IIe) - (D-Leu) - (L-AIa) - (L-GIu) ,\n\n\n(L-IIe) - (D-Leu) - (D-AIa) - (L-GIu) ,\n\n\n(L-IIe) - (L-Leu) - (D-AIa) - (D-GIu) , (D-IIe) - (L-Leu) - (L-AIa) - (D-GIu) ,\n\n\n(L-IIe) - (D-Leu) - (D-AIa) - (L-GIu) , (D-IIe) - (L-Leu) - (D-AIa) - (L-GIu) , (L-IIe) - (D-Leu) - (L-AIa) - (D-GIu) ,\n\n\n(L-GIu) - (L-Leu) - (L-Leu) - (L-IIe) , (L-GIu) - (L-AIa) - (L-Leu) - (L-IIe) ,\n\n\n(D-GIu) - (L-Leu) - (L-Leu) - (L-IIe) , (L-GIu) - (D-Leu) - (L-Leu) - (L-IIe) , (L-GIu) - (L-Leu) - (D-Leu) - (L-IIe) , (L-GIu) - (L-Leu) - (L-Leu) - (D-IIe) , \n\n (D-GIu) - (L-AIa) - (L-Leu) - (L-IIe) , (L-GIu) - (D-AIa) - (L-Leu) - (L-IIe) , (L-GIu) - (L-AIa) - (D-Leu) - (L-IIe) , (L-GIu) - (L-AIa) - (L-Leu) - (D-IIe) ,\n\n\n(D-GIu) - (D-Leu) - (L-Leu) - (L-IIe) , (L-GIu) - (D-Leu) - (D-Leu) - (L-IIe) , (L-GIu) - (L-Leu) - (D-Leu) - (D-IIe) , (D-GIu) - (L-Leu) - (L-Leu) - (D-IIe) , (L-GIu) - (D-Leu) - (D-Leu) - (L-IIe) , (D-GIu) - (L-Leu) - (D-Leu) - (L-IIe) , (L-GIu) - (D-Leu) - (L-Leu) - (D-IIe) ,\n\n\n(D-GIu) - (D-AIa) - (L-Leu) - (L-IIe) , (L-GIu) - (D-AIa) - (D-Leu) - (L-IIe) ,\n\n\n(L-GIu) - (L-AIa) - (D-Leu) - (D-IIe) ,\n\n\n(D-GIu) - (L-AIa) - (L-Leu) - (D-IIe) ,\n\n\n(L-GIu) - (D-AIa) - (D-Leu) - (L-IIe) ,\n\n\n(D-GIu) - (L-AIa) - (D-Leu) - (L-IIe) , (L-GIu) - (D-AIa) - (L-Leu) - (D-IIe) ,\n\n\nOligomers and multimers\n\n\nThe second aspect of the invention encompasses, oligomers or multimers of molecules of the compound of formula I, said oligomers and multimers comprising 2 or more molecules of the compound of formula I each linked to a common scaffold moiety via an amide bond formed between an amine or carboxylic acid group present in molecules of the compound of formula I and an opposite amino or carboxylic acid group on a scaffold moiety said scaffold moiety participating in at least 2 amide \n\nbonds as it is reported in Tarn, J. P. (1988) Proc Natl Acad Sci U S A 85(15), 5409-5413.\n\n\nAccording to certain embodiments the common scaffold may be the amino acid lysine. Lysine is a tri- functional amino acid, having in addition to the functional groups which define it as an amino acid, a amino group on its side claim. This tri-functional nature allows it to form up to three amide bonds with peptides or similar molecules. Other tri-functional standard amino acids which may be used as a common scaffold include α, β-diaminopropionic acid (Dap), α,δ- diaminobutirric acid (Dab),\n\n\nOrnitine. Other tri-functional non-standard amino acids may also be used in accordance with the invention. The common scaffold may also comprise branched peptides which incorporate tri-functional amino acids within their sequence and have at least three functionally active terminal groups able to form amide bonds.\n\n\nFatty acids\n\n\nFatty acid derivatives of a compound of the invention comprising a compound of formula I, linked to a fatty acid via a disulfide linkage may be used for delivery of a compound of the invention to cells and tissues. Lipidisation markedly increases the absorption of the compounds relative to the rate of absorption of the corresponding unlipidised compounds, as well as prolonging blood and tissue retention of the compounds. Moreover, the disulfide linkage in lipidised derivative is relatively labile in the cells and thus facilitates intracellular release of the molecule from the fatty acid moieties. Suitable lipid-containing moieties are \n\nhydrophobic substituents with 4 to 26 carbon atoms, preferably 5 to 19 carbon atoms. Suitable lipid groups include, but are not limited to, the following: palmityl (C15H31,), oleyl (C15H29) , stearyl (C17H35) , cholate; linolate, and deoxycholate.\n\n\nSalts and solvates\n\n\nSalts and solvates of compounds of the invention that are suitable for use in a medicament are those wherein a counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non- pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of the compounds of formula (I) and their pharmaceutically acceptable salts or solvates. Suitable salts according to the invention include those formed with organic or inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed with hydrochloric, hydrobromic, sulphuric, nitric, citric, tartaric, acetic, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, perchloric, fumaric, maleic, glycollic, lactic, salicylic, oxaloacetic, methanesulfonic, ethanesulfonic, p- toluenesulfonic, formic, benzoic, malonic, naphthalene- 2-sulfonic, benzenesulfonic, and isethionic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutical acceptable salts. Pharmaceutically acceptable salts with bases include ammonium salts, alkali metal salts, for example \n\npotassium and sodium salts, alkaline earth metal salts, for example calcium and magnesium salts, and salts with organic bases, for example dicyclohexylamine and N- methyl-D-glucosamine . Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. Such complexes are known as \"solvates\". For example, a complex with water is known as a \"hydrate\". The present invention provides solvates of compounds of the invention.\n\n\nExamples of preferred molecules of formula I include: L-normal peptides\n\n\n1 : H- (L) Tyr- (L) Ala- (L) He- (L) Asp- (L) -Thr- (L) -He-\n\n\n(L) Leu- (L) Leu- (L) GIu) - (L) He- (L) Lys- (L) Asn- (L) He- (L) Asn- (L)AIa- (L)Asp-NH2\n\n\n2: H- (L) Tyr- (L)Ala- (L) lie- (L)Asp- (L) -Thr- (L)-IIe-\n\n\n(L) Leu- (L) Ala- (L) GIu) - (L) He- (L) Lys- (L) Asn- (L) He- (L) Asn- (L)AIa- (L) Asp-NH2\n\n\n3 : H- (L) Thr- (L) -He- (L) Leu- (L) Leu- (L) GIu) - (L) He- (L) Lys- (L) Asn- (L) He- (L)Asn- (L)Ala- (L)Asp-NH2\n\n\n4 : H- (L) -Thr- (L) -He- (L) Leu- (L) Ala- (L) GIu) - (L) He-\n\n\n(L) Lys- (L) Asn- (L) He- (L) Asn- (L)AIa- (L) Asp-NH2\n\n\nD-normal peptides \n\n 5 : H-(D) Tyr- (D) Ala- (D) He- (D) Asp- (D) -Thr- (D) -He-\n\n\n(D) Leu- (D) Leu- (D) GIu) - (D) He- (D) Lys- (D) Asn- (D) He- (D) Asn- (D)AIa- (D) Asp-NH2\n\n\n6: H- (D) Tyr- (D)AIa- (D) lie- (D)Asp- (D) -Thr- (D)-IIe-\n\n\n(D) Leu- (D) Ala- (D) GIu) - (D) He- (D) Lys- (D) Asn- (L) He- (D) Asn- (D)AIa- (D) Asp-NH2\n\n\n7 : H- (D) Thr- (D) -He- (D) Leu- (D) Leu- (D) GIu) - (D) He- (D) Lys- (D) Asn- (D) He- (D) Asn- (D)AIa- (D)Asp-NH2\n\n\n8 : H- (D) -Thr- (D) -He- (D) Leu- (D) Ala- (D) GIu) - (D) He-\n\n\n(D) Lys- (D) Asn- (D) He- (D) Asn- (D)AIa- (D) Asp-NH2\n\n\nD-retro peptides\n\n\n9 : H- (D) Asp- (D) Ala- (D) Asn- (D) He- (D) Asn- (D) Lys-\n\n\n(D) He- (D) GIu- (D) Leu- (D) Leu- (D) He- (D) Thr- (D) Asp- (D)IIe- (D)AIa- (D) Tyr-NH2\n\n\n10: H-(D)ASp-(D)AIa-(D)ASn-(D)He-(D)ASn-(D)LyS-\n\n\n(D) He- (D) GIu- (D)AIa- (D) Leu- (D) He- (D) Thr- (D) Asp- (D) He- (D)AIa- (D) Tyr-NH2\n\n\n11 : H- (D) Asp- (D)AIa- (D) Asn- (D) He- (D) Asn- (D) Lys- (D) He- (D) GIu- (D) Leu- (D) Leu- (D) He- (D) Thr -NH2\n\n\n12: H-(D)ASp-(D)AIa-(D)ASn-(D)He-(D)ASn- (D) Lys-\n\n\n(D) He- (D) GIu- (D) Ala- (D) Leu- (D) He- (D) Thr -NH2\n\n\nPharmaceutical compositions\n\n\nAccording to a third aspect of the invention, there is provided a pharmaceutical composition comprising a \n\ncompound according to the first and second aspect of the invention and a pharmaceutically acceptable carrier .\n\n\nWhile it is possible for the active ingredient to be administered alone, it is preferable for it to be present in a pharmaceutical formulation or composition. Accordingly, the invention provides a pharmaceutical formulation comprising a compound of formula (I) or derivatives thereof, or a salt or solvate thereof, as defined above and a pharmaceutically acceptable carrier. Pharmaceutical compositions of the invention may take the form of a pharmaceutical formulation as described below. The pharmaceutical formulations according to the invention include those suitable for oral, parenteral\n\n\n(including subcutaneous, intradermal, intramuscular, intravenous, and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered does pressurized aerosols, nebulizers or insufflators), rectal and topical (including dermal, transdermal, transmucosal, buccal, sublingual, and intraocular) administration, although the most suitable route may depend upon, for example, the condition and disorder of the recipient.\n\n\nThe formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately \n\n bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil- in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or 'paste. Various pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988. A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. The present compounds can, for \n\n example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The present compounds can also be administered liposomally. Preferably, compositions according to the invention are suitable for subcutaneous administration, for example by injection.\n\n\nExemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The compounds of formula I or variant, derivative, salt or solvate thereof can also be delivered through the oral cavity by sublingual and/or buccal administration. Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those formulating the present compound (s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins . Also \n\nincluded in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG) . Such formulations can also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC) , hydroxy propyl methyl cellulose (HPMC) , sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez) , and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934) . Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.\n\n\nFormulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi- dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for- injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Exemplary compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1, 3-butanediol, water, Ringer' s solution, an isotonic sodium chloride \n\n solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor. An aqueous carrier may be, for example, an isotonic buffer solution at a pH of from about 3.0 to about 8.0, preferably at a pH of from about 3.5 to about 7.4, for example from 3.5 to 6.0, for example from 3.5 to about 5.0. Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphoric acid, and sodium acetate/acetic acid buffers. The composition preferably does not include oxidizing agents and other compounds that are known to be deleterious to the compound of formula I and related molecules. Excipients that can be included are, for instance, other proteins, such as human serum albumin or plasma preparations. If desired, the pharmaceutical composition may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate .\n\n\nExemplary compositions for nasal aerosol or inhalation administration include solutions in saline, which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art. Conveniently in compositions for nasal aerosol or inhalation administration the compound of the invention is delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer, with the use of a suitable propellant, e.g., \n\n dichlorodifluoro-methane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be formulated to contain a powder mix of the compound and a suitable powder base, for example lactose or starch. In one specific, non-limiting example, a compound of the invention is administered as an aerosol from a metered dose valve, through an aerosol adapter also known as an actuator. Optionally, a stabilizer is also included, and/or porous particles for deep lung delivery are included (e.g., see U.S. Patent No. 6,447,743) .\n\n\nFormulations for rectal administration may be presented as a retention enema or a suppository with the usual carriers such as cocoa butter, synthetic glyceride esters or polyethylene glycol. Such carriers are typically solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.\n\n\nFormulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerine or sucrose and acacia. Exemplary compositions for topical administration include a topical\n^\n carrier such as Plastibase (mineral oil gelled with polyethylene) . \n\n Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient. It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents. The compounds of the invention are also suitably administered as sustained-release systems. Suitable examples of sustained-release systems of the invention include suitable polymeric materials, for example semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules; suitable hydrophobic materials, for example as an emulsion in an acceptable oil; or ion exchange resins; and sparingly soluble derivatives of the compound of the invention, for example, a sparingly soluble salt. Sustained-release systems may be administered orally; rectally; parenterally; intracistemally; intravaginally; intraperitoneally; topically, for example as a powder, ointment, gel, drop or transdermal patch; bucally; or as an oral or nasal spray. Preparations for administration can be suitably formulated to give controlled release of compounds of the invention. For example, the pharmaceutical compositions may be in the form of particles comprising one or more of biodegradable polymers, polysaccharide jellifying and/or bioadhesive polymers, amphiphilic polymers, agents capable of modifying the interface properties of the particles of the compound of formula \n\n (I) . These compositions exhibit certain biocompatibility features which allow a controlled release of the active substance. See U.S. Patent No. 5,700,486. A compound of the invention may be delivered by way of a pump (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201, 1987; Buchwald et al . , Surgery 88:507, 1980; Saudek et al., N. Engl. J. Med. 321:574, 1989) or by a continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533, 1990). In another aspect of the disclosure, compounds of the invention are delivered by way of an implanted pump, described, for example, in U.S. Patent No. 6,436,091; U.S. Patent No. 5,939,380; U.S. Patent No. 5,993,414.\n\n\nImplantable drug infusion devices are used to provide patients with a constant and long term dosage or infusion of a drug or any other therapeutic agent.\n\n\nEssentially such device may be categorized as either active or passive. A compound of the present invention may be formulated as a depot preparation. Such a long acting depot formulation can be administered by implantation, for example subcutaneously or intramuscularly; or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials, for example as an emulsion in an acceptable oil; or ion exchange resins; or as a sparingly soluble derivatives, for example, as a sparingly soluble salt. \n\n A therapeutically effective amount of a compound of the invention may be administered as a single pulse dose, as a bolus dose, or as pulse doses administered over time. Thus, in pulse doses, a bolus administration of a compound of the invention is provided, followed by a time period wherein no a compound of the invention is administered to the subject, followed by a second bolus administration. In specific, non-limiting examples, pulse doses of a compound of the invention are administered during the course of a day, during the course of a week, or during the course of a month. In one embodiment, a therapeutically effective amount of a compound of the invention is administered with a therapeutically effective amount of another agent, for example a further anti-neoplastic chemotherapeutic agent (for example, thalidomide, dexamethasone, bortezomib, and lenalidomide) or an agent to treat anaemia (for example erythropoietin) , or an agent to prevent bone fractures (for example a bisphosphonate such as pamidronate or zoledronic acid) .\n\n\nAccording to the fourth aspect of the invention, there is provided a method of treating cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases, comprising administering a therapeutically effective amount of a compound according to the first and second aspect of the invention or a pharmaceutical composition according to the third aspect of the invention to a subject in need thereof.\n\n\nAccording to a fifth aspect of the invention, there is provided a compound according to the first and second \n\n aspect of the invention or a composition according to the third aspect of the invention for use as a medicament .\n\n\nAccording to a sixth aspect of the invention, there is provided use of a compound according to the first and second aspect of the invention or a pharmaceutical composition according to the third aspect of the invention for the manufacture of a medicament for the treatment of cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases. Said diseases and subject being defined in certain preferred embodiments as described above in reference to the fourth aspect of the invention.\n\n\nExamples\n\n\nThe following non-limiting examples illustrate the invention.\n\n\nExample 1 - Synthesis of Compounds 1 to 4.\n\n\nBy way of example, synthesis of Compounds 1 to 4 is reported. Compounds 1 to 4 comprises L-normal peptides with a free N-terminus and a protected C-terminus by means of an amide bond.\n\n\nPeptide 1 to 4 were prepared following the Fmoc/tBu solid phase method (Fields G. B. and Noble R. L. 1990 Int J Pept Protein Res; 35: 161-214; Bodansky, M. and Bodansky A. 1995) . The practice of peptide synthesis, 2nd edn., Springer Verlag, Berlin) using a SYRO multiple peptide synthesizer (Multisynthech, Germany) . The synthesis scale was 50 μmoles. 100 mg of RINK amide \n\n polystyrene resin (Fmoc-RINK-AM-resin, GL Biochem,\n\n\nShangai, China), having a substitution of 0.50 iranoles/g was used for all the synthesis. The resin was placed in\n\n\n5 πiL polypropylene vessels endowed with a 20 μm teflon septum. At the beginning the resin was swollen with 3.0 mL of a 50:50 dichloromethane (DCM) : dimethyl formamide\n\n\n(DMF) mixture (both from LabScan, Stillorgan, Ireland) for 20 minutes. The 4 reaction vessels were placed in the synthesizer and a protocol with in situ preactivation steps by using a 0.5 M solution of Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP, Novabiochem) in DCM, and pure di-iso-propyl-ethylamine (DIEA, Sigma-Aldrich) was adopted to attach the first aminoacids and to elongate the chain. The aminoacids, in their Fmoc-protected form were also employed at 0.5 M in DMF (Fields G. B. and Noble R. L. 1990 Int J Pept Protein Res; 35: 161-214) . The acylation time was 30 minutes, at room temperature (RT) . The Fmoc deprotection was achieved by a solution of DMF-Piperidine 6:4 mixture (Piperidine, Pip, Sigma- Aldrich, Milan, Italy) for 20 minutes at RT. The reactante were removed under vacuum and the resins washed 3 times with 1.5 mL of DMF after each cycle of coupling and deprotection. After synthesis completion, the resins were extensively washed with DMF, DCM,\n\n\nMethyl Alcohol (MeOH, LabScan) , and Ethyl Alcohol\n\n\n(Et20, LabScan) , and dried under vacuum. To cleave the peptides from the resins, they wer treated with 3.0 mL/each with a mixture composed of TFA-H2O-TIS 90:5:5 (v/v/v) mixture (TFA, Trifluoroacetic acid, Sigma- Aldrich; TIS, tri-iso-propylsilane, Sigma-Aldrich) for 3 hours at RT. Resins were removed by filtration, then \n\n 20 mL of cold Et2O was added to the trifluoroacetic solution, leading to the formation of a white precipitate. After removal of the solvents by centrifugation, the precipitates were washed with 10.0 mL of cold Et2O, dissolved in 5.0 mL of H2O/CH3CN 50:50\n\n\n(v/v) and lyophilized. Peptides were characterized by\n\n\nLC-MS using a narrow bore 30x2 mm ID ONYX C18 column\n\n\n(Phenomenex, Torrance, CA, USA) , equilibrated at 600 μL/min with 5% CH3CN, 0.05% TFA. The analysis was carried out applying a gradient of CH3CN, 0.05% TFA from 5% to 60% over 3 minutes. The peptide was purified by semi-preparative RP-HPLC using a 10x1 cm C18 ONYX column (Phenomenex, Torrance, CA, USA), equilibrated at 20 mL/min, injecting 10 mg in each run. A gradient from 5% to 65% over 8 minutes was applied to elute the peptides. Pure fractions were pooled and characterized by LC-MS. The determined MW of Peptides 1 to 4 are reported in the following Table I . Products more than 95% pure (by HPLC) were obtained. A typical yield of about 40% was achieved after purification of all the crude products.\n\n\nTable I\n\n\n \n\nExample 2 Identification and isolation of the inhibitor Sso0767.\n\n\nA computational analysis of the S. solfataricus genome revealed the presence of a single gene (sso0767) encoding a putative protein inhibitor belonging to the PEBP family 151. This protein is one of 1323 cytosolic proteins identified from the organism and expressed in the middle exponential phase of growth (Chong, et al, 2005), although no functional role has yet been assigned. The S. solfataricus inhibitor was isolated following its ability to inhibit the activity of bovine alpha - chymotrypsin.\n\n\nExample 3 Isolation, cloning and recombinant expression in E. coll of the gene sso0767.\n\n\nGene sso0767 (reported hereinafter as SEQUENCE 1) was obtained by PCR amplification directly from total genomic DNA of S. solfataricus P2, using the following oligonucleotides :\n\n\nPl S'-CCATGGGCTTGAATAGTGAAAGTATATA-S 'and P2 5'-GAGCTCTTTTCTCTTATATTTACCCATTACGAAT-S '. The Ncol and Xhol restriction sites, underlined, were introduced to allow the insertion of the gene in expression vector. The experiments by PCR amplification (Hybaid) were performed under standard conditions and PCR product was cloned into the vector pMOS (Promega) and subcloned into expression vector pET-28 (Novagen) . Cells of E. coli BL21 - CodonPlus RIL (Stratagene) containing the plasmid pET28-0767 were grown at 37 ° C in the middle LB (50 ml) containing kanamycin (0.05 mg \n\n mL-1) until reaching an OD600 of 0.6. Protein expression was induced by the addition of 1 mM IPTG followed by 4 h growth.\n\n\nSequence of the gene sso0767: (Sequence 1)\n\n\nNucleot±d±c sequence\n\n\nsso0767 ttgaatagtg aaagtatata ttcgatgaga gtagtatctt cagcctttaa gaatgaggat tttataccta ttaaatatac ttgtgatgga caagatctgt ctccggagtt agagtgggat cttgttacta acgctaaaag ttatgcgata atcgtagaag atccagatgc gcctggagga actttcatac attgggtaat atacaacata actaccaata gattgccaga aggagtgcca agactgtaca aatcacaata tggtgtacaa ggtgtaaacg attttgggaa tatagggtat aacggtccgt gtcctcctaa gacacatcca cctcatagat attattttta tgtttatgca attgatacaa tactacttga aattaaaaat attaatgctg ataagttaaa atcactaatg gagggacatg ggatagagag aggattcgta atgggtaaat ataagagaaa ataa\n\n\nAminoacidic sequence :\n\n\nMNSESIYSMRVVSSAFKNEDFIPIKYTCDGQDLSPELEWDLVTNAKSYAIIVE\n\n\nDPDAPGGTFIHWVIYNITTNRLPEGVPRLYKSQYGVQGVNDFGNIGYNGPCPP\n\n\nKTHPPHRYYFYVYAIDTILLEIKNINADKLKSLMEGHGIERGFVMGKYKRK\n\n\nExample 4 - Purification and characterization of the recombinant S. solfatarlcus inhibitor Sso0767.\n\n\nThe E. coli recombinant cells were suspended in 0.05 M sodium phosphate buffer and broken with a French press. The supernatant was heated for 30 min at 70 ° C and after centrifugation the inhibitor, 'HIS-tagged\n1\n to the C-terminus, was purified using a HIS-Select Spin column \n\n (Sigma) . The further purification of recombinant inhibitor was obtained by molecular exclusion chromatography on Superdex G75 column. The homogeneity of the protein has been demonstrated by\n\"\n SDS-PAGE analysis, Edman degradation and molecular exclusion chromatography. The inhibitor was purified as a monomer with an isoelectric point of 6.7 and a molecular mass of 19.0 kDa as determined by SDS-PAGE analysis, molecular exclusion chromatography and electrospray mass spectrometry. The sequence of the isolated gene and the deduced amino acid sequence (157 amino acids) was already shown as SEQUENCE 1. Analysis of sequence similarity by utilizing different database searching revealed that the Sso0767 is a member of the family 151 of protease inhibitors, showing all the structural features typical of PEBP proteins (phosphoethanolamine- binding protein) , which are the members this inhibitor cluster (Hengst U, et al 2001; Mima et al 2003) . The purified inhibitor shows high resistance to the common protein denaturants and is resistant to several digestive proteases. Furthermore, the inhibitor is highly thermostable, in fact no reduction in inhibitory activity was observed even after 4 days of protein incubation at 90 \n0\nC. Figure 1 shows the alignment of the amino acid sequence of the inhibitor with that of a homologous protein, the YBCL from E. coli (IFUX), a member of \"151\" family. Regions highlighted in black are the conserved regions among SsCEI and the analyzed protein, while those in gray correspond to segments with accepted amino acid substitution. Gaps are denoted by dashes. \n\n The 3D structure of the E. coli protein (Serre et al 2001) was used as template to build a very reliable 3D model of the S. solfataricus Sso0767. Based on this model it was assumed that the inhibitor, as evidenced in YBCL, contains a disulfide bridge linking the cysteine in position 29 and 114.\n\n\nExample 5 - Substrate specificity, kinetics, and analysis of Ssol273 reactive site loop.\n\n\nTo identify the biological function of the purified inhibitor Sso0767, the ability to inhibit a number of proteases was tested. The set of the proteases examined includes: the alpha-chymotrypsin, trypsin, elastase, carboxypeptidase Y, subtilisin, thrombin and two thermophilic proteases, the kumamolisin-ac and pernisine. Beside inhibition activity toward α- chymotrypsin which is the best target protease among those tested, results showed a clear activity versus elastase, while trypsin, carboxypeptidase Y, subtilisin or thrombin were not affected by Ssol273. The specific interaction between the inhibitor and the target proteases was also examined by incubating Ssol273 in a reaction mixture containing all the proteases investigated. In these conditions, the catalytic performance of the inhibitor was identical to that observed by assaying each protease alone. Figure 2 shows the binding of Sso0767 to alpha- chymotrypsin . The inhibition of Ssol273 versus α-chymotrypsin followed a hyperbolic pattern with increasing concentrations of the inhibitor and the IC50 value (50% \n\n inhibitory concentration) was 0.10 μM (Table II) . Since the secondary plot (the slope of inhibition graph versus Ssol273 concentration) was linear, it was suggested that the application of Michaelis-Menten inhibition kinetics was appropriate in this study. The inhibition constant Ki, determined by the double reciprocal plot was 0.08 μM, revealing a higher affinity of Ssol273 for α-chymotrypsin with respect to the cognate PEBP serine protease inhibitors. Figure 3 shoes the inhibition kinetics analysis, α- chymotrypsin (0.12 μM) was incubated, without (•) or with Sso0767 at 0.1 μM and 0.2 μM concentrations and assayed at increasing substrate concentrations. The reciprocals of the rate of the substrate hydrolysis for each inhibitor concentration were plotted against the reciprocals of the substrate concentrations. Ki was determined from the formula as per the competitive type of inhibition. Figure 3 shoes the inhibition kinetics analysis, α- chymotrypsin (0.12 μM) was incubated, without (•) or with Sso0767 at 0.1 μM and 0.2 μM concentrations and assayed at increasing substrate concentrations. The reciprocals of the rate of the substrate hydrolysis for each inhibitor concentration were plotted against the reciprocals of the substrate concentrations. Ki was determined from the formula as per the competitive type of inhibition.\n\n\nThe Lineweaver- Burk reciprocal plot showed that Ssol273 was a competitive inhibitor for α-chymotrypsin. The Ssol273 IC50 value versus elastase was 0.15 μM (Table II), while the inhibition constant Ki determined \n\n using the double reciprocal plot was 0.10 μM (Table II) . On the basis of these results, it can be claimed that Ssol273 substrate specificity reflects that of the 151 family typically inhibiting a-chymotrypsin, but not trypsin. In Table II are reported Ki and IC50 values that are the average of 3-5 separate determinations.\n\n\nA careful study of the 3D model Of\n1\n Sso0767, taking into account the general structural implications needed for the interaction of the inhibitor with alpha- chymotrypsin and elastase, allowed identifying the aminoacidic region responsible for interacting with the target proteases. This sequence includes the structural motif T123-N130, in which the Pl - Pl\n1\n site occurs between the residues L126 and E127. The T123-N130 sequence is located in an external loop posessing an extended conformation, as observed in other protein inhibitors of proteases [Palmieri G, Catara G, Saviano M, Langella E, Gogliettino M, Rossi M.J \"First Archaeal PEPB-Serine Protease Inhibitor from Sulfolobus solfataricus with Noncanonical Amino Acid Sequence in the Reactive-Site Loop\", Proteome Res. 2009 Jan; 8 (I)- : 327-34] . All these suggestions were confirmed by the design of several specific point mutations of the sequence inhibitor, including the replacement of the residue L126 (Pl) with alanine or serine. Purified mutant inhibitors showed no ability to inhibit the target enzymes, although an analysis of secondary structure did not reveal any detectable conformational changes. Table III shows the sequence of the reactive site loop of the S. solfataricus inhibitor Sso0767 in comparison to that of several serine protease inhibitors. The results of these studies revealed that \n\nthe inhibitor Sso0767contains a new sequence in the protease binding site, that cannot be classified among the canonical consensus sequences of all serine protease inhibitors so far characterized. This unique motif may provide new insights into the inhibitor/protease binding mode.\n\n\nTable II - kinetic parameters of Ssol273 versus the target proteases bovine a- chymotrypsin and porcine Elastase\n\n\n\n\n\n\n\n\nTable III - The four conserved motifs found within the reactive site loops (P3-P3') of several serine protease inhibitors are compared with that of SsCEI*\n\n\nMotif P3 P2 Pl P'l P'2 P'3\n\n\n1: Cys(P3)-\n\n\nCys Pro Aaa Aaa Aaa Aaa Pro(P2)\n\n\n2: Thr(P2) Aaa Thr Aaa Aaa Aaa Aaa\n\n\n3: Cys(P2) Aaa Cys Aaa Aaa Aaa Aa\n\n\n4: Pro(P3) Pro Aaa Aaa Aaa Aaa Aaa\n\n\nSso0767 He Leu Leu GIu He Lys \n\n *The four conserved motifs (1-4) are indicated with the canonical residue/s found in the reactive site loop as previously reported (Apostoluk, et al, 1998) . Each of the conserved sequence motif is representative of hundreds of serine protease inhibitors belonging to different families (Apostoluk, et al, 1998) . Aaa denotes any amino acid..\n\n\nExample 6 - Inhibition of human acylamino-acid- releasing enzyme (named AARE) by the S. solfatarlσus inhibitor Sso0767.\n\n\nThe binding of Sso0767 to human acylamino-acid- releasing enzyme is shown in fig. 4 where the hyperbolic curve indicates the best fit for the percentage inhibition data obtained, and the IC50 value was calculated from the graph.\n\n\nInhibitor effectiveness was determined by measuring enzyme activity both in the presence and absence of inhibitor. The activity of human acylamino-acid- releasing enzyme (AARE) (Takara) was measured by using the chromogenic substrate N-acetyl-Ala-pNA (Bachem) (40 μM in DMSO 100%) . Stock solutions of lyophilized enzyme (0.5 -uM) were- prepared in distilled water and stored at -20 \n0\nC. Hydrolysis of the substrate was performed at 37 \n0\nC for 15 min in 25 mM Tris-HCl buffer, pH 7.5. The reaction was stopped chilling the mixture in ice. Substrate hydrolysis was followed by recording the absorbance at 410 nm against a blank on a Hewlett- Packard spectrophotometer. The rate of increase in absorbance is a measure of the enzymatic activity and \n\n the decrease in this rate relative to a suitable control is used to ascertain inhibition. One unit of AARE activity (U) is defined as the amount of enzyme required to hydrolyze 1 nmol of substrate per min under the conditions of the assay using £\n410\n = 8800 M\n\"1\n cm\n\"1\n. The IC50 value of the S. solfataricus inhibitor was determined by incubating increasing concentrations of the inhibitor with the enzyme AARE for 30 min at 37 \n0\nC in 25 mM Tris-HCl buffer, pH 7.5. Then, the substrate was added to the incubation mixture and the hydrolysis was performed for 30 min at 37 °C. The data were fitted with the GraphPad Prism software. This analysis allowed the determination of IC50 values, which represent the concentrations at which the inhibition reached 50%. The inhibition followed a hyperbolic pattern with increasing concentrations of the inhibitor and IC\n5\n0 value at 37\n0\nC was 20 nM.\n\n\nExample 7. Inhibition of human acylamino-acid- releasing enzyme (AARE) by inhibitor compounds 1-4\n\n\nInhibition activity of the Compound 3 versus AARE (0.2 μg is shown in fig.5 wherein the protease was incubated with different compound concentrations and the residual protease activity was measured.\n\n\nInhibitor effectiveness of the present invention was determined by measuring enzyme activity both in the presence and absence of inhibitor compounds using in vitro assay. \n\nVelocities were fit to the equation for competitive inhibition for individual reactions of inhibitors with the enzyme using.\n\n\nThe Compounds 1 to 4 reported in the Example 1 were tested for ability to inhibit the activity of human acylamino-acid-releasing enzyme. Stock solutions (1 mM) of each lyophilized compounds were prepared in DMSO 100% and stored at 4 \n0\nC. Inhibition effectiveness of each compound was determined by measuring enzyme activity both in the presence and absence of compounds.\n\n\nThe activity of human acylamino-acid-releasing enzyme\n\n\n(AARE) was measured by using the chromogenic substrate\n\n\nN-acetyl-Ala-pNA (Bachem) (40 μM in DMSO 100%) as described above. The IC50 values of the S. solfataricus compouds were determined by incubating increasing concentrations of the each compound with the enzyme AARE for 20 min at 37 \n0\nC in 25 mM Tris-HCl buffer, pH 7.5. Then, the substrate was added to the incubation mixture and the hydrolysis was performed for 20 min at 37 \n0\nC (Figure 5) . The data were fitted with the GraphPad Prism software. This analysis allowed the determination of IC50 values, which represent the concentrations at which the inhibition reached 50%. Using this methodology Compound 3 and Compound 4 of the present invention were found to exhibit inhibition activity towards human AARE protease. The IC50 values (See Table IV) , obtained as average of 3-5 separate determinations, confirmed the utility of the compounds +of the present invention as effective AARE inhibitors. Table IV - IC\n50\n values relative to compounds 1-4 towards human acylamino-acid-releasing enzyme. \n\n \n\n\n\n\n\nReferences\n\n\nApostoluk, W.; Otlewski, J. (1998) Variability of the Canonical Loop Conformations in Serine Proteinases Inhibitors and Other Proteins. Proteins : Structure, Function, and Genetics, 32, 459-474.\n\n\nBruun AW, Svendsen I, Sorensen SO, Kielland-Brandt MC, Winther JR (1998) A high-affinity inhibitor of yeast carboxypeptidase Y is encoded by TFSl and shows homology to a family of lipid binding proteins. Biochemistry 37:3351-3357.\n\n\nChen Q, Wang S, Thompson SN, Halland ED, Guttmann RP (2006) Identification and characterization of PEBP as a calpain substrate. J Neurochem 99:1133-1141.\n\n\nChong PK, Wright PC (2005) Identification and characterization of the Sulfolobus solfataricus P2 proteome. J Proteome Res 4:1789-1798\n\n\nHengst U, Albrecht H, Hess D, Monard D (2001) The phosphatidyletanolamine-binding protein is the prototype of a novel family of serine protease inhibitors. J Biol Chem 276:535-540. \n\nMima J, Narita Y, Chiba H, Hayashi R (2003) The multiple site binding of carboxypeptidase Y inhibitor\n\n\n(IC) to the cognate proteinase. Implications for the biological roles of the phosphatidylethanolamine- binding protein. J Biol Chem 278:29792-29800.\n\n\nSerre L, Vallee B, Bureaud N, Schoentgen F, Zelwer C\n\n\n(1998) Crystal structure of the phosphatidylethanolamine-binding protein from bovine brain: a novel structural class of phospholipid-binding proteins. Structure 6:1255-1265.\n\n\nSerre, L.; de Jesus, K. P.; Zelwer, C; Bureaud, N.; Schoentgen, F.; Benedetti, H. (2001) Crystal structures of YBHB and YBCL from Escherichia coli, two bacterial homologues to a Raf kinase inhibitor protein. J MoI Biol., 310, 617-634\n\n\nYeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis K D, Rose DW, Mischak H, Sedivy JM, Koich W (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401: 173-177.\n\n\nRawlings N. D., Tolle P. D., Barret J. A. (2004) Evolutionary families of peptidase inhibitors. Biochem. J. 378: 705-716"
  },
  {
    "id": "WO2010048190A2",
    "text": "Antibodies that bind to il-12 and methods of purifying the same AbstractAnti-IL-12 antibodies are disclosed herein, including antigen-binding portions thereof. One or more methods for isolating and purifying anti-IL-12 antibodies from a sample matrix is presented. These isolated anti-IL-12 antibodies can be used in a clinical setting as well as in research and development. Pharmaceutical compositions comprising isolated anti-IL-12 antibodies are also described. Claims\n\n\n\n\n CLAIMSWhat is claimed is:\n\n\n\n\n1. A method for producing a host cell-protein (HCP) reduced antibody preparation from a sample mixture comprising an antibody and at least one HCP, said method comprising:\n\n\n(a) subjecting said sample matrix to a reduction in pH thus forming a primary recovery sample, wherein said reduction in pH is to between 3 and 4;\n\n\n(b) adjusting said primary recovery sample to a pH of between about 4.5 and 6 followed by applying said primary recovery sample to an ion exchange resin and collecting an ion exchange sample;\n\n\n(c) applying said ion exchange sample to a hydrophobic interactive chromatography (HIC) resin and collecting an HIC sample, wherein said HIC sample comprises said HCP-reduced antibody preparation.\n\n\n\n\n\n\n2. The method of claim 1 , wherein said reduction in pH is accomplished by admixing a suitable acid with said sample mixture, and wherein said suitable acid is selected from the group consisting of citric acid, acetic acid, caprylic acid, and the like.\n\n\n\n\n\n\n3. The method of claim 1, wherein said ion exchange resin is either an anion exchange resin or a cation exchange resin.\n\n\n\n\n\n\n4. The method of claim 3, wherein said ion exchange resin is a cation exchange resin.\n\n\n\n\n\n\n5. The method of claim 4, wherein said cation exchange resin is selected from the group consisting of carboxymethyl (CM), sulfoethyl(SE), sulfopropyl(SP), phosphate(P) and sulfonate(S).\n\n\n\n\n\n\n6. The method of claim 5, wherein said cation exchange resin is carboxymethyl.  \n\n\n\n\n\n\n7. The method of claim 3, wherein said ion exchange resin is an anion exchange resin.\n\n\n\n\n\n\n8. The method of claim 7, wherein said anion exchange resin is selected from the group consisting of Q sepharose, diethylaminoethyl (DEAE), quaternary aminoethyl(QAE), and quaternary amine(Q) groups.\n\n\n\n\n\n\n9. The method of claim 8, wherein said anion exchange resin is Q-sepharose.\n\n\n\n\n\n\n10. The method of claim 1, wherein said ion exchange step comprises a first ion exchange step and a second ion exchange step.\n\n\n\n\n\n\n11. The method of claim 10, wherein said first ion exchange step is a cation exchange step followed by a second anion exchange step.\n\n\n\n\n\n\n12. The method of claim 10 further comprising an intermediate step, wherein said intermediate step is a filtration step occurring between said first and said second ion exchange step.\n\n\n\n\n\n\n13. The method of claim 12, wherein said filtration step is accomplished by capture ultrafiltration/diafiltration.\n\n\n\n\n\n\n14. The method of claim 1, wherein said HIC is accomplished using a column comprising one or more hydrophobic groups.\n\n\n\n\n\n\n15. The method of claim 14, wherein said one or more hydrophobic groups are selected from the group consisting of alkyl-, aryl-groups, and a combination thereof.\n\n\n\n\n\n\n16. The method of claim 14, wherein said column is selected from the group consisting of phenyl sepharose (such as Phenyl Sepharose™ 6 Fast Flow column, Phenyl Sepharose™ High Performance column), Octyl Sepharose™ High Performance column, Fractogel™ EMD Propyl, Fractogel™ EMD Phenyl columns, Macro-Prep™ Methyl, Macro-Prep™ t-Butyl Supports, WP HI-Propyl (C\n3\n)™ column, and Toyopearl™ ether, phenyl or butyl columns.\n\n\n\n\n\n\n17. The method of claim 16, wherein said column comprises phenyl sepharose.  \n\n\n\n\n\n\n18. The method of claim 1 further comprising a filtration step, wherein said HIC sample is subjected to filtration to remove viral particles and to facilitate buffer exchange.\n\n\n\n\n\n\n19. The method of claim 1 , wherein said HCP -reduced antibody preparation comprises an anti-IL-12 antibody or an antigen-binding portion thereof.\n\n\n\n\n\n\n20. The method of claim 19, wherein said anti-IL-12 antibody or antigen-binding portion thereof is a humanized antibody, a chimeric antibody, or a multivalent antibody.\n\n\n\n\n\n\n21. The method of claim 20, wherein said anti-IL-12 antibody or antigen-binding portion thereof is a humanized antibody.\n\n\n\n\n\n\n22. The method of claim 20, wherein said anti-IL-12 antibody or antigen-binding portion thereof is an isolated human antibody that dissociates from human IL- 12 with a IC\nd\n of about 1 x 10\n\"8\n M or less and a K\noff\n rate constant of about 1 x 10\n\"3\n s\n\"1\n or less both determined by surface Plasmon resonance.\n\n\n\n\n\n\n23. The method of claim 19, wherein said anti-IL-12 antibody or antigen-binding portion thereof neutralizes IL-12 both in vivo and in vitro.\n\n\n\n\n\n\n24. The method of claim 1, wherein said preparation is substantially free of HCPs.\n\n\n\n\n\n\n25. A method for producing a host cell-protein (HCP) reduced antibody preparation from a sample mixture comprising an antibody and at least one HCP, said method comprising:\n\n\n(a) subjecting said sample matrix to a reduction in pH thus forming a primary recovery sample, wherein said reduction in pH is to about 3.5;\n\n\n(b) adjusting said primary recovery sample to a pH of about 4.9 followed by applying said primary recovery sample to a cation exchange resin and collecting a cation exchange sample;\n\n\n(c) applying said cation exchange sample to an anion exchange resin and collecting a anion exchange sample; and  (d) applying said anion exchange sample to a hydrophobic interactive chromatography (HIC) resin and collecting an HIC sample, wherein said HIC sample comprises said HCP-reduced antibody preparation.\n\n\n\n\n\n\n26. A method for producing a host cell-protein (HCP) reduced antibody preparation from a sample mixture comprising an antibody and at least one HCP, said method comprising:\n\n\n(a) subjecting said sample matrix to a reduction in pH thus forming a primary recovery sample, wherein said reduction in pH is to about 3.5;\n\n\n(b) adjusting said primary recovery sample to a pH of about 4.9 followed by applying said primary recovery sample to a cation exchange resin and collecting a cation exchange sample;\n\n\n(c) subjecting said cation exchange sample to filtration and collecting a filtrate.\n\n\n(d) applying said filtrate from (c) to an anion exchange resin and collecting an anion exchange sample; and\n\n\n(e) applying said anion exchange sample to a hydrophobic interactive chromatography (HIC) resin and collecting an HIC sample, wherein said HIC sample comprises said HCP-reduced antibody preparation.\n\n\n\n\n\n\n27. A pharmaceutical composition comprising an HCP-reduced antibody preparation produced by the method of claim 1 and a pharmaceutically acceptable carrier.\n\n\n\n\n\n\n28. The pharmaceutical composition of claim 27, wherein said antibody is an anti- IL- 12 antibody or antigen-binding portion thereof.\n\n\n\n\n\n\n29. The pharmaceutical composition of claim 27, wherein said composition is substantially free of HCPs.\n\n\n\n\n\n\n30. The pharmaceutical composition of claim 27 used to neutralize IL- 12 facilitated disorders.  \n\n\n\n\n\n\n31. The pharmaceutical composition of claim 30, wherein said disorders are selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, atopic dermatitis, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthopathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthopathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anemia, Coombs positive haemolytic anaemia, acquired pernicious anemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease,  dermatomyositis/polymyositis associated lung disease, Sjodgren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drag-induced interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, idiopathic leucopenia, autoimmune neutropenia, renal disease NOS, glomerulonephritides, microscopic vasulitis of the kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), insulin-dependent diabetes mellitus, sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis and vitiligo. The human antibodies, and antibody portions of the invention can be used to treat autoimmune diseases, in particular those associated with inflammation, including, rheumatoid spondylitis, allergy, autoimmune diabetes, and autoimmune uveitis.\n\n\n\n\n\n\n32. The pharmaceutical composition of claim 27 further comprising a nonsteroidal or steroidal anti-inflammatory drug.\n\n\n\n\n\n\n33. The pharmaceutical composition of claim 32 comprising a non-steroidal antiinflammatory drug.\n\n\n\n\n\n\n34. The pharmaceutical composition of claim 33, wherein said non-steroidal antiinflammatory drug is selected from the group consisting of ibuprofen, corticosteroids, prednisolone,  \n\n\n\n\n\n\n35. The pharmaceutical composition of claim 32 comprising a steroidal antiinflammatory drug.\n\n\n\n\n\n\n36. The pharmaceutical composition of claim 27 further comprising one or more other antibodies or antigen-binding portions thereof. \n\n\n\n\n\n\n37. The pharmaceutical composition of claim 27 further comprising a pharmaceutical agent.\n\n\n\n\n\n\n38. The pharmaceutical composition of claim 37, wherein said pharmaceutical agent is selected from the group consisting of methotrexate, 6-MP, azathioprine sulphasalazine, mesalazine, olsalazine chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate, azathioprine, cochicine, corticosteroids, β-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines (theophylline, aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, phosphodiesterase inhibitors, adensosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signaling by proinflammatory cytokines such as TNFα or IL-I (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL- lβ converting enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein ligand (PSGL), TNFα converting enzyme (TACE) inhibitors, T-cell signaling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors and the derivatives p75TNFRIgG (Enbrel™)and p55TNFRIgG (Lenercept), sIL-1 RI, sIL-lRII, sIL-6R, soluble IL- 13 receptor (sIL-13)) and antiinflammatory cytokines (e.g., IL-4, IL-10, IL-Il, IL- 13 and TGFβ). \n\n\n\n\n\n\n39. The methods of claims 1, 25 and 26, wherein said HCP-reduced antibody preparation comprises one or more anti-IL-12 antibodies or antigen-binding portions thereof and are labeled.\n\n\n\n\n\n\n40. The methods of claim 39, wherein said label is radioactive.\n\n\n\n\n\n\n41. The methods of claim 40, wherein said radioactive label is selected from the group consisting of \n125\n 1, \n!31\n 1, \n35\n S, and \n3\n H.  \n\n\n\n\n\n\n42. The methods of claim 39, wherein said label is non-radioactive.\n\n\n\n\n\n\n43. The methods of claims 1, 25 and 26, wherein said HCP-reduced antibody preparation comprises one or more anti-IL-12 antibodies or antigen-binding portions thereof and are pegylated. Description\n\n\n\n\n ANTIBODIES THAT BIND TO IL-12 AND METHODS OF PURIFYING THE SAME\n\n\nCROSS REFERENCE TO RELATED APPLICATIONS\n\n\nThis application claims the benefit of U.S. Provisional Application\n\n\nSerial No. 61/196,752 filed October 20, 2008, which is hereby incorporated by reference in its entirety.\n\n\nBACKGROUND OF THE INVENTION\n\n\nHuman interleukin 12 (IL-12) has been characterized as a cytokine with a unique structure and pleiotropic effects. IL-12 plays a critical role in the pathology associated with several diseases involving immune and inflammatory responses. A review of IL-12, its biological activities, and its role in disease can be found in Gately et al. (1998) Ann. Rev. Immunol. 16:495-521.\n\n\nStructurally, IL-12 is a heterodimeric protein comprising a 35 kDa subunit (p35) and a 40 kDa subunit (p40), which are both linked together by a disulfide bridge (referred to as the \"p70 subunit\"). The heterodimeric protein is produced primarily by antigen-presenting cells such as monocytes, macrophages, and dendritic cells. These cell types also secrete an excess of the p40 subunit relative to the p70 subunit. The p40 and p35 subunits are genetically unrelated and neither has been reported to possess biological activity, although the p40 homodimer may function as an IL-12 antagonist.\n\n\nFunctionally, IL-12 plays a central role in regulating the balance between antigen specific T helper type (ThI) and type 2 (Th2) lymphocytes. The ThI and Th2 cells govern the initiation and progression of autoimmune disorders and IL- 12 is critical in the regulation of ThI -lymphocyte differentiation and maturation.\n\n\nCytokines released by the ThI cells are inflammatory and include interferon-γ (EFNγ), IL-2 and lymphotoxin (LT). Th2 cells secrete IL-4, IL-5, IL-6, IL-IO and IL-13 to facilitate humoral immunity, allergic reactions, and immunosuppression.\n\n\nConsistent with the preponderance of ThI responses in autoimmune diseases and the proinflammatory activities of EFNγ, IL-12 may play a major role in \n\n the pathology associated with many autoimmune and inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), and Crohn's disease.\n\n\nHuman patients with MS have demonstrated an increase in IL- 12 expression as documented by p40 mRNA levels in acute MS plaques. In addition, ex vivo stimulation of antigen-presenting cells with CD40L-expressing T cells from MS patients resulted in increased IL- 12 production compared with control T cells, consistent with the observation that CD40/CD40L interactions are potent inducers of IL- 12.\n\n\nElevated levels of IL- 12 p70 have been detected in the synovia of RA patients compared with healthy controls. Cytokine messenger ribonucleic acid (mRNA) expression profile in the RA synovia identified predominantly ThI cytokines. IL-12 also appears to play a critical role in the pathology associated with Crohn's disease (CD). Increased expression of IFNγ and IL-12 has been observed in the intestinal mucosa of patients with this disease. The cytokine secretion profile of T cells from the lamina propria of CD patients is characteristic of a predominantly ThI response, including greatly elevated IFNγ levels. Moreover, colon tissue sections from CD patients show an abundance of IL-12 expressing macrophages and IFNγ expressing T cells.\n\n\nDue to the role of human IL-12 in a variety of human disorders, therapeutic strategies have been designed to inhibit or counteract IL-12 activity. In particular, antibodies that bind to, and neutralize, IL-12 have been sought as a means to inhibit IL-12 activity. It is important that a therapeutic regime comprising antibodies against IL-12 be of high purity. The present invention addresses this need without the use of a Protein A column or an equivalent Protein A-based purification step.\n\n\nSUMMARY OF THE INVENTION\n\n\nhi certain embodiments, the present invention is directed to purified, isolated antibodies and antibody fragments that bind to IL-12 as well as pharmaceutical compositions comprising such antibodies and fragments. In certain embodiments, the invention pertains to isolated antibodies, or antigen-binding portions thereof, that bind to human IL-12. The isolated anti-IL-12 antibodies of the present invention can be used in a clinical setting as well as in research and \n\n development. In certain embodiments, the present invention is directed to the anti-IL- 12 antibody comprising the heavy and light chain sequences identified in SEQ ID NOs. 1 and 2.\n\n\nCertain embodiments of the invention are directed toward methods of purifying anti-IL-12 antibodies, or antigen-binding portions thereof, from a sample matrix to render them substantially free of host cell proteins (\"HCPs\"). In certain aspects, the sample matrix (or simply \"sample\") comprises a cell line employed to produce anti-IL-12 antibodies of the present invention. In particular aspects, the sample comprises a cell line used to produce human anti-IL-12 antibodies. In certain embodiments of the present invention a sample matrix comprising the putative anti-IL-12 antibody, or antigen-binding portion thereof, is subjected to a pH adjustment. In certain aspects, the pH is adjusted to about 3.5. The low pH, among other things, promotes the reduction and/or inactivation of pH- sensitive viruses that may be contaminating the sample. After a suitable period of time, the pH is adjusted to approximately 5.0 and the sample is subjected to ion exchange chromatography to produce an eluate. In certain aspects, the ion exchange eluate is collected and further subjected to hydrophobic interactive chromatography to produce an eluate. The hydrophobic interactive chromatography eluate can then be collected for further processing or use. In certain embodiments the present invention provides for a method of purifying IL- 12 antibodies that comprises a primary recovery step to, among other things, remove cells and cellular debris. In certain embodiments of the above- described method, the primary recovery step includes one or more centrifugation or depth filtration steps. For example, and not by way of limitation, such centrifugation steps can be performed at approximately 7000 x g to approximately 11,000 x g. In addition, certain embodiments of the above-described method will include a depth filtration step, such as a delipid depth filtration step.\n\n\nIn certain embodiments of the above-described method, the ion exchange step can be either cation or anion exchange chromatography, or a combination of both. This step can include multiple ion exchange steps such as a cation exchange step followed by an anion exchange step or visa versa. In certain aspects, the ion exchange step involves a two step ion exchange process. Such two step processes can be accomplished, for example, and not by way of limitation, by a first cation exchange step, followed by a second anion exchange step. An exemplary \n\n cation exchange column is a column whose stationary phase comprises anionic groups, such as a CM Hyper DF™ column. This ion exchange capture chromatography step facilitates the isolation of the anti-IL-12 antibodies from the primary recovery mixture. A suitable anion exchange column is a column whose stationary phase comprises cationic groups. An example of such a column is a Q Sepharose™ column. One or more ion exchange step further isolates anti-IL-12 antibodies by reducing impurities as host cell proteins and DNA and, where applicable, affinity matrix protein. This anion exchange procedure is a flow through mode of chromatography wherein the anti-IL-12 antibodies do not interact or bind to the anion exchange resin (or solid phase). However, many impurities do interact with and bind to the anion exchange resin.\n\n\nIn certain embodiments, a first and second ion exchange step is performed following primary recovery. In certain of such embodiments, the ion exchange sample is subjected to an intermediate filtration step, either prior to the first ion exchange step, between the two ion exchange steps, or both. In certain aspects, this filtration step comprises capture ultrafiltration/diafiltration (\"UF/DF\"). Among other activities, such filtration facilitates the concentration and buffer exchange of anti-IL-12 antibodies and antigen-binding portions thereof.\n\n\nCertain embodiments of the invention provide for a method comprising one or more hydrophobic interactive chromatography (\"HIC\") step. A suitable HIC column is one whose stationary phase comprises hydrophobic groups. A non-limiting example of such a column is a Phenyl HP Sepharose™ column. In certain circumstances anti-IL-12 antibodies will form aggregates during the isolation/purification process. Inclusion of one or more HIC step facilitates the reduction or elimination of such aggregations. HIC also assists in the removal of impurities, hi certain embodiments the HIC step employs a high salt buffer to promote interaction of the anti-IL-12 antibodies (or aggregations thereof) with the hydrophobic column. The anti-IL-12 antibodies can then be eluted using lower concentrations of salt. In certain embodiments, the HIC eluate is filtered using a viral removal filter such as, but not limited to, an Ultipor DV50™ filter (Pall Corporation, East Hills, N.Y.). Alternative filters, such as Viresolve™ filters (Millipore, Billerica, Mass.); Zeta Plus VR™ filters (CUNO; Meriden, Conn.); and Planova™ filters \n\n (Asahi Kasei Pharma, Planova Division, Buffalo Grove, 111.), can also be used in such embodiments.\n\n\nIn certain embodiments, the invention is directed to one or more pharmaceutical composition comprising an isolated anti-IL-12 antibody or antigen- binding portion thereof and an acceptable carrier. In one aspect, the composition further comprises one or more antibody or antigen-binding portion thereof in addition to the anti-IL-12 antibody. In another aspect, the compositions further comprise one or more pharmaceutical agents.\n\n\nBRIEF DESCRIPTION OF THE DRAWINGS\n\n\nFigure 1. Figure 1 discloses the heavy and light chain variable region sequences of a non-limiting example of an anti-IL-12 antibody (ABT-847). DETAILED DESCRIPTION OF THE INVENTION\n\n\nThe present invention is directed to antibodies that bind to IL- 12. hi one aspect, the invention pertains to isolated antibodies, or antigen-binding portions thereof, that bind to human IL-12. The isolated anti-IL-12 antibody of the present invention can be used in a clinical setting as well as in research and development. The present invention also pertains to methods for purifying anti-IL-12 antibodies, or antigen-binding portions thereof. Suitable anti-IL-12 antibodies that may be purified in the context of the instant invention are disclosed in U.S. Patent No. 6,914,128\n\n\n(which is hereby incorporated by reference in its entirety) including, but not limited to the anti-IL-12 antibody identified in that patent as J695, and which has subsequently been identified as ABT-874. The sequences of the heavy and light chain variable regions of ABT-874 are set forth in Figure 1 and SEQ ID NOs. 1 and 2. The present invention also relates to pharmaceutical compositions comprising the anti-IL-12 antibodies or antigen-binding portions thereof described herein.\n\n\nFor clarity and not by way of limitation, this detailed description is divided into the following sub-portions: 1. Definitions; 2. Antibody Generation;\n\n\n3. Antibody Production;\n\n\n4. Antibody Purification; \n\n 5. Methods of Assaying Sample Purity;\n\n\n6. Further Modifications;\n\n\n7. Pharmaceutical Compositions; and\n\n\n8. Antibody Uses.\n\n\n1. Definitions\n\n\nIn order that the present invention may be more readily understood, certain terms are first defined.\n\n\nThe term \"antibody\" includes an immunoglobulin molecule comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region (CH). The heavy chain constant region is comprised of three domains, CHl, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4.\n\n\nThe term \"antigen-binding portion\" of an antibody (or \"antibody portion\") includes fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., hIL-12). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term \"antigen-binding portion\" of an antibody include (i) a Fab fragment, a monovalent fragment comprising the VL, VH, CL and CHl domains; (ii) a F(ab')\n2\n fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment comprising the VH and CHl domains; (iv) a Fv fragment comprising the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al, (1989) Nature 341 :544-546, the entire teaching of which is incorporated herein by reference), which comprises a VH domain; and (vi) an isolated complementarity determining \n\n region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883, the entire teachings of which are incorporated herein by reference). Such single chain antibodies are also intended to be encompassed within the term \"antigen-binding portion\" of an antibody. Other forms of single chain antibodies, such as diabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see, e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123, the entire teachings of which are incorporated herein by reference). Still further, an antibody or antigen-binding portion thereof may be part of a larger immunoadhesion molecule, formed by covalent or non-covalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6:93-101, the entire teaching of which is incorporated herein by reference) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) MoI. Immunol. 31:1047-1058, the entire teaching of which is incorporated herein by reference). Antibody portions, such as Fab and F(ab')2 fragments, can be prepared from whole antibodies using conventional techniques, such as papain or pepsin digestion, respectively, of whole antibodies. Moreover, antibodies, antibody portions and immunoadhesion molecules can be obtained using standard recombinant DNA techniques, as described herein, hi one aspect, the antigen binding portions are complete domains or pairs of complete domains.\n\n\nThe phrase \"human interleukin 12\" (abbreviated herein as hIL-12, or IL- 12), as used herein, includes a human cytokine that is secreted primarily by macrophages and dendritic cells. The term includes a heterodimeric protein \n\n comprising a 35 kD subunit (ρ35) and a 40 kD subunit (ρ40) which are linked together with a disulfide bridge. The heterodimeric protein is referred to as a \"p70 subunit\". The structure of human IL- 12 is described further in, e.g., Kobayashi, et al. (1989) J. Exp Med. 170:827-845; Seder, et al. (1993) Proc. Natl. Acad. Sci. 90:10188-10192; Ling, et al. (1995) J. Exp Med. 154:116-127; Podlaski, et al. (1992) Arch. Biochem. Biophys. 294:230-237, the entire teachings of which are incorporated herein by reference. The nucleic acid encoding IL- 12 is available as GenBank Accession No. NM_000882 and the polypeptide sequence is available as GenBank Accession No. NP_000873.2. The term human IL-12 is intended to include recombinant human IL-12 (rh IL-12), which can be prepared by standard recombinant expression methods.\n\n\nThe terms \"Kabat numbering\", \"Kabat definitions\" and \"Kabat labeling\" are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable {i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci. 190:382-391 and, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, the entire teachings of which are incorporated herein by reference). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDRl, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDRl, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3. The term \"human antibody\" includes antibodies having variable and constant regions corresponding to human germline immunoglobulin sequences as described by Kabat et al. (See Kabat, et al. (1991) Sequences of proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences {e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), e.g., in the CDRs and in particular CDR3. The mutations can be introduced using the \"selective mutagenesis approach.\" The human antibody can have at least one position replaced with an amino acid residue, e.g., an \n\n activity enhancing amino acid residue which is not encoded by the human germline immunoglobulin sequence. The human antibody can have up to twenty positions replaced with amino acid residues which are not part of the human germline immunoglobulin sequence. In other embodiments, up to ten, up to five, up to three or up to two positions are replaced, hi one embodiment, these replacements are within the CDR regions. However, the term \"human antibody\", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The phrase \"selective mutagenesis approach\" includes a method of improving the activity of an antibody by selecting and individually mutating CDR amino acids at least one suitable selective mutagenesis position, hypermutation, and/or contact position. A \"selectively mutated\" human antibody is an antibody which comprises a mutation at a position selected using a selective mutagenesis approach. In another aspect, the selective mutagenesis approach is intended to provide a method of preferentially mutating selected individual amino acid residues in the CDRl, CDR2 or CDR3 of the heavy chain variable region (hereinafter Hl, H2, and H3, respectively), or the CDRl, CDR2 or CDR3 of the light chain variable region (hereinafter referred to as Ll, L2, and L3, respectively) of an antibody. Amino acid residues may be selected from selective mutagenesis positions, contact positions, or hypermutation positions. Individual amino acids are selected based on their position in the light or heavy chain variable region. It should be understood that a hypermutation position can also be a contact position. In one aspect, the selective mutagenesis approach is a \"targeted approach\". The language \"targeted approach\" is intended to include a method of mutating selected individual amino acid residues in the CDRl, CDR2 or CDR3 of the heavy chain variable region or the CDRl, CDR2 or CDR3 of the light chain variable region of an antibody in a targeted manner, e.g., a \"Group-wise targeted approach\" or \"CDR-wise targeted approach\". In the \"Group- wise targeted approach\", individual amino acid residues in particular groups are targeted for selective mutations including groups I (including L3 and H3), II\n\n\n(including H2 and Ll) and III (including L2 and Hl), the groups being listed in order of preference for targeting. In the \"CDR-wise targeted approach\", individual amino acid residues in particular CDRs are targeted for selective mutations with the order of preference for targeting as follows: H3, L3, H2, Ll, Hl and L2. The selected amino \n\n acid residue is mutated, e.g., to at least two other amino acid residues, and the effect of the mutation on the activity of the antibody is determined. Activity is measured as a change in the binding specificity/affinity of the antibody, and/or neutralization potency of the antibody. It should be understood that the selective mutagenesis approach can be used for the optimization of any antibody derived from any source including phage display, transgenic animals with human IgG germline genes, human antibodies isolated from human B-cells. The selective mutagenesis approach can be used on antibodies which can not be optimized further using phage display technology. It should be understood that antibodies from any source including phage display, transgenic animals with human IgG germline genes, human antibodies isolated from human B-cells can be subject to back-mutation prior to or after the selective mutagenesis approach.\n\n\nThe phrase \"recombinant human antibody\" includes human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library, antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see, e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295, the entire teaching of which is incorporated herein by reference) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo. In certain embodiments, however, such recombinant antibodies are the result of selective mutagenesis approach or back-mutation or both.\n\n\nAn \"isolated antibody\" includes an antibody that is substantially free of other antibodies having different antigenic specificities {e.g., an isolated antibody that \n\n specifically binds ML- 12 is substantially free of antibodies that specifically bind antigens other than hIL-12). An isolated antibody that specifically binds hIL-12 may bind IL- 12 molecules from other species. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals. A \"neutralizing antibody\" (or an \"antibody that neutralized hIL-12 activity\") includes an antibody whose binding to hIL-12 results in inhibition of the biological activity of hIL-12. This inhibition of the biological activity of hIL-12 can be assessed by measuring one or more indicators of hIL-12 biological activity, such as inhibition of human phytohemagglutinin blast proliferation in a phytohemagglutinin blast proliferation assay (PHA), or inhibition of receptor binding in a human IL- 12 receptor binding assay. These indicators of ML- 12 biological activity can be assessed by one or more of several standard in vitro or in vivo assays known in the art.\n\n\nThe term \"activity\" includes activities such as the binding specificity/affinity of an antibody for an antigen, e.g., an anti-hIL-12 antibody that binds to an IL- 12 antigen and/or the neutralizing potency of an antibody, e.g., an anti- ML- 12 antibody whose binding to ML- 12 inhibits the biological activity of ML- 12, e.g., inhibition of PHA blast proliferation or inhibition of receptor binding in a human IL- 12 receptor binding assay.\n\n\nThe phrase \"surface plasmon resonance\" includes an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, e.g., using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ.). For further descriptions, see Jonsson, U., et al. (1993) Ann. Biol. Clin. 51:19- 26; Jonsson, U., et al. (1991) Biotechniques 11:620-627; Johnsson, B., el al. (1995) J. MoI. Recognit. 8:125-131; and Johnnson, B., et al. (1991) Anal. Biochem. 198:268- 277, the entire teachings of which are incorporated herein.\n\n\nThe term \"K\noff\n \", as used herein, is intended to refer to the off rate constant for dissociation of an antibody from the antibody/antigen complex.\n\n\nThe term \"K\nd\n \", as used herein, is intended to refer to the dissociation constant of a particular antibody-antigen interaction.\n\n\nThe phrase \"nucleic acid molecule\" includes DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but in one aspect is double-stranded DNA. \n\n The phrase \"isolated nucleic acid molecule,\" as used herein in reference to nucleic acids encoding antibodies or antibody portions (e.g., VH, VL, CDR3) that bind hIL-12 (including \"isolated antibodies\"), includes a nucleic acid molecule in which the nucleotide sequences encoding the antibody or antibody portion are free of other nucleotide sequences encoding antibodies or antibody portions that bind antigens other than ML- 12, which other sequences may naturally flank the nucleic acid in human genomic DNA. Thus, e.g, an isolated nucleic acid of the invention encoding a VH region of an anti-IL-12 antibody contains no other sequences encoding other VH regions that bind antigens other than IL- 12. The phrase \"isolated nucleic acid molecule\" is also intended to include sequences encoding bivalent, bispecific antibodies, such as diabodies in which VH and VL regions contain no other sequences other than the sequences of the diabody.\n\n\nThe phrase \"recombinant host cell\" (or simply \"host cell\") includes a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term \"host cell\" as used herein. The term \"modifying\", as used herein, is intended to refer to changing one or more amino acids in the antibodies or antigen-binding portions thereof. The change can be produced by adding, substituting or deleting an amino acid at one or more positions. The change can be produced using known techniques, such as PCR mutagenesis. The term \"about\", as used herein, is intended to refer to ranges of approximately 10-20% greater than or less than the referenced value. In certain circumstances, one of skill in the art will recognize that, due to the nature of the referenced value, the term \"about\" can mean more or less than a 10-20% deviation from that value. The phrase \"viral reduction/inactivation\", as used herein, is intended to refer to a decrease in the number of viral particles in a particular sample (\"reduction\"), as well as a decrease in the activity, for example, but not limited to, the infectivity or ability to replicate, of viral particles in a particular sample (\"inactivation\"). Such decreases in the number and/or activity of viral particles can be \n\n on the order of about 1% to about 99%, preferably of about 20% to about 99%, more preferably of about 30% to about 99%, more preferably of about 40% to about 99%, even more preferably of about 50% to about 99%, even more preferably of about 60% to about 99%, yet more preferably of about 70% to about 99%, yet more preferably of about 80% to 99%, and yet more preferably of about 90% to about 99%. In certain non-limiting embodiments, the amount of virus, if any, in the purified antibody product is less than the ID50 (the amount of virus that will infect 50 percent of a target population) for that virus, preferably at least 10-fold less than the ID50 for that virus, more preferably at least 100-fold less than the ID50 for that virus, and still more preferably at least 1000-fold less than the ID50 for that virus.\n\n\nThe phrase \"contact position\" includes an amino acid position in the CDRl, CDR2 or CDR3 of the heavy chain variable region or the light chain variable region of an antibody which is occupied by an amino acid that contacts antigen in one of the twenty-six known antibody-antigen structures. If a CDR amino acid in any of the twenty-six known solved structures of antibody-antigen complexes contacts the antigen, then that amino acid can be considered to occupy a contact position. Contact positions have a higher probability of being occupied by an amino acid which contact antigens than in a non-contact position. In one aspect, a contact position is a CDR position which contains an amino acid that contacts antigen in greater than 3 of the 26 structures (>1.5%). In another aspect, a contact position is a CDR position which contains an amino acid that contacts antigen in greater than 8 of the 25 structures (>32%).\n\n\n2. Antibody Generation\n\n\nThe term \"antibody\" as used in this section refers to an intact antibody or an antigen binding fragment thereof.\n\n\nThe antibodies of the present disclosure can be generated by a variety of techniques, including immunization of an animal with the antigen of interest followed by conventional monoclonal antibody methodologies e.g., the standard somatic cell hybridization technique of Kohler and Milstein (1975) Nature 256: 495. Although somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibody can be employed e.g., viral or oncogenic transformation of B lymphocytes. \n\n One preferred animal system for preparing hybridomas is the murine system. Hybridoma production is a very well-established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.\n\n\nAn antibody preferably can be a human, a chimeric, or a humanized antibody. Chimeric or humanized antibodies of the present disclosure can be prepared based on the sequence of a non-human monoclonal antibody prepared as described above. DNA encoding the heavy and light chain immunoglobulins can be obtained from the non-human hybridoma of interest and engineered to contain non- murine (e.g., human) immunoglobulin sequences using standard molecular biology techniques. For example, to create a chimeric antibody, murine variable regions can be linked to human constant regions using methods known in the art (see e.g., U.S. Patent No. 4,816,567 to Cabilly et al.). To create a humanized antibody, murine CDR regions can be inserted into a human framework using methods known in the art (see e.g., U.S. Patent No. 5,225,539 to Winter, and U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen et al.).\n\n\nIn one non-limiting embodiment, the antibodies of this disclosure are human monoclonal antibodies. Such human monoclonal antibodies directed against IL- 12 can be generated using transgenic or transchromosomic mice carrying parts of the human immune system rather than the mouse system. These transgenic and transchromosomic mice include mice referred to herein as the HuMAb Mouse® (Medarex, Inc.), KM Mouse® (Medarex, Inc.), and XenoMouse® (Amgen).\n\n\nMoreover, alternative transchromosomic animal systems expressing human immunoglobulin genes are available in the art and can be used to raise anti-IL- 12 antibodies of this disclosure. For example, mice carrying both a human heavy chain transchromosome and a human light chain tranchromosome, referred to as \"TC mice\" can be used; such mice are described in Tomizuka et al. (2000) Proc. Natl. Acad. Sci. USA 97:722-727 \n'\n. Furthermore, cows carrying human heavy and light chain transchromosomes have been described in the art (e.g., Kuroiwa et al. (2002) Nature Biotechnology 20:889-894 and PCT application No. WO 2002/092812) and can be used to raise anti-IL-12 antibodies of this disclosure.\n\n\nRecombinant human antibodies of the invention, including anti-IL-12 antibodies or an antigen binding portion thereof, or anti-IL-12-related antibodies \n\n disclosed herein can be isolated by screening of a recombinant combinatorial antibody library, e.g., a scFv phage display library, prepared using human VL and VH cDNAs prepared from mRNA derived from human lymphocytes. Methodologies for preparing and screening such libraries are known in the art. In addition to commercially available kits for generating phage display libraries (e.g. , the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and the Stratagene SurfZApTM phage display kit, catalog no. 240612, the entire teachings of which are incorporated herein), examples of methods and reagents particularly amenable for use in generating and screening antibody display libraries can be found in, e.g., Ladner et al U.S. Patent No. 5,223,409; Kang et al PCT Publication No. WO 92/18619; Dower et al PCT Publication No. WO 91/17271; Winter et al. PCT Publication No. WO 92/20791; Markland et al. PCT Publication No. WO 92/15679; Breitling et al. PCT Publication No. WO 93/01288; McCafferty et al PCT Publication No. WO 92/01047; Garrard et al PCT Publication No. WO 92/09690; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; McCafferty et al, Nature (1990) 348:552-554; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et al (1992) JMoI Biol 226:889-896; Clackson ef α/. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrard et al (1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas ^ α/. (1991) PNAS 88:7978-7982; the entire teachings of which are incorporated herein.\n\n\nHuman monoclonal antibodies of this disclosure can also be prepared using SCID mice into which human immune cells have been reconstituted such that a human antibody response can be generated upon immunization. Such mice are described in, for example, U.S. Patent Nos. 5,476,996 and 5,698,767 to Wilson et al. hi one embodiment, the methods of the invention include anti-IL-12 antibodies and antibody portions, anti-IL-12-related antibodies and antibody portions, and human antibodies and antibody portions with equivalent properties to anti-IL-12 antibodies, such as high affinity binding to hIL-12 with low dissociation kinetics and high neutralizing capacity, hi one aspect, the invention provides treatment with an isolated human antibody, or an antigen-binding portion thereof, that dissociates from hIL-12 with a K^ of about 1 x 10\n\"8\n M or less and a Koff rate constant of 1 x 10\n\"3\n s\n~\nl or less, both determined by surface plasmon resonance. In specific non-limiting \n\n embodiments, an anti-IL12 antibody purified according to the invention competitively inhibits binding of ABT-874 to ILl 2 under physiological conditions.\n\n\nIn yet another embodiment of the invention, anti-IL-12 antibodies or fragments thereof can be altered wherein the constant region of the antibody is modified to reduce at least one constant region-mediated biological effector function relative to an unmodified antibody. To modify an antibody of the invention such that it exhibits reduced binding to the Fc receptor, the immunoglobulin constant region segment of the antibody can be mutated at particular regions necessary for Fc receptor (FcR) interactions (see, e.g., Canfield and Morrison (1991) J. Exp. Med. 173:1483- 1491 ; and Lund et al. (1991) J. of Immunol. WL:2651-2662, the entire teachings of which are incorporated herein). Reduction in FcR binding ability of the antibody may also reduce other effector functions which rely on FcR interactions, such as opsonization and phagocytosis and antigen-dependent cellular cytotoxicity. 3. Antibody Production To express an antibody of the invention, DNAs encoding partial or full-length light and heavy chains are inserted into one or more expression vector such that the genes are operatively linked to transcriptional and translational control sequences. (See, e.g., U.S. Pat. No. 6,914,128, the entire teaching of which is incorporated herein by reference.) In this context, the term \"operatively linked\" is intended to mean that an antibody gene is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the antibody gene. The expression vector and expression control sequences are chosen to be compatible with the expression host cell used. The antibody light chain gene and the antibody heavy chain gene can be inserted into a separate vector or, more typically, both genes are inserted into the same expression vector. The antibody genes are inserted into an expression vector by standard methods {e.g., ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present). Prior to insertion of the antibody or antibody-related light or heavy chain sequences, the expression vector may already carry antibody constant region sequences. For example, one approach to converting the anti-IL-12 antibody or anti- IL-12 antibody-related VH and VL sequences to full-length antibody genes is to insert them into expression vectors already encoding heavy chain constant and light chain constant regions, respectively, such that the VH segment is operatively linked to the \n\n CH segment(s) within the vector and the VL segment is operatively linked to the CL segment within the vector. Additionally or alternatively, the recombinant expression vector can encode a signal peptide that facilitates secretion of the antibody chain from a host cell. The antibody chain gene can be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the antibody chain gene. The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein).\n\n\nIn addition to the antibody chain genes, a recombinant expression vector of the invention can carry one or more regulatory sequence that controls the expression of the antibody chain genes in a host cell. The term \"regulatory sequence\" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, e.g., in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990), the entire teaching of which is incorporated herein by reference. It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. Suitable regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)) and polyoma. For further description of viral regulatory elements, and sequences thereof, see, e.g., U.S. Patent No. 5,168,062 by Stinski, U.S. Patent No. 4,510,245 by Bell et al. and U.S. Patent No. 4,968,615 by Schaffner et al., the entire teachings of which are incorporated herein by reference.\n\n\nIn addition to the antibody chain genes and regulatory sequences, a recombinant expression vector of the invention may carry one or more additional sequences, such as a sequence that regulates replication of the vector in host cells (e.g., origins of replication) and/or a selectable marker gene. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Patents Nos. 4,399,216, 4,634,665 and 5,179,017, all by Axel et al, the entire teachings of which are incorporated herein by reference). For example, \n\n typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Suitable selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).\n\n\nAn antibody, or antibody portion, of the invention can be prepared by recombinant expression of immunoglobulin light and heavy chain genes in a host cell. To express an antibody recombinantly, a host cell is transfected with one or more recombinant expression vectors carrying DNA fragments encoding the immunoglobulin light and heavy chains of the antibody such that the light and heavy chains are expressed in the host cell and secreted into the medium in which the host cells are cultured, from which medium the antibodies can be recovered. Standard recombinant DNA methodologies are used to obtain antibody heavy and light chain genes, incorporate these genes into recombinant expression vectors and introduce the vectors into host cells, such as those described in Sambrook, Fritsch and Maniatis (eds), Molecular Cloning; A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), Ausubel et al. (eds.) Current Protocols in Molecular Biology, Greene Publishing Associates, (1989) and in U.S. Patent Nos. 4,816,397 & 6,914,128, the entire teachings of which are incorporated herein. For expression of the light and heavy chains, the expression vector(s) encoding the heavy and light chains is (are) transfected into a host cell by standard techniques. The various forms of the term \"transfection\" are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like. Although it is theoretically possible to express the antibodies of the invention in either prokaryotic or eukaryotic host cells, expression of antibodies in eukaryotic cells, such as mammalian host cells, is suitable because such eukaryotic cells, and in particular mammalian cells, are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active antibody. Prokaryotic expression of antibody genes has been reported to be ineffective for production of high yields of active antibody (Boss and Wood (1985) Immunology Today 6:12-13, the entire teaching of which is incorporated herein by reference). \n\n Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram- positive organisms, e.g., Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710 published Apr. 12, 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. One suitable E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.\n\n\nIn addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070); Candida;\n\n\nTrichoderma reesia (EP 244,234); Neurospora crassa; Schwanniomyces such as Schwanniomyces occidentalis; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger. Suitable host cells for the expression of glycosylated antibodies are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-I variant of Autographa californica\n\n\nNPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts. \n\n Suitable mammalian host cells for expressing the recombinant antibodies of the invention include Chinese Hamster Ovary (CHO cells) (including dhfr- CHO cells, described in Urlaub and Chasin, (1980) PNAS USA 77:4216-4220, used with a DHFR selectable marker, β.g., as described in Kaufman and Sharp (1982) MoI. Biol. 159:601-621, the entire teachings of which are incorporated herein by reference), NSO myeloma cells, COS cells and SP2 cells. When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or secretion of the antibody into the culture medium in which the host cells are grown. Other examples of useful mammalian host cell lines are monkey kidney CVl line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al, J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cellsADHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CVl ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL- 1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (Wl 38, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al, Annals N. Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2), the entire teachings of which are incorporated herein by reference. Host cells are transformed with the above-described expression or cloning vectors for antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.\n\n\nThe host cells used to produce an antibody may be cultured in a variety of media. Commercially available media such as Ham's F 10™ (Sigma), Minimal Essential Medium™ ((MEM), (Sigma), RPMI- 1640 (Sigma), and Dulbecco's Modified Eagle's Medium™ ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al, Meth. Enz. 58:44 (1979), Barnes et al, Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; \n\n 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Pat. No. Re. 30,985 may be used as culture media for the host cells, the entire teachings of which are incorporated herein by reference. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as gentamycin drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.\n\n\nHost cells can also be used to produce portions of intact antibodies, such as Fab fragments or scFv molecules. It is understood that variations on the above procedure are within the scope of the present invention. For example, it may be desirable to transfect a host cell with DNA encoding either the light chain or the heavy chain (but not both) of an antibody of this invention. Recombinant DNA technology may also be used to remove some or all of the DNA encoding either or both of the light and heavy chains that is not necessary for binding to IL- 12, specifically hIL-12. The molecules expressed from such truncated DNA molecules are also encompassed by the antibodies of the invention. In addition, bifunctional antibodies may be produced in which one heavy and one light chain are an antibody of the invention and the other heavy and light chain are specific for an antigen other than IL-12 by crosslinking an antibody of the invention to a second antibody by standard chemical crosslinking methods.\n\n\nIn a suitable system for recombinant expression of an antibody, or antigen-binding portion thereof, of the invention, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr-CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are each operatively linked to CMV enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been \n\n transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody from the culture medium.\n\n\nWhen using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. In one aspect, if the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed cells (e.g., resulting from homogenization), can be removed, e.g., by centrifugation or ultrafiltration. Where the antibody is secreted into the medium, supernatants from such expression systems can be first concentrated using a commercially available protein concentration filter, e.g., an Aniicon or Millipore Pellicon ultrafiltration unit. Prior to the process of the invention, procedures for purification of antibodies from cell debris initially depend on the site of expression of the antibody. Some antibodies can be secreted directly from the cell into the surrounding growth media; others are made intracellularly. For the latter antibodies, the first step of a purification process typically involves: lysis of the cell, which can be done by a variety of methods, including mechanical shear, osmotic shock, or enzymatic treatments. Such disruption releases the entire contents of the cell into the homogenate, and in addition produces subcellular fragments that are difficult to remove due to their small size. These are generally removed by differential centrifugation or by filtration. Where the antibody is secreted, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, e.g., an Amicon or Millipore Pellicon ultrafiltration unit. Where the antibody is secreted into the medium, the recombinant host cells can also be separated from the cell culture medium, e.g., by tangential flow filtration. Antibodies can be further recovered from the culture medium using the antibody purification methods of the invention. \n\n 4. Antibody Purification\n\n\n4.1 Antibody Purification Generally\n\n\nThe invention provides a method for producing a purified (or \"HCP- reduced\") antibody preparation from a mixture comprising an antibody and at least one HCP. The purification process of the invention begins at the separation step when the antibody has been produced using methods described above and conventional methods in the art. Typically in the art, antibody-HCP mixtures are subjected to protein A capture (e.g., a protein A column) as an initial purification step, since the antibody binds to protein A whereas HCP will flow through. The purification methods of the present invention have the advantage that it is not necessary to subject the mixture comprising an antibody and at least one HCP to protein A capture (e.g., a protein A column) as an initial step, or as any step in the purification method. Table 1 summarizes one embodiment of a purification scheme. Variations of this scheme are envisaged and are within the scope of this invention.\n\n\nTable 1 Purification steps with their associated purpose\n\n\n\n\n\n\n\n\nOnce a clarified solution or mixture comprising the antibody has been obtained, separation of the antibody from the other proteins produced by the cell, such as HCPs, is performed using a combination of different purification techniques, including ion exchange separation step(s) and hydrophobic interaction separation step(s). The separation steps separate mixtures of proteins on the basis of their charge, degree of hydrophobicity, or size. In one aspect of the invention, separation is \n\n performed using chromatography, including cationic, anionic, and hydrophobic interaction. Several different chromatography resins are available for each of these techniques, allowing accurate tailoring of the purification scheme to the particular protein involved. The essence of each of the separation methods is that proteins can be caused either to traverse at different rates down a column, achieving a physical separation that increases as they pass further down the column, or to adhere selectively to the separation medium, being then differentially eluted by different solvents. In some cases, the antibody is separated from impurities when the impurities specifically adhere to the column and the antibody does not, i.e., the antibody is present in the flow through.\n\n\nAs noted above, accurate tailoring of a purification scheme relies on consideration of the protein to be purified. In certain embodiments, the separation steps of the instant invention are employed to separate an antibody from one or more HCPs. Antibodies that can be successfully purified using the methods described herein include, but are not limited to, human IgAi, IgA\n2\n, IgD, IgE, IgGi, IgG\n2\n, IgG\n3\n, IgG\n4\n, and IgM antibodies. In certain embodiments, the purification strategies of the instant invention exclude the use of Protein A affinity chromatography. Such embodiments are particularly useful for the purification OfIgG\n3\n antibodies, as IgG\n3\n antibodies are known to bind to Protein A inefficiently. Other factors that allow for specific tailoring of a purification scheme include, but are not limited to: the presence or absence of an Fc region {e.g., in the context of full length antibody as compared to an Fab fragment thereof); the particular germline sequences employed in generating to antibody of interest; and the amino acid composition of the antibody {e.g., the primary sequence of the antibody as well as the overall charge/hydrophobicity of the molecule). Antibodies sharing one or more characteristic can be purified using purification strategies tailored to take advantage of that characteristic.\n\n\n4.2 Primary Recovery\n\n\nThe initial steps of the purification methods of the present invention involve the first phase of clarification and primary recovery of anti-IL-12 antibody from a sample matrix. In addition, the primary recovery process can also be a point at which to inactivate viruses that can be present in the sample matrix. For example, any one or more of a variety of methods of viral inactivation can be used during the \n\n primary recovery phase of purification including heat inactivation (pasteurization), pH inactivation, solvent/detergent treatment, UV and γ-ray irradiation and the addition of certain chemical inactivating agents such as β-propiolactone or e.g., copper phenanthroline as in U.S. Pat. No. 4,534,972, the entire teaching of which is incorporated herein by reference. In certain embodiments of the present invention, the sample matrix is exposed to pH viral inactivation during the primary recovery phase.\n\n\nMethods of pH viral inactivation include, but are not limited to, incubating the mixture for a period of time at low pH, and subsequently neutralizing the pH and removing particulates by filtration. In certain embodiments the mixture will be incubated at a pH of 2 to 5, preferably at a pH of 3 to 4, and more preferably at a pH of 3.5. The pH of the sample mixture may be lowered by any suitable acid including, but not limited to, citric acid, acetic acid, caprylic acid, or other suitable acids. The choice of pH level largely depends on the stability profile of the antibody product and buffer components. It is known that the quality of the target antibody during low pH virus inactivation is affected by pH and the duration of the low pH incubation. In certain embodiments the duration of the low pH incubation will be from 0.5hr to 2hr, preferably 0.5hr to 1.5hr, and more preferably the duration will be lhr. Virus inactivation is dependent on these same parameters in addition to protein concentration, which may reduce inactivation at high concentrations. Thus, the proper parameters of protein concentration, pH, and duration of inactivation can be selected to achieve the desired level of viral inactivation.\n\n\nIn certain embodiments viral inactivation can be achieved via the use of suitable filters. A non-limiting example of a suitable filter is the Ultipor DV50™ filter from Pall Corporation. Although certain embodiments of the present invention employ such filtration during the primary recovery phase, in other embodiments it is employed at other phases of the purification process, including as either the penultimate or final step of purification. In certain embodiments, alternative filters are employed for viral inactivation, such as, but not limited to, Viresolve™ filters (Millipore, Billerica, Mass.); Zeta Plus VR™ filters (CUNO; Meriden, Conn.); and Planova™ filters (Asahi Kasei Pharma, Planova Division, Buffalo Grove, 111.).\n\n\nIn those embodiments where viral inactivation is employed, the sample mixture can be adjusted, as needed, for further purification steps. For example, \n\n following low pH viral inactivation the pH of the sample mixture is typically adjusted to a more neutral pH, e.g., from about 5.0 to about 8.5 prior to continuing the purification process. Additionally, the mixture may be flushed with water for injection (WFI) to obtain a desired conductivity. In certain embodiments, the primary recovery will include one or more centrifugation steps to further clarify the sample matrix and thereby aid in purifying the anti-IL-12 antibodies. Centrifugation of the sample can be run at, for example, but not by way of limitation, 7,000 x g to approximately 12,750 x g. hi the context of large scale purification, such centrifugation can occur on-line with a flow rate set to achieve, for example, but not by way of limitation, a turbidity level of 150 NTU in the resulting supernatant. Such supernatant can then be collected for further purification. In certain embodiments, the primary recovery will include the use of one or more depth filtration steps to further clarify the sample matrix and thereby aid in purifying the anti-IL-12 antibodies. Depth filters contain filtration media having a graded density. Such graded density allows larger particles to be trapped near the surface of the filter while smaller particles penetrate the larger open areas at the surface of the filter, only to be trapped in the smaller openings nearer to the center of the filter. In certain embodiments the depth filtration step can be a delipid depth filtration step. Although certain embodiments employ depth filtration steps only during the primary recovery phase, other embodiments employ depth filters, including delipid depth filters, during one or more additional phases of purification. Non- limiting examples of depth filters that can be used in the context of the instant invention include the Cuno™ model 30/60ZA depth filters (3M Corp.), and 0.45/0.2μm Sartopore™ bi-layer filter cartridges.\n\n\n4.3 Ion Exchange Chromatography\n\n\nIn certain embodiments, the instant invention provides methods for producing a HCP-reduced antibody preparation from a mixture comprising an antibody and at least one HCP by subjecting the mixture to at least one ion exchange separation step such that an eluate comprising the antibody is obtained. Ion exchange separation includes any method by which two substances are separated based on the difference in their respective ionic charges, and can employ either cationic exchange material or anionic exchange material. \n\n The use of a cationic exchange material versus an anionic exchange material is based on the overall charge of the protein. Therefore, it is within the scope of this invention to employ an anionic exchange step prior to the use of a cationic exchange step, or a cationic exchange step prior to the use of an anionic exchange step. Furthermore, it is within the scope of this invention to employ only a cationic exchange step, only an anionic exchange step, or any serial combination of the two.\n\n\nIn performing the separation, the initial antibody mixture can be contacted with the ion exchange material by using any of a variety of techniques, e.g., using a batch purification technique or a chromatographic technique. For example, in the context of batch purification, ion exchange material is prepared in, or equilibrated to, the desired starting buffer. Upon preparation, or equilibration, a slurry of the ion exchange material is obtained. The antibody solution is contacted with the slurry to adsorb the antibody to be separated to the ion exchange material. The solution comprising the HCP(s) that do not bind to the ion exchange material is separated from the slurry, e.g., by allowing the slurry to settle and removing the supernatant. The slurry can be subjected to one or more wash steps. If desired, the slurry can be contacted with a solution of higher conductivity to desorb HCPs that have bound to the ion exchange material. In order to elute bound polypeptides, the salt concentration of the buffer can be increased. Ion exchange chromatography may also be used as an ion exchange separation technique. Ion exchange chromatography separates molecules based on differences between the overall charge of the molecules. For the purification of an antibody, the antibody must have a charge opposite to that of the functional group attached to the ion exchange material, e.g., resin, in order to bind. For example, antibodies, which generally have an overall positive charge in the buffer pH below its pi, will bind well to cation exchange material, which contain negatively charged functional groups.\n\n\nIn ion exchange chromatography, charged patches on the surface of the solute are attracted by opposite charges attached to a chromatography matrix, provided the ionic strength of the surrounding buffer is low. Elution is generally achieved by increasing the ionic strength (i.e., conductivity) of the buffer to compete with the solute for the charged sites of the ion exchange matrix. Changing the pH and thereby altering the charge of the solute is another way to achieve elution of the \n\n solute. The change in conductivity or pH may be gradual (gradient elution) or stepwise (step elution).\n\n\nAnionic or cationic substituents may be attached to matrices in order to form anionic or cationic supports for chromatography. Non-limiting examples of anionic exchange substituents include diethylaminoethyl (DEAE), quaternary aminoethyl(QAE) and quaternary amine(Q) groups. Cationic substitutents include carboxymethyl (CM), sulfoethyl(SE), sulfopropyl(SP), phosphate(P) and sulfonate(S). Cellulose ion exchange resins such as DE23™, DE32™, DE52™, CM-23™, CM- 32™, and CM-52™ are available from Whatman Ltd. Maidstone, Kent, U.K. SEPHADEX®-based and -locross-linked ion exchangers are also known. For example, DEAE-, QAE-, CM-, and SP- SEPHADEX® and DEAE-, Q-, CM-and S- SEPHAROSE® and SEPHAROSE® Fast Flow are all available from Pharmacia AB. Further, both DEAE and CM derivitized ethylene glycol-methacrylate copolymer such as TOYOPEARL™ DEAE-650S or M and TOYOPEARL™ CM-650S or M are available from Toso Haas Co., Philadelphia, Pa.\n\n\nA mixture comprising an antibody and impurities, e.g., HCP(s), is loaded onto an ion exchange column, such as a cation exchange column. For example, but not by way of limitation, the mixture can be loaded at a load of about 80 g protein/L resin depending upon the column used. An example of a suitable cation exchange column is a 80 cm diameter x 23 cm long column whose bed volume is about 116 L. The mixture loaded onto this cation column can subsequently washed with wash buffer (equilibration buffer). The antibody is then eluted from the column, and a first eluate is obtained.\n\n\nThis ion exchange step facilitates the capture of the antibody of interest while reducing impurities such as HCPs. hi certain aspects, the ion exchange column is a cation exchange column. For example, but not by way of limitation, a suitable resin for such a cation exchange column is CM HyperDF resin. These resins are available from commercial sources such as Pall Corporation. This cation exchange procedure can be carried out at or around room temperature.\n\n\n4.4 Ultrafiltration/Diafiltration\n\n\nCertain embodiments of the present invention employ ultrafiltration and/or diafiltration steps to further purify and concentration the anti-IL-12 antibody \n\n sample, Ultrafiltration is described in detail in, Microfiltration and Ultrafiltration: Principles and Applications, L. Zeman and A. Zydney (Marcel Dekker, Inc., New York, N. Y., 1996); and in: Ultrafiltration Handbook, Munir Cheryan (Technomic Publishing, 1986; ISBN No. 87762-456-9). A preferred filtration process is Tangential Flow Filtration as described in the Millipore catalogue entitled \"Pharmaceutical Process Filtration Catalogue\" pp. 177-202 (Bedford, Mass., 1995/96). Ultrafiltration is generally referred to filtration using filters with a pore size of smaller than 0.1 μm. By employing filters having such small pore size, the volume of the sample can be reduced through permeation of the sample buffer through the filter while the anti-IL-12 antibodies is be retained.\n\n\nDiafiltration is a method of using ultrafilters to remove and exchange salts, sugars, non-aqueous solvents, separation of free from bound species, removal of material of low molecular weight, or cause the rapid change of ionic and/or pH environments. Such microsolutes are removed most efficiently by adding solvent to the solution being ultrafiltered at a rate equal to the ultratfϊltration rate. This washes microspecies from the solution at a constant volume, effectively purifying the retained antibody. In certain embodiments of the present invention, a diafiltration step is employed to exchange the various buffers used in connection with the instant invention, optionally prior to further chromatography or other purification steps, as well as to remove impurities from the antibody preparations.\n\n\n4.5 Hydrophobic Interaction Chromatography\n\n\nThe present invention also features methods for producing a HCP- reduced antibody preparation from a mixture comprising an antibody and at least one HCP further comprising a hydrophobic interaction separation step. For example, a first eluate obtained from an ion exchange column can be subjected to a hydrophobic interaction material such that a second eluate having a reduced level of HCP is obtained. Hydrophobic interaction chromatography steps, such as those disclosed herein, are generally performed to remove protein aggregates, such as antibody aggregates, and process-related impurities. hi performing the separation, the sample mixture is contacted with the HIC material, e.g., using a batch purification technique or using a column. Prior to \n\n HIC purification it may be desirable to remove any chaotropic agents or very hydrophobic substances, e.g., by passing the mixture through a pre-column.\n\n\nFor example, in the context of batch purification, HIC material is prepared in or equilibrated to the desired equilibration buffer. A slurry of the HIC material is obtained. The antibody solution is contacted with the slurry to adsorb the antibody to be separated to the HIC material. The solution comprising the HCPs that do not bind to the HIC material is separated from the slurry, e.g., by allowing the slurry to settle and removing the supernatant. The slurry can be subjected to one or more washing steps. If desired, the slurry can be contacted with a solution of lower conductivity to desorb antibodies that have bound to the HIC material. In order to elute bound antibodies, the salt concentration can be decreased.\n\n\nWhereas ion exchange chromatography relies on the charges of the antibodies to isolate them, hydrophobic interaction chromatography uses the hydrophobic properties of the antibodies. Hydrophobic groups on the antibody interact with hydrophobic groups on the column. The more hydrophobic a protein is the stronger it will interact with the column. Thus the HIC step removes host cell derived impurities (e.g., DNA and other high and low molecular weight product- related species).\n\n\nHydrophobic interactions are strongest at high ionic strength, therefore, this form of separation is conveniently performed following salt precipitations or ion exchange procedures. Adsorption of the antibody to a HIC column is favored by high salt concentrations, but the actual concentrations can vary over a wide range depending on the nature of the antibody and the particular HIC ligand chosen. Various ions can be arranged in a so-called soluphobic series depending on whether they promote hydrophobic interactions (salting-out effects) or disrupt the structure of water (chaotropic effect) and lead to the weakening of the hydrophobic interaction. Cations are ranked in terms of increasing salting out effect as Ba\n++\n; Ca\n+\n*; Mg\n++\n; Li\n+\n ; Cs\n+\n ; Na\n+\n ; K\n+\n ; Rb\n+\n ; NH\n4\n \n+\n, while anions maybe ranked in terms of increasing chaotropic effect as P0\n~\n ; SO\n4\n \n\"\n ; CH\n3\nCO\n3\n \n\"\n ; Cl\n\"\n ; Bf ; NO\n3\n \n\"\n ; ClO\n4\n \n\"\n ; T ; SCN\n\"\n . In general, Na, K or NH\n4\n sulfates effectively promote ligand-protein interaction in HIC. Salts may be formulated that influence the strength of the interaction as given by the following relationship: (NH\n4\n)\n2\nSO\n4\n > Na\n2\nSO\n4\n > NaCl > NH\n4\nCl > NaBr > NaSCN. In general, salt concentrations of between about 0.75 and about 2 M ammonium sulfate or between about 1 and 4 M NaCl are useful. \n\n HIC columns normally comprise a base matrix (e.g., cross-linked agarose or synthetic copolymer material) to which hydrobobic ligands (e.g., alkyl or aryl groups) are coupled. A suitable HIC column comprises an agarose resin substituted with phenyl groups (e.g., a Phenyl Sepharose™ column). Many HIC columns are available commercially. Examples include, but are not limited to, Phenyl Sepharose™ 6 Fast Flow column with low or high substitution (Pharmacia LKB Biotechnology, AB, Sweden); Phenyl Sepharose™ High Performance column (Pharmacia LKB Biotechnology, AB, Sweden); Octyl Sepharose™ High Performance column (Pharmacia LKB Biotechnology, AB, Sweden); Fractogel™ EMD Propyl or Fractogel™ EMD Phenyl columns (E. Merck, Germany); Macro-Prep™ Mehyl or Macro-Prep™ t-Butyl Supports (Bio-Rad, California); WP HI-Propyl (C\n3\n)™ column (J. T. Baker, New Jersey); and Toyopearl™ ether, phenyl or butyl columns (TosoHaas, PA).\n\n\n4.6 Exemplary Purification Strategies\n\n\nhi certain embodiments, primary recovery can proceed by sequentially employing pH reduction, centrifugation, and filtration steps to remove cells and cell debris (including HCPs) from the production bioreactor harvest. For example, but not by way of limitation, a culture comprising antibodies, media, and cells can be subjected to pH inactivation using a pH of about 3.5 for approximately 1 hour. The pH reduction can be facilitated using known acid preparations such as citric acid, e.g., 3 M citric acid. Such pH reduction reduces and/or inactivates, if not completely eliminates, pH sensitive virus contaminants and precipitates some media/cell contaminants. Following such reduction, the pH is adjusted to about 4.9 or 5.0 using a base such as sodium hydroxide, e.g., 3 M sodium hydroxide, for about twenty to about forty minutes. This adjustment can occur at around 2O\n0\nC. hi certain embodiments, the pH adjusted culture then centrifuged at approximately 7000 x g to approximately 11,000 x g. hi certain embodiments, the resulting sample supernatant is then passed through a filter train comprising multiple depth filters, hi certain embodiments, the filter train comprises around twelve 16-inch Cuno™ model\n\n\n30/60ZA depth filters (3M Corp.) and around three round filter housings fitted with three 30-inch 0.45/0.2 μm Sartopore™ 2 filter cartridges (Sartorius). The clarified supernatant is collected in a vessel such as a pre-sterilized harvest vessel and held at \n\n approximately 8\n0\nC. This temperature is then adjusted to approximately 2O\n0\nC prior to the capture chromatography step or steps outlined below. It should be noted that one skilled in the art may vary the conditions recited above and still be within the scope of the present invention. The clarified supernatant can then be further purified using a cation exchange column. In certain embodiments, the equilibrating buffer used in the cation exchange column is a buffer having a pH of about 5.0. An example of a suitable buffer is about 210 mM sodium acetate, pH 5.0. Following equilibration, the column is loaded with sample prepared from the primary recovery step above. The column is packed with an cation exchange resin, such as CM Sepharose™ Fast Flow from GE Healthcare. The column is then washed using the equilibrating buffer. The column is next subjected to an elution step using a buffer having a greater ionic strength as compared to the equilibrating or wash buffer. For example, a suitable elution buffer can be about 790 mM sodium acetate, pH 5.0. The anti-IL-12 antibodies will be eluted and can be monitored using a UV spectrophotometer set at OD\n2\nscnm- In a particular example, elution collection can be from upside 3 OD\n280nm\n to downside 8 OD\n28\no\nnm\n- It should be understood that one skilled in the art may vary the conditions and yet still be within the scope of the invention.\n\n\nIn certain embodiments the clarified supernatant obtained from the primary recovery is instead further purified using an anion exchange column. A non- limiting example of a suitable column for this step is a 60 cm diameter x 30 cm long column whose bed volume is about 85 L. The column is packed with an anion exchange resin, such as Q Sepharose™ Fast Flow from GE Healthcare. The column can be equilibrated using about seven column volumes of an appropriate buffer such as Tris/sodium chloride. An example of suitable conditions are 25 mM Tris, 50 mM sodium chloride at pH 8.0. Again, a skill artisan may vary the conditions but still be within the scope of the present invention. The column is loaded with the collected sample from the primary recovery step outlined above. In another aspect, the column is loaded from the eluate collected during cation exchange. Following the loading of the column, the column is washed with the equilibration buffer (e.g. , the Tris/sodium chloride buffer). The flow-through comprising the anti-IL-12 antibodies can be monitored using a UV spectrophotometer at OD\n2\nsonm- This anion exchange step reduces process related impurities such as nucleic acids like DNA, and host cell proteins. The separation occurs due to the fact that the antibodies of interest do not \n\n interact with nor bind to the solid phase of the column, e.g., to the Q Sepharose™, but many impurities do interact with and bind to the column's solid phase. The anion exchange can be performed at about 12\n0\nC.\n\n\nIn certain embodiments, the cation exchange or anion exchange eluate, depending on which ion exchange step is employed first, is next filtered using, e.g., a 16 inch Cuno™ delipid filter. This filtration, using the delipid filter, can be followed by, e.g., a 30-inch 0.45/0.2 μm Sartopore™ bi-layer filter cartridge. The ion exchange elution buffer can be used to flush the residual volume remaining in the filters and prepared for ultrafiltration/diafiltration. In order to accomplish the ultratfiltration/diafiltration step, the filtration media is prepared in a suitable buffer, e.g., 20 mM sodium phosphate, pH 7.0. A salt such as sodium chloride can be added to increase the ionic strength, e.g., 100 mM sodium chloride. This ultrafiltration/diafiltration step serves to concentrate the anti-IL-12 antibodies, remove the sodium acetate and adjust the pH. Commercial filters are available to effectuate this step. For example, Millipore manufactures a 30 kD molecular weight cut-off (MWCO) cellulose ultrafilter membrane cassette. This filtration procedure can be conducted at or around room temperature.\n\n\nIn certain embodiments, the sample from the capture filtration step above is subjected to a second ion exchange separation. Preferably this second ion exchange separation will involve separation based on the opposite charge of the first ion exchange separation. For example, if an anion exchange step is employed after primary recovery, the second ion exchange chromatographic step be a cationic exchange step. Conversely, if the primary recovery step was followed by a cationic exchange step, that step would be followed by an anionic exchange step. In certain embodiments the first ion exchange elute can be subjected directly to the second ion exchange chromatographic step where the first ion exchange elute is adjusted to the appropriate buffer conditions. Suitable anionic and cationic separation materials and conditions are described above.\n\n\nIn certain embodiments of the instant invention the sample containing anti-IL-12 antibodies will be further processed using a hydrophobic interaction separation step. A non-limiting example of a suitable column for such a step is an 80 cm diameter x 15 cm long column whose bed volume is about 75 L, which is packed with an appropriate resin used for HIC such as, but not limited to, Phenyl HP Sepharose™ from Amersham Biosciences, Upsala, Sweden. The flow-through \n\n preparation obtained from the previous anion exchange chromatography step comprising the antibodies of interest can be diluted with an equal volume of around 1.7 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0. This then can be subjected to filtration using a 0.45/0.2 μm Sartopore™ 2 bi-layer filter, or its equivalent. In certain embodiments, the hydrophobic chromatography procedure involves two or more cycles.\n\n\nIn certain embodiments, the HIC column is first equilibrated using a suitable buffer. A non-limiting example of a suitable buffer is 0.85 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0. One skilled in the art can vary the equilibrating buffer and still be within the scope of the present invention by altering the concentrations of the buffering agents and/or by substituting equivalent buffers. In certain embodiments the column is then loaded with an anion exchange flow- through sample and washed multiple times, e.g., three times, with an appropriate buffer system such as ammonium sulfate/sodium phosphate. An example of a suitable buffer system includes 1.1 M ammonium sulfate, 50 mM sodium phosphate buffer with a pH of around 7.0. Optionally, the column can undergo further wash cycles. For example, a second wash cycle can include multiple column washes, e.g., one to seven times, using an appropriate buffer system. A non-limiting example of a suitable buffer system includes 0.85 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0. In one aspect, the loaded column undergoes yet a third wash using an appropriate buffer system. The column can be washed multiple times, e.g., one to three times, using a buffer system such as 1.1 M ammonium sulfate, 50 mM sodium phosphate at a pH around 7.0. Again, one skilled in the art can vary the buffering conditions and still be within the scope of the present invention The column is eluted using an appropriate elution buffer. A suitable example of such an elution buffer is 0.5 M ammonium sulfate, 15 mM sodium phosphate at a pH around 7.0. The antibodies of interest can be detected and collected using a conventional spectrophotometer from the upside at 3 OD\n280 nm\n to downside of peak at 3 OD\n28\nO nm- In certain aspects of the invention, the eluate from the hydrophobic chromatography step is subjected to filtration for the removal of viral particles, including intact viruses, if present. A non-limiting example of a suitable filter is the Ultipor DV50™ filter from Pall Corporation. Other viral filters can be used in this filtration step and are well known to those skilled in the art. The HIC eluate is passed \n\n through a pre-wetted filter of about 0.1 μm and a 2 x 30-inch Ultipor DV50™ filter train at around 34 psig. In certain embodiments, following the filtration process, the filter is washed using, e.g., the HIC elution buffer in order to remove any antibodies retained in the filter housing. The filtrate can be stored in a pre-sterilized container at around 12\n0\nC.\n\n\nIn a certain embodiments, the filtrate from the above is again subjected to ultrafiltration/diafiltration. This step is important if a practitioner's end point is to use the antibody in a, e.g., pharmaceutical formulation. This process, if employed, can facilitate the concentration of antibody, removal of buffering salts previously used and replace it with a particular formulation buffer. In certain embodiments, continuous diafiltration with multiple volumes, e.g., two volumes, of a formulation buffer is performed. A non-limiting example of a suitable formulation buffer is 5 mM methionine, 2% mannitol, 0.5% sucrose, pH 5.9 buffer (no Tween). Upon completion of this diavolume exchange the antibodies are concentrated. Once a predetermined concentration of antibody has been achieved, then a practitioner can calculate the amount of 10% Tween that should be added to arrive at a final Tween concentration of about 0.005% (v/v).\n\n\nCertain embodiments of the present invention will include further purification steps. Examples of additional purification procedures which can be performed prior to, during, or following the ion exchange chromatography method include ethanol precipitation, isoelectric focusing, reverse phase HPLC, chromatography on silica, chromatography on heparin Sepharose™, further anion exchange chromatography and/or further cation exchange chromatography, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography (e.g., using protein A, protein G, an antibody, a specific substrate, ligand or antigen as the capture reagent).\n\n\nIn certain embodiments of the present invention, the anti-IL-12 antibody is an IgAi, IgA\n2\n, IgD, IgE, IgGi, IgG\n2\n, IgG\n3\n, IgG\n4\n, or IgM isotype antibody comprising the heavy and light chain variable region sequences outlined in Figure 1. In preferred embodiments, the anti-IL-12 antibody is an IgGi, IgG\n2\n, IgG\n3\n or IgG\n4\n isotype antibody comprising the heavy and light chain variable region sequences outlined in Figure 1, more preferably the anti-IL-12 antibody is an IgGi antibody comprising the heavy and light chain variable region sequences outlined in Figure 1. \n\n 5. Methods of Assaying Sample Purity\n\n\nThe present invention also provides methods for determining the residual levels of host cell protein (HCP) concentration in the isolated/purified antibody composition. As described above, HCPs are desirably excluded from the final target substance product, the anti-IL-12 antibody. Exemplary HCPs include proteins originating from the source of the antibody production. Failure to identify and sufficiently remove HCPs from the target antibody may lead to reduced efficacy and/or adverse subject reactions. As used herein, the term \"HCP ELISA\" refers to an ELISA where the second antibody used in the assay is specific to the HCPs produced from cells, e.g., CHO cells, used to generate the antibody, anti-IL-12 antibody. The second antibody may be produced according to conventional methods known to those of skill in the art. For example, the second antibody may be produced using HCPs obtained by sham production and purification runs, i.e., the same cell line used to produce the antibody of interest is used, but the cell line is not transfected with antibody DNA. In an exemplary embodiment, the second antibody is produced using HPCs similar to those expressed in the cell expression system of choice, i.e., the cell expression system used to produce the target antibody. Generally, HCP ELISA comprises sandwiching a liquid sample comprising HCPs between two layers of antibodies, i.e., a first antibody and a second antibody. The sample is incubated during which time the HCPs in the sample are captured by the first antibody, for example, but not limited to goat anti-CHO, affinity purified (Cygnus). A labeled second antibody, or blend of antibodies, specific to the HCPs produced from the cells used to generate the antibody, e.g., anti-CHO HCP Biotinylated, is added, and binds to the HCPs within the sample. In certain embodiments the first and second antibodies are polyclonal antibodies. In certain aspects the first and second antibodies are blends of polyclonal antibodies raised against HCPs, for example, but not limited to Biotinylated goat anti Host Cell Protein Mixture 599/626/748. The amount of HCP contained in the sample is determined using the appropriate test based on the label of the second antibody.\n\n\nHCP ELISA may be used for determining the level of HCPs in an antibody composition, such as an eluate or flow-through obtained using the process \n\n described in section III above. The present invention also provides a composition comprising an antibody, wherein the composition has no detectable level of HCPs as determined by an HCP Enzyme Linked Immunosorbent Assay (\"ELISA\").\n\n\n6. Further Modifications\n\n\nThe anti-IL-12 antibodies of the present invention can be modified. In some embodiments, the anti-IL-12 antibodies or antigen binding fragments thereof, are chemically modified to provide a desired effect. For example, pegylation of antibodies and antibody fragments of the invention may be carried out by any of the pegylation reactions known in the art, as described, e.g., in the following references: Focus on Growth Factors 3:4-10 (1992); EP 0 154 316; and EP 0401 384, each of which is incorporated by reference herein in its entirety, hi one aspect, the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer). A suitable water-soluble polymer for pegylation of the antibodies and antibody fragments of the invention is polyethylene glycol (PEG). As used herein, \"polyethylene glycol\" is meant to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (Cl-ClO) alkoxy- or aryloxy- polyethylene glycol. Methods for preparing pegylated antibodies and antibody fragments of the invention will generally comprise the steps of (a) reacting the antibody or antibody fragment with polyethylene glycol, such as a reactive ester or aldehyde derivative of PEG, under suitable conditions whereby the antibody or antibody fragment becomes attached to one or more PEG groups, and (b) obtaining the reaction products. It will be apparent to one of ordinary skill in the art to select the optimal reaction conditions or the acylation reactions based on known parameters and the desired result.\n\n\nPegylated antibodies and antibody fragments may generally be used to treat IL-12-related disorders of the invention by administration of the anti-IL-12 antibodies and antibody fragments described herein. Generally the pegylated antibodies and antibody fragments have increased half-life, as compared to the nonpegylated antibodies and antibody fragments. The pegylated antibodies and \n\n antibody fragments may be employed alone, together, or in combination with other pharmaceutical compositions.\n\n\nAn antibody or antibody portion of the invention can be derivatized or linked to another functional molecule {e.g., another peptide or protein). Accordingly, the antibodies and antibody portions of the invention are intended to include derivatized and otherwise modified forms of the human anti-hIL-12 antibodies described herein, including immunoadhesion molecules. For example, an antibody or antibody portion of the invention can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g. , a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate associate of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).\n\n\nOne type of derivatized antibody is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m- maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate). Such linkers are available from Pierce Chemical Company, Rockford, IL.\n\n\nUseful detectable agents with which an antibody or antibody portion of the invention may be derivatized include fluorescent compounds. Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin and the like. An antibody may also be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like. When an antibody is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product. For example, when the detectable agent horseradish peroxidase is present, the addition of hydrogen peroxide and diaminobenzidine leads to a colored reaction product, which is detectable. An antibody may also be derivatized with biotin, and detected through indirect measurement of avidin or streptavidin binding. \n\n 7. Pharmaceutical Compositions\n\n\nThe antibodies and antibody-portions of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject. Typically, the pharmaceutical composition comprises an antibody or antibody portion of the invention and a pharmaceutically acceptable carrier. As used herein, \"pharmaceutically acceptable carrier\" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it is desirable to include isotonic agents, e.g., sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody or antibody portion.\n\n\nThe antibodies and antibody-portions of the invention can be incorporated into a pharmaceutical composition suitable for parenteral administration. The antibody or antibody-portions can be prepared as an injectable solution containing, e.g., 0.1-250 mg/mL antibody. The injectable solution can be composed of either a liquid or lyophilized dosage form in a flint or amber vial, ampule or pre- filled syringe. The buffer can be L-histidine approximately 1-50 mM, (optimally 5-10 mM), at pH 5.0 to 7.0 (optimally pH 6.0). Other suitable buffers include but are not limited to sodium succinate, sodium citrate, sodium phosphate or potassium phosphate. Sodium chloride can be used to modify the toxicity of the solution at a concentration of 0-300 mM (optimally 150 mM for a liquid dosage form).\n\n\nCryoprotectants can be included for a lyophilized dosage form, principally 0-10% sucrose (optimally 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose. Bulking agents can be included for a lyophilized dosage form, principally 1- 10% mannitol (optimally 24%). Stabilizers can be used in both liquid and lyophilized dosage forms, principally 1-50 mM L-methionine (optimally 5-10 mM). Other suitable bulking agents include glycine, arginine, can be included as 0-0.05% polysorbate-80 (optimally 0.005-0.01%). Additional surfactants include but are not limited to polysorbate 20 and BRIJ surfactants. \n\n In one aspect, the pharmaceutical composition includes the antibody at a dosage of about 0.01 mg/kg-10 mg/kg. In another aspect, the dosages of the antibody include approximately 1 mg/kg administered every other week, or approximately 0.3 mg/kg administered weekly. A skilled practitioner can ascertain the proper dosage and regime for administering to a subject.\n\n\nThe compositions of this invention may be in a variety of forms. These include, e.g., liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The form depends on, e.g., the intended mode of administration and therapeutic application. Typical compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies. One mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In one aspect, the antibody is administered by intravenous infusion or injection. In another aspect, the antibody is administered by intramuscular or subcutaneous injection.\n\n\nTherapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the active compound (i.e., antibody or antibody portion) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile, lyophilized powders for the preparation of sterile injectable solutions, the methods of preparation are vacuum drying and spray-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, e.g., by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.\n\n\nProlonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, e.g., monostearate salts and gelatin. The antibodies and antibody-portions of the present invention can be administered by a variety of methods known in the art, one route/mode of \n\n administration is subcutaneous injection, intravenous injection or infusion. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978, the entire teaching of which is incorporated herein by reference.\n\n\nIn certain aspects, an antibody or antibody portion of the invention may be orally administered, e.g., with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To administer a compound of the invention by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.\n\n\nSupplementary active compounds can also be incorporated into the compositions. In certain aspects, an antibody or antibody portion of the invention is co-formulated with and/or co-administered with one or more additional therapeutic agents that are useful for treating disorders in which IL- 12 activity is detrimental. For example, an anti-hIL-12 antibody or antibody portion of the invention may be co- formulated and/or co-administered with one or more additional antibodies that bind other targets (e.g., antibodies that bind other cytokines or that bind cell surface molecules). Furthermore, one or more antibodies of the invention may be used in combination with two or more of the foregoing therapeutic agents. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies. It will be appreciated by the skilled practitioner that when the \n\n antibodies of the invention are used as part of a combination therapy, a lower dosage of antibody may be desirable than when the antibody alone is administered to a subject {e.g., a synergistic therapeutic effect may be achieved through the use of combination therapy which, in turn, permits use of a lower dose of the antibody to achieve the desired therapeutic effect).\n\n\nIt should be understood that the antibodies of the invention or antigen binding portion thereof can be used alone or in combination with an additional agent, e.g., a therapeutic agent, said additional agent being selected by the skilled artisan for its intended purpose. For example, the additional agent can be a therapeutic agent art- recognized as being useful to treat the disease or condition being treated by the antibody of the present invention. The additional agent also can be an agent which imparts a beneficial attribute to the therapeutic composition, e.g., an agent which effects the viscosity of the composition.\n\n\nIt should further be understood that the combinations which are to be included within this invention are those combinations useful for their intended purpose. The agents set forth below are illustrative and not intended to be limited. The combinations which are part of this invention can be the antibodies of the present invention and at least one additional agent selected from the lists below. The combination can also include more than one additional agent, e.g., two or three additional agents if the combination is such that the formed composition can perform its intended function.\n\n\nSome combinations are non-steroidal anti-inflammatory drug(s) also referred to as NSAIDS which include drugs like ibuprofen. Other combinations are corticosteroids including prednisolone; the well known side-effects of steroid use can be reduced or even eliminated by tapering the steroid dose required when treating patients in combination with the anti-IL-12 antibodies of this invention. Non-limiting examples of therapeutic agents for rheumatoid arthritis with which an antibody, or antibody portion, of the invention can be combined to include the following: cytokine suppressive anti-inflammatory drug(s) (CSAEDs); antibodies to or antagonists of other human cytokines or growth factors, for example, TNF, LT, IL-I, IL-2, IL-6, IL-7, IL- 8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, or antigen binding portions thereof, can be combined with antibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, \n\n CD69, CD80 (B7.1), CD86 (B7.2), CD90, or their ligands including CD 154 (gp39 or CD40L).\n\n\nSome combinations of therapeutic agents may interfere at different points in the autoimmune and subsequent inflammatory cascade; examples include TNF antagonists like chimeric, humanized or human TNF antibodies, D2E7, (U.S. application Ser. No. 08/599,226 filed Feb. 9, 1996, the entire teaching of which is incorporated herein by reference), cA2 (Remicade™), CDP 571, anti-TNF antibody fragments (e.g., CDP870), and soluble p55 or p75 TNF receptors, derivatives thereof, (p75TNFRIgG (Enbrel™) or p55TNFRlgG (Lenercept), soluble IL-13 receptor (sIL- 13), and also TNFα converting enzyme (TACE) inhibitors; similarly IL-I inhibitors (e.g., Interleukin-1 -converting enzyme inhibitors, such as Vx740, or IL-IRA, etc.) may be effective for the same reason. Other combinations include Interleukin 11, anti-P7s and p-selectin glycoprotein ligand (PSGL). Yet other combinations involve other key players of the autoimmune response which may act parallel to, dependent on or in concert with IL- 12 function; especially included are IL- 18 antagonists including IL- 18 antibodies or soluble IL- 18 receptors, or IL-18 binding proteins. It has been shown that IL- 12 and IL- 18 have overlapping but distinct functions and a combination of antagonists to both may be most effective. Yet another combination includes non-depleting anti-CD4 inhibitors. Yet other combinations include antagonists of the co-stimulatory pathway CD80 (B7.1 ) or CD86 (B7.2) including antibodies, soluble receptors or antagonistic ligands.\n\n\nThe antibodies of the invention, or antigen binding portions thereof, may also be combined with agents, such as methotrexate, 6-MP, azathioprine sulphasalazine, mesalazine, olsalazine chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate (intramuscular and oral), azathioprine, cochicine, corticosteroids (oral, inhaled and local injection), β-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines (theophylline, aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adensosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signalling by proinflammatory cytokines such as TNFα or IL-I (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-lβ converting enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein ligand (PSGL), \n\n TNFα converting enzyme (TACE) inhibitors, T-cell signaling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6- mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors and the derivatives p75TNFRIgG (Enbrel.TM.)and p55TNFRIgG (Lenercept), sIL-1 RI, sIL- IRII, sIL-6R, soluble IL-13 receptor (sIL-13)) and anti-inflammatory cytokines (e.g., IL-4, IL-IO, IL-11, IL-13 and TGFβ). Some combinations include methotrexate or leflunomide and in moderate or severe rheumatoid arthritis cases, cyclosporine.\n\n\nNon-limiting examples of therapeutic agents for inflammatory bowel disease with which an antibody, or antibody portion, of the invention can be combined include the following: budenoside, epidermal growth factor, corticosteroids, cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole, lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide, antioxidants, thromboxane inhibitors, IL-I receptor antagonists, anti-IL- lα monoclonal antibodies, anti-IL-6 monoclonal antibodies, growth factors, elastase inhibitors, pyridinyl-imidazole compounds, antibodies to or antagonists of other human cytokines or growth factors, e.g., TNF, LT, IL-I, IL-2, IL-6, IL-7, IL-8, IL-15, IL- 16, IL- 18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, or antigen binding portions thereof, can be combined with antibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands. The antibodies of the invention, or antigen binding portions thereof, may also be combined with agents, such as methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, e.g., ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signaling by proinflammatory cytokines such as TNFα or IL-I (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL- lβ converting enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein ligand (PSGL), TNFα converting enzyme inhibitors, T-cell signaling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors, sIL-lRI, sIL-lRII, sIL-6R, soluble IL-13 receptor (sIL-13)) and anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-11, IL-13 and TGFβ). \n\n Examples of therapeutic agents for Crohn's disease in which an antibody or an antigen binding portion can be combined include the following: TNF antagonists, e.g., anti-TNF antibodies, D2E7 (U.S. application Ser. No. 08/599,226, filed Feb. 9, 1996, the entire teaching of which is incorporated herein by reference), cA2 (Remicade™), CDP 571, anti-TNF antibody fragments (e.g., CDP870), TNFR-Ig constructs(p75TNFRIgG (Enbrel™) and p55TNFRIgG (Lenercept)), anti-P7s, p- selectin glycoprotein ligand (PSGL), soluble IL- 13 receptor (sIL-13), and PDE4 inhibitors. Antibodies of the invention or antigen binding portions thereof, can be combined with corticosteroids, e.g., budenoside and dexamethasone. Antibodies of the invention or antigen binding portions thereof, may also be combined with agents such as sulfasalazine, 5-aminosalicylic acid and olsalazine, and agents which interfere with synthesis or action of proinflammatory cytokines such as IL-I, e.g., IL-I converting enzyme inhibitors (e.g., Vx740) and IL-lra. Antibodies of the invention or antigen binding portion thereof may also be used with T cell signaling inhibitors, e.g., tyrosine kinase inhibitors 6-mercaptopurines. Antibodies of the invention or antigen binding portions thereof, can be combined with IL-11.\n\n\nNon-limiting examples of therapeutic agents for multiple sclerosis with which an antibody, or antibody portion, of the invention can be combined include the following: corticosteroids, prednisolone, methylprednisolone, azathioprine, cyclophosphamide, cyclosporine, methotrexate, 4-aminopyridine, tizanidine, IFNβla (Avonex; Biogen), IFNβlb (Betaseron; Chiron/Berlex), Copolymer 1 (Cop-1, Copaxone, Teva Pharmaceutical Industries, Inc.), hyperbaric oxygen, intravenous immunoglobulin, clabribine, antibodies to or antagonists of other human cytokines or growth factors, e.g., TNF, LT, IL-I, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, or antigen binding portions thereof, can be combined with antibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. The antibodies of the invention, or antigen binding portions thereof, may also be combined with agents, such as methotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSADDs, e.g., ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adensosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signaling by proinflammatory cytokines such as TNFα or IL-I (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL- lβ converting \n\n enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein ligand (PSGL), TACE inhibitors, T-cell signaling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaρtopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors, sIL-1 RI, sIL-1 RII, sIL-6R, soluble IL- 13 receptor (sIL-13)) and anti-inflammatory cytokines (e.g., IL-4, IL-10, IL- 13 and TGFβ).\n\n\nExamples of therapeutic agents for multiple sclerosis in which the antibody or antigen binding portion thereof can be combined to include IFNβ, e.g., IFNβ Ia and IFNβ Ib, Copaxone, corticosteroids, IL-I inhibitors, TNF inhibitors, and antibodies to CD40 ligand and CD80.\n\n\nThe pharmaceutical compositions of the invention may include a \"therapeutically effective amount\" or a \"prophylactically effective amount\" of an antibody or antibody portion of the invention. A \"therapeutically effective amount\" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the antibody or antibody portion may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A \"prophylactically effective amount\" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.\n\n\nDosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. In certain embodiments it is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit comprising a predetermined quantity of active compound calculated to produce the \n\n desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.\n\n\nAn exemplary, non-limiting range for a therapeutically or prophylactically effective amount of an antibody or antibody portion of the invention is 0.01-20 mg/kg, or 1-10 mg/kg, or 0.3-1 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.\n\n\n8. Uses of the Antibodies of the Invention\n\n\n8.1. Uses Generally\n\n\nGiven their ability to bind to IL- 12, the anti-IL-12 antibodies, or portions thereof, of the invention can be used to detect IL- 12, in one aspect, hIL-12 (e.g., in a sample matrix, in one aspect, a biological sample, such as serum or plasma), using a conventional immunoassay, such as an enzyme linked immunosorbent assays (ELISA), an radioimmunoassay (RIA) or tissue immunohistochemistry. The invention provides a method for detecting IL- 12 in a biological sample comprising contacting a sample with an antibody, or antibody portion, of the invention and detecting either the antibody (or antibody portion) bound to IL- 12 or unbound antibody (or antibody portion), to thereby detect IL- 12 in the sample. The antibody is directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic \n\n group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include \n125\n 1, \n131\n 1, \n35\n S, or \n3\n H. Detection of IL- 12 in a sample may be useful in a diagnostic context, for example in the diagnosis of a condition associated with increased IL-12, and/or may be useful in identifying a subject who may benefit from treatment with an anti-IL-12 antibody.\n\n\nAlternative to labeling the antibody, IL-12 can be assayed in a sample by a competition immunoassay utilizing, e.g. , rhIL-12 standards labeled with a detectable substance and an unlabeled anti-IL-12 antibody, such as an anti-hIL-12 antibody. In this assay, the sample, the labeled rhIL-12 standards, and the anti-hIL-12 antibody are combined and the amount of labeled rhIL-12 standard bound to the unlabeled antibody is determined. The amount of ML- 12 in the sample is inversely proportional to the amount of labeled rhIL-12 standard bound to the anti-hIL-12 antibody.\n\n\nThe antibodies and antibody portions of the invention are capable of neutralizing IL-12 activity in vitro and in vivo, in one aspect, a hIL-12 activity. Accordingly, the antibodies and antibody portions of the invention can be used to inhibit IL-12 activity, e.g., in a cell culture containing IL-12, in human subjects or in other mammalian subjects having IL-12 with which an antibody of the invention cross-reacts (e.g., primates such as baboon, cynomolgus and rhesus). In a one aspect, the invention provides an isolated human antibody, or antigen-binding portion thereof, that neutralizes the activity of human IL-12, and at least one additional primate IL-12 selected from the group consisting of baboon IL-12, marmoset IL-12, chimpanzee IL- 12, cynomolgus IL-12 and rhesus IL-12, but which does not neutralize the activity of the mouse IL-12. In one aspect, the IL-12 is human IL-12. For example, in a cell culture containing, or suspected of containing hIL-12, an antibody or antibody portion of the invention can be added to the culture medium to inhibit hIL-12 activity in the culture.\n\n\nIn another aspect, the invention provides a method for inhibiting IL-12 activity in a subject suffering from a disorder in which IL-12 activity is detrimental. IL-12 has been implicated in the pathophysiology of a wide variety of disorders (Windhagen et al., (1995) J. Exp. Med. 182: 1985-1996; Morita et al. (1998) Arthritis \n\n and Rheumatism. 41: 306-314; Bucht et al, (1996) Clin. Exp. Immunol. 103: 347- 367; Fais et al. (1994) J. Interferon Res. 14:235-238; Pyrronchi et al, (1997) Am. J. Path. 150:823-832; Monteleone et al, (1997) Gastroenterology. 112:1169-1178, and Berrebi et al, (1998) Am. J. Path 152:667-672; Pyrronchi et al. (1997) Am. J. Path. 150:823-832, the entire teachings of which are incorporated herein by reference). The invention provides methods for inhibiting IL- 12 activity in a subject suffering from such a disorder, which method comprises administering to the subject an antibody or antibody portion of the invention such that IL- 12 activity in the subject is inhibited. In one aspect, the IL- 12 is human IL- 12 and the subject is a human subject. Alternatively, the subject can be a mammal expressing IL- 12 with which an antibody of the invention cross-reacts. Still further the subject can be a mammal into which has been introduced hIL-12 (e.g., by administration of hIL-12 or by expression of an hlL- 12 transgene). An antibody of the invention can be administered to a human subject for therapeutic purposes. Moreover, an antibody of the invention can be administered to a non-human mammal expressing a IL- 12 with which the antibody cross-reacts for veterinary purposes or as an animal model of human disease. Regarding the latter, such animal models may be useful for evaluating the therapeutic efficacy of antibodies of the invention (e.g., testing of dosages and time courses of administration) . As used herein, the phrase \"a disorder in which IL- 12 activity is detrimental\" is intended to include diseases and other disorders in which the presence of IL-12 in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor that contributes to a worsening of the disorder. Accordingly, a disorder in which IL-12 activity is detrimental is a disorder in which inhibition of IL-12 activity is expected to alleviate the symptoms and/or progression of the disorder. Such disorders may be evidenced, e.g., by an increase in the concentration of IL-12 in a biological fluid of a subject suffering from the disorder (e.g., an increase in the concentration of IL-12 in serum, plasma, synovial fluid, etc. of the subject), which can be detected, e.g., using an anti-IL- 12 antibody as described above. There are numerous examples of disorders in which IL-12 activity is detrimental. In one aspect, the antibodies or antigen binding portions thereof, can be used in therapy to treat the diseases or disorders described herein. In another aspect, the antibodies or antigen binding portions thereof, can be used for the manufacture of a medicine for treating the \n\n diseases or disorders described herein. The use of the antibodies and antibody portions of the invention in the treatment of a few non-limiting specific disorders is discussed further below.\n\n\nInterleukin 12 plays a critical role in the pathology associated with a variety of diseases involving immune and inflammatory elements. These diseases include, but are not limited to, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, atopic dermatitis, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II,\n\n\nSchmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthopathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthopathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anemia, Coombs positive haemolytic anaemia, acquired pernicious anemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung \n\n disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjodgren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, idiopathic leucopenia, autoimmune neutropenia, renal disease NOS, glomerulonephritides, microscopic vasulitis of the kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), insulin-dependent diabetes mellitus, sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis and vitiligo. The human antibodies, and antibody portions of the invention can be used to treat autoimmune diseases, in particular those associated with inflammation, including, rheumatoid spondylitis, allergy, autoimmune diabetes, and autoimmune uveitis. In certain aspects, the antibodies of the invention or antigen-binding portions thereof, are used to treat rheumatoid arthritis, Crohn's disease, multiple sclerosis, insulin dependent diabetes mellitus and psoriasis. \n\n 8.2 Use in Rheumatoid Arthritis\n\n\nInterleukin-12 has been implicated in playing a role in inflammatory diseases such as rheumatoid arthritis. Inducible IL-12p40 message has been detected in synovia from rheumatoid arthritis patients and IL- 12 has been shown to be present in the synovial fluids from patients with rheumatoid arthritis (see, e.g., Morita et al., (1998) Arthritis and Rheumatism 41: 306-314, the entire teaching of which is incorporated herein by reference). IL- 12 positive cells have been found to be present in the sublining layer of the rheumatoid arthritis synovium. The human antibodies, and antibody portions of the invention can be used to treat, e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, Lyme arthritis, rheumatoid spondylitis, osteoarthritis and gouty arthritis. Typically, the antibody, or antibody portion, is administered systemically, although for certain disorders, local administration of the antibody or antibody portion may be beneficial. An antibody, or antibody portion, of the invention also can be administered with one or more additional therapeutic agents useful in the treatment of autoimmune diseases.\n\n\nIn the collagen induced arthritis (CIA) murine model for rheumatoid arthritis, treatment of mice with an anti-IL-12 mAb (rat anti-mouse IL- 12 monoclonal antibody, C 17.15) prior to arthritis profoundly suppressed the onset, and reduced the incidence and severity of disease. Treatment with the anti-IL-12 mAb early after onset of arthritis reduced severity, but later treatment of the mice with the anti-IL-12 mAb after the onset of disease had minimal effect on disease severity.\n\n\n8.3 Use in Crohn's Disease\n\n\nInterleukin-12 also plays a role in the inflammatory bowel disease, Crohn's disease. Increased expression of IFN-γ and IL- 12 occurs in the intestinal mucosa of patients with Crohn's disease (see, e.g., Fais et al, (1994) J. Interferon Res.\n\n\n14: 235-238; Pyrronchi et al, (1997) Amer. J. Pathol. 150: 823-832; Monteleone et al, (1997) Gastroenterology 112: 1169-1178; Berrebi et al, (1998) Amer. J. Pathol.\n\n\n152: 667-672, the entire teachings of which are incorporated herein by reference). Anti-IL-12 antibodies have been shown to suppress disease in mouse models of colitis, e.g., TNBS induced colitis IL-2 knockout mice, and recently in IL-10 knock- \n\n out mice. Accordingly, the antibodies, and antibody portions, of the invention, can be used in the treatment of inflammatory bowel diseases.\n\n\n8.4 Use in Multiple Sclerosis\n\n\nInterleukin-12 has been implicated as a key mediator of multiple sclerosis. Expression of the inducible IL- 12 p40 message or IL- 12 itself can be demonstrated in lesions of patients with multiple sclerosis (Windhagen et al, (1995) J. Exp. Med 182: 1985-1996, Drulovic et al, (1997) J. Neurol. Sci. 147:145-150, the entire teachings of which are incorporated herein by reference). Chronic progressive patients with multiple sclerosis have elevated circulating levels of IL-12.\n\n\nInvestigations with T-cells and antigen presenting cells (APCs) from patients with multiple sclerosis revealed a self-perpetuating series of immune interactions as the basis of progressive multiple sclerosis leading to a ThI -type immune response. Increased secretion of EFN-γ from the T cells led to increased IL-12 production by APCs, which perpetuated the cycle leading to a chronic state of a ThI -type immune activation and disease (Balashov et al, (1997) Proc. Natl. Acad. Sci. 94: 599-603, the entire teaching of which is incorporated herein by reference). The role of IL-12 in multiple sclerosis has been investigated using mouse and rat experimental allergic encephalomyelitis (EAE) models of multiple sclerosis. In a relapsing-remitting EAE model of multiple sclerosis in mice, pretreatment with anti-IL-12 mAb delayed paralysis and reduced clinical scores. Treatment with anti-IL-12 mAb at the peak of paralysis or during the subsequent remission period reduced clinical scores. Accordingly, the antibodies or antigen binding portions thereof of the invention nay serve to alleviate symptoms associated with multiple sclerosis in humans.\n\n\n8.5 Use in Insulin-Dependent Diabetes Mellitus\n\n\nInterleukin-12 has been implicated as an important mediator of insulin- dependent diabetes mellitus (IDDM). EDDM was induced in NOD mice by administration of IL-12, and anti-IL-12 antibodies were protective in an adoptive transfer model of IDDM. Early onset IDDM patients often experience a so-called \"honeymoon period\" during which some residual islet cell function is maintained. These residual islet cells produce insulin and regulate blood glucose levels better than \n\n administered insulin. Treatment of these early onset patients with an anti-IL-12 antibody may prevent further destruction of islet cells, thereby maintaining an endogenous source of insulin.\n\n\n8.6 Use in Psoriasis\n\n\nInterleukin-12 has been implicated as a key mediator in psoriasis. Psoriasis involves acute and chronic skin lesions that are associated with a TH 1-type cytokine expression profile. (Hamid et al. (1996) J. Allergy Clin. Immunol. 1:225- 231; Turka et al. (1995) MoI. Med. 1:690-699, the entire teachings of which are incorporated herein by reference). IL-12 p35 and p40 niRNAs were detected in diseased human skin samples. Accordingly, the antibodies or antigen binding portions thereof of the invention may serve to alleviate chronic skin disorders such psoriasis. EXAMPLES\n\n\n1. The Isolation / Purification of Anti-IL-12 Antibodies\n\n\nThis example provides one scheme of purifying anti-IL-12 antibodies from host cell proteins (HCP) as well as from other impurities.\n\n\nPrimary recovery\n\n\nPrimary recovery by pH reduction, centrifugation and filtration was used to remove cells and cell debris from a production bioreactor harvest. The culture comprising the antibodies of interest, media, and cells was pH inactivated to 3.5 for 1 hour to kill possible pH sensitive virus contaminates and to precipitate media/cell contaminates in the 3000 L production bioreactor. The culture was then adjusted up to pH 4.9. The pH reduction was achieved with 3 M citric acid over the course of 20 to 40 minutes. The pH increase was performed using 3 M sodium hydroxide over the course of 20 to 40 minutes. These operations occured at a temperature of 2O\n0\nC. Post pH inactivation the culture was centrifuged into another bioreactor used as a holding tank. The centrifuge was run at 11,000 x g at a feed rate of 28 L/min. The discharge interval volume was set at 300 seconds to achieve a low turbidity level of 150. The centrifuge filtrate was passed through a filter train comprising twelve 16-inch Cuno™ \n\n model 30/60ZA depth filters and a three round filter housing fitted with three 30-inch 0.45/0.2 μm Sartopore™ filter cartridges. The clarified supernatant was collected in a pre-sterilized 3000 L fixed harvest tank and held at 8°C. The temperature was adjusted up to 2O\n0\nC prior to ion exchange chromatography.\n\n\nTiters of ABT-874 at harvest, for various samples designated 28O85BI, 28204BI, 28206BI, 28207BI, and 34142BI, ranged from 3.76 to 4.05 mg/mL with an average of 3.91 mg/mL. The pH reduction hold of the cell culture broth and subsequent pH increase and centrifugation of harvest resulted in mass recovery yields ranging from 77% to 84% with an average of 82% and a standard deviation of 2.11 (see Tables 2 and 3). Antibody quantitation was determined using a Poros A™ quantitation assay (well known to those skilled in the art) throughout this step.\n\n\nTable 2 Primary recovery data of various sample lots\n\n\n \n\n Table 3 Analysis of the primary recovery step\n\n\n\n\n\n\n\n\n* AVE = average; SD = standard deviation; %CV = Percent coefficient of variation\n\n\nCation exchange The objective of the cation exchange capture chromatography step is the capture of antibody from depth filtrate and the reduction of process-related impurities (e.g., host cell proteins, related antibody low molecular weight species and medium components). CM HyperDF™ resin (Pall Corporation) was utilized for this process step. The CM HyperDF™ capture step was performed at ambient temperature.\n\n\nA 80 cm diameter x 23 cm long column (bed volume 116 L) was used for this operation. Pre-equilibration, equilibration, load, wash, and regeneration column steps were performed at 16.0 L/min (linear velocity = 191 cm/hr). The elution, strip, wash, neutralization, sanitize, and store column steps were performed at 9.2 L/min (linear velocity = 110 cm/hr). The column was equilibrated with 210 mM sodium acetate, pH 5.0. Following equilibration, the column was loaded with clarified harvest that is diluted in-line with USP purified water. The column was loaded at a maximum of 80 g of protein per liter of resin (< 9248 g per cycle). The column was then washed to baseline with equilibration buffer. The product was eluted with 790 mM sodium acetate, pH 5.0. Elution collection was from upside at 3 OD\n28\nonm to downside 8 OD\n280nm\n of the antibody elution peak.\n\n\nThe column was regenerated with 1 M sodium chloride, washed with lipid wash 1 M acetic acid/ 20% isopropyl alcohol, washed with 790 mM sodium acetate, pH 5.0, sanitized with 0.5 M sodium hydroxide, followed with 790 mM \n\n sodium acetate, pH 5.0, and stored with 25 mM sodium phosphate, 20% isopropyl alcohol (IPA).\n\n\nOne cycle of the CM HyperDF™ chromatography step was performed for each sample lot examined. The average load for the sample lots was 67.38 g antibody/L of CM HyperDF™ resin with standard deviation of 1.37; ranging from 65.27 to 68.62 g/L (see Tables 4 and 5). The product recovery yields ranged from 83% to 96% with an average of 88% for lots 29001BF, 29008BF, 30005BF, 30006BF, and 35036BF and standard deviation of 5.17. For the clarified harvest, antibody quantitation was determined using a Poros A™ quantitation assay and for the CM HyperDF™ eluate, A\n2g0\nn\nm\n quantitation was used. The cutting criteria for the downside of the CM HyperDF™ elution product peak was high to cut the double light chain product related antibody species to achieve product purity. This made the overall CM HyperDF™ chromatography step yields go from around 95% to mid 80%.\n\n\nNo significant differences in purity by size exclusion (SE)-HPLC were noted for the five cycles. Table 16 shows the average of 94.76% for monomeric IgG with a standard deviation of 0.67.\n\n\nTable 4 CM HyperDF™ chromatography data\n\n\n \n\n Table 5 Analysis of the CM HyperDF™ chromatography step\n\n\n\n\n\n\n\n\nCapture Ultrafiltration/Diafϊltration (UF/DF)\n\n\nThe CM HyperDF™ eluate was filtered via delipid depth filter (1 X 16-inch, Cuno™ Corporation) followed with a 0.45/0.2 μm Sartopore™ bi-layer filter cartridge (1 X 30-inch). CM HyperDF™ eluate buffer 790 mM sodium acetate, pH 5.0 was used to flush the residual volume left in the filters. Ultrafiltration/difiltration (UF/DF) of the delipid CM HyperDF™ eluate was performed to concentrate the antibodies of interest, remove sodium acetate and buffer exchange of product in 100 mM sodium chloride, 20 mM sodium phosphate, pH 7.0. Millipore Corporation regenerated cellulose ultrafilter type membrane cassettes with a 30 kD molecular weight cut-off (MWCO) were used for this step at ambient temperature.\n\n\nThe 30 kD regenerated cellulose membrane was flushed with 790 mL sodium acetate, pH 5.0 before the start of the addition of product. The delipid-CM HyperDF™ eluate was concentrated to 40 g/L protein with inlet pressures of 20-30 psig and outlet pressures of 10-15 psig and retentate flow rate from 52 L/min to 104 L/min. Continuous diafiltration with a minimum of six volumes of 100 mM sodium chloride, 20 mM sodium phosphate, pH 7.0 was performed. The UF system was then drained of product at a target concentration of 42.5 g/L protein. The system was rinsed with diafiltration buffer to recover product held up in the system. The \n\n concentrate and wash were combined to produce the diafiltered ABT-874. This step was performed at ambient temperature. The sample matrix was filtered with an OpticapXUBO™ capsule 2.0/1.2 μm filter followed with a 0.45/0.2 μm Sartopore™ bi-layer filter cartridge (1 X 30-inch).\n\n\nThe delipid filtration and UF/DF of CM HyperDF™ eluate step resulted in an average product recovery yield of 5.92 Kg for the various sample lots (i.e., 29001BF, 29008BF, 30005BF, 30006BF, and 35036BF); ranging from 80 %- 94 % (see Tables 6 and 7).\n\n\nPurity by SE-HPLC were acceptable for the five cycles. Table 16 shows the average of 95.79% for the IgG with a standard deviation of 0.57.\n\n\nTable 6 Delipid filtering and UF/DF of CM HyperDF eluate data of sample lots\n\n\n \n\n Table 7 Analysis delipid filtering and UF/DF of CM HyperDF™ eluate data\n\n\n\n\n\n\n\n\nAnion exchange chromatography\n\n\nAnion exchange chromatography reduces process-related impurities such as DNA and host cell proteins. This process step is a flow through mode chromatography where the main antibody product does not bind to the Q Sepharose™, but the impurities do. This and subsequent steps were performed in a Class 10,000 purification suite at 12 ±2°C after the capture UF/DF intermediate product was transferred to the fine purification suite in a mobile, closed tank. A 60 cm diameter x 30 cm long column (bed volume 85 L) was used.\n\n\nThe column was packed with Q Sepharose™ Fast Flow anion exchange chromatography resin (Amersham Biosciences, Uppsala, Sweden). All column steps were performed at 7.0 L/min (linear velocity = 150 cm/hr), except for storage of the column which is run at 3.5 L/min. The column was equilibrated using seven column volumes (CVs) of\n\n\n50 mM sodium chloride, 25 mM Tris, pH 8.0. The maximum protein loading for this step was 50 g of protein per L of resin (< 4250 g per cycle). This column was cycled twice with only a regeneration of 1 M sodium chloride between cycles. Capture UF/DF material was diluted approximately two fold with 25 mM Tris, pH 8.0. This became the Q load at about 7.0 mS/cm, pH 7.5 to 8.1. After loading of the diluted capture UF/DF material, the column was washed with equilibration buffer. Flow- through comprising the antibodies of interest was collected from the upside at 3 OD\n2\n80nm to downside of peak at 3 OD\n2\n8o\nnm\n including the wash after the load. This was the Q flow-through plus wash (Q FTW). \n\n After the second cycle, the column was regenerated with 1 M sodium chloride, washed with Water For Injection (WFI), sanitized for 1 hour with 1 M sodium hydroxide, washed with 1 M sodium chloride, 25 mM sodium phosphate, pH 7.0, to bring the pH down and then stored with 25 mM sodium phosphate, 20% IPA.\n\n\nTwo cycles of the Q Sepharose™ column were performed for each of the sample lots produced. The average load per cycle were 34.8 and 31 g/L resin (cycle A and cycle B, respectively); ranging from 29.01 to 37.13 g/L (see Tables 8 and 9). The overall step yield including both cycles was 92% with a standard deviation of 17.8. This step typically yields 99 to 101% (sample lots 29001BF, 29008BF, 30005BF, and 30006BF). The Q Sepharose™ FTW overall yield was 25.81 kg for the five batches. Q load pH was pH 7.5 with conductivities about 6.0 to 6.7 mS/cm for lot 30006BF.\n\n\nPurity by SE-HPLC for the five cycles shows an average of 96.75% for the IgG with a standard deviation of 0.53 (Table 16). \n\n\n\n\nTable 8 Q Sepharose™ FF chromatography data of sample lots\n\n\n\n\n\n\n\n\n\n\nTable 9 Analysis Q Sepharose™ FF chromatography data\n\n\n \n\n HIC Chromatography\n\n\nHydrophobic interaction chromatography (HIC) is used for the removal of antibody aggregates and process-related impurities to final product specifications. This step is a bind and elute mode of chromatography. The anion exchange product (sample) was put in a high salt buffer (ammonium sulfate), bound to the column, and eluted from the column after three washes.\n\n\nAn 80 cm diameter x 15 cm long column (bed volume 75 L) was used for this procedure. The column was packed with Phenyl HP Sepharose™ hydrophobic interaction resin (Amersham Biosciences, Upsala, Sweden). The Q FTW (putatively comprising the antibodies of interest) was diluted with an equal volume of 1.7 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0, then filtered through a 0.45/0.2 μm Sartopore™ bi-layer filter (1 X 30-inch). Phenyl Sepharose™ HP was run in two cycles with a maximum loading of 40 g ABT-874 per L of Phenyl Sepharose™ HP resin (< 3000 g per cycle).\n\n\nPhenyl load was loaded on the column and equilibrated with five CVs of 0.85 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0. Following the loading of product, the column was washed with three CVs of wash 1 (1.1 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0), one to seven CVs of wash 2 (85 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0), then three CVs of wash 3 (1.1 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0).\n\n\nThe column was eluted with elution buffer, 0.5 M ammonium sulfate, 15 mM sodium phosphate, pH 7.0. The sample product was collected from the upside at 3 OD\n2\n80nm to downside of peak at 3 OD\n280nm\n. Equilibration, load, wash 1 wash 2, and wash 3 were performed at\n\n\n6.2 L/min (linear velocity = 74 cm/hr). Elution, regeneration, WFI wash, sanitize, and store column steps were performed at 3.1 L/min (linear velocity = 37 cm/hr).\n\n\nThe column was regenerated between cycles with four CVs of Water For Injection (WFI), three CVs of 1 M NaOH, and four CVs of WFI between cycles. After the last cycle, the column was subjected to five CVs of storage buffer, 25 mM sodium phosphate, 20% IPA.\n\n\nTwo cycles of HIC were performed for each sample lot. The average load per cycle were 32.54 and 34.00 g/L resin (cycle A and cycle B, respectively); \n\n ranging from 21.77 to 37.79 g/L (see Tables 10 and 11). The overall product recovery yields for cycle A and B combined ranged from 81% to 86% with an average of 84% with a standard deviation of 1.87 for sample lots 29001BF, 29008BF, 30005BF, 30006BF, and 35036BF. A total of 20.94 Kg of ABT-874 was produced across all the aggregated Phenyl Sepharose HP chromatography steps.\n\n\nPurity by SEC-HPLC for the Phenyl batches had an average of 99.63% for the IgG with a standard deviation of 0.11 (Table 16). The percent purity increased during the hydrophobic chromatography procedure with the purification of the antibodies of interest reducing the antibody related aggregate IgG and double light chain (low molecular weight species). This was achieved with a wash 2 buffer (SR- 342: 25 mM sodium phosphate, 0.85 M ammonium sulfate, pH 7). This buffer elutes the low molecular weight species of double light chain antibody and is implemented after the A280 nm increases slightly and levels off at about one column volume with a flow rate that is half the load and wash 1 flow rate (flow rate reduction of 6.2 to 3.1 L per minute). Aggregates were removed by binding to Phenyl resin of the column and not eluting at the 0.5 M ammonium sulfate buffer criteria when the antibody was eluting. \n\n\n\n\nTable 10 Phenyl Sepharose™ HP chromatography data of sample lots\n\n\n\n\n\n\n\n\n* The volume used is from the actual chromatography OIT volume reading during the cycle A and cycle B end of load for Phenyl Sepharose™ HP. \n\n Table 11 Analysis Phenyl Sepharose™ HP chromatography data\n\n\n\n\n\n\n\n\nVirus Filtration\n\n\nThe Phenyl eluate from the HIC step was filtered using an Ultipor DV50™ viral removal filtration step. The Ultipor DV50™ step provides for the physical removal of adventitious viruses > 50 nm in diameter that may be present in the Phenyl Sepharose™ HP column eluate.\n\n\nThe hydrophobic interaction column eluate was passed through the pre-wet 0.1 μm filter and 2 x 30-inch Ultipor DV50™ filter train (Pall Corporation) at < 34 psig. Post filtration, the filter was flushed with HIC elution buffer to remove any ABT-874 retained in the filter housing. The Ultipor DV50™ filtrate was stored in a pre-sterilized tank at 12°C ± 2°C prior to the final UF/DF formulation step.\n\n\nProduct recovery yield from the DV50™ filtration step ranged from 97% to 102% with an average yield of 100% for the various sample runs (see Tables 12 and 13). A total of 20.99 Kg of antibody product was processed for the five sample lots. \n\n\n\n\nTable 12 Viral filtration data of sample lots\n\n\n\n\n\n\n\n\n*Correction for density of 0.5 M ammonium sulfate, 50 mM sodium phosphate divide Kg weight by density 1.04 g/mL = volume in L. \n\n\n\n\nTable 13 Analysis virus filtration data\n\n\n\n\n\n\n\n\nFinal Ultrafiltration/Diafϊltration (UF/DF):\n\n\nThe final UF/DF step was the concentration of antibody, removal of ammonium sulfate and the formulation of antibody product in 5 mM histidine, 5 mM methionine, 2% mannitol, 0.5% sucrose, 0.005% Tween 80, pH 5.9. Millipore Corporation regenerated cellulose ultrafiltration type membrane cassettes with a 30 kD molecular weight cut-off (MWCO) were used for this step.\n\n\nThe Ultipor DV50™ filtrate was concentrated to 30 g/L protein. Continuous diafiltration with two volumes of 5 mM methionine, 2% mannitol, 0.5% sucrose, pH 5.9 buffer (no Tween) was performed. The product was then concentrated to 40 g/L now that most of the ammonium sulfate was removed. Continuous diafiltration with six volumes of 5 mM methionine, 2% mannitol, 0.5% sucrose, pH 5.9 buffer (no Tween) was performed. Upon completion of these six diavolume exchange, the antibody was concentrated to 75 g/L. The UF system was then drained of product and rinsed with diafiltration buffer to recover product held up in the system. The concentrate and wash were combined to produce the diafiltered ABT-874 and was subsequently adjusted to > 65 g/L with additional formulation buffer. Once the target concentration had been confirmed, a calculation was performed to determine the quantity of formulation buffer containing 10% Tween 80 that must be added to the concentrated UF retentate to bring the final Tween 80 concentration in drug substance to 0.005% (v/v). Final concentration of formulated \n\n drag substance was > 65 g/L. The antibody sample was filtered through an OpticapXLT30™ capsule 2.0/1.2 μm filter followed with a 0.45/0.2 μm Sartopore™ bi-layer filter into a sterile container, then transferred to a Class 100 area in preparation for final bottling. Product recovery yield from the UF/DF step ranged from 94% to 100% with an average yield of 97.0% with a standard deviation of 2.22 for five runs. (See Tables 14 and 15.) There was a total of 20.51 Kg of antibody product at the end of this Final UF/DF. Overall, the UF/DF filtration step was very consistent run to ran. Use of the 30 kD cutoff membrane rather than a 10 kD cutoff membrane allowed for faster processing time without sacrificing yield. \n\n\n\n\nTable 14 Final UF/DF data of sample lots\n\n\n \n\n Table 15 Analysis final UFfDF data\n\n\n\n\n\n\n\n\nTable 16 Analysis of five sample lots in-process QC analytical samples\n\n\n\n\n\n\n\n\n2. Determination of Host Cell Protein Concentration in anti-IL-12 Antibody Compositions\n\n\nThis procedure describes the testing methodology for the determination of residual Host Cell Protein concentration in anti-IL-12 antibody samples. Enzyme Linked Immunosorbent Assay (ELISA) is used to sandwich the Host Cell Protein (Antigens) between two layers of specific antibodies. This is followed by the blocking of non-specific sites with Casein. The Host Cell Proteins are then incubated during which time the antigen molecules are captured by the first antibody (Coating Antibody). A second antibody (anti- Host Cell Protein Biotinylated) is then added which fixes to the antigen (Host Cell Proteins). Neutravidin HRP-conjugated is added which binds to the Biotinylated anti-Host Cell Protein. This is followed by the addition of K blue substrate. The chromogenic substrate is hydrolyzed by the bound enzyme conjugated antibody, producing a blue color. Reaction is stopped with 2M H\n3\nPO\n4\n, changing color to yellow. Color intensity is directly proportional to the amount of antigen bound in the well.\n\n\nPreparation of 50 niM Sodium Bicarbonate (Coating Buffer), pH 9.4. To a 1 L beaker add: 900 mL Milli-Q water; 4.20 g ± 0.01 g Sodium Bicarbonate. Stir until completely dissolved. Adjust pH to 9.4 with 1 N NaOH. Transfer to a 1 L volumetric flask and bring to volume with Milli-Q water. Mix by inversion until homogeneous. Filter through a 0.22 μm sterile filter unit. Store at nominal 4\n0\nC for up to 7 days from the date of preparation.\n\n\nPreparation of 0.104 M Na\n2\nHPO\n4\n * 7H\n2\nO, 1.37 M NaCl, 0.027 M KCl, 0.0176 M KH\n2\nPO\n4\n, pH - 6.8 - 6.9 (1OX PBS). Add approximately 400 mL of Milli-Q water to a glass beaker. Add 13.94 g ± 0.01 g OfNa\n2\nHPO\n4\n x 7H\n2\nO. Add 40.0 g ± 0.1 g of NaCl. Add 1.00 g ± 0.01 g of KCl. Add 1.20 g ± 0.01 g OfKH\n2\nPO\n4\n. Stir until homogeneous. Transfer to a 500 mL volumetric flask. QS to 500 mL volume with Milli-Q water. Mix by inversion. Filter through a 0.2 μm sterile filter unit. Store at room temperature for up to 7 days.\n\n\nPreparation of IX PBS + 0.1% Triton X-100, pH 7.40: (Plate Wash Buffer). In a 4 L graduated cylinder, mix 400 mL 10 X PBS (step 5.2) with 3500 mL Milli-Q Water. Check pH, and adjust if necessary to 7.40 ± 0.05 with 1 N HCl or 1 N NaOH. Bring to volume with Milli-Q water. Tightly parafilm the cylinder and mix by inversion until homogeneous. Transfer to a 4 L bottle. Remove 4 mL of the 1 X \n\n PBS and discard. Add 4 rnL of triton X-IOO to the 3996 niL of 1 X PBS. Place on stir plate and stir to completely dissolve. Filter the amount of plate wash buffer needed for dilution buffer preparation through a 0.22 μm sterile filter unit. Store at room temperature for up to 7 days. Preparation of Coating Antibody Mixture: goat anti CHO 599/626/748\n\n\n(lot # Gl 1201 @ 1.534 mg/mL), affinity purified: NOTE: Stocks stored at nominal - 80°C in vials. Prepare aliquots. Take out one aliquot per plate at time of use. Immediately before use: Dilute antibody mixture to have a final concentration of 4 μg/mL in cold 50 mM Sodium Bicarbonate as follows. For example: add 31 μLs coating antibody mixture to 11969 μLs cold coating buffer. Mix gently by inversion.\n\n\nPreparation of Biotinylated goat anti Host Cell Protein Mixture, 599/626/748 (lot# Gl 1202 @ 0.822 mg/mL): NOTE: Stocks stored at nominal -80\n0\nC in vials. Prepare aliquots. Take out one aliquot per plate at time of use. Immediately before use: dilute biotinylated antibody mixture to have a final concentration of 1 μg/mL in 37\n0\nC ± 2\n0\nC Casein as follows. For example: add 14.6 μLs biotinylated antibody mixture to 11985 μLs 37°C ± 2°C Casein. Mix gently by inversion.\n\n\nPreparation of Neutravidin-HRP. Reconstitute new lots (2 mg/vial) to 1 mg/mL as follows: Add 400 μL of Milli-Q water to the vial, then add 1600 μL IX PBS, for a total of 2 mL. Vortex gently to mix. Store at nominal - 20\n0\nC. Prepare aliquots with desired volume so that 1 aliqout per plate is used. Prepare in polypropylene tube. Qualify new lots to determine working concentration. Assign expiry of 6 months from the date of preparation. For example, if the working concentration was determined to be 0.2 μg/mL then prepare as follows. Immediately before use: thaw an aliquot of Neutravidin-HRP at room temperature. Dilute the 1 mg/mL Neutravidin solution to 0.1 mg/mL (100 μg/mL) with 37°C ± 2°C Casein. For example: Dilute XlO, add 50 μL of neutravidin to 450 μL of Casein. Vortex gently to mix. Further dilute the 100 μg/mL solution to 0.2 μg/mL with 37°C ± 2°C Casein. For example: Dilute X500, add 24 μL neutravidin (100 μg/mL) to 11976 μL of Casein. Vortex gently to mix. Preparation of 5.7 2M Phosphoric Acid (Stop Solution). Prepare a 2 M\n\n\nPhosphoric acid solution from concentrated phosphoric acid as follows. From the % phosphoric acid stated on the label, density (1.685g/mL) and formula weight (98 g/mole), calculate the volume of concentrated phosphoric acid needed to prepare 500 mL of 2M phosphoric acid. Add the volume of concentrated phosphoric acid \n\n calculated above to the flask. Bring to volume with Milli-Q water and mix by inversion until homogeneous. Store at ambient temperature for up to 6 months from the date of preparation.\n\n\nPreparation of Dilution Buffer (Casein diluted XlOO in IX PBS + 0.1 % Triton XlOO, pH 7.4). Dilute 37°C ± 2 \n0\nC Casein XlOO in 0.22 μm sterile filtered IX PBS + 0.1 % Triton XlOO, pH 7.4 (from above). For example: Add 1 rnL of 37°C ± 2 \n0\nC Casein to 99 mL 0.22 μm sterile filtered IX PBS + 0.1 % Triton XlOO, pH 7.4. Mix well. Prepare fresh for each use.\n\n\nPreparation of Standards. Host cell Protein Standards (Antigen Standards) (lot # Gl 1203 @ 1.218 mg/mL): NOTE: Stocks stored at nominal -80\n0\nC in 70 μL aliquots. Thaw an aliquot at room temperature. Perform serial dilutions in polypropylene tubes using Dilution buffer.\n\n\nPreparation of Samples. In polypropylene tubes, dilute final bulk samples to 24 mg/mL in Dilution Buffer. Record concentration. NOTE: use the solutions below to prepare spiked samples and to prepare the 12 mg/mL solutions referenced below. In polypropylene microtubes, further dilute the 24 mg/mL solutions to 12 mg/mL in Dilution Buffer. Load triplicate wells for each of the 12 mg/mL solutions on the plate for a total of 6 wells.\n\n\nPreparation of Spike. In a polypropylene microtube, prepare a 10 ng/mL Host Cell Protein spike from the 20 ng/mL standard prepared above by diluting it 2 X with Dilution Buffer. Load three wells for the 10 ng/mL spike solution onto the plate. Use the 20 ng/mL standard solution from step 6.1 for spiking samples.\n\n\nPreparation of Spiked Samples. In polypropylene microtubes, spike 300 μL of each 24 mg/mL final bulk solution with 300 μL of the 20 ng/mL spike solution (6.1). Load triplicate wells for each spiked sample solution for a total of 6 wells.\n\n\nPreparation of Control. A control range must be set for every new control stock solution, before use in routine testing. Control Stock: Prepare 150 μL aliquots of a batch of ABT-874 Drug Substance Concentrate and store frozen at nominal -80°C for up to three years.\n\n\nPreparation of Working Control. Thaw an aliquot of control at room temperature. In polypropylene tubes, dilute control to 24 mg/mL with Dilution Buffer. In polypropylene microtubes, further dilute the 24 mg/mL control solution with \n\n dilution buffer to 12 mg/mL. Prepare a single dilution and load control into 3 wells of the plate.\n\n\nELISA procedures. Fill plate wash bottle with plate wash buffer (refer to step 5.3, IX PBS + 0.1% Triton X-100). Prime plate washer. Check the following parameters: Parameters should be set to: Plate Type: 1 For each Cycle (a total of 5 cycles): Volume: 400 μls; Soak Time: 10 seconds; Asp. Time: 4 seconds.\n\n\nAssay Procedure. Coat plates with 100 μL/well of 4 μg/mL goat coating antibody mixture in cold 50 mM Sodium Bicarbonate. Tap the side of the plate until the coating solution covers the bottom of the wells uniformly, cover with sealing tape and incubate at nominal 4 \n0\nC while shaking on plate shaker (or equivalent) at speed 3 for 18 hours ± 1 hour. After overnight incubation, remove plate from refrigerator and allow to equilibrate to room temperature. Shake out coating. Blot plate on paper towels. Block with 300 μL/well of 37\n0\nC ± 2\n0\nC Casein, cover with sealing tape and incubate at 37°C ± 2\n0\nC while shaking on Lab-line Environ plate shaker (or equivalent) at 80 rpm ± 5 rpm for 1 hour. Prepare standard, sample, control, spike, and spiked samples during blocking incubation. Wash the plate 5 times with Wash Buffer. Blot plate on paper towels. Using an 8-channel pipette, pipet 100 μL/well of standards, samples, spikes, spiked samples, and control into triplicate wells of the plate. Pipette 100 μL/well of Dilution Buffer into all empty wells of the plate to serve as blanks. Cover with sealing tape and incubate at 37\n0\nC ± 2 \n0\nC while shaking on Lab-line Environ plate shaker (or equivalent) at 80 rpm ± 5 rpm for 1 hour. Fill out a template to use as a guide when loading plate.\n\n\nPlate Reader Set-Up. Set up template, entering concentrations for standards. Do not enter dilution factors for samples, control, spike, or spiked samples. Assign the wells containing diluent as blanks to be subtracted from all wells. Wash the plate 5 times with Wash Buffer. Blot plate on paper towels. Add 100 μL/well biotinylated goat antibody. Cover with sealing tape and incubate at 37°C ± 2°C while shaking on Lab-line Environ plate shaker (or equivalent) at 80 rpm ± 5 rpm for 1 hour. Wash the plate 5 times with Wash Buffer. Blot plate on paper towels. Add 100 μL/well Neutravidin-HRP conjugate solution. Cover with sealing tape and incubate at 37\n0\nC ± 2°C while shaking on Lab-line Environ plate shaker (or equivalent) at 80 rpm ± 5 rpm for 1 hour. Wash the plate 5 times with Wash Buffer. Blot plate on paper towels. Add 100 μL/well cold K-Blue substrate, cover with sealing tape and incubate at room temperature for 10 minutes (start timer as soon as substrate is added \n\n to first row), while shaking speed 3 on Lab-line titer plate shaker (or equivalent). Stop the reaction by adding 100 μL/well 2M Phosphoric Acid (Step 5.7). Place plate on a plate shaker at speed 3 for 3-5 minutes. Read plate at 450 ran.\n\n\nData Analysis and Calculations. NOTE: only samples, spikes, spiked samples, and control, with optical densities falling within the practical quantitation limit (2.5 ng/mL standard) of the standard curve and meeting the % CV or % difference criteria stated below, are accepted. If sample OD's fall below the 2.5 ng/mL standard, result should be reported as less than 2.5 ng/mL. This value should then be divided by the diluted sample concentration (12 mg/mL) to report value in ng/mg. If sample is high in host cell concentration causing the non-spiked and/or the spiked sample to be above standard curve, report value as > 100 ng/mL. This value should then be divided by the diluted sample concentration (12 mg/mL) to report value in ng/mg. Consider sample value zero for spike recovery calculations when the sample is below the 2.5 ng/mL standard. Standard Curve. Standard concentrations should be entered into the protocol template. A quadratic curve fit is used. Coefficient of determination must be = 0.99 and the % CV between triplicate wells must be = 20%. If this criteria is not met: One standard (1 level, 3 wells) may be dropped. If the 1.25 ng/mL is dropped, only samples and spiked samples with optical densities falling within the 2.5 ng/mL and 100 ng/mL (the remaining standard curve points) optical densities are acceptable. Additionally, for the triplicates of each standard level, if a single well is clearly contaminated or shows low binding, it may be dropped. If a well is dropped from a standard level, the remaining replicates must have a % difference = 20%. The % CV for the lowest standard, which shows OD values close to the background (blanks) of the plate, should be = 30%. If one well is dropped, the % difference for the remaining replicates must be = 35%. If the lowest standard is dropped, only samples and spiked samples with optical densities falling within the remaining standard curve level optical densities are acceptable.\n\n\nSamples. % CV should be = 20% between triplicate wells. Report % CV between triplicate wells. One well from each sample dilution may be dropped. The remaining replicates must have a % difference of = 20%. Note: if non-spiked sample OD is below the 2.5 ng/mL standard OD the % difference criteria does not apply to the non-spiked results. Refer to calculation above. \n\n Calculate actual Host Cell Concentration in ng/mg from the mean (ng/mL) value as follows: CHO Host Cell Protein (ng/mg) = Mean \"Non-spiked sample result (ng/mL)\"_ Diluted sample concentration (12 mg/mL).\n\n\nSpikes. % CV should be = 20% between triplicate wells. Record % CV. One well from the spike may be dropped. The remaining points must have a % difference = 20%. Refer to calculation in above. Report host cell concentration in ng/mL. This result will be used in spike recovery calculations. The resulting concentration for the spike (ng/mL) must be ± 20% of the theoretical spike concentration. Record result and indicate Pass or Fail. If the spike result is not within 20% of theoretical, the assay must be repeated. Mean Spike Concentration (ng/mL) x 100 = must be 100% ± 20% 10 ng/mL.\n\n\nSpiked Samples. % CV should be = 20% between triplicate wells. Record % CV between triplicate wells. One well from each spiked sample dilution may be dropped. The remaining replicates must have a % difference of = 20%. Refer to calculation above. Report \"Spiked sample result\" for each dilution in ng/mL.\n\n\nRecord % difference between duplicate dilutions. The % difference between dilutions should be = 25%. These results will be used in the spike recovery calculations.\n\n\nCalculate % Spike Recovery for each dilution set using the formula below: % Spike Recovery = Spiked sample value - Non-Spiked Sample Value X 100 Spike Value. NOTE: (1) If non-spiked sample value OD's fall below the 2.5 ng/mL standard consider value as zero in % spike recovery calculation. % Spike recovery must be 100% ± 50% (50% - 150%) for each dilution for each sample. Record results and Pass / Fail.\n\n\nControl. % CV should be = 20% between triplicate wells. Record % CV result. One well from the control may be dropped. The remaining replicates must have a % difference of = 20%. Refer to calculation above. Report Host Cell concentration in the control in ng/mL. Calculate Host Cell concentration in ng/mg as follows: Host Cell Protein (ng/mg) = Control Host Cell Protein result in ng/mL.\n\n\nVarious publications are cited herein, the contents of which are hereby incorporated by reference in their entireties."
  },
  {
    "id": "WO2010048701A1",
    "text": "Ingestibles containing sugar and cinnamon or ginseng AbstractA composition of ingestible ingredients containing a first ingestible ingredient which has an undesired effect on the human body when ingested, wherein preferably the ingredient is sugar and the undesired effect is blood sugar fluctuations which can lead to diabetes, and at least one other ingestible ingredient which reduces the impact or the undesired effect of the first ingestible ingredient, wherein the other ingredient is either cinnamon or polyphenols from cinnamon, or ginseng or ginsenosides from ginseng. The composition may be in a package, a bulk mix or a product. Claims\n\n\n\n\n\n\n1. A package of ingestible ingredients, each package containing a first ingestible ingredient having an undesired effect, when ingested, on the human body and at least one ingestible ingredient in an effective non-toxic amount which reduces the impact of the undesired effect of the first ingestible ingredient when the contents of the package are ingested.\n\n\n\n\n\n\n2. A bulk mix containing a first ingestible ingredient having an undesired effect, when ingested, on the human body and at least one ingestible ingredient which reduces the impact of the undesired effect of the first ingestible ingredient when ingested.\n\n\n\n\n\n\n3. A package containing table sugar and at least one ingestible beneficial ingredient in an effective non-toxic amount for reducing the impact of the undesired effect of the ingestion of the table sugar on the human body.\n\n\n\n\n\n\n4. A bulk mix containing table sugar and at least one ingestible beneficial ingredient for reducing the impact of the undesired effect of the ingestion of the table sugar on the human body.\n\n\n\n\n\n\n5. The package of claim 3 wherein the at least one beneficial ingredient is selected from an effective amount of cinnamon (or polyphenols found therein), an effective amount of ginseng (or ginsenosides found therein) or combinations thereof.  \n\n\n\n\n\n\n6. The mix of claim 4 wherein the at least one beneficial ingredient is selected from an effective amount of cinnamon (or polyphenols found therein), an effective amount of ginseng (or ginsenosides found therein) or combinations thereof.\n\n\n\n\n\n\n7. A packet comprised of a first ingestible ingredient having an undesired effect on the human body when ingested and at least one ingestible ingredient in an effective non-toxic amount which reduces the impact of the undesired effect of the first ingestible ingredient when the contents of the package are ingested wherein the at least one ingestible ingredient comprises at least two ingestible ingredients (in effective non-toxic amounts) which reduce the impact of the effect of the first ingestible ingredient when the contents of the package are ingested.\n\n\n\n\n\n\n8. A mix containing a first ingestible ingredient having an undesired effect on the human body when ingested and at least one ingestible ingredient in an effective non-toxic amount which reduces the impact of the undesired effect of the first ingestible ingredient ingested wherein the at least one ingestible ingredient comprises at least two ingestible ingredients (in effective non-toxic amounts) which reduce the impact of the effect of the first ingestible ingredient when ingested.\n\n\n\n\n\n\n9. A paper package containing table sugar and at least one ingestible ingredient selected from an effective amount of cinnamon (or polyphenols found in cinnamon), ginseng (or ginsenosides found in ginseng, and combinations thereof, for reducing the effect of the ingestion of the table sugar on the human body when all are ingested.  \n\n\n\n\n\n\n10. A bulk mix containing table sugar and at least one ingestible ingredient selected from an effective amount of cinnamon (or polyphenols found in cinnamon), ginseng (or ginsenosides found in ginseng, and combinations thereof, for reducing the effect of the ingestion of the table sugar on the human body when all are ingested.\n\n\n\n\n\n\n11. A comestible product suitable for ingestion by a human comprising a combination of Products A and B packaged together, Product A being an ingestible product which has an undesired effect(s) on the human when ingested by the human and Product B reduces the impact of the effects of the ingestion of Product A on the human body.\n\n\n\n\n\n\n12. The product of claim 11 wherein Product A is table sugar and Product B comprises cinnamon or ginseng or combinations thereof, each in effective non-toxic amounts.\n\n\n\n\n\n\n13. The product of claim 12 wherein when Product B is cinnamon, the amount of cinnamon present comprises an effective non-toxic amount to impact the undesirable effect of table sugar.\n\n\n\n\n\n\n14. The product of claim 13 wherein the effective amount of cinnamon comprises polyphenols or polyphenol polymers present in the cinnamon in the effective nontoxic amount of at least about 12% (w/w) polyphenols.  \n\n\n\n\n\n\n15. The product of claim 13 wherein when Product B is ginseng, the effective amount of ginseng present is in the form of ginseng extract standardized 1.5 to 7% of ginsenosides.\n\n\n\n\n\n\n16. The package of claim 5 wherein the at least one ingestible ingredient comprises effective amounts of cinnamon and ginseng and the amounts may be from cinnamon extract and ginseng extract mixed with the table sugar.\n\n\n\n\n\n\n17. The package of claim 16 wherein the cinnamon extract includes cinnamon aqueous extract TCl 12 which has at least about 12% (w/w) polyphenols.\n\n\n\n\n\n\n18. The package of claim 17 wherein the ginseng extract includes ginseng extract standardized at 1.5 to 7% of ginsenosides.\n\n\n\n\n\n\n19. The package of claim 16, 17 or 18 wherein the ratio of cinnamon extract to ginseng extract is 1 to 1 by weight.\n\n\n\n\n\n\n20. The mix of claim 6 wherein the at least one beneficial ingredient comprises effective non-toxic amounts of cinnamon and ginseng and the amounts may be from cinnamon extract and ginseng extract mixed with the table sugar.\n\n\n\n\n\n\n21. The mix of claim 20 wherein the cinnamon extract includes cinnamon aqueous extract TCl 12 which has at least about 12% (w/w) polyphenols.  \n\n\n\n\n\n\n22. The mix of claim 20 or 21 wherein the ginseng extract includes ginseng extract standardized at 1.5 to 7% of ginsenosides.\n\n\n\n\n\n\n23. The mix of claim 20, 21, or 22 wherein the ratio of cinnamon extract to ginseng extract is 1 to 1 by weight.\n\n\n\n\n\n\n24. The product of claim 13, 14, 15, 16 or 17 wherein the polyphenols contain at least about 1% polyphenol Type A polymers.\n\n\n\n\n\n\n25. The mix of claim 20, 21, or 22 wherein the polyphenols contain at least about 1% polyphenol Type A polymers.\n\n\nHBdocs - 72\n22\n447vl Description\n\n\n\n\n TITLE OF INVENTION\n\n\nIngestibles containing sugar and cinnamon or ginseng\n\n\nFIELD OF INVENTION This invention relates to packages for example recyclable paper packets or sachets of ingestible ingredients, each package containing a first ingestible ingredient having an undesired effect on the human body and at least one ingestible ingredient which reduces the impact of the undesired effect(s) of the first ingestible ingredient when the contents of the package are ingested. This invention also relates to the bulk mix of a first ingestible ingredient having an undesired effect on the human body and at least one ingestible ingredient which reduces the impact of the undesired effect(s) of the first ingestible ingredient when ingested.\n\n\nBACKGROUND OF INVENTION Coffee is one of the most popular hot beverage drinks in the world. Table sugar and milk and/or cream are popular additions to the hot beverage. For take out of cups of coffee from restaurants and coffee shops, the proprietors provide the customers usually with packets or sachets of sweetener, including table sugar in the packets or sachets set near the coffee pot for the user to help herself/himself when the coffee is poured into the disposable drinking cup. Each such sachet or packet usually contains about 3 grams (1 teaspoon) of table sugar. Some proprietors use sugar bowls of table sugar.\n\n\nSugars affect the human body in many ways. Some of these ways are good, some are bad and some are worse. \n\n Energy created for the human from ingested sugars is the good since humans need the energy to function. The best sugars are those having a low glycemic index rating. These sugars are released by the body into the blood stream at a slower, more healthy absorption rate. The bad and worse news associated with sugars is that many are processed into all kinds of foods humans ingest. These sugars often carry a high glycemic index rating (such as table sugar) thereby being more quickly released into the bloodstream. This faster release and subsequent absorption causes the pancreas (the organ which controls sugar levels) to release insulin which drops the blood-sugar levels in the body. Fluctuation in blood-sugar levels by the human ingesting these sugars not only stresses the human body, but over time can lead to diabetes.\n\n\nThree types of sugars that are processed into everyday foods include sucrose (known most often in its white crystalline form, as \"table sugar\"), fructose or high- fructose (corn syrup) and dextrose, a sugar derived from corn. Almost all processed foods have one or more of these processed sugars. Common foods such as bread, peanut butter, sauces, jams, syrups and condiments (for example ketchup) have table sugar processed into them, often to keep them fresh or to preserve them and to enhance their flavours.\n\n\nThe white crystalline substance, table sugar, is an unnatural substance produced by industrial processes (mostly from sugar cane or sugar beets) by\n\n\n\"refining\", for example the sugar cane or sugar beets, down to pure sucrose, after stripping away all the vitamins, minerals, proteins, enzymes and other beneficial nutrients.\n\n\nWhat is left is a concentrated \"unnatural\" substance which the human body is not able to process comfortably, at least not in anywhere near the quantities that are \n\n now ingested in today's accepted lifestyle. The average American (man, woman and child) now consumes approximately 115 pounds of sugar per year.\n\n\nTable sugar does so much damage when ingested because it is considered and marketed as a \"food\", and is ingested in huge quantities starting early in life yet is pure chemical and through refining has been stripped of all the natural food nutrition that it originally had in the plant itself. For example, from the day a baby is born and nursed by his/her mother, if the mother eats table sugar (usually the case), the baby ingests the table sugar. If the baby is given formula, table sugar is in the formula.\n\n\nThe ingestion of this \"alien\" chemical, table sugar, in such quantities that humans ingest, damages the body over the years including the pancreas, adrenal glands and throws the whole endocrine system out of kilter causing diabetes, hyperglycemia and hypoglycemia. Sugar thus has an extremely harmful effect in unbalancing the endocrine system and injuring its component glands such as the adrenal glands, pancreas and liver, fluctuating the blood sugar level widely. Table sugar when ingested as discussed is processed by insulin, the hormone produced by the pancreas that helps the body control the level of the sugar in the blood. If the body makes little or no insulin or the body cannot use it readily, the person has diabetes.\n\n\nDiabetes is a lifelong condition where either the human body (pancreas) does not produce enough insulin, or the body cannot use the insulin it produces. The human body needs the insulin to change the \"table sugar\" from food into energy.\n\n\nWhen the body cannot do so, it has one of three types of diabetes:\n\n\n• Type 1, where the body makes little or no insulin;\n\n\n• Type 2, where the body (pancreas) makes either not enough insulin but cannot use it properly; and \n\n • Gestational Diabetes, where the body is not able to properly use insulin during pregnancy. This type of diabetes usually goes away after the baby is born.\n\n\nNine out often people with diabetes have Type 2 diabetes. Thus people having Type 2 diabetes (in which the pancreas does not produce enough insulin, or the body does not properly use the insulin it makes) build up glucose in the blood instead of the glucose being used for energy - a dangerous condition.\n\n\nDiabetics having Type 2 diabetes (including those marginally diabetic) who drink coffee picked up for take out, in many instances sweeten their coffee, not by artificial sweeteners which have their own undesirable effects, but by emptying the contents of at least one packet or sachet of table sugar into the hot coffee (or tea).\n\n\nSome coffee (tea) drinkers do it automatically without thought.\n\n\nSUMMARY OF INVENTION AND DETAILED DISCUSSION OF EMBODIMENTS THEREOF\n\n\nIt is, therefore, an object of this invention to provide packages for example recyclable paper packets or sachets, of ingestible ingredients, each package containing a first ingestible ingredient having an undesired effect on the human body and at least one ingestible ingredient in an effective non-toxic amount which reduces the impact of the undesired effect of the first ingestible ingredient when the contents of the package are ingested.\n\n\nIt is a further object of this invention to provide a bulk mix containing a first ingestible ingredient having an undesired effect on the human body and at least one ingestible ingredient (in an effective non-toxic amount) which reduces the impact of the undesired effect of the first ingestible ingredient when ingested. \n\n It is a further object of this invention to provide in one embodiment, a package (packet or sachet) and a mix containing table sugar and at least one ingestible ingredient (for example an effective amount of cinnamon (or polyphenols for example found therein) or ginseng (or ginsenosides for example found therein) or combinations thereof) for reducing the impact of the undesired effect of the ingestion of the table sugar on the human body.\n\n\nThus according to one aspect of the invention there are provided packages (for example recyclable or disposable paper packets or sachets) containing a first ingestible ingredient having an undesired effect on the human body when ingested and at least one ingestible ingredient in an effective non-toxic amount which reduces the impact of the undesired effect of the first ingestible ingredient when the contents of the package are ingested.\n\n\nThe at least one ingestible ingredient may comprise for example at least two ingestible ingredients (in effective non-toxic amounts) which reduce the impact of the effect of the first ingestible ingredient when the contents of the package are ingested.\n\n\nAccording to another aspect of the invention there is provided a mix, and a paper package (or sachet), containing table sugar (as the first ingredient)and at least one ingestible ingredient (for example an effective amount of cinnamon (or polyphenols, for example found in cinnamon) or ginseng (or ginsenosides for example found in ginseng or combinations thereof) for reducing the effect of the ingestion of the table sugar on the human body when all are ingested.\n\n\nAccording to another aspect of the invention, a comestible product suitable for ingestion by a human is provided comprising a combination of Products A and B together (for example packaged together), Product A being an ingestible product which has (an) undesired effect(s) on the human when ingested by the human (for \n\n example such as table sugar) and Product B reduces the impact of the effects of the ingestion of Product A on the human body.\n\n\nAccording to another aspect of the invention Product B is a product (preferably a Natural Product\") with medicinal benefits. A \"Natural Product\" includes both cinnamon and ginseng.\n\n\nAccording to another aspect of the invention the packaging may comprise disposable/recyclable paper packets or sachets.\n\n\nAccording to still another aspect of the invention Product A is table sugar and Product B comprises cinnamon or ginseng or combinations thereof, each in effective amounts.\n\n\nWhere the ingredient or Product B is cinnamon, the amount of cinnamon present comprises an effective amount to impact (for example reduce) the undesirable effect of for example, table sugar. Preferably the effective amount of cinnamon comprises polyphenols (water soluble polyphenol polymers present in the cinnamon) in the effective non-toxic amount of at least about 12% (w/w) polyphenols (preferably containing at least about 1% doubly-linked polyphenol Type A polymers). Thus preferably the effective amount of the cinnamon present is in the form of a cinnamon extract, such as cinnamon extract TCl 12 prepared by Finzelberg (Andernach, Germany). 112 mg of aqueous cinnamon extract TCl 12 corresponds to 1 gm of cinnamon with respect to equivalent amounts of polyphenols. The extract contains at least about 12% (w/w) of polyphenols. Preferably the extract contains at least about 1% polyphenol Type A polymers.\n\n\nThis cinnamon product is discussed in \"effects of a cinnamon extract on plasma glucose, HbAi \nc\n, and serum lipids in diabetes mellitus type 2\", European Journal of Clinical Investigation 36, 340-344, 2006 by B. Mang et al., where it was \n\n disclosed that cinnamon extract seemed to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control. A cinnamon capsule was used which contained 112 mg of the aqueous cinnamon extract TCl 12 prepared by Finzelberg (Andernach, Germany) corresponding to 1 g of cinnamon.\n\n\nThe use of purified aqueous cinnamon extract for 4 months resulted in a 10.3% decrease in fasting blood sugar compared to 3.3% in the placebo group. TCl 12 capsules 112 mg of aqueous cinnamon extract corresponding to Ig of cinnamon.\n\n\n\n\n\n\n\n\nMang et al Effects of a cinnamon extract on plasma glucose, HbAIc, serum lipids in diabetes mellitus type 2. Eur J CHn Investig 36:340-344, 2006\n\n\nThe beneficial effects of cinnamon extract are the Polyphenols found in its water-soluble fractions. The major active component of the cinnamon extract appears to be doubly linked procyanidin type-A polymers (Anderson et al, 2004). CE has been reported to have anti-oxidant effects in rats (Lee et al., 2003; Lin et al., 2003; Anderson et al, 2004) and humans, insulin-potentiating effects in rats (Qin et al, 2003; 2004), mice (Kim et al, 2006) and humans (Khan et al, 2003; Ziegenfuss et al, 2006; Wang et al, 2007). Cinnamon extract also prevents insulin resistance induced by a high-fructose diet in rats (Qin et al, 2004). In addition, cinnamon \n\n decreases levels of glucose, triglycerides, and LDL cholesterol in people with type-2 diabetes {Khan et al, 2003).\n\n\nWater-soluble polyphenol polymers are believed to be the key components responsible for its beneficial metabolic effects {Anderson et al, J. AgHc. Food Chem. 2004, 52, 65-70); they enhance the activity of insulin and are antioxidants. The polyphenol type-A polymers from cinnamon upregulate genes involved in blood sugar control {Imparl-Radosevich et al, Horm res 50(3): 177-182, 1998). These polymers are composed of monomelic units with a molecular mass of 288. Two trimers with a molecular mass of 864 and a tetramer with a mass of 1152. Their protonated molecular masses indicated that they are A type doubly linked procyanidin oligomers of the catechins and/or epicatechins. (J. Agric. Food Chem. 2004, 52, 65- 70).\n\n\nIn \"Cinnamon improves glucose and lipids of people with type 2 diabetes.\", Diabetes Care 26:3215-3218, 2003 by A. Khan et al., a human study was conducted involving subjects with type 2 diabetes consuming cinnamon. Subjects consumed 1, 3, or 6 g of cinnamon per day for 40 days with 3 placebo groups corresponding to the three groups that consumed different numbers of capsules containing cinnamon. Decreases in fasting serum glucose (18-29%), triclycerides (23-30%), total cholesterol (12-26%), and LDL cholesterol (7-27%) were found after 40 days. Benefits in insulin sensitivity were also likely to lead to decreased incidence of cardiovascular diseases, which is more than double in people with diabetes.\n\n\nThe following Table 1 from Khan, et al., illustrates the effects of cinnamon on glucose levels in people with type 2 diabetes\n\n\nFasting serum glucose level (mmol/r/\n\n\nBefore After\n\n\nDoses of cinnamon During cinnamon intake cinnamon cinnamon intake intake\n\n\nGroup* (g/day) Day O Day 20 Day Day 60\n\n\n40 \n\n 1 1 11.6 ± 1.7° 10.5 ± 1.8\nfli\n 8.7 ± 1.6\nC\n 9.1 ± lA\nbc\n \n\n\n2 3 11.4 ± 1.2\" 9.9 ± l.l\naέ\n 9.4± 1.1* 9.9 ± 1.6\na\n*\n\n\n3 6 13.0 ± 1.4\" 10.2 ± 1.3\n4c\n 9.2 ± 1.5\nC\n 11.4 ± 1.8^\n\n\n4 Placebo 1 12.2 ± 1.0\" 12.7 ± 0.8° 12.4 ± l.l\nα\n 12.6 ± 1.0\"\n\n\n5 Placebo 2 12.4 ± 1.0\nα\n 11.8 ± 0.9\" 12.7 ± 1.0° 12.6 ± 1.3\"\n\n\n6 Placebo 3 16.7 ± 1.4\nα\n 16.7 ± 1.6\nΩ\n 16.8 ± 1.7° 17.0 ± 1.3\"\n\n\nData are means ± SD. *Ten individuals in each group; ^eans followed by different superscript letters in the same row are significantly different at P< 0.05.\n\n\nIn \"Isolation and Characterization of Polyphenol Type-A Polymers from Cinnamon with Insulin-like Biological Activity\", J. agric food chem.. 52(l):65-70, 2004 by Anderson et al., it was disclosed that water-soluble polyphenol polymers from cinnamon would increase insulin dependent in vitro glucose metabolism roughly 20-fold and display antioxidant activity. Certain studies demonstrated that water- soluble polymeric compounds isolated from cinnamon have insulin-enhancing biological activity in the in vitro assay measuring the insulin dependent effects on glucose metabolism and also function as antioxidants. These same compounds have been shown to inhibit phosphotyrosine phosphatase in the insulin-receptor domain and to activate insulin receptor kinase and function as a mimetic for insulin 3T3-L1 adipocytes. There are two types of cinnamon: Ceylon and cassia, both derived from the bark of evergreen trees. Ceylon cinnamon is grown in South America, Southeast Asia, and the West Indies, while cassia cinnamon is grown in Central America, China, and Indonesia. Ceylon cinnamon bark looks like tightly rolled scrolls, while cassia cinnamon is more loosely rolled. Cassia is the variety most commonly sold in the United States.\n\n\nSeveral polyphenolic polymer compounds have been isolated from cinnamon bark. In test tube assays using fat cells, the polyphenolic polymers were found to increase sugar metabolism a whopping 20-fold. Previous studies suggest that \n\n compounds from cinnamon exhibit insulin-like activity in cells, intact animals and people with type 2 diabetes.\n\n\nTo understand the molecular basis of the insulin-like activity and explore additional benefits of cinnamon, the effects of compounds from cinnamon were investigated on the utilization of sugar and control of insulin function. The results showed that factors from cinnamon improve/inhibit factors involved in inflammation. These results suggest that compounds from cinnamon were involved in the use of sugar by cells.\n\n\nIt has also been shown that cinnamon improves glucose and lipid profiles of people with type 2 diabetes and that a water-soluble cinnamon extract and HPLC- purifϊed cinnamon polyphenols (CP) display insulin-like activity. The objective of the study was to investigate the biochemical basis for the insulin-like effects of cinnamon. Immunoblotting procedure was employed to analyze three proteins, insulin receptor (IR), glucose transporter 4 (GLUT4), and the anti-inflammatory protein tristetraprolin (TTP) involved in insulin signal transduction pathway in mouse 3T3-L1 adipocytes. The results showed that both insulin and CP increased the levels of the three proteins, and recombinant TTP was phosphorylated in vitro by glycogen synthase kinase 3 beta and protein kinases A, B, and C. These results suggest that like insulin, CP increase the amount of the three critically important proteins involved in insulin signaling, glucose transport and inflammatory response. A model of actions was proposed to link CP and TTP in insulin signal transduction pathway. The study provided new biochemical evidence for the beneficial effects of CP in insulin- like action and suggests anti-inflammatory properties of CP.\n\n\nPreferably the type of cinnamon extract to be used should contain at least 12% (w/w) of water-soluble polyphenol polymers without volatile oils. The polyphenol \n\n polymers should preferably be Type-A polymers doubly linked procyanidin oligomers of the catechins and/or epicatechins.\n\n\nCinnamon extract can be used in doses ranging between about 50 to about\n\n\n1,000 mg/day. Cinnamon extract in the amounts of 50 to 1,000 mg/day which contain 12% of polyphenols are approximately equivalent to 0.5 to 6 grams per day of Cinnamon powder. These polyphenol polymers are composed of monomelic units with a molecular mass of 288, two trimers with a molecular mass of 864 and a tetramer with a mass of 1152. The major active component of cinnamon extract, it is believed, appears to be the doubly linked procyanidin Type-A polymers.\n\n\nThe total phenolic content of cinnamon extract and its antioxidant potential are both predictive of the extract's ability to inhibit protein glycation (Dearlove et al,\n\n\nJ of Medicinal Food 11(2):275-281. 2008). Glucose and fructose form glycation products linked to serious diseases. For example, postprandial fructose has been linked to retinopathy in diabetics (Kawsaki et al, Metabolism 53: 583-588, 2004) and fructose has been implicated in symptoms of metabolic syndrome {Kawasaki et al,\n\n\nDiabetes Care 25:353-357, 2002).\n\n\nReference should also be had to Hlebowicz et al, Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J\n\n\nClin Nutr 85:1552-6, 2007 which teaches the following:\n\n\nCinnamon (6g) reduced postprandial blood glucose AUC by 52% at 45 minutes (from 68.1 to 32.4, table 1) in healthy people. TABLE 1\n\n\nPostprandial blood glucose areas under the curve (AUCs) in healthy subjects after ingestion of meals consisting of rice pudding with or without added cinnamon\n1\n\n\n\n\n\n\n \n1\nAIl values are x ± SEM; n = 14. Significant differences in postprandial blood glucose AUCs were evaluated with Wilcoxon's t test. 2Significantly different from rice pudding without cinnamon, P<0.05.\n\n\nCinnamon (6g) was also shown to have reduced fasting blood glucose by 54% (from 2.6 to 1.2 mmol/L, Fig 1) in healthy people.\n\n\n\n\n\n\n\n\n0 15 30 45 60 75 9D 105 120 135 Time {mtnϊ\n\n\nFigure 1 - Mean (± SEM) incremental blood glucose concentrations in 14 healthy subjects after ingestion of meals consisting of rice pudding with (■) and without (\nA\n) cinnamon. Δ, change. * Significantly different from the response to rice pudding with cinnamon, P<0.05.\n\n\nZiegenfuss et al., also showed the effect of water-soluble cinnamon extract in pre- diabetic men and women. J Int Soc Sports Nutrition 3(2):45-53, 2006 \n\n \n\n\n\n\n\nFigure 2. Significant Changes in Primary Endpoints During the Study. Data are expressed as change scores (week 12 - week 0). Values represent group means ± SE. P-values were calculated from repeated measures (group x time) ANOVA, except for % fat where a dependent t-test was used following a marginally significant (P<0.06) interaction term.\n\n\nCinnulin (2 capsules of 250 mg twice per day, 500 mg/day), for 12 weeks, reduced FBS by 8.4% (from 116.3 to 106.5 mg/dL)\n\n\nCinnulin PF\n®\n 500 mg = 1Og of whole cinnamon powder (i.e., 20: 1 extract) containing at least 1% doubly-linked polyphenol type a polymers.\n\n\nGinseng also reduces plasma glucose concentration in the human. The effective amount of ginseng preferably present, is in the form of ginseng extract standardized at 1.5 to 7% of ginsenosides.\n\n\nThe term ginseng refers to several species of the genus Panax. For more than two thousand years, the roots of this slow-growing plant have been valued in Chinese medicine. The two most commonly used species are Asian ginseng (Panax ginseng CA. Meyer), which is mostly extinct in its natural range but is still cultivated, and American ginseng (P. quinquefolius L.), which is both harvested from the wild and cultivated. Panax ginseng should not be confused with Siberian ginseng (Eleutherococcus senticosus). In Russia, Siberian ginseng was promoted as a cheaper \n\n alternative to ginseng and was believed to have identical benefits. However, Siberian ginseng does not contain the ginsenosides that are present in the Panax species, which are believed to be active ingredients and have been studied scientifically.\n\n\nIn \"Ginsengs: A Review of Safety and Efficacy\", Nutrition in Clinical Care 3(2):90, 2000 by Gail E. Mahady et al., an investigation of ginseng involved a standardized extract of panax ginseng containing 1.5 to 7% of ginsenosides. The recommended dose was 0.5 to 2g per day of dried root, corresponding to 100 to 300 mg per day of this extract.\n\n\nIn another example, in Ginsana G2G® (a ginseng supplement) the recommended daily dose is 200 mg of ginseng extract per day.\n\n\nAccording to the U.S. National Institutes of Health website, the daily therapeutic dosage of ginseng root is 0.5-2g of the dried root, or 100 to 300 mg per day of a standardized extract containing 1.5 to 7% ginsenosides, or other preparations taken correspondingly. The German Commission E recommends Panax ginseng at the dosage of 1 -2g of root or equivalent preparations taken daily.\n\n\nStandardized extracts are recommended with the dosage of 200-500mg daily. Capsules of powdered root extracts are recommended with the dosage of 200-500mg daily or l-4g of powdered root per day. Tincture is recommended at the dosage of l-2ml daily of 1 :1 extract\n\n\n(equivalent to 1-2 grams ginseng root).\n\n\nPositive clinical trials with Panax ginseng generally involve a dosage of greater than 1 gram per day.\n\n\nAccording to the U.S. National Institutes of Health, exceeding the recommended dose of Asian ginseng may cause adverse reactions such as \n\n hypertension, diarrhea, nervousness and insomnia. They also note that while there are no contraindications, Panax ginseng should be used with caution during pregnancy, nursing, and in children under the age of 12 years old, as safety data is currently unavailable. Ginsenosides are a group of triterpenoid saponins that can be classified into two groups by the skeleton of their aglycones, namely dammarane- and oleanane- type. Ginsenosides are found nearly exclusively in Panax species (ginseng) and up to now more than 150 naturally occurring ginsenosides have been isolated from roots, leaves/stems, fruits, and/or flower heads of ginseng. Ginsenosides have been the target of a lot of research as they are believed to be the main active principles behind the claims of ginseng's efficacy. The potential health effects of ginsenosides include antidiabetic effects. Ginsenosides can be metabolized in the stomach (acid hydrolysis) and in the gastrointestinal tract (bacterial hydrolysis) or transformed to other ginsenosides by drying. Where the at least one ingestible ingredient comprises effective amounts of cinnamon and/or ginseng, the amounts may be from cinnamon extract and ginseng extract mixed with the table sugar. Thus, the cinnamon extract may include cinnamon aqueous extract TCl 12 which has at least about 12% (w/w) polyphenols (preferably containing at least about 1% doubly-linked polyphenol Type A polymers). The ginseng extract may include ginseng extract from panax ginseng standardized at 1.5 to 7% of ginsenosides. In one embodiment, the ratio of cinnamon extract to ginseng extract is 1 to 1 by weight.\n\n\nWith respect to daily dosages of the cinnamon extract which is 120 mg of cinnamon aqueous extract having at least about 12% (w/w) polyphenols and the \n\n ginseng extract is equivalent of 120 mg of ginseng standardized at 1.5 to 7% of ginsenosides.\n\n\nThus in one embodiment the packets or sachets of , for example table sugar, preferably contain an effective amount of a form cinnamon (and/or polyphenols) or an effective amount of a form of ginseng (and/or gensenosides) or an effective amount of a combination of the two for the maintenance or lowering of blood-sugar levels (for consumption for example by diabetics, those marginally diabetic or those who are diabetic but do not know they are).\n\n\nBecause the average person consumes 3 \n1\nA cups of coffee (or tea) a day, each packet or sachet may for example contain 2/7 of the suggested daily dosage of the beneficial ingredient(s). such as cinnamon (or the polyphenols) or ginseng (or the ginsenosides) or combinations thereof. Therefore the user in 3 \n1\nA cups of coffee (or tea) would have his/her daily dose of the beneficial ingredients. This is assuming the amount of table sugar in each packet is 1 teaspoon. Where the packets contain larger amounts, for example containing two teaspoons of table sugar, the packets contents of the beneficial ingredient would be adjusted for example by increasing the amounts of their contents.\n\n\nThere are no concerns of overdoses with cinnamon given in moderation. The same is expected with respect to ginseng which is relatively safe even in relatively large amounts. Thus over the long run the coffee user (or tea user) is helped to deal with health issues related to diabetes and excess table sugar.\n\n\nPreparation of packages and/or sachets of the ingredients may be by combining the ingredients to be put in each package by mixing them together in a mixer (where the ingredients are solids) or by spray drying the liquid(s) (for example where one ingredient is a liquid for example cinnamon extract) onto the table sugar \n\n during mixing, drying the material and then granulating to form the mix or before packaging in the packets and/or sachets as would be understood by persons skilled in the art. The mixed material may instead of being packaged in the packages or sachets, may be bulk packaged. The bulk material may then be used to fill for example sugar bowls.\n\n\nThus, in another embodiment, where cinnamon extract is used instead of raw cinnamon, the extract would have for example a polyphenol content at least equivalent to or slightly greater than the polyphenol content of the raw cinnamon used. This is because cinnamon extracts are more concentrated than raw cinnamon. Thus cinnamon extracts used would have equivalent polyphenol content as for example between about .01 grams of raw cinnamon to about .4 grams of raw cinnamon per gram of sugar.\n\n\nThus a packet of sugar (3 grams of sugar or one teaspoon) may have for example between about .03 grams of raw cinnamon or equivalent to about 1.2 grams of raw cinnamon or equivalent.\n\n\nFurther where ginseng extract is used instead of raw ginseng, the extract would have for example a ginsenoside content at least equivalent to or slightly greater than the ginsenoside content of the raw ginseng used. This is because ginseng extract is more concentrated than raw ginseng. Thus ginseng extracts used would have equivalent ginsenoside content as for example between about 0.14 grams of raw ginseng to about 0.6 grams of raw ginseng per gram of sugar.\n\n\nThus a packet of sugar (3 grams or one teaspoon) may have for example between about 0.14 grams of raw ginseng or equivalent and about 0.6 grams of raw ginseng or equivalent. \n\n These amounts of cinnamon and ginseng can be adjusted up or down as desired. As may be the equivalent amount of extract of each or the amount of polyphenols or ginsenosides.\n\n\nThe ginseng and cinnamon may be combined with the sugar as discussed above.\n\n\nA Certificate of Analysis for Batch No. CC/08007 from Natural Remedies Private Limited yielded the following test results in respect of suitable cinnamomum cassia extract suitable for use herein.\n\n\n> 12% total polyphenols. Botanical name Cinnamomum cassia\n\n\nPart used bark\n\n\nExtract ratio 20:1\n\n\nSolvent used Water, Methanol\n\n\nExcipients Collodal silicon dioxide (0-2% approx.)\n\n\nSL.\n\n\nNO. TESTS SPECIFICATION RESULT TEST PROTOCOL\n\n\n1. Description Reddish brown to Brown\n\n\nDark brown powder powder\n\n\n2. HPLC Fingerprint To pass the test Compiles By HPLC\n\n\n[NR/QCD/APM04 WI(49)]\n\n\n3. Moisture (% w/w) <8.0 4.3 As per USP <921> Method II\n\n\n4. pH (5% w/v solution) 4.0 - 7.0 5.1 As per USP <791>\n\n\n5. Total ash content (% < 15.0 6.4 As per USP <561> w/w)\n\n\n6. Acid insoluble Ash (% < 5.0 0.2 As per USP <561> w/w)\n\n\n7. Bulk density (g/cc) 0.15 - 0.60 0.42 As per USP <616> \n\n SL.\n\n\nNO. TESTS SPECIFICATION RESULT TEST PROTOCOL\n\n\n8. Tapped bolk density 0.20 - 0.80 0.64 Method -I\n\n\n(g/cc)\n\n\n9. Total soluble solids > 90.0 90.8 As per USP <561>\n\n\n(%w/w)\n\n\n10. Material passing >99.0 100 As per USP <786> through 30# BS/35 Particle size\n\n\nASTM (% w/w) distribution\n\n\n11. Heavy Metals\n\n\nLead < 5.0 ppm < 0.1\n\n\nArsenic < 2.0 ppm < 0.1 AAS/ICP-ES\n\n\nCadmium < 0.2 ppm < 0.1\n\n\nMercury < 0.1 ppm < 0.1\n\n\n12. Microbiology Test\n\n\nTotal viable < 10\n3\n CfU g \n1\n 200 aerobic count\n\n\nTotal fungal < 10\n3\n fs g\n'1\n No growth count < 10\n3\n org g \n1\n < 100 As per\n\n\nTotal WHO/PHARM/92.559/ enterbacteriaceae Absent Complies Rev. 1, Pg. 49\n\n\nE. coli Absent Complies\n\n\nSalmonella Absent Complies species\n\n\nS. aureus\n\n\n13. Courmarin content < 100.0 Complies ByHPLC\n\n\n(ppm)\n\n\n14. Bio-assay α-amylase\n\n\n< 100.0 Complies [NR/BSY/SOP/004/01] Inhibition IC\n50\n \n\n\n(mcg/ml)\n\n\n15. Phytochemical Analysis > 12.0 12.5 By Spectrophotometry\n\n\nTotal [NR/QCD/APM06 polyphenols (% WI(18)] w/w)\n\n\nA Certificate of Analysis for Ginseng Dry Extract 108, Analysis Certificate N. 68297/1 in respect of Panax ginseng CA. Meyer suitable for use herein gave the following test results in respect of the extract.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAs many changes can be made to the embodiments of the invention without departing from the scope of the invention, it is intended that all material herein be interpreted as illustration of the invention and no in a limiting sense.\n\n\nHBdocs - 7222377vl"
  },
  {
    "id": "WO2010047839A1",
    "text": "Modified plant virus particles and uses therefor AbstractAspects of the invention provide modified virus-like particles that are designed for therapeutic applications. In particular, aspects of the invention provide CCMV coat proteins that are modified to generate virus-like particles, including mosaic virus-like particles, that can package and/or deliver one or more diagnostic and/or therapeutic agents. The invention also provides methods for treating subjects with one or more modified virus-like particles. Claims\n\n\n\n\nCLAIMS:\n\n\n\n\n1. A virus-like particle (VLP) preparation comprising: a mosaic VLP of two or more different CCMV coat proteins, wherein at least one of the coat proteins is modified to include a targeting peptide that comprises an integrin-binding motif.\n\n\n\n\n\n\n2. The VLP preparation of claim 1, wherein at least one of the coat proteins has a N- terminal deletion within the first 26 amino acids and wherein the deletion is of 1 to 26 amino acids in length.\n\n\n\n\n\n\n3. The VLP preparation of claim 1 or claim 2, wherein at least one of the coat proteins comprises an amino acid sequence of a bacteriophage coat protein or functional portion thereof.\n\n\n\n\n\n\n4. The VLP preparation of any of claims 1 to 3, wherein at least one of the coat proteins comprises one or more amino acid substitutions within the first 26 N-terminal amino acids and/or the coat protein comprises one or more amino acid substitutions and/or amino acid deletions within amino acids 52-176 of the coat protein.\n\n\n\n\n\n\n5. The VLP preparation of any of claims 1 to 4, wherein at least one of the coat proteins comprises a moiety selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid, a natural or synthetic polymer, a histidine tag, folic acid, a second targeting peptide not comprising an integrin-binding sequence, an antibody or functional fragment thereof, and a receptor ligand molecule.\n\n\n\n\n\n\n6. The VLP preparation of any of claims 1 to 5, wherein at least one of the coat proteins comprises an amino acid sequence that interacts selectively with a nucleic acid motif that is present on a heterologous RNA molecule.\n\n\n\n\n\n\n7. The VLP preparation of any of claims 1 to 6, further comprising a heterologous RNA molecule.  \n\n\n\n\n\n\n8. The VLP preparation of claim 7, wherein the heterologous RNA molecule is a microRNA (miRNA), a short interfering RNA (siRNA), a double-stranded RNA (dsRNA), a short hairpin RNA (shRNA), RNAu, or an antisense RNA molecule.\n\n\n\n\n\n\n9. The VLP preparation of any of claims 1 to 5, further comprising a therapeutic molecule.\n\n\n\n\n\n\n10. The VLP preparation of any of claims 1 to 5, further comprising a diagnostic molecule.\n\n\n\n\n\n\n11. The VLP preparation of any of claims 7 to 10, wherein the molecule is present in the interior of the assembled mosaic VLP.\n\n\n\n\n\n\n12. The VLP preparation of claims 7 or 8, wherein the heterologous RNA molecule targets a cellular RNA associated with a disease or disorder.\n\n\n\n\n\n\n13. The VLP preparation of claim 3, wherein the bacteriophage coat protein is selected from the group consisting of bacteriophage MS2 coat protein and bacteriophage Qbeta coat protein.\n\n\n\n\n\n\n14. The VLP preparation of claim 13, further comprising a heterologous RNA molecule, wherein the a heterologous RNA molecule comprises a sequence selected from the group consisting of MS2 hairpin/translational operator (TR) and Qbeta hairpin/translational operator (TR).\n\n\n\n\n\n\n15. The VLP preparation of claim 14, wherein the heterologous RNA molecule is a microRNA (miRNA), a short interfering RNA (siRNA), a chemically modified short interfering RNA, a double-stranded RNA (dsRNA), a short hairpin RNA (shRNA), RNAu, a circular siRNA, a hybrid DNA-siRNA, a crook siRNA or an antisense RNA molecule.\n\n\n\n\n\n\n16. The VLP preparation of claim 1, wherein the integrin-binding motif comprises a RGD amino acid sequence.  \n\n\n\n\n\n\n17. The VLP preparation of claim 16, wherein the integrin-binding motif comprises the sequence of the RGD-4C peptide.\n\n\n\n\n\n\n18. The VLP preparation of claim 17, wherein the integrin-binding motif comprises the sequence of NA VPNLRGDLQ VLAQK VART (SEQ ID NO: 505).\n\n\n\n\n\n\n19. The VLP preparation of claim 2, wherein the deletion comprises amino acids 1-26.\n\n\n\n\n\n\n20. The VLP preparation of claim 4, wherein the one or more amino acids that are substituted are selected from the group consisting of Lys8, Argl 1, Argl4, Argl5, Argl9, Lys20, Lys22, Arg23, Arg26 of SEQ ID NO:1.\n\n\n\n\n\n\n21. The VLP preparation of claim 20, wherein the one or more amino acids are substituted with Asp and/or GIu.\n\n\n\n\n\n\n22. The VLP preparation of claim 4, wherein one or more amino acids of the first 26 N- terminal amino acids MSTVGTGX\n1\nLTX\n2\n AQX\n3\n X\n4\n AAAX\n5\nX\n6\nNX\n7\nX\n8\nNTX\n9\n (SEQ ID NO: 2) are substituted, wherein one or more positions of Xj -Xg are modified by substituting a wild- type amino acid as set forth in SEQ ID NO:1 for an amino acid selected from the group consisting of Asp, GIu, His, Cys, Phe, Tyr, or Trp at one or more positions of X]-X\n9\n.\n\n\n\n\n\n\n23. The VLP preparation of claim 1, wherein the targeting peptide is fused to the modified coat protein as part of a chimeric protein.\n\n\n\n\n\n\n24. The VLP preparation of claim 18, wherein the targeting peptide is chemically attached, directly or indirectly, to the modified coat protein.\n\n\n\n\n\n\n25. The VLP preparation of claim 5, wherein the moiety is chemically attached, directly or indirectly, to the modified coat protein.\n\n\n\n\n\n\n26. The VLP preparation of claim 5, wherein the moiety is a targeting peptide that is fused to the modified coat protein as part of a chimeric protein.  \n\n\n\n\n\n\n27. The VLP preparation of claim 25, wherein the moiety reduces immunogenicity of the VLP in vivo.\n\n\n\n\n\n\n28. The VLP preparation of claim 27, wherein the modification is a chemical modification that masks immunogenic antigens of the coat protein on the exposed surface of the VLP.\n\n\n\n\n\n\n29. The VLP preparation of claim 27, wherein the moiety reduces immunogenicity of the VLP in humans.\n\n\n\n\n\n\n30. The VLP preparation of any of claims 1-30, wherein the therapeutic molecule is selected from the group consisting of an anti-cancer drug, an antibiotic, an anti-viral agent, an anti-microbial agent, an anti-inflammatory agent, and an immunostimulatory agent.\n\n\n\n\n\n\n31. The VLP preparation of claim 31 , wherein the targeting moiety directs the VLP to a tumor, a site of inflammation, a site of wound healing, a site of soft tissue damage, a site of bone or cartilage damage, a site of immune cell regeneration, across the blood-brain barrier, or a site of fat cell deposition.\n\n\n\n\n\n\n32. The VLP preparation of claim 7 or 30, wherein the integrin targeting peptide directs the VLP to a tumor.\n\n\n\n\n\n\n33. The VLP preparation of claim 32, wherein the tumor is a melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer.\n\n\n\n\n\n\n34. The VLP preparation of claim 30, wherein the anti-cancer drug is selected from the group consisting of Docetaxel, Paclitaxel, Capecitabine, Doxorubicin, and Rapamycin.\n\n\n\n\n\n\n35. The VLP preparation of claim 10, wherein the diagnostic molecule is an imaging agent.\n\n\n\n\n\n\n36. The VLP preparation of claim 35, wherein the imaging agent is useful for detection with Magnetic Resonance Imaging (MRI).  \n\n\n\n\n\n\n37. The VLP preparation of any of claims 1 to 5, further comprising a heterologous nucleic acid molecule.\n\n\n\n\n\n\n38. The VLP preparation of claim 37, wherein the heterologous nucleic acid molecule is an expression vector for a gene.\n\n\n\n\n\n\n39. The VLP preparation of claim 38, wherein the gene encodes a cytokine or other signaling molecule.\n\n\n\n\n\n\n40. The VLP preparation of claim 39, wherein the cytokine or other signaling molecule is pro- or anti-inflammatory.\n\n\n\n\n\n\n41. The VLP preparation of claim 39, wherein the cytokine or other signaling molecule is pro- or anti-apoptotic.\n\n\n\n\n\n\n42. The VLP preparation of any one of claims 4, and 20 to 22, wherein the modified coat protein comprises a modification that promotes its interaction with a heterologous therapeutic or diagnostic molecule.\n\n\n\n\n\n\n43. The VLP preparation of claim 42, wherein the heterologous therapeutic molecule is 5- fluorouracil, leucovorin, capecitabine, cyclosphosphamide, docetaxel, paclitaxel, or gemcitabine.\n\n\n\n\n\n\n44. The VLP preparation of any one of claims 35-42, wherein the integrin targeting peptide directs the VLP to cells or tissues that express integrins.\n\n\n\n\n\n\n45. The VLP preparation of claim 1-44, wherein the integrin expressed by the cells or tissues is an αv integrin.\n\n\n\n\n\n\n46. The VLP preparation of claim 2, wherein the N-terminal deletion within the first 26 amino acids is a deletion of amino acids 8-26.\n\n\n\n\n\n\n47. A synthetic DNA encoding the modified coat protein of any one of claims 1-4.  \n\n\n\n\n\n\n48. The DNA of claim 47, wherein the coding sequence is codon optimized for expression in yeast.\n\n\n\n\n\n\n49. The DNA of claim 47, wherein the coding sequence is codon optimized for expression in human cells.\n\n\n\n\n\n\n50. The DNA of claim 47, wherein the coding sequence is codon optimized for expression in bacteria.\n\n\n\n\n\n\n51. A host cell comprising the synthetic DNA of any one of claims 47-50.\n\n\n\n\n\n\n52. The host cell of claim 51, wherein the host cell is a mammalian cell, a bacteria, or a yeast.\n\n\n\n\n\n\n53. The host cell of claim 52, wherein the bacterial host cell is E.coli and wherein the yeast host cell is P.pastoris.\n\n\n\n\n\n\n54. A pharmaceutical composition comprising the VLP preparation of any one of claims 1-46 and 65-81.\n\n\n\n\n\n\n55. A pharmaceutical preparation comprising the VLP preparation of any one of claims 1-46 and 65-81 in combination with a non-VLP pharmaceutical compound.\n\n\n\n\n\n\n56. A method of treating a subject having an adverse condition, the method comprising administering to the subject the VLP preparation of any one of claims 1-46 and 65-81 or a pharmaceutical composition of claim 54 or 55 in an amount effective to treat the condition.\n\n\n\n\n\n\n57. The method of claim 56, wherein the adverse condition is selected from the group consisting of tumor, asthma, liver disease, heart disease, and Alzheimer's disease.\n\n\n\n\n\n\n58. The method of claim 57, wherein the tumor is a melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer.  \n\n\n\n\n\n\n59. A method of preparing a mosaic VLP preparation, the method comprising combining at least two different CCMV coat proteins, wherein at least one coat protein is modified according to any one of claims 1-6, 13-29, 30-33, 44-46, and 69-81, so that a mosaic VLP is generated.\n\n\n\n\n\n\n60. The method of claim 59, further comprising combining a therapeutic molecule, a diagnostic molecule, or a heterologous nucleic acid with the at least two different CCMV coat proteins.\n\n\n\n\n\n\n61. Use of a VLP preparation of any one of claims 1-46 and 65-81 for preventing or treating an adverse condition.\n\n\n\n\n\n\n62. Use of a VLP preparation of any one of claims 1-46 and 65-81 for the manufacture of a medicament for preventing or treating an adverse condition.\n\n\n\n\n\n\n63. The use of claim 61 or 62, wherein the adverse condition is selected from the group consisting of tumor, asthma, liver disease, heart disease, and Alzheimer's disease.\n\n\n\n\n\n\n64. The use of claim 63, wherein the tumor is a melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer.\n\n\n\n\n\n\n65. The VLP preparation of claim 12, wherein the cellular RNA is mammalian.\n\n\n\n\n\n\n66. The VLP preparation of claim 65, wherein the cellular RNA is mammalian.\n\n\n\n\n\n\n67. The VLP preparation of claim 12, wherein the disease or disorder is selected from the group consisting of a tumor, asthma, liver disease, heart disease, and Alzheimer's disease.\n\n\n\n\n\n\n68. The VLP preparation of claim 67, wherein the tumor is a melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer.\n\n\n\n\n\n\n69. The VLP preparation of claim 4, wherein the coat protein comprises one or more amino acid substitutions and/or amino acid deletions within amino acids 52-176 of the coat protein and wherein the amino acid substitutions and/or amino acid deletions are made within  one or more of the five exterior surface-exposed loops, selected from the group consisting of βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72- 75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29-135), and βH-βl (SAALTEGD (SEQ ID NO: 22), aal61-168).\n\n\n\n\n\n\n70. The VLP preparation of claim 4, wherein the coat protein comprises one or more amino acid substitutions within amino acids 52-176 of the coat protein and wherein the substitution promotes direct or indirect attachment of a moiety, selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid, a natural or synthetic polymer, a histidine tag, folic acid, a second targeting peptide not comprising an integrin-binding sequence, an antibody or functional fragment thereof, and a receptor ligand molecule.\n\n\n\n\n\n\n71. The VLP preparation of claim 70, wherein the one or more amino acid substitutions within amino acids 52-176 of the coat protein are selected form the group consisting of cysteine, lysine, aspartic acid and glutamic acid.\n\n\n\n\n\n\n72. The VLP preparation of claim 71, wherein the number of total cysteine, lysine, aspartic acid and/or glutamic acid is increased to provide an increased number of sites allowing chemical conjugation of moieties selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid, a natural or synthetic polymer, a histidine tag, folic acid, a second targeting peptide not comprising an integrin-binding sequence, an antibody or functional fragment thereof, and a receptor ligand molecule.\n\n\n\n\n\n\n73. The VLP preparation of claim 72, wherein cysteine, lysine, aspartic acid and/or glutamic acid amino acids provide surface-exposed functional groups on the VLP that can be chemically modified.\n\n\n\n\n\n\n74. The VLP preparation of claim 73, wherein the surface-exposed functional groups are thiol, amine and/or carboxyl groups.\n\n\n\n\n\n\n75. The VLP preparation of claim 74, wherein the surface-exposed functional groups on the VLP are chemically conjuged with one or more of the moieties of claim 72 using maleimide derivatives, N-hydroxysuccinimide (NHS) esters, N-ethyl-N'-(3- dimethylaminopropyl) carbodiimide (EDC) and/or NHS.  \n\n\n\n\n\n\n76. The VLP preparation of claim 45, wherein the αv integrin is selected from the group consisting of αvβl, αvβ3, αvβ5, αvβ6, and αllβvβ3 integrin.\n\n\n\n\n\n\n77. A VLP preparation comprising: a mosaic VLP of two or more different CCMV coat proteins, wherein at least one of the coat proteins comprises a targeting peptide and one or more additional modifications, wherein the targeting peptide comprises an integrin-binding motif.\n\n\n\n\n\n\n78. The VLP preparation of claim 77, wherein the one or more additional modifications are selected from the group consisting of :\n\n\n(a) a N-terminal deletion within the first 26 amino acids and wherein the deletion is of 1 to 26 amino acids in length;\n\n\n(b) an N-terminal substitution, wherein the substitution comprises an amino acid sequence of a bacteriophage coat protein or functional portion thereof;\n\n\n(c) an amino acid substitution within the first 26 N-terminal amino acids;\n\n\n(d) an amino acid substitutions and/or amino acid deletion within amino acids 52-176 of the coat protein; and\n\n\n(e) an addition of a moiety selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid, a natural or synthetic polymer, a histidine tag, folic acid, a second targeting peptide not comprising an integrin-binding sequence, an antibody or functional fragment thereof, and a receptor ligand molecule.\n\n\n\n\n\n\n79. The VLP preparation of claim 78, wherein the amino acid substitutions and/or amino acid deletion within amino acids 52-176 of the coat protein is within one or more of the five exterior surface-exposed loops, selected from the group consisting of βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29- 135), and βH-βl (SAALTEGD (SEQ ID NO: 22), aal61-168).\n\n\n\n\n\n\n80. The VLP preparation of claim 78, wherein the amino acid substitution within the first 26 N-terminal amino acids interacts selectively with a nucleic acid motif that is present on a heterologous RNA molecule.  \n\n\n\n\n\n\n81. The VLP preparation of any one of claims 1-46, and 65-80, wherein at least one of the coat proteins is unmodified wild-type CCMV coat protein.\n\n\n\n\n\n\n82. The method of claim 60, wherein the therapeutic molecule is selected from the group consisting of an anti-cancer drug, an antibiotic, an anti-viral agent, an anti -microbial agent, an anti-inflammatory agent, and an immunostimulatory agent; the diagnostic molecule is an imaging agent; and the heterologous nucleic acid is selected from the group consisting of a heterologous RNA molecule, a microRNA (miRNA), a short interfering RNA (siRNA), a chemically modified short interfering RNA, a double-stranded RNA (dsRNA), a short hairpin RNA (shRNA), RNAu, a circular siRNA, a hybrid DNA- siRNA, a crook siRNA, an antisense RNA molecule, and an expression vector comprising a gene.\n\n\n\n\n\n\n83. The method of claim 82, wherein wherein the anti-cancer drug is selected from the group consisting of Docetaxel, Paclitaxel, Capecitabine, Doxorubicin, and Rapamycin.\n\n\n\n\n\n\n84. The VLP preparation of any one of claims 1 to 4, wherein the targeting peptide is integrated within one or more of the five exterior surface-exposed loops, selected from the group consisting of βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29-135), and βH-βl (SAALTEGD (SEQ ID NO: 22), aal61-168).\n\n\n\n\n\n\n85. The VLP preparation of any one of claims 1 to 4, comprising at least two different CCMV coat proteins that are present in a relative ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, or at a higher ratio.\n\n\n\n\n\n\n86. The VLP preparation of claim 85, wherein the coat protein that is present at a higher level in the VLP preparation forms a more stable VLP alone, and/or self-assembles alone more efficiently to form a VLP.\n\n\n\n\n\n\n87. The VLP preparation of claim 85 or 86, comprising 2, 3, 4, 5, 6, 7, 8, 9, or 10 different CCMV coat proteins.  \n\n\n\n\n\n\n88. The method of claim 59, 60, or 82, wherein at least two different CCMV coat proteins are mixed in a relative ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, or at a higher ratio in a reassembly reaction to form a mosaic VLP preparation.\n\n\n\n\n\n\n89. The method of claim 88, wherein the coat protein that is provided at a higher level in the reassembly reaction forms a more stable VLP alone, and/or self-assembles alone more efficiently to form a VLP.\n\n\n\n\n\n\n90. The method of claim 88 or 89, wherein 2, 3, 4, 5, 6, 7, 8, 9, or 10 different CCMV coat proteins are used in the reassembly reaction.\n\n\n\n\n\n\n91. The method of any of claims 60, 82, or 88-90, wherein the therapeutic molecule, diagnostic molecule, or heterologous nucleic acid is either mixed with the different coat proteins during assembly of the VLP or is loaded into the VLP after assembly. Description\n\n\n\n\n MODIFIED PLANT VIRUS PARTICLES AND USES THEREFOR\n\n\nRELATED APPLICATIONS This application claims the benefit of the filing date of U.S. provisional patent application 61/197,400, filed October 25, 2008 and entitled \"Modified Plant Virus Particles and Uses Therefor\". The entire teachings of the referenced provisional patent application are expressly incorporated herein by reference.\n\n\nBACKGROUND OF THE INVENTION\n\n\nThe efficacy of many new classes of pharmaceuticals and biologies (e.g., peptides, proteins and DNA-based therapeutics) as well as many traditional therapeutics based on small molecules is often limited by difficulties delivering these agents in vivo. Many drugs typically cannot be effectively delivered by conventional means, such as oral ingestion, injection, or inhalation. Not only are many drugs subjected to rapid degradation or metabolism, but they often are characterized by general low bioavailability, and systemic administration often causes many undesired side-effects.\n\n\nFor example, although oral delivery is probably the most widely accepted form of drug delivery, it presents difficulties for a number of important classes of drugs where oral delivery mechanisms can only provide a bioavailability of a few percent, and dose limiting toxicity levels are caused by lack of selectivity. Accordingly, there is an unmet need for delivery strategies that increase drug half-life, bioavailability and targeted, sustained release of key drugs.\n\n\nSUMMARY OF THE INVENTION\n\n\nAspects of the invention relate to drug delivery methods and compositions. In particular, aspects of the invention relate to virus-like particles (VLPs) containing one or more viral coat proteins that have been modified to deliver a heterologous agent to a subject (e.g., a human subject, or an animal subject). In some embodiments, viral coat proteins are modified to improve loading and/or stable packaging of a heterologous agent. In some embodiments, viral coat proteins are modified to improve stability of the coat protein and associated heterologous agent within a subject (e.g., within the plasma of a subject). In some \n\n embodiments, viral coat proteins are modified to enhance the release of a heterologous agent at a target site (e.g., within a target cell) of a subject. In some embodiments, mosaic VLPs are used. Mosaic VLPs include two or more different viral coat proteins in a single particle. One of the coat proteins may be a wild-type protein. However, both or all of the different coat proteins may be modified. In some embodiments, one of the coat proteins is modified to contain a targeting motif such as an RGD motif. Aspects of the invention are based, at least in part, on i) the discovery that RGD motifs can destabilize VLPs, and ii) the identification of mosaic structures that can form stable VLP preparations that incorporate coat proteins modified to include an RGD motif. Mosaic VLPs can be used to deliver one or more therapeutic or diagnostic agents as described herein. In some embodiments, a mosaic may include coat proteins that are modified to include a targeting motif and coat proteins that are modified (e.g., with an N-terminal deletion and/or modification) to facilitate the loading and/or delivery of a heterologous agent.\n\n\nIt should be appreciated that a heterologous agent may be a diagnostic agent, a reporter molecule (e.g., gene, protein, and/or RNA), and/or a therapeutic molecule. A therapeutic molecule may be a small molecule, a polypeptide, a nucleic acid (e.g., an RNA, a DNA, or other natural or synthetic nucleic acid molecule) a gene encoding a polypeptide, any other naturally occurring or synthetic therapeutic molecule, or any combination of two or more thereof. Aspects of the invention may be used to package and/or deliver a therapeutic agent that is an anti-cancer drug. In some embodiments, an anti-cancer drug may be 5-fluorouracil, leucovorin, capecitabine, cyclosphosphamide, docetaxel, placitaxel, or gemcitabine. In some embodiments, an anti-cancer drug may be a platin-based drug such as cisplatin, carboplatin, oxaliplatin, or satraplatin. However, other anti-cancer drugs may be used as described as the invention is not limited in this respect.\n\n\nAspects of the invention may be used to package and/or deliver a therapeutic agent that is useful to treat an infection, an inflammatory disorder, cancer, and/or any other disease or disorder.\n\n\nAspects of the invention may be used to package and/or deliver a nucleic acid that may be used to silence the expression of one or more target genes. For example, methods and compositions of the invention may be used to deliver an siRNA, an antisense RNA, or any combination thereof. It should be appreciated that RNAi and/or antisense RNA may be used to treat cancer, an infectious disease (e.g., hepatitis B or C), or any other disease or disorder as described herein. \n\n It should be appreciated that the choice of VLP may be governed in some embodiments, at least in part, by the ability to disassemble the VLPs after their production and then to reassemble them in the presence of a heterologous agent and/or to load them with the heterologous agent after assembly such that said agent is encapsulated. A number of VLPs are potentially suitable for applications described herein, including the bacteriophages MS, Qβ, Rl 7, fr, GA, Sp, MI, I, MXI, NL95, AP205, f2, PP7, and the plant viruses Turnip crinkle virus (TCV), Tomato bushy stunt virus (TBSV), Southern bean mosaic virus (SBMV) and members of the genus Bromovirus including Broad bean mottle virus, Brome mosaic virus, Cassia yellow blotch virus, Cowpea chlorotic mottle virus (CCMV), Melandrium yellow fleck virus, and Spring beauty latent virus. However, other VLPs also may be used as aspects of the invention are not limited in this respect.\n\n\nIt should be appreciated that in some embodiments VLP coat proteins may be isolated directly from an expression system without isolating and disassembling a formed VLP. Certain variant coat proteins may self-assemble less efficiently than wild-type or other variant coat proteins. However, according to aspects of the invention, variant coat proteins that are self-assembly defective may self-assemble under certain conditions and/or in the presence of one or more efficiently self-assembling variants and/or wild-type coat proteins. Accordingly, poorly self-assembling variants are nonetheless referred to as self-assembling proteins herein to indicate that they are capable of forming VLPs or mosaic VLPs under certain conditions. In some embodiments, a mosaic VLP is prepared by mixing two or more different coat proteins under conditions that promote reassembly of a VLP. One or more of the different coat proteins may be obtained either directly from an expression system, from disassembly of a VLP (e.g., a homogeneous VLP), or from any other suitable source or combination thereof. In some embodiments, a reassembled VLP preparation may be used without any further processing. In some embodiments, a reassembled VLP preparation may be further processed (e.g., to add one or more agents, to remove non-assembled coat proteins, to remove precipitated VLP or coat protein, to sterilized the preparation, etc., or any combination thereof) to form a VLP preparation that is used, for example, in therapy (e.g., administered to a subject, e.g., a human subject). In some embodiments, aspects of the invention relate to compositions comprising a\n\n\nVLP preparation, e.g., a mosaic VLP preparation. In some embodiments, provided herein are virus-like particle (VLP) preparations comprising a mosaic VLP of two or more different self-assembling CCMV coat proteins, wherein at least one of the coat proteins is modified to include a targeting peptide that comprises an integrin-binding sequence. \n\n In some embodiments, provided herein are VLP preparations comprising a mosaic VLP of two or more different self-assembling CCMV coat proteins wherein at least one of the coat proteins has a N-terminal deletion within the first 26 amino acids and wherein the deletion is of 1 to 26 amino acids in length. In some embodiments, provided herein are VLP preparations comprising a mosaic\n\n\nVLP of two or more different self-assembling CCMV coat proteins, wherein at least one of the coat proteins comprises a bacteriophage coat protein sequence.\n\n\nIn some embodiments, provided herein are VLP preparations comprising a mosaic VLP of two or more different self-assembling CCMV coat proteins, wherein at least one of the coat proteins comprises one or more amino acid substitutions within the first 26 N- terminal amino acids.\n\n\nIn some embodiments, provided herein are VLP preparations comprising a mosaic VLP of two or more different self-assembling CCMV coat proteins, wherein at least one of the coat proteins comprises a moiety selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid, a natural or synthetic polymer, a histidine tag, folic acid, a second targeting peptide not comprising an integrin-binding sequence, an antibody or functional fragment thereof, and a receptor ligand molecule.\n\n\nIn some embodiments, provided herein are VLP preparations comprising a mosaic VLP of two or more different self-assembling CCMV coat proteins, wherein at least two of the coat proteins are modified according to any of the forgoing claims.\n\n\nIn some embodiments, provided herein are VLP preparations comprising a mosaic VLP of two or more different self-assembling CCMV coat proteins, wherein at least one of the coat proteins is modified using any of the techniques described herein and at least one coat protein is unmodified. Aspects of the invention are based, at least in part, on the recognition that specific combinations of subunits aid the assembly of specific therapeutically useful mosaic VLPs. In some embodiments, mosaics are useful to promote VLP formation including one or more targeting peptides such as integrin-binding motifs. Integrin-binding motifs are useful moieties for in vivo targeting of drugs and/or delivery vehicles, such as VLPs. In certain embodiments, VLPs are provided that comprise one or more peptides that are nine amino acids in length and that contain an RGD sequence in a cyclic conformation with two disulfide bonds that are highly selective for the αv-integrins. In certain embodiments, VLPs are provided that comprise one or more peptides that are about nine amino acids in length (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in length) and \n\n that contain an RGD sequence in a cyclic conformation with two disulfide bonds. In certain embodiments, the amino acids that preceed the RGD motif are serine and/or threonine. In certain embodiments, the amino acids that follow RGD are glycine and/or serine. In certain embodiments, the amino acids that preceed the RGD motif are serine and/or threonine and the amino acids that follow RGD are glycine and/or serine. In certain embodiments, the amino acids that are adjacent to the N-terminus of the RGD tri-peptide motif also include residues with hydrophobic or charged side chains. In certain embodiments, the RGD tri- peptide motif is flanked by cysteine residues, generating potentially cyclic disulfides, in which the RGD peptide is conformational Iy constrained. In certain embodiments, targeting peptides comprise one or more αv-containing integrin-binding motifs, for example the arginine-glycine-aspartic acid (RGD) motif. In certain embodiments, RGD targeting peptides comprise the sequence motif RGDLXXL/I (SEQ ID NO: 491), wherein LXXL/I is contained within an alpha helical structure. In certain embodiments, the RGD targeting peptide is NAVPNLRGDLQVLAQKVART (SEQ ID NO: 505).\n\n\nIn certain embodiments, targeting peptides are organ homing peptides (e.g., that preferentially bind to a particular cell, cell-type, tissue, etc.), for example comprising the motif SRL (serine-arginine-lysine). In certain embodiments, organ homing peptides comprise the peptide sequence CLSSRLDAC (SEQ ID NO: 492). In certain embodiments, organ homing peptides comprise the motif VLR (valine-leucine-arginine). In certain embodiments, organ homing peptides comprise the peptide sequence WRCVLREGPAGGCAWFNRHRL (SEQ ID NO: 493).\n\n\nOther examples of peptides are those that selectively home tumors and/or the vasculature supporting the tumor. Tumor homing peptides that contain the motif asparagines-glycine-arginine (NGR) or glycine-serine-leucine (GSL), or vasculature targeting peptides which comprise the NGR peptide.\n\n\nSome integrin-binding motifs due to their structure and/or charge, such as integrin- binding motifs comprising the RGD sequence, are prone to precipitation. It was discovered by the inventors that VLPs comprising CCMV coat protein subunits comprising a RGD peptide inserted in one of the surface-exposed loops of the CCMV coat protein unexpectedly were also prone to precipitation and would not efficiently assemble into VLPs that could be used for in vivo delivery of therapeutic agents to cells and tissues expressing specific integrins. Surprisingly, it was found that careful titration of CCMV coat protein subunits with different characteristics during the VLP assembly reaction prevented precipitation of the \n\n CCMV subunit comprising the RGD peptide leading to stable mosaic VLPs. Based on this strategy, in certain embodiments, methods are provided that promote VLP assembly of subunits that would not readily assemble under normal VLP assembly conditions, for example, of subunits comprising peptides which comprise the sequence motif RGDLXXL/I (SEQ ID NO: 491), wherein LXXL/I is contained within an alpha helical structure, thereby broadening the array of therapeutically useful VLPs that can be generated. In certain embodiments, the RGD targeting peptide is NAVPNLRGDLQVLAQKVART (SEQ ID NO: 505).\n\n\nIn certain embodiments, mosaic VLPs are provided that are mosaic on the outer and inner surface of the VLP. Aspects of the invention are based at least in part on the recognition that by generating mosaic VLP comprising subunits with different chemical characteristics on the inner and/or the outer surface of the mosaic VLP allows tailoring of the VLP to specific therapeutic needs.\n\n\nIn some embodiments, mosaic VLPs are provided comprising two or more different wild-type or modified CCMV coat proteins described herein. In certain embodiments, mosaic VLPs are provided comprising two or more different coat proteins selected from the following different CCMV coat protein subunits, described herein: /) wild-type; if) N- terminal deletion mutants (e.g., deletion of amino acids 1-5, 1-10, 1-15, 1-20, 1-25, 1-26, 1- 30, 1-34, 5-10, 10-15, 15-20, 20-25, 5-25, 10-25, 15-25, 1-25, 2-25, 1-26, 2-26, 2-34, 3-26, 4- 26, 5-26, 8-26 and any amino acid deletions in between); Ui) N-terminal substitution mutants (e.g., substitutions that alter charged amino acids of the wild-type sequence, e.g., one or more of the 9 (e.g., 1 or more, 2 or more, 3, 4, 5, 6, 7, 8, or 9) basic residues (Arg, Lys), e.g., to net negative (GIu or Asp) residues, or any other substitutions that alter the charge based on SEQ ID NO: 1); /v) N-terminal substitution mutants e.g., comprising portions of the MS2 coat protein; v) chimeric fusion proteins comprising one or more targeting peptides in one or more of the surface exposed loops (e.g., in amino acids 52-176 of the coat protein comprising the five exterior surface-exposed loops, βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC- αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29-135), βH-βl (SAALTEGD (SEQ ID NO: 22), aal 61-168); vf) wild-type or modified subunits comprising chemically attached targeting moieties (e.g., antibodies or antibody fragments, signaling or targeting peptides, or receptor ligand molecules); and/or viϊ) wild-type or modified subunits comprising chemically conjugated moieties that e.g., reduce in vivo immunogenicity of the VLP (e.g., PEG) or aid cellular uptake or themselves provide attachment points for further moieties (e.g., HA). It \n\n should be appreciated that the two or more different CCMV coat proteins may be different variants within any one of categories ii)-vii). In some embodiments, all of the different CCMV coat proteins in a VLP preparation may be different variants within any one of categories ii)-vii). In some embodiments, a mosaic VLP preparation may include 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different VLP coat proteins.\n\n\nIn certain embodiments, modified CCMV coat proteins are provided that each can comprise one or more features, such as those described in i) and vi); i) and vii); H) and v); ii) and vi); H) and vii); Ui) and v); Hi) and vii); Hi) and vii); iv) and v); /v) and vi); iv) and vii). In certain embodiments, mosaic VLP are provided comprising two or more subunits comprising one or more of the features described in i) to vii). In certain embodiments, mosaic VLP are provided comprising different ratios of the two or more different subunits comprising one or more of the features described in i) to vii).\n\n\nIn some embodiments, to ensure the most efficient incorporation of a heterologous molecule (e.g., drug), the pKa of the interior surface of the coat protein of a VLP can be adjusted to promote appropriate interactions between the coat protein and the heterologous molecule. In certain embodiments, the hydrophobicity of the interior surface of the coat protein of the VLP may be modified to match that of the heterologous molecule.\n\n\nIn some embodiments, a heterologous agent (e.g., a diagnostic agent or therapeutic agent) also is modified to be compatible with the modified VLP. For example, the heterologous agent may be modified to improve efficient packaging within a VLP, to improve stability within the VLP, and/or to improve release of the agent at the desired location (e.g., tissue or cell) within a subject.\n\n\nIn some embodiments, VLPs may be modified to contain one or more targeting moieties (e.g., targeting peptides) for target tissues or cell types within a subject. In some embodiments, VLPs may be modified to improve delivery within an endosome (e.g., at relatively low pH and/or under low divalent cation concentrations).\n\n\nIn some embodiments, VLPs may be modified to reduce immunogenicity within a subject (e.g., within a human subject, or an animal subject).\n\n\nModifications may be changes in charge, changes in hydrophobicity, changes in salt bridges, or any combination thereof.\n\n\nModifications may be chemical modifications (e.g., pegylation or hyaluronic acid modification). In some embodiments, a VLP may be a mosaic of modified (e.g., pegylated) and non-modified coat proteins. In some embodiments, a VLP may be a mosaic of two or more differently modified coat proteins with or without other non-modified coat proteins \n\n (e.g., wild-type coat proteins). It should be appreciated, that each modified coat protein molecule may contain one or more types and/or examples of modifications described herein.\n\n\nIn some embodiments, a composition of the invention comprises a mosaic VLP preparation wherein a targeting peptide is integrated within one or more of the five exterior surface-exposed loops, selected from the group consisting of βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29-135), and βH-βl (SAALTEGD (SEQ ID NO: 22), aal61-168), on one or more of the different coat proteins in the mosaic. In some embodiments, at least two different CCMV coat proteins are present in a relative ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, or at a higher ratio. In some embodiments, the coat protein that is present at a higher level in a mosaic VLP preparation is the one that forms a more stable VLP alone, and/or self-assembles alone more efficiently to form a VLP. In some embodiments, a mosaic VLP preparation comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different CCMV coat proteins. In certain embodiments, methods of preparing a mosaic VLP preparation are provided, the method comprising combining at least two different CCMV coat proteins, wherein at least one coat protein is modified as described herein so that a mosaic VLP is generated. In some embodiments, at least two different CCMV coat proteins are mixed in a relative ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, or at a higher ratio in a reassembly reaction to form a mosaic VLP preparation. In some embodiments, the coat protein that is provided at a higher level in the reassembly reaction is the one that forms a more stable VLP alone, and/or self-assembles alone more efficiently to form a VLP. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different CCMV coat proteins are used in the reassembly reaction. In certain embodiments, the methods further comprise combining a therapeutic molecule, a diagnostic molecule, a heterologous nucleic acid, and/or other agent with the at least two different CCMV coat proteins during reassembly. In some embodiments, a therapeutic molecule, diagnostic molecule, heterologous nucleic acid, and/or other agent is loaded into the VLP after assembly, regardless of whether the therapeutic molecule, diagnostic molecule, heterologous nucleic acid, and/or other agent was present during assembly. Accordingly, aspects of the invention relate to mosaic VLP preparations that are essentially empty shells that do not contain any additional agent or large molecule (e.g., other than water or a suitable buffer). Such preparations may be provided for subsequent loading with an agent of interest. It should be appreciated that the relative concentrations of agent \n\n and CCMV coat proteins during assembly, and/or during subsequent loading of a VLP preparation may be optimized to achieve desired levels of the agent within the VLP preparation. Accordingly, certain agents (e.g., nucleic acids, small molecules, peptides, proteins, etc.) that are inefficiently loaded can nonetheless be incorporated into VLP preparations (e.g., mosaic VLP preparations) by using sufficiently high amounts of the agent and/or optimizing the reassembly and/or loading conditions to promote loading of the agent.\n\n\nIn some embodiments, VLPs may be formulated for delivery to a subject (e.g., a human subject. In some embodiments, VLPs may be formulated for oral delivery. However, any form of delivery may be used as the invention is not limited in this respect. In some embodiments, VLP preparations and/or the components of the VLP preparations may be sterilized for storage and/or administration to a subject. It should be appreciated that any suitable sterilization technique may be used. However, the selection of a suitable sterilization technique may be based in part on the size of the VLP, the properties of the VLP coat proteins and/or the agent(s) contained within the VLP. It should be appreciated that the aspects of the invention described herein may be used in conjunction with coat protein molecules each having one or more of the types or examples of modifications described herein as the invention is not limited in this respect.\n\n\nAspects of the invention relate to therapeutic methods for treating one or more conditions, including cancer, infection, and/or other diseases or conditions. In certain embodiments, methods of treating a subject having an adverse condition are provided, the methods comprising administering to the subject a VLP preparation described herein or a pharmaceutical composition comprising a VLP preparation and optionally a non- VLP pharmaceutical composition in an amount effective to treat the condition. In certain embodiments, the adverse condition is a tumor, asthma, liver disease, heart disease, and/or Alzheimer's disease, but is not so limited. In certain embodiments, where the adverse condition is a tumor, the tumor can be a melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer, but is not so limited.\n\n\nIn certain embodiments, uses of a VLP preparation for preventing or treating an adverse condition are provided. Further, in certain embodiments, uses of a VLP preparation for the manufacture of a medicament for preventing or treating an adverse condition are provided.\n\n\nAspects of the invention relate to pharmaceutical compositions comprising a VLP preparation described herein optionally further comprising a non-VLP pharmaceutical compound. \n\n Aspects of the invention are described in connection with modified VLPs. However, it should be appreciated that aspects of the invention also provide modified viral coat proteins (e.g., isolated and/or purified coat proteins) regardless of whether they are assembled to form VLPs, nucleic acids (e.g., isolated and/or purified nucleic acids) that encode one or more coat proteins and/or heterologous agents described herein, related vectors and/or host-cells, VLPs (e.g., isolated and/or purified VLPs) with or without packaged heterologous agent, or any combination thereof.\n\n\nBRIEF DESCRIPTION OF THE DRAWINGS\n\n\nFIG. 1 is a non-limiting illustration of the synthetic CCMV coat protein gene structure showing (A) specific sites and functions, and (B) wild-type and modified nucleotide sequences (mutations that generate amino acid substitutions at the following residues in the corresponding amino acid sequence: R26H, P75G, L131R). FIG. 2 is a non-limiting illustration of the CCMV coat protein structure showing surface exposed loops (loops that were tested for targeting peptide insertions are in bold), core structure, C-terminus and non-resolved (highly mobile) N-terminal RNA binding domain.\n\n\nFIG. 3 is a non-limiting illustration of the synthetic CCMV coat protein gene cloned into pPICZ vector (A) pPICZ-CCMV, and (B) pPICZ-CCMV/N 1.\n\n\nFIG. 4 is a non-limiting illustration of (A) Coomassie stain of purified CCMV coat protein (wt: wild-type, Nl: N-terminal deletion, amino acids 8-26) on 12% PAGE, and (B) Coomassie stain (left) of purified CCMV coat protein (wt, Nl) and ethidium bromide stain on 1% agarose gel (right). FIG. 5 is a non-limiting illustration of electron microscopic images of reassembled\n\n\nVLP of wild-type (left) and Nl (right).\n\n\nFIG. 6 is a non-limiting illustration of the synthetic CCMV coat protein gene cloned into pPICZ vector (A) pPICZ-CCMV-RGD-bCaCDl, (B) pPICZ-CCMV-RGD-bFbG, (C) pPICZ-CCMV/Nl-RGD-bCaCDl, and (D) pPICZ-CCMV/Nl-RGD-bFbG. FIG. 7 is a non-limiting illustration of a western blot showing reassembled Nl and\n\n\nRGD-bCaCDl VLPs when mixed together in different ratios.\n\n\nFIG. 8 is a non-limiting illustration of various cloning constructs and sequences. \n\n DETAILED DESCRIPTION OF THE INVENTION\n\n\nDescribed herein are delivery agents, such as plant virus particles, for the delivery of agents such as diagnostic or therapeutic agents (e.g., anti-cancer agents). By \"delivery agent,\" \"delivery vehicle\" or \"protein carrier\" herein is meant a proteinaceous shell that self- assembles to form a structure with an interior cavity which is either naturally accessible to a solvent or can be made to be so by altering for example the solvent concentration, pH, or equilibria ratios, and that may contain one or more agents as discussed herein.\n\n\nIn some embodiments, a delivery vehicle is based on a modified Bromovirus particle such as a Cowpea chlorotic mottle virus (CCMV) particle. CCMV (Speir, J. A., et al., 1995, Structure 3:63-78) is a member of the bromovirus group of the Bromoviridae (Ahlquist, P., 1992, Curr. Opin. Gen. and Dev. 2:71-76; Dasgupta, R., and P. Kaesberg, 1982, Nucleic Acid Res. 5:987-998; and Lane, L. C, 1981, The Bromoviruses. In E. Kurstak (ed.), \"Handbook of plant virus infection and comparative diagnosis,\" Elsevier/North-Holland, Amsterdam). Bromoviruses are 25-28 nm icosahedral viruses with a four component (+) sense single stranded RNA genome. Purified CCMV RNA and CCMV coat protein self-assemble in vitro to produce infectious virions (Bancroft, J. B., et al., 1969, Virology 38:324-335; Bancroft, J. B., and E. Hiebert, 1967, Virology 32:354-356; Bancroft, J. B., et al., 1968, Virology 36:146- 149; Hiebert, E., and J. B. Bancroft, 1969, Virology 39:296-311; and Hiebert, E., et al., 1968, Virology 34:492-508). CCMV undergoes a reversible pH-dependent structural transition between a closed and open form resulting in the opening of 60 pores of approximately 2 nm in diameter allowing access between the interior and exterior environments.\n\n\nIn some embodiments, empty or hollow virus-like particles (VLPs) are obtained from CCMV or other plant virus or other non-plant virus (e.g., Hepatitis B core antigen, Human Papiloma virus, human immunodeficiency virus, human influenza virus, etc.). An \"empty\" or \"hollow\" VLP comprises a membrane-enclosed vesicle, which can provide a luminal space, which is filled with a substance, which can be any gaseous, liquid, semi-solid or solid substance. A VLP may generally be spherical, but may have other shapes. The \"membrane\" can consist of any material, for example, lipids, proteins, polysaccharides, other carbohydrates, synthetic or natural polymers. In certain embodiments, the membrane comprises wild-type or modified CCMV coat protein. VLPs described herein may be used in some embodiments to deliver therapeutic agents to a subject in need of such a therapeutic intervention.\n\n\nAspects of the invention are based, at least in part, on the recognition that the functionality of a VLP (therapeutic agent loading capacity/capability, in vivo \n\n immunogenicity, cell or tissue specificity/targeting, stability, etc.) can be fine-tuned by assembly of different mosaic VLP comprising subunits with one or more different features in different ratios.\n\n\nIn some embodiments, mosaic VLPs are provided comprising two or more different CCMV coat proteins described herein (e.g., wild-type and/or modified). In certain embodiments, mosaic VLPs are provided comprising two or more different CCMV coat protein subunits, independently selected from the following: i) wild-type; if) N-terminal deletion mutants (e.g., deletion of amino acids 1-5, 1-10, 1-15, 1-20, 1-25, 1-26, 1-30, 1-34, 5-10, 10-15, 15-20, 20-25, 5-25, 10-25, 15-25, 2-25, 2-26, 2-34, 3-26, 4-26, 5-26, 8-26 and any amino acid deletions in between); Hf) N-terminal substitution mutants (e.g., substitutions that alter charged amino acids of the wild-type sequence, e.g., one or more of the 9 (e.g.,, 1 or more, 2 or more, 3, 4, 5, 6, 7, 8, or 9) basic residues (Arg, Lys), e.g., to net negative (GIu or Asp) residues, or any other substitutions that alter the charge based on SEQ ID NO:1); iv) N- terminal substitution mutants e.g., comprising portions of the MS2 coat protein; v) chimeric fusion proteins comprising one or more targeting peptides in one or more of the surface exposed loops (e.g., in amino acids 52-176 of the coat protein comprising the five exterior surface-exposed loops, βB-βC (CATSAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29-135), βH-βl (SAALTEGD (SEQ ID NO: 22), aalόl- 168); vi) wild-type or modified subunits comprising chemically attached targeting moieties (e.g., antibodies or antibody fragments, signaling or targeting peptides, or receptor ligand molecules); and/or vif) wild-type or modified subunits comprising chemically conjugated moieties that e.g., reduce in vivo immunogenicity of the VLP (e.g., PEG) or aid cellular uptake or themselves provide attachment points for further moieties (e.g., HA). It should be appreciated that the two or more different CCMV coat proteins may be different variants within any one of categories ii)-vii). In some embodiments, all of the different CCMV coat proteins in a VLP preparation may be different variants within any one of categories ii)-vii). In some embodiments, a mosaic VLP preparation may include 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different VLP coat proteins. In certain embodiments, modified CCMV coat proteins are provided that each can comprise one or more features, such as those described in i) and vi); i) and vif); if) and v); if) and vi); if) and vif); Hf) and v); Hf) and vif); Hf) and vif); iv) and v); iv) and vi); iv) and vif). In certain embodiments, mosaic VLPs are provided comprising two or more subunits comprising one or more of the features described in i) to vif). In certain embodiments, \n\n mosaic VLPs are provided comprising different ratios of the two or more different subunits comprising one or more of the features described in i) to vii).\n\n\nIt should be appreciated that certain variant coat proteins may self-assemble at different rates and/or to different extents. In some embodiments, a variant coat protein may self-assemble less efficiently than a wild-type protein. In some embodiments, assembly of a variant coat protein may be increased by altering the assembly conditions and/or by assembling the variant in the presence of a different coat protein (e.g., a wild-type coat protein or a coat-protein variant that assembles more efficiently) to form a mosaic VLP. As used herein, a self-assembling coat protein refers to both wild-type and variant coat proteins, including variant coat proteins that precipitate when alone and/or that do not assemble efficiently relative to wild-type coat proteins when alone, but for which assembly can be restored, for example, by reassembling the variant in the presence of a different variant and/or a wild-type coat protein.\n\n\nIn certain embodiments, VLPs are provided comprising one subunit comprising an N-terminal deletion of the CCMV coat protein (e.g., amino acids 8-26, 1-25 or 1-26) and one subunit comprising a RGD targeting peptide integrated into a surface-exposed loop of the CCMV coat protein. In a particular embodiment, VLPs are provided comprising one subunit comprising an N-terminal deletion of the N-terminal amino acids 8-26 of the CCMV coat protein and one subunit comprising the RGD-4C targeting peptide integrated into the βCαCD surface-exposed loop of the CCMV coat protein.\n\n\nAspects of the invention are based, at least in part, on the recognition that specific combinations of subunits aid the assembly of specific therapeutically useful mosaic VLPs. Peptides comprising integrin-binding motifs, such as those comprising a RGD motif, are useful moieties for in vivo targeting of drugs and/or delivery vehicles, such as VLPs. However, it was found that peptides comprising the RGD motif are prone to precipitation, possibly due to their specific structure and/or charge. It was discovered by the inventors that VLPs comprising CCMV coat protein subunits comprising a RGD peptide inserted in one of the surface-exposed loops of the CCMV coat protein was also prone to precipitation and would not efficiently assemble into VLPs that could be used for in vivo delivery of therapeutic agents to cells and tissues expressing specific integrins. This was surprising, because the art suggested that CCMV coat proteins comprising targeting peptides inserted into surface exposed loops (such as peptide 11) could be expressed and assembled into VLPs near wild-type levels (e.g., WO 2008/048288) and suggested that other (targeting) peptides should likewise be expressed. According to the invention, several possible routes to solve the \n\n problem of precipitation can be contemplated, such as making the insertions of the targeting peptide in different positions of the the five exterior surface-exposed loops, βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD- βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29- 135), βH-βl (SAALTEGD (SEQ ID NO: 22), aal61-168); modifying (genetically, chemically) the charge, influencing the (secondary) structure or varying the length of the targeting peptide; altering the buffer conditions (e.g., salt, pH, ions) and/or protein concentration (dilute/concentrate) of the added CCMV subunits for the VLP assembly reaction. Surprisingly, it was found that careful titration of CCMV coat protein subunits with different characteristics during the VLP assembly reaction prevented precipitation of the CCMV subunit comprising the RGD peptide leading to stable mosaic VLPs.\n\n\nIntegrins are alpha-beta heterodimers expressed on a wide variety of cells. The ligands for several of the integrins are extracellular matrix proteins such as fibronectin, vitronectin, collagens, and laminin. Many of the integrins recognize the sequence RGD in „ fibronectin and a number of other adhesive proteins (Piershbacher and Ruoshlati, 1984, Ruoshlati and Piershbacher, 1987). This tri-peptide sequence is recognized at least by the integrins α5β6, (Pytela et al, 1985), αvβl (Vogel et al, 1990), αllβvβ3 (Plow et al, 1985), αvβ3 (Pytela et al 1985), αvβ5 (Cheresh et al, 1989), avb6 (Busk et al, 1992). In certain embodiments, VLPs are provided that comprise one or more peptides that are nine amino acids in length and that contain an RGD sequence in a cyclic conformation with two disulfide bonds and that are highly selective for the αv-integrins. In certain embodiments, VLPs are provided that comprise one or more peptides that are about nine amino acids in length (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in length) and that contain an RGD sequence in a cyclic conformation with two disulfide bonds. In certain embodiments, the amino acids that preceed the RGD motif are serine and/or threonine. In certain embodiments, the amino acids that follow RGD are glycine and/or serine. In certain embodiments, the amino acids that preceed the RGD motif are serine and/or threonine and the amino acids that follow RGD are glycine and/or serine. In certain embodiments, the amino acids that are adjacent to the N-terminus of the RGD tri-peptide motif also include residues with hydrophobic or charged side chains. In certain embodiments, the RGD tri-peptide motif is flanked by cysteine residues, generating potentially cyclic disulfides, in which the RGD peptide is conformationally constrained. In certain embodiments, the RGD targeting peptide is NAVPNLRGDLQVLAQKVART (SEQ ID NO: 505). \n\n It should be appreciated that the outer surface of a VLP is defined by certain portions of the coat proteins that are exposed on the outer surface of the assembled VLP (for example, the surface exposed loops of the CCMV coat protein). Similarly, the inner surface of a VLP is defined by certain portions of the coat proteins that are exposed on the inner surface of the assembled VLP (e.g., the N-terminal region of the CCMV coat protein). The inner and outer portions can be determined from the structure (e.g., the crystal structure) of an assembled VLP, or using any other suitable technique. In certain embodiments, mosaic VLPs are provided that are mosaic on the outer and inner surface of the VLP. In certain embodiments, the inner surface of the mosaic VLP comprises a mixure of CCMV coat protein subunits that have either N-terminal alterations, deletions, substitutions or are wild-type, in various ratios. In certain embodiments, the outer surface of the mosaic VLP comprises a mixure of CCMV coat protein subunits that have either one or more different targeting moieties (e.g., chemically linked or genetically inserted), moieties that reduce immunogenicity or are wild- type, in various ratios. In certain embodiments, the inner and the outer surface of the mosaic VLP comprises a mixure of CCMV coat protein subunits that have specific features, thereby allowing tailoring of the VLP to specific therapeutic needs and/or enabling VLP assembly of subunits that would not readily assemble under normal VLP assembly conditions, thereby broadening the array of therapeutically useful VLPs that can be generated.\n\n\nIn certain embodiments, methods of producing mosaic VLPs that are mosaic on the outer and/or inner surface of the VLP are provided. These methods allow the assembly of CCMV coat protein subunits into VLP that would not readily assemble under normal VLP assembly conditions, such as subunits comprising peptides that are large (e.g., 10, 15, 20, 25, 30, 40, or more amino acids) in that they may disrupt the overall CCMV coat protein structure due to size; strongly charged (basic, acidic), particularly hydrophobic or amphipathic; peptides that may disrupt the overall CCMV coat protein structure due to a particular secondary structure of the peptide. Such peptides include integrin-binding peptides, such as RGD peptides. In certain embodiments, the RGD targeting peptide is NAVPNLRGDLQVLAQKVART (SEQ ID NO: 505). Careful mixing of CCMV coat protein subunits comprising such peptides with CCMV coat protein that do not express such peptides was found to efficiently produce VLPs with the desired targeting ability in various ratios. In certain embodiments, the ratio of targeting peptide expressing subunits and non- peptide expressing subunits is 50% : 50%. In other embodiments, the ratio is 10% : 90%, 20% : 80%, 30% : 70%, 40% : 60%. It should be appreciated that in some embodiments these ratios may be used as input ratios in a reassembly reaction. However, in some \n\n embodiments these ratios may be the desired output ratios from an assembly reaction and slightly different input ratios may be required in order to generate these output ratios as described herein. In any of the assembly or reassembly reactions described herein in the context of VLP or mosaic VLP preparation, the relative ratios of different coat protein preparations may be evaluated using any suitable technique for detecting and/or measuring protein concentrations or amounts. It should be appreciated that in some embodiments the ratios described herein may be approximate and similar or intermediate or higher or lower ratios also may be used.\n\n\nThe VLPs, in some embodiments, may be used to deliver anti-cancer agents, such as for example XELOD A/Capecitabine, GEMZAR/Gemcitabine, 5-fluoro-uracil,\n\n\nTAXOTERE/Docataxel, CAMPTO/Irinotecan, TAXOL/Paclitaxel, and/or cisplatinum compounds in vivo to a subject having cancer.\n\n\nIn some embodiments, the VLPs described herein may be loaded in vitro with a therapeutic, diagnostic, or other agent by inducing the reversible pH-dependent structural transition between a closed and open form of the VLP and allowing agents to enter the VLP. Upon changing the conditions the VLP reverts back to the closed form thereby entrapping the therapeutic agent. In some embodiments, the VLPs described herein may be loaded in vitro with a therapeutic, diagnostic, or other agent by mixing the agent with one or more different CCMV coat proteins during reassembly. In some embodiments, the VLP may consist entirely of CCMV coat proteins. In other embodiments, the VLP may further comprise one or more additional viral or heterologous proteins or protein fragments. In certain embodiments, such heterologous proteins or protein fragments may be derived from mammals, such as e.g., humans. In some embodiments, the heterologous proteins or protein fragments may comprise targeting peptides, providing means to specifically target the VLP in vivo to specific tissues or cells expressing antigens, such as tumor-associated antigens, tumor-specific antigens, tissue-specific antigens, or cell type- specific antigens.\n\n\nIn some embodiments, the heterologous proteins or protein fragments may comprise one or more targeting peptides, providing means to specifically target the VLP in vivo to specific tissues or cells expressing cell surface receptors.\n\n\nIn some embodiments, targeting peptides may selectively target the vasculature supporting the tumor. In certain embodiments, such peptides comprise the NGR amino acid sequence. Other tumor homing peptides may contain the motif glycine-serine-leucine (GSL). Other tumor homing peptides such as the peptides CGRECPRLCQSSC (SEQ ID NO: 494) \n\n and CNGRCVSGCAGRC (SEQ ID NO: 495) have been identified based on their ability to home to a breast carcinoma. The peptide CLSGSLSC (SEQ ID NO: 497) has been identified based on its ability to home to a melanoma. Such tumor homing peptides were identified using in vivo panning (see U.S. Pat. No. 5,622,699, issued Apr. 22, 1997; Pasqualini and Ruoslahti, Nature 380:364-366 (1996), each of which is incorporated herein by reference). Additional tumor homing peptides are known in the art and/or can be identified by in vivo panning.\n\n\nIn some embodiments, the targeting peptide identifies the lymphatic vasculature of a tumor comprising the amino acid sequence GNKRTRG (SEQ ID NO: 498). In some embodiments, the targeting peptide identifies a specific organ. In some embodiments, the targeting peptide is a brain homing peptide that comprise the motif SRL (serine-arginine- lysine), such as the peptide CLSSRLDAC (SEQ ID NO: 492) or the homing peptide comprises the motif VLR, such as the peptide WRCVLREGPAGGC AWFNRHRL (SEQ ID NO: 493). In some embodiments, the targeting peptide is a kidney homing peptide, such as CLPVASC (SEQ ID NO: 496) or CGAREMC (SEQ ID NO: 499). In some embodiments the targeting peptide is a heart homing peptide that contains the amino acid sequence GGGVFWQ (SEQ ID NO: 500), HGRVRPH (SEQ ID NO: 501), VVLVTSS (SEQ ID NO: 502), CLHRGNSC (SEQ ID NO: 503) , or CRSWNKADNRSC (SEQ ID NO: 504). In some embodiments, the peptides target a cell surface receptor which may be selected from the group consisting of insulin receptor (insulin), insulin-like growth factor receptor (including both IGF-I and IGF-2), growth hormone receptor, glucose transporters (particularly GLUT 4 receptor), transferrin receptor (transferrin), epidermal growth factor receptor (EGF), low density lipoprotein receptor, high density lipoprotein receptor, leptin receptor, estrogen receptor (estrogen); interleukin receptors including IL-I, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-13, IL-15, and IL-17 receptors, human growth hormone receptor, VEGF receptor (VEGF), PDGF receptor (PDGF), transforming growth factor receptor (including TGF- and TGF-), EPO receptor (EPO), TPO receptor (TPO), ciliary neurotrophic factor receptor, prolactin receptor, and T-cell receptors.\n\n\nIn some embodiments, the heterologous proteins or protein fragments may comprise one or more targeting peptides, providing means to specifically target the VLP in vivo to specific tissues or cells expressing integrins, such as αvβ3, αvβ5, and αvβό integrins, wherein the targeting peptide comprises an RGD motif. In certain embodiments, the RGD targeting peptide is NAVPNLRGDLQVLAQKVART (SEQ ID NO: 505). \n\n In some embodiments, the heterologous proteins or protein fragments may comprise one or more targeting peptides derived from viruses other than CCMV, providing means to specifically target the VLP in vivo to specific tissues or cells. In certain embodiments targeting peptides derived from virus that have been identified to be responsible for viral- mediated cell entry are provided. For example peptides derived from the Hepatitis B surface antigen which identifies hepatocytes may be used for the treatment of liver disease and hepatocellular carcinoma. Peptides derived from the Human Papilloma Virus which identifies cervical epithelial cells may be used for the treatment of cervical cancer and cervical dysplasia. Peptides derived from the Epstein Barr Virus which identifies lymphocytes may be used for the treatment of lymphoma.\n\n\nIn certain embodiments, the human complement receptor 2 (CR2) binding domain of glycoprotein gp350/220 of the Epstein-Barr virus is a virus-derived targeting peptide that may be used for targeting as described herein.\n\n\nIn certain embodiments, the carboxyl terminus of the HPV Ll protein is a virus- derived targeting peptide that may be used for targeting as described herein.\n\n\nIn certain embodiments, the pre-S2 region of HBV is a virus-derived targeting peptide that may be used for targeting as described herein.\n\n\nIn certain embodiments, the HCV envelope glycoproteins (HC Vpp) El and E2, specifically amino acids 412-447 within E2 are used for targeting as described herein. In some embodiments, peptides are used to enhance oral delivery. In certain embodiments, the target tissue is follicle associated epithelium (FAE) overlying Peyer's patches which contains M-cells that have an increased capacity for uptake of particulate antigens. In certain embodiments, an integrin-adherent peptide motif, RGD, can be utilized to achieve selective and improved transport of VLPs into human Peyer's patches to improve oral delivery. In certain embodiments, the RGD targeting peptide is NA VPNLRGDLQ VLAQKV ART (SEQ ID NO: 505).\n\n\nIn certain embodiments, the targeting moiety directs the VLP to a tumor, a site of inflammation, a site of wound healing, a site of soft tissue damage, a site of bone or cartilage damage, a site of immune cell regeneration, across the blood-brain barrier, or a site of fat cell deposition.\n\n\nIt should be appreciated that any targeting peptide or motif described herein (or other peptide described herein) may be inserted into one or more surface exposed loops of a CCMV coat protein (e.g., in one or more copies of a CCMV coat protein in a mosaic VLP preparation). In some embodiments, a peptide may be inserted into one or more of the \n\n following five exterior surface-exposed loops, selected from the group consisting of βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD- βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29- 135), and βH-βl (SAALTEGD (SEQ ID NO: 22), aal61-168). In some embodiments, two or more different peptides may be present in a single coat protein variant (e.g., at different positions in a single surface exposed loops or in different surface exposed loops). It should be appreciated that each peptide may be inserted at the N-terminal end, the C-terminal end, or in between, of each surface exposed loop that is so modified. In some embodiments, a stable (e.g., the most stable or one of the most stable) insertion site variants is selected, e.g., using standard techniques to evaluate the stability of the resulting VLP particle or a mosaic VLP particle containing the modified coat protein.\n\n\nIn a natural CCMV particle, the 180 copies of the coat protein encapsidate the viral RNAs (RNA-I, RNA-2 or RNA-3+RNA-4). However, VLPs may be produced without these RNAs. In some embodiments, VLPs with a wild type N-terminus can encapsidate heterologous RNAs from a host.\n\n\nIn some embodiments of the invention, the VLP may be wild-type, e.g., it may be derived directly form CCMV. However, it should be appreciated that aspects of the invention relate to a modified or altered VLP. By \"modified\" or \"altered\" herein is meant a VLP that has been genetically altered or modified by physical, chemical or biochemical means as described herein.\n\n\nIn some embodiments, the VLP provided is modified in that certain amino acids are genetically altered (e.g., by insertion of a point mutation via site-directed mutagenesis) providing a VLP with altered assembly, stability or disassembly characteristics, or altered loading and/or delivery capacity with regard to therapeutic agents, altered bioavailability, or other altered characteristics.\n\n\nIn some embodiments, the 3.2 A resolution structure of CCMV which is publicly available may be used to predict the role of individual amino acids in controlling virion assembly, stability, and/or disassembly (Speir, J. A., et al., 1995, Structure 3:63-78). The virion is made up of 180 copies of the coat protein subunit arranged with a T=3 quasi- symmetry and organized in 20 hexamer and 12 pentameric capsomers to give particles with an external diameter of 28.6 nm. This architecture is shared by many icosahedral viruses. The individual subunits consist of 190 amino acids and have a molecular weight of 19.8 kDa. Each subunit contains several distinct domains. \n\n In certain embodiments, the CCMV coat protein subunit features N- and C-terminal extensions that extend away from the central, eight-stranded, antiparallel β-barrel core. Each coat protein consists of a canonical β-barrel fold (formed by amino acids 52-176) from which long N-terminal (residues 1-51; 1-26 are not ordered in the crystal structure) and C-terminal arms (residues 176-190) extend in opposite directions. These N- and C-terminal extensions provide interaction surfaces between subunits.\n\n\nFIG. 2 shows a non-limiting representation of a CCMV coat protein. The natural RNA-binding domain is indicated. In some embodiments, mutations of basic residues prevents encapsidation of heterologous RNA. However, in some embodiments, modifications in this region may be used to promote encapsidation of one or more different types of RNA or other agents as described herein.\n\n\nThe following paragraphs relate to CCMV sequences and structures. However, it should be appreciated that similar modifications may be made in other virus derived particles described herein. Amino acids 1-26: The first 25 amino acids are found lining the interior surface of the virion and are not visible in the crystallographic structure of the virus (Rao, A. L. and G. L. Grantham, 1996, Virology 226:294-305; and, Zhao, X., et al., 1995, Virology, 207:486- 494). These 25 amino acids are thought to be highly mobile and to be important for efficient viral RNA packaging. Nine of the first 25 amino acids are basic, positively charged residues (Arg, pK\na\n 12.48; Lys pK\na\n 10.53) and are thought to neutralize the negatively charged RNA.\n\n\nAmino acids 27-51: Amino acids 27-51 form an N-terminal extension to the main β- barrel domain. Together with the C-terminal extension, these form a network which ties the subunits together in the assembled particle.\n\n\nAmino acids 52-176: The orientation of the coat protein β-barrel fold, which contains 8 strands of anti-parallel β-sheet, is nearly parallel to the five-fold and quasi six-fold axes. This orientation results in five exterior loops, βB-βC, βD-βE, βF-βG, βC-αCDl, βH-βl, being exposed on the surface of the virus particle.\n\n\nAmino acids 177-190: These amino acids interact both with the RNA and the β- barrel domain and are important for stabilizing the quaternary structure of the virus. Surrounding each of the 60 quasi three-fold axes located on the interface between hexamer and pentamer capsomers are Ca\n2+\n binding sites. There are 180 Ca\n2+\n binding sites per virion. Each Ca\n2+\n binding site consists of five residues (Glu81, Gln85, Glul48 from one subunit; GIn 149 and Asp 153 from an adjacent subunit) in a position to coordinate Ca\n2+\n binding. \n\n In some embodiments, VLPs are provided comprising coat protein that has amino acids 1-26 deleted or modified. Amino acids 1-26 of the coat protein (MSTVGTGTi-LT RAORRAAARKNKRNTR (SEQ ID NO: 1), RNA-binding domain, underlined; positively charged residues in italics), are not required for empty virion or particle assembly (devoid of viral RNA) and can be deleted without abolishing the ability of the expressed coat protein to form VLPs (Douglas et al., 2002; Adv. Mater. 14: 415-418). Deletion of amino acids 1-26 of the coat protein may be partial or complete, e.g., the deletion may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 amino acids. The deletion may be N-terminal, or may comprise any region and any number of amino acids within amino acids 1-26 of the coat protein (e.g., amino acids 8-26 or 1-26). Amino acids may also be modified. Modification of amino acids includes amino acid substitutions, which may be conservative or non-conservative substitutions. For example, one or more amino acids of amino acids 1-26 of the coat protein may be modified to change the electrostatic nature of the amino acids. The N-terminus contains nine amino acids residues with positively charged side chains (Lys8, Argl 1, Argl4, Argl5, Argl9\ns\n Lys20, Lys22, Arg23, Arg26; Arg, pK\na\n 12.4; Lys pK\na\n 10.5) that can be modified, individually or in groups, so that the N- terminus changes its net charge, for example either with non-charged amino acid residue side chains, or negatively charged amino acid residue side chains (Asp, pK\na\n 3.7; GIu pK\na\n 4.3) at neutral pH. Other amino acid residue side chains that are sensitive to pH changes in the physiological range are for example His, pK\na\n 6.1 and Cys, pK\na\n 8.00. At pH = pK\na\n 50% of molecules will be deprotonated in solution. Other amino acid residue side chains that carry no net charge and provide increased hydrophobicity are for example Phe, Tyr, or Trp.\n\n\nIn certain embodiments, a number of residues outside the N-terminus that contribute to an overall positively charged capsid interior may be modified provided that this modification does not affect particle assembly. In these embodiments, Lys42, Lys45, and Arg 179, which are indicated on surface rendered representations of the capsid as exposed positive charge and may be involved in subunit interactions (Speir et al., 1995; Structure 3: 63-78) may be altered to carry less positive charge, no charge, more negative charge, or to carry hydrophobic residues, provided that thes modifications do not affect particle assembly. In some embodiments, Lys42, Lys45, and Argl79 are not altered but kept constant.\n\n\nIn some embodiments one or more amino acids of amino acids 1-26 of the coat protein may be modified or deleted to increase the solubility of a anti-cancer drug.\n\n\nIn some embodiments one or more amino acids of amino acids 1-26 of the coat protein may be modified or deleted to prolong the half-life of the anti-cancer drug. \n\n In some embodiments one or more amino acids of amino acids 1-26 of the coat protein may be modified or deleted to increase stability of the anti-cancer drug in solution.\n\n\nIn some embodiments one or more amino acids of amino acids 1-26 of the coat protein may be modified or deleted to avoid the need for chemical modification of the anti- cancer drug so that the drug is liberated in the cell in its active form.\n\n\nIn some embodiments one or more amino acids of amino acids 1-26 of the coat protein may be modified by reducing the positive charge to reduce the incorporation of heterologous RNAs during capsid assembly, which may eliminate possible competition between the heterologous RNA and the anti-cancer drug to be encapsidated. In some embodiments, deletions or modifications may be made to provide an empty particle that then can be disassembled and reassembled in the presence of an agent of interest. In some embodiments, one or more amino acids of N-terminal amino acids 1-26: M S TVGTGXi LTX\n2\nAQX\n3\nX\n4\nAAAX\n5\nX\n6\nNX\n7\nX\n8\nNTX\n9\n (SEQ ID NO: 2) are modified, particularly at Xi -X\n9\n with one or more of the following amino acid residues: Asp, GIu, His, Cys, Phe, Tyr, or Trp. In these embodiments, any particular number and combination of amino acid residues at positions Xi-X\n9\n may be modified with any particular combination of amino acid residues Asp, GIu, His, Cys, Phe, Tyr, or Trp, or any residue may be modified to any particular one residue of Asp, GIu, His, Cys, Phe, Tyr, or Trp.\n\n\nIn some embodiments, one or more of positions Xi-X\n9\n may be modified to any known amino acid, natural and non-natural. In some embodiments, one or more of positions X\n1\n-X7 may be modified to any known amino acid, natural and non-natural.\n\n\nIn some embodiments, positions other than X,-X\n9\ninMSTVGTGX|LTX\n2\nAQ X\n3\n X\n4\n A A A X\n5\n X\n6\n N X\n7\n X\n8\n N T X\n9\n (SEQ ID NO: 2) may be modified to any known amino acid, natural and non-natural. In some embodiments, positions other than X]-X\n9\n in MSTVGTG Xi LT X\n2\n AQ\n\n\nX\n3\n X\n4\n A A A X\n5\n X\n6\n N X\n7\n X\n8\n N T X\n9\n (SEQ ID NO: 2) are not modified and are kept constant. For example, a positively charged N-terminus may comprise the wild-type sequence: MSTY GTGKLT RAQRRAAARKNKRNT R (SEQ ID NO: 3). A positively charged N-terminus may also comprise, for example: M ST V GTGJfLTZSTAQA\n\"\n UTA A AuT ϋTNJf UTNTZiT(SEQIDNO: 4) or MSTVGTGRLTRAQRRAAARRNRRNTR (SEQ ID NO: 5). A weakly positively charged N-terminus may comprise, for example: \n\n MSTVGTGϋTLT/lAQΛGAAAΛlGN/lΛNTG (SEQ ID NO: 6), wherein, for example, all but one amino acid is positively charged and the other positive residues are, for example, modified to alanines and/or glycines, or an intermediately charged N-terminus: MSTVGT GΛLTΛAQ/f GAAA VKN KL N T /(SEQ ID NO: 7) , wherein, for example, four amino acids are positively charged and the other positive residues are, for example, modified to alanines, and/or glycines, and/or leucines, and/or isoleucines, and/or valines.\n\n\nFor example, a negatively charged N-terminus may comprise: M S T V G T G D L T D A Q D D A A A D D N D D N T D (SEQ ID NO: 8), or MSTVGTG£LTi?AQ££AAA££N££NT£(SEQIDNO:9). A weakly negatively charged N-terminus may comprise, for example: MSTVGTGZ)LTFAQ/16AAAI/N FyINTG(SEQIDNO: 10), wherein, for example, two amino acids are negatively charged and the other positive residues are, for example, are modified to alanines, and/or glycines, and/or leucines, and/or isoleucines, and/or valines.\n\n\nMixed charges may also be possible, for example: MSTVGTGZiTLTZiAQFZ)AAAZfJiTNZ)FNT^(SEQIDNO: 11).\n\n\nIn some embodiments, the one or more positively charged wild-type amino acids may be changed to be more hydrophobic, for example: MSTVGTGyLT JFAQFFAAAyFN //NT W(SEQIDNO: 12), or MSTYGTG WLTRAQ YRAAAFKNK WN T R (SEQ ID NO: 13), or MSTVGTGJTLTiJAQFZ)AAA WKN FYNTR (SEQ ID NO: 14).\n\n\nIn some embodiments, introduction of His, Cys residues may be desired, for example: MSTYGTGHLTCAQRRAAACKNKRNTH (SEQ ID NO: 15) , or MSTVGTGFLTZ)AQHFAAAZ)CNHHNTZ)(SEQIDNO: 16) , or\n\n\nM STVGTG CLTH AQA FAAAZfUTNZG\n1\nNTW(SEQIDNO: 17), wherein, for example, the other positive residues are modified to alanines, and/or glycines, and/or leucines, and/or isoleucines, and/or valines, and/or tyrosines, and/or phenylalanines, and/or tryptophanes. In some embodiments, one or more (e.g., all) of positions Xj-X\n7\n or X\n1\n-X\n9\n may be maintained as in the wild type sequence and positions 8-25 or 8-26 or 10-25 or 10-26 may be deleted. In some embodiments, one or more (e.g., all) of positions XpX\n7\n or X\n1\n-X\n9\n may be altered and positions 8-25 or 8-26 or 10-25 or 10-26 may be deleted. \n\n In some embodiments, the net charge of the N-terminus is altered to strengthen the electrostatic interaction between the therapeutic agent and the interior surface of the VLP to enhance retention of the agent during loading. For example, additional residues in amino acids 1-26 of the N-terminus of the coat protein may be modified to carry positively charged side chains, e.g., arginine or lysine, at neutral pH, to enhance retention of negatively charged therapeutic agents, such as phosphorylated drug or pro-drug molecules.\n\n\nIn some embodiments, the net charge of the N-terminus is altered to weaken the electrostatic interaction between the therapeutic agent and the interior surface of the VLP to enhance delivery of the agent in the target cell. For example, one or more of amino acids 1- 26 of the N-terminus of the coat protein may be modified to carry negatively charged side chains, e.g., aspatic acid or glutamic acid, to weaken retention of negatively charged therapeutic agents\n\n\nIt is understood that the opposite of the aforementioned situations can also be achieved. That is that an increased positive charge of the N-terminus can be used to weaken the interaction with a positively charged therapeutic agent and that an increased negative charge of the N-terminus can be used to strengthen the interaction with a positively charged therapeutic agent.\n\n\nIn some embodiments, the N-terminus domain is altered by the addition of negatively charged amino acids or the elimination of positively charged amino acids so that e.g., Gemcitabine (Cytidine, 2'-deoxy-2',2'-difluoro-, monohydrochloride, pK\na\n 3.58) may become complexed through electrostatic interaction. In certain embodiments, the loading of the drug may be carried out with gemcitabine in HCl-solution, as it is presented in currently available i.v. formulations. In these embodiments, replacement of Arg or Lys residues in the terminal region with GIu or Asp may reduce the overall positive charge on the inner surface of the VLP.\n\n\nIn some embodiments a reduction in the overall positive charge on the inner surface of the VLP, or an introduction of additional negative charges may be used to increase the electrostatic interaction of the VLP with e.g., Cisplatinum, an inorganic and water-soluble platinum complex, carrying a net charge of +2. In some embodiments, the N-terminus domain is altered by the elimination of positively charged amino acids, or by deletion of the domain, partially or fully, so that e.g., XELODA (capecitabine), which does not carry a net charge may be stabilized and efficiently loaded into the VLP. \n\n In some embodiments, e.g., PACLIT AXEL may be loaded into VLPs with neutral charge, wherein the N-terminus domain is altered by the elimination of positively charged amino acids, or by partial or full deletion of the domain. In these embodiments, providing a VLPs with neutral charge in the interior provided by the N-terminus prevents crystal formation and aggregation of PACLIT AXEL due to an excess of negative charge in the PACLITAXEL formulation. In some embodiments, Taxol may be loaded into the VLPs in an ethanol-saline formulation, avoiding the need for Cremophor EL\n®\n (polyethoxylated castor oil), which is highly toxic.\n\n\nIn some embodiments, the net charge of the N-terminus is altered to increase the hydrophobic interaction between the therapeutic agent and the interior surface of the VLP. For example, one or more residues of amino acids 1-26 of the N-terminus of the coat protein may be modified to carry uncharged hydrophobic residues, e.g., phenylalanine, tyrosine, or tryptophan, to strengthen retention of hydrophobic therapeutic agents that are difficult or impossible to solubilize in aqueous solutions, such as e.g., DOCETAXEL. In some embodiments, mosaic VLPs are provided comprising two or more different self-assembling coat proteins as described herein (e.g., a wild-type and one or more variant forms, or two or more variant forms without a wild-type form, etc.). In certain embodiments, the self-assembling proteins are CCMV coat proteins. In certain embodiments, mosaic VLP are provided that comprise two or more different wild-type or genetically modified CCMV coat proteins. For example, mosaic VLP may be produced comprising wild-type CCMV coat protein and genetically modified CCMV coat proteins that are modified as described herein, such as, for example modified in the N-terminal domain (e.g., amino acids 1-26) to e.g., strengthen or weaken the electrostatic interaction between a therapeutic agent and the interior surface of the modified VLP, e.g., to enhance loading of the VLP with the therapeutic agent or to enhance delivery of the agent in the target cell. In certain embodiments, the wild-type CCMV coat proteins and genetically modified CCMV coat proteins may be, described herein, may be disassembled in vitro and the two types of subunits may be reassembled together, producing mosaic VLPs comprising genetically modified subunits (e.g., with an altered interior charge as a consequence of mutating one or more charged amino acids of the N- terminal domain, e.g., amino acids 1-26) and unmodified (wild-type) subunits. The ratio between the two types may be varied at will, for example by adding different concentrations of subunits together for reassembly. Mosaic VLP may be produced (reaasembled) that contain just one subunit of one class of CCMV coat protein (e.g., genetically modified) while all other subunits are of the other class (e.g., wild-type) or they may contain equal amounts of \n\n subunits (that is about 50% each of the total number of subunits), or nearly equal amounts (e.g., 40% of the total number of subunits of a VLP are genetically modified and 60% are wild-type). It should be appreciated that any ratio can be produced, and the genetically modified subunits may outnumber the wild-type subunits. It should further be appreciated that the invention is not limited to VLPs comprising wild-type and genetically modified subunits. VLPs are also provided that comprise two or more different modified coat proteins. For example, one modified subunit may comprise mutations in the N-terminus (e.g., amino acids 1-26) that alter the interior charge, as described herein. The second modified subunit may comprise an N-terminal deletion (e.g., amino acids 1-26 or 8-26). Mosaic VLP may be produced (reaasembled) that contain mixures of two or more classes of modified CCMV coat protein. The ratio between the two types may be varied at will.\n\n\nVLPs are also provided that comprise three or more different modified coat proteins or wild-type coat proteins. For example, VLPs may comprise two different kinds of modified coat proteins and additionally wild-type coat protein. The ratio between the three types may be varied at will.\n\n\nIn some embodiments, VLPs are provided comprising an N-terminal deletion of the coat protein. For example, some coat protein subunits comprising deletions of N-terminal amino acids assemble into T=I (60 subunits) and T=2 (120 subunits), as well as the wild-type T=3 (180 subunits) particles. In certain embodiments, ratios for two different subunits (e.g., wild-type and modified) that might be desirable are, e.g., for T=3, 1:179, 2:178, 3:177 subunits, until an equal ratio is achieved, e.g., 90:90, and all ratios in between. For T=2, the ratio may be any ratio between 1:119 and 60:60. For T=I, the ratio may be any ratio between 1 :59 and 30:30. For three different subunits, the ratios can range from for T=3, 1:1:178, 1 :2:177, 1:3:176, 2:2:176, 1 :4:175, 2:3:175 subunits etc., until an equal ratio is achieved, e.g., 60:60:60, and all ratios in between. For T=2, the ratio may be any ratio between 1:1 :118 and 40:40:40. For T=I, the ratio may be any ratio between 1:1:58 and 20:20:20.\n\n\nIt should be appreciated that the resulting ratio after VLP assembly may not necessarily be the ratio in which the different subunits may be added to the reassembly reaction (reassembly mix). For example, certain subunits may be prone to aggregation and/or precipitation during VLP reassembly. Such subunits may not contribute equally to the resulting VLP since they may not be equally freely accessible in solution for VLP reassembly as non-aggregated/non-precipitated subunits. For example, certain subunits my be sterically (structurally), electrostatically or in other ways thermodynamically disadvantaged during VLP reassembly and integration of these subunits occurs less frequently than expected based \n\n on subunit concentration in the reassembly mix in comparison to other subunits (e.g., wild- type subunits). It should be appreciated that because of these and other reasons input ratios may not equal output ratios. Input ratio is the ratio of subunits that are added to a reassembly reaction (reassembly mix). Output ratio is the ratio of subunits in the assembled VLP. For example, a subunit that is prone to precipitation and/or that has been significantly altered sterically, e.g., by insertion of a large targeting peptide or electrostatically, e.g., by altering the charged residues of the N-terminal domain, may have to be added in 2X, 3X, 4X, 5X, 6X, 7X, 8X, 9X, 10X, 15X, 2OX, 30X, 4OX, 5OX, 10OX, IOOOX excess (e.g., as judged by input coat protein concentration) to contribute equally (e.g., to about 50% for two subunits or about 33% for three subunits) to the resulting VLP.\n\n\nIn some embodiments, the N-terminus is altered to increase the specific incorporation of one or more nucleic acid molecules. In certain embodiments, the wild-type N-terminus of a CCMV or other viral coat protein may be replaced with functional portions of the MS2 coat protein from bacteriophage to increase the interaction of the nucleic acid and the VLP. In these embodiments, the nucleic acids may be fused to a sequence from the hairpin/translational operator (TR) from the bacteriophage MS2 (e.g., the 19 nucleotide sequence from the hairpin/translational operator). In some embodiments, this sequence is derived from the start of the replicase gene of MS2 and interacts specifically with a pocket formed by a dimer of the MS2 coat protein. In these embodiments, the N-terminal replacement of the wild-type N-terminus of the CCMV coat protein with portions of the MS2 coat protein from bacteriophage generates the MS2-derived pocket that specifically interacts with the TR sequence of the nucleic acid to increase specific encapsidation of such nucleic acids. In some embodiments, the modified CCMV coat protein comprises a RNA bacteriophage Qbeta coat protein sequence and the heterologous RNA molecule comprises a sequence from the Qbeta hairpin/translational operator (TR) that interacts with (binds to) the Qbeta coat protein sequence. In certain embodiments, the modified CCMV coat protein comprises a different RNA binding amino acid sequence and the heterologous RNA molecule comprises a motif that binds to this RNA binding amino acid sequence. The RNA motif and RNA binding amino acid sequences may be derived from natural binding molecules or may be synthetic binding partners. For example, translational operators may be derived from other RNA viruses such as other RNA bacteriophages (e.g., Qβ, Rl 7, fr, GA, Sp, Mi I, MXI, NL95, AP205, f2, or PP7) and corresponding RNA binding amino acids from these viruses may be used. In some embodiments, RNA binding amino acids and RNA motifs may be \n\n derived from other virus proteins and their packaged RNA (e.g., Hepatitis B core antigen, Human Papiloma virus, human immunodeficiency virus, human influenza virus, etc.).\n\n\nIn certain embodiments, VLP are provided comprising coat protein subunits that lack the N-terminal domain or portions thereof (e.g., amino acids 1-26 or 8-26). The first 25 amino acids face the interior surface of the virion. These 25 amino acids are highly disordered/mobile and are thought to be required for efficient viral RNA packaging. Nine of the first 25 amino acids are basic (Arg, Lys) and are thought to neutralize the negatively charged RNA. The N-terminal 25 amino acids are thought not to be involved in the structural integrity of the virion and are thought not to be required for virion assembly. It was found that deletion of amino acids 8-26 of the N-terminal domain, a region which contains all 8 of the basic residues, but retaining the first 7 N-terminal amino acids (MSTVGTG, SEQ ID NO: 506) generates coat proteins that maintain their ability to self-assemble into VLP that are empty, that is the VLP are devoid of, or essentially devoid of nucleic acids (e.g., viral RNA). In certain embodiments the VLP are further devoid of host cell nucleic acids (e.g., residual RNA and/or DNA originating from the host cell of the expression system, e.g., P.pastoris or E. coli). In certain embodiments, N-terminal deletion mutants are provided that maintain the ability to self-assemble and that assemble into VLP that are essentially devoid of, or devoid of, nucleic acids (e.g., RNA and/or DNA) originating from the virus and/or the host cell. It should be appreciated that the ability to self-assemble (rates of reassembly) can be tested by analysis using e.g., electron microscopy. Assembled particles can be tested for lack of nucleic acids e.g., by agarose gel separation of samples of disrupted VLP (to release any nucleic acid) and staining (after separation) with dyes that interact (e.g.\n1\n, intercalate) with nucleic acids (e.g., ethidium bromide). In certain embodiments, N-terminal deletion mutants are provided that maintain the ability to self-assemble and that assemble to VLP that are essentially devoid of, or devoid of, RNA and/or DNA originating from the virus and/or the host cell for use as drug delivery vehicles. In certain embodiments, the drugs are small molecules.\n\n\nIn some embodiments, mosaic VLPs are provided comprising two or more different wild-type or modified self-assembling CCMV coat proteins. In certain embodiments, mosaic VLP are provided that comprise two or more different wild-type or genetically modified CCMV coat proteins. For example, mosaic VLP may be produced comprising wild-type CCMV coat protein and the N-terminal deletion mutants of the CCMV coat protein (e.g., deletion of amino acids 1-26) to e.g., to produce VLP delivery vehicles that are (essentially) devoid of all viral and non-viral nucleic acids useful for in vivo delivery of small nucleic acid \n\n molecules, including antisense nucleic acids and short interfering nucleic acid (siNA), the latter include, for example: microRNA (miRNA), short interfering RNA (siRNA), double- stranded RNA (dsRNA), short hairpin RNA (shRNA) molecules, circular siRNA, hybrid DNA-siRNA (for example crook siRNA). The ratio between the two types of subunits may be varied at will. In certain embodiments, mosaic VLP may be produced (reaasembled) that contain just one subunit of wild-type CCMV coat protein, e.g., to allow binding of siNA molecules to be loaded into the VLP while all other subunits are N-terminal deletion mutants, e.g., to avoid any (contaminating) nucleic acids derived from the virus and/or expression system host cell remaining in the VLP after VLP reassembly. It will be appreciated that other ratios (e.g., of wild-type to N-terminal deletion subunits) are also possible and the invention is not limited in this regard. In some embodiments, the ratio may be 50% : 50%, in other embodiments, the ratio may be, for example, 1% : 99%, 5% : 95%, 10% : 90%, 20% : 80%, 30% : 70%, or 40% : 60%. It should further be appreciated that two or more, three or more different subunits may be assembled into VLPs, e.g., subunits that are wild-type, subunits that are N-terminal deletions and subunits that comprise a targeting peptide in one or more of the surface exposed loops. The ratio between the three types of subunits may be varied at will. For example, for three different subunits, the ratios can range from for T=3, 1:1:178, 1:2:177, 1:3:176, 2:2:176, 1:4:175, 2:3:175 subunits etc., until an equal ratio is achieved, e.g., 60:60:60, and all ratios in between. For T=2, the ratio may be any ratio between 1:1:118 and 40:40:40. For T=I, the ratio may be any ratio between 1:1:58 and 20:20:20. It should be appreciated that in some embodiments these ratios may be used as input ratios in a reassembly reaction. However, in some embodiments these ratios may be the desired output ratios from an assembly reaction and slightly different input ratios may be required in order to generate these output ratios as described herein. In any of the assembly or reassembly reactions described herein in the context of VLP or mosaic VLP preparation, the relative ratios of different coat protein preparations may be evaluated using any suitable technique for detecting and/or measuring protein concentrations or amounts. It should be appreciated that in some embodiments the ratios described herein may be approximate and similar or intermediate or higher or lower ratios also may be used. It should be appreciated that in order to produce empty particles, that are are essentially devoid of, or devoid of, nucleic acids {e.g., RNA and/or DNA) originating from the virus and/or the host cell (i.e heterologous nucleic acids) it may not be necessary to delete the N-terminal 25 or 26 amino acids or delete amino acids 8-26. For example mutations that increase the negative charge of the N-terminal region (e.g., substitutions of the arginines (R) \n\n and or lysines (K) of the N-terminal amino acids 1-26: Lys8, Argl 1, Argl4, Argl5, Argl9, Lys20, Lys22, Arg23, and/or Arg26 with glutamic (D) or aspartic acid (E)) may be generated to avoid or reduce contamination with heterologous nucleic acids (e.g., through electrostatic repulsion). In certain embodiments, amino acids may be selected in this region (e.g., amino acids\n\n\n1-26 or 8-26) for mutagenesis (amino acid substitution) that enhance exclusion of heterologous nucleic acids during VLP production and/or assembly thereby producing empty VLP that are are essentially devoid of, or devoid of, heterologous nucleic acids but the substituted N-terminal amino acids still promote interactions (e.g., electrostatic) during packaging or loading of small interfering nucleic acids (e.g., siRNAs or miRNAs), as described herein. These amino acid substitutions can be determined for example by mutagenesis screening of the N-terminal region, e.g., amino acids 1-26 or 8-26 using standard laboratory protocols and techniques.\n\n\nIn certain embodiments, mosaic VLP are provided comprising CCMV coat proteins comprising a N-terminal replacement of the wild-type N-terminus with portions of the MS2 coat protein from bacteriophage to generate the MS2-derived pocket that specifically interacts with the TR sequence of the nucleic acid to increase specific encapsidation of such nucleic acids. In certain embodiments, mosaic VLP are provided comprising CCMV coat proteins comprising a N-terminal replacement of the wild-type N-terminus with portions of the MS2 coat protein from bacteriophage the mosaic VLP further comprising a N-terminal deletion mutant of the CCMV coat protein.\n\n\nNucleic acids that may be used (e.g., packaged) in connection with VLPs and mosaic VLPs can be DNA and/or RNA molecules. In some aspects, the invention relates to the use of small nucleic acid molecules, including antisense nucleic acids and short interfering nucleic acid (siNA), the latter include, for example: microRNA (miRNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), and short hairpin RNA (shRNA) molecules to knockdown expression of target genes associated with a disease or disorder. An siNA of the invention can be unmodified or chemically-modified. An siNA of the instant invention can be chemically synthesized, expressed from a vector or enzymatically synthesized. The instant invention also features various chemically-modified synthetic short interfering nucleic acid (siNA) molecules capable of modulating gene expression or activity in cells by RNA interference (RNAi). The use of chemically-modified siNA improves various properties of native siNA molecules through, for example, increased resistance to nuclease degradation in vivo and/or through improved cellular uptake. Furthermore, siNA having multiple chemical \n\n modifications may retain its RNAi activity. The siNA molecules of the instant invention provide useful reagents and methods for a variety of therapeutic applications.\n\n\nChemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases can increase their potency (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al, 1990 Nature 344, 565; Pieken et al., 1991, Science 253, 314; Usman and Cedergren, 1992, Trends in Biochem. ScL 17, 334; Usman et al., International Publication No. WO 93/15187; and Rossi et al., International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; and Burgin et al., supra; all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules herein). In some embodiments, modifications which enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.\n\n\nThere are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides can be modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'amino, 2'-C-allyl, 2'-flouro, 2'-O-methyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, TIBS. 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163; Burgin et al., 1996, Biochemistry, 35, 14090). Sugar modification of nucleic acid molecules has been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al. Nature, 1990, 344, 565 568; Pieken et al. Science, 1991, 253, 314317; Usman and Cedergren, Trends in Biochem. Sci., 1992, 17, 334 339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995, J. Biol. Chem., 270, 25702; Beigelman et al., International PCT publication No. WO 97/26270; Beigelman et al., U.S. Pat. No. 5,716,824; Usman et al.). In some embodiments, a molecule comprises one or more chemical modifications.\n\n\nIn some embodiments, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a target RNA or a portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence identical to the nucleotide sequence or a portion thereof of the targeted RNA. In another embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is substantially complementary to a nucleotide \n\n sequence of a target RNA or a portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of the target RNA. In another embodiment, each strand of the siNA molecule comprises about 19 to about 23 nucleotides, and each strand comprises at least about 19 nucleotides that are complementary to the nucleotides of the other strand.\n\n\nIn some embodiments an siRNA is an shRNA, shRNA-mir, or microRNA molecule encoded by and expressed from a genomically integrated transgene or a plasmid-based expression vector. Thus, in some embodiments a molecule capable of inhibiting mRNA expression, or microRNA activity, is a transgene or plasmid-based expression vector that encodes a small-interfering nucleic acid. Such transgenes and expression vectors can employ either polymerase II or polymerase III promoters to drive expression of these shRNAs and result in functional siRNAs in cells. The former polymerase permits the use of classic protein expression strategies, including inducible and tissue-specific expression systems. In some embodiments, transgenes and expression vectors are controlled by tissue specific promoters. In certain embodiments transgenes and expression vectors are controlled by inducible promoters, such as tetracycline inducible expression systems.\n\n\nIn some embodiments, a small interfering nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. The recombinant mammalian expression vector may be capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the myosin heavy chain promoter, albumin promoter, lymphoid-specific promoters, neuron specific promoters, pancreas specific promoters, and mammary gland specific promoters. Developmentally-regulated promoters are also encompassed, for example the murine hox promoters and the a-fetoprotein promoter. siRNA molecules are well know in the art and many siRNAs are known that target tumor-specific proteins that may be mutated, overexpressed and/or deregulated, such as for example cyclin/cdk, EGFR, brc/abl and the like.\n\n\nAccordingly, aspects of the invention can be used to deliver molecules that promote RNA interference using any of a variety of molecules known in the art, e.g., short interfering RNA molecules (siRNA), which are double stranded RNA molecules. As described herein, RNA interference (RNAi) is a phenomenon describing double-stranded (ds)RNA-dependent gene specific posttranscriptional silencing. Synthetic duplexes of 21 nucleotide RNAs can mediate gene specific RNAi in mammalian cells, without invoking generic antiviral defense \n\n mechanisms (Elbashir et al. Nature 2001, 411:494-498; Caplen et al. PNAS 200\\, 98:9742- 9747).\n\n\nIn some embodiments, polynucleotides are provided comprising an RNAi sequence that acts through an RNAi mechanism to attenuate or inhibit expression of a gene of interest, e.g., a gene that is overexpressed in cancer. In some embodiments, the siRNA sequence is between about 19 nucleotides and about 75 nucleotides in length, or between about 25 base pairs and about 35 base pairs in length. An RNAi construct contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the mRNA transcript of a gene of interest. In certain embodiments, the double- stranded RNA need only be sufficiently similar to natural RNA that it has the ability to mediate RNAi. In certain embodiments, the number of tolerated nucleotide mismatches between the target sequence and the RNAi construct sequence is no more than 1 in 5 basepairs, or 1 in 10 basepairs, or 1 in 20 basepairs, or 1 in 50 basepairs. Mismatches in the center of the siRNA duplex are most critical and may essentially abolish cleavage of the target RNA. In contrast, nucleotides at the 3' end of the siRNA strand that is complementary to the target RNA do not significantly contribute to specificity of the target recognition.\n\n\nIn certain embodiments, sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991) and calculating the percent difference between the nucleotide sequences by, for example, the Smith- Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g., University of Wisconsin Genetic Computing Group). In certain embodiments, the sequence identity between the inhibitory RNA and the portion of the target gene is greater than 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or is 100%. Production of polynucleotides comprising RNAi sequences is well known in the art.\n\n\nFor example, polynucleotides comprising RNAi sequences can be produced by chemical synthetic methods or by recombinant nucleic acid techniques. Endogenous RNA polymerase of the treated cell may mediate transcription in vivo, or cloned RNA polymerase can be used for transcription in vitro. In certain embodiments, the polynucleotides that modulate target gene activity by RNAi mechanisms, may include modifications to either the phosphate-sugar backbone or the nucleoside, e.g., to reduce susceptibility to cellular nucleases, improve bioavailability, improve formulation characteristics, and/or change other pharmacokinetic properties. For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications in RNA structure may \n\n be tailored to allow specific genetic inhibition while avoiding a general response to dsRNA. Likewise, bases may be modified to block the activity of adenosine deaminase. In certain embodiments, the siRNA polynucleotides may be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide can be introduced by in vitro enzymatic or organic synthesis.\n\n\nMethods of chemically modifying RNA molecules can be adapted for modifying RNAi constructs (see, for example, Heidenreich et al. (1997) Nucleic Acids Res, 25:776-780; Wilson et al. (1994) J MoI Recog 7:89-98; Chen et al. (1995) Nucleic Acids Res 23:2661- 2668; Hirschbein et al. (1997) Antisense Nucleic Acid Drug Dev 7:55-61). Merely to illustrate, the backbone of an RNAi construct can be modified with phosphorothioates, phosphoramidate, phosphodithioates, chimeric methylphosphonate-phosphodiesters, peptide nucleic acids, 5-propynyl-pyrimidine containing oligomers or sugar modifications (e.g., 2'- substituted ribonucleosides).\n\n\nThe double-stranded structure may be formed by a single self-complementary RNA strand or two complementary RNA strands. RNA duplex formation may be initiated either inside or outside the cell. The RNA may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of double-stranded material may yield more effective inhibition, while lower doses may also be useful for specific applications. Inhibition is sequence-specific in that nucleotide sequences corresponding to the duplex region of the RNA are targeted for genetic inhibition.\n\n\nIn certain embodiments, the subject RNAi constructs are \"siRNAs.\" These nucleic acids are between about 19-35 nucleotides in length, and even more preferably 21-23 nucleotides in length, e.g., corresponding in length to the fragments generated by nuclease \"dicing\" of longer double-stranded RNAs. The siRNAs are understood to recruit nuclease complexes and guide the complexes to the target mRNA by pairing to the specific sequences. As a result, the target mRNA is degraded by the nucleases in the protein complex or translation is inhibited. In a particular embodiment, the 21-23 nucleotides siRNA molecules comprise a 3' hydroxyl group.\n\n\nThe siRNA molecules can be purified using a number of techniques known to those of skill in the art. For example, gel electrophoresis can be used to purify such molecules.\n\n\nAlternatively, non-denaturing methods, such as non-denaturing column chromatography, can be used to purify the siRNA molecules. In addition, chromatography (e.g., size exclusion chromatography), glycerol gradient centrifugation, affinity purification with antibody can be used to purify siRNAs. \n\n In certain embodiments, at least one strand of the siRNA sequence of an effector domain has a 3' overhang from about 1 to about 6 nucleotides in length, or from 2 to 4 nucleotides in length. In other embodiments, the 3' overhangs are 1-3 nucleotides in length. In certain embodiments, one strand has a 3' overhang and the other strand is either blunt- ended or also has an overhang. The length of the overhangs may be the same or different for each strand. In order to further enhance the stability of the siRNA sequence, the 3' overhangs can be stabilized against degradation. In one embodiment, the RNA is stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotide 3' overhangs by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNAi. The absence of a 2' hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium and may be beneficial in vivo.\n\n\nExamples of siRNA that can be delivered according to aspects of the invention include siRNA that mediate silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer (Singh et al., Cancer Research 68, 7975-7984, October 1, 2008); anti-chlesterolemic siRNA (Frank-Kamenetsky et al., PNAS, August 19, 2008, vol. 105, no. 33, pp 11915-11920); ophthalmic siRNA; or any other siRNA as the invention is non limited in this respect.\n\n\nTools for design and quality of siRNAs, shRNAs and/or miRNAs are known in the art. Web-based online software system for designing siRNA sequences and scrambled siRNA sequences are for example siDirect, siSearch, SEQ2SVM, Deqor, siRNA Wizard (InvivoGen). The specificity can be predicted using for example SpecificityServer, miRacle. Target sequences can be researched for example at HuSiDa (Human siRNA Database), and siRNAdb (a database of siRNA sequences). Exemplary sequences that may be used to target specific proteins are listed in Table 1. It should be appreciated that these sequences may be modified as described herein to include a sequence motif that binds to an RNA binding amino acid sequence that may be incorporated into a modified coat protein of a VLP as described herein (e.g., in the amino terminal region). In some embodiments, the sequences listed in Table 1 may be used to design RNA or DNA molecules (e.g., siRNA, antisense, etc.). Accordingly, the sequences listed as RNA or DNA may be used to design corresponding\n\n\nDNA or RNA molecules, respectively. In some embodiments, DNA or RNA molecules may have the sequences listed in Table 1 or the complements thereof. In some embodiments, DNA or RNA molecules having any of the sequences described herein may be used as \n\n therapeutic agents. In some embodiments, the sequences may be incorporated into longer DNA or RNA molecules. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIt should be appreciated that the sequences listed in Table 1 are non-limiting. Where the sequence listed in Table 1 is an RNA sequence (or where an RNA molecule is prepared having a sequence of, or complementary to, a sequence listed in Table 1), modifications known in the art to stabilize such oligonucleotides {e.g., to reduce RNAse activity), such as the addition of, e.g., dTdT at the 3' end of the oligonucleotide, such modifications are not reflected in the sequences listed. However, one of ordinary skill would be able to readily envision such modifications and to make such modifications using only standard laboratory protocols and methodology. It should be appreciated that the sequences listed comprise the target-specific sequences and making any additional modifications at the 3' or 5' end are within the capabilities of one of ordinary skill and such modified oligomers (RNA and DNA) are included herein.\n\n\nOther inhibitor molecules that can be used (e.g., packaged in a VLP) include sense and antisense nucleic acids (single or double stranded), ribozymes, peptides, DNAzymes, peptide nucleic acids (PNAs), triple helix forming oligonucleotides, antibodies, and aptamers \n\n and modified form(s) thereof directed to sequences in gene(s), RNA transcripts, or proteins. Antisense and ribozyme suppression strategies have led to the reversal of a tumor phenotype by reducing expression of a gene product or by cleaving a mutant transcript at the site of the mutation (Carter and Lemoine Br. J. Cancer. 67(5):869-76, 1993; Lange et al., Leukemia. 6(11):1786-94, 1993; Valera et al., J. Biol. Chem. 269(46):28543-6, 1994; Dosaka-Akita et al, Am. J. Clin. Pathol. 102(5):660-4, 1994; Feng et al., Cancer Res. 55(10):2024-8, 1995; Quattrone et al., Cancer Res. 55(l):90-5, 1995; Lewin et al., Nat Med. 4(8):967-71, 1998). For example, neoplastic reversion was obtained using a ribozyme targeted to an H-Ras mutation in bladder carcinoma cells (Feng et al., Cancer Res. 55(10):2024-8, 1995). Ribozymes have also been proposed as a means of both inhibiting gene expression of a mutant gene and of correcting the mutant by targeted trans-splicing (Sullenger and Cech Nature 371(6498):619-22, 1994; Jones et al., Nat. Med. 2(6):643-8, 1996). Ribozyme activity may be augmented by the use of, for example, non-specific nucleic acid binding proteins or facilitator oligonucleotides (Herschlag et al., Embo J. 13(12):2913-24, 1994; Jankowsky and Schwenzer, Nucleic Acids Res. 24(3):423-9, 1996). Multitarget ribozymes\n\n\n(connected or shotgun) have been suggested as a means of improving efficiency of ribozymes for gene suppression (Ohkawa et al., Nucleic Acids Symp Ser. (29): 121-2, 1993).\n\n\nAntisense nucleic acids include modified or unmodified RNA, DNA, or mixed polymer nucleic acids, and primarily function by specifically binding to matching sequences resulting in modulation of peptide synthesis (Wu-Pong, November 1994, BioPharm, 20-33). Antisense nucleic acid binds to target RNA by Watson Crick base-pairing and blocks gene expression by preventing ribosomal translation of the bound sequences either by steric blocking or by activating RNase H enzyme. Antisense molecules may also alter protein synthesis by interfering with RNA processing or transport from the nucleus into the cytoplasm (Mukhopadhyay & Roth, 1996, Crit. Rev. in Oncogenesis 7, 151-190).\n\n\nAs used herein, the term \"antisense nucleic acid\" describes a nucleic acid that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend \n\n upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence.\n\n\nTriple helix approaches have also been investigated for sequence-specific gene suppression. Triple helix forming oligonucleotides have been found in some cases to bind in a sequence-specific manner (Postel N., PNAS U.S.A. 88(18):8227-31, 1991; Duval-Valentin et al., PNAS U.S.A. 89(2):504-8, 1992; Hardenbol and Van Dyke PNAS U.S.A. 93(7):2811-6, 1996; Porumb et al., Cancer Res. 56(3):515-22, 1996). Similarly, peptide nucleic acids have been shown to inhibit gene expression (Hanvey et al., Antisense Res. Dev. l(4):307-17, 1991; Knudsen and Nielson, Nucleic Acids Res. 24(3):494-500, 1996; Taylor et al., Arch. Surg. 132(11): 1177-83, 1997). Minor-groove binding polyamides can bjnd in a sequence- specific manner to DNA targets and hence may represent useful small molecules for future suppression at the DNA level (Trauger et al., Chem. Biol. 3(5):369-77, 1996). In addition, suppression has been obtained by interference at the protein level using dominant negative mutant peptides and antibodies (Herskowitz, Nature 329(6136):219-22, 1987; Rimsky et al., Nature 341(6241):453-6, 1989; Wright et al., PNAS U.S.A. 86(9):3199-203, 1989). In some cases suppression strategies have led to a reduction in RNA levels without a concomitant reduction in proteins, whereas in others, reductions in RNA have been mirrored by reductions in protein.\n\n\nIn some embodiments, VLPs of the invention may be used to package and/or deliver small activating RNAs (saRNAs) and/or snRNA Ul (uRNAs).\n\n\nIt should be appreciated that any of the therapeutic nucleic acids (e.g., siRNA, antisense, etc., nucleic acids) described herein may be prepared (e.g., synthesized or isolated, etc.) and loaded directly into a VLP. However, in some embodiments, a vector nucleic acid (e.g., a linear or circular vector, or plasmid, etc.) encoding one or more of the therapeutic nucleic acids (e.g., operatively connected to a suitable promoter, e.g., a tissue-specific or nonspecific promoter) may be loaded into the VLP. As a result, the therapeutic nucleic acid may be expressed at the site of delivery (e.g., when released from the VLP). In some embodiments, a VLP may include both therapeutic nucleic acid(s) and vector nucleic acid(s) encoding therapeutic nucleic acid(s). Aspects of the invention relate to using VLPs to package and deliver any one or more of the different types of RNA or other nucleic acid molecules described herein. It should be appreciated that in some embodiments any of the different types and/or examples of RNA or onther nucleic acid described herein may be modified as described herein to include a sequence motif that binds to an RNA binding amino acid sequence that may be incorporated \n\n into a modified coat protein of a VLP as described herein (e.g., in the amino terminal region). One or more such RNA motifs (e.g., translational operators) may be added at the 5' end, 3' end, and/or in the middle of any type and/or example of RNA described herein.\n\n\nAspects of the invention relate to methods for packaging heterologous agents described herein into VLPs. In some embodiments, methods for packaging may be based on properties of wild-type viral particles and may be adapted for modified viral particles or VLPs.\n\n\nAn electrostatic model for understanding the reversible gating in CCMV has been developed (See Speir, J. A., et al. supra 1995; Zlotnick, A., R. et al., 2000 Virology 277:450- 456). The wild type CCMV capsid remains closed below about pH 6.5. Increasing the pH, for example, above pH 6.5, in the absence of Ca\n2+\n, results in an 10% expansion (swelling) in the overall dimensions of the virion. Swelling results in the creation of sixty 2θA holes which provide access between the interior and exterior of the virion and the possibility to load of the therapeutic agent. By subsequently lowering the pH to, for example, about pH 5.0 the structural transition of the CCMV capsid from the swollen form to the non-swollen form occurs, thus trapping material, such as a therapeutic agent, within the viral capsid.\n\n\nIn some embodiments, loading of the therapeutic agents into the VLP occurs at about pH 6.0, pH 6.5, pH 7.0, pH 7.5, pH 8.0, pH 8.5, pH 9.0, pH 9.5, pH 10.0, or pH 10.5.\n\n\nIn some embodiments, trapping of the therapeutic agents in the VLP occurs at about pH 6.5, pH 6.0, pH 5.5, pH 5.0, pH 4.5, pH 4.0, pH 3.5, pH 3.0, pH 2.5, or pH 2.0.\n\n\nIn some embodiments, loading and/or trapping may be performed in the absence of Ca\n2+\n. In some embodiments, loading and/or trapping may be performed in the presence of a chelating agent (e.g., EDTA or other chelating agent). In some embodiments, VLPs are provided that comprise amino acid substitutions in the N-terminal 1-26 amino acids of the coat protein to change the net electrostatic charge of the N-terminal 1-26 amino acids to allow optimal (desired) electrostatic interaction with a therapeutic substance based on the pH used for the swelling of the VLP, the pK\na\n of the therapeutic agent and the desired loading density of the agent in the VLP. Additionally, conditions in the target cell during delivery of the therapeutic agent may be taken into account and amino acid substitutions in the N-terminal 1- 26 amino acids of the coat protein to change the net electrostatic charge of the N-terminal 1-26 amino acids may be made to generate electrostatic interaction between the inside of the VLP and the therapeutic substance to allow optimal (desired) release of the therapeutic agent at the target site, based on the prevalent pH at the target site, such as e.g., a pH in the physiological range. In some embodiments, a VLP may modified to promote release at a physiological pH \n\n within the serum of a subject. However, in some embodiments, a VLP may be modified to reduce or prevent release within the serum of a subject. In some embodiments, a VLP may be modified to promote release at about the pH within a cell or cellular compartment (e.g., endosome and/or lysosome). In some embodiments, VLPs are provided comprising an N-terminal deletion of the coat protein. For example, a deletion of 34 amino acids at its N terminus (mutant NΔ34) assembles into T=I (60 subunits) and T=2 (120 subunits), as well as the wild-type T=3 (180 subunits) particles. These VLPs have outer diameters of 18, 24 and 28 nm, and inner diameters of about 14, 20 and 24 nm respectively. In certain embodiments, VLPs are provided that may vary in size, e.g., between 10 and 50 nm, or between 15 and 30 nm, or between 18 and 28 nm, particularly VLPs that have an outer diameter of 18 nm, or 24 nm or 28 nm. VLPs of different sizes may be used to control the number of therapeutic molecules that can be loaded into the VLP and the number of therapeutic molecules that can be delivered by the VLP to the target cell or tissue. VLPs of different sizes may also be used to control the bioavailability of the therapeutic agent to the cell by controlling e.g., the rate of resorption or cellular take-up of the VLP by the cell.\n\n\nIn some embodiments, VLPs from viruses other than CCMV can be generated and loaded with therapeutic agents as described herein. For example, VLPs derived from southern bean mosaic virus (a member of the genus sobemovirus) swell similarly to those of CCMV, when treated with EDTA or other chelating agents under mild alkaline conditions.\n\n\nIn some embodiments, VLPs are provided comprising coat protein comprising one or more amino acid deletions and/or substitutions in amino acids 52-176 of the coat protein comprising the five exterior surface-exposed loops, βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29-135), βH-βl (SAALTEGD (SEQ ID NO: 22), aal61-168). These loops are not involved in holding the VLPs together and may therefore be modified.\n\n\nIn some embodiments, the external loops are deleted, partially or fully, singly or in groups, or amino acids comprising the loops are substituted, singly or in groups, to reduce the immunogenicity of the VLP while maintaining the ability of the VLP to self-assemble. By \"maintaining the ability to self-assemble\" it is meant that the VLP maintains some ability to self-assemble. This ability may be reduced if compared to an unmodified VLP.\n\n\nIn some embodiments, amino acids present in loops exposed on the virus surface can be deleted to reduce the immunogenicity of the VLPs. \n\n In some embodiments, the external loops are deleted, partially or fully, singly or in groups, and replaced or substituted, partially or fully, with polypeptides encoding tag sequences that allow the VLP to be purified or labeled, without destroying the ability of the coat protein to form VLPs. In certain embodiments, VLPs are provided comprising insertion of a protein tag, such as an epitope tag, into either the βF-βG or βC-αCDl loop, which still permits VLP assembly. The resulting chimeric coat protein is a fusion protein of the viral coat protein and the epitope tag sequence(s).\n\n\nIn some embodiments, such a chimeric molecule comprises a fusion of a viral coat protein polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. Provision of the epitope tag enables the VLP comprising the chimeric polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In other embodiments, the epitope tag enables the VLP comprising the chimeric polypeptide to be readily detectable by contacting the VLP with a labeled anti-tag antibody, or an anti-tag antibody that provides chemical groups that can be utilized for labeling. In some embodiments, the tag may be inserted without deleting or replacing any viral amino acids (e.g., into an external loop without deleting or replacing an external loop amino acid).\n\n\nVarious tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., MoI. Cell. Biol, 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., PNAS USA, 87:6393-6397 (1990)]. In some embodiments, the tag may be inserted without deleting or replacing any viral amino acids (e.g., into an external loop without deleting or replacing an external loop amino acid). In some embodiments, the external loops are deleted, partially or fully, singly or in groups, and replaced or substituted, partially or fully, with polypeptides encoding targeting sequences (peptide or moiety) that allow the VLP to be targeted to specific organs, tissues or cells, without destroying the ability of the coat protein to form VLPs. In certain embodiments, VLPs are provided comprising insertion of a targeting peptide into either the \n\n βF-βG or βC-αCDl loop, which still permits VLP assembly. The resulting chimeric coat protein is a fusion protein of the viral coat protein and the targeting peptide sequence(s). In some embodiments, the targeting polypeptide may be inserted without deleting or replacing any viral amino acids (e.g., into an external loop without deleting or replacing an external loop amino acid).\n\n\nBy \"targeting moiety\" herein is meant a functional group which serves to target or direct the complex to a particular location, cell type, diseased tissue, or association. In general, the targeting moiety is directed against a target molecule and allows concentration of the VLP loaded with the therapeutic agent in a particular localization within a subject. In some embodiments, wherein the targeting moiety is provided as an amino acid sequence comprising a targeting peptide as part of a fusion protein of the coat protein and the targeting peptide, the targeting peptide may be for example RGD targeting peptides (Arap, W., et al., 1998, Science 279:377-80; Pasqualini, R., E. et al., 1995, JCeIl Biol 130:1189-96). In certain embodiments, VLPs comprising targeting peptides comprising RGD motifs enter mammalian cells as intact VLPs via active cellular transport, such as receptor-mediated endocytosis or other vesicular traffic mechanisms. In embodiments wherein the VLPs enter the target cell mediated by receptor mediated endocytosis, the VLPs may enter and leave animal cells via the binding interaction between ligand molecules (e.g., the targeting peptides) expressed and displayed by the VLP and their corresponding receptor molecules on the target cell membrane, which causes the membrane to wrap around and engulf the VLP.\n\n\nIn certain embodiments, the VLP may enter the target cell via receptor-mediated endocytosis as a consequence of interaction of the cellular receptor with a targeting peptide displayed on the surface of the VLP. In certain embodiments, the VLP membrane may fuse with the membrane of the endosome membrane, which leads to the release of the therapeutic agent trapped inside the VLP. In certain embodiments, interactions between the interior amino acid residues on the VLP and the therapeutic agent may be optimized for delivery in endosomes that have an acidic pH, about pH 6, ranging from about pH 5.4 to about pH 6.2. As described herein ionic interactions with the therapeutic agent may be altered (e.g., optimized) by altering the net charge of the VLP interior and thereby optimizing delivery at acidic pHs in the endosomes. In certain embodiments, the VLP membrane may fuse with endosomes and/or lysosomes, which have a significantly more acidic pH than endosomes, about pH 4.5. In these embodiments, release of the therapeutic agent may occur in lysosomes. In some embodiments, the release of the therapeutic agent may occur in the cytosol, which is about pH 7.2. As described herein, VLPs can be modified to optimize the \n\n release of therapeutic agents into the target cell under various pHs encountered in different structures {e.g., organelles) of the target cell.\n\n\nIn certain embodiments, targeting molecules may be presented on the surface of the VLP either by genetic modifications of the coat protein gene sequence coding for the various loops, creating a (chimeric) fusion protein, or this may be accomplished by chemical means, such as coupling chemistry. In certain embodiments, the CCMV derived VLPs behave similar to those derived from CPMV. For example, the surface exposed loops in CPMV can be changed successfully to display targeting peptides. The RGD-4C peptide, for example, which selectively binds to integrins can be utilized as a cancer cell targeting agent. CPMV particles displaying the 'FMDV loop', which contains an RGD motif, in the βB-βC loop of the small protein, is successfully targeted to integrins, the chimeric particles are able to bind to integrin αvβό (the natural FMDV receptor), which can be measured, e.g., in an ELISA- based assay. The interaction is highly specific as neither wild-type CPMV nor a mutant in which the RGD motif is mutated to RGE is able to bind (see, for example, N.P. Montague's Ph.D. thesis, \"Development of CPMV-based particle technology\" University of East Anglia, 2007).\n\n\nIn some embodiments, VLPs are provided comprising fusions of a targeting peptides containing an integrin binding motif. Integrin-binding motifs are characterized in that they comprise the αv-containing integrin binding motif, arginine-glycine-aspartic acid (RGD). For example CDCRGDCFC (SEQ ID NO: 507) (Ruoshlati et al. 2003; Aoki et al., \"Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif,\" Cancer Gene. Ther. 8:783-787 (2001); Pasqualini et al., \"αv Integrins as receptors for tumor targeting by circulating ligands,\" Nat Biotechno\\., 15(6):542-546 (1997); E. Koivunen et al., \"Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins,\" Biotechnology, 13(3):265-170 (1995); Healy et al., \"Peptide Ligands for Integrin αvβ3 Selected from Random Phage Display Libraries,\" Biochem., 34:3948-3955 (1995)). In certain embodiments, the RGD targeting peptide is NAVPNLRGDLQVLAQKVART (SEQ ID NO: 505).\n\n\nIn some embodiments, VLPs are provided comprising fusions of one or more targeting peptides containing an RGD motif. The RGD-4C peptide, specific to cell surface exposed αvβ3 and αvβ5 integrins, may be expressed as part of the chimeric coat protein described herein, to specifically target melanoma cells that are known to express these integrins. In certain embodiments, increased cellular uptake may also be achieved by these modifications. \n\n In other embodiments, VLPs are provided comprising fusions of one or more targeting peptides containing an RGD motif directed against the αvββ integrin receptor and the coat protein, wherein the RGD motif is accessible in the surface-exposed outer shell loops of the VLP. The integrin receptor αvβ6 usually is absent from most healthy adult tissues but is over- expressed in a range of tumours including more than 90% of oral squamous cell carcinomas (OSCC) and approximately 40% of lung and breast carcinomas. As such, αvββ is a tumour- specific target. Furthermore, αvβό promotes tumorigenesis in vivo through effects on invasion, migration, cell survival and activation of TGFβ. αvββ over-expression is associated with poor prognosis in OSCC, colon and breast cancer patients. Generally, cancers that may be targeted by the VLP comprising one or more targeting peptides provided herein include, but are not limited to melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer.\n\n\nIn other embodiments, the targeting moiety is all or a portion (e.g., a binding portion) of a ligand for a cell surface receptor. Suitable ligands include, but are not limited to, all or a functional portion of the ligands that bind to a cell surface receptor selected from the group consisting of insulin receptor (insulin), insulin-like growth factor receptor (including both IGF-I and IGF-2), growth hormone receptor, glucose transporters (particularly GLUT 4 receptor), transferrin receptor (transferrin), epidermal growth factor receptor (EGF), low density lipoprotein receptor, high density lipoprotein receptor, leptin receptor, estrogen receptor (estrogen); interleukin receptors including IL-I, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-13, IL-15, and IL-17 receptors, human growth hormone receptor, VEGF receptor (VEGF), PDGF receptor (PDGF), transforming growth factor receptor (including TGF- and TGF-), EPO receptor (EPO), TPO receptor (TPO), ciliary neurotrophic factor receptor, prolactin receptor, and T-cell receptors. In some embodiments, wherein the targeting peptide is basic, acidic amino acids (Asp or GIu) may be further added to the N-terminal and/or C-terminal portion of the targeting peptide to prevent potential problems of particle aggregation that may occur when expressing very basic targeting peptides. Alternatively, the acidic residues may be expressed in an adjacent loop(s) to provide the necessary charge-neutralization. In some embodiments, the external loops and/or additional parts of the coat protein may be deleted, partially or fully, singly or in groups, and replaced or substituted, partially or fully, with polypeptides encoding e.g., antibodies or antigen-specific fragments, single chain antibodies, nanobodies and/or camel bodies directed against specific receptor molecules such as e.g., the integrin receptor family, the VEGF receptor family, the FGF receptor Family, the \n\n IGF receptor family, the EGF receptor family and the hepatocyte receptor. In other embodiments, antibodies or antigen-specific fragments expressed in the external loops of the VLP are directed against one or more tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), such as viral tumor antigens, cellular oncogene proteins, and/or tumor- associated differentiation antigens, including, but not limited to, CEA, TAG-72 (Yokata et al.,\n\n\n1992, Cancer Res. 52:3402-3408), CO17-1A (Ragnhammar et al., 1993, Int. J. Cancer 53:751-758); GICA 19-9 (Herlyn et al., 1982, J. Clin. Immunol. 2:135), CTA-I and LEA, Burkitt's lymphoma antigen-38.13, CD19 (Ghetie et al., 1994, Blood 83:1329-1336), human B-lymphoma antigen-CD20 (Reffet al., 1994, Blood 83:435-445), CD33 (Sgouros et al., 1993, J. Nucl. Med. 34:422-430), melanoma specific antigens such as ganglioside GD2 (Saleh et al.,\n\n\n1993, J. Immunol., 151, 3390-3398), ganglioside GD3 (Shitara et al., 1993, Cancer Immunol. Immunother. 36:373-380), ganglioside GM2 (Livingston et al., 1994, J. Clin. Oncol 12:1036- 1044), ganglioside GM3 (Hoon et al., 1993, Cancer Res. 53:5244-5250), tumor-specific transplantation type of cell-surface antigen (TSTA) such as virally-induced tumor antigens including T-antigen DNA tumor viruses and Envelope antigens of RNA tumor viruses, oncofetal antigen-alpha-fetoprotein such as CEA of colon, bladder tumor oncofetal antigen (Hellstrom et al., 1985, Cancer. Res. 45:2210-2188), differentiation antigen such as human lung carcinoma antigen L6, L20 (Hellstrom et al., 1986, Cancer Res. 46:3917-3923), antigens of fibrosarcoma, human leukemia T cell antigen-Gp37 (Bhattacharya-Chatterjee et al., 1988, J. oflmmunospeciβcally. 141:1398-1403), neoglycoprotein, sphingolipids, breast cancer antigen such as EGFR (Epidermal growth factor receptor), HER2 antigen (pl85\nHER2\n), polymorphic epithelial mucin (PEM) (Hilkens et al., 1992, Trends in Bio. Chem. ScL 17:359), malignant human lymphocyte antigen-APO-1 (Bernhard et al., 1989, Science 245:301-304), differentiation antigen (Feizi, 1985, Nature 314:53-57) such as I antigen found in fetal erythrocytes, primary endoderm, I antigen found in adult erythrocytes, preimplantation embryos, I(Ma) found in gastric adenocarcinomas, Ml 8, M39 found in breast epithelium, SSEA-I found in myeloid cells, VEP8, VEP9, MyI, VIM-D5, Di 55-22 found in colorectal cancer, TRA- 1-85 (blood group H), C 14 found in colonic adenocarcinoma, F3 found in lung adenocarcinoma, AH6 found in gastric cancer, Y hapten, Le* found in embryonal carcinoma cells, TL5 (blood group A), EGF receptor found in A431 cells, Ei series (blood group B) found in pancreatic cancer, FC 10.2 found in embryonal carcinoma cells, gastric adenocarcinoma antigen, CO-514 (blood group Le\na\n) found in Adenocarcinoma, NS-10 found in adenocarcinomas, CO-43 (blood group Le\n1*\n), G49 found in EGF receptor of A431 cells, MH2 (blood group ALe\nb\n/Le\ny\n) found in colonic adenocarcinoma, 19.9 found in colon cancer, \n\n gastric cancer mucins, T5A7 found in myeloid cells, R\n24\n found in melanoma, 4.2, GD3, D 1.1, OFA-I, G\nM2\n, OFA-2, G\nD2\n, and Ml:22:25:8 found in embryonal carcinoma cells, and SSEA-3 and SSEA-4 found in 4 to 8-cell stage embryos T cell receptor derived peptides from Cutaneous T cell Lymphoma (Edelson, 1998, The Cancer Journal 4:62), IL-I, IL-2, IL-3, IL- 4, IL-5, IL-6, IL-7, IL-8, IL-9, IL- 10, IL- 11 , IL- 12, IFN-α, IFN-β, IFN-β 17 mutants, IFN-65, CD2, CD3, CD4, CD5, CD8, CDl Ia, CDl Ib, CDl Ic, CD16, CD18, CD21, CD28, CD32, CD34, CD35, CD40, CD44, CD45, CD54, CD56, OX40L, 4-1BBL, K2, Kl, Pβ, Oa, Ma, Mβ2, Mβl, Hepsin, Pim-1, LMPl, TAP2, LMP7, TAPl, TRP, Oβ, IAβ, IAa, IEβ, IEβ2, IEa, CYP21, C4B, CYP21P, C4A, Bf, C2, HSP, G7a/b, TNF-α, TNF-β, D, L, Qa, TIa, COLl 1A2, DPβ2, DPα2, DPβl, DPαl, DNa, DMa, DMβ, LMP2, TAPiI, LMP7, DOβ, DQβ2, DQa2, DQβ3, DQβl, DQaI, DRβ, DRa, G250, HSP-70, HLA-B, HLA-C, HLA-X, HLA-E, HLA-J, HLA-A, HLA-H, HLA-G, HLA-F, nerve growth factor, somatotropin, somatomedins, parathormone, FSH, LH, EGF, TSH, THS-releasing factor, HGH, GRHR, PDGF, IGF-I, IGF- II, TGF-β, GM-CSF, M-CSF, G-CSFl, erythropoietin, β-HCG, 4-N- acetylgalactosaminyltransferase, GM2, GD2, GD3, JADE, MART, BAGE, GAGE, MAGE-I, MAGE-2, MAGE-3, XAGE, MUC-I, MUC-2, MUC-3, MUC-4, MUC- 18, ICAM-I, C-CAM, V-CAM, ELAM, NM23, EGFR, E-cadherin, N-CAM, LFA-3 (CD58), EpCAM, B7.1, CEA, DCC, PSA, Her2-neu, UTAA, melanoma antigen p75, K 19, HKer 8, pMel 17, TPlO, tyrosinase related proteins 1 and 2, p97, p53, RB, APC, DCC, NF-I, NF-2, WT-I, MEN-I, MEN-II, BRCAl, VHL, FCC and MCC, ras, myc, neu, raf, erb, src, fins, jun, trk, ret, gsp, hst, bcl and abl, CIq, CIr, CIs, C4, C2, Factor D, Factor B, properdin, C3, C5, C6, C7, C8, C9, Cllnh, Factor H, C4b-binding protein, DAF, membrane cofactor protein, anaphylatoxin inactivator S protein, HRF, MIRL, CRl, CR2, CR3, CR4, C3a/C4a receptor, C5a receptor, Epstein-Barr Virus antigens (EBNA), BZLF-I, BXLF-I, and Nuclear Matrix Proteins, modified TAAs or TSAs, splice variants of TAAs or TSAs, functional epitopes, epitope agonists, and degenerate variations thereof.\n\n\nIn some embodiments, the external loops and/or additional parts of the coat protein may be deleted, partially or fully, singly or in groups, and replaced or substituted, partially or fully, with polypeptides encoding e.g., targeting peptides derived from virus that have been identified to be responsible for viral-mediated cell entry are provided. For example peptides derived from the Hepatitis B surface antigen which identifies hepatocytes may be used for the treatment of liver disease and hepatocellular carcinoma. Peptides derived from the Human Papilloma Virus which identifies cervical epithelial cells may be used for the treatment of \n\n cervical cancer and cervical dysplasia. Peptides derived from the Epstein Barr Virus which identifies lymphocytes may be used for the treatment of lymphoma.\n\n\nIn certain embodiments, the human complement receptor 2 (CR2) binding domain of glycoprotein gp350/220 of the Epstein-Barr virus is a virus-derived targeting peptide that may be used for targeting as described herein.\n\n\nIn certain embodiments, the carboxyl terminus of the HPV Ll protein is a virus- derived targeting peptide that may be used for targeting as described herein.\n\n\nIn certain embodiments, the pre-S2 region of HBV is a virus-derived targeting peptide that may be used for targeting as described herein. In certain embodiments, the HCV envelope glycoproteins (HC Vpp) El and E2, specifically amino acids 412—447 within E2 are used for targeting as described herein.\n\n\nIn some embodiments, peptides are used to enhance oral delivery. In certain embodiments, the target tissue is follicle associated epithelium (FAE) overlying Peyer's patches which contains M-cells that have an increased capacity for uptake of particulate antigens. In certain embodiments, an integrin-adherent peptide motif, RGD, can be utilized to achieve selective and improved transport of VLPs into human Peyer's patches to improve oral delivery.\n\n\nIn certain embodiments, mosaic VLP are provided that comprise two or more different wild-type or genetically modified CCMV coat proteins. For example, mosaic VLP may be produced comprising wild-type CCMV coat protein and a modified CCMV coat protein comprising one or more targeting peptides in the one or more surface-exposed loops of the coat protein, e.g., to produce delivery vehicle specific for certain tissues or cells in vivo. In another example, mosaic VLP may be produced comprising wild-type CCMV coat protein, an N-terminal deletion mutant (e.g., amino acids 8-26) of the CCMV coat protein and a modified CCMV coat protein comprising one or more targeting peptides in the one or more surface-exposed loops of the coat protein. In another example, mosaic VLP may be produced comprising wild-type CCMV coat protein, an N-terminal deletion mutant (e.g., amino acids 8-26) of the CCMV coat protein further comprising one or more targeting peptides in the one or more surface-exposed loops of the coat protein. The ratio between the two or more different types of subunits may be varied at will.\n\n\nIn certain embodiments, mosaic VLP may be produced (reassembled) that contain just one subunit comprising a targeting peptide, e.g., to allow specific targeting of the VLP in vivo while all other subunits are wild-type. In certain embodiments, mosaic VLP may be produced that contain just one subunit comprising a targeting peptide while all other subunits \n\n are N-terminal deletion mutants (e.g., amino acids 8-26). In certain embodiments, mosaic VLP may be produced that contain just one subunit comprising a targeting peptide while all other subunits comprise N-terminal amino acid substitutions that alter the charge of the interior of the VLP. It will be appreciated that other ratios (e.g., of subunits comprising targeting peptides, N-terminal deletions, N-terminal substitutions, etc. and/or wild-type subunits) are also possible and the invention is not limited in this regard. In some embodiments, the ratio may be 50% : 50%, in other embodiments, the ratio may be, for example, 1% : 99%, 5% : 95%, 10% : 90%, 20% : 80%, 30% : 70%, or 40% : 60%. It should further be appreciated that two or more, three or more different subunits may be assembled into VLPs, e.g., subunits that are wild-type, subunits that are N-terminal deletions and subunits that comprise one or more targeting peptides in one or more of the surface exposed loops (or one or more subunits that comprise different targeting peptides, e.g., peptides that target the VLP to specific tissues or cells and peptides that aid cellular uptake). The ratio between the three types of subunits may be varied at will. For example, for three different subunits, the ratios can range from for T=3, 1:1:178, 1:2:177, 1 :3:176, 2:2:176,\n\n\n1:4:175, 2:3:175 subunits etc., until an equal ratio is achieved, e.g., 60:60:60, and all ratios in between. For T=2, the ratio may be any ratio between 1:1:118 and 40:40:40. For T=I, the ratio may be any ratio between 1 :1:58 and 20:20:20. In certain embodiments, mosaic VLP are provided comprising CCMV coat proteins comprising a targeting peptide comprising a RGD motif. In certain embodiments, mosaic VLP are provided comprising CCMV coat proteins comprising a targeting peptide comprising the RGD-4C peptide. In certain embodiments, mosaic VLP are provided comprising CCMV coat proteins comprising a targeting peptide comprising a RGD motif specific to cell surface exposed αvβ3, αvβ5, and/or αvβ6 integrins. In certain embodiments, the RGD targeting peptide is NAVPNLRGDLQVLAQKVART (SEQ ID NO: 505).\n\n\nIt should be appreciated that the different ratios of wild type and/or variant VLP described herein in the context of mosaic VLP may refer to either the ratios of VLP coat proteins in an assembled VLP preparation and/or the ratios of VLP coat proteins that are mixed together in a reassembly reaction. Accordingly, when a ratio is described, that ratio may be used as an input ratio for the assembly reaction or that ratio may be the output ratio obtained from an assembly reaction that uses either the same input ratio or a different input ratio that is required to obtain the desired output ratio due to the different properties of the different coat protein variants during the reassembly reaction. Accordingly, in some embodiments, the ratio that is present in a VLP preparation may be the same as that used in \n\n the reassembly reaction. However, in some embodiments, the ratios may be different, because one or more variants VLP coat proteins may reassemble less efficiently and/or precipitate and/or otherwise not end up in the final VLP preparation obtained from the reassembly reaction. In certain embodiments, mosaic VLP are provided comprising (i) CCMV coat proteins comprising the wild-type N-terminal sequence for amino acids 1-26 (SEQ ID NO:1) and optionally comprising one or more targeting moieties and (if) CCMV coat proteins that comprise N-terminal deletions (e.g., 1-25, 1-26, or 8-26) or modifications (e.g., one or more R to E, R to D, K to E or K to D substitutions within amino acids 8-26) and optionally comprising one or more targeting moieties. In certain embodiments, such mosaic VLP comprise just one subunit that is a CCMV coat protein comprising the wild-type N-terminal sequence for amino acids 1-26 (SEQ ID NO:1), optionally further comprising one or more targeting moieties, while all other subunits of the VLP are CCMV coat proteins that comprise N-terminal deletions or modifications and optionally further comprise one or more targeting moieties. In other embodiments, the mosaic VLP may comprise 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more subunits of comprising the wild-type N-terminal sequence for amino acids 1-26 (SEQ ID NO:1), optionally further comprising one or more targeting moieties. In certain embodiments, the ratio of these subunits in such mosaic VLPs is optimized to avoid the encapsidation of heterologous nucleic acid (e.g., RNA of the expression host) during the manufacturing process, while allowing an optimal interaction and stability of the heterologous siRNA that is loaded into the VLP, e.g., for the purpose of in vivo delivery. In certain embodiments, subunit ratios are provided that allow assembly of mosaic VLP comprising targeting peptides (such as integrin-binding peptides) that would not assemble otherwise, or would be very difficult to assemble in reactions with different ratios and/or subunits because of e.g., solubility problems, as described. In certain embodiments, subunit ratios are provided that allow assembly of mosaic VLP comprising targeting peptides (such as integrin-binding peptides) where a majority of subunits (e.g., 60%, 70%, 80%, 90%, 95%, 98%, 99%, 99.9%) is sourced from a preparation of CCMV coat proteins that is made using a nucleic acid encoding for a CCMV coat protein that expresses well in an expression host (e.g., E. coli or P. Pastoris) and the minority (<50%) of subunits is sourced from a preparation of CCMV coat proteins that is made using a nucleic acid encoding for a CCMV coat protein that does not express well in an expression host. It should be appreciated that the expression of the wild-type CCMV coat protein can be easily optimized, whereas expression of certain modified CCMV coat proteins (e.g., modified coat proteins comprising targeting \n\n peptides comprising an integrin-binding motif) may be far less optimal. For example expression of such modified coat proteins in a host expression system may be IX, 2X, 3X, 4X, 5X, 6X, 7X, 8X, 9X, 1OX, 2OX, 3OX, 4OX, 50X, 75X, 10OX, 500X, 100OX, or less efficient (as measured, e.g., by protein yield) than the expression (production yield) of wild- type CCMV coat protein. As one non-limiting example, precipitation of the modified subunit during coat protein purification from the expression host system may occur and may limit protein yield.\n\n\nIn certain embodiments, one or more surface-exposed amino acids residing in the external loops and/or in other parts of the coat protein may be replaced, substituted or modified, partially or fully, to allow the chemical conjugation of targeting moieties without changing the ability of the protein to self-assemble into VLPs. In certain embodiments, targeting moieties that may be chemically conjugated are antibodies, nanobodies, camel bodies, nucleic acids and aptamers.\n\n\nIn certain embodiments, the total amount of surface-exposed cysteine, and/or lysine, and/or aspartic acid and/or glutamic acid may be increased to provide an increased number of sites allowing chemical conjugation of targeting moieties such as antibodies, nanobodies, camel bodies, nucleic acids and/or aptamers. Surface-exposed thiol (cysteine), amine (lysine) and carboxyl groups (aspartic and glutamic acid) on the VLP may be chemically modified using standard conjugation chemistry, which is well known in the art. As an example, thiols may be conjugated using maleimide derivatives, lysines may be conjugated with N- hydroxysuccinimide (NHS) esters, and carboxylates may be conjugated with N-ethyl-N'-(3- dimethylaminopropyl) carbodiimide (EDC) and/or NHS. The conjugated targeting moieties may be directed against e.g., specific receptor molecules or tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), as described herein. In other embodiments, cell surface receptor ligands and hormones, lipids, sugars and dextrans, alcohols, bile acids, fatty acids, amino acids, peptides and nucleic acids may all be attached as described herein to localize or target the VLP to a particular site.\n\n\nIn other embodiments, the targeting moiety is a peptide. Peptides may be attached via chemical linkages to reactive groups on the surface exposed amino acids of the coat protein (Flenniken, M. L., et al. 2005. Chemical Communications:447-449), (Flenniken, M. L., et al. 2003. Nano Letters 3:1573-1576), (Gillitzer, E., et al. 2002. Chemical Communications:2390- 2391), (Hermanson, G. T. 1996. Academic Press, San Diego), (Wang, Q., et al. 2002. Chemistry & Biology 9:805-811; Wang, Q., et al. 2002. Chemistry & Biology 9:813-819; Wang, Q., et al. 2002. Angewandte Chemie-International Edition 41:459-462)). In some \n\n embodiments, peptides are attached to endogenous or engineered reactive functional groups on the surface exposed amino acids of the coat protein.\n\n\nIn some embodiments, one or more surface-exposed amino acids residing in the external loops and/or in other parts of the coat protein may be replaced, substituted or modified, partially or fully, to allow the chemical conjugation of poly(ethylene glycol) PEG or other molecule as described herein.\n\n\nIn certain embodiments, the total amount of surface-exposed lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine, and/or tyrosine residues may be increased to provide an increased number of sites allowing chemical conjugation PEG or other molecule. PEGylation is routinely achieved by incubation of a reactive derivative of PEG with the target macromolecule, such as a VLP. The covalent attachment of PEG or other molecule to the VLP can \"mask\" the VLP from the host's immune system and reduces immunogenicity and antigenicity and also improves bioavailability, by influencing the binding affinity of the VLP to the target cell receptors. PEGylation may also alter the absorption and distribution patterns of the VLP.\n\n\nIn some embodiments, mosaic VLPs are provided. In these embodiments, wild-type or genetically modified VLPs, described herein, may be chemically modified by, for example, by PEGylation and then disassembled in vitro. Additionally, chemically unmodified but genetically modified VLPs expressing the inserted (targeting) peptide (or displaying chemically attached targeting moieties), described herein, may be disassembled in vitro and the two types of subunits may be reassembled together, producing mosaic VLPs comprising chemically modified subunits and chemically unmodified subunits expressing the targeting peptide (or displaying chemically attached targeting moieties). The ratio between the two types may be varied at will, e.g., for T=3, 1:179, 2:178, 3:177 subunits, until an equal ratio is achieved, e.g., 90:90, and all ratios in between. For T=2, the ratio may be any ratio between 1 :119 and 60:60. For T=I, the ratio may be any ratio between 1:59 and 30:30.\n\n\nIn some embodiments, a VLP comprises just a single subunit expressing the targeting peptide and one or more of the other subunits (e.g., all other subunits) are coated with PEG, polymers like carboxymethyl dextran, a hexahistidine tag, hyaluronic acid, and/or one or more other masking molecules as the invention is not limited in this respect. In these embodiments, the single targeting peptide may be sufficient to allow cell attachment and resorption of the VLP, and PEG, or similar masking molecules, effectively masks the VLP from the immune system of the host even if they are not attached to every subunit. However, it should be appreciated that in some embodiments more than one targeting peptide may be attached to \n\n each VLP (e.g., more than one coat protein molecule may have a targeting peptide) as the invention is not limited in this respect.\n\n\nIn some embodiments, to achieve VLPs with just a single subunit expressing the targeting peptide, coat protein subunits are mixed at ratios lower than 1 :179, 1:119, or 1:59 (subunit expressing the targeting peptide: PEGylated subunit not expressing the targeting peptide), for example ratios of 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05, 0.01 subunits expressing the targeting peptide to 180, 120, or 60 PEGylated subunits not expressing the targeting peptide, respectively. In these embodiments, VLPs may form that contain either 1 or 0 subunits expressing the targeting peptide. In these embodiments, the subunit expressing the targeting peptide may also express a tag-sequence or other distinguishable sequence, as described herein, in the same loop or a different loop, or at a different solvent-exposed, exterior site of the coat protein subunit. This tag-sequence may then be used to isolate the VLPs containing 1 subunit expressing the targeting peptide from the VLPs containing no subunits expressing the targeting peptide, using conventional biochemical methods, such as e.g., affinity chromatography.\n\n\nIn certain embodiments, one or more surface-exposed amino acids residing in the external loops and/or in other parts of the coat protein may be replaced, substituted or modified, partially or fully, to allow coating with hyaluronic acid (HA).\n\n\nHA, a non-sulfated glycosaminoglycan, is a polymer of disaccharides, themselves composed of D-glucuronic acid and D-N-acetylglucosamine, linked together via alternating β-1,4 and β-1,3 glycosidic bonds. The carboxylic acid group of the D-gluconic acid sub-unit can be readily activated to facilitate coupling to amine (lysine) groups on the surface of CCMV or (e.g., using chemical reactions described in Q. Wang, E. Kaltgrad, T. Lin, J. E. Johnson and M. G. Finn. Natural Supramolecular Building Blocks: Wild-Type Cowpea Mosaic Virus. Chemistry & Biology (2002), 9, 805-811 ; and A. Chatterji, W. F. Ochoa, M. Paine, B. R. Ratna, J. E. Johnson and T. Lin,. New Addresses on an Addressable Virus Nanoblock Uniquely Reactive Lys Residues on Cowpea Mosaic Virus. Chemistry & Biology (2004), 11, 855-863), alternatively, modified so as to introduce acetylene or azide functionalities that can then be conjugated to complementary chemically modified sites on the capsid surface via \"click\"-chemistry (e.g., using chemical reactions described in Q.\n\n\nWang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless and M. G. Finn, Bioconjugation by Copper(I)-Catalyzed Azide-Alkyne [3+2] Cycloaddition. J. Amer. Chem. Soc, (2003) 125, 3192-3193; S. S. Gupta, K. S. Raja, E. Kaltgrad, E. Strable and M. G. Finn, Virus- \n\n Glycopolymer Conjugates by Copper(I) Catalysis of Atom Transfer Radical Polymerization and Azide-Alkyne Cycloaddition. Chem. Commun., (2005) 4315-4317).\n\n\nIn certain embodiments, the total amount of surface-exposed positively charged residues, such as lysine, and arginine residues may be increased to provide an increased number of positively charged sites allowing coating with hyaluronic acid, a linear negatively charged macromolecule containing a disaccharide repeat unit of N-actylglucosamine and glucuronic acid, present in mammalian extracellular matrix.\n\n\nIn some embodiments, the HA coating solution may be functionalized with targeting moieties, for example, peptides, aptamers, monoclonal antibodies, nanobodies and such, described herein. In other embodiments, the HA coating solution may be functionalized with targeting moieties that are non-protein molecules, such as certain cell receptor ligands, hormones, and lipids, sugars and dextrans, alcohols, bile acids, fatty acids, and nucleic acids. It should be appreciated that mosaic particles also may be assembled to include one or more proteins that have been modified with hyaluronic acid. In some embodiments, folic acid may be used as a targeting agent for tumour-specific drug delivery. Folic acid is a well studied targeting agent that binds to a receptor found in abundance on many types of cancer cells. The folic acid receptor is up-regulated in malignancies of the ovary, brain, kidney, breast and lung. In certain embodiments, solvent- exposed amines on the surface of the VLP may be utilized as anchor groups for the selective attachment of folic acid. In certain embodiments, the folic acid may be activated with N- ethyl-N '-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N- hydroxysuccinimide (NHS) and the activated ester may then be coupled to the amine groups exposed on the VLP surface. In certain embodiments, the integrity of the VLP after folic acid attachment may be monitored by dynamic light scattering, transmission electron microscopy or FT-IR.\n\n\nIt should be appreciated that mosaic particles also may be assembled to include one or more proteins that have been modified with folic acid.\n\n\nIn some embodiments, antibodies may be conjugated using standard coupling methods. For example, antibodies or fragments or derivatives thereof may be conjugated to surface-exposed carboxylates on a VLP. In certain embodiments, the integrity of the antibody-conjugated VLPs may be monitored by HPLC or ELISA.\n\n\nIt should be appreciated that mosaic particles also may be assembled to include one or more proteins that have been modified to include a peptide targeting moiety as described herein. \n\n In certain embodiments, VLPs are provided comprising coat protein comprising amino acid substitutions that allow for control of the opening and closing of the viral perticle. For example, amino acid residues may be substituted for existing amino acid residues to alter the pH sensitivity. The CCMV capsid undergoes a pH and metal ion dependent reversible structural transition where 60 separate pores in the capsid open or close, exposing the interior of the VLP to the bulk medium. In certain embodiments, VLPs may act as delivery vehicles because of their ability to undergo reversible structural changes allowing for the formation of open pores through which material can pass and can be entrapped. These reversible changes can be controlled by factors such as pH and ionic strength. For example, pH can be used to control the expansion and contraction of the VLP. When the VLP is expanded, e.g., opened, pores are formed allowing for the free exchange of soluble material between the inside and outside of the VLP. When the VLP is contracted, e.g., closed, the pores are closed and any material inside the VLP is trapped within. As this process is freely reversible, the material may be released by placing the VLP under conditions that allow for the expansion of the VLP and the formation of open pores.\n\n\nIn some embodiments, VLPs are provided having a reversible gating mechanism. Such a mechanism may provide controlled encapsulation and release of therapeutic agent. An electrostatic model for understanding the reversible gating in CCMV has been developed, which allows the design of mutants that can alter the pH dependence of this gating structural transition. (See Speir, J. A., et al. supra 1995; Zlotnick, A., R. et al., 2000 Virology 277:450-456). The wild type cage remains closed below pH 6.5 due to protonation of acidic residues at the pseudo-3-fold axes of the cage. At higher pH, deprotonation results in an electrostatic repulsion at these sites resulting in a swelling transition. Replacement of the acidic residues with neutral or basic residues may have an effect on pH-dependent gating of the protein cage architecture.\n\n\nIn some embodiments, VLPs are modified to provide improved or new chemical switching or gating mechanisms, e.g., chemical switches, that control the reversible swelling of the cages. At pH values lower than about pH 6.5 the virion exists in its compact or closed form. Increasing the pH above, for example, pH 6.5, in the absence OfCa\n2+\n, results in an 10% expansion (swelling) in the overall dimensions of the virion. Swelling results in the creation of sixty 2θA holes which provide access between the interior and exterior of the virion. By lowering the pH to, for example, about pH 5.0 the structural transition of the CCMV virion from the swollen form to the non-swollen form occurs, thus trapping material within the viral \n\n cage. In these embodiments, pH acts as a chemical switch for controlling access to and from the central cavity of the CCMV virion.\n\n\nIn some embodiments, loading of the therapeutic agents into the VLP occurs at about pH 6.0, pH 6.5, pH 7.0, pH 7.5, pH 8.0, pH 8.5, pH 9.0, pH 9.5, pH 10.0, or pH 10.5. In some embodiments, trapping of the therapeutic agents in the VLP occurs at about pH 6.5, pH 6.0, pH 5.5, pH 5.0, pH 4.5, pH 4.0, pH 3.5, pH 3.0, pH 2.5, or pH 2.0.\n\n\nIn some embodiments, loading and/or trapping may be performed in the absence of Ca\n2+\n. In some embodiments, loading and/or trapping may be performed in the presence of a chelating agent (e.g., EDTA or other chelating agent). In some embodiments, VLP are modified to provide improved or new chemical switches for the introduction and delivery of therapeutic agents. By \"chemical switch\" herein is meant a factor present in the microenvironment of the VLP in vitro (e.g., during drug loading) or in vivo (e.g., during drug delivery) that can be used to control the access to and from the VLP' s interior. Such a switch can be activated to open and close the pores of the VLP to allow passage of material in and out of the VLP. Examples of chemical switches include pH, ionic strength of the medium, and the like.\n\n\nIn some embodiments, VLPs are genetically modified to be more stable. Native CCMV virions are stable over a broad pH range (pH 2-8) and temperature (-80°C to 72°C.) (Zhao, X., et al., 1995, Virology, 207:486-494). Empty CCMV virions are stable over this range when assembled from mutants of the coat protein. The salt stable coat protein mutation (K42R) (Fox, J. M., et al., 1996, Virology 222:115-122) and the cysteinyl mutation (R26C) (Fox, J., et al., 1997, Virology 227:229-233.32) both result in empty virions that are stable over this broad pH and temperature range.\n\n\nDeletions, additions and substitutions of amino acids 52-176 comprising the surface- exposed loops can be generated using standard molecular cloning methods that are well known in the art.\n\n\nIn some embodiments, mosaic VLPs are provided comprising two or more different CCMV coat proteins as described herein. However, it should be appreciated that the invention is not limited to any combinations of two or more different subunits described herein. For example, mosaic VLPs are provided comprising two or more different CCMV coat protein subunits independently selected from the following: /) wild-type; ii) N-terminal deletion mutants (e.g., deletion of amino acids 1-5, 1-10, 1-15, 1-20, 1-25, 1-26, 1-30, 1-34, 5-10, 10-15, 15-20, 20-25, 5-25, 10-25, 15-25, 2-25, 2-26, 2-34, 3-26, 4-26, 5-26, 8-26 and \n\n any amino acid deletions in between); Hi) N-terminal substitution mutants {e.g., substitutions that alter charged amino acids of the wild-type sequence, e.g., one or more of the 9 (e.g., 1 or more, 2 or more, 3, 4, 5, 6, 7, 8, or 9) basic residues (Arg, Lys), e.g., to net negative (GIu or Asp) residues, or any other substitutions that alter the charge based on SEQ ID NO: 1); iv) N- terminal substitution mutants e.g., comprising portions of the MS2 coat protein; v) chimeric fusion proteins comprising one or more targeting peptides in one or more of the surface exposed loops (e.g., in amino acids 52-176 of the coat protein comprising the five exterior surface-exposed loops, βB-βC (CAAAEAK (SEQ ID NO: 18), aa59-65), βC-αCDl (ISLP (SEQ ID NO: 19), aa72-75), βD-βE (LPSVSGT (SEQ ID NO: 20), aa98-104), βF-βG (NSKDVVA (SEQ ID NO: 21), aal29-135), βH-βl (SAALTEGD (SEQ ID NO: 22), aalόl- 168); vz) wild-type or modified subunits comprising chemically attached targeting moieties (e.g., antibodies or antibody fragments, signaling or targeting peptides, or receptor ligand molecules); and/or vii) wild-type or modified subunits comprising chemically conjugated moieties that e.g., reduce in vivo immunogenicity of the VLP (e.g., PEG) or aid cellular uptake or themselves provide attachment points for further moieties (e.g., HA). It should be appreciated that the two or more different CCMV coat proteins may be different variants within any one of categories ii)-vii). In some embodiments, all of the different CCMV coat proteins in a VLP preparation may be different variants within any one of categories ii)-vii). In some embodiments, a mosaic VLP preparation may include 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different VLP coat proteins.\n\n\nIt should be appreciated that some of the feature described here for individual subunits may also be combined in one subunit, while others are mutually exclusive. One obvious example of a mutually exclusive combination is a subunit that comprises a N- terminal deletion of amino acids 1-26 and N-terminal amino acid substitutions in amino acids 8, 11, 14, and 15. Other examples of a mutually exclusive combination will be apparent to one of ordinary skill.\n\n\nCombinations that could be combined in one subunit are, for example, features described in ι) and vi); i) and vii); H) and v); H) and vi); H) and vii); Hi) and v); Hi) and vii); Hi) and vii); iv) and v); iv) and vi); iv) and vii). Other such combinations of features described herein will be apparent to one of ordinary skill. It should be appreciated that one or more different subunits with combined features may also be used in the assembly of mosaic VLP. The ratio between the two, three, four, five or more different types of subunits may be varied at will, as described herein. In certain embodiments, ratios for two different subunits that might be desirable are, e.g., for T=3, 1:179, 2:178, 3:177 subunits, until an equal ratio is \n\n achieved, e.g., 90:90, and all ratios in between. For T=2, the ratio may be any ratio between 1:119 and 60:60. For T=I, the ratio may be any ratio between 1:59 and 30:30. For three different subunits, the ratios can range from for T=3, 1:1:178, 1 :2:177, 1:3:176, 2:2:176, 1:4:175, 2:3:175 subunits etc., until an equal ratio is achieved, e.g., 60:60:60, and all ratios in between. For T=2, the ratio may be any ratio between 1:1:118 and 40:40:40. For T=I , the ratio may be any ratio between 1:1:58 and 20:20:20.\n\n\nIt should be appreciated that the resulting ratio after VLP assembly may not necessarily be the ratio in which the different subunits may be added to the reassembly reaction (reassembly mix). It should be appreciated that for various reasons input ratios may not equal output ratios. Input ratio is the ratio of subunits that are added to a reassembly reaction (reassembly mix). Output ratio is the ratio of subunits in the assembled VLP. For example, a subunit having one or more of the feature H) to vii), may have to be added in 2X, 3X, 4X, 5X, 6X, 7X, 8X, 9X, 10X, 15X, 2OX, 30X, 4OX, 50X, 10OX, IOOOX excess {e.g., as compared to wild-type (/)) to contribute equally (e.g., to about 50% for two subunits of about 33% for three subunits) to the resulting VLP. In certain embodiments, VLPs are provided that are useful as delivery agents, such as for the in vivo delivery of one or more therapeutic agents, e.g., one or more anti-cancer agents, to a subject. Anti-cancer agents that may be delivered by the VLPs described herein include, but are not limited to, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; capsitabine; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; \n\n interleulin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine, mechlorethamine oxide hydrochloride rethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafϊir; teloxantrone hydrochloride; temoporfϊn; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride; improsulfan; benzodepa; carboquone; triethylenemelamrine; triethylenephosphoramide; triethylenethiophosphoramide; trimethylolomelainine; chlomaphazine; novembichin; phenesterine; trofosfamide; estermustine; chlorozotocin; gemzar; nimustine; ranimustine; dacarbazine; mannomustine; mitobronitol; aclacinomycins; actinomycin F(I); azaserine; bleomycin; carubicin; carzinophilin; chromomycin; daunorubicin; daunomycin; 6-diazo-5-oxo-l-norleucine; doxorubicin; olivomycin; plicamyciri; porfiromycin; puromycin; tubercidin; zorubicin; denopterin; pteropterin; 6-mercaptopurine; ancitabine; 6-azauridine; carmofur; cytarabine; dideoxyuridine; enocitabine; pulmozyme; aceglatone; aldophosphamide glycoside; bestrabucil; defofamide; demecolcine; elfornithine; elliptinium acetate; etoglucid; flutamide; hydroxyurea; lentinan; phenamet; podophyllinic acid; 2-ethylhydrazide; razoxane; spirogermanium; tamoxifen; taxotere; tenuazonic acid; triaziquone; 2,2',2\"- trichlorotriethylamine; urethan; vinblastine; vincristine; vindesine and related agents; 20-epi- \n\n 1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfUlvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti- dorsalizing morphogenetic protein- 1 ; antiandrogen; prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol; 9-; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fiudarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; \n\n itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopraminde; MIF inhibitor; mifepristone; miltefosine; nirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody; human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; taxel; taxel analogues; taxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors; microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rheniuim\n\n\nRe 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense \n\n oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1 ; squalamine; stem cell inhibitor; stem-cell division ibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor;.translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system; erythrocyte gene therapy; velaresol; veramine; verdins; verteporfϊn; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; or zinostatin stimalamer. In some embodiments, anticancer drugs such as 5-fluorouracil, leucovorin, capsitabine, cyclosphosphamide, and gemcitabine may be used alone or in combination with other drugs as described herein (e.g., delived in a VLP, and optionally also as a pharmaceutical preparation in addition to in a VLP).\n\n\nGemcitabine, difluorodeoxycytidine, GEMZAR (l-(2-Oxo-4-amino-l,2- dihydropyrimidin-l-yl)-2-deoxy-2,2-difluororibose, or 2'-Deoxy-2',2'-difluorocytidine, or 2'Deoxy-2',2'-Difluorocytidine) is a nucleoside analog used as chemotherapy. Gemcitabine is a prodrug that is initially phosphorylated by deoxycytidine kinase to gemcitabine monophosphate, and subsequent phosphorylation steps yield gemcitabine diphosphate and gemcitabine triphosphate (dFdCTP) (Heinemann V et al. Cancer Res 48:4024-4031, 1988). Deamination of dFdCTP to 2'-2'-difluorodeoxyuridine monophosphate (dFdUMP) by the action of dCP-deaminase and subsequently to dFdU represents an important inactivation pathway of gemcitabine.\n\n\nGemcitabine is a pyrimidine analog (such as fluorouracil (5-FU)) in which the hydrogens on the 2' carbons of deoxycytidine are replaced by fluorines. Gemcitabine is converted intracellular^ to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP disrupts the progression of DNA replication by inhibiting \n\n ribonucleotide reductase thereby decreasing the deoxynucleotide pool available for DNA synthesis. Additionally, dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Gemcitabine is used to treat various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types. Gemcitabine is the standard treatment in pancreatic cancer care.\n\n\nGemcitabine may be given as a drip (infusion) through a fine tube (cannula) inserted into a vein, over a short period of time through a central line, which is inserted under the skin into a vein near the collarbone, or a PICC line inserted into a vein in the crook of your arm. (Martindale: The Complete Drug Reference (35th edition). Eds. Sweetman et al.\n\n\nPharmaceutical Press, 2007. British National Formulary (54th edition). British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2007).\n\n\nExamples of other therapeutic agents or imaging agents that may also be delivered in vivo to a subject by the VLPs provided herein, are additional cellular components, genetically engineered or native, recombinant, soluble or any other type of proteins, peptides, cytokines or other signaling molecules, which can have pro- or anti-inflammatory effects, or pro- or anti- apoptotic effects, polysaccharides, glycoproteins, heterogeneous mixtures of macromolecules {e.g., a natural product extract) and hybrid macromolecules (e.g., protein/nucleic acid hybrids, albumin conjugated proteins, drugs, inorganic molecules, organic molecules, or combinations thereof), or other bioactive molecules, such as growth factors, for example members of the transforming growth factor - β (TGF-β) super family, bone morphogenetic proteins (BMPs), fibroblast growth factors, growth hormone, and insulin-like growth factors (IGFs), antibodies, other nucleic acids (e.g., RNA, DNA, PNA, multiplexes of them (e.g., triplex)), preferably siRNA and antisense RNA, and/or cytotoxic drugs. The diagnostic, prophylactic or therapeutic substances used may be sterile. In some embodiments, the substances and/or agents are sterilized prior to loading into a VLP. In some embodiments, the loaded VLP may sterilized. Sterilization may be achieved using any suitable technique including chemical, radiation, and/or filtering provided that the technique does not inactivate or remove the agent or VLP of interest. Accordingly, a filter may be used if it has a cut-off that is larger than the size of the loaded VLP. Radiation may be used provided that the VLP does not contain an active nucleic acid, unless the level of radiation is sufficient to sterilize the preparation without inactivating the nucleic acid to such an extent that the preparation is rendenred ineffective. \n\n A therapeutic substance may also be any of the following agents: adrenergic agent; adrenocortical steroid; adrenocortical suppressant; agents for treating cognition, antiplatelets, aldosterone antagonist; amino acid; anabolic; analeptic; analgesic; anesthetic; anorectic; antiacne agent; anti-adrenergic; anti-allergic; anti-Alzheimer's, anti-amebic; anti-anemic; anti- anginal; anti-arthritic; anti-asthmatic; anti-atherosclerotic; antibacterial; anticholinergic; anticoagulant; anticonvulsant; antidepressant; antidiabetic; antidiarrheal; antidiuretic; antiemetic; anti-epileptic; antifibrinolytic; antifungal; antihemorrhagic; antihistamine; antihyperlipidemia; antihypertensive; antihypotensive; anti-infective; anti-inflammatory; antimicrobial; antimigraine; antimitotic; antimycotic, antinauseant, antineoplastic, antineutropenic, antiparasitic; antiproliferative; antipsychotic; antirheumatic; antiseborrheic; antisecretory; antispasmodic; antithrombotic; anti-ulcerative; antiviral; anxiolytics, appetite suppressant; blood glucose regulator; bone resorption inhibitor; bronchodilator; cardiovascular agent; cholinergic; COXl inhibitors, COX2 inhibitors, direct thrombin inhibitors, depressant; diagnostic aid; diuretic; dopaminergic agent; estrogen receptor agonist; fibrinolytic; fluorescent agent; free oxygen radical scavenger; gastrointestinal motility effector; glucocorticoid; GPIIbIIIa antagonists, hair growth stimulant; hemostatic; histamine H2 receptor antagonists; hormone; human growth hormone, hypocholesterolemic; hypoglycemic; hypolipidemic; hypnotics, hypotensive; imaging agent; immunological agents such as immunizing agents, immunomodulators, immunoregulators, immunostimulants, and immunosuppressants; keratolytic; LHRH agonist; mood regulator; mucolytic; mydriatic; nasal decongestant; neuromuscular blocking agent; neuroprotective; NMDA antagonist; non- hormonal sterol derivative; plasminogen activator; platelet activating factor antagonist; platelet aggregation inhibitor; proton pump inhibitors, psychotropic; radioactive agent; scabicide; sclerosing agent; sedative; sedative-hypnotic; selective adenosine Al antagonist; serotonin antagonist; serotonin inhibitor; serotonin receptor antagonist; statins, steroid; thyroid hormone; thyroid inhibitor; thyromimetic; tranquilizer; amyotrophic lateral sclerosis agent; cerebral ischemia agent; Paget's disease agent; unstable angina agent; vasoconstrictor; vasodilator; wound healing agent; or xanthine oxidase inhibitor, but it is not so limited.\n\n\nIn certain embodiments, the therapeutic molecule is an anti-cancer drug, an antibiotic, an anti-viral agent, an anti-microbial agent, an anti-inflammatory agent, or an immunostimulatory agent, but is not so limited.\n\n\nA \"diagnostic substance\" is any substance that has diagnostic capabilities, for example imaging agents, such as detectable markers, for example heavy metals, Gadolinium, Quantum dots, magnetic particle, radioactive particles, labeled antibodies, luciferase and other \n\n chemoluminescent agents. These agents may be substances inside the hollow nanoparticle, and/or on the surface (e.g., outer-surface) of the particle (e.g., membrane). These agents may be used to detect an adverse condition by any medical detection device or method, such as for example Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Computerized Axial Tomography (CAT), X-rays, or other imaging modalities. These applications may provide for immediate monitoring and/or diagnosis of early metastasis. It should be appreciated that these imaging embodiments may be combined with delivery embodiments, for example, to allow for simultaneous treatment and monitoring (e.g., to confirm that treatment is appropriately localized to a target site such as a tumor or other diseased tissue).\n\n\nIn certain embodiments, the therapeutic molecule may be a gene. In certain embodiments, VLP can be used for gene delivery, for example comprising a heterologous nucleic acid molecule that is an expression vector for a gene. Expression vectors useful for gene delivery are known in the art. In some embodiments, the gene to be delivered in vivo by the VLP encodes a cytokine or other signaling molecule. In certain embodiments, the cytokine or other signaling molecule is pro- or anti-inflammatory. In other embodiments, the cytokine or other signaling molecule is pro- or anti-apoptotic. Suitable cytokines or signaling molecules are known in the art.\n\n\nIn some embodiments, CCMV particles may be expressed in plants using the CPMV- HT system for the expression of foreign proteins in plants as described in Sainsbury, F. and Lomonossoff, G.P. Extremely High-Level and Rapid Transient Protein Production in Plants without the Use of Viral Replication. Plant Physiol. 2008 Sep 5. In these embodiments, the sequence of the CCMV coat protein and its derivatives, as described herein, may be inserted into the CPMV-Hr expression cassette in a binary plasmid and the constructs may be agro- infiltrated into N. benthamiana and assembled particles extracted from the leaves.\n\n\nIn some embodiments, a yeast-based heterologous protein expression system (e.g., Pichia pastoris) for the large scale production of wild type and modified CCMV proteins (e.g., protein cages). In some embodiments, an E. co//-based CCMV coat protein expression system can be used (Zhao, X., et al., 1995. Virology 207:486-494). However, other prokaryotic (e.g., bacterial), eukaryotic (e.g., yeast, insect, mammalian, including human) cells may be used.\n\n\nIn certain embodiments, synthetic DΝAs and polynucleotides encoding the modified coat protein, targeting peptides or portions thereof described herein are provided (see, e.g., \n\n Figures 1, 3, 6 and 8). In certain embodiments, the coding sequence is codon optimized for expression in a particular host, e.g., yeast, human cells or bacteria.\n\n\nIn certain embodiments, host cells are provided comprising the synthetic DNA or polynucleotides described herein. In certain embodiments, the host cell is a mammalian cell, a bacteria (e.g., E. coli), or a yeast, (e.g., P.pastoris).\n\n\nThe individual coat protein subunits can be produced in heterologous systems such as Escherichia coli or Pichia pastoris, and can be purified by conventional methods.\n\n\nIn some embodiments, CCMV coat protein particles assemble in vitro into empty, RNA-free VLPs, that is they can assemble without the presence of CCMV viral RNA, or any other RNA. In certain embodiments, the therapeutic agent to be loaded is added to the coat proteins prior or during VLP assembly. In certain embodiments, the therapeutic agent to be loaded is added to the coat proteins after they have formed a VLP. The ability to produce coat protein subunits in heterologous systems makes it feasible to scale-up the low-cost production of the agent-loaded VLPs to gram or kilogram quantities, so that any pharmaceutical or therapeutic applications will be economically viable.\n\n\nIn vitro assembly of a VLP can be performed by reassembling disassembled coat proteins that are obtained from any suitable source. In some embodiments, coat proteins (e.g., unassembled coat proteins) may be isolated by disassembling a VLP (e.g., an assembled or partially assembled VLP isolated from a cell culture). A VLP may be disassembled using any suitable method including varying the pH or salt concentration, adding a denaturant, a detergent, a chaotropic agent, a chelating agent, or any combination thereof. In some embodiments, a VLP is disassembled without denaturing the coat proteins. However, in some embodiments, coat proteins may be denatured or partially denatured. In some embodiments, unassembled coat proteins are isolated directly from an expression system that does not promote assembly of the VLP (e.g., an in vitro expression system, or a cell that does not support significant assembly of the VLP). In some embodiments, a modified VLP described herein may not assemble efficiently (e.g., even in a system that promotes or supports assembly of a wild-type CCMV VLP). Accordingly, the modified VLP may be isolated directly in a form that is suitable for reassembly (e.g., without requiring disassembly). Regardless of the procedure used to obtain one or more coat proteins suitable for reassembly, the coat proteins may be reassembled using any suitable technique. For example, a coat protein in a solution or buffer that promotes disassembly (or that stabilizes unassembled coat proteins) may be reassembled by changing the solution or buffer to one that promotes assembly (e.g., by dilution, dialysis, changing the pH, adding a salt, using a column, or any \n\n combination thereof). Accordingly, a mosaic may be made by mixing unassembled proteins of different types. It should be appreciated that in some embodiments an unassembled protein preparation as used herein may nonetheless contain a small percentage of assembled VLPs, but the protein preparation should be sufficiently disassembled and/or the assembled VLPs should be sufficiently unstable to allow reassembly, e.g., to form mosaic VLPs. Techniques for the disassembly and reassembly of CCMV coat proteins are known in the art, see, for example, Lavelle et al., J. Virol. Methods, 2007 Dec, 146(1-2): 311-6, the disassembly, reassembly and stability techniques of which are incorporated herein by reference.\n\n\nIn some embodiments, synthetic coat protein genes are expressed in E. coli or P. pastoris or other suitable prokaryotic or eukaryotic host cells. In some embodiments, a host cell may include two or more different coat protein genes that express different coat proteins (e.g., wild-type and one or more variants, or two or more variants with no wild-type). Coat protein preparations from such cells may be used directly to form mosaic VLP. It should be appreciated that the relative expression levels of the different coat proteins may be selected and determined using different promoters and/or regulatory sequences.\n\n\nSynthetic coat protein genes may be produced synthetically by one of the companies specializing in this technology (e.g., GeneArt, Sloning). In these embodiments, gene synthesis is carried out to optimize codon usage for the host system that produced the coat protein and/or to eliminate unwanted restriction sites. In some embodiments, altered forms of the coat protein, such as the NΔ34 mutant are generated, that give rise to VLPs that have diameters of about 18, 24 and 28 nm. In some embodiments, modifications may be made to produce VLPs having other diameters. VLPs of a particular size may be isolated from other sized VLPs using methods known in the art.\n\n\nIn some embodiments, the synthetic genes may be inserted into pET-based expression plasmids and expressed in E. coli or P. pastoris using procedures which are routinely used in the art. In certain embodiments, the expressed CCMV coat protein may be extracted, purified and assembled into VLPs using routine procedures.\n\n\nIn some embodiments, the synthetic CCMV coat protein genes may be inserted into the pPICZ shuttle vector (InVitrogen, Inc.) and integrated into the P. pastoris genome. Expression of the coat protein may be under the control of a strong methanol inducible promoter (e.g., the AOXl promoter). In certain embodiments, methanol induction results in the high level expression of the coat protein that self-assembles into empty virus particles within P. pastoris. \n\n In certain embodiments, methods of preparing a mosaic VLP preparation are provided, the method comprising combining at least two different CCMV coat proteins, wherein at least one coat protein is modified as described herein so that a mosaic VLP is generated. In certain embodiments, the methods further comprise combining a therapeutic molecule, a diagnostic molecule, or a heterologous nucleic acid with the at least two different CCMV coat proteins. Combining or loading of the therapeutic molecule, diagnostic molecule, or heterologous nucleic acid may be done e.g., during VLP assembly, as described herein. In certain embodiments, the therapeutic molecule is an anti-cancer drug, an antibiotic, an antiviral agent, an anti-microbial agent, an anti-inflammatory agent, or an immunostimulatory agent; the diagnostic molecule is an imaging agent; and the heterologous nucleic acid is a heterologous RNA molecule, a microRNA (miRNA), a short interfering RNA (siRNA), a chemically modified short interfering RNA, a double-stranded RNA (dsRNA), a short hairpin RNA (shRNA), RNAu, a circular siRNA, a hybrid DNA-siRNA, a crook siRNA, an antisense RNA molecule, or an expression vector comprising a gene, but is not so limited. In certain embodiments, the anti-cancer drug can be Docetaxel, Paclitaxel, Capecitabine, Doxorubicin, or Rapamycin, but is not so limited.\n\n\nIn some embodiments, VLPs are provided to deliver a therapeutic agent (e.g., Gemcitabine) in vivo to a target cell or tissue in a subject. It should be appreciated that VLPs may protect a therapeutic agent (e.g., Gemcitabine) from modification (e.g., deamination) in the plasma of a subject, thereby enhancing the amount of active drug in the targeted cells.\n\n\nIn some embodiments, VLPs may be delivered orally. In certain embodiments, VLPs can be used for oral delivery of cytotoxic drugs.\n\n\nIn some embodiments, VLPs may be delivered subcutaneously, intravenously, intra- peritoneally, or via any other suitable route. In certain embodiments, methods of treating a subject having an adverse condition are provided, the methods comprising administering to the subject a VLP preparation described herein or a pharmaceutical composition comprising a VLP preparation and optionally a non- VLP pharmaceutical composition in an amount effective to treat the condition. In certain embodiments, the adverse condition is a tumor, asthma, liver disease, heart disease, and Alzheimer's disease, but is not so limited. In certain embodiments, where the adverse condition is a tumor, the tumor can be a melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer, but is not so limited.\n\n\nProvided herein, in certain embodiments, are uses of a VLP preparation for preventing or treating an adverse condition. In certain embodiments, use of a VLP preparation for the \n\n manufacture of a medicament for preventing or treating an adverse condition are provided. In certain embodiments, the adverse condition is selected from the group consisting of a tumor, asthma, liver disease, heart disease, and Alzheimer's disease, but is not so limited. In certain embodiments, where the adverse condition is a tumor, the tumor can be a melanoma, squamous cell carcinoma, gastric, colon, non small cell lung cancer, or breast cancer, but is not so limited.\n\n\nThe term \"effective amount\" of a composition refers to the amount necessary or sufficient for a composition alone, or together with further doses, to realize a desired biologic effect. A compound or composition, such as a VLP preparation when \"administered in a sufficient amount,\" alone or together with further doses or, where indicated, together with additional compound or compositions, realizes a desired biologic effect. The desired response or effect, of course, will depend on the particular condition being treated. Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side- effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or adverse condition being treated, the size of the subject, or the severity of the disease or adverse condition. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons. One of ordinary skill in the art can empirically determine the effective amount without necessitating undue experimentation.\n\n\nFor any compound described herein the therapeutically effective amount can be initially determined from animal models. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.\n\n\nAs used herein, the terms \"treat,\" \"treated,\" or \"treating\" when used with respect to an adverse condition, such as a disorder or disease (e.g., cancer, infection, neurodegenerative disorder, or any other disease or disorder) may refer to prophylaxis, amelioration, prevention and/or cure of the condition. Treatment after a condition (e.g., disease or disorder) has \n\n started aims to reduce, ameliorate or altogether eliminate the condition, and/or its associated symptoms, or prevent it from becoming worse. Treatment of subjects before a condition has started (e.g., prophylactic treatment) aims to reduce the risk of developing the condition and/or lessen its severity if the condition does develop. As used herein, the term \"prevent\" refers to the prophylactic treatment of a subject who is at risk of developing a condition resulting in a decrease in the probability that the subject will develop the disorder, and/or to the inhibition of further development of an already established disorder. Desired outcomes may include a stabilization of the condition, a slowdown in progression of the disease or a full disease-free recovery of the subject. The VLPs described herein may be administered per se (neat) or in the form of a pharmaceutically acceptable formulation. If the VLPs are administered in pharmaceutically acceptable solutions, they may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients. The solutions used preferably are sterile. The pharmaceutical compositions contain an effective amount of VLPs optionally included in a pharmaceutically- acceptable carrier, and may be sterilized as described herein.\n\n\nProvided herein are pharmaceutical compositions comprising the VLP preparation described herein optionally further comprising a non-VLP pharmaceutical compound.\n\n\nModes of administering the VLPs and therapeutic agents described herein will vary depending upon the specific agents used and the disease being treated, as would either be known to those skilled in the art or can be established by routine experimentation using methods commonly employed in the art. Dependent upon these factors, the agents may be administered orally or parenterally. In some embodiments, oral formulations may include immediate release particle coatings. In some embodiments, oral formlulations may include controlled release particle coatings. In some embodiments, oral formulations may include extended release particle coatings. Parenteral modes of administration include intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intralesional, intrapleural, intrathecal, intra-arterial, and into lymphatic vessels or nodes and to bone or bone marrow. The VLPs and therapeutic agents of the invention may also be administered topically or transdermally, buccally or sublingually, or by a nasal, pulmonary, vaginal, or anal route. Accordingly, in some embodiments, compositions of the invention may be provided in the form of tablets, capsules, softgels, liquids, powders, or other forms for oral administration. In some embodiments, compositions of the invention may be provided in the form of liquid or lyophilized preparations for injection. In some embodiments, compositions of the invention \n\n may be provided in the form of a metered dose, a dry powder, a nebulized, or a nasal preparation for respiratory delivery. In some embodiments, these or other formulations may be used for ophthalmic, otic, topical, and/or other forms of delivery.\n\n\nFor oral administration, the pharmaceutical compositions can be formulated readily by combining the active compound(s), e.g., the VLPs described herein and optionally additional therapeutic agents, with pharmaceutically acceptable carriers well known in the art. Such carriers enable the VLPs and optionally additional therapeutic agents to be formulated as tablets, pills, dragees, capsules, liquids, gels, hydrogels, pellets, granules, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.\n\n\nDragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.\n\n\nPharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral \n\n administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.\n\n\nFor buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner. The compositions may be administered by inhalation to pulmonary tract, especially the bronchi and more particularly into the alveoli of the deep lung, using standard inhalation devices. The compositions may be delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. An inhalation apparatus may be used to deliver the compositions to a subject. An inhalation apparatus, as used herein, is any device for administering an aerosol, such as dry powdered form of the compositions. This type of equipment is well known in the art and has been described in detail, such as that description found in Remington: The Science and Practice of Pharmacy, 19\nth\n Edition, 1995, Mac Publishing Company, Easton, Pennsylvania, pages 1676-1692. Many U.S. patents also describe inhalation devices, such as U.S. Patent No. 6,116,237.\n\n\n\"Powder\" as used herein refers to a composition that consists of finely dispersed solid particles. Preferably the compositions are relatively free flowing and capable of being dispersed in an inhalation device and subsequently inhaled by a subject so that the compositions reach the lungs to permit penetration into the alveoli. A \"dry powder\" refers to a powder composition that has a moisture content such that the particles are readily dispersible in an inhalation device to form an aerosol. The moisture content is generally below about 10% by weight (% w) water, and in some embodiments is below about 5% w and preferably less than about 3% w. The powder may be formulated with polymers or optionally may be formulated with other materials such as liposomes, albumin and/or other carriers.\n\n\nAerosol dosage and delivery systems may be selected for a particular therapeutic application by one of skill in the art, such as described, for example in Gonda, I. \"Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract,\" in Critical Reviews in Therapeutic Drug Carrier Systems, 6:273-313 (1990), and in Moren, \"Aerosol dosage forms and formulations,\" in Aerosols in Medicine. Principles, Diagnosis and Therapy, Moren, et al., Eds., Esevier, Amsterdam, 1985. \n\n The compositions, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.\n\n\nPharmaceutical formulations for parenteral administration include aqueous solutions of the active compositions in water-soluble form. Additionally, suspensions of the active compositions may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compositions to allow for the preparation of highly concentrated solutions.\n\n\nAlternatively, the active compositions may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.\n\n\nThe compositions may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.\n\n\nIn addition to the formulations described previously, the compositions may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.\n\n\nThe pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also may include granules, powders, tablets, coated tablets, (micro)capsules, \n\n suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer, Science 249:1527-1533, 1990, which is incorporated herein by reference.\n\n\nIn some embodiments, Gemcitabine packaged inside the VLPs described herein, may be protected from deamination in the plasma during in vivo delivery. In certain embodiments, delivery of Gemcitabine through VLPs in vivo to a subject reduces drug induced side-effects.\n\n\nIn some embodiments, VLP preparations of the invention may be administered to a subject in combination (e.g., simultaneously or separately but as part of the same therapeutic regimen) with a compound or other pharmaceutical preparation for treating one or more conditions or diseases described herein. Accordingly, aspects of the invention relate to combination preparations or kits that contain one or more VLPs of the invention along with one or more separate compounds (e.g., drugs) that are not packaged in a VLP.\n\n\nEXAMPLES\n\n\nExample 1\n\n\nIn a non-limiting example, a VLP is produced such that it is modified to be optimized for loading siRNA. The VLP contains either wild-type coat proteins that are already positively charged, or coat proteins engineered to carry additional positive charges, e.g., in the N-terminal region of amino acids 1- 26. Some VLPs are optimized for targeted delivery and a targeting peptide is fused in frame to be expressed in one or more of the surface exposed loops of the VLP. In one example, the targeting peptide is RGD. Coat proteins are produced in E. coli and P. pastoris. Modified coat proteins are purified. Some coat proteins are chemically linked to hyaluronic acid to mask immunogenic sites on the VLP. SeIf- assembly of the modified coat proteins is measured. Immune reactivity of the resulting VLP is measured in a mouse model system. VLPs are loaded with siRNA molecules and these are delivered to a mouse model in vivo. A reporter gene mouse model (GFP, luciferase, beta- galactosidase) is used and siRNA that are delivered in vivo are siRNAs directed against \n\n reporter genes. Loss of expression of the reporter gene is measured. Specific cellular targeting is followed in vivo via immunostaining and in vivo imaging techniques.\n\n\nExample 2 In some non-limiting examples, anti-growth activity is first measured in vitro in cell culture systems of transformed breast cancer cell lines. Successful delivery of siRNA molecules targeting oncogenes by the drug-loaded VLPs to the cells is measured by colony forming assays, cell cycle analysis, and/or measurement of apoptosis by FACS, immunofluorescence, immunoblotting, and/or colorimetric assays. In further non-limiting examples, the anti-cancer activity of target siRNA molecules directed against oncogenes is tested in cancer mouse models. Survival curves are prepared and tumor spreading and tumor mass is monitored by sacrificing and dissecting mice at regular intervals.\n\n\nSome VLPs, genetically optimized to interact with Gemcitabine are loaded with Gemcitabine by swelling the VLP at pH 6.5 and trapping the solubilized Gemcitabine in the VLP by lowering the pH to pH 5.0. VLPs are administered to a pancreatic xenograph mouse model via oral and injection routes. Cytotoxicity is tested in vivo. Cancer progression is carefully monitored.\n\n\nSome VLPs are modified to express targeting molecules specific for the integrin receptor and are loaded with Gemcitabine. Some coat proteins that express the integrin receptor-specific molecule are additionally chemically modified by PEGylation to reduce immunogenicity. These coat proteins are self-assembled and loaded with Gemcitabine. Cytotoxicity tests and anti-cell growth effects are monitored in vitro using pancreatic tumor cell lines. Cytotoxicity and anti-tumor effects, as well as specific targeting efficiency are analyzed in vivo using a pancreatic xenograph mouse model. Some VLPs are modified to express MUC-I antibody as a fusion protein and loaded with Gemcitabine. Cytotoxicity tests and anti-cell growth effects are monitored in vitro using breast cancer cell lines. Cytotoxicity and anti-tumor effects, as well as specific targeting efficiency are analyzed in vivo using a breast cancer xenograph mouse model.\n\n\nIn some examples, a VLP is loaded with cisplatinum and/or similar molecules.\n\n\nExample 3\n\n\nIn a non-limiting example, empty particles of Cowpea chlorotic mottle virus (CCMV) which can be used to encapsidate drug molecules and which can be targeted to defined cells were produced. Expression of the empty particles was undertaken in the yeast, Pischia \n\n pastoris, since this system has been previously used successfully for the production of empty CCMV particles. The anti-cancer drug Gemcitabine is encapsidated in the CCMV particles. The RGD-4C peptide, which binds integrins, was integrated into surface exposed loops of the viral coat protein and was expressed on the surface of the CCMV capsids. CCMV capsids expressing the RGD-4C peptide will be used to target cells which express integrins.\n\n\nProduction of a synthetic CCMV coat protein gene\n\n\nTo produce a version of the CCMV coat protein (CP) which can be easily modified on both its outer (to incorporate cell targeting sequences) and inner (to optimise drug binding) surfaces, a synthetic gene was made by Geneart (Regensburg, Germany) (Fig. 1). The gene was so designed as to allow the removal of the N-terminal section, which controls RNA encapsidation and is on the inner surface of the assembled particles, and the insertion of targeting sequences in either the βC-αCDl or βF-βG loops on the outer surface of the virus- like particles (VLPs). Accoringly, a wild-type CCMV coat protein sequence is similar to that shown in Fig. IB, but it includes R, P, and K at positions 26, 75, and 131 respectively, instead of the substituions to H, G, and R shown for those positions in Fig. IB. The positions of the inserts are shown in Fig. 2.\n\n\nFor the deletion, the first 7 amino acids (MSTVGTG, SEQ ID NO: 506) were added back after deleting the first 26 amino acids, effectively deleting residues 8-26 (the region which contains all 8 of the basic residues). The deletion and the insertions into the bCaCDl and bFbG loops (CCMV CP insertions) are shown in Figure 8. The RGD peptide used has the following nucleic acid and amino acid sequence: FMDV-O-20mer (RGD peptide): N A V P N L R G D L Q V L A Q K V\n\n\nAAT GCT GTT CCT AAT TTG AGA GGT GAT TTG CAA GTT TTG GCT CAA AAA GTT TTA CGA CAA GGA TTA AAC TCT CCA CTA AAC GTT CAA AAC CGA GTT TTT CAA\n\n\nA R T (SEQ ID NO: 505) GCT AGA ACT (SEQ ID NO: 508)\n\n\nCGA TCT TGA (SEQ ID NO: 509)\n\n\nExpression of synthetic untargeted wt and Nl CP genes in Pischia pastoris\n\n\nFor expression of the CCMV coat proteins in Pischia pastoris, the EasySelect™ Pischia expression kit (Invitrogen, Carlsbad, CA) was used. The sequences encoding the full- length and CCMV7N1 mutant CPs were inserted into the multiple cloning site of plasmid pPICZ-A to give plasmids pPICZ-CCMV and pPICZ-CCMV/Nl, respectively (Fig. 3). P. \n\n pastoris strain X-33 was used for expression. All liquid growth was at 30 \n0\nC and 250 rpm in baffled flasks. Cultures were started in 8 ml in MGY and grown overnight (up to 24 hours) in falcon tubes, leading to OD\n6O0\n of about 8.0. Cells were collected by centrifugation at 200Og for 5 minutes and re-suspended in 32 ml of MM with 0.5% methanol in 250 ml flasks. 16 to 24 hours later the cells were harvested by centrifugation at 10 minutes at 350Og.\n\n\nExtraction/Purification of wt and Nl CCMV particles from Pischia pastoris\n\n\nThe following method was used:\n\n\nRe-suspend pellet in 3-9 ml of 0.2M NaOAc (pH4.8); combine smaller volumes for extraction in the cell disruptor (takes 10 ml); 3 passes at 30 KPSI on cell disruptor; clear cell debris at 12 00Og for 10 minutes; collect particles by centrifugation at 118 00Og for 2 hours 15 minutes; re-suspend in 50 mM NaOAc (pH4.8); for three 32 ml cultures resuspended to a collective 9 ml about 30 μg of wt and Nl particles were obtained.\n\n\nCharacterisation of wt and Nl particles produced in Pischia pastoris\n\n\nApproximately lμg samples of wt and Nl particles were denatured and examined by SDS/PAGE on a 12% polyacrylamide gel. Staining with Coomassie blue revealed prominent bands in the correct positions for the wt and Nl coat proteins (Fig. 4). Some contaminating proteins were also seen suggesting that further purification might be required in some embodiments. Analysis by non-denaturing agarose gel electrophoresis was used to examine 5μg samples intact particles. To detect protein, the gels were stained with Coomassie blue. As is usual with this technique, the samples ran as a broad band in each case. However, the Nl sample ran more slowly than the wt, consistent with the particles having a different charge. When the gel was stained with ethidium bromide to reveal any encapsidated nucleic acid, only the wt sample gave a signal, wt CCMV CP is known to encapsidate heterogeneous RNAs. When the N-terminal sequence is deleted, as in the case of Nl, heterogeneous RNAs is no longer encapsidated leading to particles that are likely entirely free of nucleic acid contaminants and therefore better suited as delivery vehicles, e.g., for RNAi molecules. Fig. 4 shows that no nucleic acid is detected in the Nl variant based on eithidium staining (whereas nucleic acid is present in the wt particle). TEM confirmed the presence of CCMV- like particles in both the wt and Nl samples (Fig. 5). Accordingly, Nl and similar variants do not contain detectable viral RNA or nucleic acid from the host cell. These particles are empty of viral or host RNA or DNA and can be used directly to load one or more agents of interest. \n\n Insertion of targeting peptides\n\n\nOligonucleotides encoding the RGD-4C peptide were inserted into the βC-αCDl or βF-βG loop of full-length or the Nl mutant of the CCMV CP to give the four plasmids shown in Fig. 6. These plasmids were used to transform P. pastoris. Only those colonies containing plasmid pPICZ-CCMV-RGD-bCaCDl, containing the RGD-4C peptide inserted into the BC- αCDl site of the wt CP grew at an appreciable rate and produced detectable CCMV CP. This construct was used for further analysis.\n\n\nAttempts to purify particles produced by pPICZ-CCMV-RGD-bCaCD 1 using the\n\n\nCCMV purification protocol (applied successfully to wt and Nl CP) were unsuccessful as the particles were lost in the first clearing spin. This was attributed to a change in charge on the particle surface (caused by the basic nature of the RGD-containing peptide) causing particle aggregation. Attempts were made to prevent aggregation by carrying out the extractions at a higher pH and/or creating \"mosaic\" in which only a proportion of the 180 CP molecules in the particle bear the RGD-sequence. To investigate these possibilities, a revised extraction protocol was applied to Psichia expressing the Nl CP and the pPICZ-CCMV-RGD-bCaCDl CP. The extracts were then mixed in various proportions: 6:0, 5:1, 4:2, 3:3, 2:4, 1 :5, 0:6.\n\n\nSolubilisation of particles at higher pH and creations of Mosaics:\n\n\nThe following method was used:\n\n\nDisruption as described herein but in 50 mM Tris (pH 7.5) with 0.5 M CaCl\n2\n and 1 mM DTT plus 200 μM PMSF; incubate 60 minutes on ice with occasional mixing; clear cell debris at 12 00Og for 10 minutes; mix supernatants at various ratios for mosaic particles and incubate a further 30 minutes on ice; dialyse overnight against 0.1M NaOAc (pH 4.8) with 0.1M NaCl and 200 μM PMSF; dialyse a further 6 hours against 50 mM NaOAc (pH4.8); precipitate forms; clarify with 15 minutes at 20 000g; collect particles from supernatant with 2 hours and 15 minutes at 118 00Og.\n\n\nThe particles were then examined by SDS/PAGE and western blotting using the anti- CCMV rabbit antibody PVAS-299. The Nl mutant and the pPICZ-CCMV-RGD-bCaCDl CPs can readily be distinguished by their sizes (Fig. 7).\n\n\nThe results showed that both types of coat protein can be extracted with higher pH buffer but expression/extraction appears to be more efficient in the case of Nl (Sample 6:0) than pPICZ-CCMV-RGD-bCaCDl (Sample 0:6). When the two types of CPs were \n\n reassembled in ratios shown above each lane, both types of coat protein could be seen in the sample. When Nl and pPICZ-CCMV-RGD-bCaCDl extracts were mixed in a ratio of 1:5 prior to assembly, approximately equal amounts of the two CPs can be found in the samples. This is consistent with the expression/extraction of Nl being more efficient than pPICZ- CCMV-RGD-bCaCDl . The resulting preparation may be analyzed to determine the extent to which mosaic VLP and/or mixtures of two types of particles, those containing exclusively Nl CP and those containing exclusively pPICZ-CCMV-RGD-bCaCDl, or all three different particles are present in the preparation. This analysis may be performed, for example, by differentially labeling the different coat proteins and determining the extent to which the different coat proteins (e.g., as determined by measuring the different labels) are present in the same particles. It should be appreciated that the preparation may be homogeneous in some embodiments, and only contain mosaic YLP having the same ratio of different coat proteins. In some embodiments, a preparation may be heterogeneous and contain a mixture of different types of mosaic VLP, each type having a different ratio of different coat proteins. It should be appreciated that since the preparations containing pPICZ-CCMV-RGD-bCACDl alone rapidly precipitate out of solution, at a minimum, the presence of the Nl CP is providing a solubilising effect, whether present as separate particles or in mosaic particles comprising both CP types.\n\n\nAll publications, patents and sequence database entries mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.\n\n\nWhat is claimed is:"
  },
  {
    "id": "WO2010046710A1",
    "text": "Therapeutics for neurological disorders AbstractThe present invention relates to therapeutic compounds that are Nrf2-ARE pathway activators suitable for the treatment of diseases known to be mediated by oxidative stress such as motor neurone disease. The invention also includes compounds identified by the methods of the invention for treatment of neurodegenerative diseases. Claims\n\n\n\n\n\n\n1. A therapeutic agent for the treatment of motor neurone disease, the therapeutic agent being a Nrf2-ARE pathway activator selected from the group comprising andrographolide and S [+] apomorphine\n\n\n\n\n\n\n2. Use of a Nrf2-ARE pathway activator selected from the group comprising andrographolide and S [ + ] apomorphine for the manufacture of a medicament for the treatment of motor neurone disease.\n\n\n\n\n\n\n3. A therapeutic agent for the treatment of a neurodegenerative condition that occurs as a result of oxidative stress, the therapeutic agent being a Nrf2-ARE pathway activator selected from the group comprising andrographolide and S [+] apomorphine.\n\n\n\n\n\n\n4. A therapeutic agent according to claim 3 wherein the neurodegenerative condition know to be mediated by oxidative stress is selected from the group comprising motor neurone disease, amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS), Huntington's disease, age related macular degeneration, preservation of organs for transplant/surgical procedures, stabilisation of cell cultures, photogenic oxidative stress and skin ageing and the treatment of radiation-induced cell damage.\n\n\n\n\n\n\n5. Use of andrographolide for the treatment of a disease or condition that occurs as a result of oxidative stress, the disease or condition being selected from the group comprising motor neurone disease, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), Huntington's disease, Alzheimer's disease, Parkinson's disease, age related macular degeneration, preservation of organs for transplant/surgical procedures, stabilisation of cell cultures, photogenic oxidative stress and skin ageing and the treatment of radiation-induced cell damage.\n\n\n\n\n\n\n6. A therapeutic agent according to any of claims 1 , 3, 4 or use according to either claim 2 or 5 further including an additional pharmaceutical ingredient or excipient diluent or carrier.\n\n\n\n\n\n\n7. A therapeutic agent according to any of claims 1 , 3, 4 or use according to either claim 2 or 5 that is formulated for parenteral, intravenous, intramuscular,  intraperitoneal, or subcutaneous administration or for direct delivery into a target organ or tissue by injection or infusion. Description\n\n\n\n\n THERAPEUTICS FOR NEUROLOGICAL DISORDERS\n\n\nThe present invention relates to therapeutic agents for the treatment of neurological disorders known to be mediated by oxidative stress and in particular for the treatment of motor neurone disease and amyotrophic lateral scierosis. The invention includes inter alia products for the treatment of neurological disorders.\n\n\nBACKGROUND\n\n\nOxidative stress refers to the cytopathoiogic consequences of a mismatch between the production of free-radicals and the ability of the cell to defend against them. Growing data from experimental models and human brain studies suggest that oxidative stress may play an important role in neuronal degenerative diseases. Oxidative stress has been implicated in both normal aging and in various neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral scierosis and may be a common mechanism underlying various forms of cell death including necrosis, apoptosts, and excitotoxicity.\n\n\nMotor neurone disease (MND) is more commonly called Amyotrophic lateral sclerosis (ALS) in the USA and is a progressive, fatal, neurodegenerative disease characterised by the loss of motor neurones in the motor cortex, brain stem and spinal cord, this leads to weakness and atrophy. ALS typically leads to death within 2-3 years of diagnosis. ALS occurs in both sporadic (90% of ail cases) and familial forms (10% of ali cases). In 20% of familial ALS\n1\n mutations have been found in the copper, zinc superoxide dismutase gene (SOD1). The genes involved in the sporadic cases and in the remaining 80% of familial cases have yet to be identified. Currently there is no treatment which prevents or reverses the course of the disorder. Available treatments (such as riluzole and antioxidants) can at best only extend survival to a modest degree.\n\n\nThe mechanisms underlying the disease are not fully understood. However, the identification of SOD1 mutations as causative in a proportion of familial cases of ALS has allowed the generation of both cellular and mouse models of the disease which have greatly enhanced the understanding of disease mechanisms. Evidence from these models, as well as from patients, has provided very good evidence for a role of oxidative stress in disease pathogenesis. Oxidative stress has significant crosstalk to other potential mechanisms of neuronal injury, such as mitochondrial dysfunction, \n\n excitotoxicity, protein aggregation, cytoskeieta! dysfunction and glial cell activation. It can feed into these mechanisms or is enhanced, in turn, by them. This central rofe in pathogenesis is reflected in a meta-analysis of studies in the most commonly used mouse model of ALS (transgenic mice expressing the G93A mutant form of human SOD1) where therapies targeting oxidative stress have been highlighted as demonstrating greatest promise in slowing disease progression.\n\n\nDespite this central role, targeting oxidative stress in ALS has failed to translate into clinical benefit for patients, which may in part be due to the lack of sufficiently potent anti-oxidants able to access the CNS, A novel approach to limiting oxidative stress in neurodegenerative disease is to promote activation of the transcription factor, NFE2- related factor 2 (Nrf2). Nrf2 drives expression of a battery of Phase Il detoxification and anti-oxidant enzymes via its interaction with the antioxidant response element (ARE). When activated, this 'programmed cell life' response is neuroprotective and conversely, attenuation of this pathway can enhance neuronal sensitivity to a range of neurotoxic challenges. Dysregulation of this pathway has been observed in ALS cellular models and confirmed in human tissue. Nrf2 itseff and multiple target genes were repressed in a motor neuronal ceil line expressing mutant (G93A) human SOD1. Further, a target of this pathway which plays an important role in mitochondrial anti-oxidant defence, peroxiredoxin3 (PRDX3), was downregulated in both this cellular model and human tissue from familial and sporadic ALS. G93A SOD1 transgenic mice, when crossed with an ARE reporter mouse, showed activation of the Nrf2~ARE pathway in muscle from 30 days of age, with marginal activation in spinal cord at 90 days and more robust activation at the 110 day time-point. At 90 days of age, mice have already begun to show muscle weakness and motor neuron loss and at 110 days they show significant motor neuron pathology. This suggests that activation of the Nrf2-ARE pathway in this murine model may be qualitatively insufficient or too late to protect motor neurons from significant damage. Taken in combination with other reports, this may reflect a defect in the capacity of cells expressing mutant SOD1 to activate this pathway.\n\n\nThe Nrf2-ARE pathway is an attractive therapeutic target in ALS because it is well defined, amenable to activation by small molecules and activation of cellular defences may confer a more lasting protection against oxidative stress than, for example a direct scavenging approach. It is known from the prior art that a flavonoid derived from green tea catechin -(-) epigallocatechin-3-gailate (EGCG) shows neuroprotective effects in a motor neuronal cell line expressing mutant (G93A) human SOD1. This cell line was \n\n partially protected from H\n2\nO\n2\n induced cell death at concentrations of EGCG greater than 20μM. This compound has also been tested in the G93A mouse model of ALS at a range of doses, once a day, orally from 60 days of age. At higher doses a significant extension in survival was seen with an increase in mean survival. This therapeutic effect is found in spite of the fact that EGCG is itself pro-oxidant, narrowing its therapeutic window, and highly polar, making it unlikely to cross the blood brain barrier in significant concentrations.\n\n\nThere is a need for therapeutic agents that are effective in the treatment of diseases known to be mediated by oxidative stress and especially diseases like motor neurone disease, ALS, Parkinson's and other neurodegenerative diseases.\n\n\nThere is a need for therapeutic agents for the treatment of neurodegenerative diseases that possess minima! toxicity and have the ability to cross the blood-brain barrier and so can penetrate the CNS.\n\n\nBRIEF SUMMARY OF THE DISCLOSURE\n\n\nAccording to a first aspect of the invention there is provided a therapeutic agent for the treatment of motor neurone disease, the therapeutic agent being a Nrf2-ARE pathway activator selected from the group comprising andrographolide and S [+] apomorphine\n\n\nMotor Neurone Disease (MND) is an all embracing term used to cover a number of illnesses of the motor neurone. Amyotrophic Lateral Sclerosis (ALS), Progressive Muscular Atrophy (PMA), Progressive Bulbar Palsy (PBP), Primary Lateral Sclerosis (PLS) are ail subtypes. MND is the generic term used more in Europe whilst ALS is sometimes used more generically in the USA. It will be appreciated by the skilled person that references to motor neurone disease (MND) also extend to references to ALS, PMA, PBP and PLS and these named disease states may be used interchangeably.\n\n\nThroughout the description and claims of this specification, the words \"comprise\" and \"contain\" and variations of the words, for example \"comprising\" and \"comprises\", means \"including but not limited to\", and is not intended to (and does not) exclude other moieties, additives, components, integers or steps. \n\n Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.\n\n\nFeatures, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.\n\n\nThe present invention has demonstrated through a cascade of screens and tests that andrographolide and S [+] apomorphine are potent and 'drug-like' Nrf2-ARE activators which also have the capacity to penetrate the CNS.\n\n\nThe compounds of the present invention may be used prophylactically or therapeutically either on their own or as part of a treatment regimen.\n\n\nIt will be appreciated that the term \"treatment\" and \"treating\" as used herein means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relieve the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. The patient to be treated is preferably a mammal, in particular a human being, but it may also include animals, such as dogs, cats, cows, sheep and pigs.\n\n\nAccording to a yet further aspect of the invention there is provided use of a Nrf2-ARE pathway activator selected from the group comprising andrographolide and S [+] apomorphine for the manufacture of a medicament for the treatment of motor neurone disease. \n\n Apomorphine is a dopamine agonist typically administered subcutaneously as intermittent injections or in a continuous infusion. It is useful in managing advanced Parkinson's disease, and provides an alternative to neurosurgical procedures. There has been no previous clinical indication that [S] + enantiomer of the compound may be useful in treating ALS or other disease states. Results have shown that in particular the S enantiomer which does not have dopamine agonist activity has the correct criteria for being an ALS therapeutic as defined by the methods of the present invention and as described hereinbefore. The present invention therefore recognises new therapeutic effects of the [S] + enantiomer of apomorphine.\n\n\nThe chemical structure of apomorphine is given below and it will be appreciated that any variants and substitutions of the [S]+ enantiomer is encompassed within the compounds of the present invention. In addition any derivatives or sails of the [S]+ enantiomer are included within the scope of the present invention and the contents of PCT/US03/08448 are incorporated herein by reference.\n\n\n\n\n\n\n\n\nAndrographolide is a diterpenoid lactone of the plant Andrographis paniculata , known to possess anti-tumour activity for certain specific cancers such as breast cancer and to have an antiinflammatory effect . There has been no previous clinical indication that the compound may be useful in treating diseases associated with oxidative stress for example and without limitation ALS. The present invention therefore recognises new therapeutic effects of andrographolide.\n\n\nThe chemical structure of andrographolide is given below and it will be appreciated that any variations and substitutions are encompassed within the compounds of the present invention. For example andrographolide and its derivatives may be of the formula where R.sub.1 , R.sub.2 and R.sub.3 can independently represent hydrogen, acyl, phenyl, \n\n mono- or polyphosphate, mono- or polysuifate, glycosyl, cyclic or acycfic aikyl, afkenyl or aikynyl, wherein said phosphate or sulfate derivatives may be in the form of free acids or as salts.\n\n\n \n\n Preferably, the compounds of the present invention may be formulated into pharmaceutical forms suitable for administration to a patient in need of treatment.\n\n\nThe pharmaceutical compositions can be in any form suitable for oral, parenteral, topical, intranasal, ophthalmic, otic, recta! or transdermal administration. Where the compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery. The delivery can be by bolus injection, short term infusion or longer term infusion and can be via passive delivery or through the utilisation of a suitable infusion pump.\n\n\nAccordingly the compounds of the present invention may further include pharmaceutical ingredients or excipients.\n\n\n\"Pharmaceutical ingredient\" or \"excipient\" means a pharmacologically inactive pharmaceutically acceptable compound added to the compositions of the invention. The ingredient or excipient does not have any pharmacological properties.\n\n\nAccording to a further aspect of the invention there is provided a therapeutic agent for the treatment of a neurodegenerative condition that occurs as a result of oxidative stress, the therapeutic agent being a Nrf2-ARE pathway activator selected from the group comprising andrographolide and S [+] apomorphine.\n\n\nPreferably, the neurodegenerative condition know to be mediated by oxidative stress is selected from the group comprising motor neurone disease, amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS), Huntington's disease, age related macular degeneration, preservation of organs for transplant/surgical procedures, \n\n stabilisation of cell cultures, photogenic oxidative stress and skin ageing and the treatment of radiation-induced ceil damage.\n\n\nAccording to a yet further aspect of the invention there is provided use of andrographoiide for the treatment of a disease or condition that occurs as a result of oxidative stress, the disease or condition being selected from the group comprising motor neurone disease, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis\n\n\n(PLS), Huntington's disease, Alzheimer's disease, Parkinson's disease, age related macular degeneration, preservation of organs for transplant/surgical procedures, stabilisation of cell cultures, photogenic oxidative stress and skin ageing and the treatment of radiation-induced cell damage.\n\n\nAccording to a yet further aspect of the invention there is provided a method of treating an individual suffering from a neurodegenerative disease that occurs as a result of oxidative stress comprising administering a therapeutically effective amount of a Nrf2- ARE pathway activator selected from the group comprising andrographoiide and S [+1 apomorphine\n\n\nAccording to a yet further aspect of the invention there is provided an in vitro method of screening a library of candidate therapeutic agents for their suitability to treat diseases know to be mediated by oxidative stress, the method comprising:\n\n\n(i) exposing control or normal cells of non-neuronal origin to the candidate therapeutic and identifying candidate agents that possess an ability to activate the Nrf2-ARE pathway; (ii) exposing cells of neuronal origin with candidate agents having a positive effect in step (i) and assessing their ability to activate the Nrf2~ARE pathway; (iii) assessing the ability of the candidate agent to protect cells of neuronal origin against an oxidative stress insult; and (iv) performing a series of in silico tests to ascertain physical and chemical parameters, wherein a candidate therapeutic having positive results in step (i-iii) and having suitable physico-chemical properties is likely to be suitable for the treatment of diseases know to be mediated by oxidative stress. \n\n The present invention provides a convenient cascade of tests as a screening method for identifying more potent and 'drug-like' Nrf2-ARE activators which also have the capacity to penetrate the CNS. The methods of the present invention provide a robust screening cascade to select a smaii number of promising molecules for further in vivo testing. These \"hit\" molecules are tested initially for their capacity to activate the Nrf2-ARE pathway in cell lines derived from normal non-human animals and cell lines of human origin and subsequently used as \"tool\" molecules to determine whether the pathway could be activated in neuronal cells derived by primary culture from the CNS of non- human animals.\n\n\nPreferably, the non-human animal from which cells are derived are selected from the group comprising monkeys, dogs, cats, rabbits, rats and mice. Rodent species are preferred, and the mouse is the most preferred species.\n\n\nPreferably, in one embodiment of the invention the ceifs are stably transfected with an ARE reporter construct, optionally the reporter is a fluorescent agent such as and without limitation GFP or the like.\n\n\nPreferably, ceils are assayed for increased expression of Nrf2 regulated genes. Suitable methods for detecting activation are described herein after.\n\n\nPreferably, the cells of neuronal origin are CNS ceils and especially are astrocytes. In one embodiment of the invention they are derived from transgenic non-human animals expressing the G93A mutant form of human SODl\n\n\nPreferably, the oxidative stress test of step (iii) comprises withdrawal of serum and measurement of oxidative stress optionally with dichloroflourescein or derivatives or incubation with mitochondrial toxins (menadione) and measurement of cell survival. However, it will be appreciated that other stress test can be employed in the methods of the present invention.\n\n\nPreferably, the suitable physical and chemical parameters of step (iv) are a cLogP <5, molecular mass <500, <5 hydrogen bond donors (OH+NH count) and <10 hydrogen bond acceptors (O plus N atoms). The suitable physical and chemical parameters are typically referred to as Lipinski's rule of 5. In addition AlogP less than 4 but greater than 1, and a molecular Polar Surface Areasbelow 100 (ideally 80) are optimal for passive \n\n diffusion across the blood-brain barrier (BBB) however further preferred characteristics may also be applied to best select candidate therapeutic agents.\n\n\nAny features ascribed to a particular aspect of the invention are intended to apply to each and every aspect mutatis mutandis.\n\n\nBRIEF DESCRIPTION OF THE DRAWINGS\n\n\nFigure 1 shows a schematic representation of the NRF2-ARE assay used in the present invention.\n\n\nFigure 2 shows the results of assay validation. Figure 1a shows concentration response curves for tBHQ (open squares) and EGCG (closed squares) in the CHO-4xARE-TK cell line. Both molecules have a narrow window of ARE activation peaking at 10μM and IQOμM respectively. Figure 1b shows results of Z' score determination. The average +/- SD for vehicle (192 welis) and positive control (10μM Ebselen, 192 wells) from a single 384 well plate are shown. The T score for this assay was 0.51 with signal to noise (S/N) and signal to background (S/B) ratios of 12.8 and 2.9 respectively.\n\n\nFigure 3 shows example spectrum library screening data for one 384 well plate. GFP fluorescence versus well number. Weils 1-24 and 360-384 contain alternate positive (10μM Ebselen) and negative (vehicle) controls. Dotted line represents the average +3SD of the negative controls and all compounds above this line are counted as 'hits'. Some wells show reduced fluorescence, most likely due to toxicity.\n\n\nFigure 4a shows overlaid concentration response curves for all 46 hit compounds. Note that the profiles for many of the hit compounds follow a bell shaped dose response curve with reduced fluorescence due to toxicity at higher concentrations and have a narrow window of ARE induction. Figure 4b shows examples of compounds with minimal toxicity at high concentrations or a broad window of ARE induction, note most of these compounds showed some toxicity at 100μM.\n\n\nFigure 5 shows pharmacophore model and alignment of compounds from A/ Primary screen (compounds with EC50 <5μM) and B/ Astrocytic oxidative stress assay in 1321N1 cells (compounds with EC50 <3μM). Aromatic/Hydrophobic feature in green,\n\n\nHydrogen Bond Acceptor feature in blue. For (B) a basic pharmacophore emerges with \n\n two hydrophobic features associated with a hydrogen bond acceptor. This is consistent with known NRF2 activators which may act by nucleophiiic attack of suiphydry! groups on KEAP1, the cytoplasmic NRF2 regulator.\n\n\nFigure 6 shows the results of ARE reporter assay in C6 astrocyte cell line for 17 best hit compounds and S [+] apomorphrne. Overall the response is similar to that seen in the CHO cell line and both R[-] and S[+] apomorphiπe induce the Nrf2-ARE pathway to a similar degree suggesting that this activity is unrelated to the dopamine agonist activity of RH apomorphine. The response in the NSC34 cell line was substantially reduced or non-existent for the majority of compounds (not shown).\n\n\nFigure 7 shows quantitative RT-PCR analysis for NRF2 regulated genes in the rat C6 astrocyte cell line (C6 astrocytes, Figure 7a and Figure 7b) and primary mouse astrocytes (Figure 7c and Figure 7d) following 24h treatment with Andrographolide (Andro) and S[+] Apomorphine (Apo S) at EC\n50\n and EC\n90\n concentrations, determined in C6~4xARE-TK reporter cells. Mutliplex PCR was used to interrogate expression levels of 9 genes of interest including Nrf2 itseif following drug treatment in C6 cells. Only two genes, Haem oxygenase 1 and NQO1 , showed statistically significant changes in gene expression, shown in (a) and (b) respectively. Standard quantitative RT-PCR of these two genes in primary mouse astrocytes under the same conditions were also performed (c) and (d). Asterisks indicate significant difference in DMSO control by one way ANOVA.\n\n\nFigure 8 shows NRF2 inducers protect motor neurones (MN) in primary mouse astrocyte/MN co-cultures from menadione stress. Co-cultures were pre-treated for 24h with S[+] Apomorphine (Apo S) and Andrographolide (Andro) at their EC\n50\n and ECg\n0\n concentrations respectively, as determined in rat C6 4xARE-TK reporter cells. The co- cultures were then challenged for 6 hours with 1GμM menadione to induce oxidative stress. In DMSO control cells an approximately 25% reduction in motor neurone number was observed which was not seen in wells treated with either drug\n\n\nFigure 9 shows immunoflourescence staining for Haem Oxygenase 1 in primary mouse astrocytes following treatment with Nrf2 Inducers at EC\n50\n and EC\n90\n concentrations. Area and staining intensity were quantified using Image J and used to calculate a staining index. \n\n Figure 10 shows total Glutathione levels in primary mouse astrocytes (Figure 10a) and in conditioned media collected from primary mouse astrocytes (Figure 10b) following treatment with Nrf2 Inducers at EC\n50\n and EC\n90\n concentrations. Total glutathione levels were measured using standard methods following 24h pre-treatmeπt with Nrf2 inducers. All treatments significantly increased glutathione levels in astrocytes relative to DMSO control and the EC\n90\n concentrations of both drugs significantly increased extracellular glutathione levels (*p values <0.005). Data are average of three independent experiments\n\n\nFigure 11 shows quantitative RT-PCR analysis for the Nrf2 regulated genes NQO1 (a) and Haem oxygenase 1 (HOX1) in primary mouse astrocytes overexpressing G93A mutant SOD1 following 24h treatment with Andrographolide (Andro) and S[+] Apomorphine (Apo S) at EC\n50\n and EC\n90\n concentrations. Asterisks indicate significant difference from DMSO control by one way ANOVA.\n\n\nFigure 12A shows the in vivo pharmacokinetic time course for S[+] Apomorphine (Apo S) and Figure 12B shows the corresponding PK parameters in mice (n=3 or 4 per time point). Figure 12C shows the QRT-PCR for HO-1 and NQO- 1 in mice 6, 24 and 48 hours after a single subcutaneous injection of either 2.5 or 5.0 mg/kg S[+] Apomorphine (Apo S).\n\n\nDETAILED DESCRIPTION\n\n\nCell culture Chinese Hamster Ovary (CHO), NSC34 mouse motor neuronal cells, C6 (rat) and 1321N1 (human) astrocytic lines were routinely maintained in DMEM supplemented with 10% FBS and penicillin/streptomycin. The TK-EGFP reporter construct consists of a 123bp thymidine kinase promoter inserted in the multiple cloning site of pEGFP (Clontech) and the ARE-TK-EGFP also contains four repeats of a 41 bp GST ARE motif (TAGCTTGGAAATGACATTGCTAATCGTGACAAAGCAACTTT) (SEQ ID NO: 1) 3' to the TK promoter. These plasmids were transfected into CHO, C6 and 1321N1 cell lines using Lipofectamine 2000 (Invitrogeπ) and following 10-14 days of selection in 0.5mg/ml G418 they were expanded and selected for basal eGFP expression using fluorescence activated cell sorting (BD, FACSAria) with two sequential cell sorts for each cell line. These mixed populations of stable transfectants with basal eGFP expression were used in subsequent assays and designated 4xARE-TK-GFP for the ARE containing line and \n\n TK-GFP for the control cell line. The NSC34 cells lines were transfected with G93A mutant SOD1 and stably transfected single cell clones were isolated by selection in 250μg/ml G418 and cioning by limiting dilution.\n\n\nARE reporter assay - Spectrum library screen validation\n\n\nIn order to screen the spectrum library of 2000 small molecule drugs and natural products the TK-GFP CHO ARE reporter cell line was subjected to a Z\n1\n score assay in a 384 well plate (Greiner Bio-one, μClear, black) using a range of plating densities (5- 20x10\n4\n/weli plated 24 hours prior to assay) and different media. Alternate wells were incubated with 10μM of Ebselen and vehicle (0.1 % DMSO) for 24 hours followed by replacement of media with PBS containing 0.3μM of ethidium homodimer-1 (EthD1). This concentration of Ebselen represents an approximate ECgo for this drug. GFP fluorescence (ARE induction) was then measured at Ex\n48\n5\nnm\n/Em\n53\nonm using a Fusion universal piate reader (Packard Bioscience), The z score was calculated as follows\n\n\n \n\n where\n\n\nSD\n*\n = standard deviation of positive control wells 3SD\n'\n = standard deviation of negative control wells Ave\n+\n = Average fluorescence reading of positive control wells Ave\n\"\n = Average fluorescence reading of negative control wells\n\n\nSignal to noise (S/N= Ave\n+\n/SD\n+\n) and signal to background (S/B = Ave\n+\n/Ave\n\"\n) ratios were also determined for the different assay conditions. Acceptable Z\" scores were >0.5. For the library screen, cells were plated at a density of 20x10\n4\n in normal DMEM media containing 10% FBS on day -1 and on day 0, cells were incubated for 24 hours with drug in serum free media. Media was removed by hand and replaced (1 compound/well) with the Spectrum library diluted to 10μM in 0,1% DMSO using a Q-bot liquid handling system (Genetix, New Milton, UK). The media was removed after 24 hours and replaced with the same volume of PBS containing 0.3μM EthDl GFP fluorescence (ARE induction, Ex485nm/Em\n5\n3onm) and Eth D1 fluorescence (toxicity Ex\n530\n nrτ/Em\n6\n45 nm) were then measured using a Fusion universal plate reader (Packard Bioscience) The TK-GFP CHO ARE cell line was screened twice in a single point assay and the control TK-GFP \n\n CHO eel! line was screened once to eliminate false positives. Figure 1 shows a schematic representation of the NRF2-ARE assay.\n\n\nARE reporter assay - determination of ECso Confluent cultures of 4xARE-TK-GFP CHO or TK-GFP CHO expressing cells in 96 or 384-wel! tissue-culture plates were treated with drug (0.01-10ODM in triplicate) or vehicle (0.1-1% DMSO) in FCS-free DMEM in triplicate for 24 hours. The media was removed and replaced with the same volume of PBS containing 0.3μM EthD1. GFP fluorescence (ARE induction, Ex485nm/Em\nS\n3onm) and Eth D1 fluorescence (toxicity Ex\n530\n nm/Ern^s nm) were then measured using a Fusion universal plate reader (Packard Bioscience). Nonlinear regression was used to fit a sigmoidai dose-response curve on a semi-Log plot to calculate the EC\n50\n using GraphPad Prism (GraphPad Software). The reporter assay was conducted in a similar fashion in C6 and 1321N1 astrocyte cell lines stably transfected with the 4xARE-TK-GFP and TK-GFP constructs except that Eth D1 was added directly in the media and read prior to washing the cells once and reading the DCF signal.\n\n\nOxidative stress assay\n\n\nA simple oxidative stress assay was used to determine whether preconditioning with NRF2-ARE inducing drugs couid protect against a subsequent oxidative stress insult (serum withdrawal). The NSC34, C6 and 1321N1 cells were plated in 96 well tissue culture plates to achieve 30% confluency. They were incubated with drug in triplicate wells as a 9 point titration (100GM to 1OnM) for 24 hours. Cell density was observed to ensure no significant toxicity or growth inhibition occurred. Media was then replaced with serum free, phenol free media for 5 hrs. Dichlorofluorescein (DCF) and ethidium homodimer (EthD1) (Molecular Probes, Paisley, UK) was added to the cells to a final concentration of 5 μM and 0.3 μM, and DCF and EthD1 fluorescence was read at Ex\n485\n \nnm\n/Em\n53\no \nπm\n, EX\n530 H\nmZEm\n645 nm\n respectively after 1 hour. Cell survival assay was then performed on the cells as protection is measured as % reduction in DCF signal, therefore data points were excluded where a decrease in cell number was measured.\n\n\nCell viability assay\n\n\nThe method used was essentially as described previously in the art. Briefly methylthiazolyldiphenyl-tetrazolium bromide (MTT) was added to the cells and a blank well to a final concentration Q.5mg/ml and incubated at 37 \n0\nC for 1-3 hrs depending on \n\n the cell line used. Cells and reaction product were solubilised in 20%SDS/50%DMF for 1 hr with shaking at room temperature before reading the absorbance at Exs\n9S πm\n.\n\n\nBasal oxidative stress assay in G93A SOD1 expressing NSC34 cells (ALS cellular model)\n\n\nThe G93A SOD1 expressing NSC34 cells were piated in 96-well tissue-culture plates in phenol red-free DMEM containing 10 % FBS until 30-40 % confluent. They were then incubated with drug at 0.01, 0.1, 1, 10μM or vehicle (0.1% DMSO) in triplicate wells for 24hours. Cytosolic reactive oxygen species levels were measured using DCF and EthD1 as in the oxidative stress assay.\n\n\nPrimary mouse motor neurone/astrocyte co-cultures\n\n\nMouse glial cultures were established from C57BI/6 cortices from 1 - 2 day old pups.\n\n\nCortices were dissected out and cells dissociated by trituration following incubation in DNasel, collagenase and trypsin. The incubation and trituration steps were repeated to ensure complete dissociation of cells. Cells were plated at 45,000 cells/cm\n2\n in DMEM containing 10 % FBS, 100 U/mi penicillin, and 100 μg/ml streptomycin. After 24 hours, cultures were washed in PBS and grown for 2 - 3 weeks until confluent, changing the medium once a week. Confluent glial cultures were enriched for astrocytes by shaking and mild trypsinisation. Enriched astrocytes were grown to confluency and plated onto coverslips coated with poly-D-ornithine {1.5 mg/ml; Sigma, Poole, UK) at 40,000 ceils/cm\n2\n, and grown for 1 week.\n\n\nPrimary spinal cord motor neurons (MNs) were cultured from E13.5 wild-type C7BI/6 mouse embryos. Briefly, spinal chord preparations were dissociated by trituration following incubation in trypsin and DNasel. MNs were then isolated by density gradient centrifugation. Co-cultures were established by plating MNs at 8000/cm\n2\n, on astrocytes, in Neurobasai medium supplemented with 1% B27, 2% horse serum, 50 mg/ml streptomycin, 50 U/ml penicillin, 0.5 mM L-glutamine, 25 mM glutamic acid (all from Invitrogen, Paisley, UK), 1ng/ml BDNF, 10 ng/ml CNTF, and 100 pg/ml GDNF (all from\n\n\nR&D Systems, Abingdon, UK).\n\n\nWhen co-cultures were established for 2 weeks, neuroprotection assays were performed by 24 hrs exposure to drug or vehicle followed by a 6 hour 10 micromolar menadione oxidative stress or glutamate. Following stress treatment, coverslips were washed 3 times, fixed and permeabilised to selectively stain motor neurons with SMI32 (Covance). \n\n Total MNs were counted by fluorescent microscopy in a 1.5cm\n2\n area per coverslip. Minimum three repeats in triplicate were performed per condition. Both vehicle and drug treatments were counted before and after stress treatment, and results were statistically analysed by 2 way anova using Bonferroni post tests.\n\n\nTotal glutathione assay\n\n\nPrimary astrocytes were grown to confiuency in 24 well plates and then treated with drug (or 0.05% DMSO vehicle) in phenol red-free DMEM containing 10 % FBS and penicillin/streptomycin for 24 hours. Conditioned medium was collected and astrocytes were then washed in ice-cold PBS before addition of 250 μl/well of suSphosalicylic acid (SSA, 5 % (w/v)). Plates were frozen at -8O\n0\nC and thawed at 37\n0\nC, twice, and then incubated at 4°C for 15 minutes. The supernatant was removed and centrifuged at 13,000 x g for 5 minutes. Conditioned medium samples were incubated at 8O\n0\nC for 15 minutes and then centrifuged at 13,000 x g for 5 minutes. Samples were either used immediately or stored at -80\n0\nC. Reaction mixture (150 μl/well; 10OmM potassium phosphate buffer, pH 7.0, 1mM EDTA, 6 Units/ml glutathione reductase, 1.5 mg/ml 5,5'- dithiobis(2-nttrobenzoic acid)) was added to 10 μl of each sample or glutathione standard (0 - 50 μM reduced glutathione) in a 96-weSl plate and incubated at room temperature for 5 minutes before addition of 50 μi/well of NADPH solution (0.16 mg/ml). A\n4120n\n, was measured every minute for 15 minutes and the total glutathione concentration (GSH + GSSG) was calculated from initial rates. Samples were tested in triplicate.\n\n\nIn silico analysis\n\n\nIn order to select drug-like molecules for further screening, Pipeline Pilot (SciTegic, London, UK) was used for in silico analysis. The molecular polar surface area (mPSA) was calculated for all 2000 molecules from the SPECTRUM collection as a crude measure of likely CNS penetrance {Ertl, 2000 #834} and a Lipinski Filter was also applied to determine which molecules were most drug-iϊke. This filter applies the 'rule of five' which selects compounds with a cLogP <5, molecular mass <500, <5 hydrogen bond donors (OH+NH count) and <10 hydrogen bond acceptors (O plus N atoms).\n\n\nQuantitative RT-PCR\n\n\nWiutiplex PCr was used to detect changes in expression levels of target genes in the\n\n\n1321N1 astrocyte cell line following treatment with Andrographolide and S(+) Apomorphine at EC\n50\n and EC\n90\n concentrations as determined in the NRF2-ARE reporter assay in C6 cells. The GenorneLab™ GeXP Genetic Analysis system (Beckman Coulter) \n\n was used to identify changes in gene expression in a multiplexed reaction for 9 genes of interest (Hmoxi, FtM, Keapi , Gdc, Nfe2l2, Gsr, Nqo1 , Sqstml and EphX1) and three housekeeping genes (18s GAPDH and ACTB) using the following primers, outlined in the Table 1 below:\n\n\n\n\n\n\n\n\nThose shown in bold flank intronic sequences, preventing genomic background. The RT reaction mixture was assembled in a 96 well rnicropiate as follows 3μl DNase/RNase Free H2O, 4μl RT Buffer 5X, 2μl RT Rev Primer Plex Reverse Transcriptase, 5μl KANr RNA, 5μl Sample RNA (20 ng/μL) to gve a total reaction volume of 20μl. The samples were then incubated as follows, 48°C 1 minute, 37°C 5 minutes, 42\n0\nC 60 minutes, 95\n0\nC 5 minutes, 4°C Hold. The PCR reaction mixture was assembled as \n\n follows in a 96-well sample microptate; 4.0μl PCR Buffer 5X, 4.0μl 25 mM MgC!2 (Abgene), 2.0μl PCR Fwd Primer Plex, 0.7μl Thermo-Starf DNA Polymerase, (ABgene AB-0908/A), 9,3μl cDNA Samples from RT reaction. The PCR was run as follows, (1) 95°C 10 minutes, (2) 94\nD\nC 30 seconds, (3) 55°C 30 seconds, (4) 70\n0\nC 1 minute, (5) Repeat steps 2-4 for an additional 34 cycles, (6) 4°C Hold. On the basis of preliminary experiments reverse RT primer concentrations were optimised to allow detection of all products in a single reaction. PCR reaction products were diluted in SLS (sample loading solution) and separated on the GeXP capillary electrophoresis unit and the data analysed using the GeXP software and Microsoft Excel data package to give a fold change in expression relative to GAPDH and ACTB.\n\n\nStandard QPCR\n\n\nQPCR was carried out as previously described in the publication Wood-Allum et al 2005 with the essential difference that RNA was isolated from primary astrocytes or the astrocyte cell line using the RNeasy kit (Qiagen) following manufacturers' instructions. cDNA was prepared using Superscript Il (Invitrogen) driven by oligo dT following manufacturers' guidelines. Quantitative RT-PCR. (Q-PCR) was performed using 25 ng of cDNA, 1x SYBR Green PCR Master Mix (Stratagene) and optimised concentrations of forward and reverse primers (Table 1), in a total volume of 20 μl and in triplicate for each sample. Following denaturation at 95 \n0\nC for 10 min, products were amplified by 40 cycles of 95°C for 15 s and 60 \n0\nC for 1min, on an MX3000P Real Time PCR System (Stratagene). To ensure amplification of a single product the dissociation curve was produced for each amplification. The relative levels of the genes of interest in the samples was determined by normalizing the level of expression to that of gapdh in each of the samples and by using the ddCt calculation (SYBR Green PCR mix and RT-PCR protocol, Applied Biosystems). Overall relative concentrations of the genes of interest were calculated following drug treatment by normalising the data to the cells grown in the vehicle (DMSO).\n\n\nStatistical analysis\n\n\nFor the Spectrum library screen, each 384 well plate contained 32 wells incubated with vehicle only (0.1% DMSO in media). The average fluorescence reading and standard deviation of these wells was calculated on a plate by plate basis. Hits were classified as having a GFP fluorescence value greater than the vehicle average plus three standard deviations. Toxicity was defined in the same way (i.e. EthD1 fluorescence value greater than the vehicle average plus three standard deviations). \n\n EXAMPLE 1\n\n\nThe 4xARE-TK-GFP and TK-GFP reporter cell lines were tested for their response to the known ARE inducers tert-Buiyl Hydroquinone (tBHQ) and the flavonoid EGCG stt a range of concentrations. The compounds were applied in triplicate to confluent cells in\n\n\n96 well plates in serum free medium for 24 hours and the induction of GFP measured in a fluorescence plate reader. Both compounds induced GFP expression in a narrow window, with EGCG peaking at 100μl\\/l and tBHQ peaking at 10μM (Fig 2a). At concentrations higher than this peak expression, both compounds showed signs of toxicity by direct observation (cell loss) or increased Ethidium Homodimer fluorescence.\n\n\nNo increase in fluorescence was seen in the control TK-GFP celi line (not shown).\n\n\nEXAMPLE 2\n\n\nIn order to screen the SPECTRUM collection of 2000 molecules the reporter assay was scaled down to a 384 well-plate format. To assess the suitability of the assay for library screening, a Z' score calculation was performed by treating alternate wells with vehicle (0.1% DMSO) and 10 μM Ebseien as a positive control (see cafculation in Methods). We have shown Ebseien gives a robust concentration response curve in this assay. The calculated Z' score was 0.51 (Fig 2b) which is acceptable for library screening, In addition, signal to noise (S/N) and signal to background (S/B) ratios were acceptable at 12.8 and 2.9 respectively. The library was subsequently screened at a single concentration per compound of 10μM. Drug library dilutions and plating were carried out by a Q-BOT liquid handling system and both the 4xARE-TK-GFP reporter cell line and TK-GFP control ceil line were tested for their response to the compounds. An example set of data for the ARE-TK-GFP cell line from a single 384 well plate is shown in Figure 3. Hits were identified as having data points more than three standard deviations above the background level, which was the average value of 24 wells treated with vehicle (0.1% DMSO) only. Hit compounds were checked to see if they generated a response in the control cell line due to either non-specific activation of transcription or autofluorescence of the compounds. In addition, any compounds showing signs of toxicity by enhancing ethidium homodimer fluorescence were excluded. The library screen was repeated with the 4xARE -TK-CHO cell line only and compounds which emerged as hits from both screens were taken forward for further assessment. A total of 46 compounds were identified on this basis. The next step was to determine the compound concentration required to give a 50% response (EC\nS0\n) for these 46 hit compounds. Each compound was subjected to a 7 point concentration response curve in \n\n duplicate wel!s. Many compounds showed a beli shaped dose response curve simitar to that seen for standard ARE inducers such as tBHQ and EGCG\n1\n due to toxicity at higher concentrations. Figure 4a shows all 46 dose response curves in the first assay. The majority of compounds exhibit a bell-shaped dose response curve with toxicity at higher concentrations and many also have a very narrow window of ARE induction. Figure 4b shows a set of compounds with enhancement of reporter expression over a broader concentration range (>1 log unit) or with minimal toxicity at higher concentrations. The concentration response curves for all 46 hits were repeated and the average EC\n50\n and average maximum fold induction of GFP fluorescence measured. The lowest concentration which caused a toxic response was also noted and the data are summarised in Table 2 (presented herein after), together with a brief description of the known bioactivity of these compounds. The lowest dose at which toxicity was observed is also included in the table. Compounds are ranked according to activity in the reporter assay. The most potent ARE inducer was the natural product andrographolide, the only compound with a sub-micromo!ar EC\n50\n (740 nM), this compound comes from the natural product Aπdrographis paniculata, and is used widely in Chinese and Indian herbal medicine. Of the 26 other natural products, a further two have been used in man; securinine, a GABAA receptor antagonist and CNS stimulant and isoϋquiritigenin, a component of liquorice root which is an aldose reductase inhibitor. The remaining 19 products were synthetic small molecules or derivatives and of these a total of six molecules were approved drugs. Two alkylating antineoplastic drugs (pipobroman and mechiorethamine) a dopamine agonist (apomorphine hydrochloride), a topical skin whitener (hydroquinone), a loop diuretic (ethacrynic acid) and a vasodilator (isoxsuprine hydrochloride). One of the synthetic small molecules had reached phase three clinical trials in stroke (Ebselen). \n\n\n\n\nEXAMPLE 3\n\n\nThe effects of Nrf2-ARE inducing hit compounds on oxidative stress induced by serum withdrawal in motor neuronal and astrocytic cells was investigated. Since the activation of this pathway may vary depending on the cell type, we then went on to screen how well these hit compounds couid protect a motor neuronal cell line (NSC34 cells) and rat (Cδ) and human (1321N1) astrocyte cell lines from oxidative stress induced by serum withdrawal. The cell lines were pre-treated with hit compound at a range of concentrations for 24 hours to activate the NRF2-ARE pathway. The compound was then removed and the cells subjected to a six hour serum withdrawal to induce oxidative stress. The degree of oxidative stress was measured using dichlorofluorescein (DCF) fluorescence and the degree of protection is shown in Table 3 as percentage reduction in DCF fluorescence for each of the three cell lines. Where it was possible to fit a curve, the concentration required to give a half maximal effect (IC\nS\no) is also quoted. In general, hit compounds were more likely to show protective effects in the astrocyte cell lines than in the motor neuronal cell line. Table 3 (presented herein after) gives the assay results for all compounds, ranked by activity in the motor neuronal cell line. Only 9/46 compounds reduced the oxidative stress DCF signal induced by serum withdrawal in NSC34 cells, 18/46 compounds had no effect in this assay and the remaining 17 compounds were pro-oxidant in this assay. In other words as opposed to decreasing the oxidative stress caused by serum withdrawal they contributed to it and increased DCF fluorescence. In contrast only one compound was pro-oxidant in the 1321 N1 astrocyte cell line and 29/46 reduced the DCF signal by 30% or more. For the C6 cell line no compounds were pro-oxidant and 32/46 compounds reduced the DCF signal by 30% or more.\n\n\nEXAMPLE 4\n\n\nIn order to rationalize the biological results obtained, a general pharmacophore for the compounds reported in Table 1 was investigated, using the Pharmacophore Elucidator implemented in MOE (Molecular Operating Environment) [Molecular Operating Environment (MOE 2007.09). Chemical Computing Group, Inc. Montreal, Quebec, Canada http://www.chemcomp.com1. Considering the 24 molecules with an EC\n50\n of less than 10μM for induction of the NRF2-ARE pathway in the CHO 4x ARE-TK cell line (Table 2), upon alignment, 22 of them presented two common features: an aromatic/hydrophobic moiety and a hydrogen bond acceptor moiety (Figure 5a). It should be noted that EGCG also possesses these structural features and positively matches the calculated pharmacophore. Furthermore, when the 1321 N1 astrocyte \n\n oxidative stress assay results (Table 3) were used for constructing the pharmacophore with a 3 μM activity threshold, one additional common aromatic/hydrophobic feature was identified (Figure 5b). This is consistent with known Nrf2 activators which may act by electrophiiic attack of sufphydryl groups on KEAP1, the cytoplasmic Nrf2 regulator. These preliminary modelling data can be used to understand the structural requirements of potential activators of the Nrf2-ARE pathway and couid be taken into consideration in the design of novel structures for this class of compounds.\n\n\nEXAMPLE 5 The physical/chemical properties of the compounds were assessed, In addition to screening the compounds for functional effects in relevant cell types we also used Pipeline Pilot, a chemi-informatics programme to calculate chemical/physical properties, also shown in Table 3. ALogP (log of the partition coefficient in octanol/water) and Molecular polar surface area (mPSA) are different measures of the iϊpophϊϊicity of the compounds and allow crude prediction of likely CNS penetrance. For CNS penetrance an AlogP less than 4 but greater than 1, and a mPSA below 100 (ideally 80) are optimal for passive diffusion across the BBB. In addition, the Lipinski filter was used to identify the non-drug like molecules and four were excluded-(swietenolide-3-acetate, endecaphyiin X, lobaric acid and euphol acetate).\n\n\nTo filter out unwanted molecules only those with a protective or neutral effect in the NSC34 oxidative stress assay (Table 3) were selected and known cytotoxic molecules excluded (ptpobroman, chlordane, alachSor, propachlor). Applying the AlogP and mPSA criteria to the remaining 22 molecules left 17 molecules for further investigation. These molecules are highlighted in bold in Table 3 and are designated the 'best hit' molecules. In addition the minimum dose at which toxicity was observed is shown. NA, not applicable (insufficient data, no concentration response or no inhibition). For Table 3 compounds are sorted by protective capacity in the NSC34 cell line. ARE inducers were far more effective at protecting the astrocyte eel! lines (1321N1 and C6) from oxidative stress compared to NSC34 cells.\n\n\nEXAMPLE 6\n\n\nNRF2-ARE Inducing activity of the best hit compounds in neuronal and astrocytic cell lines was investigated. In order to determine whether the differences in protection in astrocytic and motor neuronal ceil lines was due to differences in the degree of activation of the NRF2-ARE pathway in these cell types, the NRF2-ARE reporter construct was stably expressed in both the astrocytic (C6) and motor neuronal (NSC34) \n\n ceil lines. The 17 best hit molecules were then screened in each cell line. We also screened the S [+] enantiomer of apomorphine as it can exist as either an R[-] or S[+] enantiomer. The R[+] enantiomer has dopamine agonist activity whereas the S[÷] enantiomer has lost this activity and so we wanted to determine whether it retains NRF2- ARE inducing activity. The results for the C6 reporter cell line are shown in Figure 6. In general activation of the NRF2-ARE pathway in the C6 cells was similar to that seen in the CHO cell line. The NSC34 reporter cell line showed minimal if any activation with the same set of concentration response curves suggesting the underlying cause for greater protection against oxidative stress in astrocytic cell lines versus the NSC34 ceils seen earlier was due to a much more robust activation of the NRF2-ARE pathway in astrocyte cell lines. In addition, the S[+] enantiomer of apomorphine was equally potent in terms of NRF2-ARE activation compared with the R[+] enantiomer indicating that this activity is unrelated to agonism of dopamine receptors as the S[+] enantiomer is not a dopamine agonist.\n\n\nIt was an objective to identify molecules with potential to be fast-tracked for clinical testing in Motor Neurone Disease. One of the key criteria in this regard was that the molecules have a history of use in man albeit not for MND. Of the 17 best hit molecules, two had a history of use in man as natural products (securinine, andrographolide) and one was a currently approved drug used for the acute rescue of 'off episodes in Parkinsons Disease (apomorphine hydrochloride as the R enantiomer). In addition, hydroquinoine has a history of use, although as a topically applied skin whitener. Of these drugs andrographolide and the S[+] enantiomer of apomorphine were selected for further assessment as securinine has well described convulsant properties in mice and man and the lack of dopamine agonism in the S[+] enantiomer of apomorphine was considered a distinct advantage.\n\n\nEXAMPLE 7\n\n\nInduction of ARE target gene expression in C6 cells and primary mouse astrocytes by andrographolide and S[+] apomorphine was investigated. To confirm that these preferred or 'iead' molecules were able to activate the NRF2-ARE pathway leading to target gene expression in astrocytes, a multiplex RT-PCR assay was developed on the\n\n\nGenomeLab™ GeXP genetic analysis system for 9 genes of interest. Cδ cells were treated for 24h with Andrographolide and S[+] Apomorphine at EC\n50\n and EC\n80\n concentrations as determined in C6-4xARE-TK reporter cells. Only two genes, Haem \n\n oxygenase 1 and NQO1, showed statistically significant changes in gene expression, which was confirmed by standard quantitative RT-PCR (Figures 7A and 7B).\n\n\nEXAMPLE 8 Since the lead NRF2 inducing molecules were able to increase expression of target genes in primary mouse motor neurones, co-cultures consisting of primary mouse motor neurones (MN) on an astrocyte feeder layer were exposed to an oxidative insult following pre-treatment with either Andrographolide of [S+] apomorphine (Figure 8). The co- cultures were then challenged for 6 hours with 10μM menadione to induce oxidative stress and motor neurones stained and counted. In DMSO control cells an approximately 25% reduction in motor neurone number was observed which was not seen in wells treated with either drug. These results indicate that NRF2 inducers protect motor neurones (MN) from oxidative stress in primary mouse astrocyte/MN co-cultures.\n\n\nStandard quantitative RT-PCR of the NQO1 and HCM genes in primary mouse astrocytes under the same conditions also evinced significant increases in gene expression (Figures 7C and 7D). In order to confirm that changes in gene expression lead to concomitant increases in protein expression, primary mouse astrocytes were assessed for elevated levels of HO-1 by immunofluoresence staining (Fig 9) which confirmed a dose-dependent enhancement of expression over that seen in DMSO treated ceils. We aiso examined a functional effect of this enhanced anti-oxidant capacity by examining total glutathione levels under the same conditions in both the primary astrocytes themselves and in the media collected from treated astrocytes (Fig 10). This showed that glutathione levels were elevated in both the cells themselves and in media - providing one mechanism by which Nrf2 responsive astrocytes may protect neighbouring non-ARE responsive MNs from oxidative challenge.\n\n\nEXAMPLE 9\n\n\nIn an attempt to rationalize the biological results obtained, we have tried do identify a general pharmacophore for the compounds reported in Table 2, using the\n\n\nPharmacophore Elucidator implemented in MOE (Molecular Operating Environment) [\n\n\nMolecular Operating Environment (MOE 2007.09). Chemical Computing Group, Inc.\n\n\nMontreal, Quebec, Canada http://www.chemcomp.coml. Considering the 24 molecules with an EC50 of less than 10μM for induction of the NRF2-ARE pathway in the CHO ARE-TK cell line (Table 2), upon alignment, 22 of them presented two common features: an Aromatic/Hydrophobic moiety and a Hydrogen Bond Acceptor moiety (Figure 4a). it \n\n should be noted that EGCG also possesses these structural features and positively matches the calculated pharmacophore. Furthermore, when the 1321 N1 astrocyte oxidative stress assay results (Table 3) were used for constructing the pharmacophore, using a 3 μM activity threshold, one extra common Aromatic/Hydrophobic feature was identified (Figure 5b). This is consistent with known NRF2 activators which may act by nucleophilic attack of sulphydryl groups on KEAP1 , the cytoplasmic NRF2 regulator. These preliminary modelling data can be used to understand the structural requirements of potential activators of the NRF2-ARE pathway and could be taken in consideration in the design of novel structures for this class of compounds. EXAMPLE 10\n\n\nSince previous work had demonstrated an attenuated Nrf2 response in motor neuronal cell lines expressing mutant SOD and in post mortem material in astrocytes from familial human SOD1 cases we investigated whether our lead inducers could still activate Nrf2 in astrocytes expressing G93A mutant SOD1. It was first determined whether the Nrf2 regulated genes NAD(P)H:quinine oxidoreductase (NQO1) and heme oxygenase 1 (HOX1) could be induced in primary mouse astrocytes from G93A mutant SOD1 transgenic mice (Figure 11). Quantitative RT-PCR demonstrated a significant increase in transcripts for NQO1 and HO1 following a 24 hour pre-treatment with AndrographoSide and S[+] Apomorphine at their EC\n90\n concentrations (Figure 11).\n\n\nEXAMPLE 11\n\n\nFigure 12 shows the in vivo pharmacokinetics and pharmacodynamics of [S+] apomorphine in male C57BI/6 mice. Following a single intravenous dose of [S+] apomorphine levels of the compound were detected in plasma, brain and cerebral spinal fluid (Figures 12A and 12B) and following subcutaneous doses there was significant induction at 24 hours post dose of HO-1 and NQO-1 transcriptsas determined by QRT- PCR (Figure 12C). Accordingly, [S+] apomorphine can lead to a prolonged increase in expression of anti-oxidant enzymes through transcriptional activation.\n\n\nThese data demonstrate that several compounds have been identified that are NF2-ARE pathway activators in vitro and that they may also activate this pathway in vivo."
  },
  {
    "id": "WO2010046855A1",
    "text": "Bridged tetrahydronaphthalene derivatives AbstractThe invention relates to compounds of formula (I) wherein R1, R2, R3, R4, A, B, W and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. Claims\n\n\n\n\nClaims\n\n\n\n\n1. A compound of the formula (I)\n\n\n\n\n\n\n\n\nFormula (I) wherein R\n1\n and R\n2\n independently represent hydrogen or halogen;\n\n\nA represents a linear (d-3)alkan-diyl chain, wherein said linear (d-3)alkan-diyl chain is optionally substituted with one or more methyl;\n\n\nR\n3\n represents hydrogen, (d\n-5\n)alkyl, or -CO-R\n31\n;\n\n\nR\n31\n represents (Ci\n-5\n)alkyl, (d\n-3\n)fluoroalkyl, (C\n3\n-6)cycloalkyl, (C\n3\n-6)cycloalkyl-(d\n-3\n)alkyl,\n\n\n(d\n-5\n)alkoxy, (d\n-2\n)alkoxy-(d\n-3\n)alkyl, or R\n32\nR\n33\nN-;\n\n\nR\n32\n represents (d\n-5\n)alkyl;\n\n\nR\n33\n represents hydrogen, or (d\n-5\n)alkyl; n represents the integer 1 , 2, 3, or 4;\n\n\nB represents a group -(CH\n2\n)\nm\n-, wherein m represents the integer 1 , 2, 3, 4, or 5; or B together with R\n4\n and the nitrogen atom to which B and R\n4\n are attached forms a 4- to\n\n\n6-membered saturated ring, wherein said ring may optionally be mono-substituted with phenyl;\n\n\nR\n4\n represents hydrogen; (d\n-5\n)alkyl; (d\n-2\n)alkoxy-(d\n-3\n)alkyl; (d\n-3\n)fluoroalkyl; (C\n3\n-\n6\n)cycloalkyl; (C\n3\n-\n6\n)cycloalkyl-(d\n-3\n)alkyl; or R\n4\n together with B and the nitrogen atom to which R\n4\n and B are attached forms a 4- to 6-membered saturated ring, wherein said ring may optionally be mono-substituted with phenyl; and  \n wherein\n\n\nR\n5\n represents hydrogen, or (Ci\n-5\n)alkyl; and R\n6\n, R\n7\n and R\n8\n independently represent hydrogen, halogen, (Ci\n-5\n)alkyl, hydroxy, (Ci\n-5\n)alkoxy, -O-CO-(Ci\n-5\n)alkyl, (d\n-3\n)fluoroalkyl, (Ci\n-3\n)fluoroalkoxy, -COOH, -CO-(d\n-5\n)alkoxy, (d\n-2\n)alkoxy- (Ci\n-4\n)alkoxy, or -NH-CO-(Ci\n-5\n)alkyl; or a salt of such a compound.\n\n\n\n\n\n\n2. A compound of formula (I) according to claim 1 , the configuration of the bridged tetrahydronaphthalene moiety is such that the R\n3\n-O- substituent and the bridge A of the tetrahydronaphthalene moiety are in cis relation; or a salt of such a compound.\n\n\n\n\n\n\n3. A compound of formula (I) according to claim 1 or 2, wherein R\n1\n and R\n2\n both represent hydrogen; or a salt of such a compound.\n\n\n\n\n\n\n4. A compound of formula (I) according to any one of claims 1 to 3, wherein A represents -(CH\n2\n)\nP\n-, wherein p represents the integer 2 or 3; or a salt of such a compound.\n\n\n\n\n\n\n5. A compound of formula (I) according to any one of claims 1 to 4, wherein R\n3\n represents hydrogen, or -CO-R\n31\n; or a salt of such a compound.\n\n\n\n\n\n\n6. A compounds of formula (I) according to any one of claims 1 to 5, wherein R\n31\n represents (Ci\n-5\n)alkyl, (Ci\n-3\n)fluoroalkyl, (C\n3-6\n)cycloalkyl, or (Ci\n-2\n)alkoxy-(Ci\n-3\n)alkyl; or a salt of such a compound.\n\n\n\n\n\n\n7. A compounds of formula (I) according to any one of claims 1 to 6, wherein B represents a group -(CH\n2\n)\nm\n-, wherein m represents the integer 3; or a salt of such a compound.  \n\n\n\n\n\n\n8. A compounds of formula (I) according to any one of claims 1 to 7, wherein n represents the integer 2; or a salt of such a compound.\n\n\n\n\n\n\n9. A compound of formula (I) according to any one of claims 1 to 8, wherein R\n4\n represents (Ci\n-5\n)alkyl; or a salt of such a compound.\n\n\n\n\n\n\n10. A compound of formula (I) according to claim 9, wherein\n\n\nR\n6\n, R\n7\n and R\n8\n independently represent hydrogen, halogen, (Ci\n-5\n)alkyl, (Ci\n-5\n)alkoxy, (Ci\n-3\n)fluoroalkyl, or (Ci\n-3\n)fluoroalkoxy. or a salt of such a compound.\n\n\n\n\n\n\n11. A compound of formula (I) according to any one of claims 1 to 11 , wherein R\n5\n represents hydrogen; or a salt of such a compound.\n\n\n\n\n\n\n12. A compound of formula (I) according to claim 1 , selected from the following compounds:\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol;\n\n\nMethoxy-acetic acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.2.2.02,7]dodeca-2,4,6-trien-9-yl ester; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\nCyclopropanecarboxylic acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1S,8S,9S)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol;\n\n\n(1 R,8R,9R)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 S,8S,9S)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester; lsobutyric acid (1 R,8R,9R)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-[3-(1 H-Benzoimidazol-2-yl)-propyl]-[2-(9-methoxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-\n\n\n2,4,6-trien-9-yl)-ethyl]-methyl-amine;  (1 R\n*\n,8R\n*\n,9S\n*\n)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2l7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9S\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester; (1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-Benzoimidazol-2-yl)-piperidin-1 -yl]-ethyl}- tricyclo[6.2.2.0\n2l7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[(3RS)-3-(1 H-Benzoimidazol-2-yl)-piperidin-1 -yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[(3RS)-3-(1 H-benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-Benzoimidazol-2-yl)-4-phenyl-piperidin-1 -yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-benzoimidazol-2-yl)-4-phenyl-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-4,5-difluoro- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- 4,5-difluoro-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\nMethoxy-acetic acid (1 R\n*\n,8R\n*\n, 12R\n*\n)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n(1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\n(1 R,8R,12R)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;  (1S,8S,12S)-12-(2-{[3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\n(1 R,8R,12R)-12-(2-{[3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1 S,8S,12S)-12-(2-{[3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(4-methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 S,8S, 12S)- 12-(2-{[3-(4-methoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 R,8R, 12R)-12-(2-{[3-(4-methoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester;\n\n\n(1S,8S,12S)-12-(2-{[3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; (1 R,8R, 12R)-12-(2-{[3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1S,8S,12S)-12-(2-{[3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(4-methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 S,8S,12S)-12-(2-{[3-(4-methoxy-7-methyl-1 H-benzoimidazol-\n\n\n2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 R,8R, 12R)-12-(2-{[3-(4-methoxy-7-methyl-1 H-benzoimidazol-\n\n\n2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; (1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n(1S,8S,12S)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\n(1 R,8R,12R)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1 S,8S, 12S)-12-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; and  lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; or a salt of such a compound.\n\n\n\n\n\n\n13. As a medicament, a compound of formula (I) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof.\n\n\n\n\n\n\n14. A pharmaceutical composition containing, as active principle, a compound of formula (I) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.\n\n\n\n\n\n\n15. Use of a compound of formula (I) according to any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 14, for the manufacture of a medicament for the treatment or prevention of chronic stable angina, hypertension, ischemia (renal and cardiac), cardiac arrhythmias including atrial fibrillation, cardiac hypertrophy, or congestive heart failure. Description\n\n\n\n\n Bridged Tetrahydronaphthalene Derivatives\n\n\nField of the invention:\n\n\nThe present invention relates to novel bridged tetrahydronaphthalene derivatives and their use as potent calcium channel blockers in the treatment or prevention of angina pectoris, ischemia, arrhythmias, high blood pressure and cardiac insufficiency, to pharmaceutical compositions containing these derivatives and to processes for their preparation. In particular, such derivatives may be used alone or in pharmaceutical compositions for the treatment of both chronic and acute of angina pectoris, cardiac arrhythmias, high blood pressure, cardiac insufficiency, renal disease, diabetes and its complications, hyperaldosteronism, epilepsy, neuropathic pain, Parkinson's disease, depression anxiety, sleep disturbances, psychosis, schizophrenia, contraception and cancer in humans and other mammals.\n\n\nBackground of the invention:\n\n\nMany cardiovascular disorders have been associated with a 'calcium overload' resulting from an abnormal elevated calcium influx through the plasma membrane of cardiac and vascular smooth muscle cells. There are 3 major pathways through which extracellular calcium can enter these cells: 1 ) receptor-activated calcium channels, 2) ligand-gated calcium channels and 3) voltage-operated calcium channels (VOCs).\n\n\nVOCs have been classified into 6 main categories: L (Long-lasting), T (Transient), N (Neuronal), P (Purkinje cells), Q (after P) and R (Remaining or Resistant).\n\n\nL-type calcium channels are responsible for the inward movement of calcium that initiates contraction in cardiac and smooth muscle cells suggesting a putative application for blockers of these channels in the cardiovascular field. In this view, L-type calcium channel blockers have been used in clinic since the early 60s and are now recommended as a first line of treatment for systolic-diastolic hypertension and angina pectoris.\n\n\nT-type calcium channels are found in various tissues such as coronary and peripheral vasculature, SA node and Purkinje fibres, brain, adrenal glands and in the kidney. This broad distribution suggests a T-type channel blocker to have a putative cardiovascular protection, to have en effect on sleep disorders, mood disorders, depression, migraine, hyperaldosteroneemia, preterm labor, urinary incontinence, brain aging or neurodegenerative disorders such as Alzheimers disease. \n\n Mibefradil (Posicor®), the first L-type and T-type calcium channels blocker demonstrated a superior effect over calcium channel blockers, which target the L channel predominantly.\n\n\nMibefradil was used for the treatment of hypertension and angina without showing negative side-effects often seen by L channel blockers like inotropy, reflex tachycardia, vasoconstrictive hormone release or peripheral edema. Additionally mibefradil showed a potentially cardioprotective effect (Villame, Cardiovascular Drugs and Therapy 15, 41-28, 2001 ; Ramires, J MoI Cell Cardiol 30, 475-83, 1998), a renal protective effect (Honda, Hypertension 19, 2031-37, 2001 ), and showed a positive effect in the treatment of heart failure (Clozel, Proceedings Association American Physicians 1 11 , 429-37, 1999) Despite the enormous demand for a compound of this profile, mibefradil was withdrawn from the market in 1998 (one year after its launch), due to unacceptable CYP 3A4 drug interactions. Moreover, ECG abnormalities (i.e. QT prolongations) and interaction with the MDR-1 mediated digoxin efflux were also reported, (du Souich, Clin Pharmacol Ther 67, 249- 57, 2000; Wandel, Drug Metab Dispos 28, 895-8, 2000). There clearly is a demand for novel compounds, which act as T-type calcium channel blockers but have an improved safety profile with respect to mibefradil.\n\n\nDescription of the invention:\n\n\nThe compounds of the present invention are potent T/L channel blockers and therefore useful in diseases where both, T and L channels are involved. 1 ) A first aspect of the invention relates to compounds of the formula (I)\n\n\n\n\n\n\n\n\nFormula (I) wherein R\n1\n and R\n2\n independently represent hydrogen or halogen;\n\n\nA represents a linear (d\n-3\n)alkan-diyl chain, wherein said linear (d\n-3\n)alkan-diyl chain is optionally substituted with one or more methyl; \n\n R\n3\n represents hydrogen, (d\n-5\n)alkyl, or -CO-R\n31\n;\n\n\nR\n31\n represents (Ci\n-5\n)alkyl, (d\n-3\n)fluoroalkyl, (C\n3-6\n)cycloalkyl, (C\n3\n-\n6\n)cycloalkyl-(Ci\n-3\n)alkyl, (Ci\n-5\n)alkoxy, (Ci\n-2\n)alkoxy-(Ci\n-3\n)alkyl, or R\n32\nR\n33\nN-; R\n32\n represents (Ci\n-5\n)alkyl; R\n33\n represents hydrogen, or (Ci\n-5\n)alkyl; n represents the integer 1 , 2, 3, or 4;\n\n\nB represents a group -(CH\n2\n)\nm\n-, wherein m represents the integer 1 , 2, 3, 4, or 5; or B together with R\n4\n and the nitrogen atom to which B and R\n4\n are attached forms a 4- to 6-membered saturated ring, wherein said ring may optionally be mono-substituted with phenyl;\n\n\nR\n4\n represents hydrogen; (C\n1-5\n)alkyl; (C\n1-2\n)alkoxy-(C\n1-3\n)alkyl; (C\n1-3\n)fluoroalkyl; (C\n3-6\n)cycloalkyl; (C\n3-6\n)cycloalkyl-(C\n1-3\n)alkyl; or R\n4\n together with B and the nitrogen atom to which R\n4\n and B are attached forms a 4- to 6-membered saturated ring, wherein said ring may optionally be mono-substituted with phenyl; and W represents\n\n\n \n\n wherein\n\n\nR\n5\n represents hydrogen, or (Ci\n-5\n)alkyl; and\n\n\nR\n6\n, R\n7\n and R\n8\n independently represent hydrogen, halogen, (Ci\n-5\n)alkyl, hydroxy, (Ci\n-5\n)alkoxy, -O-CO-(Ci\n-5\n)alkyl, (Ci\n-3\n)fluoroalkyl, (Ci\n-3\n)fluoroalkoxy, -COOH, -CO-(d\n-5\n)alkoxy, (d\n-2\n)alkoxy- (Ci\n-4\n)alkoxy, or -NH-CO-(Ci\n-5\n)alkyl.\n\n\nThe following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and are intended to apply uniformly throughout the specification and claims, unless an otherwise expressly set out definition provides a broader or narrower definition. \n\n -A-\n\n\nIn this patent application, a bond interrupted by a wavy line shows the point of attachment of the radical drawn. For example, the radical drawn below\n\n\n \n\n is a benzimidazol-2-yl group which is further substituted with R\n5\n, R\n6\n, R\n7\n and R\n8\n. The term \"(C\n1-5\n)alkyl\" means a straight-chain or branched-chain alkyl group with 1 to 5 carbon atoms. Preferred are groups with 1 to 4 carbon atoms. The term \"(C\nx-y\n)alkyl\" (x and y being an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms. Examples of (Ci\n-5\n)alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. -butyl, tert.-butyl, isobutyl, n-pentyl, and isopentyl. Preferred are methyl, ethyl, n-propyl, and isopropyl. Most preferred is methyl. For the substituent R\n4\n, and R\n5\n a preferred example of a (Ci\n-5\n)alkyl group is methyl. For the substituent R\n31\n a preferred example of a (Ci\n-5\n)alkyl group is isopropyl.\n\n\nThe term \"linear (d^alkan-diyl chain, wherein said linear (d^alkan-diyl chain is optionally substituted with one or more methyl\" as used for the substituent A means a straight-chain alkan-diyl group with 1 to 3 carbon atoms which is unsubstituted, or wherein 1 up to the maximum of hydrogen atoms have been replaced by methyl. Examples of such groups are methylen, ethane-1 ,1-diyl, propane-2,2-diyl, ethane-1 ,2-diyl, 1 ,2-dimethyl-ethane-1 ,2-diyl, 1 , 1 -dimethyl-ethane-1 ,2-diyl, 2,2-dimethyl-ethane-1 ,2-diyl, 1 , 1 ,2,2-tetramethyl-ethane-1 ,2- diyl, propane-1 ,3-diyl, and 2,2-dimethyl-propane-1 ,3-diyl. Preferred are methylen, propane- 2,2-diyl, ethane-1 ,2-diyl, and propane-1 ,3-diyl. Most preferred are ethane-1 ,2-diyl, and propane-1 ,3-diyl.\n\n\nThe term \"(C\n1-3\n)fluoroalkyl\" means a straight-chain or branched-chain (C\n1-3\n)alkyl group which is substituted with 1 to 7 fluorine atoms. Examples of (C\n1-3\n)fluoroalkyl groups are trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, and pentafluoroethyl. Preferred are trifluoromethyl, 2,2,2-trifluoroethyl, and pentafluoroethyl. Most preferred are (especially) trifluoromethyl and 2,2,2-trifluoroethyl. For the substituent R\n31\n, 2,2,2-trifluoroethyl is preferred. For the substituent R\n4\n, 2-fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl are preferred. \n\n The term \"(d\n-3\n)fluoroalkoxy\" means a straight-chain or branched-chain (d\n-3\n)alkyl-O- group which is substituted with 1 to 7 fluorine atoms. Examples of (Ci_3)fluoroalkoxy groups are trifluoromethoxy, and 2,2,2-trifluoroethoxy. Preferred is trifluoromethoxy.\n\n\nThe term \"(C\n3-6\n)cycloalkyl\" means a saturated cyclic alkyl group with 3 to 6 carbon atoms. Examples of (C\n3-\n6)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Preferred is cyclopropyl.\n\n\nThe term \"(C\n3-6\n)cycloalkyl-(Ci\n-3\n)alkyr means a (C\n3-6\n)cycloalkyl group as defined before which is attached to the rest of the molecule via a (Ci\n-3\n)alkyl group as defined before. Examples are cyclopropyl-methyl, cyclopentyl-methyl and cyclohexyl-methyl; preferred is cyclopropyl- methyl.\n\n\nExamples of groups wherein \"B together with R\n4\n and the nitrogen atom to which B and R\n4\n are attached forms a 4- to 6-membered saturated ring, wherein said ring may optionally be mono-substituted with phenyl\" are azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl and 4-phenyl-piperidin-4-yl. Preferred are piperidin-3-yl, piperidin-4-yl and 4-phenyl-piperidin- 4-yl. In another embodiment preferred are those examples wherein the thus formed 4- to 6- membered saturated ring is unsubstituted, such as azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl and piperidin-4-yl, especially piperidin-3-yl and piperidin-4-yl.\n\n\nThe term \"(Ci\n-5\n)alkoxy\" means a group of the formula (Ci\n-5\n)alkyl-O- in which the term (Ci_5)alkyl has the previously given significance. The term \"(C\nx-y\n)alkoxy\" (x and y being an integer) refers to a straight or branched chain alkoxy group containing x to y carbon atoms. Examples of (Ci\n-5\n)alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert.-butoxy. Preferred are methoxy and ethoxy.\n\n\nThe term \"(Ci-\n2\n)alkoxy-(Ci\n-3\n)alkyl\" means a (Ci\n-2\n)alkoxy-group as defined before which is attached to the rest of the molecule via a (Ci\n-3\n)alkyl group as defined before. Examples are methoxy-methyl, 2-methoxy-ethyl, 2-methoxy-2-methyl-ethyl and 3-methoxy-propyl. For the substituent R\n31\n, 2-methoxy-2-methyl-ethyl and especially methoxy-methyl are preferred.\n\n\nAn example of a \"(Ci-\n2\n)alkoxy-(Ci-\n4\n)alkoxy\" group is 2-methoxy-ethoxy. An example of a \"-O-CO-(C\n1-5\n)alkyl\" group is -O-CO-CH(CH\n3\n)\n2\n. An example of a \"-CO-(C\n1-5\n)alkoxy\" group is -CO-OCH\n3\n. An example of a \"-NH-CO-(C\n1-5\n)alkyl\" group is acetamido.\n\n\nThe term \"halogen\" means fluorine, chlorine, bromine or iodine, especially fluorine or chlorine. \n\n 2) A further embodiment of the invention relates to compounds of formula (I) according to embodiment 1 ), wherein the configuration of the bridged tetrahydronaphthalene moiety is such that the R\n3\n-O- substituent and the bridge A of the tetrahydronaphthalene moiety are in cis relation (i.e. the absolute configuration is as depicted in either formula (l\nE\ni) or formula (I\nE2\n) below).\n\n\n3) A further embodiment of the invention relates to compounds of formula (I) according to embodiments 1 ) or 2), wherein the absolute configuration is as depicted in formula (l\nE\ni)\n\n\n \n\n 4) A further embodiment of the invention relates to compounds of formula (I) according to embodiments 1 ) or 2), wherein the absolute configuration depicted is as in formula (I\nE2\n)\n\n\n\n\n\n\n\n\n5) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 4), wherein R\n1\n and R\n2\n both represent hydrogen.\n\n\n6) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 4), wherein R\n1\n and R\n2\n both represent halogen (especially fluorine).\n\n\n7) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 6), wherein A represents -(CH\n2\n)\nP\n-, wherein p represents the integer 2 or 3.\n\n\n8) A further embodiment of the invention relates to compounds of formula (I) according to embodiment 7), wherein p represents the integer 2.\n\n\n9) A further embodiment of the invention relates to compounds of formula (I) according to embodiment 7), wherein p represents the integer 3. \n\n 10) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 9), wherein R\n3\n represents hydrogen, or -CO-R\n31\n.\n\n\n11 ) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 10), wherein R\n3\n represents -CO-R\n31\n. 12) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 11 ), wherein R\n31\n represents (Ci\n-5\n)alkyl, (Ci\n-3\n)fluoroalkyl, (C\n3-6\n)cycloalkyl, or (Ci.\n2\n)alkoxy-(Ci\n-3\n)alkyl.\n\n\n13) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 12), wherein R\n31\n represents (Ci\n-5\n)alkyl, (Ci\n-3\n)fluoroalkyl, or (C\n3-6\n)cycloalkyl.\n\n\n14) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 13), wherein\n\n\nR\n31\n represents (C\n1-5\n)alkyl (preferred), or (C\n3-6\n)cycloalkyl.\n\n\n15) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 10), wherein R\n3\n represents hydrogen.\n\n\n16) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 15), wherein B represents a group -(CH\n2\n)\nm\n--\n\n\n17) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 15), wherein B together with R\n4\n and the nitrogen atom to which B and R\n4\n are attached forms a 4- to 6-membered saturated ring, wherein said ring may optionally be mono-substituted with phenyl.\n\n\n18) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 16), wherein m represents the integer 1 to 3 (preferably 2 or 3). 19) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 16), wherein m represents the integer 3.\n\n\n20) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 19), wherein n represents the integer 2.\n\n\n21 ) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 20), wherein R\n4\n represents (C\n1-5\n)alkyl. \n\n 22) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 21 ), wherein\n\n\nR\n6\n, R\n7\n and R\n8\n independently represent hydrogen, halogen, (Ci\n-5\n)alkyl, (Ci\n-5\n)alkoxy, (Ci\n-3\n)fluoroalkyl, or (Ci\n-3\n)fluoroalkoxy (especially hydrogen, (Ci\n-5\n)alkyl, or (Ci\n-5\n)alkoxy).\n\n\n23) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 22), wherein W represents\n\n\n \n\n wherein one of R\n6\n, R\n7\n or R\n8\n is (Ci\n-5\n)alkoxy in position 4 of the benzimidazole ring.\n\n\n24) A further embodiment of the invention relates to compounds of formula (I) according to embodiment 23), wherein W represents\n\n\n \n\n wherein one of R\n6\n, R\n7\n or R\n8\n is (Ci\n-5\n)alkoxy (especially methoxy) in position 4 of the benzimidazole ring, one of R\n6\n, R\n7\n or R\n8\n is hydrogen, and the remaining is selected from the group consisting of hydrogen, (Ci\n-5\n)alkyl, and (Ci\n-5\n)alkoxy.\n\n\n25) A further embodiment of the invention relates to compounds of formula (I) according to embodiment 24), wherein W represents\n\n\n \n\n wherein one of R\n6\n, R\n7\n or R\n8\n is \n\n\n (especially methoxy) in position 4 of the benzimidazole ring, one of R\n6\n, R\n7\n or R\n8\n is hydrogen and the remaining is selected from (Ci\n-5\n)alkoxy (especially methoxy). \n\n 26) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 22) to 25), wherein W represents\n\n\n \n\n wherein two of R\n6\n, R\n7\n or R\n8\n are in position 4 and 7, respectively, of the benzimidazole ring; wherein said two of R\n6\n, R\n7\n or R\n8\n are preferably different from hydrogen.\n\n\n27) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 26), wherein W represents\n\n\n \n\n wherein R\n6\n and R\n8\n are independently (d^alkoxy (especially methoxy), and R\n7\n represents hydrogen.\n\n\n28) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 22), wherein R\n6\n, R\n7\n and R\n8\n all represent hydrogen.\n\n\n29) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 28), wherein R\n5\n represents hydrogen. 30) A further embodiment of the invention relates to compounds of formula (I) according to any one of embodiments 1 ) to 28), wherein R\n5\n represents (C-i^alkyl. \n\n\n\n\n31 ) A further embodiment of the invention relates to compounds of formula (I) according to embodiment 1 ) which are also compounds of formula (I\nCE\n) \n\n\n\n\n\nFormula (I\nC\nE) wherein\n\n\nR\n1\n and R\n2\n independently represent hydrogen, or halogen (especially fluorine); and preferably R\n1\n and R\n2\n are both the same; p represents the integer 2 or 3;\n\n\nR represents hydrogen, (Ci\n-5\n)alkoxy (especially methoxy), or -CO-R 31. ;\n\n\nR i31 represents (Ci\n-5\n)alkyl, (d\n-3\n)fluoroalkyl, (C\n3-6\n)cycloalkyl, or (Ci.\n2\n)alkoxy-(Ci\n-3\n)alkyl;\n\n\nB represents a group -(CH\n2\n)\nm\n-, wherein m represents the integer 3; or B together with R\n4\n and the nitrogen atom to which B and R\n4\n are attached forms a 4- to 6-membered (especially 6-membered) saturated ring, wherein said ring may optionally be mono-substituted with phenyl;\n\n\nR\n4\n represents (C\n1-5\n)alkyl; or R\n4\n together with B and the nitrogen atom to which R\n4\n and B are attached forms a 4- to 6-membered (especially 6-membered) saturated ring, wherein said ring may optionally be mono-substituted with phenyl;\n\n\nR\n7\n represents hydrogen; and\n\n\nR\n6\n and R\n8\n independently represent hydrogen, (Ci\n-5\n)alkyl, or (Ci\n-5\n)alkoxy.\n\n\nThe present invention also includes isotopically, especially \n2\nH (deuterium) labelled compounds of formula (I) which compounds are identical to the compound of formula (I) wherein one or more atoms have been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially \n2\nH (deuterium) labelled compounds of formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope \n2\nH (deuterium) may lead to greater metabolic stability, resulting eg. in increased in-vivo half- \n\n life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of formula (I) are not isotopically labelled, or labelled with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled. Isotopically labelled compounds of formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.\n\n\nThe compounds of formula (I) contain stereogenic or asymmetric centers, such as asymmetric carbon atoms. The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.\n\n\nWhere the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.\n\n\nAny reference to a compound of formulae (I), (I\nCE\n), O\nEI\n), and/or (I\nE2\n) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.\n\n\nThe term \"pharmaceutically acceptable salts\" refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to \"Salt selection for basic drugs\", Int. J. Pharm. 1986, 33, 201-217.\n\n\nIn one embodiment examples of preferred compounds of formula (I) are selected from the group consisting of:\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol;\n\n\nMethoxy-acetic acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.2.2.02,7]dodeca-2,4,6-trien-9-yl ester; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\nCyclopropanecarboxylic acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester; (1 S,8S,9S)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; \n\n (1 R,8R,9R)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2l7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 S,8S,9S)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester; lsobutyric acid (1 R,8R,9R)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-[3-(1 H-Benzoimidazol-2-yl)-propyl]-[2-(9-methoxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-\n\n\n2,4,6-trien-9-yl)-ethyl]-methyl-amine;\n\n\n(1 R\n*\n,8R\n*\n,9S\n*\n)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9S\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-Benzoimidazol-2-yl)-piperidin-1 -yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[(3RS)-3-(1 H-Benzoimidazol-2-yl)-piperidin-1 -yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[(3RS)-3-(1 H-benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-Benzoimidazol-2-yl)-4-phenyl-piperidin-1 -yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-{2-[4-(1 H-benzoimidazol-2-yl)-4-phenyl-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester; (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-4,5-difluoro- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol; lsobutyric acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-\n\n\n4,5-difluoro-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\nMethoxy-acetic acid (1 R\n*\n,8R\n*\n, 12R\n*\n)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; \n\n (1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\n(1 R,8R,12R)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n(1S,8S,12S)-12-(2-{[3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\n(1 R,8R,12R)-12-(2-{[3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1 S,8S,12S)-12-(2-{[3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(4-methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 S,8S, 12S)-12-(2-{[3-(4-methoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 R,8R, 12R)- 12-(2-{[3-(4-methoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester;\n\n\n(1S,8S,12S)-12-(2-{[3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol;\n\n\n(1 R,8R,12R)-12-(2-{[3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1S,8S,12S)-12-(2-{[3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(4-methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 S,8S,12S)-12-(2-{[3-(4-methoxy-7-methyl-1 H-benzoimidazol- 2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n3,3,3-Trifluoro-propionic acid (1 R,8R, 12R)-12-(2-{[3-(4-methoxy-7-methyl-1 H-benzoimidazol-\n\n\n2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester;\n\n\n(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; \n\n lsobutyric acid (1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; (1S,8S,12S)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; (1 R,8R,12R)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol; lsobutyric acid (1 S,8S, 12S)- 12-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester; and lsobutyric acid (1 R,8R,12R)-12-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-yl ester.\n\n\nThe relative configuration of stereoisomers is denoted as follows: for example, (1 R\n*\n,8R\n*\n,9R\n*\n)-[3-(1 H-Benzoimidazol-2-yl)-propyl]-[2-(9-methoxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca- 2,4,6-trien-9-yl)-ethyl]-methyl-amine denominates\n\n\n(1 R,8R,9R)-[3-(1 H-Benzoimidazol-2-yl)-propyl]-[2-(9-methoxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6- trien-9-yl)-ethyl]-methyl-amine, or\n\n\n(1S,8S,9S)-[3-(1 H-Benzoimidazol-2-yl)-propyl]-[2-(9-methoxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6- trien-9-yl)-ethyl]-methyl-amine, or mixtures of these two enantiomers such as for example a racemate.\n\n\nThe compounds of formulae (I), (I\nCE\n), (I\nEI\n) and/or (I\nE\n2) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration.\n\n\nThe production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition 2005, Part 5, \"Pharmaceutical Manufacturing\" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I), or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.\n\n\nThe compounds of formula (I), or pharmaceutically acceptable salts thereof, are useful in the preparation of a medicament, and/or are suitable \n\n • for the treatment or prevention of chronic stable angina, hypertension, ischemia (renal and cardiac), cardiac arrhythmias including atrial fibrillation, cardiac hypertrophy, or congestive heart failure.\n\n\nThe compounds of formula (I), or pharmaceutically acceptable salts thereof, are further also useful in the preparation of a medicament, and/or are suitable, for the following disease groups alone or in any combination:\n\n\n• for the treatment of renal diseases, diabetes and its complications, hyperaldosteronism, epilepsy, neuropathic pain, or cancer in humans and other mammals;\n\n\n• for use as anti-fibrillatory agent, anti-asthmatic agent, anti-atherosclerotic agent, additive to cardioplegic solutions for pulmonary bypasses, adjunct to thrombolytic therapy, as antiaggregant agent, or as agent for the treatment of unstable angina;\n\n\n• for the treatment or prophylaxis of hypertension, especially portal hypertension, hypertension secondary to treatment with erythropoietin and low renin hypertension;\n\n\n• for use in hypoxic or ischemic diseases, or as anti ischemic agent for the treatment of e.g. cardiac, renal and cerebral ischemia and reperfusion (e.g. occurring after cardiopulmonary bypass surgery), coronary and cerebral vasospasm and the like, therapy for peripheral vascular diseases (e.g. Raynaud's disease, intermittent claudication, Takayashus disease), sickle cell disease including initiation and/or evolution of the pain crisis; • for the treatment or prophylaxis of disorders related to renal, glomerular and mesangial cell function, including acute and chronic renal failure, diabetic nephropathy, hypertension-induced nephropathy, glomerular injury, renal damage related to age or dialysis, nephrosclerosis, nephrotoxicity related to imaging and contrast agent and to cyclosporine, renal ischemia, primary vesicoureteral reflux, or glomerulosclerosis; • for use in therapy for myocardial infarction, treatment of cardiac hypertrophy, primary and secondary pulmonary hypertension, therapy for congestive heart failure including inhibition of fibrosis, inhibition of left ventricular dilatation, remodelling and dysfunction, or restenosis following angioplasty or stenting;\n\n\n• for the treatment of endotoxemia or endotoxin shock, or hemorrhagic shock; • for the treatment of sexual dysfunction in both men (erectile dysfunction e.g. due to diabetes mellitus, spinal cord injury, radical prostatectomy, psychogenic etiology and other causes) and women by improving blood flow to the genitalia, especially corpus cavern osum;\n\n\n• for the prevention and/or reduction of cancer or end-organ damage associated with cell proliferation; \n\n • for therapy of metabolic disorders or chronic inflammatory diseases, insulin-dependent and non insulin-dependent diabetes mellitus and their complications (e.g. neuropathy, retinopathy), hyperaldosteronism, bone remodelling, psoriasis, arthritis, rheumatoid arthritis, osteoarthritis sarcoidosis, or eczematous dermatitis; • for the treatment of hepatotoxicity and sudden death, early and advanced liver disease and injury including attendant complication (e.g. hepatotoxicity, fibrosis, cirrhosis), deleterious consequences of tumors such as hypertension resulting from hemangiopericytoma, spastic diseases of the urinary tract and/or bladder, hepatorenal syndrome, immunological diseases involving vasculitis such as lupus, systemic sclerosis, mixed cryoglobulinemia, fibrosis associated with renal dysfunction and hepatotoxicity;\n\n\n• for use in gastrointestinal diseases such as ulcerative colitis, Crohn's disease, gastric mucosal damage, ulcer inflammatory bowel disease and ischemic bowel disease, gall bladder or bile duct-based diseases such as cholangitis, pancratitis, regulation of cell growth, begning prostatic hypertrophy, or transplantation, or for use as anti-diarrheal agent;\n\n\n• for the treatment of disorders involving bronchoconstriction or disorders of chronic or acute inflammation such as obstructive pulmonary disease and adult distress syndrome;\n\n\n• for the alleviation of pain including neuropathic pain, peripheral pain and pain associated with cancer such as pain associated with prostate cancer or bone-cancer; • for the treatment of central nervous system vascular disorders such as stroke, transient ischemic attacks, migraine and subarachnoid hemorrhage, central nervous system behavioural disorders, treatment of dementia including Alzheimer's dementia, senile dementia and vascular dementia, epilepsy, or sleep disorders; or\n\n\n• for reduction of general morbidity and/or mortality as a result of above utilities. The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I).\n\n\nFurthermore, the compounds of the formula (I) may also be used favourably in combination with one or more agents selected from lipid lowering agents such as statins, anticoagulants such as coumarins, antithrombotic agents such as clopidogrel, β-blockers, and other cardioprotective agents.\n\n\nBesides, any preferences indicated for the compounds of formula (I) (whether for the compounds themselves, salts thereof, compositions containing the compounds or salts \n\n thereof, uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of formulae (I\nC\nE), (IEI ), and/or (I\nE\n2) and vice versa.\n\n\nPreparation of compounds of formula (I):\n\n\nA further aspect of the invention is a process for the preparation of compounds of formulae (I), (IC\nE\n), (I\nEI\n), and/or (I\nE\n2) of the present invention. The compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.\n\n\nIn general, all chemical transformations can be performed according to well-known standard methodologies as described in the literature or as described in the procedures as summarized in Schemes 1 to 4 below. If not indicated otherwise, the generic groups or integers W, R\n1\n, R\n2\n, R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, R\n8\n, p, m and n are as defined for formula (I). Other abbreviations used are defined in the experimental section. In some instances the generic groups W, R\n1\n, R\n2\n, R\n3\n, R\n5\n, R\n6\n, R\n7\n, or R\n8\n, might be incompatible with the assembly illustrated in the schemes below and so will require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example \"Protective Groups in Organic Synthesis\", T.W. Greene, P. G. M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups as are necessary are in place.\n\n\nCompounds of formula (I), wherein R\n3\n represents -CO-R\n31\n, are prepared following the procedures outlined in Scheme 1 below. Intermediate Il is reduced to the corresponding diol III using standard reducing reagents and conditions such as LiAIH\n4\n and solvents like Et\n2\nO or THF, preferably at temperatures between -20\n0\nC and rt. The primary alcohol group in compounds of formula III is transformed into a leaving group L\n1\n in compound IV, wherein L\n1\n is OTs, OMs, OTf, Cl or Br, using well known methods such as Ts-Cl in the presence of bases such as NEt\n3\n, DMAP, and in an adequate solvent such as toluene. Treatment of IV with the appropriate amine R\n4\n-NH-B-W in presence of a non-nuclear base such as DIPEA at temperatures between rt and 110\n0\nC gives compounds of formula (I) wherein R\n3\n represents H.\n\n\nAlcohols of formula (I) wherein R\n3\n represents H can be acylated using standard reagents such as acid chlorides, acid anhydrides, chloroformates, isocyanates, or carbamoylchlorides, if necessary in presence of a Lewis acid such as MgBr\n2\n, or in presence of a base such as NEt\n3\n in inert solvents such as DCM or THF at temperatures between 0°C and rt to give compounds of formula (I) wherein R\n3\n represents -CO-R\n31\n. \n\n Scheme 1 :\n\n\n\n\n\n\n\n\n(I) IV\n\n\nCompounds of formula (I), wherein R\n3\n represents (Ci\n-5\n)alkyl, are prepared following the procedures outlined in Scheme 2 below. Protection of the primary OH group in intermediates III with standard O-protecting groups such as TBS or TBDPS applying standard chemistry described in the literature and known to those skilled in the art leads to intermediates Vl which can then be O-alkylated with an alkyl halogenide such as MeI in the presence of a base like NaH in a solvent like acetone, DMF or THF at temperatures between 0\n0\nC to rt yielding ethers VII. Deprotection of the primary alcohol using standard deprotection reagents and procedures known to ones skilled in the art (e.g. TBAF in THF for silyl ethers) gives the desired monoalcohols VIII. Transformation of the alcohol group into a leaving group L\n1\n (under the aforementioned conditions) followed by substitution with the appropriate amine R\n4\n-NH-B- W as described below leads to compounds of formula (I) wherein R\n3\n represents (C\n1-5\n)alkyl. \n\n\n\n\nScheme 2:\n\n\n\n\n\n\n\n\nThe intermediates Il are prepared according to Scheme 3.\n\n\nA Diels-Alder cycloaddition of 1 ,4-benzoquinones X, which are commercially available or synthesized according to the methods given in the experimental part below, with 1 ,3-dienes under either thermal conditions (heating in benzene or DCM) or in the presence of a Lewis acid catalyst such as BF\n3\n-dietherate or AICI3 in an appropriate solvent like DCM, as described by P.A. Crooks, Synth. Comm. 2002, 24, 3813-3819, leads to intermediates Xl. Diols XII can be obtained by reducing diones Xl under Luche conditions using CeCI\n3\n and a reducing agent like NaBH\n4\n in an appropriate solvent such as MeOH at temperatures around 0\n0\nC. Dehydration using POCI\n3\n in pyridine at temperatures between 0\n0\nC and rt leads to compounds of formula XIII. Alcohols XIV can be formed by hydroboration of intermediates XIII using standard conditions such as BH\n3\n in THF. Subsequent oxidation of alcohols XIV using e.g. Dess-Martins-Periodinane in DCM at rt yields ketones of formula XV. Ketones XV are transformed into the desired intermediates Il wherein n>2 by addition of nucleophiles such as Grignard reagents or lithiated alkyl groups such as lithiated tert.-butylacetate (prepared in situ using te/t-butyl acetate, n-butyllithium and DIPA at temperatures of -50\n0\nC in an adequate mixture of solvents such as toluene-THF or hexane-THF) at temperatures between -50\n0\nC and rt. Intermediates Il wherein n=1 can be obtained by hydrocyanation of ketone derivatives XV under standard conditions using e.g. KCN or TMSCN in appropriate solvents like MeCN or DCM at rt to get intermediates XVI followed by hydrolysis under standard acidic conditions in the presence of an alcohol such as te/t-BuOH. \n\n Scheme 3:\n\n\n\n\n\n\n\n\nThe amino building blocks R\n4\n-NH-B-W can be prepared according to the description below in Scheme 4. A suitably substituted dianiline derivative XVII, which is commercially available or synthesized according to the methods given in the experimental part below, is coupled to an accordingly protected N-alkylamino-alkanoic acid derivative, which is commercially available or synthesized following known literature procedures, using standard coupling reagents and conditions such as EDC/HOBt in presence of a base such as DIPEA, in solvents like THF at rt to give the aniline derivatives XVIII. Heating of XVIII, preferably under microwave conditions to about 150\n0\nC, neat or in appropriate solvents such as toluene preferably in the presence of TsOH or acetic acid leads to the protected aminoalkyl benzimidazole derivatives XIX. Optionally, in case R\n5\n is (C\n1-5\n)alkyl, the substituent can be introduced using standard reactions such as alkylation with an appropriate alkyl halogenide in presence of a base like NaH or K\n2\nCO3 in a solvent like acetone, DMF or THF at temperatures of about 0\n0\nC. Deprotection using standard deprotection reagents and procedures known to the ones skilled in the art (hydrogen for PG = Cbz, TFA or HCI for PG = BOC) gives the desired aminoalkyl benzimidazole derivatives V. \n\n Scheme 4:\n\n\n\n\n\n\n\n\nXVIl XVIII\n\n\n\n\n\n\n\n\nWhenever the compounds of formula (I) are obtained in the form of mixtures of enantiomers, the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-O1 (R\n1\nR) (10 μm) column, a Daicel ChiralCel OD-H (5-10 μm) column, or a Daicel ChiralPak IA (10 μm) or AD-H (5 μm) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of an amine such as NEt\n3\n, diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.\n\n\nEXPERIMENTAL PART\n\n\nThe following examples illustrate the invention but do not at all limit the scope thereof.\n\n\nAll temperatures are stated in \n0\nC. Compounds are characterized by \n1\nH-NMR (300 MHz, 400 MHz) or \n13\nC-NMR (100 MHz) (Bruker/Varian; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, q = quartett, p = pentuplet, hex = hexet, hept = heptet, m = multiplet, br = broad, coupling constants are given in Hz); by LC- MS (system A) Finnigan Navigator with HP 1100 Binary Pump and DAD, column: 4.6x50 mm, Zorbax SB-AQ, 5 μm, 120 A, gradient: 5-95% MeCN in water, 1 min, with 0.04% TFA, flow: 4.5 mL/min or by LC-MS (system B) column: X-terra\n®\n MS C18, 2.1x50mm, 5 μm, gradient: 5-95% MeCN in water, 1 min, with 0.06% formic acid, flow: 3 ml/min, t\nR\n is given in min; by TLC (TLC-plates from Merck, Silica gel 60 F\n2\n5\n4\n); or by melting point. Compounds are purified by preparative HPLC (column: X-terra RP18, 50x19 mm, 5 μm, gradient: 10-95% \n\n MeCN in water containing 0.5 % of formic acid) or by column chromatography on silica gel. Racemates can be separated into their enantiomers by preparative HPLC (preferred conditions: specified below).\n\n\nAbbreviations: (as used herein or in the description above) aq. aqueous\n\n\nAc acetyl\n\n\nAcOH acetic acid anh. anhydrous\n\n\nBOC te/t-butoxycarbonyl\n\n\nBSA bovine serum albumin\n\n\nBu butyl\n\n\nCbz benzyloxycarbonyl\n\n\nCC column chromatography on silica gel\n\n\nDCM dichloromethane dil. diluted\n\n\nDIPA diisopropylamine\n\n\nDIPEA diisopropyl-ethylamine, Hϋnig's base, ethyl-diisopropylamine\n\n\nDMAP dimethylaminopyridine\n\n\nDMP Dess-Martins-Periodinane\n\n\nDMF dimethylformamide\n\n\nDMSO dimethylsulfoxide\n\n\nEDC Λ/-(3-dimethylaminopropyl)-Λ/'-ethylcarbodiimide eq. equivalent(s)\n\n\nEt ethyl\n\n\nEtOAc ethyl acetate\n\n\nEtOH ethanol\n\n\nEt\n2\nO diethyl ether h hour(s)\n\n\nHept heptane\n\n\nHex hexane\n\n\nHOBt 1 -hydroxybenzotriazole\n\n\nHPLC high performance liquid chromatography\n\n\nLC-MS liquid chromatography - mass spectrometry\n\n\nMe methyl\n\n\nMeCN acetonitrile \n\n min minute(s)\n\n\nMs methanesulfonyl\n\n\nNEt\n3\n triethylamine\n\n\nOAc O-acetyl, acetate\n\n\nPd/C palladium on carbon prep. preparative\n\n\nPyBOP benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate rt room temperature sat. saturated tert - tertiary (tert. -butyl = t-butyl = tertiary butyl)\n\n\nTBAF tetra-n-butylammonium fluoride\n\n\nTBDPS te/t-butyldiphenylsilyl\n\n\nTBS te/t-butyldimethylsilyl\n\n\nTf trifluoromethanesulfonyl\n\n\nTFA trifluoroacetic acid\n\n\nTHF tetrahydrofuran\n\n\nTLC thin layer chromatography\n\n\nTMS trimethylsilyl t\nR\n retention time\n\n\nTs para-toluenesulfonyl\n\n\nPreparation of examples\n\n\nExample 1 : rac-(1R*,8R*,9R*)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyO-tricycloIΘ^^.O^ldodeca^^.e-trien-θ-ol\n\n\n1.1 Tricvclor6.2.2.0\n2\n'\n7\nldodeca-4.9-diene-3.6-dione\n\n\nA solution of 40 g of 1 ,4-benzoquinone and 35 ml. of 1 ,3-cyclohexadiene in 90 ml. of benzene was stirred in a closed vessel for 3 days at rt. The reaction mixture was concentrated and the residue was crystallized in EtOH to obtain 57 g of the desired compound as mixture of stereoisomers as greenish solid.\n\n\n \n1\nH-NMR ((CDa)\n2\nSO): 6.70 (s, 2H); 6.18 (m, 2H); 3.03 (m, 4H); 1.65 (m, 2H); 1.20 (m, 2H). \n\n 1.2 Tricvclor6.2.2.0\n2\n'\n7\nldodeca-4.9-diene-3.6-diol\n\n\nTo a solution of 25.6 g of tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-4,9-diene-3,6-dione in 600 ml. of MeOH were added 58.0 g of CeCU 7H\n2\nO. Then, 5.7 g of NaBH\n4\n were portionwise added at 0\n0\nC and the mixture was stirred for 1 h at the same temperature. After evaporation of the solvent the residue was redissolved in EtOAc, it was washed with H\n2\nO, dried over MgSO\n4\n and concentrated in vacuo. The crude was again redissolved in EtOAc and triturated with Hept to obtain 27.9 g of the desired compound as mixture of stereoisomers as brownish solid.\n\n\nLC-MS (A): t\nR\n = 0.73 min; [M-H\n2\nO+H]\n+\n: 175.21\n\n\n1.3 rac-(1 R\n*\n.8S\n*\n1-Tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6.9-tetraene To a solution of 27.9 g of tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-4,9-diene-3,6-diol in 165 ml. of pyridine were portionwise added 30 ml. of POCI\n3\n at 0\n0\nC. The reaction was stirred for 3 days at rt before it was quenched by careful addition of ice under cooling. The resulting mixture was extracted with Hept (4x50 ml_). The combined organic phases were washed with H\n2\nO, 15% HCI solution and again with H\n2\nO. The organic phase was dried over MgSO\n4\n and concentrated in vacuo to obtain 10.6 g of the desired compound as yellow oil.\n\n\n \n1\nH-NMR ((CDa)\n2\nSO): 7.18 (m, 2H); 7.02 (m, 2H); 6.48 (m, 2H); 3.97 (s, 2H); 1.43 (m, 2H); 1.25 (m, 2H).\n\n\n1.4 (9RSVd R\n*\n.8S\n*\nVTricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ol\n\n\nA solution of 15.8 g of tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6,9-tetraene in 42 ml. of THF was added to 82 ml. of 1 M BH\n3\n in THF at 0\n0\nC. The reaction mixture was stirred overnight while the temperature reached rt. The reaction was quenched by addition of 40 ml. of 0.3N NaOH solution followed by 134 ml. of a 35% H\n2\nO\n2\n solution. The mixture was extracted with Et\n2\nO, washed with H\n2\nO, dried over MgSO\n4\n and concentrated in vacuo to obtain 17.7 g of the desired compound as yellow oil. LC-MS (A): t\nR\n = 0.84 min; [M-H\n2\nO+H]\n+\n: 157.19\n\n\n1.5 rac-(1 R\n*\n.8R\n*\nVTricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-one\n\n\nTo a solution of 5.6 g of tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol in 30 mL of DCM were added 1 10 mL of a 15% DMP solution in DCM. After stirring overnight 300 mL of EtOAc/Hept (1 :1 ) were added, the obtained suspension was filtered over a pad of celite and the filtrated was concentrated in vacuo. The residue was treated again with EtOAc/Hept (1 :1 ) and filtered over celite. This procedure was repeated twice to obtain 4.9 g of the desired compound as yellow oil. \n\n LC-MS (A): t\nR\n = 0.88 min; [M+H+CH\n3\nCN]\n+\n: 214.19\n\n\n1.6 rac-(1 R\n*\n.8R\n*\n.9R\n*\nV(9-Hvdroxy-tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-vn-acetic acid tert-butyl ester and rac-(1 R\n*\n.8R\n*\n.9S\n*'\n)-(9-hvdroxy-tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-vn- acetic acid tert-butyl ester To a solution of 3.5 ml. of DIPA in 6 ml. THF were added dropwise 9.9 ml. of n-butyllithium (2.5M in Hept) at -20\n0\nC. After 20 min, 12 ml. of toluene were added and the solution was stirred for 30 min. The mixture was cooled to -50\n0\nC, 4.5 ml. of te/t-butyl acetate were added and stirring was continued for 1 h at -50\n0\nC. Then, 2.5 g of rac-(1 R\n*\n,8R\n*\n)- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-one dissolved in 6 ml. of toluol were added and the solution was stirred at -50 to -20\n0\nC over 2.5 h. The reaction mixture was poured on ice/aq. HCI, the organic phase was separated, washed with sat. aq. NaHCO\n3\n, dried over Na\n2\nSO\n4\n and concentrated in vacuo. The crude reaction product was purified by CC with Hept/EtOAc (4:1 ) to yield 2.6 g of the major racemate, rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-(9-hydroxy- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl)-acetic acid tert-butyl ester as beige solid and 0.4 g of the minor racemate, rac-(1 R\n*\n,8R\n*\n,9S\n*\n)-(9-hydroxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9- yl)-acetic acid tert-butyl ester as yellow oil.\n\n\nLC-MS (A), (major racemate): t\nR\n = 1.04 min; [M+H]\n+\n: 288.85 LC-MS (A), (minor racemate): t\nR\n = 1.03 min; [M+H]\n+\n: 289.20\n\n\n1.7 rac-(1 R\n*\n.8R\n*\n.9R\n*\nV9-(2-Hvdroxy-ethvn-tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ol A solution of 2.6 g of rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-(9-hydroxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl)- acetic acid tert-butyl ester in 10 mL of THF was added to 15.3 mL of a 1 M LiAIH\n4\n solution in THF at -10°C. The mixture was stirred for 4 h while the temperature reached slowly 0°C. The reaction was quenched by addition of a 15% aq. NaOH solution. The mixture was diluted with EtOAc, washed with H\n2\nO, dried over MgSO\n4\n and concentrated in vacuo to obtain 1.6 g of the desired compound as white solid.\n\n\nLC-MS (A): t\nR\n = 0.78 min; [M-H\n2\nO+H]\n+\n: 201.15\n\n\n1.8 (1 S.8S.9SV9-(2-Hvdroxy-ethvn-tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ol and (1 R,8R,9R)-9-(2-hvdroxy-ethyl)-tricvclor6.2.2.0\n27\nldodeca-2,4,6-trien-9-ol rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-Hydroxy-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol was separated into the respective enantiomers using prep, chiral HPLC (column: Chiralcel OD 20x250mm, 10um; Hex/EtOH 95:5, flow 16 mL/min).\n\n\nChiral analytic HPLC (Chiralcel OD 4.6x250mm, 10um; Hex/EtOH 95:5, flow 0.8 mL/min). \n\n Enantiomer A: t\nR\n = 9.98 min. Enantiomer B: t\nR\n = 11.31 min.\n\n\n1.9 rac-Toluene-4-sulfonic acid (1 R\n*\n.8R\n*\n.9R\n*\nV2-(9-hvdroxy-tricvclor6.2.2.0\n2\n'\n7\nldodeca- 2.4.6-trien-9-ylVethyl ester A mixture of 2.0 g of rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-hydroxy-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6- trien-9-ol, 1.9 g of TsCI, 1.5 ml. of NEt\n3\n and 0.22 g of DMAP in 120 ml. of toluene was stirred overnight at rt. The reaction mixture was quenched with water, the organic phase was separated, washed with brine, dried over MgSO\n4\n and concentrated in vacuo. The residue was purified by CC with Hept/EtOAc (1 :1 ) to yield 2.7 g of the desired compound as yellow oil.\n\n\nLC-MS (A): t\nR\n = 1.03 min; [M-H\n2\nO+H]\n+\n: 355.05\n\n\n1.10 rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{r3-(1 H-Benzoimidazol-2-yl)-propyll-methyl-amino}-ethyl)- tricvclor6.2.2.0\n27\nldodeca-2A6-trien-9-ol\n\n\nA mixture of 1000 mg of rac-toluene-4-sulfonic acid (1 R\n*\n,8R\n*\n,9R\n*\n)- 2-(9-hydroxy- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl)-ethyl ester and 508 mg of [3-(1 H-benzoimidazol-2- yl)-propyl]-methyl-amine in 2 ml. of DIPEA was heated to 1 10\n0\nC for 30 min. The reaction mixture was cooled to rt, quenched with MeOH-water and extracted with EtOAc. The organic phase was separated, dried over Na\n2\nSO\n4\n and concentrated in vacuo to obtain 1.0 g as beige solid. A part of the crude product was purified by CC with EtOAc/MeOH (2:1 ) to obtain the desired compound as beige foam.\n\n\nLC-MS (A): t\nR\n = 0.67 min; [M+H]\n+\n: 390.35.\n\n\nExample 1A: rac-Methoxy-acetic acid (1R*,8R*,9R*)-9-(2-{[3-(1H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-yl ester\n\n\n1 A.1 rac-Methoxy-acetic acid (1 R\n*\n.8R\n*\n.9R\n*\nV9-(2-fr3-(1 H-benzoimidazol-2-vn-propyll- methyl-amino>-ethvn-tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-yl ester\n\n\nTo a solution of 250 mg of rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-aminoJ-ethyO-tricycloβ^^.O^dodeca^Aβ-trien-θ-ol in 10 mL of toluol and 0.1 mL of NEt\n3\n were added 0.1 mL of methoxyacetyl chloride at 0\n0\nC. The reaction mixture was stirred for 2 h at rt and then quenched with sat. aq. NaHCO\n3\n. The product was extracted with EtOAc, dried over Na\n2\nSO\n4\n and concentrated in vacuo. Purification by CC with EtOAc/MeOH (1 :1 ) yielded 130 mg of the desired compound as beige foam.\n\n\nLC-MS (A): t\nR\n = 0.71 min; [M+H]\n+\n: 462.21. \n\n 1 A.2 rac-Methoxy-acetic acid (1 R\n*\n.8R\n*\n.9R\n*\nV9-(2-fr3-(1 H-benzoimidazol-2-vn-DroDyll- methyl-aminol-ethvO-tricvclorB^^.O^ldodeca^AB-trien-g-yl ester dihydrochloride\n\n\nThe above product may be transformed into the corresponding dihydrochloride salt using the following procedure. 130 mg of rac-methoxy-acetic acid (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-aminoJ-ethy^-tricyclotθ^^.O^Jdodeca^AΘ-trien-θ-yl ester were dissolved in 2 ml_ EtOAc, the solution was cooled with an ice bath and 2 ml. of 1.5N HCI in EtOAc was added. The reaction mixture was evaporated to dryness without heating to give the desired compound as dihydrochloride. Example 1 B: rac-lsobutyric acid (1R*,8R*,9R*)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.78 min; [M+H]\n+\n: 460.28. Example 1C: rac-Cyclopropanecarboxylic acid (1R*,8R*,9R*)-9-(2-{[3-(1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien- 9-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , cyclopropanecarbonyl chloride replacing methoxyacetyl chloride. LC-MS (A): t\nR\n = 0.77 min; [M+H]\n+\n: 458.27.\n\n\nExample 2: (1S,8S,9S)-9-(2-{[3-(1H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-ol or (1 R,8R,9R)-9-(2-{[3-(1 H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, using enantiomer A of rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-hydroxy-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien- 9-ol (intermediate 1.8) in step 1.9.\n\n\nLC-MS (A): t\nR\n = 0.71 min; [M+H]\n+\n: 390.17. \n\n Example 2A: lsobutyric acid (1S,8S,9S)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-yl ester or isobutyric acid (1R,8R,9R)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-yl ester This compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 2 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.82 min; [M+H]\n+\n: 460.64.\n\n\nExample 3: (1S,8S,9S)-9-(2-{[3-(1H-Benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-ol or (1 R,8R,9R)-9-(2-{[3-(1H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, using enantiomer B of rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-hydroxy-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien- 9-ol (intermediate 1.8) in step 1.9. LC-MS (A): t\nR\n = 0.72 min; [M+H]\n+\n: 390.44.\n\n\nExample 4: rac-(1 R*,8R*,9R*)-[3-(1 H-Benzoimidazol-2-yl)-propyl]-[2-(9-methoxy- tricycloIΘ^^.O^ldodeca^Aβ-trien-θ-yO-ethyll-methyl -amine\n\n\n4.1 rac-(1 R\n*\n.8R\n*\n.9R\n*\n')-9-r2-(tert-Butyl-dimethyl-silanyloxyVethyll-tricvclor6.2.2.0\n2\n'\n7\nldodeca- 2.4.6-trien-9-ol A mixture of 200 mg of rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-hydroxy-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6- trien-9-ol, 138 mg of TBSCI and 62 mg of imidazole in 2 mL of DCM was stirred overnight at rt. The reaction was quenched with H\n2\nO, the organic phase was washed with brine, dried over Na\n2\nSO\n4\n and concentrated in vacuo to yield 300 mg of the desired compound as yellow oil. LC-MS (A): t\nR\n = 1.16 min; [M+H]\n+\n: 333.20.\n\n\n4.2 rac-(1 R\n*\n.8R\n*\n.9R\n*\n')-2-(9-Methoxy-tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-vn-ethanol\n\n\nTo a solution of 135 mg of rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]- tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol in 2 mL of THF were added 29 mg of NaH (60%, oil dispersion) followed by 74 uL of MeI at 0\n0\nC. The ice bath was removed after 10 min and the mixture was stirred overnight at rt. The yellow suspension was carefully quenched with H\n2\nO, extracted with EtOAc, washed with brine, dried over Na\n2\nSO\n4\n and then concentrated in vacuo to obtain 98 mg of a yellow oil. The crude product was then dissolved in 2 mL of THF, 0.2 mL \n\n of 1 M TBAF in THF was added and the mixture was stirred overnight at rt. The reaction mixture was quenched with H\n2\nO, extracted with EtOAc, dried over Na\n2\nSO\n4\n and concentrated in vacuo. Purification by CC with Hept/EtOAc (4:1 ) yielded 56 mg of the desired compound as yellow oil. 1H-NMR (CD\n3\nOD): 7.13 (m, 4H); 3.50 (m, 2H); 3.22 (s, 3H); 3.08 (m, 1 H); 2.95 (m, 1 H); 2.08 (m, 1 H); 1.80 (m, 1 H); 1.65 (m, 1 H); 1.43 (m, 1 H); 1.33 (m, 2H); 1.12 (m, 2H).\n\n\n4.3 rac-(1 R\n*\n.8R\n*\n.9R\n*\nH3-(1 H-Benzoimidazol-2-yl)-DroDvn-r2-(9-methoxy- tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ylVethyll-methyl-amine\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, intermediate 4.2 replacing intermediate 1.7 in step 1.9.\n\n\nLC-MS (A): t\nR\n = 0.75 min; [M+H]\n+\n: 404.21\n\n\nExample 5: rac-(1 R*,8R*,9S*)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.2.2.0\n2>7\n]dodeca-2,4,6-trien-9-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.7 to 1.10, rac- (1 R\n*\n,8R\n*\n,9S\n*\n)-(9-hydroxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl)-acetic acid tert-butyl ester replacing rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-(9-hydroxy-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl)-acetic acid tert-butyl ester in step 1.7.\n\n\nLC-MS (A): t\nR\n = 0.65 min; [M+H]\n+\n: 390.39\n\n\nExample 5A: rac-lsobutyric acid (1 R*,8R*,9S*)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 5 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.76 min; [M+H]\n+\n: 460.31 Example 6: rac-(1R*,8R*,9R*)-9-{2-[4-(1H-Benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-ol\n\n\n6.1 4-(2-Amino-phenylcarbamoyl)-piperidine-1-carboxylic acid benzyl ester\n\n\nA mixture of 3.5 g of piperidine-1 ,4-dicarboxylic acid monobenzyl ester, 1.5 g of phenylendiamine, 2.3 mL of DIPEA and 6.9 g of PyBOP in 40 mL of DCM was stirred overnight at rt. The reaction was quenched with H\n2\nO, extracted with DCM, dried over MgSO\n4\n and concentrated in vacuo to obtain 10 g of the desired compound as crude brown solid. \n\n LC-MS (A): t\nR\n = 0.76 min; [M+H]\n+\n: 354.26.\n\n\n6.2 4-(1 H-Benzoimidazol-2-yl)-piperidine-1-carboxylic acid benzyl ester\n\n\nA solution of crude 10 g of 4-(2-amino-phenylcarbamoyl)-piperidine-1-carboxylic acid benzyl ester was dissolved in 200 ml. glacial AcOH and heated to 90\n0\nC for 1.5 h. The reaction mixture was evaporated to dryness, redissolved in 20 ml. MeOH and concentrated in vacuo. Purification by CC with EtOAc/Hept (9:1 ) to EtOAc yielded 1.3 g of the desired compound as beige solid.\n\n\nLC-MS (B): t\nR\n = 0.78 min; [M+H]\n+\n: 336.12.\n\n\n6.3 2-Piperidin-4-yl-1 H-benzoimidazole Dissolved 1.3 g of 4-(1 H-benzoimidazol-2-yl)-piperidine-1-carboxylic acid benzyl ester in 4OmL degassed EtOH. Added 200 mg of 10wt% Pd/C and stirred the mixture under a H\n2\n atmosphere for 4 h at rt. The reaction mixture was then filtered over a pad of celite and washed with EtOH. Concentration in vacuo afforded 0.85 g of the desired compound as beige solid. LC-MS (A): t\nR\n = 0.30 min; [M+H]\n+\n: 202.14.\n\n\n6.4 rac-(1 R\n*\n.8R\n*\n.9R\n*\nV9-f2-[4-(1 H-Benzoimidazol-2-vn-piperidin-1-yll-ethyl>- tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ol\n\n\nThis compound was prepared using a method analogous to that of example 1 , step 1.10, intermediate 6.3 replacing [3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amine. LC-MS (A): t\nR\n = 0.65 min; [M+H]\n+\n: 402.32\n\n\nExample 6A: rac-lsobutyric acid (1R*,8R*,9R*)-9-{2-[4-(1 H-benzoimidazol-2-yl)- piperidin-i -yll-ethylHricycloIΘ^^.O^ldodeca^Aβ-trien-θ-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 6 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.74 min; [M+H]\n+\n: 472.37 \n\n Example 7: (1 R*,8R*,9R*)-9-{2-[(3RS)-3-(1 H-Benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}- tricyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-ol\n\n\n7.1 2-Piperidin-3-yl-1 H-benzoimidazole\n\n\nPrepared according to procedures analogous to that of example 6, steps 6.1 to 6.3, piperidine-1 ,3-dicarboxylic acid monobenzyl ester replacing piperidine-1 ,4-dicarboxylic acid monobenzyl ester in step 6.1.\n\n\nLC-MS (A): t\nR\n = 0.34 min; [M+H]\n+\n: 202.14\n\n\n7.2 (1 R\n*\n.8R\n*\n.9R\n*\n>9-f2-K3RS)-3-(1 H-Benzoimidazol-2-yl>piperidin-1-yll-ethyl}- tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ol This compound was prepared using a method analogous to that of example 1 , step 1.10, intermediate 7.1 replacing [3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amine.\n\n\nLC-MS (A): t\nR\n = 0.73 min; [M+H]\n+\n: 402.04\n\n\nExample 7A: lsobutyric acid (1 R*,8R*,9R*)-9-{2-[(3RS)-3-(1H-benzoimidazol-2-yl)- piperidin-1 -yl]-ethyl}-tιϊcyclo[6.2.2.0\n27\n]dodeca-2,4,6-trien-9-yl ester This compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 7 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.85 min; [M+H]\n+\n: 472.82\n\n\nExample 8: rac-(1 R*,8R*,9R*)-9-{2-[4-(1 H-Benzoimidazol-2-yl)-4-phenyl-piperidin-1 -yl]- ethy^-tricycloIΘ^^.O^^dodeca^^.e-trien-θ-ol\n\n\n8.1 2-(4-Phenyl-piperidin-4-yl)-1 H-benzoimidazole\n\n\nPrepared according to procedures analogous to that of example 6, steps 6.1 to 6.3, 4-phenyl- piperidine-1 ,4-dicarboxylic acid monobenzyl ester replacing piperidine-1 ,4-dicarboxylic acid monobenzyl ester in step 6.1. LC-MS (A): t\nR\n = 0.57 min; [M+H]\n+\n: 278.22\n\n\n8.2 rac-(1 R\n*\n.8R\n*\n.9R\n*\n)-9-f2-F4-(1 H-Benzoimidazol-2-vn-4-phenyl-piperidin-1-yll-ethyl>- tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ol\n\n\nThis compound was prepared using a method analogous to that of example 1 , step 1.10, intermediate 8.1 replacing [3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amine. LC-MS (A): t\nR\n = 0.75 min; [M+H]\n+\n: 478.19 \n\n Example 8A: rac-lsobutyric acid (1R*,8R*,9R*)-9-{2-[4-(1H-benzoimidazol-2-yl)-4- phenyl-piperidin-i-yll-ethy^-tricycloIΘ^^.O^ldodeca^^.θ-trien-θ-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 8 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.86 min; [M+H]\n+\n: 548.19\n\n\nExample 9: rac-(1R*,8R*,9R*)-9-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}- ethylH.S-difluoro-tricycloIΘ^^.O^ldodeca^Aβ-trien-θ-ol\n\n\n9.1 4.5-Difluoro-tricvclor6.2.2.0\n2\n'\n7\nldodeca-4.9-diene-3.6-dione A solution of 1.7 g of 2,3-difluoro-1 ,4-benzoquinone (G. Haufe, Perkin Transactions 1 (2002), (23), 2719-2728), 2.2 ml. of 1 ,3 cyclohexadiene in 25 ml. of Et\n2\nO was heated in a closed vessel at 50\n0\nC for 2 h. After cooling to rt the mixture was concentrated in vacuo to obtain 1.4 g of the desired compound as mixture of stereoisomers as yellow solid.\n\n\n \n1\nH-NMR (DMSO): 6.20 (s, 2H); 3.18 (s, 2H); 3.03 (s, 2H); 1.71 (m, 2H); 1.21 (m, 2H). 9.2 rac-(1 R\n*\n.8R\n*\n.9R\n*\nV9-(2-fr3-(1 H-Benzoimidazol-2-yl>DroDvπ-methyl-amino)-ethvn-4.5- difluoro-tricvclor6.2.2.0\n2\n'\n7\nldodeca-2.4.6-trien-9-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.2 to 1.10, 4,5- difluoro-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-4,9-diene-3,6-dione (step 9.1 ) replacing tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-4,9-diene-3,6-dione (step 1.1 ) in step 1.2. LC-MS (A): t\nR\n = 0.70 min; [M-H\n2\nO+H]\n+\n: 426.04\n\n\nExample 9A: rac-lsobutyric acid (1R*,8R*,9R*)-9-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-4,5-difluoro-tricyclo[6.2.2.0\n2 7\n]dodeca-2,4,6-trien-9-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 9 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (B): t\nR\n = 0.78 min; [M+H]\n+\n: 496.13. \n\n Example 10: rac-(1R*,8R*,12R*)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol\n\n\n10.1 Tricvclor6.3.2.0\n2\n'\n7\nltrideca-4.12-diene-3.6-dione\n\n\nTo a solution of 17.2 g of 1 ,4-benzoquinone in 240 ml. DCM were added 7.6 mL of BF\n3\n- diethyletherate followed by 17.2 mL of 1 ,3-cycloheptadiene at -20\n0\nC. The cooling bath was removed after 20 min and the mixture furthermore stirred for 30 min at rt. The reaction mixture was then poured into ice cold KOH (30% aq.) solution and it was vigorously stirred for 10 min. After filtration over celite the organic phase was dried over K\n2\nCO3 and concentrated in vacuo to obtain 21.7 g of the desired compound as mixture of stereoisomers as brown solid.\n\n\n \n1\nH-NMR (CD\n3\nOD): 6.71 (s, 2H); 6.04 (m, 2H); 3.02 (m, 2H); 1.65 (m, 8H).\n\n\n10.2 rac-(1 R\n*\n,8R\n*\n, 12R\n*\n)-12-(2-Hvdroxy-ethylHricvclor6.3.2.0\n2\n'\n7\nltrideca-2 A6-trien-12-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.2 to 1.7, tricyclo[6.3.2.0\n2\n'\n7\n]trideca-4,12-diene-3,6-dione (step 10.1 ) replacing tricyclo[6.2.2.0\n2\n'\n7\n]dodeca- 4,9-diene-3,6-dione (step 1.1 ) in step 1.2.\n\n\nLC-MS (A): t\nR\n = 0.83 min; [M+Na+H]\n+\n: 256.23\n\n\n10.3 (1 S.8S.12SV12-(2-Hvdroxy-ethvn-tricvclor6.3.2.0\n2\n'\n7\nltrideca-2.4.6-trien-12-ol and (1 R.8R.12R)-12-(2-hvdroxy-ethyl)-tricvclor6.3.2.0\n2\n-\n7\n1trideca-2.4.6-trien-12-ol rac-(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-Hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol was separated into the respective enantiomers using prep, chiral HPLC (column: Chiralcel OJ 250x4.6mm, 20um; Hept/EtOH 95:5, flow 2.0 mL/min).\n\n\nChiral analytic HPLC (Chiralcel OD 4.6x250mm, 10um; Hex/EtOH 95:5, flow 0.8 mL/min). Enantiomer A: t\nR\n = 9.43 min. Enantiomer B: t\nR\n = 10.58 min. 10.4 rac-(1 R\n*\n.8R\n*\n.12R\n*\nV12-(2-fr3-(1 H-Benzoimidazol-2-vn-DroDyll-methyl-amino>-ethvn- tricvclor6.3.2.0\n2\n'\n7\nltrideca-2.4.6-trien-12-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 to 1.10, rac- (1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol replacing rac- (1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-hydroxy-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol in step 1.9. LC-MS (A): t\nR\n = 0.75 min; [M+H]\n+\n: 404.07. \n\n Example 1OA: rac-Methoxy-acetic acid (1 R*,8R*,12R*)-12-(2-{[3-(1 H-benzoimidazol-2- yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 10 replacing the compound of example 1. LC-MS (A): t\nR\n = 0.78 min; [M+H]\n+\n: 476.49.\n\n\nExample 10B: rac-lsobutyric acid (1 R*,8R*,12R*)-12-(2-{[3-(1H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 10 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.84 min; [M+H]\n+\n: 474.12.\n\n\nExample 11 : (1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol or (1 R,8R,12R)-12-(2-{[3-(1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien- 12-c-l\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, using enantiomer A of rac-(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6- trien-12-ol (intermediate 10.3) in step 1.9.\n\n\nLC-MS (A): t\nR\n = 0.74 min; [M+H]\n+\n: 404.08. Example 11 A: Isobutyric acid (1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester or isobutyric acid (1R,8R,12R)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 11 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.84 min; [M+H]\n+\n:474.29. \n\n Example 12: (1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol or (1 R,8R,12R)-12-(2-{[3-(1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien- 12-ol Prepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, using enantiomer B of rac-(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6- trien-12-ol (intermediate 10.3) in step 1.9.\n\n\nLC-MS (A): t\nR\n = 0.74 min; [M+H]\n+\n: 404.03\n\n\nExample 12A: lsobutyric acid (1S,8S,12S)-12-(2-{[3-(1 H-Benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester or isobutyric acid (1R,8R,12R)-12-(2-{[3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 12 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.84 min; [M+H]\n+\n: 474.30.\n\n\nExample 13: (1S,8S,12S)-12-(2-{[3-(4-Methoxy-1H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol or (1 R,8R,12R)-12-(2-{[3-(4- methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6-trien-12-ol\n\n\n13.1 r3-(2-Amino-3-methoxy-phenylcarbamoyl)-propyll-methyl-carbamic acid benzyl ester\n\n\nTo a solution of 1.40 g 4-(benzyloxycarbonyl-methyl-amino)-butyric acid (obtained from 4- (methylamino)butyric acid and benzylchloroformate) in 25 mL THF were added 2.9 mL of DIPEA, 0.97 g of HOBt and 1.38 g EDC. After stirring for 5 min 0.80 g of 3-methoxy- benzene-1 ,2-diamine were added and the mixture was stirred for 3 h at rt. Sat. aq. NaHCOs solution was added, the phases were separated and the organic phase was washed with brine. The combined organic phases were dried over MgSO\n4\n, and concentrated in vacuo.\n\n\nLC-MS (A): t\nR\n = 0.80 min; [M+H]\n+\n: 372.27.\n\n\n13.2 [3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyl1-methyl-carbamic acid benzyl ester To a mixture of crude [3-(2-amino-3-methoxy-phenylcarbamoyl)-propyl]-methyl-carbamic acid benzyl ester acid in 7 mL toluene were added a few drops of DMF and 523 mg of TsOH and the reaction mixture was heated at 150\n0\nC for 2.5 h in the microwave. Sat. aq. NaHCO\n3\n \n\n solution was added, the phases were separated and the organic phase was washed with brine. The combined organic phases were dried over MgSO\n4\n, and concentrated in vacuo. Purification by CC EtOAc/MeOH (10:1 ) yielded 0.74 g of the desired compound as brown foam. LC-MS (A): t\nR\n = 0.77 min; [M+H]\n+\n: 354.40.\n\n\n13.3 [3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyll-methyl-amine\n\n\nA solution of 0.74 g of [3-(4-methoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-carbamic acid benzyl ester in 20 ml. EtOH was evacuated 3 times with N\n2\n before 90 mg of 10 wt% Pd/C were added. The reaction mixture was then stirred under a H\n2\n atmosphere (balloon) at rt overnight. Filtration over a pad of celite and washing with 100 ml. EtOH yielded after concentration in vacuo 450 mg of the desired compound as beige solid.\n\n\nLC-MS (A): t\nR\n = 0.45 min; [M+H]\n+\n: 220.32.\n\n\n13.4 (1 S,8S,12S)-12-(2-{r3-(4-Methoxy-1 H-benzoimidazol-2-yl)-propyll-methyl-amino}- ethyl)-tricvclor6.3.2.0\n2\n'\n7\nltrideca-2,4,6-trien-12-ol or (1 R,8R,12R)-12-(2-{r3-(4-methoxy-1 H- benzoimidazol-2-yl)-propyll-methyl-amino}-ethyl)-tricvclor6.3.2.0\n2\n'\n7\nltrideca-2,4,6-trien-12-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, using enantiomer A of rac-(1 R\n*\n,8R\n*\n, 12R\n*\n)-12-(2-hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6- trien-12-ol (intermediate 10.3) in step 1.9 and [3-(4-methoxy-1 H-benzoimidazol-2-yl)-propyl]- methyl-amine (intermediate 13.3) replacing [3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amine in step 1.10.\n\n\nLC-MS (A): t\nR\n = 0.71 min; [M+H]\n+\n: 434.34.\n\n\nExample 13A: lsobutyric acid (1S,8S,12S)-12-(2-{[3-(4-Methoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester or isobutyric acid (1R,8R,12R)-12-(2-{[3-(4-methoxy-1H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 13 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.80 min; [M+H]\n+\n: 504.39. \n\n Example 13B: 3,3,3-Trifluoro-propionic acid (1S,8S,12S)-12-(2-{[3-(4-methoxy-1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien- 12-yl ester or 3,3,3-trifluoro-propionic acid (1R,8R,12R)-12-(2-{[3-(4-methoxy-1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien- 12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 13 replacing the compound of example 1 and 3,3,3- trifluoroproprionyl chloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.82 min; [M+H]\n+\n: 544.44. Example 14: (1S,8S,12S)-12-(2-{[3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol or (1R,8R,12R)-12-(2-{[3- (4-methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol\n\n\n14.1 3-Methoxy-6-methyl-benzene-1 ,2-diamine 3-Methoxy-6-methyl-benzene-1 ,2-diamine was synthesized by suspending 3.3 g of 1-methoxy-4-methyl-2,3-dinitro-benzene (Can.J.Chem. 65,1233-1240, 1987) in 100 ml_ EtOH, evacuating 3 times with N\n2\n and addition of 450 mg of 10wt% Pd/C. The reaction mixture was stirred under a H\n2\n atmosphere (balloon) overnight. Filtration over a pad of celite and washing with 100 ml. EtOH yielded after concentration in vacuo 2.2 g of the desired compound as brown oil.\n\n\nLC-MS (A): t\nR\n = 0.45 min; [M+H]\n+\n: 153.35.\n\n\n14.2 r3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-yl)-propyll-methyl-amine\n\n\nPrepared according to procedures analogous to that of example 13, steps 13.1 to 13.3, intermediate 14.1 replacing 3-methoxy-benzene-1 ,2-diamine in step 13.1. LC-MS (A): t\nR\n = 0.52 min; [M+H]\n+\n: 234.18.\n\n\n14.3 (1 S.8S.12SV12-(2-fr3-(4-Methoxy-7-methyl-1 H-benzoimidazol-2-vn-propyll-methyl- amino>-ethvn-tricvclor6.3.2.0\n2\n'\n7\nltrideca-2.4.6-trien-12-ol or (1 R.8R.12RV12-(2-fr3-(4-methoxy- 7-methyl-1 H-benzoimidazol-2-yl)-propyl1-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n1trideca-2,4,6- trien-12-ol Prepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, using enantiomer A of rac-(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6- trien-12-ol (intermediate 10.3) in step 1.9 and [3-(4-methoxy-7-methyl-1 H-benzoimidazol-2- \n\n yl)-propyl]-methyl-amine (intermediate 14.2) replacing [3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-amine in step 1.10.\n\n\nLC-MS (A): t\nR\n = 0.73 min; [M+H]\n+\n: 448.38.\n\n\nExample 14A: lsobutyric acid (1S,8S,12S)-12-(2-{[3-(4-Methoxy-7-methyl-1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien- 12-yl ester or isobutyric acid (1 R,8R,12R)-12-(2-{[3-(4-methoxy-7-methyl-1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien- 12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 14 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.84 min; [M+H]\n+\n: 518.24.\n\n\nExample 14B: 3,3,3-Trifluoro-propionic acid (1S,8S,12S)-12-(2-{[3-(4-methoxy-7-methyl- 1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6- trien-12-yl ester or 3,3,3-trifluoro-propionic acid (1 R,8R,12R)-12-(2-{[3-(4-methoxy-7- methyl-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n2>7\n]trideca- 2,4,6-trien-12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 14 replacing the compound of example 1 and 3,3,3- trifluoroproprionyl chloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.83 min; [M+H]\n+\n: 558.28.\n\n\nExample 15: rac-(1 R*,8R*,12R*)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol\n\n\n15.1 3,6-Dimethoxy-benzene-1 ,2-diamine 3,6-Dimethoxy-benzene-1 ,2-diamine was synthesized by dissolving 6.0 g of 1 ,4-dimethoxy- 2,3-dinitro-benzene (Eur.J.Org.Chem. 2006, 2786-2794) in 220 mL EtOH, evacuating 3 times with N\n2\n and adding 600 mg of 10wt% Pd/C. The reaction was stirred under a H\n2\n atmosphere (balloon). Another 300 mg of 10wt% Pd/C were added after 2 days and the mixture was stirred for another 24 h. Filtration over a pad of celite and washing with EtOH and EtOAc yielded after concentration in vacuo 4.3 g of the desired compound as black solid.\n\n\nLC-MS (A): t\nR\n = 0.48 min; [M+H]\n+\n: 169.09. \n\n 15.2 r3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyll-methyl-amine\n\n\nPrepared according to procedures analogous to that of example 13, steps 13.1 to 13.3, intermediate 15.1 replacing 3-methoxy-benzene-1 ,2-diamine in step 13.1.\n\n\nLC-MS (A): t\nR\n = 0.57 min; [M+H]\n+\n: 250.13. 15.3 rac-(1 R\n*\n.8R\n*\n.12R\n*\n')-12-(2-fr3-(4.7-Dimethoxy-1 H-benzoimidazol-2-vn-propyll-methyl- amino>-ethvn-tricvclor6.3.2.0\n2\n'\n7\nltrideca-2.4.6-trien-12-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, recti R%8R%12R\n*\n)-12-(2-hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6^ (step 10.2) replacing rac-(1 R\n*\n,8R\n*\n,9R\n*\n)-9-(2-hydroxy-ethyl)-tricyclo[6.2.2.0\n2\n'\n7\n]dodeca-2,4,6-trien-9-ol in step 1.9 and [3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amine (intermediate 15.2) replacing [3-(1 H-benzoimidazol-2-yl)-propyl]-methyl-amine in step 1.10.\n\n\nLC-MS (A): t\nR\n = 0.78 min; [M+H]\n+\n: 464.17.\n\n\nExample 15A: rac-lsobutyric acid (1 R*,8R*,12R*)-12-(2-{[3-(4,7-dimethoxy-1 H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien- 12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 15 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.88 min; [M+H]\n+\n: 534.35. Example 16: (1S,8S,12S)-12-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol or (1R,8R,12R)-12-(2-{[3- (4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-ol\n\n\nPrepared according to procedures analogous to that of example 1 , steps 1.9 and 1.10, using enantiomer A of rac-(1 R\n*\n,8R\n*\n,12R\n*\n)-12-(2-hydroxy-ethyl)-tricyclo[6.3.2.0\n2\n'\n7\n]trideca-2,4,6- trien-12-ol (intermediate 10.3) in step 1.9 and [3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amine (intermediate 15.2) replacing [3-(1 H-benzoimidazol-2-yl)-propyl]- methyl-amine in step 1.10.\n\n\nLC-MS (A): t\nR\n = 0.78 min; [M+H]\n+\n: 464.29. \n\n Example 16A: lsobutyric acid (1S,8S,12S)-12-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol- 2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester or isobutyric acid (1 R,8R,12R)-12-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]- methyl-amino}-ethyl)-tricyclo[6.3.2.0\n27\n]trideca-2,4,6-trien-12-yl ester\n\n\nThis compound was prepared using a method analogous to that of example 1A, step 1.A1 , the compound of example 16 replacing the compound of example 1 and isobutyrylchloride replacing methoxyacetyl chloride.\n\n\nLC-MS (A): t\nR\n = 0.87 min; [M+H]\n+\n: 534.56.\n\n\nBiological tests\n\n\nIn vitro assay L channel\n\n\nThe L channel antagonistic activity (IC\n50\n values) of the compounds of formula (I) is determined in accordance with the following experimental method.\n\n\nHuman embryonic kidney (HEK293) cells expressing the human Ca\nv\n1.2 channel in addition to the auxiliary subunits β-2a and α2δ-1 , are grown in culture medium (DMEM containing 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin, 100μg/ml G418, 40μg/ml zeocin and 100μg/ml hygromycin). The cells are seeded at 20.000 cells/well into 384-well black clear bottom sterile plates (poly-L-lysine-coated, Becton Dickinson). The seeded plates are incubated overnight at 37°C in 5% CO\n2\n. The KCI solution is prepared as 80 mM stock solution in assay buffer (HBSS containing 0.1 % BSA, 20 mM HEPES, 0.375g/l NaHCO\n3\n, adjusted to pH 7.4 with NaOH) for use in the assay at a final concentration of 20 mM. Antagonists are prepared as 10 mM stock solutions in DMSO, then diluted in 384w plates first in DMSO, then in assay buffer to obtain 3x stocks. On the day of the assay, 25 μl of staining buffer (HBSS containing 20 mM HEPES, 0.375g/l NaHCO\n3\n, and 3 μM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well of the seeded plate. The 384-well cell-plates are incubated for 60 min at 37° C in 5% CO\n2\n followed by washing with 2 x 50μl per well using assay buffer leaving 50 μl/well of this buffer for equilibration at room temperature (30-60 min). Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 25 μl/well, incubated for 3 min and finally 25 μl/well of KCI solution is added for cellular depolarization. Fluorescence is measured for each well at 2 second intervals for 8 minutes, and the area under the curve of each fluorescence peak is \n\n compared to the area of the fluorescence peak induced by 20 mM KCI with vehicle in place of antagonist. For each antagonist, the IC\n50\n value (the concentration (in nM) of compound needed to inhibit 50 % of the KCI-induced fluorescence response) up to 10μM is determined.\n\n\nCompounds of examples 13, 13A, 13B, 14, 14A, 14B, 15, 15A, 16 and 16A have not been tested in this assay. IC\n50\n values of the remaining 25 example compounds are in the range of 1022 to 8739 nM with an average of 2536 nM.\n\n\nIn vitro assay T channel:\n\n\nThe T channel antagonistic activity (IC\n50\n values) of the compounds of formula (I) is determined in accordance with the following experimental method and data for example compounds are shown in Table 1.\n\n\nHuman embryonic kidney (HEK293) cells expressing the human Ca\nv\n3.1 Ca\nv\n3.2 or Ca\nv\n3.3 channel, respectively, are grown in culture medium (DMEM containing 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin and 1 mg/ml G418). The cells are seeded at 20.000 cells/well into 384-well black clear bottom sterile plates (poly-L- lysine-coated, Becton Dickinson). The seeded plates are incubated overnight at 37°C in 5% CO\n2\n. The Ca\n2+\n solution is prepared as 100 mM stock solution in 100 mM tetraethylammoniumchloride (TEA-chloride), 50 mM HEPES, 2.5 mM CaCI\n2\n, 5 mM KCI, 1 mM MgCI\n2\n, adjusted to pH 7.2 with TEA-hydroxide, for use in the assay at a final concentration of 10 mM. Antagonists are prepared as 10 mM stock solutions in DMSO, then diluted in 384w plates first in DMSO, then in 100 mM TEA-chloride, 50 mM HEPES, 2.5 mM CaCI\n2\n, 5 mM KCI, 1 mM MgCI\n2\n, adjusted to pH 7.2 with TEA-hydroxide, to obtain 9x stocks. On the day of the assay, 25 μl of staining buffer (HBSS containing 20 mM HEPES, 0.375g/l NaHCO\n3\n and 3 μM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well of the seeded plate. The 384-well cell-plates are incubated for 60 min at 37° C in 5% CO\n2\n followed by washing with 2 x 50μl per well using HBSS containing 0.1% BSA, 20 mM HEPES, 0.375g/l NaHCO\n3\n, leaving 50 μl/well of this buffer for equilibration at room temperature (30-60 min). Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 6.25 μl/well, incubated for 3 min, and finally 6.25 μl/well of Ca\n2+\n solution is added. Fluorescence is measured for each well at 2 second intervals for 8 minutes, and the area under the curve of each fluorescence peak is compared to the area of the fluorescence peak induced by 10 mM Ca\n2+\n with vehicle in place of antagonist. For each antagonist, the IC50 \n\n value (the concentration (in nM) of compound needed to inhibit 50 % of the Ca\n2+\n-induced fluorescence response) up to 10μM is determined.\n\n\nTable 1 :\n\n\n\n\n\n\n\n\nNA = not available / not tested\n\n\nEffect on Isolated Hearts according to the Lanqendorff method (Lqdff)\n\n\nThe compounds were tested for their potential to reduce blood pressure and their effect on the contractility of the heart muscle. EC50 values on isolated mouse hearts were determined according to Literature (Doring HJ., The isolated perfused heart according to Langendorff technique— function— application, Physiol. Bohemoslov. 1990, 39(6), 481-504; Kligfield P, Horner H, Brachfeld N., A model of graded ischemia in the isolated perfused rat heart, J. Appl. Physiol. 1976 Jun, 40(6), 1004-8).\n\n\n15 example compounds have been measured using the procedure described above for the Langendorff experiment. Results for selected compounds are given in table 2.\n\n\nTable 2:"
  },
  {
    "id": "WO2010046639A1",
    "text": "Fused pyridine derivatives as kinase inhibitors AbstractA series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Claims\n\n\n\n\nClaims:\n\n\n\n\n1. A compound of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof:\n\n\n\n\n\n\n\n\n(D\n\n\nwherein\n\n\nQ represents the residue of an optionally substituted five-membered heteroaromatic ring selected from furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl and triazolyl; or an optionally substituted six-membered heteroaromatic ring selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl;\n\n\nAIk\n1\n represents an optionally substituted straight or branched Ci\n-3\n alkylene chain;\n\n\nL\n1\n represents oxygen, sulfur, NR\n2\n or a covalent bond;\n\n\nY represents an optionally substituted mono- or bicyclic heteroaryl group containing at least one nitrogen atom;\n\n\nR\n1\n represents a group of formula (a):\n\n\n \n in which the asterisk (*) represents the point of attachment of the ring A to the remainder of the molecule;\n\n\nA represents a saturated, partially saturated or unsaturated 4-, 5-, 6- or 7- membered monocyclic ring containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S, but containing no more than one O or S atom;\n\n\nR\nla\n, R\nlb\n and R\nlc\n independently represent hydrogen, halogen, cyano, nitro, oxo, Ci\n-6\n alkyl, C\n3-7\n cycloalkyl, aryl, C\n3-7\n heterocycloalkyl (optionally substituted by Ci\n-6\n alkyl), heteroaryl, trifluoromethyl, hydroxy, Ci\n-6\n alkoxy, difluoromethoxy,  trifluoromethoxy, Ci\n-6\n alkylthio, Ci\n-6\n alkylsulfinyl, Ci\n-6\n alkylsulfonyl, amino, Ci\n-6\n alkylamino, di(Ci.\n6\n)alkylamino, C\n2-6\n alkylcarbonylamino, C\n2-6\n alkoxycarbonylamino, Ci\n-6\n alkylsulfonylamino, formyl, C\n2-6\n alkylcarbonyl, carboxy, C\n2-6\n alkoxycarbonyl, aminocarbonyl, Ci\n-6\n alkylaminocarbonyl, di(Ci\n-6\n)alkylaminocarbonyl, aminosulfonyl, Ci\n-6\n alkylaminosulfonyl or di(Ci\n-6\n)alkylaminosulfonyl; and R\n2\n represents hydrogen or Ci\n-6\n alkyl.\n\n\n\n\n\n\n2. A compound as claimed in claim 1 wherein Q represents the residue of a thienyl ring, which is unsubstituted, or substituted by one or two substituents.\n\n\n\n\n\n\n3. A compound as claimed in claim 1 or claim 2 represented by formula (HA) or an iV-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof:\n\n\n\n\n\n\n\n\n(UA)\n\n\nwherein AIk\n1\n, L\n1\n, Y and R\n1\n are as defined in claim 1; and\n\n\nR\ny\n and R\nz\n independently represent hydrogen, Ci\n-6\n alkyl, C\n3-7\n cycloalkyl, C\n3-7\n cycloalkyl(Ci\n-6\n)alkyl, aryl, aryl(Ci\n-6\n)alkyl, C\n3-7\n heterocycloalkyl, C\n3-7\n heterocycloalkyl- (Ci\n-6\n)alkyl, heteroaryl, heteroaryl(Ci\n-6\n)alkyl, hydroxy, Q\n-6\n alkoxy, C\n)-6\n alkylthio, Ci\n-6\n alkylsulphinyl, Ci\n-6\n alkylsulphonyl, C\n2-6\n alkylcarbonyl, amino, Ci\n-6\n alkylamino, di(Ci\n-6\n)- alkylamino, halogen, cyano or trifluoromethyl.\n\n\n\n\n\n\n4. A compound as claimed in any one of the preceding claims wherein AIk\n1\n represents methylene, (methyl)methylene or (ethyl)methylene.\n\n\n\n\n\n\n5. A compound as claimed in any one of the preceding claims wherein L\n1\n represents oxygen or sulfur.  \n\n\n\n\n\n\n6. A compound as claimed in any one of the preceding claims wherein Y represents quinolinyl, pyrimidinyl, triazinyl, quinoxalinyl, purinyl or pyridopyrimidin-4- yl, any of which groups may be optionally substituted by one or more substituents.\n\n\n\n\n\n\n7. A compound as claimed in any one of the preceding claims wherein Y is unsubstituted, or substituted by one or more substituents selected from Ci\n-6\n alkyl and amino.\n\n\n\n\n\n\n8. A compound as claimed in any one of the preceding claims wherein R\n1\n represents phenyl.\n\n\n\n\n\n\n9. A compound as herein specifically disclosed in any one of the Examples.\n\n\n\n\n\n\n10. A compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.\n\n\n\n\n\n\n11. A compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment and/or prevention of a disorder for which the administration of a selective PI3K inhibitor is indicated.\n\n\n\n\n\n\n12. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof, in association with a pharmaceutically acceptable carrier.\n\n\n\n\n\n\n13. The use of a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prevention of a disorder for which the administration of a selective PI3K inhibitor is indicated.\n\n\n\n\n\n\n14. A method for the treatment and/or prevention of a disorder for which the administration of a selective PI3K inhibitor is indicated which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as  defined in claim 1 or an jV-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof. Description\n\n\n\n\n FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS\n\n\nThe present invention relates to a class of fused pyridine derivatives, and to their use in therapy. These compounds are selective inhibitors of phosphoinositide 3 -kinase (PI3K) enzymes, and are accordingly of benefit as pharmaceutical agents, especially in the treatment of adverse inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive and ophthalmic conditions.\n\n\nThe PI3K pathway is implicated in a variety of physiological and pathological functions that are believed to be operative in a range of human diseases. Thus, PI3Ks provide a critical signal for cell proliferation, cell survival, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, superoxide production, actin reorganization and chemotaxis (cf. S. Ward et al., Chemistry & Biology, 2003, 10, 207- 213; and S.G. Ward & P. Finan, Current Opinion in Pharmacology, 2003, 3, 426-434); and are known to be involved in the pathology of cancer, and metabolic, inflammatory and cardiovascular diseases (cf. M.P. Wymann et al., Trends in Pharmacol. Sci., 2003, 24, 366-376). Aberrant upregulation of the PI3K pathway is implicated in a wide variety of human cancers (cf. S. Brader & S.A. Eccles, Tumori, 2004, 90, 2-8).\n\n\nThe compounds in accordance with the present invention, being potent and selective PI3K inhibitors, are therefore beneficial in the treatment and/or prevention of various human ailments. These include autoimmune and inflammatory disorders such as rheumatoid arthritis, multiple sclerosis, asthma, inflammatory bowel disease, psoriasis and transplant rejection; cardiovascular disorders including thrombosis, cardiac hypertrophy, hypertension, and irregular contractility of the heart (e.g. during heart failure); neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, amyotrophic lateral sclerosis, spinal cord injury, head trauma and seizures; metabolic disorders such as obesity and type 2 diabetes; oncological conditions including leukaemia, glioblastoma, lymphoma, melanoma, and human cancers of the liver, bone, skin, brain, pancreas, lung, breast, stomach, colon, rectum, prostate, ovary and cervix; pain and nociceptive disorders; and ophthalmic disorders including age- related macular degeneration (ARMD).\n\n\nIn addition, the compounds in accordance with the present invention may be beneficial as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents. Thus, the compounds of this invention \n\n may be useful as radioligands in assays for detecting compounds capable of binding to human POK enzymes.\n\n\nWO 2008/118454, WO 2008/118455 and WO 2008/118468 describe structurally related series of quinoline and quinoxaline derivatives that are stated to be useful to inhibit the biological activity of human PDKδ and to be of use in treating PI3K-mediated conditions or disorders.\n\n\nCopending international patent application PCT/GB2008/004171, published on 2 July 2009 as WO 2009/081105 (claiming priority from United Kingdom patent applications 0725030.1 and 0815177.1), describes a class of quinoline and quinoxaline derivatives as selective inhibitors of PI3K enzymes that are of benefit in the treatment of adverse inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive and ophthalmic conditions.\n\n\nNone of the prior art available to date, however, discloses or suggests the precise structural class of fused pyridine derivatives as provided by the present invention.\n\n\nThe compounds of the present invention are potent and selective PI3K inhibitors having a binding affinity (IC\n50\n) for the human PI3 Ka and/or PI3Kβ and/or PI3Kγ and/or PI3Kδ isoform of 50 μM or less, generally of 20 μM or less, usually of 5 μM or less, typically of 1 μM or less, suitably of 500 nM or less, ideally of 100 nM or less, and preferably of 20 nM or less (the skilled person will appreciate that a lower IC\n50\n figure denotes a more active compound). The compounds of the invention may possess at least a 10-fold selective affinity, typically at least a 20-fold selective affinity, suitably at least a 50-fold selective affinity, and ideally at least a 100-fold selective affinity, for the human PI3Kα and/or PI3Kβ and/or PI3Kγ and/or PDKδ isoform relative to other human kinases.\n\n\nThe present invention provides a compound of formula (I) or an TV-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof:\n\n\n\n\n\n\n\n\n(D\n\n\nwherein \n\n Q represents the residue of an optionally substituted five-membered heteroaromatic ring selected from furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl and triazolyl; or an optionally substituted six-membered heteroaromatic ring selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl;\n\n\nAIk\n1\n represents an optionally substituted straight or branched Ci\n-3\n alkylene chain;\n\n\nL\n1\n represents oxygen, sulfur, NR\n2\n or a covalent bond;\n\n\nY represents an optionally substituted mono- or bicyclic heteroaryl group containing at least one nitrogen atom;\n\n\nR\n1\n represents a group of formula (a):\n\n\n \n\n in which the asterisk (*) represents the point of attachment of the ring A to the remainder of the molecule;\n\n\nA represents a saturated, partially saturated or unsaturated 4-, 5-, 6- or 7- membered monocyclic ring containing 0, 1 , 2, 3 or 4 heteroatoms selected from N, O and S, but containing no more than one O or S atom;\n\n\nR\nla\n, R\nlb\n and R\nlc\n independently represent hydrogen, halogen, cyano, nitro, oxo, Ci\n-6\n alkyl, C\n3-7\n cycloalkyl, aryl, C\n3-7\n heterocycloalkyl (optionally substituted by Ci\n-6\n alkyl), heteroaryl, trifluoromethyl, hydroxy, Ci\n-6\n alkoxy, difluoromethoxy, trifluoromethoxy, C\n1-6\n alkylthio, Ci\n-6\n alkylsulfinyl, C\n)-6\n alkylsulfonyl, amino, Ci\n-6\n alkylamino, di(Ci\n-6\n)alkylamino, C\n2-6\n alkylcarbonylamino, C\n2-6\n alkoxycarbonylamino, Ci\n-6\n alkylsulfonylamino, formyl, C\n2-6\n alkylcarbonyl, carboxy, C\n2-6\n alkoxycarbonyl, aminocarbonyl, C\n]-6\n alkylaminocarbonyl, di(C\n)-6\n)alkylaminocarbonyl, aminosulfonyl, C\n)-6\n alkylaminosulfonyl or di(Ci\n-6\n)alkylaminosulfonyl; and\n\n\nR\n2\n represents hydrogen or Ci\n-6\n alkyl.\n\n\nWhere any of the groups in the compounds of formula (I) above is stated to be optionally substituted, this group may be unsubstituted, or substituted by one or more substituents. Typically, such groups will be unsubstituted, or substituted by one or two substituents.\n\n\nFor use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation \n\n of the compounds of the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound of the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, e.g. carboxy, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.\n\n\nThe present invention includes within its scope solvates of the compounds of formula (I) above. Such solvates may be formed with common organic solvents, e.g. hydrocarbon solvents such as benzene or toluene; chlorinated solvents such as chloroform or dichloromethane; alcoholic solvents such as methanol, ethanol or isopropanol; ethereal solvents such as diethyl ether or tetrahydrofuran; or ester solvents such as ethyl acetate. Alternatively, the solvates of the compounds of formula (I) may be formed with water, in which case they will be hydrates.\n\n\nSuitable alkyl groups which may be present on the compounds of the invention include straight-chained and branched Ci\n-6\n alkyl groups, for example Cj\n-4\n alkyl groups. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl, «-butyl, sec-butyl, isobutyl, tert-buty\\, 2,2-dimethylpropyl and 3-methylbutyl. Derived expressions such as \"Ci\n-6\n alkoxy\", \"Ci\n-6\n alkylthio\", \"Ci\n-6\n alkylsulphonyl\" and \"Ci\n-6\n alkylamino\" are to be construed accordingly.\n\n\nThe expression \"Ci\n-3\n alkylene chain\" refers to a divalent straight or branched alkylene chain containing 1 to 3 carbon atoms. Typical examples include methylene, ethylene, methylmethylene, ethylmethylene and dimethylmethylene.\n\n\nSpecific C\n3-7\n cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.\n\n\nSuitable aryl groups include phenyl and naphthyl, preferably phenyl.\n\n\nSuitable aryl(Ci\n-6\n)alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl. \n\n Suitable heterocycloalkyl groups, which may comprise benzo-fused analogues thereof, include azetidinyl, tetrahydrofuranyl, dihydrobenzofuranyl, pyrrolidinyl, indolinyl, thiazolidinyl, imidazolidinyl, tetrahydropyranyl, chromanyl, piperidinyl, 1,2,3,4- tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, piperazinyl, 1,2,3,4-tetrahydro- quinoxalinyl, homopiperazinyl, morpholinyl, benzoxazinyl and thiomorpholinyl.\n\n\nSuitable heteroaryl groups include furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, dibenzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-Z>]pyridinyl, pyrrolo[3,2- cjpyridinyl, pyrazolyl, pyrazolo[l,5-α]pyridinyl, indazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, imidazo[l,2-α]pyridinyl, imidazo[4,5-6]pyridinyl, imidazo[l,2-α]pyrimidinyl, imidazo[l,2-α]pyrazinyl, oxadiazolyl, thiadiazolyl, triazolyl, benzotriazolyl, tetrazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, cinnolinyl, pyrimidinyl, pyrazinyl, quinoxalinyl and chromenyl groups.\n\n\nThe term \"halogen\" as used herein is intended to include fluorine, chlorine, bromine and iodine atoms, typically fluorine, chlorine or bromine.\n\n\nWhere the compounds of formula (I) have one or more asymmetric centres, they may accordingly exist as enantiomers. Where the compounds of the invention possess two or more asymmetric centres, they may additionally exist as diastereomers. The invention is to be understood to extend to all such enantiomers and diastereomers, and to mixtures thereof in any proportion, including racemates. Formula (I) and the formulae depicted hereinafter are intended to represent all individual stereoisomers and all possible mixtures thereof, unless stated or shown otherwise. In addition, compounds of formula (I) may exist as tautomers, for example keto (CH\n2\nC=O)<→enol (CH=CHOH) tautomers or amide (NHC=O)<→hydroxyimine (N=COH) tautomers. Formula (I) and the formulae depicted hereinafter are intended to represent all individual tautomers and all possible mixtures thereof, unless stated or shown otherwise.\n\n\nIt is to be understood that each individual atom present in formula (I), or in the formulae depicted hereinafter, may in fact be present in the form of any of its naturally occurring isotopes, with the most abundant isotope(s) being preferred. Thus, by way of example, each individual hydrogen atom present in formula (I), or in the formulae depicted hereinafter, may be present as a \n1\nH, \n2\nH (deuterium) or \n3\nH (tritium) atom, preferably \n1\nH. Similarly, by way of example, each individual carbon atom present in formula (I), or in the formulae depicted hereinafter, may be present as a C, C or \n14\nC atom, preferably C. \n\n In the compounds of formula (I), the moiety Q is defined as representing the residue of an optionally substituted five-membered or six-membered heteroaromatic ring as specified above. From this it is to be understood that the variable Q, when taken together with the two carbon atoms of the pyridine ring to which the Q-containing ring is fused, represents an optionally substituted five-membered or six-membered heteroaromatic ring as specified above.\n\n\nIn one embodiment, the moiety Q in the compounds of formula (I) above represents the residue of an optionally substituted five-membered heteroaromatic ring selected from furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl. In another embodiment, the moiety Q in the compounds of formula (I) above represents the residue of an optionally substituted six-membered heteroaromatic ring selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl.\n\n\nSuitably, the moiety Q represents the residue of a thienyl ring, which may be optionally substituted by one or two substitutents. In one embodiment, the moiety Q represents the residue of an unsubstituted thienyl ring.\n\n\nThe five-membered or six-membered heteroaromatic ring of which the moiety Q is the residue may be unsubstituted, or may suitably be substituted, where possible, by one more, typically by one or two, substituents. In one embodiment, this ring is unsubstituted. In another embodiment, this ring is monosubstituted. In a further embodiment, this ring is disubstituted. Examples of typical substituents on the five-membered or six-membered heteroaromatic ring of which the moiety Q is the residue include Ci\n-6\n alkyl, C\n3-7\n cycloalkyl, C\n3-7\n cycloalkyl(Ci\n-6\n)alkyl, aryl, aryl(Ci\n-6\n)alkyl, C\n3-7\n heterocycloalkyl, C\n3\n.\n7\n heterocycloalkyl(Ci\n-6\n)alkyl, heteroaryl, heteroaryl(Ci\n-6\n)alkyl, hydroxy, Ci\n-6\n alkoxy, Ci\n-6\n alkylthio, Ci\n-6\n alkylsulphinyl, Ci\n-6\n alkylsulphonyl, C\n2-6\n alkylcarbonyl, amino, Ci\n-6\n alkylamino, di(Ci\n-6\n)alkylamino, halogen, cyano and trifluoromethyl.\n\n\nExamples of suitable substituents on the alkylene chain represented by AIk\n1\n include trifluoromethyl, aryl, oxo, hydroxy, Ci\n-6\n alkoxy, C\n2-6\n alkoxycarbonyl(Ci\n-6\n)alkoxy, aminocarbonyl(Ci\n-6\n)alkoxy, trifluoromethoxy, aminocarbonyl, Ci\n-6\n alkylaminocarbonyl and di(Ci\n-6\n)alkylaminocarbonyl.\n\n\nExamples of particular substituents on the alkylene chain represented by AIk include trifluoromethyl, phenyl, oxo, hydroxy, ethoxy, ethoxycarbonylmethoxy, \n\n aminocarbonylmethoxy, trifluoromethoxy, aminocarbonyl, methylaminocarbonyl and dimethylaminocarbonyl.\n\n\nTypical values of AIk\n1\n include methylene (-CH\n2\n-), (methyl)methylene, ethylene (-CH\n2\nCH\n2\n-), (ethyl)methylene, (dimethyl)methylene, (methyl)ethylene and (dimethyl)- ethylene, any of which chains may be optionally substituted by one or more substituents. Suitably, such chains are unsubstituted, monosubstituted or disubstituted. Preferably, such chains are unsubstituted or monosubstituted. In one embodiment, such chains are unsubstituted. In another embodiment, such chains are monosubstituted.\n\n\nSuitable values of AIk\n1\n include -CH\n2\n- (methylene), -CH(CH\n3\n)- (methyl- methylene) and -CH(CH\n2\nCH\n3\n)- (ethylmethylene).\n\n\nAIk\n1\n typically represents methylene.\n\n\nSuitably, L\n1\n represents oxygen or sulfur.\n\n\nIn one embodiment, L\n1\n represents oxygen. In another embodiment, L\n1\n represents sulfur. In a further embodiment, L\n1\n represents NR\n2\n. In a still further embodiment, L\n1\n represents a covalent bond.\n\n\nThe expression \"mono- or bicyclic heteroaryl group containing at least one nitrogen atom\" in relation to the group Y refers in particular to a mono- or bicyclic aromatic ring system containing one, two, three or four heteroatoms selected from oxygen, sulfur and nitrogen atoms, with at least one of the heteroatoms being nitrogen. The ring Y may be linked to the group L\n1\n through any available carbon or nitrogen atom. Suitable examples include pyrrolyl, pyridinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indazolyl, benzimidazolyl, furopyridinyl, thienopyridinyl, benzoxazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, imidazopyridinyl, pyrazolopyridinyl, purinyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, naphthyridinyl and pteridinyl.\n\n\nSuitably, Y represents optionally substituted pyrimidinyl or optionally substituted purinyl. In one embodiment, Y represents optionally substituted pyrimidinyl. In another embodiment, Y represents optionally substituted purinyl.\n\n\nAlternative values of Y include pyrrolyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrazinyl, triazinyl, indazolyl, benzimidazolyl, furopyridinyl, thienopyridinyl, benzoxazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, triazolopyrimidinyl, pyridopyrimidin-4-yl, \n\n pyridopyrazinyl, pyridopyridazinyl, naphthyridinyl and pteridinyl, any of which groups may be optionally substituted by one or more substituents. Particular alternative values of Y include quinolinyl, triazinyl, quinoxalinyl and pyridopyrimidin-4-yl, any of which groups may be optionally substituted by one or more substituents.\n\n\nExamples of optional substituents which may be present on the group Y include one, two or three substituents independently selected from halogen, cyano, nitro, oxo, C\n1-6\n alkyl, trifluoromethyl, hydroxy, Ci\n-6\n alkoxy, difluoromethoxy, trifluoromethoxy, Ci\n-6\n alkylthio, Ci\n-6\n alkylsulfinyl, Ci\n-6\n alkylsulfonyl, amino, Ci\n-6\n alkylamino, di(Ci\n-6\n)alkyl- amino, arylamino, C\n2-6\n alkylcarbonylamino, Ci\n-6\n alkylsulfonylamino, formyl, C\n2-6\n alkylcarbonyl, C\n3-6\n cycloalkylcarbonyl, C\n3-6\n heterocycloalkylcarbonyl, carboxy, C\n2-6\n alkoxycarbonyl, aminocarbonyl, Ci\n-6\n alkylaminocarbonyl, di(Ci\n-6\n)alkylaminocarbonyl, aminosulfonyl, Ci\n-6\n alkylaminosulfonyl and di(Ci\n-6\n)alkylaminosulfonyl.\n\n\nTypical examples of optional substituents on the group Y include Ci\n-6\n alkyl and amino.\n\n\nExamples of particular substituents on the group Y include fluoro, chloro, bromo, cyano, nitro, oxo, methyl, isopropyl, trifluoromethyl, hydroxy, methoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, tert- butylamino, dimethylamino, phenylamino, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, cyclopropylcarbonyl, azetidinylcarbonyl, TV- methylazetidinylcarbonyl, pyrrolidinylcarbonyl, -/V-methylpyrrolidinylcarbonyl, piperidinylcarbonyl, N-methylpiperidinylcarbonyl, piperazinylcarbonyl, N- methylpiperazinylcarbonyl, morpholinylcarbonyl, carboxy, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl and dimethylaminosulfonyl.\n\n\nTypical examples of particular substituents on the group Y include amino and methyl.\n\n\nTypical values of Y include purinyl (especially purin-6-yl) and (amino)(methyl)- pyrimidinyl (especially 2-amino-4-methylpyrimidin-6-yl).\n\n\nSuitable values for the group -Alk'-L'-Y include purin-6-ylthiomethyl and (2- amino-4-methylpyrimidin-6-yl)oxymethyl.\n\n\nIn one embodiment, A is a four-membered monocyclic ring. In another embodiment, A is a five-membered monocyclic ring. In a further embodiment, A is a six- \n\n _\n\n\nmembered monocyclic ring. In an additional embodiment, A is a seven-membered monocyclic ring.\n\n\nIn one embodiment, ring A is fully saturated. In another embodiment, ring A is partially saturated. In a further embodiment, ring A is unsaturated.\n\n\nIn one embodiment, ring A contains no heteroatoms (i.e. it is a carbocyclic ring). In another embodiment, ring A contains one heteroatom selected from N, O and S. In a further embodiment, ring A contains two heteroatoms selected from N, O and S, of which not more than one is O or S. In a still further embodiment, ring A contains three heteroatoms selected from N, O and S, of which not more than one is O or S. In a yet further embodiment, ring A contains four heteroatoms selected from N, O and S, of which not more than one is O or S.\n\n\nSuitably, ring A represents phenyl.\n\n\nTypical values of R\nla\n, R\nlb\n and/or R\nlc\n include hydrogen, halogen, Ci\n-6\n alkyl, trifluoromethyl, Ci\n-6\n alkoxy, trifluoromethoxy, C\n2-6\n alkylcarbonylamino and aryl.\n\n\nSuitably, R\nla\n, R\nlb\n and R\nlc\n independently represent hydrogen, fluoro, chloro, bromo, cyano, nitro, oxo, methyl, ethyl, isopropyl, cyclopropyl, azetidinyl, N- methylazetidinyl, tetrahydrofuranyl, pyrrolidinyl, iV-methylpyrrolidinyl, imidazolidinyl, N-methylimidazolidinyl, tetrahydropyranyl, piperidinyl, iV-methylpiperidinyl, piperazinyl, iV-methylpiperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, tetrazolyl, triazinyl, trifluoromethyl, hydroxy, methoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfϊnyl, methylsulfonyl, amino, methylamino, dimethylamino, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl or dimethylaminosulfonyl.\n\n\nTypically, R\nla\n represents hydrogen, halogen, Ci\n-6\n alkyl, trifluoromethyl, Ci\n-6\n alkoxy, trifluoromethoxy, C\n2-6\n alkylcarbonylamino or aryl.\n\n\nSuitably, R\nla\n represents hydrogen.\n\n\nTypically, R\nlb\n represents hydrogen, halogen or Ci\n-6\n alkyl.\n\n\nSuitably, R\nlb\n represents hydrogen.\n\n\nTypically, R\nlc\n represents hydrogen.\n\n\nIn a particular embodiment, R\nlb\n and R\nlc\n both represent hydrogen. \n\n In one embodiment, R\n2\n represents hydrogen. In another embodiment, R\n2\n represents Ci\n-6\n alkyl, especially methyl.\n\n\nSuitable values of the group R\n2\n include hydrogen and methyl.\n\n\nOne sub-class of compounds according to the invention is represented by the compounds of formula (HA) and iV-oxides thereof, and pharmaceutically acceptable salts and solvates thereof:\n\n\n\n\n\n\n\n\n(IIA)\n\n\nwherein AIk\n1\n, L\n1\n, Y and R\n1\n are as defined above; and\n\n\nR\ny\n and R\nz\n independently represent hydrogen, C\n1-6\n alkyl, C\n3-7\n cycloalkyl, C\n3-7\n cycloalkyl(Ci\n-6\n)alkyl, aryl, aryl(Ci\n-6\n)alkyl, C\n3-7\n heterocycloalkyl, C\n3-7\n heterocycloalkyl- (C\n1-6\n)alkyl, heteroaryl, heteroaryl(Ci\n-6\n)alkyl, hydroxy, Ci\n-6\n alkoxy, Ci\n-6\n alkylthio, Ci\n-6\n alkylsulphinyl, Ci\n-6\n alkylsulphonyl, C\n2-6\n alkylcarbonyl, amino, Ci\n-6\n alkylamino, di(Ci\n-6\n)- alkylamino, halogen, cyano or trifluoromethyl.\n\n\nSuitably, R\ny\n represents hydrogen.\n\n\nSuitably, R\nz\n represents hydrogen.\n\n\nSpecific novel compounds in accordance with the present invention include each of the compounds whose preparation is described in the accompanying Examples, and pharmaceutically acceptable salts and solvates thereof.\n\n\nThe present invention also provides a pharmaceutical composition which comprises a compound in accordance with the invention as described above, or a pharmaceutically acceptable salt or solvate thereof, in association with one or more pharmaceutically acceptable carriers.\n\n\nPharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.\n\n\nFor oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with \n\n pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles or preservatives. The preparations may also contain buffer salts, flavouring agents, colouring agents or sweetening agents, as appropriate.\n\n\nPreparations for oral administration may be suitably formulated to give controlled release of the active compound.\n\n\nFor buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.\n\n\nThe compounds of formula (I) may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.\n\n\nIn addition to the formulations described above, the compounds of formula (I) may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.\n\n\nFor nasal administration or administration by inhalation, the compounds according to the present invention may be conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases. \n\n -\n\n\nThe compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.\n\n\nFor topical administration the compounds of use in the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water. Alternatively, the compounds of use in the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.\n\n\nFor ophthalmic administration the compounds of use in the present invention may be conveniently formulated as micronized suspensions in isotonic, pH-adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate. Alternatively, for ophthalmic administration compounds may be formulated in an ointment such as petrolatum.\n\n\nFor rectal administration the compounds of use in the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component. Such materials include, for example, cocoa butter, beeswax and polyethylene glycols.\n\n\nThe quantity of a compound of use in the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen and the condition of the patient to be treated. In general, however, daily dosages may range from around 10 ng/kg to 1000 mg/kg, typically from 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight, for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and from around 0.05 mg to around 1000 mg, e.g. from around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.\n\n\nThe compounds of formula (I) above may be prepared by a process which comprises reacting a compound of formula (III) with a compound of formula (IV): \n\n \n\n\n\n\n\n(III)\n\n\nwherein Q, AIk\n1\n, L\n1\n, Y and R\n1\n are as defined above, and LG\n1\n represents a suitable leaving group.\n\n\nThe leaving group LG\n1\n is typically a halogen atom, e.g. bromo.\n\n\nThe reaction is conveniently effected at ambient or elevated temperature in a suitable solvent, e.g. ΛζN-dimethylformamide or acetonitrile. The reaction may be performed in the presence of a suitable base, e.g. an inorganic base such as potassium carbonate, cesium carbonate, sodium hydride or aqueous sodium hydroxide.\n\n\nThe intermediates of formula (III) above wherein LG\n1\n is bromo may be prepared from a compound of formula (V):\n\n\n\n\n\n\n\n\n(V)\n\n\nwherein Q, AIk\n1\n and R\n1\n are as defined above; by bromination.\n\n\nThe reaction is conveniently effected by stirring compound (V) with an appropriate brominating agent, e.g. phosphorus tribromide, in a suitable solvent, e.g. a halogenated hydrocarbon such as dichloromethane.\n\n\nAlternatively, the intermediates of formula (III) above wherein AIk\n1\n represents methylene and LG\n1\n is bromo may be prepared from a compound of formula (VI): \n\n - -\n\n\n\n\n\n\n\n\n(VI)\n\n\nwherein Q and R\n1\n are as defined above; by bromination.\n\n\nThe reaction is conveniently effected at an elevated temperature in a suitable solvent, e.g. a halogenated solvent such as carbon tetrachloride, in the presence of a suitable brominating agent, e.g. jV-bromosuccinimide, typically in the presence of a catalyst such as benzoyl peroxide.\n\n\nIn another procedure, the compounds of formula (I) wherein L\n1\n represents oxygen may be prepared by a process which comprises reacting a compound of formula (V) as defined above with a compound of formula LG\n2\n-Y, in which Y is as defined above and LG\n2\n represents a suitable leaving group.\n\n\nThe leaving group LG\n2\n is typically a halogen atom, e.g. chloro.\n\n\nThe reaction is conveniently effected by stirring compound (V) with a compound LG\n2\n-Y in a suitable solvent, e.g. N, N-dimethylformamide, typically under basic conditions, e.g. in the presence of an inorganic base such as sodium hydride.\n\n\nIn another procedure, the compounds of formula (I) wherein L\n1\n represents sulfur may be prepared by a process which comprises reacting a compound of formula LG\n2\n- Y with a compound of formula (VII):\n\n\n\n\n\n\n\n\n(VII)\n\n\nwherein Q, AIk\n1\n, Y, R\n1\n and LG\n2\n are as defined above.\n\n\nThe reaction is conveniently effected by stirring compound (VII) with a compound LG\n2\n-Y in a suitable solvent, e.g. a lower alkanol such as methanol, typically under basic conditions, e.g. in the presence of an alkali metal alkoxide such as sodium methoxide. \n\n The intermediates of formula (VII) may typically be prepared by treating a suitable compound of formula (III) above with thiolacetic acid; followed by treatment of the resulting compound with a base, e.g. an alkali metal alkoxide such as sodium methoxide.\n\n\nIn another procedure, the compounds of formula (I) wherein L\n1\n represents NR\n2\n may be prepared by a process which comprises reacting a compound of formula LG\n2\n- Y with a compound of formula (VIII):\n\n\n\n\n\n\n\n\n(VIII)\n\n\nwherein Q, AIk\n1\n, Y, R\n1\n, R\n2\n and LG\n2\n are as defined above.\n\n\nThe reaction is conveniently effected at an elevated temperature in a suitable solvent, e.g. tetrahydrofuran, «-butanol or l-methyl-2-pyrrolidinone (NMP). The reaction may be performed in the presence of a suitable base, e.g. an organic base such as N,N- diisopropylethy lamine .\n\n\nThe intermediates of formula (VIII) wherein R\n2\n represents hydrogen may be prepared by treating a suitable compound of formula (III) above with potassium phthalimide; followed by treatment of the resulting compound with hydrazine. Alternatively, they may be prepared by treating a suitable compound of formula (III) above with sodium azide; followed by treatment of the resulting compound with triphenylphosphine.\n\n\nIn an additional procedure, the compounds of formula (I) wherein AIk\n1\n represents methylene and L\n1\n represents NR\n2\n may be prepared by a process which comprises reacting a compound of formula Y-N(H)R\n2\n with a compound of formula (IX):\n\n\n\n\n\n\n\n\n(IX) \n\n wherein Q, Y, R\n1\n and R\n2\n are as defined above; under reducing conditions.\n\n\nThe reaction is conveniently effected by stirring compound (IX) with a compound Y-N(H)R\n2\n at an elevated temperature in a suitable solvent, e.g. a cyclic ether such as tetrahydrofuran, in the presence of a reducing agent. A suitable reducing agent comprises a mixture of di-«-butyltin dichloride and phenylsilane.\n\n\nThe intermediates of formula (VIII) wherein AIk\n1\n represents methylene and R\n2\n represents Ci\n-6\n alkyl, e.g. methyl, may be prepared by treating a suitable compound of formula (IX) above with a Ci\n-6\n alkylamine, e.g. methylamine, in the presence of titanium(IV) rc-propoxide and a base, e.g. an organic base such as N,iV-diisopropylamine; followed by treatment of the resulting compound with a reducing agent, e.g. sodium triacetoxyborohydride .\n\n\nThe intermediates of formula (V) wherein AIk\n1\n represents methylene may be prepared from the corresponding compound of formula (IX) by treatment with a reducing agent, e.g. sodium borohydride.\n\n\nWhere they are not commercially available, the starting materials of formula (IV), (VI) and (IX) may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art. By way of illustration, the group R\n1\n may be introduced into the molecule by standard techniques, such as Suzuki conditions.\n\n\nIt will be understood that any compound of formula (I) initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula (I) by techniques known from the art. By way of illustration, a compound of formula (I) wherein the moiety Y is substituted by a halogen atom, e.g. chloro, may be converted into the corresponding compound wherein Y is substituted by amino (-NH\n2\n) by treatment with ammonia. Similarly, a compound of formula (I) wherein the moiety Y is substituted by a halogen atom, e.g. chloro, may be converted into the corresponding compound wherein Y is substituted by Ci\n-6\n alkylamino (e.g. methylamino or tert-butylamino), di(Ci\n-6\n)alkylamino (e.g. dimethylamino) or arylamino (e.g. phenyl- amino) by treatment with the appropriate Ci\n-6\n alkylamine (e.g. methylamine or tert- butylamine), di(Ci ^alkylamine (e.g. dimethylamine) or arylamine (e.g. aniline) respectively.\n\n\nWhere a mixture of products is obtained from any of the processes described above for the preparation of compounds according to the invention, the desired product can be \n\n _ _\n\n\nseparated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.\n\n\nWhere the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques. In particular, where it is desired to obtain a particular enantiomer of a compound of formula (I) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers. Thus, for example, diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (I), e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then be separated by any convenient means, for example by crystallisation, and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt. In another resolution process a racemate of formula (I) may be separated using chiral HPLC. Moreover, if desired, a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above. Alternatively, a particular enantiomer may be obtained by performing an enantiomer-specifϊc enzymatic biotransformation, e.g. an ester hydrolysis using an esterase, and then purifying only the enantiomerically pure hydrolysed acid from the unreacted ester antipode. Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.\n\n\nDuring any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3\nrd\n edition, 1999. The protecting groups may be removed at any convenient subsequent stage utilising methods known from the art.\n\n\nThe following Examples illustrate the preparation of compounds according to the invention.\n\n\nThe compounds in accordance with this invention potently inhibit the activity of human PI3Kα and/or PI3Kβ and/or PI3Kγ and/or PI3Kδ. \n\n Enzyme Inhibition Assays\n\n\nMeasurement of the ability of compounds to inhibit the lipid kinase activity of the four class 1 PD kinase isoforms (α, β, γ and δ) was performed using a commercially available homogeneous time-resolved fluorescence assay as described by Gray et al., Anal. Biochem., 2003, 313, 234-245, according to the manufacturer's instructions (Upstate). All assays were performed at 2 μM ATP and a concentration of purified class 1 PI3 kinase known to generate product within the linear range of the assay. Dilutions of inhibitor in DMSO were added to the assay and compared with assays run in the presence of 2% (v/v) DMSO alone (100% activity). The concentration of inhibitor required to inhibit the enzyme activity by 50% is quoted as the IC\n5O\n-\n\n\nWhen tested in the above assay, the compounds of the accompanying Examples were all found to possess IC\n50\n values for inhibition of activity of human PI3Kα and/or PI3Kβ and/or PI3Kγ and/or PDKδ of 50 μM or better.\n\n\nEXAMPLES\n\n\nAbbreviations\n\n\nDCM: dichloromethane DME: ethylene glycol dimethyl ether\n\n\nDMF: N,N-dimethylformamide DMSO: dimethylsulfoxide\n\n\nEt\n2\nO: diethyl ether EtOAc: ethyl acetate\n\n\nMeCN: acetonitrile MeOH: methanol\n\n\nPd(PPh\n3\n )\n4\n : tetrakis(triphenylphosphine)palladium(0) br: broad h: hour\n\n\nM: mass r.t.: room temperature\n\n\nRT: retention time SiO\n2\n: silica\n\n\nES+: electrospray positive ionisation\n\n\nHPLC: high performance liquid chromatography\n\n\nLCMS: liquid chromatography mass spectrometry\n\n\nAnalytical Conditions\n\n\nAll NMRs were obtained either at 300 MHz or 400 MHz. Compounds were named with the aid of Beilstein Autonom. \n\n All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen atmosphere using dried solvents and glassware. Degassing was performed by bubbling nitrogen through the reaction mixture.\n\n\nCompounds that required preparative HPLC were purified using Method 1.\n\n\nMethod 1: Phenomenex Luna C 18(2) 250 x 21.2 mm, 5 μm column. Mobile phase A: 99.92% water, 0.08% formic acid. Mobile phase B: 99.92% MeCN, 0.08% formic acid. Gradient program (flow rate 25.0 rnL/min), column temperature: ambient, variable gradient.\n\n\nThe analytical method used for LCMS was Method 2 below.\n\n\nMethod 2: Phenomenex Luna C 18(2) 100 x 4.6 mm, 5 μm column. Mobile phase A: 99.92% water, 0.08% formic acid. Mobile phase B: 99.92% MeCN, 0.08% formic acid.\n\n\nGradient program (flow rate 3.0 niL/min, column temperature 35°C):\n\n\nTime A % B %\n\n\n0.00 95.0 5.0\n\n\n4.40 5.0 95.0\n\n\n5.30 5.0 95.0\n\n\n5.32 95.0 5.0\n\n\n6.50 95.0 5.0\n\n\nINTERMEDIATE 1\n\n\n5-Phenylthieno[3,2-61pyridine-6-carbaldehvde\n\n\nTo a solution of 5-chlorothieno[3,2-Z>]pyridine-6-carbaldehyde (396 mg, 2.01 mmol) in DME/water (10 mL/2 mL) was added phenylboronic acid (306 mg, 2.51 mmol), K\n2\nCO\n3\n (833 mg, 6.03 mmol) and Pd(PPh\n3\n)\n4\n (1 16 mg, 0.1 mmol). The mixture was degassed before being heated in a sealed tube at 100\n0\nC for 5 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (25 mL), washed with water (2 x 10 mL) and washed with brine (10 mL). The organic layer was separated, dried (MgSO\n4\n), filtered and the solvent removed in vacuo. The residue was purified by column chromatography (SiO\n2\n, 0-40% EtOAc in heptane) to give the title compound (416 mg, 86%) as a white solid. δ\nH\n (CDCl\n3\n) 10.15 (s, IH), 8.88 (s, IH), 8.97 (d, J6 Hz, IH), 7.69 \n\n _\n\n\n(d, J 6 Hz, IH), 7.50-7.65 (m, 5H). LCMS (ES+) 240.2 (M+H)\n+\n, RT 3.46 minutes (Method 2).\n\n\nINTERMEDIATE 2\n\n\n(5-Phenylthieno[3,2-61pyridin-6-yl)methanol\n\n\nTo a solution of Intermediate 1 (416 mg, 1.74 mmol) in DCM/MeOH (7.5 niL/2.5 mL) was added NaBH\n4\n (87 mg, 2.26 mmol) and the mixture stirred at r.t. for 2 h. 2M Aqueous NaOH (5 mL) was added and the organic phase separated. The aqueous layer was extracted with DCM (5 mL). The organic layers were combined, washed with water (2 x 5 mL), dried (MgSO\n4\n), filtered and concentrated in vacuo to give the title compound (416 mg, 99%) as a white solid. δ\nH\n (CDCl\n3\n) 8.28 (s, IH), 7.70 (d, J6 Hz, IH), 7.53 (d, J 6 Hz, IH), 7.30-7.45 (m, 5H), 4.57 (s, 2H), 3.83 (br s, IH). LCMS (ES+) 242.2 (M+H)\n+\n, RT 2.17 minutes (Method 2).\n\n\nINTERMEDIATE 3\n\n\n6-Bromomethyl-5-phenylthieno[3,2-Z>1pyridine\n\n\nTo a solution of Intermediate 2 (416 mg, 1.73 mmol) in DCM (10 mL) was added phosphorus tribromide (0.81 mL, 8.63 mmol) and the reaction mixture was stirred at r.t. for 5 h. The mixture was neutralised by the cautious addition of saturated aqueous NaHCO\n3\n solution and the aqueous layer extracted with DCM (2 x 15 mL). The combined organic layers were washed with water (15 mL), separated, dried (MgSO\n4\n), filtered and concentrated in vacuo to give the title compound (586 mg, quantitative) as a white solid. δ\nH\n (CDCl\n3\n) 8.39 (s, IH), 7.83 (d, J6 Hz, IH), 7.65-7.69 (m, 2H), 7.60 (d, J6 Hz, IH), 7.44-7.55 (m, 3H), 4.63 (s, 2H). LCMS (ES+) 304.1, 306.1 (M+H)\n+\n, RT 3.94 minutes (Method 2).\n\n\nEXAMPLE 1\n\n\n6-(5-Phenylthienor3,2-61pyridin-6-ylmethylsulfanyl)-9H-purine\n\n\nTo a solution of Intermediate 3 (293 mg, 0.96 mmol) in dry DMF (15 mL) under nitrogen at r.t. was added K\n2\nCO\n3\n (140 mg, 1.01 mmol) and 6-mercaptopurine (172 mg, \n\n 1.01 mmol). The reaction mixture was stirred at r.t. for 5 h and partitioned between EtOAc (50 rnL) and water (20 niL). A white precipitate formed in the aqueous layer and this was collected by filtration, washed with water, washed with Et\n2\nO and dried in a vacuum oven to give the title compound (183 mg, 52%) as a white solid. 5\nH\n (DMSO-d\n6\n) 13.50 (br s, IH), 8.73 (s, IH), 8.64 (s, IH), 8.41 (s, IH), 8.18 (d, J6 Hz, IH), 7.43-7.68 (m, 6H), 4.77 (s, 2H). LCMS (ES+) 376.1 (M+H)\n+\n, RT 2.71 minutes {Method 2).\n\n\nEXAMPLE 2\n\n\n4-Methyl-6-(5-phenylthieno[3,2-61pyridin-6-ylmemoxy)pyrimidin-2-ylamine\n\n\nTo a suspension of sodium hydride (48 mg, 1.20 mmol, 60% dispersion in mineral oil) was added 2-amino-4-hydroxy-6-methylpyrimidine (133 mg, 1.06 mmol). After stirring at r.t. for 0.5 h, addition of a solution of Intermediate 3 (293 mg, 0.96 mmol) in DMF (10 mL) took place. The reaction mixture was heated at 100\n0\nC for 2 h. Water (10 mL) was added and mixture extracted with EtOAc (50 mL). The organic layer was washed with water (3 x 25 mL), washed with brine (25 mL), separated, dried (MgSO\n4\n), filtered and the solvent removed in vacuo. Purification was by preparative HPLC (Method 1). The fractions containing the desired product were combined, neutralised with aqueous NaHCO\n3\n solution and concentrated in vacuo. The residue was redissolved in water (20 mL) and extracted with DCM (2 x 15 mL). The organic layers were combined, washed with water (10 mL), separated, dried (MgSO\n4\n), filtered and the solvent removed in vacuo to give the title compound (34 mg, 9%) as a white solid. 6\nH\n (CDCl\n3\n) 8.40 (s, IH), 7.80 (d, J6 Hz, IH), 7.58-7.62 (m, 3H), 7.42-7.50 (m, 3H), 6.00 (s, IH), 5.40 (s, 2H), 4.90 (s, 2H), 2.26 (s, 3H). LCMS (ES+) 349.1 (M+H)\n+\n, RT 1.93 minutes (Method 2)."
  },
  {
    "id": "WO2010048191A1",
    "text": "Thioamide compounds, method of making and method of using thereof AbstractThe present invention relates to novel thioamide derivatives of formula (I) and formula (Ia): wherein, R3, R4, R5, R6, R7, P, Q, T, V, W, X, Y, Z, a, m and n are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides. Claims\n\n\n\n\nPATENT MER 08-116PCTCLAIMSWhat is claimed is:\n\n\n\n\n1. A thioamide compound of formula (I) or formula (Ia):\n\n\n\n\n\n\n\n\n(I) (Ia)\n\n\nwherein\n\n\nR\n1\n, R\n2\n, R\n8\n, R\n9\n, R-io and R\n11\n, independently of one another, are hydrogen, cyano, nitro, halogen, C\n1\n-C\n6\n- alkyl, C\n3\n-C\n7\n-cycloalkyl, halo-CrCe-alkyl, CrCe-alkylthio, halo CrCe-alkylthio, CrCe-alkylsulfinyl, halo C\n1\n- C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, halo C-ι-C\n6\n-alkylsulfonyl, SF\n5\n, arylthio, C-ι-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-C-ι-C\n6\n-alkoxy, C-ι-C\n6\n-alkylcarbonyl, halo-C-ι-C\n6\n-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo- C-|-C\n6\n-alkylsulfinyl, C-|-C\n6\n-alkylsulfonyl, C-|-C\n6\n-alkylamino, di(C-|-C\n6\n-alkyl)amino, unsubstituted or substituted aryl, or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C\n1\n-C\n6\n- alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C\n1\n- C\n6\n-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, halo-C-i-C\n6\n-alkylsulfonyl, SF\n5\n, and methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n5\n, independently of one another, are hydrogen, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl; C\n3\n-C\n7\n- cycloalkyl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of halogen and C-rC\n6\n-alkyl; and phenyl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C\n1\n-C\n6\n- alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Cε-alkylcarbonyl, 1IaIo-C\n1\n-C\n6\n- alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, halo-C-i-Ce-alkylsulfonyl, SF\n5\n, C-ι-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino;\n\n\nor R\n4\n and R\n5\n together signify C\n2\n-C\n6\n-alkylene;  PATENT MER 08-116PCT\n\n\nR\n6\n is hydrogen, Ci-C\n6\n-alkyl, Ci-C\n6\n-alkoxy- Ci-C\n6\n-alkyl, C-i-Cβ-alkylcarbonyl, Ci-Cβ-alkylthiocarbonyl or benzyl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-|-C\n6\n-alkyl, 1IaIo-C\n1\n-C\n6\n- alkyl, C-rC\n6\n-alkylthio, halo-C-i-Cβ-alkylthio, arylthio, C-rC\n6\n-alkoxy, halo-C-i-Cβ-alkoxy, d-Cβ-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C-i-Cβ-alkylsulfinyl, halo-C-i-Cβ-alkylsulfinyl, C-i-Cβ-alkylsulfonyl, 1IaIo-C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, C-i-Cβ-alkylamino, and di(C-ι-C\n6\n-alkyl)amino;\n\n\nR\n7\n is hydrogen, C-τC\n6\n-alkyl, C-τC\n6\n-alkoxy- C-τC\n6\n-alkyl, d-Cβ-alkylcarbonyl, C-i-Cβ-alkylthiocarbonyl, phenyl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, Ci-C\n6\n-alkyl, 1IaIo-C\n1\n-C\n6\n- alkyl, C-rC\n6\n-alkylthio, halo-C-pCe-alkylthio, arylthio, C-|-C\n6\n-alkoxy, halo-C-rC\n6\n-alkoxy, C-pCe-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, SF\n5\n, C\n1\n-C\n6\n- alkylamino, and di(C-ι-C\n6\n-alkyl)amino; heteroaryl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C\n1\n-C\n6\n- alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Ce-alkylcarbonyl, halo-C-i-Cε-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-ι-C\n6\n- alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, SF\n5\n, C-ι-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino; or naphtyl or quinlyl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-|-C\n6\n-alkyl, halo-C-|-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Cβ-alkylcarbonyl, halo- C-ι-C\n6\n-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, C-ι-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino;\n\n\nP is C-R\n1\n or N;\n\n\nQ is C-R\n2\n or N;\n\n\nV is C-R\n8\n or N;\n\n\nW is C-R\n9\n or N;\n\n\nX is C-R\n10\n Or N;\n\n\nY is C-R\n11\n or N;\n\n\nZ is a direct bond, C(O), C(S) or S(O)\nP\n;\n\n\nT is independently O, S or N; a is 1 , 2 or 3; and\n\n\nP is 1 or 2.\n\n\n\n\n\n\n2. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nP and Q is N; V is C-R\n8\n;  PATENT MER 08-116PCT\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY Js C-R\n11\n;\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are cyano, nitro, halogen, C-ι-C\n6\n-alkyl, C\n3\n-C\n7\n- cycloalkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo C-ι-C\n6\n-alkylthio, C-ι-C\n6\n-alkylsulfinyl, halo C\n1\n-C\n6\n- alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, halo C-ι-C\n6\n-alkylsulfonyl, SF\n5\n, arylthio, C-ι-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-C-i- C\n6\n-alkoxy, C-i-Cβ-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, C-i-Ce-alkylamino, CIi(C\n1\n-C\n6\n- alkyl)amino, unsubstituted or substituted aryl or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, Ci-C\n6\n-alkyl, halo-C-pCe-alkyl, C-rC\n6\n-alkylt.hio, halo-C\nr\n C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Cβ-alkylcarbonyl, halo-C-ι-C\n6\n- alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, halo-C-ι-C\n6\n- alkylsulfonyl, SF\n5\n, and methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n are H;\n\n\nR\n5\n is methyl or C-ι-C\n3\n-alkyl;\n\n\nR\n7\n is unsubstituted or substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-|-C\n6\n-alkyl, halo-C-p C\n6\n-alkyl, C-|-C\n6\n-alkylthio, halo-C-|-C\n6\n-alkylthio, arylthio, C-|-C\n6\n-alkoxy, halo-C-|-C\n6\n-alkoxy, C\n1\n-C\n6\n- alkylcarbonyl, halo-C-i-Ce-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-ι-C\n6\n-alkylsulfinyl, C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, C-ι-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino; unsubstituted or substituted heteroaryl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Ce-alkylcarbonyl, 1IaIo-C\n1\n-C\n6\n- alkylcarbonyl, C-rC\n6\n-alkylsulfinyl, halo-C-pCe-alkylsulfinyl, C-rC\n6\n-alkylsulfonyl, SF\n5\n, C\n1\n-C\n6\n- alkylamino, and di(C\n1\n-C\n6\n-alkyl)amino; or unsubstituted or substituted naphthyl or quinolyl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-i-Cε-alkoxy, C-i-Cβ-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-ι-C\n6\n- alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, C-ι-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino;\n\n\nZ is a direct bond, C(O), C(S) or S(O)\nP\n; and a is 1.\n\n\n\n\n\n\n3. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nP and Q is N;  PATENT MER 08-116PCT\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY Js C-R\n11\n;\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, is cyano, nitro, halogen, C-ι-C\n6\n-alkyl, C\n3\n-C\n7\n- cycloalkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo C-ι-C\n6\n-alkylthio, C-ι-C\n6\n-alkylsulfinyl, halo C\n1\n-C\n6\n- alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, halo C-ι-C\n6\n-alkylsulfonyl, SF\n5\n, arylthio, C-ι-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-C-i- C\n6\n-alkoxy, C-i-Cε-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, C\"rC\n6\n-alkylamino, di(C\n1\n- C\n6\n-alkyl)amino, unsubstituted or substituted aryl or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Cβ-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, halo-C-i-Cβ-alkylsulfonyl, SF\n5\n, and methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl or C-ι-C\n3\n-alkyl;\n\n\nR\n7\n is unsubstituted or substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-|-C\n6\n-alkyl, halo-C-p C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C\n1\n-C\n6\n- alkylcarbonyl, halo-C-i-Ce-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-ι-C\n6\n-alkylsulfinyl, C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, C-ι-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino; unsubstituted or substituted heteroaryl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo- C-rC\n6\n-alkylthio, arylthio, C\n1\n-C^aIkOXy, halo-C-rC\n6\n-alkoxy, C-pCe-alkylcarbonyl, 1IaIo-C\n1\n-C\n6\n- alkylcarbonyl, C-rC\n6\n-alkylsulfinyl, halo-C-pCe-alkylsulfinyl, C-rC\n6\n-alkylsulfonyl, SF\n5\n, C\n1\n-C\n6\n- alkylamino, and di(C-ι-C\n6\n-alkyl)amino;\n\n\nZ is C(O);\n\n\nT is independently O, S or N; and a is 1.\n\n\n\n\n\n\n4. The compound of claim 1 , wherein the compound has formula (I) , and wherein:\n\n\nP and Q is N;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY is C-R\n11\n;  PATENT MER 08-116PCT\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, is cyano, nitro, halogen, C-ι-C\n6\n-alkyl, C\n3\n-C\n7\n- cycloalkyl, halo-C-|-C\n6\n-alkyl, C-|-C\n6\n-alkylthio, halo C\n1\n-C\n6\n-alkylthio, C-|-C\n6\n-alkylsulfinyl, halo C\n1\n-C\n6\n- alkylsulfinyl, C-|-C\n6\n-alkylsulfonyl, halo C-|-C\n6\n-alkylsulfonyl, SF\n5\n, arylthio, C-|-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-C-ι-C\n6\n-alkoxy, C-i-Cβ-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, C-i-Ce-alkylamino, di(C\n1\n- C\n6\n-alkyl)amino, unsubstituted or substituted aryl or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Cβ-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-pCe-alkylsulfinyl, C-rC\n6\n-alkylsulfonyl, halo-C-pCe-alkylsulfonyl, SF\n5\n, and methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nR\n7\n is unsubstituted or substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-i- C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C\n1\n-C\n6\n- alkylcarbonyl, halo-C-i-Ce-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, C-|-C\n6\n-alkylamino, and di(C-|-C\n6\n-alkyl)amino; unsubstituted or substituted heteroaryl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-ι-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo- C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-i-Ce-alkylcarbonyl, 1IaIo-C\n1\n-C\n6\n- alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-C-ι-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, SF\n5\n, C\n1\n-C\n6\n- alkylamino, and di(C-ι-C\n6\n-alkyl)amino;\n\n\nZ is C(O) a is 1 ; m and n are independently 0 or 1.\n\n\n\n\n\n\n5. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n1\n, R\n2\n, R\n8\n, Rg, R\n1O\n and R\n11\n, independently of one another, is hydrogen, cyano, halogen, halomethyl or methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl or C-ι-C\n3\n-alkyl;\n\n\nP is C-R\n1\n or N;\n\n\nQ is C-R\n2\n or N;\n\n\nV is C-R\n8\n or N;\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n;  PATENT MER 08-116PCT\n\n\nY is C-Rn or N; T is O or S;\n\n\nZ is C(O); and a is 1.\n\n\n\n\n\n\n6. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n1\n, R\n2\n, Rs, Rg, Rio and R\n11\n, independently of one another, is hydrogen, cyano, chloro or trifluoromethyl; R\n3\n, R\n4\n and R\n6\n is H; R\n5\n is methyl; P is C-R\n1\n or N;\n\n\nQ is C-R\n2\n or N;\n\n\nY is C-R\n8\n or N; W is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY is C-R\n11\n or N; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-|-C\n6\n-alkyl, halo-C-p C\n6\n-alkyl, C-|-C\n6\n-alkylthio, halo-C-|-C\n6\n-alkylthio, arylthio, C-|-C\n6\n-alkoxy, halo-C-|-C\n6\n-alkoxy, C-pCe-alkylcarbonyl, 1IaIo-C\n1\n-C\n6\n- alkylcarbonyl, and a is 1.\n\n\n\n\n\n\n7. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, is hydrogen, cyano, chloro or trifluoromethyl; R\n3\n, R\n4\n and R\n6\n is H; R\n5\n is methyl; P is N;\n\n\nQ is N;\n\n\nY is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY Js C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halogen, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, C-ι-C\n6\n-alkoxy, and halo-C-ι-C\n6\n-alkoxy, and a is 1.  PATENT MER 08-116PCT\n\n\n\n\n\n\n8. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, is hydrogen, cyano, chloro or trifluoromethyl; R\n3\n, R\n4\n and R\n6\n is H; R\n5\n is methyl; P is N;\n\n\nQ is N;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY Js C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-ι-C\n6\n-alkylthio and halo-C-ι-C\n6\n-alkoxy, and a is 1.\n\n\n\n\n\n\n9. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n1\n, R\n8\n, R\n9\n, R\n10\n and R\n11\n, independently of one another, is hydrogen, cyano, chloro, triifluoromethyl or methylamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is C-R\n1\n or N;\n\n\nV is C-R\n8\n or N; W is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY is C-R\n11\n or N; Z is C(O);\n\n\nT is O;\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-i- C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo-C-ι-C\n6\n-alkylthio, arylthio, C-ι-C\n6\n-alkoxy, halo-C-ι-C\n6\n-alkoxy, C-ι-C\n6\n-alkylcarbonyl, halo-C-ι-C\n6\n- alkylcarbonyl, and a is 1.\n\n\n\n\n\n\n10. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n9\n, R\n10\n and R\n11\n, independently of one another, are hydrogen, cyano, chloro, bromo, methyl or trifluoromethyl;  PATENT MER 08-116PCT\n\n\nR\n3\n, R\n4\n and R\n6\n are H;\n\n\nR\n2\n is H, chloro, bromo or C-|-C\n6\n-alkoxy;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nQ is C-R\n2\n;\n\n\nV is N;\n\n\nW is C-R\n9\n; \n \n\n\nY Js C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-ι-C\n6\n-alkylthio and halo-C-ι-C\n6\n-alkoxy, and a is 1.\n\n\n\n\n\n\n11. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, chloro, bromo, methyl or trifluoromethyl;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n2\n is H, chloro, bromo or C-|-C\n6\n-alkoxy;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nQ is C-R\n2\n;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY Js C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-ι-C\n6\n-alkylthio and halo-C-ι-C\n6\n-alkoxy, and a is 1.\n\n\n\n\n\n\n12. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n9\n, R\n10\n and R\n11\n, independently of one another, is hydrogen, cyano, chloro , bromo, methyl or trifluoromethyl;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nQ is N;  PATENT MER 08-116PCT\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY Js C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-ι-C\n6\n-alkylthio and halo-C-ι-C\n6\n-alkoxy, and a is 1.\n\n\n\n\n\n\n13. The compound of claim 1 , wherein the compound has formula (I), and wherein: R\n9\n, R\n10\n and R\n11\n, independently of one another, are hydrogen, chloro, bromo or methyl; R\n3\n, R\n4\n and R\n6\n are H;\n\n\nR\n2\n is H, chloro, bromo or methoxy; R\n5\n is methyl; P is N;\n\n\nQ is C-R\n2\n;\n\n\nV is N;\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY is C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-ι-C\n6\n-alkylthio and halo-C-ι-C\n6\n-alkoxy, and a is 1.\n\n\n\n\n\n\n14. The compound of claim 1 , wherein the compound has formula (I), and wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, chloro, bromo, methyl or trifluoromethyl;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n2\n is H, chloro, bromo, methoxy, ethoxy, propoxy or butoxy;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nQ is C-R\n2\n;\n\n\nV is C-R\n8\n;\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY Js C-R\n11\n;\n\n\nZ is C(O);  PATENT MER 08-116PCT\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-|-C\n6\n-alkylthio and halo-C-|-C\n6\n-alkoxy, and a is 1.\n\n\n\n\n\n\n15. The compounds of claim 1 , wherein for the compounds of formula (Ia):\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, is hydrogen, cyano, chloro, trifluoromethyl or methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY Js C-R\n11\n; Z is C(O); T is O;\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halogen, C\n1\n-C\n6\n-alkylthio, halo-C-|-C\n6\n-alkylthio, C-|-C\n6\n-alkoxy, and halo-C-|-C\n6\n-alkoxy, and a is 1.\n\n\n\n\n\n\n16. The compounds of claim 1 , wherein for the compounds of formula (Ia):\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, is hydrogen, cyano, chloro, trifluoromethyl or methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY Js C-R\n11\n; Z is C(O); T is O;\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-ι-C\n6\n-alkylthio and halo-C-ι-C\n6\n-alkoxy, and a is 1.  PATENT MER 08-116PCT\n\n\n\n\n\n\n17. A method of producing the compounds of claim 1 , wherein the compound of formula (I) are produced by a process which comprises:\n\n\n(i) reacting a compound of formula (II)\n\n\n\n\n\n\n\n\n(H) is with ammonium sulfide or sodium hydrosulfide wherein R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, P, Q, V, W, X, Y, Z, a, are as defined above for the compounds of formula (I); and wherein the compounds of formula (Ia) are produced by a process which comprises\n\n\n(ii) reacting a compound of formula (Ma)\n\n\n\n\n\n\n\n\n(Ma) with ammonium sulfide wherein R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, P, Q, V, W, X, Y, Z, a, are as defined above for the compounds of formula (Ia) in a solvent with or without the presence of base.\n\n\n\n\n\n\n18. A method of treating an animal against endoparasitic infection by administering an endoparasiticidally effective amount of the compound of claim 1 to an animal in need thereof.\n\n\n\n\n\n\n19. The method of claim 13, wherein the endoparasitic infection is a helminth.\n\n\n\n\n\n\n20. The method of claim 14, wherein the helminth is Haemonchus contortus. Description\n\n\n\n\n PATENT MER 08-116PCT\n\n\nTITLE OF THE INVENTION\n\n\nTHIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF\n\n\nINCORPORATION BY REFERENCE\n\n\nThis application claims the benefit of U.S. Provisional Application No. 61/107,114, which is incorporated herein by reference in its entirety.\n\n\nAny foregoing applications and all documents cited therein or during their prosecution\n\n\n(\"application cited documents\") and all documents cited or referenced in the application cited documents, and all documents cited or referenced herein (\"herein cited documents\"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.\n\n\nFIELD OF THE INVENTION\n\n\nThe present invention relates to novel thioamide derivatives of formula (I) and (Ia):\n\n\n\n\n\n\n\n\n(I) (Ia) wherein, R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, P, Q, T, V, W, X, Y, Z, a, m and n are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.\n\n\nBACKGROUND OF THE INVENTION\n\n\nThe control of parasites, particularly endoparasites which parasitize animals, by means of active material having a cyanoethylamide group has been described by many patents or patent application such as International Patent Publications No. WO 2002/049641 , WO 2003/097036, WO 2003/097585, WO 2003/104187, WO 2004/000793, WO 2005/044784, WO 2005/05802, WO 2005/121075 and WO 2006/043654 as well as in EP 953565 (U.S. Patent 6,239,077) and EP 1445251. \n\n PATENT MER 08-116PCT\n\n\nNovel aryl-azol-2-yl-cyanoethylamide derivatives of the formula:\n\n\n\n\n\n\n\n\nare described in US 2003/0312272 A1 to Soil et al., which is hereby incorporated by reference in . However, none of the foregoing publications describe the compounds of formula (I) or formula\n\n\n(Ia), the method of making or the method of using possess activity as pesticides, particularly for controlling endoparasitic pests in animals.\n\n\nOBJECTS AND SUMMARY OF THE INVENTION\n\n\nThe present invention relates to novel thioamide derivatives of formula (I) and (Ia):\n\n\n\n\n\n\n\n\n(I) (Ia)\n\n\nwherein: R\n1\n, R\n2\n Rs, R\n9\n, R-io and R\n11\n, independently of one another, are hydrogen, cyano, nitro, halogen, alkyl, cycloalkyl, haloalkyl, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, SF\n5\n, arylthio, alkoxy, cycloalkyloxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, alkylamino, di(alkyl)amino, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, or SF\n5\n;\n\n\nR\n3\n, R\n4\n and R\n5\n, independently of one another, are hydrogen, halogen, alkyl, haloalkyl; unsubstituted or substituted cycloalkyl, wherein the substituents may each be independent of one another and are selected from the group consisting of halogen and alkyl; unsubstituted or substituted aryl, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, SF\n5\n, alkylamino, di(alkyl)amino; or \n\n PATENT MER 08-116PCT\n\n\nR\n4\n and R\n5\n together with the carbon to which they are attached form a cycloalkyl ring;\n\n\nR\n6\n is hydrogen, alkyl, alkoxyalkyl, alkylcarbonyl, alkylthiocarbonyl or unsubstituted or substituted benzyl, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, SF\n5\n, alkylamino, di(alkyl)amino;\n\n\nR\n7\n is hydrogen, alkyl, alkoxyalkyl, alkylcarbonyl, alkylthiocarbonyl, unsubstituted or substituted aryl, including phenyl and naphthyl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, SF\n5\n, alkylamino, di(alkyl)amino; unsubstituted or substituted heteroaryl, including quinolyl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, SF\n5\n, alkylamino, dι(alkyl)amιno;\n\n\nP is C-R\n1\n or N;\n\n\nQ is C-R\n2\n Or N;\n\n\nV is C-R\n8\n or N;\n\n\nW is C-R\n9\n or N;\n\n\nX is C-R\n10\n Or N;\n\n\nY is C-R\n11\n or N;\n\n\nT is O, S or NH;\n\n\nZ is a direct bond, C(O), C(S) or S(O)\nP\n; a is 1 , 2 or 3; and\n\n\nP is 1 or 2.\n\n\nIt is an object of the present invention to provide new pesticidal compounds of the thioamide derivatives of formula (I) and (Ia) together with processes for their preparation. A second object of the present invention is to provide pesticidal compositions and pesticidal methods of use of the pesticidal thioamide derivatives of formula (I) and (Ia) in the field of pest control which are well tolerated by warm-blooded species, fish and plants, including in particular for controlling endo- and ectoparasites which parasitize animals.\n\n\nAnother object of the present invention is to provide compounds with high activity and improved safety to the user and the environment, which are obtained by optimization of chemical, physical and biological properties such as solubility, melting point, stability, electronic and steric parameters, and the like.\n\n\nFor the purposes of this application, unless otherwise stated in the specification, the following terms have the definitions cited below. \n\n PATENT MER 08-116PCT\n\n\n(1 ) Alkyl refers to both straight and branched carbon chains; references to individual alkyl groups are specific for the straight chain (e.g. butyl = n-butyl). In one embodiment of alkyl, the number of carbons atoms is 1-20, in another embodiment of alkyl, the number of carbon atoms is 1-8 carbon atoms and in yet another embodiment of alkyl, the number of carbon atoms is 1-4 carbon atoms. Other ranges of carbon numbers are also contemplated depending on the location of the alkyl moiety on the molecule,\n\n\n(2) Alkenyl refers to both straight and branched carbon chains which have at least one carbon- carbon double bond. In one embodiment of alkenyl, the number of double bonds is 1-3, in another embodiment of alkenyl, the number of double bonds is one. In one embodiment of alkenyl, the number of carbons atoms is 2-20, in another embodiment of alkenyl, the number of carbon atoms is 2- 8 and in yet another embodiment of alkenyl, the number of carbon atoms is 2-4 Other ranges of carbon-carbon double bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the molecule;\n\n\n(3) Alkynyl refers to both straight and branched carbon chains which have at least one carbon- carbon triple bond. In one embodiment of alkynyl, the number of triple bonds is 1-3; in another embodiment of alkynyl, the number of triple bonds is one. In one embodiment of alkynyl, the number of carbons atoms is 2-20, in another embodiment of alkynyl, the number of carbon atoms is 2-8 and in yet another embodiment of alkynyl, the number of carbon atoms is 2-4. Other ranges of carbon- carbon double bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the molecule;\n\n\n(4) Aryl refers to a C\n6\n-C\n14\n aromatic carbocyclic ring structure having a single ring or multiple fused rings. Aryl groups include, but are not limited to, phenyl, biphenyl, and naphthyl. In some embodiments aryl includes tetrahydronapthyl, phenylcyclopropyl and indanyl. Aryl groups may be unsubstituted or substituted by one or more moieties selected from halogen, cyano, nitro, hydroxy, mercapto, amino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, halocycloalkenyl, alkoxy, alkenyloxy, alkynyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, cycloalkoxy, cycloalkenyloxy, halocycloalkoxy, halocycloalkenyloxy, alkylthio, haloalkylthio, arylthio, cycloalkylthio, halocycloalkylthio, alkylsulfinyl, alkenylsulfinyl, alkynyl-sulfinyl, haloalkylsulfinyl, haloalkenylsulfinyl, haloalkynylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, haloalkyl-sulfonyl, haloalkenylsulfonyl, haloalkynylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkylamino, alkenylamino, alkynylamino, di(alkyl)amino, di(alkenyl)-amino, di(alkynyl)amino, or SF\n5\n \n\n\n(5) Alkoxy refers to -O-alkyl, wherein alkyl is as defined in (1 );\n\n\n(6) Alkanoyl refers to formyl (-C(=O)H) and -C(=O)-alkyl, wherein alkyl is as defined in (1 );\n\n\n(7) Alkanoyloxy refers to -O-C(=O)-alkyl, wherein alkanoyl is as defined in (6); (8) Alkanoylamino refers to -NH\n2\n-C(=O)-alkyl, wherein alkanoyl is as defined in (6) and the amino (NH\n2\n) moiety can be substituted by alkyl as defined in (1 );\n\n\n(9) Aminocarbonyl refers to -NH\n2\n-C(=O), wherein the amino (NH\n2\n) moiety can be substituted by alkyl as defined in (1 );\n\n\n(10) Alkoxycarbonyl refers to -C(=O)-O-alkyl, wherein alkoxy is as defined in (5); (11 ) Alkenoyl refers to -C(=O)-alkenyl, wherein alkenyl is as defined in (2); \n\n PATENT MER 08-116PCT\n\n\n(12) Alkynoyl refers to -C(=O)-alkynyl, wherein alkynyl is as defined in (3);\n\n\n(13) Aroyl refers to -C(=O)-aryl, wherein aryl is as defined above;\n\n\n(14) Cyclo as a prefix (e.g. cycloalkyl, cycloalkenyl, cycloalkynyl) refers to a saturated or unsaturated cyclic ring structure having from three to eight carbon atoms in the ring the scope of which is intended to be separate and distinct from the definition of aryl above. In one embodiment of cyclo, the range of ring sizes is 4-7 carbon atoms, in another embodiment of cyclo the range of ring sizes is 3-4. Other ranges of carbon numbers are also contemplated depending on the location of the cyclo- moiety on the molecule;\n\n\n(15) Halogen means the atoms fluorine, chlorine, bromine and iodine. The designation of \"halo\" (e.g. as illustrated in the term haloalkyl) refers to all degrees of substitutions from a single substitution to a perhalo substitution (e g. as illustrated with methyl as chloromethyl (-CH\n2\nCI), dichloromethyl (- CHCI\n2\n), trichloromethyl (-CCI\n3\n));\n\n\n(16) Heterocycle, heterocyclic or heterocyclo refer to fully saturated or unsaturated, cyclic groups, for example, 4 to 7 membered monocyclic, 7 to 1 1 membered bicyclic, or 10 to 15 membered tricyclic ring systems, which have at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1 , 2, 3 or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system. (17) Heteroaryl refers to a monovalent aromatic group of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, having one or more oxygen, nitrogen, and sulfur heteroatoms within the ring, preferably 1 to 4 heteroatoms, or 1 to 3 heteroatoms. The nitrogen and sulfur heteroatoms may optionally be oxidized. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple fused rings provided that the point of attachment is through a heteroaryl ring atom. Preferred heteroaryls include pyridyl, piridazinyl, pyrimidinyl, triazinyl, pyrrolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinnyl, furanyl, thiophenyl, furyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyrazolyl, benzofuranyl, and benzothiophenyl. Heteroaryl rings may be unsubstituted or substituted by one or more moieties as described for aryl above.\n\n\nExemplary monocyclic heterocyclic or heteroaryl groups also include pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyridinyl, pyrazinyl, pyridazinyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1 ,3-dioxolane and tetrahydro-1 , 1-dioxothienyl, triazolyl, and the like. Exemplary bicyclic heterocyclic or heteroaryl groups include indolyl, benzothiazolyl, benzoxazolyl, benzodioxolyl, benzothienyl, quinuclidinyl, tetra-hydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl]or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), tetrahydroquinolinyl and the like. \n\n PATENT MER 08-116PCT\n\n\nExemplary tricyclic heterocyclic or heteroaryl groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl and the like.\n\n\nUnless otherwise specifically noted or apparent by context, \"active agent\" or \"active ingredient\" or \"therapeutic agent\" as used in this specification, means a arylazol-2-yl-methylthiamide amido compound of the invention.\n\n\nThe compounds of the invention also are intended to encompass salt forms, racemic mixtures, specific stereoisomers, crystalline and amorphous forms of the compound.\n\n\nIt is further noted that the invention does not intend to encompass within the scope of the invention any previously disclosed product, process of making the product or method of using the product, which meets the written description and enablement requirements of the USPTO (35 U. S. C. 112, first paragraph) or the EPO (Article 83 of the EPC), such that applicant(s) reserve the right and hereby disclose a disclaimer of any previously described product, method of making the product or process of using the product.\n\n\nIt is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as \"comprises\", \"comprised\", \"comprising\" and the like can have the meaning attributed to it in U.S. Patent law, e.g., they can mean \"includes\", \"included\", \"including\", and the like; and that terms such as \"consisting essentially of\" and \"consists essentially of\" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention. These and other embodiments are disclosed or are apparent from and encompassed by, the following Detailed Description.\n\n\nDETAILED DESCRIPTION OF THE INVENTION\n\n\nA first aspect of the invention provides novel thioamide derivatives of formula (I) and (Ia):\n\n\n\n\n\n\n\n\n(I) (Ia)\n\n\nwherein\n\n\nRi , R\n2\n, Re, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, cyano, nitro, halogen, C\n1\n-C\n6\n- alkyl, C\n3\n-C\n7\n-cycloalkyl, halo-d-C\nβ\n-alkyl, d-C\ne\n-alkylthio, halo d-C\n6\n-alkylthio, d-C\n6\n-alkylsulfinyl, halo d-C\n6\n-alkylsulfinyl, d-C\n6\n-alkylsulfonyl, halo d-C\n6\n-alkylsulfonyl, SF\n5\n, arylthio, C-ι-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-CrC\n6\n-alkoxy, CrC\n6\n-alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, d-C\n6\n-alkylsulfinyl, halo-d-Cβ-alkylsulfinyl, d-Cβ-alkylsulfonyl, d-Cβ-alkylamino, di(d-C\ne\n-alkyl)amino, unsubstituted or substituted aryl, or unsubstituted or substituted aryloxy including phenoxy, or unsubstituted or substituted heteroaryl, whereby the substituents may each be independent of one another and are \n\n PATENT MER 08-116PCT selected from the group consisting of cyano, nitro, halogen, C\n1\n-C\n6\n-SIkYl, halo-C-ι-C\n6\n-alkyl, C\n1\n-C\n6\n- alkylthio, halo-Ci-C\n6\n-alkylthio, arylthio, d-C\n6\n-alkoxy, halo-d-C\n6\n-alkoxy, d-C\n6\n-alkylcarbonyl, halo-d- C\n6\n-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-d-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, 1IaIo-C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, and methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n5\n, independently of one another, are hydrogen, halogen, d-C\n6\n-alkyl, halo-d-C\n6\n-alkyl; C\n3\n- Cy-cycloalkyl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of halogen and d-C\n6\n-alkyl; and aryl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C\n1\n- C\n6\n-alkyl, halo-d-C\n6\n-alkyl, d-C\n6\n-alkylthio, halo-d-C\n6\n-alkylthio, arylthio, d-C\n6\n-alkoxy, 1IaIo-C\n1\n-C\n6\n- alkoxy, d-C\n6\n-alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, d-C\n6\n-alkylsulfinyl, halo-d-C\n6\n-alkylsulfinyl, C\n1\n- C\n6\n-alkylsulfonyl, halo-d-C\n6\n-alkylsulfonyl, SF\n5\n, d-Cβ-alkylamino, and di(C-ι-C\ne\n-alkyl)amino;\n\n\nor R\n4\n and R\n5\n together signify C\n2\n-C\n6\n-alkylene;\n\n\nR\n6\n is hydrogen, d-C\n6\n-alkyl, d-C\n6\n-alkoxy- CrC\n6\n-alkyl, Ci-C\n6\n-alkylcarbonyl, d-C\n6\n-alkylthiocarbonyl or benzyl that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, d-C\n6\n-alkyl, halo- d-ds-alkyl, d-C\n6\n-alkylthio, halo-d-C\n6\n-alkylthio, arylthio, d-C\n6\n-alkoxy, halo-d-C\n6\n-alkoxy, C\n1\n-C\n6\n- alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, d-C\n6\n-alkylsulfinyl, halo-C-ι-C\n6\n-alkylsulfinyl, C\n1\n-C\n6\n- alkylsulfonyl, halo-d-C\n6\n-alkylsulfonyl, SF\n5\n, d-C\n6\n-alkylamino, and di(C-|-C\n6\n-alkyl)amino;\n\n\nR\n7\n is hydrogen, d-C\n6\n-alkyl, C-i-C\n3\n-alkoxy- C-ι-C\n6\n-alkyl, d-Cβ-alkylcarbonyl, d-C\n6\n-alkylthiocarbonyl or aryl, including phenyl and naphthyl, that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, d-C\n6\n-alkyl, halo-d-C\n6\n-alkyl, d-Cβ-alkylthio, halo-d-C\n6\n-alkylthio, arylthio, C\n1\n-\n\n\nC\n6\n-alkoxy, halo-Ci-C\n6\n-alkoxy, d-C\n6\n-alkylcarbonyl, halo-d-Ce-alkylcarbonyl, Ci-C\ne\n-alkylsulfinyl, halo- d-C\n6\n-alkylsulfinyl, d-Cβ-alkylsulfonyl, SF\n5\n, d-C\n6\n-alkylamino, and di(C\n1\n-C\n6\n-alkyl)amino; heteroaryl, including quinolyl, that is either unsubstituted or substituted, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C\n1\n-\n\n\nC\n6\n-alkyl, halo-d-Cβ-alkyl, d-Cβ-alkylthio, halo-d-Cβ-alkylthio, arylthio, d-Cβ-alkoxy, 1IaIo-C\n1\n-C\n6\n- alkoxy, d-Cβ-alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, Ci-C\ne\n-alkylsulfinyl, halo-d-C\ne\n-alkylsulfinyl, C\n1\n-\n\n\nC\n6\n-alkylsulfonyl, SF\n5\n, Ci-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino;\n\n\nP is C-R -i or N;\n\n\nQ is C-R \n2\n or N;\n\n\nV is C-R \n8\n or N;\n\n\nW is C-R \n9\n or N;\n\n\nX is C-R in or N; \n\n PATENT MER 08-116PCT\n\n\nY is C-R\n11\n or N;\n\n\nZ is a direct bond, C(O), C(S) or S(O)\nP\n;\n\n\nT is independently O, S or N; a is 1 , 2 or 3; and p is 1 or 2.\n\n\nIn one embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein. P and Q are N; V is C-R\n8\n;\n\n\nW is C-R\n9\n; \n\n\n\n\n\nY Js C-R\n11\n;\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are cyano, nitro, halogen, C-ι-C\n6\n-alkyl, C\n3\n-C\n7\n- cycloalkyl, halo-d-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo C-ι-C\n6\n-alkylthio, d-C\n6\n-alkylsulfinyl, halo C\n1\n-\n\n\nC\n6\n- alkylsulfinyl, d-C\n6\n-alkylsulfonyl, halo Ci-C\n6\n-alkylsulfonyl, SF\n5\n, arylthio, C-ι-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-d- C\ne\n-alkoxy, d-Cβ-alkylcarbonyl, halo-d-Ce-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-|-C\n6\n-alkylsulfinyl, C-|-C\n6\n-alkylsulfonyl, d-Cβ-alkylamino, di(C\n1\n-C\n6\n- alkyl)amino, unsubstituted or substituted aryl or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, Ci-C\n6\n-alkyl, halo-Ci-C\n6\n-alkyl, d-C\n6\n-alkylthio, halo- C\n1\n- Ce-alkylthio, arylthio, d-C\n6\n-alkoxy, halo-d-C\ne\n-alkoxy, d-Ce-alkylcarbonyl, 1IaIo-C\n1\n-C\n6\n- alkylcarbonyl, C-|-C\n6\n-alkylsulfinyl, halo-C-i-Cβ-alkylsulfinyl, d-C\n6\n-alkylsulfonyl, 1IaIo-C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, and methylthioamino; R\n3\n, R\n4\n and R\n6\n are H;\n\n\nR\n5\n is methyl or d-C\n3\n-alkyl;\n\n\nR\n7\n is unsubstituted or substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, Ci-Cβ-alkyl, halo-d-C\n6\n-alkyl, d-Cβ-alkylthio, halo-d-C\n6\n-alkylthio, arylthio, d-C\n6\n-alkoxy, halo-CrC\n6\n- alkoxy, d-Cβ-alkylcarbonyl, halo-d-C\n6\n-alkylcarbonyl, d-C\n6\n-alkylsulfinyl, 1IaIo-C\n1\n-C\n6\n- alkylsulfinyl, d-C\n6\n-alkylsulfonyl, SF\n5\n, d-C\n6\n-alkylamino, and di(C-ι-C\n6\n-alkyl)amino; unsubstituted or substituted heteroaryl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-|-C\n6\n-alkyl, halo-d-C\n6\n-alkyl, d-Cβ-alkylthio, halo-d-C\n6\n-alkylthio, arylthio, d-C\n6\n-alkoxy, halo-CrC\n6\n- alkoxy, d-Cβ-alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, d-C\nβ\n-alkylsulfinyl, halo-C-ι-C\n6\n- alkylsulfinyl, d-C\n6\n-alkylsulfonyl, SF\n5\n, d-Cβ-alkylamino, and di(C-ι-C\n6\n-alkyl)amino; or unsubstituted or substituted naphthyl or quinolyl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, d-Ce-alkyl, halo-C\nr\nC\n6\n-alkyl, d-C\ne\n-alkylthio, halo-C\nr\nC\n6\n-alkylthio, arylthio, C\n1\n-C\n6\n- \n\n PATENT MER 08-116PCT alkoxy, halo-d-C\n6\n-alkoxy, d-C\n6\n-alkylcarbonyl, halo-C-i-Cβ-alkylcarbonyl, d-C\n6\n-alkylsulfinyl, halo-d- C\n6\n- alkylsulfinyl, Ci-C\n6\n-alkylsulfonyl, Ci-C\n6\n-alkylamino, and di(Ci-C\n6\n-alkyl)amino; Z is a direct bond, C(O), C(S) or S(O)\nP\n; and a is 1. In yet another embodiment of the first aspect of the invention, compounds of formula formula\n\n\n(I) or (Ia) above are compounds wherein. P and Q are N;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n;\n\n\nY is C-R\n11\n;\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are cyano, nitro, halogen, CrC\n6\n-alkyl, C\n3\n-C\n7\n- cycloalkyl, halo-d-C\n6\n-alkyl, C-ι-C\n6\n-alkylthio, halo d-Cβ-alkylthio, d-C\n6\n-alkylsulfinyl, halo C\n1\n- C\n6\n- alkylsulfinyl, d-C\n6\n-alkylsulfonyl, halo d-Cβ-alkylsulfonyl, SF\n5\n, arylthio, d-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-d- C\n6\n-alkoxy, d-C\n6\n-alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-|-C\n6\n-alkylsulfinyl, C-|-C\n6\n-alkylsulfonyl, d-C\n6\n-alkylamino, CU(C\n1\n- C\n6\n- alkyl)amino, unsubstituted or substituted aryl or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, d-C\n6\n-alkyl, halo-d-C\n6\n-alkyl, d-C\n6\n-alkylthio, halo-d-C\n6\n- alkylthio, arylthio, Ci-C\n6\n-alkoxy, halo-Ci-C\n6\n-alkoxy, d-C\n6\n-alkylcarbonyl, halo-d-C\n6\n- alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-d-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, 1IaIo-C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, and methylthioamino; R\n3\n, R\n4\n and R\n6\n are H; R\n5\n is methyl or d-C\n3\n-alkyl; R\n7\n is unsubstituted or substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, d-C\n6\n-alkyl, halo- Ci- Cβ-alkyl, d-Cβ-alkylthio, halo-Ci-C\n6\n-alkylthio, arylthio, d-Cβ-alkoxy, halo-d-C\n6\n-alkoxy, C\n1\n-C\n6\n- alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, d-Cβ-alkylsulfmyl, halo-C-i-Ce-alkylsulfinyl, C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, d-C\n6\n-alkylamino, and d^d-Ce-alky^amino; unsubstituted or substituted heteroaryl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, d-C\n6\n-alkyl, halo-d-C\n6\n-alkyl, C\n1\n-C\n6\n- alkylthio, halo- Ci-C\n6\n-alkylthio, arylthio, d-Cβ-alkoxy, halo-Ci-C\n6\n-alkoxy, d-C\n6\n-alkylcarbonyl, halo- Ci-C\n6\n- alkylcarbonyl, C-i-Ce-alkylsulfinyl, halo-C-i-Ce-alkylsulfinyl, d-C\ne\n-alkylsulfonyl, SF\n5\n, C\n1\n-C\n8\n- alkylamino, and di(C-ι-C\n6\n-alkyl)amino; Z is C(O);\n\n\nT is independently O, S or N; and a is 1.\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) or (Ia) above are compounds wherein. P and Q is N; \n\n PATENT MER 08-116PCT\n\n\nV is C-R\n8\n;\n\n\nW is C-R\n9\n; \n\n\n\n\n\nY is C-R\n11\n; R\n8\n, R\n9\n, R\n1O\n and R\n11\n , independently of one another, are cyano, nitro, halogen, d-C\n6\n-alkyl, C\n3\n-C\n7\n- cycloalkyl, halo-d-C\n6\n-alkyl, C-|-C\n6\n-alkylthio, halo C-|-C\n6\n-alkylthio, d-C\n6\n-alkylsulfinyl, halo C\n1\n- C\n6\n- alkylsulfinyl, d-C\n6\n-alkylsulfonyl, halo d-C\n6\n-alkylsulfonyl, SF\n5\n, arylthio, C-|-C\n6\n-alkoxy, C\n3\n-C\n7\n- cycloalkyloxy, halo-C-ι-C\n6\n-alkoxy, d-d-alkylcarbonyl, halo-d-d-alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-i-Cβ-alkylsulfinyl, d-C\n6\n-alkylsulfonyl, Ci-C\n6\n-alkylamino, di(d- C\n6\n- alkyl)amιno, unsubstituted or substituted aryl or unsubstituted or substituted phenoxy, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, CrC\n6\n-alkyl, halo-CrC\n6\n-alkyl, d-C\n6\n-alkylthio, 1IaIo-C\n1\n-C\n6\n- alkylthio, arylthio, C-i-Cβ-alkoxy, halo-d-Cβ-alkoxy, d-d-alkylcarbonyl, halo-d-C\n6\n- alkylcarbonyl, C\n1\n-C\n6\n- alkylsulfinyl, halo-C-rC\n6\n-alkylsulfinyl, d-Cβ-alkylsulfonyl, halo-C-rC\n6\n- alkylsulfonyl, SF\n5\n, and methylthioamino; R\n3\n, R\n4\n and R\n6\n are H; R\n5\n is methyl;\n\n\nR\n7\n is unsubstituted or substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo- C\n1\n- C\n6\n-alkyl, d-Ce-alkylthio, halo-d-C\n6\n-alkylthio, arylthio, d-C\n6\n-alkoxy, halo-d-C\n6\n-alkoxy, C\n1\n-C\n6\n- alkylcarbonyl, halo-d-Cβ-alkylcarbonyl, C-ι-C\n6\n-alkylsulfinyl, halo-d-C\n6\n-alkylsulfinyl, C\n1\n-C\n6\n- alkylsulfonyl, SF\n5\n, C-|-C\n6\n-alkylamino, and di(C-|-C\n6\n-alkyl)amino; unsubstituted or substituted heteroaryl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, Ci-C\n6\n-alkyl, halo-d-C\n6\n-alkyl, C\n1\n-C\n6\n- alkylthio, halo- d-C\n6\n-alkylthio, arylthio, Ci-Ce-alkoxy, halo-d-C\n6\n-alkoxy, d-C\n6\n-alkylcarbonyl, halo- C\n1\n-C\n6\n- alkylcarbonyl, d-C\n6\n-alkylsulfinyl, halo-C-i-C\n6\n-alkylsulfinyl, C-ι-C\n6\n-alkylsulfonyl, SF\n5\n, C\n1\n-C\n6\n- alkylamino, and di(C-ι-C\ne\n-alkyl)amino; Z is C(O) a is 1 ; m and n are independently 0 or 1 .\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) or (Ia) above are compounds wherein:\n\n\nR\n1\n , R\n2\n, Re, R\n9\n, R\n1O\n and R\n11\n , independently of one another, are hydrogen, cyano, halogen, d-C\n6\n-alkyl, halomethyl or methylthioamino; R\n3\n, R\n4\n and R\n6\n are H;\n\n\nR\n5\n is methyl or d-C\n3\n-alkyl; P is C-R\n1\n or N;\n\n\nQ is C-R\n2\n or N;\n\n\nV is C-R\n8\n or N; W is C-R\n9\n; \n\n PATENT MER 08-116PCT\n\n\n\n\n\nY is C-R\n11\n or N; T is O or S;\n\n\nZ is C(O); and a is 1.\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein:\n\n\nRi , R\n2\n, Re, R\n9\n, R\n1O\n and R\n11\n , independently of one another, are hydrogen, cyano, chloro, bromo, methyl or trifluoromethyl;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is C-R\n1\n or N;\n\n\nQ is C-R\n2\n or N; V is C-R\n8\n or N;\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY is C-R\n11\n or N; Z is C(O); R\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, C-ι-C\n6\n-alkyl, halo-C-i- C\n6\n-alkyl, C\n1\n-\n\n\nC\n6\n-alkylthio, halo-CrC\n6\n-alkylthio, arylthio, C-|-C\n6\n-alkoxy, halo-C-|-C\n6\n-alkoxy, C-pCβ-alkylcarbonyl, halo- d-C\n6\n-alkylcarbonyl, and a is 1.\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, cyano, chloro, bromo, methyl or trifluoromethyl; R\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nQ is N;\n\n\nV is C-R\n8\n;\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY is C-R\n11\n;\n\n\nZ is C(O); \n\n PATENT MER 08-116PCT\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halogen, d-C\n6\n-alkylthio, halo-d-Cβ-alkylthio, Ci-C\n6\n-alkoxy, and halo-d-C\n6\n-alkoxy, and a is 1.\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, cyano, chloro, bromo, methyl, or trifluoromethyl; R\n3\n, R\n4\n and R\n6\n is H; R\n5\n is methyl, P is N;\n\n\nQ is N;\n\n\nV is C-R\n8\n; W is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nV Js C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-Ci-C\n6\n-alkylthio and halo-Ci-C\n6\n-alkoxy, and a is 1\n\n\nIn another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein: R\n9\n, R-io and R\n11\n, independently of one another, are hydrogen, cyano, chloro, bromo, methyl or trifluoromethyl;\n\n\nR\n3\n, R\n4\n and R\n6\n are H;\n\n\nR\n2\n is H, chloro, bromo or C-ι-C\n6\n-alkoxy;\n\n\nR\n5\n is methyl; P is N;\n\n\nQ is C-R\n2\n;\n\n\nV is N;\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n; Y Js C-R\n11\n;\n\n\nZ is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-d-Ce-alkylthio and halo-d-Cβ-alkoxy, and a is 1. \n\n PATENT MER 08-116PCT\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, chloro, bromo, methyl or trifluoromethyl; R\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n2\n is H, chloro, bromo or C-|-C\n6\n-alkoxy; R\n5\n is methyl; P is N;\n\n\nQ is C-R\n2\n; V is C-R\n8\n;\n\n\nW is C-R\n9\n; X is C-R\n10\n;\n\n\nY is C-R\n11\n; Z is C(O); R\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-|-C\n6\n-alkylthio and halo-C-|-C\n6\n-alkoxy, and a is 1.\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein:\n\n\nR\n9\n, R\n10\n and R\n11\n, independently of one another, are hydrogen, cyano, chloro , bromo, methyl or trifluoromethyl;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl; P is N;\n\n\nQ is N;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n; Y Js C-R\n11\n;\n\n\nZ is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-i-Ce-alkylthio and halo-C-i-Ce-alkoxy, and a is 1.\n\n\nIn another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein:\n\n\nR\n9\n, R\n10\n and R\n11\n, independently of one another, are hydrogen, chloro, bromo or methyl;\n\n\nR\n3\n, R\n4\n and R\n6\n are H; R\n2\n is H, chloro, bromo or methoxy; \n\n PATENT MER 08-116PCT\n\n\nR\n5\n is methyl,\n\n\nP is N;\n\n\nQ is C-R\n2\n;\n\n\nV is N; W is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nV Js C-R\n11\n; Z is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-d-Ce-alkylthio and halo-d-Ce-alkoxy, and a is 1\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (I) above are compounds wherein: R\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, chloro, bromo, methyl or trifluoromethyl;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n2\n is H, chloro, bromo, methoxy, ethoxy, propoxy or butoxy;\n\n\nR\n5\n is methyl; P is N;\n\n\nQ is C-R\n2\n;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n; Y Js C-R\n11\n;\n\n\nZ is C(O);\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-C-i-Ce-alkylthio and halo-C-i-Ce-alkoxy, and a is 1.\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (Ia) above are compounds wherein:\n\n\nR\n1\n , R\n8\n, R\n9\n, R\n10\n and R\n11\n, independently of one another, are hydrogen, cyano, chloro, triifluoromethyl or methylamino; R\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is C-R\n1\n or N;\n\n\nV is C-R\n8\n or N; W is C-R\n9\n; X is C-R\n10\n; \n\n PATENT MER 08-116PCT\n\n\nY is C-R\n11\n or N; Z is C(O);\n\n\nT is O;\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, Ci-C\nβ\n-alkyl, halo-d-C\ne\n-alkyl, C\n1\n-C\n6\n- alkylthio, halo-C-|-C\n6\n-alkylthio, arylthio, C-|-C\n6\n-alkoxy, halo-C-|-C\n6\n-alkoxy, C-|-C\n6\n-alkylcarbonyl, halo-Cr C\n6\n-alkylcarbonyl, and a is 1.\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (Ia) above are compounds wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, cyano, chloro, trifluoromethyl or methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H; R\n5\n is methyl;\n\n\nP is N;\n\n\nV is C-R\n8\n; W is C-R\n9\n; X is C-R\n10\n; Y Js C-R\n11\n;\n\n\nZ is C(O);\n\n\nT is O;\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halogen, C-ι-C\n6\n-alkylthio, halo-Ci-C\n6\n-alkylthio, C-ι-C\n6\n-alkoxy, and halo-C-rC\n6\n-alkoxy, and a is 1\n\n\nIn still another embodiment of the first aspect of the invention, compounds of formula (Ia) above are compounds wherein:\n\n\nR\n8\n, R\n9\n, R\n10\n and R\n11\n , independently of one another, are hydrogen, cyano, chloro, trifluoromethyl or methylthioamino;\n\n\nR\n3\n, R\n4\n and R\n6\n is H;\n\n\nR\n5\n is methyl;\n\n\nP is N;\n\n\nV is C-R\n8\n;\n\n\nW is C-R\n9\n;\n\n\nX is C-R\n10\n;\n\n\nY is C-R\n11\n;\n\n\nZ is C(O);\n\n\nT is O; \n\n PATENT MER 08-116PCT\n\n\nR\n7\n is a substituted phenyl wherein the substituents may each be independent of one another and are selected from the group consisting of halo-Ci-C\n6\n-alkylthio and halo-Ci-C\n6\n-alkoxy, and a is 1.\n\n\nTables 1 , 2 and 3 below provide additional particularly preferred compounds of the invention of formula (Ib), (Ic) and (Id) that are encompassed by formula (I). Table 1\n\n\n\n\n\n\n\n\nV = C-R\n8\n; W = C-R\n9\n; X = C-R\n10\n; Y = C-R\n11\n ; Q = P = N;\n\n\nR\n3\n \n=\n R\n4\n \n=\n Re \n=\nH; a = 1 ; R\n5\n = CH\n3\n; Z = C(O); R\n7\n = p-phenyl-R\n\n\n \n\n PATENT MER 08-116PCT\n\n\n PATENT MER 08-116PCT\n\n\n PATENT MER 08-116PCT\n\n\nTable 2\n\n\n\n\n\n\n\n\nV = C-R\n8\n; W = C-R\n9\n; X = C-R\n10\n; Y = C-R\n11\n ;\n\n\nQ = C-R\n2\n; P = N;\n\n\nR\n3\n = R\n4\n = Re = H; a = 1 ; R\n5\n = CH\n3\n;\n\n\nZ = C(O); R\n7\n = p-phenyl-R\n\n\n \n\n PATENT MER 08-116PCT\n\n\n\n\n\n\n\n\nTable 3\n\n\n\n\n\n\n\n\nV = N; W = C-R\n9\n; X = C-R\n10\n; Y = C-R\n11\n ;\n\n\nQ = C-R\n2\n where R\n2\n is as defined for formula (I) above; P = N;\n\n\nR\n3\n = R\n4\n = R\n6\n = H; a = 1 ; R\n5\n = CH\n3\n;\n\n\nZ = C(O); R\n7\n = p-phenyl-R \n\n PATENT MER 08-116PCT\n\n\n\n\n\n\n\n\nFormulations and Administration for Pharmaceutical/Veterinary Use\n\n\nAnother aspect of the invention is the formation of antiparasiticidal compositions which comprise the thioamide compounds of the invention. The composition of the invention can also be in a variety of forms which include, but are not limited to, oral formulations, injectable formulations, and topical, dermal or subdermal formulations.\n\n\nThe composition of the invention may be in a form suitable for oral use, for example, as baits (see, e.g., U.S. Patent No. 4,564,631 ), dietary supplements, troches, lozenges, chewables, tablets, hard or soft capsules, emulsions, aqueous or oily suspensions, aqueous or oily solutions, oral drench formulations, dispersible powders or granules, syrups or elixirs, enteric formulations or pastes. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, bittering agents, flavoring agents, coloring \n\n PATENT MER 08-116PCT agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.\n\n\nTablets may contain the active ingredient in admixture with non-toxic, pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc, the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in U.S. Patent Nos. 4,256, 108; 4,166,452; and 4,265,874 (incorporated herein by reference) to form osmotic therapeutic tablets for controlled release.\n\n\nFormulations for oral use may be hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. Capsules may also be soft gelatin capsules, wherein the active ingredient is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.\n\n\nThe compositions of the invention may also be in the form of oil-in-water or water-in-oil emulsions. The oily phase maybe a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening agents, bittering agents, flavoring agents, and/or preservatives.\n\n\nIn one embodiment of the formulation, the composition of the invention is in the form of a microemulsion. Microemulsions are well suited as the liquid carrier vehicle. Microemulsions are quaternary systems comprising an aqueous phase, an oily phase, a surfactant and a cosurfactant. They are translucent and isotropic liquids. Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or conversely of microdroplets of the oily phase in the aqueous phase. The size of these microdroplets is less than 200 nm (1000 to 100,000 nm for emulsions). The interfacial film is composed of an alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial tension, allows the microemulsion to be formed spontaneously. In one embodiment of the oily phase, the oily phase can be formed from mineral or vegetable oils, from unsaturated polyglycosylated glycerides or from triglycerides, or alternatively from mixtures of such compounds. In one embodiment of the oily phase, the oily phase comprises of triglycerides; in another embodiment of the oily phase, the triglycerides are medium-chain triglycerides, for example C\n8\n-Ci\n0\n caprylic/capric triglyceride. In another embodiment of the oily phase will represent a % v/v \n\n PATENT MER 08-116PCT range selected from the group consisting of about 2 to about 15%, about 7 to about 10%; and about 8 to about 9% v/v of the microemulsion.\n\n\nThe aqueous phase includes, for example water or glycol derivatives, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol. In one embodiment of the glycol derivatives, the glycol is selected from the group consisting of propylene glycol, diethylene glycol monoethyl ether, dipropylene glycol monoethyl ether and mixtures thereof. Generally, the aqueous phase will represent a proportion from about 1 to about 4% v/v in the microemulsion.\n\n\nSurfactants for the microemulsion include diethylene glycol monoethyl ether, dipropyelene glycol monomethyl ether, polyglycolyzed C\n8\n-Ci\n0\n glycerides or polyglyceryl-6 dioleate. In addition to these surfactants, the cosurfactants include short-chain alcohols, such as ethanol and propanol.\n\n\nSome compounds are common to the three components discussed above, i.e., aqueous phase, surfactant and cosurfactant. However, it is well within the skill level of the practitioner to use different compounds for each component of the same formulation. In one embodiment for the amount of surfactant/cosurfactant, the cosurfactant to surfactant ratio will be from about 1/7 to about 1/2. In another embodiment for the amount of cosurfactant, there will be from about 25 to about 75% v/v of surfactant and from about 10 to about 55% v/v of cosurfactant in the microemulsion\n\n\nOily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, atachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as sucrose, saccharin or aspartame, bittering agents, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid, or other known preservatives.\n\n\nAqueous suspensions may contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally- occuring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide, with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p- hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents and/or bittering agents, such as those set forth above.\n\n\nDispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, bittering, flavoring and coloring agents, may also be present. \n\n PATENT MER 08-116PCT\n\n\nSyrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring agent(s) and/or coloring agent(s).\n\n\nIn another embodiment of the invention, the composition can be in paste form. Examples of embodiments in a paste form include but are not limited to those described in U.S. Patent Nos.\n\n\n6,787,342 and 7,001 ,889 (each of which are incorporated herein by reference). In addition to the compound(s) of the invention, the paste can also contain fumed silica; a viscosity modifier; a carrier; optionally, an absorbent; and optionally, a colorant, stabilizer, surfactant, or preservative.\n\n\nThe process for preparing a paste formulation comprises the steps of: (a) dissolving or dispersing the 1-aryl-5-alkyl compound into the carrier by mixing;\n\n\n(b) adding the fumed silica to the carrier containing the dissolved active compound and mixing until the silica is dispersed in the carrier;\n\n\n(c) allowing the intermediate formed in (b) to settle for a time sufficient in order to allow the air entrapped during step (b) to escape; and (d) adding the viscosity modifier to the intermediate with mixing to produce a uniform paste. The above steps are illustrative, but not limiting. For example, step (a) can be the last step\n\n\nIn one embodiment of the formulation, the formulation is a paste containing a thioamide compound of the invention, fumed silica, a viscosity modifier, an absorbent, a colorant; and a hydrophilic carrier which is triacetin, a monoglyceride, a diglyceride, or a triglyceride. The paste may also include, but is not limited to, a viscosity modifier selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene (20) sorbitan mono-oleate (polysorbate 80 or Tween 80), and polyoxamers (e.g., Pluronic L 81 ); an absorbent selected from the group consisting of magnesium carbonate, calcium carbonate, starch, and cellulose and its derivatives; and a colorant selected from the group consisting of titanium dioxide iron oxide, and FD&C Blue #1 Aluminum Lake.\n\n\nThe compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-aceptable diluent or solvent, for example, as a solution in 1 ,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. Preservatives, such as phenol or benzyl alcohol, may be used.\n\n\nIn addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.\n\n\nTopical, dermal and subdermal formulations can include emulsions, creams, ointments, gels, pastes, powders, shampoos, pour-on formulations, ready-to-use formulations, spot-on solutions and suspensions. Topical application of an inventive compound or of a composition including at least one inventive compound among active agent(s) therein, a spot-on composition, can allow for the inventive \n\n PATENT MER 08-116PCT compound to be distributed through the glands (e.g. sebaceous glands) of the animal and/or allow active agent(s) to achieve a systemic effect (plasma concentration) or throughout the haircoat. When the compound is distributed throughout glands, the glands can act as a reservoir, whereby there can be a long-lasting, e.g. 1-2 months effect. Spot-on formulations are typically applied in a localized region which refers to an area other than the entire animal. In one embodiment of a localized region, the location is between the shoulders. In another embodiment of a localized region is a stripe, e.g. a stripe from head to tail of the animal.\n\n\nPour-on formulations are described in U.S. Patent No. 6,010,710, incorporated herein by reference. The pour-on formulations are advantageously oily, and generally comprise a diluent or vehicle and also a solvent (e.g. an organic solvent) for the active ingredient if the latter is not soluble in the diluent.\n\n\nOrganic solvents that can be used in the invention include but are not limited to: acetyltri butyl citrate, fatty acid esters such as the dimethyl ester, diisobutyl adipate, acetone, acetonitrile, benzyl alcohol, butyl diglycol, dimethylacetamide, dimethylformamide, dipropylene glycol n-butyl ether, ethanol, isopropanol, methanol, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, monomethylacetamide, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol, 2-pyrrolidone (e.g. N-methylpyrrolidone), diethylene glycol monoethyl ether, ethylene glycol and diethyl phthalate, or a mixture of at least two of these solvents.\n\n\nAs vehicle or diluent, mention may be made of plant oils such as, but not limited to soybean oil, groundnut oil, castor oil, corn oil, cotton oil, olive oil, grape seed oil, sunflower oil, etc.; mineral oils such as, but not limited to, petrolatum, paraffin, silicone, etc ; aliphatic or cyclic hydrocarbons or alternatively, for example, medium-chain (such as C8 to C12) triglycerides.\n\n\nIn another embodiment of the invention, an emollient and/or spreading and/or film-forming agent will be added. One embodiment of the emollient and/or spreading and/or film-forming agent are those agents selected from the group consisting of :\n\n\n(a) polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters; lecithin, sodium carboxymethylcellulose, silicone oils, polydiorganosiloxane oils (such as polydimethylsiloxane (PDMS) oils), for example those containing silanol functionalities, or a 45V2 oil, (b) anionic surfactants such as alkaline stearates, sodium, potassium or ammonium stearates; calcium stearate, triethanolamine stearate; sodium abietate; alkyl sulphates (e.g. sodium lauryl sulphate and sodium cetyl sulphate); sodium dodecylbenzenesulphonate, sodium dioctylsulphosuccinate; fatty acids (e.g. those derived from coconut oil),\n\n\n(c) cationic surfactants such as water-soluble quaternary ammonium salts of formula N\n+\nR'R\"R'\"R\"\", Y\n\"\n in which the radicals R are optionally hydroxylated hydrocarbon radicals and Y\n\"\n is an anion of a strong acid such as the halide, sulphate and sulphonate anions; cetyltrimethylammonium bromide is among the cationic surfactants which can be used,\n\n\n(d) amine salts of formula N\n+\n R'R\"R'\" in which the radicals R are optionally hydroxylated hydrocarbon radicals; octadecylamine hydrochloride is among the cationic surfactants which can be used, \n\n PATENT MER 08-116PCT\n\n\n(e) nonionic surfactants such as sorbitan esters, which are optionally polyoxyethylenated (e.g. polysorbate 80), polyoxyethylenated alkyl ethers; polyoxypropylated fatty alcohols such as polyoxypropylene-styrol ether; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide,\n\n\n(f) amphoteric surfactants such as the substituted lauryl compounds of betaine; or\n\n\n(g) a mixture of at least two of these agents.\n\n\nThe solvent will be used in proportion with the concentration of the thioamide compound of formula (I) or (Ia) and its solubility in this solvent. It will be sought to have the lowest possible volume. The vehicle makes up the difference to 100%.\n\n\nIn one embodiment of the amount of emollient, the emollient is used in a proportion selected from the group consisting of from 0.1 to 10% and 0.25 to 5%, by volume.\n\n\nIn another embodiment of the invention, the composition can be in ready-to-use solution form as is described in U.S. Patent No. 6,395,765, incorporated herein by reference. In addition to the thioamide compound of formula (I) or (Ia), the ready-to-use solution can contain a crystallization inhibitor, an organic solvent and an organic co-solvent.\n\n\nIn one embodiment of the amount of crystallization inhibitor, the crystallization inhibitor can be present in a proportion selected from the group consisting of about 1 to about 20% (w/v) and about 5 to about 15%. In another embodiment of the amount of crystallization inhibitor, the amount corresponds to the test in which 0.3 ml of a solution comprising 10% (w/v) of the thioamide compound in the liquid carrier and 10% of the inhibitor are deposited on a glass slide at 20\n0\nC and allowed to stand for 24 hours. The slide is then observed with the naked eye. Acceptable inhibitors are those whose addition provides for few (e.g. less than ten crystals) or no crystal.\n\n\nThe organic solvent has a dielectric constant of a range selected from the group consisting of between about 10 and 35 and between about 20 and 30, the content of this organic solvent in the overall composition representing the complement to 100% of the composition; and the organic co- solvent having a boiling point selected from the ranges consisting of below 100° C, and below 80° C, and having a dielectric constant of a range selected from the group consisting of between about 10 and 40 and between about 20 and 30; this co-solvent may be present in the composition in a organic co-solvent/organic solvent weight/weight (W/W) ratio of between about 1/15 and 1/2. The solvent is volatile so as to act as a drying promoter, and is miscible with water and/or with the organic solvent.\n\n\nThe formulation can also comprise an antioxidizing agent intended to inhibit oxidation in air, this agent being present in a proportion selected from a range consisting of about 0.005 to about 1 % (w/v) and about 0.01 to about 0.05% Crystallization inhibitors which are useful for the invention include but are not limited to:\n\n\n(a) polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and of vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol or polyoxyethylenated esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as methacrylates and others; \n\n PATENT MER 08-116PCT\n\n\n(b) anionic surfactants, such as alkaline stearates (e.g. sodium, potassium or ammonium stearate); calcium stearate or triethanolamine stearate; sodium abietate; alkyl sulphates, which include but are not limited to sodium lauryl sulphate and sodium cetyl sulphate; sodium dodecylbenzenesulphonate or sodium dioctyl sulphosuccinate; or fatty acids (e.g. coconut oil); (c) cationic surfactants, such as water-soluble quaternary ammonium salts of formula N\n+\nR'R\"R'\"R\"\"Y , in which the R radicals are identical or different optionally hydroxylated hydrocarbon radicals and Y\n~~\n is an anion of a strong acid, such as halide, sulphate and sulphonate anions; cetyltrimethylammonium bromide is one of the cationic surfactants which can be used;\n\n\n(d) amine salts of formula N\n+\nR\n1\nR\n11\nR'\", in which the R radicals are identical or different optionally hydroxylated hydrocarbon radicals; octadecylamine hydrochloride is one of the cationic surfactants which can be used;\n\n\n(e) non-ionic surfactants, such as optionally polyoxyethylenated esters of sorbitan, e.g. Polysorbate 80, or polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids or copolymers of ethylene oxide and of propylene oxide;\n\n\n(f) amphoteric surfactants, such as substituted lauryl compounds of betaine; or\n\n\n(g) a mixture of at least two of the compounds listed in (a)-(f) above.\n\n\nIn one embodiment of the crystallization inhibitor, a crystallization inhibitor pair will be used. Such pairs include, for example, the combination of a film-forming agent of polymeric type and of a surface- active agent. These agents will be selected from the compounds mentioned above as crystallization inhibitor.\n\n\nIn one embodiment of the film-forming agent, the agents are of the polymeric type which include but are not limited to the various grades of polyvinylpyrrolidone, polyvinyl alcohols, and copolymers of vinyl acetate and of vinylpyrrolidone. In one embodiment of the surface-active agents, the agents include but are not limited to those made of non-ionic surfactants; in another embodiment of the surface active agents, the agent is a polyoxyethylenated esters of sorbitan and in yet another embodiment of the surface-active agent, the agents include the various grades of polysorbate, for example Polysorbate 80.\n\n\nIn another embodiment of the invention, the film-forming agent and the surface-active agent can be incorporated in similar or identical amounts within the limit of the total amounts of crystallization inhibitor mentioned elsewhere\n\n\nThe pair thus constituted secures, in a noteworthy way, the objectives of absence of crystallization on the coat and of maintenance of the cosmetic appearance of the skin or fur, that is to say without a tendency towards sticking or towards a sticky appearance, despite the high concentration of active material.\n\n\nIn one embodiment of the antioxidizing agents, the agents are those conventional in the art and include but is not limited to butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate, sodium thiosulphate or a mixture of not more than two of them.\n\n\nThe formulation adjuvants discussed above are well known to the practitioner in this art and may be obtained commercially or through known techniques. These concentrated compositions are \n\n PATENT MER 08-116PCT generally prepared by simple mixing of the constituents as defined above; advantageously, the starting point is to mix the active material in the main solvent and then the other ingredients or adjuvants are added.\n\n\nThe volume applied can be of the order of about 0.3 to about 1 ml. In one embodiment for the volume, the volume is on the order of about 0.5 ml, for cats and on the order of about 0.3 to about 3 ml for dogs, depending on the weight of the animal.\n\n\nIn another embodiment of the invention, application of a spot-on formulation according to the present invention can also provide long-lasting and broad-spectrum efficacy when the solution is applied to the mammal or bird. The spot-on formulations provide for topical administration of a concentrated solution, suspension, microemulsion or emulsion for intermittent application to a spot on the animal, generally between the two shoulders (solution of spot-on type).\n\n\nFor spot-on formulations, the carrier can be a liquid carrier vehicle as described in U.S. Patent\n\n\nNo. 6,426,333 (incorporated herein by reference), which in one embodiment of the spot-on formulation comprises a solvent and a cosolvent wherein the solvent is selected from the group consisting of acetone, acetonitrile, benzyl alcohol, butyl diglycol, dimethylacetamide, dimethylformamide, dipropylene glycol n-butyl ether, ethanol, isopropanol, methanol, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, monomethylacetamide, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol, 2-pyrrolidone (e.g.\n\n\nN-methylpyrrolidone), diethylene glycol monoethyl ether, ethylene glycol, diethyl phthalate fatty acid esters, such as the diethyl ester or diisobutyl adipate, and a mixture of at least two of these solvents and the cosolvent is selected from the group consisting of absolute ethanol, isopropanol or methanol. The liquid carrier vehicle can optionally contain a crystallization inhibitor selected from the group consisting of an anionic surfactant, a cationic surfactant, a non-ionic surfactant, an amine salt, an amphoteric surfactant or polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters; lecithin, sodium carboxymethylcellulose, and acrylic derivatives, or a mixture of these crystallization inhibitors.\n\n\nSpot-on formulations may be prepared by dissolving the active ingredients into the pharmaceutically or veterinary acceptable vehicle. Alternatively, the spot-on formulation can be prepared by encapsulation of the active ingredient to leave a residue of the therapeutic agent on the surface of the animal These formulations will vary with regard to the weight of the therapeutic agent in the combination depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host.\n\n\nDosage forms may contain from about 0.5 mg to about 5 g of an active agent. In one embodiment of the dosage form, the dosage is from about 1 mg to about 500 mg of an active agent, typically about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg.\n\n\nIn one embodiment of the invention, the active agent is present in the formulation at a concentration of about 0.05 to 10% weight/volume. In another embodiment of the invention, the active agent is present in the formulation as a concentration from about 0.1 to 2% weight/volume. In \n\n PATENT MER 08-116PCT yet another embodiment of the invention, the active agent is present in the formulation as a concentration from about 0.25 to about 1.5% weight/volume. In still another embodiment of the invention, the active agent is present in the formulation as a concentration about 1 % weight/volume. Formulations and Administration for Aqrochemical Use The compounds of the formula (I) and (Ia) or their salts can be employed as such or in the form of their preparations (formulations) as combinations with other pesticidally active substances, such as, for example, insecticides, attractants, sterilants, acaricides, nematicides, herbicides, fungicides, and with safeners, fertilizers and/or growth regulators, for example as a premix/readymix.\n\n\nThe insecticides include, for example, phosphoric esters, carbamates, carboxylic esters, chlorinated hydrocarbons, phenylureas, substances prepared by microorganisms.\n\n\nExamples of insecticides which may optionally be admixed include but are not limited to: phosphoric esters, such as azinphos-ethyl, azinphos-methyl, α-1(4-chlorophenyl)-4-(O-ethyl, S- propyl)phosphoryloxy-pyrazole, chlorpyrifos, coumaphos, demeton, demeton-S-methyl, diazinon, dichlorvos, dimethoate, ethoate, ethoprophos, etrimfos, fenitrothion, fenthion, heptenophas, parathion, parathion-methyl, phosalone, poxim, pirimiphos-ethyl, pirimiphos-methyl, profenofos, prothiofos, sulfprofos, triazophos and trichlorphon; carbamates, such as aldicarb, bendiocarb, α-2-(1-methylpropyl)-phenyl methylcarbamate, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, cloethocarb, isoprocarb, methomyl, oxamyl, pirimicarb, promecarb, propoxur and thiodicarb; organosilicon compounds (e.g. dimethyl(phenyl)silyl-methyl 3-phenoxybenzyl ethers, such as dimethyl-(4-ethoxyphenyl)-silylmethyl 3-phenoxybenzyl ether) or (dimethylphenyl)-silyl-methyl 2- phenoxy-6-pyridylmethyl ethers such as, for example, dimethyl-(9-ethoxy-phenyl)-silylmethyl 2- phenoxy-6-pyridylmethyl ether or [(phenyl)-3-(3-phenoxyphenyl)-propyl[(dimethyl)-silanes such as, for example, (4-ethoxyphen-yl)-[3-(4-fluoro-3-phenoxyphenyl-propyl]dimethyl-silane, silafluofen; pyrethroids (which are also useful for their repellent properties, e.g. against mosquitoes), such as allethrin, alphamethrin, bioresmethrin, byfenthrin, cycloprothrin, cyfluthirin, decamethrin, cyhalothrin, cypermethrin, deltamethrin, alpha-cyano-3-phenyl-2-methylbenzyl 2,2-dimethyl-3-(2- chloro-2-trifluoro-methylvinyl)cyclopropane-carboxylate, fenpropathrin, fenfluthrin, fenvalerate, flucythrinate, flumethrin, fluvalinate, permethrin, resmethrin and tralomethrin; nitroimines and nitromethylenes, such as 1-[(6-chloro-3-pyridinyl)-methyl]-4,5-dihydro-N-nitro-\n\n\n1 H-imidazole-2-amine (imidacloprid), N-^δ-chloro-S-pyridy^-methyll-N^cyano-N^methylacetamide (NI-25); abamectin, AC 303, 630 (chlorfenapyr), acephate, acrinathrin, alanycarb, aldoxycarb, aldrin, amitraz, azamethiphos, Bacillus thunngiensis, phosmet, phosphamidon, phosphine, prallethrin, propaphos, propetamphos, prothoate, pyraclofos, pyrethrins, pyridaben, pyridafenthion, pyriproxyfen, quinalphos, RH-7988, rotenone, sodium fluoride, sodium hexafluorosilicate, sulfotep, sulfuryl fluoride, tar oils, teflubenzuron, tefluthrin, temephos, terbufos, tetrachlorvinphos, tetramethrin, O-2-tert-butyl-pyrimidin- 5-yl-o-isopropylphosphorothιate, thiocyclam, thiofanox, thiometon, tralomethrin, triflumuron, trimethacarb, vamidothion, Verticillium Lacanii, XMC, xylylcarb, benfuracarb, bensultap, bifenthrin, bioallethrin, MERbioallethrin (S)-cyclopentenyl isomer, bromophos, bromophos-ethyl, buprofezin, \n\n PATENT MER 08-116PCT cadusafos, calcium polysulphide, carbophenothion, cartap, quinomethionate, chlordane, chlorfenvinphos, chlorfluazuron, chlormephos, chloropicrin, chlorpyrifos, cyanophos, beta-cyfluthrin, alphacypermethrin, cyophenothrin, cyromazine, dazomet, DDT, demeton-S-methylsulphone, diafenthiuron, dialifos, dicrotophos, diflubenzuron, dinoseb, deoxabenzofos, diazacarb, disulfoton, DNOC, empenthrin, endosulfan, EPN, esfenvalerate, ethiofencarb, ethion, etofenprox, fenobucarb, fenoxycarb, fensulfothion, fipronil, flucycloxuron, flufenprox, flufenoxuron, fonofos, formetanate, formothion, fosmethilan, furathiocarb, heptachlor, hexaflumuron, hydramethylnon, hydrogen cyanide, hydroprene, IPSP, isazofos, isofenphos, isoprothiolane, isoxathion, iodfenphos, kadethrin, lindane, malathion, mecarbam, mephosfolan, mercurous chloride, metam, metarthizium, anisopliae, methacrifos, methamidophos, methidathion, methiocarb, methoprene, methoxychlor, methyl isothiocyanate, metholcarb, mevinphos, monocrotophos, naled, Neodiprion sertifer NPV, nicotine, omethoate, oxydemeton-methyl, pentachlorophenol, petroleum oils, phenothrin, phenthoate, phorate. Other insecticides that may optionally be admixed may also be from the class of the compounds described by U.S. Patent 7,001 ,903. Fungicides which may optionally be admixed are include but are not limited to:\n\n\n(1 ) Triazoles which include but are not limited to: azaconazole, propiconazole, tebuconazole, cyproconazole, metconazole, amitrole, azocyclotin, BAS 480F, bitertanol, difenoconazole, fenbuconazole, fenchlorazole, fenethanil, fluquinconazole, flusilazole, flutriafol, imibenconazole, isozofos, myclobutanil, paclobutrazol, (±)-cis-1-(4-chlorophenyl)- 2-(1 H-1 ,2,4-triazol-1-yl)-cycloheptanol, tetraconazole, triadimefon, triadimenol, triapenthenol, triflumizole, triticonazole, uniconazole and their metal salts and acid adducts.\n\n\n(2) Imidazoles which include but are not limited to: imazalil, pefurazoate, prochloraz, triflumizole, 2-(1 -tert-butyl)-1-(2-chlorophenyl)-3-(1 ,2,4-triazol-1-yl)- propan-2-ol, thiazolecarboxanilides such as 2',6'-dibromo-2-methyl-4-trifluoromethoxy-4'- trifluoromethyl-1 ,3-thiazole-5-carboxanilide, 1-imidazolyl-1-(4'-chlorophenoxy)-3,3-dimethylbutan-2- one and their metal salts and acid adducts.\n\n\n(3) \"Methyl (E)-2-phenyl-3-methoxyacrylate\" compounds which include but are not limited to: methyl (E)-2-[2-[6-(2-cyanophenoxy)pyrimιdin-4-yloxy]phenyl]3-methoxyacrylate, methyl (E)-2-[2-[6-(2-thioamidophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-fluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2,6-difluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(pyrimidin-2-yloxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(5-methylpyrimιdin-2-yloxy)-phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(phenyl-sulphonyloxy)phenoxy]phenyl-3-methoxyacrylate, methyl (E)-2-[2-[3-(4-nitrophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-phenoxyphenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3,5-dimethyl-benzoyl)pyrrol-1-yl]-3-methoxyacrylate, methyl (E)-2-[2-(3-methoxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2[2-(2-phenylethen-1-yl)-phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3,5-dichlorophenoxy)pyridin-3-yl]-3-methoxyacrylate, \n\n PATENT MER 08-116PCT methyl (E)-2-(2-(3-(1 ,1 ,2,2-tetrafluoroethoxy)phenoxy)phenyl)-3-methoxyacrylate, methyl (E)-2-(2-[3-(alpha-hydroxybenzyl)phenoxy]phenyl)-3-methoxyacrylate, methyl (E)-2-(2-(4-phenoxypyridin-2-yloxy)phenyl)-3-methoxyacrylate, methyl (E)-2-[2-(3-n-propyloxyphenoxy)phenyl]3-methoxyacrylate, methyl (E)-2-[2-(3-isopropyloxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(2-fluorophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3-ethoxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(4-tert-butyl-pyridin-2-yloxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(3-cyanophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[(3-methylpyridin-2-yloxymethyl)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-methylphenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(5-bromo-pyridin-2-yloxymethyl)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3-(3-iodopyridin-2-yloxy)phenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-chloropyridin-3-yloxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-(5,6-di-methylpyrazin-2-ylmethyloximinomethyl)phenyl]-3-methoxyacrylate, methyl (E)-2-{2-[6-(6-methylpyridin-2-yloxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate, methyl\n\n\n(E),(E)-2-{2-(3-methoxyphenyl)methyloximinomethyl]-phenyl}-3-methoxyacrylate, methyl (E)-2-{2-(6-\n\n\n(2-azidophenoxy)-pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate, methyl (E),(E)-2-{2-[6-phenylpyrimidin-4-yl)-methyloximinomethyl]phenyl}-3-methoxyacrylate, methyl (E),(E)-2-{2-[(4-chlorophenyl)-methyloximinomethyl]-phenyl}-3-methoxyacrylate, methyl (E)-2-\n\n\n{2-[6-(2-n-propylphenoxy)-1 ,3,5-triazin-4-yloxy]phenyl}-3-methoxyacrylate, and methyl (E),(E)-2-{2-[(3- nitrophenyl)methyloximinomethyl]phenyl}-3-methoxyacrylate;\n\n\n(4) Succinate Dehydrogenase Inhibitors which include but are not limited to:\n\n\n(a) fenfuram, furcarbanil, cyclafluramid, furmecyclox, seedvax, metsulfovax, pyrocarbolid, oxycarboxin, shirlan, mebenil (mepronil), benodanil, flutolanil (Moncut);\n\n\n(b) naphthalene derivatives such as terbinafine, naftifine, butenafine, 3-chloro-7-(2-aza- 2,7,7-trimethyl-oct-3-en-5-ine);\n\n\n(c) sulphenamides such as dichlofluanid, tolylfluanid, folpet, fluorfolpet; captan, captofol;\n\n\n(d) benzimidazoles such as carbendazim, benomyl, furathiocarb, fuberidazole, thiophonatmethyl, thiabendazole or their salts;\n\n\n(e) morpholine derivatives such as fenpropimorph, falimorph, dimethomorph, dodemorph, aldimorph, fenpropidine and their arylsulphonates, such as, for example, p-toluenesulphonic acid and p-dodecylphenyl-sulphonic acid;\n\n\n(f) dithiocarbamates, cufraneb, ferbam, mancopper, mancozeb, maneb, metam, metiram, thiram zeneb, ziram;\n\n\n(g) benzothiazoles, such as 2-mercaptobenzothiazole;\n\n\n(h) benzamides, such as 2,6-dichloro-N-(4-trifluoromethylbenzyl)-benzamide; (i) boron compounds, such as boric acid, boric esters, borax; \n\n PATENT MER 08-116PCT\n\n\n(j) formaldehyde and formaldehyde-releasing compounds, such as benzyl alcohol mono- (poly)-hemiformal, oxazolidine, hexa-hydro-S-triazines, N-methylolchloroacetamide, paraformaldehyde, nitropyrin, oxolinic acid, tecloftalam;\n\n\n(k) tris-N-(cyclohexyldiazeniumdioxy)-aluminium, N-(cyclo-hexyldiazeniumdioxy)-tri- butyltin or K salts, bis-N-(cyclohexyldiazeniumdioxy)-copper, N-methylisothiazolin-3- one, 5-chloro-N-methylisothiazolin-3-one, 4,5-dichloro-N-octylisothiazolin-3-one, N- octyl-isothiazolin-3-one, 4,5-trimethylene-isothiazolinone, 4,5-benzoisothiazolinone, N-methylolchloroacetamide;\n\n\n(I) aldehydes, such as cinnamaldehyde, formaldehyde, glutaraldehyde, β-bromo- cinnamaldehyde;\n\n\n(m) thiocyanates, such as thiocyanatomethylthiobenzothiazole, methylenebisthiocyanate, and the like;\n\n\n(n) quaternary ammonium compounds, such as benzyldimethyltetradecylammonium chloride, benzyldimethyldodecylanmuonium chloride, didecyldimethylammonium chloride;\n\n\n(o) iodine derivatives, such as diiodomethyl p-tolyl sulphone, 3-iodo-2-propinyl alcohol, 4- chlorophenyl-3-iodopropargyl formal, 3-bromo-2,3-diiodo-2-propenyl ethylcarbamate, 2,3,3-triiodoallyl alcohol, 3-bromo-2,3-diiodo-2-propenyl alcohol, 3-iodo-2-propinyl n- butylcarbamate, 3-iodo-2-propinyl n-hexylcarbamate, 3-iodo-2-propinyl cyclohexyl- carbamate, 3-iodo-2-propinyl phenylcarbamate;\n\n\n(p) phenol derivatives, such as tribromophenol, tetrachlorophenol, 3-methyl-4- chlorophenol, 3,5-dimethyl-4-chlorophenol, phenoxyethanol, dichlorophene, o- phenylphenol, m-phenylphenol, p-phenylphenol, 2-benzyl-4-chlorophenol and their alkali metal and alkaline earth metal salts; (q) microbicides having an activated halogen group, such as chloroacetamide, bronopol, bronidox, tectamer, such as 2-bromo-2-nitro-1 ,3-propanediol, 2-bromo-4'- hydroxyacetophenone, 2,2-dibromo-3-nitrile-propionamide, 1 ,2-dibromo-2,4- dicyanobutane, β-bromo-β-nitrostyrene;\n\n\n(r) pyridines, such as 1-hydroxy-2-pyridinethione (and their Na, Fe, Mn, Zn salts), tetrachloro-4-methylsulphonylpyridine, pyrimethanol, mepanipyrim, dipyrithion, 1- hydroxy-4-methyl-6-(2,4,4-tri methyl pentyl)-2(1 H)-pyridine;\n\n\n(s) metal soaps, such as tin naphthenate, copper naphthenate, zinc naphthenate, tin octoate, copper octoate, zinc octoate, tin 2-ethylhexanoate, copper 2-ethylhexanoate, zinc 2-ethylhexanoate, tin oleate, copper oleate, zinc oleate, tin phosphate, copper phosphate, zinc phosphate, tin benzoate, copper benzoate and zinc benzoate;\n\n\n(t) metal salts, such as copper hydroxycarbonate, sodium dichromate, potassium dichromate, potassium chromate, copper sulphate, copper chloride, copper borate, zinc fluorosilicate, copper fluorosilicate, and mixtures with fixatives;\n\n\n(u) oxides, such as tributyltin oxide, Cu\n2\nO, CuO, ZnO, \n\n PATENT MER 08-116PCT\n\n\n(v) dialkyldithiocarbamates, such as Na and Zn salts of dialkyldithiocarbamates, tetramethylthiuram disulphide, potassium N-methyl-dithiocarbamate; (w) nitriles, such as 2,4,5,6-tetrachloroisophthalodinitrile, disodium cyano-dithioimido- carbamate; (x) quinolines, such as 8-hydroxyquιnoline, and their Cu salts;\n\n\n(y) mucochloric acid, 5-hydroxy-2(5H)-furanone, (z) 4,5-dichlorodithiazolinone, 4,5-benzodithiazolinone, 4,5-trimethylenedithiazolinone,\n\n\n4,5-dichloro-(3H)-1 ,2-dithiol-3-one, 3,5-dimethyl-tetrahydro-1 ,3,5-thiadiazine-2-thione, N-(2-p-chlorobenzoylethyl)-hexaminium chloride, potassium N-hydroxymethyl-N'- methyl-dithiocarbamate, 2-oxo-2-(4-hydroxy-phenyl)acetohydroximic acid chloride, phenyl-(2-chloro-cyano-vinyl)sulphone, phenyl-(1 ,2-dichloro-2-cyano-vinyl)sulphone; and (aa) Ag-, Zn- or Cu-containing zeolites, alone or enclosed in polymeric active compounds, or (bb) mixtures of more than one of the abovementioned fungicides.\n\n\nHerbicides which are known from the literature and which can be mentioned, which can be combined with the compounds of the formula (I) and (Ia), are, for example, the following active substances (Note: the compounds are either designated by the common name according to the\n\n\nInternational Organization for Standardization (ISO) or using the chemical name, if appropriate together with a customary code number): acetochlor; acifluorfen(-sodium); aclonifen; AKH 7088, i.e.\n\n\n[[[1-[5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-2-methoxyethylidene]amino]oxy]acetic acid and its methyl ester; alachlor; alloxydim(-sodium); ametryn; amicarbazone, amidochlor, amidosulfuron; amitrol; AMS, i.e. ammonium sulfamate; anilofos; asulam; atrazine; azafenidin; azimsulfuron (DPX-A8947); aziprotryn; barban; BAS 516 H, i.e. 5-fluoro-2-phenyl-4H-3,1-benzoxazin- 4-one; beflubutamid; benazolin(-ethyl); benfluralin; benfuresate; bensulfuron(-methyl); bensulide; bentazone(-sodium); benzobicyclone; benzofenap; benzofluor; benzoylprop(-ethyl); benzthiazuron; bialaphos (bilanafos); bifenox; bispyribac(-sodium); bromacil; bromobutide; bromofenoxim; bromoxynil; bromuron; buminafos; busoxinone; butachlor; butafenacil; butamifos; butenachlor; buthidazole, butralin; butroxydim; butylate; cafenstrole (CH-900); carbetamide; carfentrazone(-ethyl); caloxydim, CDAA, i.e. 2-chloro-N,N-di-2-propenylacetamide; CDEC, i.e. 2-chloroallyl diethyldithiocarbamate; chlomethoxyfen; chloramben; chlorazifop-butyl; chlorbromuron; chlorbufam; chlorfenac; chlorflurenol-methyl; chloridazon; chlorimuron(-ethyl); chlornitrofen; chlorotoluron; chloroxuron; chlorpropham; chlorsulfuron; chlorthal-dimethyl; chlorthiamid; chlortoluron, cinιdon(- methyl or -ethyl), cinmethylin; cinosulfuron; clethodim; clefoxydim, clod inafop and its ester derivatives (for example clodinafop-propargyl); clomazone; clomeprop; cloproxydim; clopyralid; clopyrasulfuron(- methyl); cloransulam(-methyl); cumyluron (JC 940); cyanazine; cycloate; cyclosulfamuron (AC 104); cycloxydim; cycluron; cyhalofop and its ester derivatives (for example butyl-ester, DEH-1 12); cyperquat; cyprazine; cyprazole; daimuron; 2,4-D; 2,4-DB; dalapon; dazomet, desmedipham; desmetryn, di-allate; dicamba, dichlobenil, dichlorprop(-P); diclofop and its esters such as diclofop-methyl; diclosulam, diethatyl(-ethyl); difenoxuron; difenzoquat; diflufenican; diflufenzopyr; \n\n PATENT MER 08-116PCT dimefuron; dimepiperate, dimethachlor; dimethametryn; dimethenamid (SAN-582H); dimethenamid(-\n\n\nP); dimethazone, dimethipin; dimexyflam, dimetrasulfuron, dinitramine; dinoseb; dinoterb; diphenamid; dipropetryn; diquat; dithiopyr; diuron; DNOC; eglinazine-ethyl; EL 77, i.e. 5-cyano-1-(1 ,1-dimethyl- ethyl)-N-methyl-1 H-pyrazole-4-carboxamide; endothal; epoprodan, EPTC; esprocarb; ethalfluralin; ethametsulfuron-methyl; ethidimuron; ethiozin; ethofumesate; ethoxyfen and its esters (for example ethyl ester, HC-252), ethoxysulfuron, etobenzanid (HW 52); F5231 , i.e. N-[2-chloro-4-fluoro-5-[4-(3- fluoropropyl)-4,5-dihydro-5-oxo-1 H-tetrazol-1-yl]-phenyl]ethanesulfonamide; fenoprop; fenoxan, fenoxaprop and fenoxaprop-P and their esters, for example fenoxaprop-P-ethyl and fenoxaprop-ethyl; fenoxydim; fentrazamide; fenuron; flamprop(-methyl or -isopropyl or -isopropyl-L); flazasulfuron; florasulam; fluazifop and fluazιfop-P and their esters, for example fluazifop-butyl and fluazifop-P-butyl; fluazolate, flucarbazone(-sodium); fluchloralin, flufenacet (FOE 5043), flufenpyr, flumetsulam; flumeturon; flumiclorac(-pentyl); flumioxazin (S-482); flumipropyn; fluometuron; fluorochloridone, fluorodifen; fluoroglycofen(-ethyl); flupoxam (KNW-739); flupropacil (UBIC-4243); fluproanate, flupyrsulfuron(-methyl, or -sodium); flurenol(-butyl); fluridone; flurochloridone; fluroxypyr(-meptyl); flurprimidol, flurtamone; fluthiacet(-methyl); fluthiamide (also known as flufenacet); fomesafen; foramsulfuron, fosamine, furilazole (MON 13900), furyloxyfen, glufosinate(-ammonium); glyphosate(-isopropylammonium); halosafen; halosulfuron(-methyl) and its esters (for example the methyl ester, NC-319); haloxyfop and its esters; haloxyfop-P (= R-haloxyfop) and its esters; HC-252\n\n\n(diphenylether), hexazinone; imazamethabenz(-methyl); imazamethapyr; imazamox; imazapic, imazapyr; imazaquin and salts such as the ammonium salts; imazethamethapyr; imazethapyr, imazosulfuron; indanofan; iodosulfuron-(methyl)-(sodium), ioxynil; isocarbamid; isopropalin; isoproturon; isouron; isoxaben; isoxachlortole; isoxaflutole; isoxapyrifop; karbutilate; lactofen; lenacil; linuron; MCPA; MCPB; mecoprop; mefenacet; mefluidid; mesosulfuron(-methyl); mesotrione; metam, metamifop, metamitron; metazachlor; methabenzthiazuron; methazole; methoxyphenone; methyl- dymron; metobenzuron, metobromuron; (S-)metolachlor; metosulam (XRD 51 1 ); metoxuron; metribuzin; metsulfuron-methyl; MK-616; molinate; monalide; monocarbamide dihydrogensulfate; monolinuron; monuron; MT 128, i.e. 6-chloro-N-(3-chloro-2-propenyl)-5-methyl-N-phenyl-\n\n\n3-pyrιdazinamine; MT 5950, i.e. N-[3-chloro-4-(1-methylethyl)-phenyl]-2-methylpentanamιde; naproanilide; napropamide; naptalam; NC 310, i.e. 4-(2,4-dichlorobenzoyl)-1-methyl-5- benzyloxypyrazole; neburon; nicosulfuron; nipyraclophen; nitralin; nitrofen; nitrofluorfen; norflurazon; orbencarb; oryzalin; oxadiargyl (RP-020630); oxadiazone; oxasulfuron; oxaziclomefone; oxyfluorfen; paraquat; pebulate; pelargonic acid; pendimethalin; penoxulam; pentanochlor, pentoxazone; perfluidone; pethoxamid, phenisopham; phenmedipham; picloram; picolinafen; piperophos; piributicarb; pirifenop-butyl; pretilachlor, primisulfuron(-methyl); procarbazone(-sodium); procyazine; prodiamine; profluazole, profluralin; proglinazine(-ethyl); prometon; prometryn; propachlor; propanil; propaquizafop; propazine; propham; propisochlor; propoxycarbazone(-sodium), propyzamide; prosulfalin; prosulfocarb; prosulfuron (CGA-152005); prynachlor; pyraclonil, pyraflufen(-ethyl); pyrazolinate; pyrazon; pyrazosulfuron(-ethyl); pyrazoxyfen; pyribenzoxim; pyributicarb; pyridafol; pyridate; pyriftalid, pyrimidobac(-methyl), pyrithiobac(-sodium) (KIH-2031 ); pyroxofop and its esters (for example propargyl ester); quinclorac; quinmerac; quinoclamine, quinofop and its ester derivatives, \n\n PATENT MER 08-116PCT quizalofop and quizalofop-P and their ester derivatives, for example quizalofop-ethyl; quizalofop-P-tefuryl and -ethyl; renriduron; rimsulfuron (DPX-E 9636); S 275, i.e. 2-[4-chloro-2-fluoro- 5-(2-propynyloxy)phenyl]-4,5,6,7-tetrahydro-2H-indazole; secbumeton; sethoxydim; siduron; simazine; simetryn; SN 106279, i.e. 2-[[7-[2-chloro-4-(trifluoromethyl)phenoxy]-2-naphthalenyl]oxy]propanoic acid and its methyl ester; sulcotrione; sulfentrazone (FMC-97285, F-6285); sulfazuron; sulfometuron(- methyl); sulfosate (ICI-A0224); sulfosulfuron; TCA; tebutam (GCP-5544); tebuthiuron; tepraloxydim; terbacil; terbucarb; terbuchlor; terbumeton; terbuthylazine; terbutryn; TFH 450, i.e. N,N-diethyl-3-[(2- ethyl-6-methylphenyl)sulfonyl]-1 H-1 ,2,4-triazole-1 -carboxamide; thenylchlor (NSK-850); thiafluamide; thiazafluron; thiazopyr (Mon-13200); thidiazimin (SN-24085); thifensulfuron(-methyl); thiobencarb; tiocarbazil; tralkoxydim; tri-allate; triasulfuron; triaziflam; triazofenamide; trιbenuron(-methyl); 2,3,6- trichlorobenzoic acid (2,3,6-TBA), triclopyr; tridiphane; trietazine; trifloxysulfuron(-sodium), trifluralin; triflusulfuron and esters (e.g. methyl ester, DPX-66037); trimeturon; tritosulfuron; tsitodef; vernolate; WL 110547, i.e. 5-phenoxy-1-[3-(trifluoromethyl)phenyl]-1 H-tetrazole; UBH-509; D-489; LS 82-556; KPP-300; NC-324; NC-330; KH-218; DPX-N8189; SC-0774; DOWCO-535; DK-8910; V-53482; PP- 600; MBH-001 ; KIH-9201 ; ET-751 ; KIH-6127; KIH-2023 and KIH5996.\n\n\nAppropriate herbicide safeners include but are not limited to benoxacor, cloquintocet, cyometrinil, cyprosulfamide, dichlormid, dicyclonon, dietholate, fenchlorazole, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen, mefenpyr, mephenate, naphthalic anyhydride and oxabetrinil.\n\n\nComponents which may be employed for the active substances according to the invention in mixed formulations, for example, known active compounds which are based on an inhibition of, for example, acetolactate synthase, acetyl-coenzyme A carboxylase, PS I, PS II, HPPDO, phytoene desaturase, protoporphyrinogen oxidase, glutamine synthetase, cellulose biosynthesis, 5-enolpyruvylshikimate-3-phosphate synthetase. Such compounds, and also other compounds which can be employed, whose mechanism of action is to a degree unknown or different, are described, for example, in Weed Research 26, 441-445 (1986), or \"The Pesticide Manual\", 12th Edition 2000 (hereinbelow also abbreviated to \"PM\"), The British Crop Protection Council and the Royal Soc. of Chemistry (editors) and literature cited therein.\n\n\nThe compounds of formula (I) and formula (Ia) can be formulated in various ways, depending on the prevailing biological and/or chemico-physical parameters. Examples of possible formulations which are suitable are: wettable powders (WP), water-soluble powders (SP), water-soluble concentrates, emulsifiable concentrates (EC), emulsions (EW) such as oil-in-water and water-in-oil emulsions, sprayable solutions, suspension concentrates (SC), dispersions on an oil or water basis, solutions which are miscible with oil, capsule suspensions (CS), dusts (DP), seed-dressing products, granules for broadcasting and soil application, granules (GR) in the form of microgranules, spray granules, coated granules and adsorption granules, water-dispersible granules (WG), water-soluble granules (SG), ULV formulations, microcapsules and waxes.\n\n\nThe formulations mentioned can be prepared in a manner known per se, for example by mixing the active compounds with at least one solvent or diluent, emulsifier, dispersant and/or binder or fixative, water repellent and optionally one or more of a desiccant, UV stabilizer, a colorant, a pigment and other processing auxiliaries. \n\n PATENT MER 08-116PCT\n\n\nThese individual formulation types are known in principle and described, for example, in: Winnacker-Kϋchler, \"Chemische Technologie\" [Chemical Technology], Volume 7, C. Hauser Verlag, Munich, 4th Edition 1986; Wade van Valkenburg, \"Pesticide Formulations\", Marcel Dekker, N.Y., 1973; K. Martens, \"Spray Drying Handbook\", 3rd Ed. 1979, G. Goodwin Ltd. London. The necessary formulation auxiliaries such as inert materials, surfactants, solvents and other additives are also known and described, for example, in: Watkins, \"Handbook of Insecticide Dust Diluents and Carriers\", 2nd Ed., Darland Books, Caldwell N. J.; H.v. Olphen, \"Introduction to Clay Colloid Chemistry\", 2nd Ed., J. Wiley & Sons, N.Y.; C. Marsden, \"Solvents Guide\", 2nd Ed., Interscience, N.Y. 1963; McCutcheon's \"Detergents and Emulsifiers Annual\", MC Publ. Corp., Ridgewood N. J.; Sisley and Wood, \"Encyclopedia of Surface Active Agents\", Chem. Publ. Co. Inc., N.Y. 1964; Schδnfeldt, \"Grenzflachenaktive Athylenoxidaddukte\" [Surface-active ethylene oxide adducts], Wiss. Verlagsgesell., Stuttgart 1976; Winnacker-Kuchler, \"Chemische Technologie\" [Chemical Technology], Volume 7, C. Hauser Verlag, Munich, 4th Ed. 1986.\n\n\nWettable powders are preparations which are uniformly dispersible in water and which, besides the compounds of formula (I) and formula (Ia), also comprise ionic and/or nonionic surfactants (wetters, dispersants), for example, polyoxyethylated alkylphenols, polyoxyethylated fatty alcohols, polyoxyethylated fatty amines, fatty alcohol polyglycol ether sulfates, alkanesulfonates or alkylbenzenesulfonar.es, sodium lignosulfonate, sodium 2,2'-dinaphthylmethane-6,6'-disulfonate, sodium dibutylnaphthalenesulfonate or else sodium oleoylmethyltaurinate, in addition to a diluent or inert substance. To prepare the wettable powders, the compounds of formula (I) and (Ia) are, for example, ground finely in conventional apparatuses such as hammer mills, blower mills and air-jet mills and mixed with the formulation auxiliaries, either concomitantly or thereafter.\n\n\nEmulsifiable concentrates are prepared, for example, by dissolving the compounds of formula (I) and formula (Ia) in an organic solvent, for example butanol, cyclohexanone, dimethylformamide, xylene or else higher-boiling aromatics or hydrocarbons or mixtures of these, with addition of one or more ionic and/or nonionic surfactants (emulsifiers). Emulsifiers which can be used are, for example: calcium salts of alkylarylsulfonic acids, such as calcium dodecylbenzenesulfonate or nonionic emulsifiers, such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide/ethylene oxide condensates, alkyl polyethers, sorbitan esters such as sorbitan fatty acid esters or polyoxyethylene sorbitan esters such as polyoxyethylene sorbitan fatty acid esters.\n\n\nDusts are obtained by grinding the active substance with finely divided solid substances, for example talc or natural clays, such as kaolin, bentonite or pyrophyllite, or diatomaceous earth.\n\n\nSuspension concentrates may be water- or oil-based. They can be prepared, for example, by wet grinding by means of commercially available bead mills, if appropriate with addition of surfactants, as they have already been mentioned above for example in the case of the other formulation types.\n\n\nEmulsions, for example oil-in-water emulsions (EW), can be prepared for example by means of stirrers, colloid mills and/or static mixtures using aqueous organic solvents and, if appropriate, surfactants as they have already been mentioned above for example in the case of the other formulation types. \n\n PATENT MER 08-116PCT\n\n\nGranules can be prepared either by spraying the compounds of formula (I) and formula (Ia) onto adsorptive, granulated inert material or by applying active substance concentrates onto the surface of carriers such as sand, kaolinites or of granulated inert material, by means of binders, for example polyvinyl alcohol, sodium polyacrylate or alternatively mineral oils. Suitable active substances can also be granulated in the manner which is conventional for the production of fertilizer granules, if desired in a mixture with fertilizers.\n\n\nWater-dispersible granules are prepared, as a rule, by the customary processes such as spray-drying, fluidized-bed granulation, disk granulation, mixing in high-speed mixers and extrusion without solid inert material. To prepare disk, fluidized-bed, extruder and spray granules, see, for example, processes in \"Spray-Drying Handbook\" 3rd ed. 1979, G. Goodwin Ltd., London; J. E. Browning, \"Agglomeration\", Chemical and Engineering 1967, pages 147 et seq.; \"Perry's Chemical Engineer's Handbook\", 5th Ed., McGraw-Hill, New York 1973, p. 8-57.\n\n\nIn general, the agrochemical preparations comprise a range selected from the group consisting of about 0.1 to about 99% by weight and about 0.1 to about 95% by weight, of compounds of formula (I) and (Ia).\n\n\nThe concentration of compounds of formula (I) and (Ia) in wettable powders is, for example, about 10 to about 90% by weight, the remainder to 100% by weight being composed of customary formulation components. In the case of emulsifiable concentrates, the concentration of compounds of formula (I) and formula (Ia) can amount to ranges selected from the group consisting of about 1 % to about 90% and about 5% to about 80% by weight. Formulations in the form of dusts usually comprise in the range selected from the group consisting of about 1 % to about 30% by weight of compounds of formula (I) and formula (Ia) and about 5% to about 20% by weight of compounds of formula (I). For sprayable solutions comprise a range selected from the group consisting of about 0.05% to about 80% by weight of compounds of formula (I) and formula (Ia) and about 2% to about 50% by weight of compounds of formula (I) and formula (Ia). In the case of water-dispersible granules, the content of compounds of formula (I) and formula (Ia) depends partly on whether the compounds of formula (I) and formula (Ia) are in liquid or solid form and on which granulation auxiliaries, fillers and the like are being used. The water-dispersible granules, for example, comprise a range selected from the group consisting of between about 1 and about 95% and between about 10% and about 80% by weight. In addition, the formulations of compounds of formula (I) and formula (Ia) mentioned comprise, if appropriate, the adhesives, wetters, dispersants, emulsifiers, penetrants, preservatives, antifreeze agents, solvents, fillers, carriers, colorants, antifoams, evaporation inhibitors, pH regulators and viscosity regulators which are conventional in each case.\n\n\nThe mixtures according to the invention can be applied via the soil either pre-emergently or post-emergently. The mixtures according to the invention can also be applied via the leaf. The mixtures according to the invention can be employed for seed dressing. It is also possible to apply the mixtures according to the invention via an irrigation system, for example via the water for irrigation. \n\n PATENT MER 08-116PCT\n\n\nOther Active Agents for Pharmaceutical/Veterinary Use\n\n\nAdditional pesticidally or veterinarily active ingredients, which include, but are not limited to, acaricides, anthelmintics, anti-parasitics and insecticides, may also be added to the compositions of the invention in combination with compounds of formula (I) or (Ia). Anti-parasitic agents can include both ectoparasiticisal and endoparasiticidal agents. These agents are well-known in the art (see e.g. Plumb' Veterinary Drug Handbook, 5\nth\n Edition, ed. Donald C. Plumb, Blackwell Publishing, (2005) or The Merck Veterinary Manual, 9\nth\n Edition, (January 2005)) and include but are not limited to acarbose, acepromazine maleate, acetaminophen, acetazolamide, acetazolamide sodium, acetic acid, acetohydroxamic acid, acetylcysteine, acitretin, acyclovir, albendazole, albuterol sulfate, alfentanil HCI, allopurinol, alprazolam, altrenogest, amantadine HCI, amikacin sulfate, aminocaproic acid, aminopentamide hydrogen sulfate, aminophylline/theophylline, amiodarone HCI, amitraz, amitriptyline HCI, amlodipine besylate, ammonium chloride, ammonium molybdenate, amoxicillin, amoxicillin, clavulanate potassium, amphotericin B desoxycholate, amphotericin B lipid-based, ampicillin, amprolium HCI, antacids (oral), antivenin, apomorphione HCI, apramycin sulfate, ascorbic acid, asparaginase, aspiring, atenolol, atipamezole HCI, atracurium besylate, atropine sulfate, aurnofin, aurothioglucose, azaperone, azathioprine, azithromycin, baclofen, barbituates, benazepril HCI, betamethasone, bethanechol chloride, bisacodyl, bismuth subsalicylate, bleomycin sulfate, boldenone undecylenate, bromides, bromocriptine mesylate, budenoside, buprenorphine HCI, buspirone HCI, busulfan, butorphanol tartrate, cabergoline, calcitonin salmon, calcitrol, calcium salts, captopril, carbenicillin indanyl sodium, carbimazole, carboplatin, carnitine, carprofen, carvedilol, cefadroxil, cefazolin sodium, cefixime, cefoperazone sodium, cefotaxime sodium, cefotetan disodium, cefoxitin sodium, cefpodoxime proxetil, ceftazidime, ceftiofur sodium, ceftiofur HCI, ceftiaxone sodium, cephalexin, cephalosporins, cephapirin, charcoal (activated), chlorambucil, chloramphenicol, chlordiazepoxide, chlordiazepoxide +/- clidinium bromide, chlorothiazide, chlorpheniramine maleate, chlorpromazine HCI, chlorpropamide, chlortetracycline, chorionic gonadotropin (HCG), chromium, cimetidine, ciprofloxacin, cisapride, cisplatin, citrate salts, clarithromycin, clemastine fumarate, clenbuterol HCI, clindamycin, clofazimine, clomipramine HCI, clonazepam, clonidine, cloprostenol sodium, clorazepate dipotassium, clorsulon, cloxacillin, codeine phosphate, colchicine, corticotropin (ACTH), cosyntropin, cyclophosphamide, cyclosporine, cyproheptadine HCI, cytarabine, dacarbazine, dactinomycin/actinomycin D, dalteparin sodium, danazol, dantrolene sodium, dapsone, decoquinate, deferoxamine mesylate, deracoxib, deslorelin acetate, desmopressin acetate, desoxycorticosterone pivalate, detomidine HCI, dexamethasone, dexpanthenol, dexraazoxane, dextran, diazepam, diazoxide (oral), dichlorphenamide, dichlorvos, diclofenac sodium, dicloxacillin, diethylcarbamazine citrate, diethylstilbestrol (DES), difloxacin HCI, digoxin, dihydrotachysterol (DHT), diltiazem HCI, dimenhydrinate, dimercaprol/BAL, dimethyl sulfoxide, dinoprost tromethamine, diphenylhydramine HCI, disopyramide phosphate, dobutamine HCI, docusate/DSS, dolasetron mesylate, domperidone, dopamine HCI, doramectin, doxapram HCI, doxepin HCI, doxorubicin HCI, doxycycline, edetate calcium disodium. calcium EDTA, edrophonium chloride, enalapril/enalapnlat, enoxaparin sodium, enrofloxacin, ephedrine sulfate, epinephrine, epoetin/erythropoietin, eprinomectin, epsiprantel, erythromycin, esmolol HCI, estradiol cypionate, ethacrynic acid/ethacrynate sodium, ethanol (alcohol), \n\n PATENT MER 08-116PCT etidronate sodium, etodolac, etomidate, euthanasia agents w/pentobarbital, famotidine, fatty acids (essential/omega), felbamate, fenbendazole, fentanyl, ferrous sulfate, filgrastim, finasteride, fipronil, florfenicol, fluconazole, flucytosine, fludrocortisone acetate, flumazenil, flumethasone, flunixin meglumine, fluorouracil (5-FU), fluoxetine, fluticasone propionate, fluvoxamine maleate, fomepizole (4-MP), furazolidone, furosemide, gabapentin, gemcitabine HCL, gentamicin sulfate, glimepiride, glipizide, glucagon, glucocorticoid agents, glucosamine/chondroitin sulfate, glutamine, glyburide, glycerine (oral), glycopyrrolate, gonadorelin, grisseofulvin, guaifenesin, halothane, hemoglobin glutamer-200 (oxyglobin®), heparin, hetastarch, hyaluronate sodium, hydrazaline HCI, hydrochlorothiazide, hydrocodone bitartrate, hydrocortisone, hydromorphone, hydroxyurea, hydroxyzine, ifosfamide, imidacloprid, imidocarb dipropinate, impenem-cilastatin sodium, imipramine, inamrinone lactate, insulin, interferon alfa-2a (human recombinant), iodide (sodium/potassium), ipecac (syrup), ipodate sodium, iron dextran, isoflurane, isoproterenol HCI, isotretinoin, isoxsuprine HCI, itraconazole, ivermectin, kaolin/pectin, ketamine HCI, ketoconazole, ketoprofen, ketorolac tromethamine, lactulose, leuprolide, levamisole, levetiracetam, levothyroxine sodium, lidocaine HCI, lincomycin HCI, liothyronine sodium, lisinopril, lomustine (CCNU), lufenuron, lysine, magnesium, mannitol, marbofloxacin, mechlorethamine HCI, meclizine HCI, meclofenamic acid, medetomidine HCI, medium chain triglycerides, medroxyprogesterone acetate, megestrol acetate, melarsomine, melatonin, meloxican, melphalan, meperidine HCI, mercaptopurine, meropenem, metformin HCI, methadone HCI, methazolamide, methenamine mandelate/hippurate, methimazole, methionine, methocarbamol, methohexital sodium, methotrexate, methoxyflurane, methylene blue, methylphenidate, methylprednisolone, metoclopramide HCI, metoprolol, metronidaxole, mexiletine HCI, mibolerlone, midazolam HCI milbemycin oxime, mineral oil, minocycline HCI, misoprostol, mitotane, mitoxantrone HCI, morantel tartrate, morphine sulfate, moxidectin, naloxone HCI, mandrolone decanoate, naproxen, narcotic (opiate) agonist analgesics, neomycin sulfate, neostigmine, niacinamide, nitazoxanide, nitenpyram, nitrofurantoin, nitroglycerin, nitroprusside sodium, nizatidine, novobiocin sodium, nystatin, octreotide acetate, olsalazine sodium, omeprazole, ondansetron, opiate antidiarrheals, orbifloxacin, oxacillin sodium, oxazepam, oxfendazole, oxibutynin chloride, oxymorphone HCI, oxytretracycline, oxytocin, pamidronate disodium, pancreplipase, pancuronium bromide, paromomycin sulfate, parozetine HCI, pencillamine, general information penicillins, penicillin G, penicillin V potassium, pentazocine, pentobarbital sodium, pentosan polysulfate sodium, pentoxifylline, pergolide mesylate, phenobarbital, phenoxybenzamine HCI, pheylbutazone, phenylephrine HCL, phenypropanolamine HCI, phenytoin sodium, pheromones, parenteral phosphate, phytonadione/vitamin K-1 , pimobendan, piperazme, pirlimycin HCL, piroxicam, polysulfated glycosaminoglycan, ponazuril, potassium chloride, pralidoxime chloride, praziquantel, prazosin HCI, prednisolone/prednisone, primidone, procainamide HCI, procarbazine HCI, prochlorperazine, propantheline bromide, propionibacterium acnes injection, propofol, propranolol HCI, protamine sulfate, pseudoephedrine HCI, psyllium hydrophilic mucilloid, pyrantel pamoate, pyridostigmine bromide, pyrilamine maleate, pyrimethamine, quinacrine HCI, quinidine, ranitidine HCI, rifampin, s-adenosyl-methionine (SAMe), saline/hyperosmotic laxative, selamectin, selegiline HCL/I- deprenyl, sertraline HCI, sevelamer HCI, sevoflurane, silymarin/milk thistle, sodium bicarbonate, \n\n PATENT MER 08-116PCT sodium polystyrene sulfonate, sodium stibogluconate, sodium sulfate, sodum thiosulfate, somatotropin, sotalol HCI, spectinomycin HCI, spironolactone, stanozolol, streptokinase, streptozocin, succimer, succinylcholine chloride, sucralfate, sufentanil citrate, sulfachlorpyridazine sodium, sulfadiazine/trimethroprim, sulfamethoxazole/trimethoprim, sulfadimentoxine, sulfadimethoxine/ormetoprim, sulfasalazine, taurine, tepoxaline, terbinafline HCI, terbutaline sulfate, testosterone, tetracycline HCI, thiabendazole, thiacetarsamide sodium, thiamine HCI, thioguanine, thiopental sodium, thiotepa, thyrotropin, tiamulin, ticarcilin disodium, tiletamine HCI/zolazepam HCI, tilmocsin, tiopronin, tobramycin sulfate, tocainide HCI, tolazoline HCI, telfenamic acid, topiramate, tramadol HCI, trimcinolone acetonide, trientine HCI, trilostane, trimepraxine tartrate w/prednisolone, tripelennamine HCI, tylosin, urdosiol, valproic acid, vanadium, vancomycin HCI, vasopressin, vecuronium bromide, verapamil HCI, vinblastine sulfate, vincristine sulfate, vitamin E/selenium, warfarin sodium, xylazine HCI, yohimbine HCI, zafirlukast, zidovudine (AZT), zinc acetate/zinc sulfate, zonisamide and mixtures thereof.\n\n\nIn one embodiment of the invention, arylpyrazole compounds including phenylpyrazoles such as fipronil and derivatives of fipronil, are known in the art and are suitable for combination with the compounds of the invention Examples of such arylpyrazole compounds include but are not limited to those described in U.S. Patent Nos. 6,001 ,384; 6,010,710; 6,083,519; 6,096,329; 6,174,540; 6,685,954 and 6,998,131 , which are all incorporated herein by reference in their entirety, - each assigned to Merial, Ltd., Duluth, GA). In another embodiment of the invention, nodulisporic acid and its derivatives (a class of known acaricidal, anthelminitic, anti-parasitic and insecticidal agents) can be added to the compositions of the invention. These compounds are used to treat or prevent infections in humans and animals and are described, for example, in U.S. Patent No. 5,399,582 and 5,962,499. The composition can include one or more of the known nodulisporic acid derivatives in the art, including all stereoisomers, such as those described in the literature cited above.\n\n\nIn another embodiment, anthelmintic compounds of the amino acetonitrile class (AAD) of compounds such as monepantel (ZOLVIX) and the like may be added to the compositions of the invention. These compounds are described, for example, in WO 2004/024704; Sager et al., Veterinary Parasitology, 2009, 159, 49-54; Kaminsky et al., Nature vol. 452, 13 March 2008, 176-181. The compositions of the invention may also be combined with paraherquamide compounds and derivatives of these compounds, including derquantel (see Ostlind et al., Research in Veterinary Science, 1990, 48, 260-61 ; and Ostlind et al., Medical and Veterinary Entomology, 1997, 11 , 407- 408). The paraherquamide family of compounds compounds are known class of compounds that include a spirodioxepino indole core with activity against certain parasites (see Tet. Lett. 1981 , 22, 135; J. Antibiotics 1990, 43, 1380, and J. Antibiotics 1991 , 44, 492). In addition, the structurally related marcfortine family of compounds, such as marcfortines A-C, are also known and may be combined with the formulations of the invention (see J. Chem. Soc. - Chem. Comm. 1980, 601 and Tet. Lett. 1981 , 22, 1977). Further references to the paraherquamide derivatives can be found, for example, in WO 91/09961 , WO 92/22555, WO 97/03988, WO 01/076370, WO 09/004432, U.S. \n\n PATENT MER 08-116PCT\n\n\nPatent 5,703,078 and U.S. Patent 5,750,695, all of which are hereby incorported by reference in their entirety.\n\n\nIn another embodiment, the compositions of the invention may be combined with cyclo- depsipeptide anthelmintic compounds including emodepside (see Willson et al., Parasitology, Jan. 2003, 126(Pt 1 ):79-86).\n\n\nIn another embodiment of the invention, one or more macrocyclic lactones, which act as an acaricide, anthelmintic agent and insecticide, can be added to the compositions of the invention. The macrolides are well-known in the art (see e.g. Macrolides - Chemistry, pharmacology and clinical uses - edited by Bryskier et al., publ.. by Arnette Blackwell, (1993)) and include but are not limited to 12-membered ring macrolides (e.g. methymycin, neomethymycin, YC-17, litorin); 14-membered ring macrolides (e.g. erythromycin A-F, oleandomycin, sporeamicin, roxithromycin, dirithromycin, flurithromycin, clarithromycin, davercin); 15-membered ring macrolides (e.g. azithromycin); 16- membered ring macrolides (e.g. josamycin, kitasamycin, spiramycin, midecamycin, rokitamycin, miokamicin) and 17-membered ring macrolides (e.g. lankadicin). The macrocyclic lactones also include, but are not limited to, avermectins, such as abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin and milbemycins, such as milbemectin, milbemycin D, moxidectin and nemadectin. Also included are the 5-oxo and 5-oxime derivatives of said avermectins and milbemycins. Examples of combinations of active pesticides with with macrocyclic lactones include but are not limited to those described in U.S. Patent Nos. 6,426,333; 6,482,425; 6,962,713 and 6,998, 131 , each of which is incorporated herein by reference - each assigned to Merial, Ltd , Duluth, GA\n\n\nThe macrocyclic lactone compounds are known in the art and can easily be obtained commercially or through synthesis techniques known in the art. Reference is made to the widely available technical and commercial literature. For avermectins, ivermectin and abamectin, reference may be made, for example, to the work \"Ivermectin and Abamectin\", 1989, by M. H. Fischer and H. Mrozik, William C. Campbell, published by Springer Verlag., or Albers-Schόnberg et al (1981 ), \"Avermectins Structure Determination\", J. Am. Chem. Soα, 103, 4216-4221. For doramectin, \"Veterinary Parasitology\", vol. 49, No. 1 , July 1993, 5-15 may be consulted. For milbemycins, reference may be made, inter alia, to Davies H. G. et al., 1986, \"Avermectins and Milbemycins\", Nat. Prod. Rep., 3, 87-121 , Mrozik H. et al., 1983, Synthesis of Milbemycins from Avermectins, Tetrahedron Lett., 24, 5333-5336, U.S. Patent No 4,134,973 and EP 0 677 054.\n\n\nMacrocyclic lactones are either natural products or are semi-synthetic derivatives thereof. The structure of the avermectins and milbemycins are closely related, e.g., by sharing a complex 16- membered macrocyclic lactone ring; milbemycins lack the glycosidic moiety of the avermectins. The natural product avermectins are disclosed in U.S. Patent No. 4,310,519 to Albers-Schόnberg et al., and the 22,23-dihydro avermectin compounds are disclosed in Chabala et al., U.S. Patent No. 4,199,569. Mention is also made of Kitano, U.S. Patent No. 4,468,390, Beuvry et al., U.S. Patent No. 5,824,653, EP 0 007 812 A1 , U.K. Patent Specification 1 390 336, EP 0 002 916, and Ancare New Zealand Patent No. 237 086, inter alia. Naturally occurring milbemycins are described in Aoki et al., U.S. Patent No. 3,950,360 as well as in the various references cited in \"The Merck Index\" 12\nth\n ed., \n\n PATENT MER 08-116PCT\n\n\nS. Budavari, Ed., Merck & Co., Inc. Whitehouse Station, New Jersey (1996). Latidectin is described in the \"International Nonproprietary Names for Pharmaceutical Substances (INN)\", WHO Drug Information, vol. 17, no. 4, pp. 263- 286, (2003). Semisynthetic derivatives of these classes of compounds are well known in the art and are described, for example, in U.S. Patent No. 5,077,308, U.S. Patent No. 4,859,657, U.S. Patent No. 4,963,582, U.S. Patent No. 4,855,317, U.S. Patent No. 4,871 ,719, U.S. Patent No. 4,874,749, U.S. Patent No. 4,427,663, U.S. Patent No. 4,310,519, U.S. Patent No. 4, 199,569, U.S. Patent No. 5,055,596, U.S. Patent No. 4,973,71 1 , U.S. Patent No. 4,978,677, U.S. Patent No. 4,920,148 and EP 0 667 054.\n\n\nIn another embodiment of the invention, the class of acaricides or insecticides known as insect growth regulators (IGRs) can also be added to the compositions of the invention. Compounds belonging to this group are well known to the practitioner and represent a wide range of different chemical classes. These compounds all act by interfering with the development or growth of the insect pests. Insect growth regulators are described, for example, in U.S. Patent No. 3,748,356; U.S. Patent No. 3,818,047; U.S. Patent No. 4,225,598, U.S. Patent No. 4,798,837, U.S. Patent No. 4,751 ,225, EP 0 179 022 or U.K. 2 140 010 as well as U.S. Patent Nos. 6,096,329 and 6,685,954 (both assigned to Merial Ltd., Duluth, GA), all of which are incorporated herein by reference. Examples of IGRs suitable for use include but are not limited to methoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, novaluron, pyrethroids, formamidines and 1-(2, 6- difluorobenzoyl)-3-(2-fluoro-4-(trifluoromethyl)phenylurea. An anthelmintic agent that can be combined with the compound of the invention to form a composition can be a benzenedisulfonamide compound, which includes but is not limited to clorsulon; or a cestodal agent, which includes but is not limited to praziquantel, pyrantel or morantel.\n\n\nAn antiparasitic agent that can be combined with the compound of the invention to form a composition can be a biologically active peptide or protein including, but not limited to, depsipeptides, which act at the neuromuscular junction by stimulating presynaptic receptors belonging to the secretin receptor family resulting in the paralysis and death of parasites. In one embodiment of the depsipeptide, the depsipeptide is emodepside.\n\n\nAn insecticidal agent that can be combined with the compound of the invention to form a composition can be a spinosyn (e.g. spinosad) or a substituted pyridylmethyl derivative compound such as imidacloprid. Agents of this class are described above, and for example, in U.S. Patent No. 4,742,060 or in EP 0 892 060, both which are incorporated herein by reference It would be well within the skill level of the practitioner to decide which individual compound can be used in the inventive formulation to treat a particular infection of an insect.\n\n\nWhere appropriate the anthelmintic, antiparasitic and insecticial agent may also be selected from the group of compounds described above as suitable for agrochemical use.\n\n\nIn general, the additional pesticidal agent is included in a dose of between about 0.1 μg and about 10 mg. In one embodiment of the invention, the additional pesticidal agent is included in a dose of between about 1 μg and about 10 mg. In another embodiment of the invention, the additional pesticidal agent is included in a dose of about 5 to about 200 μg/kg of weight of animal. In yet another embodiment of the invention, the additional pesticidal agent is included in a dose between \n\n PATENT MER 08-116PCT about 0.1 to about 10 mg/kg of weight of animal. In still another embodiment of the invention, the additional pesticidal agent is included in a dose between about 0.5 to 50 mg/kg.\n\n\nThe proportions, by weight, of the benzotriazol-2-yl-acetamidonitrile compound and the additional pesticidal agent are for example between about 5/1 and about 10,000/1. However, one of ordinary skill in the art would be able to select the appropriate ratio of benzotriazol-2-yl- acetamidonitrile compound and the additional pesticidal agent for the intended host and use thereof.\n\n\nAnother aspect of the invention is the process of making the arylazol-2-yl-cyanoethylamide compounds of the invention. Method of Synthesizing the Compounds of the Invention\n\n\nThe compounds of formula (I) and (Ia) may be prepared by the application or adaptation of known methods to form thioamides (i.e methods heretofore used or described in the chemical literature). A summary of such methods is found on the first page of the publication describing the conversion of nitriles to thioamides with ammonium sulfide in methanol with microwave irradiation \"Simple Microwave-Assisted Method for the Synthesis of Primary Thioamides from Nitriles\", M. C. Bagley, K. Chapaneri, C. Glover, E. A. Merritt, Synlett, 2004, 14, 2615-2617.\n\n\n\n\n\n\n\n\n(I)\n\n\nFor example, compounds of formula (I) are obtainable by a process wherein compound of formula (II) is reacted with ammonium sulfide or sodium hydrosulfide wherein R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, P, Q, V, W, X, Y, Z, a, are as defined above for the compounds of formula (I).\n\n\n\n\n\n\n\n\n(H) (I)\n\n\nSimilarly, compounds of formula (Ia) are obtainable by a process wherein compound of formula (Ma) is reacted with ammonium sulfide wherein R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, P, Q, V, W, X, Y, Z, a, are as defined above for the compounds of formula (Ia)\n\n\n\n\n\n\n\n\n(Ma) (Ia) \n\n PATENT MER 08-116PCT\n\n\nThe reaction is generally carried out in a solvent with or without the presence of base.\n\n\nThe solvent to be used in the reaction includes, for example but not limited to, water, alcoholic solvent such as methanol, ethanol and the like, and a combination of water and such alcoholic solvent. The base that can be used in this reaction includes, for example but not limited to, organic bases such as triethylamine, diisopropylamine, pyridine and the like.The reaction temperature is usually in the range of -50\n0\nC to 200\n0\nC, preferably in the range of -20°C to 130°C and the reaction time is usually in the range of 0.1 to 72 hours.\n\n\nThe reaction can be carried out under pressure with or without microwave irradiation. After completion of the reaction, the compounds of formula (I) and (Ia) can be isolated by employing conventional methods such as adding the reaction mixture to water, extracting with an organic solvent, concentrating the extract and the like. The isolated compound of formula (I) and (Ia) can be purified by a technique such as chromatography, recrystallization and the like, if necessary. Compound of formula (II) are described in U.S. Provisional Application SN: 60/930,485 and the compound of formula (Ma) are described in WO 2002/049641 , WO 2003/097036, WO 2003/097585, WO 2003/104187, WO 2004/000793, WO 2005/044784, WO 2005/05802, WO 2005/121075 and WO 2006/043654 as well as in EP 953565 (U.S. Patent 6,239,077) and EP 1445251.\n\n\nMethod of treatment with compounds of the invention Another aspect of the invention is a method for preventing or treating an endoparasitic infestation/infection (e.g filariae or worms) in an animal (e.g. a mammal or bird), comprising administering an endoparasiticidally effective amount of a compound or a composition of the invention. Mammals which can be treated include but are not limited to humans, cats, dogs, cattle, chickens, cows, deer, goats, horses, llamas, pigs, sheep and yaks. In one embodiment of the invention, the mammals treated are humans, cats or dogs.\n\n\nThe endoparasites treated include but are not limited to those helminths selected from the group consisting of Anaplocepheda, Ancylostoma, Anecator, Ascaris, Caenorhabditis, Capillaria, Cooperia, Dipyllidinum, Dirofilaria, Echinococcus, Enterobius, Fasciola, Haemonchus, Oesophagostumum, Ostertagia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus and combinations thereof.\n\n\nIn one embodiment of the endoparasites treated the endoparasite is Haemonchus contortus (H. contortus).\n\n\nYet another aspect of the invention is also directed toward a method of treating an animal (e.g. a mammal or bird), against ectoparasitic infection (e.g. insects) by administering an ectoparasiticidally effective amount of the composition of the invention. Mammals which can be treated include but are not limited to humans, cats, dogs, cattle, chickens, cows, deer, goats, horses, llamas, pigs, sheep and yaks. In one embodiment of the invention, the mammals treated are humans, cats or dogs.\n\n\nIn another embodiment for treatment against ectoparasites, the ectoparasite is one or more insect or arachnid including those of the genera Ctenocephalides, Rhipicephalus, Dermacentor, \n\n PATENT MER 08-116PCT\n\n\nIxodes, Boophilus, Ambylomma, Haemaphysahs, Hyalomma, Sarcoptes, Psoroptes, Otodectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Haematopmus, Solenoptes, Tnchodectes, and Felicola\n\n\nIn another embodiment for the treatment against ectoparasites the ectoparasite is from the genera Ctenocephalides, Rhipicephalus, Dermacentor, Ixodes and/or Boophilus The ectoparasites treated include but are not limited to fleas, ticks, mites, mosquitoes, flies lice, blowfly and combinations thereof Specific examples include but are not limited to cat and dog fleas (Ctenocephalides felis, Ctenocephalides sp and the like), ticks (Rhipicephalus sp , Ixodes sp , Dermacentor sp , Amblyoma sp and the like), and mites (Demodex sp , Sarcoptes sp , Otodectes sp and the like), lice (Tnchodectes sp Cheyletiella sp , Lignonathus sp , and the like), mosquitoes (Aedes sp , Culex sp , Anopheles sp , and the like) and flies (Hematobia sp , Musca sp , Stomoxys sp , Dematobia sp , Cochhomyiα sp , and the like) In yet another embodiment for the treatment against ectoparasites, the ectoparasite is a flea and/or tick Additional examples of ectoparasites include but are not limited to the tick genus Boophilus, especially those of the species microplus (cattle tick), decoloratus and αnnulαtus, myiases such as Dermatobia hominis (known as Berne in Brazil) and Cochliomyiα homimvorax (greenbottle), sheep myiases such as Lucilia seπcata, Lucilia cuprina (known as blowfly strike in Australia, New Zealand and South Africa) Flies proper, namely those whose adult constitutes the parasite, such as Haematobia irritans (horn fly), lice such as Linognathus vitulorum, etc , and mites such as Sarcoptes scabici and Psoroptes ovis The above list is not exhaustive and other ectoparasites are well known in the art to be harmful to animals and humans These include, for example migrating dipterous larvae\n\n\nIn another embodiment of the invention, the compounds and compositions of the invention are suitable for controlling pests such as insects selected from the group consisting of Blatella germanica, Heliothis virescens, Leptinotarsa decemlmeata, Tetramorium caespitum and combinations thereof The phytoparasitic nematodes include, for example, Anguina spp , Aphelenchoides spp ,\n\n\nBelonoaimus spp , Bursaphelenchus spp , Ditylenchus dipsaci, Globodera spp Heliocotylenchus spp , Heterodera spp , Longidorus spp , Meloidogyne spp , Pratylenchus spp , Radopholus similis, Rotylenchus spp , Trichodorus spp , Tylenchorhynchus spp , Tylenchulus spp , Tylenchulus semipenetrans, Xiphinema spp In addition, with or without the other pesticidal agents added to the composition, the invention can also be used to treat other pests which include but are not limited to pests\n\n\n(1) from the class of Isopoda, for example Oniscus asellus, Armadillidium vulgare and Porcellio scaber,\n\n\n(2) from the class of Diplopoda, for example Blaniulus guttulatus, (3) from the class of Chilopoda, for example Geophilus carpophagus and Scutigera spp ,\n\n\n(4) from the class of Symphyla, for example Scutigerella immaculata,\n\n\n(5) from the class of Thysanura, for example Lepisma saccharine,\n\n\n(6) from the class of Collembola, for example Onychiurus armatus, \n\n PATENT MER 08-116PCT\n\n\n(7) from the class of Blattaria, for example Blatta onentalis, Periplaneta ameπcana, Leucophaea maderae and Blattella germanica,\n\n\n(8) from the class of Phthiraptera, for example Pediculus humanus corporis, Haematopinus spp , Lmognathus spp , Tnchodectes spp and Damalinia spp , (9) from the class of Hymenoptera, for example Diprion spp , Hoplocampa spp , Lasius spp , Monomoπum pharaonis and Vespa spp ,\n\n\n(10) from the class of Siphonaptera, for example Xenopsylla cheopis and Ceratophyllus spp ,\n\n\n(11 ) from the class of Anoplura (Phthiraptera), for example, Damalinia spp , Haematopinus spp , Lmognathus spp , Pediculus spp , Tnchodectes spp , (12) from the class of Arachnida, for example, Acarus siro, Aceria sheldom, Aculops spp , Aculus spp , Amblyomma spp Argas spp , Boophilus spp , Brevipalpus spp , Bryobia praetiosa, Chorioptes spp , Dermanyssus gallmae, Eotetranychus spp , Epitrimerus pyri, Eutetranychus spp , Eriophyes spp , Hemitarsonemus spp , Hyalomma spp , Ixodes spp , Latrodectus mactans, Metatetranychus spp , Oligonychus spp , Ornithodoros spp , Panonychus spp , Phyllocoptruta oleivora, Polyphagotarsonemus latus, Psoroptes spp , Rhipicephalus spp ,\n\n\nRhizoglyphus spp , Sarcoptes spp , Scorpio maurus, Stenotarsonemus spp , Tarsonemus spp , Tetranychus spp , Vasates lycopersici ,\n\n\n(13) from the class of Bivalva, for example, Dreissena spp ,\n\n\n(14) from the class of Coleoptera, for example, Acanthoscelides obtectus, Adoretus spp , Agelastica aim, Agriotes spp , Amphimallon solstitialis, Anobium punctatum, Anoplophora spp , Anthonomus spp , Anthrenus spp , Apogonia spp , Atomaria spp , Attagenus spp , Bruchidius obtectus, Bruchus spp , Ceuthorhynchus spp , Cleonus mendicus, Conoderus spp , Cosmopolites spp , Costelytra zealandica, Curculio spp , Cryptorhynchus lapathi, Dermestes spp , Diabrotica spp , Epilachna spp , Faustinus cubae, Gibbium psylloides, Heteronychus arator, Hylamorpha elegans, Hylotrupes bajulus, Hypera postica,\n\n\nHypothenemus spp , Lachnosterna consangumea, Leptinotarsa decemlmeata, Lissorhoptrus oryzophilus, Lixus spp , Lyctus spp , Mehgethes aeneus, Melolontha melolontha, Migdolus spp , Monochamus spp , Naupactus xanthographus, Niptus hololeucus, Oryctes rhinoceros, Oryzaephilus surinamensis, Otiorrhynchus sulcatus, Oxycetonia jucunda, Phaedon cochleaπae, Phyllophaga spp , Popillia japonica, Premnotrypes spp Psylliodes chrysocephala, Ptinus spp , Rhizobius ventrahs, Rhizopertha dominica, Sitophilus spp , Sphenophorus spp , Sternechus spp , Symphyletes spp , Tenebrio molitor, Tribolium spp , Trogoderma spp , Tychius spp , Xylotrechus spp , Zabrus spp ,\n\n\n(15) from the class of Diptera, for example, Aedes spp , Anopheles spp , Bibio hortulanus, Calliphora erythrocephala, Ceratitis capitata, Chrysomyia spp , Cochliomyia spp , Cordylobia anthropophaga, Culex spp , Cuterebra spp , Dacus oleae, Dermatobia hominis Drosophila spp , Fannia spp , Gastrophilus spp , Hylemyia spp , Hyppobosca spp , Hypoderma spp , Linomyza spp , Lucilia spp , Musca spp , Nezara spp , Oestrus spp , Oscinella frit, Pegomyia hyoscyami, Phorbia spp , Stomoxys spp , Tabanus spp , Tannia spp , 77pι//a paludosa, Wohlfahrtia spp , \n\n PATENT MER 08-116PCT\n\n\n(16) from the class of Gastropoda, for example, Arion spp., Biomphalaria spp., Bulinus spp., Deroceras spp., Galba spp., Lymnaea spp., Oncomelania spp., Succinea spp ;\n\n\n(17) from the class of helminths, for example, Ancylostoma duodenale, Ancylostoma ceylanicum, Acylostoma braziliensis, Ancylostoma spp., Ascaris lubricoides, Ascaris spp , Brugia malayi, Brugia timon, Bunostomum spp., Chabertia spp., Clonorchis spp., Coopena spp.,\n\n\nDicrocoelium spp, Dictyocaulus filaria, Diphyllobothrium latum, Dracunculus medinensis, Echinococcus granulosus, Echinococcus multilocularis, Enterobius vermicularis, Faciola spp., Haemonchus spp , Heterakis spp., Hymenolepis nana, Hyostrongulus spp., Loa Loa, Nematodirus spp., Oesophagostomum spp., Opisthorchis spp., Onchocerca volvulus, Ostertagia spp , Paragonimus spp., Schistosomen spp., Strongyloses fuelleborni,\n\n\nStrongyloides stercoralis, Stronyloides spp , Taenia sagmata, Taenia solium, Tπchinella spiralis, Trichinella nativa, Trichinella britovi, Trichinella nelsoni, Trichinella pseudopsiralis, Tnchostrongulus spp., Trichuris trichuria, Wuchereria bancrofti.;\n\n\n(18) from the class of Heteroptera, for example, Anasa tristis, Antestiopsis spp , Blissus spp., Calocoπs spp., Campylomma livida, Cavelerius spp., Cimex spp., Creontiades dilutus,\n\n\nDasynus piperis, Dichelops furcatus, Diconocoris hewetti, Dysdercus spp , Euschistus spp , Eurygaster spp , Heliopeltis spp., Horcias nobilellus, Leptocorisa spp., Leptoglossus phyllopus, Lygus spp , Macropes excavatus, Miridae, Nezara spp., Oebalus spp., Pentomidae, Piesma quadrata, Piezodorus spp., Psallus senatus, Pseudacysta persea, Rhodnius spp., Sahlbergella singularis, Scotinophora spp., Stephanitis nashi, Tibraca spp.,\n\n\nTnatoma spp ;\n\n\n(19) from the class of Homoptera, for example, Acyrthosipon spp , Aeneolamia spp , Agonoscena spp., Aleurodes spp., Aleurolobus barodensis, Aleurothrixus spp., Amrasca spp , Anuraphis cardui, Aonidiella spp., Aphanostigma piri, Aphis spp., Arboridia apicalis, Aspidiella spp., Aspidiotus spp., Atanus spp., Aulacorthum solani, Bemisia spp., Brachycaudus helichrysii,\n\n\nBrachycolus spp , Brevicoryne brassicae, Calligypona marginata, Carneocephala fulgida, Ceratovacuna lanigera, Cercopidae, Ceroplastes spp., Chaetosiphon fragaefolii, Chionaspis tegalensis, Chlonta onukn, Chromaphis juglandicola, Chrysomphalus ficus, Cicadulina mbila, Coccomytilus halli, Coccus spp., Cryptomyzus ribis, Dalbulus spp., Dialeurodes spp., Diaphorina spp., Diaspis spp., Doralis spp., Drosicha spp., Dysaphis spp., Dysmicoccus spp.,\n\n\nEmpoasca spp , Eriosoma spp , Erythroneura spp , Euscelis bilobatus, Geococcus coffeae, Homalodisca coagulata, Hyalopterus arundinis, lcerya spp., ldiocerus spp., ldioscopus spp., Laodelphax stnatellus, Lecanium spp., Lepidosaphes spp., Lipaphis erysimi, Macrosiphum spp., Mahanarva fimbriolata, Melanaphis sacchari, Metcalfiella spp., Metopolophium dirhodum, Monellia costalis, Monelhopsis pecanis, Myzus spp., Nasonovia nbisnigri,\n\n\nNephotettix spp., Nilaparvata lugens, Oncometopia spp , Orthezia praelonga, Parabemisia myricae, Paratrioza spp., Parlatoria spp., Pemphigus spp., Peregnnus maidis, Phenacoccus spp., Phloeomyzus passeπnii, Phorodon humuli, Phylloxera spp , Pinnaspis aspidistrae, Planococcus spp., Protopulvinaπa pyriformis, Pseudaulacaspis pentagona, Pseudococcus spp., Psy//a spp., Pteromalus spp., Pyr/7/a spp., Quadraspidiotus spp., Quesada gigas, \n\n PATENT MER 08-116PCT\n\n\nRastrococcus spp , Rhopalosiphum spp , Saissetia spp , Scaphoides titanus, Schizaphis grammum, Selenaspidus articulatus, Sogata spp , Sogatella furcifera, Sogatodes spp , Stictocephala festma Tenalaphara malayensis, Tinocallis caryaefoliae, Tomaspis spp , Toxoptera spp , Tπaleurodes vaporanorum, Tnoza spp , Typhlocyba spp , Unaspis spp , Viteus vitifolii ,\n\n\n(20) from the class of Isoptera, for example, Reticulitermes spp , Odontotermes spp ,\n\n\n(21) from the class of Lepidoptera, for example, Acronicta major, Aedia leucomelas, Agrotis spp , Alabama argillacea, Anticarsia spp , Barathra brassicae, Bucculatnx thurbenella, Bupalus pinianus, Cacoecia podana, Capua reticulana Carpocapsa pomonella, Cheimatobia brumata, Chilo spp , Choristoneura fumiferana, Clysia ambiguella, Cnaphalocerus spp , Earias insulana, Ephestia kuehniella, Euproctis chrysorrhoea, Euxoa spp , Feltia spp , Galleπa mellonella, Helicoverpa spp Heliothis spp , Hofmannophila pseudospretella, Homona magnanima, Hyponomeuta padella, Laphygma spp , Lithocolletis blancardella, Lithophane antennata, Loxagrotis albicosta, Lymantna spp , Malacosoma neustna, Mamestra brassicae, Mocis repanda, Mythimna separata, Oria spp , Oulema oryzae, Panolis flammea,\n\n\nPectinophora gossypiella, Phyllocnistis citrella, Piens spp Plutella xylostella, Prodenia spp , Pseudaletia spp , Pseudoplusia includens, Pyrausta nubilalis, Spodoptera spp , Thermesia gemmatalis, Tinea pellionella, Tineola bisselliella, Tortnx viπdana, Trichoplusia spp ,\n\n\n(22) from the class of Orthoptera, for example, Acheta domesticus, Blatta onentalis, Blattella germanica, Gryllotalpa spp , Leucophaea maderae, Locusta spp , Melanoplus spp ,\n\n\nPeriplaneta americana, Schistocerca gregaria ,\n\n\n(23) from the class of Thysanoptera, for example, Baliothrips biformis Enneothrips flavens, Frankliniella spp , Heliothrips spp , Hercinothnps femoralis, Kakothnps spp , Rhipiphorothrips cruentatus, Scirtothπps spp , Taeniothπps cardamom, Thrips spp , (24) from the class of Protozoa, for example, Eimeria spp\n\n\nIn each aspect of the invention, the compounds and compositions of the invention can be applied against a single pest or combinations thereof\n\n\nIf appropriate, the compounds according to the invention can, at certain concentrations or application rates, also be used as herbicides, safeners, growth regulators or agents to improve plant properties, or as microbicides, for example as fungicides, antimycotics, bactericides, viricides (including agents against viroids) or as agents against MLO (mycoplasma-like organisms) and RLO (rickettsia-like organisms) If appropriate, they can also be employed as intermediates or precursors for the synthesis of other active compounds\n\n\nThe active compounds according to the invention, in combination with good plant tolerance and favourable toxicity to warm-blooded animals and being tolerated well by the environment, are suitable for protecting plants and plant organs, for increasing the harvest yields, for improving the quality of the harvested material and for controlling animal pests, in particular insects, arachnids, helminths, nematodes and molluscs, which are encountered in agriculture, in horticulture, in animal husbandry, in forests, in gardens and leisure facilities, in the protection of stored products and of materials, and in the hygiene sector They may be preferably employed as plant protection agents \n\n PATENT MER 08-116PCT\n\n\nThey are active against normally sensitive and resistant species and against all or some stages of development.\n\n\nThe invention is further described by the following non-limiting examples which further illustrate the invention, and are not intended, nor should they be interpreted to, limit the scope of the invention.\n\n\nEXAMPLES\n\n\nAll temperatures are given in degrees Centigrade; room temperature means 20 to 25°C.\n\n\nReagents were purchased from commercial sources or prepared following literature procedures.\n\n\nProton and fluorine magnetic resonance (respectively 1 H NMR and 19F NMR) spectra were recorded on a Varian INOVA NMR spectrometer [400 MHz (1 H) or 500 MHz (1 H) and 377 MHz (19F)]. All spectra were determined in the solvents indicated. Chemical shifts are reported in ppm downfield of tetramethylsilane (TMS), referenced to the residual proton peak of the respective solvent peak for 1 H\n\n\nNMR. lnterproton coupling constants are reported in Hertz (Hz).\n\n\nLC-MS spectra were either obtained using a Thermofinnigan AQA MS ESI instrument, using a Phenomenex Aqua 5 micron C18 125A 50 x 4.60 mm column and a linear gradient from 55% methanol 1 % acetonitrile in water to 100% methanol over 3 minutes. 100% methanol was maintained for 2 minutes. Alternatively, LCMS spectra were obtained using an Agilent 1200SL HPLC equipped with a 6130 mass spectrometer operating with electrospray ionization; chromatographic data were obtained using a Shimadzu Shim-pack XR-ODS, 3.0 x 30 mm, 2.2 micron particle size column and a wateπmethanol gradient from 15% methanol to 95% methanol in 2.2 minutes under a 1.5 mL/min flow; a hold at 95% methanol was applied at the end of the gradient for\n\n\n0.8 minutes; and both water and methanol mobile phases contained 0.1 % formic acid.\n\n\nEXAMPLE 1. W-[1-Methyl-1 -thiocarbamoyl-2-(4,5,7-trichloro-2H-benzotriazol-2-yl)-ethyl]-4- trifluoromethoxybenzamide (compound No 1 )\n\n\n\n\n\n\n\n\nA solution of Λ/-[1-Cyano-1-methyl-2-(4,5,7-trichloro-2/-/-benzotriazol-2-yl)-ethyl]-4- trifluoromethoxybenzamide (60 mg, 0.12 mmole, described in U.S. Provisional Application SN:\n\n\n60/930,485 as compound 1.064) and ammonium sulfide (0.04mL, 40-48 wt.% in water from Sigma-\n\n\nAldrich) in methanol (4 mL) was irradiated for 20 minute in a self-tunable CEM microwave Discover synthesizer at 80 \n0\nC (initial power 100 Watts) and then cooled using a flow of compressed air, evaporated in vacuo and partitioned between ethyl acetate and water. The aqueous layer was further extracted with ethyl acetate. The organic extracts were combined, washed with brine, washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give a residue that that was purified by chromatography (SiO\n2\n, heptane/ethyl acetate) to afford the title \n\n PATENT MER 08-116PCT compound as a solid (30 mg, 47%) along with recovered starting material (22 mg, 37%). MS (ES): M/Z [M+H]=526 and [M-H]=524. 1 H NMR: (400 MHz, DMSO-O\n6\n): 1 .48 (s, 3H), 5.59 (d, J=13.3Hz, 1 H), 5.70 (, J=13.3 Hz, 1 H), 7.44 (d, J=8.0 Hz, 2H), 7.88 (s, 1 H), 7.93 (d, J=8.8 Hz, 2H), 8.16 (s, 1 H), 9.34 (s, 1 H) and 9.83 (s, 1 H). 19F NMR (376 MHz, DMSO-O\n6\n): -57.2 (s, 3F).\n\n\nEXAMPLE 2. Λ/-[1-Methyl-1 -thiocarbamoyl-2-(4,5,7-trichloro-2H-benzotriazol-2-yl)-ethyl]-4- trifluoromethylthiobenzamide (compound No 2)\n\n\n\n\n\n\n\n\nUsing a procedure similar to that described in Example 1 , except using /V-[1-Cyano-1-methyl- 2-(4,5,7-trichloro-2/-/-benzotriazol-2-yl)-ethyl]-4-trifluoromethylthiobenzamide (70 mg, 0.14 mmole, described in U.S. Provisional Application SN: 60/930,485 as compound No 1.065), the title compound was isolated as a solid (37 mg, 49%). MS (ES): M/Z [M+H]=542 and [M-H]=540. 1 H NMR: (400 MHz, DMSO-dβ): 1.48 (s, 3H), 5.56 - 5.64 (m, 1 H), 5.66 - 5.76 (m, 1 H), 7.80 (d, J=8.3 Hz, 2H), 7.88 (s, 1 H), 7.93 (d, J=8.4 Hz, 2H), 8.25 (s, 1 H), 9.36 (s, 1 H) and 9.84 (s, 1 H). 19F NMR (376 MHz, DMSO-d\nβ\n): - 42.2 (s, 3F).\n\n\nEXAMPLE 3. Λ/-[2-(4-Cyano-2-trifluoromethylphenoxy)-1-methyl-1-thiocarbamoyl-ethyl]-4- trifluoromethoxybenzamide (compound No 3) N\n\n\n\n\n\n\n\n\nUsing a procedure similar to that described in Example 1 , except using Λ/-[1-Cyano-2-(4- cyano-2-trifluoromethylphenoxy)-1-methyl-ethyl]-4-trifluoromethoxybenzamide (588 mg, 1.28 mmole, described in WO 2005/044784 as compound 2.6), the title compound was isolated as a solid (180 mg, 28%). MS (ES): M/Z [M+H]=492 and [M-H]=490. 1 H NMR: (400 MHz, DMSO-d\ne\n): 1.67 (s, 3H), 4.82 (d, J=9.4 Hz, 1 H), 4.98 (d, J=9.4 Hz, 1 H), 7.38 (d, J=8.5 Hz, 1 H), 7.45 (d, J=8.0 Hz, 2H), 7.90 - 8.01 (m, 2H), 8.07 (d, J=2.1 Hz, 2H), 8.68 (s, 1 H), 9.19 (s, 1 H) and 9.82 (s, 1 H). 19F NMR (376 MHz, DMSO-d\n6\n): -61.9 (s, 3F) and -57.1 (s, 3F).\n\n\nEXAMPLE 4. Λ/-[1-Methyl-1 -thiocarbamoyl-2-(4-thiocarbamoyl-2-trifluoromethylphenoxy)- ethyl]-4-trifluoromethoxybenzamide (compound No 4). \n\n PATENT MER 08-116PCT\n\n\n\n\n\n\n\n\nFrom the same reaction mixture described in Example 3 above was also isolated the corresponding bis-thioamide title compound No 4 (380 mg, 56%). MS (ES): IWZ [M+H]=526 and [M- H]=524. 1 H NMR: (400 MHz, DMSO-d\n6\n): 1.68 (s, 3H), 4.77 (d, J=9.4 Hz, 1 H), 4.94 (d, J=9.4 Hz, 1 H), 7.23 (d, J=9.6 Hz, 1 H), 7.45 (d, J=8.1 Hz, 2H), 7.91 - 8.05 (m, 2H), 8.20 (d, J=2.3 Hz, 2H), 8.66 (s, 1 H), 9.18 (s, 1 H), 9.54 (s, 1 H), 9.81 (s, 1 H) and 9.85 (br. s., 1 H). 19F NMR (376 MHz, DMSO-d\ne\n): - 61.4 (s, 3F) and -57.1 (s, 3F).\n\n\nEXAMPLE 5. Λ/-[2-(5-Cyano-2-trifluoromethylphenoxy)-1-methyl-1-thiocarbamoyl-ethyl]-4- trifluoromethylthiobenzamide (compound No 5).\n\n\n\n\n\n\n\n\nUsing a procedure similar to that described in Example 1 , except using /V-[1-Cyano-2-(5- cyano-2-trifluoromethylphenoxy)-1-methyl-ethyl]-4-trifluoromethylthiobenzamide (672 mg, 1.42 mmole, described in WO 2005/044784 as compound 3.16), the title compound was isolated as a solid (124 mg, 17%). MS (ES): M/Z [M+H]=508 and [M-H]=506. 1 H NMR: (400 MHz, DMSO-O\n6\n): 1.68 (s, 3H), 4.78 (d, J=9.5 Hz, 1 H), 4.93 (d, J=9.4 Hz, 1 H), 7.55 (d, J=8.0 Hz, 1 H), 7.74 (s, 1 H), 7.77 (d, J=8.1 Hz, 1 H), 7.80 (d, J=8.2 Hz, 2H), 7.95 (d, J=8.4 Hz, 2H), 8.75 (s, 1 H), 9.17 (s, 1 H) and 9.83 (s, 1 H). 19F NMR (376 MHz, DMSO-d\n6\n): -62.1 (s, 3F) and -42.1 (s, 3F).\n\n\nEXAMPLE 6. 4-Hvdroxv-N-ri-methvl-2-(2-methvl-5-thiocarbamovl-phenoxv)-1 -thiocarbamovl- ethyl]-4-trifluoromethylthiobenzamide (compound No 6).\n\n\n \n\n PATENT MER 08-116PCT\n\n\nFrom the same reaction mixture described in Example 5 above was also isolated the corresponding bis-thioamide title compound No 6 (152 mg, 20%). MS (ES): IWZ [M+H]=542 and [M- H]=540. 1 H NMR: (400 MHz, DMSO-d\n6\n): 1.69 (s, 3H), 4.75 (d, J=9.2 Hz, 1 H), 4.93 (d, J=9.1 Hz, 1 H), 7.50 (d, J=8.1 Hz, 1 H), 7.56 (s, 1 H), 7.61 (d, J=Q.2 Hz, 1 H), 7.80 (d, J=8.1 Hz, 2H), 7.97 (d, J=8.2 Hz, 2H), 8.73 (s, 1 H), 9.20 (br. s., 1 H), 9.76 (br. s., 1 H), 9.82 (br. s., 1 H) and 10.11 (br. s., 1 H). 19F NMR (376 MHz, DMSO-O\n6\n). -61.4 (s, 3F) and -42.1 (s, 3F).\n\n\nEXAMPLE 7. Λ/-[2-(5-Cyano-2-trifluoromethylphenoxy)-1-methyl-1-thiocarbamoyl-ethyl]-4- trifluoromethoxybenzamide (compound No 7).\n\n\n\n\n\n\n\n\nUsing a procedure similar to that described in Example 1 , except using Λ/-[1-Cyano-2-(5- cyano-2-trifluoromethylphenoxy)-1-methyl-ethyl]-4-trifluoromethoxybenzamide (230 mg, 0.5 mmole, described in WO 2005/044784 as compound 2.6), the title compound was isolated as a solid (39 mg, 16%). MS (ES): M/Z [M+H]=492 and [M-H]=490. 1 H NMR: (400 MHz, DMSO-O\n6\n): 1.68 (s, 3H), 4.79 (d, J=9.5 Hz, 1 H), 4.92 (d, J=9.5 Hz, 1 H), 7.45 (d, J=8.0 Hz, 1 H), 7.55 (d, J=8.2 Hz, 1 H), 7.77 (d, J=8.1 Hz, 2 H), 7.88 - 8.08 (m, 2H), 8 67 (s, 1 H), 9.15 (s, 1 H) and 9.83 (s, 1 H). 19F NMR (376 MHz, DMSO-d\n6\n): -62.1 (s, 3F) and -57.1 (s, 3F).\n\n\nEXAMPLE 8. 4-Hydroxy-Λ/-[1 -methyl-2-(2-methyl-5-thiocarbamoyl-phenoxy)-1-thiocarbamoyl- ethyl]-4-trifluoromethoxybenzamide (compound No 8).\n\n\n\n\n\n\n\n\nFrom the same reaction mixture described in Example 7 above was also isolated the corresponding bis-thioamide title compound No 8 (21 mg, 8%). MS (ES): M/Z [M+H]=526 and [M- H]=524. 1 H NMR: (400 MHz, DMSO-O\n6\n): 1.68 (s, 3H), 4.75 (d, J=9.3 Hz, 1 H), 4.92 (d, J=9.2 Hz, 1 H), 7.45 (d, J=8.0 Hz, 2H), 7.51 (s, 1 H), 7.56 (s, 1 H), 7.61 (d, J=8.2 Hz, 1 H), 7.94 - 8.05 (m, 2H), 8.66 (s, 1 H), 9.18 (s, 1 H), 9.76 (br. s., 1 H), 9.81 (s, 1 H) and 10.1 1 (br. s., 1 H). 19F NMR (376 MHz, DMSO- Cf\n6\n)\n1\n -61.4 (s, 3F) and -57 1 (s, 3F). \n\n PATENT MER 08-116PCT\n\n\nMethod of Use Examples\n\n\nMETHOD A: Screening method to test activity of compounds against Haemonchus contortus.\n\n\nTwenty L1 Haemonchus contortus larvae were added to wells of a microtitre plate containing a nutrient medium and the test compound in DMSO. The microtitre plate was then held at 27°C where the L1 larvae were allowed to develop. An analysis was conducted at 4 days to determine successful development to the L3 stage. Larvae exposed to DMSO and no test compound served as controls.\n\n\nCompounds numbers 3, 4, 6 and 8 gave at least 90% motility inhibition at a test concentration of 0.15 ppm at the 4 days assessment. Compounds numbers 1 , 2, 5 and 7 gave at least 90% motility inhibition at a test concentration of 0.01 ppm at the 4 days assessment.\n\n\nMETHOD B: Screening method to test activity of compounds against Haemonchus contortus in vivo on Mongolian jirds (Meriones unguiculatus).\n\n\nMongolian jirds, at least five weeks old, were immunosuppressed and artificially infected with ca. 1000 ensheathed Haemonchus contortus third instar larvae. Six days after infection, the jirds were treated by oral gavage with the test compounds, dissolved in a mixture of 2 parts DMSO and 1 part polyethylene glycol (PEG400), at doses of 100 mg/kg and 10 mg/kg. Jirds treated only with the placebo (2 parts DMSO and 1 part PEG400) served as controls. On day 9 (3 days after treatment) the jirds were euthanized and necropsied for recovery of parasites from the stomach. Efficacy was calculated as the average % reduction in the number of worms in each test group compared with the average number of worms from the control group. In this screen, a vast reduction in nematode infestation was achieved with compounds of formula (I) and (Ia). Compound number 1 , provided at least 95% reduction in nematode infestation at a dose as low as 1 or 10 mg/kg.\n\n\n \n***\n Having thus described in detail various embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention."
  },
  {
    "id": "WO2010046034A1",
    "text": "Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine AbstractThe invention relates to sulfone-substituted anilinopyrimidine derivatives of formula (I), to a method for producing the same, and to the use thereof as a medication for treating various illnesses. Claims\n\n\n\n\n\n\n \n Patentansprϋche\n Patentansprϋche\n\n\n\n\n\n\n\n\n \n1. Verbindungen der allgemeinen Formel (I),\n1. Compounds of the general formula (I)\n\n\n\n\n\n\n \n \n in der\n \n in the\n\n\n\n\n\n\n \nR\n1\n für einen d-C\n6\n-Alkyl-, C\n2\n-C\n6\n-Alkenyl-, C\n2\n-C\n6\n-Alkinylrest oder einen\nR \n1\n is a dC \n6\n alkyl, C \n2\n -C \n6\n alkenyl, C \n2\n -C \n6\n alkynyl, or\n\n\n\n\n\n\n \nC\n3\n-C\n7\n-Cycloalkyl oder Phenylring steht, jeweils gegebenenfalls mit Hydroxy, -NR\n3\nR\n4\n, Cyano, Halogen, -CF\n3>\n C\nr\nC\n6\n-Alkoxy, -OCF\n3\n und/oder Ci-C\n6\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert, und\nC \n3\n -C \n7\n -cycloalkyl or phenyl ring is in each case optionally substituted by hydroxy, -NR \n3\n R \n4\n , cyano, halogen, -CF \n3>\n C \nr\n C \n6\n -alkoxy, -OCF \n3\n and / or C \n1\n -C \n6\n -alkyl - or polysubstituted by identical or different substituents, and\n\n\n\n\n\n\n \nR\n2\n für einen Ci-C\n10\n-Alkyl-, C\n3\n-Ci\n0\n-Alkenyl- oder C\n3\n-Ci\n0\n-Alkinylrest oder einen\nR \n2\n represents a Ci-C \n10\n alkyl, C \n3\n -C \n0\n alkenyl or C \n3\n -C \n0\n alkynyl, or\n\n\n\n\n\n\n \nC\n3\n-C\n7\n-Cycloalkylring steht, jeweils gegebenenfalls ein- oder mehrfach, gleich oder verschieden substituiert mit a) Halogen, Hydroxy, -NR\n3\nR\n4\n, Cyano, -CF\n3\n, -OCF\n3\n, und/oder b) Ci-C\n6\n-Alkoxy, C\nr\nC\n6\n-Alkyl, C\n2\n-C\n6\n-Alkenyl, C\n2\n-C\n6\n-Alkinyl, oder C\n3\n-C\n8\n-Cycloalkyl, -O-CH\n2\n-Phenyl, C\nn\n-Alkoxycarbonyl, jeweils gegebenenfalls selbst ein- oder mehrfach, gleich oder verschieden mit Halogen, Hydroxy, einem C\nr\nC\n6\n-Alkyl, C,-C\n6\n-Alkoxy, -NR\n3\nR\n4\n, -CF\n3\n und/oder -OCF\n3\n substituiert, und\nC \n3\n -C \n7\n -cycloalkyl ring, in each case optionally mono- or polysubstituted by identical or different substituents with a) halogen, hydroxy, -NR \n3\n R \n4\n , cyano, -CF \n3\n , -OCF \n3\n , and / or b) ci C \n6\n alkoxy, C \nr\n C \n6\n alkyl, C \n2\n -C \n6\n alkenyl, C \n2\n -C \n6\n alkynyl, or C \n3\n -C \n8\n cycloalkyl, -O-CH \n2\n -phenyl, C \nn\n alkoxycarbonyl, in each case optionally itself mono- or polysubstituted, identically or differently with halogen, hydroxy, a C \nr\n C \n6\n alkyl, C, -C \n6\n alkoxy, -NR \n3\n R \n4,\n -CF \n3\n and / or -OCF \n3\n substituted, and\n\n\n\n\n\n\n \nR\n3\n und R\n4\n unabhängig voneinander für Wasserstoff und/oder einen C]-C\n6\n-Alkylrest, C\n2\n-C\n6\n-Alkenylrest, C\n3\n-C\n8\n-Cycloalkyl- und/oder Phenylring, einen Heterocyclylring mit 3 bis 8 Ringatomen und/oder einen monocyclischen Heteroarylring, gegebenenfalls mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, Ci-C\nδ\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sind,  oder\nR \n3\n and R \n4\n independently of one another represent hydrogen and / or a C 1 -C \n6\n -alkyl radical, C \n2\n -C \n6\n -alkenyl radical, C \n3\n -C \n8\n -cycloalkyl and / or phenyl ring, a heterocyclyl ring having 3 to 8 ring atoms and Activating / or a monocyclic heteroaryl, optionally substituted with hydroxy, -NR \n5\n R \n6,\n cyano, halogen, \n-CF3,\n Ci-C \nδ\n alkoxy and / or -OCF \n3\n or polysubstituted by identical or different substituents,  or\n\n\n\n\n\n\n \nR\n3\n und R\n4\n gemeinsam mit dem Stickstoffatom einen 5- bis 7-gliedrigen Ring bilden, der gegebenenfalls zusätzlich zum Stickstoffatom 1 oder 2 weitere Heteroatome enthält und der mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, C\nr\nC\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sein kann, und\nR \n3\n and R \n4\n together with the nitrogen atom form a 5- to 7-membered ring which optionally contains in addition to the nitrogen atom 1 or 2 further heteroatoms and which with hydroxy, -NR \n5\n R \n6\n , cyano, halogen, -CF \n3\n , C \nr\n C \n6\n alkoxy and / or -OCF \n3 may be\n mono- or polysubstituted by identical or different substituents, and\n\n\n\n\n\n\n \nR\n5\n und R\n6\n unabhängig voneinander für Wasserstoff oder einen Ci-C\n6\n-Alkylrest stehen, der gegebenenfalls mit Hydroxy, Cyano, Halogen, -CF\n3\n, Ci-C\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert ist. sowie deren Salze, Diatereomere und Enantiomere.\nR \n5\n and R \n6\n independently of one another are hydrogen or a C \n1\n -C \n6\n -alkyl radical which is optionally monosubstituted or polysubstituted by hydroxyl, cyano, halogen, -CF \n3\n , C \n1\n -C \n6\n -alkoxy and / or -OCF \n3\n or substituted differently. and their salts, diatereomers and enantiomers.\n\n\n\n\n\n\n\n\n\n\n \n2. Verbindungen gemäß Anspruch 1, wobei\n2. Compounds according to claim 1, wherein\n\n\n\n\n\n\n \nR\n1\n für einen Ci-C\n6\n-Alkyl-, C\n2\n-C\n6\n-Alkenyl-, C\n2\n-C\n6\n-Alkinylrest oder einen C\n3\n-C\n7\n-Cycloalkyl oder Phenylring steht, jeweils gegebenenfalls mit Hydroxy,\nR \n1 is\n a C \n1\n -C \n6\n -alkyl, C \n2\n -C \n6\n -alkenyl, C \n2\n -C \n6\n -alkynyl radical or a C \n3\n -C \n7\n -cycloalkyl or phenyl ring, in each case optionally with hydroxyl,\n\n\n\n\n\n\n \nCyano, Halogen, -CF\n3;\n C\nr\nC\n6\n-Alkoxy, -OCF\n3\n und/oder C\nr\nC\n6\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert, sowie deren Salze, Diatereomere und Enantiomere.\nCyano, halogen, -CF \n3;\n C \nr\n C \n6\n alkoxy, -OCF \n3\n and / or C \nr\n C \n6\n alkyl mono- or polysubstituted by identical or different substituents, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n\n\n\n\n \n3. Verbindungen gemäß einem der Ansprüche 1 oder 2, wobei\n3. Compounds according to any one of claims 1 or 2, wherein\n\n\n\n\n\n\n \nR\n2\n für einen C\nr\nC\n10\n-Alkyl-, C\n3\n-Ci\n0\n-Alkenyl- oder C\n3\n-Ci\n0\n-Alkinylrest oder einen\nR \n2\n is a C \nr\n C \n10\n alkyl, C \n3\n -C \n0\n alkenyl or C \n3\n -C \n0\n alkynyl, or\n\n\n\n\n\n\n \nC\n3\n-C\n7\n-Cycloalkylring steht, jeweils gegebenenfalls ein- oder mehrfach, gleich oder verschieden substituiert mit Halogen, Hydroxy, Cyano, -CF\n3\n, -OCF\n3\n, und/oder C\nr\nC\n6\n-Alkoxy, C\n1\n-C\n6\n-\nC \n3\n -C \n7\n -cycloalkyl ring, in each case optionally mono- or polysubstituted, identically or differently, is substituted by halogen, hydroxyl, cyano, -CF \n3\n , -OCF \n3\n , and / or C \nr\n C \n6\n -alkoxy, C \n1\n -C \n6\n -\n\n\n\n\n\n\n \nAlkyl, jeweils gegebenenfalls selbst ein- oder mehrfach, gleich oder verschieden mit Halogen oder Hydroxy substituiert, sowie deren Salze, Diatereomere und Enantiomere.\nAlkyl, in each case optionally even mono- or polysubstituted by identical or different substituents with halogen or hydroxy, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n\n\n\n\n \n4. Verbindungen gemäß einem der Ansprüche 1 bis 3, wobei\n4. Compounds according to any one of claims 1 to 3, wherein\n\n\n\n\n\n\n \nR\n1\n für einen Ci-C\n6\n-Alkyl- oder C\n2\n-C\n6\n-Alkenylrest oder einen C\n3\n-C\n7\n-Cycloalkyl- oder Phenylring steht, jeweils gegebenenfalls mit Hydroxy, Cyano, Halogen und/oder Ci-C\n6\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert, sowie deren Salze, Diatereomere und Enantiomere.  \nR \n1 is\n a C \n1\n -C \n6\n -alkyl or C \n2\n -C \n6\n -alkenyl radical or a C \n3\n -C \n7\n -cycloalkyl or phenyl ring, in each case optionally with hydroxy, cyano, halogen and / or C \n1\n -C \n6\n -alkyl mono- or polysubstituted by identical or different substituents, and their salts, diatereomers and enantiomers. \n\n\n\n\n\n\n\n\n\n\n \n5. Verbindungen gemäß einem der Ansprüche 1 bis 4, wobei\n5. Compounds according to any one of claims 1 to 4, wherein\n\n\n\n\n\n\n \nR\n2\n für einen C\n2\n-C\n6\n-Alkyl-, C\n3\n-C\n6\n-Alkenyl- oder C\n3\n-C\n6\n-Alkinylrest oder einen\nR \n2 is\n a C \n2\n -C \n6\n alkyl, C \n3\n -C \n6\n alkenyl or C \n3\n -C \n6\n alkynyl radical or a\n\n\n\n\n\n\n \nC\n3\n-C7-Cycloalkylring steht, der gegebenenfalls ein- oder mehrfach substituiert ist mit Hydroxy, Halogen, -CF\n3\n und/oder Ci-C\n3\n-Alkoxy, sowie deren Salze, Diatereomere und Enantiomere.\nC \n3\n -C 7 -cycloalkyl ring which is optionally mono- or polysubstituted by hydroxyl, halogen, -CF \n3\n and / or Ci-C \n3\n alkoxy, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n\n\n\n\n \n6. Verbindungen gemäß einem der Ansprüche 1 bis 5, wobei R\n2\n für die Gruppe mit der Teilformel (I-\nR\n \n2\n) steht,\n6. Compounds according to any one of claims 1 to 5, wherein R \n2 represents\n the group having the partial formula (I- \nR\n \n2\n ),\n\n\n\n\n\n\n \n \n in der\n \n in the\n\n\n\n\n\n\n \nR\na\n für eine Methyl-, Ethyl-, Propyl- oder Isopropylgruppe steht, und\nR \na is\n a methyl, ethyl, propyl or isopropyl group, and\n\n\n\n\n\n\n \nR\nb\n und R\nc\n unabhängig voneinander für Wasserstoff, eine Methyl- oder Ethylgruppe stehen. sowie deren Salze, Diatereomere und Enantiomere.\nR \nb\n and R \nc\n independently of one another represent hydrogen, a methyl or ethyl group. and their salts, diatereomers and enantiomers.\n\n\n\n\n\n\n\n\n\n\n \n7. Verbindungen gemäß Anspruch 6, wobei R\na\n und R\nb\n für eine Methylgruppe und R\nc\n für Wasserstoff oder eine Methylgruppe stehen, sowie deren Salze, Diatereomere und Enantiomere.\n7. Compounds according to claim 6, wherein R \na\n and R \nb are\n a methyl group and R \nc is\n hydrogen or a methyl group, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n\n\n\n\n \n8. Verbindungen der allgemeinen Formel (Ia)\n8. Compounds of the general formula (Ia)\n\n\n\n\n\n\n \n \n in der\n \n in the\n\n\n\n\n\n\n \nR\n1\n für eine Methylgruppe oder für einen Cyclopropylring steht, und\nR \n1 is\n a methyl group or a cyclopropyl ring, and\n\n\n\n\n\n\n \nR\na\n und R\nb\n für eine Methylgruppe stehen, und\nR \na\n and R \nb are\n a methyl group, and\n\n\n\n\n\n\n \nR\nc\n für Wasserstoff oder eine Methylgruppe steht, sowie deren Salze, Diatereomere und Enantiomere.\nR \nc is\n hydrogen or a methyl group, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n\n\n\n\n \n9. Verfahren zur Herstellung der Verbindungen gemäß einem der Ansprüche 1 bis 8 umfassend mindestens einer der Schritte ai) Funktionalisierung der 4-Position von 2,4-Dichlor-5-jod-pyrimidin (1) durch Umsetzung mit einem Alkohol der Formel (2) unter Bildung eines Intermediates der Formel (3),\n9. A process for the preparation of the compounds according to any one of claims 1 to 8 comprising at least one of the steps ai) functionalization of the 4-position of 2,4-dichloro-5-iodo-pyrimidine (1) by reaction with an alcohol of the formula (2 ) to give an intermediate of formula (3),\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(1) (3)\n(1) (3)\n\n\n\n\n\n\n \nund nachfolgende Umsetzung von Intermediat (3) unter Bildung des 5-CF\n3\n Intermediates (4)\nand subsequent reaction of intermediate (3) to give the 5-CF \n3\n intermediate (4)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(3) (4)\n(3) (4)\n\n\n\n\n\n\n \noder alternativ  a\n2\n) direkte Umsetzung von 2,4-Dichlor-5-trifluormethyl-pyrimidin (5) und einem Alkohol der Formel (2) unter Bildung des 5-CF\n3\n Intermediates (4).\nor alternatively  a \n2\n ) direct reaction of 2,4-dichloro-5-trifluoromethyl-pyrimidine (5) and an alcohol of the formula (2) to give the 5-CF \n3\n intermediate (4).\n\n\n\n\n\n\n \n \n b) Oxidation eines Thioethers der Formel (7) zum Sulfon der Formel (8).\n \n b) oxidation of a thioether of formula (7) to the sulfone of formula (8).\n\n\n\n\n\n\n \n \n c) Reduktion der Verbindung der Formel (8) zu einer Verbindung der Formel (9),\n \n c) reduction of the compound of the formula (8) to give a compound of the formula (9),\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nd) Kupplung der Verbindungen der Formel (4) und (9)\nd) Coupling of the compounds of the formula (4) and (9)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nwobei die Substituenten R\n1\n und R\n2\n die in der allgemeinen Formel (I) gemäß einem der Ansprüche 1 bis 7 angegebenen Bedeutungen aufweisen.  \nwherein the substituents R \n1\n and R \n2 have\n the meanings given in the general formula (I) according to one of claims 1 to 7. \n\n\n\n\n\n\n\n\n\n\n \n10. Verbindungen gemäß einem der Ansprüche 1 bis 8 zur Verwendung als Arzneimittel.\n10. Compounds according to any one of claims 1 to 8 for use as medicaments.\n\n\n\n\n\n\n\n\n\n\n \n11. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 8 zur Herstellung eines Arzneimittels zur Behandlung von Krebs.\n11. Use of a compound according to any one of claims 1 to 8 for the manufacture of a medicament for the treatment of cancer.\n\n\n\n\n\n\n\n\n\n\n \n12. Verbindungen gemäß einem der Ansprüche 1 bis 8 zur Verwendung als Arzneimittel gegen Krebs.\n12. Compounds according to any one of claims 1 to 8 for use as anticancer drugs.\n\n\n\n\n\n\n\n\n\n\n \n13. Pharmazeutische Formulierung enthaltend eine Verbindung gemäß einem der Ansprüche 1 bis 8. \n13. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 8. Description\n\n\n\n\n\n\n \n Sulfonsubsituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und\n Sulfonsubsituierte anilino-pyrimidine derivatives as CDK inhibitors, their preparation and\n\n\n\n\n\n\n \nVerwendung als Arzneimittel\nUse as a medicine\n\n\n\n\n\n\n \nDie vorliegende Erfindung betrifft sulfonsubsituierte Anilino-Pyrimidinderivate, deren Verfahren zur Herstellung, sowie deren Verwendung als Medikament zur Behandlung verschiedener Erkrankungen.\nThe present invention relates to sulfone-substituted anilino-pyrimidine derivatives, their process for the preparation, and their use as a medicament for the treatment of various diseases.\n\n\n\n\n\n\n \nDie Zyklin-abhängigen Kinasen (cyclin-dependent kinase, CDK) sind eine Enzymfamilie, die eine wichtige Rolle bei der Regulation des Zellzyklusses spielt und somit ein besonders interessantes Ziel für die Entwicklung kleiner inhibitorischer Moleküle darstellt. Selektive Inhibitoren der CDKs können zur Behandlung von Krebs oder anderen Erkrankungen, die Störungen der Zellproliferation zur Ursache haben, verwendet werden.\nThe cyclin-dependent kinases (CDK) are an enzyme family that plays an important role in the regulation of the cell cycle and thus represents a particularly interesting target for the development of small inhibitory molecules. Selective inhibitors of CDKs can be used to treat cancers or other diseases that cause cell proliferation disorders.\n\n\n\n\n\n\n \nPyrimidine und Analoga sind bereits als Wirkstoffe beschrieben wie beispielsweise die 2-Anilino- Pyrimidine als Fungizide (DE 4029650) oder substituierte Pyrimidinderivate zur Behandlung von neurologischen oder neurodegenerativen Erkrankungen (WO 99/19305). Als CDK-Inhibitoren werden unterschiedlichste Pyrimidinderivate beschrieben, beispielsweise 2-Amino-4-substituierte Pyrimidine (WO 01/ 14375), Purine (WO 99/02162), 5-Cyano-Pyrimidine (WO 02/04429), Anilinopyrimidine (WO 00/12486) und 2-Hydroxy-3-N,N-dimethylaminopropoxy-Pyrimidine (WO 00/39101).\nPyrimidines and analogues have already been described as active substances, for example the 2-anilino-pyrimidines as fungicides (DE 4029650) or substituted pyrimidine derivatives for the treatment of neurological or neurodegenerative diseases (WO 99/19305). As CDK inhibitors a wide variety of pyrimidine derivatives are described, for example 2-amino-4-substituted pyrimidines (WO 01/14375), purines (WO 99/02162), 5-cyano-pyrimidines (WO 02/04429), anilinopyrimidines (WO 00 / 12486) and 2-hydroxy-3-N, N-dimethylaminopropoxy-pyrimidines (WO 00/39101).\n\n\n\n\n\n\n \nInsbesondere wurden in WO 02/096888 und WO 03/076437 Pyrimidinderivate offenbart, die inhibitorische Wirkungen bezüglich CDKs aufweisen.\nIn particular, WO 02/096888 and WO 03/076437 have disclosed pyrimidine derivatives which have inhibitory effects on CDKs.\n\n\n\n\n\n\n \nWO 2005/037800 offenbart offene sulfoximinsubsituierte Anilino-Pyrimidinderivate als Inhibitoren der Zyklin-abhängigen Kinasen. Beispielhaft belegt sind Strukturen, die in der 5-Position des Pyrimidins entweder nicht oder mit Halogen, insbesondere mit Brom substituiert sind. Einen 5- Trifluormethylsubstituenten weist keine der spezifisch offenbarten Strukturen auf.\nWO 2005/037800 discloses open sulfoximine-substituted anilino-pyrimidine derivatives as inhibitors of cyclin-dependent kinases. Exemplified are structures which are either not substituted in the 5-position of the pyrimidine or substituted with halogen, in particular with bromine. A 5-trifluoromethyl substituent does not have any of the specifically disclosed structures.\n\n\n\n\n\n\n \nWO 2003/032997 offenbart sulfonsubstituierte Anilinopyrimidine, für die allerdings in der Position 4 des Pyrimidins obligat ein stickstoffhaltiger Rest vorgesehen ist.\nWO 2003/032997 discloses sulfone-substituted anilinopyrimidines, for which, however, a nitrogen-containing radical is obligately provided in position 4 of the pyrimidine.\n\n\n\n\n\n\n \nDie den erfindungsgemäßen Strukturen am nächsten kommende spezifisch offenbarte Struktur ist die Struktur 692 des Beispiels 1. \n\n Ausgehend von diesem Stand der Technik besteht die Aufgabe der vorliegenden Erfindung Verbindungen bereitzustellen, die die Aktivität der Zyklin-abhängigen Kinasen stärker inhibieren als die Verbindungen des Standes der Technik. Weiterhin sollen die Verbindungen selektiver gegenüber der Inhibition der VEGF-Rezeptorkinase-2 (VEGF-R2) sein. Die Verbindungen sollen gut permeabel in absorptiver Richtung und gering permeabel in Efflux-Richtung sein. Insbesondere sollen die Verbindungen auch in Chemotherapie-resistenten Tumorzellen stark antiproliferativ wirken.\nThe closest disclosed structure to the structures of the invention is structure 692 of Example 1.  Based on this prior art, the object of the present invention is to provide compounds which inhibit the activity of the cyclin-dependent kinases more than the compounds of the prior art. Furthermore, the compounds should be more selective to the inhibition of VEGF receptor kinase-2 (VEGF-R2). The compounds should be well permeable in the absorptive direction and slightly permeable in the efflux direction. In particular, the compounds should also have a strong antiproliferative action in chemotherapy-resistant tumor cells.\n\n\n\n\n\n\n \nEs wurde nun gefunden, dass Verbindungen der allgemeinen Formel (I)\nIt has now been found that compounds of the general formula (I)\n\n\n\n\n\n\n \n \n\n in der\n \n in the\n\n\n\n\n\n\n \nR\n1\n für einen Ci-C\n6\n-Alkyl-, C\n2\n-C\n6\n-Alkenyl-, C\n2\n-C\n6\n-Alkinylrest oder einen\nR \n1\n is a Ci-C \n6\n alkyl, C \n2\n -C \n6\n alkenyl, C \n2\n -C \n6\n alkynyl, or\n\n\n\n\n\n\n \nC\n3\n-C\n7\n-Cycloalkyl oder Phenylring steht, jeweils gegebenenfalls mit Hydroxy, -NR\n3\nR\n4\n, Cyano, Halogen, -CF\n3,\n C\nr\nC\n6\n-Alkoxy, -OCF\n3\n und/oder C\nr\nC\n6\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert, und\nC \n3\n -C \n7\n cycloalkyl or phenyl ring, each optionally with hydroxy, -NR \n3\n R \n4\n , cyano, halogen, -CF \n3,\n C \nr\n C \n6\n alkoxy, -OCF \n3\n and / or C \nr\n C \n6\n alkyl - or polysubstituted by identical or different substituents, and\n\n\n\n\n\n\n \nR\n2\n für einen Ci-Cio-Alkyl-, C\n3\n-Cio-Alkenyl- oder C\n3\n-Ci\n0\n-Alkinylrest oder einen\nR \n2 is\n a Ci-Cio-alkyl, C \n3\n -Cio-alkenyl or C \n3\n -Ci \n0\n -Alkinylrest or a\n\n\n\n\n\n\n \nC\n3\n-C\n7\n-Cycloalkylring steht, jeweils gegebenenfalls ein- oder mehrfach, gleich oder verschieden substituiert mit a) Halogen, Hydroxy, -NR\n3\nR\n4\n, Cyano, -CF\n3\n, -OCF\n3\n, und/oder b) Ci-C\n6\n-AIkOXy, C\nr\nC\n6\n-Alkyl, C\n2\n-C\n6\n-Alkenyl, C\n2\n-C\n6\n-Alkinyl, oder\nC \n3\n -C \n7\n -cycloalkyl ring, in each case optionally mono- or polysubstituted by identical or different substituents with a) halogen, hydroxy, -NR \n3\n R \n4\n , cyano, -CF \n3\n , -OCF \n3\n , and / or b) ci C \n6\n alkoxy, C \nr\n C \n6\n alkyl, C \n2\n -C \n6\n alkenyl, C \n2\n -C \n6\n alkynyl, or\n\n\n\n\n\n\n \nC\n3\n-C\n8\n-Cycloalkyl, -O-CH\n2\n-Phenyl, C\nn\n-Alkoxycarbonyl, jeweils gegebenenfalls selbst ein- oder mehrfach, gleich oder verschieden mit Halogen, Hydroxy, einem CpCβ-Alkyl, CpC\n6\n-AIkOXy, -NR\n3\nR\n4\n, -CF\n3\n und/oder -OCF\n3\n substituiert, und\nC \n3\n -C \n8\n -cycloalkyl, -O-CH \n2\n -phenyl, C \nn\n -alkoxycarbonyl, each optionally even one or more times, identically or differently with halogen, hydroxy, a CpCβ-alkyl, CpC \n6\n -alkoxy, -NR \n3\n R \n4\n , -CF \n3\n and / or -OCF \n3\n substituted, and\n\n\n\n\n\n\n \nR\n3\n und R\n4\n unabhängig voneinander für Wasserstoff und/oder einen Ci-C\nδ\n-Alkylrest,\nR \n3\n and R \n4\n independently of one another represent hydrogen and / or a Ci-C alkyl \nδ,\n \n\n\n\n\n\n\n \nC\n2\n-C\n6\n-Alkenylrest, C\n3\n-Cg-Cycloalkyl- und/oder Phenylring, einen Heterocyclylring mit 3 bis 8 Ringatomen und/oder einen monocyclischen Heteroarylring, gegebenenfalls mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, \n\n Ci-Cβ-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sind, oder\nC \n2\n -C \n6\n alkenyl radical, C \n3\n -Cg cycloalkyl and / or phenyl ring, a heterocyclyl ring having 3 to 8 ring atoms and / or a monocyclic heteroaryl ring, optionally with hydroxy, -NR \n5\n R \n6\n , cyano, halogen, -CF \n3\n ,  Ci-Cβ-alkoxy and / or -OCF \n3 are\n mono- or polysubstituted by identical or different substituents, or\n\n\n\n\n\n\n \nR\n3\n und R\n4\n gemeinsam mit dem Stickstoffatom einen 5- bis 7-gliedrigen Ring bilden, der gegebenenfalls zusätzlich zum Stickstoffatom 1 oder 2 weitere Heteroatome enthält und der mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, C\nr\nC\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sein kann, und\nR \n3\n and R \n4\n together with the nitrogen atom form a 5- to 7-membered ring which optionally contains in addition to the nitrogen atom 1 or 2 further heteroatoms and which with hydroxy, -NR \n5\n R \n6\n , cyano, halogen, -CF \n3\n , C \nr\n C \n6\n alkoxy and / or -OCF \n3 may be\n mono- or polysubstituted by identical or different substituents, and\n\n\n\n\n\n\n \nR\n5\n und R\n6\n unabhängig voneinander für Wasserstoff oder einen Ci-C\n6\n-Alkylrest stehen, der gegebenenfalls mit Hydroxy, Cyano, Halogen, -CF\n3\n, Ci-C\n6\n-AIkOXy und/oder\nR \n5\n and R \n6\n independently of one another are hydrogen or a C \n1\n -C \n6\n -alkyl radical which is optionally substituted by hydroxyl, cyano, halogen, -CF \n3\n , C \n1\n -C \n6\n -alkoxy and / or\n\n\n\n\n\n\n \n-OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert ist. sowie deren Salze, Diatereomere und Enantiomere.\n-OCF \n3 is\n mono- or polysubstituted by identical or different substituents. and their salts, diatereomers and enantiomers.\n\n\n\n\n\n\n \nDer Erfindung liegen folgende Definitionen zu Grunde:\nThe invention is based on the following definitions:\n\n\n\n\n\n\n \nCn-Alkyl:\nCn-alkyl:\n\n\n\n\n\n\n \nMonovalenter, geradkettiger oder verzweigter, gesättigter Kohlenwasserstoffrest mit n\nMonovalent, straight-chain or branched, saturated hydrocarbon radical with n\n\n\n\n\n\n\n \nKohlenstoffatomen.\nCarbon atoms.\n\n\n\n\n\n\n \nEin Ci-C\n6\n Alkylrest umfasst unter anderem beispielsweise: Methyl-, Ethyl-, Propyl-, Butyl-, Pentyl-,Hexyl-, /so-Propyl-, /so-Butyl-, sec-Butyl, ter/-Butyl-, zso-Pentyl-, 2-Methylbutyl-, 1-Methylbutyl-, 1-Ethylpropyl-, 1,2-Dimethylpropyl, weo-Pentyl-,\nA C \n1\n -C 6 -alkyl radical includes, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, / so-propyl, / n-butyl, sec-butyl, tert-butyl , zso-pentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, weo-pentyl,\n\n\n\n\n\n\n \n1,1-Dimethylpropyl-, 4-Methylpentyl-, 3-Methylpentyl-, 2-Methylpentyl-, 1 -Methylpentyl-,\n1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl,\n\n\n\n\n\n\n \n2-Ethylbutyl-, 1-Ethylbutyl-, 3,3-Dimethylbutyl-, 2,2-Dimethylbutyl-, 1,1-Dimethylbutyl-, 2,3-\n2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-\n\n\n\n\n\n\n \nDimethylbuτyl-, 1 ,3-Dimethylbutyl- 1 ,2-Dimethylbutyl-. Bevorzugt ist ein Methyl-, Ethyl-, Propyl- oder Isopropylrest.\nDimethylbutyl, 1, 3-dimethylbutyl-1, 2-dimethylbutyl. Preference is given to a methyl, ethyl, propyl or isopropyl radical.\n\n\n\n\n\n\n \nC„-Alkenyl: monovalenter, geradkettiger oder verzweigter Kohlenwasserstoffrest mit n Kohlenstoffatomen und mindestens einer Doppelbindung.\nC \"alkenyl: monovalent, straight-chain or branched hydrocarbon radical having n carbon atoms and at least one double bond.\n\n\n\n\n\n\n \nEin C\n2\n-Ci\n0\n Alkenylrest umfasst unter anderem beispielsweise: Vinyl-, Allyl-, (E)-2-Methylvinyl-, (Z)-2-Methylvinyl-, Homoallyl-, (E)-But-2-enyl-, (Z)-But-2-enyl-, (E)-BuM -enyl-, (Z)-BuM -enyl-, Pent-4-enyl-, (E)-Pent-3-enyl-, (Z)-Pent-3-enyl-, (E)-Pent-2-enyl-, (Z)-Pent-2-enyl-, (E)-Pent-l-enyl-, (Z)-Pent-l-enyl, Hex-5- enyl-, (E)-Hex-4-enyl-, (Z)-Hex-4-enyl-, (E)-Hex-3-enyl-, (Z)-Hex-3-enyl-, (E)-Hex-2-enyl-, (Z)- Hex-2-enyl-, (E)-Hex-l-enyl-, (Z)-Hex-l-enyl-, Isopropenyl-, 2-Methylprop-2-enyl-, 1- \n\n Methylprop-2-enyl-,\nA C \n2\n -C \n0\n alkenyl group includes, among others, for example: vinyl, allyl, (E) -2-methylvinyl, (Z) -2-methylvinyl, homoallyl, (E) -but-2-enyl, (Z) -but-2-enyl, (E) -BuM -enyl, (Z) -BuM -enyl, pent-4-enyl, (E) -pent-3-enyl-, (Z) Pent-3-enyl, (E) -pent-2-enyl, (Z) -pent-2-enyl, (E) -pent-1-enyl, (Z) -pent-1-enyl , Hex-5-enyl, (E) -hex-4-enyl, (Z) -hex-4-enyl, (E) -hex-3-enyl, (Z) -hex-3-enyl -, (E) -hex-2-enyl, (Z) -hex-2-enyl, (E) -hex-1-enyl, (Z) -hex-1-enyl, isopropenyl, 2 -Methylprop-2-enyl-, 1-  Methylprop-2-enyl,\n\n\n\n\n\n\n \n2-Methylprop-l-enyl-, (E)-l-Methylprop-l-enyl-, (Z)-l-Methylprop-l-enyl-, 3-Methylbut-3-enyl-, 2-Methylbut-3-enyl-, l-Methylbut-3-enyl-, 3-Methylbut-2-enyl-, (E)-2-Methylbut-2-enyl-, (Z)-2-Methylbut-2-enyl-, (E)-l-Methylbut-2-enyl-, (Z)-l-Methylbut-2-enyl-, (E)-3-Methylbut-l- enyl-, (Z)-3-Methylbut- 1 -enyl-, (E)-2-Methylbut- 1 -enyl-, (Z)-2-Methylbut- 1 -enyl-,\n2-methylprop-1-enyl, (E) -l-methylprop-1-enyl, (Z) -l-methylprop-1-enyl, 3-methylbut-3-enyl, 2-methylbut-3 enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, (E) -2-methylbut-2-enyl, (Z) -2-methylbut-2-enyl, (E) -l-methylbut-2-enyl, (Z) -l-methylbut-2-enyl, (E) -3-methylbut-1-enyl, (Z) -3-methylbut-1-enyl, ( E) -2-methylbut-1-enyl, (Z) -2-methylbut-1-enyl,\n\n\n\n\n\n\n \n(E)- 1 -Methylbut- 1 -enyl-, (Z)- 1 -Methy Ibut- 1 -enyl-, 1 , 1 -Dimethylprop-2-eny 1-, 1 -Ethylprop- 1 -enyl-, 1-Propylvinyl-, 1-Isopropylvinyl-, 4-Methylpent-4-enyl-, 3-Methylpent-4-enyl-, 2-Methylpent-4- enyl-, l-Methylpent-4-enyl-, 4-Methylpent-3-enyl-, (E)-3-Methylpent-3-enyl-, (Z)-3-Methylpent-3- enyl-, (E)-2-Methylpent-3-enyl-, (Z)-2-Methylpent-3-enyl-, (E)-l-Methylpent-3-enyl-, (Z)-l-Methylpent-3-enyl-, (E)-4-Methylpent-2-enyl-, (Z)-4-Methylpent-2-enyl-, (E)-3 -Methy lpent- 2-enyl-, (Z)-3-Methylpent-2-enyl-, (E)-2-Methylpent-2-enyl-, (Z)-2-Methylpent-2-enyl-, (E)- 1 -Methylpent-2-enyl-, (Z)- 1 -Methy lpent-2-enyl-, (E)-4-Methylpent- 1 -enyl-, (Z)-4-Methylpent- 1-enyl-, (E)-3-Methylpent-l-enyl-, (Z)-3-Methylpent-l-enyl-, (E)-2-Methylpent-l-enyl-, (Z)-2- Methylpent-1-enyl-, (E)- 1 -Methy lpent-1 -enyl-, (Z)- 1 -Methy lpent-1 -enyl-, 3-Ethylbut-3-enyl-, 2- Ethylbut-3-enyl-, l-Ethylbut-3-enyl-, (E)-3-Ethylbut-2-enyl-, (Z)-3-Ethylbut-2-enyl-, (E)-2-\n(E) -1-methylbut-1-enyl, (Z) -1-methyl-1-ynyl, 1, 1-dimethylprop-2-enyl 1-, 1-ethyl-prop-1-enyl-, 1- Propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3-methylpent-4-enyl, 2-methylpent-4-enyl, 1-methylpent-4-enyl, 4-methylpent-3 enyl, (E) -3-methylpent-3-enyl, (Z) -3-methylpent-3-enyl, (E) -2-methylpent-3-enyl, (Z) -2-methylpentane 3-enyl, (E) -l-methylpent-3-enyl, (Z) -l-methylpent-3-enyl, (E) -4-methylpent-2-enyl, (Z) -4- Methylpent-2-enyl, (E) -3-methylpent-2-enyl, (Z) -3-methylpent-2-enyl, (E) -2-methylpent-2-enyl-, (Z) 2-methylpent-2-enyl, (E) -1-methylpent-2-enyl, (Z) -1-methylpent-2-enyl, (E) -4-methylpent-1-enyl, (Z) -4-methylpent-1-enyl, (E) -3-methylpent-1-enyl, (Z) -3-methylpent-1-enyl, (E) -2-methylpent-1-enyl -, (Z) -2-methylpent-1-enyl, (E) -1-methylpent-1-enyl, (Z) -1-methylpent-1-enyl, 3-ethylbut-3-enyl , 2-ethylbut-3-enyl, 1-ethylbut-3-enyl, (E) -3-ethylbut-2-enyl, (Z) -3-ethylbut-2-enyl, (E) - 2\n\n\n\n\n\n\n \nEthylbut-2-enyl-, (Z)-2-Ethylbut-2-enyl-, (E)-l-Ethylbut-2-enyl-, (Z)-l-Ethylbut-2-enyl-, (E)-3- Ethylbut-1-enyl-, (Z)-3-Ethylbut-l-enyl-, 2-Ethylbut-l-enyl-, (E)- 1-Ethylbut-l -enyl-, (Z)-I- Ethylbut-1-enyl-, 2-Propylprop-2-enyl-, 1 -Propylprop-2-enyl-, 2-Isopropylprop-2-enyl-, 1- Isopropylprop-2-enyl-, (E)-2-Propylprop-l-enyl-, (Z)-2-Propylprop-l-enyl-, (E)- 1-Propy lprop- 1- enyl-, (Z)- 1 -Propy lprop- 1 -enyl-, (E)-2-Isopropylprop- 1 -enyl-, (Z)-2-Isopropylprop- 1 -enyl-, (E)- 1 - Isopropylprop-1-enyl-, (Z)- 1-Isopropylprop-l -enyl-, (E)-3,3-Dimethylprop-l-enyl-, (Z)-3,3- Dimethy lprop- 1 -enyl-, 1 -( 1 , 1 -Dimethylethyl)ethenyl.\nEthylbut-2-enyl, (Z) -2-ethylbut-2-enyl, (E) -l-ethylbut-2-enyl, (Z) -1-ethylbut-2-enyl, (E) - 3-ethylbut-1-enyl, (Z) -3-ethylbut-1-enyl, 2-ethylbut-1-enyl, (E) -1-ethylbut-1-enyl, (Z) -I- Ethyl but-1-enyl, 2-propylprop-2-enyl, 1-propylprop-2-enyl, 2-isopropylprop-2-enyl, 1-isopropylprop-2-enyl, (E) -2-propylprop -l-enyl, (Z) -2-propylprop-l-enyl, (E) -1-propylprop-1-enyl, (Z) -1-propylprop-1-enyl, (E) -2-isopropylprop-1-enyl, (Z) -2-isopropylprop-1-enyl, (E) -1-isopropylprop-1-enyl, (Z) -1-isopropylprop-1-enyl, ( E) -3,3-dimethylprop-1-enyl-, (Z) -3,3-dimethylprop-1-enyl-, 1 - (1, 1-dimethylethyl) ethenyl.\n\n\n\n\n\n\n \nBevorzugt ist ein Vinyl- oder Allylrest.\nPreference is given to a vinyl or allyl radical.\n\n\n\n\n\n\n \nC„-Alkinyl:\nC \"alkynyl:\n\n\n\n\n\n\n \nMonovalenter, geradkettiger oder verzweigter Kohlenwasserstoffrest mit n Kohlenstoffatomen und mindestens einer Dreifachbindung.\nMonovalent, straight-chain or branched hydrocarbon radical with n carbon atoms and at least one triple bond.\n\n\n\n\n\n\n \nEin C\n2\n-CiO Alkinylrest umfasst unter anderem beispielsweise:\nA C \n2\n -C 10 alkynyl radical includes, for example, for example:\n\n\n\n\n\n\n \nEthinyl-, Prop-1-inyl-, Prop-2-inyl-, But-1-inyl-, But-2-inyl-, But-3-inyl-, Pent-1-inyl-, Pent-2-inyl-, Pent-3-inyl-, Pent-4-inyl-, Hex-1-inyl-, Hex-2-inyl-, Hex-3-inyl-, Hex-4-inyl-, Hex-5- inyl-, 1 -Methy lprop-2-inyl-, 2-Methylbut-3-inyl-, 1 -Methy lbut-3-inyl-, l-Methylbut-2-inyl-, 3-Methylbut-l-inyl-, l-Ethylprop-2-inyl-, 3-Methylpent-4-inyl, 2-Methylpent-4-inyl, 1 -Methy lpent-4-inyl, 2-Methylpent-3-inyl, l-Methylpent-3-inyl, 4-Methylpent-2-inyl, l-Methylpent-2-inyl, 4-Methylpent-l-inyl, 3-Methylpent-l-inyl, 2-Ethylbut-3-inyl-, \n\n l-Ethylbut-3-inyl-, l-Ethylbut-2-inyl-, l-Propylprop-2-inyl-, 1 -Isopropylprop-2-inyl-, 2,2-Dimethylbut-3-inyl-, l,l-Dimethylbut-3-inyl-, l,l-Dimethylbut-2-inyl- oder 3,3-Dimethylbut-l-inyl-.\nEthynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl , Pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl , 1-methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3-methylbut-1-ynyl, Ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1-methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpent-3-ynyl, 4- Methylpent-2-ynyl, 1-methylpent-2-ynyl, 4-methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut-3-ynyl,  1-ethylbut-3-ynyl, 1-ethylbut-2-ynyl, 1-propylprop-2-ynyl, 1-isopropylprop-2-ynyl, 2,2-dimethylbut-3-ynyl, 1, l Dimethylbut-3-ynyl, 1,1-dimethylbut-2-ynyl or 3,3-dimethylbut-1-ynyl.\n\n\n\n\n\n\n \nBevorzugt ist ein Ethinyl-, Prop-1-inyl- oder Prop-2-inyl-rest.\nPreference is given to ethinyl, prop-1-ynyl or prop-2-ynyl radical.\n\n\n\n\n\n\n \nCn-Cvcloalkyl:\nCn-Cycloalkyl:\n\n\n\n\n\n\n \nMonovalenter, cyclischer Kohlenwasserstoffring mit n Kohlenstoffatomen. C\n3\n-C\n7\n-Cy clolalkylring umfasst:\nMonovalent, cyclic hydrocarbon ring with n carbon atoms. C \n3\n -C \n7\n -cycloalkyl ring comprises:\n\n\n\n\n\n\n \nCyclopropyl, Cyclobutyl, Cyclopentyl, Cyclohexyl- und Cycloheptyl. Bevorzugt ist ein Cyclopropyl-, Cylopentyl- oder ein Cyclohexylring.\nCyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Preference is given to a cyclopropyl, cyclopentyl or cyclohexyl ring.\n\n\n\n\n\n\n \nCn-Alkoxy:\nCn-Alkoxy:\n\n\n\n\n\n\n \nGeradkettiger oder verzweigter C„-Alkyletherrest der Formel -OR mit R= Q-Alkyl.\nStraight-chain or branched C \"-alkyl ether radical of the formula -OR with R = Q-alkyl.\n\n\n\n\n\n\n \nC\n3\n-Alkoxycarbonyl\nC \n3\n alkoxycarbonyl\n\n\n\n\n\n\n \nC„-Alkoxycarbonyl steht für die Gruppe -C(O)-O-C„-Alkyl.\nC \"alkoxycarbonyl represents the group -C (O) -O-C\" -alkyl.\n\n\n\n\n\n\n \nIn der Regel ist n gleich 1 bis 6, bevorzugt 1 bis 4, und besonders bevorzugt 1 bis 3.\nIn general, n is 1 to 6, preferably 1 to 4, and particularly preferably 1 to 3.\n\n\n\n\n\n\n \nBeispielhaft und vorzugsweise seien genannt:\nBy way of example and preferably:\n\n\n\n\n\n\n \nMethoxycarbonyl, Ethoxycarbonyl, Propoxycarbonyl, Isopropoxycarbonyl, tert.-Butoxycarbonyl, n-Pentoxycarbonyl und n-Hexoxycarbonyl.\nMethoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl.\n\n\n\n\n\n\n \nHalogen\nhalogen\n\n\n\n\n\n\n \nDie Bezeichnung Halogen umfasst Fluor, Chlor, Brom und Jod.\nThe term halogen includes fluorine, chlorine, bromine and iodine.\n\n\n\n\n\n\n \nBevorzugt ist Fluor.\nPreference is given to fluorine.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) kann R\n1\n stehen für: einen Ci-C\n6\n-Alkyl-, C\n2\n-C\n6\n-Alkenyl-, C\n2\n-C\n6\n-Alkinylrest oder einen C\n3\n-C\n7\n-Cycloalkyl oder Phenylring, jeweils gegebenenfalls mit Hydroxy, -NR\n3\nR\n4\n, Cyano, Halogen, -CF\n3,\n C\nr\nC\n6\n-Alkoxy, -OCF\n3\n und/oder Ci-C\n6\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert.\nIn the general formula (I), R \n1\n can represent: a Ci-C \n6\n alkyl, C \n2\n -C \n6\n alkenyl, C \n2\n -C \n6\n alkynyl or C \n3\n -C \n7\n -cycloalkyl or phenyl, each optionally substituted by hydroxy, -NR \n3\n R \n4\n , cyano, halogen, -CF \n3,\n C \nr\n C \n6\n alkoxy, -OCF \n3\n and / or Ci-C \n6\n alkyl once or more than once, same or different substituted.\n\n\n\n\n\n\n \nBevorzugt steht R\n1\n für einen Ci-Cβ-Alkyl-, C\n2\n-C\n6\n-Alkenyl-, C\n2\n-Q-Alkinylrest oder einen\nPreferably, R \n1 is\n a C \n1\n -C \n6\n -alkyl, C \n2\n -C \n6\n -alkenyl, C \n2\n -Q-alkynyl radical or a\n\n\n\n\n\n\n \nC\n3\n-C\n7\n-Cycloalkyl oder Phenylring, jeweils gegebenenfalls mit Hydroxy, Cyano, Halogen, -CF\n3-\n C\nr\nC\n6\n-Alkoxy, -OCF\n3\n und/oder Ci-C\n6\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert.\nC \n3\n -C \n7\n cycloalkyl or phenyl, each optionally substituted with hydroxy, cyano, halogen, -CF \n3\n C \nr\n C \n6\n alkoxy, -OCF \n3\n and / or Ci-C \n6\n alkyl, mono- or polysubstituted by identical or different substituted.\n\n\n\n\n\n\n \nMehr bevorzugt steht R\n1\n für einen Ci-Q-Alkyl- oder C\n2\n-C\n6\n-Alkenylrest oder einen C\n3\n-C\n7\n-\nMore preferably R \n1 is\n a C \n1\n -C \n4\n -alkyl or C \n2\n -C \n6\n -alkenyl radical or a C \n3\n -C \n7\n -\n\n\n\n\n\n\n \nCycloalkyl- oder Phenylring, jeweils gegebenenfalls mit Hydroxy, Cyano, Halogen und/oder Ci-C\n6\n- Alkyl ein- oder mehrfach, gleich oder verschieden substituiert. \n\n Mehr bevorzugt steht R\n1\n für einen d-C\n4\n-Alkyl- oder C\n2\n-C\n4\n-Alkenylrest oder einen C\n3\n-C\n5\n-CyClOaIkVl- oder Phenylring, jeweils gegebenenfalls mit Hydroxy, Cyano, Halogen und/oder Ci-C\n3\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert.\nCycloalkyl or phenyl ring, each optionally substituted with hydroxy, cyano, halogen and / or Ci-C \n6\n - alkyl once or more than once, same or different substituted.  More preferably, R \n1 is\n a C \n1\n -C \n4\n -alkyl or C \n2\n -C \n4\n -alkenyl radical or a C \n3\n -C \n5\n -cycloalkyl or phenyl ring, in each case optionally with hydroxy, cyano, halogen and / or C \n1\n -C \n3\n -alkyl mono- or polysubstituted by identical or different substituents.\n\n\n\n\n\n\n \nAußerordentlich bevorzugt steht R\n1\n für eine Methylgruppe oder für einen Cyclopropylring.\nMost preferably, R \n1 is\n a methyl group or a cyclopropyl ring.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) kann R\n2\n stehen für: einen C\nr\nCio-Alkyl-, C\n3\n-Ci\n0\n-Alkenyl- oder C\n3\n-Ci\n0\n-Alkinylrest oder einen C\n3\n-C\n7\n-Cycloalkylring, jeweils gegebenenfalls ein- oder mehrfach, gleich oder verschieden substituiert mit a) Halogen, Hydroxy, -NR\n3\nR\n4\n, Cyano, -CF\n3\n, -OCF\n3\n, und/oder b) Ci-C\n6\n-AIkOXy, C\nr\nC\n6\n-Alkyl, C\n2\n-C\n6\n-Alkenyl, C\n2\n-C\n6\n-Alkinyl, oder C\n3\n-C\n8\n-Cycloalkyl,\nIn the general formula (I), R \n2\n is: a C \nr\n Cio-alkyl, C \n3\n -C \n0\n alkenyl or C \n3\n -C \n0\n alkynyl, or C \n3\n -C \n7\n cycloalkyl, each optionally a - or polysubstituted by identical or different substituents selected from a) halo, hydroxy, -NR \n3\n R \n4,\n cyano, -CF \n3,\n -OCF \n3,\n and / or b) Ci-C \n6\n -alkoxy, C \nr\n C \n6\n alkyl, C \n2\n -C \n6\n -alkenyl, C \n2\n -C \n6\n -alkynyl, or C \n3\n -C \n8\n -cycloalkyl,\n\n\n\n\n\n\n \n-O-CH\n2\n-Phenyl, C\nn\n-Alkoxycarbonyl, jeweils gegebenenfalls selbst ein- oder mehrfach, gleich oder verschieden mit Halogen, Hydroxy, einem d-Q-Alkyl, CpC\n6\n-AIkOXy, -NR\n3\nR\n4\n, -CF\n3\n und/oder -OCF\n3\n substituiert.\n-O-CH \n2\n -phenyl, C \nn\n -alkoxycarbonyl, each optionally optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, a dQ-alkyl, CpC \n6\n -alkoxy, -NR \n3\n R \n4\n , -CF \n3\n and / or -OCF \n3\n substituted.\n\n\n\n\n\n\n \nBevorzugt steht R\n2\n für einen d-Cio-Alkyl-, C\n3\n-Ci\n0\n-Alkenyl- oder C\n3\n-Ci\n0\n-Alkinylrest oder einen C\n3\n-C\n7\n-Cycloalkylring, jeweils gegebenenfalls ein- oder mehrfach, gleich oder verschieden substituiert mit Halogen, Hydroxy, Cyano, -CF\n3\n, -OCF\n3\n, und/oder C\nr\nC\n6\n-Alkoxy, C\nr\nC\n6\n-Alkyl, jeweils gegebenenfalls selbst ein- oder mehrfach, gleich oder verschieden substituiert mit Halogen oder Hydroxy.\nPreferably R \n2\n stands for a d-Cio-alkyl, C \n3\n -C \n0\n alkenyl or C \n3\n -C \n0\n alkynyl, or C \n3\n -C \n7\n cycloalkyl, in each case optionally mono- or polysubstituted by identical or different substituents with halogen, hydroxy, cyano, -CF \n3\n , -OCF \n3\n , and / or C \nr\n C \n6\n alkoxy, C \nr\n C \n6\n alkyl, each optionally even one or more times, identically or differently substituted with halogen or hydroxy.\n\n\n\n\n\n\n \nMehr bevorzugt steht R\n2\n für einen C\n2\n-C\n6\n-Alkyl-, C\n3\n-C\n6\n-Alkenyl- oder C\n3\n-C\n6\n-Alkinylrest oder einen C\n3\n-C\n7\n-Cycloalkylring, der gegebenenfalls ein- oder mehrfach substituiert ist mit Hydroxy, Halogen, -CF\n3\n und/oder C\nr\nC\n3\n-Alkoxy. \n\n\nMore preferably R \n2 is\n a C \n2\n -C \n6\n alkyl, C \n3\n -C \n6\n alkenyl or C \n3\n -C \n6\n alkynyl radical or a C \n3\n -C \n7\n cycloalkyl ring which is optionally mono- or polysubstituted with hydroxy, halogen, -CF \n3\n and / or C \nr\n C \n3\n alkoxy. \n\n\n\n\n\n\n \nBesonders bevorzugt steht R\n2\n für die Gruppe mit der Teilformel (I-R\n2\n),\nR \n2\n particularly preferably represents the group having the partial formula (IR \n2\n ),\n\n\n\n\n\n\n \n \n\n in der\n \n in the\n\n\n\n\n\n\n \nR\na\n für eine Methyl-, Ethyl-, Propyl- oder Isopropylgruppe steht, und R\nb\n und R\nc\n unabhängig voneinander für Wasserstoff, eine Methyl- oder Ethylgruppe stehen.\nR \na represents\n a methyl, ethyl, propyl or isopropyl group, and R \nb\n and R \nc\n independently represent hydrogen, a methyl or ethyl group.\n\n\n\n\n\n\n \nFormel (Ia) fasst diese Gruppe von Verbindungen zusammen.\nFormula (Ia) summarizes this group of compounds.\n\n\n\n\n\n\n \nBevorzugt stehen R\na\n und R\nb\n für eine Methylgruppe und R\nc\n für Wasserstoff oder eine Methylgruppe.\nPreferably, R \na\n and R \nb are\n a methyl group and R \nc is\n hydrogen or a methyl group.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) können R\n3\n und R\n4\n unabhängig voneinander stehen für: Wasserstoff und/oder einen Ci-Cβ-Alkylrest, C\n2\n-C\n6\n-Alkenylrest, C\n3\n-C\n8\n-Cycloalkyl- und/oder Phenylring, einen Heterocyclylring mit 3 bis 8 Ringatomen und/oder einen monocyclischen Heteroarylring, gegebenenfalls mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, Q-C\n6\n-AIkOXy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sind, oder\nIn the general formula (I), R \n3\n and R \n4 may be\n independently of one another: hydrogen and / or a C \n1\n -C \n6\n -alkyl radical, C \n2\n -C \n6\n -alkenyl radical, C \n3\n -C \n8\n -cycloalkyl and / or phenyl ring, a heterocyclyl ring having 3 to 8 ring atoms and / or a monocyclic heteroaryl ring, optionally with hydroxy, -NR \n5\n R \n6\n , cyano, halogen, -CF \n3\n , QC \n6\n -alkoxy and / or -OCF \n3\n one or more times, identically or differently substituted or\n\n\n\n\n\n\n \nR\n3\n und R\n4\n bilden gemeinsam mit dem Stickstoffatom einen 5- bis 7-gliedrigen Ring, der gegebenenfalls zusätzlich zum Stickstoffatom 1 oder 2 weitere Heteroatome enthält und der mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, Ci-C\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sein kann.\nR \n3\n and R \n4\n together with the nitrogen atom form a 5- to 7-membered ring which optionally contains, in addition to the nitrogen atom, 1 or 2 further heteroatoms and which is substituted by hydroxy, -NR \n5\n R \n6\n , cyano, halogen, -CF \n3\n , Ci -C \n6\n alkoxy and / or -OCF \n3\n may be monosubstituted or polysubstituted by identical or different substituents.\n\n\n\n\n\n\n \nBevorzugt stehen R\n3\n und R\n4\n unabhängig voneinander für:\nPreferably, R \n3\n and R \n4 are\n independently of one another:\n\n\n\n\n\n\n \nWasserstoff und/oder einen C\nr\nC\n4\n-Alkylrest, C\n3\n-C\n6\n-Alkenylrest, C\n3\n-C\n6\n-Cycloalkyl- und/oder\nHydrogen and / or a C \nr\n C \n4\n alkyl, C \n3\n -C \n6\n alkenyl, C \n3\n -C \n6\n cycloalkyl and / or\n\n\n\n\n\n\n \nPhenylring, einen Heterocyclylring mit 5 oder 6 Ringatomen und/oder einen monocyclischen Heteroarylring, gegebenenfalls mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, Ci-C\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sind, oder\nPhenyl ring, a heterocyclyl ring having 5 or 6 ring atoms and / or a monocyclic heteroaryl ring, optionally with hydroxy, -NR \n5\n R \n6\n , cyano, halogen, -CF \n3\n , C \n1\n -C \n6\n -alkoxy and / or -OCF \n3\n one or more times , the same or different substituted, or\n\n\n\n\n\n\n \nR\n3\n und R\n4\n bilden gemeinsam mit dem Stickstoffatom einen 5- bis 7-gliedrigen Ring, der gegebenenfalls zusätzlich zum Stickstoffatom 1 weiteres Heteroatom enthält und der mit Hydroxy, -NR\n5\nR\n6\n, Cyano, Halogen, -CF\n3\n, C\nr\nC\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert sein kann. \n\n Mehr bevorzugt stehen R\n3\n und R\n4\n unabhängig voneinander für Wasserstoff und/oder einen CpC\n6\n- Alkylrest, C\n3\n-C\n8\n-Cycloalkyl- und/oder Phenylring, gegebenenfalls mit Hydroxy, Cyano, Halogen, -CF\n3\n, Ci-C\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert.\nR \n3\n and R \n4\n together with the nitrogen atom form a 5- to 7-membered ring which optionally contains, in addition to the nitrogen atom 1, further heteroatom and which is substituted by hydroxy, -NR \n5\n R \n6\n , cyano, halogen, -CF \n3\n , C \nr\n C \n6\n -alkoxy and / or -OCF \n3 may be\n mono- or polysubstituted by identical or different substituents.  More preferably, R \n3\n and R \n4\n independently of one another represent hydrogen and / or a CpC \n6\n -alkyl radical, C \n3\n -C \n8\n -cycloalkyl and / or phenyl ring, if appropriate with hydroxyl, cyano, halogen, -CF \n3\n , C \n1\n -C \n6\n Alkoxy and / or -OCF \n3\n one or more times, the same or different substituted.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) können R\n5\n und R\n6\n unabhängig voneinander stehen für:\nIn the general formula (I), R \n5\n and R \n6 may be\n independently of one another:\n\n\n\n\n\n\n \nWasserstoff oder einen Ci-C\n6\n-Alkylrest stehen, der gegebenenfalls mit Hydroxy, Cyano, Halogen, -CF\n3\n, Ci-C\n6\n-Alkoxy und/oder -OCF\n3\n ein- oder mehrfach, gleich oder verschieden substituiert ist.\nAre hydrogen or a C \n1\n -C \n6\n -alkyl radical which is optionally monosubstituted or polysubstituted, identically or differently, by hydroxy, cyano, halogen, -CF \n3\n , C \n1\n -C \n6\n -alkoxy and / or -OCF \n3\n .\n\n\n\n\n\n\n \nBevorzugt stehen R\n5\n und R\n6\n unabhängig voneinander für Wasserstoff und/oder einen Ci-C\n3\n- Alkylrest.\nPreferably, R \n5\n and R \n6\n independently of one another are hydrogen and / or a C \n1\n -C \n3\n -alkyl radical.\n\n\n\n\n\n\n \nEine bevorzugte Untergruppe bilden Verbindungen der allgemeinen Formel (I), in der\nA preferred subgroup are compounds of the general formula (I) in which\n\n\n\n\n\n\n \nR\n1\n für einen C\nr\nC\n6\n-Alkyl-, C\n2\n-C\n6\n-Alkenyl-, C\n2\n-C\n6\n-Alkinylrest oder einen C\n3\n-C\n7\n-Cycloalkyl oder Phenylring steht, jeweils gegebenenfalls mit Hydroxy,\nR \n1 is\n a C \nr\n C \n6\n -alkyl, C \n2\n -C \n6\n -alkenyl, C \n2\n -C \n6\n -alkynyl radical or a C \n3\n -C \n7\n -cycloalkyl or phenyl ring, in each case optionally with hydroxyl,\n\n\n\n\n\n\n \nCyano, Halogen, -CF\n3i\n Ci-C\n6\n-Alkoxy, -OCF\n3\n und/oder CpQ-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert, und R\n2\n für einen CpCio-Alkyl-, C\n3\n-Ci\n0\n-Alkenyl- oder C\n3\n-Cio-Alkinylrest oder einen\nCyano, halogen, -CF \n3i\n Ci-C \n6\n alkoxy, -OCF \n3\n mono- and / or CPQ alkyl or polysubstituted by identical or different substituents, and R \n2\n is a CpCio alkyl, C \n3\n -C \n0\n alkenyl - or C \n3\n -Cio-alkynyl or a\n\n\n\n\n\n\n \nC\n3\n-C\n7\n-Cycloalkylring steht, jeweils gegebenenfalls ein- oder mehrfach, gleich oder verschieden substituiert mit Halogen, Hydroxy, Cyano, -CF\n3\n, -OCF\n3\n, und/oder C\nr\nC\n6\n-Alkoxy, C\nr\nC\n6\n- Alkyl, jeweils gegebenenfalls selbst ein- oder mehrfach, gleich oder verschieden substituiert mit Halogen oder Hydroxy, sowie deren Salze, Diatereomere und Enantiomere.\nC \n3\n -C \n7\n -cycloalkyl ring, in each case optionally mono- or polysubstituted by identical or different substituents, with halogen, hydroxyl, cyano, -CF \n3\n , -OCF \n3\n , and / or C \nr\n C \n6\n -alkoxy, C \nr\n C \n6\n - Alkyl, in each case optionally even one or more times, the same or different substituted with halogen or hydroxy, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \nEine mehr bevorzugte Untergruppe bilden Verbindungen der allgemeinen Formel (I) in der\nA more preferred subgroup is represented by compounds of the general formula (I) in the\n\n\n\n\n\n\n \nR\n1\n für einen C,-C\n6\n-Alkyl- oder C\n2\n-C\n6\n-Alkenylrest oder einen C\n3\n-C\n7\n-Cycloalkyl- oder Phenylring steht, jeweils gegebenenfalls mit Hydroxy, Cyano, Halogen und/oder Ci-C\n6\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert, und R\n2\n für einen C\n2\n-C\n6\n-Alkyl-, C\n3\n-C\n6\n-Alkenyl- oder C\n3\n-C\n6\n-Alkinylrest oder einen C\n3\n-\nR \n1 is\n a C \n1\n -C \n6\n -alkyl or C \n2\n -C \n6\n -alkenyl radical or a C \n3\n -C \n7\n -cycloalkyl or phenyl ring, in each case optionally with hydroxyl, cyano, halogen and / or C \n1\n -C \n6\n - Alkyl mono- or polysubstituted by identical or different substituents, and R \n2 is\n a C \n2\n -C \n6\n -alkyl, C \n3\n -C \n6\n -alkenyl or C \n3\n -C \n6\n -alkynyl radical or a C \n3\n -\n\n\n\n\n\n\n \nC\n7\n-Cycloalkylring steht, der gegebenenfalls ein- oder mehrfach substituiert ist mit Hydroxy, Halogen, -CF\n3\n und/oder C\nr\nC\n3\n-Alkoxy, sowie deren Salze, Diatereomere und Enantiomere. \n\n Eine besonders bevorzugte Untergruppe bilden Verbindungen der allgemeinen Formel (Ia)\nC \n7\n -cycloalkyl ring which is optionally mono- or polysubstituted by hydroxy, halogen, -CF \n3\n and / or C \nr\n C \n3\n alkoxy, and their salts, diate isomers and enantiomers.  A particularly preferred subgroup is formed by compounds of the general formula (Ia)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nin der R\n1\n für einen Ci-C\n4\n-Alkyl- oder C\n2\n-C\n4\n-Alkenylrest oder einen C\n3\n-C\n5\n-Cycloalkyl- oder\nin the R \n1 is\n a Ci-C \n4\n alkyl or C \n2\n -C \n4\n alkenyl or a C \n3\n -C \n5\n cycloalkyl or\n\n\n\n\n\n\n \nPhenylring steht, jeweils gegebenenfalls mit Hydroxy, Cyano, Halogen und/oder\nPhenyl ring, each optionally with hydroxy, cyano, halogen and / or\n\n\n\n\n\n\n \nC\nr\nC\n3\n-Alkyl ein- oder mehrfach, gleich oder verschieden substituiert, und\nC \nr\n C \n3\n alkyl mono- or polysubstituted by identical or different substituents, and\n\n\n\n\n\n\n \nR\na\n für eine Methyl-, Ethyl-, Propyl- oder Isopropylgruppe steht, und R\nb\n und R\nc\n unabhängig voneinander für Wasserstoff, eine Methyl- oder Ethylgruppe stehen, sowie deren Salze, Diatereomere und Enantiomere.\nR \na represents\n a methyl, ethyl, propyl or isopropyl group, and R \nb\n and R \nc\n independently of one another represent hydrogen, a methyl or ethyl group, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \nEine bevorzugte Untergruppe der Verbindungen der allgemeinen Formel (Ia) bildet die Gruppe von\nA preferred subgroup of the compounds of general formula (Ia) forms the group of\n\n\n\n\n\n\n \nVerbindungen, in der\nCompounds in which\n\n\n\n\n\n\n \nR\n1\n für eine Methylgruppe oder für einen Cyclopropylring steht, und\nR \n1 is\n a methyl group or a cyclopropyl ring, and\n\n\n\n\n\n\n \nR\na\n und R\nb\n für eine Methylgruppe stehen, und\nR \na\n and R \nb are\n a methyl group, and\n\n\n\n\n\n\n \nR\nc\n für Wasserstoff oder eine Methylgruppe steht, sowie deren Salze, Diatereomere und Enantiomere.\nR \nc is\n hydrogen or a methyl group, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \nDie erfindungsgemäßen Verbindungen eignen sich zur Behandlung\nThe compounds of the invention are suitable for treatment\n\n\n\n\n\n\n \n• von Krebs, wie solide Tumore, Tumormetastasen, und Hämatologische Tumoren, insbesondere: Kopf- und Halstumore; Lungen- und Bronchialtumore; Gastrointestinaltumore wie z.B. Magenkarzinom, Kolorektales Karzinom, Pankreaskarzinom, Hepatozelluläres Karzinom; Endokin aktive Tumore; Mammakarzinome und Gynäkologische Tumore; Urogenitaltumore, wie z.B. Nierenzellkarzinom, Harnblasenkarzinom, Prostatakarzinom; Tumore der Haut; Sarkome; Leukämien und Lymphome.\n• of cancer, such as solid tumors, tumor metastases, and hematological tumors, especially: head and neck tumors; Lung and bronchial tumors; Gastrointestinal tumors such as e.g. Gastric carcinoma, colorectal carcinoma, pancreatic carcinoma, hepatocellular carcinoma; Endokin active tumors; Breast and gynecological tumors; Genitourinary tumors, e.g. Renal cell carcinoma, bladder carcinoma, prostate carcinoma; Tumors of the skin; sarcomas; Leukemias and lymphomas.\n\n\n\n\n\n\n \n• von viralen Erkrankungen, sowie \n\n • von kardiovaskulären Erkrankungen wie Stenosen, Arteriosklerosen und Restenosen, Stent- induzierte Restenosen.\n• of viral diseases, as well  • cardiovascular diseases such as stenosis, arteriosclerosis and restenosis, stent-induced restenosis.\n\n\n\n\n\n\n \nDie Formulierung der erfindungsgemäßen Verbindungen zu pharmazeutischen Präparaten erfolgt in an sich bekannter Weise, indem man den oder die Wirkstoffe mit den in der Galenik gebräuchlichen Hilfsstoffen in die gewünschte Applikationsform überführt.\nThe formulation of the compounds according to the invention into pharmaceutical preparations is carried out in a manner known per se by converting the active substance (s) into the desired administration form with the auxiliaries customary in galenicals.\n\n\n\n\n\n\n \nAls Hilfsstoffe können dabei beispielsweise Trägersubstanzen, Füllstoffe, Sprengmittel,\nAs excipients, for example, vehicles, fillers, disintegrants,\n\n\n\n\n\n\n \nBindemittel, Feuchthaltemittel, Gleitmittel, Ab- und Adsorptionsmittel, Verdünnungsmittel, Lösungsmittel, Cosolventien, Emulgatoren, Lösungsvermittler, Geschmackskorrigentien,\nBinders, humectants, lubricants, ab- and adsorbents, diluents, solvents, cosolvents, emulsifiers, solubilizers, flavoring agents,\n\n\n\n\n\n\n \nFärbemittel, Konservierungs-, Stabilisierungs-, Netzmittel, Salze zur Veränderung des osmotischen\nColorants, preservatives, stabilizers, wetting agents, salts for altering the osmotic\n\n\n\n\n\n\n \nDrucks oder Puffer zum Einsatz kommen.\nPressure or buffer are used.\n\n\n\n\n\n\n \nDabei ist auf Remington's Pharmaceutical Science, 15th ed. Mack Publishing Company, East\nAttention is directed to Remington's Pharmaceutical Science, 15th ed. Mack Publishing Company, East\n\n\n\n\n\n\n \nPennsylvania (1980) hinzuweisen.\nPennsylvania (1980).\n\n\n\n\n\n\n \nDie pharmazeutischen Formulierungen können in fester Form, zum Beispiel als Tabletten, Dragees, Pillen, Suppositorien, Kapseln, transdermale\nThe pharmaceutical formulations may be in solid form, for example as tablets, dragees, pills, suppositories, capsules, transdermal\n\n\n\n\n\n\n \nSysteme oder in halbfester Form , zum Beispiel als Salben, Cremes, Gele, Suppositiorien, Emulsionen oder in flüssiger Form, zum Beispiel als Lösungen, Tinkturen, Suspensionen oder Emulsionen vorliegen.\nSystems or in semi-solid form, for example as ointments, creams, gels, suppositories, emulsions or in liquid form, for example as solutions, tinctures, suspensions or emulsions.\n\n\n\n\n\n\n \nHilfsstoffe im Sinne der Erfindung können beispielsweise Salze, Saccharide (Mono-, Di-, Tri-, Oligo-, und/oder Polysaccharide), Proteine, Aminosäuren, Peptide, Fette, Wachse, Öle, Kohlenwasserstoffe sowie deren Derivate sein, wobei die Hilfsstoffe natürlichen Ursprungs sein können oder synthetisch bzw. partial synthetisch gewonnen werden können.\nAuxiliaries for the purposes of the invention may be, for example, salts, saccharides (mono-, di-, tri-, oligo-, and / or polysaccharides), proteins, amino acids, peptides, fats, waxes, oils, hydrocarbons and derivatives thereof, the auxiliaries may be of natural origin or synthetically or partially synthetically obtained.\n\n\n\n\n\n\n \nFür die orale oder perorale Applikation kommen insbesondere Tabletten, Dragees, Kapseln, Pillen, Pulver, Granulate, Pastillen, Suspensionen, Emulsionen oder Lösungen in Frage. Für die parenterale Applikation kommen insbesondere Suspensionen, Emulsionen und vor allem Lösungen in Frage. \n\n Herstellung der erfindungsgemäßen Verbindungen\nFor oral or oral administration, in particular tablets, dragees, capsules, pills, powders, granules, lozenges, suspensions, emulsions or solutions come into question. For parenteral administration in particular suspensions, emulsions and above all solutions in question.  Preparation of the compounds of the invention\n\n\n\n\n\n\n \nDie nachfolgenden Beispiele erläutern die Herstellung der erfindungsgemäßen Verbindungen, ohne den Umfang der beanspruchten Verbindungen auf diese Beispiele zu beschränken.\nThe following examples illustrate the preparation of the compounds of the invention without limiting the scope of the claimed compounds to these examples.\n\n\n\n\n\n\n \nDie erfindungsgemäßen Verbindungen können hergestellt werden durch ein Verfahren, das durch folgende Schritte gekennzeichnet ist:\nThe compounds according to the invention can be prepared by a process which is characterized by the following steps:\n\n\n\n\n\n\n \nai) Funktionalisierung der 4-Position von 2,4-Dichlor-5-jod-pyrimidin (1) durch Umsetzung mit einem Alkohol der Formel (2) unter Bildung eines Intermediates der Formel (3)\nai) functionalization of the 4-position of 2,4-dichloro-5-iodopyrimidine (1) by reaction with an alcohol of the formula (2) to give an intermediate of the formula (3)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(1) (3) und nachfolgende Umsetzung von Intermediat (3) unter Bildung des 5-CF\n3\n Intermediates (4)\n(1) (3) and subsequent reaction of intermediate (3) to give the 5-CF \n3\n intermediate (4)\n\n\n\n\n\n\n \n \n\n oder alternativ a\n2\n) direkte Umsetzung von 2,4-Dichlor-5-trifiuormethyl-pyrimidin (5) und einem Alkohol der Formel (2) unter Bildung des 5-CF\n3\n Intermediates (4).\n \n or alternatively a \n2\n ) direct reaction of 2,4-dichloro-5-trifluoromethyl-pyrimidine (5) and an alcohol of formula (2) to give the 5-CF \n3\n intermediate (4).\n\n\n\n\n\n\n \n \n\n b) Oxidation eines Thioethers der Formel (7) zum Sulfon der Formel (8).\n \n b) oxidation of a thioether of formula (7) to the sulfone of formula (8).\n\n\n\n\n\n\n \n \n\n c) Reduktion der Verbindung der Formel (8) zu einer Verbindung der Formel (9).\n \n c) reduction of the compound of formula (8) to a compound of formula (9).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nd) Kupplung der Verbindungen der Formel (4) und (9).\nd) coupling of the compounds of formula (4) and (9).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(4) (9) (I) Gegebenfalls erfordert die Herstellung der erfindungsgemäßen Verbindungen das Einführen und anschließende Abspalten von Schutzgruppen (siehe z.B.: PJ. Kocienski, Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994) wie z.B. in der Seitenkette der 4-Position.\n(4) (9) (I) Optionally, the preparation of the compounds of the invention requires the introduction and subsequent cleavage of protecting groups (see, e.g., PJ Kocienski, Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994), e.g. in the side-chain of the 4-position.\n\n\n\n\n\n\n \nVerfahrensschritt aΛ Die Umsetzung von 2,4-Dichlor-5-jod-pyrimidin (1) mit einem Alkohol der Formel (2) unter basischen Bedingungen ermöglicht die Darstellung eines Produktes der Formel (3) (siehe z.B.: (a) U. Lücking et al, WO 2007/071455). Besonders geeignet für die Darstellung ist die beschriebene Verwendung von Natriumhydrid. \n\n Für den Austausch eines Halogens gegen eine Trifluormethylgruppe in einem stickstoffhaltigen Heteroaromaten stehen prinzipiell verschiedene Methoden zur Verfugung (siehe z.B: a) G.E. Carr, R.D. Chambers, T.F. Holmes, J. Chem. Soc. Perkin Trans. 1, 1988, 921; b) F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2002, 327; c) F.G. Njoroge et al, J. Med. Chem 1997, 40, 4290). Besonders geeignet für den Austausch des Jods in der 5-Position des Pyrimidins (3) gegen eine CF\n3\n-Gruppe unter Bildung einer Verbindung der Formel (4) ist die beschriebene Verwendung Kupfer(I)jodid, Kaliumfluorid und (Trifluormethyl)-trimethylsilan in N-Methyl-2-pyrrolidinon und THF.\nProcess Step aΛ The reaction of 2,4-dichloro-5-iodopyrimidine (1) with an alcohol of the formula (2) under basic conditions makes possible the preparation of a product of the formula (3) (see, for example: (a) U. Lücking et al., WO 2007/071455). Particularly suitable for the illustration is the described use of sodium hydride.  In principle, various methods are available for the replacement of a halogen for a trifluoromethyl group in a nitrogen-containing heteroaromatic radical (see, for example: a) GE Carr, RD Chambers, TF Holmes, J. Chem. Soc. Perkin Trans. 1, 1988, 921; b) F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2002, 327; c) FG Njoroge et al, J.Med.Chem 1997, 40, 4290). Particularly suitable for the exchange of the iodine in the 5-position of pyrimidine (3) for a CF \n3\n group to form a compound of formula (4), the described use is copper (I) iodide, potassium fluoride and (trifluoromethyl) trimethylsilane in N-methyl-2-pyrrolidinone and THF.\n\n\n\n\n\n\n \nVerfahrensschritt a?)\nMethod step a?)\n\n\n\n\n\n\n \nDie Umsetzung von 2,4-Dichlor-5-trifluormethyl-pyrimidin (5) mit einem Alkohol der Formel (2) unter basischen Bedingungen ermöglicht die Darstellung der Produkte (4) und (6). Die Regioisomeren können in der Regel chromatographisch getrennt werden, (siehe z.B.: (a) T.M. Caldwell et al, WO 2006/081388, S. 50, Example 1, D). Besonders geeignet für die Darstellung ist die beschriebene Verwendung von Natriumhydrid.\nThe reaction of 2,4-dichloro-5-trifluoromethyl-pyrimidine (5) with an alcohol of the formula (2) under basic conditions allows the preparation of the products (4) and (6). The regioisomers can as a rule be separated by chromatography (see, for example: (a) T. M. Caldwell et al, WO 2006/081388, p. 50, Example 1, D). Particularly suitable for the illustration is the described use of sodium hydride.\n\n\n\n\n\n\n \nVerfahrensschritt b)\nProcess step b)\n\n\n\n\n\n\n \nEine Verbindung der Formel (7) wird zum Sulfon der Formel (8) oxidiert. Für die Überführung eines Thioethers in ein Sulfon stehen zahlreiche Methoden zur Verfügung, z.B. unter Verwendung der Oxidationsmittel Wasserstoffperoxid oder Kaliumpermanganat. Besonders geeignet für die Darstellung von Verbindungen der Formel (8) ist die beschriebene Verwendung von meta- Chlorperbenzoesäure (MCPBA).\nA compound of the formula (7) is oxidized to the sulfone of the formula (8). For the conversion of a thioether to a sulfone there are numerous methods available, e.g. using the oxidizing agent hydrogen peroxide or potassium permanganate. Particularly suitable for the preparation of compounds of formula (8) is the described use of meta-chloroperbenzoic acid (MCPBA).\n\n\n\n\n\n\n \nVerfahrensschritt c) Für die anschließende Reduktion der aromatischen Nitrogruppe zu einer Verbindung der Formel (9) stehen prinzipiell eine Reihe von Reaktionsbedingungen zur Verfügung (siehe z.B.: R.C. Larock, Comprehensive Organic Transformations, VCH, New York, 1989, 411). Besonders geeignet ist beispielsweise die beschriebene Hydrierung unter Verwendung von Raney Nickel in THF.\nProcess Step c) For the subsequent reduction of the aromatic nitro group to a compound of the formula (9), a number of reaction conditions are available in principle (see, for example: R. C. Larock, Comprehensive Organic Transformations, VCH, New York, 1989, 411). For example, the described hydrogenation using Raney nickel in THF is particularly suitable.\n\n\n\n\n\n\n \nVerfahrensschritt d)\nProcess step d)\n\n\n\n\n\n\n \nEine Verbindung der Formel (4) kann mit einem Anilin der Formel (9) zu einer Verbindung der\nA compound of formula (4) can be reacted with an aniline of formula (9) to form a compound of\n\n\n\n\n\n\n \nFormel (I) umgesetzt werden (siehe z.B.: (a) J. Bryant et al, WO 2004/048343). \n\n Allgemeine Hinweise\nFormula (I) are reacted (see, for example: (a) J. Bryant et al, WO 2004/048343).  General information\n\n\n\n\n\n\n \nAlle Reaktionen mit oxidations- oder hydrolyseempfindlichen Verbindungen wurden unter Argon und mit getrockneten Lösungsmitteln durchgeführt.\nAll reactions with oxidation- or hydrolysis-sensitive compounds were carried out under argon and with dried solvents.\n\n\n\n\n\n\n \nDie Substanzbenennung erfolgte unter Verwendung des Programms Autonom 2000 Name, welches in MDL ISIS Draw implementiert ist.\nSubstance naming was done using the program Autonom 2000 Name, which is implemented in MDL ISIS Draw.\n\n\n\n\n\n\n \nAbkürzungen\nAbbreviations\n\n\n\n\n\n\n \n \n\n Beispiel 1\n \n example 1\n\n\n\n\n\n\n \n(2R,3R)-3-[2-(4-CycIopropansulfonyl-phenylamino)-5-trifluormethyl-pyrimidin-4-yloxy]- butan-2-ol\n(2R, 3R) -3- [2- (4-Cyciopropanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-yloxy] -butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nIa) Herstellung der Zwischenprodukte Verbindung 1.1 l-Cyclopropylsulfanyl-4-nitro-benzol\nIa) Preparation of Intermediates Compound 1.1 1-Cyclopropylsulfanyl-4-nitrobenzene\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine 4%ige Lösung von 3,00 g (40,5 mmol) Cyclopropanthiol (Herstellung nach: E. Block et al, J. Am. Chem. Soc. 1992, 114, 3492) in THF / Diethylether (1 :1) wurde portionsweise mit 1,78 g (44,6 mmol) Natriumhydrid (60%) versetzt und 30 Minuten bei Raumtemperatur gerührt. Anschließend erfolgte die portionsweise Zugabe von 6,00 g (38,7 mmol) l-Fluor-4-nitro-benzol. Der Ansatz wurde 2 Stunden bei 40\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz in Wasser gegeben und mit Benzol extrahiert (3x). Die vereinten organischen Phasen wurden eingeengt und der Rückstand chromatographisch (Hexan / Essigester 95:5) gereinigt. Man erhielt 4,6 g (23,6 mmol; Ausbeute: 61%) des Produktes.\nA 4% solution of 3.00 g (40.5 mmol) of cyclopropanethiol (prepared according to E. Block et al., J. Am. Chem. Soc. 1992, 114, 3492) in THF / diethyl ether (1: 1). was added in portions with 1.78 g (44.6 mmol) of sodium hydride (60%) and stirred for 30 minutes at room temperature. This was followed by the portionwise addition of 6.00 g (38.7 mmol) of 1-fluoro-4-nitrobenzene. The mixture was stirred at 40 \n°\n C. for 2 hours. After cooling, the reaction was poured into water and extracted with benzene (3x). The combined organic phases were concentrated and the residue was purified by chromatography (hexane / ethyl acetate 95: 5). This gave 4.6 g (23.6 mmol, yield: 61%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ= 8.12 (m, 2H), 7.54 (m, 2H), 2.35 (m, IH), 1.16 (m, 2H), 0.61 (m, 2H). \n\n Verbindung 1.2 l-CyclopropansulfonyI-4-nitro-benzol\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.12 (m, 2H), 7.54 (m, 2H), 2.35 (m, IH), 1.16 (m, 2H), 0.61 (m, 2H).  Compound 1.2 l-CyclopropanesulfonyI-4-nitro-benzene\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1,00 g (5,12 mmol) l-CyclopropylsulfanyM-nitro-benzol in 120 ml DCM wurde bei 0\n0\nC mit 2,3 g meta-Chlorperbenzoesäure (max. 77%) versetzt und anschließend 4,5 Stunden bei Raumtemperatur gerührt. Der Ansatz wurde unter Rühren in eine gesättigte Natriumhydrogencarbonat -Lösung gegeben. Die organische Phase wurde über einem Whatman Filter filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (DCM / MeOH 95:5) gereinigt. Man erhielt 1,07 g (4,70 mmol; Ausbeute: 92%) des Produktes.\nA solution of 1.00 g (5.12 mmol) of 1-cyclopropylsulfanylM-nitrobenzene in 120 ml of DCM was treated at 0 \n°\n C. with 2.3 g of meta-chloroperbenzoic acid (maximum 77%) and then 4.5 hours stirred at room temperature. The reaction was added with stirring to a saturated sodium bicarbonate solution. The organic phase was filtered over a Whatman filter and concentrated. The residue obtained was purified by chromatography (DCM / MeOH 95: 5). 1.07 g (4.70 mmol, yield: 92%) of the product was obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.41 (m, 2H), 8.15 (m, 2H), 2.98 (m, IH), 1.11 (m, 4h).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.41 (m, 2H), 8.15 (m, 2H), 2.98 (m, IH), 1.11 (m, 4h).\n\n\n\n\n\n\n \nVerbindung 1.3 4-CyclopropansuIfonyl-phenylamin\nCompound 1.3 4-Cyclopropanesulfonyl-phenylamine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1,60 g (7,0 mmol) l-Cyclopropansulfonyl-4-nitro-benzol in 50 ml Ethanol und 50 ml THF wurde mit 3,2 g Raney-Nickel (50% wasserfeucht) versetzt und 1,5 Stunden unter\nTo a solution of 1.60 g (7.0 mmol) of 1-cyclopropanesulfonyl-4-nitrobenzene in 50 ml of ethanol and 50 ml of THF was added 3.2 g of Raney nickel (50% water wet) and 1.5 hours under\n\n\n\n\n\n\n \nNormaldruck bei 0\n0\nC hydriert. Der Ansatz wurde filtriert und eingeengt. Man erhielt 1,28 g (6,5 mmol; Ausbeute: 92 %) des Produktes.\nNormal pressure at 0 \n0\n C hydrogenated. The reaction was filtered and concentrated. This gave 1.28 g (6.5 mmol, yield: 92%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 7.41 (m, 2H), 6.60 (m, 2H), 6.05 (br, 2H), 2.58 (m, IH), 0.92 (m, 4H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 7.41 (m, 2H), 6.60 (m, 2H), 6.05 (br, 2H), 2.58 (m, IH), 0.92 (m, 4H).\n\n\n\n\n\n\n \nMS: 198 (ESI+). \n\n Verbindung 1.4 (2R,3R)-3-BenzyIoxy-butan-2-ol\nMS: 198 (ESI +).  Compound 1.4 (2R, 3R) -3-Benzyloxybutan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,0 g (44,4 mmol) (2R,3R)-Butan-2,3-diol in 300 ml THF wurde bei Raumtemperatur mit 5,0 g (44,6 mmol) Kalium-tert.-butylat versetzt und der Ansatz 15 Minuten refluxiert. Der Ansatz wurde auf ca. 50\n0\nC abgekühlt und mit 5,3 ml (44,6 mmol) Benzylbromid versetzt. Man refluxierte für 3 Stunden, danach wurde über Nacht bei Raumtemperatur gerührt. Der Ansatz wurde mit Essigester und Natriumchlorid-Lösung verdünnt und anschließend mit IN\nA solution of 4.0 g (44.4 mmol) (2R, 3R) -butane-2,3-diol in 300 ml of THF was added at room temperature with 5.0 g (44.6 mmol) of potassium tert-butoxide and the batch is refluxed for 15 minutes. The batch was cooled to about 50 \n0\n C and treated with 5.3 ml (44.6 mmol) of benzyl bromide. It was refluxed for 3 hours, then it was stirred at room temperature overnight. The mixture was diluted with ethyl acetate and sodium chloride solution and then with IN\n\n\n\n\n\n\n \nChlorwasserstoff-Lösung (Ix) und Natriumchlorid-Lösung (2x) gewaschen. Die organische Phase wurde getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 1:1) gereinigt. Man erhielt 3,4 g (18,9 mmol; Ausbeute: 43 %) des Produktes.\nHydrogen chloride solution (Ix) and sodium chloride solution (2x). The organic phase was dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 1: 1). This gave 3.4 g (18.9 mmol, yield: 43%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 7.35 (m, 4H), 7.28 (m, IH), 4.52 (m, 3H), 3.67 (m, IH), 3.37 (m, IH), 1.05 (d, 3H), 1.01 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 7.35 (m, 4H), 7.28 (m, IH), 4.52 (m, 3H), 3.67 (m, IH), 3.37 (m, IH), 1.05 ( d, 3H), 1.01 (d, 3H).\n\n\n\n\n\n\n \nVerbindung 1.5 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-jod-pyrimidin\nCompound 1.5 4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -2-chloro-5-iodo-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n8,55 g (47,4 mmol) (2R,3R)-3-Benzyloxy-butan-2-ol in 56 ml Diethylether wurden bei 0\n0\nC unter Rühren portionsweise mit 2,07 g Natriumhydrid (55%) versetzt. Nach 10 Minuten wurde das Eisbad entfernt und weitere 3 Minuten bei Raumtemperatur gerührt. Die gebildete Suspension wurde bei 0\n0\nC zu einer Lösung von 6,52 g (23,7 mmol) 2,4-Dichlor-5-jod-pyrimidin in 65 ml Acetonitril gegeben. Der Ansatz wurde 4 Stunden bei 40\n0\nC gerührt und anschließend mit verdünnter Natriumchlorid-Lösung versetzt. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand \n\n wurde chromatographisch (Hexan / Essigester 4:1) gereinigt. Man erhielt 4,12 g (9,8 mmol; Ausbeute: 41%) des Produktes.\n8.55 g (47.4 mmol) of (2R, 3R) -3-benzyloxy-butan-2-ol in 56 ml of diethyl ether were added in portions with 2.07 g of sodium hydride (55%) at 0 \n°\n C. with stirring. After 10 minutes, the ice bath was removed and stirred for a further 3 minutes at room temperature. The resulting suspension was added at 0 \n°\n C. to a solution of 6.52 g (23.7 mmol) of 2,4-dichloro-5-iodopyrimidine in 65 ml of acetonitrile. The mixture was stirred for 4 hours at 40 \n0\n C and then treated with dilute sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained  was purified by chromatography (hexane / ethyl acetate 4: 1). This gave 4.12 g (9.8 mmol, yield: 41%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.78 (s, IH), 7.29 (m, 5H), 5.27 (m, IH), 4.64 (d, IH), 4.53 (d, IH), 3.73 (m, IH), 1.30 (d, 3H), 1.19 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.78 (s, IH), 7.29 (m, 5H), 5.27 (m, IH), 4.64 (d, IH), 4.53 (d, IH), 3.73 ( m, IH), 1.30 (d, 3H), 1.19 (d, 3H).\n\n\n\n\n\n\n \nVerbindung 1.6 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chIor-5-trifluormethyl-pyrimidin\nCompound 1.6 4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -2-chloro-5-trifluoromethyl-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,66 g (11,1 mmol) 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-jod- pyrimidin in 15,8 ml NMP und 15,8 ml THF wurde bei Raumtemperatur unter Rühren mit 3,82 g (20,0 mmol) Kupfer(I)jodid, 0,97 g (16,7 mmol) Kaliumfluorid und 2,47 ml (16,7 mmol) (Trifluormethyl)-trimethylsilan versetzt. Der Ansatz wurde 5,5 Stunden bei 80\n0\nC gerührt. Nach dem Erkalten wurde der Ansatz in verdünnte Natriumchlorid-Lösung gegeben und mit Essigester extrahiert (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1) gereinigt. Man erhielt 2,17 g (6,0 mmol; Ausbeute: 54%) des Produktes.\nA solution of 4.66 g (11.1 mmol) of 4- ((IR, 2R) -2-benzyloxy-1-methyl-propoxy) -2-chloro-5-iodopyrimidine in 15.8 ml of NMP and 15 , 8 ml of THF was stirred at room temperature with 3.82 g (20.0 mmol) of copper (I) iodide, 0.97 g (16.7 mmol) of potassium fluoride and 2.47 ml (16.7 mmol) (trifluoromethyl ) -trimethylsilane. The batch was stirred at 80 \n°\n C. for 5.5 hours. After cooling, the batch was added to dilute sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1). This gave 2.17 g (6.0 mmol, yield: 54%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.81 (s, IH), 7.21 (m, 5H), 5.40 (m, IH), 4.57 (d, IH), 4.42 (d, IH), 3.70 (m, IH), 1.28 (d, 3H), 1.13 (d, 3H).\n \n1\n H NMR (400 MHz, DMSO): δ = 8.81 (s, IH), 7.21 (m, 5H), 5.40 (m, IH), 4.57 (d, IH), 4.42 (d, IH), 3.70 ( m, IH), 1.28 (d, 3H), 1.13 (d, 3H).\n\n\n\n\n\n\n \nVerbindung 1.6 wurde alternativ auch durch folgende Vorschrift hergestellt:\nCompound 1.6 was alternatively prepared by the following procedure:\n\n\n\n\n\n\n \nEine Lösung von 5,00 g (23,0 mmol) 2,4-Dichlor-5-trifluormethyl-pyrirnidin und 5,40 g (30,0 mmol) (2R,3R)-3-Benzyloxy-butan-2-ol in 60 ml Diethylether und 65 ml Acetonitril wurde bei 0\n0\nC mit 1,21 g (27,7 mmol) Natriumhydrd (55%ig), aufgeteilt in 3 Portionen, versetzt und anschließend 90 Minuten bei 15°C gerührt. Der Ansatz wurde mit verdünnter Natriumchlorid-Lösung versetzt und mit Essigester extrahiert (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 95:5) gereinigt. Man erhielt 1,60 g (4,4 mmol; Ausbeute: 19%) des Produktes. \n\n Verbindung 1.7\nA solution of 5.00 g (23.0 mmol) of 2,4-dichloro-5-trifluoromethyl-pyrirnidine and 5.40 g (30.0 mmol) of (2R, 3R) -3-benzyloxy-butan-2-ol in 60 ml of diethyl ether and 65 ml of acetonitrile was added at 0 \n0\n C with 1.21 g (27.7 mmol) of sodium hydrate (55%), divided into 3 portions, and then stirred at 15 ° C for 90 minutes. The batch was treated with dilute sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 95: 5). This gave 1.60 g (4.4 mmol, yield: 19%) of the product.  Connection 1.7\n\n\n\n\n\n\n \n[4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5-trifluormethyl-pyrimidin-2-yl]-(4- cyclopropansulfonyl-phenyl)-amin\n[4 - ((1R, 2R) -2-Benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - (4-cyclopropanesulfonyl-phenyl) -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n700 mg (1,94 mmol) 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-trifluormethyl- pyrimidin und 460 mg (2,33 mmol) 4-Cyclopropansulfonyl-phenylamin in 9,5 ml Acetonitril wurden mit 0,49 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 5,5 Stunden bei 80\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz mit Essigester verdünnt und mit gesättigter Natriumhydrogencarbonat-Lösung und gesättigter Natriumchlorid-Lösung gewaschen, getrocknet (Na\n2\nSC^), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (DCM / Ethanol 95:5) gereinigt. Man erhielt 649 mg (1,24 mmol, Ausbeute: 64%) des Produktes.\n700 mg (1.94 mmol) of 4 - ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-trifluoromethylpyrimidine and 460 mg (2.33 mmol) of 4-cyclopropanesulfonyl Phenylamine in 9.5 ml of acetonitrile were mixed with 0.49 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 80 \n0\n C for 5.5 hours. After cooling, the mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried (Na \n2\n SC ^), filtered and concentrated. The residue obtained was purified by chromatography (DCM / ethanol 95: 5). 649 mg (1.24 mmol, yield: 64%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.58 (s, IH), 7.96 (m, 2H), 7.79 (m, 2H), 7.22 (m, 5H), 5.48 (m, IH), 4.57 (d, IH), 4.46 (d, IH), 3.73 (m, IH), 2.71 (m, IH), 1.31 (d, 3H), 1.15 (d, 3H), 1.05 (m, 2H), 0.96 (m, 2H). MS: 522 (ESR)\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.58 (s, IH), 7.96 (m, 2H), 7.79 (m, 2H), 7.22 (m, 5H), 5.48 ( m, IH), 4.57 (d, IH), 4.46 (d, IH), 3.73 (m, IH), 2.71 (m, IH), 1.31 (d, 3H), 1.15 (d, 3H), 1.05 (m , 2H), 0.96 (m, 2H). MS: 522 (ESR)\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \nEine Lösung von 541 mg (1,04 mmol) [4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5- trifluormethyl-pyrimidin-2-yl]-(4-cyclopropansulfonyl-phenyl)-amin in 110 ml Ethanol wurde mit 541 mg Palladium auf Kohle (10%ig) versetzt und unter Normaldruck bei Raumtemperatur für eine Stunde hydriert. Der Ansatz wurde filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (DCM / EtOH 98:2) gereinigt. Man erhielt 175 mg (0,41 mmol; Ausbeute: 39 %) des Produktes.\nA solution of 541 mg (1.04 mmol) of [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - (4-cyclopropanesulfonyl-phenyl) Amine in 110 ml of ethanol was treated with 541 mg of palladium on carbon (10%) and hydrogenated under atmospheric pressure at room temperature for one hour. The reaction was filtered and concentrated. The residue obtained was purified by chromatography (DCM / EtOH 98: 2). 175 mg (0.41 mmol, yield: 39%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.54 (s, IH), 8.56 (s, IH), 7.95 (m, 2H), 7.79 (m, 2H), 5.28 (m, IH), 4.86 (d, IH), 3.83 (m, IH), 2.76 (m, IH), 1.26 (d, 3H), 1.01 (m, 7H). MS: 432 (ESI+). \n\n Beispiel 2\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.54 (s, IH), 8.56 (s, IH), 7.95 (m, 2H), 7.79 (m, 2H), 5.28 (m, IH), 4.86 ( d, IH), 3.83 (m, IH), 2.76 (m, IH), 1.26 (d, 3H), 1.01 (m, 7H). MS: 432 (ESI +).  Example 2\n\n\n\n\n\n\n \n(2R,3R)-3-[2-(4-MethansuIfonyl-phenylamino)-5-trifluormethyl-pyrimidin-4-yloxy]-butan-2- ol\n(2R, 3R) -3- [2- (4-Methanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-yloxy] -butan-2-ol\n\n\n\n\n\n\n \n \n\n 2a) Herstellung der Zwischenprodukte Verbindung 2.1\n \n 2a) Preparation of Intermediates Compound 2.1\n\n\n\n\n\n\n \n[4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5-trifluormethyl-pyrimidin-2-yl]-(4- methansulfonyl-phenyl)-amin\n[4 - ((1R, 2R) -2-Benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - (4-methanesulfonyl-phenyl) -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n810 mg (2,25 mmol) 4-(( 1 R,2R)-2-Benzy loxy- 1 -methyl-propoxy)-2-chlor-5-trifluormethyl- pyrimidin und 559 mg (2,69 mmol) 4-Methansulfonyl-phenylamin Hydrochlorid (Acros) in 11 ml Acetonitril wurden 16 Stunden bei 80\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz mit Essigester verdünnt und mit gesättigter Natriumhydrogencarbonat-Lösung und gesättigter NaCl- Lösung gewaschen, getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 1:1) gereinigt. Man erhielt 770 mg (1,55 mmol; Ausbeute: 69%) des Produktes.\n810 mg (2.25 mmol) of 4 - ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-trifluoromethylpyrimidine and 559 mg (2.69 mmol) 4 Methanesulfonyl-phenylamine hydrochloride (Acros) in 11 ml of acetonitrile were stirred at 80 \n0\n C for 16 hours. After cooling, the batch was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and saturated NaCl solution, dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 1: 1). This gave 770 mg (1.55 mmol, yield: 69%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.58 (s, IH), 7.95 (m, 2H), 7.83 (m, 2H), 7.22 (m, 5H), 5.48 (m, IH), 4.57 (d, IH), 4.46 (d, IH), 3.72 (m, IH), 3.12 (s, 3H), 1.31 (d, 3H), 1.15 (d, 3H). MS: 496 (ESI+) \n\n b) Herstellung des Endproduktes\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.58 (s, IH), 7.95 (m, 2H), 7.83 (m, 2H), 7.22 (m, 5H), 5.48 ( m, IH), 4.57 (d, IH), 4.46 (d, IH), 3.72 (m, IH), 3.12 (s, 3H), 1.31 (d, 3H), 1.15 (d, 3H). MS: 496 (ESI +)  b) Preparation of the final product\n\n\n\n\n\n\n \nEine Lösung von 750 mg (1,51 mmol) [4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5- trifluormethyl-pyrimidin-2-yl]-(4-methansulfonyl-phenyl)-amin in 20 ml Ethanol wurde mit 152 mg Palladium auf Kohle (10%ig) versetzt und unter Normaldruck bei Raumtemperatur für 30 Minuten hydriert. Man versetzte erneut mit 152 mg Palladium auf Kohle (10%ig) und hydrierte für 1,5 Stunden. Weitere 152 mg Palladium auf Kohle (10%ig) wurden zugegeben und der Ansatz für 1 Stunde hydriert. Abschließend wurden nochmals 152 mg Palladium auf Kohle (10%ig) zugegeben und 15 Minuten hydriert. Der Ansatz wurde filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (DCM / EtOH 95:5) gereinigt. Man erhielt 512 mg (1,26 mmol; Ausbeute: 83 %) des Produktes.\nA solution of 750 mg (1.51 mmol) of [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - (4-methanesulfonyl-phenyl) -amine in 20 ml of ethanol was treated with 152 mg of palladium on carbon (10%) and hydrogenated under atmospheric pressure at room temperature for 30 minutes. Re-addition of 152 mg of palladium on carbon (10%) and hydrogenation for 1.5 hours. An additional 152mg of palladium on carbon (10%) was added and the reaction hydrogenated for 1 hour. Finally, another 152 mg of palladium on carbon (10%) were added and hydrogenated for 15 minutes. The reaction was filtered and concentrated. The residue obtained was purified by chromatography (DCM / EtOH 95: 5). 512 mg (1.26 mmol, yield: 83%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ=10.55 (s, IH), 8.57 (s, IH), 7.96 (m, 2H), 7.83 (m, 2H), 5.27 (m, IH), 4.86 (d, IH), 3.82 (m, IH), 3.14 (s, 3H), 1.25 (d, 3H), 1.07 (d, 3H). MS: 405 (EI+).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.57 (s, IH), 7.96 (m, 2H), 7.83 (m, 2H), 5.27 (m, IH), 4.86 ( d, IH), 3.82 (m, IH), 3.14 (s, 3H), 1.25 (d, 3H), 1.07 (d, 3H). MS: 405 (EI +).\n\n\n\n\n\n\n \nBeispiel 3\nExample 3\n\n\n\n\n\n\n \n(R)-3-[2-(4-Methansulfonyl-phenylamino)-5-trifluormethyl-pyrimidin-4-yloxy]-2-methyl- butan-2-oI\n(R) -3- [2- (4-Methanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-yloxy] -2-methyl-butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n3a) Herstellung der Zwischenprodukte Verbindung 3.1. (R)-2-Methyl-butan-2,3-diol\n3a) Preparation of Intermediates Compound 3.1. (R) -2-methyl-butan-2,3-diol\n\n\n\n\n\n\n \nOH\nOH\n\n\n\n\n\n\n \nHO\nHO\n\n\n\n\n\n\n \nEine Lösung von 10,0 g (96,1 mmol) (R)-(+)-Milchsäuremethylester in 20 ml THF wurde langsam zu 160 ml (480,0 mmol) einer eisgekühlten 3N Lösung von Methylmagnesiumchlorid in THF getropft. Der Ansatz wurde zunächst langsam auf Raumtemperatur erwärmt und anschließend 30 Minuten refluxiert. Nach dem Abkühlen wurde der Ansatz auf eine gesättigte Ammoniumchlorid- \n\n Lösung gegeben und mit Essigester extrahiert (3x). Die vereinten organischen Phasen wurden über einem Whatman Filter filtriert und eingeengt. Man erhielt 4,5 g (43,1 mmol) des Rohproduktes, das ohne weitere Reinigung eingesetzt wurde.\nA solution of 10.0 g (96.1 mmol) of (R) - (+) - lactic acid methyl ester in 20 ml of THF was slowly added dropwise to 160 ml (480.0 mmol) of an ice-cold 3N solution of methylmagnesium chloride in THF. The mixture was first slowly warmed to room temperature and then refluxed for 30 minutes. After cooling, the reaction was started on a saturated ammonium chloride  Solution and extracted with ethyl acetate (3x). The combined organic phases were filtered through a Whatman filter and concentrated. This gave 4.5 g (43.1 mmol) of the crude product, which was used without further purification.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 4.21 (d, IH), 3.93 (s, IH), 3.29 (m, IH), 0.97 (m, 9H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 4.21 (d, IH), 3.93 (s, IH), 3.29 (m, IH), 0.97 (m, 9H).\n\n\n\n\n\n\n \nVerbindung 3.2. (R)-3-(2-Chlor-5-jod-pyrimidin-4-yloxy)-2-methyl-butan-2-ol\nConnection 3.2. (R) -3- (2-chloro-5-iodo-pyrimidin-4-yloxy) -2-methyl-butan-2-ol\n\n\n\n\n\n\n \n \n\n Eine Lösung von 4,40 g (42,3 mmol) (R)-2-Methyl-butan-2,3-diol in 83 ml Diethylether wurde unter Rühren bei O\n0\nC portionsweise mit 1,84 g (42,3 mmol) Natriumhydrid (55%) versetzt und 10 Minuten gerührt. Man rührte weitere 3 Minuten bei Raumtemperatur und gab den Ansatz anschließend zu einer eisgekühlten Lösung von 9,68 g (35,2 mmol) 2,4-Dichlor-5-jod-pyrimidin in 97 ml Acetonitril. Der Ansatz wurde 4 Stunden bei 40\n0\nC gerührt und nach dem Erkalten mit Eis und gesättigter NaCl-Lösung versetzt. Man extrahierte mit Essigester (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO^, filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1) gereinigt. Man erhielt 4,96 g (14,5 mmol; Ausbeute: 41%) des Produktes.\n \n A solution of 4.40 g (42.3 mmol) of (R) -2-methyl-butane-2,3-diol in 83 ml of diethyl ether was added with stirring at \n0\n ° C. in portions with 1.84 g (42.3 mmol ) Sodium hydride (55%) and stirred for 10 minutes. The mixture was stirred at room temperature for a further 3 minutes and then the batch was added to an ice-cooled solution of 9.68 g (35.2 mmol) of 2,4-dichloro-5-iodopyrimidine in 97 ml of acetonitrile. The mixture was stirred for 4 hours at 40 \n0\n C and added after cooling with ice and saturated NaCl solution. It was extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO 4, filtered and concentrated, the residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1) to give 4.96 g (14.5 mmol, yield: 41%) of the product ,\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.73 (s, IH), 4.96 (q, IH), 4.62 (s, IH), 1.21 (d, 3H), 1.13 (s, 6H). ES: 343 (CI+).\n \n1\n H NMR (400 MHz, DMSO): δ = 8.73 (s, IH), 4.96 (q, IH), 4.62 (s, IH), 1.21 (d, 3H), 1.13 (s, 6H). ES: 343 (CI +).\n\n\n\n\n\n\n \nVerbindung 3.3. 2-Chlor-4-[(R)-l,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5-jod-pyrimidin\nConnection 3.3. 2-chloro-4 - [(R) -l, 2-dimethyl-2- (tetrahydro-pyran-2-yloxy) propoxy] -5-iodo-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,96 g (14,5 mmol) (R)-3-(2-Chlor-5-jod-pyrimidin-4-yloxy)-2-methyl-butan-2-ol in 30 ml DCM wurde mit 2,64 ml (29,0 mmol) Dihydropyran und 0,36 g (1,5 mmol) \n\n Pyridiniumtosylat versetzt und 22 Stunden bei Raumtemperatur gerührt. Der Ansatz wurde mit DCM verdünnt und mit gesättigter Natriumhydrogencarbonat-Lösung gewaschen. Die organische Phase wurde getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1) gereinigt. Man erhielt 5,50 g (12,9 mmol; Ausbeute: 89%) des Diastereomerengemisches.\nA solution of 4.96 g (14.5 mmol) of (R) -3- (2-chloro-5-iodo-pyrimidin-4-yloxy) -2-methyl-butan-2-ol in 30 ml of DCM was washed with 2.64 ml (29.0 mmol) of dihydropyran and 0.36 g (1.5 mmol)  Pyridinium tosylate and stirred for 22 hours at room temperature. The reaction was diluted with DCM and washed with saturated sodium bicarbonate solution. The organic phase was dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1). This gave 5.50 g (12.9 mmol, yield: 89%) of the diastereomer mixture.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO):δ = 8.75 (s, IH), 8.74 (s, IH), 5.15 (m, 2H), 4.91 (m, 2H), 3.70 (m, 2H), 3.30 (m, 2H), 1.31 (m, 30H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.75 (s, IH), 8.74 (s, IH), 5.15 (m, 2H), 4.91 (m, 2H), 3.70 (m, 2H), 3.30 ( m, 2H), 1.31 (m, 30H).\n\n\n\n\n\n\n \nVerbindung 3.4.\nConnection 3.4.\n\n\n\n\n\n\n \n2-Chlor-4-[(R)-l,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5-trifluormethyl- pyrimidin\n2-Chloro-4 - [(R) -l, 2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethyl-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1 ,00 g (2,34 mmol) 2-Chlor-4-[(R)- 1 ,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)- propoxy]-5-jod-pyrimidin in 3,3 ml NMP und 3,3 ml THF wurde bei Raumtemperatur mit 1,61 g (8,44 mmol) Kupfer(I)jodid, 0,41 g (7,03 mmol) Kaliumfluorid und 1,04 ml (7,03 mmol) (Trifluormethyl)-trimethylsilan versetzt. Der Ansatz wurde 2 Stunden bei 90\n0\nC gerührt. Nach dem Erkalten wurde der Ansatz in verdünnte Natriumchlorid-Lösung gegeben und mit Essigester extrahiert (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1) gereinigt. Man erhielt 0,53 g (1,43 mmol; Ausbeute: 61%) des Produktes.\nA solution of 1.00 g (2.34 mmol) of 2-chloro-4 - [(R) -1,2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-iodo-pyrimidine in 3.3 ml of NMP and 3.3 ml of THF at room temperature was charged with 1.61 g (8.44 mmol) of copper (I) iodide, 0.41 g (7.03 mmol) of potassium fluoride and 1.04 ml (7 , 03 mmol) (trifluoromethyl) trimethylsilane. The batch was stirred at 90 \n°\n C. for 2 hours. After cooling, the batch was added to dilute sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1). This gave 0.53 g (1.43 mmol, yield: 61%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.84 (s, IH), 5.32 (m, IH), 4.85 (m, IH), 3.68 (m, IH), 3.30 (m, IH), 1.31 (m, 15H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.84 (s, IH), 5.32 (m, IH), 4.85 (m, IH), 3.68 (m, IH), 3.30 (m, IH), 1.31 ( m, 15H).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \n100 mg (0,27 mmol) 2-Chlor-4-[(R)-l,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5- trifluormethyl-pyrimidin und 37 mg (0,22 mmol) 4-Methansulfonyl-phenylamin in 2,5 ml Ethanol wurden 150 Minuten bei 70\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt, mit 3,1 ml\n100 mg (0.27 mmol) of 2-chloro-4 - [(R) -l, 2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethyl-pyrimidine and 37 mg (0 , 22 mmol) of 4-methanesulfonyl-phenylamine in 2.5 ml of ethanol were stirred at 70 \n0\n C for 150 minutes. The reaction was concentrated to dryness, with 3.1 ml\n\n\n\n\n\n\n \nEthanol aufgenommen und mit 12 mg (0,05 mmol) Pyridiniumtosylat versetzt. Der Ansatz wurde 4 Stunden bei 45°C gerührt. Nach dem Erkalten wurde der Ansatz mit verdünnter \n\n Natriumhydrogencarbonat-Lösung versetzt und mit Essigester extrahiert (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (DCM / Ethanol 95:5) gereinigt. Man erhielt 42 mg (0,10 mmol; Ausbeute: 45%) des Produktes.\nEthanol was added and treated with 12 mg (0.05 mmol) of pyridinium tosylate. The batch was stirred for 4 hours at 45 ° C. After cooling, the approach was diluted with dilute  Sodium bicarbonate solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (DCM / ethanol 95: 5). This gave 42 mg (0.10 mmol, yield: 45%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.57 (s, IH), 7.96 (m, 2H), 7.84 (m, 2H), 5.14 (q, IH), 4.66 (s, IH), 3.14 (s, 3H), 1.28 (d, 3H), 1.12 (s, 6H). MS: 419 (EI+)\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.57 (s, IH), 7.96 (m, 2H), 7.84 (m, 2H), 5.14 (q, IH), 4.66 ( s, IH), 3.14 (s, 3H), 1.28 (d, 3H), 1.12 (s, 6H). MS: 419 (EI +)\n\n\n\n\n\n\n \nBeispiel 4\nExample 4\n\n\n\n\n\n\n \n(R)-3-[2-(4-Cyclopropansulfonyl-phenylamino)-5-trifluormethyl-pyrimidin-4-yloxy]-2- methyl-butan-2-ol\n(R) -3- [2- (4-Cyclopropanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-yloxy] -2-methyl-butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nHerstellung des Endproduktes\nProduction of the final product\n\n\n\n\n\n\n \n200 mg (0,54 mmol) 2-Chlor-4-[(R)-l,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5- trifluormethyl-pyrimidin und 64 mg (0,33 mmol) 4-Cyclopropansulfonyl-phenylamin in 5,0 ml Ethanol wurden 210 Minuten bei 70\n0\nC gerührt. Der Ansatz wurde erneut mit 100 mg (0,27 mmol) 2-Chlor-4-[(R)-l,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5-trifluormethyl-pyrimidin versetzt und weitere 210 Minuten bei 7O\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt und der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 91 mg (0,20 mmol; Ausbeute: 61%) des Produktes.\n200 mg (0.54 mmol) of 2-chloro-4 - [(R) -l, 2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethyl-pyrimidine and 64 mg (0 , 33 mmol) 4-Cyclopropanesulfonyl-phenylamine in 5.0 ml of ethanol was stirred for 210 minutes at 70 \n0\n C. The reaction was repeated with 100 mg (0.27 mmol) of 2-chloro-4 - [(R) -l, 2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethyl-pyrimidine and stirred for a further 210 minutes at 7O \n0\n C stirred. The reaction was concentrated to dryness and the resulting residue was purified by HPLC. 91 mg (0.20 mmol, yield: 61%) of the product were obtained.\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.2% NH\n3\n \nEluent A: H \n2\n O / 0.2% NH \n3\n \n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 50%A 50%B\nGradient: 0 min 50% A 50% B\n\n\n\n\n\n\n \n1.00 min 50%A 50%B\n1.00 min 50% A 50% B\n\n\n\n\n\n\n \n7.50 min 20%A 80%B\n7.50 min 20% A 80% B\n\n\n\n\n\n\n \n7.52 min 1%A 99%B\n7.52 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min \n\n Detektor: DAD scan ränge 210-400 nm\nFlow: 50.0 mL / min  Detector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z Temperatur: Raumtemperatur\nMS ESI +, ESI-, scan ranges 160-1000 m / z Temperature: Room temperature\n\n\n\n\n\n\n \nRetentionszeit: 4,6-5,5 min\nRetention time: 4.6-5.5 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): 10.56 (br, IH), 8.57 (s, IH), 7.96 (m, 2H), 7.80 (m, 2H), 5.14 (q, IH), 4.66 (s, IH), 2.77 (m, IH), 1.28 (d, 3H), 1.12 (m, 6H), 1.07 (m, 2H), 0.97 (m, 2H). MS: 445 (EI+)\n \n1\n H-NMR (400 MHz, DMSO): 10.56 (br, IH), 8.57 (s, IH), 7.96 (m, 2H), 7.80 (m, 2H), 5.14 (q, IH), 4.66 (s, IH), 2.77 (m, IH), 1.28 (d, 3H), 1.12 (m, 6H), 1.07 (m, 2H), 0.97 (m, 2H). MS: 445 (EI +)\n\n\n\n\n\n\n \nBeispiel 5\nExample 5\n\n\n\n\n\n\n \n(2R,3R)-3-[2-(4-Benzolsulfonyl-phenyIamino)-5-trifluormethyl-pyrimidin-4-yIoxy]-butan-2-ol\n(2R, 3R) -3- [2- (4-benzenesulfonyl-phenyIamino) -5-trifluoromethyl-pyrimidin-4-yloxy] -butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n5a) Herstellung der Zwischenprodukte Verbindung 5.1 (4-Benzolsulfonyl-phenyl)-[4-((lR,2R)-2-benzyloxy-l-methyl-propoxy)-5-trifluormethyl- pyrimidin-2-yl]-amin\n5a) Preparation of Intermediates Compound 5.1 (4-benzenesulfonyl-phenyl) - [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n110 mg (0,30 mmol) 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-trifluormethyl- pyrimidin und 85 mg (0,37 mmol) 4-Benzolsulfonyl-phenylamin in 1,5 ml Acetonitril wurden mit 0,08 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 5 Stunden bei 80\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand mittels HPLC gereinigt. Man erhielt 121 mg (0,22 mmol, Ausbeute: 71%) des Produktes. \n\n System: Waters Autopurification\n110 mg (0.30 mmol) of 4 - ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-trifluoromethylpyrimidine and 85 mg (0.37 mmol) of 4-benzenesulfonyl Phenylamine in 1.5 ml of acetonitrile were treated with 0.08 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 80 \n0\n C for 5 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by HPLC. 121 mg (0.22 mmol, yield: 71%) of the product were obtained.  System: Waters Autopurification\n\n\n\n\n\n\n \nSäule: XBridge Cl 8 5μ 100x30 mm\nColumn: XBridge Cl 8 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.56 (s, IH), 8.56 (s, IH), 7.89 (m, 6H), 7.58 (m, 3H), 7.22 (m, 5H), 5.44 (m, IH), 4.55 (d, IH), 4.44 (d, IH), 3.71 (m, IH), 1.29 (d, 3H), 1.14 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.56 (s, IH), 8.56 (s, IH), 7.89 (m, 6H), 7.58 (m, 3H), 7.22 (m, 5H), 5.44 ( m, IH), 4.55 (d, IH), 4.44 (d, IH), 3.71 (m, IH), 1.29 (d, 3H), 1.14 (d, 3H).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \nEine Lösung von 116 mg (0,21 mmol) (4-Benzolsulfonyl-phenyl)-[4-((lR,2R)-2-benzyloxy-l- methyl-propoxy)-5-trifluormethyl-pyrimidin-2-yl]-amin in 5 ml Ethanol wurde 2,5 Stunden bei Raumtemperatur unter einer Wasserstoffatmosphäre hydriert. Dabei wurde der Ansatz 6x mit jeweils 50 mg Portionen von Palladium auf Kohle (10%ig) versetzt. Der Ansatz wurde filtriert und eingeengt. Man erhielt 63 mg (0,13 mmol; Ausbeute: 65 %) des Produktes.\nA solution of 116 mg (0.21 mmol) of (4-benzenesulfonyl-phenyl) - [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] Amine in 5 ml of ethanol was hydrogenated for 2.5 hours at room temperature under a hydrogen atmosphere. The batch was mixed 6x with 50 mg portions of palladium on carbon (10%). The reaction was filtered and concentrated. 63 mg (0.13 mmol, yield: 65%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.55 (s, IH), 7.89 (m, 6H), 7.59 (m, 3H), 5.25 (m, IH), 4.86 (d, IH), 3.80 (m, IH), 1.24 (d, 3H), 1.06 (d, 3H). MS: 468 (ESI+)\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.55 (s, IH), 7.89 (m, 6H), 7.59 (m, 3H), 5.25 (m, IH), 4.86 ( d, IH), 3.80 (m, IH), 1.24 (d, 3H), 1.06 (d, 3H). MS: 468 (ESI +)\n\n\n\n\n\n\n \nBeispiel 6\nExample 6\n\n\n\n\n\n\n \n(2R,3R)-3-{2-[4-(Difluor-methansulfonyl)-phenylamino]-5-trifluormethyl-pyrimidin-4-yloxy}- butan-2-ol\n(2R, 3R) -3- {2- [4- (difluoro-methanesulfonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-yloxy} -butan-2-ol\n\n\n\n\n\n\n \n \n\n 6a) Herstellung der Zwischenprodukte Verbindung 6.1\n \n 6a) Preparation of Intermediates Compound 6.1\n\n\n\n\n\n\n \n[4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5-trifluormethyl-pyrimidin-2-yl]-[4-(difluor- methansulfonyl)-phenyl]-amin\n[4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - [4- (difluoromethanesulfonyl) -phenyl] -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n100 mg (0,28 mmol) 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-trifluormethyl- pyrimidin und 69 mg (0,33 mmol) 4-(Difluor-methansulfonyl)-phenylamin in 1 ,4 ml Acetonitril wurden mit 0,07 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 3 Stunden bei 80\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand mittels HPLC gereinigt. Man erhielt 104 mg (0,20 mmol; Ausbeute: 71%) des Produktes.\n100 mg (0.28 mmol) of 4- ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-trifluoromethylpyrimidine and 69 mg (0.33 mmol) of 4- (difluoro -methanesulfonyl) -phenylamine in 1, 4 ml of acetonitrile were treated with 0.07 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 80 \n0\n C for 3 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by HPLC. 104 mg (0.20 mmol, yield: 71%) of the product were obtained.\n\n\n\n\n\n\n \nSystem: Waters Autopurification\nSystem: Waters Autopurification\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur 1H-NMR (400 MHz, DMSO): δ = 10.77 (s, IH), 8.62 (s, IH), 8.07 (m, 2H), 7.88 (m, 2H), 7.22 (m, 6H), 5.47 (m, IH), 4.57 (d, IH), 4.45 (d, IH), 3.72 (m, IH), 1.31 (d, 3H), 1.15 (d, 3H). b) Herstellung des Endproduktes\nTemperature: room temperature 1H-NMR (400 MHz, DMSO): δ = 10.77 (s, IH), 8.62 (s, IH), 8.07 (m, 2H), 7.88 (m, 2H), 7.22 (m, 6H), 5.47 (m, IH), 4.57 (d, IH), 4.45 (d, IH), 3.72 (m, IH), 1.31 (d, 3H), 1.15 (d, 3H). b) Preparation of the final product\n\n\n\n\n\n\n \nEine Lösung von 100 mg (0,19 mmol) [4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5- trifluormethyl-pyrimidin-2-yl]-[4-(difluor-methansulfonyl)-phenyl]-amin in 5 ml Ethanol wurde 1,5 Stunden bei Raumtemperatur unter einer Wasserstoffatmosphäre hydriert. Dabei wurde der Ansatz 3x mit jeweils 100 mg Portionen von Palladium auf Kohle (10%ig) versetzt. Der Ansatz wurde filtriert und eingeengt. Man erhielt 45 mg (0,10 mmol; Ausbeute: 54 %) des Produktes.\nA solution of 100 mg (0.19 mmol) of [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - [4- (difluoro-methanesulfonyl ) -phenyl] -amine in 5 ml of ethanol was hydrogenated for 1.5 hours at room temperature under a hydrogen atmosphere. In this case, the mixture was 3x each with 100 mg portions of palladium on carbon (10%) added. The reaction was filtered and concentrated. 45 mg (0.10 mmol, yield: 54%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ =10.77 (s, IH), 8.61 (s, IH), 8.08 (m, 2H), 7.88 (m, 2H), 7.20 (tr, IH), 5.29 (m, IH), 4.88 (d, IH), 3.84 (m, IH), 1.26 (d, 3H), 1.07 (d, 3H). MS: 442 (ESI+) \n\n Beispiel 7\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.77 (s, IH), 8.61 (s, IH), 8.08 (m, 2H), 7.88 (m, 2H), 7.20 (tr, IH), 5.29 ( m, IH), 4.88 (d, IH), 3.84 (m, IH), 1.26 (d, 3H), 1.07 (d, 3H). MS: 442 (ESI +)  Example 7\n\n\n\n\n\n\n \n(2R,3R)-3-[2-(4-Cyclopentansulfonyl-phenylamino)-5-trifluormethyl-pyrimidin-4-yloxy]- butan-2-ol\n(2R, 3R) -3- [2- (4-cyclopentanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-yloxy] -butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n7a) Herstellung der Zwischenprodukte Verbindung 7.1\n7a) Preparation of Intermediates Compound 7.1\n\n\n\n\n\n\n \n[4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5-trifluormethyl-pyrimidin-2-yl]-(4- cyclopentansulfonyl-phenyl)-amin\n[4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - (4-cyclopentanesulfonyl-phenyl) -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n100 mg (0,28 mmol) 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-trifluorrnethyl- pyrimidin und 75 mg (0,33 mmol) 4-Cyclopentansulfonyl-phenylamin in 1,4 ml Acetonitril wurden mit 0,07 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 5 Stunden bei 80\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand mittels HPLC gereinigt. Man erhielt 118 mg (0,21 mmol, Ausbeute: 77%) des Produktes. \n\n System: Waters Autopuπfication\n100 mg (0.28 mmol) of 4 - ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-trifluoromethylpyrimidine and 75 mg (0.33 mmol) of 4-cyclopentanesulfonyl- Phenylamine in 1.4 ml of acetonitrile was treated with 0.07 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 80 \n0\n C for 5 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by HPLC. 118 mg (0.21 mmol, yield: 77%) of the product were obtained.  System: Waters Autopuπfication\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.57 (s, IH), 8.58 (s, IH), 7.96 (m, 2H), 7.77 (m, 2H), 7.22 (m, 5H), 5.48 (m, IH), 4.56 (d, IH), 4.46 (d, IH), 3.72 (m, IH), 3.63 (m, IH), 1.76 (m, 4H), 1.51 (m, 4H), 1.30 (d, 3H), 1.14 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.57 (s, IH), 8.58 (s, IH), 7.96 (m, 2H), 7.77 (m, 2H), 7.22 (m, 5H), 5.48 ( m, IH), 4.56 (d, IH), 4.46 (d, IH), 3.72 (m, IH), 3.63 (m, IH), 1.76 (m, 4H), 1.51 (m, 4H), 1.30 (i.e. , 3H), 1.14 (d, 3H).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \nEine Lösung von 112 mg (0,20 mmol) [4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5- trifluormethyl-pyrimidin-2-yl]-(4-cyclopentansulfonyl-phenyl)-amin in 5 ml Ethanol wurde 2,5\nA solution of 112 mg (0.20 mmol) of [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - (4-cyclopentanesulfonyl-phenyl) amine in 5 ml of ethanol became 2.5\n\n\n\n\n\n\n \nStunden bei Raumtemperatur unter einer Wasserstoffatmosphäre hydriert. Dabei wurde der Ansatz 5x mit jeweils 100 mg Portionen von Palladium auf Kohle (10%ig) versetzt. Der Ansatz wurde filtriert und eingeengt. Man erhielt 75 mg (0,16 mmol; Ausbeute: 80 %) des Produktes.\nHydrogenated hours at room temperature under a hydrogen atmosphere. In this case, the batch was mixed 5x with 100 mg portions of palladium on carbon (10%). The reaction was filtered and concentrated. 75 mg (0.16 mmol, yield: 80%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ=10.58 (s, IH), 8.57 (s, IH), 7.97 (m, 2H), 7.78 (m, 2H), 5.28 (m, IH), 4.88 (d, IH), 3.83 (m, IH), 3.68 (m, IH), 1.76 (m, 4H), 1.55 (m, 4H), 1.25 (d, 3H), 1.07 (d, 3H). MS: 460 (ESI+)\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.58 (s, IH), 8.57 (s, IH), 7.97 (m, 2H), 7.78 (m, 2H), 5.28 (m, IH), 4.88 ( d, IH), 3.83 (m, IH), 3.68 (m, IH), 1.76 (m, 4H), 1.55 (m, 4H), 1.25 (d, 3H), 1.07 (d, 3H). MS: 460 (ESI +)\n\n\n\n\n\n\n \nBeispiel 8\nExample 8\n\n\n\n\n\n\n \n(R)-2-Methyl-3-{2-[4-(prop-2-en-l-sulfonyl)-phenylamino]-5-trifluormethyl-pyrimidin-4- yloxy}-butan-2-ol\n(R) -2-Methyl-3- {2- [4- (prop-2-en-1-sulfonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-yloxy} -butan-2-ol\n\n\n\n\n\n\n \n \n\n Herstellung des Endproduktes\n \n Production of the final product\n\n\n\n\n\n\n \n104 mg (0,28 mmol) 2-Chlor-4-[(R)-l,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5- trifluormethyl-pyrimidin und 33 mg (0,17 mmol) 4-(Prop-2-en-l-sulfonyl)-phenylamin in 2,6 ml Ethanol wurden 10 Stunden bei 70\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt und der Rückstand mittels HPLC gereinigt. Man erhielt 12 mg (0,03 mmol; Ausbeute: 10%) des Produktes.\n104 mg (0.28 mmol) of 2-chloro-4 - [(R) -l, 2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethyl-pyrimidine and 33 mg (0 , 17 mmol) 4- (prop-2-en-l-sulfonyl) -phenylamine in 2.6 ml of ethanol were stirred at 70 \n0\n C for 10 hours. The batch was concentrated to dryness and the residue was purified by HPLC. 12 mg (0.03 mmol, yield: 10%) of the product were obtained.\n\n\n\n\n\n\n \nSystem: Waters Autopuπfication\nSystem: Waters Autopuπfication\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.57 (s, IH), 8.58 (s, IH), 7.95 (m, 2H), 7.76 (m, 2H), 5.64 (m, IH), 5.25 (m, IH), 5.17 (m, 2H), 4.67 (s, IH), 4.04 (d, 2H), 1.28 (d, 3H), 1.12 (s, 6H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.57 (s, IH), 8.58 (s, IH), 7.95 (m, 2H), 7.76 (m, 2H), 5.64 (m, IH), 5.25 ( m, IH), 5.17 (m, 2H), 4.67 (s, IH), 4.04 (d, 2H), 1.28 (d, 3H), 1.12 (s, 6H).\n\n\n\n\n\n\n \nBeispiel 9 (2R,3R)-3-{2-[4-(Propan-2-sulfonyl)-phenylamino]-5-trifluormethyl-pyrimidin-4-yloxy}- butan-2-ol\nExample 9 (2R, 3R) -3- {2- [4- (Propane-2-sulfonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-yloxy} -butan-2-ol\n\n\n\n\n\n\n \n \n\n 9a) Herstellung der Zwischenprodukte Verbindung 9.1\n \n 9a) Preparation of Intermediates Compound 9.1\n\n\n\n\n\n\n \n[4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5-trifluormethyl-pyrimidin-2-yl]-[4-(propan-2- sulfonyl)-phenyl]-amin\n[4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - [4- (propane-2-sulfonyl) -phenyl] -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n103 mg (0,29 mmol) 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-trifluormethyl- pyrimidin und 68 mg (0,34 mmol) 4-(Propan-2-sulfonyl)-phenylamin in 1 ,4 ml Acetonitril wurden mit 0,07 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 5 Stunden bei 80\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand mittels HPLC gereinigt. Man erhielt 123 mg (0,22 mmol, Ausbeute: 82%) des Produktes.\n103 mg (0.29 mmol) of 4- ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-trifluoromethylpyrimidine and 68 mg (0.34 mmol) of 4- (propane -2-sulfonyl) -phenylamine in 1, 4 ml of acetonitrile were treated with 0.07 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 80 \n0\n C for 5 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by HPLC. 123 mg (0.22 mmol, yield: 82%) of the product were obtained.\n\n\n\n\n\n\n \nSystem: Waters Autopurification\nSystem: Waters Autopurification\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.59 (s, IH), 8.58 (s, IH), 7.96 (m, 2H), 7.75 (m, 2H), 7.22 (m, 5H), 5.48 (m, IH), 4.55 (d, IH), 4.45 (d, IH), 3.72 (m, IH), 3.27 (m, IH), 1.30 (d, 3H), 1.14 (d, 3H), 1.09 (d, 6H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.59 (s, IH), 8.58 (s, IH), 7.96 (m, 2H), 7.75 (m, 2H), 7.22 (m, 5H), 5.48 ( m, IH), 4.55 (d, IH), 4.45 (d, IH), 3.72 (m, IH), 3.27 (m, IH), 1.30 (d, 3H), 1.14 (d, 3H), 1.09 (i.e. , 6H).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \nEine Lösung von 118 mg (0,23 mmol) [4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5- trifluormethyl-pyrimidin-2-yl]-[4-(propan-2-sulfonyl)-phenyl]-amin in 5 ml Ethanol wurde 1,5 Stunden bei Raumtemperatur unter einer Wasserstoffatmosphäre hydriert. Dabei wurde der Ansatz 4x mit jeweils 50 mg Portionen von Palladium auf Kohle (10%ig) versetzt. Der Ansatz wurde filtriert und eingeengt. Man erhielt 43 mg (0,10 mmol; Ausbeute: 44 %) des Produktes. \n\n \n1\nH-NMR (400 MHz, DMSO): δ= 10.58 (s, IH), 8.57 (s, IH), 7.98 (m, 2H), 7.76 (m, 2H), 5.27 (m, IH), 4.87 (d, IH), 3.81 (m, IH), 3.31 (m, IH), 1.25 (d, 3H), 1.11 (d, 6H), 1.06 (d, 3H). MS: 434 (ESI+)\nA solution of 118 mg (0.23 mmol) of [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-yl] - [4- (propane-2 -sulfonyl) -phenyl] -amine in 5 ml of ethanol was hydrogenated for 1.5 hours at room temperature under a hydrogen atmosphere. The batch was mixed 4x with 50 mg portions of palladium on carbon (10% strength). The reaction was filtered and concentrated. 43 mg (0.10 mmol, yield: 44%) of the product were obtained.  \n1\n H-NMR (400 MHz, DMSO): δ = 10.58 (s, IH), 8.57 (s, IH), 7.98 (m, 2H), 7.76 (m, 2H), 5.27 (m, IH), 4.87 ( d, IH), 3.81 (m, IH), 3.31 (m, IH), 1.25 (d, 3H), 1.11 (d, 6H), 1.06 (d, 3H). MS: 434 (ESI +)\n\n\n\n\n\n\n \nBeispiel 10\nExample 10\n\n\n\n\n\n\n \n(R)-2-Methyl-3-{2-[4-(prop-2-in-l-sulfonyl)-phenylamino]-5-trifluormethyl-pyrimidin-4- yloxy}-butan-2-ol\n(R) -2-Methyl-3- {2- [4- (prop-2-yn-1-sulfonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-yloxy} -butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nHerstellung des Endproduktes\nProduction of the final product\n\n\n\n\n\n\n \n150 mg (0,41 mmol) 2-Chlor-4-[(R)-l,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5- trifluormethyl-pyrimidin und 47 mg (0,24 mmol) 4-(Prop-2-in-l-sulfonyl)-phenylamin in 3,6 ml Ethanol wurden 200 Minuten bei 70\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt. Man erhielt ca. 147 mg des Rohproduktes von dem 60 mg mittels HPLC gereinigt wurden. Man erhielt 31 mg (0,07 mmol) des Produktes.\n150 mg (0.41 mmol) of 2-chloro-4 - [(R) -l, 2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethyl-pyrimidine and 47 mg (0 , 24 mmol) of 4- (prop-2-in-l-sulfonyl) -phenylamine in 3.6 ml of ethanol was stirred for 200 minutes at 70 \n0\n C. The batch was concentrated to dryness. About 147 mg of the crude product were obtained from which 60 mg were purified by HPLC. This gave 31 mg (0.07 mmol) of the product.\n\n\n\n\n\n\n \nSystem: Waters Autopurification\nSystem: Waters Autopurification\n\n\n\n\n\n\n \nSäule: XBridge Cl 8 5μ 100x30 mm\nColumn: XBridge Cl 8 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 ran\nDetector: DAD scan ranks 210-400 ran\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.60 (s, IH), 8.58 (s, IH), 7.98 (m, 2H), 7.83 (m, 2H), 5.14 (q, IH), 4.67 (s, IH), 4.45 (d, 2H), 3.38 (tr, IH), 1.28 (d, 3H), 1.10 (m, 6H). MS: 444 (ESI+)\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.60 (s, IH), 8.58 (s, IH), 7.98 (m, 2H), 7.83 (m, 2H), 5.14 (q, IH), 4.67 ( s, IH), 4.45 (d, 2H), 3.38 (tr, IH), 1.28 (d, 3H), 1.10 (m, 6H). MS: 444 (ESI +)\n\n\n\n\n\n\n \nBeispiel 11 \n\n (2R,3R)-3-{2-[4-(2-Hydroxy-ethansulfonyl)-phenylamino]-5-trifluormethyl-pyrimidin-4- yloxy}-butan-2-ol\nExample 11  (2R, 3R) -3- {2- [4- (2-hydroxy-ethanesulfonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-yloxy} -butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nIIa) Herstellung der Zwischenprodukte Verbindung 11.1\nIIa) Preparation of Intermediates Compound 11.1\n\n\n\n\n\n\n \n2-{4-[4-((lR,2R)-2-BenzyIoxy-l-methyl-propoxy)-5-trifluormethyl-pyrimidin-2-ylamino]- benzolsulfonylj-ethanol\n2- {4- [4 - ((1R, 2R) -2-Benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-ylamino] -benzenesulfonyl-ethanol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n102 mg (0,28 mmol) 4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-2-chlor-5-trifluormethyl- pyrimidin und 68 mg (0,34 mmol) 2-(4-Amino-benzolsulfonyl)-ethanol in 1,4 ml Acetonitril wurden mit 0,07 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 4 Stunden bei 80\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand mittels HPLC gereinigt. Man erhielt 72 mg (0,14 mmol, Ausbeute: 48%) des Produktes.\n102 mg (0.28 mmol) of 4- ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-trifluoromethylpyrimidine and 68 mg (0.34 mmol) of 2- (4 -Amino-benzenesulfonyl) ethanol in 1.4 ml of acetonitrile were treated with 0.07 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 80 \n0\n C for 4 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by HPLC. 72 mg (0.14 mmol, yield: 48%) of the product were obtained.\n\n\n\n\n\n\n \nSystem: Waters Autopurification\nSystem: Waters Autopurification\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min \n\n Detektor: DAD scan ränge 210-400 nm\nFlow: 50.0 mL / min  Detector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z Temperatur: Raumtemperatur\nMS ESI +, ESI-, scan ranges 160-1000 m / z Temperature: Room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.56 (s, IH), 8.58 (s, IH), 7.94 (m, 2H), 7.79 (m, 2H), 7.22 (m, 5H), 5.46 (m, IH), 4.83 (tr, IH), 4.56 (d, IH), 4.46 (d, IH), 3.72 (m, IH), 3.62 (m, 2H), 3.35 (m, 2H), 1.30 (d, 3H), 1.15 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.56 (s, IH), 8.58 (s, IH), 7.94 (m, 2H), 7.79 (m, 2H), 7.22 (m, 5H), 5.46 ( m, IH), 4.83 (tr, IH), 4.56 (d, IH), 4.46 (d, IH), 3.72 (m, IH), 3.62 (m, 2H), 3.35 (m, 2H), 1.30 (i.e. , 3H), 1.15 (d, 3H).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \nEine Lösung von 68 mg (0,13 mmol) (2-{4-[4-((lR,2R)-2-Benzyloxy-l-methyl-propoxy)-5- trifluormethyl-pyrimidin-2-ylamino]-benzolsulfonyl}-ethanol in 5 ml Ethanol wurde eine Stunden bei Raumtemperatur unter einer Wasserstoffatmosphäre hydriert. Dabei wurde der Ansatz mit jeweils 68 mg von Palladium auf Kohle (10%ig) versetzt. Der Ansatz wurde filtriert und eingeengt. Man erhielt 28 mg (0,06 mmol; Ausbeute: 50 %) des Produktes.\nA solution of 68 mg (0.13 mmol) of (2- {4- [4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -5-trifluoromethyl-pyrimidin-2-ylamino] -benzenesulfonyl ethanol in 5 ml of ethanol was hydrogenated for one hour at room temperature under a hydrogen atmosphere, in each case 68 mg of palladium on carbon (10%) were added to the batch, the mixture was filtered and concentrated, giving 28 mg (0, 06 mmol, yield: 50%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.57 (s, IH), 7.95 (m, 2H), 7.79 (m, 2H), 5.27 (m,\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.55 (s, IH), 8.57 (s, IH), 7.95 (m, 2H), 7.79 (m, 2H), 5.27 (m,\n\n\n\n\n\n\n \nIH), 4.87 (d, IH), 4.84 (tr, IH), 3.82 (m, IH), 3.63 (m, 2H), 3.36 (m, 2H), 1.25 (d, 3H), 1.07 (d,\nIH), 4.87 (d, IH), 4.84 (tr, IH), 3.82 (m, IH), 3.63 (m, 2H), 3.36 (m, 2H), 1.25 (d, 3H), 1.07 (d,\n\n\n\n\n\n\n \n3H).\n3H).\n\n\n\n\n\n\n \nMS: 436 (ESI+)\nMS: 436 (ESI +)\n\n\n\n\n\n\n \nBeispiel 12\nExample 12\n\n\n\n\n\n\n \n(4-Methansulfonyl-phenyl)-[4-((R)-2-methoxy-l-methyl-ethoxy)-5-trifluormethyl-pyrimidin-\n(4-methanesulfonyl-phenyl) - [4 - ((R) -2-methoxy-l-methyl-ethoxy) -5-trifluoromethyl-pyrimidin-\n\n\n\n\n\n\n \n2-yl]-amin\n2-yl] -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) Herstellung der Zwischenprodukte\na) Preparation of the intermediates\n\n\n\n\n\n\n \nVerbindung 12.1\nConnection 12.1\n\n\n\n\n\n\n \n2-Chlor-4-((R)-2-methoxy-l-methyl-ethoxy)-5-trifluormethyl-pyrimidin\n2-chloro-4 - ((R) -2-methoxy-l-methyl-ethoxy) -5-trifluoromethyl-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 2,00 g (9,2 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 1,08 g (12,0 mmol) (R)- 1 -Methoxy-propan-2-ol in 24,4 ml Diethylether und 24,4 ml Acetonitril wurde bei 0\n0\nC unter Rühren portionsweise mit 0,48 g Natriumhydrid (55%) versetzt. Der Ansatz wurde im Eisbad langsam auf Raumtemperatur erwärmt. Nach 3,5 Stunden wurde der Ansatz mit Eis und verdünnter Natriumchlorid-Lösung versetzt. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 7:3) gereinigt. Man erhielt 0,59 g (2,2 mmol; Ausbeute: 24%) des Produktes.\nA solution of 2.00 g (9.2 mmol) of 2,4-dichloro-5-trifluoromethylpyrimidine and 1.08 g (12.0 mmol) of (R) -1-methoxy-propan-2-ol in 24 , 4 ml of diethyl ether and 24.4 ml of acetonitrile was added dropwise at 0 \n0\n C with stirring in portions with 0.48 g of sodium hydride (55%). The batch was slowly warmed to room temperature in an ice bath. After 3.5 hours, the mixture was treated with ice and dilute sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 7: 3). This gave 0.59 g (2.2 mmol, yield: 24%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.83 (s, IH), 5.50 (m, IH), 3.50 (d, 2H), 3.24 (s, 3H), 1.26 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.83 (s, IH), 5.50 (m, IH), 3.50 (d, 2H), 3.24 (s, 3H), 1.26 (d, 3H).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \n100 mg (0,37 mmol) 2-Chlor-4-((R)-2-methoxy-l-methyl-ethoxy)-5-trifluormethyl-pyrimidin und 63 mg (0,37 mmol) 4-Methansulfonyl-phenylamin in 2,6 ml Acetonitril wurden mit 0,13 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 18 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde nach dem Abkühlen mit wenigen Tropfen einer Natriumhydrogencarbonat-Lösung versetzt und einrotiert. Der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 65 mg (0,16 mmol; Ausbeute: 43%) des Produktes. \n\n System: Waters Autopurification\n100 mg (0.37 mmol) of 2-chloro-4 - ((R) -2-methoxy-1-methyl-ethoxy) -5-trifluoromethyl-pyrimidine and 63 mg (0.37 mmol) of 4-methanesulfonyl-phenylamine 2.6 ml of acetonitrile were mixed with 0.13 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 18 hours. The mixture was mixed after cooling with a few drops of a sodium bicarbonate solution and concentrated by rotary evaporation. The resulting residue was purified by HPLC. 65 mg (0.16 mmol, yield: 43%) of the product were obtained.  System: Waters Autopurification\n\n\n\n\n\n\n \nSäule: XBridge Cl 8 5μ 100x30 mm\nColumn: XBridge Cl 8 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 tun\nDetector: DAD scan ranks 210-400 do\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.57 (s, IH), 8.58 (s, IH), 7.93 (m, 2H), 7.82 (m, 2H), 5.51 (m, IH), 3.52 (m, 2H), 3.26 (s, 3H), 3.14 (s, 3H), 1.30 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.57 (s, IH), 8.58 (s, IH), 7.93 (m, 2H), 7.82 (m, 2H), 5.51 (m, IH), 3.52 ( m, 2H), 3.26 (s, 3H), 3.14 (s, 3H), 1.30 (d, 3H).\n\n\n\n\n\n\n \nBeispiel 13 (4-MethansulfonyI-phenyI)-(4-prop-2-inyloxy-5-trifluormethyl-pyrimidin-2-yl)-amin\nExample 13 (4-Methanesulfonyl-phenyl) - (4-prop-2-ynyloxy-5-trifluoromethyl-pyrimidin-2-yl) -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) Herstellung der Zwischenprodukte Verbindung 13.1 2-Chlor-4-prop-2-inyloxy-5-trifluormethyl-pyrimidin\na) Preparation of Intermediates Compound 13.1 2-Chloro-4-prop-2-ynyloxy-5-trifluoromethyl-pyrimidine\n\n\n\n\n\n\n \n \n\n Eine Lösung von 2,00 g (9,2 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 0,71 ml (12,0 mmol) Prop-2-in-l-ol in 24,4 ml Diethylether und 24,4 ml Acetonitril wurde bei O\n0\nC unter Rühren portionsweise mit 0,48 g Natriumhydrid (55%) versetzt. Der Ansatz wurde im Eisbad langsam auf Raumtemperatur erwärmt. Nach 3,5 Stunden wurde der Ansatz mit Eis und verdünnter Natriumchlorid-Lösung versetzt. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 0,29 g (1,2 mmol; Ausbeute: 13%) des Produktes.\n \n A solution of 2.00 g (9.2 mmol) of 2,4-dichloro-5-trifluoromethyl-pyrimidine and 0.71 ml (12.0 mmol) of prop-2-yn-1-ol in 24.4 ml of diethyl ether and 24.4 ml of acetonitrile was treated portionwise with 0.48 g of sodium hydride (55%) was added at \n0\n ° C with stirring. The batch was slowly warmed to room temperature in an ice bath. After 3.5 hours, the mixture was treated with ice and dilute sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The resulting residue was purified by HPLC. This gave 0.29 g (1.2 mmol, yield: 13%) of the product.\n\n\n\n\n\n\n \nSäule: Chiralpak IA 5μ 250x30 mm Eluenten: Hexan / Ethanol 95:5\nColumn: Chiralpak IA 5μ 250x30 mm Eluent: hexane / ethanol 95: 5\n\n\n\n\n\n\n \nFluß: 40.0 mL/min\nFlow: 40.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD 210 nm\nDetector: DAD 210 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 4,8 - 5,3 min\nRetention time: 4.8 - 5.3 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.91 (s, IH), 5.18 (d, 2H), 3.71 (tr, IH).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.91 (s, IH), 5.18 (d, 2H), 3.71 (tr, IH).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes\nb) Preparation of the final product\n\n\n\n\n\n\n \n60 mg (0,25 mmol) 2-Chlor-4-prop-2-inyloxy-5-trifluormethyl-pyrimidin und 43 mg (0,25 mmol) 4-Methansulfonyl-phenylamin in 1,8 ml Acetonitril wurden mit 0,06 ml einer 4N Lösung von\n60 mg (0.25 mmol) of 2-chloro-4-prop-2-ynyloxy-5-trifluoromethyl-pyrimidine and 43 mg (0.25 mmol) of 4-methanesulfonyl-phenylamine in 1.8 ml of acetonitrile were added with 0.06 ml of a 4N solution of\n\n\n\n\n\n\n \nChlorwasserstoff in Dioxan versetzt und 18 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand mittels HPLC gereinigt. Man erhielt 29 mg (0,08 mmol, Ausbeute: 31%) des Produktes.\nHydrogen chloride in dioxane and stirred at 60 \n0\n C for 18 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by HPLC. 29 mg (0.08 mmol, yield: 31%) of the product were obtained.\n\n\n\n\n\n\n \nSystem: Waters Autopuπfication\nSystem: Waters Autopuπfication\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99%A 1%B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99%A 1%B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1%A 99%B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.71 (s, IH), 8.64 (s, IH), 7.98 (m, 2H), 7.82 (m, 2H), 5.16 (d, 2H), 3.68 (tr, IH), 3.14 (s, 3H). \n\n Beispiel 14 (4-MethansuIfonyl-phenyl)-[5-trifluormethyl-4-(3,3,3-trifluor-propoxy)-pyrimidin-2-yl]-amin\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.71 (s, IH), 8.64 (s, IH), 7.98 (m, 2H), 7.82 (m, 2H), 5.16 (d, 2H), 3.68 ( tr, IH), 3.14 (s, 3H).  Example 14 (4-Methanesulfonyl-phenyl) - [5-trifluoromethyl-4- (3,3,3-trifluoro-propoxy) -pyrimidin-2-yl] -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1 ,00 g (4,63 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 0,68 g (5,99 mmol) 3,3,3-Trifluor-l-propanol in 12,2 ml Diethylether und 12,2 ml Acetonitril wurde bei O\n0\nC unter Rühren portionsweise mit 0,24 g Natriumhydrid (55%) versetzt. Der Ansatz wurde im Eisbad langsam über Nacht auf Raumtemperatur erwärmt. Der Ansatz wurde mit Eis und verdünnter Natriumchlorid-Lösung versetzt. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 1,50 g des Rohproduktes. 1,03 g des Rohproduktes und 0,59 g (3,48 mmol) 4-Methansulfonyl-phenylamin in 24,1 ml Acetonitril wurden mit 0,87 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 24 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde mit wenig Natriumhydrogencarbonat-Lösung versetzt und einrotiert. Der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 0,07 g (0,15 mmol) des Produktes.\nA solution of 1.00 g (4.63 mmol) of 2,4-dichloro-5-trifluoromethyl-pyrimidine and 0.68 g (5.99 mmol) of 3,3,3-trifluoro-1-propanol in 12.2 ml of diethyl ether and 12.2 ml of acetonitrile was treated portionwise with 0.24 g of sodium hydride (55%) was added at \n0\n ° C with stirring. The batch was slowly warmed to room temperature in an ice bath overnight. The mixture was mixed with ice and dilute sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. This gave 1.50 g of the crude product. 1.03 g of the crude product and 0.59 g (3.48 mmol) of 4-methanesulfonyl-phenylamine in 24.1 ml of acetonitrile were treated with 0.87 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 24 hours , The batch was mixed with a small amount of sodium bicarbonate solution and concentrated by rotary evaporation. The resulting residue was purified by HPLC. This gave 0.07 g (0.15 mmol) of the product.\n\n\n\n\n\n\n \nSystem: Waters Autopuπfication\nSystem: Waters Autopuπfication\n\n\n\n\n\n\n \nSäule: XBridge Cl 8 5μ 100x30 mm\nColumn: XBridge Cl 8 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0-1 min 30% B\nGradient: 0-1 min 30% B\n\n\n\n\n\n\n \n1-7.5 min 30-80% B\n1-7.5 min 30-80% B\n\n\n\n\n\n\n \n7.5-7.6 min 80-99% B\n7.5-7.6 min 80-99% B\n\n\n\n\n\n\n \n7.6-10 min 99% B\n7.6-10 min 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 6,3 - 6,7 min\nRetention time: 6.3 - 6.7 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.66 (s, IH), 8.65 (s, IH), 7.99 (m, 2H), 7.88 (m, 2H), 4.72 (tr, 2H), 3.17 (s, 3H), 2.68 (m, 2H). \n\n Beispiel 15 (4-AHyloxy-5-trifluormethyl-pyrimidin-2-yl)-(4-methansulfonyl-phenyl)-amin\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.66 (s, IH), 8.65 (s, IH), 7.99 (m, 2H), 7.88 (m, 2H), 4.72 (tr, 2H), 3.17 ( s, 3H), 2.68 (m, 2H).  Example 15 (4-AHyloxy-5-trifluoromethyl-pyrimidin-2-yl) - (4-methanesulfonyl-phenyl) -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1,00 g (4,63 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 0,41 ml (5,99 mmol) 2-Propen-l-ol in 12,2 ml Diethy lether und 12,2 ml Acetonitril wurde bei 0\n0\nC unter Rühren portionsweise mit 0,24 g Natriumhydrid (55%) versetzt. Der Ansatz wurde im Eisbad langsam über Nacht auf Raumtemperatur erwärmt. Der Ansatz wurde mit Eis und verdünnter Natriumchlorid- Lösung versetzt. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 1,14 g des Rohproduktes. 0,76 g des Rohproduktes und 0,55 g (3,19 mmol) 4-Methansulfonyl-phenylamin in 22,0 ml Acetonitril wurden mit 0,80 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 24 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde mit wenig Natriumhydrogencarbonatlösung versetzt und einrotiert. Der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 32 mg (0,09 mmol) des Produktes.\nA solution of 1.00 g (4.63 mmol) of 2,4-dichloro-5-trifluoromethyl-pyrimidine and 0.41 ml (5.99 mmol) of 2-propen-1-ol in 12.2 ml of diethyl ether and 12.2 ml of acetonitrile was stirred at 0 \n0\n C (55%) was added portionwise under stirring with 0.24 g of sodium hydride. The batch was slowly warmed to room temperature in an ice bath overnight. The mixture was mixed with ice and dilute sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. 1.14 g of the crude product were obtained. 0.76 g of the crude product and 0.55 g (3.19 mmol) of 4-methanesulfonyl-phenylamine in 22.0 ml of acetonitrile were mixed with 0.80 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 24 hours , The batch was mixed with a small amount of sodium bicarbonate solution and concentrated by rotary evaporation. The resulting residue was purified by HPLC. 32 mg (0.09 mmol) of the product were obtained.\n\n\n\n\n\n\n \nSystem: Waters Autopuπfication\nSystem: Waters Autopuπfication\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1% HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0-1 min 30% B\nGradient: 0-1 min 30% B\n\n\n\n\n\n\n \n1-7.5 min 30-80% B\n1-7.5 min 30-80% B\n\n\n\n\n\n\n \n7.5-7.6 min 80-99% B\n7.5-7.6 min 80-99% B\n\n\n\n\n\n\n \n7.6-10 min 99% B\n7.6-10 min 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 6,1 - 6,3 min\nRetention time: 6.1-6.3 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.61 (s, IH), 8.61 (s, IH), 7.95 (m, 2H), 7.83 (m, 2H), 6.04 (m, IH), 5.38 (m, IH), 5.27 (m, IH), 5.02 (m, 2H), 3.14 (s, 3H). \n\n Beispiel 16 (4-Cyclohexyloxy-5-trifluormethyl-pyrimidin-2-yl)-(4-methansulfonyl-phenyl)-ainin\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.61 (s, IH), 8.61 (s, IH), 7.95 (m, 2H), 7.83 (m, 2H), 6.04 (m, IH), 5.38 ( m, IH), 5.27 (m, IH), 5.02 (m, 2H), 3.14 (s, 3H).  Example 16 (4-Cyclohexyloxy-5-trifluoromethyl-pyrimidin-2-yl) - (4-methanesulfonyl-phenyl) -amine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1 ,00 g (4,63 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 0,64 ml (5,99 mmol) Cyclohexanol in 12,2 ml Diethy lether und 12,2 ml Acetonitril wurde bei 0°C unter Rühren portionsweise mit 0,24 g Natriumhydrid (55%) versetzt. Der Ansatz wurde im Eisbad langsam über Nacht auf Raumtemperatur erwärmt. Der Ansatz wurde mit Eis und verdünnter Natriumchlorid- Lösung versetzt. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO^, filtriert und eingeengt. Man erhielt 1,30 g des Rohproduktes. 0,65 g des Rohproduktes und 0,40 g (2,3 mmol) 4-Methansulfonyl-phenylamin in 16,0 ml Acetonitril wurden mit 0,80 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 24 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde mit wenig Natriumhydrogencarbonatlösung versetzt und einrotiert. Der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 0,05 g (0,12 mmol) des Produktes.\nA solution of 1.00 g (4.63 mmol) of 2,4-dichloro-5-trifluoromethylpyrimidine and 0.64 ml (5.99 mmol) of cyclohexanol in 12.2 ml of diethyl ether and 12.2 ml of acetonitrile 0.24 g of sodium hydride (55%) was added in portions at 0 ° C. with stirring. The batch was slowly warmed to room temperature in an ice bath overnight. The mixture was mixed with ice and dilute sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO 4), filtered and concentrated to give 1.30 g of the crude product, 0.65 g of the crude product and 0.40 g (2.3 mmol) of 4-methanesulfonyl-phenylamine in 16, 0 ml of acetonitrile were added 0.80 ml of a 4N solution of hydrogen chloride in dioxane and stirred for 24 hours at 60 \n0\n C. The reaction was treated with a little sodium bicarbonate and concentrated by rotary evaporation. The residue obtained was purified by HPLC. This gave 0.05 g of (0.12 mmol) of the product.\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO\nEluent A: H \n2\n O\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 50%A 50%B\nGradient: 0 min 50% A 50% B\n\n\n\n\n\n\n \n1.00 min 50%A 50%B\n1.00 min 50% A 50% B\n\n\n\n\n\n\n \n7.50 min 20%A 80%B\n7.50 min 20% A 80% B\n\n\n\n\n\n\n \n7.52 min 1%A 99%B\n7.52 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 210-400 nm\nDetector: DAD scan range 210-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 6,2 - 6,5 min\nRetention time: 6.2 - 6.5 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.56 (s, IH), 8.57 (s, IH), 7.95 (m, 2H), 7.82 (m, 2H), 5.24 (m, IH), 3.14 (s, 3H), 1.91 (m, 2H), 1.53 (m, 8H). \n\n Herstellung der Vergleichsverbindungen\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.56 (s, IH), 8.57 (s, IH), 7.95 (m, 2H), 7.82 (m, 2H), 5.24 (m, IH), 3.14 ( s, 3H), 1.91 (m, 2H), 1.53 (m, 8H).  Preparation of the comparative compounds\n\n\n\n\n\n\n \nBeispiel Vl\nExample Vl\n\n\n\n\n\n\n \n(2R,3R)-3-[2-(4-CyclopropansulfonyI-phenylamino)-5-trifluormethyl-pyrimidin-4-ylamino]- butan-2-ol\n(2R, 3R) -3- [2- (4-Cyclopropanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-ylamino] -butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nHerstellung des Endproduktes\nProduction of the final product\n\n\n\n\n\n\n \n566 mg (2,10 mmol) (2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-butan-2-ol und 414 mg (2,10 mmol) 4-Methansulfonyl-phenylamin in 10,2 ml Acetonitril wurden mit 0,52 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 17 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand chromatographisch (DCM / Ethanol 95:5) gereinigt. Man erhielt 670 mg (1,56 mmol, Ausbeute: 74%) des Produktes.\n566 mg (2.10 mmol) of (2R, 3R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol and 414 mg (2.10 mmol) of 4-methanesulfonyl Phenylamine in 10.2 ml of acetonitrile were treated with 0.52 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 17 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by chromatography (DCM / ethanol 95: 5). 670 mg (1.56 mmol, yield: 74%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.13 (s, IH), 8.27 (s, IH), 7.97 (m, 2H), 7.75 (m, 2H), 6.08 (d, IH), 5.07 (d, IH), 4.14 (m, IH), 3.77 (m, IH), 2.74 (m, IH), 1.20 (d, 3H), 1.00 (m, 7H). MS: 431 (ESI+)\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.13 (s, IH), 8.27 (s, IH), 7.97 (m, 2H), 7.75 (m, 2H), 6.08 (d, IH), 5.07 ( d, IH), 4.14 (m, IH), 3.77 (m, IH), 2.74 (m, IH), 1.20 (d, 3H), 1.00 (m, 7H). MS: 431 (ESI +)\n\n\n\n\n\n\n \nBeispiel V2 (2R,3R)-3-[2-(4-Methansulfonyl-phenylamino)-5-trifluormethyl-pyrimidin-4-ylamino]-butan- 2-ol\nExample V2 (2R, 3R) -3- [2- (4-methanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-ylamino] -butan-2-ol\n\n\n\n\n\n\n \n \n\n a) Herstellung der Zwischenprodukte Verbindung V2.1 (2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-yIamino)-butan-2-ol Trifluoracetat\n \n a) Preparation of Intermediates Compound V2.1 (2R, 3R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol trifluoroacetate\n\n\n\n\n\n\n \n \n\n 7,60 g (35,0 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 4,40 g (35,0 mmol) (2R,3R)-3- Amino-butan-2-ol Hydrochlorid in 139 ml Acetonitril wurden bei 0\n0\nC unter Rühren tropfenweise mit 9,71 ml (70,0 mmol) Triethylamin versetzt. Der Ansatz wurde im Eisbad langsam auf Raumtemperatur erwärmt. Nach 3 Tagen wurde der Ansatz in halbkonzentrierte Natriumchlorid- Lösung gegeben. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO,»), filtriert und eingeengt. Der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 2,49 g (6,5 mmol; Ausbeute: 19%) des Produktes.\n \n 7.60 g (35.0 mmol) of 2,4-dichloro-5-trifluoromethylpyrimidine and 4.40 g (35.0 mmol) of (2R, 3R) -3-amino-butan-2-ol hydrochloride in 139 Acetonitrile was added dropwise at 0 \n°\n C. while stirring with 9.71 ml (70.0 mmol) of triethylamine. The batch was slowly warmed to room temperature in an ice bath. After 3 days, the batch was added to half-concentrated sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The resulting residue was purified by HPLC. This gave 2.49 g (6.5 mmol, yield: 19%) of the product.\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 100x30 mm\nColumn: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluenten: A: H\n2\nO B: MeCN\nEluent: A: H \n2\n OB: MeCN\n\n\n\n\n\n\n \nPuffer: A / 0,1% TFA Gradient: 60% A + 40% B (2 ')_40^ 70% B (5,5 ') -» 99% B (0, 1 ')\nBuffer: A / 0.1% TFA Gradient: 60% A + 40% B (2 ') _40 ^ 70% B (5,5') - »99% B (0, 1 ')\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD (200-400 nm) TAC; MS-ESI+ (125-925 m/z) TIC\nDetector: DAD (200-400 nm) TAC; MS-ESI + (125-925 m / z) TIC\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 3,1 - 3,8 min\nRetention time: 3.1 - 3.8 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.38 (s, IH), 6.73 (d, IH), 4.07 (m, IH), 3.71 (m, IH), 1.12 (d,\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.38 (s, IH), 6.73 (d, IH), 4.07 (m, IH), 3.71 (m, IH), 1.12 (d,\n\n\n\n\n\n\n \n3H), 1.01 (d, 3H).\n3H), 1.01 (d, 3H).\n\n\n\n\n\n\n \nb) Herstellung des Endproduktes 84 mg (0,22 mmol) (2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-butan-2-ol Trifluoracetat und 46 mg (0,22 mmol) 4-Methansulfonyl-phenylamin Hydrochlorid in 1 ,4 ml Acetonitril wurden mit 0,06 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und bei 50\n0\nC gerührt. Nach 19 Stunden wurden erneut 21 mg (0,06 mmol) (2R,3R)-3-(2-Chlor-5- trifluormethyl-pyrimidin-4-ylamino)-butan-2-ol Trifluoracetat zugegeben und weitere 24 Stunden bei 50\n0\nC gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand chromatographisch (DCM / Ethanol 95:5) gereinigt. Man erhielt 42 mg (0,10 mmol, Ausbeute: 45%) des Produktes.\nb) Preparation of the final product 84 mg (0.22 mmol) of (2R, 3R) -3- (2-chloro-5-trifluoromethylpyrimidin-4-ylamino) -butan-2-ol trifluoroacetate and 46 mg (0.22 mmol) mmol) of 4-methanesulfonyl-phenylamine hydrochloride in 1, 4 ml of acetonitrile were added 0.06 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 50 \n0\n C. After 19 hours, 21 mg (0.06 mmol) of (2R, 3R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol trifluoroacetate were again added and the mixture was stirred at 50 for another 24 hours \n0\n C stirred. The batch was concentrated by rotary evaporation and the residue obtained was purified by chromatography (DCM / ethanol 95: 5). This gave 42 mg (0.10 mmol, yield: 45%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.13 (s, IH), 8.26 (s, IH), 7.96 (m, 2H), 7.78 (m, 2H), 6.08 (d, IH), 5.07 (br, IH), 4.14 (m, IH), 3.76 (m, IH), 3.12 (s, 3H), 1.20 (d, 3H), 1.05 (d, 3H). MS: 405 (ESI+)\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.13 (s, IH), 8.26 (s, IH), 7.96 (m, 2H), 7.78 (m, 2H), 6.08 (d, IH), 5.07 ( br, IH), 4.14 (m, IH), 3.76 (m, IH), 3.12 (s, 3H), 1.20 (d, 3H), 1.05 (d, 3H). MS: 405 (ESI +)\n\n\n\n\n\n\n \nBeispiel V3 \n\n (R)-3-[2-(4-Methansulfonyl-phenylamino)-5-trifluormethyl-pyrimidin-4-ylamino]-2-methyl- butan-2-ol\nExample V3  (R) -3- [2- (4-Methanesulfonyl-phenylamino) -5-trifluoromethyl-pyrimidin-4-ylamino] -2-methyl-butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) Herstellung der Zwischenprodukte Verbindung V3.1\na) Preparation of intermediates Compound V3.1\n\n\n\n\n\n\n \n(R)-3-(2-ChIor-5-trifluormethyl-pyrimidin-4-ylamino)-2-methyl-butan-2-ol\n(R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n12,4 g (57,4 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 5,90 g (57,3 mmol) (R)-3-Amino- 2-methyl-butan-2-ol in 227 ml Acetonitril wurden bei 0\n0\nC unter Rühren tropfenweise mit 15,85 ml (114,4 mmol) Triethylamin versetzt. Der Ansatz wurde im Eisbad langsam auf Raumtemperatur erwärmt. Nach 18 Stunden wurde der Ansatz in halbkonzentrierte Natriumchlorid-Lösung gegeben. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde mittels HPLC gereinigt. Man erhielt 6,39 g (22,5 mmol; Ausbeute: 39%) des Produktes.\n12.4 g (57.4 mmol) of 2,4-dichloro-5-trifluoromethyl-pyrimidine and 5.90 g (57.3 mmol) of (R) -3-amino-2-methyl-butan-2-ol in 227 ml of acetonitrile were added dropwise at 0 \n0\n C while stirring with 15.85 ml (114.4 mmol) of triethylamine. The batch was slowly warmed to room temperature in an ice bath. After 18 hours, the batch was added to half-concentrated sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The resulting residue was purified by HPLC. This gave 6.39 g (22.5 mmol, yield: 39%) of the product.\n\n\n\n\n\n\n \nSäule: XBridge Cl 8 5μ 150x30 mm\nColumn: XBridge Cl 8 5μ 150x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.2% NH\n3\n \nEluent A: H \n2\n O / 0.2% NH \n3\n \n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 99% A 1% B\nGradient: 0 min 99% A 1% B\n\n\n\n\n\n\n \n1.00 min 99% A 1% B\n1.00 min 99% A 1% B\n\n\n\n\n\n\n \n7.50 min 1% A 99% B\n7.50 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1% A 99% B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50,0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektor: DAD scan ränge 200-400 nm\nDetector: DAD scan range 200-400 nm\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 120-1000 m/z\nMS ESI +, ESI-, scan ranges 120-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 6,9 - 8.3 min\nRetention time: 6.9 - 8.3 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.45 (s, IH), 6.55 (d, IH), 5.00 (s, IH), 4.11 (m, IH), 1.14 (m,\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.45 (s, IH), 6.55 (d, IH), 5.00 (s, IH), 4.11 (m, IH), 1.14 (m,\n\n\n\n\n\n\n \n9H). b) Herstellung des Endproduktes \n\n 199 mg (0,70 mmol) (R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-2-methyl-butan-2-ol und 146 mg (0,70 mmol) 4-Methansulfonyl-phenylamin Hydrochlorid in 3,4 ml Acetonitril wurden 16 Stunden bei 60°C gerührt. Der Ansatz wurde einrotiert und der erhaltene Rückstand chromatographisch (DCM / Ethanol 95:5) gereinigt. Man erhielt 151 mg (0,36 mmol, Ausbeute: 51%) des Produktes.\n9H). b) Preparation of the final product  199 mg (0.70 mmol) of (R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol and 146 mg (0.70 mmol) 4 Methanesulfonyl-phenylamine hydrochloride in 3.4 ml of acetonitrile were stirred at 60 ° C for 16 hours. The batch was concentrated by rotary evaporation and the residue obtained was purified by chromatography (DCM / ethanol 95: 5). 151 mg (0.36 mmol, yield: 51%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.14 (s, IH), 8.27 (s, IH), 7.96 (m, 2H), 7.78 (m, 2H), 6.06 (d, IH), 4.91 (br, IH), 4.11 (m, IH), 3.12 (s, 3H), 1.11 (m, 9H). MS: 419 (ESI+)\n \n1\n H NMR (400 MHz, DMSO): δ = 10.14 (s, IH), 8.27 (s, IH), 7.96 (m, 2H), 7.78 (m, 2H), 6.06 (d, IH), 4.91 ( br, IH), 4.11 (m, IH), 3.12 (s, 3H), 1.11 (m, 9H). MS: 419 (ESI +)\n\n\n\n\n\n\n \nBeispiel 17\nExample 17\n\n\n\n\n\n\n \nAssay 1: CDKl/CycB Kinase Assay Rekombinante CDKl- und CycB-GST-Fusionsproteine, gereinigt aus Bakulovirus-infizierten Insektenzellen (Sf9), wurden von ProQinase GmbH, Freiburg, gekauft. Das als Kinase-Substrat verwendet Histon HIS ist über die Fa. Sigma käuflich zu erwerben.\nAssay 1: CDK1 / CycB Kinase Assay Recombinant CDK1 and CycB-GST fusion proteins purified from baculovirus-infected insect cells (Sf9) were purchased from ProQinase GmbH, Freiburg. The histone HIS used as kinase substrate can be purchased through the company Sigma.\n\n\n\n\n\n\n \nCDKl /Cy cB (200 ng/Messpunkt) wurde für 10 min bei 22°C in Anwesenheit verschiedener Konzentrationen an Testsubstanzen (0 μM, sowie innerhalb des Bereiches 0,001 - 10 μM) in Assaypuffer [50 mM Tris/HCl pH8,0; 10 mM MgCl\n2\n; 0,1 mM Na Ortho- Vanadat; 1,0 mM Dithiothreitol; 0,5 μM Adenosintrisphosphat (ATP); 10 μg/Messpunkt Histon IHS; 0,2 μCi/Messpunkt \n33\nP-gamma ATP; 0,05% NP40; 1,25% Dimethylsulfoxid] inkubiert. Die Reaktion wurde durch Zugabe von EDTA-Lösung (250 mM; pH8,0; 15 μl/Messpunkt) gestoppt. Von jedem Reaktionsansatz wurden 15 μl auf P30 Filterstreifen (Fa. Wallac) aufgetragen, und nicht-eingebautes \n33\nP-ATP wurde durch dreimaliges Waschen der Filterstreifen für je 10 min in 0,5%iger Phosphorsäure entfernt. Nach dem Trocknen der Filterstreifen für 1 Stunde bei 70\n0\nC wurden die Filterstreifen mit Szintillator-Streifen (MeltiLex™ A, Fa. Wallac) bedeckt und für 1 Stunde bei 9O\n0\nC eingebrannt. Die Menge an eingebautem \n33\nP (Substratphosphorylierung) wurde durch Szintillationsmessung in einem Gamma-Strahlungsmessgerät (Wallac) bestimmt. Die Messdaten wurden normalisiert auf 0% Inhibition (Enzymreaktion ohne Inhibitor) und 100%\nCDK1 / Cy cB (200 ng / measurement point) was incubated for 10 min at 22 ° C in the presence of various concentrations of test substances (0 μM, as well as within the range 0.001-10 μM) in assay buffer [50 mM Tris / HCl pH8.0; 10 mM MgCl \n2\n ; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 μM adenosine trisphosphate (ATP); 10 μg / measuring point histone IHS; 0.2 μCi / measuring point \n33\n P-gamma ATP; 0.05% NP40; 1.25% dimethylsulfoxide]. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 μl / measuring point). From each reaction, 15 μl was applied to P30 filter strips (Wallac) and unincorporated \n33\n P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 \n0\n C., the filter strips were baked (MeltiLex ™ A, Fa. Wallac) and for 1 hour at 9O \n0\n C with scintillator strips. The amount of incorporated \n33\n P (substrate phosphorylation) was determined by scintillation measurement in a gamma radiation meter (Wallac). The measured data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100%\n\n\n\n\n\n\n \nInhibition (alle Assaykomponenten außer Enzym). Die Bestimmung der IC50 Werte erfolgte mittels eines 4-Parameter Fits unter Benutzung firmeneigener Software. \n\n Assay 2: CDK2/CycE Kinase Assay\nInhibition (all assay components except enzyme). The IC50 values were determined using a 4-parameter fit using proprietary software.  Assay 2: CDK2 / CycE kinase assay\n\n\n\n\n\n\n \nRekombinante CDK2- und CycE-GST-Fusionsproteine, gereinigt aus Bakulovirus-infizierten Insektenzellen (Sf9), wurden von ProQinase GmbH, Freiburg, gekauft. Histon IHS, das als Kinase- Substrat verwendet wurde, wurde bei der Fa. Sigma gekauft. CDK2/CycE (50 ng/Messpunkt) wurde für 10 min bei 22°C in Anwesenheit verschiedener Konzentrationen an Testsubstanzen (0 μM, sowie innerhalb des Bereiches 0,001 - 10 μM) in Assaypuffer [50 mM Tris/HCl pH8,0; 10 mM MgCl\n2\n; 0,1 mM Na Ortho- Vanadat; 1,0 mM Dithiothreitol; 0,5 μM Adenosintrisphosphat (ATP); 10 μg/Messpunkt Histon HIS; 0,2 μCi/Messpunkt \n33\nP-gamma ATP; 0,05% NP40; 1,25% Dimethylsulfoxid] inkubiert. Die Reaktion wurde durch Zugabe von EDTA-Lösung (250 mM; pH8,0; 15 μl/Messpunkt) gestoppt.\nRecombinant CDK2 and CycE GST fusion proteins purified from baculovirus-infected insect cells (Sf9) were purchased from ProQinase GmbH, Freiburg. Histone IHS, which was used as a kinase substrate, was purchased from Sigma. CDK2 / CycE (50 ng / measuring point) was incubated for 10 min at 22 ° C in the presence of various concentrations of test substances (0 μM, as well as within the range 0.001-10 μM) in assay buffer [50 mM Tris / HCl pH8.0; 10 mM MgCl \n2\n ; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 μM adenosine trisphosphate (ATP); 10 μg / measuring point histone HIS; 0.2 μCi / measuring point \n33\n P-gamma ATP; 0.05% NP40; 1.25% dimethylsulfoxide]. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 μl / measuring point).\n\n\n\n\n\n\n \nVon jedem Reaktionsansatz wurden 15 μl auf P30 Filterstreifen (Fa. Wallac) aufgetragen, und nicht-eingebautes \n33\nP-ATP wurde durch dreimaliges Waschen der Filterstreifen für je 10 min in 0,5%iger Phosphorsäure entfernt. Nach dem Trocknen der Filterstreifen für 1 Stunde bei 70\n0\nC wurden die Filterstreifen mit Szintillator-Streifen (MeltiLex™ A, Fa. Wallac) bedeckt und für 1 Stunde bei 90\n0\nC eingebrannt. Die Menge an eingebautem \n33\nP (Substratphosphorylierung) wurde durch Szintillationsmessung in einem Gamma-Strahlungsmessgerät (Wallac) bestimmt. Die Messdaten wurden normalisiert auf 0% Inhibition (Enzymreaktion ohne Inhibitor) und 100% Inhibition (alle Assaykomponenten außer Enzym). Die Bestimmung der IC50 Werte erfolgte mittels eines 4-Parameter Fits unter Benutzung firmeneigener Software.\nFrom each reaction, 15 μl was applied to P30 filter strips (Wallac) and unincorporated \n33\n P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 \n0\n C., the filter strips were baked (MeltiLex ™ A, Fa. Wallac) and for 1 hour at 90 \n0\n C with scintillator strips. The amount of incorporated \n33\n P (substrate phosphorylation) was determined by scintillation measurement in a gamma radiation meter (Wallac). The data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100% inhibition (all assay components except enzyme). The IC50 values were determined using a 4-parameter fit using proprietary software.\n\n\n\n\n\n\n \nAssay 3: CDK4/CycD Kinase Assay\nAssay 3: CDK4 / CycD kinase assay\n\n\n\n\n\n\n \nRekombinante CDK4- und CycDl-GST-Fusionsproteine, gereinigt aus Bakulovirus-infizierten Insektenzellen (Sf9), wurden von ProQinase GmbH, Freiburg, gekauft. CDK4/CycDl (250 ng/Messpunkt) wurde für 3 Stunden bei 22°C in Anwesenheit verschiedener Konzentrationen an Testsubstanzen (0 μM, sowie innerhalb des Bereiches 0,001 - 10 μM) in 31 μl Assaypuffer [50 mM Hepes pH7,0; 2,5 mM MnCl; 0,05 mM Na ortho-Vanadat; 1,0 mM Dithiothreitol; 0,25 μM Adenosintrisphosphat (ATP); 0,5 μM biotinyliertes myelin basic protein (bio-MBP, GE Healthcare); 0,05 μCi/Messpunkt \n33\nP-gamma ATP; 0,005% NP40; 0,025% bovines Serumalbumin; 3% Dimethylsulfoxid] inkubiert. Die Reaktion wurde durch Zugabe von 50 μl Stopp-Mix [100 μM ATP; 10 mM EDTA pH8,0; 0.2% Triton X100; 0.125 mg Streptavidin-SPA Beads (GE Healthcare)] abgestoppt. Nach 10 min Inkubation bei Raumtemperatur wurden die SPA Beads durch Zentrifugation (10 min; 1500g) pelletiert. Die Menge an eingebautem \n33\nP (Substratphosphorylierung) wurde durch Szintillationsmessung in einem beta-Strahlungsmessgerät (Microbeta, Perkin Eimer) bestimmt. Die Messdaten wurden normalisiert auf 0% Inhibition (Enzymreaktion ohne Inhibitor) und 100% Inhibition (alle Assaykomponenten außer Enzym). \n\n Die Bestimmung der IC50 Werte erfolgte mittels eines 4-Parameter Fits unter Benutzung firmeneigener Software.\nRecombinant CDK4 and CycDl-GST fusion proteins purified from baculovirus-infected insect cells (Sf9) were purchased from ProQinase GmbH, Freiburg. CDK4 / CycDl (250 ng / measuring point) was incubated for 3 hours at 22 ° C in the presence of various concentrations of test substances (0 μM, as well as within the range 0.001-10 μM) in 31 μl assay buffer [50 mM Hepes pH 7.0; 2.5 mM MnCl; 0.05 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.25 μM adenosine trisphosphate (ATP); 0.5 μM biotinylated myelin basic protein (bio-MBP, GE Healthcare); 0.05 μCi / measuring point \n33\n P-gamma ATP; 0.005% NP40; 0.025% bovine serum albumin; 3% dimethylsulfoxide]. The reaction was stopped by adding 50 μl stop mix [100 μM ATP; 10mM EDTA pH8.0; 0.2% Triton X100; 0.125 mg streptavidin-SPA beads (GE Healthcare)]. After 10 min incubation at room temperature, the SPA beads were pelleted by centrifugation (10 min, 1500 g). The amount of incorporated \n33\n P (substrate phosphorylation) was determined by scintillation measurement in a beta radiometer (Microbeta, Perkin Elmer). The data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100% inhibition (all assay components except enzyme).  The IC50 values were determined using a 4-parameter fit using proprietary software.\n\n\n\n\n\n\n \nAssay 4: VEGF Rezeptor-2 Kinase Assay\nAssay 4: VEGF receptor-2 kinase assay\n\n\n\n\n\n\n \nRekombinante VEGF Rezeptortyrosinkinase-2 wurde als GST-Fusionsprotein aus Bakulovirus- infizierten Insektenzellen (Sf9) gereinigt. Poly-(Glu4Tyr), das als Kinase-Substrat verwendet wurde, wurde bei der Fa. Sigma gekauft. VEGF Rezeptortyrosinkinase (90 ng/Messpunkt) wurde für 10 min bei 22°C in Anwesenheit verschiedener Konzentrationen an Testsubstanzen (0 μM, sowie innerhalb des Bereiches 0,001 - 10 μM) in 30 μl Assaypuffer [40 mM Tris/HCl pH5,5; 10 mM MgCl\n2\n; 1 mM MnCl\n2\n; 3 μM Na ortho- Vanadat; 1,0 mM Dithiothreitol; 8 μM Adenosintrisphosphat (ATP); 0,96 μg/Messpunkt poly- (Glu\n4\nTyr); 0,2 μCi/Messpunkt \n33\nP-gamma ATP; 1.4% Dimethylsulfoxid] inkubiert. Die Reaktion wurde durch Zugabe von EDTA-Lösung (250 mM; pH8,0; 15 μl/Messpunkt) gestoppt. Von jedem Reaktionsansatz wurden 15 μl auf P30 Filterstreifen (Fa. Wallac) aufgetragen, und nicht-eingebautes \n33\nP-ATP wurde durch dreimaliges Waschen der Filterstreifen für je 10 min in 0,5%iger Phosphorsäure entfernt. Nach dem Trocknen der Filterstreifen für 1 Stunde bei 70\n0\nC wurden die Filterstreifen mit Szintillator-Streifen (MeltiLex™ A, Fa. Wallac) bedeckt und für 1 Stunde bei 90\n0\nC eingebrannt. Die Menge an eingebautem \n33\nP (Substratphosphorylierung) wurde durch Szintillationsmessung in einem gamma- Strahlungsmessgerät (Wallac) bestimmt. Die Messdaten wurden normalisiert auf 0% Inhibition (Enzymreaktion ohne Inhibitor) und 100% Inhibition (alle Assaykomponenten außer Enzym). Die Bestimmung der IC50 Werte erfolgte mittels eines 4-Parameter Fits unter Benutzung firmeneigener Software.\nRecombinant VEGF receptor tyrosine kinase-2 was purified as a GST fusion protein from baculovirus-infected insect cells (Sf9). Poly (Glu4Tyr), which was used as a kinase substrate, was purchased from Sigma. VEGF receptor tyrosine kinase (90 ng / measurement point) was incubated for 10 min at 22 ° C in the presence of various concentrations of test substances (0 μM, as well as within the range 0.001-10 μM) in 30 μl assay buffer [40 mM Tris / HCl pH 5.5; 10 mM MgCl \n2\n ; 1 mM MnCl \n2\n ; 3 μM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 μM adenosine trisphosphate (ATP); 0.96 μg / measuring point poly (Glu \n4\n Tyr); 0.2 μCi / measuring point \n33\n P-gamma ATP; 1.4% dimethylsulfoxide]. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 μl / measuring point). From each reaction, 15 μl was applied to P30 filter strips (Wallac) and unincorporated \n33\n P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 \n0\n C., the filter strips were baked (MeltiLex ™ A, Fa. Wallac) and for 1 hour at 90 \n0\n C with scintillator strips. The amount of incorporated \n33\n P (substrate phosphorylation) was determined by scintillation measurement in a gamma radiation meter (Wallac). The data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100% inhibition (all assay components except enzyme). The IC50 values were determined using a 4-parameter fit using proprietary software.\n\n\n\n\n\n\n \nAssay 5: Proliferationsassays\nAssay 5: proliferation assays\n\n\n\n\n\n\n \nKultivierte humane Tumorzellen (MCF7, hormonunabhängige menschliche Mammakarzinomazellen, bezogen von ATCC HTB22; NCI-H460, menschliche nicht kleinzellige Lungenkarzinomazellen, ATCC HTB- 177; DU 145, hormonunabhängige menschliche Prostatakarzinomzellen, ATCC HTB-81; HeLa-MaTu, menschliche Cervix-Karzinomzellen, EPO- GmbH, Berlin; HeLa-MaTu-MDR, multiple Arzneimittel resistente menschliche Cervix- Karzinomzellen, EPO-GmbH, Berlin; Caco-2, menschliche Colon-Karzinomazellen, ATCC HTB- 37; Bl 6F10, murine Melanomzelle, ATCC CRL-6475) wurden in einer Dichte von ca. 1000-5000 Zellen/Messpunkt, je nach Wachstumsgeschwindigkeit der jeweiligen Zellen, in einer 96-Loch Multititerplatte in 200 μl des entsprechenden Wachstumsmediums ausplattiert. Nach 24 Stunden wurden die Zellen einer Platte (Nullpunkt-Platte) mit Kristallviolett gefärbt (s.u.), während das \n\n Medium der anderen Platten durch frisches Kulturmedium (200 μl), dem die Testsubstanzen in verschiedenen Konzentrationen (0 μM, sowie im Bereich 0,003 - 3 μM; die finale Konzentration des Lösungsmittels Dimethylsulfoxid betrug 0,5%) zugesetzt waren, ersetzt. Die Zellen wurden für 4 Tage in Anwesenheit der Testsubstanzen inkubiert. Die Zellproliferation wurde durch Färbung der Zellen mit Kristallviolett bestimmt: Die Zellen wurden durch Zugabe von 20 μl/Messpunkt einer 1 l%igen Glutaraldehyd-Lösung 15 min bei Raumtemperatur fixiert. Nach dreimaligem Waschen der fixierten Zellen mit Wasser wurden die Platten bei Raumtemperatur getrocknet. Die Zellen wurden durch Zugabe von 100 μl/Messpunkt einer 0,l%igen Kristallviolett-Lösung (pH durch Zugabe von Essigsäure auf pH3 eingestellt) gefärbt. Nach dreimaligem Waschen der gefärbten Zellen mit Wasser wurden die Platten bei Raumtemperatur getrocknet. Der Farbstoff wurde durch Zugabe von 100 μl/Messpunkt einer 10%igen Essigsäure-Lösung gelöst. Die Extinktion wurde photometrisch bei einer Wellenlänge von 595 nm bestimmt. Die Messdaten wurden normalisiert auf 0% Inhibition [unbehandelte (0 μM) Zellen] und 100% Inhibition (Extinktionwerte der Nullpunktplatte). Die Bestimmung der IC50 Werte erfolgte mittels eines 4- Parameter Fits unter Benutzung firmeneigener Software.\nCultured human tumor cells (MCF7, hormone-independent human breast carcinoma cells purchased from ATCC HTB22, NCI-H460, human non-small cell lung carcinoma cells, ATCC HTB-177, DU 145, hormone-independent human prostate carcinoma cells, ATCC HTB-81, HeLa-MaTu, human cervical carcinoma cells, EPO GmbH, Berlin; HeLa-MaTu-MDR, multiple drug-resistant human cervical carcinoma cells, EPO GmbH, Berlin; Caco-2, human colon carcinoma cells, ATCC HTB-37; Bl 6F10, murine melanoma cell, ATCC CRL-6475 ) were plated in a density of about 1000-5000 cells / measuring point, depending on the growth rate of the respective cells, in a 96-well multititer plate in 200 .mu.l of the corresponding growth medium. After 24 hours, the cells of a plate (zero point plate) were stained with crystal violet (see below), while the  Medium of the other plates was replaced by fresh culture medium (200 μl) to which the test substances had been added at various concentrations (0 μM, as well as in the range 0.003-3 μM, the final concentration of the solvent dimethyl sulfoxide was 0.5%). The cells were incubated for 4 days in the presence of the test substances. The cell proliferation was determined by staining the cells with crystal violet. The cells were fixed by adding 20 μl / measuring point of a 1 1% glutaraldehyde solution for 15 minutes at room temperature. After washing the fixed cells three times with water, the plates were dried at room temperature. The cells were stained by adding 100 μl / measuring point of a 0.1% crystal violet solution (pH adjusted to pH 3 by addition of acetic acid). After washing the stained cells three times with water, the plates were dried at room temperature. The dye was dissolved by adding 100 μl / measuring point of a 10% acetic acid solution. The extinction was determined photometrically at a wavelength of 595 nm. The measurement data were normalized to 0% inhibition [untreated (0 μM) cells] and 100% inhibition (absorbance values of the zero plate). The IC50 values were determined using a 4-parameter fit using proprietary software.\n\n\n\n\n\n\n \nAssay 6: Permeabilitätsassays\nAssay 6: permeability assays\n\n\n\n\n\n\n \nDer Caco-2 Monolayer stellt eine Barriere zwischen 2 Kompartimenten dar. Die Zellen verhalten sich dabei ähnlich der Dünndarmzellen. Wirkstoffe können sowohl para- wie auch transzellulär transportiert werden. Dabei erfolgt der Transport meist von apikal {luminaϊ) nach basolateral {serosa!). Bei p-Glycoproteinsubstraten wird in der Regel auch der Rücktransport von basolateral nach apikal beobachtet. Versuchsdurchführung: Der Permeabilitätsversuch wird sowohl von apikal nach basolateral als auch von basolateral nach apikal durchgeführt. Dabei werden pro Substanz 2 Filter verwendet; die Inkubation erfolgt über 90 min bei 37°C im Wasserbad. Neben der bidirektionalen Permeabilität von Test- und Referenzsubstanzen (Referenzen: geringe Permeabilität: PEG4000; hohe Permeabilität: Clonidin; direktionale Permeabilität: Digoxin), wird durch die Bestimmung des transepithelialen Widerstandes (TEER) die Integrität des Zellmonolayers sichergestellt. Als Referenzsubstanzen werden (i) PEG 4000 als hydrophiler Marker benutzt. Es ist wegen seines hohen Molekulargewichtes unfähig in die Zellmembran oder in die Poren der Tight junctions zu permeieren. PEG 4000 ist daher ein Marker für die Unversehrtheit des Zellmonolayers und die Enge der Tight junctions. PEG 4000 wird im Menschen nicht absorbiert, (ii) Clonidine ist bekannt als vollständig absorbierte Substanzen beim Menschen (100 %). Sie dienen als Marker für sehr gut- permeable Substanzen mit Papp- Werten über 100 nm/s. (iii) Digoxin ist ein bekanntes Pgp Substrat. Es zeigt eine geringe Permeabilität von apikal nach basolateral. Beim Rückversuch {basolateral \n\n nach apikal) sollten die Papp- Werte bedingt durch den aktiven direktionalen Transport ins apikale Kompartment um ca. Faktor 10 höher liegen.\nThe Caco-2 monolayer is a barrier between two compartments. The cells behave similarly to the small intestine cells. Active substances can be transported both para- and transcellularly. The transport usually takes place from apical {luminaϊ) to basolateral {serosa!). In the case of p-glycoprotein substrates, the return transport from basolateral to apical is usually also observed. Experimental procedure: The permeability test is carried out apically to basolaterally as well as from basolateral to apical. Two filters are used per substance; Incubation is carried out for 90 min at 37 ° C in a water bath. In addition to the bidirectional permeability of test and reference substances (references: low permeability: PEG4000, high permeability: clonidine, directional permeability: digoxin), the determination of transepithelial resistance (TEER) ensures the integrity of the cell monolayer. As reference substances (i) PEG 4000 are used as a hydrophilic marker. Due to its high molecular weight, it is unable to permeate into the cell membrane or into the pores of the tight junctions. PEG 4000 is therefore a marker of the integrity of the cell monolayer and the tightness of the tight junctions. PEG 4000 is not absorbed in humans, (ii) clonidine is known to be fully absorbed substances in humans (100%). They serve as markers for highly permeable substances with pulp values above 100 nm / s. (iii) Digoxin is a known Pgp substrate. It shows a low permeability from apical to basolateral. In the reverse trial {basolateral  apical), the Papp values should be about 10 times higher due to the active directional transport into the apical compartment.\n\n\n\n\n\n\n \nAuswertung: Der Permeationskoefϊϊzient (Papp) wird über die Substanzkonzentration auf der Donor- und Rezeptorseite nach folgender Formel berechnet: Papp = (Vc res / A * Q\n0\n, \ndon\n) * (delta C\nres\n/delta T), wobei Vres: Puffervolumen auf der Rezeptorseite,\nEvaluation: The permeation coefficient (Papp) is calculated from the substance concentration on the donor and receptor side according to the following formula: Papp = (Vc res / A * Q \n0\n , \ndon\n ) * (delta C \nres\n / delta T), where Vres: buffer volume on the receptor side,\n\n\n\n\n\n\n \nA: Filterfläche = 1 cm\n2\n,\nA: filter area = 1 cm \n2\n ,\n\n\n\n\n\n\n \nC,o\n, don\n: Substanzkonzentration auf der Donorseite zum Zeitpunkt 0, delta C\nres\n/delta T: Änderung der Substanzkonzentration über die Zeit auf der Rezeptorseite.\nC, o \n, don\n : substance concentration on the donor side at time 0, delta C \nres\n / delta T: change in substance concentration over time on the receptor side.\n\n\n\n\n\n\n \nDer Permeationskoeffizient Papp wird zur Einschätzung der Absorption beim Menschen nach folgendem Schema genutzt:\nThe permeation coefficient Papp is used to estimate the absorption in humans according to the following scheme:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nErgebnisse aus den Enzym- und Zellassays\nResults from the enzyme and cell assays\n\n\n\n\n\n\n \nTab.1 : Ergebnisse der Enzymassays \n\n\n \n\n Tab.2: Ergebnisse der Proliferationsassays (Assay 5) \n\n\n\nTab.1: Results of the enzyme assays \n Table 2: Results of proliferation assays (Assay 5) \n \n\n\n\n\n\n\n \nTab.3: Ergebnisse der Permeabilitätsassays (Assay 6)\n\n\n \n\n Schlußfolgerungen aus den Enzym- und Zellassays\nTable 3: Results of the permeability assays (Assay 6) \n Conclusions from the enzyme and cell assays\n\n\n\n\n\n\n \nDie Beispielverbindungen 1-3 zeigen eine 2- bis 6-fach stärke Inhibition der Aktivität der Zyklin- abhängigen Kinase CDKl und eine 3- bis 7-fach stärkere Inhibition der CDK2 im Vergleich zu der Struktur 692 des Beispiels 1 aus WO 2003/032997 (Tab.l). Die Beispielverbindungen 1-3 zeigen eine potente Inhibition der CDK4 bei nanomolaren Konzentrationen während die Struktur 692 des Beispiels 1 aus WO 2003/032997 die halb-maximale Hemmung der CDK4 Aktivität bei zu einer Konzentration von 1000 nM noch nicht erreicht hat. Gleichzeitig ist die Selektivität hinsichtlich der CDK-Inhibition gegenüber der Inhibition der VEGF-Rezeptorkinase-2 (VEGF-R2) bei den Beispielen 1-3 deutlich erhöht (15- bis 50-fach stärkere inhibition der CDKs), während die Struktur 692 des Beispiels 1 aus WO 2003/032997 nur eine ca. 2-fache Selektivität aufweist. In den Zellproliferationsassays zeigen die Beispielverbindungen 1-3 die 50%ige Inhibition der Proliferation bereits bei deutlich niedrigeren Konzentrationen als die Struktur 692 des Beispiels 1 aus WO 2003/032997 (Tab. 2, Ausnahme: Bsp. 2 an MCF7 Zellen). Überraschenderweise ist dieser Effekt bei den Zellinien DU145, Caco-2, HeLa-MaTu-ADR, und B16F10 besonders ausgeprägt (bis zu 130-fach bessere antiproliferative Aktivität der Beispielverbindungen 1-3 gegenüber der Struktur 692 des Beispiels 1 aus WO 2003/032997). Die Permeabilitätsassays (Tab. 3) zeigen, dass die Beispielverbindungen 1-2 eine gute und freie Permeation über eine geschlossene Caco-2 Zellschicht aufweisen. Die Struktur 692 des Beispiels 1 aus WO 2003/032997 ist durch eine sehr schlechte Permeation in absorptiver Richtung und durch eine hohe Permeation in Efflux-Richtung gekennzeichnet.\nExample compounds 1-3 show a 2- to 6-fold increase in the inhibition of the activity of the cyclic-dependent kinase CDK1 and a 3- to 7-fold stronger inhibition of CDK2 compared to the structure 692 of Example 1 of WO 2003/032997 ( Tab.l). Example compounds 1-3 show a potent inhibition of CDK4 at nanomolar concentrations while structure 692 of example 1 of WO 2003/032997 has not yet reached the half-maximal inhibition of CDK4 activity at to a concentration of 1000 nM. At the same time, selectivity to CDK inhibition over inhibition of VEGF receptor kinase-2 (VEGF-R2) is markedly increased in Examples 1-3 (15 to 50-fold greater inhibition of CDKs), while Structure 692 of Example 1 from WO 2003/032997 has only about a 2-fold selectivity. In the cell proliferation assays, example compounds 1-3 show the 50% inhibition of proliferation even at significantly lower concentrations than structure 692 of example 1 from WO 2003/032997 (Tab. 2, exception: Ex. 2 on MCF7 cells). Surprisingly, this effect is particularly pronounced in the case of the cell lines DU145, Caco-2, HeLa-MaTu-ADR, and B16F10 (up to 130-fold better antiproliferative activity of the example compounds 1-3 compared to the structure 692 of Example 1 from WO 2003/032997). , The permeability assays (Table 3) show that Exemplified Compounds 1-2 exhibit good and free permeation across a closed Caco-2 cell layer. The structure 692 of Example 1 of WO 2003/032997 is characterized by a very poor permeation in the absorptive direction and by a high permeation in the efflux direction.\n\n\n\n\n\n\n \nDer direkte Vergleich der Beispiele 1-3 mit den analogen 4-N Verbindungen (Vergleichsbeispiele V1-V3) zeigt eine Verbesserung der Kinaseselektivität der Beispielverbindungen 1-3 gegenüber der VEGF-Rezeptorkinase-2 um mindestens den Faktor 2. Die Beispielverbindungen 1-2 zeigen gegenüber den Vergleichsbeispielen eine Verbesserung der Inhibition der CDK4 und zeigen an den Zellinien DU145 und HeLa-MaTu-ADR eine um mehr als den Faktor 2 verstärkte antiproliferative Wirkung.\nThe direct comparison of Examples 1-3 with the analogous 4-N compounds (Comparative Examples V1-V3) shows an improvement in the kinase selectivity of Exemplified Compounds 1-3 over VEGF receptor kinase-2 by at least a factor of 2. Example Compounds 1-2 show compared to the comparative examples, an improvement in the inhibition of CDK4 and show on the cell lines DU145 and HeLa-MaTu-ADR increased by more than a factor of 2 antiproliferative effect.\n\n\n\n\n\n\n \nDiese Daten belegen die Überlegenheit der erfindungsgemäßen Verbindungen (Beispiele 1-3) gegenüber dem nächstliegenden Stand der Technik (WO 2003/032997). Dies wird insbesondere deutlich gezeigt anhand der verstärkten antiproliferativen Aktivität der Beispielverbindungen in den als Chemotherapie-resistent bekannten Zellinien DU 145, HeLa-MaTu-ADR und Caco-2. \n\nThese data demonstrate the superiority of the compounds of the invention (Examples 1-3) over the closest prior art (WO 2003/032997). This is particularly clearly demonstrated by the enhanced antiproliferative activity of the example compounds in the chemotherapy-resistant cell lines DU 145, HeLa-MaTu-ADR and Caco-2."
  },
  {
    "id": "WO2010047611A1",
    "text": "Process for preparing chlorins and their pharmaceutical uses AbstractThe invention provides the methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacterioclorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalies that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging. Claims\n\n\n\n\n\n\n1. A process for the preparation of a chlorin or bacteriochlorin derivative having the formula:\n\n\n\n\n\n\n\n\nFormula (I)\n\n\nwherein: represents a carbon-carbon single bond or a carbon-carbon double bond;\n\n\nX\n1\n. X\", X\n3\n. X\n4\n, X\\ X\n6\n, X\n7\n, X\n8\n are each independently chosen from halogen (F, Cl. Br) and hydrogen atoms, provided that either all of X\n2\n, X\n4\n. X\n6\n and X\n8\n or all of X\n1\n. X\n3\n, X\n5\n and X\n7\n are halogens, or all X are halogens;\n\n\nR i, R\n2\n, R\n3\n, R-i, Rs, R\nO\n, R\n?\n. R^. are independently chosen from H, -OH and -SO\n2\nR, where R are each independently chosen from -Cl. -OH, -aminoacid, -OR\nn\n, -NHR\nn\n and -NR\n2\n\" where R\" are alkyl of 1 to\n\n\n12 carbon atoms:\n\n\nY is either fluorine or hydrogen;\n\n\ncomprising the following step:\n\n\n(i) the solid-state reduction of the corresponding substituted porphyrin to the chlorin derivative or bacteriochlorin derivative using hydrazides in the absence of solvents and, optionally, in the absence of bases; wherein the corresponding substituted porphyrin has the formula:  \n\n\n\n\n\n\n\n\nFormula (II).\n\n\n\n\n\n\n2. A process for the preparation of a chlorin or bacteriochlorin derivative having the formula:\n\n\n\n\n\n\n\n\nFoπnula (III)\n\n\nwherein: represents a carbon-carbon single bond or a carbon-carbon double bond;\n\n\nX\n2\n are chosen from halogen (F, Cl, Br), X\n1\n are chosen from hydrogen or halogen (F, Cl, Br), and R' are -SO\n2\nR:\n\n\nR are each independently chosen from -Cl, -OH, -aminoacid, -OR\", -NHR\" and -NR\n2\n\" where R\nn\n are alkyl of 1 to 12 carbon atoms;\n\n\ncomprising the following step:  (i) the solid-state reduction of the corresponding substituted porphyrin to the chlorin derivative or bacteriochlorin derivative using hydrazides in the absence of solvents and, optionally, in the absence of bases; wherein the corresponding substituted porphyrin has the formula:\n\n\n\n\n\n\n\n\nFormula (IV).\n\n\n\n\n\n\n3. A pharmaceutical composition comprising: (a) a chlorin or bacteriochlorin derivative thereof having the formula:\n\n\n\n\n\n\n\n\nFormula (III)\n\n\nor a pharmaceutically acceptable composition derivative thereof.\n\n\nwherein:\n\n\nrepresents a carbon-carbon single bond or a carbon-carbon double bond;  X\n:\n are chosen from halogen (F, Cl. Br), X\n1\n are chosen from hydrogen or halogen (F, Cl, Br). and R\n\"\n are -SO\n2\nR:\n\n\nR are each independently chosen from -Cl, -OH, -aminoacid, -OR\". -NHR\nn\n and -NR\n2\n\" where R\nn\n are alkyl of 1 to 12 carbon atoms;\n\n\nwherein the chlorin or bacteriochlorin derivative is effective in a photodynamic therapy treatment for ameliorating the symptoms of a hyperproliferative disorder; and\n\n\n(b) a surface penetration enhancer.\n\n\n\n\n\n\n4. A pharmaceutical composition according to claim 3, wherein the surface penetration enhancer is selected from dialkylsulphoxides, N- Methylformamide, dimethylformamide. dimethylacetamide, glycols, pyrrolidone derivatives and 1 -substituted azacycloalkan-2-ones.\n\n\n\n\n\n\n5. Use of a chlorin or a bacteriochlorin derivative, or a pharmaceutically acceptable composition derivative thereof, in the detection of hyperproliferative tissue; wherein the chlorin or bacteriochlorin derivative has the formula:\n\n\n\n\n\n\n\n\nFormula (III)\n\n\nwherein;\n\n\nrepresents a carbon-carbon single bond or a carbon-carbon double bond;  X\n2\n are chosen from halogen (F. CL Br), X\n1\n are chosen from hydrogen or halogen (F. Cl, Br). and R' are -SO\n2\nR:\n\n\nR are each independently chosen from -Cl, -OH. -aminoacid, -OR\", -NHR\" and -NR\n2\n\" where R\" are alkyl of 1 to 12 carbon atoms.\n\n\n\n\n\n\n6. A method for detecting the presence of a hyperproliferative tissue in a subject comprising:\n\n\n(i) administering to the subject a diagnosticallv sufficient quantity of a chlorin or bacteriochlorin derivative having the formula\n\n\n\n\n\n\n\n\nFormula (III)\n\n\nwherein:\n\n\nrepresents a carbon-carbon single bond or a carbon-carbon double bond;\n\n\nX\n*\n are chosen from halogen (F, CL Br), X\n1\n are chosen from hydrogen or halogen (F, Cl, Br). and R\n\"\n are -SO\n2\nR;\n\n\nR are each independently chosen from -Cl. -OH, -aminoacid. -OR\". -NHR\" and -NR\n2\n\" where R\" are alkyl of 1 to 12 carbon atoms,\n\n\nor a pharmaceutically acceptable composition derivative thereof that preferentially associates with the target.  (ii) allowing sufficient time for the chlorin or bacteriochlorin derivative to associate with the target and for any chlorin or bacteriochlorin derivative that is not preferentially associated with the target tissue to clear from the non-target tissue, and (iii) visualizing the compound within the patient.\n\n\n\n\n\n\n7. The method of claim 6 wherein the step of visualizing is accomplished by generating an MRI image of at least a part of the patient's body.\n\n\n\n\n\n\n8. The method of claim 6 wherein the step of visualizing is accomplished by exposing the compound to light of sufficient energy to cause the compound to fluoresce.\n\n\n\n\n\n\n9. A pharmaceutically acceptable composition for use in the treatment of a skin cancer or of a skin disorder selected from actinic keratoses, squamous cell carcinoma, Bowen's disease, basal cell carcinoma, psoriasis, acne vulgaris and rosacea; wherein the composition comprises:\n\n\n(i) a chlorin or bacteriochlorin derivative with the formula:\n\n\n\n\n\n\n\n\nFormula (III)\n\n\nwherein:\n\n\nrepresents a carbon-carbon single bond or a carbon-carbon double bond;\n\n\nX\" are chosen from halogen (F, Cl. Br), X\n1\n are chosen from hydrogen or halogen (F, Cl, Br), and R\n\"\n are -SO\n2\nR;  R are each independently chosen from -Cl. -OH, -aminoacid, -OR\", -NHR\" and -NR\n2\n\" where R\nn\n are alkyl of 1 to 12 carbon atoms; and\n\n\n(ii) a pharmaceutically acceptable carrier for intradermal or transdermal delivery of such compound, wherein the carrier comprises a surface penetration enhancer that transiently penneabilizes the skin and facilitates the permeation of the compound through the various skin layers;\n\n\nwherein\n\n\n(a) the composition is administered to a subject;\n\n\n(b) sufficient time is allowed for the chlorin or bacteriochlorin derivative to preferentially locate near the target of the dermatological treatment: and\n\n\n(c) the target is irradiated to obtain the desired response of the skin cancer or of the skin disorder.\n\n\n\n\n\n\n10. A pharmaceutical composition according to claim 9, wherein the surface penetration enhancer is selected from dialkylsulphoxides, N- Methylformamide, dimethylformamide, dimethylacetamide. glycols, pyrrolidone derivatives and 1 -substituted azacycloalkan-2-ones. Description\n\n\n\n\n PROCESS FOR PREPARING CHLORINS AND THEIR PHARMACEUTICAL USES\n\n\nFIELD OF THE INVENTION\n\n\nThe present invention relates to the methods of preparation, properties, pharmaceutical compositions and use in therapy of sulfonated chlorins and bacterioclorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or anomalies that are responsive to PDT. In particular, the present invention relates to a novel method capable of chemically synthesizing stable chorins and bacteriochlorins in a large scale, which is characterized by the absence of solvent and the absence of base. In another embodiment, pharmaceutical compositions and methods for their use in therapy with systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods for their use in therapy with topical administration are also provided. Also provided are methods for the detection of hyperproliferative tissues such as tumors, using photodynamic methods or MRI.\n\n\nI. BACKGROUND OF THE INVENTION LA. State-of-the-art\n\n\nVarious tetrapyrrolic macrocycles, such as purpurins, chlorins. bacteriochlorins, phthalocyanines and benzochlorins. have shown the ability both to preferentially collect in hyperproliferative tissues when injected into an organism, and to absorb light to form an activated state in response to the light. These macrocycles then exhibit a cytotoxic effect on the cells or other tissues in which they are localized when irradiated at the appropriate wavelength. Moreover, these compounds also cause emission of energy from the tissue that can be used to detect their location.\n\n\nIn PDT the patient is injected with a photosensitizer (usually between about 0.1 and about 10 mg/kg of body weight) which shows some selectivity for photodamage to tumor tissue and then, after a certain time, the tumor area is irradiated with visible or near-infrared light (from about 50 to 200 J/cm~). The photosensitizer absorbs light and fluoresces, or reacts with substrate molecules in the tissues by electron or hydrogen transfer reactions (Type I processes), or transfers its energy to ground-state molecular oxygen generating singlet oxygen O\n2\n (\n1\nA\ng\n) that attacks the tissues (Type II process). A major contributor to Type I process is the superoxide (O\n2\n \n\"\n), formed by electron transfer from the electronically excited sensitizer. There is evidence favoring the Type II photooxygenation process over Type I processes in cells [1,2], but there are also claims of an amplified PDT response \n\n when superoxide is also generated [3]. In the case of detection, fluorescence is determined upon exposure to light at the desired wavelength, and lower energies are required than for treatment. Efficient treatment usually requires the formation of high yields of singlet oxygen in the tissue, which may have a synergistic effect with the concomitant formation of superoxide or other reactive oxygen species.\n\n\nThe properties of optimal sensitizers for PDT treatment include: (i) simple, efficient and economical synthesis; (ii) stability, purity and long shelf-life: (iii) solubility in biocompatible solvents or vehicles; (iv) high absorption coefficient in the ''phototerapeutic window\" (600-900 nm): (v) singlet molecular oxygen sensitization and/or superoxide generation with a high quantum yield; (vi) reduced or no dark toxicity; (vii) selective accumulation and prolonged retention in tumor tissues; (viii) low skin photosensitization under systemic administration; (ix) controlled photobleaching; (x) facile metabolism or excretion after treatment. The sensitizer is only the precursor of the cytotoxic species, notably singlet oxygen and other reactive oxygen species such as the superoxide ion. The immediate precursor of singlet oxygen, and often of superoxide, is the triplet state of the sensitizer. Thus, a high singlet oxygen quantum yield requires at least three sensitizer triplet state properties: (i) a near unity quantum yield, (ii) an electronic energy at least 20 kJ/mol above that of singlet oxygen (94 kJ/mol), (iii) and a long lifetime (hundreds of microseconds). The accumulation and retention in tumor tissues can be enhanced with the addition of specific vectors, but a relevant intrinsic property of the sensitizer for these purposes is the hydrophilicity/lipofilicity of the sensitizer and the ability to tailor such properties to attain desired targets is a most welcome property.\n\n\nThe lower end of the phototerapeutic window is determined by the presence of heme proteins. that account for most of the absorption of light in the visible region in tissues. The penetration of light in tissues drops off rapidly below 550 nm. However, there is a significant increase in penetration from 550 to 630 nm, and penetration doubles again to 700 nm. This is followed by a 10% increase in tissue penetration as the wavelength moves towards 800 nm. The higher end of the photo therapeutic window is determined by the absorption of infrared radiation by water and by the energy requirements for efficient energy transfer to oxygen. Indeed, diffusion-controlled triplet energy transfer from the sensitizer to molecular oxygen requires that the triplet energy of the sensitizer is at least 1 15 kJ/mol. Additionally, the singlet-triplet energy splitting in tetrapyrrolic macrocycles is ca. 40 kJ/mol [4], which requires that the sensitizer must have a singlet energy larger than 150 k.I/mol. Considering that the Stokes shift of such these sensitizers is usually small, they should absorb light just below 800 nm. The conclusion is that an ideal sensitizer must strongly absorb \n\n light with wavelengths ca. 750 nm. The strong absorption of bacteriochlorins at this wavelength makes them ideal candidates for PDT sensitizers. For applications where light penetration is not as critical, chlorins are also suitable candidates for PDT.\n\n\nPhotofrin*, a hematoporphyrin derivative [5], is the most widely used photosensitizer. and has been approved for the treatment of a variety of solid tumors [6]. Hematoporphyrin derivative (HpD) is prepared by mixing hematoporphyrin with glacial acetic acid and sulfuric acid, followed by hydrolysis and precipitation under acidic conditions. This method was partially described by Lipson et al [7]. HpD thus produced consists of a complex mixture of porphyrins. When HpD is separated into its two main fractions by gel filtration with Sephadex LH-20. the higher molecular weight portion, called Photofrin*. is a more efficient PDT agent [8]. The recommended human dosage of Photofrin* is 1 -2 mg/kg of body weight. The main components of Photofrin* are dimers and higher oligomers linked with ether, ester and possibly carbon-carbon linkages [9].\n\n\nPhotofrin* has some desirable characteristics, including good efficacy, water solubility, reasonable yield of singlet oxygen, and ease of manufacture. However, Photofrin\n®\n also has some disadvantageous properties: (i) it is a complex mixture of porphyrin dimers and higher oligomers linked by ether, ester, and/or carbon-carbon bonds; (ii) it shows skin phototoxicity in patients lor four to six weeks after administration; (iii) due to its relatively weak absorbance in the red region (630 nm). lack of penetration of light through tissue limits current clinical applications of Photofrin* in PDT to the destruction of cancerous tissue located less than 4 mm from the source of light used in the therapy. Thus, there is a need for more efficient, chemically pure, less phototoxic, better localizing sensitizers that absorb light more intensely and in the infrared.\n\n\nIt is known in the art that the chemical reduction of one of the tetrapyrrole rings, corresponding to the transformation of a porphyrin into a chlorin, leads to a displacement of the longest wavelength absorption band further into the red. concomitant with an increase of its absorption coefficient. Such properties were explored in the second-generation of PDT photosensitisers, and 5,10.15,20- tetrakis(3-hydroxyphenyl)chlorin (m-THPC), commercialized under the name Foscan®, emerged as one of the most potent of this second-generation photosensitisers [ 10]. Further reduction of the opposite pyrrole ring, corresponding to the transformation of a chlorin into a bacteriochlorin, leads to the displacement of the absorption band into the infrared and an additional increase of its absorption coefficient. However, until recently, it was a widely shared belief that bacteriochlorins are very unstable compounds [10] and research efforts on PDT sensitizers focused on chlorins [ 1 1]. Subsequently, it has been shown that stable bacteriochlorins can indeed be synthesized [12]. This was \n\n not fully appreciated in the scientific literature, where it was claimed that synthesis of stable bacteriochlorins with this approach was limited for preparing bacteriochlorins with inert functionalities [13]. However, bacteriochlorins with further functionalities have been prepared (see PCT/EP2005/012212. WO/2006/053707). The obvious interest of bacteriochlorins as PDT sensitizers and reports that some naturally occurring bacteriochlorins were effective photosensitizers both in vitro and as in vivo [14,15], motivated many attempts to synthesize bacteriochlorins. Synthetic bacteriochlorins have been prepared by derivatization of the corresponding porphyrins via vicinal dihydroxylation with osmium tetroxide [16], intramolecular cyclization [17], Diels-Alder reactions using porphyrins as dienophile [ 18] or Diels-Alder reactions with vinyl porphyrins where the prophyrin is the diene [19]. via 1,3- dipolar cycloaditions [20] and also by self-condensation of dehydrodipyrrin-acetal derivatives [21]. Additionally, there is the classic method, developed several decades ago by Whitlock for preparing bacteriochlorins. by reduction the 7,8- 17.18-pyrrolic porphyrin positions with diimide [22]. This was the method used by Bonnet to synthesize Foscan and 5,10,15,20-tetrakis(3- hydrophenyl)bacteriochlorin [23]. Meanwhile, the very intensive research carried out on the synthesis of bacteriochlorin derivatives lead to a number of patents based on the methods described above (see, for example. US2007/7.166,719; US2003/6,624.187; US2003/6.569,846; US2002/6,376,483: US 1999/5.864,035; US 1998/5,831,088; WO90/ 12573; WO94/001 18; WO95/32206; WO96/13504; WO97/32885; US2006/ 194.960). Some of the newly synthesized bacteriochlorins have a negligible dark toxicity and a high tumor selectivity, are partially water soluble and have marked absorption bands in the range from 700 nm to 800 nm. However, some disadvantages remain, namely: (i) a complicated and expensive synthesis involving laborious purifications; (ii) limited water solubility which, in the case of a systemic application, results in a dissolution in organic solvents, with an additional chemical burden on the organism, or binding to a vehicle, increasing the cost of the treatment; (iii) chemical instability, specially in the presence of light; (iv) low or unknown singlet oxygen quantum yields. An interesting representative of this third generation of photosensitizers is a palladium- bacteriopheophorbide currently known as Tookad®. which has been approved for Phase 111 clinical studies. Tookadϋ? is derived from bacteriochlorophyll and, as most of the naturally occurring bacteriochlorins, is very sensitive to oxygen, which results in rapid oxidation to the chlorin state. which has an absorption maximum at or below 660 nm. Furthermore, if a laser is used to excite the bacteriochlorin in vivo, oxidation may result in the formation of a new chromophore absorbing \n\n outside the laser window, which reduces the photosensitizing efficacy. The photochemical degradation of this family of compounds was measured with 778 ran (13 mW) illumination in TX- 100/PBS, and revealed that 90% of the compound was irreversibly lost in 5 min (4 J), with the concomitant growth of a chlorin band at 660 nm [3]. PDT has also been extensively tested for the treatment of skin disorders, namely actinic keratoses, squamous cell carcinoma, Bowen's disease (intra-epithelial squamous cell carcinoma), basal cell carcinoma, but little information is available on malignant melanoma [24]. The high pigmentation of melanoma tissues limits the efficiency of PDT when visible light is employed, because melanin attenuates light penetration in tissues for wavelengths below 700 nm. There are also reports of topical PDT use in nontumoral condition, such as psoriasis. Earlier studies employed hernatoporphyrin derivative [25] and meso-tetraphenylporphinesulfonate tetrasodium salt [26] in liquid formulations containing percutaneous penetration enhancers. However, typically, when HpD or other porphyrins are applied topically in a (liquid, gel, cream, emulsion, etc.) formulation containing a vehicle intended to enhance their diffusion through tissue, the porphyrins tend to be retained as the dilution of the permeation enhancer by normal tissue fluids takes place. In such circumstances, the porphyrins can no longer diffuse through the tissue (or even remain in solution). Consequently, the topical application of porphyrins often is associated with a loss of specificity for malignant tissues, and normal tissues near the site of application may develop persistent photosensitization as a result of the localized concentration of porphyrin To overcome these problems, it was suggested that rather than applying a porphyrin topically it would be advantageous to use an agent which is not in itself a photosensitizer but which induces the synthesis of endogenous porphyrins in vivo, namely protoporphyrin-IX (PpIX) [27]. It is known that 5-amino-4-oxopentanoic acid, otherwise known as 5-aminolevulinic acid (or ALA), is a biological precursor of protoporphyrin IX. An excess of ALA leads to a biological accumulation of PpIX. which is the actual photosensitizing agent. Thus, by applying ALA topically to skin tumors, and then after several hours exposing the tumors to light, a beneficial phototherapeutic effect may be obtained (see, for example, WO91/01727). Since the skin covering basilomas and squamous cell carcinomas is more readily penetrated by ALA than healthy skin, and since the biosynthesis of PpIX is more efficient in skin tumors, it has been found that topical application of ALA leads to a selectively enhanced production of PpIX in tumors. This has been the basis for a number of deπnatological formulations of ALA, or some of its derivatives, that have been approved and are in clinical use, most notably Levulan® and Metvix®. \n\n However, whilst the use of ALA represents a significant advance in the art, photodynamic therapy with ALA is not entirely satisfactory. Patients repeatedly report having experienced pain in\n\n\nALA-PDT [28]. ALA is a pro-dug and the efficiency of the drug production varies with the biosynthesis in the subject. Only a very limited amount of PpIX can be biosynthesized by the cells. It lends to be unstable in pharmaceutical formulations. It is not able to penetrate all tumors and other tissues with sufficient efficacy to enable treatment of a wide range of tumors or other conditions. Its preferred wavelength of the photoactivating light is about 635 nm, whereas it has been shown that only between 1 and 10 percent of incident red light (600-700 nm) can pass through a slab of human tissue 1 cm thick. A need therefore exists for improved photodynamic therapeutic agents for topical applications.\n\n\nLB. Summary of the invention\n\n\nAccording to a first aspect, the present invention provides a process for the preparation of a chlorin or bacteriochlorin derivative having the formula:\n\n\n\n\n\n\n\n\nFoπnula (I) wherein: represents a carbon-carbon single bond or a carbon-carbon double bond:\n\n\nX\n1\n, X\n2\n. X\n3\n, X\n4\n, X\n5\n, X\n6\n, X\n7\n. X\ns\n are each independently chosen from halogen (F, CI. Br) and hydrogen atoms, provided that either all of X\n2\n. X\n4\n. X\nft\n and X\n8\n or all of X\n1\n, X\n3\n, X\n5\n and X\n7\n are halogens, or all X are halogens; \n\n Ri, R\n2\n, R\n3\n, R\n4\n. Rs- R^, R~. Rs, are independently chosen from H, -OH and -SChR, where R are each independently chosen from -Cl, -OH, -aminoacid, -OR\", -NHR\" and -NR\n2\n\" where R\nn\n are alkyl of 1 to 12 carbon atoms; Y is either fluorine or hydrogen; comprising the following step:\n\n\n(i) the solid-state reduction of the corresponding substituted porphyrin to the chlorin derivative or bacteriochlorin derivative using hydrazides in the absence of solvents and, optionally, in the absence of bases; wherein the corresponding substituted porphyrin has the formula:\n\n\n \n\n Formula (II).\n\n\nHence, the compound of Formula (I) may be a chlorin derivative having the formula:\n\n\n\n\n\n\n\n\nFormula (V). \n\n Alternatively, the compound of Formula (I) may be a bacteriochorin derivative having the formula\n\n\n \n\n Fonυula (VI).\n\n\nSuitably X\n2\n, X\n4\n, X\n6\n, X\n8\n are each independently chosen from halogen (F, Cl, Br) .\n\n\nSuitably R\n5\n, R\n6\n, R\n7\n, R\n8\n, are H.\n\n\nSuitably Y is H.\n\n\nSuitably Ri, R\n2\n, R^, R\n4\n, are -SO\n2\nR, where R are each independently chosen from -Cl, -OH, - aminoacid, -OR\". -NHR\" and -NR\n2\n\" where R\" are alkyl of 1 to 12 carbon atoms.\n\n\nIn a further aspect. X\", X\n4\n, X\nft\n, X are each independently chosen from halogen (F. Cl. Br);\n\n\nR\n5\n, R\n6\n, R\n7\n, R«. are H;\n\n\nY is H; and\n\n\nRi, R\n2\n, Rj, R\n4\n, are -SO\n2\nR, where R are each independently chosen from -Cl. -OH, - aminoacid, -OR\", -NHR\" and -NR;\" where R\" are alkyl of 1 to 12 carbon atoms.\n\n\nIn a further aspect, the present invention provides a process for the preparation of a chlorin or bacteriochlorin derivative having the foπnula: \n\n \n\n\n\n\n\nFormula (III)\n\n\nwherein: represents a carbon-carbon single bond or a carbon-carbon double bond:\n\n\nX\n2\n are chosen from halogen (F, CL Br). X\n1\n are chosen from hydrogen or halogen (F, Cl, Br); and R' are -SO\n2\nR, where R are each independently chosen from -Cl, -OH, -aminoacid, -OR\", -NHR\" and -NR\n2\n\" where R\" are alkvl of 1 to 12 carbon atoms.\n\n\ncomprising the following step:\n\n\n(i) the solid-state reduction of the corresponding substituted porphyrin to the chlorin derivative or bacteriochlorin derivative using hydrazides in the absence of solvents and, optionally, in the absence of bases; wherein the corresponding substituted porphyrin has the formula:\n\n\n\n\n\n\n\n\nFormula (IV). \n\n Hence, the compound of Formula (III) may be a chlorin derivative having the formula:\n\n\n\n\n\n\n\n\nFormula (VIl).\n\n\nAlternatively, the compound of Formula (III) may be a bacteriochlorin derivative having the formula\n\n\n\n\n\n\n\n\nFormula (VIII).\n\n\nIn a further aspect. R' is -SO\n2\nR. where R is -Cl for the corresponding substituted porphyrin of\n\n\nFormula (IV); and the process comprises the further step of:\n\n\n(ii) bonding the chlorin or a bacteriochlorin derivative with an amine H-NHR\" or H-NR\n2\n\": an aminoacid, or an alcohol H-OR\", where R\" are alkyl of 1 to 12 carbon atoms: to provide a chlorine or bacteriochlorin derivative wherein , R\n'\n is -SO\n2\nR. where R is - aminoacid, -OR\", -NHR\" or -NR\n2\n\" where R\nn\n are alkyl of 1 to 12 carbon atoms.\n\n\nIn a further aspect, the present invention provides a phaπnaceutical composition comprising: \n\n (a) a chlorin or a bacteriochlorin derivative having the formula;\n\n\n \n\n Formula (III)\n\n\nor a pharmaceutically acceptable composition derivative thereof.\n\n\nwherein: represents a carbon-carbon single bond or a carbon-carbon double bond;\n\n\nX\n*\n are chosen from halogen (F, Cl, Br), X\n1\n are chosen from hydrogen or halogen (F, Cl. Br), and R' are -SO\n2\nR;\n\n\nR are each independently chosen from -Cl, -OH, -aminoacid, -OR\n11\n. -NHR\" and -NR\n2\n\" where R\" are alkyl of 1 to 12 carbon atoms,\n\n\nwherein the chlorin or bacteriochlorin derivative is effective in a photodynamic therapy treatment for ameliorating the symptoms of a hyperproliferative disorder; and\n\n\n(b) a surface penetration enhancer.\n\n\nIn a further aspect the present invention provides the use of a chlorin or a bacteriochlorin derivative, or a pharmaceutically acceptable composition derivative thereof, in the detection of hyperproliferative tissue; wherein the chlorin or bacteriochlorin derivative has the formula: \n\n\n\n\n\n\n\n\n\n\nFoπnula (III)\n\n\nwherein:\n\n\n^^^^^ represents a carbon-carbon single bond or a carbon-carbon double bond;\n\n\nX\n2\n are chosen from halogen (F, Cl, Br). X\n1\n are chosen from hydrogen or halogen (F, Cl. Br), and R' are -SO\n2\nR;\n\n\nR are each independently chosen from -Cl, -OH. -aminoacid. -OR\". -NHR\" and -NR\n2\n\" where R\nn\n are alkyl of 1 to 12 carbon atoms,\n\n\nIn a further aspect of the present invention there is provided a method for detecting the presence of a hyperproliferative tissue in a subject comprising:\n\n\n(i) administering to the subject a diagnostically sufficient quantity of a chlorin or bacteriochlorin derivative having the formula\n\n\n\n\n\n\n\n\nFoπnula (III) \n\n wherein: represents a carbon-carbon single bond or a carbon-carbon double bond:\n\n\nX\n\"\n are chosen from halogen (F, Cl, Br), X\n1\n are chosen from hydrogen or halogen (F. Cl, Br). and R' are -SO\n2\nR; R are each independently chosen from -Cl, -OH, -aminoacid. -OR\", -NHR\" and -NR\n2\n\" where R\nn\n are alkyl of I to 12 carbon atoms,\n\n\nor a pharmaceutically acceptable composition derivative thereof that preferentially associates with the target,\n\n\n(ii) allowing sufficient time for the chlorin or bacteriochlorin derivative to associate with the target and for any chlorin or bacteriochlorin derivative that is not preferentially associated with the target tissue to clear from the non-target tissue, and\n\n\n(iii) visualizing the compound within the patient.\n\n\nThe step of visualizing may be accomplished by generating an MRI image of at least a part of the patient\n'\ns body.\n\n\nAlternatively, the step of visualizing may be accomplished by exposing the compound to light of sufficient energy to cause the compound to fluoresce.\n\n\nIn a further aspect of the present invention there is provided a pharmaceutically acceptable composition for use in the treatment of a skin cancer or of a skin disorder selected from actinic keratoses, squamous cell carcinoma. Bowen's disease, basal cell carcinoma, psoriasis, acne vulgaris and rosacea; wherein the composition comprises:\n\n\n(i) a chlorin or bacteriochlorin derivative with the foπnula: \n\n \n\n\n\n\n\nFormula (III)\n\n\nwherein:\n\n\nrepresents a carbon-carbon single bond or a carbon-carbon double bond;\n\n\nX\n\"\n are chosen from halogen (F, Cl. Br), X\n1\n are chosen from hydrogen or halogen (F. Cl. Br), and R' are -SO\n:\nR;\n\n\nR are each independently chosen from -Cl, -OH. -aminoacid, -OR\", -NHR\" and -NR\n2\n\" where R\nn\n are alkyl of 1 to 12 carbon atoms; and\n\n\n(ii) a pharmaceutically acceptable carrier for intradermal or transdeπnal delivery of such compound. wherein the carrier comprises a surface penetration enhancer that transiently permeabilizes the skin and facilitates the permeation of the compound through the various skin layers;\n\n\nwherein\n\n\n(a) the composition is administered to a subject;\n\n\n(b) sufficient time is allowed for the chlorin or bacteriochlorin derivative to preferentially locate near the target of the dermatological treatment: and (c) the target is irradiated to obtain the desired response of the skin cancer or of the skin disorder. \n\n Process for the preparation of the derivatives\n\n\nSuitably the hydrazine is p-toluenesulphonyl hydrazide, 4-chlorobenzenesulfonic hydrazide, 4,4\n*\n-oxybis(benzenesulfony]) hydrazide. benzenesulfonyl hydrazide. 4-methoxybenzenesulfonyl hydrazide or benzoic hydrazide.\n\n\nSolid-state reactions require the use of a temperature that is above the melting point of one of the reaetants. such that the other reactant or reactants are partially dissolved, or dispersed, in the melted one. For the solid-state reactions between hydrazides and phorphyrin derivatives the solid- state reaction is suitably carried out above the melting point of the hydrazide.\n\n\nSuitably the reduction step is carried out at a temperature of at least 70 \n0\nC. Suitably the reduction step is carried out at a temperature of at least 100 \n0\nC. In a further aspect, reduction step is carried out at a temperature of from 70 to 200 \"C. Suitably, the reduction step is carried out for at least 5 minutes.\n\n\nSuitably the reduction step is carried out under a vacuum or an inert atmosphere.\n\n\nPharmaceutical compositions\n\n\nSuitably the pharmaceutical composition comprises at least 0.01% by weight of the chlorin or bacteriochlorin derivative or a pharmaceutically acceptable salt thereof based on the overall weight of the composition. Suitably the pharmaceutical composition comprises from 0.01% to 30% by weight of the chlorin or bacteriochlorin derivative or a pharmaceutically acceptable salt thereof based on the overall weight of the composition. Suitably pharmaceutical composition comprises from 0.01 % to\n\n\n10% by weight of the chlorin or bacteriochlorin derivative or a pharmaceutically acceptable salt thereof based on the overall weight of the composition. Suitably pharmaceutical composition comprises from 0.1% to 1% by weight of the chlorin or bacieriochlorin or a pharmaceutically acceptable salt thereof derivative based on the overall weight of the composition.\n\n\nWhen a surface penetration enhancer is present in a pharmaceutical composition, suitably the composition comprises 0.05 to 10% by weight of the surface penetration enhancer based on the \n\n overall weight of the composition. Suitably the composition comprises 0.1 to 10% by weight of the surface penetration enhancer. Suitably such surface penetration enhancer may be selected from dimethylsulphoxide and other dialkylsulphoxides, N- Methylfoπnamide. dimethylformamide, dimethylaceiamide, glycols, various pyrrolidone derivatives and various 1 -substituted azacycloalkan- 2-ones.\n\n\nSuitable glycols may be selected from Polyethylene glycol. Polypropylene glycol 425, Trimethviene glycol and Propylene glycol monolauratc.\n\n\nSuitable pyrrolidone derivatives may be selected from N-Dodecyl pyrrolidine-3,5-dione, N-\n\n\nDodecyl pyrrolidinc-2-thione, N-Dodecyl-2-pyrrolidone, N- (2, Hydroxyethyl)-2-pyrrolidone. N- Cyclohexyl-2-pyrrolidone. l -Buiyl-3-dodecyI-2-pyrrolidone, 1 , 5 Dimethyl-2-pyrrolidone. l-Ethyl-2- pyrrolidone. l -Hexyl-4-methyloxycarbonyl-2 -pyrrolidone, 1- Hexyl-2-pyrrolidone. 1- (2 Hydroxyethyl) pyrrol id i none, 3-Hydroxy-N-methyl-2- pyrrolidinone. l-Lauryl-4- methyloxycarbonyl-2-pyrrolidone and N-Methyl-2-pyrrolidone.\n\n\nSuitable 1 -substituted azacycloalkan-2-ones including l-dodecylazacycloheptan-2-one referred to hereinafter as Azone® are disclosed in U.S. Pat. Nos. 4.562.075, 4,405,616, 4,326,893 and 3,989.816.\n\n\nDetection of hyperproliferative tissue\n\n\nWhen chlorin and bacteriochlorin derivatives or pharmaceutically acceptable salts thereof are used in the detection of hyperproliferative tissue, suitably the hyperproliferative tissue may be selected from a vascular endothelial tissue, a neovasculature tissue, a neovasculature tissue present in the eye, an abnormal vascular wall of a tumor, a solid tumor, a tumor of a head, a tumor of a neck, a tumor of an eye. a tumor of a gastrointestinal tract, a tumor of a liver, a tumor of a breast, a tumor of a prostate, a tumor of a lung, a nonsolid tumor, malignant cells of one of a hematopoietic tissue and a lymphoid tissue, lesions in the vascular system, a diseased bone marrow, and diseased cells in which the disease is one of an autoimmune and an inflammatory disease.\n\n\nTreatment of hyperproliferative disorders \n\n In a further aspect, the present invention provides the use of a chlorin or bacteriochlorin derivative as described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of hyperproliferative disorders.\n\n\nWhen chlorin or bacteriochlorin derivative or a pharmaceutically acceptable salts thereof are used in the treatment of hyperproliferative disorders, suitably the hyperproliferative disorder is selected from cancers or carcinomas, myelomas, psoriasis, macular degeneration. Suitable examples are gastric cancer, enteric cancer, lung cancer, breast cancer, uterine cancer, esophageal cancer. ovarian cancer, pancreatic cancer, pharyngeal cancer, sarcomas, hepatic cancer, cancer of the urinary bladder, cancer of the upper jaw, cancer of the bile duct, head and neck cancer, cancer of the tongue, cerebral tumor, skin cancer, malignant goiter, prostatic cancer, colorectal cancer, cancer of the parotid gland, Hodgkin's disease, multiple myeloma, renal cancer, leukemia, and malignant lymphocytoma.\n\n\nSuch treatments suitably include irradiating the chlorin or bacteriochlorin derivative or pharmaceutically acceptable composition derivative thereof with light of a wavelength matching the absorption bands of the chlorine or bacteriochlorin derivative. Suitably the light has a wavelength of from 600 to 800 nm. Suitably when chlorins are used the light has a wavelength of from 630 to 690 nm. Suitably when bacteriochlorins are used the light has a wavelength of from 720 to 780 nm.\n\n\nSuitably the light dose is from 1 to 250 J/cm\n2\n. In some aspects, suitably the light dose is less than 50 J/cm\n*\n, less than 20 J/cm\n2\n, less than 10 J/cm\n2\n.\n\n\nSuitably the dosage of the chlorin or bacteriochlorin derivatives or pharmaceutically acceptable salts thereof is from 0.01 mg to 200 mg per kilogram of body weight per day. Suitably a dosage of from 0.01 mg to 100 mg per kilogram of body weight per day.\n\n\nThe present invention was made in view of the prior art described above. The synthesis described in WO 2006/053707 (PCT/EP2005/012212) comprised just three almost quantitative steps:\n\n\n(i) functionalization of halogenated tetrakisphenylporphyrins via chlorosulfonation of phenyl ring;\n\n\n(ii) synthesis of amphyphilic compounds via reaction of the chlorosulfonic group with nucleophilcs. \n\n water, namely amines or alcohols; iii) reduction of the letrapyrrolic macrocycle with hydrazide derivatives in the presence of inorganic or organic non-nucleophilic bases. However, as illustrated in Figure 2 of patent WO 2006<\n;\n053707, the synthesis of halogenated sulfonated bacteriochlorins by this method is associated with the contamination by the analogous chlorin, and the purification requires a laborious separation. The object of the present invention is to provide an economical, environmentally-friendly. large-scale synthesis of pure, stable and functionalized tetrakisphenylchlorins and tetrakisphenylbacteriochlorins bearing electron-withdrawing groups in the ortho positions of the phenyl rings. It is also an object of the present invention to provide chemical and therapeutic properties of said chlorins and bacteriochlorins. methods of therapy and pharmaceutical compositions with these molecules and evidence of their effectiveness in PDT.\n\n\nHalogenated sulfonated bacteriochlorins have distinct features that make them preferred photosensitizers for PDT:\n\n\n1 ) The presence of halogen atoms in the ortho positions of the phenyl groups performs three functions. First, they produce a controlled \"heavy atom effect\", increasing the yield of the sensitizer triplet state without compromising the triplet lifetime and its ability to transfer the electronic energy efficiently to molecular oxygen [29]. Second, they stabilize the reduced state of tetrapyrrolic macrocycles, both by electronic and steric effects. Third, they accelerate the rate constant of energy transfer to molecular oxygen through charge transfer interactions, leading to large yields of singlet oxygen, superoxide and other reactive oxygen species. 2) The presence of the sulfonic acid group in the meta positions of the phenyl groups performs two functions. First, it provides a handle to tailor the hydrophilicity/lipophilicity of the sensitizers, because very hydrophobic sensitizers seem to be less pholotoxic. probably due to the low solubility and low ability to relocate from the plasma membrane into other intracellular compartments, whereas very hydrophilic dyes may predominantly localize in the tumor stroma and have reduced PDT efficacy [30]. Second, the sulfonic group, especially with bulky or long subslituents attached to it, provides an additional steric protection against the oxidation of the bacteriochlorin core of the dyes.\n\n\n3) The simultaneous presence of halogen atoms in the ortho positions and sulfonic acid group in the rncla positions of the phenyl groups performs an additional function. Molecular modeling and experimental data show that when there is a restricted rotation of the single bond at the meso-position on 5.10, 15.20-tetraphenylporphyrins with unsymmetrical phenyl rings, geometric isomers (known as atropisomers) result from the different position of the ortho and/or meta substituents relative to the porphyrin plane [31 ]. The atropisomers have significantly different polarities and the absorption \n\n coefficients of the longest wavelength absorption band that may differ by nearly one order of magnitude. In particular, the 0:\n4\n isomer, with the four sulfamoyl substituents at the same side of the porphyrin plane, has the highest absorption coefficient and is the most amphiphilic of the atropisomers. The widespread use of sulfonated chlorins and bacteriochlorins in PDT requires an economical and environmentally-friendly synthesis that can be performed on a industrial scale. It is a central object of the present invention to provide a new method for the preparation of such compounds based only on the precursor porphyrin and a hydrazide, where the latter is added in the solid state, heated above the melting temperature in a sealed reactor, in the absence of oxygen and base, and the desired product is obtained after some time.\n\n\nIt is also an object of the present invention to provide methods for PDT using topical administration of a said sulfonated chlorin or bacteriochlorin with a suitable vehicle. Vehicles for the topical administration of photosensitizers may take different forms, including liquid solutions, gels, creams, emulsions, ointments, etc. Typically, the formulation of such vehicles includes at least one surface penetration enhancer. Against the conventional wisdom in this field that drugs with molecular weights in excess of 500 Dalton do not peπneate well through the skin [32], we provide formulations for the efficient intradermal delivery of said sulfonated chlorins or bacteriochlorins to skin disorders, where the said molecules attain molecular weights slightly in excess of 1 kD.\n\n\nThis invention relates to compounds for treatment and detection of hyperproliferative tissues such as tumors, using photodynamic methods. The compounds of the present invention are also useful for the treatment of dermatological disorders such as psoriasis, acne vulgaris and rosacea; gynecological disorders such as dysfunctional uterine bleeding; urological disorders such as condyloma virus: cardiovascular disorders such as restenosis and atherosclerotic plaques; photodynamic destruction of bacteria or viruses: hair removal and cosmetics; inhibition of immune responses following the transplant of organs or tissues.\n\n\nFinally, it is a further object of the invention to provide methods for the diagnosis of hyperproliferalive tissues using halogenated sulfonated chlorins or bacteriochlorins. Provided that these compounds preferentially accumulate in such tissues, the additional property required for diagnostic purposes is the unambiguous detection of very minute quantities of such compounds. These compounds have very distinct absorption bands in the red and infrared, where the tissues are most transparent. The selective excitation of these compounds leads to distinct fluorescence at wavelengths where biological molecules do not emit. The detection of fluorescence can be made with \n\n very sensitive equipment and sub-nanomolar quantities of halogenated sulfonated chlorins or bacteriochiorins can be measured in biological media. The source of irradiation for photodiagnosis and phototherapy is not restricted, but a laser beam is preferable because intensive light rays in a desired wavelength range can be selectively applied. It is necessary that the light rays have sufficient intensity to cause the compounds to emit fluorescence for diagnosis and to exert a cell killing effect for therapy. Additionally, when fluorinated sulfonated chlorins or bacteriochiorins are employed. fluorine-MRI (Magnetic Resonance Imaging) can detect the accumulation of these compounds in small regions of the body and follow the metabolites formed in its clearance form the body.\n\n\nII. DETAILED DESCRIPTION II. A. Definitions\n\n\nAs used herein, \"hyperproliferative disorders'\n\"\n means those condition disorders sharing as underlying pathology excessive cell proliferation caused by unregulated or abnormal cell growth, and include uncontrolled angiogenesis. Examples of hyperproliferative disorders includes, but is not limited to. cancers or carcinomas, myelomas, psoriasis, macular degeneration.\n\n\n\"Hyperproliferative tissue\" as used herein means tissue that grows out of control and includes tumors and unbridled vessel growth such as blood vessel growth found in age-related macular degeneration.\n\n\nAs use herein, \"tumor'\n\"\n denotes a neoplasm, and included both benign and malignant tumors. This term particularly includes malignant tumors that can be either solid or non-solid (such as leukemia). Examples of tumors are gastric cancer, enteric cancer, lung cancer, breast cancer, uterine cancer, esophageal cancer, ovarian cancer, pancreatic cancer, pharyngeal cancer, sarcomas, hepatic cancer, cancer of the urinary bladder, cancer of the upper jaw. cancer of the bile duct, head and neck cancer, cancer of the tongue, cerebral tumor, skin cancer, malignant goiter, prostatic cancer, colorectal cancer, cancer of the parotid gland, Hodgkin's disease, multiple myeloma, renal cancer, leukemia, and malignant lymphocytoma.\n\n\nAs use herein, \"'infecting agent\n\"\n denotes invading microbes or parasites. As used herein, \"microbe\" denotes virus, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganisms, and \"parasite\n\"\n denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms thereof, which arc susceptible to antibody-induced clearance or lytic or phagocytic destruction. \n\n As used herein, a \"pharmaceutical agent\" or \"drug\" refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylatic effect when properly administered to a subject. It includes, but is not limited to photosensitizers that absorb light and use it either to act as a drug or to activate other chemical compounds that subsequently act as drugs. As used herein, a 'pharmaceutically acceptable composition derivative' refers to compositions where the photosensitizers are bonded to biologically active groups, that is, any group that selectively promotes the binding, accumulation, or elimination in a particular biological environment. Examples known in the art include substituents derived from sugars, aminoacid derivatives, oligonucleotides, or ligands specific for receptors (steroid hoπnones. growth factors, neurotransmitters or antibodies). It also includes the salts of the photosensitizers.\n\n\nAs used herein, a \"pharmaceutically acceptable carrier\" includes any and all solvents, dispersion media, excipients to formulate tablets, pills, capsules, creams, solutions, suspensions or emulsions. It is well known in the art how to foπnulate these phaπnaceutical compositions.\n\n\nAs used herein, a '\"surface penetration enhancer\" refers to a chemical compound or composition capable of increasing or accelerating the transport of the drug across a barrier, such as the skin and other tissues, and including dimethylsulphoxide and other dialkylsulphoxides, dimethylformamide, dimethylacetamide, glycols, various pyrrolidone derivatives, Azone®, or any other of the skin- permeation assisting agents described in the literature, or mixtures thereof.\n\n\nAs used herein, \"irradiation'\n\"\n means exposing a subject to all the frequencies of the electromagnetic spectrum. Preferably, the irradiation wavelength is selected to match the wavelength(s) where the drug absorbs light.\n\n\nAs used herein. \"Luzitin'\n\"\n refers to any sulfonated tetrakisphenylchlorin or tetrakisphenylbacteriochlorin bearing electron-withdrawing groups in the ortho positions of the phenyl groups, and the following acronyms refer to specific chemical compounds that are non- limiting examples of this portfolio of molecules:\n\n\n- Luzitin-Cl-c is 5.10,15.20-tetrakis(2-chloro-5-sulfonylphenyl)chlorin,\n\n\n- Luzitin-FMet-c is 5, 10,15,20-tetrakis(2-fluoro-5-N-methylsulfamoylphenyl)chlorin, Luzitin-F is 5, 10.15,20-tetrakis(2-fluoro-5-sulfonylphenyl)bacteriochlorin,\n\n\n- Luzitin-Cl is 5, 10, 15,20-tetrakis(2-chloro-5-sulfonylphenyl)bacteriochlorin, - Luzitin-Cl; is 5, 10, 15.20-tetrakis(2,6-dichloro-3-sulfonylphenyl)bacteriochlorin.\n\n\nLuzitin-FMet is 5.10, 15.20-tetrakis(2-fluoro-5-N-methylsulfamoylphenyl)bacteriochlorin.\n\n\n- Luzitin-F^Met is 5.10, 15.20-tetrakis(2.6-fluoro-3-N-methylsulfamoylphenyl)bacteriochlorin. \n\n - Luzitin-CKEt is 5, 10, 15.20-letrakis(2,6-dichloro-3-N-ethylsu]famoylphenyl)bactcriochlorin,\n\n\n- Luzitin-CMlep is 5, 1 ϋ.15.20-tetrakis(2,6-dichbro-3-N-hcptylsulfamoylphenyl)bacteriochlorin.\n\n\n- Luzitin-FMet\n2\n is 5.10, 15.20-tetrakis(2-fluoro-5-N,N-dimethysulfamoylphenyl)bacteriochlorin,\n\n\nAlso used herein, are the acronyms - Cl\n2\nPhB which is 5, 10, 15,2ϋ-tetrakis(2.6-dichlorophenyl)bacteriochlorin\n\n\n- BMPO which is 5-tert-butoxyGarbonyl-5-methyl-l-pyrroline-N-oxide\n\n\n- DMPO which is 5-dimethyl-l-pyrroline-N-oxide\n\n\n- DMSO which is dimethylsulibxide\n\n\nII. B. Precursor compounds\n\n\n5, 10, 15.20-tetrakis(halogenated-phenyl)porphyrins and 5.10, 15,20-tetrakis(2- cyanophenyOporphyrins. 5,10, 15,20-tetrakis(2-triπuoromethylphenyl)poφhyrins , 5,10,15.20- tetrakis(2-nitrophenyl)porphyrins and 5.10.15,20-tctrakis(2-carboxymethylphenyl)poφhyrins were synthesized by the nitrobenzene method [33], mixing the pyrrol with the desired halogenated phenyl aldehydes in a mixture of acetic acid/ nitrobenzene at 120 \n0\nC. After cooling the pure porphyrin crystallizes directly from the reaction medium. All the characterization data (TMMR, FAB, and microanalysis) arc in good agreement with previously described porphyrins.\n\n\nChlorosulfonation of the said porphyrins was carried out according to a method developed previously [34.35], The required porphyrin (200 mg) and chlorosulfonic acid (10 niL, 150 mmol) were stirred at temperatures between 50 and 250 \n0\nC for 1 to 3h. After this period, dichloromethane (200 mJL) was added to the solution. A continuous water extraction was carried out. with stirring, until neutralization. The dichloromethane solution was then washed with sodium hydrogen carbonate and dried over anhydrous Na\n2\nSO\n4\n. Purification by column chromatography in silica gel using dieloromcthane as eluent. and subsequent solvent evaporation, yielded the desired chlorosulfonated porphyrins as purple crystals.\n\n\nHydrolysis of the above chlorosulfonated porphyrins was conducted suspending 100 mg of the desired compound in distilled water (120 mJL) and refluxing for 12h. The resulting solutions were concentrated by rotary evaporation and the solid obtained was dried at 120 \n0\nC. The sulfonic acid porphyrin derivatives were obtained with quantitative yields. Their characterization by NMR. FAB and microanalysis, is good agreement with literature data [34,35]. \n\n II. C. Instruments\n\n\nAbsorption spectra were recorded on a Shimadzu UV-2100 spectrophotometer or with a Carry 50 Biospectrophotometer (Varian, MuI grave, USA). Fluorescence spectra were measured with a Spex Fluorolog 3 spectrophotometer, with correction for the wavelength dependence system (RCA C31034 photomultiplier), or with a PerkinElmer LS 50 spectrofluorimeter. Transient absorption spectra were measured with an Applied Photophysics LKS 60 nanosecond laser flash photolysis kinetic spectrometer, using the third harmonic of a Spectra-Physics Quanta Ray GCR 130-01 Nd/YAG laser for excitation, a Hamamatsu 1P28 photomultiplier and a Hewlett-Packard Infinium oscilloscope ( 1 GS's). Flash photolysis measurements were made in the presence of air and in argon saturated solutions. Photoacoustic calorimetry employed the same Nd YAG laser, a home-made front-face photoacoustic cell with a 2.25 MHz Panametrics transducer (model 5676) and a Tektronix DSA 601 transient recorder [36]. Room-temperature singlet-oxygen phosphorescence was measured at 1270 nm with a Hamamatsu R5509-42 photomultiplier, cooled to 193 K in a liquid nitrogen chamber (Products for Research model PC176TSCE005), following laser excitation of aerated solutions at 355 nm. using an adapted Applied Photophysics spectrometer [37], Singlet oxygen emission at 1270 nm was also monitored with a liquid nitrogen-cooled germanium detector (North Coast) coupled to a Tectronix Digitizing scope (TDS 520B), following sample excitation with 5 ns laser pulses of the third harmonic (355 nm) generated by a Q-switched Nd: YAG laser (Continuum Surelite II). Elemental analyses were carried out on a Fisons Instruments EA 1108 CHNS-O elemental analyser. Melting points were measured on a Electrothermal capillar)' melting point apparatus. \n1\nH- NMR and \n19\nF-NMR and \n13\nC-NMR spectra were recorded on a 300 MHz Bmckcr-Amx. \n1\nH assignments were made using 2D COSY and NOESY experiments, while \n13\nC assignments were made using 2D HSQC and HMBC experiments. MALDI-TOFMS data were acquired using an Applied Biυsyslems Voyager DE-STR instrument (Framingham, MA, U.S.A.). which is equipped with a nitrogen laser (λ = 337 nm).\n\n\nElectron paramagnetic resonance (EPR) spectra of species with at least one unpaired electron were carried out using a Bruker ESP 300 spectrometer (IBM Instruments Inc.). Typical instrument setting were: microwave power 10 mW, modulation amplitude 0.8 G. sweep width, 60.0 G. The EPR spectra were recorded under in situ irradiation with a Hamamatsu diode laser. The following settings were employed to register the spectra: high power (4 mW). low modulation amplitude (0.2 G) and narrow scan range (60 G). and 20 scans were recorded for each spectrum. \n\n Irradiation in in vitro experiments was performed using either a halogen lamp or a laser source. In the first case, a 500 W halogen lamp was placed 50 cm from the irradiated plate to insure a homogeneous irradiation. A cooled water filter (d = 35 mm) and a 600 nm cut off filter were placed between the lamp and samples. The fluence rate reaching samples was 3 mW/cm\n2\n. The emission spectrum of the halogen lamp was recorded using a spectroradiometer IL2000 (Spectrocube), Figure 1. In the second case, three Lynx external cavity diode lasers TEC 500 powered by PilotPC 500 Laser Controllers (Sacher Lasertechnik, Marburg. Germany) were employed. The laser energies were stable at 40 mW for the 748 nm laser. 10 mW for the 649 laser and 10 mW for the 633 laser. The laser energies were regularly measured with a Coherent LaserCheck. In some in vitro experiments, the laser light was focused on an optical fiber through a collimator in microbench, and delivered to the cells. This system reduced the 748 nm laser light to 30 mW.\n\n\nThe irradiation of bacteriochlorins in the photobleaching experiments employed the 748 nm Lynx diode laser. For animal studies we employed a costumer-made Hamamatsu diode laser, type LAO873. S\n7\nN M070301. which delivered 140 mW at 748 nm. This diode laser was controlled by a ThorLabs 500 mA ACC/APC Laser Diode Controller and in-house electronics. The laser energies of this and the other higher-energy lasers employed in this work were regularly checked with an Ophir model AN/2E laser power meter.\n\n\nThe time-dependent cellular uptake of the photosensitizers and the viability of the cells were confirmed by fluorescence microscopy using a Nikon ECLIPSE TS-100F instrument. The fluorescence skin samples was analyzed with an Olympus Fluorescence Microscopy, model BX51 M, using a U-MSWG2 fluorescence mirror unit (excitation filter 480-550, emission filter 590, dichromatic filter 570 nm). Confocal microscopy was performed with a Leica TCS SP5 (Leica Mycrosystems CMS GmbH, Mannheim. Geπnany) inverted microscope (DMI6000) with a\n\n\n63\n'\n water ( 1.2 numerical aperture) apochromatic objective. Before turning to the confocal mode, the GUV suspension was directly observed using a sodium lamp as the light source, and a filter to select Rhod-DOPE fluorescence to evaluate yield of GUV formation. The excitation source in confocal fluorescence microscopy was either the 514 nm line from a Ar\n*\n laser, or the 745 nm line of a Ti:Sa laser. The emission was collected from 550 to 800 nm. taking advantage of the acoustic-optical tunable fiber and beam splitter of the Leica TCS SPC5 system. Stray light is minimized, in agreement with a \"smart offset\" that remained always below 0.5 % (usually between -0.1% and 0.1%), and negligible photon counts outside the lipid structures. Confocal sections of thickness below 0.5 mm \n\n were obtained using the gaivanometric motor stage. The 3D projections were obtained using the Leica Application Suite - Advanced Fluorescence software.\n\n\nII. D. Methods ILD. I . Partition coefficients\n\n\nThe «-octanol: water partition coefficients (CP) were measured using a minor modification of the shake-flask method described by some of us in the literature [35]. The modification concerned the excitation of the absorption band ca 500 nm and the collection of the fluorescence in the red/lR region.\n\n\n//. D, 2. Photochemistry and photophysics\n\n\nPhotobleaching experiments were conducted in PBS. PBS.methanol (50:50) and methanol solutions. The solutions were irradiated in a cuvette with an optical path of 1 cm and the Lynx diode laser. The initial absorption of the solutions was ca. 0.8. The mechanism of photobleaching was assessed with the irradiation of the sensitizer using the Hamamatsu diode laser at 80 mW. The sensitizer was irradiated in PBS and in the presence of ascorbic acid or azide.\n\n\nFluorescence quantum yields (Φ|.-) where determined in ethanol taking as reference the fluorescence quantum yield of Cl\n2\nPhB in toluene [4]. The absorptions of both reference and sample solutions were matched at ca 0.2 at the excitation wavelength of 515.5 nm, and the solutions were diluted by a factor 10 before collecting the fluorescence. The fluorescence quantum yield was obtained from the ratio of the fluorescence bands of the sample vs the reference, multiplied by the fluorescence quantum yield of the reference, 0.012 according to [12J, after correction for the difference of refractive indexes of ethanol and toluene.\n\n\nThe triplet-triplet absorption spectra and the triplet lifetimes of the photosensitisers (τγ) were measured with the transient absorption spectra equipment described above, with excitation at 355 nm, where the solutions had absorbances between 0.25 and 0.30.\n\n\nTime-resolved photoacoustic calorimetry (PAC) was made with the set-up described above using a procedure described by some of us [4]. All the measurements were made in ethanol using Manganese 5.10, 15.20-tetraphenylporphyrin as photoacoustic reference. Singlet oxygen quantum yields in ethanol were obtained using a procedure described by some of us [37], using phcnalenone as reference. The literature value for the singlet oxygen quantum yield obtained with phenalenone in ethanol is Φ\nΔ\n=0.95 [38]. \n\n II. D.3. Electronic Paramagnetic Resonance ( EPR)\n\n\nReactive oxygen species produced by irradiation of photosensitizers in PBS. namely the superoxide ion and the hydroxyl radical, form adducts with various spin traps. Such adducts can be identified by EPR. The PBS buffer employed in these measurements was previously treated with chelating resin, Chelex 100, in order to remove any contaminating metal ions that may catalyze decomposition of peroxides. Two spin traps were employed: BMPO and DMPO. DMPO was first purified with activated charcoal/benzene, and then a 1.0 M stock concentration was deteπnined spectrophotometrically using \n\n\n M\n\"1\n cm\n\" 1\n. EPR measurements were performed at room temperature using the Bruker spectrometer described above, with in situ irradiation with the\n\n\nHamamatsu diode laser.\n\n\n11. D.4. Skin permeation tests\n\n\nThe best animal model to test skin permeation is the minipig, in view of the similarities between minipig and human skin characteristics [39]. Different formulations of creams, ointments, gels and liquid solutions were employed to enhance the permeation of the photosensitizer through skin samples of minipigs. The formulations incorporated the photosensitizers in quantities varying from 0.1 to 10%, permeation enhancers such as Azone® and DMSO. and various excipients. Ex vivo tests employed skin excised from the back of the minipigs. In vivo tests were made on the back of minipigs. In each test the formulation was applied in area ca. 1 cm\" of skin for the desired amount of time, under occlusive dressing. Once that time had elapsed, the formulation was removed with a spatula and washed with medical cotton embedded in ethanol, until no traces of the sensitizer could be seen in the medical cotton. In the in vivo tests, the skin samples were surgically removed and the animals were then sacrificed. The first step of the procedure for tissue fixation of the skin samples was immersion in paraformaldehyde (4% in aqueous solution) for at least 24 h. Next, the samples were transferred to a 25% sucrose solution for at least 48 h. Following this treatment, the skin samples become denser than the sucrose solution. An aliquot was extracted with a biopsy punch, frozen in dry ice and then mounted in holder with Tissue-Tek O. C. T. Compound (Sakura Finetek Europe B. V., Zoeterwoude. The Netherlands) and cut in slices with controlled thicknesses selected between 25 and 100 mm in a cryostate. The skin slices were collected in microscope slides and kept refrigerated until they were analyzed by fluorescence microscopy and confocal microscopy. Alternatively, rather than using \n\n paraformaldehyde as a fixative, the skin samples were directly frozen in dry ice.\n\n\nH.D.5. In vitro experiments\n\n\nThe drugs described herein have been evaluated in in vitro studies. One set of in vitro studies employed irradiation with a halogen lamp equipped with several filters. The other set employed diode laser irradiation to deliver the light to each cell culture.\n\n\nII.D.5.J) In vitro experiments with halogen lamp irradiation\n\n\nThe cell lines employed in halogen lamp irradiation were the MCF7 (human breast carcinoma). SKMEL 188 (human melanoma) and S91/13 (mouse melanoma) cells. They were used both for cytotoxicity and photocytotoxicity experiments. MCF7 cells were grown supplemented with 10% fetal calf (FBS) serum, 25 units/ml of penicillin, and 25 μg/ml of streptomycin. Human melanoma cells SKMEL-188 were grown in FlO medium supplemented with 10 % fetal calf serum (FCS). 100 units/ml of penicillin, and 100 μg/ml of streptomycin. 13 subline of Cloudman S91 melanoma cells were cultured in RPMl 1640 medium supplemented with 100 units/ml of penicillin, 100 μg ml streptomycin and 5% fetal calf serum (FCS) (Gibco BRL). All cell lines were cultivated as monolayer in Petri dishes of 60 mm diameter and incubated at 37 \n0\nC in a humid atmosphere containing 5% CCK\n\n\nCytotoxicity. Cell metabolic efficiency and viability were deteπnined by the uptake and reduction of 3-(4,5-dimethylthiazol-2-yI)-2,5-diphenyl tetrazolium bromide (MTT) to an insoluble formazan dye by cellular microsomal enzymes. The cell lines were grown in RPMI medium with 10% fetal calf serum, penicillin and streptomycin. Cells were maintained in 5% CO\n2\n, 95% air and 100% humidity. For determining cytotoxicity, these cells were plated in 96-well plates at a density of I x I O\n4\n cells well in complete media. After 24 h, the cells were incubated with photoscnsitizers at different concentrations (0.25 up to 50 μM) for 18 hours at 37 \n0\nC. The cells were then washed twice with PBS and incubated in growth medium at 37°C for 24 h. Next, the medium was replaced by 100 μl of fresh medium and 20 μl of MTT, and the cells were incubated with MTT for 3 h, with a final concentration of 0.5 mg/ml. Then the culture medium was replaced with DMSO-meihanol solution ( 1 : 1 ) to dissolve the blue formazan crystals. The 96-well culture plate was shaken for 0.5 min at room temperature and immediately read for optical density at 560 nm using an ELISA reader (GEN ios Plus: Tecan Trading AG, Switzerland). The cell survival was expressed by the absorbance changes of the formazan salt, and survival rate was given as the percent ratio of viable treated cells \n\n vs. the number of viable untreated cells. Number of cells was determined from linear regression of a calibration curve.\n\n\nTime-Dependent Cellular Uptake. SKMEL 188, S91 and MCF7 cells were seeded on 96- well plates at 1 x10 cells per well and exposed to 20 μM concentrations of chlorins and bacteriochlorins photosensitizers in PBS for various time intervals, from 10 min up to 180 min to probe time- dependent drug accumulation. At the end of the incubation interval, the cells were washed three times with PBS and re-suspended in 100 μL of 0.25% Triton X-100 in PBS. The retention of cell- associated photosensitizers was detected by fluorescence measurement of the accumulated photosensitizers using an ELlSA reader. In addition, the uptake of photosensitizer and the viability of the cells were confirmed by fluorescence microscopy. In these experiments. SKMEL 188. S91 and MCF7 cells were incubated for 2 hours with 20 μM of photosensitizer. followed by washing the cells three times with PBS, re-suspension in PBS and examination by fluorescence microscopy.\n\n\nCell photυscnsitization. SKMEL 188, S91 and MCF7 cells were prepared as described above. On the basis of cytotoxicity assays, a 5 μM concentration of photosensitizer was selected for the photosensitization assays. The cells were incubated for 12 h at 37\n0\nC and then irradiated at a 0.53 mW cm\" fluence rate and in doses ranging from 0.1 to 0.64 J cm\". We recall that photosensitizer uses only ca. 1/5 of the available fluence rate of the filtered halogen lamp. The MTT test was performed 24 h after irradiation. The values were obtained from three independent experiments and expressed as percent of cell survival with reference to control cells, which were manipulated in the same manner but without incubation with photosensitizer and without illumination.\n\n\nU.D.S.ii) In vitro experiments with laser irradiation\n\n\nThe cell lines employed in laser irradiation were the HT-29 (human colon carcinoma). PC-3 (human prostate carcinoma), SW2 (human small cell lung cancer), A-549 (human non-small cell lung cancer). S91/I3 (mouse melanoma) and CT26 (mouse colon carcinoma). They were used both for cytotoxicity and photocytotoxicity experiments. PC-3, SW2 and S91/I3 cells were cultured in RPMI- 1640 medium (Sigma- Aldrich, Steinheim, Germany) and HT-29, A-549 and CT26 cells were cultured in Dulbecco\n\"\ns Modified Eagle Medium (DMEM) (Cambrex Bioscience. Verviers. Belgium). Both cell culture mediums were supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) (Cambrex Bioscience, Verviers. Belgium) and 100 IU/ml penicillin- 100 μg'ml streptomycin (Cambrex Bioscience. Verv iers, Belgium). The DMEM medium used for CT26 cells was also supplemented with HEPES 10 niM. Cell lines were maintained in 75 cm\n2\n flasks (Orange Scientific. \n\n Brainc-l'Alleud, Belgium) at 37 \n0\nC in humidified atmosphere with 5% CO;. For the in vitro studies, cells at 85-90% confluence, were detached with Trypsin-Versene-EDTA solution (Cambrex Bioscience. Verviers, Belgium), counted and seeded in flat-bottom 96-well plates at the desired densities. Cell viability assay. In the end of the experiences cell viability was evaluated by the resazurin reduction assay [40], Briefly, resazurin (Sigma-Aldrich. Steinhelm, Germany) stock solution (0.1 mg/ml in phosphate buffer saline (PBS) pH 7.4) was diluted 10% in culture medium without FBS or antibiotics and 200 μl were added to the cells in each well. Plates were incubated for 3-4h at 37°C. The absorbance values of each well were measured at 540 nm and 630 nm using a microplate reader Multiskan Ex (Thermo - Electron Corporation. Vartaa, Finland).\n\n\nCytotoxicity. Cells were seeded in flat-bottom 96-well plates (Orange Scientific. Braine- l'Alleud. Belgium) in 100 μl of culture medium and were allowed to adhere overnight. The photosensitizer was added to the cells (diluted in 100 μl culture medium) at final concentrations between 0.01 and 1 mM. Each concentration was tested in quadruplicate. The incubation periods in the dark at 37 \n0\nC were two times the doubling time for the tested cell line. After the incubation the cell viability was evaluated. In parallel control experiments, cells were incubated without the drug. Cytotoxicity was quantified by expressing cell death relatively to untreated cells (% of control cells). The results were plotted as dose response curves (% of cell death as a function of the concentration of the DRUG), which allow the determination of the concentration that inhibit 50% of cell growth\n\n\nCell photosensUi∑atioti. Cells were seeded in DB Falcon black 96-well plates with clear flat- bottom (DB Biosciences - Labware. NJ, USA) in 100 μl of culture medium and were allowed to adhere overnight. The drug was added to the cells (diluted in 100 μl culture medium) in order to obtain the desired concentration. Cells were incubated with the drug in the dark at 37 \n0\nC for a given period of time. This period of incubation is usually referred as drug-to-light interval. After incubation cells were washed once with 200 μl of PBS to remove the non-internalized drug and 100 μl of fresh culture medium was added. Cells were irradiated (each well individually) with the 748 nm light of the Lynx diode laser described above, at a power of 100.7 mW/cm\n2\n. The irradiation time was chosen in order to obtain the desired light dose. Two parallel control conditions were tested: cells were incubated in the dark with the highest dose of drug and were not irradiated, and cells were irradiated with the highest light dose without drug. After the irradiation 100 μl of fresh culture medium was added. Cell viability was evaluated approximately 24 h after the irradiation. \n\n ILD.6. In vivo experiments\n\n\nThe mice used in the present study were form two sources. Dark toxicity, biodistribution and farmacokinetic studies employed DBA '2 mice, weighing 20-30 g. from the animal breeding facility at the Faculty of Biochemistry. Biophysics and Biotechnology, Jagiellonian University. Krakow. The mice were kept on a standard laboratory diet with free access to drinking water. The use of such animals for experimental purposes was approved by the Jagiellonian University Committee for Ethics of Experiments on Animals (decision No. 384\n;\n99). Such mice were also employed in PDT.\n\n\nThe other mice were Balb/C weighing 20-25 g, from the animal breeding facility of Charles River Laboratories (Barcelona). The mice were kept on a standard laboratory diet with free access to drinking water. The use of such animals for experimental purposes was approved by the Board of Centro de Neurociencias e Biologia Celular (Coimbra).\n\n\nThe four minipigs used in the present study were obtained from IMIDRA (Instituto Madrilefio de Investigaciόn y Desarrollo Rural. Agrario y Alimentario) - Aranjuez (Madrid). They were all females, aged 6-8 months, white with brown spots, average weight 56.8 kg (66.2. 57.1. 43.5. 60.6 kg). They were received at Estacao Zootecnica Nacional, Vale de Santarem, where they were accommodated in individual boxes with 1.5 m\n~\n, feed with a standard diet for pigs and water ad libidum, for an acclimation period of three weeks. The study was performed in accordance to the Portuguese ethical guidelines on a license granted by Direccao de Serviςos de Saύde e Proteccao Animal, ref. 0420/000/000/2007. Access to food was suspended 24h hours before treatment. The backs of the animals were shaved 24 h prior to the application of the formulations. The topical administration of photosensitizers was done under anesthesia. The pre-medication employed 30 min in advance was: Azaperone (Stresnil® - Veterinaria ESTEVE - Spain), 2 mg/kg intramuscular injection + atropine sulphate, 50 mg SC. The induction was done with ketamine (Clorketam® - Vetoquinol. France), 20 mg^cg, intramuscular injection. The anesthesia was maintained with endotracheal intubation, using spontaneous ventilation with 2-3 1/min of oxygen \n+\n 3% isoflurane (Isoflo® - Veterinaria ESTEVE. Spain). The samples were collected from 3 minipigs under the anesthesia described above. Skin aliquots with sizes 20x20x10 (length, side, depth) were obtained by surgical excision. After the collection of the skin samples, the animals were then killed with an overdose of sodium thiopental (25 mg/kg) + 20 ml of 7.5% potassium chloride. The fourth minipig was followed by 3 weeks while feed with a standard diet for pigs and w\n;\nater ad libidum. After 3 weeks, the topical administration of photosensitizers was performed again under anaesthesia. The \n\n animal was rendered unconscious by electrical shock and killed by jugular venesection.\n\n\nII. E. Properties of the compounds\n\n\nH.E.1. Physical properties As mentioned in the Background, the most important physical and chemical properties of the drugs relevant for PDT are a strong absorption in the 600-800 nm range, high efficiency of singlet oxygen generation, chemical stability, controlled photobleaching and octanol:water partition coefficients between -2 and 5. These properties meet the desired light absorbance in the phototerapeutic window, the efficient photogeneration of cytotoxic species, reduce side effect such as prolonged skin photosensitivity, and facilitate systemic or transdermal administration routes.\n\n\nThe absorptivities of the compounds were measured at several concentrations, from 1 Io 20 μM, and in all cases were observed to follow the Beer-Lambert law. Additionally, the wavelength of maximum absorption (λ\nmax\n) in the infrared did not vary in the concentration range studied. This is indicative of little aggregation between the molecules, which exist mostly as monomers at these concentrations in the solvents studied. Table 1 presents typical red and infrared molar absorption coefficients (ε\nmΛX\n) and wavelength maxima. The same table also presents representative fluorescence quantum yields (Φ\nF\n) of Luzitins. The fluorescence quantum yields decrease of these molecules decrease in the presence of chlorine substituents, a fingerprint of the heavy atom effect expected for such molecules. The triplet-triplet absorption spectra of the Luzitins measured in this work were in good agreement with that in the literature data for chlorins and bacteriochlorins. All triplet decays were clearly mono-exponential. In de-aerated solutions, produced by flushing N\n2\n for at least 30 min, the triplet lifetimes (τi ) are in the millisecond range, demonstrating inefficient photochemistry in the absence of oxygen. Representative values are given in Table 1. In air-saturated ethanol the triplet lifetimes dropped to a 200-300 nanoseconds, significantly shorter than the lifetimes of the corresponding porphyrins. Such values are consistent with diffusion limited energy transfer from the triplet slate of the sensitizer to molecular oxygen through a charge-transfer interaction.\n\n\nAll the singlet oxygen emissions measured in aerated ethanol solutions are very well described by mono-exponential decays, with typical singlet oxygen lifetimes (τ\nΔ\n). The Φ\nΛ\n values of Table 1 were obtained by the procedures described above and are representative of these photosensitisers. \n\n Table 1 , Fluorescence quantum yields, triplet lifetimes, singlet oxygen quantum yields and singlet oxygen lifetimes of representative photosensitizers in air-saturated ethanol solutions.\n\n\n \n\n the form of dimers with Φ\nΔ\n=0.1 1 [42]. \ncι\n In aqueous solution. \nd)\n Corrected for the chlorin content. \ndt\n [43]. \ncl\n In methanol, but drops to half this value in 65% water in methanol [44]. \nn\n In methanol [45].\n\n\nTypically, the sum of the fluorescence and singlet oxygen quantum yields of Luzitins is 0.6-0.8, and 20 to 40% of the light absorbed in used for other processes. These processes were investigated with time-resolved photoacoustic calorimetry (PAC) and electron paramagnetic resonance (EPR). PAC measures the amount of energy released by radiationless processes (internal conversion, intersystems crossing, chemical reactions) in the decay of the electronically excited states. EPR measures the amount of species with unpaired electrons (free radicals) present in the sample, and was employed here under direct laser irradiation to measure the photoinduced generation of superoxide ion, hydroxyl radical and other reactive oxygen species (ROS). The energy release measured by PAC is consistent with the formation of bacteriochlorin triplet states with nearly unit quantum yields and triplet energies of 105- 125 kJ'mol, consistent with literature data on halogenated bacleriochlorins [ 12]. EPR spectra collected during the irradiation of Luzitins in PBS and in the presence of DMPO and BMPO revealed the presence of superoxide ion and hydroxyl radical. Together, the EPR and PAC data show unambiguously that irradiation of these photosensitizers at 748 nm leads to the formation of superoxide ion and, subsequently, of hydroxyl radical, which contribute to the \n\n phototoxicity of Luzitins. Thus, the phototoxicity of the sensitizers is higher than that anticipated from their singlet oxygen quantum yields, which are already 5 times higher than that of Photofrin®.\n\n\nThe chemical stability of the compounds was studied exposing them to light, air, and pH changes. The most significant degradation occurs for aerated solutions irradiated by light of the appropriate wavelength. In such circumstances the photobleaching of the compounds follows a first- order rale and is proportional to the energy of the incident laser light. In general, it was also observed that the phoiobleaching rate increases with the amount of water present in the solution. Bonnett reported the photoconversion of Foscan® (m-THPC) and of the analogous bacteriochlorin (m-THPB) in PBS:melhanol (50:50) [46]. Scherz reported the photoconversion of Tookad® in acetone and Triton-X:PBS [3]. For the purpose of comparing the photostability of Luzitins with that of Foscan® and Tookad®, we present in Table 2 the half-lives (/\nt 2\n) of representative drugs described herein, together with those of Foscan and Tookadd? normalized for a laser power of 100 mW.\n\n\nTable 2. Half-lives of bacterioclorins under 100 mW laser irradiation at 748 nm. and their n- octanolrwater partition coefficients (KQV. )■\n\n\n\n\n\n\n\n\nWe distinguish the photobleaching of our bacteriochlorins from the photoconversion of m-\n\n\nTHPB or Tookad®. This distinction is based on the fact that after prolonged laser irradiation most of our bacteriochlorins are transformed into products that do not have a detectable visible absorption, \n\n and can appropriately be described as photobleaching. On the other hand, the laser irradiation of m- THPB or Tookad® produces large amounts of the corresponding chlorins, that do not absorb the same laser light, and this is more appropriately described as a photoconvcrsion into another dye. The photobleaching of our bacteriochlorins is advantageous because it leads to less skin photosensitivity, as opposed to the photoconversion to another dye.\n\n\n[I.E. I, Biological properties\n\n\nPhoto frin® provides important benchmarks for dark toxicity and PDT efficacy in vitro. The toxicity of Photofrin® in the dark towards the non-small cell lung cancer cell line H 1299 was evaluated for several Photofrin® concentrations and the cell viability decreased to 50% for IC\ndark\nscpδ.O μg/ml [47]. A similar study on the dark toxicity of Photofrin® towards Colo-26. a murine colon carcinoma cell line, gave lC\ndark5\no~20 μg/ml (30 μM. assuming a monomer) [48]. The human adenocarcinoma (HT29) cell line has been one of the most widely studied cell lines in PDT. The concentration-dependence studies of Photofrin® in HT29 cells gave the lethal dosage of 50% killing under 5 J/cnT filtered halogen light of ICs\nO\n=\".5 μg/ml. For 90% killing the concentration raises to lC9o\n~\n4O μg/ml [49]. For the same cell line. Foscan® is much more phototoxic with ICso-0.8 μg ml when a dye laser at 650 nm is used to deliver 10 J /cm\n2\n; however, for this light dose, IC\n9\n(K* H) μg/ml and falls within the limits of its dark toxicity, IC\ndark\nso\" 13 μg/ml [50]. As opposed to Photofrin®, the molecular composition of Foscan® is known and it is more convenient to express its ICs in molar units. In these units, the dark cytotoxicity of Foscan® is ICd\nar\nk\n5\nø\n=\n19 μM, and the toxicity for a light dose of 10 J/cm\n2\n is IC\n50\n= 1.2 μM. Finally, it is interesting to refer that Tookad® causes a 50% death rate in HT29 cells for a dose of 48 μM under an irradiation of 25 J/cm\n*\n (patent L\nT\nS2003/6.569,846). Although the values of IC\n50\n and IC\n90\n depend on modes of administration, incubation times, light fluences and other details of the experiments, the values given above are indicative of the best practice in this field.\n\n\nTable 3 compares die dark toxicity of Photofrin® and Foscan® with that of Luzitins. Using the methods described above and further detailed in the examples below, the light doses required to kill 50% and 90% of several cell lines under filtered halogen light in the presence of a halogenated and sulfonated chlorin are presented in Table 4, and the corresponding values for a halogenated and sulfonated bacteriochlorin are presented in Table 5. Table 6 presents the phototoxicity in teπns of the concentration of various Luzitins required to kill 90% of the cells under a laser light dose of 6 J/cm\n2\n. \n\n \n\n\n d Cells were incubated for two times the population DT in complete culture medium, in the dark, in the presence of varying concentrations of the photosensitizer.\n\n\nTable 4. Light doses, in J/cnT, required to kill 50% and 90% of the cells in the cell lines indicated, for [Luzitin-Cl-c]=20 μM (=20 μg/ml) under filtered halogen lamp irradiation.\n\n\n\n\n\n\n\n\nTable 5. Light doses, in J/cmf. required to kill 50% and 90% of the cells in the cell lines indicated, for [Luzitin-Cl]=20 μM (~20 μg/ml) under filtered halogen lamp irradiation.\n\n\n\n\n\n\n\n\nTable 6. The concentration of sensitizer, in μM. required to kill 90% of cells human prostate carcinoma (PC-3). human adenocarcinoma (HT-29). human non-small cell lung carcinoma (A-549). mouse melanoma (S91 I3), and murine colon carcinoma (CT26) cell lines under 6 J/cnT diode laser irradiation at 28.5 mW.\n\n\n \n\n Tables 4-6 show the low dark toxicity of Luzitins and their very high phototoxicity. Table 6 shows that the Luzitin concentrations required to kill 90% of the cells in various cell lines are up to 100 times smaller than those required by Photofrin®, and up to 20 times smaller than those required by Foscan®. With laser light doses of 6 J/cm\" (60 seconds irradiation in our experimental conditions) it was possible to kill 100% of the cells in any of the cell lines studied with Luzitin concentrations of negligible cytotoxicity in the dark.\n\n\nII. F. Methods of use of the compounds and compositions Luzitins may be administered by topical, oral, intravenous, subcutaneous, intraperitoneal, rectal, sublingual, nasal, ocular, ear or inhalation foπnulation, depending on the clinical situation. The pharmaceutical foπnulation is adapted to the chosen route of administration. The formulations comprise besides the Luzitins (individually or in combination with each other), a pharmaceutically acceptable carrier. The Luzitins may be derivatized as the corresponding salts, esters, enol ether or esters, acetals, ketals, orthoesters, hemiacetals. hemiketals, acids, bases, solvates, hydrates or prodrugs prior to formulation.\n\n\nFollowing topical or systemic administration, or both, the area treated is exposed to light of the appropriate wavelength, preferably between 630 and 690 nm for chlorins or between 720 and 780 nm for bacteriochlorins, and most preferably using a laser. Methods of irradiating various areas of the body are well known in the art. The drug-to-lighl interval may range from a few minutes to several days, depending on the mode of administration. The light dose depends on the administration route, light source and therapeutic target. For continuous laser irradiation, the light dose should be between 10 and 250 Joules'cm\n2\n, with a laser power between 20 and 200 mW cm\". It is also possible to use pulsed laser irradiation with energies per pulse between 0.001 and 10 \n\n\n The light dose may be applied in one or several sessions. For diagnostic purposes, the light dose may be reduced. When broadband light sources are employed in the irradiation, the light doses are increased to maintain the energy of the light source in the spectral regions where the Luzitin absorbs, at the level prescribed for laser irradiation.\n\n\nThe Luzitins may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. Luzitins may be administered in conjunction with other medicaments to obtain synergistic effects. The light doses administered after the drug-to-light interval fall in the ranges given above for a single dose. The treatment may be repeated several times \n\n at various time intervals. It is understood that the precise dosage and duration of the treatment is a function of the disease being treated and may be determined empirically using protocols known in the art.\n\n\nJI. F. I. Systemic administration (oral, intertables, aerosols, rectal)\n\n\nA common limitation associated to oral administration is the putative digestion of the drug under the acidic conditions found in the stomach. As shown in an example below, Luzitins are relatively stable at pH 1 for 3 hours. The spectral changes observed at low pH are due to the prolonation of the pyrrole ring, but are reversed when the acidity are neutralized. Another difficulty frequently encountered in oral administration is that of bioavailability. It is possible to make Luzitins that come close to meet Lipinsky rule of five [51] for intestinal absorption. Luzitins can have log 4 hydrogen bond donors, 12 hydrogen bond acceptors and molecular weight of 1 kD. Only this last parameter significantly exceeds the limits of the above-mentioned rule.\n\n\nTaking into account the physical-chemical properties of Luzitins, both solid, semi-solid and liquid dosage forms can be considered. In this regard, the state-of-the-art in terms of phaπnaceutical adjuvants for the various phaπnaceutical dosage foπns and modes of administration should be considered.\n\n\nThe preferred drug-to-light interval in systemic administration may range from a few minutes to 3 days, depending on the mode of administration. The phaπnaceutical compositions should provide a dosage from 0.01 mg to 100 mg of Luzitin (or combination of Luzitins) per kilogram of body weight per day. The preferred daily dose of Luzitins is between 0.1 and 10 mg per kilogram of body weight.\n\n\nII.F.2. Topical administration Topical administration can be achieved with appropriate formulations containing one or various surface penetration enhancers and other excipienls in the form of liquid, gel. hydrogel, cream, ointments, sprays or any other acceptable dermatological formulation. As mentioned in the Background, the skin permeation achieved for Photofrin® or other large molecular mass photosensitizers is insufficient for efficient PDT of skin disorders. Luzitins also fail to meet most of the criteria for good transdermal delivery [32]. However, our ability to modulate the amphiphilicity and hydrogen bonding ability of these compounds and, to a certain extent, their molecular mass, simplifies the task of finding formulations that promote their passive diffusion to the dermis. A gel \n\n formulation presenled in Example 21, is shown to produce fast and efficient topical delivery to the derails.\n\n\nThe preferred drug-to-light interval in topical administration is between 15 min and 3 h. The formulation should contain 0.01 to 10% the Luzitin. In a preferred embodiment, the percentage of the sensitizer in the formulation is between 0.1 and 1%.\n\n\nTopical administration also contemplates application to the eye. Applications intended for ophthalmic use may be formulated as 0.01% - 10% isotonic solutions, pH 5-7. with appropriate salts. \n\n\n\n\nThis invention will now be described in more detail in the following non-limiting Examples, with reference to the drawings in which:\n\n\nFigure 1. Spectral density of the 500 W halogen lamp with a 600 nm cut-off filter and infrared absorption spectrum of a chlorin (dotted line) and of a bacteriochlorin (dashed line).\n\n\nFigure 2, Absorption spectrum of Luzitin-FMet-c obtained from the reduction of the corresponding poφhyrin in a synthetic route characterized by the total absence of organic solvent and bases.\n\n\nFigure 3. Absorption spectrum of Luzitin-ChEt obtained from the reduction of the corresponding porphyrin in a synthetic route characterized by the total absence of organic solvent and bases. Figure 4. Absorption spectrum of the more polar fraction (βα\n3\n+α\n4\n) of atropoisomers of Luzitin-CTaEt illustrating the increased absorptivity in the infrared, estimated to reach C\nn13x\n=ISO\n1\nOOO M\n\"1\n cm\n\" 1\n at 748 nm.\n\n\nFigure 5. Absorption spectrum of Luzitin-Cl; in neutral aqueous solution (full line), after 2 hours at a pH of 1 (dotted line) and after neutralization (dashed line). The spectra were corrected for the dilution effect produced by the drop wise addition of HCl and NaOH in aqueous solution.\n\n\nFigure 6. Absorption spectra of Luzitin-FMet in PBS:methanol (3:2) before (left) and after (right) 65 min irradiation with the 748 nm Lynx diode laser at 28.8 mW ( 1 10 J). illustrating controlled photobleaching.\n\n\nFigure 7. Singlet oxygen phosphorescence intensity collected at 1270 nm. following excitation at 355 nm of Luzitin-CNHep or phenalenone in air-saturated ethanol. The slope of the phosphorescence vs laser intensity dependence was employed to determine the singlet oxygen quantum yield of the sensitizer.\n\n\nFigure 8. EPR spectra obtained in the presence of 80 μM of Luzitin-Cl under irradiation. Left: with\n\n\n40 mM BMPO in PBS the spectrum corresponds to that of the spin adduct of BMPO with the hydroxyl radical. Right: with 40 mM DMPO in DMSO the spectrum corresponds to that of the spin adduct of DMPO with the superoxide ion.\n\n\nFigure 9. Survival fraction of S91 cells (percentage) for various light doses in the presence of\n\n\n[Luzitin-Cl-c]- 20 μM. The non- internalized photosensitizer was not removed before irradiation.\n\n\nInset: Cytotoxicity in the dark of Luzitin-Cl-c towards S91 cells cell lines at different concentrations of sensitizer.\n\n\nFigure 10. Survival fraction of MCF7 cells (percentage) for various light doses in the presence of fLuzitin-CIJ- 5 μM, after 12 h of incubation time. The non-internalized photosensitizer was removed \n\n before irradiation. Inset: cytotoxicity in the dark of Luzitin-Cl towards MCF cells cell lines at different concentrations of sensitizer. The effective light power is 0.53 mW/cm\n2\n. Figure 1 1. Phototoxic effect of Luzitin-Cl; in prostate cancer cell line PC-3 after a drug-to-light interval of 24 hours. Cells in culture medium were irradiated with laser light of 748 nm for 30 or 60 seconds, which corresponds to light doses of 3 and 6 J ''cm\n2\n, respectively.\n\n\nFigure 12. Percentage of cell survival relative to control for various Luzitin-Cl\n2\nEt concentrations in mouse colon carcinoma cell lines after a drug-to-light interval of 18 hours. The non-internalized photosensitizer was removed before irradiation. Cells in culture medium were irradiated with laser light of 748 nm for 60 seconds, which corresponds to light doses of 6 J/cm\". Figure 13. Percentage of cell survival relative to control for various Luzitin-FMet concentrations in human adenocarcinoma cell lines after an incubation time of 18 hours. The non-internalized photosensitizer was removed before irradiation. Cells in culture medium were irradiated with laser light of 748 nm for 60 seconds, which corresponds to light doses of 6 J/cm . Figure 14. Percentage of cell survival relative to control for various Luzitin-F\n2\nMet concentrations in human non-small cell lung cancer lines after an incubation time of 18 hours. The non-internalized photosensitizer was removed before irradiation. Cells in culture medium were irradiated with laser light of 748 nm for 60 seconds, which corresponds to light doses of 6 J/cm\".\n\n\nFigure 15. Fluorescence of LuZiUn-Cl\n2\nEt at human serum concentrations of 3.26 nM (full line) and 0.26 nM (dashed line) used to determine its detection limit. Also shown is the base line (dash-dotted line) and Gaussian curve (dotted line) used to simulate the lowest concentration for a more precise determination of low intensity fluorescence.\n\n\nFigure 16. Fluorescence of Luzitin-Cl-c divided by the mass of liver, blood and brain, respectively in order of intensity, following ip administration of 10 mg/kg in DBA/2 mice. Figure 17. Farmacokinetics and biodistribution of Luzitin-Cl following ip administration of 10 mg/kg in DBA/2 mice. The fluorescence intensity in the various tissues (blood, tumor, heart, lungs, spleen, liver, kidneys, intestine, muscle, skin) was normalized by their respective masses. Figure 18. Fluorescence of Luzitin-Cl\n2\nEt divided by the mass of tumor and blood, respectively in order of intensity, following ip administration of 10 mg/kg in DBA/2 mice. Figure 19. Volume of the tumors in Balb/C mice with implanted CT26 tumors and treated with Luzitin-FMet. The thick line represents the average tumor sizes in four control animals, to which Luzitin-FMet was administered but not irradiated. The error bars are standard deviations. The thin lines represent individual animals treated with Luzitin-FMet and 132 J/cm\" of laser light at 748 nm. \n\n Figure 20. Size of implanted S91 tumors in DBA/2 mice treated with Luzitin-Cl\n2\nEt. Two laser light doses at 748 nm were employed.\n\n\nFigure 21. Confocal fluorescence of Luzitin-FMet 3 h after topical application in the back of a minipig. Multiphoton excitation at 744 nm: full noise elimination; fluorescence plane images constructed by 6 pictures; 800 V @ detector: pinhole - 379 μm. The photosensistizer diffused through 50 microns of stratum corneum and epideπnis.\n\n\nFigure 22. Absorption spectra of Luzitin-FMet 3 h after topical application in the back of a minipig, obtained with confocal spectroscopy. The various lines correspond to measurements in different parts of the sample. \n\n\n\n\nEXAMPLES\n\n\nEXAMPLE 1. SOLID STATE SYNTHETIC PROCEDURE FOR BACTERIOCHLORINS WITH ELECTRON-WITHDRAWING SUBSTITUENTS This example illustrates the wide range of bacteriochlorins that can be synthesized by a procedure characterized by the absence of solvent and base, hence where only a porphyrin and a hydrazide (both in the solid state) are employed as starting materials.\n\n\nIn one preparation we mixed 60 mg (6.8 x IO \n3\n mol) of 5.10.15.20-tetrakis(2- trifluoromethylphenyl)porphyrin with 500 mg (2.7 x K)\n'3\n mol) ofp-toluenesulphonylhydrazide, both in very fine powders. They were added to a reactor, which was evacuated, sealed under N\n2\n and heated to a temperature higher than 100 \n0\nC for several minutes. After cooling (room temperature) the solid was removed and several portions of />-toluenesulphonylhydrazide 250 mg (1.4 x 10\n\"3\n mol) were added, until complete disappearance of the porphyrin Soret band. The bacteriochlorin was extracted with a small amount of organic solvent. The excess of hydrazide was removed by a short filtration on silica gel (column height 8 cm; column internal diameter 2.5 cm) using dichloromethane/n-hexane as elutant. After solvent evaporation and recrystalization from diethyl ether'pentane 90% of CFiPhB was obtained with less than 5% of chlorin contamination. The NMR of the isolated product is: RMN \n1\nH: (400, 13 MHz. CDCh) δ. ppm: 7.47-7.45 (m, 4H); 7.26- 7.20 (m, 8H); 7.15-7.12 (m, 4H); 2.42 (s, 4H): 2.37 (s, 4H); -1.27 (s. 2H).\n\n\nEXAMPLE 2. SOLID STATE SYNTHETIC PROCEDURE FOR HALOGENATED CHLORINS\n\n\nIn one preparation of 5,10,15,20-tetrakis(2-fluorophenyl-5-N-methylsulfamoylphenyl) chlorin, Luzitin-FMet-c, we mixed 50 mg (4.72x10\n\"5\n mol) of 5,10,15,20-tetrakis(2-fluorophenyl-5-N- methylsulfamoylphenyl)porphyrin with 18 mg (9.44x 10\n\"\n'\" mol) of p-toluenesulphonylhydrazide. The reactor is evacuated, sealed under N\n^\n and is heated at a temperature higher than 100 \n0\nC for several minutes. After cooling (room temperature) the solid was removed with a small amount of organic solvent, and the excess of hydrazide was removed by a short filtration on silica gel using ethylacetatc'hexane as elutant. A mixture of chlorin contaminated with approximately 10% of bacteriochlorin was obtained. The mixture of chlorin and bacteriochlorin was dissolved in dichloromethane and oxidized to the corresponding chorin by heating at 50\"C in the presence of air. \n\n After recrystalization from diethyl ether/pentane 90% of Luzitin-FMet-c was obtained with less than 1% of bacteriochlorin contamination. Figure 2 shows the absorption spectrum of the final product.\n\n\nEXAMPLE 3. SOLID STATE SYNTHETIC PROCEDURE FOR HALOGENATED BACTERIOCHLORINS\n\n\nThis example describes a clean, simple, economical and environmentally-benign synthetic method, involving a sol vent- free one-pot synthesis of halogenated amphiphilic bacteriochlorins.\n\n\nThe appropriate porphyrin (solid) and the /Moluenesulphonylhydrazide (solid) are ground into very fine powders and thoroughly mixed. Next they are introduced into a reactor and evacuated to high vacuum. The reactor is then sealed and kept under vacuum, or repeatedly washed with an inert gas. Finally, the reactor is heated (70-200 \"C) during 1-340 min, while sealed. Once the reaction is completed and the reactor brought to room temperature, the corresponding bacteriochlorin is obtained with 90% yield. After a short filtration by silica gel column, a bacteriochlorin with a contamination of less than 5% of the corresponding chlorin is obtained.\n\n\nIn one preparation of 5, 10.15,20-tetrakis(2,6-dichloro-3-N-ethylsulfamoylphenyI) bacteriochlorin, Luzitin-C^Et, with this method we mixed 50 mg (3.8 x 10\n\"5\n mol) of 5.10,15,20- tetrakis(2.6-dichloro-3-sulphoethylphenyl)porphyrin with 188 mg ( 10\n\"3\n mol) of p- toluenesulphonylhydrazide. evacuated the reactor with an Edwards pump, sealed and then healed the reactor to more than 70 \n0\nC for several minutes. After cooling (room temperature), the solid is removed with a small amount of diethyl ether and the excess of hydrazide is removed by a short filtration on silica gel (column height 4 cm; column internal diameter 2.5 cm) using ethyl acetate'diethyl ether, as elutant. After solvent evaporation the resulting solid is recrystallized from diethyl ether/pentane to give Luzitin-C12Et with 90% yield. The absorption spectrum in Figure 3 reveals the presence of less than 5% of the corresponding chlorin. The molar absorption coefficient of this and other bacteriochlorins is presented in Table 1 , corrected for the amount of chlorin sometimes present in the samples. The comparison between the spectra of Figure 3 below and that of Figure 2 in the patent PCT/EP2005/012212, also of the University of Coimbra, reveals that the chlorin impurity is reduced by at least a factor of 10 by this new synthetic procedure, which is also is more economical, less laborious and environmentally benign. The NMR and MS of the isolated product are as follows: \n\n RMN \n1\nH: (300 MHz, CDCl\n3\n) δ, ppm: 8.42 (d. J = 8,55 Hz . 4H. p-U): 7,88 (d, J = 8,55 Hz. 4H. m-H);\n\n\n7.84- 7,82 (m, 4H. /?-H);5,01(m, 4H, N-H); 3,9 l(s, 8H, β-H): 3.22 (m, 8H, CH\n2\n ); 1.24 (t, 12H, J =\n\n\n6,73 Hz. CH\n3\n ); -1-29 (s, 2H, NH).\n\n\nMS: (MALDl-TOF). m/z: 1322,0 [M]\n+\n.\n\n\nEXAMPLE 4. ATROPISOM ERS IN HALOGENATED BACTERIOCHLORINS\n\n\nThis example shows that stable atropisomers exist in halogenated and sulfonated bacteriochlorins and that they can be easily separated. It also shows that the more polar atropisomers have higher extinction coefficient in the infrared. Using the procedure described in Example 3 but using a larger column (column height 8 cm; column internal diameter 2.5 cm) with ethyl acetate/«-hexane (1: 1) as first elutant and ethyl acetate w-hexane (3: 1) as last elutant, we observed a separation of 5.10.15.20-tetrakis(2,6-dichloro-3-\n\n\nN-ethylsulfamoylphenyl)bacieriochlorin. Luzitin-CljEt. in two fractions. Each fraction showed two spots in TLC, that were identified as a mixture of the less polar airopisomers αβαβ+α\n2\nβ\n2\n or of more polar ones βα^+cu. Figure 4 shows the absorption spectrum of the mixture of the atropisomers with higher polarity. This fraction exhibits a 50% enhancement of the ε at 750 nm band, that reaches\n\n\n150,000 M-\n1\n Cm\n\"1\n.\n\n\nEXAMPLE 5. pH STABILITY OF HALOGENATED AND SULFONATED BACTERIOCHLORINS\n\n\nThis example demonstrates the stability of halogenated and sulfonated bacteriochlorins at pH 1 and 37 \n0\nC. that is. in the acidity found in the stomach.\n\n\nLuzitin-Ch was dissolved in neutral aqueous solution and equilibrated to 37 \n0\nC to give the absorption spectrum represented in Figure 5. HCl in aqueous solution was added drop wise, to lower the pH to 1 and 2 hours later the absorption spectrum of Luzitin-C12 at pH 1 was registered. Then, an aqueous solution of NaOH was added to neutralize the solution and a new absorption spectrum was registered 3 hours later. Figure 5 shows the absorption spectra corrected for the dilution produced by the addition of HCl and NaOH in aqueous solution. The spectral changes observed at low pH are due to the protonation of the pyrrole ring, but are reversed when the acidity is neutralized. Under these conditions, nearly half of Luzitin-Ch is recovered and the other half in transformed into the corresponding chloπn. \n\n EXAMPLE 6. LIGHT STABILITY OF HALOGENATED AND SULFONATED BACTERIOCHLORINS\n\n\nThis example demonstrates the increased stability of halogenated and sulfonated bacteriochlorins towards irradiation by infrared light, that resolves problems of lability found in other bacteriochlorins, either of synthetic origin, such as 5,10,15,20-tetrakis(3- hydroxyphenyl)bacteriochlorin. or derived from natural products, such as Tookad®.\n\n\nLuzitin-FMet was dissolved in PBS:methanol (2:3), transferred to a 1 cm quartz cell and its absorption spectrum was registered, Figure 6. The quartz cell was then placed in the beam of the 748 nm Lynx diode laser, previously unfocused to have a beam diameter coincident with the window of the quartz cell. The laser power measured under these conditions was 28.8 mW. Every 5 minutes the irradiation was interrupted and a new absorption spectrum was registered. This procedure was followed for 65 minutes. The photobleaching follows the kinetics of a first-order reaction in the time window of the experiment. Figure 6 also shows the absorption spectrum after the irradiation. Whereas the bacteriochlorin peak at 743 nm is reduced from an absorbance of 1.128 to 0.337. the absorption of the chlorin only increases from 0.1 14 to 0.151. Taking into consideration the molar absorption coefficients of the compounds at these wavelengths, it is clear that whereas 70% of the bacteriochlorin is destroyed during the irradiation, only a few percent of chlorin are formed. The remaining products, do not have well-resolved spectra in the visible/IR. and the dominant photodegradation process can be described as photobleaching. The half-live of the photobleaching was measured for different laser intensities and it was shown to be proportional to the laser power. The half-lives of other bacterioclorins normalized 100 mW laser irradiation at 748 nm are presented in Table 1. together with the literature data for the photodegradation of Foscan® and Tookad® normalized for the same light intensity. It was also observed that the half-live to Luzitin-Cl is increased by a factor of 30 when the PBS solution of the photosensitizer is saturated with Argon, which reduces the oxygen concentration in the solution. This shows the participation of ROS in the photobleaching.\n\n\nEXAMPLE 7. EFFICIENT PHOTOGENERATION OF SINGLET OXYGEN\n\n\nThis example describes the efficiency generation of singlet oxygen in the presence of Luzitins, light of an appropriate wavelength and molecular oxygen dissolved in solution.\n\n\nAn air-saturated solution of Luzitin-Cl;Hep in ethanol with an absorbance ca. 0.2 at 355 nm was excited in a 1 cm quartz cuvette by a pulsed Nd:YAG laser, and the singlet oxygen emission was \n\n followed at 1270 nm, using the equipment and methods previously described. The intensity of the singlet oxygen phosphorescence was studied as a function of the laser intensity. A similar study was made with phenalenone in ethanol, at a concentration matching the absorbance of Luzitin-ChHep at 355 nm. Figure 7 shows the laser energy dependence of the singlet oxygen phosphorescence intensity measured at 1270 nm after Luzitin-CbHep or phenalenone excitation at 355 nm in air-saturated ethanol. Various laser energies were employed and from the slopes of the energy dependence of singlet oxygen emission and the value of Φ\nΔ\n=0.95 for phenalenone in this ethanol. we obtained Φ\nΔ\n-0.78 for Luzitin-CliHep. Values for other bacteriochlorins are presented in Table 1.\n\n\nThe photostability of these bacteriochlorins associated with their ca. 70% quantum efficiency of singlet oxygen production, implies that one given molecule of bacteriochlorin under continuous irradiation will produce locally a very large amount of electronically excited oxygen molecules before it photobleaches. Some 30% of the energy absorbed by the sensitizer is lost to other processes, some of them identified in the following example.\n\n\nEXAMPLE 8. PHOTOGENERATION OF REACTIVE OXYGEN SPECIES (ROS)\n\n\nThis example describes the generation of reactive oxygen species, namely the superoxide ion and the hydroxyl radical using Luzitin-Cl as sensitizer.\n\n\nIn order to assess the photogeneration of superoxide ion and the hydroxyl radical by Luzitin-Cl, EPR spectra in the presence of 30-80 μM of Luzitin-Cl and 40 niM BMPO were measured in the following conditions: a) Air-saturated aqueous solution in the dark. b) Nitrogen-saturated aqueous solution irradiated with the Hamamatsu diode laser for 8 minutes. c) Air-saturated aqueous solution irradiated with the Hamamatsu diode laser for 4 minutes. d) Air-saturated aqueous solution irradiated with the Hamamatsu diode laser for 8 minutes. e) Air-saturated aqueous solution irradiated with the Hamamatsu diode laser for 16 minutes. f) Air-saturated aqueous solution irradiated with the Hamamatsu diode laser for 16 minutes, in the presence of superoxide dismutase (50 μg/ml). g) Air-saturated aqueous solution irradiated with the Hamamatsu diode laser for 16 minutes, in the presence of catalase (30 μg/ml). Under experimental conditions (a) and (b) no ROS-BMPO adduct was detected. However, experimental conditions (c), (d) and (e) lead to the detection of a BMPO adduct which is that formed between BMPO and the hydroxyl radical. Figure 8. The presence of light is necessary to form such \n\n adduct. Experimental condition (f) gives no signal, with means that superoxide dismutase, a known scavenger of superoxide ion, inhibits the formation of the BMPO-hydroxyl radical adduct. Additionally, experimental condition (g) also gives no signal, and proves that catalase, which breaks down hydrogen peroxide into water and molecular oxygen, also inhibits the formation of the BMPO- hydroxyl radical adduct. These results indicate that hydroxyl radicals are not formed directly from the photosensitizer and molecular oxygen but rather as a secondary product. The inhibition observed by superoxide dismutase is compelling evidence for the foπnation of superoxide ion. The inhibition observed by catalase suggests that hydrogen peroxide is also a precursor of the hydroxyl radical.\n\n\nSimilar experiments were conducted with DMPO in DMSO. We detected the DMPO- superoxide adduct in the presence of air and light, Figure 8. However, in the absence of air or light, or in the presence of superoxide dismutase, this adduct was not observed.\n\n\nTaken together, these data indicate the formation of superoxide ion, followed the formation of hydrogen peroxide and, subsequently, of the hydroxyl radical, all of them are very well documented reactive oxygen species capable of producing damage to cells. These ROS complement the ca. 70% singlet oxygen formation efficiency of these bacteriochlorins and shows that remaining 30% of the energy absorbed by the sensitizer are not lost, but rather employed in the formation of other cytotoxic species, in addition to singlet oxygen.\n\n\nEXAMPLE 9. IN VITRO PHOTOTOXICITY OF Luzitin-CI-c TOWARDS MOUSE MELANOMA CELL LINES UNDER STANDARD LAMP IRRADIATION\n\n\nThis example shows that Luzitins are very toxic to mouse melanoma cells under filtered halogen light irradiation, at concentrations where their dark toxicity is negligible.\n\n\nThe cytotoxicity in the dark and the photosensitizing activity of Luzitin-CI-c in S91 (mouse melanoma) cell lines were measured with the materials and methods described before, except that after incubation cells were not washed to remove the non-internalized photosensitizer before irradiation. The inset in Figure 9 shows the cytotoxicity in the dark of different concentrations of Luzitin-Cl-c for an incubation time of 120 minutes. Figure 9 shows the survival fraction of S91 cells for different light doses, when the cells are irradiated in the presence of [Luzitin-Cl-cJ=20 μM. Light doses required to kill 90% (LDQ\nØ\n) or 50% (LD\n50\n) of the cells in the culture are presented in Table 3.\n\n\nEXAMPLE 10. IN VITRO PHOTOTOXICITY OF Luzitin-CI TOWARDS MOUSE MELANOMA CELL LINES UNDER STANDARD LAMP IRRADIATION \n\n This example shows that Luzitins are very toxic to human breast carcinoma cells under filtered halogen light irradiation, at concentrations where their dark toxicity is negligible.\n\n\nThe cytotoxicity in the dark and the photosensitizing activity of Luzitin-Cl in MCF7 (human breast carcinoma) cell lines were measured with the materials and methods described before. The inset in Figure 10 shows the cytotoxicity in the dark of different concentrations of Luzitin-Cl and an incubation time of 12 hours. Figure 10 shows the survival fraction of MCF7 cells for [Luzitin-Cl]=5 μM and various light doses. Clearly, a 5 μM concentration of Luzitin-Cl produced 100% cell kill on exposing to filtered halogen light at a dose of 0.6 J/cm\n2\n. Light doses required to kill 90% (LD\n90\n) or 50% (LD\n5\n0) of the cells in the culture are presented in Table 4.\n\n\nEXAMPLE 11. IN VITRO PHOTOTOXICITY OF Luzitin-CI\n2\n TOWARDS HUMAN PROSTATE CARCINOMA UNDER LASER IRRADIATION\n\n\nThis example shows that Luzitins are very toxic to human prostate carcinoma cells under laser irradiation, at concentrations where their dark toxicity is negligible. The cytotoxicity in the dark of Luzitin-C^ in PC-3 (human prostate carcinoma) cell lines were measured with the materials and methods described before. According to these experiments, 0.05 niM is the highest concentration of Luzitin-Cl: that causes relatively no effect in the viability of the cell lines in test in the dark. This will be the reference concentration in the following phototoxicity studies. The photosensitizing activity of Luzitin-Cl; in PC-3 cell lines were measured with the materials and methods described before. Survival fraction for light doses of 3 and 6 J/cm\n2\n and an incubation time of 24 hours is depicted in Figure 1 1 for various concentrations of this photosensitizer. According to Figure 1 1 , [Luzitin-Cl;]=20 μM produces 100% cell kill on exposing to a laser light dose of 6 J/cm\".\n\n\nEXAMPLE 12. IN VITRO PHOTOTOXICITY OF Luzitin-Cl\n2\nEt TOWARDS MOUSE COLON CARCINOMA CELL LINES UNDER LASER IRRADIATION\n\n\nThis example shows that Luzitins are very toxic to mouse colon carcinoma cells under laser irradiation, at concentrations where their dark toxicity is negligible. The cytotoxicity in the dark of Luzitin-Cl\n2\nEt in CT26 (mouse colon carcinoma) cell lines could not be measured in terms of ICs\n0\n because the compound precipitates in the culture medium before \n\n attaining this level of cytotoxicity. A concentration of 50 μM is the highest concentration of Luzitin- ChEt that causes relatively no effect in the viability of these cell lines in the dark.\n\n\nThe photosensitizing activity of Luzitin-CliEt in CT26 cell lines were measured with the materials and methods described before. Survival fraction for light doses of 6 J/cm\n2\n and an incubation time of 18 hours is depicted in Figure 12 for various concentrations of this photosensitizer. This Figure shows that Luzitin-C^Et at a concentration of 5 μM produced 90% cells kill on exposing to laser light dose of 6 J/cm\n*\n. LD<?o=5 μM. According to Figure 12, [Luzitin-Cb]=10 μM produces 100% cell kill on exposing to a laser light dose of 6 J/cm\n2\n. Table 6 presents the Luzitin-\n\n\nCl\n2\nEt concentrations required to attain LD\n%\n in various other cell lines under 6 J/cm\n2\n diode laser irradiation at 28.5 mW.\n\n\nEXAMPLE 13. IN VITRO PHOTOTOXICITY OF Luzitin-FMet TOWARDS HUMAN COLON CARCINOMA CELL UNDER LASER IRRADIATION\n\n\nThis example shows that Luzitins are very toxic to human colon carcinoma cells under laser irradiation, at concentrations where their dark toxicity is negligible.\n\n\nThe cytotoxicity in the dark of Luzitin-FMet in HT-29 (human colon adenocarcinoma) cell lines could not be measured in terms of ICso because the compound precipitates in the culture medium before attaining this level of cytotoxicity. A concentration of 50 μM is the highest concentration of Luzitin-FMel that causes relatively no effect in the viability of the cell lines in test in the dark.\n\n\nThe photosensitizing activity of Luzitin-FMet in HT-29 cell lines were measured with the materials and methods described before. Survival fraction for light doses of 6 J/cm\" and an incubation time of 18 hours is depicted in Figure 13 for various concentrations of this photosensitizer. This Figure shows that Luzitin-FMet at a concentration of 0.5 μM produced 90% cells kill on exposing to laser light dose of 6 J/cm\n2\n, LDw=I μM. According to Figure 13, [Luzitin- FMet]=l μM produces 100% cell kill on exposing to a laser light dose of 6 J/cm\n2\n. Table 6 presents the Luzitin-FMet concentrations required to attain LDy\n0\n in various other cell lines under 6 J/cm\n2\n diode laser irradiation at 28.5 mW.\n\n\nEXAMPLE 14. IN VITRO PHOTOTOXICITY OF Luzitin-F\n2\nMet TOWARDS HUMAN NON- SMALL CELL LUNG CARCINOMA UNDER LASER IRRADIATION \n\n This example shows that Luzitins are very toxic to human non-small cell lung cancer cells under laser irradiation, at concentrations where their dark toxicity is negligible.\n\n\nThe cytotoxicity in the dark of Luzitin-F\n2\nMet in A-549 (human non-small cell lung cancer) cell lines could not be measured in terms of IC\n50\n because the compound precipitates in the culture medium before attaining this level of cytotoxicity. A concentration of 50 mM is the highest concentration of LuZiUn-F\n2\nMCt that causes relatively no effect in the viability of the cell lines in test in the dark.\n\n\nSurvival fraction for light doses of 6 J/cm\n2\n and an incubation time of 18 hours is depicted in\n\n\nFigure 14 for various concentrations of this photosensitizer. This Figure shows that Luzitin-F\n2\nMet at a concentration of 0.5 μM produced 90% cells kill on exposing to laser light dose of 6 J/cm\n\"\n, μM. According to Figure 14. [Luzitin-F\n2\nMet]=0.5 μM produces 100% cell kill on exposing to a laser light dose of 6 J/cm\". Table 6 presents the Luzitin-F\n2\nMet concentrations required to attain\n\n\nLDωi in various other cell lines under 6 J/cm'\" diode laser irradiation at 28.5 mW.\n\n\nEXAMPLE 15. FLUORESCENCE DETECTION LIMIT\n\n\nThis example shows the extreme sensitivity and selectivity of detection of Luzitins in biological samples.\n\n\nSolutions of different concentrations where prepared by dilution to in human serum of a 1% stock solution of Luzitin-Cl\n2\nEt in ethanol. The concentrations ranged from 0.2 nM to 10 nM. The samples were excited at 514 nm in the spectra fluorimeter described above, using slits 4:5:3: for excitation and emission. The emission was collected in the infrared as illustrated in Figure 15.\n\n\nThe detection limit was determined using the equation\n\n\nL.D.Λ -_J h where S\ny x\n is the standard deviation of the calibration curve and b is its slope. The detection limit of 0.17 nM (or 0.2 ng/g) was obtained.\n\n\nEXAMPLE 16. IN VIVO TOXICITY IN THE DARK\n\n\nThis example shows that Luzitins are not toxic to mice at concentrations much higher that those approved for PDT with commercially available photosensitizers. The mice were divided into the following experimental groups: a) 10 animals received 2 mg/kg of Luzitin-Cl \n\n b) 10 animals received 5 mg/kg Luzitin-Cl c) 10 animals received 10 mg/kg Luzitin-Cl d) 10 animals, received 15 mg'kg Luzitin-Cl e) ! 0 animals received 20 mg kg Luzitin-Cl f) 10 animals received no treatment, and are the control group.\n\n\nThe solutions of Luzitin-Cl (0.5 ml) were injected subcutaneously and for 30 da>'s the animals were closely observed. In first 6 days after injection the animals from the group (e) revealed sensitivity to the light and some of the group (d) also revealed a slight sensitivity. They manifested such sensitivity by moving away from light sources directly pointed at them. The animals were weighted regularly but no significant mass changes were observed for any of them. After 30 days the animals were anaesthetized using Morbital (Biowet, Poland), their organs and tissue samples were excised, and blood morphology as well as histology of selected organs tests was performed. No changes were observed in the blood or in organs.\n\n\nThe doses employed in these dark toxicity assays were 10 times higher than those recommended for the use of Photofrin® and 100 timer higher than the doses employed with Foscan®. And yet, the threshold for measurable dark toxicity in mice was not attained. This provides evidence that higher doses of Luzitins can be employed in PDT than of Photofrin® or Foscan®.\n\n\nEXAMPLE 17. CHLORlN BIODISTRIBUTION FOLLOWING IP ADMINISTRATION This example shows that Luzitins can cross the blood-brain barrier two hours after ip administration.\n\n\nLuzitin-Cl-c was administered at a dose of 10 mg/kg to DBA/2 mice via intraperitoneal injection. Chlorin distribution in the tissues was analyzed 2 h after administration. The animals were anaesthetized using Morbital (Biowet. Poland), and some of their organs, including the brain, were excised, weighted and then stored at -30 \n0\nC until further analysis. The content of pigments in the tissue samples was analyzed spectrofluorometrically. In order to extract the pigments, tissue samples were homogenized 1 min in 7 ml of ice-cold 90% aqueous acetone, using a tissue homogenizer MPW- 120 (Medical Instruments, Poland) at the speed of 10 000 rpm. The homogenate was centrifuged at 2000 g for 10 min at 4 \n0\nC, the supernatant was collected and the pellet was re-extracted with 90% aqueous acetone to ensure a complete recovery of the pigment. The extracts were pooled and analyzed for pigment content. The samples were excited at 413 nm and the fluorescence spectra \n\n were recorded in the range between 600 and 800 nm. Figure 16 illustrates the fluorescence intensity from the brain, blood and liver, normalized by their respective masses.\n\n\nThe blood-brain distribution of the sensitizer was 4:1 two hours after ip administration in\n\n\nDBA/2 mice. This is the proof-of-principle that suitable Luzitins can cross the blood-brain barrier in significant amounts to become an active photosensitizer in the brain. It is shown in the subsequent example that this class of sensitizers tends to accumulate in tumors, further increasing the amount of photosensitizer that will be available for the treatment of brain tumors.\n\n\nEXAMPLE 18. BACTERIOCHLORIN FARMACOKINETICS FOLLOWING IP ADMINISTRATION\n\n\nThis example shows that after ip administration Luzitins first accumulate in tumors, and then are cleared at slower rates.\n\n\nThe tumor model was S91 Cloudman melanoma cells, cultured as monolayer in the RPMl medium, containing 5% fetal calf serum and supplemented with antibiotics. The cells were grown at 37 \n0\nC in humidified atmosphere containing 5% CO\n2\n. The melanoma cells (~lxlθ\n6\n) were taken up in 0.1 ml phosphate buffered saline (PBS) and implanted subcutaneously to the right flank of the animal. The tumors grew visible in ten days after the implantation. The animals were treated three weeks after the injection.\n\n\nLuzitin-Cl was administered at a dose of 10 mg/kg to DBA '2 mice via intraperitoneal injection. Bacteriochlorin tissue distributions were analyzed at following intervals: 2 h, 6h, 12 h. 24 h and 48 h after intraperitoneal administration. The animals were anaesthetized with ketamine and xylazine, their organs and tissue samples were excised, weighted and then stored at -30 \n0\nC until further analysis. The content of pigments in the tissue samples was analyzed spectrofluorometrically. In order to extract the pigments, tissue samples were homogenized 1 min in 7 ml of ice-cold solution ethanol/DMSO (75:25), using a tissue homogenizer MPW- 120 (Medical Instruments. Poland) at the speed of 10 000 rpm. The homogenate was centrifuged at 2000 g for 10 min at 4 °C, the supernatant was collected and the pellet was re-extracted with the ethanol: DMSO solution to ensure a complete recovery of the pigment. The extracts were pooled and analyzed for pigment content. The samples were excited at 517 nm and the fluorescence spectra were recorded in the range between 600 and 850 nm. Figure 17 illustrates the fluorescence intensity from the tumor and several organs, normalized by their respective masses. \n\n There is a significant accumulation of this photosensilizer in the tumor one day after the intraperitoneal administration, when it reaches a concentration 3 times higher than in muscle. Additionally, the accumulation in the skin is negligible, which explains the lack of photosensitivity of the mice in the dark toxicity studies. Finally, the photosensitizer was cleared from most of the organs in 24 h. These farmacokinetics are very favorable for the selection of a time-window for PDT treatment where side effects are reduced and the efficiency of the treatment is maximized.\n\n\nSimilar studies were performed with other Luzitins, and Luzitin-Cl^Et showed a very strong tumor vs muscle selectivity. Figure 18.\n\n\nEXAMPLE 19. PDT OF MOLSE COLON CARCINOMA IN Balb/C MICE USING Luzitin- FMet\n\n\nThis example shows that Luzitins when exposed to light of an appropriate wavelength produce rumor regression-'necrosis.\n\n\nThe tumor model was CT26 mouse colon carcinoma, cultured as monolayer in the RPMI medium, containing 5% fetal calf serum and supplemented with antibiotics. The cells were grown at 37 \n0\nC in humidified atmosphere containing 5% CO\n2\n. The carcinoma cells (-1x10\n6\n) were taken up in 0.1 ml phosphate buffered saline (PBS) and implanted subcutaneously to the right flank of the Balb/C mice. The tumors grew to reach 5 mm in diameter in about one week after the implantation. No spontaneous necrosis was observed. The treatment was initiated when the tumor attained 5 mm in diameter in each animal. The day the tumors reached the treatment size, the mice were injected via i.p. with a dose of 10 mg/kg of Luzitin-FMet in PEG400. At 24 h post-injection, four mice were anesthetized with ketamine and xylazine, and treated with the Hamamatsu 748 nm diode laser described before, at a lluence rale of 100 mW/cm\n*\n for 22 minutes (total fluence of 132 J/cm\n2\n). Four other mice were not treated and served as control. The mice were checked daily, the tumors were measured using two orthogonal measurements L and W (perpendicular to L) and the volumes were calculated using the formula V=Lx W\n2\n/2 and recorded.\n\n\nFigure 19 shows the relative tumor volume measured at different days after laser irradiation. The size of the tumors in the animals treated are smaller than the average size of the control animals and in one case the tumor completely disappeared.\n\n\nEXAMPLE 20. PDT OF MELANOMA CELLS IN DBA/2 MICE USING Luzitin-Cl\n2\nEt \n\n This example shows that Luzitins when exposed to light of an appropriate wavelength produce tumor regression/necrosis.\n\n\nThe tumor model were S91 Cloudman melanoma cells, cultured as monolayer in the RPMI medium, containing 5% fetal calf serum and supplemented with antibiotics. The cells were grown at 37 \n0\nC in humidified atmosphere containing 5% C(X The melanoma cells (~lxl O\n6\n) were taken up in 0.1 ml phosphate buffered saline (PBS) and implanted subcutaneously to the right flank of the DBA/2 mice. The tumors grew to reach 5 mm in about one week after the implantation. No spontaneous necrosis was observed. The treatment was initiated when the tumor attained 5 mm in diameter in each animal. The day the tumors reached the treatment size, the mice were injected via i.p. with a dose of 10 mg/kg of Luzitin-C12Et in PEG400. At 24 h post-injection, the mice were anesthetized with ketamine and xylazine, and restrained in plastic holders, then treated with different light doses with the Hamamatsu 748 nm diode laser described before. Within minutes of the irradiation, the tumor area presented evident signals of necroses, that extended to all the irradiated area within a few hours. The mice were checked daily, and the size of the tumors was measured and recorded. Figure 20 shows the tumor size measured at different days after laser irradiation. Clearly, one single treatment session produced a long-lasting tumor regression.\n\n\nEXAMPLE 21. FORMULATIONS FOR TOPICAL ADMINISTRATION\n\n\nThis example shows that Luzitins can diffuse rapidly through the skin when applied with a suitable transdermal formulation. Four minipigs where employed to test the diffusion into the skin of the photosensitizers Luzitin-FMet. and to evaluate the eventual side effects of the formulations for topical administration.\n\n\nThe photosensitizer was first dissolved in absolute ethanol (5 mg in 0.556 ml), next 1.737 ml of propylene glycol were added, followed by 0.22 ml of Azone and 0.3 ml of water. The mixture was thoroughly mixed in vortex and sonicated to facilitate the solubilization, and then added to the gel base, composed of water (76.65%), 96% ethanol ( 15%) glycerin (6%), triethanolamine (1.35%), carbopol 940 ( 1%). The mixture is thoroughly mixed to achieve a good homogenization. In this formulation, the final concentration of photosensitizer is 0.1 % and that of Azone® in 4%.\n\n\nThe handling of the animals was described above. While calm under the anesthesia, the formulations were applied by hand, using surgical gloves, in pre-determined areas. Each application covered an approximately circular area 3 cm in diameter, with a thickness of a few millimeters of the gel. The application was covered with an occlusive patch. In some animals the same procedure was \n\n repeated 3 hour later, in a different area of the back. In one of the animals the formulations were removed 6 h after the application, the back of the animal was cleaned and it was kept alive for 10 days for subsequent evaluation. The skin samples were collected as described before. Each sample was approximately rectangular, with 2 cm sides, and a thickness of 1 cm. None of the animals, and in particular the animal that remained alive, showed evidence for side effects caused by the formulation with our without any of the sensitizers.\n\n\nAfter fixative treatment, each sample was cut into slice for evaluations by fluorescence microscopy and by confocal microscopy. A representative example of the images collected from the samples is presented in Figure 21. The images reveal that, within 3 h of the application of the gel, Luzitin-FMet diffused through all the epidermis. The fluorescence of Luzitin-FMet was further confirmed by its absorption spectrum in Figure 22. Thus, it is possible to formulate a composition for topical application of Luzitins that diffuses through the stratum corneum and the epidermis within a few hours, which is very convenient for PDT of skin disorders. \n\n\n\n\n( 1 ) K. Berg, in H. Hδnigsmann, G. Jori, A.R. Young (Eds.). The Fundamental Bases of Phototherapy. OEMF spa, Milano, 1996. p. 181-207.\n\n\n(2) R. V. Bensasson, EJ. Land, T.G. Truscott: Excited States and Free Radicals in Biology and Medicine, Oxford Univ. Press. Oxford, 1993.\n\n\n(3) Y. Vakrat-Haglili, L. Weiner, V. Brumfeld. A. Brandis, Y. Salomon, B. Mcllroy, B.C. Wilson. A. Pawlak, M. Rozanowska, T. Sarna, A. Scherz, J. Am. Chem. Soc. 127 (2005) 6487.\n\n\n(4) M. Pineiro, A. L. Carvalho, M.M. Pereira, A.M.d.A.R. Gonsalves, L.G. Arnaut. SJ. Formosinho, Chem. Eur. J. 4 (1998) 2299.\n\n\n(5) TJ. Dougherty, D.G. Boyle. K.R. Weishaupt: Photodynamic Therapy-Clinical and Drug Advances, Porphyrin Photosensitization, Plenum Press. New York. 1983.\n\n\n(6) TJ. Dougherty. CJ. Gomer, B.W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, Q. Peng. J. Natl. Cancer Inst. 90 (1998) 889.\n\n\n(7) R.L. Lipson, E.J. Baldes, A.M. Olsen, J. Natl. Cancer Inst. 26 (1961) 1.\n\n\n(8) TJ. Dougherty. D.G. Boyle, K.R. Weishaupt. B. Henderson, W. Potter, D. A. Bellnier, K.E. Wityk, Adv. Exp. Biol. Med. 160 (1983) 3.\n\n\n(9) R. K. Pandey, M.M. Siegel, R. Tsao. J.M. McReynolds, T.J. Dougherty, Biomed. And Environ. Mass Spectrometry 19 ( 1990) 405.\n\n\n( 10) R. Bonnett, G. Martinez, Tetrahedron 57 (2001 ) 9513.\n\n\n( 1 1) E.D. Sternberg, D. Dolphin, C. Brucker, Tetrahedron 54 ( 1998) 4151.\n\n\n(12) M. Pineiro, A.M.d.A. Rocha Gonsalves. M.M. Pereira, SJ. Formosinho, L.G. Arnaut, J. Phys. Chem. A 106 (2002) 3787.\n\n\n( 13) Y. Chen. G. Li, R.K. Pandey, Current Org. Chem. 8 (2004) 1 105.\n\n\n( 14) E.M. Beems, T.M.A.R. Dubbelman, J. Lugtenburg. J.A.B. Best. M.F.M.A. Smeets, J.P.J. Boehgeim, Photochem. Photobiol. 46 (1987) 639.\n\n\n(15) S. Schastak, B. Jean. R. Handzel. G. Kostenich. R. Hermann. U. Sack, A. Orenstein, Y. Wang. P. Wiedemann, J. Photochem. Photobiol. B: Biol. 78 (2005) 203.\n\n\n( 16) CK. Chang, C. Sotiriou. W. Wu, J. Chem. Soc. Chem. Commun. (1986) 1213.\n\n\n( 17) A.R. Morgan, D. Skalkos. G.M. Garbo, R.W. Keck, S.H. Selamn, J. Med. Chem. 34 (1991 ) 2126.\n\n\n( 18) P. Yong-Hin. T.P. Wijesekcra. D. Dolphin, Tetrahedron Lett. 32 ( 1991) 2875.\n\n\n( 19) G. Zheng. A. Kozyrev. TJ. Dougherty. K.M. Smith. R.K. Pandey. Chemistry Lett. ( 1996) 1 19.\n\n\n(20) A.C. Tome. P.S.S. Lacerda, M.G.P.M.S. Neves, J.A. S. Cavaleiro. Chem Commun (1997) 1 199.\n\n\n(21) H.-J. Kim, J.S. Lindsey. J. Org. Chem. 70 (2005) 5475.\n\n\n(22) H.W. Whitlock Jr.. R. Hanauer, M.Y. Oester, B.K. Bower, J. Am. Chem. Soc. 91 (1969) 7485.\n\n\n(23) R. Bonnett, R.D. White, U.-J. Winfield, M.C. Berenbaum, Biochem. J. 261 ( 1989) 277.\n\n\n(24) F.S. De Rosa. M.V.L.B. Bentley, Pharm. Res. 17 (2000) 1447.\n\n\n(25) J.L. McCullough, G. D. Weinstein, L.L. Lemus. W. Rampone. JJ. Jenkins, J. Invest. Dermatol. 81 (1983) 528.\n\n\n(26) O. Santoro, G. Bandieramonte, E. Melloni, R. Marchesini, F. Zunino, P. Lepera, G. De Palo, Cancer Res. 50 (1990) 4501.\n\n\n(27) J.C. Kennedy, R.H. Pottier, D.C. Pross, J. Photochem. Photobiol. B 6 ( 1990) 143.\n\n\n(28) S.R. Wiegell, I.-M. Stender. R. Na, H.C. WuIf, Arch. Dermatol. 139 (2003). \n\n (29) E.G. Azenha, A.C. Serra. M. Pineiro. MM. Pereira, J. Seixas de MeIo, L.G. Amaut, SJ. Formosinho, A.M.d.A.R. Gonsalves. Chem. Phys 280 (2002) 177.\n\n\n(30) R.W. Boyle. D. Dolphin, Photochem. Photobiol. 64 ( 1996) 469.\n\n\n(31 ) A. S. M. Ressurreieao. M. Pineiro, L.G. Arnaut, A.M.d.A.R. Gonsalves, J. Porphyrins Phthalocyanines 1 1 (2007) 50.\n\n\n(32) B.M. Magnusson, WJ. Pugh. M.S. Roberts, Pharm. Res. 21 (2004) 1047.\n\n\n(33) A.M.d.A.R. Gonsalves, J.M.T.B. Varejao, M.M. Pereira, J. Heterocycl. Chem. 28 ( 1991 ) 635.\n\n\n(34) A.M.D.R. Gonsalves, R.A.W. Johnstone, M.M. Pereira, A.M.P. deSantAna, A.C. Serra, AJ.F.N. Sobral, P.A. Stocks, HETEROCYCLES 43 (1996) 829.\n\n\n(35) CJ.P. Monteiro. M.M. Pereira, S.M.A. Pinto. A.V.C. Simδes. G.F.F. Sa, L.G. Arnaut, SJ. Formosinho, S. Simδes. M.F. Wyatt, Tetrahedron 64 (2008) 5132.\n\n\n(36) C. Serpa. PJ. S. Gomes, L.G. Amaut, SJ. Formosinho, J. Pina, J. Seixas de MeIo, Chem. Eur. J. 12 (2006).\n\n\n(37) J. M. Dabrowski, M.M. Pereira, L.G. Arnaut. CJ.P. Monteiro, A. F. Peixoto, A. Karocki. K. Urbanska, G. Stochel, Photochem. Photobiol. 83 (2007) 897.\n\n\n(38) R. Schmidt. C. Tanielian. R. Dunsbach, C. Wolff, J. Photochem. Photobiol. A: Chem. 79 (1994) 1 1.\n\n\n(39) M.H. Ovist, U. Hoeck, B. Kreilgaard, F. Madsen, S. Frokjaer. Eur. J. Pharm. Sc. 1 1 (2000) 59.\n\n\n(40) J. O'Brien, I. Wilson, T. Orton, F. Pognan. Eur. J. Biochem. 267 (2000) 5421.\n\n\n(41) M. Niedre, M.S. Patterson, B.C. Wilson. Photochem. Photobiol. 75 (2002) 382-91.\n\n\n(42) C. Tanielian, C. Schweitzer, R. Mechin. C. Wolff. Free Radic. Biol. Med. 30 (2001 ) 208-12.\n\n\n(43) C. Hadjur, N. Lange, J. Rebstein, P. Monnier, H. van der Bergh, G. Wagnieres, J. Photochem. Photobiol. B: Biol. 45 ( 1998) 170-78.\n\n\n(44) R. Bonnett, B. D. Djelal. A. Nguyen. J. Porphyrins Phthalocyanines 5 (2001) 652.\n\n\n(45) R. Bonnett. P. Charlesworth. B. D. Djelal, D.J. McGarvey, T.G. Truscott. J. Chem. Soc, Perkin Trans. 2 (1999) 325.\n\n\n(46) R. Bonnett. B.D. Djelal, P.A. Hamilton. G. Martinez. F. Wierrani, J. Photochem. Photobiol. B: Biol. 53 (1999) 136-43.\n\n\n(47) E. Crescenzi. A. Chiaviello, G. Canti, E. Reddi. B.M. Veneziani, G. Palumbo, MoI. Cancer Ther. 5 (2006) 776-85.\n\n\n(48) D.G. Hilmey, M. Abe, M.I. Nelen. CE. Stilts, G.A. Baker, S.N. Baker, F.V. Bright. S.R. Davies. S.O. Gollnick, A.R. Oseroff, S.L. Gibson, R. HiIf, M.R. Detty, J. Med. Chem. 45 (2002) 449-61.\n\n\n(49) A. Hajri. S. Wack. C. Meyer, M. K. Smith, C. Leberquier, M. Kedinger, M. Aprahamian, Photochem. Photobiol. 7s\n'\n (2002) 140.\n\n\n(50) H. Rezzoug, L. Bezdetnaya, O. A'amar, J. L. Merlin, F. Guillemin, Lasers Med. Sci. 13 ( 1998) 1 19.\n\n\n(51 ) CA. Lipinski, F. Lombardo, B.W. Dominy. PJ. Feeney. Adv. Drug Del. Rev. 46 (2001 ) 3."
  },
  {
    "id": "JP2010202526A",
    "text": "Invasion inhibitor of hepatitis c virus to host cell and medicinal composition containing the same AbstractTranslated fromJapanese【課題】HCVの宿主細胞への侵入を阻害することにより、Ｃ型肝炎を予防し、治療することを目的とする。【解決手段】本発明は、以下の一般式（Ｉ）で示されるフェニルカルバモイル誘導体又はそれらの薬学的に許容される塩からなる、HCVの宿主細胞への侵入阻害剤を提供する。【化１】［式中、R1は、置換基で置換された若しくは置換されていない、アリール基又はヘテロアリール基を表し、R2は、水素、ハロゲン、低級アルキル基、低級アルケニル基又は低級アルキニル基を表し、X1及びX2は、それぞれ独立して、O、S、NH又はCH2を表す］【選択図】なしAn object of the present invention is to prevent and treat hepatitis C by inhibiting the entry of HCV into host cells.The present invention provides an inhibitor of HCV entry into a host cell, comprising a phenylcarbamoyl derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof.[Chemical 1][Wherein, R1represents an aryl group or a heteroaryl group substituted or unsubstituted with a substituent, and R2represents hydrogen, halogen, a lower alkyl group, a lower alkenyl group, or a lower alkynyl group. , X1and X2each independently represents O, S, NH or CH2][Selection figure] None Claims (\n4\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  以下の一般式（Ｉ）で示されるフェニルカルバモイル誘導体、一般式（ＩＩ）で示されるレゾルシノール誘導体及びそれらの薬学的に許容される塩からなる群から選択される、Ｃ型肝炎ウイルスの宿主細胞への侵入阻害剤。\n\n\n \n \n\n［式中、R\n1\nは、置換基で置換された若しくは置換されていない、アリール基又はヘテロアリール基を表し、R\n2\nは、ハロゲン、低級アルキル基、低級アルケニル基又は低級アルキニル基を表し、X\n1\n及びX\n2\nは、それぞれ独立して、酸素原子（O）、硫黄原子（S）、NH又はCH\n2\nを表す。］\n\n\n \n \n\n［式中、R\n3\n及びR\n4\nは、それぞれ独立して、水素原子（H）、ハロゲン、低級アルキル基、低級アルケニル基又は低級アルキニル基を表す。］\n\nTo a hepatitis C virus host cell selected from the group consisting of the following phenylcarbamoyl derivatives represented by general formula (I), resorcinol derivatives represented by general formula (II) and pharmaceutically acceptable salts thereof: Invasion inhibitor. \n \n \n \n [Wherein, R \n1\n represents an aryl group or a heteroaryl group substituted or unsubstituted with a substituent, R \n2\n represents a halogen, a lower alkyl group, a lower alkenyl group, or a lower alkynyl group; \n1\n and X \n2\n each independently represents an oxygen atom (O), a sulfur atom (S), NH or CH \n2\n . ] \n \n \n \n [Wherein, R \n3\n and R \n4\n each independently represent a hydrogen atom (H), a halogen, a lower alkyl group, a lower alkenyl group, or a lower alkynyl group. ]\n\n\n\n\n\n\n\n\n\n\n \n\n  式（ＩＩＩ）で示される化合物である、請求項１記載の侵入阻害剤。\n\n\n \n \n\n［式中、Phはフェニル基を表す。］\n\nThe invasion inhibitor according to claim 1, which is a compound represented by the formula (III). \n \n \n \n [Wherein Ph represents a phenyl group. ]\n\n\n\n\n\n\n\n\n\n\n \n\n  式（ＩＶ）で示される化合物である、請求項１記載の侵入阻害剤。\n\n\n \n \n\n［式中、Meはメチル基を表す。］\n\nThe invasion inhibitor according to claim 1, which is a compound represented by the formula (IV). \n \n \n \n [In the formula, Me represents a methyl group. ]\n\n\n\n\n\n\n\n\n\n\n \n\n  請求項１〜３のいずれか一項記載の侵入阻害剤を少なくとも１以上含有する、Ｃ型肝炎ウイルスの宿主細胞への侵入を阻害するための医薬組成物。\n\n\n  A pharmaceutical composition for inhibiting entry of hepatitis C virus into a host cell, comprising at least one entry inhibitor according to any one of claims 1 to 3. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は、Ｃ型肝炎ウイルスの宿主細胞への侵入阻害剤及びこれを含有する医薬組成物に関する。\n\n\n  The present invention relates to an inhibitor of hepatitis C virus entry into a host cell and a pharmaceutical composition containing the same.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  Ｃ型肝炎ウイルス（HCV：Hepatitic C Virus、以下、一部を除きHCVと記載する）は、フラビウイルス科ヘパシウイルス（Hepacivirus）属に分類されるRNAウイルスである。本ウイルスは、一本鎖RNA（＋）ゲノムとエンベロープからなる構造を有する（非特許文献１）。\n\n\n  Hepatitis C virus (HCV: Hepatitic C Virus, hereinafter referred to as HCV except for a part) is an RNA virus classified into the genus Hepacivirus in the Flaviviridae family. This virus has a structure consisting of a single-stranded RNA (+) genome and an envelope (Non-patent Document 1).\n\n\n\n\n\n\n\n \n\n  同じ肝炎ウイルスであっても、DNAウイルスであるB型肝炎ウイルス（HBV）は、免疫能の未熟な新生児及び乳幼児期以外では感染しても免疫機構により排除され、急性感染で終わる。一方、HCVは、未だ明らかではない原因により宿主の免疫機構を回避する。そのため免疫機構の発達した大人に感染した場合であっても、持続性感染に移行することが多い。\n\n\n  Even if it is the same hepatitis virus, hepatitis B virus (HBV), which is a DNA virus, is eliminated by the immune mechanism and ends in acute infection even if it is infected other than immature newborns and infants. HCV, on the other hand, circumvents the host's immune mechanism due to an unclear cause. Therefore, even when an adult with a developed immune system is infected, it often shifts to persistent infection.\n\n\n\n\n\n\n\n \n\n  HCV感染により引き起こされる肝炎（Ｃ型肝炎）は、その後二十数年の経過の中で肝硬変に至り、最終的には肝癌になる可能性がある。肝癌は、手術で癌を摘出しても非癌部で引き続き起こる炎症のため再発患者の多いことが知られている。\n\n\n  Hepatitis caused by HCV infection (hepatitis C) can lead to cirrhosis over the course of more than 20 years, and may eventually become liver cancer. It is known that liver cancer has many recurrence patients due to inflammation that continues in the non-cancerous part even if the cancer is removed by surgery.\n\n\n\n\n\n\n\n \n\n  HCV感染者は、日本国内で約２００万人おり、世界では約２億人いると推定されている。また、HCVに感染していることを自覚していない無症候性キャリアも多数存在している。現在、日本国内では、肝細胞癌による犠牲者は年間約３．５万人となっており、その８割はHCV感染によるものである(非特許文献２)。\n\n\n  There are approximately 2 million HCV-infected people in Japan and an estimated 200 million people worldwide. There are also many asymptomatic carriers who are not aware of being infected with HCV. Currently, there are about 35,000 victims of hepatocellular carcinoma annually in Japan, 80% of which are due to HCV infection (Non-patent Document 2).\n\n\n\n\n\n\n\n \n\n  Ｃ型肝炎に対しては、現在、インターフェロンとリバビリン（Ribavirin：1-β-D-リボフラノシル-1H-1,2,4-トリアゾール-3-カルボキサミド）の併用療法が一般的である(非特許文献３)。しかしながら、この併用療法は、患者全体の約50％にしか有効ではなく、また、血球減少症・溶血性貧血等重篤な副作用を起こすことが知られている（非特許文献４）。\n\n\n  For hepatitis C, combination therapy of interferon and ribavirin (Ribavirin: 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) is currently common (non-patent literature) 3). However, this combination therapy is effective only for about 50% of all patients and is known to cause serious side effects such as cytopenia and hemolytic anemia (Non-patent Document 4).\n\n\n\n\n\n\n\n \n\n  それ故、薬効の優れた新たなHCV阻害剤を創出することが求められている。そのためには、HCVがどのようにして宿主細胞に侵入し、複製増殖するのか、そして宿主細胞にどのような影響を与えるのかといったHCVの生活環の詳細を明らかにし、HCV阻害剤を探索する必要がある。\n\n\n  Therefore, it is required to create a new HCV inhibitor with excellent medicinal effects. To that end, it is necessary to clarify the details of the HCV life cycle, such as how HCV enters the host cell, replicates, and how it affects the host cell, and searches for HCV inhibitors There is.\n\n\n\n\n\n\n\n \n\n  図１は、HCVの生活環を示している。HCV（００１）は、まず、宿主細胞（００３）のウイルス受容体（００２）に結合し（A）、エンドサイトーシスによって宿主細胞内に取り込まれる（B）。次に、HCVゲノムRNA（００４）がウイルス粒子から宿主細胞質内に放出される（脱殻）（C）。続いて、当該放出されたHCVゲノムRNAにコードされたHCVタンパク質前駆体（００５）が翻訳され（D）、プロセッシング（E）によって各ウイルスタンパク質（００６）が生成される。その後、HCVゲノムRNAが生成されたウイルスタンパク質の一つであるRNAポリメラーゼ（００７）によって複製される（F）。複製されたHCVゲノムRNAは、ウイルスタンパク質であるコアタンパク質及びエンベロープタンパク質によってパッケージングされ、新たなウイルス粒子が形成される（G）。最後に、ウイルス粒子は、宿主細胞膜を破り、細胞外に放出される（H）。よって、このHCVの生活環のいずれかの経路を阻害する化合物は、HCV阻害剤となり得るといえる。\n\n\n  FIG. 1 shows the life cycle of HCV. HCV (001) first binds to the viral receptor (002) of the host cell (003) (A) and is taken up into the host cell by endocytosis (B). Next, HCV genomic RNA (004) is released from the viral particle into the host cytoplasm (hulling) (C). Subsequently, the HCV protein precursor (005) encoded by the released HCV genomic RNA is translated (D), and each viral protein (006) is generated by processing (E). Thereafter, HCV genomic RNA is replicated (F) by RNA polymerase (007), which is one of the viral proteins produced. The replicated HCV genomic RNA is packaged by the core protein and envelope protein, which are viral proteins, and new viral particles are formed (G). Finally, the viral particles break the host cell membrane and are released extracellularly (H). Therefore, it can be said that a compound that inhibits any pathway in the life cycle of HCV can be an HCV inhibitor.\n\n\n\n\n\n\n\n \n\n  １９９９年に、HCVを人工的に複製させる実験システムとしてサブゲノミックHCVレプリコンシステムが登場した（非特許文献５）。このシステムでは、HCVゲノムの複製に必須のNS3〜NS5B領域及びゲノムの両末端からなるHCVサブゲノムが細胞内で複製されるように構成されており、１細胞あたりのHCVサブゲノムのコピー数は数千というレベルに達する。それ故、当該評価系を用いて、HCV感染を阻害する化合物を探索することが可能となった（非特許文献６）。\n\n\n  In 1999, a subgenomic HCV replicon system appeared as an experimental system for artificially replicating HCV (Non-patent Document 5). In this system, the NS3 to NS5B region essential for HCV genome replication and the HCV subgenome consisting of both ends of the genome are replicated within the cell, and the number of copies of the HCV subgenome per cell is thousands. Reach the level. Therefore, it has become possible to search for a compound that inhibits HCV infection using the evaluation system (Non-patent Document 6).\n\n\n\n\n\n\n\n \n\n  前記サブゲノミックHCVレプリコンシステムから選択されたHCV阻害剤には、HCV感染後の後期のウイルスゲノムの複製過程（図１F）とウイルスタンパク質の翻訳後のプロセッシング過程（図１E）とに作用するRNAポリメラーゼ、ヘリカーゼ、プロテアーゼ等のウイルス酵素を標的とした酵素阻害剤が知られている（特許文献１、２）。しかしながら、ウイルス酵素をコードする遺伝子は変異を生じ易い。それ故、これらの酵素阻害剤に対する耐性ウイルス株が容易に出現するため、薬効としては不十分である（非特許文献７)。したがって、HCVの生活環において他の経路を阻害する阻害剤を見出すことが課題となっている。\n\n\n  HCV inhibitors selected from the subgenomic HCV replicon system include RNA polymerases that act in the late viral genome replication process after HCV infection (FIG. 1F) and post-translational processing of viral proteins (FIG. 1E). In addition, enzyme inhibitors targeting viral enzymes such as helicase and protease are known (\nPatent Documents\n 1 and 2). However, genes encoding viral enzymes are prone to mutation. Therefore, since resistant virus strains against these enzyme inhibitors easily appear, their medicinal effects are insufficient (Non-patent Document 7). Therefore, finding an inhibitor that inhibits other pathways in the life cycle of HCV is a challenge.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n国際公開ＷＯ２００８／０９８８５９\nInternational Publication WO2008 / 09859\n\n\n\n\n\n\n\n\n\n\n \n特表２００７−５１３９７１\nSpecial table 2007-513971\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nRosenberg, S. J. Mol. Biol., (2001) 313, 451-464\nRosenberg, S. J. Mol. Biol., (2001) 313, 451-464\n\n\n\n\n\n\n\n\n\n\n \nSaito, I., et al Proc. Natl, Acad. Sci. USA, (1990) 87, 6547-6549\nSaito, I., et al Proc. Natl, Acad. Sci. USA, (1990) 87, 6547-6549\n\n\n\n\n\n\n\n\n\n\n \nHcHutchinson, JG et al.,. N. Engl. J. Med., (1998) 339, 1485-1492\nHcHutchinson, JG et al.,. N. Engl. J. Med., (1998) 339, 1485-1492\n\n\n\n\n\n\n\n\n\n\n \nMori, S., et al., Biochem. Biophis. Res. Commun., (1992) 183, 334-342\nMori, S., et al., Biochem. Biophis. Res. Commun., (1992) 183, 334-342\n\n\n\n\n\n\n\n\n\n\n \nLomann V, et al., Science, (1999) 285, 110-113\nLomann V, et al., Science, (1999) 285, 110-113\n\n\n\n\n\n\n\n\n\n\n \nBartenschlager R., Nature Rev. Drug Discovery, (2002) 1, 911-916\nBartenschlager R., Nature Rev. Drug Discovery, (2002) 1, 911-916\n\n\n\n\n\n\n\n\n\n\n \nLu, L., et al. Antimicro Agents Chemother., (2004) 48, 2260-2266)\nLu, L., et al. Antimicro Agents Chemother., (2004) 48, 2260-2266)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明は、HCVの宿主細胞への侵入を阻害することにより、Ｃ型肝炎を予防し、治療することを目的としている。\n\n\n  The object of the present invention is to prevent and treat hepatitis C by inhibiting the entry of HCV into host cells.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  上記目的を達成するため、本発明者らは鋭意研究を重ねた結果、植物及び微生物由来の純天然物を含む化合物ライブラリーからHCVが宿主細胞へ侵入するのを阻害できる化合物を新たに見出し、本発明を完成させるに至った。すなわち、本発明は、以下を提供するものである。\n\n\n  In order to achieve the above object, as a result of intensive research, the present inventors have newly found a compound capable of inhibiting entry of HCV into a host cell from a compound library containing pure natural products derived from plants and microorganisms. The present invention has been completed. That is, the present invention provides the following.\n\n\n\n\n\n\n\n \n\n（１）  以下の一般式（Ｉ）で示されるフェニルカルバモイル誘導体、一般式（ＩＩ）で示されるレゾルシノール誘導体及びそれらの薬学的に許容される塩からなる群から選択される、HCVの宿主細胞への侵入阻害剤。\n\n\n(1) To an HCV host cell selected from the group consisting of the following phenylcarbamoyl derivatives represented by the general formula (I), resorcinol derivatives represented by the general formula (II), and pharmaceutically acceptable salts thereof. Invasion inhibitor.\n\n\n\n\n\n\n\n \n \n \n \n\n［式中、R\n1\nは、置換基で置換された若しくは置換されていない、アリール基又はヘテロアリール基を表し、R\n2\nは、ハロゲン、低級アルキル基、低級アルケニル基又は低級アルキニル基を表し、X\n1\n及びX\n2\nは、それぞれ独立して、酸素原子（O）、硫黄原子（S）、NH又はCH\n2\nを表す。］\n\n \n \n \n [Wherein, R \n1\n represents an aryl group or a heteroaryl group substituted or unsubstituted with a substituent, R \n2\n represents a halogen, a lower alkyl group, a lower alkenyl group, or a lower alkynyl group; \n1\n and X \n2\n each independently represents an oxygen atom (O), a sulfur atom (S), NH or CH \n2\n . ]\n\n\n\n\n\n\n \n \n \n \n\n［式中、R\n3\n及びR\n4\nは、それぞれ独立して、水素原子（H）、ハロゲン、低級アルキル基、低級アルケニル基又は低級アルキニル基を表す。］\n\n \n \n \n [Wherein, R \n3\n and R \n4\n each independently represent a hydrogen atom (H), a halogen, a lower alkyl group, a lower alkenyl group, or a lower alkynyl group. ]\n\n\n\n\n\n\n \n\n（２）  式（ＩＩＩ）で示される化合物である、上記（１）記載の侵入阻害剤。\n\n\n(2) The entry inhibitor according to the above (1), which is a compound represented by the formula (III).\n\n\n\n\n\n\n\n \n \n \n \n\n［式中、Phはフェニル基を表す。］\n\n \n \n \n [Wherein Ph represents a phenyl group. ]\n\n\n\n\n\n\n \n\n（３）  式（ＩＶ）で示される化合物である、上記（１）記載の侵入阻害剤。\n\n\n(3) The entry inhibitor according to the above (1), which is a compound represented by the formula (IV).\n\n\n\n\n\n\n\n \n \n \n \n\n［式中、Meはメチル基を表す。］\n\n \n \n \n [In the formula, Me represents a methyl group. ]\n\n\n\n\n\n\n \n\n（４）  上記（１）〜（３）のいずれかに記載の侵入阻害剤を少なくとも１以上含有する、HCVの宿主細胞への侵入を阻害するための医薬組成物。\n\n\n(4) A pharmaceutical composition for inhibiting entry of HCV into a host cell, comprising at least one entry inhibitor according to any one of (1) to (3) above.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明によれば、HCVの宿主細胞への侵入を阻害する化合物及びそれを含有する医薬組成物を提供することができる。それによって、HCV感染を予防し又は治療することができる。\n\n\n  ADVANTAGE OF THE INVENTION According to this invention, the compound which inhibits the penetration | invasion to the host cell of HCV, and pharmaceutical composition containing the same can be provided. Thereby, HCV infection can be prevented or treated.\n\n\n\n\n\n\n\n \n\n  他の発明によれば、Ｃ型肝炎治療用又は予防用の医薬組成物を製造するための前記化合物の使用を提供することができる。\n\n\n  According to another invention, it is possible to provide use of the compound for producing a pharmaceutical composition for treating or preventing hepatitis C.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nHCVの生活環。\nHCV life cycle.\n\n\n\n\n\n\n \nHCVの感染阻害化合物スクリーニング方法の概要。\nOutline of screening method for HCV infection inhibitory compounds.\n\n\n\n\n\n\n \n感染性完全長ゲノムHCVレプリコンを含む感染性HCV粒子作製用プラスミドベクター。\nA plasmid vector for producing infectious HCV particles containing an infectious full-length genomic HCV replicon.\n\n\n\n\n\n\n \nHCV感染阻害剤（化合物１６、化合物２０）と対照用HCV感染阻害剤（NN-DNJ）。\nHCV infection inhibitor (compound 16, compound 20) and control HCV infection inhibitor (NN-DNJ).\n\n\n\n\n\n\n \nHCVccアッセイの結果：化合物１６、化合物２０は、細胞毒性のない濃度（10nM〜10μM）で量依存的にHCVccの感染を阻害することが示された。\nResults of HCVcc assay: Compound 16 and \nCompound\n 20 were shown to inhibit HCVcc infection in a dose-dependent manner at non-cytotoxic concentrations (10 nM to 10 μM).\n\n\n\n\n\n\n \nサブゲノミックHCVレポーターレプリコン作製ベクター(pSGR-JFH/Luc)の構造。\nStructure of subgenomic HCV reporter replicon production vector (pSGR-JFH / Luc).\n\n\n\n\n\n\n \nレプリコンアッセイの結果：化合物１６、化合物２０は細胞毒性のない濃度（10nM〜10μM）でHCVの複製を阻害しないことが示された。\nResults of replicon assay: \nCompounds\n 16 and 20 were shown not to inhibit HCV replication at non-cytotoxic concentrations (10 nM to 10 μM).\n\n\n\n\n\n\n \nシュードウイルス作製用ベクター群。\nVector group for pseudovirus production.\n\n\n\n\n\n\n \nHCVppアッセイの結果：化合物１６、化合物２０は、VSV-Gppの侵入を阻害しない濃度（0.1μM、１μM）でHCVpp（JFH１）、HCVpp（J6）の侵入を阻害することが示された。また、NN-DNJにはHCVppの侵入阻害活性がないことが示された。\nResults of HCVpp assay: \nCompounds\n 16 and 20 were shown to inhibit HCVpp (JFH1) and HCVpp (J6) invasion at concentrations that do not inhibit VSV-Gpp invasion (0.1 μM, 1 μM). It was also shown that NN-DNJ has no HCVpp entry inhibitory activity.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n１．HCV侵入阻害剤\n\n  本発明のHCVの宿主細胞への侵入阻害剤（HCV侵入阻害剤）は、以下の一般式（Ｉ）で示されるフェニルカルバモイル誘導体、一般式（ＩＩ）で示されるレゾルシノール誘導体及びそれらの薬学的に許容される塩からなる群から選択されることを特徴としている。\n\n1. HCV entry inhibitor The HCV entry inhibitor (HCV entry inhibitor) of the present invention includes a phenylcarbamoyl derivative represented by the following general formula (I), a resorcinol derivative represented by the general formula (II), and those Selected from the group consisting of the following pharmaceutically acceptable salts.\n\n\n\n\n\n\n \n \n \n \n\n［式中、R\n1\nは、置換基で置換された若しくは置換されていない、アリール基又はヘテロアリール基を表し、R\n2\nは、ハロゲン、低級アルキル基、低級アルケニル基又は低級アルキニル基を表し、X\n1\n及びX\n2\nは、それぞれ独立して、酸素原子（O）、硫黄原子（S）、NH又はCH\n2\nを表す。］\n\n \n \n \n [Wherein, R \n1\n represents an aryl group or a heteroaryl group substituted or unsubstituted with a substituent, R \n2\n represents a halogen, a lower alkyl group, a lower alkenyl group, or a lower alkynyl group; \n1\n and X \n2\n each independently represents an oxygen atom (O), a sulfur atom (S), NH or CH \n2\n . ]\n\n\n\n\n\n\n \n \n \n \n\n［式中、R\n3\n及びR\n4\nは、それぞれ独立して、水素原子（H）、ハロゲン、低級アルキル基、低級アルケニル基又は低級アルキニル基を表す。］\n\n \n \n \n [Wherein, R \n3\n and R \n4\n each independently represent a hydrogen atom (H), a halogen, a lower alkyl group, a lower alkenyl group, or a lower alkynyl group. ]\n\n\n\n\n\n\n \n\n  「HCV」（Ｃ型肝炎ウイルス：Hepatitic C Virus）とは、フラビウイルス科ヘパシウイルス属に分類される一本鎖RNAウイルスであって、本発明の標的ウイルスである。\n\n\n  “HCV” (Hepatitic C Virus) is a single-stranded RNA virus classified into the Flaviviridae hepacivirus genus and is the target virus of the present invention.\n\n\n\n\n\n\n\n \n\n  「宿主細胞」とは、HCVの標的細胞をいう。具体的には、肝細胞又はリンパ球が該当する。本発明の宿主細胞は、ヒト、チンパンジーまたはツパイ由来の細胞である。宿主細胞は、ヒトの初代培養肝細胞や肝癌細胞株若しくはその両者を融合させた細胞、チンパンジーやツパイの初代肝細胞又はヒトリンパ球由来細胞株のいずれであってもよい。\n\n\n  “Host cell” refers to a target cell of HCV. Specifically, it corresponds to hepatocytes or lymphocytes. The host cell of the present invention is a cell derived from human, chimpanzee or pine tree. The host cell may be any of human primary cultured hepatocytes, hepatoma cell lines or cells fused with both, chimpanzee and pine primary hepatocytes, or human lymphocyte-derived cell lines.\n\n\n\n\n\n\n\n \n\n  「侵入」とは、HCV感染における一過程であって、図１で示すウイルス生活環においてHCV粒子(HCV様粒子、HCVエンベロープタンパク質を含む)が宿主細胞の細胞表面に結合（A）し、細胞内に入り込む（B）までの過程をいう。具体的には、HCVが宿主細胞表面に存在するCD81（Bartosch, B. et al., J. Exp. Med., (2003) 197:633-642）及びClaudin-1(Evans, MJ, Nature,（2008） 446,801-805)等の受容体に結合し、その後エンドサイトーシスによって宿主細胞内のエンドソーム中に取り込まれるまでの過程を意味する。なお、本明細書で「感染」とは、ウイルス粒子、すなわちここではHCV粒子が宿主細胞の細胞表面に結合し、宿主細胞内で増殖された後、細胞外に放出されるまでの過程（図1A〜H）である。\n\n\n  “Invasion” is a process in HCV infection. In the viral life cycle shown in FIG. 1, HCV particles (including HCV-like particles and HCV envelope proteins) bind (A) to the cell surface of the host cell, The process up to (B). Specifically, CD81 (Bartosch, B. et al., J. Exp. Med., (2003) 197: 633-642) in which HCV is present on the host cell surface and Claudin-1 (Evans, MJ, Nature, (2008) 446,801-805) and the like, and then the process until it is taken up into endosomes in host cells by endocytosis. In this specification, “infection” refers to a process in which a virus particle, that is, HCV particle here binds to the cell surface of a host cell, grows in the host cell, and is released to the outside of the cell (FIG. 1A-H).\n\n\n\n\n\n\n\n \n\n  「HCV侵入阻害剤」とは、HCVの宿主細胞への侵入に必要な少なくとも一の機能を阻害する化合物であり、Ｃ型肝炎の治療剤又は予防剤における有効成分である。つまり、HCV侵入阻害剤は、HCVの侵入過程を阻害することでHCVの感染を阻害することができる化合物である。\n\n\n  An “HCV entry inhibitor” is a compound that inhibits at least one function required for entry of HCV into a host cell, and is an active ingredient in a therapeutic or prophylactic agent for hepatitis C. That is, an HCV entry inhibitor is a compound that can inhibit HCV infection by inhibiting the HCV entry process.\n\n\n\n\n\n\n\n \n\n  なお、「治療」とは、Ｃ型肝炎及び／又はそれに伴う症状を緩和又は除去することをいい、「予防」とは被験者がＣ型肝炎に罹患しないようにすることをいう。\n\n\n  “Treatment” refers to alleviating or eliminating hepatitis C and / or symptoms associated therewith, and “prevention” refers to preventing a subject from suffering from hepatitis C.\n\n\n\n\n\n\n\n \n\n  以下、HCV侵入阻害剤について詳細に説明をする。  \n\n１−１.フェニルカルバモイル誘導体\n\n  本発明におけるHCV侵入阻害剤の一つであるフェニルカルバモイル誘導体は、上記の一般式（Ｉ）で示される化学構造を有する。\n\nHereinafter, the HCV entry inhibitor will be described in detail. \n 1-1. Phenylcarbamoyl derivative The phenylcarbamoyl derivative which is one of the HCV entry inhibitors in the present invention has a chemical structure represented by the above general formula (I).\n\n\n\n\n\n\n \n\n  「アリール基」とは、多不飽和の、通常は芳香族の単環又は多環炭化水素基を意味し、単環又は多環が縮合又は共有結合したアリール環も包含する。具体的には、例えば、フェニル基、ナフチル基、ビフェニル基、フェナンスリル基等が挙げられる。\n\n\n  The “aryl group” means a polyunsaturated, usually aromatic monocyclic or polycyclic hydrocarbon group, and includes an aryl ring in which monocyclic or polycyclic rings are condensed or covalently bonded. Specific examples include a phenyl group, a naphthyl group, a biphenyl group, and a phenanthryl group.\n\n\n\n\n\n\n\n \n\n  「ヘテロアリール基」は、N（窒素原子）、O、Sからなる群から選択されるヘテロ原子を１〜４個含む５〜６員の芳香環基を意味し、単環又は多環が縮合又は共有結合したヘテロアリール環も包含する。N及びSは必要に応じて酸化されてもよい。また、Nは必要に応じて４級となる。さらに、ヘテロアリール基はヘテロ原子を介して分子の残部に結合してもよい。ヘテロアリール基の具体例としては、例えば、フリル基、チエニル基、ピロリル基、オキサゾリル基、チアゾリル基、イミダゾリル基、ピラゾリル基、トリアゾリル基、ピラジニル基、ピリダジニル基、ピリミジニル基、ピリジル基、トリアジニル基、ピロリニル基、ピラジニル基、ベンゾチエル基、プリニル基、ベンゾイミダゾリル基、インドリル基、イソキノリル基、キノキサリニル基又はキノリル基等が挙げられる。\n\n\n  “Heteroaryl group” means a 5- to 6-membered aromatic ring group containing 1 to 4 heteroatoms selected from the group consisting of N (nitrogen atom), O, and S. Or a covalently bonded heteroaryl ring. N and S may be oxidized as necessary. N is grade 4 as necessary. Furthermore, the heteroaryl group may be attached to the remainder of the molecule through a heteroatom. Specific examples of heteroaryl groups include, for example, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl, triazinyl, Examples include pyrrolinyl group, pyrazinyl group, benzothiyl group, purinyl group, benzimidazolyl group, indolyl group, isoquinolyl group, quinoxalinyl group, and quinolyl group.\n\n\n\n\n\n\n\n \n\n  「置換基で置換された若しくは置換されていない」とは、本発明の化合物がHCV侵入阻害活性を有する限り、任意の置換基を有してもよいことを意味する。ここでいう「置換基」は、低級アルキル基、低級アルケニル基、低級アルキニル基、低級アルコキシ基、ハロゲン、低級アルキルカルボニル基、低級アルキルカルボニルオキシ基、低級アルキルスルホニル基、水酸基、アミノ基、（モノ又はジ）低級アルキルアミノ基、アミド基、N-（モノ又はジ）低級アルキルアミド基、シアノ基、ニトロ基、カルボキシル基、カルバモイル基、硫酸基又は亜硫酸基等が含まれる。置換基の数は、１個若しくは複数個、例えば、１〜４個、好ましくは１又２個である。\n\n\n  “Substituted or unsubstituted by a substituent” means that the compound of the present invention may have any substituent as long as it has HCV entry inhibitory activity. The “substituent” herein is a lower alkyl group, lower alkenyl group, lower alkynyl group, lower alkoxy group, halogen, lower alkylcarbonyl group, lower alkylcarbonyloxy group, lower alkylsulfonyl group, hydroxyl group, amino group, (mono Or di) a lower alkylamino group, an amide group, an N- (mono or di) lower alkylamide group, a cyano group, a nitro group, a carboxyl group, a carbamoyl group, a sulfate group, or a sulfite group. The number of substituents is one or more, for example, 1 to 4, preferably 1 or 2.\n\n\n\n\n\n\n\n \n\n  「ハロゲン」は、F(フッ素)、Cl(塩素)、Br(臭素)又はI(ヨウ素)原子を意味する。\n\n  「低級アルキル基」は、炭素数１〜８個、好ましくは１〜４個の直鎖状又は分岐状のアルキル基である。具体的にはメチル、エチル、ｎ−プロピル、イソプロピル、ｎ−ブチル、イソブチル、sec−ブチル、tert−ブチル、ｎ−ぺンチル、イソぺンチル、ネオぺンチル、tert−ぺンチル、ヘキシル、ヘプチル又はオクチル等が含まれる。\n\n“Halogen” means an F (fluorine), Cl (chlorine), Br (bromine) or I (iodine) atom. \n The “lower alkyl group” is a linear or branched alkyl group having 1 to 8 carbon atoms, preferably 1 to 4 carbon atoms. Specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl or Octyl etc. are included.\n\n\n\n\n\n\n \n\n  「低級アルケニル基」は、炭素数２〜８個、好ましくは２〜４個の直鎖状又は分岐状のアルケニル基である。具体的にはエテニル、プロペニル、ブテニル、ブタジエニル、ペンテニル、ペンタジエニル、ヘキセニル、ヘキサジエニル、ヘプテニル、ヘプタジエニル、オクテニル、オクタジエニル又はこれらの異性体等が含まれる。\n\n\n  The “lower alkenyl group” is a linear or branched alkenyl group having 2 to 8 carbon atoms, preferably 2 to 4 carbon atoms. Specific examples include ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl, heptenyl, heptadienyl, octenyl, octadienyl or isomers thereof.\n\n\n\n\n\n\n\n \n\n  「低級アルキニル基」は、炭素数２〜８個、好ましくは２〜４個の直鎖状又は分岐状のアルキニル基である。具体的には、エチニル、プロピニル、ブチニル、ブタジイニル、ペンチニル、ペンタジイニル、ヘキシニル、ヘキサジイニル、ヘプチニル、ヘプタジイニル、オクチニル又はオクタジイニル等が含まれる。\n\n\n  The “lower alkynyl group” is a linear or branched alkynyl group having 2 to 8 carbon atoms, preferably 2 to 4 carbon atoms. Specific examples include ethynyl, propynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl, heptynyl, heptadiynyl, octynyl, octadiynyl and the like.\n\n\n\n\n\n\n\n \n\n  「低級アルコキシ基」は、炭素数１〜６個、好ましくは１〜４個の直鎖状又は分岐状のアルコキシ基である。具体的にはメトキシ、エトキシ、n−プロポキシ、イソプロポキシ、n−ブトキシ、イソブトキシ、s−ブトキシ、t−ブトキシ、n−ペンチルオキシ、イソペンチルオキシ、n−ヘキシルオキシ又はイソヘキシルオキシ等が含まれる。\n\n\n  The “lower alkoxy group” is a linear or branched alkoxy group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Specific examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, s-butoxy, t-butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy or isohexyloxy. .\n\n\n\n\n\n\n\n \n\n  「低級アルキルカルボニル基」は、カルボニル基に前記の低級アルキルが置換して形成される基である。\n\n  「低級アルキルスルホニル基」は、スルホニル基に前記の低級アルキルが置換して形成される基である。\n\n  「低級アルキルアミノ基」は、アミノ基に前記の低級アルキルが１つ又は２つ置換して形成される基である。\n\nThe “lower alkylcarbonyl group” is a group formed by substituting the above lower alkyl with a carbonyl group. \n The “lower alkylsulfonyl group” is a group formed by substituting the aforementioned lower alkyl with a sulfonyl group. \n The “lower alkylamino group” is a group formed by substituting one or two of the aforementioned lower alkyls on the amino group.\n\n\n\n\n\n\n \n\n  上記の一般式（Ｉ）で示されるフェニルカルバモイル誘導体において、R\n1\nとしては、置換基で置換された若しくは置換されていないアリール基が好ましく、置換基で置換された若しくは置換されていないフェニル基がより好ましい。\n\nIn the phenylcarbamoyl derivative represented by the above general formula (I), R \n1\n is preferably an aryl group substituted or unsubstituted with a substituent, and a phenyl group substituted or unsubstituted with a substituent is More preferred.\n\n\n\n\n\n\n \n\n  上記の一般式（Ｉ）で示されるフェニルカルバモイル誘導体において、R\n2\nとしては、ハロゲン又は低級アルキル基が好ましく、ハロゲンがより好ましい。R\n2\nの置換位置としては、CONH基に対してメタ位又はパラ位が好ましく、パラ位がより好ましい。\n\n  上記の一般式（Ｉ）で示されるフェニルカルバモイル誘導体において、X\n1\nとしては、NHが好ましい。また、X\n2\nとしては、O又はSが好ましく、Oが特に好ましい。\n\nIn the phenylcarbamoyl derivative represented by the above general formula (I), R \n2\n is preferably halogen or a lower alkyl group, more preferably halogen. As the substitution position of R \n2,\n the meta position or the para position is preferable with respect to the CONH group, and the para position is more preferable. \n In the phenylcarbamoyl derivative represented by the above general formula (I), X \n1\n is preferably NH. X \n2\n is preferably O or S, and particularly preferably O.\n\n\n\n\n\n\n \n\n  上記の一般式（Ｉ）で示されるフェニルカルバモイル誘導体において、以下の式（ＩＩＩ）で示される化合物は特に好ましい。\n\n\n  In the phenylcarbamoyl derivative represented by the above general formula (I), the compound represented by the following formula (III) is particularly preferable.\n\n\n\n\n\n\n\n \n \n \n \n\n［式中、Phはフェニル基を表す。］\n\n \n \n \n [Wherein Ph represents a phenyl group. ]\n\n\n\n\n\n\n \n\n１−２．レゾルシノール誘導体\n\n  本発明におけるHCV侵入阻害剤であるレゾルシノール誘導体は、上記の一般式（ＩＩ）で示される化学構造を有する。\n\n  ハロゲン、低級アルキル基、低級アルケニル基及び低級アルキニル基は、上記のフェニルカルバモイル誘導体と同様である。\n\n1-2. Resorcinol derivative The resorcinol derivative which is the HCV entry inhibitor in the present invention has a chemical structure represented by the above general formula (II). \n The halogen, lower alkyl group, lower alkenyl group and lower alkynyl group are the same as the above phenylcarbamoyl derivative.\n\n\n\n\n\n\n \n\n  R\n3\n及びR\n4\nとしては、低級アルキル基が好ましく、以下の式（ＩＶ）で示される化合物、すなわち、R\n3\n及びR\n4\nがメチル基（Me）の化合物は特に好ましい。\n\nAs R \n3\n and R \n4\n , a lower alkyl group is preferable, and a compound represented by the following formula (IV), that is, a compound in which R \n3\n and R \n4\n are methyl groups (Me) is particularly preferable.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  上記のレゾルシノール誘導体、すなわち、上記の式（ＩＩ）又は（ＩＶ）で示される化合物は、ラセミ体、ジアステレオマー、S体、R体、L体、D体のいずれかを含む。\n\n\n  The resorcinol derivative, that is, the compound represented by the above formula (II) or (IV) includes any of a racemate, a diastereomer, an S form, an R form, an L form, and a D form.\n\n\n\n\n\n\n\n \n\n１−３.薬学的に許容される塩\n\n  「薬学的に許容される塩」とは、前記フェニルカルバモイル誘導体及び／又はレゾルシノール誘導体の塩であって、これらの化合物上の特定の置換基により、塩基又は酸を用いて調製された薬学的に非毒性の活性化合物の塩をいう。使用した塩基又は酸により塩基性付加塩と酸付加塩とに分類できる。\n\n1-3. Pharmaceutically acceptable salt “Pharmaceutically acceptable salt” is a salt of the phenylcarbamoyl derivative and / or resorcinol derivative, wherein a base is substituted with a specific substituent on these compounds. Or a salt of a pharmaceutically non-toxic active compound prepared with an acid. Depending on the base or acid used, basic addition salts and acid addition salts can be classified.\n\n\n\n\n\n\n \n\n  塩基性付加塩としては、例えば、ナトリウム塩若しくはカリウム塩のようなアルカリ金属塩、カルシウム塩若しくはマグネシウム塩のようなアルカリ土類金属塩、トリメチルアミン塩、トリエチルアミン塩、ジシクロヘキシルアミン塩、エタノールアミン塩、ジエタノールアミン塩、トリエタノールアミン塩若しくはブロカイン塩のような脂肪族アミン塩、Ｎ,Ｎ-ジベンジルエチレンジアミンのようなアラルキルアミン塩、ピリジン塩、ピコリン塩、キノリン塩若しくはイソキノリン塩のような複素環芳香族アミン塩、アルギニン塩若しくはリジン塩のような塩基性アミノ酸塩、アンモニウム塩又はテトラメチルアンモニウム塩、テトラエチルアモニウム塩、ベンジルトリメチルアンモニウム塩、ベンジルトリエチルアンモニウム塩、ベンジルトリブチルアンモニウム塩、メチルトリオクチルアンモニウム塩若しくはテトラブチルアンモニウム塩のような第４級アンモニウム塩が挙げられる。\n\n\n  Examples of basic addition salts include alkali metal salts such as sodium salt or potassium salt, alkaline earth metal salts such as calcium salt or magnesium salt, trimethylamine salt, triethylamine salt, dicyclohexylamine salt, ethanolamine salt, diethanolamine. Salt, aliphatic amine salt such as triethanolamine salt or brocaine salt, aralkylamine salt such as N, N-dibenzylethylenediamine, heterocyclic aromatic amine such as pyridine salt, picoline salt, quinoline salt or isoquinoline salt Salt, basic amino acid salt such as arginine salt or lysine salt, ammonium salt or tetramethylammonium salt, tetraethylammonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzi Tributylammonium salts include quaternary ammonium salts such as methyl trioctyl ammonium salts or tetrabutylammonium salts.\n\n\n\n\n\n\n\n \n\n  酸付加塩としては、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩、炭酸塩、炭酸水素塩若しくは過塩素酸塩のような無機酸塩、酢酸塩、プロピオン酸塩、乳酸塩、マレイン酸塩、フマール酸塩、酒石酸塩、リンゴ酸塩、クエン酸塩若しくはアスコルビン酸塩のような有機酸塩、メタンスルホン酸塩、イセチオン酸塩、ベンゼンスルホン酸塩若しくはｐ−トルエンスルホン酸塩のようなスルホン酸塩又はアスパラギン酸塩及びグルタミン酸塩のような酸性アミノ酸等が挙げられる。\n\n\n  Examples of acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate or perchlorate, acetate, propionate, lactate, and maleic acid. Salt, fumarate, tartrate, malate, citrate or ascorbate such as organic acid salt, methanesulfonate, isethionate, benzenesulfonate or p-toluenesulfonate Examples include sulfonic acid salts or acidic amino acids such as aspartate and glutamate.\n\n\n\n\n\n\n\n \n\n  薬学的に許容される塩は、本発明の医薬組成物中でプロドラッグの形態であってもよい。ここでいう「プロドラッグ」は、生理学的条件下で容易に化学変化を受け、その結果として前記HCV侵入阻害剤又はその活性形態を提供する化合物である。例えば、投与前は、上記の一般式（Ｉ）及び（ＩＩ）で示される化合物とは異なる化合物であるが、消化管内で消化酵素の作用によって上記の一般式（Ｉ）及び（ＩＩ）で示される化合物又はその活性型に変換されるものをいう。あるいは、ex vivo環境で化学的又は生化学的方法によって前記化合物に変換されるものも含み得る。プロドラッグの形態は、例えば、親薬剤を経口投与しても生体内で直接利用ができない若しくは困難な場合に特に有効である。また、プロドラッグは親薬剤より医薬組成物での溶解度が高い場合が多く、その点においても有用である。\n\n\n  The pharmaceutically acceptable salt may be in the form of a prodrug in the pharmaceutical composition of the present invention. As used herein, a “prodrug” is a compound that readily undergoes a chemical change under physiological conditions, thereby providing the HCV entry inhibitor or its active form. For example, before administration, the compound is different from the compounds represented by the above general formulas (I) and (II), but is represented by the above general formulas (I) and (II) by the action of digestive enzymes in the digestive tract. Or a compound converted to its active form. Alternatively, it may include those that are converted to the compounds by chemical or biochemical methods in an ex vivo environment. The prodrug form is particularly effective when, for example, the parent drug is orally difficult to use directly or in vivo. Prodrugs are often more soluble in pharmaceutical compositions than the parent drug and are also useful in that respect.\n\n\n\n\n\n\n\n \n\n２．HCV侵入阻害組成物\n\n  本発明のHCVの宿主細胞への侵入を阻害するための医薬組成物（HCV侵入阻害組成物）は、上記のHCV侵入阻害剤を少なくとも１以上含有することを特徴としており、上記のHCV侵入阻害剤に、薬学的に許容可能な担体を含んだ医薬組成物のことである。\n\n2. HCV entry inhibitor composition A pharmaceutical composition (HCV entry inhibitor composition) for inhibiting entry of HCV into a host cell of the present invention comprises at least one HCV entry inhibitor described above, It is a pharmaceutical composition containing a pharmaceutically acceptable carrier in the HCV entry inhibitor.\n\n\n\n\n\n\n \n\n２−１．薬学的に許容可能な担体\n\n  「薬学的に許容可能な担体」とは、製剤技術分野において通常使用し得る溶媒及び／又は添加剤をいう。\n\n2-1. Pharmaceutically acceptable carrier \"Pharmaceutically acceptable carrier\" refers to a solvent and / or an additive that can be generally used in the field of pharmaceutical technology.\n\n\n\n\n\n\n \n\n  薬学的に許容可能な溶媒には、例えば、水、エタノール、プロピレングリコール、エトキシ化イソステアリルアルコール、ポリオキシ化イソステアリルアルコール、ポリオキシエチレンソルビタン脂肪酸エステル類等が挙げられる。これらは、殺菌されていることが望ましく、必要に応じて血液と等張に調整されていることが好ましい。\n\n  また、薬学的に許容可能な添加剤には、例えば、賦形剤、結合剤、崩壊剤、充填剤、乳化剤、流動添加調節剤、滑沢剤等が挙げられる。\n\nExamples of the pharmaceutically acceptable solvent include water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters and the like. These are preferably sterilized and preferably adjusted to be isotonic with blood as necessary. \n Examples of the pharmaceutically acceptable additive include an excipient, a binder, a disintegrant, a filler, an emulsifier, a fluid addition modifier, and a lubricant.\n\n\n\n\n\n\n \n\n  賦形剤としては、例えば、単糖、二糖類、シクロデキストリン及び多糖類のような糖（より具体的には、限定はしないが、グルコース、スクロース、ラクトース、ラフィノース、マンニトール、ソルビトール、イノシトール、デキストリン、マルトデキストリン、デンプン及びセルロースを含む）、金属塩（例えば、塩化ナトリウム、リン酸ナトリウム若しくはリン酸カルシウム、硫酸カルシウム、硫酸マグネシウム、炭酸カルシウム)、クエン酸、酒石酸、グリシン、低、中、高分子量のポリエチレングリコール（PEG）、プルロニック、カオリン、ケイ酸、あるいはそれらの組み合わせが挙げられる。\n\n\n  Excipients include, for example, sugars such as monosaccharides, disaccharides, cyclodextrins and polysaccharides (more specifically, but not limited to glucose, sucrose, lactose, raffinose, mannitol, sorbitol, inositol, dextrin , Maltodextrin, starch and cellulose), metal salts (eg sodium chloride, sodium phosphate or calcium phosphate, calcium sulfate, magnesium sulfate, calcium carbonate), citric acid, tartaric acid, glycine, low, medium, high molecular weight polyethylene Glycol (PEG), pluronic, kaolin, silicic acid, or combinations thereof.\n\n\n\n\n\n\n\n \n\n  結合剤としては、例えば、トウモロコシ、コムギ、コメ、若しくはジャガイモのデンプンを用いたデンプン糊、単シロップ、グルコース液、ゼラチン、トラガカント、メチルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロースナトリウム、セラック及び／又はポリビニルピロリドン等が挙げられる。\n\n\n  Examples of the binder include starch paste using corn, wheat, rice, or potato starch, simple syrup, glucose solution, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, shellac and / or polyvinylpyrrolidone, etc. Is mentioned.\n\n\n\n\n\n\n\n \n\n  崩壊剤としては、例えば、前記デンプンや、乳糖、カルボキシメチルデンプン、架橋ポリビニルピロリドン、アガー、ラミナラン末、炭酸水素ナトリウム、炭酸カルシウム、アルギン酸若しくはアルギン酸ナトリウム、ポリオキシエチレンソルビタン脂肪酸エステル、ラウリル硫酸ナトリウム、ステアリン酸モノグリセリド又はそれらの塩が挙げられる。\n\n\n  Examples of the disintegrant include the starch, lactose, carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, laminaran powder, sodium bicarbonate, calcium carbonate, alginic acid or sodium alginate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearin. Examples include acid monoglycerides or salts thereof.\n\n\n\n\n\n\n\n \n\n  充填剤としては、例えば、前記糖及び／又はリン酸カルシウム（例えば、リン酸三カルシウム、若しくはリン酸水素カルシウム）が挙げられる。\n\n  乳化剤としては、例えば、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル、プロピレングリコール脂肪酸エステルが挙げられる。\n\n  流動添加調節剤及び滑沢剤としては、例えば、ケイ酸塩、タルク、ステアリン酸塩又はポリエチレングリコールが挙げられる。\n\nExamples of the filler include the sugar and / or calcium phosphate (for example, tricalcium phosphate or calcium hydrogen phosphate). \n Examples of the emulsifier include sorbitan fatty acid ester, glycerin fatty acid ester, sucrose fatty acid ester, and propylene glycol fatty acid ester. \n Examples of the flow addition modifier and the lubricant include silicate, talc, stearate or polyethylene glycol.\n\n\n\n\n\n\n \n\n  このような担体は、主として前記剤形形成を容易にし、また剤形及び薬剤効果を維持するために用いられるものであり、必要に応じて適宜使用すればよい。上記の添加剤の他、必要に応じて矯味矯臭剤、溶解補助剤（可溶化剤）、懸濁剤、希釈剤、界面活性剤、安定剤、吸収促進剤（例えば、第４級アンモニウム塩類、ラウリル硫酸ナトリウム）、増量剤、付湿剤、保湿剤（例えば、グリセリン、澱粉）、吸着剤（例えば、澱粉、乳糖、カオリン、ベントナイト、コロイド状ケイ酸）、崩壊抑制剤（例えば、白糖、ステアリン、カカオバター、水素添加油）、コーティング剤、着色剤、保存剤、抗酸化剤、香料、風味剤、甘味剤、緩衝剤等を含むこともできる。\n\n\n  Such a carrier is mainly used for facilitating the formation of the dosage form and maintaining the dosage form and the drug effect, and may be appropriately used as necessary. In addition to the above additives, flavoring agents, solubilizers (solubilizers), suspending agents, diluents, surfactants, stabilizers, absorption enhancers (for example, quaternary ammonium salts, Sodium lauryl sulfate), bulking agent, moisturizer, humectant (eg, glycerin, starch), adsorbent (eg, starch, lactose, kaolin, bentonite, colloidal silicic acid), disintegration inhibitor (eg, sucrose, stearin) , Cocoa butter, hydrogenated oil), coating agents, colorants, preservatives, antioxidants, fragrances, flavoring agents, sweetening agents, buffering agents, and the like.\n\n\n\n\n\n\n\n \n\n  本発明の医薬組成物は、上記の式（Ｉ）〜（ＩＶ）で示される化合物又はそれらの薬学的に許容される塩が有する薬理効果を失わない範囲において、他の薬剤を含有することもできる。例えば、経口投与剤の場合であれば、必要に応じて胃粘膜保護剤を所定量含有していても良い。\n\n\n  The pharmaceutical composition of the present invention may contain other drugs as long as the pharmacological effects of the compounds represented by the above formulas (I) to (IV) or pharmaceutically acceptable salts thereof are not lost. it can. For example, in the case of an oral administration agent, a predetermined amount of a gastric mucosa protective agent may be contained as necessary.\n\n\n\n\n\n\n\n \n\n２−２．HCV侵入阻害組成物の製造\n\n  上記のHCV侵入阻害剤をHCV侵入阻害組成物として製剤化するには、原則として当業者に公知の方法を利用することができる。例えば、Remington's Pharmaceutical Sciences (Merck Publishing Co., Easton, Pa.)に記載の方法を用いればよい。\n\n2-2. Production of HCV Invasion Inhibiting Composition To formulate the above HCV invasion inhibitor as an HCV invasion inhibiting composition, in principle, methods known to those skilled in the art can be used. For example, the method described in Remington's Pharmaceutical Sciences (Merck Publishing Co., Easton, Pa.) May be used.\n\n\n\n\n\n\n \n\n  HCV侵入阻害組成物における上記のHCV侵入阻害剤の含有量は、使用するHCV侵入阻害剤の種類及び／又はその有効量（後述）、並びに医薬組成物の剤型（形態、大きさを含む）、添加する担体の種類によって異なり、それぞれの条件において適宜選択される。\n\n\n  The content of the HCV entry inhibitor in the HCV entry inhibitor composition is the type and / or effective amount (described later) of the HCV entry inhibitor used, and the dosage form (including form and size) of the pharmaceutical composition. Depending on the type of carrier to be added, it is appropriately selected under each condition.\n\n\n\n\n\n\n\n \n\n  一例として、錠剤であれば、１錠重量に対して通常0.1重量％〜30重量％、好ましくは0.5重量％〜20重量％、より好ましくは1重量％〜10重量％の上記HCV侵入阻害剤を含むことができる。具体的には、例えば、1錠200mgの錠剤を製造する場合、上記の式（ＩＩＩ）で示される化合物を１錠あたり通常200μg〜60mg含む。これ以外には、薬学的に許容可能な担体として、上記の賦形剤、結合剤、崩壊剤、崩壊抑制剤、吸収促進剤、保湿剤、吸着剤、潤沢剤を当該分野で公知の含有率で含むことができる。\n\n\n  For example, in the case of a tablet, the HCV entry inhibitor is usually 0.1% to 30% by weight, preferably 0.5% to 20% by weight, more preferably 1% to 10% by weight, based on the weight of one tablet. Can be included. Specifically, for example, when producing a tablet of 200 mg per tablet, the compound represented by the above formula (III) is usually contained in an amount of 200 μg to 60 mg per tablet. In addition to this, as the pharmaceutically acceptable carrier, the above-mentioned excipients, binders, disintegrants, disintegration inhibitors, absorption promoters, moisturizers, adsorbents, and lubricants are contained in the contents known in the art. Can be included.\n\n\n\n\n\n\n\n \n\n  注射剤として調製する場合には、前記HCV侵入阻害剤を薬学的に許容可能な担体である溶媒で溶解し、好ましくは血液と等張にした希釈剤を用いて当該分野で慣用されている方法により製造することができる。一投与単位の注射剤中に含有される前記HCV侵入阻害剤量は、一投与単位あたり通常0.1％(w/v)〜30％(w/v)、好ましくは0.1％(w/v)〜20％(w/v)、より好ましくは0.1％(w/v)〜30％(w/v)である。具体的には、例えば、１回2m1の注射剤を製造する場合、上記の式（ＩＩＩ）で示される化合物を通常2μg〜600μg含む。\n\n\n  When preparing as an injection, the HCV entry inhibitor is dissolved in a solvent that is a pharmaceutically acceptable carrier, and preferably a method commonly used in the art using a diluent that is made isotonic with blood. Can be manufactured. The amount of the HCV entry inhibitor contained in one injection unit is usually 0.1% (w / v) to 30% (w / v), preferably 0.1% (w / v) to one injection unit. It is 20% (w / v), more preferably 0.1% (w / v) to 30% (w / v). Specifically, for example, when a 2 ml injection is produced at a time, the compound represented by the above formula (III) is usually contained in an amount of 2 μg to 600 μg.\n\n\n\n\n\n\n\n \n\n  注射剤には、等張性の溶液を調製するのに充分な量の食塩、グルコース又はグリセリン及び通常の溶解補助剤、緩衝剤、ｐＨ調整剤、無痛化剤等も配合することができる。これら溶液、乳剤及び懸濁剤は、上記の式（Ｉ）〜（ＩＶ）の化合物及びそれらの薬学的に許容される塩の所定量を、前記水性や油性の非毒性の溶媒及び希釈剤に溶解又は懸濁し、さらに必要に応じて等張化剤等を加え、滅菌することにより調製することができる。\n\n\n  The injection may contain a sufficient amount of sodium chloride, glucose or glycerin and usual solubilizer, buffer, pH adjuster, soothing agent, etc. to prepare an isotonic solution. These solutions, emulsions and suspensions are prepared by adding predetermined amounts of the compounds of the above formulas (I) to (IV) and their pharmaceutically acceptable salts to the aqueous and oily non-toxic solvents and diluents. It can be prepared by dissolving or suspending, adding an isotonic agent or the like as necessary, and sterilizing.\n\n\n\n\n\n\n\n \n\n  局所剤らは、上記の式（Ｉ）〜（ＩＶ）の化合物及びそれらの薬学的に許容される塩の所定量を、外用製剤の目的に適合する香料、着色料、充填剤、界面活性剤、保湿剤、皮膚軟化剤、ゲル化剤、担体、保存剤、安定剤等のうちの一種以上と組み合わせることにより調製することができる。\n\n\n  The topical agents include a predetermined amount of the compounds of the above formulas (I) to (IV) and their pharmaceutically acceptable salts, and a fragrance, a coloring agent, a filler, and a surfactant that are suitable for the purpose of the external preparation. , Moisturizers, emollients, gelling agents, carriers, preservatives, stabilizers and the like.\n\n\n\n\n\n\n\n \n\n  坐剤の形態に調製するに際しては、基材としてこの分野で従来公知のものを広く使用できる。このような基材としては、例えばパルミチン酸ミリスチルエステル等の高級エステル類、高級アルコール類、ポリエチレングリコール、カカオ脂、ゼラチン、半合成グリセリド、これらの混合物などの低融点基材を挙げることができる。座剤は、上記の式（Ｉ）〜（ＩＶ）の化合物及びそれらの薬学的に許容される塩の所定量を上記基材に混入し、成型することにより調製することができる。\n\n\n  In preparing a suppository, a variety of conventionally known base materials in this field can be used. Examples of such a substrate include low-melting-point substrates such as higher esters such as myristyl palmitate, higher alcohols, polyethylene glycol, cocoa butter, gelatin, semi-synthetic glycerides, and mixtures thereof. Suppositories can be prepared by mixing a predetermined amount of the compounds of the above formulas (I) to (IV) and their pharmaceutically acceptable salts into the base material, followed by molding.\n\n\n\n\n\n\n\n \n\n２−３．HCV侵入阻害組成物の剤型\n\n  HCV侵入阻害組成物の剤型は、その投与方法によって異なり、また処方条件に応じて適宜選択される。投与方法については後述するが、通常は経口投与及び非経口投与に大別することができる。\n\n2-3. HCV entry inhibitor composition dosage form \n The dosage form of the HCV entry-inhibiting composition varies depending on the administration method, and is appropriately selected according to the formulation conditions. Although the administration method will be described later, it can be roughly classified into oral administration and parenteral administration.\n\n\n\n\n\n\n \n\n  経口投与に適した剤型としては、例えば、錠剤、糖衣剤、丸剤、カプセル剤、ドロップ剤、舌下剤、末剤、散剤、顆粒剤、液剤、トローチ剤等を挙げることができる。さらに錠剤は、必要に応じ、当該分野で公知の剤皮を施した錠剤、例えば、糖衣錠、ゼラチン被包錠、腸溶錠、フィルムコーティング錠、二重錠又は多層錠とすることができる。  \n\n\n  Examples of the dosage form suitable for oral administration include tablets, dragees, pills, capsules, drops, sublinguals, powders, powders, granules, liquids, lozenges and the like. Furthermore, the tablet can be a tablet coated with a coating known in the art, for example, a sugar-coated tablet, a gelatin-encapsulated tablet, an enteric tablet, a film-coated tablet, a double tablet or a multilayer tablet, if necessary.\n\n\n\n\n\n\n\n \n\n  非経口剤に適した剤型としては、例えば、注射剤、懸濁剤、乳剤、点眼剤、点鼻剤、クリーム剤、粉剤、ペースト剤、ゲル剤、軟膏剤、硬膏剤又は座剤等が挙げられる。これらは、組織内投与、局所投与又は経直腸的投与のように、その投与方法に適した剤型にすることができる。\n\n\n  Examples of dosage forms suitable for parenterals include injections, suspensions, emulsions, eye drops, nasal drops, creams, powders, pastes, gels, ointments, plasters or suppositories. Can be mentioned. These can be made into dosage forms suitable for the administration method, such as intra-tissue administration, local administration, or rectal administration.\n\n\n\n\n\n\n\n \n\n  組織内投与に適した剤型としては、例えば、注射剤を挙げることができる。\n\n  局所投与に適した剤型としては、例えば、液剤、クリーム剤、粉剤、ペースト剤、ゲル剤、軟膏剤、硬膏剤、点眼剤又は点鼻剤等を挙げることができる。\n\n  経直腸的投与に適した剤型としては、例えば、坐剤を挙げることができる。\n\n  前記各剤型の形状、大きさについては、いずれも当該分野で公知の剤型の範囲内にあればよく、特に限定はしない。\n\nExamples of dosage forms suitable for intra-tissue administration include injections. \n Examples of dosage forms suitable for topical administration include liquids, creams, powders, pastes, gels, ointments, plasters, eye drops, or nasal drops. \n Examples of dosage forms suitable for rectal administration include suppositories. \n The shape and size of each dosage form are not particularly limited as long as they are within the range of dosage forms known in the art.\n\n\n\n\n\n\n \n\n３．HCV侵入阻害剤及びHCV侵入阻害組成物の投与方法\n\n  上記のHCV侵入阻害剤及びHCV侵入阻害組成物は、投与単位形態で投与することが好ましく、経口投与、組織内投与（例えば、皮下投与、筋肉内投与、静脈内投与）、局所投与（例えば、経皮投与）又は経直腸的投与で投与することができる。上記のHCV侵入阻害剤及びHCV侵入阻害組成物は、これらの投与方法に適した剤型で投与されることが好ましい。\n\n  例えば、経口投与用製剤であれば、固形、粉末又は液剤の用量単位で投与することができる。\n\n3. Method of administering HCV entry inhibitor and HCV entry inhibitor composition The HCV entry inhibitor and HCV entry inhibitor composition described above are preferably administered in a dosage unit form, and are administered orally, intra-tissue (eg, subcutaneous administration, muscle Administration, intravenous administration), local administration (for example, transdermal administration) or rectal administration. The above HCV entry inhibitor and HCV entry inhibitor composition are preferably administered in dosage forms suitable for these administration methods. \n For example, in the case of a preparation for oral administration, it can be administered in a solid, powder or liquid dosage unit.\n\n\n\n\n\n\n \n\n  組織内投与の場合、皮下投与、筋肉内投与又は静脈内投与等のいずれの方法も使用できる。本発明の目的が上記の式（Ｉ）〜（ＩＶ）で示される化合物の作用でHCVが宿主細胞内へ侵入することを阻害し、それによりＣ型肝炎を治療又は予防すること、また、HCVが体液を介して伝播されること、さらに、主たる宿主細胞である肝細胞が存在する肝臓が無数の毛細血管を有することを鑑みれば、血流を介した投与が好ましい。それ故、好ましい投与方法は注射である。\n\n\n  In the case of intra-tissue administration, any method such as subcutaneous administration, intramuscular administration or intravenous administration can be used. The object of the present invention is to inhibit the entry of HCV into the host cell by the action of the compounds represented by the above formulas (I) to (IV), thereby treating or preventing hepatitis C, and HCV Administration through the bloodstream is preferable in view of the fact that the liver is propagated through bodily fluids and that the liver in which hepatocytes, which are the main host cells, have countless capillaries. Therefore, the preferred method of administration is injection.\n\n\n\n\n\n\n\n \n\n  注射の場合、注入部位は特に限定しない。例えば、静脈内、動脈内、肝臓内、筋肉内、関節内、骨髄内、髄腔内、心室内、経皮、皮下、皮内、腹腔内、鼻腔内、腸内又は舌下等が挙げられる。好ましくは、静脈内注射又は動脈内注射等の血管内への注射である。血流を介して本発明の医薬組成物を直ちに全身に行き渡らせることが可能であり、また侵襲性が比較的低く、被験者に与える負担が小さいからである。あるいは、肝臓内又は肝門脈に注射してもよい。これは、上記のHCV侵入阻害剤及びHCV侵入阻害組成物をHCVが局在する部位に直接的に作用させることができるからである。\n\n\n  In the case of injection, the injection site is not particularly limited. Examples include intravenous, intraarterial, intrahepatic, intramuscular, intraarticular, intramedullary, intrathecal, intraventricular, percutaneous, subcutaneous, intradermal, intraperitoneal, intranasal, intestinal, or sublingual. . Intravenous injection such as intravenous injection or intraarterial injection is preferable. This is because the pharmaceutical composition of the present invention can be immediately distributed to the whole body through the bloodstream, is less invasive, and has less burden on the subject. Alternatively, it may be injected into the liver or into the portal vein. This is because the above HCV entry inhibitor and HCV entry inhibitor composition can directly act on the site where HCV is localized.\n\n\n\n\n\n\n\n \n\n  上記のHCV侵入阻害剤及びHCV侵入阻害組成物を投与する場合、一投与単位中には、HCV侵入阻害活性が発揮され得る有効量が含有されていることが好ましい。本明細書で使用する場合、「有効量」とは、有効成分がその機能を発揮する上で必要な量、すなわち、本発明ではHCV侵入阻害剤がHCVの宿主細胞侵入を阻害する上で必要な量であって、かつ投与する被験者に対して有害な副作用をほとんど又は全く付与しない量をいう。この有効量は、被験者の情報、剤型及び投与経路等の様々な条件によって変化し得る。錠剤、丸剤又はカプセル剤のような剤型の場合、HCV侵入阻害剤の有効量は、剤数によって調整する分割投与が可能であるため、必ずしも１錠中に有効量を含有する必要はない。\n\n\n  When administering the above-mentioned HCV entry inhibitor and HCV entry inhibitor composition, it is preferable that one dosage unit contains an effective amount capable of exerting HCV entry inhibitory activity. As used herein, “effective amount” means an amount necessary for an active ingredient to exert its function, that is, in the present invention, an HCV entry inhibitor is necessary for inhibiting host cell entry of HCV. And an amount that causes little or no adverse side effects on the subject to be administered. This effective amount may vary depending on various conditions such as subject information, dosage form and route of administration. In the case of a dosage form such as a tablet, pill, or capsule, the effective amount of the HCV entry inhibitor can be divided and adjusted according to the number of agents, so it is not always necessary to contain the effective amount in one tablet. .\n\n\n\n\n\n\n\n \n\n  「被験者の情報」とは、病気の進行度若しくは重症度、全身の健康状態、年齢、体重、性別、食生活、薬剤感受性、併用医薬の有無及び治療に対する耐性等を含む。上記のHCV侵入阻害剤及びHCV侵入阻害組成物の最終的な投与量及び有効量は、個々の被験者の情報等に応じて、医師の判断によって決定される。HCV侵入阻害効果を得る上で、上記のHCV侵入阻害剤及びHCV侵入阻害組成物の大量投与が必要な場合、被験者に対する負担軽減のために数回に分割して投与することもできる。\n\n\n  “Subject information” includes the degree or severity of illness, general health, age, weight, sex, diet, drug sensitivity, presence or absence of concomitant drugs, resistance to treatment, and the like. The final dose and effective amount of the HCV entry inhibitor and the HCV entry inhibitor composition are determined according to the judgment of a doctor according to the information of individual subjects. When a large dose of the above HCV entry inhibitor and HCV entry inhibitor composition is required to obtain the HCV entry inhibitory effect, it can be divided into several times to reduce the burden on the subject.\n\n\n\n\n\n\n\n \n\n  具体的な投与量の一例として、例えば、Ｃ型肝炎発症初期であって、他の医薬の併用を必要としないヒト成人男子（体重60kg）に投与する場合、一日当たりのHCV侵入阻害剤の有効量は、通常1〜2000mg、好ましくは1〜1000mg、より好ましくは1〜500mgの範囲である。被験者の状態又は投与経路等に応じて、前記範囲未満又は前記範囲を超える用量を投与することもできる。\n\n\n  As an example of a specific dose, for example, when administered to a human adult male (60 kg body weight) who is in the early stage of hepatitis C onset and does not require the use of other drugs, the effectiveness of an HCV entry inhibitor per day The amount is usually in the range of 1 to 2000 mg, preferably 1 to 1000 mg, more preferably 1 to 500 mg. Depending on the condition of the subject, the route of administration, etc., a dose less than or exceeding the range can also be administered.\n\n\n\n\n\n\n\n \n\n  上記のHCV侵入阻害剤及びHCV侵入阻害組成物は、実施例で示すように、HCVの宿主細胞への侵入過程を阻害する薬剤である。このような薬剤は、現在臨床試験が進行中であるHCV酵素阻害剤と比較すると、耐性ウイルス株が出現しにくいことが期待される。したがって、これらをＣ型肝炎の予防又は治療に有効な医薬品として利用できる。\n\n\n  The above HCV entry inhibitor and HCV entry inhibitor composition are agents that inhibit the entry process of HCV into host cells, as shown in the Examples. Such drugs are expected to be resistant to the emergence of resistant virus strains compared to HCV enzyme inhibitors that are currently undergoing clinical trials. Therefore, these can be used as pharmaceuticals effective for the prevention or treatment of hepatitis C.\n\n\n\n\n\n\n\n\n\n \n\n  以下、実施例を挙げて本発明について具体的に説明するが、本発明は以下の実施例によって限定されるものではない。\n\n  本実施形態に係るHCV侵入阻害剤は、HCVの生活環（図１）を利用した３つのスクリーニング評価方法によって得られた。すなわち、第一の方法は、HCVの感染（図１のA〜Hの経路に相当）を阻害する化合物（HCV感染阻害剤）をスクリーニングする評価方法である。第二の方法は、HCVの生活環のうちHCVゲノムの翻訳及び複製過程（図１のD〜Fの経路に相当）を阻害する化合物（HCV複製翻訳阻害剤）をスクリーニングする評価方法である。そして、第三の方法は、HCVの生活環のうちHCVの細胞への侵入（図１のA〜Bの経路に相当）を阻害する化合物（HCV侵入阻害剤）をスクリーニングするための評価方法である。\n\nEXAMPLES Hereinafter, although an Example is given and this invention is demonstrated concretely, this invention is not limited by a following example. \n The HCV entry inhibitor according to the present embodiment was obtained by three screening evaluation methods using the life cycle of HCV (FIG. 1). That is, the first method is an evaluation method for screening for a compound (HCV infection inhibitor) that inhibits HCV infection (corresponding to the pathways A to H in FIG. 1). The second method is an evaluation method for screening a compound (HCV replication translation inhibitor) that inhibits the translation and replication process of the HCV genome (corresponding to the pathways D to F in FIG. 1) in the HCV life cycle. The third method is an evaluation method for screening for a compound (HCV entry inhibitor) that inhibits HCV entry into cells (corresponding to the route A to B in FIG. 1) in the life cycle of HCV. is there.\n\n\n\n\n\n\n \n\n  以下、各スクリーニング評価方法とその結果について説明をする。\n\n１．HCVの感染を阻害する化合物（HCV感染阻害剤）のスクリーニング\n\n（１）感染性HCVの調製：\n\n  国際公開WO07/037428に記載の方法に従い、図３に示すように、RNA PolIプロモーター／ターミネーター系を利用して、JFH1株（遺伝子型2a)のHCV cDNAを含むプラスミドベクター（pHH/ZeoJFH1）を構築した。pHH/ZeoJFH1は、感染性完全長ゲノムHCVレプリコン、すなわち、少なくともコアタンパク質、２つのエンベロープタンパク質（E1、E2）及び複製に必要な非構造タンパク質（NS2、NS3、NS4A、NS4B、NS5A、NS5B）を含み、コアタンパク質をコードする配列の上流にPolIプロモーター配列を、またNS5Bタンパク質をコードする配列の下流にPolIターミネーター配列を配置させてなる。\n\nHereinafter, each screening evaluation method and the result will be described. \n 1. Screening for compounds that inhibit HCV infection (HCV infection inhibitors) (1) Preparation of infectious HCV: \n According to the method described in International Publication WO07 / 037428, a plasmid vector (pHH / ZeoJFH1) containing HCV cDNA of JFH1 strain (genotype 2a) is constructed using RNA PolI promoter / terminator system as shown in FIG. did. pHH / ZeoJFH1 contains infectious full-length genomic HCV replicons, ie, at least core protein, two envelope proteins (E1, E2) and nonstructural proteins required for replication (NS2, NS3, NS4A, NS4B, NS5A, NS5B) A PolI promoter sequence upstream of the sequence encoding the core protein and a PolI terminator sequence downstream of the sequence encoding the NS5B protein.\n\n\n\n\n\n\n \n\n  なお、プロモーター配列は、ヒト肝癌由来Huh7細胞においてHCVが自律複製能を発揮しうるように配置されるものであればよく、特に限定されない。また、ターミネーター配列は、必要に応じて除くこともできる。さらに、コアタンパク質をコードする配列の上流に１つのIRES配列を含んでもよく、加えて一の選択マーカー遺伝子やリポーター遺伝子を含んでいてもよい。\n\n\n  The promoter sequence is not particularly limited as long as it is arranged so that HCV can exhibit autonomous replication ability in human liver cancer-derived Huh7 cells. In addition, the terminator sequence can be removed as necessary. Furthermore, one IRES sequence may be included upstream of the sequence encoding the core protein, and in addition, one selectable marker gene or reporter gene may be included.\n\n\n\n\n\n\n\n \n\n  感染性HCVを得るために、前記プラスミドベクターpHH/ZeoJFH1をヒト肝癌由来のHuh7.5.1細胞に導入した。得られた細胞株（Huh7.5.1/JFH1zeoR細胞）を、5％CO\n2\n下で37℃にて150cm\n2\nのフラスコ当たり30〜50mlの細胞培養用培地(10%FCS、10mM Hepes緩衝液、1mM MEMピルビン酸ナトリウム、1×MEM非必須アミノ酸溶液、１００単位/mlペニシリン及び100μg/mlストレプトマイシンを含有するダルベッコ変法イーグル培地)を用いて６日間培養し、得られた培養液上清を感染性HCVストック液とした。なお、培養期間は、３〜１０日間、好ましくは４〜７日間、より好ましくは５〜６日間とすることができる。培養液上清中のHCVコアタンパク質の数（fmol/ml）を「HCV量」とした。HCV量の測定にはオーソHCV抗原IRMAテストを用いた（Aoyagi et al., J. Clin. Microbiol., (1999), 37, p.1802-1808）。\n\nIn order to obtain infectious HCV, the plasmid vector pHH / ZeoJFH1 was introduced into Huh7.5.1 cells derived from human liver cancer. The obtained cell line (Huh7.5.1 / JFH1zeoR cells) was transferred to 30-50 ml cell culture medium (10% FCS, 10 mM Hepes buffer, 1 mM MEM per 150 cm \n2\n flask at 37 ° C. under 5% CO \n2.\n Dulbecco's modified Eagle medium containing sodium pyruvate, 1 × MEM non-essential amino acid solution, 100 units / ml penicillin and 100 μg / ml streptomycin), and the resulting culture supernatant is infected with infectious HCV The stock solution was used. The culture period can be 3 to 10 days, preferably 4 to 7 days, more preferably 5 to 6 days. The number of HCV core proteins (fmol / ml) in the culture supernatant was defined as “HCV amount”. Ortho HCV antigen IRMA test was used for the measurement of HCV amount (Aoyagi et al., J. Clin. Microbiol., (1999), 37, p.1802-1808).\n\n\n\n\n\n\n \n\n（２）HCV感染阻害剤のスクリーニング方法：\n\n  HCV感染阻害剤のスクリーニング方法の概要は図２に示す通りである。まず、ヒト肝癌由来Huh7.5.1細胞に試験化合物を加え、続いて感染性HCVを添加して、培養した。次に、培養液中のHCV量及び試験化合物で処理したヒト肝癌由来Huh7細胞の生存率（survival rate）（％）をそれぞれ測定し、生存率が約80％以上で、かつHCV量から算出されるHCV感染率（％）が約50％以下となる物質を第１候補化合物として選出した。次に、得られた第１候補化合物のうち選択性（selective index：Si）が１０以上の化合物をHCV感染阻害剤とした。ここで、「選択性」とは、CC\n50\n/EC\n50\nの値をいう。本式中、CC\n50\nは細胞が50％傷害を受ける薬剤の濃度であり、EC\n50\n値はウイルスの増殖を50％抑制する薬剤の濃度である。\n\n(2) HCV infection inhibitor screening method: \n The outline of the screening method for HCV infection inhibitors is as shown in FIG. First, a test compound was added to human liver cancer-derived Huh7.5.1 cells, and then infectious HCV was added and cultured. Next, the amount of HCV in the culture solution and the survival rate (%) of human hepatoma-derived Huh7 cells treated with the test compound were measured, and the survival rate was about 80% or more and calculated from the amount of HCV. Substances with an HCV infection rate (%) of about 50% or less were selected as the first candidate compounds. Next, among the obtained first candidate compounds, compounds having a selectivity (selective index: Si) of 10 or more were used as HCV infection inhibitors. Here, “selectivity” refers to the value of CC \n50\n / EC \n50\n . In this formula, CC \n50\n is the concentration of a drug that causes 50% cell damage, and the EC \n50\n value is the concentration of a drug that inhibits virus growth by 50%.\n\n\n\n\n\n\n \n\n  以下、HCV感染阻害剤の検出方法を詳述する。\n\nｉ）HCV感染率の算出：\n\n  まず、Huh7.5.1細胞（継代数が４３回目までのものを使用）を前記細胞培養用培地に懸濁し、1×10\n4\n個／100μl／ウェルとなるように９６ウェルのマイクロプレートに播種した。\n\nHereinafter, a method for detecting an HCV infection inhibitor will be described in detail. \n i) Calculation of HCV infection rate: \n First, Huh7.5.1 cells (use those having passage numbers up to the 43rd passage) were suspended in the cell culture medium and seeded on a 96-well microplate at 1 × 10 \n4\n cells / 100 μl / well.\n\n\n\n\n\n\n \n\n  次に、5μMの試験化合物を、前記マイクロプレートの細胞を培養した各ウェルに加えた。試験化合物には２８種類の化合物（化合物1〜化合物２８）を用いた。これらの化合物は、６００万種の化合物を含むバーチャルライブラリー（virtual library）に対してα‐グリコシダーゼ（alpha-glycosidase）の活性中心に対するドッキングシミュレーション（docking simulation）を行った結果、選択されたものである。シミュレーションでは１０２種類の化合物が選択されたが、このうち入手可能な３０種類（並木商事より購入）のみを対象とし、さらに溶解性の悪い２種類の化合物を除いている。なお、ドッキングシュミレーションとは、in silicoで標的分子に結合可能な分子を予測することをいう。また、対照サンプルとして試験化合物を添加しないウェル（候補阻害剤なし）を同時に調製した。\n\n\n  Next, 5 μM of the test compound was added to each well in which the cells of the microplate were cultured. 28 kinds of compounds (\ncompound\n 1 to compound 28) were used as test compounds. These compounds were selected as a result of a docking simulation of the active center of alpha-glycosidase on a virtual library containing 6 million compounds. is there. In the simulation, 102 types of compounds were selected. Of these, only 30 types (purchased from Namiki Shoji) that were available were targeted, and two types of compounds with poor solubility were excluded. Docking simulation refers to predicting a molecule that can bind to a target molecule in silico. As a control sample, a well (no candidate inhibitor) to which no test compound was added was prepared at the same time.\n\n\n\n\n\n\n\n \n\n  続いて、試験化合物の添加１５分後に、感染性HCVを0.2fmol／ウェルで播種し、培養した。播種７２時間後と１２０時間後に培養液から50μlを回収し、培養液中のHCV量を測定した。対照サンプル中のHCV量を100％としたときの各試験化合物添加サンプル中のHCV量をHCV感染率（％）として算出した。\n\n\n  Subsequently, 15 minutes after the addition of the test compound, infectious HCV was seeded at 0.2 fmol / well and cultured. After 72 hours and 120 hours after sowing, 50 μl was collected from the culture solution, and the amount of HCV in the culture solution was measured. The amount of HCV in each test compound-added sample when the amount of HCV in the control sample was taken as 100% was calculated as the HCV infection rate (%).\n\n\n\n\n\n\n\n \n\nｉｉ）Huh7.5.1細胞生存率の算出：\n\n  試験化合物で処理したHuh7.5.1細胞生存率は、Premix WST細胞増殖アッセイキット（タカラバイオ）を用いて試験化合物の細胞毒性アッセイ法により測定した。本キットは、テトラゾリウム塩WST-1の生成したホルマザンの吸光度を直接測定する方法に基づくものである。\n\nii) Calculation of Huh7.5.1 cell viability: \n The viability of Huh7.5.1 cells treated with the test compound was measured by test compound cytotoxicity assay using Premix WST cell proliferation assay kit (Takara Bio). This kit is based on a method for directly measuring the absorbance of formazan produced by the tetrazolium salt WST-1.\n\n\n\n\n\n\n \n\n  まず、Huh7.5.1細胞（継代数が４３回目までのものを使用）を前記細胞培養用培地に懸濁し、1×10\n4\n個／100μl／ウェルとなるように９６ウェルのマイクロプレートに播種した。\n\n  次に、5μMの前記２８種類の試験化合物を前記各ウェルに加えた。\n\nFirst, Huh7.5.1 cells (use those having passage numbers up to the 43rd passage) were suspended in the cell culture medium and seeded on a 96-well microplate at 1 × 10 \n4\n cells / 100 μl / well. \n Next, 5 μM of the 28 test compounds was added to each well.\n\n\n\n\n\n\n \n\n  続いて、試験化合物の添加した４８時間後（HCV感染率測定用の実験における感染性HCV添加の７２時間後に相当する）に各ウェルにPremix WST-1溶液を10μl加え、引き続き４時間培養して、EIAリーダーにて420nm〜48nmの波長で吸光度を測定し、細胞生存率を算出した。\n\n\n  Subsequently, 10 μl of Premix WST-1 solution was added to each well 48 hours after the addition of the test compound (corresponding to 72 hours after the addition of infectious HCV in the experiment for measuring the HCV infection rate), followed by culturing for 4 hours. Then, the absorbance was measured at a wavelength of 420 nm to 48 nm with an EIA reader, and the cell viability was calculated.\n\n\n\n\n\n\n\n \n\n（３）結果：\n\n  スクリーニングの結果、４つの化合物（化合物１６、化合物１９、化合物２０、化合物２１）が、第１候補化合物として得られた。これらの化合物は、HCVの感染を60％以上阻害（HCV感染率40％未満）し、かつWSTアッセイによる細胞毒性が低かった（生存率80％以上）（図４；化合物１９、２１は図示せず）。ここで、化合物１６は、本明細書における式（ＩＩＩ）で示されるフェニルカルバモイル誘導体であり、化合物２０は、本明細書における式（ＩＶ）で示されるレゾルシノール誘導体である。\n\n(3) Results: \n As a result of screening, four compounds (compound 16, compound 19, \ncompound\n 20, and compound 21) were obtained as the first candidate compounds. These compounds inhibited HCV infection by 60% or more (HCV infection rate of less than 40%) and showed low cytotoxicity by WST assay (survival rate of 80% or more) (FIG. 4; compounds 19 and 21 are not shown) ) Here, the compound 16 is a phenylcarbamoyl derivative represented by the formula (III) in the present specification, and the \ncompound\n 20 is a resorcinol derivative represented by the formula (IV) in the present specification.\n\n\n\n\n\n\n \n\n  次に、第１候補株のうち化合物１６及び化合物２０を100μMから0.3μＭまで３倍段階希釈し、各濃度の感染阻害効果を評価した。同様に、HCV阻害活性を有することが知られているα‐グルコシダーゼの活性阻害剤であるNN-DNJ（米国特許出願２００５-０２５６１６８Ａ１号）（図４）を30μMから0.1μMまで３倍段階希釈し、対照として評価に使用した。\n\n\n  Next, among the first candidate strains, Compound 16 and \nCompound\n 20 were diluted 3-fold from 100 μM to 0.3 μM, and the infection inhibitory effect at each concentration was evaluated. Similarly, NN-DNJ (US Patent Application No. 2005-0256168A1) (FIG. 4), an α-glucosidase activity inhibitor known to have HCV inhibitory activity, was serially diluted from 30 μM to 0.1 μM three times. , Used as a control for evaluation.\n\n\n\n\n\n\n\n \n\n  結果を図５に示す。N-DNJJは、EC\n50\n＝4.4μM及びCC\n50\n＞100μMであったことからSI＞22.7であり、化合物１６は、EC\n50\n＝7.3μＭ及びCC\n50\n＞100μMであったことからSI＞13.7〜100であり、そして化合物２０は、EC\n50\n＝6.1μM及びCC\n50\n＞100μMであったことからSI＞16.4であった。したがって、化合物１６及び化合物２０は、いずれも新規HCV感染阻害剤として同定された。また、N-DNJJについては、HCV感染阻害剤であることが再確認された。\n\nThe results are shown in FIG. N-DNJJ is, EC \n50\n = 4.4μM and CC \n50>\n a SI> 22.7 since there was a 100 [mu] M, compound 16, EC \n50\n = 7.3μM and CC \n50>\n SI since was 100 [mu] M> 13.7 to 100 And compound 20 had SI> 16.4 since EC \n50\n = 6.1 μM and CC \n50\n > 100 μM. Therefore, both Compound 16 and \nCompound\n 20 were identified as novel HCV infection inhibitors. N-DNJJ was reconfirmed to be an HCV infection inhibitor.\n\n\n\n\n\n\n \n\n２．HCVゲノムの複製過程を阻害する化合物（HCV複製翻訳阻害剤）としての評価\n\n  新規HCV感染阻害剤として単離された化合物１６及び化合物２０がHCVゲノムの複製過程を阻害する化合物であるか否かを評価した。評価には、サブゲノミックHCVレポーターレプリコンRNAを複製する細胞を用いた。本明細書で「サブゲノミックHCVレポーターレプリコン」とは、サブゲノミックHCVレプリコン中にレポーター遺伝子を含むものをいう。後述するように、本実施例における評価では、レポーター遺伝子としてルシフェラーゼ遺伝子を用いている。それ故、本レプリコンRNAを導入した細胞が該サブゲノミックHCVレポーターレプリコンを複製しているか否かを確認するには、レポーターレプリコンRNAから翻訳されるルシフェラーゼの活性を測定するか又はHCVタンパク質をウエスタンブロット等で検出することで確認できる。本実施例では、前記選択性（Si）が１０以上の化合物をHCV複製翻訳阻害剤とした。\n\n2. Evaluation as a compound that inhibits the replication process of the HCV genome (HCV replication translation inhibitor) Whether or not Compound 16 and \nCompound\n 20 isolated as novel HCV infection inhibitors are compounds that inhibit the replication process of the HCV genome evaluated. For the evaluation, cells replicating the subgenomic HCV reporter replicon RNA were used. As used herein, “subgenomic HCV reporter replicon” refers to a subgenomic HCV replicon containing a reporter gene. As will be described later, in the evaluation in this example, a luciferase gene is used as a reporter gene. Therefore, in order to confirm whether or not the cell into which this replicon RNA is introduced replicates the subgenomic HCV reporter replicon, the activity of luciferase translated from the reporter replicon RNA is measured, or the HCV protein is Western blotted. It can be confirmed by detecting with etc. In this example, a compound having a selectivity (Si) of 10 or more was used as an HCV replication translation inhibitor.\n\n\n\n\n\n\n \n\n  サブゲノミックHCVレポーターレプリコンRNAを複製する細胞に試験物質であるHCV感染阻害剤を接触させ、ルシフェラーゼの活性又はHCVタンパク質の発現レベルを、該HCV感染阻害剤を接触させない時のそれらと比較することで、得られたHCV感染阻害剤がHCVの複製翻訳を阻害する化合物であるか否かを評価することができる。\n\n\n  By contacting a cell that replicates the subgenomic HCV reporter replicon RNA with an HCV infection inhibitor that is a test substance, and comparing the luciferase activity or the expression level of the HCV protein with those when the HCV infection inhibitor is not contacted It is possible to evaluate whether or not the obtained HCV infection inhibitor is a compound that inhibits HCV replication.\n\n\n\n\n\n\n\n \n\n（１）サブゲノミックHCVレプリコンRNAの合成：\n\n  まず、図６に示すpSGR-JFH/Luc(Kato et al. J Clin Microbiol. 2005; 43(11): 5679-5684.)プラスミドを制限酵素XbaIで開裂し、Mung Bean Nuclease（タカラバイオ）で平滑末端とした。得られた直鎖状DNAを鋳型として、MEGAscript（Ambion社）を用いてサブゲノミックHCVレプリコンRNAをin vitro合成した。\n\n(1) Synthesis of subgenomic HCV replicon RNA: \n First, the pSGR-JFH / Luc (Kato et al. J Clin Microbiol. 2005; 43 (11): 5679-5684.) Plasmid shown in FIG. 6 is cleaved with the restriction enzyme XbaI and smoothed with Mung Bean Nuclease (Takara Bio). The end. Using the obtained linear DNA as a template, subgenomic HCV replicon RNA was synthesized in vitro using MEGAscript (Ambion).\n\n\n\n\n\n\n \n\n（２）サブゲノミックHCVレプリコンRNA複製細胞の調製：\n\n  次に、Huh7.5.1細胞（継代数が４３回目までのものを使用）を細胞培養用培地に4×10\n5\n/mlとなるように懸濁し、25cm\n2\n培養フラスコに10ml播種した。その後、ディッシュを5％CO\n2\n下で37℃にて培養した。２４時間後、合成したサブゲノミックHCVレプリコンRNAをHuh7.5.1細胞にリポフェクション法で導入した。なお、細胞導入にはエレクトロポレーション法を用いることもできる。翌日、ディッシュから細胞を剥離し、5×10\n4\n個/mlになるように培地で調製した後、９６ウェルのマイクロプレートの各ウェルに90μlずつ播種し（4,500個/ウェル)、5％CO\n２\n下で37℃にて約２０時間培養した。その後、30μMから00.1μMまで３倍段階希釈した前記HCV感染阻害剤及び対照用N-DNJJを10μl加え、引き続き同条件下で培養した。化合物を添加してから７２時間後、細胞をPBSで２回洗浄した。測定キットに添付の細胞溶解バッファ（Promega社）で溶解し、ルシフェラーゼの活性を測定した。ルシフェラーゼの測定にはPromega社のSteady-Glo抽出測定キットを使用した。\n\n(2) Preparation of subgenomic HCV replicon RNA replicating cells: \n Next, Huh7.5.1 cells (with passage numbers up to the 43rd passage) were suspended in a cell culture medium so as to be 4 × 10 \n5\n / ml, and 10 ml were seeded in a 25 cm \n2\n culture flask. The dishes were then cultured at 37 ° C. with 5% CO \n2\n . After 24 hours, the synthesized subgenomic HCV replicon RNA was introduced into Huh7.5.1 cells by lipofection. In addition, electroporation can also be used for cell introduction. The next day, the cells are detached from the dish and prepared in a medium to 5 × 10 \n4\n cells / ml, then inoculated into each well of a 96-well microplate by 90 μl (4,500 cells / well), and 5% CO \n2.\n Under culture at 37 ° C. for about 20 hours. Thereafter, 10 μl of the HCV infection inhibitor and N-DNJJ for control, which were diluted 3-fold from 30 μM to 00.1 μM, were added, followed by culturing under the same conditions. 72 hours after compound addition, cells were washed twice with PBS. Lysis was performed with a cell lysis buffer (Promega) attached to the measurement kit, and the luciferase activity was measured. For the measurement of luciferase, a Promega Steady-Glo extraction measurement kit was used.\n\n\n\n\n\n\n \n\n（３）結果：\n\n  図７に結果を示す。NN-DNJは、EC\n50\n＞100μM及びCC\n50\n＞100μMであったことからSIは正確には算出できないが、１に近似すると推定された。一方、化合物１６は、EC\n50\n＝62μM及びCC\n50\n＞100μMであったことからSi＜1.6であった。また、化合物２０は、EC\n50\nは17.3μM及びCC\n50\nは25.4μMであったことからSI＝1.5であった。これらの結果は、いずれの化合物もHCV感染阻害剤ではあるがHCVの複製翻訳過程を阻害しないことを示している。したがって、化合物１６及び２０は、HCV生活環のうち、翻訳、HCVタンパク質のプロセッシング及び/又は複製工程に作用しないこと、すなわちHCV複製翻訳阻害剤ではないことが判明した。\n\n(3) Results: \n The results are shown in FIG. Since NN-DNJ had EC \n50\n > 100 μM and CC \n50\n > 100 μM, SI could not be calculated accurately, but it was estimated to approximate 1. On the other hand, Compound 16 had Si <1.6 because EC \n50\n = 62 μM and CC \n50\n > 100 μM. \nCompound\n 20 had SI = 1.5 because EC \n50\n was 17.3 μM and CC \n50\n was 25.4 μM. These results indicate that none of the compounds is an HCV infection inhibitor but inhibits the replication translation process of HCV. Therefore, it has been found that \ncompounds\n 16 and 20 do not act on translation, HCV protein processing and / or replication process in the HCV life cycle, that is, are not HCV replication translation inhibitors.\n\n\n\n\n\n\n \n\n３．HCVの細胞への侵入を阻害する化合物としての評価\n\n  続いて、新規HCV感染阻害剤が、HCVの侵入過程を阻害するか否かを評価した。HCVのエンベロープタンパク質を感染性レトロウイルスに提示させたシュードウイルスは、HCV受容体の１つと考えられているCD81を介して宿主細胞内に侵入することが報告されている（Bartosch, B. et al., J. Exp. Med. 197:633-642, 2003）。したがって、このシュードウイルスを用いてHCV侵入阻害剤を評価することができる。\n\n3. Evaluation as a Compound that Inhibits HCV Invasion into Cells Subsequently, it was evaluated whether a novel HCV infection inhibitor inhibits the HCV entry process. It has been reported that a pseudovirus in which an HCV envelope protein is presented to an infectious retrovirus enters a host cell via CD81, which is considered to be one of the HCV receptors (Bartosch, B. et al , J. Exp. Med. 197: 633-642, 2003). Therefore, this pseudovirus can be used to evaluate HCV entry inhibitors.\n\n\n\n\n\n\n \n\n（１）シュードウイルスHCVppの作製：\n\n  HCVppを作製するためのベクターを図８に示す。マウス白血病ウイルスのgag及びpolタンパク質をコードする発現ベクターとして、マウスレトロウイルス（MLV）Gag-Pol発現ベクター（A）を用いた。また、HCVのエンベロープタンパク質であるE1、E2タンパク質をコードする発現ベクターとしては、HCVエンベロープ質発現ベクター（B、C）を用いた。図中「JFH1」は、HCVのJFH１株由来のエンベロープタンパク質を有する発現ベクターであることを意味し、同様に「J6CF」は、HCVのJ6CF株由来のエンベロープタンパク質を有する発現ベクターであることを意味する。さらに、ルシフェラーゼタンパク質をコードし、かつレトロウイルスパッケージングサイトを持つ発現ベクターとしてルシフェラーゼ発現ベクター（D）を用いた。\n\n(1) Production of pseudovirus HCVpp: \n A vector for producing HCVpp is shown in FIG. As an expression vector encoding mouse leukemia virus gag and pol protein, mouse retrovirus (MLV) Gag-Pol expression vector (A) was used. Moreover, HCV envelope quality expression vectors (B, C) were used as expression vectors encoding E1 and E2 proteins which are HCV envelope proteins. In the figure, “JFH1” means an expression vector having an envelope protein derived from the HCV JFH1 strain, and similarly “J6CF” means an expression vector having an envelope protein derived from the HCV J6CF strain. To do. Furthermore, a luciferase expression vector (D) was used as an expression vector encoding a luciferase protein and having a retroviral packaging site.\n\n\n\n\n\n\n \n\n  対照用シュードウイルスとして、HCVのE１、E2タンパク質をコードする発現ベクターに代えて水泡性口内炎ウイルス(VSV)のG糖タンパク質をコードした発現ベクター（VSV−Gタンパク質発現ベクター；E）を用いた。これをVSVストックとした。\n\n\n  As a control pseudovirus, an expression vector (VSV-G protein expression vector; E) encoding a G glycoprotein of vesicular stomatitis virus (VSV) was used instead of the expression vector encoding HCV E1 and E2 proteins. This was taken as VSV stock.\n\n\n\n\n\n\n\n \n\n  これらの発現ベクターを293T細胞にリポフェクション法で共導入することにより、ルシフェラーゼがHCVのE１及びE2タンパク質の外皮（エンベロープ）で包れたシュードウイルスHCVppが産生される。このHCVppをHCV侵入阻害剤の評価に利用することができる。一方、対照用のVSV−Gタンパク質発現ベクターをレトロウイルスGag-Pol発現ベクター及びルシフェラーゼ発現ベクターと共に293T細胞にリポフェクション法で共導入した場合にはシュードウイルスVSVppが生産される。\n\n\n  By co-introducing these expression vectors into 293T cells by the lipofection method, pseudovirus HCVpp in which luciferase is enveloped by the envelope (envelope) of E1 and E2 proteins of HCV is produced. This HCVpp can be used for evaluating HCV entry inhibitors. On the other hand, when a VSV-G protein expression vector for control is co-introduced into a 293T cell together with a retrovirus Gag-Pol expression vector and a luciferase expression vector by a lipofection method, pseudovirus VSVpp is produced.\n\n\n\n\n\n\n\n \n\n（２）HCVppを用いたHCVの侵入過程阻害効果の評価：\n\n  Huh7.5.1細胞を1×10\n4\n個/ウェルとなるように９６ウェルのマイクロプレートに播種し、37℃の5％CO\n2\nインキュベーターにて一夜培養した。\n\n(2) Evaluation of HCV invasion process inhibition effect using HCVpp: \n Huh7.5.1 cells were seeded on a 96-well microplate at 1 × 10 \n4\n cells / well and cultured overnight in a 5% CO \n2\n incubator at 37 ° C.\n\n\n\n\n\n\n \n\n  次に９６ウェルのマイクロプレートに培養したHuh7.5.1細胞から培養液を除去し、新規HCV感染阻害剤（化合物１６若しくは化合物２０）又はN-DNJJを図中の各最終濃度（0.1、1、10μM）の1.5倍となるように細胞培養液で希釈調製し、この溶液をウェル当たり100μl加え、直ちに調製したHCVppを各ウェルに50μｌ加えた。その後、37℃の5％CO\n2\nインキュベーターにて６時間培養した。培養後、上清を除去し、PBSで洗浄後、新鮮な培地100μlを加え、引き続き同条件下で培養した。６６時間後（化合物を添加して７２時間後）、細胞をPBSで２回洗浄し、60μlの測定キットに添付の細胞溶解バッファ（Promega社）を加え、ピペッティングにより細胞を溶解した。細胞溶解液中のルシフェラーゼ活性をPromega社のSteady-Glo抽出測定キットを用いて測定した。化合物無添加のサンプルにおけるルシフェラーゼ活性を100％としたときの、新規HCV感染阻害剤（化合物１６、化合物２０）又はN-DNJJを添加したルシフェラーゼの活性（％）を算出した。HCVppには、JFH１株のエンベロープタンパク質を持つHCVpp（JFH１）（図８B）と遺伝子型２aのJ6CF株のエンベロープタンパク質を持つHCVpp（J6CF）（図８C）を用いた。新規HCV感染阻害剤の非特異的侵入阻害活性については、VSVのG糖タンパク質を発現するシュードウイルスVSVppを使用して算出した。化合物１６、化合物２０及びNN−DNJは、0.1、１.0及び10μＭの濃度で評価した。\n\nNext, the culture solution is removed from Huh7.5.1 cells cultured in a 96-well microplate, and a novel HCV infection inhibitor (compound 16 or compound 20) or N-DNJJ is added to each final concentration (0.1, 1, 10 μM in the figure). The solution was diluted with cell culture medium so that the ratio was 1.5 times that of (1)), 100 μl of this solution was added per well, and 50 μl of HCVpp prepared immediately was added to each well. Thereafter, the cells were cultured for 6 hours in a 37 ° C. 5% CO \n2\n incubator. After culture, the supernatant was removed, washed with PBS, 100 μl of fresh medium was added, and the culture was continued under the same conditions. After 66 hours (72 hours after the addition of the compound), the cells were washed twice with PBS, the cell lysis buffer (Promega) attached to 60 μl of the measurement kit was added, and the cells were lysed by pipetting. The luciferase activity in the cell lysate was measured using the Stedy-Glo extraction measurement kit from Promega. The luciferase activity (%) with the addition of a novel HCV infection inhibitor (Compound 16, Compound 20) or N-DNJJ when the luciferase activity in the sample with no compound added was taken as 100% was calculated. As HCVpp, HCVpp (JFH1) (FIG. 8B) having an envelope protein of JFH1 strain and HCVpp (J6CF) (FIG. 8C) having an envelope protein of J6CF strain of genotype 2a were used. The non-specific entry inhibitory activity of the novel HCV infection inhibitor was calculated using pseudovirus VSVpp expressing VSV G glycoprotein. Compound 16, \ncompound\n 20 and NN-DNJ were evaluated at concentrations of 0.1, 1.0 and 10 μM.\n\n\n\n\n\n\n \n\n（３）結果：\n\n  図９に結果を示す。化合物１６及び化合物２０は、１μMの濃度でHCVppの侵入過程を阻害したが、VSVppの侵入過程は阻害しなかった（図９B、C）。一方、NN-DNJは0.1、1及び10μMの濃度であってもHCVppの侵入過程を阻害しなかった（図９A）。以上の結果から、化合物１６及び化合物２０はHCVの宿主細胞への侵入を阻害する化合物、すなわちHCV侵入阻害剤であることが判明した。\n\n(3) Results: \n FIG. 9 shows the result. Compound 16 and \nCompound\n 20 inhibited the entry process of HCVpp at a concentration of 1 μM, but did not inhibit the entry process of VSVpp (FIGS. 9B and 9C). On the other hand, NN-DNJ did not inhibit the entry process of HCVpp even at concentrations of 0.1, 1 and 10 μM (FIG. 9A). From the above results, it was found that Compound 16 and \nCompound\n 20 are compounds that inhibit HCV entry into host cells, that is, HCV entry inhibitors.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  HCV・・・００１、HCV受容体（CD8を含む）・・・００２、宿主細胞・・・００３、HCVゲノムRNA・・・００４、HCVタンパク質前駆体・・・００５、HCVタンパク質・・・００６、HCV RNAポリメラーゼ・・・００７\n\n\n  HCV ... 001, HCV receptor (including CD8) ... 002, host cell ... 003, HCV genomic RNA ... 004, HCV protein precursor ... 005, HCV protein ... 006, HCV RNA polymerase ... 007"
  },
  {
    "id": "JP2010202597A",
    "text": "Composition derived from plant of genus salacia, and method for producing the same composition AbstractTranslated fromJapanese【課題】サラシア属植物由来の抽出物、該抽出物を含有する血糖値上昇抑制用医薬組成物および健康食品、さらに前記抽出物の品質評価方法を提供する。【解決手段】脱硫酸コタラノールを高濃度で含有することにより、マルターゼ阻害活性の高いサラシア属植物由来の抽出物を得ることができる。【選択図】なしAn extract derived from a plant of the genus Salacia, a pharmaceutical composition for suppressing an increase in blood glucose level containing the extract, a health food, and a method for evaluating the quality of the extract are provided.An extract derived from a plant of the genus Salacia having a high maltase inhibitory activity can be obtained by containing a high concentration of desulfated cotaranol.[Selection figure] None Claims (\n11\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  脱硫酸コタラノールおよびサラシノールを含む組成物。\n\n\n  A composition comprising desulfated cotaranol and salacinol.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  前記組成物がサラシア属植物由来の抽出物である、請求項１に記載の組成物。\n\n\n  The composition according to claim 1, wherein the composition is an extract derived from a plant of the genus Salacia.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  前記組成物中の脱硫酸コタラノール（カウンターイオンを含まない）の含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）が以下の式\n\n        Ｙ≧１．６Ｘ\n\nの関係を有する、\n\n請求項１または２に記載の組成物。\n\nThe content (Y wt%) of desulfated cotaranol (not including counter ions) and the content of salacinol (X wt%) in the composition are represented by the following formula: Y ≧ 1.6X \n Having a relationship \n The composition according to claim 1 or 2.\n\n\n\n\n\n\n\n\n\n\n \n\n  前記Ｙ重量％が０．４６以上である、請求項１〜３のいずれか１項に記載の組成物。\n\n\n  The composition according to any one of claims 1 to 3, wherein the Y wt% is 0.46 or more.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  前記Ｙ重量％とＸ重量％の合計が０．７５以上である、請求項１〜４のいずれか１項に記載の組成物。\n\n\n  The composition of any one of Claims 1-4 whose sum total of the said Y weight% and X weight% is 0.75 or more.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  請求項１〜５のいずれか１項に記載の組成物を含んでなる飲食品。\n\n\n  The food-drinks which comprise the composition of any one of Claims 1-5.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  前記飲食品が健康食品または機能性食品である、請求項６に記載の飲食品。\n\n\n  The food or drink according to claim 6, wherein the food or drink is a health food or a functional food.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  請求項１〜５のいずれか１項に記載の組成物を含んでなる、血糖値上昇抑制用医薬組成物。\n\n\n  A pharmaceutical composition for suppressing an increase in blood glucose level, comprising the composition according to any one of claims 1 to 5.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  前記組成物が水または熱水抽出物である、請求項１〜５のいずれか１項に記載の組成物。\n\n\n  The composition according to any one of claims 1 to 5, wherein the composition is water or a hot water extract.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  脱硫酸コタラノールおよびサラシノールを含む組成物の製造方法であって、\n\n  サラシア属植物を水または熱水で処理して抽出物を得ること；\n\n  前記抽出物中の脱硫酸コタラノール（カウンターイオンを含まない）の含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）を測定すること；および\n\n  前記ＹとＸが以下：\n\n        Ｙ≧１．６Ｘ\n\n        Ｘ＋Ｙ≧０．７５\n\n        Ｙ≧０．４６\n\nのいずれか一つの関係を有する抽出物を選択し、これを前記組成物とすること；\n\nを含んでなる、\n\n前記組成物の製造方法。\n\nA process for producing a composition comprising desulfated cotaranol and salacinol, comprising: \n Treating Salacia plants with water or hot water to obtain an extract; \n Measuring the content (Y wt%) of desulfated cotaranol (not including counter ions) and the content (X wt%) of salacinol in the extract; and \n Y ≧ 1.6X \n X + Y ≧ 0.75 \n Y ≧ 0.46 \n And selecting an extract having any one of the following relationships as the composition; \n Comprising \n A method for producing the composition.\n\n\n\n\n\n\n\n\n\n\n \n\n  脱硫酸コタラノールおよびサラシノールを含む抽出物の品質評価方法であって、\n\n  前記抽出物中の脱硫酸コタラノール（カウンターイオンを含まない）の含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）を測定すること；および\n\n  前記ＸおよびＹが以下：\n\n        Ｙ≧１．６Ｘ\n\n        Ｘ＋Ｙ≧０．７５\n\n        Ｙ≧０．４６\n\nのいずれか一つの関係を有する抽出物を選択すること；\n\nを含んでなる、\n\n前記抽出物の品質評価方法。\n\n\nA method for evaluating the quality of an extract containing desulfated cotaranol and salacinol, \n Measuring the content (Y wt%) of desulfated cotaranol (excluding counter ions) and the content of salacinol (X wt%) in the extract; and the X and Y are: \n Y ≧ 1.6X \n X + Y ≧ 0.75 \n Y ≧ 0.46 \n Selecting an extract having any one of the following relationships: \n Comprising \n A method for evaluating the quality of the extract. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は、サラシア属植物由来の組成物、特に脱硫酸コタラノールを含有する組成物、該組成物の利用および製造法に関する。\n\n\n  The present invention relates to a composition derived from a plant of the genus Salacia, in particular, a composition containing desulfurized cotaranol, a method for using the composition and a method for producing the composition.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  古来よりサラシア属植物由来の抽出物には糖尿病を予防する効果があることが知られており、インドやスリランカなどで伝承療法として用いられている。最近の研究により、サラシア属植物由来の抽出物には小腸に存在する糖質分解酵素（α−グルコシダーゼ）を強く阻害する作用があり、該抽出物を飲用すると食後の高い血糖濃度が低下することが明らかになっている。当該効果は、食事由来の糖の吸収が遅延することに基づいている。また、サラシア属植物由来の抽出物からサラシノール（特許文献１）、コタラノール（特許文献２）等の化合物が発見され、当該化合物がα−グルコシダーゼ阻害活性を有することが開示されている。\n\n\n  Since ancient times, extracts derived from plants of the genus Salacia have been known to have an effect of preventing diabetes, and have been used as a traditional therapy in India and Sri Lanka. According to recent research, extracts derived from plants of the genus Salacia have the effect of strongly inhibiting the saccharide-degrading enzyme (α-glucosidase) present in the small intestine, and drinking this extract decreases the high blood glucose level after meals. Has been revealed. The effect is based on delayed absorption of dietary sugar. Further, compounds such as salacinol (patent document 1) and kotalanol (patent document 2) have been discovered from extracts derived from plants of the genus Salacia, and it is disclosed that the compounds have α-glucosidase inhibitory activity.\n\n\n\n\n\n\n\n \n\n  これまでに、サラシア属植物由来の抽出物はスクロースを基質とする酵素（スクラーゼ）に対する強い阻害作用を有し、当該作用がα−グルコシダーゼ阻害の基礎になっていると考えられてきた（非特許文献１）。\n\n\n  To date, extracts derived from plants of the genus Salacia have a strong inhibitory action on an enzyme (sucrose) using sucrose as a substrate, and it has been considered that this action is the basis of α-glucosidase inhibition (non-patented). Reference 1).\n\n\n\n\n\n\n\n \n\n  また、サラシア属植物は、品種、産地、保存状態などによって品質が変動するため、サラシア属植物由来の抽出物の品質評価方法が求められている。品質評価法として、マンギフェリンを指標とした間接的な方法（特許文献３）が開示されている。\n\n\n  Further, since the quality of Salacia plants varies depending on the variety, production area, storage state, etc., there is a need for a quality evaluation method for extracts derived from Salacia plants. As a quality evaluation method, an indirect method (Patent Document 3) using mangiferin as an index is disclosed.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n特許３０３０００８号\nPatent 3030008\n\n\n\n\n\n\n\n\n\n\n \n特開２０００−８６６５３号\nJP 2000-86653 A\n\n\n\n\n\n\n\n\n\n\n \n特許３３８６７９６号\nJapanese Patent No. 3386696\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n日本食品新素材研究会誌８(２)１０５−１１７（２００５）\nJournal of Japan Society for New Material Research 8 (2) 105-117 (2005)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  食品にはデンプン由来の糖質が多く含まれているため、食事由来の糖の吸収を効果的に遅延させるには、マルターゼ活性を阻害することが重要と考えられた。さらに、マルターゼ阻害活性に着目した品質評価方法は存在しない。そこで、本発明は、高いマルターゼ阻害活性を有し、優れた血糖値上昇抑制効果を発揮する植物由来の抽出物、およびマルターゼ阻害に着目した植物由来の抽出物の品質評価方法を提供することを目的とする。\n\n\n  Since foods contain a large amount of starch-derived carbohydrates, it was considered important to inhibit maltase activity in order to effectively delay the absorption of diet-derived sugars. Furthermore, there is no quality evaluation method focusing on maltase inhibitory activity. Therefore, the present invention provides a plant-derived extract having high maltase inhibitory activity and exhibiting an excellent inhibitory effect on increase in blood glucose level, and a method for evaluating the quality of plant-derived extracts focusing on maltase inhibition. Objective.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  上記の課題を達成すべく、本発明者は、脱硫酸コタラノール含量を指標とする、マルターゼ阻害活性の高いサラシア属植物由来の抽出物の製造法を見出した。本発明は、かかる知見に基づいて完成されたものである。\n\n\n  In order to achieve the above object, the present inventor has found a method for producing an extract derived from a plant belonging to the genus Salacia having a high maltase inhibitory activity, using the desulfurized cotaranol content as an index. The present invention has been completed based on such findings.\n\n\n\n\n\n\n\n \n\n  本発明の１つの側面によれば、脱硫酸コタラノールおよびサラシノールを含む組成物が提供される。本発明における脱硫酸コタラノールは、以下の式（Ｉ）で表される構造を有する。\n\n\n  According to one aspect of the invention, a composition comprising desulfated cotaranol and salacinol is provided. The desulfurized cotaranol in the present invention has a structure represented by the following formula (I).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\nここで、Ｘ\n−\nはカウンターイオンであって、任意の陰イオンを意味する。本発明においては、例えば、Ｃｌ\n−\n、Ｂｒ\n−\n、Ｉ\n−\n、Ｆ\n−\nなどのハロゲンイオン；ＢＦ\n４\n \n−\nなどのルイス酸イオン；その他、酢酸イオン、トリフルオロ酢酸イオン、プロピオン酸イオン、安息香酸イオン等のカルボン酸イオン；リン酸イオン、シアン酸イオン、チオシアン酸イオン等の無機酸イオン；アルキルスルホン酸又はアルキルスルフィン酸イオン；などがあげられるが、これに限定されない。\n\nHere, X \n−\n is a counter ion and means an arbitrary anion. In the present invention, for \n \n \nexample, Cl -, Br -, I\n \n \n -, F - halogen ions such as; \n-\n BF \n4\n include Lewis acid ions and the like; acetate ion, trifluoroacetate ion, propionate ion, benzoate ion, etc. Carboxylate ions; inorganic acid ions such as phosphate ions, cyanate ions, and thiocyanate ions; alkylsulfonic acid or alkylsulfinate ions; and the like, but not limited thereto.\n\n\n\n\n\n\n \n\n  本発明におけるサラシノールとは、以下の式（ＩＩ）で表される構造を有する。\n\n\n  Salacinol in the present invention has a structure represented by the following formula (II).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明における組成物とは、脱硫酸コタラノールとサラシノールを含んでいる限り特に限定されない。一つの態様として、当該組成物は、植物を原料として調製することができ、例えば、サラシア属の植物を原料としてもよい。また、本発明における組成物は、当該組成物中の脱硫酸コタラノールの含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）が、例えば以下\n\n                Ｙ≧１．６Ｘ\n\nの関係を有する組成物、あるいは、さらにＹ重量％とＸ重量％の合計（Ｘ＋Ｙ）が０．７５重量％以上、特に１．０５重量％以上であってよい。ここで、脱硫酸コタラノールの含量は、カウンターイオンを含めない含量である。\n\nThe composition in the present invention is not particularly limited as long as it contains desulfurized cotaranol and salacinol. In one embodiment, the composition can be prepared from a plant as a raw material, for example, a plant of the genus Salacia. The composition of the present invention has a desulfurized cotaranol content (Y wt%) and a salacinol content (X wt%) in the composition, for example: \n Y ≧ 1.6X \n Or a total (X + Y) of Y weight% and X weight% (X + Y) may be 0.75 weight% or more, particularly 1.05 weight% or more. Here, the content of desulfated cotaranol is a content not including counter ions.\n\n\n\n\n\n\n \n\n  本発明の一つの態様において、上記組成物の脱硫酸コタラノール含量（Ｙ重量％）は、例えば０．４６重量％以上であり、好ましくは０．７８重量％以上であり、さらに好ましくは０．８６重量％以上である。\n\n\n  In one embodiment of the present invention, the desulfated cotaranol content (Y wt%) of the composition is, for example, 0.46 wt% or more, preferably 0.78 wt% or more, and more preferably 0.86 wt%. % By weight or more.\n\n\n\n\n\n\n\n \n\n  また、本発明における組成物は、マルターゼ阻害活性を有する。ここで、阻害活性とは、ある化合物または組成物による酵素活性の阻害の程度を示す指標を意味する。阻害活性は、例えば、酵素活性を５０％阻害するのに必要な組成物濃度（ＩＣ\n５０\n）として表すことができる。本発明におけるＩＣ\n５０\nは、Ｗｉｓｔａｒ系雄性ラットの小腸より得た酵素溶液を用いるマルターゼ活性阻害試験（本発明の試験例１（１）マルターゼ阻害活性試験）の条件において、例えば、８４μｇ／ｍＬ以下、特に７９μｇ／ｍＬである。また、本発明の組成物は、例えば、水または熱水抽出により得ることができる。\n\nMoreover, the composition in this invention has a maltase inhibitory activity. Here, the inhibitory activity means an index indicating the degree of inhibition of enzyme activity by a certain compound or composition. Inhibitory activity can be expressed, for example, as the composition concentration (IC \n50\n ) required to inhibit enzyme activity by 50%. IC \n50\n in the present invention is, for example, 84 μg / mL or less under the conditions of a maltase activity inhibition test (Test Example 1 (1) Maltase inhibition activity test of the present invention) using an enzyme solution obtained from the small intestine of Wistar male rats. Especially 79 μg / mL. Moreover, the composition of this invention can be obtained by water or hot water extraction, for example.\n\n\n\n\n\n\n \n\n  本発明の別の側面によれば、脱硫酸コタラノールおよびサラシノールを含む組成物を含んでなる、血糖値上昇抑制用医薬組成物または飲食品が提供される。前記飲食品として、例えば健康食品または機能性食品などが挙げられる。\n\n\n  According to another aspect of the present invention, there is provided a pharmaceutical composition or food or drink for suppressing an increase in blood glucose level, comprising a composition containing desulfated cotaranol and salacinol. Examples of the food and drink include health foods and functional foods.\n\n\n\n\n\n\n\n \n\n  本発明の別の側面によれば、脱硫酸コタラノールおよびサラシノールを含む組成物の製造方法が提供される。前記製造方法は、例えば、サラシア属植物を水または熱水で処理して抽出物を得た後、特定の成分組成を有する前記抽出物を選択し、これを組成物とする工程を含む方法が本発明の一態様としてあげられる。前記特定の成分組成を有する抽出物とは、限定されないが、例えば、抽出物中の脱硫酸コタラノールの含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）が以下\n\n        Ｙ≧１．６Ｘ\n\n        Ｘ＋Ｙ≧０．７５\n\nのいずれか一つの関係を有する抽出物をあげることができる。ここで、脱硫酸コタラノールの含量は、カウンターイオンを含めない含量である。\n\nAccording to another aspect of the present invention, a method for producing a composition comprising desulfated cotaranol and salacinol is provided. The production method includes, for example, a process comprising a step of treating a plant of the genus Salacia with water or hot water to obtain an extract, selecting the extract having a specific component composition, and using the extract as a composition. It is mentioned as one aspect of the present invention. The extract having the specific component composition is not limited. For example, the content of desulfurized cotaranol (Y wt%) and the content of salacinol (X wt%) in the extract are as follows: Y ≧ 1.6X \n X + Y ≧ 0.75 \n The extract which has any one of these can be mention | raise | lifted. Here, the content of desulfated cotaranol is a content not including counter ions.\n\n\n\n\n\n\n \n\n  また、本発明の一態様において、上記抽出物は一定以上のＹ重量％、例えば０．４６重量％以上、好ましくは０．７８重量％以上、さらに好ましくは０．８６重量％以上を有する抽出物である。\n\n\n  In one embodiment of the present invention, the extract may have a certain amount or more of Y wt%, such as 0.46 wt% or more, preferably 0.78 wt% or more, more preferably 0.86 wt% or more. It is.\n\n\n\n\n\n\n\n \n\n  本発明の別の側面によれば、脱硫酸コタラノールとサラシノールを含む植物由来の抽出物の品質評価方法であって、前記抽出物の脱硫酸コタラノールの含量とサラシノールの含量に基づいて抽出物を評価する前記方法が提供される。上記側面の一態様において、前記抽出物中の脱硫酸コタラノール（カウンターイオンを含まない）の含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）を定量し、前記ＸおよびＹが以下：\n\n        Ｙ≧１．６Ｘ\n\n        Ｘ＋Ｙ≧０．７５\n\nのいずれか一つの関係を有する抽出物を選択する。\n\nAccording to another aspect of the present invention, there is provided a method for evaluating the quality of a plant-derived extract containing desulfated cotaranol and salacinol, wherein the extract is evaluated based on the content of desulfated cotaranol and the content of salacinol in the extract. The method is provided. In one embodiment of the above aspect, the content (Y wt%) of desulfated cotaranol (excluding counter ions) and the content of salacinol (X wt%) in the extract are quantified, and the X and Y are the following: \n Y ≧ 1.6X \n X + Y ≧ 0.75 \n Extracts having any one of the following relationships are selected.\n\n\n\n\n\n\n \n\n  植物由来の抽出物としては、例えばサラシア属植物由来の抽出物を使用することができる。この品質評価法によれば、α−グルコシダーゼ阻害活性、特にマルターゼ阻害活性の高い抽出物を容易に識別し、これを選択することができる。\n\n\n  As the plant-derived extract, for example, an extract derived from a Salacia plant can be used. According to this quality evaluation method, an extract having high α-glucosidase inhibitory activity, particularly maltase inhibitory activity, can be easily identified and selected.\n\n\n\n\n\n\n\n \n\n  また、本発明の一態様において、上記抽出物は一定以上のＹ重量％、例えば０．４６重量％以上、好ましくは０．７８重量％以上、さらに好ましくは０．８６重量％以上を有する抽出物である。\n\n\n  In one embodiment of the present invention, the extract may have a certain amount or more of Y wt%, such as 0.46 wt% or more, preferably 0.78 wt% or more, more preferably 0.86 wt% or more. It is.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明により、α−グルコシダーゼ、特にマルターゼ阻害活性の高い植物由来の組成物が提供される。当該組成物を医薬品または飲食品に使用すれば、食事中に豊富に含まれるデンプン由来の糖の吸収速度を効果的に遅延させ、高血糖濃度を効果的に低下させることができる。さらに、上記組成物の製造方法および品質評価方法によれば、植物由来の組成物を安定して製造することが可能になるため、組成物の品質の均一化および製造コストの低減を実現することができる。\n\n\n  The present invention provides a plant-derived composition having high α-glucosidase, particularly maltase inhibitory activity. If the composition is used for pharmaceuticals or foods and drinks, the absorption rate of starch-derived sugars abundantly contained in meals can be effectively delayed, and the high blood sugar concentration can be effectively reduced. Furthermore, according to the production method and quality evaluation method of the above composition, it becomes possible to stably produce a plant-derived composition, thereby realizing uniform quality of the composition and reduction of production cost. Can do.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nサラシノールの擬分子イオンの選択イオンクロマトグラムを示す図である。\nIt is a figure which shows the selective ion chromatogram of the pseudo | simulator molecular ion of salacinol.\n\n\n\n\n\n\n \nコタラノールの擬分子イオンの選択イオンクロマトグラムを示す図である。\nIt is a figure which shows the selective ion chromatogram of the quasi-molecular ion of a kotalanol.\n\n\n\n\n\n\n \n脱硫酸サラシノールの擬分子イオンの選択イオンクロマトグラムを示す図である。\nIt is a figure which shows the selective ion chromatogram of the quasi-molecular ion of desulfating salacinol.\n\n\n\n\n\n\n \n脱硫酸コタラノールの擬分子イオンの選択イオンクロマトグラムを示す図である。\nIt is a figure which shows the selection ion chromatogram of the quasimolecular ion of a desulfurization kotalanol.\n\n\n\n\n\n\n \n組成物中のサラシノール含量とマルターゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the salacinol content in a composition, and a maltase inhibition rate.\n\n\n\n\n\n\n \n組成物中のサラシノール含量とスクラーゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the salacinol content in a composition, and a sucrase inhibition rate.\n\n\n\n\n\n\n \n組成物中のコタラノール含量とマルターゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the kotalanol content in a composition, and a maltase inhibition rate.\n\n\n\n\n\n\n \n組成物中のコタラノール含量とスクラーゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the kotalanol content in a composition, and a sucrase inhibition rate.\n\n\n\n\n\n\n \n組成物中の脱硫酸サラシノール含量とマルターゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the desulfating salacinol content in a composition, and a maltase inhibition rate.\n\n\n\n\n\n\n \n組成物中の脱硫酸サラシノール含量とスクラーゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the desulfating salacinol content in a composition, and a sucrase inhibition rate.\n\n\n\n\n\n\n \n組成物中の脱硫酸コタラノール含量とマルターゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the desulfated cotaranol content in a composition, and a maltase inhibition rate.\n\n\n\n\n\n\n \n組成物中の脱硫酸コタラノール含量とスクラーゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the desulfated cotaranol content in a composition, and a sucrase inhibition rate.\n\n\n\n\n\n\n \n組成物中のサラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノール含量の合計とマルターゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the sum total of the salacinol in a composition, a cotaranol, a desulfurization salacinol, and a desulfurization cotaranol, and a maltase inhibition rate.\n\n\n\n\n\n\n \n組成物中のサラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノール含量の合計とスクラーゼ阻害率との関係を示す図である。\nIt is a figure which shows the relationship between the sum total of the salacinol in a composition, a cotaranol, a desulfurization salacinol, and a desulfurization cotaranol, and a sucrase inhibition rate.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  以下、本発明をさらに具体的に説明する。\n\n  本発明の１つの側面は、脱硫酸コタラノールおよびサラシノールを含む組成物に関する。本発明における脱硫酸コタラノールとは、コタラノールの硫酸基が脱離した式（Ｉ）の構造を有する化合物である。脱硫酸コタラノールは、例えば、以下のように式（ＩＩＩ）の構造を有するコタラノールの脱硫酸化反応によりカウンターイオンがＣＨ\n３\nＯＳＯ\n３\n \n−\nの脱硫酸コタラノールを得ることができる（ＨＥＴＥＲＯＣＹＣＬＥＳ，Ｖｏｌ.７５，Ｎｏ．６，１３９７−１４０５，２００８を参照）。脱硫酸コタラノールのカウンターイオンは、他の任意のカウンターイオンに変換可能である。例えば、上記ＣＨ\n３\nＯＳＯ\n３\n \n−\nをカウンターイオンに持つ脱硫酸コタラノールを、他の陰イオンをカウンターイオンに持つ陰イオン交換樹脂に供することによって、脱硫酸コタラノールのカウンターイオンを交換する事ができる。例えば、陰イオン交換樹脂であるＩＲＡ４００(Ｃｌ\n−\n形)樹脂とＣＨ\n３\nＯＳＯ\n３\n \n−\nをカウンターイオンに持つ脱硫酸コタラノールを室温で１２時間攪拌することによって、Ｃｌ\n−\nをカウンターイオンに持つ脱硫酸コタラノールを得ることができる。詳細は、Ｇ.  Ｔａｎａｂｅ  ｅｔ  ａｌ．  /Ｂｉｏｏｒｇ．  Ｍｅｄ．  Ｃｈｅｍ．  １５（２００７）３９２６−３９３７を参照。\n\nHereinafter, the present invention will be described more specifically. \n One aspect of the present invention relates to a composition comprising desulfated cotaranol and salacinol. The desulfurized cotaranol in the present invention is a compound having the structure of the formula (I) from which the sulfate group of cotaranol is eliminated. The desulfated cotaranol can be obtained, for example, by desulfating a cotaranol having the structure of the formula (III) as described below to obtain a desulfated cotaranol having a counter ion of CH \n3\n OSO \n3\n \n−\n (HETEROCYCLES, Vol. 75, No. 6, 1397-1405, 2008). The counter ion of desulfated cotaranol can be converted to any other counter ion. For example, the counter ion of desulfurized cotaranol can be exchanged by applying the desulfurized cotaranol having CH \n3\n OSO \n3\n \n−\n as a counter ion to an anion exchange resin having another anion as a counter ion. For example, ITA400 (Cl \n−\n form) resin, which is an anion exchange resin, and desulfated cotaranol having CH \n3\n OSO \n3\n \n−\n as a counter ion are stirred at room temperature for 12 hours to obtain desulfated cotaranol having Cl \n−\n as a counter ion. Obtainable. For details, see G. Tanabet et al. / Bioorg. Med. Chem. 15 (2007) 3926-3937.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\nここで、Ｘ\n−\nは先に定義した通りである。\n\n  脱硫酸コタラノールは、これまで上記のような合成的手法による入手方法が報告されているのみであった。本発明者は、植物抽出物に脱硫酸コタラノールが存在することを確認した。サラシノールは、式（ＩＩ）の構造を有し、α−グルコシダーゼ阻害活性を有することが知られている。\n\nHere, X \n−\n is as defined above. \n So far, desulfated cotaranol has only been reported to be obtained by the synthetic method as described above. The inventor has confirmed that desulfated cotaranol is present in the plant extract. Salacinol has a structure of the formula (II) and is known to have α-glucosidase inhibitory activity.\n\n\n\n\n\n\n \n\n  本発明の組成物は、脱硫酸コタラノールおよびサラシノールを含んでいれば特に限定されないが、好ましくは、植物抽出物を原料に使用することができる。原料の植物としては、例えば、サラシア属の植物があげられる。サラシア属の植物としては、例えば、サラシア・オブロンガ（Ｓａｌａｃｉａ  ｏｂｌｏｎｇａ）、サラシア・レティキュラータ（Ｓａｌａｃｉａ  ｒｅｔｉｃｕｌａｔａ）、サラシア・キネンシス（Ｓａｌａｃｉａ  ｃｈｉｎｅｎｓｉｓ）、サラシア・プリノイデス（Ｓａｌａｃｉａ  ｐｒｉｎｏｉｄｅｓ）、サラシア・フルティコーサ（Ｓａｌａｃｉａ  ｆｒｕｔｉｃｏｓａ）、サラシア・マクロスペルマ（Ｓａｌａｃｉａ  ｍａｃｒｏｓｐｅｒｍａ）などがあげられる。\n\n\n  The composition of the present invention is not particularly limited as long as it contains desulfated cotaranol and salacinol, but preferably, a plant extract can be used as a raw material. Examples of the plant material include plants belonging to the genus Salacia. Examples of plants of the genus Salacia include, for example, Salacia oblonga, Salacia reticulata, Salacia chinensis, Salacia prinoides, Salacia prinoides. -A macrosperma (Salacia macrosperma) etc. are mention | raise | lifted.\n\n\n\n\n\n\n\n \n\n  本願の発明者は、高いマルターゼ阻害活性を有する組成物は、脱硫酸コタラノールを多く含んでいることを初めて発見した。さらに、組成物中の脱硫酸コタラノールの含量は、他の活性成分：例えばサラシノール、コタラノール、脱硫酸サラシノール、の含量との関係で特定の比率で存在することを見出した。すなわち、脱硫酸コタラノール含量とその他の成分の含量との存在比から本発明の組成物を特定することができる。したがって、本発明の別の側面は、脱硫酸コタラノールと他の活性成分が特定の比率で存在する組成物に関する。一例として、脱硫酸コタラノール含量とサラシノール含量の組成物中の比率に基づいて本発明の組成物を特定する場合について以下に説明する。\n\n\n  The inventor of the present application has discovered for the first time that a composition having a high maltase inhibitory activity contains a large amount of desulfurized cotaranol. Furthermore, it has been found that the content of desulfated cotaranol in the composition is present in a specific ratio in relation to the content of other active ingredients: eg salacinol, cotaranol, desulfated salacinol. That is, the composition of the present invention can be specified from the abundance ratio of the desulfated cotaranol content and the content of other components. Accordingly, another aspect of the invention relates to compositions in which desulfated cotaranol and other active ingredients are present in a specific ratio. As an example, the case where the composition of the present invention is specified based on the ratio of the desulfated cotaranol content and the salacinol content in the composition will be described below.\n\n\n\n\n\n\n\n \n\n  本発明の組成物中の脱硫酸コタラノールの含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）の関係は、以下の式\n\n        Ｙ≧αＸ\n\nで表すことができる。前記Ｙ重量％およびＸ重量％は、それぞれ、組成物中の脱硫酸コタラノール量（ｙ）およびサラシノール量（ｘ）の組成物全体の重量（ｚ）にしめる重量パーセントを意味する。すなわち、前記Ｙ重量％およびＸ重量％は以下の式により算出することができる。\n\nThe relationship between the content of desulfated cotaranol (Y wt%) and the content of salacinol (X wt%) in the composition of the present invention is expressed by the following formula: Y ≧ αX \n Can be expressed as Said Y weight% and X weight% mean the weight percentages that make up the total weight (z) of the desulfated cotaranol amount (y) and salacinol amount (x) in the composition, respectively. That is, the Y weight% and X weight% can be calculated by the following equations.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  脱硫酸コタラノールおよびサラシノールの定量は、これらの化合物が定量できる限りにおいていずれの方法を用いてもよいが、例えば、一般的に知られた方法を使用するのが簡便である。このような方法として、例えば、高速液体クロマトグラフィー（ＨＰＬＣ）を利用した方法、酵素免疫測定法（ＥＬＩＳＡ）があげられる。\n\n\n  Any method may be used for quantification of desulfated cotaranol and salacinol as long as these compounds can be quantified. For example, it is convenient to use a generally known method. Examples of such a method include a method using high performance liquid chromatography (HPLC) and an enzyme immunoassay (ELISA).\n\n\n\n\n\n\n\n \n\n  あるいは、上記方法と異なる方法として、質量分析計などにより化合物を分析した際に生成する特徴的な擬分子イオンを指標とする方法がある。擬分子イオンとは、化合物に対して水素イオンが０もしくは１つ付加した分子イオン、または水素イオンが０もしくは１つ脱離した分子イオンを意味する。当該方法は、例えば、液体クロマトグラフィーと質量分析計を接続したＬＣ−ＭＳにより行うことができる。例えば、サラシノールを下記の分析条件−１に設定したＬＣ−ＭＳで分析すると、質量対電荷比（ｍ／ｚ）＝３３３の擬分子イオンが生成する（保持時間８．２分）。当該擬分子イオンを選択的にモニタリングすれば、当該分子イオンのピーク面積を算出することができる。\n\n\n  Alternatively, as a method different from the above method, there is a method using as an index a characteristic pseudo-molecular ion generated when a compound is analyzed by a mass spectrometer or the like. The quasi-molecular ion means a molecular ion in which 0 or 1 hydrogen ion is added to a compound, or a molecular ion in which 0 or 1 hydrogen ion is eliminated. This method can be performed, for example, by LC-MS connecting a liquid chromatography and a mass spectrometer. For example, when salacinol is analyzed by LC-MS set to the following analysis condition-1, a pseudo-molecular ion having a mass-to-charge ratio (m / z) = 333 is generated (retention time 8.2 minutes). If the quasi-molecular ion is selectively monitored, the peak area of the molecular ion can be calculated.\n\n\n\n\n\n\n\n \n \n分析条件−１\n \n\n＜LC条件＞\n\n・カラム： Asahipak NH2P-50 (2.0 mm i.d.×150 mm、昭和電工株式会社)\n\n・移動相： アセトニトリル：水＝78：22 (v/v)\n\n・流量： 0.2 mL/min\n\n・カラム温度： 40℃\n\n・注入量： 1.0 μL\n\n＜MS条件＞\n\n・イオン化： ESIネガティブモード\n\n・ネブライズガス： 1.5 L/min\n\n・窒素ガス圧： 0.15 MPa\n\n・CDL 温度： 250℃\n\n・ブロックヒーター温度： 200℃\n\n・CDL 電圧： Constant-mode (-25V)\n\n・Q array DS & RF voltage： Scan-mode\n\n・SIM： ｍ／ｚ＝333（サラシノール）、ｍ／ｚ＝423（コタラノール）\n \n\n  一方、脱硫酸コタラノールを下記の分析条件−２に設定したＬＣ−ＭＳで分析すると、ｍ／ｚ＝３４５の擬分子イオン（保持時間４．９分）が得られ、上記と同様にピーク面積を算出することができる。\n\n \nAnalysis condition-1\n \n <LC conditions> \n・ Column: Asahipak NH2P-50 (2.0 mm id × 150 mm, Showa Denko KK) \n -Mobile phase: Acetonitrile: Water = 78:22 (v / v) \n・ Flow rate: 0.2 mL / min \n・ Column temperature: 40 ℃ \n・ Injection volume: 1.0 μL \n <MS conditions> \n・ Ionization: ESI negative mode ・ Nebulization gas: 1.5 L / min \n・ Nitrogen gas pressure: 0.15 MPa \n・ CDL temperature: 250 ℃ \n・ Block heater temperature: 200 ℃ \n・ CDL voltage: Constant-mode (-25V) \n・ Q array DS & RF voltage: Scan-mode \n SIM: m / z = 333 (Saracinol), m / z = 423 (Kotaranol) \n \n On the other hand, when desulfurized cotaranol was analyzed by LC-MS set to the following analysis condition-2, a quasi-molecular ion (retention time 4.9 minutes) of m / z = 345 was obtained, and the peak area was reduced as described above. Can be calculated.\n\n\n\n\n\n\n \n \n分析条件−２\n \n\n＜LC条件＞\n\n・カラム： Inertsil ODS-3 (2.1 mm i.d.×150 mm、GLサイエンス)\n\n・移動相： 5 mM HFBA / MeOH＝99：1 (v/v)\n\n・流量： 0.2 mL/min\n\n・カラム温度： 40℃\n\n・注入量： 1.0 μL\n\n＜MS条件＞\n\n・イオン化： ESIポジティブモード\n\n・ネブライズガス： 1.5 L/min\n\n・窒素ガス圧： 0.15 MPa\n\n・CDL 温度： 250℃\n\n・ブロックヒーター温度： 250℃\n\n・CDL 電圧： Constant-mode (-25V)\n\n・Q array DS & RF voltage： Scan-mode\n\n・SIM： ｍ／ｚ＝255（脱硫酸サラシノール）、ｍ／ｚ＝345（脱硫酸コタラノール）\n \n\n  上記の方法により測定した、サラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの各擬分子イオンのピーク面積とそれぞれの標準品濃度との関係を表す検量線を作成すれば、組成物中の各化合物の含量を算出することができる。\n\n \nAnalysis condition-2\n \n <LC conditions> \n・ Column: Inertsil ODS-3 (2.1 mm id × 150 mm, GL Sciences) \n・ Mobile phase: 5 mM HFBA / MeOH = 99: 1 (v / v) \n・ Flow rate: 0.2 mL / min \n・ Column temperature: 40 ℃ \n・ Injection volume: 1.0 μL \n <MS conditions> \n・ Ionization: ESI positive mode ・ Nebulization gas: 1.5 L / min \n・ Nitrogen gas pressure: 0.15 MPa \n・ CDL temperature: 250 ℃ \n・ Block heater temperature: 250 ℃ \n・ CDL voltage: Constant-mode (-25V) \n・ Q array DS & RF voltage: Scan-mode \n SIM: m / z = 255 (desulfurized salacinol), m / z = 345 (desulfurized cotaranol) \n \n If a calibration curve representing the relationship between the peak area of each quasi-molecular ion of salacinol, cotaranol, desulfated salacinol and desulfurized cotaranol measured by the above method and the concentration of each standard product is prepared, each compound in the composition The content of can be calculated.\n\n\n\n\n\n\n \n\n  上記関係式中のαは、実験的に求めることができる。詳しくは、脱硫酸コタラノール（Ｙ重量％）とサラシノール含量（Ｘ重量％）の比率とマルターゼ阻害活性との関係から導き出すことができる。αは１．６以上であればよく、好ましくは２．７以上、より好ましくは２．９以上であってよい。αの値は、脱硫酸コタラノールと対比する他の活性成分の種類によって変化することは、容易に理解できる。\n\n\n  Α in the above relational expression can be obtained experimentally. Specifically, it can be derived from the relationship between the ratio of desulfated cotaranol (Y wt%) and salacinol content (X wt%) and maltase inhibitory activity. α may be 1.6 or more, preferably 2.7 or more, more preferably 2.9 or more. It can be easily understood that the value of α varies depending on the type of other active ingredient compared with desulfated cotaranol.\n\n\n\n\n\n\n\n \n\n  あるいは、上記方法において検量線を作成せず、組成物に含まれる各活性成分に対応する擬分子イオンの単位重量当たりのピーク面積比およびピーク面積の和を指標にすることもできる。例えば、脱硫酸コタラノールのｍ／ｚ＝３４５のピーク面積とサラシノールのｍ／ｚ＝３３３のピーク面積の比、およびこれらのピーク面積の和を指標にできる。この手法によれば、分析によって得られるピーク面積を直接使用するため、検量線を作成する上記方法に比べてより簡便で迅速に目的の組成物を選択することができる。\n\n\n  Alternatively, a calibration curve may not be created in the above method, and the peak area ratio per unit weight and the sum of peak areas corresponding to each active ingredient contained in the composition may be used as an index. For example, the ratio of the peak area of m / z = 345 of desulfurized cotaranol and the peak area of m / z = 333 of salacinol and the sum of these peak areas can be used as an index. According to this method, since the peak area obtained by analysis is directly used, the target composition can be selected more easily and quickly than the above-described method for creating a calibration curve.\n\n\n\n\n\n\n\n \n\n  本発明の別の側面は、組成物が上記Ｙ≧１．６Ｘの関係を満たし、さらにＸ＋Ｙが一定以上である組成物に関する。Ｘ＋Ｙは、例えば０．７５重量％以上であり、好ましくは１．０５重量％以上、さらに好ましくは１．１８重量％以上である。\n\n\n  Another aspect of the present invention relates to a composition in which the composition satisfies the relationship of Y ≧ 1.6X and X + Y is not less than a certain value. X + Y is, for example, 0.75% by weight or more, preferably 1.05% by weight or more, and more preferably 1.18% by weight or more.\n\n\n\n\n\n\n\n \n\n  また、本発明の一態様として、上記組成物のＹ重量％は、例えば０．４６重量％以上、好ましくは０．７８重量％以上、さらに好ましくは０．８６重量％以上である。\n\n  本発明の別の側面は、マルターゼ阻害活性が一定以上の組成物に関する。阻害活性は、例えば、マルターゼ活性を５０％阻害するのに必要な組成物の濃度（ＩＣ\n５０\n）で表すことができる。ＩＣ\n５０\nは特に限定されないが、例えば、Ｗｉｓｔａｒ系雄性ラットの小腸より得た酵素溶液を用いるマルターゼ活性阻害試験（本発明の試験例１（１）マルターゼ阻害活性試験）の条件では８４μｇ／ｍＬ以下、好ましくは７９μｇ／ｍＬ以下、さらに好ましくは７５μｇ／ｍＬ以下である。\n\nMoreover, as 1 aspect of this invention, Y weight% of the said composition is 0.46 weight% or more, for example, Preferably it is 0.78 weight% or more, More preferably, it is 0.86 weight% or more. \n Another aspect of the present invention relates to a composition having a certain level of maltase inhibitory activity. Inhibitory activity can be expressed, for example, by the concentration of the composition required to inhibit maltase activity by 50% (IC \n50\n ). IC \n50\n is not particularly limited. For example, under the conditions of a maltase activity inhibition test using an enzyme solution obtained from the small intestine of a Wistar male rat (Test Example 1 (1) Maltase inhibition activity test of the present invention), it is 84 μg / mL or less. Preferably it is 79 microgram / mL or less, More preferably, it is 75 microgram / mL or less.\n\n\n\n\n\n\n \n\n  本発明の組成物は、特に限定されないが、例えば抽出物であってもよい。抽出物は、例えば、サラシア属の植物を水、熱水、有機溶媒、好ましくは水または熱水で処理することにより得ることができる。\n\n\n  Although the composition of this invention is not specifically limited, For example, an extract may be sufficient. The extract can be obtained, for example, by treating a plant of the genus Salacia with water, hot water, an organic solvent, preferably water or hot water.\n\n\n\n\n\n\n\n \n\n  本発明の別の側面は、本発明の組成物を含んでなる血糖値上昇抑制用医薬組成物に関する。当該医薬組成物は、マルターゼ活性を効果的に阻害することにより、食事デンプン由来の糖の吸収を抑制することができるため、血糖値の上昇を抑制することができる。\n\n\n  Another aspect of the present invention relates to a pharmaceutical composition for suppressing an increase in blood glucose level, comprising the composition of the present invention. Since the said pharmaceutical composition can suppress the absorption of the sugar derived from a meal starch by inhibiting the maltase activity effectively, it can suppress the raise of a blood glucose level.\n\n\n\n\n\n\n\n \n\n  本発明の別の側面は、本発明の組成物を含んでなる飲食品に関する。飲食品とは、固体状、液状、ゲル状、その形式は特に制限されない。健康食品および機能性食品などが飲食品の例としてあげられる。飲食品の製造において本発明の組成物を添加する工程を設けてもよいし、飲食品の完成後に本発明の組成物を添加してもよい。\n\n\n  Another aspect of the present invention relates to a food or drink comprising the composition of the present invention. The food and drink are not particularly limited in solid form, liquid form, gel form, and the form thereof. Examples of food and drink include health foods and functional foods. The process of adding the composition of this invention may be provided in manufacture of food / beverage products, and the composition of this invention may be added after completion of food / beverage products.\n\n\n\n\n\n\n\n \n\n  上記医薬組成物、飲食品、健康食品および機能性食品は、糖尿病、糖尿病合併症および腎症の予防、治療または症状の軽減などに有効である。当該事項は、容易に理解できる。\n\n  前記医薬組成物および飲食品は、必要に応じ、従来公知の着色剤、保存剤、香料、風味剤、コーティング剤などの成分を配合して調製することもできる。\n\nThe pharmaceutical composition, food and drink, health food and functional food are effective for the prevention, treatment or reduction of symptoms of diabetes, diabetic complications and nephropathy. This matter can be easily understood. \n The said pharmaceutical composition and food-drinks can also mix | blend and prepare components, such as a conventionally well-known coloring agent, a preservative, a fragrance | flavor, a flavor agent, and a coating agent, as needed.\n\n\n\n\n\n\n \n\n  また、本発明の医薬組成物および飲食品は、１以上の追加成分を配合して調製してもよい。追加成分の例としては、抗酸化剤、血糖降下剤、抗コレステロール剤、免疫賦活剤、ビタミン、アミノ酸、ペプチド、タンパク質、ミネラル分（鉄、亜鉛、マグネシウム、ヨードなど）、脂肪酸（ＥＰＡ、ＤＨＡなど）などをあげることができる。\n\n\n  Moreover, you may mix | blend the pharmaceutical composition and food-drinks of this invention, mix | blending one or more additional components. Examples of additional components include antioxidants, hypoglycemic agents, anticholesterol agents, immunostimulants, vitamins, amino acids, peptides, proteins, minerals (iron, zinc, magnesium, iodine, etc.), fatty acids (EPA, DHA, etc.) ) Etc.\n\n\n\n\n\n\n\n \n\n  ここで、抗酸化剤の例としては、特に限定はされないが、乾燥酵母、グルタチオン、リポ酸、ケルセチン、カテキン、コエンザイムＱ１０、エンゾジノール、プロアントシアニジン類、アントシアニジン、アントシアニン、カロチン類、リコピン、フラボノイド、リザベラトロール、イソフラボン類、亜鉛、メラトニン、および植物由来成分（例えば、イチョウ葉、月桃葉、ハイビスカス、またはそれらの抽出物）などが挙げられる。\n\n\n  Here, examples of the antioxidant are not particularly limited, but include dry yeast, glutathione, lipoic acid, quercetin, catechin, coenzyme Q10, enzogenol, proanthocyanidins, anthocyanidins, anthocyanins, carotenes, lycopene, flavonoids, lysas Examples include veratrol, isoflavones, zinc, melatonin, and plant-derived components (for example, ginkgo biloba, moon peach leaf, hibiscus, or an extract thereof).\n\n\n\n\n\n\n\n \n\n  血糖降下剤の例としては、特に限定はされないが、難消化性デキストリン、α−リノレン酸、豆鼓エキス、小麦アルブミン、Ｌ−アラビノース、および植物由来成分（例えば、グアバ葉、桑葉、しょうが、アマチャヅル、オオムギ、キダチアロエ、セイヨウタンポポ、ダイダイ、チョウセンアザミ、ニンニク、ハトムギ、バナバ、ビルベリー、ブラックコホシュ、マコモ、杜仲葉、月見草、カイアポ、ニガウリ、マデグルシルまたはそれらの抽出物）などが挙げられる。\n\n\n  Examples of hypoglycemic agents include, but are not limited to, indigestible dextrin, α-linolenic acid, bean extract, wheat albumin, L-arabinose, and plant-derived components (eg, guava leaf, mulberry leaf, ginger, Candy, barley, yellow aloe vera, dandelion, daidai, daffodil, garlic, pearl barley, banaba, bilberry, black cohosh, makomo, chunaka, evening primrose, caiapo, bitter gourd, madeglucill or an extract thereof.\n\n\n\n\n\n\n\n \n\n  抗コレステロール剤の例としては、特に限定はされないが、大豆タンパク質、リン脂質結合大豆ペプチド、キトサン、植物ステロール、植物ステロールエステル、植物スタノールエステル、難消化性デキストリン、アルギン酸ナトリウム、サイリウム種皮、アスタキサンチン、イノシトール、コエンザイムＡ、カルシウム、マグネシウム、カルニチン、シルクプロテイン、タウリン、メチオニン、α-リノレン酸、グアガム、コンドロイチン硫酸、大豆サポニン、および植物由来成分（例えば、アマチャヅル、アルファルファ、イチョウ、オオバコ、オオムギ、オーツ麦、オリーブ、ガジュツ、ギムネマ、キャッツクロー、クコ、クロレラ、スピルリナ、西洋サンザシ、唐辛子、ニンニク、ビルベリー、ベニバナ、ユッカ、ラフマ、アガリクス、紅麹、またはそれらの抽出物）などがあげられる。\n\n\n  Examples of anticholesterol agents include, but are not limited to, soy protein, phospholipid-bound soy peptide, chitosan, plant sterol, plant sterol ester, plant stanol ester, resistant digestive dextrin, sodium alginate, psyllium seed coat, astaxanthin, inositol , Coenzyme A, calcium, magnesium, carnitine, silk protein, taurine, methionine, α-linolenic acid, guar gum, chondroitin sulfate, soy saponin, and plant-derived components (eg, macaque, alfalfa, ginkgo, plantain, barley, oat, Olive, Gadju, Gymnema, Cat's Claw, Cuco, Chlorella, Spirulina, Hawthorn, Chili, Garlic, Bilberry, Safflower, Yucca, Ruffa, Agaricus Monascus or extracts thereof) and the like.\n\n\n\n\n\n\n\n \n\n  免疫賦活剤の例としては、特に限定はされないが、ラクトフェリン、アルギニン、トリプトファン、バリン、ロイシン、キチン、キトサン、および植物由来成分（例えば、アガリクス、冬虫夏草、アロエ、キダチアロエ、エキナセア、オウギ、キャッツクロー、クコ、スピルリナ、ハトムギ、紅花、マカ、マコモ、ラフマ、またはそれらの抽出物）などが挙げられる。\n\n\n  Examples of immunostimulants include, but are not limited to, lactoferrin, arginine, tryptophan, valine, leucine, chitin, chitosan, and plant-derived components (e.g., Agaricus, Cordyceps, Aloe, Kidachi Aloe, Echinacea, Ogi, Cats Claw, Wolfberry, spirulina, pearl barley, safflower, maca, makomo, luffa, or an extract thereof).\n\n\n\n\n\n\n\n \n\n  ビタミンの例としては、特に限定はされないが、ビタミンＡ群に属するビタミン［例えば、レチナール、レチノール、レチノイン酸、カロチン、デヒドロレチナール、リコピンおよび薬理学的に許容されるそれらの塩類（例えば、酢酸レチノール、パルミチン酸レチノールなど）など］、ビタミンＢ群に属するビタミン［例えば、チアミン、チアミンジスルフィド、ジセチアミン、オクトチアミン、シコチアミン、ビスイブチアミン、ビスベンチアミン、プロスルチアミン、ベンフォチアミン、フルスルチアミン、リボフラビン、フラビンアデニンジヌクレオチド、ピリドキシン、ピリドキサール、ヒドロキソコバラミン、シアノコバラミン、メチルコバラミン、デオキシアデノコバラミン、葉酸、テトラヒドロ葉酸、ジヒドロ葉酸、ニコチン酸、ニコチン酸アミド、ニコチニックアルコール、パントテン酸、パンテノール、ビオチン、コリン、イノシトール、パンガミン酸およびそれらの薬理学的に許容されるこれらの塩類（例えば、塩酸チアミン、硝酸チアミン、塩酸ジセチアミン、塩酸フルスルチアミン、酪酸リボフラビン、フラビンアデニンジヌクレオチドナトリウム、塩酸ピリドキシン、リン酸ピリドキサール、リン酸ピリドキサールカルシウム、塩酸ヒドロキソコバラミン、酢酸ヒドロキソコバラミン、パントテン酸カルシウム、パントテン酸ナトリウムなど）など］、ビタミンＣ群に属するビタミン［アスコルビン酸及びその誘導体、エリソルビン酸及びその誘導体、および薬理学的に許容されるそれらの塩類（例えば、アスコルビン酸ナトリウム、エリソルビン酸ナトリウムなど）など］、ビタミンＤ群に属するビタミン［例えば、エルゴカルシフェロール、コレカルシフェロール、ヒドロキシコレカルシフェロール、ジヒドロキシコレカルシフェロール、ジヒドロタキステロール、および薬理学的に許容されるそれらの塩類など］、ビタミンＥ群に属するビタミン［例えば、トコフェロール及びその誘導体、ユビキノン誘導体及びそれらの薬理学的に許容される塩類（酢酸トコフェロール、ニコチン酸トコフェロール、コハク酸トコフェロール、コハク酸トコフェロールカルシウムなど）など］、その他のビタミン［例えば、カルニチン、フェルラ酸、γ−オリザノール、オロチン酸、ルチン（ビタミンＰ）、エリオシトリン、ヘスペリジン、および薬理学的に許容されるそれらの塩類（塩化カルニチンなど）など〕などが挙げられる。\n\n\n  Examples of vitamins include, but are not limited to, vitamins belonging to the vitamin A group [eg, retinal, retinol, retinoic acid, carotene, dehydroretinal, lycopene, and pharmacologically acceptable salts thereof (eg, retinol acetate). , Retinol palmitate, etc.), vitamins belonging to vitamin B group [for example, thiamine, thiamine disulfide, dicetiamine, octothiamine, chicotiamine, bisbutiamine, bisbenchamine, prosultiamine, benfotiamine, fursultiamine, Riboflavin, flavin adenine dinucleotide, pyridoxine, pyridoxal, hydroxocobalamin, cyanocobalamin, methylcobalamin, deoxyadenocobalamin, folic acid, tetrahydrofolic acid, dihydrofolic acid, nicoti Acids, nicotinamide, nicotinic alcohol, pantothenic acid, panthenol, biotin, choline, inositol, pangamic acid and their pharmacologically acceptable salts thereof (eg thiamine hydrochloride, thiamine nitrate, dicetiamine hydrochloride, hydrochloric acid) Belonging to the vitamin C group, such as flusultiamine, riboflavin butyrate, sodium flavin adenine dinucleotide, pyridoxine hydrochloride, pyridoxal phosphate, calcium pyridoxal phosphate, hydroxocobalamin hydrochloride, hydroxocobalamin acetate, calcium pantothenate, sodium pantothenate) Vitamins [ascorbic acid and its derivatives, erythorbic acid and its derivatives, and pharmacologically acceptable salts thereof (for example, sodium ascorbate, erythorbic acid Etc.), vitamins belonging to the vitamin D group [for example, ergocalciferol, cholecalciferol, hydroxycholecalciferol, dihydroxycholecalciferol, dihydrotaxosterol, and pharmacologically acceptable salts thereof] Vitamins belonging to the vitamin E group [for example, tocopherol and derivatives thereof, ubiquinone derivatives and pharmacologically acceptable salts thereof (tocopherol acetate, tocopherol nicotinate, tocopherol succinate, calcium tocopherol succinate, etc.), etc. Vitamins [eg carnitine, ferulic acid, γ-oryzanol, orotic acid, rutin (vitamin P), eriocitrin, hesperidin and their pharmacologically acceptable salts (carnitine chloride] Etc.), etc.] and the like.\n\n\n\n\n\n\n\n \n\n  アミノ酸の例としては、特に限定はされないが、ロイシン、イソロイシン、バリン、メチオニン、トレオニン、アラニン、フェニルアラニン、トリプトファン、リジン、グリシン、アスパラギン、アスパラギン酸、セリン、グルタミン、グルタミン酸、プロリン、チロシン、システイン、ヒスチジン、オルニチン、ヒドロキシプロリン、ヒドロキシリジン、グリシルグリシン、アミノエチルスルホン酸（タウリン）、シスチン、または薬理学的に許容されるそれらの塩類（例えばアスパラギン酸カリウム、アスパラギン酸マグネシウム、塩酸システインなど）などが挙げられる。好ましい例は、バリン、ロイシンおよびイソロイシン等の分岐鎖アミノ酸、グルタチオン、システイン、グルタミン酸、グリシン、セリン、トリプトファン、チロシン、フェニルアラニン、ヒスチジン、メチオニン、スレオニン、リジン、シスチン、アルギニン、アラニン、アスパラギン酸、プロリン、アミノエチルスルホン酸である。\n\n\n  Examples of amino acids include, but are not limited to, leucine, isoleucine, valine, methionine, threonine, alanine, phenylalanine, tryptophan, lysine, glycine, asparagine, aspartic acid, serine, glutamine, glutamic acid, proline, tyrosine, cysteine, histidine. Ornithine, hydroxyproline, hydroxylysine, glycylglycine, aminoethylsulfonic acid (taurine), cystine, or pharmacologically acceptable salts thereof (eg, potassium aspartate, magnesium aspartate, cysteine hydrochloride, etc.) Can be mentioned. Preferred examples include branched chain amino acids such as valine, leucine and isoleucine, glutathione, cysteine, glutamic acid, glycine, serine, tryptophan, tyrosine, phenylalanine, histidine, methionine, threonine, lysine, cystine, arginine, alanine, aspartic acid, proline, Aminoethylsulfonic acid.\n\n\n\n\n\n\n\n \n\n  本発明の組成物は、医薬組成物または飲食品（特に、機能性食品、健康食品、サプリメントなど）として継続的な摂取が行いやすいように、例えば顆粒剤（ドライシロップを含む）、カプセル剤（軟カプセル剤、硬カプセル剤）、錠剤（チュアブル剤などを含む）、散剤（粉末剤）、丸剤などの各種の固形製剤、または内服用液剤（液剤、懸濁剤、シロップ剤を含む）などの液状製剤などの形態で調製することができ、成分の安定性や摂取の簡便さの点からカプセル剤または錠剤の形態が好ましいが、特に限定されるものではない。\n\n\n  The composition of the present invention can be used as a pharmaceutical composition or a food or drink (especially functional food, health food, supplement, etc.), for example, granule (including dry syrup), capsule (soft syrup) Various solid preparations such as capsules, hard capsules), tablets (including chewables), powders (powder), pills, or liquids for internal use (including liquids, suspensions, syrups), etc. It can be prepared in the form of a liquid preparation or the like, and is preferably in the form of a capsule or a tablet from the viewpoint of stability of ingredients and ease of ingestion, but is not particularly limited.\n\n\n\n\n\n\n\n \n\n  カプセル剤または錠剤の形態の本発明の組成物は、医薬または食品として許容される公知の添加物を用いて製造することができ、医薬または食品の分野で採用されている通常の製剤化手法を適用することができる。例えば、錠剤は、各成分を処方に従って添加配合し、粉砕、造粒、乾燥、整粒および混合を行い、得られた調製混合物を打錠することによって調製することができる。\n\n\n  The composition of the present invention in the form of a capsule or a tablet can be produced by using a known additive acceptable as a medicine or food, and a conventional formulation method adopted in the field of medicine or food is used. Can be applied. For example, a tablet can be prepared by adding and blending each component according to the formulation, crushing, granulating, drying, sizing and mixing, and tableting the resulting preparation mixture.\n\n\n\n\n\n\n\n \n\n  製剤化のための添加物としては、限定はされないが、例えば、賦形剤、滑沢剤、結合剤、崩壊剤、流動化剤、分散剤、湿潤剤、防腐剤、粘稠剤、ｐＨ調整剤、着色剤、矯味矯臭剤、界面活性剤、溶解補助剤などが挙げられる。また、液剤の形態にする場合は、ペクチン、キサンタンガム、グアガムなどの増粘剤を配合することができる。また、コーティング剤を用いてコーティング錠剤にしたり、ペースト状の膠剤とすることもできる。さらに、他の形態に調製する場合であっても、従来の方法に従えばよい。\n\n\n  Additives for formulation are not limited, but include, for example, excipients, lubricants, binders, disintegrants, fluidizers, dispersants, wetting agents, preservatives, thickeners, pH adjustments. Agents, coloring agents, flavoring agents, surfactants, solubilizing agents and the like. Moreover, when making it into the form of a liquid agent, thickeners, such as pectin, xanthan gum, and guar gum, can be mix | blended. Moreover, it can also be set as a coating tablet using a coating agent, or it can also be set as a paste-form glue. Furthermore, even if it is a case where it prepares in another form, what is necessary is just to follow the conventional method.\n\n\n\n\n\n\n\n \n\n  さらに、本発明の組成物は、例えば、飲料、菓子類、パン類、スープ類などの各種飲食品またはその添加成分として；またはドッグフード、キャットフードなどの各種ペットフードまたはその添加成分として使用することができる。これらの飲食品の製造方法は、本発明の効果を損なわないものであれば特に限定されず、各用途で当業者によって使用されている方法に従えばよい。\n\n\n  Furthermore, the composition of the present invention can be used, for example, as various foods and beverages such as beverages, confectionery, breads and soups or as additive components thereof; or as various pet foods such as dog foods and cat foods or additive components thereof. it can. The method for producing these foods and drinks is not particularly limited as long as the effects of the present invention are not impaired, and may follow the methods used by those skilled in the art for each application.\n\n\n\n\n\n\n\n \n\n  本発明の別の側面は、本発明の組成物の製造方法に関する。一態様として、例えば、以下の工程を含む製造方法があげられる：\n\n工程１）  サラシア属植物を水または熱水で処理すること；および\n\n工程２）  抽出物中の脱硫酸コタラノールの含量（Ｙ重量％）とサラシノールの含量（Ｘ重量％）が以下の\n\n        Ｙ≧αＸ\n\n        Ｘ＋Ｙ≧β\n\n        Ｙ≧γ\n\nのいずれか一つの関係を有する抽出物を選択し、これを組成物とする工程。ここで、脱硫酸コタラノールの含量は、カウンターイオンを含めない含量である。\n\nAnother aspect of the present invention relates to a method for producing the composition of the present invention. One embodiment includes, for example, a production method including the following steps: \n Step 1) Treating the plant of the genus Salacia with water or hot water; and Step 2) The content of desulfated cotaranol (Y wt%) and the content of salacinol (X wt%) in the extract are as follows: Y ≧ αX \n X + Y ≧ β \n Y ≧ γ \n The process which selects the extract which has any one relationship of these, and makes this a composition. Here, the content of desulfated cotaranol is a content not including counter ions.\n\n\n\n\n\n\n \n\n  上記工程１は、サラシア属植物から有効成分を抽出する工程である。サラシア属植物としては、例えば、採取後に乾燥した幹、根、葉、または幹および根部の樹皮を裁断または粉砕したものを使用することができる。\n\n\n  Step 1 is a step of extracting an active ingredient from a plant of the genus Salacia. As the plant belonging to the genus Salacia, for example, a plant obtained by cutting or pulverizing a trunk, a root, a leaf, or a bark of a trunk and a root part which has been dried after collection can be used.\n\n\n\n\n\n\n\n \n\n  抽出は慣用の方法を適宜利用して行うことができ、例えば、連続抽出、浸漬抽出、向流抽出、超臨界抽出などの方法により行ってもよい。\n\n  抽出溶媒としては特に限定されないが、水、低級アルコール（メタノールおよびエタノール）、アセトンなどの親水性溶媒、またはそれらの混合溶媒を用いることが好ましく、特に水を使用することが好ましい。抽出時には加熱することが好ましく、例えば、抽出溶媒の還流温度で抽出を行うことができる。水を溶媒として使用する場合は、例えば、６０〜１１０℃、好ましくは８０〜９０℃の温度下、例えば１〜２４時間、好ましくは１〜４時間の抽出時間で抽出を行うことができる。\n\nThe extraction can be performed by appropriately using a conventional method, and may be performed by a method such as continuous extraction, immersion extraction, countercurrent extraction, or supercritical extraction. \n Although it does not specifically limit as an extraction solvent, It is preferable to use hydrophilic solvents, such as water, a lower alcohol (methanol and ethanol), acetone, or those mixed solvents, and it is preferable to use water especially. It is preferable to heat at the time of extraction, for example, extraction can be performed at the reflux temperature of the extraction solvent. When water is used as a solvent, for example, extraction can be performed at a temperature of 60 to 110 ° C., preferably 80 to 90 ° C., for example, for an extraction time of 1 to 24 hours, preferably 1 to 4 hours.\n\n\n\n\n\n\n \n\n  本発明で使用する抽出物として、抽出液の原液、抽出液の濃縮液または抽出液濃縮物を乾燥して得られる固体を使用することができ、摂取の効率性の観点から固体化した濃縮物を使用するのが好ましい。抽出液の濃縮方法としては従来技術を適宜利用することができ、例えば、減圧乾燥法、凍結乾燥法、噴霧乾燥法などを行うことができる。\n\n\n  As the extract used in the present invention, a solid obtained by drying a stock solution of the extract, a concentrate of the extract or the extract concentrate can be used, and the concentrate is solidified from the viewpoint of ingestion efficiency. Is preferably used. As a method for concentrating the extract, conventional techniques can be appropriately used. For example, a vacuum drying method, a freeze drying method, a spray drying method, or the like can be performed.\n\n\n\n\n\n\n\n \n\n  サラシア属植物の抽出液は精製処理に付してもよい。精製処理としては、例えば、活性炭、イオン吸着樹脂などの吸着剤による処理、液−液向流分配処理などがあげられる。\n\n  サラシア属植物の抽出物は市販品を購入したものを使用してもよい。\n\nThe extract of Salacia plant may be subjected to a purification treatment. Examples of the purification treatment include treatment with an adsorbent such as activated carbon and ion adsorption resin, liquid-liquid countercurrent distribution treatment, and the like. \n As the extract of the genus Salacia, a commercially available product may be used.\n\n\n\n\n\n\n \n\n  上記工程２は、工程１で得られた抽出物から、脱硫酸コタラノールとサラシノールの含量が一定の関係を満たす抽出物を選択し、これを組成物とする工程である。ここで、脱硫酸コタラノールの含量は、カウンターイオンを含めない含量である。抽出物中の脱硫酸コタラノールとサラシノールの含量が以下：\n\n        Ｙ≧αＸ\n\n        Ｘ＋Ｙ≧β\n\n        Ｙ≧γ\n\nのいずれか一つの条件を満たす植物由来の抽出物を選択し、これを高いマルターゼ阻害活性を有する組成物とすることができる。\n\nThe step 2 is a step of selecting an extract satisfying a certain relationship between the contents of desulfated cotaranol and salacinol from the extract obtained in the step 1, and using this as a composition. Here, the content of desulfated cotaranol is a content not including counter ions. The content of desulfated cotaranol and salacinol in the extract is as follows: \n Y ≧ αX \n X + Y ≧ β \n Y ≧ γ \n An extract derived from a plant that satisfies any one of the conditions can be selected, and this can be used as a composition having high maltase inhibitory activity.\n\n\n\n\n\n\n \n\n  ここにおいて、αは１．６以上であればよく、好ましくは２．７以上、より好ましくは２．９以上であってよい。βは０．７５以上であればよく、特に１．０５以上であってよい。γは０．４６以上、好ましくは０．７８以上、さらに好ましくは０．８６以上であってよい。\n\n\n  Here, α may be 1.6 or more, preferably 2.7 or more, and more preferably 2.9 or more. β may be 0.75 or more, particularly 1.05 or more. γ may be 0.46 or more, preferably 0.78 or more, and more preferably 0.86 or more.\n\n\n\n\n\n\n\n \n\n  別の側面において、本発明は、脱硫酸コタラノールとサラシノールを含む植物由来の抽出物の品質評価方法であって、評価対象となる抽出物中の脱硫酸コタラノール（カウンターイオンを含まない）含量（Ｙ重量％）およびサラシノール含量（Ｘ重量％）を定量し、ＹとＸの関係が以下：\n\n        Ｙ≧αＸ\n\n        Ｘ＋Ｙ≧β\n\n        Ｙ≧γ\n\nのいずれか一つの条件を満たす場合には、α−グルコシダーゼ阻害活性、特にマルターゼ阻害活性の高い植物由来の抽出物であると判断する。上記品質評価方法により、α−グルコシダーゼ阻害活性の高い植物由来の抽出物を選択することできる。\n\nIn another aspect, the present invention is a method for evaluating the quality of a plant-derived extract containing desulfated cotaranol and salacinol, wherein the content of desulfated cotaranol (excluding counter ions) in the extract to be evaluated (Y %) And salacinol content (X wt%) were quantified, and the relationship between Y and X is as follows: \n Y ≧ αX \n X + Y ≧ β \n Y ≧ γ \n If any one of the conditions is satisfied, it is determined that the extract is derived from a plant having high α-glucosidase inhibitory activity, particularly maltase inhibitory activity. By the said quality evaluation method, the plant-derived extract with high alpha-glucosidase inhibitory activity can be selected.\n\n\n\n\n\n\n \n\n  ここにおいて、αは１．６以上であればよく、好ましくは２．７以上、より好ましくは２．９以上であってよい。βは０．７５以上であればよく、特に１．０５以上であってよい。γは０．４６以上、好ましくは０．７８以上、さらに好ましくは０．８６以上であってよい。\n\n\n  Here, α may be 1.6 or more, preferably 2.7 or more, and more preferably 2.9 or more. β may be 0.75 or more, particularly 1.05 or more. γ may be 0.46 or more, preferably 0.78 or more, and more preferably 0.86 or more.\n\n\n\n\n\n\n\n\n\n \n\n  本発明をより具体的に説明するが、本発明の範囲はこれに限定されるものではない。\n\n［実施例１］  サラシノールおよびコタラノールの標準品の調製\n\n  自然乾燥させたタイ産サラシア・キネンシス幹部（１５ｋｇ）を粉砕し、水（１５０Ｌ）を加えて９５〜１００℃で２時間、加熱抽出を行った。ろ過によりろ液を回収した。残渣に水（１５０Ｌ）を加え、上記と同様の操作を行った。上記２回の操作により得られたろ液を一つに合わせた。これを減圧濃縮させた後、噴霧乾燥させることによって熱水抽出物（収量１．４１ｋｇ、収率９．３７％）を得た。続いて当該熱水抽出物（１ｋｇ）にメタノール（１０Ｌ）を加え、８０℃で３時間処理し、ろ過によりろ液を回収した。残渣にメタノール（１０Ｌ）を加え、上記と同様の操作を２回繰り返した。上記３回の操作により得られたメタノール抽出液を一つに合わせ、減圧下で溶媒を留去させ、メタノール抽出エキス（収量３４７．５４ｇ、収率３．２６％）を得た。当該抽出エキス（３０３．８ｇ）を蒸留水５Ｌに溶解し、これをＤＩＡＩＯＮ-ＨＰ２０樹脂（４ｋｇ、三菱化学株式会社）を用いたカラムクロマトグラフィーに供し、水溶出部（収量１６７．６４ｇ、収率１．８０％）を得た。当該水溶出部（１５０ｇを）を蒸留水（７．５Ｌ）に溶かした後、Ｄｕｏｌｉｔｅ  Ａ３６８Ｓ樹脂（ＯＨ形、３．７５Ｌ、住化ケムテックス株式会社）を用いたカラムクロマトグラフィーに供し、蒸留水を通液後、酢酸水溶液（０．１Ｎ）を用いて酢酸溶出部（収量８．１０ｇ、収率０．１０％）を得た。次に、当該酢酸溶出部（７．０ｇ）を７５％（ｖ／ｖ）アセトニトリル（７００ｍＬ）に溶かした後、Ｃｈｒｏｍａｔｏｒｅｘ  ＮＨ樹脂（２１０ｇ、富士シリシア化学株式会社）を用いたカラムクロマトグラフィーに供し、７５％（ｖ／ｖ）アセトニトリル溶出部（収量２．７８ｇ、収率０．０３９％）、５０％（ｖ／ｖ）アセトニトリル溶出部（収量１．８０ｇ、収率０．０２５％）をそれぞれ得た。次にそれぞれをＣＯＳＭＯＳＩＬ  Ｓｕｇａｒ-Ｄ  （２０×２５０ｍｍ、ナカライテスク株式会社）を用いた高速液体クロマトグラフィーに供し、最終的にサラシノール（収量６８１．７ｍｇ、収率０．００９４％）、コタラノール（収量２３０．４ｍｇ、収率０．００３２％）を得た。両化合物の構造を\n１\nＨ−ＮＭＲ、\n１３\nＣ−ＮＭＲおよび質量分析計で解析した結果、以下の式（ＩＩ）および式（ＩＩＩ）の構造を有する化合物であることが確認された。これらをサラシノールの標準品およびコタラノールの標準品として使用した。\n\nThe present invention will be described more specifically, but the scope of the present invention is not limited thereto. \n [Example 1] Preparation of standard products of salacinol and kotalanol A naturally dried Thai Salacia chinensis trunk (15 kg) was pulverized, water (150 L) was added, and heat extraction was performed at 95-100 ° C for 2 hours. . The filtrate was collected by filtration. Water (150 L) was added to the residue, and the same operation as above was performed. The filtrates obtained by the above two operations were combined into one. This was concentrated under reduced pressure and then spray-dried to obtain a hot water extract (yield 1.41 kg, yield 9.37%). Subsequently, methanol (10 L) was added to the hot water extract (1 kg), treated at 80 ° C. for 3 hours, and the filtrate was recovered by filtration. Methanol (10 L) was added to the residue, and the same operation as described above was repeated twice. The methanol extracts obtained by the above three operations were combined and the solvent was distilled off under reduced pressure to obtain a methanol extract (yield 347.54 g, yield 3.26%). The extract (303.8 g) was dissolved in 5 L of distilled water, and this was subjected to column chromatography using DIAION-HP20 resin (4 kg, Mitsubishi Chemical Corporation), and the water elution part (yield 167.64 g, yield). 1.80%). After the water elution part (150 g) was dissolved in distilled water (7.5 L), it was subjected to column chromatography using Duolite A368S resin (OH form, 3.75 L, Sumika Chemtex Co., Ltd.). After passing through, an acetic acid elution part (yield 8.10 g, yield 0.10%) was obtained using an acetic acid aqueous solution (0.1 N). Next, the acetic acid elution part (7.0 g) was dissolved in 75% (v / v) acetonitrile (700 mL) and then subjected to column chromatography using Chromatorex NH resin (210 g, Fuji Silysia Chemical Ltd.). 75% (v / v) acetonitrile eluate (yield 2.78 g, yield 0.039%) and 50% (v / v) acetonitrile eluate (yield 1.80 g, yield 0.025%) were obtained, respectively. It was. Next, each was subjected to high performance liquid chromatography using COSMOSIL Sugar-D (20 × 250 mm, Nacalai Tesque Co., Ltd.). Finally, salacinol (yield 681.7 mg, yield 0.0094%), kotalanol (yield 230) 0.4 mg, yield 0.0032%). The structure of both compounds \n1\n \nH-NMR,\n 13 results of the analysis by C-NMR and mass spectrometry, it was confirmed that the compound having the structure of formula (II) and formula (III). These were used as a standard product of salacinol and a standard product of cotaranol.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n［実施例２］  脱硫酸サラシノールおよび脱硫酸コタラノールの標準品の調製\n\n  サラシノール標準品（２８ｍｇ）を５％（ｖ／ｖ）塩化水素含有メタノール（０．６ｍＬ）に溶解し、４５℃で３時間反応させた。反応後、減圧下で溶媒を留去させて残渣を得た。当該残渣をＫｉｅｓｅｌｇｅｌ  ６０（７０−２３０ｍｅｓｈ、メルク株式会社）を用いたカラムクロマトグラフィーに供し、最終的に下記構造式に示される脱硫酸サラシノール（カウンターイオンとしてＣＨ\n３\nＯＳＯ\n３\n \n−\nがイオン結合したもの、２７ｍｇ）を得た。同様に、コタラノール（１０ｍｇ）を５％（ｖ／ｖ）塩化水素含有メタノール（１．４ｍＬ）に溶解し、４５℃で３時間反応させた。反応後、減圧下で溶媒を留去させて残渣を得た。当該残渣をＫｉｅｓｅｌｇｅｌ  ６０（７０−２３０ｍｅｓｈ、メルク株式会社）を用いたカラムクロマトグラフィーに供し、最終的に下記構造式に示される脱硫酸コタラノール（カウンターイオンとしてＣＨ\n３\nＯＳＯ\n３\n \n−\nがイオン結合したもの、１０ｍｇ）を得た。両化合物の構造を\n１\nＨ−ＮＭＲ、\n１３\nＣ−ＮＭＲおよび質量分析にかけた結果、以下の式（ＩＶ）および式（Ｉ）の構造を有する化合物であることが確認された。これらを脱硫酸サラシノールの標準品および脱硫酸コタラノールの標準品として使用した。\n\n[Example 2] Preparation of desulfated salacinol and desulfurized cotaranol standard products Salacinol standard product (28 mg) was dissolved in methanol (0.6 mL) containing 5% (v / v) hydrogen chloride and reacted at 45 ° C for 3 hours. I let you. After the reaction, the solvent was distilled off under reduced pressure to obtain a residue. The residue was subjected to column chromatography using Kieselgel 60 (70-230 mesh, Merck Ltd.) and finally desulfated salacinol represented by the following structural formula (an ion-bonded CH \n3\n OSO \n3\n \n−\n as a counter ion, 27 mg) was obtained. Similarly, kotalanol (10 mg) was dissolved in 5% (v / v) hydrogen chloride-containing methanol (1.4 mL) and reacted at 45 ° C. for 3 hours. After the reaction, the solvent was distilled off under reduced pressure to obtain a residue. The residue was subjected to column chromatography using Kieselgel 60 (70-230 mesh, Merck Ltd.), and finally desulfurized cotaranol represented by the following structural formula (an ion-bonded CH \n3\n OSO \n3\n \n−\n as a counter ion, 10 mg) was obtained. As a result of subjecting the structures of both compounds to \n1\n H-NMR, \n13\n C-NMR and mass spectrometry, it was confirmed that they were compounds having the structures of the following formulas (IV) and (I). These were used as desulfated salacinol standard and desulfurized cotaranol standard.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\nここで、Ｘ\n−\nは先に定義した通りである。\n\n［実施例３］  サラシア属植物由来の抽出物の調製\n\n  表１に示したサラシア属植物（Ｎｏ．１〜２１）をそれぞれ小型超高速粉砕機ＷＢ−１（大阪ケミカル株式会社）で粉砕し、破砕粉末を得た。当該破砕粉末（２ｇ）に蒸留水（２０ｍＬ）を加え、９５℃で１２０分間、撹拌しながら加熱還流による抽出を行った。その後、遠心分離（１５００×ｇ、室温、５分間）を行い、上清を回収した。残渣に蒸留水（２０ｍＬ）を加え、９５℃で１２０分間、上記と同様に加熱還流による抽出を行った。その後、遠心分離（１５００×ｇ、室温、５分間）を行い、上清を回収した。上記のようにして得られた上清を一つにして１００ｍＬ容メスフラスコに移し、蒸留水で１００ｍＬにメスアップした。当該液（１０ｍＬ）をメンブレンフィルター（孔径０．４５μｍ）でろ過し、得られたろ液をサラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの定量分析に使用した。一方、当該液の残り（９０ｍＬ）は、減圧濃縮させた後、凍結乾燥させた。これをα−グルコシダーゼ阻害活性の測定用のサンプルとした。なお、抽出物の調製に用いた上記破砕粉末については、別に１０５℃、８時間での乾燥減量を測定し、抽出に用いた破砕粉末の乾燥重量を算出した。\n\nHere, X \n−\n is as defined above. \n [Example 3] Preparation of an extract derived from a plant belonging to the genus Salacia The plant belonging to the genus Salacia (No. 1 to 21) shown in Table 1 was pulverized and crushed with a small ultrahigh-speed pulverizer WB-1 (Osaka Chemical Co., Ltd.) A powder was obtained. Distilled water (20 mL) was added to the crushed powder (2 g), and extraction was performed by heating and refluxing with stirring at 95 ° C. for 120 minutes. Thereafter, centrifugation (1500 × g, room temperature, 5 minutes) was performed, and the supernatant was collected. Distilled water (20 mL) was added to the residue, and extraction was performed by heating and refluxing at 95 ° C. for 120 minutes in the same manner as described above. Thereafter, centrifugation (1500 × g, room temperature, 5 minutes) was performed, and the supernatant was collected. The supernatants obtained as described above were combined and transferred to a 100 mL volumetric flask and made up to 100 mL with distilled water. The liquid (10 mL) was filtered through a membrane filter (pore size: 0.45 μm), and the obtained filtrate was used for quantitative analysis of salacinol, cotaranol, desulfated salacinol, and desulfurized cotaranol. On the other hand, the remaining liquid (90 mL) was concentrated under reduced pressure and then lyophilized. This was used as a sample for measurement of α-glucosidase inhibitory activity. In addition, about the said crushing powder used for preparation of an extract, the drying loss in 105 degreeC and 8 hours was measured separately, and the dry weight of the crushing powder used for extraction was computed.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n［実施例４］  組成物中の成分の定量分析\n\n  上記実施例３で調製した組成物中のサラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの定量分析は、高速液体クロマトグラフ質量分析装置（ＬＣ−ＭＳ）によって行った。\n\n[Example 4] Quantitative analysis of components in composition Quantitative analysis of salacinol, cotaranol, desulfated salacinol and desulfurized cotaranol in the composition prepared in Example 3 was performed using a high performance liquid chromatograph mass spectrometer (LC- MS).\n\n\n\n\n\n\n \n\n  ＬＣ部分は、システムコントローラ：ＣＢＭ−２０Ａ、ポンプ：Ｓｈｉｍａｄｚｕ  ＬＣ−２０ＡＢ、紫外分光光度計検出器（ＵＶ）：Ｓｈｉｍａｄｚｕ  ＳＰＤ−２０Ａ、カラムオーブン：ＣＴＯ−２０Ａ、オートサンプラー：ＳＩＬ−２０Ａ、から構成される（いずれも株式会社島津製作所）。ＭＳ部分は、Ｓｈｉｍａｄｚｕ  ＬＣ−ＭＳ−２０１０ＥＶ（株式会社島津製作所）を用いた。\n\n\n  The LC part is composed of system controller: CBM-20A, pump: Shimadzu LC-20AB, ultraviolet spectrophotometer detector (UV): Shimadzu SPD-20A, column oven: CTO-20A, autosampler: SIL-20A. (Both are Shimadzu Corporation). For the MS portion, Shimadzu LC-MS-2010EV (Shimadzu Corporation) was used.\n\n\n\n\n\n\n\n \n\n  サラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールのＭＳ部分よる検出は、各化合物に特徴的な擬分子イオンを選択的にモニタリングすることによって行った。各化合物の擬分子イオンのｍ／ｚは、サラシノール：ｍ／ｚ＝３３３、コタラノール：ｍ／ｚ＝４２３、脱硫酸サラシノール：ｍ／ｚ＝２５５および脱硫酸コタラノール：ｍ／ｚ＝３４５である。分析条件を以下に示す。\n\n\n  Detection of salacinol, kotalanol, desulfated salacinol and desulfated cotaranol by the MS moiety was carried out by selectively monitoring the quasimolecular ions characteristic of each compound. The m / z of the quasimolecular ion of each compound is salacinol: m / z = 333, cotaranol: m / z = 423, desulfated salacinol: m / z = 255, and desulfurized cotaranol: m / z = 345. The analysis conditions are shown below.\n\n\n\n\n\n\n\n \n \n \n分析条件−１：サラシノールおよびコタラノールの分析条件\n \n\n＜ＬＣ条件＞\n\n・カラム： Ａｓａｈｉｐａｋ  ＮＨ\n２\nＰ−５０（２．０ｍｍｉ.ｄ.×１５０ｍｍ、昭和電工株式会社）\n\n・移動相： アセトニトリル：水＝７８：２２ (v/v)\n\n・流量： ０．２ｍＬ／ｍｉｎ\n\n・カラム温度： ４０℃\n\n・注入量： １．０μＬ\n\n＜ＭＳ条件＞\n\n・イオン化： ＥＳＩネガティブモード\n\n・ネブライズガス： １．５Ｌ／ｍｉｎ\n\n・窒素ガス圧： ０．１５ＭＰａ\n\n・ＣＤＬ温度： ２５０℃\n\n・ブロックヒーター温度： ２００℃\n\n・ＣＤＬ電圧： Ｃｏｎｓｔａｎｔ−ｍｏｄｅ（−２５Ｖ）\n\n・Ｑ  ａｒｒａｙ  ＤＳ  ＆  ＲＦ  ｖｏｌｔａｇｅ： Ｓｃａｎ−ｍｏｄｅ\n\n・ＳＩＭ： ｍ／ｚ＝３３３（サラシノール）、ｍ／ｚ＝４２３（コタラノール）\n \n \n分析条件−２：脱硫酸サラシノールおよび脱硫酸コタラノールの分析条件\n \n\n＜ＬＣ条件＞\n\n・カラム： Ｉｎｅｒｔｓｉｌ  ＯＤＳ−３（２．1ｍｍｉ．ｄ．×１５０ｍｍ、ジーエルサイエンス株式会社）\n\n・移動相： ５ｍＭ  ＨＦＢＡ／ＭｅＯＨ＝９９：１ (v/v)\n\n・流量： ０．２ｍＬ／ｍｉｎ\n\n・カラム温度： ４０℃\n\n・注入量： １．０μＬ\n\n＜ＭＳ条件＞\n\n・イオン化： ＥＳＩポジティブモード\n\n・ネブライズガス： １．５Ｌ／ｍｉｎ\n\n・窒素ガス圧： ０．１５ＭＰａ\n\n・ＣＤＬ温度： ２５０℃\n\n・ブロックヒーター温度： ２５０℃\n\n・ＣＤＬ電圧： Ｃｏｎｓｔａｎｔ−ｍｏｄｅ（−２５Ｖ）\n\n・Ｑ  ａｒｒａｙ  ＤＳ  ＆  ＲＦ  ｖｏｌｔａｇｅ： Ｓｃａｎ−ｍｏｄｅ\n\n・ＳＩＭ： ｍ／ｚ＝２５５（脱硫酸サラシノール）、ｍ／ｚ＝３４５（脱硫酸コタラノール）\n \n\n  分析結果は、表１のＮｏ．１〜２１のサンプル全てについて得ることができた。代表例として、表１のＮｏ．１のサンプルのクロマトチャートを示す（図１〜４）。ｍ／ｚ＝３３３（サラシノール）は８．２分、ｍ／ｚ＝４２３（コタラノール）は１６．１分、ｍ／ｚ＝２５５（脱硫酸サラシノール）は５．８分、ｍ／ｚ＝３４５（脱硫酸コタラノール）は４．９分の保持時間にピークが現れた。これらピークの保持時間は、各標準品のピークの保持時間と一致した。\n\n \n \nAnalysis condition-1: Analysis conditions of salacinol and cotaranol\n <LC conditions> \n -Column: Asahipak NH \n2\n P-50 (2.0 mm.d. × 150 mm, Showa Denko KK) \n -Mobile phase: Acetonitrile: Water = 78:22 (v / v) \n・ Flow rate: 0.2mL / min \n -Column temperature: 40 ° C \n・ Injection volume: 1.0 μL \n <MS conditions> \n・ Ionization: ESI negative mode ・ Nebulization gas: 1.5 L / min \n・ Nitrogen gas pressure: 0.15 MPa \n CDL temperature: 250 ° C \n・ Block heater temperature: 200 ℃ \n CDL voltage: Constant-mode (-25V) \n・ Q array DS & RF voltage: Scan-mode \n SIM: m / z = 333 (saracinol), m / z = 423 (kotalanol) \n \n \nAnalytical condition-2: Analytical condition of desulfated salacinol and desulfurized cotaranol\n <LC condition> \n Column: Inertsil ODS-3 (2.1 mm.d. × 150 mm, GL Sciences Inc.) \n Mobile phase: 5 mM HFBA / MeOH = 99: 1 (v / v) \n・ Flow rate: 0.2mL / min \n -Column temperature: 40 ° C \n・ Injection volume: 1.0 μL \n <MS conditions> \n・ Ionization: ESI positive mode ・ Nebulization gas: 1.5 L / min \n・ Nitrogen gas pressure: 0.15 MPa \n CDL temperature: 250 ° C \n・ Block heater temperature: 250 ℃ \n CDL voltage: Constant-mode (-25V) \n・ Q array DS & RF voltage: Scan-mode \n SIM: m / z = 255 (desulfurized salacinol), m / z = 345 (desulfurized cotaranol) \n \n The analysis results are shown in Table 1. All samples 1 to 21 could be obtained. As a representative example, No. 1 in Table 1 is used. The chromatogram of 1 sample is shown (FIGS. 1-4). m / z = 333 (Saracinol) is 8.2 minutes, m / z = 423 (Kotaranol) is 16.1 minutes, m / z = 255 (Desulfated Saracinol) is 5.8 minutes, m / z = 345 ( (Desulfurized Kotalanol) showed a peak at a retention time of 4.9 minutes. The retention times of these peaks coincided with the retention times of the peaks of each standard product.\n\n\n\n\n\n\n \n\n  実施例１および２で調製した各標準品を用いて作成した検量線に基づいて、上記擬分子イオンのピーク面積からサラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの含量を絶対検量線法にて算出した（表２）。なお、脱硫酸サラシノール、および脱硫酸コタラノールの標準品は、カウンターイオン（ＣＨ\n３\nＯＳＯ\n３\n \n−\n）を含んでいるため、以下の式によりカウンターイオンを含まない濃度に換算してこれらの検量線を作成した。\n\nBased on the calibration curve prepared using each standard prepared in Examples 1 and 2, the content of salacinol, cotaranol, desulfated salacinol and desulfurized cotaranol was determined by the absolute calibration curve method from the peak area of the pseudo-molecular ion. Calculated (Table 2). In addition, since desulfated salacinol and desulfurized cotaranol standard products contain counter ions (CH \n3\n OSO \n3\n \n−\n ), these calibration curves are prepared by converting to concentrations not containing counter ions by the following formula. did.\n\n\n\n\n\n\n \n \n\nＡ＝Ｂ×２５５／３６６\n \n\nＡ：[カウンターイオンを含まない脱硫酸サラシノール濃度]\n\nＢ：[カウンターイオン（ＣＨ\n３\nＯＳＯ\n３\n \n−\n）を含む脱硫酸サラシノール濃度]\n \n\nＣ＝Ｄ×３４５／４５６\n \n\nＣ：[カウンターイオンを含まない脱硫酸コタラノール濃度]\n\nＤ：[カウンターイオン（ＣＨ\n３\nＯＳＯ\n３\n \n−\n）を含む脱硫酸コタラノール濃度]\n \n \n A = B × 255/366 \n \n A: [Desulfated salacinol concentration without counter ions] \n B: [Desulfated salacinol concentration containing counter ion (CH \n3\n OSO \n3\n \n−\n )] \n \n C = D × 345/456 \n \n C: [Desulfurized cotaranol concentration without counter ions] \n D: [Concentration of desulfurized cotaranol containing counter ion (CH \n3\n OSO \n3\n \n−\n )] \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n［試験例１］  α−グルコシダーゼ活性阻害試験\n\n（１）マルターゼ活性阻害試験\n\n  酵素溶液：Ｗｉｓｔａｒ系雄性ラットの小腸を摘出後、小腸内面の粘膜をスライドガラスを用いて採取した。採取した前記粘膜をマンニトール（５０ｍＭ）を含有するトリス緩衝液（２ｍＭ、ｐＨ７．１）中でホモジナイズした後、塩化カルシウム（終濃度１０ｍＭ）を添加し、混合した。得られた懸濁液を遠心分離（３０００×ｇ、４℃、５分間）し、上清を回収した。当該上清をさらに超遠心分離（２７０００×ｇ、４℃、３０分間）し、得られた沈殿をマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）に懸濁させ、回収した。当該懸濁液はα−グルコシダーゼを含んでいるため、当該懸濁液を酵素溶液として使用した。当該酵素溶液は、マルターゼ活性とスクラーゼ活性を有する。\n\nTest Example 1 α-Glucosidase Activity Inhibition Test (1) Maltase Activity Inhibition Test Enzyme solution: After removing the small intestine of Wistar male rats, the mucosa on the inner surface of the small intestine was collected using a glass slide. The collected mucous membrane was homogenized in a Tris buffer (2 mM, pH 7.1) containing mannitol (50 mM), and calcium chloride (final concentration 10 mM) was added and mixed. The obtained suspension was centrifuged (3000 × g, 4 ° C., 5 minutes), and the supernatant was collected. The supernatant was further subjected to ultracentrifugation (27000 × g, 4 ° C., 30 minutes), and the resulting precipitate was suspended in maleic acid buffer (0.1 M, pH 6.0) and collected. Since the suspension contains α-glucosidase, the suspension was used as an enzyme solution. The enzyme solution has maltase activity and sucrase activity.\n\n\n\n\n\n\n \n\n  基質溶液：マルトース（ナカライテスク株式会社）をマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）に溶解し、マルトース基質溶液（７４ｍＭ）を調製した。\n\n  試料溶液：実施例３で調製した各サンプルをジメチルスルホキシドおよびマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）に溶解し、試料溶液（２４０μｇ／ｍＬ、１０％ジメチルスルホキシドを含む）を調製した。\n\nSubstrate solution: Maltose (Nacalai Tesque, Inc.) was dissolved in a maleic acid buffer (0.1 M, pH 6.0) to prepare a maltose substrate solution (74 mM). \n Sample solution: Each sample prepared in Example 3 was dissolved in dimethyl sulfoxide and maleic acid buffer (0.1 M, pH 6.0) to prepare a sample solution (containing 240 μg / mL, 10% dimethyl sulfoxide).\n\n\n\n\n\n\n \n\n  酵素反応：基質溶液（５０μＬ）に試料溶液（２５μＬ）を加えた後、酵素液（２５μＬ）を加え、３７℃で３０分間反応させた。沸騰水浴中で２分間加熱し、酵素を失活させて反応を停止させた。これを評価サンプルとした。一方、酵素溶液の代わりにマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）を加えて上記と同じ反応操作を行ったものを酵素ブランク１とした。また、試料溶液の代わりにマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）を加えて上記と同じ反応操作を行ったものを試料ブランクとした。さらに、酵素溶液の代わりにマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）、および試料溶液の代わりにマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）を加えて上記と同じ反応操作を行ったものを酵素ブランク２とした。また、比較例として、α−グルコシダーゼ阻害活性を有する医薬品であるベイスン錠（商標、武田薬品工業株式会社、１錠（２００ｍｇ）あたりボグリボース０．３ｍｇ）についても同様の操作を行った。\n\n\n  Enzyme reaction: After adding a sample solution (25 μL) to a substrate solution (50 μL), an enzyme solution (25 μL) was added and reacted at 37 ° C. for 30 minutes. The reaction was stopped by heating in a boiling water bath for 2 minutes to deactivate the enzyme. This was used as an evaluation sample. On the other hand, an enzyme blank 1 was prepared by adding maleate buffer (0.1 M, pH 6.0) in place of the enzyme solution and performing the same reaction operation as above. A sample blank was prepared by adding maleate buffer (0.1 M, pH 6.0) in place of the sample solution and performing the same reaction operation as above. Further, maleate buffer (0.1 M, pH 6.0) is added instead of the enzyme solution, and maleate buffer (0.1 M, pH 6.0) is added instead of the sample solution, and the same reaction operation as described above is performed. This was designated as enzyme blank 2. Further, as a comparative example, the same operation was performed for Basin tablets (trademark, Takeda Pharmaceutical Co., Ltd., voglibose 0.3 mg per tablet (200 mg)) which is a pharmaceutical having α-glucosidase inhibitory activity.\n\n\n\n\n\n\n\n \n\n  遊離グルコースの定量：反応を停止させた上記反応液中のＤ−グルコースの濃度をグルコースＣＩＩテストワコー（和光純薬工業株式会社）により測定し、酵素反応によって生成したＤ−グルコース濃度を以下の式により算出した。\n\n\n  Quantification of free glucose: The concentration of D-glucose in the reaction solution in which the reaction was stopped was measured by Glucose CII Test Wako (Wako Pure Chemical Industries, Ltd.), and the concentration of D-glucose produced by the enzyme reaction was expressed by the following formula: Calculated by\n\n\n\n\n\n\n\n \n \n\n[評価サンプルの生成Ｄ−グルコース濃度（Ａ）]＝[評価サンプルのＤ−グルコース濃度]−[酵素ブランク１のＤ−グルコース濃度]\n \n\n[試料ブランクの生成Ｄ−グルコース濃度（Ｂ）]＝[試料ブランクのＤ−グルコース濃度]−[酵素ブランク２のＤ−グルコース濃度]\n \n\n  さらに、上記のようにして算出した、評価サンプルの生成Ｄ−グルコース濃度および試料ブランクの生成Ｄ−グルコース濃度を下式にあてはめることによって、各サンプルのマルターゼ阻害率を算出した。\n\n \n [Production D-glucose concentration of evaluation sample (A)] = [D-glucose concentration of evaluation sample]-[D-glucose concentration of enzyme blank 1] \n \n [Production D-glucose concentration of sample blank (B)] = [D-glucose concentration of sample blank]-[D-glucose concentration of enzyme blank 2] \n \n Furthermore, the maltase inhibition rate of each sample was calculated by applying the generated D-glucose concentration of the evaluation sample and the generated D-glucose concentration of the sample blank calculated as described above to the following equations.\n\n\n\n\n\n\n \n \n\nマルターゼ阻害率（％）＝１００−{（Ａ／Ｂ）×１００}\n \n\n結果を表３に示す。\n\n \n Maltase inhibition rate (%) = 100 − {(A / B) × 100} \n \n The results are shown in Table 3.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n（２）スクラーゼ阻害活性試験\n\n  基質溶液：スクロース（ナカライテスク株式会社）をマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）に溶解し、スクロース基質溶液（７４ｍＭ）を調製した。\n\n(2) Sucrase inhibitory activity test Substrate solution: Sucrose (Nacalai Tesque, Inc.) was dissolved in a maleic acid buffer (0.1 M, pH 6.0) to prepare a sucrose substrate solution (74 mM).\n\n\n\n\n\n\n \n\n  試料溶液：実施例３で調製した各サンプルをジメチルスルホキシドおよびマレイン酸緩衝液（０．１Ｍ、ｐＨ６．０）に溶解し、試料溶液（８０μｇ／ｍＬ、１０％ジメチルスルホキシドを含む）を調製した。\n\n\n  Sample solution: Each sample prepared in Example 3 was dissolved in dimethyl sulfoxide and maleic acid buffer (0.1 M, pH 6.0) to prepare a sample solution (80 μg / mL, containing 10% dimethyl sulfoxide).\n\n\n\n\n\n\n\n \n\n  当該基質溶液および試料溶液を用いる以外は、上記（１）の方法に従った。比較例として、α−グルコシダーゼ阻害活性を有する医薬品であるベイスン錠についても同様の操作を行った。これにより各サンプルのスクラーゼ阻害率を算出した。結果を表４に示す。\n\n\n  The method (1) was followed except that the substrate solution and the sample solution were used. As a comparative example, the same operation was performed on a basin tablet which is a pharmaceutical having an α-glucosidase inhibitory activity. Thereby, the sucrase inhibition rate of each sample was calculated. The results are shown in Table 4.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n［試験例２］\n\n  上記試験例１（１）の試験法において、各試料溶液中のサンプル濃度を変化（２０００、８００、２４０、８０、２４μｇ／ｍＬ）させ、各サンプルのマルターゼ阻害活性ＩＣ\n５０\n（マルターゼ活性を５０％阻害する濃度）を測定した。また、比較例としてα−グルコシダーゼ阻害活性を有する医薬品であるベイスン錠についても同様の操作を行った。結果を表５に示す。\n\n[Test Example 2] \n In the test method of Test Example 1 (1), the sample concentration in each sample solution was changed (2000, 800, 240, 80, 24 μg / mL), and the maltase inhibitory activity IC \n50\n (maltase activity was 50% of each sample). Inhibitory concentration) was measured. Moreover, the same operation was performed also about the basin tablet which is a pharmaceutical which has alpha-glucosidase inhibitory activity as a comparative example. The results are shown in Table 5.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  上記試験例１〜３の結果（表３〜５）を考慮すると、α−グルコシダーゼ阻害活性（マルターゼ阻害活性およびスクラーゼ阻害活性）は、サンプルごとにバラツキがあることが判明した。これは、原料となるサラシア植物の品質がその種類、生産国および樹齢や採取時期などによって異なることを示唆し、さらに品質が一定した原料の供給が極めて困難であることも示唆する。すなわち、最終製品のα−グルコシダーゼ阻害活性が一定しないことになり、ひいては目的の効果を十分に発揮できない製品が製造されることになるため、品質保証の観点から好ましくない。そこで、α−グルコシダーゼ阻害活性と各サンプル中に含まれるサラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの含量との関係について以下のような検討を行った。\n\n\n  Considering the results of Test Examples 1 to 3 (Tables 3 to 5), it was found that the α-glucosidase inhibitory activity (maltase inhibitory activity and sucrase inhibitory activity) varies from sample to sample. This suggests that the quality of the Salacia plant used as a raw material varies depending on the type, the country of origin, the age of the tree, the harvesting time, etc., and further suggests that it is extremely difficult to supply a raw material with a constant quality. That is, the α-glucosidase inhibitory activity of the final product is not constant, and as a result, a product that does not sufficiently exhibit the target effect is manufactured, which is not preferable from the viewpoint of quality assurance. Then, the following examination was performed about the relationship between the α-glucosidase inhibitory activity and the contents of salacinol, cotaranol, desulfated salacinol and desulfurized cotaranol contained in each sample.\n\n\n\n\n\n\n\n \n\n  表２〜４の結果に基づいて、上記サラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの含量とマルターゼ阻害率もしくはスクラーゼ阻害率との関係を表す図を作成した（図５〜１２）。さらに、各図のプロットに基づいて線形近似式および相関係数（ｒ）を算出した（表６）。\n\n\n  Based on the results shown in Tables 2 to 4, diagrams showing the relationship between the contents of salacinol, cotaranol, desulfated salacinol and desulfated cotaranol and the maltase inhibition rate or sucrase inhibition rate were prepared (FIGS. 5 to 12). Furthermore, a linear approximation formula and a correlation coefficient (r) were calculated based on the plots in each figure (Table 6).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  これらの結果から、サラシノールと脱硫酸サラシノール含量は、マルターゼ阻害率またはスクラーゼ阻害率のいずれとも相関はほとんどないことが判明した(図５〜８)。コタラノール含量は、スクラーゼ阻害率（図１０）とある程度の相関があることが示唆されるものの、マルターゼ阻害率（図９）との相関は明らかでなかった。唯一、脱硫酸コタラノール含量のみがマルターゼ阻害率（図１１）およびスクラーゼ阻害率（図１２）の両方と高い相関があることが判明した。\n\n\n  From these results, it was found that the contents of salacinol and desulfated salacinol had little correlation with either the maltase inhibition rate or the sucrase inhibition rate (FIGS. 5 to 8). Although the cotaranol content was suggested to have a certain degree of correlation with the sucrase inhibition rate (FIG. 10), the correlation with the maltase inhibition rate (FIG. 9) was not clear. Only the desulfated cotaranol content was found to be highly correlated with both maltase inhibition rate (FIG. 11) and sucrase inhibition rate (FIG. 12).\n\n\n\n\n\n\n\n \n\n  さらに、各サンプル中のサラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの含量の合計とマルターゼ阻害率およびスクラーゼ阻害率との関係について検討を行った（図１３および１４）。当該検討結果から、上記４つの化合物によるマルターゼ阻害率は、脱硫酸コタラノール含量にほぼ依存していることが明らかになった。また、スクラーゼ阻害率に関しても、その大部分が脱硫酸コタラノール含量に依存していることが示された。\n\n\n  Furthermore, the relationship between the total content of salacinol, cotaranol, desulfated salacinol and desulfated cotaranol in each sample and the maltase inhibition rate and sucrase inhibition rate was examined (FIGS. 13 and 14). From the examination results, it has been clarified that the maltase inhibition rate by the above four compounds almost depends on the content of desulfated cotaranol. In addition, it was shown that the sucrase inhibition rate largely depends on the desulfated cotaranol content.\n\n\n\n\n\n\n\n \n\n  以上の結果を鑑みると、本発明の組成物においては、脱硫酸コタラノールがα−グルコシダーゼ阻害活性の主な活性成分であることが明らかである。特に、マルターゼ阻害活性との高い相関が示された。本願出願時において、サラシノール、コタラノール、脱硫酸サラシノールおよび脱硫酸コタラノールの単離された化合物は、α−グルコシダーゼ活性を同程度で阻害することが技術常識として知られている。このような技術常識を考慮すると、上記の結果は全くの予想外といえる。\n\n\n  In view of the above results, in the composition of the present invention, it is clear that desulfated cotaranol is the main active ingredient of α-glucosidase inhibitory activity. In particular, a high correlation with maltase inhibitory activity was shown. At the time of filing this application, it is known as technical common sense that the isolated compounds of salacinol, cotaranol, desulfated salacinol and desulfurized cotaranol inhibit α-glucosidase activity to the same extent. Considering such common technical knowledge, the above results are completely unexpected.\n\n\n\n\n\n\n\n \n\n  さらに、本発明者は、高いα−グルコシダーゼ阻害活性を有するサンプルを選択するための指標について検討を行った。各サンプル中の脱硫酸コタラノール含量、サラシノール含量、およびマルターゼ阻害活性（ＩＣ\n５０\n）の関係を以下にまとめた（表７）。\n\nFurthermore, the present inventor examined an index for selecting a sample having high α-glucosidase inhibitory activity. The relationship between the desulfated cotaranol content, salacinol content, and maltase inhibitory activity (IC \n50\n ) in each sample is summarized below (Table 7).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  表７の結果から、ＩＣ\n５０\nが特に低い（マルターゼ阻害活性が高いことを意味する）サンプル（表７の判定の欄に○があるもの）は、脱硫酸コタラノールとサラシノールの含量比（ＤｅｓＫｏ／Ｓａ）が１．６以上であることが明らかとなった。さらに、サンプル中の脱硫酸コタラノールの存在量が０．０９重量％以上であればマルターゼ阻害活性が認められ、さらに０．４６重量％以上であれば極めて高いマルターゼ阻害活性が認められることが明らかとなった。このような指標を用いれば、サラシア属植物から組成物を調製した場合に、目的の効果を奏する組成物を迅速、容易に選択することができるため、組成物のα−グルコシダーゼ阻害活性の品質評価を容易に行うことができる。さらに、当該品質評価方法は、組成物のα−グルコシダーゼ阻害活性を任意の規格値に調整する用途にも適しているため、α−グルコシダーゼ阻害活性が均一な組成物を安定的に製造することができる。\n\nFrom the results of Table 7, a sample with a particularly low IC \n50\n (meaning that maltase inhibitory activity is high) (a sample having a circle in the judgment column of Table 7) is a content ratio (DesKo / Sa) of desulfated cotaranol and salacinol. ) Was found to be 1.6 or more. Furthermore, it is clear that maltase inhibitory activity is observed when the amount of desulfated cotaranol present in the sample is 0.09% by weight or more, and extremely high maltase inhibitory activity is observed when 0.46% by weight or more. became. By using such an index, when a composition is prepared from a plant of the genus Salacia, it is possible to quickly and easily select a composition that exhibits the desired effect. Therefore, the quality evaluation of the α-glucosidase inhibitory activity of the composition Can be easily performed. Furthermore, since the quality evaluation method is also suitable for use in adjusting the α-glucosidase inhibitory activity of the composition to an arbitrary standard value, it is possible to stably produce a composition having a uniform α-glucosidase inhibitory activity. it can.\n\n\n\n\n\n\n \n\n  また、上記の０．０９重量％および０．４６重量％の脱硫酸コタラノールを含有する組成物は、それぞれサンプルＮｏ．１６および６に対応する。当該サンプルＮｏ．１６および６の製造に用いた原料の脱硫酸コタラノール含量は、表２から、それぞれ０．０１８重量％および０．０５５重量％である。すなわち、この値を指標にすれば、本発明の組成物を調製するために適した原料を選択することができる。これにより、高いα−グルコシダーゼ阻害活性、特にマルターゼ阻害活性を有する植物由来の組成物の製造を容易かつ効率的に行うこと、および組成物の品質評価をより容易に行うことができる。\n\n\n  The compositions containing 0.09% by weight and 0.46% by weight of desulfurized cotaranol were sample Nos. Corresponding to 16 and 6. Sample No. From Table 2, the desulfurized cotaranol content of the raw materials used for the production of 16 and 6 is 0.018 wt% and 0.055 wt%, respectively. That is, using this value as an index, a raw material suitable for preparing the composition of the present invention can be selected. Thereby, manufacture of the plant-derived composition which has high alpha-glucosidase inhibitory activity, especially maltase inhibitory activity can be performed easily and efficiently, and the quality evaluation of a composition can be performed more easily."
  },
  {
    "id": "JP2010180133A",
    "text": "alpha-GLUCOSIDASE INHIBITOR Abstract<P>PROBLEM TO BE SOLVED: To determine the α-glucosidase inhibition active component in an extract of Ecklonia stolonifera.  <P>SOLUTION: The α-glucosidase inhibitor includes dieckol as an active ingredient. A food and drink product contains the α-glucosidase inhibitor.  <P>COPYRIGHT: (C)2010,JPO&INPIT Claims (\n3\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  ダイエコールを有効成分とすることを特徴とするα−グルコシダーゼ阻害剤。\n\n\n  An α-glucosidase inhibitor characterized by comprising diacor as an active ingredient.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  請求項１記載のα−グルコシダーゼ阻害剤を含有することを特徴とする飲食品。\n\n\n  A food or drink comprising the α-glucosidase inhibitor according to claim 1.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  請求項１記載のα−グルコシダーゼ阻害剤を含有することを特徴とする糖尿病予防・治療用飲食品。\n\n\n  A food or drink for diabetes prevention / treatment comprising the α-glucosidase inhibitor according to claim 1. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は褐藻類より抽出・精製された物質を有効成分とするα−グルコシダーゼ阻害剤に関する。\n\n\n  The present invention relates to an α-glucosidase inhibitor containing a substance extracted and purified from brown algae as an active ingredient.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  二糖類分解酵素であるα−グルコシダーゼは、小腸に存在し、食物中の二糖類を単糖類へ分解し、小腸からの糖類の吸収を促進するため、体内において重要な役割をする酵素である。\n\n\n  Α-Glucosidase, which is a disaccharide-degrading enzyme, is an enzyme that plays an important role in the body because it exists in the small intestine and decomposes disaccharides in food into monosaccharides and promotes absorption of saccharides from the small intestine.\n\n\n\n\n\n\n\n \n\n  このα−グルコシダーゼの活性を阻害する阻害剤は、二糖類から単糖類への分解を遅らせる作用を有するため、腸管での糖類の消化吸収が遅らすことができる。その結果、食後の血糖上昇が抑えられるので、糖尿病等の治療・予防に大変有用なものである。\n\n\n  Since the inhibitor that inhibits the activity of α-glucosidase has an action of delaying the decomposition of disaccharides into monosaccharides, digestion and absorption of saccharides in the intestinal tract can be delayed. As a result, an increase in blood glucose after meals can be suppressed, which is very useful for the treatment and prevention of diabetes and the like.\n\n\n\n\n\n\n\n \n\n  これまでα−グルコシダーゼ阻害剤としては、種々の植物や、微生物の培養液等から得られたものが知られている。\n\n\n  So far, α-glucosidase inhibitors that have been obtained from various plants, culture solutions of microorganisms, and the like are known.\n\n\n\n\n\n\n\n \n\n  本発明者らも、以前、褐藻類であるツルアラメの抽出物の乾燥パウダーに強力なα−グルコシダーゼ阻害活性があることを見出し、遺伝的糖尿病モデルマウスおよびショ糖負荷モデルラットに対してツルアラメ抽出物の経口投与が有意な血糖値上昇抑制効果を示すことを報告している（非特許文献１及び２）。\n\n\n  The present inventors have previously found that a dried powder of an extract of brown algae, a pickled lime, has a potent α-glucosidase inhibitory activity, and a pickled pea extract against a genetic diabetes model mouse and a sucrose loaded model rat. Has been reported to show a significant blood glucose level inhibitory effect (Non-patent \nDocuments\n 1 and 2).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n岩井 邦久， 松江 一：褐藻ツルアラメの糖尿病モデルマウスにおける抗酸化および高血糖抑制効果. 第60 回日本栄養・食糧学会大会,2006年5月20日.\nKunihisa Iwai, Hajime Matsue: Antioxidative and hyperglycemic inhibitory effect of brown alga tsuruarame in diabetic model mice. The 60th Annual Meeting of the Japan Society of Nutrition and Food, May 20, 2006.\n\n\n\n\n\n\n\n\n\n\n \n原高明, 八木勇三, 泉水直人：ショ糖負荷ラットの血糖値推移に対するSeametaherblineの効果, Food Function, 3, 85‐90, 2007.\nTakaaki Hara, Yuzo Yagi, Naoto Izumi: Effects of Seametaherbline on blood glucose level changes in sucrose-loaded rats, Food Function, 3, 85-90, 2007.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  しかしながら、これらの報告では、α−グルコシダーゼを阻害する物質が何であるかについては全く検討していなかった。\n\n\n  However, these reports did not consider at all what substances inhibit α-glucosidase.\n\n\n\n\n\n\n\n \n\n  従って、本発明は、上記ツルアラメの抽出物中のα−グルコシダーゼ阻害活性成分を突き止めることをその課題とするものである。\n\n\n  Therefore, this invention makes it the subject to locate the alpha-glucosidase inhibitory active component in the extract of the said pickled pea.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明者らは、上記課題を解決すべく鋭意検討を行った結果、上記阻害活性成分がダイエコールであることを見出し、本発明を完成した。\n\n\n  As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the inhibitory active ingredient is diacor and completed the present invention.\n\n\n\n\n\n\n\n \n\n  すなわち本発明は、ダイエコールを有効成分とすることを特徴とするα−グルコシダーゼ阻害剤である。\n\n\n  That is, the present invention is an α-glucosidase inhibitor characterized by using diecol as an active ingredient.\n\n\n\n\n\n\n\n \n\n  また、本発明は、上記α−グルコシダーゼ阻害剤を含有することを特徴とする飲食品、特に糖尿病予防・治療用飲食品である。\n\n\n  Moreover, this invention is the food-drinks containing the said alpha-glucosidase inhibitor, Especially the food-drinks for diabetes prevention and treatment.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明のα−グルコシダーゼ阻害剤は天然物由来のものであり、安全に摂取できるものである。\n\n\n  The α-glucosidase inhibitor of the present invention is derived from a natural product and can be safely ingested.\n\n\n\n\n\n\n\n \n\n  従って、本発明のα−グルコシダーゼ阻害剤は、糖尿病の予防・治療薬等や、糖尿病予防・治療用飲食品に有用である。\n\n\n  Therefore, the α-glucosidase inhibitor of the present invention is useful for diabetes preventive / therapeutic agents and the like, and food and drink for diabetes prevention / treatment.\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明のα−グルコシダーゼ阻害剤（以下、「本発明阻害剤」という）の有効成分であるダイエコール（Dieckol）は以下に示される公知の物質であり、例えば、文献（Hye Sook Kang, Hae Young Chung, Jee Hyung Jung, Byeng Wha Son, and Jae Sue Choi: A new phlorotannin from the brown alga Ecklonia stolonifera. Chem. Pharm. Bull. 51, 1012-1014, 2003.  ）に記載の方法により得ることができる。このダイエコールは、ツルアラメ以外にもクロメやカジメ等の褐藻類に見出されており、抗菌活性等が報告されているが、α−グルコシダーゼ阻害活性があることについては報告されていないものである。\n\n\n  Dieckol, which is an active ingredient of the α-glucosidase inhibitor of the present invention (hereinafter referred to as “the inhibitor of the present invention”), is a known substance shown below, for example, literature (Hye Sook Kang, Hae Young Chung, Jee Hyung Jung, Byeng Wha Son, and Jae Sue Choi: A new phlorotannin from the brown alga Ecklonia stolonifera. Chem. Pharm. Bull. 51, 1012-1014, 2003.). This Daicol is found in brown algae such as chrome and scallops other than creepers and has antibacterial activity, but it has not been reported to have an α-glucosidase inhibitory activity. .\n\n\n\n\n\n\n\n \n\n  なお、本発明においてα−グルコシダーゼ阻害活性とは、マルトース等の二糖類分解酵素の阻害活性をいい、これは一般的な方法で測定できる。また、本発明阻害剤のα−グルコシダーゼ阻害活性は、下記参考例１と同様にして測定した場合に、０.４〜０.８ｍＭ程度である。\n\n\n  In addition, in this invention, (alpha) -glucosidase inhibitory activity means the inhibitory activity of disaccharide-degrading enzymes, such as maltose, and this can be measured by a general method. Further, the α-glucosidase inhibitory activity of the inhibitor of the present invention is about 0.4 to 0.8 mM when measured in the same manner as in Reference Example 1 below.\n\n\n\n\n\n\n\n \n\n＜ダイエコールの性質＞\n\n（分子式）Ｃ\n３６\nＨ\n２２\nＯ\n１８\n \n\n（分子量）７４２.６\n\n（構造式）\n\n\n \n \n\n（その他の性質）\n\n  水に難溶\n\n  アルコールに可溶\n\n  茶褐色\n\n<Characteristics of Daikoru> \n (Molecular formula) C \n36\n H \n22\n O \n18\n \n (Molecular weight) 742.6 \n (Structural formula) \n \n \n \n (Other properties) \n Insoluble in water Soluble in alcohol Brown\n\n\n\n\n\n\n \n\n  上記ダイエコールはコンブ目コンブ科の褐藻であるツルアラメ（Ecklonia stolonifera）を原料として次のようにしても得ることができる。\n\n\n  The above-mentioned Daikoru can also be obtained as follows using a raw alga (Ecklonia stolonifera), which is a brown alga belonging to the order of the family Coleoptera.\n\n\n\n\n\n\n\n \n\n  まず、ツルアラメの葉部１００〜５００ｇ程度を包丁等で細断し、これにメタノール、エタノール等の溶媒を０.３〜２Ｌ程度添加した後、ホモジナイザー等で攪拌する。その後、ホモジネートを４〜１０℃程度で遮光した状態で１日間程度放置し、抽出液を得る。次に、この抽出液を遠心し、上清を得る。更にその上清から溶媒を蒸発させた後、５０〜５００ｍＬ程度の水に溶解させて溶解液を得る。この溶解液をＳｅｐ−Ｐａｋ Ｖａｃ Ｃ\n１８\nカラム（Ｗａｔｅｒｓ製）に通液させ、その後、更に４０％（以下、単に「％」という）メタノール水溶液を通液させて得られる画分を採取する。\n\nFirst, about 100 to 500 g of a leaf portion of a pickled arame is shredded with a knife or the like, and about 0.3 to 2 L of a solvent such as methanol or ethanol is added thereto, followed by stirring with a homogenizer or the like. Thereafter, the homogenate is allowed to stand for about 1 day while being shielded from light at about 4 to 10 ° C. to obtain an extract. Next, the extract is centrifuged to obtain a supernatant. Further, after evaporating the solvent from the supernatant, it is dissolved in about 50 to 500 mL of water to obtain a solution. This solution is passed through a Sep-Pak Vac C \n18\n column (manufactured by Waters), and then a 40% (hereinafter simply referred to as “%”) aqueous methanol solution is passed through to collect a fraction.\n\n\n\n\n\n\n \n\n  上記で採取された画分は、更に、１％ギ酸水溶液とメタノールを４０：６０の質量比で含有する溶液に溶解させる。その後、これについて以下の条件で高速液体クロマトグラフィー（ＨＰＬＣ）を行い、保持時間が９.５〜１１分の画分を採取する。この画分にはダイエコールおよびこれらの重合体のみが含まれる。\n\n\n  The fraction collected above is further dissolved in a solution containing 1% formic acid aqueous solution and methanol in a mass ratio of 40:60. Thereafter, this is subjected to high performance liquid chromatography (HPLC) under the following conditions, and a fraction having a retention time of 9.5 to 11 minutes is collected. This fraction contains only dietol and these polymers.\n\n\n\n\n\n\n\n \n\n  ＜ＨＰＬＣ条件＞\n\n  カラム：Ａｔｌａｎｔｉｓ  ｄＣ\n１８\n（４.６ｍｍＩＤ×１５０ｍｍＬ：Ｗａｔｅｒｓ社）\n\n  移動相：１％ギ酸（Ａ液）およびメタノール（Ｂ液）\n\n  グラジエント：スタート時のＡ：Ｂ＝４５：５５が１５分間でＡ：Ｂ＝３０：７０となるリニアグラジェント\n\n  流速：０.８ｍＬ／ｍｉｎ\n\n  カラム温度：４０℃\n\n  検出器：フォトダイオードアレイ検出器\n\n  検出波長：２８０ｎｍ\n\n  分取間隔：０.５分間\n\n  注入量：１０ｍｇ\n\n<HPLC conditions> \n Column: Atlantis dC \n18\n (4.6 mm ID × 150 mm L: Waters) \n Mobile phase: 1% formic acid (liquid A) and methanol (liquid B) \n Gradient: linear gradient where A: B = 45: 55 at start becomes A: B = 30: 70 in 15 minutes Flow rate: 0.8 mL / min \n Column temperature: 40 ° C \n Detector: Photodiode array detector Detection wavelength: 280 nm \n Preparative interval: 0.5 minutes Injection volume: 10 mg\n\n\n\n\n\n\n \n\n  本発明阻害剤は、上記ダイエコールを有効成分として含有していればよく、ダイエコールそのものあるいは従来の製剤担体と組み合わせて製剤化したものの何れであってもよい。また、製剤の剤形としては、丸剤、散剤、液剤、懸濁剤、乳剤、顆粒剤、タブレット剤、カプセル剤等が挙げられる。これら製剤におけるダイエコールの配合量は、特に制限されないが、例えば、それぞれが１日当たり４０ｍｇ以上、好ましくは２００〜５００ｍｇとなる量である。また、本発明阻害剤の摂取方法は、特に制限されないが、これを摂取することにより、食後の血糖上昇が抑えることができるため、上記配合量を１日１回または複数回、好ましくは３回に分けて食事後に摂取することが好ましい。更に、本発明阻害剤の効果を継続させるには、本発明阻害剤の摂取を２〜４週間程度連続で行うことが好ましい。\n\n\n  The inhibitor of the present invention only needs to contain the above-mentioned daicol as an active ingredient, and may be any of daicol itself or those formulated in combination with conventional pharmaceutical carriers. Examples of the dosage form of the preparation include pills, powders, solutions, suspensions, emulsions, granules, tablets, capsules and the like. Although the compounding quantity of the diecol in these preparations is not restrict | limited in particular, For example, each is the quantity used as 40 mg or more per day, Preferably it is 200-500 mg. In addition, the method of ingesting the inhibitor of the present invention is not particularly limited, but by ingesting this, since the increase in blood glucose after meals can be suppressed, the above compounding amount is once or more times a day, preferably 3 times a day. It is preferable to take after meals. Furthermore, in order to continue the effect of the inhibitor of the present invention, it is preferable to continuously take the inhibitor of the present invention for about 2 to 4 weeks.\n\n\n\n\n\n\n\n \n\n  なお、本発明阻害剤は、従来のα−グルコシダーゼ阻害と同様に糖尿病の予防・治療薬等にも利用できる。この場合の製剤あたりの配合量や摂取方法は上記と同様である。\n\n\n  In addition, the inhibitor of the present invention can be used for a prophylactic / therapeutic agent for diabetes in the same manner as conventional α-glucosidase inhibition. In this case, the amount per formulation and the method of intake are the same as described above.\n\n\n\n\n\n\n\n \n\n  また、本発明阻害剤は、従来の飲食品にも添加することができる。この場合には、本発明阻害剤を一般的によく知られている他の食品原料に加えることにより、α−グルコシダーゼ阻害作用を有する飲食品、特に、糖尿病予防・治療用となる飲食品を得ることができる。この飲食品には、α−グルコシダーゼ阻害剤をダイエコールとして、０.１％以上、好ましくは０.５〜２％含有させればよい。\n\n\n  Moreover, this invention inhibitor can be added also to the conventional food-drinks. In this case, by adding the inhibitor of the present invention to other food ingredients that are generally well known, a food or drink having an α-glucosidase inhibitory action, particularly a food or drink for diabetes prevention / treatment is obtained. be able to. In this food and drink, an α-glucosidase inhibitor may be contained as a dietol in an amount of 0.1% or more, preferably 0.5 to 2%.\n\n\n\n\n\n\n\n \n\n  本発明阻害剤を含有させることが好ましい飲食品としては、例えば、パン類、麺類、菓子類、サプリメント等が挙げられる。なお、飲食品には動物の飼料も含まれる。\n\n\n  Examples of foods and drinks that preferably contain the inhibitor of the present invention include breads, noodles, confectionery, and supplements. The food and drink includes animal feed.\n\n\n\n\n\n\n\n\n\n \n\n  以下、実施例によって本発明を更に具体的に説明するが、この実施例により本発明は何ら制約されるものではない。\n\n\n  EXAMPLES Hereinafter, although an Example demonstrates this invention further more concretely, this invention is not restrict | limited at all by this Example.\n\n\n\n\n\n\n\n \n\n  参  考  例  １\n\n      ツルアラメの各種溶媒抽出物のグルコシダーゼ阻害活性（ＩＣ\n５０\n）：\n\n（１）ツルアラメ抽出物の調製\n\n  生のツルアラメ（Ecklonia stolonifera）葉部１００ｇを蒸留水で洗浄し、包丁で細かく切った後、蒸留水、エタノールおよびメタノールの３種類の溶媒４００ｍＬをそれぞれ加え、ミキサー（ＳＭ−ＫＭ３９：三洋電機株式会社）でホモジナイズした。３種類のホモジネートを遮光、４℃で一晩撹拌抽出し、それを遠心分離（４℃、１０，０００ｒｐｍ、３０分）によって上清と沈殿に分け、以下の処理により３種類の抽出物を調製した。\n\nReference example 1 \n Glucosidase inhibitory activity (IC \n50\n ) of various solvent extracts of pickled arame: \n (1) Preparation of extract of pickled lambs 100 g of fresh pickled lime (Ecklonia stolonifera) leaves were washed with distilled water, cut into small pieces with a knife, and then added with 400 mL of three kinds of solvents, distilled water, ethanol and methanol, respectively. SM-KM39: Sanyo Electric Co., Ltd.). Three kinds of homogenates were extracted by stirring at 4 ° C overnight, and separated into supernatant and precipitate by centrifugation (4 ° C, 10,000 rpm, 30 minutes). Three kinds of extracts were prepared by the following treatment. did.\n\n\n\n\n\n\n \n\n  蒸留水で抽出した抽出物の上清はろ紙（Ｎｏ.２）でろ過後、ロータリーエバポレーターで濃縮したものを凍結乾燥した（ツルアラメ水抽出物）。また、エタノールで抽出した抽出物の上清をろ過後、濃縮したものを少量の蒸留水に再度溶解し、凍結乾燥した（ＥｔＯＨ抽出物）。更に、メタノールで抽出した抽出物の上清をろ過後に濃縮し、少量の蒸留水に再度溶解し、凍結乾燥した（ＭｅＯＨ抽出物）。これら３種の抽出物について以下の方法を用いてグルコシダーゼ阻害活性を測定した。\n\n\n  The supernatant of the extract extracted with distilled water was filtered with a filter paper (No. 2), and then concentrated with a rotary evaporator and freeze-dried (Tsurarame water extract). Further, after filtering the supernatant of the extract extracted with ethanol, the concentrated one was dissolved again in a small amount of distilled water and freeze-dried (EtOH extract). Furthermore, the supernatant of the extract extracted with methanol was concentrated after filtration, dissolved again in a small amount of distilled water, and freeze-dried (MeOH extract). The glucosidase inhibitory activity was measured for these three extracts using the following method.\n\n\n\n\n\n\n\n \n\n（２）グルコシダーゼ阻害活性の測定\n\n  ラット小腸粉末（ＳＩＧＭＡ社）０.５ｇに５６ｍＭマレイン酸緩衝液（ｐＨ６.０）５ｍＬを添加し、ポリトロンにてホモジナイズした。これを３,０００ｒｐｍで１０分間遠心分離した後、上清を粗酵素液とし、それを適宜希釈して使用した。各グルコシダーゼ活性測定の基質として、スクロースについてはスクラーゼ、マルトースについてはマルターゼ、デンプンについてはグルコアミラーゼ、パラチノースについてはイソマルターゼを使用した。各基質はいずれも５６ｍＭマレイン酸緩衝液（ｐＨ６.０）を用いて２０ｍｇ／ｍＬに調製した。\n\n(2) Measurement of glucosidase \ninhibitory activity\n 5 mL of 56 mM maleic acid buffer (pH 6.0) was added to 0.5 g of rat small intestine powder (SIGMA), and homogenized with polytron. This was centrifuged at 3,000 rpm for 10 minutes, and then the supernatant was used as a crude enzyme solution, which was appropriately diluted and used. As substrates for measuring each glucosidase activity, sucrose was used for sucrose, maltase was used for maltose, glucoamylase was used for starch, and isomaltase was used for palatinose. Each substrate was adjusted to 20 mg / mL using 56 mM maleate buffer (pH 6.0).\n\n\n\n\n\n\n \n\n  各抽出物は５６ｍＭマレイン酸緩衝液（ｐＨ６.０）に種々の濃度で溶解させ、その２０μＬを採取したチューブに２０ｍｇ／ｍＬの各基質溶液１００μＬを添加し、混合後３７℃で５分間ブレインキュベートした。この混合液に希釈した各酵素液を２０μＬ添加し、混合後３７℃でインキュベートした。インキュベートから０、１５、３０、６０、９０および１２０分後に反応液１５μＬを試験管に採取し、直ちに１０分間煮沸して酵素を失活させた。冷却後、反応液中のグルコース濃度をグルコースＣII−テストワコー（和光純薬工業社）を使用して測定した。\n\n\n  Each extract was dissolved in 56 mM maleate buffer (pH 6.0) at various concentrations, 20 μL of each extract was added to 100 μL of each 20 mg / mL substrate solution, mixed, and incubated at 37 ° C. for 5 minutes. did. 20 μL of each diluted enzyme solution was added to this mixed solution, and incubated at 37 ° C. after mixing. At 0, 15, 30, 60, 90 and 120 minutes after the incubation, 15 μL of the reaction solution was collected in a test tube and immediately boiled for 10 minutes to inactivate the enzyme. After cooling, the glucose concentration in the reaction solution was measured using Glucose CII-Test Wako (Wako Pure Chemical Industries).\n\n\n\n\n\n\n\n \n\n  各反応液中グルコース生成量から各酵素の反応速度を算出した。酵素と基質のみの反応速度を１００％とし、各試料添加時の反応速度からその酵素阻害率を算出した。更に、各試料の濃度と阻害率をプロットし、その近似曲線から各酵素の５０％阻害濃度（ＩＣ\n５０\n）を算出した。その結果を表１に示した。\n\nThe reaction rate of each enzyme was calculated from the amount of glucose produced in each reaction solution. The reaction rate of only the enzyme and the substrate was taken as 100%, and the enzyme inhibition rate was calculated from the reaction rate when each sample was added. Furthermore, the concentration and inhibition rate of each sample were plotted, and the 50% inhibitory concentration (IC \n50\n ) of each enzyme was calculated from the approximate curve. The results are shown in Table 1.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  何れの抽出物にもスクラーゼおよびイソマルターゼ阻害活性は認められなかったが、ＥｔＯＨ抽出物およびＭｅＯＨ抽出物には、マルターゼとグルコアミラーゼの強い阻害活性が認められた。一方、ツルアラメ水抽出物には期待できるマルターゼとグルコシダーゼの阻害活性は見られなかった。\n\n\n  None of the extracts showed sucrase and isomaltase inhibitory activity, but EtOH extract and MeOH extract showed strong inhibitory activity of maltase and glucoamylase. On the other hand, no effective activity of maltase and glucosidase was observed in the water extract of creeper jelly.\n\n\n\n\n\n\n\n \n\n  以上の結果から、ツルアラメの阻害作用がフルクトースの結合分解には作用しないこと、あるいはツルアラメの阻害作用がα１→４結合の分解しかしないことが予想された。\n\n\n  From the above results, it was predicted that the inhibitory action of creeper lambs does not affect the fructose bond degradation, or that the inhibitory action of creeper lambs only decomposes the α1 → 4 bond.\n\n\n\n\n\n\n\n \n\n  実  施  例  １\n\n      ダイエコールの抽出：\n\n（１）ＥｔＯＨ抽出物の分画\n\n  参考例１で調製したＥｔＯＨ抽出物２００ｍｇに蒸留水１０ｍＬを加え、超音波照射しながら溶解させて試料溶液を得た。一方、Ｓｅｐ−Ｐａｋ Ｖａｃ Ｃ\n１８\nカラム（５ｇ／２０ｃｃ：Ｗａｔｅｒｓ社）にメタノール１２０ｍＬおよび蒸留水１２０ｍＬをこの順番で流し、コンディショニングしておいた。\n\nExample 1 \n Extracting diacor: \n (1) Fractionation of EtOH extract 10 mL of distilled water was added to 200 mg of the EtOH extract prepared in Reference Example 1 and dissolved while irradiating with ultrasonic waves to obtain a sample solution. On the other hand, a Sep-Pak Vac C \n18\n column (5 g / 20 cc: Waters) was conditioned by flowing 120 mL of methanol and 120 mL of distilled water in this order.\n\n\n\n\n\n\n \n\n  続いて、２０ｍｇ／ｍＬの試料溶液１０ｍＬをＳｅｐ−Ｐａｋ Ｖａｃ Ｃ\n１８\nカラムに負荷し、負荷した液量分を溶出（素通り画分）させた後、蒸留水（０％メタノール）、２０％メタノール水溶液、４０％メタノール水溶液、６０％メタノール水溶液、８０％メタノール水溶液および１００％メタノールをそれぞれ７０ｍＬずつこの順番で通液した。各溶出液を収集し、ロータリーエバポレーターで濃縮し、流した順に素通り画分、Ｅ０Ｍ（０％メタノール画分）、Ｅ２０Ｍ（２０％メタノール画分）、Ｅ４０Ｍ（４０％メタノール画分）、Ｅ６０Ｍ（６０％メタノール画分）、Ｅ８０Ｍ（８０％メタノール画分）およびＥ１００Ｍ（１００％メタノール画分）とした。素通り画分からＥ６０Ｍまではそれぞれ凍結乾燥させ、分画物を得た。Ｅ８０ＭおよびＥ１００Ｍは濃縮後に真空デシケーター中で乾固し、分画物を得た。各分画物のマルターゼおよびグルコアミラーゼの５０％阻害活性（ＩＣ\n５０\n）を参考例１と同様にして測定した。その結果を表２に示した。なお、Ｅ８０Ｍは殆ど回収されなかったため活性の測定などは行わなかった。\n\nSubsequently, 10 mL of a 20 mg / mL sample solution was loaded onto a Sep-Pak Vac C \n18\n column, and the loaded liquid was eluted (through fraction), and then distilled water (0% methanol), 20% aqueous methanol solution. 40% methanol aqueous solution, 60% methanol aqueous solution, 80% methanol aqueous solution and 100% methanol were each passed through in this order in an amount of 70 mL. Each eluate was collected, concentrated on a rotary evaporator, and passed through in the order of flow, E0M (0% methanol fraction), E20M (20% methanol fraction), E40M (40% methanol fraction), E60M (60 % Methanol fraction), E80M (80% methanol fraction) and E100M (100% methanol fraction). The flow-through fraction to E60M were freeze-dried to obtain fractions. E80M and E100M were concentrated to dryness in a vacuum desiccator to obtain a fraction. The 50% inhibitory activity (IC \n50\n ) of maltase and glucoamylase of each fraction was measured in the same manner as in Reference Example 1. The results are shown in Table 2. Since almost no E80M was recovered, the activity was not measured.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  ＥｔＯＨ抽出物からの収量はＥ４０Ｍが最も多かった。また、マルターゼ阻害活性はＥ４０ＭとＥ６０Ｍに強く認められ、グルコアミラーゼ阻害活性はＥ２０Ｍ、Ｅ４０Ｍ、Ｅ６０Ｍに認められた。なお、Ｅ４０Ｍは分画前に比べて酵素の阻害活性が１.５〜１.９倍上昇した。\n\n\n  The yield from the EtOH extract was highest at E40M. Moreover, the maltase inhibitory activity was recognized strongly by E40M and E60M, and the glucoamylase inhibitory activity was recognized by E20M, E40M, and E60M. E40M increased the enzyme inhibitory activity by 1.5 to 1.9 times compared to that before fractionation.\n\n\n\n\n\n\n\n \n\n  以上の結果より、Ｅ４０Ｍにグルコシダーゼ阻害活性成分が含まれていることが示された。また、ＥｔＯＨ抽出物中のグルコシダーゼ阻害成分は４０％〜６０％メタノール水溶液で溶出できることが分かった。\n\n\n  From the above results, it was shown that E40M contains a glucosidase inhibitory active ingredient. Moreover, it turned out that the glucosidase inhibitory component in an EtOH extract can be eluted with 40%-60% methanol aqueous solution.\n\n\n\n\n\n\n\n \n\n（２）Ｅ４０ＭのＨＰＬＣ分析\n\n  （１）で調製した試料溶液は、１％ギ酸水溶液とメタノールを４０：６０の質量比で含有する溶液に溶解させ、１回分を約２ｍｇとして以下の条件でＨＰＬＣ分析を行った。収集した溶出液は、遠心エバポレーターにて減圧乾固し、分取物としてＨＰＬＣピークに合致させた。\n\n  ＜ＨＰＬＣ条件＞\n\n  カラム：Ａｔｌａｎｔｉｓ  ｄＣ\n１８\n（４.６ｍｍＩＤ×１５０ｍｍＬ：Ｗａｔｅｒｓ社）\n\n  移動相：１％ギ酸（Ａ液）およびメタノール（Ｂ液）\n\n  グラジエント：スタート時のＡ：Ｂ＝４５：５５が１５分間でＡ：Ｂ＝３０：７０となるリニアグラジェント\n\n  流速：０.８ｍＬ／ｍｉｎ\n\n  カラム温度：４０℃\n\n  検出器：２９９６フォトダイオードアレイ検出器（Ｗａｔｅｒｓ社）\n\n  検出波長：２８０ｎｍ\n\n  分取間隔：０.５分間\n\n  注入量：２ｍｇ\n\n(2) HPLC analysis of E40M The sample solution prepared in (1) was dissolved in a solution containing a 1% formic acid aqueous solution and methanol at a mass ratio of 40:60, and the HPLC analysis was performed under the following conditions with about 1 mg serving as one dose. Went. The collected eluate was dried under reduced pressure using a centrifugal evaporator and matched with the HPLC peak as a fraction. \n <HPLC conditions> \n Column: Atlantis dC \n18\n (4.6 mm ID × 150 mm L: Waters) \n Mobile phase: 1% formic acid (liquid A) and methanol (liquid B) \n Gradient: linear gradient where A: B = 45: 55 at start becomes A: B = 30: 70 in 15 minutes Flow rate: 0.8 mL / min \n Column temperature: 40 ° C \n Detector: 2996 photodiode array detector (Waters) \n Detection wavelength: 280 nm \n Preparative interval: 0.5 minutes Injection volume: 2 mg\n\n\n\n\n\n\n \n\n  ＨＰＬＣ分析を行ったところ、クロマトグラムには主要なピークが４本検出され（図１のＦｒ.１〜Ｆｒ.４）、それらをフラクションコレクターで分取した。各フラクションについて酵素（マルターゼの）の５０％阻害活性を実施例１と同様にして測定した。その結果を表３に示した。\n\n\n  As a result of HPLC analysis, four main peaks were detected in the chromatogram (Fr. 1 to Fr. 4 in FIG. 1), and they were fractionated with a fraction collector. The 50% inhibitory activity of the enzyme (of maltase) was measured in the same manner as in Example 1 for each fraction. The results are shown in Table 3.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  上記より、Ｆｒ.４の阻害活性が０.５３２ｍｇ／ｍＬと最も強く、これはＥ４０Ｍの阻害活性の３.１倍に相当した。また、分取したＦｒ.４について、上記と同様の条件で再度ＨＰＬＣ分析を行ったところ、Ｆｒ.４には他のピークは混在しておらず、精製が確認された（図２）。このＦｒ.４を試料（Ｅ４０ＭＦｒ４）とし、これについて以下の構造解析を行った。\n\n\n  From the above, the inhibitory activity of Fr.4 was the strongest at 0.532 mg / mL, corresponding to 3.1 times the inhibitory activity of E40M. Further, when the fractionated Fr.4 was subjected to HPLC analysis again under the same conditions as described above, no other peaks were present in Fr.4, and purification was confirmed (FIG. 2). This Fr.4 was used as a sample (E40MFr4), and the following structural analysis was performed.\n\n\n\n\n\n\n\n \n\n（３）構造解析\n\n  （ａ）Ｅ４０ＭＦｒ４のＮＭＲの測定\n\n  Ｅ４０ＭＦｒ４はアセトニトリル−ｄ３に溶解し、これの\n１\nＨ−ＮＭＲ、\n１３\nＣ−ＮＭＲおよびＤＥＰＴをＪＮＭ  ＥＸ−２７０（２７０ＭＨｚ：ＪＥＯＬ社）を使用して測定した。\n\n(3) Structural analysis (a) NMR measurement of E40MFr4 E40MFr4 is dissolved in acetonitrile-d3, and \n1\n H-NMR, \n13\n C-NMR and DEPT of this are analyzed using JNM EX-270 (270 MHz: JEOL). It was measured.\n\n\n\n\n\n\n \n\n  （ｂ）Ｅ４０ＭＦｒ４のＬＣ／ＭＳ／ＭＳの測定\n\n  ＡＰＩＬＣ／ＭＳ／ＭＳシステム（アプライドバイオシステムズ社）を使用し、Ｅ４０ＭＦｒ４のＭＳおよびＭＳ／ＭＳを測定した。ＬＣのカラムにはＴＳＫｇｅｌＯＤＳ１００Ｖ（２ｍｍＩＤ×５０ｍｍＬ：東ソー社）、移動相には１％ギ酸（Ａ液）および１％ギ酸含有メタノール（Ｂ液）を使用し、Ａ：Ｂが０〜１８分間で９０：１０から１０：９０に変化するリニアグラジェントで、カラム温度４０℃、流速０.２ｍＬ／ｍｉｎで溶出させた。Ｅ４０ＭＦｒ４を１％ギ酸水溶液とメタノールを４０：６０の質量比で含有する溶液に溶解させ、１０ｍｇ／ｍＬとしたものを前記システムに５μＬ注入し、２８０ｎｍの吸光度検出とともに、ポジティブイオンモードでｍ／ｚ５０〜３０００の範囲でＭ＋Ｈを測定した。さらに、Ｍ＋Ｈの推定質量を親イオンとして解裂させたＭＳ／ＭＳ（娘イオンフラグメント）を測定した。\n\n(B) Measurement of LC / MS / MS of E40MFr4 Using an APILC / MS / MS system (Applied Biosystems), MS and MS / MS of E40MFr4 were measured. TSKgelODS100V (2mmID × 50mmL: Tosoh Corporation) is used for the LC column, 1% formic acid (liquid A) and 1% formic acid-containing methanol (liquid B) are used for the mobile phase, and A: B is 90 to 90 minutes in 0 to 18 minutes. Elution was performed at a column temperature of 40 ° C. and a flow rate of 0.2 mL / min. E40MFr4 was dissolved in a solution containing 1% formic acid aqueous solution and methanol at a mass ratio of 40:60, and 10 μl / mL was injected into the system in an amount of 5 μL. The absorbance was detected at 280 nm and m / z 50 in positive ion mode. M + H was measured in the range of ~ 3000. Furthermore, MS / MS (daughter ion fragment) obtained by cleaving the estimated mass of M + H as a parent ion was measured.\n\n\n\n\n\n\n \n\n  （ｃ）Ｅ４０ＭＦｒ４構造同定の結果\n\n\n１３\nＣ−ＮＭＲの測定の結果（図３）からは、Ｅ４０ＭＦｒ４に含まれる物質の炭素数が３６個であることが示された。ＤＥＰＴの測定の結果（図４）からは３６個の炭素はＣＨとＣで構成されており、ＣＨ\n３\nおよびＣＨ\n２\nは存在しないことが示された。\n１\nＨ−ＮＭＲの測定の結果（図５）からは、５.８〜６.３ｐｐｍにおけるケミカルシフト値が既知フロロタンニン化合物の文献値と一致することが示された。\n\n(C) Result of E40MFr4 structure identification \n \nFrom\n the result of the \n13\n C-NMR measurement (FIG. 3), it was shown that the number of carbon atoms contained in E40MFr4 was 36. The DEPT measurement result (FIG. 4) showed that 36 carbons were composed of CH and C, and CH \n3\n and CH \n2\n were not present. \nFrom\n the result of the \n1\n H-NMR measurement (FIG. 5), it was shown that the chemical shift value at 5.8 to 6.3 ppm coincided with the literature value of the known fluorotannin compound.\n\n\n\n\n\n\n \n\n  ＬＣ／ＭＳ／ＭＳの測定の結果（図６）からは、ＵＶ２８０ｎｍ検出ピークにおいてＥ４０ＭＦｒ４はほぼ単一のピークであることが分かった（図６（Ａ））。また、そのピークの分子量を測定したところＭ＋Ｈは最もシグナルの大きいｍ／ｚ７４３.０であることが分かった（図６（Ｃ））。さらに、Ｅ４０ＭＦｒ４の分子量を測定したデータからｍ／ｚ７４３.０を有するピークを探す（スキャンする）と、単一のピークがＵＶ２８０ｎｍの検出ピークで観察された位置と殆ど重なって得られた（図６（Ｂ））。これらのことから、Ｅ４０ＭＦｒ４の分子量は７４２.０であることが示された。また、ＭＳ／ＭＳスペクトルからは、ダイエコールの一部構造に一致するフラグメントがｍ／ｚ６１８、４９４、４１２、３８７、３７１、３０１、２８８に観察された（図６の（Ｄ））。\n\n\n  From the LC / MS / MS measurement results (FIG. 6), it was found that E40MFr4 is a substantially single peak in the \nUV\n 280 nm detection peak (FIG. 6 (A)). Further, when the molecular weight of the peak was measured, it was found that M + H was m / z 743.0 having the largest signal (FIG. 6C). Furthermore, when a peak having m / z 743.0 was searched (scanned) from the data obtained by measuring the molecular weight of E40MFr4, a single peak was obtained almost overlapping with the position observed at the detection peak of UV280 nm (FIG. 6). (B)). From these, it was shown that the molecular weight of E40MFr4 is 742.0. Further, from the MS / MS spectrum, fragments corresponding to a partial structure of diacor were observed at m / z 618, 494, 412, 387, 371, 301, and 288 ((D) in FIG. 6).\n\n\n\n\n\n\n\n \n\n  この分子量とＮＭＲの解析から、有力な候補化合物として既知フロロタンニン化合物であるダイエコール（Ｃ\n３６\nＨ\n２２\nＯ\n１８\n）が推定された。なお、分子量７４２.６のフロロタンニン化合物としては８,８'−バイエコールも存在するが、今回の構造解析結果からは８,８'−バイエコールに該当するデータは得られていない。\n\nFrom this molecular weight and NMR analysis, Daicol (C \n36\n H \n22\n O \n18\n ), which is a known fluorotannin compound, was estimated as a promising candidate compound. As a fluorotannin compound having a molecular weight of 742.6, 8,8′-bayecol also exists, but no data corresponding to 8,8′-bayecol has been obtained from the results of this structural analysis.\n\n\n\n\n\n\n \n\n  なお、ｍ／ｚ３０００までのＭＳスペクトルには、ｍ／ｚ１４８５および２２２７が観察され（図７（Ａ））、ｍ／ｚ１４８５を親イオンとした時のＭＳ／ＭＳスペクトル（図７（Ｂ））には、ダイエコールを示唆するｍ／ｚ７４３のフラグメントが観察され、ｍ／ｚ２２２７を親イオンとしたＭＳ／ＭＳスペクトルでは（図７（Ｃ））、ｍ／ｚ１４８５とｍ／ｚ７４３のフラグメントが観察された。これはダイエコールの二量体や三量体が存在する可能性を示している。\n\n\n  In addition, m / \nz\n 1485 and 2227 are observed in the MS spectrum up to m / z 3000 (FIG. 7A), and in the MS / MS spectrum when m / \nz\n 1485 is a parent ion (FIG. 7B). In the MS / MS spectrum with m / \nz\n 2227 as the parent ion (FIG. 7C), m / \nz\n 1485 and m / \nz\n 743 fragments were observed. . This indicates the possibility of a dimer or trimer of diecol.\n\n\n\n\n\n\n\n \n\n  以上の結果より、Ｅ４０ＭＦｒ４に含まれる物質はダイエコールと同定された。\n\n\n  From the above results, the substance contained in E40MFr4 was identified as dietol.\n\n\n\n\n\n\n\n \n\n  実  施  例  ２\n\n      Ｅ４０Ｍの単回投与によるマウス血糖上昇抑制効果：\n\n（１）正常マウスにおけるＥ４０Ｍ投与時の経口糖負荷試験\n\n  正常マウスとして雄性Ｃ５７ＢＬマウス（日本クレア社）を購入し、１週間馴化飼育した後に、１８時間の絶食下で以下の試験に使用した。実験時のマウスは１２週齢で体重２０〜２２ｇであった。これらのマウスにヘパリン処理したプラスチック製キャピラリーチューブを用いて眼窩底採血した。引き続き、これらのマウスに実施例１の（１）で得られたＥ４０Ｍ（ダイエコールを１８％含有する）およびマルトースの混合溶液を単回経口投与した。Ｅ４０Ｍの投与量は０（Ｅ４０Ｍ−０）、５０（Ｅ４０Ｍ−５０）および３００（Ｅ４０Ｍ−３００）ｍｇ／ｋｇとし、マルトースの投与量は１.５ｇ／ｋｇとした。また、投与液量は１０ｍＬ／ｋｇとした。混合溶液投与後、０.５、１、２および４時間で、上記と同様に眼窩底採血した。採血後、直ちにキャピラリーチューブをヘマトクリット遠心機で遠心分離し（１２,０００ｒｐｍ×２分）、血漿を採取した。この血漿を適宜０.１５Ｍの塩化ナトリウム溶液で希釈し、血漿中グルコース濃度を富士ドライケム（ＦＤＣ３５００：ＧＬＵ−ＰＩＩＩ：冨士フィルム社）にて測定した。その結果を図８の（Ａ）に示した。\n\nExample 2 \n Inhibitory effect on mouse blood glucose elevation by single administration of E40M: \n (1) Oral glucose tolerance test in E40M administration in normal mice Male C57BL mice (CLEA Japan, Inc.) were purchased as normal mice, bred for 1 week, and used for the following tests under fasting for 18 hours. The mice at the time of the experiment were 12 weeks old and weighed 20-22 g. In these mice, blood was collected from the orbit using a plastic capillary tube treated with heparin. Subsequently, a mixed solution of E40M (containing 18% Daichol) and maltose obtained in Example 1 (1) and maltose was orally administered to these mice once orally. The dose of E40M was 0 (E40M-0), 50 (E40M-50) and 300 (E40M-300) mg / kg, and the dose of maltose was 1.5 g / kg. The administration liquid volume was 10 mL / kg. Orbital bottom blood was collected in the same manner as described above at 0.5, 1, 2, and 4 hours after administration of the mixed solution. Immediately after blood collection, the capillary tube was centrifuged with a hematocrit centrifuge (12,000 rpm × 2 minutes) to collect plasma. The plasma was appropriately diluted with a 0.15 M sodium chloride solution, and the plasma glucose concentration was measured with Fuji Dry Chem (FDC3500: GLU-PIII: Fuji Film Co., Ltd.). The results are shown in FIG.\n\n\n\n\n\n\n \n\n（２）糖尿病マウスにおけるＥ４０Ｍ投与時の経口糖負荷試験\n\n  ２型糖尿病モデル動物として雄性ＫＫ−Ａ\nｙ\nマウス（日本クレア社）を購入し、１週間の馴化飼育後に１８時間の絶食下で以下の試験に使用した。実験時の週齢は１２週齢で、体重は３８〜４０ｇであった。Ｅ４０Ｍおよびマルトースの投与量ならびに実験手法は上記（１）と同様に行った。測定結果を図８のＢに示した。\n\n(2) Oral glucose tolerance test in E40M administration in diabetic mice Male KK-A \ny\n mice (CLEA Japan, Inc.) were purchased as a \ntype\n 2 diabetes model animal, and the following test was performed under fasting for 18 hours after acclimation breeding for 1 week. Used for. The age at the time of the experiment was 12 weeks old, and the body weight was 38 to 40 g. The dosage of E40M and maltose and the experimental procedure were the same as in (1) above. The measurement results are shown in FIG.\n\n\n\n\n\n\n \n\n（３）結果\n\n  Ｅ４０Ｍ−０はマルトース投与後０.５時間で４１０ｍｇ／ｄＬに血糖値が上昇し、その後減少した。Ｅ４０Ｍ−５０およびＥ４０Ｍ−３００も投与後０.５時間で血糖値が上昇しその後時間とともに減少したが、０.５時間での血糖値は約３００ｍｇ／ｄＬとＥ４０Ｍ−０より低く、Ｅ４０Ｍ−３００は０.５時間および１時間での血糖値がＥ４０Ｍ−０より有意に低値となった。\n\n(3) Results E40M-0 increased in blood glucose level to 410 mg / dL and then decreased 0.5 hours after maltose administration. E40M-50 and E40M-300 also increased in blood glucose level at 0.5 hours after administration and then decreased with time, but the blood glucose level at 0.5 hour was about 300 mg / dL, lower than E40M-0, and E40M-300 The blood glucose level at 0.5 hour and 1 hour was significantly lower than that of E40M-0.\n\n\n\n\n\n\n \n\n  Ｃ５７ＢＬマウスと同様に、いずれの群もマルトース投与後０.５時間で血糖値が最大となり、その後時間とともに減少したが、血糖値の上昇はＣ５７ＢＬより高く、Ｅ４０Ｍ−０は５４０ｍｇ／ｄＬであった。また、Ｃ５７ＢＬマウスは投与後２時間で投与前の血糖値レベルに低下したが、ＫＫ−Ａ\nｙ\nマウスでは２時間後でも約１.５倍高いレベルであった。このような糖尿病マウスの血糖特性において、Ｅ４０Ｍを投与することにより血糖値上昇の抑制が見られた。Ｅ４０Ｍ−０と有意な低値を示したのはＥ４０Ｍ−３００の１時間だけであったが、０.５時間では７０〜１００ｍｇ／ｄＬ低く、また２時間後には投与前のレベルに近似した。\n\nSimilar to C57BL mice, in all groups, blood glucose levels reached a maximum at 0.5 hours after maltose administration and then decreased with time, but the increase in blood glucose levels was higher than that in C57BL, and E40M-0 was 540 mg / dL. . In addition, the C57BL mouse decreased to the blood glucose level before the \nadministration\n 2 hours after the administration, whereas the KK-A \ny\n mouse had a level approximately 1.5 times higher even after 2 hours. In the blood glucose characteristics of such diabetic mice, suppression of an increase in blood glucose level was observed by administering E40M. Only 1 hour of E40M-300 showed a significantly lower value than E40M-0, but it was 70-100 mg / dL lower at 0.5 hour and approximated the level before administration after 2 hours.\n\n\n\n\n\n\n \n\n  また、血糖値の変化を評価するために、濃度−時間曲線下面積（ＡＵＣ）を測定した。その結果を表４に示した。\n\n\n  Moreover, in order to evaluate the change of a blood glucose level, the area under a concentration-time curve (AUC) was measured. The results are shown in Table 4.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  濃度−時間曲線下面積は、Ｅ４０Ｍ−０と比べて、Ｅ４０Ｍ−５０が１２〜２０％、Ｅ４０Ｍ−３００が１７〜２４％減少した。この結果は、ある一時点だけではなく、実験時間を通じてグルコースの体内暴露量がＥ４０Ｍ投与によって減少したことを示している。また、Ｅ４０Ｍ−５０とＥ４０Ｍ−３００で容量依存性は顕著ではなかったが、単回同時投与で一部有意な抑制および抑制傾向が示されたことは、Ｅ４０Ｍの５０ｍｇ／ｋｇ投与あるいはそれ以下の投与量でも反復投与によって血糖上昇抑制効果が得られることが考えられる。\n\n\n  The area under the concentration-time curve decreased by 12 to 20% for E40M-50 and 17 to 24% for E40M-300 compared to E40M-0. This result shows that the amount of glucose exposed to the body decreased by administration of E40M not only at a certain point but also during the experiment time. In addition, the dose dependency was not significant in E40M-50 and E40M-300, but some significant suppression and suppression tendency was shown by single simultaneous administration. E40M was administered at 50 mg / kg or less. It is conceivable that the effect of suppressing the increase in blood sugar can be obtained by repeated administration even at a dose.\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明のα−グルコシダーゼ阻害剤は糖尿病の予防・治療薬等や、糖尿病予防・治療用飲食品に利用できる。\n\n\n  The α-glucosidase inhibitor of the present invention can be used in diabetes preventive / therapeutic agents and foods for diabetes prevention / treatment.\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nＥ４０ＭのＨＰＬＣクロマトグラムである。\nIt is an HPLC chromatogram of E40M.\n\n\n\n\n\n\n \nＥ４０ＭのＦｒ.４のＨＰＬＣクロマトグラムである。\nIt is a HPLC chromatogram of Fr.4 of E40M.\n\n\n\n\n\n\n \nＥ４０ＭのＦｒ.４に含まれる物質の\n１３\nＣ−ＮＭＲ測定の結果である。\nIt is a result of the \n13\n C-NMR measurement of the substance contained in Fr.4 of E40M.\n\n\n\n\n\n\n \nＥ４０ＭのＦｒ.４に含まれる物質のＤＥＰＴ測定の結果である。\nIt is a result of DEPT measurement of the substance contained in Fr.4 of E40M.\n\n\n\n\n\n\n \nＥ４０ＭのＦｒ.４に含まれる物質の\n１\nＨ−ＮＭＲ測定の結果である。\nIt is a result of \n1\n H-NMR measurement of a substance contained in Fr.4 of E40M.\n\n\n\n\n\n\n \nＥ４０ＭのＦｒ.４に含まれる物質のＬＣ／ＭＳ／ＭＳ測定の結果である（図中、（Ａ）はＥ４０ＭＦｒ４のＵＶ２８０ｎｍ検出ピーク、（Ｂ）はＥ４０ＭＦｒ４をｍ／ｚ７４３でスキャンして得られたピーク、（Ｃ）はＥ４０ＭＦｒ４のＵＶ２８０ｎｍ検出で得られたピークの分子量を測定したスペクトル、（Ｄ）は（Ｃ）と同じピークを親イオンｍ／ｚ７４３で分解した時に得られる子イオンを測定したスペクトル、をそれぞれ示す）。\nIt is a result of LC / MS / MS measurement of a substance contained in F40 of E40M (in the figure, (A) is a UV280 nm detection peak of E40MFr4, (B) was obtained by scanning E40MFr4 at m / z 743) Peak, (C) is a spectrum obtained by measuring the molecular weight of a peak obtained by \nUV\n 280 nm detection of E40MFr4, (D) is a spectrum obtained by measuring a child ion obtained by decomposing the same peak as (C) with parent ion m / \nz\n 743. , Respectively).\n\n\n\n\n\n\n \nＥ４０ＭのＦｒ.４に含まれる物質のＬＣ／ＭＳ／ＭＳ測定の結果である（図中、（Ａ）はｍ／ｚ３０００までのＭＳスペクトル、（Ｂ）はｍ／ｚ１４８５を親イオンとした時のＭＳ／ＭＳスペクトル、（Ｃ）はｍ／ｚ２２２７を親イオンとした時のＭＳ／ＭＳスペクトル、をそれぞれ示す）。\nIt is a result of LC / MS / MS measurement of a substance contained in Fr.4 of E40M (in the figure, (A) is an MS spectrum up to m / z 3000, (B) is when m / \nz\n 1485 is a parent ion. MS / MS spectrum, (C) shows MS / MS spectrum when m / \nz\n 2227 is the parent ion).\n\n\n\n\n\n\n \nＥ４０Ｍを用いた経口糖負荷試験の結果を示す図面である（図中、（Ａ）は正常マウスの結果、（Ｂ）は糖尿病マウスの結果、をそれぞれ示す）。\nIt is drawing which shows the result of the oral glucose tolerance test using E40M (In the figure, (A) shows the result of a normal mouse, (B) shows the result of a diabetic mouse, respectively)."
  },
  {
    "id": "JP2010202587A",
    "text": "Composition comprising proton pump inhibitor Abstract<P>PROBLEM TO BE SOLVED: To provide a composition that prevents or ameliorates occurrence of pigmentation caused by exposure to ultraviolet rays.  <P>SOLUTION: The composition useful for preventing or ameliorating pigmentation comprises (1) a compound, 4-n-butylresorcinol and/or a pharmacologically acceptable salt thereof and (2) an extract of a galenical exhibiting a proton pump-inhibiting action, that is, an action of acidifying the inside of a melanocyte and is provided as a cosmetic and/or a skin care preparation for external use. The composition prevents aggravation of skin symptoms such as spots, wrinkles, flabbiness and the like caused by factors such as ageing, stress, exposure to ultraviolet rays or the like thereby keeping appearances of the skin beautiful.  <P>COPYRIGHT: (C)2010,JPO&INPIT Claims (\n13\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n１）下記一般式（１）で表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤とを含有することを特徴とする、組成物。\n\n\n \n \n\n（１）\n\n[式中、R１は、分岐構造又は環構造を有していてもよい炭素数１〜８のアルキル基を表す]\n\nA composition comprising 1) a compound represented by the following general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor. \n \n \n \n (1) \n [Wherein R 1 represents an alkyl group having 1 to 8 carbon atoms which may have a branched structure or a ring structure]\n\n\n\n\n\n\n\n\n\n\n \n\n前記一般式（１）で表される化合物が、４−ｎ−ブチルレゾルシノ−ル及び／又はその薬理学的に許容される塩であることを特徴とする、請求項１に記載の組成物。\n\n\nThe composition according to claim 1, wherein the compound represented by the general formula (1) is 4-n-butylresorcinol and / or a pharmacologically acceptable salt thereof.\n\n\n\n\n\n\n\n\n\n\n\n \n\n前記プロトンポンプ阻害剤が、生薬抽出物に由来することを特徴とする、請求項１又は２に記載の組成物。\n\n\nThe composition according to claim 1 or 2, wherein the proton pump inhibitor is derived from a herbal extract.\n\n\n\n\n\n\n\n\n\n\n\n \n\nプロトンポンプ阻害剤が、Na＋／H＋交換輸送系の阻害であることを特徴とする、請求項１〜３の何れか一項に記載の組成物。\n\n\n4. Composition according to any one of claims 1 to 3, characterized in that the proton pump inhibitor is an inhibition of the Na + / H + exchange transport system.\n\n\n\n\n\n\n\n\n\n\n\n \n\n前記一般式（１）で表される化合物及び／又はそれらの薬理学的に許容される塩が、皮膚外用剤全量に対し、０．０００１質量％〜５質量％含有されることを特徴とする、請求項１〜４の何れか一項に記載の組成物。\n\n\nThe compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof is contained in an amount of 0.0001% by mass to 5% by mass with respect to the total amount of the external preparation for skin. The composition as described in any one of Claims 1-4.\n\n\n\n\n\n\n\n\n\n\n\n \n\n前記プロトンポンプ阻害剤が、皮膚外用剤全量に対し、０．００００１質量％〜５質量％含有されることを特徴とする、請求項１〜５の何れか一項に記載の組成物。\n\n\nThe composition according to any one of claims 1 to 5, wherein the proton pump inhibitor is contained in an amount of 0.00001% by mass to 5% by mass with respect to the total amount of the external preparation for skin.\n\n\n\n\n\n\n\n\n\n\n\n \n\n前記プロトンポンプ阻害剤は、メラノサイトにおいてメラノサイト内を酸性化する作用を有することを特徴とする、請求項１〜６の何れか一項に記載の組成物。\n\n\nThe composition according to any one of claims 1 to 6, wherein the proton pump inhibitor has an action of acidifying the inside of melanocytes in melanocytes.\n\n\n\n\n\n\n\n\n\n\n\n \n\n化粧料（但し、医薬部外品を含む）であることを特徴とする、請求項１〜７の何れか一項に記載の組成物。\n\n\nThe composition according to any one of claims 1 to 7, wherein the composition is a cosmetic (however, including a quasi-drug).\n\n\n\n\n\n\n\n\n\n\n\n \n\n皮膚外用剤であることを特徴とする、請求項１〜８の何れか一項に記載の組成物。\n\n\nIt is a skin external preparation, The composition as described in any one of Claims 1-8 characterized by the above-mentioned.\n\n\n\n\n\n\n\n\n\n\n\n \n\n油中水乳化剤形であることを特徴とする、請求項９に記載の皮膚外用剤。\n\n\nThe skin external preparation according to claim 9, which is in the form of a water-in-oil emulsifier.\n\n\n\n\n\n\n\n\n\n\n\n \n\n色素沈着予防用であることを特徴とする、請求項９又は１０に記載の皮膚外用剤。\n\n\nThe skin external preparation according to claim 9 or 10, which is used for preventing pigmentation.\n\n\n\n\n\n\n\n\n\n\n\n \n\n紫外線暴露の直後に使用するための、請求項９〜１１に記載の皮膚外用剤。\n\n\nThe external preparation for skin according to claim 9 to 11 for use immediately after exposure to ultraviolet rays.\n\n\n\n\n\n\n\n\n\n\n\n \n\n１）一般式（１）で表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤を含有する皮膚外用剤。\n\n\n1) A skin external preparation containing a compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は、１）下記一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤を含有する組成物に関し、詳しくは、色素沈着の予防又は改善に有用な皮膚外用剤に関する。\n\n\n  The present invention relates to a composition comprising 1) a compound represented by the following general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor. The present invention relates to an external preparation for skin useful for prevention or improvement of the above.\n\n\n\n\n\n\n\n \n \n \n \n\n （１）\n\n[式中、R１は、分岐構造又は環構造を有していてもよい炭素数１〜８のアルキル基を表す]\n \n \n \n \n (1) \n [Wherein R 1 represents an alkyl group having 1 to 8 carbon atoms which may have a branched structure or a ring structure] \n \n\n\n\n\n\n\n\n\n\n\n \n\n  加齢、ストレス、紫外線暴露などの要因により引き起こされるシミ、シワ、たるみ等の皮膚症状の悪化に対し、肌の美観を美しく保つことは、女性にとって非常に重要な関心事であり、このような皮膚症状の悪化を防止・改善するための手段を求め、様々な研究がなされてきた。特に、シミ、ソバカスや日焼け後の色素沈着は、皮膚に存在する色素細胞（メラノサイト）の活性化によりメラニン生成が著しく亢進することが原因で起こる。これらの皮膚色素関連のトラブルを防止・改善するために、アスコルビン酸類、過酸化水素、コロイド硫黄、グルタチオン、ハイドロキノン、又は、カテコ−ル等の美白成分を配合した皮膚外用剤が開発されている（例えば、非特許文献１及び非特許文献２を参照）。しかしながら、これらの美白剤を含有する皮膚外用剤には、一定の美白効果は認められるものの、何れも満足する美白効果が得るまでには至らず、安定性または安全性等の面に課題を有しているものも存した。\n\n\n  Keeping the beauty of the skin beautiful against the deterioration of skin symptoms such as spots, wrinkles and sagging caused by factors such as aging, stress, and UV exposure is a very important concern for women. Various studies have been conducted in search of means for preventing and improving the deterioration of skin symptoms. In particular, stains, buckwheat, and pigmentation after sunburn are caused by markedly enhanced melanin production due to activation of pigment cells (melanocytes) present in the skin. In order to prevent and improve these skin pigment-related troubles, external preparations for skin containing whitening ingredients such as ascorbic acids, hydrogen peroxide, colloidal sulfur, glutathione, hydroquinone, or catechol have been developed ( For example, see Non-Patent Document 1 and Non-Patent Document 2.) However, although these skin whitening agents contain a certain whitening effect, none of them achieves a satisfactory whitening effect and have problems in terms of stability and safety. Some of them were there.\n\n\n\n\n\n\n\n \n\n日焼け、シミ、ソバカスに加え、多くの皮膚色素関連トラブルには、メラノサイトにおいて産生されるメラニン量が深く関与している。メラニンは、表皮最下層の基底層などにあるメラノサイト（色素細胞）の小器官であるメラノソ−ムにおいて、アミノ酸のチロシンより合成され、メラノサイトの樹状突起を通じて隣接する周囲のケラチノサイトに移行した後、表皮細胞に貧食され核上部に集まり紫外線から核を守る働きをする。メラニン産生における重要な酵素としては、糖タンパクの活性中心に金属イオンを有し、メラノソ−ム膜に結合した膜タンパクであるチロシナ−ゼ及びチロシナ−ゼ関連タンパク（ＴＲＰ１：チロシナ−ゼ関連タンパク１、ＴＲＰ２：チロシナ−ゼ関連タンパク２）が知られている。特に、メラニン産生における律速酵素のチロシナ−ゼは、メラニン産生を制御するための標的分子として注目され、直接的又は間接的にチロシナ−ゼに作用する物質の研究が盛んに行われている。チロシナ−ゼに働きかけメラニン産生を抑制する物質としては、アルブチン誘導体に代表される直接的なチロシナ−ゼ酵素阻害作用を示すチロシナ−ゼ阻害剤（例えば、非特許文献２を参照）、チロシナ−ゼmRNA発現抑制作用によるチロシナ−ゼ発現抑制剤（例えば、特許文献１を参照）、チロシナ−ゼ酵素分解促進剤（例えば、特許文献２を参照）などが見出され、美白用の化粧料などに広く使用されている。また、この様なチロシナ−ゼ酵素に働きかける物質を単独で使用するのみならず、複数の物質を配合した化粧料も数多く開発されているが、その効果は必ずしも満足のいくものとは言えず、さらには、安定性又は安全性に課題を有するものも少なくない。このため、高い美白効果、安全性及び安定性が期待出来る、新たな作用機序を有する美白剤が強く望まれている。\n\n\nIn addition to sunburn, blemishes and buckwheat, many skin pigment-related problems are closely related to the amount of melanin produced in melanocytes. Melanin is synthesized from amino acid tyrosine in melanosomes, which are organelles of melanocytes (pigment cells) in the basal layer of the lowermost epidermis, etc. It is eaten by epidermal cells and gathers at the top of the nucleus to protect the nucleus from ultraviolet rays. Important enzymes in melanin production include tyrosinase and tyrosinase-related protein (TRP1: tyrosinase-related protein 1), which are membrane proteins having a metal ion at the active center of glycoprotein and bound to the melanosome membrane. TRP2: tyrosinase-related protein 2) is known. In particular, tyrosinase, a rate-limiting enzyme in melanin production, has attracted attention as a target molecule for controlling melanin production, and studies on substances that directly or indirectly act on tyrosinase have been actively conducted. Examples of substances that act on tyrosinase to suppress melanin production include tyrosinase inhibitors that exhibit a direct tyrosinase enzyme inhibitory action typified by arbutin derivatives (see, for example, Non-Patent Document 2), tyrosinase. A tyrosinase expression inhibitor (for example, see Patent Document 1) and a tyrosinase enzymatic degradation accelerator (see, for example, Patent Document 2) due to an mRNA expression inhibitory action have been found, and are used for whitening cosmetics, etc. Widely used. In addition to using a substance that acts on such a tyrosinase enzyme alone, many cosmetics containing a plurality of substances have been developed, but the effect is not necessarily satisfactory, Furthermore, there are many things which have a problem in stability or safety. For this reason, a whitening agent having a new action mechanism that can be expected to have a high whitening effect, safety and stability is strongly desired.\n\n\n\n\n\n\n\n \n\n新たな作用機序を有する美白剤を求め、現在も盛んに研究が行われている。チロシナ−ゼは、細胞又は細胞小器官における重要な周辺環境のひとつであるプロトン濃度（pH）により活性が調整されるpH依存性の酵素であり、メラノサイト内を中性に近ずけることにより、酵素活性及びメラニン量が影響を受けることが報告されている（例えば、非特許文献３を参照）。しかしながら、化粧料に適応可能な成分において、かかるプロトンポンプ阻害作用を有するものは知られていないし、化粧料の美白剤において、かかるプロトンポンプ阻害作用を機作とするものも全く知られておらず、細胞内プロトン濃度を調節するプロトンポンプ阻害剤が、メラノサイト内の酸性化を誘引し、チロシナ−ゼ活性を低下させることにより、メラニン産生を抑制し、美白をはじめとする皮膚色素異常関連疾患に有効であることも全く知られていなかった。一方、マメ科ハギ属の植物の抽出物がメラニン産生抑制作用を有する物質を含んでいることは知られているが、かかるメラニン産生抑制作用の機作に付いては全く知られていなかった（例えば、特許文献３、特許文献４、特許文献５、特許文献６、特許文献７を参照）。\n\n\nIn search of a whitening agent having a new mechanism of action, active research is ongoing. Tyrosynase is a pH-dependent enzyme whose activity is regulated by proton concentration (pH), which is one of the important surrounding environments in cells or organelles. By approaching neutrality in melanocytes, It has been reported that the enzyme activity and the amount of melanin are affected (see, for example, Non-Patent Document 3). However, none of the ingredients applicable to cosmetics has such a proton pump inhibitory action, and no cosmetic whitening agent is known to have such a proton pump inhibitory action as a mechanism. , A proton pump inhibitor that regulates intracellular proton concentration induces acidification in melanocytes and decreases tyrosinase activity, thereby suppressing melanin production and treating skin pigment abnormality-related diseases such as whitening. Neither was known to be effective. On the other hand, although it is known that the extract of the leguminous hagi genus plant contains a substance having an inhibitory action on melanin production, the mechanism of the inhibitory action on melanin production was not known at all ( For example, see Patent Document 3, Patent Document 4, Patent Document 5, Patent Document 6, and Patent Document 7.)\n\n\n\n\n\n\n\n \n\n  アルキルレゾルシノ−ル誘導体には、抗菌作用、メラニン産生抑制作用（例えば、特許文献８を参照)、好中球抑制作用（例えば、特許文献９を参照）などの生物活性が報告されている。特に、４−ｎ−ヘキシルレゾルシノ−ルは、既に防腐剤や駆虫剤としての使用実績もある。また、４−ｎ−ブチルレゾルシノ−ルには、強力なチロシナ−ゼ阻害活性を有することが知られており（例えば、特許文献１０を参照）、美白効果を期待した該成分を配合した化粧料などが、開発されている。しかしながら、化粧料などの皮膚外用剤に４−アルキルレゾルシノ−ルを配合する場合には、非常に水溶性が高いため、汗や水によって落ち易く、皮膚上に貯留する時間が短いことなどの課題も認められている。実際、４−アルキルレゾルシノ−ル誘導体を配合した皮膚外用剤などにおいては、一定の美白効果が認められるものの、その効果は、必ずしも使用者を満足させるものではない。このため、さらに高い生物活性を有する新規なアルキルレゾルシノ−ル誘導体に関する研究が現在も盛んに行われている（例えば、特許文献１１を参照）。他方、アルキルレゾルシノ−ルに代表される高い生物活性を有する新規な有効成分を見出すことは容易なことではないため、アルキルレゾルシノ−ルの美白効果を最大限活用出来る有効成分の組み合わせ及び製剤化技術が切望されている。\n\n\n  Biological activities such as antibacterial action, melanin production inhibitory action (see, for example, Patent Document 8), and neutrophil inhibitory action (see, for example, Patent Document 9) have been reported for alkylresorcinol derivatives. . In particular, 4-n-hexyl resorcinol has already been used as a preservative and an anthelmintic agent. In addition, 4-n-butylresorcinol is known to have a strong tyrosinase inhibitory activity (see, for example, Patent Document 10), and a cosmetic containing the component expected for a whitening effect. Has been developed. However, when 4-alkylresorcinol is blended in a skin external preparation such as cosmetics, it is very water-soluble, so it easily falls off with sweat and water, and has a short storage time on the skin. Is also recognized. In fact, in a skin external preparation containing a 4-alkylresorcinol derivative, a certain whitening effect is recognized, but the effect does not necessarily satisfy the user. For this reason, research on new alkylresorcinol derivatives having higher biological activity is still actively conducted (see, for example, Patent Document 11). On the other hand, since it is not easy to find a new active ingredient having high biological activity represented by alkylresorcinol, a combination of active ingredients that can make maximum use of the whitening effect of alkylresorcinol And formulation technology is eagerly desired.\n\n\n\n\n\n\n\n \n\nチロシナ−ゼ阻害剤とその他の作用機序を介し美白作用を発揮する物質を組み合わせることにより美白作用を増強させる試み（例えば、特許文献１２を参照）も盛んになされている。この様な試みにおいては、チロシナ−ゼ阻害剤と他の作用機序を介し美白作用を発揮する物質を組み合わせ皮膚外用剤に配合した場合には、組み合わせによる効果は全く存しなかったり、相加的効果であったり、相乗的効果であったりと一定の結果は得られておらず、さらに、その原因などに付いても全く知られていない。これは、メラニン産生抑制の機作が殆ど知られていないことも一因であると考えられる。このため、既存の美白剤による組み合わせ効果を超えるものとして、新たな作用機序を有する物質に注目が集まっている。さらに、新しい作用機序を有する物質と既存美白剤との組み合わせによる美白効果の増強にも期待が寄せられている。\n\n\nAttempts to enhance the whitening effect by combining a tyrosinase inhibitor with a substance that exhibits a whitening effect through other mechanisms of action (see, for example, Patent Document 12) have been actively made. In such attempts, when a tyrosinase inhibitor and a substance that exerts a whitening effect through other mechanisms of action are combined in a topical skin preparation, the combination does not have any effect or an additive effect. There are no specific results, such as the effects or synergistic effects, and the cause is not known at all. This may be due to the fact that little is known about the mechanism of melanin production suppression. For this reason, attention has been focused on substances having a new mechanism of action that exceed the combined effects of existing whitening agents. Furthermore, the enhancement of the whitening effect by combining a substance having a new mechanism of action with an existing whitening agent is also expected. \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n特開２００４−３５２６９７号公報\nJP 2004-352697 A\n\n\n\n\n\n\n\n\n\n\n \n特開２００４−３５２６４７号公報\nJP 2004-352647 A\n\n\n\n\n\n\n\n\n\n\n \n特開２００７−１８６４２２号公報\nJP 2007-186422 A\n\n\n\n\n\n\n\n\n\n\n \n特開２００７−１８６４４１号公報\nJP 2007-186441 A\n\n\n\n\n\n\n\n\n\n\n \n特開２００７−１８６４３９号公報\nJP 2007-186439 A\n\n\n\n\n\n\n\n\n\n\n \n特開２００７−００８８２０号公報\nJP 2007-008820 A\n\n\n\n\n\n\n\n\n\n\n \n特開２０００７−００８８１８号公報\nJapanese Patent Laid-Open No. 200070-008818\n\n\n\n\n\n\n\n\n\n\n \n特開平０７−００２６４３号公報\nJP 07-002643 A\n\n\n\n\n\n\n\n\n\n\n \n特開２００１−３０２５０６号公報\nJP 2001-302506 A\n\n\n\n\n\n\n\n\n\n\n \n特表２００２−５４００９５号公報\nSpecial Table 2002-540095\n\n\n\n\n\n\n\n\n\n\n \n特開２００６−１２４３５８号公報\nJP 2006-124358 A\n\n\n\n\n\n\n\n\n\n\n \n特表２００２−５４００９５号公報\nSpecial Table 2002-540095\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n武田克之ら監修、「化粧品の有用性、評価技術と将来展望」、薬事日報社刊（2001年）\nSupervised by Katsuyuki Takeda et al., “Usefulness of cosmetics, evaluation technology and future prospects”, published by Yakuji Nippo (2001)\n\n\n\n\n\n\n\n\n\n\n \nメラニン色素の制御と美白剤の開発、フレグランスジャ−ナル社、Ｎｏ１４（１９９５）\nControl of melanin pigment and development of whitening agent, Fragrance Journal, No14 (1995)\n\n\n\n\n\n\n\n\n\n\n \nJanis Ancans et. al.、Experimental Cell Research、２６８、２６−３５（２００１）\nJanis Ancans et. Al., Experimental Cell Research, 268, 26-35 (2001)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明は、この様な状況下において為されたものであり紫外線暴露後の色素沈着の発生を予防する手段、或るいは、出来た色素沈着をより効果的に改善する手段を提供することにある。\n\n\n  The present invention has been made under such circumstances, and provides a means for preventing the occurrence of pigmentation after exposure to ultraviolet rays, or a means for more effectively improving the resulting pigmentation. is there.\n\n\n\n\n\n\n\n \n\n  この様な状況に鑑みて、本発明者等は、紫外線暴露後の色素沈着を予防、改善する技術を求めて、鋭意努力、研究を重ねた結果、１）下記一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤を含有する組成物が、これらの効果に優れることを見出し、本発明を完成させるに至った。本発明は、以下に示す通りである。\n\n＜１＞  １）下記一般式（１）で表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤とを含有することを特徴とする、組成物。\n\nIn view of such circumstances, the present inventors have intensively studied and sought for a technique for preventing and improving pigmentation after exposure to ultraviolet rays. 1) As expressed in the following general formula (1) And / or a pharmacologically acceptable salt thereof and 2) a composition containing a proton pump inhibitor were found to be excellent in these effects, and the present invention was completed. The present invention is as follows. \n <1> 1) A composition comprising the compound represented by the following general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor.\n\n\n\n\n\n\n \n \n \n \n\n（１）\n\n[式中、R１は、分岐構造又は環構造を有していてもよい炭素数１〜８のアルキル基を表す]\n\n \n \n \n (1) \n [Wherein R 1 represents an alkyl group having 1 to 8 carbon atoms which may have a branched structure or a ring structure]\n\n\n\n\n\n\n \n\n＜２＞  前記一般式（１）で表される化合物が、４−ｎ−ブチルレゾルシノ−ル及び／又はその薬理学的に許容される塩であることを特徴とする、＜１＞に記載の組成物。\n\n＜３＞  前記プロトンポンプ阻害剤が、生薬抽出物に由来することを特徴とする、＜１＞又は＜２＞に記載の組成物。\n\n＜４＞  プロトンポンプ阻害剤が、Na＋／H＋交換輸送系の阻害であることを特徴とする、＜１＞〜＜３＞の何れか一項に記載の組成物。\n\n＜５＞  前記一般式（１）で表される化合物及び／又はそれらの薬理学的に許容される塩が、皮膚外用剤全量に対し、０．０００１質量％〜５質量％含有されることを特徴とする、＜１＞〜＜４＞の何れか一項に記載の組成物。\n\n＜６＞  前記プロトンポンプ阻害剤が、皮膚外用剤全量に対し、０．００００１質量％〜５質量％含有されることを特徴とする、＜１＞〜＜５＞の何れか一項に記載の組成物。\n\n＜７＞  前記プロトンポンプ阻害剤は、メラノサイトにおいてメラノサイト内を酸性化する作用を有することを特徴とする、＜１＞〜＜６＞の何れか一項に記載の組成物。\n\n＜８＞  化粧料（但し、医薬部外品を含む）であることを特徴とする、＜１＞〜＜７＞の何れか一項に記載の組成物。\n\n＜９＞  皮膚外用剤であることを特徴とする、＜１＞〜＜８＞の何れか一項に記載の組成物。\n\n＜１０＞  油中水乳化剤形であることを特徴とする、＜９＞に記載の皮膚外用剤。\n\n＜１１＞  色素沈着予防用であることを特徴とする、＜９＞又は＜１０＞に記載の皮膚外用剤。\n\n＜１２＞  紫外線暴露の直後に使用するための、＜９＞〜＜１１＞に記載の皮膚外用剤。\n\n＜１３＞  １）一般式（１）で表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤を含有する皮膚外用剤。\n\n\n<2> The composition according to <1>, wherein the compound represented by the general formula (1) is 4-n-butylresorcinol and / or a pharmacologically acceptable salt thereof. object. \n <3> The composition according to <1> or <2>, wherein the proton pump inhibitor is derived from a herbal extract. \n <4> The composition according to any one of <1> to <3>, wherein the proton pump inhibitor is inhibition of a Na + / H + exchange transport system. \n <5> The compound represented by the general formula (1) and / or the pharmacologically acceptable salt thereof is contained in an amount of 0.0001% by mass to 5% by mass with respect to the total amount of the external preparation for skin. The composition according to any one of <1> to <4>, which is characterized. \n <6> The proton pump inhibitor according to any one of <1> to <5>, wherein the proton pump inhibitor is contained in an amount of 0.00001% by mass to 5% by mass with respect to the total amount of the external preparation for skin. Composition. \n <7> The composition according to any one of <1> to <6>, wherein the proton pump inhibitor has an action of acidifying melanocytes in melanocytes. \n <8> The composition according to any one of <1> to <7>, which is a cosmetic (including a quasi-drug). \n <9> The composition according to any one of <1> to <8>, which is a skin external preparation. \n <10> The external preparation for skin according to <9>, which is in the form of a water-in-oil emulsifier. \n <11> The external preparation for skin according to <9> or <10>, which is for preventing pigmentation. \n <12> The external preparation for skin according to <9> to <11>, which is used immediately after exposure to ultraviolet rays. \n <13> 1) A skin external preparation containing a compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor. \n \n\n\n\n\n\n\n\n\n\n\n \n\n  本発明によれば、紫外線暴露後の色素沈着の発生を予防、改善する手段を提供することが出来る。\n\n\nAccording to the present invention, it is possible to provide means for preventing or improving the occurrence of pigmentation after exposure to ultraviolet rays. \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n本発明の化合物１〜３のチロシナ−ゼファミリ−タンパクの減少作用の検討結果を示す図である。\nIt is a figure which shows the examination result of the reduction | decrease effect | action of the tyrosinase family protein of the compounds 1-3 of this invention.\n\n\n\n\n\n\n \n本発明の化合物１〜３のメラノソ−ム内酸性化の検討結果を示す図である。\nIt is a figure which shows the examination result of the acidification in the melanosomes of the compounds 1-3 of this invention.\n\n\n\n\n\n\n \n本発明のマメ科ハギ属キハギより得られる抽出物のメラノソ−ム内酸性化の検討結果を示す図である。\nIt is a figure which shows the examination result of the acidification in the melanosome of the extract obtained from the leguminous genus kihagi of this invention.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n＜本発明の一般式（１）に表される化合物＞\n\n  本発明の組成物は、１）前記一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤とを含有することを特徴とする。前記一般式（１）に表される化合物であれば、特段の限定なく適応することが出来る。ここで一般式（１）に表される化合物に付いて述べれば、一般式（１）において、Ｒ１は、分岐構造又は環状構造を有していてもよい炭素数１〜８のアルキル基を表す。具体的には、メチル基、エチル基、ｎ−プロピル基、イソプロピル基、ｎ−ブチル基、イソブチル基、tert-ブチル基、ｎ−ペンチル基、アミル基、イソアミル基、ｎ−ヘキシル基、ｎ−ヘプチル基、ｎ−オクチル基、イソオクチル基、１−メチルプロピル基、１−メチルブチル基、１−エチルプロピル基、１−エチル−２−メチルプロピル基、１−イソプロピル−２−メチルプロピル基、１，１−ジメチル−３−メチルブチル基、１−ブチルペンチル基、１−イソブチル−３−メチルブチル基、イソステアリル基、シクロペンチル基、シクロヘキシル基、シクロヘプチル基、シクロオクチル基などが好ましく例示出来、これらの内、ｎ−ブチル基が特に好ましく例示出来る。また、Ｒ１の置換位置は、特段の限定なく適応することが出来るが、特に、４位が好ましい。\n\n<Compound represented by the general formula (1) of the present invention> \n The composition of the present invention comprises 1) a compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor. . Any compound represented by the general formula (1) can be applied without particular limitation. Here, if it mentions about the compound represented by General formula (1), in General formula (1), R1 represents the C1-C8 alkyl group which may have a branched structure or a cyclic structure. . Specifically, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, amyl group, isoamyl group, n-hexyl group, n- Heptyl group, n-octyl group, isooctyl group, 1-methylpropyl group, 1-methylbutyl group, 1-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1-isopropyl-2-methylpropyl group, 1, Preferred examples include 1-dimethyl-3-methylbutyl group, 1-butylpentyl group, 1-isobutyl-3-methylbutyl group, isostearyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, and cyclooctyl group. , N-butyl group is particularly preferable. Further, the substitution position of R1 can be applied without any particular limitation, but the 4-position is particularly preferred.\n\n\n\n\n\n\n \n\n一般式（１）に表される化合物、特に、４−アルキルレゾルシノ−ルは、レゾルシンと前記アルキル基に対応するカルボン酸を塩化亜鉛の存在下縮合し、亜鉛アマルガム／塩酸で還元する方法や、レゾルシンと前記アルキル基に対応するアルコ−ルとを２００〜４００℃の高温下で縮合させる方法等の公知の合成方法により製造できる（例えば、Lille ,J. ; Bitter, L. A.; Peiner, V. Trudy-Nauchono-Issledovatel' skii Institut Slantsev （1969）、No．18、 127−134、特開2006−124358号公報、特開2006−124357号公報を参照）。また、４−アルキルレゾルシノ−ルとして好ましいものは、４−ｎ−ブチルレゾルシノ−ルが好適に例示出来る。\n\n\nA compound represented by the general formula (1), particularly 4-alkylresorcinol, is a method in which resorcinol and a carboxylic acid corresponding to the alkyl group are condensed in the presence of zinc chloride and reduced with zinc amalgam / hydrochloric acid. Or a known synthesis method such as a method of condensing resorcin and an alcohol corresponding to the alkyl group at a high temperature of 200 to 400 ° C. (for example, Lille, J .; Bitter, LA; Peiner, V Trudy-Nauchono-Issledovatel 'skii Institut Slantsev (1969), No. 18, 127-134, JP 2006-124358 A, JP 2006-124357 A). A preferred example of 4-alkyl resorcinol is 4-n-butyl resorcinol.\n\n\n\n\n\n\n\n \n\nまた、斯くして得られた一般式（１）に表される化合物は、そのまま使用することも出来るし、薬理学的に許容出来る酸又は塩基と共に処置して塩の形に変換し、塩として使用することも可能である。例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩、炭酸塩などの鉱酸塩、マレイン酸塩、フマル酸塩、シュウ酸塩、クエン酸塩、乳酸塩、酒石酸塩、メタンスルホン酸塩、パラトルエンスルホン酸塩、ベンゼンスルホン酸塩などの有機酸塩、ナトリウム塩、カリウム塩などのアルカリ金属塩、カルシウム塩、マグネシウム塩などのアルカリ土類金属塩、トリエチルアミン塩、トリエタノ−ルアミン塩、アンモニウム塩、モノエタノ−ルアミン塩、ピペリジン塩などの有機アミン塩、リジン塩、アルギニン酸塩などの塩基性アミノ酸塩などが好適に例示出来る。かかる成分は唯一種含有させることも出来るし、二種以上を組み合わせて含有させることも出来る。前記一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩の含有量は、皮膚外用剤全量に対し０．０００１質量％〜５質量％、より好ましくは、０．００１質量％〜３質量％、さらに好ましくは、０．０１〜１質量％含有させることがより好ましい。これは、一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩の含有量が、少なすぎると一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩が有するチロシナ−ゼ酵素に対する直接阻害作用、並びに、後記のプロトンポンプ阻害作用との併用効果を奏しない場合が存し、多すぎても、効果が頭打ちになり、この系の自由度を損なう場合が存するためである。\n\n\nIn addition, the compound represented by the general formula (1) thus obtained can be used as it is, or can be treated with a pharmacologically acceptable acid or base to be converted into a salt form, and used as a salt. It is also possible to use it. For example, mineral salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, maleate, fumarate, oxalate, citrate, lactate, tartrate, methanesulfonate, para Organic acid salts such as toluene sulfonate and benzene sulfonate, alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, triethylamine salt, triethanolamine salt, ammonium salt, Preferred examples include organic amine salts such as monoethanolamine salts and piperidine salts, and basic amino acid salts such as lysine salts and arginate salts. These components can be contained alone or in combination of two or more. The content of the compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof is 0.0001% by mass to 5% by mass, more preferably 0%, based on the total amount of the external preparation for skin. It is more preferable to make it contain 0.001 mass%-3 mass%, More preferably, 0.01-1 mass%. This is because if the content of the compound represented by the general formula (1) and / or their pharmacologically acceptable salt is too small, the compound represented by the general formula (1) and / or their drug There are cases where there is no direct inhibitory action on the tyrosinase enzyme possessed by a physically acceptable salt, as well as a combined effect with the proton pump inhibitory action described later. This is because the degree of freedom of the system may be lost.\n\n\n\n\n\n\n\n \n\n＜本発明のプロトンポンプ阻害剤＞\n\n本発明の組成物は、１）前記一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤を含有することを特徴とする。本発明におけるプロトンポンプ阻害剤としては、細胞又は細胞小器官内などにおける能動的なプロトン輸送を担うH＋−ATPaseのみならず、Na＋／K＋−ATPase等のイオンポンプと共役的に働き受動的にプロトンを輸送するNa＋／H＋交換輸送体などに作用する物質も包含する。本発明のプロトンポンプ阻害剤としては、プロトンポンプ阻害作用を示すものであれば特段の限定なく適応することが出来る。本発明のプロトンポンプ阻害剤の内、好ましいものとしては、後述するメラノサイト内の酸性化作用を指標とするメラノソ−ム内酸性化（プロトンポンプ阻害作用）検討において、プロトンポンプ阻害作用を有する物質が好適に例示出来る。本発明のメラノサイト内の酸性化作用を有するプロトンポンプ阻害剤とは、pH感受性蛍光色素の発色強度が、レ−ザ−顕微鏡による目視的観察により発色強度の増強が認められる場合を意味する。さらに、前記プロトンポンプ阻害剤の内、特に好ましいものとしては、１）メラニン産生抑制作用を示し、２）チロシナ−ゼ直接阻害作用を示さない、３）チロシナ−ゼファミリ−タンパクの減少作用を示さない性質を有するプロトンポンプ阻害剤が好適に例示出来る。\n\n<Proton pump inhibitor of the present invention> \n The composition of the present invention comprises 1) a compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor. Proton pump inhibitors in the present invention include not only H + -ATPase responsible for active proton transport in cells or organelles but also passively protons acting in conjunction with ion pumps such as Na + / K + -ATPase. Also included are substances that act on Na + / H + exchange transporters, etc. The proton pump inhibitor of the present invention can be applied without particular limitation as long as it exhibits a proton pump inhibitory action. Among the proton pump inhibitors of the present invention, preferred are substances having a proton pump inhibitory action in the study of melanosome acidification (proton pump inhibitory action) using the acidification action in melanocytes described later as an index. It can illustrate suitably. The proton pump inhibitor having an acidifying action in the melanocyte of the present invention means a case where the coloring intensity of the pH-sensitive fluorescent dye is enhanced by visual observation with a laser microscope. Further, among the proton pump inhibitors, particularly preferred are 1) melanin production inhibitory action, 2) no tyrosinase direct inhibitory action, and 3) no tyrosinase family protein reducing action. Preferred examples include proton pump inhibitors having properties.\n\n\n\n\n\n\n \n\n本発明のプロトンポンプ阻害剤とは、単純な化学物質、生薬及び動植物からの抽出物を意味し、かかる成分を唯１種のみ含有させることも出来るし、２種以上を組み合わせて含有させることも出来る。ここで、本発明の抽出物とは、抽出物自体、抽出物の分画、精製した分画、抽出物乃至は分画、精製物の溶媒除去物の総称を意味する。かかる成分の内、化学物質としては、オメプラゾ−ル、ランソプラゾ−ル、ラベプラゾ−ル及び／又はそれらの薬理学的に許容される塩が好適に例示出来る。また、かかる成分の内、生薬及び動植物より得られる抽出物としては、マメ科ハギ属に属する植物より得られる抽出物、シソ科に属する植物より得られる抽出物、ユキノシタ科に属する植物より得られる抽出物、サルノコシカケ科の菌類より得られる抽出物、マメ科に属する植物より得られる抽出物、ショウガ科に属する植物より得られる抽出物、ショウブ科に属する植物より得られる抽出物、ウリ科に属する植物より得られる抽出物などが好適例示出来、より好ましくは、マメ科ハギ属に属する植物より得られる抽出物が、さらに好ましくは、マメ科ハギ属のヤマハギ（Lespedeza  bicolor）、マルバハギ（Lespedeza  cyrtobotrya）、ツクシハギ（Lespedeza  homoloba）、ニシキハギ（Lespedeza  japonica）、ネコハギ（Lespedeza  pilosa）、メドハギ（Lespedeza  juncea）、ヤハズソウ（Lespedeza  striata）、マキエハギ（Lespedeza  virgata）、キハギ（Lespedeza  buergeri）、トウクサハギ（Lespedeza  floribunda）などが好適に例示出来る。かかるマメ科ハギ属に属する植物の抽出物作製に用いる植物部位としては、植物体、地上部又は木幹部が好適に例示出来る。かかるマメ科ハギ属に属する植物は、日本においてその生育が認められる植物である。特に、後記の実施例に記載のマメ科ハギ属キハギは、本州・四国・九州においてその成育が認められる植物であり、マメ科ハギ属キハギの抽出物作製に用いる部位としては、植物体、地上部、木幹部又は根茎部が好適に例示出来き、植物体がより好ましい。本発明の実施例においては、日本で育成されたキハギを使用した。抽出に際し、植物体、地上部、木幹部又は根茎部は予め、粉砕或いは細切して抽出効率を向上させるように加工することが好ましい。抽出物は、植物体、地上部、木幹部又は根茎部乃至はその乾燥物１質量に対して、溶媒を１〜３０質量部加え、室温であれば数日間、沸点付近の温度であれば数時間浸漬する。浸漬後は、室温まで冷却し、所望により不溶物を除去した後、溶媒を減圧濃縮するなどにより除去することが出来る。しかる後、シリカゲルやイオン交換樹脂を充填したカラムクロマトグラフィ−などで分画精製し、所望の抽出物を得ることが出来る。\n\n\nThe proton pump inhibitor of the present invention means simple chemical substances, herbal medicines and extracts from animals and plants, and can contain only one kind of such ingredients, or can contain two or more kinds in combination. I can do it. Here, the extract of the present invention means a general term for the extract itself, the fraction of the extract, the purified fraction, the extract or fraction, and the solvent-removed product of the purified product. Among these components, preferred examples of the chemical substance include omeprazole, lansoprazole, rabeprazole and / or pharmacologically acceptable salts thereof. Among these components, extracts obtained from herbal medicines and animals and plants include extracts obtained from plants belonging to the genus Leguminosae, extracts obtained from plants belonging to the family Lamiaceae, and plants obtained from the plants belonging to the family Yukinoshita Extracts, extracts obtained from fungi belonging to the family Sarnococcidae, extracts obtained from plants belonging to the leguminous family, extracts obtained from plants belonging to the ginger family, extracts obtained from plants belonging to the family Ginger family, belonging to the family Cucurbitaceae An extract obtained from a plant can be preferably exemplified, and more preferably, an extract obtained from a plant belonging to the genus Leguminosae is more preferably a legume of the genus Leguminosae (Lespedeza bicolor), Malbahagi (Lespedeza cyrtobotrya) , Tsukushihagi (Lespedeza homoloba), Nishikihagi (Lespedeza japonica), Catfish (Lespedeza pilosa), Meadowagi (Lespedeza juncea) Suitable examples include Yashizou (Lespedeza striata), Makiehagi (Lespedeza virgata), Kihagi (Lespedeza buergeri), Tokusahagi (Lespedeza floribunda) and the like. As a plant part used for producing an extract of a plant belonging to the genus Leguminosae, a plant body, an above-ground part or a tree trunk part can be preferably exemplified. Such a plant belonging to the genus Leguminosae is a plant whose growth is recognized in Japan. In particular, the legume genus Kihagi described in the examples below is a plant whose growth is recognized in Honshu, Shikoku, and Kyushu. Part, tree trunk or rhizome can be suitably exemplified, and a plant is more preferred. In the examples of the present invention, kihagi grown in Japan were used. In the extraction, it is preferable to process the plant body, the above-ground part, the tree trunk part or the rhizome part in advance so as to improve the extraction efficiency by crushing or chopping. The extract is 1 to 30 parts by mass of solvent with respect to 1 mass of plant body, above-ground part, tree trunk or rhizome part or its dried product, and if it is room temperature, it is several days, and if it is a temperature near the boiling point, Immerse for hours. After the immersion, the solution can be cooled to room temperature, insoluble matter can be removed if desired, and then the solvent can be removed by concentration under reduced pressure. Thereafter, fractionation and purification can be performed by column chromatography packed with silica gel or an ion exchange resin to obtain a desired extract.\n\n\n\n\n\n\n\n \n\n  前記抽出溶媒としては、極性溶媒が好ましく、水、エタノ−ル、イソプロピルアルコ−ル、ブタノ−ルなどのアルコ−ル類、１，３−ブタンジオ−ル、ポリプロピレングリコ−ルなどの多価アルコ−ル類、アセトン、メチルエチルケトンなどのケトン類、ジエチルエ−テル、テトラヒドロフランなどのエ−テル類から選択される１種乃至は２種以上が好適に例示出来る。\n\n\n  The extraction solvent is preferably a polar solvent, and alcohols such as water, ethanol, isopropyl alcohol, and butanol, and polyvalent alcohols such as 1,3-butanediol and polypropylene glycol. One or two or more selected from ketones such as alcohols, acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran can be preferably exemplified.\n\n\n\n\n\n\n\n \n\nまた、かかる成分は、細胞膜に存在するプロトンポンプ（H＋−ATPase）阻害作用、又は、イオンポンプであるNa＋／K＋−ATPaseと共役的に働くNa＋／H＋交換輸送系などに作用し、細胞又は細胞小器官に於けるプロトン輸送を阻害することにより、細胞又は細胞小器官内の酸性化作用に優れる。細胞又は細胞小器官内の酸性化は、細胞内又は細胞小器官に存在するpH依存的な機能分子（例えば、酵素、イオンチャネル等）の生物活性を調整する。細胞内又は細胞小器官における酸性化は、この様なpH依存的な機能分子のひとつであるチロシナ−ゼ等の酵素活性を低下させ、メラニン産生を抑制し、美白をはじめとする皮膚色素異常関連疾患に対する予防又は治療効果が期待される。\n\n\nIn addition, such a component acts on a proton pump (H + -ATPase) inhibitory action existing in a cell membrane or a Na + / H + exchange transport system that works in combination with Na + / K + -ATPase which is an ion pump. By inhibiting proton transport in organelles, it excels in acidification in cells or organelles. Acidification within a cell or organelle modulates the biological activity of pH-dependent functional molecules (eg, enzymes, ion channels, etc.) present in the cell or organelle. Acidification in cells or organelles reduces enzyme activity such as tyrosinase, one of such pH-dependent functional molecules, suppresses melanin production, and is related to skin pigment abnormality such as whitening. Expected to prevent or treat diseases.\n\n\n\n\n\n\n\n \n\nかかる成分は、細胞膜に存在するプロトンポンプ（H＋−ATPase）阻害作用、又は、イオンポンプであるNa＋／K＋−ATPaseと共役的に働くNa＋／H＋交換輸送系などのプロトンポンプに作用し、細胞又は細胞小器官に於けるプロトン輸送を阻害することにより酸性化を誘引する作用、標的部位への集積性及び選択性に優れ、高い安全性及び安定性を有するために、医薬、食品、化粧料などへの使用が好ましい。\n\n\nSuch a component acts on a proton pump (H + -ATPase) inhibitory action existing in a cell membrane or a proton pump such as a Na + / H + exchange transport system that works in combination with Na + / K + -ATPase which is an ion pump, Inhibits proton transport in organelles, induces acidification, has excellent accumulation and selectivity at target sites, and has high safety and stability. Use in is preferred.\n\n\n\n\n\n\n\n \n\n本発明のプロトンポンプ阻害剤は、皮膚外用剤全量に対し０．００００１質量％〜５質量％、より好ましくは、０．００００３質量％〜３質量％、さらに好ましくは、０．００００５〜１質量％含有させることがより好ましい。これは、プロトンポンプ阻害剤の含有量が、少なすぎると細胞又は細胞小器官内における酸性化作用（プロトンポンプ阻害作用）を介するチロシナ−ゼ酵素の活性低下及びメラニン産生抑制作用を奏さない、並びに、前記のアルキルレゾルシノ−ルとの併用効果を奏しない場合が存し、多すぎても、効果が頭打ちになり、この系の自由度を損なう場合が存するためである。また、かかる成分は、細胞内に於ける標的分子に対し高い選択性を有するため、高い安全性が期待される。さらに、一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩を含有する皮膚外用剤に於いて、マメ科ハギ属の植物の抽出物を、保湿などのプロトンポンプ阻害作用以外の作用を目的に配合した場合であっても、前記抽出物が、プロトンポンプ阻害作用を有する場合は、本願発明の構成と効果を充足するので、本発明の技術的範囲に属する。\n\n\nThe proton pump inhibitor of the present invention is 0.00001% by mass to 5% by mass, more preferably 0.00003% by mass to 3% by mass, and further preferably 0.00005% by mass to 1% by mass with respect to the total amount of the external preparation for skin. It is more preferable to make it contain. This is because, if the content of the proton pump inhibitor is too small, the activity of the tyrosinase enzyme via the acidifying action (proton pump inhibitory action) in the cell or organelle (proton pump inhibitory action) and the melanin production inhibitory action are not achieved. This is because there are cases where the combined effect with the above-mentioned alkyl resorcinol is not achieved, and even when the amount is too large, the effect reaches a peak and the degree of freedom of this system may be impaired. In addition, since such components have high selectivity for target molecules in cells, high safety is expected. Furthermore, in an external preparation for skin containing the compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof, an extract of a leguminous genus plant is added to a proton such as moisturizing. Even when blended for the purpose other than the pump inhibitory action, if the extract has a proton pump inhibitory action, it satisfies the configuration and effect of the present invention, and therefore belongs to the technical scope of the present invention. .\n\n\n\n\n\n\n\n \n\n＜製造例１：マメ科ハギ属キハギより得られる抽出物の製造製法＞\n\n本発明におけるプロトンポンプ阻害剤は、マメ科ハギ属キハギより抽出し、評価に用いた。\n\nマメ科ハギ属キハギ（Lespedeza  buergeri  Miq．）  １（ｋｇ）の地上部にメタノ−ル  ５（L）を加え還流下、３時間抽出し、吸引濾過により抽出液を得た。得られた抽出液を減圧下にて濃縮し、熱水５００（ｍL）に懸濁した後、エ−テルにて連続抽出を３時間行った。エ−テル層を減圧下にて濃縮し、褐色のエキス  ５．８３（ｇ）を得た。\n\n<Production Example 1: Manufacturing method of extract obtained from leguminous genus Kihagi> \n The proton pump inhibitor in the present invention was extracted from leguminous genus Kihagi and used for evaluation. \n Methanol 5 (L) was added to the above-ground part of a leguminous genus Kihagi (Lespedeza buergeri Miq.) 1 (kg), extracted under reflux for 3 hours, and an extract was obtained by suction filtration. The obtained extract was concentrated under reduced pressure, suspended in hot water 500 (mL), and then continuously extracted with ether for 3 hours. The ether layer was concentrated under reduced pressure to obtain brown extract 5.83 (g).\n\n\n\n\n\n\n \n\n＜製造例２：マメ科ハギ属キハギより得られる化合物１〜３の精製方法＞\n\n前記のマメ科ハギ属キハギより得られたエ−テル層をシリカゲルカラムクロマトグラフィ−（PSQ−１００B、富士シリシア化学株式会社、展開溶媒：クロロホルム：メタノ−ル＝９７：３→９０：１０）に付した後、さらに、液体クロマトグラフィ−（カラム：Iｎertsil  ODS−３  ３×５０ｃｍ、溶媒：水：アセトニトリル＝４２：５８→１９：８１、UV検出：２０５nm）により分取を行い、一般式（１）に表される化合物、特に、Euchrenone a６（化合物１）、Euchrenone a３（化合物２）、amorisin（化合物３）を得た。\n\n<Production Example 2: Purification method of compounds 1 to 3 obtained from leguminous genus Kihagi> \n The ether layer obtained from the above-mentioned leguminous genus Kihagi was subjected to silica gel column chromatography (PSQ-100B, Fuji Silysia Chemical Ltd., developing solvent: chloroform: methanol = 97: 3 → 90: 10). After that, further fractionation was performed by liquid chromatography (column: Innertsil ODS-3 3 × 50 cm, solvent: water: acetonitrile = 42: 58 → 19: 81, UV detection: 205 nm) to obtain the general formula (1). The compounds represented, in particular Euchrenone a6 (Compound 1), Euchrenone a3 (Compound 2) and amorisin (Compound 3) were obtained.\n\n\n\n\n\n\n \n\n＜評価１：マメ科ハギ属キハギより得られる抽出物、化合物１〜３のメラニン産生抑制作用＞\n\n  前記の方法により得られたマメ科ハギ属キハギの抽出物及び化合物１〜３のメラニン産生抑制作用を以下の手順に従い評価した。２４穴プレ−トにヒト正常メラノサイト（クラボウ株式会社）を２２５００（cells/ｃｍ２）播種し、翌日、評価サンプルを含有した培地  ０．５（ｍL/well）に交換し、０．２５（μCi）２−[２−１４C]チオウラシル（GEヘルスケアバイオサイエンス社）を添加し培養を継続した。播種４日後、培地を除去しPBSで１回プレ−トを洗浄した後、細胞生存率を評価するため生細胞数測定試薬SF（ナカライテスク社）溶液を添加した培地に交換し、３７℃、３時間呈色反応を行った。反応後、４５０（nm）の吸光度をマイクロプレ−トリ−ダ−Benchmark  Plus（Bio-Rad Laboratories）を用いて測定した。コントロ−ルとして評価サンプルを含まないサンプルを前記同様に調製し、コントロ−ルに対する各化合物の吸光度の百分率を求め細胞生存率とした。\n\n  メラニン量測定のため吸光度測定後、PBSで１回プレ−トを洗浄し、TCAを添加し、細胞を溶解した後、蒸留水を加え溶液をバイアルに移した。さらに蒸留水を添加し、溶液を回収した。氷上にて放置後、１５０００ｒｐｍ、５分間遠心した後、上清を除去した。再度、各バイアルに１０％ＴＣＡを添加し、氷上にて放置した。１５０００ｒｐｍ、５分間遠心した後、上清を除去した。残渣にアクアゾ−ル−２（パ−キンエルマ−社）  １（ｍＬ）を添加し、液体シンチレ−ションカウンタ−  ＬＳＣ−６１００（アロカ社製）にて放射線量を測定した。コントロ−ルとして化合物を含まないサンプルを前記同様に調製し、コントロ−ルに対する各化合物の放射線量の百分率を求めメラニン量（％）とした。メラニン産生量の５０％阻害濃度（ＩＣ５０値）は、細胞毒性の認められない範囲でＳＡＳ software version 9.1.3（SAS  Institute Inc.）を用い算出した。本発明に於いて、メラニン産生抑制作用を有する物質とは、ヒト正常メラノサイトを用いたメラニン産生抑制作用評価において、細胞毒性の認められない濃度においてコントロ−ルと比較しメラニン産生量を５０％以下のレベルに低下させる作用を有する場合を意味する。これは、メラニン産生抑制作用が低い物質を配合した場合には、期待されるメラニン産生抑制作用が現われないためである。また、メラニン産生抑制作用を有する陽性対照としては、ハイドロキノンを用いた。結果を表１に表す。\n\n<Evaluation 1: Extract obtained from leguminous genus Kihagi, melanin production inhibitory action of compounds 1 to 3> \n The melanin production inhibitory action of the leguminous genus Kihagi obtained by the above method and the compounds 1 to 3 was evaluated according to the following procedure. A 24-well plate was seeded with 22500 (cells / cm 2) of normal human melanocytes (Kurabo Co., Ltd.), and the following day, the medium was replaced with 0.5 (mL / well) containing an evaluation sample, and 0.25 (μCi) 2- [2-14C] thiouracil (GE Healthcare Bioscience) was added and the culture was continued. Four days after seeding, the medium was removed, and the plate was washed once with PBS. Then, in order to evaluate cell viability, the medium was replaced with a medium to which a viable cell count reagent SF (Nacalai Tesque) was added, The color reaction was carried out for 3 hours. After the reaction, the absorbance at 450 (nm) was measured using a microplate reader Benchmark Plus (Bio-Rad Laboratories). A sample containing no evaluation sample as a control was prepared in the same manner as described above, and the percentage of the absorbance of each compound relative to the control was determined to obtain the cell viability. \n After measuring the absorbance to measure the amount of melanin, the plate was washed once with PBS, TCA was added, the cells were lysed, distilled water was added, and the solution was transferred to a vial. Further distilled water was added and the solution was recovered. After leaving it on ice, it was centrifuged at 15000 rpm for 5 minutes, and then the supernatant was removed. Again, 10% TCA was added to each vial and left on ice. After centrifugation at 15000 rpm for 5 minutes, the supernatant was removed. Aquazol-2 (Perkin Elmer) 1 (mL) was added to the residue, and the radiation dose was measured with a liquid scintillation counter LSC-6100 (Aloka). A sample containing no compound as a control was prepared in the same manner as described above, and the percentage of the radiation dose of each compound with respect to the control was determined and used as the amount of melanin (%). The 50% inhibitory concentration (IC50 value) of melanin production was calculated using SAS software version 9.1.3 (SAS Institute Inc.) within a range where cytotoxicity was not observed. In the present invention, a substance having an inhibitory action on melanin production refers to a melanin production amount of 50% or less compared to control at a concentration where cytotoxicity is not observed in the evaluation of melanin production inhibitory action using normal human melanocytes. It means a case where it has an action of lowering to the level of. This is because when a substance having a low melanin production inhibitory effect is blended, the expected melanin production inhibitory effect does not appear. Moreover, hydroquinone was used as a positive control having a melanin production inhibitory effect. The results are shown in Table 1.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  表１の結果より、本発明のフラボノイド誘導体（化合物１〜３）は、顕著なメラニン産生抑制作用を有していることが判った。陽性対照のハイドロキノンも優れたメラニン産生抑制作用を示しており、この評価系の客観性も認められた。かかる陽性対照に比して、化合物１及び２は優れたメラニン産生抑制作用を示しており、化合物３は、陽性対照と同等乃至はそれ以上のメラニン産生抑制作用を示していることが判る。また、マメ科ハギ属キハギより得られる抽出物は、０．０００４４（ｗ/ｖ％）の濃度において、メラニン産生を５０％抑制した。前記結果より、マメ科ハギ属キハギより得られる抽出物は、顕著なメラニン産生抑制作用を有することが判る。\n\n\n  From the results in Table 1, it was found that the flavonoid derivatives (compounds 1 to 3) of the present invention have a remarkable melanin production inhibitory action. The positive control hydroquinone also showed an excellent melanin production inhibitory effect, and the objectivity of this evaluation system was also observed. Compared to such a positive control, compounds 1 and 2 show an excellent melanin production inhibitory action, and compound 3 shows that the melanin production inhibitory action is equal to or higher than that of the positive control. In addition, the extract obtained from the legume genus Kihagi inhibited melanin production by 50% at a concentration of 0.00044 (w / v%). From the above results, it can be seen that the extract obtained from the leguminous genus Kihagi has a remarkable melanin production inhibitory action.\n\n\n\n\n\n\n\n \n\n＜評価２：マメ科ハギ属キハギより得られる化合物１〜３のチロシナ−ゼ直接阻害作用＞\n\n  前記の如くマメ科ハギ属キハギより得られる化合物１〜３に関し、以下の手順に従いチロシナ−ゼ阻害活性を測定した。ヒト正常メラノサイト（クラボウ株式会社）をセルスクレ−パ−にて剥離し、バイアルに移し、５０００ｒｐｍ、５分間遠心して細胞を回収した後、ｌysis  buffer[１％  nonidet  P-４０、１００mM  NaCｌ、２mM  EDTA、０．５％deoxycholate（DOC）、２mM  phenylmethylsulfonyl  fluoride（PMSF）、１mM  Na3VO4、１０μｇ/mL  aprotinin及び１０μｇ／mL  leupeptin]を含有した５０mM  Tris-HCｌ  buffer（pH７．６）]にて溶解した。溶解液を１５０００ｒｐｍ、５分間遠心し、上清を回収し細胞抽出液とした。細胞抽出液のタンパク量は、Bio-Rad Dc Protein Assay Kit（Bio-Rad Laboratories）を用いて定量した。９６穴プレ−トの１ウェルあたりに評価物質又はフェニルチオウレア（陽性対照）を含有する培地  １０μLと基質の０．１％dihydroxyphenylalanine（L-DOPA）（和光純薬工業株式会社）  ５０μLを添加・混合し、さらに細胞抽出液（蛋白量１０μｇ）を添加・混合して酵素反応を行い、マイクロプレ−トリ−ダ−を用いて３７℃保温下にて４５０nmの吸光度を１５分間測定した。コントロ−ルとして評価物質を含まないサンプルも前記同様に調製し、測定した。チロシナ−ゼ活性の５０％阻害濃度（IC５０値）は、評価物質無添加サンプル（陰性対照）の吸光度を１００％とした場合の各評価物質添加サンプルの吸光度の割合を算出し、縦軸に吸光度（％陰性対照）、横軸に各評価物質添加サンプル添加濃度を設定したグラフを作成し、近類曲線の傾きにより求めた。本発明に於いて、チロシナ−ゼ直接阻害作用を有しない物質とは、ヒト正常メラノサイトの細胞抽出液を用いたチロシナ−ゼ直接阻害作用評価において、メラニン産生抑制作用を示した被験物質の濃度に比較し、１００倍以上の濃度の評価物質を反応系に添加してもチロシナ−ゼ直接阻害作用を示さなかった物質を意味する。表２に、上記方法により測定されたフラバノン誘導体（化合物１〜３）及びフェニルチオウレア（陽性対照）のチロシナ−ゼ直接阻害作用検討に関する結果を示す。\n\n<Evaluation 2: Tyrosinase direct inhibitory action of compounds 1 to 3 obtained from leguminous genus Kihagi> \n As described above, tyrosinase inhibitory activity was measured for compounds 1 to 3 obtained from the leguminous genus Kihagi according to the following procedure. Human normal melanocytes (Kurabo Co., Ltd.) were peeled off with a cell scraper, transferred to a vial, centrifuged at 5000 rpm for 5 minutes, and the cells were collected, followed by lysis buffer [1% nonidet P-40, 100 mM NaCl, 2 mM EDTA, It was dissolved in a 50 mM Tris-HCl buffer (pH 7.6) containing 0.5% deoxycholate (DOC), 2 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM Na3VO4, 10 μg / mL aprotinin and 10 μg / mL leupeptin]. The lysate was centrifuged at 15000 rpm for 5 minutes, and the supernatant was collected to obtain a cell extract. The amount of protein in the cell extract was quantified using the Bio-Rad Dc Protein Assay Kit (Bio-Rad Laboratories). Add 10 μL of the medium containing the evaluation substance or phenylthiourea (positive control) and 50 μL of 0.1% dihydroxyphenylalanine (L-DOPA) (Wako Pure Chemical Industries, Ltd.) as a substrate per well of 96-well plate Further, a cell extract (protein amount 10 μg) was added and mixed to carry out an enzyme reaction, and the absorbance at 450 nm was measured for 15 minutes at 37 ° C. using a microplate reader. A sample containing no evaluation substance as a control was prepared and measured in the same manner as described above. The 50% inhibitory concentration (IC50 value) of tyrosinase activity is calculated by calculating the ratio of the absorbance of each sample added with the evaluation substance when the absorbance of the sample without addition of the evaluation substance (negative control) is 100%. (% Negative control), a graph in which the concentration of each sample to be evaluated was added on the horizontal axis was prepared, and obtained from the slope of the related curve. In the present invention, the substance having no direct inhibitory effect on tyrosinase refers to the concentration of a test substance that showed an inhibitory action on melanin production in the evaluation of the direct inhibitory action of tyrosinase using a cell extract of normal human melanocytes. In comparison, it means a substance that did not show a tyrosinase direct inhibitory effect even when an evaluation substance having a concentration of 100 times or more was added to the reaction system. In Table 2, the result regarding the tyrosinase direct inhibitory effect examination of the flavanone derivative (compounds 1-3) and phenylthiourea (positive control) measured by the said method is shown.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n表２の結果より、前記キハギから得られるフラバノン誘導体（化合物１〜３）は、チロシナ−ゼ直接阻害作用を示さなかったのに対し、陽性対照のフェニルチオウレアは、顕著なチロシナ−ゼ直接阻害作用を示した。前記フラバノン誘導体（化合物１〜３）には、チロシナ−ゼ直接阻害作用がないことが判った。\n\n\nFrom the results of Table 2, the flavanone derivatives (compounds 1 to 3) obtained from the kihagi did not show a tyrosinase direct inhibitory action, whereas the positive control phenylthiourea showed a significant tyrosinase direct inhibitory action. showed that. It has been found that the flavanone derivatives (compounds 1 to 3) do not have a direct inhibitory effect on tyrosinase.\n\n\n\n\n\n\n\n \n\n＜評価３：マメ科ハギ属キハギより得られる化合物１〜３のWestern  Blot法によるチロシナ−ゼファミリ−タンパクの減少作用＞\n\n前記マメ科ハギ属キハギより得られる化合物１〜３に関し、以下の手順に従いWestern  Blot法によるチロシナ−ゼファミリ−タンパクの減少作用を測定した。\n\n  φ６ｃｍディッシュにヒト正常メラノサイト（クラボウ株式会社）を２２５００cells／cm２播種し、翌日、評価物質を含有する培地  ５ｍL/dishに交換し培養を継続した。播種後４日後、実施例２に記載の方法に従い細胞生存率を測定した。本発明のマメ科ハギ属キハギより得られる抽出物で処理した細胞を実施例３に記載の方法に従い細胞抽出液を得た。コントロ−ルとして評価物質を含有しないサンプルも前記同様に調製した。１２．５％ポリアクリルアミドゲルを用いて、１レ−ンあたりに細胞抽出液（タンパク量１０μｇ）を添加し、SDS-PAGE（ドデシル硫酸ナトリウム−ポリアクリルアミドゲル電気泳動にて分離したタンパク質をＰＶＤＦ膜にブロッティングし、３％スキムミルク／０．４％Tween２０含有PBSにて室温１時間ブロッキングを行った。０．４％Tween２０含有PBSにて洗浄後、抗体反応を実施した。１次抗体は、それぞれ抗チロシナ−ゼ（H-１０９）抗体、抗TYRP1（H-９０）抗体、抗TYRP２（D-１８）抗体（いずれもSanta Cruz  Biotechnology,  Inc.）を０．５％スキムミルク／０．４％Tween２０含有PBSにて１：４００希釈し、室温１時間、PVDF膜と共にインキュベ−ションした。なお、内部標準としてβ−actinを用いた。０．４％Tween２０含有PBSにて洗浄後、ペルオキシダ−ゼ標識された二次抗体と共に再度室温１時間、PVDF膜をインキュベ−ションし、抗体反応を行った。反応終了後、０．４％Tween２０含有PBSにて洗浄し、ECLPlus  Western Blotting Detection Reagents（GEヘルスケアバイオサイエンス社）を用いて検出した。本発明に於いて、チロシナ−ゼファミリ−タンパク減少作用を有しない物質とは、ヒト正常メラノサイト細胞抽出液を用いたチロシナ−ゼファミリ−タンパクに対する影響の検討において、コントロ−ルと比較し、有意なチロシナ−ゼファミリ−タンパク減少作用を有しない場合を意味する。結果を図１に示す。\n\n<Evaluation 3: Reduction effect of tyrosinase family protein by Western Blot method of compounds 1 to 3 obtained from leguminous genus Kihagi> \n With respect to the compounds 1 to 3 obtained from the leguminous genus Kihagi, the tyrosinase family protein reducing action by Western Blot method was measured according to the following procedure. \n A normal human melanocyte (Kurabo Co., Ltd.) was seeded in a φ6 cm dish at 22500 cells / cm 2, and the next day, the medium was replaced with a 5 mL / dish medium containing an evaluation substance, and the culture was continued. Four days after seeding, cell viability was measured according to the method described in Example 2. A cell extract was obtained according to the method described in Example 3 for cells treated with an extract obtained from the leguminous genus Kihagi of the present invention. A sample containing no evaluation substance as a control was prepared in the same manner as described above. Using a 12.5% polyacrylamide gel, a cell extract (protein amount 10 μg) was added per lane, and the protein separated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) was converted into a PVDF membrane. And washed with PBS containing 3% skim milk / 0.4\n% Tween\n 20 at room temperature for 1 hour, washed with PBS containing 0.4\n% Tween\n 20, and then subjected to an antibody reaction. Tyrosinase (H-109) antibody, anti-TYRP1 (H-90) antibody, anti-TYRP2 (D-18) antibody (both Santa Cruz Biotechnology, Inc.) containing 0.5% skim milk / 0.4% Tween20 Dilute 1: 400 in PBS, and incubate with PVDF membrane for 1 hour at room temperature, β-actin was used as an internal standard. The PVDF membrane was incubated again for 1 hour at room temperature with the labeled secondary antibody, and the antibody reaction was carried out.After completion of the reaction, the membrane was washed with PBS containing 0.4\n% Tween\n 20, and ECLPlus Western Blotting Detection Reagents (GE Health In the present invention, a substance that does not have a tyrosinase family protein-reducing action is used in the examination of effects on tyrosinase family proteins using human normal melanocyte cell extracts. In comparison with the control, this means that there is no significant tyrosinase family protein-reducing effect, and the results are shown in FIG.\n\n\n\n\n\n\n \n\n図１の結果より、前記フラバノン誘導体（化合物１〜３）には、チロシナ−ゼファミリ−タンパクの減少作用を有していないことが判った。\n\n\nFrom the results of FIG. 1, it was found that the flavanone derivatives (compounds 1 to 3) do not have a tyrosinase family protein reducing action.\n\n\n\n\n\n\n\n \n\n＜評価４：前記マメ科ハギ属キハギより得られる化合物１〜３及び抽出物のメラノソ−ム内酸性化検出＞\n\n前記マメ科ハギ属キハギより得られる化合物１〜３及び抽出物に関し、以下の手順に従い、生細胞内酸性化検出を行った。\n\nヒト正常メラノサイト（クラボウ株式会社）を４ウェルLab-Tek chamber slide（Thormo Fisher Scientific社）に１００００cells／cm２播種し、翌日、評価物質を含有する培地  ０．５ｍL／wellに交換し、１時間３０分培養した。コントロ−ルとして評価物質を含まないサンプルを前記同様に調製した。その後、３−（２，４−dinotroanilino）−３’−amino−Ｎ−methyldipropylamine（DAMP、Biomedical  Research社）を加え、３０分間培養した。培養終了後、PBSにて洗浄し、４％パラホルムアルデヒドで室温１５分固定を行った。次いで、PBSにてウェルを洗浄し、４℃、２分間放置した、その後、１０％FBS／PBSで室温、３０分ブロッキングを行った。抗体反応として抗チロシナ−ゼ抗体（C-１９：Santa Cruz Biotechnology, Inc）と抗DAMP抗体（ab２４３１９：abcam）をそれぞれブロッキング溶液で１：１００希釈した溶液を添加し、３７℃、４５分間インキュベ−ションした。反応終了後、ＰＢＳにてウェルを洗浄し、Ｃｙ３標識ウサギ抗ヤギ抗体（Invitrogen Corporation）とFITC標識ラット抗マウスIgE抗体（American  research  Products、Inc.）をそれぞれブロッキング溶液で１：１００希釈した溶液を添加し、３７℃、４５分間インキュベ−ションした。PBSにてウェルを洗浄し、スライドガラスでサンプルを封入し、共焦点レ−ザ−顕微鏡（LSM５１０：Zeiss）にて観察した。本発明に於いて、プロトンポンプ阻害作用を有する物質とは、前記のヒト正常メラノサイトを用いたメラノソ−ム内酸性化（プロトンポンプ阻害作用）評価において、pH感受性蛍光色素の発色強度が、レ−ザ−顕微鏡による目視的観察により発色強度の増強が認められる場合を意味する。結果を図２及び図３に示す。\n\n<Evaluation 4: Detection of acidification in melanosomes of compounds 1 to 3 and extracts obtained from the leguminous genus Kihagi> \n With respect to the compounds 1 to 3 and the extract obtained from the legume genus Kihagi, live cell acidification was detected according to the following procedure. \n Normal human melanocytes (Kurabo Co., Ltd.) were seeded in a 4-well Lab-Tek chamber slide (Thormo Fisher Scientific) at 10000 cells / cm 2, and the next day, the medium containing the evaluation substance was replaced with 0.5 mL / well, and 1 hour 30 minutes. Cultured. A sample containing no evaluation substance as a control was prepared in the same manner as described above. Thereafter, 3- (2,4-dinotroanilino) -3′-amino-N-methyldipropylamine (DAMP, Biomedical Research) was added and cultured for 30 minutes. After completion of the culture, the cells were washed with PBS and fixed with 4% paraformaldehyde for 15 minutes at room temperature. Next, the wells were washed with PBS and allowed to stand at 4 ° C. for 2 minutes, and then blocked with 10% FBS / PBS at room temperature for 30 minutes. As an antibody reaction, an anti-tyrosinase antibody (C-19: Santa Cruz Biotechnology, Inc) and an anti-DAMP antibody (ab24319: abcam) were each diluted 1: 100 with a blocking solution and incubated at 37 ° C. for 45 minutes. I did. After completion of the reaction, the wells were washed with PBS, and a solution obtained by diluting Cy3-labeled rabbit anti-goat antibody (Invitrogen Corporation) and FITC-labeled rat anti-mouse IgE antibody (American research Products, Inc.) 1: 100 with a blocking solution, respectively. And incubated at 37 ° C. for 45 minutes. The wells were washed with PBS, the sample was sealed with a slide glass, and observed with a confocal laser microscope (LSM510: Zeiss). In the present invention, the substance having a proton pump inhibitory action means that the coloring intensity of the pH-sensitive fluorescent dye is the label in the above-described evaluation of acidification (proton pump inhibitory action) in melanosomes using normal human melanocytes. It means a case where an increase in coloring intensity is observed by visual observation with a scanning microscope. The results are shown in FIGS.\n\n\n\n\n\n\n \n\n評価物質無処理のコントロ−ルに比較し、評価物質処理によりDAMPの蛍光強度（緑色）が増強していれば、ヒト正常メラノサイト内の酸性化が亢進したと考えられる。さらに、チロシナ−ゼの検出も同時に行い、DAMP染色領域と重ねあわせることで酸性化領域とメラノソ−ムの共局在性を確認できる。即ち、チロシナ−ゼの局在を示す赤色と、酸性化領域の局在を示す緑色が重ね合わさった黄色の発色が認められれば、メラノソ−ム内が酸性化していることが判る。結果を図２及び図３に示す。図２において、コントロ−ルでは、酸性化度を示す緑色の染色は薄く、チロシナ−ゼの存在を示す赤色の染色は濃く、これを重ね合わせた写真はオレンジ色を呈しており、化合物１においては、酸性化度を示す緑色の染色が濃くなっており、チロシナ−ゼの存在を示す赤色の染色はコントロ−ルと同程度であり、これを重ね合わせた写真は黄色を呈している。化合物２においては、緑色の染色は、コントロ−ルより明確に濃くなっているが、化合物１には及ばず、チロシナ−ゼの存在は、コントロ−ル、化合物１と同程度であり、この重ね合わせは黄色より幾分オレンジ色がかっている。化合物３では、化合物２よりも緑色の染色が少ないが、コントロ−ルよりは強く、チロシナ−ゼの存在は同程度であり、重ね合わせは、化合物２によりオレンジがかっているが、コントロ−ルほどではない。これらから、酸性化度の度合いは、化合物１＞化合物２>化合物３＞コントロ−ルであることが判る。また、図３においては、図２と同様にコントロ−ルは、酸性化度を示す緑色の染色は薄く、チロシナ−ゼの存在を示す赤色の染色は濃く、これを重ね合わせた写真はほぼ赤色を呈しており、抽出物においては、酸性化度を示す緑色の染色が濃くなっており、チロシナ−ゼの存在を示す赤色の染色はコントロ−ルと同程度であり、これを重ね合わせた写真は黄色を呈している。\n\n図２及び図３の結果より、マメ科ハギ属キハギより得られた化合物１〜３及び抽出物は、顕著なメラノサイト内における酸性化作用（プロトンポンプ阻害作用）を示すことが判った。\n\n尚、前記の結果を踏まえ、プロトンポンプ阻害作用を介するメラノサイト内の酸性化を以って、メラノサイト内のチロシナ−ゼ活性を阻害する機作のメラニン産生抑制作用の代替値として、このメラノソ−ム内の酸性化作用を用いることが出来ることも判る。かかる作用を有する成分を、プロトンポンプ阻害作用を機作とするメラニン産生抑制剤と見なし、本発明の組成物においては、かかるプロトンポンプ阻害作用を機作とするメラニン産生抑制剤を以て、プロトンポンプ阻害剤として扱う。これはかかるメラノソーム内のｐHを酸性化し、チロシナーゼ活性を低下させることが本発明の効果に関わるからである。\n\nIf the fluorescence intensity (green) of DAMP is enhanced by treatment with the evaluation substance compared to the control without treatment with the evaluation substance, it is considered that acidification in normal human melanocytes is enhanced. Furthermore, tyrosinase is simultaneously detected, and the co-localization of the acidified region and melanosomes can be confirmed by overlapping with the DAMP stained region. That is, if a red color indicating the localization of tyrosinase and a yellow color that overlaps the green color indicating the localization of the acidified region are recognized, it can be understood that the melanosomes are acidified. The results are shown in FIGS. In FIG. 2, in the control, the green staining indicating the acidification degree is light, the red staining indicating the presence of tyrosinase is dark, and the photograph in which these are superimposed shows an orange color. The green staining indicating the degree of acidification is dark, the red staining indicating the presence of tyrosinase is similar to the control, and the photograph in which this is superimposed is yellow. In compound 2, the green staining is clearly darker than that of the control, but does not reach that of compound 1, and the presence of tyrosinase is similar to that of control, compound 1, and this overlap. The combination is a little more orange than yellow. Compound 3 has less green staining than Compound 2, but is stronger than the control and has the same presence of tyrosinase, and the overlay is orange due to Compound 2, but the control is not. From these, it can be seen that the degree of acidification is compound 1> compound 2> compound 3> control. In FIG. 3, as in FIG. 2, the control shows that the green staining indicating acidity is thin, the red staining indicating the presence of tyrosinase is dark, and the superimposed photo is almost red. In the extract, the green staining indicating the degree of acidification is dark, and the red staining indicating the presence of tyrosinase is the same as the control. Is yellow. \n From the results of FIGS. 2 and 3, it was found that the compounds 1 to 3 and the extract obtained from the leguminous genus Kihagi showed a remarkable acidifying action (proton pump inhibitory action) in melanocytes. \n Based on the above results, this melanosome can be used as an alternative value for the melanin production inhibitory action of the mechanism that inhibits tyrosinase activity in melanocytes by acidification in melanocytes via proton pump inhibitory action. It can also be seen that the acidification effect can be used. The component having such an action is regarded as a melanin production inhibitor whose mechanism is a proton pump inhibitory action. In the composition of the present invention, a proton pump inhibitor is used with a melanin production inhibitor whose mechanism is such a proton pump inhibitory action. Treat as an agent. This is because acidifying the pH in such melanosomes and reducing the tyrosinase activity is related to the effect of the present invention.\n\n\n\n\n\n\n \n\n＜本発明の組成物＞\n\n本発明の組成物は、１）前記一般式（１）に表される化合物及び／又はそれらの薬理学的に許容される塩と、２）プロトンポンプ阻害剤とを含有することを特徴とする。前記必須成分を含有する組成物の作製にあたっては、前記必須成分以外に、通常医薬、化粧品、食品、飲料の製剤化で使用される任意成分を含有することが出来る。また、本発明の組成物の投与経路としては、経口投与、経皮投与の何れもが可能である。また、かかる成分が連続投与される場合、さらには安全性を考慮した場合、経皮的に投与されることが好ましい。経皮的に投与されるものであれば特段の限定なく応用出来、例えば、医薬部外品を含む化粧料、皮膚外用医薬、皮膚外用雑貨等が好ましく例示できる。これは本発明の皮膚外用剤が、比類無き使用感の良さを有しているため、使用感が重要な化粧料に特に好適であるためである。化粧料としては、油中水乳化剤形を応用できるものであれば、特段の限定はなく、例えば、エッセンス、乳液、クリ−ム等の基礎化粧料、アンダ−メ−クアップ、ファンデ−ション、チ−クカラ−、マスカラ、アイライナ−などのメ−クアップ化粧料、ヘアクリ−ムなどの毛髪化粧料などが好適に例示できる。\n\n<Composition of the present invention> \n The composition of the present invention comprises 1) a compound represented by the general formula (1) and / or a pharmacologically acceptable salt thereof, and 2) a proton pump inhibitor. . In preparing the composition containing the essential ingredients, in addition to the essential ingredients, optional ingredients that are usually used in the preparation of pharmaceuticals, cosmetics, foods, and beverages can be contained. Moreover, as an administration route of the composition of the present invention, either oral administration or transdermal administration is possible. In addition, when such a component is continuously administered, and further in consideration of safety, it is preferably administered transdermally. As long as it is administered transcutaneously, it can be applied without any particular limitation. For example, cosmetics including quasi-drugs, external medicines for skin, sundry goods and the like can be preferably exemplified. This is because the external preparation for skin of the present invention has an unparalleled feeling of use and is particularly suitable for cosmetics where the feeling of use is important. The cosmetic is not particularly limited as long as the water-in-oil emulsifier form can be applied. For example, basic cosmetics such as essence, milky lotion, cream, under-makeup, foundation, -Makeup cosmetics such as kukara, mascara, and eyeliner, and hair cosmetics such as hair cream can be preferably exemplified.\n\n\n\n\n\n\n \n\n本発明の皮膚外用剤に於いては、前記必須成分に加えて、油中水乳化剤形を形成するための乳化剤を含有することが好ましく、該乳化剤としては、有機変性粘土鉱物やジグリセリンモノオレ−トやトリグリセリンジイソステアレ−ト等が好適に例示できる。ジグリセリンモノオレ−トを乳化剤として用いる場合に於いては、必須成分としての量に、乳化のための量を積算し、安定化作用のための役割と、乳化のための役割を兼ねさせることもできる。\n\n\nThe skin external preparation of the present invention preferably contains an emulsifier for forming a water-in-oil emulsifier form in addition to the essential components, and the emulsifier includes an organically modified clay mineral or diglycerin monooleate. -Glycine and triglycerin diisostearate can be preferably exemplified. When diglycerin monooleate is used as an emulsifier, the amount for emulsification is added to the amount as an essential component, and the role for stabilization and the role for emulsification are combined. You can also.\n\n\n\n\n\n\n\n \n\n前記有機変性粘土鉱物に於いて、有機変性とは、粘土鉱物の一部に有機化合物の一部を共有結合乃至はイオン結合を介して強固乃至は緩やかな結合を生ぜしめ、有機化合物の性質の一部乃至は全部を粘土鉱物に付与させることを意味し、この様な変性としては４級アミン基と粘土鉱物のアニオン部分を結合させる方法、カルボキシル基と粘土鉱物のカチオン部分を結合させる方法等が例示でき、４級アミン基と粘土鉱物のアニオン部分を結合させる方法が特に好ましく例示できる。\n\n\nIn the organically modified clay mineral, organically modified means that a part of the organic compound is bonded to a part of the clay mineral to form a strong or loose bond through a covalent bond or an ionic bond. This means that a part or all of the mineral is imparted to the clay mineral. Examples of such modifications include a method of bonding a quaternary amine group and an anion portion of the clay mineral, a method of bonding a carboxyl group and a cation portion of the clay mineral, etc. And a method of binding a quaternary amine group and an anion portion of a clay mineral is particularly preferable.\n\n\n\n\n\n\n\n \n\n粘土鉱物を変性させる４級アミノ基を有する化合物としては、特に限定されるわけではないが、クオタニウムと称される化合物が例示される。クオタニウムとは、低分子の置換第４級アンモニウム塩であって、国際基準化粧品原材料（ＩＮＣＩ）に登録された化粧料原料が好ましい。さらに、粘土鉱物を変性させる４級アミノ基を有する化合物は、クオタニウム化合物のなかでも、従来の皮膚外用剤に含有されるクオタニウム化合物であることが好ましい。従来の皮膚外用剤で使用されているクオタニウム化合物としては、ステアリルトリメチルアンモニウムクロリド、ジメチルジステアリルアンモニウムクロリド等が好ましく例示される。ステアリルトリメチルアンモニウムクロリド、ジメチルジステアリルアンモニウムクロリド等は、粘土鉱物とともに安定な油中水乳化構造を形成することができるので好ましい。\n\n\nAlthough it does not necessarily limit as a compound which has a quaternary amino group which modifies a clay mineral, The compound called quaternium is illustrated. Quotanium is a low molecular weight substituted quaternary ammonium salt, and is preferably a cosmetic raw material registered in International Standard Cosmetic Ingredients (INCI). Furthermore, the compound having a quaternary amino group that modifies the clay mineral is preferably a quaternium compound contained in a conventional external skin preparation among quaternium compounds. Preferred examples of the quaternium compound used in conventional external preparations for skin include stearyl trimethyl ammonium chloride and dimethyl distearyl ammonium chloride. Stearyl trimethyl ammonium chloride, dimethyl distearyl ammonium chloride and the like are preferable because they can form a stable water-in-oil emulsion structure together with clay minerals.\n\n\n\n\n\n\n\n \n\n一方、４級アミノ基を有する化合物で変性される粘土鉱物（未変性粘土鉱物）としては、従来の皮膚外用剤に含有される粘土鉱物であれば特段の限定無く使用することができる。従来の皮膚外用剤に含有される粘土鉱物としては、スメクタイト系のヘクトライト、ベントナイトやモンモリロナイト；カオリナイト；イライト；マリ−ン粘土鉱物（海泥）；デザ−トロ−ズ粘土鉱物；パスカライトなどが好ましく挙げられる。これらのうち、油中水乳化構造を安定化させることができるベントナイト、ヘクトライト、モンモリロナイト又はカオリナイトが好ましく例示される。\n\n\nOn the other hand, as a clay mineral (unmodified clay mineral) modified with a compound having a quaternary amino group, any clay mineral contained in a conventional skin external preparation can be used without any particular limitation. Examples of clay minerals contained in conventional external preparations for skin include smectite-type hectorite, bentonite and montmorillonite; kaolinite; illite; marine clay mineral (sea mud); dezatroze clay mineral; Preferably mentioned. Among these, bentonite, hectorite, montmorillonite or kaolinite which can stabilize the water-in-oil emulsion structure is preferably exemplified.\n\n\n\n\n\n\n\n \n\n本発明の皮膚外用剤に含有される４級アミノ基を有する化合物で変性された粘土鉱物の製造方法の一例を以下に説明する。前記未変性粘土鉱物を分散媒に分散させる。該分散剤は水系の溶媒であることが好ましく、水であってもよい。分散未変性粘土鉱物を含む分散液に、さらに４級アミノ基を有する化合物を加え、よく撹拌する。４級アミノ基を有する化合物は、水に溶解されて加えられてもよい。加えられる４級アミノ基を有する化合物の量は、分散未変性粘土鉱物の量に対して０．１〜２０質量％であることが好ましく、０．５〜１５質量％であることがより好ましい。この様な構成を取ることにより、乳化系において、好ましい使用感を呈するためである。撹拌後、分散質を濾取し、脱水、乾固することにより本発明における変性粘土鉱物を得ることができる。あるいは、分散質を濾取することなく、減圧濃縮することにより分散剤を除去して乾固させることにより、本発明における変性粘土鉱物を得ることもできる。得られた変性粘土鉱物は、好ましくは所望のサイズ（粒径が１〜１０００μｍであることが好ましい）に粉砕され、本発明の皮膚外用剤に含有される。\n\n\nAn example of a method for producing a clay mineral modified with a compound having a quaternary amino group contained in the external preparation for skin of the present invention will be described below. The unmodified clay mineral is dispersed in a dispersion medium. The dispersant is preferably an aqueous solvent, and may be water. A compound having a quaternary amino group is further added to the dispersion containing the dispersed unmodified clay mineral and stirred well. The compound having a quaternary amino group may be added after being dissolved in water. The amount of the compound having a quaternary amino group to be added is preferably 0.1 to 20% by mass, and more preferably 0.5 to 15% by mass with respect to the amount of the dispersed unmodified clay mineral. This is because by taking such a configuration, a preferable feeling of use is exhibited in the emulsification system. After stirring, the dispersoid is filtered, dehydrated and dried to obtain the modified clay mineral in the present invention. Or the modified clay mineral in this invention can also be obtained by removing a dispersing agent by concentrating under reduced pressure without filtering a dispersoid, and making it dry. The obtained modified clay mineral is preferably pulverized to a desired size (preferably having a particle size of 1 to 1000 μm) and contained in the skin external preparation of the present invention.\n\n\n\n\n\n\n\n \n\n本発明における変性粘土鉱物は、前述したように調製して使用されることもできるが、市販されているものを使用することもできる。市販されている変性粘土鉱物には、化粧料などの皮膚外用剤などとして用いられているものもある。市販されている変性粘土鉱物としては、例えば、エレメンティス社より「ベントン３８Ｖ」の名称で販売されている、ジメチルジステアリルアンモニウム変性ヘクトライトなどが好ましく例示される。\n\n\nThe modified clay mineral in the present invention can be prepared and used as described above, but commercially available ones can also be used. Some modified clay minerals on the market are used as external preparations for skin such as cosmetics. Preferable examples of commercially available modified clay minerals include dimethyl distearyl ammonium modified hectorite sold under the name “Benton 38V” by Elementis.\n\n\n\n\n\n\n\n \n\n本発明の皮膚外用剤においては、かかる成分は０．５〜１０質量％好ましく含有され、より好ましくは１〜５質量％含有される。かかる成分は、前記の含有量の範囲において、乳化剤として、高内相の油中水乳化剤形を形成すべく働く。\n\n\nIn the skin external preparation of this invention, this component is contained preferably 0.5-10 mass%, More preferably, 1-5 mass% is contained. Such an ingredient acts as an emulsifier in the above-mentioned content range to form a high internal phase water-in-oil emulsifier form.\n\n\n\n\n\n\n\n \n\nジグリセリンモノオレ−ト及び／又はトリグリセリンジイソステアレ−トを乳化剤として含有する場合には、かかる乳化剤の質量の０．５〜２倍のマルチト−ルやソルビト−ルの様な多価アルコ−ルをともに含有させることが好ましい。前記ジグリセリンモノオレ−トの化粧料用の原料としては、「ニッコ−ルＤＧＭＯ−Ｃ」（日本サ−ファクタント株式会社製）が好ましく例示できるし、トリグリセリンジイソステアレ−トの化粧料用の原料としては、「エメレスト２４５２」（エメリ−社製）などが好ましく例示できる。かかる成分の好ましい含有量は、皮膚外用剤全量に対して、１〜１０質量％であり、より好ましくは２〜７質量％である。これはこの量範囲を逸脱すると乳化できない場合や安定性が損なわれる場合が存するためである。\n\n\nWhen diglycerin monooleate and / or triglycerin diisostearate is contained as an emulsifier, a polyhydric alcohol such as a multi-toll or sorbitol having a mass of 0.5 to 2 times the mass of the emulsifier. -It is preferable to contain together. Preferred examples of the raw material for the diglycerin monooleate cosmetics include “Nikko DGMO-C” (manufactured by Nippon Surfactant Co., Ltd.), and triglycerin diisostearate for cosmetics. Preferred examples of the raw material include “Emerest 2452” (manufactured by Emery). The preferable content of this component is 1 to 10% by mass, more preferably 2 to 7% by mass, based on the total amount of the external preparation for skin. This is because if the amount is out of the range, emulsification may not be possible or stability may be impaired.\n\n\n\n\n\n\n\n \n\n本発明の皮膚外用剤に於いては、前記必須成分の他に、油性成分、水性成分ともに溶解しにくい成分、取り分け、ジメチコンなどのシリコ−ン類や流動パラフィンなどの炭化水素類のような非極性成分に難溶な成分を好ましく含有する。該溶解しにくい成分としては、例えば、フィトステロ−ル配糖体、スフィンゴ糖脂質、ウルソ−ル酸、ウルソ−ル酸のエステル及びこれらの塩が好適に例示できる。かかる成分は、皮膚に対して、光老化防止効果、タ−ンオ−バ−調整効果、保湿効果などの好ましい働きを有する、有効成分であり、前記フィトステロ−ルは、植物性ステロ−ル類の総称であり、植物性のステロ−ル類には、スチグマスタノ−ル、カンペステロ−ル、シトステロ−ルなどが存し、これらを一括して、フィトステロ−ルと総称している。フィトステロ−ル配糖体は、このフィトステロ−ルに糖鎖が結合したもので、該フィトステロ−ル配糖体としては小麦胚芽などの植物体から、複数のフィトステロ−ル配糖体を含有するステロ−ル配糖体分画を取り出して用いる場合が多く、この様な分画のみを精製した化粧料原料も市販されており、本発明のかかる市販原料を購入して利用することができる。通常この様な成分には、スフィンゴ糖脂質も同時に抽出されて含まれていることが多い。この様な市販原料としては、例えば、岡安商店株式会社から販売されている「フィトステサイド」などが存する。かかる「フィトステサイド」は約８５質量％がフィトステロ−ルの配糖体であり、約１５質量％がスフィンゴ糖脂質である。又、ウルソ−ル酸はロ−ズマリ−などの植物体に含有されるトリテルペン酸であり、このエステルは、ウルソ−ル酸から誘導される酸クロリドをアルカリの存在下、対応するアルコ−ルと縮合させることにより得ることができ、例えば、ウルソ−ル酸エチルエステル、ウルソ−ル酸ステアリルエステル、ウルソ−ル酸オレイルエステル、ウルソ−ル酸ベンジルエステル、ウルソ−ル酸フェネチルエステルなどが好適に例示できる。これらの内、特に好ましいものは、ウルソ−ル酸ベンジルエステル及びウルソ−ル酸リン酸エステルである。この様な溶けにくい有効成分、取り分け固形の成分の好ましい含有量は、それぞれ０．０５〜０．５質量％である。\n\n\nIn the external preparation for skin of the present invention, in addition to the essential components, oily components and aqueous components are difficult to dissolve, especially non-silicone such as dimethicone and non-hydrocarbons such as liquid paraffin. A component hardly soluble in the polar component is preferably contained. Preferable examples of the hardly soluble component include phytosterol glycosides, glycosphingolipids, ursolic acid, esters of ursolic acid, and salts thereof. Such an ingredient is an active ingredient having preferable functions such as a photoaging prevention effect, a turnover adjusting effect, a moisturizing effect on the skin, and the phytosterol is a phytosterol. The plant-based sterols include stigmasterol, campesterol, sitosterol, and the like, and these are collectively referred to as phytosterol. A phytosterol glycoside is obtained by binding a sugar chain to this phytosterol. As the phytosterol glycoside, a sterol containing a plurality of phytosterol glycosides from a plant such as wheat germ is used. -Glucose glycoside fractions are often taken out and used, and cosmetic raw materials obtained by purifying only such fractions are also commercially available, and such commercial raw materials of the present invention can be purchased and used. Usually, such components often contain glycosphingolipids extracted at the same time. Examples of such commercially available materials include “Phytosteside” sold by Okayasu Shoten Co., Ltd. About 85% by mass of such “phytosteside” is a glycoside of phytosterol, and about 15% by mass is a glycosphingolipid. Ursolic acid is triterpenic acid contained in plants such as rosemary, and this ester is obtained by converting acid chloride derived from ursolic acid to the corresponding alcohol in the presence of alkali. For example, ursolic acid ethyl ester, ursolic acid stearyl ester, ursolic acid oleyl ester, ursolic acid benzyl ester, ursolic acid phenethyl ester and the like are preferable examples. it can. Of these, ursolic acid benzyl ester and ursolic acid phosphate are particularly preferred. The preferable content of such an insoluble active ingredient, especially a solid component, is 0.05 to 0.5% by mass.\n\n\n\n\n\n\n\n \n\n本発明の皮膚外用剤は、油中水乳化剤形に形態を取るため、油中水乳化剤形の使用感、仕上がり感の欠点を補うために、シリコ−ン、特に好ましくは、シクロメチコン及び／又は粘度１ｍＰａ・ｓ以下のジメチコンを含有することが好ましく、該シリコ−ンの含有量としては、化粧料全量に対しては、１０〜５０質量％含有することが好ましく、より好ましくは、２０〜４０質量％であり、シクロメチコン及び粘度１ｍＰａ・ｓ以下のジメチコンの含有量の和が油相全量に対して、５０質量％以上、より好ましくは５５質量％以上であることが好ましい。\n\n\nSince the external preparation for skin of the present invention takes the form of a water-in-oil emulsifier form, in order to compensate for the drawbacks of the feeling of use and finish of the water-in-oil emulsifier form, silicone, particularly preferably cyclomethicone and / or It is preferable to contain dimethicone having a viscosity of 1 mPa · s or less, and the content of the silicone is preferably 10 to 50% by mass, more preferably 20 to 40% with respect to the total amount of the cosmetic. The sum of the contents of cyclomethicone and dimethicone having a viscosity of 1 mPa · s or less is 50% by mass or more, more preferably 55% by mass or more, based on the total amount of the oil phase.\n\n\n\n\n\n\n\n \n\n又、本発明の皮膚外用剤では、乳化剤として前記有機変性粘土鉱物を用いる場合、前記有機変性粘土鉱物の乳化作用を補助する意味で、ＰＯＥ変性メチルポリシロキサン、ＰＯＰ変性メチルポリシロキサン、ＰＯＰ・ＰＯＥ変性メチルポリシロキサン等のポリエ−テル変性メチルポリシロキサンを含有することが好適に例示できる。かかるポリエ−テル変性メチルポリシロキサンの好ましい含有量は、０．５〜５質量％、１〜３質量％がより好ましい。\n\n\nMoreover, in the skin external preparation of this invention, when using the said organic modified clay mineral as an emulsifier, in the meaning which assists the emulsification effect | action of the said organic modified clay mineral, POE modified methylpolysiloxane, POP modified methylpolysiloxane, POP · POE A suitable example is the inclusion of a polyether-modified methylpolysiloxane such as a modified methylpolysiloxane. The preferable content of such polyether-modified methylpolysiloxane is more preferably 0.5 to 5% by mass and 1 to 3% by mass.\n\n\n\n\n\n\n\n \n\n乳化剤として前記有機変性粘土鉱物を用いる場合、更に、上記の成分以外の好ましい任意成分としては、乳化状態を安定化できる、多価アルコ−ルが例示できる。特に、グリセリン、ジグリセリン、ジプロピレングリコ−ルが好適に例示できる。かかる成分は唯一種を含有することもできるし、二種以上を組み合わせて含有させることもできる。好ましい含有量は、総量で、皮膚外用剤全量に対して、５〜３０質量％であり、より好ましくは１０〜２５質量％である。更に加えて、１，２−ペンタンジオ−ル、１，２−ヘキサンジオ−ル及び１，２−オクタンジオ−ルから選択される１種乃至は２種以上を１〜７質量％含有させることも、防腐力を向上させる見地から好ましい。\n\n\nWhen the organically modified clay mineral is used as an emulsifier, a preferred optional component other than the above-described components can be exemplified by a polyhydric alcohol that can stabilize the emulsified state. Particularly preferred are glycerin, diglycerin and dipropylene glycol. Such a component may contain only one species or may contain two or more species in combination. A preferable content is 5-30 mass% with respect to the total amount of skin external preparations in total, More preferably, it is 10-25 mass%. In addition, 1 to 7% by mass of one or more selected from 1,2-pentanediol, 1,2-hexanediol, and 1,2-octanediol can also be contained. It is preferable from the viewpoint of improving power.\n\n\n\n\n\n\n\n \n\n上記以外にも、本発明の皮膚外用剤に於いては、本発明の効果を損ねない限度に於いて、通常使用される任意成分を含有することもできる。この様な任意成分としては、例えば、マカデミアナッツ油、アボガド油、トウモロコシ油、オリ−ブ油、ナタネ油、ゴマ油、ヒマシ油、サフラワ−油、綿実油、ホホバ油、ヤシ油、パ−ム油、液状ラノリン、硬化ヤシ油、硬化油、モクロウ、硬化ヒマシ油、ミツロウ、キャンデリラロウ、カルナウバロウ、イボタロウ、ラノリン、還元ラノリン、硬質ラノリン、ホホバロウ等のオイル、ワックス類；流動パラフィン、スクワラン、プリスタン、オゾケライト、パラフィン、セレシン、ワセリン、マイクロクリスタリンワックス等の炭化水素類；オレイン酸、イソステアリン酸、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘン酸、ウンデシレン酸等の高級脂肪酸類；セチルアルコ−ル、ステアリルアルコ−ル、イソステアリルアルコ−ル、ベヘニルアルコ−ル、オクチルドデカノ−ル、ミリスチルアルコ−ル、セトステアリルアルコ−ル等の高級アルコ−ル等；イソオクタン酸セチル、ミリスチン酸イソプロピル、イソステアリン酸ヘキシルデシル、アジピン酸ジイソプロピル、セバチン酸ジ−２−エチルヘキシル、乳酸セチル、リンゴ酸ジイソステアリル、ジ−２−エチルヘキサン酸エチレングリコ−ル、ジカプリン酸ネオペンチルグリコ−ル、ジ−２−ヘプチルウンデカン酸グリセリン、トリ−２−エチルヘキサン酸グリセリン、トリ−２−エチルヘキサン酸トリメチロ−ルプロパン、トリイソステアリン酸トリメチロ−ルプロパン、テトラ−２−エチルヘキサン酸ペンタンエリトリット等の合成エステル油類等の油剤類；脂肪酸セッケン（ラウリン酸ナトリウム、パルミチン酸ナトリウム等）、ラウリル硫酸カリウム、アルキル硫酸トリエタノ−ルアミンエーテル等のアニオン界面活性剤類；塩化ステアリルトリメチルアンモニウム、塩化ベンザルコニウム、ラウリルアミンオキサイド等のカチオン界面活性剤類；イミダゾリン系両性界面活性剤（２−ココイル−２−イミダゾリニウムヒドロキサイド−１−カルボキシエチロキシ２ナトリウム塩等）、ベタイン系界面活性剤（アルキルベタイン、アミドベタイン、スルホベタイン等）、アシルメチルタウリン等の両性界面活性剤類；ソルビタン脂肪酸エステル類（ソルビタンモノステアレ−ト、セスキオレイン酸ソルビタン等）、グリセリン脂肪酸類（モノステアリン酸グリセリン等）、プロピレングリコ−ル脂肪酸エステル類（モノステアリン酸プロピレングリコ−ル等）、硬化ヒマシ油誘導体、グリセリンアルキルエ−テル、ＰＯＥソルビタン脂肪酸エステル類（ＰＯＥソルビタンモノオレエ−ト、モノステアリン酸ポリオキエチレンソルビタン等）、ＰＯＥソルビット脂肪酸エステル類（ＰＯＥ−ソルビットモノラウレ−ト等）、ＰＯＥグリセリン脂肪酸エステル類（ＰＯＥ−グリセリンモノイソステアレ−ト等）、ＰＯＥ脂肪酸エステル類（ポリエチレングリコ−ルモノオレ−ト、ＰＯＥジステアレ−ト等）、ＰＯＥアルキルエ−テル類（ＰＯＥ２−オクチルドデシルエ−テル等）、ＰＯＥアルキルフェニルエ−テル類（ＰＯＥノニルフェニルエ−テル等）、プルロニック型類、ＰＯＥ・ＰＯＰアルキルエ−テル類（ＰＯＥ・ＰＯＰ２−デシルテトラデシルエ−テル等）、テトロニック類、ＰＯＥヒマシ油・硬化ヒマシ油誘導体（ＰＯＥヒマシ油、ＰＯＥ硬化ヒマシ油等）、ショ糖脂肪酸エステル、アルキルグルコシド等の非イオン界面活性剤類；ポリエチレングリコ−ル、グリセリン、エリスリト−ル、ソルビト−ル、キシリト−ル、マルチト−ル、プロピレングリコ−ル、２，４−ヘキサンジオ−ル等の多価アルコ−ル類；ピロリドンカルボン酸ナトリウム、乳酸、乳酸ナトリウム等の保湿成分類；表面を処理されていても良い、マイカ、タルク、カオリン、合成雲母、炭酸カルシウム、炭酸マグネシウム、無水ケイ酸（シリカ）、酸化アルミニウム、硫酸バリウム等の粉体類、；表面を処理されていても良い、ベンガラ、黄酸化鉄、黒酸化鉄、酸化コバルト、群青、紺青、酸化チタン、酸化亜鉛の無機顔料類；表面を処理されていても良い、雲母チタン、魚燐箔、オキシ塩化ビスマス等のパ−ル剤類；レ−キ化されていても良い赤色２０２号、赤色２２８号、赤色２２６号、黄色４号、青色４０４号、黄色５号、赤色５０５号、赤色２３０号、赤色２２３号、橙色２０１号、赤色２１３号、黄色２０４号、黄色２０３号、青色１号、緑色２０１号、紫色２０１号、赤色２０４号等の有機色素類；ポリエチレン末、ポリメタクリル酸メチル、ナイロン粉末、オルガノポリシロキサンエラストマ−等の有機粉体類；パラアミノ安息香酸系紫外線吸収剤；アントラニル酸系紫外線吸収剤；サリチル酸系紫外線吸収剤、；桂皮酸系紫外線吸収剤、；ベンゾフェノン系紫外線吸収剤；糖系紫外線吸収剤；２−（２’−ヒドロキシ−５’−ｔ−オクチルフェニル)ベンゾトリアゾ−ル、４−メトキシ−４’−ｔ−ブチルジベンゾイルメタン等の紫外線吸収剤類；エタノ−ル、イソプロパノ−ル等の低級アルコ−ル類；ビタミンＡ又はその誘導体、ビタミンＢ６塩酸塩、ビタミンＢ６トリパルミテ−ト、ビタミンＢ６ジオクタノエ−ト、ビタミンＢ２又はその誘導体、ビタミンＢ１２、ビタミンＢ１５又はその誘導体等のビタミンＢ類；α−トコフェロ−ル、β−トコフェロ−ル、γ−トコフェロ−ル、ビタミンＥアセテ−ト等のビタミンＥ類、ビタミンＤ類、ビタミンＨ、パントテン酸、パンテチン、ピロロキノリンキノン等のビタミン類等；フェノキシエタノ−ル等の抗菌剤などが好ましく例示できる。\n\n\nIn addition to the above, the external preparation for skin of the present invention may contain any commonly used optional component as long as the effects of the present invention are not impaired. Such optional ingredients include, for example, macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, palm oil, palm oil, liquid Lanolin, hydrogenated palm oil, hydrogenated oil, molasses, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ibotarou, lanolin, reduced lanolin, hard lanolin, jojoba wax and other oils, waxes; liquid paraffin, squalane, pristane, ozokerite, Hydrocarbons such as paraffin, ceresin, petrolatum, microcrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, undecylenic acid; cetyl alcohol, stearyl alcohol -Le, Isosteari Higher alcohols such as alcohol, behenyl alcohol, octyl decanol, myristyl alcohol, cetostearyl alcohol; cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, Di-2-ethylhexyl sebacate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, tri-2- Oil agents such as synthetic ester oils such as glyceryl ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentane erythritol tetra-2-ethylhexanoate; fatty acid soap (Natrilaurate) Anionic surfactants such as potassium lauryl sulfate, triethanolamine ether alkyl sulfate; cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride, laurylamine oxide; imidazoline-based amphoteric Amphoterics such as surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine surfactants (alkyl betaine, amide betaine, sulfobetaine, etc.), acylmethyl taurine, etc. Surfactants: sorbitan fatty acid esters (such as sorbitan monostearate and sorbitan sesquioleate), glycerin fatty acids (such as glyceryl monostearate), propylene glycol fatty acid esters (monostearic acid) Propylene glycol, etc.), hydrogenated castor oil derivative, glycerin alkyl ether, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbite fatty acid esters (POE- Sorbit monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ether (POE2-octyldodecyl ether, etc.), POE alkylphenyl ethers (POE nonylphenyl ether, etc.), Pluronic types, POE / POP alkyl ethers (POE / POP2-decyltetradecyl ether) Tel), Tetro Nonionic surfactants such as sucrose, POE castor oil / hardened castor oil derivatives (POE castor oil, POE hardened castor oil, etc.), sucrose fatty acid ester, alkyl glucoside; polyethylene glycol, glycerin, erythritol , Polyhydric alcohols such as sorbitol, xylitol, maltitol, propylene glycol, 2,4-hexanediol; moisturizing components such as sodium pyrrolidonecarboxylate, lactic acid, sodium lactate; surface Mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, silicic anhydride (silica), aluminum oxide, barium sulfate, etc .; surface may be treated , Bengara, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine, bitumen, titanium oxide, zinc oxide inorganic pigments; table Pal agents such as mica titanium, fish phosphorus foil, bismuth oxychloride, which may be treated; red 202, red 228, red 226, yellow 4 which may be laked , Blue 404, Yellow 5, Red 505, Red 230, Red 223, Orange 201, Red 213, Yellow 204, Yellow 203, Blue 1, Green 201, Purple 201, Red Organic dyes such as No. 204; organic powders such as polyethylene powder, polymethyl methacrylate, nylon powder, organopolysiloxane elastomer; paraaminobenzoic acid UV absorbers; anthranilic acid UV absorbers; salicylic acid UV absorbers Cinnamate UV absorbers; benzophenone UV absorbers; sugar UV absorbers; 2- (2'-hydroxy-5'-t-octylphenyl) ben UV absorbers such as triazole and 4-methoxy-4'-t-butyldibenzoylmethane; lower alcohols such as ethanol and isopropanol; vitamin A or a derivative thereof, vitamin B6 hydrochloride, Vitamin B6 such as vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or a derivative thereof, vitamin B12, vitamin B15 or a derivative thereof; α-tocopherol, β-tocopherol, γ-tocopherol, Preferable examples include vitamins E such as vitamin E acetate, vitamins D, vitamin H, pantothenic acid, panthetin, pyrroloquinoline quinone and the like; and antibacterial agents such as phenoxyethanol.\n\n\n\n\n\n\n\n \n\n本発明の皮膚外用剤は、前述の成分を常法に従って処理することにより本発明の皮膚外用剤を製造することができる。\n\n\nThe skin external preparation of this invention can manufacture the skin external preparation of this invention by processing the above-mentioned component in accordance with a conventional method.\n\n\n\n\n\n\n\n \n\n以下に、実施例をあげて、本発明について更に詳細に説明を加えるが、本発明がかかる実施例にのみ、限定されないことは言うまでもない。\n\n\nHereinafter, the present invention will be described in more detail with reference to examples, but it is needless to say that the present invention is not limited to such examples.\n\n\n\n\n\n\n\n\n\n \n\n  表３に示す処方に従って、本発明の皮膚外用剤である、油中水乳化剤形である化粧料を製造した。即ち、イ、ロ及びハの成分をそれぞれ８０℃に加温し、イを混練してゲルを形成させ、この中にハを加えて溶解させ、これに撹拌下徐々にロを加え乳化し、撹拌冷却して油中水乳化剤形の化粧料１を作製した。さらに、表３に示した処方成分中、前記「マメ科ハギ属キハギより得られた植物抽出物」及び「４−ｎ−ブチルレゾルシノ−ル」の含有量を、表４に示す成分含有量に変えた化粧料２〜６を作製した。表３に於ける「マメ科ハギ属キハギより得られた抽出物」及び「４−ｎ−ブチルレゾルシノ−ル」の質量％増減分は、ロに於ける水の質量％を増減させることにより調整した。同様に操作し、プロトンポンプ阻害剤である、前記「マメ科ハギ属キハギより得られた抽出物」を水に置換した比較例１、「４−n-ブチルレゾルシノ−ル」を水に置換した比較例２、前記「マメ科ハギ属キハギより得られる抽出物」及び「４−アルキルレゾルシノ−ル」の両方を水に置換した比較例３を作製した。\n\n\n  According to the formulation shown in Table 3, cosmetics in the form of a water-in-oil emulsifier, which is an external preparation for skin of the present invention, were produced. That is, each of the components (a), (b) and (c) is heated to 80 ° C., kneads (i) to form a gel, and (c) is added and dissolved therein. The water-in-oil emulsifier type cosmetic 1 was prepared by stirring and cooling. Furthermore, in the prescription components shown in Table 3, the contents of the “plant extract obtained from the leguminous genus Kihagi” and “4-n-butylresorcinol” are changed to the component contents shown in Table 4. Cosmetics 2-6 were prepared. In Table 3, the \"% extract of leguminous genus Kihagi\" and \"4-n-butylresorcinol\" mass% increase / decrease was adjusted by increasing / decreasing the mass% of water in B. . Comparative Example 1 operated in the same manner and replaced the above-mentioned “extract obtained from leguminous genus Kihagi”, which was a proton pump inhibitor, with water, and the comparison with “4-n-butylresorcinol” replaced with water Example 2 Comparative Example 3 was prepared, in which both the “extract obtained from leguminous genus Kihagi” and “4-alkylresorcinol” were replaced with water.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n＜紫外線照射後の色素沈着に対する予防効果の検討＞\n\n  紫外線照射後炎症を起こし、該炎症部位が色素沈着を起こす特性を有するパネラ−（ｎ＝１）を用いて、色素沈着予防効果を検討した。即ち、前腕内側部に１．５ｃｍ×１．５ｃｍの部位を上下２段に分け３箇所ずつ合計６箇所、両腕合計１１ケ所を設け、部位１〜１０は最少紅斑量（ＭＥＤ）の１．５倍の紫外線照射を行い、部位１〜９には、照射後直ちに化粧料１〜６、比較例１〜３をそれぞれ４０μＬ投与し、部位１０は照射対照とし、部位１１は無処置対照とした。照射後２４時間に紅斑の程度をドレ−ズの基準（−：無反応、±：擬陽性反応、＋：明瞭な紅斑を伴う反応、＋＋：浮腫を伴う反応）に従って判定し、更に、その１０日後に、色素沈着の指標となる、無処置部位とのＬ値の差をコニカミノルタ色彩色差計ＣＲ４００で計測した。結果を表５に示す。これより、「４−n−ブチルレゾルシノ−ル」と「本発明のマメ科ハギ属キハギより得られる抽出物」の組み合わせ効果が確認された。この組み合わせ効果により、色素沈着が抑制できることが判る。\n\n\n<Examination of preventive effect against pigmentation after UV irradiation> \n The effect of preventing pigmentation was examined using a panel (n = 1) having the property of causing inflammation after ultraviolet irradiation and causing the inflammation site to cause pigmentation. That is, a 1.5 cm × 1.5 cm part is divided into two upper and lower parts on the inner side of the forearm, and a total of six places for three places and a total of 11 places for both arms are provided. 5 times of ultraviolet irradiation was performed, and in parts 1 to 9, 40 μL of cosmetics 1 to 6 and Comparative Examples 1 to 3 were administered immediately after irradiation, part 10 was an irradiation control, and part 11 was an untreated control. . 24 hours after irradiation, the degree of erythema was determined according to the criteria of drainage (-: no reaction, ±: false positive reaction, +: reaction with clear erythema, ++: reaction with edema), and 10 days thereafter Later, the difference in L value from an untreated site, which is an index of pigmentation, was measured with a Konica Minolta color difference meter CR400. The results are shown in Table 5. From this, the combined effect of “4-n-butylresorcinol” and “extract obtained from the legume genus Kihagi of the present invention” was confirmed. It can be seen that pigmentation can be suppressed by this combination effect. \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明は、色素沈着の予防又は改善に有用な皮膚外用剤に応用出来る。\n\n\n  The present invention can be applied to a skin external preparation useful for preventing or improving pigmentation."
  },
  {
    "id": "JP2010202551A",
    "text": "Novel calcium sensitizer useful for treating heart failure AbstractTranslated fromJapanese【課題】拡張型心筋症の改善および進行防止、ならびに当該拡張型心筋症に起因して生じる心不全、特に酸化ストレスを伴う鬱血性心不全の改善および予防に有効に使用できる新規なカルシウムセンシタイザーを提供する。また拡張型心筋症、ならびに当該心筋症に起因して生じる心不全などの心疾患の予防または治療剤を提供する。【解決手段】上記課題は、プロピルガレートを有効成分とする医薬製剤によって解決することができる。【選択図】なし[PROBLEMS] To provide a novel calcium sensitizer that can be used effectively for the improvement and prevention of dilated cardiomyopathy and the improvement and prevention of heart failure caused by dilated cardiomyopathy, particularly congestive heart failure accompanied by oxidative stress. To do. The present invention also provides a prophylactic or therapeutic agent for dilated cardiomyopathy and heart diseases such as heart failure caused by the cardiomyopathy.The above problems can be solved by a pharmaceutical preparation containing propyl gallate as an active ingredient.[Selection figure] None Claims (\n6\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  プロピルガレートを有効成分とするカルシウムセンシタイザー。\n\n\n  Calcium sensitizer with propyl gallate as an active ingredient.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  上記カルシウムセンシタイザーを有効成分とする心疾患の予防または治療剤。\n\n\n  A preventive or therapeutic agent for heart disease comprising the above calcium sensitizer as an active ingredient.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  心疾患が拡張型心筋症である請求項２に記載する、心疾患の予防または治療剤。\n\n\n  The agent for preventing or treating heart disease according to claim 2, wherein the heart disease is dilated cardiomyopathy.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  心疾患が心不全である請求項２に記載する、心疾患の予防または治療剤。\n\n\n  The preventive or therapeutic agent for heart disease according to claim 2, wherein the heart disease is heart failure.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  心不全が酸化ストレスを伴う鬱血性心不全である、請求項４に記載する心疾患の予防または治療剤。\n\n\n  The preventive or therapeutic agent for heart disease according to claim 4, wherein the heart failure is congestive heart failure accompanied by oxidative stress.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  経口投与形態を有する薬剤である、請求項２乃至５のいずれかに記載する心疾患の予防または治療剤。\n\n\n  The preventive or therapeutic agent for heart disease according to any one of claims 2 to 5, which is a drug having an oral dosage form. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は新規カルシウムセンシタイザーに関する。また本発明は、当該新規カルシウムセンシタイザーを有効成分とする心疾患、特に拡張型心筋症、およびそれに起因する心不全の予防または治療剤に関する。\n\n\n  The present invention relates to a novel calcium sensitizer. The present invention also relates to a preventive or therapeutic agent for heart diseases, particularly dilated cardiomyopathy, and heart failure caused thereby, comprising the novel calcium sensitizer as an active ingredient.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  拡張型心筋症は、心室の円周に沿って心筋細胞が長軸方向に肥大することによって、心室が拡大し心室内部の空間が大きくなる病気である（心室内腔の拡張）。その結果、心室の壁に大きな負荷がかかるため血液をうまく送り出せなくなり（心筋収縮不全）、左室駆出率と心拍出量の低下をきたして、鬱血性心不全を引き起こしやすい状態になる。\n\n\n  Dilated cardiomyopathy is a disease in which myocardial cells enlarge in the long axis direction along the circumference of the ventricle, thereby expanding the ventricle and increasing the space inside the ventricle (expansion of the intraventricular lumen). As a result, a large load is applied to the walls of the ventricles, making it impossible to pump blood (myocardial contraction failure), resulting in a decrease in left ventricular ejection fraction and cardiac output, leading to congestive heart failure.\n\n\n\n\n\n\n\n \n\n  発症は急性のことも、また潜行性のこともあるが、末期では難治性心不全を呈することが多い。その予後は極めて不良で、拡張型心筋症発症後５年および１０年生存率は、それぞれ５４％および３６％と低く（非特許文献１および２）、突然死の発生も稀ではない。このため、欧米では心臓移植適応の最優先疾患の一つとなっている。我が国でもこの疾患の患者数は約１万７０００人、年間で約２０００人が死亡していること、また心臓移植を必要とする患者の９割が拡張型心筋症であることから、難病に指定され、その病因究明と治療法確立を目指して、日夜研究が進められている。\n\n\n  Onset may be acute or insidious, but often has intractable heart failure at the end. The prognosis is extremely poor, and the 5-year and 10-year survival rates after the onset of dilated cardiomyopathy are as low as 54% and 36%, respectively (Non-patent \nDocuments\n 1 and 2), and the occurrence of sudden death is not uncommon. For this reason, it has become one of the top priorities for cardiac transplantation in the West. In Japan, the number of patients with this disease is approximately 17,000, and approximately 2000 people have died annually. In addition, 90% of patients requiring heart transplantation are dilated cardiomyopathy. Research has been conducted day and night with the aim of investigating the etiology and establishing treatments.\n\n\n\n\n\n\n\n \n\n  現在、外科的治療法として、「バチスタ手術」と呼ばれる「左室縮小形成手術」が保健適応となっており、普及が進みつつある。また対症療法としては、降圧剤としてアンギオテンシンII変換酵素阻害剤（ＡＣＥ阻害剤）、アンギオテンシン受容体ブロッカー、利尿薬、強心剤、血管拡張剤、およびβ受容体遮断薬などが用いられる。また、重症の場合にはカルシウムセンシタイザーであるピモべンダン（商品名：アカルディ）が用いられることがあるが、いずれも有効性および安全性が十分であるとはいえない。\n\n\n  Currently, as a surgical treatment method, “left ventricular reduction surgery” called “batista surgery” has become a health indication and is spreading. As symptomatic treatment, angiotensin II converting enzyme inhibitor (ACE inhibitor), angiotensin receptor blocker, diuretic, cardiotonic agent, vasodilator, β receptor blocker and the like are used as antihypertensive agents. In severe cases, Pimobendan (trade name: Acardi), which is a calcium sensitizer, may be used, but none of the efficacy and safety are sufficient.\n\n\n\n\n\n\n\n \n\n  ところで、カルシウムセンシタイザーは、心筋ミオフィラメントのカルシウムに対する感受性を増加させることによって陽性変力作用を発揮する強心薬である（非特許文献３および４）。ピモべンダンに代表されるように、かかるカルシウムセンシタイザーはミオフィラメントカルシウム感受性の低下を伴う拡張型心筋症の治療に有益であることが知られている（非特許文献５）。特に、β受容体刺激薬（β受容体刺激作用に基づく強心薬）は、心筋酸素消費量を増加させるため、カルシウム過負荷と酸化ストレスを発生させるのに対して、カルシウムセンシタイザーは、鬱血性心不全の治療において心筋酸素消費量を増加させないため、カルシウム過負荷や、心筋虚血再灌流傷害に関与する酸化ストレスの発生を避けることができるという利点を有している（非特許文献６および７）。\n\n\n  By the way, a calcium sensitizer is a cardiotonic agent that exerts a positive inotropic action by increasing the sensitivity of cardiac myofilament to calcium (Non-patent Documents 3 and 4). As represented by pimobendan, it is known that such a calcium sensitizer is useful for the treatment of dilated cardiomyopathy accompanied by a decrease in myofilament calcium sensitivity (Non-patent Document 5). In particular, β-receptor stimulants (cardiotonic drugs based on β-receptor stimulating effects) increase myocardial oxygen consumption and thus cause calcium overload and oxidative stress, whereas calcium sensitizers are congestive Since the myocardial oxygen consumption is not increased in the treatment of heart failure, there is an advantage that it is possible to avoid the generation of oxidative stress related to calcium overload and myocardial ischemia reperfusion injury (Non-patent Documents 6 and 7). ).\n\n\n\n\n\n\n\n \n\n  そこで、拡張型心筋症や酸化ストレスを伴う鬱血性心不全の改善、治療ならびに進行予防に有効な、ピモべンダンに代わる新規カルシウムセンシタイザーの開発が求められている。\n\n\n  Therefore, there is a need for the development of a new calcium sensitizer that replaces pimobendan that is effective in improving, treating, and preventing progression of congestive heart failure associated with dilated cardiomyopathy and oxidative stress.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n河合忠一ら、昭和57年度厚生省特定疾患特発性心筋症調査研究班研究報告書、第63頁、1983年\nKawai Tadaichi et al., 1982 Ministry of Health and Welfare Idiopathic Cardiomyopathy Research Report, p. 63, 1983\n\n\n\n\n\n\n\n\n\n\n \nDiaz et al. Prediction of outcome of dilated cardiomyopathy. Br Heart J. 1987;58:393-399\nDiaz et al. Prediction of outcome of dilated cardiomyopathy. Br Heart J. 1987; 58: 393-399\n\n\n\n\n\n\n\n\n\n\n \nKass DA, Solaro RJ. Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart. Circulation 2006;113:305-315.\nKass DA, Solaro RJ. Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart. Circulation 2006; 113: 305-315.\n\n\n\n\n\n\n\n\n\n\n \nTadano N, Morimoto S, Yoshimura A, Miura M, Yoshioka K, Sakato M, et al. SCH00013, a novel Ca2+ sensitizer with positive inotropic and no chronotropic action in heart failure. J Pharmacol Sci 2005;97:53-60.\nTadano N, Morimoto S, Yoshimura A, Miura M, Yoshioka K, Sakato M, et al. SCH00013, a novel Ca2 + sensitizer with positive inotropic and no chronotropic action in heart failure.J Pharmacol Sci 2005; 97: 53-60.\n\n\n\n\n\n\n\n\n\n\n \nDu CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res. 2007;101:185-194.\nDu CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res. 2007; 101: 185-194.\n\n\n\n\n\n\n\n\n\n\n \nShinke T, Shite J, Takaoka H, Hata K, Inoue N, Yoshikawa R, et al. Vitamin C restores the contractile response to dobutamine and improves myocardial efficiency in patients with heart failure after anterior myocardial infarction. Am Heart J. 2007;154:645 e641-648.\nShinke T, Shite J, Takaoka H, Hata K, Inoue N, Yoshikawa R, et al. Vitamin C restores the contractile response to dobutamine and improves myocardial efficiency in patients with heart failure after anterior myocardial infarction. Am Heart J. 2007; 154 : 645 e641-648.\n\n\n\n\n\n\n\n\n\n\n \nGivertz MM, Sawyer DB, Colucci WS. Antioxidants and myocardial contractility: illuminating the \"Dark Side\" of b-adrenergic receptor activation? Circulation. 2001;103:782-783.\nGivertz MM, Sawyer DB, Colucci WS. Antioxidants and myocardial contractility: illuminating the \"Dark Side\" of b-adrenergic receptor activation? Circulation. 2001; 103: 782-783.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明は、拡張型心筋症の改善および進行防止、ならびに当該拡張型心筋症に起因して生じる心不全、特に酸化ストレスを伴う鬱血性心不全の改善および予防に有効に使用できる新規なカルシウムセンシタイザーを提供すること目的とする。また、本発明は当該カルシウムセンシタイザーを有効成分とする心疾患の予防または治療剤、より詳細には拡張型心筋症、ならびに当該心筋症に起因して生じる上記心不全の予防または治療剤を提供することを目的とする。\n\n\n  The present invention relates to a novel calcium sensitizer that can be used effectively for the improvement and prevention of dilated cardiomyopathy and the improvement and prevention of heart failure caused by the dilated cardiomyopathy, particularly congestive heart failure associated with oxidative stress. The purpose is to provide. The present invention also provides a preventive or therapeutic agent for heart diseases comprising the calcium sensitizer as an active ingredient, more specifically dilated cardiomyopathy, and a prophylactic or therapeutic agent for the above-mentioned heart failure caused by the cardiomyopathy. For the purpose.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明者らは、上記課題を解決するために鋭意検討を行っていたところ、抗酸化作用を有し、従来より酸化防止剤（食品添加剤、医薬品添加剤）として使用されているプロピルガレート（没食子酸プロピル）に、用量依存的かつ可逆的に、心筋ミオフィラメントのカルシウム感受性を増加させる作用があることを見出し（実験例１）、当該プロピルガレートが心筋収縮力を増加させるカルシウムセンシタイザーであること、これが心不全の原因の多くを占めている拡張型心筋症の治療に有効であることを、拡張型心筋症のモデル動物に対する経口投与実験で確認した（実験例２）。\n\n\n  The inventors of the present invention have made extensive studies to solve the above-mentioned problems. As a result, propyl gallate having an antioxidant action and conventionally used as an antioxidant (food additive, pharmaceutical additive) ( (Propyl gallate) has a dose-dependent and reversible action to increase myocardial myofilament calcium sensitivity (Experimental Example 1), and the propyl gallate is a calcium sensitizer that increases myocardial contractility. It was confirmed by an oral administration experiment on a model animal of dilated cardiomyopathy that this is effective for the treatment of dilated cardiomyopathy, which accounts for many causes of heart failure (Experimental Example 2).\n\n\n\n\n\n\n\n \n\n  本発明は、かかる知見に基づいて完成したものであり、下記の実施形態を有するものである：\n\n項１．プロピルガレートを有効成分とするカルシウムセンシタイザー。\n\n項２．上記カルシウムセンシタイザーを有効成分とする心疾患の予防または治療剤。なお、当該発明は「プロピルガレートを有効成分とする心疾患の予防または治療剤」と言い換えることができる。\n\n項３．心疾患が拡張型心筋症である項２に記載する、心疾患の予防または治療剤。\n\n項４．心疾患が心不全である項２に記載する、心疾患の予防または治療剤。\n\n項５．心不全が酸化ストレスを伴う鬱血性心不全である、項４に記載する心疾患の予防または治療剤。\n\n項６．経口投与形態を有する薬剤である、項２乃至５のいずれかに記載する心疾患の予防または治療剤。\n\n項７．プロピルガレートを、拡張型心筋症の患者に投与することを特徴とする拡張型心筋症の改善方法。\n\n項８．プロピルガレートを、拡張型心筋症の患者に投与することを特徴とする心不全への進展予防方法。\n\n項９．拡張型心筋症の予防または治療剤の調製のためのプロピルガレートの使用。\n\n項１０．拡張型心筋症の予防または治療のためのプロピルガレート。\n\nThe present invention has been completed based on such findings and has the following embodiments: \n \nItem\n 1. Calcium sensitizer with propyl gallate as an active ingredient. \n \nItem\n 2. A preventive or therapeutic agent for heart disease comprising the above calcium sensitizer as an active ingredient. In addition, the said invention can be paraphrased as \"the preventive or therapeutic agent of the heart disease which uses a propyl gallate as an active ingredient.\" \n Item 3. Item 3. The preventive or therapeutic agent for heart disease according to \nItem\n 2, wherein the heart disease is dilated cardiomyopathy. \n Item 4. Item 3. The preventive or therapeutic agent for heart disease according to \nItem\n 2, wherein the heart disease is heart failure. \n Item 5. Item 5. The preventive or therapeutic agent for heart disease according to Item 4, wherein the heart failure is congestive heart failure accompanied by oxidative stress. \n Item 6. Item 6. The preventive or therapeutic agent for heart disease according to any one of \nItems\n 2 to 5, which is a drug having an oral dosage form. \n \nItem\n 7. A method for improving dilated cardiomyopathy, comprising administering propyl gallate to a patient with dilated cardiomyopathy. \n Item 8. A method for preventing the progression to heart failure, comprising administering propyl gallate to a patient with dilated cardiomyopathy. \n Item 9. Use of propyl gallate for the preparation of a prophylactic or therapeutic agent for dilated cardiomyopathy. \n \nItem\n 10. Propyl gallate for the prevention or treatment of dilated cardiomyopathy.\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明によれば、従来より酸化防止剤（食品添加剤、医薬品添加剤）として使用されているプロピルガレート（没食子酸プロピル）について、カルシウムセンシタイザーとしての新規用途、並びに心疾患、特に拡張型心筋症およびそれに起因する心不全の予防または治療剤としての新規用途を提供することができる。プロピルガレートは、抗酸化活性を有する全く新しいタイプのカルシウムセンシタイザーであり、酸化ストレスを伴う鬱血性心不全の治療に対して、従来のカルシウムセンシタイザーより有益であると思われる。\n\n\n  According to the present invention, propyl gallate (propyl gallate), which has been conventionally used as an antioxidant (food additive, pharmaceutical additive), has a novel use as a calcium sensitizer, and heart disease, particularly dilated myocardium. The present invention can provide a novel use as a preventive or therapeutic agent for heart failure and heart failure caused thereby. Propyl gallate is a completely new type of calcium sensitizer with antioxidant activity and appears to be more beneficial than conventional calcium sensitizers for the treatment of congestive heart failure with oxidative stress.\n\n\n\n\n\n\n\n \n\n  本発明の心疾患の予防または治療剤は、これまで血圧降下、利尿作用といった対処療法、若しくは心臓移植、バチスタ手術といった外科的治療法しか確立されていなかった拡張型心筋症の新たな治療薬となりえる。また、拡張型心筋症に起因する心不全の予防薬としても期待することができる。また、本発明の心疾患の予防または治療剤は、移植が制限されている小児の治療法としても期待することができる。\n\n\n  The preventive or therapeutic agent for heart disease of the present invention is a new therapeutic agent for dilated cardiomyopathy for which only therapeutic treatment such as hypotension and diuretic action or surgical treatment such as heart transplantation and batista surgery has been established so far. Yeah. It can also be expected as a prophylactic agent for heart failure caused by dilated cardiomyopathy. Further, the preventive or therapeutic agent for heart disease of the present invention can be expected as a therapeutic method for children whose transplantation is restricted.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n各種のフェノール化合物（トロロクス(Trolox)、クルクミン(Curcumin)、ケルセチン(Quercetin)、クロロゲン酸（Chlorogenate）、ガレート(Gallate)、ドデシルガレート(Dodecyl gallate)およびプロピルガレート(Propyl gallate)）の心筋スキンドファイバー張力発生に対する効果を調べた結果を示す。図Ａは、各フェノール化合物（100μＭ）の存在下で測定した張力（Relative force (%)）とカルシウム濃度（pCa）との関係を示す。図Ｂは、各フェノール化合物（100μＭ）について、張力発生のカルシウム感受性（pCa\n50\n）に対する効果を示す。「Vehicle」は、フェノール化合物を配合せず０.１％ＤＭＳＯの存在下で実験を行った結果を示す。張力は各ファイバーの最大張力に対して正規化した。データは５−８ファイバーに対する平均値±標準誤差を示す。**p<0.01 vs. vehicle (Student’s t-test).\nMyocardial skinned fibers of various phenolic compounds (Trolox, Curcumin, Quercetin, Chlorogenate, Gallate, Dodecyl gallate and Propyl gallate) The result of having investigated the effect with respect to tension generation is shown. FIG. A shows the relationship between the tension (Relative force (%)) measured in the presence of each phenol compound (100 μM) and the calcium concentration (pCa). FIG. B shows the effect of tension generation on calcium sensitivity (pCa \n50\n ) for each phenolic compound (100 μM). “Vehicle” indicates a result of an experiment conducted in the presence of 0.1% DMSO without blending a phenol compound. The tension was normalized to the maximum tension of each fiber. Data show mean ± standard error for 5-8 fibers. ** p <0.01 vs. vehicle (Student's t-test).\n\n\n\n\n\n\n \nプロピルガレート(Propyl gallate)の心筋スキンドファイバー張力発生に対する効果を示す図である。 図Ａは、種々濃度のプロピルガレート（30、100および300μＭ）について、張力（Relative force (%)）とカルシウム濃度（pCa）との関係を示す。図Ｃは、張力発生のカルシウム感受性（pCa\n50\n）に対するプロピルガレートの用量依存的効果を示す。「Vehicle」は、フェノール化合物を配合せず０.１％ＤＭＳＯの存在下で実験を行った結果を示す。張力は各ファイバーの最大張力に対して正規化した。データは５−８ファイバーに対する平均値±標準誤差を示す。統計学的有意性はＡＮＯＶＡとそれにつづくDunnettの多重比較検定により決定した。**p<0.01 vs. control.\nIt is a figure which shows the effect with respect to myocardial skinned fiber tension generation | occurrence | production of propyl gallate (Propyl gallate). FIG. A shows the relationship between tension (Relative force (%)) and calcium concentration (pCa) for various concentrations of propyl gallate (30, 100 and 300 μM). FIG. C shows the dose-dependent effect of propyl gallate on tension-generated calcium sensitivity (pCa \n50\n ). “Vehicle” indicates a result of an experiment conducted in the presence of 0.1% DMSO without blending a phenol compound. The tension was normalized to the maximum tension of each fiber. Data show mean ± standard error for 5-8 fibers. Statistical significance was determined by ANOVA followed by Dunnett's multiple comparison test. ** p <0.01 vs. control.\n\n\n\n\n\n\n \nフェノール化合物（トロロクス、クルクミン、ガレートおよびプロピルガレート）の抗酸化活性（antioxidant activity (%)）を測定した結果を示す。データは３回の測定に対する平均値±標準誤差を示す。\nThe result of measuring the antioxidant activity (antioxidant activity (%)) of phenolic compounds (trolox, curcumin, gallate and propyl gallate) is shown. Data show the mean value ± standard error for three measurements.\n\n\n\n\n\n\n \n野生型マウス（白抜棒グラフ）と拡張型心筋症モデルマウス(DCM mice)（黒塗棒グラフ）の心重量/体重量比（HW/BW ratio）(mg/g)に対するプロピルガレート経口投与(１日１回)の効果を示す。データは括弧内の数字で示された数のマウスに対する平均値±標準誤差を示す。統計学的有意性はＡＮＯＶＡとそれにつづくDunnettの多重比較検定により決定した。**p<0.01 vs. wild-type mice.\nOral administration of propyl gallate to heart weight / body weight ratio (HW / BW ratio) (mg / g) of wild-type mice (white bars) and dilated cardiomyopathy model mice (DCM mice) (black bars) (1 day) 1 time). Data represent mean ± standard error for the number of mice indicated by the number in parentheses. Statistical significance was determined by ANOVA followed by Dunnett's multiple comparison test. ** p <0.01 vs. wild-type mice.\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n（Ｉ）カルシウムセンシタイザー\n \n\n  本発明は、プロピルガレート（没食子酸プロピル）を有効成分とするカルシウムセンシタイザーである。鬱血性心不全の治療においてないため\n\n  ここでカルシウムセンシタイザーは、心筋ミオフィラメントのカルシウムに対する感受性を増加させることによって心筋酸素消費量を増加させることなく陽性変力作用を発揮する強心薬である。このため、カルシウムセンシタイザーは、心筋ミオフィラメントのカルシウムに対する感受性の低下を伴う拡張型心筋症の治療および予防に有効に使用することができる（Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res. 2007;101:185-194）。\n\n \n(I) Calcium Sensitizer The\n present invention is a calcium sensitizer containing propyl gallate (propyl gallate) as an active ingredient. Since it is not in the treatment of congestive heart failure, a calcium sensitizer is a cardiotonic agent that exerts a positive inotropic effect without increasing myocardial oxygen consumption by increasing the sensitivity of myocardial myofilaments to calcium. For this reason, calcium sensitizers can be used effectively for the treatment and prevention of dilated cardiomyopathy associated with reduced sensitivity of cardiac myofilament to calcium (Du CK, Morimoto S, Nishii K, Minakami R, Ohta M , Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res. 2007; 101: 185-194).\n\n\n\n\n\n\n \n\n  従って、プロピルガレート（没食子酸プロピル）もまた心筋ミオフィラメントのカルシウムに対する感受性を増加させることにより心筋収縮力の低下した拡張型心筋症の治療および予防に有効に使用することができる。\n\n\n  Therefore, propyl gallate (propyl gallate) can also be effectively used for the treatment and prevention of dilated cardiomyopathy with decreased myocardial contractility by increasing the sensitivity of myocardial myofilaments to calcium.\n\n\n\n\n\n\n\n \n \n（II）心疾患の予防または治療剤\n \n\n  本発明は、またプロピルガレート（没食子酸プロピル）を有効成分とする心疾患の予防または治療剤である。\n\n \n(II) Preventive or therapeutic agent for heart disease The\n present invention is also a preventive or therapeutic agent for heart disease containing propyl gallate (propyl gallate) as an active ingredient.\n\n\n\n\n\n\n \n\n  ここで本発明が対象とする心疾患は、前述する心筋ミオフィラメントのカルシウムに対する感受性の低下等による心筋収縮力の低下を伴う拡張型心筋症、およびこれに関連する心疾患であり、例えば拡張型心筋症の進展によって生じる鬱血性心不全、不整脈による突然死、心臓内血栓形成による脳梗塞などを挙げることができる。\n\n\n  Here, the heart disease targeted by the present invention is dilated cardiomyopathy accompanied by a decrease in myocardial contractility due to a decrease in sensitivity of the myocardial myofilament to calcium or the like, and a heart disease related thereto. Examples include congestive heart failure caused by the development of cardiomyopathy, sudden death due to arrhythmia, and cerebral infarction due to intracardiac thrombus formation.\n\n\n\n\n\n\n\n \n\n  なお、拡張型心筋症の診断は、心不全、不整脈、心音異常、心電図異常、胸部Ｘ線写真異常、心エコー異常などにより行われるが、診断のより具体的な項目は、例えば厚生省特定疾患特発性心筋症調査研究班の昭和60年度研究報告書に記載されている。\n\n\n  Diagnosis of dilated cardiomyopathy is performed by heart failure, arrhythmia, heart sound abnormality, electrocardiogram abnormality, chest radiograph abnormality, echocardiogram abnormality, etc. More specific items of diagnosis are, for example, idiopathic disease specific to the Ministry of Health and Welfare It is described in the 1985 research report of the cardiomyopathy research group.\n\n\n\n\n\n\n\n \n \n（III）医薬製剤\n \n\n  本発明のカルシウムセンシタイザーおよび心疾患の予防または治療剤（以下、単に「本発明の医薬製剤」という）は、有効成分としてプロピルガレートを含む以外、他の成分を含むことができる。他の成分としては、当該製剤の用法（使用形態）に応じて必要とされる製薬上の各種成分（薬学的に許容し得る各種担体等）が挙げられる。これらの他の成分は、本発明の有効成分により発揮される効果が損なわれない範囲で適宜含有することができる。\n\n \n(III) Pharmaceutical Formulation\n The calcium sensitizer of the present invention and the preventive or therapeutic agent for heart disease (hereinafter simply referred to as “the pharmaceutical formulation of the present invention”) may contain other components in addition to propyl gallate as an active ingredient. it can. Examples of the other components include various pharmaceutical components (various pharmaceutically acceptable carriers and the like) required depending on the usage (form of use) of the preparation. These other components can be appropriately contained as long as the effects exhibited by the active ingredient of the present invention are not impaired.\n\n\n\n\n\n\n \n\n  本発明の医薬製剤において、有効成分であるプロピルガレートの配合割合は、限定はされないが、例えば、製剤全体に対して通常５重量％以上であり、好ましくは１０〜１００重量％である。\n\n\n  In the pharmaceutical preparation of the present invention, the mixing ratio of propyl gallate which is an active ingredient is not limited, but is usually 5% by weight or more, preferably 10 to 100% by weight, based on the whole preparation.\n\n\n\n\n\n\n\n \n\n  本発明の医薬製剤は、ヒト又は非ヒト哺乳動物に対し、種々の投与経路、具体的には、経口又は非経口（例えば静脈注射、筋肉注射、皮下投与、皮内投与、直腸投与、経皮投与）で投与することができる。好ましくは経口投与である。\n\n\n  The pharmaceutical preparation of the present invention can be administered to human or non-human mammals by various administration routes, specifically oral or parenteral (eg, intravenous injection, intramuscular injection, subcutaneous administration, intradermal administration, rectal administration, transdermal). Administration). Oral administration is preferred.\n\n\n\n\n\n\n\n \n\n  従って、有効成分であるプロピルガレートは、単独で用いることも可能であるが、上記投与経路に応じて、慣用される方法により薬学的に許容し得る担体を用いて適当な剤形に製剤化することができる。\n\n\n  Accordingly, propyl gallate, which is an active ingredient, can be used alone, but is formulated into an appropriate dosage form using a pharmaceutically acceptable carrier by a conventional method according to the administration route. be able to.\n\n\n\n\n\n\n\n \n\n  例えば、経口投与剤では、錠剤、散剤、細粒剤、顆粒剤、被覆錠剤、カプセル剤、シロップ剤、及びトローチ剤等を例示することができる。また、非経口投与剤では、吸入剤、坐剤、注射剤（点滴剤を含む）、軟膏剤、点鼻剤、パップ剤、ローション剤、及びリポソーム剤等を例示することができる。\n\n\n  For example, in the case of oral administration, tablets, powders, fine granules, granules, coated tablets, capsules, syrups, lozenges and the like can be exemplified. Examples of parenteral agents include inhalants, suppositories, injections (including drops), ointments, nasal drops, poultices, lotions, and liposomes.\n\n\n\n\n\n\n\n \n\n  これらの医薬製剤の製剤化に用い得る担体としては、例えば、通常用いられる賦形剤、結合剤、崩壊剤、滑沢剤、着色剤、及び矯味矯臭剤のほか、必要に応じて、安定化剤、乳化剤、吸収促進剤、界面活性剤、ｐＨ調整剤、防腐剤、抗酸化剤、増量剤、湿潤化剤、表面活性化剤、分散剤、緩衝剤、保存剤、溶解補助剤、及び無痛化剤等が挙げられ、医薬製剤の原料として用いることができる公知の成分を配合して常法により製剤化することが可能である。\n\n\n  Carriers that can be used to formulate these pharmaceutical preparations include, for example, commonly used excipients, binders, disintegrants, lubricants, coloring agents, and flavoring agents, as well as stabilization as necessary. Agent, emulsifier, absorption enhancer, surfactant, pH adjuster, preservative, antioxidant, extender, wetting agent, surfactant, dispersant, buffer, preservative, solubilizer, and painless A known component that can be used as a raw material for pharmaceutical preparations can be blended to form a preparation by a conventional method.\n\n\n\n\n\n\n\n \n\n  本発明の医薬製剤に使用可能な無毒性の成分としては、例えば、大豆油、牛脂、及び合成グリセライド等の動植物油；流動パラフィン、スクワラン、及び固形パラフイン等の炭化水素；ミリスチン酸オクチルドデシル、及びミリスチン酸イソプロピル等のエステル油；セトステアリルアルコール、及びベヘニルアルコール等の高級アルコール；シリコン樹脂；シリコン油；ポリオキシエチレン脂肪酸エステル、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレン硬化ひまし油、及びポリオキシエチレン−ポリオキシプロピレンブロックコポリマー等の界面活性剤；ヒドロキシエチルセルロース、ポリアクリル酸、カルボキシビニルポリマー、ポリエチレングリコール、ポリビニルピロリドン、及びメチルセルロース等の水溶性高分子；エタノール、及びイソプロパノール等の低級アルコール；グリセリン、プロピレングリコール、ジプロピレングリコール、ソルビトール、及びポリエチレングリコール等の多価アルコール（ポリオール）；グルコース、及びショ糖等の糖；無水ケイ酸、ケイ酸アルミニウムマグネシウム、及びケイ酸アルミニウム等の無機粉体；塩化ナトリウム、リン酸ナトリウム等の無機塩；精製水等が挙げられ、いずれもその塩またはその水和物であってもよい。\n\n\n  Non-toxic ingredients that can be used in the pharmaceutical formulation of the present invention include, for example, animal and vegetable oils such as soybean oil, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane and solid paraffin; octyldodecyl myristate; Ester oil such as isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicone resin; silicone oil; polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene cured Castor oil and surfactants such as polyoxyethylene-polyoxypropylene block copolymer; hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol Water-soluble polymers such as polyvinylpyrrolidone and methylcellulose; lower alcohols such as ethanol and isopropanol; polyhydric alcohols (polyols) such as glycerin, propylene glycol, dipropylene glycol, sorbitol, and polyethylene glycol; glucose and sucrose Inorganic powders such as silicic anhydride, magnesium aluminum silicate, and aluminum silicate; inorganic salts such as sodium chloride and sodium phosphate; purified water, etc., all of which are salts or hydrates thereof. There may be.\n\n\n\n\n\n\n\n \n\n  賦形剤としては、例えば、乳糖、果糖、コーンスターチ、白糖、ブドウ糖、マンニトール、ソルビット、結晶セルロース、及び二酸化ケイ素等が、結合剤としては、例えば、ポリビニルアルコール、ポリビニルエーテル、メチルセルロース、エチルセルロース、アラビアゴム、トラガント、ゼラチン、シェラック、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、ポリビニルピロリドン、ポリプロピレングリコール・ポリオキシエチレン・ブロックポリマー、及びメグルミン等が、崩壊剤としては、例えば、澱粉、寒天、ゼラチン末、結晶セルロース、炭酸カルシウム、炭酸水素ナトリウム、クエン酸カルシウム、デキストリン、ペクチン、及びカルボキシメチルセルロース・カルシウム等が、滑沢剤としては、例えば、ステアリン酸マグネシウム、タルク、ポリエチレングリコール、シリカ、及び硬化植物油等が、着色剤としては医薬品に添加することが許可されているものが、矯味矯臭剤としては、例えば、ココア末、ハッカ脳、芳香散、ハッカ油、竜脳、及び桂皮末等が、それぞれ好ましく挙げられ、いずれもその塩又はそれらの水和物であってもよい。\n\n\n  Examples of excipients include lactose, fructose, corn starch, sucrose, glucose, mannitol, sorbit, crystalline cellulose, and silicon dioxide. Examples of binders include polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, and gum arabic. , Tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polypropylene glycol polyoxyethylene block polymer, and meglumine. Examples of disintegrants include starch, agar, gelatin powder, crystalline cellulose, Examples of lubricants include calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, and carboxymethylcellulose / calcium. , Magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc. are permitted to be added to pharmaceuticals as coloring agents, and as flavoring agents, for example, cocoa powder, mint brain, aroma Powder, mint oil, Borneolum, cinnamon powder and the like are preferably mentioned, and any of them may be a salt thereof or a hydrate thereof.\n\n\n\n\n\n\n\n \n\n  本発明の医薬製剤が経口投与製剤の場合は、有効成分であるプロピルガレートに、賦形剤、さらに必要に応じ、例えば、結合剤、崩壊剤、滑沢剤、着色剤、及び矯味矯臭剤等を加えた後、常法により、例えば、散剤、細粒剤、顆粒剤、錠剤、被覆錠剤、及びカプセル剤等とすることができる。錠剤及び顆粒剤の場合には、例えば、糖衣するほか、必要に応じ、その他の公知の手法で適宜コーティングすることもできる。シロップ剤及び注射用製剤等の場合は、例えば、ｐＨ調整剤、溶解剤、及び等張化剤等、並びに必要に応じて溶解補助剤、及び安定化剤等を加えて、常法により製剤化することができる。また、外用剤の場合は、製法は限定されず、常法により製造することができる。使用する基剤原料としては、医薬品、医薬部外品、及び化粧品等に通常使用される各種原料を用いることが可能であり、例えば、動植物油、鉱物油、エステル油、ワックス類、高級アルコール類、脂肪酸類、シリコン油、界面活性剤、リン脂質類、アルコール類、多価アルコール類、水溶性高分子類、粘土鉱物類、及び精製水等の原料が挙げられ、必要に応じ、ｐＨ調整剤、抗酸化剤、キレート剤、防腐防黴剤、着色料、及び香料等を添加することができる。さらに必要に応じて、血流促進剤、殺菌剤、消炎剤、細胞賦活剤、ビタミン類、アミノ酸、保湿剤、及び角質溶解剤等の成分を配合することもできる。この場合、担体に対するプロピルガレートの割合は、限定はされず、１〜９０重量％の間で適宜設定することができる。\n\n\n  When the pharmaceutical preparation of the present invention is a preparation for oral administration, propyl gallate which is an active ingredient, an excipient, and if necessary, for example, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent, etc. Can be made into powders, fine granules, granules, tablets, coated tablets, capsules and the like by conventional methods. In the case of tablets and granules, for example, in addition to sugar coating, if necessary, they can be appropriately coated by other known techniques. In the case of syrups and injectable preparations, for example, pH adjusters, solubilizers, tonicity agents, etc., and if necessary, solubilizing agents, stabilizers, etc. are added, and formulated by conventional methods can do. Moreover, in the case of an external preparation, a manufacturing method is not limited and can be manufactured by a conventional method. As the base material to be used, various raw materials usually used for pharmaceuticals, quasi drugs, cosmetics, etc. can be used. For example, animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols , Fatty acids, silicone oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals, and purified water, etc. Antioxidants, chelating agents, antiseptic / antifungal agents, coloring agents, fragrances and the like can be added. Furthermore, components such as blood flow promoters, bactericides, anti-inflammatory agents, cell activators, vitamins, amino acids, humectants, and keratolytic agents can be added as necessary. In this case, the ratio of propyl gallate to the carrier is not limited and can be appropriately set between 1 to 90% by weight.\n\n\n\n\n\n\n\n \n\n  本発明の医薬製剤を経口投与する場合、その投与形態及び有効な投与量は、投与対象、投与経路、製剤の性質、患者の状態、及び医師の判断等に左右されるものであり、限定はされないが、例えば、体重60kgの成人に対して１日１回あたり、プロピルガレート10〜500mg程度、好ましくは50〜300mgを投与することができる。なお、１日に複数回に分けて投与することもできる。\n\n\n  When the pharmaceutical preparation of the present invention is orally administered, its dosage form and effective dosage depend on the subject of administration, administration route, nature of the preparation, patient condition, doctor's judgment, etc. However, for example, about 10 to 500 mg of propyl gallate, preferably 50 to 300 mg can be administered once a day to an adult weighing 60 kg. The administration can be divided into a plurality of times per day.\n\n\n\n\n\n\n\n \n\n  本発明の製剤を非経口投与（例えば注射投与）する場合、その有効な投与量は、例えば、症状の程度、年齢、性別、体重、投与形態等に応じて異なり、限定はされないが、例えば、体重60kgの成人に対して１日１回あたり、1〜500mgの範囲から適宜調整して投与することができる。\n\n\n  When the preparation of the present invention is administered parenterally (for example, by injection), the effective dose varies depending on, for example, the degree of symptoms, age, sex, body weight, dosage form, etc., and is not limited, for example, For an adult with a body weight of 60 kg, it can be administered once a day by appropriately adjusting from the range of 1 to 500 mg.\n\n\n\n\n\n\n\n\n\n \n\n  以下に、実験例を挙げて本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。\n\n\n実験例１\n \n\n（１）アルビノウサギ（雄；2−2.5kg）の左心室肉柱より細胞膜を透過性にしたスキンドファイバーを作成し、その発生張力を、Morimotoら（Ca\n2+\n-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol. 1998;275:C200-207.）に記載されている方法に従って測定した。\n\nHereinafter, the present invention will be described more specifically with reference to experimental examples, but the present invention is not limited thereto. \n \nExperimental example 1\n \n (1) A skinned fiber with a cell membrane permeabilized from the left ventricular meat column of an albino rabbit (male; 2-2.5 kg) was prepared, and its tension was measured by Morimoto et al. (Ca \n2+\n -sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol. 1998; 275: C200-207.).\n\n\n\n\n\n\n \n\n  具体的には、まず、アルビノウサギの左心室肉柱から調製した、ガラス毛細管に結び付けた小さな肉柱束を、５０％グリセリン含有弛緩溶液（50 mM MOPS/KOH(pH7.0), 100 mM KCl, 6mM MgCl\n2\n, 5mM ATP, 4mM EGTA, 0.5mM DTT, and 10mM creatinine phosphate, 35 units/ml creatine kinase）に浸漬することによりスキンド処理を行った。次いで、得られたスキンド処理肉柱束より小さなファイバー（スキンドファイバー）（直径約200μｍ）を切り出し、０．２ｍｌ容量の温度制御された測定槽に装着した。フック間ファイバー長を約１ｍｍに、また弛緩時サルコメア長を、レーザー回折により２．３μｍに設定した。\n\nSpecifically, first, a small meat column bundle prepared from the left ventricular meat column of an albino rabbit and tied to a glass capillary was used as a 50% glycerol-containing relaxing solution (50 mM MOPS / KOH (pH 7.0), 100 mM KCl). , 6 mM MgCl \n2\n , 5 mM ATP, 4 mM EGTA, 0.5 mM DTT, and 10 mM creatinine phosphate, 35 units / ml creatine kinase). Next, a smaller fiber (skinned fiber) (diameter of about 200 μm) was cut out from the obtained skinned processed meat column bundle and mounted in a 0.2 ml capacity temperature-controlled measuring tank. The fiber length between hooks was set to about 1 mm, and the relaxed sarcomere length was set to 2.3 μm by laser diffraction.\n\n\n\n\n\n\n \n\n  次いで、抗酸化作用が知られている各種のフェノール化合物（トロロクス（トコフェロールの水溶性誘導体）、クルクミン、ケルセチン、クロロゲン酸、ガレート（ガレート一水和物）、ドデシルガレートおよびプロピルガレート）が、心筋スキンドファイバーのカルシウム依存性張力発生に及ぼす影響を調べるために、各フェノール化合物１００μＭの存在下、２５℃の条件で、カルシウム濃度を累積的に増加させて（pCa7.0−4.75）、スキンドファイバーから発生する力を、ひずみゲージＵＬ−２ＧＲ（Minebea,Nagano）により測定した。なお、トロロックスはSigmaから、他のフェノール化合物（クルクミン、ケルセチン、クロロジェン酸、ガレート一水和物、ドデシルガレートおよびプロピルガレート）は和光純薬より購入した。すべてのフェノール化合物はジメチルスルフォキシド（ＤＭＳＯ）に溶解し、最終濃度０．１％ＤＭＳＯにて使用した。\n\n\n  Next, various phenolic compounds known for their antioxidant action (trolox (water-soluble derivative of tocopherol), curcumin, quercetin, chlorogenic acid, gallate (gallate monohydrate), dodecyl gallate and propyl gallate) In order to investigate the effect of defiber on the calcium-dependent tension generation, the calcium concentration was cumulatively increased at 25 ° C. in the presence of 100 μM of each phenol compound (pCa7.0−4.75), and skinned fiber. The force generated from the strain was measured with a strain gauge UL-2GR (Minebea, Nagano). Trolox purchased from Sigma and other phenolic compounds (curcumin, quercetin, chlorogenic acid, gallate monohydrate, dodecyl gallate and propyl gallate) from Wako Pure Chemical. All phenolic compounds were dissolved in dimethyl sulfoxide (DMSO) and used at a final concentration of 0.1% DMSO.\n\n\n\n\n\n\n\n \n\n  結果を図１に示す。図１（Ａ）は、各フェノール化合物（100μＭ）の存在下で測定した張力（Relative force (%)）とカルシウム濃度（pCa）との関係を示す。図１（Ｂ）は、各フェノール化合物（100μＭ）について、張力発生のカルシウム感受性（pCa\n50\n）に対する効果を示す。各図において「Vehicle」は、フェノール化合物を配合せず０.１％ＤＭＳＯの存在下で実験を行った結果を示す。この結果からわかるように、プロピルガレート以外のフェノール化合物は、張力―カルシウム曲線を有意に変化させなかったのに対して、プロピルガレートは張力―カルシウム曲線を左方移動させ（図１（Ａ））、有意なカルシウム感受性増加作用を示した（図１（Ｂ））。なお、上記フェノール化合物は、いずれも心筋スキンドファイバーの最大張力および張力―カルシウム曲線の傾斜（ヒル係数）には有意な影響を与えなかった（結果示さず）。\n\nThe results are shown in FIG. FIG. 1 (A) shows the relationship between the tension (Relative force (%)) measured in the presence of each phenol compound (100 μM) and the calcium concentration (pCa). FIG. 1B shows the effect of tension generation on calcium sensitivity (pCa \n50\n ) for each phenolic compound (100 μM). In each figure, “Vehicle” indicates the result of an experiment conducted in the presence of 0.1% DMSO without blending a phenol compound. As can be seen from this result, phenol compounds other than propyl gallate did not significantly change the tension-calcium curve, whereas propyl gallate moved the tension-calcium curve to the left (FIG. 1 (A)). And showed a significant calcium sensitivity increasing action (FIG. 1 (B)). None of the above phenol compounds significantly affected the maximum tension of the myocardial skinned fiber and the slope (hill coefficient) of the tension-calcium curve (results not shown).\n\n\n\n\n\n\n \n\n  この結果から、プロピルガレートは、心筋ミオフィラメントのカルシウム感受性を直接増加させる作用を有するカルシウムセンシタイザーであることが示された。\n\n\n  From this result, it was shown that propyl gallate is a calcium sensitizer having an action of directly increasing the calcium sensitivity of cardiac myofilament.\n\n\n\n\n\n\n\n \n\n  （２）次いで、種々濃度のプロピルガレート（30、100および300μＭ）を用いて、（１）と同様の方法により、当該プロピルガレートの存在下で、２５℃条件で、カルシウム濃度を累積的に増加させて（pCa7.0−4.75）（図２（Ｂ）参照）、スキンドファイバーから発生する力を測定した。\n\n\n  (2) Next, using various concentrations of propyl gallate (30, 100 and 300 μM), the calcium concentration is cumulatively increased in the presence of the propyl gallate at 25 ° C. in the same manner as (1). (PCa7.0-4.75) (see FIG. 2B), the force generated from the skinned fiber was measured.\n\n\n\n\n\n\n\n \n\n  結果を図２に示す。図２（Ａ）は、種々濃度のプロピルガレート（30、100および300μＭ）について、張力（Relative force (%)）とカルシウム濃度（pCa）との関係を示す。図２（Ｃ）は、張力発生のカルシウム感受性（pCa\n50\n）に対するプロピルガレートの用量依存的効果を示す。また、図１と同様に、「Vehicle」は、フェノール化合物を配合せず０.１％ＤＭＳＯの存在下で実験を行った結果を示す。\n\nThe results are shown in FIG. FIG. 2 (A) shows the relationship between tension (Relative force (%)) and calcium concentration (pCa) for various concentrations of propyl gallate (30, 100 and 300 μM). FIG. 2 (C) shows the dose-dependent effect of propyl gallate on tension-induced calcium sensitivity (pCa \n50\n ). Similarly to FIG. 1, “Vehicle” indicates the result of an experiment conducted in the presence of 0.1% DMSO without blending a phenol compound.\n\n\n\n\n\n\n \n\n  この結果から、プロピルガレートは心筋スキンドファイバー張力発生のカルシウム感受性を用量依存性に増加させ（図２（Ａ））、１００μＭ以上の濃度で統計学的に有意なカルシウム感受性の増加が検出された（図２（Ｃ））。但し、プロピルガレートのカルシウム感受性増強作用は可逆的であり、洗浄により即座に消失した（結果示さず）。\n\n\n  From this result, propyl gallate increased the calcium sensitivity of myocardial skinned fiber tension generation in a dose-dependent manner (FIG. 2 (A)), and a statistically significant increase in calcium sensitivity was detected at concentrations of 100 μM or higher. (FIG. 2 (C)). However, the calcium sensitivity enhancing action of propyl gallate was reversible and disappeared immediately after washing (results not shown).\n\n\n\n\n\n\n\n \n\n  このことから、プロピルガレートのカルシウム感受性増強作用は、用量依存的でかつ可逆的であることが確認された。\n\n\n  From this, it was confirmed that the calcium sensitivity enhancing action of propyl gallate is dose-dependent and reversible.\n\n\n\n\n\n\n\n \n\n  （３）フェノール化合物の抗酸化活性の測定\n\n  上記で使用した各フェノール化合物のうち、プロピルガレート、トロロクス、クルクミン、およびガレート一水和物について抗酸化活性を測定した。抗酸化活性は、Shirwaikarら（Shirwaikar A, Rajendran K, Punitha IS. In vitro antioxidant studies on the benzyl tetra isoquinoline alkaloid berberine. Biol Pharm Bull. 2006;29:1906-1910.）によって記載された方法に従い、安定フリーラジカル1,1-diphenyl-2-picryl hydrazyl (DPPH)に対するスカベンジ作用により評価した。\n\n(3) Measurement of antioxidant activity of phenol compound Among the phenol compounds used above, antioxidant activity was measured for propyl gallate, trolox, curcumin, and gallate monohydrate. Antioxidant activity is stable according to the method described by Shirwaikar et al. (Shirwaikar A, Rajendran K, Punitha IS. In vitro antioxidant studies on the benzyl tetraisoquinoline alkaloid berberine. Biol Pharm Bull. 2006; 29: 1906-1910.). The scavenging action on free radical 1,1-diphenyl-2-picryl hydrazyl (DPPH) was evaluated.\n\n\n\n\n\n\n \n\n  具体的には、10μＭ ＤＰＰＨと種々濃度の各フェノール化合物（プロピルガレート、トロロクス、クルクミン、またはガレート一水和物）を含む反応溶液を遮光下室温にて１０分間インキュベート後、５１７ｎｍにおけるＤＰＰＨ光吸収の減少度（％）を抗酸化活性として計算した。\n\n\n  Specifically, a reaction solution containing 10 μM DPPH and various concentrations of each phenol compound (propyl gallate, trolox, curcumin, or gallate monohydrate) was incubated at room temperature for 10 minutes in the dark, and then the DPPH light absorption at 517 nm was observed. The degree of reduction (%) was calculated as antioxidant activity.\n\n\n\n\n\n\n\n \n\n  結果を図３に示す。トロロクス、クルクミン、ガレートおよびプロピルガレートのフリーラジカル（DPPH）スカベンジ効果のＥＣ\n５０\n値は、それぞれ8.4、10.4、9.0 および1.3μＭであった。この結果からわかるように、フリーラジカル（DPPH）スカベンジ作用により評価すると、プロピルガレートは、他のフェノール化合物（トロロクス、クルクミンおよびガレート）と同程度の強い抗酸化活性を示した。\n\nThe results are shown in FIG. The EC \n50\n values for the free radical (DPPH) scavenging effect of Trolox, curcumin, gallate and propyl gallate were 8.4, 10.4, 9.0 and 1.3 μM, respectively. As can be seen from the results, propyl gallate showed strong antioxidant activity comparable to other phenolic compounds (trolox, curcumin and gallate) when evaluated by free radical (DPPH) scavenging action.\n\n\n\n\n\n\n \n \n実験例２\n \n\n  拡張型心筋症(DCM)モデルマウス（Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res. 2007;101:185-194）に対してプロピルガレートの経口投与を行い、病的な心拡大に対する抑制効果を心重量/体重比（mg/g）の変化によって評価した。\n\n \nExperimental example 2\n \n Dilated cardiomyopathy (DCM) model mouse (Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res. 2007; 101 : 185-194) was administered orally with propyl gallate, and its inhibitory effect on pathological heart enlargement was evaluated by the change in heart weight / body weight ratio (mg / g).\n\n\n\n\n\n\n \n\n  プロピルガレートは0.25％メチルセルロースに懸濁し、体重1kgあたり10mgあるいは30mgを、１日１回４週間経口ゾンデを用いて強制的に経口投与した。対照となる野生型(wild-type)マウスおよびDCMマウスには、vehicleである0.25%メチルセルロースのみを経口投与した。\n\n\n  Propyl gallate was suspended in 0.25% methylcellulose, and 10 mg / kg body weight was forcibly orally administered once a day for 4 weeks using an oral sonde. Only wild type 0.25% methylcellulose was orally administered to wild-type mice and DCM mice as controls.\n\n\n\n\n\n\n\n \n\n  結果を図４に示す。この結果からわかるように、プロピルガレートは用量依存的にDCMマウスの心重量/体重比(HW/BW ratio)を有意に減少させた。この結果から、プロピルガレートは、経口投与によって病的心拡大リモデリング反応を抑制する効果を有することが確認され、プロピルガレートが拡張型心筋症の進行防止ならびに鬱血性心不全の予防に有効であることが確認された。\n\n\n  The results are shown in FIG. As can be seen from this result, propyl gallate significantly decreased the heart weight / body weight ratio (HW / BW ratio) of DCM mice in a dose-dependent manner. This result confirms that propyl gallate has an effect of suppressing pathological heart expansion remodeling reaction by oral administration, and that propyl gallate is effective in preventing the progression of dilated cardiomyopathy and preventing congestive heart failure. Was confirmed."
  },
  {
    "id": "WO2010046035A1",
    "text": "Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine AbstractThe invention relates to sulfoximine-substituted anilinopyrimidine derivatives of formula (I), to a method for producing the same, and to the use thereof as a medication for treating various illnesses. Claims\n\n\n\n\n\n\n\n\n \n Patentansprüche\n claims\n\n\n\n\n\n\n \n1. Verbindungen der allgemeinen Formel (I)\n1. Compounds of the general formula (I)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nin der\nin the\n\n\n\n\n\n\n \nX für -O- oder -NH- steht, und\nX is -O- or -NH-, and\n\n\n\n\n\n\n \nR\n1\n für eine Methyl-, Ethyl-, Propyl- oder Isopropylgruppe steht, und R\n2\n und R\n3\n unabhängig voneinander für Wasserstoff, eine Methyl- oder\nR \n1 represents\n a methyl, ethyl, propyl or isopropyl group, and R \n2\n and R \n3\n independently represent hydrogen, a methyl or\n\n\n\n\n\n\n \nEthylgruppe stehen, und R\n4\n für eine Ci-Cβ-Alkylgruppe oder einen C\n3\n-C\n7\n-Cycloalkylring steht, sowie deren Salze, Diatereomere und Enantiomere.\nEthyl group, and R \n4 is\n a Ci-Cβ-alkyl group or a C \n3\n -C \n7\n cycloalkyl ring, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \n2. Verbindungen gemäß Anspruch 1 , wobei X für -O- steht, sowie deren Salze, Diatereomere und Enantiomere.\n2. Compounds according to claim 1, wherein X is -O-, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \n3. Verbindungen gemäß einem der Ansprüche 1 oder 2, wobei R\n1\n für eine Methylgruppe steht, sowie deren Salze, Diatereomere und Enantiomere.\n3. Compounds according to any one of claims 1 or 2, wherein R \n1 is\n a methyl group, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \n4. Verbindungen gemäß einem der Ansprüche 1 bis 3, wobei R\n2\n für eine Methylgruppe steht, sowie deren Salze, Diatereomere und Enantiomere. \n\n\n4. Compounds according to any one of claims 1 to 3, wherein R \n2 is\n a methyl group, and their salts, diate isomers and enantiomers. \n\n\n\n\n\n\n \n5. Verbindungen gemäß einem der Ansprüche 1 bis 4, wobei R\n3\n für Wasserstoff oder eine Methylgruppe s sowie deren Salze, Diatereomere und Enantiomere.\n5. Compounds according to any one of claims 1 to 4, wherein R \n3 is\n hydrogen or a methyl group s and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \n6. Verbindungen gemäß einem der Ansprüche 1 bis 5, wobei R\n4\n für eine Methyl- oder Ethylgruppe oder für einen Cyclopropylring, sowie deren Salze, Diatereomere und Enantiomere.\n6. Compounds according to any one of claims 1 to 5, wherein R \n4 is\n a methyl or ethyl group or a cyclopropyl ring, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \nVerbindungen der allgemeinen Formel (I) gemäß Anspruch 1 , in der\nCompounds of general formula (I) according to claim 1, in which\n\n\n\n\n\n\n \nX für -O- oder -NH- steht, und\nX is -O- or -NH-, and\n\n\n\n\n\n\n \nR\n1\n für eine Methylgruppe steht, und\nR \n1 is\n a methyl group, and\n\n\n\n\n\n\n \nR\n2\n für eine Methylgruppe steht, und\nR \n2 is\n a methyl group, and\n\n\n\n\n\n\n \nR\n3\n für Wasserstoff oder eine Methylgruppe steht, und\nR \n3 is\n hydrogen or a methyl group, and\n\n\n\n\n\n\n \nR\n4\n eine Methyl- oder Ethylgruppe oder für einen Cyclopropylring steht, sowie deren Salze, Diatereomere und Enantiomere.\nR \n4 is\n a methyl or ethyl group or a cyclopropyl ring, and their salts, diate isomers and enantiomers.\n\n\n\n\n\n\n \n8. Verfahren zur Herstellung von Verbindungen der allgemeinen Formel (Ia), umfassend mindestens einen der Schritte a)-h) a) Oxidation einer Verbindung der Formel (IVd) zum Sulfoxid der Formel (IVc).\n8. A process for the preparation of compounds of general formula (Ia), comprising at least one of the steps a) -h) a) oxidation of a compound of formula (IVd) to the sulfoxide of formula (IVc).\n\n\n\n\n\n\n \n \n\n bi) Direkte Iminierung des Sulfoxides der Formel (IVc) zu einem geschützten Sulfoximin der Formel (IVa).\n \n b) Direct imination of the sulfoxide of the formula (IVc) into a protected sulfoximine of the formula (IVa).\n\n\n\n\n\n\n \n \n\n oder\n \n or\n\n\n\n\n\n\n \nD\n2\n) Iminierung des Sulfoxides der Formel (IVc) zu einem ungeschützten\nD \n2\n ) Imination of the sulfoxide of the formula (IVc) to an unprotected\n\n\n\n\n\n\n \nSulfoximin der Formel (IVb) und anschließende Einführung der Schutzgruppe zu einer Verbindung der Formel (IVa).\nSulfoximine of formula (IVb) and subsequent introduction of the protective group to a compound of formula (IVa).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nc) Reduktion der Verbindung der Formel (IVa) zu einer Verbindung der\nc) reduction of the compound of formula (IVa) to a compound of\n\n\n\n\n\n\n \nFormel (IV)\nFormula (IV)\n\n\n\n\n\n\n \n \n\n d) Funktionalisierung der 4-Position von 2,4-Dichlor-5-jod-pyrimidin (VII) durch Umsetzung mit einem mono-geschützten Diol der Formel (VI) unter Bildung eines Intermediates der Formel (Va).\n \n d) functionalization of the 4-position of 2,4-dichloro-5-iodo-pyrimidine (VII) by reaction with a mono-protected diol of the formula (VI) to give an intermediate of the formula (Va).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(VII) (Va)\n(VII) (Va)\n\n\n\n\n\n\n \ne) Herstellung des 5-CF\n3\n Intermediates (V).\ne) Preparation of the 5-CF \n3\n Intermediate (V).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(Va) (V)\n(Va) (V)\n\n\n\n\n\n\n \nf) Kupplung der Verbindungen der Formel (IV) und (V) zum Intermediat der Formel (III).\nf) coupling of the compounds of the formula (IV) and (V) to the intermediate of the formula (III).\n\n\n\n\n\n\n \n \n\n g) Abspaltung der Schutzgruppe PG unter Bildung von (II).\n \n g) Cleavage of the protective group PG to form (II).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(III) (ll)\n(III) (II)\n\n\n\n\n\n\n \nh) Abspaltung der Schutzgruppe am Sulfoximin unter Bildung von (Ia).\nh) Cleavage of the protecting group on the sulfoximine to form (Ia).\n\n\n\n\n\n\n \n \n\n wobei die Substituenten R\n1\n, R\n2\n, R\n3\n und R\n4\n die in der allgemeinen Formel (I) der Ansprüche 1 bis 7 angegebenen Bedeutungen aufweisen. \n\n \n wherein the substituents R \n1\n , R \n2\n , R \n3\n and R \n4 have\n the meanings given in the general formula (I) of claims 1 to 7. \n\n\n\n\n\n\n \n9. Verfahren zur Herstellung von Verbindungen der allgemeinen Formel (Ib), umfassend mindestens einen der Schritte a)-f)\n9. A process for the preparation of compounds of the general formula (Ib), comprising at least one of the steps a) -f)\n\n\n\n\n\n\n \na) Oxidation einer Verbindung der Formel (IVd) zum Sulfoxid der Formel (IVc).\na) oxidation of a compound of formula (IVd) to the sulfoxide of the formula (IVc).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nbi) Direkte Iminierung des Sulfoxides der Formel (IVc) zu einem geschützten Sulfoximin der Formel (IVa).\nb) Direct imination of the sulfoxide of the formula (IVc) into a protected sulfoximine of the formula (IVa).\n\n\n\n\n\n\n \n \n\n oder b\n2\n) Iminierung des Sulfoxides der Formel (IVc) zu einem ungeschützten Sulfoximin der Formel (IVb) und anschließende Einführung der Schutzgruppe zu einer Verbindung der Formel (IVa).\n \n or b \n2\n ) iminating the sulfoxide of the formula (IVc) to give an unprotected sulfoximine of the formula (IVb) and then introducing the protective group into a compound of the formula (IVa).\n\n\n\n\n\n\n \n \n\n c) Reduktion der Verbindung der Formel (IVa) zu einer Verbindung der Formel (IV)\n \n c) reduction of the compound of the formula (IVa) to give a compound of the formula (IV)\n\n\n\n\n\n\n \n \n\n d) Funktionalisierung der 4-Position von 2,4-Dichlor-5-trifluormethyl-pyrimidin (VIIb) durch Umsetzung mit einem Amin der Formel (VIa) unter Bildung eines Intermediates der Formel (Vb).\n \n d) functionalization of the 4-position of 2,4-dichloro-5-trifluoromethyl-pyrimidine (VIIb) by reaction with an amine of the formula (VIa) to give an intermediate of the formula (Vb).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(VIIb) (Vb) (Vc) e) Kupplung der Verbindungen der Formel (Vb) und (IV) zum Intermediat der Formel (IIb).\n(VIIb) (Vb) (Vc) e) Coupling of the compounds of the formula (Vb) and (IV) to the intermediate of the formula (IIb).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(Vb) (IV) (IIb) \n\n f) Abspaltung der Schutzgruppe am Sulfoximin unter Bildung von (Ib).\n(Vb) (IV) (IIb)  f) Cleavage of the protecting group on the sulfoximine to form (Ib).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(IIb) (Ib)\n(IIb) (Ib)\n\n\n\n\n\n\n \nwobei die Substituenten R\n1\n, R\n2\n, R\n3\n und R\n4\n die in der allgemeinen Formel (I) der Ansprüche 1 bis 7 angegebenen Bedeutungen aufweisen.\nwherein the substituents R \n1\n , R \n2\n , R \n3\n and R \n4 have\n the meanings given in the general formula (I) of claims 1 to 7.\n\n\n\n\n\n\n \n10. Verbindungen gemäß einem der Ansprüche 1 bis 7 zur Verwendung als Arzneimittel.\n10. Compounds according to any one of claims 1 to 7 for use as medicaments.\n\n\n\n\n\n\n \n11. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 7 zur Herstellung eines Arzneimittels zur Behandlung von Krebs.\n11. Use of a compound according to any one of claims 1 to 7 for the manufacture of a medicament for the treatment of cancer.\n\n\n\n\n\n\n \n12. Verbindungen gemäß einem der Ansprüche 1 bis 7 zur Verwendung als Arzneimittel gegen Krebs.\n12. Compounds according to any one of claims 1 to 7 for use as anticancer drugs.\n\n\n\n\n\n\n \n13. Pharmazeutische Formulierung enthaltend eine Verbindung gemäß einem der Ansprüche 1 bis 7. \n\n13. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 7. Description\n\n\n\n\n\n\n \n SULFOXIMINSUBSTITUIERTE ANILINOPYRIMIDINDERATIVE ALS CDK-INHIBITOREN, DEREN HERSTELLUNG UND VERWENDUNG ALS ARZEINMITTEL\n SULFOXIMIN-SUBSTITUTED ANILINOPYRIMIDINDERATIVE AS CDK-INHIBITORS, THEIR PREPARATION AND USE AS PHARMACEUTICALS\n\n\n\n\n\n\n \nDie vorliegende Erfindung betrifft ausgewählte sulfoximinsubsituierte Anilino- Pyrimidinderivate, deren Verfahren zur Herstellung sowie deren Verwendung als Medikament zur Behandlung verschiedener Erkrankungen.\nThe present invention relates to selected sulfoximinesubsituierte anilino-pyrimidine derivatives, their process for the preparation and their use as a medicament for the treatment of various diseases.\n\n\n\n\n\n\n \nDie Zyklin-abhängigen Kinasen (cyclin-dependent kinase, CDK) sind eine Enzymfamilie, die eine wichtige Rolle bei der Regulation des Zellzyklusses spielt und somit ein besonders interessantes Ziel für die Entwicklung kleiner inhibitorischer\nThe cyclin-dependent kinases (CDK) are an enzyme family that plays an important role in the regulation of the cell cycle and thus a particularly interesting target for the development of small inhibitory\n\n\n\n\n\n\n \nMoleküle darstellt. Selektive Inhibitoren der CDKs können zur Behandlung von Krebs oder anderen Erkrankungen, die Störungen der Zellproliferation zur Ursache haben, verwendet werden.\nRepresents molecules. Selective inhibitors of CDKs can be used to treat cancers or other diseases that cause cell proliferation disorders.\n\n\n\n\n\n\n \nPyrimidine und Analoga sind bereits als Wirkstoffe beschrieben wie beispielsweise die 2-Anilino-Pyrimidine als Fungizide (DE 4029650) oder substituierte Pyrimidinderivate zur Behandlung von neurologischen oder neurodegenerativen Erkrankungen (WO 99/19305). Als CDK-Inhibitoren werden unterschiedlichste Pyrimidinderivate beschrieben, beispielsweise 2-Amino-4-substituierte Pyrimidine (WO 01/ 14375), Purine (WO 99/02162), 5-Cyano-Pyrimidine (WO 02/04429), Anilinopyrimidine (WO 00/12486) und 2-Hydroxy-3-N,N-dimethylaminopropoxy- Pyrimidine (WO 00/39101 ).\nPyrimidines and analogues have already been described as active ingredients such as, for example, the 2-anilino-pyrimidines as fungicides (DE 4029650) or substituted pyrimidine derivatives for the treatment of neurological or neurodegenerative diseases (WO 99/19305). As CDK inhibitors a wide variety of pyrimidine derivatives are described, for example 2-amino-4-substituted pyrimidines (WO 01/14375), purines (WO 99/02162), 5-cyano-pyrimidines (WO 02/04429), anilinopyrimidines (WO 00 / 12486) and 2-hydroxy-3-N, N-dimethylaminopropoxy-pyrimidines (WO 00/39101).\n\n\n\n\n\n\n \nInsbesondere wurden in WO 02/096888 und WO 03/076437 Pyrimidinderivate offenbart, die inhibitorische Wirkungen bezüglich CDKs aufweisen.\nIn particular, WO 02/096888 and WO 03/076437 have disclosed pyrimidine derivatives which have inhibitory effects on CDKs.\n\n\n\n\n\n\n \nVerbindungen, die eine Phenylsulfonamid-Gruppe enthalten, sind als Inhibitoren der humanen Carboanhydrasen (insbes. Carboanhydrase-2) bekannt und werden als Diuretica u.a. zur Behandlung von Glaucom eingesetzt. Das Stickstoffatom und die Sauerstoffatome des Sulfonamids binden über Wasserstoffbrücken mit dem Zink\n2+\n- Ion und der Aminosäure Thr 199 im aktiven Zentrum der Carboanhydrase-2 und blockieren dadurch deren enzymatische Funktion (A. Casini, F. Abbate, A. Scozzafava, CT. Supuran, Bioorganic. Med. Chem. Lett. 2003, 1 , 2759). Die klinische Verwendung von CDK-Inhibitoren, die eine Phenylsulfonamid-Gruppe \n\n enthalten, könnte durch die Möglichkeit der Inhibition der Carboanhydrasen und ein daraus resultierendes Nebenwirkungsspektrum eingeschränkt sein.\nCompounds which contain a phenylsulfonamide group are known as inhibitors of human carbonic anhydrases (in particular carbonic anhydrase-2) and are used as diuretics, inter alia, for the treatment of glaucoma. The nitrogen atom and the oxygen atoms of the sulfonamide bind by hydrogen bonding with the zinc \n2+\n ion and the amino acid Thr 199 in the active center of carbonic anhydrase-2 and thereby block their enzymatic function (A. Casini, F. Abbate, A. Scozzafava, CT. Supuran, Bioorganic, Med. Chem. Lett., 2003, 1, 2759). The clinical use of CDK inhibitors containing a phenylsulfonamide group  could be limited by the possibility of inhibiting the carbonic anhydrases and a resulting side effect spectrum.\n\n\n\n\n\n\n \nBeispiele für Sulfoximin-Wirkstoffe sind sulfonimidoyl-modifizierte Triazole als Fungizide (H. Kawanishi, H. Morimoto, T. Nakano, T. Watanabe, K. Oda, K.\nExamples of sulfoximine active substances are sulfonimidoyl-modified triazoles as fungicides (H. Kawanishi, H. Morimoto, T. Nakano, T. Watanabe, K. Oda, K.\n\n\n\n\n\n\n \nTsujihara, Heterocycles 1998, 49, 181) oder Arylalkylsulfoximine als Herbizide und Pestizide (Shell International Research, Ger. P. 2 129 678).\nTsujihara, Heterocycles 1998, 49, 181) or arylalkyl sulfoximines as herbicides and pesticides (Shell International Research, Ger. P. 2,129,678).\n\n\n\n\n\n\n \nWO 2005/037800 offenbart offene sulfoximinsubsituierte Anilino-Pyrimidinderivate als Inhibitoren der Zyklin-abhängigen Kinasen. Beispielhaft belegt sind Strukturen, die in der 5-Position des Pyrimidins entweder nicht oder mit Halogen, insbesondere mit Brom substituiert sind. Einen 5-Trifluormethylsubstituenten weist keine der spezifisch offenbarten Strukturen auf.\nWO 2005/037800 discloses open sulfoximine-substituted anilino-pyrimidine derivatives as inhibitors of cyclin-dependent kinases. Exemplified are structures which are either not substituted in the 5-position of the pyrimidine or substituted with halogen, in particular with bromine. A 5-trifluoromethyl substituent does not have any of the specifically disclosed structures.\n\n\n\n\n\n\n \nAusgehend von diesem Stand der Technik besteht die Aufgabe der vorliegenden\nBased on this prior art, the object of the present\n\n\n\n\n\n\n \nErfindung Verbindungen bereitzustellen, die nicht nur CDK potent inhibieren, sondern die auch das Tumorwachstum effektiv hemmen. Zwar ist die potente CDK-Inhibition eine notwendige, aber nicht hinreichende Vorraussetzung für eine effektive Tumorhemmung. Hierfür sind weitere Eigenschaften der Strukturen notwendig, wie zum Beispiel die Penetrationseigenschaften in die Tumorzelle.\nInvention to provide compounds which not only potently inhibit CDK, but which also effectively inhibit tumor growth. Although potent CDK inhibition is a necessary but not sufficient prerequisite for effective tumor inhibition. For this purpose, further properties of the structures are necessary, such as the penetration properties into the tumor cell.\n\n\n\n\n\n\n \nEs wurde nun gefunden, dass Verbindungen der allgemeinen Formel (I)\nIt has now been found that compounds of the general formula (I)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nin der \n\n X für -O- oder -NH- steht, und\nin the  X is -O- or -NH-, and\n\n\n\n\n\n\n \nR\n1\n für eine Methyl-, Ethyl-, Propyl- oder Isopropylgruppe steht, und\nR \n1 is\n a methyl, ethyl, propyl or isopropyl group, and\n\n\n\n\n\n\n \nR\n2\n und R\n3\n unabhängig voneinander für Wasserstoff, eine Methyl- oder\nR \n2\n and R \n3 are\n independently hydrogen, methyl or\n\n\n\n\n\n\n \nEthylgruppe stehen, und R\n4\n für eine CrC\n6\n-Alkylgruppe oder einen C\n3\n-C\n7\n-Cycloalkylring steht, sowie deren Salze, Diatereomere und Enantiomere, nicht nur CDK potent inhibieren, sondern auch das Tumorwachstum besonders effektiv hemmen.\nEthyl group, and R \n4 is\n a CrC \n6\n alkyl group or a C \n3\n -C \n7\n cycloalkyl ring, and their salts, diate isomers and enantiomers, not only inhibit CDK potent, but also inhibit tumor growth particularly effective.\n\n\n\n\n\n\n \nVerbindungen, in denen X für -O- steht, werden mit der Formel (Ia) zusammengefasst.\nCompounds in which X is -O- are summarized by the formula (Ia).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nVerbindungen, in denen X für -NH- steht, werden mit der Formel (Ib) zusammengefasst.\nCompounds in which X is -NH- are summarized by the formula (Ib).\n\n\n\n\n\n\n \n \n\n -A-\n \n -A-\n\n\n\n\n\n\n \nDer Anmeldung liegen folgende Definitionen zugrunde:\nThe application is based on the following definitions:\n\n\n\n\n\n\n \nCi-C\nfi\n-Alkyl\nCi-C \nfi\n -alkyl\n\n\n\n\n\n\n \nUnter einer Ci-C\n6\n-Alkylgruppe ist jeweils ein geradkettiger oder verzweigter Alkylrest zu verstehen, wie beispielsweise ein Methyl-, Ethyl-, Propyl- Isopropyl-, Butyl-, Isobutyl-, sek. Butyl-, tert. Butyl-, Pentyl-, Isopentyl- oder ein Hexylrest.\nA C \n1\n -C \n6\n -alkyl group is in each case to be understood as meaning a straight-chain or branched alkyl radical, such as, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl or a hexyl radical.\n\n\n\n\n\n\n \nC^-C\n7\n-CvClOaIkVl\nC ^ -C \n7\n -CvClOaIkVl\n\n\n\n\n\n\n \nUnter einem C\n3\n-C\n7\n-Cycloalkylring ist ein Cyclopropyl- Cyclobutyl-, Cyclopentyl-, Cyclohexyl- oder ein Cycloheptylring zu verstehen.\nA C \n3\n -C \n7\n cycloalkyl ring is to be understood as meaning a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl ring.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) kann X stehen für -O- oder -NH-. Bevorzugt steht X für -O-.\nIn the general formula (I), X may be -O- or -NH-. Preferably, X is -O-.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) kann R\n1\n stehen für eine Methyl-, Ethyl-, Propyl- oder Isopropylgruppe. Bevorzugt steht R\n1\n für eine Methylgruppe.\nIn the general formula (I), R \n1 may\n represent a methyl, ethyl, propyl or isopropyl group. Preferably, R \n1 is\n a methyl group.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) können R\n2\n und R\n3\n unabhängig voneinander stehen für Wasserstoff, eine Methyl- oder Ethylgruppe. BBeevvoorrzzuuggtt sstteefhen R\n2\n und R\n3\n unabhängig voneinander für Wasserstoff oder eine Methylgruppe. BBeessoonnddeerrss bbee\n1\nvorzugt steht R\n2\n für eine Methylgruppe und R\n3\n für Wasserstoff oder eine Methylgruppe.\nIn the general formula (I), R \n2\n and R \n3 may\n independently represent hydrogen, a methyl or ethyl group. BBeevvoorrzzuuggtt sstteefhen R \n2\n and R \n3\n independently represent hydrogen or a methyl group. BBeessoonnddeerrss bbee vorzugt \n1,\n R \n2\n is a methyl group and R \n3\n represents hydrogen or a methyl group.\n\n\n\n\n\n\n \nIn der allgemeinen Formel (I) kann R\n4\n stehen für einen Ci-Cβ-Alkylrest oder einen C\n3\n-\nIn the general formula (I), R \n4\n may be a C \n1\n -C \n6\n -alkyl radical or a C \n3\n -\n\n\n\n\n\n\n \nCr-Cycloalkylring.\nCr-cycloalkyl.\n\n\n\n\n\n\n \nBevorzugt steht R\n4\n für eine Methyl- oder Ethylgruppe oder für einen Cyclopropylring. \n\n Eine bevorzugte Untergruppe der Verbindungen gemäß der allgemeinen Formel (I) sind Verbindungen gemäß allgemeiner Formel (I) , in der\nPreferably, R \n4 is\n a methyl or ethyl group or a cyclopropyl ring.  A preferred subgroup of the compounds according to the general formula (I) are compounds according to general formula (I) in which\n\n\n\n\n\n\n \nX für -O- oder -NH- steht, und R\n1\n für eine Methylgruppe steht, und R\n2\n für eine Methylgruppe steht, und R\n3\n für Wasserstoff oder eine Methylgruppe steht, und R\n4\n eine Methyl- oder Ethylgruppe oder für einen Cyclopropylring steht, sowie deren Salze, Diatereomere und Enantiomere.\nX is -O- or -NH-, and R \n1 is\n a methyl group, and R \n2 is\n a methyl group, and R \n3 is\n hydrogen or a methyl group, and R \n4 is\n a methyl or ethyl group or a cyclopropyl ring , as well as their salts, diatereomers and enantiomers.\n\n\n\n\n\n\n \nDie erfindungsgemäßen Verbindungen eignen sich zur Behandlung\nThe compounds of the invention are suitable for treatment\n\n\n\n\n\n\n \n• von Krebs, wie solide Tumore, Tumormetastasen, und Hämatologische Tumoren, insbesondere:\n• of cancer, such as solid tumors, tumor metastases, and hematologic tumors, in particular:\n\n\n\n\n\n\n \nKopf- und Halstumore; Lungen- und Bronchialtumore; Gastrointestinaltumore wie z.B. Magenkarzinom, Kolorektales Karzinom, Pankreaskarziom,\nHead and neck tumors; Lung and bronchial tumors; Gastrointestinal tumors such as e.g. Gastric carcinoma, colorectal carcinoma, pancreatic carcinoma,\n\n\n\n\n\n\n \nHepatozelluläres Karzinom; Endokin aktive Tumore; Mammakarzinome und Gynäkologische Tumore; Urogenitaltumore, wie z.B. Nierenzellkarzinom, Harnblasenkarzinom, Prostatakarzinom; Tumore der Haut; Sarkome; Leukämien und Lymphome. • von viralen Erkrankungen, sowie\nHepatocellular carcinoma; Endokin active tumors; Breast and gynecological tumors; Genitourinary tumors, e.g. Renal cell carcinoma, bladder carcinoma, prostate carcinoma; Tumors of the skin; sarcomas; Leukemias and lymphomas. • of viral diseases, as well\n\n\n\n\n\n\n \n• von kardiovaskulären Erkrankungen wie Stenosen, Arteriosklerosen und Restenosen, Stent-induzierte Restenosen.\n• cardiovascular diseases such as stenosis, arteriosclerosis and restenosis, stent-induced restenosis.\n\n\n\n\n\n\n \nDie Formulierung der erfindungsgemäßen Verbindungen zu pharmazeutischen Präparaten erfolgt in an sich bekannter Weise, indem man den oder die Wirkstoffe mit den in der Galenik gebräuchlichen Hilfsstoffen in die gewünschte Applikationsform überführt.\nThe formulation of the compounds according to the invention into pharmaceutical preparations is carried out in a manner known per se by converting the active substance (s) into the desired administration form with the auxiliaries customary in galenicals.\n\n\n\n\n\n\n \nAls Hilfsstoffe können dabei beispielsweise Trägersubstanzen, Füllstoffe, Sprengmittel, Bindemittel, Feuchthaltemittel, Gleitmittel, Ab- und Adsorptionsmittel, Verdünnungsmittel, Lösungsmittel, Cosolventien, Emulgatoren, Lösungsvermittler, Geschmackskorrigentien, Färbemittel, Konservierungs-, Stabilisierungs-, Netzmittel, Salze zur Veränderung des osmotischen Drucks oder Puffer zum Einsatz kommen. \n\n Dabei ist auf Remington\n'\ns Pharmaceutical Science, 15th ed. Mack Publishing Company, East Pennsylvania (1980) hinzuweisen.\nAs auxiliaries may, for example, vehicles, fillers, disintegrants, binders, humectants, lubricants, adsorbents and agents, diluents, solvents, cosolvents, emulsifiers, solubilizers, flavoring agents, colorants, preservatives, stabilizers, wetting agents, salts for changing the osmotic pressure or buffers are used.  Reference may be made to Remington \n's\n Pharmaceutical Science, 15th ed. Mack Publishing Company, East Pennsylvania (1980).\n\n\n\n\n\n\n \nDie pharmazeutischen Formulierungen können in fester Form, zum Beispiel als Tabletten, Dragees, Pillen, Suppositorien, Kapseln, transdermale Systeme oder in halbfester Form , zum Beispiel als Salben, Cremes, Gele, Suppositiorien, Emulsionen oder in flüssiger Form, zum Beispiel als Lösungen, Tinkturen, Suspensionen oder Emulsionen vorliegen.\nThe pharmaceutical formulations may be in solid form, for example as tablets, dragees, pills, suppositories, capsules, transdermal systems or in semisolid form, for example as ointments, creams, gels, suppositories, emulsions or in liquid form, for example as solutions, Tinctures, suspensions or emulsions are present.\n\n\n\n\n\n\n \nHilfsstoffe im Sinne der Erfindung können beispielsweise Salze, Saccharide (Mono-, Di-, Tri-, Oligo-, und/oder Polysaccharide), Proteine, Aminosäuren, Peptide, Fette, Wachse, Öle, Kohlenwasserstoffe sowie deren Derivate sein, wobei die Hilfsstoffe natürlichen Ursprungs sein können oder synthetisch bzw. partial synthetisch gewonnen werden können.\nAuxiliaries for the purposes of the invention may be, for example, salts, saccharides (mono-, di-, tri-, oligo-, and / or polysaccharides), proteins, amino acids, peptides, fats, waxes, oils, hydrocarbons and derivatives thereof, the auxiliaries may be of natural origin or synthetically or partially synthetically obtained.\n\n\n\n\n\n\n \nFür die orale oder perorale Applikation kommen insbesondere Tabletten, Dragees, Kapseln, Pillen, Pulver, Granulate, Pastillen, Suspensionen, Emulsionen oder Lösungen in Frage.\nFor oral or oral administration, in particular tablets, dragees, capsules, pills, powders, granules, lozenges, suspensions, emulsions or solutions come into question.\n\n\n\n\n\n\n \nFür die parenterale Applikation kommen insbesondere Suspensionen, Emulsionen und vor allem Lösungen in Frage.\nFor parenteral administration in particular suspensions, emulsions and above all solutions in question.\n\n\n\n\n\n\n \nHerstellung der erfindungsqemäßen Verbindungen Sulfoximine besitzen in Bezug auf Struktur und Konfiguration in der Regel eine hohe Stabilität (C. BoIm, J.P. Hildebrand, J. Org. Chem. 2000, 65, 169). Diese Eigenschaften der funktionellen Gruppe erlauben oftmals auch drastische Reaktionsbedingungen und ermöglichen die einfache Derivatisierung der Sulfoximine am Imin-Stickstoff und dem α-Kohlenstoff. Enantiomerenreine Sulfoximine werden auch als Auxiliare in der diastereoselektiven Synthese verwendet ((a) S. G. Pyne, Sulfur Reports 1992, 12, 57; (b) CR. Johnson, Aldrichimica Acta 1985, 18, 3). Die Darstellung enantiomerenreiner Sulfoximine ist z.B. über die Racematspaltung mit enantiomerenreiner Campher-10-sulfonsäure beschrieben ((a) CR. Johnson, \n\n CW. Schroeck, J. Am. Chem. Soc. 1973, 95, 7418; (b) CS. Shiner, A.H. Berks, J. Org. Chem. 1988, 53, 5542). Eine weitere Methode zur Darstellung optisch aktiver Sulfoximine besteht in der stereoselektiven Iminierung von optisch aktiven Sulfoxiden ((a) C BoIm, P. Müller, K. Harms, Acta Chem. Scand. 1996, 50, 305; (b) Y. Tamura, J. Minamikawa, K. Sumoto, S. Fujii, M. Ikeda, J. Org. Chem. 1973, 38, 1239; (c) H. Okamura, C. BoIm, Org. Lett. 2004, 6, 1305).\nPreparation of the Compounds According to the Invention Sulfoximines generally have a high stability in terms of structure and configuration (C. Boim, JP Hildebrand, J. Org. Chem. 2000, 65, 169). These properties of the functional group also often allow for drastic reaction conditions and allow the simple derivatization of the sulfoximines on the imine nitrogen and the α-carbon. Enantiomerically pure sulfoximines are also used as auxiliaries in diastereoselective synthesis ((a) SG Pyne, Sulfur Reports 1992, 12, 57; (b) CR Johnson, Aldrichimica Acta 1985, 18, 3). The preparation of enantiomerically pure sulfoximines is described, for example, via the racemate resolution with enantiopure camphor-10-sulfonic acid ((a) CR Johnson,  CW. Schroeck, J. Am. Chem. Soc. 1973, 95, 7418; (b) CS. Shiner, AH Berks, J. Org. Chem. 1988, 53, 5542). Another method for the preparation of optically active sulfoximines consists in the stereoselective imination of optically active sulfoxides ((a) C BoIm, P. Muller, K. Harms, Acta Chem. Scand. 1996, 50, 305; (b) Y. Tamura, J. Minamikawa, K. Sumoto, S. Fujii, M. Ikeda, J. Org. Chem. 1973, 38, 1239; (c) H. Okamura, C. Boim, Org. Lett. 2004, 6, 1305).\n\n\n\n\n\n\n \nFür Übersichtsartikel zu Sulfoximinen siehe z.B.: a) M. Regglin, C. Zur, Synthesis 2000, 1 ; (b) CR. Johnson, Aldrichimica Acta 1985, 18, 3).\nFor reviews on sulfoximines see, for example: a) M. Regglin, C. Zur, Synthesis 2000, 1; (b) CR. Johnson, Aldrichimica Acta 1985, 18, 3).\n\n\n\n\n\n\n \nDie nachfolgenden Beispiele erläutern die Herstellung der erfindungsgemäßen Verbindungen, ohne den Umfang der beanspruchten Verbindungen auf diese Beispiele zu beschränken.\nThe following examples illustrate the preparation of the compounds of the invention without limiting the scope of the claimed compounds to these examples.\n\n\n\n\n\n\n \nHerstellung der Verbindungen der Formel (Ia) (4-0 Derivate) Die erfindungsgemäßen Verbindungen können hergestellt werden durch ein Verfahren, das durch folgende Schritte gekennzeichnet ist:\nPreparation of the compounds of the formula (Ia) (4-O derivatives) The compounds according to the invention can be prepared by a process which is characterized by the following steps:\n\n\n\n\n\n\n \na) Oxidation einer Verbindung der Formel (IVd) zum Sulfoxid der Formel (IVc).\na) oxidation of a compound of formula (IVd) to the sulfoxide of the formula (IVc).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nbi) Direkte Iminierung des Sulfoxides der Formel (IVc) zu einem geschützten Sulfoximin der Formel (IVa).\nb) Direct imination of the sulfoxide of the formula (IVc) into a protected sulfoximine of the formula (IVa).\n\n\n\n\n\n\n \n \n\n oder \n\n b\n2\n) Iminierung des Sulfoxides der Formel (IVc) zu einem ungeschützten Sulfoximin der Formel (IVb) und anschließende Einführung der Schutzgruppe zu einer Verbindung der Formel (IVa).\n \n or  b \n2\n ) Imination of the sulfoxide of the formula (IVc) to give an unprotected sulfoximine of the formula (IVb) and subsequent introduction of the protective group to a compound of the formula (IVa).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nReduktion der Verbindung der Formel (IVa) zu einer Verbindung der Formel (IV)\nReduction of the compound of the formula (IVa) to give a compound of the formula (IV)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nd) Funktionalisierung der 4-Position von 2,4-Dichlor-5-jod-pyrimidin (VII) durch Umsetzung mit einem mono-geschützten Diol der Formel (VI) unter Bildung eines Intermediates der Formel (Va).\nd) functionalization of the 4-position of 2,4-dichloro-5-iodo-pyrimidine (VII) by reaction with a mono-protected diol of the formula (VI) to give an intermediate of the formula (Va).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(VII) (Va) \n\n e) Herstellung des 5-CF\n3\n lntermediates (V).\n(VII) (Va)  e) Preparation of the 5-CF \n3\n Intermediate (V).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(Va) (V)\n(Va) (V)\n\n\n\n\n\n\n \nf) Kupplung der Verbindungen der Formel (IV) und (V) zum Intermediat der Formel (III).\nf) coupling of the compounds of the formula (IV) and (V) to the intermediate of the formula (III).\n\n\n\n\n\n\n \n \n\n g) Abspaltung der Schutzgruppe (PG) unter Bildung von (II).\n \n g) Cleavage of the protecting group (PG) to give (II).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(III) (ll) \n\n h) Abspaltung der Schutzgruppe am Sulfoximin unter Bildung von (Ia).\n(III) (II)  h) Cleavage of the protecting group on the sulfoximine to form (Ia).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(II) (Ia) wobei die Substituenten R\n1\n, R\n2\n, R\n3\n und R\n4\n die in der allgemeinen Formel (I) angegebenen Bedeutungen aufweisen.\n(II) (Ia) where the substituents R \n1\n , R \n2\n , R \n3\n and R \n4 have\n the meanings given in the general formula (I).\n\n\n\n\n\n\n \nVerfahrensschritt a)\nProcess step a)\n\n\n\n\n\n\n \nEine Verbindung der Formel (IVd) wird zum Sulfoxid der Formel (IVc) oxidiert. Für die Überführung eines Thioethers in ein Sulfoxid stehen zahlreiche Methoden, auch stereoselektive, zur Verfügung (siehe z.B.: (a) M. H. Ali et al, Synthesis 1997, 764; b) M.C. Carreno, Chem. Rev. 1995, 95, 1717; c) I. Patel et al, Org. Proc. Res. Dev.\nA compound of formula (IVd) is oxidized to the sulfoxide of formula (IVc). Many methods, including stereoselective ones, are available for the conversion of a thioether into a sulfoxide (see, for example: (a) M.H. Ali et al., Synthesis 1997, 764. b) M.C. Carreno, Chem. Rev. 1995, 95, 1717; c. I. Patel et al, Org. Proc. Res. Dev.\n\n\n\n\n\n\n \n2002, 6, 225; c) N. Khiar et al, Chem. Rev. 2003, 103, 3651 ). Besonders geeignet für die Darstellung von Verbindungen der Formel (IVc) ist die beschriebene Verwendung von Perjodsäure / Eisen(lll)chlorid.\n2002, 6, 225; c) N. Khiar et al, Chem. Rev. 2003, 103, 3651). Particularly suitable for the preparation of compounds of formula (IVc) is the described use of periodic acid / iron (III) chloride.\n\n\n\n\n\n\n \nVerfahrensschritt bi)\nProcedural step bi)\n\n\n\n\n\n\n \nDie Umsetzung eines Sulfoxides der Formel (IVc) mit Trifluoracetamid in Kombination mit Jodbenzol-diacetat, Magnesiumoxid und katalytischen Mengen von Rhodium(ll)-acetat Dimer ermöglicht die Darstellung eines geschützten Sulfoximins der Formel (IVa). Diese Reaktion ist stereospezifisch und verläuft unter Retention der Konfiguration am Stereozentrum (siehe: (a) H. Okamura, C. BoIm, Org. Lett. 2004, 6, 1305). \n\n Verfahrensschritt b?)\nThe reaction of a sulfoxide of the formula (IVc) with trifluoroacetamide in combination with iodobenzene diacetate, magnesium oxide and catalytic amounts of rhodium (II) acetate dimer allows the preparation of a protected sulfoximine of the formula (IVa). This reaction is stereospecific and proceeds with retention of configuration at the stereocenter (see: (a) H. Okamura, C. BoIm, Org. Lett. 2004, 6, 1305).  Method step b?)\n\n\n\n\n\n\n \nHierbei erfolgt zunächst die Umsetzung eines Sulfoxides der Formel (IVc) zu einem ungeschützten Sulfoximin der Formel (IVb). Geeignete Methoden sind beispielsweise: a) Die Umsetzung des Sulfoxides mit Natriumazid / konz. Schwefelsäure (siehe z.B.: (a) CR. Johnson, P.E. Rogers, J. Org. Chem. 1973, 38, 1793). b) Die Umsetzung des Sulfoxides mit Natriumazid / Oleum (siehe z.B.: (a) N.V. Kondratenko, O.A. Radchenko, L. M. Yagupol\n'\nski, J. Org. Chem. USSR 1984, 20, 2051 ). c) Die Umsetzung des Sulfoxides mit o-Mesitylensulfonylhydroxylamin (MSH) (siehe z.B.: (a) CR. Johnson, R.A. Kirchhoff, H.G. Corkins, J. Org. Chem. 1974, 39, 2458). Die anschließende Einführung der Schutzgruppe unter Bildung von Verbindungen der Formel (IVa) kann beispielsweise wie beschrieben durch die Umsetzung mit Trifluoracetanhydrid unter basischen Bedingungen erfolgen.\nIn this case, the reaction of a sulfoxide of the formula (IVc) initially takes place to form an unprotected sulfoximine of the formula (IVb). Suitable methods are, for example: a) The reaction of the sulfoxide with sodium azide / conc. Sulfuric acid (see eg: (a) CR Johnson, PE Rogers, J. Org. Chem. 1973, 38, 1793). b) The reaction of the sulfoxide with sodium azide / oleum (see, for example: (a) NV Kondratenko, OA Radchenko, LM Yagupol \n'\n ski, J. Org. Chem. USSR 1984, 20, 2051). c) The reaction of the sulfoxide with o-mesitylenesulfonylhydroxylamine (MSH) (see eg: (a) CR Johnson, RA Kirchhoff, HG Corkins, J. Org. Chem. 1974, 39, 2458). The subsequent introduction of the protective group to form compounds of the formula (IVa) can be carried out, for example, as described by the reaction with trifluoroacetic anhydride under basic conditions.\n\n\n\n\n\n\n \nVerfahrensschritt c)\nProcess step c)\n\n\n\n\n\n\n \nFür die anschließende Reduktion der aromatischen Nitrogruppe zu einer Verbindung der Formel (IV) stehen prinzipiell eine Reihe von Reaktionsbedingungen zur Verfügung (siehe z.B.: R.C Larock, Comprehensive Organic Transformations, VCH, New York, 1989, 411 ). Besonders geeignet ist beispielsweise die beschriebene Verwendung von Titan(lll)chlorid oder die Hydrierung unter Verwendung von Palladium auf Kohle.\nFor the subsequent reduction of the aromatic nitro group to a compound of the formula (IV), a number of reaction conditions are available in principle (see, for example: R. C. Larock, Comprehensive Organic Transformations, VCH, New York, 1989, 411). Particularly suitable is, for example, the described use of titanium (III) chloride or hydrogenation using palladium on carbon.\n\n\n\n\n\n\n \nVerfahrensschritt d) Die Umsetzung von 2,4-Dichlor-5-jod-pyrimidin (VII) mit einem Alkohol der Formel (VI) ermöglicht die Darstellung eines Intermediates der Formel (Va) (siehe z.B.: U. Lücking et al, WO2007/071455).\nProcess Step d) The reaction of 2,4-dichloro-5-iodopyrimidine (VII) with an alcohol of the formula (VI) enables the preparation of an intermediate of the formula (Va) (see, for example: U. Lücking et al, WO2007 / 071455).\n\n\n\n\n\n\n \nVerfahrensschrit e) Für den Austausch eines Halogens gegen eine Trifluormetyhlgruppe in einem stickstoffhaltigen Heteroaromaten stehen prinzipiell verschiedene Methoden zur Verfügung (siehe z.B: a) G.E. Carr, R.D. Chambers, T.F. Holmes, J. Chem. Soc. Perkin Trans. 1 , 1988, 921 ; b) F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2002, 327; c) F.G. Njoroge et al, J. Med. Chem 1997, 40, 4290). \n\n Für die Einführung in die 5-Position des Pyrimidins (Va) unter Bildung von lntermediat (V) ist besonders die beschriebene Verwendung von Kupfer(l)jodid, Kaliumfluorid und (Trifluormethyl)-trimethylsilan in N-Methyl-2-pyrrolidinon und THF geeignet.\nProcess step e) In principle, various methods are available for the replacement of a halogen for a trifluoromethyl group in a nitrogen-containing heteroaromatic radical (see, for example: a) GE Carr, RD Chambers, TF Holmes, J. Chem. Soc. Perkin Trans. 1, 1988, 921; b) F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2002, 327; c) FG Njoroge et al, J.Med.Chem 1997, 40, 4290).  For the introduction into the 5-position of the pyrimidine (Va) to form intermediate (V), the described use of copper (I) iodide, potassium fluoride and (trifluoromethyl) trimethylsilane in N-methyl-2-pyrrolidinone and THF is particularly suitable ,\n\n\n\n\n\n\n \nVerfahrensschritt f)\nProcess step f)\n\n\n\n\n\n\n \nEin 2-Chlor-pyrimidin der Formel (V) kann mit einem Anilin der Formel (IV) zu einem lntermediat der Formel (III) umgesetzt werden (siehe z.B.: (a) J. Bryant et al, WO 2004/048343).\nA 2-chloro-pyrimidine of formula (V) can be reacted with an aniline of formula (IV) to give an intermediate of formula (III) (see, for example: (a) J. Bryant et al, WO 2004/048343).\n\n\n\n\n\n\n \nVerfahrensschritt g)\nProcess step g)\n\n\n\n\n\n\n \nDie Abspaltung der Schutzgruppe (PG) aus dem lntermediat (Ml) liefert das lntermediat (II) (siehe z.B.: PJ. Kocienski, Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994). Für die beschriebene Abspaltung einer Benzylgruppe ist die beschriebene Hydrierung besonders geeignet. Die Abspaltung einer THP-Gruppe kann ggf. bereits unter den Bedingungen des Verfahrensschrittes f) erfolgen.\nCleavage of the protecting group (PG) from the intermediate (M1) yields the intermediate (II) (see, e.g., PJ Kocienski, Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994). For the described cleavage of a benzyl group, the described hydrogenation is particularly suitable. The cleavage of a THP group may possibly already take place under the conditions of process step f).\n\n\n\n\n\n\n \nVerfahrensschritt h) Die Abspaltung der Trifluoracetogruppe am Sulfoximin (II) liefert die Verbindung der Formel (Ia). Besonders geeignet ist hierfür die beschriebene Methodik unter Verwendung von Kaliumcarbonat in Methanol bei Raumtemperatur (siehe z.B.: (a) H. Okamura, C. BoIm, Org. Lett. 2004, 6, 1305).\nProcess Step h) The cleavage of the trifluoroaceto group on the sulfoximine (II) yields the compound of the formula (Ia). Particularly suitable for this purpose is the described methodology using potassium carbonate in methanol at room temperature (see, for example, (a) H. Okamura, C. Boim, Org. Lett. 2004, 6, 1305).\n\n\n\n\n\n\n \nAllgemeine Hinweise\nGeneral information\n\n\n\n\n\n\n \nAlle Reaktionen mit oxidations- oder hydrolyseempfindlichen Verbindungen wurden unter Argon und mit getrockneten Lösungsmitteln durchgeführt. Die Substanzbenennung mit Ausnahme der Sulfoximinderivate erfolgte unter Verwendung des Programms Autonom 2000 Name, welches in MDL ISIS Draw implementiert ist. Autonom 2000 Name akzeptiert keine Sulfoximine, daher erfolgte die Benennung der Sulfoximine anhand der IUPAC Regeln (IUPAC, Nomenclature of Organic Chemistry, 1979 Edition, C-6.3. Sulfoxides and Sulfones, RuIe C-633, 633.1 Sulfimide and Sulfoximide). \n\n Abkürzungen\nAll reactions with oxidation- or hydrolysis-sensitive compounds were carried out under argon and with dried solvents. Substance naming except sulfoximine derivatives was done using the program Autonom 2000 Name, which is implemented in MDL ISIS Draw. Autonom 2000 name does not accept sulfoximines, therefore the sulfoximines were named by the IUPAC rules (IUPAC, Nomenclature of Organic Chemistry, 1979 Edition, C-6.3, Sulfoxides and Sulfones, RuIe C-633, 633.1 Sulfimides and Sulfoximides).  Abbreviations\n\n\n\n\n\n\n \n \n\n Beispiel 1\n \n example 1\n\n\n\n\n\n\n \n(RSJ-S-Cyclopropyl-S-^-fl^KIR^R^-hydroxy-i-methylpropylloxy^δ-\n(RSJ-S-Cyclopropyl-S - ^ - ^ fl KIR ^ R ^ -hydroxy-i ^ methylpropylloxy δ-\n\n\n\n\n\n\n \n(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid\n(Trifluoromethyl) pyrimidin-2-yl] amino} phenyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n1a) Herstellung der Zwischenprodukte Verbindung 1.1 i-Cyclopropylsulfanyl-4-nitro-benzol\n1a) Preparation of Intermediates Compound 1.1 i-Cyclopropylsulfanyl-4-nitro-benzene\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 3,00 g (40,5 mmol) Cyclopropanthiol (Herstellung nach: E. Block et al, J. Am. Chem. Soc. 1992, 114, 3492) in 100 ml THF / 100 ml Diethylether wurde portionsweise mit 1 ,78 g (44,6 mmol) Natriumhydrid (60%) versetzt und 30 Minuten bei Raumtemperatur gerührt. Anschließend erfolgte die portionsweise Zugabe von 6,00 g (38,7 mmol) 1-Fluor-4-nitro-benzol. Der Ansatz wurde 2 Stunden bei 40\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz in Wasser gegeben und mit Benzol extrahiert (3x). Die vereinten organischen Phasen wurden eingeengt und der Rückstand chromatographisch (Hexan / Essigester 95:5) gereinigt. Man erhielt 4,6 g (23,6 mmol; Ausbeute: 61 %) des Produktes.\nA solution of 3.00 g (40.5 mmol) of cyclopropanethiol (preparation according to: E. Block et al., J. Am. Chem. Soc., 1992, 114, 3492) in 100 ml of THF / 100 ml of diethyl ether was added in portions with 1 , 78 g (44.6 mmol) of sodium hydride (60%) and stirred for 30 minutes at room temperature. This was followed by the portionwise addition of 6.00 g (38.7 mmol) of 1-fluoro-4-nitro-benzene. The mixture was stirred at 40 \n°\n C. for 2 hours. After cooling, the reaction was poured into water and extracted with benzene (3x). The combined organic phases were concentrated and the residue was purified by chromatography (hexane / ethyl acetate 95: 5). This gave 4.6 g (23.6 mmol, yield: 61%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.12 (m, 2H), 7.54 (m, 2H), 2.35 (m, 1 H), 1.16 (m, 2H), 0.61 (m, 2H). \n\n Verbindung 1.2 (RS)-1-Cyclopropansulfinyl-4-nitro-benzol\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.12 (m, 2H), 7.54 (m, 2H), 2.35 (m, 1H), 1.16 (m, 2H), 0.61 (m, 2H).  Compound 1.2 (RS) -1-Cyclopropanesulfinyl-4-nitro-benzene\n\n\n\n\n\n\n \n \n\n Ein Ansatz mit 7,2 g (36,88 mmol) i-Cyclopropylsulfanyl-4-nitro-benzol in 140 ml Acetonitril wurde mit 179 mg (1 ,11 mmol) Eisen(lll)-chlorid versetzt und 15 Minuten bei Raumtemperatur gerührt. Anschließend versetzte man bei 25 \n0\nC portionsweise mit 9,25 g (40,57 mmol) Perjodsäure. Der Ansatz wurde 30 Minuten gerührt und anschließend unter Rühren auf eine gekühlte, gesättigte Natriumthiosulfat-Lösung gegeben. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 1 :1 ) gereinigt. Man erhielt 5,93 g (28,07 mmol; Ausbeute: 76 %) des Produktes.\n \n A batch of 7.2 g (36.88 mmol) of i-cyclopropylsulfanyl-4-nitrobenzene in 140 ml of acetonitrile was admixed with 179 mg (1.11 mmol) of iron (III) chloride and stirred at room temperature for 15 minutes. Subsequently, it was added at 25 \n°\n C. in portions with 9.25 g (40.57 mmol) of periodic acid. The reaction was stirred for 30 minutes and then added with stirring to a cooled, saturated sodium thiosulfate solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 1: 1). This gave 5.93 g (28.07 mmol, yield: 76%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO):δ = 8.41 (m, 2H), 7.98 (m, 2H), 2.60 (m, 1 H), 1.01 (m, 3H), 0.86 (m, 1 H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.41 (m, 2H), 7.98 (m, 2H), 2.60 (m, 1H), 1.01 (m, 3H), 0.86 (m, 1H).\n\n\n\n\n\n\n \nVerbindung 1.3 (RS)-S-Cyclopropyl-S-(4-nitrophenyl)-N-(trifluoracetyl)sulfoximid\nCompound 1.3 (RS) -S-cyclopropyl-S- (4-nitrophenyl) -N- (trifluoroacetyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Suspension aus 15,1 g (71 ,53 mmol) (RS)-1-Cyclopropansulfinyl-4-nitro-benzol, 17,8 g (157,37 mmol) Trifluoracetamid, 38,0 g (118,02 mmol) Jodbenzoldiacetat und 12,7 g (314,73 mmol) Magnesiumoxid in 801 ml DCM wurde unter Argon mit 1 ,58 g (3,58 mmol) Rhodium(ll)acetat Dimer versetzt und über Nacht bei Raumtemperatur gerührt. Der Ansatz wurde über Celite abgesaugt und eingeengt. Der verbleibende \n\n Rückstand wurde chromatographisch (Hexan / Essigester 2:1 ) gereinigt. Man erhielt 18,0 g (55,97 mmol; Ausbeute: 78 %) des Produktes.\nA suspension of 15.1 g (71. 53 mmol) of (RS) -1-cyclopropanesulfinyl-4-nitro-benzene, 17.8 g (157.37 mmol) of trifluoroacetamide, 38.0 g (118.02 mmol) of iodobenzene diacetate and 12.7 g (314.73 mmol) of magnesium oxide in 801 ml of DCM under argon were admixed with 1.85 g (3.58 mmol) of rhodium (II) acetate dimer and stirred overnight at room temperature. The mixture was filtered off with suction through Celite and concentrated. The remaining one  Residue was purified by chromatography (hexane / ethyl acetate 2: 1). This gave 18.0 g (55.97 mmol, yield: 78%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.49 (m, 2H), 8.25 (m, 2H), 3.56 (m, 1 H)\n1\n 1.51 (m, 1H), 1.41 (m, 1 H), 1.18 (m, 2H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.49 (m, 2H), 8.25 (m, 2H), 3.56 (m, 1H) \n1\n 1.51 (m, 1H), 1.41 (m, 1H), 1.18 (m, 2H).\n\n\n\n\n\n\n \nVerbindung 1.4 (RS)-S-(4-Aminophenyl)-S-cyclopropyl-N-(trifluoracetyl)sulfoximid\nCompound 1.4 (RS) -S- (4-aminophenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 6,9 g (21 ,44 mmol) (RS)-S-Cyclopropyl-S-(4-nitrophenyl)-N- (trifluoracetyl)sulfoximid in 214 ml Ethanol und 39 ml THF wurde mit 1 ,4 g Palladium auf Kohle (10%ig / 50% wasserfeucht) versetzt und 1 Stunde unter Normaldruck bei 25 \nC\nC hydriert. Man versetzte erneut mit 1 ,4 g Palladium auf Kohle und hydrierte weitere 4,5 Stunden bei Normaldruck. Der Ansatz wurde filtriert, das Filtrat erneut mit 1 ,4 g Palladium auf Kohle versetzt und abschließend 45 Minuten hydriert. Der Ansatz wurde filtriert und eingeengt. Man erhielt 5,8 g (19,91 mmol; Ausbeute: 93 %) des Produktes.\nA solution of 6.9 g (21.44 mmol) of (RS) -S-cyclopropyl-S- (4-nitrophenyl) -N- (trifluoroacetyl) sulfoximide in 214 ml of ethanol and 39 ml of THF was added with 1.4 g of palladium on carbon (10% / 50% water wet) and hydrogenated at 25 \nC for\n 1 hour under atmospheric pressure. It was added again with 1, 4 g of palladium on carbon and hydrogenated for another 4.5 hours at atmospheric pressure. The mixture was filtered, the filtrate again treated with 1.4 g of palladium on carbon and finally hydrogenated for 45 minutes. The reaction was filtered and concentrated. This gave 5.8 g (19.91 mmol, yield: 93%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 7.53 (m, 2H), 6.71 (m, 2H), 6.40 (br, 2H), 3.21 (m, 1 H), 1.28 (m, 2H), 1.08 (m, 2H). \n\n \n1\n H-NMR (400 MHz, DMSO): δ = 7.53 (m, 2H), 6.71 (m, 2H), 6.40 (br, 2H), 3.21 (m, 1H), 1.28 (m, 2H), 1.08 (m, 2H). \n\n\n\n\n\n\n \nVerbindung 1.5 (2R,3R)-3-Benzyloxy-butan-2-ol\nCompound 1.5 (2R, 3R) -3-Benzyloxy-butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,00 g (44,4 mmol) (2R,3R)-Butan-2,3-diol in 300 ml THF wurde bei Raumtemperatur mit 5,00 g (44,6 mmol) Kalium-tert.-butylat versetzt und der Ansatz 15 Minuten refluxiert. Der Ansatz wurde auf ca. 50\n0\nC abgekühlt und mit 5,3 ml (44,6 mmol) Benzylbromid versetzt. Man refluxierte für 3 Stunden, danach wurde über Nacht bei Raumtemperatur gerührt. Der Ansatz wurde mit Essigester und\nA solution of 4.00 g (44.4 mmol) of (2R, 3R) -butane-2,3-diol in 300 ml of THF was added at room temperature with 5.00 g (44.6 mmol) of potassium tert-butoxide and the batch is refluxed for 15 minutes. The batch was cooled to about 50 \n0\n C and treated with 5.3 ml (44.6 mmol) of benzyl bromide. It was refluxed for 3 hours, then it was stirred at room temperature overnight. The approach was with ethyl acetate and\n\n\n\n\n\n\n \nNatriumchlorid-Lösung verdünnt und anschließend mit 1 N Chlorwasserstoff-Lösung (1x) und Natriumchlorid-Lösung (2x) gewaschen. Die organische Phase wurde getrocknet (Na\n∑\nSO-O, filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 1 :1 ) gereinigt. Man erhielt 3,41 g (18,9 mmmol; Ausbeute: 43 %) des Produktes.\nSodium chloride solution and then washed with 1 N hydrogen chloride solution (1x) and sodium chloride solution (2x). The organic phase was dried (Na \n2\n SO 2 O, filtered and concentrated, the residue obtained was purified by chromatography (hexane / ethyl acetate 1: 1) to give 3.41 g (18.9 mmol, yield 43%) of the product ,\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 7.35 (m, 4H), 7.28 (m, 1 H), 4.52 (m, 3H), 3.67 (m, 1 H), 3.37 (m, 1 H), 1.05 (d, 3H), 1.01 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 7.35 (m, 4H), 7.28 (m, 1H), 4.52 (m, 3H), 3.67 (m, 1H), 3.37 (m, 1H) , 1.05 (d, 3H), 1.01 (d, 3H).\n\n\n\n\n\n\n \nVerbindung 1.6\nConnection 1.6\n\n\n\n\n\n\n \n4-((1R,2R)-2-Benzyloxy-1-methyl-propoxy)-2-chlor-5-jod-pyrimidin\n4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -2-chloro-5-iodo-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n8,55 g (47,4 mmol) (2R,3R)-3-Benzyloxy-butan-2-ol in 56 ml Diethylether wurden bei 0\n0\nC unter Rühren portionsweise mit 2,07 g Natriumhydrid (55%) versetzt. Nach 10 Minuten wurde das Eisbad entfernt und weitere 3 Minuten bei Raumtemperatur gerührt. Die gebildete Suspension wurde bei 0\n0\nC zu einer Lösung von 6,52 g (23,7 mmol) 2,4-Dichlor-5-jod-pyrimidin gegeben. Der Ansatz wurde 4 Stunden bei 40\n0\nC \n\n gerührt und anschließend mit verdünnter Natriumchlorid-Lösung versetzt. Man extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1 ). Man erhielt 4,12 g (9,8 mmol; Ausbeute: 41%) des Produktes.\n8.55 g (47.4 mmol) of (2R, 3R) -3-benzyloxy-butan-2-ol in 56 ml of diethyl ether were added in portions with 2.07 g of sodium hydride (55%) at 0 \n°\n C. with stirring. After 10 minutes, the ice bath was removed and stirred for a further 3 minutes at room temperature. The resulting suspension was added at 0 \n°\n C. to a solution of 6.52 g (23.7 mmol) of 2,4-dichloro-5-iodopyrimidine. The batch was 4 hours at 40 \n0\n C.  stirred and then treated with dilute sodium chloride solution. It was extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was chromatographed (hexane / ethyl acetate 4: 1). This gave 4.12 g (9.8 mmol, yield: 41%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.78 (s, 1 H), 7.29 (m, 5H), 5.27 (m, 1 H), 4.64 (d, 1 H), 4.53 (d, 1 H), 3.73 (m, 1 H), 1.30 (d, 3H), 1.19 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.78 (s, 1H), 7.29 (m, 5H), 5.27 (m, 1H), 4.64 (d, 1H), 4.53 (d, 1H ), 3.73 (m, 1H), 1.30 (d, 3H), 1.19 (d, 3H).\n\n\n\n\n\n\n \nVerbindung 1.7\nConnection 1.7\n\n\n\n\n\n\n \n4-((1R,2R)-2-Benzyloxy-1-methyl-propoxy)-2-chIor-5-trifluormethyl-pyrimidin\n4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -2-chloro-5-trifluoromethyl-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,66 g (11 ,1 mmol) 4-((1 R,2R)-2-Benzyloxy-1-methyl-propoxy)-2- chlor-5-jod-pyrimidin in 15,8 ml NMP und 15,8 ml THF wurde bei Raumtemperatur unter Rühren mit 3,82 g (20,0 mmol) Kupfer(l)jodid, 0,97 g (16,7 mmol) Kaliumfluorid und 2,47 ml (16,7 mmol) (Trifluormethyl)-trimethylsilan versetzt. Der Ansatz wurde 5,5 Stunden bei 80\n0\nC gerührt. Nach dem Erkalten wurde der Ansatz in verdünnte Natriumchlorid-Lösung gegeben und mit Essigester extrahiert (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1 ). Man erhielt 2,17 g (6,0 mmol; Ausbeute: 54%) des Produktes.\nA solution of 4.66 g (11.1 mmol) of 4 - ((1R, 2R) -2-benzyloxy-1-methylpropoxy) -2-chloro-5-iodopyrimidine in 15.8 ml of NMP and 15.8 ml of THF was added at room temperature with stirring to 3.82 g (20.0 mmol) of copper (I) iodide, 0.97 g (16.7 mmol) of potassium fluoride and 2.47 ml (16.7 mmol) ( Trifluoromethyl) trimethylsilane added. The batch was stirred at 80 \n°\n C. for 5.5 hours. After cooling, the batch was added to dilute sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was chromatographed (hexane / ethyl acetate 4: 1). This gave 2.17 g (6.0 mmol, yield: 54%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.81 (s, 1 H), 7.21 (m, 5H), 5.40 (m, 1 H)\n1\n 4.57 (d, 1 H), 4.42 (d, 1 H), 3.70 (m, 1 H), 1.28 (d, 3H), 1.13 (d, 3H). \n\n Verbindung 1.8\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.81 (s, 1H), 7.21 (m, 5H), 5.40 (m, 1H) \n1\n 4.57 (d, 1H), 4.42 (d, 1H ), 3.70 (m, 1H), 1.28 (d, 3H), 1.13 (d, 3H).  Connection 1.8\n\n\n\n\n\n\n \n(RS)-S-(4-{[4-{[(1R,2R)-2-(Benzyloxy)-1-methylpropyl]oxy}-5-(trifluormethyl) pyrimidin-2-yl]amino}phenyl)-S-cyclopropyl-N-(trifluoracetyl)sulfoximid\n(RS) -S- (4 - {[4 - {[(1R, 2R) -2- (benzyloxy) -1-methylpropyl] oxy} -5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) - S-cyclopropyl-N- (trifluoroacetyl) sulphoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n1 ,39 g (3,85 mmol) 4-((1 R,2R)-2-Benzyloxy-1 -methyl-propoxy)-2-chlor-5- trifluormethyl-pyrimidin und 1 ,35 g (4,62 mmol) (RS)-S-(4-Aminophenyl)-S- cyclopropyl-N-(trifluoracetyl)sulfoximid in 18,8 ml Acetonitril wurden mit 0,96 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 5 Stunden bei 80\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz mit Essigester verdünnt und mit gesättigter Natriumhydrogencarbonat-Lösung und gesättigter Natriumchlorid-Lösung gewaschen, getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1) gereinigt. Man erhielt 1 ,32 g (2,14 mmol, Ausbeute: 56%) des Produktes.\n1.39 g (3.85 mmol) of 4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -2-chloro-5-trifluoromethyl-pyrimidine and 1.35 g (4.62 mmol ) (RS) -S- (4-aminophenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide in 18.8 ml of acetonitrile were treated with 0.96 ml of a 4N solution of hydrogen chloride in dioxane and 5 hours at 80 \n0\n C. touched. After cooling, the mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1). This gave 1.32 g (2.14 mmol, yield: 56%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.71 (s, 1 H), 8.84 (s, 1 H), 8.08 (m, 2H), 7.93 (m, 2H), 7.26 (m, 5H), 5.52 (m, 1 H), 4.62 (d, 1 H), 4.51 (d, 1 H), 3.78 (m, 1 H), 3.35 (m, 1 H), 1.37 (m, 5H), 1.16 (m, 5H). \n\n Verbindung 1.9\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.71 (s, 1H), 8.84 (s, 1H), 8.08 (m, 2H), 7.93 (m, 2H), 7.26 (m, 5H), 5.52 (m, 1H), 4.62 (d, 1H), 4.51 (d, 1H), 3.78 (m, 1H), 3.35 (m, 1H), 1.37 (m, 5H), 1.16 (m , 5H).  Connection 1.9\n\n\n\n\n\n\n \n(RSJ-S-Cyclopropyl-S^^μ^KIR^RJ^-hydroxy-i-methylpropylloxy}^-\n(RSJ-S-cyclopropyl-S ^^ μ ^ KIR ^ ^ RJ-hydroxy-i-methylpropylloxy} ^ -\n\n\n\n\n\n\n \n(trifluormethyl)pyrimidin-2-yl]amino}phenyl)-N-(trifIuoracetyl)sulfoximid\n(Trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -N- (trifIuoracetyl) sulphoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1 ,31 g (2,12 mmol) (RS)-S-(4-{[4-{[(1 R,2R)-2-(Benzyloxy)-1- methylpropyl]oxy}-5-(trifluormethyl) pyrimidin-2-yl]amino}phenyl)-S-cyclopropyl-N- (trifluoracetyl)sulfoximid in 66 ml Ethanol wurde mit 1 ,64 g Palladium auf Kohle (10%ig) versetzt und unter Normaldruck bei Raumtemperatur hydriert. Der Ansatz wurde filtriert und eingeengt. Man erhielt 0,88 g (1 ,67 mmol; Ausbeute: 79 %) des Produktes.\nA solution of 1.31 g (2.12 mmol) of (RS) -S- (4 - {[4 - {[(1R, 2R) -2- (benzyloxy) -1-methylpropyl] oxy} -5- (Trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide in 66 ml of ethanol was treated with 1.64 g of palladium on carbon (10%) and hydrogenated under normal pressure at room temperature. The reaction was filtered and concentrated. 0.88 g (1.67 mmol, yield: 79%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.65 (s, 1 H), 8.58 (s, 1 H), 8.04 (m, 2H), 7.89 (m, 2H), 5.28 (m, 1 H), 4.86 (d, 1 H), 3.82 (m, 1 H), 3.35 (m, 1 H), 1.45 (m, 5H)\n1\n 1.15 (m, 5H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.65 (s, 1H), 8.58 (s, 1H), 8.04 (m, 2H), 7.89 (m, 2H), 5.28 (m, 1H) , 4.86 (d, 1H), 3.82 (m, 1H), 3.35 (m, 1H), 1.45 (m, 5H) \n1\n 1.15 (m, 5H).\n\n\n\n\n\n\n \n1b) Herstellung des Endproduktes\n1b) Preparation of the end product\n\n\n\n\n\n\n \n863 mg (1 ,64 mmol) (RS)-S-Cyclopropyl-S-(4-{[4-{[(1 R,2R)-2-hydroxy-1- methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)-N- (trifluoracetyl)sulfoximid in 35 ml Methanol wurden mit 1130 mg (8,20 mmol) Kaliumcarbonat versetzt und 1 ,5 Stunden bei Raumtemperatur gerührt. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 709 mg (1 ,64 mmol) des Rohproduktes.\n863 mg (1.64 mmol) of (RS) -S-cyclopropyl-S- (4 - {[4 - {[(1R, 2R) -2-hydroxy-1-methylpropyl] oxy} -5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -N- (trifluoroacetyl) sulfoximide in 35 ml of methanol were treated with 1130 mg (8.20 mmol) of potassium carbonate and stirred for 1.5 hours at room temperature. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. 709 mg (1.64 mmol) of the crude product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.50 (s, 1 H), 8.59 (s, 1 H), 7.94 (m, 2H), 7.84 (m, 2H), 5.32 (m, 1 H), 4.91 (d, 1 H), 4.07 (s, 1 H), 3.86 (m, 1 H), 2.63 (m, 1 H), 1.30 (d, 3H), 1.11 (m, 4H), 0.91 (m, 3H). MS: 431 (ES+). \n\n Das Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.50 (s, 1H), 8.59 (s, 1H), 7.94 (m, 2H), 7.84 (m, 2H), 5.32 (m, 1H) , 4.91 (d, 1H), 4.07 (s, 1H), 3.86 (m, 1H), 2.63 (m, 1H), 1.30 (d, 3H), 1.11 (m, 4H), 0.91 (m , 3H). MS: 431 (ES +).  The diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak IA 5μ 250x30 mm\nColumn: Chiralpak IA 5μ 250x30 mm\n\n\n\n\n\n\n \nEluenten: Hexan / Ethanol 8:2\nEluent: hexane / ethanol 8: 2\n\n\n\n\n\n\n \nFluß: 40,0 mL/min\nFlow: 40.0 mL / min\n\n\n\n\n\n\n \nDetektor: UV 254 nm\nDetector: UV 254 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 10,8-13,4 min; Stereoisomer 1 (=Beispiel 1-SI-1)\nRetention time: 10.8-13.4 min; Stereoisomer 1 (= Example 1-SI-1)\n\n\n\n\n\n\n \n13,6-18,5 min; Stereoisomer 2 (=Beispiel 1-SI-2)\n13.6-18.5 min; Stereoisomer 2 (= Example 1-SI-2)\n\n\n\n\n\n\n \nBeispiel 2\nExample 2\n\n\n\n\n\n\n \n(RS)-S-(4-{[4-{[(1 R,2R)-2-Hydroxy-1 -methylpropyl]oxy}-5-\n(RS) -S- (4 - {[4 - {[(1R, 2R) -2-hydroxy-1-methylpropyl] oxy} -5-\n\n\n\n\n\n\n \n(trifluormethyl)pyrimidin-2-yl]amino}phenyl)-S-methylsulfoximid\n(Trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -S-methylsulphoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n2a) Herstellung der Zwischenprodukte Verbindung 2.1 (RS)-S-(4-Nitrophenyl)-S-methylsulfoximid\n2a) Preparation of Intermediates Compound 2.1 (RS) -S- (4-nitrophenyl) -S-methylsulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n1 ,56 g (8,42 mmol) 1-(Methylsulfinyl)-4-nitrobenzol in 20 ml DCM wurden mit 0,70 g (10,76 mmol) Natriumazid versetzt. Der Ansatz wurde bei 0 \n0\nC langsam mit 2,3 ml konzentrierter Schwefelsäure versetzt und anschließend auf 45 \n0\nC erwärmt. Nach 16 \n\n h wurde der Ansatz auf Raumtemperatur abgekühlt, mit Wasser versetzt und gegen DCM extrahiert. Die wässrige Phase wurde mit 15%iger Natriumhydroxid-Lösung auf pH 11 gestellt und gegen DCM extrahiert (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 1 ,08 g (5,39 mmol; Ausbeute: 63 %) des Produktes.\n1. 56 g (8.42 mmol) of 1- (methylsulfinyl) -4-nitrobenzene in 20 ml of DCM were treated with 0.70 g (10.76 mmol) of sodium azide. The mixture was slowly added at 0 \n°\n C. with 2.3 ml of concentrated sulfuric acid and then heated to 45 \n°\n C. After 16  The reaction was cooled to room temperature, water was added and the mixture was extracted with DCM. The aqueous phase was adjusted to pH 11 with 15% sodium hydroxide solution and extracted with DCM (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. This gave 1. 08 g (5.39 mmol, yield: 63%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.43 (m, 2H), 8.17 (m, 2H), 4.62 (s, 1 H), 3.18 (s, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.43 (m, 2H), 8.17 (m, 2H), 4.62 (s, 1H), 3.18 (s, 3H).\n\n\n\n\n\n\n \nVerbindung 2.2 (RS)-S-Methyl-S-(4-nitrophenyl)-N-(trifluoracetyl)sulfoximid\nCompound 2.2 (RS) -S-methyl-S- (4-nitrophenyl) -N- (trifluoroacetyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1000 mg (4,99 mmol) (RS)-S-(4-Nitrophenyl)-S-methylsulfoximid, 55 mg (0,45 mmol) DMAP und 0,76 ml (5,49 mmol) Triethylamin in 32 ml DCM wurde unter Eiskühlung tropfenweise mit 1 ,00 ml (7,08 mmol) Trifluoracetanhydrid versetzt. Der Ansatz wurde weitere 2 Stunden im Eisbad gerührt. Man verdünnte mit DCM und wusch mit halbkonzentrierter Natriumchlorid-Lösung. Die organische Phase wurde getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 60:40) gereinigt. Das erhaltene Produkt wurde abschließend mit Diisopropylether verrührt. Der Feststoff wurde abgesaugt und getrocknet. Man erhielt 1444 mg (4,87 mmol; Ausbeute: 98%) des Produktes.\nA solution of 1000 mg (4.99 mmol) of (RS) -S- (4-nitrophenyl) -S-methylsulfoximide, 55 mg (0.45 mmol) of DMAP and 0.76 ml (5.49 mmol) of triethylamine in 32 1 ml of DCM was added dropwise while stirring with ice, with 1.00 ml (7.08 mmol) of trifluoroacetic anhydride. The batch was stirred for an additional 2 hours in an ice bath. It was diluted with DCM and washed with half-concentrated sodium chloride solution. The organic phase was dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 60:40). The resulting product was finally stirred with diisopropyl ether. The solid was filtered off with suction and dried. 1444 mg (4.87 mmol, yield: 98%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.50 (m, 2H), 8.24 (m, 2H), 3.87 (s, 3H). \n\n Verbindung 2.3 (RS)-S-(4-Aminophenyl)-S-methyl-N-(trifluoracetyl)sulfoximid\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.50 (m, 2H), 8.24 (m, 2H), 3.87 (s, 3H).  Compound 2.3 (RS) -S- (4-aminophenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1 ,34 g (4,52 mmol) (RS)-S-Methyl-S-(4-nitrophenyl)-N-\nA solution of 1.34 g (4.52 mmol) of (RS) -S-methyl-S- (4-nitrophenyl) -N-\n\n\n\n\n\n\n \n(trifluoracetyl)sulfoximid in 45 ml Ethanol und 8 ml THF wurde mit 292 mg Palladium auf Kohle (10%ig / 50% wasserfeucht) versetzt und 45 Minuten unter Normaldruck bei 24 \n0\nC hydriert. Der Ansatz wurde filtriert und eingeengt. Der erhaltene Rückstand wurde mit Diisopropylether verrührt. Der Feststoff wurde abgesaugt und getrocknet. Man erhielt 1 ,07 g (4,03 mmol; Ausbeute: 89 %) des Produktes.\n(Trifluoroacetyl) sulfoximide in 45 ml of ethanol and 8 ml of THF was mixed with 292 mg of palladium on carbon (10% / 50% water wet) and hydrogenated at 24 \n0\n C for 45 minutes under atmospheric pressure. The reaction was filtered and concentrated. The resulting residue was stirred with diisopropyl ether. The solid was filtered off with suction and dried. 1.07 g (4.03 mmol, yield: 89%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 7.54 (m, 2H), 6.67 (m, 2H), 6.35 (s, 2H), 3.55 (s, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 7.54 (m, 2H), 6.67 (m, 2H), 6.35 (s, 2H), 3.55 (s, 3H).\n\n\n\n\n\n\n \nVerbindung 2.4 (RS)-S-(4-{[4-{[(1R,2R)-2-(Benzyloxy)-1-methylpropyl]oxy}-5-(trifluormethyl) pyrimidin-2-yl]amino}phenyl)-S-methyl-N-(trifluoracetyl)sulfoximid\nCompound 2.4 (RS) -S- (4 - {[4 - {[(1R, 2R) -2- (benzyloxy) -1-methylpropyl] oxy} -5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl ) -S-methyl-N- (trifluoroacetyl) sulphoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n1,40 g (3,88 mmol) 4-((1 R,2R)-2-Benzyloxy-1-methyl-propoxy)-2-chlor-5- trifluormethyl-pyrimidin und 1 ,20 g (4,51 mmol) (RS)-S-(4-Aminophenyl)-S-methyl-N- (trifluoracetyl)sulfoximid in 19,0 ml Acetonitril wurden mit 0,97 ml einer 4N Lösung \n\n von Chlorwasserstoff in Dioxan versetzt und 6 Stunden bei 80\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz mit Essigester verdünnt und mit gesättigter Natriumhydrogencarbonat-Lösung und gesättigter Natriumchlorid-Lösung gewaschen, getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 1 :1 ) gereinigt. Man erhielt 1 ,76 g (2,98 mmol, Ausbeute: 77%) des Produktes.\n1.40 g (3.88 mmol) of 4 - ((1R, 2R) -2-benzyloxy-1-methyl-propoxy) -2-chloro-5-trifluoromethyl-pyrimidine and 1.20 g (4.51 mmol ) (RS) -S- (4-aminophenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide in 19.0 ml of acetonitrile was mixed with 0.97 ml of a 4N solution  of hydrogen chloride in dioxane and stirred at 80 \n0\n C for 6 hours. After cooling, the mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 1: 1). This gave 1.76 g (2.98 mmol, yield: 77%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.66 (s, 1 H), 8.60 (s, 1 H), 8.02 (m, 2H), 7.93 (m, 2H), 7.21 (m, 5H), 5.46 (m, 1 H), 4.57 (d, 1 H), 4.46 (d, 1 H), 3.72 (m, 1 H), 3.68 (s, 3H), 1.31 (d, 3H), 1.16 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.66 (s, 1H), 8.60 (s, 1H), 8.02 (m, 2H), 7.93 (m, 2H), 7.21 (m, 5H), 5.46 (m, 1H), 4.57 (d, 1H), 4.46 (d, 1H), 3.72 (m, 1H), 3.68 (s, 3H), 1.31 (d, 3H), 1.16 (d, 3H).\n\n\n\n\n\n\n \nVerbindung 2.5\nConnection 2.5\n\n\n\n\n\n\n \n(RS)-S-(4-{[4-{[(1R,2R)-2-Hydroxy-1-methylpropyl]oxy}-5-(trifIuormethyl) pyrimidin-2-yl]amino}phenyl)-S-methyl-N-(trifluoracetyl)sulfoximid\n(RS) -S- (4 - {[4 - {[(1R, 2R) -2-hydroxy-1-methylpropyl] oxy} -5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -S- methyl-N- (trifluoroacetyl) sulphoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1 ,75 g (2,96 mmol) (RS)-S-(4-{[4-{[(1 R,2R)-2-(Benzyloxy)-1- methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)-S-methyl-N- (trifluoracetyl)sulfoximid in 35 ml Ethanoi wurde mit 0,18 g Palladium auf Kohle (10%ig) versetzt und unter Normaldruck bei Raumtemperatur hydriert. Der Ansatz wurde filtriert und eingeengt. Man erhielt 1 ,40 g des Rohproduktes.\nA solution of 1.75 g (2.96 mmol) of (RS) -S- (4 - {[4 - {[(1R, 2R) -2- (benzyloxy) -1-methylpropyl] oxy} -5- (Trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide in 35 ml of ethanol was added 0.18 g of palladium on carbon (10%) and hydrogenated under normal pressure at room temperature. The reaction was filtered and concentrated. This gave 1.40 g of the crude product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.65 (s, 1 H), 8.58 (s, 1 H), 8.04 (m, 2H), 7.93 (m, 2H), 5.28 (m, 1 H), 4.86 (d, 1 H), 3.83 (m, 1 H), 3.70 (s, 3H), 1.26 (d, 3H), 1.07 (d, 3H). \n\n 2b) Herstellung des Endproduktes\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.65 (s, 1H), 8.58 (s, 1H), 8.04 (m, 2H), 7.93 (m, 2H), 5.28 (m, 1H) , 4.86 (d, 1H), 3.83 (m, 1H), 3.70 (s, 3H), 1.26 (d, 3H), 1.07 (d, 3H).  2b) Preparation of the final product\n\n\n\n\n\n\n \n1 ,39 g (2,78 mmol) (RS)-S-(4-{[4-{[(1 R,2R)-2-Hydroxy-1-methylpropyl]oxy}-5- (trifluormethyl) pyrimidin-2-yl]amino}phenyl)-S-methyl-N-(trifluoracetyl)sulfoximid in 60 ml Methanol wurden mit 1 ,92 g (13,89 mmol) Kaliumcarbonat versetzt und 1 ,5 Stunden bei Raumtemperatur gerührt. Man verdünnte mit gesättigter Natriumchlorid- Lösung und extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der Rückstand wurde chromatographisch (DCM / EtOH 9:1) gereinigt. Man erhielt 862 mg (2,13 mmol; Ausbeute: 77%) des Produktes.\n1.39 g (2.78 mmol) of (RS) -S- (4 - {[4 - {[(1R, 2R) -2-hydroxy-1-methylpropyl] oxy} -5- (trifluoromethyl) pyrimidine 2-yl] amino} phenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide in 60 ml of methanol were treated with 1, 92 g (13.89 mmol) of potassium carbonate and stirred for 1.5 hours at room temperature. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (2 ×). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue was purified by chromatography (DCM / EtOH 9: 1). This gave 862 mg (2.13 mmol, yield: 77%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.47 (s, 1 H), 8.55 (s, 1 H), 7.90 (m, 2H), 7.83 (m, 2H), 5.27 (m, 1 H), 4.86 (d, 1 H), 4.04 (s, 1 H), 3.82 (m, 1 H), 3.00 (s, 3H), 1.26 (d, 3H), 1.07 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.47 (s, 1H), 8.55 (s, 1H), 7.90 (m, 2H), 7.83 (m, 2H), 5.27 (m, 1H) , 4.86 (d, 1H), 4.04 (s, 1H), 3.82 (m, 1H), 3.00 (s, 3H), 1.26 (d, 3H), 1.07 (d, 3H).\n\n\n\n\n\n\n \nDas Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\nThe diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak IC 5μ 250x20 mm\nColumn: Chiralpak IC 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: Hexan / Ethanol 8:2 Puffer: Hexan/ 0.1% DEA\nEluent: hexane / ethanol 8: 2 buffer: hexane / 0.1% DEA\n\n\n\n\n\n\n \nFluß: 25,0 mL/min\nFlow: 25.0 mL / min\n\n\n\n\n\n\n \nDetektor: UV 280 nm\nDetector: UV 280 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 9,5-12,1 min; Stereoisomer 1 (=Beispiel 2-SI-1 ) 13,1-16,0 min; Stereoisomer 2 (=Beispiel 2-SI-2)\nRetention time: 9.5-12.1 min; Stereoisomer 1 (= Example 2-SI-1) 13.1-16.0 min; Stereoisomer 2 (= Example 2-SI-2)\n\n\n\n\n\n\n \nBeispiel 3\nExample 3\n\n\n\n\n\n\n \n(RS)-S-(4-{[4-{[(R)-2-Hydroxy-1,2-dimethylpropyl]oxy}-5-\n(RS) -S- (4 - {[4 - {[(R) -2-hydroxy-1,2-dimethylpropyl] oxy} -5-\n\n\n\n\n\n\n \n(trifluormethyl)pyrimidin-2-yl]amino}phenyl)-S-methylsulfoximid\n(Trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -S-methylsulphoximide\n\n\n\n\n\n\n \n \n\n 3a) Herstellung der Zwischenprodukte Verbindung 3.1. (R)-2-Methyl-butan-2,3-diol\n \n 3a) Preparation of Intermediates Compound 3.1. (R) -2-methyl-butan-2,3-diol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 10,0 g (96,1 mmol) (R)-(+)-Milchsäuremethylester in 20 ml THF wurde langsam zu 160 ml (480,0 mmol) einer eisgekühlten 3 N Lösung von Methylmagnesiumchlorid in THF getropft. Der Ansatz wurde zunächst langsam auf Raumtemperatur erwärmt und anschließend 30 Minuten refluxiert. Nach dem\nA solution of 10.0 g (96.1 mmol) of (R) - (+) - lactic acid methyl ester in 20 ml of THF was slowly added dropwise to 160 ml (480.0 mmol) of an ice-cold 3N solution of methylmagnesium chloride in THF. The mixture was first slowly warmed to room temperature and then refluxed for 30 minutes. After this\n\n\n\n\n\n\n \nAbkühlen wurde der Ansatz auf eine gesättigte Ammoniumchlorid-Lösung gegeben und mit Essigester extrahiert (3x). Die vereinten organischen Phasen wurden über einem Whatman Filter filtriert und eingeengt. Man erhielt 4,5 g (43,1 mmol) des Rohproduktes, das ohne weitere Reinigung eingesetzt wurde.\nAfter cooling, the batch was added to a saturated ammonium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were filtered through a Whatman filter and concentrated. This gave 4.5 g (43.1 mmol) of the crude product, which was used without further purification.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 4.21 (d, 1 H), 3.93 (s, 1 H), 3.29 (m, 1 H), 0.97 (m, 9H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 4.21 (d, 1H), 3.93 (s, 1H), 3.29 (m, 1H), 0.97 (m, 9H).\n\n\n\n\n\n\n \nVerbindung 3.2. (R)-3-(2-Chlor-5-jod-pyrimidin-4-yloxy)-2-methyl-butan-2-ol\nConnection 3.2. (R) -3- (2-chloro-5-iodo-pyrimidin-4-yloxy) -2-methyl-butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,40 g (42,3 mmol) (R)-2-Methyl-butan-2,3-diol in 83 ml Diethylether wurde unter Rühren bei 0\n0\nC portionsweise mit 1 ,84 g (42,3 mmol) Natriumhydrid (55%) versetzt und 10 Minuten gerührt. Man rührte weitere 3 Minuten bei\nA solution of 4.40 g (42.3 mmol) of (R) -2-methyl-butane-2,3-diol in 83 ml of diethyl ether was added under stirring at 0 \n0\n C in portions with 1, 84 g (42.3 mmol ) Sodium hydride (55%) and stirred for 10 minutes. It was stirred for a further 3 minutes\n\n\n\n\n\n\n \nRaumtemperatur und gab den Ansatz anschließend zu einer eisgekühlten Lösung von 9,68 g (35,2 mmol) 2,4-Dichlor-5-jod-pyrimidin in 97 ml Acetonitril. Der Ansatz wurde 4 Stunden bei 40\n0\nC gerührt und nach dem Erkalten mit Eis und gesättigter NaCI-Lösung versetzt. Man extrahierte mit Essigester (3x). Die vereinten organischen \n\n Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1 ) gereinigt. Man erhielt 4,96 g (14,5 mmol; Ausbeute: 41 %) des Produktes.\nRoom temperature and then gave the mixture to an ice-cooled solution of 9.68 g (35.2 mmol) of 2,4-dichloro-5-iodo-pyrimidine in 97 ml of acetonitrile. The mixture was stirred for 4 hours at 40 \n0\n C and added after cooling with ice and saturated NaCl solution. It was extracted with ethyl acetate (3x). The united organic  Phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1). 4.96 g (14.5 mmol, yield: 41%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.73 (s, 1 H), 4.96 (q, 1 H), 4.62 (s, 1 H), 1.21 (d, 3H), 1.13 (s, 6H). ES: 343 (Cl+).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.73 (s, 1H), 4.96 (q, 1H), 4.62 (s, 1H), 1.21 (d, 3H), 1.13 (s, 6H) , ES: 343 (Cl +).\n\n\n\n\n\n\n \nVerbindung 3.3. 2-Chlor-4-[(R)-1,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5-jod- pyrimidin\nConnection 3.3. 2-Chloro-4 - [(R) -1,2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-iodo-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,96 g (14,5 mmol) (R)-3-(2-Chlor-5-jod-pyrimidin-4-yloxy)-2-methyl- butan-2-ol in 30 ml DCM wurde mit 2,64 ml (29,0 mmol) Dihydropyran und 0,36 g (1 ,5 mmol) Pyridiniumtosylat versetzt und 22 Stunden bei Raumtemperatur gerührt. Der Ansatz wurde mit DCM verdünnt und mit gesättigter Natriumhydrogencarbonat- Lösung gewaschen. Die organische Phase wurde getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1 ) gereinigt. Man erhielt 5,50 g (12,9 mmol; Ausbeute: 89%) des Diastereomerengemisches.\nA solution of 4.96 g (14.5 mmol) of (R) -3- (2-chloro-5-iodopyrimidin-4-yloxy) -2-methyl-butan-2-ol in 30 ml of DCM was washed with 2.64 ml (29.0 mmol) of dihydropyran and 0.36 g (1, 5 mmol) of pyridinium tosylate and stirred for 22 hours at room temperature. The reaction was diluted with DCM and washed with saturated sodium bicarbonate solution. The organic phase was dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1). This gave 5.50 g (12.9 mmol, yield: 89%) of the diastereomer mixture.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.75 (s, 1 H), 8.74 (s, 1 H), 5.15 (m, 2H), 4.91 (m, 2H), 3.70 (m, 2H), 3.30 (m, 2H), 1.31 (m, 30H). \n\n Verbindung 3.4.\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.75 (s, 1H), 8.74 (s, 1H), 5.15 (m, 2H), 4.91 (m, 2H), 3.70 (m, 2H), 3.30 (m, 2H), 1.31 (m, 30H).  Connection 3.4.\n\n\n\n\n\n\n \n2-Chlor-4-[(R)-1,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)-propoxy]-5- trifluormethyl-pyrimidin\n2-Chloro-4 - [(R) -1,2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethyl-pyrimidine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 1 ,00 g (2,34 mmol) 2-Chlor-4-[(R)-1 ,2-dimethyl-2-(tetrahydro-pyran- 2-yloxy)-propoxy]-5-jod-pyrimidin in 3,3 ml NMP und 3,3 ml THF wurde bei Raumtemperatur mit 1 ,61 g (8,44 mmol) Kupfer(l)jodid, 0,41 g (7,03 mmol) Kaliumfluorid und 1 ,04 ml (7,03 mmol) (Trifluormethyl)-trimethylsilan versetzt. Der Ansatz wurde 2 Stunden bei 90\n0\nC gerührt. Nach dem Erkalten wurde der Ansatz in verdünnte Natriumchlorid-Lösung gegeben und mit Essigester extrahiert (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde chromatographisch (Hexan / Essigester 4:1) gereinigt. Man erhielt 0,53 g (1 ,43 mmol; Ausbeute: 61 %) des Produktes.\nA solution of 1.00 g (2.34 mmol) of 2-chloro-4 - [(R) -1,2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-iodo-pyrimidine in 3.3 ml of NMP and 3.3 ml of THF was added at room temperature with 1.61 g (8.44 mmol) of copper (I) iodide, 0.41 g (7.03 mmol) of potassium fluoride and 1.04 ml (7 , 03 mmol) (trifluoromethyl) trimethylsilane. The batch was stirred at 90 \n°\n C. for 2 hours. After cooling, the batch was added to dilute sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was purified by chromatography (hexane / ethyl acetate 4: 1). This gave 0.53 g (1, 43 mmol, yield: 61%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.84 (s, 1 H)\n1\n 5.32 (m, 1 H), 4.85 (m, 1 H), 3.68 (m, 1 H), 3.30 (m, 1 H), 1.31 (m, 15H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.84 (s, 1H) \n1\n 5.32 (m, 1H), 4.85 (m, 1H), 3.68 (m, 1H), 3.30 (m, 1 H), 1.31 (m, 15H).\n\n\n\n\n\n\n \n3b) Herstellung des Endproduktes 200 mg (0,54 mmol) 2-Chlor-4-[(R)-1 ,2-dimethyl-2-(tetrahydro-pyran-2-yloxy)- propoxy]-5-trifluormethyl-pyrimidin und 87 mg (0,33 mmol) (RS)-S-(4-Aminophenyl)- S-methyl-N-(trifluoracetyl)sulfoximid in 5 ml Ethanol wurden 6 Stunden bei 70\n0\nC gerührt. Der Ansatz wurde zur Trockene einrotiert und der Rückstand in 11 ,6 ml Methanol aufgenommen. Die Lösung wurde mit 373 mg (2,70 mmol) Kaliumcarbonat versetzt und 1 ,5 Stunden bei Raumtemperatur gerührt. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der Rückstand wurde mittels HPLC gereinigt. Man erhielt 31 mg (0,07 mmol; Ausbeute: 14%) des Produktes. \n\n Säule: XBridge C18 5μ 100x30 mm\n3b) Preparation of the final product 200 mg (0.54 mmol) of 2-chloro-4 - [(R) -1,2-dimethyl-2- (tetrahydro-pyran-2-yloxy) -propoxy] -5-trifluoromethylpyrimidine and 87 mg (0.33 mmol) (RS) -S- (4-aminophenyl) - S-methyl-N- (trifluoroacetyl) sulfoximide in 5 ml of ethanol was stirred for 6 hours at 70 \n0\n C. The batch was concentrated to dryness and the residue was taken up in 11.6 ml of methanol. The solution was treated with 373 mg (2.70 mmol) of potassium carbonate and stirred for 1.5 hours at room temperature. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (2 ×). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue was purified by HPLC. 31 mg (0.07 mmol, yield: 14%) of the product were obtained.  Column: XBridge C18 5μ 100x30 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.1 % HCOOH\nEluent A: H \n2\n O / 0.1% HCOOH\n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 0 min 70%A 30%B\nGradient: 0 min 70% A 30% B\n\n\n\n\n\n\n \n1.00 min 70%A 30%B\n1.00 min 70% A 30% B\n\n\n\n\n\n\n \n7.50 min 40%A 60%B\n7.50 min 40% A 60% B\n\n\n\n\n\n\n \n7.52 min 1%A 99%B\n7.52 min 1% A 99% B\n\n\n\n\n\n\n \n10.00 min 1%A 99%B\n10.00 min 1% A 99% B\n\n\n\n\n\n\n \nFluß: 50.0 mL/min\nFlow: 50.0 mL / min\n\n\n\n\n\n\n \nDetektion: DAD scan ränge 210-400 nm;\nDetection: DAD scan range 210-400 nm;\n\n\n\n\n\n\n \nMS ESI+, ESI-, scan ränge 160-1000 m/z\nMS ESI +, ESI-, scan ranges 160-1000 m / z\n\n\n\n\n\n\n \nTemperatur: Rt\nTemperature: Rt\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.48 (s, 1 H), 8.56 (s, 1 H), 7.90 (m, 2H), 7.83 (m, 2H), 5.13 (q, 1 H), 4.67 (s, 1 H), 4.06 (s, 1 H), 3.01 (s, 3H), 1.28 (d, 3H), 1.12 (m, 6H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.48 (s, 1H), 8.56 (s, 1H), 7.90 (m, 2H), 7.83 (m, 2H), 5.13 (q, 1H) , 4.67 (s, 1H), 4.06 (s, 1H), 3.01 (s, 3H), 1.28 (d, 3H), 1.12 (m, 6H).\n\n\n\n\n\n\n \nHerstellung der Verbindungen der allgemeinen Formel (Ib) (4-N Derivate)\nPreparation of the compounds of general formula (Ib) (4-N derivatives)\n\n\n\n\n\n\n \nDie erfindungsgemäßen Verbindungen können hergestellt werden durch ein Verfahren, das durch folgende Schritte gekennzeichnet ist:\nThe compounds according to the invention can be prepared by a process which is characterized by the following steps:\n\n\n\n\n\n\n \na) Oxidation einer Verbindung der Formel (IVd) zum Sulfoxid der Formel (IVc).\na) oxidation of a compound of formula (IVd) to the sulfoxide of the formula (IVc).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nbi) Direkte Iminierung des Sulfoxides der Formel (IVc) zu einem geschützten Sulfoximin der Formel (IVa).\nb) Direct imination of the sulfoxide of the formula (IVc) into a protected sulfoximine of the formula (IVa).\n\n\n\n\n\n\n \n \n\n oder \n\n b\n2\n) Iminierung des Sulfoxides der Formel (IVc) zu einem ungeschützten Sulfoximin der Formel (IVb) und anschließende Einführung der Schutzgruppe zu einer Verbindung der Formel (IVa).\n \n or  b \n2\n ) Imination of the sulfoxide of the formula (IVc) to give an unprotected sulfoximine of the formula (IVb) and subsequent introduction of the protective group to a compound of the formula (IVa).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nc) Reduktion der Verbindung der Formel (IVa) zu einer Verbindung der Formel (IV)\nc) reduction of the compound of the formula (IVa) to give a compound of the formula (IV)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nd) Funktionalisierung der 4-Position von 2,4-Dichlor-5-trifluormethyl-pyrimidin (VIIb) durch Umsetzung mit einem Amin der Formel (VIa) unter Bildung eines Intermediates der Formel (Vb).\nd) functionalization of the 4-position of 2,4-dichloro-5-trifluoromethyl-pyrimidine (VIIb) by reaction with an amine of the formula (VIa) to give an intermediate of the formula (Vb).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(VIIb) (Vb) (Vc) \n\n e) Kupplung der Verbindungen der Formel (Vb) und (IV) zum Intermediat der Formel (IIb).\n(VIIb) (Vb) (Vc)  e) coupling of the compounds of the formula (Vb) and (IV) to the intermediate of the formula (IIb).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(Vb) (IV)\n(Vb) (IV)\n\n\n\n\n\n\n \n(IIb) f) Abspaltung der Schutzgruppe am Sulfoximin unter Bildung von (Ib).\n(IIb) f) Cleavage of the protecting group on the sulfoximine to give (Ib).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n(Hb) (Ib) wobei die Substituenten R\n1\n, R\n2\n, R\n3\n und R\n4\n die in der allgemeinen Formel (I) angegebenen Bedeutungen aufweisen.\n(Hb) (Ib) where the substituents R \n1\n , R \n2\n , R \n3\n and R \n4 have\n the meanings given in the general formula (I).\n\n\n\n\n\n\n \nVerfahrensschritte a)-c) Diese Verfahrensschritte sind identisch zu den Verfahrensschritten a)-d) zur Herstellung von Verbindungen gemäß allgemeiner Formel (Ia).\nProcess steps a) -c) These process steps are identical to the process steps a) -d) for the preparation of compounds according to general formula (Ia).\n\n\n\n\n\n\n \nVerfahrensschritt d)\nProcess step d)\n\n\n\n\n\n\n \nDie Umsetzung von 2,4-Dichlor-5-trifluormethyl-pyrimidin (VIIb) mit einem Amin der Formel (VIa) liefert ein Gemisch der Produkte (Vb) und (Vc). Das gewünschte Produkt (Vb) kann z.B. chromatographisch abgetrennt werden (siehe z.B.: (a) J. Bryant et al, WO 2004/048343). \n\n Verfahrensschritt e)\nThe reaction of 2,4-dichloro-5-trifluoromethyl-pyrimidine (VIIb) with an amine of the formula (VIa) gives a mixture of the products (Vb) and (Vc). The desired product (Vb) can be separated, for example, by chromatography (see, for example: (a) J. Bryant et al, WO 2004/048343).  Process step e)\n\n\n\n\n\n\n \nEin 2-Chlor-pyrimidin der Formel (Vb) kann mit einem Anilin der Formel (IV) zu einem Intermediat der Formel (IIb) umgesetzt werden (siehe z.B.: (a) J. Bryant et al, WO 2004/048343).\nA 2-chloro-pyrimidine of the formula (Vb) can be reacted with an aniline of the formula (IV) to give an intermediate of the formula (IIb) (see, for example: (a) J. Bryant et al., WO 2004/048343).\n\n\n\n\n\n\n \nVerfahrensschritt f)\nProcess step f)\n\n\n\n\n\n\n \nDie Abspaltung der Trifluoracetogruppe am Sulfoximin (IIb) liefert die Verbindung der Formel (Ib). Besonders geeignet ist hierfür die beschriebene Methodik unter Verwendung von Kaliumcarbonat in Methanol bei Raumtemperatur.\nThe cleavage of the trifluoroaceto group on the sulfoximine (IIb) gives the compound of the formula (Ib). Particularly suitable for this purpose is the described methodology using potassium carbonate in methanol at room temperature.\n\n\n\n\n\n\n \nBeispiel 4\nExample 4\n\n\n\n\n\n\n \n(RS)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]amino}\n(RS) -S-cyclopropyl-S- (4 - {[4 - {[(1R, 2R) -2-hydroxy-1-methylpropyl] amino}\n\n\n\n\n\n\n \n-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid\n-5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n4a) Herstellung der Zwischenprodukte\n4a) Preparation of intermediates\n\n\n\n\n\n\n \nVerbindung 4.1\nConnection 4.1\n\n\n\n\n\n\n \n(2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-butan-2-ol\n(2R, 3R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n56,5 g (260,35 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin und 32,7 g (260,35 mmol) (2R,3R)-3-Amino-butan-2-ol Hydrochlorid in 1035 ml Acetonitril wurden bei 0\n0\nC tropfenweise mit 72,2 ml (520,71 mmol) Triethylamin versetzt. Der Ansatz wurde über \n\n Nacht langsam auf Raumtemperatur erwärmt. Der Ansatz wurde in halbkonzentrierte Natriumchlorid-Lösung gegeben und mit Essigester extrahiert (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der verbleibende Rückstand wurde chromatographisch (Hexan / Essigester 0-100%) gereinigt. Man erhielt 18,6 g (68,97 mmol; Ausbeute: 27 %) des Produktes.\n56.5 g (260.35 mmol) of 2,4-dichloro-5-trifluoromethylpyrimidine and 32.7 g (260.35 mmol) of (2R, 3R) -3-amino-butan-2-ol hydrochloride in 1035 Acetonitrile at 0 \n0\n C were added dropwise with 72.2 ml (520.71 mmol) of triethylamine. The approach was over  Night slowly warmed to room temperature. The batch was placed in semiconcentrated sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The remaining residue was purified by chromatography (hexane / ethyl acetate 0-100%). 18.6 g (68.97 mmol, yield: 27%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.38 (s, 1 H), 6.71 (d, 1 H), 5.00 (d, 1 H), 4.08 (m, 1 H), 3.71 (m, 1 H), 1.12 (d, 3H), 1.01 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.38 (s, 1H), 6.71 (d, 1H), 5.00 (d, 1H), 4.08 (m, 1H), 3.71 (m, 1 H), 1.12 (d, 3H), 1.01 (d, 3H).\n\n\n\n\n\n\n \nDie Herstellung von (RSJ-S-^-AminophenyO-S-cyclopropyl-N-^rifluoracetyOsulfoximid ist beschrieben als Verbindung 1.4.\nThe preparation of (RSJ-S - ^ - aminophenyO-S-cyclopropyl-N-trifluoroacetyl sulfoximide is described as Compound 1.4.\n\n\n\n\n\n\n \n4b) Herstellung des Endproduktes\n4b) Production of the final product\n\n\n\n\n\n\n \n250 mg (0,86 mmol) (RS)-S-(4-Aminophenyl)-S-cyclopropyl-N- (trifluoracetyl)sulfoximid und 231 mg (0,86 mmol) (2R,3R)-3-(2-Chlor-5-trifluormethyl- pyrimidin-4-ylamino)-butan-2-ol in 3,75 ml Acetonitril wurden mit 0,21 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 3,5 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt. Man versetzte mit 18,4 ml Methanol und 590 mg (4,28 mmol) Kaliumcarbonat und rührte eine Stunde bei Raumtemperatur. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (^\n2\nSO\n4\n), filtriert und eingeengt. Der verbleibende Rückstand wurde chromatographisch (DCM / MeOH 4:1 ) gereinigt. Man erhielt 242 mg (0,56 mmol; Ausbeute: 65%) des Produktes.\n250 mg (0.86 mmol) of (RS) -S- (4-aminophenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide and 231 mg (0.86 mmol) of (2R, 3R) -3- (2- Chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol in 3.75 ml of acetonitrile were treated with 0.21 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 3.5 hours. The batch was concentrated to dryness. 18.4 ml of methanol and 590 mg (4.28 mmol) of potassium carbonate were added and the mixture was stirred at room temperature for one hour. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (2 ×). The combined organic phases were dried (^ \n2\n SO \n4\n ), filtered and concentrated. The remaining residue was purified by chromatography (DCM / MeOH 4: 1). This gave 242 mg (0.56 mmol, yield: 65%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.04 (s, 1 H), 8.25 (s, 1 H), 7.91 (m, 2H), 7.74 (m, 2H), 6.05 (d, 1 H), 5.07 (d, 1 H), 4.14 (m, 1 H), 3.97 (s, 1 H), 3.77 (m, 1 H), 2.56 (m, 1 H), 1.19 (d, 3H), 1.05 (m, 4H), 0.86 (m, 3H). MS: 430 (ESI+). \n\n Das Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.04 (s, 1H), 8.25 (s, 1H), 7.91 (m, 2H), 7.74 (m, 2H), 6.05 (d, 1H) , 5.07 (d, 1H), 4.14 (m, 1H), 3.97 (s, 1H), 3.77 (m, 1H), 2.56 (m, 1H), 1.19 (d, 3H), 1.05 ( m, 4H), 0.86 (m, 3H). MS: 430 (ESI +).  The diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak IA 5μ 250x20 mm\nColumn: Chiralpak IA 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: Hexan / 2-Propanol 50:50\nEluent: hexane / 2-propanol 50:50\n\n\n\n\n\n\n \nPuffer: Hexan/ 0,1 % DEA\nBuffer: hexane / 0.1% DEA\n\n\n\n\n\n\n \nFluß: 15,0 mL/min\nFlow: 15 mL / min\n\n\n\n\n\n\n \nDetektor: UV 254 nm\nDetector: UV 254 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 5,9-6,6 min; Stereoisomer 1 (=Beispiel 4-SI-1)\nRetention time: 5.9-6.6 min; Stereoisomer 1 (= Example 4-SI-1)\n\n\n\n\n\n\n \n7,1-8,8 min; Stereoisomer 2 (=Beispiel 4-SI-2)\n7.1-8.8 min; Stereoisomer 2 (= Example 4-SI-2)\n\n\n\n\n\n\n \nBeispiel 5\nExample 5\n\n\n\n\n\n\n \n(RS)-S-Cyclopropyl-S-(4-{[4-{[(R)-2-hydroxy-1,2-dimethylpropyl]amino}\n(RS) -S-cyclopropyl-S- (4 - {[4 - {[(R) -2-hydroxy-1,2-dimethylpropyl] amino}\n\n\n\n\n\n\n \n-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid\n-5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n5a) Herstellung der Zwischenprodukte\n5a) Preparation of intermediates\n\n\n\n\n\n\n \nVerbindung 5.1\nConnection 5.1\n\n\n\n\n\n\n \n(R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-2-methyl-butan-2-ol\n(R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n3,6 g (35,03 mmol) (R)-3-Amino-2-methyl-butan-2-ol wurden tropfenweise zu einer Lösung von 7,6 g (35,03 mmol) 2,4-Dichlor-5-trifluormethyl-pyrimidin in 139 ml Acetonitril gegeben. Bei 0 \n0\nC wurden nun 9,7 ml (70,1 mmol) Triethylamin zugetropft und der Ansatz langsam über Nacht auf Raumtemperatur erwärmt. Man rührte weitere 2 Tage bei Raumtemperatur. Der Ansatz wurde in halbkonzentrierte Natriumchlorid-Lösung gegeben und mit Essigester extrahiert (2x). Die vereinten \n\n organischen Phasen wurden getrocknet (NaaSO-O, filtriert und eingeengt. Der verbleibende Rückstand wurde mittels präparativer HPLC gereinigt. Man erhielt 3,0 g (10,65 mmol; Ausbeute: 30 %) des Produktes.\n3.6 g (35.03 mmol) of (R) -3-amino-2-methyl-butan-2-ol was added dropwise to a solution of 7.6 g (35.03 mmol) of 2,4-dichloro-5 trifluoromethylpyrimidine in 139 ml of acetonitrile. At 0 \n°\n C., 9.7 ml (70.1 mmol) of triethylamine were then added dropwise, and the mixture was slowly warmed to room temperature overnight. The mixture was stirred for a further 2 days at room temperature. The batch was placed in semiconcentrated sodium chloride solution and extracted with ethyl acetate (2x). The united  The organic phases were dried (Na 2 SO 4 O, filtered and concentrated, and the remaining residue was purified by preparative HPLC to give 3.0 g (10.65 mmol, yield: 30%) of the product.\n\n\n\n\n\n\n \nSäule: XBridge C18 5μ 150x20 mm\nColumn: XBridge C18 5μ 150x20 mm\n\n\n\n\n\n\n \nEluent A: H\n2\nO / 0.2% NH\n3\n \nEluent A: H \n2\n O / 0.2% NH \n3\n \n\n\n\n\n\n\n \nEluent B: Acetonitril\nEluent B: acetonitrile\n\n\n\n\n\n\n \nGradient: 70%A+30%B(2') 30->60%B(10') 60->99%B(0.1')\nGradient: 70% A + 30% B (2 ') 30-> 60% B (10') 60-> 99% B (0.1 ')\n\n\n\n\n\n\n \nFluß: 50,0 mL/min Detektor: DAD (200-400 nm) TAC ; MS-ESI+ (160-1000 m/z) TIC\nFlow: 50.0 mL / min detector: DAD (200-400 nm) TAC; MS-ESI + (160-1000 m / z) TIC\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 5,6-6,4 min\nRetention time: 5.6-6.4 min\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.42 (s, 1 H), 6.52 (d, 1 H), 5.01 (s, 1 H), 4.10 (m, 1 H), 1.11 (m, 9H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.42 (s, 1H), 6.52 (d, 1H), 5.01 (s, 1H), 4.10 (m, 1H), 1.11 (m, 9H ).\n\n\n\n\n\n\n \nDie Herstellung von (RS)-S-(4-Aminophenyl)-S-cyclopropyl-N-(trifluoracetyl)sulfoximid ist beschrieben als Verbindung 1.4.\nThe preparation of (RS) -S- (4-aminophenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide is described as compound 1.4.\n\n\n\n\n\n\n \n5b) Herstellung des Endproduktes\n5b) Preparation of the end product\n\n\n\n\n\n\n \n400 mg (1 ,37 mmol) (RS)-S-(4-Aminophenyl)-S-cyclopropyl-N- (trifluoracetyl)sulfoximid und 388 mg (1 ,37 mmol) (R)-3-(2-Chlor-5-trifluormethyl- pyrimidin-4-ylamino)-2-methyl-butan-2-ol in 6,0 ml Acetonitril wurden mit 0,34 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 3,5 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt. Man versetzte mit 29,4 ml Methanol und 950 mg (6,84 mmol) Kaliumcarbonat und rührte eine Stunde bei Raumtemperatur. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 600 mg (1 ,35 mmol) des Rohproduktes.\n400 mg (1.37 mmol) of (RS) -S- (4-aminophenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide and 388 mg (1.37 mmol) of (R) -3- (2-chloro) 5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol in 6.0 ml of acetonitrile were treated with 0.34 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 3.5 hours , The batch was concentrated to dryness. It was mixed with 29.4 ml of methanol and 950 mg (6.84 mmol) of potassium carbonate and stirred for one hour at room temperature. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (2 ×). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. 600 mg (1.35 mmol) of the crude product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.08 (s, 1 H), 8.30 (s, 1 H), 7.94 (m, 2H), 7.80 (m, 2H), 6.07 (d, 1 H), 4.95 (s, 1 H), 4.16 (m, 1 H), 4.02 (s, 1 H), 2.62 (m, 1 H), 1.20 (m, 6H), 1.10 (m, 4H), 0.89 (m, 3H). MS: 444 (ESI+). \n\n Das Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.08 (s, 1H), 8.30 (s, 1H), 7.94 (m, 2H), 7.80 (m, 2H), 6.07 (d, 1H) , 4.95 (s, 1H), 4.16 (m, 1H), 4.02 (s, 1H), 2.62 (m, 1H), 1.20 (m, 6H), 1.10 (m, 4H), 0.89 (m , 3H). MS: 444 (ESI +).  The diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak AD-H 5μ 250x20 mm\nColumn: Chiralpak AD-H 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: Hexan / 2-Propanol 60:40\nEluent: hexane / 2-propanol 60:40\n\n\n\n\n\n\n \nPuffer: Hexan/ 0,1% DEA\nBuffer: hexane / 0.1% DEA\n\n\n\n\n\n\n \nFluß: 20,0 mL/min\nFlow: 20.0 mL / min\n\n\n\n\n\n\n \nDetektor: UV 280 nm\nDetector: UV 280 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 5,1-6,3 min; Stereoisomer 1 (=Beispiel 5-SI-1 )\nRetention time: 5.1-6.3 min; Stereoisomer 1 (= Example 5-SI-1)\n\n\n\n\n\n\n \n8,0-10,8 min; Stereoisomer 2 (=Beispiel 5-SI-2)\n8.0-10.8 min; Stereoisomer 2 (= Example 5-SI-2)\n\n\n\n\n\n\n \nBeispiel 6\nExample 6\n\n\n\n\n\n\n \n(RS)-S-Ethyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]amino}\n(RS) -S-ethyl-S- (4 - {[4 - {[(1R, 2R) -2-hydroxy-1-methylpropyl] amino}\n\n\n\n\n\n\n \n-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid\n-5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n6a) Herstellung der Zwischenprodukte Verbindung 6.1 1-Ethylsulfanyl-4-nitro-benzol\n6a) Preparation of Intermediates Compound 6.1 1-Ethylsulfanyl-4-nitrobenzene\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,27 g (106,76 mmol) Natriumhydroxid in 320 ml Ethanol wurde unter Wasserkühlung mit 16,56 g (106,72 mmol) 4-Nitrothiophenol versetzt und 15 Minuten bei Raumtemperatur gerührt. Anschießend wurden unter Wasserkühlung 8,63 ml (106,79 mmol) Ethyljodid zugegeben und der Ansatz über Nacht bei \n\n Raumtemperatur gerührt. Der Ansatz wurde in gesättigte Natriumchlorid-Lösung gegeben und mit Essigester extrahiert (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Anschließend wurde in DCM gelöst und erneut filtriert und zur Trockene eingeengt. Man erhielt 16,86 g (92,02 mmol) des Rohproduktes.\nA solution of 4.27 g (106.76 mmol) of sodium hydroxide in 320 ml of ethanol was added under cooling with 16.56 g (106.72 mmol) of 4-nitrothiophenol and stirred for 15 minutes at room temperature. Anhießend were added under water cooling 8.63 ml (106.79 mmol) of ethyl iodide and the approach overnight at  Room temperature stirred. The batch was added to saturated sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. It was then dissolved in DCM and filtered again and concentrated to dryness. This gave 16.86 g (92.02 mmol) of the crude product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz\n1\n DMSO): δ = 8.14 (m, 2H), 7.49 (m, 2H), 3.14 (q, 2H), 1.31 (tr, 3H).\n \n1\n H-NMR (400 MHz \n1\n DMSO): δ = 8.14 (m, 2H), 7.49 (m, 2H), 3.14 (q, 2H), 1.31 (tr, 3H).\n\n\n\n\n\n\n \nVerbindung 6.2\nConnection 6.2\n\n\n\n\n\n\n \n(RS)-1-Ethylsulfinyl-4-nitro-benzol\n(RS) -1-ethylsulfinyl-4-nitro-benzene\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEin Ansatz mit 16,86 g (92,02 mmol) 1-Ethylsulfanyl-4-nitro-benzol in 75 ml Acetonitril wurde mit 428 mg (2,64 mmol) Eisen(lll) chlorid versetzt und 10 Minuten bei Raumtemperatur gerührt. Anschließend versetzte man portionsweise mit 22,44 g (98,44 mmol) Perjodsäure, so dass die Temperatur 30\n0\nC nicht überschritt. Der Ansatz wurde 50 Minuten gerührt und anschließend unter Rühren in ein Gemisch aus 170 ml DCM, 500 ml Eiswasser und 100 g Natriumthiosulfat Pentahydrat gegeben. Man extrahierte mit DCM (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Der erhaltene Rückstand wurde aus Essigester / Hexan umkristallisiert. Man erhielt 12,49 g (62,69 mmol; Ausbeute: 68 %) des Produktes.\nA batch of 16.86 g (92.02 mmol) of 1-ethylsulfanyl-4-nitrobenzene in 75 ml of acetonitrile was treated with 428 mg (2.64 mmol) of iron (III) chloride and stirred for 10 minutes at room temperature. It was then added in portions with 22.44 g (98.44 mmol) of periodic acid, so that the temperature did not exceed 30 \n0\n C. The reaction was stirred for 50 minutes and then added with stirring to a mixture of 170 ml of DCM, 500 ml of ice-water and 100 g of sodium thiosulfate pentahydrate. Extracted with DCM (2x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. The residue obtained was recrystallized from ethyl acetate / hexane. This gave 12.49 g (62.69 mmol, yield: 68%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.35 (m, 2H), 7.88 (m, 2H), 3.12 (m, 1 H), 2.84 (m, 1 H), 0.99 (tr, 3H). \n\n Verbindung 6.3 (RS)-S-Ethyl-S-(4-nitrophenyl)sulfoximid\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.35 (m, 2H), 7.88 (m, 2H), 3.12 (m, 1H), 2.84 (m, 1H), 0.99 (tr, 3H).  Compound 6.3 (RS) -S-ethyl-S- (4-nitrophenyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n6,00 g (30,12 mmol) (RS)-I -Ethylsulfinyl-4-nitro-benzol wurden im Eisbad vorsichtig mit 30,5 ml Oleum (20% SO\n3\n) versetzt. Anschließend wurden unter Argon vorsichtig 2,35 g (36,14 mmol) Natriumazid portionsweise unter Rühren zugegeben und der Ansatz dann auf 45°C erwärmt. Nach 6 Stunden wurde der Ansatz auf Raumtemperatur abgekühlt und vorsichtig auf Eis gegossen. Der Ansatz wurde mit Natriumhydrogencarbonat basisch gestellt und mit Essigester extrahiert (2x). Die vereinten organischen Phasen wurden getrocknet (NaaSO-O, filtriert und eingeengt. Man erhielt 5,74 g (26,79 mmol; Ausbeute: 89%) des Produktes.\n6.00 g (30.12 mmol) of (RS) -I-ethylsulfinyl-4-nitro-benzene were cautiously mixed with 30.5 ml of oleum (20% SO \n3\n ) in an ice bath. Subsequently, 2.35 g (36.14 mmol) of sodium azide were added under argon carefully in portions while stirring and the batch was then heated to 45 ° C. After 6 hours, the reaction was cooled to room temperature and poured cautiously on ice. The mixture was basified with sodium bicarbonate and extracted with ethyl acetate (2x). The combined organic phases were dried (Na 2 SO 4 O, filtered and concentrated to give 5.74 g (26.79 mmol, yield: 89%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.37 (m, 2H), 8.09 (m, 2H), 4.56 (s, 1 H), 3.18 (q, 2H), 1.04 (tr, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.37 (m, 2H), 8.09 (m, 2H), 4.56 (s, 1H), 3.18 (q, 2H), 1.04 (tr, 3H).\n\n\n\n\n\n\n \nVerbindung 6.4 (RS)-S-Ethyl-S-(4-nitrophenyl)-N-(trifluoracetyl)sulfoximid\nCompound 6.4 (RS) -S-ethyl-S- (4-nitrophenyl) -N- (trifluoroacetyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 5,72 g (26,70 mmol) (RS)-S-Ethyl-S-(4-nitrophenyl)sulfoximid und 4,07 ml (29,37 mmol) Triethylamin in 175 ml DCM wurde unter Eiskühlung tropfenweise mit 4,53 ml (32,04 mmol) Trifluoracetanhydrid versetzt. Der Ansatz wurde weitere 3 Stunden im Eisbad gerührt, wobei die Temperatur auf ca. 10\n0\nC anstieg. Man verdünnte mit DCM und wusch mit halbkonzentrierter Natriumchlorid- Lösung. Die organische Phase wurde getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 8,17 g (26,33 mmol) des Produktes.\nA solution of 5.72 g (26.70 mmol) of (RS) -S-ethyl-S- (4-nitrophenyl) sulfoximide and 4.07 ml (29.37 mmol) of triethylamine in 175 ml of DCM was added dropwise under ice-cooling 4.53 ml (32.04 mmol) of trifluoroacetic anhydride were added. The mixture was stirred for a further 3 hours in an ice bath, the temperature rising to about 10 \n°\n C. It was diluted with DCM and washed with half-concentrated sodium chloride solution. The organic phase was dried (Na \n2\n SO \n4\n ), filtered and concentrated. This gave 8.17 g (26.33 mmol) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 8.52 (m, 2H), 8.22 (m, 2H), 3.99 (m, 2H), 1.16 (tr, 3H). \n\n Verbindung 6.5 (RS)-S-(4-Aminophenyl)-S-ethyl-N-(trifluoracetyl)sulfoximid\n \n1\n H-NMR (400 MHz, DMSO): δ = 8.52 (m, 2H), 8.22 (m, 2H), 3.99 (m, 2H), 1.16 (tr, 3H).  Compound 6.5 (RS) -S- (4-aminophenyl) -S-ethyl-N- (trifluoroacetyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nEine Lösung von 4,05 g (13,05 mmol) (RS)-S-Ethyl-S-(4-nitrophenyl)-N- (trifluoracetyl)sulfoximid in 191 ml THF wurde unter Eiskühlung langsam mit 88,5 ml einer 15%igen Lösung von Titan(lll)chlorid in etwa 10%iger Salzsäure versetzt. Der Ansatz wurde 3,5 Stunden bei Raumtemperatur gerührt, mit Essigester verdünnt und anschließend mit halbkonzentrierter Natriumchlorid-Lösung gewaschen (3x). Die organische Phase wurde getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 3,17 g (11 ,31 mmol) des Produktes.\nA solution of 4.05 g (13.05 mmol) of (RS) -S-ethyl-S- (4-nitrophenyl) -N- (trifluoroacetyl) sulfoximide in 191 ml of THF was added slowly with 88.5 ml of a 15 ml under ice-cooling % solution of titanium (III) chloride in about 10% hydrochloric acid. The reaction was stirred for 3.5 hours at room temperature, diluted with ethyl acetate and then washed with half-concentrated sodium chloride solution (3x). The organic phase was dried (Na \n2\n SO \n4\n ), filtered and concentrated. 3.17 g (11.31 mmol) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 7.48 (m, 2H), 6.68 (m, 2H), 3.64 (m, 2H), 1.06 (tr, 3H). Die Herstellung von (2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-butan-2- ol ist beschrieben als Verbindung 4.1.\n \n1\n H-NMR (400 MHz, DMSO): δ = 7.48 (m, 2H), 6.68 (m, 2H), 3.64 (m, 2H), 1.06 (tr, 3H). The preparation of (2R, 3R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol is described as Compound 4.1.\n\n\n\n\n\n\n \n6b) Herstellung des Endproduktes 400 mg (1 ,43 mmol) (RS)-S-(4-Aminophenyl)-S-ethyl-N-(trifluoracetyl)sulfoximid und 385 mg (1 ,43 mmol) (2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-butan-2- ol in 7,0 ml Acetonitril wurden mit 0,36 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 4,5 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt. Man versetzte mit 19,0 ml Methanol und 608 mg (4,40 mmol) Kaliumcarbonat und rührte 1 Stunde bei Raumtemperatur. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 590 mg (1 ,41 mmol) des Rohproduktes.\n6b) Preparation of the final product 400 mg (1, 43 mmol) of (RS) -S- (4-aminophenyl) -S-ethyl-N- (trifluoroacetyl) sulfoximide and 385 mg (1, 43 mmol) (2R, 3R) - 3- (2-Chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol in 7.0 ml of acetonitrile was added 0.36 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 for 4.5 hours \n0\n C stirred. The batch was concentrated to dryness. 19.0 ml of methanol and 608 mg (4.40 mmol) of potassium carbonate were added and the mixture was stirred at room temperature for 1 hour. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (2 ×). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. 590 mg (1.41 mmol) of the crude product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.10 (s, 1H), 8.30 (s, 1 H), 7.96 (m, 2H), 7.78 (m, 2H), 6.10 (d, 1 H), 5.11 (d, 1 H), 4.19 (m, 1H), 4.00 (s, 1 H), 3.82 (m, 1 H), 3.07 (q, 2H), 1.24 (d, 3H), 1.06 (m, 6H). MS: 418 (ESI+). \n\n Das Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.10 (s, 1H), 8.30 (s, 1H), 7.96 (m, 2H), 7.78 (m, 2H), 6.10 (d, 1H), 5.11 (d, 1H), 4.19 (m, 1H), 4.00 (s, 1H), 3.82 (m, 1H), 3.07 (q, 2H), 1.24 (d, 3H), 1.06 (m, 6H ). MS: 418 (ESI +).  The diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak AD-H 5μ 250x20 mm\nColumn: Chiralpak AD-H 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: Hexan / 2-Propanol 60:40 Puffer: Hexan/ 0,1 % DEA\nEluent: hexane / 2-propanol 60:40 buffer: hexane / 0.1% DEA\n\n\n\n\n\n\n \nFluß: 20,0 mL/min\nFlow: 20.0 mL / min\n\n\n\n\n\n\n \nDetektor: UV 280 nm\nDetector: UV 280 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 6,2-6,8 min; Stereoisomer 1 (=Beispiel 6-SI-1 ) 7,2-8,9 min; Stereoisomer 2 (=Beispiel 6-SI-2)\nRetention time: 6.2-6.8 min; Stereoisomer 1 (= Example 6-SI-1) 7.2-8.9 min; Stereoisomer 2 (= Example 6-SI-2)\n\n\n\n\n\n\n \nBeispiel 7\nExample 7\n\n\n\n\n\n\n \n(RS)-S-Ethyl-S-(4-{[4-{[(R)-2-hydroxy-1,2-dimethylpropyl]amino}\n(RS) -S-ethyl-S- (4 - {[4 - {[(R) -2-hydroxy-1,2-dimethylpropyl] amino}\n\n\n\n\n\n\n \n-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid\n-5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) sulfoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n7a) Herstellung der Zwischenprodukte\n7a) Preparation of the intermediates\n\n\n\n\n\n\n \nDie Herstellung von (RS)-S-(4-Aminophenyl)-S-ethyl-N-(trifluoracetyl)sulfoximid ist beschrieben als Verbindung 6.5. Die Herstellung von (R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-2-methyl- butan-2-ol ist beschrieben als Verbindung 5.1.\nThe preparation of (RS) -S- (4-aminophenyl) -S-ethyl-N- (trifluoroacetyl) sulfoximide is described as Compound 6.5. The preparation of (R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol is described as Compound 5.1.\n\n\n\n\n\n\n \n7b) Herstellung des Endproduktes\n7b) Preparation of the end product\n\n\n\n\n\n\n \n400 mg (1 ,43 mmol) (RS)-S-(4-Aminophenyl)-S-ethyl-N-(trifluoracetyl)sulfoximid und 405 mg (1 ,43 mmol) (R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-2-methyl- butan-2-ol in 7,0 ml Acetonitril wurden mit 0,36 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 4,5 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt. Man versetzte mit 25,0 ml Methanol und 788 mg (5,70 mmol) Kaliumcarbonat und rührte eine Stunde bei Raumtemperatur. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (2x). \n\n Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 620 mg (1 ,43 mmol) des Rohproduktes.\n400 mg (1.43 mmol) of (RS) -S- (4-aminophenyl) -S-ethyl-N- (trifluoroacetyl) sulfoximide and 405 mg (1, 43 mmol) of (R) -3- (2-chloro) 5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol in 7.0 ml of acetonitrile were mixed with 0.36 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 4.5 hours , The batch was concentrated to dryness. 25.0 ml of methanol and 788 mg (5.70 mmol) of potassium carbonate were added and the mixture was stirred at room temperature for one hour. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (2 ×).  The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. 620 mg (1.43 mmol) of the crude product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ =10.06 (s, 1 H), 8.28 (s, 1 H), 7.92 (m, 2H), 7.74 (m, 2H)\n1\n 6.03 (d, 1 H), 4.90 (s, 1 H), 4.12 (m, 1 H), 3.96 (s, 1 H), 3.03 (q, 2H), 1.16 (m, 6H), 1.08 (m, 3H), 1.02 (tr, 3H). MS: 432 (ESI+).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.06 (s, 1H), 8.28 (s, 1H), 7.92 (m, 2H), 7.74 (m, 2H) \n1\n 6.03 (d, 1H) , 4.90 (s, 1H), 4.12 (m, 1H), 3.96 (s, 1H), 3.03 (q, 2H), 1.16 (m, 6H), 1.08 (m, 3H), 1.02 (tr, 3H). MS: 432 (ESI +).\n\n\n\n\n\n\n \nDas Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt: Säule: Chiralpak AD-H 5μ 250x20 mm\nThe diastereomeric mixture was separated by preparative HPLC into the pure stereoisomers: Column: Chiralpak AD-H 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: A:Hexan B:2-Propanol\nEluent: A: hexane B: 2-propanol\n\n\n\n\n\n\n \nPuffer: Hexan/ 0,1% DEA\nBuffer: hexane / 0.1% DEA\n\n\n\n\n\n\n \nGradient: 20->40%B(20')+40%B(5')\nGradient: 20-> 40% B (20 ') + 40% B (5')\n\n\n\n\n\n\n \nFluß: 10,0 mL/min Detektor: UV 280 nm\nFlow: 10.0 mL / min Detector: UV 280 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 17,5-19,8 min; Stereoisomer 1 (=Beispiel 7-SI-1 )\nRetention time: 17.5-19.8 min; Stereoisomer 1 (= Example 7-SI-1)\n\n\n\n\n\n\n \n20,1-22,0 min; Stereoisomer 2 (=Beispiel 7-SI-2)\n20.1-22.0 min; Stereoisomer 2 (= Example 7-SI-2)\n\n\n\n\n\n\n \nBeispiel 8\nExample 8\n\n\n\n\n\n\n \n(RS)-S-(4-{[4-{[(1R,2R)-2-Hydroxy-1-methylpropyl]amino}-5-(trifluormethyl) pyrimidin-2-yl]amino}phenyl)-S-methylsulfoximid\n(RS) -S- (4 - {[4 - {[(1R, 2R) -2-hydroxy-1-methylpropyl] amino} -5- (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) -S- methylsulphoximide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n8a) Herstellung der Zwischenprodukte\n8a) Preparation of the intermediates\n\n\n\n\n\n\n \nDie Herstellung von (RS)-S-(4-Aminophenyl)-S-methyl-N-(trifluoracetyl)sulfoximid ist beschrieben als Verbindung 2.3.\nThe preparation of (RS) -S- (4-aminophenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide is described as compound 2.3.\n\n\n\n\n\n\n \nDie Herstellung von (2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-butan-2- ol ist beschrieben als Verbindung 4.1. \n\n 8b) Herstellung des Endproduktes\nThe preparation of (2R, 3R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -butan-2-ol is described as Compound 4.1.  8b) Preparation of the final product\n\n\n\n\n\n\n \n399 mg (1 ,50 mmol) (RS)-S-(4-Aminophenyl)-S-methyl-N-(trifluoracetyl)sulfoximid und 404 mg (1 ,50 mmol) (2R,3R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)- butan-2-ol in 7,3 ml Acetonitril wurden mit 0,38 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 9 Stunden bei 6O\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt. Man versetzte mit 32,2 ml Methanol und 1040 mg (7,50 mmol) Kaliumcarbonat und rührte 1 ,5 Stunden bei Raumtemperatur. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 565 mg (1 ,40 mmol) des Rohproduktes.\n399 mg (1.50 mmol) of (RS) -S- (4-aminophenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide and 404 mg (1.50 mmol) of (2R, 3R) -3- (2- Chloro-5-trifluoromethyl-pyrimidin-4-ylamino) - butan-2-ol in 7.3 ml of acetonitrile were mixed with 0.38 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 6O \n0\n C for 9 hours. The batch was concentrated to dryness. It was mixed with 32.2 ml of methanol and 1040 mg (7.50 mmol) of potassium carbonate and stirred for 1.5 hours at room temperature. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. 565 mg (1.40 mmol) of the crude product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): 10.09 (s, 1 H), 8.30 (s, 1 H), 7.96 (m, 2H), 7.83 (m, 2H), 6.10 (d, 1 H), 5.11 (d, 1 H), 4.18 (m, 1 H), 4.03 (s, 1 H), 3.82 (m, 1 H), 3.03 (s, 3H), 1.25 (d, 3H), 1.10 (d, 3H).\n \n1\n H-NMR (400 MHz, DMSO): 10.09 (s, 1H), 8.30 (s, 1H), 7.96 (m, 2H), 7.83 (m, 2H), 6.10 (d, 1H), 5.11 (d, 1H), 4.18 (m, 1H), 4.03 (s, 1H), 3.82 (m, 1H), 3.03 (s, 3H), 1.25 (d, 3H), 1.10 (d, 3H ).\n\n\n\n\n\n\n \nDas Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\nThe diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak IC 5μ 250x20 mm\nColumn: Chiralpak IC 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: Hexan / Ethanol 50:50\nEluents: hexane / ethanol 50:50\n\n\n\n\n\n\n \nPuffer: Hexan/ 0,1 % DEA\nBuffer: hexane / 0.1% DEA\n\n\n\n\n\n\n \nFluß: 20,0 mL/min\nFlow: 20.0 mL / min\n\n\n\n\n\n\n \nDetektor: UV 254 nm\nDetector: UV 254 nm\n\n\n\n\n\n\n \nTemperatur: Raumtemperatur\nTemperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 5,1-5,8 min; Stereoisomer 1 (=Beispiel 8-SI-1 )\nRetention time: 5.1-5.8 min; Stereoisomer 1 (= Example 8-SI-1)\n\n\n\n\n\n\n \n6,1-6,7 min; Stereoisomer 2 (=Beispiel 8-SI-2)\n6.1-6.7 min; Stereoisomer 2 (= Example 8-SI-2)\n\n\n\n\n\n\n \nBeispiel 9\nExample 9\n\n\n\n\n\n\n \n \n\n9a) Herstellung der Zwischenprodukte\n \n 9a) Preparation of the intermediates\n\n\n\n\n\n\n \nDie Herstellung von (RS)-S-(4-Aminophenyl)-S-methyl-N-(trifluoracetyl)sulfoximid ist beschrieben als Verbindung 2.3.\nThe preparation of (RS) -S- (4-aminophenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide is described as compound 2.3.\n\n\n\n\n\n\n \nDie Herstellung von (R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-2-methyl- butan-2-ol ist beschrieben als Verbindung 5.1.\nThe preparation of (R) -3- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol is described as Compound 5.1.\n\n\n\n\n\n\n \n9b) Herstellung des Endproduktes\n9b) Production of the end product\n\n\n\n\n\n\n \n399 mg (1 ,50 mmol) (RS)-S-(4-Aminophenyl)-S-methyl-N-(trifluoracetyl)sulfoximid und 425 mg (1 ,50 mmol) (R)-3-(2-Chlor-5-trifluormethyl-pyrimidin-4-ylamino)-2- methyl-butan-2-ol in 7,3 ml Acetonitril wurden mit 0,38 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 4 Stunden bei 60\n0\nC gerührt. Der Ansatz wurde zur Trockene eingeengt. Man versetzte mit 32,2 ml Methanol und 1040 mg (7,50 mmol) Kaliumcarbonat und rührte 1 ,5 Stunden bei Raumtemperatur. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (2x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO4), filtriert und eingeengt. Man erhielt 600 mg (1 ,44 mmol) des Rohproduktes.\n399 mg (1.50 mmol) of (RS) -S- (4-aminophenyl) -S-methyl-N- (trifluoroacetyl) sulfoximide and 425 mg (1.50 mmol) of (R) -3- (2-chloro) 5-trifluoromethyl-pyrimidin-4-ylamino) -2-methyl-butan-2-ol in 7.3 ml of acetonitrile were mixed with 0.38 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 4 hours. The batch was concentrated to dryness. It was mixed with 32.2 ml of methanol and 1040 mg (7.50 mmol) of potassium carbonate and stirred for 1.5 hours at room temperature. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (2 ×). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. 600 mg (1.44 mmol) of the crude product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.05 (s, 1 H), 8.26 (s, 1 H)\n1\n 7.91 (m, 2H), 7.79 (m, 2H), 6.03 (d, 1 H), 4.91 (s, 1 H), 4.11 (m, 1 H), 3.99 (s, 1 H), 2.99 (s, 3H), 1.16 (m, 6H), 1.10 (m, 3H). MS: 418 (ESI+).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.05 (s, 1H), 8.26 (s, 1H) \n1\n 7.91 (m, 2H), 7.79 (m, 2H), 6.03 (d, 1H) , 4.91 (s, 1H), 4.11 (m, 1H), 3.99 (s, 1H), 2.99 (s, 3H), 1.16 (m, 6H), 1.10 (m, 3H). MS: 418 (ESI +).\n\n\n\n\n\n\n \nDas Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\nThe diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak IC 5μ 250x20 mm\nColumn: Chiralpak IC 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: Hexan / Ethanol 80:20\nEluent: hexane / ethanol 80:20\n\n\n\n\n\n\n \nFluß: 30,0 mL/min\nFlow: 30.0 mL / min\n\n\n\n\n\n\n \nDetektor: UV 254 nm Temperatur: Raumtemperatur\nDetector: UV 254 nm Temperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 6,0-6,7 min; Stereoisomer 1 (=Beispiel 9-SI-1 ) 7,1-8,9 min; Stereoisomer 2 (=Beispiel 9-SI-2) \n\n Herstellung der Vergleichssubstanzen\nRetention time: 6.0-6.7 min; Stereoisomer 1 (= Example 9-SI-1) 7.1-8.9 min; Stereoisomer 2 (= Example 9-SI-2)  Preparation of the comparison substances\n\n\n\n\n\n\n \nDie in-vitro und in-vivo-Effektivität der erfindungsgemäßen Verbindungen gekennzeichnet u.a. durch einen 5-CF\n3\n-Substituenten in Position 5 des Pyrimidins wurden mit ihren 5-Br-Analoga verglichen, die entweder explizit in\nThe in vitro and in vivo efficacy of the compounds of the invention characterized, inter alia, by a 5-CF \n3\n substituent in position 5 of the pyrimidine was compared with their 5-Br analogs, which are either explicitly described in US Pat\n\n\n\n\n\n\n \nWO 2005/037800 offenbart sind oder aber unter deren generische Offenbarung fallen.\nWO 2005/037800 are disclosed or fall under the generic disclosure.\n\n\n\n\n\n\n \nV11 = 5-Br-Vergleichsubstanz in Beispiel 11\nV11 = 5-Br comparison substance in Example 11\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nDie Vergleichssubstanz in Beispiel 11 ist das aktivere Stereoisomer des Diastereomerengemisches (RS)-S-[4-({5-Brom-4-[(R)-(2-hydroxy-1 ,2- dimethylpropyl)amino]pyrimidin-2-yl}amino)phenyl]-S-cyclopropyl-sulfoximid, das als Beispiels 1.6 in der Anmeldung WO 2005/037800 (S. 35), offenbart wird.\nThe reference substance in Example 11 is the more active stereoisomer of the diastereomeric mixture (RS) -S- [4 - ({5-bromo-4 - [(R) - (2-hydroxy-1,2-dimethylpropyl) amino] pyrimidine-2 yl} amino) phenyl] -S-cyclopropyl-sulfoximide, which is disclosed as Example 1.6 in the application WO 2005/037800 (page 35).\n\n\n\n\n\n\n \nFür den Vergleich in-vivo wurde in Beispiel 11 das Diastereomer (R)-S-[4-({5-Brom-4- [(R)-(2-hydroxy-1 ,2-dimethylpropyl)amino]pyrimidin-2-yl}amino)phenyl]-S-cyclopropyl- sulfoximid, das eine stärkere in vitro Effektivität als (S)-S-[4-({5-Brom-4-[(R)-(2-hydroxy-1 ,2-dimethylpropyl)amino]pyrimidin-2- yl}amino)phenyl]-S-cyclopropyl-sulfoximid aufweist, verwendet. V11 wurde dazu nach folgender Methode hergestellt: \n\n V11a) Herstellung des Zwischenproduktes\nFor comparison in vivo, in Example 11, the diastereomer was (R) -S- [4 - ({5-bromo-4- [(R) - (2-hydroxy-1,2-dimethylpropyl) amino] pyrimidine-2 -yl} amino) phenyl] -S-cyclopropylsulfoximide, which has a stronger in vitro effectiveness than (S) -S- [4 - (5-bromo-4 - [(R) - (2-hydroxy-1, 2-dimethylpropyl) amino] pyrimidin-2-yl} amino) phenyl] -S-cyclopropylsulfoximide. V11 was prepared by the following method:  V11a) Preparation of the intermediate product\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n988 mg (3,35 mmol) (R)-3-(5-Brom-2-chlor-pyrimidin-4-ylamino)-2-methyl-butan-2-ol und 750 mg (2,79 mmol) (R)-S-(4-Aminophenyl)-N-(ethoxycarbonyl)-S- cyclopropylsulfoximid (Herstellung nach: U. Lücking et al, WO 2007 / 071455, S. 112, Example 4) in 16,50 ml Butanol und 1 ,65 ml Methanol wurden mit 0,07 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 3 Tage bei 60\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz zur Trockene eingeengt und chromatographisch (DCM / EtOH 9:1 ) gereinigt. Man erhielt 319 mg (0,61 mmol, Ausbeute: 22%) des Produktes.\n988 mg (3.35 mmol) of (R) -3- (5-bromo-2-chloro-pyrimidin-4-ylamino) -2-methyl-butan-2-ol and 750 mg (2.79 mmol) (R. ) -S- (4-aminophenyl) -N- (ethoxycarbonyl) -S-cyclopropylsulfoximide (preparation according to: U. Lücking et al, WO 2007/071455, p. 112, Example 4) in 16.50 ml of butanol and 1, 65 ml of methanol were treated with 0.07 ml of a 4N solution of hydrogen chloride in dioxane and stirred at 60 \n0\n C for 3 days. After cooling, the batch was concentrated to dryness and purified by chromatography (DCM / EtOH 9: 1). This gave 319 mg (0.61 mmol, yield: 22%) of the product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 9.96 (s, 1 H), 8.13 (s, 1 H), 7.92 (m, 2H), 7.73 (m, 2H), 6.28 (d, 1 H), 4.05 (m, 1 H), 3.84 (m, 2H), 2.96 (m, 1 H), 1.05 (m, 16H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 9.96 (s, 1H), 8.13 (s, 1H), 7.92 (m, 2H), 7.73 (m, 2H), 6.28 (d, 1H) , 4.05 (m, 1H), 3.84 (m, 2H), 2.96 (m, 1H), 1.05 (m, 16H).\n\n\n\n\n\n\n \nV11b) Herstellung des Endproduktes\nV11b) Preparation of the end product\n\n\n\n\n\n\n \n319 mg (0,61 mmol) des Zwischenproduktes in 4,3 ml Ethanol wurden mit 2,0 ml einer frisch hergestellten 1 ,5M Natriumethanolat-Lösung versetzt und 18 Stunden bei 60\n0\nC gerührt. Nach dem Abkühlen wurde der Ansatz in gesättigte Natriumchlorid- Lösung gegeben und mit Essigester extrahiert (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Nach abschließender Umkristallisation (DCM / Essigester) erhielt man 215 mg (0,47 mmol; Ausbeute: 78%) des Produktes.\n2.09 ml of a freshly prepared 1.5M sodium ethoxide solution were added to 319 mg (0.61 mmol) of the intermediate in 4.3 ml of ethanol, and the mixture was stirred at 60 \n°\n C. for 18 hours. After cooling, the reaction was poured into saturated sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. After concluding recrystallization (DCM / ethyl acetate), 215 mg (0.47 mmol, yield: 78%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 9.68 (s, 1 H), 8.08 (s, 1 H), 7.86 (m, 2H), 7.70 (m, 2H), 6.07 (d, 1H), 4.82 (s, 1H), 4.05 (m, 1H), 3.93 (s, 1 H), 2.55 (m, 1 H), 1.15 (m, 6H), 1.10 (m, 3H), 1.03 (m, 1 H), 0.83 (m, 3H). \n\n Säule: Chiralpak AD-H 5μ 150x4,6 mm\n \n1\n H-NMR (400 MHz, DMSO): δ = 9.68 (s, 1H), 8.08 (s, 1H), 7.86 (m, 2H), 7.70 (m, 2H), 6.07 (d, 1H), 4.82 (s, 1H), 4.05 (m, 1H), 3.93 (s, 1H), 2.55 (m, 1H), 1.15 (m, 6H), 1.10 (m, 3H), 1.03 (m, 1H ), 0.83 (m, 3H).  Column: Chiralpak AD-H 5μ 150x4.6 mm\n\n\n\n\n\n\n \nEluenten: Hexan / Ethanol 80.20\nEluent: hexane / ethanol 80.20\n\n\n\n\n\n\n \nFluß: 1 ,0 mL/min\nFlow: 1, 0 mL / min\n\n\n\n\n\n\n \nDetection: PDA 280 nm\nDetection: PDA 280 nm\n\n\n\n\n\n\n \nTemperatur: 25°C\nTemperature: 25 ° C\n\n\n\n\n\n\n \nRetentionszeit: 11 ,64 min\nRetention time: 11, 64 min\n\n\n\n\n\n\n \nV12 = 5-Br-Vergleichssubstanz in Beispiel 12\nV12 = 5 Br comparative substance in Example 12\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nDie Vergleichssubstanz in Beispiel 12 wurde gemäß Beispiel 1.52 der WO 2005/037800 hergestellt. Beispiel 1.52 hat eine stärkere in vitro Effektivität als Beispiel 1.53.\nThe comparison substance in Example 12 was prepared according to Example 1.52 of WO 2005/037800. Example 1.52 has a stronger in vitro effectiveness than Example 1.53.\n\n\n\n\n\n\n \nV13 = 5-Br-Verqleichssubstanz in Beispiel 13\nV13 = 5 Br substance in Example 13\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nDie Vergleichssubstanz in Beispiel 13 wurde gemäß Beispiel 3.13 der WO 2005/037800 hergestellt. Beispiel 3.13 hat eine stärkere in vitro Effektivität als Beispiel 3.12. \n\n V14 = 5-Br-Vergleichssubstanz in Beispiel 14\nThe comparison substance in Example 13 was prepared according to Example 3.13 of WO 2005/037800. Example 3.13 has a stronger in vitro effectiveness than Example 3.12.  V14 = 5 Br comparative substance in Example 14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nV14a) Herstellung des Zwischenproduktes\nV14a) Preparation of the intermediate product\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n845 mg (3,00 mmol) (2R,3R)-3-(5-Brom-2-chlor-pyrimidin-4-yloxy)-butan-2-ol (Herstellung nach: WO 2005 / 037800, S. 93) und 877 mg (3,00 mmol) (RS)-S-(4- AminophenyO-S-cyclopropyl-N-^rifluoracetyOsulfoximid in 13,1 ml Acetonitril wurden mit 1 ,5 ml einer 4N Lösung von Chlorwasserstoff in Dioxan versetzt und 5 Stunden bei 8O\n0\nC gerührt. Man versetzte den Ansatz mit weiteren 422 mg (1 ,50 mmol)\n845 mg (3.00 mmol) of (2R, 3R) -3- (5-bromo-2-chloro-pyrimidin-4-yloxy) -butan-2-ol (preparation according to: WO 2005/037800, p. 93) and 877 mg (3.00 mmol) of (RS) -S- (4-aminophenyO-S-cyclopropyl-N-trifluoroacetyl sulfoximide in 13.1 ml of acetonitrile were admixed with 1.5 ml of a 4N solution of hydrogen chloride in dioxane, and 5 Stirred for hours at 8O \n0\n C. The batch was treated with a further 422 mg (1, 50 mmol)\n\n\n\n\n\n\n \n(2R,3R)-3-(5-Brom-2-chlor-pyrimidin-4-yloxy)-butan-2-ol und rührte weiter bei 80\n0\nC. Nach 3 Stunden wurde erneut mit 0,75 ml der 4N Lösung von Chlorwasserstoff in Dioxan versetzt und weiter bei 80\n0\nC gerührt. Nach 33 Stunden wurde erneut mit 175 mg (0,60 mmol) (RS)-S-(4-Aminophenyl)-S-cyclopropyl-N-(trifluoracetyl)sulfoximid versetzt und abschließend 18 Stunden bei 80\n0\nC gerührt.\n(2R, 3R) was -3- (5-bromo-2-chloro-pyrimidin-4-yloxy) butan-2-ol and stirring was continued at 80 \n0\n C. After 3 hours, again with 0.75 ml of 4N solution of hydrogen chloride in dioxane and stirred at 80 \n0\n C further. After 33 hours, again with 175 mg (0.60 mmol) (RS) -S- (4-aminophenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide and stirred finally 18 hours at 80 \n0\n C.\n\n\n\n\n\n\n \nNach dem Abkühlen wurde der Ansatz eingeengt und der verbleibende Rückstand chromatographisch gereinigt (DCM / EtOH 9:1 ). Man erhielt 740 mg (1 ,38 mmol, Ausbeute: 46%) des Produktes.\nAfter cooling, the mixture was concentrated and the remaining residue was purified by chromatography (DCM / EtOH 9: 1). 740 mg (1.38 mmol, yield: 46%) of the product were obtained.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.31 (s, 1 H), 8.44 (s, 1 H), 8.01 (m, 2H), 7.84 (m, 2H), 5.19 (m, 1H), 4.88 (d, 1H), 3.81 (m, 1H), 3.31 (m, 1H), 1.40 (m, 1H), 1.29 (m, 4H), 1.08 (m, 5H). \n\n V14b) Herstellung des Endproduktes\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.31 (s, 1H), 8.44 (s, 1H), 8.01 (m, 2H), 7.84 (m, 2H), 5.19 (m, 1H), 4.88 (d, 1H), 3.81 (m, 1H), 3.31 (m, 1H), 1.40 (m, 1H), 1.29 (m, 4H), 1.08 (m, 5H).  V14b) Preparation of the end product\n\n\n\n\n\n\n \n735 mg (1 ,37 mmol) des Zwischenproduktes in 29 ml Methanol wurden mit 950 mg (6,84 mmol) Kaliumcarbonat versetzt und 1 ,5 Stunden bei Raumtemperatur gerührt. Man verdünnte mit gesättigter Natriumchlorid-Lösung und extrahierte mit Essigester (3x). Die vereinten organischen Phasen wurden getrocknet (Na\n2\nSO\n4\n), filtriert und eingeengt. Man erhielt 607 mg (1 ,37 mmol) des Rohproduktes.\n735 mg (1.37 mmol) of the intermediate in 29 ml of methanol were mixed with 950 mg (6.84 mmol) of potassium carbonate and stirred for 1.5 hours at room temperature. It was diluted with saturated sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were dried (Na \n2\n SO \n4\n ), filtered and concentrated. This gave 607 mg (1, 37 mmol) of the crude product.\n\n\n\n\n\n\n \n \n1\nH-NMR (400 MHz, DMSO): δ = 10.08 (s, 1 H), 8.40 (s, 1 H), 7.86 (m, 2H), 7.75 (m, 2H), 5.19 (m, 1 H), 4.87 (d, 1 H), 3.97 (s, 1 H), 3.82 (m, 1 H), 2.56 (m, 1 H), 1.25 (d, 3H), 1.09 (d, 3H), 1.05 (m, 1 H), 0.86 (m, 3H).\n \n1\n H-NMR (400 MHz, DMSO): δ = 10.08 (s, 1H), 8.40 (s, 1H), 7.86 (m, 2H), 7.75 (m, 2H), 5.19 (m, 1H) , 4.87 (d, 1H), 3.97 (s, 1H), 3.82 (m, 1H), 2.56 (m, 1H), 1.25 (d, 3H), 1.09 (d, 3H), 1.05 (m , 1H), 0.86 (m, 3H).\n\n\n\n\n\n\n \nDas Diastereomerengemisch wurde mittels präparativer HPLC in die reinen Stereoisomere aufgetrennt:\nThe diastereomer mixture was separated by preparative HPLC into the pure stereoisomers:\n\n\n\n\n\n\n \nSäule: Chiralpak IC 5μ 250x20 mm\nColumn: Chiralpak IC 5μ 250x20 mm\n\n\n\n\n\n\n \nEluenten: Hexan / Ethanol 7:3\nEluent: hexane / ethanol 7: 3\n\n\n\n\n\n\n \nFluß: 20,0 mL/min\nFlow: 20.0 mL / min\n\n\n\n\n\n\n \nDetektor: UV 280 nm Temperatur: Raumtemperatur\nDetector: UV 280 nm Temperature: room temperature\n\n\n\n\n\n\n \nRetentionszeit: 9.6-11.2 min; Stereoisomer 1 11.3-14.9 min; Stereoisomer 2\nRetention time: 9.6-11.2 min; Stereoisomer 1 11.3-14.9 min; Stereoisomer 2\n\n\n\n\n\n\n \nStereoisomer 2 zeigte die stärkere in-vitro Effektivität als Stereoisomer 1 und wurde daher als Vergleichssubstanz in Beispiel 14 verwendet.\nStereoisomer 2 showed the greater in vitro effectiveness than stereoisomer 1 and was therefore used as reference in Example 14.\n\n\n\n\n\n\n \nBeispiel 10\nExample 10\n\n\n\n\n\n\n \n10.1 Assay 1 : CDK1/CycB Kinase Assay\n10.1 Assay 1: CDK1 / CycB Kinase Assay\n\n\n\n\n\n\n \nRekombinante CDK1- und CycB-GST-Fusionsproteine, gereinigt aus Bakulovirus- infizierten Insektenzellen (Sf9), wurden von ProQinase GmbH, Freiburg, gekauft. Das als Kinase-Substrat verwendet Histon MIS ist über die Fa. Sigma käuflich zu erwerben. CDK1/CycB (200 ng/Messpunkt) wurde für 10 min bei 22°C in Anwesenheit verschiedener Konzentrationen an Testsubstanzen (0 μM, sowie innerhalb des Bereiches 0,01 - 100 μM) in Assaypuffer [50 mM Tris/HCI pH8,0, 10 mM MgCI\n2\n, 0,1 mM Na ortho-Vanadat, 1 ,0 mM Dithiothreitol, 0,5 μM Adenosintrisphosphat (ATP), 10 μg/Messpunkt Histon HIS, 0,2 μCi/Messpunkt \n33\nP-gamma ATP, 0,05% NP40, 1 ,25% \n\n Dimethylsulfoxid] inkubiert. Die Reaktion wurde durch Zugabe von EDTA-Lösung (250 mM, pH8,0, 15 μl/Messpunkt) gestoppt.\nRecombinant CDK1 and CycB GST fusion proteins purified from baculovirus-infected insect cells (Sf9) were purchased from ProQinase GmbH, Freiburg. The histone MIS used as kinase substrate can be purchased through Sigma. CDK1 / CycB (200 ng / measuring point) was incubated for 10 min at 22 ° C. in the presence of various concentrations of test substances (0 μM, as well as within the range 0.01-100 μM) in assay buffer [50 mM Tris / HCl pH8.0, 10 mM MgCl \n2\n , 0.1 mM Na ortho-vanadate, 1.0 mM dithiothreitol, 0.5 μM adenosine trisphosphate (ATP), 10 μg / measuring point histone HIS, 0.2 μCi / measuring point \n33\n P-gamma ATP, 0, 05% NP40, 1, 25%  Dimethyl sulfoxide] incubated. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 μl / measuring point).\n\n\n\n\n\n\n \nVon jedem Reaktionsansatz wurden 15 μl auf P30 Filterstreifen (Fa. Wallac) aufgetragen, und nicht-eingebautes \n33\nP-ATP wurde durch dreimaliges Waschen der Filterstreifen für je 10 min in 0,5%iger Phosphorsäure entfernt. Nach dem Trocknen der Filterstreifen für 1 Stunde bei 70\n0\nC wurden die Filterstreifen mit Szintillator- Streifen (MeltiLex™ A, Fa. Wallac) bedeckt und für 1 Stunde bei 90\n0\nC eingebrannt. Die Menge an eingebautem \n33\nP (Substratphosphorylierung) wurde durch Szintillationsmessung in einem Gamma-Strahlungsmessgerät (Wallac) bestimmt. Die Messdaten wurden normalisiert auf 0% Inhibition (Enzymreaktion ohne Inhibitor) und 100% Inhibition (alle Assaykomponenten außer Enzym). Die Bestimmung der IC\n50\n Werte erfolgte mittels eines 4-Parameter Fits unter Benutzung firmeneigener Software.\nFrom each reaction, 15 μl was applied to P30 filter strips (Wallac) and unincorporated \n33\n P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 \n0\n C., the filter strips were baked (MeltiLex ™ A, Fa. Wallac) and for 1 hour at 90 \n0\n C with scintillator strips. The amount of incorporated \n33\n P (substrate phosphorylation) was determined by scintillation measurement in a gamma radiation meter (Wallac). The data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100% inhibition (all assay components except enzyme). The IC \n50\n values were determined by means of a 4-parameter fit using proprietary software.\n\n\n\n\n\n\n \n10.2 Assay 2: CDK2/CycE Kinase Assay\n10.2 Assay 2: CDK2 / CycE Kinase Assay\n\n\n\n\n\n\n \nRekombinante CDK2- und CycE-GST-Fusionsproteine, gereinigt aus Bakulovirus- infizierten Insektenzellen (Sf9), wurden von ProQinase GmbH, Freiburg, gekauft. Histon INS, das als Kinase-Substrat verwendet wurde, wurde bei der Fa. Sigma gekauft.\nRecombinant CDK2 and CycE GST fusion proteins purified from baculovirus-infected insect cells (Sf9) were purchased from ProQinase GmbH, Freiburg. Histone INS, which was used as a kinase substrate, was purchased from Sigma.\n\n\n\n\n\n\n \nCDK2/CycE (50 ng/Messpunkt) wurde für 10 min bei 22°C in Anwesenheit verschiedener Konzentrationen an Testsubstanzen (0 μM, sowie innerhalb des Bereiches 0,01 - 100 μM) in Assaypuffer [50 mM Tris/HCI pH8,0, 10 mM MgCI\n2\n, 0,1 mM Na ortho-Vanadat, 1 ,0 mM Dithiothreitol, 0,5 μM Adenosintrisphosphat (ATP), 10 μg/Messpunkt Histon IHS, 0,2 μCi/Messpunkt \n33\nP-gamma ATP, 0,05% NP40, 1 ,25% Dimethylsulfoxid] inkubiert. Die Reaktion wurde durch Zugabe von EDTA-Lösung (250 mM, pH8,0, 15 μl/Messpunkt) gestoppt.\nCDK2 / CycE (50 ng / measuring point) was incubated for 10 min at 22 ° C. in the presence of various concentrations of test substances (0 μM, as well as within the range 0.01-100 μM) in assay buffer [50 mM Tris / HCl pH8.0, 10 mM MgCl \n2\n , 0.1 mM Na ortho-vanadate, 1.0 mM dithiothreitol, 0.5 μM adenosine trisphosphate (ATP), 10 μg / measurement point histone IHS, 0.2 μCi / measurement point \n33\n P-gamma ATP, 0, 05% NP40, 1.25% dimethylsulfoxide]. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 μl / measuring point).\n\n\n\n\n\n\n \nVon jedem Reaktionsansatz wurden 15 μl auf P30 Filterstreifen (Fa. Wallac) aufgetragen, und nicht-eingebautes \n33\nP-ATP wurde durch dreimaliges Waschen der Filterstreifen für je 10 min in 0,5%iger Phosphorsäure entfernt. Nach dem Trocknen der Filterstreifen für 1 Stunde bei 70\n0\nC wurden die Filterstreifen mit Szintillator- Streifen (MeltiLex™ A, Fa. Wallac) bedeckt und für 1 Stunde bei 90\n0\nC eingebrannt. Die Menge an eingebautem \n33\nP (Substratphosphorylierung) wurde durch Szintillationsmessung in einem Gamma-Strahlungsmessgerät (Wallac) bestimmt. Die \n\n Messdaten wurden normalisiert auf 0% Inhibition (Enzymreaktion ohne Inhibitor) und 100% Inhibition (alle Assaykomponenten außer Enzym). Die Bestimmung der IC\n50\n Werte erfolgte mittels eines 4-Parameter Fits unter Benutzung firmeneigener Software.\nFrom each reaction, 15 μl was applied to P30 filter strips (Wallac) and unincorporated \n33\n P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 \n0\n C., the filter strips were baked (MeltiLex ™ A, Fa. Wallac) and for 1 hour at 90 \n0\n C with scintillator strips. The amount of incorporated \n33\n P (substrate phosphorylation) was determined by scintillation measurement in a gamma radiation meter (Wallac). The  Measurement data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100% inhibition (all assay components except enzyme). The IC \n50\n values were determined by means of a 4-parameter fit using proprietary software.\n\n\n\n\n\n\n \n10.3 Assay 3: VEGF Rezeptor-2 Kinase Assay\n10.3 Assay 3: VEGF receptor-2 kinase assay\n\n\n\n\n\n\n \nRekombinante VEGF Rezeptortyrosinkinase-2 wurde als GST-Fusionsprotein aus Bakulovirus-infizierten Insektenzellen (Sf9) gereinigt. Poly-(Glu4Tyr), das als Kinase- Substrat verwendet wurde, wurde bei der Fa. Sigma gekauft.\nRecombinant VEGF receptor tyrosine kinase-2 was purified as a GST fusion protein from baculovirus-infected insect cells (Sf9). Poly (Glu4Tyr), which was used as a kinase substrate, was purchased from Sigma.\n\n\n\n\n\n\n \nVEGF Rezeptortyrosinkinase (90 ng/Messpunkt) wurde für 10 min bei 22°C in Anwesenheit verschiedener Konzentrationen an Testsubstanzen (0 μM, sowie innerhalb des Bereiches 0,001 - 30 μM) in 30 μl Assaypuffer [40 mM Tris/HCI pH5,5, 10 mM MgCI\n2\n, 1 mM MnCI\n2\n, 3 μM Na ortho-Vanadat, 1 ,0 mM Dithiothreitol, 8 μM Adenosintrisphosphat (ATP), 0,96 μg/Messpunkt poly-(GIU\n4\nTyr), 0,2 μCi/Messpunkt \n33\nP-gamma ATP, 1.4% Dimethylsulfoxid] inkubiert. Die Reaktion wurde durch Zugabe von EDTA-Lösung (250 mM, pH8,0, 15 μl/Messpunkt) gestoppt. Von jedem Reaktionsansatz wurden 15 μl auf P30 Filterstreifen (Fa. Wallac) aufgetragen, und nicht-eingebautes \n33\nP-ATP wurde durch dreimaliges Waschen der Filterstreifen für je 10 min in 0,5%iger Phosphorsäure entfernt. Nach dem Trocknen der Filterstreifen für 1 Stunde bei 70\n0\nC wurden die Filterstreifen mit Szintillator- Streifen (MeltiLexTM A, Fa. Wallac) bedeckt und für 1 Stunde bei 90\n0\nC eingebrannt. Die Menge an eingebautem \n33\nP (Substratphosphorylierung) wurde durch Szintillationsmessung in einem gamma-Strahlungsmessgerät (Wallac) bestimmt. Die Messdaten wurden normalisiert auf 0% Inhibition (Enzymreaktion ohne Inhibitor) und 100% Inhibition (alle Assaykomponenten außer Enzym). Die Bestimmung der IC\n5O\n Werte erfolgte mittels eines 4-Parameter Fits unter Benutzung firmeneigener Software. \n\n 10.4 Assay 4: Proliferationsassay\nVEGF receptor tyrosine kinase (90 ng / measuring point) was incubated for 10 min at 22 ° C. in the presence of various concentrations of test substances (0 μM and within the range 0.001-30 μM) in 30 μl assay buffer [40 mM Tris / HCl pH 5.5, 10 mM MgCl \n2\n , 1 mM MnCl \n2\n , 3 μM Na ortho-vanadate, 1, 0 mM dithiothreitol, 8 μM adenosine trisphosphate (ATP), 0.96 μg / assay poly (GIU \n4\n Tyr), 0.2 μCi / assay \n33\n P-gamma ATP, 1.4% dimethylsulfoxide]. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 μl / measuring point). From each reaction, 15 μl was applied to P30 filter strips (Wallac) and unincorporated \n33\n P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 \n0\n C., the filter strips were (MeltiLexTM A, Fa. Wallac) and for 1 hour at 90 \n0\n C baked with scintillator strips. The amount of incorporated \n33\n P (substrate phosphorylation) was determined by scintillation measurement in a gamma radiation meter (Wallac). The data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100% inhibition (all assay components except enzyme). The determination of the IC \n50\n values was carried out by means of a 4-parameter \nfit\n using proprietary software.  10.4 Assay 4: proliferation assay\n\n\n\n\n\n\n \nKultivierte humane HeLa-MaTu Cervix-Karzinomazellen (bezogen von EPO-GmbH, Berlin) wurden in einer Dichte von 3000 Zellen/Messpunkt in einer 96-Loch Multititerplatte in 200 μl Wachstumsmedium (DMEM/HAMS F12, 2 mM L-Glutamin, 10% Fötales Kälberserum) ausplattiert. Nach 24 Stunden wurden die Zellen einer Platte (Nullpunkt-Platte) mit Kristallviolett gefärbt (s.u.), während das Medium der anderen Platten durch frisches Kulturmedium (200 μl), dem die Testsubstanzen in verschiedenen Konzentrationen (0 μM, sowie im Bereich 0,01 - 30 μM; die finale Konzentration des Lösungsmittels Dimethylsulfoxid betrug 0,5%) zugesetzt waren, ersetzt. Die Zellen wurden für 4 Tage in Anwesenheit der Testsubstanzen inkubiert. Die Zellproliferation wurde durch Färbung der Zellen mit Kristallviolett bestimmt: Die Zellen wurden durch Zugabe von 20 μl/Messpunkt einer 11 %igen Glutaraldehyd- Lösung 15 min bei Raumtemperatur fixiert. Nach dreimaligem Waschen der fixierten Zellen mit Wasser wurden die Platten bei Raumtemperatur getrocknet. Die Zellen wurden durch Zugabe von 100 μl/Messpunkt einer 0,1 %igen Kristallviolett-Lösung (pH durch Zugabe von Essigsäure auf pH3 eingestellt) gefärbt. Nach dreimaligem Waschen der gefärbten Zellen mit Wasser wurden die Platten bei Raumtemperatur getrocknet. Der Farbstoff wurde durch Zugabe von 100 μl/Messpunkt einer 10%igen Essigsäure-Lösung gelöst. Die Extinktion wurde photometrisch bei einer Wellenlänge von 595 nm bestimmt. Die prozentuale Änderung des Zellwachstums wurde durch Normalisierung der Messwerte auf die Extinktionwerte der Nullpunktplatte (=0%) und die Extinktion der unbehandelten (0 μM) Zellen (=100%) berechnet. Die Messdaten wurden normalisiert auf 0% Inhibition (Zellproliferation ohne Inhibitor) und 100% Inhibition (Nullpunktplatte). Die Bestimmung der IC\n50\n Werte erfolgte mittels eines 4- Parameter Fits unter Benutzung firmeneigener Software. \n\n 10.5 Ergebnisse aus den Enzym- und Proliferationsassay\nCultured human HeLa-MaTu cervical carcinoma cells (obtained from EPO GmbH, Berlin) were incubated at a density of 3000 cells / measuring point in a 96-well multititer plate in 200 μl growth medium (DMEM / HAMS F12, 2 mM L-glutamine, 10%). Fetal calf serum). After 24 hours, the cells of one plate (zero point plate) were stained with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 μl) containing the test substances at various concentrations (0 μM and in the range 0.01 - 30 μM, the final concentration of the solvent dimethylsulfoxide was 0.5%) were added replaced. The cells were incubated for 4 days in the presence of the test substances. Cell proliferation was determined by staining the cells with crystal violet. The cells were fixed by adding 20 μl / measuring point of an 11% glutaraldehyde solution for 15 minutes at room temperature. After washing the fixed cells three times with water, the plates were dried at room temperature. The cells were stained by adding 100 μl / measuring point of a 0.1% crystal violet solution (pH adjusted to pH3 by addition of acetic acid). After washing the stained cells three times with water, the plates were dried at room temperature. The dye was dissolved by adding 100 μl / measuring point of a 10% acetic acid solution. The extinction was determined photometrically at a wavelength of 595 nm. The percentage change in cell growth was calculated by normalizing the measurements to the absorbance values of the zero plate (= 0%) and the absorbance of the untreated (0 μM) cells (= 100%). The measurement data were normalized to 0% inhibition (cell proliferation without inhibitor) and 100% inhibition (zero plate). The IC \n50\n values were determined by means of a 4-parameter fit using proprietary software.  10.5 Results from the enzyme and proliferation assay\n\n\n\n\n\n\n \nTab.1 \n\n\n\nTable 1 \n \n\n\n\n\n\n\n \nDie Ergebnisse aus den Enzym- und Proliferationsassays zeigen keine systematische Überlegenheit der erfindungsgemäßen Verbindungen gegenüber den Verbindungen des Standes der Technik.\nThe results from the enzyme and proliferation assays show no systematic superiority of the compounds of the invention over the compounds of the prior art.\n\n\n\n\n\n\n \nVergleich in-vivo\nComparison in vivo\n\n\n\n\n\n\n \nDie in-vivo Effektivität von Beispiel 5-SI-2 wurde in Beispiel 11 mit V11 vergleichend untersucht.\nThe in vivo effectiveness of Example 5-SI-2 was compared in Example 11 with V11.\n\n\n\n\n\n\n \nDie in-vivo Effektivität von Beispiel 6-SI-2 wurde in Beispiel 12 mit Beispiel 1.52 aus WO 2005/037800 (= Vergleichsubstanz V12) vergleichend untersucht. Die in-vivo Effektivität von Beispiel 2-SI-2 wurde in Beispiel 13 mit Beispiel 3.13 aus WO 2005/037800 (= Vergleichsubstanz V13) vergleichend untersucht. Die in-vivo Effektivität von Beispiel 1-SI-2 wurde in Beispiel 14 mit V14 vergleichend untersucht. \n\n Beispiel 11\nThe in-vivo effectiveness of example 6-SI-2 was investigated comparatively in example 12 with example 1.52 from WO 2005/037800 (= reference substance V12). The in-vivo effectiveness of example 2-SI-2 was investigated comparatively in example 13 with example 3.13 from WO 2005/037800 (= reference substance V13). The in vivo effectiveness of Example 1-SI-2 was compared in Example 14 with V14.  Example 11\n\n\n\n\n\n\n \nHeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI Nacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 150 mm\n2\n erreichten.\nHeLa-MaTu (EPO GmbH, Berlin) human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 150 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet:\nThe following experimental groups were used:\n\n\n\n\n\n\n \nGruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (40% PEG400/60% Wasser) Gruppe 2: Stereoisomer 2 hergestellt gemäß Beispiel 5 (= Beispiel 5-SI-2) 5 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12)\nGroup 1: control, treatment with solubilizer (40% PEG400 / 60% water) group 2: stereoisomer 2 prepared according to example 5 (= example 5-SI-2) 5 mg / kg, orally, twice daily on day 4, 5, 11, 12)\n\n\n\n\n\n\n \nDie Studie war zur Bestimmung des initialen Ansprechens eines humanen\nThe study was designed to determine the initial response of a human\n\n\n\n\n\n\n \nCervixkarzinom-Xenograftmodells auf die Therapien mit Beispiel 5-SI-2 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa-MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. Beispiel 5-SI-2 wurde in dem Lösungsvermittler 40% Polyethylenglykol (PEG) 400 / 60% Wasser zu einer finalen Konzentration von 0.5 mg/ml vollständig gelöst. Die Behandlung der etablierten Tumore wurde an Tag 4 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 17 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 150 mm\n2\n überschritten hatten. Die Ergebnisse der Studien (Fig. 1) zeigen, dass Beispiel 5-SI-2 in der gewählten Dosierung von 5 mg/kg oral in einem zyklischen Behandlungsschema (an 2 aufeinanderfolgenden Tagen 2x tägliche Behandlung gefolgt von 5 behandlungsfreien Tagen) das Tumorwachstum stark gehemmt (Gruppe 3, Reduktion des Tumorgewichtes am Ende der Studie auf 7% der Kontrollgruppe, p<0.05). \n\n 5-Br-Verqleichssubstanz (= V11 )\nCervical carcinoma xenograft model for the therapies with Example 5-SI-2. The growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. Example 5-SI-2 was completely dissolved in the solubilizer 40% polyethylene glycol (PEG) 400/60% water to a final concentration of 0.5 mg / ml. The treatment of the established tumors was started on day 4 after inoculation of the tumors. The study was terminated on day 17 after the tumor size of the animals of group 1 (control) exceeded the size of about 150 mm \n2\n . The results of the studies (Figure 1) show that Example 5-SI-2 at the selected dosage of 5 mg / kg orally in a cyclic regimen (on 2 consecutive days 2x daily treatment followed by 5 treatment-free days) strongly inhibited tumor growth (Group 3, reduction of tumor weight at the end of the study to 7% of the control group, p <0.05).  5 Br equivalent substance (= V11)\n\n\n\n\n\n\n \nHeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI Nacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 150 mm\n2\n erreichten.\nHeLa-MaTu (EPO GmbH, Berlin) human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 150 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet:\nThe following experimental groups were used:\n\n\n\n\n\n\n \nGruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (30% HPßCD/70% Wasser)\nGroup 1: Control, treatment with solubilizer (30% HPSSCD / 70% water)\n\n\n\n\n\n\n \nGruppe 2: Verbindung gemäß WO 2005/037800 hergestellt nach oben offenbarter\nGroup 2: compound according to WO 2005/037800 prepared as disclosed above\n\n\n\n\n\n\n \nHerstellung V11 (8 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12)\nPreparation V11 (8 mg / kg, oral, 2x daily on day 4, 5, 11, 12)\n\n\n\n\n\n\n \nDie Studie war zur Bestimmung des initialen Ansprechens eines humanen\nThe study was designed to determine the initial response of a human\n\n\n\n\n\n\n \nCervixkarzinom-Xenograftmodells auf die Therapien mit der 5-Br-Vergleichssubstanz V11 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa- MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. V11 wurde in dem Lösungsvermittler 30% ß-Hydroxypropyl-Cyclodextrin (HPßCD) / 70% Wasser zu einer finalen Konzentration von 0.8 mg/ml vollständig gelöst. Die Behandlung der etablierten Tumore wurde an Tag 4 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 17 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 150 mm\n2\n überschritten hatten. Die Ergebnisse der Studien (Fig. 2) zeigen, dass V11 in der gewählten Dosierung von 8 mg/kg oral 2x täglich an 2 aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen das Tumorwachstum im HeLa-MaTu-Xenograftmodell hemmt (Gruppe 2, Reduktion des Tumorgewichtes am Ende der Studie auf 39% der Kontrollgruppe, p<0.05).\nCervical carcinoma xenograft model was designed for the therapies with the 5-Br comparison substance V11. The growth-inhibiting effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. V11 was completely dissolved in the solubilizer 30% β-hydroxypropyl cyclodextrin (HPβCD) / 70% water to a final concentration of 0.8 mg / ml. The treatment of the established tumors was started on day 4 after inoculation of the tumors. The study was terminated on day 17 after the tumor size of the animals of group 1 (control) exceeded the size of about 150 mm \n2\n . The results of the studies (Figure 2) show that V11 inhibits tumor growth in the HeLa-MaTu xenograft model at the selected dose of 8 mg / kg orally 2 times daily for 2 consecutive days followed by 5 treatment-free days (Group 2, reduction of tumor weight at the end of the study on 39% of the control group, p <0.05).\n\n\n\n\n\n\n \nSchlussfolgerung\nconclusion\n\n\n\n\n\n\n \nDas Stereoisomer 2 des Beispieles 5 (Beispiel 5-SI-2 (5-CF\n3\n)) erreicht in den zyklischen Behandlungsschema bestehend aus zwei täglichen oralen Applikationen mit einer Dosis von 5 mg/kg an zwei aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen eine komplette Tumorwachstumshemmung im HeLa-MaTu Xenograftmodell (Behandlungs-/Kontroll-Verhaltnis T/C=0.07). Die 5-Br- \n\n Vergleichssubstanz (= V11 ) erreicht in dem entsprechenden verträglichen, zyklischen Behandlungsschema bei einer Dosis von 8 mg/kg lediglich eine Tumorwachstumsverzögerung im HeLa-MaTu Xenograftmodell (Behandlungs- /Kontroll-Verhaltnis T/C=0.39). Überraschenderweise zeigt das Beispiel 5-SI-2 (5- CF\n3\n) im Vergleich zu V11 (5-Br) eine höhere Potenz (5 mg/kg Dosis für das Beispiel 5-SI-2 im Vergleich zu 8 mg/kg für V11 ) und eine deutlich bessere antitumorale Effektivität (komplette Tumorwachstumshemmung mit einem T/C=0.07 für das Beispiel 5-SI-2 im Vergleich zu Tumorwachstumsverlangsamung mit einem T/C=0.39 für V11 ).\nThe stereoisomer 2 of Example 5 (Example 5-SI-2 (5-CF \n3\n )) achieves a complete cycle in the cyclic regimen consisting of two daily oral applications at a dose of 5 mg / kg on two consecutive days followed by 5 treatment-free days Tumor growth inhibition in the HeLa-MaTu xenograft model (treatment / control ratio T / C = 0.07). The 5-br  Comparative substance (= V11) achieved in the corresponding compatible, cyclic treatment regimen at a dose of 8 mg / kg only a tumor growth delay in HeLa-MaTu xenograft model (treatment / control ratio T / C = 0.39). Surprisingly, Example 5-SI-2 (5-CF \n3\n ) shows a higher potency (5 mg / kg dose for Example 5-SI-2 compared to 8 mg / kg for V11 compared to V11 (5-Br) ) and a significantly better antitumoral efficacy (complete tumor growth inhibition with a T / C = 0.07 for the example 5-SI-2 compared to tumor growth retardation with a T / C = 0.39 for V11).\n\n\n\n\n\n\n \nBeispiel 12\nExample 12\n\n\n\n\n\n\n \nHeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI Nacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 150 mm\n2\n erreichten.\nHeLa-MaTu (EPO GmbH, Berlin) human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 150 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet:\nThe following experimental groups were used:\n\n\n\n\n\n\n \nGruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (40% PEG 400/60% Wasser)\nGroup 1: Control, treatment with solubilizer (40% PEG 400/60% water)\n\n\n\n\n\n\n \nGruppe 2: Stereoisomer 2 hergestellt gemäß Beispiel 6 (= Beispiel 6-SI-2) (3 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12, 17, 18)\nGroup 2: stereoisomer 2 prepared according to example 6 (= example 6-SI-2) (3 mg / kg, orally, twice daily on day 4, 5, 11, 12, 17, 18)\n\n\n\n\n\n\n \nGruppe 3: Stereoisomer 2 hergestellt gemäß Beispiel 6 (= Beispiel 6-SI-2) (4 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12, 17, 18)\nGroup 3: Stereoisomer 2 prepared according to Example 6 (= Example 6-SI-2) (4 mg / kg, orally, twice daily on day 4, 5, 11, 12, 17, 18)\n\n\n\n\n\n\n \nGruppe 4: Stereoisomer 2 hergestellt gemäß Beispiel 6 (= Beispiel 6-SI-2) (5 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12, 17, 18)\nGroup 4: stereoisomer 2 prepared according to example 6 (= example 6-SI-2) (5 mg / kg, orally, twice daily on day 4, 5, 11, 12, 17, 18)\n\n\n\n\n\n\n \nDie Studie war zur Bestimmung des initialen Ansprechens eines humanen Cervixkarzinom-Xenograftmodells auf die Therapien mit Beispiel 6-SI-2 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa-MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. Beispiel 6-SI-2 wurde in dem Lösungsvermittler 40% Polyethylenglykol 400 (PEG 400) / 60% Wasser zu einer finalen Konzentration von 0.3 mg/ml (Gruppe 2), 0.4 mg/ml \n\n (Gruppe 3), oder 0.5 mg/ml (Gruppe 4) vollständig gelöst. Die Behandlung der etablierten Tumore wurde an Tag 4 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 20 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 150 mm\n2\n überschritten hatten. Die Ergebnisse der Studien (Fig. 3) zeigen, dass das Beispiel 6-SI-2 in einem Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an 2 aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen das Tumorwachstum im HeLa-MaTu-Xenograftmodell Dosis-abhängig hemmt. In der höchsten Dosisgruppe (Gruppe 4) wird das Tumorwachstum fast vollständig gehemmt und eine Reduktion des Tumorgewichtes am Ende der Studie auf 8% der Kontrollgruppe erreicht (T/C=0.08, p<0.05).\nThe study was designed to determine the initial response of a human cervical carcinoma xenograft model to the 6-SI-2 therapies. The growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. Example 6-SI-2 was dissolved in the solubilizer 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.3 mg / ml (Group 2), 0.4 mg / ml  (Group 3), or 0.5 mg / ml (Group 4) completely dissolved. The treatment of the established tumors was started on day 4 after inoculation of the tumors. The study was terminated on day 20 after the tumor size of the animals of group 1 (control) exceeded the size of about 150 mm \n2\n . The results of the studies (Figure 3) show that Example 6-SI-2 inhibits tumor growth in the HeLa-MaTu xenograft model dose-dependently in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days. In the highest dose group (group 4) tumor growth is almost completely inhibited and a reduction of the tumor weight at the end of the study to 8% of the control group is achieved (T / C = 0.08, p <0.05).\n\n\n\n\n\n\n \n5-Br-Verqleichssubstanz (= V12) HeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI Nacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 150 mm\n2\n erreichten.\n5 Br Comparative Substance (= V12) HeLa-MaTu (EPO GmbH, Berlin) Human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 150 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet:\nThe following experimental groups were used:\n\n\n\n\n\n\n \nGruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (40% PEG 400/60% Wasser) Gruppe 2: Verbindung gemäß Beispiel 1.52 aus WO 2005/037800 (= V12) (7 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12, 17, 18, 23, 24)\nGroup 1: Control, treatment with solubilizer (40% PEG 400/60% water) Group 2: compound according to example 1.52 from WO 2005/037800 (= V12) (7 mg / kg, orally, twice daily on day 4, 5, 11, 12, 17, 18, 23, 24)\n\n\n\n\n\n\n \nGruppe 3: Verbindung gemäß Beispiel 1.52 aus WO 2005/037800 (= V12)\nGroup 3: compound according to example 1.52 from WO 2005/037800 (= V12)\n\n\n\n\n\n\n \n(8.5 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12, 17, 18, 23, 24) Gruppe 4: Verbindung gemäß Beispiel 1.52 aus WO 2005/037800 (= V12)\n(8.5 mg / kg, orally, twice daily on day 4, 5, 11, 12, 17, 18, 23, 24) Group 4: compound according to Example 1.52 from WO 2005/037800 (= V12)\n\n\n\n\n\n\n \n(10 mg/kg, oral, 2x täglich an Tag 4, 5, 11 , 12, 17, 18, 23, 24)\n(10 mg / kg, orally, 2x daily on day 4, 5, 11, 12, 17, 18, 23, 24)\n\n\n\n\n\n\n \nDie Studie war zur Bestimmung des initialen Ansprechens eines humanen Cervixkarzinom-Xenograftmodells auf die Therapien mit der 5-Br-Vergleichssubstanz V12 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa- MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. V12 wurde in dem Lösungsvermittler 40% Polyethylenglykol 400 (PEG 400) / 60% Wasser zu \n\n einer finalen Konzentration von 0.7 mg/ml (Gruppe 2), 0.85 mg/ml (Gruppe 3), oder 1.0 mg/ml (Gruppe 4) vollständig gelöst. Die Behandlung der etablierten Tumore wurde an Tag 4 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 28 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 150 mm\n2\n überschritten hatten.\nThe study was designed to determine the initial response of a human cervical carcinoma xenograft model to the 5-Br comparator V12 therapies. The growth-inhibiting effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. V12 in the solubilizer was added to 40% polyethylene glycol 400 (PEG 400) / 60% water  a final concentration of 0.7 mg / ml (Group 2), 0.85 mg / ml (Group 3), or 1.0 mg / ml (Group 4) completely dissolved. The treatment of the established tumors was started on day 4 after inoculation of the tumors. The study was terminated on day 28 after the tumor size of the animals of group 1 (control) exceeded the size of about 150 mm \n2\n .\n\n\n\n\n\n\n \nDie Ergebnisse der Studien (Fig. 4) zeigen, dass V12 in einem Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an 2 aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen das Tumorwachstum im HeLa-MaTu- Xenograftmodell Dosis-abhängig schwach hemmt. In der höchsten Dosisgruppe (Gruppe 4) wird das Tumorwachstum auf circa die Hälfte im Vergleich zur Kontrollgruppe gehemmt (T/C=0.51 ).\nThe results of the studies (Figure 4) show that V12, in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days, weakly inhibits tumor growth in the HeLa-MaTu xenograft model in a dose-dependent manner. In the highest dose group (group 4), tumor growth was inhibited by about half compared to the control group (T / C = 0.51).\n\n\n\n\n\n\n \nSchlussfolgerung:\nConclusion:\n\n\n\n\n\n\n \nDas Stereoisomer 2 des Beispieles 6 (Beispiel 6-SI-2 (5-CF\n3\n)) erreicht in den zyklischen Behandlungsschema bestehend aus zwei täglichen oralen Applikationen mit einer Dosis von 5 mg/kg an zwei aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen eine fast vollständige Tumorwachstumshemmung im HeLa-MaTu Xenograftmodell (Behandlungs-/Kontroll-Verhaltnis T/C=0.08). Die Verbindung gemäß Beispiel 1.52 aus WO 2005/037800 (= V12 (5-Br)) erreicht in dem entsprechenden verträglichen, zyklischen Behandlungsschema bei einer Dosis von 10 mg/kg lediglich eine Tumorwachstumsverzögerung im HeLa-MaTu Xenograftmodell (Behandlungs-/Kontroll-Verhaltnis T/C=0.51 ). Überraschenderweise zeigt das Beispiel 6-SI-2 (5-CF\n3\n) im Vergleich zu V12 (5-Br) eine höhere Potenz (5 mg/kg Dosis für das Beispiel 6-SI-2 im Vergleich zu 10 mg/kg für V12) und eine deutlich bessere antitumorale Effektivität (komplette Tumorwachstumshemmung mit einem T/C=0.08 für das Beispiel 6-SI-2 im Vergleich zu Tumorwachstumsverlangsamung mit einem T/C=0.51 für V12). \n\n Beispiel 13\nThe stereoisomer 2 of Example 6 (Example 6-SI-2 (5-CF \n3\n )) almost reaches the cyclic regimen consisting of two daily oral applications at a dose of 5 mg / kg on two consecutive days followed by 5 treatment-free days complete tumor growth inhibition in the HeLa-MaTu xenograft model (treatment / control ratio T / C = 0.08). The compound according to Example 1.52 from WO 2005/037800 (= V12 (5-Br)) achieved in the corresponding compatible, cyclic treatment regimen at a dose of 10 mg / kg only a tumor growth delay in HeLa-MaTu xenograft model (treatment / control ratio T / C = 0.51). Surprisingly, Example 6-SI-2 (5-CF \n3\n ) shows a higher potency (5 mg / kg dose for Example 6-SI-2 compared to 10 mg / kg for V12 compared to V12 (5-Br) ) and significantly better antitumoral efficacy (complete tumor growth inhibition with a T / C = 0.08 for Example 6-SI-2 compared to tumor growth retardation with a T / C = 0.51 for V12).  Example 13\n\n\n\n\n\n\n \nHeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI Nacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 160 mm\n2\n erreichten.\nHeLa-MaTu (EPO GmbH, Berlin) human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet:\nThe following experimental groups were used:\n\n\n\n\n\n\n \nGruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (40% PEG 400/60% Wasser) Gruppe 2: Stereoisomer 2 hergestellt gemäß Beispiel 2 (= Beispiel 2-SI-2)\nGroup 1: Control, treatment with solubilizer (40% PEG 400/60% water) Group 2: Stereoisomer 2 prepared according to Example 2 (= Example 2-SI-2)\n\n\n\n\n\n\n \n(1.5 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20) Gruppe 3: Stereoisomer 2 hergestellt gemäß Beispiel 2 (= Beispiel 2-SI-2) (2.0 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20)\n(1.5 mg / kg, oral, twice daily on day 5, 6, 12, 13, 19, 20) Group 3: stereoisomer 2 prepared according to Example 2 (= Example 2-SI-2) (2.0 mg / kg, oral, 2x daily on day 5, 6, 12, 13, 19, 20)\n\n\n\n\n\n\n \nGruppe 4: Stereoisomer 2 hergestellt gemäß Beispiel 2 (= Beispiel 2-SI-2)\nGroup 4: stereoisomer 2 prepared according to Example 2 (= Example 2-SI-2)\n\n\n\n\n\n\n \n(2.5 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20)\n(2.5 mg / kg, orally, 2x daily on days 5, 6, 12, 13, 19, 20)\n\n\n\n\n\n\n \nDie Studie war zur Bestimmung des initialen Ansprechens eines humanen Cervixkarzinom-Xenograftmodells auf die Therapien mit Beispiel 2-SI-2 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa-MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. Beispiel 2-SI-2 wurde in dem Lösungsvermittler 40% Polyethylenglykol 400 (PEG 400) / 60% Wasser zu einer finalen Konzentration von 0.15 mg/ml (Gruppe 2), 0.2 mg/ml (Gruppe 3), oder 0.25 mg/ml (Gruppe 4) vollständig gelöst. Die Behandlung der etablierten Tumore wurde an Tag 5 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 20 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 160 mm\n2\n überschritten hatten. Die Ergebnisse der Studien (Fig. 5) zeigen, dass das Beispiel 2-SI-2 in einem Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an 2 aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen das Tumorwachstum im HeLa-MaTu-Xenograftmodell Dosis-abhängig hemmt. In der höchsten Dosisgruppe (2.5 mg/kg, Gruppe 4) wird das Tumorwachstum fast vollständig gehemmt und eine Reduktion des Tumorgewichtes am Ende der Studie auf 18% der Kontrollgruppe erreicht (T/C=0.18, p<0.05). \n\n 5-Br-Vergleichssubstanz (=V13)\nThe study was designed to determine the initial response of a human cervical carcinoma xenograft model to the 2-SI-2 therapies. The growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. Example 2-SI-2 in the solubilizer was 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.15 mg / ml (Group 2), 0.2 mg / ml (Group 3), or 0.25 mg / ml (Group 4) completely solved. The treatment of the established tumors was started on day 5 after inoculation of the tumors. The study was terminated on day 20 after the tumor size of animals of group 1 (control) exceeded the size of about 160 mm \n2\n . The results of the studies (Figure 5) show that Example 2-SI-2 inhibits tumor growth in the HeLa-MaTu xenograft model dose-dependently in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days. In the highest dose group (2.5 mg / kg, group 4) tumor growth is almost completely inhibited and a reduction of the tumor weight at the end of the study to 18% of the control group was achieved (T / C = 0.18, p <0.05).  5 Br comparison substance (= V13)\n\n\n\n\n\n\n \nHeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI Nacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 160 mm\n2\n erreichten.\nHeLa-MaTu (EPO GmbH, Berlin) human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet:\nThe following experimental groups were used:\n\n\n\n\n\n\n \nGruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (40% PEG 400/60% Wasser) Gruppe 2: Verbindung gemäß Beispiel 3.13 aus WO 2005/037800 (= V13)\nGroup 1: Control, treatment with solubilizer (40% PEG 400/60% water) Group 2: compound according to Example 3.13 from WO 2005/037800 (= V13)\n\n\n\n\n\n\n \n(6 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20) Gruppe 3: Verbindung gemäß Beispiel 3.13 aus WO 2005/037800 (= V13) (8 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20)\n(6 mg / kg, orally, twice daily on day 5, 6, 12, 13, 19, 20) Group 3: Compound according to Example 3.13 from WO 2005/037800 (= V13) (8 mg / kg, orally, twice daily on days 5, 6, 12, 13, 19, 20)\n\n\n\n\n\n\n \nGruppe 4: Verbindung gemäß Beispiel 3.13 aus WO 2005/037800 (= V13)\nGroup 4: compound according to Example 3.13 from WO 2005/037800 (= V13)\n\n\n\n\n\n\n \n(10 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20)\n(10 mg / kg, orally, 2x daily on day 5, 6, 12, 13, 19, 20)\n\n\n\n\n\n\n \nDie Studie war zur Bestimmung des initialen Ansprechens eines humanen Cervixkarzinom-Xenograftmodells auf die Therapien mit der\nThe study was designed to determine the initial response of a human cervical carcinoma xenograft model to the therapies with the\n\n\n\n\n\n\n \n5-Br-Vergleichssubstanz V13 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa-MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. V13 wurde in dem Lösungsvermittler 40% Polyethylenglykol 400 (PEG 400) / 60% Wasser zu einer finalen Konzentration von 0.6 mg/ml (Gruppe 2), 0.8 mg/ml (Gruppe 3), oder 1.0 mg/ml (Gruppe 4) vollständig gelöst. Die\n5 Br comparison substance V13 designed. The growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. V13 was completely solubilized in the solubilizer 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.6 mg / ml (Group 2), 0.8 mg / ml (Group 3), or 1.0 mg / ml (Group 4) solved. The\n\n\n\n\n\n\n \nBehandlung der etablierten Tumore wurde an Tag 5 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 20 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 160 mm\n2\n überschritten hatten. Die Ergebnisse der Studien (Fig. 6) zeigen, dass V13 in einem Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an 2 aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen das Tumorwachstum im HeLa-MaTu- Xenograftmodell Dosis-abhängig hemmt. In der höchsten Dosisgruppe (10 mg/kg, Gruppe 4) wird das Tumorwachstum sehr stark gehemmt und eine Reduktion des Tumorgewichtes am Ende der Studie auf 23% der Kontrollgruppe erreicht (T/C=0.23, p<0.05). \n\n Schlussfolgerunq:\nTreatment of the established tumors was started on day 5 after inoculation of the tumors. The study was terminated on day 20 after the tumor size of animals of group 1 (control) exceeded the size of about 160 mm \n2\n . The results of the studies (Figure 6) show that V13 dose-dependently inhibited tumor growth in the HeLa-MaTu xenograft model in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days. In the highest dose group (10 mg / kg, group 4) tumor growth is very strongly inhibited and a reduction of the tumor weight at the end of the study to 23% of the control group was achieved (T / C = 0.23, p <0.05).  Schlussfolgerunq:\n\n\n\n\n\n\n \nDas Stereoisomer 2 des Beispieles 2 (Beispiel 2-SI-2 (5-CF\n3\n)) erreicht in den zyklischen Behandlungsschema bestehend aus zwei täglichen oralen Applikationen mit einer Dosis von 2.5 mg/kg an zwei aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen eine fast vollständige Tumorwachstumshemmung im HeLa-MaTu Xenograftmodell (Behandlungs-/Kontroll-Verhaltnis T/C=0.18). Die Verbindung gemäß Beispiel 3.13 aus WO 2005/037800 (= V13 (5-Br)) erreicht in dem entsprechenden verträglichen, zyklischen Behandlungsschema bei einer Dosis von 10 mg/kg eine etwas geringere Tumorwachstumsverzögerung im HeLa-MaTu Xenograftmodell (Behandlungs-/Kontroll-Verhaltnis T/C=0.23). Überraschenderweise zeigt das Beispiel 2-SI-2 (5-CF\n3\n) im Vergleich zu V13 (5-Br) eine deutlich höhere Potenz (2.5 mg/kg Dosis für das Beispiel 2-SI-2 im Vergleich zu 10 mg/kg für V13) und eine etwas bessere antitumorale Effektivität (Tumorwachstumshemmung mit einem T/C=0.18 für das Beispiel 2-SI-2 im Vergleich zu Tumorwachstumshemmung mit einem T/C=0.23 für V13).\nThe stereoisomer 2 of Example 2 (Example 2-SI-2 (5-CF \n3\n )) almost reaches in the cyclic treatment regimen consisting of two daily oral applications with a dose of 2.5 mg / kg on two consecutive days followed by 5 treatment-free days complete tumor growth inhibition in the HeLa-MaTu xenograft model (treatment / control ratio T / C = 0.18). The compound according to Example 3.13 from WO 2005/037800 (= V13 (5-Br)) achieves a slightly lower tumor growth delay in the HeLa-MaTu xenograft model in the corresponding, compatible, cyclic treatment regimen at a dose of 10 mg / kg (treatment / control Ratio T / C = 0.23). Surprisingly, the example 2-SI-2 (5-CF \n3\n ) compared to V13 (5-Br) shows a significantly higher potency (2.5 mg / kg dose for example 2-SI-2 compared to 10 mg / kg for V13) and a slightly better antitumoral efficacy (tumor growth inhibition with a T / C = 0.18 for the example 2-SI-2 compared to tumor growth inhibition with a T / C = 0.23 for V13).\n\n\n\n\n\n\n \nBeispiel 14\nExample 14\n\n\n\n\n\n\n \nHeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI\nHeLa-MaTu (EPO GmbH, Berlin) human cervical carcinoma cells cultured in cell culture were subcutaneously inserted into the flank of female NMRI\n\n\n\n\n\n\n \nNacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 160 mm\n2\n erreichten.\nNude mice implanted. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet:\nThe following experimental groups were used:\n\n\n\n\n\n\n \nGruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (40% PEG 400/60% Wasser) Gruppe 2: Stereoisomer 2 hergestellt gemäß Beispiel 1 (= Beispiel 1-SI-2)\nGroup 1: Control, treatment with solubilizer (40% PEG 400/60% water) Group 2: stereoisomer 2 prepared according to Example 1 (= Example 1-SI-2)\n\n\n\n\n\n\n \n(1.5 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20) Gruppe 3: Stereoisomer 2 hergestellt gemäß Beispiel 1 (= Beispiel 1-SI-2)\n(1.5 mg / kg, orally, twice daily on day 5, 6, 12, 13, 19, 20) Group 3: stereoisomer 2 prepared according to Example 1 (= Example 1-SI-2)\n\n\n\n\n\n\n \n(2.0 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20) Gruppe 4: Stereoisomer 2 hergestellt gemäß Beispiel 1 (= Beispiel 1-SI-2)\n(2.0 mg / kg, orally, twice daily on day 5, 6, 12, 13, 19, 20) Group 4: stereoisomer 2 prepared according to Example 1 (= Example 1-SI-2)\n\n\n\n\n\n\n \n(2.5 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20) \n\n Die Studie war zur Bestimmung des initialen Ansprechens eines humanen Cervixkarzinom-Xenograftmodells auf die Therapien mit Beispiel 1-SI-2 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa-MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. Beispiel 1-SI-2 wurde in dem Lösungsvermittler 40% Polyethylenglykol 400 (PEG 400) / 60% Wasser zu einer finalen Konzentration von 0.15 mg/ml (Gruppe 2), 0.2 mg/ml (Gruppe 3), oder 0.25 mg/ml (Gruppe 4) vollständig gelöst. Die Behandlung der etablierten Tumore wurde an Tag 5 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 20 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 160 mm\n2\n überschritten hatten. Die Ergebnisse der Studien (Fig. 7) zeigen, dass das Beispiel 1-SI-2 in einem Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an 2 aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen das Tumorwachstum im HeLa-MaTu-Xenograftmodell Dosis-abhängig hemmt. In der höchsten Dosisgruppe (2.5 mg/kg, Gruppe 4) wird das Tumorwachstum fast vollständig gehemmt und eine Reduktion des Tumorgewichtes am Ende der Studie auf 19% der Kontrollgruppe erreicht (T/C=0.19, p<0.05).\n(2.5 mg / kg, orally, 2x daily on days 5, 6, 12, 13, 19, 20)  The study was designed to determine the initial response of a human cervical carcinoma xenograft model to the therapies in Example 1-SI-2. The growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. Example 1-SI-2 in the solubilizer was 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.15 mg / ml (Group 2), 0.2 mg / ml (Group 3), or 0.25 mg / ml (Group 4) completely solved. The treatment of the established tumors was started on day 5 after inoculation of the tumors. The study was terminated on day 20 after the tumor size of animals of group 1 (control) exceeded the size of about 160 mm \n2\n . The results of the studies (Figure 7) show that Example 1-SI-2 inhibits tumor growth in the HeLa-MaTu xenograft model dose-dependently in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days. In the highest dose group (2.5 mg / kg, group 4) tumor growth is almost completely inhibited and a reduction in tumor weight at the end of the study to 19% of the control group was achieved (T / C = 0.19, p <0.05).\n\n\n\n\n\n\n \n5-Br- Vergleichssubstanz (= V14)\n5 Br comparison substance (= V14)\n\n\n\n\n\n\n \nHeLa-MaTu (EPO-GmbH, Berlin) humane Cervix-Karzinomzellen, die in Zellkultur gezüchtet wurden, wurden subkutan in die Flanke von weiblichen NMRI Nacktmäusen implantiert. Die Behandlung wurde begonnen sobald die Tumoren zu einer Größe von ca. 20 mm\n2\n herangewachsen waren. Die Studie wurde beendet sobald die Tumoren in einer der Gruppen eine Größe von ca. 160 mm\n2\n erreichten.\nHeLa-MaTu (EPO GmbH, Berlin) human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm \n2\n . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm \n2\n .\n\n\n\n\n\n\n \nFolgende Versuchsgruppen wurden verwendet: Gruppe 1 : Kontrolle, Behandlung mit Lösungsvermittler (40% PEG 400/60% Wasser) Gruppe 2: Verbindung gemäß WO 2005/037800 hergestellt nach oben offenbarter Herstellung V14 (6 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20) \n\n Gruppe 3: Verbindung gemäß WO 2005/037800 hergestellt nach oben offenbarter\nThe following experimental groups were used: Group 1: Control, treatment with solubilizer (40% PEG 400/60% water) Group 2: Compound according to WO 2005/037800 prepared as described above V14 (6 mg / kg, orally, twice a day 5, 6, 12, 13, 19, 20)  Group 3: compound according to WO 2005/037800 prepared as disclosed above\n\n\n\n\n\n\n \nHerstellung V14\nProduction V14\n\n\n\n\n\n\n \n(8 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20)\n(8 mg / kg, orally, 2x daily on days 5, 6, 12, 13, 19, 20)\n\n\n\n\n\n\n \nGruppe 4: Verbindung gemäß WO 2005/037800 hergestellt nach oben offenbarter Herstellung V14\nGroup 4: compound according to WO 2005/037800 prepared according to the above-disclosed preparation V14\n\n\n\n\n\n\n \n(10 mg/kg, oral, 2x täglich an Tag 5, 6, 12, 13, 19, 20)\n(10 mg / kg, orally, 2x daily on day 5, 6, 12, 13, 19, 20)\n\n\n\n\n\n\n \nDie Studie war zur Bestimmung des initialen Ansprechens eines humanen Cervixkarzinorn-Xenograftmodells auf die Therapien mit der 5-Br- Vergleichssubstanz V14 ausgelegt. Der wachstumshemmende Effekt der Verbindungen wurde im HeLa-MaTu Cervixtumor-Modell als Xenograft auf NMRI Nacktmäusen geprüft. V14 wurde in dem Lösungsvermittler 40% Polyethylenglykol 400 (PEG 400) / 60% Wasser zu einer finalen Konzentration von 0.6 mg/ml (Gruppe 2), 0.8 mg/ml (Gruppe 3), oder 1.0 mg/ml (Gruppe 4) vollständig gelöst. Die Behandlung der etablierten Tumore wurde an Tag 5 nach der Inokulation der Tumore begonnen. Die Studie wurde an Tag 20 beendet nachdem die Tumorgröße der Tiere der Gruppe 1 (Kontrolle) die Größe von ca. 160 mm\n2\n überschritten hatten. Die Ergebnisse der Studien (Fig. 8) zeigen, dass V14 in einem Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an 2 aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen das Tumorwachstum im HeLa-MaTu- Xenograftmodell Dosis-abhängig hemmt. In der höchsten Dosisgruppe (10 mg/kg, Gruppe 4) wird das Tumorwachstum schwach gehemmt und eine Reduktion des Tumorgewichtes am Ende der Studie auf 44% der Kontrollgruppe erreicht (T/C=0.44, statistische Signifikanz wurde nicht erreicht).\nThe study was designed to determine the initial response of a human cervical carcinoma xenograft model to the 5-Br comparator V14 therapies. The growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice. V14 was completed in the solubilizer 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.6 mg / ml (Group 2), 0.8 mg / ml (Group 3), or 1.0 mg / ml (Group 4) solved. The treatment of the established tumors was started on day 5 after inoculation of the tumors. The study was terminated on day 20 after the tumor size of animals of group 1 (control) exceeded the size of about 160 mm \n2\n . The results of the studies (Figure 8) show that V14 dose-dependently inhibited tumor growth in the HeLa-MaTu xenograft model in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days. In the highest dose group (10 mg / kg, group 4), tumor growth was slightly inhibited and a reduction in tumor weight at the end of the study to 44% of the control group was achieved (T / C = 0.44, statistical significance was not achieved).\n\n\n\n\n\n\n \nSchlussfolqerunq:\nSchlussfolqerunq:\n\n\n\n\n\n\n \nDas Stereoisomer 2 des Beispieles 1 (Beispiel 1-SI-2 (5-CF\n3\n)) erreicht in den zyklischen Behandlungsschema bestehend aus zwei täglichen oralen Applikationen mit einer Dosis von 2.5 mg/kg an zwei aufeinanderfolgenden Tagen gefolgt von 5 behandlungsfreien Tagen eine fast vollständige Tumorwachstumshemmung im\nThe stereoisomer 2 of Example 1 (Example 1-SI-2 (5-CF \n3\n )) almost reaches in the cyclic treatment regimen consisting of two daily oral applications with a dose of 2.5 mg / kg on two consecutive days followed by 5 treatment-free days complete tumor growth inhibition in\n\n\n\n\n\n\n \nHeLa-MaTu Xenograftmodell (Behandlungs-/Kontroll-Verhaltnis T/C=0.19). Die 5-Br- Verbindung gemäß WO 2005/037800 (= V14 (5-Br) ) erreicht in dem entsprechenden verträglichen, zyklischen Behandlungsschema bei einer Dosis von 10 mg/kg eine \n\n schwache Tumorwachstumshemmung im HeLa-MaTu Xenograftmodell (Behandlungs-/Kontroll-Verhaltnis T/C=0.44). Überraschenderweise zeigt das Beispiel 1-SI-2 (5-CF\n3\n) im Vergleich zu V14 (5-Br) eine deutlich höhere Potenz (2.5 mg/kg Dosis für das Beispiel 1-SI-2 im Vergleich zu 10 mg/kg für V14) und eine deutlich überlegene antitumorale Effektivität (Tumorwachstumshemmung mit einem T/C=0.19 für das Beispiel 1-SI-2 im Vergleich zu Tumorwachstumshemmung mit einem T/C=0.44 für V14). \n\n\nHeLa-MaTu xenograft model (treatment / control ratio T / C = 0.19). The 5-Br compound according to WO 2005/037800 (= V14 (5-Br)) achieves one in the corresponding, compatible, cyclic treatment regimen at a dose of 10 mg / kg  weak tumor growth inhibition in the HeLa-MaTu xenograft model (treatment / control ratio T / C = 0.44). Surprisingly, the example 1-SI-2 (5-CF \n3\n ) compared to V14 (5-Br) shows a significantly higher potency (2.5 mg / kg dose for Example 1-SI-2 compared to 10 mg / kg for V14) and a clearly superior antitumoral efficacy (tumor growth inhibition with a T / C = 0.19 for the example 1-SI-2 compared to tumor growth inhibition with a T / C = 0.44 for V14). \n\n\n\n\n\n\n \nBeschreibung der Figuren\nDescription of the figures\n\n\n\n\n\n\n \nFig. 1 zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit Beispiel 5-SI-2. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 4 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die\nFig. 1 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 5-SI-2. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. Treatment started on day 4 after the tumors had reached a size of about 20 mm \n2\n . The\n\n\n\n\n\n\n \nBehandlungen wurden in folgenden Dosierungen und Applikationsschemata durchgeführt:\nTreatments were performed in the following dosages and application regimens:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (40% PEG400 / 60% Wasser) Gruppe 2: Beispiel 5-SI-2, zyklisches Behandlungsschema,\nGroup 1: (control group) - solubilizer (40% PEG400 / 60% water) group 2: example 5-SI-2, cyclic treatment scheme,\n\n\n\n\n\n\n \n2x täglich oral an Tagen 4, 5, 11 , 12, Dosierung 5 mg/kg.\nTwice a day orally on days 4, 5, 11, 12, dosage 5 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore.\nA) Time course of growth of HeLa-MaTu xenograft tumors.\n\n\n\n\n\n\n \nB) Gewicht der HeLa-MaTu Tumore am Tag 17, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der Behandlungsgruppe zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C).\nB) Weight of HeLa-MaTu tumors on day 17, as well as the ratio of the average tumor weight of the treatment group to the average tumor weight of the control group (T / C).\n\n\n\n\n\n\n \nFig. 2 zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit V11. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 4 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die Behandlungen wurden in folgenden Dosierungen und Applikationsschemata durchgeführt:\nFig. 2 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V11. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. Treatment started on day 4 after the tumors had reached a size of about 20 mm \n2\n . The treatments were carried out in the following dosages and application schemes:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (30% HPßCD / 70% Wasser,\nGroup 1: (control group) - solubilizer (30% HPSSCD / 70% water,\n\n\n\n\n\n\n \n1x täglich oral an Tag 4-17); Gruppe 2: V11 , zyklisches Behandlungsschema,\nOnce a day orally on days 4-17); Group 2: V11, cyclic treatment scheme,\n\n\n\n\n\n\n \n2x täglich oral an Tagen 4, 5, 11 , 12, Dosierung 8 mg/kg.\nTwice a day orally on days 4, 5, 11, 12, dosage 8 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore.\nA) Time course of growth of HeLa-MaTu xenograft tumors.\n\n\n\n\n\n\n \nB) Gewicht der HeLa-MaTu Tumore am Tag 17, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der jeweiligen Behandlungsgruppen zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C). \n\n Fig. 3: zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit dem Beispiel 6-SI-2. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 4 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die Behandlungen wurden in folgenden Dosierungen und in einem zyklischen\nB) Weight of HeLa-MaTu tumors on day 17, as well as the ratio of the average tumor weight of the respective treatment groups to the average tumor weight of the control group (T / C).  Fig. 3: shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 6-SI-2. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. Treatment started on day 4 after the tumors had reached a size of about 20 mm \n2\n . The treatments were given in following dosages and in a cyclic\n\n\n\n\n\n\n \nBehandlungsschema bestehend aus zwei täglichen oralen Applikationen an Tagen 4, 5, 11 , 12, 17, und 18 durchgeführt:\nTreatment regimen consisting of two daily oral applications performed on days 4, 5, 11, 12, 17, and 18:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (40% PEG400 / 60% Wasser); Gruppe 2: Beispiel 6-SI-2, Dosierung 3 mg/kg;\nGroup 1: (control group) - solubilizer (40% PEG400 / 60% water); Group 2: Example 6-SI-2, dosage 3 mg / kg;\n\n\n\n\n\n\n \nGruppe 3: Beispiel 6-SI-2, Dosierung 4 mg/kg;\nGroup 3: Example 6-SI-2, dosage 4 mg / kg;\n\n\n\n\n\n\n \nGruppe 4: Beispiel 6-SI-2, Dosierung 5 mg/kg.\nGroup 4: Example 6-SI-2, dosage 5 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore. B) Gewicht der HeLa-MaTu Tumore am Tag 20, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der jeweiligen Behandlungsgruppen zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C).\nA) Time course of growth of HeLa-MaTu xenograft tumors. B) Weight of HeLa-MaTu tumors on day 20, as well as the ratio of the average tumor weight of the respective treatment groups to the average tumor weight of the control group (T / C).\n\n\n\n\n\n\n \nFig. 4: zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit V12. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 4 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die Behandlungen wurden in folgenden Dosierungen und in einem zyklischen Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an Tagen 4, 5, 11 , 12, 17, 18, 23 und 24 durchgeführt:\nFig. 4: shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V12. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. Treatment started on day 4 after the tumors had reached a size of about 20 mm \n2\n . The treatments were performed in the following dosages and in a cyclic regimen consisting of two daily oral applications on days 4, 5, 11, 12, 17, 18, 23 and 24:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (40% PEG400 / 60% Wasser);\nGroup 1: (control group) - solubilizer (40% PEG400 / 60% water);\n\n\n\n\n\n\n \nGruppe 2: V12, Dosierung 7 mg/kg;\nGroup 2: V12, dosage 7 mg / kg;\n\n\n\n\n\n\n \nGruppe 3: V12, Dosierung 8.5 mg/kg; Gruppe 4: V12, Dosierung 10 mg/kg.\nGroup 3: V12, dosage 8.5 mg / kg; Group 4: V12, dosage 10 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore.\nA) Time course of growth of HeLa-MaTu xenograft tumors.\n\n\n\n\n\n\n \nB) Gewicht der HeLa-MaTu Tumore am Tag 28, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der jeweiligen Behandlungsgruppen zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C). \n\n Fig. 5: zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit dem Beispiel 2-SI-2. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 5 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die Behandlungen wurden in folgenden Dosierungen und in einem zyklischen\nB) Weight of HeLa-MaTu tumors on day 28, as well as the ratio of the average tumor weight of the respective treatment groups to the average tumor weight of the control group (T / C).  Fig. 5: shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 2-SI-2. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm \n2\n . The treatments were given in following dosages and in a cyclic\n\n\n\n\n\n\n \nBehandlungsschema bestehend aus zwei täglichen oralen Applikationen an Tagen 5, 6, 12, 13, 19, und 20 durchgeführt:\nTreatment schedule consisting of two daily oral applications performed on days 5, 6, 12, 13, 19, and 20:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (40% PEG400 / 60% Wasser); Gruppe 2: Beispiel 2-SI-2, Dosierung 1.5 mg/kg; Gruppe 3: Beispiel 2-SI-2, Dosierung 2 mg/kg; Gruppe 4: Beispiel 2-SI-2, Dosierung 2.5 mg/kg.\nGroup 1: (control group) - solubilizer (40% PEG400 / 60% water); Group 2: Example 2-SI-2, dosage 1.5 mg / kg; Group 3: Example 2-SI-2, dosage 2 mg / kg; Group 4: Example 2-SI-2, dosage 2.5 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore. B) Gewicht der HeLa-MaTu Tumore am Tag 20, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der jeweiligen Behandlungsgruppen zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C).\nA) Time course of growth of HeLa-MaTu xenograft tumors. B) Weight of HeLa-MaTu tumors on day 20, as well as the ratio of the average tumor weight of the respective treatment groups to the average tumor weight of the control group (T / C).\n\n\n\n\n\n\n \nFig. 6: zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit V13. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 5 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die Behandlungen wurden in folgenden Dosierungen und in einem zyklischen Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an Tagen 5, 6, 12, 13, 19, und 20 durchgeführt:\nFig. 6: shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V13. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm \n2\n . The treatments were performed in the following dosages and in a cyclic regimen consisting of two daily oral applications on days 5, 6, 12, 13, 19, and 20:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (40% PEG400 / 60% Wasser); Gruppe 2: V13, Dosierung 6 mg/kg; Gruppe 3: V13, Dosierung 8 mg/kg; Gruppe 4: V13, Dosierung 10 mg/kg.\nGroup 1: (control group) - solubilizer (40% PEG400 / 60% water); Group 2: V13, dosage 6 mg / kg; Group 3: V13, dosage 8 mg / kg; Group 4: V13, dosage 10 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore.\nA) Time course of growth of HeLa-MaTu xenograft tumors.\n\n\n\n\n\n\n \nB) Gewicht der HeLa-MaTu Tumore am Tag 20, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der jeweiligen Behandlungsgruppen zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C). \n\n Fig. 7: zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit dem Beispiel 1-SI-2. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 5 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die Behandlungen wurden in folgenden Dosierungen und in einem zyklischen\nB) Weight of HeLa-MaTu tumors on day 20, as well as the ratio of the average tumor weight of the respective treatment groups to the average tumor weight of the control group (T / C).  Fig. 7: shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 1-SI-2. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm \n2\n . The treatments were given in following dosages and in a cyclic\n\n\n\n\n\n\n \nBehandlungsschema bestehend aus zwei täglichen oralen Applikationen an Tagen 5, 6, 12, 13, 19, und 20 durchgeführt:\nTreatment schedule consisting of two daily oral applications performed on days 5, 6, 12, 13, 19, and 20:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (40% PEG400 / 60% Wasser); Gruppe 2: Beispiel 1-SI-2, Dosierung 1.5 mg/kg; Gruppe 3: Beispiel 1-SI-2, Dosierung 2 mg/kg; Gruppe 4: Beispiel 1-SI-2, Dosierung 2.5 mg/kg.\nGroup 1: (control group) - solubilizer (40% PEG400 / 60% water); Group 2: Example 1-SI-2, dosage 1.5 mg / kg; Group 3: Example 1-SI-2, dosage 2 mg / kg; Group 4: Example 1-SI-2, dosage 2.5 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore. B) Gewicht der HeLa-MaTu Tumore am Tag 20, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der jeweiligen Behandlungsgruppen zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C).\nA) Time course of growth of HeLa-MaTu xenograft tumors. B) Weight of HeLa-MaTu tumors on day 20, as well as the ratio of the average tumor weight of the respective treatment groups to the average tumor weight of the control group (T / C).\n\n\n\n\n\n\n \nFig. 8: zeigt die Tumorwachstumshemmung im humanen HeLa-MaTu Cervixtumor- Xenograftmodell unter Behandlung mit V14. HeLa-MaTu Zellen wurden an Tag 0 subkutan in NMRI Nacktmäusen implantiert. Die Behandlung begann an Tag 5 nachdem die Tumoren eine Größe von ca. 20 mm\n2\n erreicht hatten. Die Behandlungen wurden in folgenden Dosierungen und in einem zyklischen Behandlungsschema bestehend aus zwei täglichen oralen Applikationen an Tagen 5, 6, 12, 13, 19, und 20 durchgeführt:\nFIG. 8: shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V14. HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm \n2\n . The treatments were performed in the following dosages and in a cyclic regimen consisting of two daily oral applications on days 5, 6, 12, 13, 19, and 20:\n\n\n\n\n\n\n \nGruppe 1 : (Kontrollgruppe) - Lösungsvermittler (40% PEG400 / 60% Wasser); Gruppe 2: V14, Dosierung 6 mg/kg; Gruppe 3: V14, Dosierung 8 mg/kg; Gruppe 4: V14, Dosierung 10 mg/kg.\nGroup 1: (control group) - solubilizer (40% PEG400 / 60% water); Group 2: V14, dosage 6 mg / kg; Group 3: V14, dosage 8 mg / kg; Group 4: V14, dosage 10 mg / kg.\n\n\n\n\n\n\n \nA) zeitlicher Verlauf des Wachstums der HeLa-MaTu Xenografttumore.\nA) Time course of growth of HeLa-MaTu xenograft tumors.\n\n\n\n\n\n\n \nB) Gewicht der HeLa-MaTu Tumore am Tag 20, sowie das Verhältnis des durchschnittlichen Tumorgewichtes der jeweiligen Behandlungsgruppen zu dem durchschnittlichen Tumorgewicht der Kontrollgruppe (T/C). \n\nB) Weight of HeLa-MaTu tumors on day 20, as well as the ratio of the average tumor weight of the respective treatment groups to the average tumor weight of the control group (T / C)."
  },
  {
    "id": "WO2010046857A1",
    "text": "Salts of isobutyric acid (1 r*, 2r*, 4r* ) -2- (2-{ [3- (4, 7-dimeth0xy-1 h-benzoimidazol-2-yl) -propyl] -methyl-amino } -ethyl) -5-phenyl-bicyclo [2.2.2] oct-5- en- 2 -yl AbstractThe invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers. Claims\n\n\n\n\n Claims\n\n\n\n\n1. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-S-phenyl-bicycloP^^loct-δ-en^-yl ester; wherein said crystalline salt consists of: • 1 equivalent of isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H- benzoimidazol^-y^-propyll-methyl-aminoJ-ethy^-S-phenyl-bicycloP^^oct-δ-en^-yl ester;\n\n\n• an acid component consisting of 1 to 2 equivalents of an acid selected from the group consisting of hydrobromic acid, sulfuric acid, maleic acid, fumaric acid, methanesulfonic acid, para-toluenesulfonic acid, benzenesulfonic acid, naphthalene-\n\n\n1 ,5-disulfonic acid, naphthalene-2-sulfonic acid, and ethanesulfonic acid; and\n\n\n• 0 to 5 equivalents of water.\n\n\n\n\n\n\n2. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-δ-phenyl-bicycloP^^loct-δ-en^-yl ester according to claim 1 , wherein the compound is enantiomerically enriched isobutyric acid (1 R,2R,4R)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester.\n\n\n\n\n\n\n3. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-δ-phenyl-bicycloP^^loct-δ-en^-yl ester according to claims 1 or 2, wherein the acid component of said crystalline salt consists of 1 or 2 equivalents of hydrobromic acid, 1 or 2 equivalents of sulfuric acid, 1 or 2 equivalents of maleic acid, 1 to 2 equivalents of fumaric acid, 1 or 2 equivalents of methanesulfonic acid, 1 or 2 equivalents of para-toluenesulfonic acid, 1 or 2 equivalents of benzenesulfonic acid, 1 to 2 equivalents of naphthalene-1 ,5-disulfonic acid, 1 or 2 equivalents of naphthalene-2-sulfonic acid, or 1 or 2 equivalents of ethanesulfonic acid.\n\n\n\n\n\n\n4. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-yO-propyO-methyl-aminoJ-ethyO-S-phenyl-bicycloP^^loct-δ-en^-yl ester according to any one of claims 1 to 3, wherein the acid component of said crystalline salt consists of 2 equivalents of hydrobromic acid, 2 equivalents of maleic acid, or 1.5 equivalents of fumaric acid. \n\n\n\n\n\n\n\n\n5. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-S-phenyl-bicycloP^^loct-δ-en^-yl ester according to any one of claims 1 to 4, wherein said crystalline salt consists of:\n\n\n• 1 equivalent of compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H- benzoimidazol^-y^-propyll-methyl-aminoj-ethy^-δ-phenyl-bicyclop^^loct-δ-en^-yl ester;\n\n\n• 2 equivalents of maleic acid; and\n\n\n• 0 equivalents of water.\n\n\n\n\n\n\n6. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- 1 H-benzoimidazol^-yO-propyO-methyl-aminoJ-ethyO-S-phenyl-bicycloβ^^oct-δ-en^-yl ester according to claim 5, characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 10.15°, 20.39°, and 22.63°; wherein said X-ray powder diffraction diagram is obtained by using Cu Kα1 radiation; and the accuracy of the 2Θ values is in the range of 2Θ +/- 0.2°. 7. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,\n\n\n\n\n\n\n7-dimethoxy- I H-benzoimidazol^-yO-propyO-methyl-aminoJ-ethyO-S-phenyl-bicycloP^^loct-δ-en^-yl ester according to claim 5, characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 5.07°, 8.19°, 10.15°, 15.26°, 17.61 °, 20.39°, 22.63°, 23.93°, 24.27°, and 25.61 °; wherein said X-ray powder diffraction diagram is obtained by using Cu Kα1 radiation; and the accuracy of the 2Θ values is in the range of 2Θ +/- 0.2°.\n\n\n\n\n\n\n8. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-yO-propyO-methyl-aminoJ-ethyO-S-phenyl-bicycloP^^loct-δ-en^-yl ester according to claim 5, which essentially shows the X-ray powder diffraction pattern as depicted in Fig.5.\n\n\n\n\n\n\n9. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-δ-phenyl-bicycloP^^loct-δ-en^-yl ester according to claim 5, which has a melting point of about 147°C as determined by differential scanning calorimetry using the method as described herein. \n\n\n\n\n\n\n\n\n10. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-S-phenyl-bicycloP^^loct-δ-en^-yl ester according to claim 5, obtainable by:\n\n\n1. refluxing a solution of COMPOUND (682 g, 84% w/w, 1.05 mol) in EtOAc (6.3 L, 11 volumes);\n\n\n2. adding maleic acid (256 g, 2.2 mol, 2.1 eq) dissolved in MeOH (630 ml_, 1.1 volumes);\n\n\n3. stirring the resulting mixture under reflux for 15 minutes and cooling to 65-68°C within 30 minutes; 4. optional seeding with 0.04% w/w of seeding crystals;\n\n\n5. cooling the mixture to 40\n0\nC within 3 hours;\n\n\n6. cooling the mixture to 20\n0\nC within 1 hour;\n\n\n7. filtering the solid under 0.2 bar of nitrogen and rinsing the solid with EtOAc (1500 ml_ 2.6 volumes); and 8. drying the solid under 1 atmosphere of nitrogen for 24 hours.\n\n\n\n\n\n\n11. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-ylJ-propylJ-methyl-aminoϊ-ethylJ-S-phenyl-bicyclop^^Joct-δ-en^-yl ester according to any one of claims 1 to 4, wherein the acid component of said crystalline salt consists of 1.5 equivalents of fumaric acid. \n\n\n\n\n\n\n12. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-δ-phenyl-bicycloP^^loct-δ-en^-yl ester according to claim 1 1 , characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 5.27°, 8.05°, and 20.61 °; wherein said X-ray powder diffraction diagram is obtained by using Cu Kα1 radiation; and the accuracy of the 2Θ values is in the range of 2Θ +/- 0.2°.\n\n\n\n\n\n\n13. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-ylJ-propylJ-methyl-aminoϊ-ethylJ-S-phenyl-bicyclop^^Joct-δ-en^-yl ester according to any one of claims 1 to 4, wherein the acid component of said crystalline salt consists of 2 equivalents of hydrobromic acid. \n\n\n\n\n\n\n14. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-y^-propyO-methyl-aminoJ-ethy^-δ-phenyl-bicycloP^^loct-δ-en^-yl ester according to claim 13, characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 9.3°, 15.6°, and 17.3°; wherein said X-ray powder diffraction diagram is obtained by using Cu Kα1 radiation; and the accuracy of the 2Θ values is in the range of 2Θ +/- 0.2°. \n\n\n\n\n\n\n\n\n15. A pharmaceutical composition comprising a crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}- ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester according to any one of claims 1 to 14, and a pharmaceutically acceptable carrier. \n\n\n\n\n\n\n16. A crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy- I H-benzoimidazol^-yO-propyO-methyl-aminoJ-ethyO-S-phenyl-bicycloP^^loct-δ-en^-yl ester according to any one of claims 1 to 14, or a pharmaceutical composition according to claim 15, for use as a medicament.\n\n\n\n\n\n\n17. Use of a crystalline salt of the compound isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7- dimethoxy-I H-benzoimidazol^-y^-propyll-methyl-aminoJ-ethy^-S-phenyl-bicycloP^^loct-δ- en-2-yl ester according to any one of claims 1 to 14 for the preparation of a pharmaceutical composition for the treatment or prevention of chronic stable angina, hypertension, ischemia (renal and cardiac), cardiac arrhythmias including atrial fibrillation, cardiac hypertrophy, or congestive heart failure. Description\n\n\n\n\n SALTS OF ISOBUTYRIC ACID ( 1 R* , 2R* , 4R* ) -2- ( 2- { [3- (4 , 7-DIMETHOXY-l\n\n\nH-BENZOIMIDAZOL-2-YL) -PROPYL] -METHYL-AMINO J -ETHYL ) -5-PHENYL-BICYCLO [2 . 2 . 2 ] OCT-5- EN- 2 -YL\n\n\nSalt Forms\n\n\nThe invention relates to novel crystalline salt forms of isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3- (4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl- 5 bicyclo[2.2.2]oct-5-en-2-yl ester (hereinafter also referred to as \"COMPOUND\") or enantiomers thereof, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salt forms, and their use as calcium channel blockers in the treatment or prevention of chronic stable angina, hypertension, ischemia (renal and cardiac), cardiac arrhythmias including atrial fibrillation, cardiac hypertrophy, or congestive heart0 failure. Said crystalline salt forms of the present invention may also be used, alone or in pharmaceutical compositions, for the treatment of renal diseases, diabetes and its complications, hyperaldosteronism, epilepsy, neuropathic pain, or cancer in humans and other mammals.\n\n\nBackground of the Invention 5 Many cardiovascular disorders have been associated with a 'calcium overload' resulting from an abnormal elevated calcium influx through the plasma membrane of cardiac and vascular smooth muscle cells. There are 3 major pathways through which extracellular calcium can enter these cells: 1 ) receptor-activated calcium channels, 2) ligand-gated calcium channels and 3) voltage-operated calcium channels (VOCs). 0 VOCs have been classified into 6 main categories: L (Long-lasting), T (Transient), N (Neuronal), P (Purkinje cells), Q (after P) and R (Remaining or Resistant).\n\n\nL-type calcium channels are responsible for the inward movement of calcium that initiates contraction in cardiac and smooth muscle cells suggesting a putative application for blockers of these channels in the cardiovascular field. In this view, L-type calcium channel blockers5 have been used in clinic since the early 60s and are now recommended as a first line of treatment for systolic-diastolic hypertension and angina pectoris.\n\n\nT-type calcium channels are found in various tissues such as coronary and peripheral vasculature, sinoatrial node and Purkinje fibres, brain, adrenal glands and in the kidney. This broad distribution suggests a T-type channel blocker to have a putative cardiovascular0 protection, to have en effect on sleep disorders, mood disorders, depression, migraine, hyperaldosteroneemia, preterm labor, urinary incontinence, brain aging or neurodegenerative disorders such as Alzheimers disease.\n\n\nMibefradil (Posicor®), the first L-type and T-type calcium channels blocker demonstrated a superior effect over calcium channel blockers, which target the L channel predominantly. \n\n Mibefradil was used for the treatment of hypertension and angina without showing negative side-effects often seen by L channel blockers like inotropy, reflex tachycardia, vasoconstrictive hormone release or peripheral edema. Additionally, mibefradil showed a potentially cardioprotective effect (Villame, Cardiovascular Drugs and Therapy 15, 41-28, 2001 ; Ramires, J MoI Cell Cardiol 1998, 30, 475-83), a renal protective effect (Honda, Hypertension 19, 2031-37, 2001 ), and showed a positive effect in the treatment of heart failure (Clozel, Proceedings Association American Physicians 1999, 1 11 , 429-37).\n\n\nDespite the enormous demand for a compound of this profile, mibefradil was withdrawn from the market in 1998 (one year after its launch), due to unacceptable CYP 3A4 drug interactions. Moreover, ECG abnormalities (i.e. QT prolongations) and interaction with the MDR-1 mediated digoxin efflux were also reported (du Souich, Clin Pharmacol Ther 67, 249- 57, 2000; Wandel, Drug Metab Dispos 2000, 28, 895-8).\n\n\nIt has now been found that crystalline salt forms of COMPOUND (isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)- 5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester) may under certain conditions be found. Said crystalline salt forms of COMPOUND are novel and may have advantageous properties, especially compared to the free base (WO2008/132679) or the di-hydrochloride salt of COMPOUND. Such advantages may include better flow properties, better solubility, less hygroscopicity, better reproducibiliy in manufacturing (for example better filtration parameters, better reproducibility of formation, better sedimentation), defined morphology and/or better long term stability.\n\n\nDescription of the Figures\n\n\nFig. 1 shows the X-ray powder diffraction diagram of the di-hydrochloric acid salt of COMPOUND in a crystalline form as obtained from Reference Example S1. The X-ray diffraction diagram measured with method 1 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (2Θ) (selected peaks from the range 2-40°, 2theta with relative intensity larger then 10% are reported): 3.02° (100%), 9.19° (88%), 9.77° (81%), 10.81 ° (16%), 12.50° (19%), 12.94° (21 %), 13.15° (30%), 14.30° (26%), 14.62° (24%), 15.36° (66%), 16.14° (37%), 17.08° (73%), 18.12° (76%), 19.46° (45%), 19.71 ° (40%), 20.54° (35%), 20.92° (31 %), 21.17° (29%), 21.56° (41 %), 22.47° (29%), 22.90° (22%), 23.99° (24%), 25.41 ° (52%), 26.05° (31 %), 26.90° (32%), 27.28° (24%), and 28.45° (37%).\n\n\nFig. 2 shows the X-ray powder diffraction diagram of the di-methylsulfonic acid salt of COMPOUND in a crystalline form as obtained from Example S2. The X-ray diffraction \n\n diagram measured with method 1 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 2-40° 2theta with relative intensity larger then 10% are reported): 3.97° (100%), 7.21 ° (42%), 10.00° (39%), 14.09° (40%), 14.45° (29%), 15.99° (55%), 16.38° (22%), 17.16° (51 %), 18.12° (44%), 18.34° (53%), 18.60° (19%), 19.38° (25%), 20.62° (35%), 21.02° (74%), 21.79° (18%), 22.24° (25%), 26.66° (30%), and 27.63° (29%).\n\n\nFig. 3 shows the X-ray powder diffraction diagram of the di-toluenesulfonic acid salt of COMPOUND in a crystalline form as obtained from Example S3. The X-ray diffraction diagram measured with method 1 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 2-40° 2theta with relative intensity larger then 10% are reported): 4.35° (31%), 5.79° (100%), 7.43° (16%), 8.62° (17%), 10.93° (19%), 1 1.51 ° (31 %), 13.98° (34%), 15.81 ° (26%), 18.06° (30%), 19.00° (20%), 19.39° (21%), 19.84° (31 %), 20.30° (25%), and 25.51 ° (20%).\n\n\nFig. 4 shows the X-ray powder diffraction diagram of the sulfuric acid salt of COMPOUND in a crystalline form as obtained from Example S4. The X-ray diffraction diagram measured with method 1 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 2-30° 2theta with relative intensity larger then 10% are reported): 2.85° (100%), 8.50° (21 %), 9.50° (28%), 11.78° (85%), 13.26° (41 %), 13.69° (51 %), 14.19° (82%), 15.78° (40%), 16.47° (39%), 17.12° (38%), 18.91 ° (40%), 19.48° (43%), 26.77° (65%), and 27.24° (63%).\n\n\nFig. 5 shows the X-ray powder diffraction diagram of the di-maleic acid salt of COMPOUND in a crystalline form as obtained from Example S5. The X-ray diffraction diagram measured with method 1 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 2-40°\n\n\n2theta with relative intensity larger then 10% are reported): 5.07° (26%), 8.19° (12%), 10.15° (93%), 15.26° (39%), 17.20° (12%), 17.61 ° (18%), 20.39° (100%), 20.88° (12%), 22.63°\n\n\n(47%), 23.93° (43%), 24.27° (26%), 24.51 ° (13%), 24.73° (17%), 25.61 ° (21 %), 29.42°\n\n\n(25%), and 32.93° (16%),\n\n\nFig. 6 shows the X-ray powder diffraction diagram of the sesqui-fumaric acid salt of\n\n\nCOMPOUND in a crystalline form as obtained from Example S6. The X-ray diffraction diagram measured with method 1 shows peaks having a relative intensity, as compared to \n\n the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 2-40° 2theta with relative intensity larger then 10% are reported): 5.27° (57%), 8.05° (100%), 12.93° (18%), 15.20° (10%), 15.50° (20%), 19.45° (14%), 20.31 ° (31 %), 20.61 ° (62%), 21.11 ° (27%), 22.77° (15%), 25.42° (1 1%), 26.22° (11%), and 31.27° (21%).\n\n\nFig. 7 shows the X-ray powder diffraction diagram of the di-hydrobromic acid salt of COMPOUND in a crystalline form as obtained from Example S7. The X-ray diffraction diagram measured with method 1 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 2-40° 2theta with relative intensity larger then 10% are reported): 3.1 ° (59%), 6.2° (28%), 9.3° (18%), 14.4° (1 1%), 15.6° (100%), 17.3° (33%), 18.1 ° (15%), 19.4° (20%), 20.0° (37%), 21.4° (14%), 22.8° (16%), and 34.8° (43%).\n\n\nFig. 8 shows the X-ray powder diffraction diagram of the sesqui-naphthalene-1 ,5-disulfonic acid salt of COMPOUND in a crystalline form as obtained from the general procedure for salt formation. The X-ray diffraction diagram measured with method 2 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 8-26.5° 2theta with relative intensity larger then 10% are reported): 9.9° (40%), 10.4° (18%), 12.8° (42%), 14.2° (100%), 15.0° (73%),\n\n\n18.3° (68%), 19° (54%), 20.1 ° (39%), 20.6° (48%), 21.3° (83%), 23.8° (13%), 24.9° (14%), and 26.2° (22%).\n\n\nFig. 9 shows the X-ray powder diffraction diagram of the di-benzenesulfonic acid salt of COMPOUND in a crystalline form as obtained from the general procedure for salt formation. The X-ray diffraction diagram measured with method 2 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 8-26.5° 2theta with relative intensity larger then 10% are reported): 8.1 ° (16%), 8.5° (18%), 10.9° (20%), 11.4° (16%), 12.3° (20%), 12.6° (37%), 12.9° (22%), 13.4° (55%), 14.6° (32%), 15.3° (37%), 16.1 ° (27%), 17.5° (71 %), 17.9° (37%), 19.1 ° (22%), 19.4° (25%), 20.1 ° (46%), 21.3° (91 %), 21.8° (46%), 22.7° (100%), 23.6° (18%), 24.5° (20%), and 25.5° (21 %).\n\n\nFig. 10 shows the X-ray powder diffraction diagram of the di-ethanesulfonic acid salt of\n\n\nCOMPOUND in a crystalline form as obtained from the general procedure for salt formation. The X-ray diffraction diagram measured with method 2 shows peaks having a relative \n\n intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 8-26.5° 2theta with relative intensity larger then 10% are reported): 9.6° (25%), 9.9° (21%), 10.5° (23.3%), 11.2° (27%), 11.9° (17%), 12.9° (48%), 14.5° (53%), 15.0° (40%), 15.7° (100%), 16.5° (65%), 17.0° (40%), 17.7° (49%), 19.0° (67%), 19.7° (69%), 20.4° (68%), 21.5° (55%), 22.6° (67%), and 23.3° (47%).\n\n\nFig. 1 1 shows the X-ray powder diffraction diagram of the di-naphthalene-2-sulfonic acid salt of COMPOUND in a crystalline form as obtained from the general procedure for salt formation. The X-ray diffraction diagram measured with method 2 shows peaks having a relative intensity, as compared to the most intense peak in the diagram, of the following percentages (relative peak intensitites given in parenthesis) at the indicated angles of refraction 2theta (selected peaks from the range 8-26.5° 2theta with relative intensity larger then 10% are reported): 9.8° (98%), 11.2° (45%), 11.8° (24%), 13.7° (20%), 14.6° (33%), 15.6° (100%), 16.9° (90%), 19.4° (96%), 22.4° (45%), and 23.9° (23%). In the X-ray diffraction diagrams of Fig. 1 to Fig 11 the angle of refraction 2theta (2Θ) is plotted on the horizontal axis and the counts on the vertical axis.\n\n\nDetailed Description of the Invention\n\n\n1 ) The invention relates to a crystalline salt, especially an essentially pure crystalline salt, of COMPOUND (isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)- propyO-methyl-aminoJ-ethy^-δ-phenyl-bicyclo^^^loct-δ-en^-yl ester); wherein said crystalline salt consists of:\n\n\n• 1 equivalent of COMPOUND;\n\n\n• an acid component consisting of 1 to 2 equivalents of an acid selected from the group consisting of hydrobromic acid, sulfuric acid, maleic acid, fumaric acid, methanesulfonic acid, para-toluenesulfonic acid, benzenesulfonic acid, naphthalene- 1 ,5-disulfonic acid, naphthalene-2-sulfonic acid, and ethanesulfonic acid; and\n\n\n• 0 to 5 equivalents of water.\n\n\n2) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 1 ), wherein COMPOUND is enantiomerically enriched isobutyric acid (1 R,2R,4R)-2-(2-{[3-\n\n\n(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl- bicyclo[2.2.2]oct-5-en-2-yl ester.\n\n\n3) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 1 ), wherein COMPOUND is enantiomerically enriched isobutyric acid (1 S,2S,4S)-2-(2-{[3- \n\n (4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl- bicyclo[2.2.2]oct-5-en-2-yl ester.\n\n\n4) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 1 ), wherein COMPOUND is isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H- benzoimidazol^-y^-propyll-methyl-aminoj-ethy^-δ-phenyl-bicyclop^^loct-δ-en^-yl ester in enantiomerically enriched form having negative optical rotation.\n\n\n5) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 4), wherein said crystalline salt contains 0 to 3 (especially 0.5 to 3, notably 1 to 2) equivalents of water. 6) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 4), wherein said crystalline salt contains 0 equivalents of water.\n\n\n7) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 6), wherein the acid component of said crystalline salt consists of 1 or 2 (especially 2) equivalents of hydrobromic acid, 1 or 2 equivalents of sulfuric acid, 1 or 2 (especially 2) equivalents of maleic acid, 1 to 2 (especially 1.5) equivalents of fumaric acid, 1 or 2 (especially 2) equivalents of methanesulfonic acid, 1 or 2 (especially 2) equivalents of para-toluenesulfonic acid, 1 or 2 (especially 2) equivalents of benzenesulfonic acid, 1 to 2 (especially 1.5) equivalents of naphthalene-1 ,5-disulfonic acid, 1 or 2 (especially 2) equivalents of naphthalene-2-sulfonic acid, or 1 or 2 (especially 2) equivalents of ethanesulfonic acid.\n\n\nIn a sub-embodiment, the acid component of said crystalline salt preferably consists of 2 equivalents of hydrobromic acid, 1 or 2 equivalents of sulfuric acid, 2 equivalents of maleic acid, 1 to 2 (especially 1.5) equivalents of fumaric acid, 2 equivalents of methanesulfonic acid, 2 equivalents of para-toluenesulfonic acid, or 2 equivalents of benzenesulfonic acid. In another sub-embodiment, the acid component of said crystalline salt preferably consists of 1 or 2 (especially 2) equivalents of maleic acid, or 1 to 2 (especially 1.5) equivalents of fumaric acid.\n\n\n8) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 2 equivalents of hydrobromic acid. A sub-embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 5) or 7), wherein the acid component of said crystalline salt consists of 2 equivalents of hydrobromic acid; and wherein said crystalline salt contains about 3 equivalents of water. \n\n 9) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 1 or 2 equivalents of sulfuric acid.\n\n\n10) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 2 equivalents of maleic acid.\n\n\n11 ) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 1 to 2 (especially 1.5) equivalents of fumaric acid. 12) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 2 equivalents of methanesulfonic acid.\n\n\n13) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 2 equivalents of para-toluenesulfonic acid.\n\n\n14) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 2 equivalents of benzenesulfonic acid.\n\n\n15) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 1 to 2\n\n\n(especially 1.5) equivalents of naphthalene-1 ,5-disulfonic acid.\n\n\n16) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 2 equivalents of naphthalene-2-sulfonic acid. 17) Another embodiment relates to a crystalline salt of COMPOUND according to any one of embodiments 1 ) to 7), wherein the acid component of said crystalline salt consists of 2 equivalents of ethanesulfonic acid.\n\n\n18) Another embodiment relates to a crystalline salt, especially an essentially pure crystalline salt, of COMPOUND according to embodiment 1 ) or 10), wherein said crystalline salt consists of:\n\n\n• 1 equivalent of COMPOUND, or of enantiomerically enriched COMPOUND as defined in any one of embodiments 2) to 4);\n\n\n• 2 equivalents of maleic acid; and \n\n • 0 equivalents of water.\n\n\n19) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 10) or 18), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 10.15°, 20.39°, and 22.63°. 20) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 10) or 18), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 5.07°, 8.19°, 10.15°, 15.26°, 17.61 °, 20.39°, 22.63°, 23.93°, 24.27°, and 25.61 °.\n\n\n21 ) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 10) or 18), which essentially shows the X-ray powder diffraction pattern as depicted in Fig.5.\n\n\n22) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 10) or 18) to 21 ), which has a melting point of about 147°C as determined by differential scanning calorimetry using the method as described herein. 23) In another embodiment the present invention relates to a crystalline salt according to any one of embodiments 10) or 18) to 22), obtainable by:\n\n\n1. refluxing a solution of COMPOUND (682 g, 84% w/w, 1.05 mol) in EtOAc (6.3 L, 1 1 volumes);\n\n\n2. adding maleic acid (256 g, 2.2 mol, 2.1 eq) dissolved in MeOH (630 ml_, 1.1 volumes);\n\n\n3. stirring the resulting mixture under reflux for 15 minutes and cooling to 65- 68°C within 30 minutes;\n\n\n4. optional seeding with 0.04% w/w of seeding crystals;\n\n\n5. cooling the mixture to 40°C within 3 hours; 6. cooling the mixture to 20°C within 1 hour;\n\n\n7. filtering the solid under 0.2 bar of nitrogen and rinsing the solid with EtOAc (1500 ml. 2.6 volumes); and\n\n\n8. drying the solid under 1 atmosphere of nitrogen for 24 hours.\n\n\n24) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 8), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 9.3°, 15.6°, and 17.3°.\n\n\n25) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 8) or 24), characterised by the presence of peaks in the X-ray powder diffraction \n\n diagram at the following angles of refraction 2Θ: 6.2, 9.3°, 15.6°, 17.3°, 18.1 °, 19.4°, 20.0°, and 22.8°.\n\n\n26) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 8), 24) or 25), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 7.\n\n\n27) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 11 ), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 5.27°, 8.05°, and 20.61 °.\n\n\n28) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 1 1 ) or 27), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 5.27°, 8.05°, 12.93°, 19.45°, 20.61 °, 21.11 ° and 31.27°.\n\n\n29) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 1 1 ), 27) or 28), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 6.\n\n\n30) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 1 1 ), or 27) to 29), which has a melting point of about 180°C as determined by differential scanning calorimetry using the method as described herein.\n\n\n31 ) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 12), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 7.21 ° and 10.00°.\n\n\n32) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 12) or 31 ), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 3.97°, 7.21 °, 10.00°, 15.99°, 17.16°, and 21.02°.\n\n\n33) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 12), 31 ) or 32), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 2.\n\n\n34) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 13), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 5.79° and 19.84°.\n\n\n35) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 13) or 34), characterised by the presence of peaks in the X-ray powder \n\n diffraction diagram at the following angles of refraction 2Θ: 4.35°, 5.79°, 10.93°, 13.98°, 15.81 ° and 19.84°.\n\n\n36) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 13), 34) or 35), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 3.\n\n\n37) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 14), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 13.4°, 17.5°, and 21.3°.\n\n\n38) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 14) or 37), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 12.6°, 13.4°, 14.7°, 17.5°, 21.3°, and 22.7°.\n\n\n39) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 14), 37) or 38), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 9.\n\n\n40) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 15), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 9.9°, 14.2°, and 21.3°.\n\n\n41 ) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 15) or 40), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 9.9°, 12.9°, 14.2°, 20.1 °, 20.6°, and 21.3°.\n\n\n42) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 15), 40) or 41 ), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 8.\n\n\n43) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 16), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 9.8°, 1 1.2°, and 15.6°.\n\n\n44) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 16) or 43), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 9.8°, 11.2°, 15.6°, 22.4°, and 23.9°. \n\n45) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 16), 43) or 44), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 1 1.\n\n\n46) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 17), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 11.2°, 15.7°, and 20.4°.\n\n\n47) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 17) or 46), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 11.2°, 14.5°, 15.7°, 17.7°, 20.4°, and 22.6°.\n\n\n48) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 17), 46) or 47), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 10.\n\n\n49) The invention further relates to a crystalline salt, especially an essentially pure crystalline salt, of COMPOUND (isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H- benzoimidazol^-yO-propyll-methyl-aminoJ-ethyO-S-phenyl-bicycloP^^loct-δ-en^-yl ester); wherein said crystalline salt consists of:\n\n\n• 1 equivalent of COMPOUND;\n\n\n• an acid component consisting of about 1 equivalent of sulfuric acid; and • about 6 equivalents of water.\n\n\n50) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 49), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 11.78°, 13.69°, and 14.19°.\n\n\n51 ) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 49) or 50), characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2Θ: 2.85°, 8.50°, 9.50°, 1 1.78°, 13.26°, 13.69°, and 14.19°.\n\n\n52) Another embodiment relates to a crystalline salt of COMPOUND according to embodiment 49), 50) or 51 ), which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 4.\n\n\nFor avoidance of any doubt, whenever one of the above embodiments, especially one of embodiments 19), 20), 24), 25), 27), 28), 31 ), 32), 34), 35), 37), 38), 40), 41 ), 43), 44), 46), 47), 50) and 51 ), refers to \"peaks in the X-ray powder diffraction diagram at the following \n\n angles of refraction 2Θ\", said X-ray powder diffraction diagram is obtained by using Cu Kα1 radiation (λ = 1.5406 A); and it should be understood that the accuracy of the 2Θ values as provided herein is in the range of +/- 0.1-0.2°. Notably, when specifying an angle of refraction 2theta (2Θ) for a peak in the invention embodiments and the claims, the 2Θ value given is to be understood as an interval from said value minus 0.2° to said value plus 0.2° (2Θ +/- 0.2°); and preferably from said value minus 0.1 ° to said value plus 0.1 ° (2Θ +/- 0.1 °).\n\n\nFor avoidance of any doubt, the relative configuration of stereoisomers is denoted as follows: isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester denominates isobutyric acid (1 R,2R,4R)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, or isobutyric acid (1 S,2S,4S)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl- amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, or mixtures of these two enantiomers such as for example the racemate. Encompassed in the scope of the present invention are the crystalline salt forms of COMPOUND, i.e. isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2- yO-propylJ-methyl-aminoJ-ethyO-S-phenyl-bicycloβ^^Joct-S-en^-yl ester, described herein; wherein COMPOUND may be in racemic form; in enantiomerically enriched form of the enantiomer of absolute configuration (1 R,2R,4R); in enantiomerically enriched form of the enantiomer of absolute configuration (1 S,2S,4S); or in form of any mixture of these two enantiomers. Preferred is the enantiomerically enriched form having negative optical rotation as determined using the method as described herein.\n\n\nWhere the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like. The term \"enantiomerically enriched\" is understood in the context of the present invention to mean especially that at least 90, preferably at least 95, and most preferably at least 99 per cent by weight of the COMPOUND are present in form of one enantiomer of the COMPOUND.\n\n\nThe term \"essentially pure\" is understood in the context of the present invention to mean especially that at least 90, preferably at least 95, and most preferably at least 99 per cent by weight of the crystals of a COMPOUND are present in a crystalline form according to the present invention, especially in a single crystalline form of the present invention.\n\n\nWhen defining the presence of peak in e.g. an X-ray powder diffraction diagram, a common approach is to do this in terms of the S/N ratio (S = signal, N = noise). According to this \n\n definition, when stating that a peak has to be present in an X-ray powder diffraction diagram, it is understood that the peak in the X-ray powder diffraction diagram is defined by having an S/N ratio (S = signal, N = noise) of greater than x (x being a numerical value greater than 1 ), usually greater than 2, especially greater than 3. In the context with stating that the crystalline form essentially shows an X-ray powder diffraction pattern as depicted in Fig. 1 to Fig. 1 1 , respectively, the term \"essentially\" means that at least the major peaks of the diagram depicted in said figures, i.e. those having a relative intensity of more than 10%, especially more than 20%, as compared to the most intense peak in the diagram, have to be present. However, the person skilled in the art of X-ray powder diffraction will recognize that relative intensities in X-ray powder diffraction diagrams may be subject to strong intensity variations due to preferred orientation effects.\n\n\nUnless used regarding temperatures, the term \"about\" placed before a numerical value \"X\" refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X. In the particular case of temperatures, the term \"about\" placed before a temperature \"Y\" refers in the current application to an interval extending from the temperature Y minus 10 \n0\nC to Y plus 10 \n0\nC, and preferably to an interval extending from Y minus 5 \n0\nC to Y plus 5 \n0\nC. Room temperature means a temperature of about 25 \n0\nC. When in the current application the term n equivalent(s) is used wherein n is a number, it is meant and within the scope of the current application that n is referring to about the number n, preferably n is referring to the exact number n.\n\n\nThe crystalline salts, especially the essentially pure crystalline salts, of COMPOUND according to any one of embodiments 1 ) to 51 ) can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration. The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, \"Pharmaceutical Manufacturing\" [published by Lippincott Williams & Wilkins]) by bringing the crystalline forms of the present invention, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.\n\n\nThe crystalline salts, especially the essentially pure crystalline salts, of COMPOUND according to any one of embodiments 1 ) to 51 ) may be used as single component or as mixtures with other crystalline forms or the amorphous form of COMPOUND. \n\n The crystalline salts, especially the essentially pure crystalline salts, of COMPOUND according to any one of embodiments 1 ) to 51 ) are useful in the preparation of a medicament and/or are suitable\n\n\n• for the treatment or prevention of chronic stable angina, hypertension, ischemia (renal and cardiac), cardiac arrhythmias including atrial fibrillation, cardiac hypertrophy, or congestive heart failure.\n\n\nThe crystalline salts, especially the essentially pure crystalline salts, of COMPOUND according to any one of embodiments 1 ) to 51 ) are further also useful in the preparation of a medicament and/or are suitable for the following disease groups alone or in any combination: » for the treatment of renal diseases, diabetes and its complications, hyperaldosteronism, epilepsy, neuropathic pain, or cancer in humans and other mammals;\n\n\n• for use as anti-fibrillatory agent, anti-asthmatic agent, anti-atherosclerotic agent, additive to cardioplegic solutions for pulmonary bypasses, adjunct to thrombolytic therapy, as antiaggregant agent, or as agent for the treatment of unstable angina; » for the treatment or prophylaxis of hypertension, especially portal hypertension, hypertension secondary to treatment with erythropoietin and low renin hypertension;\n\n\n• for use in hypoxic or ischemic diseases, or as anti ischemic agent for the treatment of e.g. cardiac, renal and cerebral ischemia and reperfusion (e.g. occurring after cardiopulmonary bypass surgery), coronary and cerebral vasospasm and the like, therapy for peripheral vascular diseases (e.g. Raynaud's disease, intermittent claudication,\n\n\nTakayashus disease), sickle cell disease including initiation and/or evolution of the pain crisis;\n\n\n• for the treatment or prophylaxis of disorders related to renal, glomerular and mesangial cell function, including acute and chronic renal failure, diabetic nephropathy, hypertension-induced nephropathy, glomerular injury, renal damage related to age or dialysis, nephrosclerosis, nephrotoxicity related to imaging and contrast agent and to cyclosporine, renal ischemia, primary vesicoureteral reflux, or glomerulosclerosis;\n\n\n• for use in therapy for myocardial infarction, treatment of cardiac hypertrophy, primary and secondary pulmonary hypertension, therapy for congestive heart failure including inhibition of fibrosis, inhibition of left ventricular dilatation, remodelling and dysfunction, or restenosis following angioplasty or stenting;\n\n\n• for the treatment of endotoxemia or endotoxin shock, or hemorrhagic shock;\n\n\n• for the treatment of sexual dysfunction in both men (erectile dysfunction e.g. due to diabetes mellitus, spinal cord injury, radical prostatectomy, psychogenic etiology and other causes) and women by improving blood flow to the genitalia, especially corpus cavern osum; \n\n • for the prevention and/or reduction of cancer or end-organ damage associated with cell proliferation;\n\n\n• for therapy of metabolic disorders or chronic inflammatory diseases, insulin-dependent and non insulin-dependent diabetes mellitus and their complications (e.g. neuropathy, retinopathy), hyperaldosteronism, bone remodelling, psoriasis, arthritis, rheumatoid arthritis, osteoarthritis sarcoidosis, or eczematous dermatitis;\n\n\n• for the treatment of hepatotoxicity and sudden death, early and advanced liver disease and injury including attendant complication (e.g. hepatotoxicity, fibrosis, cirrhosis), deleterious consequences of tumors such as hypertension resulting from hemangiopericytoma, spastic diseases of the urinary tract and/or bladder, hepatorenal syndrome, immunological diseases involving vasculitis such as lupus, systemic sclerosis, mixed cryoglobulinemia, fibrosis associated with renal dysfunction and hepatotoxicity;\n\n\n• for use in gastrointestinal diseases such as ulcerative colitis, Crohn's disease, gastric mucosal damage, ulcer inflammatory bowel disease and ischemic bowel disease, gall bladder or bile duct-based diseases such as cholangitis, pancratitis, regulation of cell growth, begning prostatic hypertrophy, or transplantation, or for use as anti-diarrheal agent;\n\n\n• for the treatment of disorders involving bronchoconstriction or disorders of chronic or acute inflammation such as obstructive pulmonary disease and adult distress syndrome; • for the alleviation of pain including neuropathic pain, peripheral pain and pain associated with cancer such as pain associated with prostate cancer or bone-cancer;\n\n\n• for the treatment of central nervous system vascular disorders such as stroke, transient ischemic attacks, migraine and subarachnoid hemorrhage, central nervous system behavioural disorders, treatment of dementia including Alzheimer's dementia, senile dementia and vascular dementia, epilepsy, or sleep disorders; or\n\n\n• for reduction of general morbidity and/or mortality as a result of above utilities.\n\n\nThe present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a crystalline salt, especially of an essentially pure crystalline salt, of COMPOUND according to any one of embodiments 1 ) to 51 ).\n\n\nFurthermore, the crystalline salts, especially the essentially pure crystalline salts, of COMPOUND according to any one of embodiments 1 ) to 51 ) may also be used favourably in combination with one or more agents selected from lipid lowering agents such as statins, anticoagulants such as coumarins, antithrombotic agents such as clopidogrel, β-blockers, and other cardioprotective agents. \n\n The present invention also relates to a process for the preparation of COMPOUND in racemic and enantiomerically enriched form, and to processes for the preparation and characterization of crystalline salts of COMPOUND according to any one of embodiments 1 ) to 51 ), said processes are described in the experimental part below.\n\n\nExperimental Part\n\n\nThe following Examples illustrate the invention in more detail. Temperatures are given in degrees Celsius. If not stated otherwise percentages are given by weight.\n\n\nAbbreviations as used herein and in the description above: aq. aqueous ca. about\n\n\nCC column chromatography on silica gel\n\n\nDCM dichloromethane\n\n\nDIPA diisopropyl-amine\n\n\nDIPEA diisopropyl-ethylamine, Hϋnig's base, ethyl-diisopropylamineDMAP\n\n\n4-dimethylamino-pyridine\n\n\nDMF dimethylformamide\n\n\nDSC differential scanning calorimetry eq. equivalent(s)\n\n\nEt\n2\nO diethyl ether\n\n\nEtOAc ethyl acetate\n\n\nEtOH ethanol\n\n\nFig. figure h hour(s)\n\n\n \n1\nH-NMR hydrogen-1 nuclear magnetic resonance\n\n\nHept heptane\n\n\nHex hexane\n\n\nHOBt 1 -hydroxybenzotriazole\n\n\nMEK 2-butanone\n\n\nMeCN acetonitrile\n\n\nMeOH methanol\n\n\nNEt\n3\n triethylamine\n\n\nPd/C palladium on carbon\n\n\n2-PrOH isopropanol\n\n\nRed-AI sodium-bis(2-methoxyethoxy)aluminumhydride \n\n RH relative humidity rt room temperature rpm rotations per minute sat. saturated TBME tert-butyl methyl ether tert. tertiary\n\n\nTHF tetrahydrofuran\n\n\nTsOH para (p)-toluene sulfonic acid\n\n\nXRPD X-ray powder diffraction X-ray powder diffraction analysis (XRPD):\n\n\nMethod 1 : X-ray powder diffraction patterns were collected on a Bruker D8 Advance X-ray diffractometer equipped with a LynxEye detector with 3° window operated with Cu Ka- radiation in reflection geometry (Bragg-Brentano). Typically, the X-ray tube was run at 40kV/40mA. A step size of 0.02° (2Θ) and a step time of 37 sec over a scanning range of 2 - 50° in 2theta (2Θ) were applied. The divergence slit was set to variable V12 or V20, dependent on sample holder depth. The powder (about 15 mg for 0.1 mm depth and about 80 mg for 1 mm depth) was slightly pressed into a silicon single crystal sample holder with depth of 0.1 mm or 1 mm and samples were rotated in their own plane during the measurement. Selected samples were covered with Kapton foil. Diffraction data are reported using Cu Kα1 (λ = 1.5406 A), after the Kα2 component has been stripped using the instrument evaluation software (EVA). In addition, the background signal has been removed using the instrument evaluation software (EVA), for samples that were covered by Kapton during data acquisition. The accuracy of the 2Θ values as provided herein is in the range of +/- 0.1-0.2° as it is generally the case for conventionally recorded X-ray powder diffraction patterns.\n\n\nMethod 2: X-ray powder diffraction patterns were collected on a Bruker D8 HTS X-ray diffractometer equipped with a GADDS HiStar detector operated with Cu Kα-radiation in reflection geometry. Typically, the X-ray tube was run at 40kV/40mA. The instrument is performance checked using a certified Corundum standard (NIST 1976). Samples run under ambient conditions were prepared as flat plate specimens using powder as received. Approximately 3 mg of the sample was gently pressed on a microscopy slide. The data were collected over an angular range of 7.6° to 26.7° 2Θ in 1 frame with an acquisition time of 180second. Diffraction data are reported without Kα2 component stripping and the background signal has been removed using the instrument evaluation software (EVA). The \n\n accuracy of the 2Θ values as provided herein is in the range of +/- 0.1-0.2° as it is generally the case for conventionally recorded X-ray powder diffraction patterns.\n\n\nMelting points were measured on a Buchi B-540 apparatus and are not corrected; or were measured, if explicitly stated, by differential scanning calorimetry (DSC): DSC data were collected on a Perkin Elmer DSC7. Typically 2-3 mg of sample, previously stored open under dry nitrogen for 16 hours, were heated in a closed gold pan at 20°C min\n\"1\n from -20°C to 200°C. Melting points are reported as peak temperatures.\n\n\nOptical rotations were measured on a Jasco P-1030 apparatus at room temperature using the D-line of sodium (λ = 589 nm). 1H-NMR were measured on a Bruker Avance 400 (400 MHz); chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentuplet, hex = hexet, sept = septuplet, m = multiplet, dm = doublet of multiplet, br = broad, coupling constants are given in Hz). NMR assays were measured using hydroquinone dimethylether as internal standard. Hvgroscopicity was assessed through scanned gravimetric vapour sorption measurements on a SPS1 1-100m (Projekt Messtechnik, UIm, Germany) (scan rate was 5% relative humidity change per hour, cycle started at 50% relative humidity followed by a scan to dryness and an upwards scan to 95% relative humidity). Classification was done according to the European Pharmacopea Technical Guide (1999 edition) (e.g. slightly hygroscopic: increase in mass is less than 2% and equal to or greater than 0.2% mass/mass). The mass change between 40% relative humidity and 80% relative humidity in the upwards scan was considered.\n\n\nLC-MS were run using the following conditions: Finnigan Navigator with HP 1 100 Binary Pump and DAD, column: 4.6x50 mm, Zorbax SB-AQ, 5 μm, 120 A, gradient: 5-95% acetonitrile in water, 1 min, with 0.04% trifluoroacetic acid, flow: 4.5 mL/min, t\nR\n is given in min.\n\n\nCompounds are purified by preparative HPLC (column: X-terra RP18, 50x19 mm, 5 μm, gradient: 10-95% acetonitrile in water containing 0.5 % of formic acid) or by column chromatography on silica gel. Racemates can be separated into their enantiomers by preparative HPLC (preferred conditions: Daicel, ChiralCel OD 20x250 mm, 10 μm, 4% ethanol in hexane, flow 10-20 mL/min). \n\n L Preparation and characterization of COMPOUND\n\n\nThe preparation of COMPOUND is known from WO2008/132679: Preparation of intermediates\n\n\nGeneral procedures for the preparation of key intermediates K: Key intermediates K1A and K2A which are bicyclo[2.2.2]oct-5-en-2-yl or bicyclo[3.2.2]non-8- en-6-yl derivatives are obtained as a mixture between the major racemate having the relative configuration (R\n*\n, R\n*\n, R\n*\n) (i.e. the bridge -(CH\n2\n)\n2\n- of the cyclohexene moiety is cis to the group -OR\n2\n being hydroxy) and the minor racemate having the relative configuration (R\n*\n, S\n*\n, R\n*\n) (i.e. the bridge -(CH\n2\n)\n2\n- of the cyclohexene moiety is trans to the group -OR\n2\n being hydroxy). The major and the minor racemates can be separated as described for key intermediate K1A in procedure A1.5. The major racemate is isolated and used in the preparation of the examples below.\n\n\nK1 A: rac-(1 R*,2R*,4R*)-(2-Hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert. -butyl ester K1 A.1 (Procedure A1.1 ): rac-(1 R\n*\n.4R\n*\nVBicvclor2.2.21octane-2.5-dione\n\n\n25 ml. of 2-(trimethylsilyloxy)-1 ,3-cyclohexadiene and 13 ml. of α-acetoxyacrylonitrile were mixed and heated at 150\n0\nC in a closed vessel for 22 h. The obtained dark orange viscous oil was dissolved in 200 ml. of MeOH. After dropwise addition of a solution of 2.2 g of sodium methoxide in 150 ml. of MeOH the reaction mixture was stirred for 3 h at rt, poured into ice/water and extracted with DCM. The organic phases were concentrated in vacuo and the crude residue was purified by CC with EtOAc-Hept (1 :2) to yield 7.9 g of rac-(1 R\n*\n,4R\n*\n)- bicyclo[2.2.2]octane-2,5-dione. LC-MS: t\nR\n = 0.44 min.\n\n\nK1A.2 (Procedure A1.2): rac-(1 R\n*\n.4R\n*\nVSpirorbicvclor2.2.2loctane-2.2'-ri .3ldioxolanl-5-one To 4.0 g of rac-(1 R\n*\n,4R\n*\n)-bicyclo[2.2.2]octane-2,5-dione (intermediate K1A.1 ), dissolved in 120 ml. of toluene, 1.7 ml. of ethylene glycol and 0.27 g of TsOH were added and the solution was heated under vigorous stirring to reflux for 3.5 h. The reaction mixture was cooled to rt, quenched with saturated aq. NaHCO\n3\n, extracted with Et\n2\nO, and the organic phase was evaporated. The crude product was purified by CC with Hex-EtOAc (7:3) to yield 2.41 g of rac-(1 R\n*\n,4R\n*\n)-spiro[bicyclo[2.2.2]octane-2,2'-[1 ,3]dioxolan]-5-one as yellow oil. LC-MS: t\nR\n = 0.64 min; [M+H+CH\n3\nCN]\n+\n: 224.35. \n\n K1A.3 (Procedure A1.3): Mixture of rac-(7R\n*\n.8R\n*\n.10R\n*\nV and rac-(7R\n*\n.8S\n*\n.10R\n*\nV7.10-(1.2- Ethylen)-8-phenyl-1 ,4-dioxa-spiror4.5ldecan-8-ol\n\n\nTo a solution of 2.41 g of rac-(1 R\n*\n,4R\n*\n)-spiro[bicyclo[2.2.2]octane-2,2'-[1 ,3]dioxolan]-5-one\n\n\n(intermediate K1A.2) in 80 ml. Et\n2\nO, 14.5 ml. phenylmagnesium bromide solution (1 M in Et\n2\nO) was added dropwise over 10 min. The reaction mixture was stirred for 4 h at rt. Then, the mixture was quenched carefully with ice, 8 ml. 2N HCI were added and the phases were separated. The organic phase was evaporated and the crude product was purified by CC with Hept-EtOAC (7:3) to give 0.37 g of 7,10-(1 ,2-ethylen)-8-phenyl-1 ,4-dioxa- spiro[4.5]decan-8-ol as colorless oil. (Separation of the diastereomers by CC is possible but was not performed here.)\n\n\nLC-MS: t\nR\n = 0.84 min; [M-H\n2\nO+H]\n+\n: 243.34.\n\n\nK1A.4 (Procedure A1.4): rac-(1 R\n*\n,4R\n*\n)-5-Phenyl-bicvclor2.2.2loct-5-en-2-one\n\n\nTo a solution of 0.54 g of 7,10-(1 ,2-ethylen)-8-phenyl-1 ,4-dioxa-spiro[4.5]decan-8-ol (intermediate K1A.3) in 20 ml. acetone was added 200 mg of TsOH and then the mixture was stirred for 2 d at rt. The reaction mixture was quenched with sat. aq. NaHCO\n3\n, extracted with EtOAC and the organic phase was evaporated. The crude product was purified by CC with Hept-EtOAC (7:3) to give 0.34 g of rac-(1 R\n*\n,4R\n*\n)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-one as colorless oil. LC-MS: t\nR\n = 0.93 min; [M+H+CH\n3\nCN]\n+\n: 240.1 1. K1A.5 (Procedure A1.5): rac-(1 R\n*\n.2R\n*\n.4R\n*\nH2-Hvdroxy-5-phenyl-bicvclor2.2.2loct-5-en-2-vn- acetic acid tert.-butyl ester and rac-(1 R\n*\n,2S\n*\n,4R\n*\nH2-hvdroxy-5-phenyl-bicvclor2.2.2loct-5-en- 2-yl)-acetic acid tert.-butyl ester\n\n\nTo a solution of 0.51 mL of DIPA in 0.5 mL THF 2.2 mL of n-butyllithium (1.6M in Hex) were added dropwise at -20\n0\nC. After 10 min, 0.5 mL of toluene were added and the solution was stirred for 30 min. The mixture was cooled to -50\n0\nC, 0.73 mL of tert.-butyl acetate were added and stirring was continued for 1 h at -50\n0\nC. Then 0.32 g of rac-(1 R\n*\n,4R\n*\n)-5-phenyl- bicyclo[2.2.2]oct-5-en-2-one (intermediate K1A.4) dissolved in 1 mL of THF was added and the solution was stirred at -50 to -20\n0\nC over 2.5 h. The reaction mixture was poured on ice/aq. HCI, the organic phase was separated, washed and evaporated. The crude reaction product was purified by CC with Hept-EtOAc (9:1 ) to yield 0.30 g of the major racemate, rac- (1 R\n*\n,2R\n*\n,4R\n*\n)-2-hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert.-butyl ester, as white solid and 0.07 g of the minor racemate, rac-(1 R\n*\n,2S\n*\n,4R\n*\n)-2-hydroxy-5-phenyl- bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert.-butyl ester, as colorless oil. LC-MS (major racemate): t\nR\n = 1.06 min; [M-(CH\n3\n)\n3\n-H\n2\nO+H]\n+\n: 241.1 1. LC-MS (minor racemate): t\nR\n = 1.05 min; [M+H]\n+\n: 315.18. \n\n K1A.6: (1 S.2S.4SV(2-Hvdroxy-5-Dhenyl-bicvclor2.2.2loct-5-en-2-vn-acetic acid tert.-butyl ester and (1 R,2R,4R)-(2-Hvdroxy-5-phenyl-bicvclor2.2.2loct-5-en-2-yl)-acetic acid tert.-butyl ester rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-(2-Hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert.-butyl ester was separated into the respective enantiomers using prep, chiral HPLC (column: Daicel ChiralPak AD-H, 20x250 mm, 5 μm; Hex/ EtOH 95:5, flow 16 mL/min) Chiral analytic HPLC (Daicel ChiralPak AD-H, 4.6x250 mm, 5 μm; Hex/ EtOH 95:5, flow 0.8 mL/min):\n\n\n(1 R,2R,4R)-(2-Hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert.-butyl ester: Enantiomer A: t\nR\n = 6.70 min.\n\n\n(1S,2S,4S)-(2-Hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert.-butyl ester: Enantiomer B: t\nR\n = 7.93 min.\n\n\nBB. [3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amine\n\n\nBB.1 3,6-Dimethoxy-benzene-1 ,2-diamine 3, 6-Dimethoxy-benzene-1 ,2-diamine was synthesized by dissolving 6.0 g of 1 ,4-dimethoxy- 2,3-dinitro-benzene (Eur.J.Org.Chem. 2006, 2786-2794) in 220 mL EtOH, evacuating 3 times with N\n2\n and adding 600 mg of 10wt% Pd/C. The reaction was stirred under a H\n2\n atmosphere (balloon). Another 300 mg of 10wt% Pd/C were added after 2 days and the mixture was stirred for another 24 h. Filtration over a pad of celite and washing with EtOH and EtOAc yielded after concentration in vacuo 4.3 g of 3, 6-dimethoxy-benzene-1 ,2-diamine as black solid. LC-MS: t\nR\n = 0.48 min; [M+H]\n+\n: 169.09.\n\n\nBB.2 r3-(2-Amino-3,6-dimethoxy-phenylcarbamoyl)-propyll-methyl-carbamic acid benzyl ester To a solution of 3.1 g of 4-(benzyloxycarbonyl-methyl-amino)-butyric acid in 80 mL DCM were added 6.5 mL of DIPEA, 1.8 g of HOBt, 2.6 g of EDC and 154 mg of DMAP. After stirring for 10 min, 2.1 g of 3, 6-dimethoxy-benzene-1 ,2-diamine, dissolved in 20 mL DCM, were added and the mixture was stirred at rt overnight. The reaction was quenched with sat. aq. NaHCO\n3\n, the phases were separated and the organic phase was washed with brine, dried over MgSO\n4\n and concentrated in vacuo to yield the crude title compound as black oil. LC-MS: t\nR\n = 0.88 min; [M+H]\n+\n: 402.06.\n\n\nBB.3 [3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl1-methyl-carbamic acid benzyl ester\n\n\nTo a mixture of the above crude 3-(2-amino-3,6-dimethoxy-phenylcarbamoyl)-propyl]-methyl- carbamic acid benzyl ester in 16 mL toluene were added 4 mL of DMF and 1.9 g of TsOH \n\n and the reaction was heated to 150\n0\nC for 2 h in the microwave. Sat. aq. NaHCO\n3\n was added and the phases were separated. The organic phase was washed with brine, dried over MgSO\n4\n, concentrated in vacuo, filtered over a short pad of silica gel with EtOAc and concentrated again. Purification by CC with EtOAc yielded 2.7 g of 3-(4,7-dimethoxy-1 H- benzoimidazol-2-yl)-propyl]-methyl-carbamic acid benzyl ester as brown resin. LC-MS: t\nR\n = 0.85 min; [M+H]\n+\n: 384.62.\n\n\nBB.4 r3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyll-methyl-amine\n\n\nA solution of 2.6 g of 3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-carbamic acid benzyl ester in 60 ml. EtOH was evacuated 3 times with N\n2\n before 260 mg of 10 wt% Pd/C were added. The reaction mixture was then stirred under a H\n2\n atmosphere (balloon) for 5 h at rt. Filtration over a pad of celite and washing with EtOH yielded after concentration in vacuo 1.7 g of 3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amine as brown foam. LC-MS: t\nR\n = 0.57 min; [M+H]\n+\n: 250.13.\n\n\nPreparation of COMPOUND Reference Example 1A: rac-lsobutyric acid (1 R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester\n\n\n1.1 (Procedure P1.1 V rac-(1 R\n*\n.2R\n*\n.4R\n*\nH2-Hvdroxy-5-phenyl-bicvclor2.2.2loct-5-en-2-vn- acetic acid To a solution of 4.0 g of rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-(2-hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)- acetic acid tert.-butyl ester in 25 mL EtOH were added 2.1 g of LiOH-H\n2\nO, 8 mL H\n2\nO and 22 mL MeOH. The reaction mixture was stirred at rt for 3 d and then concentrated. The residue was partitioned between water and Et\n2\nO. The aq. layer was separated and acidified with 1 N HCI resulting in the formation of a white solid. The solid was filtrated, washed with 5 mL aq. HCI and dried in vacuo to obtain 3.2 g of rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-(2-hydroxy-5-phenyl- bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid as white solid. LC-MS: t\nR\n = 0.86 min; [M-H\n2\nO+H]\n+\n: 241.28.\n\n\n1.2 (Procedure P1.2): rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-N-r3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)- propyl1-2-(2-hvdroxy-5-phenyl-bicvclo[2.2.21oct-5-en-2-yl)-N-methyl-acetamide To a solution of 280 mg of rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-(2-hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2- yl)-acetic acid in 7 mL THF were added 0.58 mL of DIPEA, 175 mg of HOBt and 250 mg of EDC at rt. After stirring for 10 min, 270 mg of 3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)- propyl]-methyl-amine were added and the reaction mixture was stirred at rt overnight. The \n\n reaction mixture was quenched with sat. aq. NaHCO\n3\n, the phases were separated and the organic phase was washed with water and brine, dried over MgSO\n4\n and concentrated in vacuo. Purification by CC using EtOAc-MeOH (5:1 to 2:1 ) yielded 475 mg of rac- (1 R\n*\n,2R\n*\n,4R\n*\n)-N-[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-2-(2-hydroxy-5-phenyl- bicyclo[2.2.2]oct-5-en-2-yl)-N-methyl-acetamide as white foam. LC-MS: t\nR\n = 0.91 min; [M+H]\n+\n: 490.06.\n\n\n1.3 (Procedure P1.3): rac-(1 R\n*\n.2R\n*\n.4R\n*\nV2-(2-fr3-(4.7-Dimethoxy-1 H-benzoimidazol-2-ylV propyll-methyl-amino}-ethyl)-5-phenyl-bicvclor2.2.21oct-5-en-2-ol\n\n\nTo a solution of 310 mg of rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-N-[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)- propyl]-2-(2-hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-N-methyl-acetamide in 8 mL toluene were added dropwise 0.77 ml. of a Red-AI solution (65% in toluene) at 0\n0\nC. After stirring for 10 min at 0\n0\nC, the cooling bath was removed and stirring was continued for 3 h at rt. The reaction mixture was then carefully poured onto a mixture of 1 M NaOH/ice and stirred for 10 min. The aq. phase was extracted with toluene, the combined organic phases were washed with brine, dried over MgSO\n4\n and concentrated in vacuo. Purification by CC using EtOAc-MeOH (2:1 ) yielded 230 mg of rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H- benzoimidazol^-y^-propyll-methyl-aminoj-ethy^-δ-phenyl-bicyclop^^loct-δ-en^-ol as white foam. LC-MS: t\nR\n = 0.79 min; [M+H]\n+\n: 476.13. 1.4: rac-lsobutyric acid (1 R\n*\n.2R\n*\n.4R\n*\n')-2-(2-fr3-(4.7-dimethoxy-1 H-benzoimidazol-2-vn- propyll-methyl-amino}-ethyl)-5-phenyl-bicvclor2.2.21oct-5-en-2-yl ester\n\n\nTo a solution of 199 mg of rac-(1 R\n*\n,2R\n*\n,4R\n*\n)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2- yO-propyO-methyl-aminoJ-ethy^-δ-phenyl-bicycloP^^loct-δ-en^-ol in 4 mL DCM were added 0.2 mL of NEt\n3\n and 0.1 mL of isobutyrylchloride at 0°C. The reaction mixture was stirred overnight allowing the temperature to reach slowly rt. The reaction was quenched with sat. aq. NaHCO\n3\n, the phases were separated and the water phase was re-extracted with DCM. The combined organic phases were washed with brine, dried over MgSO\n4\n and concentrated in vacuo. The residue was redissolved in 3 mL EtOAc, silica gel and 1.5 mL MeOH were added and the mixture was stirred vigorously for 7 d. The mixture was filtered, thouroughly washed with EtOAc-MeOH (2:1 ) and evaporated. Purification by CC using EtOAc-MeOH (5:1 to 3:1 + 0.1 % NEt\n3\n) yielded 186 mg of rac-isobutyric acid (1 R\n*\n,2R\n*\n,4R\n*\n)-2- (2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl- bicyclo[2.2.2]oct-5-en-2-yl ester as beige foam. LC-MS: t\nR\n = 0.90 min; [M+H]\n+\n: 546.23. \n\n Reference Example 2A: lsobutyric acid (1S,2S,4S)-2-(2-{[3-(4,7-dimethoxy-1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester\n\n\n2.1 : (1S.2S.4SV(2-Hvdroxy-5-Dhenyl-bicvclor2.2.2loct-5-en-2-vn-acetic acid Prepared according to procedure P1.1 in Reference Example 1A using enantiomer B of rac- (1 R\n*\n,2R\n*\n,4R\n*\n)-(2-hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert.-butyl ester (see K1A.6). LC-MS: t\nR\n = 0.91 min; [M-H\n2\nCHH]\n+\n: 241.10.\n\n\n2.2: (1S.2S.4SV2-(2-fr3-(4.7-Dimethoxy-1 H-benzoimidazol-2-ylVDroDyll-methyl-amino>- ethyl)-5-phenyl-bicvclor2.2.21oct-5-en-2-ol\n\n\nPrepared according to procedures P1.2 to P1.3 in Reference Example 1A using the above (2-hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid. LC-MS: t\nR\n = 0.78 min; [M+H]\n+\n: 476.09.\n\n\n2.3: Isobutyric acid (1S,2S,4S)-2-(2-{[3-(4J-dimethoxy-1 H-benzoimidazol-2-yl)-propyl1- methyl-amino}-ethyl)-5-phenyl-bicvclor2.2.21oct-5-en-2-yl ester\n\n\nPrepared according to procedure P1.4 in Reference Example 1A using the above 2-(2-{[3-\n\n\n(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl- bicyclo[2.2.2]oct-5-en-2-ol.\n\n\nLC-MS: t\nR\n = 0.89 min; [M+H]\n+\n: 546.19. Reference Example 3A: lsobutyric acid (1 R,2R,4R)-2-(2-{[3-(4,7-dimethoxy-1H- benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester\n\n\n3.1 : (1 R.2R.4RH2-Hvdroxy-5-phenyl-bicvclor2.2.21oct-5-en-2-vn-acetic acid\n\n\nPrepared according to procedure P1.1 in Reference Example 1 using enantiomer A of rac- (1 R\n*\n,2R\n*\n,4R\n*\n)-(2-hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid tert.-butyl ester (see K1A.6). LC-MS: t\nR\n = 0.91 min; [M-H\n2\nCHH]\n+\n: 241.16.\n\n\n3.2: (1 R,2R,4R)-2-(2-{[3-(4,7-Dimethoxy-1 H-benzoimidazol-2-yl)-propyl1-methyl-amino}- ethvD-δ-phenyl-bicvclo^^^loct-δ-en^-ol Prepared according to procedures P1.2 to P1.3 in Reference Example 1 using the above (2- hydroxy-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl)-acetic acid. LC-MS: t\nR\n = 0.79 min; [M+H]\n+\n: 476.09. \n\n 3.3: Isobutyric acid (1 R.2R.4RV2-(2-{r3-(4.7-dimethoxy-1 H-benzoimidazol-2-ylVpropyll- methyl-amino}-ethyl)-5-phenyl-bicvclor2.2.21oct-5-en-2-yl ester\n\n\nPrepared according to procedure P1.4 in Reference Example 1A using the above 2-(2-{[3- (4,7-dimethoxy-1 H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl- bicyclo[2.2.2]oct-5-en-2-ol.\n\n\nLC-MS: t\nR\n = 0.89 min; [M+H]\n+\n: 546.11. Optical rotation: alpha D (c = 10 mg/mL EtOH) = -21.5°.\n\n\n1 H NMR (MeOD, 400 MHz) δ 7.39-7.37 (m, 2H), 7.30 (t, J = 6.4 Hz, 2H), 7.24-7.20 (m, 1 H), 6.60 (s, 2 H), 6.43 (br d, J = 7.6 Hz, 1 H), 3.91 (s, 6H), 3.27-3.23 (m, 1 H), 3.18-3.15 (m, 1 H), 2.87 (t, J = 7.6 Hz, 2H), 2.54 (sept, J = 7.0 Hz, 1 H), 2.47-2.37 (m, 4H), 2.21 (s, 3H), 2.19- 2.12 (m, 1 H), 2.01-1.92 (m, 5H), 1.75-1.65 (m, 2H), 1.48-1.38 (m, 1 H), 1.27-1.19 (m, 1 H), 1.16 (d, J = 7.0 Hz, 6H).\n\n\nBiological tests\n\n\nIn vitro assay L channel The L channel antagonistic activity (IC50 values) of Reference Examples 1A, 2A, and 3A is determined in accordance with the following experimental method.\n\n\nHuman embryonic kidney (HEK293) cells expressing the human CaJ .2 channel in addition to the auxiliary subunits β-2a and α2δ-1 , are grown in culture medium (DMEM containing 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin, 100μg/ml G418, 40μg/ml zeocin and 100μg/ml hygromycin). The cells are seeded at 20.000 cells/well into 384-well black clear bottom sterile plates (poly-L-lysine-coated, Becton Dickinson). The seeded plates are incubated overnight at 37°C in 5% CO\n2\n. The KCI solution is prepared as 80 mM stock solution in assay buffer (HBSS containing 0.1 % BSA, 20 mM HEPES, 0.375g/l NaHCO\n3\n, adjusted to pH 7.4 with NaOH) for use in the assay at a final concentration of 20 mM. Antagonists are prepared as 10 mM stock solutions in DMSO, then diluted in 384w plates first in DMSO, then in assay buffer to obtain 3x stocks. On the day of the assay, 25 μl of staining buffer (HBSS containing 20 mM HEPES, 0.375g/l NaHCO\n3\n, and 3 μM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well of the seeded plate. The 384-well cell-plates are incubated for 60 min at 37° C in 5% CO\n2\n followed by washing with 2 x 50μl per well using assay buffer leaving 50 μl/well of this buffer for equilibration at room temperature (30-60 min). Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 25 μl/well, incubated for 3 min and finally 25 μl/well of KCI solution is added for cellular depolarization. Fluorescence is measured for each well at 2 \n\n second intervals for 8 minutes, and the area under the curve of each fluorescence peak is compared to the area of the fluorescence peak induced by 20 mM KCI with vehicle in place of antagonist. For each antagonist, the IC\n50\n value (the concentration (in nM) of compound needed to inhibit 50 % of the KCI-induced fluorescence response) up to 10μM is determined. IC\n50\n values of reference example compounds 1A, 2A, and 3A have been measured and are in the range of 156 to 439 nM.\n\n\nIn vitro assay T channel:\n\n\nThe T channel antagonistic activity (IC\n50\n values) of Reference Examples 1A, 2A, and 3A is determined in accordance with the following experimental method and data are shown in Table 1.\n\n\nHuman embryonic kidney (HEK293) cells expressing the human Ca\nv\n3.1 Ca\nv\n3.2 or Ca\nv\n3.3 channel, respectively, are grown in culture medium (DMEM containing 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin and 1 mg/ml G418). The cells are seeded at 20.000 cells/well into 384-well black clear bottom sterile plates (poly-L- lysine-coated, Becton Dickinson). The seeded plates are incubated overnight at 37°C in 5% CO\n2\n. The Ca\n2+\n solution is prepared as 100 mM stock solution in 100 mM tetraethylammoniumchloride (TEA-chloride), 50 mM HEPES, 2.5 mM CaCI\n2\n, 5 mM KCI, 1 mM MgCI\n2\n, adjusted to pH 7.2 with TEA-hydroxide, for use in the assay at a final concentration of 10 mM. Antagonists are prepared as 10 mM stock solutions in DMSO, then diluted in 384w plates first in DMSO, then in 100 mM TEA-chloride, 50 mM HEPES, 2.5 mM CaCI\n2\n, 5 mM KCI, 1 mM MgCI\n2\n, adjusted to pH 7.2 with TEA-hydroxide, to obtain 9x stocks. On the day of the assay, 25 μl of staining buffer (HBSS containing 20 mM HEPES, 0.375g/l NaHCO\n3\n and 3 μM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well of the seeded plate. The 384-well cell-plates are incubated for 60 min at 37° C in 5% CO\n2\n followed by washing with 2 x 50μl per well using HBSS containing 0.1% BSA, 20 mM HEPES, 0.375g/l NaHCO\n3\n, leaving 50 μl/well of this buffer for equilibration at room temperature (30-60 min). Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 6.25 μl/well, incubated for 3 min, and finally 6.25 μl/well of Ca\n2+\n solution is added. Fluorescence is measured for each well at 2 second intervals for 8 minutes, and the area under the curve of each fluorescence peak is compared to the area of the fluorescence peak induced by 10 mM Ca\n2+\n with vehicle in place of antagonist. For each antagonist, the IC50 value (the concentration (in nM) of compound needed to inhibit 50 % of the Ca\n2+\n-induced fluorescence response) up to 10μM is determined. \n\n Table 1 :\n\n\n\n\n\n\n\n\nEffect on Isolated Hearts according to the Langendorff method (Lgdff)\n\n\nThe Reference Examples 1A, 2A, and 3A were tested for their potential to reduce blood pressure and their effect on the contractility of the heart muscle. EC\n50\n values on isolated mouse hearts were determined according to Literature (Doring HJ., The isolated perfused heart according to Langendorff technique— function— application, Physiol. Bohemoslov. 1990, 39(6), 481-504; Kligfield P, Homer H, Brachfeld N., A model of graded ischemia in the isolated perfused rat heart, J. Appl. Physiol. 1976 Jun, 40(6), 1004-8).\n\n\nThe compound of reference example 1A has been measured using the procedure described above for the Langendorff experiment with an EC\n50\n of 5 nM.\n\n\nII. Preparation of salt forms of COMPOUND\n\n\nII. a) General procedure for salt formation with COMPOUND:\n\n\n1 eq. of COMPOUND was dissolved in SOLVENT1. The solution was brought to 50\n0\nC. 2 Equivalents of acid dissolved in SOLVENT2 was added. The mixture was stirred at 50\n0\nC for 5 min and the heating source was turned off. The mixture was allowed to cool to rt within 1 hour. If a precipitate was observed the mixture was filtered and the solid was isolated. In case that no solid was obtained the mixture was evaporated to dryness and 6 volumes of heptane were added. The mixture was heated to reflux, 3 volumes of EtOAc were added until all dissolved. In case that dissolution was not complete further 3 volumes EtOAc were added. If dissolution was still not complete, as less as possible MeOH was added until complete dissolution. The mixture was allowed to cool slowly to rt. At rt the vessel was scratched with a spatula and was further cooled to 0°C. The mixture was filtered and the solution was evaporated to dryness on the rotavapor.\n\n\nThe term \"volumes\" as used herein signifies 1 L for 1 kg of solid material. \n\n SOLVENT1 = 8 volumes EtOAc for: benzensulfonic acid, benzoic acid, salicylic acid, saccharin, para-toluenesulfonic acid, malonic acid, methanesulfonic acid, naphthalene-2- sulfonic acid, naphthalene-1 ,5-disulfonic acid, ethanesulfonic acid, malic acid, glycolic acid, ketoglutaric acid, and fumaric acid; SOLVENT1 = 1.8 volumes EtOAc for: hydrobromic acid, and hydrochloric acid; SOLVENT1 = 8 volumes acetone for: sulfuric acid, and phosphoric acid; SOLVENT1 = 7 volumes acetone for: citric acid, succinic acid, and tartaric acid.\n\n\nSOLVENT2 = 7 volumes EtOAc for: citric acid;\n\n\nSOLVENT2 = 3 volumes EtOAc for: benzensulfonic acid, benzoic acid, methanesulfonic acid, salicylic acid, and saccharin (partially soluble);\n\n\nSOLVENT2 = 3 volumes MeOH for: para-toluenesulfonic acid, malonic acid, naphthalene-2- sulfonic acid, naphthalene-1 ,5-disulfonic acid, malic acid, glycolic acid, ketoglutaric acid, and fumaric acid;\n\n\nSOLVENT2 = 15 volumes acetone for: succinic acid; SOLVENT2 = 12 volumes EtOH for: tartaric acid;\n\n\nSOLVENT2 = water for: hydrobromic acid, hydrochloric acid, sulfuric acid, and phosphoric acid.\n\n\nResults obtained using the general procedure described above are summarized in Tables 1 and 2. In case particular procedures have been used to prepare crystalline salt forms of COMPOUND, such procedures are described in Reference Example S1 and the Examples S2 to S7 below. \n\n\n\n\nTable 1 : Characterisation data for crystalline salt forms of COMPOUND gained according to the general procedure \n\n\n\n\n\n \n\n Table 2: Characterisation data for further salt forms of COMPOUND gained according to general procedure\n\n\n\n\n\n\n\n\nReference Example S1 : Preparation and characterization of the di-hydrochloric acid salt of COMPOUND\n\n\n7.598 ml. aq. HCI (0.1 N) was added to 200.7 mg COMPOUND resulting in a white suspension. 5 ml. 2-PrOH were added and the obtained clear solution was evaporated to dryness under nitrogen. 4 ml. TBME were added to the residue and the suspension was shaken with a temperature cycle (T 1 = 20\n0\nC, T2 = 25°C, holding time 1 h, respectively; heating and cooling rate 5°C/h, 500 rpm). After 18 repetitions the suspension was filtered and the solid was dried in vacuum to yield 265 mg of the di-hydrochloric acid salt of COMPOUND. \n\n Table S1 : Characterisation data for the di-hydrochloric acid salt of COMPOUND\n\n\n\n\n\n\n\n\nExample S2: Preparation and characterization of the di-methanesulfonic acid salt of COMPOUND\n\n\n0.0476 ml. Methanesulfonic acid was added to a clear solution of 199.7 mg of COMPOUND dissolved in 7 ml EtOAc. The clear solution was evaporated to dryness under nitrogen and the obtained residue was suspended and shaken in 4 ml. of a EtOAc/heptane (1 :3) mixture with a temperature cycle (T1 = 20°C, T2 = 25°C, holding time 1 h, respectively; heating and cooling rate 5°C/h, 500 rpm). After 18 repetitions the suspension was filtered and the solid was dried in vacuum. The obtained solid was suspended and shaken in 1 ml. TBME (temperature cycle: T1 = 20°C, T2 = 25°C, holding time 1 h, respectively; heating and cooling rate 5°C/h, 500 rpm). After 18 repetitions the suspension was filtered and the solid was dried in vacuum to yield the di-methanesulfonic acid salt of COMPOUND. \n\n Table S2: Characterisation data for the di-methanesulfonic acid salt of COMPOUND\n\n\n\n\n\n\n\n\nExample S3: Preparation and characterization of the di-para-toluenesulfonic acid salt of COMPOUND\n\n\n199.7 mg of COMPOUND was dissolved in 7 ml. EtOAc. 139.2 mg para-toluenesulfonic acid dissolved in 10 ml. EtOAc was added. The clear solution was evaporated to dryness under nitrogen and the residue was suspended in 4 ml. of a EtOAc/Hept (1 :3) mixture, and shaken with a temperature cycle (temperature cycle: T1 = 20\n0\nC, T2 = 25°C, holding time 1 h, respectively; heating and cooling rate 5°C/h, 500 rpm). After 18 cycles the solvent was evaporated under vacuum and the solid residue was suspended in 2 ml EtOAc. After brief sonication (3 min) the suspension was shaken with a temperature cycle (temperature cycle: T1 = 20\n0\nC, T2 = 25°C, holding time 1 h, respectively; heating and cooling rate 5°C/h, 500 rpm). After 18 repetitions the suspension was filtered and the solid was dried in vacuum to yield 173.8 mg of the di-para-toluenesulfonic acid salt of COMPOUND. \n\n Table S3: Characterisation data for the di-para-toluenesulfonic acid salt of COMPOUND\n\n\n\n\n\n\n\n\nExample S4: Preparation and characterization of the sulfuric acid salt of COMPOUND\n\n\n0.733 ml. aqueous sulfuric acid (0.5M) was added to a solution of 200.2 mg COMPOUND in 10 ml. MEK resulting in a clear solution. After 2 days the obtained suspension was filtered and the solid was dried in vacuum for 1 h yielding the mono-sulfuric acid salt of COMPOUND containing about 6 equivalents of water.\n\n\nTable S4: Characterisation data for the di-sulfuric acid salt of COMPOUND\n\n\n \n\n Example S5: Preparation and characterization of the di-maleic acid salt of COMPOUND\n\n\nMaleic acid (256 g, 2.2 mol, 2.1 eq), dissolved in MeOH (630 ml_, 1.1 volumes) was added to a refluxing solution of COMPOUND (682 g, 84% w/w (NMR assay), 1.05 mol) in EtOAc (6.3 L, 11 volumes). The resulting mixture was stirred under reflux for 15 minutes and was then cooled to 65-68°C within 30 minutes and seeded with 0.04% w/w of seeding crystals of di- maleic acid salt of COMPOUND (Seeding crystals were obtained after careful crystallisation using the same protocol.). The mixture was then cooled from 65-68°C to 40\n0\nC within 3 h. The obtained suspension was then cooled down to 20\n0\nC over 1 h, filtered under 0.2 bar of nitrogen and rinsed with EtOAc (1500 ml. 2.6 volumes). The obtained white solid was then dried under 1 atmosphere of nitrogen for 24 hours to yield 715 g (88%) of the di-maleic acid salt of COMPOUND.\n\n\nTable S5: Characterisation data for the di-maleic acid salt of COMPOUND\n\n\n \n\n Example S6: Preparation of the sesqui-fumarate salt of COMPOUND\n\n\n199.5 mg of COMPOUND were dissolved in 5 mL EtOAc. A clear solution of 85.4 mg fumaric acid in 5 mL THF was slowly added. The obtained clear solution was concentrated to 3 mL solution under nitrogen resulting in precipitation. The mixture was filtered and the solid was dried in vacuum. The obtained solid was the sesqui-fumaric acid salt of COMPOUND.\n\n\nTable S6: Characterisation data for the sesqui-fumaric acid salt of COMPOUND\n\n\n\n\n\n\n\n\nExample S7: Preparation of the di-hydrobromic acid salt of COMPOUND\n\n\n0.3665 ml. of aqueous 2 molar hydrobromic acid was slowly added to a solution of 199.8 mg COMPOUND in 0.4 ml THF and the obtained suspension was heated (heat gun). The clear solution was cooled to r.t. resulting in a precipitation. 3 ml. THF was added, the suspension was shaken, filtered and the solid was vacuum dried (1 h, 3 mbar).. The obtained solid was the di-hydrobromic acid salt of COMPOUND containing about 3 equivalents of water.\n\n\nTable S7: Characterisation data for the di-hydrobromic acid salt of COMPOUND"
  },
  {
    "id": "JP2010180208A",
    "text": "Cycloalkyl inhibitor of potassium channel function Abstract<P>PROBLEM TO BE SOLVED: To develop new inhibitors of potassium channel function (especially inhibitors of the K<SB>v</SB>1 subfamily of voltage gated K<SP>+</SP>channels, especially inhibitors K<SB>v</SB>1.5 which have been linked to the ultra-rapidly activating delayed rectifier K<SP>+</SP>current I<SB>Kur</SB>).  <P>SOLUTION: The present invention relates to new cycloalkyl compounds, methods of using such compounds in the prevention and treatment of arrythmia and I<SB>Kur</SB>-associated conditions, and pharmaceutical compositions containing such compounds.  <P>COPYRIGHT: (C)2010,JPO&INPIT Claims (\n8\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  式（１）：\n\n\n \n \n\n［式中、\n\n  Ｒ\n1\nは水素、またはヒドロキシであり、\n\n  Ｒ\n2\nは水素またはメトキシであり、\n\n  Ｒ\n3\nはＳＯ\n2\n−ＮＲ\n4\nＲ\n5\nまたはＣＯＮＨ−ＳＯ\n2\n−Ｒ\n6\nであり、\n\n  Ｒ\n4\nは、水素、Ｃ\n1-3\nアルキル、ヒドロキシエチル、またはメトキシエチルであり、\n\n  Ｒ\n5\nは、\n\n  水素；アリル；トリフルオロエチル；シクロヘキシルメチル；ＣＨ\n3\nＣ（＝ＣＨ\n2\n）ＣＨ\n2\n−；インダニル；ヒドロキシインダニル；フェニル−ＮＨＣＨ\n2\nＣＨ\n2\n−；\n\n  ヒドロキシ、メトキシおよびエトキシから独立して選択される１または２個で置換されていてもよいＣ\n1-5\nアルキル；\n\n  フェニル−（ＣＨＲ\n7\n）\nn\n− （フェニルはメチル、メトキシ、フルオロ、シアノ、アミノ、エトキシカルボニルメチル、ヒドロキシエチル、ヒドロキシメチルから独立して選択される１または２個の置換基で置換されていてもよく；Ｒ\n7\nは水素、メチル、ヒドロキシメチル、メトキシメチル；ｎは０、１または２である）；\n\n  （Ｃ\n1-2\nアルキル）\n2\nＮ（Ｃ\n2-3\nアルキレン）− （アルキレンは２つまでのメチルで置換されていてもよい）；\n\n  窒素原子を１〜３個含む６員ヘテロ環−Ｒ\n8\n− （６員ヘテロ環はＣｌ、Ｂｒ、メチル、エチル、ＣＦ\n3\n、メトキシ、ブトキシ、ＣＮ、ＮＨ\n2\n、ジエチルアミノ、およびメトキシカルボニルから独立して選択される１または２個で置換されていてもよく、Ｒ\n8\nは結合、メチレン、エチレン、メチルメチレン、エチルメチレン、または−ＣＨ\n2\nＣＨ\n2\nＮＨ−である）；または\n\n  イソキサゾリル、ピラゾリル、メチルピラゾリル、イミダゾリル、トリアゾリル、テトラゾリル、テトラヒドロフリル、ジヒドロピラニル、ピロリジニル、Ｎ−エチルピロリジニル、モルホリニル、ピペリジル、ベンゾイミダゾリル、またはＮ−メチルベンゾイミダゾリルから選択されるヘテロ環置換基（これらはＣ\n1-3\nアルキレンを介して結合してもよい）；\n\nであるか、あるいはＲ\n4\nとＲ\n5\nは一緒になって、それらに結合する窒素原子と共に、\n\n\n \n \n\nのいずれかの環を形成してもよく；\n\n  Ｒ\n6\nは、メチル、ヒドロキシ、ＣＦ\n3\n、ＮＨ\n2\n、フェニル、\n\n\n \n \n\nのいずれかである］\n\nの化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\nFormula (1): \n \n \n \n [Where: \n R \n1\n is hydrogen or hydroxy; \n R \n2\n is hydrogen or methoxy; \n R \n3\n is SO \n2\n —NR \n4\n R \n5\n or CONH—SO \n2\n —R \n6\n ; \n R \n4\n is hydrogen, C \n1-3\n alkyl, hydroxyethyl, or methoxyethyl; \n R \n5\n is \n Allyl; trifluoroethyl; cyclohexylmethyl; CH \n3\n C (═CH \n2\n ) CH \n2\n —; indanyl; hydroxyindanyl; phenyl-NHCH \n2\n CH \n2\n —; \n C \n1-5\n alkyl optionally substituted by 1 or 2 independently selected from hydroxy, methoxy and ethoxy; \n Phenyl- (CHR \n7\n ) \nn\n — (Phenyl may be substituted with 1 or 2 substituents independently selected from methyl, methoxy, fluoro, cyano, amino, ethoxycarbonylmethyl, hydroxyethyl, hydroxymethyl. Well; R \n7\n is hydrogen, methyl, hydroxymethyl, methoxymethyl; n is 0, 1 or 2); \n (C \n1-2\n alkyl) \n2\n N (C \n2-3\n alkylene) - (alkylene may be substituted with a methyl up to two); \n 6-membered heterocycles containing 1 to 3 nitrogen atoms —R \n8\n — (6-membered heterocycles are independent of Cl, Br, methyl, ethyl, CF \n3\n , methoxy, butoxy, CN, NH \n2\n , diethylamino, and methoxycarbonyl. Or R \n8\n is a bond, methylene, ethylene, methylmethylene, ethylmethylene, or —CH \n2\n CH \n2\n NH—); or isoxazolyl, pyrazolyl, methylpyrazolyl Heterocyclic substituents selected from, imidazolyl, triazolyl, tetrazolyl, tetrahydrofuryl, dihydropyranyl, pyrrolidinyl, N-ethylpyrrolidinyl, morpholinyl, piperidyl, benzimidazolyl, or N-methylbenzimidazolyl (these are C \n1-3\n alkylene May be coupled through); \n Or R \n4\n and R \n5\n together, together with the nitrogen atom bound to them, \n \n \n \n Any of the rings may be formed; \n R \n6\n is methyl, hydroxy, CF \n3\n , NH \n2\n , phenyl, \n \n \n \n Any of] \n Or an enantiomer, diastereomer, solvate or salt thereof.\n\n\n\n\n\n\n\n\n\n\n \n\n  Ｒ\n1\nが水素であり、Ｒ\n2\nが水素であり、Ｒ\n3\nがＳＯ\n2\n−ＮＲ\n4\nＲ\n5\nである請求項１の化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\nThe compound of claim 1, or an enantiomer, diastereomer, solvate or salt thereof, wherein R \n1\n is hydrogen, R \n2\n is hydrogen and R \n3\n is SO \n2\n —NR \n4\n R \n5\n .\n\n\n\n\n\n\n\n\n\n\n \n\n  以下のいずれかの化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\nAny of the following compounds, or an enantiomer, diastereomer, solvate or salt thereof: \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n  以下のいずれかの化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\n\n \n \n\n\n \n \n\n\nAny of the following compounds, or an enantiomer, diastereomer, solvate or salt thereof: \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n  以下のいずれかの化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\n\n \n \n\n\n \n \n\n\nAny of the following compounds, or an enantiomer, diastereomer, solvate or salt thereof: \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n  以下のいずれかの化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\n\n \n \n\n\n \n \n\n\nAny of the following compounds, or an enantiomer, diastereomer, solvate or salt thereof: \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n  以下のいずれかの化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\n\n \n \n\n\n \n \n\n\nAny of the following compounds, or an enantiomer, diastereomer, solvate or salt thereof: \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n  以下のいずれかの化合物、またはそのエナンチオマー、ジアステレオマー、溶媒和物もしくは塩。\n\n\n \n \n\n\nAny of the following compounds, or an enantiomer, diastereomer, solvate or salt thereof: Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は、カリウムチャネル機能の阻害薬（特に電位ゲート（gated）Ｋ\n+\nチャネルのＫｖ１サブファミリーの阻害薬、とりわけ超急速に活性化する遅延整流器Ｋ\n+\n電流Ｉ\nKur\nにリンクしたＫ\nv\n１．５阻害薬）として有用なシクロアルキル化合物、および該化合物を含有する医薬組成物を提供する。さらに本発明は、該化合物を不整脈、Ｉ\nKur\n−関連障害、およびイオンチャネル機能によって仲介される他の障害の処置に使用する方法に関係する。\n\nThe present invention relates to inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of gated gated K \n+\n channels, in particular K \nv\n 1.5 linked to a very rapidly activated delayed rectifier K \n+\n current I \nKur.\n A cycloalkyl compound useful as an inhibitor) and a pharmaceutical composition containing the compound are provided. The invention further relates to methods of using the compounds for the treatment of arrhythmias, I \nKur\n -related disorders, and other disorders mediated by ion channel function.\n\n\n\n\n\n\n\n\n\n\n \n\n  カリウムイオンの重要性は最初に、カリウムイオンがイカの巨大軸索を刺激する電流に寄与することをＨodgkinおよびＨuxleyが発見したぼぼ５０年前に認められた。しかしながら、野（area）のリサーチは、カリウムチャネルのための選択的な高親和性リガンドの欠乏によって妨げられた。しかし、組換えＤＮＡ技法や単細胞および全細胞電位クランプ（voltage  clamp）技法の出現が、領域（field）のスローペースを変えた。実際に、機能的、薬理学的および組織分布特性を示すカリウムチャネルは、クローン化された。これらのクローン化カリウムチャネルは、各種疾患状態の処置用の候補化合物を同定するアッセイの有用な標的である。カリウムチャネルは、現在までに発見されたイオンチャネルの中で、最も多様なファミリーであることが判明した。カリウムチャネルは、多くの細胞事象、たとえば筋肉収縮、神経内分泌腺の分泌、活動電位（action  potentials）の頻度と持続、電解質恒常性、および静止膜電位を調節する。\n\n\n  The importance of potassium ions was first recognized about 50 years ago when Hodgkin and Huxley discovered that potassium ions contribute to the current that stimulates squid giant axons. However, area research was hampered by the lack of selective high affinity ligands for potassium channels. However, the advent of recombinant DNA techniques and single cell and whole cell voltage clamp techniques changed the slow pace of the field. Indeed, potassium channels exhibiting functional, pharmacological and tissue distribution characteristics have been cloned. These cloned potassium channels are useful targets for assays that identify candidate compounds for the treatment of various disease states. Potassium channels have been found to be the most diverse family of ion channels discovered to date. Potassium channels regulate many cellular events, such as muscle contraction, neuroendocrine secretion, frequency and duration of action potentials, electrolyte homeostasis, and resting membrane potential.\n\n\n\n\n\n\n\n \n\n  カリウムチャネルは、真核生物および原核生物の細胞で発現され、かつ電気的および非電気的細胞機能のコントロールにおける要素である。カリウムチャネルは、その生物物理学的および薬理学的特性に従って分類されている。これらチャネルのサブクラスは、アミノ酸配列および機能性質に基づき命名される。これらの中で顕著なものは、電位依存性カリウムチャネルであって、たとえば電位ゲート（voltage  gated）カリウムチャネル（Ｋ\nv\n１、Ｋ\nv\n２、Ｋ\nv\n３、Ｋ\nv\n４など）である。これらサブクラスの中の亜類型は、細胞および組織におけるその推定機能、薬理学および分布に関して特性決定される［ＣhandyおよびＧutmanの「Ｈandbook  of  Ｒeceptors  and  Ｃhannels−Ｌigand  and  Ｖoltage−gated  Ｉon  Ｃhannels」（Ｒ．Ａ．Ｎorth編、１９９５年），“電位ゲートカリウムチャネル遺伝子”；Ｄoupnikらの「Ｃurr．Ｏpin．Ｎeurobiol．」（５：２６８、１９９５年）］。\n\nPotassium channels are expressed in eukaryotic and prokaryotic cells and are elements in the control of electrical and non-electrical cell functions. Potassium channels are classified according to their biophysical and pharmacological properties. These channel subclasses are named based on amino acid sequence and functional properties. These Prominent among is a voltage-gated potassium channels, for example, level gate (Voltage gated) potassium channels (such as \n \nK v 1, K v 2,\n \n K v 3, K v 4). Subtypes within these subclasses are characterized with respect to their putative function, pharmacology and distribution in cells and tissues [Chandy and Gutman, “Handbook of Receptors and Channels-Ligand and Voltage-gated Ion Channels” (RA). North, 1995), “potential-gated potassium channel gene”; Doupnik et al., “Curr. Opin. Neurobiol.” (5: 268, 1995)].\n\n\n\n\n\n\n \n\n  たとえば、Ｋ\nv\n１クラスのカリウムチャネルはさらに、チャネルの分子配列、たとえばＫ\nv\n１．１、Ｋ\nv\n１．２、Ｋ\nv\n１．３、Ｋ\nv\n１．４、Ｋ\nv\n１．５、Ｋ\nv\n１．６およびＫ\nv\n１．７に基づき、細別される。機能的電位ゲートＫ\n+\nチャネルは、同一または異なるサブユニットの連合によって形成される多重結合構造として存在しうる。この現象は、Ｋ\n+\nチャネルの幅広い多様性の事実を説明していると思われる。しかしながら、自然のままのＫ\n+\nチャネルのサブユニット組成や、個々のチャネルが演じる生理的役割は、ほとんどの場合、なお不明確である。\n\nFor example, the K \nv\n 1 class potassium channels are further linked to the molecular arrangement of the channels, eg K \nv\n 1.1, K \nv\n 1.2, K \nv\n 1.3, K \nv\n 1.4, K \nv\n 1.5, K \nv.\n Subdivide based on 1.6 and K \nv\n 1.7. The functional potential gate K \n+\n channel can exist as a multiple bond structure formed by the association of the same or different subunits. This phenomenon seems to explain the fact of the wide diversity of K \n+\n channels. However, the natural K \n+\n channel subunit composition and the physiological roles played by individual channels are still unclear in most cases.\n\n\n\n\n\n\n \n\n  Ｋ\nv\n１．３阻害による膜脱分極は、Ｔ−細胞増殖を防止する有効な方法であることが認められ、従って、多くの自己免疫病態で適用される。ヒトＴ−リンパ球の血漿膜におけるＫ\n+\nチャネルの阻害は、細胞内のＣａ\n++\n恒常性を調整することにより、免疫抑制レスポンスを顕在化させるときの役割を演じることが仮定され、これはＴ−細胞活性化で重要であることがわかった。\n\nMembrane depolarization by K \nv\n 1.3 inhibition has been found to be an effective way to prevent T-cell proliferation and is therefore applied in many autoimmune conditions. Inhibition of K \n+\n channels in the plasma membrane of human T-lymphocytes is hypothesized to play a role in eliciting an immunosuppressive response by modulating intracellular Ca \n++\n homeostasis, which -Found to be important in cell activation.\n\n\n\n\n\n\n \n\n  Ｋ\nv\n１．３電位ゲートカリウムチャネルは、ニューロン、血球、破骨細胞およびＴ−リンパ球で見られる。ＣhandyおよびＣahalanの研究所は、Ｋ\nv\n１．３チャネルのブロックが免疫抑制薬レスポンスを顕在化させるという仮設を提案した［Ｃhandyらの「Ｊ．Ｅxp．Ｍed．」（１６０、３６９、１９８４年）；Ｄecourseyらの「Ｎature」（３０７、４６５、１９８４年）］。しかしながら、その実験で用いたＫ\n+\nチャネル遮断薬は、非選択的であった。サソリの毒液に見られるペプチドの１種の、ペプチド・マルガトキシン（margatoxin）によるリサーチまで、この仮説を試験するＫ\nv\n１．３チャネルの特別な阻害薬は全く存在しなかった。ある研究所は、カリュブドトキシン（charybdotoxin）がヒトＴ−細胞においてＫ\nv\n１．３をブロックすることを示したが［Ｐriceらの「Ｐroc．Ｎatl．Ａcad．Ｓci．」（ＵＳＡ、８６、１０１７１、１９８９年）］、カリュブドトキシンはその後、ヒトＴ−リンパ球において４種のＫ\n+\nチャネル（Ｋ\nv\n１．３と３種の異なる小コンダクタンスＣａ\n++\n活性化Ｋ\n+\nチャネル）を阻害することが認められ、このことは該トキシンの、Ｋ\nv\n１．３の生理学的役割のプローブとしての使用を制限する［Ｌeonardらの「Ｐroc．Ｎatl．Ａcad．Ｓci．」（ＵＳＡ、８９、１００９４、１９９２年）］。\n\nK \nv\n 1.3 voltage-gated potassium channels are found in neurons, blood cells, osteoclasts and T-lymphocytes. Chandy and Chalan's laboratory proposed a hypothesis that block of the K \nv\n 1.3 channel reveals an immunosuppressant response [Chandy et al., “J. Exp. Med.” (160, 369, 1984). Decoursey et al., “Nature” (307, 465, 1984)]. However, the K \n+\n channel blocker used in the experiment was non-selective. Until the research by the peptide margatoxin, one of the peptides found in scorpion venom, there was no specific inhibitor of the K \nv\n 1.3 channel to test this hypothesis. One laboratory has shown that charybdotoxin blocks K \nv\n 1.3 in human T-cells [Pric et al., “Proc. Natl. Acad. Sci.” (USA, 86, 10171). 1989)], calubudotoxin subsequently inhibits four K \n+\n channels (K \nv\n 1.3 and three different small conductance Ca \n++\n activated K \n+\n channels) in human T-lymphocytes. Which restricts the use of the toxin as a probe for the physiological role of K \nv\n 1.3 [Leonard et al., Proc. Natl. Acad. Sci. (USA, 89, 10094, 1992). Year)].\n\n\n\n\n\n\n \n\n  これに反して、マルガトキシンはＴ−細胞でＫ\nv\n１．３のみをブロックし、かつインビトロおよびインビボモデルの両方で免疫抑制薬活性を有する［Ｌinらの「Ｊ．exp．Ｍed．」（１７７、６３７、１９９３年）］。しかしながら、この化合物の治療実用性は、その強い毒性によって制限される。最近、ある種の化合物が上記薬物の魅力のある代替となりうる旨報告されている（たとえばＵ．Ｓ．特許Ｎｏ．５６７０５０４、５６３１２８２、５６９６１５６、５６７９７０５および５６９６１５６参照）。先の薬物の活性／毒性問題の幾つかと取り組むかぎり、これらの化合物は分子量が大きい傾向にあり、かつ一般に、単離が厄介で大きな労働力を要する、天然産出物の合成操作によって製造される。\n\nIn contrast, margatoxin blocks only K \nv\n 1.3 in T-cells and has immunosuppressive activity in both in vitro and in vivo models [Lin et al., “J. exp. Med.” (177 637, 1993)]. However, the therapeutic utility of this compound is limited by its strong toxicity. Recently, it has been reported that certain compounds can be attractive alternatives to the above drugs (see, for example, US Patent Nos. 5670504, 563282, 5696156, 5679705 and 5696156). As long as some of the previous drug activity / toxicity issues are addressed, these compounds tend to be of high molecular weight and are generally produced by synthetic operations on natural products that are cumbersome to isolate and require significant labor.\n\n\n\n\n\n\n \n\n  幅広く種々の自己免疫および慢性炎症性疾患において、免疫調整性異常の存在が認められており、かかる疾患としては、全身性紅斑性狼瘡、慢性関節リウマチ、ＩおよびＩＩ型真性糖尿病、炎症性腸疾患、胆汁性肝硬変、ブドウ膜炎、多発性硬化症および他の障害、たとえばクローン病、潰瘍性大腸炎、水疱性類天疱瘡、サルコイド−シス、乾癬、魚鱗癬、Ｇraves眼障害およびぜん息が包含される。\n\n\n  The presence of immunoregulatory abnormalities has been recognized in a wide variety of autoimmune and chronic inflammatory diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type I and type II diabetes mellitus, inflammatory bowel disease , Including biliary cirrhosis, uveitis, multiple sclerosis and other disorders such as Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves eye disorders and asthma The\n\n\n\n\n\n\n\n \n\n  これら病態のそれぞれの根本的な病因は、全く異なるかもしれないが、それらは共に、種々の自己抗体および自己反応性リンパ球が出現する。かかる自己反応性は、一部分、正常な免疫系が作動する恒常性コントロールのロスに基づくかもしれない。同様に、骨髄または器官の移植の後、宿主リンパ球は異質の組織抗原を受け入れ、そして、移植拒絶に導く抗体を産生し始める。\n\n\n  Although the underlying etiology of each of these pathologies may be quite different, they both manifest various autoantibodies and autoreactive lymphocytes. Such self-reactivity may be based in part on the loss of homeostatic control by which the normal immune system operates. Similarly, after bone marrow or organ transplantation, host lymphocytes accept foreign tissue antigens and begin to produce antibodies that lead to transplant rejection.\n\n\n\n\n\n\n\n \n\n  自己免疫または拒絶プロセスの終止結果の１つは、炎症性細胞とそれらが放出するメディエイタによって起こる組織破壊である。ＮＳＡＩＤ’ｓなどの抗炎症性作用物質は主に、これらのメディエイタの作用あるいは分泌をブロックするが、疾患の免疫学的根拠を改変することは何もしないことによって作用する。これに反して、シクロホスファミドなどの細胞毒作用物質は、正常および自己免疫レスポンスの両方がさえぎられるような非特異的な仕方で作用する。実際に、このような非特異的免疫抑制性作用物質で処置された患者は、その自己免疫疾患による場合と同様に感染によっても倒れるようである。\n\n\n  One consequence of termination of the autoimmune or rejection process is tissue destruction caused by inflammatory cells and the mediators they release. Anti-inflammatory agents such as NSAID's act primarily by blocking the action or secretion of these mediators, but doing nothing to alter the immunological basis of the disease. On the other hand, cytotoxic agents such as cyclophosphamide act in a non-specific manner such that both normal and autoimmune responses are blocked. Indeed, patients treated with such non-specific immunosuppressive agents appear to fall down by infection as well as by their autoimmune disease.\n\n\n\n\n\n\n\n \n\n  シクロスポリンＡ（ＣｓＡ）は、１９８３年にＵＳ  ＦＤＡで承認されたが、今では、移植器官の拒絶を防止するのに用いられる主な薬物である。１９９３年に、ＦＫ−５０６（Ｐrograf）が、肝臓移植における拒絶予防用として、ＵＳ  ＦＤＡによって承認された。ＣｓＡおよびＦＫ−５０６は、体の免疫系が、移植片の異質たん白を拒絶する自然保護作用物質のその広大な蓄積を動員するのを阻害することによって作用する。１９９４年に、ＣｓＡはきびしい乾癬の処置用として、ＵＳ  ＦＤＡによって承認され、かつアトピー性皮膚炎の処置用として、ヨーロッパ調整部局で承認されている。それらは移植拒絶と戦うのに有効であるが、ＣｓＡおよびＦＫ−５０６は、腎毒性、神経毒性および胃腸不快を含む幾つかの望ましくない副作用を起こすことが知られている。従って、これらの副作用のない選択的な免疫抑制薬が、なお開発されている状態にある。カリウムチャネル阻害薬は、この問題の解決となる見込みがある。\n\n\n  Cyclosporine A (CsA), approved by the US FDA in 1983, is now the main drug used to prevent transplant rejection. In 1993, FK-506 (Prograf) was approved by the US FDA for prevention of rejection in liver transplantation. CsA and FK-506 act by inhibiting the body's immune system from mobilizing its vast accumulation of natural protective agents that reject the foreign protein of the graft. In 1994, CsA was approved by the US FDA for the treatment of severe psoriasis and approved by the European Regulatory Authority for the treatment of atopic dermatitis. Although they are effective in combating transplant rejection, CsA and FK-506 are known to cause several undesirable side effects including nephrotoxicity, neurotoxicity and gastrointestinal discomfort. Therefore, selective immunosuppressive drugs without these side effects are still being developed. Potassium channel inhibitors are likely to solve this problem.\n\n\n\n\n\n\n\n \n\n  心房細動（ＡＦ）および心房粗動は、臨床業務における最も普通の不整脈であり、母集団の老化による有病率が増すと思われる。目下、ＡＦは毎年１００万以上のアメリカ人に影響を及ぼし、心臓血管病として全認可の５％以上を示し、アメリカ合衆国で各年８００００以上の発作を引き起こす。ＡＦはまれに致命的な不整脈であるが、それは実質的な罹患率が原因であり、そして、うっ血性心不全あるいは血栓塞栓症の発現などの合併症に導きうる。現在入手しうるクラスＩおよびクラスＩＩの抗不整脈薬物は、ＡＦの再発の速度を縮小するが、心室前不整脈を含む種々の潜在的悪影響のため、使用が制限される。現行の療法は不適当で、副作用が伴うので、新しい治療アプローチを開発する必要が明らかにある。\n\n\n  Atrial fibrillation (AF) and atrial flutter are the most common arrhythmias in clinical practice and are likely to increase the prevalence of population aging. Currently, AF affects more than 1 million Americans each year, represents over 5% of all approvals for cardiovascular disease, and causes more than 80000 attacks each year in the United States. AF is rarely a fatal arrhythmia, but it is due to substantial morbidity and can lead to complications such as the development of congestive heart failure or thromboembolism. Currently available class I and class II antiarrhythmic drugs reduce the rate of AF recurrence, but have limited use due to various potential adverse effects including preventricular arrhythmias. Since current therapies are inadequate and have side effects, there is clearly a need to develop new therapeutic approaches.\n\n\n\n\n\n\n\n \n\n  クラスＩＩＩの抗不整脈作用物質は、重大な心機能低下のない、活動電位の持続の選択的延長を起こす薬物である。このクラスの入手しうる薬物は、数に制限がある。ソタロールやアミオダロンなどの実例は、興味を起こさせるクラスＩＩＩ性質を有することが認められているが［Ｓingh  Ｂ．Ｎ．、Ｖaughan  Ｗilliams  Ｅ．Ｍ．の「Ｂｒ．Ｊ．Ｐharmacol．」（３９：６７５−６８９、１９７０年），“第３クラスの抗不整脈作用：ＭＪ１９９９およびＡＨ３７４７の、心房および心室細胞内電位に関する効果と、心筋に関する他の薬理学的作用”；およびＳingh  Ｂ．Ｎ．、Ｖaughan  Ｗilliams  Ｅ．Ｍ．の「Ｂｒ．Ｊ．Ｐharmacol．」（３９：６５７−６６７、１９７０年），“心筋に関する、新しい抗狭心症薬物であるアミオダロンの効果”］、これらは選択的なクラスＩＩＩ作用物質ではない。\n\n\n  Class III antiarrhythmic agents are drugs that cause a selective prolongation of the duration of action potential without significant cardiac decline. There are a limited number of drugs available in this class. Examples such as sotalol and amiodarone have been found to have interesting class III properties [Singh B. et al. N. Vaughan Williams E .; M.M. “Br. J. Pharmacol.” (39: 675-689, 1970), “Class 3 antiarrhythmic effects: effects of MJ1999 and AH3747 on atrial and ventricular intracellular potentials and other pharmacology of the myocardium. ”; And Singh B .; N. Vaughan Williams E .; M.M. “Br. J. Pharmacol.” (39: 657-667, 1970), “Effects of Amiodarone, a New Antianginal Drug on the Myocardium”], these are not selective class III agonists.\n\n\n\n\n\n\n\n \n\n  またソタロールは、心機能低下を起こしうるクラスＩＩ作用を有し、かつ特定の感じやすい患者において禁忌を示す。またアミオダロンも選択的クラスＩＩＩ抗不整脈作用物質でなく、何故なら、多数の電気生理学的作用を有し、かつ副作用によって厳格に制限されるからである［Ｎademanee  Ｋ．の「Ｊ．Ａｍ．Ｃoll．Ｃardiol．」（２０：１０６３−１０６５、１９９２年），“アミオダロン・オデッセイ”］。このクラスの薬物は、心室細動の防止に有効であることが予想される。選択的クラスＩＩＩ作用物質は、定義付け（definition）により、クラスＩ抗不整脈作用物質の場合に見られる活動電位の伝導の阻害に基づき、心筋層の機能低下あるいは不整脈の誘発を起こすとは考えられない。\n\n\n  Also, sotalol has a class II action that can cause decreased cardiac function and is contraindicated in certain susceptible patients. Amiodarone is also not a selective class III antiarrhythmic agent because it has numerous electrophysiological effects and is severely limited by side effects [Nademanee K. et al. \"J. Am. Coll. Cardiol.\" (20: 1063-1065, 1992), \"Amiodarone Odyssey\"]. This class of drugs is expected to be effective in preventing ventricular fibrillation. Selective class III agonists, by definition, are thought to cause myocardial hypofunction or induction of arrhythmias based on the inhibition of action potential conduction seen with class I antiarrhythmic agents. Absent.\n\n\n\n\n\n\n\n \n\n  クラスＩＩＩ作用物質は、心活動電位持続の延長を介して、心筋層の治療抵抗性を増加する。理論上、心活動電位の延長は、内部電流（すなわち、Ｎａ\n+\nまたはＣａ\n2+\n電流で、以下それぞれＩ\nNa\nおよびＩ\nca\nと称す）を上げるか、または外部再分極カリウム（Ｋ\n+\n）電流を下げることによって達成することができる。遅延整流器（Ｉ\nK\n）Ｋ\n+\n電流は、活動電位安定期中の全再分極プロセスで必要とされる主要外部電流であるのに対し、一時的外部（Ｉ\nto\n）および内部整流器（Ｉ\nKI\n）Ｋ\n+\n電流はそれぞれ、再分極の急速初期および末端位相の責を負う。細胞の電気生理学的実験は、Ｉ\nK\nが２つの薬理学的および動力学的に異なるＫ\n+\n電流亜類型の、Ｉ\nKr\n（急速活性化および非活性化）およびＩ\nKs\n（低速活性化および非活性化）から成ることを証明している［ＳanguinettiおよびＪurkiewiczの「Ｊ．Ｇen．Ｐhysiol．」（９６：１９５−２１５、１９９０年），“心臓の遅延整流器Ｋ\n+\n電流の２成分：クラスＩＩＩ抗不整脈作用物質によるブロックに対する示差感受性”］。\n\nClass III agents increase myocardial treatment resistance through prolongation of cardiac action potential duration. Theoretically, an increase in cardiac action potential increases the internal current (ie, Na \n+\n or Ca \n2+\n current, hereinafter referred to as I \nNa\n and I \nca\n , respectively) or decreases the external repolarized potassium (K \n+\n ) current. Can be achieved. The delayed rectifier (I \nK\n ) K \n+\n current is the main external current required for the entire repolarization process during action potential stabilization, whereas the transient external (I \nto\n ) and internal rectifier (I \nKI\n ) K \n+\n Each current is responsible for the rapid initial and terminal phases of repolarization. Cell electrophysiological experiments have shown that I \nK\n is two pharmacologically and kinetically distinct K \n+\n current subtypes, I \nKr\n (rapid activation and deactivation) and I \nKs\n (slow activation and deactivation). [Sanguinetti and Jurkiewicz, “J. Gen. Physiol.” (96: 195-215, 1990), “Delayed Rectifier K \n+\n Current in Two Components: Class III Antiarrhythmia] “Differential sensitivity to blocking by agents”].\n\n\n\n\n\n\n \n\n  現在開発中のクラスＩＩＩ抗不整脈作用物質として、ｄ−ソタロール、ドフェチリド（dofetilide）（ＵＫ−６８７９８）、アルモカラント（almokalant）（Ｈ−２３４／０９）、Ｅ−４０３１およびメタンスルホンアミド−Ｎ−［１’−６−シアノ−１，２，３，４−テトラヒドロ−２−ナフタレニル）−３，４−ジヒドロ−４−ヒドロキシスピロ［２Ｈ−１−ベンゾピラン−２，４’−ピペリジン］−６−イル］モノクロリドが含まれるが、これらは、排泄的でなくても、Ｉ\nKr\nを支配的にブロックする。アミオダロンはＩ\nKs\nの遮断薬ではあるが［Ｂalser  Ｊ．Ｒ．、Ｂennett  Ｐ．Ｂ，Ｈondeghem  Ｌ．Ｍ．およびＲoden  Ｄ．Ｍ．の「Ｃirc．Ｒes．」（６９：５１９−５２９、１９９１年），“モルモットの心室筋細胞における時間依存性外部電流の抑制：キニジンおよびアミオダロンの作用”］、それはまた、Ｉ\nNa\nおよびＩ\nca\nをブロックし、非特異的アドレナリン作用遮断薬のように甲状腺機能を果たし、かつ酵素ホスホリパーゼの阻害薬として作用する［Ｎademanee  Ｋ．の「Ｊ．Ａｍ．Ｃoll．Ｃardiol．」（２０：１０６３−１０６５、１９９２年），“アミオダロン・オデッセイ”］。従って、その不整脈を処置する方法は不確定である。開発中であることが知られているクラスＩＩＩ作用物質のほとんどは、支配的にＩ\nKr\nをブロックする。\n\nClass III antiarrhythmic agents currently under development include d-sotalol, dofetilide (UK-68798), alumokalant (H-234 / 09), E-4031 and methanesulfonamide-N- [ 1′-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl) -3,4-dihydro-4-hydroxyspiro [2H-1-benzopyran-2,4′-piperidin] -6-yl Monochlorides are included, but these predominantly block I \nKr\n even if not excretory. Amiodarone is a blocker of I \nKs\n is [Balser J. R. Bennett P .; B, Hondeghem L. M.M. And Roden D.C. M.M. “Circ. Res.” (69: 519-529, 1991), “Suppression of time-dependent external currents in guinea pig ventricular myocytes: the action of quinidine and amiodarone”], which also demonstrated I \nNa\n and I \nca.\n Blocks, performs thyroid function like a nonspecific adrenergic blocker, and acts as an inhibitor of the enzyme phospholipase [Nademanee K. et al. \"J. Am. Coll. Cardiol.\" (20: 1063-1065, 1992), \"Amiodarone Odyssey\"]. Therefore, the method for treating the arrhythmia is indeterminate. Most class III agents known to be in development predominantly block I \nKr\n .\n\n\n\n\n\n\n \n\n  凹部（reentrant）刺激（リエントリー）は、人間の上室不整脈の根底にある顕著なメカニズムであることが認められている。凹部刺激は、同時に共存してＡＦを維持する多様なリエントリー回路の開始およびメインテナンスを可能ならしめる、遅い伝導速度と十分に短い治療抵抗期間の臨界バランスを要する。活動電位持続（ＡＰＤ）の延長による心筋層治療抵抗性の増加は、凹部不整脈を防止しおよび／または終わらせる。現在開発中の選択的クラスＩＩＩ抗不整脈作用物質のほとんど、たとえばｄ−ソタロールおよびドフェチリドは、排他的でなくても、Ｉ\nKr\n（ヒト房および室の両方で見られるＩ\nK\nの急速活性化成分）を支配的にブロックする。\n\nReentrant stimulation (re-entry) has been recognized as a prominent mechanism underlying human supraventricular arrhythmias. Recess stimulation requires a critical balance of slow conduction velocity and a sufficiently short treatment resistance period that allows for the initiation and maintenance of various reentry circuits that co-exist and maintain AF at the same time. Increased myocardial treatment resistance by prolonging action potential duration (APD) prevents and / or terminates recess arrhythmias. Most of the selective class III antiarrhythmic agents currently under development, such as d-sotalol and dofetilide, if not exclusive, are I \nKr\n (a rapidly activating component of I \nK\n found in both human tufts and chambers) Block dominantly.\n\n\n\n\n\n\n \n\n  これらのＩ\nKr\n遮断薬は、伝導そのものに影響を及ぼさずに、房および室の両方でのＡＰＤおよび治療抵抗性を増加するので、理論上、それらはＡＦのような不整脈の処置用として可能性のある有用な作用物質に相当する。これらの作用物質は、心拍数が遅いとき前不整脈の危険が高いという不都合を有する。たとえば、これらの化合物を利用すると、トルサード・ド・ポワント（心室頻拍の発作）が見られる［Ｒoden  Ｄ．Ｍ．の「Ａｍ．Ｊ．Ｃardiol．」（７２：４４Ｂ−４９Ｂ、１９９３年），“クラスＩＩＩ抗不整脈薬物療法の電流状態”］。この遅い心拍数での誇張した作用は、“逆頻度（reverse  frequency）−依存”と呼ばれており、頻度−独立もしくは頻度−依存の作用と対照をなす［Ｈondeghem  Ｌ．Ｍ．の「Ｊ．Ｃadiovasc．Ｃardiol．」（２０（Ｓuppl．２）：Ｓ１７−Ｓ２２），“クラスＩＩＩ抗不整脈作用物質の開発”］。\n\nThese I \nKr\n blockers increase APD and treatment resistance in both the chamber and chamber without affecting the conduction itself, so in theory they are potential for the treatment of arrhythmias such as AF. It corresponds to a certain useful agent. These agents have the disadvantage that the risk of prearrhythmia is high when the heart rate is slow. For example, when these compounds are used, torsades de pointes (attack of ventricular tachycardia) are seen [Roden D. et al. M.M. \"Am. J. Cardiol.\" (72: 44B-49B, 1993), \"Current Status of Class III Antiarrhythmic Drug Therapy\"]. This exaggerated effect at slow heart rate is called “reverse frequency-dependent” and contrasts with frequency-independent or frequency-dependent effects [Hondeghem L. et al. M.M. “J. Cadiovasc. Cardiol.” (20 (Suppl. 2): S17-S22), “Development of Class III Antiarrhythmic Agents”].\n\n\n\n\n\n\n \n\n  遅延整流器（Ｉ\nKs\n）の遅く活性化する成分は、心室不整脈に関連するＩ\nKr\n遮断薬の幾つかの制限を潜在的に克服する。しかしながら、心房再分極におけるＩ\nKs\nの役割は、その遅い活性化動態のために、房の比較的短いＡＰＤに基づき制限されるかもしれない。結果として、Ｉ\nKs\n遮断薬は心室不整脈の場合に明瞭な利点を付与しうるが、それらのＳＶＴに作用する能力は、最小限であるとみなされる。\n\nThe late activating component of the delayed rectifier (I \nKs\n ) potentially overcomes some of the limitations of I \nKr\n blockers associated with ventricular arrhythmias. However, the role of I \nKs\n in atrial repolarization may be limited due to its relatively short APD due to its slow activation kinetics. As a result, I \nKs\n blockers may provide a clear advantage in the case of ventricular arrhythmias, but their ability to act on SVT is considered minimal.\n\n\n\n\n\n\n \n\n  超急速に活性化する遅延整流器Ｋ\n+\n電流（Ｉ\nKur\n）は、クローン化カリウムチャネル（Ｋ\nv\n１．５指定）の自然のままの対応品に相当すると思われ、そしてそれは、ヒトの房には存在するが、ヒトの室には存在しないようである。さらに、Ｉ\nKur\nは、その活性化の急速と限られた遅い不活性化のために、ヒト房における再分極にかなり寄与すると思われる。結果として、Ｉ\nKur\nの特異的遮断薬、すなわち、Ｋ\nv\n１．５をブロックする化合物は、今のクラスＩＩＩ薬物による処置中に見られる脱分極および後天的な長いＱＴ症候群後の不整脈惹起性の根底にある、心室再分極における遅延を起こすことなく、ヒト房の再分極を阻止して治療抵抗を長くすることにより、他の化合物の短い到来（coming）を克服するだろう。\n\nThe ultra-rapidly activated delayed rectifier K \n+\n current (I \nKur\n ) appears to represent the natural counterpart of the cloned potassium channel (K \nv\n 1.5 designation), which is It exists but seems not to exist in the human chamber. Furthermore, I \nKur\n appears to contribute significantly to repolarization in the human chamber due to its rapid activation and limited slow inactivation. As a result, a specific blocker of I \nKur\n , a compound that blocks K \nv\n 1.5, has been shown to be arrhythmogenic after the depolarization and acquired long QT syndrome seen during treatment with current class III drugs. By preventing human chamber repolarization and increasing treatment resistance without causing an underlying delay in ventricular repolarization, the short arrival of other compounds would be overcome.\n\n\n\n\n\n\n \n\n  ヒトの無傷で完全な心房筋細胞において、超急速に活性化する遅延整流器Ｋ\n+\n電流（Ｉ\nKur\n（維持された外部電流の、Ｉ\nsus\nまたはＩ\nso\nとしても公知）が同定され、この電流は、ヒトの心臓から単離され、かつヒト（ＨＥＫ−２９３）細胞系で安定して発現され［Ｗangらの「Ｃirc．Ｒes．」（７３：１０６１−１０７６、１９９３年）；Ｆedidaらの「Ｃirc．Ｒes．」（７３：２１０−２１６、１９９３年）；Ｓnydersらの「Ｊ．Ｇen．Ｐhysiol．」（１０１：５１３−５４３、１９９３年）］、そしてラットの脳から最初にクローン化されたとき［Ｓwansonらの「Ｎeuron」（４：９２９−９３９、１０月）］、ヒトＫ\n+\nチャネルクローン（ｈＫ\nv\n１．５，ＨＫ２）によって発現されるものと同一の性質および動態を有する。\n\nIn intact full atrial muscle cells of human, the ultra-rapid delayed rectifier K \n+\n current that activates (I \nKur\n (sustained external current, also known) are identified as I \nsus\n or I \nso,\n this current, Isolated from the human heart and stably expressed in human (HEK-293) cell lines [Wang et al., “Circ. Res.” (73: 1061-1076, 1993); Fedida et al., “Circ. Res. \"(73: 210-216, 1993); Snyders et al.,\" J. Gen. Physiol. \"(101: 513-543, 1993)], and when first cloned from rat brain [ Swanson et al. “Neuron” (4: 929-939, October)], with the same properties and kinetics as expressed by the human K \n+\n channel clone (hK \nv\n 1.5, HK2).\n\n\n\n\n\n\n \n\n  種々の抗不整脈作用物質は現在、市場で入手しうるが、満足な効力とマージンの高い安全性の両方を有するものは、得られていない。たとえば、Ｖaughan−Ｗilliamsの分類大系［Ｅ．Ｓandoe、Ｅ．Ｆlensted−Ｊensen、Ｋ．Ｏlesen著「Ｃardiac  Ａrrhythmias」（スウェーデン、アストラ、Ｓodertalje、４４９−４７２頁、１９８１年），“抗不整脈薬物の分類”］による、クラスＩの抗不整脈作用物質は、活動電位の上昇行程の最大速度（max）の選択的阻害を起こすが、心室細動の防止には不適当である。\n\n\n  A variety of antiarrhythmic agents are currently available on the market, but none have both satisfactory efficacy and high margin safety. For example, Vaughan-Williams taxonomy [E. Sandoe, E.M. Flensted-Jensen, K.M. According to Olesen's “Cardiac Arrhythmias” (Astra, Sodertalje, 449-472, 1981), “Classification of Antiarrhythmic Drugs”], class I antiarrhythmic agents have a maximum rate of action potential increase ( max), but is inappropriate for prevention of ventricular fibrillation.\n\n\n\n\n\n\n\n \n\n  加えて、それらは安全性に関して問題を有し、すなわち、それらは心筋収縮性の機能低下を引き起こし、かつインパルス伝導の阻害のため、不整脈を誘発する傾向にある。それぞれクラスＩＩおよびＩＶに属する、ベータ−アドレノセプタ遮断薬およびカルシウム拮抗薬は、心臓血管病を持つ一定患者におけるその心機能低下性質のために、その効果が特定種の不整脈に制限されるか、または禁忌を示すという欠点を有する。しかして、それらの安全性は、クラスＩの抗不整脈作用物質のそれよりも高い。\n\n\n  In addition, they have safety issues, i.e., they tend to cause myocardial contractile hypofunction and to induce arrhythmias due to the inhibition of impulse conduction. Beta-adrenoceptor blockers and calcium antagonists, belonging to classes II and IV, respectively, have their effects limited to certain types of arrhythmias due to their hypocardiographic properties in certain patients with cardiovascular disease, or Has the disadvantage of showing contraindications. Thus, their safety is higher than that of class I antiarrhythmic agents.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明は、不整脈やＩ\nKur\n−関連障害などの障害の処置のため、カリウムチャネル機能の阻害薬（特に電位ゲートＫ\n+\nチャネルのＫ\nv\n１サブファミリーの阻害薬、とりわけ超急速に活性化する遅延整流器Ｋ\n+\n電流，Ｉ\nKur\nにリンクしたＫ\nv\n１．５の阻害薬）として有用な、下記式Ｉで示されるシクロアルキル化合物（そのエナンチオマー、ジアステレオマーおよび塩を含む）を提供する。\n\n\n \n \n\n\nThe present invention relates to inhibitors of potassium channel function (especially inhibitors of the K \nv\n 1 subfamily of voltage-gated K \n+\n channels, especially ultra-rapidly activated delays, for the treatment of disorders such as arrhythmias and I \nKur\n -related disorders. Provided are cycloalkyl compounds of the formula I below, including enantiomers, diastereomers and salts thereof, useful as rectifier K \n+\n currents, inhibitors of K \nv\n 1.5 linked to I \nKur\n . \n \n \n \n \n\n\n\n\n\n\n \n\n  式中、破線は任意の二重結合、但し、二重結合が存在するとき、Ｒ\n1a\nは存在せず；\n\n  ｍおよびｐはそれぞれ独立して、０、１、２または３；\n\n  Ｒ\n1\nは\n\n\n \n \n\n任意に置換されるアリール、任意に置換されるヘテロアリール、任意に置換されるヘテロシクロ、ハロ、パーフルオロアルキル、シアノ、ニトロ、ヒドロキシ、任意に置換されるアルコキシ、任意に置換されるアリールオキシ、任意に置換されるヘテロアリールオキシ、任意に置換されるアルキル、任意に置換されるアルケニル、または任意に置換されるアルキニル；\n\nWhere the dashed line is any double bond, provided that when a double bond is present, R \n1a\n is not present; \n m and p are each independently 0, 1, 2, or 3; \n R \n1\n is \n \n \n \n Optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, halo, perfluoroalkyl, cyano, nitro, hydroxy, optionally substituted alkoxy, optionally substituted aryloxy, optional Heteroaryloxy substituted with, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;\n\n\n\n\n\n\n \n\n  Ｒ\n1a\nはＨ、またはＲ\nX\nの定義で列挙した基、またはＲ\n1\nとＲ\n1a\nは共に合して、オキソを形成、あるいはＲ\n1\nとＲ\n1a\nはそれらが結合する炭素原子と共に合して、任意に置換されるスピロ−縮合ヘテロシクロ基を形成、あるいはＲ\n1\nとＲ\n1a\nは共に合して、\n\n\n \n \n\nの基を形成；\n\n  Ｒ\n2\nはヘテロアリール、（ヘテロアリール）アルキル、アリール、（アリール）アルキル、ヘテロシクロ、（ヘテロシクロ）アルキル、アルキル、アルケニルまたはシクロアルル（これらのいずれも独立して、Ｔ\n1\n、Ｔ\n2\nまたはＴ\n3\nの基の１個以上で任意に置換されてよい）；\n\n  Ｊは結合、独立してＴ\n1a\n、Ｔ\n2a\nまたはＴ\n3a\nの基の１個以上で任意に置換されるＣ\n1-4\nアルキレン、または独立してＴ\n1a\n、Ｔ\n2a\nまたはＴ\n3a\nの基の１個以上で任意に置換されるＣ\n1-4\nアルケニレン；\n\nR \n1a\n is H or a group listed in the definition of R \nX\n , or R \n1\n and R \n1a\n together form an oxo, or R \n1\n and R \n1a\n together with the carbon atom to which they are attached, Or a spiro-fused heterocyclo group substituted with R \n1\n and R \n1a\n together \n \n \n \n Forming a group of \n R \n2\n is heteroaryl, (heteroaryl) alkyl, aryl, (aryl) alkyl, heterocyclo, (heterocyclo) alkyl, alkyl, alkenyl or cycloalkyl (all of which are independently a group of T \n1\n , T \n2\n or T \n3\n Optionally substituted with one or more of \n J is a bond, independently C \n1-4\n alkylene optionally substituted with one or more of the groups T \n1a\n , T \n2a\n or T \n3a\n , or independently one of the groups T \n1a\n , T \n2a\n or T \n3a\n A C \n1-4\n alkenylene optionally substituted as above;\n\n\n\n\n\n\n \n\n  Ｒ\n3\nは\n\n\n \n \n\n  Ｒ\n4\nはアルキル、ハロアルキル、アルケニル、シクロアルキル、ヘテロシクロ、アリールまたはヘテロアリール（これらのいずれも独立して、Ｔ\n1b\n、Ｔ\n2b\nまたはＴ\n3b\nの基の１個以上で任意に置換されてよい）；\n\n  Ｒ\n4a\nはＲ\n4\nまたはＯＲ\n4\n；\n\nR \n3\n is \n \n \n \n R \n4\n is alkyl, haloalkyl, alkenyl, cycloalkyl, heterocyclo, aryl or heteroaryl, any of which may be optionally substituted with one or more of T \n1b\n , T \n2b\n or T \n3b\n groups; \n R \n4a\n is R \n4\n or OR \n4\n ;\n\n\n\n\n\n\n \n\n  Ｒ\n5\nは−ＮＲ\n6a\nＲ\n7a\n、ヘテロアリール、（ヘテロアリール）アルキル、アリール、（アリール）アルキル、アルキル、シクロアルキル、（シクロアルキル）アルキル、ヘテロシクロ、（ヘテロシクロ）アルキル、アルキル、アルケニルまたはアルキニル（これらのいずれも独立して、Ｔ\n1c\n、Ｔ\n2c\nまたはＴ\n3c\nの基の１個以上で任意に置換されてよい）；\n\n  Ｒ\n6\n，Ｒ\n6a\n，Ｒ\n7\n，Ｒ\n7a\n，Ｒ\n8\n，Ｒ\n8a\n，Ｒ\n8a1\n，Ｒ\n8a2\n，Ｒ\n8a3\n，Ｒ\n8a4\n，Ｒ\n8a5\nおよびＲ\n9\nはそれぞれ独立して、Ｈ、アルキル、ヒドロキシ、アルコキシ、アリールオキシ、ヘテロシクロオキシ、ヘテロアリールオキシ、（ヒドロキシ）アルキル、（アルコキシ）アルキル、（アリールオキシ）アルキル、（ヘテロシクロオキシ）アルキル、（ヘテロアリールオキシ）アルキル、（シアノ）アルキル、（アルケニル）アルキル、（アルキニル）アルキル、シクロアルキル、（シクロアルキル）アルキル、アリール、（アリール）アルキル、ヘテロアリール、（ヘテロアリール）アルキル、ヘテロシクロ、（ヘテロシクロ）アルキル、−Ｃ（Ｏ）Ｒ\n12\n、−ＣＯ\n2\nＲ\n12\n、−Ｃ（Ｏ）−ＮＲ\n12\nＲ\n13\nまたは−ＮＲ\n12\nＲ\n13\n（これらのいずれも独立して、Ｔ\n1d\n、Ｔ\n2d\nまたはＴ\n3d\nの基の１個以上で任意に置換されてよい）、\n\n  またはＲ\n6\nとＲ\n7\n、またはＲ\n6a\nとＲ\n7a\nは共に、それらが結合する窒素原子と合して、独立してＴ\n1d\n、Ｔ\n2d\nまたはＴ\n3d\nの基の１個以上で任意に置換される飽和または不飽和の４〜８員環（シクロアルキルまたはヘテロシクロのいずれか）を形成、\n\n  またはＲ\n6\nもしくはＲ\n7\nの１つはＲ\n8\n、Ｒ\n8a\nもしくはＲ\n9\nの１つと共に合して、独立してＴ\n1d\n、Ｔ\n2d\nまたはＴ\n3d\nの基の１個以上で任意に置換される飽和または不飽和の５〜８員環（シクロアルキルまたはヘテロシクロのいずれか）を形成、\n\n  またはＲ\n6a\nもしくはＲ\n7a\nの１つはＲ\n8a1\nと共に合して、独立してＴ\n1d\n、Ｔ\n2d\nまたはＴ\n3d\nの基の１個以上で任意に置換される飽和または不飽和の５〜８員環（シクロアルキルまたはヘテロシクロのいずれか）を形成；\n\nR \n5\n is —NR \n6a\n R \n7a\n , heteroaryl, (heteroaryl) alkyl, aryl, (aryl) alkyl, alkyl, cycloalkyl, (cycloalkyl) alkyl, heterocyclo, (heterocyclo) alkyl, alkyl, alkenyl or alkynyl (these Any of which may be optionally substituted with one or more of the groups T \n1c\n , T \n2c\n or T \n3c\n ); \n \n \n \nR 6, R 6a, R 7\n \n \n , R 7a, R 8, R 8a, R 8a1, R 8a2, R 8a3, R 8a4, R 8a5 and R \n9\n are each, independently, H, alkyl, hydroxy, alkoxy, aryl Oxy, heterocyclooxy, heteroaryloxy, (hydroxy) alkyl, (alkoxy) alkyl, (aryloxy) alkyl, (heterocyclooxy) alkyl, (heteroaryloxy) alkyl, (cyano) alkyl, (alkenyl) alkyl, (Alkynyl) alkyl, cycloalkyl, (cycloalkyl) alkyl, aryl, (aryl) alkyl, heteroaryl, (heteroaryl) alkyl, heterocyclo, (heterocyclo) alkyl, —C (O) R \n12\n , —CO \n2\n R \n12\n , —C (O) —NR \n12\n R \n13\n or —NR \n12\n R \n13\n (both of which are independently , Optionally substituted with one or more of T \n1d\n , T \n2d\n or T \n3d\n groups), \n Or R \n6\n and R \n7\n , or R \n6a\n and R \n7a\n , together with the nitrogen atom to which they are attached, are optionally substituted independently with one or more of the groups T \n1d\n , T \n2d,\n or T \n3d.\n Forming a saturated or unsaturated 4- to 8-membered ring (either cycloalkyl or heterocyclo), \n Or one of R \n6\n or R \n7\n together with one of R \n8\n , R \n8a\n or R \n9\n is independently saturated optionally substituted with one or more of the groups T \n1d\n , T \n2d\n or T \n3d\n Or form an unsaturated 5- to 8-membered ring (either cycloalkyl or heterocyclo), \n Or one of R \n6a\n or R \n7a\n together with R \n8a1\n is independently a saturated or unsaturated 5- to 8-membered ring optionally substituted with one or more of T \n1d\n , T \n2d\n or T \n3d\n groups Forming (either cycloalkyl or heterocyclo);\n\n\n\n\n\n\n \n\n  Ｒ\n8b\nは独立して、Ｈ、アルキル、アリール、シアノ、ニトロ、アシルまたは−ＳＯ\n2\n（アルキル）；\n\n  Ｒ\n8c\nは独立して、Ｈ、アルキル、シクロアルキル、アルケニル、アルキニル、アリール、アリールアルキル、シクロヘテロアルキル、ヘテロアリール、アミノまたはアルコキシ；\n\n  Ｒ\n8d\nはＲ\n4\n、ＣＯＲ\n4\n、ＣＯ\n2\nＲ\n4\n、ＳＯ\n2\nＲ\n4\n、ＣＯＮＲ\n6\nＲ\n7\n、またはＳＯ\n2\n−ＮＲ\n6\nＲ\n7\n；\n\n  Ｒ\n10\n，Ｒ\n10a\n，Ｒ\n11\nおよびＲ\n11a\nはそれぞれ独立して、Ｈ、アルキル、アリール、（アリール）アルキル、アルコキシ、（アルコキシ）アルキル、ハロ、ヒドロキシ、（ヒドロキシ）アルキル、アミノ、アミド、ヘテロアリール、（ヘテロアリール）アルキル、ヘテロシクロ、（ヘテロシクロ）アルキル、スルホンアミド、シクロアルキル、（シクロアルキル）アルキルまたはシアノ（これらのいずれも独立して、Ｔ\n1e\n、Ｔ\n2e\nまたはＴ\n3e\nの基の１個以上で有効原子（原子価によって可能）が任意に置換されてよい）、\n\n  またはＲ\n10\nとＲ\n10a\n、またはＲ\n11\nとＲ\n11a\nは共に合して、オキソを形成、\n\n  またはＲ\n10a\nはＲ\n11a\nと共に合して、結合を形成、\n\n  またはＲ\n10\nはＲ\n9\nと共に合して、飽和または不飽和環を形成；\n\nR \n8b\n is independently H, alkyl, aryl, cyano, nitro, acyl or —SO \n2\n (alkyl); \n R \n8c\n is independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloheteroalkyl, heteroaryl, amino or alkoxy; \n R \n8d\n is R \n4\n , COR \n4\n , CO \n2\n R \n4\n , SO \n2\n R \n4\n , CONR \n6\n R \n7\n , or SO \n2\n —NR \n6\n R \n7\n ; \n R \n10\n , R \n10a\n , R \n11\n and R \n11a\n are each independently H, alkyl, aryl, (aryl) alkyl, alkoxy, (alkoxy) alkyl, halo, hydroxy, (hydroxy) alkyl, amino, amide, heteroaryl , (Heteroaryl) alkyl, heterocyclo, (heterocyclo) alkyl, sulfonamido, cycloalkyl, (cycloalkyl) alkyl or cyano, each independently one or more of the groups T \n1e\n , T \n2e\n or T \n3e\n Effective atoms (possible by valence) may be optionally substituted), \n Or R \n10\n and R \n10a\n , or R \n11\n and R \n11a\n together form an oxo; \n Or R \n10a\n together with R \n11a\n forms a bond; \n Or R \n10\n together with R \n9\n forms a saturated or unsaturated ring;\n\n\n\n\n\n\n \n\n  Ｒ\n12\nおよびＲ\n13\nはそれぞれ独立して、Ｈ、アルキル、ヒドロキシ、アルコキシ、アリールオキシ、ヘテロシクロオキシ、ヘテロアリールオキシ、（ヒドロキシ）アルキル、（アルコキシ）アルキル、（アリールオキシ）アルキル、（ヘテロシクロオキシ）アルキル、（ヘテロアリールオキシ）アルキル、シクロアルキル、（シクロアルキル）アルキル、アリール、（アリール）アルキル、ヘテロアリール、（ヘテロアリール）アルキル、ヘテロシクロまたは（ヘテロシクロ）アルキル（これらのいずれも独立して、Ｔ\n1f\n、Ｔ\n2f\nまたはＴ\n3f\nの基の１個以上で任意に置換されてよい）、\n\n  またはＲ\n12\nとＲ\n13\nは共に、それらが結合する窒素原子と合して、独立してＴ\n1f\n、Ｔ\n2f\nまたはＴ\n3f\nの基の１個以上で任意に置換される飽和または不飽和環（シクロアルキルまたはヘテロシクロのいずれか）を形成；\n\n  Ｗは＝ＮＲ\n8a2\n、＝Ｎ−ＣＯ\n2\nＲ\n8a2\n、＝Ｎ−ＣＯＲ\n8a2\n、＝Ｎ−ＣＮ、または＝Ｎ−ＳＯ\n2\nＲ\n8a2\n；\n\nR \n12\n and R \n13\n are each independently H, alkyl, hydroxy, alkoxy, aryloxy, heterocyclooxy, heteroaryloxy, (hydroxy) alkyl, (alkoxy) alkyl, (aryloxy) alkyl, (heterocyclooxy ) Alkyl, (heteroaryloxy) alkyl, cycloalkyl, (cycloalkyl) alkyl, aryl, (aryl) alkyl, heteroaryl, (heteroaryl) alkyl, heterocyclo or (heterocyclo) alkyl, each of which is independently Optionally substituted with one or more of T \n1f\n , T \n2f\n or T \n3f\n groups), \n Or R \n12\n and R \n13\n together with the nitrogen atom to which they are attached, independently a saturated or unsaturated ring (cyclo) optionally substituted with one or more of T \n1f\n , T \n2f\n or T \n3f\n groups. Forming either alkyl or heterocyclo); \n W is \n= NR 8a2, = N-CO\n 2 R 8a2, = N-COR 8a2, = N-CN or \n \n= N-SO 2 R 8a2,\n \n ;\n\n\n\n\n\n\n \n\n  Ｘは\n\n\n \n \n\n  Ｚ，Ｚ\n1\nおよびＺ\n2\nはそれぞれ独立して、＝Ｏ、＝Ｓ、＝ＮＲ\n8a4\nまたは＝Ｎ−ＣＮ；\n\n  Ｒ\n14\nは独立して、\n\n\n \n \n\n、ここで、ｑは１、２または３、\n\n  Ｒ\nY\nは環中のいずれかの有効炭素原子に結合する任意のオキソ置換基、\n\n  Ｘ\n1\nはＯ、Ｓ、ＮＲ\n8a5\nまたはＣＨ\n2\n、および\n\n  Ｘ\n2\nはＮＲ\n8a5\nまたはＣＨ\n2\n；\n\nX is \n \n \n \n Z, Z \n1\n and Z \n2\n are each independently ═O, ═S, ═NR \n8a4\n or \n═N\n —CN; \n R \n14\n is independently \n \n \n \n Where q is 1, 2 or 3, \n R \nY\n is any oxo substituent attached to any available carbon atom in the ring; \n X \n1\n is O, S, NR \n8a5\n or CH \n2\n , and X \n2\n is NR \n8a5\n or CH \n2\n ;\n\n\n\n\n\n\n \n\n  Ｒ\nX\nは環中のいずれかの有効炭素原子に結合する、独立してＴ\n1g\n、Ｔ\n2g\nまたはＴ\n3g\nから選ばれる１個以上の任意の置換基；\n\n  Ｔ\n1-1g\n、Ｔ\n2-2g\nおよびＴ\n3-3g\nはそれぞれ独立して、\n\n  （１）水素またはＴ\n6\n、ここで、Ｔ\n6\nは\n\n    （ｉ）アルキル、（ヒドロキシ）アルキル、（アルコキシ）アルキル、アルケニル、    アルキニル、シクロアルキル、（シクロアルキル）アルキル、シクロアルケニル、（    シクロアルケニル）アルキル、アリール、（アリール）アルキル、ヘテロシクロ、（    ヘテロシクロ）アルキル、ヘテロアリール、または（ヘテロアリール）アルキル、\n\n    （ｉｉ）それ自体が同一もしくは異なる基（ｉ）の１個以上で置換された基（ｉ）、    または\n\n    （ｉｉｉ）Ｔ\n1-1g\n、Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中の下記基（２）〜（１３）の    １個以上（好ましくは１〜３個）で独立して置換された基（ｉ）または（ｉｉ）、\n\n  （２）−ＯＨまたは−ＯＴ\n6\n、\n\n  （３）−ＳＨまたは−ＳＴ\n6\n、\n\n  （４）−Ｃ（Ｏ）ｔＨ、−Ｃ（Ｏ）ｔＴ\n6\nまたは−Ｏ−Ｃ（Ｏ）Ｔ\n6\n、ここで、ｔは１  または２、\n\n  （５）−ＳＯ\n3\nＨ、−Ｓ（Ｏ）ｔＴ\n6\nまたは−Ｓ（Ｏ）ｔＮ（Ｔ\n9\n）Ｔ\n6\n、\n\n  （６）ハロ、\n\n  （７）シアノ、\n\n  （８）ニトロ、\n\n  （９）−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、\n\n  （１０）−Ｔ\n4\n−Ｎ（Ｔ\n9\n）−Ｔ\n5\n−ＮＴ\n7\nＴ\n8\n、\n\n  （１１）−Ｔ\n4\n−Ｎ（Ｔ\n10\n）−Ｔ\n5\n−Ｔ\n6\n、\n\n  （１２）−Ｔ\n4\n−Ｎ（Ｔ\n10\n）−Ｔ\n5\n−Ｈ、または\n\n  （１３）オキソ；\n\nR \nx\n is one or more optional substituents independently selected from T \n1g\n , T \n2g,\n or T \n3g\n , bonded to any available carbon atom in the ring; \n T \n1-1g\n , T \n2-2g\n and T \n3-3g\n are each independently \n (1) Hydrogen or T \n6\n , where T \n6\n is (i) alkyl, (hydroxy) alkyl, (alkoxy) alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, cycloalkenyl, (cycloalkenyl) alkyl , Aryl, (aryl) alkyl, heterocyclo, (heterocyclo) alkyl, heteroaryl, or (heteroaryl) alkyl, \n (Ii) a group (i) substituted by one or more of the same or different groups (i) per se, or (iii) the \nfollowing\n in the definition of T \n1-1g\n , T \n2-2g\n and T \n3-3g\n A group (i) or (ii) independently substituted with one or more (preferably 1 to 3) of groups (2) to (13), \n (2) -OH or -OT \n6,\n \n (3) -SH or -ST \n6,\n \n (4) -C (O) tH , -C (O) tT 6 or \n-O-C (O) T 6\n , where, t is 1 or 2, \n \n(5) -SO 3 H, -S\n (O) tT 6 or \n-S (O) tN (T 9\n ) T 6, \n (6) Halo, \n (7) Cyano, \n (8) Nitro, \n (9) -T \n4\n -NT \n7\n T \n8\n , \n \n(10) -T 4 -N (T\n 9) -T 5 -NT 7 T 8, \n (11) -T \n4\n -N (T \n10\n ) -T \n5\n -T \n6\n , \n (12) -T \n4\n -N (T \n10\n ) -T \n5\n -H, or (13) oxo;\n\n\n\n\n\n\n \n\n  Ｔ\n4\nおよびＴ\n5\nはそれぞれ独立して、\n\n  （１）単結合、\n\n  （２）−Ｔ\n11\n−Ｓ（Ｏ）ｔ−Ｔ\n12\n−、\n\n  （３）−Ｔ\n11\n−Ｃ（Ｏ）−Ｔ\n12\n−、\n\n  （４）−Ｔ\n11\n−Ｃ（Ｓ）−Ｔ\n12\n−、\n\n  （５）−Ｔ\n11\n−Ｏ−Ｔ\n12\n−、\n\n  （６）−Ｔ\n11\n−Ｓ−Ｔ\n12\n−、\n\n  （７）−Ｔ\n11\n−Ｏ−Ｃ（Ｏ）−Ｔ\n12\n−、\n\n  （８）−Ｔ\n11\n−Ｃ（Ｏ）−Ｏ−Ｔ\n12\n−、\n\n  （９）−Ｔ\n11\n−Ｃ（＝ＮＴ\n9a\n）−Ｔ\n12\n−、または\n\n  （１０）−Ｔ\n11\n−Ｃ（Ｏ）−Ｃ（Ｏ）−Ｔ\n12\n−；\n\nT \n4\n and T \n5\n are each independently \n (1) single bond, \n \n(2) -T 11 -S (O\n ) t-T 12 -, \n \n(3) -T 11 -C (O\n ) -T 12 -, \n \n(4) -T 11 -C (S\n ) -T 12 -, \n \n(5) -T 11 -O-T\n 12 -, \n \n(6) -T 11 -S-T\n 12 -, \n \n(7) -T 11 -O-C\n (O) -T 12 -, \n \n(8) -T 11 -C (O\n ) -O-T 12 -, \n \n(9) -T 11 -C (=\n NT 9a) -T 12 -, or \n(10) -T 11 -C (O\n ) -C (O) -T 12 -;\n\n\n\n\n\n\n \n\n  Ｔ\n7\n，Ｔ\n8\n，Ｔ\n9\n，Ｔ\n9a\nおよびＴ\n10\nは、\n\n  （１）それぞれ独立して、水素またはＴ\n6\nの定義で規定の基、または\n\n  （２）Ｔ\n7\nとＴ\n8\nは共に合してアルキレンまたはアルケニレンとなり、かつそれらが結合する原子と共に３員〜８員の飽和または不飽和環を形成し、該環は非置換またはＴ\n1-1g\n、Ｔ\n2-2g\nまたはＴ\n3-3g\nの定義で列挙した１個以上の基で置換、または\n\n  （３）Ｔ\n7\nまたはＴ\n8\nはＴ\n9\nと共に合してアルキレンまたはアルケニレンとなり、かつそれらが結合する窒素原子と共に３員〜８員の飽和または不飽和環を形成し、該環は非置換またはＴ\n1-1g\n、Ｔ\n2-2g\nまたはＴ\n3-3g\nの定義で列挙した１個以上の基で置換、または\n\n  （４）Ｔ\n7\nとＴ\n8\nまたはＴ\n9\nとＴ\n10\nは、それらが結合する窒素原子と共に合して、−Ｎ＝ＣＴ\n13\nＴ\n14\n（ここで、Ｔ\n13\nおよびＴ\n14\nはそれぞれ独立して、ＨまたはＴ\n6\nの定義で規定の基）の基を形成；\n\nT \n7\n , T \n8\n , T \n9\n , T \n9a\n and T \n10\n are \n (1) each independently hydrogen or a group as defined in the definition of T \n6\n , or (2) T \n7\n and T \n8\n together form an alkylene or alkenylene, and together with the atoms to which they are attached, 3 to 8 members saturated or form an unsaturated ring, said ring unsubstituted or T \n1-1g,\n substituted with one or more groups listed in the definition of T \n2-2g,\n or T \n3-3G,\n or (3) T \n7\n or T \n8\n together with T \n9\n forms an alkylene or alkenylene and together with the nitrogen atom to which they are attached forms a 3- to 8-membered saturated or unsaturated ring, which ring is unsubstituted or T \n1-1g\n , T \n2\n substituted with one or more groups listed in the definition of \n-2g\n or T \n3-3G,\n or (4) T \n7\n and T \n8\n or T \n9\n and T \n10\n are taken together with the nitrogen atom to which they are attached, -N = CT \n13\n T \n14\n (where, in T \n13\n and T \n14\n are each independently regulations in the definition of H or T \n6\n Form a group of the group);\n\n\n\n\n\n\n \n\n  Ｔ\n11\nおよびＴ\n12\nはそれぞれ独立して、\n\n  （１）単結合、\n\n  （２）アルキレン、\n\n  （３）アルケニレン、または\n\n  （４）アルキニレン；\n\nである。\n\nT \n11\n and T \n12\n are each independently \n (1) single bond, \n (2) alkylene, \n (3) alkenylene, or (4) alkynylene; \n It is.\n\n\n\n\n\n\n \n\n  本発明は、式Ｉの化合物、そのエナンチオマー、ジアステレオマーまたは医薬的に許容しうる塩の１種以上を用いる、不整脈やＩ\nKur\n−関連障害の予防および処置のための新規方法を提供する。特に本発明は、上室不整脈の選択的予防および処置のための新規方法を提供する。\n\nThe present invention provides a novel method for the prevention and treatment of arrhythmias and I \nKur\n -related disorders using one or more of the compounds of formula I, enantiomers, diastereomers or pharmaceutically acceptable salts thereof. In particular, the present invention provides a novel method for the selective prevention and treatment of supraventricular arrhythmias.\n\n\n\n\n\n\n \n\n  式Ｉの範囲の中で好ましい化合物としては、下記式Ｉａ、ＩｂおよびＩｃで示される化合物が包含される。\n\n\n \n \n\n\nPreferred compounds within the scope of Formula I include compounds of Formulas Ia, Ib and Ic below. \n \n \n \n \n\n\n\n\n\n\n \n\n  式Ｉの範囲の中で好ましい化合物としては、Ｒ\n1\n、Ｒ\n1a\n、Ｒ\n2\n、ＪおよびＲ\n3\nの１つ以上、特にそれらの全てが以下に示す定義から選択される化合物およびその塩が包含される。\n\n  Ｒ\n1\nは水素、ヒドロキシ、−ＮＲ\n6\nＲ\n7\n、−Ｏ−Ｃ（Ｏ）−ＮＲ\n6\nＲ\n7\n、−Ｏ−Ｃ（Ｏ）−Ｒ\n4\n、−Ｎ（Ｒ\n8\n）−ＳＯ\n2\n−ＮＲ\n6\nＲ\n7\n、−Ｎ（Ｒ\n8\n）−Ｃ（Ｚ）−Ｎ（Ｒ\n8a\n）−ＳＯ\n2\n−Ｒ\n4\n、−Ｎ（Ｒ\n8\n）−Ｃ（Ｚ）−Ｎ（Ｒ\n8a\n）−ＳＯ\n2\n−ＯＨ、−ＳＯ\n2\n−Ｒ\n8c\n、−Ｎ（Ｒ\n8\n）−Ｃ（Ｗ）−ＮＲ\n6\nＲ\n7\n、または\n\n\n \n \n\nの基である。\n\nPreferred compounds within the scope of Formula I include compounds and salts thereof in which one or more of R \n1\n , R \n1a\n , R \n2\n , J and R \n3\n , in particular all of which are selected from the definitions given below. The \n R \n1\n is hydrogen, hydroxy, —NR \n6\n R \n7\n , —O—C (O) —NR \n6\n R \n7\n , —O—C (O) —R \n4\n , —N (R \n8\n ) —SO \n2\n —NR \n6\n R \n \n7, -N (R 8) -C\n \n (Z) -N (R 8a) -SO 2 -R 4, -N (R 8) -C (Z) -N (R 8a) -SO 2 -OH, - \n \nSO 2 -R 8c, -N (R\n \n 8) -C (W) -NR 6 R 7 or, \n \n \n \n It is the basis of.\n\n\n\n\n\n\n \n\n  Ｒ\n1a\nはＨ、またはＲ\n1a\nとＲ\n1\nは共に合してオキソまたは任意に置換されるスピロ−縮合ヘテロシクロ基を形成する。\n\n  Ｒ\n2\nは任意に置換されるアルキル、任意に置換されるアルケニル、任意に置換されるアリール（特にフェニルまたはナフチル）、任意に置換される（アリール）アルキル（特にベンジル）、または任意に置換されるヘテロアリール（特にチエニル、ベンゾチエニル、ピリジニルまたはイソキサゾリル）である。\n\n  Ｊは結合、任意に置換されるＣ\n1-4\nアルキレン（特にメチレン）または任意に置換されるＣ\n1-4\nアルケニレン（特にエテニレン）である。\n\nR \n1a\n is H, or R \n1a\n and R \n1\n together form an oxo or optionally substituted spiro-fused heterocyclo group. \n R \n2\n is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl (especially phenyl or naphthyl), optionally substituted (aryl) alkyl (especially benzyl), or optionally substituted Heteroaryl (especially thienyl, benzothienyl, pyridinyl or isoxazolyl). \n J is a bond, optionally substituted C \n1-4\n alkylene (especially methylene) or optionally substituted C \n1-4\n alkenylene (especially ethenylene).\n\n\n\n\n\n\n \n\n  Ｒ\n3\nは−Ｒ\n5\n、−ＯＲ\n5\n、−Ｃ（Ｚ\n1\n）−Ｒ\n5\n、−Ｃ（Ｚ\n1\n）−Ｏ−Ｒ\n5\n、−Ｏ−Ｃ（Ｚ\n1\n）−Ｒ\n5\n、−Ｎ（Ｒ\n8a1\n）−Ｃ（Ｚ\n1\n）−Ｒ\n5\n、−Ｎ（Ｒ\n8a1\n）−Ｃ（Ｚ\n1\n）−Ｏ−Ｒ\n5\n、または−Ｎ（Ｒ\n8a1\n）−ＳＯ\n2\n−Ｒ\n5\nである。\n\n  Ｒ\n5\nは任意に置換されるアリール、任意に置換される（アリール）アルキル、任意に置換されるヘテロアリール、任意に置換される（ヘテロアリール）アルキル、任意に置換されるヘテロシクロ、任意に置換される（ヘテロシクロ）アルキル、任意に置換されるシクロアルキル、任意に置換される（シクロアルキル）アルキル、任意に置換されるアルキル、任意に置換されるアルケニル、任意に置換されるアルキニル、−ＮＲ\n6a\nＲ\n7a\nまたは\n\n\n \n \n\nの基である。\n\nR \n3\n is —R \n5\n , —OR \n5\n , —C (Z \n1\n ) —R \n5\n , —C (Z \n1\n ) —O—R \n5\n , —O—C (Z \n1\n ) —R \n5\n , —N (R \n8a1\n ) —C (Z \n1\n ) —R \n5\n , —N (R \n8a1\n ) —C (Z \n1\n ) —O—R \n5\n , or —N (R \n8a1\n ) —SO \n2\n —R \n5\n . \n R \n5\n is optionally substituted aryl, optionally substituted (aryl) alkyl, optionally substituted heteroaryl, optionally substituted (heteroaryl) alkyl, optionally substituted heterocyclo, optionally substituted (Heterocyclo) alkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl) alkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, —NR \n6a\n R \n7a\n or \n \n \n \n It is the basis of.\n\n\n\n\n\n\n \n\n  Ｒ\n6\n、Ｒ\n6a\n、Ｒ\n7\nおよびＲ\n7a\nはそれぞれ独立して、Ｈ、任意に置換されるアリール、任意に置換されるヘテロアリール、任意に置換されるシクロアルキル、任意に置換されるヘテロシクロ、任意に置換される（アリール）アルキル、任意に置換される（ヘテロアリール）アルキル、任意に置換される（ヘテロシクロ）アルキル、任意に置換されるアルキル、またはＣＯＲ\n12\nであり；\n\n  またはＲ\n6\nとＲ\n7\n、またはＲ\n6a\nとＲ\n7a\nは共に、それらが結合する窒素と合して、任意に置換される飽和または不飽和の５〜８員環を形成する。\n\n  Ｒ\n4\n，Ｒ\n8\n，Ｒ\n8a1\n，Ｒ\n8c\n，Ｒ\n9\n，Ｒ\n10\n，Ｒ\n10a\n，Ｒ\n11\n，Ｒ\n11a\n，Ｒ\nX\n，Ｘ，Ｘ\n1\n，Ｚ\n1\nおよびＷは前記と同意義である。\n\nR \n6\n , R \n6a\n , R \n7\n and R \n7a\n are each independently H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally (Aryl) alkyl, optionally substituted (heteroaryl) alkyl, optionally substituted (heterocyclo) alkyl, optionally substituted alkyl, or COR \n12\n ; \n Or R \n6\n and R \n7\n or R \n6a\n and R \n7a\n together with the nitrogen to which they are attached form an optionally substituted saturated or unsaturated 5-8 membered ring. \n R \n4\n , R \n8\n , R \n8a1\n , R \n8c\n , R \n9\n , R \n10\n , R \n10a\n , R \n11\n , R \n11a\n , R \nX\n , X, X \n1\n , Z \n1\n and W are as defined above.\n\n\n\n\n\n\n \n\n  式Ｉの範囲の中でより好ましい化合物としては、Ｒ\n1\n、Ｒ\n1a\n、Ｒ\n2\n、ＪおよびＲ\n3\nの１つ以上、特にそれらの全てが以下に示す定義から選ばれる化合物およびその塩が包含される。\n\n  Ｒ\n1\nは水素、ヒドロキシ、−Ｏ−Ｃ（Ｏ）−ＮＲ\n6\nＲ\n7\n、−Ｏ−Ｃ（Ｏ）−Ｒ\n4\n、−Ｎ（Ｒ\n8\n）−ＳＯ\n2\n−ＮＲ\n6\nＲ\n7\n、−ＳＯ\n2\n−Ｒ\n8c\n、−Ｎ（Ｒ\n8\n）−Ｃ（Ｗ）−ＮＲ\n6\nＲ\n7\n、−Ｎ（Ｒ\n8\n）−Ｃ（Ｚ）−Ｎ（Ｒ\n8a\n）−ＳＯ\n2\n−Ｒ\n4\n、−Ｎ（Ｒ\n8\n）−Ｃ（Ｚ）−Ｎ（Ｒ\n8a\n）−ＳＯ\n2\n−ＯＨ、または\n\n\n \n \n\nの基である。\n\nMore preferred compounds within the scope of Formula I include compounds and salts thereof in which one or more of R \n1\n , R \n1a\n , R \n2\n , J and R \n3\n , in particular all of which are selected from the definitions given below. The \n R \n1\n is hydrogen, hydroxy, —O—C (O) —NR \n6\n R \n7\n , —O—C (O) —R \n4\n , —N (R \n8\n ) —SO \n2\n —NR \n6\n R \n7\n , —SO \n2\n —. \n \nR 8c, -N (R 8)\n \n -C (W) -NR 6 R 7, -N (R 8) -C (Z) -N (R 8a) -SO 2 -R 4, -N (R 8) \n-C (Z) -N (R 8a\n ) -SO 2 -OH or \n \n \n \n It is the basis of.\n\n\n\n\n\n\n \n\n  Ｒ\n1a\nはＨである。\n\n  Ｒ\n2\nはフェニル、ナフチル、チエニル、ベンゾチエニル、アルキルまたはアルケニル（これらのいずれも、上述の如く任意に置換されてよい）である。\n\n  Ｊは結合、メチレンまたはエチレンである。\n\n  Ｒ\n3\nは−Ｒ\n5\n、−Ｃ（Ｚ\n1\n）−Ｒ\n5\n、−Ｏ−Ｃ（Ｚ\n1\n）−Ｒ\n5\n、または−Ｎ（Ｒ\n8a1\n）−Ｃ（Ｚ\n1\n）−Ｒ\n5\nである。\n\n  Ｒ\n5\nは任意に置換されるアルキル、任意に置換されるシクロアルキル、任意に置換されるヘテロアリール、任意に置換されるアリールまたは−ＮＲ\n6a\nＲ\n7a\nである。\n\nR \n1a\n is H. \n R \n2\n is phenyl, naphthyl, thienyl, benzothienyl, alkyl or alkenyl, any of which may be optionally substituted as described above. \n J is a bond, methylene or ethylene. \n R \n3\n is —R \n5\n , —C (Z \n1\n ) —R \n5\n , —O—C (Z \n1\n ) —R \n5\n , or —N (R \n8a1\n ) —C (Z \n1\n ) —R \n5\n . \n R \n5\n is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl or —NR \n6a\n R \n7a\n .\n\n\n\n\n\n\n \n\n  Ｒ\n6\n、Ｒ\n6a\n、Ｒ\n7\nおよびＲ\n7a\nはそれぞれ独立して、Ｈ、任意に置換されるアリール、任意に置換されるヘテロアリール、任意に置換されるシクロアルキル、任意に置換されるヘテロシクロ、任意に置換される（アリール）アルキル、任意に置換される（ヘテロアリール）アルキル、任意に置換される（ヘテロシクロ）アルキル、任意に置換されるアルキル、またはＣＯＲ\n12\nであり；\n\n  またはＲ\n6\nとＲ\n7\n、またはＲ\n6a\nとＲ\n7a\nは共に、それらが結合する窒素と合して、任意に置換される飽和または不飽和の５〜８員環を形成する。\n\n  Ｒ\n4\n，Ｒ\n8\n，Ｒ\n8a1\n，Ｒ\n8c\n，Ｒ\n9\n，Ｒ\n10\n，Ｒ\n10a\n，Ｒ\n11\n，Ｒ\n11a\n，Ｘ，Ｚ\n1\nおよびＷは前記と同意義である。\n\nR \n6\n , R \n6a\n , R \n7\n and R \n7a\n are each independently H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally (Aryl) alkyl, optionally substituted (heteroaryl) alkyl, optionally substituted (heterocyclo) alkyl, optionally substituted alkyl, or COR \n12\n ; \n Or R \n6\n and R \n7\n or R \n6a\n and R \n7a\n together with the nitrogen to which they are attached form an optionally substituted saturated or unsaturated 5-8 membered ring. \n R \n4\n , R \n8\n , R \n8a1\n , R \n8c\n , R \n9\n , R \n10\n , R \n10a\n , R \n11\n , R \n11a\n , X, Z \n1\n and W are as defined above.\n\n\n\n\n\n\n \n\n  式Ｉの範囲の中で最も好ましい化合物としては、Ｒ\n1\n、Ｒ\n1a\n、Ｒ\n2\n、ＪおよびＲ\n3\nの１つ以上、特にそれらの全てが以下に示す定義から選ばれる化合物およびその塩が包含される。\n\n  Ｒ\n1\nは\n\n  （ａ）水素、またはヒドロキシ；\n\n  （ｂ）−Ｏ−Ｃ（Ｏ）−ＮＲ\n6\nＲ\n7\n、−Ｎ（Ｒ\n8\n）−ＳＯ\n2\n−ＮＲ\n6\nＲ\n7\n、または−Ｎ（Ｒ\n8\n）−Ｃ（Ｗ）−ＮＲ\n6\nＲ\n7\n；\n\nMost preferred compounds within the scope of Formula I include compounds and salts thereof in which one or more of R \n1\n , R \n1a\n , R \n2\n , J and R \n3\n , in particular all of which are selected from the definitions given below. The \n R \n1\n is (a) hydrogen or hydroxy; \n (B) -O-C (O ) -NR 6 R 7, -N (R 8) -SO 2 -NR 6 R 7 or \n-N (R 8), -C (\n W) -NR 6 R 7;\n\n\n\n\n\n\n \n\n  ここで、Ｒ\n6\nおよびＲ\n7\nはそれぞれ独立して、\n\n  （ｉ）Ｈ、または\n\n  （ｉｉ）アルキル、シクロアルキル、アルケニル、アルキニル、アリール、ヘテロアリール、ヘテロシクロ、アルコキシ、（アリール）アルキル、（シクロアルキル）アルキル、（ヘテロアリール）アルキル、（ヘテロシクロ）アルキル、（アルコキシ）アルキルまたは−ＮＲ\n12\nＲ\n13\n（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）、\n\nであり、または\n\nWhere R \n6\n and R \n7\n are each independently \n (I) H, or (ii) alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxy, (aryl) alkyl, (cycloalkyl) alkyl, (heteroaryl) alkyl, (heterocyclo) alkyl, ( Alkoxy) alkyl or —NR \n12\n R \n13\n (all of which are independently OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, Aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH) alkyl, (OT \n6\n ) alkyl, (ST \n6\n ) alkyl, (C (O) tT \n6\n ) alkyl, (NT \n7\n T \n8\n ) alkyl, (cyano) Alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl May be optionally substituted with one or more), \n Or\n\n\n\n\n\n\n \n\n  Ｒ\n6\nとＲ\n7\nは共に合して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されるヘテロシクロ環を形成し；および\n\nR \n6\n and R \n7\n together are OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH) alkyl, (OT \n6)\n alkyl, (ST \n6)\n alkyl, (C (O) tT \n6)\n alkyl, (NT \n7\n T \n8)\n alkyl, (cyano) alkyl, (aryl) alkyl, Forming a heterocyclo ring optionally substituted with one or more of (heteroaryl) alkyl or (heterocyclo) alkyl; and\n\n\n\n\n\n\n \n\n  Ｒ\n8\nは\n\n  （ｉ）Ｈ；または\n\n  （ｉｉ）アルキル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（シクロアルキル）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキル（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）\n\nであり、\n\nR \n8\n is (i) H; or (ii) alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, (cycloalkyl) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl (both of these Independently, OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH ) Alkyl, (OT \n6\n ) alkyl, (ST \n6\n ) alkyl, (C (O) tT \n6\n ) alkyl, (NT \n7\n T \n8\n ) alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) alkyl or ( Optionally substituted with one or more of heterocyclo) alkyl) \n And\n\n\n\n\n\n\n \n\n  （ｃ）−Ｏ−Ｃ（Ｏ）−Ｒ\n4\n、−Ｎ（Ｒ\n8\n）−Ｃ（Ｚ）−Ｎ（Ｒ\n8a\n）−ＳＯ\n2\n−Ｒ\n4\nまたは−Ｎ（Ｒ\n8\n）−Ｃ（Ｚ）−Ｎ（Ｒ\n8a\n）−ＳＯ\n2\n−ＯＨ；\n\n  ここで、Ｒ\n4\nは\n\n  （ｉ）Ｈ；または\n\n  （ｉｉ）アルキル、シクロアルキル、アルケニル、アルキニル、アリール、ヘテロアリール、ヘテロシクロ、アルコキシ、（アリール）アルキル、（シクロアルキル）アルキル、（ヘテロアリール）アルキル、（ヘテロシクロ）アルキル、（アルコキシ）アルキルまたは−ＮＲ\n12\nＲ\n13\n（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）；および\n\n(C) -O-C (O ) -R 4, -N (R 8) -C (Z) -N (R 8a) -SO 2 -R 4 or \n-N (R 8) -C (Z\n ) - \n \nN (R 8a) -SO 2 -OH\n \n ; \n Wherein R \n4\n is (i) H; or (ii) alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxy, (aryl) alkyl, (cycloalkyl) alkyl, (heteroaryl) alkyl, (Heterocyclo) alkyl, (alkoxy) alkyl or —NR \n12\n R \n13\n (all of which are independently OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH) alkyl, (OT \n6)\n alkyl, (ST \n6)\n \nalkyl, (C (O) tT 6\n ) alkyl, (NT \n7\n T \n8\n ) Alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (hetero) Black) may be optionally substituted with one or more alkyl); and\n\n\n\n\n\n\n \n\n  Ｒ\n8\nおよびＲ\n8a\nはそれぞれ独立して、\n\n  （ｉ）Ｈ；または\n\n  （ｉｉ）アルキル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（シクロアルキル）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキル（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）\n\nであり；または\n\n  （ｄ）\n\n\n \n \n\nの基である。\n\nR \n8\n and R \n8a\n are each independently \n (I) H; or (ii) alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, (cycloalkyl) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl, each of which is independently , OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH) alkyl, (OT \n6\n ) alkyl, (ST \n6\n ) alkyl, (C (O) tT \n6\n ) alkyl, (NT \n7\n T \n8\n ) alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl Optionally substituted with one or more of \n Or (d) \n \n \n \n It is the basis of.\n\n\n\n\n\n\n \n\n  Ｒ\n1a\nがＨである。\n\n  Ｒ\n2\nはフェニル、（フェニル）アルキル、ナフチル、チエニル、ベンゾチエニル、アルキルまたはアルケニル（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）である。\n\n  Ｊが結合、メチレンまたはエチレンである。\n\nR \n1a\n is H. \n R \n2\n is phenyl, (phenyl) alkyl, naphthyl, thienyl, benzothienyl, alkyl or alkenyl (all of which are independently OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH) alkyl, (OT \n6)\n alkyl, (ST \n6)\n \nalkyl, (C (O) tT 6\n ) alkyl, (NT \n7\n T \n8\n ) alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl, optionally substituted with one or more). \n J is a bond, methylene or ethylene.\n\n\n\n\n\n\n \n\n  Ｒ\n3\nは\n\n  （ａ）−Ｒ\n5\n；\n\n  ここで、Ｒ\n5\nはヘテロアリール、ヘテロシクロまたは−ＮＲ\n6a\nＲ\n7a\n（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）\n\nであり、\n\n  （ｂ）−Ｃ（Ｚ\n1\n）−Ｒ\n5\n、または−Ｏ−Ｃ（Ｚ\n1\n）−Ｒ\n5\n；\n\nR \n3\n is (a) -R \n5\n ; \n Where R \n5\n is heteroaryl, heterocyclo or —NR \n6a\n R \n7a\n (all of which are independently OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo , oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH) alkyl, (OT \n6)\n alkyl, (ST \n6)\n \nalkyl, (C (O) tT 6\n ) alkyl, (NT \n7\n T \n8\n ) optionally substituted with one or more of alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl) \n And \n \n(B) -C (Z 1)\n -R 5 or \n-O-C (Z 1),\n -R 5;\n\n\n\n\n\n\n \n\n  ここで、Ｒ\n5\nはアリール、（アリール）アルキル、ヘテロアリール、（ヘテロアリール）アルキルまたは−ＮＲ\n6a\nＲ\n7a\n；および\n\n  Ｒ\n6a\nおよびＲ\n7a\nはそれぞれ独立して、\n\n  （ｉ）Ｈ；または\n\n  （ｉｉ）アルキル、シクロアルキル、アリール、（アリール）アルキル、ヘテロアリール、（ヘテロアリール）アルキル、ヘテロシクロまたは（ヘテロシクロ）アルキル（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）\n\nであり；または\n\n  （ｃ）−Ｎ（Ｒ\n8a1\n）−Ｃ（Ｚ\n1\n）−Ｒ\n5\n、または−Ｎ（Ｒ\n8a1\n）−ＳＯ\n2\n−Ｒ\n5\n；\n\nWherein R \n5\n is aryl, (aryl) alkyl, heteroaryl, (heteroaryl) alkyl or —NR \n6a\n R \n7a\n ; and R \n6a\n and R \n7a\n are each independently \n (Ii) H; or (ii) alkyl, cycloalkyl, aryl, (aryl) alkyl, heteroaryl, (heteroaryl) alkyl, heterocyclo or (heterocyclo) alkyl, each of which is independently OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH) alkyl, (OT \n6\n ) alkyl, Any one or more of (ST \n6\n ) alkyl, (C (O) tT \n6\n ) alkyl, (NT \n7\n T \n8\n ) alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl May be substituted) \n Or (c) —N (R \n8a1\n ) —C (Z \n1\n ) —R \n5\n , or —N (R \n8a1\n ) —SO \n2\n —R \n5\n ;\n\n\n\n\n\n\n \n\n  ここで、Ｒ\n5\nはアリール、（アリール）アルキル、ヘテロアリール、（ヘテロアリール）アルキル、ヘテロシクロ、（ヘテロシクロ）アルキル、アルキル、アルケニル、アルキニル、シクロアルキル、（アルコキシ）アルキルまたは（シクロアルコキシ）アルキル（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）；および\n\nWhere R \n5\n is aryl, (aryl) alkyl, heteroaryl, (heteroaryl) alkyl, heterocyclo, (heterocyclo) alkyl, alkyl, alkenyl, alkynyl, cycloalkyl, (alkoxy) alkyl or (cycloalkoxy) alkyl (these Are independently OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl , (SH) alkyl, (OT \n6\n ) alkyl, (ST \n6\n ) alkyl, (C (O) tT \n6\n ) alkyl, (NT \n7\n T \n8\n ) alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) Optionally substituted with one or more of alkyl or (heterocyclo) alkyl) And\n\n\n\n\n\n\n \n\n  Ｒ\n8a1\nは\n\n  （ｉ）Ｈ；または\n\n  （ｉｉ）アルキル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（シクロアルキル）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキル（これらのいずれも独立して、ＯＨ、ＳＨ、ＯＴ\n6\n、ＳＴ\n6\n、Ｃ（Ｏ）ｔＴ\n6\n、ＮＴ\n7\nＴ\n8\n、シアノ、ハロ、オキソ、アルキル、ハロアルキル、アリール、ヘテロアリール、ヘテロシクロ、（ＯＨ）アルキル、（ＳＨ）アルキル、（ＯＴ\n6\n）アルキル、（ＳＴ\n6\n）アルキル、（Ｃ（Ｏ）ｔＴ\n6\n）アルキル、（ＮＴ\n7\nＴ\n8\n）アルキル、（シアノ）アルキル、（アリール）アルキル、（ヘテロアリール）アルキルまたは（ヘテロシクロ）アルキルの１個以上で任意に置換されてよい）\n\nである。\n\nR \n8a1\n is (i) H; or (ii) alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, (cycloalkyl) alkyl, (aryl) alkyl, (heteroaryl) alkyl or (heterocyclo) alkyl (any of these) Independently, OH, SH, OT \n6\n , ST \n6\n , C (O) tT \n6\n , NT \n7\n T \n8\n , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH) alkyl, (SH ) Alkyl, (OT \n6\n ) alkyl, (ST \n6\n ) alkyl, (C (O) tT \n6\n ) alkyl, (NT \n7\n T \n8\n ) alkyl, (cyano) alkyl, (aryl) alkyl, (heteroaryl) alkyl or ( Optionally substituted with one or more of heterocyclo) alkyl) \n It is.\n\n\n\n\n\n\n \n\n  Ｒ\n5\nは任意に置換されるアルキル、任意に置換されるシクロアルキル、任意に置換されるヘテロアリール、任意に置換されるアリール、または−ＮＲ\n6a\nＲ\n7a\nである。\n\n  Ｒ\n6\n、Ｒ\n6a\n、Ｒ\n7\nおよびＲ\n7a\nはそれぞれ独立して、Ｈ、任意に置換されるアリール、任意に置換されるヘテロアリール、任意に置換されるシクロアルキル、任意に置換されるヘテロシクロ、任意に置換される（アリール）アルキル、任意に置換される（ヘテロアリール）アルキル、任意に置換される（ヘテロシクロ）アルキル、任意に置換されるアルキル、またはＣＯＲ\n12\nであり；または\n\n  Ｒ\n6\nとＲ\n7\n、またはＲ\n6a\nとＲ\n7a\nは共に、それらが結合する窒素と合して、任意に置換される飽和または不飽和の５〜８員環を形成する。\n\n  Ｒ\n4\n，Ｒ\n8\n，Ｒ\n8a1\n，Ｒ\n8c\n，Ｒ\n9\n，Ｒ\n10\n，Ｒ\n10a\n，Ｒ\n11\n，Ｒ\n11a\n，Ｘ，Ｚ\n1\nおよびＷは前記と同意義である。\n\nR \n5\n is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, or —NR \n6a\n R \n7a\n . \n R \n6\n , R \n6a\n , R \n7\n and R \n7a\n are each independently H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally (Aryl) alkyl, optionally substituted (heteroaryl) alkyl, optionally substituted (heterocyclo) alkyl, optionally substituted alkyl, or COR \n12\n ; or R \n6\n and R \n7\n , Or R \n6a\n and R \n7a\n together with the nitrogen to which they are attached form an optionally substituted saturated or unsaturated 5- to 8-membered ring. \n R \n4\n , R \n8\n , R \n8a1\n , R \n8c\n , R \n9\n , R \n10\n , R \n10a\n , R \n11\n , R \n11a\n , X, Z \n1\n and W are as defined above.\n\n\n\n\n\n\n \n\n（発明の詳細）\n\n  本明細書で用いる語句の定義は、以下の通りである。本明細書の基または語句について規定される最初の定義は、他に特別な指示がない限り、本明細書を通じて個別にまたは別の基の一部として用いられる基または語句に適用される。\n\n  語句“alk”または“アルキル”とは、１〜１２個、好ましくは１〜８個の炭素原子を有する直鎖または分枝鎖炭化水素基を指称し、たとえばメチル、エチル、ｎ−プロピル、ｉ−プロピル、ｎ−ブチル、ｉ−ブチル、ｔ−ブチル、ペンチル、ヘキシル、ヘプチル、オクチル等が挙げられる。低級アルキル基、すなわち、炭素数１〜６のアルキル基が一般に、最も好ましい。語句“置換アルキル”とは、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されたアルキル基を指称する。\n\n(Details of the invention) \n Definitions of terms used in the present specification are as follows. The initial definition provided for a group or phrase herein applies to that group or phrase used throughout this specification, individually or as part of another group, unless otherwise indicated. \n The term “alk” or “alkyl” refers to a straight or branched chain hydrocarbon group having 1 to 12, preferably 1 to 8, carbon atoms, for example methyl, ethyl, n-propyl, i -Propyl, n-butyl, i-butyl, t-butyl, pentyl, hexyl, heptyl, octyl and the like. Lower alkyl groups, i.e., alkyl groups having 1 to 6 carbon atoms are generally most preferred. The phrase \"substituted alkyl\" refers, T \n1-1g,\n 1 or more listed in the definition of T \n2-2g\n and \nT\n 3-3g, preferably cyano, halo, oxo, hydroxy, -OT \n6,\n -C \n(O) tT 6, -OC (\n O) T 6, -T 4 -NT 7 T 8, -T 4 -N (T 9) -T 5 -T 6, -S (O) tT 6 or -S ( O) refers to an alkyl group substituted with a group selected from tN (T \n9\n ) T \n6\n .\n\n\n\n\n\n\n \n\n  語句“アルケニル”とは、２〜１２個、好ましくは２〜４個の炭素原子、および少なくとも１つの二重炭素−炭素結合（シスまたはトランスのいずれか）を有する直鎖または分枝鎖炭化水素基を指称し、たとえばエテニルが挙げられる。語句“置換アルケニル”とは、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されたアルケニル基を指称する。\n\nThe term “alkenyl” refers to a straight or branched chain hydrocarbon having 2 to 12, preferably 2 to 4 carbon atoms, and at least one double carbon-carbon bond (either cis or trans). Refers to the group, for example ethenyl. The phrase \"substituted alkenyl\" is, T \n1-1g,\n 1 or more listed in the definition of T \n2-2g\n and \nT\n 3-3g, preferably cyano, halo, oxo, hydroxy, -OT \n6,\n -C \n(O) tT 6, -OC (\n O) T 6, -T 4 -NT 7 T 8, -T 4 -N (T 9) -T 5 -T 6, -S (O) tT 6 or -S ( O) An alkenyl group substituted with a group selected from tN (T \n9\n ) T \n6\n is designated.\n\n\n\n\n\n\n \n\n  語句“アルキニル”とは、２〜１２個、好ましくは２〜４個の炭素原子、および少なくとも１つの三重炭素−炭素結合を有する直鎖または分枝鎖炭化水素基を指称し、たとえばエチニルが挙げられる。語句“置換アルキニル”とは、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されたアルキニル基を指称する。\n\nThe term “alkynyl” refers to a straight or branched chain hydrocarbon group having 2 to 12, preferably 2 to 4 carbon atoms and at least one triple carbon-carbon bond, for example ethynyl. It is done. The phrase \"substituted alkynyl\" is, T \n1-1g,\n 1 or more listed in the definition of T \n2-2g\n and \nT\n 3-3g, preferably cyano, halo, oxo, hydroxy, -OT \n6,\n -C \n(O) tT 6, -OC (\n O) T 6, -T 4 -NT 7 T 8, -T 4 -N (T 9) -T 5 -T 6, -S (O) tT 6 or -S ( O) refers to an alkynyl group substituted with a group selected from tN (T \n9\n ) T \n6\n .\n\n\n\n\n\n\n \n\n  語句“アルキレン”とは、単結合で連結する１〜４個の炭素原子の直鎖橋（たとえば、−(ＣＨ\n2\n)x−、ここで、ｘは１〜５）を指称し、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されてよい。\n\nThe term “alkylene” refers to a straight bridge of 1 to 4 carbon atoms connected by a single bond (eg, — (CH \n2\n ) x —, where x is 1 to 5), and T \n1— 1 g,\n T \n2-2g\n and of T \n3-3G\n of one or more listed in the definition, preferably cyano, halo, oxo, \nhydroxy, -OT 6, -C (O)\n tT 6, -OC (O) \n \n \nT 6, -T 4 -NT 7 T\n \n \n 8, -T 4 -N (T 9) -T 5 -T 6, selected from -S (O) tT \n6\n or \n-S (O) tN (T 9\n ) T 6 It may be substituted with a group.\n\n\n\n\n\n\n \n\n  語句“アルケニレン”とは、単結合で連結し、１または２つの二重結合を有する２〜５個の炭素原子の直鎖橋を指称し、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されてよい。アルケニレン基の具体例は、−ＣＨ＝ＣＨ−ＣＨ＝ＣＨ、−ＣＨ\n2\n−ＣＨ＝ＣＨ−、−ＣＨ\n2\n−ＣＨ＝ＣＨ−ＣＨ\n2\n−、−Ｃ(ＣＨ\n3\n)\n2\nＣＨ＝ＣＨ−および−ＣＨ(Ｃ\n2\nＨ\n5\n)−ＣＨ＝ＣＨ−である。\n\nThe term \"alkenylene\", connected by single bonds, called finger straight bridges 2 to 5 carbon atoms having one or two double bonds, T \n1-1g,\n T \n2-2g\n and T \n3- 3g\n of one or more listed in the definition of, preferably cyano, halo, oxo, \nhydroxy, -OT 6, -C (O)\n tT 6, -OC (O) T 6, -T 4 -NT 7 T \n8\n , -T \n4\n -N (T \n9\n ) -T \n5\n -T \n6\n , -S (O) tT \n6\n or -S (O) tN (T \n9\n ) T \n6\n may be substituted. Examples of alkenylene groups, -CH = CH-CH = CH , -CH 2 -CH = CH -, - CH 2 -CH = CH-CH 2 -, - C (CH 3) 2 CH = CH- and - CH (C \n2\n H \n5)\n is -CH = CH-.\n\n\n\n\n\n\n \n\n  語句“アルキニレン”とは、単結合で連結し、三重結合を有する２〜５個の炭素原子の直鎖橋を指称し、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されてよい。アルキニレン基の具体例は、−Ｃ≡Ｃ−、−ＣＨ\n2\n−Ｃ≡Ｃ−、−ＣＨ(ＣＨ\n3\n)−Ｃ≡Ｃ−および−Ｃ≡Ｃ−ＣＨ(Ｃ\n2\nＨ\n5\n)ＣＨ\n2\n−である。\n\nThe term \"alkynylene\", connected by single bonds, called 2-5 fingers straight bridge carbon atoms having a triple bond, T \n1-1g,\n in the definition of T \n2-2g\n and \nT\n 3-3g one or more listed in, preferably cyano, halo, oxo, \nhydroxy, -OT 6, -C (O)\n tT 6, -OC (O) T 6, -OC (O) T 6, -T 4 - It may be substituted with a group selected from NT \n7\n T \n8\n , -T \n4\n -N (T \n9\n ) -T \n5\n -T \n6\n , -S (O) tT \n6\n or -S (O) tN (T \n9\n ) T \n6\n . Specific examples of alkynylene groups are —C≡C—, —CH \n2\n —C≡C—, —CH (CH \n3\n ) —C≡C— and —C≡C—CH (C \n2\n H \n5\n ) CH \n2\n —. is there.\n\n\n\n\n\n\n \n\n  語句“ar”または“アリール”とは、好ましくは６〜１４員の、芳香族同素環式（すなわち、炭化水素）のモノ、ジまたはトリ環式環含有の基を指称し、たとえばフェニル、ナフチルおよびビフェニル、並びにかかる環がシクロアルキル、シクロアルケニル、ヘテロシクロまたはヘテロアリール環に縮合したものが挙げられる。具体例としては、\n\n\n \n \n\n等が挙げられる。\n\nThe phrase “ar” or “aryl” refers to a group preferably containing 6 to 14 members of an aromatic homocyclic (ie, hydrocarbon) mono, di or tricyclic ring, such as phenyl, Naphtyl and biphenyl, and such rings fused to a cycloalkyl, cycloalkenyl, heterocyclo or heteroaryl ring. As a specific example, \n \n \n \n Etc.\n\n\n\n\n\n\n \n\n  語句“置換アリール”とは、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されたアリール基を指称する。\n\nThe phrase \"substituted aryl\" means, T \n1-1g,\n 1 or more listed in the definition of T \n2-2g\n and \nT\n 3-3g, preferably cyano, halo, oxo, hydroxy, -OT \n6,\n -C \n(O) tT 6, -OC (\n O) T 6, -T 4 -NT 7 T 8, -T 4 -N (T 9) -T 5 -T 6, -S (O) tT 6 or -S ( O) An aryl group substituted with a group selected from tN (T \n9\n ) T \n6\n is designated.\n\n\n\n\n\n\n \n\n  語句“シクロアルキル”とは、モノ環式アルキル、ジ環式アルキルおよびトリ環式アルキルを含め、１〜３つの環を含有し、該環を構成するトータル３〜２０個、好ましくは３〜７個の炭素を含有する、飽和および一部不飽和（１または２つの二重結合を含有）の環式炭化水素基を指称し、かつ１つまたは２つの芳香族またはヘテロシクロ環に縮合してもよく、たとえばシクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル、シクロヘプチル、シクロオクチル、シクロデシル、シクロドデシル、シクロヘキセニル、\n\n\n \n \n\n等が挙げられる。\n\nThe phrase “cycloalkyl” includes 1 to 3 rings, including monocyclic alkyl, dicyclic alkyl, and tricyclic alkyl, and a total of 3 to 20, preferably 3 to 7, constituting the ring. Saturated and partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon radicals containing 1 carbon and referred to as fused to one or two aromatic or heterocyclo rings Well, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, cyclohexenyl, \n \n \n \n Etc.\n\n\n\n\n\n\n \n\n  語句“置換シクロアルキル”とは、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換されたシクロアルキル基を指称する。\n\n  語句“ハロゲン”および“ハロ”とは、フッ素、塩素、臭素および沃素を指称する。\n\nThe term \"substituted cycloalkyl\", T \n1-1g,\n T \n2-2g\n and \nT\n 3-3g of one or more listed in the definition, preferably cyano, halo, oxo, hydroxy, -OT \n6,\n - \nC (O) tT 6, -OC\n (O) T 6, -T 4 -NT 7 T 8, -T 4 -N (T 9) -T 5 -T 6, -S (O) tT 6 or -S (O) refers to a cycloalkyl group substituted with a group selected from tN (T \n9\n ) T \n6\n . \n The phrases “halogen” and “halo” refer to fluorine, chlorine, bromine and iodine.\n\n\n\n\n\n\n \n\n  語句“複素環”、“複素環式”、“複素環式基”または“ヘテロシクロ”とは、少なくとも１個の炭素原子含有環に少なくとも１個のヘテロ原子を有する、完全飽和または部分もしくは不飽和環式基（たとえば３〜１３員モノ環式環系、７〜１７員ジ環式環系、または１０〜２０員トリ環式環系、好ましくはトータル３〜１０個の環原子を含有）を指称する。ヘテロ原子含有の複素環式基の各環は、窒素原子、酸素原子および／または硫黄原子から選ばれる１、２、３または４個のヘテロ原子を有してよく、この場合、窒素および硫黄へテロ原子は必要に応じて酸化されてよく、また窒素へテロ原子は必要に応じて置換または第４級化されてもよい。\n\n\n  The terms “heterocycle”, “heterocyclic”, “heterocyclic group” or “heterocyclo” are fully saturated or partially or unsaturated having at least one heteroatom in a ring containing at least one carbon atom. Cyclic groups (eg 3 to 13 membered monocyclic ring systems, 7 to 17 membered dicyclic ring systems, or 10 to 20 membered tricyclic ring systems, preferably containing a total of 3 to 10 ring atoms) Refer to it. Each ring of the heteroatom-containing heterocyclic group may have 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and / or sulfur atoms, in this case to nitrogen and sulfur The tero atom may be oxidized as necessary, and the nitrogen heteroatom may be substituted or quaternized as necessary.\n\n\n\n\n\n\n\n \n\n  複素環式基は、環または環系のへテロ原子または炭素原子のいずれでも結合することができる。多環複素環の各環は、１つ以上のスピロ結合により、縮合、橋かけ（bridged）および／または結合してもよい。複素環式基の具体例としては、\n\n\n \n \n\n\n \n \n\n等が挙げられる。\n\nThe heterocyclic group can be attached at any of the ring or ring system heteroatoms or carbon atoms. Each ring of the polycyclic heterocycle may be fused, bridged and / or joined by one or more spiro linkages. Specific examples of the heterocyclic group include \n \n \n \n \n \n \n Etc.\n\n\n\n\n\n\n \n\n  語句“置換複素環”、“置換複素環式”、“置換複素環式基”および“置換ヘテロシクロ”とは、Ｔ\n1-1g\n，Ｔ\n2-2g\nおよびＴ\n3-3g\nの定義の中で列挙した１個以上の、好ましくはシアノ、ハロ、オキソ、ヒドロキシ、−ＯＴ\n6\n、−Ｃ(Ｏ)tＴ\n6\n、−ＯＣ(Ｏ)Ｔ\n6\n、−Ｔ\n4\n−ＮＴ\n7\nＴ\n8\n、−Ｔ\n4\n−Ｎ(Ｔ\n9\n)−Ｔ\n5\n−Ｔ\n6\n、−Ｓ(Ｏ)tＴ\n6\nまたは−Ｓ(Ｏ)tＮ(Ｔ\n9\n)Ｔ\n6\nから選ばれる基で置換された複素環、複素環式およびヘテロシクロ基を指称する。\n\nThe \nterms\n “substituted heterocycle”, “substituted heterocycle”, “substituted heterocycle” and “substituted heterocyclo” are \nlisted in\n the definition of T \n1-1g\n , T \n2-2g\n and T \n3-3g\n . of one or more, preferably cyano, halo, oxo, \nhydroxy, -OT 6, -C (O)\n tT 6, -OC (O) T 6, -T 4 -NT 7 T 8, -T 4 -N ( \n \n \nT 9) -T 5 -T 6,\n \n \n -S (O) tT 6 or \n-S (O) tN (T 9\n ) heterocycle substituted with a group selected from the T \n6,\n the heterocyclic and heterocyclo groups referred to finger .\n\n\n\n\n\n\n \n\n  本明細書で単独または別の基の一部として用いる語句“ヘテロアリール”とは、１〜４個の窒素原子および／または１または２個の酸素もしくは硫黄原子を含有する（但し、少なくとも１個の炭素原子と４個を越えないヘテロ原子を含有）、５、６または７員芳香族環を指称する。ヘテロアリール環は、有効炭素または窒素原子を介して結合する。ヘテロアリールの定義の中には、かかる環がシクロアルキル、アリール、シクロヘテロアルキルまたは別のヘテロアリール環に縮合したものも含まれる。\n\n\n  The term “heteroaryl” as used herein alone or as part of another group contains 1 to 4 nitrogen atoms and / or 1 or 2 oxygen or sulfur atoms, provided that at least one Of carbon atoms and no more than 4 heteroatoms), refer to 5, 6 or 7 membered aromatic rings. The heteroaryl ring is attached via an available carbon or nitrogen atom. Also included within the definition of heteroaryl are those rings fused to a cycloalkyl, aryl, cycloheteroalkyl or another heteroaryl ring.\n\n\n\n\n\n\n\n \n\n  ヘテロアリール環中の１、２または３個の有効炭素または窒素原子は、必要に応じてＴ\n1\n、Ｔ\n2\nおよびＴ\n3\nの定義の中で列挙した置換基で置換されてよい。またヘテロアリール環中の有効窒素または硫黄原子は酸化することもできる。ヘテロアリール環の具体例としては、\n\n\n \n \n\n\n \n \n\n\n \n \n\n等が挙げられる。\n\nOne, two or three available carbon or nitrogen atoms in the heteroaryl ring may be optionally substituted with the substituents listed in the definitions of T \n1\n , T \n2\n and T \n3\n . Also, the effective nitrogen or sulfur atom in the heteroaryl ring can be oxidized. Specific examples of the heteroaryl ring include \n \n \n \n \n \n \n \n \n \n Etc.\n\n\n\n\n\n\n \n\n  本明細書を通じて、これらの基や置換基は、安定な成分および化合物を付与するよう選定されてよい。\n\n  式Ｉの化合物は塩を形成し、該塩も本発明の技術的範囲に属する。本明細書で式Ｉの化合物の言及は、他に特別な指示がない限り、その塩の言及も含むと理解される。本明細書で用いる語句“塩”は、無機および／または有機の酸および塩基によって形成される酸性および／または塩基性塩を意味する。\n\nThroughout this specification, these groups and substituents may be selected to provide stable components and compounds. \n The compounds of formula I form salts which are also within the scope of the invention. References herein to compounds of formula I are understood to include reference to salts thereof, unless otherwise indicated. As used herein, the phrase “salt” means acidic and / or basic salts formed with inorganic and / or organic acids and bases.\n\n\n\n\n\n\n \n\n  加えて、式Ｉの化合物が塩基性成分と酸性成分の両方を含有するとき、両性イオン（“内部塩”）を形成でき、これも本明細書使用の語句“塩”の中に含まれる。医薬的に許容しうる（すなわち、非毒性の生理学的に許容しうる）塩が好ましいが、他の塩も、たとえば製造工程で採用しうる単離または精製工程で使用できる。式Ｉの化合物の塩は、たとえば、化合物Ｉを媒体中、たとえば該塩が析出する媒体または水性媒体中で、一定量、たとえば当量の酸または塩基と反応させた後、凍結乾燥を行うことにより形成しうる。\n\n\n  In addition, when a compound of Formula I contains both a basic component and an acidic component, it can form a zwitterion (“internal salt”), which is also included within the phrase “salt” as used herein. Although pharmaceutically acceptable (ie, non-toxic, physiologically acceptable) salts are preferred, other salts can be used in isolation or purification steps that may be employed, for example, in the manufacturing process. A salt of a compound of formula I can be obtained, for example, by reacting compound I with a certain amount, for example an equivalent amount of acid or base, in a medium, for example in a medium in which the salt precipitates or in an aqueous medium, followed by lyophilization. Can be formed.\n\n\n\n\n\n\n\n \n\n  塩基性成分を含有する式Ｉの化合物は、種々の有機および無機酸と共に塩を形成しうる。酸付加塩の具体例としては、アセテート塩（たとえば酢酸、またはトリフルオロ酢酸などのトリハロ酢酸によって形成される塩）、アジペート塩、アルギネート塩、アスコルベート塩、アスパルテート塩、ベンゾエート塩、ベンゼンスルホネート塩、ビスルフェート塩、ボレート塩、ブチレート塩、シトレート塩、カンフォレート塩、カンフォルスルホネート塩、シクロペンタンプロピオネート塩、ジグルコネート塩、ドデシルスルフェート塩、エタンスルホネート塩、フマレート塩、グルコヘプタノエート塩、グリセロホスフェート塩、ヘミスルフェート塩、ヘプタノエート塩、ヘキサノエート塩、塩酸塩（塩化水素酸によって形成）、臭酸塩（臭化水素によって形成）、沃化水素塩、２−ヒドロキシエタンスルホネート塩、ラクテート塩、マレエート塩（マレイン酸によって形成）、メタンスルホネート塩（メタンスルホン酸によって形成）、２−ナフタレンスルホネート塩、ニコチネート塩、硝酸塩、シュウ酸塩、ペクチネート塩、過硫酸塩、３−フェニルプロピオネート塩、リン酸塩、ピクレート塩、ピバレート塩、プロピオネート塩、サリチレート塩、スクシネート塩、スルフェート塩（たとえば硫酸によって形成される塩）、スルホネート塩（たとえば本明細書に記載のもの）、タートレート塩、チオシアネート塩、トシレート塩などのトルエンスルホネート塩、ウンデカノエート塩等が挙げられる。\n\n\n  Compounds of formula I containing basic components can form salts with various organic and inorganic acids. Specific examples of acid addition salts include acetate salts (for example, acetic acid or salts formed with trihaloacetic acids such as trifluoroacetic acid), adipate salts, alginate salts, ascorbate salts, aspartate salts, benzoate salts, benzenesulfonate salts. Bisulphate salt, borate salt, butyrate salt, citrate salt, camphorate salt, camphorsulfonate salt, cyclopentanepropionate salt, digluconate salt, dodecyl sulfate salt, ethanesulfonate salt, fumarate salt, glucoheptanoate salt, glycero Phosphate salt, hemisulphate salt, heptanoate salt, hexanoate salt, hydrochloride (formed by hydrochloric acid), odorate (formed by hydrogen bromide), hydrogen iodide salt, 2-hydroxyethanesulfonate salt, lactate salt Maleate salt (formed by maleic acid), methanesulfonate salt (formed by methanesulfonic acid), 2-naphthalenesulfonate salt, nicotinate salt, nitrate, oxalate, pectinate salt, persulfate, 3-phenylpropionate salt, phosphorus Acid salts, picrate salts, pivalate salts, propionate salts, salicylate salts, succinate salts, sulfate salts (for example, salts formed with sulfuric acid), sulfonate salts (for example those described herein), tartrate salts, thiocyanate salts, Examples include toluene sulfonate salts such as tosylate salts, undecanoate salts, and the like.\n\n\n\n\n\n\n\n \n\n  酸性成分を含有する式Ｉの化合物は、種々の有機および無機塩基と共に塩を形成しうる。塩基性塩の具体例としては、アンモニウム塩；アルカリ金属塩、たとえばナトリウム、リチウムおよびカリウム塩；アルカリ土類金属塩、たとえばカルシウムおよびマグネシウム塩；有機塩基（たとえば有機アミン）による塩、たとえばベンザチン塩、ジシクロヘキシルアミン塩、ヒドラバミン塩（Ｎ,Ｎ−ビス（デヒドロアビエチル）エチレンジアミンによって形成）、Ｎ−メチル−Ｄ−グルカミン塩、Ｎ−メチル−Ｄ−グルカミド塩、ｔ−ブチルアミン塩；およびアルギニン、リシンなどのアミン酸による塩等が挙げられる。\n\n\n  Compounds of formula I containing an acidic component can form salts with various organic and inorganic bases. Specific examples of basic salts include ammonium salts; alkali metal salts such as sodium, lithium and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; salts with organic bases such as organic amines such as benzathine salts, Dicyclohexylamine salt, hydrabamine salt (formed by N, N-bis (dehydroabiethyl) ethylenediamine), N-methyl-D-glucamine salt, N-methyl-D-glucamide salt, t-butylamine salt; and arginine, lysine, etc. And salts with amine acids.\n\n\n\n\n\n\n\n \n\n  塩基性窒素−含有基は、低級アルキルハライド（たとえばメチル、エチル、プロピルおよびブチルクロリド、ブロミドおよびヨージド）、ジアルキルスルフェート（たとえばジメチル、ジエチル、ジブチルおよびジアミルスルフェート）、長鎖ハライド（たとえばデシル、ラウリル、ミリスチルおよびステアリルクロリド、ブロミドおよびヨージド）、アラルキルハライド（たとえばベンジルおよびフェネチルブロミド）、およびその他などの物質で第４級化してもよい。\n\n\n  Basic nitrogen-containing groups include lower alkyl halides (eg methyl, ethyl, propyl and butyl chloride, bromide and iodide), dialkyl sulfates (eg dimethyl, diethyl, dibutyl and diamyl sulfate), long chain halides (eg decyl). , Lauryl, myristyl and stearyl chloride, bromide and iodide), aralkyl halides (eg benzyl and phenethyl bromide), and others.\n\n\n\n\n\n\n\n \n\n  また本発明化合物のプロドラッグおよび溶媒化合物も、本発明において企図される。本明細書で用いる語句“プロドラッグ”とは、被険者に投与されたとき、代謝または化学プロセスによる化学変換をうけて、式Ｉの化合物、あるいはその塩および／または溶媒化合物を生成する化合物を意味する。式Ｉの化合物の溶媒化合物は、水和物が好ましい。\n\n  式Ｉの化合物、およびその塩が互変異性形状で存在しうる範囲で、本発明において、かかる互変異性体の全ては本発明の一部として企図される。\n\nProdrugs and solvates of the compounds of the present invention are also contemplated in the present invention. As used herein, the term “prodrug” refers to a compound that, when administered to a subject, undergoes a chemical transformation by metabolism or a chemical process to produce a compound of formula I, or a salt and / or solvate thereof. Means. The solvate of the compound of formula I is preferably a hydrate. \n To the extent that the compounds of Formula I, and salts thereof, can exist in tautomeric forms, all such tautomers are contemplated as part of this invention.\n\n\n\n\n\n\n \n\n  本発明化合物の全ての立体異性体、たとえばエナンチオマー体（不斉炭素の非存在下でも存在しうる）やジアステレオマー体を含む、各種ＲおよびＺ置換基上の不斉炭素に基づき存在しうる立体異性体は、本発明の技術的範囲に属することが企図される。本発明化合物の個々の立体異性体は、たとえば、実質的に他の異性体から遊離しているか、あるいはたとえばラセミ化合物としてまたは全てのもしくは選定した他の立体異性体と混ぜてもよい。本発明のキラル中心は、ＩＵＰＡＣ  １９７４規格で規定の、ＳまたはＲ配置を有することができる。\n\n  語句“包含，含む”、“など”、“たとえば”等は、例示的な具体化を指称し、本発明の技術的範囲を限定するものでない。\n\nAll stereoisomers of the compounds of the present invention may exist based on asymmetric carbons on various R and Z substituents, including enantiomers (which may exist even in the absence of asymmetric carbon) and diastereomers. Stereoisomers are intended to be within the scope of this invention. Individual stereoisomers of the compounds of the invention may be, for example, substantially free from other isomers, or may be mixed, for example, as racemates or with all or selected other stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 standard. \n The phrases “including, including”, “etc.”, “for example”, etc. refer to exemplary embodiments and do not limit the scope of the invention.\n\n\n\n\n\n\n \n\n  式Ｉの化合物は、下記に概説される工程順序に従って製造することができる。より詳しくは、Ｒ\n1\nが−Ｏ−ＣＯ−ＮＲ\n6\nＲ\n7\n、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリール、および−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式１に従って製造しうる。\n\n  反応式１：\n\n\n \n \n\n\nCompounds of formula I can be prepared according to the process sequence outlined below. More particularly, R \n1\n is —O—CO—NR \n6\n R \n7\n , R \n2\n is aryl, substituted aryl or heteroaryl, and —J—R \n3\n is —CH \n2\n —NH—CO—R \n5.\n The compound can be produced according to the following reaction scheme 1. \n Reaction formula 1: \n \n \n \n \n\n\n\n\n\n\n \n\n  アセトニトリル２へのＢis  Ｍichael付加、次いでＤieckmann縮合によって、中間体シクロヘキシルβ−ケトエステル４が生成する。該ケトンにＫrapcho脱カルボキシル化を行った後、ケトン保護およびニトリル６の還元を行って、第１アミン７を生成する。次いで第１アミンをアシル化し、脱保護し、得られるケトン９を還元する。シスおよびトランスアルコールを分離し、次いで最終生成物のエステルとカルバメートとすることができる。\n\n\n  Bis Michael addition to acetonitrile 2 followed by Dieckmann condensation produces the intermediate cyclohexyl β-ketoester 4. The ketone is subjected to Krapcho decarboxylation followed by ketone protection and nitrile 6 reduction to produce the primary amine 7. The primary amine is then acylated and deprotected and the resulting ketone 9 is reduced. The cis and trans alcohols can be separated and then the final product esters and carbamates.\n\n\n\n\n\n\n\n \n\n  Ｒ\n1\nが−ＮＲ\n8\n−Ｃ(ＮＣＮ)−ＮＲ\n6\nＲ\n7\n、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリールおよび−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式２に従って製造しうる。\n\n  反応式２：\n\n\n \n \n\n\nA compound of formula I wherein R \n1\n is —NR \n8\n —C (NCN) —NR \n6\n R \n7\n , R \n2\n is aryl, substituted aryl or heteroaryl and —JR \n3\n is —CH \n2\n —NH—CO—R \n5\n . Can be prepared according to the following reaction scheme 2. \n Reaction formula 2: \n \n \n \n \n\n\n\n\n\n\n \n\n  商業上入手しうる化合物１のケトン成分の保護を行った後、ニトリルをＬＡＨで還元して、ケトン４を得る。アミンをアシル化し、ケタール成分を脱保護して、ケトン４を得る。還元アミノ化により、アミン５を生成する。ジフェニルシアノウレアからのフェノキシ基の置換によって、式６の化合物が製造されうる。化合物６とアミンをアルコール溶媒中、６０〜７５℃で加温して、化合物７を得る。\n\n\n  After protection of the commercially available ketone component of Compound 1, the nitrile is reduced with LAH to give ketone 4. Acylation of the amine and deprotection of the ketal component provides ketone 4. Reductive amination produces amine 5. By substitution of the phenoxy group from diphenylcyanourea, the compound of formula 6 can be prepared. Compound 6 and amine are heated in an alcohol solvent at 60 to 75 ° C. to obtain compound 7.\n\n\n\n\n\n\n\n \n\n  別法として、Ｒ\n1\nが−ＮＲ\n8\n−Ｃ(ＮＣＮ)−ＮＲ\n6\nＲ\n7\n、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリールおよび−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式３に従って製造されてよい。\n\n  反応式３：\n\n\n \n \n\n\nAlternatively, R \n1\n is —NR \n8\n —C (NCN) —NR \n6\n R \n7\n , R \n2\n is aryl, substituted aryl or heteroaryl, and —J—R \n3\n is —CH \n2\n —NH—CO—R \n5\n . Compounds of formula I may be prepared according to Scheme 3 below. \n Reaction formula 3: \n \n \n \n \n\n\n\n\n\n\n \n\n  この製造で用いる化合物１は、商業上入手しうる物質から、当業者に周知の方法で容易に製造される。置換シクロヘキシルシアノグアニジン化合物、たとえば化合物３のアセンブリーは、上記反応式２で説明した方法を用いて行うことができる。ＴＦＡ保護基の加水分解およびアミン４のアシル化により、式５の化合物を得ることができる。\n\n\n  Compound 1 used in this production is easily produced from commercially available materials by methods well known to those skilled in the art. The assembly of the substituted cyclohexyl cyanoguanidine compound, for example, Compound 3, can be carried out using the method described in Reaction Scheme 2 above. Hydrolysis of the TFA protecting group and acylation of amine 4 can give compounds of formula 5.\n\n\n\n\n\n\n\n \n\n  Ｒ\n1\nが−ＮＨ−ＳＯ\n2\n−ＮＲ\n6\nＲ\n7\n、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリールおよび−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式４に従って製造しうる。\n\n  反応式４：\n\n\n \n \n\n\nCompounds of formula I wherein R \n1\n is —NH—SO \n2\n —NR \n6\n R \n7\n , R \n2\n is aryl, substituted aryl or heteroaryl and —JR \n3\n is —CH \n2\n —NH—CO—R \n5\n are: It can be prepared according to Scheme 4. \n Reaction formula 4: \n \n \n \n \n\n\n\n\n\n\n \n\n  アミン１を、文献［Ｄewynter  Ｇ．らの「Ｔetrahedron」（５２、１４２１７−１４２２４、１９９６年）］に記載の方法で、対応するスルホニルオキサゾリジンに変換することができる。オキサゾリジン２をエタノールおよびイソプロパノールなどのアルコール溶媒中、６５〜７５℃の温度にてアミンと置換反応させることによって、式３の化合物を製造することができる。\n\n\n  Amine 1 is described in the literature [Dewynter G. et al. [Tetrahedron] (52, 14217-14224, 1996)] can be converted to the corresponding sulfonyloxazolidines. The compound of formula 3 can be prepared by substitution reaction of oxazolidine 2 with an amine in an alcohol solvent such as ethanol and isopropanol at a temperature of 65-75 ° C.\n\n\n\n\n\n\n\n \n\n  Ｒ\n1\nが−ＮＨ−Ｃ（＝ＮＣＯ\n2\nＲ\n8\n）−ＮＲ\n6\nＲ\n7\n、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリールおよび−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式５に従って製造しうる。\n\n  反応式５：\n\n\n \n \n\n  アミン１をイソチオシアノホルメートで処理して、チオウレア化合物２を得、これをＥＤＣlの存在下アミンとカップリング反応させて、式３の化合物を得ることができる。\n\nA formula wherein R \n1\n is —NH—C (═NCO \n2\n R \n8\n ) —NR \n6\n R \n7\n , R \n2\n is aryl, substituted aryl or heteroaryl and —JR \n3\n is —CH \n2\n —NH—CO—R \n5.\n The compound I can be prepared according to the following reaction scheme 5. \n Reaction formula 5: \n \n \n \n Amine 1 can be treated with isothiocyanoformate to give thiourea compound 2, which can be coupled with an amine in the presence of EDCl to give a compound of formula 3.\n\n\n\n\n\n\n \n\n  Ｒ\n1\nがヒダントイン複素環、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリールおよび−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式６に従って製造しうる。\n\n  反応式６：\n\n\n \n \n\n  アミン１をホスゲンで処理すると、イソシアネート２が得られる。イソシアネート２をエタノールまたはイソプロパノールなどのアルコール溶媒中、６５〜７５℃の温度にて置換アミノエステルで処理することにより、式３の化合物を得ることができる。\n\nCompounds of formula I wherein R \n1\n is a hydantoin heterocycle, R \n2\n is aryl, substituted aryl or heteroaryl and —JR \n3\n is —CH \n2\n —NH—CO—R \n5\n may be prepared according to the following reaction scheme 6 . \n Reaction formula 6: \n \n \n \n Treatment of amine 1 with phosgene gives isocyanate 2. Treatment of isocyanate 2 with a substituted amino ester in an alcohol solvent such as ethanol or isopropanol at a temperature of 65-75 ° C. can give a compound of formula 3.\n\n\n\n\n\n\n \n\n  別法として、式３の化合物は、アミン１を適当な溶媒、たとえばジクロロメタンまたはＴＨＦ中、置換イソシアノアセテートで処理した後、下記反応式７に従って、酸性条件下で閉環を行うことによって得ることができる。\n\n  反応式７：\n\n\n \n \n\n\nAlternatively, the compound of formula 3 can be obtained by treating amine 1 with a substituted isocyanoacetate in a suitable solvent such as dichloromethane or THF, followed by ring closure under acidic conditions according to Scheme 7 below. it can. \n Reaction formula 7: \n \n \n \n \n\n\n\n\n\n\n \n\n  Ｒ\n1\nがイミダゾリジン−２−オン複素環、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリールおよび−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式８に従って製造しうる。\n\n  反応式８：\n\n\n \n \n\n  ケトン１の置換エチレンジアミン２による還元アミノ化により、シクロヘキシルアミン化合物３を得ることができる。このアミン化合物３をＴＨＦまたはジクロロメタンなどの溶媒中、カルボニルジイミダゾール４で処理すると、式５の対応する環式ウレアに変換することができる。\n\nA compound of formula I wherein R \n1\n is an imidazolidin-2-one heterocycle, R \n2\n is aryl, substituted aryl or heteroaryl and —J—R \n3\n is —CH \n2\n —NH—CO—R \n5\n is 8 can be produced. \n Reaction formula 8: \n \n \n \n Cyclohexylamine compound 3 can be obtained by reductive amination of ketone 1 with substituted ethylenediamine 2. This amine compound 3 can be converted to the corresponding cyclic urea of formula 5 by treatment with carbonyldiimidazole 4 in a solvent such as THF or dichloromethane.\n\n\n\n\n\n\n \n\n  Ｒ\n1\nがイミダゾリジン−２−イリジンシアナミド複素環、Ｒ\n2\nがアリール、置換アリールまたはヘテロアリールおよび−Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−ＣＯ−Ｒ\n5\nである式Ｉの化合物は、下記反応式９に従って製造しうる。\n\n  反応式９：\n\n\n \n \n\n  上記反応式７の同じ中間体１から、これをエタノールまたはイソプロパノールなどのアルコール溶媒中、６５〜７５℃の温度にてジフェニルシアノカルボニデート２で処理すると、式３の化合物が生成しうる。\n\nCompounds of formula I wherein R \n1\n is an imidazolidine-2-ylidine cyanamide heterocycle, R \n2\n is aryl, substituted aryl or heteroaryl and —JR \n3\n is —CH \n2\n —NH—CO—R \n5\n are: It can be prepared according to Scheme 9. \n Reaction formula 9: \n \n \n \n From the same intermediate 1 of Reaction Scheme 7 above, treatment of this with diphenylcyanocarbonidate 2 in an alcohol solvent such as ethanol or isopropanol at a temperature of 65-75 ° C. can yield the compound of Formula 3.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが−ＣＨ\n2\n−ＮＨ−Ｒ\n6\n（ここで、Ｒ\n6\nはアリールまたはヘテロアリール）である式Ｉの化合物は、下記反応式１０に従って製造しうる。\n\n  反応式１０：\n\n\n \n \n\n  中間体１をＰd\n2\n(dba)\n3\nなどのパラジウム触媒の存在下、ＸがＣl、Ｂr、Ｉ、ＯＴfまたは類似の脱離可能基である置換アリールまたはヘテロアリール化合物と反応させて、化合物２を生成しうる。\n\n-J-R \n3\n is -CH \n2\n -NH-R \n6\n (wherein, R \n6\n is aryl or heteroaryl) compound of formula I in which may be prepared according to the following reaction scheme 10. \n Reaction formula 10: \n \n \n \n The presence of a palladium catalyst intermediate 1 like Pd \n2\n (dba) \n3,\n X is Cl, Br, I, is reacted with OTf or similar leaving group capable substituted aryl or heteroaryl compound, compound 2 Can be generated.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが−ＣＯＮＲ\n6\nＲ\n7\nである式Ｉの化合物は、下記反応式１１に従って製造しうる。\n\n  反応式１１：\n\n\n \n \n\n  文献公知の種々の標準カップリング操作を用い、カルボン酸１をアミンＨＮＲ\n6\nＲ\n7\nと反応させて、式２のアミド化合物を得る。カルボン酸を塩化メチレンまたはアセトニトリル中、カルボン酸クロリドまたはカルボン酸フルオリドへ変換する活性化、次いでトリエチルアミンまたはピリジンなどの塩基存在下のアミンとの反応は、特に有用なカップリング操作である。\n\nA compound of formula I wherein -J-R \n3\n is -CONR \n6\n R \n7\n may be prepared according to reaction scheme 11 below. \n Reaction formula 11: \n \n \n \n Carboxylic acid 1 is reacted with amine HNR \n6\n R \n7\n using various standard coupling procedures known in the literature to give amide compounds of formula 2. Activation of the conversion of carboxylic acid into carboxylic acid chloride or carboxylic acid fluoride in methylene chloride or acetonitrile, followed by reaction with an amine in the presence of a base such as triethylamine or pyridine is a particularly useful coupling procedure.\n\n\n\n\n\n\n \n\n  Ｒ\n1\nが−Ｏ−ＣＯ−ＮＲ\n6\nＲ\n7\n、および−Ｊ−Ｒ\n3\nが複素環、たとえばオキサジアゾールである式Ｉの化合物は、下記反応式１２に従って製造しうる。\n\n  反応式１２：\n\n\n \n \n\n\nCompounds of formula I wherein R \n1\n is —O—CO—NR \n6\n R \n7\n and —J—R \n3\n is a heterocycle, such as oxadiazole, may be prepared according to Scheme 12 below. \n Reaction formula 12: \n \n \n \n \n\n\n\n\n\n\n \n\n  ニトリル１をｎ−プロパノールなどの有機溶媒中、ヒドロキシルアミンと反応させて、カルボキシアミジン２を得る。カルボキシアミジン２を標準カップリング操作により、種々のカルボン酸、カルボン酸クロリドまたはカルボン酸フルオリドでアシル化し、得られる中間体を加熱下の環化に付して、１，２，４−オキサジアゾール３を得る。１，２，４−オキサジアゾール３のケタール基の脱保護後、テトラヒドロフランなどの有機溶媒中、ホウ水素化ナトリウムなどの還元剤を用いケトンの還元を行って、ヒドロキシ化合物４を得る。ヒドロキシ化合物４を以下の手順でカルバメート５に変換しうる。すなわち、最初にヒドロキシ化合物を４−ニトロフェニルクロロホルメートと反応させて、カーボネート中間体を得、次いでこれをアミンと反応させて、カルバメートを形成する。\n\n\n  Nitrile 1 is reacted with hydroxylamine in an organic solvent such as n-propanol to give carboxyamidine 2. Carboxyamidine 2 is acylated with various carboxylic acids, carboxylic acid chlorides or carboxylic acid fluorides by standard coupling procedures and the resulting intermediate is subjected to cyclization under heating to give 1,2,4-oxadiazole. Get 3. After deprotecting the ketal group of 1,2,4-oxadiazole 3, the ketone is reduced using a reducing agent such as sodium borohydride in an organic solvent such as tetrahydrofuran to obtain hydroxy compound 4. Hydroxy compound 4 can be converted to carbamate 5 by the following procedure. That is, the hydroxy compound is first reacted with 4-nitrophenyl chloroformate to give a carbonate intermediate, which is then reacted with an amine to form a carbamate.\n\n\n\n\n\n\n\n \n\n  Ｒ\n1\nが−Ｏ−ＣＯ−ＮＲ\n6\nＲ\n7\n、および−Ｊ−Ｒ\n3\nが複素環、たとえばテトラゾールである式Ｉの化合物は、下記反応式１３に従って製造できる。\n\n  反応式１３：\n\n\n \n \n\n\nCompounds of formula I where R \n1\n is —O—CO—NR \n6\n R \n7\n and —J—R \n3\n is a heterocycle, such as tetrazole, can be prepared according to Scheme 13 below. \n Reaction formula 13: \n \n \n \n \n\n\n\n\n\n\n \n\n  ニトリル１をＮ，Ｎ−ジメチルホルムアミドなどの有機溶媒中、高温にてナトリウムアジドと反応させて、テトラゾール化合物２を形成する。テトラゾール化合物２をアセトニトリルなどの有機溶媒中、炭酸カリウムなどの塩基の存在下、アルキルハライドで処理してアルキル化することができる。アルキル化テトラゾール化合物３のケタール基の脱保護後、テトラヒドロフランなどの有機溶媒中、ホウ水素化ナトリウムなどの還元剤を用い、ケトンの還元を行って、ヒドロキシ化合物４を得る。ヒドロキシ化合物４を以下の手順でカルバメート５に変換しうる。すなわち、最初にヒドロキシ化合物を４−ニトロフェニルクロロホルメートと反応させて、カーボネート中間体を得、次いでこれをアミンと反応させて、カルバメートを形成する。\n\n\n  Nitrile 1 is reacted with sodium azide in an organic solvent such as N, N-dimethylformamide at high temperature to form tetrazole compound 2. The tetrazole compound 2 can be alkylated by treating with an alkyl halide in the presence of a base such as potassium carbonate in an organic solvent such as acetonitrile. After deprotection of the ketal group of the alkylated tetrazole compound 3, the ketone is reduced using a reducing agent such as sodium borohydride in an organic solvent such as tetrahydrofuran to obtain the hydroxy compound 4. Hydroxy compound 4 can be converted to carbamate 5 by the following procedure. That is, the hydroxy compound is first reacted with 4-nitrophenyl chloroformate to give a carbonate intermediate, which is then reacted with an amine to form a carbamate.\n\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが複素環、たとえば３Ｈ−キナゾリン−４−オンである式Ｉの化合物は、下記反応式１４に従って製造できる。\n\n  反応式１４：\n\n\n \n \n\n  文献公知の種々の標準カップリング操作を用い、カルボン酸１をアントラニル酸と反応させて、アミド化合物２を得る。化合物２をエタノールなどの有機溶媒中、塩基性条件下高温にて環化反応に付し、式３の化合物を得る。\n\nCompounds of formula I wherein -JR \n3\n is a heterocycle, such as 3H-quinazolin-4-one, can be prepared according to the following reaction scheme 14. \n Reaction formula 14: \n \n \n \n Carboxylic acid 1 is reacted with anthranilic acid using various standard coupling procedures known in the literature to give amide compound 2. Compound 2 is subjected to a cyclization reaction in an organic solvent such as ethanol at high temperature under basic conditions to obtain a compound of formula 3.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが複素環、たとえばベンゾキサゾールである式Ｉの化合物は、下記反応式１５に従って製造できる。\n\n  反応式１５：\n\n\n \n \n\n  文献公知の種々の標準カップリング操作を用い、カルボン酸１を２−アミノフェノール誘導体と反応させて、アミド化合物２を得る。化合物２をｐ−キシレンなどの有機溶媒中、酸性条件下高温にて環化反応に付し、式３の化合物を得る。\n\nCompounds of formula I wherein -JR \n3\n is a heterocycle, such as benzoxazole, can be prepared according to Scheme 15 below. \n Reaction formula 15: \n \n \n \n Carboxylic acid 1 is reacted with a 2-aminophenol derivative using various standard coupling procedures known in the literature to give amide compound 2. Compound 2 is subjected to a cyclization reaction in an organic solvent such as p-xylene at high temperature under acidic conditions to obtain a compound of formula 3.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが複素環、たとえばベンズイミダゾールである式Ｉの化合物は、下記反応式１６に従って製造できる。\n\n  反応式１６：\n\n\n \n \n\n  文献公知の種々の標準カップリング操作を用い、カルボン酸１をｏ−フェニレンジアミン誘導体と反応させて、アミド化合物２を得る。化合物２を酢酸などの溶媒中、酸性条件下高温にて環化反応に付し、式３の化合物を得る。\n\nCompounds of formula I wherein -JR \n3\n is a heterocycle, such as benzimidazole, can be prepared according to the following reaction scheme 16. \n Reaction formula 16: \n \n \n \n Carboxylic acid 1 is reacted with an o-phenylenediamine derivative using various standard coupling procedures known in the literature to give amide compound 2. Compound 2 is subjected to a cyclization reaction in a solvent such as acetic acid at a high temperature under acidic conditions to obtain a compound of formula 3.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが−ＣＯ−ＮＲ\n6a\nＲ\n7a\nおよびＲ\n1\nが−Ｏ−ＣＯ−ＮＲ\n6\nＲ\n7\nである式Ｉの化合物は、下記反応式１７に従って製造できる。\n\n  反応式１７：\n\n\n \n \n\n\nCompounds of formula I -J-R \n3\n is -CO-NR \n6a\n R \n7a\n and R \n1\n is -O-CO-NR \n6\n R \n7\n may be prepared according to the following reaction formula 17. \n Reaction formula 17: \n \n \n \n \n\n\n\n\n\n\n \n\n  ニトリル１をエチレングリコールなどの溶媒中、高温にて水酸化ナトリウムなどの塩基で処理して、カルボン酸２に変換しうる。文献公知の種々の標準カップリング操作を用い、カルボン酸２をアミンＨＮＲ\n6a\nＲ\n7a\nと反応させて、アミド化合物３を得る。アミド化合物３のケタール基の脱保護後、テトラヒドロフランなどの有機溶媒中、ホウ水素化ナトリウムなどの還元剤を用い、ケトンの還元を行ってヒドロキシ化合物４を得る。ヒドロキシ化合物４を以下の手順で式５のカルバメートに変換しうる。すなわち、最初にヒドロキシ化合物４を４−ニトロフェニルクロロホルメートと反応させてカーボネート中間体を得、次いでこれをＨＮＲ\n6\nＲ\n7\nと反応させ、カーボネートを形成する。\n\nNitrile 1 can be converted to carboxylic acid 2 by treatment with a base such as sodium hydroxide in a solvent such as ethylene glycol at an elevated temperature. Carboxylic acid 2 is reacted with amine HNR \n6a\n R \n7a\n using various standard coupling procedures known in the literature to give amide compound 3. After deprotection of the ketal group of the amide compound 3, the ketone is reduced using a reducing agent such as sodium borohydride in an organic solvent such as tetrahydrofuran to obtain the hydroxy compound 4. Hydroxy compound 4 can be converted to the carbamate of formula 5 by the following procedure. That is, hydroxy compound 4 is first reacted with 4-nitrophenyl chloroformate to give a carbonate intermediate, which is then reacted with HNR \n6\n R \n7\n to form a carbonate.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが−ＣＯ−ＮＲ\n6a\nＲ\n7a\nおよびＲ\n1\nが−ＮＲ\n8\n−ＣＯ−Ｒ\n4\nである式Ｉの化合物は、下記反応式１８に従って製造できる。\n\n  反応式１８：\n\n\n \n \n\n\nCompounds of formula I wherein -J-R \n3\n is -CO-NR \n6a\n R \n7a\n and R \n1\n is -NR \n8\n -CO-R \n4\n can be prepared according to Scheme 18 below. \n Reaction formula 18: \n \n \n \n \n\n\n\n\n\n\n \n\n  文献公知の種々の標準カップリング操作を用い、カルボン酸１をアミンＨＮＲ\n6a\nＲ\n7a\nと反応させて、アミド化合物２を得る。アミド化合物２のケタール基の脱保護後、最初にケトンをアミンＨ\n2\nＮＲ\n8\nで処理してイミン中間体を形成し、次いでメタノールなどの有機溶媒中、シアノホウ水素化ナトリウムなどの還元剤でイミンの還元を行い、ケトンの還元アミノ化を行うことにより、アミノ化合物３を得る。種々の標準カップリング操作を用い、アミノ化合物３をカルボン酸Ｒ\n4\nＣＯ\n2\nＨと反応させて、化合物４を得る。\n\nCarboxylic acid 1 is reacted with amine HNR \n6a\n R \n7a\n using various standard coupling procedures known in the literature to give amide compound 2. After deprotection of the ketal group of amide compound 2, the ketone is first treated with amine H \n2\n NR \n8\n to form an imine intermediate, and then the imine is reacted with a reducing agent such as sodium cyanoborohydride in an organic solvent such as methanol. Amino compound 3 is obtained by performing reduction and reductive amination of the ketone. Using various standard coupling procedures, amino compound 3 is reacted with carboxylic acid R \n4\n CO \n2\n H to give compound 4.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが−ＣＯＮＲ\n6a\nＲ\n7a\nおよびＲ\n1\nが−ＮＲ\n8\n−Ｃ（ＮＣＮ）−ＮＲ\n6\nＲ\n7\nである式Ｉの化合物は、下記反応式１９に従って製造できる。\n\n  反応式１９：\n\n\n \n \n\n  アミン１をアセトニトリルなどの溶媒中、高温にてジフェニルシアノカルボンイミデートと反応させて、中間体２を得、さらにアミンＨＮＲ\n6\nＲ\n7\nと反応させて、化合物３を得ることができる。\n\nA compound of formula I in which —J—R \n3\n is —CONR \n6a\n R \n7a\n and R \n1\n is —NR \n8\n —C (NCN) —NR \n6\n R \n7\n can be prepared according to Reaction Scheme 19 below. \n Reaction formula 19: \n \n \n \n In a solvent the amine 1 such as acetonitrile, is reacted with diphenyl cyanocarbonimidate at elevated temperature, to give the intermediate 2, further reacted with an amine HNR \n6\n R \n7,\n to give compound 3.\n\n\n\n\n\n\n \n\n  −Ｊ−Ｒ\n3\nが（アミノ）メチル基である式Ｉの化合物は、後記実施例３２３に記載のような方法を用い、あるいは下記反応式２０および２１に従って製造しうる。\n\n  反応式２０：\n\n\n \n \n\n  反応式２１：\n\n\n \n \n\n\nCompounds of formula I wherein -JR \n3\n is a (amino) methyl group may be prepared using methods such as those described in Example 323 below, or according to reaction schemes 20 and 21 below. \n Reaction formula 20: \n \n \n \n Reaction formula 21: \n \n \n \n \n\n\n\n\n\n\n \n\n  本発明の技術的範囲に属する追加の化合物については、上述の方法で得た化合物から、以下の実施例で例示の如く、化学合成の通常の方法により、各置換基を他の官能基に変換することによって製造することができる。\n\n  キラル中心を含有する式Ｉの化合物は、非ラセミ合成または当業者に周知方法の分割によって、非ラセミ形状で得ることができる。実施例において、非ラセミの化合物を“キラル”と称す。\n\nFor the additional compounds belonging to the technical scope of the present invention, each substituent is converted into other functional groups from the compounds obtained by the above-mentioned method by the usual method of chemical synthesis as exemplified in the following examples. Can be manufactured. \n Compounds of formula I containing chiral centers can be obtained in non-racemic form by non-racemic synthesis or by resolution of methods well known to those skilled in the art. In the examples, non-racemic compounds are referred to as “chiral”.\n\n\n\n\n\n\n \n\n  下記の実施例において、反応性官能基、たとえばヒドロキシ、アミノ、チオまたはカルボキシ基が最終生成物において望まれる場合、反応中の望ましくない関与を避けるため、これらの基を保護することが必要かもしれない。保護基の導入および除去は、当業者にとって周知である［たとえばＧreen  Ｔ．Ｗ．の“有機合成の保護基”（ジョーン・ウィリー・アンド・サンズ、１９９１年）参照］。\n\n\n  In the examples below, if reactive functional groups such as hydroxy, amino, thio or carboxy groups are desired in the final product, it may be necessary to protect these groups to avoid unwanted involvement in the reaction. Absent. The introduction and removal of protecting groups is well known to those skilled in the art [see, eg, Green T. et al. W. \"Protecting groups for organic synthesis\" (Joan Willie and Sons, 1991)].\n\n\n\n\n\n\n\n \n \n有用性\n \n\n  本発明の技術的範囲に属する化合物は、電位ゲートＫ\n+\nチャネルのＫ\nv\n１サブファミリーを阻害し、たとえば以下に示す各種の障害の処置および／または予防に有用である。\n\n  かかる障害としては、上室不整脈、心房不整脈、心房粗動、心房細動、心虚血の合併症、および心拍数制御剤としての使用を含む心不整脈；Ｐrinzmetal症状、血管痙れん症状および変異体症状の軽減を含む狭心症；消化性食道炎、機能性消化不良、運動性障害（便秘および下痢を含む）、および過敏腸症候群を含む胃腸障害；ぜん息、慢性閉塞性肺疾患、成人呼吸促進症候群、末梢血管病（間欠跛行を含む）、静脈不全、インポテンス、脳および冠痙れんおよびレーノー病を含む血管および内臓平滑筋の障害；\n\n \nUtility\n Compounds belonging to the technical scope \nof the\n present invention inhibit the K \nv\n 1 subfamily of voltage-gated K \n+\n channels and are useful, for example, in the treatment and / or prevention of various disorders shown below. \n Such disorders include supraventricular arrhythmias, atrial arrhythmias, atrial flutter, atrial fibrillation, complications of cardiac ischemia, and cardiac arrhythmias including use as heart rate regulators; Prinzmetal symptoms, vasospasm symptoms and variant symptoms Angina including relief of gastrointestinal tract; digestive esophagitis, functional dyspepsia, motility disorders (including constipation and diarrhea), and gastrointestinal disorders including irritable bowel syndrome; asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome Vascular and visceral smooth muscle disorders, including peripheral vascular disease (including intermittent claudication), venous insufficiency, impotence, brain and coronary spasm, and Lehno's disease;\n\n\n\n\n\n\n \n\n炎症性腸疾患、慢性関節リウマチ、移植拒絶、ぜん息、慢性閉塞性肺疾患、嚢胞性線維症およびアテローム性硬化症を含む炎症性および免疫疾患；再狭窄および癌（白血病を含む）を含む細胞増殖障害；聴覚系の障害；黄斑変性および白内障を含む視覚系の障害；糖尿病網膜症、糖尿病腎症および糖尿病ニューロパシーを含む糖尿病；筋緊張症およびるいそうを含む筋肉障害；末梢ニューロパシー；認識障害；片頭痛；アルツハイマー病および痴呆を含む記憶喪失；パーキンソン病および運動失調を含むＣＮＳ仲介運動機能不全；てんかん；および他のイオンチャネル仲介障害が挙げられる。\n\n\nInflammatory bowel disease, rheumatoid arthritis, transplant rejection, asthma, chronic obstructive pulmonary disease, inflammatory and immune diseases including cystic fibrosis and atherosclerosis; cell proliferation including restenosis and cancer (including leukemia) Disorders; auditory system disorders; visual system disorders including macular degeneration and cataract; diabetes including diabetic retinopathy, diabetic nephropathy and diabetic neuropathy; muscle disorders including myotonia and itch; peripheral neuropathy; cognitive impairment; Memory loss including Alzheimer's disease and dementia; CNS-mediated motor dysfunction including Parkinson's disease and ataxia; epilepsy; and other ion channel-mediated disorders.\n\n\n\n\n\n\n\n \n\n  本発明化合物は、電位ゲートＫ\n+\nチャネルのＫ\nv\n１サブファミリーの阻害薬として、以下に示す種々の障害の処置に有用である。すなわち、器官または組織の移植による抵抗、骨髄移植によって起こる対宿主性移植片病、慢性関節リウマチ、全身性紅斑性狼瘡、橋本甲状腺炎、多発性硬化症、重症筋無力症、Ｉ型糖尿病ブドウ膜炎、若年型または近代型真性糖尿病、後部ブドウ膜炎、アレルギー性脳脊髄炎、糸球体腎炎、病原性微生物によって起こる感染病、炎症性および高増殖性皮膚病、\n\nThe compounds of the present invention are useful for the treatment of various disorders shown below as inhibitors of the K \nv\n 1 subfamily of voltage gated K \n+\n channels. Resistance due to organ or tissue transplantation, graft-versus-host disease caused by bone marrow transplantation, rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetic uvea Inflammation, juvenile or modern diabetes mellitus, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, infectious diseases caused by pathogenic microorganisms, inflammatory and hyperproliferative skin diseases,\n\n\n\n\n\n\n \n\n乾癬、アトピー性皮膚炎、接触皮膚炎、湿疹性皮膚炎、脂漏性皮膚炎、扁平苔癬、天疱瘡、水疱性類天疱瘡、表皮水疱症、じんま疹、血管性水腫、脈管炎、紅斑、皮膚好酸球増加症、紅斑性狼瘡、座瘡、円形脱毛症、角結膜炎、春季結膜炎、ベーチェット病に付随するブドウ膜炎、角膜炎、ヘルペス性角膜炎、円錐角膜炎、上皮角膜ジストロフィー、角膜白斑、目天疱瘡、モーレン潰瘍強膜炎、Ｇraves眼障害、フォークト−小柳−原田症候群、サルコイドーシス、花粉アレルギー、可逆閉塞性気道病、\n\n\nPsoriasis, atopic dermatitis, contact dermatitis, eczema dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitis Erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, spring conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, keratokeratitis, epithelial cornea Dystrophies, corneal vitiligo, pemphigoid, Moren's ulcer scleritis, Graves eye disorders, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergy, reversible obstructive airway disease,\n\n\n\n\n\n\n\n \n\n気管支ぜん息、アレルギー性ぜん息、内因性ぜん息、外因性ぜん息、ダストぜん息、慢性または難治性ぜん息、末期ぜん息および気道過剰反応、気管支炎、胃潰瘍、虚血病および血栓症によって起こる血管損傷、虚血性腸疾患、炎症性腸疾患、壊死性腸炎、熱傷およびロイコトリエンＢ\n4\n−仲介病に付随する腸外傷、Ｃoeliaz病、直腸炎、好酸性胃腸炎、肥満細胞症、クローン病、潰瘍性大腸炎、片頭痛、鼻炎、湿疹、間質性腎炎、グッドパスチャー症候群、溶血性尿毒症症候群、糖尿病腎症、多発性筋炎、ギャン−バレー症候群、\n\nBronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dusty asthma, chronic or refractory asthma, end-stage asthma and airway hyperreactivity, bronchitis, gastric ulcer, vascular injury caused by ischemic disease and thrombosis, ischemic intestine Disease, inflammatory bowel disease, necrotizing enterocolitis, burns and intestinal trauma associated with leukotriene B \n4\n -mediated disease, Coeliaz disease, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine Rhinitis, eczema, interstitial nephritis, Goodpasture syndrome, hemolytic uremic syndrome, diabetic nephropathy, polymyositis, Gann-Barre syndrome,\n\n\n\n\n\n\n \n\nメニエール病、多発性神経炎、単神経炎、神経根障害、甲状腺機能亢進症、バーゼドー病、赤芽球ろう、再生不良性貧血、低形成貧血、特発性血小板減少性紫斑病、自己免疫性溶血性貧血、顆粒球減少症、悪性貧血、巨赤芽球性貧血、赤血球形成不全、骨粗しょう症、サルコイドーシス、肺線維症、特発性間質性肺炎、皮膚筋炎、尋常性魚鱗癬、光アレルギー感受性、皮膚Ｔ細胞リンパ腫、動脈硬化症、アテローム性硬化症、大動脈炎症候群、結節性多発動脈炎、心筋症、強皮症、Ｗegener肉芽腫、シェーグレン症候群、\n\n\nMeniere's disease, polyneuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedaw disease, erythroblastic fistula, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolysis Anemia, granulocytopenia, pernicious anemia, megaloblastic anemia, erythropoiesis, osteoporosis, sarcoidosis, pulmonary fibrosis, idiopathic interstitial pneumonia, dermatomyositis, ichthyosis vulgaris, photoallergic susceptibility Cutaneous T-cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, cardiomyopathy, scleroderma, Wegener granulomas, Sjogren's syndrome,\n\n\n\n\n\n\n\n \n\n脂肪症、好酸球性筋膜炎、歯肉、歯周組織、歯槽支持骨、セメント質の外傷、糸球体腎炎、脱毛防止または毛生育付与および／または発毛や増毛促進による男性型脱毛症または老人性脱毛症、筋ジストロフィー、膿皮症およびセザリー症候群、アディソン病、保存、移植または虚血性疾患のときに起こる器官の虚血−再灌流傷害、内毒素性ショック、偽膜性腸炎、薬物または放射線によって起こる大腸炎、虚血性急性腎機能不全、慢性腎機能不全、肺−酸素または薬物によって起こる中毒症、\n\n\nSteatosis, eosinophilic fasciitis, gingiva, periodontal tissue, alveolar support bone, cementitious trauma, glomerulonephritis, hair loss prevention or hair growth and / or male pattern alopecia by hair growth or hair growth promotion or By senile alopecia, muscular dystrophy, pyoderma and Sezary syndrome, Addison's disease, preservation, transplantation or organ ischemia-reperfusion injury, endotoxic shock, pseudomembranous enteritis, drugs or radiation Colitis occurring, ischemic acute renal dysfunction, chronic renal dysfunction, lung-oxygen or drug-induced poisoning,\n\n\n\n\n\n\n\n \n\n肺癌、肺気腫、白内障、鉄症、色素性網膜炎、老人性黄斑変性、瘢痕、角膜アルカリ熱傷、紅斑多型皮膚炎、線状ＩｇＡバロウス（ballous）皮膚炎およびセメント皮膚炎、歯肉炎、歯周炎、敗血症、膵炎、環境汚染、加齢、発癌、癌腫の転移および高山病によって起こる疾患、ヒスタミンまたはロイコトリエン−Ｃ\n4\n放出によって起こる疾患、ベーチェット病、自己免疫肝炎、原発性胆汁性肝硬変、原発性硬化性胆管炎、部分肝臓切除、\n\nLung cancer, emphysema, cataract, iron disease, retinitis pigmentosa, senile macular degeneration, scar, corneal alkali burn, erythema polymorphic dermatitis, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontal flame, sepsis, pancreatitis, environmental pollution, aging, carcinogenesis, disease caused by metastases and altitude sickness carcinomas, disorders caused by histamine or leukotriene -C \n4\n release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, primary Sclerosing cholangitis, partial liver resection,\n\n\n\n\n\n\n \n\n急性肝臓壊死、トキシン、ウイルス性肝炎、ショックまたは無酸素によって起こる壊死、Ｂ型ウイルス性肝炎、非Ａ型／非Ｂ型肝炎、肝硬変、アルコール性肝硬変、肝不全、激症肝不全、末期発症肝不全、“急性−オン−慢性”肝不全、化学療法作用の増大、サイトメガロウイルス感染、ＨＣＭＶ感染、ＡＩＤＳ、癌、老人痴呆、外傷性障害、および慢性細菌感染が挙げられる。\n\n\nAcute liver necrosis, toxin, viral hepatitis, necrosis caused by shock or anoxia, viral hepatitis B, non-A / non-B hepatitis, cirrhosis, alcoholic cirrhosis, liver failure, severe liver failure, end-stage onset liver Failure, “acute-on-chronic” liver failure, increased chemotherapeutic action, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, traumatic disorder, and chronic bacterial infection.\n\n\n\n\n\n\n\n \n\n  本発明化合物は、抗不整脈作用物質であって、不整脈の予防および処置（部分軽減もしくは治癒を含む）に有用である。本発明の技術的範囲に属する化合物は、Ｋ\nv\n１．５の阻害薬として特に、心房細動や心房粗動などの上室不整脈の選択的予防および処置に有用である。“上室不整脈の選択的予防および処置”とは、心房の有効治療抵抗性期間（不応期）の延長と心室の有効治療抵抗性期間（不応期）の延長の比が、１：１より大である、上室不整脈の予防または処置を意味する。この比は好ましくは、４：１より大で、より好ましくは１０：１より大であり、最も好ましくは、心房の有効治療抵抗性レスポンス期間が、心室の有効治療抵抗性期間の意味ありげに検出できる延長を伴うことなく、達成されるような比である。\n\nThe compound of the present invention is an antiarrhythmic agent and is useful for the prevention and treatment (including partial alleviation or cure) of arrhythmia. Compounds belonging to the technical scope of the present invention are particularly useful as inhibitors of K \nv\n 1.5 for the selective prevention and treatment of supraventricular arrhythmias such as atrial fibrillation and atrial flutter. “Selective prevention and treatment of supraventricular arrhythmia” means that the ratio of the prolongation of the effective treatment resistance period (refractory period) of the atrium to the prolongation of the effective treatment resistance period (refractory period) of the ventricle is greater than 1: 1. Means prevention or treatment of supraventricular arrhythmia. This ratio is preferably greater than 4: 1, more preferably greater than 10: 1, and most preferably the atrial effective treatment resistant response period is detected meaningfully of the ventricular effective treatment resistant period. The ratio is achieved without the possible extension.\n\n\n\n\n\n\n \n\n  加えて、本発明の技術的範囲に属する化合物は、Ｉ\nKur\nをブロックすることにより、全てのＩ\nKur\n−関連病態の予防や処置に使用できる。“Ｉ\nKur\n−関連病態”は、Ｉ\nKur\n遮断薬の投与によって予防、部分軽減または治癒されうる障害である。Ｋ\nv\n１．５遺伝子は、胃組織、腸／結腸組織、肺動脈、および膵ベータ細胞で発現されることが知られている。すなわち、Ｉ\nKur\n遮断薬の投与は、消化性食道炎、機能性消化不良、便秘、ぜん息および糖尿病などの障害のための有用な処置を付与しうるだろう。さらに、Ｋ\nv\n１．５は下垂体前葉製剤で発現されることが知られている。すなわち、Ｉ\nKur\n遮断薬の投与は、成長ホルモン分泌を刺激しうるだろう。Ｉ\nKur\n阻害薬は追加として、白血病などの細胞増殖障害や、慢性関節リウマチおよび移植拒絶などの自己免疫疾患にも使用できる。\n\nIn addition, compounds within the scope of the present invention, by blocking the I \nKur,\n all I \nKur\n - can be used for the prevention and treatment of related conditions. An “I \nKur\n -related condition” is a disorder that can be prevented, partially alleviated or cured by administration of an I \nKur\n blocker. The K \nv\n 1.5 gene is known to be expressed in stomach tissue, intestine / colon tissue, pulmonary artery, and pancreatic beta cells. That is, administration of an I \nKur\n blocker could confer useful treatment for disorders such as peptic esophagitis, functional dyspepsia, constipation, asthma and diabetes. Furthermore, K \nv\n 1.5 is known to be expressed in the anterior pituitary formulation. That is, administration of an I \nKur\n blocker could stimulate growth hormone secretion. In addition, I \nKur\n inhibitors can be used for cell proliferation disorders such as leukemia, and autoimmune diseases such as rheumatoid arthritis and transplant rejection.\n\n\n\n\n\n\n \n\n  このように本発明は、上述の障害の１つ以上の予防または処置法を提供するもので、該方法はこれを必要とする被険者に対し、有効量の式Ｉの化合物の少なくとも１種を投与する工程から成る。かかる方法において、下記に示されるような他の治療剤も本発明化合物と共に使用されてもよい。本発明の方法において、かかる他の治療剤は、本発明化合物の投与の前、同時、または後に投与されてよい。\n\n\n  Thus, the present invention provides a method for the prevention or treatment of one or more of the above-mentioned disorders, which method is provided to a subject in need thereof for an effective amount of at least one compound of formula I. Comprising the steps of: In such methods, other therapeutic agents as shown below may also be used with the compounds of the present invention. In the method of the present invention, such other therapeutic agent may be administered before, simultaneously with, or after the administration of the compound of the present invention.\n\n\n\n\n\n\n\n \n\n  また本発明は、上記障害の１つ以上を予防または処置でき、そのために有効な量の、式Ｉの化合物またはその塩の少なくとも１腫、および医薬的に許容しうるビヒクルまたは希釈剤から成る医薬組成物も提供する。本発明組成物は、下記の他の治療剤を含有してもよく、かつたとえば、医薬配合の分野で周知とされているような技法に従い、通常の固体または液体ビヒクルまたは希釈剤、並びに所望の投与モードに適する種類の医薬用添加成分（たとえば賦形剤、結合剤、保存剤、安定化剤、フレーバー等）を用いて配合されてよい。\n\n\n  The invention also provides a medicament that can prevent or treat one or more of the above disorders, and therefore comprises an effective amount of at least one tumor of a compound of formula I or a salt thereof, and a pharmaceutically acceptable vehicle or diluent. Compositions are also provided. The compositions of the present invention may contain other therapeutic agents as described below and, for example, according to techniques well known in the field of pharmaceutical formulation, conventional solid or liquid vehicles or diluents, as well as desired It may be formulated with a type of pharmaceutical additive suitable for the mode of administration (eg, excipients, binders, preservatives, stabilizers, flavors, etc.).\n\n\n\n\n\n\n\n \n\n  式Ｉの化合物は、適当ないずれの手段によっても、たとえば非毒性の医薬的に許容しうるビヒクルまたは希釈剤を含有する投与単位製剤にて、錠剤、カプセル剤、顆粒または粉末などの形状で経口投与；舌下投与；口内投与；皮下、静脈内、筋肉内または胸骨内注射または注入技法によるなどの非経口投与（たとえば無菌注射用水性または非水性溶液または懸濁液で）；吸入スプレーなどによる鼻腔内投与；クリームまたは軟膏などの形状での局所投与；または坐剤などの形状での直腸投与を行なうことができる。\n\n\n  The compound of formula I can be administered orally in any suitable means, for example in dosage unit formulations containing non-toxic pharmaceutically acceptable vehicles or diluents, in the form of tablets, capsules, granules or powders. Administration; sublingual administration; buccal administration; parenteral administration such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (eg, in a sterile injectable aqueous or non-aqueous solution or suspension); by inhalation spray etc. Intranasal administration; topical administration in the form of a cream or ointment; or rectal administration in the form of a suppository can be performed.\n\n\n\n\n\n\n\n \n\n  本発明化合物はたとえば、即座または長期放出に適した形態で投与してもよい。即座または長期放出は、本発明化合物を含有する適切な医薬組成物の使用により、あるいは特に長期放出の場合は、皮下インプラントもしくは浸透ポンプなどの器具の使用によって達成しうる。不整脈の予防または処置に式Ｉの化合物を投与する場合、該化合物の投与により、化学変換を正常な洞調律で行なうことができ、あるいは該化合物を必要に応じて電気的心臓変換（cardioconversion）と共に使用することができる。\n\n\n  The compounds of the invention may be administered, for example, in a form suitable for immediate or extended release. Immediate or extended release may be achieved by use of a suitable pharmaceutical composition containing a compound of the present invention, or in the case of extended release, particularly by the use of devices such as subcutaneous implants or osmotic pumps. When administering a compound of formula I for the prevention or treatment of arrhythmia, administration of the compound allows chemical conversion to occur in normal sinus rhythm, or the compound can be combined with electrical cardioversion as needed. Can be used.\n\n\n\n\n\n\n\n \n\n  経口投与用の具体的な組成物としては、たとえば嵩を付与する微結晶セルロース、沈澱防止剤としてのアルギン酸もしくはアルギン酸ナトリウム、増粘剤としてのメチルセルロース、および当該分野で公知とされているような甘味剤もしくはフレーバーを含有しうる懸濁液；およびたとえば微結晶セルロース、リン酸二カルシウム、スターチ、ステアリン酸マグネシウムおよび／またはラクトースおよび／または他の賦形剤、当該分野で公知とされているような結合剤、エキステンダー、崩壊剤、希釈剤および潤滑剤を含有しうる即座放出錠剤が挙げられる。また式Ｉの化合物は、舌下および／または口内投与により、口腔を介してデリバリーしてもよい。\n\n\n  Specific compositions for oral administration include, for example, microcrystalline cellulose that imparts bulk, alginic acid or sodium alginate as a precipitation inhibitor, methylcellulose as a thickener, and sweetness as known in the art. Suspensions that may contain agents or flavors; and, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and / or lactose and / or other excipients, as known in the art Immediate release tablets may be included which may contain binders, extenders, disintegrants, diluents and lubricants. The compounds of formula I may also be delivered via the oral cavity by sublingual and / or buccal administration.\n\n\n\n\n\n\n\n \n\n  成形錠剤、圧縮錠剤または凍結乾燥錠剤は、使用しうる具体的剤形である。具体的な組成物としては、本発明化合物を急速に溶解する希釈剤、たとえばマンニトール、ラクトース、スクロースおよび／またはシクロデキストリンと配合したものが挙げられる。またかかる配合物に、高分子量賦形剤、たとえばセルロース（アビセル（avicel））またはポリエチレングリコール（ＰＥＧ）を含ませてもよい。またかかる配合物は、粘膜密着を助成する賦形剤、たとえばヒドロキシプロピルセルロース（ＨＰＣ）、ヒドロキシプロピルメチルセルロース（ＨＰＭＣ）、ナトリウム・カルボキシメチルセルロース（ＳＣＭＣ）、無水マレイン酸コポリマー（たとえばＧantrez）、および放出を制御する物質、たとえばポリアクリル酸コポリマー（たとえばＣarbopol９３４）も含有しうる。また成形加工や使用を容易にするため、潤滑剤、滑剤、フレーバー、着色剤および安定化剤を加えてもよい。\n\n\n  Molded tablets, compressed tablets or lyophilized tablets are specific dosage forms that can be used. Specific compositions include those formulated with a diluent that rapidly dissolves the compound of the present invention, such as mannitol, lactose, sucrose and / or cyclodextrin. Such formulations may also include high molecular weight excipients such as cellulose (avicel) or polyethylene glycol (PEG). Such formulations also provide excipients that aid mucoadhesion, such as hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), sodium carboxymethylcellulose (SCMC), maleic anhydride copolymers (eg, Gantrez), and release. Control substances, such as polyacrylic acid copolymers (eg Carbopol 934) may also be included. In order to facilitate molding and use, lubricants, lubricants, flavors, colorants and stabilizers may be added.\n\n\n\n\n\n\n\n \n\n  鼻腔内の噴霧または吸入投与用の具体的な組成物としては、たとえばベンジルアルコールまたは他の適当な保存剤、生物学的利用能を高める吸収促進剤、および／または当該分野で公知とされているような他の可溶化または分散剤を含有しうる食塩水溶液が挙げられる。\n\n  非経口投与用の具体的な組成物としては、たとえば、適当な非毒性で非経口的に許容しうる希釈剤または溶剤（マンニトール、１，３−ブタンジオール、水、リンゲル液、等張性塩化ナトリウム溶液など）、または合成モノもしくはジグリセリドを含む他の適当な分散もしくは湿潤および沈澱防止剤、およびオレイン酸を含む脂肪酸を含有しうる、注射用の溶液または懸濁液が挙げられる。\n\nSpecific compositions for intranasal spray or inhalation administration include, for example, benzyl alcohol or other suitable preservatives, absorption enhancers that enhance bioavailability, and / or are known in the art. Examples include saline solutions that may contain other solubilizing or dispersing agents. \n Specific compositions for parenteral administration include, for example, suitable non-toxic parenterally acceptable diluents or solvents (mannitol, 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride Solutions), or other suitable dispersing or wetting and precipitation preventing agents including synthetic mono- or diglycerides, and fatty acids including oleic acid, or injectable solutions or suspensions.\n\n\n\n\n\n\n \n\n  直腸投与用の具体的な組成物としては、たとえば常温で固体であるが、直腸腔で液化および／または溶解して薬物を放出する、適当な非刺激性賦形剤（カカオ脂、合成グリセリドエステルまたはポリエチレングリコールなど）を含有しうる坐剤が挙げられる。\n\n  局所投与用の具体的な組成物としては、局所用キャリヤー、たとえばＰlastibase（鉱油をポリエチレンでゲル化したもの）が挙げられる。\n\nSpecific compositions for rectal administration include, for example, suitable non-irritating excipients (cocoa butter, synthetic glyceride esters) that are solid at room temperature but liquefy and / or dissolve in the rectal cavity to release the drug. Or a suppository that may contain polyethylene glycol or the like. \n Specific compositions for topical administration include topical carriers such as Plastibase (mineral oil gelled with polyethylene).\n\n\n\n\n\n\n \n\n  本発明化合物の有効量は、当業者によって決定されてよく、たとえば成人の場合で、１日当りの活性化合物約０．００１〜１００ｍｇ／体重（ｋｇ）の投与量が挙げられ、たとえば１日１回の単一用量で、あるいは２〜４回の個々の分割用量の形態で投与されてよい。個々のいずれの被険者にも対する特別な投与量および投与頻度は、適宜に変化させてよく、かつ使用する特定化合物の活性、該化合物の代謝安定性および作用長さ、被険者の人種、年令、体重、通常の健康状態、性別および規定食、投与のモードおよび時間、排泄速度、薬物併用、および個々の病態の厳しさを含む種々のファクターに依存することが理解されよう。処置に好ましい被険体としては、動物、最も好ましくは、上述の障害にかかり易い哺乳類、たとえばヒト、およびイヌ、ネコなどの家庭用動物が包含される。\n\n\n  The effective amount of the compound of the present invention may be determined by those skilled in the art. For example, in the case of an adult, a dose of about 0.001 to 100 mg / kg body weight of active compound per day can be mentioned, for example, once a day. May be administered in a single dose or in the form of 2-4 individual divided doses. The specific dose and frequency of administration for any individual subject may vary as appropriate, and the activity of the particular compound used, the metabolic stability and length of action of the compound, the individual of the subject It will be appreciated that it depends on various factors including species, age, weight, normal health, sex and diet, mode and time of administration, excretion rate, drug combination, and severity of individual pathology. Preferred subjects for treatment include animals, most preferably mammals susceptible to the disorders described above, such as humans, and domestic animals such as dogs, cats and the like.\n\n\n\n\n\n\n\n \n\n  本発明化合物は、それ単独または相互におよび／または上記障害もしくは他の障害の処置に使用される他の適当な治療剤と組合せて使用することができ、かかる他の治療剤としては、他の抗不整脈作用物質（抗不整脈剤）、たとえばクラスＩ作用物質（たとえばプロパフェノン（propafenone））、クラスＩＩ作用物質（たとえばカルバジオール（carvadiol）およびプロプラノロール）、クラスＩＩＩ作用物質（たとえばソタロール、ドフェチリド（dofetilide）、アミオダロン、アジミリド（azimilide）およびイブチリド（ibutilide））、クラスＩＶ作用物質（たとえばジルチアゼムおよびベラパミル）、５ＨＴ拮抗薬（たとえばスラムセロド（sulamserod）、セラリン（serraline）およびトロプセトロン（tropsetron））、およびドロンダロン（dronedarone）；カルシウムチャネル遮断薬（Ｌ型およびＴ型の両方）、たとえばジルチアゼム、ベラパミル、ニフェジピン、アムロジピン（amlodipine）およびミベフラジル（mybefradil）；\n\n\n  The compounds of the present invention can be used alone or in combination with each other and / or with other suitable therapeutic agents used in the treatment of the above disorders or other disorders, such other therapeutic agents include other Antiarrhythmic agents (antiarrhythmic agents), such as class I agents (eg, propafenone), class II agents (eg, carvadiol and propranolol), class III agents (eg, sotalol, dofetilide) ), Amiodarone, azimilide and ibutilide), class IV agonists (eg diltiazem and verapamil), 5HT antagonists (eg sulamserod, serraline and tropsetron), and drondalone ( dronedarone); Cal Sium channel blockers (both L and T), such as diltiazem, verapamil, nifedipine, amlodipine and mybefradil;\n\n\n\n\n\n\n\n \n\nシクロオキシゲナーゼ阻害薬（すなわち、ＣＯＸ−１および／またはＣＯＸ−２阻害薬）、たとえばアスピリン、インドメタシン、イブプロフェン、ピロキシカム、ナプロキセン、セレブレックス（celebrex）、ビオエックスエックス（vioxx）およびＮＳＡＩＤｓ；抗血小板物質、たとえばＧＰＩＩｂ／ＩＩＩａ遮断薬（たとえばアブシキシマブ（abciximab）、エプチフィバチド（eptifibatide）およびチロフイバン（tirofiban））、Ｐ２Ｙ\n12\n拮抗薬（たとえばクロピドグレル（clopidogrel）、チクロピジン（ticlopidine）およびＣＳ−７４７）、トロンボキサン・レセプタ拮抗薬（たとえばイフエトロバン（ifetroban））、アスピリン、およびアスピリンを伴なうまたは伴なわないＰＤＥ−ＩＩＩ阻害薬（たとえばジピリダモール）；利尿薬、たとえばクロロチアジド、ヒドロクロロチアジド、フルメチアジド、ヒドロフルメチアジド、ベンドロフルメチアジド、メチルクロロチアジド、トリクロロメチアジド、ポリチアジド、ベンズチアジド、エタクリン酸、トリクリナフェン（tricrynafen）、クロルタリドン、フロセミド、ムソリミン、ブメタニド、トリアムトレネン、アミロリドおよびスピロノラクトン；\n\nCyclooxygenase inhibitors (ie, COX-1 and / or COX-2 inhibitors) such as aspirin, indomethacin, ibuprofen, piroxicam, naproxen, celebrex, biooxx and NSAIDs; GPIIb / IIIa blockers (eg, abciximab, eptifibatide and tirofiban), P2Y \n12\n antagonists (eg, clopidogrel, ticlopidine and CS-747), thromboxane receptor antagonists (Eg, ifetroban), aspirin, and PDE-III inhibitors with or without aspirin (eg, dipyridamole); diuretics, eg, chloro Azide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid, tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtoleno Spironolactone;\n\n\n\n\n\n\n \n\n抗高血圧剤、たとえばアルファアドレナリン作用遮断薬、ベータアドレナリン作用遮断薬、カルシウムチャネル遮断薬、利尿薬、レニン阻害薬、ＡＣＥ阻害薬（たとえばカプトプリル、ゾフェノプリル、ホシノプリル、エナラプリル、セラノプリル、シラゾプリル、デラプリル、ペントプリル、キナプリル、ラミプリル、リシノプリル）、ＡＩＩ拮抗薬（たとえばロサルタン（losartan）、アーベサルタン（irbesartan）、バルサルタン（valsartan））、ＥＴ拮抗薬（たとえばシタックスセンタン（sitaxsentan）、アトルセンタン（atrsentan）およびＵ．Ｓ．特許Ｎｏ．５６１２３５９および６０４３２６５に開示の化合物）、二元ＥＴ／ＡＩＩ拮抗薬（たとえばＷＯ００／０１３８９に開示の化合物）、中性エンドペプチダーゼ（ＮＥＰ）阻害薬、バソペプシダーゼ阻害薬（二元ＮＥＰ−ＡＣＥ阻害薬）（たとえばオマパトリラット（omapatrilat）およびゲモパトリラット（gemopatrilat））、ニトレート、およびこれら抗高血圧剤の組合せ；\n\n\nAntihypertensive agents such as alpha adrenergic blockers, beta adrenergic blockers, calcium channel blockers, diuretics, renin inhibitors, ACE inhibitors (eg captopril, zofenopril, fosinopril, enalapril, ceranopril, silazopril, delapril, pentopril, Quinapril, ramipril, lisinopril), AII antagonists (eg, losartan, irbesartan, valsartan), ET antagonists (eg, sitaxsentan, atrsentan) and U.S. Patent Nos. 5612359 and 6043265), binary ET / AII antagonists (eg compounds disclosed in WO00 / 01389), neutral endopeptidase (NEP) inhibitors, batho Pushidaze inhibitors (two NEP-ACE inhibitors) (e.g., omapatrilat (omapatrilat) and gemopatrilat (Gemopatrilat)), nitrates and combinations thereof antihypertensives;\n\n\n\n\n\n\n\n \n\n抗血栓／抗血栓崩壊剤、たとえば組織プラスミノゲン・アクチベータ（ｔＰＡ）、組換えｔＰＡ、テネクテプラーゼ（tenecteplase）（ＴＮＫ）、ラノテプラーゼ（lanoteplase）（ｎＰＡ）、ＶＩＩａ因子阻害薬、Ｘａ因子阻害薬、トロンビン阻害薬（たとえばヒルジンおよびアルガトロバン（argatroban）、ＰＡＩ−１阻害薬（すなわち、組織プラスミノゲン・アクチベータ阻害薬の不活性化剤）、α２−アンチプラスミン阻害薬、ストレプトキナーゼ、ウロキナーゼ、プロウロキナーゼ、アニソイル化プラスミノゲン−ストレプトキナーゼ・アクチベータ複合体、および動物または唾液腺プラスミノゲン・アクチベータ；抗凝血薬、たとえばワルファリン（warfarinおよびヘパリン（未分別および低分子量ヘパリン、たとえばエノキサパリン（enoxaparin）およびダルテパリン（dalteparin）を含む）；ＨＭＧ−ＣｏＡレダクターゼ阻害薬、たとえばプラバスタチン、ロバスタチン、アトルバスタチン、シンバスタチン、ＮＫ−１０４（ａ．ｋ．ａ．イタバスタチン、またはニスバスタチン（nisvastatinもしくはnisbastatin））およびＺＤ−４５２２（ａ．ｋ．ａ．ロスバスタチン、またはアタバスタチンもしくはビサスタチン）；\n\n\nAntithrombotic / antithrombolytic agents, eg tissue plasminogen activator (tPA), recombinant tPA, tenecteplase (TNK), lanoteplase (nPA), factor VIIa inhibitor, factor Xa inhibitor, thrombin inhibitor (Eg, hirudin and argatroban, PAI-1 inhibitors (ie, tissue plasminogen activator inhibitor inactivators), α2-antiplasmin inhibitors, streptokinase, urokinase, prourokinase, anisoylated plasminogen-strepto Kinase-activator complexes, and animal or salivary gland plasminogen activators; anticoagulants such as warfarin (warfarin and heparin (unsorted and low molecular weight heparin such as enoxaparin And HMG-CoA reductase inhibitors such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (aka itavastatin or nisvastatin or nisbastatin) and ZD-4522 (Aka rosuvastatin or atorvastatin or visastatin);\n\n\n\n\n\n\n\n \n\n他のコレステロール／脂質低下剤、たとえばスクアレン・シンセターゼ阻害薬、フィブレート、および胆汁酸金属イオン封鎖剤（たとえばクエストラン（questran））；抗増殖剤、たとえばシクロスポリンＡ、タキソル、ＦＫ５０６およびアドリアマイシン；抗腫瘍剤、たとえばタキソル、アドリアマイシン、エポチロン、シスプラチンおよびカルボプラチン；抗糖尿病剤、たとえばビグアニド（たとえばメトホルミン）、グルコシダーゼ阻害薬（たとえばアカーボース（acarbose））、インスリン、メグリチニド（たとえばレパグリニド）、スルホニルウレア（たとえばグリメピリド、グリブリドおよびグリピジド）、ピグアニド／グリブリド併用（すなわち、グルコバンス（glucovance））、チオゾリジンジオン（たとえばトログリタゾン、ロシグリタゾンおよびピオグリタゾン）、ＰＰＡＲ−ガンマ作用薬、ａＰ２阻害薬およびＤＰ４阻害薬；\n\n\nOther cholesterol / lipid lowering agents such as squalene synthetase inhibitors, fibrates, and bile acid sequestrants (eg questran); antiproliferative agents such as cyclosporin A, taxol, FK506 and adriamycin; antitumor agents For example, taxol, adriamycin, epothilone, cisplatin and carboplatin; antidiabetic agents such as biguanides (eg metformin), glucosidase inhibitors (eg acarbose), insulin, meglitinides (eg repaglinide), sulfonylureas (eg glimepiride, glyburide and glipizide ), Piguanide / glyburide combinations (ie glucovance), thiozolidinediones (eg troglitazone, rosi Ritazon and pioglitazone), PPAR-gamma agonists, aP2 inhibitors, and DP4 inhibitors;\n\n\n\n\n\n\n\n \n\n甲状腺擬症薬（thyroid  mimetics）（甲状腺レセプタ拮抗薬を含む）（たとえばチロトロピン、ポリチロイド、ＫＢ−１３００１５、およびドロンダロン）；鉱質コルチコイドレセプタ拮抗薬、たとえばスピロノラクトンおよびエプレリノン；成長ホルモン分泌促進薬；抗骨粗しょう症剤（たとえばアレンドロネートおよびラロキシフェン）；ホルモン置換療法剤、たとえばエストロゲン（共役エストロゲン／プレマリンを含む）、およびエストラジオール；抗うつ薬、たとえばネファゾドンおよびセルトラリン；抗不安薬、たとえばジアゼパム、ロラゼパム、ブスピロン（buspirone）およびヒドロキシジン・パモエート；経口避妊薬；\n\n\nThyroid mimetics (including thyroid receptor antagonists) (eg thyrotropin, polythyroid, KB-130015, and drondalone); mineralocorticoid receptor antagonists such as spironolactone and eplerinone; growth hormone secretagogues; antibones Pulmonary agents (eg, alendronate and raloxifene); hormone replacement therapies such as estrogen (including conjugated estrogens / premarin), and estradiol; antidepressants such as nefazodone and sertraline; anxiolytics such as diazepam, lorazepam, buspirone (Buspirone) and hydroxyzine pamoate; oral contraceptives;\n\n\n\n\n\n\n\n \n\n抗潰瘍および胃食道逆流疾患剤、たとえばファモチジン、ラニチジンおよびオメプラゾール；抗肥満剤、たとえばオルリスタット（orlistat）；強心配糖体（ジギタリスおよびウアバイン（ouabain）を含む）；ホスホジエステラーゼ阻害薬（ＰＤＥ  ＩＩＩ阻害薬、たとえばシロスタゾール（cilostazol）、およびＰＤＥ  Ｖ阻害薬、たとえばシルデナフィル（sildenafil）を含む）；たん白チロシン・キナーゼ阻害薬；ステロイド系抗炎症剤、たとえばプレドニゾンおよびデキサメタゾン；および他の抗炎症剤、たとえばエンブレル（enbrel）が包含される。\n\n\nAnti-ulcer and gastroesophageal reflux disease agents such as famotidine, ranitidine and omeprazole; anti-obesity agents such as orlistat; cardiac glycosides (including digitalis and ouabain); phosphodiesterase inhibitors (PDE III inhibitors, Including cilostazol and PDE V inhibitors such as sildenafil); protein tyrosine kinase inhibitors; steroidal anti-inflammatory agents such as prednisone and dexamethasone; and other anti-inflammatory agents such as embrel ( enbrel).\n\n\n\n\n\n\n\n \n\n  上記他の治療剤は、本発明化合物と組合せて使用するとき、たとえばザ・フィジシャンズ・デスク・リファレンス（the  Ｐhysicians’  Ｄesk  Ｒeference）（ＰＤＲ）に示される量で、さもなければ当業者によって決定されるようにして使用されてよい。\n\n  化合物のＩ\nKur\n阻害薬としての活性の程度を測定するアッセイは、当該分野で周知であり、かつたとえば「Ｊ．Ｇen．Ｐhysiol．４月号」（１０１（４）：５１３−５４３）；および「Ｂｒ．Ｊ．Ｐharmacol．」（１１５（２）：２６７−２７４、１９９５年５月）などの文献に記載されている。\n\nThese other therapeutic agents are used in combination with the compounds of the present invention, for example, in the amounts indicated in the Physicians' Desk Reference (PDR), or otherwise determined by one skilled in the art. May be used as such. \n Assays that measure the degree of activity of a compound as an I \nKur\n inhibitor are well known in the art and are described, for example, in “J. Gen. Physiol. April” (101 (4): 513-543); Br. J. Pharmacol. \"(115 (2): 267-274, May 1995).\n\n\n\n\n\n\n \n\n  化合物の、Ｋ\nv\n１サブファミリーの他のメンバーの阻害薬としての活性の程度を測定するアッセイも、当該分野で周知である。Ｋ\nv\n１．１、Ｋ\nv\n１．２およびＫ\nv\n１．３の阻害は、Ｇrissmer  Ｓ．らの「Ｍol．Ｐharmacol．」（４５（６）：１２２７−１２３４、１９９４年６月）に記載の手順に従って評価することができる。Ｋ\nv\n１．４の阻害は、Ｐetersen  Ｋ．Ｒ．およびＮerbonne  Ｊ．Ｍ．の「Ｐflugers  Ａrch．」（４３７（３）：３８１−３９２、１９９９年２月）に記載の手順に従って評価することができる。Ｋ\nv\n１．６の阻害は、Ｂowlby  Ｍ．Ｒ．およびＬevitan  Ｉ．Ｂ．の「Ｊ．Ｎeurophysiol.」（７３（６）：２２２１−２２２９、１９９５年６月）に記載の手順に従って評価することができる。Ｋ\nv\n１．７の阻害は、Ｋalman  Ｋ．らの「Ｊ．Ｂiol．Ｃhem．」（２７３（１０）：５８５１−５８５７、１９９８年３月）に記載の手順に従って評価することができる。\n\n  本発明の技術的範囲に属する化合物は、上記のようなＫ\nv\n１アッセイでの活性を立証する。\n\n  本明細書で引用した全ての文書を、参考までにそっくりそのままの状態で本明細書に導入する。\n\nAssays that measure the degree of activity of compounds as inhibitors of other members of the K \nv\n 1 subfamily are also well known in the art. Inhibition of K \nv\n 1.1, K \nv\n 1.2 and K \nv\n 1.3 is described by Grissmer S. et al. \"Mol. Pharmacol.\" (45 (6): 1227-1234, June 1994). Inhibition of K \nv\n 1.4 is shown in Petersen K. et al. R. And Nerbonne J. et al. M.M. \"Pflugers Arch.\" (437 (3): 381-392, February 1999). Inhibition of K \nv\n 1.6 was observed by Bowlby M. et al. R. And Levitan I. B. In \"J. Neurophysiol.\" (73 (6): 2222-1229, June 1995). Inhibition of K \nv\n 1.7 is shown in Kalman K. et al. \"J. Biol. Chem.\" (273 (10): 5851-5857, March 1998). \n Compounds within the scope of the present invention demonstrate activity in the K \nv\n 1 assay as described above. \n All documents cited herein are hereby incorporated by reference in their entirety for reference.\n\n\n\n\n\n\n\n\n\n\n \n\n  次に挙げる実施例および製造例は、本発明化合物の製造および使用する方法を記載し、かつ限定よりはむしろ例示のものである。理解すべき点は、特許請求の範囲で規定される本発明の技術的範囲および精神に属する他の具体例が存在しうることである。\n\n\n  The following examples and preparations describe the preparation and use of the compounds of the present invention and are illustrative rather than limiting. It should be understood that there may be other embodiments that fall within the scope and spirit of the invention as defined by the claims.\n\n\n\n\n\n\n\n \n\n  実施例１\n\n  シスおよびトランス−Ｎ−（４−ヒドロキシ−１−チオフェン−２−イル−シクロヘキシルメチル）−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 1 \n Cis and trans-N- (4-hydroxy-1-thiophen-2-yl-cyclohexylmethyl) -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物２：\n\n  アセトニトリル（２７ｍＬ）中の２−チオフェンアセトニトリル（５００ｍｇ、４．０６ミリモル）の溶液に室温にて、トリトンＢ（メタノールの４０重量％溶液、０．１９ｍＬ、０．４２ミリモル）を加える。反応混合物を窒素下で９５℃に加熱し、アクリル酸メチル（３．６ｍＬ、４０ミリモル）をゆっくり加える（激しく発熱）。５ｈ後、反応混合物を冷却せしめ、５０ｍＬのエーテルで希釈する。溶液を分液漏斗に移し、ＨＣｌ（１Ｎ、２０ｍＬ×２）および飽和ＮａＣｌ（２０ｍＬ×１）で連続して洗う。有機部分を無水Ｎａ\n2\nＳＯ\n4\n上で乾燥し、デカントし、濃縮して１．１０ｇ（粗収率９２％）の化合物２を暗褐色油状物で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：２．２ｐｐｍ、２Ｈ、多重；２．３ｐｐｍ、２Ｈ、多重；２．４ｐｐｍ、２Ｈ、多重；３．６５ｐｐｍ、６Ｈ、一重；６．９７ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝３．６および６．２Ｈｚ；７．１３ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および３．６Ｈｚ；７．３２ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および５．１Ｈｚ\n\nCompound 2: \n To a solution of 2-thiopheneacetonitrile (500 mg, 4.06 mmol) in acetonitrile (27 mL) at room temperature is added Triton B (40 wt% solution of methanol, 0.19 mL, 0.42 mmol). The reaction mixture is heated to 95 ° C. under nitrogen and methyl acrylate (3.6 mL, 40 mmol) is slowly added (violent exotherm). After 5 h, the reaction mixture is allowed to cool and diluted with 50 mL of ether. Transfer the solution to a separatory funnel and wash successively with HCl (1N, 20 mL × 2) and saturated NaCl (20 mL × 1). The organic portion is dried over anhydrous Na \n2\n SO \n4\n , decanted and concentrated to give 1.10 g (92% crude yield) of compound 2 as a dark brown oil. \n \n1\n H-NMR (CDCl \n3\n ): 2.2 ppm, 2 H, multiplex; 2.3 ppm, 2 H, multiplex; 2.4 ppm, 2 H, multiplex; 3.65 ppm, 6 H, single; 6.97 ppm, 1 H, dd, J = 3.6 and 6.2 Hz; 7.13 ppm, 1 H, dd, J = 1.2 and 3.6 Hz; 7.32 ppm, 1 H, dd, J = 1.2 and 5.1 Hz\n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物２（１．１０ｇ、３．７２ミリモル）を、無水ジメチルエチレングリコール（２０ｍＬ）に溶解する。該溶液に、水素化ナトリウム（鉱油中６０％分散液、３６０ｍｇ、１１．２ミリモル）をゆっくり加え、得られる褐色スラリーを窒素下９５℃に４．５ｈ加熱し、次いで一夜（１２ｈ）冷却せしめる。スラリーを１５ｍＬの水に注意深く注ぎ、１００ｍＬのエーテルで希釈する。有機部分をＨＣｌ（３．７Ｎ、２０ｍＬ×２）で洗い、無水Ｎａ\n2\nＳＯ\n4\n上で乾燥し、デカントし、濃縮して褐色油状物を得る。粗油状物をシリカゲルフラッシュクロマトグラフィー（ヘキサン／酢酸エチル＝３：１で溶離）で精製して、２９８ｍｇ（単離収率３１％）の化合物３を淡褐色油状物で得る。\n\nCompound 3: \n Compound 2 (1.10 g, 3.72 mmol) is dissolved in anhydrous dimethylethylene glycol (20 mL). To the solution is slowly added sodium hydride (60% dispersion in mineral oil, 360 mg, 11.2 mmol) and the resulting brown slurry is heated to 95 ° C. under nitrogen for 4.5 h and then allowed to cool overnight (12 h). Carefully pour the slurry into 15 mL water and dilute with 100 mL ether. The organic portion is washed with HCl (3.7 N, 20 mL × 2), dried over anhydrous Na \n2\n SO \n4\n , decanted and concentrated to give a brown oil. The crude oil is purified by flash chromatography on silica gel (eluting with hexane / ethyl acetate = 3: 1) to give 298 mg (31% isolated yield) of compound 3 as a light brown oil.\n\n\n\n\n\n\n \n\n  ＨＰＬＣ：Ｒｔ３．１０分、純度１００％，ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の４分勾配、２２０ｎｍでＵＶ検出\n\n  ＬＣＭＳ：Ｒｔ１．６１分、［Ｍ＋Ｎａ］２８６．１０、ＹＭＣ  Ｓ５カラム４．６×３０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の２分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：２．２ｐｐｍ、２Ｈ、多重；２．４ｐｐｍ、２Ｈ、多重；２．７ｐｐｍ、２Ｈ、多重；２．７５ｐｐｍ、１Ｈ、ｄ、Ｊ＝１３．６Ｈｚ；３．１５ｐｐｍ、１Ｈ、ｄ、Ｊ＝１５．０Ｈｚ；７．００ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝３．６および５．１Ｈｚ；７．１８ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および３．６Ｈｚ；７．２９ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および５．２Ｈｚ；１２．２ｐｐｍ、１Ｈ、一重\n\nHPLC: Rt 3.10 min, purity 100%, YMC S5 column 4.6 × 50 mm, 4 min gradient from 0-100% MeOH (90% in water, TFA 0.1%), UV detection at 220 nm LCMS: Rt 1.61 min , [M + Na] 286.10, YMC S5 column 4.6 × 30 mm, 2-minute gradient of 0-100% MeOH (90% in water, TFA 0.1%), UV detection at 220 nm \n \n1\n H-NMR (CDCl \n3\n ): 2.2 ppm, 2 H, multiplex; 2.4 ppm, 2 H, multiplex; 2.7 ppm, 2 H, multiplex; 2.75 ppm, 1 H, d, J = 13.6 Hz; 3.15 ppm 1H, d, J = 15.0 Hz; 7.00 ppm, 1H, dd, J = 3.6 and 5.1 Hz; 7.18 ppm, 1H, dd, J = 1.2 and 3.6 Hz; 7.29 ppm 1H, dd, J = 1.2 and 5.2 Hz; 12.2 ppm, 1H, single\n\n\n\n\n\n\n \n\n  化合物４：\n\n  ＤＭＳＯ（８ｍＬ、水０．５ｍＬ含有）中のβ−ケトエステル３（２９８ｍｇ、１．１３ミリモル）の溶液に、ＮａＣｌ（４２０ｍｇ、７．２４ミリモル）を加える。反応混合物を１５０℃に５ｈ加熱し、次いで周囲温度まで冷却せしめる。溶液をエーテル／酢酸エチル（１：１、５０ｍＬ）で希釈し、分液漏斗に移し、１０％ＬｉＣｌ（２０ｍＬ×３）で洗う。有機部分を無水Ｎａ\n2\nＳＯ\n4\n上で乾燥し、デカントし、濃縮して化合物４を淡褐色粉末で得る（次工程に使用するのに十分に純粋、１８４ｍｇ、収率８０％）。\n\n  ＨＰＬＣ：Ｒｔ２．３６分、純度９７％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：２．３ｐｐｍ、２Ｈ、多重；２．６ｐｐｍ、４Ｈ、多重；２．９ｐｐｍ、２Ｈ、多重；７．００ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝３．６および６．２Ｈｚ；７．２０ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および３．６Ｈｚ；７．３２ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および５．１Ｈｚ\n\nCompound 4: \n To a solution of β-ketoester 3 (298 mg, 1.13 mmol) in DMSO (8 mL, containing 0.5 mL water) is added NaCl (420 mg, 7.24 mmol). The reaction mixture is heated to 150 ° C. for 5 h and then allowed to cool to ambient temperature. The solution is diluted with ether / ethyl acetate (1: 1, 50 mL), transferred to a separatory funnel and washed with 10% LiCl (20 mL × 3). The organic portion is dried over anhydrous Na \n2\n SO \n4\n , decanted and concentrated to give compound 4 as a light brown powder (enough pure for use in the next step, 184 mg, 80% yield). \n HPLC: Rt 2.36 min, purity 97%, YMC S5 column 4.6 × 50 mm, 4 min gradient from 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm \n \n1\n H-NMR (CDCl \n3\n ): 2.3 ppm, 2 H, multiplex; 2.6 ppm, 4 H, multiplex; 2.9 ppm, 2 H, multiplex; 7.00 ppm, 1 H, dd, J = 3.6 and 6.2 Hz 7.20 ppm, 1 H, dd, J = 1.2 and 3.6 Hz; 7.32 ppm, 1 H, dd, J = 1.2 and 5.1 Hz\n\n\n\n\n\n\n \n\n  化合物５：\n\n  化合物４をトルエン（２ｍＬ）およびエチレングリコール（０．５４ｍＬ、９．６ミリモル）に溶解し、トルエンスルホン酸（９ｍｇ、０．０５ミリモル）を加える。溶液を加熱還流して、ディーン−スターク（Ｄean−Ｓtark）共沸脱水を１４ｈ行なう。冷却した反応混合物をエーテル（１００ｍＬ）で希釈し、水（２０ｍＬ×３）で洗う。有機部分を無水Ｎａ\n2\nＳＯ\n4\n上で乾燥し、デカントし、濃縮して化合物５を淡褐色油状物で得る（３２３ｍｇ、粗定量収率）。\n\n  ＨＰＬＣ：Ｒｔ２．９０分、純度８３．０％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：１．９ｐｐｍ、２Ｈ、多重；２．０ｐｐｍ、２Ｈ、多重；２．１ｐｐｍ、２Ｈ、多重；２．２ｐｐｍ、２Ｈ、多重；４．００ｐｐｍ、４Ｈ、多重；６．９８ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および３．６Ｈｚ；７．１４ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および５．１Ｈｚ；７．２７ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．２および５．１Ｈｚ\n\nCompound 5: \n Compound 4 is dissolved in toluene (2 mL) and ethylene glycol (0.54 mL, 9.6 mmol) and toluenesulfonic acid (9 mg, 0.05 mmol) is added. The solution is heated to reflux and Dean-Stark azeotropic dehydration is performed for 14 h. Dilute the cooled reaction mixture with ether (100 mL) and wash with water (20 mL × 3). The organic portion is dried over anhydrous Na \n2\n SO \n4\n , decanted and concentrated to give compound 5 as a light brown oil (323 mg, crude quantitative yield). \n HPLC: Rt 2.90 min, purity 83.0%, YMC S5 column 4.6 × 50 mm, 4 min gradient of 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm \n \n1\n H-NMR (CDCl \n3\n ): 1.9 ppm, 2H, multiplex; 2.0 ppm, 2H, multiplex; 2.1 ppm, 2H, multiplex; 2.2 ppm, 2H, multiplex; 4.00 ppm, 4H, multiplex; 6 .98 ppm, 1 H, dd, J = 1.2 and 3.6 Hz; 7.14 ppm, 1 H, dd, J = 1.2 and 5.1 Hz; 7.27 ppm, 1 H, dd, J = 1.2 and 5 .1Hz\n\n\n\n\n\n\n \n\n  化合物６：\n\n  ＴＨＦ（５ｍＬ）中の化合物５の溶液に、周囲温度でＬｉＡｌＨ\n4\n溶液（ＴＨＦ中１．０Ｍ、１．３５ｍＬ、１．３５ミリモル）を加える。得られるスラリーを窒素下で３ｈ加熱還流し、次いで０℃に冷却する。１Ｎ−ＮａＯＨ（０．３ｍＬ）を滴下し、１０分の激しい攪拌後、無水Ｎａ\n2\nＳＯ\n4\nを加える。スラリーをガラスフリットで濾過し、濾液をＴＨＦで洗い、次いで濾液を濃縮して、１５１ｍｇ（収率６６％）の化合物６を無色油状物で得る。\n\n  ＨＰＬＣ：Ｒｔ１．４７分、純度９８％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：１．７ｐｐｍ、４Ｈ、多重；１．８ｐｐｍ、２Ｈ、多重；２．１ｐｐｍ、２Ｈ、多重；２．７ｐｐｍ、２Ｈ、多重；３．９２ｐｐｍ、４Ｈ、多重；６．８６ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．９および３．５Ｈｚ；６．９７ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝３．５および５．０Ｈｚ；７．２１ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．９および５．０Ｈｚ\n\nCompound 6: \n To a solution of compound 5 in THF (5 mL) is added LiAlH \n4\n solution (1.0 M in THF, 1.35 mL, 1.35 mmol) at ambient temperature. The resulting slurry is heated to reflux under nitrogen for 3 h and then cooled to 0 ° C. 1N-NaOH (0.3 mL) is added dropwise, and after vigorous stirring for 10 minutes, anhydrous Na \n2\n SO \n4\n is added. The slurry is filtered through a glass frit, the filtrate is washed with THF, and then the filtrate is concentrated to give 151 mg (66% yield) of compound 6 as a colorless oil. \n HPLC: Rt1.47 min, Purity 98%, YMC S5 column 4.6 × 50 mm, 4 min gradient of 0~100% MeOH (90% in \n \nwater, H 3 PO 4 0.2%)\n \n , UV detection at 220nm \n \n1\n H-NMR (CDCl \n3\n ): 1.7 ppm, 4 H, multiplex; 1.8 ppm, 2 H, multiplex; 2.1 ppm, 2 H, multiplex; 2.7 ppm, 2 H, multiplex; 3.92 ppm, 4 H, multiplex; 6 .86 ppm, 1H, dd, J = 0.9 and 3.5 Hz; 6.97 ppm, 1H, dd, J = 3.5 and 5.0 Hz; 7.21 ppm, 1H, dd, J = 0.9 and 5 .0Hz\n\n\n\n\n\n\n \n\n  化合物７：\n\n  ジクロロメタン（２ｍＬ）およびＴＥＡ（６３ｍｇ、０．６３ミリモル）中のアミン６の溶液に、周囲温度でオルト−塩化アニソイル（１０７ｍｇ、０．５９７ミリモル）を加える。得られる淡黄色溶液を１ｈ攪拌し、次いでシリカゲルクロマトグラフィーカラムに直接装填する。カラムをヘキサン／酢酸エチル（１：１）で溶離して、１９５ｍｇ（収率８５％）のアミド７を無色油状物で得る。\n\n  ＨＰＬＣ：Ｒｔ３．３４分、純度９７％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n  ＬＣＭＳ：Ｒｔ１．７３分、［Ｍ＋１］３８８．１３、ＹＭＣ  Ｓ５カラム４．６×３０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の２分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：１．７ｐｐｍ、４Ｈ、多重；２．０ｐｐｍ、２Ｈ、多重；２．２ｐｐｍ、２Ｈ、多重；３．６８ｐｐｍ、２Ｈ、ｄ、Ｊ＝６．０Ｈｚ；３．７３ｐｐｍ、３Ｈ、ｓ；４．１ｐｐｍ、４Ｈ、多重；６．８９ｐｐｍ、１Ｈ、ｄ、Ｊ＝８．３Ｈｚ；６．９５ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．９および３．５Ｈｚ；７．０１ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝３．５および５．１Ｈｚ；７．０６ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝７．４および８．０Ｈｚ；７．２７ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．８および４．９Ｈｚ；７．４０ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．１および１．７Ｈｚ；７．８ｐｐｍ、１Ｈ、ｂｒ  ｓ；８．１９ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および７．８Ｈｚ\n\nCompound 7: \n To a solution of amine 6 in dichloromethane (2 mL) and TEA (63 mg, 0.63 mmol) is added ortho-anisoyl chloride (107 mg, 0.597 mmol) at ambient temperature. The resulting pale yellow solution is stirred for 1 h and then loaded directly onto a silica gel chromatography column. The column is eluted with hexane / ethyl acetate (1: 1) to give 195 mg (85% yield) of amide 7 as a colorless oil. \n HPLC: Rt 3.34 min, purity 97%, YMC S5 column 4.6 × 50 mm, 4 min gradient of 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm LCMS: Rt 1.73 min, [M + 1] 388.13, YMC S5 column 4.6 × 30 mm, 2 min gradient of 0-100% MeOH (90% in water, TFA 0.1%), UV detection at 220 nm \n \n1\n H-NMR (CDCl \n3\n ): 1.7 ppm, 4 H, multiplex; 2.0 ppm, 2 H, multiplex; 2.2 ppm, 2 H, multiplex; 3.68 ppm, 2 H, d, J = 6.0 Hz; 3.73 ppm 3 H, s; 4.1 ppm, 4 H, multiplex; 6.89 ppm, 1 H, d, J = 8.3 Hz; 6.95 ppm, 1 H, dd, J = 0.9 and 3.5 Hz; 7.01 ppm, 1 H , Dd, J = 3.5 and 5.1 Hz; 7.06 ppm, 1H, dd, J = 7.4 and 8.0 Hz; 7.27 ppm, 1H, dd, J = 0.8 and 4.9 Hz; 7 .40 ppm, 1 H, dd, J = 1.1 and 1.7 Hz; 7.8 ppm, 1 H, br s; 8.19 ppm, 1 H, dd, J = 1.8 and 7.8 Hz\n\n\n\n\n\n\n \n\n  化合物８：\n\n  化合物７（１９５ｍｇ、０．５０４ミリモル）を、ＴＨＦ（４ｍＬ）に溶解し、２Ｎ−ＨＣｌ（１ｍＬ）を加える。得られる溶液を４０℃に３ｈ加熱し、冷却せしめ、エーテル（５０ｍＬ）で希釈し、飽和ＮａＨＣＯ\n3\n（２０ｍＬ×３）で洗う。有機部分を無水Ｎａ\n2\nＳＯ\n4\n上で乾燥し、デカントし、濃縮して２００ｍｇ（粗定量収率）の化合物８を無色油状物で得る。\n\n  ＨＰＬＣ：Ｒｔ３．００分、純度９２％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n  ＬＣＭＳ：Ｒｔ１．５５分、［Ｍ＋１］３３３．０８、ＹＭＣ  Ｓ５カラム４．６×３０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の２分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：２．２ｐｐｍ、２Ｈ、多重；２．５ｐｐｍ、６Ｈ、多重；３．７５ｐｐｍ、３Ｈ、ｓ；３．７９ｐｐｍ、１Ｈ、ｄ、Ｊ＝６．２Ｈｚ；６．９２ｐｐｍ、１Ｈ、ｄ、Ｊ＝８．３Ｈｚ；７．０３ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．９および３．５Ｈｚ；７０８ｐｐｍ、２Ｈ、多重；７．３５ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．８および５．１Ｈｚ；７．４３ｐｐｍ、１Ｈ、ｄｄｄ、Ｊ＝１．８、７．５および８．５Ｈｚ；７．９ｐｐｍ、１Ｈ、ｂｒ  ｔ；８．２０ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および７．８Ｈｚ\n\nCompound 8: \n Compound 7 (195 mg, 0.504 mmol) is dissolved in THF (4 mL) and 2N HCl (1 mL) is added. The resulting solution is heated to 40 ° C. for 3 h, allowed to cool, diluted with ether (50 mL) and washed with saturated NaHCO \n3\n (20 mL × 3). The organic portion is dried over anhydrous Na \n2\n SO \n4\n , decanted and concentrated to give 200 mg (crude quantitative yield) of compound 8 as a colorless oil. \n HPLC: Rt 3.00 min, purity 92%, YMC S5 column 4.6 × 50 mm, 4 min gradient of 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm LCMS: Rt 1.55 min, [M + 1] 333.08, YMC S5 column 4.6 × 30 mm, 2 min gradient of 0-100% MeOH (90% in water, TFA 0.1%), UV detection at 220 nm \n \n1\n H-NMR (CDCl \n3\n ): 2.2 ppm, 2 H, multiple; 2.5 ppm, 6 H, multiple; 3.75 ppm, 3 H, s; 3.79 ppm, 1 H, d, J = 6.2 Hz; 6.92 ppm 1H, d, J = 8.3 Hz; 7.03 ppm, 1H, dd, J = 0.9 and 3.5 Hz; 708 ppm, 2H, multiplex; 7.35 ppm, 1H, dd, J = 0.8 and 5 1 Hz; 7.43 ppm, 1 H, ddd, J = 1.8, 7.5 and 8.5 Hz; 7.9 ppm, 1 H, br t; 8.20 ppm, 1 H, dd, J = 1.8 and 7. 8Hz\n\n\n\n\n\n\n \n\n  化合物９および１０：\n\n  ＴＨＦ（４ｍＬ）中の粗ケトン８（粗２００ｍｇ、０．５０４ミリモル）の溶液に、ＮａＢＨ\n4\n（４４ｍｇ、１．５ミリモル）を加える。反応混合物を窒素下周囲温度で１４ｈ攪拌し、次いでスラリーをジクロロメタン（１００ｍＬ）で希釈する。スラリーを分液漏斗に移し、有機部分を１Ｎ−ＨＣｌ（２０ｍＬ×２）で洗い、無水Ｎａ\n2\nＳＯ\n4\n上で乾燥し、デカントし、濃縮して化合物９および１０の混合物を無色油状物で得る。かかる異性体を、分取薄層クロマトグラフィー（２５×２５ｃｍ、２５４ｎｍのＵＶ指示器を持つ１ｍｍプレート、溶離剤としてジクロロメタン／ＭＴＢＥ＝２：１を使用）で分離する。化合物９（４３ｍｇ）を低極性成分として単離する。\n\n  ＨＰＬＣ：Ｒｔ３．１６分、純度９５％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n  ＬＣＭＳ：Ｒｔ１．６４分、［Ｍ＋１］３４６．１０、ＹＭＣ  Ｓ５カラム４．６×３０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の２分勾配\n\n\n1\nＨ−ＮＭＲ（ＭｅＯＤ）：１．３ｐｐｍ、２Ｈ、多重；１．５ｐｐｍ、２Ｈ、多重；２．１ｐｐｍ、２Ｈ、ｂｒ  ｄ；３．３７ｐｐｍ、２Ｈ、ｓ；３．５ｐｐｍ、１Ｈ、多重；３．６４ｐｐｍ、３Ｈ、ｓ；６．８ｐｐｍ、４Ｈ、多重；７．２２ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．７および５．４Ｈｚ；７．３２ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および８．７Ｈｚ；７．７８ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．７および７．８Ｈｚ；８．０ｐｐｍ、１Ｈ、ｂｒ  ｓ\n\nCompounds 9 and 10: \n To a solution of crude ketone 8 (crude 200 mg, 0.504 mmol) in THF (4 mL) is added NaBH \n4\n (44 mg, 1.5 mmol). The reaction mixture is stirred at ambient temperature under nitrogen for 14 h, then the slurry is diluted with dichloromethane (100 mL). The slurry is transferred to a separatory funnel and the organic portion is washed with 1N HCl (20 mL × 2), dried over anhydrous Na \n2\n SO \n4\n , decanted and concentrated to give a mixture of compounds 9 and 10 as a colorless oil. . The isomers are separated by preparative thin layer chromatography (25 × 25 cm, 1 mm plate with 254 nm UV indicator, using dichloromethane / MTBE = 2: 1 as eluent). Compound 9 (43 mg) is isolated as a low polarity component. \n HPLC: Rt 3.16 min, purity 95%, YMC S5 column 4.6 × 50 mm, 4 min gradient from 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm LCMS: Rt 1.64 min, [M + 1] 346.10, YMC S5 column 4.6 × 30 mm, 2 min gradient from 0-100% MeOH (90% in water, 0.1% TFA) \n \n1\n H-NMR (MeOD): 1.3 ppm, 2H, multiplex; 1.5 ppm, 2H, multiplex; 2.1 ppm, 2H, br d; 3.37 ppm, 2H, s; 3.5 ppm, 1H, multiplex; 3 6.4 ppm, 3 H, s; 6.8 ppm, 4 H, multiplex; 7.22 ppm, 1 H, dd, J = 0.7 and 5.4 Hz; 7.32 ppm, 1 H, dd, J = 1.8 and 8.7 Hz 7.78 ppm, 1 H, dd, J = 1.7 and 7.8 Hz; 8.0 ppm, 1 H, br s;\n\n\n\n\n\n\n \n\n  化合物１０（４７ｍｇ）の高極性成分として単離する。\n\n  ＨＰＬＣ：Ｒｔ２．９５分、純度９４％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n  ＬＣＭＳ：Ｒｔ１．５２分、［Ｍ＋１］３４６．１３、ＹＭＣ  Ｓ５カラム４．６×３０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の２分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＭｅＯＤ）：１．６ｐｐｍ、４Ｈ、多重；１．８ｐｐｍ、２Ｈ、多重；２．０ｐｐｍ、２Ｈ、多重；３．６２ｐｐｍ、１Ｈ、ｄ、Ｊ＝５．９Ｈｚ；３．６３ｐｐｍ、１Ｈ、ｂｒ、多重；３．６４ｐｐｍ、３Ｈ、ｓ；６．９ｐｐｍ、４Ｈ、多重；７．２６ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝０．６および４．６Ｈｚ；７．３６ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および８．７Ｈｚ；７．８７ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および７．８Ｈｚ；８．０ｐｐｍ、１Ｈ、ｂｒ  ｔ\n\nIsolated as the highly polar component of Compound 10 (47 mg). \n HPLC: Rt 2.95 min, 94% purity, YMC S5 column 4.6 × 50 mm, 4 min gradient from 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm LCMS: Rt 1.52 min, [M + 1] 346.13, YMC S5 column 4.6 × 30 mm, 2 min gradient of 0-100% MeOH (90% in water, TFA 0.1%), UV detection at 220 nm \n \n1\n H-NMR (MeOD): 1.6 ppm, 4 H, multiplex; 1.8 ppm, 2 H, multiplex; 2.0 ppm, 2 H, multiplex; 3.62 ppm, 1 H, d, J = 5.9 Hz; 3.63 ppm, 1H, br, multiplex; 3.64 ppm, 3H, s; 6.9 ppm, 4H, multiplex; 7.26 ppm, 1H, dd, J = 0.6 and 4.6 Hz; 7.36 ppm, 1H, dd, J = 1.8 and 8.7 Hz; 7.87 ppm, 1 H, dd, J = 1.8 and 7.8 Hz; 8.0 ppm, 1 H, br t\n\n\n\n\n\n\n \n\n  実施例２〜１２\n\n  実施例１に記載の方法を用い、以下に示す実施例２〜１２の化合物を製造する。\n\n\n \n \n\n\nExamples 2-12 \n Using the method described in Example 1, the compounds of Examples 2-12 shown below are prepared. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例１３\n\n  トランス−エチル−カルバミン酸４−［（２−メトキシ−ベンゾイルアミノ）−メチル］−４−チオフェン−２−イル−シクロヘキシルエステル\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 13 \n Trans-ethyl-carbamic acid 4-[(2-methoxy-benzoylamino) -methyl] -4-thiophen-2-yl-cyclohexyl ester \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例１に記載されている。\n\n  化合物２：\n\n  トリエチルアミン（約３８ｍｇ）含有のジクロロメタン（１０ｍＬ）中のアルコール１（４３ｍｇ、０．１２ミリモル）の溶液に、周囲温度で４−ニトロフェニルクロロホルメート（４５ｍｇ、０．２２ミリモル）を加える。得られる黄色溶液を７２ｈ攪拌し、次いで直接シリカゲルクロマトグラフィー（ヘキサン／酢酸エチル＝２：１で溶離）で精製して、３２ｍｇ（収率５２％）の化合物２を無色油状物で得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 1. \n Compound 2: \n To a solution of alcohol 1 (43 mg, 0.12 mmol) in dichloromethane (10 mL) containing triethylamine (approximately 38 mg) is added 4-nitrophenyl chloroformate (45 mg, 0.22 mmol) at ambient temperature. The resulting yellow solution was stirred for 72 h and then purified directly by silica gel chromatography (eluting with hexane / ethyl acetate = 2: 1) to give 32 mg (52% yield) of compound 2 as a colorless oil.\n\n\n\n\n\n\n \n\n  ＨＰＬＣ：Ｒｔ３．９１分、純度８４％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：１．８ｐｐｍ、４Ｈ、多重；２．１ｐｐｍ、２Ｈ、多重；２．３ｐｐｍ、２Ｈ、多重；３．６９ｐｐｍ、１Ｈ、ｄ、Ｊ＝６．０Ｈｚ；３．７５ｐｐｍ、３Ｈ、ｓ；４．８ｐｐｍ、１Ｈ、多重；６．９ｐｐｍ、３Ｈ、多重；７．０５ｐｐｍ、２Ｈ、多重；７．３２ｐｐｍ、１Ｈ、ｄ、Ｊ＝８．０Ｈｚ；７．４５ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および８．７Ｈｚ；７．９ｐｐｍ、１Ｈ、ｂｒ  ｔ；８．１５ｐｐｍ、１Ｈ、ｄ、Ｊ＝８．０Ｈｚ；８．２０ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および７．８Ｈｚ\n\nHPLC: Rt3.91 min, Purity 84%, YMC S5 column 4.6 × 50 mm, 4 min gradient of 0~100% MeOH (90% in \n \nwater, H 3 PO 4 0.2%)\n \n , UV detection at 220nm \n \n1\n H-NMR (CDCl \n3\n ): 1.8 ppm, 4 H, multiplex; 2.1 ppm, 2 H, multiplex; 2.3 ppm, 2 H, multiplex; 3.69 ppm, 1 H, d, J = 6.0 Hz; 3.75 ppm 3H, s; 4.8ppm, 1H, multiplex; 6.9ppm, 3H, multiplex; 7.05ppm, 2H, multiplex; 7.32ppm, 1H, d, J = 8.0Hz; 7.45ppm, 1H, dd , J = 1.8 and 8.7 Hz; 7.9 ppm, 1 H, br t; 8.15 ppm, 1 H, d, J = 8.0 Hz; 8.20 ppm, 1 H, dd, J = 1.8 and 7. 8Hz\n\n\n\n\n\n\n \n\n  化合物３：\n\n  ジクロロメタン（３ｍＬ）中の化合物２（３２ｍｇ、０．０６２ミリモル）の溶液に周囲温度にて、エチルアミン溶液（ＴＨＦ中２．０Ｍ、０．８ｍＬ）を加える。１ｈ後、黄色溶液を直接、分取薄層クロマトグラフィープレート（２５×２５ｃｍ、２５４ｎｍのＵＶ指示器を持つ１ｍｍプレート）に装填する。プレートをヘキサン／酢酸エチル＝１：１で溶離して、１１ｍｇ（収率４３％）の化合物３を無色ガラス状物で得る。\n\n  ＨＰＬＣ：Ｒｔ３．３７分、純度９６％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n  ＬＣＭＳ：Ｒｔ１．７１分、［Ｍ＋１］４１７．１４、ＹＭＣ  Ｓ５カラム４．６×３０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の２分勾配\n\nCompound 3: \n To a solution of compound 2 (32 mg, 0.062 mmol) in dichloromethane (3 mL) is added an ethylamine solution (2.0 M in THF, 0.8 mL) at ambient temperature. After 1 h, the yellow solution is loaded directly onto a preparative thin layer chromatography plate (25 × 25 cm, 1 mm plate with 254 nm UV indicator). The plate is eluted with hexane / ethyl acetate = 1: 1 to give 11 mg (43% yield) of compound 3 as a colorless glass. \n HPLC: Rt 3.37 min, purity 96%, YMC S5 column 4.6 × 50 mm, 4 min gradient of 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm LCMS: Rt 1.71 min, [M + 1] 417.14, YMC S5 column 4.6 × 30 mm, 2 min gradient from 0-100% MeOH (90% in water, TFA 0.1%)\n\n\n\n\n\n\n \n \n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：１．０９ｐｐｍ、３Ｈ、ｔ、Ｊ＝７．１Ｈｚ；１．６ｐｐｍ、２Ｈ、多重；１．８ｐｐｍ、２Ｈ、多重；２．０ｐｐｍ、２Ｈ、多重；２．２ｐｐｍ、２Ｈ、多重；３．１８ｐｐｍ、２Ｈ、多重；３．６５ｐｐｍ、２Ｈ、ｄ、Ｊ＝６．０Ｈｚ；３．７４ｐｐｍ、３Ｈ、ｓ；４．７２ｐｐｍ、１Ｈ、ｂｒ  ｓ；４．４８ｐｐｍ、１Ｈ、ｂｒ  ｓ；６．９０ｐｐｍ、１Ｈ、ｄ、Ｊ＝８．２Ｈｚ；６．９５ｐｐｍ、１Ｈ、ｄ、Ｊ＝３．０Ｈｚ；７．１５ｐｐｍ、２Ｈ、多重；７．２８ｐｐｍ、１Ｈ、ｄ、Ｊ＝５．０Ｈｚ；７．４５ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８および８．８Ｈｚ；７．８ｐｐｍ、１Ｈ、ｂｒ  ｓ；８．２０ｐｐｍ、１Ｈ、ｄ、Ｊ＝２．２および７．７Ｈｚ\n\n \n1\n H-NMR (CDCl \n3\n ): 1.09 ppm, 3 H, t, J = 7.1 Hz; 1.6 ppm, 2 H, multiplex; 1.8 ppm, 2 H, multiplex; 2.0 ppm, 2 H, multiplex; 2.2 ppm 2H, multiplex; 3.18 ppm, 2H, multiplex; 3.65 ppm, 2H, d, J = 6.0 Hz; 3.74 ppm, 3H, s; 4.72 ppm, 1H, br s; 4.48 ppm, 1H, br s; 6.90 ppm, 1H, d, J = 8.2 Hz; 6.95 ppm, 1H, d, J = 3.0 Hz; 7.15 ppm, 2H, multiplex; 7.28 ppm, 1H, d, J = 5 0.0 Hz; 7.45 ppm, 1 H, dd, J = 1.8 and 8.8 Hz; 7.8 ppm, 1 H, br s; 8.20 ppm, 1 H, d, J = 2.2 and 7.7 Hz\n\n\n\n\n\n\n \n\n  実施例１４〜２７\n\n  実施例１３に記載の方法を用い、以下に示す実施例１４〜２７の化合物を製造する。\n\n\n \n \n\n\nExamples 14-27 \n Using the method described in Example 13, the compounds of Examples 14-27 shown below are prepared. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例２８\n\n  酢酸４［（２−メトキシ−ベンゾイルアミノ）−メチル］−４−チオフェン−３−イル−シクロヘキシルエステル\n\n\n \n \n\n\nExample 28 \n Acetic acid 4 [(2-methoxy-benzoylamino) -methyl] -4-thiophen-3-yl-cyclohexyl ester \n \n \n \n \n\n\n\n\n\n\n \n\n  合成：\n\n\n \n \n\n\nSynthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例１に記載されている。\n\n  化合物２：\n\n  ＴＥＡ（約８ｍｇ）含有のジクロロメタン（１０ｍＬ）中のアルコール１（１４ｍｇ、０．０４０ミリモル）の溶液に、周囲温度で塩化アセチル（６ｍｇ、０．０８ミリモル）を加える。得られる黄色溶液を１６ｈ攪拌し、次いで直接分取ＨＰＬＣ（ＹＭＣ  ＯＤＳ  Ｓ５，２０×１００ｍｍカラム、３０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）、８分にわたる勾配、流速２０ｍＬ／分および２２０ｎｍでＵＶ検出）で精製する。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 1. \n Compound 2: \n To a solution of alcohol 1 (14 mg, 0.040 mmol) in dichloromethane (10 mL) containing TEA (about 8 mg) is added acetyl chloride (6 mg, 0.08 mmol) at ambient temperature. The resulting yellow solution was stirred for 16 h, then directly preparative HPLC (YMC ODS S5, 20 × 100 mm column, 30-100% MeOH (90% in water, TFA 0.1%), gradient over 8 minutes, flow rate 20 mL / min and Purify by UV detection at 220 nm).\n\n\n\n\n\n\n \n\n  エステル２を８．６分の保持時間で溶離し、無色油状物で単離する（６．６ｍｇ、収率４３％）。\n\n  ＨＰＬＣ：Ｒｔ３．４２分、純度１００％、ＹＭＣ  Ｓ５カラム４．６×５０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、Ｈ\n3\nＰＯ\n4\n０．２％）の４分勾配、２２０ｎｍでＵＶ検出\n\n  ＬＣＭＳ：Ｒｔ１．７８分、［Ｍ＋１］３８８．１３、ＹＭＣ  Ｓ５カラム４．６×３０ｍｍ、０〜１００％ＭｅＯＨ（水中９０％、ＴＦＡ０．１％）の２分勾配、２２０ｎｍでＵＶ検出\n\nEster 2 elutes with a retention time of 8.6 minutes and is isolated as a colorless oil (6.6 mg, 43% yield). \n HPLC: Rt 3.42 min, 100% purity, YMC S5 column 4.6 × 50 mm, 4 min gradient from 0-100% MeOH (90% in water, H \n3\n PO \n4\n 0.2%), UV detection at 220 nm LCMS: Rt 1.78 min, [M + 1] 388.13, YMC S5 column 4.6 × 30 mm, 2 min gradient of 0-100% MeOH (90% in water, TFA 0.1%), UV detection at 220 nm\n\n\n\n\n\n\n \n \n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n）：１．７ｐｐｍ、２Ｈ、多重；１．８ｐｐｍ、２Ｈ、多重；１．９ｐｐｍ、４Ｈ、多重；２．０６ｐｐｍ、３Ｈ、ｓ；３．７１ｐｐｍ、３Ｈ、ｓ；３．７１ｐｐｍ、２Ｈ、ｄ、Ｊ＝８．０Ｈｚ；５．３ｐｐｍ、１Ｈ、七重；６．９０ｐｐｍ、１Ｈ、ｄ、Ｊ＝８．３Ｈｚ；７．０６ｐｐｍ、１Ｈ、ｔ；７．１ｐｐｍ、２Ｈ、多重；７．４ｐｐｍ、２Ｈ、多重；７．７４ｐｐｍ、１Ｈ、ｂｒ  ｔ；８．１９ｐｐｍ、１Ｈ、ｄｄ、Ｊ＝１．８Ｈｚおよび７．８Ｈｚ\n\n \n1\n H-NMR (CDCl \n3\n ): 1.7 ppm, 2 H, multiplex; 1.8 ppm, 2 H, multiplex; 1.9 ppm, 4 H, multiplex; 2.06 ppm, 3 H, s; 3.71 ppm, 3 H, s; 3 .71 ppm, 2 H, d, J = 8.0 Hz; 5.3 ppm, 1 H, heptad; 6.90 ppm, 1 H, d, J = 8.3 Hz; 7.06 ppm, 1 H, t; 7.1 ppm, 2 H, multiple 7.4 ppm, 2 H, multiplex; 7.74 ppm, 1 H, br t; 8.19 ppm, 1 H, dd, J = 1.8 Hz and 7.8 Hz\n\n\n\n\n\n\n \n\n  実施例２９〜３０\n\n  実施例２８に記載の方法を用い、以下に示す実施例２９〜３０の化合物を合成する。\n\n\n \n \n\n\nExamples 29-30 \n Using the method described in Example 28, the compounds of Examples 29 to 30 shown below are synthesized. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例３１\n\n  シス−２−メトキシ−Ｎ−［４−（Ｎ−メチル−Ｎ’−シアノグアニジノ）−１−フェニル−シクロヘキシルメチル］−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 31 \n Cis-2-methoxy-N- [4- (N-methyl-N′-cyanoguanidino) -1-phenyl-cyclohexylmethyl] -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  ２００ｍＬのトルエン中の４−フェニル−４−シアノ−シクロヘキサン−１−オン１（１０ｇ、５０ミリモル）の溶液に、ｐ−トルエンスルホン酸モノ水和物（２．５ｇ、１３．１ミリモル）とエチレングリコール（２０ｍＬ、３６０ミリモル）をそれぞれ、一度に加える。得られる溶液を還流下で５ｈ攪拌する。反応混合物を減圧濃縮して、油状残渣を得る。次いでこれをＥｔＯＡｃ（２００ｍＬ）で希釈し、水性ＮａＨＣＯ\n3\n（５０ｍＬ×２）および塩水（５０ｍＬ×１）で洗う。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物（１２．９ｇ、＞９５％）を得、次いでこれをさらに精製せずに、次の反応に付す。\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n To a solution of 4-phenyl-4-cyano-cyclohexane-1-one 1 (10 g, 50 mmol) in 200 mL of toluene was added p-toluenesulfonic acid monohydrate (2.5 g, 13.1 mmol) and ethylene. Glycol (20 mL, 360 mmol) is added in one portion each. The resulting solution is stirred at reflux for 5 h. The reaction mixture is concentrated under reduced pressure to give an oily residue. It is then diluted with EtOAc (200 mL) and washed with aqueous NaHCO \n3\n (50 mL × 2) and brine (50 mL × 1). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give an oil (12.9 g,> 95%) which is then subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  １００ｍＬのＴＨＦ中のニトリル２（１２．９ｇ）の溶液に、６０ｍＬの１Ｍ−ＬＡＨ／ＴＨＦを滴下し、得られる溶液を還流下で２ｈ攪拌する。反応混合物を０℃に冷却し、水を用いて注意深く反応を抑える。反応混合物をＥｔＯＡｃ（５００ｍＬ）で希釈し、水性ＬｉＯＨ−ＮａＣｌ（５０ｍＬ×３）で洗う。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物（１３．６ｇ、＞９５％）を得、次いでこれをさらに精製せずに、次の反応に付す。\n\nCompound 3: \n To a solution of nitrile 2 (12.9 g) in 100 mL of THF, 60 mL of 1M LAH / THF is added dropwise and the resulting solution is stirred at reflux for 2 h. The reaction mixture is cooled to 0 ° C. and carefully quenched with water. The reaction mixture is diluted with EtOAc (500 mL) and washed with aqueous LiOH-NaCl (50 mL × 3). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give an oil (13.6 g,> 95%) which is then subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  １００ｍＬのＣＨ\n2\nＣｌ\n2\n中のアミン３（５．９ｇ、２４ミリモル）およびＥｔ\n3\nＮ（６．０ｍＬ、４３ミリモル）の溶液に、０℃で塩化アニソイル（４．５ｍＬ、３０．４ミリモル）を滴下し、得られる溶液を２ｈ攪拌する。反応混合物を減圧濃縮して、白色固体残渣を得、これをＥｔＯＡｃ（２００ｍＬ）と水性ＮａＨＣＯ\n3\n（５０ｍＬ）間に分配する。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物を得、これを５０ｍＬのＴＨＦおよび５０ｍＬの２Ｎ水性ＨＣｌで希釈する。得られる溶液を２５℃で１２ｈ攪拌する。反応混合物をＥｔＯＡｃ（２００ｍＬ）で希釈する。有機層を分離し、塩水（５０ｍＬ×２）で洗い、ＭｇＳＯ\n4\n上で乾燥する。有機層の濃縮で油状残渣を得、これをカラムクロマトグラフィー（５０％ＥｔＯＡｃ／Ｈｅｘ）で精製して、６．８ｇ（２０．２ミリモル、２工程で８４％）の所望生成物を得る。\n\nCompound 4: \n To a solution of amine 3 (5.9 g, 24 mmol) and Et \n3\n N (6.0 mL, 43 mmol) in 100 mL CH \n2\n Cl \n2 is\n added anisoyl chloride (4.5 mL, 30.4 mmol) at 0 ° C. Add dropwise and stir the resulting solution for 2 h. The reaction mixture is concentrated in vacuo to give a white solid residue that is partitioned between EtOAc (200 mL) and aqueous NaHCO \n3\n (50 mL). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give an oil that is diluted with 50 mL of THF and 50 mL of 2N aqueous HCl. The resulting solution is stirred at 25 ° C. for 12 h. The reaction mixture is diluted with EtOAc (200 mL). The organic layer is separated, washed with brine (50 mL × 2) and dried over MgSO \n4\n . Concentration of the organic layer gives an oily residue that is purified by column chromatography (50% EtOAc / Hex) to give 6.8 g (20.2 mmol, 84% over 2 steps) of the desired product.\n\n\n\n\n\n\n \n\n  化合物５：\n\n  １００ｍＬのＭｅＯＨ中のケトン４（１３ｇ、３８．６ミリモル）の溶液に、ＮＨ\n4\nＯＡｃ（２３．２ｇ、３００ミリモル）およびＮａＢＨ(ＯＡｃ)\n3\n（１２．２ｇ、５７．８ミリモル）を加え、得られる混合物を２５℃で１２ｈ攪拌する。反応混合物を減圧濃縮して、固体残渣を得、これをＥｔＯＡｃ（２００ｍＬ）と１Ｎ水性ＮａＯＨ（３０ｍＬ×２）間に分配する。有機層をＭｇＳＯ\n4\n上で乾燥する。有機溶液の濃縮で油状残渣を得、次いでこれをカラムクロマトグラフィー（１０％ＮＨ\n3\n−ＭｅＯＨ／ＣＨ\n2\nＣｌ\n2\n）に付して、１０．８ｇの所望生成物を２ジアステレオ異性体（１：１）混合物で得る。\n\nCompound 5: \n To a solution of ketone 4 (13 g, 38.6 mmol) in 100 mL MeOH was added NH \n4\n OAc (23.2 g, 300 mmol) and NaBH (OAc) \n3\n (12.2 g, 57.8 mmol) to give The resulting mixture is stirred at 25 ° C. for 12 h. The reaction mixture is concentrated in vacuo to give a solid residue which is partitioned between EtOAc (200 mL) and 1N aqueous NaOH (30 mL × 2). The organic layer is dried over MgSO \n4.\n Concentration of the organic solution gave an oily residue which was then subjected to column chromatography (10% NH \n3\n -MeOH / CH \n2\n Cl \n2\n ) to give 10.8 g of the desired product to the 2 diastereoisomers (1: 1) Obtain as a mixture.\n\n\n\n\n\n\n \n\n  化合物６および７：\n\n  アミン５（３．６ｇ、１０．７ミリモル）をＣＨ\n3\nＣＮ（１００ｍＬ）に溶解する。３０ｍＬのＣＨ\n3\nＣＮに溶解したジ−ｔ−ブチルジカーボネート（３．５ｇ、１６ミリモル）溶液を滴下する。混合物を２５℃で２ｈ攪拌する。反応混合物を減圧濃縮して、油状残渣を得、これをカラムクロマトグラフィー（５０％Ｈｅｘ／ＥｔＯＡｃ）に付して、ｂｏｃ保護アミンの２．１ｇのトランス異性体（保持時間２．４３分）と１．９ｇのシス異性体（保持時間２．６７分）を得る。各アミンを４０ｍＬの２５％ＴＦＡ／ＣＨ\n2\nＣｌ\n2\nに溶解し、２５℃で２ｈ攪拌する。それらを減圧濃縮して、油状残渣を得、これをＥｔＯＡｃ（それぞれ１５０ｍＬ）に溶解し、１Ｎ水性ＮａＯＨ（１００ｍＬ×２）で洗う。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物を得、これは単一ジアステレオ異性体のアミンに相当する。\n\nCompounds 6 and 7: \n Amine 5 (3.6 g, 10.7 mmol) is dissolved in CH \n3\n CN (100 mL). A solution of di-t-butyl dicarbonate (3.5 g, 16 mmol) dissolved in 30 mL CH \n3\n CN is added dropwise. The mixture is stirred at 25 ° C. for 2 h. The reaction mixture was concentrated in vacuo to give an oily residue that was subjected to column chromatography (50% Hex / EtOAc) to give 2.1 g of the trans isomer of the boc protected amine (retention time 2.43 min). 1.9 g of cis isomer (retention time 2.67 min) are obtained. Each amine was dissolved in 25% TFA / CH \n2\n Cl \n2\n in 40 mL, is 2h stirring at 25 ° C.. They are concentrated in vacuo to give an oily residue which is dissolved in EtOAc (150 mL each) and washed with 1N aqueous NaOH (100 mL × 2). The organic layer was dried over MgSO \n4 and\n concentrated in vacuo to give an oil, which corresponds to a single diastereoisomeric amine.\n\n\n\n\n\n\n \n\n  化合物９：\n\n  ４０ｍＬの２−プロパノール中のシス異性体のアミン６（７００ｍｇ、２．０７ミリモル）の溶液に、ジフェニル・シアノカルボンイミデート（０．４８ｇ、２．０７ミリモル）を加え、反応混合物を還流下で４ｈ攪拌する。これを減圧濃縮して油状物を得、これをさらに精製せずに、次の反応に用いる。\n\nCompound 9: \n To a solution of cis isomer amine 6 (700 mg, 2.07 mmol) in 40 mL 2-propanol was added diphenyl cyanocarbonimidate (0.48 g, 2.07 mmol) and the reaction mixture was refluxed. Stir for 4 h. This is concentrated under reduced pressure to give an oil which is used in the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物１０：\n\n  ２ｍＬの２−プロパノール中の化合物９（１００ｍｇ、０．２１ミリモル）の溶液に、２ｍＬのＭｅＮＨ\n2\n（ＴＨＦ中２Ｎ）を加える。混合物を密封チューブ中、７５℃で２ｈ攪拌する。反応混合物を室温まで冷却し、減圧濃縮して油状残渣を得、これを分取ＨＰＬＣ（ＹＭＣ  Ｓ５  ＯＤＳ３０×２５０ｍｍ逆相カラム、Ａ／Ｂ＝７０／３０から１００％Ｂの３０分勾配、ここで溶剤Ａ＝Ｈ\n2\nＯ／ＭｅＯＨ／ＴＦＡ（９０：１０：０．１）、溶剤Ｂ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（９０：１０：０．１））で精製して、凍結乾燥（ＭｅＯＨ／Ｈ\n2\nＯ）後５３．４ｍｇ（０．１３ミリモル、６２％）の所望生成物を白色固体で得る。［Ｍ＋Ｈ］＝４２０\n\nCompound 10: \n To a solution of compound 9 (100 mg, 0.21 mmol) in 2 mL 2-propanol is added \n2\n mL MeNH \n2\n (2N in THF). The mixture is stirred in a sealed tube at 75 ° C. for 2 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to give an oily residue, which was preparative HPLC (YMC S5 ODS 30 × 250 mm reverse phase column, A / B = 70/30 to 100% B 30 min gradient, where Solvent A = H \n2\n O / MeOH / TFA (90: 10: 0.1), Solvent B = MeOH / H \n2\n O / TFA (90: 10: 0.1)) and lyophilized (MeOH / H \n2\n O) after 53.4 mg (0.13 mmol, the desired product of 62%) as a white solid. [M + H] = 420\n\n\n\n\n\n\n \n\n  実施例３２〜５２\n\n  実施例３１に記載の方法を用い、以下に示す実施例３１〜５２の化合物を合成する。\n\n\n \n \n\n\nExamples 32-52 \n Using the method described in Example 31, the following compounds of Examples 31 to 52 are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例５３\n\n  トランス−２−メトキシ−Ｎ−［４−（Ｎ−メチル−Ｎ’−シアノグアニジノ）−１−フェニル−シクロヘキシルメチル］−ベンズアミド\n\n\n \n \n\n\nExample 53 \n Trans-2-methoxy-N- [4- (N-methyl-N′-cyanoguanidino) -1-phenyl-cyclohexylmethyl] -benzamide \n \n \n \n \n\n\n\n\n\n\n \n\n  合成：\n\n\n \n \n\n\nSynthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例３１の記載に準じ合成する。\n\n  化合物２：\n\n  ２０ｍＬの２−プロパノール中のトランス−アミン１（３００ｍｇ、１．２６ミリモル）の溶液に、ジフェニル・シアノカルボニデート（０．２４ｇ、１．２６ミリモル）を加え、得られる混合物を還流下で４ｈ攪拌する。反応混合物を減圧濃縮して油状物を得、これをさらに精製せずに、次の反応に用いる。\n\nCompound 1: \n Compound 1 is synthesized according to the description in Example 31. \n Compound 2: \n To a solution of trans-amine 1 (300 mg, 1.26 mmol) in 20 mL of 2-propanol was added diphenyl cyanocarbonidate (0.24 g, 1.26 mmol) and the resulting mixture was refluxed for 4 h. Stir. The reaction mixture is concentrated under reduced pressure to give an oil that is used in the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  ２ｍＬの２−プロパノール中の中間体２（１００ｍｇ、０．２１ミリモル）の溶液に、２ｍＬのメチルアミン（ＴＨＦ中２Ｎ）を加える。混合物を密封チューブ中、７５℃で２ｈ攪拌する。反応混合物を冷却し、減圧濃縮して油状残渣を得、これを分取ＨＰＬＣ（実施例１に記載）で精製して、凍結乾燥(ＭｅＯＨ／Ｈ\n2\nＯ)後、４９．３ｍｇ（０．１２ミリモル、５７％）の所望生成物を白色固体で得る。\n\nCompound 3: \n To a solution of intermediate 2 (100 mg, 0.21 mmol) in 2 mL of 2-propanol is added 2 mL of methylamine (2N in THF). The mixture is stirred in a sealed tube at 75 ° C. for 2 h. The reaction mixture was cooled and concentrated in vacuo to give an oily residue, which was purified by preparative HPLC (described in Example 1) and after lyophilization (MeOH / H \n2\n O), 49.3 mg (0.12). Mmol, 57%) of the desired product is obtained as a white solid.\n\n\n\n\n\n\n \n\n  実施例５４〜６１\n\n  実施例５３に記載の方法を用い、以下に示す実施例５４〜６１の化合物を合成する。\n\n\n \n \n\n\nExamples 54-61 \n Using the method described in Example 53, the compounds of Examples 54 to 61 shown below are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例６２および６３\n\n  トランスおよびシス−Ｎ−［４−（Ｎ，Ｎ’−ジエチル−シアノグアニジノ）−１−フェニル−１−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExamples 62 and 63 \n Trans and cis-N- [4- (N, N′-diethyl-cyanoguanidino) -1-phenyl-1-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  ３５ｍＬのジクロロメタン中のケトン１（０．３４ｇ、１ミリモル）の溶液に、ＥｔＮＨ\n2\n（ＴＨＦ中２Ｍ溶液１ｍＬ、２ミリモル）、ＮａＢＨ(ＯＡｃ)\n3\n（０．４２ｇ、２ミリモル）および数滴のＡｃＯＨを加える。得られる溶液を２５℃で３ｈ攪拌する。反応混合物を減圧濃縮して油状残渣を得、これを２５０ｍＬのＡｃＯＨで希釈し、１Ｎ水性ＮａＯＨ（２０ｍｌ×２）で洗う。有機層をＮａ\n2\nＳＯ\n4\n上で乾燥し、減圧濃縮して化合物２を油状物で得（０．３５ｇ、＞９５％）、これをさらに精製せずに、次の反応に付す。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of ketone 1 (0.34 g, 1 mmol) in 35 mL dichloromethane was added EtNH \n2\n (1 mL of 2M solution in THF, 2 mmol), NaBH (OAc) \n3\n (0.42 g, 2 mmol) and a few drops of AcOH. Add The resulting solution is stirred at 25 ° C. for 3 h. The reaction mixture is concentrated under reduced pressure to give an oily residue which is diluted with 250 mL AcOH and washed with 1N aqueous NaOH (20 ml × 2). The organic layer was dried over Na \n2\n SO \n4 and\n concentrated in vacuo to give compound 2 as an oil (0.35 g,> 95%), which was subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  １０ｍＬの２−プロパノール中のジフェニル・シアノカルボニデート（２．４ｇ、１０ミリモル）およびＥｔＮＨ\n2\n（ＭｅＯＨ中２Ｍ溶液５ｍＬ、１０ミリモル）の溶液を、密封チューブ中７０℃で４ｈ攪拌する。反応混合物を減圧濃縮して白色固体を得、これをカラムクロマトグラフィー（３０％ＥｔＯＡｃ／Ｈｅｘ）で精製して、１．６ｇ（８５％）の所望生成物３を白色固体で得る。\n\nCompound 3: \n A solution of diphenyl cyanocarbonidate (2.4 g, 10 mmol) and EtNH \n2\n (5 mL of 2M solution in MeOH, 10 mmol) in 10 mL of 2-propanol is stirred for 4 h at 70 ° C. in a sealed tube. The reaction mixture is concentrated under reduced pressure to give a white solid, which is purified by column chromatography (30% EtOAc / Hex) to give 1.6 g (85%) of the desired product 3 as a white solid.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  ５ｍＬの２−プロパノール中の化合物２（１１０ｍｇ、０．３ミリモル）および化合物３（７４ｍｇ、０．３９ミリモル）の溶液を、７０℃で１２ｈ攪拌する。反応混合物を濃縮し、分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、シスおよびトランス−ジアステレオ異性体を得る。トランス化合物（保持時間３．１９分）（２３ｍｇ）およびシス化合物（保持時間３．０３６分）（１４ｍｇ）を無色油状物で得る。質量分析［Ｍ＋Ｈ]\n+\n４６２\n\nCompound 4: \n A solution of compound 2 (110 mg, 0.3 mmol) and compound 3 (74 mg, 0.39 mmol) in 5 mL of 2-propanol is stirred at 70 ° C. for 12 h. The reaction mixture is concentrated and purified by preparative HPLC (described in the synthesis of Example 31) to give the cis and trans-diastereoisomers. The trans compound (retention time 3.19 minutes) (23 mg) and the cis compound (retention time 3.036 minutes) (14 mg) are obtained as a colorless oil. Mass Spectrometry [M + H] \n+\n 462\n\n\n\n\n\n\n \n\n  実施例６４\n\n  トランス−２−メトキシ−Ｎ−［４−（Ｎ−エチル−Ｎ’−スルフェニルウレイド）−１−フェニル−シクロヘキシルメチル］−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 64 \n Trans-2-methoxy-N- [4- (N-ethyl-N′-sulfenylureido) -1-phenyl-cyclohexylmethyl] -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  クロロスルホニルイソシアネート（０.３７mL、４.１ミリモル）を４０mLのジクロロメタンに溶解し、０℃に冷却する。クロロエタノール（０.２７mL、４.１ミリモル）をゆっくり加え、反応混合物を０℃でさらに１.５ｈ撹拌する。反応混合物に、５０mLのジクロロメタン中のアミン１（１.４g、４.１ミリモル）およびＥt\n3\nＮ（１.３mL、１２.４ミリモル）の溶液をゆっくり加え、反応温度が５℃を越えないようにする。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n Chlorosulfonyl isocyanate (0.37 mL, 4.1 mmol) is dissolved in 40 mL of dichloromethane and cooled to 0 ° C. Chloroethanol (0.27 mL, 4.1 mmol) is added slowly and the reaction mixture is stirred at 0 ° C. for an additional 1.5 h. To the reaction mixture is slowly added a solution of amine 1 (1.4 g, 4.1 mmol) and Et \n3\n N (1.3 mL, 12.4 mmol) in 50 mL of dichloromethane so that the reaction temperature does not exceed 5 ° C. To.\n\n\n\n\n\n\n \n\n  反応混合物を２５℃に加温せしめ、一夜撹拌する。２Ｎ−ＨＣlの滴下で反応を抑え、ＮaＣlで飽和にする。有機層を分離し、水性層をジクロロメタン（１００mL×３）で抽出する。コンバインした有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して化合物２を白色固体で得（２.０g）、これらさらに精製せずに、次の反応に付す。\n\n  化合物３：\n\n  ２mLのＣＨ\n3\nＣＮ中の化合物２（９０mg、０.１８ミリモル）、ＥtＮＨ\n2\n（０.４ミリモル、ＭeＯＨ中２Ｍ溶液０.２mL）およびＥt\n3\nＮ（０.１mL）の溶液を、６５℃で２ｈ撹拌する。反応混合物を分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、１２.１mgの化合物３を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４４６\n\nThe reaction mixture is warmed to 25 ° C. and stirred overnight. The reaction is quenched with the dropwise addition of 2N HCl and saturated with NaCl. The organic layer is separated and the aqueous layer is extracted with dichloromethane (100 mL × 3). The combined organic layer was dried over MgSO \n4 and\n concentrated in vacuo to give compound 2 as a white solid (2.0 g), which was subjected to the next reaction without further purification. \n Compound 3: \n A solution of compound 2 (90 mg, 0.18 mmol), EtNH \n2\n (0.4 mmol, 0.2 mL of a 2M solution in MeOH) and Et \n3\n N (0.1 mL) in 2 mL of CH \n3\n CN at 65 ° C. Stir for 2 h. The reaction mixture is purified by preparative HPLC (described in the synthesis of Example 31) to give 12.1 mg of compound 3 as a colorless oil. Mass spectrometry [M + H] \n+\n = 446\n\n\n\n\n\n\n \n\n  実施例６５〜７２\n\n  実施例６４に記載の方法を用い、以下に示す実施例６５〜７２の化合物を合成する。\n\n\n \n \n\n\nExamples 65-72 \n Using the method described in Example 64, the following compounds of Examples 65-72 are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例７３\n\n  シス−２−メトキシ−Ｎ−｛４−［Ｎ−（４−アニソイル）−Ｎ’−スルフェニルウレイド］−１−フェニル−シクロヘキシルメチル｝−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 73 \n Cis-2-methoxy-N- {4- [N- (4-anisoyl) -N'-sulfenylureido] -1-phenyl-cyclohexylmethyl} -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  クロロスルホニルイソシアネート（０.２２mL、２.５ミリモル）を、２mLのジクロロメタンに溶解し、０℃に冷却する。クロロエタノール（０.１６mL、０.２５ミリモル）をゆっくり加え、反応混合物を０℃でさらに１.５ｈ撹拌する。反応混合物に、３０mLのジクロロメタン中のシスアミン１（０.８５g、２.５ミリモル）およびＥt\n3\nＮ（０.８mL、７.６ミリモル）の溶液をゆっくり加える。溶液を２５℃に加温せしめ、一夜撹拌する。２Ｎ−ＨＣlの滴下で反応を抑え、ＮaＣlで飽和にする。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n Chlorosulfonyl isocyanate (0.22 mL, 2.5 mmol) is dissolved in 2 mL of dichloromethane and cooled to 0 ° C. Chloroethanol (0.16 mL, 0.25 mmol) is added slowly and the reaction mixture is stirred at 0 ° C. for an additional 1.5 h. To the reaction mixture is slowly added a solution of cisamine 1 (0.85 g, 2.5 mmol) and Et \n3\n N (0.8 mL, 7.6 mmol) in 30 mL of dichloromethane. The solution is warmed to 25 ° C. and stirred overnight. The reaction is quenched with the dropwise addition of 2N HCl and saturated with NaCl.\n\n\n\n\n\n\n \n\n  有機層を分離し、水性層をジクロロメタン（６０mL×３）で抽出する。コンバインした有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して白色固体を得、これをカラムクロマトグラフィー（５０％Ｈex／ＥtＯＡc）で精製して、１.１g（２.２ミリモル、８７％）の化合物２を白色固体で得る。\n\n  化合物３：\n\n  １mLのＣＨ\n3\nＣＮ中の化合物２（１７mg、０.０３５ミリモル）およびｐ−アニシジン（１０mg、０.０８ミリモル）の溶液を、６５℃で２ｈ撹拌する。反応混合物を分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、３.２mgの化合物３を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n５２４\n\nThe organic layer is separated and the aqueous layer is extracted with dichloromethane (60 mL × 3). The combined organic layer was dried over MgSO \n4 and\n concentrated under reduced pressure to give a white solid which was purified by column chromatography (50% Hex / EtOAc) and 1.1 g (2.2 mmol, 87%). Compound 2 is obtained as a white solid. \n Compound 3: \n A solution of compound 2 (17 mg, 0.035 mmol) and p-anisidine (10 mg, 0.08 mmol) in 1 mL of CH \n3\n CN is stirred at 65 ° C. for 2 h. The reaction mixture is purified by preparative HPLC (described in the synthesis of Example 31) to give 3.2 mg of compound 3 as a colorless oil. Mass Spectrometry [M + H] \n+\n 524\n\n\n\n\n\n\n \n\n  実施例７４〜１４７\n\n  実施例７３に記載の方法を用い、以下に示す実施例７４〜１４７の化合物を合成する。\n\n\n \n \n\n\nExamples 74-147 \n Using the method described in Example 73, the compounds of Examples 74 to 147 shown below are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例１４８\n\n  シス−Ｎ−［４−（Ｎ’−エチル−グアニジノ）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n\nExample 148 \n Cis-N- [4- (N′-ethyl-guanidino) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n \n\n\n\n\n\n\n \n\n  合成：\n\n\n \n \n\n\nSynthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  １０mLのジクロロメタンおよび５mLの水性ＮaＨＣＯ\n3\n中のアミン１（０.３５g、１.０ミリモル）の溶液に、チオホスゲン（０.３mL、４.０ミリモル）を一度に加える。反応混合物を２５℃で２ｈ撹拌する。次いで有機層を分離し、減圧濃縮して油状物を得る（０.３４g、８９％）。油状物を１０mLの７Ｎ−ＮＨ\n3\n／ＭeＯＨに溶解し、２５℃で１２ｈ撹拌する。反応混合物を減圧濃縮して、化合物２を油状物で得、これをさらに精製せずに、次の反応に用いる。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of amine 1 (0.35 g, 1.0 mmol) in 10 mL dichloromethane and 5 mL aqueous NaHCO \n3\n is added thiophosgene (0.3 mL, 4.0 mmol) in one portion. The reaction mixture is stirred at 25 ° C. for 2 h. The organic layer is then separated and concentrated in vacuo to give an oil (0.34 g, 89%). The oil is dissolved in 10 mL 7N-NH \n3\n / MeOH and stirred at 25 ° C. for 12 h. The reaction mixture is concentrated under reduced pressure to give compound 2 as an oil which is used in the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  １０mLのＣＨ\n3\nＣＮ中の化合物２の溶液に、ＭeＩ（０.５mL）を加え、得られる溶液を２５℃で１２ｈ撹拌する。反応混合物を減圧濃縮して、白色固体を得、これをＥtＯＡc（５０mL）と塩水（２０mL）間に分配する。有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して３５０mg（＞９５％）の化合物３を油状物で得、これをさらに精製せずに、次の反応に付す。\n\nCompound 3: \n To a solution of compound 2 in 10 mL CH \n3\n CN is added MeI (0.5 mL) and the resulting solution is stirred at 25 ° C. for 12 h. The reaction mixture is concentrated under reduced pressure to give a white solid which is partitioned between EtOAc (50 mL) and brine (20 mL). The organic layer was dried over MgSO \n4 and\n concentrated in vacuo to give 350 mg (> 95%) of compound 3 as an oil which was subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  １０mLのジクロロメタン中の化合物３（０.１７g、０.４５ミリモル）の溶液に、トリエチルアミン（０.２mL）および塩化アセチル（０.２mL、２.８ミリモル）を加え、得られる溶液を０℃で１ｈ撹拌する。反応混合物をＥtＯＡc（５０mL）で希釈し、塩水（１０mL×２）で洗う。有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して化合物４を暗色油状物で得、これらさらに精製せずに、次の反応に付す。\n\nCompound 4: \n To a solution of compound 3 (0.17 g, 0.45 mmol) in 10 mL of dichloromethane was added triethylamine (0.2 mL) and acetyl chloride (0.2 mL, 2.8 mmol) and the resulting solution was at 0 ° C. Stir for 1 h. The reaction mixture is diluted with EtOAc (50 mL) and washed with brine (2 × 10 mL). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give compound 4 as a dark oil that is subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物５：\n\n  １mLの２−プロパノール中の化合物４（３５mg、０.０７７ミリモル）およびエチルアミン（ＴＨＦ中２Ｍ−ＮＨ\n3\n０.５mL、１ミリモル）の溶液を、密封チューブ中７０℃で１２ｈ撹拌する。次いで反応混合物を分取ＨＰＬＣ精製（実施例３１の合成で記載）に付して、１７.９mg（４０％）の所望生成物５を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４０９\n\nCompound 5: \n A solution of compound 4 (35 mg, 0.077 mmol) and ethylamine (0.5 mL of 2M-NH \n3 in\n THF, 1 mmol) in 1 mL of 2-propanol is stirred in a sealed tube at 70 ° C. for 12 h. The reaction mixture is then subjected to preparative HPLC purification (described in the synthesis of Example 31) to give 17.9 mg (40%) of the desired product 5 as a colorless oil. Mass spectrometry [M + H] \n+\n = 409\n\n\n\n\n\n\n \n\n  実施例１４９〜１５２\n\n  実施例１４８に記載の方法を用い、以下に示す実施例１４９〜１５２の化合物を合成する。\n\n\n \n \n\n\nExamples 149-152 \n Using the method described in Example 148, the compounds of Examples 149 to 152 shown below are synthesized. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例１５３\n\n  シス−２,４−ジメトキシ−Ｎ−［４−（Ｎ−メチル−Ｎ’−シアノグアニジノ）−１−フェニル−シクロヘキシルメチル］−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 153 \n Cis-2,4-dimethoxy-N- [4- (N-methyl-N′-cyanoguanidino) -1-phenyl-cyclohexylmethyl] -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  １０mLのジクロロメタン中のアミン１（１.０g、４.０ミリモル）およびトリエチルアミン（０.６７mL、４.８ミリモル）の溶液に、無水トリフルオロ酢酸（１.０mL、４.８ミリモル）を滴下し、得られる溶液を−７８℃で２ｈ撹拌する。反応混合物を減圧濃縮して、油状残渣を得、これをＥtＯＡc（１００mL）と塩水（２０mL×２）間に分配する。有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して所望生成物２（１.３g、０.３８ミリモル、＞９５％）を無色油状物で得る。これをさらに精製せずに、次の反応に付す。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of amine 1 (1.0 g, 4.0 mmol) and triethylamine (0.67 mL, 4.8 mmol) in 10 mL of dichloromethane was added dropwise trifluoroacetic anhydride (1.0 mL, 4.8 mmol). The resulting solution is stirred at −78 ° C. for 2 h. The reaction mixture was concentrated under reduced pressure to give an oily residue which was partitioned between EtOAc (100 mL) and brine (20 mL × 2). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give the desired product 2 (1.3 g, 0.38 mmol,> 95%) as a colorless oil. This is subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  中間体２（１.３g）をＴＨＦ（５０mL）に溶解する。該溶液に３０mLの２Ｎ−ＨＣlを加え、得られる溶液を２５℃で１２ｈ撹拌する。ＨＰＬＣ分析により、出発物質の完全な消失および新生成物の形成が認められる。反応混合物をＥtＯＡc（１００mL）で希釈し、水性ＮaＨＣＯ\n3\n（３０mL×２）で洗う。有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して１.２g（＞９５％）の化合物３を油状物で得る。\n\nCompound 3: \n Intermediate 2 (1.3 g) is dissolved in THF (50 mL). To the solution is added 30 mL of 2N HCl and the resulting solution is stirred at 25 ° C. for 12 h. HPLC analysis shows complete disappearance of starting material and formation of new product. The reaction mixture is diluted with EtOAc (100 mL) and washed with aqueous NaHCO \n3\n (30 mL × 2). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give 1.2 g (> 95%) of compound 3 as an oil.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  ＭeＯＨ（６０mL）中のケトン３（１.２g、４ミリモル）の溶液に、ＮＨ\n4\nＯＡc（２.５g、３１ミリモル）を加えた後、ＮaＢＨ(ＯＡc)\n3\n（１.４g、５.２ミリモル）を一度に加える。得られる溶液を２５℃で３ｈ撹拌する。反応混合物を濃縮し、得られる固体をＥtＯＡc（１００mL）に再溶解し、水性ＮaＯＨ（１Ｍ、３０mL×２）で洗う。有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して油状物を得、これは所望アミン４のシスおよびトランスジアステレオ異性体の１：１混合物である。\n\nCompound 4: \n To a solution of ketone 3 (1.2 g, 4 mmol) in MeOH (60 mL) was added NH \n4\n OAc (2.5 g, 31 mmol) followed by NaBH (OAc) \n3\n (1.4 g, 5.2 mmol). ) At once. The resulting solution is stirred at 25 ° C. for 3 h. The reaction mixture is concentrated and the resulting solid is redissolved in EtOAc (100 mL) and washed with aqueous NaOH (1M, 30 mL × 2). The organic layer was dried over MgSO \n4,\n to give an oil was concentrated under reduced pressure, which is 1 cis and trans diastereomers of the desired amine 4: 1 mixture.\n\n\n\n\n\n\n \n\n  化合物５：\n\n  ２−プロパノール（２mL）中のアミン４（０.３０g、１ミリモル）の溶液に、ジフェニル・シアノカルボニデート（２４０mg、１ミリモル）を加え、得られる溶液を７０℃で３ｈ撹拌する。ＨＰＬＣ分析は、反応の完了を示す。反応混合物を２５℃に冷却し、密封チューブに移す。密封チューブに、２mLの２Ｍ−ＭeＮＨ\n2\n（４ミリモル）を加える。得られる溶液を７０℃で５ｈ撹拌する。反応混合物を２mL溶液まで濃縮し、分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、化合物５のシス異性体（保持時間２.９０分）（７０mg）およびトランス異性体（保持時間２.６５分）（６０mg）を得る。\n\nCompound 5: \n To a solution of amine 4 (0.30 g, 1 mmol) in 2-propanol (2 mL) is added diphenyl cyanocarbonidate (240 mg, 1 mmol) and the resulting solution is stirred at 70 ° C. for 3 h. HPLC analysis indicates completion of the reaction. Cool the reaction mixture to 25 ° C. and transfer to a sealed tube. To the sealed tube, add \n2\n mL of 2M-MeNH \n2\n (4 mmol). The resulting solution is stirred at 70 ° C. for 5 h. The reaction mixture was concentrated to a 2 mL solution and purified by preparative HPLC (described in the synthesis of Example 31) to give the cis isomer of compound 5 (retention time 2.90 min) (70 mg) and the trans isomer (retention time). 2.65 min) (60 mg) is obtained.\n\n\n\n\n\n\n \n\n  化合物６：\n\n  中間体５のシス異性体（１.１g、２.９ミリモル）を４０mLのＭeＯＨ／Ｈ\n2\nＯ（１：１）混合物（７％水性Ｋ\n2\nＣＯ\n3\nを含む）に溶解し、得られる溶液を２５℃で３ｈ撹拌する。ＨＰＬＣ分析は反応の完了を示す。反応混合物を減圧濃縮して白色固体を得、これをＥtＯＡc（１００mL）と塩水（２０mL×２）間に分配する。水性層をＥtＯＡc（５０mL）で抽出する。有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して、０.８１g（＞９５％）の化合物６を油状物で得、これをさらに精製せずに、次の反応に付す。\n\nCompound 6: \n Cis isomer of intermediate 5 (1.1 g, 2.9 mmol) 40mL of \nMeOH / H 2 O (1:\n 1) was dissolved in a mixture (containing 7% aqueous K \n2\n CO \n3),\n the resulting solution Stir at 25 ° C. for 3 h. HPLC analysis indicates completion of reaction. The reaction mixture was concentrated under reduced pressure to give a white solid that was partitioned between EtOAc (100 mL) and brine (20 mL × 2). Extract the aqueous layer with EtOAc (50 mL). The organic layer was dried over MgSO \n4,\n and concentrated under reduced pressure, to give the compound 6 of 0.81g (> 95%) as an oil, without further purification, subjected to the next reaction.\n\n\n\n\n\n\n \n\n  化合物７：\n\n  ２mLのジクロロメタン中のアミン６（４０mg、０.０１４ミリモル）の溶液に、２,４−ジメトキシ安息香酸（３８mg、０.０２１ミリモル）、ＥＤＣＩ（６０mg、０.０３１ミリモル）およびジイソプロピルエチルアミン（５７μＬ、０.０３１ミリモル）を連続して加える。混合物を３５℃で３０ｈ撹拌する。反応混合物を分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、６.７mgの所望生成物７を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４５０\n\nCompound 7: \n To a solution of amine 6 (40 mg, 0.014 mmol) in 2 mL of dichloromethane was added 2,4-dimethoxybenzoic acid (38 mg, 0.021 mmol), EDCI (60 mg, 0.031 mmol) and diisopropylethylamine (57 μL, 0.031 mmol) is added continuously. The mixture is stirred at 35 ° C. for 30 h. The reaction mixture is purified by preparative HPLC (described in the synthesis of Example 31) to give 6.7 mg of the desired product 7 as a colorless oil. Mass spectrometry [M + H] \n+\n = 450\n\n\n\n\n\n\n \n\n  実施例１５４〜１７０\n\n  実施例１５３に記載の方法を用い、以下に示す実施例１５４〜１７０の化合物を合成する。\n\n\n \n \n\n\nExamples 154-170 \n The compounds of Examples 154 to 170 shown below are synthesized using the method described in Example 153. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例１７１\n\n  ２−メトキシ−Ｎ−［４−（Ｎ−エチル−Ｎ’−エトキシカルボニル−グアニジノ）−１−フェニル−シクロヘキシルメチル］−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 171 \n 2-Methoxy-N- [4- (N-ethyl-N′-ethoxycarbonyl-guanidino) -1-phenyl-cyclohexylmethyl] -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  １５ｍＬのジクロロメタン中のアミン１（シスおよびトランス異性体の混合物、０．３４ｇ、１．０ミリモル）の溶液に、０℃で０．１２ｍＬのエチル・イソチオシアナトホルメート（０．１２ｍＬ、１．０ミリモル）を加える。混合物を０℃で０．５ｈおよび２５℃で３ｈ撹拌する。反応混合物を１００ｍＬのジクロロメタンで希釈し、１Ｎ−ＨＣｌ（２０ｍＬ）および塩水（２０ｍＬ）で洗う。有機溶液をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して０．４３ｇ（９５％）の所望生成物２を無色油状物で得、これをさらに精製せずに、次の反応に付す。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of amine 1 (mixture of cis and trans isomers, 0.34 g, 1.0 mmol) in 15 mL of dichloromethane was added 0.12 mL of ethyl isothiocyanatoformate (0.12 mL, 1.0 mmol at 0 ° C.). Mmol). The mixture is stirred at 0 ° C. for 0.5 h and at 25 ° C. for 3 h. The reaction mixture is diluted with 100 mL dichloromethane and washed with 1N HCl (20 mL) and brine (20 mL). The organic solution is dried over MgSO \n4 and\n concentrated in vacuo to give 0.43 g (95%) of the desired product 2 as a colorless oil, which is subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  ５ｍＬのジクロロメタン中の中間体２（５０ｍｇ、０．１１ミリモル）の溶液に、エチルアミン（ＴＨＦ中２Ｎ、０．１ｍＬ、０．２ミリモル）、ＥＤＣＩ（４２ｍｇ、０．２２ミリモル）およびジイソプロピルエチルアミン（０．０２ｍＬ、０．１１ミリモル）を連続して加える。反応混合物を２５℃で１２ｈ撹拌する。反応混合物を分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、２２．２ｍｇ（４２％）の所望生成物３（シスおよびトランス異性体の１：１混合物）を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４８１\n\nCompound 3: \n To a solution of intermediate 2 (50 mg, 0.11 mmol) in 5 mL of dichloromethane was added ethylamine (2N in THF, 0.1 mL, 0.2 mmol), EDCI (42 mg, 0.22 mmol) and diisopropylethylamine (0 .02 mL, 0.11 mmol) is added in succession. The reaction mixture is stirred at 25 ° C. for 12 h. The reaction mixture is purified by preparative HPLC (described in the synthesis of Example 31) to give 22.2 mg (42%) of the desired product 3 (1: 1 mixture of cis and trans isomers) as a colorless oil. . Mass spectrometry [M + H] \n+\n = 481\n\n\n\n\n\n\n \n\n  実施例１７２〜１７８\n\n  実施例１７１に記載の方法を用い、以下に示す実施例１７２〜１７８の化合物を合成する。\n\n\n \n \n\n\nExamples 172-178 \n Using the method described in Example 171, the compounds of Examples 172 to 178 shown below are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例１７９\n\n  シス−Ｎ−［４−（２，５−ジオキソ−イミダゾリン−１−イル）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 179 \n Cis-N- [4- (2,5-Dioxo-imidazolin-1-yl) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  ５ｍＬのジクロロメタン中のシス−アミン（５０ｍｇ、０．１５ミリモル）の溶液に、エチル・イソシアナトアセテート（３０ｍｇ、０．１６ミリモル）を一度に加え、反応混合物を２５℃で５ｈ撹拌する。次いで反応混合物を減圧濃縮して、油状残渣を得、これを１ｍＬのＥｔＯＨ／３Ｎ水性ＨＣｌ（１：１）混合物に溶解する。混合物を４５℃で１２ｈ撹拌する。反応混合物を分取ＨＰＬＣで精製して、２３．４ｍｇ（３７％）の所望生成物２を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４２２\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of cis-amine (50 mg, 0.15 mmol) in 5 mL of dichloromethane is added ethyl isocyanatoacetate (30 mg, 0.16 mmol) in one portion and the reaction mixture is stirred at 25 ° C. for 5 h. The reaction mixture is then concentrated under reduced pressure to give an oily residue which is dissolved in 1 mL of EtOH / 3N aqueous HCl (1: 1) mixture. The mixture is stirred at 45 ° C. for 12 h. The reaction mixture is purified by preparative HPLC to give 23.4 mg (37%) of the desired product 2 as a white solid. Mass spectrometry [M + H] \n+\n = 422\n\n\n\n\n\n\n \n\n  実施例１８０\n\n  シス−Ｎ−［４−（２，５−ジオキソ−４−（ｓ）−イソプロピル−イミダゾリン−１−イル）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 180 \n Cis-N- [4- (2,5-Dioxo-4- (s) -isopropyl-imidazolin-1-yl) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  出発物質としてシス−アミン１（５０ｍｇ、０．１５ミリモル）とメチル（Ｓ）−（−）−２−イソシアナト−３−メチルブチレート（３５ｍｇ、０．２３ミリモル）を用い、実施例１７９の記載と同じ操作で反応を行って、１６．７ｍｇ（０．０３６ミリモル、２４％）の所望生成物を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４６４\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n Description of Example 179 using cis-amine 1 (50 mg, 0.15 mmol) and methyl (S)-(−)-2-isocyanato-3-methylbutyrate (35 mg, 0.23 mmol) as starting materials The reaction is carried out in the same manner as to obtain 16.7 mg (0.036 mmol, 24%) of the desired product as a white solid. Mass spectrometry [M + H] \n+\n = 464\n\n\n\n\n\n\n \n\n  実施例１８１\n\n  トランス−Ｎ−［４−（２，５−ジオキソ−イミダゾリン−１−イル）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 181 \n Trans-N- [4- (2,5-Dioxo-imidazolin-1-yl) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  出発物質としてトランス−アミン（５０ｍｇ、０．１５ミリモル）とエチル・イソシアナトアセテート（３０ｍｇ、０．１６ミリモル）を用い、実施例１７９の記載と同じ操作で反応を行って、６．４ｍｇ（０．０１５ミリモル、１０％）の所望生成物を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４２２\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n The reaction was carried out as described in Example 179 using trans-amine (50 mg, 0.15 mmol) and ethyl isocyanatoacetate (30 mg, 0.16 mmol) as starting materials to give 6.4 mg (0 .015 mmol, 10%) of the desired product as a white solid. Mass spectrometry [M + H] \n+\n = 422\n\n\n\n\n\n\n \n\n  実施例１８２\n\n  トランス−Ｎ−［４−（２，５−ジオキソ−４−（ｓ）−イソプロピル−イミダゾリン−１−イル）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 182 \n Trans-N- [4- (2,5-Dioxo-4- (s) -isopropyl-imidazolin-1-yl) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  出発物質としてトランス−アミン（５０ｍｇ、０．１５ミリモル）とメチル・（Ｓ）−（−）−２−イソシアナト−３−メチルブチレート（３５ｍｇ、０．２３ミリモル）を用い、実施例１８０の記載と同じ操作で反応を行って、２３．４ｍｇ（０．０５１ミリモル、３３％）の所望生成物を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４６４\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n Description of Example 180 using trans-amine (50 mg, 0.15 mmol) and methyl (S)-(−)-2-isocyanato-3-methylbutyrate (35 mg, 0.23 mmol) as starting materials To give 23.4 mg (0.051 mmol, 33%) of the desired product as a white solid. Mass spectrometry [M + H] \n+\n = 464\n\n\n\n\n\n\n \n\n  実施例１８３\n\n  シス−Ｎ−［４−（２，５−ジオキソ−４−（ｓ）−テトラヒドロ−ピロロ［１，２−Ｃ］イミダゾール−２−イル）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 183 \n Cis-N- [4- (2,5-dioxo-4- (s) -tetrahydro-pyrrolo [1,2-C] imidazol-2-yl) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  １０ｍＬのジクロロメタン中のシス−アミン１（２００ｍｇ、０．５９ミリモル）の溶液に、１０ｍＬの水性ＮａＨＣＯ\n3\nを加える。該不均質溶液に、１ｍＬのホスゲン（トルエン中２０％）を滴下し、得られる混合物を２５℃で５ｈ撹拌する。有機層を分離する。水性層をジクロロメタン（２０ｍＬ）で抽出する。コンバインした有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物を得、これを所望生成物２と同定し、さらに精製せずに、次の反応に付す。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of cis-amine 1 (200 mg, 0.59 mmol) in 10 mL of dichloromethane is added 10 mL of aqueous NaHCO \n3\n . To the heterogeneous solution is added 1 mL of phosgene (20% in toluene) dropwise and the resulting mixture is stirred at 25 ° C. for 5 h. Separate the organic layer. Extract the aqueous layer with dichloromethane (20 mL). The combined organic layers are dried over MgSO \n4 and\n concentrated in vacuo to give an oil that is identified as the desired product 2 and subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  １ｍＬの２−プロパノール中のイソシアネート２（前工程で生成した化合物２の１／１０）の溶液に、０．１ｍＬのトリエチルアミンとＬ−プロリン・メチルエステル・ＨＣｌ（１００ｍｇ、０．６１ミリモル）を加え、得られる溶液を２５℃で１２ｈ撹拌する。反応混合物を１ｍＬの３Ｎ水性ＨＣｌと混ぜ、得られる溶液を７０℃で１２ｈ撹拌する。これを２５℃に冷却し、分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、１４．６ｍｇ（５３％）の所望生成物３を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４６２\n\nCompound 3: \n To a solution of isocyanate 2 (1/10 of compound 2 produced in the previous step) in 1 mL 2-propanol was added 0.1 mL triethylamine and L-proline methyl ester HCl (100 mg, 0.61 mmol). The resulting solution is stirred at 25 ° C. for 12 h. The reaction mixture is mixed with 1 mL of 3N aqueous HCl and the resulting solution is stirred at 70 ° C. for 12 h. This is cooled to 25 ° C. and purified by preparative HPLC (described in the synthesis of Example 31) to give 14.6 mg (53%) of the desired product 3 as a colorless oil. Mass spectrometry [M + H] \n+\n = 462\n\n\n\n\n\n\n \n\n  実施例１８４〜１９２\n\n  実施例１８３に記載の方法を用い、以下に示す実施例１８４〜１９２の化合物を合成する。\n\n\n \n \n\n\nExamples 184-192 \n The compounds of Examples 184 to 192 shown below are synthesized using the method described in Example 183. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例１９３\n\n  シスおよびトランス−Ｎ−（２，４−ジオキソ−１−フェニル−１，３−ジアザ−スピロ［４，５］デク−８−イルメチル）−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 193 \n Cis and trans-N- (2,4-dioxo-1-phenyl-1,3-diaza-spiro [4,5] dec-8-ylmethyl) -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２および３：\n\n  ２０ｍＬの５０％水性ＥｔＯＨ中のケトン（０．４８ｇ、１．４２ミリモル）の溶液に、ＫＣＮ（０．１１ｇ、１．７０ミリモル）と（ＮＨ\n4\n）\n2\nＣＯ\n3\n（０．６８ｇ、７．１０ミリモル）をそれぞれ一度に加え、得られる溶液を５５℃で１２ｈ撹拌する。混合物を減圧濃縮して、水溶液を得、これをＥｔＯＡｃ（１００ｍＬ×３）で抽出する。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して無色油状物を得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compounds 2 and 3: \n To a solution of ketone (0.48 g, 1.42 mmol) in 20 mL of 50% aqueous EtOH was added KCN (0.11 g, 1.70 mmol) and (NH \n4\n ) \n2\n CO \n3\n (0.68 g, 7.10). Millimoles) are added in one portion and the resulting solution is stirred at 55 ° C. for 12 h. The mixture is concentrated in vacuo to give an aqueous solution that is extracted with EtOAc (100 mL × 3). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give a colorless oil.\n\n\n\n\n\n\n \n\n  この油状物をジクロロメタンに溶解すると、白色固体が析出する。白色固体（２３０ｍｇ）は、２つのジアステレオ異性体（１：１比）から成る。母液を減圧濃縮して油状物を得、これを分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、１６．１ｍｇの１つの異性体（保持時間２．８２分）を得る。白色固体を３０ｍＬの温ＥｔＯＨに溶解し、２５℃で５日間貯蔵して、他の異性体の白色固体沈澱物５５．７ｍｇを得る。両化合物の質量分析［Ｍ＋Ｈ］\n+\n＝４０８\n\nWhen this oil is dissolved in dichloromethane, a white solid precipitates. A white solid (230 mg) consists of two diastereoisomers (1: 1 ratio). The mother liquor was concentrated in vacuo to give an oil that was purified by preparative HPLC (described in the synthesis of Example 31) to give 16.1 mg of one isomer (retention time 2.82 min). The white solid is dissolved in 30 mL of warm EtOH and stored at 25 ° C. for 5 days to give 55.7 mg of a white solid precipitate of other isomers. Mass spectrometry of both compounds [M + H] \n+\n = 408\n\n\n\n\n\n\n \n\n  実施例１９４\n\n  シス−２−メトキシ−Ｎ−［４−（２−オキソ−イミダゾリジン−１−イル）−１−フェニル−シクロヘキシルメチル］−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 194 \n Cis-2-methoxy-N- [4- (2-oxo-imidazolidin-1-yl) -1-phenyl-cyclohexylmethyl] -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２および３：\n\n  １０ｍＬのジクロロエタン中のケトン１（０．５ｇ、１．５ミリモル）の溶液に、Ｎ−アセチルエチレンジアミン（０．３４ｍＬ、３．０ミリモル）とＮａＢＨ（ＯＡｃ）\n3\n（０．６４ｇ、３．０ミリモル）をそれぞれ一度に加え、得られる溶液を２５℃で１２ｈ撹拌する。これをジクロロメタン（５０ｍＬ）で希釈し、１Ｎ水性ＮａＯＨで洗う。有機層を分離し、減圧濃縮して油状残渣を得る。残渣を２０ｍＬのジクロロメタンに溶解し、１．０ｇ（４．５ミリモル）のジ−ｔ−ブチルジカーボネートと共に、２５℃で１ｈ撹拌する。反応混合物を減圧濃縮して、油状残渣を得、これを分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、シス化合物２（保持時間２．４２分）およびトランス化合物３（保持時間２．５７分）の両方を得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compounds 2 and 3: \n To a solution of ketone 1 (0.5 g, 1.5 mmol) in 10 mL dichloroethane was added N-acetylethylenediamine (0.34 mL, 3.0 mmol) and NaBH (OAc) \n3\n (0.64 g, 3.0 mmol). ) Are added each time and the resulting solution is stirred at 25 ° C. for 12 h. This is diluted with dichloromethane (50 mL) and washed with 1N aqueous NaOH. The organic layer is separated and concentrated under reduced pressure to give an oily residue. The residue is dissolved in 20 mL of dichloromethane and stirred with 1.0 g (4.5 mmol) of di-t-butyl dicarbonate at 25 ° C. for 1 h. The reaction mixture was concentrated under reduced pressure to give an oily residue, which was purified by preparative HPLC (described in the synthesis of Example 31) to give cis compound 2 (retention time 2.42 minutes) and trans compound 3 (retention time). 2.57 minutes).\n\n\n\n\n\n\n \n\n  化合物４：\n\n  化合物２を２０ｍＬの３Ｎ水性ＨＣｌに溶解し、２５℃で１２ｈ撹拌する。反応液を０℃に冷却し、２０％水性ＮａＯＨで塩基性化し、ジクロロメタン（５０ｍＬ×３）で抽出する。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して１５７ｍｇの化合物４を得る。\n\n  化合物５：\n\n  シス−アミン４（１００ｍｇ、０．２６ミリモル）を５ｍＬのジクロロメタンに溶解し、カルボニルジイミダゾール（１００ｍｇ、０．６１ミリモル）と共に、２５℃で１２ｈ撹拌する。反応混合物を濃縮し、分取ＨＰＬＣ（実施例３１の合成で記載）に付して、１４．６ｍｇの所望生成物を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４０８\n\nCompound 4: \n Compound 2 is dissolved in 20 mL of 3N aqueous HCl and stirred at 25 ° C. for 12 h. Cool the reaction to 0 ° C., basify with 20% aqueous NaOH and extract with dichloromethane (50 mL × 3). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give 157 mg of compound 4. \n Compound 5: \n Cis-amine 4 (100 mg, 0.26 mmol) is dissolved in 5 mL of dichloromethane and stirred with carbonyldiimidazole (100 mg, 0.61 mmol) at 25 ° C. for 12 h. The reaction mixture is concentrated and subjected to preparative HPLC (described in the synthesis of Example 31) to give 14.6 mg of the desired product as a white solid. Mass spectrometry [M + H] \n+\n = 408\n\n\n\n\n\n\n \n\n  実施例１９５\n\n  トランス−２−メトキシ−Ｎ−［４−（２−オキソ−イミダゾリジン−１−イル）−１−フェニル−シクロヘキシルメチル］−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 195 \n Trans-2-methoxy-N- [4- (2-oxo-imidazolidin-1-yl) -1-phenyl-cyclohexylmethyl] -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２および３：\n\n  化合物２および３の合成は、実施例１９４に記載されている。\n\n  化合物４：\n\n  化合物３を２０ｍＬの３Ｎ水性ＨＣｌに溶解し、２５℃で１２ｈ撹拌する。反応液を０℃に冷却し、２０％水性ＮａＯＨで塩基性化し、ジクロロメタン（５０ｍＬ×３）で抽出する。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して１３５ｍｇの化合物４を得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compounds 2 and 3: \n The synthesis of compounds 2 and 3 is described in Example 194. \n Compound 4: \n Compound 3 is dissolved in 20 mL of 3N aqueous HCl and stirred at 25 ° C. for 12 h. Cool the reaction to 0 ° C., basify with 20% aqueous NaOH and extract with dichloromethane (50 mL × 3). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give 135 mg of compound 4.\n\n\n\n\n\n\n \n\n  化合物５：\n\n  トランス−アミン４（１００ｍｇ、０．２６ミリモル）を５ｍＬのジクロロメタンに溶解し、カルボニルジイミダゾール（１００ｍｇ、０．６１ミリモル）と共に、２５℃で１２ｈ撹拌する。反応混合物を濃縮し、分取ＨＰＬＣ（実施例３１の合成で記載）に付して、１５．８ｍｇの所望生成物を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４０８\n\nCompound 5: \n Trans-amine 4 (100 mg, 0.26 mmol) is dissolved in 5 mL of dichloromethane and stirred with carbonyldiimidazole (100 mg, 0.61 mmol) at 25 ° C. for 12 h. The reaction mixture is concentrated and subjected to preparative HPLC (described in the synthesis of Example 31) to give 15.8 mg of the desired product as a white solid. Mass spectrometry [M + H] \n+\n = 408\n\n\n\n\n\n\n \n\n  実施例１９６\n\n  シス−Ｎ−［４−（２−シアノイミノ−イミダゾリン−１−イル）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 196 \n Cis-N- [4- (2-Cyanoimino-imidazolin-1-yl) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例１９４に記載されている。\n\n  化合物２：\n\n  ３ｍＬの２−プロパノール中のシス−アミン（７５ｍｇ、０．２０ミリモル）およびジフェニル・シアノカルボニデート（７５ｍｇ、０．３２ミリモル）の溶液を、７０℃で４ｈ撹拌する。反応混合物を分取ＨＰＬＣ（実施例３１に記載）で精製して、３２．０ｍｇ（３７％）の所望生成物２を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４３２\n\nCompound 1: \n The synthesis of Compound 1 is described in Example 194. \n Compound 2: \n A solution of cis-amine (75 mg, 0.20 mmol) and diphenyl cyanocarbonidate (75 mg, 0.32 mmol) in 3 mL of 2-propanol is stirred at 70 ° C. for 4 h. The reaction mixture is purified by preparative HPLC (described in Example 31) to give 32.0 mg (37%) of the desired product 2 as a colorless oil. Mass spectrometry [M + H] \n+\n = 432\n\n\n\n\n\n\n \n\n  実施例１９７\n\n  トランス−Ｎ−［４−（２−シアノイミノ−イミダゾリン−１−イル）−１−フェニル−シクロヘキシルメチル］−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 197 \n Trans-N- [4- (2-Cyanoimino-imidazolin-1-yl) -1-phenyl-cyclohexylmethyl] -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例１９４に記載されている。\n\n  化合物２：\n\n  出発物質として７５ｍｇ（０．２０ミリモル）のトランス−アミンとジフェニル・シアノカルボニデート（７５ｍｇ、０．３２ミリモル）を用い、実施例１９６の記載と同じ操作で反応を行って、４７．６ｍｇ（０．１１ミリモル、５５％）の所望生成物２を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４３２\n\nCompound 1: \n The synthesis of Compound 1 is described in Example 194. \n Compound 2: \n The reaction was carried out in the same manner as described in Example 196 using 75 mg (0.20 mmol) trans-amine and diphenyl cyanocarbonidate (75 mg, 0.32 mmol) as starting materials to yield 47.6 mg ( 0.11 mmol, 55%) of the desired product 2 is obtained as a white solid. Mass spectrometry [M + H] \n+\n = 432\n\n\n\n\n\n\n \n\n  実施例１９８\n\n  １−フェニル−シクロヘキサンカルボン酸ベンジルアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 198 \n 1-Phenyl-cyclohexanecarboxylic acid benzylamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  塩化メチレン（１ｍＬ）中の１−フェニル−シクロヘキサンカルボン酸１（０．０１０ｇ、０．０４９ミリモル）の懸濁液を、０℃に冷却し、トリエチルアミン（０．０１０ｍＬ、０．０７２ミリモル）で処理した後、テトラメチルフルオルホルムアミジニウム・ヘキサフルオロホスフェート（０．０１４ｇ、０．０５３ミリモル）で処理する。室温まで加熱後（約１ｈ）、溶媒を除去し、残渣を次反応に用いる。\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n A suspension of 1-phenyl-cyclohexanecarboxylic acid 1 (0.010 g, 0.049 mmol) in methylene chloride (1 mL) was cooled to 0 ° C. and treated with triethylamine (0.010 mL, 0.072 mmol). And then treated with tetramethylfluoroformamidinium hexafluorophosphate (0.014 g, 0.053 mmol). After heating to room temperature (about 1 h), the solvent is removed and the residue is used for the next reaction.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物２をアセトニトリル（１ｍＬ）に溶解する。ＰＳ−ＤＩＥＡ（ポリスチレン−ジイソプロピルエチルアミン樹脂）（０．２ｇ）を加え、得られる懸濁液をベンジルアミン（０．００６ｍｇ、０．０５６ミリモル）で処理し、室温で振とうする。１２ｈ後、ＰＳ−ＴｓＣｌ（ポリスチレン−トシルクロリドの高荷重樹脂）（０．２ｇ）を加え、反応混合物をさらに１２ｈ振とうさせる。反応混合物を濾過し、濃縮して０．０１１ｇ（７９％）の化合物３を得る。ＬＣＭＳ，ｍ／ｚ＝２９４．４（Ｍ＋Ｈ）\n+\n\n\nCompound 3: \n Compound 2 is dissolved in acetonitrile (1 mL). PS-DIEA (polystyrene-diisopropylethylamine resin) (0.2 g) is added and the resulting suspension is treated with benzylamine (0.006 mg, 0.056 mmol) and shaken at room temperature. After 12 h, PS-TsCl (polystyrene-tosyl chloride high load resin) (0.2 g) is added and the reaction mixture is shaken for an additional 12 h. The reaction mixture is filtered and concentrated to give 0.011 g (79%) of compound 3. LCMS, m / z = 294.4 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  実施例１９９〜２８９\n\n  実施例１９８に記載の方法を用い、以下に示す実施例１９９〜２８９の化合物を合成する。幾つかのケースで、逆相ＨＰＬＣを用いて、さらなる精製を行った。\n\n\n \n \n\n\nExamples 199-289 \n Using the method described in Example 198, the following compounds of Examples 199 to 289 are synthesized. In some cases, further purification was performed using reverse phase HPLC. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例２９０\n\n  １−（４−フルオロ−フェニル）−シクロヘキサンカルボン酸［２−（４−クロロ−フェニル）−エチル］−（１−メチル−１Ｈ−イミダゾール−２−イルメチル）−アミド\n\n\n \n \n\n\nExample 290 \n 1- (4-Fluoro-phenyl) -cyclohexanecarboxylic acid [2- (4-chloro-phenyl) -ethyl]-(1-methyl-1H-imidazol-2-ylmethyl) -amide \n \n \n \n \n\n\n\n\n\n\n \n\n  合成：\n\n\n \n \n\n\nSynthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  メタノール（２０mL）中の２−（４−クロロフェニル）エチルアミン（２.２５mL、１６.１ミリモル）および硫酸ナトリウム（１０.０g、７０.４ミリモル）の懸濁液を、１−メチル−１Ｈ−イミダゾール−２−カルボアルデヒド（１.８０g、１６.３ミリモル）で処理し、４０℃に加熱する。２４ｈ後、反応混合物を０℃に冷却し、ホウ水素化ナトリウム（０.７３g、１９.３ミリモル）で処理し、次いで室温までゆっくり加温せしめる。３ｈ後、溶媒を除去し、粗残渣を酢酸エチルと飽和水性重炭酸ナトリウム間に分配する。\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n A suspension of 2- (4-chlorophenyl) ethylamine (2.25 mL, 16.1 mmol) and sodium sulfate (10.0 g, 70.4 mmol) in methanol (20 mL) was added to 1-methyl-1H-imidazole. Treat with 2-carbaldehyde (1.80 g, 16.3 mmol) and heat to 40 ° C. After 24 h, the reaction mixture is cooled to 0 ° C., treated with sodium borohydride (0.73 g, 19.3 mmol) and then allowed to warm slowly to room temperature. After 3 h, the solvent is removed and the crude residue is partitioned between ethyl acetate and saturated aqueous sodium bicarbonate.\n\n\n\n\n\n\n \n\n  有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（硫酸マグネシウム）、濃縮する。油状残渣をテトラヒドロフランに溶解し、１Ｎ−ＨＣl／ジエチルエーテル溶液（３５mL）で処理する。白色沈殿物が直ちに形成し、これを集めて、５g（９６％）の［２−（４−クロロ−フェニル）−エチル］−（１−メチル−１Ｈ−イミダゾール−２−イルメチル）−アミン・２ＨＣlを得る。ＬＣＭＳ，ｍ／ｚ＝２５０.７（Ｍ＋Ｈ）\n+\n\n\nThe organic layer is separated, washed with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. The oily residue is dissolved in tetrahydrofuran and treated with a 1N HCl / diethyl ether solution (35 mL). A white precipitate immediately formed and was collected and collected in 5 g (96%) of [2- (4-chloro-phenyl) -ethyl]-(1-methyl-1H-imidazol-2-ylmethyl) -amine 2HCl. Get. LCMS, m / z = 2507 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物３：\n\n  塩化メチレン（１０mL）中の１−（４−フルオロ−フェニル）−シクロヘキサンカルボン酸（０.１０６mg、０.４８ミリモル）の懸濁液を、塩化オキサリル（０.０４２mL、０.４８ミリモル）および１滴のＮ,Ｎ−ジメチルホルムアミドで処理する。反応混合物を室温で１５分間撹拌せしめ、このとき、トリエチルアミン（０.２８mL、２.０ミリモル）および［２−（４−クロロ−フェニル）−エチル］−（１−メチル−１Ｈ−イミダゾール−２−イルメチル）−アミン・２ＨＣl（０.１６g、０.５０ミリモル）を加える。さらに３０分の撹拌後、溶媒を除去し、残渣を逆相ＨＰＬＣで精製して、０.１１４g（５２％）の化合物３を白色固体で得る。ＬＣＭＳ，ｍ／ｚ＝４５５.０（Ｍ＋Ｈ）\n+\n\n\nCompound 3: \n A suspension of 1- (4-fluoro-phenyl) -cyclohexanecarboxylic acid (0.106 mg, 0.48 mmol) in methylene chloride (10 mL) was added to oxalyl chloride (0.042 mL, 0.48 mmol) and 1 Treat with drops of N, N-dimethylformamide. The reaction mixture was allowed to stir at room temperature for 15 minutes when triethylamine (0.28 mL, 2.0 mmol) and [2- (4-chloro-phenyl) -ethyl]-(1-methyl-1H-imidazole-2- Add ylmethyl) -amine 2HCl (0.16 g, 0.50 mmol). After an additional 30 minutes of stirring, the solvent was removed and the residue was purified by reverse phase HPLC to give 0.114 g (52%) of compound 3 as a white solid. LCMS, m / z = 455.0 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  実施例２９１\n\n  １−（４−クロロ−フェニル）−シクロヘキサンカルボン酸［２−（４−クロロ−フェニル）エチル］−（１−メチル−１Ｈ−イミダゾール−２−イルメチル）−アミド\n\n\n \n \n\n  実施例２９０に記載の方法を用い、標記化合物を製造する。ＬＣＭＳ，ｍ／ｚ＝４７１.５（Ｍ＋Ｈ）\n+\n\n\nExample 291 \n 1- (4-Chloro-phenyl) -cyclohexanecarboxylic acid [2- (4-chloro-phenyl) ethyl]-(1-methyl-1H-imidazol-2-ylmethyl) -amide \n \n \n \n The title compound is prepared using the method described in Example 290. LCMS, m / z = 471.5 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  実施例２９２\n\n  １−（４−フルオロ−フェニル）−シクロヘキサンカルボン酸ベンジル−（１−メチル−１Ｈ−イミダゾール−２−イルメチル）−アミド\n\n\n \n \n\n  実施例２９０に記載の方法を用い、標記化合物を製造する。ＬＣＭＳ，ｍ／ｚ＝４０６.５（Ｍ＋Ｈ）\n+\n\n\nExample 292 \n 1- (4-Fluoro-phenyl) -cyclohexanecarboxylic acid benzyl- (1-methyl-1H-imidazol-2-ylmethyl) -amide \n \n \n \n The title compound is prepared using the method described in Example 290. LCMS, m / z = 406.5 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  実施例２９３\n\n  エチル−カルバミン酸４−［５−（３−メトキシ−ベンジル）−［１,２,４］オキサジアゾール−３−イル］−４−フェニル−シクロヘキシルエステル\n\n\n \n \n\n\nExample 293 \n Ethyl-carbamic acid 4- [5- (3-methoxy-benzyl)-[1,2,4] oxadiazol-3-yl] -4-phenyl-cyclohexyl ester \n \n \n \n \n\n\n\n\n\n\n \n\n  合成：\n\n\n \n \n\n\nSynthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  ｎ−プロパノール（１００mL）中の化合物１（５.８g、２３.８ミリモル）、ヒドロキシアミン塩酸塩（４.２１g、６０.６ミリモル）およびナトリウムメトキシド（３.２７g、６０.６ミリモル）の溶液を、９８℃で一夜加熱する。反応混合物を減圧濃縮し、ＥtＯＡc（１００mL）で希釈し、Ｈ\n2\nＯで洗い、無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／酢酸エチル＝１：１）で精製して、化合物２（４.６g、７１％）を白色固体で得る。ＬＣＭＳ，ｍ／ｚ＝２７７.１（Ｍ＋Ｈ）\n+\n\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n Compound 1 (5.8 g, 23.8 mmol), hydroxyamine hydrochloride (4.21 g, 60.6 mmol) and sodium methoxide (3.27 g, 60.6 mmol) in n-propanol (100 mL). The solution is heated at 98 ° C. overnight. The reaction mixture is concentrated under reduced pressure, diluted with EtOAc (100 mL), washed with H \n2\n O and dried over anhydrous sodium sulfate. Purification by flash chromatography (hexane / ethyl acetate = 1: 1) gives compound 2 (4.6 g, 71%) as a white solid. LCMS, m / z = 277.1 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物３：\n\n  ２−メトキシエチルエーテル（５mL）中の化合物２（０.１００g、０.３６ミリモル）の溶液に、炭酸カリウム（０.７２ミリモル）、次いで３−メトキシフェニルアセチルクロリド（０.０６７g、０.３６ミリモル）を加える。反応混合物を室温で３０分間撹拌し、次いで１２０℃で３ｈ加熱する。室温まで冷却後、反応混合物を水で希釈し、酢酸エチルで抽出し、無水硫酸ナトリウム上で乾燥する。シリカゲルにてカラムクロマトグラフィー（ヘキサン／酢酸エチル＝７：３）で精製して、化合物３（０.０８５g、５８％）を油状物で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）１.６５−１.８０（４Ｈ、ｍ）、２.２５−２.４０（２Ｈ、ｍ）、２.６０−２.７０（２Ｈ、ｍ）、３.７４（３Ｈ、ｓ）、３.９４（４Ｈ、ｓ）、４.１４（２Ｈ、ｓ）、６.７５−６.９０（３Ｈ、ｍ）、７.１５−７.４５（６Ｈ、ｍ）\n\n  ＬＣＭＳ，ｍ／ｚ＝４０７.２（Ｍ＋Ｈ）\n+\n\n\nCompound 3: \n To a solution of compound 2 (0.100 g, 0.36 mmol) in 2-methoxyethyl ether (5 mL) was added potassium carbonate (0.72 mmol) followed by 3-methoxyphenylacetyl chloride (0.067 g, 0.36 mmol). Mmol). The reaction mixture is stirred at room temperature for 30 minutes and then heated at 120 ° C. for 3 h. After cooling to room temperature, the reaction mixture is diluted with water, extracted with ethyl acetate and dried over anhydrous sodium sulfate. Purification by column chromatography on silica gel (hexane / ethyl acetate = 7: 3) gives compound 3 (0.085 g, 58%) as an oil. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 1.65-1.80 (4H, m), 2.25-2.40 (2H, m), 2.60-2.70 (2H M), 3.74 (3H, s), 3.94 (4H, s), 4.14 (2H, s), 6.75-6.90 (3H, m), 7.15-7. 45 (6H, m) \n LCMS, m / z = 407.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物４：\n\n  テトラヒドロフラン（１.２５mL）中の化合物３（８０mg、０.２０ミリモル）の溶液を、２Ｎ−ＨＣl（０.４mL）で処理し、４０℃で６ｈ加熱する。飽和水性重炭酸ナトリウムを加える。水性相を酢酸エチルで抽出し、有機相を無水硫酸ナトリウム上で乾燥する。シリカゲルにてカラムクロマトグラフィー（ヘキサン／酢酸エチル＝７：３）で精製して、化合物４（４０mg、６０％）を油状物で得る。ＬＣＭＳ，ｍ／ｚ＝３６３.２（Ｍ＋Ｈ）\n+\n\n\nCompound 4: \n A solution of compound 3 (80 mg, 0.20 mmol) in tetrahydrofuran (1.25 mL) is treated with 2N HCl (0.4 mL) and heated at 40 ° C. for 6 h. Add saturated aqueous sodium bicarbonate. The aqueous phase is extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate. Purification by column chromatography on silica gel (hexane / ethyl acetate = 7: 3) gives compound 4 (40 mg, 60%) as an oil. LCMS, m / z = 363.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物５：\n\n  テトラヒドロフラン（２０mL）中の化合物４（１.２g、３.３１ミリモル）の溶液を０℃にて、ホウ水素化ナトリウム（２５０mg、６.６２ミリモル）で処理する。０℃から室温まで一夜撹拌後、反応混合物に飽和水性重炭酸ナトリウムを加えて反応を抑え、酢酸エチルで抽出する。有機層を飽和水性塩化ナトリウムで洗い、無水硫酸ナトリウム上で乾燥する。シリカゲルにてカラムクロマトグラフィー（ヘキサン／酢酸エチル＝７：３）で精製して、化合物５（１.１２g、９３％）を得る。ＬＣＭＳ，ｍ／ｚ＝３６５.５（Ｍ＋Ｈ）\n+\n\n\nCompound 5: \n A solution of compound 4 (1.2 g, 3.31 mmol) in tetrahydrofuran (20 mL) is treated with sodium borohydride (250 mg, 6.62 mmol) at 0 ° C. After stirring overnight from 0 ° C. to room temperature, the reaction mixture is quenched with saturated aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer is washed with saturated aqueous sodium chloride and dried over anhydrous sodium sulfate. Purification by column chromatography on silica gel (hexane / ethyl acetate = 7: 3) gives compound 5 (1.12 g, 93%). LCMS, m / z = 365.5 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物６：\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）１.１１（３Ｈ、ｔ、Ｊ＝７.１Ｈz）、１.５０−１.７０（２Ｈ、ｍ）、１.９０−２.１８（４Ｈ、ｂｄ、Ｊ＝９.７Ｈz）、２.８８（２Ｈ、ｂｄ、Ｊ＝１３.６Ｈz）、３.１０−３.２５（２Ｈ、ｍ）、３.７４（３Ｈ、ｓ）、４.１４（２Ｈ、ｓ）、４.６０−４.８０（２Ｈ、ｍ）、６.７０−６.９０（３Ｈ、ｍ）、７.０８−７.４０（６Ｈ、ｍ）\n\n  ＬＣＭＳ，ｍ／ｚ＝４３６.２（Ｍ＋Ｈ）\n+\n\n\nCompound 6: \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 1.11 (3H, t, J = 7.1 Hz), 1.50-1.70 (2H, m), 1.90- 2.18 (4H, bd, J = 9.7 Hz), 2.88 (2H, bd, J = 13.6 Hz), 3.10-3.25 (2H, m), 3.74 (3H, s ), 4.14 (2H, s), 4.60-4.80 (2H, m), 6.70-6.90 (3H, m), 7.08-7.40 (6H, m) \n LCMS, m / z = 436.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  実施例２９４〜３２２\n\n  実施例２９３に記載の方法を用い、以下に示す実施例２９４〜３２２の化合物を合成する。幾つかのケースでは、逆相ＨＰＬＣを用いてさらなる精製を行った。\n\n\n \n \n\n\nExamples 294-322 \n Using the method described in Example 293, the compounds of Examples 294 to 322 shown below are synthesized. In some cases, further purification was performed using reverse phase HPLC. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例３２３\n\n  エチル−カルバミン酸４−（イソキノリン−１−イルアミノメチル）−４−フェニル−シクロヘキシルエステル\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 323 \n Ethyl-carbamic acid 4- (isoquinolin-1-ylaminomethyl) -4-phenyl-cyclohexyl ester \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  化合物２は商業上入手しうる。\n\n  化合物３：\n\n  トルエン（２０mL）中の化合物１（２.０g、８.０９ミリモル）、化合物２（１.１g，６.７５ミリモル）、ナトリウム−ｔ−ブトキシド（９０８mg、９.７５ミリモル）、酢酸パラジウム（７５.７mg、０.３４ミリモル）および２−（ジ−ｔ−ブチルホスフィノ）ビフェニル（１００.７mg、０.３３７４ミリモル）の混合物を、１１０℃で２０ｈ加熱する。不溶物をセライト（ＣＥＬＩＴＥ）で濾去し、溶媒を減圧除去し、残渣をシリカにて、４０％酢酸エチル／ヘキサンで溶離するフラッシュクロマトグラフィーで精製して、標記化合物（１.５g、収率５０％）を黄色油状物で得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n Compound 2 is commercially available. \n Compound 3: \n Compound 1 (2.0 g, 8.09 mmol), Compound 2 (1.1 g, 6.75 mmol), sodium-t-butoxide (908 mg, 9.75 mmol), palladium acetate (75 in toluene (20 mL). A mixture of 0.7 mg, 0.34 mmol) and 2- (di-t-butylphosphino) biphenyl (100.7 mg, 0.3374 mmol) is heated at 110 ° C. for 20 h. The insoluble material was filtered off through CELITE, the solvent was removed under reduced pressure, and the residue was purified by flash chromatography on silica eluting with 40% ethyl acetate / hexane to give the title compound (1.5 g, yield). 50%) is obtained as a yellow oil.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  ジオキソラン３（１.５g）をＴＨＦに溶解し、２Ｎ−ＨＣlで希釈し、一夜撹拌する。該溶液を、酢酸エチルと飽和重炭酸ナトリウムの混合物に加える。有機溶液を、別途２つに分けた重炭酸塩溶液、次いで塩水で洗う。溶液を硫酸ナトリウム上で乾燥し、溶媒を減圧除去して、１.２５g、（９４％）の化合物４をオレンジ色シロップで得、これをさらに精製せずに用いる。\n\nCompound 4: \n Dioxolane 3 (1.5 g) is dissolved in THF, diluted with 2N HCl and stirred overnight. The solution is added to a mixture of ethyl acetate and saturated sodium bicarbonate. The organic solution is washed with two separate bicarbonate solutions and then brine. The solution is dried over sodium sulfate and the solvent removed under reduced pressure to give 1.25 g (94%) of compound 4 as an orange syrup that is used without further purification.\n\n\n\n\n\n\n \n\n  化合物５および６：\n\n  ＴＨＦ（１０mL）中のケトン４（１.２５g、３.７９ミリモル）の溶液に、ホウ水素化ナトリウム（２１５mg、５.８２ミリモル）を加え、混合物を一夜撹拌する。反応液を酢酸エチルと希ＨＣl間に分配する。水性層を飽和重炭酸ナトリウムで塩基性化する。生成物を酢酸エチルに抽出し、硫酸ナトリウム上で乾燥し、溶媒を減圧除去する。シリカにて溶離剤として酢酸エチルを用いるフラッシュクロマトグラフィーを行い、化合物５（異性体Ａ、４６９mg）および化合物６（異性体Ｂ、１７０mg）を得る。\n\nCompounds 5 and 6: \n To a solution of ketone 4 (1.25 g, 3.79 mmol) in THF (10 mL) is added sodium borohydride (215 mg, 5.82 mmol) and the mixture is stirred overnight. The reaction is partitioned between ethyl acetate and dilute HCl. Basify the aqueous layer with saturated sodium bicarbonate. The product is extracted into ethyl acetate, dried over sodium sulfate and the solvent is removed under reduced pressure. Flash chromatography on silica using ethyl acetate as eluent gives compound 5 (isomer A, 469 mg) and compound 6 (isomer B, 170 mg).\n\n\n\n\n\n\n \n\n  化合物７：\n\n  ジクロロメタン（１０mL）中の化合物５（１１４mg、０.３４４ミリモル）の撹拌溶液に、樟脳スルホン酸（１６０.１mg、０.６８９ミリモル）を加える。５分後エチルイソシアネート（３２.７μＬ、０.４１４ミリモル）を加え、撹拌を２ｈ続ける。アンモニアのメタノール溶液で反応を抑え、溶媒を減圧除去し、残渣をシリカにてフラッシュクロマトグラフィーに付し、６０％酢酸エチル／ヘキサン、次いで５％メタノール／ジクロロメタンで溶離して、１０.２mgの標記化合物を得る。［Ｍ＋Ｈ］４０４\n\nCompound 7: \n To a stirred solution of compound 5 (114 mg, 0.344 mmol) in dichloromethane (10 mL) is added camphorsulfonic acid (160.1 mg, 0.689 mmol). After 5 minutes, ethyl isocyanate (32.7 μL, 0.414 mmol) is added and stirring is continued for 2 h. The reaction was quenched with ammonia in methanol, the solvent removed in vacuo, and the residue flash chromatographed on silica, eluting with 60% ethyl acetate / hexane, then 5% methanol / dichloromethane, 10.2 mg of the title. A compound is obtained. [M + H] 404\n\n\n\n\n\n\n \n\n  実施例３２４\n\n  エチル−カルバミン酸４−（イソキノリン−１−イルアミノメチル）−４−フェニル−シクロヘキシルエステル\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 324 \n Ethyl-carbamic acid 4- (isoquinolin-1-ylaminomethyl) -4-phenyl-cyclohexyl ester \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３２３に記載されている。\n\n  化合物２：\n\n  実施例３２３に記載のそれに類する反応において、ジクロロメタン（１０mL）中の化合物１（７６.３mg、０.２３０ミリモル）、樟脳スルホン酸（１０６.８mg、０.４６０ミリモル）およびエチルイソシアネート（２１.８μL、０.２７６ミリモル）を用いて、１６.３mgの化合物２を生成する。［Ｍ＋Ｈ］４０３\n\nCompound 1: \n The synthesis of compound 1 is described in Example 323. \n Compound 2: \n In a similar reaction as described in Example 323, compound 1 (76.3 mg, 0.230 mmol), camphorsulfonic acid (106.8 mg, 0.460 mmol) and ethyl isocyanate (21.8 μL) in dichloromethane (10 mL). , 0.276 mmol) is used to produce 16.3 mg of compound 2. [M + H] 403\n\n\n\n\n\n\n \n\n  実施例３２５\n\n  イソキノリン−１−イル−（１−フェニル−シクロヘキシルメチル）−アミン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 325 \n Isoquinolin-1-yl- (1-phenyl-cyclohexylmethyl) -amine \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  塩化メチレン（３０mL）中の１−フェニル−１−シクロヘキサンカルボン酸（０.４８４g、２.３７ミリモル）の懸濁液を、塩化オキサリル（０.２３mL，２.６４ミリモル）および１滴のＮ,Ｎ−ジメチルホルムアミドで処理する。反応混合物を室温で３０分間撹拌せしめ、このとき、トリエチルアミン（１mL、７.２ミリモル）および１−アミノイソキノリン（０.３６g、２.５０ミリモル）を加える。さらに１５分の撹拌後、反応混合物を水および飽和水性塩化ナトリウムで洗い、乾燥し（硫酸マグネシウム）、濃縮する。粗残渣をシリカゲルにて、溶離剤としてヘキサン／酢酸エチル／ジクロロメタン（３：１：１）を用いるカラムクロマトグラフィーで精製して、０.６０５gの１−フェニル−シクロヘキサンカルボン酸イソキノリン−１−イルアミドを白色泡状物で得る。ＬＣＭＳ，ｍ／ｚ＝３３１.２（Ｍ＋Ｈ）\n+\n\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n A suspension of 1-phenyl-1-cyclohexanecarboxylic acid (0.484 g, 2.37 mmol) in methylene chloride (30 mL) was added to oxalyl chloride (0.23 mL, 2.64 mmol) and 1 drop of N, Treat with N-dimethylformamide. The reaction mixture is allowed to stir at room temperature for 30 minutes, at which time triethylamine (1 mL, 7.2 mmol) and 1-aminoisoquinoline (0.36 g, 2.50 mmol) are added. After stirring for an additional 15 minutes, the reaction mixture is washed with water and saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. The crude residue was purified by column chromatography on silica gel using hexane / ethyl acetate / dichloromethane (3: 1: 1) as eluent to give 0.605 g of 1-phenyl-cyclohexanecarboxylic acid isoquinolin-1-ylamide. Obtained as a white foam. LCMS, m / z = 331.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物３：\n\n  テトラヒドロフラン（１０mL）中の１−フェニル−シクロヘキサンカルボン酸イソキノリン−１−イルアミド（０.１１７g、０.３５ミリモル）の溶液を、０℃に冷却し、水素化リチウムアルミニウム（０.０４０g、１.０５ミリモル）で処理する。反応混合物を室温までゆっくり加温せしめる。室温で１８ｈ後、さらに水素化リチウムアルミニウム（０.０４g、１.０５ミリモル）を加え、反応混合物を４０℃で２ｈ加熱する。反応混合物を元の０℃に冷却し、水を滴下して注意深く反応を抑える。蒸発でテトラヒドロフランを除去し、粗残渣を酢酸エチルおよび飽和水性重炭酸ナトリウムで希釈する。\n\nCompound 3: \n A solution of 1-phenyl-cyclohexanecarboxylic acid isoquinolin-1-ylamide (0.117 g, 0.35 mmol) in tetrahydrofuran (10 mL) was cooled to 0 ° C. and lithium aluminum hydride (0.040 g, 1.05). Mmol). Allow the reaction mixture to warm slowly to room temperature. After 18 h at room temperature, more lithium aluminum hydride (0.04 g, 1.05 mmol) is added and the reaction mixture is heated at 40 ° C. for 2 h. The reaction mixture is cooled to the original 0 ° C. and water is added dropwise to carefully quench the reaction. The tetrahydrofuran is removed by evaporation and the crude residue is diluted with ethyl acetate and saturated aqueous sodium bicarbonate.\n\n\n\n\n\n\n \n\n  有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（硫酸マグネシウム）、濾過し、濃縮する。シリカゲルにて溶離剤としてヘキサン／酢酸エチル（７：３）を用いるカラムクロマトグラフィーを行い、０.０４２gのイソキノリン−１−イル−（１−フェニル−シクロヘキシルメチル）−アミンを明黄色油状物で得る。ＬＣＭＳ，ｍ／ｚ＝３１７.２（Ｍ＋Ｈ）\n+\n \n\n\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）７.９６（１Ｈ、ｄ、Ｊ＝６.０Ｈz）、７.５４−７.２６（９Ｈ、ｍ）、６.６１（１Ｈ、ｄ、Ｊ＝６.０Ｈz）、４.８０（１Ｈ、ブロードｓ）、３.７６（２Ｈ、ｄ、Ｊ＝５.４Ｈz）、２.２６−２.２０（２Ｈ、ｍ）、１.８４−１.７７（２Ｈ、ｍ）、１.６６−１.６１（２Ｈ、ｍ）、１.５５−１.４３（４Ｈ、ｍ）\n\n\n13\nＣ−ＮＭＲ（ＣＤＣl\n3\n、７５ＭＨz）：１５５.４、１４４.９、１４１.４、１３７.１、１２９.５、１２８.９（２つの炭素）、１２７.１、１２７.０（２つの炭素）、１２６.４、１２５.８、１２１.０、１１８.１、１１０.５、５２.２、４２.６、３４.３（２つの炭素）、２６.６、２２.２（２つの炭素）\n\nThe organic layer is separated, washed with saturated aqueous sodium chloride, dried (magnesium sulfate), filtered and concentrated. Column chromatography on silica gel with hexane / ethyl acetate (7: 3) as eluent yields 0.042 g of isoquinolin-1-yl- (1-phenyl-cyclohexylmethyl) -amine as a light yellow oil. . LCMS, m / z = 317.2 (M + H) \n+\n \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 7.96 (1H, d, J = 6.0 Hz), 7.54-7.26 (9H, m), 6.61 (1H, d , J = 6.0 Hz), 4.80 (1 H, broad s), 3.76 (2 H, d, J = 5.4 Hz), 2.26-2.20 (2 H, m), 1.84− 1.77 (2H, m), 1.66-1.61 (2H, m), 1.55-1.43 (4H, m) \n \n13\n C-NMR (CDCl \n3\n , 75 MHz): 155.4, 144.9, 141.4, 137.1, 129.5, 128.9 (two carbons), 127.1, 127.0 (two Carbon), 126.4, 125.8, 121.0, 118.1, 110.5, 52.2, 42.6, 34.3 (two carbons), 26.6, 22.2 (two carbon)\n\n\n\n\n\n\n \n\n  実施例３２６〜３２９\n\n  実施例３２５に記載の方法を用い、以下に示す実施例３２６〜３２９の化合物を合成する。\n\n\n \n \n\n\nExamples 326-329 \n The compounds of Examples 326 to 329 shown below are synthesized using the method described in Example 325. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例３３０\n\n  （１−フェニル−シクロヘキシルメチル）−キナゾリン−４−イル−アミン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 330 \n (1-Phenyl-cyclohexylmethyl) -quinazolin-4-yl-amine \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  テトラヒドロフラン（１００mL）中の１−フェニル−シクロヘキサンカルボニトリル（１１.０g、５９ミリモル）の溶液を０℃に冷却し、水素化リチウムアルミニウム（１１g、２８９ミリモル）で０.５ｈにわたり数回に分けて処理する。水素化リチウムアルミニウムの添加が終了すると、冷却浴を取り除き、反応混合物を室温で１２ｈ撹拌せしめる。反応混合物を元の０℃に冷却し、２Ｎ−ＮaＯＨ（約２０mL）を滴下して注意深く反応を抑え、エチルエーテルで希釈し、セライトプラグで濾過し、乾燥する（硫酸マグネシウム）。Ｃ−（１−フェニル−シクロヘキシル）−メチルアミンが無色油状物で得られ、これをさらに精製せずに用いる。ＬＣＭＳ，ｍ／ｚ＝１９０.２（Ｍ＋Ｈ）\n+\n\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n A solution of 1-phenyl-cyclohexanecarbonitrile (11.0 g, 59 mmol) in tetrahydrofuran (100 mL) was cooled to 0 ° C. and divided with lithium aluminum hydride (11 g, 289 mmol) in 0.5 h portions. Process. When the addition of lithium aluminum hydride is complete, the cooling bath is removed and the reaction mixture is allowed to stir at room temperature for 12 h. The reaction mixture is cooled to the original 0 ° C., quenched carefully with 2N—NaOH (˜20 mL) dropwise, diluted with ethyl ether, filtered through a celite plug and dried (magnesium sulfate). C- (1-Phenyl-cyclohexyl) -methylamine is obtained as a colorless oil which is used without further purification. LCMS, m / z = 19.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物３：\n\n  テトラヒドロフラン（１０mL）中のＣ−（１−フェニル−シクロヘキシル）−メチルアミン（０.２８g、１.４８ミリモル）の溶液を室温にて、トリエチルアミン（０.３mL、２.２ミリモル）および２,４−ジクロロ−キナゾリン（０.３２g、１.６２ミリモル）で処理する。反応液を室温で１２ｈ撹拌し、このとき、回転蒸発で溶媒を除去する。粗残渣を酢酸エチルと１０％水性ＨＣl間に分配する。有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（硫酸マグネシウム）、濾過し、濃縮する。生成物を塩化メチレンより再結晶して、（２−クロロ−キナゾリン−４−イル）−（１−フェニル−シクロヘキシルメチル）−アミンを白色固体で得る。ＬＣＭＳ，ｍ／ｚ＝３５２.２（Ｍ＋Ｈ）\n+\n\n\nCompound 3: \n A solution of C- (1-phenyl-cyclohexyl) -methylamine (0.28 g, 1.48 mmol) in tetrahydrofuran (10 mL) was added at room temperature to triethylamine (0.3 mL, 2.2 mmol) and 2,4. Treat with dichloro-quinazoline (0.32 g, 1.62 mmol). The reaction is stirred at room temperature for 12 h, at which time the solvent is removed by rotary evaporation. The crude residue is partitioned between ethyl acetate and 10% aqueous HCl. The organic layer is separated, washed with saturated aqueous sodium chloride, dried (magnesium sulfate), filtered and concentrated. The product is recrystallized from methylene chloride to give (2-chloro-quinazolin-4-yl)-(1-phenyl-cyclohexylmethyl) -amine as a white solid. LCMS, m / z = 352.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  化合物４：\n\n  無水メタノール（２mL）中の（２−クロロ−キナゾリン−４−イル）−（１−フェニル−シクロヘキシルメチル）−アミン（０.０６５g、０.１８ミリモル）の溶液を、１０％パラジウム／炭素（２００mg）で処理し、水素雰囲気下（４５psi）に置く。反応混合物を室温で３ｈ振とうする。反応混合物をセライトで濾過し、蒸発する。粗残渣をシリカゲルにて、溶離剤として酢酸エチル／ヘキサン（９：１）を用いるカラムクロマトグラフィーで精製して、０.０５２gの（１−フェニル−シクロヘキシルメチル）−キナゾリン−４−イル−アミンを白色泡状物で得る。ＬＣＭＳ，ｍ／ｚ＝３１８.２（Ｍ＋Ｈ）\n+\n\n\nCompound 4: \n A solution of (2-chloro-quinazolin-4-yl)-(1-phenyl-cyclohexylmethyl) -amine (0.065 g, 0.18 mmol) in anhydrous methanol (2 mL) was added to 10% palladium / carbon (200 mg ) And place under a hydrogen atmosphere (45 psi). The reaction mixture is shaken at room temperature for 3 h. The reaction mixture is filtered through celite and evaporated. The crude residue was purified by column chromatography on silica gel using ethyl acetate / hexane (9: 1) as eluent to give 0.052 g of (1-phenyl-cyclohexylmethyl) -quinazolin-4-yl-amine. Obtained as a white foam. LCMS, m / z = 318.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  実施例３３１\n\n  Ｎ\n2\n−エチル−Ｎ\n4\n−（１−フェニル−シクロヘキシルメチル）−キナゾリン−２,４−ジアミン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 331 \n N \n2\n - ethyl -N \n4\n - (1-phenyl - cyclohexylmethyl) - quinazoline-2,4-diamine \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は上記に準じ製造する。\n\n  化合物２：\n\n  （２−クロロ−キナゾリン−４−イル）−（１−フェニル−シクロヘキシルメチル）−アミン（０.０５２g、０.１５ミリモル）を、エチルアミン／テトラヒドロフランの２Ｍ溶液１mLで処理する。反応容器をしっかりと密封し、反応混合物を６０℃で２４ｈ加熱する。揮発成分を減圧除去し、粗残渣を直接、分取ＨＰＬＣで精製して、０.０２０gのＮ\n2\n−エチル−Ｎ\n4\n−（１−フェニル−シクロヘキシルメチル）−キナゾリン−２,４−ジアミンを白色固体で得る。ＬＣＭＳ，ｍ／ｚ＝３６１.２（Ｍ＋Ｈ）\n+\n\n\nCompound 1: \n Compound 1 is produced according to the above. \n Compound 2: \n (2-Chloro-quinazolin-4-yl)-(1-phenyl-cyclohexylmethyl) -amine (0.052 g, 0.15 mmol) is treated with 1 mL of a 2M solution of ethylamine / tetrahydrofuran. The reaction vessel is tightly sealed and the reaction mixture is heated at 60 ° C. for 24 h. The volatiles were removed under reduced pressure, directly The crude residue was purified by preparative HPLC, N \n2\n of 0.020 g - Ethyl -N \n4\n - (1-phenyl - cyclohexylmethyl) - quinazoline-2,4-diamine as a white Get in solid. LCMS, m / z = 361.2 (M + H) \n+\n \n\n\n\n\n\n\n \n\n  実施例３３２\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 332 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  １００mLのアセトニトリル中の２−フルオロフェニルアセトニトリル（５mL、４１ミリモル）の還流溶液に、１００mLのアセトニトリル中のアクリル酸メチル（３６mL、４００ミリモル）を３ｈにわたり滴下する。得られる溶液を還流下で、さらに６ｈ撹拌する。反応混合物を減圧濃縮して、油状残渣を得、これをカラムクロマトグラフィー（４０％ＥtＯＡc／ヘキサン）で精製して、化合物２（１１.２g、８９％）を無色油状物で生成する。\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n To a refluxing solution of 2-fluorophenylacetonitrile (5 mL, 41 mmol) in 100 mL of acetonitrile, methyl acrylate (36 mL, 400 mmol) in 100 mL of acetonitrile is added dropwise over 3 h. The resulting solution is stirred at reflux for a further 6 h. The reaction mixture was concentrated under reduced pressure to give an oily residue that was purified by column chromatography (40% EtOAc / hexane) to yield compound 2 (11.2 g, 89%) as a colorless oil.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  ２００mLのＤＣＭ中の化合物２の溶液に、ＮaＨ（２.５g、１０８ミリモル）を一度に加え、得られる溶液を還流下で１２ｈ撹拌する。反応混合物を−７８℃に冷却し、氷を加えて反応を抑える。混合物をＥtＯＡc（１５０mL）で希釈し、有機層を濾別する。有機層の濃縮により、油状物（８.８g、８９％）を得、これはＮＭＲ分析で所望生成物に相当し、さらに精製せずに、次の反応に付す。\n\nCompound 3: \n To a solution of compound 2 in 200 mL DCM is added NaH (2.5 g, 108 mmol) in one portion and the resulting solution is stirred at reflux for 12 h. The reaction mixture is cooled to -78 ° C and ice is added to quench the reaction. The mixture is diluted with EtOAc (150 mL) and the organic layer is filtered off. Concentration of the organic layer yielded an oil (8.8 g, 89%) which corresponds to the desired product by NMR analysis and is subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  化合物３を８０mLのＤＭＳＯおよび４mLのＨ\n2\nＯに溶解する。混合物を１４０℃で１５ｈ撹拌する。反応混合物を冷却し、ＥtＯＡc（４００mL）で希釈し、１０％水性ＬiＣl（３０mL×３）で洗う。水性層をＥtＯＡc（５０mL×２）で抽出する。コンバインした有機層をＭgＳＯ\n4\n上で乾燥し、減圧濃縮して油状残渣を得、これをカラムクロマトグラフィー（２５〜５０％ＥtＯＡc／ヘキサン）で精製して、所望生成物（５.５g、６５％）を得る。\n\nCompound 4: \n Compound 3 is dissolved in 80 mL DMSO and 4 mL H \n2\n O. The mixture is stirred at 140 ° C. for 15 h. The reaction mixture is cooled, diluted with EtOAc (400 mL) and washed with 10% aqueous LiCl (30 mL × 3). Extract the aqueous layer with EtOAc (50 mL × 2). The combined organic layers were dried over MgSO \n4 and\n concentrated in vacuo to give an oily residue that was purified by column chromatography (25-50% EtOAc / hexane) to give the desired product (5.5 g, 65% )\n\n\n\n\n\n\n \n\n  化合物５：\n\n  化合物５の合成は、実施例３１の合成と同じ反応工程で実施し、なお、実施例３１の化合物１を本例の化合物４に置換した。［Ｍ＋Ｈ］＝４３８\n\nCompound 5: \n The compound 5 was synthesized in the same reaction step as the synthesis of Example 31, and the compound 1 of Example 31 was replaced with the compound 4 of this example. [M + H] = 438\n\n\n\n\n\n\n \n\n  実施例３３３〜３３４\n\n  実施例３３２に記載の方法を用い、以下に示す実施例３３３〜３３４の化合物を合成する。\n\n\n \n \n\n\nExamples 333-334 \n Using the method described in Example 332, the following compounds of Examples 333 to 334 are synthesized. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例３３５\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 335 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  化合物２は実施例３３３の合成で記載のそれと同じ手順で製造し、なお、３−フルオロフェニルアセトニトリルの代わりに実施例３３５の合成のフルオロフェニルアセトニトリルを用いた。\n\n  化合物３：\n\n  化合物３は実施例３１の合成で記載の工程で製造し、なお、実施例３１の化合物１の代わりに４−（３−フルオロフェニル）−４−シアノシクロヘキサノン２を用いた。［Ｍ＋Ｈ］＝４３８\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n Compound 2 was prepared following the same procedure as described in the synthesis of Example 333, except that the fluorophenylacetonitrile synthesized in Example 335 was used instead of 3-fluorophenylacetonitrile. \n Compound 3: \n Compound 3 was prepared by the process described in the synthesis of Example 31, and 4- (3-fluorophenyl) -4-cyanocyclohexanone 2 was used in place of Compound 1 of Example 31. [M + H] = 438\n\n\n\n\n\n\n \n\n  実施例３３６〜３４１\n\n  実施例３３５に記載の方法を用いて、以下に示す実施例３３６〜３４１の化合物を合成する。\n\n\n \n \n\n\n \n \n\n\nExamples 336-341 \n The compounds of Examples 336 to 341 shown below are synthesized using the method described in Example 335. \n \n \n \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例３４２\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 342 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  化合物２は実施例３３２の合成で記載のそれと同じ手順で製造し、なお、２−フルオロフェニルアセトニトリルの代わりに４−フルオロフェニルアセトニトリルを用いた。\n\n  化合物３：\n\n  化合物３は実施例３１の合成で記載の工程で製造し、なお、実施例３１の化合物１の代わりに上記化合物２を用いた。［Ｍ＋Ｈ］＝４３８\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n Compound 2 was prepared following the same procedure as described in the synthesis of Example 332, but using 4-fluorophenylacetonitrile instead of 2-fluorophenylacetonitrile. \n Compound 3: \n Compound 3 was produced by the process described in the synthesis of Example 31, and the above compound 2 was used in place of compound 1 of Example 31. [M + H] = 438\n\n\n\n\n\n\n \n\n  実施例３４３〜３４８\n\n  実施例３４２に記載の方法を用いて、以下に示す実施例３４３〜３４８の化合物を合成する。\n\n\n \n \n\n\n \n \n\n\nExamples 343-348 \n The compounds of Examples 343 to 348 shown below are synthesized using the method described in Example 342. \n \n \n \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例３４９\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 349 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  化合物２の合成は、実施例７３に記載されている。\n\n  化合物３：\n\n  １ｍＬのＣＨ\n3\nＣＮ中の化合物２（２０ｍｇ、０．０４１ミリモル）、４−（アミノメチル）ピリジン（１０ｍｇ、０．１０ミリモル）の溶液を、６５℃で２ｈ攪拌する。反応混合物を分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、１１．２ｍｇの化合物３を無色油状物で得る。質量分析［Ｍ＋Ｈ］＝５０９\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n The synthesis of compound 2 is described in Example 73. \n Compound 3: \n A solution of compound 2 (20 mg, 0.041 mmol), 4- (aminomethyl) pyridine (10 mg, 0.10 mmol) in 1 mL of CH \n3\n CN is stirred at 65 ° C. for 2 h. The reaction mixture is purified by preparative HPLC (described in the synthesis of Example 31) to give 11.2 mg of compound 3 as a colorless oil. Mass spectrometry [M + H] = 509\n\n\n\n\n\n\n \n\n  実施例３５０〜３９６\n\n  実施例３４９に記載の方法を用い、以下に示す実施例３５０〜３９６の化合物を合成する。\n\n\n \n \n\n\nExamples 350-396 \n Using the method described in Example 349, the following compounds of Examples 350 to 396 are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  化合物２は実施例３３２の合成で記載のそれと同じ手順で製造し、なお、実施例３３２の合成の２−フルオロフェニルアセトニトリルの代わりに２−メトキシフェニルアセトニトリルを用いた。\n\n  化合物３は実施例３１の合成で記載の工程で製造し、なお、実施例３１の化合物１の代わりに４−（２−メトキシフェニル）−４−シアノシクロヘキサノン２を用いた。［Ｍ＋Ｈ］＝４５０\n\n \n \n \n Compound 1: \n Compound 1 is commercially available. \n Compound 2: \n Compound 2 was prepared following the same procedure as described in the synthesis of Example 332, but 2-methoxyphenylacetonitrile was used in place of the 2-fluorophenylacetonitrile synthesized in Example 332. \n Compound 3 was produced by the process described in the synthesis of Example 31, and 4- (2-methoxyphenyl) -4-cyanocyclohexanone 2 was used in place of Compound 1 of Example 31. [M + H] = 450\n\n\n\n\n\n\n \n\n  実施例３９８〜４０４\n\n  実施例３９７に記載の方法を用い、以下に示す実施例３９８〜４０４の化合物を合成する。\n\n\n \n \n\n\n \n \n\n\nExamples 398-404 \n The compounds of Examples 398 to 404 shown below are synthesized using the method described in Example 397. \n \n \n \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例４０５\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 405 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３８８に記載されている。\n\n  化合物２：\n\n  化合物２の合成は、実施例７３の記載と同じ手順で行なう。\n\n  化合物３：\n\n  １ｍＬのＣＨ\n3\nＣＮ中の化合物２（４０ｍｇ、０．０８３ミリモル）、４−（アミノメチル）ピリジン（２０ｍｇ、０．２０ミリモル）の溶液を、６５℃で２ｈ攪拌する。反応混合物を分取ＨＰＬＣ（実施例３１の合成で記載）で精製して、８．９ｍｇの化合物３を無色油状物で得る。質量分析［Ｍ＋Ｈ］＝５３９\n\nCompound 1: \n The synthesis of compound 1 is described in Example 388. \n Compound 2: \n Compound 2 is synthesized according to the same procedure as described in Example 73. \n Compound 3: \n A solution of compound 2 (40 mg, 0.083 mmol), 4- (aminomethyl) pyridine (20 mg, 0.20 mmol) in 1 mL of CH \n3\n CN is stirred at 65 ° C. for 2 h. The reaction mixture is purified by preparative HPLC (described in the synthesis of Example 31) to give 8.9 mg of compound 3 as a colorless oil. Mass spectrometry [M + H] = 539\n\n\n\n\n\n\n \n\n  実施例４０６〜４１０\n\n  実施例４０５に記載の方法を用い、以下に示す実施例４０６〜４１０の化合物を合成する。\n\n\n \n \n\n\nExamples 406-410 \n Using the method described in Example 405, the following compounds of Examples 406 to 410 are synthesized. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例４１１および４１２\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExamples 411 and 412 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  マイクロ波反応器用に特別設計したバイアルに、化合物１（０．５７ｇ、２．３ミリモル）、Ｐｄ\n2\n(ｄｂａ)\n3\n（４２ｍｇ、０．０４６ミリモル）、ＢＩＮＡＰ（７９ｍｇ、０．１３ミリモル）およびｔ−ＢｕＯＮａ（０．３８ｇ、２．３ミリモル）を一度に加える。反応バイアルを減圧下に置いて、空気を除去する。次いで混合物に、２２ｍＬの脱泡ＴＨＦを加え、反応バイアルに栓をする。反応混合物をマイクロ波反応器に入れ、１８０℃で２０分間加熱する。反応混合物を冷却し、カラムクロマトグラフィー（２０〜５０％ＥｔＯＡｃ／ヘキサン）に付して、０．６２ｇ（７２％）の所望生成物を油状固体で得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n In a vial specially designed for microwave reactors, compound 1 (0.57 g, 2.3 mmol), Pd \n2\n (dba) \n3\n (42 mg, 0.046 mmol), BINAP (79 mg, 0.13 mmol) and t -BuONa (0.38 g, 2.3 mmol) is added in one portion. Place the reaction vial under vacuum to remove air. To the mixture is then added 22 mL of degassed THF and the reaction vial is capped. The reaction mixture is placed in a microwave reactor and heated at 180 ° C. for 20 minutes. The reaction mixture is cooled and subjected to column chromatography (20-50% EtOAc / hexanes) to give 0.62 g (72%) of the desired product as an oily solid.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物２（３．０ｇ、８．０ミリモル）をＴＨＦ（６０ｍｌ）および水性ＨＣｌ（１０ｍＬ）に溶解し、得られる溶液を３５℃で４ｈ攪拌する。反応混合物からＴＨＦを蒸発させ、残った水溶液をＥｔＯＡｃ（１００ｍＬ×２）で抽出する。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物（２．４ｇ、＞９５％）を得、これを所望生成物と同定し（２異性体の１：１混合物）、さらに精製せずに、次の反応に付す（純度＞９５％）。\n\nCompound 3: \n Compound 2 (3.0 g, 8.0 mmol) is dissolved in THF (60 ml) and aqueous HCl (10 mL) and the resulting solution is stirred at 35 ° C. for 4 h. THF is evaporated from the reaction mixture and the remaining aqueous solution is extracted with EtOAc (100 mL × 2). The organic layer was dried over MgSO \n4 and\n concentrated in vacuo to give an oil (2.4 g,> 95%) which was identified as the desired product (1: 1 mixture of 2 isomers) and further purified. Without being subjected to the next reaction (purity> 95%).\n\n\n\n\n\n\n \n\n  化合物４：\n\n  ５０ｍＬのＭｅＯＨ中の化合物３（１．２ｇ、３．６ミリモル）の溶液に、ＮＨ\n4\nＯＡｃ（２．２ｇ、２７ミリモル）およびＮａＢＨ(ＯＡｃ)\n3\n（０．９８ｇ、４．６ミリモル）を一度に加え、得られる溶液を室温で１２ｈ攪拌する。反応混合物を減圧濃縮して、油状残渣を得、これをＥｔＯＡｃ（２００ｍＬ）と塩水（５０ｍｌ）間に分配する。水性層をさらにＥｔＯＡｃ（５０ｍＬ×２）で抽出する。コンバインした有機溶液をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物（１．２ｇ、＞９５％）を得、これを所望生成物と同定し、さらに精製せずに、次の反応に付す（純度＞９０％）。\n\nCompound 4: \n To a solution of compound 3 (1.2 g, 3.6 mmol) in 50 mL MeOH was added NH \n4\n OAc (2.2 g, 27 mmol) and NaBH (OAc) \n3\n (0.98 g, 4.6 mmol) once. And the resulting solution is stirred at room temperature for 12 h. The reaction mixture is concentrated under reduced pressure to give an oily residue that is partitioned between EtOAc (200 mL) and brine (50 ml). The aqueous layer is further extracted with EtOAc (50 mL × 2). The combined organic solution was dried over MgSO \n4 and\n concentrated in vacuo to give an oil (1.2 g,> 95%) that was identified as the desired product and subjected to the next reaction without further purification. (Purity> 90%).\n\n\n\n\n\n\n \n\n  化合物５および６\n\n  化合物４（０．１３ｇ、０．３９ミリモル）、ジフェニル・シアノカルボンイミデート（９４ｍｇ、０．３９ミリモル）および５ｍＬの２Ｎ−ＭｅＮＨ\n2\n／ＭｅＯＨを用い、実施例３１の合成と同じ手順で、化合物４の合成を行って、２０．９ｍｇの化合物５および１２．３ｍｇの化合物６を得る。\n\nCompounds 5 and 6 \n Compound 4 (0.13 g, 0.39 mmol), diphenyl cyanocarbonimidate (94 mg, 0.39 mmol) and 5 mL of 2N-MeNH \n2\n / MeOH were used in the same procedure as the synthesis of Example 31. 4 is synthesized to give 20.9 mg of compound 5 and 12.3 mg of compound 6.\n\n\n\n\n\n\n \n\n  実施例４１３〜４１８\n\n  実施例４１１に記載の方法を用い、以下に示す実施例４１３〜４１８の化合物を合成する。\n\n\n \n \n\n\nExamples 413-418 \n The compounds of Examples 413 to 418 shown below are synthesized using the method described in Example 411. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例４１９\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 419 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例１５３に記載されている。\n\n  化合物２：\n\n  化合物２は一部のライブラリー合成（library synthesis）に準じ製造する。一般手順は以下の通りである。\n\n  １ｍＬの１，２−ジクロロエタン中の化合物１（８．３ｍｇ、０．０３ミリモル）の溶液に、３−（トリフルオロメチル）ベンゾイルクロリド（２０μＬ、０．１４ミリモル）および２０ｍｇのポリマー結合アミン（ＰＬ−ＭＰＨ樹脂、ポリマー・ラボラトリーズ）を一度に加え、得られる混合物に１２ｈ渦を巻かせる。反応混合物に、ポリマー結合樹脂ＰＬ−ＥＤＡ（５０ｍｇ、ポリマー・ラボラトリーズ）を加え、得られる混合物にさらに５ｈ渦を巻かせる。次いで反応混合物を濾過し、スピード減圧で濃縮して、８．０ｍｇ（０．０２０ミリモル、６７％）の所望生成物を無色油状物で得る。［Ｍ＋Ｈ］＝４５８\n\nCompound 1: \n The synthesis of Compound 1 is described in Example 153. \n Compound 2: \n Compound 2 is produced according to some library synthesis. The general procedure is as follows. \n To a solution of compound 1 (8.3 mg, 0.03 mmol) in 1 mL 1,2-dichloroethane was added 3- (trifluoromethyl) benzoyl chloride (20 μL, 0.14 mmol) and 20 mg polymer-bound amine (PL -MPH resin, Polymer Laboratories) is added all at once and the resulting mixture is vortexed for 12 h. To the reaction mixture, polymer-bound resin PL-EDA (50 mg, Polymer Laboratories) is added and the resulting mixture is further vortexed for 5 h. The reaction mixture is then filtered and concentrated at reduced speed to give 8.0 mg (0.020 mmol, 67%) of the desired product as a colorless oil. [M + H] = 458\n\n\n\n\n\n\n \n\n  実施例４２０〜４４９\n\n  実施例４１９に記載の方法を用い、以下に示す実施例４２０〜４４９の化合物を合成する。\n\n\n \n \n\n\nExamples 420-449 \n The compounds of Examples 420 to 449 shown below are synthesized using the method described in Example 419. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例４５０\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 450 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例１５３に記載されている。\n\n  化合物２：\n\n  化合物２は一部のライブラリー合成に準じ製造する。一般手順は以下の通りである。\n\n  １ｍＬのＤＣＭおよび０．３ｍＬのＤＭＦ中の酸（１０ｍｇ、０．０６ミリモル）の溶液に、ＥＤＣＩ（１１．５ｍｇ、０．０６ミリモル）およびＨＯＡｔ（８．２ｍｇ、０．０６ミリモル）を加える。該溶液に、１．２ｍＬのＤＣＥ／ＤＭＦ（２：１）中の化合物１（１１ｍｇ、０．０４ミリモル）を加える。反応混合物を２５℃で１２ｈ攪拌せしめる。反応混合物を分取ＨＰＬＣ（実施例３１参照）で精製し、スピード減圧で濃縮して、１０．８ｍｇ（０．０２１ミリモル、４１％）の所望生成物を無色油状物で得る。\n\nCompound 1: \n The synthesis of Compound 1 is described in Example 153. \n Compound 2: \n Compound 2 is produced according to some library synthesis. The general procedure is as follows. \n To a solution of acid (10 mg, 0.06 mmol) in 1 mL DCM and 0.3 mL DMF is added EDCI (11.5 mg, 0.06 mmol) and HOAt (8.2 mg, 0.06 mmol). To the solution is added compound 1 (11 mg, 0.04 mmol) in 1.2 mL DCE / DMF (2: 1). The reaction mixture is allowed to stir at 25 ° C. for 12 h. The reaction mixture is purified by preparative HPLC (see Example 31) and concentrated at speed reduced pressure to give 10.8 mg (0.021 mmol, 41%) of the desired product as a colorless oil.\n\n\n\n\n\n\n \n\n  実施例４５１〜５６２\n\n  実施例４５０に記載の方法を用い、以下に示す実施例４５１〜５６２の化合物を合成する。\n\n\n \n \n\n\nExamples 451-562 \n Using the method described in Example 450, the compounds of Examples 451 to 562 shown below are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例５６３\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 563 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  ＤＣＭ（１５ｍＬ）およびＤＭＦ（５ｍＬ）中の６−メトキシサリチル酸（４．２ｇ、２５ミリモル）の溶液に、ＥＤＣＩ（３．８ｇ、１．３２５ミリモル）およびＨＯＡｔ（３３．４ｇ、２５ミリモル）をそれぞれ一度に加え、得られる溶液を０．５ｈ攪拌する。この混合物を、１５ｍＬのＤＣＭ中の化合物１（４．７ｇ、１９ミリモル）の溶液に滴下する。得られる溶液を２５℃で１２ｈ攪拌する。反応混合物を減圧蒸発して、油状残渣を得、これをカラムクロマトグラフィー（２０〜５０％ＥｔＯＡｃ／ヘキサン）で精製して、化合物２（５．８ｇ、７７％）を無色油状物で得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of 6-methoxysalicylic acid (4.2 g, 25 mmol) in DCM (15 mL) and DMF (5 mL) was added EDCI (3.8 g, 1.325 mmol) and HOAt (33.4 g, 25 mmol), respectively. Add in one portion and stir the resulting solution for 0.5 h. This mixture is added dropwise to a solution of compound 1 (4.7 g, 19 mmol) in 15 mL DCM. The resulting solution is stirred at 25 ° C. for 12 h. The reaction mixture was evaporated under reduced pressure to give an oily residue that was purified by column chromatography (20-50% EtOAc / hexanes) to give compound 2 (5.8 g, 77%) as a colorless oil.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物２（５．８ｇ、１４．６ミリモル）を、ＴＨＦ（８０ｍＬ）および２Ｎ−ＨＣｌ／ＭｅＯＨ（４０ｍＬ）に溶解する。混合物を５０℃で５ｈ攪拌せしめる。次いで反応混合物を、ＥｔＯＡｃ（３００ｍＬ）に注ぎ、有機層を分離する。水性層をＥｔＯＡｃ（５０ｍＬ×２）で抽出する。コンバインした有機層を水性ＮａＨＣＯ\n3\nで洗い、Ｎａ\n2\nＳＯ\n4\n上で乾燥し、減圧濃縮して所望生成物（４．０ｇ、８０％）を得、これは純粋で（＞９５％）、さらに精製せずに次の反応に付す。\n\nCompound 3: \n Compound 2 (5.8 g, 14.6 mmol) is dissolved in THF (80 mL) and 2N HCl / MeOH (40 mL). The mixture is allowed to stir at 50 ° C. for 5 h. The reaction mixture is then poured into EtOAc (300 mL) and the organic layer is separated. Extract the aqueous layer with EtOAc (50 mL × 2). The combined organic layers were washed with aqueous NaHCO \n3\n , dried over Na \n2\n SO \n4 and\n concentrated in vacuo to give the desired product (4.0 g, 80%) which was pure (> 95%) and further purified Without attaching to the next reaction.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  化合物３（４．０ｇ、１１．３ミリモル）をＭｅＯＨ（１００ｍＬ）に溶解し、ＮａＢＨ\n4\n（０．５０ｇ、１３ミリモル）と共に−７８℃で３ｈ攪拌する。ＨＰＬＣ分析により、反応の完了が認められる。混合物を減圧濃縮して、白色固体混合物を得、これをＥｔＯＡｃ（２００ｍＬ）と塩水（５０ｍＬ）間に分配する。有機層をＮａ\n2\nＳＯ\n4\n上で乾燥し、減圧濃縮してアルコール（４．０ｇ、＞９５％）を油状物で得る。アルコールを３０ｍＬのＤＣＭに溶解し、０℃でピリジン（１０ｍＬ）およびメタンスルホニルクロリド（１．１ｍＬ、１３．６ミリモル）を加える。得られる溶液を２５℃で１２ｈ攪拌する。水を加えて反応を抑える。さらに水性層を、ＤＣＭ（２０ｍＬ×２）で抽出する。コンバインした有機溶液を、１Ｎ水性ＨＣｌ（３０ｍＬ×２）で洗い、Ｎａ\n2\nＳＯ\n4\n上で乾燥する。有機溶液の濃縮で、所望生成物（５．２ｇ、純度８５％）を油状物で得、これをさらに精製せずに、次の反応に付す。\n\nCompound 4: \n Compound 3 (4.0 g, 11.3 mmol) is dissolved in MeOH (100 mL) and stirred with NaBH \n4\n (0.50 g, 13 mmol) at −78 ° C. for 3 h. Completion of the reaction is observed by HPLC analysis. The mixture is concentrated under reduced pressure to give a white solid mixture that is partitioned between EtOAc (200 mL) and brine (50 mL). The organic layer is dried over Na \n2\n SO \n4 and\n concentrated in vacuo to give the alcohol (4.0 g,> 95%) as an oil. Dissolve the alcohol in 30 mL DCM and add pyridine (10 mL) and methanesulfonyl chloride (1.1 mL, 13.6 mmol) at 0 ° C. The resulting solution is stirred at 25 ° C. for 12 h. Add water to suppress reaction. The aqueous layer is further extracted with DCM (20 mL × 2). The combined organic solution is washed with 1N aqueous HCl (30 mL × 2) and dried over Na \n2\n SO \n4\n . Concentration of the organic solution gives the desired product (5.2 g, 85% purity) as an oil which is subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物５：\n\n  上記の化合物４を２０ｍＬのＤＭＦに溶解し、ＮａＮ\n3\n（１．２ｇ、１５ミリモル）を加える。混合物を８０℃で１２ｈ攪拌せしめる。反応混合物を減圧濃縮して、ＤＭＦを除去し、ＥｔＯＡｃ（１００ｍＬ）と塩水（３０ｍＬ）間に分配する。水性層をＥｔＯＡｃ（５０ｍＬ×２）で抽出する。コンバインした有機溶液をＣombiＦlashにて精製し（０〜２０％ＥｔＯＡｃ／ヘキサン）、所望生成物（２．０ｇ、５．３ミリモル、２工程で５３％）を、シスおよびトランス異性体（４：１比）の混合物で得る。\n\nCompound 5: \n Compound 4 above is dissolved in 20 mL DMF and NaN \n3\n (1.2 g, 15 mmol) is added. The mixture is allowed to stir at 80 ° C. for 12 h. The reaction mixture is concentrated under reduced pressure to remove DMF and partitioned between EtOAc (100 mL) and brine (30 mL). Extract the aqueous layer with EtOAc (50 mL × 2). The combined organic solution was purified by CombiFlash (0-20% EtOAc / hexane) and the desired product (2.0 g, 5.3 mmol, 53% over 2 steps) was converted to the cis and trans isomers (4: 1 Ratio).\n\n\n\n\n\n\n \n\n  化合物６：\n\n  化合物５を３０ｍＬのＭｅＯＨに溶解し、触媒量の１０％Ｐｄ／Ｃを加える。混合物をＨ\n2\n下に置き、２５℃で２ｈ攪拌する。反応混合物をセライトで濾過し、濾液を減圧濃縮して、所望生成物（１．４ｇ、７５％）を無色油状物で得る。\n\n  化合物７：\n\n  １０ｍＬのイソプロパノール中の化合物６（０．３６ｇ、１ミリモル）の溶液に、ジフェニル・シアノカルボンイミデート（０．２４ｇ、１ミリモル）を加え、得られる溶液を６０℃で５ｈ攪拌する。次いで反応混合物を減圧濃縮して、油状残渣を得、これを１０ｍＬのＭｅＮＨ\n2\n／ＭｅＯＨ溶液に溶解し、密封チューブにて８０℃で５ｈ攪拌する。反応混合物を濃縮し、ＣombiＦlashにて精製し、（２０〜１００％ＥｔＯＡｃ／ヘキサン）、所望生成物（０．３４ｇ、７８％）を得る。［Ｍ＋Ｈ］＝４３６\n\nCompound 6: \n Compound 5 is dissolved in 30 mL MeOH and a catalytic amount of 10% Pd / C is added. The mixture is placed under H \n2\n and stirred at 25 ° C. for 2 h. The reaction mixture is filtered through celite and the filtrate is concentrated in vacuo to give the desired product (1.4 g, 75%) as a colorless oil. \n Compound 7: \n To a solution of compound 6 (0.36 g, 1 mmol) in 10 mL isopropanol is added diphenyl cyanocarbonimidate (0.24 g, 1 mmol) and the resulting solution is stirred at 60 ° C. for 5 h. The reaction mixture is then concentrated under reduced pressure to give an oily residue, which is dissolved in 10 mL of MeNH \n2\n / MeOH solution and stirred at 80 ° C. for 5 h in a sealed tube. The reaction mixture is concentrated and purified on CombiFlash (20-100% EtOAc / hexanes) to give the desired product (0.34 g, 78%). [M + H] = 436\n\n\n\n\n\n\n \n\n  実施例５６４〜５７１\n\n  実施例５６３に記載の方法を用い、以下に示す実施例５６４〜５７１の化合物を合成する。\n\n\n \n \n\n\nExamples 564-571 \n The compounds of Examples 564 to 571 shown below are synthesized using the method described in Example 563. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例５７２および５７３\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExamples 572 and 573 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例５５４に記載されている。\n\n  化合物２：\n\n  １ｍＬのＤＣＭ中のクロロスルホニルイソシアネート（２２μＬ、０．２５ミリモル）の溶液に、０℃でクロロエタノール（１７μＬ、０．２５ミリモル）を加える。次いで反応液をさらに、２５℃で４ｈ攪拌せしめる。反応混合物を再度０℃に冷却し、２ｍＬのＤＣＭ中の９０ｍｇ（０．２５ミリモル）の化合物１を加える。反応混合物をさらに２５℃で１２ｈ攪拌する。次いで反応混合物を１０ｍＬのＤＣＭで希釈し、１Ｎ水性ＨＣｌで洗う。有機溶液をＮａ\n2\nＳＯ\n4\n上で乾燥し、減圧濃縮して１３０ｍｇの所望生成物を得、これをさらに精製せずに、次の反応に付す。\n\n  化合物３および４：\n\n  化合物２（３０ｍｇ、０．０７ミリモル）および４−（アミノメチル）ピリジン（１６ｍＬ、０．１４ミリモル）を、１ｍＬのＣＨ\n3\nＣＮに希釈し、６０℃で１２ｈ攪拌する。反応混合物を分取ＨＰＬＣ（実施例３１参照）で精製して、１２．７ｍｇの実施例５７２化合物および３．３ｍｇの実施例５７３化合物を得る。\n\nCompound 1: \n The synthesis of Compound 1 is described in Example 554. \n Compound 2: \n To a solution of chlorosulfonyl isocyanate (22 μL, 0.25 mmol) in 1 mL DCM is added chloroethanol (17 μL, 0.25 mmol) at 0 ° C. The reaction is then further stirred at 25 ° C. for 4 h. The reaction mixture is again cooled to 0 ° C. and 90 mg (0.25 mmol) of compound 1 in 2 mL of DCM is added. The reaction mixture is further stirred at 25 ° C. for 12 h. The reaction mixture is then diluted with 10 mL DCM and washed with 1N aqueous HCl. The organic solution is dried over Na \n2\n SO \n4 and\n concentrated in vacuo to give 130 mg of the desired product, which is subjected to the next reaction without further purification. \n Compounds 3 and 4: \n Compound 2 (30 mg, 0.07 mmol) and 4- (aminomethyl) pyridine (16 mL, 0.14 mmol) are diluted in 1 mL of CH \n3\n CN and stirred at 60 ° C. for 12 h. The reaction mixture is purified by preparative HPLC (see Example 31) to give 12.7 mg of the Example 572 compound and 3.3 mg of the Example 573 compound.\n\n\n\n\n\n\n \n\n  実施例５７４〜５７９\n\n  実施例５７２に記載の方法を用い、以下に示す実施例５７４〜５７９の化合物を合成する。\n\n\n \n \n\n\nExamples 574-579 \n Using the method described in Example 572, the compounds of Examples 574 to 579 shown below are synthesized. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例５８０\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 580 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  ５ｍＬのＤＣＭ中の化合物１（０．２０ｇ、０．６０ミリモル）およびＥｔ\n3\nＮ（０．５ｍＬ）の溶液に、トリホスゲン（０．２０ｇ、０．６７ミリモル）を少しづつ加え、得られる溶液を２５℃で１ｈ攪拌する。反応混合物を減圧濃縮して油状残渣を得、これをカラムクロマトグラフィー（５０％ＥｔＯＡｃ／ヘキサン）で精製して、２１３ｍｇ（０．５８ｇ、＞９５％）の所望生成物を油状物で得る。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of compound 1 (0.20 g, 0.60 mmol) and Et \n3\n N (0.5 mL) in 5 mL DCM was added triphosgene (0.20 g, 0.67 mmol) in small portions and the resulting solution was added. Stir at 25 ° C. for 1 h. The reaction mixture is concentrated in vacuo to give an oily residue that is purified by column chromatography (50% EtOAc / hexanes) to give 213 mg (0.58 g,> 95%) of the desired product as an oil.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  ２ｍＬのアセトン中の化合物２（２０ｍｇ、０．０５５ミリモル）およびベンゼンスルホンアミド（２０ｍｇ、０．１３ミリモル）の溶液に、０．２ｍＬの１Ｎ水性ＮａＯＨを少しづつ加え、得られる溶液を２５℃で１ｈ攪拌する。溶液を０．２ｍＬの水性ＨＣｌの添加で中和し、分取ＨＰＬＣ（実施例３１参照）に付して、スピード減圧で濃縮後、１０．１ｍｇ（０．０１９ミリモル、３０％）の所望生成物を白色固体で得る。［Ｍ＋Ｈ］＝５２２\n\nCompound 3: \n To a solution of compound 2 (20 mg, 0.055 mmol) and benzenesulfonamide (20 mg, 0.13 mmol) in 2 mL of acetone, 0.2 mL of 1N aqueous NaOH is added in portions and the resulting solution at 25 ° C. Stir for 1 h. The solution was neutralized by addition of 0.2 mL of aqueous HCl, subjected to preparative HPLC (see Example 31) and concentrated at speed reduced pressure, then 10.1 mg (0.019 mmol, 30%) of the desired product. Product is obtained as a white solid. [M + H] = 522\n\n\n\n\n\n\n \n\n  実施例５８１〜５９０\n\n  実施例５８０に記載の方法を用い、以下に示す実施例５８１〜５９０の化合物を合成する。\n\n\n \n \n\n\nExamples 581-590 \n The compounds of Examples 581 to 590 shown below are synthesized using the method described in Example 580. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例５９１\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 591 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、実施例３１に記載されている。\n\n  化合物２：\n\n  １０ｍＬのエタノール中の化合物１（３３８ｍｇ、１．０ミリモル）の溶液に、ジメチル・Ｎ−シアノジチオールイミノカーボネート（１４７ｍｇ、１．０ミリモル）を少しづつ加え、得られる溶液を７０℃で２ｈ攪拌する。ＨＰＬＣおよびＬＣ−ＭＳ分析で、反応の完了が認められる。反応混合物を減圧濃縮して油状物を得、これをさらに精製せずに、次の反応に付す。\n\nCompound 1: \n The synthesis of compound 1 is described in Example 31. \n Compound 2: \n To a solution of compound 1 (338 mg, 1.0 mmol) in 10 mL of ethanol is added dimethyl N-cyanodithioliminocarbonate (147 mg, 1.0 mmol) in portions and the resulting solution is stirred at 70 ° C. for 2 h. . Completion of the reaction is observed by HPLC and LC-MS analysis. The reaction mixture is concentrated under reduced pressure to give an oil which is subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物２（４０ｍｇ、０．０９ミリモル）、ＮａＯＨ（３．７μｇ、０．０９ミリモル）および４−クロロベンゼンスルホンアミド（３４ｍｇ、０．１８ミリモル）を、１ｍＬのジオキサンに溶解する。得られる溶液をマイクロ波反応器中、２３０℃で１５分間攪拌する。次いで反応混合物を冷却し、分取ＨＰＬＣ（実施例３１参照）で精製して、溶出液の濃縮で６．２ｍｇ（０．０１１ミリモル、１１％）の所望生成物を、明灰色固体で得る。［Ｍ＋Ｈ］＝５８１\n\nCompound 3: \n Compound 2 (40 mg, 0.09 mmol), NaOH (3.7 μg, 0.09 mmol) and 4-chlorobenzenesulfonamide (34 mg, 0.18 mmol) are dissolved in 1 mL of dioxane. The resulting solution is stirred for 15 minutes at 230 ° C. in a microwave reactor. The reaction mixture is then cooled and purified by preparative HPLC (see Example 31) to give 6.2 mg (0.011 mmol, 11%) of the desired product as a light gray solid upon concentration of the eluate. [M + H] = 581\n\n\n\n\n\n\n \n\n  実施例５９２および５９３\n\n  実施例５９１に記載の方法を用い、以下に示す実施例５９２および５９３の化合物を合成する。\n\n\n \n \n\n\nExamples 592 and 593 \n The compounds of Examples 592 and 593 shown below are synthesized using the method described in Example 591. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例５９４\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 594 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  １００ｍＬの乾燥ＴＨＦ中の化合物１（４．６ｍＬ、４０ミリモル）の溶液に、ＭｅＬｉ（ＴＨＦ中２Ｎ、４０ミリモル）を滴下し、得られる溶液を−７８℃で１ｈ攪拌する。該溶液に、ブロモエピヒドリン（３．４ｍＬ、４０ミリモル）／５０ｍＬのＴＨＦを３０分にわたって滴下し、反応混合物をさらに−７８℃で１ｈ攪拌する。該反応混合物に、ＭｅＭｇＢｒ（ＴＨＦ中３Ｍ、４０ミリモル）を加える。反応混合物を周囲温度で１２ｈ攪拌する。次いで反応混合物を、ＥｔＯＡｃ（２５０ｍＬ）で希釈し、塩水（５０ｍＬ×３）で洗う。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状残渣を得、これをＣombi  Ｆlashにて精製し（０〜１００％ＥｔＯＡｃ／ヘキサン）、５．６ｇ（２９ミリモル、７３％）の所望生成物をシスおよびトランス異性体（４:１）混合物で得る。\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n To a solution of compound 1 (4.6 mL, 40 mmol) in 100 mL dry THF, MeLi (2N in THF, 40 mmol) is added dropwise and the resulting solution is stirred at −78 ° C. for 1 h. To the solution, bromoepihydrin (3.4 mL, 40 mmol) / 50 mL of THF is added dropwise over 30 minutes and the reaction mixture is further stirred at −78 ° C. for 1 h. To the reaction mixture is added MeMgBr (3M in THF, 40 mmol). The reaction mixture is stirred at ambient temperature for 12 h. The reaction mixture is then diluted with EtOAc (250 mL) and washed with brine (50 mL × 3). The organic layer was dried over MgSO \n4 and\n concentrated in vacuo to give an oily residue that was purified by Combi Flash (0-100% EtOAc / hexanes), 5.6 g (29 mmol, 73%) of the desired product. Is obtained as a mixture of cis and trans isomers (4: 1).\n\n\n\n\n\n\n \n\n  化合物３：\n\n  ３０ｍＬのＴＨＦ中の化合物２（１．６ｇ、９．０ミリモル）の溶液に、ＬＡＨ（ＴＨＦ中１．０Ｍ、１０ミリモル）を加え、得られる溶液を７０℃で４ｈ攪拌する。氷片を加えて反応を抑え、混合物をセライトで濾過する。濾液の濃縮で油状物（１．５ｇ、＞９５％）を得、これをさらに精製せずに、次の反応に付す。\n\nCompound 3: \n To a solution of compound 2 (1.6 g, 9.0 mmol) in 30 mL of THF is added LAH (1.0 M in THF, 10 mmol) and the resulting solution is stirred at 70 ° C. for 4 h. Ice pieces are added to quench the reaction and the mixture is filtered through celite. Concentration of the filtrate gave an oil (1.5 g,> 95%), which was subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  ５０ｍＬのＴＨＦおよびＥｔ\n3\nＮ（２．０ｍＬ）中の化合物３（１．５ｇ、９．０ミリモル）の溶液に、塩化アニソイル（１．３ｍＬ、９．０ミリモル）を滴下し、得られる溶液を２５℃で１ｈ攪拌する。次いで反応混合物をＥｔＯＡｃ（１００ｍＬ）で希釈し、塩水で洗う。有機溶液をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物を得、これをビス−アシル化生成物と同定する。生成物を３０％水性ＴＨＦ（２０ｍＬ）に溶解し、これにＬｉＯＨ（３００ｍｇ）を加える。得られる混合物を７０℃で１２ｈ攪拌する。混合物をＥｔＯＡｃ（５０ｍＬ）で希釈し、塩水（３０ｍＬ）で洗う。ＭｇＳＯ\n4\n上の乾燥後、有機層の濃縮で油状残渣を得、これをＣombiＦlashにて精製し、１．５ｇ（４．５ミリモル、２工程で５０％）の所望生成物を無色油状物で得る。\n\nCompound 4: \n To a solution of compound 3 (1.5 g, 9.0 mmol) in 50 mL THF and Et \n3\n N (2.0 mL) was added anisoyl chloride (1.3 mL, 9.0 mmol) dropwise and the resulting solution was Stir at 25 ° C. for 1 h. The reaction mixture is then diluted with EtOAc (100 mL) and washed with brine. The organic solution is dried over MgSO \n4 and\n concentrated in vacuo to give an oil that is identified as the bis-acylated product. The product is dissolved in 30% aqueous THF (20 mL) to which LiOH (300 mg) is added. The resulting mixture is stirred at 70 ° C. for 12 h. The mixture is diluted with EtOAc (50 mL) and washed with brine (30 mL). After drying over MgSO \n4\n , concentration of the organic layer gave an oily residue that was purified by CombiFlash to give 1.5 g (4.5 mmol, 50% over 2 steps) of the desired product as a colorless oil. .\n\n\n\n\n\n\n \n\n  化合物５：\n\n  化合物４を１０ｍＬのＤＣＭおよび２ｍＬのピリジンに溶解する。該溶液に、メタンスルホニルクロリド（１ｍＬ、１３ミリモル）を加え、得られる溶液を２５℃で２ｈ攪拌する。反応混合物をＥｔＯＡｃ（２００ｍＬ）で希釈し、塩水（３０ｍＬ×２）で洗う。有機層をＭｇＳＯ\n4\n上で乾燥し、減圧濃縮して油状物を得、これをさらに精製せずに、次の反応に付す。\n\nCompound 5: \n Compound 4 is dissolved in 10 mL DCM and 2 mL pyridine. To the solution is added methanesulfonyl chloride (1 mL, 13 mmol) and the resulting solution is stirred at 25 ° C. for 2 h. The reaction mixture is diluted with EtOAc (200 mL) and washed with brine (30 mL × 2). The organic layer is dried over MgSO \n4 and\n concentrated in vacuo to give an oil that is subjected to the next reaction without further purification.\n\n\n\n\n\n\n \n\n  化合物６：\n\n  化合物５およびＮａＮ\n3\n（１．３ｇ、８．９ミリモル）を、１０ｍＬのＤＭＦに溶解し、混合物を１２０℃で５ｈ攪拌する。反応混合物をＥｔＯＡｃ（１００ｍＬ）で希釈し、塩水（２０ｍＬ×３）で洗う。有機溶液をＮａ\n2\nＳＯ\n4\n上で乾燥し、減圧濃縮して油状物を得、これをＣombiＦlashにて精製し（０〜３０％ＥｔＯＡｃ／ヘキサン）、１．１ｇのアジドを得る。アジドを２０ｍｌのＭｅＯＨに溶解し、該溶液に触媒量の１０％Ｐｄ／Ｃを加える。反応混合物をＨ\n2\n下で２ｈ攪拌する。反応混合物を漏斗（Ｗhatman、０．４５μｍＮＹＬ）で濾過し、減圧濃縮して所望生成物（１．１ｇ、化合物４から７９％）を、無色油状物で得る。\n\nCompound 6: \n Compound 5 and NaN \n3\n (1.3 g, 8.9 mmol) are dissolved in 10 mL of DMF and the mixture is stirred at 120 ° C. for 5 h. The reaction mixture is diluted with EtOAc (100 mL) and washed with brine (20 mL × 3). The organic solution is dried over Na \n2\n SO \n4 and\n concentrated in vacuo to give an oil that is purified on CombiFlash (0-30% EtOAc / hexanes) to give 1.1 g of azide. The azide is dissolved in 20 ml MeOH and a catalytic amount of 10% Pd / C is added to the solution. The reaction mixture is stirred under H \n2\n for 2 h. The reaction mixture is filtered through a funnel (Whatman, 0.45 μm NYL) and concentrated in vacuo to give the desired product (1.1 g, 79% from compound 4) as a colorless oil.\n\n\n\n\n\n\n \n\n  化合物７：\n\n  ５ｍＬのイソプロパノール中の化合物６（１８０ｍｇ、０．５８ミリモル）の溶液に、ジフェニル・シアノカルボンイミデート（１５０ｍｇ、０．６４ミリモル）を加え、得られる溶液を８０℃で２ｈ攪拌する。次いで反応混合物を減圧濃縮して、油状残渣を得る。これを５ｍＬの２Ｎ−ＭｅＮＨ\n2\n／メタノールに溶解し、密封チューブ中８０℃で５ｈ攪拌する。反応の進行をＨＰＬＣで監視する。反応混合物を減圧濃縮して、油状残渣を得、これをＣombiＦlashにて精製し（０〜１００％ＥｔＯＡｃ／ヘキサン）、０．１２ｇ（０．２９ミリモル、５０％）の所望生成物を、シスおよびトランス異性体混合物で得る。［Ｍ＋Ｈ］＝４１０\n\nCompound 7: \n To a solution of compound 6 (180 mg, 0.58 mmol) in 5 mL of isopropanol is added diphenyl cyanocarbonimidate (150 mg, 0.64 mmol) and the resulting solution is stirred at 80 ° C. for 2 h. The reaction mixture is then concentrated under reduced pressure to give an oily residue. This is dissolved in 5 mL of 2N-MeNH \n2\n / methanol and stirred in a sealed tube at 80 ° C. for 5 h. The progress of the reaction is monitored by HPLC. The reaction mixture was concentrated in vacuo to give an oily residue that was purified by CombiFlash (0-100% EtOAc / hexanes) and 0.12 g (0.29 mmol, 50%) of the desired product was converted to cis and Obtained as a mixture of trans isomers. [M + H] = 410\n\n\n\n\n\n\n \n\n  実施例５９５〜５９８\n\n  実施例５９４に記載の方法を用い、以下に示す実施例５９５〜５９８の化合物を合成する。\n\n\n \n \n\n\nExamples 595-598 \n The compounds of Examples 595 to 598 shown below are synthesized using the method described in Example 594. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例５９９\n\n  シス−Ｎ−｛４−［Ｎ’−シアノ−Ｎ”−エチル−Ｎ−（２−メトキシエチル）−グアニジノ］−１−フェニル−シクロヘキシルメチル｝−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 599 \n Cis-N- {4- [N'-cyano-N \"-ethyl-N- (2-methoxyethyl) -guanidino] -1-phenyl-cyclohexylmethyl} -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１の合成は、先に記載されている。\n\n  化合物２および３\n\n  １，２−ジクロロエタン（２ｍＬ）中の化合物１（１８５ｍｇ、０．５５ミリモル）の溶液に、２−メトキシエチルアミン（０．０４８ｍＬ、０．５５ミリモル）を加えた後、トリアセトキシホウ水素化ナトリウム（１６３ｍｇ、０．７７ミリモル）および酢酸（０．０３１ｍＬ、０．５５ミリモル）を加え、次いで反応液を１．５時間攪拌する。１Ｎ−ＮａＯＨ（２ｍＬ）を加えて反応を抑え、次いでＥｔ\n2\nＯ（４ｍＬ×３）で抽出する。コンバインした有機抽出物を塩水（２ｍＬ）で洗い、乾燥し（ＭｇＳＯ\n4\n）、濾過し、減圧濃縮する。残渣をシリカにてクロマトグラフィーに付し、ＮＨ\n4\nＯＨ／ＭｅＯＨ／ＣＨＣｌ\n3\n＝１：１：９８〜１：５：９４で勾配溶離して、化合物２［８０ｍｇ、収率３７％、ＨＰＬＣ：Ｒｔ１．５０分、Ｐhenomenex ３０×４．６  ５μカラム、２分勾配、流速５ｍＬ／分、０〜１００％溶剤Ｂ：溶剤Ａ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（１０／９０／０．１％），溶剤Ｂ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（９０／１０／０．１％）、Ｍ＋Ｈ＝３９７．３］および化合物３［６６ｍｇ、収率３０％、ＨＰＬＣ：Ｒｔ１．４３分、Ｐhenomenex ３０×４．６  ５μカラム、２分勾配、流速５ｍＬ／分、０〜１００％溶剤Ｂ：溶剤Ａ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（１０／９０／０．１％），溶剤Ｂ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（９０／１０／０．１％）、Ｍ＋Ｈ＝３９７．３］を白色固体で得る。\n\nCompound 1: \n The synthesis of compound 1 has been described previously. \n Compounds 2 and 3 \n To a solution of compound 1 (185 mg, 0.55 mmol) in 1,2-dichloroethane (2 mL) was added 2-methoxyethylamine (0.048 mL, 0.55 mmol) followed by sodium triacetoxyborohydride ( 163 mg, 0.77 mmol) and acetic acid (0.031 mL, 0.55 mmol) are added and the reaction is then stirred for 1.5 hours. The reaction is quenched with 1N NaOH (2 mL) and then extracted with Et \n2\n O (4 mL × 3). The combined organic extracts are washed with brine (2 mL), dried (MgSO \n4\n ), filtered and concentrated in vacuo. The residue was chromatographed on silica eluting with a gradient of NH \n4\n OH / MeOH / CHCl \n3\n = 1: 1: 98 to 1: 5: 94 to give compound 2 [80 mg, 37% yield, HPLC: Rt 1 50 min, Phenomenex 30 × 4.6 5μ column, 2 min gradient, flow rate 5 mL / min, 0-100% Solvent B: Solvent A = MeOH / H \n2\n O / TFA (10/90 / 0.1%), Solvent B = MeOH / H \n2\n O / TFA (90/10 / 0.1%), M + H = 397.3] and Compound 3 [66 mg, 30% yield, HPLC: Rt 1.43 min, Phenomenex 30 × 4. 6 5μ column, 2 min gradient, flow rate 5 mL / min, 0-100% Solvent B: Solvent A = MeOH / H \n2\n O / TFA (10/90 / 0.1%), Solvent B = MeOH / H \n2\n O / TFA (90/10 / 0.1%), M + H = 397.3 The obtained white solid.\n\n\n\n\n\n\n \n\n  化合物４：\n\n  ２−プロパノール（１ｍＬ）中のアミン２のシス異性体（１５ｍｇ、０．０３８ミリモル）の溶液に、１−シアノ−３−エチル−２−フェニル−イソウレア（３６ｍｇ、０．１９ミリモル）を加え、次いで反応混合物を７５℃油浴にて５日間加熱する。溶媒を窒素流下で除去し、次いで残渣を分取ＴＬＣにてＭｅＯＨ／ＥｔＯＡｃ＝ヘキサン（５：２０：７５）で溶離して精製し、化合物４［９．５ｍｇ、収率５１％、ＨＰＬＣ：Ｒｔ１．８８分、Ｐhenomenex ３０×４．６  ５μカラム、２分勾配、流速５ｍＬ／分、０〜１００％溶剤Ｂ：溶剤Ａ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（１０／９０／０．１％），溶剤Ｂ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（９０／１０／０．１％）、Ｍ＋Ｈ＝４９２．３］を白色固体で得る。\n\nCompound 4: \n To a solution of amine 2 cis isomer (15 mg, 0.038 mmol) in 2-propanol (1 mL) was added 1-cyano-3-ethyl-2-phenyl-isourea (36 mg, 0.19 mmol), The reaction mixture is then heated in a 75 ° C. oil bath for 5 days. The solvent was removed under a stream of nitrogen, then the residue was purified by preparative TLC eluting with MeOH / EtOAc = hexane (5:20:75) to give compound 4 [9.5 mg, 51% yield, HPLC: Rt1 .88 min, Phenomenex 30 × 4.6 5μ column, 2 min gradient, flow rate 5 mL / min, 0-100% Solvent B: Solvent A = MeOH / H \n2\n O / TFA (10/90 / 0.1%), Solvent B = MeOH / H \n2\n O / TFA (90/10 / 0.1%), M + H = 492.3] is obtained as a white solid.\n\n\n\n\n\n\n \n\n  実施例６００〜６０４\n\n  実施例５９９に記載の方法を用い、以下に示す実施例６００〜６０４の化合物を製造する。\n\n\n \n \n\n\nExamples 600-604 \n Using the method described in Example 599, the compounds of Examples 600-604 shown below are prepared. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６０５\n\n  トランス−Ｎ−｛４−［Ｎ’−シアノ−Ｎ”−エチル−Ｎ−（２−メトキシエチル）−グアニジノ］−１−フェニル−シクロヘキシルメチル｝−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 605 \n Trans-N- {4- [N'-cyano-N \"-ethyl-N- (2-methoxyethyl) -guanidino] -1-phenyl-cyclohexylmethyl} -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物３の合成は、実施例５９９に記載されている。\n\n  化合物５：\n\n  ２−プロパノール（１ｍＬ）中のアミン３のトランス異性体（１５ｍｇ、０．０３８ミリモル）の溶液に、１−シアノ−３−エチル−２−フェニル−イソウレア（３６ｍｇ、０．１９ミリモル）を加え、次いで反応混合物を７５℃油浴にて、５日間加熱する。溶媒を窒素流下で除去し、次いで残渣を分取ＴＬＣにてＭｅＯＨ／ＥｔＯＡｃ／ヘキサン（５：２０：７５）で溶離して精製し、化合物５［１０．８ｍｇ、収率５８％、ＨＰＬＣ：Ｒｔ１．７７分、Ｐhenomenex ３０×４．６  ５μカラム、２分勾配、流速５ｍＬ／分、０〜１００％溶剤Ｂ：溶剤Ａ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（１０／９０／０．１％），溶剤Ｂ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（９０／１０／０．１％）、Ｍ＋Ｈ＝４９２．３］を白色固体で得る。\n\nCompound 3: \n The synthesis of compound 3 is described in Example 599. \n Compound 5: \n To a solution of the trans isomer of amine 3 (15 mg, 0.038 mmol) in 2-propanol (1 mL) was added 1-cyano-3-ethyl-2-phenyl-isourea (36 mg, 0.19 mmol), The reaction mixture is then heated in a 75 ° C. oil bath for 5 days. The solvent was removed under a stream of nitrogen and the residue was then purified by preparative TLC eluting with MeOH / EtOAc / hexane (5:20:75) to give compound 5 [10.8 mg, 58% yield, HPLC: Rt1 .77 min, Phenomenex 30 × 4.6 5μ column, 2 min gradient, flow rate 5 mL / min, 0-100% Solvent B: Solvent A = MeOH / H \n2\n O / TFA (10/90 / 0.1%), Solvent B = MeOH / H \n2\n O / TFA (90/10 / 0.1%), M + H = 492.3] is obtained as a white solid.\n\n\n\n\n\n\n \n\n  実施例６０６〜６０９\n\n  実施例６０５に記載の方法を用い、以下に示す実施例６０６〜６０９の化合物を製造する。\n\n\n \n \n\n\nExamples 606-609 \n Using the method described in Example 605, the compounds of Examples 606-609 shown below are prepared. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６１０\n\n  シス−２−メトキシ−Ｎ−｛４−［（２−メトキシ−エチル）−（モルホリン−４−スルホニル）−アミノ］−１−フェニル−シクロヘキシルメチル｝−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 610 \n Cis-2-methoxy-N- {4-[(2-methoxy-ethyl)-(morpholine-4-sulfonyl) -amino] -1-phenyl-cyclohexylmethyl} -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物２：\n\n  化合物２の合成は、実施例５９９に記載されている。\n\n  化合物６：\n\n  ジメチルホルムアミド（０．５ｍＬ）中のアミン２のシス異性体（１５ｍｇ、０．０３８ミリモル）の溶液に、トリエチルアミン（０．００７ｍＬ、０．０５ミリモル）を加えた後、モルホリン−４−スルホニルクロリド（８．４ｍｇ、０．０４５ミリモル）および触媒量のＤＭＡＰを加える。反応液を５日間攪拌し、次いで５０％ＥｔＯＡｃ／ヘキサン（４ｍＬ）で希釈し、０．１Ｎ−ＨＣｌ（２ｍＬ）および塩水（２ｍＬ）で洗う。有機相を乾燥し（Ｎａ\n2\nＳＯ\n4\n）、濾過し、減圧濃縮する。残渣を分取ＴＬＣにてＭｅＯＨ／ヘキサン／ＥｔＯＡｃで溶離して精製し、化合物６［７．８ｍｇ、収率３８％、ＨＰＬＣ：Ｒｔ２．３０分、Ｐhenomenex ３０×４．６  ５μカラム、１分保持時間の２分勾配、流速５ｍＬ／分、０〜１００％溶剤Ｂ：溶剤Ａ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（１０／９０／０．１％），溶剤Ｂ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（９０／１０／０．１％）、Ｍ＋Ｈ＝５４６．１］を白色固体で得る。\n\nCompound 2: \n The synthesis of compound 2 is described in Example 599. \n Compound 6: \n To a solution of amine 2 cis isomer (15 mg, 0.038 mmol) in dimethylformamide (0.5 mL) was added triethylamine (0.007 mL, 0.05 mmol) followed by morpholine-4-sulfonyl chloride ( 8.4 mg, 0.045 mmol) and a catalytic amount of DMAP. The reaction is stirred for 5 days, then diluted with 50% EtOAc / hexanes (4 mL) and washed with 0.1 N HCl (2 mL) and brine (2 mL). The organic phase is dried (Na \n2\n SO \n4\n ), filtered and concentrated under reduced pressure. The residue was purified by preparative TLC eluting with MeOH / hexane / EtOAc, compound 6 [7.8 mg, 38% yield, HPLC: Rt 2.30 min, Phenomenex 30 × 4.6 5μ column, 1 min hold 2-minute gradient of time, flow rate 5 mL / min, 0-100% Solvent B: Solvent A = MeOH / H \n2\n O / TFA (10/90 / 0.1%), Solvent B = MeOH / H \n2\n O / TFA ( 90/10 / 0.1%), M + H = 546.1] as a white solid.\n\n\n\n\n\n\n \n\n  実施例６１１〜６１５\n\n  実施例６１０に記載の方法を用い、以下に示す実施例６１１〜６１５の化合物を製造する。\n\n\n \n \n\n\nExamples 611-615 \n The compounds of Examples 611 to 615 shown below are prepared using the method described in Example 610. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６１６\n\n  トランス−２−メトキシ−Ｎ−｛４−［（２−メトキシ−エチル）−（モルホリン−４−スルホニル）−アミノ］−１−フェニル−シクロヘキシルメチル｝−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 616 \n Trans-2-methoxy-N- {4-[(2-methoxy-ethyl)-(morpholine-4-sulfonyl) -amino] -1-phenyl-cyclohexylmethyl} -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物３の合成は、実施例５９９に記載されている。\n\n  化合物７：\n\n  ジメチルホルムアミド（０．５ｍＬ）中のアミン３のトランス異性体（１５ｍｇ、０．０３８ミリモル）の溶液に、トリエチルアミン（０．００７ｍＬ、０．０５ミリモル）を加えた後、モルホリン−４−スルホニルクロリド（８．４ｍｇ、０．０４５ミリモル）および触媒量のＤＭＡＰを加える。反応液を５日間攪拌し、次いで５０％ＥｔＯＡｃ／ヘキサン（４ｍＬ）で希釈し、０．１Ｎ−ＨＣｌ（２ｍＬ）および塩水（２ｍＬ）で洗う。有機相を乾燥し（Ｎａ\n2\nＳＯ\n4\n）、濾過し、減圧濃縮する。残渣を分取ＴＬＣにてＭｅＯＨ／ヘキサン／ＥｔＯＡｃ（３：２５：７２）で溶離して精製し、化合物７［３．８ｍｇ、収率１８％、ＨＰＬＣ：Ｒｔ２．２０分、Ｐhenomenex ３０×４．６  ５μカラム、１分保持時間の２分勾配、流速５ｍＬ／分、０〜１００％溶剤Ｂ：溶剤Ａ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（１０／９０／０．１％），溶剤Ｂ＝ＭｅＯＨ／Ｈ\n2\nＯ／ＴＦＡ（９０／１０／０．１％）、Ｍ＋Ｈ＝５４６．１］を白色固体で得る。\n\nCompound 3: \n The synthesis of compound 3 is described in Example 599. \n Compound 7: \n To a solution of the trans isomer of amine 3 (15 mg, 0.038 mmol) in dimethylformamide (0.5 mL) was added triethylamine (0.007 mL, 0.05 mmol) followed by morpholine-4-sulfonyl chloride ( 8.4 mg, 0.045 mmol) and a catalytic amount of DMAP. The reaction is stirred for 5 days, then diluted with 50% EtOAc / hexanes (4 mL) and washed with 0.1 N HCl (2 mL) and brine (2 mL). The organic phase is dried (Na \n2\n SO \n4\n ), filtered and concentrated under reduced pressure. The residue was purified by preparative TLC eluting with MeOH / hexane / EtOAc (3:25:72) to give compound 7 [3.8 mg, 18% yield, HPLC: Rt 2.20 min, Phenomenex 30 × 4. 6 5μ column, 2 minute gradient with 1 minute retention time, flow rate 5 mL / min, 0-100% Solvent B: Solvent A = MeOH / H \n2\n O / TFA (10/90 / 0.1%), Solvent B = MeOH / H \n2\n O / TFA (90/10 / 0.1%), M + H = 546.1] as a white solid.\n\n\n\n\n\n\n \n\n  実施例６１７〜６２１\n\n  実施例６１６に記載の方法を用い、以下に示す実施例６１７〜６２１の化合物を製造する。\n\n\n \n \n\n\nExamples 617-621 \n Using the method described in Example 616, the compounds of Examples 617-621 shown below are prepared. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６２２\n\n  Ｎ−（１−ベンジル−シクロヘキシルメチル）−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 622 \n N- (1-benzyl-cyclohexylmethyl) -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  テトラヒドロフラン（４０mL）中のシクロヘキサンカルボニトリル（６.１４g、５６.２ミリモル）の溶液を、アルゴン下−７８℃に冷却し、ＴＨＦ／ｎ−ヘプタン中のリチウム・ジイソプロピルアミドの２Ｍ溶液（３６mL、７２ミリモル）で処理する。冷却浴を取り除き、反応混合物を室温で１０分間撹拌せしめる。反応混合物を元の−７８℃に冷却し、テトラヒドロフラン（１０mL）中の臭化ベンジル（９.８g、５７.３ミリモル）の溶液で処理し、室温まで一夜ゆっくりと加温せしめる。反応混合物を濃縮し、残渣をエチルエーテルと１０％塩酸間に分配する。有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（無水硫酸ナトリウム）、濾過し、濃縮する。シリカゲルにて溶離剤としてヘキサン／酢酸エチル＝９：１を用いるカラムクロマトグラフィーを行い、１１gの化合物２を透明油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２００\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n A solution of cyclohexanecarbonitrile (6.14 g, 56.2 mmol) in tetrahydrofuran (40 mL) was cooled to −78 ° C. under argon and a 2 M solution of lithium diisopropylamide in THF / n-heptane (36 mL, 72 Mmol). The cooling bath is removed and the reaction mixture is allowed to stir at room temperature for 10 minutes. The reaction mixture is cooled to the original −78 ° C., treated with a solution of benzyl bromide (9.8 g, 57.3 mmol) in tetrahydrofuran (10 mL) and allowed to warm slowly to room temperature overnight. The reaction mixture is concentrated and the residue is partitioned between ethyl ether and 10% hydrochloric acid. The organic layer is separated, washed with saturated aqueous sodium chloride, dried (anhydrous sodium sulfate), filtered and concentrated. Column chromatography on silica gel using hexane / ethyl acetate = 9: 1 as eluent gives 11 g of compound 2 as a clear oil. Mass spectrometry [M + H] \n+\n = 200\n\n\n\n\n\n\n \n\n  化合物３：\n\n  テトラヒドロフラン（４０mL）中の化合物２（３.８g、１９.１ミリモル）の溶液を０℃に冷却し、水素化リチウムアルミニウム（３.８g、１００.１ミリモル）で処理する。反応混合物を室温まで一夜ゆっくりと加温せしめる。反応混合物に２Ｎ水酸化ナトリウム（約２mL）を注意深く加えて反応を抑え、セライトプラグで濾過し、溶離剤として酢酸エチルを用い、乾燥し（無水硫酸ナトリウム）、濾過し、濃縮して３.８gの化合物３を透明油状物で得、これを別途精製せずに、次工程に用いる。質量分析［Ｍ＋Ｈ］\n+\n＝２０４\n\nCompound 3: \n A solution of compound 2 (3.8 g, 19.1 mmol) in tetrahydrofuran (40 mL) is cooled to 0 ° C. and treated with lithium aluminum hydride (3.8 g, 100.1 mmol). The reaction mixture is allowed to warm slowly to room temperature overnight. The reaction mixture was quenched by careful addition of 2N sodium hydroxide (ca. 2 mL), filtered through a celite plug, dried (anhydrous sodium sulfate) using ethyl acetate as eluent, filtered and concentrated to 3.8 g. Compound 3 was obtained as a clear oil, which was used in the next step without further purification. Mass spectrometry [M + H] \n+\n = 204\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  テトラヒドロフラン（２０mL）中の化合物３（０.３８g、１.８ミリモル）の溶液を、室温にてトリエチルアミン（０.２mL、１.４ミリモル）、次いでｏ−塩化アニソイル（０.３４g、２.０ミリモル）で処理する。反応液を４８ｈ撹拌せしめ、このとき、溶媒を減圧下で除去する。残渣を酢酸エチルと１０％塩酸間に分配する。有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（無水硫酸ナトリウム）、濾過し、濃縮する。シリカゲルにて溶離剤としてヘキサン／酢酸エチル＝８：１を用いるカラムクロマトグラフィーを行い、０.４６gのＮ−（１−ベンジル−シクロヘキシルメチル）−２−メトキシ−ベンズアミドを透明油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３３８\n\nTitle compound: \n A solution of compound 3 (0.38 g, 1.8 mmol) in tetrahydrofuran (20 mL) was added at room temperature to triethylamine (0.2 mL, 1.4 mmol) followed by o-anisoyl chloride (0.34 g, 2.0 mmol). Mmol). The reaction is allowed to stir for 48 h, at which time the solvent is removed under reduced pressure. The residue is partitioned between ethyl acetate and 10% hydrochloric acid. The organic layer is separated, washed with saturated aqueous sodium chloride, dried (anhydrous sodium sulfate), filtered and concentrated. Column chromatography on silica gel with hexane / ethyl acetate = 8: 1 as eluent gives 0.46 g of N- (1-benzyl-cyclohexylmethyl) -2-methoxy-benzamide as a clear oil. Mass spectrometry [M + H] \n+\n = 338\n\n\n\n\n\n\n \n\n  実施例６２３〜６４７\n\n  実施例６２２に記載の方法を用い、以下に示す実施例６２３〜６４７の化合物を製造する。\n\n\n \n \n\n\nExamples 623 to 647 \n The compounds of Examples 623 to 647 shown below are prepared using the method described in Example 622. \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  実施例６４８\n\n  ２−メトキシ−Ｎ−（１−フェニル−シクロヘキシルメチル）−ニコチンアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 648 \n 2-methoxy-N- (1-phenyl-cyclohexylmethyl) -nicotinamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例３３０の記載に準じ製造する。\n\n  標記化合物：\n\n  塩化メチレン（１５mL）中の２−メトキシニコチン酸（０.２３g、１.５ミリモル）の懸濁液を、塩化オキサリル（０.１４mL、１.６ミリモル）および２滴のＮ,Ｎ−ジメチルホルムアミドで処理する。反応混合物を室温で３０分間撹拌せしめ、このとき、トリエチルアミン（０.３mL、２.２ミリモル）および化合物１（０.３１５g、１.６６ミリモル）を加える。さらに１５分間の撹拌後、反応混合物を水および飽和水性塩化ナトリウムで洗い、乾燥し（硫酸マグネシウム）、濃縮する。粗残渣をシリカゲルにて、溶離剤としてヘキサン／酢酸エチル＝７：３を用いるカラムクロマトグラフィーで精製して、０.３７gの２−メトキシ−Ｎ−（１−フェニル−シクロヘキシルメチル）−ニコチンアミドを白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３２５\n\nCompound 1: \n Compound 1 is prepared as described in Example 330. \n Title compound: \n A suspension of 2-methoxynicotinic acid (0.23 g, 1.5 mmol) in methylene chloride (15 mL) was added to oxalyl chloride (0.14 mL, 1.6 mmol) and 2 drops of N, N-dimethylformamide. Process with. The reaction mixture is allowed to stir at room temperature for 30 minutes, at which time triethylamine (0.3 mL, 2.2 mmol) and compound 1 (0.315 g, 1.66 mmol) are added. After an additional 15 minutes of stirring, the reaction mixture is washed with water and saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. The crude residue is purified by column chromatography on silica gel using hexane / ethyl acetate = 7: 3 as eluent to give 0.37 g of 2-methoxy-N- (1-phenyl-cyclohexylmethyl) -nicotinamide. Obtained as a white solid. Mass spectrometry [M + H] \n+\n = 325\n\n\n\n\n\n\n \n\n  実施例６４９\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 649 \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例３３０の記載に準じ製造する。\n\n  化合物２：\n\n  無水アセトニトリル（３０mL）中の化合物１（１.２g、６.３ミリモル）の溶液を、ジフェニル・Ｎ−シアノカルボンイミデート（２.２g、９.２ミリモル）で処理し、８０℃で４ｈ加熱する。反応混合物を室温で一夜静置せしめる。形成する白色沈殿物を濾取し、ヘキサンで洗って、１.０gの化合物２を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３３４\n\nCompound 1: \n Compound 1 is prepared as described in Example 330. \n Compound 2: \n A solution of compound 1 (1.2 g, 6.3 mmol) in anhydrous acetonitrile (30 mL) was treated with diphenyl N-cyanocarbonimidate (2.2 g, 9.2 mmol) and heated at 80 ° C. for 4 h. To do. The reaction mixture is allowed to stand overnight at room temperature. The white precipitate that forms is filtered off and washed with hexane to give 1.0 g of compound 2 as a white solid. Mass spectrometry [M + H] \n+\n = 334\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  化合物２（０.０２７g、０.０８ミリモル）を、エチルアミン／ＴＨＦの２Ｍ溶液（０.５mL、１ミリモル）で処理し、ねじぶたバイアル中６０℃で一夜加熱する。蒸発して溶媒および過剰のエチルアミンを除去し、粗生成物を分取逆相液体クロマトグラフィーで精製して、０.００８gの標記化合物を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２８５\n\nTitle compound: \n Compound 2 (0.027 g, 0.08 mmol) is treated with a 2M solution of ethylamine / THF (0.5 mL, 1 mmol) and heated in a screw cap vial at 60 ° C. overnight. Evaporation removes the solvent and excess ethylamine and the crude product is purified by preparative reverse phase liquid chromatography to give 0.008 g of the title compound as a white solid. Mass spectrometry [M + H] \n+\n = 285\n\n\n\n\n\n\n \n\n  実施例６５０〜６６０\n\n  実施例６４９に記載の方法を用い、以下に示す実施例６５０〜６６０の化合物を製造する。\n\n\n \n \n\n\n \n \n\n\nExamples 650-660 \n The compounds of Examples 650-660 shown below are prepared using the method described in Example 649. \n \n \n \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６６１\n\n  ５−ベンジル−３−（１−フェニル−シクロヘキシルメチル）−イミダゾリジン−２,４−ジオン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 661 \n 5-Benzyl-3- (1-phenyl-cyclohexylmethyl) -imidazolidine-2,4-dione \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例３３０の記載に準じ製造する。\n\n  標記化合物：\n\n  無水ジクロロメタン（８mL）中の化合物１（０.２５５g、１.３５ミリモル）の溶液を、エチル・２−イソシアナト−３−フェニルプロピオネート（０.３２５g、０.３８ミリモル）で処理し、室温で一夜撹拌する。溶媒を蒸発除去し、残渣をエタノール（１mL）、６Ｎ塩酸（０.５mL）および水（０.５mL）に溶解し、反応混合物を５０℃に加熱する。５０℃で３ｈ後、別途６Ｎ塩酸（１mL）を加え、反応混合物を６５℃で一夜加熱する。反応混合物を濃縮し、粗生成物を直接シリカゲルにて、溶離剤として酢酸エチル／ヘキサン＝１：１を用いるカラムクロマトグラフィーで精製して、０.０５３gの５−ベンジル−３−（１−フェニル−シクロヘキシルメチル）−イミダゾリジン−２,４−ジオンを白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３６３\n\nCompound 1: \n Compound 1 is prepared as described in Example 330. \n Title compound: \n A solution of compound 1 (0.255 g, 1.35 mmol) in anhydrous dichloromethane (8 mL) was treated with ethyl 2-isocyanato-3-phenylpropionate (0.325 g, 0.38 mmol) at room temperature. Stir overnight. The solvent is evaporated off, the residue is dissolved in ethanol (1 mL), 6N hydrochloric acid (0.5 mL) and water (0.5 mL) and the reaction mixture is heated to 50 ° C. After 3 h at 50 ° C., additional 6N hydrochloric acid (1 mL) is added and the reaction mixture is heated at 65 ° C. overnight. The reaction mixture is concentrated and the crude product is purified directly by column chromatography on silica gel using ethyl acetate / hexane = 1: 1 as eluent to give 0.053 g of 5-benzyl-3- (1-phenyl). -Cyclohexylmethyl) -imidazolidine-2,4-dione is obtained as a white solid. Mass spectrometry [M + H] \n+\n = 363\n\n\n\n\n\n\n \n\n  実施例６６２\n\n  １−イソプロペニル−シクロヘキサンカルボン酸（３−フェニル−プロピル）−アミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 662 \n 1-Isopropenyl-cyclohexanecarboxylic acid (3-phenyl-propyl) -amide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  ＴＨＦ（３０mL）中のジイソプロピルアミン（４.２mL）の溶液に０℃にて、ｎ−ＢuＬi／ヘキサン（１.６Ｍ、１９mL）を加える。３０分間撹拌後、反応混合物を−７８℃に冷却し、シクロヘキサンカルボニトリル（１.０９g、１０ミリモル）／ＴＨＦ（１０mL）を滴下する。２ｈ後、アセトン（１.１６g、２０ミリモル）を加える。反応混合物を−７８℃からｒｔまで一夜撹拌し、Ｅt\n2\nＯ（１００mL）で希釈し、１Ｎ−ＨＣl、Ｈ\n2\nＯ、塩水で洗い、無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／Ｅt\n2\nＯ＝１：１）で精製して、１−（１−ヒドロキシ−１−メチルエチル）−シクロヘキサンカルボニトリル（１.２７g、７６％）を無色油状物で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）０.８６−１.９１（８Ｈ、ｍ）、１.３５（６Ｈ、ｓ）、２.０１（２Ｈ、ｄ、Ｊ＝１２.８Ｈz）、３.６５（１Ｈ、ｔ、Ｊ＝６.４Ｈz）\n\n  質量分析［Ｍ＋Ｈ］\n+\n＝１６８.１\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n To a solution of diisopropylamine (4.2 mL) in THF (30 mL) at 0 ° C. is added n-BuLi / hexane (1.6 M, 19 mL). After stirring for 30 minutes, the reaction mixture is cooled to −78 ° C. and cyclohexanecarbonitrile (1.09 g, 10 mmol) / THF (10 mL) is added dropwise. After 2 h, acetone (1.16 g, 20 mmol) is added. The reaction mixture is stirred overnight from −78 ° C. to rt, diluted with Et \n2\n O (100 mL), washed with 1N HCl, H \n2\n O, brine and dried over anhydrous sodium sulfate. Purification by flash chromatography (hexane / Et \n2\n O = 1: 1) gives 1- (1-hydroxy-1-methylethyl) -cyclohexanecarbonitrile (1.27 g, 76%) as a colorless oil. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 0.86-1.91 (8H, m), 1.35 (6H, s), 2.01 (2H, d, J = 12.8 Hz) ), 3.65 (1H, t, J = 6.4 Hz) \n Mass spectrometry [M + H] \n+\n = 168.1\n\n\n\n\n\n\n \n\n  化合物３：\n\n  ＣＨＣl\n3\n（１２mL）中の化合物２（５３０mg、３.１７ミリモル）およびオキシ塩化リン（１１.７g、７６.１ミリモル）を、１８ｈ加熱還流し、次いでｒｔまで冷却する。水（７５mL）をゆっくり加える。水性層をＣＨ\n2\nＣl\n2\n（２回）で抽出し、コンバインした抽出物を無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／ＣＨ\n2\nＣl\n2\n＝２：１）で精製して、１−イソプロペニル−シクロヘキサンカルボニトリル（１.２７g、７６％）を無色油状物で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）１.１６−２.１７（１３Ｈ、ｍ）、４.９６（１Ｈ、ｓ）、５.１１（１Ｈ、ｓ）\n\n  質量分析［Ｍ＋Ｈ］\n+\n＝１５０.１\n\nCompound 3: \n CHCl \n3\n (12 mL) solution of Compound 2 (530 mg, 3.17 mmol) and phosphorus oxychloride (11.7 g, 76.1 mmol) was 18h heated to reflux, then cooled to rt. Slowly add water (75 mL). The aqueous layer is extracted with CH \n2\n Cl \n2\n (twice) and the combined extracts are dried over anhydrous sodium sulfate. Purification by flash chromatography (hexane / CH \n2\n Cl \n2\n = 2: 1) gives 1-isopropenyl-cyclohexanecarbonitrile (1.27 g, 76%) as a colorless oil. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 1.16-2.17 (13H, m), 4.96 (1H, s), 5.11 (1H, s) \n Mass spectrometry [M + H] \n+\n = 150.1\n\n\n\n\n\n\n \n\n  化合物４：\n\n  エチレングリコール（３.７mL）中の化合物３（２８０mg、１.８７ミリモル）およびＫＯＨ（４６０mg、８.２０ミリモル）を、１８５℃で１８ｈ加熱し、次いでｒｔまで冷却する。反応混合物をＨ\n2\nＯで希釈し、次いでＥt\n2\nＯ（２回）で抽出する。水性相を６Ｎ−ＨＣlで酸性化し、次いでＣＨ\n2\nＣl\n2\n（３回）で抽出し、無水硫酸ナトリウム上で乾燥して、１−イソプロペニル−シクロヘキサンカルボン酸（２３４mg、７４％）をワックス状白色固体で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）１.１６−１.６５（９Ｈ、ｍ）、１.７９（３Ｈ、ｓ）、２.１６−２.２０（２Ｈ、ｍ）、４.９９（２Ｈ、ｓ）\n\n  質量分析［Ｍ＋Ｈ］\n+\n＝１６９.１\n\nCompound 4: \n Compound 3 (280 mg, 1.87 mmol) and KOH (460 mg, 8.20 mmol) in ethylene glycol (3.7 mL) are heated at 185 ° C. for 18 h and then cooled to rt. The reaction mixture is diluted with H \n2\n O and then extracted with Et \n2\n O (twice). The aqueous phase was acidified with 6N HCl, then extracted with CH \n2\n Cl \n2\n (3 times) and dried over anhydrous sodium sulfate to give 1-isopropenyl-cyclohexanecarboxylic acid (234 mg, 74%) as a waxy white Get in solid. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 1.16-1.65 (9H, m), 1.79 (3H, s), 2.16-2.20 (2H, m), 4.99 (2H, s) \n Mass spectrometry [M + H] \n+\n = 169.1\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  実施例７４に記載の方法を用い、化合物４を３−フェニルプロピルアミンと反応させて、１−イソプロペニル−シクロヘキサンカルボン酸（３−フェニルプロピル）−アミドを得る。質量分析［Ｍ＋Ｈ］\n+\n＝２８６.１\n\nTitle compound: \n Using the method described in Example 74, compound 4 is reacted with 3-phenylpropylamine to give 1-isopropenyl-cyclohexanecarboxylic acid (3-phenylpropyl) -amide. Mass spectrometry [M + H] \n+\n = 286.1\n\n\n\n\n\n\n \n\n  実施例６６３〜６６５\n\n  実施例６６２に記載の方法を用い、以下に示す実施例６６３〜６６５の化合物を製造する。\n\n\n \n \n\n\nExamples 663 to 665 \n The compounds of Examples 663 to 665 shown below are prepared using the method described in Example 662. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６６６\n\n  １−イソプロピル−シクロヘキサンカルボン酸（３−フェニルプロピル）−アミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 666 \n 1-isopropyl-cyclohexanecarboxylic acid (3-phenylpropyl) -amide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６６２の記載に準じ製造しうる。\n\n  標記化合物：\n\n  ＥtＯＨ（１mL）中の化合物１（３３mg、０.１２ミリモル）および１０％Ｐd／炭素（３０mg）を、水素下で１８ｈ撹拌する。反応混合物をセライトで濾過し、濃縮して１−イソプロピル−シクロヘキサンカルボン酸（３−フェニルプロピル）−アミド（３３mg、１００％）を無色油状物で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）０.８６（６Ｈ、ｄ、Ｊ＝６.８Ｈz）、１.００−１.４０（５Ｈ、ｍ）、１.５０−１.６５（４Ｈ、ｍ）、１.８０−１.９０（４Ｈ、ｍ）、２.６７（２Ｈ、ｔ、Ｊ＝７.５Ｈz）、３.３３−３.４８（２Ｈ、ｍ）、５.５９（１Ｈ、ｓ）、７.１７−７.３１（５Ｈ、ｍ）\n\n  質量分析［Ｍ＋Ｈ］\n+\n＝２８８\n\nCompound 1: \n Compound 1 can be prepared according to the description in Example 662. \n Title compound: \n Compound 1 (33 mg, 0.12 mmol) and 10% Pd / carbon (30 mg) in EtOH (1 mL) are stirred under hydrogen for 18 h. The reaction mixture was filtered through celite and concentrated to give 1-isopropyl-cyclohexanecarboxylic acid (3-phenylpropyl) -amide (33 mg, 100%) as a colorless oil. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 0.86 (6H, d, J = 6.8 Hz), 1.00-1.40 (5H, m), 1.50-1.65 (4H, m), 1.80-1.90 (4H, m), 2.67 (2H, t, J = 7.5 Hz), 3.33-3.48 (2H, m), 5.59 (1H, s), 7.17-7.31 (5H, m) \n Mass spectrometry [M + H] \n+\n = 288\n\n\n\n\n\n\n \n\n  実施例６６７〜６６８\n\n  実施例６６６に記載の方法を用い、以下に示す実施例６６７〜６６８の化合物を製造する。\n\n\n \n \n\n\nExamples 667-668 \n Using the method described in Example 666, the following compounds of Examples 667-668 are prepared. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６６９\n\n  Ｎ−（１−イソプロペニル−シクロヘキシルメチル）−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 669 \n N- (1-Isopropenyl-cyclohexylmethyl) -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６６２の記載に準じ製造しうる。\n\n  化合物２：\n\n  ０℃に冷却したＴＨＦ（３mL）中の化合物１（１００mg、０.６７ミリモル）に、ＬＡＨ（１０２mg、２.６８ミリモル）を加える。反応混合物を０℃からｒｔまで一夜撹拌し、次いでＨ\n2\nＯ（０.１mL）、１５％ＮaＯＨ（０.１mL）、Ｈ\n2\nＯ（０.３mL）で反応を抑え、濾過し、無水硫酸ナトリウム上で乾燥して、（１−イソプロペニル−シクロヘキシル）メチルアミン（６３mg、６１％）を無色油状物で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣl\n3\n、３００ＭＨz）：δ（ppm）１.０５−１.８０（１５Ｈ、ｍ）、２.４６（２Ｈ、ｓ）、４.７６（１Ｈ、ｓ）、５.０７（１Ｈ、ｓ）\n\n  質量分析［Ｍ＋Ｈ］\n+\n＝１５４\n\nCompound 1: \n Compound 1 can be prepared according to the description in Example 662. \n Compound 2: \n To compound 1 (100 mg, 0.67 mmol) in THF (3 mL) cooled to 0 ° C., LAH (102 mg, 2.68 mmol) is added. The reaction mixture was stirred overnight from 0 ° C. to rt, then quenched with H \n2\n O (0.1 mL), 15% NaOH (0.1 mL), H \n2\n O (0.3 mL), filtered and anhydrous sodium sulfate Drying above gives (1-isopropenyl-cyclohexyl) methylamine (63 mg, 61%) as a colorless oil. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 1.05-1.80 (15H, m), 2.46 (2H, s), 4.76 (1H, s), 5.07 ( 1H, s) \n Mass spectrometry [M + H] \n+\n = 154\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  実施例１に記載の方法を用い、化合物２をｏ−塩化アニソイルと反応させて、Ｎ−（１−イソプロペニル−シクロヘキシルメチル）−２−メトキシ−ベンズアミドを得る。質量分析［Ｍ＋Ｈ］\n+\n＝２８８\n\nTitle compound: \n Using the method described in Example 1, compound 2 is reacted with o-anisoyl chloride to give N- (1-isopropenyl-cyclohexylmethyl) -2-methoxy-benzamide. Mass spectrometry [M + H] \n+\n = 288\n\n\n\n\n\n\n \n\n  実施例６７０\n\n  実施例６６９に記載の方法を用い、以下に示す実施例６７０の化合物を製造する。\n\n\n \n \n\n\nExample 670 \n The compound of Example 670 shown below is prepared using the method described in Example 669. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６７１\n\n  Ｎ−（１−イソプロピル−シクロヘキシルメチル）−２−メトキシ−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 671 \n N- (1-Isopropyl-cyclohexylmethyl) -2-methoxy-benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６６９の記載に準じ製造する。\n\n  標記化合物：\n\n  実施例６６９に記載の方法を用いて、標記化合物を製造する。質量分析［Ｍ＋Ｈ］\n+\n＝２９０\n\nCompound 1: \n Compound 1 is prepared as described in Example 669. \n Title compound: \n The title compound is prepared using the method described in Example 669. Mass spectrometry [M + H] \n+\n = 290\n\n\n\n\n\n\n \n\n  実施例６７２\n\n  ２−メチル−３−（１−フェニル−シクロヘキシルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 672 \n 2-Methyl-3- (1-phenyl-cyclohexylmethyl) -3H-imidazo [4,5-b] pyridine \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例３３０の記載に準じ製造しうる。\n\n  化合物２：\n\n  無水テトラヒドロフラン（３０ｍＬ）中の化合物１（１．２１ｇ、６．３９ミリモル）の溶液を、Ｎ，Ｎ−ジイソプロピルエチルアミン（１ｍＬ、５．７３ミリモル）および２−ブロモ−３−ニトロ−ピリジン（１．１８ｇ、５．８１ミリモル）で処理する。反応混合物を６０℃で２１ｈ加熱する。溶媒を減圧下で除去し、残渣を酢酸エチルおよび１０％塩酸で処理する。有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（無水硫酸ナトリウム）、濾過し、濃縮する。生成物を最小量の酢酸エチルより再結晶して精製し、１．３ｇの（３−ニトロ−ピリジン−２−イル）−（１−フェニル−シクロヘキシルメチル）−アミンを明黄褐色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３１２\n\nCompound 1: \n Compound 1 can be prepared as described in Example 330. \n Compound 2: \n A solution of compound 1 (1.21 g, 6.39 mmol) in anhydrous tetrahydrofuran (30 mL) was added to N, N-diisopropylethylamine (1 mL, 5.73 mmol) and 2-bromo-3-nitro-pyridine (1. 18 g, 5.81 mmol). The reaction mixture is heated at 60 ° C. for 21 h. The solvent is removed under reduced pressure and the residue is treated with ethyl acetate and 10% hydrochloric acid. The organic layer is separated, washed with saturated aqueous sodium chloride, dried (anhydrous sodium sulfate), filtered and concentrated. The product is purified by recrystallization from a minimum amount of ethyl acetate to give 1.3 g of (3-nitro-pyridin-2-yl)-(1-phenyl-cyclohexylmethyl) -amine as a light tan solid. Mass spectrometry [M \n+\n H] \n+\n = 312\n\n\n\n\n\n\n \n\n  化合物３：\n\n  テトラヒドロフラン（２５ｍＬ）およびメタノール（１０ｍＬ）中の化合物２（０．９６ｇ、３．１ミリモル）の溶液を、アルゴン下０℃に冷却する。ホウ水素化ナトリウム（０．６２ｇ、１６．４ミリモル）および塩化ニッケル（ＩＩ）（０．０６ｇ、０．４６ミリモル）を加え、冷却浴を取り除く。反応混合物を室温で１ｈ撹拌し、このとき、ＴＬＣ分析により出発物質の残存のないことが認められる。２Ｎ−ＮａＯＨ（５ｍＬ）で反応を抑え、揮発成分を減圧下で除去する。残渣を酢酸エチルおよび１Ｎ−ＮａＯＨで処理する。有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（無水硫酸ナトリウム）、濾過し、濃縮する。生成物を最小量の酢酸エチルおよび数滴のメタノールより再結晶して精製し、０．４７ｇのＮ２−（１−フェニル−シクロヘキシルメチル）−ピリジン−２，３−ジアミンを白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２８２\n\nCompound 3: \n A solution of compound 2 (0.96 g, 3.1 mmol) in tetrahydrofuran (25 mL) and methanol (10 mL) is cooled to 0 ° C. under argon. Sodium borohydride (0.62 g, 16.4 mmol) and nickel (II) chloride (0.06 g, 0.46 mmol) are added and the cooling bath is removed. The reaction mixture was stirred at room temperature for 1 h, when TLC analysis shows no starting material left. The reaction is quenched with 2N NaOH (5 mL) and volatile components are removed under reduced pressure. The residue is treated with ethyl acetate and 1N NaOH. The organic layer is separated, washed with saturated aqueous sodium chloride, dried (anhydrous sodium sulfate), filtered and concentrated. The product is purified by recrystallization from a minimum amount of ethyl acetate and a few drops of methanol to give 0.47 g of N2- (1-phenyl-cyclohexylmethyl) -pyridine-2,3-diamine as a white solid. Mass spectrometry [M + H] \n+\n = 282\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  化合物３（０．０８７ｇ、０．３１ミリモル）、酢酸（１ｍＬ）およびＥＥＤＱ（０．０９４ｇ、０．３８ミリモル）をコンバインし、アルゴン下で１２０℃に４ｈ加熱する。反応混合物を室温まで冷却し、アセトニトリルおよび水で希釈し、分取逆相液体クロマトグラフィーで精製して、０．０１ｇの２−メチル−３−（１−フェニル−シクロヘキシルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジンを白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３０６\n\nTitle compound: \n Compound 3 (0.087 g, 0.31 mmol), acetic acid (1 mL) and EEDQ (0.094 g, 0.38 mmol) are combined and heated to 120 ° C. for 4 h under argon. The reaction mixture was cooled to room temperature, diluted with acetonitrile and water and purified by preparative reverse phase liquid chromatography to give 0.01 g of 2-methyl-3- (1-phenyl-cyclohexylmethyl) -3H-imidazo [ 4,5-b] pyridine is obtained as a white solid. Mass spectrometry [M + H] \n+\n = 306\n\n\n\n\n\n\n \n\n  実施例６７３\n\n  ３−（１−フェニル−シクロヘキシルメチル）−１，３−ジヒドロ−イミダゾ［４，５−ｂ］ピリジン−２−オン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 673 \n 3- (1-Phenyl-cyclohexylmethyl) -1,3-dihydro-imidazo [4,5-b] pyridin-2-one \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６７２の記載に準じ製造する。\n\n  標記化合物：\n\n  ジクロロメタン（２ｍＬ）中の化合物１（０．０９５ｇ、０．３４ミリモル）の溶液を、トリエチルアミン（０．０５ｍＬ、０．３６ミリモル）およびジホスゲン（０．０４１ｍＬ、０．３４ミリモル）で処理し、室温で２ｈ撹拌せしめる。反応混合物に別途ジクロロメタンおよび５％塩酸を加える。有機層を分離し、飽和水性塩化ナトリウムで洗い、濃縮する。残渣をアセトニトリル／水混合物に溶解し、凍結乾燥して０．０４ｇの３−（１−フェニル−シクロヘキシルメチル）−１，３−ジヒドロ−イミダゾ［４，５−ｂ］ピリジン−２−オンを白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３０８\n\nCompound 1: \n Compound 1 is prepared as described in Example 672. \n Title compound: \n A solution of compound 1 (0.095 g, 0.34 mmol) in dichloromethane (2 mL) was treated with triethylamine (0.05 mL, 0.36 mmol) and diphosgene (0.041 mL, 0.34 mmol) at room temperature. Let stir for 2 h. Separately add dichloromethane and 5% hydrochloric acid to the reaction mixture. The organic layer is separated, washed with saturated aqueous sodium chloride and concentrated. The residue was dissolved in an acetonitrile / water mixture and lyophilized to give 0.04 g of 3- (1-phenyl-cyclohexylmethyl) -1,3-dihydro-imidazo [4,5-b] pyridin-2-one in white Get in solid. Mass spectrometry [M + H] \n+\n = 308\n\n\n\n\n\n\n \n\n  実施例６７４\n\n  ｛２−［（１−フェニル−シクロヘキシルメチル）−アミノ］−ピリジン−３−イル｝−メタノール\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 674 \n {2-[(1-Phenyl-cyclohexylmethyl) -amino] -pyridin-3-yl} -methanol \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例３３０の記載に準じ製造しうる。\n\n  化合物２：\n\n  化合物２は、実施例６７２に記載の方法を用い、２−ブロモ−３−ニトロ−ピリジンの代わりにエチル・２−クロロニコチネートを用いて製造しうる。シリカゲルにて溶離剤としてヘキサン／酢酸エチル＝８：２を用いるカラムクロマトグラフィーにより、生成物を無色油状物で単離する。質量分析［Ｍ＋Ｈ］\n+\n＝３３９\n\nCompound 1: \n Compound 1 can be prepared as described in Example 330. \n Compound 2: \n Compound 2 can be prepared using the method described in Example 672 using ethyl 2-chloronicotinate instead of 2-bromo-3-nitro-pyridine. The product is isolated as a colorless oil by column chromatography on silica gel using hexane / ethyl acetate = 8: 2 as eluent. Mass spectrometry [M + H] \n+\n = 339\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  テトラヒドロフラン（６ｍＬ）中の化合物２（０．１５ｇ、０．４３ミリモル）の溶液を、アルゴン下０℃に冷却する。水素化リチウムアルミニウム（０．０７３ｇ、１９．２ミリモル）を１０ｍｇづつ加える。添加終了後、冷却浴を取り除き、反応混合物を室温で０．５ｈ撹拌せしめる。水（１ｍＬ）で反応を抑え、反応混合物を減圧濃縮する。残渣を酢酸エチルおよび飽和水性重炭酸ナトリウムで処理する。有機層を分離し、飽和水性塩化ナトリウムで洗い、乾燥し（無水硫酸ナトリウム）、濾過し、濃縮する。シリカゲルにて溶離剤としてヘキサン／酢酸エチル＝１：１を用いるカラムクロマトグラフィーを行い、０．０６ｇの｛２−［（１−フェニル−シクロヘキシルメチル）−アミノ］−ピリジン−３−イル｝−メタノールを白色泡状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２９７\n\nTitle compound: \n A solution of compound 2 (0.15 g, 0.43 mmol) in tetrahydrofuran (6 mL) is cooled to 0 ° C. under argon. Lithium aluminum hydride (0.073 g, 19.2 mmol) is added in 10 mg increments. After the addition is complete, the cooling bath is removed and the reaction mixture is allowed to stir at room temperature for 0.5 h. The reaction is quenched with water (1 mL) and the reaction mixture is concentrated under reduced pressure. The residue is treated with ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer is separated, washed with saturated aqueous sodium chloride, dried (anhydrous sodium sulfate), filtered and concentrated. Column chromatography on silica gel using hexane / ethyl acetate = 1: 1 as eluent and 0.06 g of {2-[(1-phenyl-cyclohexylmethyl) -amino] -pyridin-3-yl} -methanol Is obtained as a white foam. Mass spectrometry [M + H] \n+\n = 297\n\n\n\n\n\n\n \n\n  実施例６７５\n\n  Ｎ−（４−メチル−ピリジン−２−イル）−３−フェニル−Ｎ−（１−フェニル−シクロヘキシルメチル）−プロピオンアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 675 \n N- (4-Methyl-pyridin-2-yl) -3-phenyl-N- (1-phenyl-cyclohexylmethyl) -propionamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  化合物２は、実施例３２５に記載の方法を用い、イソキノリン−１−イルアミンの代わりに４−メチル−ピリジン−２−イルアミンを用いて製造しうる。生成物を最小量の酢酸エチル、数滴のメタノールおよび数滴のヘキサンより再結晶して精製し、化合物２を褐色粉末で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２９５\n\n  化合物３：\n\n  化合物３は、実施例３２５に記載の方法を用い製造しうる。生成物を無色油状物で単離する。質量分析［Ｍ＋Ｈ］\n+\n＝２８１\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n Compound 2 can be prepared using the method described in Example 325 using 4-methyl-pyridin-2-ylamine instead of isoquinolin-1-ylamine. The product is purified by recrystallization from a minimum amount of ethyl acetate, a few drops of methanol and a few drops of hexane to give compound 2 as a brown powder. Mass spectrometry [M + H] \n+\n = 295 \n Compound 3: \n Compound 3 can be prepared using the method described in Example 325. The product is isolated as a colorless oil. Mass spectrometry [M + H] \n+\n = 281\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  アセトニトリル（２ｍＬ）中の化合物３（０．０３５ｇ、０．１３ミリモル）の溶液を、ポリスチレン−ジイソプロピルエチルアミン（ＰＳ−ＤＩＥＡ）（２００ｍｇ）およびヒドロシンナモイルクロリド（０．０５ｇ、０．３ミリモル）で処理する。反応液を６ｈ振とうさせる。反応混合物を直接、分取逆相液体クロマトグラフィーで精製して、０．０２ｇのＮ−（４−メチル−ピリジン−２−イル）−３−フェニル−Ｎ−（１−フェニル−シクロヘキシルメチル）−プロピオンアミドを白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４１３\n\nTitle compound: \n A solution of compound 3 (0.035 g, 0.13 mmol) in acetonitrile (2 mL) was added with polystyrene-diisopropylethylamine (PS-DIEA) (200 mg) and hydrocinnamoyl chloride (0.05 g, 0.3 mmol). Process. Shake the reaction for 6 h. The reaction mixture was directly purified by preparative reverse phase liquid chromatography to yield 0.02 g of N- (4-methyl-pyridin-2-yl) -3-phenyl-N- (1-phenyl-cyclohexylmethyl)- Propionamide is obtained as a white solid. Mass spectrometry [M + H] \n+\n = 413\n\n\n\n\n\n\n \n\n  実施例６７６〜６８０\n\n  実施例６７５に記載の方法を用い、以下に示す実施例６７６〜６８０の化合物を製造する。\n\n\n \n \n\n\nExamples 676-680 \n Using the method described in Example 675, the following compounds of Examples 676-680 are prepared. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６８１\n\n  ３−フェニル−Ｎ−（１−フェニル−シクロヘキシロメチル）−Ｎ−ピリミジン−２−イル−プロピオンアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 681 \n 3-Phenyl-N- (1-phenyl-cyclohexylomethyl) -N-pyrimidin-2-yl-propionamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例３３０の記載に準じ製造しうる。\n\n  化合物２：\n\n  化合物２は実施例６７２に記載の方法を用いて製造しうる。質量分析［Ｍ＋Ｈ］\n+\n＝２６８\n\n  化合物３：\n\n  テトラヒドロフラン（２ｍＬ）中の化合物２（０．１ｇ、０．３７ミリモル）の溶液を、トリエチルアミン（０．１ｍＬ、０．７２ミリモル）およびヒドロシンナモイルクロリド（０．０８ｇ、０．４７ミリモル）で処理する。反応混合物を室温で４８ｈ撹拌せしめる。溶媒を蒸発除去し、残渣を直接、分取逆相液体クロマトグラフィーで精製して、０．０１８ｇの３−フェニル−Ｎ−（１−フェニル−シクロヘキシルメチル）−Ｎ−ピリミジン−２−イル−プロピオンアミドを白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝４００\n\nCompound 1: \n Compound 1 can be prepared as described in Example 330. \n Compound 2: \n Compound 2 can be prepared using the method described in Example 672. Mass spectrometry [M + H] \n+\n = 268 \n Compound 3: \n Treatment of a solution of compound 2 (0.1 g, 0.37 mmol) in tetrahydrofuran (2 mL) with triethylamine (0.1 mL, 0.72 mmol) and hydrocinnamoyl chloride (0.08 g, 0.47 mmol). To do. The reaction mixture is allowed to stir at room temperature for 48 h. The solvent was removed by evaporation and the residue was purified directly by preparative reverse phase liquid chromatography to give 0.018 g of 3-phenyl-N- (1-phenyl-cyclohexylmethyl) -N-pyrimidin-2-yl-propion. The amide is obtained as a white solid. Mass spectrometry [M + H] \n+\n = 400\n\n\n\n\n\n\n \n\n  実施例６８２\n\n  ２−メトキシ−Ｎ−［２−（１−フェニル−シクロヘキシル）−エチル］−ベンズアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 682 \n 2-Methoxy-N- [2- (1-phenyl-cyclohexyl) -ethyl] -benzamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は商業上入手しうる。\n\n  化合物２：\n\n  ０℃に冷却したＬＡＨ（３．８ｇ、０．１ミリモル）の懸濁液に、１−フェニル−シクロヘキサンカルボン酸（１０．２ｇ、５０．０ミリモル）をゆっくり加える。０℃からｒｔまで一夜撹拌後、反応混合物にＨ\n2\nＯ（３．８ｍＬ）、１５％ＮａＯＨ（３．８ｍＬ）、Ｈ\n2\nＯ（１１．４ｍＬ）を加えて反応を抑え、濾過する。塩をＥｔ\n2\nＯで洗い、コンバインした有機相を無水硫酸ナトリウム上で乾燥して、（１−フェニル−シクロヘキシル）−メタノール（８．４８ｇ、８９％）を白色固体で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n、３００ＭＨｚ）：δ（ｐｐｍ）１．３０−１．７０（９Ｈ、ｍ）、２．１５−２．３６（２Ｈ、ｍ）、３．５１（２Ｈ、ｓ）、７．２０−７．２７（１Ｈ、ｍ）、７．３４−７．４１（４Ｈ、ｍ）\n\n  質量分析［Ｍ＋Ｈ］\n+\n＝１９１．１\n\nCompound 1: \n Compound 1 is commercially available. \n Compound 2: \n To a suspension of LAH (3.8 g, 0.1 mmol) cooled to 0 ° C., 1-phenyl-cyclohexanecarboxylic acid (10.2 g, 50.0 mmol) is slowly added. After stirring overnight from 0 ° C. to rt, the reaction mixture is quenched with H \n2\n O (3.8 mL), 15% NaOH (3.8 mL), H \n2\n O (11.4 mL) and filtered. The salt is washed with Et \n2\n O and the combined organic phases are dried over anhydrous sodium sulfate to give (1-phenyl-cyclohexyl) -methanol (8.48 g, 89%) as a white solid. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 1.30-1.70 (9H, m), 2.15-2.36 (2H, m), 3.51 (2H, s), 7.20-7.27 (1H, m), 7.34-7.41 (4H, m) \n Mass spectrometry [M + H] \n+\n = 191.1\n\n\n\n\n\n\n \n\n  化合物３：\n\n  化合物２（５．０ｇ、２６．３ミリモル）／ＣＨ\n2\nＣｌ\n2\n（５０ｍＬ）に、１３．４ｇ（３１．６ミリモル）のデス−マーチン（Ｄess−Ｍartin）ヨージナンを加える。２ｈ後、チオ硫酸ナトリウム（５８ｇ）、次いで飽和ＮａＨＣＯ\n3\n（２００ｍＬ）を加える。１ｈ撹拌後、反応混合物をＥｔＯＡｃで希釈し、次いでＨ\n2\nＯ、塩水で洗い、無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／ＥｔＯＡｃ＝３：１）で精製して、１−フェニル−シクロヘキサンカルブアルデヒド（４．４７ｇ、９０％）を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝１８９．１\n\nCompound 3: \n To compound 2 (5.0 g, 26.3 mmol) / CH \n2\n Cl \n2\n (50 mL) is added 13.4 g (31.6 mmol) Dess-Martin iodinane. After 2 h, sodium thiosulfate (58 g) is added followed by saturated NaHCO \n3\n (200 mL). After stirring for 1 h, the reaction mixture is diluted with EtOAc, then washed with H \n2\n O, brine, and dried over anhydrous sodium sulfate. Purification by flash chromatography (hexane / EtOAc = 3: 1) gives 1-phenyl-cyclohexanecarbaldehyde (4.47 g, 90%) as a colorless oil. Mass spectrometry [M + H] \n+\n = 189.1\n\n\n\n\n\n\n \n\n  化合物４：\n\n  化合物３（４．４７ｇ、２３．７ミリモル）／ＰｈＣＨ\n3\n（１３０ｍＬ）に０℃にて、３６ｍＬのジエチルアルミニウムシアニド（１．０Ｍ／ＰｈＣＨ\n3\n）を加える。０℃で３ｈ撹拌後、反応混合物に飽和ロッシエル塩を加えて反応を抑え、ｒｔで２ｈ撹拌する。水性層をＣＨ\n2\nＣｌ\n2\n（２回）で抽出し、コンバインした抽出物を無水硫酸ナトリウム上で乾燥する。得られるヒドロキシ−（１−フェニル−シクロヘキシル）−アセトニトリルを、精製せずに用いる。質量分析［Ｍ＋Ｈ］\n+\n＝２１６．１\n\nCompound 4: \n To compound 3 (4.47 g, 23.7 mmol) / PhCH \n3\n (130 mL) at 0 ° C. is added 36 mL of diethylaluminum cyanide (1.0 M / PhCH \n3\n ). After stirring at 0 ° C. for 3 h, the reaction mixture is quenched with saturated Rossiel salt and stirred at rt for 2 h. The aqueous layer is extracted with CH \n2\n Cl \n2\n (twice) and the combined extracts are dried over anhydrous sodium sulfate. The resulting hydroxy- (1-phenyl-cyclohexyl) -acetonitrile is used without purification. Mass spectrometry [M + H] \n+\n = 216.1\n\n\n\n\n\n\n \n\n  化合物５：\n\n  化合物４（２３．７ミリモル）／ＣＨ\n2\nＣｌ\n2\n（８０ｍＬ）に、５．０７ｇ（２８．４ミリモル）の１，１’−チオカルボニルジイミダゾール、次いでＤＭＡＰ（０．５７９ｇ、４．７４ミリモル）を加える。一夜撹拌後、反応混合物をＨ\n2\nＯで洗い、無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／ＥｔＯＡｃ＝３：１）で精製して、イミダゾール−１−カルボチオン酸Ｏ−［シアノ−（１−フェニル−シクロヘキシル）−メチル］エステル（６．２７ｇ、８１％）を黄色シロップで得る。質量分析［Ｍ＋Ｈ］\n+\n＝３２６．１\n\nCompound 5: \n Compound 4 (23.7 mmol) / CH \n2\n Cl \n2\n (80 mL) to 5.07 g (28.4 mmol) of 1,1′-thiocarbonyldiimidazole and then DMAP (0.579 g, 4.74 mmol) Add After stirring overnight, the reaction mixture is washed with H \n2\n O and dried over anhydrous sodium sulfate. Purification by flash chromatography (hexane / EtOAc = 3: 1) to give imidazole-1-carbothioic acid O- [cyano- (1-phenyl-cyclohexyl) -methyl] ester (6.27 g, 81%) as a yellow syrup Get in. Mass spectrometry [M \n+\n H] \n+\n = 326.1\n\n\n\n\n\n\n \n\n  化合物６：\n\n  化合物５（６．２７ｇ、１９．３ミリモル）、Ｂｕ\n3\nＳｎＨ（１６．８ｇ、５７．８ミリモル）およびＡＩＢＮ（０．６３ｇ、３．８５ミリモル）／ＰｈＣＨ\n3\n（１００ｍＬ）を、１ｈ加熱還流し、次いで濃縮する。フラッシュクロマトグラフィー（ヘキサン、次いでヘキサン／ＥｔＯＡｃ＝４：１）で精製して、（１−フェニル−シクロヘキシル）−アセトニトリル（３．８４ｇ、１００％）を無色油状物で得る。\n\n\n1\nＨ−ＮＭＲ（ＣＤＣｌ\n3\n、３００ＭＨｚ）：δ（ｐｐｍ）１．２０−１．８０（８Ｈ、ｍ）、２．２５−２．４９（２Ｈ、ｍ）、２．４９（２Ｈ、ｓ）、７．３５−７．４６（５Ｈ、ｍ）\n\n  質量分析［Ｍ＋Ｈ］\n+\n＝２１０．１\n\nCompound 6: \n Compound 5 (6.27 g, 19.3 mmol), Bu \n3\n SnH (16.8 g, 57.8 mmol) and AIBN (0.63 g, 3.85 mmol) / PhCH \n3\n (100 mL) were heated to reflux for 1 h. And then concentrated. Purification by flash chromatography (hexane then hexane / EtOAc = 4: 1) gives (1-phenyl-cyclohexyl) -acetonitrile (3.84 g, 100%) as a colorless oil. \n \n1\n H-NMR (CDCl \n3\n , 300 MHz): δ (ppm) 1.20-1.80 (8H, m), 2.25-2.49 (2H, m), 2.49 (2H, s), 7.35-7.46 (5H, m) \n Mass spectrometry [M \n+\n H] \n+\n = 210.1\n\n\n\n\n\n\n \n\n  化合物７：\n\n  ０℃に冷却した化合物６（５００ｍｇ、２．５１ミリモル）／ＴＨＦ（１０ｍＬ）に、３８２ｍｇ（１０．０４ミリモル）のＬＡＨをゆっくり加える。０℃からｒｔまで一夜撹拌後、反応混合物を０℃に冷却し、次いでＨ\n2\nＯ（０．３８ｍＬ）、１５％ＮａＯＨ（０．３８ｍＬ）、Ｈ\n2\nＯ（１．１４ｍＬ）で反応を抑え、濾過する。塩をＥｔ\n2\nＯで洗い、コンバインした有機相を無水硫酸ナトリウム上で乾燥して、２−（１−フェニル−シクロヘキシル）−エチルアミン（５１０ｍｇ、１００％）を無色油状物で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２０４．２\n\n  標記化合物：\n\n  実施例１に記載の方法を用い、２−メトキシ−Ｎ−［２−（１−フェニル−シクロヘキシル）−エチル］−ベンズアミドを製造しうる。質量分析［Ｍ＋Ｈ］\n+\n＝３３８\n\nCompound 7: \n To compound 6 (500 mg, 2.51 mmol) / THF (10 mL) cooled to 0 ° C., 382 mg (10.04 mmol) of LAH is slowly added. After stirring overnight from 0 ° C. to rt, the reaction mixture was cooled to 0 ° C. and then quenched with H \n2\n O (0.38 mL), 15% NaOH (0.38 mL), H \n2\n O (1.14 mL), Filter. The salt is washed with Et \n2\n O and the combined organic phases are dried over anhydrous sodium sulfate to give 2- (1-phenyl-cyclohexyl) -ethylamine (510 mg, 100%) as a colorless oil. Mass spectrometry [M \n+\n H] \n+\n = 204.2 \n Title compound: \n Using the method described in Example 1, 2-methoxy-N- [2- (1-phenyl-cyclohexyl) -ethyl] -benzamide can be prepared. Mass spectrometry [M + H] \n+\n = 338\n\n\n\n\n\n\n \n\n  実施例６８３\n\n  実施例６８２に記載の方法を用い、以下に示す実施例６８３の化合物を製造する。\n\n\n \n \n\n\nExample 683 \n The compound of Example 683 shown below is prepared using the method described in Example 682. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６８４\n\n  Ｎ−（２−メトキシ−フェニル）−２−（１−フェニル−シクロヘキシル）−アセトアミド\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 684 \n N- (2-methoxy-phenyl) -2- (1-phenyl-cyclohexyl) -acetamide \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６８２の記載に準じ製造する。\n\n  化合物２：\n\n  化合物１（３．５８ｇ、１７．９６ミリモル）およびＫＯＨ（４．４２ｇ、７８．７７ミリモル）／エチレングリコール（３５ｍＬ）を、１７０℃で４８ｈ加熱し、次いでｒｔに冷却する。反応混合物をＨ\n2\nＯで希釈し、次いでＥｔ\n2\nＯ（２回）で抽出する。水性相を６Ｎ−ＨＣｌで酸性化し、次いでＥｔ\n2\nＯ（３回）で抽出し、無水硫酸ナトリウム上で乾燥して、（１−フェニル−シクロヘキシル）−酢酸（３．４３ｍｇ、８８％）を黄褐色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２１９．１\n\nCompound 1: \n Compound 1 is prepared as described in Example 682. \n Compound 2: \n Compound 1 (3.58 g, 17.96 mmol) and KOH (4.42 g, 78.77 mmol) / ethylene glycol (35 mL) are heated at 170 ° C. for 48 h and then cooled to rt. The reaction mixture is diluted with H \n2\n O and then extracted with Et \n2\n O (2 ×). The aqueous phase was acidified with 6N HCl, then extracted with Et \n2\n O (3 times) and dried over anhydrous sodium sulfate to give (1-phenyl-cyclohexyl) -acetic acid (3.43 mg, 88%) as yellow Obtained as a brown solid. Mass spectrometry [M + H] \n+\n = 219.1\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  化合物２（５０ｍｇ、０．２３ミリモル）／ＣＨ\n2\nＣｌ\n2\n（１ｍＬ）に、２４μＬ（０．２７ミリモル）の塩化オキサリル、次いで１滴のＤＭＦを加える。１ｈ後、ｏ−アニシジン（２８ｍｇ、０．２３ミリモル）、次いでＥｔ\n3\nＮ（９７μＬ、０．２７ミリモル）を加える。３ｈ撹拌後、反応混合物をＥｔＯＡｃで希釈し、１Ｎ−ＨＣｌ、１Ｎ−ＮａＯＨ、Ｈ\n2\nＯ、塩水で洗い、無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／ＥｔＯＡｃ＝９：１）で精製して、Ｎ−（２−メトキシ−フェニル）−２−（１−フェニル−シクロヘキシル）−アセトアミド（３７ｍｇ、５０％）を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３２４\n\nTitle compound: \n To compound 2 (50 mg, 0.23 mmol) / CH \n2\n Cl \n2\n (1 mL) is added 24 μL (0.27 mmol) oxalyl chloride followed by 1 drop of DMF. After 1 h, o-anisidine (28 mg, 0.23 mmol) is added followed by Et \n3\n N (97 μL, 0.27 mmol). After stirring for 3 h, the reaction mixture is diluted with EtOAc, washed with 1N HCl, 1N NaOH, H \n2\n O, brine and dried over anhydrous sodium sulfate. Purification by flash chromatography (hexane / EtOAc = 9: 1) gives N- (2-methoxy-phenyl) -2- (1-phenyl-cyclohexyl) -acetamide (37 mg, 50%) as a white solid. Mass spectrometry [M + H] \n+\n = 324\n\n\n\n\n\n\n \n\n  実施例６８５\n\n  ２−（１−フェニル−シクロヘキシルメチル）−１Ｈ−ベンゾイミダゾール\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 685 \n 2- (1-Phenyl-cyclohexylmethyl) -1H-benzimidazole \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６８４の記載に準じ製造する。\n\n  化合物２：\n\n  化合物１（１００ｍｇ、０．０４６ミリモル）／ＣＨ\n2\nＣｌ\n2\n（２ｍＬ）に、４８μＬ（０．５４ミリモル）の塩化オキサリル、次いで１滴のＤＭＦを加える。１．５ｈ後、得られる酸クロリドを、１，２−フェニレンジアミン（２８ｍｇ、０．２３ミリモル）の溶液に加え、次いでＥｔ\n3\nＮ（１９０μＬ、０．１３８ミリモル）を加える。１ｈ撹拌後、反応混合物をＥｔＯＡｃで希釈し、１Ｎ−ＨＣｌ、１Ｎ−ＮａＯＨ、Ｈ\n2\nＯ、塩水で洗い、無水硫酸ナトリウム上で乾燥する。得られるＮ−（２−アミノ−フェニル）−２−（１−フェニル−シクロヘキシル）−アセトアミドを、精製せずに次工程に用いる。\n\nCompound 1: \n Compound 1 is prepared as described in Example 684. \n Compound 2: \n To compound 1 (100 mg, 0.046 mmol) / CH \n2\n Cl \n2\n (2 mL) is added 48 μL (0.54 mmol) oxalyl chloride followed by 1 drop of DMF. After 1.5 h, the resulting acid chloride is added to a solution of 1,2-phenylenediamine (28 mg, 0.23 mmol) followed by Et \n3\n N (190 μL, 0.138 mmol). After stirring for 1 h, the reaction mixture is diluted with EtOAc, washed with 1N HCl, 1N NaOH, H \n2\n O, brine, and dried over anhydrous sodium sulfate. The resulting N- (2-amino-phenyl) -2- (1-phenyl-cyclohexyl) -acetamide is used in the next step without purification.\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  化合物２（０．４６ミリモル）／氷ＡｃＯＨ（２ｍＬ）を、１００℃で２ｈ加熱し、次いでｒｔまで冷却する。反応混合物を濃縮し、残渣をフラッシュクロマトグラフィー（ヘキサン／ＥｔＯＡｃ＝１：１）で精製して、２−（１−フェニル−シクロヘキシルメチル）−１Ｈ−ベンゾイミダゾール（７３ｍｇ、５４％）を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝２９１\n\nTitle compound: \n Compound 2 (0.46 mmol) / ice AcOH (2 mL) is heated at 100 ° C. for 2 h and then cooled to rt. The reaction mixture was concentrated and the residue was purified by flash chromatography (hexane / EtOAc = 1: 1) to give 2- (1-phenyl-cyclohexylmethyl) -1H-benzimidazole (73 mg, 54%) as a white solid. obtain. Mass spectrometry [M + H] \n+\n = 291\n\n\n\n\n\n\n \n\n  実施例６８６〜６８７\n\n  実施例６８５に記載の方法を用い、以下に示す実施例６８６〜６８７の化合物を製造する。\n\n\n \n \n\n\nExamples 686-687 \n Using the method described in Example 685, the compounds of Examples 686-687 shown below are prepared. \n \n \n \n \n\n\n\n\n\n\n \n\n  実施例６８８\n\n  ２−（１−フェニル−シクロヘキシルメチル）−３Ｈ−キナゾリン−４−オン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 688 \n 2- (1-Phenyl-cyclohexylmethyl) -3H-quinazolin-4-one \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６８４の記載に準じ製造する。\n\n  化合物２：\n\n  化合物１（７５ｍｇ、０．０３４ミリモル）／ＣＨ\n2\nＣｌ\n2\n（１ｍＬ）に、３６μＬ（０．０４１ミリモル）の塩化オキサリル、次いで１滴のＤＭＦを加える。１ｈ後、アントラニルアミド（４６ｍｇ、０．０３４ミリモル）、次いでＥｔ\n3\nＮ（１５０μＬ、１．０２ミリモル）を加える。一夜撹拌後、反応混合物をＥｔＯＡｃで希釈し、１Ｎ−ＨＣｌ、１Ｎ−ＮａＯＨ、Ｈ\n2\nＯ、塩水で洗い、無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／ＥｔＯＡｃ＝１：１）で精製して、２−［２−（１−フェニル−シクロヘキシル）−アセチルアミノ］−ベンズアミド（７８ｍｇ、６８％）を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３３７．２\n\nCompound 1: \n Compound 1 is prepared as described in Example 684. \n Compound 2: \n To compound 1 (75 mg, 0.034 mmol) / CH \n2\n Cl \n2\n (1 mL) is added 36 μL (0.041 mmol) oxalyl chloride followed by 1 drop of DMF. After 1 h, anthranilamide (46 mg, 0.034 mmol) is added followed by Et \n3\n N (150 μL, 1.02 mmol). After stirring overnight, the reaction mixture is diluted with EtOAc, washed with 1N HCl, 1N NaOH, H \n2\n O, brine, and dried over anhydrous sodium sulfate. Purify by flash chromatography (hexane / EtOAc = 1: 1) to give 2- [2- (1-phenyl-cyclohexyl) -acetylamino] -benzamide (78 mg, 68%) as a white solid. Mass spectrometry [M + H] \n+\n = 337.2\n\n\n\n\n\n\n \n\n  標記化合物：\n\n  アミド（７３ｍｇ、０．２１７ミリモル）／ＥｔＯＨ（１ｍＬ）および２Ｎ−ＮａＯＨ（１ｍＬ）を、８０℃で１ｈ加熱する。反応混合物を濃縮し、ＣＨ\n2\nＣｌ\n2\n（３回）で抽出し、次いで無水硫酸ナトリウム上で乾燥する。フラッシュクロマトグラフィー（ヘキサン／ＥｔＯＡｃ＝１：１）で精製して、２−（１−フェニル−シクロヘキシルメチル）−３Ｈ−キナゾリン−４−オン（６６ｍｇ、９６％）を白色固体で得る。質量分析［Ｍ＋Ｈ］\n+\n＝３１９．２\n\nTitle compound: \n Amide (73 mg, 0.217 mmol) / EtOH (1 mL) and 2N-NaOH (1 mL) are heated at 80 ° C. for 1 h. The reaction mixture is concentrated and extracted with CH \n2\n Cl \n2\n (3 times) and then dried over anhydrous sodium sulfate. Purify by flash chromatography (hexane / EtOAc = 1: 1) to give 2- (1-phenyl-cyclohexylmethyl) -3H-quinazolin-4-one (66 mg, 96%) as a white solid. Mass spectrometry [M + H] \n+\n = 319.2\n\n\n\n\n\n\n \n\n  実施例６８９\n\n  １−（１−フェニル−シクロヘキシルメトキシ）−イソキノリン\n\n\n \n \n\n  合成：\n\n\n \n \n\n\nExample 689 \n 1- (1-Phenyl-cyclohexylmethoxy) -isoquinoline \n \n \n \n Synthesis: \n \n \n \n \n\n\n\n\n\n\n \n\n  化合物１：\n\n  化合物１は実施例６８２に記載の方法を用いて製造する。\n\n  標記化合物：\n\n  テトラヒドロフラン（１０ｍＬ）中の化合物１（０．２３ｇ、１．２３ミリモル）の溶液を、アルゴン下０℃に冷却する。水素化ナトリウム（０．０８０ｇ、３．３ミリモル）を、５〜１０ｍｇづつゆっくり加える。添加終了後、反応混合物を０℃で０．２５ｈ撹拌せしめ、１−クロロイソキノリン（０．３２ｇ、２．０ミリモル）を加える。反応混合物を室温まで一夜ゆっくりと加温せしめる。別途水素化ナトリウム（０．０８０ｇ、３．３ミリモル）を加え、反応混合物を６０℃で７ｈ加熱する。溶媒を蒸発除去し、残渣をシリカゲルにて、溶離剤としてヘキサン／酢酸エチル＝８：２を用いるカラムクロマトグラフィーで精製して、０．０２ｇの１−（１−フェニル−シクロヘキシルメトキシ）−イソキノリンを得る。質量分析［Ｍ＋Ｈ］\n+\n＝３１８\n\nCompound 1: \n Compound 1 is prepared using the method described in Example 682. \n Title compound: \n A solution of compound 1 (0.23 g, 1.23 mmol) in tetrahydrofuran (10 mL) is cooled to 0 ° C. under argon. Sodium hydride (0.080 g, 3.3 mmol) is slowly added in 5-10 mg increments. After the addition is complete, the reaction mixture is allowed to stir at 0 ° C. for 0.25 h and 1-chloroisoquinoline (0.32 g, 2.0 mmol) is added. The reaction mixture is allowed to warm slowly to room temperature overnight. Separately sodium hydride (0.080 g, 3.3 mmol) is added and the reaction mixture is heated at 60 ° C. for 7 h. The solvent is evaporated off and the residue is purified by column chromatography on silica gel with hexane / ethyl acetate = 8: 2 as eluent to give 0.02 g of 1- (1-phenyl-cyclohexylmethoxy) -isoquinoline. obtain. Mass spectrometry [M + H] \n+\n = 318\n\n\n\n\n\n\n \n\n  実施例６９０〜６９４\n\n  実施例３２５に記載の方法を用い、以下に示す実施例６９０〜６９４の化合物を製造する。\n\n\n \n \n\n\nExamples 690-694 \n The compounds of Examples 690-694 shown below are prepared using the method described in Example 325."
  },
  {
    "id": "WO2010045948A1",
    "text": "Isoquinolinone derivatives as nk3 antagonists AbstractIsoquinolone derivatives of the general formula (I) are NK3 antagonists. Claims\n\n\n\n\n Claims\n\n\n\n\n1. A compound according to formula I\n\n\n\n\n\n\n\n\n[I] wherein A represents N, CH or CR\n1\n; each R\n1\n independently represents hydrogen, Ci_\n6\nalkyl, C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, -\n\n\nC(O)-Ci\n-6\nalkyl, -C(O)-C\n2-6\nalkenyl, -C(O)-C\n2-6\nalkynyl, -C(O)-O-C i\n-6\nalkyl, -C(O)-O-\n\n\nC\n2\n-\n6\nalkenyl, -C(O)-O-C\n2\n-\n6\nalkynyl or phenyl, wherein said phenyl, \n C\n2-\n \n\n\n6alkenyl or C2-6alkynyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, haloCi-6alkyl, nitro, \n and NR\n2\nR\n3\n;\n\n\nX represents hydrogen, \n or - CR\na\nR\nb\n-X', wherein X' represents a monocyclic saturated moiety having 5-6 ring atoms one of which is N and wherein one or two additional ring atom may be a hetero atom selected from N, O and S, which monocyclic ring may be substituted with one or more substituent W, wherein W is selected from \n C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, Ci-\nό\nhaloalkyl or (=0);\n\n\nR\na\n and R\nb\n each individually represent hydrogen, -CH\n3\n or halogen;\n\n\nQ represents -CH\n2\n- or -NH-;\n\n\nY represents heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S, or Y represents phenyl, wherein said heteroaryl or phenyl may be substituted with one or more substituents selected from halogen, \n C\n2-\n \n\n\n \n6\nalkenyl, C\n2-6\nalkynyl or Ci-\n6\nalkoxy;  wherein each of R\n2\n and R\n3\n independently represents hydrogen, C\n1-6\nalkyl, C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, hydroxyCi_\n6\nalkyl, or haloCi-\n6\nalkyl;\n\n\neach of R\n4\n-R\n8\n and R\n9\n-R\n12\n independently represent hydrogen, C\n1-6\nalkyl, C\n2\n-\n6\nalkenyl, C2-6alkynyl, halogen, NR\n2\nR\n3\n, hydroxy, cyano, nitro, \n or hydroxyC i -6alkyl; and pharmaceutically acceptable salts thereof.\n\n\n\n\n\n\n2. The compound according to claim 1, wherein A represents CH.\n\n\n\n\n\n\n3. The compound according to claim lor 2, wherein R\n1\n represents C\n1-6\nalkyl.\n\n\n\n\n\n\n4. The compound according to claim 3, wherein R\n1\n represents ethyl, cyclopropyl or cyclobutyl.\n\n\n\n\n\n\n5. The compound according to any of claims 1-4, wherein each of R\n4\n-R\n8\n independently represent hydrogen or halogen.\n\n\n\n\n\n\n6. The compound according to claim 5, wherein R\n7\n represents halogen and R\n4\n, R\n5\n and R\n8\n represent hydrogen.\n\n\n\n\n\n\n7. The compound according to any of claims 1-6, wherein each of R\n9\n-R\n12\n independently represent hydrogen of halogen.\n\n\n\n\n\n\n8. The compound according to claim 7, wherein R 12 represents halogen and R -\n\n\nR\n1 !\n represent hydrogen.\n\n\n\n\n\n\n9. The compound according to claim 8, wherein all of R\n9\n-R\n12\n represent hydrogen.\n\n\n\n\n\n\n10. The compound according to claim 1 according to formula F  \n\n\n\n\n\n\n\n\n[I\n1\n] wherein R\n1\n represents C\n1-6\nalkyl; X represents C\n1-6\nalkyl; Q represents -CH\n2\n- or -NH-;\n\n\nY represents a heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S, or alternatively Y represents phenyl, wherein said heteroaryl or phenyl may be substituted with one or more substituents selected from halogen and C\n1-6\nalkyl; each of R\n4\n-R\n9\n and R\n9\n-R\n12\n independently represent hydrogen or halogen; and pharmaceutically acceptable salts thereof.\n\n\n\n\n\n\n11. The compound according to claim 10 wherein R represents ethyl, cyclopropyl or cyclobutyl;\n\n\nQ represents -CH\n2\n-; Y represents a heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S, wherein said heteroaryl may be substituted with one or more substituents selected from halogen and C\n1-6\nalkyl.\n\n\n\n\n\n\n12. The compound according to any of claims 10-11, wherein R\n7\n represents halogen, and R\n5\n, R\n6\n and R\n8\n represent hydrogen.  \n\n\n\n\n\n\n13. The compound according to any of claims 10-12, wherein R\n12\n is halogen, and R\n9\n-R* \n!\n represent hydrogen.\n\n\n\n\n\n\n14. The compound according to any of claims 10-13, wherein Y represents furazanyl, thiazolyl, thienyl, furanyl, imidazolyl, oxazolyl, pyrazolyl, isoxazolyl, pyridyl or 4H[l,2,4]triazolyl.\n\n\n\n\n\n\n15. The compound according to claim 10, wherein Q represents -NH, and Y represent phenyl, wherein said phenyl may be substituted with one or more substituents selected from halogen.\n\n\n\n\n\n\n16. The compound according to claim 1 selected from\n\n\n1 a 3-Methyl- 1 -oxo-2-phenylamino- 1 ,2-dihydro-isoquinoline-4-carboxylic acid\n\n\n((S)- 1 -phenyl-propyl)-amide Ib 2-Benzyl-3-methyl-l-oxo-l,2-dihydro-isoquinoline-4-carboxylic acid ((S)-I- phenyl-propyl)-amide 1 c 3-Methyl- 1 -oxo-2-(pyridin-2-ylamino)- 1 ,2-dihydro-isoquinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide\n\n\n1 d 2-Furan-3-ylmethyl-3 -methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide\n\n\n2a 8-Fluoro-2-furan-3-ylmethyl-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2b 8-Fluoro-3-methyl- 1 -oxo-2-pyridin-3-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2c 8-Fluoro-3-methyl- 1 -oxo-2-pyridin-4-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2d 2-(2,5-Difluoro-benzyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2e 2-(2,6-Difluoro-benzyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide  2f 2-(3,4-Difluoro-benzyl)-8-fluoro-3-methyl-l-oxo-l,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2g 8-Fluoro-3-methyl- 1 -oxo-2-thiophen-3-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2h 8-Fluoro-3-methyl-2-(5-methyl-isoxazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]- amide 2i 8-Fluoro-3-methyl- 1 -oxo-2-thiophen-2-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2j 8-Fluoro-2-(lH-imidazol-2-ylmethyl)-3-methyl-l -oxo- 1,2-dihydro-isoquino line-\n\n\n4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2k 8-Fluoro-2-(lH-imidazol-2-ylmethyl)-3-methyl-l -oxo- 1,2-dihydro-isoquino line-\n\n\n4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 21 8-Fluoro-2-furan-3-ylmethyl-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n2m 8-Fluoro-3-methyl-2-(5-methyl-isoxazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2n 8-Fluoro-3-methyl- 1 -oxo-2-thiazol-2-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2o 8-Fluoro-3-methyl-2-(5-methyl-4H-[l,2,4]triazol-3-ylmethyl)-l -oxo- 1,2- dihydro-isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide 2p 8-Fluoro-3-methyl-2-(5-methyl-2H-pyrazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2q 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-pyrazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2r 8-Fluoro-3-methyl-2-(4-methyl-thiazol-5-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2s 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide  2t 8-Fluoro-3-methyl-2-oxazol-4-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2u 8-Fluoro-3-methyl-2-(5-methyl-thiazol-2-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2v 8-Fluoro-3-methyl-2-(4-methyl-furazan-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2w 2-(4,5-Dimethyl- 1 H-imidazol-2-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide 2x 2-(2,5-Dimethyl-furan-3-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2y 8-Fluoro-3-methyl-l-oxo-2-(l,3,5-trimethyl-lH-pyrazol-4-ylmethyl)-l,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide 2z 2-( 1 ,5-Dimethyl- 1 H-pyrazol-3-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2aa 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-imidazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ac 8-Fluoro-3-methyl-2-(2-methyl-thiazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n2ad 8-Fluoro-3-methyl-2-(2-methyl-furan-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ae 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-pyrazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2af 8-Fluoro-3-methyl-2-(3-methyl-3H-imidazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ag 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-imidazol-2-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ah 2-( 1 -Ethyl- 1 H-imidazol-2-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide  2ai 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(4-fluoro-phenyl)-methyl]-amide 2aj 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2ak 8-Fluoro-2-(3H-imidazol-4-ylmethyl)-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-\n\n\n4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2al 8-Fluoro-3-methyl-2-(3-methyl-isoxazol-5-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2am 8-Fluoro-2-isoxazol-5-ylmethyl-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n3a 2-(l -Ethyl- lH-imidazol-2-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]- amide\n\n\n4a 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3,5-difluoro-phenyl)-methyl]-amide\n\n\n4b 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3,4-difluoro-phenyl)-methyl]-amide 4c 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(4-fluoro-phenyl)-methyl]-amide 5a 8-Fluoro-2-oxazol-2-ylmethyl-l-oxo-l,2-dihydro-isoquinoline-4-carboxylic acid\n\n\n[(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 5b 8-Fluoro-2-oxazol-2-ylmethyl- 1 -oxo-3-(2-oxo-pyrrolidin- 1 -ylmethyl)- 1 ,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide 5c 3-(4-tert-Butyl-piperazin- 1 -ylmethyl)-8-fluoro-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl]-amide.\n\n\n\n\n\n\n17. A compound according to any of claims 1-16 for use in therapy.  \n\n\n\n\n\n\n18. A pharmaceutical composition comprising a compound according to any of claims 1-16 and one or more pharmaceutically acceptable carrier or excipient.\n\n\n\n\n\n\n19. A compound according to any of claims 1-16 for use in the treatment of a disease selected from psychosis; schizophrenia; schizophrenoform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance or drug induced psychotic disorder (cocaine, alcohol, amphetamine etc); schizoid personality disorder; schizotypal personality disorder; psychosis or schizophrenia associated with major depression, bipolar disorder, Alzheimer's disease or\n\n\nParkinson's disease; major depression; general anxiety disorder; bipolar disorder (maintenance treatment, recurrence prevention and stabilization); mania; hypomania; cognitive impairment; ADHD; obesity; appetite reduction; Alzheimer's disease; Parkinson's disease; pain; convulsions; cough; asthma; airway hyperresponsiveness; microvascular hypersensitivity; bronchoconstriction; chronic obstructive pulmonary disease; urinary incontinence; gut inflammation; and inflammatory bowel syndrome.\n\n\n\n\n\n\n20. The use of a compound according to any of claims 1-16 for the manufacture of a medicament for the treatment of a disease selected from psychosis; schizophrenia; schizophrenoform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance or drug induced psychotic disorder (cocaine, alcohol, amphetamine etc); schizoid personality disorder; schizotypal personality disorder; psychosis or schizophrenia associated with major depression, bipolar disorder, Alzheimer's disease or Parkinson's disease; major depression; general anxiety disorder; bipolar disorder (maintenance treatment, recurrence prevention and stabilization); mania; hypomania; cognitive impairment; ADHD; obesity; appetite reduction; Alzheimer's disease; Parkinson's disease; pain; convulsions; cough; asthma; airway hyperresponsiveness; microvascular hypersensitivity; bronchoconstriction; chronic obstructive pulmonary disease; urinary incontinence; gut inflammation; and inflammatory bowel syndrome.  \n\n\n\n\n\n\n21. A method for the treatment of a disease selected from psychosis; schizophrenia; schizophrenoform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance or drug induced psychotic disorder (cocaine, alcohol, amphetamine etc); schizoid personality disorder; schizotypal personality disorder; psychosis or schizophrenia associated with major depression, bipolar disorder, Alzheimer's disease or Parkinson's disease; major depression; general anxiety disorder; bipolar disorder (maintenance treatment, recurrence prevention and stabilization); mania; hypomania; cognitive impairment; ADHD; obesity; appetite reduction; Alzheimer's disease; Parkinson's disease; pain; convulsions; cough; asthma; airway hyperresponsiveness; microvascular hypersensitivity; bronchoconstriction; chronic obstructive pulmonary disease; urinary incontinence; gut inflammation; and inflammatory bowel syndrome, the method comprising the administration of a therapeutically effective amount of a compound according to any of claims 1-16 to a patient in need thereof. Description\n\n\n\n\n Isoquinolinone derivatives as NK3 antagonists\n\n\nField of the invention\n\n\nThe present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.\n\n\nBackground of the invention\n\n\nThe currently approved antipsychotic drugs share the common feature of reducing dopamine signalling in the brain. This is achieved through either a dopamine D2 receptor antagonistic or partial agonistic effect. The first generation antipsychotics (also referred to as \"typical\") are often associated with extra-pyramidal side effects for which reason the use of these agents have diminished. Second generation or \"atypical\" antipsychotics in addition to the D2 receptor affinity have affinity to the serotonin receptor 2A (5-HT\n2\nA)- Some atypical antipsychotics in addition have affinity for the 5-HT\n2\nC, 5-HT\n6\n, or 5-HT\n7\n receptors. Atypical antipsychotics give rise to fewer extra-pyramidal side effects, but are still hampered by weight gain and QTc effects. Examples of atypicals are clozapine, olanzapine and risperidone.\n\n\nMore recently, neurokinin receptors have been suggested as targets for CNS diseases [Albert, Expert Opin. Ther. Patents, 14, 1421-1433, 2004]. Neurokinins (or tachykinins) are a family of neuropeptides, which include substance P (SP), neurokinin A (NKA), and neurokinin B (NKB). The biological effects of these substances are primarily effected through binding to and activation of the three neurokinin receptors NKl, NK2, and NK3. Although some cross reactivity probably exists, SP has the highest affinity and is believed to be the endogenous ligand for NKl, and likewise for NKA and NK2, and for NKB and NK3. NK3 is primarily expressed centrally in regions including cortical regions, such as frontal, parietal and cingulated cortex; nuclei of the amygdale, such as the basal, central and lateral nuclei; the hippocampus; and mesencephalon structures, such as ventral tegmental area, substantia nigra pars compacta, and dorsal raphe nuclei [Spooren et al, Nature Reviews, 4, 967-975, 2005]. The NK3 receptor is expressed on \n\n dopaminergic neurons, and Spooren et al has suggested that the antipsychotic effects of NK3 antagonists are mediated by an inhibition of the dopamine tone, particularly at the D2 receptor combined with a reduction of the serotonergic tone, particularly at the 5-HT\n2\nA receptor.\n\n\nTwo structurally distinct NK3 antagonists, namely talnetant and osanetant, have been clinically tested for antipsychotic, and in particular antischizophrenic effects.\n\n\n\n\n\n\n\n\nOsanetant Talnetant\n\n\nOsanetant proved superior to placebo in clinical trials, in particular on positive symptoms of psychosis, i.e. delusions, hallucinations and paranoia [AmJ. Psychiatry, 161, 2004, 975-984]. Similarly, talnetant has been shown in clinical trials to ameliorate the cognitive behaviour of schizophrenics [Curr.Opion.Invest.Drug, 6, 717-721, 2005]. Nevertheless, both compounds are hampered by poor pharmacokinetic and pharmacodynamic properties including poor solubility, poor bioavailability, relatively high clearance, and poor blood-brain barrier penetration [Nature reviews, 4, 967-975, 2005]. These results lend support to the notion that the NK3 receptor is a promising target for the treatment of e.g. psychosis, however emphasising the need for identifying compounds with adequate pharmacokinetic and pharmacodynamic properties. WO95/32948 discloses a range of quinoline derivatives, including talnetant as\n\n\nNK3 antagonists.\n\n\nMore recently, WO 2006/130080 discloses compounds having the core structure \n\n \n\n\n which compounds are said to be NK3 antagonists; and WO 2006/050991 and WO 2006/050992 disclose further quinolinecarboxamides derivatives, which derivatives are said to be NK3 antagonists.\n\n\nWO 2005/014575 discloses compounds of the formula\n\n\nacetyl\n\n\n \n\n wherein R represents N-containing heterocycles, i.e. pyrazolyl, triazolyl and tetrazolyl.\n\n\nInd.J.Chem. Section B, 18B, 304-306, 1979 discloses a study on the synthesis of compounds with the following core structure\n\n\n\n\n\n\n\n\nThe chemical supplier Ambinter provides a compound of the structure \n\n\n\n\n \n\n and with the chemical name 2-methyl-l-oxo-l,2-dihydro-isoquinoline-4-carboxylic acid l-phenyl-ethyl)-amide.\n\n\nSummary of the invention\n\n\nThe present inventors have surprisingly found that certain isoquinolinone derivatives are potent NK3 antagonists, which may as such be used in the treatment of e.g. psychosis. Accordingly, in one embodiment the invention relates to compounds of formula I\n\n\n\n\n\n\n\n\nwherein A represents N, CH or CR ; each R\n1\n independently represents hydrogen, Ci_\n6\nalkyl, C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, - C(O)-Ci\n-6\nalkyl, -C(O)-C\n2-6\nalkenyl, -C(O)-C\n2-6\nalkynyl, -C(O)-O-C i\n-6\nalkyl, -C(O)-O- C\n2\n-\n6\nalkenyl, -C(O)-O-C\n2\n-\n6\nalkynyl or phenyl, wherein said phenyl, C\nh\nalky!, C\n2\n- \n\n βalkenyl or C2-6alkynyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, haloCi.6alkyl, nitro, \n\n\n and NR 2\nπ\n R3 ;.\n\n\nX represents hydrogen, C^aUcyl or - CR i a\na\n \nπ\nRb -X', wherein X' represents a monocyclic saturated moiety having 5-6 ring atoms one of which is N and wherein one or two additional ring atom may be a hetero atom selected from N, O and S, which monocyclic ring may be substituted with one or more substituent W, wherein W is selected from C\n1-6\nalkyl, C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, Ci-\nό\nhaloalkyl or (=0);\n\n\nR\na\n and R\nb\n each individually represent hydrogen, -CH\n3\n or halogen;\n\n\nQ represents -CH\n2\n- or -NH-; Y represents heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S, or Y represents phenyl, wherein said heteroaryl or phenyl may be substituted with one or more substituents selected from halogen, C\n1-6\nalkyl, C\n2-\n \n\n\n \n6\nalkenyl, C\n2\n-\n6\nalkynyl or Ci-\n6\nalkoxy; wherein each of R\n2\n and R\n3\n independently represents hydrogen, C\n1-6\nalkyl, C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, hydroxyC i ^alkyl, or haloC i ^alkyl; each of R\n4\n-R\n8\n and R\n9\n-R\n12\n independently represent hydrogen, C\n1-6\nalkyl, C\n2\n-\n6\nalkenyl,\n\n\nC2-6alkynyl, halogen, NR\n2\nR\n3\n, hydroxy, cyano, nitro, \n\n\n haloCi-6alkyl or hydroxyC \n1-6\nalkyl; and pharmaceutically acceptable salts thereof. In on embodiment, the invention relates to the use of compounds of formula I and pharmaceutically acceptable salts thereof in therapy.\n\n\nIn one embodiment, the invention relates to a pharmaceutical composition comprising compounds of formula I and pharmaceutically acceptable salts in combination with one or more pharmaceutically acceptable carrier or excipient. In one embodiment, the invention relates to the use of compounds of formula I and pharmaceutically acceptable salts in the manufacture of medicaments.\n\n\nIn one embodiment, the invention relates to compounds of formula I and pharmaceutically acceptable salts for use in the treatment of diseases.\n\n\nIn one embodiment, the invention relates to a method a treatment, said method comprising the administration of a therapeutically effective amount of compounds of formula I and pharmaceutically acceptable salts to a patient in need thereof. \n\n Definitions\n\n\nIn the present context, \"alkyl\" is intended to indicate a straight, branched and/or cyclic saturated hydrocarbon. In particular \"Ci-\n6\nalkyl\" is intended to indicate such hydrocarbon having 1, 2, 3, 4, 5, or 6 carbon atoms. Examples\n\n\n include methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-methyl-propyl, tert.-butyl, and cyclopropylmethyl.\n\n\nIn the present context, \"alkenyl\" is intended to indicate a non-aromatic, straight, branched and/or cyclic hydrocarbon comprising at least one carbon-carbon double bond. In particular \"C\n2\n-\n6\nalkenyl\" is intended to indicate such hydrocarbon having 2, 3, 4, 5, or 6 carbon atoms. Examples of C\n2\n-\n6\nalkenyl include ethenyl, 1- propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, and cyclohexenyl.\n\n\nIn the present context, \"alkynyl\" is intended to indicate a non-aromatic, straight, branched and/or cyclic hydrocarbon comprising at least one carbon-carbon triple bond and optionally also one or more carbon-carbon double bonds. In particular \"C\n2\n-\n6\nalkynyl\" is intended to indicate such hydrocarbon having 2, 3, 4, 5, or 6 carbon atoms. Examples of C\n2\n-\n6\nalkynyl include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl and 5-but-l-en-3-ynyl.\n\n\nIn the present context \"halogen\" is intended to indicate members of the 7\nth\n group of the periodic system, e.g. flouro, chloro, bromo, and iodo. In the present context, \"alkoxy\" is intended to indicate a moiety of the formula\n\n\n-OR', wherein R' indicates alkyl as defined above. In particular \"Ci-6alkoxy\" is intended to indicate such moiety wherein the alkyl part has 1, 2, 3, 4, 5, or 6 carbon atoms.\n\n\nIn the present context, pharmaceutically acceptable salts include pharmaceutical acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids.\n\n\nExamples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like. \n\n Examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8- bromotheophylline and the like. Further examples of pharmaceutical acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977,66,2, which is incorporated herein by reference.\n\n\nExamples of metal salts include lithium, sodium, potassium, magnesium salts and the like.\n\n\nExamples of ammonium and alkylated ammonium salts include ammonium, methyl-, dimethyl-, trimethyl-, ethyl-, hydroxy ethyl-, diethyl-, n-butyl-, sec-butyl-, tert-butyl-, tetramethylammonium salts and the like.\n\n\nIn the present context, a \"ring atom\" is intended to indicate the atoms constituting a ring, and ring atoms are selected from C, N, O and S. As an example, benzene and toluene both have 6 carbons as ring atoms whereas pyridine has 5 carbons and 1 nitrogen as ring atoms. In the present context, the term \"therapeutically effective amount\" of a compound means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications in a therapeutic intervention comprising the administration of said compound. An amount adequate to accomplish this is defined as \"therapeutically effective amount\". Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician. In the present context, the term \"treatment\" and \"treating\" means the management and care of a patient for the purpose of combating a condition, such as a \n\n disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. Nonetheless, prophylactic (preventive) and therapeutic (curative) treatments are two separate aspects of the invention. The patient to be treated is preferably a mammal, in particular a human being.\n\n\nDetailed description of the invention\n\n\nIn one embodiment, the invention relates to compounds of formula I\n\n\n\n\n\n\n\n\n[I] wherein A represents N, CH or CR\n1\n; each R\n1\n independently represents hydrogen, Ci_\n6\nalkyl, C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, - C(O)-Ci\n-6\nalkyl, -C(O)-C\n2-6\nalkenyl, -C(O)-C\n2-6\nalkynyl, -C(O)-O-C i\n-6\nalkyl, -C(O)-O- C\n2\n-\n6\nalkenyl, -C(O)-O-C\n2\n-\n6\nalkynyl or phenyl, wherein said phenyl, \n\n\n C\n2\n- 6alkenyl or C2-6alkynyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, haloCi-6alkyl, nitro, \n\n\n and NR\n2\nR\n3\n; \n\n X represents hydrogen, C^aUcyl or - CR\na\nR\nb\n-X', wherein X' represents a monocyclic saturated moiety having 5-6 ring atoms one of which is N and wherein one or two additional ring atom may be a hetero atom selected from N, O and S, which monocyclic ring may be substituted with one or more substituent W, wherein W is selected from C\n1-6\nalkyl, C\n2\n-\n6\nalkenyl, C\n2\n-\n6\nalkynyl, Ci-\nό\nhaloalkyl or (=0);\n\n\nR\na\n and R\nb\n each individually represent hydrogen, -CH\n3\n or halogen;\n\n\nQ represents -CH\n2\n- or -NH-;\n\n\nY represents heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S, or Y represents phenyl, wherein said heteroaryl or phenyl may be substituted with one or more substituents selected from halogen, C\n1-6\nalkyl, C\n2-\n \n\n\n \n6\nalkenyl, C\n2\n-\n6\nalkynyl or Ci_\n6\nalkoxy; wherein each of R\n2\n and R\n3\n independently represents hydrogen, C\n1-6\nalkyl, C\n2\n-\n6\nalkenyl,\n\n\nC\n2\n-\n6\nalkynyl, \n\n\n each of R\n4\n-R\n8\n and R\n9\n-R\n12\n independently represent hydrogen, C\n1-6\nalkyl, C\n2-6\nalkenyl, C\n2-6\nalkynyl, halogen, NR\n2\nR\n3\n, hydroxy, cyano, nitro, C\n1-6\nalkoxy, haloC\n1-6\nalkyl or hydroxyC i -βalkyl; and pharmaceutically acceptable salts thereof, i.e. the compounds of the invention.\n\n\nExamples of such heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S include furazanyl, thiazolyl, thienyl, furanyl, imidazolyl, oxazolyl, pyrazolyl, isoxazolyl, 4H[l,2,4]triazolyl, pyrrolyl, isothiazole, pyrazinyl, pyrimidinyl, pyridazinyl and pyridyl.\n\n\nExamples of such monocyclic saturated moiety having 5-6 ring atoms on e of which is N and wherein one or two additional ring atoms may be a hetero atom selected from N, O and S include pyrrolidinyl and piperazinyl. In on embodiment, A represents CH.\n\n\nIn one embodiment, R\n1\n represents Ci_\n6\nalkyl, in particular R\n1\n represents ethyl, cyclopropyl or cyclobutyl.\n\n\nIn one embodiment, each of R\n4\n-R\n8\n independently represent hydrogen or halogen. In particular, R\n7\n represents halogen and R\n4\n, R\n5\n and R\n8\n represent hydrogen. In one embodiment R\n4\n-R\n8\n represent hydrogen. \n\n In one embodiment, each of R\n9\n-R\n12\n independently represent hydrogen or halogen. In particular, R\n12\n represents halogen and R\n9\n-R\nπ\n represent hydrogen. In one embodiment, all of R\n9\n-R\n12\n represent hydrogen.\n\n\nIn one embodiment, the compounds of the invention are defined by formula F\n\n\n\n\n\n\n\n\nwherein R\n1\n represents C\n1-6\nalkyl;\n\n\nX represents C\n1-6\nalkyl;\n\n\nQ represents -CH\n2\n- or -NH-;\n\n\nY represents a heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S, or alternatively Y represents phenyl, wherein said heteroaryl or phenyl may be substituted with one or more substituents selected from halogen and\n\n\nCi-βalkyl; each of R\n4\n-R\n9\n and R\n9\n-R\n12\n independently represent hydrogen or halogen; and pharmaceutically acceptable salts thereof. In one embodiment relating to formula F, R\n1\n represents ethyl, cyclopropyl or cyclobutyl; Q represents -CH\n2\n-; Y represents a heteroaryl with 5-6 ring atoms, wherein 1, 2 or 3 ring atoms are selected from O, N or S, wherein said heteroaryl may be substituted with one or more substituents selected from halogen and C\n1-6\nalkyl.\n\n\nIn one embodiment relating to formula F, R\n7\n represents halogen, and R\n5\n, R\n6\n and R\n8\n represent hydrogen. \n\n In one embodiment relating to formula F, R\n12\n is halogen, and R\n9\n-R\nπ\n represent hydrogen.\n\n\nIn one embodiment relating to formula F, Y represents furazanyl, thiazolyl, thienyl, furanyl, imidazolyl, oxazolyl, pyrazolyl, isoxazolyl, or 4H[l,2,4]triazolyl. In one embodiment relating to formula F, Q represents -NH, and Y represent phenyl, wherein said phenyl may be substituted with one or more substituents selected from halogen.\n\n\nIn one embodiment, compounds of the invention are selected from 1 a 3-Methyl- 1 -oxo-2-phenylamino- 1 ,2-dihydro-isoquinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide\n\n\nIb 2-Benzyl-3 -methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4-carboxylic acid ((S)- 1 - phenyl-propyl)-amide 1 c 3-Methyl- 1 -oxo-2-(pyridin-2-ylamino)- 1 ,2-dihydro-isoquinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide Id 2-Furan-3-ylmethyl-3-methyl-l-oxo-l,2-dihydro-isoquinoline-4-carboxylic acid\n\n\n((S)- 1 -phenyl-propyl)-amide 2a 8-Fluoro-2-furan-3-ylmethyl-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2b 8-Fluoro-3-methyl- 1 -oxo-2-pyridin-3-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n2c 8-Fluoro-3-methyl- 1 -oxo-2-pyridin-4-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2d 2-(2,5-Difluoro-benzyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2e 2-(2,6-Difluoro-benzyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2f 2-(3,4-Difluoro-benzyl)-8-fluoro-3-methyl-l-oxo-l,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2g 8-Fluoro-3-methyl- 1 -oxo-2-thiophen-3-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide \n\n 2h 8-Fluoro-3-methyl-2-(5-methyl-isoxazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]- amide\n\n\n2i 8-Fluoro-3-methyl- 1 -oxo-2-thiophen-2-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n2j 8-Fluoro-2-(lH-imidazol-2-ylmethyl)-3-methyl-l -oxo- 1,2-dihydro-isoquino line-\n\n\n4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 2k 8-Fluoro-2-(lH-imidazol-2-ylmethyl)-3-methyl-l -oxo- 1,2-dihydro-isoquino line-\n\n\n4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 21 8-Fluoro-2-furan-3-ylmethyl-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2m 8-Fluoro-3-methyl-2-(5-methyl-isoxazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2n 8-Fluoro-3-methyl- 1 -oxo-2-thiazol-2-ylmethyl- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n2o 8-Fluoro-3-methyl-2-(5-methyl-4H-[l,2,4]triazol-3-ylmethyl)-l -oxo- 1,2- dihydro-isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide\n\n\n2p 8-Fluoro-3-methyl-2-(5-methyl-2H-pyrazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n2q 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-pyrazol-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2r 8-Fluoro-3-methyl-2-(4-methyl-thiazol-5-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2s 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2t 8-Fluoro-3-methyl-2-oxazol-4-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2u 8-Fluoro-3-methyl-2-(5-methyl-thiazol-2-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquino line-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide \n\n 2v 8-Fluoro-3-methyl-2-(4-methyl-furazan-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2w 2-(4,5-Dimethyl- 1 H-imidazol-2-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide\n\n\n2x 2-(2,5-Dimethyl-furan-3-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2y 8-Fluoro-3-methyl-l-oxo-2-(l,3,5-trimethyl-lH-pyrazol-4-ylmethyl)-l,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide\n\n\n2z 2-(l,5-Dimethyl-lH-pyrazol-3-ylmethyl)-8-fluoro-3-methyl-l-oxo-l,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2aa 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-imidazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ac 8-Fluoro-3-methyl-2-(2-methyl-thiazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ad 8-Fluoro-3-methyl-2-(2-methyl-furan-3-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ae 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-pyrazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n2af 8-Fluoro-3-methyl-2-(3-methyl-3H-imidazol-4-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ag 8-Fluoro-3-methyl-2-( 1 -methyl- 1 H-imidazol-2-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ah 2-( 1 -Ethyl- 1 H-imidazol-2-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2ai 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(4-fluoro-phenyl)-methyl]-amide 2aj 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide \n\n 2ak 8-Fluoro-2-(3H-imidazol-4-ylmethyl)-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-\n\n\n4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2al 8-Fluoro-3-methyl-2-(3-methyl-isoxazol-5-ylmethyl)- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 2am 8-Fluoro-2-isoxazol-5-ylmethyl-3-methyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide 3a 2-(l -Ethyl- lH-imidazol-2-ylmethyl)-8-fluoro-3-methyl- 1 -oxo- 1 ,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]- amide 4a 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3,5-difluoro-phenyl)-methyl]-amide 4b 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3,4-difluoro-phenyl)-methyl]-amide 4c 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(4-fluoro-phenyl)-methyl]-amide\n\n\n5a 8-Fluoro-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4-carboxylic acid\n\n\n[(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amide\n\n\n5b 8-Fluoro-2-oxazol-2-ylmethyl- 1 -oxo-3-(2-oxo-pyrrolidin- 1 -ylmethyl)- 1 ,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide\n\n\n5c 3-(4-tert-Butyl-piperazin- 1 -ylmethyl)-8-fluoro-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2- dihydro-isoquinoline-4-carboxylic acid [(S)-cyclobutyl-(3-fluoro-phenyl)- methyl] -amide\n\n\nFurther, the compounds of the invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.\n\n\nThe compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers (i.e. enantiomers or diastereomers), in the form of separated, pure or partially purified optical isomers and any mixtures thereof including racemic mixtures, i.e. a mixture of stereoisomeres, are included \n\n within the scope of the invention. In particular, when A represents CH or CR\n1\n, A may be an asymmetric centre giving rise to two optical isomers, an R form and an S form. In one embodiment, the compounds of the present invention have the S form.\n\n\nIn a particular embodiment, the compounds of the present invention have the following absolute configuration around A, A being CH\n\n\n \n\n or\n\n\nIn this context is understood that when specifying the enantiomeric form, then the compound is in enantiomeric excess, e.g. essentially in a pure, mono-enantiomeric form. Accordingly, one embodiment of the invention relates to a compound of the invention having an enantiomeric excess of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%.\n\n\nRacemic forms can be resolved into the optical antipodes by known methods, for example by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography of an optically active matrix. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in \"Enantiomers, Racemates, and Resolutions\", John Wiley and Sons, New York (1981). Optically active compounds can also be prepared from optically active starting materials.\n\n\nFurthermore, when a double bond or a fully or partially saturated ring system is present in the molecule geometric isomers may be formed. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules \n\n having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.\n\n\nFurthermore, some of the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms that the compounds are able to form are included within the scope of the present invention.\n\n\nNK3 receptor antagonists have been implicated in various diseases in addition to psychosis and schizophrenia discussed above. Langlois et al in J Pharm.Exp.Ther., 299, 712-717, 2001, concludes that NK3 antagonists may be applicable in CNS diseases in general, and in anxiety and depression in particular. Yip et al in Br.J.Phar., 122, 715-722, 1997 further implicates NK3 antagonists in diverse brain functions, such as cortical processing, learning and memory, neuroendocrine and behavioral regulation. Additional studies have shown that NKB and NK3 receptors are involved in pain, and that NK3 antagonists have an antinociceptive and analgesic effect [Fioramonti, Neurogastroenterol.Motil.,\\5, 363-369, 2003]. Mazelin et al in Life Sd., 63, 293-304, 1998 show that NK3 antagonists have an effect in gut inflammation and concludes that such antagonists may be used in the treatment of irritable bowel syndrome (IBS). In addition, NK3 antagonists have in in vivo models been demonstrated to be useful in the treatment of airway related diseases, such as asthma, airway hyperresponsiveness, cough, and bronchorestriction [Daoui, AmJ.Respir.Crit.Care Med., 158, 42-48, 1998]. Maubach et al in Neurosd., 83, 1047- 1062, 1998 show that NKB and the NK3 agonist senktide increase the frequency and duration of epileptiform discharges, and thus by inference that NK3 antagonists have a anticonvulsive potential. Finally, Kernel et al in J.Neurosd., 22, 1929-1936, 2002, suggests the use of NK3 antagonists in the treatment of Parkinson's Disease. Accordingly, clinical, pre-clinical, in vivo and in vitro studies support that\n\n\nNK3 receptor antagonists are of relevance for the treatment or prevention of various disorders including psychosis, schizophrenia, depression, anxiety, cognitive impairment, obesity, Alzheimer's disease, Parkinson's disease, pain, convulsions, cough, asthma, airway hyperresponsiveness, microvascular hypersensitivity, bronchoconstriction, gut inflammation, and inflammatory bowel syndrome. \n\n Schizophrenia is classified into subgroups. The paranoid type is characterised by delusions and hallucinations and absence of thought disorder, disorganized behavior and affective flattening. The disorganized type, which is also named 'hebephrenic schizophrenia' in the ICD, in which thought disorder and flat affect are present together. The catatonic type, in which prominent psychomotor disturbances are evident, and symptoms may include catatonic stupor and waxy flexibility. The undifferentiated type in which psychotic symptoms are present but the criteria for paranoid, disorganized, or catatonic types have not been met. The symptoms of schizophrenia normally manifest themselves in three broad categories, i.e. positive, negative and cognitive symptoms. Positive symptoms are those, which represent an \"excess\" of normal experiences, such as hallucinations and delusions. Negative symptoms are those where the patient suffers from a lack of normal experiences, such as anhedonia and lack of social interaction. The cognitive symptoms relate to cognitive impairment in schizophrenics, such as lack of sustained attention and deficits in decision making. The current antipsychotics are fairly successful in treating the positive symptoms but fare less well for the negative and cognitive symptoms. Contrary to that, NK3 antagonists have been shown clinically to improve on both positive and negative symptoms in schizophrenics [Am. J. Psychiatry, 161, 975-984, 204], and according to the above discussion they are also expected to deliver an effect on the cognitive symptoms.\n\n\nCognitive impairment include a decline in cognitive functions or cognitive domains, e.g. working memory, attention and vigilance, verbal learning and memory, visual learning and memory, reasoning and problem solving e.g. executive function, speed of processing and/or social cognition. In particular, cognitive impairment may indicate deficits in attention, disorganized thinking, slow thinking, difficulty in understanding, poor concentration, impairment of problem solving, poor memory, difficulties in expressing thoughts and/or difficulties in integrating thoughts, feelings and behaviour, or difficulties in extinction of irrelevant thoughts.\n\n\nIn one embodiment, the present invention relates to the compounds of the present invention for use in therapy. \n\n In one embodiment, the present invention relates to a method of treating a disease selected from psychosis; schizophrenia; schizophrenoform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance or drug induced psychotic disorder (cocaine, alcohol, amphetamine etc); schizoid personality disorder; schizotypal personality disorder; psychosis or schizophrenia associated with major depression, bipolar disorder, Alzheimer's disease or Parkinson's disease; major depression; general anxiety disorder; bipolar disorder (maintenance treatment, recurrence prevention and stabilization); mania; hypomania; cognitive impairment; ADHD; obesity; appetite reduction; Alzheimer's disease;\n\n\nParkinson's disease; pain; convulsions; cough; asthma; airway hyperresponsiveness; microvascular hypersensitivity; bronchoconstriction; chronic obstructive pulmonary disease; urinary incontinence; gut inflammation; inflammatory bowel syndrome; PTSD (post traumatic stress disorder); dementia; and agitation and delirium in the elderly the method comprising the administration of a therapeutically effective amount of a compound of the present invention to a patient in need thereof.\n\n\nIn one embodiment, the present invention relates to a method for the treatment of schizophrenia, the method comprising the administration of a therapeutically effective amount of a compound of the present invention to a patient in need thereof. In particular, said treatment includes the treatment of the positive, negative and/or cognitive symptoms of schizophrenia.\n\n\nIn one embodiment, the present invention relates to a method of treating cognitive impairment, the method comprising the administration of a therapeutically effective amount of a compound of the present invention to a patient in need thereof. In particular, said cognitive impairment is manifested as a decline in working memory, attention and vigilance, verbal learning and memory, visual learning and memory, reasoning and problem solving e.g. executive function, speed of processing and/or social cognition.\n\n\nThe antipsychotic effect of typical and atypical anti-psychotics, in particular D2 antagonists is exerted via an inhibition of the post-synaptic D2 receptors. Presynaptic D2 auto-receptors, however, are also affected by the administration of these \n\n compounds giving rise to an increase in the dopamine neuron firing rate, which, in fact, counteracts the antipsychotic effects. The increased firing rate continues until the effect of the pre-synaptic auto-receptors is blocked (the depolarization block), typically after approximately 3 weeks of chronic treatment with typical or atypical anti-psychotics. This model explains the up to 3 weeks delay of clinical effect normally seen when D2 antagonist treatment is initiated. NK3 antagonists seem to inhibit the increase in the dopamine neuron firing mediated by the pre-synaptic D2 auto -receptors brought about by D2 antagonists, wherefore the combined administration of NK3 antagonists (e.g. compounds of the present invention) and D2 antagonists is expected to give rise to a faster onset of the clinical effect. Moreover, D2 antagonists are known to increase prolactin levels, which may give rise to serious side effects, such as osteoporosis. It is known that NK3 agonists give rise to an increase in prolactin from which it may be deduced that a NK3 antagonist will lower an increased prolactin level, i.e bring about a normalisation of the prolactin level. A combined use of NK3 antagonists (e.g. compounds of the present invention) and D2 antagonists may thus address some of the safety issues associated with D2 antagonists administration. Similarly, NK3 antagonists (e.g. compounds of the present invention) may be administered together with antagonists/inverse agonists/negative modulators/partial agonists of one or more of the targets dopamine D2 receptor, dopamine D3 receptor, dopamine D4 receptor, phosphodiesterase PDElO, serotonin 5-HTiA receptor, serotonin 5-HT\n2\nA receptor, serotonin 5-HT\n6\n receptor, adrenergic alpha 2 receptor, cannabinoid type 1 receptor, histamine H3 receptor, cyclooxygenases, sodium channels or glycine transporter GIyTl; or with agonists/positive modulators/partial agonists of one or more of the targets serotonin 5- HT\n2\nC receptor, KCNQ channels, NMDA receptor, AMPA receptor, nicotinic alpha-7 receptor, muscarinic Ml receptor, muscarinic M4 receptor, metabotropic glutamate receptor mGluR2, metabotropic glutamate receptor mGluR5, dopamine Dl receptor or dopamine D5 receptor.\n\n\nSuch combined administration of compounds of the present invention and other anti-psychotic compounds may be sequential or concomitant. Examples of D2 \n\n antagonists or partial agonists include haloperidol, chlorpromazine, sulpirid, risperidone, ziprasidon, olanzapine, quetiapin, clozapine and aripiprazole.\n\n\nIn one embodiment, the compound of the present invention is administered in an amount from about 0.001 mg/kg body weight to about 100 mg/kg body weight per day. In particular, daily dosages may be in the range of 0.01 mg/kg body weight to about 50 mg/kg body weight per day. The exact dosages will depend upon the frequency and mode of administration, the sex, the age the weight, and the general condition of the subject to be treated, the nature and the severity of the condition to be treated, any concomitant diseases to be treated, the desired effect of the treatment and other factors known to those skilled in the art.\n\n\nA typical oral dosage for adults will be in the range of 1-1000 mg/day of a compound of the present invention, such as 1-500 mg/day, such as 1-100 mg/day or 1- 50 mg/day.\n\n\nIn one embodiment, the present invention relates to the use of the compounds of the present invention in the manufacture of a medicament for the treatment of a disease selected from psychosis; schizophrenia; schizophrenoform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance or drug induced psychotic disorder (cocaine, alcohol, amphetamine etc); schizoid personality disorder; schizotypal personality disorder; psychosis or schizophrenia associated with major depression, bipolar disorder, Alzheimer's disease or Parkinson's disease; major depression; general anxiety disorder; bipolar disorder (maintenance treatment, recurrence prevention and stabilization); mania; hypomania; cognitive impairment; ADHD; obesity; appetite reduction; Alzheimer's disease; Parkinson's disease; pain; convulsions; cough; asthma; airway hyperresponsiveness; microvascular hypersensitivity; bronchoconstriction; chronic obstructive pulmonary disease; urinary incontinence; gut inflammation; inflammatory bowel syndrome; PTSD; dementia; and agitation and delirium in the elderly.\n\n\nIn one embodiment, the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of \n\n schizophrenia. In particular, said treatment includes the treatment of the positive, negative and/or cognitive symptoms of schizophrenia.\n\n\nIn one embodiment, the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of cognitive impairment. In particular, said cognitive impairment is manifested as a decline in working memory, attention and vigilance, verbal learning and memory, visual learning and memory, reasoning and problem solving e.g. executive function, speed of processing and/or social cognition.\n\n\nIn one embodiment, the present invention relates to a compound of the present invention for use in the treatment of a disease selected from psychosis; schizophrenia; schizophrenoform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance or drug induced psychotic disorder (cocaine, alcohol, amphetamine etc); schizoid personality disorder; schizotypal personality disorder; psychosis or schizophrenia associated with major depression, bipolar disorder, Alzheimer's disease or Parkinson's disease; major depression; general anxiety disorder; bipolar disorder (maintenance treatment, recurrence prevention and stabilization); mania; hypomania; cognitive impairment; ADHD; obesity; appetite reduction; Alzheimer's disease; Parkinson's disease; pain; convulsions; cough; asthma; airway hyperresponsiveness; microvascular hypersensitivity; bronchoconstriction; chronic obstructive pulmonary disease; urinary incontinence; gut inflammation; inflammatory bowel syndrome; PTSD; dementia; and agitation and delirium in the elderly.\n\n\nIn one embodiment, the present invention relates to a compound of the present invention for use in the treatment of schizophrenia. In particular, said treatment includes the treatment of the positive, negative and/or cognitive symptoms of schizophrenia.\n\n\nIn one embodiment, the present invention relates to a compound of the present invention for use in the treatment of cognitive impairment. In particular, said cognitive impairment is manifested as a decline in working memory, attention and \n\n vigilance, verbal learning and memory, visual learning and memory, reasoning and problem solving e.g. executive function, speed of processing and/or social cognition. The compounds of the present invention may be administered alone as a pure compound or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen. Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings. Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.\n\n\nPharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.\n\n\nOther suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants, etc.\n\n\nConveniently, the compounds of the invention are administered in a unit dosage form containing said compounds in an amount of about 0.1 to 500 mg, such as 1 mg, 5 mg, 10 mg, 50 mg 100 mg, 150 mg, 200 mg or 250 mg of a compound of the present invention. \n\n For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration.\n\n\nFor parenteral administration, solutions of the compound of the invention in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.\n\n\nSuitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospho lipids, fatty acids, fatty acid amines, polyoxyethylene and water. The pharmaceutical compositions formed by combining the compound of the invention and the pharmaceutical acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.\n\n\nFormulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. Furthermore, the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.\n\n\nIf a solid carrier is used for oral administration, the preparation may be tablet, e.g. placed in a hard gelatine capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier may vary but will usually be from about 25 mg to about 1 g. \n\n If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or nonaqueous liquid suspension or solution.\n\n\nTablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents followed by the compression of the mixture in a conventional tabletting machine. Examples of adjuvants or diluents comprise: Corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.\n\n\nIn one embodiment, the invention relates to a pharmaceutical composition comprising a compound of the present invention together with a second anti-psychotic agent. In one embodiment, said second anti-psychotic agent is selected from antagonists/inverse agonists/negative modulators/partial agonists of the targets dopamine D2 receptor, dopamine D3 receptor, dopamine D4 receptor, phosphodiesterase PDElO, serotonin 5-HT\nIA\n receptor, serotonin 5-HT\n2\nA receptor, serotonin 5-HT\n6\n receptor, adrenergic alpha 2 receptor, cannabinoid type 1 receptor, histamine H3 receptor, cyclooxygenases, sodium channels or glycine transporter GIyTl; or from agonists/positive modulators/partial agonists of the targets serotonin 5-HT\n2\nC receptor, KCNQ channels, NMDA receptor, AMPA receptor, nicotinic alpha- 7 receptor, muscarinic Ml receptor, muscarinic M4 receptor, metabotropic glutamate receptor mGluR2, metabotropic glutamate receptor mGluR5, dopamine Dl receptor or dopamine D5 receptor. Particular examples of such anti-psychotics include haloperidol, chlorpromazine, sulpirid, risperidone, ziprasidon, olanzapine, quetiapine, clozapine and aripoprazole\n\n\nIn one embodiment, the invention relates to a pharmaceutical kit comprising a container comprising a compound of the present invention and a separate container comprising an anti-psychotic drug, such as typical anti-psychotics, atypical antipsychotics, antagonists/inverse agonists/negative modulators/partial agonists of one or more of the targets dopamine D2 receptor, dopamine D3 receptor, dopamine D4 receptor, phosphodiesterase PDElO, serotonin 5-HT\nIA\n receptor, serotonin 5-HT\n2\nA \n\n receptor, serotonin 5-HT\n6\n receptor, adrenergic alpha 2 receptor, cannabinoid type 1 receptor, histamine H3 receptor, cyclooxygenases, sodium channels or glycine transporter GIyTl; or with agonists/positive modulators/partial agonists of one or more of the targets serotonin 5-HT\n2\nC receptor, KCNQ channels, NMDA receptor, AMPA receptor, nicotinic alpha-7 receptor, muscarinic Ml receptor, muscarinic M4 receptor, metabotropic glutamate receptor mGluR2, metabotropic glutamate receptor mGluR5, dopamine Dl receptor or dopamine D5 receptor.\n\n\nParticular examples of such anti-psycho tics include haloperidol, chlorpromazine, sulpirid, risperidone, ziprasidon, olanzapine, quetiapine, clozapine and aripiprazole.\n\n\nAll references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law), regardless of any separately provided incorporation of particular documents made elsewhere herein.\n\n\nThe use of the terms \"a\" and \"an\" and \"the\" and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. For example, the phrase \"the compound\" is to be understood as referring to various \"compounds\" of the invention or particular described aspect, unless otherwise indicated.\n\n\nUnless otherwise indicated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement can be considered to also provide a corresponding approximate measurement, modified by \"about,\" where appropriate).\n\n\nThe description herein of any aspect or aspect of the invention using terms such as \"comprising\", \"having,\" \"including,\" or \"containing\" with reference to an element or elements is intended to provide support for a similar aspect or aspect of the invention that \"consists of, \"consists essentially of, or \"substantially comprises\" that particular element or elements, unless otherwise stated or clearly contradicted by \n\n context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).\n\n\nSYNTHETIC ROUTES\n\n\nThe compounds of the present invention of the general formula I, wherein R\n1\n- R\n12\n, A, X, Q, and Y are as defined above can be prepared by the methods outlined in the following reaction schemes and examples. In the described methods it is possible to make use of variants or modifications, which are themselves known to chemists skilled in the art or could be apparent to the person of ordinary skill in this art.\n\n\nFurthermore, other methods for preparing compounds of the invention will be readily apparent to the person skilled in the art in light of the following reaction schemes and examples.\n\n\nIn the intermediate compounds of the general formulae II - XXXI, R\n1\n -R\n12\n, A, X, Q, and Y are as defined under formula I.\n\n\nFor compounds, which can exist as a mixture or equilibrium between two or more tautomers, only one tautomer is represented in the schemes, although it may not be the most stable tautomer. For compounds, which can exist in enantiomeric, stereoisomeric or geometric isomeric forms their geometric configuration is specified; otherwise the structure represents a mixture of stereoisomers. Such compounds include, but not limited to 1,3-ketoesters or enamines of the general formula IV and VII, which can exist in equilibrium between keto or enol forms and the latter may also exist in isomeric Z- and E-forms as well-known to chemists skilled in the art. Such compounds also include compounds of the present invention of the general formula I, which may exist as a mixture of atropisomers due to restricted rotation around carbon- carbon single bonds similar to atropisomerism in ortho, ortho'-disubstituted biaryl compounds also well-known to the person skilled in the art.\n\n\nStarting materials of the general formulae II, III, VI, XI, XX, and XXI are either obtained from commercial sources as summarized in the Table 2 or they can be readily prepared by standard methods or their modifications described in the literature. \n\n 2-Bromobenzoic acids of the general formula II are coupled with keto-esters of the general formula III in the presence of a strong base such as sodium hydride and copper or copper salts such as copper (I) bromide in a suitable solvent such as 1,4- dioxane, acetonitrile or an excess of the above keto-esters at suitable temperature such as reflux or at 70\n0\nC with the formation of compounds of the general formula IV (Scheme 1). Such arylation reaction is well known in general as copper-catalyzed Ullmann-type coupling reaction (review: S. V. Ley, A. W. Thomas Angew. Chem. Int. Ed. 2003, 42, 5400). Also, in this particular case when the coupling reaction involves activated methylene compounds such as compounds of the general formula IV in the presence of copper or copper salts the reaction is known as the Hurtley reaction (W.R.H. Hurtley J Chem. Soc. 1929, 1870).\n\n\nThe obtained compounds of the general formula IV are then condensed with amino compounds of the general formula VI with or without appropriate solvent under the heating conditions with the formation of isoquinolinones of the general formula VIII via intermediate formation of enamines of the general formula VII which are usually not separated from the reaction mixture. Alternatively, the enamines of the general formula VII can be obtained from amino compounds of the general formula VI in the presence of the appropriate dehydrating agent such as tetraethoxysilane under heating conditions or at ambient temperature in the presence of a catalytic amount of acid such as acetic acid. Then, the cyclisation reaction with the formation of isoquinolinones of the general formula VIII can be carried out under the heating conditions as mentioned above or at ambient temperature in the presence of an appropriate coupling reagent such as EDC/HOBT (Scheme 1).\n\n\nFurthermore, isoquinolinones of the general formula VIII can be obtained directly from the starting 2-bromobenzoic acids of the general formula II and deprotonated enamines of the general formula V in a modified one-pot procedure involving Hurtley reaction performed at 70\n0\nC with the formation of the compounds of the general formula VII and subsequent cyclisation performed at higher temperature. Enamines of the general formula V are readily available from ketoesters III and amino compounds VI under conditions described above for preparation of enamines of the general formula VII (Scheme 1). \n\n Compounds of the general formula VIII are readily hydro lyzed to acids of the general formula IX under conditions for ester hydrolysis well known to chemists skilled in the art. Finally, the subsequent coupling with amines (A = C) or hydrazines (A = N) of the general formula XI leads to the formation of the compounds of the invention of the general formula I (Scheme 1). Such coupling reactions usually performed via activation of the acid with an appropriate coupling or activation reagent such as but not limited to thionyl chloride with the formation of corresponding acid chloride or in the presence EDC/HOBT. Hydrazides of the general formula I (A = N) where Rl = H can be converted to disubstituted hydrazides of the same general formula where Rl is not hydrogen by acylation, alkylation or arylation reactions with appropriate acylation or alkylation reagents such as but not limited to acid chlorides, carbamoyl chlorides, chloroformates or alkylhalogenides.\n\n\nCompounds of the general formula I where X is methyl can be converted to the compounds of the general formula XII by regio selective bromination reaction in the presence of bromination reagent such as bromine. Then the bromine atom can be substituted by various nucleophiles of the general formula X'-H or X'\n\"\n with the formation of the compounds of the invention of the general formula I as shown in Scheme 2. Those skilled in the art will readily appreciate that many nitrogen, carbon and sulphur nucleophiles such as but not limited to amines, aromatic amines, amides, heterocycles, alcohols, phenols, cyanides or thiols are commercially or readily available in the neutral or in the deprotonated anionic form required for such transformation.\n\n\nIf necessary, further derivatisation or transformation can be performed in the substituents R\n4\n-R\n12\n and X using standard methods of organic synthesis known to the person of ordinary skill in the art. \n\n\n\n\n\n\n\nI (X = Me) XII \n\n\n\n\n \n\n Scheme 5 \n\n\n\n\n\n\n\n\n\n\n\nI (X=CH\n3\n\n\n\n\nScheme 6\n\n\nX=H or Me \n\n\n\n\n\nXantphos\n\n\nAlternatively, compounds of the general formula I can be prepared starting from substituted homophthalic anhydrides of the general formula XVIII as shown in Scheme 4. Homophthalic anhydrides are either commercially available or can be prepared as shown in Scheme 3 starting from corresponding fiuorobenzonitriles or fluorobenzoates of the general formula XIII and XVII, respectively. They undergo aromatic nucleophilic substitution reaction with ethyl cyanoacetate XIV in the presence of base such as potassium carbonate or cesium carbonate under heating conditions in appropriate solvent such as dimethylsulfoxide. The coupling products are hydrolyzed in the presence of strong acids such as sulfuric or hydrochloric acids in water under heating conditions with the formation of diacids of the general formula XVI. Finally, the diacids are converted into the homophthalic anhydrides of the general formula XVIII in the presence of dehydrating agent such as but not limited to acetyl chloride without a solvent or in the appropriate solvent such as toluene under heating conditions such as reflux.\n\n\nHomophthalic anhydrides of the general formula XVIII can be regioselectively converted into the acid-amides of the general formula XIX at room temperature or \n\n under heating conditions in the appropriate solvent such as acetonitrile. Then they are treated with appropriate acid anhydrides or acid chlorides of the general formula XX and XXI, respectively, in the absence or presence of base such as triethyl amine and DMAP in the appropriated solvent, usually in acetonitrile, at room temperature or under mild heating conditions (T < +100\n0\nC). This transformation first provides intermediate ketene-aminals of the general formula XXII, which undergo further acylation reaction with the formation of ketene-aminals of the general formula XXIII. Further heating at higher temperature such as at +150\n0\nC leads to the rearrangement with the formation of amides of the general formula XIV. Compounds of the general formula XXIII and XXIV can be readily hydro lyzed at ambient temperature with an appropriate base such as sodium hydroxide in aqueous methanol or aqueous tetrahydrofurane as a solvent. The obtained keto-acids of the general formula XXV or ketene-aminals of the general formula XXIII are converted to the final compounds of the invention of the general formula I by condensation with amino compounds of the general formula VI under the same conditions as described above for condensation with keto-acids of the general formula IV.\n\n\nAlternatively, acid-amides of the general formula XIX can be converted directly to the compounds of the invention of the general formula I by condensation with appropriate imidoyl chlorides of the general formula XXVII which are readily available from corresponding amide of the general formula XXVI, which are easily prepared by well-known coupling between amino compounds of the general formula VI and corresponding carboxylic acids or their anhydrides or acid chlorides of the general formula XX and XXI, respectively.\n\n\nIn addition to the above methods, carbonylation reaction, in particular, the three-component coupling of an aryl halide, carbon monoxide, and a nucleophile, such as amine or alcohol (Schoenberg, A.; Bartoletti, L; Heck, R. F. J Org. Chem. 1974, 39, 3318; Schoenberg, A.; Heck, R. F. J Org. Chem. 1974, 39, 3327) can be used in a key step as illustrated in scheme 5. Thus, diacids of the general formula XVI are converted into keto-acids of the general formula XXVIII in one-pot acylation - decarboxylation reaction in acetic anhydride (in the case of acetic anhydride, the substituent X is Me) and in the presence of pyridine followed by condensation with \n\n amino compounds of the general formula VI with formation of isoquinolinones of the formula XXIX. They are regioselectively brominated with N-bromosuccinimide with formation of bromides of the general formula XXX. The aminocarbonylation reaction with bromides of the general formula XXX in the presence of amines of the general formula XI under an atmosphere of carbon monoxide promoted by a catalyst, for example palladium acetate - Xanthphos (Kranenburg, M.; van der Burgt, Y. E. M.; Kamer, P. C. J.; van Leeuwen, P. W. N. M. Organometallics 1995, 14, 3081) leads to the formation of compounds of the invention of the general formula I where X is Me. Alternatively, carbonylation reaction in the presence of alcohols such as benzyl alcohol under the same conditions leads to formation of benzyl esters of the general formula XXXI, which are readily converted into acids of the general formula IX by palladium catalyzed hydrogenation reaction followed by condensation with amines of the general formula XI as described above (see scheme I).\n\n\nAlternatively, homophthalic anhydrides of the general formula XVIII are converted into enolethers of the general formula XXXII by refiuxing in ortho-esters such as triethyl orthoacetate or trimethyl orthoformate. Depending on the substituent X (X=Me or H) and the amino compound of the general formula VI, the reaction with VI under heating conditions in the appropriate solvent such as ethanol or acetonitrile may provide either acids of the general formula IX or decarboxylated compounds of the general formula XXIX. The latter can be converted into acids of the general formula IX as described above (scheme 5) by bromination and carbonylation reactions. As also described above, acids of the general formula IX are readily converted into compounds of the invention.\n\n\nExamples\n\n\nAnalytical LC-MS, method A (used in most cases unless noted otherwise): data were obtained on a Sciex API 150EX analytical LC/MS system equipped with Applied Biosystems API150EX single qaudrupole mass spectrometer and atmospheric pressure photo ionisation (APPI) ion source, Shimadzu LClOADvp LC pumps (3X), Shimadzu SPD-M20A photodiode array detector, SEDERE Sedex 85 - low \n\n temperature Evaporative Light Scattering Detector (ELSD), Shimadzu CBM-20A system controller, Gilson 215 autosampler and Gilson 864 degasser controlled by Analyst Software. Column: 30 X 4.6 mm Waters Symmetry C18 column with 3.5 μm particle size; Injection Volume: 15 μL; Column temperature: 60\n0\nC; Solventsystem: A = water/trifluoroacetic acid (100:0.05) and B = water/acetonitrile/trifiuoroacetic acid (5:95:0.035); Method: Linear gradient elution with 10% B to 100% B in 2.4 minutes then with 10% B in 0.4 minutes and with a flow rate of 3.3 mL/minute. The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.\n\n\nAnalytical LC-MS, method B: data were obtained on a Sciex API300 analytical LC/MS system equipped with Applied Biosystems API300 triple qaudrupole mass spectrometer with atmospheric pressure photo ionisation (APPI) ion source, Shimadzu LClOADvp LC pumps (3X), Shimadzu SPD-M20A photodiode array detector, Polymer Labs PL-ELS 2100 - low temperature Evaporative Light Scattering Detector (ELSD), Shimadzu SCLlOA VP system controller, Gilson 215 autosampler and Gilson 864 degasser controlled by Analyst Software. Column:\n\n\nSymmetry Cl 8 3.5 μm, 4.6 x 30 mm 30 X 4.6 mm; Injection Volume: 5 μL; Column temperature: 60\n0\nC; Solventsystem: A = water/trifluoroacetic acid (100:0.05) and B = water/acetonitrile/trifluoroacetic acid (5:95:0.035); Method: Linear gradient elution with 10% B to 100% B in 1.45 minutes then with 10% B in 0.55 minutes and with a flow rate of 5.5 mL/minute:\n\n\nTime, min. %B\n\n\n0.00 10.0\n\n\n1.45 100.0\n\n\n1.55 10.0\n\n\n2.0 10.0\n\n\nThe retention times ^\nR\n) are expressed in minutes based on UV-trace at 254 nm.\n\n\nPreparative LC-MS purification was performed on the same Sciex API 150EX system equipped with Gilson 333 and 334 pumps, Shimadzu LClOADvp pump, Gilson UV/VIS 155 UV detector, Gilson 233XL autosampler, Gilson FC204 fraction, \n\n Gilson 506C system interface, Gilson 864 degasser, DIY flowsplitter (approx. 1:1000), and LC Packings Accurate flowsplitter (1:10.000 @ 140 ml/min). The MS and fraction collector was controlled by Masschrom software (Macintosh PC), the LC system was controlled by Unipoint software. For a small scale (<20 mg) purification fractions were collected in 4 ml vials using Symmetry Cl 8 5 μm, 10 x 50 mm column, injection volume of 0-300 μL, flow rate of 5.7 ml/min and duration of 8 min. Gradient:\n\n\nTime, min. %B\n\n\n0.00 10.0-50.0 (variable, depending on the sample)\n\n\n7.00 100.0\n\n\n7.10 10.0-50.0\n\n\n8.00 10.0-50.0\n\n\nLC- High resolution MS was performed on Bruker Daltonics micrOTOF instrument with electrospray ion source and time-of- flight mass detector.\n\n\n \n1\nH NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX-500 instrument at T=303.3 K. \n13\nC NMR and \n19\nF NMR were recorded on the same instrument. Variable temperature \n1\nH NMR spectra were recorded at 250 MHz on a Bruker Avance DPX-250 instrument. Deuterated dimethyl sulfoxide (DMSOd\n6\n, 99.8%D) was used as solvent unless noted otherwise. Tetramethylsilane was used as internal reference standard unless noted otherwise. Chemical shift values are expressed in ppm- values relative to tetramethylsilane unless noted otherwise. The following abbreviations or their combinations are used for multiplicity of NMR signals: s = singlet, d = doublet, t = triplet, q = quartet, qui = quintet, h = heptet, dd = double doublet, ddd = double double doublet, dt = double triplet, dq = double quartet, tt = triplet of triplets, m = multiplet and br = broad or broad singlet.\n\n\nMicrowave experiments were performed in sealed process vials or reactors using an Emrys Synthesizer or Emrys Optimizer EXP from Personal Chemistry or a Milestone Microsynth instrument from Milestone. When a reaction was heated in a microwave instrument, it was cooled to 25°C before the next process step. \n\n Preparation of intermediates\n\n\nSynthesis of homophthalic anhydrides of the general formula XVIII:\n\n\n\n\n\n\n\n\nCyano-(2-cyano-3-fluoro-phenyl)-acetic acid ethyl ester. A mixture of cyanoacetic acid ethyl ester (26.7 mL, 251 mmol), 2,6- difiuorobenzonitrile (33.2 g, 239 mmol) and potassium carbonate (82.5 g, 597 mmol) in dimethyl sulfoxide (120 mL) was stirred at +55°C for 16 hours and poured into ice- water mixture (ca. 400 mL). It was acidified with cone. aq. HCl with caution (CO\n2\n evolution) and extracted with ethyl acetate (600 ml). The organic phase was washed with brine (100 mL) and evaporated to give 55.1 g of a pale yellow solid that was used in the next step without further purification. \n1\nH NMR (500 MHz, CDCl\n3\n): 1.35 (t, J=7.0 Hz, 3H), 4.34 (m, 2H), 5.13 (s, IH), 7.33 (t, J=8.4 Hz, IH), 7.57 (d, J=7.9 Hz, IH), 7.33 (dd, J=7.9 Hz, J=13.9 Hz, IH).\n\n\n \n\n 2-Carboxymethyl-6-fluoro-benzoic acid.\n\n\nA mixture of 62% sulfuric acid (2:1 cone. H2SO4 in water, 400 ml) and cyano-(2- cyano-3-fluoro-phenyl)-acetic acid ethyl ester (52.0 g, 224 mmol) was stirred at +150\n0\nC overnight (16 hours). The reaction mixture was poured into ice (ca. 500 g) and 10.8 N aq. NaOH (500 mL) was added with cooling. The mixture was extracted with ethyl acetate (3 x 50OmL) and the combined organic solution was washed with brine, dried over MgSO\n4\n and evaporated to give 40.28 g of crude product that was used in the next step without further purification. The analytical sample was prepared by recrystallisation from toluene - ethyl acetate. \n1\nH NMR (500 MHz, DMSO-d\n6\n): 3.4 \n\n (br, CO\n2\nH + H\n2\nO), 3.77 (s, 2H), 7.17 (d, J=7.9 Hz, IH), 7.2 (overlapping t (unres. dd), IH), 7.45 (dd, J=7.9 Hz, J=13.9 Hz, IH), 12.95 (br, CO\n2\nH).\n\n\n\n\n\n\n\n\n8-Fluoro-isochroman-l ,3-dione. 2-Carboxymethyl-6-fluoro-benzoic acid (130 mg, 0.65 mmol) in acetyl chloride (2 ml) was heated under microwave irradiation at 150\n0\nC for 10 min then concentrated in vacuo to give the title product (120 mg, 100% yield). The compound is hydroscopic and slowly decomposes back to the starting diacid in wet solvents or under moisturised atmosphere. \n1\nR NMR (500 MHz, DMSO-d\n6\n): 4.29 (s, 2H), 7.27 (d, J=7.8 Hz, IH), 7.34 (dd, J=8.5 Hz, J=I 1 Hz, IH), 7.76 (dt, J=5.3 Hz, J=8 Hz, IH).\n\n\nSynthesis of chiral and racemic amines of the general formula XI:\n\n\nO\n\n\nI l\n\n\n\"NH,\n\n\n(S)-(-)-2-Methyl-2-propanesulfinamide.\n\n\nThe title chiral auxiliary was prepared according to a described procedure for the (R)- (+)-enantiomer by DJ. Weix and J.A. Ellman Organic Syntheses 2005, 82, 157.\n\n\n \n\n (S)-2-Methyl-2-propanesulfinic acid l-cyclopropyl-methylideneamide.\n\n\nThe title compound was prepared according to a general procedure described by G. Liu, D.A. Cogan, T.D. Owens, T.P. Tang, and J.A. Ellman J. Org. Chem. 1999, 64, 1278: A mixture of cyclopropanecarboxaldehyde (35.0 g, 0.5 mol), 2-methyl-2- propanesulfinic acid l-cyclopropyl-methylideneamide (30 g, 0.25 mol) and anhydrous CuSO\n4\n (120 g, 0.75 mol) in CH\n2\nCl\n2\n (1500 mL) was stirred at room temperature overnight. The reaction mixture was filtered and evaporated to give the title \n\n compound (39 g, yield 95%), which was used in the next step without further purification.\n\n\n \n\n {S)-2-Methyl-2-propanesulfinic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methylJ- amide and (S)-2-Methyl-2-propanesulfinic acid [(R)-cyclopropyl-(3-fluoro-phenyl)- methylj -amide.\n\n\nThe title compounds were obtained according to a general described procedure for 1 ,2-stereoselective addition of organometallic reagents to sulfinyl imines by D.A. Cogan, G. Liu, J. A. Ellman, Tetrahedron 1999, 55, 8883.\n\n\nProcedure A: To anhydrous lithium chloride (1.7 g, 40 mmol) THF (20 ml) was added under nitrogen followed by slow addition of /-PrMgCl (22 mL, 2 M in THF) and the obtained mixture was stirred at r.t. overnight. The obtained /-PrMgCl-LiCl solution was added dropwise to a stirred solution of l-bromo-3-fluorobenzene (5.6 g, 33 mmol) in THF (25 ml) at 0\n0\nC and stirring continued for 2 hours. The obtained\n\n\nGrignard reagent was added to a solution of (S)-2-methyl-2-propanesulfmic acid 1- cyclopropyl-methylideneamide (2.5 g, 14 mmol) in CH\n2\nCl\n2\n (60 mL) at -48\n0\nC. The mixture was stirred at -48\n0\nC for 5 hours and then at room temperature overnight. The reaction mixture was quenched by addition of aq. sat. NH4CI (50 mL) and extracted with CH\n2\nCl\n2\n (3x100 mL). The combined organic solution was dried (Na\n2\nSO\n4\n) and evaporated to give a crude mixture, which was purified by column chromatography on silica gel (EtO Ac/petroleum ether = 1/10). The obtained mixture of diastereoisomers was resolved by SFC to give the title (S,S)-isomer as the major product (1.5 g, yield 37.5%) and the title (S,R)-isomer (0.16 g, yield: 4.0%). Procedure B: Alternatively, to a suspension of Mg (13.4 g, 0.55 mol) in 50 mL of anhydrous THF at 5O\n0\nC a solution of l-bromo-3-fluorobenzene (89.0 g, 0.50 mol) was added dropwise. The mixture was stirred for 2 hours at +50\n0\nC and then it was added dropwise to a solution of (S)-2-methyl-2-propanesulfmic acid 1-cyclopropyl- \n\n methylideneamide (78.0 g, 0.46 mol) in 100 mL of THF at 50-60\n0\nC and stirred for 2 hours. It was quenched with aq. sat. NH4CI (100 ml), water (300 mL), filtered, and the both solid and filtrate were extracted with hot ethyl acetate (600 mL) and evaporated in vacuo. The residue was crystallized from a mixture of ethyl acetate and petroleum ether (1:1, 200 mL) at -2O\n0\nC to give 80 g of the title (S,S)-isomer as a white powder, 66% yield, de 100% according to chiral HPLC. \n1\nU NMR (CDCl\n3\n, 400 MHz, TMS=O ppm): 7.34-7.28 (m, IH), 7.16-7.12 (m, 2H), 7.00-6.96 (m, IH), 3.68 (dd, J= 8.8 Hz, 3.2 Hz, IH), 3.52 (s, IH), 1.42 (s, 9H), 1.15-1.08 (m, IH), 0.84-0.75 (m, IH), 0.69- 0.61 (m, IH), 0.55-0.46 (m, IH), 0.28-0.21 (m, IH).\n\n\n\n\n\n\n\n\n(S) - (+) - C-[C- Cyclopropyl- C- (3-fluoro-phenyl)] -methylamine hydrochloride To a saturated solution of HCl in anhydrous dioxane (400 ml) (S)-2-methyl-2- propanesulfinic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide (80 g, 0.3 mol) was added at O\n0\nC. After stirring at r.t. for 1 hour, the reaction mixture was evaporated in vacuo. The residue was washed with anhydrous ether (2x100 ml) and dried in vacuo to give 56 g of the title compound as a white solid, yield 93%, ee 100% according to chiral HPLC. [α]\n20\n,D = + 52.69 (c = 10 mg/mL, CH\n3\nOH). \n1\nU NMR (CD\n3\nOD, 400 MHz, TMS=O): 7.44-7.39 (m, IH), 7.25-7.19 (m, 2H), 7.12-7.07 (m, IH), 3.56 (d, J= 10.0 Hz, IH), 1.37-1.28 (m, IH), 0.78-0.75 (m, IH), 0.61-0.55 (m, 2H), 0.39-0.36 (m, IH).\n\n\n\n\n\n\n\n\n(R)-(-)-C-[C-Cyclopropyl-C-(3-fluoro-phenyl)] -methylamine hydrochloride. The title compound was prepared according to the above identical procedure from (S)-2-methyl-2-propanesulfmic acid [(R)-cyclopropyl-(3-fluoro-phenyl)-methyl]- \n\n amide (0.16g, 0.6 mmol) to give 0.116 g of the title compound as a white solid.\n\n\n[α]\n20\n,D = - 49.18 (c = 10 mg/mL, CH\n3\nOH), ee 100%. \n1\nH NMR (CD\n3\nOD, 400 MHz, TMS=O): identical with (S)-enantiomer.\n\n\nThe following enantiomerically pure amine hydrochlorides were obtained analogously in three-step procedure starting from condensation of the corresponding aldehyde with chiral auxiliary, stereoselctive Grignard addition where the mixture of diastereoisomers was resolved either by recrystallisation or by chromatography (SFC or column) and the major (S,S)-diastereoisomer was finally converted to a chiral amine with HCl.\n\n\n \n \n\n Synthesis of acid-amides of the general formula XIX:\n\n\n\n\n\n\n\n\n2- [((S)-I -Phenyl-propylcarbamoyl)-methyl] -benzoic acid. A mixture of homophthalic anhydride (810 mg, 5 mmol) and (S)-(-)-l- phenylpropylamine (676 mg, 5 mmol) in acetonitrile (15 ml) was heated under microwave irradiation at +150\n0\nC for 15 min. White precipitate was collected by filtration, washed with heptane and dried in vacuo to give pure title compound in 72% yield (1.065g). Alternatively, to a stirred solution of homophthalic anhydride (16.214 g, 0.1 mol) in acetonitrile (100 ml) (S)-(-)-l -phenylpropylamine (13.83 g, 0.102 mol) was added dropwise (exothermic reaction) and the obtained reaction mixture was re fluxed for 5 min. It was allowed to cool and the product was isolated by filtration as above to give 23.4 g of colourless solid, 79% yield. LC-MS (m/z) 298.5 (MH\n+\n); t\nR\n = 1.11. \n1\nH NMR (500 MHz, DMSOd\n6\n): 0.84 (t, J=7.3 Hz, 3H), 1.67 (quintet, J=7.3 Hz, 2H), 3.85 (d of AB system, J=15.1 Hz, IH), 3.95 (d of AB system, J=15.1 Hz, IH), 4.66 (q, J=7.6 Hz, IH), 7.2 (unres. m, IH), 7.25-7.34 (m, 5H), 7.45 (t, J=7.3 Hz, IH), 7.8 (d, J=7.8 Hz, IH), 8.39 (br. d, J=7.7 Hz, IH, NH).\n\n\nThe following compounds were obtained analogously from corresponding homophthalic anhydrides and amines of the general formula XVIII and XI, respectively. The reactions were usually run at room temperature and the products were isolated by extraction or filtration and used in the next steps without further purification. \n\n\n\n\n\n\n\n\n\n\n2-({[(S)-Cyclopropyl-(3-fluoro-phenyl)-methyl]-carbamoyl}-methyl)-6-fluoro-benzoic acid.\n\n\nLC-MS (m/z) 346.2 (MH\n+\n); t\nR\n = 1.14. \n1\nR NMR (500 MHz, DMSO-d\n6\n): 0.35 (m, IH), 0.39 (m, IH), 0.5 (m, 2H), 1.12 (m, IH), 3.68 & 3.74 (two d of AB system, J= 15.2 Hz, 2H, CH\n2\n), 4.25 (t, J= 8.5 Hz, IH), 7.05 (dt, J=2.2, 8.05 Hz, IH), 7.13 (d, J= 8.1 Hz, IH), 7.16-7.21 (m, 2H), 7.35 (m, IH), 7.42 (m, IH), 8.66 (d, J= 8.2 Hz, IH, NH), 13.44 (br., CO\n2\nH).\n\n\n \n\n 2-({[(S)-Cyclobutyl-(3-fluoro-phenyl)-methyl]-carbamoyl}-methyl)-6-fluoro-benzoic acid.\n\n\nLC-MS (m/z) 360.2 (MH\n+\n); t\nR\n = 1.31. \n\n\n\n\n\n\n\n\n\n\n2-{[((S)-Cyclopropyl-phenyl-methyl)-carbamoyl]-methyl}-6-fluoro-benzoic acid. LC-MS (m/z) 328.4 (MH\n+\n); t\nR\n = 1.12.\n\n\nSynthesis of compounds of the general formula XXIII:\n\n\n\n\n\n\n\n\n4-Acetyl-3-((S)-l-phenyl-propylamino)-isochromen-l-one.\n\n\nA mixture of 2-[((S)-I -phenyl-propylcarbamoyl)-methyl] -benzoic acid (10 g), acetic anhydride (50 ml), and N,N-dimethylaminopyridine (100 mg) was heated at gentle reflux (T\nma\nχ = +124°C) for 7 min and evaporated in vacuo at +50\n0\nC to give the title compound as a yellow-brown solid (11.1 g, purity 98% by NMR). LC-MS (m/z) 322.3 (MH\n+\n); t\nR\n = 1.72. \n1\nR NMR (500 MHz, DMSOd\n6\n): 0.89 (t, J=7.2 Hz, 3H), 1.86- 1.97 (m, 2H), 2.56 (s, 3H), 4.95 (q, J= 7.1 Hz, IH, CH-NH), 7.26 (t, J=7.5 Hz, IH), 7.29 (unres. m, IH), 7.36-7.41 (unres m., 3H), 7.71 (t, J=7.5 Hz, IH), 7.75 (d, J=8.3 Hz, IH), 7.98 (d, J=7.8 Hz, IH), 11.53 (d, J=7.6 Hz, IH, NH). \n13\nC APT NMR (125 MHz, DMSOd\n6\n, δ(DMSO-de)=39.87 ppm): 10.68 (CH\n3\n), 30.0 (CH\n2\n), 31.57 (CH\n3\n), 57.01 (CH), 92.44 (C), 114.88 (C), 124.2 (CH), (CH), 124.26 (CH), 126.65 (CH), 127.8 (CH), 129.05 (CH), 129.93 (CH), 135.71 (CH), 138.68 (C), 141.86 (C), 158.51 (C), 160.55 (C), 194.82 (C, MeCO). \n\n \n\n\n\n\n\n4-Acetyl-3-{[(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amino}-8-fluoro-isochromen- 1-one.\n\n\nA mixture of 2-({[(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-carbamoyl}-methyl)-6- fluoro -benzoic acid (12.92 g, 37.41 mmol) and acetic anhydride (100 mL, 1 mol) was stirred at +65°C for 20 hours and evaporated in vacuo (65°C, 10 mbar, 2 hours) to give the title compound as a thick brown oil, which was used in the next step without purification (14.30 g, yield 103.5%, purity 95% according to \n1\nH NMR). LC-MS (m/z) 370.1 (MH\n+\n); t\nR\n = 1.65. \n1\nR NMR (500 MHz, DMSOd\n6\n): 0.45-0.59 (m, 3H), 0.64 (m, IH), 1.41 (m, IH), 2.53 (s, 3H), 4.36 (t (unres. dd), IH), 7.03 (dd, J = 8.3, 10.7 Hz, IH), 7.12 (dt, J = 1.9, 8.5Hz, IH), 7.27 (d, J=10.2 Hz, IH), 7.3 (d, J=7.8 Hz, IH), 7.42 (q, J=7.8 Hz, IH), 7.53 (d, 8.5 Hz, IH), 7.7 (m, IH), 11.3 (d, J=7.3 Hz, IH, NH).\n\n\n \n\n 4-Acetyl-3-{[(S)-cyclobutyl-(3-fluoro-phenyl)-methyl]-amino}-8-fluoro-isochromen-l- one.\n\n\nLC-MS (m/z) 384.4 (MH\n+\n); t\nR\n = 1.82.\n\n\n\n\n\n\n\n\n4-Acetyl-3-[((S)-cyclopropyl-phenyl-methyl)-amino]-8-fluoro-isochromen-l-one. \n\n LC-MS (m/z) 352.6 (MH\n+\n); t\nR\n = 1.62. \n1\nR NMR (500 MHz, DMSO-d\n6\n): 0.48 (m, 2H), 0.54 (m, IH), 0.64 (m, IH), 1.39 (m, IH), 2.53 (s, 3H), 4.39 (t (unres. dd), IH), 7.04 (dd, J = 8.2, 10.8 Hz, IH), 7.3 (t, J=7.3 Hz, IH), 7.39 (t, J=7.6 Hz, 2H), 7.43 (d, J=7.3 Hz, 2H), 7.53 (d, 8.5 Hz, IH), 7.7 (m, IH), 11.39 (d, J=7.5 Hz, IH, NH).\n\n\n\n\n\n\n\n\n(2- Oxo-pyrrolidin- 1 -yl) -acetic acid.\n\n\nA mixture of 2-pyrrolidone (2.66 ml, 34 mmol) and NaH (60% in oil, 1.25 g, 31.3 mmol) in THF (75 ml) was stirred until gas evolution ceased (30 min). tert-Butyl 2- bromoacetate (4.45 ml, 30 mmol) was added and stirred at r.t. overnight then partitioned between water (200 ml) and ethyl acetate (200 ml) to give intermediate 2- (oxo-pyrrolidin-l-yl)-acetic acid tert-butyl ester (5.8 g). It was dissolved in acetic acid (40 ml ) and cone. aq. HCl (6 ml) with gas evolution observed. After stirring at r.t. for 2 hours it was evaporated and recrystallized from toluene/ethanol to give 2.58 g of the title compound (60% yield). \n1\nR NMR (500 MHz, DMSOd\n6\n): 1.95 (quintet, J= 7.7 Hz, 2H), 2.24 (t, J= 8.1 Hz, 2H), 3.38 (m, overalapping with H\n2\nO (3.35 ppm), 2H), 3.91 (s, 2H), 12.77 (br., IH).\n\n\n \n\n l-{2-[8-Fluoro-l-oxo-3-((S)-l-phenyl-propylamino)-lH-isochromen-4-yl]-2-oxo- ethylj-pyrrolidin-2-one.\n\n\nTo a solution of 2-oxo-pyrrolidin-l-yl-acetic acid (1.56 g, 10.9 mmol) in 1,2- dichloroethane (40 ml) oxalyl chloride (0.95 ml, 10.9 mmol) and DMF (1 drop) were added with gas evolution observed. After stirring at r.t. for 1 hour, 2-fiuoro-6-[((S)-l- phenyl-propylcarbamoyl)-methyl] -benzoic acid (1.56 g, 4.95 mmol), triethylamine \n\n (2.1 ml, 14.9 mmol) and DMAP (85 mg, 0.1 eq.) were added and stirred at r.t. overnight. It was partitioned between mixture of 0.2 M aq. HCl (100 ml) - brine (100 ml) and ethyl acetate (250 ml), washed with water and evaporated to give 1.89 g of crude title compound used in the next step without further purification.\n\n\n \n1\nR NMR (500 MHz, DMSOd\n6\n, selected resonances): 4.51 & 4.58 (two d of AB system, J=16.3 Hz, N-CH\n2\n-CO), 4.99 (q, J= 7.5 Hz, IH, CH-NH), 11.31 (d, J= 7.9 Hz, IH, NH).\n\n\n \n\n 1 -[2- (S- {[(S) - Cyclopropyl- (3-fluoro-phenyl) -methyl] -amino} -8-fluoro- 1 -oxo- IH- isochromen-4-yl)-2-oxo-ethyl]-pyrrolidin-2-one.\n\n\nThe title compound was prepared analogously and purified by flash chromatography on SiO\n2\n. LC-MS (m/z) 453.3 (MH\n+\n); t\nR\n = 1.48.\n\n\n \n\n l-(2-{3-[((S)-Cyclopropyl-phenyl-methyl)-amino]-8-fluoro-l-oxo-lH-isochromen-4- yl}-2-oxo-ethyl)-pyrrolidin-2-one. The title compound was prepared analogously. LC-MS (m/z) 435.3 (MH\n+\n); tR = 1.43. \n\n\n l-{2-Oxo-2-[l-oxo-3-((S)-l-phenyl-propylamino)-lH-isochromen-4-yl] -ethyl}- pyrrolidin-2-one.\n\n\nThe title compound was prepared analogously. LC-MS (m/z) 405.6 (MH\n+\n); tR = 1.47.\n\n\nHydrolysis of compounds of the general formula XXIII into compounds of the general formula XXV:\n\n\n\n\n\n\n\n\n2-(l- {[(S) - Cyclopropyl- (3-fluoro-phenyl) -methyl] -carbamoyl} -2-oxo-propyl) - 6- fluoro-benzoic acid.\n\n\n4-Acetyl-3-{[(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amino}-8-fluoro-2- benzopyran-1-one (14.30 g, 38.72 mmol) was dissolved in a mixture of tetrahydrofuran (50 mL) and methanol (50 mL) and placed on an ice/water bath with stirring. NaOH (1 M in H\n2\nO, 100 ml) was added and stirring continued for 1 hour. The cold bath removed and the mixture was allowed to warm to r.t. (20\n0\nC) during 1 hour. The reaction mixture was poored into ice-water mixture (200 g + 200 ml), followed by slow addition of 2 M aq. HCl (200 mL) and extracted with ethyl acetate (200 mL), washed with sat. aq. NaCl, dried (Na\n2\nSO\n4\n), filtered and evaporated to give the title compound (14.65 g, yield 97.7%) as a pale brown foam. The crude product was used in the next step without further purification. LC-MS (m/z) 388.3 (MH\n+\n); t\nR\n = 1.2. \n1\nH NMR (500 MHz, DMSO-dό): a mixture of tautomers and diastereoisomers. \n\n The following compound was prepared analogously:\n\n\n\n\n\n\n\n\n2-(l-{[(S)-Cyclobutyl-(3-fluoro-phenyl)-methyl]-carbamoyl}-2-oxo-propyl)-6-fluoro- benzoic acid.\n\n\nLC-MS (m/z) 402.2 (MH\n+\n); t\nR\n = 1.36.\n\n\nSynthesis of compounds of the general formula XXIV and XXV: Compounds of general formula XXIV obtained analogously as described above for compounds of general formula XXIII but at higher temperature (150\n0\nC, 15 min) and they are usually hydro lyzed to compounds of the general formula XXV without isolation and characterization, so only two examples of compounds XXIV are given below.\n\n\n\n\n\n\n\n\n3-Methyl-l -oxo-1 H-isochromene-^carboxylic acid ((S)- 1 -phenyl-propyl) -amide. The title compound was purified by flash chromatography on SiO\n2\n. LC-MS (m/z) 322.1 (MH\n+\n); t\nR\n = 1.27. \n1\nH NMR (500 MHz, CDCl\n3\n): 1.03 (t, J=I.3 Hz, 3H), 1.91- 2.06 (complex m, 2H, CH\n2\n), 2.19 (s, 3H), 5.11 (q, J=7.8 Hz, IH), 7.06 (br. d, J=8.3 Hz, IH, NH), 7.22-7.33 (m, 3H), 7.36-7.43 (m, 4H), 7.54 (t, J= 7.6 Hz, IH), 7.95 (d, J= 7.8 Hz, IH). \n1\nR NMR (500 MHz, DMSOd\n6\n): 0.92 (t, J= 7.3 Hz, 3H), 1.76 (m, 2H), 2.18 (s, 3H), 4.93 (q, J=8.3 Hz, IH), 7.21-7.41 (m, 6H), 7.59 (t, J=7.7 Hz, IH), 7.82 (t, J=7.2 Hz, IH), 8.17 (d, J=7.8 Hz, IH), 9.1 (br. d, J=8.4 Hz, IH, NH). \n\n\n\n\n\n\n\n\n\n\n2- [2-Oxo-l-((S)-l-phenyl-propylcarbamoyl)-butyl] -benzoic acid. A sealed mixture of 2- [((S)-I -phenyl-propylcarbamoyl)-methyl] -benzoic acid (409 mg, 1.38 mmol), propionic anhydride (10 ml) and 4-N,N-dimethylaminopyridine (15 mg) was heated under microwave irradiation at 150\n0\nC for 20 min and partitioned between IM HCl (50 ml) and ethyl acetate (100 ml). The organic layer was washed with sat. aq. NaHCO\n3\n (2x50 ml) and brine and concentrated in vacuo. To the obtained residue methanol (25 ml) tetrahydrofurane (25 ml) and 2M aq. NaOH (50 ml) was added and stirred at r.t. for 1 hour. The organic volatiles were removed in vacuo and the pH was adjusted to 1 with 3M aq. HCl. The crude title product (495 mg) was separated by extraction with ethyl acetate (150 ml) and used in the next step without further purification. \n1\nH NMR (500 MHz, DMSO-dό): a mixture of tautomers and diastereoisomers.\n\n\nThe following compound was obtained analogously:\n\n\n\n\n\n\n\n\n2 -Fluor O- 6-[2-oxo- 1-((S) - 1 -phenyl-propylcarbamoyl) -propyl] -benzoic acid. LC-MS (m/z) 358.4 (MH\n+\n); t\nR\n = 1.17. \n\n \n\n\n\n\n\n4-[l-Ethoxy-eth-(E)-ylidene] -8-fluoro-isochroman-l ,3-dione. A suspension of 8-fluoro-isochroman-l, 3-dione (7.125 g, 39.55 mmol) and triethyl orthoacetate (50.0 mL, 273 mmol) was heated to a gentle reflux during 5 min and reflux continued for 10 min. It was allowed to cool to r.t. with formation of crystalline product. It was cooled further on dry ice-EtOH bath, filtered, washed with cold ethanol (3x15 ml) and dried in vacuo (50\n0\nC, 30 min) to give 4.600 g of the title compound as a pink solid. The supernatant was evaporated and the purple oil residue was quenched with ethanol (20 ml) with formation of crystalline product, separated by filtration to give 693 mg more of the title product, total yield 53.5%. LC-MS (m/z) 251.2 (MH\n+\n), t\nR\n=1.05. \n1\nR NMR (500 MHz, DMSOd\n6\n): 1.41 (t, J=7.0 Hz, 3H, Me of Et), 2.68 (s, 3H, Me), 4.46 (q, J=7.0 Hz, 2H, CH\n2\n of Et), 7.21 (dd, J= 8.5 Hz, 10.7 Hz, IH, C(7)-H), 7.72 (dt, J(d)=5.9 Hz, J(t)=8.3 Hz, IH, C(6)-H), 8.08 (d, J=8.3 Hz, IH, C(5)-H). \n19\nF NMR (470.59 MHz): -110.2 ppm (dd, J= 5.9 Hz, 10.7 Hz). \n13\nC APT (125.76 MHz, DMSO-d\n6\n=39.89 ppm): 14.8 (CH\n3\n of Et), 17.97 (CH\n3\n), 66.79 (CH\n2\n), 99.71 (C4), 109.04 (d, J=7.9 Hz, C9), 114.04 (d, J=20.6 Hz, CH, C7), 123.43 (d, J=3.3 Hz, CH, C5), 136.28 (d, J=10.5 Hz, CH, C6), 137.43 (s, C3=O), 157.22 (d, J=4.3 Hz, Cl=O), 161.77 (C), 162.19 (d, J=262 Hz, C8), 178.45 (=C-OEt).\n\n\n\n\n\n\n\n\nS-Fluoro-S-methyl-l-oxazol-l-ylmethyl-lH-isoquinolin-l-one.\n\n\nA mixture of 2-fluoro-6-(2-oxo-propyl)-benzoic acid (500 mg, 2 mmol) and oxazol-2- yl-methylamine hydrochloride (715 mg) in toluene (14 mL) was heated under reflux overnight. The reaction mixture was allowed to cool diluted with 50 mL toluene, washed with 2x50 ml water and brine, dried (MgSO\n4\n) and concentrated to \n\n approximately to 10 mL. The title product was separated by filtration to give 271 mg of a colourless solid, yield 40%. LC-MS (m/z) 259.3 (MH\n+\n), t\nR\n=0.82. \n1\nR NMR (CDCl\n3\n, 500 MHz, TMS=O ppm): 2.47 (s, 3H, Me), 5.43 (s, 2H, CH\n2\n), 6.36 (s, IH, C4-H), 7.035 (overlapping dd, J=8.2 Hz, J=I 1.4 Hz, IH, C7-H), 7.055 (overlapping s, IH, oxazol), 7.17 (d, J=8 Hz, IH, C5-H), 7.52 (dt, J(t)=8 Hz, J(HF)=4.8 Hz, IH, C6- H), 7.6 (s (unres. d, KlHz), IH, oxazole).\n\n\n\n\n\n\n\n\n^BromoS-fluoroS-methyl-l-oxazol-l-ylmethyl-lH-isoquinolin-l-one. A mixture of 8-fluoro-3-methyl-2-oxazol-2-ylmethyl-2H-isoquinolin-l-one (271 mg, 1.05 mmol) and N-bromosuccinimide (192 mg, 1.08 mmol) in N,N- dimethylformamide (4.8 mL) was stirred at 50\n0\nC for 60 minutes. The reaction mixture was poured into diethyl ether (50 mL) and ethyl acetate (20 mL). A white solid precipitated, which was removed by filtration. The filtrate was washed with diluted brine (wateπsat. NaCl(aq.) = 1:1; 4 x 2OmL), dried over MgSO\n4\n and evaporated to give a 321 mg of a solid (yield 90%), which was used in the next step without further purification. LC-MS (m/z) 337.3&339.4 (MH\n+\n), t\nR\n=l .l. \n1\nR NMR (CDCl\n3\n, 500 MHz, TMS=O ppm): 2.75 (s, 3H, Me), 5.52 (s, 2H, CH\n2\n), 7.07 (s (unres. d, J<1 Hz), IH, oxazol), 7.16 (dd, J=8.1 Hz, J=I Ll Hz, IH, C7-H), 7.62 (s (unres. d, J<lHz), IH, oxazole), 7.66 (dt, J(t)=8.1 Hz, J(HF)=4.9 Hz, IH, C6-H), 7.78 (d, J=8.2 Hz, IH, C5- H).\n\n\n \n\n 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl-l -oxo-1, 2-dihydro-isoquinoline-4-carboxylic acid.\n\n\nA mixture of palladium acetate (21 mg, 0.095 mmol), 4,5-bis-diphenylphosphanyl- 9,9-dimethyl-9H-xanthene (=Xantphos, 55 mg, 0.095 mmol), sodium carbonate (303 mg, 2.86 mmol), 4-bromo-8-fluoro-3-methyl-2-oxazol-2-ylmethyl-2H-isoquinolin-l- one (321 mg, 0.952 mmol), and benzyl alcohol (0.297 mL, 2.87 mmol) in toluene (3 mL, 30 mmol) was stirred under an atmosphere of carbon monoxide (P=3 bar) at 110\n0\nC overnight. LC/MS indicated the formation of the title product and its benzyl ester (8-fluoro-3-methyl-2-oxazol-2-ylmethyl- 1 -oxo- 1 ,2-dihydro-isoquinoline-4- carboxylic acid benzyl ester) in ca. 1:1 ratio. The reaction mixture was dissolved in 5 ml of ethanol, filtered through a short plug of celite and evaporated. It was partitioned between ethyl acetate (50 ml) and 0.5M aq. NaOH (2x25 ml). The combined aqueous solution was acidified with cone. aq. HCl, extracted with ethyl acetate (40 ml), the organic phase was washed with brine, dried (MgSO\n4\n) and evaporated to give 105 mg of the title product, yield 36.5%. LC-MS (m/z) 303.3 (MH\n+\n), t\nR\n=0.57. \n\n\n\n\nCompounds of the invention\n\n\nExample 1\n\n\n \n\n Ia 3-Methyl-l-oxo-2-phenylamino-l,2-dihydro-isoquinoline-4-carboxylic acid ((S)-I- phenyl-propyl) -amide.\n\n\nA mixture of 4-acetyl-3 -((S)-I -phenyl-propylamino)-isochromen-l -one (60 mg) and phenylhydrazine (28 mg, 0.259 mmol) in acetonitrile (0.5 mL) was heated under microwave irradiation at 160\n0\nC for 15 min and evaporated. The title compound was separated by flash chromatography on SiO\n2\n (20 g, gradient heptane - ethyl acetate, the product came out with 50% ethyl acetate) to give 51 mg of a white solid, yield 66%. LC-MS (m/z) 412.2 (MH\n+\n); t\nR\n = 1.48. \n1\nU NMR (250 MHz, 70\n0\nC, DMSOd\n6\n): 0.97 (t, J=7.3 Hz, 3H, Me of Et), 1.75-1.94 (m, 3H, CH\n2\n of Et), 2.25 (s, 3H, Me), 4.98 (q (unresolved dt), J(d)=7 Hz, J(t)=8.1 Hz, IH, CH-NH), 6.68 (d, J=7.9Hz, 2H, PhN), 6.83 (t, J=7.3 Hz, IH, PhN), 7.14-7.51 (m, 9H), 7.69 (unres dt, J(t)=7.7 Hz, J(d)=l Hz, IH), 8.75 (s, IH, NHPh), 8.8 (br. d, J=8.3 Hz, NHCO).\n\n\nThe following compounds were obtained analogously from corresponding ketene- aminals of the general formula XXIII and appropriate amino compound of the general formula VI: \n\n \n\n\n\n\n\nIb 2-Benzyl-3-methyl-l-oxo-l,2-dihydro-isoquinoline-4-carboxylic acid ((S)-I- phenyl-propyl)-amide.\n\n\nLC-MS (m/z) 411.5 (MH\n+\n); t\nR\n = 1.49.\n\n\n\n\n\n\n\n\nIc 3-Methyl-l-oxo-2-(pyridin-2-ylamino)-l,2-dihydro-isoquinoline-4-carboxylic acid ((S) -1-ph enyl-propyl) -amide.\n\n\nThe title compound was isolated by preparative LC-MS. LC-MS (m/z) 413.5 (MH\n+\n); t\nR\n = 1.03.\n\n\n\n\n\n\n\n\nId 2-Furan-3-ylmethyl-3-methyl-l -oxo-1, 2-dihydro-isoquinoline-4-carboxylic acid ((S) -1-ph enyl-propyl) -amide. LC-MS (m/z) 401.1 (MH\n+\n); t\nR\n = 1.37. \n\n Example 2\n\n\nThe following compounds were prepared by condensation between appropriate keto- acids of the general formula XXV and corresponding amino compounds of the general formula VI under the same conditions described for example 1 :\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n*LC-MS method A was used unless noted otherwise. \n\n Example 3\n\n\n\n\n\n\n\n\nSa 2-(l-Ethyl-lH-imidazol-2-ylmethyl)-8-fluoro-3-methyl-l -oxo-1, 2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl] -amide. A mixture of 8-fluoro-2-(lH-imidazol-2-ylmethyl)-3-methyl-l-oxo-l,2-dihydro- isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl] -amide (2j, 15 mg, 0.033 mmol) and iodoethane (0.013 mL, 0.16 mmol) in N ,N- dimethylformamide (1 ml) was stirred at +100\n0\nC for 30 min and evaporated. The title product was isolated by flash chromatography (2 g SiO\n2\n, gradient heptane - ethyl acetate, the product came out with 60% ethyl acetate) to give 4 mg of the title compound, yield 20%. LC-MS (m/z) 477.2 (MH\n+\n); t\nR\n = 0.88. \n1\nR NMR (250 MHz, 70\n0\nC, DMSOd\n6\n, DMSO-d\n5\n=2.5 ppm): 0.42-0.67 (m, 4H, Cp), 1.21-1.35 (m, IH, Cp), 1.4 (t, J=7.2 Hz, 3H, Me of Et), 2.52 (overlapping s (with DMSOd\n5\n), 3H, Me), 4.19 (q, J=7.2 Hz, 2H, CH\n2\n of Et), 4.51 (t, J=8.8 Hz, IH, CHN), 5.31 (s, 2H, NCH\n2\nN), 6.78 (d, J=Ll Hz, IH, imidazole), 7.02-7.19 (overlapping m, 2H), 7.1 (overlapping d,\n\n\nJ=Ll Hz, imidazole), 7.24-7.34 (m, 2H), 7.41 (dt, J(d)=6 Hz, J(t)=8 Hz, IH, C6-H), 7.62 (dt, J(d)=5.1 Hz, J(t)=8.1 Hz, IH), 9.01 (br. d, J=8.3 Hz, NH). \n\n\n\n\n\n\n\n\n\n\n4a 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl-l-oxo-l,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3, 5 -difluoro-phenyl) -methyl] -amide. A mixture of 8-fluoro-3-methyl-2-oxazol-2-ylmethyl-l-oxo-l,2-dihydro-isoquinoline- 4-carboxylic acid (30 mg, 0.1 mmol), C-[(S)-C-cyclobutyl-C-(3,5-difiuoro-phenyl)]- methylamine hydrochloride (35 mg), N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride (=EDC, 28 mg, 0.15 mmol), 1-hydroxybenzotriazole (=HOBT, 20.1 mg, 0.149 mmol), N,N-dimethylformamide (1 mL) and triethylamine (0.021 mL, 0.15 mmol) was stirred on at r.t. overnight and evaporated. The residue was partitioned between ethyl acetate (2 ml) and 2xlmL of 0.5M aq. NaOH, 2xlmL of 0.5 M aq. HCl and ImL of brine. The organic layer was dried (MgSO\n4\n) and evaporated. The title compound was isolated by preparative LC/MS to give 14 mg of the title compound, 30% yield. LC-MS (m/z) 482.3 (MH\n+\n); t\nR\n = 1.34. The following compounds were obtained analogously:\n\n\n\n\n\n\n\n\n4b 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl-l-oxo-l,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(3 ,4-difluoro-phenyl)-methyl] -amide. \n\n LC-MS (m/z) 482.3 (MH+); t\nR\n = 1.33.\n\n\n\n\n\n\n\n\n4c 8-Fluoro-3-methyl-2-oxazol-2-ylmethyl-l-oxo-l,2-dihydro-isoquinoline-4- carboxylic acid [(S)-cyclobutyl-(4-fluoro-phenyl)-methyl] -amide. LC-MS (m/z) 464.5 (MH+); t\nR\n = 1.28. \n\n\n\n\nReagents used for the preparation of the compounds.\n\n\n\n\n\n\n\n\nAmines of the general formula VI used for the preparation of the compounds.\n\n\n\n\n\n\n\n\n\n\n\n\n\nExample 5 NK3 receptor binding assay\n\n\nMembranepreparation: BHK cells stably expressing the human NK3 receptor were seeded in harvesting plates in Dulbeccos MEM containing GlutaMax (862 mg/1), ImM sodium pyruvate, 10% fetal calf serum, 1% Pen/Strep, 1 mg/ml G418 and were grown at 34 \n0\nC in a humidified atmosphere containing 10% CO\n2\n. To increase receptor expression, 10 μM trichotatin A was added to the media 24 hours before harvest of the cells at a confiuency of app 90%. Prior to the harvesting, the cells were washed twice with PBS without Mg\n2+\n og Ca\n2+\n and subsequently scrapped of in 10 ml PBS pr harvesting plate. The cell suspension were centrifuged at 150OxG in three minutes before resuspension in 15 mM Tris-HCl pH 7,5 buffer containing 2 mM MgCl\n2\n; 0,3 mM EDTA and 1 mM EGTA (buffer A). The cell suspention was homogenised and subsequently centrifuged at 4000OxG in 30 minutes. The membrane-pellet was resuspended in buffer A containing 250 mM sucrose, alliquoted and stored at - 80 \n0\nC.\n\n\nAffinity assay description: The assay was performed as a SPA-based competition- binding assay in a 50 mM Tris pH 7.4 assay buffer containing 120 mM NaCl, 3 mM MnCl\n2\n, 40 μg/ml bacitracin, 2 μg/ml Chymostatin, 1 μg/ml Phosphoramidon and 4 μg/ml Leupeptin. App 0.02 nM \n125\nI-NKB was mixed with test compound before addition of 4 μg of the homogenised NK3 membrane preparation and 0,025 mg SPA beads in a total volume of 60 μl. The assay plate was subsequently under agitation \n\n incubated for 90 min at RT. The plate was centrifugated 10 minutes at 50OxG and counted in a topcounter 5 minuttes pr well.\n\n\nThe total binding, which comprised less than 5 % of added radioligand, was defined using assay buffer whereas the non-specific binding was defined in the presence of 1 μM osanetant. The non-specific binding constituted app 5 % of the total binding.\n\n\nData points were expressed in percent of the specific binding of \n125\nI-NKB and the IC\n50\n values (concentration causing 50 percent inhibition of \n125\nI-NKB specific binding) were determined by non-linear regression analysis using a sigmoidal variable slope curve fitting. The dissociation constant (K\n1\n) was calculated from the Cheng\n\n\nPrusoff equation (K\n1\n = IC\nSO\n/(1+(L/K\nD\n))), where the concentration of free radioligand L is approximated to the concentration of added \n125\nI-NKB in the assay (app 0,02 nM).\n\n\nThe K\nD\n Of \n125\nI-NKB was determined to be 0,7 nM from three independent saturation assays each performed with duplicate determinations. Bmax was app 2 pmol/mg. The compounds of the present invention generally have K\n1\n values of 1000 nM or less, such as 500 nM. Many compounds, in fact, have K\n1\n values below 100 nM and down to single digit values.\n\n\nExample 6 NK3 receptor efficacy and potency assay BHK cells stably expressing the human NK3 receptor were seeded in 100 μl media in black walled clear-base 96-wells plates (Costar) aiming at a confluency of 95-100% at the day of assay. The assay was performed according to the FLIPR Calcium 4 Assay kit (Molecular Devices). At the day of the assay, the media was removed and the cells were washed once with the HBSS buffer (Hanks BSS buffer, pH 7,4 containing 20 mM Hepes) before 100 μl of a solution of the calcium assay reagent dissolved in the HBSS buffer containing 2,5 mM probinicid was added to the cells. The plates were incubated for 60 min at 34\n0\nC, 10% CO\n2\n before use in the FLIPR for examination of fluorescence.\n\n\nOne representative plate was examined with a dose-response curve with NKB in a setup in which the wells initially were added HBSS buffer and 15 min later the various concentrations of NKB were added in order to determine the EC50 and ECss of \n\n NKB. All compound plates used for NKB were precoated with a 1% BSA solution and subsequently washed three times with H\n2\nO. NKB was diluted in HBSS buffer containing 0,1% BSA.\n\n\nFor efficacy and potency evaluation of compounds, these were diluted in HBSS buffer prior to test. For test of agonist activity, 25 μl of the diluted compound solution was added and the plate was analyzed for 5 minutes in the FLIPR. For test of antagonist activity, the plate was incubated for another 45 minutes before addition of 25 μl of the ECss concentration of NKB (app. 1 nM) as described above. The plates were subsequently analyzed for 5 minutes before the assay was terminated. The maximal increase in fluorescence over background following each ligand addition was determined. The IC50 value was calculated using sigmoidal variable slope curve fitting, and the cICso value was determined using the equation (cICso = IC5o/(l+(EC85/EC5o))), where ECss and EC50 for NKB were determined as described above.\n\n\nAll isoquinolinones of the present invention characterized in the NK3 receptor efficacy and potency assay have been antagonists without any observed significant agonist activity at relevant doses. The table below shows the affinity and potency for the NK3 receptor."
  },
  {
    "id": "WO2009047360A9",
    "text": "Il-21 antibodies AbstractIsolated human monoclonal antibodies and other proteins, which bind to human IL-21, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies, proteins, and other molecules. Claims\n\n\n\n\n\n\n1. An IL-21 binding peptide, which is capable of antagonizing the action of IL-21 on the human IL-21 receptor.\n\n\n\n\n\n\n2. An IL-21 binding peptide according to claim 1 , wherein the antagonism of said IL-21 binding peptide is determined by use of an assay as described in Example 3.\n\n\n\n\n\n\n3. An IL-21 binding peptide, which competes with an anti-IL-21 antibody, wherein said antibody has an amino acid sequence for V\nL\n as presented in SEQ ID No. 1 and an amino acid sequence for V\nH\n as presented in SEQ ID No. 2 for binding to IL-21.\n\n\n\n\n\n\n4. An IL-21 binding peptide according to claim 1 or claim 2, which competes with an anti-IL- 21 antibody, wherein said antibody has an amino acid sequence for V\nL\n as presented in SEQ ID No. 1 and an amino acid sequence for V\nH\n as presented in SEQ ID No. 2 for binding to IL- 21.\n\n\n\n\n\n\n5. An IL-21 binding peptide according to claim 3 or claim 4, wherein the competition is determined as described in Example 2.\n\n\n\n\n\n\n6. An IL-21 binding peptide, which IL-21 binding peptide specifically binds to i) a IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and/or ii) an IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10.\n\n\n\n\n\n\n7. An IL-21 binding peptide according to any of claims 1 to 5, which IL-21 binding peptide specifically binds to i) a IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and/or ii) an IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10.\n\n\n\n\n\n\n8. An IL-21 binding peptide according to any of claims 1 to 7, which peptide comprises the amino acid sequence of SEQ ID No. 8.  \n\n\n\n\n\n\n9. An IL-21 binding peptide according to any of claims 1 to 8, which peptide comprises the amino acid sequence of SEQ ID No. 5.\n\n\n\n\n\n\n10. An IL-21 binding peptide according to claim 8 or claim 9, which comprises the amino acid sequence of SEQ ID No. 2.\n\n\n\n\n\n\n11. An IL-21 binding peptide according to any of claims 8 to 10, which comprises the amino acid sequence of SEQ ID No. 1.\n\n\n\n\n\n\n12. An IL-21 binding peptide according to any of claims 1 to 7, which peptide comprises the amino acid sequence of SEQ ID No. 16.\n\n\n\n\n\n\n13. An IL-21 binding peptide according to any of claims 1 to 7 or claim 12, which peptide comprises the amino acid sequence of SEQ ID No. 13.\n\n\n\n\n\n\n14. An IL-21 binding peptide according to claim 12 or claim 13, which comprises the amino acid sequence of SEQ ID No. 10.\n\n\n\n\n\n\n15. An IL-21 binding peptide according to any of claims 12 to 14, which comprises the amino acid sequence of SEQ ID No. 9.\n\n\n\n\n\n\n16. An IL-21 binding peptide according to any of claims 8 to 15, which IL-21 binding peptide is an anti-IL-21 antibody.\n\n\n\n\n\n\n17. An IL-21 binding peptide according to any of claims 1 to 7, which peptide is an anti-IL-21 antibody.\n\n\n\n\n\n\n18. A nucleic acid encoding an IL-21 binding peptide according to any of claims 1 to 17.\n\n\n\n\n\n\n19. An isolated or recombinant eukaryotic or prokaryotic host cell which produces an IL-21 binding protein according to any of claims 1 to 17.\n\n\n\n\n\n\n20. An expression vector comprising a nucleic acid according to claim 18.  \n\n\n\n\n\n\n21. A pharmaceutical composition comprising an IL-21 binding peptide according to any of claims 1 to 17 and a pharmaceutically acceptable carrier.\n\n\n\n\n\n\n22. An IL-21 binding peptide according to any one of claims 1 to 17 for use in therapy.\n\n\n\n\n\n\n23. Use of an IL-21 binding peptide according to any one of claims 1 to 17 or a pharmaceutical composition according to claims 21 , for use in treating a disease or disorder, wherein said disease or disorder may be treatable by use of an IL-21 antagonist.\n\n\n\n\n\n\n24. Use of an IL-21 binding peptide according to any one of claims 1 to 17 for preparation of a pharmaceutical composition for treating a disease or disorder, wherein said disease or disorder may be treatable by use of an IL-21 antagonist.\n\n\n\n\n\n\n25. A method of treating a disease or disorder, wherein said disease or disorder may be treatable by use of an IL-21 antagonist., comprising administering to a subject an IL-21 binding peptide according to any of claims 1 to 17, a pharmaceutical composition according to claim 21 in an amount effective to treat or prevent the disease.\n\n\n\n\n\n\n26. An in vitro method for detecting the presence of IL-21 antigen in a sample, which method comprises a) contacting the sample with an IL-21 binding peptide according to any of claims 1 to 17 under conditions that allow for formation of a complex between the IL-21 binding peptide and IL-21 ; and b) detecting the formation of a complex.\n\n\n\n\n\n\n27. A kit for detecting the presence of IL-21 antigen in a sample comprising an IL-21 binding peptide according to any of claims 1 to 17.\n\n\n\n\n\n\n28. An in vivo method for detecting IL-21 antigen in an subject comprising a) administering an IL-21 binding peptide according to any of claims 1 to 17 under conditions that allow for formation of a complex between the IL-21 binding peptide and IL-21 ; and b) detecting the formed complex.\n\n\n\n\n\n\n29. An anti-idiotypic antibody binding to an antibody according to claim 17. Description\n\n\n\n\n IL-21 ANTIBODIES\n\n\nFIELD OF THE INVENTION\n\n\nThe field of the invention is generation of anti-IL-21 antibodies for use in treatment of inflammatory diseases, such as human autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis and inflammatory bowel disease, and other immunologically related diseases, such as graft transplant rejection.\n\n\nBACKGROUND OF THE INVENTION lnterleukin 21 (IL-21) is a 4-helical bundle cytokine produced by activated T cells and belonging to the family of cytokines signalling through the common γ-chain receptor in a complex with a private IL-21 R chain (Parrish-Novak et al., Nature 408, 57-63 (2000)).\n\n\nIL-21 and/or IL-21 R has been shown to be upregulated in several human autoimmune diseases, for instance rheumatoid arthritis, systemic sclerosis and inflammatory bowel disease. In addition, IL-21 -antagonism has been shown to be beneficial in animal models for rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease (see for instance Young et al., Arthritis & Rheumatism 56, 1152-1163 (2007), Herber et al., J. Immunol. 178, 3822-3830 (2007), and Fina et al., Gastroenterology 134, 1038-1048 (2008)). Recently has IL-21 been shown to be important for induction of the subset of autoreactive T cells known as T\nH\n17-cells. This subset of T cells is also potent producers of IL-21 suggesting an autocrine loop of enhancing auto-aggression in inflammatory diseases (Korn T., Nature 448, 484-487 (2007), Nurieva R., Nature 448, 480-483 (2007) and Zhou L., Nat. Immunol. 8(9), 967-974 (2007)). It is suggested that antibodies specific for IL-21 can be used for treatment of such conditions. IL21 antagonism has also been implicated in graft rejection (Baan CC, Transplantation 83(11 ), 1485-1492 (2007).\n\n\nWO2006057027 concerns antigenic epitopes of IL-21 and antibodies binding thereto. WO20071 11714 concerns anti-IL21 antibodies directed against specific epitopes\n\n\nSUMMARY OF THE INVENTION\n\n\nThere are many aspects and features of the invention described herein. As such, this Summary of the Invention provides only a non-limiting description of certain advantageous aspects of the invention. In one aspect, this invention provides antibodies specific for IL-21 having an amino acid sequence comprising one or more of the CDR regions of an anti-IL-21 antibody having \n\n an amino acid sequence for V\nL\n as presented in SEQ ID No. 1 and an amino acid sequence for V\nH\n as presented in SEQ ID No. 2 or of an anti-IL-21 antibody having an amino acid sequence for V\nL\n as presented in SEQ ID No. 9 and an amino acid sequence for V\nH\n as presented in SEQ ID No. 10 as well as anti-IL-21 antibodies and other IL-21 binding proteins competing with such antibodies for binding to IL-21.\n\n\nIn one aspect, this invention provides nucleic acids encoding such peptides, expression vectors comprising such nucleic acid as well as host cells expressing them.\n\n\nIn one aspect, this invention provides methods of treating diseases and disorders, wherein said disease or disorder may be treatable by use of an IL-21 antagonist, such as autoimmune and/or inflammatory disease, such as systemic lupus erythematosus, rheumatoid arthritis or inflammatory bowel disease, using, either alone or in combination with other agents, the IL-21 binding peptides of the invention.\n\n\nBRIEF DESCRIPTION OF THE FIGURES\n\n\nFigure 1. Binding analysis of NL-21-1 F1 and N-L21-1 F22 in a direct ELISA as described in Example 1.\n\n\nFigure 2: BAF-3(hlL21 R) cells were stimulated with serial dilutions of two different preparations of hlL-21. As controls, BAF-3(hlL-21 R) cells were left unstimulated or stimulated with an irrelevant cytokine. From the generated curves the IC\n50\n and maximal induced proliferative response was calculated (by GraphPad Prism software). Further information in Example 3.\n\n\nFigure 3: BAF-3(hlL21 R) cells were initially stimulated with 10\n\"9\nM hlL-21 and added serial dilutions of two different rabbit anti hlL-21 polyclonal antibodies. As negative control is shown cells with no stimulation by hlL-21. Further information in Example 3.\n\n\nBRIEF DESCRIPTION OF SEQUENCE LISTING SEQ ID No. 1 is the amino acid sequence of V\nL\n of the antibody 1 F1.\n\n\nSEQ ID No. 2 is the amino acid sequence of V\nH\n of the antibody 1 F1.\n\n\nSEQ ID No. 3 is the amino acid sequence of V\nL\n-CDR1 of the antibody 1 F1.\n\n\nSEQ ID No. 4 is the amino acid sequence of V\nL\n-CDR2 of the antibody 1 F1.\n\n\nSEQ ID No. 5 is the amino acid sequence of V\nL\n-CDR3 of the antibody 1 F1. SEQ ID No. 6 is the amino acid sequence of V\nH\n-CDR1 of the antibody 1 F1.\n\n\nSEQ ID No. 7 is the amino acid sequence of V\nH\n-CDR2 of the antibody 1 F1.\n\n\nSEQ ID No. 8 is the amino acid sequence of V\nH\n-CDR3 of the antibody 1 F1.\n\n\nSEQ ID No. 9 is the amino acid sequence of V\nL\n of the antibody 1 F22. \n\n SEQ ID No. 10 is the amino acid sequence of V\nH\n of the antibody 1 F22.\n\n\nSEQ ID No. 11 is the amino acid sequence of V\nL\n-CDR1 of the antibody 1 F22.\n\n\nSEQ ID No. 12 is the amino acid sequence of V\nL\n-CDR2 of the antibody 1 F22.\n\n\nSEQ ID No. 13 is the amino acid sequence of V\nL\n-CDR3 of the antibody 1 F22. SEQ ID No. 14 is the amino acid sequence of V\nH\n-CDR1 of the antibody 1 F22.\n\n\nSEQ ID No. 15 is the amino acid sequence of V\nH\n-CDR2 of the antibody 1 F22.\n\n\nSEQ ID No. 16 is the amino acid sequence of V\nH\n-CDR3 of the antibody 1 F22.\n\n\nSEQ ID No. 17 is the nucleic acid sequence encoding the V\nL\n of the antibody 1 F1.\n\n\nSEQ ID No. 18 is the nucleic acid sequence encoding the V\nH\n of the antibody 1 F1. SEQ ID No. 19 is the nucleic acid sequence encoding the V\nL\n of the antibody 1 F22.\n\n\nSEQ ID No. 20 is the nucleic acid sequence encoding the V\nH\n of the antibody 1 F22.\n\n\nSEQ ID No. 21 is the amino acid sequence of human IL-21.\n\n\nSEQ ID No. 22 is the amino acid sequence of C\nH\n for murine lgG2a.\n\n\nSEQ ID No. 23 is the amino acid sequence of C\nH\n for murine IgGL SEQ ID No. 24 is the amino acid sequence of C\nL\n for the murine IgGI and lgG2a.\n\n\nDETAILED DESCRIPTION OF THE INVENTION\n\n\nThe present invention provides IL-21 binding peptides (\"IL-21 BPs\"), which may be useful in the treatment, diagnosis and prevention of a variety of disorders, in which IL-21 antagonism is considered a potentially viable treatment. The terms \"IL-21\" and \"IL-21 antigen\" or \"antigen IL-21\" are used interchangeably herein, and is intended to describe an IL-21 polypeptide having an amino acid sequence as shown in SEQ ID No. 21.\n\n\nIn one embodiment, the present invention provides an IL-21 binding peptide, which is capable of antagonizing the action of IL-21 on the human IL-21 receptor. In one embodiment, such IL-21 binding peptide is capable of decreasing the activity of IL-21 on the human IL-21 receptor by at least 25%, such as at least 50%, for instance at least 75%, such as at least 90% In one embodiment, the antagonism of said IL-21 binding peptide is determined by use of an assay as described in Example 3.\n\n\nThe IL-21 BPs according to the present invention competes with an anti-IL21 antibody having a) a V\nL\n domain having the amino acid sequence of SEQ ID No. 1 and a V\nH\n domain having the amino acid sequence of SEQ ID No. 2 and/or b) an anti-IL21 antibody having a V\nL\n domain having the amino acid sequence of SEQ ID No. 9 and a V\nH\n domain having the amino acid sequence of SEQ ID No. 10 for binding to IL-21. The anti-IL21 antibody 1 F1 is a murine lgG2a antibody having a V\nL\n domain having the amino acid sequence of SEQ ID No. 1 and a V\nH\n domain having the amino acid sequence of SEQ ID No. \n\n 2. The C\nH\n region of murine lgG2a is presented in SEQ ID No. 22. The anti-IL21 antibody 1 F22 is a murine IgGI antibody having a V\nL\n domain having the amino acid sequence of SEQ ID No. 9 and a V\nH\n domain having the amino acid sequence of SEQ ID No. 10. The C\nH\n region of murine IgGI is presented in SEQ ID No. 23. The CL region of the two antibodies are identical and shown as SEQ ID No. 24. The generation of the anti-IL21 antibodies 1 F1 and 1 F22 are described in the examples.\n\n\nAntibodies interact with target antigens primarily through amino acid residues that are located in the six heavy and light chain complementarity determining regions (CDRs). For this reason, the amino acid sequences within CDRs are more diverse between individual antibodies than sequences outside of CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of specific naturally occurring antibodies by constructing expression vectors that include CDR sequences from the specific naturally occurring antibody grafted onto framework sequences from a different antibody with different properties (see for instance Riechmann, L. et al., Nature 332, 323-327 (1998), Jones, P. et al., Nature 321, 522-525 (1986) and Queen, C. et al., PNAS USA 86, 10029-10033 (1989)).\n\n\nSince it is well known in the art that antibody heavy and light chain CDR3 domains play a particularly important role in the binding specificity/affinity of an antibody for an antigen (Barbas et al. J. Am. Chem. Soc. V\\6, 2161-2162 (1994); Barbas et al. PNAS USA 92, 2529- 2533 (1995), Ditzel et al., J. of Immunol. 157, 739-749 (1996) and Park et al., Nature\n\n\nBiotech. 18, 194-198 (2000)), the recombinant antibodies of the present invention prepared as set forth above may comprise the heavy and light chain CDR3s of 1 F1 and 1 F22. Antibodies of the present invention may further comprise the CDR2s of 1 F1 and 1 F22, and the antibodies of the present invention may further comprise the CDR1 s of 1 F1 and 1 F22.\n\n\nFor sake of convenience, a number of terms used in the description of this invention are provided here (others are provded in other portions of the specification). Unless otherwise stated or clearly indicated by context, such terms described in the plural are intended to encompass the singular and vice versa. The term \"peptide\" with respect to both I L-21 -binding peptides and non-IL-21 peptides described herein includes any suitable peptide and may be used synonymously with the terms polypeptide and protein, unless otherwise stated or contradicted by context; provided that the reader recognize that each type of respective amino acid polymer- containing molecules may be associated with significant differences and thereby form individual embodiments of the present invention (for example, a peptide such as an antibody, \n\n which is composed of multiple polypeptide chains, is significantly different from, for example, a single chain antibody, a peptide immunoadhesin, or single chain immunogenic peptide). Therefore, the term peptide herein should generally be understood as referring to any suitable peptide of any suitable size and composition (with respect to the number of amino acids and number of associated chains in a protein molecule). Moreover, peptides in the context of the inventive methods and compositions described herein may comprise non- naturally occurring and/or non-L amino acid residues, unless otherwise stated or contradicted by context.\n\n\nAs will be discussed further herein, unless otherwise stated or contradicted by context, the term peptide (and if discussed as individual embodiments of the term(s) polypeptide and/or protein) also encompasses derivatized peptide molecules. Briefly, in the context of the present invention, a derivative is a peptide in which one or more of the amino acid residues of the peptide have been chemically modified (for instance by alkylation, acylation, ester formation, or amide formation) and/or associated with one or more non- amino acid organic and/or inorganic atomic or molecular substituents (for instance a polyethylene glycol (PEG) group, a lipophilic substituent (which optionally may be linked to the amino acid sequence of the peptide by a spacer residue or group such as β-alanine, γ-aminobutyric acid (GABA), L/D-glutamic acid, succinic acid, and the like), a fluorophore, biotin, a radionuclide, etc.); a peptide may also or alternatively comprise non-essential, non- naturally occurring, and/or non-L amino acid residues, unless otherwise stated or contradicted by context. It should be recognized that derivatives may, in and of themselves, be considered independent features of the present invention and inclusion of such molecules within the meaning of peptide is done for the sake of convenience in describing the present invention rather than to imply any sort of equivalence between \"naked\" (underivatized) peptides and derivatives. Non-limiting examples of unusual amino acid residues that can be incorporated into a peptide include, for instance, 2-aminoadipic acid, 3-aminoadipic acid, β-alanine, β-aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diaminobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allohydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, alloisoleucine, N-methylglycine, N-methylisoleucine, 6-N-methyllysine, N-methylvaline, norvaline, norleucine, ornithine, and statine halogenated amino acids.\n\n\n\"Antigen binding peptides\" refers to any peptide that specifically binds to a portion of a given antigen under cellular and/or physiological conditions for an amount of time sufficient \n\n to induce, promote, enhance, and/or otherwise modulate a physiological effect associated with the antigen; to allow detection by ELISA, Western blot, or other similarly suitable protein binding technique described herein and/or known in the art; and/or to otherwise be detectably bound thereto after a relevant period of time (for instance at least about 15 minutes, at least about 30 minutes, at least about 45 minutes, at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 12 hours, about 1-24 hours, about 1 -36 hours, about 1 -48 hours, about 1-72 hours, about one week, or longer).\n\n\nA \"IL-21 binding peptide\", or \"IL-21 BP\", is an antigen binding peptide that specifically binds to the antigen IL-21.\n\n\nThe term \"immunoglobulin\" refers to a molecule belonging to a class of structurally related glycoproteins consisting of two pairs of polypeptide chains, one pair of light (L) low molecular weight chains and one pair of heavy (H) chains, all four inter-connected by disulfide bonds. The structure of immunoglobulins has been well characterized. See for instance Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N. Y. (1989)). Briefly, each heavy chain typically is comprised of a heavy chain variable region (abbreviated herein as V\nH\n) and a heavy chain constant region. The heavy chain constant region typically is comprised of three domains, C\nH\n1 , C\nH\n2, and C\nH\n3. Each light chain typically is comprised of a light chain variable region (abbreviated herein as V\nL\n) and a light chain constant region. The light chain constant region typically is comprised of one domain, C\nL\n. The V\nH\n and V\nL\n regions may be further subdivided into regions of hypervariability (or hypervariable regions which may be hypervariable in sequence and/or form of structurally defined loops), also termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Each V\nH\n and V\nL\n is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. MoI. Biol. 196, 901-917 (1987)). Typically, the numbering of amino acid residues in this region is performed by the method described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991 ) (phrases such as variable domain residue numbering \"as in Kabat\" or \"according to Kabat\" herein refer to this numbering system for heavy chain variable domains or light chain variable domains). Using this numbering system, the actual linear amino acid sequence of a peptide may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino \n\n acid insert (residue 52a according to Kabat) after residue 52 of V\nH\n CDR2 and inserted residues (for instance residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a \"standard\" Kabat numbered sequence.\n\n\nThe term \"antibody\" (abbreviated \"Ab\") in the context of the present invention refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or a derivative of either thereof, which has the ability to specifically bind to an antigen under typical physiological conditions for significant periods of time such as at least about 30 minutes, at least about 45 minutes, at least about one hour, at least about two hours, at least about four hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or more days, etc., or any other relevant functionally- defined period (such as a time sufficient to induce, promote, enhance, and/or modulate a physiological response associated with antibody binding to the antigen). The variable regions of the heavy and light chains of the immunoglobulin molecule contain a binding domain that interacts with an antigen. The constant regions of the antibodies (Abs) may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (such as effector cells) and the first component (CIq) of the classical complement system. An anti-IL-21 antibody may be a bispecific antibody, diabody, or similar molecule\n\n\n(see for instance PNAS USA 90(14), 6444-8 (1993) for a description of diabodies). Indeed, bispecific antibodies, diabodies, and the like, provided by the present invention may bind any suitable target in addition to a portion of IL-21.\n\n\nAs indicated above, the term antibody herein, unless otherwise stated or clearly contradicted by context, includes fragments of any suitable full lenght antibody, which fragment retains the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody may be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term \"antibody\" include (i) a Fab fragment, a monovalent fragment consisting of the V\nL\n, V\nH\n, C\nL\n and C\nH\n1 domains; (ii) F(ab)\n2\n and F(ab')\n2\n fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting or consisting essentially of the V\nH\n and C\nH\n1 domains; (iv) a Fv fragment consisting or consisting essentially of the V\nL\n and V\nH\n domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341 , 544-546 (1989)), which consists or consists essentially of a V\nH\n domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv \n\n fragment, V\nL\n and V\nH\n, are coded for by separate genes, they may be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V\nL\n and V\nH\n regions pair to form monovalent molecules (known as single chain antibodies or single chain Fv (scFv), see for instance Bird et al., Science 242, 423-426 (1988) and Huston et al., PNAS USA 85, 5879-5883 (1988)). Such single chain antibodies are also encompassed within the term antibody unless otherwise noted or clearly indicated by context. As already noted, other forms of single chain antibodies, such as diabodies are included within the term antibody. Although such fragments are generally included within the meaning of antibody, they collectively and each independently are unique features of the present invention, exhibiting different biological properties and utility. These and other useful antibody fragments in the context of the present invention are discussed further herein.\n\n\nIt also should be understood that the term antibody also generally includes antibodies that can be classified by various other structural properties, such as polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides, such as chimeric antibodies and humanized antibodies, anti-idiotypic (anti-Id) antibodies to antibodies, and antibody fragments retaining the ability to specifically bind to the antigen (antigen-binding fragments) provided by any known technique, such as enzymatic cleavage, peptide synthesis, and recombinant techniques. Unless otherwise stated or clearly contradicted by context, an antibody in the context of the invention can possess any isotype. An \"anti-IL-21 antibody\" is an antibody as described above, which binds specifically to the antigen IL-21.\n\n\nThe term \"epitope\" means a protein determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. The epitope may comprise amino acid residues directly involved in the binding (also called immunodominant component of the epitope) and other amino acid residues, which are not directly involved in the binding, such as amino acid residues which are effectively blocked by the specifically antigen binding peptide (in other words, the amino acid residue is within the footprint of the specifically antigen binding peptide).\n\n\nThe term \"bispecific molecule\" is intended to include any agent, such as a protein, peptide, or protein or peptide complex, which has two different binding specificities. For example, the molecule may bind to, or interact with, (a) a cell surface antigen and (b) an Fc \n\n receptor on the surface of an effector cell. The term \"multispecific molecule\" is intended to include any agent, for instance a protein, peptide, or protein or peptide complex, which has more than two different binding specificities. For example, the molecule may bind to, or interact with, (a) a cell surface antigen, (b) an Fc receptor on the surface of an effector cell, and (c) at least one other component. Accordingly, the present invention includes, but is not limited to, bispecific, trispecific, tetraspecific, and other multispecific molecules which are directed to IL-21 , and to other cell surface antigens or targets, such as Fc receptors on effector cells.\n\n\nThe term \"bispecific antibodies\" is intended to include any anti-IL-21 antibody, which is a bispecific molecule. The term \"bispecific antibodies\" also includes diabodies. Diabodies are bivalent, bispecific antibodies in which the V\nH\n and V\nL\n domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see for instance Holliger, P. et al., PNAS USA 90, 6444-6448 (1993), Poljak, R.J. et al., Structure 2, 1121-1123 (1994)). As used herein, the term \"effector cell\" refers to an immune cell which is involved in the effector phase of an immune response, as opposed to the cognitive and activation phases of an immune response. Exemplary immune cells include cells of a myeloid or lymphoid origin, for instance lymphocytes (such as B cells and T cells including cytolytic T cells (CTLs)), killer cells, natural killer cells, macrophages, monocytes, eosinophils, neutronphils, polymorphonuclear cells, granulocytes, mast cells, and basophils. Some effector cells express specific Fc receptors (FcR) and carry out specific immune functions. In some embodiments, an effector cell is capable of inducing antibody-dependent cellular cytotoxicity (ADCC), such as a neutrophil capable of inducing ADCC. For example, monocytes, macrophages, which express FcR are involved in specific killing of target cells and presenting antigens to other components of the immune system, or binding to cells that present antigens. In some embodiments, an effector cell may phagocytose a target antigen, target cell, or microorganism. The expression of a particular FcR on an effector cell may be regulated by humoral factors such as cytokines. For example, expression of FcγRI has been found to be up-regulated by interferon Y (IFN-γ) and/or G-CSF. This enhanced expression increases the cytotoxic activity of FcγRI-bearing cells against targets. An effector cell can phagocytose or lyse a target antigen or a target cell.\n\n\nThe term \"human antibody\", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the present invention may include amino acid residues not encoded by \n\n human germline immunoglobulin sequences (for instance mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term \"human antibody\", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.\n\n\nAs used herein, a human antibody is \"derived from\" a particular germline sequence if the antibody is obtained from a system using human immunoglobulin sequences, for instance by immunizing a transgenic mouse carrying human immunoglobulin genes or by screening a human immunoglobulin gene library, and wherein the selected human antibody is at least 90%, such as at least 95%, for instance at least 96%, such as at least 97%, for instance at least 98%, or such as at least 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, a human antibody derived from a particular human germline sequence will display no more than 10 amino acid differences, such as no more than 5, for instance no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene.\n\n\nThe term \"chimeric antibody\" refers to an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies. The term \"chimeric antibody\" includes monovalent, divalent, or polyvalent antibodies. A monovalent chimeric antibody is a dimer (HL)) formed by a chimeric H chain associated through disulfide bridges with a chimeric L chain. A divalent chimeric antibody is tetramer (H\n2\nL\n2\n) formed by two HL dimers associated through at least one disulfide bridge. A polyvalent chimeric antibody may also be produced, for example, by employing a CH region that aggregates (for instance from an IgM H chain, or μ chain). Typically, a chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see for instance US 4,816,567 and Morrison et al., PNAS USA 81., 6851-6855 (1984)). Chimeric antibodies are produced by recombinant processes well known in the art (see for instance Cabilly et al., PNAS USA 8_1, 3273-3277 (1984), Morrison et al., PNAS USA 8J., 6851-6855 (1984), Boulianne et al., Nature 312, 643-646 (1984), EP125023, Neuberger et al., Nature 314, 268-270 (1985), EP171496, EP173494, WO86/01533, EP184187, Sahagan et al., J. Immunol. 137, 1066-1074 (1986), WO87/02671 , Liu et al., PNAS USA 84. 3439-3443 (1987), Sun et al., \n\n PNAS USA 84, 214-218 (1987), Better et al., Science 240, 1041 -1043 (1988) and Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988)).\n\n\nA \"humanized antibody\" is an antibody that is derived from a non-human species, in which certain amino acids in the framework and constant domains of the heavy and light chains have been mutated so as to avoid or abrogate an immune response in humans. Humanized forms of non-human (for instance murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. A humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 32J., 522-525 (1986), Riechmann et al., Nature 332. 323-329 (1988) and Presta, Curr. Op. Struct. Biol. 2, 593-596 (1992).\n\n\nThe terms \"monoclonal antibody\" or \"monoclonal antibody composition\" as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Accordingly, the term \"human monoclonal antibody\" refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline immunoglobulin sequences. The human monoclonal antibodies may be generated by a hybridoma which includes a B cell obtained from a transgenic or transchromosomal nonhuman animal, such as a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene, fused to an immortalized cell.\n\n\nThe term \"recombinant human antibody\", as used herein, includes all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as \n\n (a) antibodies isolated from an animal (such as a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described further elsewhere herein), (b) antibodies isolated from a host cell transformed to express the antibody, such as from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial human antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies may be subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the V\nH\n and V\nL\n regions of the recombinant antibodies are sequences that, while derived from and related to human germline V\nH\n and V\nL\n sequences, may not naturally exist within the human antibody germline repertoire in vivo. As used herein, a \"heterologous antibody\" is defined in relation to the transgenic non-human organism producing such an antibody. This term refers to an antibody having an amino acid sequence corresponding to that found in an organism not consisting of the non- human animal, and generally from a species other than that of the transgenic non-human animal. An \"isolated antibody,\" as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (for instance an isolated antibody that specifically binds to IL-21 is substantially free of antibodies that specifically bind antigens other than IL-21). An isolated antibody that specifically binds to an epitope, isoform or variant of human IL-21 may, however, have cross-reactivity to other related antigens, for instance from other species (such as IL-21 species homologs).\n\n\nMoreover, an isolated antibody may be substantially free of other cellular material and/or chemicals. In one embodiment of the present invention, a combination of \"isolated\" monoclonal antibodies having different specificities are combined in a well defined composition. As used herein, \"specific binding\" refers to the binding of an antigen binding peptide, such as an antibody, to a predetermined antigen. Typically, the antigen binding peptide, such as an antibody, binds with an affinity corresponding to a K\nD\n of about 10\n'7\n M or less, such as about 10\n'8\n M or less, such as about 10\n'9\n M or less, about 10\n'10\n M or less, or about 10\n'11\n M or even less when determined by for instance surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using the antigen as the ligand and the antibody as the analyte, \n\n and binds to the predetermined antigen with an affinity corresponding to a K\nD\n that is at least ten-fold lower, such as at least 100 fold lower, for instance at least 1000 fold lower, such as at least 10,000 fold lower, for instance at least 100,000 fold lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen. The amount with which the affinity is lower is dependent on the K\nD\n of the antigen binding peptide, so that when the K\n0\n of the antigen binding peptide is very low (that is, the antigen binding peptide is highly specific), then the amount with which the affinity for the antigen is lower than the affinity for a non-specific antigen may be at least 10,000 fold. The phrases \"an antigen binding peptide recognizing an antigen\" and \"an antigen binding peptide specific for an antigen\" are used interchangeably herein with the term \"an antigen binding peptide which binds specifically to an antigen\". Likewise, the phrases \"an antibody recognizing an antigen\" and \"an antibody specific for an antigen\" are used interchangeably herein with the term \"an antibody which binds specifically to an antigen\"\n\n\nThe term \"k\nd\n\" (sec \n1\n), as used herein, refers to the dissociation equilibrium rate constant of a particular antibody-antigen interaction. Said value is also referred to as the k\noff\n value.\n\n\nThe term \"k\na\n\" (M\n'1\n x sec\n'1\n), as used herein, refers to the association equilibrium rate constant of a particular antibody-antigen interaction.\n\n\nThe term \" K\n0\n\" (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction.\n\n\nThe term \"K\nA\n\" (M\n'1\n), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction and is obtained by dividing the k\na\n by the k\nd\n.\n\n\nAs used herein, \"isotype\" refers to the immunoglobulin class (for instance IgGI , lgG2, lgG3, lgG4, IgD, IgA, IgE, or IgM) that is encoded by heavy chain constant region genes.\n\n\nAs used herein, \"isotype switching\" refers to the phenomenon by which the class, or isotype, of an antibody changes from one immunoglobulin class to one of the other immunoglobulin classes.\n\n\nAs used herein, \"nonswitched isotype\" refers to the isotypic class of heavy chain that is produced when no isotype switching has taken place; the CH gene encoding the nonswitched isotype is typically the first CH gene immediately downstream from the functionally rearranged VDJ gene. Isotype switching has been classified as classical or non- classical isotype switching. Classical isotype switching occurs by recombination events which involve at least one switch sequence region in the transgene. Non-classical isotype switching may occur by, for example, homologous recombination between human σμ and human ∑μ \n\n (δ-associated deletion). Alternative non-classical switching mechanisms, such as intertransgene and/or interchromosomal recombination, among others, may occur and effectuate isotype switching.\n\n\nAs used herein, the term \"switch sequence\" refers to those DNA sequences responsible for switch recombination. A \"switch donor\" sequence, typically a μ switch region, will be 5' (i.e., upstream) of the construct region to be deleted during the switch recombination. The \"switch acceptor\" region will be between the construct region to be deleted and the replacement constant region (for instance Y, ε, etc.). As there is no specific site where recombination always occurs, the final gene sequence will typically not be predictable from the construct.\n\n\nAs used herein, \"glycosylation pattern\" is defined as the pattern of carbohydrate units that are covalently attached to a protein, more specifically to an immunoglobulin (antibody) protein. A glycosylation pattern of a heterologous antibody may be characterized as being substantially similar to glycosylation patterns which occur naturally on antibodies produced by the species of the non-human transgenic animal, when one of ordinary skill in the art would recognize the glycosylation pattern of the heterologous antibody as being more similar to said pattern of glycosylation in the species of the non-human transgenic animal than to the species from which the CH genes of the transgene were derived.\n\n\nThe term \"naturally-occurring\" as used herein as applied to an object refers to the fact that an object may be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that may be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.\n\n\nThe term \"rearranged\" as used herein refers to a configuration of a heavy chain or light chain immunoglobulin locus wherein a V segment is positioned immediately adjacent to a D-J or J segment in a conformation encoding essentially a complete V\nH\n or V\nL\n domain, respectively. A rearranged immunoglobulin (antibody) gene locus may be identified by comparison to germline DNA; a rearranged locus will have at least one recombined heptamer/nonamer homology element. The term \"unrearranged\" or \"germline configuration\" as used herein in reference to a\n\n\nV segment refers to the configuration wherein the V segment is not recombined so as to be immediately adjacent to a D or J segment.\n\n\nThe term \"nucleic acid molecule\", as used herein, is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double- stranded, but is preferably double-stranded DNA. The nucleic acids may be present in whole \n\n cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is \"isolated\" or \"rendered substantially pure\" when purified away from other cellular components or other contaminants, such as other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCI banding, column chromatography, agarose gel electrophoresis and others well known in the art. See, F. Ausubel et al., ed.\n\n\nCurrent Protocols in Molecular Biology, Greene Publishing and Wiley InterScience New York (1987).\n\n\nA nucleic acid is \"operably linked\" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. With respect to transcription of regulatory sequences, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. For switch sequences, operably linked indicates that the sequences are capable of effecting switch recombination. As used herein, the term \"inhibits growth\" (for instance when referring to cells) is intended to include any measurable decrease in the cell growth when contacted with an IL-21 BP, such as an anti-IL-21 antibody, as compared to the growth of the same cells not in contact with an IL-21 BP, such as an anti-IL-21 antibody, for instance an inhibition of growth of a cell culture by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%.\n\n\nAs used herein, the terms \"inhibits binding\" and \"blocks binding\" (for instance when referring to inhibition/blocking of binding of an IL-21 binding partner to IL-21) are used interchangeably and encompass both partial and complete inhibition/blocking. The inhibition/blocking of binding of an IL-21 binding partner to IL-21 may reduce or alter the normal level or type of cell signaling that occurs when an IL-21 binding partner binds to IL-21 without inhibition or blocking. Inhibition and blocking are also intended to include any measurable decrease in the binding affinity of an IL-21 binding partner to IL-21 when in contact with an IL-21 BP, such as an anti-IL-21 antibody, as compared to the ligand not in contact with an IL-21 BP, such as an anti-IL-21 antibody, for instance a blocking of binding of an IL-21 binding partner to IL-21 by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%.\n\n\nThe term \"vector,\" as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a \"plasmid\", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA \n\n segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (for instance bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (such as non-episomal mammalian vectors) may be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.\n\n\nMoreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as \"recombinant expression vectors\" (or simply, \"expression vectors\"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, \"plasmid\" and \"vector\" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the present invention is intended to include such other forms of expression vectors, such as viral vectors (such as replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.\n\n\nThe term \"recombinant host cell\" (or simply \"host cell\"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term \"host cell\" as used herein. Recombinant host cells include, for example, transfectomas, such as CHO cells, NS/0 cells, and lymphocytic cells.\n\n\nThe term \"regulatory sequence\" is intended to include promoters, enhancers and other expression control elements (for instance polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology. Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. Examples of regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV), Simian Virus 40 (SV40), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)) and polyoma. Alternatively, nonviral regulatory sequences may be used, such as the ubiquitin promoter or β-globin promoter. \n\n As used herein, the term \"subject\" includes any human or non-human animal. The term \"non-human animal\" includes all vertebrates, for instance mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.\n\n\nThe various forms of the term \"transfection\" are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection, lipofectin transfection and the like.\n\n\nThe term \"transfectoma\", as used herein, includes recombinant eukaryotic host cells expressing the antibody, such as CHO cells, NS/0 cells, HEK293 cells, plant cells, or fungi, including yeast cells.\n\n\nThe terms \"transgenic, non-human animal\" refers to a non-human animal having a genome comprising one or more human heavy and/or light chain transgenes or transchromosomes (either integrated or non-integrated into the animal's natural genomic DNA) and which is capable of expressing fully human antibodies. For example, a transgenic mouse can have a human light chain transgene and either a human heavy chain transgene or human heavy chain transchromosome, such that the mouse produces human anti-IL-21 antibodies when immunized with IL-21 antigen. The human heavy chain transgene may be integrated into the chromosomal DNA of the mouse, as is the case for transgenic mice, for instance HuMAb mice, such as HCo7 or HCo12 mice, or the human heavy chain transgene may be maintained extrachromosomally, as is the case for transchromosomal KM mice as described in WO02/43478. Such transgenic and transchromosomal mice (collectively referred to herein as \"transgenic mice\") are capable of producing multiple isotypes of human monoclonal antibodies to a given antigen (such as IgG, IgA, IgM, IgD and/or IgE) by undergoing V-D-J recombination and isotype switching. Transgenic, nonhuman animal can also be used for production of antibodies against a specific antigen by introducing genes encoding such specific antibody, for example by operatively linking the genes to a gene which is expressed in the milk of the animal.\n\n\nThe term \"specificity\" herein refers to the ability of an IL-21 binding peptide, such as an anti-IL-21 antibody, to recognize an epitope within IL-21 , while only having little or no detectable reactivity with other portions of IL-21 (including other epitopes that are bound by other IL-21 BPs, such as anti-IL-21 antibodies). Specificity may be relatively determined by competition assays as described herein. Specificity can more particularly be determined by any of the epitope identification/characterization techniques described herein or their equivalents known in the art. \n\n An antibody with specificity for a particular antigenic determinant may nonetheless cross-react with other biomolecules that may be present in some biological context with IL-21. More typically, an IL-21 BP, such as an anti-IL-21 antibody, may cross-react with IL-21 homologues from other species. In either or both contexts, typically such cross-reactive antibodies are selective for human IL-21 with respect to relevant structure and/or environmental factors.\n\n\nThe term \"selectivity\" herein refers to the preferential binding of an IL-21 BP, such as an anti-IL-21 antibody, for a particular region, target, or peptide; typically a region or epitope in IL-21 , as opposed to one or more other biological molecules, structures, cells, tissues, etc. In one embodiment, an IL-21 BP, such as an anti-IL-21 antibody, of the present invention is selective for a portion of IL-21 in the context of colon cancer cells (i.e., the anti-IL-21 antibody will selectively bind to the portion of IL-21 over other components of a colon cancer cell). The IL-21 BPs of the present invention are typically used in and provided in an at least \"substantially isolated form\". A \"substantially isolated\" molecule is a molecule that is the predominant species in the composition wherein it is found with respect to the class of molecules to which it belongs (i.e., it makes up at least about 50% of the type of molecule in the composition and typically will make up at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more of the species of molecule, e.g., peptide, in the composition (e.g., the composition will exhibit at least about 98%, 98%, or 99% homogeneity for the IL-21 BP in the context of all present peptide species)).\n\n\nAn isolated molecule refers to a molecule that is not associated with significant levels (such as more than about 1%, more than about 2%, more than about 3%, or more than about 5%) of any extraneous and undesirable physiological factors, such as non-IL-21 binding biomolecules (or IL-21 binding molecules that may interfere with the binding and/or activity of an IL-21 BP of the present invention) contained within a cell or animal in which the IL-21 BP is produced. An isolated molecule also refers to any molecule that has passed through such a stage of purity due to human intervention (whether automatic, manual, or both). In many of the various compositions provided by the present invention, such as in a composition comprising one or more pharmaceutically acceptable carriers, an IL-21 BP may be present in relatively small amounts in terms of numbers of total molecular species in the composition (for instance in the case of a composition comprising a large amount of a pharmaceutically acceptable carrier, stabilizer, and/or preservative). In some cases additional peptides, such as BSA, may be included in such a composition with a previously purified IL-21 BP. However, provided that such additional constituents of the composition are \n\n acceptable for the intended application of the IL-21 BP, such a composition can still be described as comprising an isolated IL-21 BP.\n\n\nThe IL-21 BPs of the present invention are typically \"substantially free\" of other IL-21 BPs, such as IL-21 BPs having different antigenic specificities. However, the present invention does also provide a composition comprising a number of IL-21 BPs with different specificities and characteristics (for instance the present invention provides a \"cocktail\" of IL-21 BPs having different specificity and/or selectivity characteristics).\n\n\n\"Treatment\" means the administration of an effective amount of a therapeutically active compound of the present invention with the purpose of easing, ameliorating, or eradicating (curing) symptoms or disease states.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n region consisting essentially of the sequence of SEQ ID No. 1.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n region consisting essentially of the sequence of SEQ ID No. 2. In one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n region consisting essentially of the sequence of 1 and aV\nH\n region consisting essentially of the sequence of SEQ ID No. 2.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR1 consisting essentially of the sequence of SEQ ID No. 3. In one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n \n\n\nCDR2 consisting essentially of the sequence of SEQ ID No. 4.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR3 consisting essentially of the sequence of SEQ ID No. 5.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n CDR1 consisting essentially of the sequence of SEQ ID No. 6.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n CDR2 consisting essentially of the sequence of SEQ ID No. 7.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n CDR3 consisting essentially of the sequence of SEQ ID No. 8. In one embodiment, the present invention provides an IL-21 BP comprising V\nL\n CDRs\n\n\n(V\nL\n CDR1 , CDR2, and CDR3) consisting essentially of SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 5, respectively.\n\n\nIn one embodiment, the present invention provides an IL-21 BP that comprises V\nH\n CDRs (V\nH\n CDR1 , CDR2, and CDR3) consisting essentially of SEQ ID No. 6, SEQ ID No. 7 and SEQ ID No. 8, respectively. \n\n In one embodiment, the present invention provides an IL-21 BP that comprises\n\n\n(a) three V\nL\n CDRs, which independently consist essentially of SEQ ID No. 3, SEQ\n\n\nID No. 4 and SEQ ID No. 5 in close proximity to one another (e.g., near the spacing of V\nL\n CDRS in a wild-type anti-IL-21 antibody) in the IL-21 BP and (b) three V\nH\n CDRs which independently consist essentially of SEQ ID No. 6, SEQ ID\n\n\nNo. 7 and SEQ ID No. 8 in close proximity to one another (e.g., near the spacing of\n\n\nV\nH\n CDRS in a wild-type anti-IL-21 antibody) in the IL-21 BP.\n\n\nIn a further embodiment, the present invention provides an IL-21 BP that comprises a flexible linker positioned between the V\nL\n region and V\nH\n region of the IL-21 BP. In another further embodiment, the present invention provides an IL-21 BP, wherein the V\nL\n and V\nH\n regions are presented on separate chains in the context of an immunoglobulin fold protein and oriented such that the V\nL\n CDR1 , CDR2, CDR3 and V\nH\n CDR1 , CDR2, and CDR3 cooperatively associate to contribute in selectively and/or specifically bind an antigenic determinant on IL-21. In another further embodiment, the present invention provides an IL-21 BP that comprises two sets of variable domains (sets of associated V\nL\n and V\nH\n domains on associated separate chains), such that the IL-21 BP comprises two identical antigenic determinant binding sites.\n\n\nAny of such IL-21 BPs are expected to, at least in part, have similar epitope specificity, selectivity, and other characteristics as an antibody having a V\nL\n region comprising the sequence of SEQ ID No. 1 and a V\nH\n region comprising the sequence of SEQ ID No. 2, and, accordingly, may be useful in the treatment of multiple myeloma.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n region consisting essentially of the sequence of SEQ ID No. 9.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n region consisting essentially of the sequence of SEQ ID No. 10.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n region consisting essentially of the sequence of SEQ ID No. 9 and aV\nH\n region consisting essentially of the sequence of SEQ ID No. 10.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR1 consisting essentially of the sequence of SEQ ID No. 1 1.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR2 consisting essentially of the sequence of SEQ ID No. 12.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR3 consisting essentially of the sequence of SEQ ID No. 13. \n\n In one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n CDR1 consisting essentially of the sequence of SEQ ID No. 14.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n CDR2 consisting essentially of the sequence of SEQ ID No. 15. In one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n \n\n\nCDR3 consisting essentially of the sequence of SEQ ID No. 16.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising V\nL\n CDRs (V\nL\n CDR1 , CDR2, and CDR3) consisting essentially of SEQ ID No. 11 , SEQ ID No. 12 and SEQ ID No. 13, respectively. In one embodiment, the present invention provides an IL-21 BP that comprises V\nH\n \n\n\nCDRs (V\nH\n CDR1 , CDR2, and CDR3) consisting essentially of SEQ ID No. 14, SEQ ID No. 15 and SEQ ID No. 16, respectively.\n\n\nIn one embodiment, the present invention provides an IL-21 BP that comprises\n\n\n(a) three V\nL\n CDRs, which independently consist essentially of SEQ ID No. 1 1 , SEQ ID No. 12 and SEQ ID No. 13 in close proximity to one another (e.g., near the spacing of V\nL\n CDRs in a wild-type anti-IL-21 antibody) in the IL-21 BP and\n\n\n(b) three V\nH\n CDRs which independently consist essentially of SEQ ID No. 14, SEQ ID No. 15 and SEQ ID No. 16 in close proximity to one another (e.g., near the spacing of V\nH\n CDRs in a wild-type anti-IL-21 antibody) in the IL-21 BP. In a further embodiment, the present invention provides an IL-21 BP that comprises a flexible linker positioned between the V\nL\n region and V\nH\n region of the IL-21 BP. In another further embodiment, the present invention provides an IL-21 BP, wherein the V\nL\n and V\nH\n regions are presented on separate chains in the context of an immunoglobulin fold protein and oriented such that the V\nL\n CDR1 , CDR2, CDR3 and V\nH\n CDR1 , CDR2, and CDR3 cooperatively associate to contribute in selectively and/or specifically bind an antigenic determinant on IL-21. In another further embodiment, the present invention provides an IL-21 BP that comprises two sets of variable domains (sets of associated V\nL\n and V\nH\n domains on associated separate chains), such that the IL-21 BP comprises two identical antigenic determinant binding sites. Any of such IL-21 BPs are expected to, at least in part, have similar epitope specificity, selectivity, and other characteristics as an antibody having a V\nL\n region comprising the sequence of SEQ ID No. 9 and a V\nH\n region comprising the sequence of SEQ ID No. 10 and, accordingly, may be useful in the treatment of multiple myeloma.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR1 consisting essentially of a sequence according to any one of SEQ ID No. 3 and SEQ \n\n ID No. 11 , wherein the N-terminal residue and/or one, two, or three of the C-terminal amino acid residues are missing.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR2 consisting essentially of a sequence according to any one of SEQ ID No. 4 and SEQ ID No. 12, wherein one or two of the N-terminal residues and/or one, two, or three of the C-terminal residues are missing.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nL\n CDR3 consisting essentially of a sequence according to any one of SEQ ID No. 5 and SEQ ID No. 13, wherein the N-terminal residue and/or one, two, three, or four of the C-terminal residues are missing.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n CDR1 consisting essentially of a sequence according to any one of SEQ ID No. 6 and SEQ ID No. 14, wherein one, two, three, or four of the N-terminal residues and/or one, two, three, or four C-terminal residues are missing. In one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n \n\n\nCDR2 consisting essentially of a sequence according to any one of SEQ ID No. 7 and SEQ ID No. 15, wherein one, two, three, four, or five of the N-terminal amino acids thereof and/or one, two, three, four, five, or six of the C-terminal amino acids thereof are missing.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a V\nH\n CDR3 consisting essentially of a sequence according to any one of SEQ ID No. 8 and SEQ ID No. 16, wherein the N-terminal one, two, or three amino acid residues and/or the C-terminal one, two, three, or four amino acid residues are missing.\n\n\nThe present invention also provides IL-21 BPs wherein these \"truncated\" CDR sequences are combined with each other and/or other CDR sequences described herein. In one embodiment, the present invention provides an IL-21 BP that comprises\n\n\n(a) three V\nL\n CDRs, which independently consist essentially of SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 5 in close proximity to one another in the IL-21 BP (e.g., near the spacing of V\nL\n CDRs in a wild-type anti-IL-21 antibody) and\n\n\n(b) three V\nH\n CDRs which independently consist essentially of SEQ ID No. 6, SEQ ID No. 7 and SEQ ID No. 8 in close proximity to one another (e.g., near the spacing of\n\n\nV\nH\n CDRS in a wild-type anti-IL-21 antibody) in the IL-21 BP.\n\n\nIn a further embodiment, the present invention provides an IL-21 BP that comprises a flexible linker positioned between the V\nL\n region and V\nH\n region of the IL-21 BP.\n\n\nIn a further embodiment, the present invention provides an IL-21 BP wherein the V\nL\n and V\nH\n regions are presented on separate chains in the context of an immunoglobulin fold \n\n protein and oriented such that the V\nL\n CDR1 , CDR2, CDR3 and V\nH\n CDR1 , CDR2, and CDR3 cooperatively associate to contribute in selectively and/or specifically bind an antigenic determinant on IL-21. In a further embodiment, the present invention provides an IL-21 BP that comprises two sets of variable domains (sets of associated V\nL\n and V\nH\n domains on associated separate chains), such that the IL-21 BP comprises two identical antigenic determinant binding sites. Any of such IL-21 BPs described in this paragraph are expected to, at least in part, have similar epitope specificity, selectivity, and other characteristics with an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2.\n\n\nIn one embodiment, the present invention provides an IL-21 BP that comprises (a) three V\nL\n CDRs, which independently consist essentially of SEQ ID No. 1 1 , SEQ ID\n\n\nNo. 12 and SEQ ID No. 13 in close proximity to one another in the IL-21 BP (e.g., near the spacing of V\nL\n CDRs in a wild-type anti-IL-21 antibody) and (b) three V\nH\n CDRs which independently consist essentially of SEQ ID No. 14, SEQ ID\n\n\nNo. 15 and SEQ ID No. 16 in close proximity to one another (e.g., near the spacing of V\nH\n CDRS in a wild-type anti-IL-21 antibody) in the IL-21 BP.\n\n\nIn a further embodiment, the present invention provides an IL-21 BP that comprises a flexible linker positioned between the V\nL\n region and V\nH\n region of the IL-21 BP.\n\n\nIn a further embodiment, the present invention provides an IL-21 BP wherein the V\nL\n and V\nH\n regions are presented on separate chains in the context of an immunoglobulin fold protein and oriented such that the V\nL\n CDR1 , CDR2, CDR3 and V\nH\n CDR1 , CDR2, and CDR3 cooperatively associate to contribute in selectively and/or specifically bind an antigenic determinant on IL-21. In a further embodiment, the present invention provides an IL-21 BP that comprises two sets of variable domains (sets of associated V\nL\n and V\nH\n domains on associated separate chains), such that the IL-21 BP comprises two identical antigenic determinant binding sites. Any of such IL-21 BPs described in this paragraph are expected to, at least in part, have similar epitope specificity, selectivity, and other characteristics with an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10.\n\n\nFor the purpose of this specification, CDR's are determined as described by Kabat (ibid). The present invention also provides IL-21 BPs comprising functional variants of the\n\n\nV\nL\n region, V\nH\n region, or one or more CDRs of the antibodies of the examples. A functional variant of a V\nL\n, V\nH\n, or CDR used in the context of an IL-21 BP still allows the IL-21 BP to retain at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the affinity/avidity and/or specificity/selectivity of the parent antibody and in some cases such \n\n an IL-21 BP may be associated with greater affinity, selectivity, and/or specificity than the parent antibody.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a variant V\nL\n consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 1 and SEQ ID No. 9, wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nL\n sequence of SEQ ID No. 1 or SEQ ID No. 9, respectively, such as an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2, or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, respectively.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a variant V\nL\n CDR1 consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 3 or SEQ ID No. 11 , wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nL\n CDR1 sequence of SEQ ID No. 3 or SEQ ID No. 1 1 , respectively, such as an antibody having a V\nL\n sequence of SEQ ID No. 1 or SEQ ID No. 9, respectively, such as an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2, or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, respectively. In one embodiment, the present invention provides an IL-21 BP comprising a variant\n\n\nV\nL\n CDR2 consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 4 or SEQ ID No. 12, wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nL\n CDR2 sequence of SEQ ID No. 4 or SEQ ID No. 12, respectively, such as an antibody having a V\nL\n sequence of SEQ ID No. 1 or SEQ ID No. 9, respectively, such as an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 \n\n or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, respectively.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a variant V\nL\n CDR3 consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 5 or SEQ ID No. 13, wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nL\n CDR3 sequence of SEQ ID No. 5 or SEQ ID No. 13, respectively, such as an antibody having a V\nL\n sequence of SEQ ID No. 1 or SEQ ID No. 9, respectively, such as an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2, or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, respectively. In one embodiment, the present invention provides an IL-21 BP comprising a variant\n\n\nV\nH\n consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 2 or SEQ ID No. 10, wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nH\n sequence of SEQ ID No. 2 or SEQ ID No. 10, respectively, such as an antibody having a V\nH\n sequence of SEQ ID No. 2 and a V\nL\n sequence of SEQ ID No. 1 , or an antibody having a V\nH\n sequence of SEQ ID No. 10 and a V\nL\n sequence of SEQ ID No. 9, respectively. In one embodiment, the present invention provides an IL-21 BP comprising a variant\n\n\nV\nH\n CDR1 consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 6 or SEQ ID No. 14, wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nH\n CDR1 sequence of SEQ ID No. 6 or SEQ ID No. 14, respectively, such as an antibody having a V\nH\n sequence of SEQ ID No. 2 or SEQ ID No. 10, respectively, such as an antibody having a V\nH\n sequence of SEQ ID No. 2 and a V\nL\n sequence of SEQ ID No. 1 , \n\n or an antibody having a V\nH\n sequence of SEQ ID No. 10 and a V\nL\n sequence of SEQ ID No. 9, respectively.\n\n\nIn one embodiment, the present invention provides an IL-21 BP comprising a variant V\nH\n CDR2 consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 7 or SEQ ID No. 15, wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nH\n CDR2 sequence of SEQ ID No. 7 or SEQ ID No. 15, respectively, such as an antibody having a V\nH\n sequence of SEQ ID No. 2 or SEQ ID No. 10, respectively, such as an antibody having a V\nH\n sequence of SEQ ID No. 2 and a V\nL\n sequence of SEQ ID No. 1 , or an antibody having a V\nH\n sequence of SEQ ID No. 10 and a V\nL\n sequence of SEQ ID No. 9, respectively. In one embodiment, the present invention provides an IL-21 BP comprising a variant\n\n\nV\nH\n CDR3 consisting essentially of a sequence having at least about 50%, such as at least 60%, for instance at least about 70%, such as at least about 75%, for instance at least about 80%, such as at least about 85%, for instance at least about 90%, such as at least about 95% amino acid sequence identity to a sequence according to any one of SEQ ID No. 8 or SEQ ID No. 16, wherein the IL-21 BP has at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the epitope binding characteristics of an antibody having a V\nH\n CDR3 sequence of SEQ ID No. 8 or SEQ ID No. 16, respectively, such as an antibody having a V\nH\n sequence of SEQ ID No. 2 or SEQ ID No. 10, respectively, such as an antibody having a V\nH\n sequence of SEQ ID No. 2 and a V\nL\n sequence of SEQ ID No. 1 , or an antibody having a V\nH\n sequence of SEQ ID No. 10 and a V\nL\n sequence of SEQ ID No. 9, respectively.\n\n\nThe percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences may be accomplished using a mathematical algorithm, as described in the non-limiting examples below.\n\n\nThe percent identity between two nucleotide sequences may be determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a \n\n NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1 , 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences may also be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci 4, 11 -17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences may be determined using the Needleman and Wunsch, J. MoI. Biol. 48, 444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1 , 2, 3, 4, 5, or 6.\n\n\nThe nucleic acid and protein sequences of the present invention may further be used as a \"query sequence\" to perform a search against public databases to, for example, identify related sequences. Such searches may be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul et al., J. MoI. Biol. 215, 403-10 (1990). BLAST nucleotide searches may be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the present invention. BLAST protein searches may be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the protein molecules of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST may be utilized as described in Altschul et al., Nucleic Acids Res. 25(17), 3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) may be used. See http://www.ncbi.nlm.nih.gov.\n\n\nThe sequence of CDR variants may differ from the sequence of the CDR of the parent antibody sequences through mostly conservative substitutions; for instance at least about 35%, about 50% or more, about 60% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more (e.g., about 65-99%) of the substitutions in the variant are conservative amino acid residue replacements. In the context of the present invention, conservative substitutions may be defined by substitutions within the classes of amino acids reflected in one or more of the following three tables: \n\n Amino acid residue classes for conservative substitutions\n\n\n\n\n\n\n\n\nAlternative conservative amino acid residue substitution classes\n\n\n\n\n\n\n\n\nAlternative Physical and Functional Classifications of Amino Acid Residues\n\n\n\n\n\n\n\n\nMore conservative substitutions groupings include: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Additional groups of amino acids may also be formulated using the principles described in, e.g., Creighton (1984) Proteins: Structure and Molecular Properties (2d Ed. 1993), W.H. Freeman and Company. \n\n In one embodiment of the present invention, conservation in terms of hydropathic/hydrophilic properties and residue weight/size also is substantially retained in a variant CDR as compared to a CDR of an antibody of the examples (e.g., the weight class, hydropathic score, or both of the sequences are at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more (e.g., about 65-99%) retained). For example, conservative residue substitutions may also or alternatively be based on the replacement of strong or weak based weight based conservation groups, which are known in the art.\n\n\nThe retention of similar residues may also or alternatively be measured by a similarity score, as determined by use of a BLAST program (e.g., BLAST 2.2.8 available through the NCBI). Suitable variants typically exhibit at least about 45%, such as at least about 55%, at least about 65%, at least about 75%, at least about 85%, at least about 90%, at least about 95%, or more (e.g., about 70-99%) similarity to the parent peptide.\n\n\nSubstantial changes in function may be made by selecting substitutions that are less conservative than those shown in the defined groups, above. For example, non-conservative substitutions may be made which more significantly affect the structure of the peptide in the area of the alteration, for example, the alpha-helical, or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which generally are expected to produce the greatest changes in the peptide's properties are those where 1) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; 2) a cysteine or proline is substituted for (or by) any other residue; 3) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or 4) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) a residue that does not have a side chain, e.g., glycine. Accordingly, these and other nonconservative substitutions may be introduced into peptide variants where significant changes in function/structure is desired and such changes avoided where conservation of structure/function is desired.\n\n\nA convenient way for generating substitution variants is affinity maturation using phage using methods known in the art. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis may also be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues are likely suitable candidates for substitution. \n\n Where hypervariable region insertions are made to generate a variant antibody, the typical range of lengths of the hypervariable region in question in known antibodies should be taken into consideration. For example, for the first hypervariable region of a light chain variable domain, insertions may be introduced into the V\nL\n CDR1 sequence of a parent antibody while retaining a substantially similar and thereby expected appropriate size, which according to Kabat et al., supra, e.g., typically has an overall of about 9-20 (e.g., about 10-17) residues. Similarly, V\nL\n CDR2 typically has an overall length from about 5-10 residues; V\nL\n CDR3 typically has a length of about 7-20 residues; V\nH\n CDR1 typically has a length of about 10-15 residues; V\nH\n CDR2 typically has a length of about 15-20 residues; and V\nH\n CDR3 typically has a length of about 6-30 residues (e.g., 3-25 residues). Insertions in the V\nH\n region typically are made in V\nH\n CDR3 and typically near the C-terminal of the domain, such as about residues 97-102 of the parent V\nH\n CDR3 (for instance adjacent to, or C-terminal in sequence to, residue number 100 of the parent V\nH\n CDR3 sequence) using the alignment and numbering as described in Kabat. Antibody variants with inserted amino acid residue(s) in a hypervariable region thereof may be prepared randomly, especially where the starting binding affinity of the parent antibody for the target antigen is such that randomly produced antibody variants may be readily screened. For example, phage display provides a convenient method of screening such random variants.\n\n\nIn the design, construction, and/or evaluation of CDR variants attention may be paid to the fact that CDR regions may be altered to enable a better binding to the epitope. Antibody CDRs typically operate by building a \"pocket,\" or other paratope structure, into which the epitope fits. If the epitope is not fitting tightly, the antibody may not offer the best affinity. However, as with epitopes, there often are a few key residues in a paratope structure that account for most of this binding. Thus, CDR sequences may vary in length and composition significantly between antibodies for the same peptide. The skilled artisan will recognize that certain residues, such as tyrosine residues (e.g., in the context of V\nH\n CDR3 sequences), that are often significant contributors to such epitope binding, are typically retained in a CDR variant.\n\n\nVariants of the CDR region may also increase the amino acid contacts between the antigen and an antibody variant, as compared to the amino acid contacts between the antigen and the parent antibody, by introducing one or more amino acid residues (either by substitution or insertions) which increase the contacts or energetically favorable interactions between one or more amino acid residues present in an antigen and one or more amino acid residues present in the antibody. The amino acid interactions of interest may be selected from hydrogen bonding interactions, van der Waals interactions, and ionic interactions. \n\n Those skilled in the art will be aware of additional principles useful in the design and selection of IL-21 BP comprising CDR variants of the antibodies of the present invention.\n\n\nIn the context of CDR variants, which are variants of the CDRs of the antibodies of the examples, particularly in the context of variant CDR in anti-IL-21 antibodies or fragments thereof, residues required to support and/or orientate the CDR structural loop structure(s) may typically be retained; residues which fall within about 10 angstroms of a CDR structural loop (but optionally only residues in this area that also possess a water solvent accessible surface of about 5 angstroms\n2\n or greater) may typically be unmodified or modified only by conservative amino acid residue substitutions; and/or the amino acid sequence may typically be subject to only a limited number of insertions and/or deletions (if any), such that CDR structural loop-like structures are retained in the variant (a description of related techniques and relevant principles is provided in for instance Schiweck et al., J MoI Biol. 268(5), 934-51 (1997), Morea, Biophys Chem. 68(1-3), 9-16 (1997), Shirai et al., FEBS Lett. 399(1-2), 1 -8 (1996), Shirai et al., FEBS Lett. 455(1-2), 188-97 (1999), Reckzo et al., Protein Eng. 8(4), 389-95 (1995) and Eigenbrot et al., J MoI Biol. 229(4), 969-95 (1993). See also WO 03/048185, WO 03/070747 and WO 03/027246.\n\n\nIn one embodiment, this includes for instance an IL-21 BP that comprises a V\nL\n CDR1 that is a fusion of V\nL\n CDR1 sequences from an antibody having a V\nL\n sequence of SEQ ID No. 1 and V\nL\n CDR1 sequences from an antibody having a V\nL\n sequence of SEQ ID No. 9. In one embodiment, this includes for instance an IL-21 BP that comprises a V\nL\n CDR2 that is a fusion of V\nL\n CDR2 sequences from an antibody having a V\nL\n sequence of SEQ ID No. 1 and V\nL\n CDR2 sequences from an antibody having a V\nL\n sequence of SEQ ID No. 9.\n\n\nIn one embodiment, this includes for instance an IL-21 BP that comprises a V\nL\n CDR3 that is a fusion of V\nL\n CDR3 sequences from an antibody having a V\nL\n sequence of SEQ ID No. 1 and V\nL\n CDR3 sequences from an antibody having a V\nL\n sequence of SEQ ID No. 9\n\n\nIn one embodiment, this includes for instance an IL-21 BP that comprises a V\nH\n CDR1 that is a fusion of V\nH\n CDR1 sequences from an antibody having a V\nH\n sequence of SEQ ID No. 2 and V\nH\n CDR1 sequences from an antibody having a V\nH\n sequence of SEQ ID No. 10.\n\n\nIn one embodiment, this includes for instance an IL-21 BP that comprises a V\nH\n CDR2 that is a fusion of V\nH\n CDR2 sequences from an antibody having a V\nH\n sequence of SEQ ID No. 2 and V\nH\n CDR2 sequences from an antibody having a V\nH\n sequence of SEQ ID No. 10.\n\n\nIn one embodiment, this includes for instance an IL-21 BP that comprises a V\nH\n CDR3 that is a fusion of V\nH\n CDR3 sequences from an antibody having a V\nH\n sequence of SEQ ID No. 2 and V\nH\n CDR3 sequences from an antibody having a V\nH\n sequence of SEQ ID No. 10. \n\n In one embodiment, the present invention provides antibody and antibody like molecules derived from one of 1 F1 and 1 F22, wherein the V\nL\n CDR1 sequence of the derived antibody or antibody-like molecule is replaced with the V\nL\n CDR1 sequence of the other of 1 F1 and 1 F22. In one embodiment, the present invention provides antibody and antibody like molecules derived from one of 1 F1 and 1 F22, wherein the V\nL\n CDR2 sequence of the derived antibody or antibody-like molecule is replaced with the V\nL\n CDR2 sequence of the other of 1 F1 and 1 F22.\n\n\nIn one embodiment, the present invention provides antibody and antibody like molecules derived from one of 1 F1 and 1 F22, wherein the V\nL\n CDR3 sequence of the derived antibody or antibody-like molecule is replaced with the V\nL\n CDR3 sequence of the other of 1 F1 and 1 F22.\n\n\nIn one embodiment, the present invention provides antibody and antibody like molecules derived from one of 1 F1 and 1 F22, wherein the V\nH\n CDR1 sequence of the derived antibody or antibody-like molecule is replaced with the V\nH\n CDR1 sequence of the other of 1 F1 and 1 F22.\n\n\nIn one embodiment, the present invention provides antibody and antibody like molecules derived from one of 1 F1 and 1 F22, wherein the V\nH\n CDR2 sequence of the derived antibody or antibody-like molecule is replaced with the V\nH\n CDR2 sequence of the other of 1 F1 and 1 F22\n\n\nIn one embodiment, the present invention provides antibody and antibody like molecules derived from one of 1 F1 and 1 F22, wherein the V\nH\n CDR3 sequence of the derived antibody or antibody-like molecule is replaced with the V\nH\n CDR3 sequence of the other of 1 F1 and 1 F22. In one embodiment, the present invention provides a variant antibody derived from\n\n\n1 F1 and 1 F22, wherein the light chain of the antibody comprises one or more substitutions, insertions, or deletions that correspond to the sequence of the other antibody (e.g., the present invention provides a variant of 1 F1 wherein one or more residue changes are introduced into the light chain of the derivative based upon the residues found at corresponding positions in the light chain of 1 F22).\n\n\nIn one embodiment, the present invention provides a variant antibody derived from 1 F1 and 1 F22, wherein the heavy chain of the antibody comprises one or more substitutions, insertions, or deletions that correspond to the sequence of the other antibody (e.g., the present invention provides a variant of 1 F1 , wherein one or more residue changes are \n\n introduced into the heavy chain of the derivative based upon the residues found at corresponding positions in the heavy chain of 1 F22).\n\n\nAdditional techniques that may be used to generate variant antibodies include the directed evolution and other variant generation techniques described in for instance US 20040009498, Marks et al., Methods MoI Biol. 248, 327-43 (2004), Azriel-Rosenfeld et al., J MoI Biol. 335(1), 177-92 (2004), Park et al., Biochem Biophys Res Commun. 275(2), 553-7 (2000), Kang et al., Proc Natl Acad Sci U S A. 88(24), 11 120-3 (1991), Zahnd et al., J Biol Chem. 279(18), 18870-7 (2004), Xu et al., Chem Biol. 9(8), 933-42 (2002), Border et al., Proc Natl Acad Sci U S A. 97(20), 10701-5 (2000), Crameri et al., Nat Med. 2(1), 100-2 (1996) and as more generally described in for instance WO 03/048185.\n\n\nGenerated antibody variants may be subjected to any suitable screening technique and antibodies with suitable and desirably superior properties in one or more relevant assays may be selected for further development.\n\n\nIL-21 BPs comprising CDR sequences as described above may comprise any suitable number and combination of such V\nL\n and V\nH\n CDRs while retaining at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the affinity/avidity and/or specificity/selectivity of an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, but optionally differing in other characteristics, such as immunogenicity in a human patient, affinity for the epitope, increased half-life, etc. In some cases such an IL-21 BP may be associated with greater affinity, selectivity, and/or specificity than the parent antibody. In one embodiment, less than a full set of V\nL\n CDRs and/or V\nH\n CDRS is present in an IL-21 BP of the present invention. In one embodiment all of the V\nL\n CDRS and V\nH\n CDRs are present. Examples of other functional properties of antibodies, which may be altered or retained in variant IL-21 BPs of the present invention as compared to the antibodies of the examples, are:\n\n\n(1) high affinity binding to IL-21 ;\n\n\n(2) inhibition or blocking of IL-21 binding to the IL-21 receptor; (3) degree of inhibition of IL-21 activation of the IL-21 receptor;\n\n\n(4) immunogenicity;\n\n\n(5) pharmokinetic properties (such as half-life);and/or\n\n\n(6) the biophysical properties e.g. biophysical stability (solubility, thermostability) and chemical stability (oxidation, deamidation. fragmentation. \n\n The present invention also provides IL-21 BPs which are characterized with respect to their ability to compete (competitively inhibit) or cross-compete (i.e., relatively partially inhibit epitope binding) with an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and/or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10 for binding to IL-21.\n\n\nSuch an IL-21 BP may be, for instance, a Fab fragment, derived from an antibody that binds to an epitope identical to or overlapping with an epitope bound by an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10. Such a Fab fragment, due to its relatively small size compared to the mAb molecules, may not significantly compete with said antibodies for binding to IL-21 although the antibody from which it derived does. Nonetheless, such an IL-21 BP may be useful in similarly targeting nearby regions of IL-21 (e.g., in the context of targeting a cytotoxin, radionuclide, or the like in the context of an immunoconjugate IL-21 BP). Therefore, such IL-21 BPs may be useful in the context of the methods of the present invention and, accordingly, are also provided by the present invention.\n\n\nCompetition for binding to IL-21 or a portion of IL-21 by two or more IL-21 binding peptides may be determined by any suitable technique. In one embodiment, competition is determined by an ELISA assay as described, for example, in Example 2.\n\n\nCompetition in the context of the present invention refers to any detectably significant reduction in the propensity for a particular molecule to bind a particular binding partner in the presence of another molecule that binds the binding partner. Typically, competition means an at least about 10% reduction, such as an at least about 15%, or an at least about 20% reduction in binding between an IL-21 BP and (a) a form of IL-21 (e.g.\n\n\n\"unprocessed\", \"not processed\" or \"immature\" IL-21 ); (b) a form of free IL-21 (e.g., an IL-21 promigratory fragment and/or IL-21 fragment produced by in vivo processing); (c) a portion of IL-21 ; or (d) a portion of IL-21 , caused by the presence of another IL-21 BP as determined by, e.g., ELISA analysis using sufficient amounts of the two or more competing IL-21 BPs and IL-21. It may also be the case that competition may exist between IL-21 BPs with respect to more than one of IL-21 , and/or a portion of IL-21 , e.g. in a context where the binding properties of a particular region of IL-21 are retained in fragments thereof, such as in the case of a well-presented linear epitope located in various tested fragments or a conformational epitope that is presented in sufficiently large IL-21 fragments as well as in IL-21. \n\n Assessing competition typically involves an evaluation of relative inhibitory binding using a first amount of a first molecule; a second amount of a second molecule; and a third amount of a third molecule (or a standard determined by binding studies that may be reasonably compared to new binding data with respect to the first and second molecules as a surrogate for actual contemporaneous data), wherein the first, second, and third amounts all are sufficient (in quantity and properties) to make a comparison that imparts information about the selectivity and/or specificity of the molecules at issue with respect to the other present molecules. The first, second, and third amounts may vary with the nature of the IL-21 BP and potential targets therefore at issue. Usually, for ELISA assessments, similar to those described in Example 2, about 5-50 μg (e.g., about 10-50 μg, about 20-50 μg, about 5-20 μg, about 10-20 μg, etc.) of IL-21 BP and/or IL-21 targets are required to assess whether competition exists. Conditions also should be suitable for binding. Typically, physiological or near-physiological conditions (e.g., temperatures of about 20-40\n0\nC, pH of about 7-8, etc.) are suitable for IL-21 BP:IL-21 binding. Often competition is marked by a significantly greater relative inhibition than about\n\n\n5% as determined by ELISA analysis. It may be desirable to set a higher threshold of relative inhibition as a criteria/determinant of what is a suitable level of competition in a particular context (e.g., where the competition analysis is used to select or screen for new antibodies designed with the intended function of blocking the binding of another peptide or molecule binding to IL-21 or naturally occurring anti-IL-21 antibody)). Thus, for example, it is possible to set a criteria for competitiveness wherein at least about 10% relative inhibition is detected; at least about 15% relative inhibition is detected; or at least about 20% relative inhibition is detected before an antibody is considered sufficiently competitive. In cases where epitopes belonging to competing antibodies are closely located in an antigen, competition may be marked by greater than about 40% relative inhibition of IL-21 binding (e.g., at least about 45% inhibition, such as at least about 50% inhibition, for instance at least about 55% inhibition, such as at least about 60% inhibition, for instance at least about 65% inhibition, such as at least about 70% inhibition, for instance at least about 75% inhibition, such as at least about 80% inhibition, for instance at least about 85% inhibition, such as at least about 90% inhibition, for instance at least about 95% inhibition, or higher level of relative inhibition).\n\n\nCompetition may be considered the inverse of cross-reactivity between a molecule and two potential binding partners. In certain embodiments, an IL-21 BP of the present invention specifically binds to one or more residues or regions in IL-21 but also does not cross-react with other peptides, peptide regions, or molecules, e.g., the present invention provides an anti-IL-21 antibody that does not cross-react with for instance IL-2, IL-4, IL, IL-9, \n\n or IL-15, which all binds to a receptor comprising the common Y chain (but otherwise have low homology to IL-21). Typically, a lack of cross-reactivity means less than about 5% relative competitive inhibition between the molecules when assessed by ELISA using sufficient amounts of the molecules under suitable assay conditions. In one embodiment, the present invention provides an IL-21 BP that competes with an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 for binding to IL-21 or a portion thereof.\n\n\nIn one embodiment, the present invention provides an IL-21 BP that cross-competes with 1 F1 and/or 1 F22 for binding to IL-21 or a portion thereof. As discussed elsewhere herein, unless otherwise stated or clearly contradicted by context, references to binding of an IL-21 BP to IL-21 are intended to refer to binding in any suitable context, such as in a conformational context where the structure of IL-21 is present; or in a linear epitope context (or a combination thereof). Of course, binding in a limited subset of such context(s) may be an important characteristic with respect to any IL-21 BP provided by the present invention. Cross-competition may be determined by any suitable method and criteria, but typically means the detection of competition among three molecules in an ELISA or other suitable assay (at similar or different levels).\n\n\nAdditional methods for determining IL-21 BP specificity by competitive inhibition may be found in for instance Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 1988), Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc, and Wiley InterScience N. Y., (1992, 1993), and Muller, Meth. Enzymol. 92, 589-601 (1983)).\n\n\nHuman IL-21 comprises a number of different epitopes, which may include (1 ) peptide antigenic determinants that are comprised within single peptide chains within human IL-21 ; (2) conformational antigenic determinants which consist one or more noncontiguous amino acids on a particular chain and/or amino acids present on spatially contiguous but separate peptide chains (typically where the respective amino acid sequences of the chains are located disjointedly along the human IL-21 polypeptide sequence); (3) post-translational antigenic determinants which consist, either in whole or part, of molecular structures covalently attached to human IL-21 , such as carbohydrate groups; or (4) combinations of (1)-(3).\n\n\nAn epitope in the context of the present invention includes any peptide or peptide- derivative determinant capable of specific binding to an immunoglobulin. An epitope may comprise any suitable number of amino acids, in any suitable position (with respect to the linear sequence of IL-21) orientation (with respect to folded IL-21 , or a fragment thereof), \n\n amino acid composition (and consequently, at least in part, charge). Thus, for example, an epitope may be composed of about 3-10 amino acids, typically 3-8 amino acids, in one or more contiguous or noncontiguous locations with respect to the primary sequence of IL-21 (for instance an epitope may consist essentially of 2, 3, 4, 5, 6, 7, or 8 amino acid residues distributed in 1 , 2, 3, 4, or 5 noncontiguous locations in IL-21 ). Alternatively, for example, an epitope may be considered to be defined by a region of about 5-40 contiguous amino acid residues (e.g., about 7-30 amino acid residues, about 5-20 amino acid residues, or about 3-15 amino acid residues) in IL-21 (solely or in combination with a portion of an adjacent IL-21 domain). In some epitopes it may be the case that just one amino acid residue or only a few amino acid residues are critical to CDR or CDR(s) recognition (and thereby most important to IL-21 BP:IL-21 antigen affinity and avidity). As such, an epitope may be characterized on the basis of one or more of such critical residues, with the recognition that other residues may also make some lesser contribution to the epitope. In the case of an epitope defined by a region of amino acids, it may be that one or more amino acids in the region make only a minor contribution or even negligible contribution to antibody binding, such that the residue may be subject to substitution with an appropriate different residue without resulting in \"a loss\" of the epitope to at least some IL-21 BPs specific for it.\n\n\nIn one embodiment, the present invention provides an IL-21 BP, such as an anti- IL-21 antibody, that specifically binds to an IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and/or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10. It is possible that IL-21 BPs having one or more CDRs that differ from the CDRs of an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2, or the CDRs of an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, may still be specific for the same epitope as an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, respectively. In some such cases, the IL-21 BP in question may recognize or be more specific/selective for particular structures or regions of the epitope than the antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and the antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, respectively.\n\n\nA IL-21 epitope bound by an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, may be identified via standard mapping and characterization techniques, further refinement of which may be identified by any suitable technique, \n\n numerous examples of which are available to the skilled artisan. These techniques may also be used to identify and/or characterize epitopes for IL-21 BPs generally. As one example of such mapping/characterization methods, an epitope for an anti-IL-21 antibody may be determined by epitope \"foot-printing\" using chemical modification of the exposed amines/carboxyls in the IL-21 protein. One specific example of such a foot-printing technique is the use of HXMS (hydrogen-deuterium exchange detected by mass spectrometry) wherein a hydrogen/deuterium exchange of receptor and ligand protein amide protons, binding, and back exchange occurs, wherein the backbone amide groups participating in protein binding are protected from back exchange and therefore will remain deuterated. Relevant regions may be identified at this point by peptic proteolysis, fast microbore high-performance liquid chromatography separation, and/or electrospray ionization mass spectrometry. See, e.g., Ehring H, Analytical Biochemistry, Vol. 267 (2) 252-259 (1999) and/or Engen, J. R. and Smith, D. L. (2001 ) Anal. Chem. 73, 256A-265A. Another example of a suitable epitope identification technique is nuclear magnetic resonance epitope mapping (NMR), where typically the position of the signals in two-dimensional NMR spectres of the free antigen and the antigen complexed with the antigen binding peptide, such as an antibody, are compared. The antigen typically is selectively isotopically labeled with \n15\nN so that only signals corresponding to the antigen and no signals from the antigen binding peptide are seen in the NMR-spectrum. Antigen signals originating from amino acids involved in the interaction with the antigen binding peptide typically will shift position in the spectres of the complex compared to the spectres of the free antigen, and the amino acids involved in the binding may be identified that way. See for instance Ernst Schering Res Found Workshop. (44), 149-67 (2004), Huang et al., Journal of Molecular Biology 281.(1), 61-67 (1998) and Saito and Patterson, Methods. 9(3), 516-24 (1996). Epitope mapping/characterization may also be performed using mass spectrometry methods. See for instance Downward, J Mass Spectrom. 35(4), 493-503 (2000) and Kiselar and Downard, Anal Chem. 71.(9), 1792-801 (1999).\n\n\nProtease digestion techniques may also be useful in the context of epitope mapping and identification. Antigenic determinant-relevant regions/sequences may be determined by protease digestion, e.g. by using trypsin in a ratio of about 1 :50 to IL-21 o/n digestion at 37°C and pH 7-8, followed by mass spectrometry (MS) analysis for peptide identification. The peptides protected from trypsin cleavage by the IL-21 BP may subsequently be identified by comparison of samples subjected to trypsin digestion and samples incubated with IL-21 BP and then subjected to digestion by e.g. trypsin (thereby revealing a foot print for the binder). Other enzymes like chymotrypsin, pepsin, etc. may also or alternatively be used in a similar \n\n epitope characterization methods. A IL-21 BP which gives the significantly same result as an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10 in these measurements are deemed to be an antibody that bind the same epitope as an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 or an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10, respectively. See for instance Manca, Ann 1st Super Sanita. 27(1), 15-9 (1991) for a discussion of similar techniques. In this respect (as well as in other respects), the invention provides a method for identifying new antibodies, sequences, and proteins that act as IL-21 BPs.\n\n\nEpitope mapping by competitive binding to IL-21 with two antibodies where one is biotinylated is another method for identifying relevant antigenic determinant regions.\n\n\nVarious phage display techniques may also be used to identify epitopes. See for instance Wang and Yu, Curr Drug Targets. 5(1), 1-15 (2004), Burton, Immunotechnology. 1(2), 87-94 (1995 Aug), Cortese et al., Immunotechnology. 1(2), 87-94 (1995) and Irving et al., Curr Opin Chem Biol. 5(3), 314-24 (2001). Consensus epitopes may also be identified through modified phage display-related techniques (see, http://www.cs.montana.edu/~mumey/papers/jcb03.pdf) for discussion.\n\n\nOther methods potentially helpful in mapping epitopes include crystallography techniques, X-ray diffraction techniques (such as the X-ray diffraction/sequence study techniques developed by Poljak and others in the 1970s-1980s), and the application of Multipin Peptide Synthesis Technology. Computer-based methods such as sequence analysis and three dimensional structure analysis and docking may also be used to identify antigenic determinants. For example, an epitope may also be determined by molecular modeling using a structure of IL-21 with docking of the structure of the Fab fragment of the individual monoclonal antibody. These and other mapping methods are discussed in Epitope Mapping A Practical Approach (Westwood and Hay Eds.) 2001 Oxford University Press.\n\n\nIn one embodiment, the present invention provides an IL-21 BP having substantially the same specific IL-21 -binding characteristics of one or more mAbs selected from an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10. To identify more specific likely antigenic determinant regions in IL-21 , various predictive analytical methods may be applied. In a first analytical approach, IL-21 may be analyzed for (1) highly hydropathic regions (using the Kyte-Doolittle method); (2) antigenicity as measured by the Protrusion Index method; (3) antigenicity as determined by the Parker \n\n method; (4) antigenicity as determined by the Hopp/Woods method; and (5) hydrophilicity as measured by the methods of Goldman, Engleman, and Steitz. Sequences ranging from 10-40 amino acids in length may be selected based on exhibiting one or more of these properties. The rationale for this approach is the general consensus that many ideal B cell epitopes are hydrophilic, surface-oriented, and flexible sequences of about 8-10 amino acids in length.\n\n\nThe present invention provides IL-21 BPs specific for IL-21-regions of IL-21 identified in such a manner. Moreover, the termini of these sequences may be compared to predicted antigenic determinant regions located through the other analyses described herein to provide additional specific likely antigenic-determinant containing regions. Other similar comparisons may readily be made to provide additional likely antigenic determinant regions, where IL-21 BPs binding to these antigenic determinant regions may be considered another feature of the present invention.\n\n\nIn one embodiment, the IL-21 BP of the present invention is an antibody. Non-limiting examples of IL-21 binding antibodies provided by the present invention include (a) a complete functional, immunoglobulin molecule comprising: (i) two identical chimeric heavy chains comprising a variable region with a human B cell surface antigen specificity and human constant region and (ii) two identical all (i.e. non-chimeric) human light chains; (b) a complete, functional, immunoglobulin molecule comprising: (i) two identical chimeric heavy chains comprising a variable region as indicated, and a human constant region, and (ii) two identical all (i.e. non-chimeric) non-human light chains; (c) a monovalent antibody, i.e., a complete, functional immunoglobulin molecule comprising: (i) two identical chimeric heavy chains comprising a variable region as indicated, and a human constant region, and (ii) two different light chains, only one of which has the same specificity as the variable region of the heavy chains. The resulting antibody molecule binds only to one end thereof and is therefore incapable of divalent binding. As another illustration, antibody/immunoglobulin-related peptides provided by the present invention may be said to include the following: (a) a whole immunoglobulin molecule; (b) an scFv; (c) a monoclonal antibody; (d) a human antibody; (e) a chimeric antibody; (f) a humanized antibody; (g) a Fab fragment; (h) an Fab' fragment; (i) an F(ab')\n2\n fragment; (j) an Fv molecule; and (k) a disulfide-linked Fv molecule.\n\n\nIn one embodiment, the IL-21 BP of the present invention is a polyclonal antibody. In one embodiment, the IL-21 BP of the present invention is an monoclonal antibody. In a further embodiment, the IL-21 BP of the present invention is a human monoclonal antibody. In another further embodiment, the IL-21 BP of the present invention is a humanized antibody. In another further embodiment, the IL-21 BP of the present invention is a chimeric antibody. \n\n In another further embodiment, the IL-21 BP of the present invention is a monoclonal antibody originating entirely from a mammalian species different from humans. In a further embodiment, the IL-21 BP of the present invention is a fully murine monoclonal antibody.\n\n\nA monoclonal antibody refers to a composition comprising a homogeneous antibody population having a uniform structure and specificity. Typically a monoclonal antibody is an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific and each monoclonal antibody is typically directed against a single epitope, which is in contrast to polyclonal antibody preparations which typically include different antibodies directed against different epitopes. That an antibody is monoclonal is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies of the present invention may be produced by the hybridoma method first described by Kohler et al., Nature 256, 495 (1975), or may be produced by recombinant DNA methods. Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in, for example, Clackson et al., Nature 352, 624-628 (1991) and Marks et al., J. MoI. Biol. 222, 581-597 (1991).\n\n\nMonoclonal antibodies may be obtained from any suitable source. Thus, for example, monoclonal antibodies may be obtained from hybridomas prepared from murine splenic B cells obtained from mice immunized with an antigen of interest or a nucleic acid encoding an antigen of interest. Monoclonal antibodies may also be obtained from hybridomas derived from antibody-expressing cells of immunized humans or non-human mammals such as rats, dogs, primates, etc.\n\n\nIn one embodiment, human monoclonal antibodies directed against IL-21 may be generated using transgenic or transchromosomal mice carrying parts of the human immune system rather than the mouse system. Such transgenic and transchromosomic mice include mice referred to herein as HuMAb mice and KM mice, respectively, and are collectively referred to herein as \"transgenic mice\".\n\n\nThe HuMAb mouse contains a human immunoglobulin gene miniloci that encodes unrearranged human heavy (μ and Y) and K light chain immunoglobulin sequences, together with targeted mutations that inactivate the endogenous μ and K chain loci (Lonberg, N. et al., Nature 368, 856-859 (1994)). Accordingly, the mice exhibit reduced expression of mouse IgM or K and in response to immunization, the introduced human heavy and light chain transgenes, undergo class switching and somatic mutation to generate high affinity human IgG\n1\nK monoclonal antibodies (Lonberg, N. et al. (1994), supra; reviewed in Lonberg, N. \n\n Handbook of Experimental Pharmacology 113, 49-101 (1994) , Lonberg, N. and Huszar, D., Intern. Rev. Immunol. Vol. 13 65-93 (1995) and Harding, F. and Lonberg, N. Ann. N. Y. Acad. Sci 764 536-546 (1995)). The preparation of HuMAb mice is described in detail in Taylor, L. et al., Nucleic Acids Research 20, 6287-6295 (1992), Chen, J. et al., International Immunology 5, 647-656 (1993), Tuaillon et al., J. Immunol. 152, 2912-2920 (1994), Taylor, L. et al., International Immunology 6, 579-591 (1994), Fishwild, D. et al., Nature Biotechnology 14, 845-851 (1996). See also US 5,545,806, US 5,569,825, US 5,625,126, US 5,633,425, US 5,789,650, US 5,877,397, US 5,661 ,016, US 5,814,318, US 5,874,299, US 5,770,429, US 5,545,807, WO 98/24884, WO 94/25585, WO 93/1227, WO 92/22645, WO 92/03918 and WO 01/09187.\n\n\nThe HCo7 mice have a JKD disruption in their endogenous light chain (kappa) genes (as described in Chen et al., EMBO J. 12, 821 -830 (1993)), a CMD disruption in their endogenous heavy chain genes (as described in Example 1 of WO 01/14424), a KCo5 human kappa light chain transgene (as described in Fishwild et al., Nature Biotechnology 14, 845-851 (1996)), and a HCo7 human heavy chain transgene (as described in US 5,770,429).\n\n\nThe HCo12 mice have a JKD disruption in their endogenous light chain (kappa) genes (as described in Chen et al., EMBO J. 12, 821 -830 (1993)), a CMD disruption in their endogenous heavy chain genes (as described in Example 1 of WO 01/14424), a KCo5 human kappa light chain transgene (as described in Fishwild et al., Nature Biotechnology 14, 845-851 (1996)), and a HCo12 human heavy chain transgene (as described in Example 2 of WO 01/14424). In the KM mouse strain, the endogenous mouse kappa light chain gene has been homozygously disrupted as described in Chen et al., EMBO J. Vl, 811 -820 (1993) and the endogenous mouse heavy chain gene has been homozygously disrupted as described in Example 1 of WO 01/09187. This mouse strain carries a human kappa light chain transgene, KCo5, as described in Fishwild et al., Nature Biotechnology 14, 845-851 (1996). This mouse strain also carries a human heavy chain transchromosome composed of chromosome 14 fragment hCF (SC20) as described in WO 02/43478.\n\n\nThe KM mouse contains a human heavy chain transchromosome and a human kappa light chain transgene. The endogenous mouse heavy and light chain genes also have been disrupted in the KM mice such that immunization of the mice leads to production of human immunoglobulins rather than mouse immunoglobulins. Construction of KM mice and their use to raise human immunoglobulins is described in detail in WO 02/43478.\n\n\nSplenocytes from these transgenic mice may be used to generate hybridomas that secrete human monoclonal antibodies according to well known techniques. Such transgenic mammals, mammals comprising an operable nucleic acid sequence coding for expression of \n\n an IL-21 BP, mammals stably transfected with one or more I L-21 -encoding nucleic acid sequences, and the like, are additional features of the present invention.\n\n\nHuman monoclonal or polyclonal antibodies of the present invention, or antibodies of the present invention originating from other species may also be generated transgenically through the generation of another non-human mammal or plant that is transgenic for the immunoglobulin heavy and light chain sequences of interest and production of the antibody in a recoverable form therefrom. In connection with the transgenic production in mammals, antibodies may be produced in, and recovered from, the milk of goats, cows, or other mammals. See for instance US 5,827,690, US 5,756,687, US 5,750,172 and US 5,741 ,957. Further, human antibodies of the present invention or antibodies of the present invention from other species may be generated through display-type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and other techniques, using techniques well known in the art and the resulting molecules may be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art (see for instance Hoogenboom et al., J. MoI. Biol. 227, 381 (1991 ) (phage display),\n\n\nVaughan et al., Nature Biotech 14, 309 (1996) (phage display), Hanes and Plucthau, PNAS USA 94, 4937-4942 (1997) (ribosomal display), Parmley and Smith, Gene 73, 305-318 (1988) (phage display), Scott TIBS 17, 241 -245 (1992), Cwirla et al., PNAS USA 87, 6378-6382 (1990), Russel et al., Nucl. Acids Research 21, 1081-1085 (1993), Hoganboom et al., Immunol. Reviews 130, 43-68 (1992), Chiswell and McCafferty TIBTECH 10, 80-84\n\n\n(1992), and US 5,733,743). If display technologies are utilized to produce antibodies that are not human, such antibodies may be humanized, for instance as described elsewhere herein.\n\n\nHumanized monoclonal antibodies of the present invention may be generated by fusing the constant domains from a human antibody to the variable domains of a non-human species. Examples of how to make humanized antibodies may be found in for instance US 6,054,297, US 5,886,152 and US 5,877,293. A humanized antibody is designed to have greater homology to a human immunoglobulin than animal-derived monoclonal antibodies. Non-human amino acid residues from an \"import\" (animal) variable domain typically are transfected into a human \"backbone\". Humanization may essentially be performed following the method of Winter and co-workers (Jones et al., Nature 321, 522-525 (1986), Riechmann et al., Nature 332, 323-327 (1988), Verhoeyen et al., Science 239, 1534-1536 (1988)), by substituting rodent complementarity determining regions (\"CDRs\") or CDR sequences for the corresponding sequences of a human antibody. Accordingly, in such \"humanized\" antibodies, the CDR portions of the human variable domain have been substituted by the corresponding sequence from a non-human species. Thus, humanized antibodies are typically human \n\n antibodies in which some CDR residues and possibly some framework residues are substituted by residues from analogous sites in rodent antibodies. The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is important to reduce antigenicity. According to the so-called \"best-fit\" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol. 151, 2296 (1993), Chothia et al., J. MoI. Biol. 196, 901 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., PNAS USA 89, 4285 (1992), Presta et al., J. Immunol. 151, 2623 (1993)).\n\n\nIt is typically also important that humanized antibodies retain high affinity for the antigen and other favorable biological properties. To achieve this goal, humanized antibodies may be prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of certain residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues may be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is maximized, although it is the CDR residues that directly and most substantially influence antigen binding.\n\n\nMurine antibodies or antibodies from other species may be humanized or primatized using any suitable techniques, a number of suitable techniques being already well known in the art (see for instance Winter and Harris Immunol Today 14, 43-46 (1993) and Wright et al., Crit. Reviews in Immunol. 125-168 (1992)). The antibody of interest may be engineered by recombinant DNA techniques to substitute the C\nH\n1 , C\nH\n2, C\nH\n3, hinge domains, and/or the framework domain with the corresponding human sequence (see WO 92/02190 and US\n\n\n5,530,101 , US 5,585,089, US 5,693,761 , US 5,693,792, US 5,714,350, and US 5,777,085).\n\n\nHumanization of antibodies may also be performed following the method of Winter and co-workers (Jones et al., Nature 321, 522-525 (1986), Riechmann et al., Nature 332, \n\n 323-327 (1988), Verhoeyen et al., Science 239, 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such \"humanized\" antibodies are, in a sense, chimeric antibodies (US 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.\n\n\nAlso, the use of Ig cDNA for construction of chimeric immunoglobulin genes is known in the art (see for instance Liu et al., PNAS USA 84, 3439 (1987) and J.Immunol. 139, 3521 (1987)). mRNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA: The cDNA of interest may be amplified by the polymerase chain reaction using specific primers (US 4,683,195 and US 4,683,202). Alternatively, a library is made and screened to isolate the sequence of interest. The DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences.\n\n\nSequences of human constant regions (as well as variable regions) may be found in Kabat et al., (1991) Sequences of Proteins of Immunological Interest, N. I. H. publication no. 91 -3242 and more recent and related data may be accessed at http://www.biochem.ucl.ac.uk/~martin/abs/Generallnfo.html. The choice of isotype typically will be guided by the desired effector functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity. Exemplary isotypes are IgGI , lgG2, lgG3, and lgG4. Either of the human light chain constant regions, kappa or lambda, may be used. The chimeric, humanized antibody may then be expressed by conventional methods.\n\n\nIL-21 BPs of the present invention may be in any suitable form with respect to multimerization. Anti-IL-21 antibodies and antibody fragments may be at least in heterotrimeric form if not in higher multimeric forms such as those associated with IgM antibodies. In other embodiments, an IL-21 BP may be presented as a dimer or monomer. Monomeric IL-21 BPs of the present invention may be, for example, modified by any suitable technique so as to form multimeric peptide compositions. If desired, the class of a anti-IL-21 antibody of the present invention may be switched by known methods. For example, an antibody of the present invention that was originally IgM may be class switched to an IgG antibody of the present invention. Further, class switching techniques may be used to convert one IgG subclass to another, for instance from IgGI to lgG2. Thus, the effector function of the antibodies of the present invention may \n\n be changed by isotype switching to, e.g., an IgGI , lgG2, lgG3, lgG4, IgD, IgA, IgE, or IgM antibody for various therapeutic uses.\n\n\nIn one embodiment an antibody of the present invention is an IgGI antibody, for instance an IgGI ,κ or IgGI ,λ isotype. In another embodiment an antibody of the present invention is an lgG3 antibody, for instance an lgG3,κ or lgG3,λ isotype. In another embodiment an antibody of the present invention is an lgG4 antibody, for instance an lgG4,κ or lgG4,λ isotype. In another embodiment an antibody of the present invention is an IgAI or lgA2 antibody. In another embodiment an antibody of the present invention is an IgM antibody. Anti-IL-21 antibodies may be recovered from recombinant combinatorial antibody libraries, such as a scFv phage display library, which may be made with human V\nL\n and V\nH\n cDNAs prepared from mRNA derived from human lymphocytes. Methods for preparing and screening such libraries are known in the art. There are a number of commercially available kits for generating phage display libraries. There are also other methods and reagents that may be used in generating and screening antibody display libraries (see for instance US\n\n\n5,223,409, WO 92/18619, WO 91/17271 , WO 92/20791 , WO 92/15679, WO 93/01288, WO 92/01047, WO 92/09690, Fuchs et al., Bio/Technology 9,1370-1372 (1991), Hay et al., Hum. Antibod. Hybridomas 3, 81-85 (1992), Huse et al., Science 246,1275-1281 (1989), McCafferty et al., Nature 348, 552-554 (1990), Griffiths et al., EMBO J 12, 725-734 (1993), Hawkins et al., J. MoI. Biol. 226, 889-896 (1992), Clackson et al., Nature 352, 624-628 (1991), Gram et al., PNAS USA 89, 3576-3580 (1992), Garrad et al., Bio/Technology 9, 1373-1377 (1991), Hoogenboom et al., Nuc Acid Res 19, 4133-4137 (1991 ) and Barbas et al., PNAS USA 88, 7978-7982 (1991)). Suitable V\nL\n and V\nH\n nucleic acid sequences may be selected using any appropriate method. For example, V\nL\n and V\nH\n nucleic acids may be selected by employing the epitope imprinting methods described in WO 93/06213. Antibody libraries, such as scFv libraries may be prepared and screened using known and suitable methods (with human IL-21-containing peptides as antigen(s)), such as those described in for instance WO92/01047, McCafferty et al., Nature 348, 552-554 (1990) and Griffiths et al., EMBO J 12, 725-734 (1993). Such antibody libraries and other combinations of IL-21 BPs (libraries, pools, etc.) are features of the present invention that may be used therapeutically to provide a more comprehensive immune response; as tools in screening methods for immunogenic peptides, small molecules, other anti-IL-21 antibodies (e.g., by way of competition assays), and the like; and/or in diagnostic methods and compositions (e.g., an immunoassay chip comprising a panel of such antibodies optionally in association with other antibodies may be prepared by standard techniques). Once initial human V\nL\n and V\nH\n \n\n segments are selected, \"mix and match\" experiments, in which different pairs of the initially selected V\nL\n and V\nH\n segments are screened for I L-21 -containing peptide binding, may be performed to select desirable V\nL\n/V\nH\n pair combinations. For example, reactivity of the peptides may be determined by ELISA or other suitable epitope analysis methods (see for instance Scott, J. K. and Smith, G. P. Science 249, 386-390 (1990), Cwirla et al., PNAS USA 87,\n\n\n6378-6382 (1990), Felici et al., J. MoI. Biol. 222, 301-310 (1991) and Kuwabara et al., Nature Biotechnology 15, 74-78 (1997) for discussion of such techniques and principles). Antibodies may be selected by their affinity for antigen and/or by their kinetics of dissociation (off-rate) from antigen (see for instance Hawkins et al., J. MoI. Biol. 226, 889-896 (1992)). To further improve the quality and/or diversity of anti-IL-21 antibodies, the V\nL\n and V\nH\n segments of V\nL\n/V\nH\n pair(s) may be randomly mutated, for instance within the CDR3 region of V\nH\n and/or V\nL\n, in a process analogous to the in vivo somatic mutation process responsible for affinity maturation of antibodies during a natural immune response. This in vitro affinity maturation may be accomplished by amplifying V\nH\n and V\nL\n regions using PCR primers complimentary to the V\nH\n CDR3 or V\nL\n CDR3, respectively, which primers typically are \"spiked\" with a random mixture of the four nucleotide bases at certain positions, such that the resultant PCR products encode V\nH\n and V\nL\n segments into which random mutations have been introduced into the V\nH\n and/or V\nL\n CDR3 regions. These randomly mutated V\nH\n and V\nL\n segments may be re-screened for binding to I L-21 -containing peptides. Following screening, nucleic acid encoding a selected antibody may be recovered from the display package (e.g., from the phage genome) and subcloned into an appropriate vector by standard recombinant DNA techniques. If desired, such an antibody-encoding nucleic acid may be further manipulated to create other antibody forms or IL-21 BPs. To express a recombinant antibody isolated by screening of a combinatorial library, typically a nucleic acid comprising a sequence encoding the antibody is cloned into a recombinant expression vector and introduced into appropriate host cells (mammalian cells, yeast cells, etc.) under conditions suitable for expression of the nucleic acid and production of the antibody.\n\n\nHigh-affinity antibody peptides, such as human single-chain Fv (scFv) and Fab antibody fragments, may also be isolated from such libraries using a panning technique in which the antigen of interest is immobilized on a solid surface, such as microtiter plates or beads (see for instance Barbas and Burton, Trends. Biotechnol. 14, 230-234 (1996) and Aujame et al., Hum. Antibodies 8, 155-68 (1997). Phage display of large naϊve libraries also makes it possible to isolate human antibodies directly without immunization (see for instance \n\n de Haard et al., J. Biol. Chem. 274(26), 18218-18230 (1999)). In these respects, the invention provides a method for producing anti-IL21 antibodies with increased affinity.\n\n\nIn one embodiment, the present invention provides variant anti-IL-21 antibodies. A \"variant\" anti-IL-21 antibody is an antibody that differs from a parent antibody (typically generated by immunization) by one or more suitable amino acid residue alterations, that is substitutions, deletions, insertions, or terminal sequence additions, in the CDRs or other V\nH\n and/or V\nL\n sequences (provided that at least a substantial amount of the epitope binding characteristics of the parent antibody are retained, if not improved upon, by such changes). Variations in an antibody variant may be made in each of the framework regions, the constant domain, and/or the variable regions (or any one or more CDRs thereof) in a single variant antibody. Alternatively, variations may be made in only one of the framework regions, the variable regions (or single CDR thereof), or the constant domain in an antibody. Alanine scanning mutagenesis techniques, such as described by Cunningham and Wells, Science 244, 1081-1085 (1989), may be used to identify suitable residues for substitution or deletion in generating IL-21 BPs comprising variant V\nL\n, V\nH\n, or particular CDR sequences, although other suitable mutagenesis techniques also may be applied. Multiple amino acid substitutions may also be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer, Science 241 , 53-57 (1988) or Bowie and Sauer, PNAS USA 86, 2152-2156 (1989). Thus, for example, in an antibody variant one or more amino acid residues may be introduced or inserted in or adjacent to one or more of the hypervariable regions of a parent antibody, such as in one or more CDRs. An anti-IL-21 antibody variant may comprise any number of inserted amino acid residues, provided again that at least a substantial amount of the epitope binding characteristics of the parent antibody are retained. An anti-IL-21 antibody variant of the present invention may for example comprise from about 1 -30 inserted amino acid residues, for instance from about 1 -10, such as for instance from about 2-10, for instance from 2-5 or such as from about 1-5 inserted amino acid residues. Likewise, an anti- IL-21 antibody variant of the present invention may for example comprise from about 1-30 deleted amino acid residues, for instance from about 1-10, such as for instance from about 2-10, for instance from 2-5 or such as from about 1 -5 deleted amino acid residues. Likewise, an anti-IL-21 antibody variant of the present invention may for example comprise from about 1-30 substituted amino acid residues, for instance from about 1-10, such as for instance from about 2-10, for instance from 2-5 or such as from about 1-5 substituted amino acid residues. Likewise, an anti-IL-21 antibody variant of the present invention may for example comprise from about 1-30 terminal sequence amino acid residue additions , for instance from about \n\n 1-10, such as for instance from about 2-10, for instance from 2-5 or such as from about 1 -5 terminal sequence amino acid residue additions. A antibody variant of the present invention may also comprise a combination of two or more of such insertions, deletings, substitutions and terminal sequence amino acid residue additions, provided that the variant possesses at least a substantial proportion of the parent antibodies affinity, specificity, and/or selectivity with respect to one or more IL-21 epitopes.\n\n\nConsiderations in the selection of antibody variants (e.g., conservation of amino acid residue functional characteristics, conservation of amino acid residues based on hydropathic characteristics, and/or conservation of amino acid residues on the basis of weight/size), are described elsewhere herein. Typically, amino acid sequence alterations, such as conservative substitution variations, desirably do not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to disrupt secondary structure that characterizes the function of the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in, e.g., Proteins, Structures and Molecular Principles (Creighton, Ed., W. H. Freeman and Company, New York (1984)), Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, N. Y. (1991)) and Thornton et at., Nature 354, 105 (1991). Additional principles relevant to the design and construction of peptide variants is discussed in for instance Collinet et al., J Biol Chem 275(23), 17428-33 (2000). Amino acid sequence variants of an antibody may be obtained by introducing appropriate nucleotide changes into the antibody-encoding nucleic acid (e.g., by site directed mutagenesis) or by chemical peptide synthesis. Such variants include, for example, deletions from, and/or insertions into and/or substitutions of and/or terminal sequence additions of residues within the amino acid sequences of the antibodies of the examples herein. Any combination of deletions, insertions, and substitutions may be made to arrive at a desired variant, provided that the variant possesses at least a substantial proportion of epitope binding characteristics of the parent antibody. Amino acid sequence changes, with respect to a parent antibody, also may alter post-translational processes of the variant antibody with respect to a parent antibody, such as by changing the number or position of glycosylation sites.\n\n\nVariant antibodies of the present invention may comprise alterations in the hypervariable region, such as in the CDRs. Examples of IL-21 BPs comprising such CDR variants are described elsewhere herein, and, as described above, such IL-21 BPs may be antibodies. \n\n Variant antibodies of the present invention may comprise framework (FR) alterations, that is outside the hypervariable region, for instance in the Fc region, which alterations may be associated with advantageous properties, such as changing the functional or pharmacokinetic properties of the antibodies. For example, a substitution or other modification (insertion, deletion, terminal sequence additions or combination of any thereof) in a framework region or constant domain may be associated with an increase in the half-life of the variant antibody with respect to the parent antibody, or may be made to alter the immunogenicity of the variant antibody with respect to the parent antibody, to provide a site for covalent or non-covalent binding to another molecule, or to alter such properties as complement fixation, for instance resulting in a decrease or increase of C1q binding and CDC or of FcyR binding and antibody-dependent cellular cytotoxicity (ADCC). Substitutions may for example be made in one or more of the amino acid residues 234, 235, 236, 237, 297, 318, 320, and 322 of the heavy chain constant region, thereby causing an alteration in an effector function while retaining binding to antigen as compared with the unmodified antibody, cf. US 5,624,821 and US 5,648,260. Further reference may be had to WO 00/42072 disclosing antibodies with altered Fc regions that increase ADCC, and WO 94/29351 disclosing antibodies having mutations in the N-terminal region of the C\nH\n2 domain that alter the ability of the antibodies to bind to FcRI and thereby decreases the ability of the antibodies to bind to C1q which in turn decreases the ability of the antibodies to fix complement. Furthermore, Shields et al., J. Biol. Chem. 276, 6591-6604 (2001) teaches combination variants, that improve FcγRIII binding, for instance T256A/S298A, S298A/E333A, and S298A/E333A/K334A, .\n\n\nThe in vivo half-life of the antibodies may also be improved by modifying the salvage receptor epitope of the Ig constant domain or an Ig-like constant domain such that the molecule does not comprise an intact C\nH\n2 domain or an intact Ig Fc region, cf. US 6,121 ,022 and US 6,194,551. The in vivo half-life may furthermore be increased by making mutations in the Fc region, e.g. by substituting threonine for leucine at position 252, threonine for serine at position 254, or threonine for phenylalanine at position 256, cf. US 6,277,375.\n\n\nIn one embodiment, the present invention provides variant anti-IL-21 antibodies wherein potential T cell epitopes in the antibody have been reduced or eliminated through rationale design. Thus, for example, in one embodiment the present invention provides a \"deimmunized\" anti-IL-21 antibody in which the potential T cell epitopes have been eliminated. The design and construction of deimmunized anti-IL-21 antibodies may be accomplished by any suitable known technique (see for instance WO9852976 with respect to methods for preparing deimmunized antibodies). Immunogenicity in humans is expected to \n\n be eliminated or substantially reduced when such IL-21 BPs (e.g., anti-IL-21 variant antibodies) are administered according to the present invention.\n\n\nOther framework mutations may include sequence changes which may reduce susceptibility to proteolysis, reduce susceptibility to oxidation, and/or confer or modify other physicochemical or functional properties on the associated variant antibody.\n\n\nAmino acid sequence variations in the framework may also result in an altered glycosylation pattern in the variant antibody with respect to a parent antibody. By altering is meant deleting one or more carbohydrate moieties found in the parent antibody, and/or adding one or more glycosylation sites that are not present in the parent antibody. Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are common recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide may create a potential glycosylation site. O-linked glycosylation refers to the attachment of sugars such as N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxy- proline or 5-hydroxylysine may also be used. Addition of glycosylation sites to the antibody may be conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).\n\n\nThe antibodies may also be expressed in a transfectoma which does not add the fucose unit normally attached to the carbohydrate attched to Asn at position 297 of Fc in order to enhance the affinity of Fc for FcγRIII which in turn will result in an increased ADCC of the antibodies in the presence of NK cells, cf. Shield et al., J. Biol. Chem. 277, 26733 (2002). Furthermore, modification of galactosylation may be made in order to modify CDC. Further reference may be had to WO 99/54342 and Umana et al., Nat. Biotechnol. X7_, 176 (1999) disclosing a CHO cell line engineered to express Gntlll resulting in the expression of monoclonal antibodies with altered glycoforms and improved ADCC activity.\n\n\nOther potentially suitable techniques for preparing novel anti-IL-21 antibodies include CDR walking mutagenesis, antibody chain shuffling, \"parsimonious mutagenesis\" (Balint and Larrick, Gene 137, 109-118 (1993)), and other affinity maturation techniques (see for instance Wu et al., PNAS USA 95, 6037-42 (1998)). Repertoire cloning procedures may also be useful in the production of variant antibodies (see for instance WO 96/33279). \n\n There are a number of techniques known for generating CDR variants, any suitable technique or combination of which may be used in the context of the present invention for generating CDR variants of the CDRs of the antibodies of the examples. Examples of such techniques include the removal of nonessential residues as described in Studnicka et al., Protein Engineering 7, 805-814 (1994) (see also Soderlind et al., Immunotechnology. 4(3-4), 279-85 (1999), CDR walking mutagenesis and other artificial affinity maturation techniques (see for instance Yang et al., Journal of Molecular Biology 254(3), 392-403 (1995), CDR shuffling techniques wherein typically CDRs are amplified from a diverse set of gene templates optionally comprising synthetic oligonucleotides, the constant regions of the V\nL\n, V\nH\n, and/or CDRs are amplified, and the various fragments mixed (in single-stranded or double- stranded format) and assembled by polymerase chain reaction (PCR) to produce a set of antibody-fragment encoding gene products carrying shuffled CDR introduced into the master framework, which is amplified using external primers annealing to sites beyond inserted restriction sites to ensure production of full-length products, which are inserted into a vector of choice and used to expressed variant CDR-containing proteins. Appropriate structure may be determined by superimposition of the variant/mimetic structures and those of the parent sequences, e.g., by comparison of NMR solution structures. Useful methods for rational design of CDR sequence variants are described in for instance WO 91/09967 and WO 93/16184. Additional examples of such methods are provided elsewhere herein. The present invention also provides \"fragments\" of antibodies (including variant antibodies) of the present invention, which fragments has the ability to bind to IL-21 (IL-21 binding fragments). IL-21 BPs thus include antibody-like molecules that comprise less than the full tetrameric structure associated with naturally-occurring antibodies. An antibody \"fragment\" may be any peptide that comprises a portion of a full length antibody, generally the antigen binding or variable region thereof (this includes, for example, fragments of humanized antibodies comprising CDRs from an antibody of the present invention, variants thereof, or other CDRs that allow the antigen fragment to compete with an antibody of the present invention for IL-21 binding). In one embodiment, an antibody fragment refers to a peptide that consists essentially or consists only of a portion of an antibody molecule. In one embodiment, the present invention provides an antibody fragment comprising at least a portion of a heavy chain variable domain containing one or more V\nH\n CDRs of an antibody of the present invention and optionally also a light chain-variable domain comprising one or more V\nL\n CDRs of an antibody of the present invention, wherein the heavy chain variable domain, and optionally the light chain variable domain, optionally is (are) fused to an additional moiety, such as an immunoglobulin constant domain. Constant domain sequences \n\n may be added to the heavy chain and/or light chain sequence(s) to form species with partial length heavy and/or light chain(s). Constant regions, or portions thereof, of any antibody isotype may be used for this purpose, including IgG, IgM, IgA, IgD, and IgE constant regions.\n\n\nExamples of IL-21-binding antibody fragments include Fab, Fab', F(ab')\n2\n, and Fv fragments. An antibody fragment in the context of the present invention may also include a a peptide comprising a CDR, and the like. In one embodiment, the present invention provides an antibody fragment comprising a first polypeptide chain that comprises any of the heavy chain CDRs described herein and a second polypeptide chain that comprises any of the light chain CDRs described herein, wherein the two polypeptide chains are covalently linked by one or more interchain disulfide bonds. In one embodiment, the present invention provides a two-chain antibody fragment having such features wherein the antibody fragment is selected from Fab, Fab', Fab'-SH, Fv, and/or F(ab')\n2\n fragments.\n\n\nAntibodies may be fragmented using conventional techniques, and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab')\n2\n fragments may be generated by treating antibody with pepsin. The resulting F(ab')\n2\n fragment may be treated to reduce disulfide bridges to produce Fab' fragments. Fab fragments may be obtained by treating an IgG antibody with papain; F(ab') fragments may be obtained with pepsin digestion of IgG antibody. A F(ab') fragment may also be produced by binding Fab' described below via a thioether bond or a disulfide bond. A Fab' fragment is an antibody fragment obtained by cutting a disulfide bond of the hinge region of the F(ab')\n2\n. A Fab' fragment may be obtained by treating a F(ab')\n2\n fragment with a reducing agent, such as dithiothreitol. Antibody fragment peptides may also be generated by expression of nucleic acids encoding such peptides in recombinant cells (see for instance Evans et al., J. Immunol. Meth. 184, 123-38 (1995)). For example, a chimeric gene encoding a portion of a F(ab')\n2\n fragment could include DNA sequences encoding the C\nH\n1 domain and hinge region of the H chain, followed by a translational stop codon to yield such a truncated antibody fragment molecule. From the aforegoing, it is understood that the term \"fragment\" does not imply any method of production (e.g., a \"fragment\" need not be made by \"fragmentation\").\n\n\nIL-21 BPs also include univalent antibodies and single chain antibodies. Single chain antibodies are peptides in which the heavy and light chain Fv regions are connected. In one embodiment, the present invention provides a single-chain Fv (scFv) wherein the heavy and light chains in the Fv of an anti-IL-21 antibody of the present invention are joined with a flexible peptide linker (typically of about 10, 12, 15 or more amino acid residues) in a single peptide chain. Methods of producing such antibodies are described in for instance US 4,946,778, Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg \n\n and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994), Bird et al., Science 242, 423-426 (1988), Huston et al., PNAS USA 85, 5879-5883 (1988) and McCafferty et al., Nature 348, 552-554 (1990). The single chain antibody may be monovalent, if only a single V\nH\n and V\nL\n are used, bivalent, if two V\nH\n and V\nL\n are used, or polyvalent, if more than two V\nH\n and V\nL\n are used.\n\n\nIn one embodiment of the present invention, an IL-21 BP may be derivatized or linked to another functional molecule, for instance another peptide or protein (such as a Fab' fragment) to generate a bispecific or multispecific molecule which binds to multiple binding sites or target epitopes (examples of bispecific and multispecific antibodies are discussed elsewhere herein). For example, an antibody of the present invention may be functionally linked (for instance by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other binding molecules, such as another antibody, peptide or binding mimetic. In one embodiment, the IL-21 BP is an antibody of the present invention.\n\n\nBispecific and multispecific molecules of the present invention may further include a third binding specificity, in addition to the anti-IL-21 binding specificity. Such molecules may for instance be prepared as described in WO2006/072620.\n\n\nIn one embodiment, the bispecific and multispecific molecules of the present invention comprise as a binding specificity at least one further antibody, including, e.g., an Fab, Fab', F(ab')2, Fv, or a scFv. The further antibody may also be a light chain or heavy chain dimer, or any minimal fragment thereof such as a Fv or a single chain construct as described in Ladner et al., in US 4,946,778. The antibody may also be a binding-domain immunoglobulin fusion protein as disclosed in US 2003/0118592 and US 2003/0133939.\n\n\nIn one embodiment, an IL-21 BP of the present invention is a multispecific anti-IL-21 antibody or antibody-like molecule, a particular example of which is a bispecific antibody comprising at least one pair of V\nH\n sequence and V\nL\n sequence chains specific for an epitope comprised at least in part in IL-21 and a second at least one pair of V\nH\n and V\nL\n sequence chains specific for a second epitope. The V\nH\n and V\nL\n sequences in a bispecific antibody may comprise complete V\nH\n and V\nL\n sequences corresponding to anti-IL-21 V\nH\n and V\nL\n regions, variant V\nH\n and/or V\nL\n sequences, or suitable portions of V\nH\n and/or V\nL\n regions, such as a suitable combination of CDR sequences and other sequences sufficient to provide binding to the epitopes of interest.\n\n\nIn one embodiment, a bispecific antibody of the present invention is a diabody. Bispecific antibodies also include cross-linked or \"heteroconjugate\" antibodies. For example, one of the antibodies in a heteroconjugate may be coupled to avidin and the other to biotin. Such antibodies have, for example, been proposed to target immune system cells \n\n to unwanted cells (see for instance US 4,676,980). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable peptide cross-linking agents and techniques are well known in the art, and examples of such agents and techniques are disclosed in for instance US 4,676,980. Thus, although the discussion herein may focus on antibodies, it should be understood that the embodiments and features of the antibodies may equally be applied to antibody fragments, such as Fab fragments, Fab' fragments, and scFv peptides, antibody- like peptides (peptides comprising a CDR), bi- and multi-specific antibodies and other IL-21 BPs, as appropriate, provided that the IL-21 BP of the present invention retains at least a substantial proportion of the antigen-binding properties of the corresponding complete antibody. In some instances, antibody fragments may be associated with lower antigen- binding affinity, but may offer other advantageous features that may offset for any such loss in affinity.\n\n\nIL-21 BPs of the present invention, and particularly anti-IL-21 antibodies may be selected based on their ability to provide the ability of complement fixation, or not. There are a number of isotypes of antibodies that are capable of complement fixation and CDC, including, without limitation, the following: murine IgM, murine lgG2a, murine lgG2b, murine lgG3, human IgM, human IgGI , and human lgG3. Those isotypes that do not include, without limitation, human lgG2 and human lgG4. lsotype determination and other methods for modifying the complement fixation and CDC functional characteristics of antibodies are known in the art.\n\n\nIL-21 BPs of the present invention also include immunoadhesins, which are molecules wherein one or more CDRs of an anti-IL-21 antibody are covalently or noncovalently associated with the molecule. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to an IL-21.\n\n\nThe present invention also provides IL-21 BP fusion proteins. IL-21 BP fusion proteins may comprise any suitable amino acid sequence or combination of sequences that are specific and/or selective for at least one domain that is at least partially comprised within IL-21 (e.g., an anti-IL-21 antibody V\nH\n domain, V\nL\n domain, or particular CDRs thereof) and at least one nonhomologous and typically substantially nonsimilar amino acid sequence (e.g., less than about 40%, less than about 35%, less than about 30%, less than about 25%, or less than about 20% amino acid sequence identity to the IL-21 -specific/selective sequence) that imparts a detectable biological function and/or characteristic to the fusion protein that \n\n cannot solely be attributed to the I L-21 -specific/selective sequence (e.g., increased in vivo half-life, fluorescence, increased targeting to a particular type of cell, etc.). Functional sequences of such a fusion protein may be separated by flexible linker(s). Secondary sequence(s) may also be derived from cytotoxic or apoptotic peptides. Secondary sequences may also confer diagnostic properties. Examples of such sequences include those derived from easily visualized enzymes such as horseradish peroxidase.\n\n\nIL-21 BP fusion proteins may also be characterized by comprising an epitope tag. An epitope tag sequence is an amino acid sequence having enough residues to provide an epitope against which an antibody may be made, in the context of the IL-21 BP, yet is short enough such that it does not substantially interfere with the activity (selectivity, specificity, affinity, and/or biological activity) of the IL-21 BP (as compared to a parent IL-21 BP lacking the epitope tag). An epitope tag desirably is sufficiently unique so that the anti-epitope tag antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least about 6 amino acid residues and usually between about 8-50 amino acid residues (e.g., about 9-30 residues). Examples of epitope tags include the flu HA tag polypeptide and its antibody 12CA5 (Field et al., MoI. Cell. Biol. 8, 2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., MoI. Cell. Biol. 5(12), 3610-3616 (1985)) and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering 3(6), 547-553 (1990)). In certain embodiments, the epitope tag is a \"salvage receptor binding epitope\". As used herein, the term \"salvage receptor binding epitope\" refers to an epitope of the Fc region of an IgG molecule (for instance IgGI , lgG2, lgG3, or lgG4) that is responsible for increasing the in vivo serum half-life of the IgG molecule.\n\n\nIL-21 BPs of the present invention also include IL-21 BP derivatives. IL-21 BP derivatives may be produced by chemically conjugating a radioisotope, protein, or other agent/moiety/compound to the N-terminal side or C-terminal side of the I L-21 BP or subunit thereof (e.g., an anti-IL-21 antibody H chain, L chain, or anti-IL-21 specific/selective fragment thereof), an appropriate substituent group or side chain or to a sugar chain in the IL-21 BP (see, e.g., Antibody Engineering Handbook, edited by Osamu Kanemitsu, published by Chijin Shokan (1994)). Derivatives may also be generated by conjugation at internal residues or sugars, where appropriate.\n\n\nA derivative may for instance be a peptide in which one or more of the amino acid residues of the peptide have been chemically modified (e.g. by alkylation, acylation, ester formation, or amide formation) or covalently associated with one or more heterologous substituents (e.g., a lipophilic substituent, a PEG moiety, a peptide side chain linked by a \n\n suitable organic moiety linker, etc.). The peptide may also be conjugated to a therapeutic moiety, such as a cytotoxin, a chemotherapeutic drug, an immunosuppressant, or a radioisotope (a socalled immunoconjugate). In general, IL-21 BPs described herein may be modified by inclusion of any suitable number of such modified amino acids and/or associations with such conjugated substituents. Suitability in this context is generally determined by the ability to at least substantially retain IL-21 selectivity and/or specificity associated with the non-derivatized parent IL-21 BP. The inclusion of one or more modified amino acids may be advantageous in, for example, increasing polypeptide serum half-life, reducing polypeptide antigenicity, or increasing polypeptide storage stability. Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production (e. g., N-linked glycosylation at N-X-S/T motifs during expression in mammalian cells) or modified by synthetic means. Non-limiting examples of a modified amino acid include a glycosylated amino acid, a sulfated amino acid, a prenlyated (e. g., farnesylated, geranylgeranylated) amino acid, an acetylated amino acid, an acylated amino acid, a PEGylated amino acid, a biotinylated amino acid, a carboxylated amino acid, a phosphorylated amino acid, and the like. References adequate to guide one of skill in the modification of amino acids are replete throughout the literature. Example protocols are found in Walker (1998) Protein Protocols On Cd-Rom, Humana Press, Towata, NJ. The modified amino acid may for instance be selected from a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, an amino acid conjugated to a lipid moiety, or an amino acid conjugated to an organic derivatizing agent.\n\n\nFor instance, antibodies may be chemically modified by covalent conjugation to a polymer to for instance increase their circulating half-life. Exemplary polymers, and methods to attach them to peptides, are illustrated in for instance US 4,766,106, US 4,179,337, US 4,495,285 and US 4,609,546. Additional illustrative polymers include polyoxyethylated polyols and polyethylene glycol (PEG) (e.g., a PEG with a molecular weight of between about 1 ,000 and about 40,000, such as between about 2000 and about 20,000, e.g., about 3,000-12,000). In one embodiment, the present invention provides an IL-21 BP that is conjugated to a second molecule that is selected from a radionuclide, an enzyme, an enzyme substrate, a cofactor, a fluorescent marker, a chemiluminescent marker, a peptide tag, or a magnetic particle. In one embodiment, an IL-21 BP may be conjugated to one or more antibody fragments, nucleic acids (oligonucleotides), nucleases, hormones, immunomodulators, chelators, boron compounds, photoactive agents, dyes, and the like. These and other \n\n suitable agents may be coupled either directly or indirectly to IL-21 BPs of the present invention. One example of indirect coupling of a second agent is coupling by a spacer moiety. These spacers, in turn, may be either insoluble or soluble (see for instance Diener et al., Science 231 , 148 (1986)) and may be selected to enable drug release from the IL-21 BP at a target site and/or under particular conditions. Additional examples of therapeutic agents that may be coupled to IL-21 BPs include lectins and fluorescent peptides.\n\n\nIn one embodiment, IL-21 BP derivatives comprising one or more radiolabeled amino acids are provided. A radiolabeled IL-21 BP may be used for both diagnostic and therapeutic purposes (conjugation to radiolabeled molecules is another possible feature). Nonlimiting examples of labels for polypeptides include, but are not limited to 3H, 14C, 15N, 35S, 9OY, 99Tc, and 1251, 1311, and 186Re. Methods for preparing radiolabeled amino acids and related peptide derivatives are known in the art (see for instance Junghans et al., in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)) and US 4,681 ,581 , US 4,735,210, US 5,101 ,827, US 5,102,990 (US RE35,500), US 5,648,471 and US 5,697,902. For example, a radioisotope may be conjugated by a chloramine T method.\n\n\nAdvantageous radionuclides in diagnostic contexts are indium isotopes and in the context of therapeutic applications yttrium isotopes, which are cytotoxic. Photon-emitting radioisotopes, in general, are advantageous in diagnostic (radioimmunoscintigraphy (RIS)) methods. Auger electrons have a very short path length (5-10 nm) and need to be internalized to be cytotoxic (see for instance Adelstein et al., Nucl. Med. Biol. 14, 165-169 (1987)). Accordingly, peptides conjugated to such isotopes may be useful in diagnostic methods, but only peptides that are internalized should be considered for radioisotopes that emit Auger electrons in therapeutic contexts. Alpha particles need to be close to a cell (within 3-4 cell diameters) to be effective as therapeutic agents (Vriesendorp et al.,\n\n\n\"Radioimmunoglobulin therapy,\" in High Dose Cancer Therapy Armitage et al., (eds). (Williams & Wilkins, Baltimore, Md. 1992)). Both Auger electrons and alpha emitters may be considered to have high selectivity because their short-range emission typically will not irradiate neighboring normal cells. The radiometals \n111\nIn and \n90\nY are, respectively, a pure γ-emitter and a pure β-emitter. lodine-125, the most commonly used emitter of Auger electrons, has a half-life of about 60 days and frequently is released by immunoconjugates in vivo (due to dehalogenation). The most commonly considered alpha emitters for clinical use, astatine-21 1 and bismuth-212, have relatively short half-lives (7.2 h and 1.0 h, respectively) and decay into radioactive isotopes that may not be retained by the immunoconjugate after the first \n\n alpha emission (Wilbur, Antibiot. Immunoconjug. Radiopharm. 4, 5-97 (1991)). For diagnostic applications, IL-21 BPs labeled with indium-11 1 or technetium-99m may be used. Both of these isotopes emit gamma rays within the appropriate energy range for imaging, (100-250 keV). Energies below this range typically are not penetrating enough to reach an external imaging device. Higher energy levels are difficult to collimate and provide diagnostic images with poor resolution. The short-half life of \n99\nTc typically restricts its use to immunoconjugates with rapid tumor uptake.\n\n\nIn one embodiment, first and second IL-21 BPs conjugated with first and second radioisotopes are provided. In another embodiment, a single IL-21 BP conjugated with two radioisotopes is provided. An advantage of using two separate radioisotopes, e.g., one for imaging and one for therapy, is that it facilitates outpatient treatment. The low amount of radioactivity used diagnostically does not represent a radiation hazard, while the radiation emitted by a therapeutic isotope, such as a pure β-emitter, typically will largely be absorbed in the vicinity of the targeted cells. Radioisotopes may be attached directly or indirectly to an IL-21 BP. The radioisotopes \n125\nI, \n131\nI, \n99\nTc, \n186\nRe, and \n188\nRe may be, for example, covalently bound to proteins (including antibodies) through amino acid functional groups. For radioactive iodine it is usually through the phenolic group found on tyrosine. There are numerous methods to accomplish this: chloramine-T (see for instance Greenwood et al., Biochem J. 89, 114-123 (1963) and lodogen (Salacinski et al., Anal. Biochem. V\\l_, 136-146 (1981)). Tc and Re isotopes may be covalently bound through the sulfhydryl group of cysteine (see for instance Griffiths et al., Cancer Res. 51., 4594-4602 (1991)). However, such compositions may be relatively better suited for diagnostic purposes as the body often can break these covalent bonds, releasing the radioisotopes to the circulatory system. A IL-21 BP may also be labeled with enzymes that are useful for detection, such as horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase, glucose oxidase, and the like. A IL-21 BP may also be labeled with biotin, and accordingly detected through indirect measurement of avidin or streptavidin binding. A IL-21 BP may also be labeled with a predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags, etc.). Additional examples of enzyme conjugate candidates include malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, α-glycerophosphate dehydrogenase, triose phosphate isomerase, asparaginase, glucose oxidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholinesterase. \n\n Additional exemplary labeling moieties generally include, but are not limited to spin- labeled molecules and other labeling moieties of diagnostic value.\n\n\nIn one embodiment, the present invention provides crosslinked IL-21 BP derivatives. For example, such an IL-21 BP derivative may be produced by crosslinking two or more antibodies, at least one of which is specific/selective for IL-21 (of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate). Such linkers are available from Pierce Chemical Company, Rockford, III.\n\n\nIL-21 BPs may also be derivatized with a detection agents, for instance fluorescent compounds, including fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine- 1-napthalenesulfonyl chloride, lanthanide phosphors, and the like. Additional examples of suitable fluorescent labels include a \n125\nEu label, an isothiocyanate label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an o-phthaldehyde label, a fluorescamine label, etc. Examples of chemiluminescent labels include luminal labels, isoluminal labels, aromatic acridinium ester labels, imidazole labels, acridinium salt labels, oxalate ester labels, a luciferin labels, luciferase labels, aequorin labels, etc.\n\n\nIn one embodiment, an IL-21 BP derivative comprises a conjugated nucleic acid or nucleic acid-associated molecule. In one such facet of the present invention, the conjugated nucleic acid is a cytotoxic ribonuclease. In one embodiment, the conjugated nucleic acid is an antisense nucleic acid (for instance a S100A10 targeted antisense molecule, which may also be an independent component in a combination composition or combination administration method of the present invention - see for instance Zhang et al., J Biol Chem. 279(3), 2053-62 (2004)). In one embodiment, the conjugated nucleic acid is an inhibitory RNA molecule (e.g., a siRNA molecule). In one embodiment, the conjugated nucleic acid is an immunostimulatory nucleic acid (e.g., an immunostimulatory CpG motif-containing DNA molecule). In one embodiment, the conjugated nucleic acid is an expression cassette coding for expression of a tumor suppressor gene, anti-cancer vaccine, anti-cancer cytokine, or apoptotic agent. Such derivatives also may comprise conjugation of a nucleic acid coding for expression of one or more cytotoxic proteins, such as plant and bacterial toxins.\n\n\nIn one embodiment, an IL-21 BP is conjugated to a functional nucleic acid molecule. Functional nucleic acids include antisense molecules, interfering nucleic acid molecules (e.g., siRNA molecules), aptamers, ribozymes, triplex forming molecules, and external guide sequences. The functional nucleic acid molecules may act as affectors, inhibitors, \n\n modulators, and stimulators of a specific activity possessed by a target molecule, or the functional nucleic acid molecules may possess a de novo activity independent of any other molecules. A representative sample of methods and techniques which aid in the design and use of antisense molecules may be found in the following non-limiting list of US patents: US 5,135,917, US 5,294,533, US 5,627,158, US 5,641 ,754, US 5,691 ,317, US 5,780,607, US 5,786,138, US 5,849,903, US 5,856,103, US 5,919,772, US 5,955,590, US 5,990,088, US 5,994,320, US 5,998,602, US 6,005,095, US 6,007,995, US 6,013,522, US 6,017,898, US 6,018,042, US 6,025,198, US 6,033,910, US 6,040,296, US 6,046,004, US 6,046,319 and US 6,057,437. In one embodiment, an IL-21 BP is conjugated to an aptamer. Aptamers are molecules that interact with a target molecule, for instance in a specific way. Typically aptamers are small nucleic acids ranging from 15-50 bases in length that fold into defined secondary and tertiary structures, such as stem-loops or G-quartets. Aptamers can bind small molecules, such as ATP (US 5,631 ,146) and theophiline (US 5,580,737), as well as large molecules, such as reverse transcriptase (US 5,786,462) and thrombin (US 5,543,293). Representative examples of how to make and use aptamers to bind a variety of different target molecules may be found in the following non-limiting list of US patents: US 5,476,766, US 5,503,978, US 5,631 ,146, US 5,731 ,424, US 5,780,228, US 5,792,613, US 5,795,721 , US 5,846,713, US 5,858,660, US 5,861 ,254, US 5,864,026, US 5,869,641 , US 5,958,691 , US 6,001 ,988, US 6,01 1 ,020, US 6,013,443, US 6,020,130, US 6,028,186, US 6,030,776 and US 6,051 ,698.\n\n\nIn one embodiment, the present invention provides an IL-21 BP which is conjugated to a ribozyme. Ribozymes are nucleic acid molecules that are capable of catalyzing a chemical reaction, either intramolecularly or intermolecularly. Ribozymes are thus catalytic nucleic acids. There are a number of different types of ribozymes that catalyze nuclease or nucleic acid polymerase type reactions which are based on ribozymes found in natural systems, such as (a) hammerhead ribozymes, (described in for example US 5,334,711 , US 5,436,330, US 5,616,466, US 5,633,133, US 5,646,020, US 5,652,094, US 5,712,384, US 5,770,715, US 5,856,463, US 5,861 ,288, US 5,891 ,683, US 5,891 ,684, US 5,985,621 , US 5,989,908, US 5,998,193, US 5,998,203, WO 9858058, WO 9858057 and WO 9718312), (b) hairpin ribozymes (described in for instance US 5,631 , 115, US 5,646,031 , US 5,683,902, US 5,712,384, US 5,856,188, US 5,866,701 , US 5,869,339 and US 6,022,962), and (c) tetrahymena ribozymes (described in for instance US 5,595,873 and US 5,652,107). There are also a number of ribozymes that are not found in natural systems, but which have been engineered to catalyze specific reactions de novo (examples of which are described in for \n\n instance US 5,580,967, US 5,688,670, US 5,807,718 and US 5,910,408). Ribozymes typically cleave RNA or DNA substrates, and more commonly cleave RNA substrates. Ribozymes typically cleave nucleic acid substrates through recognition and binding of the target substrate with subsequent cleavage. This recognition is often based mostly on canonical or non-canonical base pair interactions. This property makes ribozymes particularly good candidates for target specific cleavage of nucleic acids because recognition of the target substrate is based on the target substrates sequence. Representative examples of how to make and use ribozymes to catalyze a variety of different reactions may be found in the following non-limiting list of US patents: US 5,646,042, US 5,693,535, US 5,731 ,295, US 5,811,300, US 5,837,855, US 5,869,253, US 5,877,021, US 5,877,022, US 5,972,699, US 5,972,704, US 5,989,906 and US 6,017,756.\n\n\nIn one embodiment, the present invention provides an IL-21 BP that is conjugated to a triplex forming function nucleic acid. Such nucleic acid molecules can interact with either double-stranded or single-stranded nucleic acid. When triplex molecules interact with a target region, a structure called a triplex is formed, in which three strands of DNA form a complex dependant on both Watson-Crick and Hoogsteen base-pairing. Triplex molecules can bind target regions with high affinity and specificity. Representative examples of how to make and use triplex forming molecules to bind a variety of different target molecules may be found in the following non-limiting list of US patents: US 5,176,996, US 5,645,985, US 5,650,316, US 5,683,874, US 5,693,773, US 5,834,185, US 5,869,246, US 5,874,566 and US 5,962,426.\n\n\nIn one embodiment, an IL-21 BP is conjugated to an external guide sequence. External guide sequences (EGSs) are molecules that bind a target nucleic acid molecule forming a complex that is recognized by RNase P, which cleaves the target molecule. EGSs may be designed to specifically target a RNA molecule of choice. RNAse P aids in processing transfer RNA (tRNA) within a cell. Bacterial RNAse P may be recruited to cleave virtually any RNA sequence by using an EGS that causes the target RNA:EGS complex to mimic the natural tRNA substrate, (see for instance WO 92/03566 and Forster and Altman, Science 238, 407-409 (1990) for discussion). Representative examples of how to make and use EGS molecules to facilitate cleavage of a variety of different target molecules are provided in the following non-limiting list of US patents: US 5,168,053, US 5,624,824, US 5,683,873, US 5,728,521 , US 5,869,248 and US 5,877,162.\n\n\nIn one embodiment, an IL-21 BP is conjugated to an interfering nucleic acid molecule, such as a siRNA or other RNAi molecule (e.g., an inhibitory double stranded (ds) RNA molecule of about 20-25 nucleotides), which is targeted to interfere with the action of a target gene expression product, such as a gene expression product involved in an IL-21 \n\n mediated disease or condition. Methods for the production and use of interfering nucleic acid molecules are provided in for instance Nishikura, Cell. 107(4), 415-8 (2001), Fjose et al., Biotechnol Annu Rev. 7, 31-57 (2001 ), Hanon, Nature 418, 244-51 (2002), Brantl, Biochim Biophys Acta. 1575(1-3). 15-25 (2002), Tuschl, Chembiochem. 2(4), 239-45 (2001), Caplen, Expert Opin Biol Ther. 3(4), 575-86 (2003), Lu et al., Curr Opin MoI Ther. 5(3), 225-34 (2003), Shuey et al., Drug Discov Today. 7(20), 1040-6 (2002), Shi, Trends Genet. 19(1), 9-12 (2003), Kovar et al., Semin Cancer Biol. 13(4), 275-81 (2003), Lavrey et al., Curr Opin Drug Discov Devel. 6(4), 561 -9 (2003), Clewey, Commun Dis Public Health. 6(2), 162-3 (2003), Duxbury et al., J Surg Res. H7(2), 339-44 (2004), Caplen et al., Ann N Y Acad Sci. 1002, 56-62 (2003), WO 01/75164, US 6,506,559, US 20040086884, US 20040077574, US 20040063654, US 20040033602, US 20030167490, US 20030157030, US 200301 14409, US 20030108923, US 200400141 13 and US 20020132788.\n\n\nIn one embodiment, an IL-21 BP is conjugated to a tumor targeting domain peptide or molecule. In one embodiment, an IL-21 BP is conjugated to a tumor targeting factor VII sequence.\n\n\nAny method known in the art for conjugating the IL-21 BP to the conjugated molecule(s), such as those described above, may be employed, including those methods described by Hunter et al., Nature 144, 945 (1962), David et al., Biochemistry 13, 1014 (1974), Pain et al., J. Immunol. Meth. 40, 219 (1981 ) and Nygren, J. Histochem. and Cytochem. 30, 407 (1982). Linkage/conjugation may be accomplished in any suitable way. For example, a covalent linkage may take the form of a disulfide bond (if necessary and suitable, an IL-21 BP could be engineered to contain an extra cysteine codon, which desirably does not interfere with the IL-21 binding activity of the molecule. A toxin molecule, derivatized with a sulfhydryl group reactive with the cysteine of the modified IL-21 BP, may form an immunoconjugate with the IL-21 BP peptide. Alternatively, a sulfhydryl group may be introduced directly to an IL-21 BP using solid phase polypeptide techniques. For example, the introduction of sulfhydryl groups into peptides is described by Hiskey, Peptides 3, 137 (1981). The introduction of sulfhydryl groups into proteins is described in Maasen et al., Eur. J. Biochem. 134, 32 (1983). Once the correct sulfhydryl groups are present, the cytotoxin and IL-21 BP may be purified, both sulfur groups reduced; cytotoxin and ligand mixed (for instance in a ratio of about 1 :5 to 1 :20); and disulfide bond formation allowed to proceed to completion (generally about 20 to 30 minutes) at room temperature. The mixture may then be dialyzed against phosphate buffered saline or chromatographed in a resin such as Sephadex to remove unreacted ligand and toxin molecules. \n\n Numerous types of cytotoxic compounds may be joined to proteins through the use of a reactive group on the cytotoxic compound or through the use of a cross-linking agent. A common reactive group that will form a stable covalent bond in vivo with an amine is isothiocyanate (Means et al., Chemical modifications of proteins (Holden-Day, San Francisco 1971 ) pp. 105-1 10). This group preferentially reacts with the ε-amine group of lysine.\n\n\nMaleimide is a commonly used reactive group to form a stable in vivo covalent bond with the sulfhydryl group on cysteine (Ji., Methods Enzymol 91., 580-609 (1983)). Monoclonal antibodies typically are incapable of forming covalent bonds with radiometal ions, but they may be attached to the antibody indirectly through the use of chelating agents that are covalently linked to the antibodies. Chelating agents may be attached through amines\n\n\n(Meares et al., Anal. Biochem. 142, 68-78 (1984)) and sulfhydral groups (Koyama, Chem. Abstr. 120, 217262t (1994)) of amino acid residues and also through carbohydrate groups (Rodwell et al., PNAS USA 83, 2632-2636 (1986), Quadri et al., Nucl. Med. Biol. 20, 559-570 (1993)). Since these chelating agents contain two types of functional groups, one to bind metal ions and the other to joining the chelate to the antibody, they are commonly referred as bifunctional chelating agents (Sundberg et al., Nature 250, 587-588 (1974)).\n\n\nCrosslinking agents that have two reactive functional groups are classified as being homo or heterobifunctional. Examples of homobifunctional crosslinking agents include bismaleimidohexane (BMH) which is reactive with sulfhydryl groups (Chen et al., J Biol Chem 266, 18237-18243 (1991)) and ethylene glycolbis[succinimidylsucciate] (EGS) which is reactive with amino groups (Browning et al., J. Immunol. 143, 1859-1867 (1989)). An example of a heterobifunctional crosslinker is m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (Myers et al., J. Immunol. Meth.121, 129-142 (1989)). These methodologies are simple and are commonly employed. A therapeutic or diagnostic agent may also or alternatively be attached at the hinge region of a reduced antibody component via disulfide bond formation. As an alternative, such peptides may be attached to the antibody component using a heterobifunctional cross-linker, such as N-succinyl 3-(2-pyridyldithio)proprionate (SPDP). Yu et al., Int. J. Cancer 56, 244 (1994). General techniques for such conjugation are well known in the art. See, for example, Wong, Chemistry Of Protein Conjugation And Cross-Linking (CRC Press 1991 ), Upeslacis et al., \"Modification of Antibodies by Chemical Methods,\" In Monoclonal Antibodies: Principles And Applications, Birch et al., (eds.) (Wiley-Liss, Inc. 1995), Price, \"Production and Characterization of Synthetic Peptide-Derived Antibodies,\" in Monoclonal Antibodies: Production, Engineering And Clinical Application, Ritter et al., (eds.) (Cambridge University Press 1995). \n\n In some embodiments, labels or other conjugated substituents are attached to the IL-21 BP amino acid sequence by spacer arms of various lengths to reduce potential steric hindrance.\n\n\nUnlabeled IL-21 BP(s) may be used in combination with other labeled antibodies (second antibodies) that are reactive with the IL-21 BP(s), such as antibodies specific for human immunoglobulin constant regions that bind to anti-IL-21 mAbs. Alternatively, an IL-21 BP may be directly labeled. A wide variety of labels may be employed for direct or indirect labeling of IL-21 BPs, such as labeling with radionuclides, fluors, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens), etc. Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue or the antibody fused to an epitope tag. Other insertion variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody of an enzyme or a polypeptide or PEG which increases the serum half-life of the antibody. Such anti-IL-21 antibody fusion proteins and similar fusion proteins comprising IL-21 BP sequences are another feature of the present invention.\n\n\nA cytotoxin or cytotoxic agent includes any agent that is detrimental to (e.g., kills) cells. For a description of these classes of drugs which are well known in the art, and their mechanisms of action, see Goodman et al., Goodman and Gilman's The Pharmacological Basis Of Therapeutics, 8th Ed., Macmillan Publishing Co., 1990. Additional techniques relevant to the preparation of antibody immunotoxins are provided in for instance Vitetta, Immunol. Today 14, 252 (1993) and US 5,194,594. Suitable therapeutic agents for forming immunoconjugates of the present invention include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydro- testosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin, antimetabolites (such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabin, 5-fluorouracil, decarbazine, hydroxyurea, asparaginase, gemcitabine, cladribine), alkylating agents (such as mechlorethamine, thioepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin and other platinum derivatives, such as carboplatin), antibiotics (such as dactinomycin (formerly actinomycin), bleomycin, \n\n daunorubicin (formerly daunomycin), doxorubicin, idarubicin, mithramycin, mitomycin, mitoxantrone, plicamycin, anthramycin (AMC)), diphtheria toxin and related molecules (such as diphtheria A chain and active fragments thereof and hybrid molecules), ricin toxin (such as ricin A or a deglycosylated ricin A chain toxin), cholera toxin, a Shiga-like toxin (SLT-I, SLT-II, SLT-IIV), LT toxin, C3 toxin, Shiga toxin, pertussis toxin, tetanus toxin, soybean Bowman- Birk protease inhibitor, Pseudomonas exotoxin, alorin, saporin, modeccin, gelanin, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, and enomycin toxins. Therapeutic agents, which may be administered in combination with an IL-21 BP of the present invention as described elsewhere herein, may also be candidates for therapeutic moieties useful for conjugation to an IL-21 BP of the present invention.\n\n\nOther examples of therapeutic cytotoxins that may be conjugated to an IL-21 BP of the present invention include calicheamicins and duocarmycins. As indicated above, the drug moiety need not be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, an agent active at the cell surface, such as phospholipase enzymes, e.g. phospholipase C.\n\n\nThe lysing portion of a toxin typically may be readily joined to the Fab fragment of an antibody or antibody fragment of the present invention. Other suitable conjugated molecules include ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, diphtherin toxin, and Pseudomonas endotoxin. See, for example, Pastan et al., Cell 47, 641 (1986) and Goldenberg, Calif. A Cancer Journal for Clinicians 44, 43 (1994). Additional toxins suitable for use in the present invention are known to those of skill in the art (seefor instance US 6,077,499).\n\n\nConjugates of IL-21 BPs, such as antibodies, and such cytotoxic moieties may be made using a variety of bifunctional protein coupling agents. Examples of such reagents include SPDP, IT, bifunctional derivatives of imidoesters such a dimethyl adipimidate HCI, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bis-azido compounds such as bis (p-azidobenzoyl) hexanediamine, bis-diazonium derivatives such as bis-(p-diazoniumbenzoyl)-ethylenediamine, diisocyanates such as tolylene 2,6-diisocyanate, and bis-active fluorine compounds such as 1 ,5-difluoro-2,4-dinitrobenzene and anti-mitotic agents (e.g., vincristine, vinblastine, docetaxel, paclitaxel and vinorelbin).\n\n\nTechniques for conjugating such therapeutic moieties to IL-21 BPs, such as antibodies, are well known, see for instance Arnon et al., \"Monoclonal Antibodies For \n\n lmmunotargeting Of Drugs In Cancer Therapy\", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al., (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985), Hellstrom et al., \"Antibodies For Drug Delivery\", in Controlled Drug Delivery (2nd Ed.), Robinson et al., (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987), Thorpe, \"Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review\", in Monoclonal Antibodies '84: Biological And Clinical\n\n\nApplications, Pinchera et al., (eds.), pp. 475-506 (1985), \"Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy\", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al., (eds.), pp. 303-16 (Academic Press 1985) and Thorpe et al., \"The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates\", Immunol. Rev. 62, 119-58 (1982).\n\n\nIn one embodiment, the present invention provides an IL-21 BP that is conjugated to a mixed toxin. A mixed toxin molecule is a molecule derived from two different (typically polypeptide) toxins. Generally, peptide toxins comprise one or more domains responsible for generalized eukaryotic cell binding, at least one enzymatically active domain, and at least one translocation domain. The binding and translocation domains are required for cell recognition and toxin entry respectively. Naturally-occurring proteins which are known to have a translocation domain include diphtheria toxin, Pseudomonas exotoxin A, and possibly other peptide toxins. The translocation domains of diphtheria toxin and Pseudomonas exotoxin A are well characterized (see for instance Hoch et al., PNAS USA 82, 1692 (1985), Colombatti et al., J. Biol. Chem. 26J., 3030 (1986) and Deleers et al., FEBS Lett. 160, 82 (1983)), and the existence and location of such a domain in other molecules may be determined by methods such as those employed by Hwang et al., Cell 48, 129 (1987) and Gray et al., PNAS USA 8J. 2645 (1984). In view of these techniques, a useful mixed toxin hybrid molecule may be formed, for example, by fusing the enzymatically active A subunit of E. coli Shiga-like toxin (Calderwood et al., PNAS USA 84, 4364 (1987)) to the translocation domain (amino acid residues 202 through 460) of diphtheria toxin, and to a molecule targeting a particular cell type, as described in US 5,906,820. The targeting portion of the three-part hybrid can cause the molecule to attach specifically to the targeted cells, and the diphtheria toxin translocation portion can act to insert the enzymatically active A subunit of the Shiga-like toxin into a targeted cell. The enzymatically active portion of Shiga-like toxin, like diphtheria toxin, acts on the protein synthesis machinery of the cell to prevent protein synthesis, thus killing the targeted cell.\n\n\nImmunoconjugates according to the present invention may also comprise a radioisotope, e.g., iodine-131 , yttrium-90 or indium-1 11 , to generate cytotoxic radiopharmaceuticals for treating an I L-21 -related disorder. \n\n In one embodiment, the IL-21 BPs, such as the human antibodies of the present invention are attached to a linker-chelator, e.g., tiuxetan, which allows for the antibody to be conjugated to a radioisotope.\n\n\nAdditionally useful conjugate substituents include anti-cancer retinoids. Taxane conjugates (see for instance Jaime et al., Anticancer Res. 21.(2A), 1 119-28 (2001), cisplatin conjugates, thapsigargin conjugates, linoleic acid conjugates, calicheamicin conjugates (see for instance Damle et al., Curr Opin Pharmacol. 3(4), 386-90 (2003), doxorubicin conjugates, geldanamycin conjugates, and the like, also may be useful in promoting the treatment of cancer (see, generally, Trail et al., Cancer Immunol Immunother. 52(5), 328-37 (2003)). In one embodiment, the present invention provides secondary and anti-idiotypic antibodies raised against anti-IL-21 antibodies of the present invention. A secondary antibody refers to an antibody specific for, and typically raised against, an anti-IL-21 antibody. An anti-idiotypic (Id) antibody is an antibody which recognizes unique determinants generally associated with the antigen-binding site of an antibody. An Id antibody may be prepared by immunizing an animal of the same species and genetic type as the source of an anti-IL-21 mAb with the mAb to which an anti-Id is being prepared. The immunized animal typically can recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the anti-Id antibody). Such antibodies are described in for instance US 4,699,880. Such antibodies are further features of the present invention.\n\n\nAn anti-Id antibody may also be used as an \"immunogen\" to induce an immune response in yet another animal, producing a so-called anti-anti-ld antibody. An anti-anti-ld may be epitopically identical to the original mAb, which induced the anti-Id. Thus, by using antibodies to the idiotypic determinants of a mAb, it is possible to identify other clones expressing antibodies of identical specificity. Anti-Id antibodies may be varied (thereby producing anti-Id antibody variants) and/or derivatized by any suitable technique, such as those described elsewhere herein with respect to anti-IL-21 antibodies and other IL-21 BPs of the present invention. For example, anti-Id mAbs may be coupled to a carrier such as keyhole limpet hemocyanin (KLH) and used to immunize BALB/c mice. Sera from these mice typically will contain anti-anti-ld antibodies that have the binding properties similar if not identical to an original/parent IL-21 antibody.\n\n\nIn one embodiment, the present invention provides a nucleic acid encoding an IL-21 BP. A IL-21 BP-encoding nucleic acid may have any suitable characteristics and comprise any suitable features or combination thereof. Thus, for example, an IL-21 BP- encoding nucleic acid may be in the form of DNA, RNA, or a hybrid thereof, and may include \n\n nonnaturally-occurring bases, a modified backbone (e.g., a phosphothioate backbone that promotes stability of the nucleic acid), or both. The nucleic acid advantageously comprises features that promote desired expression in target host cell(s), replication, and/or selection. Examples of such features include an origin of replication component, a selection gene component, a promoter component, an enhancer element component, a polyadenylation sequence component, a termination component, and the like.\n\n\nIn one embodiment, the present invention provides a vector comprising an IL-21 BP- encoding nucleic acid. A vector refers to a delivery vehicle that promotes the expression of an IL-21 BP-encoding nucleic acid, the production of an IL-21 BP peptide, the transfection/transformation of target cells, the replication of the IL-21 BP-encoding nucleic acid, promotes stability of the nucleic acid, promotes detection of the nucleic acid and/or transformed/transfected cells, or otherwise imparts advantageous biological function to the IL-21 BP-encoiding nucleic acid. A vector in the context of the present invention may be any suitable vector, including chromosomal, non-chromosomal, and synthetic nucleic acid vectors (a nucleic acid sequence comprising a suitable set of expression control elements). Examples of such vectors include derivatives of SV40, bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral nucleic acid (RNA or DNA) vectors. In one embodiment, an IL-21 BP-encoding nucleic acid is comprised in a naked DNA or RNA vector, including, for example, a linear expression element (as described in for instance Sykes and Johnston, Nat Biotech X7_,\n\n\n355-59 (1997)), a compacted nucleic acid vector (as described in for instance US 6,077, 835 and/or WO 00/70087), a plasmid vector such as pBR322, pUC 19/18, or pUC 118/119, a \"midge\" minimally-sized nucleic acid vector (as described in for instance Schakowski et al., MoI Ther 3, 793-800 (2001)), or as a precipitated nucleic acid vector construct, such as a CaP04-precipitated construct (as described in for instance WO 00/46147, Benvenisty and Reshef, PNAS USA 83, 9551-55 (1986), Wigler et al., Cell 14, 725 (1978), and Coraro and Pearson, Somatic Cell Genetics 7, 603 (1981)). Such nucleic acid vectors and the usage thereof are well known in the art (see for instance US 5,589,466 and US 5,973,972). In one embodiment, the vector is suitable for expression of the IL-21 BP in a bacterial cell. Examples of such vectors include, for example, vectors which direct high level expression of fusion proteins that are readily purified (for instance multifunctional E. coli cloning and expression vectors such as BlueScript (Stratagene), pi N vectors (Van Heeke & Schuster, J Biol Chem 264, 5503-5509 (1989), pET vectors (Novagen, Madison Wl) and the like). \n\n An expression vector may also or alternatively be a vector suitable for expression in a yeast system. Any vector suitable for expression in a yeast system may be employed. Suitable vectors for use in for instance Saccharomyces cerevisiae include, for example, vectors comprising constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH (reviewed in: F. Ausubel et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley InterScience New York (1987), and Grant et al., Methods in Enzymol 153. 516-544 (1987)).\n\n\nA nucleic acid and/or vector may also comprises a nucleic acid sequence encoding a secretion/ localization sequence, which can target a polypeptide, such as a nascent polypeptide chain, to a desired cellular compartment, membrane, or organelle, or which directs polypeptide secretion to periplasmic space or into cell culture media. Such sequences are known in the art, and include secretion leader or signal peptides, organelle targeting sequences (e. g., nuclear localization sequences, ER retention signals, mitochondrial transit sequences, chloroplast transit sequences), membrane localization/anchor sequences (e. g., stop transfer sequences, GPI anchor sequences), and the like.\n\n\nIL-21 BP-encoding nucleic acids may comprise or be associated with any suitable promoter, enhancer, and other expression-facilitating elements. Examples of such elements include strong expression promoters (e. g., human CMV IE promoter/enhancer as well as RSV, SV40, SL3-3, MMTV, and HIV LTR promoters), effective poly (A) termination sequences, an origin of replication for plasmid product in E. coli, an antibiotic resistance gene as selectable marker, and/or a convenient cloning site (e.g., a polylinker). Nucleic acids may also comprise an inducible promoter as opposed to a constitutive promoter such as CMV IE (the skilled artisan will recognize that such terms are actually descriptors of a degree of gene expression under certain conditions). In one embodiment, the nucleic acid may be positioned in and/or delivered to the host cell or host animal via a viral vector. Any suitable viral vector may be used in this respect, and several are known in the art. A viral vector may comprise any number of viral polynucleotides, alone or in combination with one or more viral proteins, which facilitate delivery, replication, and/or expression of the nucleic acid of the present invention in a desired host cell. The viral vector may be a polynucleotide comprising all or part of a viral genome, a viral protein/nucleic acid conjugate, a virus-like particle (VLP), a vector similar to those described in US 5,849, 586 and WO 97/04748, or an intact virus particle comprising viral nucleic acids and the nucleic acid of the present invention. A viral particle viral vector may comprise a wild-type viral particle or a modified viral particle. The viral vector may be a vector which requires the presence of another vector or wild-type virus for replication and/or \n\n expression (i.e., it may be a helper-dependent virus), such as an adenoviral vector amplicon. Typically, such viral vectors consist essentially of a wild-type viral particle, or a viral particle modified in its protein and/or nucleic acid content to increase transgene capacity or aid in transfection and/or expression of the nucleic acid (examples of such vectors include the herpes virus/AAV amplicons). Typically, a viral vector is similar to and/or derived from a virus that normally infects humans. Suitable viral vector particles in this respect, include, for example, adenoviral vector particles (including any virus of or derived from a virus of the adenoviridae), adeno-associated viral vector particles (AAV vector particles) or other parvoviruses and parvoviral vector particles, papillomaviral vector particles, flaviviral vectors, alphaviral vectors, herpes viral vectors, pox virus vectors, retroviral vectors, including lentiviral vectors. Examples of such viruses and viral vectors are in ofr instance Fields et al., eds., Virology Raven Press, Ltd., New York (3rd ed., 1996 and 4th ed., 2001), Encyclopedia of Virology, R. G. Webster et al.,eds., Academic Press (2nd ed., 1999), Fundamental Virology, Fields et al., eds., Lippincott- Raven (3rd ed., 1995), Levine, \"Viruses,\" Scientific American Library No. 37 (1992), Medical Virology, D. O. White et al., eds., Acad. Press (2nd ed. 1994), and Introduction to Modern Virology, Dimock, N. J. et al., eds., Blackwell Scientific Publications, Ltd. (1994).\n\n\nViral vectors that may be employed with polynucleotides of the present invention and the methods described herein include adenovirus and adeno-associated vectors, as in for instance Carter, Curr Opinion Biotech 3, 533-539 (1992) and Muzcyzka, Curr Top Microbiol Immunol 158, 97-129 (1992). Additional types and aspects of AAV vectors are described in for instance Carter, Contrib. Microbiol. 4, 85-86 (2000), Smith-Arica, Curr. Cardiol. Rep. 3(1), 41-49 (2001), Taj, J. Biomed. Sci. 7(4), 279- 91 (2000), Vigna et al., J. Gene Med. 2(5), 308-16 (2000), Klimatcheva et al., Front. Biosci. 4, D481-96 (1999), Lever et al., Biochem. Soc. Trans. 27(6), 841-47 (1999), Snyder, J Gene Med. 1(3), 166-75 (1999), Gerich et al., Knee Surg. Sports Traumatol. Arthrosc. 5(2), 118-23 (1998), and During, Adv. Drug DeNv. Review 27(1), 83-94 (1997) and US 4,797,368, US 5,139,941 , US 5,173, 414, US 5,614,404, US 5,658,785, US 5,858,775 and US 5,994,136). Adeno-associated viral vectors may be constructed and/or purified using the methods set forth, for example, in US 4,797,368 and Laughlin et al., Gene 23, 65-73 (1983).\n\n\nAnother type of viral vector that may be employed with polynucleotides and methods of the present invention is a papillomaviral vector. Suitable papillomaviral vectors are known in the art and described in, e. g., Hewson, MoI Med Today 5(1), 8 (1999), Stephens, Biochem J. 248(1), 1-11 (1987) and US 5,719, 054. Examples of papillomaviral vectors are provided in for instance WO 99/21979. Alphavirus vectors may be gene delivery vectors in other \n\n contexts. Alphavirus vectors are known in the art and described in for instance Carter, Curr Opinion Biotech 3, 533-539 (1992), Muzcyzka, Curr Top Microbiol Immunol. 158, 97-129 (1992), Schlesinger, Expert Opin Biol Ther. 1(2), 177-91 (2001), Polo et al., Dev Biol (Basel). 104. 181-5 (2000), Wahlfors et al., Gene Ther. 7(6), 472-80 (2000), Colombage et al., Virology. 250(1), 151 -63 (1998) and WO 01/81609, WO 00/39318, WO 01/81553, WO 95/07994 and WO 92/10578.\n\n\nAnother group of viral vectors are herpes viral vectors. Examples of herpes viral vectors are described in for instance Lachmann et al., Curr Opin MoI Ther 1(5), 622-32 (1999), Fraefel et al., Adv Virus Res. 55, 425-51 (2000), Huard et al., Neuromuscul 7(5), 299-313 (1997), Glorioso et al., Annu Rev Microbiol. 49, 675-710 (1995), Latchman, MoI\n\n\nBiotechnol. 2(2), 179-95 (1994), and Frenkel et al., Gene Ther. KSuppl 1 ), S40-6 (1994), as well as US 6,261 ,552 and US 5,599,691.\n\n\nRetroviral vectors, including lentiviral vectors, also may be advantageous gene delivery vehicles in particular contexts. There are numerous retroviral vectors known in the art. Examples of retroviral vectors are described in for instance Miller, Curr Top Microbiol Immunol 158, 1-24 (1992), Salmons and Gunzburg, Human Gene Therapy 4, 129-141 (1993), Miller et al., Methods in Enzvmolosv 2T7, 581-599 (1994), Weber et al., Curr Opin MoI Ther. 3(5), 439-53 (2001 ), Hu et al., Pharmacol Rev. 52(4), 493-511 (2000), Kim et al., Adv Virus Res. 55, 545-63 (2000), PaIu et al., Rev Med Virol. 10(3), 185-202 (2000) and Takeuchi et al., Adv Exp Med Biol. 465, 23-35 (2000), as well as US 6,326,195, US 5,888,502, US 5,580,766, and US 5,672, 510.\n\n\nAdenoviral vectors may also be suitable viral vectors for gene transfer. Adenoviral vectors are well known in the art and described in for instance Graham et al, MoI Biotechnol 33(3), 207-220 (1995), Stephenson, Clin Diagn Virol 10(2-3), 187-94 (1998), Jacobs, Clin Sci (Lond). 85(2), 117-22 (1993), US 5,922, 576, US 5,965,358 and US 6,168, 941 and\n\n\nWO98/22588, WO98/56937, WO99/15686, WO99/54441 , and WO00/32754. Adenoviral vectors, herpes viral vectors and Sindbis viral vectors, useful in the practice of the present invention, are described in for instance Jolly Cancer Gene Therapy 1, 51-64 (1994), Latchman Molec Biotechnol 2, 179-195 (1994) and Johanning et al., Nucl Acids Res 23, 1495-1501 (1995).\n\n\nOther suitable viral vectors include pox viral vectors. Examples of such vectors are discussed in for instance Berencsi et al., J Infect Dis 183(8), 1171-9 (2001), Rosenwirth et al., Vaccine 19(13-14), 1661 -70 (2001), Kittlesen et al., J Immunol 164(8), 4204-11 (2000), Brown et al., Gene Ther 7(19), 1680-9 (2000), Kanesa-thasan et al., Vaccine 19(4- 5), 483-91 (2000), Sten, Drua 60(2), 249-71 (2000). Vaccinia virus vectors may be pox virus \n\n vectors. Examples of such vectors and uses thereof are provided in for instance Venugopal et al., Res Vet Sci 57(2), 188-193 (1994), Moss Dev Biol Stand 82, 55-63 (1994), Weisz et al., MoI Cell Biol 43, 137-159 (1994), Mahr and Payne, Immunobioloev 184(2-3), 126-146 (1992), Hruby, Clin Microbiol Rev 3(2), 153-170 (1990) and WO92/07944, WO98/13500, and WO89/08716.\n\n\nOther features of the present invention include recombinant cells, such as yeast, bacterial, and mammalian cells (e.g., immortalized mammalian cells) comprising such a nucleic acid, vector, or combinations of either or both thereof. For example, in one embodiment, the present invention provides a cell comprising a nucleic acid stably integrated into the cellular genome that comprises a sequence coding for expression of an IL-21 BP of the present invention. In one embodiment, the present invention provides a cell comprising a non-integrated nucleic acid, such as a plasmid, cosmid, phagemid, or linear expression element, which comprises a sequence coding for expression of an IL-21 BP.\n\n\nThe present invention also provides immunogenic peptides comprising any of the above-described antigenic determinant portions of IL-21 specific for the IL-21 BPs of the present invention, such as the antigenic determinant portions of IL-21 specific for 1 F1 and 1 F22. Such immunogens may be used to elicit a direct immune response in a method comprising an active immunotherapy regimen. The present invention further provides a fusion protein comprising such an IL-21 immunogen and a fusion partner sequence that improves the half-life of the fusion protein (e.g., by inclusion of an immunoglobulin domain sequence); facilitates detection and/or purification of the fusion protein (by comprising, e.g., a fluorescent peptide sequence, a reporter enzyme sequence, an epitope tag, a hexa-histidine sequence, or the like); promotes the targeting of the fusion protein (e.g., by comprising a ligand or portion of a ligand specific for a receptor on a target cell); promotes induction of a distinct immune response (e.g., corresponds to a cancer antigen or an immunogenic fragment thereof); is a cytotoxic agent; or achieves any combination thereof (e.g., a heat shock fusion protein partner can increase an immune response generated against a non- similar, heterologous antigen portion of a fusion protein, while also increasing the in vivo half- life of a fusion protein). Fusion proteins may also comprise one or more cleavage sites, particularly between domains.\n\n\nVariants of such peptides, and derivatives of such immunogenic peptides or immunogenic peptide variants are additional features of the present invention (e.g., such IL-21 immunogenic peptide derivatives may be modified by chemical coupling, genetic fusion, non-covalent association, and the like, to other molecular entities such as antibodies, toxins, radioisotope, cytotoxic agents, or cytostatic agents). Peptide mimitopes, comprising \n\n IL-21 epitope sequences may also, for example, be useful as vaccine candidates. Such peptides may also be useful in the purification of anti-IL-21 antibodies. In addition to the B-cell epitope sequences described herein, such peptides may be engineered or selected to also or alternatively comprise one or more anti-IL-21 T cell epitopes. Such epitopes may be identified by any suitable technique known in the art (e.g., by T cell epitope prediction software applications).\n\n\nIn one embodiment, the present invention provides a nucleic acid encoding such an immunogenic peptide. Such a nucleic acid may be delivered to a host in a suitable vector, such as a replication-deficient targeted vector (e.g., a targeted nucleic acid vector or a replication-deficient, targeted adenovirus vector). The present invention also provides compositions of one or more of such immunogenic peptides and/or immunogenic peptide- encoding nucleic acids.\n\n\nIL-21 BPs of the present invention include \"neutralizing\" IL-21 BPs, such as neutralizing antibodies. The terms \"neutralizing\" IL-21 BP\" and \"neutralizing antibody\" refer to an IL-21 BP or an antibody that is capable of substantially inhibiting or eliminating a biological activity of an IL-21 -associated peptide. Typically, a neutralizing IL-21 BP, such as a neutralizing anti-IL-21 antibody will inhibit IL-21 binding to the IL-21 receptor in a degree that is about equal or greater than the inhibition of such cells due to administration of an approximately equal amount of the antibodies of the examples. A IL-21 BP of the present invention may have any suitable affinity and/or avidity for one or more epitopes contained at least partially in IL-21. Affinity refers to the strength of binding of the IL-21 BP to such an epitope. Typically, affinity is measured by dissociation constant K\nd\n, defined as [Ab] x [Ag] / [Ab-Ag] where [Ab-Ag] is the molar concentration of the antibody-antigen complex (or the IL-21 BP-antigen complex), [Ab] is the molar concentration of the unbound antibody (or IL-21 BP) and [Ag] is the molar concentration of the unbound antigen. The affinity constant K\na\n is defined by 1/K\nd\n. Suitable methods for determining specificity and affinity by competitive inhibition may be found in for instance Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 1988), Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc, and Wiley InterScience N. Y., (1992, 1993) and Muller, Meth. Enzymol. 92, 589-601 (1983).\n\n\nA IL-21 BP, and particularly anti-IL-21 antibodies of the present invention may have an affinity for at least one epitope at least partially comprised in IL-21 in the range of about 10\n4\n to about 10\n10\n M\n\"1\n. The term immunoreact herein typically refers to binding of an IL-21 BP to an IL-21 epitope with a dissociation constant K\nd\n lower than about 10\n'4\n M. \n\n A IL-21 BP may have an affinity that is at least as great for IL-21 as 1 F1 and 1 F22, and in some embodiments have an affinity that is at least about as great as 1 F1 and 1 F22. Affinity may be determined by any of the methods described elsewhere herein or their known equivalents in the art. An example of one method that may be used to determine affinity is provided in Scatchard analysis of Munson & Pollard, Anal. Biochem. 107, 220 (1980).\n\n\nBinding affinity also may be determined by equilibrium methods (for instance enzyme-linked immunoabsorbent assay (ELISA) or radioimmunoassay (RIA)) or kinetics analysis (for instance BIACORE™ analysis).\n\n\nTypically, the disassociation constant for IL-21 BPs, such as anti-IL-21 antibodies, of the present invention is less than about 100 nM, less than about 50 nM, less than about 10 nM, about 5 nM or less, about 1 nM or less, about 0.5 nM or less, about 0.1 nM or less, about 0.01 nM or less, or even about 0.001 nM or less.\n\n\nAnti-IL-21 antibodies of the present invention, as well as other IL-21 BPs of the present invention, may be prepared by recombinant expression in any suitable type of cells or animals.\n\n\nRecombinant IL-21 BPs, such as recombinant antibodies, such as recombinant human antibodies, include IL-21 BPs, such as antibodies, such as human antibodies that are prepared, expressed, created or isolated by recombinant means, such as IL-21 BPs, such as antibodies, such as human antibodies expressed using a recombinant expression vector transfected into a host cell.\n\n\nRecombinant antibodies, such as recombinant human antibodies also include antibodies isolated from a recombinant, combinatorial human antibody library, antibodies isolated from an animal, such as a transgenic animal, or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin- encoding nucleic acid sequences to other nucleic acid sequences exogenous to the human immunoglobulin-encoding nucleic acids and human immunoglobulin-encoding genes. Recombinant human antibodies typically have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and, thus, the amino acid sequences of the V\nH\n and V\nL\n regions of the recombinant antibodies may be sequences that, while derived from and related to human germline V\nH\n and V\nL\n sequences, may not naturally exist within the human antibody germline repertoire in vivo. Both types of human antibodies are provided by the present invention. \n\n Suitable methods for recombinant protein production are known in the art, see for instance (Sambrook and Russell (eds.), Molecular cloning, third edition, 2001 , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA.\n\n\nLikewise, suitable methods for antibody production are known in the art and include those described in for instance Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., (1988), Harlow and Lane: Using Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press (1999)), US 4,376,110 and Ausubel et al., eds., Current Protocols In Molecular Biology, Greene Publishing Assoc, and Wiley InterScience N. Y., (1987, 1992). Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature 256, 495 (1975), or by other well-known, subsequently-developed methods (see, e.g., Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). Hybridomas useful in the production of anti-IL-21 antibodies of the present invention are also provided by the present invention. Such hybridomas may be formed by chemical fusion, electrical fusion, or any other suitable technique, with any suitable type of myeloma, heteromyeloma, phoblastoid cell, plasmacytoma or other equivalent thereof and any suitable type of antibody-expressing cell. Transformed immortalized B cells may also be used to efficiently produce antibodies of the present invention and are also provided by the present invention. Such cells may be produced by standard techniques, such as transformation with an Epstein Barr Virus, or a transforming gene. (See, e.g., \"Continuously Proliferating Human Cell Lines Synthesizing Antibody of Predetermined Specificity,\" Zurawaki, V. R. et al., in Monoclonal Antibodies, ed. by Kennett R. H. et al., Plenum Press, N. Y. 1980, pp 19-33.). Thus, stable and continuous and/or immortalized anti-IL-21 antibody expressing cells and cell lines are a feature of the present invention. Eukaryotic and prokaryotic cells (e.g., yeast cells, continuous and/or immortalized mammalian cell lines (e.g., lymphoid antibody-producing cell derived cell lines), plant cells, insect cells, and bacterial cells such as E. coli cells, etc.) comprising IL-21 BP- encoding or IL-21 BP-fragment-encoding nucleic acids are provided by the present invention. Transgenic animals, such as non-human primates, rodents (e.g., hamsters, guinea pigs, and rats - including modified strains thereof such as severe combined immunodeficient (SCID) mice and other immunocompromised animal strains), dogs, etc., expressing human anti- IL-21 antibodies of the present invention also are provided by the present invention.\n\n\nRecombinant cells comprising exogenous nucleic acids encoding IL-21 BPs may be prepared by any suitable technique (e.g., transfection/transformation with a naked DNA plasmid vector, viral vector, invasive bacterial cell vector or other whole cell vector, etc., comprising an IL-21 BP-encoding sequence (or sequences) delivered into the cell by calcium \n\n phosphate-precipitation facilitated transfection, receptor-mediated targeting and transfection, biolistic delivery, electroporation, dextran-mediated transfection, liposome-mediated transformation, protoplast fusion, direct microinjection, etc.). Methods of transforming/transfecting cells are well known in the art (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2d Edition, 1989 and 3rd Edition, 2001) and F. Ausubel et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley InterScience New York (1987). Such recombinant cells are a feature of the present invention.\n\n\nCell lines available as hosts for recombinant protein expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC). These include, inter alia, Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, and a number of other cell lines. Other cell lines that may be used are insect cell lines, such as Sf9 cells. When nucleic acids (or nucleic acid-containing vectors) encoding proteins, such as IL-21 BPs (including anti-IL-21 antibodies), are introduced into mammalian host cells, proteins, such as IL-21 BPs, may be produced by culturing the host cells for a period of time sufficient to allow for expression of the protein, such as an IL-21 BP, in the host cells or by secretion of the protein, such as an IL-21 BP, into the culture medium in which the host cells are grown. IL-21 BPs may be recovered from the culture medium using standard protein purification methods. IL-21 BPs may also be recovered from host cell lysates when directly expressed without a secretory signal.\n\n\nIL-21 BPs, such as anti-IL-21 antibodies, may also be produced in bacterial cells and eukaryotic unicellular microorganisms, such as yeast. Bacterial cell produced IL-21 BPs, such as anti-IL-21 antibodies, typically lack normal glycosylation and bacterial cell produced anti- IL-21 antibodies may thus be more or less deficient in terms of ADCC functions and other aspects of the immune response associated with anti-IL-21 antibodies produced in mammalian cells and/or animals (e.g., the recruitment of NK cells). Yeast cell produced IL-21 BPs, such as anti-IL-21 antibodies normally exhibit different types of glycosylation patterns than antibodies produced in mammalian cells. However, methods for producing antibodies with effective glycosylation in yeast are currently being developed by companies such as Glycofi, Inc. (Lebanon, NH, USA). See also Wildt S et al., Nat Rev Microbiol. 3(2), 119-28 (2005).\n\n\nWhen recombinant expression vectors encoding IL-21 BP genes (including anti-IL-21 antibody genes) are introduced into mammalian host cells, the IL-21 BPs are produced by \n\n culturing the host cells for a period of time sufficient to allow for expression of the IL-21 BP in the host cells or for secretion of the antibody into the culture medium in which the host cells are grown. The purification of antibodies and other IL-21 BPs from cell cultures, cell lysates, and animals (e.g., from the ascites fluid of a transgenic animal producing anti-IL-21 antibodies) may be achieved by application of any number of suitable techniques known in the art including, e.g., immunoaffinity column purification; sulfate precipitation; chromatofocusing; preparative SDS-PAGE, and the like.\n\n\nHuman monoclonal antibodies of the present invention may also be produced by a variety of other techniques, including conventional monoclonal antibody methodology, e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256, 495 (1975). Other techniques for producing monoclonal antibody may also be employed, e.g. phage display techniques using libraries of human antibody genes. In one embodiment, anti- IL-21 antibodies of the present invention produced by use of hybridomas generated in a murine system. Hybridoma production in the mouse is a very well established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.\n\n\nTo generate fully human monoclonal antibodies to IL-21 , transgenic or transchromosomal mice containing human immunoglobulin genes (e.g., HCo12, HCo7 or KM mice) may be immunized with an enriched preparation of IL-21 antigen, as described, for example, by Lonberg et al., (1994), supra, Fishwild et al., (1996), supra, and WO 98/24884. Alternatively, mice may be immunized with DNA encoding human IL-21. The mice may be 6-16 weeks of age upon the first infusion. For example, an enriched preparation (5-50 μg) of the IL-21 antigen may be used to immunize the HuMAb mice intraperitoneal^. Cumulative experience with various antigens has shown that the HuMAb transgenic mice respond best when initially immunized intraperitoneal^ (i.p.) or subcutaneously (s.c.) with IL-21 expressing cells in complete Freund's adjuvant, followed by every other week i.p. immunizations (up to a total of 10) with IL-21 expressing cells in PBS. The immune response may be monitored over the course of the immunization protocol with plasma samples being obtained by retroorbital bleeds. The plasma may be screened by FACS analysis, and mice with sufficient titers of anti-IL-21 human immunoglobulin may be used for fusions. Mice may be boosted intravenously with IL-21 expressing cells, for example 4 and 3 days before sacrifice and removal of the spleen..\n\n\nTo generate hybridomas producing human monoclonal antibodies to human IL-21 , splenocytes and lymph node cells from immunized mice may be isolated and fused to an \n\n appropriate immortalized cell line, such as a mouse myeloma cell line. The resulting hybridomas may then be screened for the production of antigen-specific antibodies. For example, single cell suspensions of splenic lymphocytes from immunized mice may be fused to SP2/0 nonsecreting mouse myeloma cells (ATCC, CRL 1581) with 50% PEG (w/v). Cells may be plated at approximately 1 x 105 per well in flat bottom microtiter plate, followed by a two week incubation in selective medium containing besides usual reagents 10% fetal Clone Serum, 5-10% origen hybridoma cloning factor (IGEN) and 1X HAT (Sigma). After approximately two weeks, cells may be cultured in medium in which the HAT is replaced with HT. Individual wells may then be screened by ELISA for human kappa-light chain containing antibodies and by FACS analysis using IL-21 expressing cells for IL-21 specificity. Once extensive hybridoma growth occurs, medium may be observed usually after 10-14 days. The antibody secreting hybridomas may be replated, screened again, and if still positive for human IgG, anti-IL-21 monoclonal antibodies may be subcloned at least twice by limiting dilution. The stable subclones may then be cultured in vitro to generate antibody in tissue culture medium for characterization.\n\n\nHuman antibodies of the present invention may also be produced in a host cell transfectoma using, for example, a combination of recombinant DNA techniques and gene transfection methods as is well known in the art, see for instance Morrison, S., Science 229, 1202 (1985). For example, to express the antibodies, or antibody fragments thereof, DNAs encoding partial or full-length light and heavy chains, may be obtained by standard molecular biology techniques (for instance PCR amplification, site directed mutagenesis) and may be inserted into expression vectors such that the genes are operatively linked to transcriptional and translational control sequences. In this context, the term \"operatively linked\" is intended to mean that an antibody gene is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the antibody gene. The expression vector and expression control sequences are chosen to be compatible with the expression host cell used. The antibody light chain gene and the antibody heavy chain gene may be inserted into separate vectors or, more typically, both genes are inserted into the same expression vector. The antibody genes may be inserted into the expression vector by standard methods (e.g., ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present). The light and heavy chain variable regions of the antibodies described herein may be used to create full-length antibody genes of any antibody isotype by inserting them into expression vectors already encoding heavy chain \n\n constant and light chain constant regions of the desired isotype such that the V\nH\n segment is operatively linked to the CH segment(s) within the vector and the V\nL\n segment is operatively linked to the CL segment within the vector. Additionally or alternatively, the recombinant expression vector may encode a signal peptide that facilitates secretion of the antibody chain from a host cell. The antibody chain gene may be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the antibody chain gene. The signal peptide may be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein).\n\n\nIn addition to the antibody chain genes, the recombinant expression vectors of the present invention carry regulatory sequences that allows and control the expression of the antibody chain genes in a host cell.\n\n\nIn addition to the antibody chain genes and regulatory sequences, the recombinant expression vectors of the present invention may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see for instance US 4,399,216, US 4,634,665 and US 5,179,017). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Examples of selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr-host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).\n\n\nFor expression of the light and heavy chains, the expression vector(s) encoding the heavy and light chains is transfected into a host cell by standard techniques. The host cells may be prokaryotic or eukaryotic, such as mammalian, host cells. For instance antigen binding fragments may be expressed in prokaryotic host cells and full-length antibodies may be expressed in eukaryotic host cells.\n\n\nIn one embodiment the antibodies are expressed in eukaryotic cells, such as mammalian host cells. Examples of mammalian host cells for expressing the recombinant antibodies of the present invention include CHO cells (including dhfr-CHO cells, described in Urlaub and Chasin, PNAS USA 77, 4216-4220 (1980), used with a DHFR selectable marker, for instance as described in R. J. Kaufman and P. A. Sharp, MoI. Biol. 159, 601-621 (1982)), NS/0 myeloma cells, COS cells, HEK293 cells and SP2.0 cells. In particular for use with NS/0 myeloma cells, another example of a expression system is the GS (glutamine synthetase) gene expression system disclosed in WO87/04462, WO89/01036 and EP338841. \n\n The IL-21 BP genes may be expressed in other expression systems, including prokaryotic cells, such as microorganisms, e.g. E. coli for the production of scFv antibodies, algi, as well as insect cells. Furthermore, the IL-21 BPs may be produced in transgenic non- human animals, such as in milk from sheep and rabbits or eggs from hens, or in transgenic plants. See for instance Verma, R. et al., J. Immunol. Meth. 2J6, 165-181 (1998), Pollock et al., J. Immunol. Meth. 231, 147-157 (1999) and Fischer, R. et al., Biol.Chem. 380, 825-839 (1999).\n\n\nBispecific and multispecific IL-21 BPs of the present invention may be made using chemical techniques (see for instance D. M. Kranz et al., PNAS USA 78, 5807 (1981)), \"polydoma\" techniques (See US 4,474,893) or recombinant DNA techniques.\n\n\nBispecific antibodies of the present invention may be produced by a variety of known methods including fusion of hybridomas or linking of Fab' fragments (see for instance Songsivilai & Lachmann, Clin. Exp. Immunol. 79, 315-321 (1990) and Kostelny et al., J. Immunol. 148, 1547-1553 (1992)). Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains have different specificities (see for instance Milstein and Cuello, Nature 305, 537 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Similar procedures are disclosed in WO 93/08829 and Traunecker et al., EMBO J. 10, 3655 (1991).\n\n\nAccording to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences by recombinant or synthetic methods. The variable domain sequence is typically fused to an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, C\nH\n2, and C\nH\n3 regions. Also typically, a first heavy-chain constant region (C\nH\n1), containing the site necessary for light chain binding, also is present in at least one of the fusion peptides. In a more specific example of this type of approach, a bispecific antibody is produced comprising a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. Such an asymmetric structure can facilitate the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations (such an approach is described in WO 94/04690). For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology 121 , 210 (1986). \n\n In another approach, the interface between a pair of antibody molecules may be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture so as to form a population of bispecific antibody molecules. Typically, such an interface comprises at least a part of the C\nH\n3 domain of an antibody constant region. Normally in such a method, one or more amino acid residues with smaller side chains from the interface of the first antibody molecule are replaced with amino acid residues with larger side chains (such as tyrosine or tryptophan). Compensatory \"cavities\" of identical or similar size to the large side chain amino acid residue(s) are created on the interface of the second antibody molecule by replacing large amino acid side chain residues with smaller ones (such as alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.\n\n\nBispecific and multispecific molecules of the present invention may be prepared by conjugating the constituent binding specificities, e.g., the anti-FcR and anti-IL-21 binding specificities, using methods known in the art. For example, each binding specificity of the bispecific and multispecific molecule may be generated separately and then conjugated to one another. When the binding specificities are proteins or peptides, a variety of coupling or cross-linking agents may be used for covalent conjugation. Examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2- nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldi- thio)propionate (SPDP) and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1 -carboxy- late (sulfo-SMCC), see for instance Karpovsky et al., J. Exp. Med. 160, 1686 (1984), Liu, M. A. et al., PNAS USA 82, 8648 (1985). In another example, Brennan et al., Science 229, 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')\n2\n fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated may then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives may then be reconverted to the Fab'-thiol by reduction with mercaptoethylamine and mixed with an equimolar amount of the other Fab'- TNB derivative to form a bispecific antibody. Shalaby et al., J. Exp. Med. 175, 217-225 (1992) describes the production of a fully humanized bispecific antibody F(ab')\n2\n molecule, according to a related technique. Other methods include those described by Paulus (Behring Ins. Mitt. No. 78, 1 18-132 (1985)) and Glennie et al., J. Immunol. 139, 2367-2375 (1987). Examples of conjugating agents are SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL). \n\n When the binding specificities are antibodies, they may be conjugated via sulfhydryl bonding of the C-terminus hinge regions of the two heavy chains. In one embodiment, the hinge region is modified to contain an odd number of sulfhydryl residues, for instance one, prior to conjugation. Alternatively, both binding specificities may be encoded in the same vector and expressed and assembled in the same host cell. This method is particularly useful where the bispecific and multispecific molecule is a mAb x mAb, mAb x Fab, Fab x F(ab')\n2\n or ligand x Fab fusion protein. A bispecific and multispecific molecule of the present invention, e.g., a bispecific molecule may be a single chain molecule, such as a single chain bispecific antibody, a single chain bispecific molecule comprising one single chain antibody and a binding determinant, or a single chain bispecific molecule comprising two binding determinants. Bispecific and multispecific molecules may also be single chain molecules or may comprise at least two single chain molecules. Methods for preparing bi- and multispecific molecules are described for example in US 5,260,203, US 5,455,030, US 4,881 ,175, US 5,132,405, US 5,091 ,513, US 5,476,786, US 5,013,653, US 5,258,498 and US 5,482,858.\n\n\nVarious techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers (see for instance Kostelny et al., J. Immunol. 148(5), 1547-1553 (1992)). Leucine zipper peptides from the Fos and Jun proteins may be linked to the Fab' portions of two different antibodies by gene fusion and the resulting antibody homodimers reduced at the hinge region to form monomers that may be re-oxidized to form the antibody heterodimers. The \"diabody\" technology described by Hollinger et al., PNAS USA 90, 6444-6448 (1993) also has provided an alternative mechanism for making bispecific antibody fragments. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See for instance Gruber et al., J. Immunol. 152, 5368 (1994).\n\n\nIn addition, bispecific antibodies may be formed as \"diabodies\" (Holliger et al., PNAS USA, 90, 6444-6448 (1993)) or \"Janusins\" (Traunecker et al., EMBO J 10, 3655-3659 (1991) and Traunecker et al., lnt J Cancer Suppl 7, 51-52 (1992)). Bispecific antibodies, by definition, do not exist in the form of fragments having a single binding site (e.g., Fab, Fab', and Fv fragments, which also are provided by the present invention).\n\n\nBinding of the bispecific and multispecific molecules to their specific targets may be confirmed by enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), FACS analysis, a bioassay (e.g., growth inhibition), or a Western Blot Assay. Each of these \n\n assays generally detects the presence of protein-antibody complexes of particular interest by employing a labeled reagent (e.g., an antibody) specific for the complex of interest. For example, the FcR-antibody complexes may be detected using e.g., an enzyme-linked antibody or antibody fragment which recognizes and specifically binds to the antibody-FcR complexes. Alternatively, the complexes may be detected using any of a variety of other immunoassays. For example, the antibody may be radioactively labeled and used in a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986). The radioactive isotope may be detected by such means as the use of a Y counter or a scintillation counter or by autoradiography.\n\n\nAs stated earlier, antibodies interact with target antigens primarily through amino acid residues that are located in the six heavy and light chain complementarity determining regions (CDRs). The present invention provides antibodies having CDR regions identical to or otherwise derived from the CDR regions of the 1 F1 and 1 F22. Such antibodies may be generated by constructing expression vectors that include CDR sequences from 1 F1 and 1 F22 grafted onto framework sequences from a different antibody with different properties.\n\n\nSuch framework sequences may be obtained from public DNA databases that include germline antibody gene sequences. These germline sequences will differ from mature antibody gene sequences because they will not include completely assembled variable genes, which are formed by V(D)J joining during B cell maturation. Germline gene sequences will also differ from the sequences of a high affinity secondary repertoire antibody which contains mutations throughout the variable gene but typically clustered in the CDRs. For example, somatic mutations are relatively infrequent in the amino terminal portion of framework region 1 and in the carboxy-terminal portion of framework region 4. For this reason, it is not necessary to obtain the entire DNA sequence of a particular antibody in order to recreate an intact recombinant antibody having binding properties similar to those of the original antibody (see WO 99/45962). Partial heavy and light chain sequence spanning the CDR regions is typically sufficient for this purpose. The partial sequence is used to determine which germline variable and joining gene segments contributed to the recombined antibody variable genes. The germline sequence is then used to fill in missing portions of the variable regions. Heavy and light chain leader sequences are cleaved during protein maturation and do not contribute to the properties of the final antibody. To add missing sequences, cloned cDNA sequences may be combined with synthetic oligonucleotides by ligation or PCR amplification. Alternatively, the entire variable region may be synthesized as a set of short, overlapping, oligonucleotides and combined by PCR amplification to create an \n\n entirely synthetic variable region clone. This process has certain advantages such as elimination or inclusion or particular restriction sites, or optimization of particular codons.\n\n\nThe nucleotide sequences of heavy and light chain transcripts from hybridomas are used to design an overlapping set of synthetic oligonucleotides to create synthetic V sequences with identical amino acid coding capacities as the natural sequences. The synthetic heavy and kappa chain sequences can differ from the natural sequences in three ways: strings of repeated nucleotide bases are interrupted to facilitate oligonucleotide synthesis and PCR amplification; optimal translation initiation sites are incorporated according to Kozak's rules (Kozak, J. Biol. Chem. 266, 19867-19870 (1991 ); and H/ndlll sites are engineered upstream of the translation initiation sites.\n\n\nFor both the heavy and light chain variable regions, the optimized coding and corresponding non-coding, strand sequences are broken down into 30-50 nucleotides approximately at the midpoint of the corresponding non-coding oligonucleotide. Thus, for each chain, the oligonucleotides may be assembled into overlapping double stranded sets that span segments of 150-400 nucleotides. The pools are then used as templates to produce PCR amplification products of 150-400 nucleotides. Typically, a single variable region oligonucleotide set will be broken down into two pools which are separately amplified to generate two overlapping PCR products. These overlapping products are then combined by PCR amplification to form the complete variable region. It may also be desirable to include an overlapping fragment of the heavy or light chain constant region (including the Bbs\\ site of the kappa light chain, or the Age\\ site of the gamma heavy chain) in the PCR amplification to generate fragments that can easily be cloned into the expression vector constructs.\n\n\nThe reconstructed heavy and light chain variable regions are then combined with cloned promoter, leader, translation initiation, constant region, 3' untranslated, polyadenylation, and transcription termination, sequences to form expression vector constructs. The heavy and light chain expression constructs may be combined into a single vector, co-transfected, serially transfected, or separately transfected into host cells which are then fused to form a host cell expressing both chains.\n\n\nA similar procedure may be followed to graft novel antigen-specificity into an existing mature antibody. Typically, an acceptor antibody is chosen which originates from the same variable germ-line gene as the CDR-donor antibody, but other acceptor antibodies may also be chosen. One or more CDRs from the donor antibody are then transferred using the techniques described above.\n\n\nIn one embodiment of the present invention, the structural features of the 1 F1 and 1 F22 are used to create structurally related anti-IL-21 antibodies, for instance human anti- \n\n IL-21 antibodies, that retain at least one functional property of 1 F1 and 1 F22, namely binding to IL-21. More specifically, one or more CDR regions of 1 F1 and 1 F22 may be combined recombinantly with known human framework regions and CDRs to create additional, recombinantly-engineered, anti-IL-21 antibodies of the present invention. Exemplary plasmids for use in construction of expression vectors for human lgGκ are described below. The plasmids were constructed so that PCR amplified V kappa heavy and V kappa light chain cDNA sequences could be used to reconstruct complete heavy and light chain minigenes. These plasmids may be used to express completely human IgGI , K or lgG4,κ antibodies. Similar plasmids may be constructed for expression of other heavy chain isotypes, or for expression of antibodies comprising lambda light chains.\n\n\nIn one embodiment, the present invention provides transgenic and transchromosomal nonhuman animals, such as transgenic or transchromosomal mice, which are capable of expressing human antibodies that specifically bind to IL-21. In a particular embodiment, the present invention provides a transgenic or transchromosomal mouse having a genome comprising a human heavy chain transgene, such that the mouse produces human anti-IL-21 antibodies when immunized with IL-21. The human heavy chain transgene may be integrated into the chromosomal DNA of the mouse, as is the case for transgenic, e.g., HuMAb mice, as described in detail herein. Alternatively, the human heavy chain transgene may be maintained extrachromosomally, as is the case for transchromosomal (e.g., KM) mice as described in WO 02/43478. Such transgenic and transchromosomal animals are capable of producing multiple isotypes of human monoclonal antibodies to IL-21 (e.g., IgG, IgA and/or IgE) by undergoing V-D-J/V-J recombination and isotype switching. The design of a transgenic or transchromosomal nonhuman animal that responds to foreign antigen stimulation with a heterologous antibody repertoire, requires that the heterologous immunoglobulin transgenes contained within the transgenic animal function correctly throughout the pathway of B cell development. This includes, for example, isotype switching of the heterologous heavy chain transgene. Accordingly, transgenes are constructed so that isotype switching may be induced and one or more of the following characteristics of antibody genes: (1) high level and cell-type specific expression, (2) functional gene rearrangement, (3) activation of and response to allelic exclusion, (4) expression of a sufficient primary repertoire, (5) signal transduction, (6) somatic hypermutation, and (7) domination of the transgene antibody locus during the immune response.\n\n\nNot all of the foregoing criteria need be met. For example, in those embodiments wherein the endogenous immunoglobulin loci of the transgenic animal are functionally \n\n disrupted, the transgene need not activate allelic exclusion. Further, in those embodiments wherein the transgene comprises a functionally rearranged heavy and/or light chain immunoglobulin gene, the second criteria of functional gene rearrangement is unnecessary, at least for that transgene which is already rearranged. For background on molecular immunology, see, Fundamental Immunology, 2nd edition (1989), Paul William E., ed. Raven Press, N.Y.\n\n\nIn certain embodiments, the transgenic or transchromosomal nonhuman animals used to generate the human monoclonal antibodies of the present invention contain rearranged, unrearranged or a combination of rearranged and unrearranged heterologous immunoglobulin heavy and light chain transgenes in the germline of the transgenic animal. Each of the heavy chain transgenes comprises at least one C\nH\n gene. In addition, the heavy chain transgene may contain functional isotype switch sequences, which are capable of supporting isotype switching of a heterologous transgene encoding multiple C\nH\n genes in the B cells of the transgenic animal. Such switch sequences may be those which occur naturally in the germline immunoglobulin locus from the species that serves as the source of the transgene C\nH\n genes, or such switch sequences may be derived from those which occur in the species that is to receive the transgene construct (the transgenic animal). For example, a human transgene construct that is used to produce a transgenic mouse may produce a higher frequency of isotype switching events if it incorporates switch sequences similar to those that occur naturally in the mouse heavy chain locus, as presumably the mouse switch sequences are optimized to function with the mouse switch recombinase enzyme system, whereas the human switch sequences are not. Switch sequences may be isolated and cloned by conventional cloning methods, or may be synthesized de novo from overlapping synthetic oligonucleotides designed on the basis of published sequence information relating to immunoglobulin switch region sequences (Mills et al., Nucl. Acids Res. 1_5, 7305-7316\n\n\n(1991) Sideras et al., Intl. Immunol. !, 631 -642 (1989)). For each of the foregoing transgenic animals, functionally rearranged heterologous heavy and light chain immunoglobulin transgenes are found in a significant fraction of the B cells of the transgenic animal (at least 10%). The transgenes used to generate the transgenic nonhuman animals of the present invention include a heavy chain transgene comprising DNA encoding at least one variable gene segment, one diversity gene segment, one joining gene segment and at least one constant region gene segment. The immunoglobulin light chain transgene comprises DNA encoding at least one variable gene segment, one joining gene segment and at least one constant region gene segment. The gene segments encoding the light and heavy chain gene \n\n segments are heterologous to the transgenic animal in that they are derived from, or correspond to, DNA encoding immunoglobulin heavy and light chain gene segments from a species not consisting of the transgenic nonhuman animal. In one embodiment of the present invention, the transgene is constructed such that the individual gene segments are unrearranged, i.e., not rearranged so as to encode a functional immunoglobulin light or heavy chain. Such unrearranged transgenes support recombination of the V, D, and J gene segments (functional rearrangement) and may support incorporation of all or a portion of a D region gene segment in the resultant rearranged immunoglobulin heavy chain within the transgenic animal when exposed to IL-21 antigen. In an alternate embodiment, the transgenes comprise an unrearranged \"mini-locus\".\n\n\nSuch transgenes typically comprise a substantial portion of the C, D, and J segments as well as a subset of the V gene segments. In such transgene constructs, the various regulatory sequences, e.g. promoters, enhancers, class switch regions, splice-donor and splice- acceptor sequences for RNA processing, recombination signals and the like, comprise corresponding sequences derived from the heterologous DNA. Such regulatory sequences may be incorporated into the transgene from the same or a related species of the nonhuman animal used in the present invention. For example, human immunoglobulin gene segments may be combined in a transgene with a rodent immunoglobulin enhancer sequence for use in a transgenic mouse. Alternatively, synthetic regulatory sequences may be incorporated into the transgene, wherein such synthetic regulatory sequences are not homologous to a functional DNA sequence that is known to occur naturally in the genomes of mammals. Synthetic regulatory sequences are designed according to consensus rules, such as, for example, those specifying the permissible sequences of a splice-acceptor site or a promoter/enhancer motif. For example, a minilocus comprises a portion of the genomic immunoglobulin locus having at least one internal (i.e., not at a terminus of the portion) deletion of a non-essential DNA portion (e.g., intervening sequence; intron or portion thereof) as compared to the naturally-occurring germline Ig locus.\n\n\nExamples of transgenic and transchromosomal nonhuman animals, such as mice, will exhibit immunoglobulin production with a significant repertoire, ideally substantially similar to that of a human after adjusting for volume.\n\n\nThe repertoire will ideally approximate that shown in a human when adjusted for volume, usually with a diversity at least about 10% as great, such as 25 to 50% or more. Generally, at least about a thousand different immunoglobulins (ideally IgG), such as 10\n4\n to 10\n6\n or more, will be produced, depending on the number of different V, J and D regions introduced into the mouse genome and driven by the additional diversity generated by \n\n V(-D-)J gene segment rearrangements and random nucleotide additions at the joining regions. Typically, the immunoglobulins will exhibit an affinity (K\n0\n) for preselected antigens of below 10\n'8\n M, such as of below 10 \n'9\n M, 10 \n10\n M or 10\n\"11\n M or even lower. Transgenic and transchromosomal nonhuman animals, e.g., mice, as described above, may be immunized with human IL-21 or DNA encoding human IL-21. The animals will then produce B cells which undergo class-switching via switch recombination (cis-switching) and express immunoglobulins reactive with IL-21. The immunoglobulins will be human antibodies (also referred to as \"human sequence antibodies\"), wherein the heavy and light chain polypeptides are encoded by human transgene sequences, which may include sequences derived by somatic mutation and V region recombinatorial joints, as well as germline-encoded sequences; these human antibodies may be referred to as being substantially identical to a polypeptide sequence encoded by a human V\nL\n and J\nL\n or V\nH\n D\nH\n and J\nH\n gene segments, even though other non-germline sequences may be present as a result of somatic mutation and differential V-J and V-D-J recombination joints. The variable regions of each antibody chain are typically at least 80 percent similar to human germline V, and J gene segments, and, in the case of heavy chains, human germline V, D, and J gene segments; frequently at least 85 percent similar to human germline sequences present on the transgene; often 90 or 95 percent or more similar to human germline sequences present on the transgene. However, since non-germline sequences are introduced by somatic mutation and VJ and VDJ joining, the human sequence antibodies will frequently have some variable region sequences which are not encoded by human V, D, or J gene segments as found in the human transgene(s) in the germline of the mice. Typically, such non-germline sequences (or individual nucleotide positions) will cluster in or near CDRs, or in regions where somatic mutations are known to cluster. The present invention also provides B cells derived from transgenic or transchromosomal nonhuman animals as described herein. The B cells may be used to generate hybridomas expressing human monoclonal antibodies which bind with high affinity (for instance with a dissociation equilibrium constant (K\nD\n) of lower than 10\n'8\n M) to human IL-21. Thus, in one embodiment, the present invention provides a hybridoma which produces a human antibody having an affinity (K\nD\n) of below 10\n'8\n M, such as of below 10\n'9\n M, 10 \n10\n M or 10\n'11\n M or even lower when determined by scatchard analysis of IL-21 expressing cells using a radio-actively labeled monoclonal antibody or by determination of the half-maximal binding concentration using FACS analysis, or by analysis using surface plasmon resonance as measured on a BIAcore instrument. \n\n The present invention provides an anti-IL-21 antibody comprising a human sequence light chain composed of (1 ) a light chain variable region having a polypeptide sequence which is substantially identical to a polypeptide sequence encoded by a human V\nL\n gene segment and a human J\nL\n segment, and (2) a light chain constant region encoded by a human C\nL\n gene segment; and a human sequence heavy chain composed of a (1) a heavy chain variable region having a polypeptide sequence which is substantially identical to a polypeptide sequence encoded by a human V\nH\n gene segment, a D region, and a human J\nH\n segment, and (2) a constant region encoded by a human C\nH\n gene segment. It should be noted that human D genes may be substantially altered by recombination and somatic mutation events such that the original human germ-line sequence may not be readily recognized.\n\n\nThe development of high affinity human monoclonal antibodies against IL-21 may be facilitated by a method for expanding the repertoire of human variable region gene segments in a transgenic nonhuman animal having a genome comprising an integrated human immunoglobulin transgene, said method comprising introducing into the genome a V gene transgene comprising V region gene segments which are not present in said integrated human immunoglobulin transgene. Often, the V region transgene is a yeast artificial chromosome (YAC) comprising a portion of a human V\nH\n or V\nL\n (V\nκ\n) gene segment array, as may naturally occur in a human genome or as may be spliced together separately by recombinant methods, which may include out-of-order or omitted V gene segments. Often at least five or more functional V gene segments are contained on the YAC. In this variation, it is possible to make a transgenic animal produced by the V repertoire expansion method, wherein the animal expresses an immunoglobulin chain comprising a variable region sequence encoded by a V region gene segment present on the V region transgene and a C region encoded on the human Ig transgene. By means of the V repertoire expansion method, transgenic animals having at least 5 distinct V genes may be generated; as can animals containing at least about 24 V genes or more. Some V gene segments may be nonfunctional (e.g., pseudogenes and the like); these segments may be retained or may be selectively deleted by recombinant methods available to the skilled artisan, if desired. Once the mouse germline has been engineered to contain a functional YAC having an expanded V segment repertoire, substantially not present in the human Ig transgene containing the J and C gene segments, the trait may be propagated and bred into other genetic backgrounds, including backgrounds where the functional YAC having an expanded V segment repertoire is bred into a nonhuman animal germline having a different human Ig transgene. Multiple functional YACs having an expanded V segment repertoire may be bred \n\n into a germline to work with a human Ig transgene (or multiple human Ig transgenes). Although referred to herein as YAC transgenes, such transgenes when integrated into the genome may substantially lack yeast sequences, such as sequences required for autonomous replication in yeast; such sequences may optionally be removed by genetic engineering (e.g., restriction digestion and pulsed-field gel electrophoresis or other suitable method) after replication in yeast is no longer necessary (i.e., prior to introduction into a mouse ES cell or mouse prozygote). Methods of propagating the trait of human sequence immunoglobulin expression, include breeding a transgenic animal having the human Ig transgene(s), and optionally also having a functional YAC having an expanded V segment repertoire. Both V\nH\n and V\nL\n gene segments may be present on the YAC. The transgenic animal may be bred into any background desired by the practitioner, including backgrounds harboring other human transgenes, including human Ig transgenes and/or transgenes encoding other human lymphocyte proteins. The present invention also provides a high affinity human sequence immunoglobulin produced by a transgenic mouse having an expanded V region repertoire YAC transgene. Although the foregoing describes a specific embodiment of the transgenic animal of the present invention, other embodiments are contemplated which have been classified in three categories:\n\n\nI. Transgenic animals containing an unrearranged heavy and rearranged light chain immunoglobulin transgene; II. Transgenic animals containing an unrearranged heavy and unrearranged light chain immunoglobulin transgene; and\n\n\nIII. Transgenic animal containing rearranged heavy and an unrearranged light chain immunoglobulin transgene.\n\n\nIL-21 BPs of the present invention, such as human anti-IL-21 antibodies of the present invention, may be isolated and characterized in a number of different ways. For example, selected hybridomas may be grown in suitable flasks for monoclonal antibody purification. Supernatants may then be filtered and concentrated before affinity chromatography with protein A-sepharose (for IgGI isotype antibodies) (Pharmacia, Piscataway, NJ) or anti-human IgG coated sepharose or protein G-sepharose in case of lgG3 isotype antibodies. Eluted IgG may be checked by gel electrophoresis and high performance liquid chromatography to ensure purity. The buffer solution may be exchanged into PBS, and the concentration may be determined by OD\n28O\n using 1.43 extinction coefficient. The monoclonal antibodies may be aliquoted and stored at -80\n0\nC. \n\n To determine if the selected IL-21 BPs, such as human anti-IL-21 monoclonal antibodies, bind to unique epitopes, site-directed or multi-site directed mutagenesis may be used.\n\n\nTo determine the isotype of purified antibodies, isotype ELISAs may be performed. Wells of microtiter plates may be coated with 10 μg/ml of anti-human Ig overnight at 4°C. After blocking with 5% BSA (bovine serum albumin), the plates are reacted with 10 μg/ml of monoclonal antibodies or purified isotype controls, at ambient temperature for two hours. The wells may then be reacted with either human IgGI, lgG2, lgG3 or lgG4, IgE, IgAI , lgA2, or human IgM-specific alkaline phosphatase-conjugated probes. After washing, the plates are developed with pNPP substrate (1 mg/ml) and analyzed by OD at 405 nm.\n\n\nIL-21 BPs, such as anti-IL-21 human IgGs, may be further tested for reactivity with IL-21 antigen by Western blotting. For instance, antigen may be transferred to nitrocellulose membranes, blocked with 20% non-fat milk, and probed with the IL-21 BPs to be tested. Human IgG binding may be detected using anti-human IgG alkaline phosphatase and developed with BCIP/NBT substrate tablets (Sigma Chem. Co., St. Louis, MO), but detecting agents directed at other specific portions of the IL-21 BP may also be used.\n\n\nIn addition to binding specifically to IL-21 , IL-21 BPs (including human anti-IL-21 antibodies) may be tested for their ability to inhibit the IL-21 mediated activation of the IL-21 receptor. In one embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of an IL-21 BP of the present invention. The pharmaceutical compositions may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.\n\n\nThe pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients should be suitable for the chosen compound of the present invention and the chosen mode of administration. Suitability for carriers and other components of pharmaceutical compositions is determined based on the lack of significant negative impact on the desired biological properties of the chosen compound or pharmaceutical composition of the present invention (e.g., less than a substantial impact (10% or less relative inhibition, 5% or less relative inhibition, etc.) on antigen binding.\n\n\nA pharmaceutical composition of the present invention may also include diluents, fillers, salts, buffers, detergents (e. g., a nonionic detergent, such as Tween-80), stabilizers, \n\n stabilizers (e. g., sugars or protein-free amino acids), preservatives, tissue fixatives, solubilizers, and/or other materials suitable for inclusion in a pharmaceutical composition.\n\n\nThe actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.\n\n\nThe pharmaceutical composition may be administered by any suitable route and mode. Suitable routes of administering a compound of the present invention in vivo and in vitro are well known in the art and may be selected by those of ordinary skill in the art.\n\n\nThe compounds of the present invention may be administered via any suitable route, such as an oral, nasal, inhalable, topical (including buccal, transdermal and sublingual), rectal, vaginal and/or parenteral route. In one embodiment, a pharmaceutical composition of the present invention is administered orally, for example, with an inert diluent or an assimilable edible carrier. The active ingredient may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. Pharmaceutical compositions of the present invention which are suitable for oral administration include ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like containing such carriers as are known in the art to be appropriate. To administer a compound of the present invention by oral administration, it may be necessary to coat the compound with, or coadminister the compound with, a material to prevent its inactivation.\n\n\nIn one embodiment, a pharmaceutical composition of the present invention is administered nasally. Pharmaceutical compositions of the present invention which are suitable for nasal administration are known in the art and typically include sprays, nose drops and inhalants containing such carriers as are known in the art to be appropriate.\n\n\nIn one embodiment, a pharmaceutical composition of the present invention is administered topically. Pharmaceutical compositions of the present invention which are suitable for topical or transdermal administration include powders, sprays, ointments, pastes, \n\n creams, lotions, gels, solutions, patches and inhalants containing such carriers as are known in the art to be appropriate.\n\n\nIn one embodiment, a pharmaceutical composition of the present invention is administered rectally. Pharmaceutical compositions of the present invention which are suitable for rectal administration are known in the art and include gels, pastes, spray formulations, suppositories containing such carriers as are known in the art to be appropriate.\n\n\nIn one embodiment, a pharmaceutical composition of the present invention is administered vaginally. Pharmaceutical compositions of the present invention which are suitable for vaginal administration include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.\n\n\nIn one embodiment, a pharmaceutical composition of the present invention is administered parenterally.\n\n\nThe phrases \"parenteral administration\" and \"administered parenterally\" as used herein means modes of administration other than enteral and topical administration, usually by injection, and include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural and intrasternal injection and infusion. In one embodiment that pharmaceutical composition is administered by intravenous or subcutaneous injection or infusion.\n\n\nIn one embodiment the compounds of the present invention are administered in crystalline form by subcutaneous injection, cf. Yang et al., PNAS USA 100(12), 6934-6939 (2003). The pharmaceutical compositions of the present invention may be administered with medical devices known in the art. For example, in one embodiment, a pharmaceutical composition of the present invention may be administered with a needleless hypodermic injection device, such as the devices disclosed in US 5,399,163, US 5,383,851 , US 5,312,335, US 5,064,413, US 4,941 ,880, US 4,790,824, or US 4,596,556. Examples of well- known implants and modules useful in the present invention include: US 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; US 4,486,194, which discloses a therapeutic device for administering medicants through the skin; US 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; US 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; US 4,439,196, which discloses an osmotic drug \n\n delivery system having multi-chamber compartments; and US 4,475,196, which discloses an osmotic drug delivery system. Many other such implants, delivery systems, and modules are known to those skilled in the art.\n\n\nPharmaceutical compositions of the present invention may be formulated for particular routes of administration, such as oral, nasal, topical (including buccal, transdermal and sublingual), rectal, vaginal and/or parenteral administration. The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy. The amount of active ingredient which may be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated, and the particular mode of administration. The amount of active ingredient which may be combined with a carrier material to produce a single dosage form will generally be that amount of the composition which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.01% to about 99% of active ingredient, such as from about 0.1% to about 70%, for instance from about 1% to about 30%.\n\n\nRegardless of the route of administration selected, the compounds of the present invention, which may be used in the form of a pharmaceutically acceptable salt or in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. A \"pharmaceutically acceptable salt\" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see for instance Berge, S. M. et al., J. Pharm. Sci. 66, 1-19 (1977)). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous acids and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanol- amine, ethylenediamine, procaine and the like.\n\n\nPharmaceutically acceptable carriers include any and all suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, antioxidants and absorption delaying agents, and the like that are physiologically compatible with a compound of the present invention. \n\n Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the present invention include water, saline, phosphate buffered saline, ethanol, dextrose, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, corn oil, peanut oil, cottonseed oil, and sesame oil, carboxymethyl cellulose colloidal solutions, tragacanth gum and injectable organic esters, such as ethyl oleate, and/or various buffers. Other carriers are well known in the pharmaceutical arts.\n\n\nPharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the present invention is contemplated.\n\n\nProper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.\n\n\nPharmaceutical compositions of the present invention may also comprise pharmaceutically acceptable antioxidants for instance (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.\n\n\nPharmaceutical compositions of the present invention may also comprise isotonicity agents, such as sugars, polyalcohols such as mannitol, sorbitol, glycerol or sodium chloride in the compositions.\n\n\nPharmaceutically acceptable diluents include saline and aqueous buffer solutions. The pharmaceutical compositions of the present invention may also contain one or more adjuvants appropriate for the chosen route of administration such as preservatives, wetting agents, emulsifying agents, dispersing agents, preservatives or buffers, which may enhance the shelf life or effectiveness of the pharmaceutical composition. Compounds of the present invention may for instance be admixed with lactose, sucrose, powders (e.g., starch powder), cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol. Other examples of \n\n adjuvants are QS21 , GM-CSF, SRL-172, histamine dihydrochloride, thymocartin, Tio-TEPA, monophosphoryl-lipid A/micobacteria compositions, alum, incomplete Freund's adjuvant, montanide ISA, ribi adjuvant system, TiterMax adjuvant, syntex adjuvant formulations, immune-stimulating complexes (ISCOMs), gerbu adjuvant, CpG oligodeoxynucleotides, lipopolysaccharide, and polyinosinic:polycytidylic acid.\n\n\nPrevention of presence of microorganisms may be ensured both by sterilization procedures and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid, and the like. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.\n\n\nPharmaceutical compositions of the present invention comprising a compound of the present invention may also include a suitable salt therefor. Any suitable salt, such as an alkaline earth metal salt in any suitable form (e.g., a buffer salt), may be used in the stabilization of the compound of the present invention. Suitable salts typically include sodium chloride, sodium succinate, sodium sulfate, potassium chloride, magnesium chloride, magnesium sulfate, and calcium chloride. In one embodiment, an aluminum salt is used to stabilize a compound of the present invention in a pharmaceutical composition of the present invention, which aluminum salt also may serve as an adjuvant when such a composition is administered to a patient. Pharmaceutical compositions according to the present invention may be in a variety of suitable forms. Such forms include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, emulsions, microemulsions, gels, creams, granules, powders, tablets, pills, powders, liposomes, dendrimers and other nanoparticles (see for instance Baek et al., Methods Enzymol. 362, 240-9 (2003), Nigavekar et al., Pharm Res. 21.(3), 476-83 (2004), microparticles, and suppositories.\n\n\nThe optima form depends on the chosen mode of administration, the nature of the composition, and the therapeutic application. Formulations may include, for instance, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles, DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semisolid gels, and semi-solid mixtures containing carbowax. Any of the foregoing may be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the pharmaceutical composition is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of \n\n administration. See also for instance Powell et al., \"Compendium of excipients for parenteral formulations\" PDA J Pharm Sci Technol. 52, 238-311 (1998) and the citations therein for additional information related to excipients and carriers well known to pharmaceutical chemists. The compounds of the present invention may be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Such carriers may include gelatin, glyceryl monostearate, glyceryl distearate, biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid alone or with a wax, or other materials well known in the art.. Methods for the preparation of such formulations are generally known to those skilled in the art. See e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.\n\n\nTo administer compositions of the present invention by certain routes of administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. For example, the compound of the present invention may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., J. Neuroimmunol. 7, 27 (1984)). Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound. For example, the compound may be administered to a subject in an appropriate carrier, for example, liposomes. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., J. Neuroimmunol. 7, 27 (1984)).\n\n\nIn one embodiment, the compounds of the present invention may be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the present invention cross the BBB (if desired), they may be formulated, for example, in liposomes. For methods of manufacturing liposomes, see for instance US 4,522,81 1 , US 5,374,548 and US 5,399,331. The liposomes may comprise one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see for instance V. V. Ranade J. Clin. Pharmacol. 29, 685 (1989)). Exemplary targeting moieties include folate or biotin (see for instance US 5,416,016), mannosides (Umezawa et al., Biochem. Biophys. Res. Commun. 153, 1038 (1988)), antibodies (P. G. Bloeman et al., FEBS \n\n Lett. 357, 140 (1995), M. Owais et al., Antimicrob. Agents Chemother. 39, 180 (1995)), surfactant protein A receptor (Briscoe et al., Am. J. Physiol. 1233, 134 (1995)), different species of which may comprise the pharmaceutical compositions of the present inventions, as well as components of the invented molecules, p120 (Schreier et al., J. Biol. Chem. 269, 9090 (1994)), see also K. Keinanen, M. L. Laukkanen, FEBS Lett. 346, 123 (1994) and J.J. Killion, I.J. Fidler, Immunomethods 4, 273 (1994).\n\n\nIn one embodiment of the present invention, the compounds of the present invention are formulated in liposomes. In a further embodiment, the liposomes include a targeting moiety. In a further embodiment, the compounds in the liposomes are delivered by bolus injection to a site proximal to the desired area, e.g., the site of inflammation or infection, or the site of a tumor. The composition should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. In one embodiment, the compounds of the present invention may be formulated to prevent or reduce their transport across the placenta. This may be done by methods known in the art, e.g., by PEGylation of the compounds or by use of F(ab')\n2\n fragments. Further reference can be made to Cunningham-Rundles C et al., J Immunol Methods. 152, 177-190 (1992) and to Landor M., Ann Allergy Asthma Immunol 74, 279-283 (1995).\n\n\nPharmaceutically acceptable carriers for parenteral administation include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the present invention is contemplated. Supplementary active compounds may also be incorporated into the compositions.\n\n\nPharmaceutical compositions for injection must typically be sterile and stable under the conditions of manufacture and storage. The composition may be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier may be a aqueous or nonaqueous solvent or dispersion medium containing for instance water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as \n\n glycerol, mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin. Sterile injectable solutions may be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients e.g. as enumerated above, as required, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients e.g. from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, examples of methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.\n\n\nSterile injectable solutions may be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, examples of methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile -filtered solution thereof.\n\n\nThe pharmaceutical composition of the present invention may contain one compound of the present invention or a combination of compounds of the present invention. Thus, in one embodiment, a pharmaceutical composition of the present invention includes a combination of multiple (e.g., two or more) compounds of the present invention which act by different mechanisms, e.g., one compound which predominately acts by inducing CDC in combination with another compound which predominately acts by inducing apoptosis. The IL-21 BPs (including anti-IL-21 antibodies, immunoconjugates, bispecific/- multispecific molecules, compositions and other derivatives described herein) of the present invention have numerous in vitro and in vivo diagnostic and therapeutic utilities involving the diagnosis and treatment of disorders involving IL-21. For example, the antibodies may be administered to cells in culture, e.g., in vitro or ex vivo, or to human subjects, e.g., in vivo, to treat, prevent and to diagnose a variety of disorders. As used herein, the term \"subject\" is intended to include human and non-human animals which respond to the IL-21 BP. Subjects \n\n may for instance include human patients having disorders that may be corrected or ameliorated by inhibiting the IL-21 receptor, such as for instance graft rejection.\n\n\nIn one embodiment, the present invention provides methods for detecting the presence of IL-21 antigen in a sample, or measuring the amount of IL-21 antigen, comprising contacting the sample, and a control sample, with an IL-21 BP which specifically binds to IL-21 , under conditions that allow for formation of a complex between the IL-21 BP or portion thereof and IL-21. The formation of a complex is then detected, wherein a difference complex formation between the sample compared to the control sample is indicative the presence of IL-21 antigen in the sample. Examples of methods for detecting immunoassays include, without limitation, an ELISA, an RIA, FACS assays, plasmon resonance assays, chromatographic assays, tissue immunohistochemistry, Western blot, and/or immunoprecipitation.\n\n\nIn one embodiment, IL-21 BPs of the present invention may be used to detect levels of circulating IL-21 , which levels can then be linked to certain disease symptoms. Alternatively, the IL-21 BPs may be used to interact with the function of cells expressing the IL-21 receptor, thereby implicating these cells as important mediators of the disease. This may be achieved by contacting a sample and a control sample with the anti-IL-21 antibody under conditions that allow for the formation of a complex between the antibody and IL-21. Any complexes formed between the antibody and IL-21 are detected and compared in the sample and the control.\n\n\nIn one embodiment, the present invention provides a method for detecting the presence or quantifying the amount of IL-21 in vivo or in vitro. The method comprises (i) administering to a subject a composition (comprising e.g., IL-21 BPs, human anti-IL-21 antibodies, and/or bispecific/multispecific antibodies) of the present invention conjugated to a detectable marker; (ii) exposing the subject to a means for detecting said detectable marker to identify areas containing IL-21.\n\n\nIn one embodiment, immunoconjugates of the present invention may be used to target compounds (e.g., therapeutic agents, labels, cytotoxins, immunosuppressants, etc.) to cells which have IL-21 bound to their surface by linking such compounds to the IL-21 BP. The present invention provides methods for treating a disease or disorder in a subject, wherein said disease or disorder may be treatable by use of an IL-21 antagonist , which method comprises administation of a therapeutically effective amount of an IL-21 BP of the present invention to a subject in need thereof. Such IL-21 BPs are used to inhibit IL-21 interaction with the IL-21 receptor. By contacting the IL-21 BP with IL-21 (e.g., by \n\n administering the antibody to a subject), the ability of IL-21 to induce such activities is inhibited and, thus, the associated disorder is treated.\n\n\nSuch a method involves administering to a subject an IL-21 BP of the present invention in an amount effective to treat or prevent the disorder. The IL-21 BP may be administered alone or along with another therapeutic agent, which acts in conjunction with or synergistically with the IL-21 BP to treat or prevent the disease.\n\n\nIn one embodiment, the present invention provides a method for treating autoimmune diseases or disorders in humans, which method comprises administation of a therapeutically effective amount of an IL-21 BP of the present invention to a subject in need thereof.\n\n\nIn one embodiment, the present invention provides the use of an IL-21 BP of the present invention for the preparation of a pharmaceutical composition for treating autoimmune diseases or disorders.\n\n\nExamples of inflammatory, immune and/or autoimmune disorders, which may be treatable with IL-21 binding peptides according to the invention, include the following: vasculitides and other vessel disorders, such as microscopic polyangiitis, Churg-Strauss syndrome, and other ANCA-associated vasculitides, polyarteritis nodosa, essential cryoglobulinaemic vasculitis, cutaneous leukocytoclastic angiitis, Kawasaki disease, Takayasu arteritis, giant cell arthritis, Henoch-Schόnlein purpura, primary or isolated cerebral angiitis, erythema nodosum, thrombangiitis obliterans, thrombotic thrombocytopenic purpura (including hemolytic uremic syndrome), and secondary vasculitides, including cutaneous leukocytoclastic vasculitis (e.g., secondary to hepatitis B, hepatitis C, Waldenstrom's macroglobulinemia, B-cell neoplasias, rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus), erythema nodosum, allergic vasculitis, panniculitis, Weber- Christian disease, purpura hyperglobulinaemica, and Buerger's disease; skin disorders, such as contact dermatitis, linear IgA dermatosis, vitiligo, pyoderma gangrenosum, epidermolysis bullosa acquisita, pemphigus vulgaris (including cicatricial pemphigoid and bullous pemphigoid), alopecia areata (including alopecia universalis and alopecia totalis), dermatitis herpetiformis, erythema multiforme, and chronic autoimmune urticaria (including angioneurotic edema and urticarial vasculitis); immune-mediated cytopenias, such as autoimmune neutropenia, and pure red cell aplasia; connective tissue disorders, such as CNS lupus, discoid lupus erythematosus, CREST syndrome, mixed connective tissue disease, polymyositis/dermatomyositis, inclusion body myositis, secondary amyloidosis, cryoglobulinemia type I and type II, fibromyalgia, phospholipid antibody syndrome, secondary hemophilia, relapsing polychondritis, sarcoidosis, stiff man syndrome, rheumatic fever, and \n\n eosinophil fasciitis; arthritides, such as ankylosing spondylitis, juvenile chronic arthritis, adult Still's disease, SAPHO syndrome, sacroileitis, reactive arthritis, Still's disease, and gout; hematologic disorders, such as aplastic anemia, primary hemolytic anemia (including cold agglutinin syndrome), hemolytic anemia with warm autoantibodies, hemolytic anemia secondary to CLL or systemic lupus erythematosus; POEMS syndrome, pernicious anemia, Waldemstrόm's purpura hyperglobulinaemica, Evans syndrome, agranulocytosis, autoimmune neutropenia, Franklin's disease, Seligmann's disease, μ chain disease, factor VIII inhibitor formation, factor IX inhibitor formation, and paraneoplastic syndrome secondary to thymoma and lymphomas; endocrinopathies, such as polyendocrinopathy, and Addison's disease; further examples are autoimmune hypoglycemia, autoimmune hypothyroidism, autoimmune insulin syndrome, de Quervain's thyroiditis, and insulin receptor antibody- mediated insulin resistance; hepato-gastrointestinal disorders, such as celiac disease, Whipple's disease, primary biliary cirrhosis, chronic active hepatitis, primary sclerosing cholangiitis, and autoimmune gastritis; nephropathies, such as rapid progressive glomerulonephritis, post-streptococcal nephritis, Goodpasture's syndrome, membranous glomerulonephritis, cryoglobulinemic nephritis, minimal change disease, and steroid- dependent nephritic syndrome; neurological disorders, such as autoimmune neuropathies, mononeuritis multiplex, Lambert-Eaton's myasthenic syndrome, Sydenham's chorea, tabes dorsalis, and Guillain-Barre's syndrome; further examples are myelopathy/tropical spastic paraparesis, myasthenia gravis, acute inflammatory demyelinating polyneuropathy, and chronic inflammatory demyelinating polyneuropathy; cardiac and pulmonary disorders, such as fibrosing alveolitis, bronchiolitis obliterans, allergic aspergillosis, cystic fibrosis, Lόffler's syndrome, myocarditis, and pericarditis; further examples are hypersensitivity pneumonitis, and paraneoplastic syndrome secondary to lung cancer; allergic disorders, such as bronchial asthma, hyper-lgE syndrome, and angioneurotic syndrome; ophthalmologic disorders, such as idiopathic chorioretinitis, and amaurosis fugax; infectious diseases, such as parvovirus B infection (including hands-and-socks syndrome); gynecological-obstretical disorders, such as recurrent abortion, recurrent fetal loss, intrauterine growth retardation, and paraneoplastic syndrome secondary to gynaecological neoplasms; male reproductive disorders, such as paraneoplastic syndrome secondary to testicular neoplasms; and transplantation-derived disorders, such as IL-21 mediated graft rejection, for instance allograft and xenograft rejection, and graft-versus-host disease.\n\n\nIn one embodiment, the disease is a transplantation-derived disorder. In one embodiment, such disorder is derived from IL-21 mediated graft rejection, for instance allograft and xenograft rejection, and graft-versus-host disease. \n\n In one embodiment, the disease is rheumatoid arthritis (RA). In one embodiment, the disease is selected from inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, juvenile onset diabetes, multiple sclerosis, immune- mediated thrombocytopenias, such as acute idiopathic thrombocytopenic purpura and chronic idiopathic thrombocytopenic purpura, hemolytic anemia (including autoimmune hemolytic anemia), myasthenia gravis, systemic sclerosis, and pemphigus vulgaris.\n\n\nIn one embodiment, the disease is selected from inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and multiple sclerosis.\n\n\nIn one embodiment, the present invention provides a method for treating or preventing systemic lupus erythematosus, rheumatoid arthritis or inflammatory bowel disease, which method comprises administation of a therapeutically effective amount of an IL-21 BP of the present invention to a subject in need thereof.\n\n\nIn one embodiment, the present invention provides the use of an IL-21 BP of the present invention for the preparation of a pharmaceutical composition for treating systemic lupus erythematosus, rheumatoid arthritis or inflammatory bowel disease.\n\n\nIn one embodiment, the IL-21 BPs of the present invention may be used in vivo or in vitro for diagnosing diseases wherein altered levels of IL-21 play an active role in the pathogenesis by detecting levels of IL-21. This may be achieved, for example, by contacting a sample to be tested, optionally along with a control sample, with the IL-21 BP under conditions that allow for formation of a complex between the antibody and IL-21. Complex formation is then detected (e.g., using an ELISA). When using a control sample along with the test sample, complex is detected in both samples and any statistically significant difference in the formation of complexes between the samples is indicative of the presence of IL-21 in the test sample. More specifically, the present invention provides methods for the identification of, and diagnosis of invasive cells and tissues, and other cells targeted by IL-21 BPs of the present invention, and for the monitoring of the progress of therapeutic treatments, status after treatment, risk of developing cancer, cancer progression, and the like.\n\n\nIn one example of such a diagnostic assay, the present invention provides a method of diagnosing the level of invasive cells in a tissue comprising forming an immunocomplex between an IL-21 BP and potential IL-21 containing tissues, and detecting formation of the immunocomplex, wherein the formation of the immunocomplex correlates with the presence of invasive cells in the tissue. The contacting may be performed in vivo, using labeled isolated antibodies and standard imaging techniques, or may be performed in vitro on tissue samples. \n\n IL-21 BPs may be used to detect IL-21-containing peptides and peptide fragments in any suitable biological sample by any suitable technique. Examples of conventional immunoassays provided by the present invention include, without limitation, an ELISA, an RIA, FACS assays, plasmon resonance assays, chromatographic assays, tissue immunohistochemistry, Western blot, and/or immunoprecipitation using an IL-21 BP. Anti- IL-21 antibodies of the present invention may be used to detect IL-21 and IL-21 -fragments from humans. Suitable labels for the IL-21 BP and/or secondary antibodies used in such techniques include, without limitation, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include \n125\nI, \n131\nI, \n35\nS, and \n3\nH.\n\n\nIL-21 BPs may also be assayed in a biological sample by a competition immunoassay utilizing IL-21 peptide standards labeled with a detectable substance and an unlabeled IL-21 BP, such as an unlabelled anti-IL-21 antibody, for example. In such an assay, the biological sample, the labeled IL-21 peptide standard(s) and the IL-21 BP are combined and the amount of labeled IL-21 standard bound to the unlabeled IL-21 BP is determined. The amount of IL-21 peptide in the biological sample is inversely proportional to the amount of labeled IL-21 standard bound to the IL-21 BP.\n\n\nIn one embodiment, the present invention provides an in vivo imaging method wherein an IL-21 BP, such as an anti-IL-21 antibody, of the present invention is conjugated to a detection-promoting radio-opaque agent, the conjugated antibody is administered to a host, such as by injection into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. Through this technique and any other diagnostic method provided herein, the present invention provides a method for screening for the presence of disease-related cells in a human patient or a biological sample taken from a human patient. For diagnostic imaging, radioisotopes may be bound to an IL-21 BP either directly, or indirectly by using an intermediary functional group. Useful intermediary functional groups include chelators, such as ethylenediaminetetraacetic acid and diethylenetriaminepentaacetic acid (see for instance US 5,057,313). In such diagnostic assays involving radioisotope-conjugated IL-21 BPs, the dosage of conjugated peptide delivered to the patient typically is maintained at as low a level as possible through the \n\n choice of isotope for the best combination of minimum half-life, minimum retention in the body, and minimum quantity of isotope, which will permit detection and accurate measurement.\n\n\nIn addition to radioisotopes and radio-opaque agents, diagnostic methods may be performed using IL-21 BPs that are conjugated to dyes (such as with the biotin-streptavidin complex), contrast agents, fluorescent compounds or molecules and enhancing agents (e.g. paramagnetic ions) for magnetic resonance imaging (MRI) (see, e.g., US Pat. No. 6,331 ,175, which describes MRI techniques and the preparation of antibodies conjugated to a MRI enhancing agent). Such diagnostic/detection agents may be selected from agents for use in magnetic resonance imaging, and fluorescent compounds. In order to load an IL-21 BP, such as an antibody, component with radioactive metals or paramagnetic ions, it may be necessary to react it with a reagent having a long tail to which are attached a multiplicity of chelating groups for binding the ions. Such a tail may be a polymer such as a polylysine, polysaccharide, or other derivatized or derivatizable chain having pendant groups to which may be bound chelating groups such as, e.g., porphyrins, polyamines, crown ethers, bisthiosemicarbazones, polyoximes, and like groups known to be useful for this purpose. Chelates may be coupled to IL-21 BPs using standard chemistries. A chelate is normally linked to an IL-21 BP, such as an anti-IL-21 mAB, by a group, which enables formation of a bond to the molecule with minimal loss of immunoreactivity and minimal aggregation and/or internal cross-linking. Other, more unusual, methods and reagents for conjugating chelates to antibodies are disclosed in for instance US 4,824,659. Examples of potentially useful metal-chelate combinations include 2-benzyl-DTPA and its monomethyl and cyclohexyl analogs, used with diagnostic isotopes in the general energy range of 60 to 4,000 keV, such as \n125\nI, \n123\nI, \n124\n1, \n62\nCu, \n64\nCu, \n18\nF, \n111\nIn, \n67\nGa, \n67\nGa, \n99\nTc, \n94\nTc, \n11\nC, \n13\nN, \n15\nO, and \n76\nBR, for radio- imaging. These and similar chelates, when complexed with non-radioactive metals, such as manganese, iron, and gadolinium may be useful for MRI diagnostic methods in connection with IL-21 BPs. Macrocyclic chelates such as NOTA, DOTA, and TETA are of use with a variety of metals and radiometals, most particularly with radionuclides of gallium, yttrium, and copper, respectively. Such metal-chelate complexes may be made very stable by tailoring the ring size to the metal of interest. Other ring-type chelates such as macrocyclic polyethers, which are of interest for stably binding nuclides, such as \n223\nRa for RAIT may also be suitable in diagnostic methods.\n\n\nThus, the present invention provides diagnostic IL-21 BP conjugates, wherein the IL-21 BP is conjugated to a contrast agent (such as for magnetic resonance imaging, computed tomography, or ultrasound contrast-enhancing agent) or a radionuclide that may \n\n be, for example, a gamma-, beta-, alpha-, Auger electron-, or positron-emitting isotope. Additional useful conjugated IL-21 BPs are described elsewhere herein, which may also be useful in diagnostic methods and compositions (e.g., diagnostic kits) provided by the present invention. In one embodiment, the present invention provides a kit for diagnosis of cancer comprising a container comprising an IL-21 BP, such as an anti-IL-21 antibody, and one or more reagents for detecting binding of the IL-21 BP to an IL-21 peptide. Reagents may include, for example, fluorescent tags, enzymatic tags, or other detectable tags. The reagents may also include secondary or tertiary antibodies or reagents for enzymatic reactions, wherein the enzymatic reactions produce a product that may be visualized. In one embodiment, the present invention provides a diagnostic kit comprising one or more IL-21 BPs, such as anti-IL-21 antibodies, of the present invention in labeled or unlabeled form in suitable container(s), reagents for the incubations for an indirect assay, and substrates or derivatizing agents for detection in such an assay, depending on the nature of the label. Control reagent(s) and instructions for use also may be included.\n\n\nDiagnostic kits may also be supplied for use with an IL-21 BP, such as a conjugated/labeled anti-IL-21 antibody, for the detection of a cellular activity or for detecting the presence of IL-21 peptides in a tissue sample or host. In such diagnostic kits, as well as in kits for therapeutic uses described elsewhere herein, an IL-21 BP typically may be provided in a lyophilized form in a container, either alone or in conjunction with additional antibodies specific for a target cell or peptide. Typically, a pharmaceutical acceptable carrier (e.g., an inert diluent) and/or components thereof, such as a Tris, phosphate, or carbonate buffer, stabilizers, preservatives, biocides, biocides, inert proteins, e.g., serum albumin, or the like, also are included (typically in a separate container for mixing) and additional reagents (also typically in separate container(s)). In certain kits, a secondary antibody capable of binding to the anti-IL-21 antibody or other IL-21 BP, which typically is present in a separate container, is also included. The second antibody is typically conjugated to a label and formulated in manner similar to the anti-IL-21 antibody or other IL-21 BP of the present invention.\n\n\nUsing the methods described above and elsewhere herein IL-21 BPs may be used to define subsets of cancer/tumor cells and characterize such cells and related tissues/growths.\n\n\nIn one example, an IL-21 BP or anti-IL-21 antibody, may be added to nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles, or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled IL-21 peptide or antibody. The solid phase support may then be \n\n washed with the buffer a second time to remove unbound peptide or antibody. The amount of bound label on the solid support may then be detected by known method steps.\n\n\nLinked enzymes that react with an exposed substrate may be used to generate a chemical moiety which may be detected, for example, by spectrophotometric, fluorometric or by visual means, in the context of an IL-21 BP conjugate and/or fusion protein. Enzymes which may be used to detectably label IL-21 BPs and anti-IL-21 antibodies include malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta- galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholinesterase. It is also possible to label an IL-21 BP with a fluorescent compound. When the fluorescent labeled antibody is exposed to light of the proper wave length, its presence may be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine.\n\n\nThe IL-21 BPS, such as anti-IL-21 antibodies, may also be detectably labeled using fluorescence-emitting metals such as \n152\nEu, or others of the lanthanide series. These metals may be attached to an anti-IL-21 antibody, for example, using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). IL-21 BPs and anti-IL-21 antibodies may also be detectably labeled by coupling to a chemiluminescent compound. The presence of the chemiluminescently labeled IL-21-BP is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt, and oxalate ester.\n\n\nLikewise, a bioluminescent compound may be used to label an IL-21 BP. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase, and aequorin. Detection of a labeled peptide or antibody, antibody fragment or derivative may be accomplished by a scintillation counter, for example, if the detectable label is a radioactive gamma emitter, or by a fluorometer, for example, if the label is a fluorescent material. In the case of an enzyme label, the detection may be accomplished by colorimetric methods which employ a substrate for the enzyme. Detection may also be accomplished by visual \n\n comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.\n\n\nThese and other diagnostic techniques may be used to screen any suitable material for IL-21 peptides or I L-21 -fragments. Examples of materials that may be screened include, for example, blood, serum, lymph, urine, inflammatory exudate, cerebrospinal fluid, amniotic fluid, a tissue extract or homogenate, and the like. However, the present invention is not limited to assays using only these samples, it being possible for one of ordinary skill in the art to determine suitable conditions which allow the use of other samples.\n\n\nIn situ detection may be accomplished by removing a histological specimen from a patient, and providing the combination of labeled IL-21 BPs, such as anti-IL-21 antibodies, of the present invention to such a specimen. The IL-21 BP, anti-IL-21 -antibody (or fragment) of the present invention may be provided by applying or by overlaying the labeled IL-21 BP, such as a labelled anti-IL-21 antibody (or fragment), of the present invention to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of IL-21 or I L-21 -fragment but also the distribution of such peptides in the examined tissue (e.g., in the context of assessing the spread of cancer cells). Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) may be modified in order to achieve such in situ detection. Compositions of the present invention may include a \"therapeutically effective amount\" or a \"prophylactically effective amount\" of an IL-21 BP. A \"therapeutically effective amount\" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount of an IL-21 BP may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the IL-21 BP to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A \"prophylactically effective amount\" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result (e.g., a reduction in the likelihood of developing a disorder, a reduction in the intensity or spread of a disorder, an increase in the likelihood of survival during an imminent disorder, a delay in the onset of a disease condition, etc.). Typically, because a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. \n\n A \"therapeutically effective amount\" for rheumatoid arthritis may result in an at least ACR\n2O\n Preliminary Definition of Improvement in the patients, such as in at least an ACR\n50\n Preliminary Definition of Improvement, for instance at least an ARC\n70\n Preliminary Definition of Improvement. ACR\n20\n Preliminary Definition of Improvement is defined as:\n\n\n≥ 20% improvement in: Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 20% improvement in 3 of following 5 assessments: Patient Pain Assessment (VAS), Patient Global assessment (VAS), Physician Global Assessment (VAS), Patent Self- Assessed Disability (HAQ), Acute Phase Reactant (CRP or ESR). ACR\n50\n and ACR\n70\n are defined in the same way with ≥ 50% and ≥ 70% improvements, respectively. For further details see Felson et al., in American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis; Arthritis Rheumatism 38, 727-735 (1995).\n\n\nAlternatively, a therapeutically effective amount for rheumatoid arthritis may be measured by DAS (disease activity score), including DAS28 and/or DAS56, as defined by The European League Against Rheumatism (www.eular.org).\n\n\nDosage regimens of compounds of and/or used in the methods of the invention typically are selected or adjusted to provide the optimum desired response (e.g., a therapeutic response). In general, any suitable dosage regimen can be used. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. Parenteral compositions may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the present invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.\n\n\nThe efficient dosages and the dosage regimens for the IL-21 BPs of the present invention depend on the disease or condition to be treated and may be determined by the persons skilled in the art. An exemplary, non-limiting range for a therapeutically effective amount of a compound of the present invention is about 0.1 -100 mg/kg, such as about \n\n 0.1 -50 mg/kg, for example about 0.1 -20 mg/kg, such as about 0.1-10 mg/kg, for instance about 0.5, about such as 0.3, about 1 , or about 3 mg/kg.\n\n\nA physician or veterinarian having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the IL-21 BPs of the present invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a composition of the present invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.\n\n\nAdministration may be intravenous, intramuscular, intraperitoneal, or subcutaneous, and for instance administered proximal to the site of the target. If desired, the effective daily dose of a pharmaceutical composition may be administered as two, three, four, five, six or more sub- doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition as described above.\n\n\nIn one embodiment, the IL-21 BPs of the present invention may be administered by infusion in a weekly dosage of from 10 to 500 mg/m\n2\n, such as of from 200 to 400 mg/m\n2\n. Such administration may be repeated, e.g., 1 to 8 times, such as 3 to 5 times. The administration may be performed by continuous infusion over a period of from 2 to 24 hours, such as of from 2 to 12 hours.\n\n\nIn one embodiment, the IL-21 BPs of the present invention may be administered by slow continuous infusion over a long period, such as more than 24 hours, in order to reduce toxic side effects.\n\n\nIn one embodiment the IL-21 BPs of the present invention may be administered in a weekly dosage of from 250 mg to 2000 mg, such as for example 300 mg, 500 mg, 700 mg, 1000 mg, 1500 mg or 2000 mg, for up to 8 times, such as from 4 to 6 times. The administration may be performed by continuous infusion over a period of from 2 to 24 hours, such as of from 2 to 12 hours. Such regimen may be repeated one or more times as necessary, for example, after 6 months or 12 months. The dosage may be determined or adjusted by measuring the amount of compound of the present invention in the blood upon administration by for instance taking out a biological sample and using anti-idiotypic antibodies which target the antigen binding region of the IL-21 BPs of the present invention. \n\n In one embodiment, the IL-21 BPs of the present invention may be administered by maintenance therapy, such as, e.g., once a week for a period of 6 months or more.\n\n\nIn one embodiment, the IL-21 BPs of the present invention may be administered by a regimen including one infusion of an IL-21 BP of the present invention followed by an infusion of an IL-21 BP of the present invention conjugated to a radioisotope. The regimen may be repeated, e.g., 7 to 9 days later.\n\n\nAs non-limiting examples, treatment according to the present invention may be provided as a daily dosage of a compound of the present invention in an amount of about 0.1 -100 mg/kg, such as 0.5, 0.9, 1.0, 1.1 , 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one of day 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively, at least one of week 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 after initiation of treatment, or any combination thereof, using single or divided doses of every 24, 12, 8, 6, 4, or 2 hours, or any combination thereof.\n\n\nThe IL-21 binding peptides of the present invention for therapeutic use may also be administered in combination therapy, i.e., combined with other therapeutic agents relevant for the disease or condition to be treated. Such administration may be simultaneous, separate or sequential. For simultaneous administration the agents may be administered as one compositons or as separate compositions, as appropriate. The present invention thus also provides methods for treating a disease or disorder treatable by use of an IL-21 antagonist as described above, which methods comprise administration of an IL-21 BP of the present invention combined with one or more additional therapeutic agents as described below. In one embodiment, the present invention provides a method for treating adisease or disorder treatable by use of an IL-21 antagonist in a subject, which method comprises administation of a therapeutically effective amount of an IL-21 BP of the present invention and at least one anti-inflammatory agent to a subject in need thereof.\n\n\nIn one embodiment such an anti-inflammatory agent may be selected from a steroidal drug and a NSAID (nonsteroidal anti-inflammatory drug).\n\n\nIn one embodiment such an anti-inflammatory agent may be selected from aspirin and other salicylates, Cox-2 inhibitors (such as rofecoxib and celecoxib), NSAIDs (such as ibuprofen, fenoprofen, naproxen, sulindac, diclofenac, piroxicam, ketoprofen, diflunisal, nabumetone, etodolac, oxaprozin, and indomethacin), anti-IL6R antibodies, anti-IL8 antibodies, anti-IL15 antibodies, anti-IL15R antibodies, anti-CD4 antibodies, anti-CD1 1a \n\n antibodies (e.g., efalizumab), anti-alpha-4/beta-1 integrin (VLA4) antibodies (e.g natalizumab), CTLA4-lg for the treatment of inflammatory diseases, prednisolone, prednisone, disease modifying antirheumatic drugs (DMARDs) such as methotrexate, hydroxychloroquine, sulfasalazine, pyrimidine synthesis inhibitors (such as leflunomide), IL-1 receptor blocking agents (such as anakinra), TNF-α blocking agents (such as etanercept, infliximab, and adalimumab) and similar agents.\n\n\nIn one embodiment, the present invention provides a method for treating a disease or disorder treatable by use of an IL-21 antagonist in a subject, which method comprises administation of a therapeutically effective amount of an IL-21 BP of the present invention and at least one immunosuppressive and/or immunomodulatory agent to a subject in need thereof.\n\n\nIn one embodiment, such an immunosuppressive and/or immunomodulatory agent may be selected from cyclosporine, azathioprine, mycophenolic acid, mycophenolate mofetil (such as Cellcept®), corticosteroids such as prednisone, methotrexate, gold salts, sulfasalazine, antimalarials, brequinar, leflunomide, mizoribine, 15-deoxyspergualine, 6-mercaptopurine, cyclophosphamide, rapamycin, tacrolimus (FK-506), OKT3, anti- thymocyte globulin, thymopentin, thymosin-α and similar agents.\n\n\nIn one embodiment, such an immunosuppressive and/or immunomodulatory agent may be selected from immunosuppressive antibodies, such as antibodies binding to p75 of the IL-2 receptor, or antibodies binding to for instance MHC, CD2, CD3, CD4, CD7, CD28, B7, CD40, CD45, IFNγ, TNF-α, IL-4, IL-5, IL-6R, IL-7, IL-8, IL-10, CD1 1a, or CD58, or antibodies binding to their ligands.\n\n\nIn one embodiment, such an immunosuppressive and/or immunomodulatory agent may be selected from soluble IL-15R, IL-10, B7 molecules (B7-1 , B7-2, variants thereof, and fragments thereof), ICOS, and OX40, an inhibitor of a negative T cell regulator (such as an antibody against CTLA4) and similar agents.\n\n\nIn one embodiment, the IL-21 BPs of the present invention may be administered in combination with two or more immunosuppressive and/or immunomodulatory agents, such as in combination with prednisone and cyclosporine; prednisone, cyclosporine and azathioprine; or prednisone, cyclosporine and mycophenolate mofetil.\n\n\nIn one embodiment, the present invention provides an IL-21 BP that is conjugated to an immunomodulator, such as an immunomodulating cytokine, stem cell growth factor, lymphotoxin (such as a TNF such as TNFα), or a hematopoietic factor. Examples of such molecules that may be useful as conjugates include IL-2, IL-3, IL-10, , colony stimulating factors (such as granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage- \n\n colony stimulating factor (GM-CSF)), interferons (such as IFNβ, and I FNY) the stem cell growth factor designated \"S1 factor,\" erythropoietin, and thrombopoietin, active fragments thereof, derivatives thereof, variants thereof, or a combination of any thereof.\n\n\nThe present invention further provides method of promoting the sale and/or use of an IL-21 BP of the present invention, comprising distributing information (such as by printed materials that are handed out, mailed, etc., by advertising signage, by television programs and advertisements, by radio programs and advertisements, by internet site postings, by email, by telemarketing, by door-to-door or person-to-person marketing, by funding and/or hosting conferences, panels, forums, etc., by employing and/or contracting for the services of salespeople and/or medical/scientific liaisons, by funding and/or hosting scientific research and publications related to such uses, etc.) related to the use of the compound in the prevention or treatment of any condition or combination of conditions as described elsewhere herein to any persons or entities of potential interest (such as pharmaceutical chains, formulary managers, insurance companies, HMOs, hospitals and hospital chains, other health care companies, pharmacy benefit managers, potential patients, cancer patients, former cancer patients, patients in remission, primary care physicians, nurses, doctors of pharmacy, and/or key opinion leaders).\n\n\nThe present invention also provides kits comprising a pharmaceutical composition of a compound of the present invention and instructions for use. The kit may further contain one or more additional agents, such as an immunosuppressive reagent, a chemotherapeutic reagent, an anti-inflammatory agent or a radiotoxic agent as described above, or one or more additional IL-21 BPs of the present invention (such as an IL-21 BP having a complementary activity). A kit of the present invention may also include diagnostic agents and/or other therapeutic agents. In one embodiment, a kit of the present invention includes an IL-21 BP of the present invention and a diagnostic agent that may be used in a diagnostic method for diagnosing the state or existence of a disorder involving IL-21 in a subject. In one embodiment, the kit includes an IL-21 BP of the present invention in a highly stable form (such as in a lyophilized form) in combination with pharmaceutically acceptable carrier(s) that may be mixed with the highly stabile composition to form an injectable composition. The following is a non-limiting list of embodiments of the present invention.\n\n\nEmbodiment 1 : An IL-21 binding peptide, which is capable of antagonizing the action of IL-21 on the human IL-21 receptor.\n\n\nEmbodiment 2: An IL-21 binding peptide according to embodiment 1 , wherein said IL-21 binding peptide is capable of decreasing the activity of IL-21 on the human IL-21 receptor by at least 25%. \n\n Embodiment 3: An IL-21 binding peptide according to embodiment 1 or embodiment 2, wherein said IL-21 binding peptide is capable of decreasing the activity of IL-21 on the human IL-21 receptor by at least 50%.\n\n\nEmbodiment 4: An IL-21 binding peptide according to any of embodiments 1 to 3, wherein said IL-21 binding peptide is capable of decreasing the activity of IL-21 on the human IL-21 receptor by at least 75%.\n\n\nEmbodiment 5: An IL-21 binding peptide according to any of embodiments 1 to 4, wherein said IL-21 binding peptide is capable of decreasing the activity of IL-21 on the human IL-21 receptor by at least 90%. Embodiment 6: An IL-21 binding peptide according to any of embodiments 1 to 5, wherein the antagonism of said IL-21 binding peptide is determined by use of an assay as described in Example 3.\n\n\nEmbodiment 7: An IL-21 binding peptide, which competes with an anti-IL-21 antibody having an amino acid sequence for V\nL\n as presented in SEQ ID No. 1 and an amino acid sequence for V\nH\n as presented in SEQ ID No. 2 for binding to IL-21.\n\n\nEmbodiment 8: An IL-21 binding peptide according to any of embodiments 1 to 6, which competes with an anti-IL-21 antibody having an amino acid sequence for V\nL\n as presented in SEQ ID No. 1 and an amino acid sequence for V\nH\n as presented in SEQ ID No. 2 for binding to IL-21. Embodiment 9: An IL-21 binding peptide according to embodiment 7 or embodiment\n\n\n8, wherein the competition is determined as described in Example 2.\n\n\nEmbodiment 10: An IL-21 binding peptide, which IL-21 binding peptide specifically binds to i) a IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and/or ii) an IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10.\n\n\nEmbodiment 11 : An IL-21 binding peptide according to any of embodiments 1 to 9, which IL-21 binding peptide specifically binds to i) a IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 1 and a V\nH\n sequence of SEQ ID No. 2 and/or ii) an IL-21 epitope that also is specifically bound by an antibody having a V\nL\n sequence of SEQ ID No. 9 and a V\nH\n sequence of SEQ ID No. 10.\n\n\nEmbodiment 12: An IL-21 binding peptide according to any of embodiments 1 to 11 , which peptide comprises the amino acid sequence of SEQ ID No. 8. \n\n Embodiment 13: An IL-21 binding peptide according to any of embodiments 1 to 12, which peptide comprises the amino acid sequence of SEQ ID No. 5.\n\n\nEmbodiment 14: An IL-21 binding peptide according to embodiment 12 or embodiment 13, which additionally comprises the amino acid sequence of SEQ ID No. 7. Embodiment 15: An IL-21 binding peptide according to any of embodiments 12 to\n\n\n14, which additionally comprises the amino acid sequence of SEQ ID No. 6.\n\n\nEmbodiment 16: An IL-21 binding peptide according to any of embodiments 12 to\n\n\n15, which comprises the amino acid sequence of SEQ ID No. 2.\n\n\nEmbodiment 17: An IL-21 binding peptide according to any of embodiments 12 to 16, which additionally comprises the amino acid sequence of SEQ ID No. 4.\n\n\nEmbodiment 18: An IL-21 binding peptide according to any of embodiments 12 to\n\n\n17, which additionally comprises the amino acid sequence of SEQ ID No. 3.\n\n\nEmbodiment 19: An IL-21 binding peptide according to any of embodiments 12 to\n\n\n18, which comprises the amino acid sequence of SEQ ID No. 1. Embodiment 20: An IL-21 binding peptide according to any of embodiments 1 to 11 , which peptide comprises the amino acid sequence of SEQ ID No. 16.\n\n\nEmbodiment 21 : An IL-21 binding peptide according to any of embodiments 1 to 11 or embodiment 20, which peptide comprises the amino acid sequence of SEQ ID No. 13.\n\n\nEmbodiment 22: An IL-21 binding peptide according to embodiment 20 or embodiment 21 , which additionally comprises the amino acid sequence of SEQ ID No. 15. Embodiment 23: An IL-21 binding peptide according to any of embodiments 20 to\n\n\n22, which additionally comprises the amino acid sequence of SEQ ID No. 14.\n\n\nEmbodiment 24: An IL-21 binding peptide according to any of embodiments 20 to\n\n\n23, which comprises the amino acid sequence of SEQ ID No. 10. Embodiment 25: An IL-21 binding peptide according to any of embodiments 20 to\n\n\n24, which additionally comprises the amino acid sequence of SEQ ID No. 12.\n\n\nEmbodiment 26: An IL-21 binding peptide according to any of embodiments 20 to\n\n\n25, which additionally comprises the amino acid sequence of SEQ ID No. 11.\n\n\nEmbodiment 27: An IL-21 binding peptide according to any of embodiments 20 to 26, which comprises the amino acid sequence of SEQ ID No. 9.\n\n\nEmbodiment 28: An IL-21 binding peptide according to any of embodiments 12 to 27, which IL-21 binding peptide is an anti-IL-21 antibody.\n\n\nEmbodiment 29: An IL-21 binding peptide according to any of embodiments 1 to 11 , which peptide is an anti-IL-21 antibody. \n\n Embodiment 30: An anti-IL-21 antibody according to embodiment 29 comprising a V\nH\n CDR3 sequence comprising the amino acid sequence of SEQ ID No. 8.\n\n\nEmbodiment 31 : An anti-IL-21 antibody according to embodiment 29 or embodiment 30 comprising a V\nL\n CDR3 sequence comprising the amino acid sequence of SEQ ID No. 5. Embodiment 32: An anti-IL-21 antibody according to embodiment 30 or embodiment\n\n\n31 , which additionally comprises a V\nH\n CDR2 sequence comprising the amino acid sequence of SEQ ID No. 7.\n\n\nEmbodiment 33: An anti-IL-21 antibody according to any of embodiments 30 to 32, which additionally comprises a V\nH\n CDR1 sequence comprising the amino acid sequence of SEQ ID No. 6.\n\n\nEmbodiment 34: An anti-IL-21 antibody according to any of embodiments 30 to 33 comprising a V\nH\n comprising the amino acid sequence of SEQ ID No. 2.\n\n\nEmbodiment 35: An anti-IL-21 antibody according to any of embodiments 30 to 34, which additionally comprises a V\nL\n CDR2 sequence comprising the amino acid sequence of SEQ ID No. 4.\n\n\nEmbodiment 36: An anti-IL-21 antibody according to any of embodiments 30 to 35, which additionally comprises a V\nL\n CDR1 sequence comprising the amino acid sequence of SEQ ID No. 3.\n\n\nEmbodiment 37: An anti-IL-21 antibody according to any of embodiments 30 to 36 comprising a V\nH\n comprising the amino acid sequence of SEQ ID No. 1.\n\n\nEmbodiment 38: An anti-IL-21 antibody according to embodiment 29 comprising a V\nH\n CDR3 sequence comprising the amino acid sequence of SEQ ID No. 16.\n\n\nEmbodiment 39: An anti-IL-21 antibody according to embodiment 29 or embodiment 38 comprising a V\nL\n CDR3 sequence comprising the amino acid sequence of SEQ ID No. 13. Embodiment 40: An anti-IL-21 antibody according to embodiment 38 or embodiment\n\n\n39, which additionally comprises a V\nH\n CDR2 sequence comprising the amino acid sequence of SEQ ID No. 15.\n\n\nEmbodiment 41 : An anti-IL-21 antibody according to any of embodiments 38 to 40, which additionally comprises a V\nH\n CDR1 sequence comprising the amino acid sequence of SEQ ID No. 14.\n\n\nEmbodiment 42: An anti-IL-21 antibody according to any of embodiments 38 to 41 comprising a V\nH\n comprising the amino acid sequence of SEQ ID No. 10.\n\n\nEmbodiment 43: An anti-IL-21 antibody according to any of embodiments 38 to 42, which additionally comprises a V\nL\n CDR2 sequence comprising the amino acid sequence of SEQ ID No. 12. \n\n Embodiment 44: An anti-IL-21 antibody according to any of embodiments 38 to 43, which additionally comprises a V\nL\n CDR1 sequence comprising the amino acid sequence of SEQ ID No. 11.\n\n\nEmbodiment 45: An anti-IL-21 antibody according to any of embodiments 38 to 44 comprising a V\nH\n comprising the amino acid sequence of SEQ ID No. 9.\n\n\nEmbodiment 46: An anti-IL-21 antibody according to any of embodiments 28 to 45, which is a monoclonal antibody.\n\n\nEmbodiment 47: An anti-IL-21 antibody according to any of embodiments 28 to 45, which is a human antibody. Embodiment 48: An anti-IL-21 antibody according to embodiment 47, which is a monoclonal antibody.\n\n\nEmbodiment 49: An anti-IL-21 antibody according to any of embodiments any of embodiments 28 to 45, which is a humanized antibody.\n\n\nEmbodiment 50: An anti-IL-21 antibody according to embodiment 49, which is a monoclonal antibody.\n\n\nEmbodiment 51 : An anti-IL-21 antibody according to any of embodiments any of embodiments 28 to 45, which is a chimeric antibody.\n\n\nEmbodiment 52: An anti-IL-21 antibody according to embodiment 51 , which is a monoclonal antibody. Embodiment 53: An anti-IL-21 antibody according to any of embodiments any of embodiments 28 to 52, wherein the antibody is an IgGI antibody.\n\n\nEmbodiment 54: An anti-IL-21 antibody according to embodiment 53, wherein the antibody is a IgGI , K antibody.\n\n\nEmbodiment 55: An anti-IL-21 antibody according to any of embodiments 28 to 52, wherein the antibody is an IgM antibody.\n\n\nEmbodiment 56: An anti-IL-21 antibody according to embodiment 55, wherein the antibody is a IgM\n1\nK antibody.\n\n\nEmbodiment 57: An anti-IL-21 antibody according to any of embodiments 28 to 56, which antibody is in substantially isolated form. Embodiment 58: An anti-IL-21 antibody according to any of embodiments 28 to 57, which is an antibody fragment or a single chain antibody.\n\n\nEmbodiment 59: An IL-21 binding peptide according to any of embodiments 1 to 27, which IL-21 binding peptide is a fusion protein between an anti-IL-21 antibody according to any of embodiments 28 to 58 and at least one nonhomologous peptide comprising an amino \n\n acid sequence, that imparts a detectable biological function and/or characteristic to the fusion protein that cannot solely be attributed to the anti-IL-21 antibody sequence.\n\n\nEmbodiment 60: A nucleic acid encoding an IL-21 binding peptide according to any of embodiments 1 to 59. Embodiment 61 : A hybridoma which produces a human monoclonal anti-IL-21 antibody encoded by human heavy chain and human light chain nucleic acids comprising a nucleotide sequence in their variable heavy chain region as set forth in SEQ ID No. 18, or conservative sequence modifications thereof, and comprising a nucleotide sequence in their variable light chain region as set forth in SEQ ID No. 17, or conservative sequence modifications thereof.\n\n\nEmbodiment 62: A hybridoma which produces a human monoclonal anti-IL-21 antibody having human heavy chain and light chain variable regions which comprise a human heavy chain variable amino acid sequence as set forth in SEQ ID No. 2, or conservative sequence modifications thereof, and the human light chain variable amino sequence as set forth in SEQ ID No. 1 , or conservative sequence modifications thereof.\n\n\nEmbodiment 63: A transfectoma which produces a human monoclonal anti-IL-21 antibody encoded by human heavy chain variable nucleic acids as set forth in SEQ ID No. 18, and human light chain nucleic acids as set forth SEQ ID No. 17, or conservative sequence modifications thereof. Embodiment 64: A transfectoma which produces a human monoclonal anti-IL-21 antibody having human heavy chain and light chain variable regions which comprise the human heavy chain variable amino acid sequence as set forth in SEQ ID No. 2, or conservative sequence modifications thereof, and the human light chain variable amino sequence as set forth in SEQ ID No. 1 , or conservative sequence modifications thereof. Embodiment 65: A hybridoma which produces a human monoclonal anti-IL-21 antibody encoded by human heavy chain and human light chain nucleic acids comprising a nucleotide sequence in their variable heavy chain region as set forth in SEQ ID No. 20, or conservative sequence modifications thereof, and comprising a nucleotide sequence in their variable light chain region as set forth in SEQ ID No. 19, or conservative sequence modifications thereof.\n\n\nEmbodiment 66: A hybridoma which produces a human monoclonal anti-IL-21 antibody having human heavy chain and light chain variable regions which comprise a human heavy chain variable amino acid sequence as set forth in SEQ ID No. 10, or conservative sequence modifications thereof, and the human light chain variable amino sequence as set forth in SEQ ID No. 9, or conservative sequence modifications thereof. \n\n Embodiment 67: A transfectoma which produces a human monoclonal anti-IL-21 antibody encoded by human heavy chain variable nucleic acids as set forth in SEQ ID No. 20, and human light chain nucleic acids as set forth SEQ ID No. 19, or conservative sequence modifications thereof. Embodiment 68: A transfectoma which produces a human monoclonal anti-IL-21 antibody having human heavy chain and light chain variable regions which comprise the human heavy chain variable amino acid sequence as set forth in SEQ ID No. 10, or conservative sequence modifications thereof, and the human light chain variable amino sequence as set forth in SEQ ID No. 9, or conservative sequence modifications thereof. Embodiment 69: An isolated or recombinant eukaryotic or prokaryotic host cell which produces an IL-21 binding protein according to any of embodiments 1 to 59.\n\n\nEmbodiment 70: An IL-21 binding peptide according to any of embodiments 1 to 59, further comprising a chelator linker for attaching a radioisotope.\n\n\nEmbodiment 71 : An immunoconjugate comprising anti-IL-21 antibody according to any of embodiments 28 to 58 linked to a cytotoxic agent, a radioisotope, or a drug.\n\n\nEmbodiment 72: An immunoconjugate comprising an anti-IL-21 antibody according to embodiment 55 or embodiment 56, wherein the anti-IL-21 antibody is a monomeric IgM antibody linked to a cytotoxic agent, a radioisotope, or a drug.\n\n\nEmbodiment 73: A bispecific molecule comprising an IL-21 binding peptide according to any of embodiments 1 to 59 and a peptide capable of binding to IL-2, IL-4, IL, IL-9, or lL-15.\n\n\nEmbodiment 74: An expression vector comprising a nucleic acid according to embodiment 60.\n\n\nEmbodiment 75: An expression vector comprising the nucleotide sequence of SEQ ID No. 18, or conservative modifications thereof, and/or the nucleotide sequence of SEQ ID No. 17, or conservative modifications thereof.\n\n\nEmbodiment 76: An expression vector comprising the nucleotide sequence of SEQ ID No. 20, or conservative modifications thereof, and/or the nucleotide sequence of SEQ ID No. 19, or conservative modifications thereof. Embodiment 77: A eukaryotic or prokaryotic host cell comprising an expression vector according to any of embodiments 74 to 76.\n\n\nEmbodiment 78: A pharmaceutical composition comprising an IL-21 binding peptide according to any of embodiments 1 to 59 and a pharmaceutically acceptable carrier.\n\n\nEmbodiment 79: A pharmaceutical composition according to embodiment 78 comprising one or more further therapeutic agents. \n\n Embodiment 80: A pharmaceutical composition comprising an expression vector according to any of embodiments 74 to 76 and a pharmaceutically acceptable carrier.\n\n\nEmbodiment 81 : An IL-21 binding peptide according to any one of embodiments 1 to 59 for use in therapy. Embodiment 82: An immunoconjugate according to embodiment 71 or embodiment\n\n\n72 for use in therapy.\n\n\nEmbodiment 83: A bispecific molecule according to embodiment 73 for use in therapy.\n\n\nEmbodiment 84: An expression vector according to any of embodiments 74 to 76 for use in therapy.\n\n\nEmbodiment 85: Use of an IL-21 binding peptide according to any one of embodiments 1 to 59 or a pharmaceutical composition according to any of embodiments 78 to 80, for use in treating a disease or disorder, wherein said disease or disorder may be treatable by use of an IL-21 antagonist. Embodiment 86: Use of an IL-21 binding peptide according to any one of embodiments 1 to 59 for preparation of a pharmaceutical composition for treating a disease or disorder, wherein said disease or disorder may be treatable by use of an IL-21 antagonist.\n\n\nEmbodiment 87: Use of an immunoconjugate according to embodiment 71 or embodiment 72, a bispecific molecule according to embodiment 73, or an expression vector according to any of embodiments 74 to 76 for preparation of a pharmaceutical composition for treating a disease or disorder, wherein said disease or disorder may be treatable by use of an IL-21 antagonist.\n\n\nEmbodiment 88: Use according to any of embodiments 85 to 87, wherein said disease or disorder is an autoimmune and/or inflammatory disease. Embodiment 89: Use according to embodiment 88, wherein said disease or disorder is systemic lupus erythematosus, rheumatoid arthritis or inflammatory bowel disease.\n\n\nEmbodiment 90: A method of treating a disease or disorder, wherein said disease or disorder may be treatable by use of an IL-21 antagonist., comprising administering to a subject an IL-21 binding peptide according to any of embodiments 1 to 59, a pharmaceutical composition according to any of embodiments 78 to 80, an immunoconjugate according to embodiment 71 or embodiment 72, a bispecific molecule according to embodiment 73, or an expression vector according to any of embodiments 74 to 76 in an amount effective to treat or prevent the disease.\n\n\nEmbodiment 91 : A method according to embodiment 90, wherein the disease or disorder is an autoimmune and/or inflammatory disease. \n\n Embodiment 92: A method according to embodiment 90, wherein the disease or disorder is systemic lupus erythematosus, rheumatoid arthritis or inflammatory bowel disease.\n\n\nEmbodiment 93: An in vitro method for detecting the presence of IL-21 antigen in a sample, which method comprises a) contacting the sample with an IL-21 binding peptide according to any of embodiments 1 to 59 under conditions that allow for formation of a complex between the IL-21 binding peptide and IL-21 ; and b) detecting the formation of a complex. Embodiment 94: A kit for detecting the presence of IL-21 antigen in a sample comprising an IL-21 binding peptide according to any of embodiments 1 to 59.\n\n\nEmbodiment 95: An in vivo method for detecting IL-21 antigen in an subject comprising a) administering an IL-21 binding peptide according to any of embodiments 1 to 59 under conditions that allow for formation of a complex between the IL-21 binding peptide and IL-21 ; and b) detecting the formed complex.\n\n\nEmbodiment 96: An anti-idiotypic antibody binding to an antibody according to any of embodiments 28 to 58. Embodiment 97: Use of an anti-idiotypic antibody according to embodiment 96 for detecting the level of human monoclonal antibody against IL-21 in a sample.\n\n\nAll references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.\n\n\nAll headings and sub-headings are used herein for convenience only and should not be construed as limiting the present invention in any way.\n\n\nAny combination of the above-described elements in all possible variations thereof is encompassed by the present invention unless otherwise indicated herein or otherwise clearly contradicted by context.\n\n\nThe use of the terms \"a\" and \"an\" and \"the\" and similar referents in the context of describing the present invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.\n\n\nRecitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless \n\n otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. Unless otherwise stated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement may be considered to also provide a corresponding approximate measurement, modified by \"about,\" where appropriate).\n\n\nAll methods described herein may be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.\n\n\nThe use of any and all examples, or exemplary language (e.g., \"such as\") provided herein, is intended merely to better illuminate the present invention and does not pose a limitation on the scope of the present invention unless otherwise indicated. No language in the specification should be construed as indicating any element is essential to the practice of the present invention unless as much is explicitly stated.\n\n\nThe citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.\n\n\nThe description herein of any embodiment of the present invention using terms such as \"comprising\", \"having,\" \"including,\" or \"containing\" with reference to an element or elements is intended to provide support for a similar embodiment of the present invention that \"consists of\", \"consists essentially of\", or \"substantially comprises\" that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context). The present invention includes all modifications and equivalents of the subject matter recited in the embodiments presented herein to the maximum extent permitted by applicable law.\n\n\nAll patents, pending patent applications and other publications cited herein are hereby incorporated by reference in their entirety. The present invention is further illustrated by the following examples which should not be construed as further limiting. \n\n EXAMPLES\n\n\nExample 1\n\n\nGeneration of anti-IL-21 antibodies 1 F1 and 1 F22\n\n\nImmunization and fusion RBF-mice were immunized three times with 20 μg soluble hlL-21 (aa 30-162 of SEQ\n\n\nID No. 21 ) in Freunds adjuvant. Ten days after the last immunisation, eye-bleeds from immunized mice were screened by ELISA for I L-21 -specific antibodies. Mice with positive titers were boosted with 10 μg of human I L-21 by intravenous injection, and sacrificed after three days. The spleen was removed aseptically and dispersed to a single cell suspension. Fusion of spleen cells and mouse myeloma cells FOX-NY was done by PEG method. Cells were seeded in microtiter plates and cultured at 37\n0\nC, 5% CO\n2\n. The tissue-culture medium containing HAT/HT for selection was changed three times over a two week's period. Primary screening of hybridomas Nunc immunoplates were coated with 1 μg/ml of human I L-21 in PBS and incubated overnight at 4°C. Plates were blocked with blocking buffer (PBS with 0.05% Tween20) for 15 min and were washed with PBS/0.05% Tween20. Culture supernatants from the hybridoma cells were added and the plates were incubated for 1 hour at room temperature. After washing, gt-anti-mouse-lgG HRP-labelled antibody was added in a dilution as described by the manufacturer. Plates were incubated 1 h, washed and developed with TMB-substate (Kem-EN-Tec). Absorbance at 450 nm was measured on an ELISA-reader. Selected clones were continued and protein was purified. The specificity of the antibodies was then confirmed by a direct ELISA. In Figure 1 , the concentration dependent binding to plate coated hi L-21 is shown.\n\n\nSub-cloning of hybridomas In order to generate monoclonal and stable hybridomas, cells were subcloned using limited dilution method. Cells were seeded into a 96 well plates by a density of 1 cell/well. After two weeks, supernatants from each well were screened in a direct ELISA, as described above. Cells from positive wells were transferred to a larger culture volume, expanded and subcloned again until a stable and two monoclonal cell lines was obtained. Antibody cloning and sequencing:\n\n\nTotal RNA was extracted from three hybridomas (hlL-21-1 F22 A6B6C3, hlL-21-1 F1 A2B2C1 , hlL-21-1 F1 A2B2C6) using RNeasy (#634914) from Qiagen. cDNA was synthesized from 1 μg total RNA using SMART-RACE cDNA amplification kit from Clonetech. The reaction was run at 42°C for 114 h and the samples were diluted in 75 μl \n\n tricine-EDTA. PCR amplification of the target was carried out in 50 μl reactions using 5 μl of cDNA as template. The forward primer for both heavy and light chain was universal primer mix (UPM) that was included in the SMART RACE kit. The reverse primer sequence for heavy chain (HC) was designed as follows: 5'- GTCTACCACAACACACGTGAC and for light chain (LC) δ'-GCTCTAGACTAACACTCATTCCTGTTGAAGCTC.\n\n\nThe PCR reactions were carried out using Phusion mastermix from Finnzymes and the PCR program was run with a single denaturing step at 98°C/30 sec followed by 29 cycles as given: 98°C/10 sec; 55°C/20 sec; 72°C/30 sec. The final extension step was 72°C/5 min. The PCR products were identified on a 1 % agarose gel containing ethidiumbromide. The PCR products were purified from the gel using GFX Purification kit from GE Healthcare followed by cloning into Zero Blunt TOPO PCR Cloning Kit (#K2875-40) and transformed into TOP10 E. coli cells from Invitrogen. Plasmids were sequenced at MWG Biotech, Matinsried, Germany using the sequencing primers M13 rev (-29) and M13 uni (-21 ). HC and LC were verified from the identified sequences by using VectorNTI. All procedures based on kits were performed according to manufactures directions.\n\n\nFrom the hybridoma F1 A2B2C1 and F1 A2B2C6 cells a single kappa LC and a single lgG2a HC were cloned and from the F22 A6B6C3 cells a single kappa LC and a single IgGI HC were cloned. The cloned sequence of the kappa LC and the lgG2a HC of the hybridomas F1 A2B2C1 and F1 A2B2C6 can be seen as SEQ ID No. 17 and 18 respectively. The cloned sequence of the kappa LC and the IgGI HC of the hybridoma F22 A6B6C3 can be seen as SEQ ID No. 19 and 20 respectively. The antibody expressed by hybridoma F1 A2B2C1 (and F1 A2B2C6) is called 1 F1 and the antibody expressed by hybridoma F22 A6B6C3 is called 1 F22.\n\n\nExample 2\n\n\nAnalysis of 1 F1 and 1 F22 using a competition experiment using Surface Plasmon Resonance (SPR). All SPR experiments described were performed on a Biacore T100 (GE Healthcare).\n\n\n1 F1 and 1 F22 were immobilized by standard amine coupling to a CM5 sensor chip (GE Healthcare). The antibodies were immobilized in individual flow-cells to a level of 500 RU. In order to test for simultaneous binding of the two antibodies to hlL-21 , the hlL-21 was \n\n injected in all flow-cells followed by injection of either 1 F1 or 1 F22. The experiment demonstrated that the antibodies are not able to bind simultaneously to hlL-21.\n\n\nThe kinetic parameters for the interaction between hlL-21 and the immobilized antibodies 1 F1 and 1 F22, were determined by injecting a concentration series of hlL-21 across the antibody surfaces. Each cone, of hlL-21 was injected for 4 min, followed by a 10 min. dissociation period with constant buffer flow. Both antibodies demonstrated affinities in the subnanomolar range - both with an apparent KD value of -0.5 nM.\n\n\nExample 3\n\n\nNeutralizing activity of anti-21 antibodies IL21R transfected BAF-3 cells:\n\n\nBAF-3 cells are murine hematopoetic pre-B cells dependent of exogeneous addition of IL-3 for growth and survival in vitro. The cells also express the common yC receptor which is one of the monomers constituting the heterodimeric IL-21 receptor. BAF-3 cells transfected with the genes encoding the human private chain of the IL-21 receptor, IL-21 Rβ, was received from Zymogenetics Institute, Seattle (transfection as described by Genetics lnstitue in WO9947675 and as it is known in the art). Human IL-21 Rβ transfected BAF-3 cells BAF-3(hlL21 R) express the IL-21 heterodimeric receptor and proliferate in the absence of IL-3, when human IL-21 is added to the culture. . This fact can be used to assess proliferation of these cells upon stimulation with different concentrations of IL-21 and can also be used to test whether antibodies against IL-21 or other potential IL-21 antagonists are capable of inhibiting hlL-21 induced stimulation of IL-21 R-expressing cells, such as the IL-21 Rβ transfected BAF-3 cells. Other alternatives for cells expressing the IL-21 receptor is for instance a human IL-2 dependent cell line NK92 from ATCC (CRL-2407), which can be used as target cells in the same proliferation assay (stimulation as well as inhibition). These cells express the IL-21 R complex endogenously.\n\n\nDefining the optimal concentration of hlL-21 inducing maximal response in BAF- 3(h IL-21 R) cell and calculating IC\n50\n.\n\n\nBAF-3(hlL-21 R) cells are kept in culture in RPMI 1640 with Glutamax, 10% heat inactivated FBS, 1% P/S, 1 mg/ml Geneticin, 200 μg/ml Zeocin and 1 nM IL-3 and should never exceed 10\n6\n c/ml. Fresh media is added to the culture three times a week and cells split accordingly.\n\n\nFor the assay, BAF-3(hlL21 R) cells were washed thoroughly in Assay medium (RPMI 1640 with Glutamax, 10% heat inactivated FBS, 1% P/S, 1 mg/ml Geneticin, 200 μg/ml Zeocin) to get rid of residual IL-3. The cells were then seeded into 96-well microtiter \n\n plates (flat-bottom view plate) at 10\n4\n - 5x10\n4\nc/w. Serial dilutions of hlL-21 (10 \n8\nM to 10 \n14\nM) were added to the wells and additional wells with cells but no hlL-21 served as negative control. Total volume of the wells was 100 μl. The cells were cultured for three days in 5% CO\n2\n at 37°C. For the last 6 hours of the culture period, 10 μl AlamarBlue was added to each well. The cells were analyzed for fluorescence intensity on a spectrofluorometer at excitation 555-12 nm and emission 590 nm. In Figure 2, an example of a typical stimulation of BAF-3 (hlL21 R) induced by hlL-21 is shown.\n\n\nInhibition assay to define neutralizing activity of the antibodies. For the inhibition analysis, a constant concentration of hlL-21 was used to stimulate the BAF-3(hlL-21 R) cells. This concentration was chosen on basis of approximately 90% of max stimulation in the proliferation assay which for the purpose of this specification means 10 \n9\nM hlL-21.\n\n\nInhibition assay to define neutralizing activity of the antibodies. 10\n4\n - 5x10\n4\nc/w of washed BAF-3(hlL-21 R) cells were seeded into 96-well microtiter wells in assay medium. 10\n'9\nM (final concentration) of hlL-21 was added to each well (except some wells used as negative control containing only cells). Serial dilutions of antibody (i.e.100 μg and 2-fold dilutions) were added to the wells already containing cells and cytokine (except wells used for positive controls which should contain only cells + hlL-21). The mixture of cells, cytokine and antibody were incubated in 100 μl/w for 72 hours in 5% CO\n2\n at 37°C. The last 6 hours of incubation included 10 μl/w of AlamarBlue. The plates were analysed for fluorescence intensity on a spectrofluorometer at excitation 555-12nm and emission 590nm. Figure 3 shows an example of test for neutralizing activity of anti-hlL-21 antibodies."
  }
]